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INVITED SESSION
SESSION 01: KEYNOTE SESSION
Monday 2 July 2018 Forum (Auditorium) 08:30–09:30
O-001 Human Reproduction Keynote Lecture - Semen quality of
young adult ICSI offspring: The ﬁrst results
F. Belva1, M. Bonduelle1, M. Roelants2, D. Michielsen3, A. Van
Steirteghem4, G. Verheyen4, H. Tournaye4
1UZ Brussel, Center for Medical Genetics, Brussels, Belgium
2KU Leuven, Environment and Health/Youth health Care- Department of Public
health and Primary Care, Leuven, Belgium
3UZ Brussel, Department of Urology, Brussels, Belgium
4UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium
Background: Up till now, the health of children conceived by ART has been
described from infancy up to pubertal age, but not beyond. Also, adverse cardi-
ometabolic and vascular outcomes have been described in both IVF and ICSI
offspring, but the impact of ART on the reproductive health of the offspring
remained unknown. Whether ICSI- conceived men born to fathers with
impaired spermatogenesis are at risk of inheriting deﬁcient spermatogenesis
from their fathers, could not be answered due to their young age. Since the old-
est ICSI offspring cohort worldwide has recently reached adulthood, their
reproductive health can now be investigated. Moreover, since these children
were conceived by ICSI because of severe male-factor infertility, there is rea-
sonable concern that male offspring have inherited the deﬁcient spermatogen-
esis from their fathers. Previously normal pubertal development and adequate
Sertoli and Leydig cell function has been described in pubertal ICSI boys, how-
ever, no information on their sperm quality is currently available. Therefore, we
investigated the semen quality of young adult men that were conceived 18-22
years ago by ICSI for male infertility.
Material and Methods: The present study was conducted at UZ Brussel
between March 2013 and April 2016 and is part of a large follow-up project
focussing on reproductive and metabolic health of young adults, between 18
and 22 years and conceived after ICSI with ejaculated sperm. Results of both a
physical examination and semen analysis were compared between young ICSI
men being part of a longitudinally followed cohort and spontaneously conceived
controls who were recruited cross-sectionally.
Results of a single semen sample in 54 young adult ICSI men and 57 spontan-
eously conceived males are reported. All young adults were individually
assessed and the results of their physical examination were completed by ques-
tionnaires. Data were analysed by multiple linear and logistic regression,
adjusted for covariates. In addition, semen parameters of the ICSI fathers dating
back from their ICSI treatment application were analysed for correlations.
Results: Young ICSI adults had a lower median sperm concentration (17.7 mil-
lion/ml), lower median total sperm count (31.9 million) and lower median total
motile sperm count (12.7 million) in comparison to spontaneously conceived
peers (37.0 million/ml; 86.8 million; 38.6 million). The median percentage pro-
gressive and total motility, median percentage normal morphology and median
semen volume were not signiﬁcantly different between these groups. After
adjustment for confounders (age, BMI, genital malformations, time from ejacula-
tion to analysis, abstinence period), the statistically signiﬁcant differences
between ICSI men and spontaneously conceived peers remained: an almost
doubled sperm concentration in spontaneously conceived peers in comparison
to ICSI men (ratio 1.9, 95% CI 1.1-3.2) and a two-fold lower total sperm count
(ratio 2.3, 95% CI 1.3-4.1) and total motile count (ratio 2.1, 95% CI 1.2-3.6) in
ICSI men compared to controls were found. Furthermore, compared to males
born after spontaneous conception, ICSI men were nearly three times more
likely to have sperm concentrations below the WHO reference value of 15 mil-
lion/ml (AOR 2.7; 95% CI 1.1–6.7) and four times more likely to have total
sperm counts below 39 million (AOR 4.3; 95% CI 1.7-11.3). In this small group
of 54 father-son pairs, a weak negative correlation between total sperm count
in fathers and their sons was found.
Conclusion: Although these ﬁrst results in a small group indicate a lower
semen quantity and quality in young adults born after ICSI for male infertility in
their fathers, results cannot be generalised to all ICSI offspring because the indi-
cations for ICSI have nowadays been extended and ICSI is also being performed
with non-ejaculated sperm and reported differences may thus either decrease
or increase.
O-002 Oocytes from stem cells and back
K. Hayashi1
Faculty of Medical Sciences- Kyushu University, Developmental Stem Cell Biology,
Fukuoka, Japan
Abstrat text
The female germline undergoes a unique sequence of differentiation pro-
cesses that ﬁnally endows the eggs with totipotency. The reconstitution in vitro
of oogenesis using pluripotent stem cells, which eventually produces functional
oocytes, has long been sought in reproductive biology and developmental biol-
ogy, since it would contribute not only to a better understanding of the basic
mechanisms underlying totipotency, but also to an alternative source of
gametes for reproduction.
We recently developed a culture systemthat reconstitutes the entire process
of oogenesis from mouse pluripotent stem cells, yielding in vitro-generated eggs
that gave rise to healthy offspring. In the culture system, primordialgerm cells
(PGCs), origin of eggs and sperm, are induced from from ESCs/iPSCs, and then
are aggregated with somatic cells from fetal ovaries. The aggregates, named
reconstituted ovaries, pass through three different culture stages: in vitro differ-
entiation (IVDi), in vitro growth (IVG) and in vitro maturation (IVM), which in
total take approximately 5 weeks. After these stages, a number of mature
oocytes are produced in the reconstituted ovaries.
The culture system is extremely useful, as genetic manipulation can be easily
done in pluripotent stem cells, and outcome can be seen quickly in culture. In
the symposium, I will introduce recent advances in oocyte production from
pluripotent stem cells and updatecurrent experiments to address molecular
mechanisms underlying oocyte differentiation.
Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology 2018.
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SELECTEDORAL COMMUNICATIONS
SESSION 02: GENOMIC ANDMITOCHONDRIAL
INTEGRITY DURINGDEVELOPMENT
Monday 2 July 2018 Forum (Auditorium) 10:00–11:30
O-003 Oocyte DNA repair capacity of controlled spermDNA
damage is affected by female age
F. Horta1, S. Catt1, B. Vollenhoven1,2, P. Temple-Smith1
1Monash University, Obstetrics and Gynaecology, Melbourne, Australia
2Monash IVF, Reproductive medice, Melbourne, Australia
Study question: Does female aging have a negative effect on oocyte DNA
repair capacity of controlled DNA damage levels introduced by spermatozoa?
Summary answer: Oocytes from older females have reduced capacity to
repair damaged DNA introduced by spermatozoa, compared to oocytes from
younger females.
What is known already: The reproductive lifespan in women declines with
age predominantly due to poor oocyte quality. This leads to decreased repro-
ductive outcomes for older women undergoing assisted reproductive technol-
ogy (ART) treatments compared to young women. Aging and oocyte quality
have been clearly associated with aneuploidy, but factors determining oocyte
quality remain unclear.
DNA repair activity prior to embryonic genomic activation is considered of
maternal origin, with maternal transcripts and proteins controlling DNA integ-
rity. With increasing maternal/oocyte age, stored mRNAs decrease, which
could result in diminished efﬁciency of DNA repair and/or negative effects on
embryo development, especially considering the presence of DNA damage.
Study design, size, duration: Oocytes from two groups of 30 super-
ovulated female mice (Young: 5-8 weeks old, n = 15; Old: 42-45 weeks old, n
= 15) were inseminated with sperm from 5 males with three different con-
trolled DNA damage levels; control:≤10%, 1GY:11-30% and 30GY:>30%.
Inseminated oocytes (Young:125, Old:78) were assessed for the percentage
zygotes (per oocyte) and blastocysts (per zygote). Five replicates of 5 GVs and
5 MII oocytes from each age group were analyzed for gene expression.
Participants/materials, setting, methods: Using the C57BL6 mouse
strain, swim-up epididymal sperm samples were divided into: control (no irradi-
ation); 1GY and 30 GY. Treated spermatozoa were irradiated at 1 Grey and 30
Grey respectively using a linear accelerator Varian 21iX. Following irradiation,
samples were removed for DNA damage assessment (Halomax) and for insem-
ination. Presumed zygotes were cultured in a time-lapse incubator (MIRI,
ESCO). Gene expression of 91 DNA repair genes was assessed using the
Fluidigm Biomark HD system.
Main results and the role of chance: Average sperm DNA damage for the
3 groups was statistically different (Control: 6.1%, 1GY: 16.1%, 30GY: 53.1%,
p < 0.0001), but following IVF showed no signiﬁcant differences in fertilization
rates within or between age groups [(Young; Control: 86.79%, 1GY: 82.75%,
30GY: 76.74%) (Old; Control: 93.1%, 1GY: 70.37%, 30GY: 68.18%) Fishers
exact]. However, blastocyst rates were signiﬁcantly different (p < 0.0001)
among groups [(Young; Control: 86.95%, 1GY: 33.33%, 30GY: 0.0%) (Old;
Control: 70.37%, 1GY: 0.0%, 30GY: 0.0%)]. Between age groups, 1GY samples
showed a signiﬁcant decrease in the blastocyst rate in old females compared to
young females (Young; 1GY: 33.33%, Old; 1GY: 0.0, p = 0.0166). Gene
expression analysis revealed a decreased relative expression of 21 DNA repair
genes in old GV oocytes compared to young GV oocytes (p < 0.05) and simi-
larly, old MII oocytes showed 23 down-regulated genes compared to young MII
oocytes (p < 0.05). The number of down-regulated genes in older GV and MII
oocytes signiﬁcantly affected pathways such as Double Strand Break (GV: 5;
MII: 6), Nucleotide excision repair (GV: 8; MII: 5), and DNA Damage Response
(GV: 4; MII: 8). The down-regulation in DNA repair gene expression of oocytes
from older females suggests a decrease in DNA repair capacity during IVF.
Limitations, reasons for caution: Ionizing radiation was used only for
experimental purposes, aiming for controlled levels of sperm DNA damage,
however it can also damage spermatozoa proteins. The female age groups
selected in mice were intended to model effects in young and old women, but
clinical studies are required to demonstrate a similar effect.
Wider implications of the ﬁndings: Fertilisation can occur with sperm
populations with medium and high DNA damage but subsequent embryo
growth is affected, and to a greater extent with aging females, supporting the
theory that oocyte DNA repair capacity decreases with age. The assessment of
oocyte DNA repair capacity could be a useful diagnostic tool.
Trial registration number:N/A.
O-004 Pronuclear transfer in zygotes from diet-induced obese
mice suggests a cytoplasmic origin of transgenerational
transmission of mitochondrial dysfunction leading to cardiac
dysfunction in offspring
K. Moley1, K. Latham2, J. Ferey3, M. Reid3
1Washington University School of Medicine, Obstetrics and Gynecology, St. Louis, U.
S.A.
2Michigan State University, Animal Science, East Lansing, U.S.A.
3Washington University, Obstetrics and Gynecology, St. Louis, U.S.A.
Study question: Is the epigenetic inheritance of mitochondrial dysfunction in
offspring from obese mothers of nuclear or mitochondrial DNA origin?
Summary answer: The cytoplasmic fraction of the zygote from obese mice
and not the pronucleus (PN) appears responsible for the abnormal cardiac
phenotype in the subsequent generations.
What is known already: Maternal obesity impairs offspring health. We have
previously shown that maternal programming of metabolic disease in offspring
can be passed through the maternal oocyte. Speciﬁcally, offspring from the
obese mice demonstrated signiﬁcant mitochondrial dysfunction and morpho-
logic changes in the heart leading to profound changes in cardiac function. We
showed by IVF with oocytes from the obese vs control mice that this pheno-
type was replicated in the IVF conceived pups, conﬁrming an oocyte origin. In
this study we use pronuclear transfer to distinguish nuclear vs mitochondrial
DNA contribution to the phenotype.
Study design, size, duration: C57Bl/6 females were fed high fat/high sugar
(HF/HS) diet vs control (CD) diet for 6-8 weeks and mated. One-cell zygotes
were recovered from both groups and four cohorts were created by control
PN transfer into enucleated HF/HS zygotes and visa versa. The manipulated
zygotes were transferred into pseudopregnant ICR females mice on a control
diet and weaned to CD. Cardiac function and heart tissues were obtained at 8
weeks.
Participants/materials, setting, methods: Four treatment groups were
created: 1) PN from HF/HS zygote transferred into enucleated zygote (EZ)
from CD; 2) PN from CD zygote into EZ from HF/HS; 3) PN from CD zygote
into EZ from CD; and 4) PN from HF/HS zygote into EZ from HF/HS. Cardiac
function was assessed by echocardiography (ECHO) and high resolution
respirometry was used to measure tissue oxygen consumption (Oxygraph).
Tissue morphology was analyzed by electron microscopy.
Main results and the role of chance: Offspring from zygotes created from
HF/HS cytoplasm and CD pronucleus demonstrated signiﬁcant alterations in
cardiac muscle morphology, and cardiac function as determined by Oxygraph
and ECHO. These changes were not seen in offspring from zygotes created
from CD cytoplasm and HF/HS pronucleus. The controls responded as pre-
dicted with no changes seen in the CD PN/CD cyto and signiﬁcant changes
seen in the HF/HS PN//HF/HS cyto. These ﬁndings suggest that the mito-
chondrial contribution, and most likely the mitochondrial DNA (mtDNA) from
the HF/HS zygotes in the cytoplasm, is responsible for the epigenetic changes
regulating the mitochondrial dysfunction phenotype in these mice. We have
shown previously that this change is seen for 3 generations, suggesting a trans-
generational inheritance.
Limitations, reasons for caution: Although this is a mouse study, the same
changes to mitochondrial function are also seen in human oocytes from obese
women. With pronuclear transfer it is difﬁcult to remove the PN without some
mitochondrial contamination. This could explain increased variability in this
study.
i2 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
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Wider implications of the ﬁndings: Epigenetic modiﬁcations to oocyte
mtDNA may occur as a result of maternal overnutrition and obesity. These
modiﬁcations affect mitochondrial function leading to cardiac dysfunction that
persists for three generations. These ﬁndings in mice may explain the epidemio-
logic data suggesting a strong correlation between maternal BMI and offspring
cardiovascular disease risk.
Trial registration number:N/A.
O-005 Tripolar mitosis underlies direct unequal cleavages in
human embryos and is associated with maternal genotype at a
quantitative trait locus spanning the centrosomal regulator PLK4
N. Zaninovic1, R.C. McCoy2, Q. Zhan1, E.R. Hoffmann3,
L.J. Newnham4, C.S. Ottolini5, Z.P. Demko6, Z. Rosenwaks1,
A.H. Handyside5
1Weill Cornell Medicine, The Center for Reproductive Medicine and Infertility, New
York- NY, U.S.A.
2Princeton University, Department of Ecology and Evolutionary Biology, Princeton, U.
S.A.
3University of Copenhagen, DNRF Center for Chromosome Stability- Department of
Cellular and Molecular Medicine, Copenhagen, Denmark
4University of Sussex- Brighton BN1 9RQ- UK, Genome Damage and Stability
Centre-, Brighton, United Kingdom
5University of Kent, School of Biosciences, Canterbury, United Kingdom
6Natera- Inc., Natera. Inc, San Carlos, U.S.A.
Study question: What causes blastomeres in diploid embryos to cleave into
three or more daughter cells during preimplantation embryo development, and
what is the underlying mechanism?
Summary answer: Direct unequal cleavages (DUCs) are induced by multi-
polar mitosis and are associated with common maternal genetic variants span-
ning PLK4, the master regulator of centrosome duplication.
What is known already: Multipolar mitosis (including tripolar mitosis, or
DUCs) has recently been documented in a substantial proportion (26%) of dip-
loid cleaving embryos based on time-lapse microscopy (TLM) and karyomap-
ping. DUCs exhibit reduced rates of blastocyst formation and implantation with
increased rates of complex aneuploidies. The gene Polo-like kinase 4 (PLK4)
plays an essential role as a master regulator of centrosome duplication. Altered
expression of PLK4 is associated with centrosome ampliﬁcation, generating
multipolar spindles. Chromosome segregation on multipolar spindles may in
turn induce complex aneuploidies. Common maternal genetic variants spanning
PLK4 have previously been associated with complex aneuploidies via an
unknown molecular mechanism.
Study design, size, duration: IVF cases that had previously undergone TLM
as well as SNP genotyping for PGT-A were included. A total of 58 IVF patients
with 742 embryos (77 biopsied on day 3 and 665 biopsied on day 5/6 embryos)
were analyzed.
Participants/materials, setting, methods: DUC embryos were identiﬁed
by TLM. DUC was deﬁned as cleavage of a single blastomere into 3+ daughter
blastomeres. Blastomeres (day 3) or trophectoderm cells (day 5/6) were used
for genotyping by SNP microarray. Copy number and parental origin of all chro-
mosomes were inferred from the SNP data using the Parental Support algo-
rithm. Binomial linear regression was used to test for an association between
the diploid tripolar pattern and maternal genotypes at rs2305957.
Main results and the role of chance: The diploid tripolar PGT-A signature
was signiﬁcantly enriched among blastomeres from embryos documented by
TLM to have undergone one or more tripolar mitosis (i.e., DUC) during the
ﬁrst three cleavage divisions compared to embryos that underwent normal
cleavage (i.e., Non-DUC; Fisher’s exact test: OR = 6.64 [95% CI: 1.34–37.4]; P
= 0.0087). The signature was most prevalent (up to 50%) among embryos
undergoing tripolar cleavage during the ﬁrst division (DUC-1) or undergoing
multiple tripolar cleavages (DUC-Plus), indicating that these cleavage pheno-
types may confer a wider distribution of abnormal cells at the time of biopsy.
For direct validation of the association with the maternal PLK4 genotype, data
from cases undergoing day-5 blastocyst biopsy were also incorporated, as the
availability of time-lapse data from these cases does not depend on embryo sur-
vival to the blastocyst stage. The minor allele of rs2305957 (“A” allele) was
positively associated with time-lapse–based incidence of tripolar mitosis (i.e.,
DUC; quasi-binomial GLM: OR = 1.53 [95% CI: 1.01–2.31]; P = 0.047).
Limitations, reasons for caution: Retrospective analysis with relatively few
genotyped patients and DUC embryos. PLK4 has yet to be validated as the cau-
sal gene, and the causal variant remains to be identiﬁed.
Wider implications of the ﬁndings: Our data support DUC/tripolar
mitosis as a key mechanism generating complex aneuploidies in cleavage-stage
embryos and implicate the maternal genotype at a quantitative trait locus span-
ning PLK4 as a factor inﬂuencing its occurrence. Our DUC data also elucidate
the molecular origins of chaotic aneuploidies affecting embryo development
and IVF success.
Trial registration number: none.
O-006 Factors associated with mitochondrial DNA (mtDNA)
levels in human blastocyst
J. Ortiz1, B. Lledo1, R. Morales1, A. Turienzo1, J. Ten2, J. Llacer3,
R. Bernabeu3
1Instituto Bernabeu, Biología Molecular y Genética, Alicante, Spain
2Instituto Bernabeu, Embriología, Alicante, Spain
3Instituto Bernabeu, Medicina Reproductiva, Alicante, Spain
Study question: Are embryo and maternal factors related with the mtDNA
content in human euploid blastocyst?
Summary answer: Maternal age, the day where the embryo biopsy is per-
formed and the embryo quality are associated with mtDNA levels in trophoec-
toderm biopsies.
What is known already: The main function of mitochrondria is to provide
energy by ATP production. The role of mitochondrial in the developing human
embryo is thought to be critical to a successful delivery. Although initial reports
supported the hypothesis that high levels of mtDNA in trophoectoderm biop-
sies are associated with low implantation potential, other publications were
unable to conﬁrm previous results. It is possible that unidentiﬁed counfounding
factors may inﬂuence the mtDNA copy number in euploid embryos. The aim of
this study is identiﬁed the main factors that could increase the mtDNA in
euploid blastocyst.
Study design, size, duration: A retrospective study was performed. We
included 159 blastocysts biopsies from 142 couples who attended to Instituto
Bernabeu for PGT-A from 2016 to 2017. The aneuploid testing was performed
by NGS using Veriseq® kit and the BlueFuse Multi software (Illumina). All blas-
tocysts were diagnosed as euploid non-mosaic. The mtDNA analysis were per-
formed once the diagnosis was known. We evaluated the relationship between
several maternal and embryo factors and trophoectoderm mtDNA levels.
Participants/materials, setting, methods: Sequencing reads mapping to
the mtDNA genome were extracted from bam ﬁles to identify copy number.
The relative measure of mtDNA copy number was calculated by diving the
mtDNA reads by the nuclearDNA value to normalize for technical variants and
the number of cells collected at the biopsy. All the results were subjected to
correction factor according to the embryo genome. The association between
variables and mtDNA was evaluated by logistic regression and chi-square
(Rv3.4).
Main results and the role of chance: Quantiﬁcation of mtDNA was suc-
cessful in all cases. The mean average of mtDNA was 0.0016 + 0.0012.
Concerning to maternal factors, there are not statistically signiﬁcant differences
according to the oocyte origin, donated or own oocyte (0.0017 vs 0.0017; p =
0.423). However, mtDNA was negatively correlated with female age when we
compare with different female age ranges (ranges 25y-30y: 0.0017, 30y-35y:
0.0012, 35y-40y: 0.0016, older 40 y: 0.0024, p = 0.044). At last, no signiﬁcance
differences were reported according to the indication for PGT-A recurrent
implantation failure (0.0016 vs 0.0015; p = 0.365) or repeated miscarriage
(0.0016 vs 0.0017; p = 0.523). With regard to embryo factors, embryos biop-
sied on day 5 were more likely to have higher quantities of mtDNA compared
with those biopsied on day 6 (0.0017 vs 0.0009; p = 0.0014). Embryo quality is
not associated with mtDNA (A:0.0017, B:0.0015, C: 0.0006; p = 0.304).
Finally, we also examined the possible relationship between the sex of the
embryo and mtDNA copy number. We did not observe any signiﬁcant
i3Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
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differences in mtDNA levels between male and female embryos (0.0016 vs
0.0016; p = 0.851).
Limitations, reasons for caution: Limitation may be due to the size of the
sample and the high-troughput sequencing technology. More research in the
mitochondrial function are needed. Evaluating the entire cohort of embryos
from each patient could detect patient variability.
Wider implications of the ﬁndings: Our data suggest that blastocyst from
older women had higher mtDNA, thus oocyte ageing could affect ooplasmic
factors. Moreover, our results show that the mtDNA in a given cell of an
embryo is dependent upon the cell divisions that preceded biopsy because high-
er mtDNA were found in D5 biopsied embryos.
Trial registration number:Not applicable.
O-007 Estimation of age-dependent decrease in blastocyst
euploidy in in vitro fertilization/intracytoplasmic sperm injection
cycles
S. Esteves1,3, P. Humaidan1,2, J. Carvalho4, M. Ciro5, A. Dias54,
C. Alviggi6, A. Conforti6, R. Fischer7, C. Andersen8, K. Bühler9,
F. Ubaldi10
1Faculty of Health, Aarhus University, Aarhus, Denmark
2Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark
3ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil
4Statistika Consulting, Campinas, Brazil
5Chromosome, Center for Genomic Medicine, São Paulo, Brazil
6Department of Neuroscience, Reproductive Science and Odontostomatology,
University of Naples Federico II
7Fertility Center Hamburg, Hamburg, Germany
8Laboratory of Reproductive Biology, University Hospital of Copenhagen, Faculty of
Health and Medical Sciences
9Center for Gynecology, Endocrinology, and Reproductive Medicine
10GENERA, Center for Reproductive Medicine, Rome, Italy
Study question: Is it possible to estimate the effect size of female age-
dependent decrease in the probability of a blastocyst being euploid?
Summary answer: The decrease in blastocyst euploidy is age-dependent,
progressing with every year of female age, from 1.2% to 24.5% in 28-44 years-
old women.
What is known already: Array comparative genomic hybridization (CGH)
data show that female age is the most signiﬁcant determinant of embryo genetic
status. Aneuploidy affects more than one-half of human embryos and is the
main reason for the decrease in live birth rate among aging women undergoing
Assisted Reproductive Technology (ART) cycles. However, estimation of the
age-dependent probability of a blastocyst being euploid and the effect size of
the decrease in this probability with every year of female age using next-
generation sequencing (NGS) analysis has not been performed yet.
Study design, size, duration: Retrospective analysis of 1,220 trophecto-
derm biopsies from 436 infertile couples undergoing intracytoplasmic sperm
injection and preimplantation genetic testing for aneuploidy (PGT-A) between
2016 and 2017. PGT-A was used for reasons of advanced maternal age, severe
male factor infertility, recurrent miscarriage, repeated implantation failure, as
well as patients who were concerned about euploidy of their embryos.
Participants/materials, setting, methods: Biopsied trophectoderm cells
were subjected to lysis, whole genome ampliﬁcation, construction of libraries,
and NGS using the Ion PGM™ platform. Logistic regression was ﬁt to the data-
set. The dependent and independent variables were embryo genetic status
(euploid/aneuploid) and female age, respectively. The method of ﬁtting was
quadratic on age, and the model was validated by splitting the data (80% and
20% to train and test the model respectively). Computations were performed
using JMP 13 (www.jmp.com).
Main results and the role of chance: The model is log[p(t)/(1−p(t))] =
7.575-0.21⋅age-0.011⋅(age-38.41)2, where p(t) is the probability of a blastocyst
being euploid for age (t) in years. There was no statistical evidence against the
ﬁtted model (p > 0.10). The model is not biased as there is linearity in the rela-
tionship between the estimated probability distribution and the distribution of
empirical data. The % decrease in probability from year (t) to year (t + 1) was
deﬁned as the ratio p(t + 1)/p(t)x100. There was a signiﬁcant (P < 0.0001)
decrease in the probability of a blastocyst being euploid with every year of
female age. The geometric mean of the yearly variation was 13.6%. However,
the decrease is progressive with every year of female age. At age 29 it was
1.2%, whereas at ages 30, 32, 35, 37, 39, 41 and 44, the decreases were 2.0%,
3.5%, 6.7%, 9.8%, 13.6%, 17.9%, and 24.5%, respectively.
Limitations, reasons for caution: The impact of other covariates that could
affect embryo genetic status and effect of cycle number were not analyzed.
Furthermore, the estimations cannot be generalized to IVF patients undergoing
cleavage-stage embryo transfer.
Wider implications of the ﬁndings: The decrease in the probability of a
blastocyst being euploid increases progressively with every year of female age,
from 1.2% to 24.5% in 28-44 years-old women. This information will aid clini-
cians counsel patients concerning their individual chances of having euploid blas-
tocysts for transfer.
Trial registration number:N/A.
O-008 Global DNAmethylation proﬁling of mouse embryo inner
cell mass following IVF
P. Rinaudo, A. Donjacour, X. Liu, E. Ruggeri
University of California, OB/GYN, San Francisco- CA, U.S.A.
Study question: Is preimplantation embryo culture (in vitro fertilization; IVF)
associated with global DNA methylation changes in the mouse inner cell mass
(ICM)?
Summary answer: Preimplantation embryo manipulation results in wide-
spread DNA methylation changes in ICM.
What is known already: Numerous imprinting disorders are correlated with
assisted reproductive technologies (ARTs) and animal models indicate that off-
spring generated by IVF have increased metabolic alterations in adulthood.
Given that the preimplantation embryos undergo dramatic changes in DNA
methylation, there is a need to understand the global DNA methylation changes
occurring in the embryo following embryo culture. Since the ICM will give rise
to the fetus and adult individual, limiting the analysis to this tissue will provide
valuable information regarding candidate gene alterations.
Study design, size, duration: Mouse blastocysts were obtained from CF-1
females crossed with B6D2F1 males and utilized for in vitro fertilization or
ﬂushed out of the uterus (FB = ﬂushed blastocyst = control). IVF was per-
formed using KSOM with amino acids and 5% O2.
Participants/materials, setting, methods: Blastocysts were collected (IVF
and in vivo) and immuno-surgery performed isolating ICM. Pooled ICM of IVF
or FB (n = 15/group, 2 replicates/group) were utilized for whole genome bisul-
ﬁte sequencing (WGBS). Methyl-MaxiSeq was used for WGBS and sequenced
on the Illumina HiSeq4000. Reads were mapped to the mouse genomes (mm9)
using Bismark and differentially methylated regions (DMR) identiﬁed using
BSSEQ Bioconductor package in R. DMR were functionally characterized using
Genomic Regions Enrichment of Annotations Tool (GREAT).
Main results and the role of chance: The low amount of starting material
allowed for an excellent quality but relatively low mapping efﬁciency (~ 12%).
As expected, only 20% of CpG were methylated, conﬁrming the low level of
DNA methylation in the blastocyst. There were 3195 differentially CpG methy-
lated regions (DMR: 1661 hypomethylated and 1534 hyper-methylated)
between IVF and control ICMs. The majority of DMR were located between 5
and 500 nucleotides from the transcription start site (TSS) and approximately
50% were located in the body of the genes.
The hypomethylated regions corresponded to genes whose function was
related to endosomal transport, regulation of neurotransmitter secretion, pro-
tein O-linked glycosylation, cytokinesis, ventricular development and adipose
tissue development,
The hypermethylated regions were in proximity of genes whose function was
involved in negative regulation of gliogenesis, cell junction assembly, gluconeo-
genesis, cellular response to peptide hormone stimulus, cell junction organiza-
tion, positive regulation of Rho GTPase activity.
Limitations, reasons for caution: The low amount of starting material (15
pooled ICM, corresponding to a total of approximately 200 cells) could intro-
duce ampliﬁcation errors.
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Wider implications of the ﬁndings: This is the ﬁrst report of global DNA
methylation changes in isolated ICMs of IVF or spontaneously conceived blasto-
cysts. The candidate gene identiﬁed as being differentially methylated in ICM of
IVF embryo can elucidate the phenotypic alterations noted in adult animal con-
ceived by IVF.
Trial registration number: not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 03: ENDOMETRIOSIS AND ENDOMETRIUM:
DISCOVERY SCIENCE
Monday 2 July 2018 Room 211 + 212 10:00–11:30
O-009 Discovery of novel loci for endometriosis in genome-wide
association analysis of 63 K cases and 700 K controls
N. Rahmioglu1, I. International Endometriosis Genomics
Consortium1, K. Zondervan1, A. Morris2
1University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, United
Kingdom
2Liverpool University, BIostatistics Department, Liverpool, United Kingdom
Study question:What common genetic variants and corresponding functional
mechanisms underlie endometriosis, and its surgical sub-types (ASRM-stages),
clinical sub-types (Infertile-endometriosis) and symptom-based sub-types
(Severe pelvic-pain with endometriosis)?
Summary answer: With the largest sample size to date for endometriosis
genome-wide-association-study (GWAS) meta-analysis, we expect to identify
many novel-susceptibility-loci for this debilitating condition and its sub-types.
What is known already: Endometriosis has an estimated heritability of ~
50%, with ~26% estimated to be related to common genetic variation. To date,
meta-analysis of endometriosis GWAS (17 K cases and 191 K controls) have
robustly identiﬁed 19 variants explaining 5.2% of disease variance. Previous
GWAS analyses also highlighted that the signals for most of the genome-wide
signiﬁcant loci are driven by ASRM stage III/IV disease, highlighting the need for
further phenotype-stratiﬁed analyses.
Study design, size, duration: IEGC consists of 25-centres contributing in
total, 63 K endometriosis cases, 7800 stage III/IV, and 700 K controls to the
GWAS meta-analysis. Some of these are population-based cohorts such as the
UK Biobank, and also clinical-investigations such as ENDOX, which is a pro-
spective study recruiting women undergoing laparoscopy, that has dense
clinical-phenotype data. Some of the centres have expression and eQTL-
datasets for endometrium, fat and ectopic-disease-tissue, allowing for evalu-
ation of functional mechanisms of the identiﬁed genetic variants.
Participants/materials, setting, methods: Each GWAS was imputed up
to reference panels from the Haplotype Reference Consortium or 1000
Genomes Project. Association testing by each centre was conducted in a
regression framework under an additive genetic model, with adjustment for
confounding due to population structure. Association testing was conducted
for overall, stage I/II, stage III/IV and infertile endometriosis groups.
Association summary statistics were aggregated across GWAS via ﬁxed-effects
meta-analysis.
Main results and the role of chance: The GWAS meta-analysis is on-going,
and results will be presented at the meeting. Preliminary results from the UK
Biobank (n = 8,190 cases) identiﬁed two novel associations at near genome-
wide signiﬁcance (p < 5 × 10-8) that map outside previously reported loci. The
ﬁrst maps to IGF2BP3 (rs550554633, p = 4.4 × 10-8), which is involved in regu-
lation of metabolism and adiposity, supporting the genetic link between endo-
metriosis and fat distribution. The second maps to GDAP1 (rs554964149, p =
7.2 × 10-8), which is involved in neuronal development that may play a role in
endometriosis-associated pain, and previously has been associated with pain
severity in dysmenorrhea. Moreover, a further 18 loci with nominal signiﬁcance
(p < 5 × 10-6) were identiﬁed, many of which are expected to increase in asso-
ciation strength in the complete IEGC meta-analysis.
Limitations, reasons for caution: For phenotype-stratiﬁed analysis we are
limited by the datasets with dense phenotypic data (i.e. infertility, pelvic pain
severity).
Wider implications of the ﬁndings: The identiﬁed genetic variants shed
light on the underlying pathogenesis of endometriosis and may point to novel
therapeutic interventions.
Trial registration number:N/A.
O-010 Understanding endometriosis heterogeneity—sub-
phenotype analysis of genetic associations
C.S.K. Cheuk1, N. Rahmioglu2, C. Becker1, K. Zondervan1
1University of Oxford, Nufﬁeld Department of Women’s and Reproductive Health,
Oxford, United Kingdom
2University of Oxford, Wellcome Centre for Human Genetics, Oxford, United
Kingdom
Study question: The aim of this study is to investigate whether sub-
phenotype analysis of established genetic variants associated with endometri-
osis reveals differential mechanisms underlying surgical and symptomatic sub-
types of the disease.
Summary answer: Preliminary results from a reduced dataset showed sug-
gestive differential effects for genome-wide association study (GWAS) loci
across surgical sub-phenotypes.
What is known already: Most of the known 14 genetic loci have been
reported based on association with overall endometriosis, with sub-phenotypic
investigations limited to ASRM stages I/II vs. III/IV. Studies using the World
Endometriosis Research Foundation-Endometriosis Phenome and Biobanking
Harmonisation Project (EPHect) standardized data collection protocols now
afford the investigation of these loci for detailed surgical and symptomatic
phenotypes.
Study design, size, duration: Cross-sectional study in which genotype infor-
mation from 358 women in the Oxford ENDOX study (294 cases, 64 controls)
undergoing laparoscopic surgery was analysed for association with EPHect-
compliant surgical and symptomatic phenotype data.
Participants/materials, setting, methods: Preliminary analysis of 108
endometriosis cases included 51% with an endometrioma (not exclusive to
other surgical subtypes), 68% with peritoneal disease and 31% with deep endo-
metriosis; 40%, 14%, 19% and 27% of women were diagnosed with ASRM
Stage I to IV respectively.
All 14 known GWAS loci for endometriosis were tested for association with
sub-phenotypes using Pearson’s chi-squared and linear-by-linear association
test.
Main results and the role of chance: The GWAS locus on 2q35
(rs1250241, located in FN1), with genotype T/A, showed a borderline associ-
ation (p = 0.035) with peritoneal endometriosis (odds ratio (OR) of TT vs. TA
= 0.08, 95% conﬁdence interval (CI): 0.01-0.78; OR of TT vs. AA = 0.13, 95%
CI: 0.01-1.25; OR of TA vs. AA = 1.68, 95% CI:0.69-4.07), but not with endo-
metrioma (p = 0.856) or deep endometriosis (p = 0.307). Analysis on add-
itional genotype data (n = 250) with more sub-phenotypes including infertility
and pain status are underway and results will be presented at the meeting.
Limitations, reasons for caution: Sample size was small in the preliminary
analysis, with limited power to discover differential association pattern.
Wider implications of the ﬁndings: Insight into aetiological heterogeneity
of endometriosis elucidated by genetics is an important avenue to ultimately
develop targeted non-invasive markers of disease and novel treatment
strategies.
Trial registration number:Not applicable.
O-011 Exosomes as biomarkers in endometriosis
H. Nazri1, M. Imran2, R. Fisher3, B. Kessler3, K. Zondervan1,
T. Tapmeier1, C. Becker1
1University of Oxford, Nufﬁeld Department of Women’s and Reproductive Health,
Oxford, United Kingdom
2Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom
3Nufﬁeld Department of Medicine, Target Discovery Institute, University of Oxford
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Study question: Could exosomes be considered as biomarkers of
endometriosis?
Summary answer: Potentially – we found exosomes in peritoneal ﬂuid of
endometriosis and control samples. The differences observed in number and
size likely translates into qualitative differences.
What is known already: Endometriosis, the presence of endometrial lesions
outside the uterus, is a common condition affecting up to 10% of women of
reproductive age. Patients suffer from pain and infertility. The current diagnostic
model relies on non-speciﬁc symptoms, the (inconsistent) application of endo-
metriosis risk factors, and invasive diagnostic laparoscopy as the gold standard.
There is no clinically relevant biomarker for endometriosis yet.Recently, nano-
sized extracellular vesicles – exosomes – produced by virtually every cell, have
been described in diseases such as cancer, diabetes and pre-eclampsia.
Exosomes could similarly be important in endometriosis and serve as biomar-
kers of the disease.
Study design, size, duration: Peritoneal ﬂuid (PF) samples were obtained
from participants in the ENDOX study at the Endometriosis CaRe Centre,
Nufﬁeld Department of Women’s and Reproductive Health, University of
Oxford (REC ref. 09/H0604/58) under WERF EPHect standards. Women
between 18-49 years of age (n = 28) who had undergone diagnostic laparos-
copy for abdominal or pelvic pain and/or subfertility investigation were classi-
ﬁed according to menstrual cycle phase (proliferative or secretory) and severity
of endometriosis (ASRM stages I + II or stages III + IV).
Participants/materials, setting, methods: Groups, control proliferative,
n = 4; control secretory, n = 2; StI+II proliferative, n = 9; StI+II secretory, n =
7; StIII+IV proliferative, n = 3; StIII+IV secretory, n = 3. Exclusion criteria:
Hormonal treatment, malignancy, pregnancy, breastfeeding and inability to
understand the consent form. 1 mL PF was centrifuged to remove cells, debris
and microvesicles. Exosomes were enriched by size-exclusion chromatography
and conﬁrmed by nanoparticle tracking analysis (NTA), immunoblotting and
transmission electron microscopy (TEM). The study of exosome cargo by mass
spectroscopy and RNA-sequencing is ongoing.
Main results and the role of chance: We conﬁrmed the presence of exo-
somes in PF from women at different stages of endometriosis and from disease‐
free patients at different menstrual cycle phases by TEM (n = 6 pooled group
samples) and NTA (n = 6 pooled group samples). Enriched exosomes were
positive for CD9 and Syntenin. The mean size of PF particles from women with
endometriosis was 217 ± 11.2 nm (n = 4 pooled group samples), whereas in
non-endometriotic women it was 182.9 ± 9.11 nm (n = 2 pooled group sam-
ples). We observed a higher concentration of PF particles in stage I-II endomet-
riosis compared to controls in both proliferative and secretory phases (p <
0.0001) (n = 2 pooled group samples). In stage III-IV endometriosis, the oppos-
ite was seen in the proliferative phase (p < 0.0001) (n = 2 pooled group
samples).
Limitations, reasons for caution: Due to the very limited material
obtained, PF samples had to be pooled according to menstrual cycle phases and
ARSM staging for analyses.
Wider implications of the ﬁndings: The difference in concentration and
size of exosomes in the patient groups is likely to translate into qualitative differ-
ences in exosome populations given genetic and phenotypic differences in
endometriosis of different stages. This will be shown by the pending proteomics
and RNA-seq results.
Trial registration number:Not applicable.
O-012 The baboonmiRNAome: small RNA sequencing of 25
baboon tissues
A. Vanhie1, D. Chai2, A. Nyachieo2, D. O3, D. Peterse3,
C. Meuleman1, P. Mestdagh4, T. D’Hooghe3
1University Hospital Leuven, Obstetrics and Gynaecology, Leuven, Belgium
2Institute of Primate Research, Reproductive Sciences, Nairobi, Kenya
3KU Leuven, Development and Regeneration, Leuven, Belgium
4UGent, Center for Medical Genetics, Ghent, Belgium
Study question: Can we identify orthologous miRNAs between baboons
(papio Anubis) and humans through deep sequencing of baboon RNA and
annotation to the human genome.
Summary answer: Mapping of the small RNA sequencing reads from a
pooled baboon sample to the human genome identiﬁed 941 orthologous
miRNAs between humans and baboons.
What is known already: Baboons (papio Anubis) are a very good model for
reproductive research because of the small phylogenetic gap and the very high
similarity in reproductive physiology and anatomy. They have been used to
study endometriosis, embryo-implantation, uterine transplantation and in the
development of contraceptives. MicroRNAs are important gene expression
regulators and their role in the pathophysiology of several reproductive diseases
has been implicated. The use of baboons in miRNA research is currently limited
because only a few miRNA genes have been described and annotated.
Study design, size, duration: One baboon was euthanized and during post-
mortem examination biopsies of 25 tissues were collected and snap frozen
(ovary, endometrium, myometrium, fallopian tube, cervix, heart, aorta, lung,
kidney, liver, pancreas, bladder, peritoneum, lymph nodes, muscle, spleen, skin,
tongue mucosa, rib cartilage, stomach mucosa, thyroid glands, pituitary glands,
intestine, brain cortex, plasma). Prior to RNA extraction tissue samples were
subsampled using a microtome (10-12 scrolls of 55 μm thickness/samples) and
stored in Qiazol reagent (Qiagen).
Participants/materials, setting, methods: RNA was isolated using the
miRNeasy serum/plasma kit (Qiagen) and the miRNeasy mini kit (Qiagen).
RNA of the 25 samples was pooled and processed as a single sample pool using
the TruSeq small RNA library preparation kit (Illumina). Single end sequencing
was performed (140 million reads, read length 75 nt) on a NextSeq 500
sequencer (Illumina). After ﬁltering and adapter trimming, the reads were col-
lapsed, mapped and annotated to the human reference genome.
Main results and the role of chance: Quality of the extracted RNA was
assessed by determining RNA concentration (Qubit 2.0 ﬂuorometer, Thermo
Fisher Scientiﬁc) and RNA integrity (Fragment Analyzer automated capillary
electrophoresis system, Advanced Analytical Technologies). On average, an
RNA concentration of 783 ng/μl and an RNA Quality Number (RQN) value of
8.1 was obtained. In total, 143 million sequencing reads were generated. Read
length distribution and annotation was evaluated to ensure enrichment of
miRNAs in the 20-24 nucleotide read fraction. Mapping the baboon sequencing
reads to the human reference genome, allowing no mismatches, detected 708
mature canonical miRNAs with identical nucleotide sequences in baboons
(papio Anubis) and humans. In a second step, the unmapped fraction of sequen-
cing reads was remapped allowing 1 and 2 mismatches, respectively. This
resulted in the detection of 233 additional miRNAs. In total, 941 unique
miRNAs were detected (708 with 0 mismatches, 749 with 1 mismatch, 607
with 2 mismatches). Because of the very high sequence homology between
baboons and humans these 941 miRNAs can be considered as orthologous
between humans and baboons.
Limitations, reasons for caution: In this study we analyzed 25 tissue sam-
ples from one baboon. Validation in more animals is required. Analysis of other
tissues than those included or deep sequencing of the individual tissues included
in this study could identify other miRNAs with tissue speciﬁc or very low levels
of expression.
Wider implications of the ﬁndings: The identiﬁcation of orthologous
miRNAs in baboons is a ﬁrst step in establishing the baboon miRNAome and
will facilitate miRNA research in baboons. All our data will be made open
access and online available so they can be used by other researchers to develop
primers for their miRNAs of interest.
Trial registration number:Not applicable.
O-013 Human endometrium demonstrate a dynamic TERRA
expression and hormone regulation: implications in endometrial
proliferative conditions
M. Adishesh1, R. Alnafakh1, J. Drury2, G. Saretzki3, B. Decruze4,
D. Hapangama1
1Institute of Translational Medicine- University of Liverpool, Women’s Health,
Liverpool, United Kingdom
2Institute of Translational Medicine - University of Liverpool, Women’s Health,
Liverpool, United Kingdom
3Institute for Cell and Molecular Biosciences and Newcastle University Institute for
Ageing, Ageing Research, Newcastle, United Kingdom
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4Liverpool Women’s Hospital, Gynaeoncology, Liverpool, United Kingdom
Study question: Does healthy endometrium express TERRAs and is their
expression altered with endometrial proliferative conditions and by ovarian
steroid hormones?
Summary answer: Healthy human endometrium expressed TERRAs with an
individual TERRA-speciﬁc dynamic thus hormonally regulated expression pat-
tern and an altered expression observed in endometrial pathologies.
What is known already: Telomeres are transcribed as long non coding
RNAs, called TERRAs (Telomeric repeat containing RNA) that are proposed
to participate in a variety of cellular regulatory functions and DNA damage
response activation. Endometrial telomere transcription has not yet been stud-
ied. Telomere length and telomerase activity change according to ovarian hor-
mones in the human endometrium and high telomerase is associated with
endometrial proliferative conditions, such as endometriosis and endometrial
cancer. The effect of ovarian steroid hormones on telomere transcription in
human endometrium is not known.
Study design, size, duration: A prospective observational study, included
endometrial biopsies of 66 women was carried out in the academic labs of
University of Liverpool/ Liverpool Women’s Hospital.
Participants/materials, setting, methods: Endometrial samples were col-
lected from women with (n = 10) or without endometriosis (n = 16), women
using mirena (n = 9), healthy postmenopausal (PM) women (n = 7) and women
with endometrial cancer (EC, n = 24). Ethical approval was obtained from
Liverpool Adult Local Research Ethics Committee (LREC) and informed written
consent was obtained from all patients. Endometrial samples analysed for
TERRA (chromosome 1, 16, 20) and hTERC levels by qPCR, TRAP assay, ki67
proliferative index and steroid receptor expression by immunohistochemistry.
Main results and the role of chance: All three TERRAs from chromosomes
1, 16, and 20, were expressed in the human endometrium. Pre-menopausal
endometrial TERRAs did not change according to cycle phase but Ch-20
TERRA levels were signiﬁcantly increased in the PM samples compared with
premenopausal proliferative phase (p = 0.017). There were no signiﬁcant differ-
ences in TERRA levels in the secretory phase endometrium of women with
endometriosis compared with the healthy women without endometriosis (p >
0.05), however the hTERC mRNA levels were signiﬁcantly upregulated in
secretory endometrium of women with endometriosis (p = 0.02). EC samples
had signiﬁcantly reduced levels of Ch-16 and Ch-20 TERRA (p = 0.001; p =
0.000 respectively) compared to PM endometrium. Ch-16 TERRA levels posi-
tively correlated with hTERC but none of the TERRA levels correlated with tel-
omerase activity (TRAP assay). Ch-16 TERRA levels negatively correlated with
progesterone receptor and both Ch-16 and Ch-20 TERRA levels negatively
correlated with the proliferative marker Ki67 (p = 0.03; p = 0.009 respect-
ively). Treatment of local progesterone, Mirena did not signiﬁcantly changed
TERRA levels compared with untreated proliferative endometrium. TERRA
expression was found to be downregulated with in vitro treatment with proges-
terone and also combined oestrogen and progesterone treatment for 72 hrs (p
= 0.02 and p = 0.04 respectively).
Limitations, reasons for caution: This is an observational study including a
modest samples number including only three different TERRAs. However, cor-
responding Telomerase and hTERC levels, proliferative indices of the samples
are included to examine TERRA levels in the context of cellular proliferation
and telomerase biology.
Wider implications of the ﬁndings: The negative correlation of TERRA
with cellular proliferation, signiﬁcant reduction in endometrial cancer and their
hormonal regulation indicate a regulatory role for TERRA in the human endo-
metrium. Further studies are warranted to explore TERRAs as therapeutic tar-
gets in endometrial pathologies.
Trial registration number:Not applicable.
O-014 CAS as a novel interacting protein of CD147 is involved in
the epithelial-to-mesenchymal transition in human endometriosis
H. Chen1, C.Wang2, J. Liu1, M. Ye1, K.L. Fok2, H.C. Chan2
1Guangdong University of Technology, Institute of Biomedical and Pharmaceutical
Sciences, Guangzhou, China
2The Chinese University of Hong Kong, Epithelial Cell Biology Research Center, Hong
Kong, Hong Kong
Study question: Does the elevated CD147 regulate the epithelial-to-
mesenchymal transition (EMT) during endometriosis progression?
Summary answer: A novel CD147-interacting protein, CAS was identiﬁed.
The upregulation of CD147 led to the disruption of CAS/E-cadherin/β-catenin
complex, which promoting EMT of endometriotic cells.
What is known already: Our previous studies have demonstrated elevated
CD147 in the ovarian endometriosis with enhanced cell survival.
Study design, size, duration: Experimental clinical study and laboratory-
based investigation. The endometriotic lesions samples were collected from 47
ovarian endometriosis women, and the normal endometrial tissues were col-
lected from 12 women without endometriosis and endometritis. CD147 and
CAS overexpression or knockdown in human endometrial Ishikawa cells (ISK)
were designed to examine the effect on cell migration and EMT marker and
related signaling.
Participants/materials, setting, methods: Expression levels of CAS were
evaluated in endometriotic tissues by quantitative real-time polymerase chain
reaction (qPCR) and western blot. The interactions of CD147, CAS and E-
cadherin were conﬁrmed by co-immunoprecipitation. ISK cells were trans-
fected with the CD147-overexpressing plasmid or infected with lentivirus pack-
aged human CAS. CAS-knockdown was achieved by transfection of CAS
siRNA in ISK cells. Gene-manipulated ISK cells were used to do cell migration
and invasion assay or explore the signaling pathway.
Main results and the role of chance: In human endometriotic tissues, both
mRNA and protein expression levels of CAS were signiﬁcantly decreased in
endometriosis lesions with elevated expression of CD147. We next deter-
mined a complex formed with CD147/CAS/E-cadherin, which stabilized the
interaction between E-cadherin and β-catenin. Furthermore, overexpression of
CD147 disrupted the interaction between CAS and E-cadherin, resulting in the
EMT process via the release of β-catenin from CAS/E-cadherin/β-catenin com-
plex. Of note, overexpression of CD147 or knockdown CAS led to the nuclear
translocation of β-catenin and further activated its downstream EMT signaling
such as EMT-promoting gene Snail. In addition, overexpression of CAS was
able to inhibit the migration and invasion capacity in CAS-overexpressing ISK
cells.
Limitations, reasons for caution: In vivo study is lacking to further conﬁrm
the function of CD147 and CAS in animal models.
Wider implications of the ﬁndings: The demonstrated increase of cell
migration and invasion through CD147-CAS-E-cadherin interactions suggest
the involvement of the CD147-regulated signaling in the progression of human
endometriosis and provide potential targets for endometriosis treatment.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 04: RECURRENT IMPLANTATION FAILURE
ANDUNEXPLAINED INFERTILITY
Monday 2 July 2018 Room 111 + 112 10:00–11:30
O-015 Androgen receptor (AR) mRNA expression is positively
associated with live birth in women undergoing in-vitro fertilization
independently of the type of ovarian response
C. Vaitsopoulou1, E. Kolibianakis1, E. Neofytou1, A. Makedos1,
M. Malandri1, A. Kalpatsanidis1, J. Bosdou1, D. Sabbaidou1,
K. Chatzimeletiou1, S. Lymperi1, A. Lambropoulos2, G. Grimbizis1,
B. Tarlatzis1
1Medical School- Aristotle University of Thessaloniki, Unit of Human Reproduction-
1st Department of Obstetrics and Gynecology, Thessaloniki, Greece
2Medical School- Aristotle University of Thessaloniki, Laboratory of Molecular Biology-
General Hospital of Thessaloniki “Papageorgiou”, Thessaloniki, Greece
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Study question: Is androgen receptor (AR) mRNA expression associated
with live birth in normal and poor responders undergoing in-vitro fertilization
(IVF)?
Summary answer: AR mRNA expression is positively associated with live
birth in women undergoing in-vitro fertilization independently of the type of
ovarian response.
What is known already: AR is a steroid hormone receptor that regulates
various genes’ expression and affects cellular proliferation and differentiation.
Androgens interact with AR, exert their paracrine action on granulosa cells and
regulate gonadotropin synthesis, follicle development, oocyte maturation and
corpus luteum function. Estrogens increase AR mRNA and testosterone binding
site in uterine endometrium and leiomyoma. In human cancer cells, low estra-
diol increases AR levels, suggesting the estrogen/androgen ratio as a predictor
of sex steroid response. AR mRNA expression is, also, regulated by progester-
one. Although AR mRNA is expressed in the female reproductive tissues, its
expression has never been studied in peripheral blood.
Study design, size, duration: A prospective clinical trial was performed
from 2014 to 2017, in 40 normal responders and 27 poor responders according
to Bologna criteria, undergoing IVF/ICSI. Ovarian stimulation was performed
with 200 IU recombinant follicle stimulating hormone (rFSH) and gonado-
trophin releasing hormone (GnRH) antagonists. Triggering of ﬁnal oocyte mat-
uration was performed by recombinant human chorionic gonadotrophic
(rhCG).
Participants/materials, setting, methods: Vaginal ultrasound evaluation
of follicular development, peripheral blood collection for RNA extraction, c-
DNA synthesis, mRNA expression and hormonal assessments were performed
on days 1, 6 and 10 of stimulation. Serum FSH, luteinizing hormone (LH), estra-
diol and progesterone were measured by ELISA. AR mRNA expression was
evaluated by Real-time PCR and analyzed by the ΔΔCT method. Statistical ana-
lysis was performed using multivariable analysis.
Main results and the role of chance: On day 6 of stimulation, AR mRNA
expression was negatively associated with LH level (p = 0.027), adjusting for
patient type. On day 10 of stimulation, AR mRNA expression was negatively
associated with estradiol (p = 0.010) and progesterone (p < 0.001) levels,
adjusting for patient type. Concomitantly, AR mRNA expression was positively
associated with the number of developing follicles (11-17 mm) (p = 0.010),
adjusting for patient type. Achievement of live birth was positively associated
with AR mRNA expression prior to initiation of stimulation (p < 0.001), adjust-
ing for female age and number of embryos transferred.
Limitations, reasons for caution: This is the ﬁrst study of AR mRNA
expression in peripheral blood mononuclear cells during ovarian stimulation for
IVF. However, it is performed on a limited number of normal and poor
responders.
Wider implications of the ﬁndings: If the association of AR mRNA expres-
sion with live birth is conﬁrmed in further studies, its assessment prior to initi-
ation of ovarian stimulation, could be used as a novel prognostic factor for the
achievement of pregnancy regardless of the type of ovarian response.
Trial registration number:NCT01984286
O-016 Endometrial receptivity analysis (ERA) using a next
generation sequencing (NGS) predictor improves reproductive
outcome in recurrent implantation failure (RIF) patients when
compared to ERA arrays
M. Clemente-Císcar1, M. Ruiz-Alonso2, D. Blesa3, J. Jimenez-
Almazan1, M. Bahceci4, M. Banker5, I. Vladimirov6, S. Mackens7,
C. Miller8, D. Valbuena2, C. Simon9,10,11,12
1Igenomix S.L., Department of Bioinformatics, Valencia, Spain
2Igenomix S.L., Medical Department, Valencia, Spain
3Igenomix S.L., Department of Product Development, Valencia, Spain
4Bahceci Fulya IVF Centre, Director of Gynecology and Obstetrics, Istambul, Turkey
5Nova Pulse IVF Clinic, Director of Reproductive Medicine, Ahmedabad, India
6SBALAGRM-Soﬁa, Director IVF unit, Soﬁa, Bulgaria
7Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussels, Belgium
8The advanced IVF Institute - Charles E. Miller- MD & Associates, Director of
Obstetrics and Gynecology, Illinois, U.S.A.
9Igenomix S.L., Scientiﬁc Director, Valencia, Spain
10Baylor College of Medicine, Department of Obstetrics and Gynecology, Texas, U.S.A.
11Stanford University, Department of Obstetrics and Gynecology, California, U.S.A.
12University of Valencia/INCLIVA, Department of Obstetrics and Gynecology,
Valencia, Spain
Study question: Does next generation sequencing (NGS) based endometrial
receptivity analysis (ERA) predictor improve reproductive outcome in recurrent
implantation failure (RIF) patients when compared to arrays based ERA
predictor?
Summary answer: Reproductive outcome in RIF patients increases signiﬁ-
cantly when performing personalized embryo transfer (pET) based on ERA
NGS predictor compared to previous ERA arrays predictor.
What is known already: ERA identiﬁes the window of implantation (WOI)
of a given patient based on the transcriptomic signature of 236 genes in an
endometrial biopsy. Subsequently, it allows pET according to this ERA result.
Several groups have reported that pET increases pregnancy rates (PR) and
implantation rates (IR) in RIF patients (Ruiz-Alonso 2013; Mahajan 2015;
Hashimoto 2017; Tan 2018). To improve the diagnostic accuracy and repro-
ductive outcome in RIF patients of endometrial origin, a NGS ERA predictor
based on our experience with more than 20,000 endometrial samples, has
recently been developed.
Study design, size, duration: This study comprises NGS predictor develop-
ment and clinical follow-up to validate its diagnostic accuracy after pET. The
NGS predictor was developed by sequencing 411 endometrial biopsies previ-
ously diagnosed by arrays. Then, 1,432 endometrial biopsies (716 patients with
two endometrial samples per patient) were used for prediction analysis. Clinical
follow-up of the NGS predictor was performed in 261 patients collected from 5
different clinics. These clinical results were compared with previously known
outcome using ERA arrays.
Participants/materials, setting, methods: Endometrial biopsies were col-
lected using a pipelle catheter during the expected WOI in natural cycles (at
LH + 7) or hormone replacement therapy cycles (at P + 5). RNA was
extracted and sequenced using the ERA gene panel. Several machine learning
methods were compared to select the one with better performance. A statis-
tical proportion test was used for reproductive outcome comparison between
samples diagnosed with NGS ERA predictor and arrays ERA predictor.
Main results and the role of chance: The machine learning method with
best performance was Random Forest, with a global accuracy of 0.88, sensitivity
0.90 and speciﬁcity 0.97. Reproductive outcome for RIF patients performing
arrays based ERA and subsequent pET was obtained based on results from 352
patients (age: 37.4 ± 4.2) previously published (Ruiz-Alonso 2013; Ruiz-Alonso
2014; Mahajan 2015; Hashimoto 2017). PR was 56.5%, IR 39.9% and ongoing
pregnancy per transfer (OT) of 43.2%. The clinical follow-up after pET based
on NGS ERA predictor in 261 patients (age: 37.3 ± 5.1), however, was 70.9%
PR, 55.7% IR and 59.4% OT. The reproductive outcome comparison thus
shows a signiﬁcant increase in PR (p-value = 0.000390), IR (p-value =
0.000003) and OT (p-value = 0.000101) in case of NGS ERA predictor.
Limitations, reasons for caution: The failure of an embryo to implant is a
complex process that not only involves endometrial receptivity but also embryo
quality. ERA only focuses on the endometrial origin or contribution of RIF.
Wider implications of the ﬁndings: These results demonstrate that the
ERA NGS predictor enhances the clinical effectiveness of endometrial diagnosis
in RIF patients when compared to ERA arrays predictor. This more accurate
predictor tool, based on a wide reference set of samples with known clinical
result, has led to signiﬁcantly better reproductive outcome following pET.
Trial registration number:Not apply.
O-017 Interventions for unexplained infertility: a systematic
review and networkmeta-analysis
R.Wang1, N.A. Danhof2, R.I. Tjon-Kon-Fat2, M.J.C. Eijkemans3,
P.M.M. Bossuyt4, M. Mochtar2, F. Van der Veen2, S. Bhattacharya5,
B.W.J. Mol6, M. VanWely2
1Robinson Research Institute, University of Adelaide, Adelaide, Australia
2Center for Reproductive Medicine, Academic Medical Center, University of
Amsterdam
3Department of Biostatistics and Research Support, Julius Center, UMC Utrecht
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5Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, united
Kingdom
6Department of Obstetrics and Gynaecology, Monash University and Monash Health,
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Study question: Which is the most effective and safe intervention in couples
with unexplained infertility, expectant management, ovarian stimulation (OS),
intrauterine insemination (IUI), OS-IUI or IVF?
Summary answer: IVF and OS-IUI were the most effective but least safe
interventions, while expectant management and IUI were the least effective but
safest interventions.
What is known already: Existing systematic reviews have conducted head to
head comparison of interventions using pairwise meta-analyses to evaluate the
effectiveness of interventions in couples with unexplained infertility. As this
approach only allows the comparison of two interventions at a time and is
dependent on the availability of appropriate primary evaluative studies, it is difﬁ-
cult to identify the best intervention in terms of effectiveness and safety.
Network meta-analysis compares multiple treatments in a single statistical mod-
el by using both direct and indirect evidence and provides a hierarchy of these
treatments which can better inform clinical decision making.
Study design, size, duration: We performed a systematic review and net-
work meta-analysis of relevant randomised controlled trials (RCTs). We
searched electronic databases including MEDLINE, Embase, PsycINFO,
CINAHL, the Cochrane Gynaecology and Fertility Group specialised register of
controlled trials, the Cochrane Central Register of Studies Online, as well as ref-
erence lists to identify eligible studies. We also searched trial registers for
ongoing trials.
Participants/materials, setting, methods: We included RCTs comparing
at least two of following interventions in couples with unexplained infertility: 1)
expectant management (including timed intercourse); 2) ovarian stimulation
using gonadotropins, aromatase inhibitors or anti-estrogens; 3) IUI alone; 4)
OS-IUI; and 5) in vitro fertilisation (IVF) or combined with intracytoplasmic
injection (ICSI). The primary effectiveness outcome is a composite of cumula-
tive live birth or ongoing pregnancy and the primary safety outcome is multiple
pregnancy.
Main results and the role of chance: Of 906 titles and abstracts initially
identiﬁed, we included 29 trials reporting on 4514 couples with unexplained
infertility. The most frequent direct comparisons were OS versus OS-IUI (7
studies, 743 couples), OS-IUI versus IVF (6 studies, 1101 couples), and IUI ver-
sus OS-IUI (6 studies, 895 couples). Thirteen studies reported data on live birth
or ongoing pregnancy in 3181 couples and 15 studies reported data on multiple
pregnancy in 2834 couples.
Network meta-analysis showed that IVF resulted in more live births/ongoing
pregnancies than expectant management (OR 2.87, 95%CI 1.31-6.29) and OS
(OR 2.63, 95%CI 1.12-6.17); and it may also result in more live birth/ongoing
pregnancies than IUI alone (OR 1.98, 95%CI 0.99-3.97) and OS-IUI (OR 1.58,
95%CI 0.96-2.59). OS-IUI may lead to higher live birth/ongoing pregnancy rate
compared to expectant management (OR 1.82, 95%CI 0.98-3.39). The ranking
showed that IVF was the most effective intervention, followed by OS-IUI, IUI
alone and OS alone, with expectant management as the least effective interven-
tion. Both IVF and OS-IUI resulted in more multiple pregnancies compared to
IUI alone (OR 5.08, 95%CI 1.15-22.51; OR 5.55, 95%CI 1.34-23.06). There
were no signiﬁcant differences in multiple pregnancy between other
interventions.
Limitations, reasons for caution: The included studies were heteroge-
neous in study population, treatment protocol and duration of follow-up. IVF in
earlier studies was not always applied with single embryo transfer. Also long-
term safety was not considered. As multiple pregnancy was not reported in
many early publications, our ﬁndings should be interpreted with caution.
Wider implications of the ﬁndings: In couples with unexplained infertility,
IVF provides the fastest way to have a baby while OS-IUI is also a competitive
intervention. Both long-term safety of the offspring and ﬁnancial costs should be
considered in the timing of IUI and IVF in the context of shared decision
making.
Trial registration number: not applicable.
O-018 Infertility diagnosis in female adolescent and young adult
survivors of non-gynecological cancers: a population-based cohort
study
M.P. Velez1, N.N. Baxter2, R. Barr3, E.M. Greenblatt4, K. Lajkosz5,
A. Korkidakis6, H. Richardson7, C.M. Booth8, T.P. Hanna8, A.
G. Robinson8, M. Green9
1Queen’s University, Obstetrics and Gynecology, Kingston, Canada
2University of Toronto, Dalla Lana School of public Health, Toronto, Canada
3McMaster University, Department of Pediatrics, Hamilton, Canada
4Mount Sinai Hospital, Department of Obstetrics and Gynecology, Toronto, Canada
5Queen’s University, ICES Queen’s, Kingston, Canada
6Queen’s University, Department of Obstetrics and Gynecology, Kingston, Canada
7Queen’s University, Department of Public Health Sciences, Kingston, Canada
8Queen’s University, Department of Oncology, Kingston, Canada
9Queen’s University, Department of Family Medicine, Kingston, Canada
Study question: Do female adolescent and young adults (AYAs) survivors of
selected non-gynecological cancers have a higher risk of subsequent infertility
diagnosis than AYAs without cancer?
Summary answer: Female AYAs survivors of certain non-gynecological can-
cers have a higher risk of subsequent infertility diagnosis. The risk is inﬂuenced
by previous parity.
What is known already: Cancer therapies have improved substantially, lead-
ing to dramatic increases in survival. As survival improves, there is increasing
emphasis on optimizing quality of life among survivors. Many cancer therapies
increase the risk of infertility. At this time, no population-based studies have
been conducted to determine the risk of subsequent infertility diagnosis in
female AYAs with non-gynecological cancers. The literature is limited to epi-
demiological studies comparing birth rates after cancer, or small studies using
markers of the ovarian reserve as a proxy of infertility.
Study design, size, duration: A population-based cohort study using universal
health care databases in the province of Ontario, Canada. All women 15-39 years
of age diagnosed with brain, breast, hematological, head/neck, thyroid, melanoma,
colorectal, or urological cancer from 1992-2011 who lived at least 5 years
recurrence-free were identiﬁed (Exposed, n = 15107). Each cancer survivor was
matched by age, census subdivision, and parity to 5 randomly selected cancer-free
women (Unexposed, n = 64314), and followed subjects until December 31, 2016.
Participants/materials, setting, methods: Infertility diagnosis after one
year of cancer was identiﬁed using information on physician billing claims
through the Ontario Health Insurance Plan database (ICD-9 code). Women
with infertility, tubal ligation, bilateral oophorectomy, or hysterectomy previous
to cancer diagnosis were excluded. Log-binomial regression models were used
to calculate the risk of infertility diagnosis adjusted for sociodemographic factors
(adjusted Relative Risk -aRR). Adjusted models were further stratiﬁed by parity
at the time of cancer diagnosis (nulliparous and parous).
Main results and the role of chance: Mean age at cancer diagnosis was 31.2
years (SD 6.3). The median follow-up time for cancer survivors was 13.9 years and
for unexposed women 14.3 years (p < 0.001). Overall, the frequency of infertility
diagnosis was higher in cancer survivors compared to unexposed women (12.0% vs.
9.4%, p < 0.001). Mean age of infertility diagnosis was 34.5 years (SD 5.7) in survi-
vors and 34.9 years (SD 5.5) in unexposed women (p < 0.001). Differences
between AYAs survivors and unexposed women varied by type of cancer, notably
survivors of breast (aRR 1.38; 95% CI 1.23–1.55), hematological (aRR 1.42; 95% CI
1.28-1.59), thyroid (aRR 1.17; 95% CI 1.08–1.27), and melanoma (aRR 1.13; 95%
CI 0.99-1.30), had a higher risk of infertility diagnosis than women without cancer.
After stratiﬁcation by parity, the association remained strong in nulliparous survivors
of breast and hematological cancers, while it disappeared in parous women. Parity
did not modify the effect on infertility in survivors of thyroid cancer, and the associ-
ation remained signiﬁcant in both groups. In survivors of melanoma and urological
cancer a signiﬁcant association was observed only in nulliparous women. Survivors
of brain, head/neck, and colorectal cancers did not have a higher risk of infertility
diagnosis compared to women without cancer.
Limitations, reasons for caution: The accuracy of infertility diagnosis using
ICD-9 codes in administrative datasets has not been validated. Non-biologic
factors that may inﬂuence the likelihood of seeking a fertility assessment may
not be captured in administrative databases. Information regarding cancer stage
or treatment was not available for this analysis.
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Wider implications of the ﬁndings: Reproductive health surveillance in
female AYAs with cancer is a priority, especially those with breast and hemato-
logical cancer diagnoses. Our ﬁnding of a potential effect of thyroid cancer (sub-
ject to over-diagnosis) and melanoma needs to be further studied, and if any
effect is conﬁrmed, possible mechanisms elucidated.
Trial registration number: not applicable.
O-019 Differential proteomic analysis of endometrial ﬂuid suggests
increased inﬂammation and extracellular matrix remodeling in non-
implantative IVF cycles
M. Azkargorta1, I. Escobes1, I. Iloro1, N. Osinalde2, B. Corral3,
A. Exposito3,4, B. Prieto3,5, F. Elortza1, R. Matorras3,4,5
1Science and Technology Park, Proteomics Platform- CIC bioGune- CIBERehd-
ProteoRed-ISCIII, Zamudio, Spain
2Department of Biochemistry and Molecular Biology, Basque Country University,
leioa, Spain
3Human Reproduction Unit., Cruces University Hospital., Bilbao, Spain
4BioCruces Health Research Institute, Basque Country University, Bilbao, Spain
5Instituto Valenciado de Infertilidad., IVI Bilbao, leioa, Spain
Study question: Is there any difference in the protein composition of the
endometrial ﬂuid aspirate obtained the day of embryo transfer in cycles achiev-
ing and not achieving pregnancy?
Summary answer: We found 212 differentially expressed proteins when
comparing ‘implantative’ and ‘non-implantative’ cycles, that is, those resulting in
implantation success and failure.
What is known already: Endometrial ﬂuid allows non-invasive characteriza-
tion of the endometrium, and may contain important information on its recep-
tivity when performing in vitro fertilization (IVF) cycles. Endometrial side of
implantation has usually been studied with endometrial biopsy in a cycle prior
to embryo transfer, focusing on “receptive/non-receptive” endometria, and
with low-throughput proteomic techniques.
Study design, size, duration: We have compared the protein expression
patterns in endometrial ﬂuid aspirated from 38 women undergoing IVF, corre-
sponding to 18 implantative and 20 non-implantative cycles using a high-
throughput differential proteomic approach. The study period was 12 months.
Participants/materials, setting, methods: The population under study
consisted of 38 women aged 18-40 years old, undergoing their ﬁrst or second
IVF/ intracytoplasmic sperm injection cycle, with normal uterus and endomet-
rium, and 1-2 good quality embryos, and embryo transfer being performed on
day 3. Endometrial ﬂuid aspiration was performed immediately before the
embryo transfer.
Filter-aided sample preparation was used for the in-solution tryptic digestion
of the proteins present in the samples, followed by label-free mass spectrom-
etry analysis.
Main results and the role of chance: From the 716 proteins detected in
the differential proteomics analysis, 212 signiﬁcantly differed in abundance
between the groups under analysis (p < 0.05). Bioinformatic analyses denoted
the deregulation of important processes governing receptivity, such as extracel-
lular matrix remodeling, proteolytic activity and inﬂammatory signaling, and anti-
microbial activity within the set of differential proteins. The results suggest
higher activity of cytokines, including TNF, OSM and IL6, as well as lower activ-
ity of progesterone in non-implantative cycles. In addition, a number of
pregnancy-related differential proteins were pinpointed in the mechanistic asso-
ciation analysis.
Limitations, reasons for caution: Our results were obtained from patients
with normal uterus and endometrium and with good quality embryos, who had
fresh day-3 embryo transfer, in stimulated cycles. Therefore, our observations
may not be applicable to poor prognosis cases or non-stimulated cycles.
Wider implications of the ﬁndings: This work provides insights into the
molecular features of implantative IVF cycles using non-invasive methods. It
reveals that endometrial ﬂuid aspirate may reﬂect an increased inﬂammatory
state in non-implantative endometrium. This knowledge opens a new avenue
for improving embryo transfer strategies and increasing pregnancy rates.
Trial registration number:Not applicable.
O-020 Pilot study investigating concentration of colony-
stimulating growth factor (CSF) in uterine ﬂushing as prognostic
criterion of IVF cycle outcome in patients with recurrent
implantation failure
D. Obidniak1, A. Gzgzyan2, D. Niauri2, A. Kalugina1
1AVA-Peter, Assisted Reproductive Technology, Saint-Petersburg, Russia C.I.S.
2Saint Petersburg State University, Medical Faculty, Saint-Petersburg, Russia C.I.S.
Study question: Study question was if colony-stimulating growth factor can
be used as reliable prognostic criterion of clinical pregnancy in “fresh” cycles of
assisted reproductive technology.
Summary answer: Evaluation of CSF level in uterine ﬂushing can be con-
sidered perspective prognostic criterion for IVF cycle outcome with sensitivity
of 87.5% and speciﬁcity of 94.3%
What is known already: The concept of recurrent implantation failure (RIF)
in assisted reproductive technology has been enlarged and the tactics for such
patients have included searching prognostic criteria of IVF outcome with the
aim to minimize the number of unsuccessful attempts and the risk of patient’s
drop-out. However the studies on this topic are limited as most suggested
methods require endometrial biopsy and subsequently do not allow to perform
fresh embryo transfer therefore there is still need for non-invasive model for
prediction of IVF cycle outcome.
Study design, size, duration: Study type: Interventional.
Design: randomized controlled pilot study.
Intervention Model: Parallel Assignment.
Masking: open-label
Size: 83 patients.
Duration: 12 months.
Participants/materials, setting, methods: After obtaining board approval
83 women aged 22–39 years were recruited. Matching criteria: recurrent
implantation failure, normal karyotype, absence of uterine factors of infertility.
The patients were randomized into study group (N = 43) and control group
(N = 40): no intervention. At the day of oocyte retrieval the uterine ﬂushing was
collected using insemination catheter (CCD). CSF concentration in uterine ﬂush-
ing was determined using ELISA with following calculation per gram of protein.
Main results and the role of chance: As a primary assessed outcome the
clinical pregnancy rate was analysed: there was no signiﬁcant difference compar-
ing between groups (X2 = 0.018, p > 0.05, CC = 0.015). Thus the method of
collection of uterine ﬂushing doesn’t affect IVF cycle outcome and can be used
routinely. The CSF concentration in uterine ﬂushing was signiﬁcantly higher in
women with clinical pregnancy. The ROC-curve showed sensitivity of 87.5%
and speciﬁcity of 94.3% with cut-off value of CSF being 0.151
Limitations, reasons for caution: As the study was considered as pilot the
number of recruited participants is limited. Thus further investigation is needed.
Wider implications of the ﬁndings: These data prove the necessity for fur-
ther research of CSF role in implantation process and need for consideration
the lack of CSF as a possible cause of recurrent implantation failure.
Trial registration number: not applicable.
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O-021 The seminiferous tubule caliber pattern as evaluated at
high magniﬁcation during microdissection testicular sperm
extraction predicts sperm retrieval in patients with non-obstructive
azoospermia
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Study question: Is the seminiferous tubule caliber pattern as evaluated during
microdissection testicular sperm extraction (microTESE) predictive of sperm
retrieval success in patients with non-obstructive azoospermia (NOA)?
Summary answer: sperm retrieval was successful in 90% of cases when
dilated tubules were found, but only in 7% of cases when only not-dilated
tubules were retrieved.
What is known already: MicroTESE proved to be the gold standard surgical
approach to patients with NOA. However, despite it was introduced in the
clinic about 20 years ago, still a great variability in sperm retrieval rates is
recorded among centers.Among the factors able to explain this issue, the pat-
tern of semiferous tubules caliber found at high magniﬁcation has been sug-
gested to be associated with the chance of retrieving sperm. Few studies in the
past, most with small sample size, have dealt with this issue, but none provided
diagnostic accuracy measures in support of the association between seminfer-
ous tubules pattern and sperm retrieval rates.
Study design, size, duration: The present cross-sectional study was con-
ducted between January 2015 and July 2017 on 143 infertile men with non-
obstructive azoospermia (NOA) undergoing unilateral (64) or bilateral (79)
microTESE. Assessment of sperm retrieval was evaluated as per testis (N =
222). Stepwise binary logistic regression was run to identify predictive factors of
successful sperm retrieval (SSR) and seminiferous tubules pattern among serum
FSH, LH and testosterone level, mean testis volume, testis histology and semin-
iferous tubules pattern.
Participants/materials, setting, methods: During microTESE, if present,
dilated tubules (DT) were retrieved, otherwise any tubule whose caliber was
greater than that of the surroundings was taken (slightly dilated tubules – SDT).
When no DT or SDT were found, not dilated tubules (NDT) were excised
according to a sort of mapping. A fragment of one or more of the tubules of the
same diameter (DT, SDT or NDT) was ﬁxed in Bouin’s solution and sent for
histological analysis.
Main results and the role of chance: Sperm were retrieved in 95 out of
222 testes (42,8%); DTs were found in 90% of testes with successful sperm
retrieval (SSR), SDTs in 47% and NDTs in only 7% (p < 0.0001). The median
number of sperm retrieved was signiﬁcantly higher in DTs compared to SDTs
and NDTs (5.000, IQ range 9.000-300.000, 1.000, IQ range 500-450.000,
500, IQ range 500 respectively; p < 0.0001). Stepwise binary logistic regres-
sion for SSR prediction excluded FSH, LH, testosterone and testicular volume
from the model; on the other hand the tubules caliber pattern allowed the
correct classiﬁcation of 82,4% of testes (chi square 133.731, p < 0.0001,
intercept odds ratio [IOR] 0.84), while histology classiﬁed 72,7% of them (chi
square 63.329, p < 0.0001, IOR 38.9), with a good (AUC 0.89) and fair
(AUC 0.70) diagnostic accuracy respectively as demonstrated by ROC AUC
estimate computed on the predictive probabilities. The combination of both
variables, however, explained the results in terms of SSR in 86,7% of cases
(chi square 156.749, p < 0.0001, IOR 28.4,) with an excellent diagnostic
accuracy (0.93). Stepwise binary logistic regression for the prediction of sem-
iniferous tubules pattern individuated testis histology as the only signiﬁcant
predictor (chi square 33.843, p < 0.0001), although with a poor diagnostic
accuracy (AUC 0.67).
Limitations, reasons for caution: the seminiferous tubules patter was sub-
jectively evaluated, but the skill and experience (about 900 microTESE proce-
dures performed to date) of the surgeon can account for the reliability of the
results.
Wider implications of the ﬁndings: the present study provides reliable
accuracy measures in support of the relationship between seminiferous tubules
caliber pattern and SSR in patients with NOA. The tubules pattern may
represent an additional outcome measure of microTESE and, together with
histology, provide additional information on the degree of spermatogenesis
impairment in individual patients.
Trial registration number:N/A.
O-022 Characterization of spermatogenic function in NOAmen
aiming at predicting success of testicular sperm retrieval
C. O’Neill, A. Parrella, M. Irani, Z. Rosenwaks, G. Palermo
Weill Cornell Medical College, CRMI, New York City- NY, U.S.A.
Study question: Can germ cell characterization of testicular biopsy samples
provide information on seminiferous tubule function in NOA men and enhance
our ability to identify spermatozoa?
Summary answer: Using germ cell stage-speciﬁc markers, we can predict the
extent of spermatogenic dysfunction in NOA men and relate it to the eventual
retrieval of spermatozoa.
What is known already: In men with non-obstructive azoospermia (NOA)
that undergo micro-TESE, about 40-60% of cases fail to yield spermatozoa. In
these patients, the array of spermatogenetic progress within the seminiferous
tubule vary from hypospermatogenesis, to maturation arrest, or germ cell apla-
sia (sertoli-cell only syndrome). These features can be difﬁcult to identify even
during surgical sperm extraction and about half of the cases fail to provide
injectable sperm cells. The utilization of immunoﬂuorescence or the isolation of
RNA targeting speciﬁc germ cell maturational stages can help to identify the
progression of spermatogenesis and offer a more complete proﬁle to the repro-
ductive physician.
Study design, size, duration: Over the course of the past year, ten samples
retrieved from NOA men were analyzed for germ cell stage identiﬁcation.
Additionally, two OA (obstructive azoospermia) samples served as control.
Patients were then categorized as to their extent of spermatogenesis using
immunoﬂuorescence markers previously validated in the OA control. Gene
expression analysis of samples (n = 6) conﬁrmed the presence of speciﬁc germ
cell stages and helped to map the extent of the spermatogenic process.
Participants/materials, setting, methods: A total of 12 men underwent
micro-TESE to identify spermatozoa for use with ICSI. All specimens were ﬁxed
and processed for immunoﬂuorescent analysis using germ cell markers, DAZL
(all germ cell stages), BOULE (meiotic), and PNA (post-meiotic). To conﬁrm
immunoﬂuorescent ﬁndings, RNA-seq assessing 60,448 genes was carried out
on some specimens for corresponding gene expression of the markers.
Main results and the role of chance: OA samples were positive for all
immunoﬂuorescent germ cell markers tested and spermatogenic line presence
was further validated via RNA-seq. Immunoﬂuorescent analysis of testicular
specimens (NOA) revealed a varying proportion of germ cells at intermediate
stages of meiosis. Of these, two NOA men displayed signal for DAZL, BOULE,
and PNA, suggesting retention of the spermatogenic line and indeed they
yielded scant spermatozoa that were used for ICSI, although neither resulted in
a pregnancy. NOA patients, in which no spermatozoa were retrieved, evi-
denced a scattered number of immature germ cells compared to the control,
which appeared smaller in size and irregular in shape. No post-meiotic stages
were identiﬁed using the acrosomal marker, PNA. Analysis of differential gene
expression corroborated our ﬁndings, revealing a signiﬁcant decrease in expres-
sion of spermatogenic markers for the germ cell stages of interest. All NOA
patients had poor expression of DAZL (all germ cells), BOLL (meiotic marker),
and ACRBP (post-meiotic marker) compared to the OA control, with the low-
est expression in NOA patients where no spermatozoa were identiﬁed (P <
0.001). Correspondingly, NOA men with spermatozoa identiﬁed in the testicu-
lar biopsy portrayed an increased expression of DAZL as compared to NOA
patients that failed to yield spermatozoa (P < 0.01).
Limitations, reasons for caution: A reﬁned method for characterization of
germ cells will further portray a detailed depiction of seminiferous tubule func-
tion. Due to sample availability, not all specimens were analyzed for both
immunoﬂuorescence and RNA-sequencing. Querying unfamiliar genes will help
in gaining information on the etiology of this severe form of male infertility.
Wider implications of the ﬁndings: The utilization of a non-invasive meth-
od to query speciﬁc genes that predict seminiferous tubule function will help to
identify the best candidates for TESE likely to yield spermatozoa, sparing
patients costs and emotional distress. Careful interpretation of RNA transcripts
will help to illuminate the etiology behind this severe condition.
Trial registration number:N/A.
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O-023 MSOME I + II: a new cut-off value for male infertility and
embryo development prediction on intracytoplasmic sperm
injection cycles
E. Borges Jr.1, B.F. Zanetti2, D.P.A.F. Braga3, R.R. Provenza4,
R.C.S. Figueira5, A. Iaconelli Jr.1
1Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
2Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida,
Scientiﬁc Department, Sao Paulo, Brazil
3Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
4Fertility Medical Group, Andrology laboratory, Sao Paulo, Brazil
5Fertility Medical Group, IVF laboratory, Sao Paulo, Brazil
Study question: Can motile sperm organelle morphology examination
(MSOME) improve semen analysis by better deﬁning male infertility and provid-
ing better prediction for intracytoplasmic sperm injection (ICSI) outcomes?
Summary answer: MSOME I + II ≥ 5.5% is a predictor for severity of the
male factor and for the rate of blastocysts.
What is known already: Human sperm morphology has been described as
an essential parameter for the diagnosis of male infertility and a prognostic indi-
cator of natural or assisted pregnancies. Nevertheless, standard morphological
assessment remains a subjective analysis and its impact on ICSI is also of limited
value. The direct selection of spermatozoa by MSOME has proved to lead to
better ICSI outcomes, such as higher implantation, pregnancy and live birth
rates. However, whether the proportion of normal spermatozoa by WHO
parameters can be correlated with MSOME classiﬁcation and whether this
could be correlated with ICSI outcomes are questions that remain to be
elucidated.
Study design, size, duration: This prospective-cohort study included data
from 483 patients undergoing conventional seminal analysis from June/2015 to
June/2017. The spermatozoa were graded as: MSOME I, normal form and no
vacuoles; MSOME II, normal form and ≤2 small vacuoles; MSOME III, normal
form >2 small vacuoles or one large vacuole; and MSOME IV, large vacuole and
abnormal head shapes or other abnormalities. The sum of MSOME Grades I
and II was used as a normal spermatozoa parameter.
Participants/materials, setting, methods: The study was performed in a
private university-afﬁliated IVFncenter. The proportion of MSOME grades were
correlated with semen volume, concentration, total sperm count, motility,
morphology and total motile sperm count (TMSC) by linear regression models.
The correlation of MSOME with ICSI outcomes (i.e. fertilization rate, high-
quality embryos and blastocyst rate, implantation, cycle’s cancelation, and preg-
nancy rates) were evaluated by linear and logistic regression models. The
MSOME normality cutoff was deﬁned by ROC curve.
Main results and the role of chance: MSOME I + II was positively corre-
lated with semen concentration (β = 0.281 p < 0.001), total sperm count (β =
0.224 p < 0.001), motility (β = 0.178 p < 0.001), progressive motility (β =
0.192 p < 0.001), morphology (β = 0.341 p < 0.001), and TMSC (β = 0.2010
p < 0.001). The MSOME I + II was statistically different betweenWHO seminal
classiﬁcations, with normozoospermia group having the highest percentage of
MSOME Grades I + II (14.10%). We observed a decreased incidence of
MSOME I + II with the increased severity of the seminal classiﬁcation, and oli-
goasthenoteratozoospermia was the most affected group (MSOME I + II 3.95%
p < 0.001). MSOME I + II was positively correlated with fertilization (β = 0.197
p = 0.044), high-quality embryos (β = 0.306 p = 0.013), and blastocyst(β =
0.248 p = 0.047) rates. The highest area under the curve (AUC) to discriminate
blastocyst rate <50% from that ≥ 50% was obtained with MSOME Grades I + II
(AUCROC = 0.66), with cut-off value of ≥ 5.5%, in which a sensitivity of 0.72
and speciﬁcity of 0.41 were obtained. Using this parameter to deﬁne normality,
a signiﬁcant difference in the blastocyst rate between MSOME I + II < 5.5% and
MSOME I + II ≥ 5.5% could be noted (28.53 ± 5.69 vs 50.14 ± 5.05 %, p =
0.005) even when adjusted for confounding variables such as: male and female
ages, ejaculatory abstinence and number of retrieved oocytes.
Limitations, reasons for caution: The limitation of the present study is the
small samples size and the lack of correlation between MSOME results and clin-
ical outcomes.
Wider implications of the ﬁndings: MSOME I + II ≥ 5.5% is a useful cut-
off for the diagnosis of infertility severity and for the prediction of ICSI
outcomes. The future use of MSOME as a routine method may be reliable for
assessing male infertility and its impact on ICSI.
Trial registration number:None.
O-024 Effect of reactive oxygen species on the methylation status
of human sperm imprinting genes, seminal plasmametabolites, and
semen parameters
M. Darbandi1, S. Darbandi2, A. Agarwal3, S. Esteves4,5,6,
P. Sengupta7, S. Dutta7, H.R. Khorram Khorshid8, M.M. Akhondi2,
S. Al-Hasani9, M.R. Sadeghi2
1Reproductive Biotechnology Research Center- Avicenna Research Institute- ACECR-
Tehran, reproductive biology, tehran, Iran
2Reproductive Biotechnology Research Center, Avicenna Research Institute, Tehran,
Iran
3American Center for Reproductive Medicine- Glickman Urological and Kidney
Institute, Cleveland Clinic, Cleveland- Ohio, U.S.A.
4Department of Surgery Division of Urology, University ofCampinas UNICAMP,
Campinas, Brazil
5Faculty of Health, Aarhus Univisity, Aarhus, Denmark
6ANDROFERT, Andrology andHuman Reproduction Clinic, Campinas, Brazil
7Department of Physiology- Faculty of Medicine, MAHSA university, Selangor,
Malaysia
8Genetics Research Center, the University of Social Welfare and Rehabilitation
Sciences, Tehran, Iran
9Reproductive Medicine Unit, University of Schleswing-Holstein, Luebeck, Germany
Study question: Is there an association between seminal plasma reactive oxy-
gen species (ROS) levels and alterations of imprinting gene methylation pat-
terns, seminal plasma metabolites, and semen parameters?
Summary answer: A positive association exists between ROS levels and
alterations in H19-Igf2 methylation as well as metabolite concentration, with an
overall detrimental effect on semen quality.
What is known already:Oxidative stress (OS) is associated with sperm dys-
function via distinct pathophysiology mechanisms. Recent studies suggest that
ROS affect methylation of genes involved in male fertility. Furthermore, OS may
alter the seminal plasma (SP) metabolite milieu and contribute to sperm dys-
function. However, it remains unknown as to what extent the effect of seminal
ROS on gene methylation, seminal metabolites, and sperm quality is level-
dependent. Also, a possible association between ROS-induced H19/Ig2 methy-
lation and SP metabolites with semen quality is yet to be conﬁrmed. Such stud-
ies may help unravel pathophysiologic pathways leading to unexplained male
infertility and allow development of targeted therapies.
Study design, size, duration: Prospective study including fresh semen speci-
mens of 150 men between April and May 2016. Each patient contributed one
specimen which was analyzed for ROS by chemiluminescence, and classiﬁed
according to seminal ROS levels [in relative light units (RLU)/sec/106 sperm]:
Group 1 (n = 39): Low (ROS < 20 RLU), Group 2 (n = 38): Mild (20
RLU≤ROS < 40 RLU), Group 3 (n = 31): Moderate (40 RLU≤ROS < 60
RLU), and Group 4 (n = 43): High (ROS≥60 RLU).
Participants/materials, setting, methods: Participants were normozoos-
permic (WHO 2010) men attending an infertility clinic. Specimens were col-
lected after 3-5 days abstinence. A comprehensive analysis of SP and sperm
function parameters were carried out, including conventional semen character-
istics (computer-assisted semen analysis; CASA), measurement of total antioxi-
dant capacity (TAC), sperm DNA fragmentation (sperm chromatin dispersion
test), chromatin maturation index (aniline blue), H19-Igf2 methylation status
(methylation-speciﬁc polymerase chain reaction), and untargeted seminal meta-
bolic proﬁling using nuclear magnetic resonance spectroscopy (1H-NMR).
Main results and the role of chance: The methylation status in promoter
region of H19 and Igf2 genes was signiﬁcantly different in specimens with high/
moderate ROS levels than mild/low counterparts (P < 0.001). Metabolic ﬁn-
gerprinting by 1H-NMR revealed upregulation of trimethylamine N-oxide (P <
0.001) and downregulation of tryptophan (P < 0.05) as well as tyrosine/tyrosol
(P < 0.01) in SP samples with high ROS levels. A signiﬁcant reduction in total
sperm motility (P < 0.05) and concentration (P < 0.001) was noted in
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specimens with high ROS levels, whereas higher CMI and sperm DNA fragmen-
tation index (DFI) were noted both in specimens with moderate (P < 0.05) and
high ROS (P < 0.005). In contrast, TAC values were decreased in all specimens
but those with low ROS levels (P < 0.001). Pearson’s and Spearman correla-
tions showed that ROS levels were positively correlated with Igf2 methylation
(r = 0.19, P < 0.05), DFI (r = 0.27, P < 0.001), CMI (r = 0.21, P < 0.01), and
trimethylamine N-oxide (r = 0.45, P < 0.05) and negatively correlated with
H19 methylation (r=-0.20, P < 0.05), tryptophan (r=-0.45, p < 0.05), sperm
motility (r=-0.18, P < 0.05), sperm vitality (r=-0.35, P < 0.001), sperm concen-
tration (r=-0.38, P < 0.001).
Limitations, reasons for caution: Although none of the subjects reported a
history of pelvic and genital infections, chronic diseases, and endocrine abnor-
malities, risk factors such as use of medication and smoking habits were not
consistently recorded. Also, the effect of ejaculatory abstinence duration was
not controlled.
Wider implications of the ﬁndings: Our study suggests a link between
ROS-induced H19/Ig2 methylation and seminal plasma metabolites with semen
quality. We speculate that deterioration of semen quality and sperm DNA
integrity in specimens with moderate/high ROS levels is mediated by alterations
in the methylation status of H19/Ig2 genes and SP metabolite concentrations.
Trial registration number:N.A.
O-025 Comparative proteomic analysis of seminal plasma proteins
from fertile men with normal or high levels of reactive oxygen
species
L. Samanta1,2, T. Dias1,3,4, A. Agarwal1, R. Sharma1,
D. Durairajanayagam5, Z. Cui6, A. Ayaz7, B.Willard8, E. Sabanegh9
1Cleveland Clinic, American Center for Reproductive Medicine- Department of
Urology, Cleveland, U.S.A.
2Department of Zoology, School of Life Science, Ravenshaw University
3University of Porto, Institute of Biomedical Sciences Abel Salazar, Porto, Portugal
4University of Beira Interior, Faculty of Health Sciences, Covilhã, Portugal
5Universiti Teknologi MARA, Faculty of Medicine, Selangor, Malaysia
6Southwest University, College of Pharmaceutical Sciences, Chongqing, China
7Tulane Medical Center, Department of Urology, New Orleans, U.S.A.
8Cleveland Clinic, Research Core Services - Proteomics, Cleveland, U.S.A.
9Cleveland Clinic, Urology, Cleveland, U.S.A.
Study question: Does seminal plasma proteome play a role in the preserva-
tion of sperm fertilizing ability in men with high levels of reactive oxygen species
(ROS)?
Summary answer: Increased antioxidant activity and endopeptidase inhibi-
tory mechanisms in seminal plasma may contribute to the preservation of the
fertilizing potential of men with high ROS levels.
What is known already: During spermatogenesis, spermatozoa shed major-
ity of their cytoplasm and thereby lose most of their antioxidant defenses.
Therefore, they become dependent on antioxidant protection provided by
seminal plasma which is largely made up of secretions from the male accessory
glands. It is known that an imbalance between ROS production and antioxidant
protection results in oxidative stress, which is linked with impaired sperm func-
tion and fertilization, ultimately contributing to male infertility. Seminal plasma
also plays a major role in preventing premature capacitation. However, the
molecular mechanisms behind the importance of seminal plasma in the preser-
vation of male fertilizing ability are largely unknown.
Study design, size, duration: Semen analysis including liquefaction, viscosity,
volume, and pH was performed in 17 semen samples. Samples were divided
into two groups according to the ROS levels measured by chemiluminescence:
Control group – ROS level <102RLU/s/million sperm (n = 8); ROS positive
group – ROS level >102 RLU/s/million sperm (n = 9). Proteomic analysis of
seminal plasma samples was performed to identify possible differential
expressed proteins (DEPs) between the experimental groups, which were fur-
ther selected for validation by Western Blot (WB).
Participants/materials, setting, methods: Semen samples were voluntar-
ily provided by proven fertile men (men with at least one child). Seminal plasma
was collected after centrifugation of liqueﬁed semen at 4000Xg and protein
concentration was estimated by the BCA assay. A pool of 5 samples from each
experimental group was used for quantitative proteomic analysis (LC-MS/MS).
The main core networks were identiﬁed by functional enrichment using
STRING software and key DEPs were selected for validation by WB.
Main results and the role of chance: A total of 44 proteins were found to
be differentially expressed between the experimental groups. Serine-type endo-
peptidase inhibitor activity (GO:0004867, false discovery rate p = 0.00006) and
antioxidant activity (GO:0016209, false discovery rate p = 0.00523) were
among the main molecular functions in which these DEPs were involved. In the
ROS positive group, semenogelin-1 and semenogelin-2, which are proteins
involved in seminal coagulum formation, were underexpressed (p = 0.00074, p
= 0.00023, respectively). On the other hand, some proteins involved in antioxi-
dant defense, haptoglobin (HP) and peroxiredoxin-4 (PRDX4) were overex-
pressed (p = 0.00349, p = 0.00099, respectively). Similarly, Serpin B6
(SERPINB6), a serine protease inhibitor, was also overexpressed in ROS posi-
tive group (p = 0.00424). The expression of these DEPs was identiﬁed by WB,
for control (n = 8) and ROS positive (n = 9) groups, and fold variation to the
control group was calculated by densitometry. MedCalc software was used for
statistical data analysis. Firstly, the Tukey test was used for outlier detection, fol-
lowed by a two-tailed Mann-Whitney test. The protein expression obtained by
WB for the selected DEPs was not statistically signiﬁcant between the experi-
mental groups: SEMG1 (p = 0.5286) SEMG2 (p = 0.2002), HP (p = 0.3865),
PRDX4 (p = 0.6304) and SERPINB6 (p = 0.6304).
Limitations, reasons for caution: The distinct results obtained between
proteomics and WB could be explained by the differences in the sensitivity and
reproducibility of these methods. Furthermore, only 5 of the 44 DEPs identiﬁed
by proteomics were validated by WB.
Wider implications of the ﬁndings:Different expression pattern of seminal
plasma proteins in fertile men with high levels of ROS may be responsible for
the preservation of the spermatozoa fertilizing capacity. This may be attributed
to the overexpression of proteins with antioxidant and endopeptidase inhibitor
activity. Other DEPs must be investigated to test this hypothesis.
Trial registration number: not applicable.
O-026 Exosomal miRNAs in seminal plasma are markers of the
origin of azoospermia and can predict the presence of sperm in
testicular tissue
S. Larriba1, M. Barceló1, A. Mata2, L. Bassas2
1Institut d’Investigació Biomèdica de Bellvitge-IDIBELL, Human Molecular Genetics
Group, Hospitalet de Llobregat- Barcelona, Spain
2Fundació Puigvert, Andrology Service, Barcelona, Spain
Study question: Are exosomal microRNAs (miRNAs) in seminal plasma (SP)
useful as markers of the origin of azoospermia and the presence of sperm in the
testis?
Summary answer: The potential of SP miRNAs contained in exosomes as
biomarkers for selecting azoospermic individuals with real chances of obtaining
spermatozoa from the testis is shown.
What is known already: There are no precise non-invasive diagnostic
methods for classifying the origin of the sperm defects and the spermatogenic
reserve of the testis in azoospermic infertile men. The diagnosis of such
individuals is often based on the practice of biopsies. In this context it is
reasonable to study the presence of organ-speciﬁc markers in human semen
that contains ﬂuid from the testis and the male reproductive glands, which
could help in the diagnosis and prognosis of azoospermia. Additionally, SP con-
tains high concentrations of small extracellular vesicles (sEVs), particularly exo-
somes, which originate from multiple cellular sources in the male reproductive
tract.
Study design, size, duration: Case and control prospective study. This
study compares the miRNA content of exosomes in semen samples obtained
from 9 normozoospermic fertile individuals (control group); 14 infertile men
diagnosed with azoospermia due to spermatogenic failure and 13 individuals
with obstructive azoospermia and conserved spermatogenesis. Additionally,
three severe oligozoospermic individuals (<5 × 106 sperm/ml) were included
in the study.
Participants/materials, setting, methods: A differential high-throughput
miRNA proﬁling analysis using miRNA qPCR panels (Exiqon) was performed in
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SP exosomes from azoospermic and fertile individuals. Unpaired two-tailed t
test was used to analyze the differences in expression of miRNAs. Validation of
miRNA candidates was performed by RT-qPCR analysis in a larger cohort of
individuals. Multivariate logistic regression and receiver operating characteristic
(ROC) curve analysis of the expression values were used to predict/identify
azoospermia origin, as well as residual spermatogenesis.
Main results and the role of chance: A total of 623 miRNA were included
in the study and 397 miRNAs (63,7%) were consistently detected in samples
from the groups of the study and statistically analysed, which revealed altered
patterns of miRNA expression in infertile patients. We focused on the miRNAs
that were differentially expressed between azoospermia as a result of an
obstruction in the genital tract (having conserved spermatogenesis) and azoo-
spermia due to spermatogenic failure, and described the expression values of
one miRNA (miR-A*) in exosomes from semen as a predictive biomarker test
for the origin of azoospermia with high sensitivity and speciﬁcity (>90%).
Furthermore a model that included the miR-B* and the miR-C* expression
values is also described as useful for predicting the presence of residual sperm-
atogenesis in individuals with severe spermatogenic disorders with diagnostic
accuracy.
*Note: The speciﬁc names of the miRNAs included in the model are not
shown as a patent is being applied for their use as diagnostic markers.Please,
consider all this information as conﬁdential material.
Limitations, reasons for caution: Further studies which involve a larger
cohort of individuals would be needed.
Wider implications of the ﬁndings: Our ﬁndings contribute to the search
for the most valuable genetic markers which are potentially useful as tools for
predicting the origin of azoospermia and the presence of residual
spermatogenesis.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 06: NON-INVASIVE OOCYTEAND EMBRYO
ASSESSMENT
Monday 2 July 2018 Room 117 10:00–11:30
O-027 Is follicular size at oocyte pick-up (OPU) a predictor of
blastocyst development? A study evaluating morphokinetic
development and cumulus cell (CC) gene expression
S. Kahraman, C. Pirkevi Cetinkaya, M. Cetinkaya
Istanbul Memorial Hospital-, ART and Reproductive Genetics Center, Istanbul, Turkey
Study question: Is follicular size at OPU a predictor of blastocyst develop-
ment when evaluated by morphokinetic variables and CC gene expression?
Summary answer: Follicular size correlated signiﬁcantly with blastocyst qual-
ity and viability as reﬂected in morphokinetic variables and is a more reliable
indicator than CC gene expression.
What is known already: A correlation between follicular size and embryo
development as reﬂected in morphokinetics was found in our previous study,
(Kahraman et al, 2017). We conducted this further study of CCs obtained from
follicles of different sizes, for the ﬁrst time evaluating both morphokinetic devel-
opment to the blastocyst stage and gene expression of CCs.
Study design, size, duration: This prospective cohort study was based on
2495 COCs belonging to 184 patients and was performed between July 2014
and September 2015. Patient inclusion criteria: age ≤ 39 years, BMI < 30 kg/
m2, ≥ 8 oocytes retrieved, < 2 previous treatment cycles, and exclusion cri-
teria: recurrent pregnancy loss, severe endometriosis, PGD or PGS, oocytes >
24, embryo transfer (ET) on day 5, PCOS, uterine anomaly, severe male
infertility.
Participants/materials, setting, methods: Morpokinetic variables for
cleavage events (t2) up to the expanded blastocyst stage were annotated
according to follicular size. Five genes (TNFAIP6, PTGS2, HAS2, PTX3 and
GDF9) were evaluated. CC gene expressions were analysed according to
patient speciﬁc variables: age, BMI, AMH and follicular size. Embryos reaching
(eRB) or failing to reach blastocyst (eFRB), developing into bad (BQ), top (TQ)
and good quality (GQ) blastocysts were analysed using generalized linear mixed
models (GLMMs) with logit link.
Main results and the role of chance: When morphokinetics of embryos
coming from large and small follicles were compared, those from small follicles
were found to develop faster than embryos coming from large follicles for all
cleavage timings. The highest rate of top and good quality blastocysts was
achieved in embryos coming from large follicles, a higher rate of direct cleavage
and developmental arrest were observed in embryos obtained from small folli-
cles. There was also a correlation between blastocyst quality and CC gene
expression of HAS2 and GDF9, but only when evaluated together with follicular
size, age, BMI and AMH. Furthermore, no such correlation was found in the
case of other gene expressions studied. Our study suggests that, for clinical pur-
poses, follicular size together with morphokinetic variables are a more practical
indicator than CC gene expression of the likelihood of oocytes developing into
transferable blastocyst.
Limitations, reasons for caution: Results were obtained in a deﬁned IVF
setting and cannot necessarily be translated in another laboratory.
Wider implications of the ﬁndings: Our study suggests that, for clinical
purposes, follicular size together with morphokinetic variables are a more prac-
tical indicator than CC gene expression of the likelihood of oocytes developing
into transferable blastocyst.
Trial registration number: clinicaltrials.gov NCT02230449.
O-028 Acetyl-CoA enrichment from acetate is higher in cumulus
cells associated with mature oocytes
S. Anderson1,2, N. Snyder3, B. Gocial1,2, D. Brasile1,2, E. Davies1,
M. Glassner1,2, J. Orris1,2
1Main Line Fertility Center, Reproductive Medicine, Bryn Mawr, U.S.A.
2Ob/Gyn Department, Drexel University College of Medicine, Philadelphia, U.S.A.
3Drexel University, A.J. Drexel Autism Institute, Philadelphia, U.S.A.
Study question: Is enrichment of acetyl-CoA from acetate in individual cumu-
lus cell complexes (CCC) associated with oocyte maturity?
Summary answer: Enrichment of acetyl-CoA from acetate is higher in cumu-
lus cells associated with mature metaphase II oocytes compared to immature
oocytes.
What is known already: Cumulus cells have been reported by others to be
highly glycolytic. However, in previous research we found that cumulus cells
had low labeling of the acetyl-CoA pool derived from glucose. In contrast, label-
ing with acetate was remarkably high into acetyl-CoA, which is indicative of
active metabolism. The objective of this study was to develop a method to
study metabolism in individual CCC to determine if this enrichment of acetyl-
CoA from acetate is associated with corresponding oocyte maturity.
Study design, size, duration: This prospective, controlled, and blinded
study was conducted at a private fertility center and collaborating university bio-
chemistry research laboratory. Patients were screened using strict inclusion/
exclusion criteria, and all patients received the same controlled ovarian stimula-
tion protocol. CCC were transported to the biochemistry research laboratory,
where they were individually analyzed. Acetyl-CoA enrichment from acetate
was measured in 490 individual sets of CCC from 31 patients pursuing in vitro
fertilization (IVF) in 2017.
Participants/materials, setting, methods: CCC were removed from
oocytes after oocyte retrieval procedure and placed individually into labeled
microcentrifuge tubes for metabolic testing. CCC were incubated with stable
isotope 13C-labeled acetate substrate. The % relative enrichment of acetyl-
CoA was determined using liquid chromatography-high resolution mass spec-
trometry (LC-HRMS), which maintains a quantitative substrate to product rela-
tionship. Therefore, the total number of cells in the CCCs, which varies
between oocytes, did not factor into the metabolic analysis.
Main results and the role of chance: Statistical signiﬁcance was set at
P<.05, and data were analyzed with SAS/STAT software. The mean % enrich-
ment of acetyl-CoA in CCC from mature metaphase II oocytes (45.9 ± 1.2)
was signiﬁcantly higher (p < 0.05) than in those CCC associated with immature
prophase I and metaphase I oocytes (39.2 ± 1.4). In addition, the mean %
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enrichment of acetyl-CoA in CCC collected from women less than 34 years of
age (45 ± 1.45) was higher than (p < 0.05) in those CCC from woman greater
than 34 years of age (40.8 ± 2.2).
Limitations, reasons for caution: Our ongoing clinical trial is being con-
ducted to determine if % enrichment of acetyl-CoA in CCC can be considered
to be predictive of oocyte maturity. In addition, biochemical analysis of CCC
using LC-HRMS may not be economically feasible in most clinical IVF settings.
Wider implications of the ﬁndings: The % acetyl-CoA enrichment from
acetate, which is indicative of active metabolism, was found to be higher in indi-
vidual CCC associated with mature oocytes compared to immature oocytes.
This stable isotope tracing methodology of individual CCC may be a promising
new non-invasive approach to study metabolism in associated oocytes.
Trial registration number: clinicaltrials.gov/ct2/show/NCT02793752
O-029 Oocyte meiotic spindle morphology is a predictive marker
of blastocyst ploidy. A prospective cohort study
L. Tilia1, C. Venetis2, S. Cooke3, M. Chapman2
1IVF Australia, Eastern Sydney, Maroubra, Australia
2University of New South Wales, School of Women’s and Children’s Health, Sydney,
Australia
3IVF Australia, Scientiﬁc Director, Greenwich- Sydney, Australia
Study question: Is oocyte meiotic spindle (OMS) morphology at the time of
intra-cytoplasmic sperm injection (ICSI) a predictive marker of blastocyst
ploidy?
Summary answer: OMS morphology is a predictive marker of blastocyst
ploidy. Oocytes with normal meiotic spindle morphology are associated with a
signiﬁcantly higher rate of blastocyst euploidy.
What is known already: Euploid embryos result in higher pregnancy rates,
fewer miscarriages and the birth of healthy offspring. However, preimplantation
genetic testing (PGT) is invasive and costly while morphologic or morphokinetic
markers are unreliable. Oocyte aneuploidy is the main cause of embryonic
aneuploidy and can result from OMS abnormalities leading to chromosome
alignment and segregation errors. The oocyte meiotic spindle can be non-
invasively visualised using polarised light microscopy (PLM). Morphologically
normal meiotic spindles are positively associated with cleavage stage embryonic
euploidy and pregnancy. The association of OMS morphology with blastocyst
ploidy has not previously been investigated.
Study design, size, duration: This is a prospective analysis of patients (194
patients, 221 cycles) undergoing ICSI with the intention to biopsy blastocysts
for PGT between 2014 and 2017. At the time of ICSI, OMS morphology was
visualized by PLM and classiﬁed as: normal, dysmorphic, translucent, not visible
or in telophase. Day 5/6 blastocyst biopsy was performed on suitably progres-
sing embryos by embryologists blind to the OMS classiﬁcation. Whole genome
sequencing was used to analyse the biopsied trophectoderm cells.
Participants/materials, setting, methods: The association between spin-
dle morphology and embryo PGT results was evaluated using generalized
equation estimating regression methods while accounting for non-
independence of data. The additional value of OMS morphology to morphology
and female age in predicting euploidy was also examined. All analyses were per-
formed both by a) ‘intention-to-treat (ITT)” where oocytes not resulting in
biopsied blastocysts were considered equivalent to an aneuploid blastocyst and
b) ‘as treated analysis (ATA)” where only biopsied blastocysts were analysed.
Main results and the role of chance:Mean female age was 37.8 years (95%
CI: 37.2-38.4) and number of oocytes collected per cycle was 12.1 (95%CI:
11.2-13.1). Overall, OMS morphology was classiﬁed for 2056 oocytes at ICSI.
Most oocytes had a normal spindle(n = 1080), followed by dysmorphic(n =
463), not visible(n = 268), translucent(n = 157) and in telophase(n = 88). OMS
morphology was strongly associated with the probability of the oocyte being
fertilized (p < 0.001), producing a day-3 embryo (p < 0.001) and resulting in a
biopsied blastocyst (p < 0.001). Oocytes with normal spindles showed the best
potential followed by dysmorphic, translucent, not visible & telophase spindles.
The presence of a normal OMS was positively associated with euploidy com-
pared to oocytes with all other OMS types combined, either per ITT: odds ratio
(OR): 2.16 [95%CI: 1.64-2.85] or ATA: OR: 1.57 (95%CI: 1.11-2.21). The type
of OMS was associated with the probability of euploidy (ATA:p = 0.043 & ITT:
p < 0.001). Blastocysts originating from oocytes with normal spindles had the
highest probability of being euploid (44.7% of biopsied blastocysts) (dys-
morphic:40.3%; translucent: 26.4%, not visible:21.9 and telophase: 0%). Even
after controlling for female age, blastocyst quality (top vs. good) and develop-
mental stage (blastocyst vs. expanding vs. hatching), the presence of a normal
spindle was strongly associated (p = 0.008) with the probability of euploidy
(normal:44.8% vs. other:33.8%).
Limitations, reasons for caution: This study was performed in patients
with an indication for PGT and hence might not be representative of the general
IVF population. The oocyte meiotic spindle reﬂects oocyte quality and only the
maternal contribution to embryo ploidy. Its assessment requires specialized
equipment and staff training.
Wider implications of the ﬁndings: Non-invasive visualisation of oocyte
meiotic spindle morphology can be used as a marker of its genetic normality
and reproductive potential. If validated in randomized controlled trials this
selective tool could beneﬁt both patients and fertility clinics by optimising
embryo selection and cycle outcome.
Trial registration number:Not Applicable.
O-030 Non-invasive imaging of embryometabolism in response to
anoxia using ﬂuorescence lifetime imaging microscopy (FLIM)
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Study question: How does embryo metabolic function depend on oxygen
availability at different stages of development?
Summary answer: Depending on developmental stage, mouse embryos dis-
played distinct metabolic responses to anoxia. This yields new insight for the
study of embryo metabolism and, therefore, viability.
What is known already: Fluorescence lifetime imaging microscopy (FLIM)
can be used to non-invasively and quantitatively measure the metabolic state of
embryos. FLIM measures the ﬂuorescence of both NADH and FAD. These
endogenous molecules are integral to cellular metabolism and are auto-
ﬂuorescent, thus avoiding the need to expose embryos to any potentially unsafe
reagents or dye.
Study design, size, duration: We conducted a prospective observational
study utilizing a mouse model. Using an engineered on-stage incubation system,
embryos/oocytes were probed by dropping oxygen from 5% to 0% over 90
minutes, monitoring metabolic state throughout. Additionally, the use of an
O2-sensitive ﬂuorophore allowed us to plot metabolic state as a direct function
of O2 concentration. Experiments were conducted over one year, in triplicate.
Participants/materials, setting, methods: Samples were equilibrated to
5% O2 for 30 minutes. 0% O2 gas was ﬂushed into the culture system for 90
minutes, causing media O2 concentration to drop according to an exponential
decay, after which 5% O2 gas was restored for 30 minutes. Metabolic measure-
ments were obtained every 6 minutes to capture the dependence of metabolic
state on O2 concentrations and mitochondrial function/recovery from anoxia.
Embryos were subsequently cultured until the blastocyst stage in standard
conditions.
Main results and the role of chance: Mouse embryos between 1-cell and
6-8 cell stages showed similar metabolic responses to transient anoxia, with an
increase in NADH ﬂuorescence intensity [1-cell: 36.6 ± 5.7%] (reﬂective of
total concentration) and a decrease in FAD intensity [1-cell: -13.7 ± 1.4%].
These trends then reversed with restoration of oxygen. Morulae and blasto-
cysts, however, showed less of a metabolic response to anoxia, with minimal
change in NADH [Blastocyst: 8.3 ± 5.5%] and FAD [Blastocyst: -4.7 ± 3.6%]
intensity.
This ﬁnding is in line with previous evidence of distinct metabolic shifts that
occur as embryos develop into blastocysts. However, our observation that
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oxygen dependence decreases at blastocyst stage was surprising, as oxygen
consumption is known to increase at blastocyst. This suggests more subtle
mechanisms for metabolic regulation, and provides a direct framework for fur-
ther elucidating these metabolic shifts.
Of note, the decrease in oxygen dependence does reﬂect a likely adaptation
to known physiologic changes in vivo. As embryos develop, they pass into the
uterus, which is known to have a lower oxygen concentration (2%). Transient
O2 deprivation proved not to be a signiﬁcant long-term perturbation, as
embryos exposed to anoxia subsequently developed to blastocysts at >80%.
Limitations, reasons for caution: Although these ﬁndings represent an
innovative mechanism of embryo evaluation, a deﬁned standard for interpreting
metabolic FLIM parameters has not been fully developed. The hardiness of the
mouse model may represent that caution is still needed when applying this
technique to human embryos and gametes.
Wider implications of the ﬁndings: We have also shown that FLIM-based
metabolic imaging provides a highly sensitive basis for detecting metabolic state,
which is known to be essential for viability. This study thus provides further evi-
dence that this technique could serve as a powerful tool for assessing embryo
quality in the future.
Trial registration number: not applicable.
O-031 A pilot study to investigate mechanical characteristics of
oocytes as a predictor of preimplantation embryo development
B. Behr1, J. Kort2, D. Meyer3, M. Fleischmann4, J.Y.J. Huang5, C.H.
Chen6, N. Zhao7, X. Yi8, C. David4
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2Stanford University, Reproductive endocrinology and infertility, Stanford, U.S.A.
3Stanford University, Department of Bioengineering, Stanford, U.S.A.
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Study question: To determine if mechanical properties of oocytes can be
obtained without harming subsequent development, and be used to predict
blastulation.
Summary answer: Obtaining mechanical measurements of oocytes does not
affect subsequent fertilization or development, and for a subgroup of oocytes,
mechanical properties may predict blastulation.
What is known already: In multiple tissues, cells’ mechanical characteristics
often predict their intrinsic health and function. Many characteristics of oocytes
noted by embryologists, including the ease of piercing the oolemma during ICSI
or blastocyst expansion, are direct manifestations of an oocyte or embryos’
mechanical properties. Our device was designed to provide objective measure-
ments of these properties using a pipette to aspirate the cell with a uniform
step negative pressure. Using this device, the mechanical properties of zygotes
has been observed to predict blastulation in humans, and in a mouse model,
measurement of the oocyte predicted fertilization after conventional insemin-
ation and blastocyst development
Study design, size, duration: This was a prospective split cohort study of
patients undergoing IVF-ICSI at two private fertility clinics collaborating with an
academic embryology lab over 6 months. Nineteen patients and the corre-
sponding 100 measured and 368 unmeasured control oocytes from clinic A
(primarily blastocyst culture), and 20 patients and the corresponding 116 mea-
sured and 111 unmesaured control oocytes from clinic B (primarily Day 3 cul-
ture) were included in the analysis.
Participants/materials, setting, methods: Patients consenting to partici-
pation and planning to undergo IVF-ICSI with >10 oocytes retrieved were
approached for consent to have at most, half of their oocytes, measured with
the micropipette aspiration device. The aspiration depth over time was mea-
sured and applied to a modiﬁed Zener bulk mechanical model to obtain mech-
anical parameters: k0, k1, tau, eta0, eta1, and zona pellucida thickness. Oocyte
fertilization, day 3 morphology, and blastocyst development were recorded and
compared to mechanical properties.
Main results and the role of chance: There was no observed differences in
fertilization rates (74% vs. 78%, p = NS), good day 3 development per oocyte
(44% vs.37%, p = NS ), and a trend towards higher blastocyst development
after measurement, (55% vs. 45%, p = 0.09) when comparing the measured
and unmeasured oocytes. There was no correlation between maternal age or
zona pellucida thickness and any of the ﬁve mechanical parameters, and the
parameters do not seem to predict normal fertilization of the oocyte; however,
among fertilized oocytes, 94% of oocytes with eta0 in the lowest quartile, 90%
of oocytes with k1 in the top quartile, 88% of oocytes with tau in the lowest
quartile, and 88% of oocytes with eta1 in the lowest quartile made blastocyst,
all being signiﬁcantly higher blastulation rates than oocytes in other quartiles
(p < 0.05). No trend was observed to be predictive among other parameters.
Limitations, reasons for caution: The higher than anticipated blastocyst
development rate (>70%/2PN) and good prognosis patients included in the
study may limit the application of these preliminary ﬁndings to a more general-
ized patient population.
Wider implications of the ﬁndings: In this pilot, mechanical parameters of
oocytes are highly speciﬁc but not sensitive for blastulation, and have potential
for a non-invasive test of oocyte competence. Measurement is safe and does
not affect fertilization or embryo development. Additional investigation with a
more diverse patient population is needed to conﬁrm these ﬁndings.
Trial registration number:NCT02530892
O-032 Comprehensive assessment of human embryo
development and estimation of implantation
F. Pennetta1, R. Rizzo2, G. Gioacchini3, N. Tarozzi1, D. Bortolotti2,
M. Lispi4, F. Barrios4, A. Borini5
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Study question: Can we improve our ability to assess embryo developmental
and implantation potential by investigating the possible relationship between
EEVA scores and embryo-derived microRNAs or sHLA-G?
Summary answer: Our preliminary results are consistent with the study
hypothesis, suggesting a correlation between EEVA scores and expression pro-
ﬁles of both sHLA-G and microRNAs (miRNAs)
What is known already: Early prediction of embryo viability and implant-
ation potential remains challenging although several non-invasive strategies have
been developed. Among the latter, the EEVA (Early Embryo Viability Assay)
system represents a time-lapse approach that applies a patented algorithm to
automatically classify Day 3 embryos in ﬁve categories, according to their high-
est (SCORE-1, S1) or lowest (SCORE-5, S5) probability of reaching blastocyst
stage. Furthermore, a central role of sHLA-G for successful implantation and
pregnancy maintenance by cytokine secretion modulation inducing immunoto-
lerance is well established. Moreover, recent studies have suggested that
miRNAs are involved in molecular signaling during maternal-conceptus dialogue
aiming at implantation success.
Study design, size, duration: This is a prospective randomized pilot study.
Human embryos obtained during routine IVF/ICSI cycles were continuously
monitored with the EEVA system just after fertilization check and EEVA scores
were generated on day 3. After day 3, embryos were cultured up to blastocyst
stage. Immediately before vitriﬁcation or transfer, 25 μl of spent blastocyst
media (SBM) of 90 samples were individually processed for miR-20a-5p and
miR-30c-5p analysis. Furthermore, 10 μl of SBM were assayed for sHLA-G pro-
tein quantiﬁcation.
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Participants/materials, setting, methods: MicroRNAs isolation was con-
ducted with miRCURY RNA Isolation Kit for Bioﬂuids (EXIQON) and miRNAs
proﬁles evaluated by miRCURY LNA™/Universal RT-SYBR® Green PCR assay
(EXIQON). UniSp6 and Unisp2 were used as reference genes. sHLA-G levels
were assessed by Bio-Plex Multiplex immunoassays (Bio-Rad). Data distribution
was analyzed by Kolmogorov-Smirnov and Shapiro-Wilk tests. Correlation was
investigated using Spearman’s rho and Wilcoxon test. MiRNAs and sHLA-G
expression levels among EEVA categories were compared using Kruskall-Wallis
and Mann-Whitney post-hoc tests.
Main results and the role of chance: Out of 90 samples, 24 were S1, 16
S2, 16 S3, 16 S4 and 18 S5. MiR-20a-5p, miR-30c-5p and sHLA-G expression
levels followed a non-normal distribution. sHLA-G concentrations increased
with decreasing EEVA scores (negative correlation: r=-0,476, p = 0,000) and
differed signiﬁcantly among EEVA categories (Kruskall Wallis, p = 0,001).
Pairwise comparisons as a post-hoc analysis revealed signiﬁcantly increased
sHLA-G levels in EEVA score 1 (ES1) group compared to EEVA score 5 (ES5)
group (p = 0,000, ES1 mean rank = 54,16 vs ES5 mean rank = 22,31). MiR-
20a-5p expression proﬁles were also negative correlated with EEVA scores
normalizing miR-20a-5p CT values both respect to UniSp2 plus UniSp6 (r=-
0,277, p = 0,01) or respect to UniSp2 (r=-0,283, p = 0,03) and UniSp6 (r=-
0,285, p = 0,01) only. Nevertheless miR-20a-5p was not differentially
expressed across EEVA categories (Kruskall-Wallis, p = 0,165) consequently
multiple comparisons were not carried out. Unexpectedly, we found a positive
relationship between EEVA scores and miR-30c-5p normalizing mir-30c-5p CT
values both relatively to UniSp2 plus UniSp6 (r = 0,357, p = 0,001) than for
UniSp2 (r = 0,294, p = 0,008) and UniSp6 (r = 0,354, p = 0,001) only.
Statistical analysis comparing miR-30c-5p proﬁles between EEVA categories
highlighted differential expression levels (Krusall-Wallis, P = 0,039) with statis-
tically signiﬁcant increased concentrations in SBM from ES5 compared to ES1
(p = 0,04, ES5 mean rank = 51,22 vs ES1 mean rank = 29,7).
Limitations, reasons for caution: Current ﬁndings are preliminary, there-
fore further evaluations are needed.
Wider implications of the ﬁndings: MiRNAs and sHLA-G characterization
is a good non-invasive approach for embryo evaluation and provides helpful
information regarding his implantation potential and his physiological state.
Therefore, proﬁling miRNAs and sHLA-G from SBM might be integrated with
EEVA scores predictivity to enhance embryo comprehensive assessment and
selection for transfer.
Trial registration number:None.
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O-033 A systematic review of fertility-related psychological
distress and reproductive concerns in cancer patients of
reproductive age: informing on improved oncofertility psychological
care
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Study question: What is the level of psychological distress and reproductive
concerns of cancer patients of reproductive age (<45 years) throughout cancer
treatment and survivorship.
Summary answer: Signiﬁcant anxiety, depression and trauma related stress
persist into survivorship, with female cancer patients particularly at risk of long
term fertility-related psychological distress.
What is known already: Actual or perceived infertility brought about by can-
cer disease and treatment leads to signiﬁcant psychological distress and impair-
ments to later quality of life for cancer survivors. However, research has yet to
investigate the degree of psychological distress and reproductive concerns at
different oncology treatment time points; diagnosis, treatment, survivorship.
One way to diminish the impact of long term distress is via the provision of
appropriate fertility-related psychological care throughout the cancer journey.
A systematic review of the oncofertility literature would inform on an improved
model of fertility-related psychological care.
Study design, size, duration: A systematic review of the literature con-
ducted in January 2018 utilised electronic databases Medline, EMBASE, PSYCH
Info, Web of Science and SCOPUS. Search terms reﬂected subheadings of can-
cer, psychological distress and fertility. Inclusion criteria included peer reviewed
articles published in English, that reported on fertility-related psychological dis-
tress or reproductive concerns of cancer patients, diagnosed at reproductive
age (<45 years). No limitations were placed on patient gender, cancer type or
time since diagnosis.
Participants/materials, setting, methods: An initial search identiﬁed 701
potentially relevant studies, with full text of 174 studies further screened for eli-
gibility. A second reviewer rated a subsection of the studies at full text to ensure
inter-rater reliability. Any discrepancies on inclusion or exclusion were further
discussed. Quality of all included studies was assessed via the Mixed Method
Appraisal Tool, with all studies of reasonable quality. A total of 40 studies were
included within the review.
Main results and the role of chance: Fertility-related psychological distress
experienced by patients throughout the cancer journey were reported in 34
papers. Clinical levels of anxiety and depression were reported in one third of
newly diagnosed patients, with anxiety and worry persisting through to sur-
vivorship. Trauma related stress were reported in survivorship, with stress
greatest in female patients. Devastation, loss of control and loneliness were
negative emotional responses experienced throughout the cancer journey.
Psychological distress was related to perceived quality of oncofertility care.
Reproductive concerns were reported in 34 papers. Reproductive concerns
were higher in younger and infertile patients, those whom life’s narrative had
been disrupted. Unfulﬁlled desire for a child in female patients was associated
with greater trauma symptoms, higher depression and poorer mental health.
Prevalence of pregnancy-related concerns were high, linked with depression or
trauma in some samples. Menopause concerns were linked to greater emo-
tional distress and higher symptoms of depression. Other common reproduct-
ive concerns linked to negative emotional expression included concerns about
future children and current or future relationships.
Limitations, reasons for caution: Included studies do not focus exclusively
on fertility-related psychological distress. As such, there is the risk that vital
information has not been captured by current literature. The limited number of
interventions also hinder the ability to draw deﬁnitive conclusions about how
services may be improved to better incorporate psychological care.
Wider implications of the ﬁndings: Cancer patients and survivors would
greatly beneﬁt from fertility-related psychological support implemented into
standard practice. The provision of this care may serve to mediate some of the
later life impacts to psychological health and reproductive quality of life in can-
cer survivors of reproductive age.
Trial registration number: not applicable.
O-034 Ten pathways to elective egg freezing: A binational
qualitative study of what leads healthy women to fertility
preservation
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Study question:Why are healthy women freezing their eggs?
Summary answer: We identiﬁed 10 different pathways leading to EEF,
mostly revolving around women’s lack of stable partnerships with men commit-
ted to marriage and parenting.
What is known already: The literature on oocyte cryopreservation suggests
that EEF is being used primarily to defer or delay childbearing among women
pursuing education and careers. However, emerging empirical data from both
anonymous surveys and interview-based studies suggest that the lack of a stable
partner might be the primary motivation for EEF.
Study design, size, duration: From June 2014 to August 2016, 150 women
(114 in the United States, 36 in Israel) who had completed at least one cycle of
EEF were interviewed by two senior medical anthropologists, one in each
country.
Participants/materials, setting, methods: Study participants were
recruited through 4 American IVF clinics (2 academic, 2 private) and 3 in Israel
(1 academic, 2 private). In-depth, semi-structured, but open-ended interviews
were audio-recorded, transcribed, and entered into a qualitative data analysis
program (Dedoose) for thematic analysis, along with detailed interview
summaries.
Main results and the role of chance: The majority (85%) of women in the
study were without partners, reﬂecting 6 different life circumstances that led
them to EEF (i.e., being single, divorced or divorcing, broken up, deployed over-
seas, single mother by choice or circumstance, career planner). EEF undertaken
for career planning was the least common of these pathways. Those with part-
ners (15%) faced 4 different life circumstances leading to EEF (i.e., not ready to
have children, relationship too new or uncertain, partner refuses to have chil-
dren, partner has multiple partners). As seen in these pathways, most women
had already pursued and completed their educational and career goals, but had
been unable to establish lasting reproductive partnerships. With only one
exception (i.e., overseas deployment), these pathways varied relatively little
among American and Israeli women in the study.
Limitations, reasons for caution: As a binational study, women were
recruited somewhat differently between the two countries, and interviewed by
two anthropologists in two languages. The number of participants was unequal,
reﬂecting national differences in population size. These were the main limita-
tions of this interview-based study, which is the largest to date.
Wider implications of the ﬁndings: Pathways to EEF may or may not be
similar for women in other national settings. Further in-depth, interview-based
research is essential. Furthermore, clinicians must be aware of the role that
partnership ‘troubles” play in the lives of EEF patients and make patient-
centered care for single women a high priority.
Trial registration number:
O-035 Two-year follow-up of a randomised controlled trial:
knowledge and reproductive outcome after online fertility
education
E. Maeda1, J. Boivin2, S. Toyokawa3, K. Murata1, H. Saito4
1Akita University Graduate School of Medicine, Environmental Health Sciences,
Akita, Japan
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Neonatal and Reproductive Medicine, Tokyo, Japan
Study question: What are the long-term effects of fertility education on
knowledge and reproductive outcome?
Summary answer: Participants in the intervention group retained some
knowledge after two years and the partnered women had another child more
quickly than those in control group1.
What is known already: Fertility education improves knowledge at least in
the short term. Attitudes toward childbearing and its timing can change after
exposure to educational materials.
Study design, size, duration: In the original randomised controlled trial
(RCT), knowledge of reproductive-aged participants was assessed before (T1)
and immediately after (T2) receiving one of three information brochures: fertil-
ity (intervention group), intake of folic acid during pregnancy (control group 1),
or family policies in Japan (control group 2). This follow-up study was con-
ducted two years later in January 2017 (T3).
Participants/materials, setting, methods: Of the T1 participants (n =
1,455), 383 men and 360 women (51%) responded to the T3 survey. Fertility
knowledge measured with the Japanese version of the Cardiff Fertility
Knowledge Scale (CFKS-J) and fertility status (e.g., new births, new medical con-
sultations, and the timing of new birth) were assessed.
Main results and the role of chance: Baseline (T1) characteristics of the T3
participants were well-balanced between groups, whereas T3 participants were
older, married, and more educated compared to those lost to follow-up.
Group comparisons of the T3 scores on the CFKS-J showed no differences.
Within-group comparison showed that, in the intervention group, the T3 score
was signiﬁcantly higher than the T1 score (4.5 and 3.6 percent higher among
men and women, respectively) and signiﬁcantly lower than the T2 score (6.0
and 11.5 percent lower among men and women, respectively). There were no
differences between groups in the proportions of those who had a new birth or
those who had a new medical consultation by T3. Among those who had a
partner at T1, the proportion of those who had a new birth in the ﬁrst year was
higher in the intervention group than in control group 1 (folic acid): 8.8% versus
1.4% (odds ratio [OR] = 6.8, 95% conﬁdence interval [CI]: 0.72 to 327.3)
among men and 10.6% versus 2.3% (OR = 5.1, 95% CI: 1.00 to 49.5) among
women.
Limitations, reasons for caution: High attrition rate may limit the generaliz-
ability of these ﬁndings.
Wider implications of the ﬁndings: Effects of one-time education were
limited but retained. Follow-up education might help people retain knowledge
and facilitate reproductive decisions. In view of the high attrition rate, especially
among young populations, educational strategies should be explored.
Trial registration number: UMIN Clinical Trials Registry number
000016168
O-036 Randomized controlled trial on the effect of an online
decision aid for young female cancer patients considering fertility
preservation
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2University Hospital Basel, Medical Oncology, Basel, Switzerland
3St. Claraspital Basel, Gynecology and Gynecologic Oncology, Basel, Switzerland
4University Hospital Basel, Gynecology and Obstetrics, Basel, Switzerland
5University Hospital Zurich, Gynecology and Obstetrics, Zurich, Switzerland
6University Hospital of Heidelberg, Gynecological Endocrinology and Reproductive
Medicine, Heidelberg, Germany
7amedes Hamburg, Centre for Infertility- Prenatal Medicine- Endocrinology and
Osteology, Hamburg, Germany
8University Hospital Friedrich-Alexander, University Women’s Hospital-
Comprehensive Cancer Center ER-MN, Erlangen-Nuernberg, Germany
Study question: Does the use of an online decision aid about fertility preser-
vation (FP) in addition to FP counseling, reduce decisional conﬂict, compared to
FP counseling alone?
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Summary answer: The additional use of the online decision aid (DA) signiﬁ-
cantly reduced decisional conﬂict (DC) in female cancer patients compared to
FP counseling alone.
What is known already: Female cancer patients may be confronted with
impaired fertility due to cancer treatment. Nowadays, several options to pre-
serve fertility are available, however having to decide whether or not to opt for
FP, within the short time frame after cancer diagnosis and before treatment
start is challenging. Various studies have already shown that there is a high DC
amongst these women and support is highly in demand. According to previous
research, DA’s may be a helpful support in decision-making. To our knowledge,
there is no evaluated DA about FP for German speaking women that, further-
more covers several cancer types.
Study design, size, duration: The study is a randomized-controlled trial
including 51 women, who were referred to one of the participating fertility cen-
ters after having been diagnosed with cancer. Participants were either assigned
to the control group (counseling only) or to the intervention group (counseling
and additional use of the online DA immediately after counseling). Recruitment
was ongoing from July 2016 to December 2017 at a total of 8 fertility centers in
Switzerland and Germany.
Participants/materials, setting, methods: The online DA was developed
by an interdisciplinary team of reproductive specialists, gynecologists and psy-
chologists. Participants were asked to complete an online questionnaire at three
time points: after counselling (control group) or after counseling and the use of
the DA (intervention group) (T1) as well as one month (T2) and 12 months
later (T3). The survey comprised questions about fertility-related knowledge,
decisional conﬂict, decisional regret, attitude towards FP, willingness to undergo
FP and socio-demographic data.
Main results and the role of chance: First analyses of the Decisional
Conﬂict Scale show a statistically signiﬁcant difference between the intervention
and control group regarding decisional conﬂict at T1 (p = 0.008). Women, who
used the DA in addition to counseling, showed a signiﬁcantly lower total score
on the Decision Conﬂict Scale (M = 23.95, SD = 13.48), compared to those in
the control group (M = 36.11, SD = 17.26). The mean score of three out of
the four subscales of the Decisional Conﬂict Scale were also signiﬁcantly lower
for the intervention group compared with the control group. First analyses
show, that there seems to be an immediate positive effect of the DA by redu-
cing DC about FP in female cancer patients. It is expected that the ﬁnal analyses
of the study will provide further insight in aspects such as patients’ fertility-
related knowledge and decisional regret.
Limitations, reasons for caution: Education was high in two thirds of the
participants. It is difﬁcult to say, whether the DA might be equally effective in
women with a lower educational background. Further analyses of the ﬁnal data
must be conducted in order to complete the evidence about the effectiveness
of the DA.
Wider implications of the ﬁndings: This study contributes to extending
the range of nowadays available DA’s about FP, as it is to our knowledge the
ﬁrst randomized controlled trial evaluating a DA covering several cancer types.
The DA seems to serve as a helpful complement of the decision-making pro-
cess for patients and professionals alike.
Trial registration number:NCT02404883 (clinicaltrials.gov)
O-037 Impact of fertility assessment and counselling on life
changing decisions in women of reproductive age – status one year
after the initial consultation
R. Sylvest1, E. Koert2, I. Vittrup2, K. Petersen3, A. Nyboe Andersen2,
A. Pinborg1, L. Schmidt4
1Copenhagen University Hospital Hvidovre, Department of Obstetrics/Gynaecology,
Hvidovre, Denmark
2Copenhagen University Hospital- Rigshospitalet, Fertility Clinic, Copenhagen,
Denmark
3University Hospital of Zealand, Fertility Clinic, Holbæk, Denmark
4University of Copenhagen, Department of Public Health, Copenhagen, Denmark
Study question: What was the impact of attending fertility assessment and
counselling on fertile women´s decisions and subsequent choices regarding their
family formation, childbearing or relationship?
Summary answer: The fertility and assessment clinic provided an individua-
lised approach that was frequently a catalyst for change concerning childbearing
decisions and behaviour.
What is known already:Over the past 30 years women and men have post-
poned family formation in high income societies. Fertility assessment and coun-
selling has been suggested as a method to reduce the negative consequences of
delayed childbearing. There is a need to investigate the impact of this type of
intervention to see if counselling inﬂuences choices on the critical issues of
delayed childbearing and gaps in fertility awareness and knowledge.
Study design, size, duration: Follow up data from a longitudinal semi-
structured qualitative interview study including 20 women aged 35-40 years
seeking individual fertility counselling. The interviews were conducted one year
after their consultation at the clinic.
Participants/materials, setting, methods: Study participants were ﬁve sin-
gle and 15 cohabiting women, residents in the Capital Region of Copenhagen,
Denmark and who had sought individual fertility assessment and counselling.
Since their consultation at the counselling clinic, ﬁve women had gone through
fertility treatment, three had delivered and seven had attempted to become
pregnant. The interviews took place in their own homes or at the clinic. Data
were analysed by qualitative content analysis.
Main results and the role of chance: Twenty different women, twenty dif-
ferent stories. The overall theme was: ‘Knowledge increased’. The women
increased their knowledge after they had attended the counselling. ‘Catalyst for
change’, ‘Staying in limbo’ and ‘Peace of mind’ were subthemes. Some of the
women saw the counselling as a catalyst for change – they changed behaviour
and relationship status. Five started fertility treatment (with their partner or as a
future solo mother), two left their partner and seven attempted to become
pregnant. The women stopped thinking about the pros and cons of childbearing
and acted instead. The counselling initiated conversations with their partner
about childbearing. Some of the women felt that they were still in limbo as they
were still in doubt concerning childbearing. The consultation had not given
them an answer with a clear deadline, and this frustrated them. But for the
others, the consultation gave them peace of mind because they realised that
they had time to ﬁgure out their future plans concerning childbearing.
Limitations, reasons for caution: The study participants had all chosen to
seek individual fertility counselling and all women were of advanced reproduct-
ive age over 35 years. Hence, the results may not be directly transferred to the
general population in regards to attitudes towards family formation and con-
cerns of reproductive lifespan.
Wider implications of the ﬁndings: Our study highlights the impact of fer-
tility assessment and counselling intervention which included an increase in
knowledge. What the women did with it depended on their current life circum-
stances, fertility status and readiness. The clinic allows for an individualised
approach which is necessary given the unique nature of childbearing decisions.
Trial registration number:Not applicable.
O-038 ‘Doing it in the right order’ – Childless young men’s
intentions regarding family formation
G.M. Malling1, T. Pitsillos2, T. Tydén2, S. Ziebe3, B. Friberg4,
K. Hammarberg5, L. Schmidt1
1University of Copenhagen, Department of Public Health, Copenhagen K, Denmark
2University Hospital Uppsala, Department of Women’s and Children’s Health,
Uppsala, Sweden
3Copenhagen University Hospital- Rigshospitalet, Fertility Clinic, Copenhagen,
Denmark
4Lund University, Molecular Reproductive Medicine- Department of Translational
Medicine, Malmö, Sweden
5Monash University, Jean Hailes Reseach Unit- School of Public Health and
Preventive Medicine, Melbourne, Australia
Study question: Which factors inﬂuence young men’s decision-making
regarding timing of family formation?
Summary answer: Social and societal expectations, following the right chron-
ology, being ready to give up individuality, and ensuring security inﬂuence young
men’s preferred timing of family formation.
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What is known already: Postponing family formation increases risk of invol-
untary childlessness or having fewer children than desired. Despite Denmark
and Sweden offering good opportunities to combine work life with having chil-
dren, the age of childbearing has increased signiﬁcantly in the last 40 years. Most
previous studies regarding family formation and fertility awareness have focused
on university-educated women. The few existing studies of men’s attitudes to
family formation indicate that prerequisites for men are to be in a stable rela-
tionship, having completed education, ensured a stable job, and having sufﬁcient
personal maturity.
Study design, size, duration: This qualitative study assessed fatherhood
intentions among childless men in Denmark and Sweden in their last year of uni-
versity education or vocational training. In total, 17 Danish and 12 Swedish
male students were interviewed. The interviews were conducted between
February-September 2017 and ranged between 30 and 90 minutes.
Participants/materials, setting, methods: The participants were
recruited face-to-face or via postings at their educational institutions, and by
snowball methods. Inclusion criteria were: being male, childless, aged 20-30
years and in the last year of education. The interviews were conducted wher-
ever the participants preferred, either at their educational institution, their
home, or in an ofﬁce. The 29 interviews were transcribed and the content ana-
lysed through a thematic content analysis.
Main results and the role of chance: Study participants were on average
25 years old (range 20-30). Through the analysis ﬁve subcategories emerged: 1)
Expectations from the society; 2) Inﬂuence from within the social circle; 3)
Enablers for earlier family formation; 4) Giving up freedom and individuality; 5)
Ensuring security and stability.
Almost all participants wanted children in the future. The young men wanted
to ﬁnd their path in life before having children. In relation to life events, they felt
that they were required to follow the right chronology – ﬁrst education, accom-
modation and career, then children. Further, they expressed the need to
explore some of the many other life experiences available to young people in
contemporary society, including travel, to ﬁgure out what they wanted in life.
Moreover, being ready to have children was associated with being ready to give
up individuality and freedom. While many stated that they felt mature enough,
this was not equated with feeling ready to have children. Other factors inﬂuen-
cing participants’ preferred timing of parenthood were being in a stable relation-
ship, having appropriate housing, ensuring ﬁnancial security, and having fulﬁlled
career aspirations. Further, both Danish and Swedish men expressed reﬂecting
themselves in their parents in relation to age at ﬁrst child.
Limitations, reasons for caution: Despite following the same interview
guide, the interview technique between countries may have differed. This may
have inﬂuenced the dialogue. Men who want children may have been more
likely to agree to participate than men who do not want children.
Wider implications of the ﬁndings: In order to promote earlier family
formation and prevent infertility this study highlights the need to educate young
men about the limitations of fertility. Exploring the many opportunities of
today’s society and chasing a career is not limited by age, however fertility is.
Trial registration number:Not applicable
INVITED SESSION
SESSION 08: LABORATORYMODELLING TO
UNDERSTAND ENDOMETRIAL FUNCTION
Monday 2 July 2018 Room 211 + 212 11:45–12:45
O-039 Endometriosis and associated pain
E. Greaves1
University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, United
Kingdom
Endometriosis is a complex chronic inﬂammatory condition associated with
debilitating pain and infertility that affects 176 million women worldwide. Current
research aims to understand the aetiology and pathophysiology of the disorder
and develop novel effective non-surgical therapies that lack the unwanted side
effects of current medical management. Tools for endometriosis research fall into
two broad categories: patient-derived tissues and ﬂuids (and cells isolated from
these sources) and laboratory models based on the use of cells or animals. There
are many different models (in vitro and in vivo) reported in the literature, all have
their advantages and drawbacks and choice of model depends largely upon the
research question. Rodent models of endometriosis in particular exist in many dif-
ferent variations and have different utilities depending whether the study is
designed to explore pain or infertility. The rat has been used most consistently
for studying mechanisms of endometriosis-associated pain with a number of dif-
ferent behaviour read-outs including those used to measure mechanical hyper-
algesia, allodynia and anxiety. Many different versions of mouse models of
endometriosis exist (with reﬁnements and standardisation being a current focus
in the ﬁeld) and their utility for the assessment of pain in the condition is becom-
ing a priority. In summary, hypothesis-driven endometriosis research can only be
facilitated with careful experimental design and selection of the most appropriate
human tissue from patients with and without endometriosis and combinations of
physiologically relevant in-vitro and in-vivo laboratory models.
O-040 Implantation and early pregnancy, the maternal
contribution
C. Simon Valles1
University of Valencia- INCLIVA- Igenomix, Obstetrics and Gynecology, Paterna -
Valencia, Spain
Abstract text
Human reproduction is a very inefﬁcient process with a probability of concep-
tion during a given menstrual cycle around 30%. In the last 40 years, reproduct-
ive medicine has emerged as one of the most rapidly developing areas of
medical science propelled by clinical and basic research advances in ovarian
physiology, induction of ovulation, and embryology. Despite all technological
advances in the understanding of the “seed”, the maternal endometrium has
been the forgotten organ. Nowadays, when a morphologically normal blasto-
cyst is transferred into a seemingly normal uterus, cycle reproductive success is
still limited, and sadly, has not signiﬁcantly improved since the 1990´s. This is
the main reason the clinical community turn its attention to embryonic implant-
ation as the end-point not only for the reproductive success but also for the
obstetric outcome and the conditioning of the origin of some adult diseases.
The human endometrium is a hormonally regulated organ that is the ana-
tomic pre-requisite to initiate and control human pregnancy while is a sentinel
for protecting the upper female reproductive from infections by a variety of
microbes. The transition from anatomical to molecular medicine has led to the
discovery of the transcriptomic signature of endometrial receptivity and its clin-
ical application in patients with implantation failure through personalized
embryo transfer. The endometrial cavity has been classically considered to be a
sterile organ, but reports challenging this dogma support the existence of an
endometrial microbiota composed of different microorganisms (speciﬁcally
Lactobacillus spp., Mycoplasma hominis, Gardnerella vaginalis, and Enterobacter
spp.) that might affect the reproductive outcome. The maternal decidua con-
trols conception and the course of pregnancy in humans. Also, failed deciduali-
zation is associated with a spectrum of reproductive defects including failed
implantation and clinical miscarriage but also late gestational complications such
as preeclampsia. New emerging data reinforce the concept that suboptimal
uterine conditions lies upstream of not only inefﬁcient conception, but also
failed trophoblast differentiation and invasion driving placentation, paving the
way to better diagnosis, prevention and treatment of late gestational diseases.
In this presentation, I will revisit the modern knowledge of the “soil” concept
and its basic and clinical contribution to the embryo implantation process.
INVITED SESSION
SESSION 09: DATA REPORTING SESSION
Monday 2 July 2018 Room 111 + 112 11:45–12:45
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O-041 Data from the ESHRE PGDConsortium
O-042 How do ESHREmembers use and evaluate the ESHRE
guidelines?
S. Gameiro1, N. Vermeulen2, M. Sousa Leite3
1Cardiff University, School of Psychology, Cardiff, United Kingdom
2European Society for Human Reproduction and Embryology, Research Specialist,
Brussels, Belgium
3University of Minho, Department of Psychology, Braga, Portugal
Introduction: From 2013 ESHRE has been publishing evidence-based guidelines
to support care providers and patients making every-day decisions about appro-
priate and effective health care {Vermeulen, 2017 #508}. So far ESHRE has mainly
focused on the development and the dissemination of the guidelines and less on
ensuring that they are being appropriately implemented across Europe. The cur-
rent study reports on dissemination, implementation and impact of the ﬁrst four
published ESHRE guidelines: Management of Endometriosis (ENDO; Dunselman
et al., 2014), Routine Psychosocial Care (RPC; Gameiro, et al., 2015), Premature
Ovarian Insufﬁciency (POI; European Society for Human Reproduction and
Embryology Guideline Group on POI, 2016) and Recurrent Pregnancy Loss (RPL;
European Society for Human Reproduction and Embryology Guideline Group on
RPL, 2018).
Methods: The online survey assessed dissemination (knowledge that the
guidelines were published [Y/N] and download [Y/N]), implementation (using
guidelines in daily practice [Y/N] and made changes to practice according to
recommendations [Y/N]) and impact (perceived patient beneﬁt [Y/N] and
referral of patients to the guidelines [Y/N]). It further investigated perceived
quality of the guidelines (1 ‘very poor’ to 5 ‘excellent’), and barriers [open ques-
tion] and beneﬁcial support (list of available support options) for their imple-
mentation. The survey was online from February 20th to April 3rd 2018. It was
advertised via the ESHRE website, social media and mailings to the ESHRE
membership. Participants were offered the opportunity to win a free registra-
tion for the ESHRE Annual Meeting in Barcelona or an ESHRE Campus Course.
Results: A total of 723 ESHRE members accessed the survey.
540 (82.1%) participants know ESHRE published the ENDO guideline. From
these, 356 (65.9%) downloaded it, 225 (41.7%) use it in their daily practice, 166
(30.7%) are changing their practice, 105 (19.4%) think that patients beneﬁted
from the guideline, and 48 (8.9%) referred them to it.
227 (54.6%) participants know ESHRE published the RPC guideline. From
these 119 (52.4%) downloaded it, 67 (29.5%) use it in their daily practice, 43
(18.9%) are changing their practice, 37 (16.3%) think that patients beneﬁted
from the guideline, and 29 (12.8%) referred them to it.
205 (56.6%) participants know ESHRE published the POI guideline. From
these 111 (54.1%) downloaded it, 69 (33.7%) use it in their daily practice, 44
are changing their practice, 33 (16.1%) think that patients beneﬁted from the
guideline and referred them to it.
199 (59.5%) participants know ESHRE published the RPL guideline. From
these, 113 (56.8% downloaded it and 63 (31.7%) intend to change their practice.
The overall perceived quality of the guidelines was: ENDO 4.18 (0.71), RPC
4.11 (0.62), POI 4.26 (0.62), and RPL 4.26 (0.68).
Data on perceived barriers to implementation will be subjected to content
analysis. Regarding perceived beneﬁcial support, 180 (68.4%) participants
would do an e-learning course on the guidelines, 164 (64.3%) would use an
app, 166 (63.8%) would use a step-by-step manual, 153 (59.8) would use a
printed pocket guideline, and 128 (50.0%) would attend a campus course.
Discussion: Considering the multi-faced dissemination strategies used by
ESHRE, one would expect higher knowledge and access to the guidelines.
Although ESHRE members perceive the quality of the guidelines to be very
good and show interest in learning about how to implement them, only around
one-third actually use them in their clinical practice. It is therefore not a surprise
that perceived patient beneﬁt is low. Results suggest that the current ESHRE
guidelines strategy is insufﬁcient to ensure their implementation. Knowledge
about perceived barriers to implementation will inform about additional sup-
port that ESHRE can provide to its community. On-line media seems to be the
members’ preferred channel to receive such support.
INVITED SESSION
SESSION 10: FERTILITY SOCIETYOF AUSTRALIA
EXCHANGE LECTURE
Monday 2 July 2018 Room 113 + 114 + 115 11:45–12:15
O-043 Rapid, non-invasive measurements of metabolic balance
can stratify embryos based on ploidy
B. Arman1, L. Sandeman1, C. Carbone1, F. Bell1,2, M. Lane1,2
1Robinson Research Institute- University of Adelaide, Obstetrics and Gynaecology,
Adelaide, Australia
2Monash IVF, Monash IVF, Melbourne, Australia
Aim: To determine whether measurements of glucose uptake and hydrogen
peroxide production in human embryo secretome can be used to predict aneu-
ploidy and subsequent viability.
Method: Samples of spent culture media (n = 123) from patients (mean mater-
nal age 36.6 ± 0.6, mean maternal BMI 26.3 ± 0.8) undergoing IVF or ICSI with
pre-implantation genetic screening (PGS) were collected following incubation of
individual embryos in G2 Plus (Vitrolife) from day 3 to day 5. Samples were frozen
and blinded before analyses of glucose (ultra-microﬂuorometric analysis) and
hydrogen peroxide (Amplex UltraRed) concentrations. These concentrations
were correlated to embryo ploidy status, morphology, and pregnancy outcomes.
Statistical analysis was conducted using a Student’s t-test.
Results: Metabolic proﬁle was not correlated with either blastocyst expansion
or inner cell mass or trophectoderm quality. When combining the rate of
hydrogen peroxide production and glucose update to approximate mitochon-
drial function as a proportion of substrate uptake, then euploid embryos had a
signiﬁcantly higher metabolic ratio than aneuploid embryos (+2.9 fold, p <
0.05). Within euploid embryos, pregnancy rates were associated with an
increase in glucose uptake (+3.0 fold, p < 0.05).
Conclusion: Metabolic balance between substrate uptake and pathway utilisa-
tion improves the ability to stratify embryos into viable and non-viable cohorts.
This study also conﬁrms that morphology is a poor predictor of viability and
metabolic output. These results suggest that metabolic balance of embryos
could be used as a rapid and inexpensive non-invasive screening tool for ranking
embryo suitability for transfer. Further studies are required to determine the
metabolic consequences of individual aneuploidies.
INVITED SESSION
SESSION 11:WHATABOUTTHE CHILDREN?
Monday 2 July 2018 Room 117 11:45–12:45
O-044 Health of ICSI children
U.B.Wennerholm
University of Göteborg, Department of OB/GYN\rInstitute for Women’s & Children’s
Health, Göteborg, Sweden
It is over 25 years since the ﬁrst child was born after ICSI treatment. Since then
there has been an ongoing debate on the use and safety of the technique.
Initially, ICSI was used to treat severe forms of male factor infertility but today it
is also used to treat mild male factor infertility, mixed male/female infertility,
unexplained infertility and fertilization failures. Both the latest European ESHRE
report and the global ICMART report reveal an increasing global use of ICSI,
with one-third of fresh assisted reproductive technology (ART) cycles using
conventional IVF and two-thirds using ICSI. Due to the invasiveness of the ICSI
procedure as well as the arbitrary selection of the spermatozoon and genetic
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and epigenetic parental factors, concerns have been expressed about the health
of ICSI children.
Adverse perinatal outcomes in ART, which includes ICSI and conventional
IVF techniques, are associated mainly with ART’s higher rates of multiple preg-
nancies. In ART singletons, the rate of very preterm birth and very low birth
weight is about two to three times higher than in the general population. When
comparing ICSI and conventional IVF, most large studies have found similar or
lower risks of very preterm and preterm birth, very low birth weight, low birth
weight and peri/neonatal mortality.
Many large national registry studies show a slight increase in birth defects in
ART children compared to the general population. Evidence regarding birth
defects in ICSI versus IVF is less clear but most large cohort studies show no dif-
ference in the incidence of birth defects between ICSI and IVF newborns, and
the different sperm sources used in ICSI do not seem to inﬂuence the rate of
birth defects negatively. However, the incidence of de novo and inherited sex
chromosomal abnormalities in ICSI offspring is slightly higher, which probably
relates to the genetics of the infertile couples. Some studies, mainly case-
control studies have reported associations between ART (but not to a speciﬁc
reproductive technique) and imprinting disorders such as Beckwith-
Wiedemann syndrome, Angelman syndrome and Prader Willi syndrome.
These disorders may be related to the underlying infertility problem. All are
rare disorders and the absolute risk of an imprinting disorder after ICSI/IVF is
extremely small.
Studies of growth and physical health are few and limited to childhood.
Looking at general physical health including such factors as hospitalizations,
childhood illnesses, surgical interventions and medical therapies, there are simi-
lar results for ICSI and IVF-conceived children. Results are also similar for age
and gender-matched controls in the general population. Most large cohort stud-
ies do not show any increase in childhood cancer in general in ART children and
provide no evidence of increased numbers of adverse outcomes in the ICSI
group.
Most studies comparing children up to eight years of age born after ICSI, IVF
and spontaneous conception, suggest their neurocognitive development is com-
parable. Sperm source or individual semen parameters do not affect neurode-
velopment. Two large recent studies reporting associations between ICSI and
autism and autistic disorders should be interpreted with caution, since the abso-
lute risks of autism and autistic disorders are small.
A few longitudinal reports on reproductive health in ICSI adolescents and
young adults have also been published recently. Onset of puberty and pubertal
development is similar for ICSI and spontaneously conceived boys and girls, but
ICSI-conceived men seem to have lower sperm concentrations and total sperm
counts than age-matched, spontaneously conceived controls.
Further monitoring and research is necessary before ﬁrm conclusions about
the safety of ICSI, as opposed to IVF, can be drawn. Large well-designed cohort
studies are still needed, taking into account parental factors and technical pro-
cedures as well as selection and surveillance biases.
O-045 Psychological and medical follow-up of children born after
Pre-implantation Genetic Testing (PGT)
J. Nekkebroeck1, B. Maryse2
1UZ Brussel, Centrum voor Reproductieve Geneeskunde, Jette- Brussels, Belgium
2UZ Brussel, Centre for Medical Genetics, Brussels, Belgium
Abstract text
Psychological and medical follow-up of children born after Pre-implantation
Genetic Testing (PGT)
Follow-up studies on the health of PGT (and PGT-Aneuploidy) children are
essential in order to provide reassurance about the safety of the technique
(ESHRE 2007; ESHRE PGD Consortium 2012).
Psychological health is translated in the cognitive and motor development of
children. Pioneering studies did not differentiate between children born after
PGT or PGT-A (Banerjee, 2008; Nekkebroeck, 2008) but found reassuring
results for cognitive development at age 2 (Nekkebroeck, 2008). In the study of
Banerjee et al. (2008) the scores for locomotor capacities of the PGT(-A) chil-
dren were signiﬁcantly lower than those of the ICSI group. In the study of
Nekkebroeck et al. (2008) PGT(-A) children presented normal motor develop-
ment compared to ICSI and naturally conceived (NC) counterparts.
Only a few studies focused solely on PGT children. Thomaidis et al. (2012)
examined 31 PGT children of different ages, 22.6% showed mild motor retard-
ation quotients but there was a lack of matched controls. The same was the
case in the study of Sacks et al. (2016) where 4-to-5 year old PGT children
showed normal neuropsychological development. Winter et al. (2014) exam-
ined 5-to-6 year old PGT singletons for cognitive and motor development and
found comparable scores to their matched ICSI and NC controls.
Psychological health is also deﬁned in terms of psycho-social development
and family functioning. In Nekkebroeck et al. (2008) the socio-emotional devel-
opment of PGT(-A) children aged 2 did not differ from the control groups (ICSI
and NC) neither did parental stress and mental health status. For PGT children
aged 5-6 similar results were found for psychosocial development (Winter
et al., 2015). In terms of family functioning the NC mothers, experienced more
parental stress while PGT/ICSI mothers had higher feelings of competence and
were more goal directed.
The neonatal and medical outcomes of PGT/PGT-A children compared to
ICSI and sometimes NC are also described and are mainly reassuring.
Two months after birth PGT/PGT-A children were examined and compared
with ICSI new-borns in research of Liebaers et al. (2010). More perinatal death
was observed in PGT/PGT-A multiples than in ICSI multiples. Gestation, birth-
weight and major malformation rates were similar. In another neonatal follow-
up study of 995 children (singletons and multiples) born after PGT no differ-
ences regarding: mean term, prematurity, birth weight, very low birth weight,
perinatal death, major malformations and neonatal hospitalizations with ICSI
singletons and multiples. However, fewer multiples born after PGT presented a
very low birth weight in comparison to ICSI multiples (Desmyttere et al. 2012).
At age 2 no differences between PGT(-A) singletons regarding weight, height
and head circumference were found when compared to ICSI singletons.
Compared to NC children the birth weight tended to be slightly lower for PGT
(-A) children. The latter were more frequently born after Caesarean section
than ICSI children (and NC) but there were no more congenital malformations,
hospital admissions and surgical interventions compared with ICSI/ NC chil-
dren (Desmyttere et al., 2009). When comparing 2-year-old twins and single-
tons again no differences were observed compared to ICSI counterparts. In a
Dutch cohort of PGT-A children there were no differences in blood pressure
and anthropometrics at age 4 and 9 compared to IVF/ICSI (Seggers et al.,
2013; Kuiper et al., 2018).
Conclusion: Methodological weaknesses are encountered in many follow-up
studies on PGT(-A) children (e.g. no distinctions between PGT/PGT-A chil-
dren, including singletons as well as multiples, including children of different
ages, no matched controls, small samples sizes). Luckily, most studies with or
without these ﬂaws indicate that young PGT(-A) children develop very similar
to ICSI and NC children. Continuous follow-up remains necessary to ensure
this positive outcome at older ages.
INVITED SESSION
SESSION 12: DEBATE: IMMUNOSUPPRESSION FOR
IMPLANTATION FAILURE - IS ITWORTH IT?
Monday 2 July 2018 Room 211 + 212 14:00–15:00
O-046 Pro
S. Quenby1
University Hospital Coventry Warwick Medical School, Division of Reproductive
Health, Warwick- Coventry, United Kingdom
Implantation failure is an increasing problem. This is a result of advances in ART
so that success rates following embryo transfer are now signiﬁcantly better than
intercourse. Hence today a lack of positive pregnancy test or a transiently posi-
tive pregnancy test after embryo transfer is now a source frustration from the
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patient and clinician’s perspective. Implantation and embryo-maternal interac-
tions are complex and still the subject of intensive research. However, some
features of this interaction are known. The embryo needs to be recognised by
the endometrium as being of high quality, a function that is achieved by the pro-
cess of decidualisation. The decidualised endometrium then needs to respond
to this embryo in a controlled fashion with an initial inﬂammatory response that
then needs to be modulated to allow trophoblast invasion. There are many
lines of evidence that indicate that failure to respond to an embryo, excessive
inﬂammation, lack of local glucocorticoid steroid synthesis and failure to down
regulate inﬂammation are all associated with implantation failure and early
pregnancy loss. This means that there are many plausible biological mechanisms
by which immunosuppression could improve implantation. Randomised
controlled clinical trials in this area have all been disappointing however, they
have lacked a personalised approach. The clinicals trials have demonstrated
safety of immunosuppression in implantation failure. It is possible that immuno-
suppression given to the right patient at the right time will improve pregnancy
outcome.
O-047 Con
INVITED SESSION
SESSION 13: MEIOSIS ANDGENOME STABILITY
Monday 2 July 2018 Room 111 + 112 14:00–15:00
O-048 Dissecting gene function in oocyte meiosis
M. Schuh1
Max Planck Institute for Biophysical Chemistry, Department of Meiosis, Göttingen,
Germany
The Department of Meiosis at the Max Planck Institute for Biophysical
Chemistry investigates mechanisms that are involved in chromosome segrega-
tion during meiosis in mammalian oocytes, the progenitor cells of eggs. This
topic is of great interest for fundamental research because chromosome segre-
gation during meiosis is still much more poorly understood than in mitosis,
especially in mammals. It is also of direct medical relevance because aneuploidy
in eggs is a leading cause of pregnancy loss and several congenital disorders
such as Down’s syndrome. Our main aim is to understand how defects at the
interface between chromosomes and cytoskeletal structures lead to aneuploid
eggs and pregnancy loss in mammals. To this end, we study how the meiotic
spindle is organized, how it segregates the chromosomes and how the spindle
interacts with actin to drive the meiotic divisions. We are also interested in the
mechanisms that lead to an increase in aneuploidy in eggs with advanced mater-
nal age.
We are also very active in developing new tools to study meiosis in mammalian
oocytes. For instance, we have recently developed a method, called Trim-Away,
that can be used to acutely remove endogenous proteins from oocytes and
embryos. We have also established methods that can be used to study the causes
of chromosome segregation errors directly in live human oocytes. In this presen-
tation, I will talk about our latest research on the causes of the maternal age
effect, which describes the decline in female fertility with advanced maternal age.
O-049 DNA damage and genome stability in the preimplantation
embryo
INVITED SESSION
SESSION 14: FEMALE FERTILITY PRESERVATION
Monday 2 July 2018 Room 113 + 114 + 115 14:00–15:00
O-050 Fertility preservation - ovarian stimulation, when, how and
in whom?
A. Germeyer1
Universitäts-Frauenklinik, Gyn. Endocrinology and Reproductive Medicine,
Heidelberg, Germany
Fertility preservation is getting more and more important for young women
with gonadotoxic therapies, as their chance for survival is highly improved due
to better therapies. Furthermore as childbearing is postponed due to social fac-
tors, such as female carriers, women are at increased cancer risk before their
family planning is complete.
Therefore cancer survivors nowadays have an increased desire for parenting
and the wish to conceive their genetic offsprings.
Currently available techniques for fertility preservation include ovarian sup-
pression with GnRHa, ovarian stimulation and egg collection, ovarian cryo-
preservation and ovarian transposition in cases of radiation of the lower
abdomen.
Ovarian stimulation for collection of mature oocytes is a, well established,
option for fertility preservation in women at risk. The chance for later concep-
tion with these cryopreserved oocytes depends on the age at retrieval and the
number of oocytes available.
An ovarian stimulation is feasible, when 2 weeks are available prior to the
start of gonadotoxic therapies.
In contrast to conventional ovarian stimulation for in vitro fertilization, ovar-
ian stimulation can be started in any cycle phase (so called random start) with
similar outcome. In order to reduce the risk for ovarian hyperstimulation syn-
drome, despite a high oocyte yield, a dose intensiﬁed antagonist protocol fol-
lowed by ovulation induction with GnRHagonist is highly recommended.
Gonadotropin doses used are typically 50IE higher than in conventional ovarian
stimulation, to optimize the number of oocytes retrieved. In women with estro-
gen dependent tumors, such as hormone receptor positive breast cancer
patients, an aromatase inhibitor (Letrozol® 5 mg/d) is given during ovarian
stimulation to minimize the estrogen production. When time is limited until
gonadotoxic therapies, in vitro maturation can be an option in women with a
high antral follicle count, as seen in PCOS. IVM is performed without prior ovar-
ian stimulation however chances of conception with the recovered cells are
lower than after conventional ovarian stimulation. On the other hand, if more
than 4 weeks are available until gonadotoxic therapies are started, a double
stimulation can be performed with a ﬁrst stimulation at random start and a
second stimulation started 2 days after ovum pickup, in order to increase the
number of oocytes available.
Recovered mature oocytes can then either be frozen without or after fertil-
isation (preferably with intracytoplasmic sperm injection in order to reduce the
risk of fertilization failure).
The only premise for the use of ovarian stimulation as fertility preservation
technique is a postpubertal stage with remaining ovarian reserve at the time of
consultation prior to the gonadotoxic therapy.
O-051 Use and efﬁciency of cryopreservedmaterial for women
with serious disease
SELECTEDORAL COMMUNICATIONS
SESSION 15: REPRODUCTIVE SURGERY
Monday 2 July 2018 Room 117 14:00–15:00
O-052 Validation of the Endometriosis Fertility Index (EFI) to
predict pregnancy in an infertile argentine population
L. Solari1, G. Botti2, G. Percivalle1, M. Gutierrez1, S. Marin1,
M.E. Mackey3
1Sanatorio Centro, Centro de Cirugía Ginecológica Mini Invasiva, Rosario, Argentina
2Sanatorio Centro, Centro de Cirugía Ginecològica Mini Invasiva, Rosario, Argentina
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3PROAR, Bioestadìstica, Rosario, Argentina
Study question: To evaluate if Endometriosis Fertility Index (EFI) is useful to
estimate the reproductive outcome in infertile argentine patients with diagnosis
and surgical treatment of endometriosis.
Summary answer: The EFI was validated as a useful tool to estimate the
reproductive prognosis of infertile argentine patients diagnosed with
endometriosis.
What is known already: Adamson y Pasta developed a scoring system, being
the only classiﬁcation of endometriosis for infertile patients that predicts the
spontaneous pregnancy rate after laparoscopy and allows to determine what
type of fertility treatment is appropriate for each patient. After being validated
in the North American population, retrospective studies in other countries
such as France, Italy, Belgium and China have also evaluated their usefulness,
although it had not yet been studied in our country.
Study design, size, duration: Retrospective cohort study. We analyze med-
ical records of 90 infertile patients (April 2011 to January 2015) with endometri-
osis diagnosed by laparoscopy. Data from surgical factors for categorization
according to EFI was obtained from videos of laparoscopies and historical fac-
tors were collected from medical records. The pregnancy rate was evaluated
after 12 months follow-up period. Patients were divided according to EFI in
group 1 (0-4), 2(5-7), 3 (8-10), cumulative pregnancy rates among these groups
were compared.
Participants/materials, setting, methods: We included infertile patients
diagnosed with endometriosis by laparoscopy performed by the same surgical
team. Patients with a uterine factor, an abnormal hysterosalpingogram, or
whose partner had a severe male factor were excluded. The treatment per-
formed was fulguration of peritoneal endometriosis lesions, adhesiolysis and
endometriomas cystectomy. A double-blind retrospective review of these vid-
eos was performed to obtain the data of the surgical factors to categorize
patients.
Main results and the role of chance: The probability of spontaneous preg-
nancy or pregnacy with ovulation induction or intrauterine insemination (IUI)
within 12 months after laparoscopy was signiﬁcantly higher in those with the
greater EFI category compared with those with lower EFI category. The total
pregnancy rate was 48.8%, 18.8% in group 1, 37.8% in group 2 and 66.66% in
group 3. These rates presented a statistically signiﬁcant linear trend (p =
0.003). When comparing the groups it is observed that the group 3 pregnancy
rate was higher with respect to group 2 (RR: 1.76, 95% CI 1.10–2.81), and
group 1 (RR: 3.67, 95% CI 1.03–13.08), both differences statistically signiﬁcant.
The pregnancy rate of the second group was double in relation to the group
with lower EFI (RR: 2.09, 95% CI 0.56–7.79), however this difference was not
statistically signiﬁcant (p = 0.22). The 65.9 % of pregnancies achieved within the
ﬁrst 6 months after surgery.
Limitations, reasons for caution: A disadvantage of this system is the sub-
jectivity when performing the Least Function Score because is possible to ﬁnd
differences between the surgeons. Also the calculation of EFI can be time con-
suming for the surgeon.
Wider implications of the ﬁndings: In patients with higher EFI category,
the probability of spontaneous pregnancy or pregnancy with ovulation induction
or IUI was increased within 12 months after laparoscopy. This allows us to val-
idate the EFI as a useful tool to estimate the reproductive prognosis of infertile
argentine patients diagnosed with endometriosis.
Trial registration number:Not applicable.
O-053 Whether the surgical indications for septate uterus are
reasonable in infertile patients before in vitro fertilization?
X. Li, Y. Ouyang, Y.Wen
Reproductive & Genetic Hospital CITIC-Xiangya, Imaging Department, Changsha,
China
Study question: Whether the surgical indications are reasonable for infertile
patients with septate uteri before in vitro fertilization-embryo transfer (IVF-ET)?
Summary answer: The surgical indications for septate uteri proposed in this
study are reasonable in infertile patients before IVF-ET.
What is known already: Up to date, there is no uniform surgical indications
for septate uteri. This anomaly has been commonly considered to be associated
with poor reproductive outcomes. However, the optimal surgical timing for
septate uteri is still controversial. Should preventive treatments be given to
reduce complications?
The incidence of uterine malformations in infertile patients is much higher
than that in the general population. Normal uterine morphology is a prerequis-
ite for successful embryo implantation, therefore, proper treatments are neces-
sary for septate uteri before IVF-ET. Then, what kind of surgical indications are
reasonable?
Study design, size, duration: A retrospective study was conducted of 937
infertile patients with septate uteri and 1578 patients with normal uteri who
obtained singleton pregnancies via IVF-ET from January 2014 to December
2015.
Hysteroscopic metroplasty was performed before IVF-ET if patients meet at
least one indication: (1) the septum depth ≥10 mm; (2) the septum depth
between 5-10 mm accompanied by unexplained recurrent miscarriage or infer-
tility history; (3) recurrent failures of IVF-ET. Conversely, patients would be
managed expectantly.
Participants/materials, setting, methods: This study was conducted at
the Reproductive and Genetic Hospital of CITIC-Xiangya (Changsha, China).
The patients with septate uteri were divided into non-surgical (n = 518) and
surgical (n = 419) groups and the uterine cavities were normal after surgery.
The septate uteri were diagnosed according to the ESHRE-ESGE system. 1578
infertile patients with normal uteri were selected as the control group. The
pregnancy and obstetric outcomes were compared among non-surgical, surgical
and normal groups.
Main results and the role of chance: Multivariate regression analysis
showed a signiﬁcantly higher early pregnancy loss (EPL, OR 1.49 (1.07-2.07), p
= 0.018) risk and much lower rates of term delivery (OR 0.72 (0.54-0.95), p =
0.023) and live birth (OR 0.67 (0.50-0.91), p = 0.010) in the surgical group than
those in the non-surgical group; compared with the normal group, the surgical
group showed signiﬁcantly higher risks of EPL (OR 1.23 (1.08-1.40), p = 0.002),
small gestational age at delivery (OR 1.26 (1.02-1.57), p = 0.041), low birth
weight (OR 1.32 (1.03-1.70), p = 0.019), and the rates of term delivery (OR
0.79 (0.70-0.88), p ≤ 0.001) and live birth (OR 0.79 (0.70-0.88), p ≤ 0.001)
were much lower; all pregnancy and perinatal outcomes were statistically simi-
lar between the non-surgical and normal groups (P > 0.05).
In the surgical group, the rates of miscarriage (OR 3.10 (2.08-4.61), p ≤
0.001) and ectopic pregnancy (OR 13.25 (6.46-27.17), p ≤ 0.001) were signiﬁ-
cantly lower and the live birth rate (OR 0.05 (0.03-0.09), p ≤ 0.001) was much
higher than before surgery. According to the ROC curves, the cut-off values for
surgery were septum length = 6.85 mm and the rate of internal indentation/
uterine wall thickness = 0.895.
Limitations, reasons for caution: Firstly, all pregnancy outcomes were
obtained via telephone calls or faxes, thus, some details were not studied.
Secondly, the control group was not screened randomly, which may cause
selection and confounding biases. Thirdly, not all patients received surgeries in
our hospital, the inconsistency of surgical effects was inevitable.
Wider implications of the ﬁndings: The surgical indications proposed in
this study can be used to guide proper treatments for infertile patients with
septate uteri before IVF-ET.
Trial registration number:None.
O-054 Fertility after salpingotomy versus salpingectomy in women
with tubal pregnancy; an individual patient data meta-analysis
N. Netteb1, P. Capmas2, H. Fernandez2, P. Hajenius1, B.W. Mol3,
M. VanWely1, F. Mol1, O.N. Behalf of the DEMETER study group2,
O.N. Behalf of the ESEP study group1
1Academic Medical Center, Q3-119 Obstetrics Gynaecology, Amsterdam, The
Netherlands
2Hôpital Bicêtre, Service de Gynécologie Obstétrique, Le Kremlin Bicêtre Cedex,
France
3Monash Medical Centre, Department of Obstetrics and Gynaecology, Clayton,
Australia
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Study question: Before surgery for ectopic pregnancy: can we distinguish
women who would beneﬁt from salpingotomy in terms of a subsequent ongoing
pregnancy, based on patient characteristics?
Summary answer: Salpingotomy did not improve fertility rates, although a
small beneﬁt could not be excluded. No subgroup was detected that would
beneﬁt more from salpingotomy.
What is known already: Tubal ectopic pregnancy can be surgically treated
by salpingectomy in which the affected tube is removed, or by salpingotomy in
which the ectopic pregnancy is removed and the tube is preserved.
Salpingotomy bears the increased risk of persistent trophoblast, requiring add-
itional treatment. Our conventional meta-analysis including data of two RCTs
(DEMETER, ESEP) did not show a large beneﬁt from salpingotomy, but a small
beneﬁt could not be excluded.
Study design, size, duration: We performed a meta-analysis with individual
patient data (IPD) of RCTs based on a search of international scientiﬁc databases
in collaboration with the Cochrane gynaecology and fertility group. We selected
trials comparing salpingotomy and salpingectomy for tubal ectopic pregnancy and
collected data on fertility prospects after surgery. The primary outcome was an
ongoing pregnancy by natural conception. We aimed to determine the pregnancy
chance over time, which will be analysed by survival methods.
Participants/materials, setting, methods: Follow up times were calcu-
lated from randomisation until last menstrual period of the ongoing pregnancy.
All analyses were performed on an intention-to-treat basis. The estimated log
hazard ratios were combined across studies using standard ﬁxed-effect and
random-effects meta-analysis methods. Subgroup effects were estimated by
treatment-by-covariate interaction terms within studies and combining these
across studies similarly. We explored the treatment modiﬁcation for maternal
age, serum hCG pre-operatively and size of tubal ectopic mass on ultrasound.
Main results and the role of chance:We identiﬁed two relevant trials, con-
taining data of 653 women randomised to salpingotomy or salpingectomy. The
cumulative ongoing pregnancy rate by natural conception was 58.3% after sal-
pingotomy and 55.0% after salpingectomy (log rank p = 0.537). The mean time
to an ongoing pregnancy was 21.9 months (95% CI 19.1 – 24.7) after salpingot-
omy and 23.8 (95% CI 21.1–26.5) after salpingectomy, resulting in a hazard
ratio of 1.07 (95% CI 0.86–1.35). There was no interaction between maternal
age, serum hCG level, size of tubal ectopic mass and treatment on ongoing
pregnancy chance. We found no associations with maternal age or size of tubal
ectopic mass. Serum hCG < 2,335 IU/l was associated with a higher ongoing
pregnancy chance with a cumulative ongoing pregnancy rate of 63.8% after sal-
pingotomy and 60.5% after salpingectomy (fecundity rate ratio 1.18; 95% CI
0.87–1.61; log rank p = 0.278).
Limitations, reasons for caution: In the ESEP study women with contralat-
eral tubal disease were excluded whereas such women were not excluded in
the DEMETER study. In the DEMETER study all women treated by salpingot-
omy also received a single shot methotrexate postoperatively. Analyses of
other pre-speciﬁed treatment modiﬁcations are ongoing.
Wider implications of the ﬁndings: This IPD meta-analysis facilitates
shared-decision- making. Salpingectomy might be the preferred treatment in
view of safety of the intervention. Women with a preference for maximizing
their pregnancy prospects might still opt for salpingotomy. Future studies need
to take costs into account.
Trial registration number: DEMETER NCT00137982, ESEP
ISRCTN37002267
O-055 Ovarian Reserve after uterine artery embolization in
women with morbidly adherent placenta
A. Mohr Sasson1, M. Spira1, R. Rahav1, D. Manela1, E. Schiff1,2,
S. Mazaki-Tovi1,2, R. Orvieto1,2, E. Sivan1,2
1Sheba Medical Center, Department of Obstetrics and Gynecology, Tel Hashomer-
Ramat Gan, Israel
2Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel
Study question: The aim of this study is to assess ovarian reserve in women
after preservative cesarean section using uterine artery embolization (UAE) due
to morbidly adherent placenta.
Summary answer: Women post preservative cesarean section using UAE due
to placenta accrete have lower ovarian reserve compare to controls matched by age.
What is known already: Conservative management of morbidly adherent pla-
centa can be considered when fertility preservation is desired, however, concern
has been raised regarding the effect of embolization on ovarian function. One pos-
sible potential risk to fertility, is the exposure of the ovaries to ionizing radiation,
being a procedure that is carried out under ﬂuoroscopic control using contrast
media for X-ray angiograms. Other mechanism, is the potentially unintentional
migration of embolization material through anastomoses between the uterine and
ovarian vessels. To the best of our knowledge, this is the ﬁrst study evaluating hor-
monal status after UAE in patients with morbidly adherent placenta.
Study design, size, duration: A prospective historical study including all preg-
nant women admitted to a single tertiary care center, since November 2011 until
July 2016 with a diagnosis of morbidly adherent placenta that had a successful
preservative cesarean section delivery with bilateral uterine arteries embolization.
Participants/materials, setting, methods: Inclusion criteria included gesta-
tional age >24 weeks, singleton pregnancy and placenta increta / percreta.
Exclusion criteria included maternal age >43 years at the time of recruitment and
women after cesarean hysterectomy. Control group included women attending
the infertility clinic due to male factor, or single women conceiving via sperm
donation, matched by age. Blood samples were collected from all patients on day
2-5 of menstruations for hormonal proﬁle and anti mullarian hormone levels.
Main results and the role of chance: 59 women underwent preservative
cesarean section and uterine artery embolization due to morbidly adherent pla-
centa during the study period. 21 women met inclusion criteria (33.9%) and
were matched controls (n = 40). Median time for post operation blood sam-
pling was 55 month (IQR 22.5-90.5). One woman was breastfeeding, 2 had
intra uterine devices, and all other women reported they were not using hor-
monal treatment for contraception at the time of blood sampling. The study
group had higher gravidity and higher rates of cesarean section as expected (2
IQR:2-4.75 vs 1 IQR:0-1, p = 0.001), (1IQR:1-2 VS 0, p = 0.001), respectively.
Circulating levels of E2 and FSH did not differ signiﬁcantly between the two
groups (p = 0.665, p = 0.396, respectively). Anti mullarian hormone (AMH)
was lower in the study group (0.8 IQR 0.44-1.80) compared to the controls
(2.08 IQR 1.68-3.71),(p = 0.001). This ﬁnding was consistent in linear multivari-
ate regression analysis where the group of cesarean section using bilateral
artery embolization due to placenta accrete was signiﬁcantly predictive for the
levels of AMH (B=-1.308, p = 0.012).
Limitations, reasons for caution: Limitations of the study is the relatively
small study group, though rarity of the condition, and the lack of information
regarding baseline AMH levels before the procedure.
Wider implications of the ﬁndings: UAE in morbidly adherent placenta
might be associated with reduced ovarian reserve, nevertheless, the alternative
of hysterectomy is deﬁnite and do not offer solution to women desiring future
fertility. Our ﬁndings support the use of UAE, while giving the proper consult-
ancy on the possible effect on ovarian reserve.
Trial registration number: The study protocol was approved by the
Institutional Review Board (ID 3178-16-SMC) and was supported by the
National Institutes of Health (NCT02821702).
SELECTEDORAL COMMUNICATIONS
SESSION 16: BASIC RESEARCH IN GAMETE AND
EMBRYO BIOLOGY
Monday 2 July 2018 Forum (Auditorium) 15:15–16:30
O-056 Maternal STAT3 regulates oocyte maturation and
development of early embryos through autophagy
Y. Kawagoe1, Y. Sato2, N. Okamoto1, B. Ishizuka1, K. Kawamura2
1Rose ladies clinic, Reproductive center, Tokyo, Japan
2International University of Health and Welfare, Obstetrics and Gynecology, Narita,
Japan
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Study question:What is the role of maternal STAT3 signaling in preimplanta-
tion embryonic development?
Summary answer: Maternal STAT3 signaling is important for optimal oocyte
maturation and cleavage-stage embryo development via autophagy activation.
What is known already: JAK2/STAT3 signaling is known as an intracellular sig-
naling pathway. JAK2 is the member of Janus protein tyrosine kinase family and
recruits and phosphorylates STAT3. Phosphorylated STAT3 is dimerized and trans-
located into the nucleus to regulate transcriptional activity. In addition, cytoplasmic
STAT3 regulates the autophagy machinery in cells. In preimplantation embryos,
STAT3 is constitutively active during fetal stage and shown to be important for
embryonic development as demonstrated by embryonic lethality in STAT3 knock-
out mice. However, its role during early cleavage stage embryos is unknown due to
the presence of maternal STAT3 in early embryos before zygote gene activation.
Study design, size, duration: GV-stage oocytes and preimplantation
embryos were obtained from ICR mice (3-4 weeks of age) for quantiﬁcation of
STAT3 expression. In addition, these oocytes and embryos were used to exam-
ine the role of maternal STAT3 in oocyte maturation and embryonic develop-
ment by inhibiting phosphorylation of JAK2 and STAT3 using STAT3 selective
inhibitors, JAK2 selective inhibitors and JAK2/STAT3 signaling inhibitors.
Participants/materials, setting, methods: The expression levels of
STAT3 in oocyte and embryos at different stages were measured using real-
time RT-qPCR. GV-stage oocytes, zygote and 8 cell-stage embryos were cul-
tured with different inhibitors to compare the proportions of oocytes under-
went maturation and embryonic development. The spindle structure in
cultured oocytes was examined using tubulin staining. To assess the autophagy
activity, expression of microtubule-associated-protein-light-chain 3 (LC3) at
mRNA and protein levels were measured by real-time RT-qPCR and immuno-
ﬂuorescence staining, respectively.
Main results and the role of chance: The expression levels of STAT3
peaked in oocytes and gradually decreased toward 4 cell-stage embryos. It was
not detected after 8 cell-stage embryos, suggesting its maternal origin. In GV-
stage oocytes, nuclear maturation rate was signiﬁcantly decreased when both
JAK2 and STAT3 signaling were inhibited (Control: 73.8 ± 5.4%, treat: 44.1 ±
4.9%, P < 0.05). When embryos were cultured with the STAT3 inhibitor S3I-
201, embryo development was signiﬁcantly suppressed at 4 cell-stage (Control:
94.5 ± 5.0%, STAT3 selective inhibitor: 9.7 ± 3.8%, P < 0.01), whereas JAK2
inhibitor Febratinib showed a weaker suppressive effects (Control: 94.5 ±
5.0%, JAK2 selective inhibitor: 57.9 ± 15.7%, P < 0.01). If both JAK2 and
STAT3 inhibitors were used, they showed synergistic effect on suppression of
embryonic development from 2 cell-stage embryos onwards (2 cell-stage;
Control: 96.4 ± 2.1%, JAK2/STAT3 inhibitor: 31.3 ± 4.8%, P < 0.01, 4 cell-
stage; Control: 94.5 ± 5.0%, JAK2/STAT3 inhibitor: 28.1 ± 4.4%, P < 0.01).
Of note, embryo development was not affected when phosphorylation of JAK2
and/or STAT3 was inhibited after 8 cell-stage embryos. Furthermore, LC3
expression was signiﬁcantly decreased in these embryos, indicating decline in
autophagy activity.
Limitations, reasons for caution: Our study was performed using mouse
oocytes and preimplantation embryos. Therefore, this result could not be dir-
ectly translated to human cases.
Wider implications of the ﬁndings: Although similar studies using human
oocytes are required to conﬁrm the importance of STAT3 activity, our ﬁndings
may provide a new strategy to help the patients with impaired oocyte matur-
ation by culturing their GV-stage oocytes with STAT3 activators to induce
oocyte maturation.
Trial registration number:Not applicable.
O-057 The human sperm basal body contributes a complexmatrix
of proteins important for proper preimplantation development of
the oocyte upon fertilization
F. Amargant1, A. Pujol2, A. Ferrer-Vaquer1, M. Durban1,
M. Martínez1, M. Barragan1, I. Vernos3, R. Vassena1
1Clinica Eugin, Assisted Reproduction, Barcelona, Spain
2Centro de Infertilidad y Reproducción Humana CIRH, Assisted Reproduction,
Barcelona, Spain
3Centre for Genomic Regulation CRG, Cell and Developmental Biology Programme,
Barcelona, Spain
Study question: What does the sperm basal body contribute to the human
zygote to ensure embryo early development?
Summary answer: The spermatozoon provides 288 centrosomal proteins to
the zygote to form a functional centrosome, which is required in order to
achieve optimal preimplantation developmental rates.
What is known already: During fertilization in the human species, the sperm
provides a centrosome, the main microtubule organizing center (MTOC) essen-
tial for the development of a new organism, to the zygote. In somatic cells, the
centrosome is comprised by 2 centrioles surrounded with pericentriolar material
(PCM) composed of several essential proteins for its activity; the current view is
that the human sperm basal body (BB) does not possess PCM, and PCM proteins
are recruited from the oocyte cytoplasm after fertilization. Although alterations in
the sperm centrosome function have been linked to infertility, its role in human
preimplantational development has not been tested directly.
Study design, size, duration: To identify the sperm BB components, prote-
omic analysis was carried out on 4 experimental samples prepared from mixtures
of 4 normozoospermic ejaculates. To study the BB function, headless sperm tails
containing the BB, were generated by microsurgery, and injected into MII oocytes,
which were further activated parthenogenetically (n = 15 sham and n = 15 tail
injections) by sequential passages of ionomycin 10 μM. Morphokinetic recording of
developing parthenotes was carried out every 5minutes during 5 days.
Participants/materials, setting, methods: For proteomics studies, sperm
were sonicated and the tail fraction, including the BB, was spun through a 30%
sucrose cushion. Tails were solubilized with Laemmli Buffer and analyzed by
mass spectrometry. In the functional study, sham- and tail-injected oocytes
were cultured in SAGE and their development recorded. Times analyzed
included second polar body extrusion, cell divisions and blastocyst expansion.
Parthenotes were ﬁxed at different times through D5 and tubulin, MTOCs, and
DNA analyzed by immunoﬂuorescence.
Main results and the role of chance:We identiﬁed 2,312 proteins as com-
ponents of the sperm tail including the BB (validated by immunoﬂuorescence
with centrin). Gene ontology analysis identiﬁed 18% of the proteins as cytoskel-
etal, including 288 proteins from centrioles and PCM. As expected, most parthe-
notes (80%) arrested their development before reaching blastocyst stage, while
morphokinetic developmental timings in both groups did not differ in any of the
annotated times. However, while tail-injected parthenotes arrested throughout
in vitro culture and irrespectively of developmental stage, 75% of the arrested
sham-injected ones (lacking the sperm derived centrosome) could not proceed
through compaction, and arrested around the time of embryonic genome activa-
tion. None of the sham- injected parthenotes that arrested before compaction,
had detectable MTOCs in immunoﬂuorescence, while MTOCs were visible in all
those that developed past compaction. Altogether, our data suggest that the
sperm BB is more complex than previously described; the high number of cen-
triolar and PCM components it contains may provide an efﬁcient conversion to a
functional centrosome in the fertilized oocyte. The presence of MTOC-like struc-
tures in parthenotes suggests a developmental control of PCM protein expres-
sion during the early phases of development and a correlation between the
presence of MTOCs and successful compaction.
Limitations, reasons for caution: The main limitations of these studies con-
cern the sample size of the injection experiments and the fact that up to one
third of the tails injected may not contain a BB, hence diluting the tail- injected
parthenotes phenotype.
Wider implications of the ﬁndings: Our proteomic and functional results
do not support the current view of “naked” centrioles in the human sperm BB;
rather, they indicate that the centrioles are transferred to the oocyte at fertiliza-
tion together with PCM proteins that may participate in the efﬁcient assembly
of the ﬁrst centrosome of the zygote.
Trial registration number:Not applicable.
O-058 Human fertilization is completely blocked by egg Juno
protein inhibition
C. Jean1, F. Haghighirad2, A. Ziyyat3, Y. Zhu2, E. Rubinstein2,
C. Gourier4, J.P.Wolf1, C. Boucheix2, V. Barraud-Lange5
1Université Paris Descartes- Sorbonne Paris Cité- Faculté de Médecine- Assistance
Publique-Hôpitaux de Paris- Hôpitaux Universitaires Paris Centre- CHU Cochin,
Laboratoire d’Histologie Embryologie Biologie de la Reproduction, Paris, France
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Study question: Is Juno protein present at the membrane surface of human
oocyte and involved in fertilization process?
Summary answer: Juno Protein is expressed on the plasma membrane of
human oocyte and its inhibition by a monoclonal antibody completely blocks
the gamete fusion.
What is known already: Gamete membrane fusion is the culminating event
of the fertilization process, driving by poorly understood molecular mechan-
isms. Until now, three molecules have been proven to be essential: The egg’s
CD9 tetraspanin, the Izumo1 sperm protein and Juno, its receptor on egg.
Gene invalidation of these three proteins causes a drastic decrease of mice fer-
tility by the loss of gamete fusion ability. CD9 and Izumo have been described in
human and the Izumo1-Juno interaction is conserved within several mammalian
species, including human. The presence of Juno on human oocyte was not yet
reported and its role in fertilization is not known.
Study design, size, duration: We investigate, in human, the presence of
Juno on egg membrane surface and study its potential involvement in mem-
brane gamete interaction during fertilization.
Participants/materials, setting, methods: Monoclonal antibodies against
human Juno (anti-hJuno mAb) were produced by immunization of mice with
HEK cells transfected with the putative human Juno sequence (HEK-hJuno).
These antibodies were used for immunostaining experiments and in vitro fertil-
ization assays on human gametes (GERMETHEQUE Biobank).
Main results and the role of chance: Three hybridoma’s supernatants,
tested by immunostaining, speciﬁcally revealed HEK-hJuno cells. The 3 puriﬁed
monoclonal antibodies FJ2E4 (IgG1), FJ8E8 (IgG1) andFJ4F5 (IgG2a) recognized
in western blot of HEK-hJuno extracts a protein with an expected MW of
25 kDa. Using these 3 anti-hJuno mAb for immunostaining, we identiﬁed the
presence of Juno protein at the plasma membrane of human eggs. The distribu-
tion of the ﬂuorescent signal appeared heterogeneous on fresh oocytes
whereas it was homogeneous and ﬁnely punctuated when the eggs were ﬁxed
before staining; suggesting a relocation of the protein induced by the binding of
the speciﬁc antibody. Furthermore, we highlighted a progressive expression of
Juno depending on oocyte maturity. Finally, we showed that human oocyte
inseminated in presence of anti-hJuno mAb wouldn’t be fertilized by human
sperm. These results suggest that anti-hJuno mAb block the interaction site of
Juno protein with Izumo1 receptor, and, as in mouse model, that Juno is
involved in membrane gamete interaction during human fertilization.
Limitations, reasons for caution: In order to respect French bioethics
laws, functional tests have been performed using zona-free eggs, which is differ-
ent from physiologic conditions.
Wider implications of the ﬁndings: This is the ﬁrst report of the presence
of Juno on human oocyte and of its involvement in human fertilization. It allows
going further in the understanding of molecular mechanisms that drive gamete
fusion; a crucial challenge in occidental and developing countries where infertil-
ity affects 16% of genitally active couples.
Trial registration number: not applicable.
O-059 PLCz knock-out sperm reveals the sole effect of altering
calcium signals during assisted oocyte activation on later mouse
embryogenesis
M. Ferrer Buitrago1, L. Tilleman2, V. Thys1, A. Hachem3,
F. Van Nieuwerburgh2, L. Leybaert4, P. De Sutter1, D. Deforce2,
J. Parrington3, B. Heindryckx1
1University Hospital Ghent UZ, Ghent Fertility And Stem cell Team G-FAST-
Department for Reproductive Medicine, Ghent, Belgium
2Ghent University, Laboratory for Pharmaceutical Biotechnology- Faculty of
Pharmaceutical Sciences., Ghent, Belgium
3University of Oxford, Department of Pharmacology, Oxford, United Kingdom
4Ghent University, Physiology Group- Department of Basic Medical Sciences, Ghent,
Belgium
Study question: Does a differing Ca2+ signature during assisted oocyte activa-
tion (AOA) have a later impact on pre-implantation mouse blastocysts?
Summary answer: Variations of Ca2+ at fertilization during ICSI-AOA do not
prove detrimental for development of the blastocyst and its associated tran-
scriptional status in mouse.
What is known already: Mammalian fertilization occurs in combination with
a series of cytoplasmic Ca2+oscillations initiated by the sperm-borne phospho-
lipase C zeta (PLCz). Oocyte activation is achieved in response to the sum of
individual Ca2+ spikes, irrespective of the Ca2+ oscillatory pattern. Hence, sev-
eral pharmacological agents can induce oocyte activation by stimuli that diverge
profoundly from the physiological Ca2+ signature. Although still controversial,
some studies showed that altering the Ca2+ oscillatory regime at fertilization
affects blastocyst establishment and post-implantation development. Novel
genome-edited PLCz-null mouse sperm provide a neat way for evaluating the
sole effect of different Ca2+ signals during ICSI-AOA on later embryogenesis.
Study design, size, duration: Assisted oocyte activation (AOA) was per-
formed after ICSI of PLCz-null sperm into mouse oocytes. Four AOA strategies
were applied: AOA1: human recombinant PLCz (Ca2+ oscillations), AOA2:
strontium (Ca2+ oscillations), AOA3: ionomycin (single Ca2+ transient) and
AOA4: TPEN (zinc chelator; absence of an initial Ca2+ trigger). Embryonic
development and blastocyst transcriptome analysis were compared to control
conditions: C1 (in vivo fertilization), C2 (ICSI using normal activating sperm) and
C3 (parthenogenesis; induced by strontium and cytochalasin-D).
Participants/materials, setting, methods: MII oocytes were collected
from B6D2F1 females after ovarian hyperstimulation. Frozen sperm samples
were thawed before ICSI, according to standard procedures. Embryos were
cultured for 5 days in sequential media. RNA isolation was carried out in indi-
vidual blastocysts following manufacturer instructions (PicoPure-RNAi kit.
Arcturus). RNA-seq was carried out on the NextSEq500. Data analysis was
conducted in R in 9380 genes with a cpm >5 in at least 4 samples per group.
Main results and the role of chance: PLCz-null sperm were mostly not able
to activate mouse oocytes (activation rate 9%). Failed fertilization was rescued in
response to AOA, with all AOA strategies showing similar efﬁciencies in oocyte
activation (91 ± 9%) compared to controls (87 ± 11%). The lack of PLCz did not
compromise pre-implantation embryonic development, and blastocyst stage was
achieved in all groups. Blastocyst formation rate (bfr) was signiﬁcantly decreased
in C2 (52%) in comparison to C1 (98%) and C3 (80%), reﬂecting the deleterious
effect of ICSI in mouse embryonic development. We further evaluated the efﬁ-
ciency of the distinct AOA methods to support embryonic development com-
pared to C2. The use of strontium (AOA2) yielded the highest bfr (75%, p <
0.05) within the AOA groups. Ionomycin (AOA3) resulted in similar output com-
pared to C2 (49% vs 52%), but signiﬁcantly reduced compared to C1 and C3.
Despite the decreased bfr observed after using human recombinant-PLCz
(AOA1; 29%) or TPEN (AOA4; 30%), differences were not statistically signiﬁcant
compared to C2. Both, AOA1 and AOA4 strategies showed signiﬁcantly lower
bfr compared to C1, C3 and AOA2. The transcriptional proﬁle of individual blas-
tocysts was further analyzed by RNA-seq, which did not identify signiﬁcant differ-
ences in global gene expression within and between the groups.
Limitations, reasons for caution: RNA-seq analysis included only coding
regions of well-annotated genes. This analysis involves only pre-implantation events.
Wider implications of the ﬁndings: Our ﬁndings provide a novel insight in
understanding the role of Ca2+oscillations beyond meiotic resumption in mam-
mals. The use of PLCz-null sperm represents a potent translational model to
explore the impact of AOA throughout early and late embryogenesis.
Trial registration number: (Non applicable).
O-060 Early steps of human embryo implantation explored in a 2D
in vitro model
A. Aberkane1, C. De Paepe2, T. Addriaenssens3,W. Essahib1,
C. Spits2, S. Mackens1, H. Tournaye4, K. Sermon2, J. Brosens5,
H. Van de Velde1
1Vrije Universiteit Brussel, Reproductive Immunology and Reproduction, Brussels,
Belgium
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3Vrije Universiteit Brussel, Research group Follicle Biology, Brussels, Belgium
4UZ Brussel, Centrum voor Reproductieve Geneeskunde, Brussels, Belgium
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Study question: Can we use a 2D in vitro adhesion model to investigate molecular
pathways involved in the early steps of human embryo implantation?
Summary answer: Human embryo implantation is initiated by apposition and
adhesion and these steps are associated with different expression proﬁles of
adhesion and extracellular matrix (ECM) transcripts.
What is known already: The few adhesion and ECM proteins analysed for
human embryo implantation are derived from similarities found in the mouse
model and leukocyte trans-endothelial migration. Both human and murine
embryos have previously been co-cultured with Ishikawa cells in a 2D in vitro
adhesion model. Only few data is reported on gene expression in human preim-
plantation blastocysts, however these studies do not provide large scale
molecular knowledge to understand fundamental pathways involved during the
implantation process.
Study design, size, duration: Vitriﬁed human blastocysts were warmed and
co-cultured in a 2D in vitro adhesion model, in which Ishikawa cells are used to
represent the human endometrial epithelium. Attachment of the embryos to
the Ishikawa cells was assessed in this study. Loosely (apposition) and ﬁrmly
(adhesion) attached embryos were compared with unattached embryos. The
early steps of implantation were investigated both on the observational (micros-
copy) and the molecular level (quantitative PCR (qPCR) and immunoﬂuores-
cence (IF)).
Participants/materials, setting, methods: Six days post fertilisation (dpf)
human embryos were co-cultured on the Ishikawa cells for 12 h, 24 h (7dpf)
or 48 h (8dpf); and attachment rate and morphological development were
investigated. Gene expression of 84 adhesion and ECM genes was analysed
by qPCR. Proteins were localised by IF staining. Neutralizing antibody was
used for functional blocking experiments. Data is reported on 109 human
embryos. Mann-Whitney U and two-way ANOVA tests were used for statis-
tical analysis (P < 0.05).
Main results and the role of chance: According to our in vitro attachment
data, the majority of the embryos attach on the polar trophectoderm. We are
also the ﬁrst to show that human embryo implantation is initiated by appos-
ition and followed by adhesion; the majority of the 6dpf embryos co-cultured
for 12 h were loosely attached and this progressed to a ﬁrm attachment in
85.7% of the 7dpf embryos. HCG positive embryonic outgrowth formation at
8dpf indicates differentiation of the trophectoderm to the invasive
syncytiotrophoblast.
Gene expression analysis was performed on loosely attached and
unattached embryos co-cultured for 12 h with the Ishikawa cells. Loosely
attached embryos were distinguished from the unattached embryos by the
additional expression of THBS1, TNC, COL12A1, CTNND2, ITGA3, ITGAV, and
LAMA3. Loose embryo attachment was also associated with the signiﬁcant
upregulation of CD44 (P = 0.014). TNC and THB1 were validated on protein
level in 7dpf ﬁrmly attached embryos. THBS1 showed cytoplasmic localisation
in the embryonic cells and TNC was present on the membrane of trophecto-
derm cells. Functional blocking of only TNC protein with a neutralizing anti-
body in 48 h co-cultured embryos did not affect the attachment rate nor hCG
secretion.
Limitations, reasons for caution: The study was performed in vitro and
made use of a carcinoma cell line. Also the sample size of the study was limited.
Contamination of the analysed embryos by Ishikawa cells can be excluded due
to the different gene expression proﬁles.
Wider implications of the ﬁndings: Taken our data together we have pro-
vided a “proof of concept” for fundamental understanding of the early steps of
human embryo implantation. Conﬁrmation of the data on a larger sample size
and larger gene expression analysis will provide insights of defective molecular
pathways involved in implantation failure.
Trial registration number:Not applicable
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O-061 Effect of annexin-V positive sperm-cells removal with
magnetic activated cell sorting (MACS) for ICSI procedures in
couples with male infertility (teratozoospermia); A randomized
controlled trial
C. Valdespin, L. Garcia, R. Avila, G. Robledo, A. Alvarez, G. Barroso
NASCERE, Reproductive Health Division, Mexico City, Mexico
Study question: Does the use of MACS and incubation with annexin-V conju-
gated microbeads (ANMB) before ICSI in couples with male infertility (terato-
zoospermia) improve the live-birth delivery rate?
Summary answer: The use of MACS-ANMB in men with teratozoospermia
improves the development and quality of oocytes/embryos, consequently
improving fertilization(FR), implantation(IR), pregnancy(PR), and live-birth-
delivery rates.
What is known already: It is proved that human spermatozoa play an exten-
sive role in the reproductive physiology, beginning with the fertilization process,
continuing with early and late stages of embryo development, that ultimately
impact on implantation and pregnancy rates. The expression of early apoptotic
markers as plasma membrane translocation of phosphatidylserine (PS) is asso-
ciated with abnormal embryo development and suboptimal results of FR, IR
and PR. Annexin-V magnetic cell separation of non-apoptotic spermatozoa is
simple, fast, inexpensive and highly speciﬁc, however, its role in late stages of
embryo development and live-birth rate is unclear.
Study design, size, duration: A prospective, randomized, triple-blinded,
and controlled trial was conducted using a parallel two-arm study. We included
a total of 200 couples with teratozoospermia undergoing ICSI assigned in a 1:1
proportion either to the experimental or the control group. Samples from the
study group were prepared by swim-up followed by MACS-ANMB to remove
Annexin-V positive sperm cells. The study was conducted from June-2012 to
March-2017 in a single reproductive center in Mexico City.
Participants/materials, setting, methods: Only those samples exhibiting
teratozoospermia (morphology <4% according to Kruger’s strict criteria) were
included in the study. In addition, patients who presented with poor ovarian
response (“Bologna” criteria) were eliminated. Samples were randomized in
two groups: i)swim-up followed by MACS-ANMB, and ii)swim-up. All embryos
were analyzed until day 5-6 (blastocyst stage) and all transfers were done on
the same embryo stage. Statics: Mann-Whitney-test, Fisher-exact-test, and
Person’s-correlation were done to analyze the results (p < 0.05, signiﬁcant).
Main results and the role of chance: Different results were obtained
between groups, however, patients demographics were similar. The Annexin-V
positive fraction was negatively correlated with sperm concentration (r
= -0.5435 p = <0.0001), progressive motility (r=-0.2975 p = 0.02), and total
motility (r = -0.2975 p = 0.02); and was positively correlated with type D
morphology (r = 0.4397 p = 0.0006). Regarding embryo development and
reproductive results, comparison between MACS-ANMB (n = 100), and con-
trol group (n = 100) showed the following results: i) FR of 40.8% (95% IC,
27.4-65.0) versus 45.2% (95% IC, 14.7-69.0) p = 0.04, ii) embryo survival on
day-3 of 97.3% (95% IC, 89.7-100) versus 98.9% (95% IC, 96.8-100) Non
Signiﬁcantly (NS), iii) mean quality of embryos on day-3 of 2.9 (95% IC, 2.8-3.0)
versus 2.9 (95% IC, 2.9-3.0) NS, iv) blastocyst development on day-5 of 61.2%
(95% IC, 51.7-70.6) versus 48.8% (95% IC, 30.2-66.6) p = 0.02, v) quality of
embryos on day-5 of 2.8 (95% IC, 2.6-3.1) versus 3.4 (95% IC, 3.3-3.6) p =
0.001, vi) percentage of arrested embryos of 32.9% (95% IC, 23.5-42.3) versus
49.9% (95% IC, 36.8-63.0) p = 0.04, vii) IR of 25.5% (95% IC, 12.7-67.1) versus
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12.5% (95% IC, 6.2-32.8) p = 0.001, viii) PR of 51.1% (95% IC, 25.5-65.7) ver-
sus 26.1% (95% IC, 13.3-34.2) p = 0.001, and ix) live-birth delivery rate 24.5%
(95% IC, 12.2-72.0) versus 9.5% (95% IC, 4.7-27.9) p=<0.0001, respectively.
Limitations, reasons for caution: In this study, we only included men with
teratozoospermia, not evaluating other men with different types of male infertil-
ity. Despite the fact that we selected sperm-cells without indicators of apop-
tosis and measure its impact on live-birth delivery rate, we didn’t evaluate its
effect on chromosomal abnormalities.
Wider implications of the ﬁndings: Through ICSI there is the possibility of
injecting a spermatozoon with an apoptotic process that by natural selection
would be condemned to die generating suboptimal results in ART; with the
help of MACS-ANMB we improve live-birth delivery rate in men with terato-
zoospermia and type-D motility.
Trial registration number: The main intervention of the study involved the
handling of the sperm samples rather that human beings, clinical trial registration
was not required.
O-062 Sperm Selection by either PICSI or MACS in cases with
abnormal SpermDNA fragmentation index for ICSI, a randomized
control trial
E. Hassanen1, H. Alkhader2, S. El Tanbouly2, K. El Koussy2, H. Zaki3,
A.G. Hussin2
1clinical embryologist, IVF lab Ganin Fertility Center, Cairo, Egypt
2Ganin Fertility Center, IVF Lab, Cairo, Egypt
3Ganin Fertility Center, Gynaecology, Cairo, Egypt
Study question: which sperm selection technique PICSI or MACS is better
for dealing with abnormal sperm DNA fragmentation patients undergoing ICSI.
Summary answer: there is no signiﬁcant difference in cleavage, blastulation,
implantation, pregnancy or ongoing pregnancy rates between both techniques.
What is known already: Sperm DNA fragmentation (SDF) has shown a
negative correlation with fertilization rate, embryo quality, and ongoing preg-
nancy rate, and a positive correlation with miscarriage rate.
PICSI and MACS have been developed for selecting a healthy mature non
apoptotic sperm for ICSI to obtain the best embryo quality and achieve higher
ongoing pregnancy rates.
Sperm membrane binding to hyaluronic acid on a PICSI Dish can improve the
likelihood of obtaining a sperm with lower SDF. MACS depends on the binding
of protein Annexin V to phosphatidylserine which is a marker for apoptosis, giv-
ing an elution of sperm with lower SDF.
Study design, size, duration: Prospective randomized controlled trial
enrolled 286 patients undergoing ICSI in Ganin Fertility Center, from
November 2016 and still recruiting. On the day of ICSI patients with abnormal
DNA fragmentation index were randomized into 2 arms; 1st arm is PICSI and it
contains 145 Patients, the 2nd arm is MACS and it contains 141 Patients.
Patients embryological parameters are recorded then pregnancy rate, implant-
ation rate and ongoing pregnancy rate is followed up.
Participants/materials, setting, methods: Couples undergoing ICSI were
included if the female age is below 40 years and had at last 5 mature oocytes,
male must have abnormal DFI (> 19%) using TUNEL assay. Cases were rando-
mized to the 2 groups, semen processing is done by double layer density gradi-
ent method then the resulted pellet is either placed on hyalornan dot of PICSI
dish or labeled by Anexin V microbeads for further separation on the MACS
column.
Main results and the role of chance:
Point of comparison PICSI MACS P value Signiﬁcance
Total no. of cases 145 141 / /
Average no. of MII oocytes 14.8 14.4 / /
Primary outcome:
Continued
Continued
Point of comparison PICSI MACS P value Signiﬁcance
Ongoing pregnancy
rate (%)
56.3 % 50.8% P = 0.3456 NS
Secondary outcome:
Cleavage rate (%) 76.20% 75.56% P = 0.5977 NS
Blasulation rate (%) 63.60% 60.61% P = 0.0555 NS
Blastocyst quality rate (%) 62.70% 60.70% P = 0.3172 NS
Pregnancy rate (%) 63.8% 59.10% P = 0.4081 NS
Implantation rate (%) 38.35% 35.40% P = 0.4214 NS
Limitations, reasons for caution: the number of enrolled patients is not
enough to be 80% statistically powered so patient recruitment is open to com-
plete 400 patients. The results could be more conﬁdent if it was applicable to
use both of the techniques for injecting sibling oocytes (case controlled study).
Wider implications of the ﬁndings: Most of the published research agree
with the beneﬁt of using a sperm selection technique whether it’s PICSI or
MACS. This comparison will tell us novel data about ongoing pregnancy rate
but more studies are needed to evaluate the live birth rate.
Trial registration number: Clinical trial registration number:
NCT03398317
O-063 Antisperm-antibodies prevalence and relationship with
seminal parameters and with post-coital test outcome. A
retrospective analysis on over 10.000 men
C. Castellini1, A. Barbonetti2, S. D’Andrea1, M. Totaro1,
A. Martorella1, E. Minaldi1, G. Cordeschi1, S. Francavilla1,
F. Francavilla1
1University of L’Aquila, Department of Life- Health and Environment Sciences,
L’Aquila, Italy
2San Raffaele Institute, Spinal cord injury, Sulmona- L’Aquila, Italy
Study question: To determine antisperm-antibodies (ASA) prevalence and
the relationship of auto-immunization degree with seminal parameters and with
post-coital test (PCT) outcome.
Summary answer: Only a 100% positivity of IgG-MAR test, detected in 2%
of the study population, was signiﬁcantly associated with lower sperm quality
and poor PCT outcome.
What is known already: Although the IgG-MAR test has been recom-
mended by WHO as an integral part of semen analysis for the screening of
antisperm-antibodies (ASA), the prevalence of positive results and their rela-
tionship with seminal parameters as well as the cut-off values of clinical rele-
vance are controversial.
Study design, size, duration: Retrospective analysis on 12.296 consecutive
men attending the Andrologic Unit of the University/Hospital of L’Aquila for
the evaluation of fertility potential.
Participants/materials, setting, methods: Immunological screening with
IgG-MAR test was performed to all ejaculates as integral part of semen analysis.
Positive samples (≥10%) were tested also for IgA-ASA. The prevalence of posi-
tive IgG-MAR tests and the relationship of the degree of the sperm-
autoimmunization with seminal parameters were analyzed. The outcome of
PCT performed in couples where the male partner exhibited a positive MAR
test was also analyzed.
Main results and the role of chance: Excluding from the analysis semen
samples with not-executable MAR-test due to azoospermia or severe oligo-
asthenozoospermia, the prevalence of positive IgG-MAR test in the remaining
10.025 men was 4% (398), 3.4% (342) and 2% (200) using a cut-off of 10%,
50% and 100% positive MAR-test. Only 100% positive MAR-tests were signiﬁ-
cant associated with a higher prevalence of the mixed pattern of positivity, as
well as with concomitant occurrence of IgA-ASA. Only 100% positive MAR-
tests were signiﬁcantly associated with a lower median value of total number of
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spermatozoa: 69 × 106 vs 132 × 106 ( p = 0,0003) in 50%-99% positive MAR
test and vs 120 × 106 (p < 0,0001) in negative samples. Furthermore, Only
100% positive MAR-tests were signiﬁcantly associated with a lower median
value of progressive motility: 40% vs 53% (p < 0,0001) in 50%-99% positive
MAR test and vs 54% (p < 0,0001) in negative samples. In 120 PCT performed
in couples where the male partner exhibited a positive MAR, only 100% positive
MAR-tests were signiﬁcantly associated with a higher percentage of poor PCT
outcome: 78% vs 30% ( p < 0.0001) in 50%-99% positive MAR test and 17% (
p < 0.0001) in >50% positive MAR-test. This association was independent
from cervical mucus score and total progressive motile sperm in the ejaculate.
Limitations, reasons for caution: Only surrogate infertility-related end-
points have been analysed in this study. However, as the impairment of sperm
penetration through the cervical mucus represents the primary mechanism of
ASA interference with fertility, the PCT outcome may represent a suitable end-
point.
Wider implications of the ﬁndings: In the context of the controversial clin-
ical relevance of ASA, this study, the largest reported, provides a more reliable
estimate of their prevalence. Although 50%- positive MAR-test has been indi-
cated by WHO as clinically-relevant cut-off, only 100%- positive MAR-tests
were signiﬁcantly associated with lower sperm quality and poor PCT outcome.
Trial registration number: not applicable.
O-064 Antioxidants in the treatment of male factor infertility:
Results from the double blind, multi-center, randomized controlled
Males, Antioxidants, and Infertility (MOXI) trial
A. Steiner1, K. Hansen2, M.P. Diamond3, C. Coutifaris4, M. Cedars5,
R. Legro6, R. Usadi7, V. Baker8, R. Coward9, N. Santoro10,
E. Eisenberg11, H. Zhang12, A. Reproductive Medicine Network.11
1University of North Carolina at Chapel Hill, Obstetrics and Gynecology, Chapel Hill-
NC, U.S.A.
2University of Oklahoma, Obstetrics and Gynecology, Oklahoma City- OK, U.S.A.
3Augusta University, Obstetrics and Gynecology, Augusta- GA, U.S.A.
4University of Pennsylvania, Obstetrics and Gynecology, Philadelphia- PA, U.S.A.
5University of California-San Francisco, Obstetrics and Gynecology, San Francisco- CA,
U.S.A.
6Penn State, Obstetrics and Gynecology, Hershey- PA, U.S.A.
7Carolina Medical Center, Obstetrics and Gynecology, Charlotte- NC, U.S.A.
8Stanford University, Obstetrics and Gynecology, Sunnyvale- CA, U.S.A.
9University of North Carolina at Chapel Hill, Urology, Chapel Hill- NC, U.S.A.
10University of Colorado, Obstetrics and Gynecology, Denver- CO, U.S.A.
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Study question: Among couples with male factor infertility, do antioxidants
improve male fertility, as measured by semen parameters and sperm DNA
integrity at 3 months, and pregnancy by 6 months of treatment?
Summary answer: Antioxidant treatment of the male partner does not
improve semen parameters, sperm DNA integrity, or in vivo pregnancy rates in
couples with male factor infertility.
What is known already: Clinical trials suggest that antioxidants have a posi-
tive effect on sperm motility, DNA integrity, and pregnancy rates in couples
undergoing assisted reproductive technologies; however, there are signiﬁcant
gaps in our knowledge of their impact on male fertility. To date research studies
have used: 1) small sample sizes, usually less than 50 subjects, 2) heterogeneous
populations and a variety of single antioxidants, 3) changes in semen parameters
or DNA integrity as the endpoint, rather than clinical outcomes, and 4) antioxi-
dants in conjunction with in vitro fertilization with intracytoplasmic sperm injec-
tion (ICSI) when assessing effectiveness.
Study design, size, duration: 174 couples were enrolled in a multi-center,
double blind, randomized, placebo-controlled trial of a daily antioxidant formu-
lation, containing 500 mg vitamin C, 2000IU vitamin D3, 400IU vitamin E, 1 mg
folic acid, 20 mg zinc, 200 mcg selenium, and 1000mg L-carnitine. Males were
treated for a minimum of 3 months and a maximum of 6 months. Couples
attempted to conceive naturally during the ﬁrst 3 months and with clomiphene
citrate with intrauterine insemination in months 4 through 6.
Participants/materials, setting, methods: Males with sperm concentra-
tion ≤ 15 M/ml, motility ≤ 40%, normal morphology ≤ 4%, or DNA fragmenta-
tion > 25% were eligible. Female partners were ≤ 40 years old, with
documented tubal patency and ovulation. Semen parameters and DNA frag-
mentation were assessed at randomization and following 3 months of treat-
ment. Data are presented as median (interquartile range) or mean ± standard
deviation.
Main results and the role of chance: After 3 months of treatment, change
in sperm concentration differed slightly between the antioxidant [-4.0 (-12.0,
6.0) M/ml] and placebo groups [+3.2 (-9.0, 15.5) M/ml] (p = 0.03). However,
there were no signiﬁcant differences between the two groups in the change in
morphology, motility, or DNA fragmentation. Among the 66 oligospermic men
at randomization, concentration did not differ at 3 months [8.5 (4.8,15.0) M/ml
versus 15.0 (6.0,24.0) M/ml; p = 0.30] between antioxidant and placebo
groups. Among the 76 asthenospermic men, motility did not differ at 3 months
(34 ± 16.3% versus 36.3 ± 15.6%; p = 0.93). Among the 40 men with teratos-
permia, normal morphology did not differ at 3 months [2.0 (0.6,4.5)% versus
3.0 (2.0,4.0)%; p = 0.28]. Among the 34 men with high DNA fragmentation,
DNA fragmentation did not differ at 3 months [28.9 (21.6,36.5)% versus 28.8
(21.6,37.4)%; p = 0.68]. In the entire cohort, cumulative pregnancy rates did
not differ at 3 months (10.5% versus 9.1%; p = 0.76) or at 6 months (22.1%
versus 29.6%; p = 0.26) between the antioxidant and placebo groups,
respectively.
Limitations, reasons for caution: While the trial was adequately powered
to examine changes in semen parameters, the trial is underpowered to assess
differences in pregnancy rates between antioxidants and controls. However,
the DSMB recommended not proceeding with the larger trial, given the results
of the internal pilot.
Wider implications of the ﬁndings: Antioxidants do not appear to
improve semen parameters or DNA fragmentation among men with male fac-
tor infertility. While previous data suggest that antioxidants improve pregnancy
rates in in vitro fertilization, these data suggest they do not improve in vivo
conception.
Trial registration number:NCT02421887
O-065 Features of metabolic disorder in late adolescence are
negatively associated with testicular function aT 20 years of age;
evidence from a birth cohort,
R. Hart1, D. Doherty2, L. Adams3, R.C. Huang4, T. Mori5, N. Minae2,
R. MacLachlan6, N. Skakkebaek7, R. Norman8, D. Handelsman9,
J. Olynyk10, L. Beilin5
1University of Western Australia & Fertility Specialists of WA, School of Women’s and
Infants Health, Perth- Western Australia, Australia
2King Edward Memorial Hospital, Women and Infants Research Foundation-, Perth-
Western Australia, Australia
3University of Western Australia, School of Medicine- Sir Charles Gardiner Hospital-,
Perth-, Australia
4University of Western Australia & Telethon Kids Institute, School of Medicine- Royal
Perth Hospital-, Perth-, Australia
5University of Western Australia, School of Medicine- Royal Perth Hospital-, Perth-,
Australia
6Hudson Institute, Monash Medical Centre, Melbourne, Australia
7University Department of Growth and Reproduction, Rigshospitalet, Copenhagen,
Denmark
8Robinson Institute Research Centre for Reproductive Health, University of Adelaide
School of Medicine & FertilitySA, Adelaide, Australia
9ANZAC Institute, University of Sydney, Sydney, Australia
10Fiona Stanley Hospital & Fremantle Hospital Group, Department of
Gastroenterology, Perth, Australia
Study question: In a population of men within a birth cohort, are features of
an adverse cardiometabolic proﬁle in late adolecence associated with impaired
testicular function at 20 years of age?
Summary answer: Despite the majority of men being only 20 years old, with
a normal BMI, features of cardiometabolic disorder were associated with signs
of testicular impairment.
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What is known already: An adverse cardiometabolic proﬁle in adulthood
has been reported to be associated with impaired testicular function; however
no data exists from younger men. Hence it is unclear whether the metabolic
disorder predates the adverse testicular function, or whether it is the lower ser-
um testosterone concentration that predisposes the man to metabolic disorder
in later life.
Study design, size, duration: The Raine Study recruited 2900 women in
pregnancy and retained the 2868 children born to form the Raine Study cohort.
At 17 years of age males underwent a liver ultrasound for fatty liver (n = 490),
and serum cytokines were measured (n = 520). At 20 years, measures included
blood biochemistry (n = 618), a DEXA scan (n = 634), and a testicular assess-
ment performed; semen sample (n = 365), testicular ultrasound (n = 404) and
serum testosterone, LH, FSH and inhibin B concentrations were assayed
(n = 620).
Participants/materials, setting, methods: Fasting bloods were analysed
for serum IL-18 by ELISA, tumor necrosis factor receptors (TNFR1 & 2) by
cytometric bead array, and liver enzymes, insulin, glucose, lipids, high sensitivity
CRP (hsCRP) and uric acid. Homeostasis model assessment (HOMA) was cal-
culated and insulin resistance (IR) was deﬁned by a HOMA>4. DEXA measure-
ment was performed for lean and total fat mass.
A cluster analysis was used to derive high-risk groups with features consistent
with the metabolic syndrome.
Main results and the role of chance: Participants that had testicular assess-
ment were similar clinically to those that declined participation. The prevalence
of metabolic syndrome was 4.1% (NCEP-ATPIII deﬁnition) (40) and 5.4% (IDF
deﬁnition).
After adjustment for age, BMI, abstinence, a history of cryptorchidism and
presence of a varicocele; total sperm output was reduced in men with a higher
IL-18, and serum TNFR1, and sperm concentration was negatively associated
with IL-18 (all p < 0.05). After adjustment, seminal volume was negatively asso-
ciated with serum hsCRP, and serum testosterone was positively associated
with serum HDL-cholesterol and lean mass, and negatively with serum insulin
(all p < 0.05).
In an unadjusted dichotomized analysis of men within the high risk metabolic
cluster compared to those low risk, their testosterone (3.6 ng/ml vs 4.8 ng/ml)
and inhibin B (167.9 pg/ml vs 223.7 pg/ml) concentrations were lower (p <
0.001 for both). Participants with IR had a smaller testicular volume (12.8mls vs
15.2mls, p = 0.010), lower testosterone (3.2 ng/ml vs 4.6 ng/ml, p < 0.001)
and inhibin B (172.4 pg/ml vs 217.8 pg/ml, p = 0.001), and higher serum FSH
concentrations (6.1iu/l vs 4.3iu/l, p = 0.046).
Ultrasound evidence of fatty liver was associated with a reduction in; total
sperm output (68.0 × 106 vs 126.0 × 106, p = 0.044), testosterone (4.0 ng/ml
vs 4.7 ng/ml, p = 0.005) and inhibin B (209.1 pg/ml vs 218.4 pg/ml, p = 0.032)
concentrations.
Limitations, reasons for caution: Although this study had a very good rate
of recruitment there is potential for recruitment bias, and the possibility of con-
founding. Univariate associations were substantiated in multivariable analyses
that controlled for confounding for age and BMI at 20 years, cryptorchidism and
presence of a varicocele.
Wider implications of the ﬁndings: This study demonstrated a potential
negative association of adverse cardiometabolic features in adolescence with
testicular function by 20 years of age. Despite the majority of men having a nor-
mal BMI, and being relatively young, a signiﬁcant minority were already showing
some features of the metabolic syndrome and impaired testicular function.
Trial registration number: NHMRC project grants (nos 634557,
35351417, 403981)
SELECTEDORAL COMMUNICATIONS
SESSION 18: HEALTH RISKS IN CHILDRENBORNAFTER
ART
Monday 2 July 2018 Room 111 + 112 15:15–16:30
O-066 Body composition and blood pressure of 6-year-old
singletons born after Pre-implantation Genetic Testing (PGT): a
matched cohort study
F. Belva1, M. Roelants2, S. Kluijfhout1, C.Winter1, F. De Schrijver1,
S. Desmyttere1, A. Buysse1, P. De Becker1, M. De Rycke1,
W. Verpoest3, I. Liebaers1, M. Bonduelle1
1UZ Brussel, Medical Genetics, Jette- Brussels, Belgium
2KU Leuven, Environment and Health/Youth Health Care- Department of Public
Health and Primary Care, Leuven, Belgium
3UZ Brussel, Centre for Reproductive Medicine, Jette- Brussels, Belgium
Study question: Do children conceived by PGT have an altered body com-
position or higher blood pressure?
Summary answer: Blood pressure and anthropometric measurements
including body mass index (BMI) and indices of peripheral and central adiposity
were comparable between PGT and ICSI children.
What is known already: Although neonatal outcomes after PGT conception
have been found comparable to those after ICSI, few studies have reported on
the medical outcome at older ages. We previously found that at age 2, mean
body mass index tended to be lower in PGT children while the prevalence of
congenital anomalies was similar. Others reported that blood pressure and
anthropometrics did not differ in 4- and 9-year old children conceived after
IVF/ICSI with or without aneuploidy testing (PGT-A). However, outcomes in
PGT-A children cannot be extrapolated to PGT children given the dissimilar
indications and parental reproductive background.
Study design, size, duration: In this single-center study, singletons conceived
by PGT reaching between 5 and 6 years during the period May 2011 and June
2017 were matched as closely as possible for gender, age, maternal educational
level and birth order to peers born after ICSI. Biopsy of cleavage-stage embryos
was performed solely for the purpose of PGT (PGT-A cycles were excluded) and
all fresh embryo transfers in PGT and ICSI cycles were carried out at day 5.
Participants/materials, setting, methods: Anthropometrics (weight,
height, BMI, skinfold thickness, waist and mid-upper arm circumference) and
blood pressure readings of 87 singletons born after PGT, including PGT for
mongenic defects (PGT-M) and chromosomal structural rearrangements (PGT-
SR), but not for aneuploidies (PGT-A), were compared with results of 87 peers
born after ICSI.
Main results and the role of chance: From the 124 eligible PGD families,
110 could be contacted, 23 declined and 87 (70.2%) children participated of
whom 39 (45%) were males. The reasons for declining were ‘no time’ and ‘living
too far from the hospital’. Neonatal characteristics, including birth weight
Standard Deviation Score (SDS) and gestational age and parental characteristics,
including maternal weight gain, smoking and alcohol consumption during preg-
nancy, maternal age, current maternal and paternal BMI were comparable
between the groups (all p > 0.05). Mean age was 5.5 years in the PGT group and
5.6 years in the ICSI group (P = 0.2). All anthropometric measurements, includ-
ing BMI SDS, waist and mid-upper arm circumference SDS were comparable
between the PGT (-0.23; 0.27; 0.17 respectively) and ICSI (-0.29; 0.10; 0.11)
group (all P > 0.05). Furthermore, skin thickness derived indices of peripheral
and central adiposity were comparable (PGT: 14.7mm; 11.6mm and ICSI:
15.5mm; 11.5mm) as well as the calculated total body fat mass (PGT: 13.7%
and ICSI: 13.9%) (all P > 0.05). Finally, also blood pressure SDS were comparable
between the two groups (all P > 0.05). Results did not change taking neonatal
(birth weight SDS, gestational age, birth order) and parental (pre-pregnancy
maternal BMI, maternal educational level) characteristics into account.
Limitations, reasons for caution: The non-participating PGT children did
not differ from the participating group in terms of gender, birth order, gesta-
tional age, birth weight or maternal educational level, which makes participation
bias less likely.
Wider implications of the ﬁndings: Our results point to no adverse effect
of embryo biopsy at cleavage-stage and fresh embryo transfer at day 5.
However, more and long-term follow-up studies are indicated as there are cur-
rently no data available for PGT children born after trophectoderm biopsy and/
or transfer of warmed embryos after vitriﬁcation.
Trial registration number: not applicable.
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O-067 Birthweight and gestational age following blastocyst
transfer compared to cleavage stage embryo transfer: an analysis of
68,042 singleton births
N. Marconi, E.A. Raja, S. Bhattacharya, A. Maheshwari
University of Aberdeen, Institute of Applied Health Sciences, Aberdeen, United
Kingdom
Study question: Are there any differences in birthweight and gestational age
in singleton births conceived after blastocyst transfer as compared to those fol-
lowing cleavage stage embryo transfer?
Summary answer: Birthweight and gestational age outcomes of singleton
pregnancies following fresh blastocyst transfer are similar to those subsequent
to cleavage-stage embryo-transfer.
What is known already: Previous observational studies and meta-analysis
suggest that risks of preterm birth (PTB) and high birthweight babies (HBW) in
singleton pregnancies are higher following blastocyst transfer than after embryo
transfer at cleavage stage. The published studies have limitations including small
sample sizes and inability to adjust for a number of potential confounders.
Hence there is a need for deﬁnitive results based on analysis of a single large
national dataset.
Study design, size, duration: This is a cohort study using anonymized
Human Fertilisation Embryology Authority (HFEA) data from the United
Kingdom (UK). This study included all fresh in-vitro fertilisation (IVF) and intra-
cytoplasmic sperm injection (ICSI) cycles between the years 1999 and 2012
that resulted in a singleton birth after the transfer of two different types of
embryo: cleavage-stage (2-3 days of culture) and blastocyst-stage embryo (5-6
days).
Participants/materials, setting, methods: IVF or ICSI cycles with single-
ton births following the fresh transfer of cleavage stage or blastocyst stage
embryo(s) were included in the study. Logistic regression was used to assess
the association between the stage of embryo transferred (cleavage stage or
blastocyst) and birthweight and gestational outcomes adjusting for potential
confounders. Risk ratios (RR) with 99.5% conﬁdence intervals (CI) were used
as a measure of strength of associations.
Main results and the role of chance: Out of 68,042 singleton pregnancies,
11,243 occurred after blastocyst-stage embryo transfer while 56,799 resulted
from cleavage-stage embryo-transfer. The proportion of low birth weight
babies in the two groups were 8.9% and 9.3% respectively (p = 0.12). The risk
of having a low birthweight baby (aRR 0.93, 99.5% CI 0.83-1.05) and that of
having a high birthweight baby (aRR 0.93, 99.5% CI 0.83-1.05) were compar-
able after adjusting for maternal age, IVF/ICSI, duration of infertility, primary
cause, number of eggs, and previous pregnancy. The proportion of babies born
preterm was 1.9% in the blastocyst-stage group and 1.8% in the cleavage stage
group (p = 0.68). The risks of preterm birth (aRR 1.03, 99.5% CI 0.91-1.18)
and very preterm birth (aRR 1.00, 99.5% CI 0.78-1.28) were similar between
the two types of embryo transfer strategies. The odds of congenital anomalies
was similar between the groups (aOR 0.89, 99.5% CI 0.69-1.16).
Limitations, reasons for caution: As the anonymized HFEA data presents
gestational age and weight in bands rather than actual values, we were unable
to adjust birth weight according to gestational age and calculate parameters
such as Z scores. Additionally, one woman could have been represented more
than once in this cycle based analysis.
Wider implications of the ﬁndings: Our ﬁndings provide reassurance to
patients undergoing blastocyst-stage embryo-transfer, in contrast to other stud-
ies that have reported increased risk of high birthweight babies and preterm
delivery. Follow up studies from randomised trials or individual patient data
meta-analysis of registry based data will be needed to answer the question
deﬁnitely.
Trial registration number: not applicable.
O-068 Diabetes risk among children born after assisted
reproductive technology: An early population-based examination
J. Hsu1, M. Price2, V. Seo2, P. Rinaudo3, A. Frolich4
1Massachusetts General Hospital- Harvard Medical School, Mongan Institute Health
Policy Center, Boston, U.S.A.
2Harvard Medical School, Mongan Institute, Boston, U.S.A.
3UCSF, Ob/Gyn, San Francisco, U.S.A.
4Bispebjerg and Frederiksberg University Hospital, Research Institute, Copenhagen,
Denmark
Study question:What is the risk of developing diabetes among children born
after Assisted Reproductive Technology (ART)?
Summary answer: ART children have a low absolute risk of developing dia-
betes by age 19, but the relative risk compared with non-Art children
approaches statistical signiﬁcance.
What is known already: Data from animal studies suggest a potential risk for
diabetes among children born after ART, which may be mediated by epigenetic
changes. In humans, however, the majority of diabetes cases develop later in
life, most of which represent type-2 diabetes. In contrast, type-1 diabetes is less
common overall, but more prevalent among children. One recent study found
increases in both types among all children ≤19 years. The existing literature has
not had sufﬁcient follow-up time to evaluate diabetes development after ART.
Early detection however, could have tremendous value, as many diabetic com-
plications can be prevented or mitigated with current therapy.
Study design, size, duration: We examine the association between ART
use and diabetes risk through 2011 within a historical population cohort con-
sisting of all residents of Denmark. We examine the time to development of
diabetes using population-based clinical registries for diabetes, and other
national datasets. We focus on children born during the ﬁrst six years of the
Danish ART registry, i.e., born between 1994 and 1999. We use insulin status
as a crude initial proxy for diabetes type.
Participants/materials, setting, methods: All children born in Denmark
between 1994 and1999 are captured in the birth registry and eligible for the
study. We examine the numbers of children who develop diabetes, as captured
by the diabetes disease registry. We then compare the risk of developing dia-
betes among children born after ART treatment (using the ART registry) with
that of children born without treatment (i.e., spontaneous births). We use pro-
portional hazard models to assess the time to disease onset.
Main results and the role of chance: The maximum follow-up time was 19
years, i.e., for children born in 1994. Between 1994 and 1999, there were
5,912 live births after ART treatment and 400,131 spontaneous births. Among
these, a total of 1,986 children developed diabetes by 2012 as captured by the
national disease registry, or 4.9 per 1,000 spontaneous birth children and 5.9
per 1,000 children born after ART. The mean age at diabetes detection was
10.2 and 8.7 years, respectively; 82.0% and 82.9% were receiving insulin among
spontaneous birth and ART children. After multivariate adjustment, children
born after ART trended towards being more likely to develop diabetes (hazard
ratio = 1.4; p-value = 0.08), but this association was not statistically signiﬁcant
at conventional thresholds (i.e., p-value = 0.05).
Limitations, reasons for caution: This study has limited follow-up time and
numbers of total children in each group, decreasing both the power to detect
events during childhood and adolescence, and the ability to detect disease later
in life. The comparisons also reﬂect associations with diabetes and do not imply
causality.
Wider implications of the ﬁndings: There is a potential increased risk and
earlier onset of diabetes associated with ART treatment, compared with spon-
taneous births, though these preliminary analyses have limited statistical power.
Ongoing work will increase the amount of follow-up time, thus improving both
power and the ability to examine risks during early adulthood.
Trial registration number:Not applicable.
O-069 The risk of urogenital anomalies in children conceived with
ICSI using fresh or frozen embryo cycles
R. Fernandez1, V. Moore1,2, K.Willson2, A. Rumbold1, M. Davies1
1University of Adelaide, Robinson Research Institute, Adelaide, Australia
2University of Adelaide, School of Public Health, Adelaide, Australia
Study question: Does the risk of urogenital anomalies in children conceived
with intracytoplasmic sperm injection (ICSI) vary by use of fresh or frozen
embryo cycles?
Summary answer: Relative to natural conceptions, urogenital anomalies
were increased in children conceived with ICSI using fresh cycles but not frozen
cycles, accounting for infertility aetiology.
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What is known already: Urogenital anomalies are among the most com-
monly diagnosed congenital anomalies, affecting up to 16 per 1000 births per
year. Higher rates of urogenital anomalies are also observed among births con-
ceived using assisted reproductive technologies (ART), particularly ICSI. Male
factor infertility, the most common indication for ICSI, is also a risk factor for
some urogenital anomalies. There is evidence linking embryo freezing to
improved perinatal outcomes. Previous studies of urogenital anomalies in ART
populations have not investigated whether embryo freezing modiﬁes the risk of
anomalies, nor accounted for the possible role of male factor infertility.
Study design, size, duration: This study involved a whole of population
data-linkage cohort for the state of South Australia, comprising 308,933 births
and terminations of greater than 20 weeks gestation, from January 1986 to
December 2002. Congenital anomalies are notiﬁed until children reached age 5
years.
Participants/materials, setting, methods: The South Australian Birth
Cohort links data from infertility clinics with government perinatal and birth
defects registries. Urogenital anomalies are coded to the British Paediatric
Association modiﬁcation of ICD-9 codes. Using children conceived naturally as
the reference, we examined the risk of urogenital anomalies among children
conceived with ICSI overall, and separately, ICSI with frozen or fresh cycles,
using logistic regression with adjustment for potential confounders. The role of
male factor infertility was also considered.
Main results and the role of chance: There were 308,933 births and termi-
nations, including 1410 resulting from ICSI (79% using fresh cycles, 21% using
frozen cycles). Male factor infertility only was the most common reason for
treatment in the fresh and the frozen ICSI cycles (75% vs 73%, respectively).
Overall, the risk of urogenital anomalies was increased in children conceived
with ICSI compared with natural conceptions (adjusted OR = 1.89, 95% CI:
1.39-2.58). The increased risk was observed in ICSI with fresh cycles (n =
1115, adjusted OR = 2.22, 95% CI: 1.62-3.04) and remained when patients
with male factor infertility were excluded from this group (adjusted OR = 2.08,
95% CI: 1.10-3.93). There was no increased risk of urogenital anomalies in chil-
dren conceived with ICSI using frozen cycles (n = 291, adjusted OR = 1.04,
95% CI: 0.43-2.48).
Limitations, reasons for caution: There was not sufﬁcient statistical power
to investigate speciﬁc subtypes of urogenital anomalies. Residual confounding
may be present, as not all patient- and treatment-related risk factors for uro-
genital anomalies, for example severity of male infertility, number of embryos
and embryo quality, were fully captured in available data.
Wider implications of the ﬁndings: The risk of urogenital anomalies asso-
ciated with ICSI may be reduced through the use of frozen embryo transfer
cycles. These ﬁndings contribute robust evidence to enhance understanding of
the relative contribution of patient and treatment factors to the increased risk
of adverse perinatal outcomes among children conceived using ART.
Trial registration number: not applicable
O-070 Does transfer of multiple embryos affect perinatal
outcomes of the resulting singleton live births? Analysis of 113 784
singleton live births following ART
M.S. Kamath1, B. Antonisamy2, H.Y. Selliah3, S.K. Sunkara4
1Christian Medical College and Hospital, Reproductive Medicine, Vellore, India
2Christian Medical College and Hospital, Department of Biostatistics, Vellore, India
3Christian Medical College and Hospital, Department of Biostatistics, Vellore, India
4Queen’s Hospital- Barking Havering Redbridge University Hospitals NHS Trust,
Reproductive Medicine, Essex, United Kingdom
Study question: Does transfer of two or more embryos affect perinatal out-
comes of resulting singleton live births following assisted reproductive technol-
ogy (ART)?
Summary answer: The risk of adverse perinatal outcomes is higher in single-
ton births following transfer of two or more embryos mainly associated with
plurality at conception.
What is known already: Singleton pregnancies following ART are at a higher
risk of adverse perinatal outcomes compared to spontaneous conceptions.
Underlying infertility, altered endocrine milieu following ovarian stimulation,
in vitro gamete manipulation and embryo culture are some of the suggested rea-
sons for adverse perinatal outcomes. Earlier studies have found an increased
risk of preterm birth (PTB) and low birth weight (LBW) in singletons following
transfer of multiple embryos versus single embryo transfer (SET). However,
these studies did not address the contributory role of plurality at conception,
the initial presence of more than one gestational sac.
Study design, size, duration: Anonymous data were obtained from the
Human Fertilization and Embryology Authority (HFEA), which collects the data
prospectively on all ART cycles performed in the UK. Data from 1991 to 2011
involving 508 410 fresh and 131 334 frozen autologous ART cycles resulting in
95 779 and 18 005 singleton live births respectively were analysed for perinatal
outcomes based on the number of embryos transferred.
Participants/materials, setting, methods: Fresh or frozen ART cycles
were analysed separately to compare perinatal outcomes of PTB and LBW in
singleton live births resulting from transfer of two or more embryos versus SET.
Logistic regression was performed adjusting for female age, infertility causes,
previous live birth and embryo stage. Subgroup analyses was planned within
ART cycles for perinatal outcomes of singleton live births following either initial
single or initial multiple gestational sacs versus singleton live birth following SET.
Main results and the role of chance: There was a signiﬁcantly higher risk of
PTB (aOR 1.14, 95% CI 1.06–1.23) and LBW (aOR 1.14, 95% CI 1.06–1.23) in
singleton births following transfer of two or more embryos compared to SET in
fresh cycles. There was a signiﬁcantly higher risk of PTB (aOR 2.70, 95% CI
2.37-3.05) and LBW (aOR 2.76, 95% CI 2.44–3.13) in singleton births with ini-
tial multiple gestational sacs compared to those following SET with fresh trans-
fers. There was no signiﬁcant difference in the risk of PTB (aOR1.08, 95% CI
1.00–1.16) and LBW (aOR 1.08, 95%CI 1.00-1.16) singleton live births when
there was an initial single gestational sac after fresh transfer of two or more
embryos compared to SET. There was no signiﬁcant difference in the risk of
PTB (aOR 1.05, 95% CI 0.91–1.21) and LBW (aOR 0.95, 95% CI 0.81-1.12) in
singleton births after transfer of two or more embryos compared to SET in fro-
zen cycles. There was a signiﬁcantly higher risk of PTB (aOR 2.13, 95% CI
1.55–2.93) and LBW (aOR 2.61, 95% CI 1.87-3.64) in singleton live births with
initial multiple gestational sacs compared to those following SET in frozen
cycles.
Limitations, reasons for caution: While the analysis was adjusted for a
number of known confounders, the dataset had no information on other con-
founders like smoking, body mass index, previous obstetric history or medical
history of women during pregnancy to allow for adjustment.
Wider implications of the ﬁndings: Current study results suggests that
there is an increased risk of adverse perinatal outcomes following transfer of
more than one embryo in singleton live births following ART and plurality at
conception or the initial multiple gestation reduced spontaneously to singleton
gestation plays the major contributory role.
Trial registration number: not applicable
SELECTEDORAL COMMUNICATIONS
SESSION 19: THE LINK BETWEEN REPRODUCTIVE
ENDOCRINOLOGYANDMETABOLISM: NEWS FROM
THE LAB
Monday 2 July 2018 Room 113 + 114 + 115 15:15–16:30
O-071 Genetic Deconstruction of Hypothalamic Neural Circuits
for Obesity-induced Infertility
P.Wang1, J. Xu2, C. Bartolome2, Y. Xinchi2, C. Low2, D. Kong2
1Beijing Chao-Yang Hospital Afﬁliated to Capital Medical University, Department for
Human Reproduction, Beijing, China
2Tufts University School of Medicine, Department of Neuroscience, Boston, U.S.A.
Study question: To investigate how the brain, especially the hypothalamus,
adjusts reproductive performance according to metabolic cues and contributes
to the pathophysiological process of obesity-induced infertility.
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Summary answer: In obesity, hyperactive agouti-related protein (AgRP) neu-
rons shut down reproductive performance by innervating preoptic area (POA)
of the hypothalamus, where critical reproduction-regulating neurons reside.
What is known already: Epidemiological evidence suggests that obesity is
tightly related to infertility, and given the role of the hypothalamus in coordinat-
ing both metabolism and reproduction, such obesity-induced infertility is likely
mediated by the hypothalamus. We propose that the AgRP neurons in arcuate
nucleus of the hypothalamus to be the key neurons in this pathophysiological
process, given that AgRP neurons are, a) known as a major regulator of body
weight and energy balance; b) heavily project to the POA of the hypothalamus,
a key reproduction-regulating region; c) dysfunctions of AgRP neurons can
result in severe obesity, which can cause infertility.
Study design, size, duration: To test the sufﬁciency and necessity of AgRP
neurons in obesity-induced infertility, genetic engineered mice were rando-
mized into control group and treatment group. Typically, each group includes
8-10 mice and 3 weeks were waited to allow sufﬁcient expression of the viral
vectors, which are used to manipulate AgRP neurons.
Participants/materials, setting, methods: AgRP-IRES-Cre mice of 6-8
weeks age were used in the current study to achieve cell-type-speciﬁc neuronal
manipulation. Taking advantage of recently developed Cre-enable viral tools,
in vivo inhibition and activation of AgRP neurons was carried out using
DREADDs (designer receptors exclusively activated by designer drugs) and
optogenetic methods. Subsequenlty, routine evaluation of reproductive per-
formance was followed. CRISPR/Cas9 technique was also used to knock out
leptin receptor in AgRP neurons.
Main results and the role of chance: To test the necessary role of AgRP
neurons in mediating obesity-induced infertility, hyperphysiological neuronal
activity of AgRP neurons in high-fat-diet-induced obese mice was suppressed
using inhibitory hm4Di/DREADDs methods. In these obese mice, meliorated
reproductive performance, as indicated by recovered estrous cycle and
improved pregnancy rate (33.3% Vs. 100%, P < 0.05), was observed following
chronic AgRP neuronal inhibition. On the other hand, to identify the sufﬁcient
role of AgRP neurons, we activated AgRP neurons in mice of normal body
weight using excitatory hm3Dq/DREADDs methods. After chronic AgRP neur-
onal activation, impaired reproductive performance was observed, as mani-
fested by lower luteinizing hormone (LH) levels (0.75 ± 0.12 Vs. 0.31 ± 0.03,
P < 0.05), reduced GnRH transcription and disrupted estrous cycles. Next, we
aimed to clarify the downstream neural network of AgRP neurons. To select-
ively manipulate AgRP afferents to the POA without affecting other AgRP-
neuron projection sites, optogenetic terminal stimulation was used. After 30-
minutes stimulation, signiﬁcantly lowered LH levels (0.81 ± 0.20 Vs. 0.25 ±
0.04, P < 0.001) and GnRH transcription was observed. Moreover, to identify
the molecular mechanism underlying AgPR neurons hyperactivity in obesity and
the subsequent infertile phenotype, we selectively knockout leptin receptor in
AgRP neurons in adult female mice and found disrupted estrous cycles and
impaired pregnancy rate (100% Vs. 20%, P < 0.05).
Limitations, reasons for caution: The neural mechanisms discovered in
this study has only been tested in mice. In the future, we are planning to extend
this results to patients and identify is this neural circuit could be used as a thera-
peutic target for obesity-induced infertility.
Wider implications of the ﬁndings: This study is likely to provide a better
understanding of the neural basis of obesity-induced infertility, which will likely
accelerate the development of novel therapies of infertility. Moreover, utilizing
newly developed genetic approaches with neuron-speciﬁc and real-time charac-
teristics will open a new vista for studying central reproductive modulation.
Trial registration number: B2014-94 (approved by institutional animal care
and use committee of Tufts University)
O-072 DNAmethylation modiﬁcations potentially participate in
the intergenerational epigenetic inheritance of prenatal
androgenized mice
Y. Cui, Z. Yan, L. Yan, J. Qiao
Peking University Third Hospital, Center for Reproductive Medicine, Beijing, China
Study question: Were there any epigenetic marks underpin the potential
intergenerational epigenetic inheritance of prenatal androgenized (PNA) mice?
Summary answer: Prenatal androgenized could induce metabolic abnormal-
ities in F2 offspring through paternal germline, when DNA methylation modiﬁ-
cations were the potential epigenetic marks passing the phenotype.
What is known already: Polycystic ovarian syndrome (PCOS) could be reca-
pitulated by prenatal androgenization across species, suggesting a developmen-
tal etiology for this disorder, when there are increasing evidences that certain
acquired traits could be transmitted from one generation to the next. It arouses
our interests that whether prenatal androgenization induced PCOS traits could
be transmitted to the next generation and whether there exist epigenetic infor-
mation carrier passing the phenotype.
Study design, size, duration: Twenty-four pregnant mice (F0) were injected
with 200 ug/day dihydrotestosterone (PNA group) or sesame oil (Control
group) at embryonic day 16-18. The offspring mice were studied as F1 when
maternal F2 offspring and paternal F2 offspring were generated after adult
female F1 and male F1 mating with normal individuals, respectively. The pheno-
types of offspring mice were separately determined at 3 month’s old and 8
month’s old.
Participants/materials, setting, methods: Male and female C57BL/6 J
mice (F0) were paired and female F1 were studied with PCOS diagnostic and
metabolic traits while male F1 were investigated with metabolic phenotypes.
The PCOS diagnostic and metabolic traits of maternal and paternal F2 female
individuals were determined to evaluate the intergenerational epigenetic effect.
Single cell whole genome bisulﬁte sequencing (scWGBS) on F1 oocytes and
WGBS on F1 sperms were performed to analyze their DNA methylation
changes.
Main results and the role of chance: PNA female F1 mice had disrupted
estrous cycles, elevated serum testosterone, increased preantral ovarian folli-
cles, impaired glucose tolerance and unaffected insulin sensitivities as previously
reported. We did not ﬁnd any PCOS diagnostic traits or metabolic abnormal-
ities in PNA maternal female F2 offspring as long as 8 month’s old. Surprisingly,
we found PNA male F1 mice represented signiﬁcantly impaired glucose toler-
ance (P < 0.01) and insulin sensitivities (P < 0.05). More importantly, although
PNA paternal female F2 offspring did not manifested PCOS diagnostic traits,
they showed markedly reduced body weights (P < 0.01) and a clear tendency
of glucose tolerance impairment (P = 0.06) at 3 month’s old. And their glucose
tolerance were even deteriorated (P < 0.01) and insulin sensitivities were also
decreased (P < 0.01) at 8 month’s old. In searching for epigenetic information
carriers, we performed single cell whole genome bisulﬁte sequencing
(scWGBS) on oocytes of female F1 mice and WGBS on sperms of male F1
mice. Bioinformatics analysis indicated the DNA methylation patterns of female
F1 oocytes in PNA and control group did not clustered while PNA F1 sperms
clearly clustered from control. We also identiﬁed 217 differentially methylated
regions (DMRs) in PNA F1 sperm epigenome which could potentially be epi-
genetic information carriers pass the phenotype.
Limitations, reasons for caution: The exact role of DNA methylation
alterations in prenatal androgenization induced epigenetic inheritance were not
fully validated, and these observations were shown only in mouse species.
Wider implications of the ﬁndings: This study provide the ﬁrst evidence
for prenatal androgenization inducing intergenerational epigenetic inheritance
potentially through paternal germline by DNA methylation modiﬁcations, shad-
ing light on explanations of PCOS prevalence and inheritance.
Trial registration number: not applicable.
O-073 Exploration of chemerin system in human granulosa cells: a
new insight for polycystic ovarian syndrome
N. Mellouk, A. Bongrani, R. Christelle, G. Fabrice, D. Joëlle
INRA- CNRS- Université François Rabelais de Tours- IFCE, UMR85 Physiologie de la
Reproduction et des Comportements, Nouzilly, France
Study question: Characterization of chemerin system in human granulosa
cells from PCOS patients and cell line and modulation of its signaling activities
using a CMKLR1 nanobody (C4910).
Summary answer: The chemerin system is differentially expressed and active
in human granulosa cells and could have a role on PCOS syndrome.
What is known already: Studies on fertility disorders related to metabolic
abnormalities have highlighted the importance of the role of hormones
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produced by adipose tissue (adipokines) on the appearance of pathologies such
as polycystic ovary syndrome (PCOS). Chemerin is a new adipokine able to
bind three G protein-coupled receptors: CMKLR1 (chemokine-like receptor
1), GPR1 (G protein-coupled receptor 1), and CCRL2 (Chemokine (CC motif)
receptor like 2). Recently, a role for the chemerin/CMKLR1 pathway in ovarian
follicle function and steroidogenesis has been reported in mammals. In human
granulosa (hCGs) and in the human ovarian granulosa-like tumour cell line
(KGN), chemerin inhibited IGF-1-induced steroids production.
Study design, size, duration: Six groups of 10 patients aged 22 to 41 years
old: control (undergoing in vitro fertilization for men infertility), obese (BMI >
30), PCOS (presenting two of the three Rotterdam criteria), ECHO (presenting
only enlarged polycystic ovaries by ultrasound), PCOS-O (PCOS and obese)
and ECHO-O (ECHO and obese). Cultured KGN cells were stimulated (5, 10,
30 and 60 minutes) or not with human recombinant chemerin (200 ng/ml, n =
3) and/or with C4910 (10-8 and 10-9 M, n = 1).
Participants/materials, setting, methods: Patient’s clinical and biological
parameters as well as granulosa cells were obtained in collaboration with the
CHRU Bretonneau (Tours, France). The mRNA expression of chemerin and its
receptors in granulosa cells was made by RT-qPCR.
After stimulation, proteins from KGN cells were extracted and co-
immunoprecipitation experiments (homodimerization / heterodimerization of
the CMKLR1) and western blot (signaling pathway) were carried out.
Main results and the role of chance: Chemerin mRNA was highly
expressed in granulosa cells of obese (3.56 ± 0.51), PCOS-O (5.14 ± 1.02) and
ECHO-O (2.47 ± 0.29) patients as compared to control (0.16 ± 0.02), PCOS
(0.18 ± 0.02) and ECHO (0.28 ± 0.05) patients and we observed opposite
proﬁle for CMKLR1. The mRNA expression of CCRL2 was lower in PCOS
(0.013 ± 0.001), obese (0.011 ± 0.001) and ECHO-O (0.013 ± 0.002) patients
as compared to control (0.017 ± 0.002), ECHO (0.014 ± 0.002) and PCOS-O
(0.014 ± 0.001). In parallel, we found that in KGN cells CMKLR1 and CCRL2
receptors formed a heterodimer after 5 minutes of stimulation with chemerin
and gradually increased until 60 minutes. We also showed that chemerin rapidly
activates (5 minutes) MAPK ERK 1/2, P38 and Akt phosphorylation and more
slowly (30 minutes) AMPK and β-arrestin phosphorylation in KGN cells.
Preliminary in vitro experiments of KGN cell co-incubated with chemerin and
the CMKLR1 nanobody (C4910) showed a lower phosphorylation of P38 after
5 minutes than in cells only incubated with chemerin.
Limitations, reasons for caution: The characterization of the chemerin sys-
tem in granulosa cells was carried out in the KGN cell line, we will conﬁrm our
results in primary granulosa cells from control women and patients.
Wider implications of the ﬁndings: According to the literature, chemerin
system was expressed in granulosa cells and a deﬁcit of CMKLR1 seems protect
against follicular development disruptions in PCOS patients. We also described
the chemerin signaling involved in inﬂammation and steroidogenesis that was
partially blocked by a potential therapeutic nanobody targeting CMKLR1.
Trial registration number: not applicable.
O-074 Anovulation, insulin resistance and Akt/mTOR signaling
pathway activated in LepRb-mutated mice
H. Xia, W. Zhang
OB/GYN Hospital of Fudan University, Gynecological endocrine, Shanghai, China
Study question: What is the reproductive alteration of female mice with
mutation in leptin receptor(LepR)? AndWhat is the mechanism?
Summary answer: The mutated female mice exhibited anovulation, follicle
loss, obesity and insulin resistance, with a decreased phosphorylation of IRS-1/
2 and an increased activation of Akt/mTOR pathway.
What is known already: Leptin and LepR play an important role in female
reproduction. In the downstream pathways of LepR, protein kinase B (Akt)/
mammalian target of rapamycin (mTOR) took part in primordial follicle activa-
tion. The phosphatase and tensin homolog deleted on chromosome 10 in
humans (PTEN) is a main negative regulator of PI3K pathway. Intracellular insu-
lin signal transduction was found to have interaction with LepRb signaling path-
way via insulin receptor substrate (IRS). IRS was in the upstream pathway of
Akt/mTOR in both LepR and insulin signal pathway, including IRS-1 and IRS-2,
both involved in regulating blood sugar.
Study design, size, duration: From September 2013 to December 2015,
adult heterozygous male and female LepR-mutated mice were raised in an ani-
mal care facility of Obstetrics and Gynecology Hospital, Fudan University; con-
sequently, fetus mice were delivered, the female ones of which were genotyped
by PCR analysis of toe/tail-tip DNA at age 4 weeks, before grouped into homo-
zygous (HOM) LepR-mutated mice and Wild Type littermates, each group
being composed of 10.
Participants/materials, setting, methods: At age of 10 weeks, a glucose
tolerance test was performed after a 6-h (8:30-14:30) fast. Glucose concentra-
tions were measured in blood collected by venous bleeding from tail vein,
before and 30, 60, and 120 min after a bolus i.p. injection of glucose at 0.75 g/
kg. Fasting insulin and anti-mullerian hormone (AMH) was detected. We com-
pared the reproduction and metabolic characteristics in the mice, analyzing the
expression of Akt/mTOR, PTEN and IRS in the ovaries.
Main results and the role of chance: The results showed that 10-week old
female mutated HOM exhibited no estrus periods, infertility, obesity, insulin
resistance, declined AMH levels in the serum and ovaries, reduced primordial
follicles, primary follicles, secondary follicles, antral follicles and hardly no corpus
lutea (all P < 0.05). The phosphorylation of downsream Akt, mTOR, p70 ribo-
somal S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein-1
(4E-BP1) of LepR were all elevated in the ovaries of the mutated female mice.
They also presented a decreased phosphorylation of IRS-1, IRS-2, and PTEN,
and a strengthened phosphorylation of Forkhead box O-3a (FOXO-3A) in the
ovaries, when compared with WT mice.
Limitations, reasons for caution: We have not examined follicles and
detected the LepR mutation, Akt/mTOR and IRS pathway in clinical obese
women.
Wider implications of the ﬁndings: Clinical trials enrolled obese women
will be designed and programed in the Ob and Gyn Hospital. Ovarian function
and LepR mutation will be detected.
Trial registration number: The current basic study has no trial registration
number.
O-075 GDNF-induced down-regulation of miR-145-5p enhances
human oocyte maturation
Y. Ye, L. Cui
Women’s Hospital- Zhejiang University School of Medicine, Reproductive
Endocrinology, Hangzhou, China
Study question: To examine the effects of glial cell line-derived neurotrophic
factor (GDNF) on human in vitro oocyte maturation and to investigate the
involvement of microRNAs (miRNAs) in GDNF-induced oocyte maturation.
Summary answer: Down-regulation of miR-145-5p may contribute to
GDNF-induced enhancement of oocyte maturation and of cell viability against
cell apoptosis.
What is known already: The maturation rate and the developmental poten-
tial of embryos derived from in vitro maturation (IVM) oocytes are signiﬁcantly
lower than those of embryos derived from oocytes matured in vivo. Though
GDNF and miRNAs have been shown to regulate oocyte maturation, little is
known about the underlying molecular mechanisms.
Study design, size, duration: A total of 200 human immature oocytes were
used to evaluate the effects of GDNF on oocyte maturation. The involvement
of miRNAs in GDNF-induced oocyte maturation were identiﬁed by comparing
the miRNA expression proﬁles of cumulus cells either with or without GDNF
stimulation. Human immature cumulus-oocyte complexes (COCs) were col-
lected from infertile patients who underwent IVF treatment between January
2015 and November 2015.
Participants/materials, setting, methods: The experiments were per-
formed in an IVF center. Immature oocytes were cultured with/without GDNF
stimulation. Human miRNA arrays were used to examine the miRNA expres-
sion patterns of cumulus cells (CCs) either with/without GDNF stimulation.
Luciferase reporter assays were performed to verify the targets of miRNA-145-
5p. MiR-145-5p inhibitor and mimic transfections were performed to study
downstream gene expression (GDNF, GDNF family receptor-alpha1(GFRA1),
ret proto-oncogene (RET), and epidermal growth factor receptor (EGFR)) in
human CCs.
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Main results and the role of chance: During the IVM process, treatment
with GDNF signiﬁcantly increased the percentage of MII-stage oocytes and
down-regulated the expression of miR-145-5p in cultured human CCs.
Expression of MiR-145-5p in CCs is negatively correlated with oocyte matur-
ation. Transfection with miR-145-5p mimic signiﬁcantly decreased the mRNA
and protein levels of GFRA1, RET, and EGFR in human CCs, whereas transfec-
tion with an miR-145-5p inhibitor reversed these effects. Treatment with
GDNF inhibited cell apoptosis in cultured CCs, and this suppressive effect was
reversed by transfection withthe miR-145-5p mimic.
Limitations, reasons for caution: The role of miR-145-5p was demon-
strated by the fact that GDNF treatment down-regulated the expression of
miR-145-5p and miR-145-5p mimic transfection decreased the expression of
GFRA1, RET, and EGFR in human CCs. But we haven’t directly shown that
miR-145-5p mediate the effects of GDNF.
Wider implications of the ﬁndings: Our ﬁndings provide insight into the
roles of GDNF and miR-145-5p in the regulation of oocyte maturation and may
be clinically applied to improve the developmental potential of immature
oocytes from infertile couples undergoing IVM.
Trial registration number: no.
SELECTEDORAL COMMUNICATIONS
SESSION 20: GENETIC DETERMINANTSOF HUMAN
REPRODUCTION
Monday 2 July 2018 Room 117 15:15–16:30
O-076 Sperm imprinting integrity in seminoma patients?
C. Bruno1, O. Blagoskonov2, J. Barberet3, M. Guilleman3, S. Daniel4,
C. Binquet4, C. Choux5, P. Fauque1
1CHU Dijon Bourgogne - INSERM UMR1231, Laboratoire de Biologie de la
Reproduction - CECOS, dijon, France
2CHU Besancon, Laboratoire de Biologie de la Reproduction - CECOS, besancon,
France
3CHU Dijon Bourgogne - INSERM UMR1231, Laboratoire de Biologie de la
Reproduction, dijon, France
4CHU Dijon Bourgogne, Centre d’Investigation Clinique- module Epidémiologie
Clinique/essais cliniques CIC-EC, dijon, France
5CHU Dijon Bourgogne- INSERM UMR1231, Service de Gynécologie-Obstétrique,
dijon, France
Study question: Does the sperm of patients with Testicular Germ Cell
Tumor, in particular seminoma, present imprinted defects?
Summary answer: Seminoma patients with oligozoospermia presented
sperm DNA methylation alterations on imprinted genes like those observed in
oligozoospermic patients.
What is known already: Testicular Germ Cell Tumor such as seminoma is
strongly associated with male reproductive problems commonly associated
with the alteration of sperm parameters as described in testicular dysgenesis
syndrome. Interestingly, numerous studies have reported that the precursor of
germ cell cancer: Germ Cell Neoplasia in situ (GCNIS), present similarities to
fetal gonocytes, speciﬁcally characterized by global DNA hypomethylation par-
ticularly on imprinting sequences. These disorders may have a common origin
derived from perturbations of embryonal programming during fetal develop-
ment. Presently, there is no available information concerning the sperm DNA
methylation patterns of testicular cancer patients.
Study design, size, duration: A total of 92 cryopreserved sperm samples
from men who gave their consent for research were included, 31 before semi-
noma treatment (S) and 61 in the context of ART procedures who served as
controls: 31 normozoospermic (N) and 30 oligozoospermic (O). Among semi-
noma patients, 23 (74%) of them were normozoospermic (SN) and 8 (26%)
were oligozoospermic (SO).
Participants/materials, setting, methods: DNA methylation levels of
seven differentially methylated regions (DMRs) of imprinted genes [H19/IGF2:
IG-DMR: CTCF3 and CTCF6 of H19 gene; IGF2-DMRs (DMR0 & DMR2);
MEG3/DLK1:IG-DMR; SNURF:TSS-DMR; KCNQ1OT1:TSS-DMR] were
assessed by pyrosequencing. All analyses were performed after adjusting for
age.
Main results and the role of chance: Comparisons of sperm DNA methy-
lation levels between seminoma (S) and normozoospermic (N) samples
showed a signiﬁcant difference for the SNURF sequence (p = 0.017), but after
taking into account the sperm parameters no difference was observed for both
SN vs N and SO vs O. However, we conﬁrmed a signiﬁcant association
between oligozoospermia (O) and imprinting defects for H19-CTCF6 (p =
0.001), MEG3/DLK1 (p = 0.017), IGF2-DMR2 (p = 0.022) and SNURF (p =
0.032) in comparison with control group (N). Moreover, signiﬁcant imprinting
defects were detected in oligozoospermic seminoma patients (SO) compared
to normozoospermic controls (N) for H19-CTCF6 (p = 0.013), IGF2-DMR2
(p = 0.019) and SNURF (p = 0.001).
Limitations, reasons for caution: Despite careful microscopic control, cel-
lular contamination cannot be fully excluded. The pyrosequencing method limits
investigations on DNA methylation to few CpGs, but yields better resolution in
imprinted sequences than for larger scale analyses.
Wider implications of the ﬁndings: This study highlights the high risk of
sperm imprinting defects in oligozoospermia cases, and shows that seminoma
patients with normal spermatogenesis presented sperm imprinting integrity.
These data disprove the idea of a common fetal imprinting defect in germ cells
leading to both CGNIS and subfertility.
Trial registration number: not applicable.
O-077 Identiﬁcation of X-linked CNVs in women with extremely
skewed X chromosome inactivation and miscarriage
E. Tolmacheva1, N. Skryabin1, A.- Kashevarova1, L. Minaycheva2,
T. Nikitina1, E. Sazhenova1, I. Lebedev1
1Research Institute of Medical Genetics- Tomsk National Research Medical Center of
Russian Academy of Sciences, Molecular Cytogenetics -Epigenetics- Reproductive
Genetics, Tomsk, Russia C.I.S.
2Research Institute of Medical Genetics- Tomsk National Research Medical Center of
Russian Academy of Sciences, genetic clinic, Tomsk, Russia C.I.S.
Study question: Do changes in copy number of X-linked regions in the mater-
nal genome may be cause of skewed X-chromosome inactivation (sXCI) in her
lymphocytes and miscarriage.
Summary answer: Copy number variations (CNVs) affected X-linked genes
are apparently associated with the formation of sXCI in mother and linked to
the death of her embryo.
What is known already: Recent data provide evidence, that sXCI is asso-
ciated with X-linked disease manifestation, cancer or adverse reproductive out-
comes. Extremely sXCI (95% or above) is associated with an advanced
incidence (>4-times) of idiopathic recurrent pregnancy loss based on meta-
analysis of 12 datasets (Su et al., 2015). Skewed XCI may have a protective
effect for woman health by suppressing X-linked lethal gene mutations or
CNVs. Therefore, one can suggest, that inheritance of these mutations or
CNVs by embryo may be incompatible with its normal development. If this
true, the male embryos or female embryos with normal X-inactivation are in
the elevated risk group.
Study design, size, duration:We investigated the status of X chromosome
inactivation in 111 women with a history of spontaneous abortions with normal
karyotype in anamnesis. Eight samples of DNA of the woman with extremely
sXCI were analyzed using aCGH. The presence and inheritance of probably
pathogenic CNVs were analyzed by quantitative Real Time PCR both in mother
and miscarriage.
Participants/materials, setting, methods: X-chromosome inactivation
was assessed by classical methylation-speciﬁc assay at the AR locus. DNA sam-
ples from 8 woman with extremely sXCI were searched for CNVs using
SurePrint G3 Human CGH + SNP 4×180 K Microarray Kit (Agilent
Technologies, USA). Array CGH was performed according to the manufactures
recommendations. Conﬁrmation studies were performed on AriaMX Real
Time PCR System (Agilent Technologies, USA) with DNA samples from
mother’s lymphocytes and extraembryonic tissues of spontaneous abortions.
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Main results and the role of chance: X-inactivation status was found to be
skewed in 8 of 111 (7%) women. Their karyotype was analyzed by aCGH. In
one case woman with sXCI had delXq24, 239 kb in size, affected 8 genes
(SLC25A43, SLC25A5-AS1, SLC25A5, CXorf56, UBE2A, NKRF, SEPT6, MIR766).
This deletion was conﬁrmed by Real-Time PCR both in mother and spontan-
eous abortion with 46,XY karyotype. The mother, 29 years old, had a history
of 5 miscarriages, 1 induced abortion and 1 healthy female child. DelXq24
encompassing UBE2A gene was revealed previously in two unrelated boys with
mental deﬁciency, heart defects, dysmorphic features (Thunstromet al., 2014)
and related to X-linked syndromic mental retardation, Nascimento type (MIM
300860). The X-inactivation study in both patients’ mothers showed skewed
X-inactivation (99%). Xq24 deletions were also among the most common dele-
tions in HER2-positive breast cancer and affected genes SLC25A43, SLC25A5-
AS1, SLC25A5 (Gabrielson et al., 2016). Products of affected genes are involved
in cell proliferation, differentiation and post-transcriptional regulation of gene
expression. Knockdown of SLC25A43 in non-tumor cells signiﬁcantly inhibited
cell cycle progression during G1-S transition and reduce proliferation rate.
Probably a lack of these genes expression leads to the shifting to sXCI in dele-
tion carriers with subsequent risk for adverse pregnancy outcomes.
Limitations, reasons for caution: The possible variation in the X-
chromosome inactivation level in different tissues as well as tissue speciﬁc
expression proﬁles of genes escaping X-inactivation should be considered.
Wider implications of the ﬁndings:Our data are applicable to understand-
ing of mechanisms responsible for coordinated control of the expression level
of X-linked loci responsible for early embryo development by epigenetic and
cytogenetic processes. They will provide new strategies for PGD in women
with recurrent pregnancy loss. This study is supported by RFBR grant 18-015-
00437_a.
Trial registration number:Not applicable.
O-078 Does fertility status in varicoceles depends on DNA
acetylation and methylation processes; cross-link with Hsp70-2 in an
experimental trial usingWistar rats
M. Razi, S. Salmani, A. Mahmoudian, F. Sarrafzadeh-Rezaei
Faculty of Veterinary Medicine- Urmia University- Urmia- Iran, Basic Science- division
of Comparative Histology and Embryology, Urmia, Iran
Study question: Does DNA acetylation, methylation and heat shock protein
(Hsp70-2) correlate with varicocele-induced DNA damage? What is the cross-
link between epigenetic factors, sperm DNA integrity and blastocyst rate?
Summary answer: Impaired Hsp70/DNA methyltransferase-1 (DNMT1)/
histone acetyltransferase (HAT)/ histone deacetylases-1 (HDA1) network
adversely affects the epigenetic pathways during spermatogenesis, reduces
sperm fertilization potential and down-regulates blastocyst rate.
What is known already: Misregulation of histone modiﬁcation and replace-
ment during spermiogenesis has been linked with varicocele-induced oxidative
DNA damage. Indeed, the epigenetic mechanisms are core regulators of DNA
relaxation, replication, repairmen and histone replacement/modiﬁcation. The
DNMT1 is a key maintenance methyltransferase during early stages of develop-
ing germ cells, which allows transcription to occur at later stages. On the other
hand, the HAT and HDA1-induced acetylation and deacetylation are involved
in chromatin-protamine remodeling and DNA repairmen. Moreover, the
Hsp70-2 protects DNA strands against oxidative stress. Thus, the correlation
between altered acetylation, methylation, histone-protamine replacement,
Hsp70-2 expression, and the pre-implantation embryo development is still
uncovered.
Study design, size, duration: Thirty mature Wistar rats were divided into
control, control-sham and varicocele-induced groups (NO = 10 rats). The
experimental left hand side varicocele was induced by semi-ligation of left renal
vein adjacent to caudal Vena cava. The animals in the control-sham group were
undergone a simple laparotomy without varicocele induction. The control
group did not undergo surgical application. Following 60 days, the left testicles
were dissected out and different molecular and biochemical analyses were
conducted.
Participants/materials, setting, methods: The DNMT1, HAT, HDA1
expressions were analyzed using qRT-PCR. The Hsp70-2 expression was
assessed by using quantitative RT-PCR, western blot and immunohistochemis-
try. To show DNA methylation, the immunoﬂourescent staining of 5 methylcy-
tidine was conducted. Testicular total antioxidant capacity (TAC), gluthatione
peroxidase (GSH-px), superoxide dismutase (SOD), catalase, malondialdehyde
(MDA) levels and sperm DNA integrity were evaluated. Following in vitro fertil-
ization, correlation between blastocyst rate and each assessed epigenetic factor
was analyzed.
Main results and the role of chance: The varicocele group exhibited
decreased mRNA of DNMT1, HAT and HDA1 versus control groups (P =
0.001). The mRNA and protein levels of Hsp70-2 and the Hsp70-2+ cells distri-
bution per mm2 of tissue were decreased in varicvocele group versus control
animals (P = 0.01). The varicocele group exhibited down-regulation of 5
methylcytidine, representing suppressed DNA methylation. The testicular
TAC, GSH-px, SOD and catalase levels were down-regulated and the MDA
content was up-regulated in varicocele group. The percentages of sperms with
DNA fragmentation were increased in varicocele animals. Analyses of HAT and
HDAT1 mRNA levels revealed an inverse correlation between HAT and
HDAT1 and sperm DNA damage (p = 0.02, r2 = -0.912) as well as the blasto-
cyst rate (P = 0.01, r2 = -0.812). No correlation was found between DNMT1
mRNA and sperm DNA damage. Meanwhile, the sperm DNA damage was
negatively correlated with decreased levels of TAC (P = 0.01, r2 = -0.812),
GSH-px (p = 0.02, r2: -0.721), SOD (p = 0.001, r2=-0.816) and catalase (P =
0.01, r2 = -0.830). An inverse correlation was found between decreased
expression of Hsp70-2 and sperm DNA damage (P = 0.02, r2: -0.761). No cor-
relation was found between mRNA and protein levels of Hsp70-2 and blasto-
cyst rate. A negative correlation was found between sperm DNA damage and
the blastocyst rate (P = 0.02, r2: -0.932).
Limitations, reasons for caution: The results of the current study may dif-
fer in different laboratory settings. Moreover, the species differences can affect
the spermatogenesis-related epigenetic pathways, and some differences
between rat and human spermatozoa can partially change the results belonging
to fertilization outcomes. Furthermore, additional studies are needed to
represent the birth rates.
Wider implications of the ﬁndings: Present study increases our under-
standing that, (i) varicocele down-regulates the intra-testicular acetylation and
methylation ratio, (ii) down-regulates the Hsp70-2 expression and antioxidant
status and (iii) Impaired acetylation in association with suppressed Hsp70-2 and
diminished antioxidant status ampliﬁes sperm DNA damage and lowers the
blastocyst rate.
Trial registration number:N/A
O-079 Distribution of MTHFR isoforms carriers and level of
homocysteine in an infertile population with assisted reproductive
technologies (ART) cycle failures
D. Cornet1, E.H. Amar2, P. Clement3, A. Clement3, Y. Menezo3
1Clinique de La Muette, Service d’AMP, Paris, France
2American Hospital of Paris, Andrology/Urology, Paris, France
3Laboratoire CLEMENT, Embryology lab, Paris, France
Study question: What is the impact of MTHFR isoforms in fertility? Can it be
related to an increase of circulating homocysteine known to affect the gametes?
Summary answer: The proportion of MTHFR mutations carriers is signiﬁ-
cantly higher in the infertile population. The average level of homocysteine is
signiﬁcantly higher in the mutations carriers.
What is known already: MTHFR isoforms induce defective folic metabolism
and affect the recycling of homocysteine to methionine. The increased levels of
homocysteine due to MTHFR polymorphisms is responsible of oxidative stress
(Guo, 2016). Oxidative stress is a common cause of infertility and ART failures.
MTHFR isoforms are responsible of spermatozoa anomalies, especially via a
defect in nucleus compaction (Cornet, 2017). Furthermore, the IVF embryos
originating from MTHFR isoforms carriers have high chromosomal problems
for the heterozygotes and higher in the homozygotes patients (Enciso, 2017).
Study design, size, duration: From January 2016 to january 2018, we fol-
lowed 198 women patients suffering from infertility and having had at least 2
ART (Assisted Reproductive Technologies) cycle failure. All those patients
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were tested for MTHFR isoforms and we also measured their level of circulating
homocysteine. We compared those results among our infertile population and
with the general population.
Participants/materials, setting, methods: The presence of MTHFR iso-
forms was determined from a venous blood sample, using real time PCR with
the RealFastTM assay (ViennaLab Diagnostic GMBH, Vienna, Austria).
The levels of homocysteine are measured with a competitive immunoassay
using direct, chemiluminescent technology.
Main results and the role of chance: Among the infertile population of our
study, 63.6% of the patients are carrying the MTHFR mutation (43.9% in a het-
erozygous and 19.7% in a homozygous state). This proportion is signiﬁcantly
more important (p < 0.05) than the proportion of patients carrying MTHFR
mutations in the general population: 50.5% (Zappacosta, 2009).
The average level of homocysteine among homozygotes and heterozygotes
patients is signiﬁcantly higher than among the wild type patients (respectively
10.7 and 8.8 vs 7.9, p = 0.01 and p = 0.02). In total, the average level of homo-
cysteine among MTHFR carriers (homozygotes+heterozygotes) is signiﬁcantly
higher than among non carriers (wild-type) patients (9.4 vs 7.9, p = 0.02).
Limitations, reasons for caution: The genetic analysis of the MTHFR gene
needs to be enlarged to other mutations in order to screen all the patients in
which fertility could be affected by oxidative stress. The proportion of MTHFR
mutation carriers is probably more important and treatments could beneﬁt to a
larger number of patients.
Wider implications of the ﬁndings: Infertile patients with ART cycle fail-
ures should be tested for MTHFR mutations and their homocysteine levels
should be measured. Indeed, the affected patients could beneﬁt from a treat-
ment available allowing to by-pass the problems linked to MTHFR impaired
activity and thus decreasing oxidative stress, and improving their ART
outcomes.
Trial registration number:None.
O-080 Novel loci for polycystic ovary syndrome (PCOS) identiﬁed
in the largest genome-wide association study (GWAS) conducted to
date
G. Galarneau1, P. Fontanillas2, C. Clementi1, U. Schick1,
D.E. Parﬁtt1, D.A. Hinds2, P. Yurttas Beim1
1Celmatix Inc., Research and Development, New York, U.S.A.
223andMe, Inc., Mountain View, U.S.A.
Study question: We aimed to explore the genetic components of PCOS by
conducting a GWAS in >285,000 women, including 20,410 PCOS cases.
Summary answer: Our GWAS identiﬁed 5 novel loci that were associated
with PCOS at genome-wide signiﬁcance (p < 5 × 10−8).
What is known already: Although the pathophysiology of PCOS is known
to involve multiple, heterogeneous mechanisms, the molecular components of
these mechanisms are still being uncovered. GWAS conducted in Han Chinese
and European populations have identiﬁed 17 loci, overlapping with genes
involved in the hormonal, metabolic, and cellular aspects of the disorder.
However, since the estimated heritability of PCOS may be as high as 70%, it is
likely that only a portion of its underlying genetic landscape has been uncov-
ered. A more complete understanding is necessary for the development of
novel molecular strategies to diagnose PCOS and target its various clinical
features.
Study design, size, duration: In collaboration with the personal genetics
company 23andMe, Inc., we conducted a GWAS in women of European ances-
try who had consented to participate in research. Among these women were
20,410 PCOS cases (4 times larger than the largest published GWAS to date)
and 265,397 controls. Inclusion or exclusion of subjects was determined by
responses to online surveys.
Participants/materials, setting, methods: Case subjects self-reported
being diagnosed and/or treated for PCOS. Control subjects self-reported not
having been diagnosed or treated for PCOS. Participant samples were geno-
typed on 1 of 4 custom genome-wide genotyping arrays targeting 556-955k
SNPs. Participant genotypes were imputed against the 1000 Genomes Project
Phase 1 reference haplotypes. We performed a logistic regression under an
additive model with age, top 5 principal components, and genotyping array ver-
sion as covariates.
Main results and the role of chance: Of the 17 loci previously identiﬁed in
PCOS GWASs, 8 reached genome-wide signiﬁcance (p < 5 × 10−8) in our ana-
lysis, and a further 7 reached nominal signiﬁcance (p < 0.05), all with a consist-
ent direction of effect. Further, we report 5 novel loci achieving genome-wide
signiﬁcance for the ﬁrst time in the context of PCOS: ZBTB16 (rs1784692, p =
2.1 × 10−15, OR[95% CI] = 1.12[1.09-1.15]), FTO (rs8047587, p = 4.3 × 10−9,
OR[95% CI] = 1.07[1.04-1.09]), ZKSCAN5-FAM200A (rs10278040, p = 5.6 ×
10−9, OR[95% CI] = 1.16[1.10-1.22]), and ZEB2 (rs13028626, p = 3.3 × 10−8,
OR[95% CI] = 1.06[1.04-1.09]). In addition, we identiﬁed a potential associ-
ation in MYO10 locus (rs9312937, p = 4.0 × 10−8, OR[95% CI] = 1.06[1.04-
1.08]). The FTO and MYO10 loci have been linked to BMI-related traits in previ-
ous GWASs but never linked to PCOS at genome-wide signiﬁcance. However,
variants in FTO have been associated with PCOS in several candidate genetic
studies. Interestingly, MYO10 has been identiﬁed as a meiotic regulator in ani-
mal studies. The ZBTB16 locus was previously identiﬁed in a PCOS GWAS but
did not reach genome-wide signiﬁcance. ZBTB16 is involved in brown adipocyte
bioenergetics and the development of metabolic syndrome, as well as androgen
receptor activity. Similarly, the ZKSCAN5-FAM200A locus overlaps with a locus
previously associated with levels of steroid hormones, such as progesterone
and dehydroepiandrosterone sulfate.
Limitations, reasons for caution: The novel associations in FTO, ZKSCAN5-
FAM200A, ZEB2, and MYO10 loci need to be replicated in an independent
population. Further, additional characterization is warranted to identify putative
causal variants and genes that may underlie the observed novel associations.
Lastly, this study used self-reported phenotypic data, which could impact the
case-control stratiﬁcation.
Wider implications of the ﬁndings: In the largest PCOS GWAS to date,
we provide evidence of novel associations with 5 genetic loci. This work
extends the understanding of the genetic underpinnings of PCOS and empha-
sizes androgenic and metabolic mechanisms in the pathophysiology of the
disease.
Trial registration number:N/A.
SELECTEDORAL COMMUNICATIONS
SESSION 21: FEMALE FERTILITY PRESERVATION:
CLINICAL AND LABORATORY
Monday 2 July 2018 Room 116 15:15–16:30
O-081 Potential leukaemic contamination in cryopreserved
ovarian tissue
D. Gook1, D.Westerman2, M. McBean2, V. Hughes1, K. Stern1
1The Women’s Hospital, Reproductive Services /Melbourne IVF, Parkville- Victoria,
Australia
2Peter MacCallum Cancer Centre, Department of Pathology, Parkville- Victoria,
Australia
Study question: Can xenografting of cryopreserved ovarian tissue from
patients with leukaemia detect the presence of contaminating leukaemic cells
within the tissue?
Summary answer: Leukaemic cells are present in ovarian tissue from the
majority of patients’ tissue examined and these cells multiply with time in an
immunodeﬁcient mouse.
What is known already: Two previous studies have examined the potential
of ovarian tissue from leukaemia patients to harbour leukaemic cells. Although
one study detected the presence of leukaemia in 5 out of 18 patients’ tissue fol-
lowing xenografting, the other did not detect any contamination even in tissue
found to be PCR positive for leukaemic cells. Similarly, in the former study, not
all the tissue positive for leukaemic cells by PCR manifested in disease in the
xenografted mice.
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Study design, size, duration: To assess whether ovarian tissue from
patients with leukaemia harboured leukaemic cells and whether these cells
were capable of proliferation over time, cryopreserved ovarian tissue was
transplanted into immunodeﬁcient mice (3 mice per patient) and left for 24
weeks. At the completion of the study, the ovarian tissue and organs were
removed, ﬁxed and examined for evidence of leukaemic cells.
Participants/materials, setting, methods: Stored ovarian tissue from 18
patients with leukaemia (5 ALL, 9 AML, 4 CML) were donated to the study.
Two slices of ovarian tissue were attached to the abdominal wall using non dis-
solvable sutures and 1 small piece placed under the kidney capsule in each
NOD SCID mouse. At 24 weeks mice were examined for tumour develop-
ment, blood taken, and spleen weight measured. One slice of ovarian tissue
was prepared for PCR analysis.
Main results and the role of chance: Tumour development was observed
in tissue from 13 out of the 18 patients examined (3/5 ALL, 6/9 AML, 4/4
CML) following xenografting. Generally 1 mouse out of the 3 xenografted with
same patient tissue developed a tumour. Tumour was only associated with the
grafted tissue in 5 mice, the remainder of tumours were detected in other
organs or in nodes. Sectioning of tumours/nodes and staining with H&E
showed inﬁltration with monomorphous leukaemic cells. In some mice other
organs were also inﬁltrated with leukaemic cells and the spleens were enlarged
to 2 to 6 times the normal size.
Tissue from 6 patients which had been cryopreserved less than 4 weeks after
the last chemotherapy dose resulted in tumour development. To date, all PCR
positive tissue resulted in tumours following xenografting (only CML evaluated).
Subsequent lineage characterization with immunohistochemistry is required
to verify tumour origin. Examination of organs from mice without obvious
tumour development is still ongoing.
Limitations, reasons for caution: Although more mice have been exam-
ined for each patient’s tissue in the present study (3 per patient) than in the 2
previous studies (1 mouse per patient), insufﬁcient numbers of mice may still be
the reason for the negative result in those where no tumour was identiﬁed.
Wider implications of the ﬁndings: There is a high risk of re-introducing
leukaemic cells to patients when grafting cryopreserved ovarian tissue. Other
alternatives need to be developed to reduce or eliminate this risk.
Trial registration number:Not applicable
O-082 LH gonadoprotection against ovarian damage induced by
alkylating drugs in adult mouse ovaries
L.M. Castillo1, A. Buigues1, L. Pellegrini2, V. Rossi3, F. Klinger3,
A. Pellicer4, S. Herraiz2
1University of Valencia, Department of Pediatrics- Obstetrics and Gynecology,
Valencia, Spain
2Fundación IVI, Research, Valencia, Spain
3University of Rome Tor Vergata, Dep. Biomedicine and Prevention, Rome, Italy
4IVI-RMA, IVI Rome, Rome, Italy
Study question: To evaluate if LH administration protects the follicular pool
against gonadotoxic effects of oncologic treatment with alkylating drugs in adult
mouse ovaries.
Summary answer: LH treatment prevents follicular depletion induced by
Busulfan and Cyclophosphamide in adult mouse ovaries by preserving higher
number of follicles, especially primordial and primary populations.
What is known already:Oncologic treatment with high-dose chemotherapy
may impose deleterious effects on the ovary. Clinically, impact ranges through
partial damage to a complete destruction of the follicular pool. The highest risk
is associated to alkylating drugs, while platinum-based compounds like cisplatin
associated a medium risk. Several methods are available to preserve fertility in
cancer patients but further research is needed to develop new alternatives.
Previous studies suggested that luteinizing hormone (LH) prevents the cisplatin-
induced apoptosis in oocytes and preserves fertility in prepubertal mouse. We
aim to validate the protective effects of LH on the mouse adult ovary against
chemotherapy with alkylating agents.
Study design, size, duration: Experimental study, with eleven 6 week-old
CD-1 female mice allocated to the following groups: Control (n = 3),
Chemotherapy (ChT, n = 4) and ChT+LH (n = 4). Mice in the ChT groups
received a dose of alkylating drugs to induce severe ovarian damage on day 0,
at the same time with their own treatment (saline or LH, respectively). Animals
were maintained during 12 days and then sacriﬁce to recover ovarian samples
for further analysis.
Participants/materials, setting, methods: A single intraperitoneal injec-
tion with 12 mg/Kg busulfan and 120 mg/Kg Cyclophosphamide was adminis-
tered to mice of the ChT treated groups while controls received saline.
Simultaneously, animals of the ChT and Ch + LH group also received 100ul of
saline or equal volume with 1IU of LH, respectively. A week after, ovarian
hyperstimulation was induced, animals mated with fertile males and sacriﬁced.
The ovarian size, follicular growth and populations, ovulation and early embryo
development were then evaluated.
Main results and the role of chance: ChT administration reduced the ovar-
ian weight after hyperstimulation (C:45.7 ± 2.0 mg, ChT:14.9 ± 0.9 mg and
ChT-LH:14.6 ± 3.2 mg; p = 0.001) and LH administration was not able to
recover control values.
When the total amount of follicles was analyzed, a 10-fold decrease was
observed after chemotherapy administration (C:1260 ± 168, ChT:182 ± 31; p
= 0.03). Nevertheless, LH administration reduced the severity of the follicular
depletion (ChT-LH: 264 ± 59; p = 0.04). This improvement was mainly due to
a better preservation of the primordial (ChT-LH:42 ± 14 vs. ChT:7 ± 5foll., p
= 0.032) and the primary populations (ChT-LH:132 ± 8 vs. ChT:68 ± 12, p =
0.034). However, LH was not able to preserve the late preantral, antral and
pre-ovulatory populations already impaired by ChT.
The percentage of quiescent follicles decreased in the ChT group due to the
burnout of dormant follicles induced by alkylating agents but LH treatment was
able to minimize this effect (p = 0.034) and to maintain values similar to con-
trols (C: 15.7 ± 3.6%, ChT:4.2 ± 3.4% and ChT-LH: 15.8 ± 4.6%).
The amount of ovulated MII-oocytes and 2-cell embryos were seriously
impaired in both ChT (MII: 8 ± 5; Embryos:7 ± 5) and ChT-LH treated mice
(MII: 10 ± 9; Embryos:7 ± 10), when compared to controls (MII: 17 ± 2; E:10
± 2). However, LH administration increased the viability of the obtained MII-
oocytes (ChT:64.3 ± 27.5% vs. ChT-LH:90.4 ± 11%) and embryos (ChT:63.9
± 29.3% vs. ChT-LH:95.2 ± 8.2%) although no statistically signiﬁcant.
Limitations, reasons for caution: This is a preliminary study with a reduced
sample size and therefore data should be conﬁrmed in a larger population.
Furthermore, LH effects on follicular development potential should be carefully
assessed.
Wider implications of the ﬁndings:We found that LH administration pro-
tects primordial and primary follicles in adult ovaries against the depletion and
over activation induced by alkylant agents. However, LH was not able to pre-
serve the already growing populations but allows the surviving follicles to pro-
duce oocytes and embryos with increased developmental potential.
Trial registration number:Not applicable.
O-083 Towards an artiﬁcial ovary: Grafting preantral follicles on
decellularized human ovarian tissue
S. Pors1, S.G. Kristensen2, K. Lundsgaard2, M. Ramløse2,
C.Y. Andersen2
1Rigshospitalet, Laboratory of Reproductive Biology, KØBENHAVN Ø, Denmark
2Rigshospitalet, Laboratory of Reproductive Biology, Copenhagen, Denmark
Study question: Can decullularized human ovarian tissue support develop-
ment of follicles and become a biocompatible and biofunctional artiﬁcial ovary?.
Summary answer:We have demonstrated an effective protocol for decellu-
larization of human ovarian tissues and successful recellularization with isolated
preantral follicles.
What is known already: Decullarization of ovarian tissue entails the removal
of cells, including possible malignancies. The physiological extracellular matrix
(ECM) left behind offers the complex milieu that facilitates the necessary inter-
action between ovarian follicles and their surroundings to ensure their growth
and development. A bioengineered ovary would thus facilitate the growth and
development of reseeded frozen-thawed early stage follicles, free of malignan-
cies. Decellularized tissue (DCT) also beneﬁts from its biocompatibility due to
clearance of immunogenic substances. Further research in developing a
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bioengineered ovary entails thorough studies into its biocompatibility and
biofunctionality.
Study design, size, duration: Donated human ovarian tissue and isolated
preantral follicles from women undergoing ovarian tissue cryopreservation for
fertility preservation. Biofunctionality of the decellularized human ovarian tissue
was evaluated by in vitro and in vivo studies. Furthermore, scaffolds were trans-
planted to immunocompetent mice and evaluated for inﬂammatory reactions.
Participants/materials, setting, methods: Ovarian cortical and medullary
tissue were decellularized (0.1% SDS for 3, 6, 24 hours; followed by 24 hours
DNase (1 mg/mL)). Decellularization and preservation of composition were
characterized by DNA and collagen quantiﬁcation, Periodic Acid-Schiff (PAS)
staining, and immunoﬂourescence for Collagen IA and DNA (4’,6-diamidino-2-
phenylindole (DAPI)). Human granulosa cells (GCs) were reseeded on the
DCT and cultured in vitro. Murine and human preantral follicles were isolated
reseeded on the DCT and grafted subcutaneously to immunodeﬁcient mice.
Main results and the role of chance: Incubation in 0.1% SDS for 6-24 hours
adequately decellularized both human ovarian cortical and medullary tissue by
eliminating all cells and leaving the ECM intact. DNA quantities in the DCT
were signiﬁcantly lower compared to matched native samples. Histological
examination using PAS staining conﬁrmed that the cortical and medullary tissues
were completely decellularized, and no visible nuclear material was found within
the decellularized sections. DCT also stained positive for collagen I and collagen
quantities in DCT constituted 88-98% of the individual baselines for native sam-
ples (n = 4). Mature human GCs were able to recellularize the DCT in vitro by
successfully repopulating and migrating into the scaffold. Xenotransplantation
experiments showed that the DCT was able to support survival of isolated
human follicles and growth of isolated murine follicles of which several grew to
antral stages. The follicular recovery rates after 3 weeks grafting were similar
for both human (25%) and murine follicles (26-32.5%). The average diameter of
isolated murine follicles increased from 114 ± 26 μm to 195 ± 143 μm follow-
ing 3 weeks grafting.
Limitations, reasons for caution: Further studies are needed to increase
recovery and survival of the reseeded follicles. Furthermore, longer grafting per-
iods should be evaluated for observing development of follicles. Survival of the
follicles might be impaired by the lack of stroma cells. This challenge must be
overcome to advance the bioprosthetic ovary further.
Wider implications of the ﬁndings: This is the ﬁrst time that isolated
human follicles have survived in a decellularized human scaffold. Therefore, this
proof-of-concept could be a potential new strategy, to eliminate the risk of
malignant cell re-occurrence in former cancer patients having cryopreserved
ovarian tissue transplanted for fertility restoration.
Trial registration number:Not applicable.
O-084 Primordial follicle activation in vitro following PTEN
inhibition is associated with increased DNA damage of bovine
ovarian follicles
M. Maidarti1, M. McLaughlin2, Y.L. Clarkson2, E.E. Telfer2,
R.A. Anderson1
1University of Edinburgh, Center for Reproductive Health, Edinburgh, United
Kingdom
2University of Edinburgh, Institute of Cell Biology and Centre for Integrative
Physiology, Edinburgh, United Kingdom
Study question: Does activation of ovarian follicle growth by phosphatase
homolog of chromosome-10 (PTEN) inhibition result in altered indices of
oocyte and granulosa cell health?
Summary answer: PTEN inhibition leads to increased primordial follicle acti-
vation, but increases DNA damage and suppresses the DNA repair capacity of
bovine ovarian follicles in vitro.
What is known already: Although the PTEN inhibitor bpv(HOpic) has been
widely used to activate primordial follicles, it’s effects on DNA damage and
repair in normal cells, including oocytes and granulosa cells, has not been deter-
mined since most of the investigations have used cancer cell lines. PTEN inhib-
ition leads to cytoplasmic sequestration of DNA repair factors BRCA-1 and
Rad-51 in breast cancer cells. Notably, unrepaired DNA damage due to
impaired DNA repair capacity both in oocytes or granulosa cells is associated
with ovarian aging. Meiotic errors are also more likely leading to chromosomal
abnormalities in mature oocytes, ultimately impacting on oocyte quality.
Study design, size, duration: This study utilised bovine ovarian cortical frag-
ments (4 × 2×1 mm). Ovarian fragments were cultured for 24 hour in medium
with and without bpv(HOpic) then for a further 5 days in control medium with-
out bpv(HOpic). A total of 57 ovarian cortical strips per group and 29,550 folli-
cles from three independent experiments were analysed.
Participants/materials, setting, methods: After 24 hours treatment, tis-
sues were subjected to Akt quantiﬁcation by Western blotting. At the end of
the culture period (total of 6 days) fragments were ﬁxed and analysed histologi-
cally and by immunohistochemistry: λH2AX as a marker of DNA damage;
RAD-51, BRCA-1 and BRCA-2 as DNA repair factors, and for nuclear exclu-
sion of Foxo3 as a marker of follicle activation.
Main results and the role of chance: There was a signiﬁcant increase in the
proportion of growing follicles cultured with bpv(HOpic) 10 μM (88.6%) com-
pared to 1 μM (76.8%, P≤0.001) or control (70.5%, P≤0.001) after 6 days. The
proportion of morphologically healthy follicles however, was lower (10 μM bpV
(HOpic) 49.4%vs78.3% in control, p < 0.001). Akt phosphorylation in bpv
(HOpic) exposed tissue was increased (P≤0.001) and was associated with
increased nuclear exclusion of Foxo3 (P≤0.001). DNA damage in oocytes was
higher in bpv(HOpic) groups (1 μM: non-growing, 83%; primary, 78%, second-
ary, 77%; 10 μM: 74%, 84% and 89%) than control (30%, 59% and 50%) as
shown by increased λH2AX expression (P≤0.005). RAD-51 and BRCA-2
expression were analysed to assess DNA repair proteins involved in homolo-
gous recombination. A reduction in RAD-51 expression occurred in bpv
(HOpic) treated groups of primary (1 and 10 μM: 34% and 24%) and non-
growing follicles (22% and 30%) compared with control (48% and 38%)
(P≤0.001). Higher dose bpv(HOpic) also resulted in lower expression of
BRCA-1 compared to control and bpv(HOpic) 1 μM (P < 0.001) in non-
growing and primary follicles, indicating a reduced response to DNA damage.
However, oocytes of primary follicles in 1 μM bpv(HOpic) exhibited a higher
level of BRCA-2 expression (36%) compared with control (20%, P = 0.011)
with a marked decrease in 10 μM (1%, P≤0.001).
Limitations, reasons for caution: This study focuses on primordial follicle
activation after 6 days culture and may not reﬂect DNA damage and repair cap-
acity in later stages of oocyte and follicle growth.
Wider implications of the ﬁndings: Exogenous activation of follicle growth
may compromise the bidirectional signalling between oocyte and granulosa cells
necessary for optimal follicle health. This large animal model may be useful in
assessing follicle activation protocols prior to their use in human ovaries.
Trial registration number: not applicable.
O-085 Can we perform ﬂexible antagonist protocol for luteal
phase ovarian stimulation for breast cancer patients seeking fertility
preservation?
M. Victoria, M. Comtet, M. Presse, C. Sonigo, I. Cedrin-Durnerin,
M. Grynberg
Hospital Jean Verdier 93140 Bondy Avenue du 14 Juillet, Reproductive medecine and
Fertility Preservation, Paris, France
Study question: Does the timing of GnRH antagonist initiation during the
luteal phase impact the outcome of fertility preservation (FP) cycles?
Summary answer: Flexible GnRH antagonist initiation during luteal phase
ovarian stimulation may not impact negatively FP outcome when compared to
simultaneous administration with exogenous FSH.
What is known already: Evidence indicates that luteal phase ovarian stimula-
tion may represent an efﬁcient option for women seeking FP, leading to com-
parable results as those obtained with early follicular phase stimulation.
Currently, GnRH antagonists are simultaneously administered with FSH in
order to induce early luteolysis and prevent premature LH surge. The feasibility
of postponing GnRH antagonist initiation during luteal phase stimulation has not
been studied.
Study design, size, duration: This prospective randomized study was con-
ducted between July 2013 and December 2017.
Participants/materials, setting, methods: Sixty-eight women undergoing
ovarian stimulation for urgent FP before breast cancer chemotherapy were
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randomized into 2 groups according to the beginning of GnRH antagonist
administration on stimulation day 1 (S1) or ﬂexibly. In the ﬂexible group, GnRH
antagonist was started when the leading follicle reached 12 mm in diameter.
Stimulation outcomes were compared between both groups.
Main results and the role of chance: As expected, both groups were com-
parable in terms of age, body mass index, antral follicle count and AMH levels.
Despite different timing in GnRH antagonist initiation, the duration of ovarian
stimulation and total amount of gonadotropins were comparable between S1
and ﬂexible groups (11.0 ± 2.5 vs. 11.05 ± 2.2 days and 3530.6 ± 1357.0 vs.
3446.3 ± 1207.7IU, respectively). Finally, the mean number of oocytes recov-
ered and vitriﬁed at metaphase 2 stage were similar in both groups (12.9 ±
10.3 vs. 14.3 ± 8.6 and 10.3 ± 9.9 vs. 10.2 ± 6.9 respectively). The mean day
of antagonist introduction in the ﬂexible group were the 6.7 day.
Limitations, reasons for caution: The limited number of patients rando-
mized in each group may represent a limitation for the interpretation of the pre-
sent results.
Wider implications of the ﬁndings: The ﬂexible GnRH antagonist adminis-
tration during luteal phase stimulation may represent a friendly and cost effect-
ive approach. Our preliminary results should be conﬁrmed in a larger
population. In addition, the endocrine proﬁle associated with such a protocol
and its further impact on oocyte quality will represent important issues.
Trial registration number: not applicable
INVITED SESSION
SESSION 22: CLINICAL UTILITYOF ANTI-MULLERIAN
HORMONEMEASUREMENT
Monday 2 July 2018 Room 211 + 212 17:00–18:00
O-086 AMHmeasurement in fertility treatment
E. Ng1
Queen Mary Hospital, Dept. of Ob/Gyn, Hong Kong, Hong Kong
Anti-Mullerian hormone (AMH) is a dimeric glycoprotein that belongs to the
transforming growth factor-beta family. In the female, AMH is solely produced
by the granulosa cells of preantral and small antral follicles, and regulates ovarian
folliculogenesis. Because of this exclusive source of production in the adult
female, AMH is a potentially useful marker of ovarian function, and there have
been increasing reports on its clinical utility (Dewailly et al, 2014).
Because of its stable production throughout the menstrual cycle with clinic-
ally insigniﬁcant intra- and inter-cycle variation and that its serum concentration
is not inﬂuenced by the use of exogenous hormones (Li et al, 2011a), AMH
serves as a useful diagnostic tool in differentiating the different causes of sec-
ondary oligo-amenorrhoea, particularly ovarian failure and polycystic ovary syn-
drome from the other causes, with very good diagnostic accuracy (Li et al,
2011b).
Basal serum AMH concentration is useful in prediction of suboptimal and
excessive ovarian responses upon ovarian stimulation for in in-vitro fertilization
(IVF) treatment cycles, (Broer et al, 2011). There is also some association
between AMH level and fresh cycle live birth rate as well as cumulative live birth
rate (Li et al, 2013), although most reports indicated a poor predictive value of
AMH on the absolute occurrence of pregnancy or live birth rate from IVF treat-
ment, as reviewed in meta-analyses (Iliodromiti et al, 2014). AMH may be
another marker for determination of individualised ovarian stimulation regime
and gonadotrophin dosing in IVF treatment programmes (La Marca and
Sunkara, 2014).
Since there is yet no international standard for AMH measurement, and the
numerical values obtained by the different existing assay methods are not
equivalent, the discordance among different assay methods may misclassify a
signiﬁcant proportion of women to an inappropriate gonadotrophin dose
(Iliodromiti et al., 2017).
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O-087 Role of AMH in the pathogenesis and diagnosis of ovulatory
disorders
INVITED SESSION
SESSION 23: CHROMOTHRYPSIS OR HOW
REARRANGINGOURCHROMOSOMES CHANGES
EVERYTHING
Monday 2 July 2018 Room 111 + 112 17:00–18:00
O-088 The characteristics and origin of chromothripsis
W. Kloosterman1
UMC Utrecht, Genetics, Utrecht, Neth. Antilles
Human genomes are continuously subjected to mutations, which can drive gen-
etic diseases and cancer. An intriguing ﬁnding has been the discovery of chro-
mothripsis, a spectacular and complex form of chromosome rearrangement
that can occur in the genomes of cancer cells and patients with congenital dis-
eases. Chromothripsis has been described in a large array of human cancers
and various types of chromothripsis have appeared, which differ in complexity
and genomic hallmarks. From the combined genomic data a consensus hypoth-
esis has been inferred, involving aberrant DNA replication and chromosome
shattering as the underlying processes explaining chromothripsis. In addition,
recent work has established several cellular models that recapitulate chromo-
thripsis under deﬁned experimental conditions.
We have used long-read nanopore single-molecule sequencing technologies
to unravel complex chromosomal rearrangement, including chromothripsis.
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We demonstrate the power of long-read sequencing by the analysis of the gen-
omes of two patients with congenital abnormalities. We developed a bioinfor-
matic method to efﬁciently map genomic structural variants (SVs) from the
long-read data. Using this method, we readily detected all de novo rearrange-
ments involving multiple chromosomes originating from complex chromothrip-
sis events. Long sequencing reads enabled efﬁcient phasing of genetic variations,
allowing the construction of genome-wide maps of phased SVs. We employed
read-based phasing to show that all de novo chromothripsis breakpoints
occurred on paternal chromosomes and we resolved the long-range structure
of the chromothripsis. Our work demonstrates the value of long-read sequen-
cing for analysis of complex chromosomal aberrations underlying human devel-
opmental disorders.
O-089 Chromothripsis in human reproduction
F. Pellestor
CHU Montpellier, Unit of Chromosomal Genetics- Department of Medical Genetics,
Montpellier Cédex 5, France
Chromothripsis and the genesis of complex chromosomal rearran-
gements in human gametes and embryos.
Franck Pellestor.
Laboratory of Chromosomal Genetics and Chromostem unit, Department
of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier CHRU,
Montpellier, France.
INSERM Unit «Plasticity of the Genome and Aging », Institute of Functional
Genomics, Montpellier, France.
Over the last 6 years, the discovery of an unexpected type of massive
chromosomal rearrangements, called chromothripsis, came revolutionized our
view of the genesis of complex chromosomal rearrangement in cancers and
congenital disorders.
Chromothripsis is characterized by the shattering of one (or a few) chromo-
some segment(s) followed by a chaotic reassembly of the fragments generated
through a single catastrophic cellular event.
Several features distinguish this phenomenon from other complex structural
aberrations. Congenital chromothripsis are characterized by their low copy
number changes and their relatively balanced status. This does not signify that
unbalanced chromothripsis events don’t occur in germline or during post-
zygotic divisions, but it strongly emphasizes the effect of selective pressure as a
bias factor in the assessment of congenital chromothripsis, since only balanced
chromothripsis outcomes compatible with life have been found in individuals to
date.
Various mechanisms, involving abortive apoptosis, telomere erosion, mitotic
errors, micronuclei formation and p53 inactivation might cause chromothripsis.
The remarkable point is that all these plausible mechanisms have been identi-
ﬁed in the ﬁeld of human reproduction as causal factors for reproductive failures
and chromosomal abnormalities genesis.
Speciﬁc features of gametogenesis and early embryonic development
such as the weakness of cell cycle and mitosis checkpoints and the rapid
kinetics of division in germ cells and early cleavage embryos, may contribute
to the emergency of chromothripsis. Existing data indicate that constitu-
tional chromothripsis occurs preferentially in the male germline. This con-
ﬁrms the great vulnerability of spermatogenesis to DNA damage and clearly
points to spermatogenesis as a critical stage in the genesis of congenital
chromothripsis. Also, the possibility of chromothripsis occurrence in female
meiosis cannot be neglected because oocytes are particularly vulnerable to
environmental attacks and DNA alteration, and can cumulate genomic and
chromosomal damages. During the fertilization process, the premature
chromosome condensation (PCC) of sperm nucleus may initiate chromo-
thripsis. In preimplantation embryos, the high incidence of chromosome
abnormalities and the frequent fragmentations observed support the
assumption that chromothripsis may arise frequently during early human
embryogenesis.
All the data support the hypothesis that this unanticipated catastrophic phe-
nomenon may arise more frequently than previously thought in both
gametogenesis and human embryogenesis, but also conﬁrmed its compatibility
with viability and transmission to subsequent generations.
The complexity of chromothripsis and the diversity of its causative mechan-
isms raise questions about the origin of this phenomenon, its ties to chromo-
some instability and its implication in human reproduction and congenital
disorders formation. Further in-depth analyses on large samples of patients and
cells (gametes and blastomeres) are needed to appreciate the contribution of
this cataclysmic process to altered human development and the generation of
congenital diseases.
INVITED SESSION
SESSION 24: SURGICAL TRAINING: EXPERIENCE FROM
EXISTING TRAINING CENTERS FOCUSEDON
TEACHINGMINIMALLY INVASIVE TECHNIQUES AND
POSSIBLE APPLICABILITY OF SIMULATION TRAININGS
IN ART CENTERS
Monday 2 July 2018 Room 113 + 114 + 115 17:00–18:00
O-090 The impact of training center activities on the real-life
operating room: how to shorten learning curves and to prevent
commonmistakes
O-091 Robotic surgery vs conventional laparoscopy in the ﬁeld of
infertility
F. Sendag1
Ege University, Obstetrics and Gynecology, Bornova - Izmir, Turkey
Abstract text
Robotic surgery vs conventional laparoscopy in the ﬁeld of infertility.
Sendag, Fatih, M.D., Professor.
Ege University Department of Obstetrics and Gynecology, Bornova, Izmir,
Turkey.
Procedures that are technically challenging with the conventional laparoscopy
can be performed with robotic assistance. It has advantages of improved visual-
ization and wrist movements allowing precise suturing. This helps to overcome
the limitations of laparoscopy, especially in complicated procedures, and may
shorten the steep learning curve in minimal invasive surgery.
Robot-assisted laparoscopy seems to be of interest in cases of complex sur-
gical treatment of infertility. Myomectomy, tubal reanastomosis, and deep inﬁl-
trating endometriosis appear to be the preferred indications. It has been shown
that robotic assistance in reproductive surgery resulted in decreased blood
loss, less post-operative pain, shorter hospital stay, and faster convalescence,
whereas reproductive outcomes were similar to laparoscopic approaches. The
main limitation to the diffusion of this technique remains its cost.
But it will be crucial to have more long-term outcomes regarding fertility:
pregnancy rate (natural and IVF), uterine rupture for myomectomy, impact on
ovarian reserve, adhesion forming, etc. These results are necessary for showing
the real contribution of robot-assisted laparoscopy in the ﬁeld of infertility.
Randomized controlled trials focusing on long-term outcomes after robotic
surgery are needed to determine which patients are likely to beneﬁt from
robotic surgery.
SELECTEDORAL COMMUNICATIONS
SESSION 25: CHANGING ETHICS, CHANGING LAWS
Monday 2 July 2018 Room 117 17:00–18:00
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O-092 Powering themitochondrial donation research by donating
their powerhouses: Mitochondrial donors for research
M. Choudhary1, J. Neilson2, K. Lennox1, S. Harrop3, M. Nesbitt4,
L. Hyslop5, A. Murdoch6, M. Herbert7
1Newcastle Hospitals NHS Foundation Trust and Wellcome Trust for Mitochondrial
Research, Newcastle Fertility Centre at Life, Newcastle upon Tyne, United Kingdom
2Newcastle University, Newcastle Fertility Centre at Life, Newcastle upon Tyne,
United Kingdom
3Newcastle upon Tyne Hospitals NHS Foundation Trust and Wellcome Trust for
Mitochondrial Research, Newcastle Fertility Centre at Life, Newcastle upon Tyne,
United Kingdom
4Newcastle University and Wellcome Trust for Mitochondrial Research, Newcastle
Fertility Centre at Life, Newcastle upon Tyne, United Kingdom
5Wellcome Trust for Mitochondrial Research and Newcastle upon Tyne Hospitals
NHS Foundation Trust, Newcastle Fertility Centre at Life, Newcastle upon Tyne,
United Kingdom
6Newcastle Fertility Centre, Biomedicine West Wing, Newcastle upon Tyne, United
Kingdom
7Wellcome Trust for Mitochondrial Research and Newcastle University, Newcastle
Fertiltiy Centre at Life, Newcastle upon Tyne, United Kingdom
Study question:What was the impact of new UK regulations and compensa-
tion policy on donor recruitment and egg availability for pre-clinical research in
preventing mitochondrial DNA disorders?
Summary answer: Despite the high initial expression of interest, only 5% of
those women became mitochondrial donors donating 584 eggs for mitochon-
drial pre-clinical research.
What is known already: UK became the ﬁrst country to legalise and permit
clinical use of reproductive technologies to prevent transmission of mitochon-
drial DNA disease following scientiﬁc reviews, extensive public consultation,
ethical and parliamentary debates. Until 2012, the source of freshly harvested
oocytes for use in research in the UK was largely limited to ‘egg sharing”
schemes in which women undergoing IVF treatment donate half of their
oocytes in return for a ﬁnancial contribution towards the cost of treatment.
Following publication of landmark reports from the Nufﬁeld Council on
Bioethics and the HFEA, UK implemented a policy permitting reasonable ﬁnan-
cial compensation to egg donors.
Study design, size, duration: A retrospective analysis of data over 35 month
period from the ﬁrst pilot scheme in UK of mitochondrial donor recruitment for
research following implementation of new regulations and compensation policy.
Participants/materials, setting, methods: Ethics and HFEA regulatory
approvals were obtained prior to mitochondrial donor recruitment for pre-
clinical research aimed at prevention of inheritable maternally derived mito-
chondrial DNA disorders. The new pilot scheme offered compensation of
£500 per donation cycle to mitochondrial donors for research as per approval
granted. All women self-injected for ovarian stimulation and underwent oocyte
retrieval under sedation. A total of 1290 women expressed interest in donating
oocytes for mitochondrial donation research over 35 month period.
Main results and the role of chance: Of 1290 women expressing interest
via a webmail contact page, only 223 (33%) attended an initial appointment
after receiving further research information. Of these, 135 (61%) met the inclu-
sion criteria for age (18-36 years), BMI (≤30) and ovarian function (antral follicle
count >10 and AMH 10-50 pmol/l). Half of the eligible women made an
informed decision to not proceed with mitochondrial donation following con-
sultation. Remaining 71 women (mean age 26.5 years ± 4.2) went ahead with
ovarian stimulation. Poor response led to 7 cancellations, thus resulting in 64
women successfully donating to research. In all, only 5% (n = 64) of those who
initially expressed interest (n = 1290) eventually became mitochondrial donors
donating a total of 584 oocytes for research. Following implementation of new
regulations and compensation policy, the number of oocytes donated for
research has doubled compared to our previous ‘egg-sharing for research’
scheme.
While the high levels of interest and the increase in oocyte availability for
research are encouraging, the high drop-out rate suggests that the ﬁnancial
compensation does not hugely inﬂuence decision to donate and the donation
procedure itself, rather than the concept of egg donation per se, is a disincen-
tive to the vast majority of women.
Limitations, reasons for caution: As the mitochondrial donor recruitment
was for research only, it is not possible to stipulate on the facilitators and bar-
riers for mitochondrial donation for treatment purposes from this study. A
qualitative study is indicated to garner insight and explore factors inﬂuencing the
decision making process for mitochondrial donor recruitment.
Wider implications of the ﬁndings: Understanding, and addressing, the
barriers to donation for the large fraction of women who initially express interest
would help to ensure an adequate supply of oocytes for clinical treatment and
for the ongoing underpinning research. Critical to this will be communicating the
distinction between conventional egg donation and mitochondrial donation.
Trial registration number:Not applicable.
This study was supported by Wellcome Trust funding (grant number
096919). Thanks to volunteers who participated in the scheme and donated
eggs for research.
O-093 The use of animals and human embryos in preclinical safety
research: is there an ideal order?
V. Jans1, W. Dondorp1, H. Mertes2, G. Pennings2, G. DeWert1
1Maastricht University, Health- Ethics and Society, Maastricht, The Netherlands
2Bioethics Institute Ghent, Department of Philosophy and Moral Sciences, Ghent,
Belgium
Study question: Should animal studies be preferred to / precede the use of
human embryo’s in preclinical safety research?
Summary answer: Although regulations suggest that animal studies should
be preferred to / precede human embryo research, there are no convincing
arguments for this.
What is known already: Legal and regulatory documents suggest that
research using human embryos may only be considered when animal studies
have either been performed or cannot answer the research question. For
instance the British Warnock Report states that human embryos should only be
used when research with animal models is not an option. Similarly, ESHRE’s
Task Force Ethics and Law has suggested an ideal chain of types of preclinical
research with animal studies as a ﬁrst and embryo research as a second step.
However, arguments supporting this order are lacking.
Study design, size, duration: A literature study and a focus group interview
with key ﬁgures in reproductive medicine were performed to identify scientiﬁc,
legal and/or ethical arguments supporting the ‘ﬁrst animals then human
embryos’ rule.
Participants/materials, setting, methods: Literature study: articles have
been selected from scientiﬁc journals focusing on normative aspects of ARTs,
animal research and human embryo research. Additionally, relevant legal texts
and regulative documents from several countries were studied. Focus group:
key ﬁgures in reproductive medicine were invited to reﬂect on the ‘ﬁrst animals
then human embryos’ rule. Conceptual and ethical analysis: the ﬁndings were
critically assessed in terms of the consistency of arguments and the normative
soundness of conclusions.
Main results and the role of chance: From a scientiﬁc perspective, there
are no valid arguments supporting the ‘ﬁrst animals then human embryos’ rule.
In fact, making this a rule stands in the way of doing good research, leading to
unnecessary animal studies for questions where it is clear that human embryos
are more appropriate research material. From an ethical perspective, welfare
and moral status arguments can be distinguished. Welfare arguments seem not
to support a moral preference for animal research, apart perhaps in view of
concerns about the welfare of oocyte donors. Whereas animals may suffer dis-
comfort and pain, preimplantation embryos are not sentient and would in so far
be the preferred research material. Status arguments will not change this:
although as ‘potential persons’ human embryos are thought to have a certain
moral status that stands in the way of using them for trivial purposes, this status
is relatively low as compared not only to that of human persons but also to that
of sentient animals whose interests can be harmed. Therefore, the requirement
that human embryos can only be used when the research question cannot be
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answered by using animal models should be adjusted and the strict order of
preclinical research steps should be loosened.
Limitations, reasons for caution: New developments may affect the rea-
soning leading to our conclusion. For instance when human embryos may in the
future be cultured for research beyond 14 days, then against the background of
the widely held view that their moral status increases with further development,
this may lead to a different assessment.
Wider implications of the ﬁndings: Holding on to the ‘ﬁrst animals then
human embryos’ rule not only stands in the way of proper science, but is also
problematic from an ethical perspective. Sacriﬁcing animals for no good reason
is at odds with the acceptance of the ‘three Rs’ (Replace, Reduce, Reﬁne) in sci-
entiﬁc research.
Trial registration number: not applicable.
O-094 National survey on the opinion of French specialists in ART
about societal issues to prepare the future revision of the French
bioethic law
H. Creux1, M. Diaz2, A. Papaxanthos2, L. Chansel-Debordeaux3,
C. Hocke2
1Clinique Saint Roch, Reproductive medicine, Montpellier, France
2hôpital Pellegrin, Reproductive centre, Bordeaux, France
3hôpital Pellegrin, Reproductive laboratory, Bordeaux, France
Study question: National survey on the opinion of French specialists in ART
about societal issues to prepare the future revision of the French Bioethics law.
Summary answer: French ART specialists promote social egg freezing, ART
in single and homosexual women, genetic screening and ﬁnancial compensation
for donors. Opinions remains divided for surrogacy.
What is known already: The French Bioethics law concerning ART is more
restricted than in other countries. Techniques can only be applied in heterosex-
ual couples presenting a documented infertility with a woman under 43 yo.
ART treatments are ﬁnanced by the French Social Security up to 6 IUI and 4 IVF
with fresh embryo transfer Donation is anonymous and free, responsible for a
lack of donors. Fertility preservation is only allowed for cancer patients or med-
ical reasons. Directed donation, surrogacy, social fertility preservation and gen-
etic screening for maternal age, repeated abortions or implantation failures are
forbidden in France.
Study design, size, duration: Descriptive study conducted in June 2017 in a
University teaching hospital by using an anonymous questionnary. The ques-
tionnary consisted of 15 questions on current issues in ART.
Participants/materials, setting, methods: An anonymous online ques-
tionnary was sent by email to 650 French specialists in ART, both clinicians and
biologists, with an average response time of 3 minutes.
Main results and the role of chance: After 3 reminders, 408 responses
were collected resulting in a participation rate of 62.7%. Participants consisted
of 130 men and 271 women; 259 clinicians and 144 biologists. Out of them,
245 were < 50 years old and 159 were ≥ 50 years old.
Concerning the genetic screening, 80% of the physicians were in favour to
expand the indications that are presently limited in France to genetic diseases
with a particular gravity.
To authorize social fertility preservation was acclaimed by 78.9% of the spe-
cialists, but without a social coverage for 69.3% of them and with the possibility
to employ unused frozen eggs for the oocyte donation program for 40.3% of
them.
Concerning gametes donation, 77.4% of the French specialists in ART were
in favor to give a ﬁnancial compensation to donors, 92% promoted to preserve
the anonymity and 80,9% were not in favor to a directed donation.
The ART for single women and for homosexual women were supported by
63.5% and 69.8% of the French specialists, respectively.
The legalisation of surrogacy, all indications confounded (including male
homosexuals), was asked by 55.2% of French specialists in ART.
Limitations, reasons for caution: Despite a satisfactory participation rate,
some French specialists in ART did not answer the questionnary on line.
Moreover, some physicians did not ﬁll in all the questions. That represents a
bias of selection.
Wider implications of the ﬁndings: This survey provides a support for the
French Bioethics comittee to know the opinion of the specialists in ART in their
country on the eve of the revised law.
Some situations could be discussed in the French legislative context while
others could require the sollicitation of the neighboring European teams.
Trial registration number:Not applicable.
O-095 Outcomes of applications for information about a person
related through donor treatment following legislative change
removing donor anonymity retrospectively
L. Johnson, K. Bourne, T. Thomson, K. Hammarberg
Victorian Assisted Reproductive Treatment Authority, Victorian Assisted Reproductive
Treatment Authority, Melbourne, Australia
Study question: What are the outcomes of retrospective removal of donor
anonymity?
Summary answer:Of the donors who were located, most agreed to be con-
tacted by their donor-conceived offspring.
What is known already: In the state of Victoria, Australia, legislation relating
to donor conception was introduced in 1988 and has changed over time to
increasingly consider the interests of the people born as a result. Since 1998
gamete donors have had to agree to the release of their identifying information
if their donor-conceived offspring request it. In March 2017 new legislation
retrospectively removed anonymity for pre 1998 donors. Applications for infor-
mation about related parties are lodged with the Victorian Assisted
Reproductive Treatment Authority (VARTA) where donor registries are mana-
ged. Donors who are located can stipulate contact preferences, including the
preference for no contact.
Study design, size, duration: A prospective study of the outcomes of all
applications for information by people related through donor conception from
March to December 2017 where donors had consented to the use of their
gametes in treatment prior to 1998.
Participants/materials, setting, methods: In the study period VARTA
counsellors received 101 applications for information about a related party:
71 by a donor-conceived person and six by a parent of a donor-conceived
person for information about the donor, and 24 by a donor for information
about their donor offspring. Outcomes of the applications were recorded in
a database.
Main results and the role of chance: By 31 January 2018, 65 of the 101
applications for information were still being processed and 36 had a known out-
come. Of these 33 were applications for information about a donor (31 from a
donor-conceived person and two from a recipient parent) and three were
applications from a donor for information about donor-conceived offspring. Of
the 33 applications for information about a donor, seven were withdrawn after
counselling and two applicants only wanted non-identifying information which
did not require the donor to be located. In the remaining 24 applications: 15
donors were located, six were not located or had missing information, and 3
donors were deceased. Of the 15 donors who were located, 11 agreed to be
contacted and four lodged a preference for no contact. In the three applications
for information about a donor-conceived offspring one agreed to be contacted
by the donor.
Limitations, reasons for caution: There is no way of knowing how many
donor-conceived people born before 1998 are aware of their donor origins.
The ﬁndings cannot be generalised to all donor-conceived people or to donors
who are not located or for whom no application for information is made.
Wider implications of the ﬁndings:Outcomes to date of the retrospective
removal of donor anonymity are mixed but indicate that some donors who
expected to remain anonymous are willing to be contacted by their donor-
conceived offspring if approached.
Trial registration number:Not applicable.
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INVITED SESSION
SESSION 26: THE AGEINGMAN
Tuesday 3 July 2018 Forum (Auditorium) 08:30–09:30
O-096 Mechanistic basis of ageing effects
J. Aitken1
University of Newcastle, Dept. of Biological Sciences, Callaghan- NSW, Australia
Abstract text
Ageing has a signiﬁcant impact on the reproductive competence of males.
When men exceed the age of 35 there is a clear age-dependent impact on
the ability of the spermatozoa to initiate a viable pregnancy, resulting in a
progressive fall of fertility and a corresponding increase in the incidence of
miscarriage. In addition, paternal ageing is associated with genetic changes in
the progeny affecting telomere length (telomeres get longer with paternal
age) and the incidence of spontaneous genetic and epigenetic mutations
(both of which increase linearly with paternal age). All of these age-
dependent changes (loss of fertility, increased miscarriage rates, increased
mutational/epimutational load carried by the offspring and increased telo-
mere length) can be attributed to two potential underlying causes. Firstly, as
males age their reproductive system comes under increasing oxidative stress
as reﬂected by an increase in oxidative damage, particularly oxidative DNA
damage in the spermatozoa. Because the precursor germ cells of the testes
(particularly spermatogonia) possess signiﬁcant telomerase activity, they have
the capacity to respond to such stress by increasing telomere length before
the germ cell differentiates into a spermatozoon. Construction of an animal
model for oxidative stress in the male reproductive system via the surgical
induction of a transient testicular ischemia, has been found to result in the
generation of spermatozoa with extremely long telomeres, which are then
passed onto both male and female offspring. At this stage we have no idea
what the inheritance of long telomeres from the paternal germ line means
in terms of the health trajectory of the offspring. Telomere length aside, oxi-
dative stress would also account for the age-dependent decline in fertility,
as a consequence of the induction of lipid peroxidation in the spermatozoa
and a consequential loss of sperm function. Antioxidants are clearly import-
ant for defending the germ line against oxidative attack since the functional
depletion of genes encoding thioredoxin domain-containing proteins
(Txndc2, Txndc3) results in accelerated age-dependent disruption of motility
and DNA integrity as well as increases in reactive oxygen species gener-
ation, enhanced formation of lipid aldehyde-protein adducts, and impaired
protamination of the sperm chromatin. The DNA damage seen in the
spermatozoa of ageing males could also be responsible for the age-
dependent increase in miscarriage rates as well as the increase in mutational
load carried by the offspring. The aberrant repair of oxidative DNA damage
in the oocyte immediately after fertilization is proposed as a major contribu-
tor to the mutational load carried by children, along with spontaneous
mutations arising as a result of replication errors in the spermatogonial stem
cell population. Together these mechanisms have a major impact on the
paternal contribution to offspring health.
O-097 The ageing male germ cell
J. Gromoll1, E. Pohl2, K. Redmann2, C. Krallmann2, J.F. Cremers2,
K. Czeloth3, S. Kliesch2, M. Zitzmann2, F. Tüttelmann4,
B. Horsthemke5, S. Laurentino2
1University Hospital of Münster, Centre of Reproductive Medicine and Andrology
Campus 1- D11, Münster/Westf., Germany
2Centre of Reproductive Medicine and Andrology, University Clinics, Muenster,
Germany
3Department of Growth and Reproduction, University Clinics, Copenhagen, Denmark
4Institute of Human Genetics, University Clinics, Muenster, Germany
5Institute of Human Genetics, University Clinics, Essen, Germany
Abstract text
Parental age has been steadily increasing in Western societies. While in women
the effects of age on reproductive function (e.g. decrease in fertility, increase in
aneuploidies) are well known, little is known of the effects of ageing on the male
germline. On the other hand, it is difﬁcult to distinguish the effects caused by
normal ageing from those of associated morbidities. Therefore, the objective of
this study was to study molecular parameters of ageing on the germline of a
cohort of healthy men.
The study cohort (FAMe – Fertility and Aging in healthy Men) is composed of
healthy men (n = 197) between 18 and 84 years of age. All participants went
through a thorough selection process which included physical evaluation and
andrological assessment and provided sperm and blood samples. DNA was iso-
lated from blood and swim-up (motile) sperm and relative telomere length
(rTL) and DNA methylation of LINE1 transposable elements were analysed.
DNA fragmentation index (DFI) was measured by an acridine orange-based
ﬂow cytometric assay. In addition WGBS was performed on sperm samples
and data validated by deep bisulﬁte sequencing (DBS).
Relative telomere length in blood decreased with age (ρ=-0,41, p < 0,001),
while sperm rTL increased (ρ = 0,39, p < 0,001). DNA methylation of LINE1
repetitive elements in blood did not show any age-related alterations in this
cohort (mean methylation = 79,29 ± 0,14). The mean sperm DFI increased
with age (ρ = 0,49, p < 0,001). WGBS revealed more than 180 age-related
DMRs, some of them located in regions associated with genes important for
embryonic development, between sperm of young and old men, which were
not present in blood DNA. Validation of selected DMRs among all groups of
the FAMe study revealed distinct patterns for DMRs with either linearly increas-
ing or decreasing methylation levels.
Telomere attrition is considered a hallmark of ageing and in our cohort
we could conﬁrm that in peripheral blood telomeres become shorter with
increasing age. In the male germline, however, telomerase has been previ-
ously shown to remain active. Our results are in agreement with this, show-
ing sperm rTL increasing with age. Epigenetic drift has been suggested as a
consequence of ageing, with some studies showing an overall age-associated
decrease of DNA methylation, including in repetitive elements. In this
cohort we were unable to detect any changes in LINE1 DNA methylation
with increasing age. Likely LINE1 methylation is probably affected by co-
morbidities associated with ageing but not by the ageing process itself. The
effect of ageing on sperm chromatin structure has previously yielded con-
ﬂicting results, probably due to the heterogeneity of the cohorts analysed.
In our cohort, we could detect an increase in the mean DFI and therefore
DNA damage with increasing age. The identiﬁcation of germ cell speciﬁc
DMRs, which are not present in blood, points to a unique intrinsic ageing
process of germ cells. Since it seems highly unlikely that this takes place dur-
ing spermatogenesis, the testicular stem cells, namely the spermatogonia,
seem to be prone to ageing processes.
Taken together healthy ageing affects the DNA integrity of male germ cells
and therefore could resemble a potential risk for the progeny of older fathers.
Supported by the DFG (GR1547-19/25)
INVITED SESSION
SESSION 27: IN VITRO POST-IMPLANTATIONMODELS
Tuesday 3 July 2018 Room 211 + 212 08:30–09:30
O-098 The use of novel imaging to decipher lineage segregation in
the early embryo
N. Plachta
Institute of Molecular and Cell Biology, Singapore, Singapore
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O-099 Self-organization of the human embryo in the absence of
maternal tissues
INVITED SESSION
SESSION 28: BIG DATA IN ENDOMETRIOSIS –HOPEOR
HYPE?
Tuesday 3 July 2018 Room 111 + 112 08:30–09:30
O-100 Big data in understanding disease
O-101 Big data in endometriosis
S. Missmer
Michigan State University, OB/GYN & Reproductive Bio, Grand Rapids, U.S.A.
Abstract text
The excitement and potential surrounding “big data” and it’s implications for
advancement of precision medicine that will revolutionize care for women and
men across the lifecourse is as pertinent to reproductive medicine as it is to
other aspects of health and wellbeing. However, there are challenges unique,
or at least of greater consequence, to reproductive medicine that must be
addressed and for which solutions must be developed. The biologic and socio-
logic diversity of factors inﬂuencing gynecologic and reproductive health is great.
This diversity is of beneﬁt to precision medicine advancement if embraced, but
this diversity also demands methodologic rigor in approaches to and interpret-
ation of big data discoveries. Reproductive health and wellbeing impacts mul-
tiple windows across an individual’s life as well as multiple generations within
families. Critical elements of multidisciplinary exploration accounting for time-
varying variables that assess data validity and reliability will be discussed.
INVITED SESSION
SESSION 29: ASRM EXCHANGE SESSION: MAXIMIZING
THE CHANCEOF PREGNANCY FOR EVERY PATIENT:
AN INTENTION-TO-TREAT ANALYSIS
Tuesday 3 July 2018 Room 113 + 114 + 115 08:30–09:30
O-102 A rational approach to themanagement of the older and
low response patient undergoing ART
O. Davis
Weill Cornell Medicine, Center for Reproductive Medicine, New York- NY, U.S.A.
Abstract text
This lecture will examine strategies for treating the poor prognosis IVF patient
(advanced age, diminished ovarian reserve), while stressing the importance and
relevance of an “intention to treat” clinical approach. Ovarian reserve markers
and deﬁnitions of diminished ovarian reserve will be reviewed, as well as ovarian
stimulation strategies for the poor response patient (micro-ﬂare, estrogen prim-
ing, minimal stimulation) as well as the evidence supporting the choice of proto-
col. An intention to treat strategy stresses the maximization of an individual
patient’s chances for success at the point of entry into treatment, i.e. once pre-
senting for initial consultation. If one deﬁnes the denominator for success as the
performance of an embryo transfer, it becomes clear that patient attrition can
occur at several points before, e.g. through not offering/initiating treatment for
the patient with a suboptimal prognosis, cycle cancellation for reduced numbers
of developing follicles, prolonging in vitro culture to day 5-6 in the setting of few
embryos and/or the performance of PGT-A as standard-operating-procedure.
A rationale for transferring a larger number of cleavage stage embryos in
women of advanced age (>43) will be presented. The focus of treatment
should be on the individual patient’s chance for success rather than an IVF
clinic’s per transfer pregnancy statistics.
O-103 Every last baby out of every last egg: Does PGS really
improve the chance of pregnancy for every patient?
R.J. Paulson
University of Southern California, Obstetrics and Gynecology, Los Angeles, U.S.A.
Abstract text
Pre-implantation genetic testing for aneuploidy (PGT-A) is a method of selec-
tion of embryos for transfer. It has been shown to increase embryo implant-
ation rates in selected groups of patients. This observation has led some clinics
to advise all patients undergoing IVF to include PGT-A as part of their treat-
ment. However, not all groups of patients beneﬁt from this form of embryo
selection, and embryo implantation rates are not increased. Furthermore, the
testing itself results in the loss of potential implantations that are lost due to
false positive test results and due to the trauma of the embryo biopsy. This
loss of potential implantations may not be a major problem in women with
large numbers of embryos, and those whose embryo implantation rates are
already high. However, in women over 40, with low implantation rates and
low numbers of embryos, the addition of PGT-A will result in decrease cumul-
tive pregnancy rates on a per-aspiration basis. This lecture will review the
approximate magnitude of both cost and beneﬁt of PGT-A and show why
women with poor prognosis should not use PGT-A to try and increase
embryo implantation rates.
INVITED SESSION
SESSION 30:WHO SESSION:WHOAND FERTILITY
CARE: TIME TO ENGAGE?
Tuesday 3 July 2018 Room 117 08:30–09:30
O-104 Introduction: HRP vision and goals regarding infertility
O-105 WHO priorities in infertility and fertility care
T. Matsaseng
WHO Headquarters, RHR, Geneva, Switzerland
Abstract text
Infertility has not been recognized as a public health priority with debates as to
whether it’s a disease or not. According to the WHO/World Bank report on
Disability, infertility following maternal sepsis and unsafe abortion (a critical
maternal morbidity) was ranked 8th highest in prevalence as a global serious
disability and in the population group under the age of 60, infertility ranked 5th
highest as a major global disability behind depression, ocular refractive errors,
unintended accidents and alcoholism.
The commonest causes of infertility in the LMIC are, severe male infertility
and bilateral tubal disease, that can only be treated by assisted reproductive
technologies (ART) and yet these techniques are not widely available and often
not affordable. Severe stigmatization, fear, shame and social complications sur-
round vulnerable individuals and couples who are viewed as childless or unable
to have children in many developing and transitional countries. Studies have
shown that to have a healthy child, couples may accept a 20% risk of death and
give up 29% of their income.
Barriers towards treatment access include, lack of infrastructure and/or high
unaffordable costs. Where available the treatment is often associated with
unsafe practices that results in undesirable complications including ovarian
hyperstimulation syndrome (OHSS) and high order multiple pregnancies
(HOMP) with inherent poor neonatal outcomes. Furthermore, ethical and
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moral issues around third party reproduction (gamete/embryo donation & sur-
rogacy), reproductive tourism and same sex couples (LGBT) have not received
adequate attention they deserve.
As we implement strategies to achieve Sustainable Development Goals
(SDG no. 3, 5) and the Global Strategy for Women’s, Children’s and
Adolescents ‘Health (2016–2030; Survive, Thrive & Transform) agenda, we
strongly advocate for inclusion of fertility services within the Reproductive,
Maternal, Newborn, Child and Adolescent health, RMNCAH plans in order to
achieve gender equality and empower all women and girls. We also wish to
promote universal access to Sexual Reproductive Health and Reproductive
Rights (SRHR), to ensure that no one is left behind.
Therefore, the aim of the presentation is to highlight WHO engagement in
infertility and fertility care and to outline key areas of priority in our agenda as
we endeavour to improve access and availability of safe and effective fertility
care equally across the globe.
O-106 Estimation of prevalence of infertility from cross-section
surveys (DHS) using time-to-pregnancy approach: preliminary
results of a pilot study
T. Matsaseng
WHO Headquarters, RHR, Geneva, Switzerland
Abstract text
Infertility is deﬁned as a disease of the reproductive system that results in an
inability to become pregnant or bring a pregnancy to term. Primary infertility is
predominantly a result of delayed childbearing, complications of childbearing
and/or congenital disorders. Secondary infertility is often a result of maternal
sepsis (infection following delivery) or of complications associated with unsafe
abortions. Both forms of infertility, primary and secondary can result from com-
plications following sexually transmitted infections (STIs), genital tuberculosis
(TB) and HIV/AIDS, or following cancer or other diseases and subsequent dis-
ease management that proves contrary to either healthy or successful sperm or
egg development.
A WHO evaluation of Demographic and Health Surveys (DHS) data from
2004, estimates that more than 186 million ever-married women of reproduct-
ive age in developing countries were maintaining an unfulﬁlled “child wish”,
translating into one in every four couples between the of age 15–49. A recent
analysis by WHO of internationally published references shows that primary
infertility rates are not decreasing (and in some countries are increasing)and
secondary infertility continues on an increasing global trend from 1990 to 2008
(unpublished, WHO, 2011). Severe stigmatization, fear, shame and social com-
plications surround vulnerable individuals and couples who are viewed as child-
less or unable to have children in many developing and transitional countries.
Besides lack of infrastructure and/or high unaffordable costs, limitation to
access to care is further complicated by underestimation of the disease magni-
tude particularly in the low middle income countries (LMIC) and to address this
issue, obtaining accurate, country-level estimates of infertility prevalence is
essential. Demographic approaches and clinical and epidemiological studies do
provide more relevant measure to assess the need for services to enhance fer-
tility. However population based methods for shorter durations are limited and
estimations approaches vary. While Time-to-pregnancy (TTP) and current dur-
ation (CD) approaches have advantages and disadvantages, their role and appli-
cation still need to be explored in various settings for accurate estimation of
disease prevalence.
Therefore, the aim of the presentation is to evaluate and report preliminary
results of the pilot study on estimation of infertility prevalence using current
duration approach to estimate TTP to data from Demographic and Health
Surveys (DHS).
O-107 The landscape of IVF in lower and middle income countries
T. Chiware1,2, N. Vermeulen3, K. Blondeel2,4, R. Farquharson3,
J. Kiarie2, K. Lundin3,5, T. Matsaseng2, W. Ombelet3, I. Toskin2
1University of Vermont Medical Center, Dept. of Obstetrics- Gynecology &
Reproductive Sciences, Burlington
2World Health Organization, Reproductive Health and Research, Geneva,
Switzerland
3European Society of Human Reproduction and Embryology, Central Ofﬁce,
Grimbergen, Belgium
4Ghent University, Faculty of Medicine and Health Sciences, Ghent, Belgium
5Sahlgrenska University Hospital, Reproductive Medicine, Gothenburg, Sweden
Study question: What are currently available and potential in vitro fertiliza-
tion (IVF) and other assisted reproductive technologies (ART), and services in
low- and middle-income countries (LMIC)?
Summary answer: The ART services available in LMIC vary from conven-
tional ART to low cost ART, depending on the region.
What is known already: Infertility affects 186 million people, 8-12% of cou-
ples worldwide, with a prevalence estimated at 3.5-16.7% in LMIC, and 30-40%
in Sub-Saharan Africa. High costs of IVF and lack of ART services, in addition to
cultural, religious, legal, efﬁcacy and safety concerns, have highlighted the need
for affordable, accessible and acceptable ART in LMIC. Infertility and childless-
ness, particularly in LMIC, have devastating consequences, resulting in consider-
able interest in developing low cost IVF procedures. However, there is a
paucity of evidence on the safety, efﬁciency and ability to replicate techniques,
under different ﬁeld conditions, and integrate low cost ART into existing
infrastructures.
Study design, size, duration: A systematic review was performed by
searching several databases for articles on low cost ART in LMIC published
from January 2010 to June 2017. Two reviewers independently screened the
titles and abstracts, then full texts of selected records were reviewed and data
extracted.
Participants/materials, setting, methods: The electronic databases
searched included PubMed, Popline, EMBASE and Global Index Medicus
(regional WHO online databases). An internet search using ‘Google” search
engine with the terms ‘infertility”, ‘low and middle income countries” and
“in vitro fertilization” or ‘assisted reproductive technologies” (limited to results
published after 2010) was performed. Similar search terms were used for grey
literature databases (worldcat.org, greylit.org). In addition, the reference lists of
included studies were checked.
Main results and the role of chance: An extensive search of the proposed
databases yielded 3443 citations. After review of the titles and abstracts, 180
studies were included. The full text of 180 articles were reviewed and a further
106 articles were excluded. The grey literature search yielded 419 citations of
which 334 were excluded after screening of the title, and a further 85 docu-
ments after full text assessment due to duplicate entries, not LMIC, not rele-
vant, or no access to the full document. A ﬁnal total of 74 citations were
included as part of the systematic review and separated into regions. The
majority of the studies were qualitative and observation studies. In general,
ART services are available and described in several LMIC, ranging from
advanced ART in China, to introduction of IUI and ART in some African coun-
tries. Efforts for low cost ART treatments have been described in feasibility
studies, or efﬁcacy studies, most of low to very low quality or providing indirect
evidence from developed countries. We found no studies from LMIC reporting
the implementation of low cost ART that is efﬁcient, accessible and affordable
to the whole population.
Limitations, reasons for caution: To our knowledge, this is the ﬁrst sys-
tematic review of ART in LMIC. Studies published prior to 2010 were excluded.
The available studies were heterogeneous making it difﬁcult to extract ﬁndings.
Wider implications of the ﬁndings: The WHO is in a unique position to
provide much needed guidance for infertility management in LMIC. This system-
atic review provides insight into the landscape of ART in LMIC in various
regions. This will guide efforts to improve availability, quality, accessibility and
acceptability of infertility care, including ART in LMIC.
Trial registration number: The protocol developed and registered with
PROSPERO International prospective register of systematic reviews, number
CRD42017064413.
O-108 Developing ART practice in low andmiddle income
countries
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O-109 Closing remarks
INVITED SESSION
SESSION 31: NURSES/MIDWIVES INVITED SESSION
Tuesday 3 July 2018 Room 116 08:30–09:30
O-110 Use of ultrasound at embryo transfer - is it necessary?
O-111 Family planning, knowledge about fertility and lifestyle prior
to conception; nurses and midwives as key persons in preconception
care
T. Tyden1, L. Salih2, J. Hultstrand2, M. Ekstrand2
1Department of Women’s and Children’s Health, Dep. of Women´s and Children´s
Health, Uppsala, Sweden
2Uppsala University, Women´s and Children´s Health, Uppsala, Sweden
Abstract text
Preconception care and family planning are identiﬁed to be of increasing import-
ance for health in a wider sense as recently highlighted in a series of articles in
the Lancet. It is relevant for all women of reproductive age. Slightly half of all
pregnancies worldwide are unplanned and of these, 50% ends in abortion, 13%
in miscarriage, and 38% in unplanned birth.
In low-income countries many women would beneﬁt from delaying and spa-
cing pregnancies. In high-income countries it is the opposite situation as many
women postpone childbearing until ages when their fecundity has decreased.
These examples highlight the need for preconception care that also should be
tailored for each individual. Furthermore, the most critical period for organ
development occurs before many women even know they are pregnant and
the ﬁrst contact with antenatal care is often too late for advice about health-
promoting changes in life style.
Lifestyle-related factors such as age, obesity and smoking affect fertility and
reproductive outcomes. Studies have shown that people underestimate the
importance of age on fertility and overestimate the success rate of in vitro fertil-
ization. Smokers have lower odds for clinical pregnancy per cycle, live birth per
cycle, and higher odds for miscarriage, ectopic pregnancy, and babies being
small for gestational age and for preterm delivery.Obesity is an increasing health
problem globally that also impact reproductive health and reproductive out-
comes. These examples emphasize the need for educating women and men
about lifestyles that are of importance for their reproduction.
A tool called the Reproductive Life Plan (RLP) is recommended by the
Centers for Disease Control and Prevention. It consists of a set of questions
that can be used by health care providers to guide a conversation about if and
when a person wants to become a parent and how to achieve their reproduct-
ive goals. The aim with the RLP is to encourage women and men to reﬂect on
their reproductive intentions, to promote a healthy lifestyle prior to conception
and to use appropriate contraceptive methods in line with their RLP. Also the
RLP aims to give information on lifestyle prior to conception.
In Sweden, midwives working with contraceptive counseling used the RLP-
concept in two randomized controlled studies. The midwives asked questions
about the RLP with the women who were allotted to the intervention group
(IG). They also handed out a specially designed brochure to women in the IG.
The brochure contained information about fertility and life styles of importance
prior to a pregnancy. Women in the IG increased their knowledge about fertil-
ity and the great majority stated that midwives should continue to discuss the
RLP in contraceptive counseling. The results and have been reported in two
articles in Human Reproduction. Recently we have used the RLP concept
among men attending STI- and sexual health clinics.
I will present lessons learned from our experiences with using the RLP in clin-
ical practice. I will also suggest how nurses and midwives can be important per-
sons in preconception care.
For young women and men Internet as an important source of information.
We have therefore developed a mobile friendly website about the RLP www.
reproduktivlivsplan.seIt has been translated into English and also into some
other commonly spoken languages in Sweden.
SELECTEDORAL COMMUNICATIONS
SESSION 32: UPDATES IN EMBRYOMORPHOKINETICS
Tuesday 3 July 2018 Forum (Auditorium) 10:00–11:30
O-112 The effect of oocyte vitriﬁcation on subsequent embryo
developmental morphokinetics and blastocyst formation: a
prospective time-lapse sibling oocyte study
S. De Gheselle, V. Muyshond, K. Tilleman, P. De Sutter
Ghent University Hospital, Department for Reproductive Medicine, Ghent, Belgium
Study question: Is there a difference in blastocyst formation between fresh
and vitriﬁed warmed sibling oocytes and can this difference be attributed to
changes in embryo morphokinetics?
Summary answer: There is a delay in morphokinetic embryo development
and blastocyst formation between fresh and vitriﬁed sibling oocytes.
What is known already:Oocyte vitriﬁcation is often used in medical assisted
reproductive treatments e.g. oocyte-donation programs, fertility-preservation
for cancer patients, social-freezing but also in IVF cycles where semen produc-
tion problems occur. The impact of oocyte vitriﬁcation on embryo develop-
ment remains controversial. Morphokinetic analyses on embryo development
from vitriﬁed oocytes are usually based on early morphokinetic parameters (De
Munck et al., 2015; Chamayou et al.,2015). A recent report by Cobo et al.,
2017, showed delayed morphokinetics from vitriﬁed oocytes up to the blasto-
cyst stage. Although this report included a lot of cycles, the study was not per-
formed on sibling oocytes.
Study design, size, duration: In a prospective study between February
2016 and December 2017, morphokinetic development and blastocyst forma-
tion was investigated between fresh (FO) and vitriﬁed sibling donor oocytes
(VITO). Blastocyts were scored according to the grading system of Gardner
and Schoolcraft(1999) and their developmental morphokinetics were analyzed
using time-lapse imaging (EmbryoscopeTM). On the day of oocyte retrieval,
and after cumulus-oocyte complex denudation, MII oocytes with normal
morphology were randomly allocated to fresh ICSI insemination or to vitriﬁca-
tion (Cryotop®).
Participants/materials, setting, methods: MII oocytes (n = 438) from 67
donor cycles (36 fresh / 31 warmed) from 27 different healthy anonymous
oocyte donors (age 30.3 ± 3.7) were allocated both to a synchronous FO
acceptor (n = 215) and to a VITO acceptor (n = 223). Morphokinetic timings
were log-transformed and linear-regression analysis (mixed models) was
applied (SPSSv24). Fixed effects were determined by comparing FO and VITO.
The variable ‘donor’ was taken into account for random effects (p < 0.05).
Main results and the role of chance: Time-lapse analysis of the 16 different
time-points and 6 time-intervals showed that there was an overall delay in the
cleavage rate from the time of pronuclei disappearance up to the time of blastu-
lation in the VITO compared to their sibling FO. Twelve morphokinetic para-
meters were statistically signiﬁcant between the VITO and FO respectively: tPNf
[Geometric mean(GM) 26.18 h versus GM 23.87 h; p = 0.000]; t2 [GM 28.51 h
versus GM 26.67 h; p = 0.004]; t3 [GM 38.81 h versus GM 36.05 h; p = 0.004];
t4 [GM 42.36 h versus GM 39.17 h; p = 0.001]; t5 [GM 51.52 h versus GM
47.09 h; p = 0.000]; t6 [GM 56.36 h versus GM 51.28 h; p = 0.000]; t7 [GM
60.12 h versus GM 54.20 h; p = 0.003]; t8 [GM 64.57 h versus GM 57.28 h;
p = 0.000]; t9+ [GM 76.73 h versus GM 68.39 h; p = 0.000]; tstart compaction
[GM 90.57 h versus GM 86.50 h; p = 0.002}; tcompaction [GM 102.09 h versus
GM 96.38 h; p = 0.000]; tstart blastulation [GM 100.92 h versus GM 97.95 h;
p = 0.013]. These morphokinetic differences resulted in a similar overall
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blastocyst formation (expansion status 1-5) in the FO group compared to the
VITO group [51.8% (80/155) versus 41.7% (60/144), P = 0.1043], however,
there was a statistically higher full (expansion status 3-5) blastocyst rate in the
FO group [46.4% (72/155) versus 31.9% (46/144), P = 0.0128].
Limitations, reasons for caution: Sperm parameters were not included in
this prospective sibling oocyte study and could have an effect on embryo
development.
Wider implications of the ﬁndings: Oocyte vitriﬁcation has an impact on
morphokinetics parameters and embryo development up to the blastocyst
stage. This could be explained by effects of vitriﬁcation on ultrastructure or bio-
logical processes in the oocytes. Diminished mitochondrial activity could also
be responsible for a delay in reactivating the cell division machinery after
vitriﬁcation.
Trial registration number: EC/2017/0086
O-113 Duration of blastomere movement post ﬁrst cytokinesis is
an effective predictor for the clinical pregnancy after fresh cleaved
embryo transfer: in a minimal stimulation program
K. Ohata1, K. Ezoe1, A. Yabuuchi1, S. Ueno2, K. Uchiyama2,
T. Okimura2, T. Kobayashi3, K. Keiichi3
1Kato ladies clinic, R&D division, Tokyo, Japan
2Kato ladies clinic, Embryology Laboratory, Tokyo, Japan
3Kato ladies clinic, Department of Gynecology, Tokyo, Japan
Study question: Does the duration of blastomere movement post ﬁrst cyto-
kinesis correlate with clinical pregnancy after fresh cleavage stage embryo trans-
fer in human?
Summary answer: The clinical pregnancy rate after fresh cleaved embryo
transfer was signiﬁcantly lower when the duration of blastomere movement
was persisted.
What is known already: Time-lapse incubator systems allow the evaluation
of embryos based on their morphokinetic and morphological assessment. Many
studies have shown that timings of human embryo divisions correlate with pre-
implantation development and subsequent pregnancy outcomes after embryo
transfer. During monitoring of embryos in time-lapse system, we observed that
blastomere movement occurred after ﬁrst cytokinesis and that there is a vari-
ability among embryos in the duration of the blastomere movement. However,
the embryo evaluation based on morphological information obtained from
time-lapse imaging is still limited. In addition, it is not known how blastomere
movement inﬂuences embryonic development and pregnancy outcomes.
Study design, size, duration: A total of 781 embryos from 779 patients,
36.4 ± 0.1 year-old, were cultured in EmbryoScope+® time-lapse system and
then transferred into patients at cleavage stage from April to July 2017. The
data of morphokinetics and morphology were retrospectively analyzed.
Blastomere movement (BMov) was observed after ﬁrst cytokinesis and the
time to end the blastomere movement (tBMovE) was annotated. The correl-
ation between the duration of blastomere movement and clinical pregnancy
after fresh cleaved embryo transfer was examined.
Participants/materials, setting, methods: Oocytes were retrieved and
inseminated either by conventional in vitro fertilization or intracytoplasmic
sperm injection. Fertilized oocytes were cultured in EmbryoScope® and the
time from insemination to pronuclear (PN) fading (tPNf), 4-cell stage (t4) and
tBMovE was annotated. The duration from ﬁrst cytokinesis to tBMovE was cal-
culated (dBMovE). The embryo quality was evaluated by Veeck’s criteria on
Day 2.
Main results and the role of chance: The average dBMovE was 6.56 ±
0.36 h [95% conﬁdential interval (CI): 5.86 – 7.26]. dBMovE was signiﬁcantly
correlated with the developmental rate to 4-cell stage on Day 2 (Odds ratio
(OR): 0.937 [95% CI: 0.911–0.965], p < 0.01). dBMovE was also associated
with the duration between tPNf and t4 (P < 0.01). Furthermore, dBMovE was
statically correlated to the morphological grade evaluated by Veeck’s criteria
(Grade 1: 2.90 ± 0.79; 2: 5.69 ± 0.69; 3: 8.11 ± 0.47; 4: 18.08 ± 3.98,
p < 0.01). Logistic regression analysis demonstrated that clinical pregnancy was
correlated with dBMovE (OR: 0.966 [95% CI: 0.943-0.986], P < 0.01).
Embryos were stratiﬁed into 4 groups according to dBMovE (group A: dBMovE
< 1.98, B: 1.98 ≤ dBMovE < 3.64, C: 3.64 ≤ dBMovE < 4.59, D: 4.59 ≤
dBMovE). The clinical pregnancy rates after fresh cleaved embryo transfer were
41.0% (50/122), 34.7% (96/277), 27.9% (41/147) and 15.7% (37/235),
respectively. There was a signiﬁcant trend that the clinical pregnancy rates
declined with increasing dBMovE (Cochran-Armitage trend test, P < 0.01).
Limitations, reasons for caution: This study is limited by the small sample
size, therefore, large scale studies are required. Furthermore, the effect of
blastomere movement on the potential of embryos to develop to the blastocyst
stage and subsequent pregnancy outcomes after blastocyst transfer should be
investigated.
Wider implications of the ﬁndings: This is the ﬁrst report demonstrating
the correlation between blastomere movement and pregnancy outcomes.
Embryos with extended blastomere movement after the ﬁrst cytokinesis have a
lower competence to initiate a clinical pregnancy after fresh cleaved embryo
transfer. Thus blastomere movement could be an effective predictive param-
eter for selecting embryos.
Trial registration number:None.
O-114 Time Lapse assessment of the occurrence and clinical
outcome of direct cleavage in a population of 10,529 embryos
cultured to the blastocyst stage
S. Montgomery1, C. Nelson2, N. Davis3, A. Campbell1, B. Peterson4,
C. Harlow2, C. Howles2
1CARE Manchester, Embryology, Manchester, United Kingdom
2University of Edinburgh, Deanery of Clinical Sciences- College of Medicine &
Veterinary Science, Edinburgh, United Kingdom
3CARE Fertility Northampton, Embryology, Northampton, United Kingdom
4BMP Analytics, Biostatistics, Viby, Denmark
Study question: Is the occurrence of direct cleavage (DC) in early stage cleav-
age embryos associated with a decreased chance of clinical pregnancy?
Summary answer: DC in early cleavage stage embryos is associated with a
highly signiﬁcant decreased chance of clinical pregnancy, particularly at the 2 cell
stage.
What is known already: DC has been reported to occur at the 2 cell stage
in around 14% of embryos. DC is a generic term for early irregular cell divisions
which encompasses both an immediate mulitchotomous mitosis (MM) (a cell
cleaves into more than 2 daughter cells), and the relatively rapid division of a
cell within a short cell cycle (SCC) (</ = 5 hours). For example, with MM, a
cell would divide directly from 1 to 3-cells or more, rather than to 2cells; or
spend <5 hours before the next mitotic division (SCC). DC can be identiﬁed
during cleavage stage embryo development.
Study design, size, duration: Anonymised time lapse data was retrospect-
ively reviewed from two sister clinics between August 2014 and January 2017.
10,529 embryos from 1651 consecutive patients using autologous oocytes,
were included. Embryos exhibiting a DC (at the 2, 4 or 8 cell cleavage stages)
were analysed for ability to reach blastocyst, and their KID (known implantation
data) rate was assessed according to maternal age, insemination method (IVF
or ICSI), and stage of embryo transfer (cleavage or blastocyst stage).
Participants/materials, setting, methods: Female age ranged from 19 to
46 years. Embryo development parameters were annotated according to
strictly deﬁned guidelines using the EmbryoScope® incubator and software
(Vitrolife). The population of embryos not displaying DC at 2, 4 and 8-cell cleav-
age stages provided the control (non-DC). All data was analysed using Chi-
square test, Fisher’s Exact test and Kruskal-Wallis test with post-hoc testing –
Dunn’s multiple comparison test to determine statistical signiﬁcance.
Main results and the role of chance: Overall, embryos exhibiting DC dur-
ing cleavage stages had a lower incidence of reaching a blastocyst (56%), com-
pared with non-DC embryos which underwent regular divisions (77%).
Embryos displaying DC at the 8-cell stage (DC8) had a higher rate (68%) of
reaching blastocyst than DC4 (52%) and DC2 (43%) embryos. Overall KID rate
of DC embryos (19.4%) was signiﬁcantly lower than non-DC embryos (38.4%)
(p < 0.0001). DC at the 2-cell stage had the most severe impact with the low-
est KID rate (7.8%) compared with 15.9% at DC-4 cell and 35.5% at DC-8.
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Women of ≥40 years experienced higher incidences of embryos having DC,
with the lowest KID rate (2.8%). No statistical difference was found between
IVF (n = 431) and ICSI (n = 1303) KID rates, in both non-DC and DC cases.
KID rate was signiﬁcantly lower (p < 0.0001) in DC embryos (7.7%), compared
with non-DC (24.6%), for day 2 to 4 transfers. For DC8 embryos, KID rate was
36% vs 50% in non-DC8 embryos (not signiﬁcant) when transferred at the
blastocyst stage.
Limitations, reasons for caution: Live birth information was not fully avail-
able for all treatment cycles. The study did not consider all patient factors,
which may inﬂuence cleavage patterns and embryo viability. The study did not
distinguish fully between multichotomous mitosis and short cell cycle.
Wider implications of the ﬁndings: DC at 2 cell stage is common and had
the most severe impact on embryo viability. The adverse effects of DC highlight
the need to select against the transfer of such embryos. Future studies may
involve tests for centriole function in contribution to this event, and embryo
ploidy assessment.
Trial registration number:Not applicable.
O-115 Is there a relation between embryo early cleavage
abnormalities and blastulation or implantation rates? A
retrospective time-lapse imaging study
R. NaamOuarezki1, X. Ferraretto1, M. Vigan2, J. Lousqui1,
M.A. Llabador de Royer1, M. Peigné3, S. Tubiana2, S. Epelboin3,
C. Patrat1
1Service de Biologie de la Reproduction, Hôpital Bichat- APHP, Paris, France
2Département d’Epidémiologie- Biostatistique et Recherche clinique, Hôpital Bichat-
APHP, Paris, France
3Service de Médecine de la Reproduction, Hôpital Bichat- APHP, Paris, France
Study question: What is the prevalence of atypical dynamic embryo pheno-
types identiﬁed by time-lapse system and are they associated with poor embryo
development and implantation rates?
Summary answer: As abnormal early cleavages are associated with low blas-
tulation and implantation rates, time-lapse and morphokinetic parameters may
offer a non-invasive mean for improving embryo selection.
What is known already: Several publications propose morphokinetics as an
additional parameter to assist in embryo selection. Most of them demonstrate
that embryos exhibiting atypical dynamic phenotypes are highly prevalent in
human embryos, and abnormal early cleavages, including Direct cleavage (DC),
Rapid cleavage (RaC) or Reverse cleavage (ReC), signiﬁcantly compromise
embryo development. Blastocyst formation rates for these embryos are signiﬁ-
cantly lower compared with control groups, culminating in poor implantation
potential (Rubio and al., 2012; Liu and al., 2014; Wirka and al., 2014; Fan and
al., 2016). However, these observations rely on small samples or are not fully
explored, especially for ReC.
Study design, size, duration: This research project is a single-center, retro-
spective cohort study conducted by the Reproductive Department at Bichat
hospital (APHP, Paris). We collected the data on all in vitro fertilization treat-
ments cycles for which the embryos were observed in the Embryoscope® time-
lapse system (Vitrolife Paris, France) from December 2015 to July 2017. The
study included 330 consecutive treatment cycles for 256 couples and a total of
1495 embryos. Embryo videos were retrospectively analyzed for dynamic
phenotypes.
Participants/materials, setting, methods: Only diploid zygotes were
included. Embryo development was evaluated on day 2 (based on cells number,
symmetry and percentage of fragmentation) and on day 5-6 (blastocyst forma-
tion (Gardner et al., 2000). The data included implantation, issue and clinical
factors whether it is factors intrinsic to patients or factors speciﬁc to IVF treat-
ment such as: couples’ parameters (age, BMI), origin of infertility, type of ovar-
ian stimulation regimen used and insemination method (IVF/ICSI).
Main results and the role of chance: A high prevalence of abnormal early
cleavage was observed among embryos: DC 23.5% (349/1486), RaC 25.9%
(388/1495) and ReC 7.4% (109/1480). A signiﬁcant lower percentage of
embryos with early atypical dynamic phenotype(s) 5.3% (30/566) had good
quality on day 2 (4 or 5 cells, typical character and <30% of fragmentation) as
compared to embryos without early cleavage anomalies (42.2% (395/936,
p < 0.001)). The same observation hold true on good quality on day 5 (≥B3
and ≥BB) (13.8% (65/470) vs 40.6% (197/485) with or without early cleavage
defects, respectively <0.001). This signiﬁcant difference was also observed at
day 2 according to the type of anomalies: DC 6.3% (22/349) vs 35.4% (403/
1138), RaC 2.6% (10/388) vs 38.3% (415/1083), ReC 9.2% (10/109) vs 30.3%
(415/1371), and on day 5: DC 8.2% (24/292) vs 37.1% (240/647), RaC 14.3%
(48/336) vs 37.1% (220/593), ReC 9.3% (9/97) vs 30.3% (253/834). Of the
521 embryos that were transferred on day 2 or 5, 104 (19.9%) were identiﬁed
as abnormal cleavage. Only 14 over 104 affected embryos were known to
implant (13.5%) when the implantation rate for embryos with a normal cleavage
pattern was 20.1% (84/417) and p = 0.116.
Limitations, reasons for caution: The present study is limited by a small
sample size of embryos known implantation. Furthermore, we do not know the
exact cause of these anomalies. At last, we can question their high prevalence
and their impact on the chances of implantation so that many of these embryos
can be eliminated?
Wider implications of the ﬁndings: The identiﬁcation of atypical dynamic
embryo phenotypes could further reﬁne the process of embryo selection by
enabling the deselection of embryos affected, in order to select and transfer the
embryo that offers the best chance of pregnancy.
Trial registration number: not applicable.
O-116 Partial embryo compaction: what’s behind? Morphokinetic
origins and chromosomal status
C. Lagalla1, R. Sciajno1, N. Tarozzi1, F. Pennetta1, G. Coticchio1,
A. Borini2
19.Baby Family and Fertility Center, IVF Laboratory Unit, Bologna, Italy
29.Baby Family and fertility Center, Reproductive Medicine IVF, Bologna, Italy
Study question: In preimplantation development, how much is partial com-
paction widespread, does it occur through different morphokinetics mechan-
isms and is it associated with embryo aneuploidy?
Summary answer: Partial compaction is frequent, is generated by two
mechanisms, blastomere exclusion and extrusion, and is associated with
embryo characteristics such as maternal age and aneuploidy.
What is known already: Compaction is a well-known developmental stage
of the preimplantation embryo, during which blastomeres change dramatically
cell shape and establish mutual and extensive cell-to-cell contacts. Overlapping
temporally with the speciﬁcation of the ﬁrst two embryonic cell lineages and
creating a selective barrier between intra- and extra-embryonic environment,
compaction is believed to be crucial for further development. Regardless, this
stage remains rather obscure and usually is not taken into consideration to
assess embryo quality. The Alpha/ESHRE Istanbul consensus on embryo
assessment barely mentions that compaction can occur completely or partially,
but implications of these two conditions are rather uncertain.
Study design, size, duration: This is a retrospective cohort study using data
from 136 PGT-A cycles carried out between May 2013 and July 2017 and
whose embryos were cultured in a time-lapse system. Embryos were annotated
for morphokinetic characteristics of compaction and analysed at the blastocyst
stage for chromosomal constitution. Treatment cycles were divided and ana-
lysed comparatively in two age groups, i.e. ≤34 and 35-39 years.
Participants/materials, setting, methods: Three morphokinetic categor-
ies of compaction were pre-deﬁned and annotated: i) full compaction, in cases
where at the expected time interval all blastomeres appeared with indistinct
boundaries and tightly connected; partial compaction in which blastomeres that
failed to compact were either ii) excluded from the outset or iii) extruded fol-
lowing an initial involvement in the compaction process. Chromosome analysis
was carried out by Array-CGH to determine embryo ploidy status, while statis-
tical analysis with chi-square test.
Main results and the role of chance: Overall, 322 blastocysts were
assessed morphokinetically and chromosomally. The total rate of partial com-
paction was 60.1%. The difference in the rates of partially compacted embryos
with excluded or extruded blastomeres was different in the younger age group
(68.3% and 31.7%, respectively; P = 0.00004), while it was almost identical
(50.4% and 49.6%, respectively) in the older age group. Blastomere exclusion
was statistically more prevalent in embryos of younger women (68.3% vs.
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50.4%, P = 0.02), whereas blastomeres were more frequently extruded in
embryos of women aged ≥35 years (31.7% vs. 49.6%, P = 0.02). The overall
rate of aneuploidy in blastocysts developed from totally or partially compacted
embryos was predictably different in the younger and older age groups (37.8%
and 49.7%, respectively; P = 0,037). In both age groups, no differences were
observed in the rate of aneuploidy in embryos with excluded or extruded blas-
tomeres. However, even if not statistically signiﬁcant, partially compacted
embryos tend to be less aneuploids compared to totally compacted embryos in
younger age group (33,3% vs. 42,9%), whereas this trend was not observed in
embryos of older women.
Limitations, reasons for caution: This study is retrospective and based on
a data set of limited size. Results should be extended with larger and prospect-
ive observations.
Wider implications of the ﬁndings: This study sheds novel light on a
neglected phase of human preimplantation development. In particular, it indi-
cates that different morphokinetic mechanisms can underlie abnormal compac-
tion. Also, it suggests possible mechanisms of self-correction of aneuploidy that
may be compromised in embryos of older women displaying partial compaction.
Trial registration number:Not applicable.
O-117 Time-lapse and NGS evaluation of human embryos cultured
in single medium versus sequential media: a prospective
randomized pilot study
Z. Yang1, Y. Kuang2, X. Zhang3, Y. Meng3, L. Tang4, Q. Lyu2, L. Su5,
S. Zhang6, J. Lin1
1Reproductive Fertility Center, ART, Irvine, U.S.A.
2Ninth People’s Hospital- Shanghai Jiao Tong University School of Medicine, Art,
Shanghai, China
3Second Afﬁliating Hospital- Kunming Medical University, Art, Kunming, China
4First Afﬁliating Hospital- Kunming Medical University, Art, Kunming, China
5Yunnan Family Planning Institute, Art, Kunming, China
6Sir Run Run Shaw Hospital- Zhe Jiang University School of Medicine, Art, Hangzhou,
China
Study question: Are there differences in morphokinetics, ploidy and implant-
ation potential of human embryos cultured in single medium versus sequential
media?
Summary answer: There were no signiﬁcant differences in key morphoki-
netic parameters, percentage of euploid blastocysts and overall clinical out-
comes between single medium and sequential media.
What is known already: Clinical studies with time-lapse culture concluded
that the most predictive morphokinetic parameters (e.g. t5, cc2 and s2) were
highly correlated with implantation potential. Various time-lapse studies were
performed to compare morphokinetics of embryos cultured in single medium
verses sequential media with controversial results. Nevertheless, ploidy of the
cultured embryos was not determined in previous studies. There is very limited
information about effects of different culture media on ploidy of human
embryos as related to implantation potential. Thus, the objective of this study
was to evaluate the morphokinetics, ploidy and clinical outcomes of embryos
cultured in single medium versus sequential medium.
Study design, size, duration:With an IRB approval, IVF patients (n = 93) at
mean age 32.1 ± 3.4 years seeking single embryo transfer (SET) were enrolled
in this prospective randomized pilot study in our IVF clinics from June 2016 to
June 2017. Sibling MII oocytes (n = 1205) were randomized into two groups
after ICSI: 1) Group A: Embryos (n = 603) were cultured in a single-step culture
medium (SSC) and 2) Group B: Embryos (n = 602) were cultured in sequential
media (G1/G2, Vitrolife).
Participants/materials, setting, methods: For both groups, embryos
were cultured to blastocyst stage in a time-lapse system (EmbryoScope,
VitroLife). Trophectoderm biopsy was performed on day 5 and the blastocysts
were vitriﬁed after biopsy. Whole genomic ampliﬁcation (WGA) and NGS ana-
lysis were performed according to manufacturer’s instructions (Yikon
Genomics, China; Illumina, USA). Single euploid blastocysts with the most pre-
dictive morphokenetic parameters available were transferred to individual
patients in FET cycles.The statistical analyses were performed using GraphPad
InStat (GraphPad Software, USA).
Main results and the role of chance: Time-lapse evaluation showed that
there were no signiﬁcant differences in key morphokinetic parameters between
the single medium and sequential media (p > 0.05). The time from insemination
to initiation of blastulation (tIB) was slightly faster in Group A compared to
Group B (96.3 ± 6.5 hpi vs. 97.1 ± 6.7 hpi, respectively, p > 0.05). There was no
signiﬁcant difference in fertilization rate between Group A and Group B (84.9%
vs. 85.8%, respectively, p > 0.05). There was no signiﬁcant difference in blasto-
cyst rate between Group A and Group B (48.4% vs. 43.1%, respectively,
p > 0.05). The percentage of biopsied blastocysts in Group A was similar to that
of Group B (93.5% vs. 94.6%, respectively, p > 0.05). NGS analysis revealed that
there were no signiﬁcant differences in euploid blastocyst rates (d5) between
Group A and Group B (43.5% vs. 42.2% respectively, p > 0.05). There was no
signiﬁcant difference in clinical pregnancy rate between Group A and Group B
(71.1% vs. 70.7% respectively, p > 0.05). The observed ongoing pregnancy rate
was comparable between Group A and Group B (68.9% vs. 65.8%, respectively,
p > 0.05). There was no signiﬁcant difference in miscarriage rate between Group
A and Group B (2.2% vs. 4.9%, respectively, p > 0.05).
Limitations, reasons for caution: Data are based on observations with
embryos from young patients with a good prognosis and may not fully general-
ize to all patients, especially those at advanced maternal age and with dimin-
ished ovarian reserve. Further randomized clinical trials with a larger number of
patients are planed to verify these initial ﬁndings.
Wider implications of the ﬁndings: Our data demonstrate that the single
culture medium supports human embryo development from zygote to blasto-
cyst stage and yields similar clinical and ongoing pregnancy rates compared to
sequential media. By minimizing exposure of embryos to the ambient atmos-
phere, non-disrupted culture with the single medium offers additional advan-
tages over sequential media.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 33: INTRAUTERINE INSEMINATIONAND
FLUSHING
Tuesday 3 July 2018 Room 211 + 212 10:00–11:30
O-118 The effect of intra-uterine slow-release insemination (SRI)
on the pregnancy rate in women designated for standard intra-
uterine insemination (IUI) –Amulticentre randomized, controlled
trial
M. Franz1, C. Egarter2, J. Campell3, E. Vyiska-Binsdorfer2, J. Ott2,
J. Marschalek2
1Gyn-Bogenhausen.de, Reproductive Medicine, Munich, Germany
2Medical University of Vienna, Dept. for Gynecology and Obstetrics, Vienna, Austria
3University of Northampton, Faculty of Health and Society-, Northampton, United
Kingdom
Study question: To investigate the effect of intra-uterine slow-release insem-
ination (SRI) on pregnancy rates in women with conﬁrmed sub-/infertility who
are eligible for standard intra-uterine insemination (IUI).
Summary answer: In women under 35 years of age the pregnancy rate is
improved by SRI compared to standard bolus IUI.
What is known already: Only a few studies have dealt with the actual IUI
technique, or have questioned the application method. A modiﬁed IUI applica-
tion technique is slow release insemination (SRI), which was ﬁrst described in
1992 (Muharib et al, 1992). The authors hypothesized that a persistent low
concentration of spermatozoa might prolong the period of potential fertilization
and thereby mimic physiological sperm transportation into the fallopian tube.
The present authors have recently published data from two pilot randomized,
controlled cross-over studies that indicate a statistically signiﬁcant advantage of
SRI over conventional bolus IUI.
Study design, size, duration: Multicentre, randomized, controlled cross-
over trial: 82 women were randomized into two treatment arms between 2012
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and 2017. A computerised randomisation programme was used to assign
women to standard IUI tor SRI. Women who failed to conceive in this ﬁrst
treatment were offered the alternative method in the second course. Sample
size was calculated using a minimum clinically signiﬁcant effect deﬁned as a rela-
tive risk of 2.0 in favour of SRI.
Participants/materials, setting, methods: Inclusion criteria: primary or
secondary infertility after six months of unprotected sexual intercourse; age
20–40 years; tubal patency; infertility due to anovulation and/or endometri-
osis and/or male partner with a minimum of >10 million of motile sperm
cells per sample and/or unexplained infertility. Women underwent either
the standard bolus IUI treatment or the SRI method. For SRI an EVIE device
was used for a four-hour continuous slow release injection of spermatozoa
into the uterus.
Main results and the role of chance: The overall observed pregnancy rate
for SRI was 13.2%, compared to 10.0% for IUI (relative risk [RR] = 1.32);
however, this difference was not statistically signiﬁcant (95% CI 0.69–2.53;
p = 0.202). For all women aged under 35 years undergoing SRI, the observed
RR for pregnancy was 2.33, with 17% of the SRI procedures resulting in preg-
nancy compared to just over 7% of the IUI procedures. This difference was stat-
istically signiﬁcant (p = 0.032). There were no signiﬁcant differences with
respect to female and male characteristics for patients aged under 35 years in
the IUI and SRI subgroups. Pregnancy rates were not different with clomiphene
citrate, rFSH or progesterone in either group, neither in the whole population
nor in the group of patients aged under 35 years. The pregnancy rate in patients
aged under 35 years using clomiphene citrate and SRI was, however, exception-
ally high (24.1%). There were no signiﬁcant differences in the use of medications
in women who successfully became pregnant after SRI or IUI.
Limitations, reasons for caution: We are aware that the crossover design
might be seen as a limitation of this study. Some authors reject the utilization of
this study design in infertility trials; however, others claim this an efﬁcient and
pragmatic design, particularly as only one cycle of each treatment is given to
each woman.
Wider implications of the ﬁndings: These data lend support to the
hypothesis that the pregnancy rate might be improved by using SRI rather than
IUI, especially in women aged under 35 years. Additional, larger, clinical trials
are required to fully prove this hypothesis, especially if an economic beneﬁt of
SRI is also to be demonstrated.
Trial registration number: Current Controlled Trials Register (registration
number NCT02315040).
O-119 What is in unexplained subfertility the impact of
gonadotropins or clomiphene citrate on endometrial thickness: a
secondary analysis of a trial on intrauterine insemination
M.H. Mochtar1, N. Danhof1, R. Van Eekelen1, B. Mol2, F. Van der
Veen1, M. VanWely1
1Academical Medical Center Amsterdam, Center for Reproductive Medicine,
Amsterdam, The Netherlands
2Monash Medical Centre, Obstetrics and Gynaecology, Clayton, Australia
Study question: What is in unexplained subfertility the impact of follicle
stimulating hormone (FSH) or clomiphene citrate (CC) in intrauterine insemin-
ation (IUI) on endometrial thickness (EMT), and is EMT related to pregnancy?
Summary answer: The mean EMT was signiﬁcant thicker in women treated
with FSH compared to treated with CC. EMT is not independently associated
with ongoing pregnancy rate.
What is known already: CC is associated with thinner EMT compared to
FSH in ovarian stimulation IUI. Whether a thin EMT has an effect on ongoing
pregnancy is unknown. We recently performed a RCT comparing ovarian
stimulation with follicle stimulating hormone (FSH) to CC in couples with unex-
plained subfertility undergoing IUI that showed no signiﬁcant difference in
ongoing pregnancy rates and live birth rates.
Study design, size, duration: This is a pre-planned secondary analysis on
the effect of EMT in terms of pregnancy outcome of a multicentre randomised
controlled superiority trial; the SUPER study, in which we investigated 738 cou-
ples diagnosed with unexplained or mild male subfertility from 24 clinics
positioned in the Dutch Consortium for Healthcare Evaluation in Obstetrics
and Gynaecology, undergoing ovarian stimulation with FSH or CC in IUI.
Participants/materials, setting, methods: 738 women received 1944
cycles. We used EMT per cycle. We measured changes over consecutive cycles
per woman. We determined difference in EMT between women randomised
to FSH and CC over all cycles using an independent samples t-test. We subse-
quently investigated the association between EMT and ongoing pregnancy using
logistic regression, with precision measures adjusted for women receiving mul-
tiple cycles. Ongoing pregnancy was deﬁned as a positive heartbeat at or
beyond 12 weeks of gestation.
Main results and the role of chance: The 1944 IUI cycles resulted in 226
(11.6%) ongoing pregnancies. The mean EMT was 8.9 mm (±2.1) in women
treated with FSH and 7.5 mm (±2.2) in women treated with CC (mean differ-
ence: 1.4 mm, p < 0.001, 95%CI 1.2-1.6). EMT was not signiﬁcantly associated
with ongoing pregnancy rate (odds ratio: 1.02 per 1 mm thicker, p = 0.59, 95%
CI 0.96-1.08). Also after correcting for allocated stimulating agent, or after
looking at nonlinear associations between EMT and pregnancy outcome, we
found a similar result.
Limitations, reasons for caution: Secondary analyses, commonly used to
investigate whether the conclusions are relevant for a particular sub population,
are prone to false positive ﬁndings. Since this analysis was pre-planned, the risk
of reporting bias is low.
Wider implications of the ﬁndings: We conﬁrmed that CC result in thin-
ner endometrium compared to FSH. Nonetheless, we found no association
between EMT and chances in ongoing pregnancy rate. So EMT should not be
used in the decision to continue CC or to switch to FSH in women undergoing
IUI with ovarian stimulation.
Trial registration number: SUPER study is registered at NTR 4057
Acknowledgement: SUPER study group.
O-120 A cost-effectiveness analysis of ovarian stimulation with
follicle stimulating hormone (FSH) compared with clomiphene
citrate (CC) in intra uterine insemination (IUI)
N. Danhof, M. VanWely, F. Van der Veen, M. Mochtar
AMC, Center for Reproductive Medicine, Amsterdam, The Netherlands
Study question: Is FSH or CC the most cost-effective stimulation regimen in
couples with unexplained or mild male subfertility undergoing IUI with adher-
ence to strict cancellation criteria?
Summary answer: The additional costs to achieve one additional ongoing
pregnancy with FSH compared with CC were €10556,87. CC is the most cost-
effective stimulation regimen in IUI.
What is known already: IUI with ovarian stimulation is the ﬁrst line treat-
ment in couples with unexplained or mild male subfertility. Almost 176000 IUI
cycles are performed in Europe each year. A Cochrane review advises to use
FSH for ovarian stimulation in IUI, but we have recently completed a multicen-
tre RCT, in which we found that ovarian stimulation with FSH is not superior to
CC in terms of ongoing pregnancies and live births. In using strict cancelation
criteria, we found a comparable but low multiple pregnancy rate for FSH and
CC.
Study design, size, duration: A cost-effectiveness analysis from a healthcare
perspective alongside the multicentre randomised controlled superiority trial;
the SUPER study. We investigated 738 couples diagnosed with unexplained or
mild male subfertility from 24 clinics positioned in the Dutch Consortium for
Healthcare Evaluation in Obstetrics and Gynaecology, undergoing ovarian
stimulation with FSH or CC in IUI with adherence to strict cancellation criteria.
Participants/materials, setting, methods:We estimated costs from pub-
lic sources and published literature. We assessed incremental cost-
effectiveness ratios (ICERs) for 75 IE FSH and for 100 mg CC for costs per
ongoing pregnancy.
Main results and the role of chance: The mean costs per couple were € 1
472,40 for FSH and € 1 014,65 for CC. The effectiveness of FSH was 4% higher
compared with CC. The additional costs to achieve one additional ongoing
pregnancy with FSH compared with CC were € 10 556,87. For a willingness-to-
pay of € 15 000 for an additional ongoing pregnancy, there is 67% chance that
FSH is cost-effective compared with CC. For a willingness-to-pay of € 45 000
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for an ongoing pregnancy, there is a 91% chance that FSH is cost-effective com-
pared with CC.
Limitations, reasons for caution: We performed the analysis from a
healthcare perspective. We focussed on direct medical costs, but we ﬁnd it
unlikely that including indirect costs of the ovarian stimulation in IUI and indirect
costs from a social perspective would change our conclusion, since the impact
of these costs is small.
Wider implications of the ﬁndings: We could save more than €27 million
in Europe on a yearly basis using CC instead of FSH in couples with unexplained
or mild male subfertility undergoing IUI with adherence to strict cancellation cri-
teria. Whether FSH should be used depends on society’s willingness to pay for
an additional ongoing pregnancy.
Trial registration number: Inapplicable.
Acknowledgement: thanks to the SUPER study group.
O-121 Is intrauterine insemination with ovarian stimulation
associated with higher chances of ongoing pregnancy compared to
expectant management in couples with unexplained subfertility?
N. Van Geloven1, R. Van Eekelen2,3, M. VanWely2, D.J. McLernon4,
F. Mol2, I.M. Custers2, P. Steures5, S. Bhattacharya6, B.W. Mol7,
F. Van der Veen2, M.J.C. Eijkemans3
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The Netherlands
6University of Aberdeen, Department of Applied Health Sciences, Aberdeen, United
Kingdom
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Study question: Does starting IUI-OS within 1.5 years after completion of
the fertility workup increase ongoing pregnancy rates compared to expectant
management in couples with unexplained subfertility?
Summary answer: IUI-OS is associated with higher chances of ongoing preg-
nancy compared to expectant management in unexplained subfertile couples,
especially those with poorer prognoses of natural conception.
What is known already: IUI-OS is often the ﬁrst-line treatment for couples
with unexplained subfertility. Two randomised controlled trials compared IUI-
OS to expectant management but found conﬂicting results. In the absence of a
consensus from these trials, a cohort of couples with unexplained subfertility
exposed to expectant management and IUI-OS offers an opportunity to deter-
mine the chances of conception under both conditions. In addition, a large
cohort allows evaluating whether the effect of IUI-OS depends on a couple’s
prognosis of natural conception, which might explain the discrepancy between
trial results.
Study design, size, duration: A prospective cohort study on couples with
unexplained or mild male subfertility who could start IUI-OS at any point after
completion of the fertility workup in 7 Dutch centres between January 2002
and February 2004. Couples with bilateral tubal occlusion, anovulation, or a
total motile sperm count <1 × 106 were excluded. Follow up was censored at
the start of IVF or at last contact and truncated at a maximum of 1.5 years after
the fertility workup.
Participants/materials, setting, methods: The endpoint was time to
ongoing pregnancy. We used the sequential Cox approach comparing in each
month ongoing pregnancy rates over the next 6 months of couples who started
IUI-OS to couples who did not. We calculated the prognosis of natural concep-
tion for individual couples and updated this over consecutive failed cycles, then
evaluated whether prognosis modiﬁed the effect of starting IUI-OS. We cor-
rected for known predictors of conception using inverse probability weighting.
Main results and the role of chance: Data from 1896 couples were avail-
able. 800 couples had at least one IUI-OS cycle within 1.5 years post fertility
workup of whom 142 couples conceived (rate: 0.50 per couple per year,
median follow up 4 months). The median period between fertility workup com-
pletion and starting IUI-OS was 6.5 months. Of 1096 couples who remained
untreated, 386 conceived naturally (rate: 0.31 per couple per year, median fol-
low up 7 months).
Starting IUI-OS was associated with a higher chance of ongoing pregnancy by
a pooled, overall hazard ratio of 1.96 (95%CI: 1.47-2.62) compared to expect-
ant management. The effect of treatment was modiﬁed by a couple’s prognosis
of achieving natural conception (p = 0.01), with poorer prognoses or additional
failed natural cycles being associated with higher relative chances after starting
treatment. The predicted 6-month ongoing pregnancy rate for a couple with a
prognosis of 25% over the next 6 cycles (approximately 40% over one year)
was 25% (95%CI: 21-28%) for expectant management and 24% (95%CI: 15-
31%) when starting IUI-OS right after the fertility workup. For a couple with the
cohort-average prognosis of 12% (20% over one year), these predicted rates
were 12% (95%CI: 10-14%) for expectant management and 24% (95%CI: 17-
30%) for starting IUI-OS.
Limitations, reasons for caution: The effect estimates are based on a pro-
spective cohort. Although we balanced known predictors of pregnancy
between treated and untreated couples using inverse probability weighting,
observational data may still be subject to residual confounding. The results
need to be conﬁrmed by large randomised controlled trials.
Wider implications of the ﬁndings: Starting IUI-OS is effective in couples
with unexplained subfertility who have a poor prognosis for natural conception
and should therefore remain their ﬁrst-line treatment. Our results may explain
the discrepancies between trials that compared IUI-OS to expectant manage-
ment, but further studies are required to conﬁrm these ﬁndings.
Trial registration number:Not applicable.
O-122 Tubal ﬂushing with oil- or water-based contrast medium at
hysterosalpingography for infertility: 3-year outcome of a
randomized clinical trial
J. Van Rijswijk1, N. VanWelie1, K. Dreyer1, H. Verhoeve2, A. Hoek3,
J.P. De Bruin4, A. Nap5, M. Van Hooff6, M. Goddijn7, A. Hooker8,
N. Lambalk1, P. Hompes1, H. Zafarmand7, V. Mijatovic1, B.W. Mol9
1VU University Medical Centre- Amsterdam, Department of Reproductive Medicine,
Amsterdam, The Netherlands
2OLVG oost, Department of Obstetrics and Gynaecology, Amsterdam, The
Netherlands
3University Medical Centre Groningen, Department of Reproductive Medicine and
Gynaecology, Groningen, The Netherlands
4Jeroen Bosch Hospital, Department of Obstetrics and Gynaecology, Den Bosch, The
Netherlands
5Rijnstate Hospital, Department of Obstetrics and Gynaecology, Arnhem, The
Netherlands
6Sint Franciscus Hospital, Department of Obstetrics and Gynaecology, Rotterdam,
The Netherlands
7Academic Medical Centre Amsterdam, Department of Obstetrics and Gynaecology,
Amsterdam, The Netherlands
8Zaans Medical Centre, Department of Obstetrics and Gynaecology, Zaandam, The
Netherlands
9Monash Medical Centre- Monash Health and Monash University, Department of
Obstetrics and Gynaecology, Melbourne, Australia
Study question:What is the impact of the use of oil- or water-based contrast
medium at hysterosalpingography (HSG) on fertility outcomes 3 years after
randomization?
Summary answer: Women who had their tubes ﬂushed with oil-based con-
trast had 3-year cumulative ongoing pregnancy rates of 83.2% versus 80.7%
after the use of water-based contrast.
What is known already: For decades it has been suggested that tubal
ﬂushing with oil-based contrast (Lipiodol) at HSG improved pregnancy
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rates (Mohiyiddeen L, et al. 2015). We recently showed in a landmark trial
published in the New England Journal of Medicine that in infertile women
tubal ﬂushing during HSG with oil-based contrast resulted in more ongoing
pregnancies than HSG with the use of water-based contrast at 6 months
after randomization(39.7% versus 29.1% (RR 1.37, 95%CI 1.16-1.61, p <
0.001)) (Dreyer et al. 2017). It is unclear whether this difference continues
beyond 6 months.
Study design, size, duration: This was a follow-up study of the H2Oil trial,
a multi-center randomized controlled trial in the Netherlands in which 1,119
women were included and randomized to hysterosalpingography with oil-based
contrast (n = 557) or water-based contrast (n = 562). Here, we present the
fertility outcomes at three years after randomization.
Participants/materials, setting, methods: All 1,119 participants were
contacted 3-5 years after randomization, and were asked to ﬁll in question-
naires about the fertility treatments and pregnancies. Additionally, we reviewed
the medical ﬁles to record all pregnancies and fertility treatments. Primary out-
come was the ﬁrst ongoing pregnancy within 36 months after randomization.
We also compared naturally conceived pregnancies, pregnancies conceived
after IUI and IVF and time to ongoing pregnancy.
Main results and the role of chance: In total, 383 ongoing pregnancies
were accomplished in the oil-based contrast group versus 344 ongoing preg-
nancies in the water-based contrast group. The cumulative ongoing preg-
nancy rate 3 years after randomization was 83.2% (95%CI:79.3-87.1%) in
the oil-based contrast group versus 80.7% (95%CI:76.4-85.0%) in the
water-based contrast group. The Kaplan-Meier survival curves for time to
ongoing pregnancy were signiﬁcantly different in favor of the oil-based con-
trast group (median time to ongoing pregnancy 10.00 versus 14.83 months,
p-value log-rank test 0.001).
Of the 383 ongoing pregnancies in the oil-based contrast group, 207 (54.3%)
were naturally conceived, 114 (29.8%) after IUI and 60 (15.7%) after IVF/ICSI.
Of the 344 ongoing pregnancies in the water-based contrast group, 174 (51.2
%) were naturally conceived, 93 (27.0%) after IUI and 73 (21.2%) after IVF/
ICSI. Conception of 2 versus 4 pregnancies was unknown.
When follow-up is censored for starting IVF/ICSI treatment, the cumulative
ongoing pregnancy rate was 74.2% (95%CI:68.1-80.3%) in the oil-based con-
trast group versus 70.1% (95%CI:63.0-77.2%) in the water-based contrast
group, with the time to ongoing pregnancy signiﬁcantly shorter in favor of the
oil-based contrast group (median time to ongoing pregnancy 10.16 versus
17.07 months, p-value log-rank test <0.001).
Limitations, reasons for caution: This study was limited to women at low
risk for tubal pathology, <39 years and without known endocrinological dis-
eases, the ﬁndings should therefore not be generalized. Here, we only report
ongoing pregnancies and not live birth.
Wider implications of the ﬁndings: Tubal ﬂushing with oil-based contrast
does not only result in higher 6-months ongoing pregnancy rates, but also in
higher 3-year cumulative ongoing pregnancy rates. Time to ongoing preg-
nancy was signiﬁcantly shorter in the oil-based contrast group. In our opin-
ion, tubal ﬂushing with oil-based contrast should be offered to infertile
women.
Trial registration number:Dutch Trial Register, NTR 6577.
O-123 Does tubal ﬂushing with oil- versus water-based contrast at
hysterosalpingography increase the chance of a second child; long
term follow-up of the H2Oil RCT
N. VanWelie1, J. Van Rijswijk1, H. Verhoeve2, H. Annemieke3,
J.P. De Bruin4, A. Nap5, M. Van Hooff6, M. Goddijn7, A. Hooker8,
N. Lambalk1, P. Hompes1, V. Mijatovic1, H. Zafarmand7, B.W. Mol9,
K. Dreyer1
1VU University Medical Centre, Reproductive Medicine, Amsterdam, The
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6Sint Franciscus Hospital, Department of Obstetrics and Gynaecology, Rotterdam,
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Study question: Does tubal ﬂushing with oil- versus water-based contrast at
hysterosalpingography (HSG) increase the chance of a second child?
Summary answer: There is no clear effect of a single procedure of tubal
ﬂushing with oil- versus water-based contrast on the chance of a second child.
What is known already: For decades it has been suggested that tubal ﬂush-
ing with oil-based contrast(Lipiodol) at HSG improved pregnancy rates
(Mohiyiddeen et al. 2015). We recently showed in a landmark trial published in
the New England Journal of Medicine that in infertile women undergoing HSG
tubal ﬂushing with oil-based contrast resulted in more ongoing pregnancies than
with the use of water-based contrast at 6 months after randomisation(39.7%
versus 29.1% (RR 1.37, 95%CI 1.16-1.61))(Dreyer et al. 2017). While the effect
of oil-ﬂushing on conception of the ﬁrst child is established, it is unclear whether
tubal ﬂushing with oil-based contrast increases the chances of subsequent
children.
Study design, size, duration: This was a follow-up study of the H2Oil trial,
a multi-center randomized controlled trial in the Netherlands in which 1,119
women were randomized to HSG with oil-based contrast (n = 557) or water-
based contrast (n = 562). Participating women were approached 3-5 years
after randomization with a questionnaire about their fertility. Additionally, we
reviewed the medical ﬁles to record all pregnancies and fertility treatments.
Here, we present the fertility outcome in terms of a second ongoing pregnancy.
Participants/materials, setting, methods: The outcome of this follow-up
study was a second ongoing pregnancy (after the birth of a ﬁrst child). We also
assessed mode of conception and time to pregnancy.
Main results and the role of chance: There were 1,119 women rando-
mized to oil-based contrast(n = 557) or water-based contrast(n = 562).
Cumulative ongoing pregnancy rates were 83.2% versus 80.7% after oil and
water ﬂushing, respectively. In the oil-based contrast group 142(25.6%) couples
had a renewed child wish, versus 129(23.1%) in the water-based contrast group.
In total, 97 women (17.5%) in the oil-based contrast group had a second
ongoing pregnancy versus 91(16.3%) women in the water-based contrast group
(p-value 0.60).
Of the 97 second ongoing pregnancies in the oil-based contrast group, 67
(69.1%) occurred naturally, 14(14.4%) after IUI and 12(12.4%) after IVF/ICSI.
Of the 91 second ongoing pregnancies in the water-based contrast group, 58
(63.7%) were naturally conceived, 9(9.9%) after IUI, and 21(23.1%) after IVF/
ICSI. Mode of conception of 4 versus 3 pregnancies was unknown.
The Kaplan-Meier curves for time to ongoing pregnancy showed no statistical
difference for the use of oil- or water-based contrast(median time to ongoing
pregnancy 50.97 versus 51.37 months respectively, p-value log-rank test 0.693).
When time to ongoing pregnancy was censored at the start of IVF/ICSI, the
Kaplan-Meier curves for time to ongoing pregnancy showed no statistical differ-
ence for the use of oil- or water-based contrast(median time to ongoing preg-
nancy 46.47 versus 51.37 months respectively, p-value log-rank test 0.717).
Limitations, reasons for caution: This study was limited to women with a
low risk of tubal pathology, <39 years and without known endocrinological dis-
eases. Furthermore the time of follow-up is relatively short, despite the large
sample size.
Wider implications of the ﬁndings: Tubal ﬂushing with oil-based contrast
does not increase the chance of a second child. However, in the oil-based
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contrast group the need for IVF/ICSI to establish this goal was reduced with
almost 50%.
Trial registration number:Dutch Trial Register, NTR 6577
INVITED SESSION
SESSION 34: LAUNCHOF THE INTERNATIONAL
EVIDENCE-BASEDGUIDELINE FOR THE ASSESSMENT
ANDMANAGEMENTOF POLYCYSTIC OVARY
SYNDROME (PCOS)
Tuesday 3 July 2018 Room 111 + 112 10:00–11:30
O-124 Building an international PCOS guideline: Initiative, process
and translation
O-125 International guideline on PCOS: Diagnosis and treatment
J. Laven1, H. Teede2, T. Piltonen3, M. Costello4
1Erasmus Medical Center, Reproductive Medicine, Rotterdam, The Netherlands
2Monash University, Monash Centre for Health Research and Implementation,
Melbourne, Australia
3Oulu University Hospital, Department of Obstetrics and Gynecology, Oulu, Finland
4University New South Wales, Obstetrics and Gynecology, Sydney, Australia
Abstract text
PCOS is common and heterogeneous with reproductive, metabolic and psy-
chological features. Diagnosis delays are common internationally, with patient
dissatisfaction with care and inadequate provided information and resources.
There are gaps in clinician knowledge and inconsistencies in care, underpinned
by a lack of quality evidence based guidelines and inadequate translation of evi-
dence into practice. The International Evidence based Guideline for the assess-
ment and treatment of polycystic ovary syndrome (PCOS) addresses health
professional and consumer priorities. It integrates the best available evidence
with international, multidisciplinary clinical expertise and consumer preferences
to provide health professionals, consumers and policy makers with guidance on
the assessment and treatment of PCOS. The guideline aims to promote accur-
ate diagnosis, optimal consistent care, prevention of complications and
improved patient experience and health outcomes for the one in ten women
worldwide with PCOS. Extensive international health professional and patient
engagement informed the need, priorities and core outcomes for the guideline.
International Society-nominated panels and co-opted experts included women
with PCOS, paediatricians, endocrinologists, gynaecologists, primary care physi-
cians, reproductive endocrinologists, psychiatrists, psychologists, dermatolo-
gists, dieticians, exercise physiologists, public health experts, researchers, and a
project management, evidence synthesis and translation team developed the
guideline.
Evidence-based guideline development followed international best practice,
involving 60 systematic and narrative reviews and applying the full Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE)
framework to reﬂect quality of evidence, and consider feasibility, acceptability,
cost, implementation and ultimately the strength of recommendations.
Governance included an international advisory board from six continents, a
project board, ﬁve guideline development groups with 8-10 members each,
advisors and a translation committee. Special Interest groups of world experts
were formulated to review and provide feedback on the guidelines. Guideline
development groups and special interest groups/ experts were nominated by
the partner and collaborator organisations. The Australian Centre for Research
Excellence in PCOS, funded by the National Health and Medical Research
Council (NHMRC), partnered with the European Society of Human
Reproduction and Embryology (ESHRE) and the American Society for
Reproductive Medicine (ASRM) to fund and complete the guideline. Four
project board and 15 guideline development group face to face meetings
occurred across Europe, USA and Australia over 15 months, and enabled train-
ing, guideline development and informed translation. Sixty prioritized clinical
questions were addressed with 40 systematic and 20 narrative reviews, gener-
ating 170 recommendations and practice points. Feedback from our over 40
partner and collaborator special interest groups was sought during consultation
to inform the ﬁnal guideline. The guidelines which cover diagnosis, emotional
well-being, lifestyle, medical therapy and infertility treatment will be launched
and presented at ESHRE.
O-126 Guideline recommendations: Treatment, emotional
wellbeing and pregnancy
T. Piltonen1, J. Laven2, B. Fauser3, D. Romualdi4,
A. Linden-Hirschberg5, R.J. Norman6, J. Tapanainen7, H. Teede8
1University of Oulu, Department of Obstetrics and Gynaecology- Oulu University
Hospital- University of Oulu and Medical Research Center and PEDEGO Research
Unit, Oulu, Finland
2University Medical Center Rotterdam, Obstetrics and Gynecology, Rotterdam, The
Netherlands
3UMC Utrecht, Obstetrics and Gynecology, Utrecht, The Netherlands
4Policlinico Universitario Agostino Gemelli, Obstetrics and Gynaecology, Rome, Italy
5Karolinska University Hospital, Gynecology and Reproductive Medicine, Stockholm,
Sweden
6The University of Adelaide, Robinson Research Institute, Adelaide, Australia
7University of Helsinki, Obstetrics and Gynecology, Helsinki, Finland
8Monash University, Monash Centre for Health Research and Implementation-,
Melbourne, Australia
Abstract text
PCOS is common and heterogeneous with reproductive, metabolic and psy-
chological features. Diagnosis delays are common internationally, with patient
dissatisfaction with care and inadequate provided information and resources.
There are gaps in clinician knowledge and inconsistencies in care, underpinned
by a lack of quality evidence based guidelines and inadequate translation of evi-
dence into practice.
The International Evidence based Guideline for the assessment and treat-
ment of polycystic ovary syndrome (PCOS) addresses health professional and
consumer priorities. It integrates the best available evidence with international,
multidisciplinary clinical expertise and consumer preferences to provide health
professionals, consumers and policy makers with guidance on the assessment
and treatment of PCOS. The guideline aims to promote accurate diagnosis,
optimal consistent care, prevention of complications and improved patient
experience and health outcomes for the one in ten women worldwide with
PCOS.Extensive international health professional and patient engagement
informed the need, priorities and core outcomes for the guideline. International
Society-nominated panels and co-opted experts included women with PCOS,
paediatricians, endocrinologists, gynaecologists, primary care physicians, repro-
ductive endocrinologists, psychiatrists, psychologists, dermatologists, dieticians,
exercise physiologists, public health experts, researchers, and a project man-
agement, evidence synthesis and translation team developed the guideline.
Evidence-based guideline development followed international best practice,
involving 60 systematic and narrative reviews and applying the full Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE)
framework to reﬂect quality of evidence, and consider feasibility, acceptability,
cost, implementation and ultimately the strength of recommendations.
Governance included an international advisory board from six continents, a
project board, ﬁve guideline development groups with 8-10 members each,
advisors and a translation committee. Special Interest groups of world experts
were formulated to review and provide feedback on the guidelines. Guideline
development groups and special interest groups/ experts were nominated by
the partner and collaborator organisations. The Australian Centre for Research
Excellence in PCOS, funded by the National Health and Medical Research
Council (NHMRC), partnered with the European Society of Human
Reproduction and Embryology (ESHRE) and the American Society for
Reproductive Medicine (ASRM) to fund and complete the guideline. Four
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project board and 15 guideline development group face to face meetings
occurred across Europe, USA and Australia over 15 months, and enabled train-
ing, guideline development and informed translation. Sixty prioritised clinical
questions were addressed with 40 systematic and 20 narrative reviews, gener-
ating 170 recommendations and practice points. Feedback from our over 40
partner and collaborator special interest groups was sought during consultation
to inform the ﬁnal guideline. The guidelines which cover diagnosis, emotional
well-being, lifestyle, medical therapy and infertility treatment will be launched
and presented at ESHRE.
SELECTEDORAL COMMUNICATIONS
SESSION 35: GENETIC CAUSESOFMALE INFERTILITY
Tuesday 3 July 2018 Room 113 + 114 + 115 10:00–11:30
O-127 Analysis of the chromosome territories dynamic in male
germ cells and its association to male infertility
M. Solé1, J. Blanco1, D. Gil2, O. Valero3, G. Fonseka4, R. Frodsham4,
F. Vidal1, Z. Sarrate1
1Universitat Autònoma de Barcelona, Departament de Biologia Cel·lular- Fisiologia i
Immunologia, Barcelona, Spain
2Computer vision Center- Universitat Autònoma de Barcelona, Computer Science
Department, Barcelona, Spain
3Universitat Autònoma de Barcelona, Servei d’Estadística Aplicada, Barcelona, Spain
4Cytocell Ltd, Technopark, Cambridge, United Kingdom
Study question: Is there a speciﬁc three-dimensional distribution pattern of
chromosomes in the different spermatogenic cells?
Summary answer: Chromosomes are arranged in a speciﬁc manner along
the different stages of spermatogenesis.
What is known already: In somatic cells, chromosomes occupy speciﬁc
nuclear regions called chromosome territories (CTs) that are arranged in cell-
type speciﬁc non-random patterns according to chromosome parameters such
as gene density and chromosome size. Moreover, CTs have a functional effect
in the regulation of the genome providing additional mechanisms to modulate
gene expression. Therefore, it has been suggested that CTs in meiotic cells may
be crucial for the proper development of spermatogenesis and early embryo
development. Actually, an altered distribution of some CTs has been observed
in infertile men. However, the CTs distribution along the spermatogenesis has
been poorly explored.
Study design, size, duration: Experiments were performed by using testes
from 5 C57BL6/6 J mice. The method includes the following steps:
i) Optimized cell ﬁxation to preserve the three-dimensionality cell morphology,
ii) Fluorescence in situ hybridization of all mouse chromosomes, iii) Three-
dimensional image captures of a minimum of 100 nuclei per cell type by con-
focal microscope, iv) Cell type identiﬁcation by immunoﬂuorescence, v) Image
analysis and data extraction by a numerical computing software, vi) Data ana-
lysis by using statistics software’s.
Participants/materials, setting, methods: Testicular tissue was disag-
gregated and cells were spread out on polylysine-coated slides. After cell
ﬁxation, three FISH rounds were carried out using the Mice OctoChrome
kit. Protein SYCP3 and histone H1T were identiﬁed by immunoﬂuorescence
to distinguish between spermatogenic cells. Serial optical sections were
obtained with a confocal microscope and images were processed by ImageJ.
Matlab scripts were used to normalize images and determine chromosome
volume and proportion, chromosome radial position and chromosome rela-
tive position.
Main results and the role of chance: The application of the developed
methodology allowed determining the territoriality of chromosomes in male
germ cells. Results showed that there is a speciﬁc three-dimensional distribution
pattern of chromosomes throughout the different spermatogenic stages. On
the one hand, the analysis of the chromosomes radial position revealed that
chromosomes are arranged in a speciﬁc manner from the center to the
periphery of the nucleus. Moreover, it has been observed preference in radial
positioning according to some chromosomal parameters such as chromosome
size, gene density or the percentage of guanine and cytosine contain. On the
other hand, in terms of chromosomes vicinity, results showed that there is a
systematic relative position of speciﬁc chromosomes pairs, showing preference
in proximity or non-proximity.
Limitations, reasons for caution: The methodology applied in this study is
complex and time consuming because of requiring three consecutive FISH
rounds and one extra round for immunoﬂuorescence.
Wider implications of the ﬁndings: Our results will provide the new basis
of future studies to ﬁnd out the relationship between chromosome positioning,
genome regulation and male fertility.
Trial registration number: not applicable.
O-128 The altered testicular environment in patients with
Klinefelter Syndrome
D. Van Saen1, V. Vloeberghs2, I. Gies3, J. De Schepper4,
H. Tournaye5, E. Goossens6
1VUB, Biology of the Testis BITE, Brussel, Belgium
2Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussel, Belgium
3Universitair Ziekenhuis Brussel, Pediatric Endocrinology, Brussel, Belgium
4UZ Brussel, Pediatric Endocrinology, Brussel, Belgium
5UZ Brussel, Centre for Reproductive Medicine, UZ Brussel, Belgium
6Vrije Universiteit Brussel, Biology of the Testis, Brussel, Belgium
Study question: Is testicular ﬁbrosis in Klinefelter syndrome (KS) related to
the altered structure of the tubular wall and/or altered vascularization?
Summary answer: An altered expression pattern in adult patients was
observed for collagen I and IV. An increase in vessel density was observed in
prepubertal KS testis.
What is known already: Patients with KS are infertile due to a massive germ
cell loss. By the time of diagnosis, adult KS testes often show extensive ﬁbrosis,
hyalinization of the seminiferous tubules and hyperplasia of the interstitium. The
architecture of the tubular wall, composed of peritubular myoid cells (PTMCs),
extracellular matrix proteins (ECM) and ﬁbroblasts, is altered in men with
impaired spermatogenesis and could be related to tubular ﬁbrosis by increased
deposits of ECM.
In a mouse model for KS, an altered vascularisation of the KS testes was sug-
gested. Angiogenesis (the formation of new blood vessels) is also related to
ﬁbrotic processes.
Study design, size, duration: In this study, we want to characterize the tes-
ticular environment in testicular biopsies from adult KS patients and compare it
with the testicular environment in testicular tissue from fertile controls and
Sertoli Cell Only patients. SCO patients also lack germ cells but do not show
the typical ﬁbrotic appearance as seen in testes from KS patients.
Participants/materials, setting, methods: Immunohistochemical analysis
of testicular tissue sections from adult control (n = 6), KS (n = 20) and SCO
(n = 20) patients was performed using markers for PTMCs (ACTA2), ECM
(laminin, ﬁbronectin, collagen I and IV) and blood vessels (VWF). The expres-
sion of tubular wall markers was characterized by identifying abnormal staining
patterns. The mean blood vessel area and the vessel density was calculated in
VWF stained testicular sections from adult (n = 25), pre- (n = 4) and peripu-
bertal (n = 15) KS patients.
Main results and the role of chance: Altered expression for ACTA2 was
observed in KS as well as in SCO patients. In SCO patients, the tubular wall
often showed two layers of ACTA+ cells interrupted by a negative ring (prob-
ably ECM deposits). However, in KS patients, the same pattern was observed
but the ring of ACTA2 staining was often interrupted indicating loss of ACTA2
staining. No statistical difference was observed in the expression patterns of
ﬁbronectin and laminin between SCO and KS patients. In KS patients, more
tubules lacking collagen I expression were observed. An altered expression pat-
tern was also observed for collagen IV. No difference in blood vessel area and
vessel density was observed in adult testicular sections from controls, SCO and
KS patients and in peripubertal sections from KS patients. However, a higher
vessel density was observed in prepubertal KS patients. When vessels were
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divided according to their size, more small blood vessels were present in these
prepubertal patients.
Limitations, reasons for caution: These data are descriptive. It is not pos-
sible to draw causal conclusions from the stainings.
Wider implications of the ﬁndings: More research is necessary to identify
causes of testicular ﬁbrosis in KS patients. If the mechanism behind this ﬁbrotic
process could be identiﬁed, this process could be inhibited to increase chances
of fertility in KS patients.
Trial registration number: not applicable.
O-129 A heterozygous DNAJB13 mutation induces multiple
morphological and structural abnormalities to the sperm ﬂagella
(MMSAF) andmay be a cause of idiopathic asthenozoospermia
L.Weina1, Z. Li2, J. Miaomiao3, S. Lin4, L. Guangxiu4,5, L. Gang4,6
1Reproductive & Genetics Hospital CITIC-XIANGYA, Andrology Laboratory,
Changsha, China
2The Xiangtan central hospital, Reproductive center, Xiangtan, China
3Shanxi Provincial maternal and child health care hospital, Reproductive center,
Xi’an, China
4Central South University, Institute of Reproduction and Stem Cell Engineering,
Changsha, China
5Reproductive & Genetics Hospital CITIC-XIANGYA, Reproductive center, Changsha,
China
6Reproductive & Genetics Hospital CITIC-XIANGYA, Clinical Laboratory, Changsha,
China
Study question: Does a novel heterozygous DNAJB13 mutation, identiﬁed in
9 out of 92 idiopathic asthenozoospermia patients affect multiple male
infertility-related genes and cause low sperm activity?
Summary answer: A heterozygous mutation c.106 T>C(p.Ser36Pro) of
DNAJB13was demonstrated to exhibit defects in sperm motility and affect mul-
tiple morphological and structural abnormalities to the sperm ﬂagella (MMSAF).
What is known already: Dnajb13, which is upregulated in cryptorchidism
mouse models and is highly expressed in the testis, encodes a member of the
heat shock protein 40 co-chaperone family (types II). Homozygous mutant
mice died before sexual maturation. However, no mutations of DNAJB13
(NM_153614.2) have been reported in patients with idiopathic
asthenozoospermia.
Study design, size, duration: This genetic study used Medical Exome micro-
arrays and Sanger sequencing to discover related-genes mutations, and was fol-
lowed by a series of studies to investigate mutant protein function. Altogether,
92 idiopathic asthenozoospermia patients and 200 fertile men from the Hunan
human sperm bank from 2010-2013 in China were screened for DNAJB13
mutations.
Participants/materials, setting, methods: Patients and fertile men were
recruited from our hospital in China. Genomic DNA samples from the indivi-
duals were extracted from peripheral blood. A proband was subjected to
Medical Exome microarrays to identify mutations. Mutational analysis in the 92
idiopathic asthenozoospermia patients and 200 fertile men were performed.
Identiﬁed DNAJB13 mutations were further investigated using bioinformatics,
indirect immunoﬂuorescence assay, papanicolaou staining, CASA, immuno-
electron microscopy, Co-IP assays, transmission electron microscopy, iTRAQ,
and multiple reaction monitoring studies.
Main results and the role of chance: We identiﬁed a heterozygous muta-
tion c.106 T>C, p.Ser36Pro in DNAJB13 in 9 (10%) idiopathic asthenozoosper-
mia patients. We failed to ﬁnd this mutation in the 200 fertile control men.
Furthermore, using papanicolaou staining, CASA analysis and sperm functional
tests, we found that spermatozoa with DNAJB13 mutations had more deform-
ities, i.e. vacuolus in the head and excessive residual cytoplasm, inﬂexible mid-
piece and asymmetric beating ﬂagellum, and abnormal sperm acrosome
reaction compared with the control group and patients without the mutation.
Immuno-electron microscopy was carried out to observe ultrastructural mul-
tiple morphological and structural abnormalities of the sperm ﬂagella (MMSAF)
due to DNAJB13 mutations. iTRAQ and multiple reaction monitoring studies
were used to analyze the changes of multiple asthenozoospermia related pro-
teins, spermatozoa structural proteins—NME5, RSPH9, sperm-egg binding and
fusion proteins—SPESP1, and energy metabolism proteins—HK1 proteins.
These proteins were signiﬁcantly decreased in spermatozoa of idiopathic asthe-
nozoospermia patients with DNAJB13mutations.
This study indicates that DNAJB13 may be involved in spermatogenesis and
sperm motility and a cause of idiopathic asthenozoospermia.
Limitations, reasons for caution: Although our in vitro assays demonstrated
the effect of the DNAJB13 mutation on sperm motility in structure and function
level, further studies are needed to validate the in vivo effects of DNAJB13
mutation.
Wider implications of the ﬁndings: This ﬁnding further expands the spec-
trum of known genetic defects associated with asthenozoospermia and pro-
vides researchers and clinicians a better understanding of the etiology and
molecular mechanism of asthenozoospermia.
Trial registration number:Not applicable.
O-130 Defective H3K9 demethylation of the male genome and
abnormal ﬁrst mitosis observed in mouse oocytes injected with
human round spermatids
Y. Kai1, K. Nakata2, J. Ito3, N. Kashiwazaki3, N. Yamashita2, Y. Mio1
1Mio Fertility Clinic, Fertility Research Centre, Yonago, Japan
2Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center-, Fujisawa,
Japan
3Azabu University, Department of Animal Science & Biotechnology School of
Veterinary Medicine, Sagamihara, Japan
Study question: Does round spermatid injection (ROSI) contribute to normal
embryo development in assisted reproductive technology?
Summary answer: ROSI tended to cause failure of H3K9 demethylation of
the male genome, formation of male pronuclei, and chromosome segregation
at the ﬁrst mitosis.
What is known already: ROSI-derived embryos are prone to exhibit abnor-
mal chromosome segregation and epigenetic abnormalities in animals. Indeed,
developmental efﬁciency is signiﬁcantly lower with ROSI than with intracyto-
plasmic sperm injection (ICSI), not only in animals, but also in humans. Despite
views to the contrary, ROSI is still an option for assisted fertilization in animals
and humans.
Study design, size, duration: This study was approved by the ethical com-
mittee of JISART (Japanese Institution for Standardizing Assisted Reproductive
Technology) and was registered with the Japan Society of Obstetrics and
Gynecology. ROSI and ICSI were conducted by injection of human round sper-
matids or spermatozoa into mouse MII oocytes. DNA/histone methylation sta-
tus, pronuclear formation and chromosome segregation were analyzed
statically and/or dynamically from injection to the ﬁrst cleavage by immuno-
ﬂuorescence and ﬂuorescence live cell imaging analysis.
Participants/materials, setting, methods: Human male gametes were
obtained after donation and ethical approval. Round spermatids were obtained
from 13 patients with non-obstructive azoospermia after testicular sperm
extraction. MII oocytes were collected from 8-week-old B6D2F1 mice and pre-
activated by CZB medium containing 7.5 mM SrCl2 without Ca
2+ for ROSI.
Immunoﬂuorescence was performed using antibodies against 5mC, 5hmC and
H3K9me3. Live cell imaging was performed using TagGFP2-H2B mRNA and
ﬂuorescent-labeled Fab313, which can react with H3S10ph next to H3K9me3.
Main results and the role of chance: Firstly, immunoﬂuorescence was per-
formed using ROSI- and ICSI-derived two-pronuclear (2PN) zygotes in order to
analyze the DNA/histone methylation status. Analysis of DNA methylation sta-
tus targeting 5mC and 5hmC revealed that all ROSI-derived zygotes (n = 10)
showed conversion of 5mC to 5hmC in the male pronucleus, as in ICSI-derived
zygotes (n = 5), but analysis of histone methylation status targeting H3K9me3
revealed that all ROSI-derived zygotes (n = 10) retained H3K9me3 in the male
pronucleus, unlike ICSI-derived zygotes (n = 7). Fluorescence live cell imaging
analysis visualizing histone H2B and H3S10ph also revealed that the male gen-
ome was positive for H3K9me3 in oocytes after ROSI (n = 89), but not after
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ICSI (n = 17). Failure of male pronucleus formation was observed in 84.3% of
oocytes after ROSI. The 2PN fertilization rate of ROSI was low in comparison
with ICSI (15.7% vs. 82.4%) and 35.7% of ROSI-derived 2PN zygotes showed
distorted male pronuclei not seen with ICSI. Furthermore, half of the ROSI-
derived 2PN zygotes showed aberrant chromosome congression at the ﬁrst
mitosis leading to aberrant chromosome segregation.
Limitations, reasons for caution: Our results came from cross-species fer-
tilization and from the limited period until ﬁrst mitosis, for ethical reasons.
Although we have conﬁrmed that oocyte pre-activation does not differ with
SrCl2 or phospholipase C-zeta cRNA injection in mouse ROSI, phospholipase
C-zeta cRNA injection was not tested in this study.
Wider implications of the ﬁndings: Defective demethylation of H3K9 in
the male genome and poor developmental ability in ROSI might arise from
incomplete protamine-histone replacement. Histone modiﬁcation could be a
key factor to utilize round spermatids in the clinical setting.
Trial registration number:Not applicable.
O-131 SPANXA/D subfamily plays a key role in nuclear
organisation, metabolism and ﬂagellar-motility of human
spermatozoa
I. Urizar Arenaza1, N. Osinalde2, V. Akimov3, I. Muñoa-Hoyos1,
M. Gianzo1, T. Ganzabal4, J. Irazusta1, N. Subirán*1,
I. Kratchmarova*3
1University of the Basque Country UPV/EHU, Physiology, Leioa, Spain
2University of the Basque Country UPV/EHU, Biochemistry and Molecular Biology,
Vitoria-Gasteiz, Spain
3University of Southern Denmark Syddansk Universitet, Biochemistry and Molecular
Biology, Odense, Denmark
4Unidad de Reproducción Asistida Quirón, Quirón Bilbao, Bilbao, Spain
Study question: Which is the physiological function of endogenous SPANX
A/D subfamily in human spermatozoa?
Summary answer: Quantitative proteomics reveals that SPANX A/D may
play a role in nuclear organisation, mitochondrial metabolism and cilium-
movement of human spermatozoa by interacting with 307 proteins.
What is known already: SPANX (Sperm Protein Associated with the
Nucleus mapped to the X chromosome) multigene protein family is considered
a Cancer Testis Antigen (CTA) whose expression is limited to the testis and
spermatozoa in normal tissues, but also to a wide variety of tumors in non-
gametic cells. This family includes two subfamilies, SPANX N and SPANX A/D.
Although, the physiological function of the whole protein family is completely
unknown, the low expression of SPANX A/D subfamily is related with asthe-
nozoospermia and globozoospermia, and hence with a lower fertility in human
spermatozoa.
Study design, size, duration: We followed a label free quantitative proteo-
mics approach, in quadruplicate, to uncover the interactome of SPANX A/D
subfamily in human spermatozoa. Additionally, a number of techniques in
molecular biology were used to analyse the expression and subcellular localiza-
tion of SPANX A/D in human spermatozoa.
Participants/materials, setting, methods: We used human normozoos-
permic seminal samples coming from the Quirón Bilbao fertility clinic. MS-based
interactome study was carried out by immunoprecipitating endogenous
SPANX A/D and subsequently, analyzing by a Q Exactive Mass spectrometer
at the University of Southern Denmark (Odense, DK). MS raw ﬁles were pro-
cessed with MaxQuant software v1.3.0.7, and output data was analyzed in
Perseus bioinformatics analysis program. The same SPANX antibody was used
to performWestern Blotting and immunoﬂurescence experiments.
Main results and the role of chance: We have described the presence of
SPANX A/D subfamily in normozoospermic human spermatozoa, in both sol-
uble and insoluble protein fractions, by immunobloting approaches.
Immunoﬂuoresce assays also show a strong immunoreactivity of SPANX A/D
in the middle section, tail, acrosome and nuclear craters of human spermato-
zoa. Indeed, label-free proteomics data conﬁrms that SPANX isoforms A, B, C
and D are expressed in human male germ cells. Additionally, the MS-based
interactome study carried out reveals a list of 307 potential interactors of
endogenous SPANX A/D. According to gene ontology analysis, these interact-
ing partners are involved in a wide range of key functions for the human
spermatozoa, including the nuclear pore organization, the cilium- or ﬂagellum-
dependent motility, the assembly of the axonemal dynein complex, the mito-
chondrial electron transport and oxidative phosphorylation. This outcome is in
line with the data obtained by immunocytochemistry indicating that SPANX is
localized in different compartments of the cell.
Limitations, reasons for caution: Further studies are needed to validate
the most intense SPANX interactors by accomplishing different molecular tech-
niques. This information could help us to ratify the physiological role of SPANX
A-D family in human spermatozoa.
Wider implications of the ﬁndings: A better understanding of the physio-
logical function of SPANX in fertility may be useful to detect new therapeutic
targets for treating infertility, as well as to develop safer polyvalent sperm con-
traceptives. Moreover, it could be essential to have a better understanding of
the physiopathological mechanisms of this CTA in cancer.
Trial registration number: CEISH/61/2011.
O-132 Copr5is associated with Miwi and modulated the piRNA
pathway, a possible mechanism involved in the human
teratozoospermia sperm phenotype
C. Innocenti1, E. Fabbrizio2, D. Haouzi3, C. Sardet2, S. Hamamah4
1INSERM U1203, Hôpital St Eloi, MONTPELLIER, France
2Université Montpellier-Institut de Recherche en Cancérologie de Montpellier, Inserm-
U1194- Campus Val d’Aurelle, Montpellier, France
3Inserm U1203- IRMB, Hôpital St-Eloi- CHU Montpellier, Montpellier, France
4Service de Biologie de la Reproduction- Hôpital Arnaud de Villeneuve- CHU
Montpellier, ART/PGD Department, Montpellier, France
Study question: Is the Prmt5-associated factor Copr5 involved in the piRNA
pathway during spermatogenesis?
Summary answer: Copr5 silencing in mice affects spermatogenesis and low
level of Copr5 mRNA correlates with human teratozoospermia sperm.
What is known already: Protein arginine methyl transferase 5 (Prmt5) was
implicated in genome defense in primordial germ cells (PGCs) via a PRMT5-
dependent methylation of the Piwi protein family that participates within the
piRNA pathway in promoting transposon silencing. However, the role of the
Prmt-5 and histone-associated protein Copr5 in the regulation of the piRNA
pathway remains unknown.
Study design, size, duration: Testes from Copr5 Knock-out (KO) mice and
wild type (WT) (n = 3 per group) were used for immunoprecipitation, western
blot analyses, immunhistochemistry (IHC) and RTqPCR experiments. Ten
human sperm samples were collected from patients with normozoospermia
(n = 3) and teratozoospermia (n = 7) for RTqPCR experiments.
Participants/materials, setting, methods: Proteins, total RNA and
parafﬁn-embedded testis sections were extracted and/or prepared from the
Copr5 KO and WT mice. 200 μl of each semen were used for total RNA
extraction using the miRNeasy serum/plasma kit (Qiagen).
Main results and the role of chance: Prmt5- and histone-associated pro-
tein Copr5 is highly expressed intestis and its depletion impacted on the matur-
ation of spermatogonia to spermatids, although Copr5 KO animals were fertile.
Extinction of Copr5 in mice testis leads to a down-regulation of the level of
Miwi protein, as conﬁrmed by western blot analyses and immunohistochemistry
of WT and KO mice testis whole cell extracts and parafﬁn-embedded testis
sections, respectively. In addition, the mRNA level of three pre-pachytene
piRNAs, prepiR1, prepiR2 and prepiR3 was decreased in KO Copr5 compared
to WTmice, whereas in KO mice the expression level of the LINE1 mRNA, the
most abundant retro-transposons that was usedas a read out of deregulation of
the piRNA pathway, was increased. Using both human GEO data and patients
with teratozoospermia, the present study reports a correlation between a low
level of Copr5 mRNA and teratozoospermia, a human pathology characterized
by abnormally shaped sperm that can negatively affect fertility.
Limitations, reasons for caution: Further investigation is needed to know
whetherthe absence of Copr5 in mice might molecularly impact more strongly
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on the piRNA pathway over generation and render mice unfertile, thus phenco-
pying the human pathology.
Wider implications of the ﬁndings: Copr5 KO in mice perturbed some
genome surveillance mechanisms in germ cells by an alteration of the expres-
sion level of two major components present in the Piwi-interacting RNA
(piRNA) pathway, the Miwi and the LINE1.
Trial registration number:Not applicable
SELECTEDORAL COMMUNICATIONS
SESSION 36: IVF LABORATORY TECHNIQUES AND
MANAGEMENT
Tuesday 3 July 2018 Room 117 10:00–11:30
O-133 A two-step protocol for oocyte In Vitro Maturation in PCO/
PCOS patients increases the yield and quality of usable embryos and
results in ongoing pregnancies
F. Sanchez1, S. Romero1, A.H. Le2, F. Lolicato1, H. Van Ranst1,
T.M. Ho2, J. Smitz1, L.N. Vuong2,3
1Vrije Universiteit Brussel, EMGE-FOBI Follicle Biology laboratory, Brussels, Belgium
2My Duc Hospital, Ivfmd, Ho Chi Minh City, Vietnam
3University of Medicine and Pharmacy at Ho Chi Minh City, Department of
Obstetrics and Gynecology, Ho Chi Minh City, Vietnam
Study question: What is the effectiveness of a two-step IVM protocol
(CAPA-IVM) involving a pre-maturation culture with C-type natriuretic peptide
(CNP) versus Standard IVM in PCO/PCOS patients?
Summary answer: Pre-maturation with CNP followed by IVM (CAPA-IVM)
increased the yield and quality of usable embryos resulting in a high ongoing
pregnancy rate from ﬁrst transfer.
What is known already: Oocyte In Vitro Maturation (IVM) is a valuable
woman-friendly assisted reproductive technology, especially suited for patients
presenting polycystic ovaries or Polycystic ovary syndrome (PCO/PCOS).
Since IVM makes use of oocytes obtained from small antral follicles (2-12 mm
diameter), embryological and clinical outcomes were proven to be reasonably
inferior to conventional stimulated IVF (ICSI) techniques.
A novel two-step IVM system (termed CAPA-IVM) using FSH priming but
omitting hCG administration has recently been translated from mouse to
human in a pilot study using sibling oocytes, indicating superior results.
This study further explores the embryological and clinical advantages of using
CAPA-IVM in PCO/PCOS patients.
Study design, size, duration: This prospective randomised controlled pilot
study includes PCO/PCOS patients (Rotterdam criteria, 2004), 24-36 years
old, BMI ≤30, without previous history of recurrent failure of ART (including
recurrent miscarriages). Enrolments took place between March and June 2017.
Patients were randomly allocated to two protocols: CAPA-IVM and Standard
IVM, via block randomization with block size of 4. Sample size was 40 (20 each
group).
Routine hormonal analyses included AMH, FSH, LH, estradiol and
progesterone.
Participants/materials, setting, methods: Patients received 3 doses of
rFSH 150IU daily, starting on day 1 or 3 after bleeding. Oocyte retrieval was
planned on day 5 to 8 without a prior hCG trigger.
The pre-maturation culture lasted 24 h whereas IVM lasted 30-32 h. The pri-
mary outcome was the yield of usable (vitriﬁed) Day 3 embryos, per patient.
Secondary outcomes were oocyte maturation, fertilization and good quality
embryo rates. A maximum of 2 embryos were transferred in a deferred cycle.
Main results and the role of chance: Mean age (28.9), BMI (21.2) and
AMH (10.8 μg/L) were not different among patients allocated to any of the
IVM protocols. Baseline values for FSH and LH were 5.82 ± 1.58 IU/L and
12.65 ± 6.12 IU/L, respectively.
The MII (maturation) rate was signiﬁcantly higher in CAPA-IVM vs Standard
IVM (60.4 ± 15.3% vs 50.8 ± 20.8%; P = 0.0454). Rates of fertilization per
mature oocyte and usable embryos per fertilized oocyte were similar among
the groups. However, there was a signiﬁcant increase (1.8-fold higher) in the
mean number of usable embryos (per patient), in CAPA-IVM vs Standard IVM
(3.9 ± 2.6 vs 2.2 ± 1; P = 0.0061).
Moreover, the rates of good quality embryos (grades 1 and 2) per fertilized
oocyte, mature oocyte or cumulus-oocyte-complex (COC), were signiﬁcantly
higher in CAPA-IVM vs Standard IVM (48.9 ± 22.8 vs 36.2 ± 23.2%,
P = 0.0248; 43.2 ± 23.4% vs 30.8 ± 22.6%, P = 0.0257; and 27.2 ± 15.3 vs
15.1 ± 12.9%, P = 0.002; respectively).
The ongoing pregnancy rate (per transfer) is currently 52.6% and 36.8%
(CAPA-IVM and Standard IVM, respectively). No signiﬁcant differences have
been yet recorded, since ongoing pregnancies are still in follow-up.
Limitations, reasons for caution: Although patients were randomly
assigned to either of the IVM protocols, the patient population is still small.
Nevertheless, the results with CAPA-IVM in Vietnamese patients are concord-
ant with those previously reported in Belgian patients and published earlier,
showing transferability of the CAPA-IVM method.
Wider implications of the ﬁndings: This study reports the ﬁrst pregnancies
of CAPA-IVM. The signiﬁcant increase in oocyte maturation, number of usable
embryos and embryo quality by the two-step IVM protocol in this prospective
randomized controlled pilot study suggests that IVM could be positioned as one
of the routine assisted reproductive techniques for PCOS patients.
Trial registration number: not applicable.
O-134 Assisted oocyte activation signiﬁcantly increases
fertilization and pregnancy rates resulting in healthy live births in
patients with oocyte activation deﬁciencies
D. Bonte, L. Dhaenens, M. Ferrer-Buitrago, S. De Gheselle, I. De
Croo, K. Tilleman, P. De Sutter, B. Heindryckx
Ghent University Hospital Ghent Fertility and Stem cell Team, Reproductive
Medicine, Gent, Belgium
Study question: To what extent does assisted oocyte activation (AOA)
improve fertilization and pregnancy outcome in patients diagnosed with oocyte
activation deﬁciencies (OADs)?
Summary answer: AOA signiﬁcantly increased fertilization and pregnancy
rates and resulted in healthy live births in patients with a history of low or failed
fertilization after ICSI.
What is known already: Whether AOA is effective in couples with low or
failed fertilization after ICSI remains controversial. This is mainly due to the fact
that most clinics applying AOA do not investigate whether the origin of OAD is
attributed to sperm- or oocyte-related factors; information that is important
for counseling couples about future treatment options. The Mouse Oocyte
Activation Test (MOAT) is one diagnostic method to discern the gamete origin
of failed fertilization. To date, large-scale studies assessing the efﬁciency of
AOA in patients experiencing failed fertilization after ICSI and undergoing a
diagnostic test to reveal the origin of OAD, are lacking.
Study design, size, duration: A retrospective analysis was performed,
involving 167 AOA cycles (April 2001 to July 2017) of 105 men with low or
failed fertilization after ICSI for whom sperm activation capacity was examined
by MOAT prior to the subsequent AOA cycle(s). The AOA efﬁciency in terms
of fertilization and pregnancy rate and neonatal outcome was investigated
according to the MOAT result and compared to 207 previous conventional
ICSI cycles of these couples.
Participants/materials, setting, methods: For MOAT, mature mouse
oocytes (B6D2F1, 7-12 weeks) were injected with patients’ spermatozoa.
Depending on the percentage of activated oocytes next day, patients were
categorized in MOAT group 1 (0-20% activation), 2 (21-84% activation) or 3
(85-100% activation) and compared to a positive fertile control. For AOA treat-
ment, mature patients’ oocytes were injected with patients’ spermatozoa along
with CaCl2 (0.1 M), followed by a two-fold exposure to ionomycin (10 μM,
10 min) with a 30 minute time interval.
Main results and the role of chance: MOAT revealed 18 patients with a
sperm-related OAD (MOAT group 1), 49 patients with a diminished oocyte
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activation capacity of the sperm (MOAT group 2) and 38 patients with a pre-
sumably oocyte-related OAD (MOAT group 3). AOA treatment signiﬁcantly
improved fertilization rates: MOAT group 1: 69.69% for 34 AOA cycles versus
10.53% in 19 prior ICSI cycles, MOAT group 2: 62.54% (76 cycles) versus
14.21% (123 cycles), MOAT group 3: 58.26% (57 cycles) versus 17.18% (65
cycles) (p < 0.001). Moreover, signiﬁcantly higher pregnancy rates were
observed after AOA treatment compared to previous ICSI cycles, in MOAT
group 1 (46.94% versus 0.00%), 2 (34.88% versus 6.35%), and 3 (29.03% versus
6.25%) patients (p < 0.05). Interestingly, AOA results for MOAT group 1
tended to be better than for MOAT group 3 in terms of fertilization rates
(69.69% versus 58.26% respectively, p < 0.05) and pregnancy rates (46.94%
versus 29.03% respectively, p = 0.05). In total, 52 healthy children were born
(28 boys and 24 girls): 19 singletons in MOAT group 1, 13 singletons and 3
twins in MOAT group 2, and 12 singletons and 1 twin in MOAT group 3.
Limitations, reasons for caution: As AOA technology is still considered
experimental, its application is thus best reserved for those cases where there
is a clear indication of an OAD. To date, our results demonstrate that AOA
seems to be a safe and effective technique. However, further follow-up of chil-
dren born after AOA is warranted.
Wider implications of the ﬁndings: Our large cohort study shows that in
cases with OAD, AOA restores fertilization and pregnancy rates to a satisfac-
tory level. More sensitive tests (e.g. calcium pattern analysis) will aid to further
distinguish those cases that are likely to beneﬁt from AOA, and additionally
guide further clinical management of these patients.
Trial registration number: not applicable.
O-135 Three babies born after pronuclear transplantation in
young women with unexplained infertility and repeated
implantation failure of euploid embryos
P. Mazur1, V. Veselovsky2, Y. Masliy2, M. Borisov2, D. Mykytenko3,
V. Zukin4
1Clinic of Reproductive Medicine ‘NADIYA’, Embryology, Kyiv, Ukraine
2Clinic of Reproductive Medicine ‘NADIYA’, Obstetrics and gynaecology, Kyiv,
Ukraine
3Clinic of Reproductive Medicine ‘NADIYA’, Genetics, Kyiv, Ukraine
4Clinic of Reproductive Medicine ‘NADIYA’, Management, Kyiv, Ukraine
Study question: Can pronuclear transplantation (PNT) be applied to women
with unexplained infertility and repeated implantation failure?
Summary answer: Three healthy babies born after PNT in a group of ﬁve
women <37 years old, who were unable to conceive using repeated cycles of
ART.
What is known already: Using nuclear transplantation or whole cytoplasm
replacement in humans is an experimental approach which avoids transmission
of mitochondrial disease. Concerns have been raised about these procedures
and particularly about later expression of potentially affected mitochondria and
the potential of nuclear-cytoplasmic incompatibility. PNT resulted in a single
ongoing twin pregnancy in 2003 for a patient with recurrent embryo arrest, but
this did not result in live birth. Maternal spindle transfer for prevention of Leigh
syndrome resulted in the ﬁrst delivery of a healthy boy in 2016.
Study design, size, duration: The study period was from September 2015
to January 2018. Patients were informed and consent to possible risks and the
experimental protocol was approved by ethics committee of Ukrainian associ-
ation of reproductive medicine. Inclusion criteria were: (1) no less than two
failed previous IVF attempts with embryo arrest, (2) low blastulation rates, (3)
recurrent implantation failure of euploid embryos; (4) age ≤ 37 years, normal
ovarian reserve, absence of endometrial or uterus factor of infertility.
Participants/materials, setting, methods: Oocyte retrievals for ﬁve infer-
tile women (from 29 to 34 years of age) were synchronized with donors;
thawed donor oocytes were used in a case of patient’s oocytes excess. ICSI
with patient’s partner’s sperm had been performed simultaneously for all
oocytes. PNT, assisted by HVJ-E cell fusion kit, was applied at ~12 h after fertil-
ization. Reconstituted zygotes were cultured until blastocyst stage in time-lapse
incubator and biopsied for aCGH or NGS analysis.
Main results and the role of chance: Overall, 36 zygotes from 43 patient’s
zygotes (84%) were successfully reconstituted, that resulted in 19 blastocysts
(53%); 14 were euploid (74%). Elective single embryo transfer (eSET) of thawed
embryos was done for each patient. Positive hCG levels (> 100 mIU/mL) were
conﬁrmed in 4/5 patients after the ﬁrst try. In two patients amniocentesis was
performed at 17 weeks of gestation to conﬁrm successful cytoplasm replace-
ment by an independent laboratory. The third patient refused amniocentesis;
however, donated umbilical cord blood after she gave birth. For two cases the
result was: “None of the variants of the biological mother and all mitochondrial
variants of the donor were detected in the fetus” and for the third one it was:
“The majority of mitochondrial variants detected in the child are shared with
the mitochondrial donor and not with its biological mother”. First baby girl was
born on 5th of January 2017 through vaginal delivery and a second baby boy
was born on 19th of February 2017; third baby boy was born on 15th of
October 2017 by Caesarean section. The three children performed well in
pediatric analyses. The fourth case was at an early stage of development at the
moment of abstract submission.
Limitations, reasons for caution: Since, nuclear transplantation in human is
still experimental and highly controversial; further investigations and long term
follow up of children is required. The number of patients included into study is
low; any broad conclusions may be premature. Patients above 37 years of age
may not beneﬁt from PNT.
Wider implications of the ﬁndings: Not only mitochondrial diseases, but a
rare condition named preimplantation embryonic lethality (embryo arrest)
could possibly be overcome by pronuclear transplantation. This experimental
technique may be used as an assessment tool to study nuclear-cytoplasmic
interactions.
Trial registration number:Not applicable.
O-136 Blastocysts collapse as an embryomarker of low
implantation potential a time-lapse study
R. Herrer Saura1, R. Sciorio2, M. Esbert3, S.J. Pickering2,
J.K. Thong2, M. Meseguer4
1IVI Zaragoza, IVF laboratory, Zaragoza, Spain
2Edinburgh Fertility Reproductive Center- Royal Inﬁrmary Edinburgh., IVF laboratory,
Edinburgh, United Kingdom
3IVI Barcelona, IVF laboratory, Barcelona, Spain
4IVI Valencia, IVF Laboratory, Valencia, Spain
Study question: To validate the relationship between blastocyst collapse and
implantation potential in in vitro human embryo culture using Time-Lapse
technology.
Summary answer: Blastocysts showing a severe collapse during development
are less likely to implant and generate a viable pregnancy compared with
embryos which do not show collapse.
What is known already: The process of hatching in mammalian embryo,
involving the escape of the blastocyst from the zona pellucida (ZP) was ﬁrst
observed by Lewis and Gregory in 1929. Whether blastocyst collapse could be
a novel marker of embryo quality, and correlated with outcome of ICSI/IVF
cycles, should be demonstrated in an independent dataset of embryos. This
study investigated the correlation between blastocyst collapse and pregnancy
and implantation rates following elective single transfer at blastocyst stage
(eSET).
Study design, size, duration: This is a retrospective multicenter analysis,
carried out between January 2016 and February 2017. Four IVF units participate
to the study: EFREC, RIE, Edinburgh, UK, IVI Valencia, IVI Barcelona and IVI
Zaragoza in Spain. Blastocyst were analysed by measuring the maximum volume
reduction during development and deﬁned as having collapsed if there was
≥50% of the surface of the TE was separated from the ZP.
Participants/materials, setting, methods: The study included 1297 ICSI/
IVF cycles having an eSET on day 5. Embryos were cultured individually in an
EmbryoSlide™, using an EmbryoScope™ imaging system in 6% CO2, 5% O2,
89% N2. Morphological assessment was made by examining a video of develop-
ment using the associated EmbryoViewer software. Following embryo transfer,
blastocyst was retrospectively allocated to one of two groups (collapsed or not
collapsed). Pregnancy and implantation rates were analysed.
Main results and the role of chance: A total of 1297 cycles were analyzed.
259 blastocysts collapsed once or more during development (19.9%) and the
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remaining 1038 either contracted minimally or neither contracted nor collapsed
during development (80.1%). A signiﬁcantly higher ongoing pregnancy rate of
51.9% (CI95% 48.9%-59.9%) was observed when blastocysts which had not
collapsed during development were replaced compared to cycles in which col-
lapsed blastocysts were transferred 37.5% (CI95% 31.6%-43.4%). A multivari-
able logistic regression analysis revealed an ongoing pregnancy 1.78 (1.33-2.40)
OR, and the stratiﬁed study demonstrated that blastocyst collapse is mainly
affecting implantation potential on good quality embryos.
Limitations, reasons for caution: Live birth rates should also be investi-
gated to see if there is a difference in ﬁnal outcome between the groups.
Wider implications of the ﬁndings: The pattern of blastocyst collapse
could improve IVF/ICSI outcome following eSET at blastocyst stage. Therefore,
it could be used as a negative marker for embryo selection.
Trial registration number: not applicable.
O-137 The impact of dry incubation on osmolality of media in
time-lapse culture dishes
G. Carpenter, E. Hammond, J. Peek, D.E. Morbeck
Fertility Associates, Embryology, Auckland, New Zealand
Study question: Does continuous culture in a dry incubator lead to an
increase in culture medium osmolality that is affected by the type of time-lapse
dish used?
Summary answer: Osmolality increased for all tested time-lapse dishes, with
a greater effect for Primovision, Miri-TL and standard microdrop culture com-
pared to Embryoscope dishes.
What is known already: Osmolality of culture media is critical for optimal
embryo development with high osmolality having adverse effects. Osmolality of
culture media is affected by factors such as humidity, temperature, dish prepar-
ation method and media droplet volume. Compared to humidiﬁed incubation,
negative effects of dry incubation on human embryo development have been
observed. However, the use of dry incubators is becoming increasingly com-
mon due to advantages of time-lapse continuous culture. Different time-lapse
systems use different dishes with various media to oil surface ratios, which may
alter the effect of dry incubation on osmolality.
Study design, size, duration: Changes in osmolality were measured in four
culture dishes over 7 days in a dry incubator (Miri-TL). The cultures dishes
were: Miri-TL culture coin (MTL), Vitrolife EmbryoSlide (ES), and Primovision
dish (PV), with a Vitrolife Micro-Droplet dish (MD) as the control. The study
was repeated three times. Osmolality was determined in duplicate at days 0, 3,
5 and 7 of culture. The impact of oil depth on osmolality was also studied for
standard MD dishes.
Participants/materials, setting, methods: Dishes were prepared with
protein supplemented media and oil. For MD dishes, the impact of 3, 5 or 7 mL
oil overlay was determined over 5 days. The time-lapse dishes were prepared
as per manufacturer. MD dishes had 20 uL microdroplets under 5 mL of oil. For
each condition, osmolality was tested on a 10 uL sample using a VAPRO
osmometer. Relative changes in osmolality were assessed (ANOVA) and
means were compared using Tukey’s HSD.
Main results and the role of chance: Culture media osmolality was affected
by oil depth, with a 3 mL oil overlay resulting in the highest osmolality compared
to either 5 or 7 mL. For time-lapse dishes, osmolality increased as the culture
continued over 7 days in the dry incubator. From a starting osmolality of 258
mOsm, media osmolality in MD, MTL and PV increased similarly over 7 days of
culture, but for ES dishes, the increase in osmolality occurred to a lesser extent,
showing that the ES condition was less prone to increasing osmolality during a 7
day dry incubation. For MD, MTL, PV and ES dishes, osmolality increased,
respectively, by 26.9, 23.7, 20.3 and 12.2 mOsm on day 3, 42.3, 42.5, 38.5 and
27.7 mOsm on day 5, and 53.5, 50.4, 57.3 and 33.2 mOsm on day 7. ES osmo-
lality was lower than the control MD dish on day 3 (p < 0.05), both MD and
MTL on day 5 (p < 0.05) and all dishes on day 7 (p < 0.01), showing that the ES
condition had the greatest ability to prevent media evaporation, resulting in
slower osmolality rise over 7 days of culture during dry incubation.
Limitations, reasons for caution: This study was performed using a MiriTL
bench top incubator; therefore the results may not be applicable to other dry
incubators. Osmolality increased in all dishes and the impact of these increases
on human embryo development is unknown.
Wider implications of the ﬁndings: The osmolality of culture media
increased with dry incubation despite oil overlay in various dishes, an increase
that was dish dependent. The ES dish, which uses deep culture wells that results
in the lowest ratio of culture medium surface area to oil, had the lowest amount
of media evaporation.
Trial registration number:Not applicable.
O-138 Utility of the Vienna consensus on ART Laboratory
Performance Indicators for managing multiple IVF laboratories
performance
G.H. Trew1, S. Nelson2
1The Fertility Partnership, IVF, London, United Kingdom
2University of Glasgow, School of Medicine, Glasgow, United Kingdom
Study question: Is the Vienna consensus on Laboratory Performance
Indicators useful in standardising performance and setting benchmarks across a
commercial group of IVF clinics?
Summary answer: The Vienna consensus facilitates a uniform reporting plat-
form, however, with the focus on extended embryo culture Day 2 embryo
development rates are less relevant.
What is known already: Laboratory performance indicators are critical for
managing laboratory quality control. Ensuring reproducible laboratory out-
comes across a growing commercial group of IVF clinics is essential, with agreed
outcomes and benchmarks conventionally set in house. The Vienna consensus,
sets 19 indicators including 12 key performance indicators (KPIs), ﬁve perform-
ance indicators (PIs) and two reference indicators (RIs) with internationally
agreed deﬁnitions, competence levels and aspirational benchmark values.
Study design, size, duration: Prospective cohort study of seven IVF clinic
performing 2418 fresh and 1300 frozen cycles between 1 January to 30 June
and nine IVF clinics performing 1799 fresh cycles and 1005 frozen transfer from
1 July to 31 October 2017.
Participants/materials, setting, methods: Nine IVF clinics in the United
Kingdom and Poland. Comprehensive data collection using IDEAS software
platform, with centralised analysis of clinic performance in accordance with the
19 laboratory indicators and associated competence and aspirational bench-
mark values described in the Vienna consensus.
Main results and the role of chance: Of the 19 indicators, 18 were rou-
tinely recorded with day 2 embryo development rate not collected by any cen-
tre due to extended embryo culture systems. For the 18 different measures,
different laboratories were able to achieve each of the predetermined compe-
tence values with only blastocyst survival (competence >90%) attained by all
laboratories (range 91.2 to 100%). However, no laboratory achieved all compe-
tency values. Despite overall high clinical pregnancy rates exceeding national
averages (47.2% per embryo transfer for fresh and 58.2% for frozen), the high-
est performing laboratory only achieved 12 of the 18 competency values. The
clinic with the lowest compliance attained only four competencies, despite
achieving clinical pregnancy and live birth rates in accordance with the Human
Fertilisation and Embryology Authority limits. The aspirational benchmarks for
ICSI fertilisation rate (≥80%), IVF fertilisation rate (≥75%) and blastocyst devel-
opment rates (≥35%) were not achieved by any clinics with the highest
observed rates being 78.0%, 73.7% and 59.5% respectively.
Limitations, reasons for caution: Patient characteristics were not taken
into account with summary data used for each clinic, adjustment for confoun-
ders is likely to enable more accurate identiﬁcation of clinical and laboratory
issues. The aspirational benchmarks may not be achievable using summary data
for a broad patient population.
Wider implications of the ﬁndings: The Vienna consensus provides an
agreed standard for clinical and laboratory reporting, with each competency
value potentially attainable by every clinic. UK regulator data on clinic outcomes
potentially provides false reassurance, with external benchmarking and group
performance providing a more accurate estimate of achievable performance.
Trial registration number:Not applicable
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SELECTEDORAL COMMUNICATIONS
SESSION 37: ENDOMETRIOSIS AND ENDOMETRIUM:
CLINICAL RESEARCH
Tuesday 3 July 2018 Room 116 10:00–11:30
O-139 Endometrial scratching by pipelle biopsy in IVF (the PIP
study): A pragmatic randomised controlled trial
S. Lensen1, D. Osavyluk1, S. Armstrong2, E. Napier3, L. Sadler1,
A. Hennes4, C. Stadelmann5, H. Hamoda6, Y. Khalaf7, L.Webber8,
P. Bhide9,W.T. Teh10, S. Wakeman11, L. Searle12, C. Farquhar1
1University of Auckland, Obstetrics and Gynaecology, Auckland, New Zealand
2Royal United Hospitals Bath NHS Foundation Trust, Obstetrics and Gynaecology,
Bath, United Kingdom
3Bath Fertility Centre, Embryology, Bath, United Kingdom
4KU Leuven, Laboratory of Experimental Gynecology and Obstetrics, Leuven, Belgium
5Sahlgrenska University Hospital, Gynaecology and Reproductive medicine,
Gothenburg, Sweden
6King’s College Hospital, Fertility, London, United Kingdom
7Guys’s Hospital, Assisted Conception Unit, London, United Kingdom
8University College London Hospital, Reproductive Medicine Unit, London, United
Kingdom
9Homerton University Hospital, Homerton Fertility Centre, London, United Kingdom
10Melbourne IVF, Melbourne IVF, Melbourne, Australia
11Fertility Associates, Fertility Associates, Christchurch, New Zealand
12Fertility Associates, Fertility Associates, Wellington, New Zealand
Study question:: Does endometrial scratching delivered by an endometrial
pipelle biopsy, increase the probability of live-birth in women undergoing IVF/
embryo transfer?
Summary answer: Endometrial scratching was not associated with any
improvement in live birth rate.
What is known already: Endometrial scratching has been suggested to
improve the probability of embryo implantation, and therefore pregnancy, in
women undergoing IVF. It is proposed that the mechanical disruption to the
endometrium results in a favourable inﬂammatory response, increasing the
endometrial receptivity. Pooled results from randomised trials suggest beneﬁt
from endometrial scratching prior to an IVF cycle, especially in women with pre-
vious implantation failure. However, many of the studies had a high risk of bias
secondary to study design, such as exposure of controls to endometrial disrup-
tion and lack of allocation concealment. Therefore, there is uncertainty about
the validity of a beneﬁcial effect.
Study design, size, duration: A pragmatic, multi-centre, open-label, rando-
mised trial was conducted between June 2014 and June 2017 in 13 centres
across ﬁve countries. Women were randomised 1:1 to either endometrial
scratching or no procedure, using an online trial-speciﬁc database which
ensured allocation concealment. Sample-size was calculated separately in
women with recurrent implantation failure (≥2 unsuccessful embryo transfers,
15% increase live-birth rate anticipated) and without (8% increase). At 80%
power and a 5% signiﬁcance level, 1300 women were required.
Participants/materials, setting, methods: Eligible women were undergo-
ing embryo transfer (fresh or frozen) using their own oocytes, with no recent
exposure to disruptive intrauterine instrumentation. Women in the endomet-
rial scratching arm underwent a pipelle biopsy between day 3 of the preceding
cycle and day 3 of the IVF/embryo transfer cycle. The primary outcome was
live-birth using an intention-to-treat approach. Risk ratio and 95% conﬁdence
intervals were calculated, and logistic regression was used to test for subgroup
differences.
Main results and the role of chance: A total of 1364 women were rando-
mised: 690 to endometrial scratching and 674 to control. Baseline and cycle
characteristics were similar between the two groups. Endometrial scratching
was not associated with any improvement in live birth rate 26.1% (180/690) vs
26.1% (176/674), odds ratio =1.00 (0.78 to 1.27). The effect remained similar
after adjusting for protocol deviations and the observation that fewer women in
the control arm underwent an embryo transfer. There was no difference in the
rate of biochemical pregnancy, ectopic pregnancy, ongoing pregnancy, clinical
pregnancy or multiple pregnancy between the two groups. Subgroup analysis
did not identify any subpopulations that may beneﬁt from endometrial scratch-
ing; there was no evidence of a beneﬁt in women: with recurrent implantation
failure, undergoing fresh or frozen cycles, or depending on the timing of the
scratch in relation to the embryo transfer. The median pain score from endo-
metrial scratching was 3.5/10 (IQR 1.9–6.0). There were 14 adverse events
related to endometrial scratching: 7 vasovagal reactions, 2 excessive bleeding
and 5 excessive pain.
Limitations, reasons for caution: Although a higher proportion of women
in the endometrial scratching arm underwent embryo transfer, this did not
impact the results. The deﬁnition of recurrent implantation failure was two or
more previous unsuccessful embryo transfers, with no consideration for the
stage or quality of the previously transferred embryos.
Wider implications of the ﬁndings: This was a large trial and the pragmatic
design increases the generalisability of the results. As the beneﬁcial effects
reported previously were not conﬁrmed by this trial, and the procedure caused
a moderate amount of pain and bleeding, the current use of endometrial
scratching in fertility clinics should be abandoned.
Study funding/competing interest(s) Research grants were provided
by (New Zealand): A+ Trust, Auckland District Health Board; The Nurture
Foundation for Reproductive Research; and Maurice & Phyllis Paykel Trust.
There are no competing interests.
Trial registration number: ACTRN12614000626662
O-140 The impact of non-cavity distorting intramural ﬁbroids on
IVF outcomes: A systematic review andmeta- analysis
M. Hamdan, M.N. Nuzaim
University of Malaya, Obstetrics and Gynaecology, Kuala Lumpur, Malaysia
Study question: To identify the impact of non- cavity distorting uterine ﬁbroid
on IVF outcomes.
Summary answer: Presence of non-cavity distorting IM ﬁbroids with or with-
out subserosal ﬁbroids will reduce LBR CPR, and MR but not IR.
What is known already: Uterine ﬁbroids (UF) including. those non-cavity
distorting variant can cause infertility. When these women require IVF treat-
ment, controversies whether its presence will negatively impact on their IVF
outcomes has been continually debated. The heterogenous nature of UF has
given inconsistence result in many published studies. Available meta analysis on
this subject however is dated and has signiﬁcant heterogeneity. Moreover, IVF
techniques and protocol have also been rapidly evolved since the last review.
An updated review and Meta-Analysis is needed to give informed choice to
patient and IVF practitioner.
Study design, size, duration: Systematic review and meta-analysis.
Participants/materials, setting, methods: We performed a systematic
review and meta-analysis on extracted data according to PRISMA. Relevant arti-
cles were selected from literature search carried out using Medline, Embase,
and Web-of-science. Randomised and non-randomised controlled studies
were included. Primary outcomes are live birth rate (LBR) and clinical preg-
nancy rate (CPR) and secondary outcomes are implantation rate (IR) and
miscarriage rate (MR). Qualities of included studies were scored using
Newcastle-Ottawa Quality Assessment Scales and meta-analysis conducted by
using RevMan 5.3.
Main results and the role of chance: We found 2482 articles but only
included 26 articles that satisfy our inclusion and exclusion criteria. All are non-
randomised studies with a total of 7733 IVF cycles. Most (26/27) are high qulity
studies. Fourteen (n = 14/27) studies included IM with SS and only (n = 12/
26) reported IM only. Our meta-analysis revealed non-cavity distorting IM
ﬁbroids with or without subserosal ﬁbroids, signiﬁcantly reduced CPR
(RR = 0.83, 95% CI = 0.63–0.99, P < 0.000, I2 = 42%, 2955 IVF cycles, 23
studies), LBR (RR = 0.80, 95% CI = 0.73-0.87, P = 0.000, I2 = 40%, 1815
cycles, 16 studies) and MR (RR = 1.26, 95% CI = 1.06-1.50, P = 0.009,
I2 = 21%, 509 cycles, 16 studies). Where as IR (RR = 0.79, 95% CI = 0.81–
1.01, P = 0.07, I2 = 33%, 1379 IVF cycles, 10 studies) is not signiﬁcanltly
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affected. Our subgroup analysis on non cavity distorting IM only, revealed sig-
niﬁcantly reduced CPR (RR = 0.84, 95% CI = 0.77-0.92, P = 0.000, I2 = 18%,
1871 IVF cycles, 12 studies), LBR (RR = 0.83, 95% CI = 0.73–0.94, P = 0.005,
I2 = 32%, 799 IVF cycles, 6 studies) and MR (RR = 0.84, 95% CI = 0.77-0.92, P
= 0.000, I2 = 18%, 1871 IVF cycles, 12 studies). However, IR (RR = 0.71, 95%
CI = 0.49 – 1.02, P = 0.07, I2 = 81%, 1511 IVF cycles, 5 studies).
Limitations, reasons for caution: included studies are non-randomised
studies. The result of this study is still subjected to confounders relating to clin-
ical heterogeneity.
Wider implications of the ﬁndings: This ﬁnding will facilitate clinician on
the decision of need for performing myomectomy in non cavity distorting uter-
ine ﬁbroid.
Trial registration number:NA.
O-141 Supplementation in adolescent girls with endometriosis
(SAGE): A double blind, randomized, placebo-controlled trial
J. Nodler1, A. DiVasta2, A. Vitonis3, S. Karevicius4, M. Malsch5,
V. Sarda2, A. Fadayomi3, S. Missmer6
1Houston IVF, REI, Houston, U.S.A.
2Boston Children’s Hospital and Harvard Medical School, Department of Medicine,
Boston, U.S.A.
3Brigham and Women’s Hospital and Harvard Medical School, Department of
Obstetrics- Gynecology- and Reproductive Biology, Boston, U.S.A.
4Boston Children’s Hospital and Brigham and Women’s Hospital, Boston Center for
Endometriosis, Boston, U.S.A.
5Boston Children’s Hospital, Institutional Centers for Clinical and Translational
Research, Boston, U.S.A.
6College of Human Medicine- Michigan State University, Department of Obstetrics-
Gynecology- and Reproductive Biology, Grand Rapidsd, U.S.A.
Study question: Does adjuvant supplementation with omega-3 fatty acids or
vitamin D remediate pain and improve quality of life in adolescents with
surgically-conﬁrmed endometriosis?
Summary answer: All groups–vitamin D, omega-3 fatty acids, and placebo
improved at three and six months in pelvic pain and mental and physical quality
of life.
What is known already: Adolescents with endometriosis are an under-
served population who struggle with chronic pain, missed school, poor social
relationships, and concerns about future infertility. Endometriosis is a pro-
inﬂammatory condition characterized by elevated levels of cytokines and
growth factors, decreased cell apoptosis, and increased angiogenesis. Vitamin
D and omega-3 fatty acids may decrease inﬂammatory factor proliferation,
which could reduce progression of endometriosis and endometriosis-
associated pain. Several articles and books exist in the lay press regarding the
use of diet and supplementation to manage endometriosis, but there are no
published data demonstrating an association between nutritional supplementa-
tion and modiﬁcation of endometriosis symptoms.
Study design, size, duration: Double blind, randomized, placebo-controlled
trial in which 69 adolescent girls and young women were randomized to receive
vitamin D3 (2000 IU), ﬁsh oil (1000 mg), or placebo daily for 6 months – admi-
nistered as identical white capsules. An independent biostatistician developed a
permuted blocks randomization schema that the research pharmacy implemen-
ted to allocate the blinded study medications. No member of the study team
nor the participants were privy to treatment assignment.
Participants/materials, setting, methods: 59 girls and young women (age
12-25) recruited from a pediatric gynecology clinic completed all study visits. 19
were allocated to placebo, 23 to vitamin D, and 17 to ﬁsh oil. All participants
had surgically-conﬁrmed endometriosis and a minimum visual analog scale
(VAS) pain score ≥ 3 out of 10 for their worst pain in the month preceding
study enrollment. There were no differences in severity of endometriosis or
pelvic pain at baseline.
Main results and the role of chance: 59 participants completed all study
visits; there were no differences in characteristics between completers and
non-completers. The majority of participants had rASRM stage 1 endometriosis
at surgical diagnosis. From baseline to 6-months, a signiﬁcant increase in serum
25(OH)D was observed only in the vitamin D arm; likewise, an increase in total
omega-3 fatty acids, eicosapentaenoic acid(EPA) and docosahexaenoic acid
(DHA) was observed only among those randomized to ﬁsh oil. Participants in
all 3 arms demonstrated improvement in VAS pain; mean(SD) worst pain in the
past month improved from baseline to 6 months in placebo [6.0 (1.9) to 4.4
(3.2), Ptrend = 0.06], vitamin D [7.0 (2.2) to 5.5 (3.0), Ptrend = 0.04], and ﬁsh oil
[5.9 (2.9) to 5.3 (3.5), Ptrend = 0.40] arms (Pheterogeneity = 0.64). The mean
number of hours that pelvic pain usually lasted improved similarly from baseline
to 6-months among participants in all 3 arms. Three participants from each arm
required a clinical visit for pain at the 6-month time point, which was similar to
baseline. Average use of non-narcotic pain medication did not change from
baseline in any study group. Quality of life similarly improved among the 3 arms
for both mean SF-12 mental component and physical component scores
(Pheterogeneity = 0.38 and 0.60 respectively).
Limitations, reasons for caution: The small sample size was powered to
detect a minimum difference in change of 1.6 in VAS pain, requiring 19 subjects
per arm, assuming standard deviation = 1.7, 80% power, and alpha-error =
0.05. Enrolled from one clinic, the experience of this population of adolescents
may not generalize to all young women.
Wider implications of the ﬁndings: The strong placebo effect evident in
multiple outcome measures demonstrates the possibility that enhanced clinical
interaction and active study involvement improves pain associated with endo-
metriosis. Vitamin D and omega-3 fatty acids may not reduce pelvic pain, pain
medication usage, or improve quality of life independent of this effect.
Trial registration number:NCT02387931
O-142 The Endometriosis Fertility Index (EFI) can be estimated
accurately prior to surgical treatment of endometriosis
C. Tomassetti1, C. Bafort1, C. Meuleman1,2, S. Fieuws3,
M.Welkenhuysen1, T. D’Hooghe2
1University Hospitals Leuven, OBGYN/Leuven University Fertility Center, Leuven,
Belgium
2KU Leuven, Organ System- Dept Development and Regeneration, Leuven, Belgium
3KU Leuven, L-Biostat, Leuven, Belgium
Study question: Can the ﬁnal EFI-score be estimated before surgical endo-
metriosis treatment, from pre-operative non-surgical ﬁndings only (type-A esti-
mation) or pre-operative plus diagnostic laparoscopy data (type-B estimation)?
Summary answer: The ﬁnal EFI can be estimated well before completion of
operative laparoscopy for endometriosis, based on non-surgical data with or
without surgical diagnostic laparoscopic data.
What is known already: The EFI is a thoroughly validated clinical instrument
to predict non-ART clinical pregnancy rate after endometriosis surgery, but as
the EFI-score is calculated at the end of an operative laparoscopy – i.e. after all
endometriosis lesions have been removed – it currently is not clear if this score
can be also estimated prior to surgical treatment. If this would be possible, then
such estimated EFI-score could be used to triage patients with endometriosis-
associated infertility to treatment with surgery or with ART (assisted reproduct-
ive technologies).
Study design, size, duration: Prospective single center cohort study on 82
patients, undergoing laparoscopic endometriosis surgery between June and
December 2016. Although the study was exploratory, the sample size (min-
imum 71) was appropriate to conﬁrm an agreement of minimally 95% between
estimated and ﬁnal EFI (one-sided test, alpha 0.05, beta 0.8). Two deﬁnitions
were used for agreement: clinical (scores within the same EFI-score range: 0-4,
5-6, 7-10) and numerical agreement (maximally allowed difference of 1 EFI-
point, irrespective of range).
Participants/materials, setting, methods: All patients underwent com-
plete CO2-laser-laparoscopic excision of any rASRM-stage endometriosis in a
tertiary referral center. A coded clinical research ﬁle (CRF) consisted of 3 parts:
type-A contained only pre-surgical information, type-B contained type-A infor-
mation plus information of the diagnostic phase of laparoscopy, and type-C
included all pre-, intra- and post-operative information. An algorithm was cre-
ated to translate pre-surgical clinical/imaging information for EFI type-A calcula-
tion. Scoring was done by one person, with an appropriate time interval.
Main results and the role of chance: For the comparison between the esti-
mated EFI type-A and the ﬁnal EFI, the rate of agreement was high, with narrow
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95% conﬁdence intervals (CI): 91.5% (95%CI 83.2%-96.5%) for clinical agree-
ment, and 87.8 (95%CI 78.7%-94.0%) for numerical agreement. For the com-
parison between estimated EFI type-B and the ﬁnal EFI, agreement rates were
even higher: 98.8% (95%CI 93.4%-100%) and 96.3% (95%CI 89.7%-99.2%) for
clinical and numerical agreement respectively. Taken together, these results
conﬁrm that the ﬁnal EFI-score (calculated after operative laparoscopy) can be
accurately estimated by pre-operative non-surgical ﬁndings only (EFI type-A
estimation), and the accuracy of estimation is increased when the information
from the diagnostic phase of the laparoscopy was added to the pre-operative
non-surgical ﬁndings (EFI type-B estimation). It is also noteworthy that estima-
tion of the rASRM stage was far less accurate, especially when based on pre-
operative non-surgical ﬁndings only (agreement between type-A and ﬁnal
rASRM stage 68.3% (95%CI 57.1%-78.1%) and type-B and ﬁnal 90.2% (81.7%-
95.7%).
Limitations, reasons for caution: Rating was done by one person, so it
remains to be conﬁrmed whether others can repeat the estimations with similar
accuracy. The high quality of the ultrasound (and report) performed by experts
- to calculate EFI-type-A –, may render implementation in general clinical prac-
tice outside endometriosis referral centers less feasible.
Wider implications of the ﬁndings: If other groups conﬁrm our accurate
pre-surgical estimation of the ﬁnal EFI, this will revolutionize the possibilities of
individualizing the management of endometriosis-associated infertility. Choice
of ﬁrst-line treatment with laparoscopic surgery or medically assisted reproduc-
tion could be based on the estimated EFI, while taking pain symptoms into
account.
Trial registration number: Institutional study registration number: S59221.
O-143 The effect of different IVF protocols for women with
endometriosis on their IVF outcomes: A Systematic review and
Meta-Analysis
K.K. Lwin, M. Hamdan, S.Z. Omar
University of Malaya, Obstetrics and Gynaecology Department- Faculty of Medicine,
Kuala Lumpur, Malaysia
Study question:What is optimal IVF protocol for women with endometriosis
and the effects of different protocols on the outcomes of Live Birth (LBR),
Clinical Pregnancy (CPR), oocyte retrieval (MOR) and miscarriage.
Summary answer: The ultra-long protocol should be the recommended
protocol for women with endometriosis and/or endometrioma. The antagonist
protocol has given non-inferiority effect to the protocol.
What is known already: Infertile women with endometriosis may require
IVF/ICSI to conceive. Women with endometrioma during IVF treatment yield
fewer oocytes during oocyte retrieval procedure despite requiring more stimu-
lation drugs. It is also established that the embryos from women with endomet-
riosis and/or endometrioma is poorer compared to women with no
endometriosis, and the exact mechanism is still left unexplained. Various treat-
ment strategies have been investigated to improve the outcomes. Several pro-
tocols are utilised including long protocol, ultra-long protocol and antagonist
protocol intended to improve the IVF outcomes, but to date, a suitable proto-
col exclusive to women with endometrioma is yet to be found.
Study design, size, duration: This is a Meta-Analysis and systematic review.
Electronic search through various Databases including Pubmed, ScienceDirect,
OVID, Cochrane, Medline and Google Scholar was performed to search for
both published and unpublished data.
Randomized Controlled Trials (RCT), cohort studies, retrospective studies
as well as prospective studies from 1980 up to 2017 were reviewed.
Participants/materials, setting, methods: A total of 2667 papers were
identiﬁed through electronic search and after screening, 15 studies were eligible
to be included for data synthesis. The quality of each paper was assessed and
scored according to Newcastle-Ottawa Assessment scale. All suitable data
were extracted and analysed using Review Manager 5 software.
Main results and the role of chance: We retrieved 2667 articles looking
into these protocols however after careful scrutiny we found several studies
comparing ultralong vs. long protocol (n = 9), long vs. antagonist (n = 4) Short
vs. antagonist (n = 1), ultralong vs. short agonists (n = 2). From the meta-
analysed data, there are signiﬁcantly higher CBR in women with ultralong proto-
col (OR CI 95% (1.23, 4.10) 853 cycles, 9 studies, I2 = 70%) as reported by the
previous meta-analysis.
There was no signiﬁcant difference in the miscarriage rate [OR CI 95% 1.19
(0.55,2.58) 361 cycles, 4 studies] and little difference in the meiosis II oocyte
retrieval rate [OR CI 95% -0.30 (-0.48,-0.12)].
Limitations, reasons for caution: Due to the observational nature of the
included studies, the result of this study is subjected to confounders relating to
clinical heterogeneity.
The relatively small number of studies and sample population within each
study may increase the risk of bias.
Wider implications of the ﬁndings: The ultra-long protocol is thought to
render the endometrioma dormant, thus improving the chance of retrieving
high-quality oocytes and embryos. However due to potential side effects,
patients can be pretreated with Dienogest (Visanne) which has been proven to
reduce symptoms and prevent recurrence, and may reduce the size of
endometrioma.
Trial registration number: not applicable.
O-144 Nationwide cohort study of the risk of major adverse
cerebrovascular and cardiovascular events in the Asian women with
endometriosis
H.J. Chiang1, K.C. Lan1, Y.H. Yang2, P.H. Sung3
1Kaohsiung Chang Gung Memorial Hospital- Kaohsiung- Taiwan, Department of
Obstetrics and Gynecology, Kaohsiung, Taiwan R.O.C.
2Chang Gung Memorial Hospital- Chiayi- Taiwan, Department for Traditional
Chinese Medicine- Health Information and Epidemiology Laboratory, Chiayi, Taiwan
R.O.C.
3Kaohsiung Chang Gung Memorial Hospital- Kaohsiung- Taiwan, Division of
Cardiology- Department of Internal Medicine, Kaohsiung, Taiwan R.O.C.
Study question: Based upon positive correlation of anti-mullerian hormone
(AMH) to cardiovascular disease in recent studies, we investigated the associ-
ation between endometriosis and major adverse cerebro-/cardio-vascular
events (MACCE) in an Asian population.
Summary answer: The risk of MACCE including major CVD or CVA
increases in the Asian women with endometriosis at reproductive age.
What is known already: Endometriosis has a negative impact on ovarian
reserve. AMH, an ovarian reserve marker, declines with increasing cardiovascu-
lar risk in women.
Study design, size, duration: Taiwan National Health Insurance Research
Database (NHIRD) was utilized to answer the question. A retrospective
population-based cohort study was held through 1997 to 2013.
Participants/materials, setting, methods: A total of 17,543 patients with
endometriosis and age between 18 and 50 years were identiﬁed from
1,000,000 general populations after excluding initially concomitant diagnoses of
MACCE. The MACCE was deﬁned as major cardiovascular disease and cere-
brovascular accident. The comparison group (n = 70,172) without endometri-
osis was selected matching in a 1:4 ratio. We compared the demographic data,
frequency of comorbidities, incidence of and risk of MACCE between the dis-
ease and non-disease groups.
Main results and the role of chance:With a median follow-up of 9.2 years,
the endometriosis patients had signiﬁcantly higher frequency and cumulative
incidence of MACCE than non-endometriosis counterparts (2.76% vs. 2.18%,
p < 0.0001). After adjusting with multivariate analysis, the patients with endo-
metriosis had 1.17-fold greater risk for future development of MACCE (95% CI
1.05-1.29, p = 0.0053). In further, the adjusted hazard ratios of endometriosis
for major CVD and CVA were 1.19 and 1.16, respectively (all p < 0.04). Apart
from endometriosis, older age, lower urbanization level, hypertension and dia-
betes were identiﬁed as risk factors for MACCE occurrence as well.
Limitations, reasons for caution: This is a retrospective study to analyze
the diagnosis of endometriosis and MACCE in a nationwide population data.
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Further investigation will be needed to clarify the trajectories of serum AMH
and associated incidence of MACCE in endometriosis patients.
Wider implications of the ﬁndings: Early awareness of deteriorating ovar-
ian reserve via checking serum AMH is important to prevent following MACCE
in endometriosis patients. Early interventions, such as surgery or medication,
would be helpful to break the vicious circle among endometriosis, deteriorating
ovarian reserve, and MACCE.
Trial registration number: not applicable.
INVITED SESSION
SESSION 38: EUROPEANANDGLOBAL ART
MONITORING
Tuesday 3 July 2018 Room 211 + 212 11:45–12:45
O-145 European IVF-monitoring of ART and development of a
strategy for vigilance
O-146 ICMARTWorld Report 2014
G.D. Adamson1, F. Zegers-Hochschild2, S. Dyer3, G. Chambers4,
O. Ishihara5, R. Mansour6, M. Banker7, J. De Mouzon8
1ARC Fertility, N/A, Cupertino, U.S.A.
2University Diego Portales- Santiago- Chile, Program of Ethics and Public Policies in
Human Reproduction, Santiago, Chile
3University of Cape Town, Department of Obstetrics & Gynaecology Groote Schuur
Hospital and Faculty of Health Sciences, Cape Town in the Western Cape province,
South Africa
4University of New South Wales, National Perinatal Epidemiology and Statistics Unit,
Sydney, Australia
5Saitama Medical University, Department of Obstetrics and Gynaecology,
Moroyama, Japan
6Egyptian IVF-ET Center, Founder, Cairo, Egypt
7Nova IVI Fertility, Co-Chairman & Medical Director, India, India
8Groupe Hospitalier Cochin-Saint Vincet de Paul, cInstitut National de la Santé et de
la Recherche Médicale Service de Gynécologie Obstétrique II et de Médecine de la
Reproduction, Paris, France
International Committee for Monitoring Assisted Reproductive
Technologies (ICMART) World Report on ART, 2014 and The
International Glossary on Infertility and Fertility Care, 2017.
Study question: In 2014 what was global utilization, effectiveness and safety
of ART, and what is status of The International Glossary on Infertility and
Fertility Care, 2017.
Summary answer: Globally, ART utilization and data collection continue to
increase but with wide variations in utilization, effectiveness and safety. The sig-
niﬁcantly expanded, revised Glossary was published.
What is known already: ICMART began ART global data collection in 1991.
Utilization, effectiveness and safety have continuously improved with more
cycles, higher pregnancy rates and lower multiple birth rates, the latter coupled
with an increase of frozen embryo transfer (FET) cycles; however, wide varia-
tions exist globally. Over 7 million ART babies have been born. ICMART has
helped develop African registries in association with the African Network and
Registry for Assisted Reproductive Technology (ANARA). Data collection and
quality remain challenging. The Glossary is an important document created
through ICMART’s leadership with a partnership of all the major global repro-
ductive medicine organizations and other stakeholders.
Study design, size, duration: Countries and regions annually collect ART
data, some prospectively and others retrospectively. ICMART retrospectively
requested these data from all known global sources for 2014, analyzed them
collaborating with Uppsala Clinical Research (UCR) at the University of
Uppsala, Sweden, and presents preliminary results. The Glossary was created
through a global partnership of major professional organizations and other sta-
keholders. ICMART’s Data Collection System (DCS) ﬁrst used for 2014 data
represents years of collaboration between ICMART and UCR.
Participants/materials, setting, methods: The European IVF Monitoring
Consortium (EIM), Society for Assisted Reproductive Technology (SART), Latin
American Network of Assisted Reproduction (REDLARA), Australian/ New
Zealand Registry, ANARA and other countries, totaling 70, contributed
national data through standardized formats to the DCS. Data were reviewed,
corrected, analyzed and summarized by ICMART working with UCR using
standard statistics. ICMART led a partnership of international stakeholders who
revised the ICMART/WHO 2009 Glossary. ICMART and UCR collaborated to
create the ICMART DCS.
Main results and the role of chance: Data collection and analysis are
ongoing. Preliminary results are presented at ESHRE. The number of ART
cycles continues to increase, but utilization is still very inﬂuenced by affordable
access to ART which is related to insurance or public funding. Regional differ-
ences persist in the age of the population treated, number of embryos trans-
ferred, rate of multiple births, and other factors.
The International Glossary on Infertility and Fertility Care, 2017, is signiﬁ-
cantly expanded and has revised many commonly used terms. The new
ICMART DCS is functional.
The role of chance is minimal. Actual global ART results are limited to
reporting countries and clinics representing approximately 2/3 of global cycles.
However, this is a very large sample size from which imputation of total global
results is performed. Many countries have limited data validation and ICMART
can perform only minimal veriﬁcation of submitted data.
Limitations, reasons for caution: Actual reported data represent 2/3 of
total performed cycles. Data validation is not universal or standardized. Routine
use of Glossary terms takes time and translation into multiple languages. The
ICMART DCS needs to have its functionality continuously assessed and
improved so that data quality can continue to expand and improve.
Wider implications of the ﬁndings: ICMART World Reports standardize
data, track trends, enable comparisons, stimulate questions and improve ART
quality. Better understanding of ART increases societal acceptance and support
for ART research and clinical access. The International Glossary on Infertility
and Fertility Care, 2017 represents a unique stakeholder partnership that har-
monizes ART terminology globally.
O-147 Gender inequality and utilisation of assisted reproductive
technology: an international analysis
G. Chambers1, O. Fitzgerald1, S. Dyer2, F. Zegers-Hochschild3, G.D.
Adamson4
1University of New South Wales, National Perinatal Epidemiology and Statistics Unit,
Sydney, Australia
2University of Cape Town, Department of Obstetrics & Gynecology- Groote Schuur
Hospital and Faculty of Health Sciences, Cape Town, South Africa
3University Diego Portales, Program of Ethics and Public Policies in Human
Reproduction- Clinica las Condes- Unit of Reproductive Medicine-, Santiago, Chile
4Fertility Physicians of Northern California, Palo Alto Medical Foundation, Palo Alto-
California, U.S.A.
Study question: Is there an association between gender inequality and utilisa-
tion of assisted reproductive technology (ART) treatment globally?
Summary answer: Countries with less gender inequality have higher rates of
ART utilisation, regardless of the country’s level of economic and human
development.
What is already known: ART utilisation varies enormously worldwide.
Previous research has indicated that consumer affordability, access to clinics,
and normative cultural acceptance are important factors in ART utilisation.
Study design, size, duration: A longitudinal cross-national analysis of ART
utilisation in 69 countries, with the outcome deﬁned as the total number of
ART cycles per million population. The Gender Inequality Index (GII), Human
Development Index (HDI), and Education Index (EI) developed by the United
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Nations Development Programme (UNDP), were used as composites mea-
sures of gender inequality, human development and education respectively.
Data is drawn from several sources (ICMART, UNDP, World Bank).
Participants/materials, setting, methods: Our sample includes data from
69 countries for the years 2002–2012. Following a descriptive graphical and
bivariate correlation analysis, mixed and ﬁxed effect regression methods served
to establish the cross-sectional and longitudinal relationship between the pre-
dictor variables and the number of ART treatments per million population in a
country.
Main results and the role of chance: A one standard deviation movement
in the GII towards greater gender equality is associated with an increase in ART
utilisation by a factor of 2.8 (95% CI: 1.5–5.2), when controlling for a country’s
level of economic and human development. There were differences in the
strengths of association of different components of gender equality and human
development with ART utilisation. Increases in a country’s female parliamentary
representation, level of male and female education and wealth had the stron-
gest longitudinal relationships with ART utilisation. Preliminary ﬁndings indicate
the following: an increase of 10% in female parliamentary representation saw a
county’s ART utilisation increase by a factor of 1.3 (95% CI: 1.1–1.6). A one
standard-deviation increase in the EI (equivalent to 2.5 additional mean years of
schooling) was associated with ART utilisation increasing by a factor of 1.9 (95%
CI: 1.0–3.5). A one-unit increase in log gross national income per capita (2011
PPP US$) was associated with ART utilisation increasing by a factor of 2.6 (95%
CI: 1.5–4.3).
Limitations, reasons for caution: Multiple imputation was used to impute
missing covariate data for 13% of observations. Countries, predominantly in the
Middle East and North Africa, with low ART clinic reporting rates were
excluded from the analysis. As the analysis was cross-national, inferences to the
individual level are not possible.
Wider implications of the ﬁndings: Access to infertility care is central to
women’s sexual and reproductive health, to women’s rights, and to human
rights. Our analysis demonstrates that as gender equality improves, so does util-
isation of assisted reproductive technologies. Progress towards global, equitable
access to infertility care can hence be expected with global improvement of
women’s status within societies.
Study funding/competing interest(s):None.
Trial registration number: n/a
INVITED SESSION
SESSION 39: NEWASPECTS IN POLYCYSTIC OVARY
SYNDROME
Tuesday 3 July 2018 Room 111 + 112 11:45–12:45
O-148 First line treatment in PCOS: what to do?
F. Van der Veen1
Academic Medical Centre, Centre for Reproductive Medicine, Amsterdam,
The Netherlands
Abstract text
There are several guidelines on ﬁrst line treatment in PCOS. The most relevant
one’s are the ESHRE/ASRM consensus, the NICE guideline and the WHO’s
global guideline which is under development. (1,2,3) The common denominator
of these guidelines is that they all -broadly speaking- recommend lifestyle modi-
ﬁcation, followed by or combined with medical ovulation. With respect to the
latter there are some variations: ESHRE/ASRM recommend Clomiphene
Citrate (CC) as ﬁrst line treatment, while NICE recommends CC, metformin
or a combination of the two, while WHO advises CC or Letrozole. The explan-
ation for these differences is probably the accumulation of evidence which has
taken place in between the dates of publication of the various guidelines.
The evidence on the commonly used drugs has been summarized in conven-
tional but authoritative Cochrane reviews, which provide the data on pairwise
meta analysis. (4,5,6) On clomiphene citrate the evidence suggests that it
improves the chance of a clinical pregnancy compared with placebo without
any differences between different anti-oestrogens (low quality evidence) On
aromatase inhibitors, speciﬁcally Letrozole, the evidence suggests that
Letrozole improves live birth and pregnancy rates compared with CC. (low
quality evidence) On insulin sensitisers, speciﬁcally metformin, the evidence is
complex, but suggests that metformin alone may be beneﬁcial over placebo for
live birth, and that any superiority of metformin over CC and vice versa is incon-
clusive, although there may be interaction with body mass index. (very low to
low quality evidence) Combined therapy with metformin and clomiphene cit-
rate improved clinical pregnancy compared with clomiphene citrate alone it is
at present unknown whether this translates into increased live births and
gastrointestinal side effects are considerable (low to moderate quality
evidence).
This traditional pairwise meta-analyses only allow the comparison of two
interventions for ovulation induction. Since many of these medications have not
been compared directly it is still not clear what the most effective treatment
option would be. A recent network meta-analysis has studied all possible com-
binations and has provided interesting data, which can be summarized as fol-
lows: all interventions are effective, Letrozole improves live birthrate compared
to CC. Combined therapy with CC and metformin is superior to CC and to
metformin in terms of pregnancy rates.
The conclusion, taking all available evidence into account, is that at present
letrozole and combined treatment with CC and metformin are the drugs of ﬁrst
choice.
References
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syndrome. Hum Reprod 2008;23:462–477.
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(6) Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising
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O-149 Does race and ethnicity matter for metabolic risks in
PCOS?
Norman RJ1, Moran L2, Teede H2
1Robinson Research Institute and Fertility SA, University of Adelaide SA 5005.
2MCHRI, Monash University, Clayton VIC 3800.
Abstract Text
The phenotypic appearance of polycystic ovary syndrome (PCOS) varies
across geography, ethnicity and race. The genotypic variation is not as marked
comparing Asian and Caucasian populations, suggesting that environmental fac-
tors may play a major role in the presentation of PCOS.
Over the past few decades, it has been recognised that hyperinsulinism, insu-
lin resistance, diabetes mellitus and hyperlipdemias are more common in peo-
ple with PCOS when compared to controls of the same body mass index. Early
studies indicated marked differences in metabolic proﬁles between immigrants
in their recently arrived country, people of the same ethnicity who remained in
their original country and other population groups of different races.
Signiﬁcant differences are found in the metabolism in PCOS between
Hispanics, African Americans and those of European decent in North America.
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These have been compared with Europeans residing in Europe with the same
ethnic background. There are also marked differences between Asians,
depending on whether they are East Asian or South Western Asian, with major
discrepancies in body mass index, diabetes mellitus and insulin resistance.
Recent studies in the Indigenous Australian population have shown the
marked change that diet and lifestyle has induced over the past thirty years as
people moved from a high exercise and traditional diet lifestyle to more west-
ern food and sedentary practices.
The increasing recognition of metabolic dysfunction in patients with PCOS
makes the diagnosis, investigation and management of the condition even more
important, afﬁrming the importance of international guidelines for PCOS.
Awareness of individual group risks will also lead to superior treatment for
metabolic and fertility dysfunction.
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O-150 To err is human: even in IVF
D. De Ziegler1, P. Pirtea2, M. Poulain3, R. Fanchin3, J.M. Ayoubi3
1Hopital Foch - Universite Paris Ouest, Obstetrics and Gynaecology, Suresnes, France
2Foch Medical Center - University de Paris Ouest, Obstetrics and Gynecology,
Suresnes, France
3Foch Medical Center - University Paris Ouest, Obstetrics and Gynecology, Suresnes,
France
The seminal publication of Kohn et al. (To Err is Human: Building a Safer Health
System. Kohn LT, Corrigan JM, Donaldson MS, editors. Washington (DC):
National Academies Press (US); 2000.), has made us aware of the fact that
safety systems need to acknowledge that we, humans, make and will continue
to make mistakes. IVF is no exception. Considering that IVF is performed in
basically healthy people, avoiding errors of possible catastrophic consequences
is of paramount importance.
The ﬁrst step for minimizing the consequences of our errors is to understand
the context in which they occur. Two distinct factors that deﬁne this context
need to be clearly apprehended. First, there are the existing hazards, which are
potential sources danger inherent to any procedure. In mountain climbing for
example, one typical hazard is height. Second, there are the prevailing risks
which are deﬁned as the possibility that something unpleasant happens – an
adverse event. Risks are inherently affected by existing hazards. In our mountain
climbing example, slipping on top of a mountain can obviously have more
dreadful consequences than if the same happens in low land. While hazards
cannot be altered – height is inherently linked to mountains – risks can be miti-
gated. In mountain climbing, roping will prevent the possibility of dreadful con-
sequences from slipping. In medicine – in ART in particular – we need to
develop safety systems that adequately prevent adverse events from occurring
in spite of the hazards and risk existing and errors occurring.
For being effective, safety systems imply an in-depth knowledge and under-
standing of the existing risks and possible consequences or adverse events. For
this, we commonly plot adverse events emanating from prevailing risks on a fre-
quency vs. severity diagram. Certain minor adverse events are frequent and of
menial consequences, which can be considered as acceptable. Other adverse
events may have serious – possibly fatal – consequences and are therefore
unacceptable. Only a proper understanding of the dynamic of each risk can per-
mit to develop and efﬁcient risk averting system.
In order to avert adverse events from occurring as a result existing risks, one
needs to develop protective measures or defenses. The choice of defenses
must result from a careful assessment of the risks existing and root cause ana-
lyses of the possible adverse events that can emanate from these risks.
Improper and poorly designed and/or too-complex defenses that impede
proper functioning will not properly avert risks and may actually constitute a
risk factor of its own. One should beware of the too often encountered ‘let’s
write another procedure attitude’ instead of conducting a proper root cause
analysis of any encountered adverse event.
Accepting that errors are made is a crucial step in the design of any safe oper-
ation, and ART is no exception. A safety system that acknowledges that it is human
to err – in IVF included – will bank on enacting a no-blame safety culture that inte-
grates and share incident reports for averting the occurrence of more severe
adverse events. Return on experience of ‘near misses’ in a positive no-blame cul-
ture is a crucial step for enacting safety systems that correct procedure based on
minor deviations before these result in catastrophes when left unheeded.
O-151 This is howmany errors occur in the IVF lab: a true analysis
M. J. De Los Santos
IVI Valencia, IVF Laboratory, Valencia, Spain
In ART as in the rest of areas of application of tissues and cells there are situa-
tions that may trigger the incidence of adverse reactions (harm to a donor,
harm to a recipient, harm to a foetus or offspring) and adverse events (risk of
harm despite no harm actually occur).
Many IVF laboratories are very complex in terms of not only the technology
and equipment being used but in the introduction of overprocesses adding
many steps during procurement, processing and distribution. These and other
factors, all contribute in creating the perfect culture media facilitating the errors
to happen, and despite hazards can be prevented from causing serious
unwanted effect by the implementation of barriers, incidents still may occurs
due to the inadvertent weakness of each barrier.
This talk focuses on identifying the steps where errors may take place, analyz-
ing the root causes in the IVF laboratory and how implement tools to measure
the error rate, decrease it and control it.
There are different strategic policies for risk management that help in asses-
sing and prioritizing the possible existing hazards, so the probability of an
adverse event occurring will be kept to a minimum. Strategies such as “Failure
mode, effects and critical analysis” (FMECA) are very useful of tools in ART.
Such approaches help to create lists of relevant steps or processes under risk,
make an estimation of any identiﬁed hazard to happen based on the severity of
the error, its frequency as well as its probability of detection. All together will
create a risk priority index which helps in ranking the risks and prioritize the
actions to take.
As some of the causes leading to error in the IVF laboratory are due to
human mistakes, the reasons of human errors will be also addressed. Among
the factors to blame on, are: complexity of the activity, lack of education and
training, perception that the procedures were not appropriate or efﬁcient or
just lack of attention to well-deﬁned procedures. A list of key factors that facili-
tate the incidence of human errors has been compiled by Toft and coworkers.
Some of them can be conscious automaticity, involuntary automaticity, ambigu-
ous accountability and stress. All of them are considered especially relevant
when considering aspect in IVF related to loosing traceability leading to sample
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mismatch that are undesirable reaction that can occur in an IVF laboratory with
important consequences for both patients and healthcare professionals.
SELECTEDORAL COMMUNICATIONS
SESSION 41: FOCUSONBLASTOCYST STAGE
Tuesday 3 July 2018 Room 117 11:45–12:45
O-152 Predicting blastocyst formation rate using a hierarchical
and data mining-based statistical model
J. Yao Serna1, R. Milewski2, D. Bodri1, T. Sugimoto1, R. Kato1,
T. Matsumoto1, S. Kawachiya1
1Kobe Motomachi Yume Clinic, Assisted Reproduction, Kobe, Japan
2Medical University of Bialystok, Department of Statistics and Medical Informatics,
Bialystok, Poland
Study question: Is it possible to establish equally efﬁcient predictive algo-
rithms for blastocyst (BT) formation using two different statistical
methodologies?
Summary answer: Combining several cleavage-stage morphokinetic vari-
ables through data mining-based statistical algorithm achieved higher predictive
power than the hierarchical model which included only the two strongest
predictors.
What is known already: In recent years increasing number of time-lapse
monitoring (TLM) studies focused on ﬁnding morphokinetic variables that could
be predictors of blastocyst formation, successfully identifying several (early)
cleavage-stage variables that were consistently associated with it. However,
only a recent study (Motato et al, 2016) has managed to establish a four-
category hierarchical score (including tM=time to morula and s3=t8-t5) pre-
dicting blastocyst development which showed a good discrimination ability
(AUC: 0.849). It is arguable however, whether including tM is really useful if a
blastocyst prediction model would be used in a clinical setting to select day-3
embryos for prolonged culture.
Study design, size, duration: All consecutive infertile patients from a single
centre whose cleavage-stage embryos were submitted to prolonged culture (n =
1133) in a TLM incubator (EmbryoScope, Vitrolife) between 2012 and 2014 were
included in this retrospective analysis. Patients (38.2 ± 3.9 years) underwent min-
imal ovarian stimulation, prolonged embryo culture and elective vitriﬁcation of
expanded blastocysts. Cleavage-stage, static (tPNf, t2-t8), and interval morphoki-
netic parameters (cc2a-b, s2-3) were scored according to recently published con-
sensus criteria and standardized to time of pronuclear fading (tPNf).
Participants/materials, setting, methods: A ﬁrst, hierarchical model -
including the two strongest BT formation predictors selected by multivariate
analysis - and a second, more robust one - based on combination of principal
component analysis (PCA) and logistic regression methods - were created. The
PCA technique is a data-mining method that relies on transformation of an ini-
tial correlated set of features into new uncorrelated variables called principal
components. For both models the area-under-the-curve values (AUC) with
95%CI were calculated.
Main results and the role of chance: The average rate of expanded blasto-
cyst formation was 44% (501/1133). The examination of detailed histograms
revealed that areas with a high, medium and low BT formation rates existed for
all, eleven cleavage-stage morphokinetic variables thus permitting their conver-
sion from continuous (hours) to categorical ones. Following multivariate analysis
combining the two strongest morphokinetic predictors (t2 and s3) resulted in a
simple, ﬁve-category (from ‘E” to ‘A”) hierarchical model, representing 9, 15, 23,
34, and 19% of the entire cohort of cultured embryos, respectively. The model
effectively distinguished between embryos of increasing BT development poten-
tial (18, 22, 40, 60 and 70% from category ‘E” through ‘A”, p < 0.0001). For the
second model quartiles of the created Sc parameter (Q1-Q4) had increasing BT
formation rates (Q1: 14%, ‘Q2”: 39%, ‘Q3”: 61%, ‘Q4”: 81%, p < 0.0001). The
AUC value of the data mining-based model was signiﬁcantly higher compared to
the hierarchical one (0.794, 95CI%: 0.77-0.82 versus 0.702, 95CI%: 0.67-0.73).
Limitations, reasons for caution: Our unselected cohort was biased
towards advanced-aged, poor-prognosis patients undergoing mild IVF treat-
ment coupled with single vitriﬁed-warmed blastocyst transfer. This might limit
generalizability to other less infertile populations or to centres that use different
treatment protocols.
Wider implications of the ﬁndings: Both models were similarly successful
in stratifying cleavage-stage embryos of different BT formation potential and
could be further tested in everyday clinical practice. However, the more robust
PCA-based methodology originally was developed in a fundamentally different
setting from ours with similarly high predictive capabilities (Milewski, 2015) sug-
gesting wider between-center applicability.
Trial registration number: not applicable.
O-153 Blastocyst morphology grading: what is the most important
predictor of live birth when accounting for endometrial receptivity?
Amulticentre analysis of 2477 single blastocyst transfers
A. Storr1, E. Bilir2, S. Cooke3, D. Garrett4, C. Venetis5
1Flinders Fertility, Embryology, Adelaide, Australia
2Koç University, School of Medicine, Istanbul, Turkey
3IVFAustralia, Embryology, Sydney, Australia
4IVFAustralia, Work Health & Safety, Sydney, Australia
5University of New South Wales, School of Women and Children’s Health, Sydney,
Australia
Study question:What is the most important embryo morphology parameter
associated with live birth (LB) rate after controlling for female age and endomet-
rial receptivity?
Summary answer: Developmental stage (DevSt) of an embryo, followed by
trophectoderm (TE) grading are the most important morphology parameters
independently associated with LB rate.
What is known already: It is well known that transferring better quality
embryos results in a higher chance of achieving a pregnancy. The move towards
single blastocyst transfers (SBT) has placed more importance on the ability to
select an embryo with the highest implantation potential, yet it remains unclear
which morphology parameters should be prioritised. Previous studies investigat-
ing the impact of embryo morphology parameters on pregnancy outcome in SBT
cycles have shown conﬂicting results. Most importantly, none of these studies
have controlled for differences in endometrial receptivity, which plays a critical
role in the establishment of a successful pregnancy and is a major confounder.
Study design, size, duration: This was a retrospective study (n = 2477 fresh
SBTs from 2183 couples) of cycles performed between January 2012 and April
2015 at three different clinics. The embryo morphology parameters that were
assessed on day of embryo transfer (day 5/6) by experienced embryologists
included DevSt (morula (M), early blastocyst (EB), full blastocyst (BL), expanded
blastocyst (XBL), hatching blastocyst (HgBL)), inner cell mass (ICM: A, B, C)
and TE (A, B, C).
Participants/materials, setting, methods: Fresh IVF/ICSI SBT cycles
where the value of serum progesterone on the day of human chorionic gonado-
trophin (P4dhCG) was available were included. P4dhCG was used as it is con-
sidered one of the best markers of endometrial receptivity after ovarian
stimulation. Generalized estimating equation regression models were used to
evaluate the independent effect of DevSt, ICM grade and TE grade on LB rates,
while controlling for female age, P4dhCG and the non-independence of data.
Main results and the role of chance: The mean age of the population was
36.0 years (95% CI: 35.8-36.2) and the mean P4dhCG was 2.95 (95% CI: 2.89-
3.00). In most cycles XBL (27.5%) were transferred, followed by BL (22.2%)
and HgBL (14.2%). DevStage was strongly associated with the probability of live
birth (p < 0.001) independently of female age (OR: 0.92, 95% CI: 0.90-0.94)
and P4dhCG (OR: 0.80, 95% CI: 0.74-0.87), both of which were also strong
predictors of LB. The predicted LB according to the DevStage was a) M: 5.3%
b) EB: 13.5% c) BL: 22.8% d) XBL: 31.1% e) HgBL: 35.2%. In BL, XBL and
HgBL, the addition of ICM and TE grading in the multivariable analysis suggested
that besides female age (OR: 0.92, 95% CI: 0.90-0.94) and P4dhCG (OR: 0.80,
95% CI: 0.73-0.88), only DevStage (p = 0.003) and TE quality (p = 0.020) were
independent predictors of LB while the predictive capacity of ICM was no long-
er signiﬁcant (p = 0.296). The mean probability of LB was higher for AA
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embryos (34.8%, 95% CI: 31.6-38.0), followed by BA embryos (30.3%, 95% CI:
25.1-35.6), AB embryos (27.9%, 95% CI: 23.7-32.1) and BB embryos (23.9%,
95% CI: 19.3-28.6). This order of implantation potential persisted regardless of
developmental stage (BL vs XBL vs HgBL).
Limitations, reasons for caution: This study is limited by its retrospective
nature as well as the subjective nature of embryo scoring. Furthermore, limited
numbers of embryos with poor quality ICM or TE (C grade) were transferred
and hence the estimates around their predictive role are not as robust.
Wider implications of the ﬁndings: This is a large study analysing for the
ﬁrst time the independent role of blastocyst morphology in predicting LB after
SBTs while controlling for both female age and P4dhCG. Its ﬁndings suggest that
DevStage and then TE grade should be prioritised over ICM grade when select-
ing an embryo for transfer.
Trial registration number:N/A.
O-154 Predicting live birth by combining cleavage- and blastocyst-
stage time-lapse variables using a hierarchical and a data mining-
based statistical model
S. Kawachiya1, D. Bodri1, R. Milewski2, T. Sugimoto1, J. Yao Serna1,
M. Kondo1, T. Matsumoto1
1Kobe Motomachi Yume Clinic, Assisted Reproduction Unit, Kobe, Japan
2Medical University of Bialystok, Department of Statistics and Medical Informatics,
Bialystok, Poland
Study question: Is it possible to establish highly predictive algorithms for live
birth (LB) by combining cleavage- and blastocyst-stage morphokinetic variables
using two different, robust statistical models?
Summary answer: The combination of cleavage- and blastocyst-stage mor-
phokinetic variables through hierarchical or data mining-based statistical algo-
rithms could be successfully used to predict live birth.
What is known already: Most of published predictive algorithms focused on
cleavage-stage morphokinetic variables only, despite the fact the prolonged
embryo culture is increasingly used as a way of improving pregnancy rates,
especially in the context of single embryo transfer. So far, only a handful of stud-
ies examined the relation between implantation potential and blastocyst-stage
morphokinetic parameters (Kirkegaard 2013, Campbell 2013, Motato 2016).
Despite these efforts time-lapse parameters extracted from later stages of
embryo development (morula, early and expanded blastocyst) are still under
investigation, although it was suggested that adding these variables to existing
cleavage-stage models could signiﬁcantly improve their predictive potential.
Study design, size, duration: All 326 single blastocyst transfers (SBT) from
all consecutive patients whose embryos were submitted to time-lapse monitor-
ing (TLM) between 2012 and 2014 were retrospectively analysed. Patients
(38.2 ± 3.9 years) underwent minimal ovarian stimulation, prolonged embryo
culture in TLM incubator, elective vitriﬁcation and vitriﬁed-warmed SBT. All
pregnancies were followed-up until live birth. Early (PNf, t2-t9), late (tM,
tearlyB, tfullB, texpB1-2) and interval morphokinetic parameters (cc2a-b, s2-3)
were scored according to published consensus criteria and standardized to
tPNf.
Participants/materials, setting, methods: A ﬁrst, hierarchical model -
including the two strongest LB predictors (t2 and texpB2) - and a second, more
robust one - based on combination of principal component analysis (PCA) and
logistic regression methods - were created. The PCA technique is a data-mining
method that relies on transformation of an initial correlated set of features into
new uncorrelated variables called principal components. For both models the
area-under-the-curve values (AUC) with 95% conﬁdence intervals were
calculated.
Main results and the role of chance: The overall LB rate per SBT was 30%
(97/326). The examination of detailed histograms revealed that areas with a
signiﬁcantly higher proportion of LBs (‘optimal LB ranges”) existed for six
cleavage-stage (t2, t3, t4, t6, cc2a, and cc2b) and four blastocyst-stage variables
(tearlyB, tBfull, texpB1 and texpB2) thus permitting the conversion of these
morphokinetic variables from continuous (hours) to categorical ones.
Combining two of the strongest variables (t2 and texpB2) resulted in a simple,
four-category (‘A” to ‘D”) hierarchical model. The model effectively distin-
guished between blastocysts with increasing live birth potential (categories ‘D”:
9%, ‘C”: 27%, ‘B”: 39%, ‘A”: 54%, p < 0.0001). For the second model quartiles
of the created Sc parameter (Q1-Q4) had increasing LB rates (Q1: 9%, ‘Q2”:
15%, ‘Q3”: 34%, ‘Q4”: 42%, p < 0.0001). AUC values for both models were
equally high (0.722, 95CI%: 0.66-0.78 versus 0.723, 95CI%: 0.67-0.78 for the
data mining-based and hierarchical models, respectively).
Limitations, reasons for caution: Our unselected patient cohort was
biased towards advanced-aged, poor-prognosis patients who undergone mild
IVF treatment coupled with single vitriﬁed-warmed blastocyst transfer exclu-
sively. This might limit generalizability to other less infertile populations or to
centres which use different treatment protocols.
Wider implications of the ﬁndings: Although we have created two differ-
ent statistical models their predictive power was similar and higher than most
previously published algorithms. The more robust, PCA-based model was
originally developed in a fundamentally different setting from ours, yet its
predictive power was similarly high in both datasets suggesting a wider,
between-center applicability.
Trial registration number: not applicable.
O-155 Day 5 versus Day 6 fresh and frozen blastocyst transfer cycle
outcomes: a systematic review andmeta-analysis
A. Finet1, M. Bourdon2, V. Grzegorczyk-Martin1, M. Poulain3,
A. Amar-Hoffet4, E. Arbo5, K. Pocate-Cheriet6, P. Santulli2
1Clinique Mathilde, Centre d’Assistance Médicale à la Procréation, Rouen, France
2Université Paris Descartes- Sorbonne Paris Cité- Faculté de Médecine- Assistance
Publique – Hôpitaux de Paris AP-HP- Hôpital Universitaire Paris Centre HUPC-
Centre Hospitalier Universitaire CHU Cochin, Department of Gynecology Obstetrics II
and Reprod,
3Hopital Foch- UVSQ- Université Versailles Saint Quentin, Department of
Reproductive Medicine, Suresnes, France
4Centre Sainte Colette- Hôpital Saint Joseph, Department of Reproductive Medicine,
Marseille, France
5Gedeon Richter France, Medical Affairs, Paris, France
6Université Paris Descartes- Sorbonne Paris Cité- Faculté de Médecine- Assistance
Publique – Hôpitaux de Paris AP-HP- Hôpital Universitaire Paris Centre HUPC-
Centre Hospitalier Universitaire CHU Cochin, Department of Reproductive Biology,
Paris, France
Study question: Is there a difference in clinical pregnancy and live
birth rates between day 5 and day 6 blastocysts following fresh and frozen
transfers?
Summary answer: Day 5 (D5) blastocyst transfers present higher clinical
pregnancy and live birth rates than day 6 (D6) in both fresh and frozen
transfers.
What is known already: Blastocyst transfer (BT) is increasingly popular in
assisted reproductive technology (ART) centers today. Numerous studies
described conﬂicting results in clinical outcomes following D5 and D6 BT. To
our knowledge, no meta-analysis has focused on clinical outcomes in both fresh
and frozen BT. Concerning frozen blastocysts, one meta-analysis found no sig-
niﬁcant difference in pregnancy outcomes between D5 and D6 blastocysts
(Sunkara et al., 2010). Yet since 2010, more articles comparing D5 and D6 fro-
zen embryo transfer cycles have been published, and ART practices have
evolved particularly with the wide use of vitriﬁcation.
Study design, size, duration: Systematic review and meta-analysis of pub-
lished controlled studies. Searches were conducted on MEDLINE, EMBASE,
Cochrane Library, Eudract and clinicaltrials.gov from 2005 to May 2017 using
the following search terms: Blastocyst; Day 5; Day 6; Pregnancy; Implantation;
live birth; embryo transfer.
Participants/materials, setting, methods: Forty-seven full-text articles
were preselected from 808 references, based on title and abstract and assessed
utilizing the Newcastle-Ottowa Quality Assessment Scales. Study selection and
data extraction were carried out by 2 independent reviewers according to
Cochrane methods. Random-effect meta-analysis was performed using Review
Manager software on all data (overall analysis) followed by subgroup analysis
(fresh, vitriﬁed/warmed, slow frozen/thawed). Risk ratio (RR) and 95% conﬁ-
dence interval (CI) were estimated using Mantel-Haenszel method. Sensitivity
analyses were performed.
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Main results and the role of chance: Data from 28 relevant articles were
extracted and integrated in the meta-analysis totaling 12,932 transfers involving
fresh and frozen D5 or D6 embryos. Meta-analysis of all transfers showed over-
all signiﬁcantly higher clinical pregnancy rates (CPR) following D5 BT (overall
RR = 1.26, 95% CI:1.14-1.40, p < 0.001), and remained unchanged after
adjustment for subgroups (RR = 1.27, 95% CI:1.15-1.40).
For CPR, calculated subgroup RRs were: 2.29, 95% CI:1.69-3.09, p < 0.001
for fresh BT; 1.27, 95% CI:1.16-1.40, p < 0.001 for vitriﬁed/warmed BT and
1.15, 95% CI: 0.93-1.41, p = 0.2 for slow frozen/thawed BT.
Live birth rate (LBR) was also signiﬁcantly higher after D5 BT (overall
RR = 1.46, 95% CI:1.25-1.70, p < 0.001), and remained unchanged after
adjustment for subgroups. The LBR calculated RRs for subgroups were: 1.65,
95% CI:1.23-2.21, p < 0.001 for fresh BT; 1.37, 95% CI:1.19-1.59, p < 0.001
for vitriﬁed/warmed BT and 1.44, 95% CI: 0.70-2.96, p = 0.32 for slow frozen/
thawed BT.
Sensitivity analysis led to similar results and conclusions: CPR and LBR were
signiﬁcantly higher following D5 compared to D6 BT.
Limitations, reasons for caution: The validity of meta-analysis
results depends mainly on the quality and the number of the published
studies available. Indeed, this meta-analysis included no randomized
controlled trial (RCT). Slow frozen/thawed subgroups showed substantial
heterogeneity.
Wider implications of the ﬁndings: In regards to results of this original
meta-analysis, ART practitioners should preferably transfer D5 rather than D6
blastocysts in both fresh and frozen cycles. Further RCTs are needed to address
the question of whether D6 embryos should be transferred in a fresh or a fro-
zen cycle.
Trial registration number: Prospero CRD42018080151
SELECTEDORAL COMMUNICATIONS
SESSION 42: NURSING ANDMIDWIFERY
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O-156 Facilitators and barriers affecting help seeking of infertile
women in the United States: A systematic review
M. Cebert
Duke University, Duke University School of Nursing, Durham, U.S.A.
Study question: What are facilitators and barriers contributing to help seek-
ing behaviors in women who experience infertility?
Summary answer: After conducting a systematic review, the literature does
not provide a clear understanding of facilitators and barriers due to limitations
in study designs.
What is known already: In the United States it is estimated that 7.4 million
women in childbearing ages 15-44 have used some type of infertility services for
family building, however this value may not reﬂect all women who experience
infertility. It is estimated that upwards to 50% of women who meet criteria for
infertility do not seek treatment.
Study design, size, duration: A systematic review was conducted and
reported using the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guide.
Participants/materials, setting, methods: A systematic review of studies
published between 2000 and 2017 was undertaken using the following data-
bases: PubMed, SocIndex, CINAHL, PsychInfo, ScienceDirect, and Google
Scholar. Primary search terms were infertility, subfertility, female, patient
acceptance of health care, help-seeking, health seeking, fertility awareness,
social support, culture, and treatment-seeking behaviors. The studies were
organized using the matrix method and critiqued using Chrisman’s Health
Seeking Model.
Main results and the role of chance: A total of 12 articles examined facili-
tators and barriers that contributed to help seeking behaviors in women who
experienced infertility. In studies that reported race/ethnicity, samples were
majority Caucasian American women. Nearly half of the studies were second-
ary analyses of self-reported data from national surveys. There were 29 unique
measurement tools used among the articles. Positive help seeking facilitators
were perceived symptom salience, positive self-esteem, life satisfaction, and
increased importance of parenthood, and fertility awareness. The most noted
barrier was lifetime diagnosis of depression and depressive symptoms. Findings
from these studies suggest there are multi-factorial barriers and facilitators for
help seeking. There were inconsistencies in reporting common demographic
factors especially race and ethnicity. A more uniform tool is needed to compre-
hensively assess mediating factors affecting help seeking.
Limitations, reasons for caution: Search, abstraction, and analysis were all
conducted by one author. Varying use of help seeking, treatment seeking, and
health seeking may have limited results. However, all 12 studies are highly
reﬂective of the main aim of this review to understand the facilitators and bar-
riers of women who sought fertility treatment.
Wider implications of the ﬁndings: Further exploration is needed to under-
stand these factors in other ethnicities. The use of theoretically guided frame-
works of help seeking may limit variations in measurement tool selection. More
understanding could lead to practice guidelines that encourage facilitators and
remove barriers to allow earlier and more consistent access to available care.
Trial registration number: not applicable.
O-157 A feasibility and acceptability study of a novel self-help
coping intervention for recurrent miscarriage
S. Bailey1, C. Bailey2, E. Kitson-Reynolds3, Y. Cheong4, J. Boivin5,
N. Macklon6
1University Hospitals Southampton NHS Foundation Trust, Women and Newborn,
Southampton, United Kingdom
2University of Nottingham, Faculty of Health Sciences, Nottingham, United Kingdom
3University of Southampton, Faculty of Health Sciences, Southampton, United
Kingdom
4University of Southampton, Human Development and Health- Faculty of Medicine,
Southampton, United Kingdom
5University of Cardiff, School of Psychology, Cardiff, United Kingdom
6London Women’s Clinic, London Women’s Clinic, London, United Kingdom
Study question: Is a multi-centre RCT to test the effectiveness of the Positive
Reappraisal Coping Intervention (PRCI) in women who have experienced
recurrent miscarriage, viable?
Summary answer: Feasibility ﬁndings ascertained that study design was suc-
cessful, there was a sizeable population willing to participate who engaged with
the intervention and found it acceptable.
What is known already: The early waiting period of a new pregnancy follow-
ing recurrent miscarriage (RM) is associated with high levels of uncertainty and
anxiety for the affected woman, yet there is limited support available and many
women are left to cope alone with managing these distressing emotions. The
PRCI, a self-administered supportive technique is effective at promoting positive
feelings and sustaining ability to cope in fertility patients awaiting the outcome
of in vitro fertilisation and seen as helpful in the ﬁrst three weeks of pregnancy
following RM, suggesting the PRCI beneﬁts could be sustained for the waiting
period before the twelve week scan.
Study design, size, duration: A two-centre RCT feasibility study established
the viability of conducting a multi-centre deﬁnitive RCT to test the hypothesis
that the PRCI can improve psychological wellbeing of women during the initial
experience of pregnancy following recurrent miscarriage. Nested within the
RCT was a qualitative process evaluation that explored participant’s subjective
experience of study methods and the intervention.
Recruitment (n = 75 feasibility RCT, n = 14 qualitative process evaluation)
took place over a two-year period.
Participants/materials, setting, methods: Participants were recruited
from Recurrent Miscarriage Clinics in two major hospitals in the United
Kingdom.
Participants were randomised, received the intervention and weekly ques-
tionnaires to assess psychological wellbeing up until twelve weeks of pregnancy,
or to simply complete the same weekly questionnaires. Descriptive statistics
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explored the feasibility of study procedures and were utilised to make an infor-
mal assessment of any impact of the intervention.
Study participants accepted an invitation to participate in qualitative process
evaluation.
Main results and the role of chance: This study successfully gathered
knowledge about the feasibility aspects of conducting a future multi-centre
deﬁnitive study to determine the effects of the PRCI on the psychological well-
being of women with RM during the challenging waiting period of a new
pregnancy.
Main themes identiﬁed included:
• The components of the protocol worked well together.
• There was a sizeable and appropriate population willing to partici-
pate in the study.
• Participants engaged with the PRCI and found it an acceptable inter-
vention to use.
• The PRCI appeared to convey beneﬁts to participants with an indi-
cation anxiety levels were lower in intervention group.
Results showed that an effectiveness RCT of the PRCI is possible but with mod-
iﬁcations to take in to account some speciﬁc issues. These included the need to:
• Introduce strategies to ensure more robust estimates of potential
participants in study sites.
• Pay careful consideration to potential barriers and facilitators to
recruitment.
• Introduce additional measures to aid monitoring of use of the
intervention.
• Introduce additional measurements of coping.
• Address the reactivity to one of the study questionnaires.
Importantly, study data provided conclusive evidence of the need for an inter-
vention such as the PRCI to address the psychological needs of women during
this time.
Limitations, reasons for caution: While every effort was made to support
the recruitment of a diverse sample to the feasibility study, the UK setting may
limit extrapolation to other national and cultural contexts.
Wider implications of the ﬁndings: If a future, deﬁnitive study of the PRCI
proves it to be an effective intervention, then this model of care has the poten-
tial to be made more widely available as a safe, low cost, convenient and easily
deliverable intervention to provide much needed support to a vulnerable
patient group.
Trial registration number: This study is funded by the National Institute of
Health Research, UK (Award reference number CDRF-2012-03-004).
It is registered with the ISCTRN registry, registration number:
ISRCTN43571276
O-158 A retrospective observational study to compare the success
rate of embryo transfer between Doctors and Nurse Practitioners in
a nurse-led fertility centre
J. Mutch1, A. Drakeley1, R. Gregoire1, R.Wheeler1, L. Briscoe2
1Liverpool Women’s Hospital, Hewitt Fertility Centre, Liverpool, United Kingdom
2Edge Hill University, Health and social care, Lancashire, United Kingdom
Study question: Is the success rate of embryo transfer between Doctors and
Nurse Practitioners comparable?
Summary answer: The rate of success of embryo transfer was signiﬁcantly
better from the Nurse Practitioner group, indicating that professional role does
have an impact on success.
What is known already: The number of embryos transferred in the UK in
2015 was 85,134 and according to HFEA data the average clinical pregnancy
rate in the same year for a couple undergoing IVF/ICSI using the woman’s own
eggs was 31%. In the North West of England alone, 3979 embryo transfers
took place in 6 different centres between July 2015 and June 2016, resulting in a
clinical pregnancy rate ranging from 13-36%. Due to the variation in treatment
outcomes between UK centres and the fact that there are very few nurse-led
fertility units, it was important to identify if professional role inﬂuences success.
Study design, size, duration: This was a retrospective observational study
based on data collected between 1st October 2015 and 31st October 2017 (25
months). Data were collected from 5,182 embryo transfers facilitated by 11
nurses and 14 doctors. The study focused around couples undergoing IVF/ICSI
using the woman’s own eggs and excluded fertility preservation, PGS, egg shar-
ing, surrogacy and donated gamete or embryo cycles.
Participants/materials, setting, methods: The study focused on the
results per embryo transfer of 11 nurses with experience ranging from 6
months to 12 years and 14 doctors with experience ranging from 6 months to
16 years, working within a large NHS fertility centre in the UK. The data were
collected from the electronic fertility database (IDEAS). Outcomes were mea-
sured for IVF/ICSI cycles using the woman’s own eggs by positive pregnancy
test and clinical pregnancy rate.
Main results and the role of chance: The cumulative success rates for posi-
tive pregnancy determination test (PPDT) and clinical pregnancy (CPR) within
the nursing group were PPDT 48.93%, CPR 37.23% respectively, and within the
doctors group were PPDT 43.24%, CPR 31.35% respectively. The nurse practi-
tioner group were signiﬁcantly better in both categories (P = 0.001/0.001
respectively). The signiﬁcant difference in PPDT and CPR following embryo
transfer by a Nurse Practitioner as compared with a doctor from these data
was achieved from a large number of cycles (>5000), indicating that the higher
PPDT and CPR achieved following transfer with a Nurse Practitioner were not
chance ﬁndings.
These ﬁndings conclude that success rates following embryo transfer by
Nurse Practitioners are not only comparable but signiﬁcantly improved on
those achieved by their medical colleagues, demonstrating that Nurse
Practitioners can positively and signiﬁcantly inﬂuence success. Experienced
nurses can be trained and with sufﬁcient exposure to embryo transfers can
become an essential part of a successful fertility team. Fertility healthcare provi-
ders may wish to consider the ﬁndings of this study when planning future work-
force requirements as the use of Nurse Practitioners can provide a sustainable
and cost effective option to a medically dominated service in which experienced
fertility doctors are often in short supply.
Limitations, reasons for caution: Quality of embryos was not included in
this data analysis.
Quality of the endometrial environment was not assessed.
Frozen versus fresh embryo transfer was not measured.
Number of embryo transfers per practitioner varied.
The degree of difﬁculty of individual cases was not taken into consideration.
Wider implications of the ﬁndings: Nurses can be trained to successfully
transfer embryos.
Trained nurses performing embryo transfer can positively inﬂuence the
chance of a successful pregnancy. A larger scale, matched cohort study would
help to measure the cost/beneﬁt and help to identify if this model should
underpin workforce development.
Trial registration number:N/A.
O-159 The importance of a genetic link between siblings after
oocyte donation
S. Somers1, V. Provoost2, H. Van Parys3, I. Stuyver1, A. Buysse3,
G. Pennings2, P. De Sutter1
1Ghent University Hospital, Department of Reproductive Medicine, Gent, Belgium
2Ghent University, Bioethics Institute Ghent - BIG. Department of Philosophy and
Moral Sciences, Gent, Belgium
3Ghent University, Department of Experimental-Clinical and Health Psychology,
Gent, Belgium
Study question: How do (aspiring) parents perceive and experience the
importance of a genetic link between siblings born after oocyte donation?
Summary answer: Because other factors co-determined the fulﬁlment of the
child wish, being able to use the same donor over time was less prominent
throughout the interviews.
What is known already: In case of sperm donation, we know that the
opportunity to use the same donor for subsequent conceptions seems
important for (aspiring) parents (Somers et al., in preparation). In case of
oocyte donation, we see at the clinic that couples starting treatment focus
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less on this topic. Scarce literature is available on the importance of a gen-
etic link between siblings after oocyte donation (Stuart-Smith et al., 2012).
The strength of this study is that we carried out couple interviews instead
of individual interviews and that we address both anonymous and known
oocyte donation.
Study design, size, duration: For this study, 19 heterosexual couples were
recruited at the Department of Reproductive Medicine of a University Hospital.
They consented for an in-depth, semi-structured couple interview. One couple
was interviewed separately, for two couples only the woman participated. The
interviews were conducted between June 2013 and May 2014. Data were ana-
lysed through step-by-step inductive thematic analysis. Approval of the clinic’s
Ethics Committee was obtained.
Participants/materials, setting, methods: 6 couples became parents after
known sister-to-sister oocyte donation and 8 couples opted for anonymous
oocyte donation. Nine of them gave birth to one child or twins, 3 couples had
consecutive children from a different donor and 2 couples had children from
the same donor. We also included aspiring parents (5 couples) who were either
already in treatment with anonymous oocyte donation or about to start.
Main results and the role of chance: When the heterosexual couples in
our study talked about their (future) family, being able to use the same oocyte
donor over time did not seem very important. The number of children in the
family depended on several external or uncontrollable factors such as: (1) the
number of oocytes retrieved per donation: a child wish could remain unfulﬁlled
because no more oocytes were left, (2) whether the recipients wanted to go
through the uncertain and intense treatment phase again, (3) the donor: if she
wanted to donate again and/or if the recipients dared to ask her to donate
again or the quest for a new donor and (4) practical reasons such as ﬁnancial
situation, professional career and housing.
Four couples talked about their preference of using the same oocyte donor.
This was perceived as positive because the children would be full siblings.
However, they mentioned that they could not decide on the same donor when
they opted for anonymous donation. Most aspiring parents focussed on having
a ﬁrst child. They also talked about other options to give meaning to their life
such as completing an adoption procedure and childlessness.
Limitations, reasons for caution: A speciﬁc question about being able to
use the same oocyte donor over time could not always be asked because the
participants co-determined the ﬂow of the interview. Future research could
focus on lesbian parents and aspiring parents in the trajectory of intra-partner
oocyte donation.
Wider implications of the ﬁndings: Similar to the counselling of couples
starting treatment with sperm donation, couples considering oocyte donation
should be asked how they see their future family. The number of desired children
should be discussed as it can inﬂuence the type of requested oocyte donation.
Trial registration number:NA.
INVITED SESSION
SESSION 43: MHR SYMPOSIUM: FIRST TRIMESTER
BIOMARKERS OF IMPAIRED PLACENTATION
Tuesday 3 July 2018 Room 211 + 212 14:00–15:00
O-160 Replication of Cytomegalovirus and Zika virus in ﬁrst-
trimester human placentas, mechanisms of viral pathogenesis and
host cell defense
L. Pereira
UCSF School of Dentistry, Cell and Tissue Biology, San Francisco CA, U.S.A.
Abstract text
Human cytomegalovirus (CMV), a Herpesvirus, is a leading viral cause of con-
genital infection and birth defects, including microcephaly, neuromotor deﬁcits,
and hearing and vision loss. Likewise, Zika virus (ZIKV), a Flavivirus, responsible
for the recent American pandemic, causes a spectrum of congenital malforma-
tions rarely seen with other neurotropic viruses. How these viruses disseminate
from maternal circulation to the fetus is poorly understood. For almost two
decades, we have investigated the biology of CMV infection in developing
human placentas and deciphered mechanisms that result in pathology observed
in placentas from newborns with congenital disease. We recently completed
studies of ZIKV infection in cells isolated from human placentas and amniochor-
ionic membranes and reported patterns of viral proteins in explants of chorionic
villi from ﬁrst-trimester placentas (Tabata, et al. Cell Host & Microbe, 2016;
Tabata, et. al. Journal of Infectious Diseases, 2017). Comparisons of CMV and
ZIKV infection and between prototype and pathogenic strains revealed
impaired replication and functional defects in infected cells. Host cell factors
were identiﬁed that modulate viral replication and prolong viremia ex vivo. Our
studies suggest novel strategies to strengthen natural protection and reduce
virus transmission at the uterine-placental interface.
O-161 Cell-free fetal hemoglobin as a biomarker of impaired place
S. Hansson
Institute of Clinical Science Lund- Lund university, Department of Obstetrics and
Gynecology-, Lund, Sweden
Abstract text
Preeclampsia (PE) is a severe pregnancy-related syndrome that annually affects
at least 8.5 million women worldwide. It is a leading cause of maternal and peri-
natal morbidity and mortality, responsible for about 18% of all maternal deaths
and up to 40% of neonatal deaths. With its aetiology still largely unknown, diag-
nosis of PE is based on maternal clinical symptoms; high blood pressure (BP)
and proteinuria manifesting after 20 weeks of gestation. Currently, delivery is
the only known cure. In addition, early disease diagnosis is challenging and there
are still no reliable biomarkers for clinical prediction or diagnosis.
We have shown elevated levels of free fetal hemoglobin (HbF) in the
maternal blood circulation in PE as early as the ﬁrst trimester and we have
shown the levels to correlate with the BP, i.e. the severity of the disease in late
pregnancy. Extracellular haemoglobin and its hydrophobic metabolite heme are
highly toxic with pro-inﬂammatory, pro-oxidative, tissue damaging as well as
vasoconstrictive effects.
By using the well-established dual-placenta perfusion model to study the
human placenta ex vivo, we have shown that free HbF causes damage to the pla-
centa barrier and endothelial cells by inducing oxidative stress and inﬂammation.
Furthermore, cell-free HbF has also been shown to increased the microcircula-
tory resistance. In different animal models, cell-free HbF has been shown to
cause kidney and placental damage similar to that seen in PE, i.e. glomerular
endotheliosis and reduction of the podocyte-speciﬁc protein, nephrin.
To prevent toxicity of cell-free hemoglobin as well as its degradation metabo-
lites heme and free iron, several scavenger proteins and degradation enzymes
protect the body. Haptoglobin (Hp) binds free hemoglobin and transports it
to macrophages and hepatocytes where the uptake is facilitated by CD163
receptor-mediated endocytosis. Hemoglobin is degraded to heme and then fur-
ther catabolized by the rate limiting enzyme heme oxygenase 1 (HO-1).
Alpha-1-microglobulin (A1M), a lipocalin protein, that in addition to heme
also binds radicals and has enzymatic reducing capacity. We have recently
shown that A1M is up regulated in early and late onset PE. Hemopexin (Hx) is
a circulating plasma glycoprotein, mainly synthesized in the liver, that binds free
heme with high afﬁnity. Hemopexin also has enzyme activity, which has been
suggested to regulate the vascular responsiveness to angiotensin II.
In a series of studies we have deciphered how maternal plasma HbF and
heme impact the scavenger enzyme systems Hx and HO-1 in patients with PE
and studied how these proteins can be used as biomarkers for PE. Logistic
regression analysis with ROC-curve analysis was performed to evaluate them
as biomarkers. In PE plasma, signiﬁcantly higher levels of HbF and heme in com-
bination with signiﬁcantly lower Hx activity, Hx and HO-1 levels was shown
compared to normal pregnancies. The Hx activity was inversely correlated to
the diastolic blood pressure and the HO-1 concentration was inversely corre-
lated to both the systolic and diastolic blood pressure. The ROC-curve analysis
showed a combined detection rate for these biomarkers of 84% at 10% false
positive rate in late pregnancy.
Studies on fetal growth restriction (FGR) have shown increased levels of
cell-free HbF, whilst elevation of its ratio with HO-1 suggests failure of the cata-
bolic compensation. Placental endothelial cells, primed with cell-free HbF,
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developed a pro-inﬂammatory phenotype and disruption of endothelial cell
ﬂow-alignment.
Conclusions: There is an important aetiological role for cell-free HbF in both
fetal growth restrictions and in preeclampsia.
By measuring components in the HbF metabolism as potential biomarkers,
they can be clinically useful to support the PE diagnosis. Future studies are
needed to evaluate the role of these biomarkers as ﬁrst trimester predictive
biomarkers for PE, particularly in late-onset PE and neonatal outcome.
INVITED SESSION
SESSION 44: LIVE SURGERY
Tuesday 3 July 2018 Room 111 + 112 14:00–17:00
INVITED SESSION
SESSION 45: MANAGING EMBRYO STRESS IN
PREIMPLANTATIONDEVELOPMENT
Tuesday 3 July 2018 Room 113 + 114 + 115 14:00–15:00
O-162 Nuclear reprogramming and chromatin functions in
oocytes and preimplantation embryos
K. E. Latham
Michigan State University, Animal Science, East Lansing, U.S.A.
Nuclear Reprogramming and Chromatin Functions in Oocytes and
Preimplantation Embryos.
Reprogramming of the genome is an essential part of creating each new life.
The genomes of two highly differentiated gamete genomes must be repro-
grammed to create an embryonic genome capable of development. This pro-
cess begins with reprogramming the genome for meiosis, continues in the early
cleaving embryo, and continues throughout preimplantation development until
the earliest lineages are established. Meiotic reprogramming, including tran-
scriptional silencing, histone deacetylation, and chromatin condensation, is
essential to create a chromatin state that is compatible with correct spindle
formation and faithful chromosome segregation. Further reprogramming is
associated with preparing and activating the embryonic genome, ﬁrst creating
transcriptional competence, and then creating a repressive chromatin environ-
ment that allows gene regulation. As the embryo cleaves, further reprogram-
ming occurs, culminating in the creation of cells with different identities,
destined to give rise to inner cell mass and embryo proper, trophectoderm,
and extraembryonic endoderm. Recent studies reveal that developmental pluri-
potency remains dependent on early embryonic chromatin states, establishing
one potential connection between early events and later progeny health.
Artiﬁcial reprogramming methods, achieved by somatic cell nuclear transfer,
induced pluripotency, and application of epigenetic drugs, display signiﬁcant lim-
itations. These limitations attest to the unique dialog between ooplasm and
gamete/embryonic genomes, the continuously shifting demands of the embry-
onic system, the opposing needs that must be satisﬁed at key points in the pro-
cess, and the potential points at which exogenous factors may intervene to
compromise development. The factors responsible for the different phases of
this unique and ongoing reprogramming dialog are still being discovered. A dee-
per understanding of the nature of these factors and the underlying chromatin
states upon which they act should be beneﬁcial in basic and applied arenas.
O-163 Mitochondrial stress in preimplantation development and
opportunities for treatment
R. Robker
University of Adelaide, School of Medicine- Robinson Research Institute, Adelaide,
Australia
Abstract text
Oocytes contain all of the cellular building blocks required to support embryo-
genesis until the blastocyst stage of development. However the quality, quantity
and composition of these cellular building blocks is determined by physiological
signals inﬂuenced by the maternal environment; which in turn have dramatic
effects on the progression of embryogenesis. In particular oocytes are lipid-rich
cells and oocyte lipid content is inﬂuenced by maternal nutrition. Similarly, oocyte
mitochondria are highly sensitive to environmental signals which can change their
capacity for energy production and biogenesis and thereby inﬂuence embryo
development and mitochondrial inheritance. Using a number of approaches in
mice we have sought to determine how these key aspects of oocyte quality,
namely lipid content and mitochondrial activity, regulate embryo developmental
kinetics during pre-implantation development to the blastocyst stage. This infor-
mation is needed because accumulating evidence demonstrates that discrete
changes to oocyte quality inﬂuence the timely formation of the inner cell mass as
well as distinct aspects of offspring phenotypes into adulthood.
To examine the effects of relevant physiological and in vitro conditions of
oocytes on subsequent developmental competence, oocytes were isolated
from female mice that were either obese or aged or that were manipulated
in vitro in order to deplete cholesterol lipid or induce oxidative stress. Embryo
morphokinetics were then assessed by continuous time-lapse monitoring, and
cell lineage allocation to the inner cell mass (Oct4+) or trophectoderm
(Cdx2+) was identiﬁed by immunohistochemistry. The results show that
exposing oocytes to different environmental conditions in vivo or in vitro causes
distinct changes to cell cycle kinetics following fertilization and deﬁciencies in
either inner cell mass or trophectoderm cell number by the blastocyst stage. In
addition, embryos fertilized in vitro exhibit altered development compared to
those fertilized in vivo, even from the 2 cell stage. These results further demon-
strate that even subtle insults to oocytes during maturation and fertilization
change zygote cell cycle kinetics, and identify differential effects on embryos in
response to distinct physiological and in vitro environments. Most importantly,
we are able to restore the developmental competence of poor quality oocytes,
damaged by obesity, aging or in vitro stress, using speciﬁc pharmaceuticals.
INVITED SESSION
SESSION 46: PATIENT SESSION: SURROGACY - THE
PATIENTS’ PERSPECTIVE
Tuesday 3 July 2018 Room 117 14:00–15:00
O-164 Surrogacy in Portugal - from struggle to accomplishment
A. Galhardo
Instituto Superior Miguel Torga- CINEICC-Faculty of Psychology and Educational
Sciences of the University of Coimbra- Associação Portuguesa de Fertilidade,
Psychology, Coimbra, Portugal
Abstract text
Relevant medical advances in the ﬁeld of reproductive medicine now allow
people previously unable to become genetic parents due to medical factors
(e.g., women without a uterus, uterine abnormalities or medical conditions
that contraindicate pregnancy) or social motives (e.g., gay men or couples)
to accomplish this usually valued objective. Gestational surrogacy policy in
Europe varies by country and it remains a controversial topic due to ethical
and legal concerns. This third-party reproductive technique is a complex sub-
ject involving the commissioning parents, the gestational surrogate and the
child to be. Recently in Portugal, July 2017, the legal context changed and
gestational surrogacy is currently possible. This was an important achieve-
ment from the patients’ perspective and one of the last steps of a long jour-
ney of struggle. In 2012 a parliament working group was formed with the aim
of revising the medically assisted reproductive legal framework. Two years
later a group of Portuguese Fertility Association (APFertilidade) members
wrote to all political parties in the parliament, to the Health Commission and
the National Council for Medically Assisted Reproduction, asking for the
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inclusion of surrogacy in their agenda. On 22nd April 2016 the ﬁrst law pro-
ject addressing gestational surrogacy was rejected and APFertilidade
requested the main right wing party to vote for. A week later a left wing party
proposed the text to be voted in a plenary session in the same date the
revised version of the law would be presented (May 13th). At the same time,
APFertilidade launched a video containing real testimonies of women with-
out a uterus who needed the law change to accomplish their dream of
becoming mothers and it was sent to all deputies. This was an interesting
piece of campaign encompassing several messages such as exclusion and stig-
ma as well as the idea of not being heard and being pushed to illegal and
cross-board scenarios. On 13th May the new law was approved by the parlia-
ment and access to assisted reproductive technologies (ART) was extended
to all women independently from their marital status or sexual orientation.
Furthermore, gestational surrogacy was also approved but in June the
President considered there were queries, mainly concerning the interest of
the child and the surrogate, and these should be clariﬁed before promulga-
tion. In June 2017 the law received the approval of the Ministries Council.
Finally, in July 2017, the President promulgated the law regulation. The
approved framework states that women facing medical conditions such as
not having a uterus or uterus malformations or other medical conditions that
clearly contraindicate pregnancy are the ones who can beneﬁt from this
treatment approach. Within this regulation it is also worth noting that
besides medical criteria, it is mandatory to include psychological support for
the parties involved and this suggests that psychological and social implica-
tions were considered by the legislator. By the end of 2017 the National
Council for Medically Assisted Reproduction approved the ﬁrst application.
Although this was a demanding and challenging process, a study conducted in
2015 (before the law change) with 518 participants to whom it was asked to
state their opinion about surrogacy, 69% agreed with legalization, 19% did
not agree and 12% were non-respondents. Moreover 38% stated that they
would support a friend in need of a gestational surrogate and 32% would sup-
port a female friend who decided to act as a gestational carrier.
Nevertheless, when the question was whether they would pursue such a
treatment option in case they needed, 50% answered “no” and 37% would
consider surrogacy if all other possibilities were to be excluded.
O-165 Surrogacy and stratiﬁed kinship
A. Pande
University of Cape Town, Department of Sociology, Cape Town, South Africa
Abstract text
Commercial surrogacy is a multi billion-dollar industry across the world, with
India being one of the world leaders. Although often couched in dystopic terms,
the topic of surrogacy is not restricted to medical or scientiﬁc circles and has
been generating feminist, ethical, legal and social debates for over three decades
now. Despite this rich and growing literature, the common perception of surro-
gacy is one of intense anxiety – with dystopic images of baby farms, breeding fac-
tories and women as cows and guinea pigs ﬂooding the media. When intended
parents travel from countries in the global north to access services in the global
south, there is an additional anxiety that such travel reiﬁes global inequalities by
making the bodies of people in resource-poor countries easily rentable by others.
In my previous works I have argued that while these images are justiﬁable, they
do not get to the complexity of the industry, the way it is unfolding in India.
Commercial surrogacy in India is a rapidly growing informal labour market, one
that needs to be understood empirically and not as an ethical dilemma (Pande
2014, 2015, 2016). Once we start unpacking these empirical realities, we realize
that much of the structural inequalities are inherent to commercial surrogacy. In
fact this industry reﬂects the global trend of “stratiﬁed motherhood” – “the hier-
archical organization of reproductive fecundity and birth experiences that sup-
ports and rewards the maternity of some women while despising or outlawing
the mother-work of others” (Rapp 1991). In this paper I use my recent ethno-
graphic ﬁndings from my ﬁeld to expand on this notion of stratiﬁcation by high-
lighting a fundamentally unequal aspect of this practice – what I label “stratiﬁed
kinship” – whereby there is legal and social acknowledgement and celebration of
only genetic parenting while making birth mothering invisible.
O-166 What is it like to be a wombless woman in the age of ART’s?
Patients’ perspectives on gestational surrogacy in Finland
K. Kivipuro
University of Helsinki, Department of Social Research, Helsinki, Finland
Abstract text
Each year in Finland, a number of fertile age women encounter an involuntary
hysterectomy or ﬁnd out they have never had a uterus. In my presentation, I
examine how Finnish wombless women of fertile age cope with their condition
and tackle their life between the imperative of procreation and the restrictions
of reproduction. Based on my ongoing sociological study, I discuss what it
means to be a wombless woman in Finland, where gestational surrogacy is for-
bidden, adoption is heavily regulated, and uterus transplants are still only a
promise for the future.
Lack of uterus is always dramatic, because the indication for involuntary hys-
terectomy can be, for instance, a gynecological cancer, a life threatening compli-
cation during delivery, or it involves a teenage girl with congenital absence of a
uterus (Mayer-Rokitansky-Küster-Hauser syndrome). Involuntary wombless-
ness is a relatively rare incident, but it has a major effect on these women’s lives
and the possibilities to have a child. The situation forces to redeﬁne the frames
of reproduction and makes the woman to think strategically how founding a
family would be possible. Furthermore, the lack of uterus does not only have a
profound effect on the woman but also on her partner and immediate family.
Since 2007, the Assisted Fertility Treatment Act has prohibited gestational
surrogacy in Finland. Based on research data, which includes 25 semi-structured
in-depth interviews conducted with wombless women during 2017 and collab-
oration with two patient organizations for involuntary childlessness, I show that
the prohibition of gestational surrogacy induces deep sorrow and resentment
for majority of those affected by the condition. In practice, the legislative limita-
tions are unable to prevent people from seeking and obtaining reproductive
services elsewhere. In Finland, proximity to Russia prompts the intended par-
ents with their Finnish surrogate to obtain the IVF from Russia, while giving
birth to the baby in Finland. Intended parents are placed in highly contradic-
tory situations, as they need to consider if they are willing to circumvent
the legislation, invest a great amount of mental and ﬁnancial resources, and
leave their home country to seek the fertility services. Without regulatory
support, evaluation of ethicality and riskiness of reproductive travel is left to
individuals.
INVITED SESSION
SESSION 47: HOWTO INCREASE PEOPLE’S FERTILITY
AWARENESS?
Tuesday 3 July 2018 Room 116 14:00–15:00
O-167 Development and impact of fertility campaigns
L. Schmidt
University of Copenhagen, Department of Public Health- Section of Social Medicine,
Copenhagen K, Denmark
Introduction: Considerable gaps have been identiﬁed in men and women’s
knowledge of fertility. Fertility education and increasing the population’s fertility
awareness has been suggested as intervention strategies to contribute to pre-
vention of infertility and to also reduce other negative consequences of delayed
childbearing.
In response to this call, a small number of studies have measured the impact
of fertility knowledge interventions. These studies show that these interventions
are successful in increasing fertility knowledge in the short term. However,
these interventions have often been developed for research and are not widely
available to the public as in a widespread fertility campaign.
Results: A review of PubMed and searching keywords via Google showed that
several fertility campaigns have been developed and launched across the globe.
The campaigns are generally driven by one or both of the following goals:
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(1) To increase men and women’s fertility knowledge in order to promote
informed and satisfying fertility/childbearing decision-making
(2) To increase knowledge and awareness of fertility in order to increase falling
birth rates.
Content generally includes information about the fertility lifespan and risks to
fertility.
The media plays a signiﬁcant role in how the campaigns are understood and
interpreted by the public and can facilitate or hinder the campaign goals. In
some cases, the media provides a wider dissemination of the fertility campaign
on a larger platform (e.g., ASRM).
In other cases, the media’s portrayal of the campaign can result in the
intended messaging being lost or misconstrued. For example, the media in
Denmark linked the increased birth rate to fertility campaigns suggesting
increasing the birth rate was the primary intention. In many cases, more
coverage can be focused on the backlash rather than the content. The most
common criticisms of fertility campaigns include blaming women for waiting
too long and/or not being aware of their fertility, encouraging women and
men to have children before they are ready, reducing women to their
biological potential and presenting a one-sided story that does not acknow-
ledge the structural and societal barriers and restrictions to younger
parenthood.
A common problem across fertility campaigns is how to determine their
impact. In the case of online campaigns, page views, social media hits and down-
loads can be tracked and provide some sense of the reach (example of
YourFertility.org.au). The fertility campaigns have largely been unevaluated
empirically so we do not know how or if they are impacting fertility knowledge
and behaviour.
Conclusions: It is of importance that fertility campaigns are developed
together with the many different stakeholders regarding fertility and family
building; e.g., national health authorities, different groups of health professionals
(medical doctors, midwives, nurses), NGO’s on family building and sexual edu-
cation as well as the target groups in the population. Further, evaluation is a
necessary next step in fertility campaigns to gain a better sense of their impact
and reach.
O-168 Preconceptional personalised mHealth lifestyle coaching:
\rFirst results of a randomized controlled trial in couples undergoing
IVF/ICSI treatment
R.P.M. Steegers-Theunissen
Erasmus MC, Dept of Obstetrics and Gynaecology Room Ee 22.71a, Rotterdam, The
Netherlands
Abstract text
Mounting evidence demonstrates that healthy maternal lifestyles, including
nutrition, signiﬁcantly improve pregnancy chances as well as maternal preg-
nancy- and neonatal outcomes, with implications for health and disease risks
across the lifecourse. Although the impact of paternal lifestyles has been largely
neglected, more data are now available showing also their inﬂuence on semen
quality and embryonic growth trajectories, with potential health consequences
for the offspring. Again, this data very much illustrate the importance of the crit-
ical periconceptional window, deﬁned as 3 months before up to 3 months after
conception, during which most adverse reproductive outcomes originate.
Therefore, in the ﬁrst part of this presentation new evidence on the impact of
periconceptional maternal and paternal lifestyles on the gametes and (pre)
implantation embryo quality and growth trajectories will be demonstrated using
questionnaire data and (non) invasive biomarkers using for example 3-
dimensional ultrasound, time-lapse and ofﬂine virtual reality techniques.
As researchers we also have the responsibility to implement evidence-based
data in patient care. Indeed more couples with a child wish and planning preg-
nancy, especially subfertile couples and health care professionals, are aware of
the impact of lifestyle on reproduction. However, adopting healthy behaviors
remains a big challenge for everyone. Therefore, following the implementation
of a preconceptional clinic on lifestyle coaching (2007-2012) at the Erasmus
MC, University Medical Center in Rotterdam, The Netherlands, we have devel-
oped the successful mHealth coaching programme ‘Smarter Pregnancy’. This
mHealth programme with CE certiﬁcation is available in the Dutch (www.
slimmerzwangeronderzoek.nl and www.slimmerzwanger.nl) and English lan-
guage (www.smarterpregnancy.co.uk/research) and aims to empower couples
of adopting healthy lifestyles before and during pregnancy. Between 2012 and
2014 a large survey was performed using ‘Smarter pregnancy’ as intervention
which showed signiﬁcantly positive results on compliance, feasibility, usability
and ﬁrst effectiveness. From 2014 onwards also a multicenter randomized con-
trolled trial is conducted in 6 IVF clinics in the Netherlands using this mHealth
programme. In the second part of this presentation the ﬁrst results will be pre-
sented of this trial that demonstrate an even higher compliance than was
revealed from the survey. Moreover, the signiﬁcant effectiveness of this
mHealth programme is conformed with regard to adopting short- and long-
term healthy lifestyles in couples undergoing IVF treatment. Subgroup analysis
also shows the beneﬁcial effects in overweight and obese women. Since
mHealth has the potential to reach and empower a large population, our next
ambition is the development in co-creation with multiple stakeholders of a
digital life course platform for implementation of lifestyle care in routine patient
care from the preconceptional period onwards. This is a societal challenge
which can also be a great opportunity for Big data collection to further improve
(cost)effectiveness of health care.
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SELECTEDORAL COMMUNICATIONS
SESSION 48: EFFECTS ONTESTICULAR DEVELOPMENT
ANDGERMCELL DIFFERENTIATION
Tuesday 3 July 2018 Forum (Auditorium) 15:15–16:30
O-169 Exposure to acetaminophen and ibuprofen affects fetal
germ cell development in both sexes in rodent and human
P. Hurtado-Gonzalez1, J. MacDonald1, K. Kilcoyne1, S. Van den
Driesche1, A. Jorgensen2, R. Anderson1, R. Sharpe1, R. Mitchell1
1University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, United
Kingdom
2Copenhagen University Hospital Rigshospitalet, Department of Growth &
Reproduction, Copenhagen, Denmark
Study question: We determined whether therapeutic doses of analgesics
affect germ cell development in the human (and rodent) fetal testis and ovary
using in-vitro, in-vivo and xenograft approaches.
Summary answer: Germ cell number was signiﬁcantly reduced (28-49%) in
human fetal testes and ovaries exposed to acetaminophen or ibuprofen, whilst
rodent studies revealed altered epigenetic regulation.
What is known already: The majority of women use an analgesic (acet-
aminophen or ibuprofen) at least once during pregnancy. Whilst some epi-
demiological studies have reported associations between analgesic use during
pregnancy and cryptorchidism in sons, the ﬁndings are inconsistent within and
between the different study populations. A recent study which utilised a xeno-
graft model of human fetal testis tissue showed that prolonged acetaminophen
exposure at human-relevant dosing reduced plasma testosterone levels, whilst
rodent studies have indicated potential for germ cell effects following acet-
aminophen exposure. However, whether germ cell effects occur in analgesic-
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exposed human fetal gonads and the mechanisms involved have not been
determined.
Study design, size, duration: First trimester human fetal testes and ovaries
(n = 8) were cultured exposed to acetaminophen and ibuprofen for 7 days.
Second trimester human fetal testes (n = 10) were xenografted into immuno-
compromised mice and exposed to vehicle, acetaminophen (60 mg/kg/day; 1
or 7 days) or ibuprofen (30 mg/kg/day; 7 days). To determine mechanism of
action, a human GC tumor-derived cell line (NT2) was used (acetaminophen
or ibuprofen +/- PGE2 agonists) as well as an in-vitro and in-vivo (n = 13-30)
rat model.
Participants/materials, setting, methods: Fetal testis sections were dou-
ble/triple immunostained for SOX9 (Sertoli cells), TFAP2C (gonocytes) and
MAGEA4 (pre-spermatogonia). mRNA Expression of epigenetic regulators in
human (TET1, EZH2, DNMT3a, DNMT3b) and rat (Tet1, Ezh2, Dnmt3a and
Dnmt3b), in addition to germ cell pluripotency (POU5F1, TFAP2C and
NANOG) genes were determined. Results were analyzed by two-factor
ANOVA with replication. Statistical signiﬁcance was indicated where p < 0.05
Main results and the role of chance: Gonocyte (TFAP2C+) number was
decreased in 1st trimester human fetal testes exposed in-vitro to acetamino-
phen (28% reduction; p = 0.008) or ibuprofen (22% reduction; p = 0.001) and
in ovaries exposed to acetaminophen (43% reduction; p = 0.016) or ibuprofen
(49% reduction; p = 0.005), compared with controls. Acetaminophen expos-
ure decreased gonocyte number in xenografted 2nd trimester human fetal tes-
tes by 17% (p = 0.044) and 30% (p = 0.014) after treatment of host mice for 1
or 7 days respectively. NT2 cell number was decreased after exposure to acet-
aminophen (19% reduction, p = 0.0002), ibuprofen (18 %reduction, p = 0.006)
or to prostaglandin E2 (PGE2) antagonists (27% reduction; p = 0.0001), and
PGE2 agonists prevented acetaminophen-induced reduction in NT2 cell num-
ber (p = 0.029). Gene expression of regulators of DNA and histone methyla-
tion and of GC pluripotency genes, differed from controls following analgesic
and PGE2 antagonist exposures. Gene expression changes also occurred in rat
fetal testis/ovary cultures and following in vivo acetaminophen exposure of
pregnant rats. One such example was expression of the epigenetic regulator
TET1, which was signiﬁcantly increased after exposure to acetaminophen in
several model systems (human NT2 cells, rat fetal testis/ovary cultures, and
fetal testes and ovaries after in vivo exposure of pregnant rats), demonstrating
robust translatability across experimental models and species.
Limitations, reasons for caution: Although the xenograft/culture models
can mimic many aspects of normal human fetal gonad development, they can-
not recreate in vivo human conditions. Despite these limitations, the consist-
ency of analgesic effects and concordance between humans and rats (including
in-vivo), suggest that mechanisms for fetal GC effects are conserved between
rodents and humans.
Wider implications of the ﬁndings: These ﬁndings provide novel evidence
for potential adverse effects of analgesics during pregnancy. They suggest that
exposure of human fetal gonads to therapeutically-relevant concentrations of
acetaminophen and ibuprofen may impact fetal germ cell number and, poten-
tially, epigenetic modiﬁcations. This could affect future fertility of the individual
and/or future generations.
Trial registration number: n/a.
O-170 Acute myeloid leukemia (AML) impairedmouse male
fertility by affecting testicular growth factors, premiotic/miotic and
posmiotic spermatogenic cell counts
Y. Michailov1, J. Kapelushnik2, S. Friedler3, E. Lunenfeld4,
M. Huleihel5
1The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel and IVF Unit-
Barzilai University Medical Center- Ashkelon- Israel., The Shraga Segal Dep. of
Microb,
2The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- Ben-Gurion University of the Negev- and Soroka Medical Center-
Beer-Sheva- Israel., Dep. of Pediatric Oncology and Dep. of Hematology- Soroka
Medical Cente,
3Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel-
and Barzilai University Medical Center- Ashkelon- Israel., IVF Unit- Barzilai University
Medical Center- Ashkelon., Beer-Sheva, Israel
4The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- and Soroka
Medical Center- Israel., Dept. OB/GYN- Soroka Medical Center, Beer-Sheva, Israel
5The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- The National Institute for Biotechnology in the Negev- Ben-Gurion
University of the Negev- Beer-Sheva- Israel., The Shraga Segal Dep. of Microbiology-
Immu,
Study question: How can AML affect mouse male fertility?
Summary answer: AML impaired the seminiferous tubules (STs) histology,
reduced the number of spermatogenic cells, increased apoptosis in the STs and
reduced production of testicular growth factors.
What is known already: It is known that some types of cancer can affect
semen quality even before anti-cancer treatment. Some studies reported signiﬁ-
cant reductions in semen parameters (motility, concentration and morphology)
in Leukemia patients before chemotherapy. In addition, a signiﬁcant reduction
in semen quality of thawed cryopreserved semen from leukemia patients com-
pared to control patients was reported. Also, a reduction in some hormones
was reported in cancer patients compared to control. However, the mechan-
isms behind these impairments parameters are not yet fully understood.
Study design, size, duration: Six-week-old males C57/BLACK mice were
used. 1. Control group – injected with saline. 2. AML group – injected (intraper-
itoneal; i.p) with 1 × 105 AML cells (murine C-1498 AML cell line). Mice were
sacriﬁced (4-6 mice in each time point) after 1,2,3,4 weeks of AML injection.
Participants/materials, setting, methods: Testes were removed and
ﬁxed in Bouin’s solution for histological evaluation, or kept at -700 C for RNA
extraction. The presence of premeiotic (SALL4,PLZF), meiotic (CREM-1) and
postmeiotic (ACROSIN) cells were examined by immunoﬂuorescence staining.
Apoptosis was examined by tunel assay. The expression of growth factors in
the testes was examined by qPCR analysis. Sperm cells were extracted from
the epididymis. The fertility capacity of the mice was examined by mating with
normal C57/BLACK females.
Main results and the role of chance: Mice were still alive 4 weeks after
AML injection. A signiﬁcant decrease in the number of cell layers and a signiﬁcant
increase in the size of the lumen of the STs were demonstrated in AML mice
compared to control. The number of premeiotic (SALL4, PLZF) cells/ST and the
percentage of STs with meiotic (CREM-1) or postmeiotic (ACROSIN) cells were
signiﬁcantly lower in AML mice compared to control. The percentage of STs with
apoptotic cells signiﬁcantly increased in AML mice compared to control. The
expression of growth factors in testicular tissue [macrophage-colony stimulating
factor (MCSF), glial cell-derived neurotrophic factor (GDNF), leukemia inhibitory
factor (LIF)] was signiﬁcantly lower in AML mice compared to control group.
Sperm concentration, motility and morphology were signiﬁcantly lower in AML
mice compared to control. The fertility capacity of the AML mice was 50% of the
control after 3 weeks of AML injection compared to control.
Limitations, reasons for caution: Animal model of leukemia may behave
different from human model.
Wider implications of the ﬁndings: This study deepens our understanding
of mechanism behind reduced fertility and infertility in AML male patients.
Understanding these mechanisms may assist in the development of future
therapeutic strategies for male fertility preservation.
Trial registration number:NA.
O-171 CRISPR/cas9 mediated HSD17B3 genemutation on mouse
Leydig cells: Effectivity of CRISPR/cas9 on testosterone synthesis
pathway
N. Karahan1, S. Karahuseyinoglu2
1Koc University, Graduate School of Health Sciences- Reproductive Biology, Istanbul,
Turkey
2Koc University, School of Medicine- Department of Histology and Embryology,
Istanbul, Turkey
Study question: Can CRISPR/cas9 method be used for gene editing to inter-
fere testosterone synthesis in mouse Leydig cells?
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Summary answer: HSD17B3 gene knock-out via CRISPR/cas9 gene editing
technology can be accomplished in mouse Leydig cells successfully to interfere
and decrease secretion of testosterone.
What is known already: CRISPR/cas9 gene editing technology comprises
programmable endonucleases that facilitate making models with precise genetic
changes to study the progress and treatment of diseases, some of which are
related to faulty testosterone production. Testosterone synthesis involves a
highly complicated cascade of sequential reactions that precise regulations are
not usually possible, since non-speciﬁc interventions affect the other steroid-
related products in the cascade, as well. CRISPR/Cas 9 has made it possible to
accomplish cell targeted interventions, which are widely used in a variety of cells
in the body in order to obtain genome based therapies.
Study design, size, duration: This study involved the knock-out of
HSD17B3 gene of Leydig cells isolated from adult CD1 mouse (n = 36) testis
via the use of CRISPR/cas9, followed by evaluation of changes in secretion of
testosterone within control group and experimental group throughout 15 days
under the effect of 100 ng/ml human chorionic gonadotropin. Quantitative ana-
lysis was performed by qRTPCR, WB and ELISA in triplicates compared by stu-
dent’s t-test. The semiquantitative analysis was accomplished by
superresolution microscopy.
Participants/materials, setting, methods: Leydig cells isolated from adult
CD1 mice were cultured 2 days with human chorionic gonadotropin to induce
maturity and secretion of testosterone before CRISPR/cas9 gene editing pro-
cedure. HSD17B3 gene was knocked-out with a speciﬁc guide-RNA specially
designed for that mouse gene. Triplicate experiments for Western Blot, qRT-
PCR, and super-resolution confocal microscopy were performed to show the
reduction in this gene expression, with altered cell morphology, as ELISA was
used to detect changes in testosterone levels.
Main results and the role of chance: This project was undertaken to design
testosterone deﬁciency model in vitro and evaluate the effect along with the
efﬁciency of CRISPR/cas9 method for Leydig cells.
The ﬁrst set of experiments was set to conﬁrm the isolation of Leydig cells and
the effect of CRISPR/Cas9 gene edition on isolated cells. Leydig cells of mouse
testis were isolated with high purity (>95%) in adequate amounts to carry out
culture and gene edition experiments. The efﬁciency of CRISPR/cas9 for the edi-
tion of HSD17B3 gene was >85% in with no suspected off-target performance.
The second set of experiments were designed to search for the efﬁcacy of gene
edition. Expression of HSD17B3 was signiﬁcantly decreased in the gene edited
group compared to control group as depicted by qRT-PCR, that was designed
with triplicate controls, and Western Blotting (p < 0.05). Testosterone produc-
tion of gene-edited Leydig cells in signiﬁcantly lower (p < 0.05), as recorded by
ELISA of the culture medium samples. Super-resolution microscopy revealed that
morphological appearance of gene-edited cells which showed a less round cell
structure with fewer steroid granules. 3BHSD stainings were found to be critically
decreased in gene edited group compared to the normal group.
Limitations, reasons for caution: As this study is based on gene edition of
primary mouse Leydig cells, various outcomes can be expected for
human Leydig cells. This study design is very useful to create effective and sim-
pler in vitro models; however, knocking out of HSD17B3 gene can be lethal
for in vivo studies.
Wider implications of the ﬁndings: The limited number of in vitro models
for testosterone deﬁciency limits research on this topic. Additionally; the litera-
ture on the effectiveness of CRISPR/cas9, which is very up-to-date knock-out
and gene editing method, is insufﬁcient regarding Leydig cells. This study releases
an effective, feasible method to interfere testosterone production in vitro.
Trial registration number: not applicable
O-172 Busulfan distinctly affected Sertoli cell activity in immature
mice
M. Huleihel1, A. AbuMadigem2, R. Solomon2, E. Lunenfeld3
1Ben-Gurion University of the Negev, The Shraga Segal Dept. of Microbiology &
Immunology, Beer - Sheva, Israel
2The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel., The Shraga
Segal Dep. of Microbiology- Immunology and Genetics, Beer-Sheva, Israel
3The Center of Advanced Research and Education in Reproduction CARER- Faculty of
Health Sciences- Soroka Medical Center and Ben-Gurion University of the Negev-
Beer-Sheva- Israel., Dep. OB/GYN, Beer-Sheva, Israel
Study question: What are the effects of busulfan on Sertoli cells from
immature-treated mice?
Summary answer: Busulfan did not affect the number of Sertoli cells, but it
signiﬁcantly and distinctly affected their function to produce different growth
factors.
What is known already: Busulfan (BU) is an aggressive chemotherapy, which
may lead to male infertility. Sertoli cells (SCs) communicate directly with germ
cells (GC) and thus regulate their development in the seminiferous tubules
(STs) to sperm. Sertoli cells produce different factors that affect proliferation
and differentiation of spermatogonial cells such as GDNF, LIF, SCF, transferrin,
ABP and others. Busulfan was shown to increase some testicular growth factors
such as GDNF and hormones such as AMH, but also to destroy vimentin ﬁla-
ments and ICAM-1 adhesion molecules that affect development of spermato-
gonial cells.
Study design, size, duration: Seven-day-old mice (immature) were injected
intraperitoneal with BU (45 mg/kg) and sacriﬁced after 10 days [a time demon-
strated by our group to severely affect spermatogenesis compared to control
(DMSO)]. Twenty-twenty ﬁve mice were used in each experiment.
Experiments were repeated at least 3 times.
Participants/materials, setting, methods: Cells from STs were enzymati-
cally isolated and double immunoﬂuorescence stained for SCs and growth fac-
tors was performed. Also, RNA expression of SCs marker and growth factors
were evaluated by qPCR analysis.
Main results and the role of chance: A signiﬁcant increase (p < 0.001) in
the percentage of vimentin-positive cells (a SCs marker) and RNA expression,
with no change in the overall number of SCs were demonstrated in BU-treated
mice compared to the control group. Also, a signiﬁcant increase (p < 0.001) in
the percentage of SCs that produce CSF1 with no change in other growth fac-
tors (GDNF, SCF, LIF) was demonstrated compared to the controls. In add-
ition, a signiﬁcant increase in the expression of FSHR, androgen-receptor,
inhibin B and transferrin, with a signiﬁcant decrease in androgen binding protein
was demonstrated in the BU-treated mice compared to controls.
Limitations, reasons for caution: Limitations, reasons for caution: Animal
model treated with chemotherapy may behave different from human model.
Wider implications of the ﬁndings: We showed for the ﬁrst time that BU
treatment of immature mice doesn’t affect SCs number, but increases their per-
centage in the testes. BU treatment distinctly affected regulatory molecules pro-
duce by SCs and play a key role in spermatogenesis. These results may partially
explain testicular response to BU.
Trial registration number:NA
O-173 The nuclear envelope: an unknown actor of human
spermiogenesis
C. Metzler-Guillemain1, R. Elkhatib2, G. Longepied2, P. Bourgeois2,
N. Levy2, M. Paci1, M. Mitchell2
1AP-HM La Conception, Biologie de la Reproduction-CECOS, Marseille, France
2Aix Marseille Univ- MMG, Marseille Medical Genetics, Marseille, France
Study question: What roles do the nuclear envelope proteins play during
normal human spermiogenesis?
Summary answer: In humans, B-type lamins, LEM-domain and BAF proteins
are involved in the speciﬁc spermatid nucleus remodelling, SUN5 is required for
solid sperm head-tail junction.
What is known already: The nuclear envelope (NE), composed by the
nuclear membrane, the nuclear pore complexes and the nuclear lamina, is inter-
posed between nuclear and cytoplasmic compartments.
In mouse, emerging evidence supports the involvement of many proteins of
the nuclear membrane, the nuclear lamina (NL), and some of their partners, in
the speciﬁc remodelling of the mammalian spermatid nucleus.
Recent studies in human, during normal spermiogenesis or in patients with
abnormal sperm phenotypes, show a strong involvement of the NE, the NL
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proteins and their associated proteins in the control of speciﬁc spermatid
nucleus remodelling and formation of the sperm head-tail junction.
Study design, size, duration: A prospective qualitative and functional ana-
lysis of NE proteins and some partners, in human testis and ejaculated sperm-
atozoa, supported by functional experiments in HeLa cells.
Participants/materials, setting, methods: Testicular samples and ejacu-
lated spermatozoa from the Germetheque biobank, Hela cells, RNA extraction,
RT-PCR, cell transfection, western blotting, immunoﬂuorescence.
Main results and the role of chance: B-type lamins are present at the
nuclear periphery, except in the region covered by the acrosome, and that as
the spermatid matures the B-type lamins recede towards the posterior pole.
We determine that, human lamin B3, but not lamin B2, induces strong nuclear
deformation, when ectopically expressed in HeLa cells. LEMD1, LEMD2,
ANKLE2, LAP2β, BAF and BAF-L, are present and Emerin, LBR and LEMD3 are
absent. In spermatids, no LEM-domain protein localised to the nuclear periph-
ery, but ﬁve were nucleoplasmic, receding towards the posterior nuclear pole
as spermatids matured. The NL appears immature in globozoospermic sperm-
atozoa. SUN5 is required for the formation of the sperm head-tail junction.
Our work therefore establishes that the lamina-chromatin interface in human
spermatids is radically distinct from that deﬁned in somatic cells. Our results in
human highlight the importance of the NE proteins in mammalian spermiogen-
esis and male fertility.
Limitations, reasons for caution: The number of samples and patients
tested for rare phenotypes should be increased.
Wider implications of the ﬁndings: In general, our results illustrate the
importance of spermatid NE components and partners in the coordination of
the cellular events, between the nuclear and cytoplasmic compartments, that
lead to the formation of functional spermatozoa. In human, spermiogenesis
represents a new model of nuclear plasticity.
Trial registration number:NA.
SELECTEDORAL COMMUNICATIONS
SESSION 49: PREMATUREOVARIAN INSUFFICIENCY
AND POOROVARIAN RESPONSE
Tuesday 3 July 2018 Room 211 + 212 15:15–16:30
O-174 High resolution array comparative genomic hybridization
contribution to uncover genetic etiologies of idiopathic premature
insufﬁciency: a cohort study
A. Sassi1, J. Désir2, B. Alvaro-Mercadal3, C. Hans2, A. Delbaere1
1Erasme Hospital-Université Libre de Bruxelles, Department of Obstetrics,
Gynecology and Human Reproduction
2Erasme Hospital-Université Libre de Bruxelles, Department of Human Genetics,
Brussels, Belgium
3Dexeus Hospital, Department of Obstetrics, Gynecology and Human Reproduction
Study question: Can high-resolution array comparative genomic hybridization
(CGH) contribute to uncover genetic etiologies of idiopathic premature ovarian
insufﬁciency (POI)?
Summary answer: High resolution CGH array analysis can identify new
candidate genes in the pathophysiology of POI as well as previously reported
ones.
What is known already: Premature ovarian insufﬁciency (POI) is a heteroge-
neous disorder affecting 1% of women and remains idiopathic in the large
majority of cases. It is deﬁned by the presence of primary or secondary amenor-
rhea and hypergonadotropic hypogonadism, occurring before the age of 40.
Familial history of POI is reported in up to 31% suggesting a signiﬁcant genetic
contribution, which remains largely unknown. Different genomic tools have
been used to elucidate the genetic etiology of POI including array-CGH.
However, different types of array platforms with various levels of resolution
were used leading to heterogeneous results generally not replicated between
studies.
Study design, size, duration: High resolution array CGH analysis was per-
formed on DNA samples from 110 patients with idiopathic POI recruited pro-
spectively from June 2016 to June 2017 in order to identify Copy number
variants (CNVs). Data were compared to Database of Genomic Variants
(DGV)
Participants/materials, setting, methods: Women were included if they
experienced POI, as deﬁned by the ESHRE guidelines. All patients had a normal
karyotype. Patients with aneuploidies, fragile X premutation, adrenal/ovarian
antibodies and iatrogenic POI were excluded from the study. Oligonucleotide
array-CGH analysis was performed using the CytoSure™ Constitutional v3
Arrays (4×180k) from OGT and analyzed with CytoSure Interpret Software.
The mean spatial resolution was approximately of 200 kb for the whole genome
and higher for 502 highly-targeted developmental delay genes.
Main results and the role of chance: Thrirty-six patients (32.7%) presented
CNVs of unknown signiﬁcance (class III CNV) and one patient presented a
pathogenic CNV (class V). As 9 of these patients presented 2 different class III
CNVs, a total of 45 class III CNVs (23 microdeletions and 22 microduplications)
were identiﬁed. These 45 CNVs were located in 32 genomic segments, 9 of
them being involved in at least 2 patients (2p16.3, 4p15.32, 7q11.22, 10q21.1,
11q14.1, 17q11.2, 20p12.1, Xp22.11, Xp22.33). Three among those have
been previously associated with POI (2p16.3, 17q11.2, Xp22.11). Different
genes were included or interrupted by these CNVs, 16 of them being poten-
tially relevant in the development of POI. Two of these genes were previously
suggested as candidate genes for POI (CPEB1, DIAPH2), while the remaining
ones could be considered as new candidate genes in POI as they were reported
to be either implicated in the development of the stock of primordial follicles
and the prevention of its depletion in non-human species, or in molecular path-
ways known to be associated with POI, or located in critical region of X
chromosome or next to genes important for folliculogenesis.
Limitations, reasons for caution: This is a descriptive analysis: neither func-
tional studies nor comparison to CNVs of patient’s family members were per-
formed. We have not considered benign CNVs for this study, which should be
considered with caution as information from DGV is related to CNVs detected
in healthy individuals without information concerning their fertility.
Wider implications of the ﬁndings: High resolution array CGH can
uncover potential genetic etiologies of POI. This analysis should be integrated in
POI assessment especially in idiopathic cases and in complement to a normal
karyotype as long as whole genome sequencing is not used routinely.
Trial registration number: P2016/196/CCB B406201628264
O-175 ACTH-stimulation in women with low functional ovarian
reserve (LFOR) conﬁrms adrenal origin of hypo-androgenism
V. Kushnir1, S. Darmon2, D. Albertini2, D. Barad2, N. Gleicher2
1The Center for Human Reproduction, n/a, New York- NY, U.S.A.
2Center for Human Reproduction, n/a, New York- NY, U.S.A.
Study question: Is the reported hypo-androgenism in women with LFOR
adrenal or ovarian in origin?
Summary answer: Insufﬁciency in androgen-production by the adrenal zona
reticularis is a characteristic feature of LFOR, profoundly contributing to hypo-
androgenism.
What is known already: LFOR, whether due to age or premature ovarian
aging (POA), also called occult primary insufﬁciency (oPOI), has been previously
associated with hypo-androgenism (Gleicher et al., Hum Reprod 2013;28
(4):1084-1091).
Study design, size, duration: Prospective cohort study involving 62 women.
Participants/materials, setting, methods: 43 LFOR and 19 normal ovar-
ian reserve (NOR) patients underwent 250 μg Cosyntropin (ACTH) stimula-
tion in AM after overnight fast. Based on levels <95% CI, 12/43 LFOR patients
were low-DHEAS. LFOR was deﬁned as FSH > 95%CI for age and/or AMH <
95%CI for age for CHR’s patient population (Barad et al., Reprod Biomed
Online 2011;22(3):284-291; Barad et al., Obstet Gynecol 2007;109(6):1404-
1410). Serum cortisol, 17-hydroxy-progesterone, DHEA, DHEAS, androstene-
dione and total testosterone (T) were evaluated at baseline and 30 mins.
Main results and the role of chance: Age did not vary between groups. As
expected, FSH (P = 0.0003) and AMH (P < 0.0001) did. At baseline, with and
i78 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
without LFOR, whether DHEAS was normal or low, all androgens, DHEA
(P < 0.0001), DHEA (P = 0.0002), androstenedione (P = 0.0005), and T
(P = 0.0033) differed signiﬁcantly. At 30 minutes after ACTH infusion, however,
only Δ DHEAS, the only exclusively adrenal androgen, was still signiﬁcantly low-
er in LFOR than NOR patients (P = 0.0265), suggesting relatively insufﬁciency
of adrenals.
Limitations, reasons for caution: To better understand adrenal control of
ovaries via androgen production, further elucidation of endocrine signaling
between adrenals and ovaries is required, including detection of yet unknown
likely feedback loops.
Wider implications of the ﬁndings: It is becoming increasingly clear that
adrenals, through diminished androgen production, may inhibit follicular func-
tion, producing a form of secondary ovarian insufﬁciency (SOI), like POI charac-
terized by low estradiol and elevated FSH but, in contrast to POI, potentially
treatable through androgen supplementation.
Trial registration number:Not applicable.
O-176 Are serum LH levels at the initiation of ovarian stimulation
associated with oocyte retrieval yield after GnRH agonist triggering?
B. Popovic - Todorovic1, S. Santos-Ribeiro1, M. De Vos1, A. Racca1,
P. Drakopoulos1, Y. Thorez2, H. Tournaye1, C. Blockeel1
1UZ Brussel, Centre for Reproductive Medicine, Jette- Brussels, Belgium
2UZ Brussel, Department of Informatics, Jette- Brussels, Belgium
Study question: To evaluate the relationship between basal serum LH levels
and oocyte retrieval yield in GnRH antagonist cycles triggered with a GnRH
agonist.
Summary answer: LH levels at the start of ovarian stimulation can identify
patients with suboptimal oocyte retrieval yield following GnRH agonist
triggering.
What is known already: GnRH agonist trigger may result in an inadequate
oocyte yield in a small subset of patients. This failure can range from empty fol-
licle syndrome to a retrieval of much fewer oocytes than expected. Suboptimal
response has been deﬁned as the presence of circulating LH values < 15 IU/l
12 h after triggering. It has been shown that patients with immeasurable LH
levels on trigger day have an up to 25% risk of suboptimal response. However,
it would be far more clinically relevant if one could identify these patients at the
start of ovarian stimulation, namely by assessing basal LH levels.
Study design, size, duration: A retrospective cohort study of all patients
from 2011 until 2017 who performed GnRH agonist triggering for ﬁnal oocyte
maturation (n = 3334) in GnRH antagonist cycles. Patients with known diagno-
sis of hypothalamic amenorrhoea were excluded from this treatment. Our pri-
mary outcome was oocyte yield, deﬁned as the ratio between the total number
of collected oocytes and the number of follicles with a mean diameter > 10 mm
prior to GnRH agonist trigger.
Participants/materials, setting, methods: Final maturation triggering was
performed using 0.2 mg of triptorelin. In order to evaluate whether LH levels at
the start of ovarian stimulation predicted oocyte yield, we performed multivari-
able regression analysis adjusting for the following confounding factors: female
age, body mass index, oral contraceptive pretreatment, basal and trigger day
estradiol levels, starting FSH and LH levels and total gonadotropin dose.
Suboptimal response to GnRH agonist trigger was deﬁned as <10th percentile
of oocyte yield.
Main results and the role of chance: The average age was 31.9 years and
the mean oocyte yield was 89%. The suboptimal response to GnRH agonist trig-
ger was 45% (<10th percentile) which was exhibited by 340 patients (10.2%).
Suboptimal responders had lower mean starting FSH, LH and estradiol levels
compared to optimal responders 6.1 vs. 6.4 IU/l (p = 0.04); 4.74 vs. 5.9 IU/l
(p < 0.001); and 33.3 vs. 36.4 ng/L (p < 0.001) respectively. They also had
lower estradiol levels at trigger: 2277.5 vs. 2796.2 ng/L (p < 0.001), respect-
ively. Pretreatment with oral contraceptive pill signiﬁcantly affected the oocyte
yield. In the suboptimal response group, 8.6% patients were pretreated with
the pill compared with 4.4% (p < 0.001) in the optimal responders. Inadequate
response was associated with longer stimulation 11.5 vs. 10.6 days (p < 0.001)
and higher gonadotropin consumption 2086.4 vs. 1838.1 IU (p < 0.001).
Following confounder adjustment, multivariable regression analysis showed
that LH levels at the initiation of ovarian stimulation remained a signiﬁcant pre-
dictor of oocyte yield.
Patients with immeasurable LH levels at the start of stimulation (<0.1IU/l)
had a risk of 45.2% of suboptimal response, while the risk decreased with
increasing basal LH levels: < 0.5 IU/L, < 2 IU/L and <5 IU/L were associated
with a 39.1%, 25.2% and 13.2% risk respectively.
Limitations, reasons for caution: The main limitation of the study is its
retrospective design.
Wider implications of the ﬁndings: This is the largest study in GnRH agon-
ist trigger cycles only, since most of the previous research on the predictive
value of basal LH levels was performed in dual trigger cycles. LH levels at the
start of ovarian stimulation are associated with suboptimal oocyte retrieval yield
following GnRH agonist trigger.
Trial registration number:None.
O-177 Luteal phase stimulation compared with conventional
follicular phase stimulation in poor ovarian responders: Results of a
randomized control trial
J. Llacer, B. Moliner, L. Luque, A. Bernabeu, E. Fernandez,
J.A. Ortiz, J.C. Castillo, J. Ten, R. Bernabeu
Instituto Bernabeu, Reproductive Medicine, Alicante, Spain
Study question: Does luteal phase stimulation (LPS) result in comparable efﬁ-
ciency to conventional follicular phase stimulation (FPS) in young bologna poor
responders (POR)?
Summary answer: LPS results in similar outcomes than FPS in terms of the
number of oocytes retrieved and gonadotropin consumption in a population of
young Bologna POR.
What is known already: POR remains one of the main therapeutic chal-
lenges in women undergoing ovarian stimulation. In the last years, LPS emerged
as a feasible way to obtain good quality oocytes. In POR, the use of LPS has
been proposed within a strategy of double stimulation starting the gonado-
tropin administration immediately after the egg retrieval of a conventional
stimulation. However, to date, the efﬁciency of LPS hasn’t been tested in a
population of POR. Therefore, the study was designed to explore beneﬁts and
pitfalls of LPS in POR.
Study design, size, duration: This is a pilot, prospective, single center, ran-
domized controlled trial in a parallel two-arm design. The study included 60
patients < 40 years fulﬁlling the “Bologna” criteria who underwent ovarian
stimulation to accumulate vitriﬁed eggs for immediate IVF treatment. The ran-
domization sequence was performed using a computer-generated randomiza-
tion list.
Participants/materials, setting, methods: Patients were randomized to be
stimulated with rFSH(300IU) + rLH(150IU) (Pergoveris® 2 ampoules per day).
FPS arm started stimulation on the 3rd day of the cycle while patients in the group
of LPS initiated the gonadotropin administration 4 days after an LH positive test.
Both groups started antagonist administration in a ﬂexible protocol. The primary
outcome was the number of vitriﬁed oocytes. Secondary outcomes included the
duration of stimulation, gonadotropin consume and cancellation rate.
Main results and the role of chance: Using an intention to treat analysis
the number of vitriﬁed oocytes per patient did not differ signiﬁcantly between
LPS group 2,1 and FPS group 2,6 (p = 0,31). Other parameters of the ovarian
stimulation were also comparable: number of cumulus-oocyte complex (COC)
2,7 in LPS and 3,1 in FPS (p = 0,44); duration of the stimulation 7,5 days in LPS
and 8,0 in FPS (p = 0,69); gonadotropin consumption 16,7 ampoules in LPS and
16,3 in FPS (p = 0,0,76); maturation rate 77,5% in LPS and 84,0% in FPS
(p = 0,47) and cancellation rate 20% in LPS and 3,3% in FPS (p = 0,08).
However, a post-hoc analysis was necessary taking into account that ovarian
reserve parameters were not comparable between groups. AMH in the 3rd
day of the cycle was lower in the LPS group (4,65 pmol LPS vs 7,30 FPS p =
0,021). Other parameters as age, weight, BMI, AFC and number of previous
stimulation attempts were not different. Creating a new variable to evaluate the
ovarian response in function of the ovarian reserve (COC/AMH) resulted in a
higher sensitivity in the LPS group 0,96 eggs per AMH pmol than in the FPS
group 0,58 (p = 0,037)
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Limitations, reasons for caution: This is a pilot study and the sample size
was not calculated. The two arms of the study were different in terms of ovar-
ian reserve.
Wider implications of the ﬁndings: Data show LPS comparable with FPS
in terms of efﬁciency in POR patients. Therefore, this way of stimulation can be
used in this group of patients when planning to accumulate eggs or embryos.
Some data suggest a higher ovarian sensitivity so more trials will be necessary to
explore this possibility.
Trial registration number: EudraCT: 2015-003856-31
ClinicalTrials.gov Identiﬁer: NCT02625532
O-178 Double stimulation in a single menstrual cycle in patients
with reduced ovarian reserve: hormonal characteristics, cumulus
cell gene expression, embryological and clinical outcome
B. Martazanova1, N. Mishieva2, K. Bogatyreva2, M. Veyukova3,
T. Kodileva3, O. Burmenskaya4, A. Abubakirov2
1Kulakov-s National Medical Research Centre of Obstetrics- Gynaecology and
Perinatology of the Russian Ministry of Healthcare, Department Of Preservation And
Restoration Of Reproductive Function, Moscow, Russia C.I.S.
2Kulakov-s National Medical Research Centre of Obstetrics- Gynaecology and
Perinatology of the Russian Ministry of Healthcare, Department of Preservation and
Restoration of Reproductive Function, Moscow, Russia C.I.S.
3Kulakov-s National Medical Research Centre of Obstetrics- Gynaecology and
Perinatology of the Russian Ministry of Healthcare, Department of Preservation and
Restoration of Reproductive Function- Embryology, Moscow, Russia C.I.S.
4Kulakov-s National Medical Research Centre of Obstetrics- Gynaecology and
Perinatology of the Russian Ministry of Healthcare, Molecular-Genetic Methods
Laboratory, Moscow, Russia C.I.S.
Study question: Does double stimulation (DuoStim) improve the embryo-
logical outcome and increase pregnancy rate in patients with reduced ovarian
reserve?
Summary answer: DuoStim results in retrieving more good quality oocytes
in a single menstrual cycle which leads to a higher clinical pregnancy rate.
What is known already: Multiple follicular waves during the menstrual cycle
make it feasible to start ovarian stimulation in luteal phase (LF). LF stimulation
and DuoStim have been suggested with the aim of fertility preservation in can-
cer patients. Previous studies showed that this approach could be a good
opportunity for poor-responder patients because it results in more oocytes and
embryos. To predict oocyte competence, cumulus cell (CC) gene expression
could be used. There are several genes which have a positive correlation with
fertilization and embryo development. However, there is limited data about
CC gene expression after LF stimulation and IVF treatment success after
DuoStim.
Study design, size, duration: This prospective randomized (Microsoft
Ofﬁce Excel 2007) study included 148 patients with reduced ovarian reserve.
Group 1 (n = 72) received stimulation on day 2 follicular phase. Group 2 (n =
76) received the DuoStim (stimulation started on day 2, then, on 4 day after
the ﬁrst oocyte retrieval (OR), stimulation repeated during LF. Plasma samples
were obtained on stimulation starter day, 6 days after, on triggering and OR
day. 40 patients were chosen to study CC gene expression.
Participants/materials, setting, methods: Inclusion criteria: age < 43
years; АМH <1,2 ng/ml; AFC < 6; basal FSH > 11 IU/ml. Exclusion criteria:
uterine ﬁbroids, deep endometriosis, cancer. Concentrations of LH, estradiol
and progesterone in serum were evaluated with immunochemiluminometric
assay. The CC gene expression was evaluated with Real-time PCR.
Main results and the role of chance: Age (36,0 ± 4,5vs.36,7 ± 3,8 in group
1 and 2, respectively) and antimullerian hormone concentrations (0,89 ±
0,3vs.0,94 ± 0,3) were similar in both groups. Comparisons of embryological
outcomes showed signiﬁcant difference between the number of retrieved
oocytes (4,4 ± 2,1vs.8,8 ± 4,2, p < 0,001), MII (3,9 ± 2,0vs.7,4 ± 3,6,
p < 0,001) and blastocysts (1,8 ± 1,5vs.2,7 ± 2,7, p = 0,039) with values being
greater in group 2. The genes HAS2, COX2, GREM1, ALCAM, CD166,
VCAN, SDC4, TP53I3, SPSB2, CALM2 expression in cumulus cells after LF
group 2 (n = 17) were similar compared to group 1 (n = 23). After embryo
transfer in cryo cycle, clinical pregnancy rate in group 2 was higher compared to
group 1 (41.7% (30/72) vs. 51,3% (39/76), in group 1 and 2, respectively
p > 0.034), but no signiﬁcant differences were observed in the rate of early
reproductive loss (16.7% (5/30) vs. 7.7% (3/39), p = 0.06). Progesterone
(0,9 ± 1,67vs.16,7 ± 13,27) and estradiol (150,94 ± 83,41vs. 384,27 ± 334,44)
levels on stimulation starter day were higher in LF group 2 compared to
group 1, however, their concentrations on triggering day were similar in
both groups (progesterone:3,49 ± 3,62vs.5,65 ± 4,58; estradiol:4630,17 ±
2469,52vs.3697,73 ± 2231,34 in group 1 and LF group 2, respectively).
Limitations, reasons for caution: Our study was carried out in a relatively
small subset of patients whose CC gene expression was studied. Therefore,
obtained results can not be extrapolated on other groups of patients and need
to be conﬁrmed in larger trials.
Wider implications of the ﬁndings: This study opens new possibilities for
ovarian stimulation in the management of patients with impaired ovarian
response.
Trial registration number:N/A
SELECTEDORAL COMMUNICATIONS
SESSION 50: GENETIC AND EPIGENETIC IMPACTOF
ASSISTED REPRODUCTIVE TECHNOLOGIES
Tuesday 3 July 2018 Room 113 + 114 + 115 15:15–16:30
O-179 Increased heteroplasmic load of coding mitochondrial DNA
variants in tissues from ART children
J. Mertens1, F. Zambelli1, F. Belva2, A. Van Montfoort3,
M. Bonduelle2, S. Seneca2, K. Sermon1, C. Spits1
1Vrije Universiteit Brussel, Reproduction and Genetics, Brussels, Belgium
2UZ Brussels, Center for Medical Genetics, Brussels, Belgium
3Maastricht University, Medical Centre, Maastricht, The Netherlands
Study question: Is there an increase in heteroplasmic mitochondrial DNA
variants in children born after ART?
Summary answer: We have found a statistically signiﬁcant increase in mean
variant load in individuals born after ART as compared to their naturally con-
ceived peers.
What is known already: Children born after ART have an increased risk of a
lower birthweight and a slightly abnormal cardio-metabolic proﬁle later in life.
Despite much research into epigenetic factors, the molecular cause of these dif-
ferences remains unknown. Mitochondrial dysfunction is associated with lower
birthweight, cardio-metabolic disease and it has been repeatedly suggested to
play a role in infertility. Therefore, we hypothesized that an increase in variants
in the mitochondrial genome (mtDNA) of ART individuals might explain the
observed differences.
Study design, size, duration: We deep-sequenced the full mtDNA of 163
ART and 98 spontaneously conceived individuals, extracted from blood (58
ART, 65 control), saliva (77 ART, 6 control) and placental tissue (28 ART, 27
control). The samples were collected at the Center for Medical Genetics of the
UZ Brussel and the Maastricht University Medical Center.
Participants/materials, setting, methods: The full mitochondrial genome
was ampliﬁed using long-range PCR, sequenced on an Illumina platform and
aligned to the reference genome (NC_012920.1) using BWA-MEM. mtDNA
server was used to call single nucleotide variants, while insertions and deletions
were detected using MuTect, with a lower threshold of 1.5%. Variants in the
non-coding regions were excluded from the analysis. We calculated the cumu-
lative heteroplasmic variant load as the sum of the loads of all variants in one
individual.
Main results and the role of chance: We found that the three DNA
sources followed similar differential distributions in cumulative mtDNA variant
load in the ART and control groups. In blood, ART individuals carried a mean
load of 9.1%±19.3, while in controls this was 5.4%±12.8. In the placental tissue,
the ART carried a mean load of 12.6%±31.4, control samples of 5.7%±12.7.
The saliva samples from ART carried a mean load of 8.5%±18.4. When all the
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data from the different tissues were pooled per mode of conception, we
observed a statistically signiﬁcant higher mean load in the ART group (ART
9.4%±21.3, control 5.3%±12.4, p = 0.042 with one-tailed t-test). This differ-
ence is mainly due to the presence of more individuals in the ART group with
higher loads. For instance,12.5% of ART individuals have cumulative loads
>30%, while this is 5.1% for the controls (2.4 fold change, p = 0.04, one-tailed
Fisher exact). We found no obvious correlation to maternal age and birth-
weight, although our current sample size is still too small to reliably test this.
Limitations, reasons for caution: The study is currently only able to show
an increase in variant load, but not to correlate these to factors such as birth-
weight, maternal age or ART procedure. For this, we require a larger sample
size; the study is still ongoing and we are currently sequencing control samples.
Wider implications of the ﬁndings: It is unclear what effect this type of
mtDNA variants can have on an individuals’ health, but studies in mouse have
shown a signiﬁcant impact of low load heteroplasmies on infertility, birthweight
and premature aging. Further research is needed to clarify this and to identify
the source of these mutations.
Trial registration number:NA.
O-180 Hypomethylation of imprinted genes in term placenta
samples conceived by IVF/ICSI is associated with concomitant
changes in post-translational histones modiﬁcations
C. CHOUX1, P. Petazzi2, M. Sanchez-Delgado2, J. Hernandez-
Mora2, A. Monteagudo2, P. Sagot1, D. Monk2, P. Fauque3
1CHU Dijon Bourgogne, Service de Gynécologie-Obstétrique, 21000 Dijon, France
2Bellvitge Biomedical Research Institute, Imprinting and Cancer group- Cancer
Epigenetic and Biology Program, 08908 L’Hospitalet de Llobregat- Barcelona, Spain
3CHU Dijon Bourgogne, Laboratoire de Biologie de la Reproduction, 21000 Dijon,
France
Study question: Is variability in DNA methylation at imprinted genes (IGs) dif-
ferentially methylated regions (DMRs) following Assisted Reproductive
Technologies (ART) associated with changes in post-translational histones
modiﬁcations?
Summary answer: After IVF/ICSI, the histones marks at IGs’ DMRs dis-
played enrichment of “active” and simultaneous loss of “repressive” modiﬁca-
tions, consistently with the previously observed DNA hypomethylation.
What is known already: ART has been associated with an increased risk of
placenta-related adverse pregnancy and perinatal outcomes, major malforma-
tions and imprinting disorders. Altogether, these data raise the concern of the
potential epigenetic vulnerability associated with ART.
We previously demonstrated that DNA methylation in the placenta was sig-
niﬁcantly lower after IVF/ICSI than following natural conception at two IGs’
DMRs: H19/IGF2 and KCNQ1OT1 (Choux et al., Human Reproduction 2017).
The aim of this original study was to proﬁle active and repressive histones marks
in placenta biopsies to reveal a better understanding of the epigenetic modiﬁca-
tions in the context of ART.
Study design, size, duration: Patients were prospectively included from
January 1st 2013 to April 30th 2015 in the Department of Obstetrics,
Gynaecology and Reproductive Biology at Dijon University Hospital, France.
Controls were singleton pregnancies of women that had conceived spontan-
eously within 1 year after stopping contraception. IVF/ICSI patients were single-
ton pregnancies achieved following fresh embryo transfer after two days of
in vitro culture.
Participants/materials, setting, methods: In our previous study, we com-
pared the placental DNA methylation by pyrosequencing in 51 IVF/ICSI vs. 48
control placentas for three IGs DMRs: H19/IGF2, KCNQ1OT1 and SNURF. In
the present study, we analysed histones marks abundance by Chromatin
ImmunoPrecipitation (ChIP) in 16 patients who presented with below the 5th
percentile of DNA methylation for at least one of these DMRs and compared
with 16 controls matched for parity, new-born’s sex, and gestational age at
delivery.
Main results and the role of chance: DNA methylation of H19/IGF2,
KCNQ1OT1 and SNURF DMRs was signiﬁcantly lower in the IVF/ICSI group
(45.1 [43.2-48.9]; 32.8 [31.7-35.7] and 38.3 [35.5-40.5], respectively) than in
the natural conception group (53.5 [49.6-59.3], P = 0.004; 39.4 [34.8-41.9],
P = 0.001 and 41.2 [38.4-42.1], P = 0.036, respectively). Quantitative PCR tar-
geting H19/IGF2 and KCNQ1OT1 DMRs in ChIP material precipitated with
H3K4me2, a permissive modiﬁcation, revealed signiﬁcantly higher quantity of
H3K4me2 in the IVF/ICSI group than in the natural conception group
(P = 0.016 and 0.003, respectively). There was no signiﬁcant difference for
H3K4me2 for SNURF, or for the others permissive marks (H3K4me3, H3K9ac).
The quantity of the repressive marks H3K9me3 and H3K9me2 at H19/IGF2
and SNURF DMRs was signiﬁcantly lower in the IVF/ICSI group than in the
natural conception group (P = 0.011 and 0.027 for H19/IGF2, respectively; and
P = 0.010 and 0.035 for SNURF, respectively) but there was no signiﬁcant differ-
ence for KCNQ1OT1.
Limitations, reasons for caution: These data were assessed on a limited
number of IGs DMRs. Therefore, it would be interesting to extend analyses to
others DMRs.
Wider implications of the ﬁndings: These novel ﬁndings highlight that
DNA hypomethylation at IGs’ DMRs after ART is linked with increased active/
decreased repressive histones marks, altogether promoting an “active” con-
formation of the chromatin. This concomitant change in epigenetic state at IGs
at birth might be an important developmental event as a consequence of ART
manipulations.
Trial registration number: not applicable.
O-181 Ovarian stimulation for IVF and risk of primary breast
cancer in BRCA1/2 mutation carriers
I. Derks-Smeets1, L. Schrijver2, C. De Die-Smulders1,3, V. Tjan-
Heijnen3,4, R. Van Golde3,5, B. Caanen1, M. Rookus2, F. Van
Leeuwen2, E. Gómez-Garcia1,3
1Maastricht University Medical Center, Clinical Genetics, Maastricht, The
Netherlands
2Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, The
Netherlands
3Maastricht University, GROW - School for Oncology and Developmental Biology,
Maastricht, The Netherlands
4Maastricht University Medical Center, Internal Medicine - division of Medical
Oncology, Maastricht, The Netherlands
5Maastricht University Medical Center, Obstetrics and Gynecology, Maastricht, The
Netherlands
Study question: Does exposure to ovarian stimulation for IVF increase the
risk of primary breast cancer for BRCA1/2 mutation carriers?
Summary answer: No increased risk for breast cancer was found after ovar-
ian stimulation for IVF in BRCA1/2mutation carriers.
What is known already: Female carriers of a pathogenic mutation in the
BRCA1 or BRCA2 gene have a high risk of breast cancer. Their breast cancer risk
rises from age 25 onwards and is particularly increased at reproductive age. In
the general population no association between exposure to ovarian stimulation
for IVF and breast cancer risk was found. However, a potential effect is rarely
examined in BRCA1/2 mutation carriers. This matter is of particular interest
since BRCA1/2 mutation carriers not only undergo IVF for infertility or fertility
preservation, but also and in an increasing extent for preimplantation genetic
diagnosis (PGD).
Study design, size, duration: 1,550 BRCA1 and 964 BRCA2 carriers were
derived from (1) the nationwide HEBON study, a retrospective cohort with
prospective follow-up among BRCA1/2 mutation families, and (2) the national
PGD registry. Observation time started at birth and ended at ﬁrst invasive
breast cancer diagnosis (event of interest), other cancer diagnosis or bilateral
prophylactic mastectomy, whichever occurred ﬁrst. In case these events did
not occur, observation time ended at the age of questionnaire or last PGD
contact.
Participants/materials, setting, methods: Eligible women were 18 years
or older and had a pathogenic mutation in the BRCA1 or BRCA2 gene.
Questionnaires were used to collect data on IVF exposure. Information on risk-
reducing surgeries and cancer diagnoses was derived from clinical records and
linkages with the Netherlands Cancer Registry, respectively. A time-dependent
IVF exposure variable was used in Cox regression analyses, stratiﬁed for birth
cohort and adjusted for infertility.
Main results and the role of chance: IVF exposure was not associated with
risk of breast cancer for BRCA1/2 mutation carriers (hazard ratio (HR) 0.79,
95%CI 0.46-1.36). Similar results were found for the subgroups of infertile
women (n = 232; HR 0.73, 95%CI 0.39-1.37) and BRCA1 mutation carriers
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(HR 1.12; 95%CI 0.60-2.09). In addition, age at ﬁrst IVF treatment and recency
of IVF treatment were not associated with breast cancer risk.
Limitations, reasons for caution: Despite the availability of a nationwide
cohort, power is still limited due to the low portion of women exposed to IVF.
The subgroup BRCA2 mutation carriers was too small for separate analysis.
Hazard ratios were slightly biased to zero due to the oversampling of breast
cancer cases.
Wider implications of the ﬁndings: Based on the current data, there is no
reason to exclude BRCA1/2 mutation carriers from IVF for fertility treatment,
fertility preservation or PGD. Obviously, ruling out pre-existing lesions before
IVF remains important because of the high a priori breast cancer risk in these
women.
Trial registration number:Not applicable.
O-182 Higher gonadotropin dosage and longer ovarian
hyperstimulation do not inﬂuence aneuploidy rates
C. Canon1, M. Irani2, N. Zaninovic2, K. Xu2, Z. Rosenwaks2
1New York Presbyterian - Weill Cornell, Obstetrics and Gynecology, New York, U.S.A.
2Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Does the gonadotropin dosage, duration of ovarian hypersti-
mulation, peak estradiol levels, or number of oocytes retrieved affect aneu-
ploidy rates?
Summary answer: Aneuploidy rates are not affected by higher gonadotropin
dosage, longer stimulation, higher estradiol levels, or larger number of oocytes
harvested, regardless of a woman’s age.
What is known already: Aneuploidy rates increase steadily with age, reach-
ing >80% in women >42 years old. Preimplantation genetic screening (PGS)
has been used along with blastocyst morphology to enhance embryo selection.
The goal of controlled ovarian hyperstimulation (COH) is to overcome this
high aneuploidy rate through the recruitment of several follicles, which increases
the chances of obtaining a euploid embryo that results in a healthy conceptus.
However, a recent study reported a signiﬁcant difference in the aneuploidy
rates (range: 39.5%–82.5%) between young oocyte donors who underwent
stimulation at different fertility centers. These ﬁndings suggest that various
methods of stimulation might affect aneuploidy rates.
Study design, size, duration: A retrospective cohort study including PGS data
was conducted to compare aneuploidy rates. A total of 1,463 IVF/PGS cycles
between January 2013 and December 2016 were included. PGS was performed using
array comparative genomic hybridization. χ2 test was used for categorical variables.
Participants/materials, setting, methods: A total of 7,980 embryos were
analyzed for ploidy status. Cycles were divided into ﬁve age groups (<35,
35–37, 37–39, 40–42, and >42 years old), and aneuploidy rates were com-
pared between different total gonadotropin dosages (<5,000 and ≥5,000 IU),
duration of stimulation (<10, 10–13, and ≥14 days), number of oocytes har-
vested (<10, 10–19, and ≥20 oocytes), and peak estradiol (E2) levels (<1,500,
1,500–3,000, and >3,000 pg/mL).
Main results and the role of chance: Within the same age group, aneu-
ploidy rates were not signiﬁcantly different between cycles with different total
gonadotropin dosages, duration of stimulation, number of oocytes retrieved, or
peak estradiol levels. In the youngest group (<35 years, n = 2,366 embryos),
aneuploidy rates were comparable between cycles of various total gonado-
tropin dosages (44.1% for <5,000 IU and 45.8% for ≥5,000 IU; P = 0.7), dur-
ation of stimulation (44.4% for <10 days, 44.2% for 10–13 days, and 40.4% for
≥14 days; P = 0.8), number of oocytes harvested (38.5% for <10 oocytes, 44%
for 10–19 oocytes, and 45.8% for ≥20 oocytes; P = 0.1), and peak estradiol
levels (45.7% for E2<1,500 pg/mL, 45.4% for E2 1,500–3,000 pg/mL, and
43.8% for E2>3,000 pg/mL; P = 0.7). Similarly, in the oldest group (>42 years,
n = 741 embryos), aneuploidy rates ranged from 90.5% for gonadotropins
<5,000 IU to 90.6% for gonadotropins ≥5,000 IU (P = 1), from 87.8% for <10
days of stimulation to 94.0% for ≥14 days of stimulation (P = 0.3), from 93.1%
for <10 oocytes to 91.3% for ≥20 oocytes (P = 0.1), and from 88.6% for
E2<1,500 pg/mL to 91.3% for E2>3,000 pg/mL (P = 0.6).
Limitations, reasons for caution: Although this large study (1,463 IVF/PGS
cycles and 7,980 embryos) demonstrates the safety of COH in terms of
aneuploidy, it would also be interesting to determine whether gonadotropin
dosage affects the implantation potential of euploid embryos. Furthermore, a
multicenter study may help to prove the generalizability of our single-center
data.
Wider implications of the ﬁndings: The ﬁndings of this study reassure pro-
viders and patients that the total gonadotropin dosage, duration of ovarian
hyperstimulation, estradiol levels, and number of oocytes retrieved do not inﬂu-
ence aneuploidy rates, regardless of a woman’s age.
Trial registration number:N/A.
O-183 Correlation between Embryo Ploidy Status and ovarian
response after controlled ovarian Stimulation in ART cycles
S. Seshadri1, X. Gonzalez Vinals1, R. Odia2, A. Alchami1,W. Saab3,
P. Serhal1
1Centre for Reproductive & Genetic Health CRGH- London, Reproductive Medicine,
London, United Kingdom
2Centre for Reproductive & Genetic Health CRGH- London, Embryology, London,
United Kingdom
3CRGH, Reproductive medicine, London, United Kingdom
Study question: Is there a relationship between ovarian response and num-
ber of euploid embryos and aneuploidy rate in preimplantation genetic testing
for aneuploidy (PGT-A)?
Summary answer:Ovarian response (OR) after conventional IVF stimulation
is positively correlated with number of euploid embryos. Euploidy rate in
younger patients decreases when OR is exacerbated.
What is known already: A positive relationship between ovarian response
and the embryo aneuploidy rate has been described when mild controlled ovar-
ian stimulation (COS) is performed in infertile patients, but this trend is not
observed in patients who undergo conventional COS treatments with higher
doses. It has been recently suggested by a published study that a threshold level
for gonadotropin doses may exist and that no more competent oocytes can be
obtained if it is exceeded. It has been shown in a retrospective study that high
ovarian response to conventional ovarian stimulation does not increase embryo
aneuploidy rates in aCGH-PGS cycles.
Study design, size, duration: 1560 blastocysts generated after ICSI between
January 2016 to January 2017, derived from 210 patients (mean age 37.4 (SD
3.5) years), were included in study. This single centre retrospective cohort
study was conducted at the Centre for Reproductive and Genetic health
(CRGH), UK. Cycles were classiﬁed according to OR: poor (<4 oocytes col-
lected), suboptimal (4-9), normal (10-14) and hyperresponse (>15). Embryo
biopsy was performed at the blastocyst stage and PGT-A performed with Next
Generation Sequencing.
Participants/materials, setting, methods: Female age was used to group
the sample according to the Human Fertilisation and Embryology Authority
(HFEA) categories into: <35 years (49/210), 35-37 years (43/210), 38-39
years (38/210), 40-42 years (40/210) and >42 (40/210). Number of euploid
embryos, euploidy rate and relevant cycle parameters (i.e oocytes collected,
embryos biopsied) was annotated for each of the categories. Statistical analysis
was done using SPSS version 23.
Main results and the role of chance: Mean age for all patients in cohort
37.4+/-3.5 years. Analysis of euploid rate (number of euploid embryos/blasto-
cysts biopsied) negatively corelates with an increase in ovarian response. This
association is evident especially for young patients (<35 years) where euploidy
rate for normal OR is 48% and drops to 32% in hyperresponse. Euploidy rate
shows the same trend with a higher OR, but is not statistically signiﬁcant in all
age groups. Spearman’s rank-order correlation was performed to determine
the relationship between oocytes retrieved and euploidy rate in the same cycle
(all ages). Analysis concluded a strong, negative correlation between both vari-
ables (rs = 0.-062, p = 0.035). The Poseidon group deﬁned a “suboptimal
response,” (4-9 oocytes), which is associated, at any given age, with a signiﬁ-
cantly lower live birth rate compared with normal responders i.e., those with
10–15 oocytes. The euploidy rate in the “Poseidon” group was 28.1%. This
rate is 0% in patients above 38 years of age when 4-9 oocytes are retrieved.
Euploidy rate per oocyte collected decreases signiﬁcantly for all age categories
when number of oocytes retrieved is + 12. Maximum euploidy is obtained
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when 8-10 oocytes are retrieved for patients (<35), 10-12 oocytes for ages 35-
39 and 9-11 oocytes for patients above 40.
Limitations, reasons for caution: Larger studies (well-designed trials) with
an increased number of biopsied embryos are needed to conﬁrm our ﬁndings
with analysis. The trials designed should also standardise the PGT-A technique
being used as different laboratories have different reported sensitivity assays.
Wider implications of the ﬁndings: The ﬁrst study that analysed the cor-
relation between ovarian response and euploidy rate where PGT-A was per-
formed using NGS technique on blastocysts. The degree of ovarian stimulation
should be tailored to individual patient’s ovarian reserve to optimise number of
eggs retrieved thus resulting in a better yield of euploid embryos.
Trial registration number:Not applicable
SELECTEDORAL COMMUNICATIONS
SESSION 51: IMMUNOLOGIC ANDOTHER TREATMENT
OPTIONS IN RM/RIF
Tuesday 3 July 2018 Room 117 15:15–16:30
O-184 Effect of Administration of Intravenous intralipid on
implantation rate in women with implantation failure after IVF/ICSI:
A randomized controlled trial
N. Singh1, A. Davis2, A. Kriplani3, S. Kumar2
1All India Institute Of Medical Sciences AIIMS, Department of Obstetrics &
Gynaecology, New Delhi, India
2All India Institute of Medical sciences, Obstetrics & Gynaecology, New delhi, India
3All India Institute Of medical Sciences-, Obstetrics & Gynaecology, New delhi, India
Study question: To measure and compare the clinical pregnancy rate in
women who receive intravenous intralipid versus placebo with previous
implantation failure after fresh non donor IVF/ICSI.
Summary answer: Administration of intravenous intralipid in women with
previous implantation failure after fresh non donor oocyte IVF/ICSI leads to a
signiﬁcant increase in clinical pregnancy rate.
What is known already: Proposed mechanisms for recurrent implantation
failure is immunological abnormalities which reduce maternal endometrial
receptivity, with focus on uterine natural killer (NK) cells and cytotoxic cyto-
kines. Intravenous intralipid, a sterile fat emulsion containing soy oil, egg yolk,
glycerin, and water, has traditionally been used in patients requiring total paren-
teral nutrition and has found to reduce the incidence of sepsis by regulating
immune dysfunction. It is hypothesized that the fatty acids in the intralipid serve
as ligands to activate peroxisome proliferators activated receptors (PPARs)
expressed by the NK cells which decreases NK cytotoxic activity, which can
enhance implantation and maintain pregnancy.
Study design, size, duration: Randomized controlled trial of 102 subjects
with previous failed IVF undergoing IVF/ICSI from June 2016 to January 2018.
Subjects were randomized after oocyte pickup into two arms.
Women with anatomical defects by diagnostic hysteroscopy, genital tubercu-
losis by endometrial aspiration for acid fast bacilli, acquired thrombophilias, and
immunological co-morbidities were excluded.
Participants/materials, setting, methods: Women in the intervention
arm(n = 52) received 2 doses of 20% intravenous intralipid (Fresenius Kabi),
4 mL diluted in 100 mL normal saline by slow infusion. The ﬁrst dose was given
immediately after oocyte recovery, second dose given one hour prior to trans-
fer. The control group ( = 50) received normal saline. All the women received
routine luteal phase support. Outcomes measured were implantation rate and
clinical pregnancy rate. No adverse effects of intralipid were observed.
Main results and the role of chance: The mean age of the participants was
(31.6+/-4) in the intervention group and (32.1+/-3.5) years in control group
(P = 0.47). The mean BMI was (24.1+/-3.1) in intervention and (24.6+/-3.3)
kg/m2 (P = 0.394) in control group. The average number of attempts of IVF
was (2.33+/-0.5) in both the groups, with minimum and maximum of 1 and 3
previous failed IVF.
The implantation rate (Beta HCG >/- 100 IU 14 days after embryo transfer)
was 38.5% and 14% in intervention and control groups (P = 0.005). Clinical
pregnancy rate as determined by sonographic fetal cardiac activity was 34.6%
and 14% in intervention and control groups (P = 0.016). Ongoing pregnancy
rate as deﬁned as pregnancy continuing beyond 16 weeks gestation was 34.6%
and 14% in intervention and control groups (P = 0.016). No adverse effects of
intralipid were observed.
Limitations, reasons for caution: None
Wider implications of the ﬁndings: This study shows a statistically signiﬁ-
cant increase in implantation rate and clinical pregnancy rate in women who
receive intravenous intralipid with prior implantation failure after IVF/ICSI, with
no adverse effects.
Trial registration number: CTRI/2017/01/017206
O-185 Recombinant Human Granulocyte - Colony Stimulating
Factor (rhG-CSF) in women with unexplained Recurrent Pregnancy
Losses (RESPONSE Study): randomised, double-blind, multicentre,
placebo controlled trial
A. Eapen1, M. Joing2, D. Lissauer3, A. Coomarasamy3
1University of Iowa Carver College of Medicine, Obstetrics and Gynecology REI
Division, Iowa City, U.S.A.
2Nora Therapeutics, Nora Therapeutics Inc, Palo Alto, U.S.A.
3Institute of Metabolism and Systems Research- University of Birmingham, Tommy’s
National Centre for Miscarriage Research, Birmingham, United Kingdom
Study question: Does administration of recombinant human granulocyte -
colony stimulating factor in the ﬁrst trimester of pregnancy improve outcomes
in women with a history of unexplained recurrent pregnancy losses?
Summary answer: There is no evidence that administration of rhG-CSF in
the ﬁrst trimester of pregnancy improves outcomes, among women with his-
tory of unexplained recurrent pregnancy losses.
What is known already: rhG-CSF is shown to improve pregnancy outcomes
by immunomodulation. The evidence prior to this study is only one RCT which
was a smaller single centre study and another 4 observational study which sug-
gested statistically signiﬁcant increase in pregnancy rates and live birth rates.
Study design, size, duration: Women between the age of 18 to 37 years
with a BMI of 19-35 (at the time of consent) and actively trying to conceive nat-
urally after being diagnosed with a history of unexplained recurrent pregnancy
losses were eligible. 340 women were screened into the study of which 150
were randsomised between June 2014 and June 2016. This was a double bind,
placebo controlled randomised trial.
Participants/materials, setting, methods: The participants were
recruited from 21 hospitals with established recurrent pregnancy loss clinics
from across the United Kingdom. Eligible participants were randomised to
receive rhG-CSF 130 mcg or placebo in a 1:1 ratio. Stratiﬁed permuted block
randomisation was used with number of prior miscarriages (3, >3), and age
(<35, 35-37 years)as the stratiﬁcation factors. An online computerised system
was used for randomisation. The primary outcome was ongoing clinical preg-
nancy at 20 weeks of gestation.
Main results and the role of chance: A total of 340 participants were
screened for eligibility, of whom 150 women were randomised. 76 were rando-
mised to rhG-CSF and 74 were randomised to placebo. All women were
followed-up to primary outcome, and beyond to live birth. The clinical preg-
nancy rate at 20 weeks, as well as the live birth rate, was 59.2% (45/76) in the
rhG-CSF group, and 64.9% (48/74) in the placebo group, giving a relative risk
of 0.9 (95% CI: 0.7 to 1.2; p = 0.48). There was no evidence of a signiﬁcant dif-
ference between the groups for any of the secondary outcomes.
Limitations, reasons for caution: The limitation of this study was that parti-
cipants were not screened prior to inclusion to demonstrate immune dysfunc-
tion as the reason for their pregnancy losses. This is because there is no
accepted test(s) for immune dysfunction in reproductive immunology. This trial
was therefore exclusively for women with unexplained recurrent miscarriages.
Wider implications of the ﬁndings: G-CSF is widely used in reproductive
medicine to treat recurrent miscarriages. Observational studies suggested
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statistically signiﬁcant improvements in clinical pregnancy rates after administra-
tion of G-CSF. However, we now have high quality evidence suggesting that G-
CSF is not an effective treatment for patients with unexplained recurrent
miscarriages.
Trial registration number: Eudract Number –2014-000084-40.
O-186 A reduction in uterine Natural Killer (uNK) cell density in
response to luteal-phase endometrial scratch (ES) is associated with
improved pregnancy outcome
M. Lokman1,2, K. Fishwick1, J. Brosens1, S. Quenby1,2
1University of Warwick, Biomedical Research Unit, Coventry, United Kingdom
2UHCW NHS Trust, Obstetrics and Gynaecology, Coventry, United Kingdom
Study question: Does a change in uNK cell density following endometrial tis-
sue injury relate to subsequent pregnancy outcome in women with recurrent
reproductive failure?
Summary answer: A reduction in uNK cell density in response to endomet-
rial scratch is associated with higher rates of ongoing pregnancies (≥12 weeks)
and live births (P = 0.007).
What is known already: Work from our laboratory demonstrated an
important role for uNK cells in maintaining tissue haemostasis in cycling endo-
metrium. Speciﬁcally, IL-15 activated uNK cells target and clear acute senescent
decidual cells during the window of implantation. Some but not all clinical trials
have suggested that endometrial injury from scratch improves pregnancy out-
come. This conﬂicting evidence could be explained by an inter-patient variation
in response to injury. We hypothesised that changes in uNK cell density nor-
malised to the day of biopsy relative to the LH surge, could be a marker of
endometrial plasticity and by extension, subsequent pregnancy outcome.
Study design, size, duration: This is a 3 year prospective cohort study of 60
women with recurrent reproductive failure (2014-2017). Participants had either
a history of recurrent miscarriage or implantation failure following IVF/ICSI. All
participants had two LH-timed, mid-luteal endometrial biopsies at 1 to 6
months apart and a pregnancy or embryo transfer within one year of the
second biopsy (2015-2017).
Participants/materials, setting, methods:Women were recruited from a
dedicated Implantation Research Clinic for couples with recurrent reproductive
failure. Participants had two pre-conceptual, mid-luteal endometrial biopsies.
Each biopsy was subjected to immunohistochemistry staining for CD56 (uNK
cell marker). uNK cell density was calculated using image analysis and normal-
ised for day of biopsy relative to LH-surge, using a published centile chart based
on 1900 samples. Inter-cycle variation was deﬁned as the difference between
uNK cell centiles of the two biopsies.
Main results and the role of chance: There was a signiﬁcant variation in
the inter-cycle difference in normalised uNK cell densities between participants
with some patients showing minimal or no inter-cycle variability whereas the
response was marked in others. In order to assess the clinical importance of
this variance, we analysed uNK cell variance in two clinical groups according to
subsequent pregnancy outcome following the second biopsy. Group 1 included
women who achieved a subsequent ongoing pregnancy beyond 12 weeks gesta-
tion or live birth (n = 29) and Group 2 consisted of women who experienced a
further ﬁrst trimester miscarriage or IVF/ICSI implantation failure (n = 31).
Group 1 had a signiﬁcant reduction in uNK cell density [P = 0.007, median dif-
ference: -13% (CI -4 to -26.7)]. In comparison, Group 2 showed no signiﬁcant
inter-cycle variation [P = 0.58, median difference: -1.5% (CI -16.6 to 10.8)].
Limitations, reasons for caution: Linking endometrial factors to pregnancy
outcome is hindered by the fact a proportion of miscarriages and implantation
failures will be due to chromosomally abnormal embryos. The ﬁndings in this
study are not yet robust and conﬁdence intervals are large. To conﬁrm or refute
these ﬁndings, a larger cohort is required.
Wider implications of the ﬁndings: Our ﬁndings support the emerging
concept of endometrial plasticity, i.e. the ability of the endometrium to adapt
from cycle to cycle in response to stress signals. In addition, the patient-speciﬁc
response to tissue injury likely determines the clinical beneﬁt, or lack thereof, of
the scratch procedure in clinical practice.
Trial registration number:N/A.
O-187 Combinatorial use of Endometrial Receptivity Array (ERA)
and PGT-A can improve the clinical outcome in cases with previous
ART failures
N. Findikli1, M. Gultomruk2, K. Boynukalin3, M. Kavrut3, E. Oral4,
M. Bahceci3
1Bahceci Fulya IVF Centre, IVF Laboratory, Istanbul, Turkey
2Bahceci Fulya IVF Centre, R&D Laboratory, Istanbul, Turkey
3Bahceci Fulya IVF Centre, Infertility Clinic, Istanbul, Turkey
4Istanbul University Cerrahpasa Faculty of Medicine, Obstetrics and Gyneocology,
Istanbul, Turkey
Study question: This study investigates whether ERA and PGT-A approaches
can be properly integrated in order to improve the clinical outcome in cases
with previous ART failures.
Summary answer: Endometrial receptivity assessment by ERA and euploidy
assessment by PGT-A can be effectively coupled in order to maximize the clin-
ical outcome in recurrent ART failures.
What is known already: It has been shown that ERA test, which is based on
the transcriptomic signature of 236 genes of a given endometrial sample, can
successfully and objectively assess the endometrial receptivity in patients under-
going ART. By using this tool, recent reports indicate that in around 30-35% of
the implantation failures can be due to pre- or post-receptive state of the endo-
metrium and subsequent pET can rescue this defect. It is also well-accepted
that majority of implantation failures can be of embryonic origin and by transfer-
ring euploid embryos high pregnancy rates can be obtained after PGT-A by
comprehensive chromosomal screening (CCS).
Study design, size, duration: This retrospective clinical study includes clin-
ical data of 632 patients with previous ART failures, whose endometrial recep-
tivity were assessed by ERA between November 2013 – August 2017. During
the study period, based on the ERA results, embryo availability as well as the
clinical treatment protocol, patients were subsequently scheduled for either
frozen embryo transfers (With embryos of unknown or known euploidy status),
a freeze-all cycle or a PGT-A cycle.
Participants/materials, setting, methods: All endometrial biopsies were
performed by a pipelle under general anesthesia after a hormone replacement
therapy cycle (HRT) adjusted for expected window of implantation (WOI; at P
+ 5). Same HRT approach was also used in the subsequent frozen embryo
replacements in patients with receptive results. In patients with displaced
receptivity, embryo warming and transfer was personalized according to produ-
cer’s recommendations. All PGT-A cycles involved Day5/6 trophectoderm
biopsy, embryo cryopreservation and CCS analysis by aCGH or NGS.
Main results and the role of chance: Of these 632 patients, mean female
age and number of previous ART trials were 35.8 ± 4.7 and 2.2 ± 2.3 respect-
ively. Out of 684 endometrial biopsy samples obtained, 657 (96.1%) were suc-
cessfully diagnosed as receptive (n = 432; 65.8%), pre-receptive (n = 160;
24.3%) and post-receptive (n = 65; 9.9%). In 27 (4.1%) of the samples, results
were not informative. Based on the test results and clinical conditions, a total of
516 frozen embryo transfer cycles were performed either by embryos with
unknown euploidy status (not screened by PGT-A; n = 171; Group I) or by
euploid embryos obtained from a previous PGT-A (n = 345; Group II) cycle.
Sixtyfour cycles (37.4%) in Group I and 108 cycles (31.3%) in Group II were
performed as pET (p = 0.35). Biochemical pregnancy, clinical pregnancy,
implantation as well as missed abortion rates were 47.4%, 43.2%, 31.8% and
20.3% for Group I and 75.9%, 70.4%, 65.8% and 16.4% for Group II respect-
ively and these rates were found to be signiﬁcantly higher in the latter (p
< 0.01). At the time of data collection, the percentage of ongoing pregnancy/
live birth cases in Group II was also signiﬁcantly higher (58.2%) than the one in
Group I (34.5%; p < 0.001).
Limitations, reasons for caution: Implantation is a complex process,
involving synchronization of a variety of known as well as yet unknown embry-
onic & maternal factors. This study aimed at analyzing the possible impact of
embryonic euploidy and endometrial receptivity assessment in patients with
previous ART failures.
Wider implications of the ﬁndings: Results indicate that around 30% of
patients with history of ART failures in this study show displaced endometrial
receptivity. Personalization of FET cycles by the integration of ERA test in
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conjunction with PGT-A can signiﬁcantly improve the clinical outcome in these
cases.
Trial registration number:None.
O-188 Immune therapies for women with history of unsuccessful
implantation undergoing IVF/ICSI treatment - A Cochrane
collaboration systematic review
S. Asif1°, H. AlAhwany2°, P. Bhave Chittawar3, M.P. Nigdelis4,
K.A. Toulis5, D.G. Goulis6, R. Kirubakaran7, N. Raine-Fenning1,
S. Seshadri8, T. Child9, I.E. Granne10
1Division of Child Health, Obstetrics and Gynaecology, and Nurture Fertility
2Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
University of Nottingham
3Department of Reproductive Medicine, Bansal Hospital, Bhopal, India
4Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology,
Aristotle University of Thessaloniki
5Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece
6Unit of Reproductive Endocrinology, Aristotle University of Thessaloniki, Thessaloniki,
Greece
7Cochrane South Asia, Prof. BV Moses Center for Evidence-Informed Health Care and
Health Policy, Christian Medical College
8The Centre for Reproductive & Genetic Health, London, UK
9Nufﬁeld Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK
10Nufﬁeld Department of Obstetrics & Gynaecology, John Radcliffe Hospital, Oxford,
UK
°Contributed Equally,
Study question: Do immune therapies improve live birth rate in women with
a history of recurrent implantation failures (RIF), who are undergoing another
cycle of assisted reproduction?
Summary answer: There is some evidence that intralipid may improve live
birth rate with PBMC,GCSF treatment conferring potential beneﬁt with regards
to clinical pregnancy rate. However, the safety proﬁle of these agents needs fur-
ther investigation.
What is known already: RIF remains a clinically and emotionally challenging
diagnosis for most patients undergoing IVF. Currently, there is lack of evidence
to support speciﬁc screening tests and therapeutic measures. This has led to an
offering of “empirical” treatment with immuno-suppressive agents to patients
who experience RIF. However, this approach has been based on very little clin-
ical evidence and treatment is offered to patients, without fully assessing the
risks and beneﬁts.
Study design, size, duration: The Cochrane Gynaecology and Fertility
Group Specialised Register, the Cochrane Central Register of Studies Online
(CRSO), MEDLINE, Embase, CINAHL and PsyINFO were searched from
inception to September 2017. Randomised controlled trials (RCTs), where
immunotherapy was given to women with a history of unexplained RIF who
were undergoing assisted reproduction, were included for data analysis. The
primary outcomes were live birth and miscarriage rates below 24 weeks of ges-
tation. Secondary outcomes included clinical pregnancy rate and adverse events
such as preterm delivery, multiple pregnancy and drug side effects. All out-
comes were reported per woman randomised.
Participants/materials, setting, methods: The systematic review included
19 studies with a total of 1748 patients. G-CSF was used in 8 studies, heparin in
4, intralipid in 2 and leukocyte inhibitory factor (LIF) in 2 studies.
Risk ratios (RRs) with 95% conﬁdence intervals (CIs) were calculated for
each study and the data were synthesized using a ﬁxed-effect model. The quality
of the evidence was assessed using the GRADE method.
Main results and the role of chance: The evidence showed that intralipid
probably improves the live birth rate compared to no treatment (RR 2.13, 95%
CI 1.35 to 3.36; participants = 303; studies = 2; I2 = 6%, moderate certainty
evidence)). Similarly heparin may slightly improve the live birth rate compared
to aspirin, however the evidence for this was graded as low certainty evidence
(RR 2.56, 95% CI 1.17 to 5.58; participants = 126; studies = 1; I2 = 0, low cer-
tainty evidence).
The evidence for miscarriage rate for intralipid, PBMC and LIF was insufﬁcient
or not reported for heparin and GCSF.
There was moderate evidence that PBMC, GCSF and Heparin treatment
may improve the clinical pregnancy rate.
The data on adverse effects, either during the IVF procedure or pregnancy
were either sparse or missing. The majority of studies had no means of blinding
and were at high risk of performance and detection bias.
Limitations, reasons for caution: The use of intralipid is still under investi-
gation and should be used with caution; PBMC is still at the experimental stage.
Therefore, these results should only be applied to the research setting; further
work is needed before it is offered in the clinical context.
Wider implications of the ﬁndings: Once the pathophysiology of RIF is
understood, and its deﬁnition is agreed upon, targeted immune therapies may
be proved effective in increasing pregnancy and live birth rates.
Trial registration number:N/A
SELECTEDORAL COMMUNICATIONS
SESSION 52: REPRODUCTIVE EPIDEMIOLOGY, SOCIO-
CULTURAL ASPECTS ANDHEALTH ECONOMY
Tuesday 3 July 2018 Room 116 15:15–16:30
O-189 The DOD (Distance Oocytes Donation) strategy: A safe,
efﬁcient and “patient friendly”way to overcome lack of egg’s
donors in different countries
F. Moffa1, F. Bongioanni2, I. Cino3, C. Garello2, A. Farreras1, L. Delle
Piane2, G.L. Gennarelli2, V. Biasoni3, M. Benigna3, A. Revelli2,
M. Lopez-Teijon1
1Institut Marques, Reproductive Medicine Service, Barcelona, Spain
2LIVET, IVF Unit, Turin, Italy
3Institut Marques, Reproductive Medicine Service, Milan, Italy
Study question: DOD (Distance Oocyte Donation) as fresh IVF-eggs donor’s
cycles with individual blastocyst vitriﬁcation and subsequent shipping to the reci-
pient’s country for thawed embryo transfers: a good alternative to reproductive
tourism?
Summary answer: As a “patient friendly” strategy with good success rates,
DOD cycles are a valid alternative to reproductive tourism in countries with
lack of egg’s donors.
What is known already: In some countries, legal statements as well as eth-
ical, cultural and social aspects generate a huge discrepancy between the need
for egg donation treatments and the availability of egg donors. Therefore, many
recipient patients will travel to a different country to seek for egg donation
treatments: it is not astonishing that in Europe more than 1/3 of all egg donor’s
cycles is performed in Spain (European registers 2013 by ESHRE). The cost of
reproductive tourism is very high for patients: physical and psychological dis-
tress, difﬁculties in the medical follow-up during and after treatment, travel
expenses, loss of working days, etc.
Study design, size, duration: This is a retrospective study of 215 DOD
cycles preformed during a two years time period (may 2015 - may 2017)
between two IVF clinics, based in two different European countries, as Spain
(Barcelona) and Italy (Turin).
Participants/materials, setting, methods: For 195 couples, a frozen sam-
ple of husband’s sperm was shipped from the Italian clinic to the Spanish clinic.
In 20 cases, we used donor’s sperm samples proceeding from a Spanish sperm
bank (Barcelona, Spain). At the Spanish clinic, a total of 215 fresh IVF-eggs
donor’s cycles were completed and blastocyst stage embryos individually vitri-
ﬁed. Frozen embryos were shipped back to the Italian clinic in liquid nitrogen
and 215 recipients underwent thawing transfer cycles.
Main results and the role of chance: When comparing DOD cycles with
standard fresh egg-donor’s cycles completed in the same time-period at the
Spanish clinic in Barcelona, no statistically signiﬁcant differences were observed
in the mean number of good morphology blastocysts/cycle obtained (3.4 vs
3.4), mean age of recipients (41.7 years vs 42.1 years) and donors (26 years vs
26 years). A mean number of 1.58 (1-4) thawed transfers/DOD cycle was
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performed. A single blastocyst transfer was performed in 90.9% of the DOD
thawed transfers, being 1.09 the mean number of transferred embryos in each
transfer. Clinical pregnancy rate was 64.6% (139/215) miscarriage rate was
12.6% (27/215), live birth rate was 52% (112/215), and twins rate was 0.9%
(2/215).
Limitations, reasons for caution: Efﬁciency and safety of the DOD strategy
depends on a strong and consistent blastocyst freezing/thawing method.
Moreover strong partnership and shared IVF protocols between clinics, are
needed to ensure a good outcome. Strict shipping rules are applied when fro-
zen gametes and embryos are shipped between different countries.
Wider implications of the ﬁndings: The DOD strategy seems to be a safe
and efﬁcient alternative to the reproductive tourism in those countries where -
for different reasons - there is a lack of eggs donors. DOD cycles are “patient
friendly” treatments, allowing patients to receive reproductive care in their own
country.
Trial registration number:Not applicable.
O-190 You did not turn up… I did not realise I was invited…:
Understanding male attitudes towards fertility awareness and poor
engagement
B. Grace1, J. Shawe2, S. Johnson3, J. Stephenson4
1University College London, Institute for Women’s Health, London, United Kingdom
2University of Plymouth, Director of The Institute of Health and Community,
Plymouth, United Kingdom
3Swiss Precsion Diagnostics, Scientiﬁc and Medical Affairs, Bedford, United Kingdom
4University College London, Insitute for Women’s Health, London, United Kingdom
Study question: What are the underlying reasons of poor male involvement
in fertility awareness and reproductive health?
Summary answer: Improving male involvement in fertility awareness repro-
ductive health will require more male focused initiatives in order to engage men
better.
What is known already: Involvement of men in fertility and reproductive
health is important for healthy pregnancies and positive outcomes for mother,
father and child. However in research studies in these areas, there is a dearth of
information on men’s perspective. Whilst many studies have postulated the
numerous reasons for lack of inclusion of men in reproductive health research,
few studies have actually included men. Poor engagement by men is often cited
as reason for this. In our study, we interviewed different groups, including men,
to understand the underlying reasons for the lack of engagement.
Study design, size, duration: The study was a qualitative component of a
wider mixed methods study. We carried out 35 qualitative in-depth interviews
on 3 population groups: 13 women, 13 men and 9 healthcare professionals.
Interviews were conducted between October 2016 and February 2017.
Interviewees were purposively sampled to include men and women from the
reproductive age range (18-45 years) and of varying ethnic and educational
backgrounds.
Participants/materials, setting, methods: Participants were sampled
from a UK cross-sectional survey on Fertility Awareness with 1080 participants
who agreed to a follow-up interview. Survey participants were recruited nation-
wide via online newspaper and social media adverts. Healthcare professionals
(HCPs) included doctors and nurses. Healthcare professionals were recruited
from professional bodies such as RCN, RCGP, RCP, doctors.org.uk. Data was
transcribed and analysed via framework analysis. Favourable ethical opinion was
given by UCL.
Main results and the role of chance: The difﬁcultly experienced recruiting
the required samplesize of men highlighted a disconnect between men and
reproductive health issues. We assessed this issue from the men’s, women’s
and HCPs’ perspectives. The reasons different groups gave for lack of male
involvement were varied and reﬂected a need to evaluate different approaches
for improving male involvement.
We found recurring themes towards men’s reluctance to engage in fertility
discussions. Women expressed that this was due to stereotypical male and
female roles. They discussed the impact of societal norms and the perception
that fertility is the ‘woman’s territory’. HCPs supported this view but also
highlighted that poor male involvement was across healthcare needs; not just
unique to fertility.
Contrary to expectations, we found that men wanted to be involved in family
building discussions and wanted to improve their knowledge. However, men
felt they did not have a voice on the topic because discussions have traditionally
focused on women. The notion that men were not expected to be interested
and engaged thus becomes a self-fulﬁlling prophecy.
To encourage male involvement, services, education programmes and
researchstudies should widen scope to include men. Additionally, typical meth-
ods for attracting and incentivising women in studies will not necessarily work
for men.
Limitations, reasons for caution: Although we gathered rich data, intervie-
wees were self-selected and results principally reﬂect views of those who we
willing to participate. Due to the online recruitment method, there is a bias
towards more educated respondents with online internet access.
Wider implications of the ﬁndings: To encourage male involvement, the
current female-oriented services and education programmes on fertility and
reproductive health should be reviewed and revised to involve men.
Additionally, educational programs on sexual and reproductive health should
be engaging and structured to include boys and adolescents from a young age.
Trial registration number:Not applicable.
O-191 Risk of prostate cancer in ICSI treatedmen
Y. Al-Jebari1, A. Elenkov2, A. Giwercman1, E.Wirestrand1,
I. Schütz1, Y. Lundberg Giwercman1
1Lund University, Department of Translational Medicine, Lund, Sweden
2Medical University Soﬁa, Department of Urology, Soﬁa, Bulgaria
Study question: At what risk for prostate cancer are clinically sub-fertile men
who have undergone ICSI as compared to men conceiving naturally?
Summary answer: Men who had undergone ICSI had a statistically signiﬁcant
increased risk of prostate cancer, in particular, early-onset prostate cancer,
compared to men conceiving naturally.
What is known already: Register-studies have reported lower risk of inci-
dent prostate cancer for childless men than biological fathers. Other studies
have indicated that men with impaired fertility are at higher risk for prostate
cancer than fertile men. The majority of the men undergoing ICSI treatment are
subfertile and since they are in contact with the health care system, these men
are well suited as target for preventive measures.
Study design, size, duration: This register-based study sourced data from
the Swedish Medical Birth Register, the Swedish Cancer Registry, and the
Swedish Quality Register for Assisted Reproduction. All fathers and their ﬁrst
child born 1994-2014 were identiﬁed. ICSI fathers were compared to those
who had become fathers by natural conception (controls) and IVF fathers
regarding incident prostate cancer during a follow up of total 51990101 person-
years until 2016. Sensitivity analysis stratiﬁed upon age at diagnosis of prostate
cancer.
Participants/materials, setting, methods: Among all fathers (n = 1 181
490), 20 618 and 14 882 had undergone IVF and ICSI, respectively; and 3 211
were diagnosed with prostate cancer. Associations between mode of concep-
tion (ICSI/IVF/natural) and subsequent prostate cancer were investigated using
Cox regression models with their date of birth as start of follow-up and
adjusted for education level. Early and late-onset prostate cancer was deﬁned
according to age at diagnosis: ≤50 and >50 years.
Main results and the role of chance: Fathers who had undergone ICSI had
a higher risk of prostate cancer (at any age) as compared to controls (HR =
1.47, CI 95% 1.15-1.89; p = 0.002). Conversely, IVF-men did not have an
increase in prostate cancer risk when compared to controls (HR = 1.14, CI
95% 0.91-1.43; p = 0.25).
When stratiﬁed into age groups at cancer, the fathers who had conceived
through ICSI had higher risk for early-onset prostate cancer (HR = 2.94, 95%
CI = 1.84–4.71; p < 0.001) i.e. diagnosed before 50 years of age. However,
ICSI-men did not have an increased risk for late-onset prostate cancer com-
pared to controls. No increased risk of early onset PCa was detected for IVF-
fathers (HR = 1.06, 95% CI = 0.57–1.98; p = 0.86).
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In sensitivity analysis excluding fathers who were diagnosed with cancer prior
to their offspring conception date, ICSI-fathers still had a statistically signiﬁcant
increased risk of PCa (HR = 1.32, 95% CI = 1.01–1.72; p = 0.045) and of early
onset PCa (HR = 2.54, 95% CI = 1.52–4.24; p < 0.001).
Limitations, reasons for caution: Even with a cohort of this size, the pros-
tate cancer cases within the ICSI group were quite limited (n = 63). The study
design did not allow inclusion of the heterogeneous group men who had never
fathered children.
Wider implications of the ﬁndings: The results show immense risk for
early-onset prostate cancer, generally considered more aggressive, in men
referred for ICSI. These men may already have a latent tumor at the time of
ICSI, why the possible beneﬁts of targeted screening could be considered.
Trial registration number:N/A.
O-192 The Canadian Assisted Reproductive Technologies Register
(CARTR) Plus database: A validation study
V. Bacal1,2,3, D.B. Fell2,4, H. Shapiro5,6, A. Lanes3,7, A. Sprague4,7,
M. Johnson7, H.Wang7, M.Walker1,2,3,7, L.M. Gaudet1,2,3
1University of Ottawa, Obstetrics and Gynecology, Ottawa, Canada
2University of Ottawa, School of Epidemiology and Public Health SEPH/ École
d’épidémiologie et de santé publique EESP, Ottawa, Canada
3The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada
4Children’s Hospital of Eastern Ontario, Children’s Hospital of Eastern Ontario
Research Institute, Ottawa, Canada
5University of Toronto, Department of Obstetrics and Gynecology, Toronto, Canada
6Mount Sinai Hospital, Mount Sinai Fertility, Toronto, Canada
7Children’s Hospital of Eastern Ontario, Better Outcomes Registry & Network
Ontario, Ottawa, Canada
Study question: Are data in the Canadian Assisted Reproductive
Technologies Register (CARTR) Plus database valid and reliable?
Summary answer: Markers of validity were strong for the majority of vari-
ables evaluated. Those with moderate agreement were FSH levels, oocyte ori-
gin and elective single embryo transfer.
What is known already: Health databases and registries are excellent
sources of data. However, as these databases are typically not established for
the primary purpose of performing research, they should be validated prior to
utilization for research both to inform the study design and to determine the
extent to which key study variables are accurately documented in the database.
CARTR Plus is Canada’s national register for collecting information on in vitro
fertilization (IVF) and corresponding pregnancy outcomes, and it has yet to be
validated.
Study design, size, duration: This validation study of the CARTR Plus data-
base examined IVF cycles performed in 2015 using patient chart reabstraction.
Six clinics across Canada were recruited to participate using a purposive sam-
pling strategy. Fixed random sampling was employed to select 146 patient
cycles at each clinic, representing unique patients.
Participants/materials, setting, methods: Twenty-ﬁve data elements
were reabstracted from patient charts, which was declared the reference stand-
ard. Data were reabstracted by two independent auditors with relevant clinical
knowledge after conﬁrming inter-rater reliability. Data from the chart were
then compared to those in CARTR Plus. We calculated kappa coefﬁcients, sen-
sitivity, speciﬁcity, positive predictive value, and negative predictive value with
95% conﬁdence intervals (CI) for categorical variables, and mean differences,
paired t-tests and intraclass coefﬁcients for continuous variables.
Main results and the role of chance: Six clinics agreed to participate in this
study representing 5 Canadian provinces. The mean age of patients was 35.5
years, which was similar between the two data sources, resulting in a near per-
fect level of agreement (ICC = 0.99; 95% CI: 0.99, 0.99). The agreement for
FSH was moderate, ICC = 0.68 (95% CI: 0.64, 0.72). There was nearly perfect
agreement for cycle type, kappa = 0.99 (95% CI: 0.98, 1.00). Over 90% of the
cycles in the reabstracted charts used autologous oocytes; however, data on
oocyte source was missing for 13% of cycles in CARTR Plus, resulting in a mod-
erate degree of agreement, kappa = 0.45 (95% CI: 0.37, 0.52). Embryo transfer
and number of embryos transferred had nearly perfect agreement with kappa
coefﬁcients greater than 0.90, whereas that for elective single or double embryo
transfer was much lower (kappa = 0.55; 95% CI: 0.49, 0.61). Validity markers
for pregnancy type, number of fetal sacs, and number of fetal hearts on ultra-
sound were nearly perfect, with kappa coefﬁcients greater than 0.90.
Limitations, reasons for caution: CARTR Plus contains over 200 variables,
of which only 25 were selected for this study. This study, therefore, represents
the ﬁrst step in the validation process for the national database. This founda-
tional validation work should be extended to other database variables in future
studies.
Wider implications of the ﬁndings: This study provides the ﬁrst assess-
ment of the quality of the CARTR Plus database and we found very high data
quality for the majority of the variables that were analyzed. The rigorous meth-
odology used can serve as a guide for future validation projects.
Trial registration number:Not applicable.
O-193 Assisted reproductive technology (ART) treatment and risk
of ovarian cancer
D. Vassard1, C.H. Glazer2, J. Lyng Forman3, M. Kamper-Jørgensen4,
A. Pinborg5, L. Schmidt1
1University of Copenhagen, Department of Public Health- Section of Social Medicine,
1014 Copenhagen K, Denmark
2Bispebjerg University Hospital, Department of Occupational and Environmental
Medicine, 2400 Copenhagen NV, Denmark
3University of Copenhagen, Department of Public Health- Section of Biostatistics,
1014 Copenhagen K, Denmark
4University of Copenhagen, Department of Public Health- Section of Epidemiology,
1014 Copenhagen K, Denmark
5Hvidovre Hospital- Copenhagen University Hospital, Fertility Clinic- Department of
Obstetrics/Gynaecology, 2650 Hvidovre, Denmark
Study question: Is ART treatment associated with risk of ovarian cancer?
Summary answer: An increased risk of ovarian cancer after ART treatment
was mainly apparent during 12 years after treatment initiation and is likely inﬂu-
enced by detection bias.
What is known already: Ovarian stimulation in ART treatment has been
suggested to increase the risk of ovarian cancer. Previous ﬁndings are inconsist-
ent and often based on few diagnosed cases, and it has proven difﬁcult to assess
potential confounders such as endometriosis in large-scale studies. Nulliparity
has been shown to be associated with ovarian cancer, although the causal rela-
tion is not clear. Ovarian cancer is often detected at an advanced stage due to a
lack of symptoms during the early stages of disease. Latency time from initiated
cancer until diagnosis has been estimated to be 30-40 years.
Study design, size, duration: The Danish National ART-Couple II
(DANAC II) cohort includes all women treated with ART at Danish fertility
clinics in 1994-2015. Each woman in ART treatment was age-matched with ten
women from the background population without a history of ART treatment.
The women were followed until ﬁrst cancer diagnosis, death, migration or end
of study December 31st 2015. The cohort consisted of 58,472 women treated
with ART and 549,210 women without a history of ART treatment.
Participants/materials, setting, methods: Multivariable analyses were
conducted using cox proportional hazards regression. Having a primary cancer
diagnosis other than ovarian cancer was incorporated as a competing risk.
Adjustment for confounders included baseline nulliparity, educational level,
partnership status, endometriosis and PCOS and time-dependent adjustment
for age and treatment year. Analyses were stratiﬁed on baseline nulliparity and
on cause of infertility. Further, the risk of being diagnosed with ovarian cancer
was observed over time in order to detect potential patterns.
Main results and the role of chance:During follow-up 393 (0.06%) women
were diagnosed with ovarian cancer, 64 (0.11%) among ART-treated women
and 329 (0.06%) among non-ART women. Women undergoing ART treatment
had a higher risk of ovarian cancer than non-ART women (HR 1.20, 95% CI
1.10-1.31). ART treatment was associated with an increased risk of ovarian
cancer among parous women (HR 1.34, 95% CI 1.11-1.62) and among nullipar-
ous women (HR 2.38, 95% CI 2.17-2.60) versus (HR 2.03, 95% CI 1.89-2.19).
ART treatment due to female factor infertility was associated with an increased
risk of ovarian cancer (HR 1.36, 95% CI 1.25-1.48), while ART treatment due
to male factor/unexplained infertility was associated with a lower risk (HR
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0.87, 95% CI 0.76-1.00). ART treatment was not associated with a long-term
increased risk of ovarian cancer which would be expected if caused by ovarian
stimulating hormones. The excess risk of ovarian cancer among ART-treated
women was highest during the ﬁrst two years after ART treatment initiation
(HR 1.24, 95% CI 1.06-1.45). The excess risk gradually declined and 12 years
after ART treatment initiation the risk was similar to the background population
(HR 1.05, 95% CI 0.87-1.27). This pattern suggests an inﬂuence of detection
bias while undergoing ART treatment.
Limitations, reasons for caution: Although we did not ﬁnd any indications
of harmful effects of ovarian stimulating hormones, it is uncertain to what extent
detection bias explains the higher risk among ART-treated women. ART treat-
ment without female factor infertility was not associated with an increased risk
of ovarian cancer.
Wider implications of the ﬁndings: Disentangling between the effect of
underlying causes of infertility and the ovarian stimulation on the risk of ovarian
cancer is a challenge. Further, detection bias should be thoroughly considered
prior to drawing conclusions.
Trial registration number:Not relevant.
SELECTEDORAL COMMUNICATIONS
SESSION 53: MACHINE LEARNINGANDARTIFICIAL
INTELLIGENCE
Tuesday 3 July 2018 Room 211 + 212 17:00–18:00
O-194 A pre-treatment counselling tool for predicting the
cumulative probability of live birth
N. Balachandren, M. Salman, N.L. Diu, D. Mavrelos
UCLH, Womens Health, London, United Kingdom
Study question: Can we predict the chance of live birth after a single cycle of
ovarian stimulation and transfer of all resulting embryos using only pre-
treatment variables?
Summary answer: Using ovarian reserve and age, our model achieved a posi-
tive predictive value of 80% and AUC of 0.776 (95%CI 0.71 – 0.83).
What is known already: Published IVF prediction models calculate the prob-
ability of live birth per embryo transfer. More recently the cumulative probabil-
ity of live birth (CPLB) has been predicted based on number of eggs collected
after ovarian stimulation (Drakopoulos et al. 2016). While this information is
useful, couples often want to know what their CPLB would be before they
make the decision to engage with IVF. A model based on pre-treatment vari-
ables to calculate CPLB after one stimulated cycle of IVF and transfer of all fro-
zen embryos would be helpful. To our knowledge there is no such model in
current published work.
Study design, size, duration: This was a retrospective cohort study of
patients who underwent their ﬁrst ovarian stimulation between January 2014
and December 2015 in a tertiary referral hospital in central London. We
reviewed all electronic and paper based records for each couple. 551
cycles were reviewed of which 335 complete cycles of IVF were included in the
study.
Participants/materials, setting, methods: To estimate the CPLB we only
included couples who had used all embryos from their initial stimulation or
achieved a live birth. We excluded: (i) cycles that involved oocyte or sperm
donation or in vitro maturation; (ii) unstimulated cycles; (iii) cycles that resulted
in neither fresh nor frozen–thawed embryo transfer; and (iv) patients who did
not have a live birth and had frozen embryos left or had discarded or trans-
ferred out their frozen embryos.
Main results and the role of chance: The cumulative live birth rate was
80% (268/335, [95% CI 76.0-84.0]). Women with a live birth had signiﬁcantly
lower median age (34 [IQR 6] vs. 36 [IQR 5], p = 0.005) and median FSH 6.6
[IQR 2] vs. 7.7 [IQR 2], p = 0.001). They had signiﬁcantly higher median AMH
(22.0 pmol/L [IQR 19] vs. 9.98 [IQR 6], p = 0.001) and AFC (18 [IQR 12] vs.
11 [IQR 8], p = 0.001). There were no signiﬁcant differences in BMI, cause of
infertility, previous pregnancy and duration of infertility.
We constructed a logistic regression model using live birth as the dependent
variable and then used a backward elimination method to create the best ﬁtting
regression model to predict the probability of a cumulative live birth without
removing age as this is a known predictor of live birth. Our model has a positive
predictive power of 80% and the area under the curve (AUC) was 0.74 (95%
CI 0.71 – 0.83).
The model was internally validated using 72 couples who had their ﬁrst IVF
cycle between January 2016 and December 2016. This model was able to cor-
rectly predict 96% of couples who had a live birth.
Limitations, reasons for caution: This was a small study and requires
external geographical validation. The study population were only those eligible
for NHS funded IVF treatment which had strict ovarian reserve criteria. The
low speciﬁcity of this model could be a result of exclusion of women with very
low ovarian reserve.
Wider implications of the ﬁndings: This model is a useful tool for couples
considering whether to undergo ovarian stimulation allowing them to appreci-
ate the full potential beneﬁt of ovarian stimulation and embryo freezing.
Couples with low probability can have realistic expectation on how many cycles
of ovarian stimulation may be needed to achieve live birth.
Trial registration number:N/A.
O-195 Development and validation of an artiﬁcial intelligence
based algorithm for the selection of an optimal stimulation
protocols in IVF patients
N. Correa1, S. Brazal2, D. García2, M. Brassesco1, R. Vassena2
1Centro de Infertilidad y Reproducción Humana CIRH, Assisted Reproduction,
Barcelona, Spain
2Clínica EUGIN, Research Department, Barcelona, Spain
Study question: Are artiﬁcial intelligence (AI) algorithms able to reliably pre-
dict ovarian response in patients undergoing their ﬁrst IVF treatment according
to different proposed ovarian stimulation protocols?
Summary answer: AI can predict with high reliability both the number of
cumulus oocyte complexes (COCs) and of MII obtained in patients undergoing
their ﬁrst IVF cycle.
What is known already: Patients accessing IVF treatment for the ﬁrst time
are prescribed a stimulation protocol based on their reproductive characteris-
tics and clinical history. Nevertheless, such initial treatment might not optimize
their ovarian response, and the objective of averting non optimal outcomes (i.e.
low response or hyperstimulation) might not be met. The analysis of large data-
bases by machine learning algorithms should allow predicting with great accur-
acy the results of ovarian stimulation with different stimulation protocols, thus
assisting the clinician in selecting the most appropriate treatment course since
the ﬁrst IVF cycle.
Study design, size, duration: Cohort database of 6952 ﬁrst IVF cycles.
Predictor variable included: patient age, BMI, blood type, smoking habit, reason
for treatment, ethnicity, antral follicular count, FSH, estrogen and LH levels, age
at menarche. 80% of the cycles in the database were used to train the algo-
rithm, and the remaining 20% were used to validate the best model. As control
in the training process we used a 5 times repeated 10-fold cross validation
technique.
Participants/materials, setting, methods: Algorithm tested included
Random Forest (RF), and two types of black box algorithms such as Support
Vector Machine (SVM, linear kernel), and Artiﬁcial Neural Network (ANN). All
of them capable of regression prediction, as the response variables that the
algorithms were trained to predict were: number of COCs and of MII retrieved
after stimulation.
Main results and the role of chance: Women in the database analyzed
were on average 37.6 ± 4.7 years old (range 18-45), and had a BMI was 24.2 ±
2.8, mean number of COCs and MII obtained was 10 ± 7.1, and 7.2 ± 5.3,
respectively. The best results were obtained using the RF algorithm (mtry =
51) and the response variable number of OCCs (correlation = 0.829, R
squared = 0.676, mean absolute error = 2.405). Nevertheless, the difference
with the RF model (mrty = 34) using as response the number of MII is
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minimum (correlation = 0.816, R squared = 0.632, mean absolute error =
2.079), and it is better to be able to predict MII as the presence of these
determine the success possibilities of the cycle. In other word, the AI algo-
rithm could predict with 81% accuracy the number of MII obtained by a
patient only considering pre-treatment characteristics and comparing them
to a large database of known cycles’ characteristics, stimulation protocols
and stimulation outcomes.
Limitations, reasons for caution: Although the dimension of the database
and the presence of both a training and a validation sample population should
ensure the robustness of the model developed, AI based applications should be
tested prospectively before release.
Wider implications of the ﬁndings: AI and machine learning algorithms
can offer the opportunity to model the outcome of the ﬁrst IVF cycle under dif-
ferent stimulation protocols, and therefore help clinicians in selecting the most
appropriate treatment for ﬁrst time patients.
Trial registration number:Not applicable.
O-196 Optimization of prediction models for live birth and
miscarriage rate in intrauterine insemination between homologous
and frozen donor semen
M.J. Soriano1, I. Molina2, J.V. Martínez2, A. Palomar2, S. Balasch3,
J.M. Rubio2
1Instituto de Investigación Sanitaria La Fe, Reproductive Medicine, Valencia, Spain
2Hospital Universitari i Politècnic La Fe, Reproducción Humana Asistida, Valencia,
Spain
3Universitat Politècnica de València, Estadística e Investigación Operativa Aplicadas y
Calidad, Valencia, Spain
Study question: Can we identify the factors predicting a positive and negative
clinical outcome in the homologous and donor intrauterine insemination?
Summary answer: It is possible to establish a prognostic model of live birth
and miscarriage rate before the intrauterine insemination (IUI) depending on
female and male factors.
What is known already: Although IUI is a commonly used treatment, it is
difﬁcult to predict the chances of gestation. The overall success rate of IUI
remains controversial and depends on several factors. Determinants of IUI suc-
cess can be classiﬁed into three categories: female infertility factors (age, weight,
hormones on the third day of the cycle, follicle development and aetiology),
male infertility factors (semen analysis and preparation technique), and
technique-dependent factors (type of insemination, number of cycles, type of
stimulation received, and total dose administered). There is a controversy
between researchers if pregnancy rates are inﬂuenced or not by these factors
among others.
Study design, size, duration: A retrospective cohort study. A total of 7582
subfertile couples undergoing IUI between April 1997 and December 2017
were analysed. 5491 couples underwent IUI with homologous semen (IUI-H)
and 2091 couples underwent IUI with frozen donor semen (IUI-D).
Participants/materials, setting, methods: All the infertile couples that
underwent IUI cycles in the last ten years. Predictive factors evaluated were
female infertility diagnosis, female age, body mass index (BMI), number of
preovulatory follicles, number of the IUI cycle, endometrial thickness and
sperm quality (total motile sperm count, TMSC). Binary and ordinal multi-
nomial logistic regression analysis by the stepwise procedure were used to
selecting the potential variables related to the live birth rate and miscarriage
rate.
Main results and the role of chance: The overall pregnancy rate (PR) in
IUI-H was 10.4% and 20.5% in IUI-D. Ordinal PR was 0.5% and 1.6%,
respectively. The overall live birth (LB) rate was 8.3% in IUI-H and 17.5% in
IUI-D, and the overall miscarriage rate (MR) was 2.1% in IUI-H and 3.0% in
IUI-D. Binary and ordinal multinomial logistic regression analysis identiﬁed
number of follicles (p = 0.03), number of IUI cycle (p = 0.02), female infertil-
ity diagnosis (p = 0.00) and TMSC (p = 0.00) as signiﬁcant predictive factors
of LB in IUI-H cycles. Number of follicles (p = 0.01), female age (p = 0.00)
and NTSM (p = 0.00) were signiﬁcant predictive factors in IUI-D cycles.
IUI-H achieves the best results with two or three follicles, carrying out a
maximum of 5 cycles, a high TMSC number and in cases of female infertility
from ovulation disorders or a normal ovarian reserve. Moreover, patients
under 30 years would signiﬁcantly increase the LB rate in the IUI-D. A single
preovulatory follicle (p = 0.04) and patients with genital malformation (p =
0.00) would be considered as prognostic miscarriage factors in IUI-H cycles.
The risk of abortion would also be greater as the age increases in IUI-D
cycles (p = 0.01).
Limitations, reasons for caution: The limitations of our study include lack
of a prospective design, instead relying on a retrospective analysis.
Wider implications of the ﬁndings: There are not studies analysing the
predictive factors of live birth between homologous and donor IUI, under the
same conditions. This study will allow deﬁning which couples will obtain a great-
er beneﬁt with the IUI technique for more effective counselling and assisted
reproduction treatment planning.
Trial registration number: This is not a clinical trial.
O-197 Comparison of machine learning models for the prediction
of live birth following IVF treatment: an analysis of 463,669 cycles
from a national database
I. Sfontouris1, A. Patelakis2, G. Panitsa2, S. Theodoratos2,
N. Raine-Fenning1
1University of Nottingham, Child Health- Obstetrics and Gynaecology, Nottingham,
United Kingdom
2Business Insight Co, Business Insight Co, Cambridge, United Kingdom
Study question:What is the comparative ability of different machine learning
models in predicting live birth following IVF based on the analysis of a large
national database?
Summary answer: Deep neural networks were associated with the highest
accuracy and speciﬁcity for live birth prediction compared to other machine
learning models.
What is known already: The increasing wealth of IVF-treatment data has
presented the opportunity, but also the challenge, to develop models for accur-
ate and personalized outcome prediction facilitating optimal treatment design
and patient counseling. Machine learning allows the construction of algorithms
that can ‘learn’ from data and make predictions. It is a powerful way to analyze
large and complex datasets, which may not be effectively interpreted by the use
of conventional statistics. Machine learning has been applied in several ﬁelds of
healthcare and may prove to be a useful tool in developing accurate persona-
lized predictions in fertility treatment.
Study design, size, duration: This population-based cohort study used
anonymous data obtained from the register of the Human Fertilization and
Embryology Authority (HFEA), the ART statutory regulator in the UK. A total
463,669 fresh autologous IVF/ICSI, non-PGD cycles, with a full set of data, per-
formed between 1991 and 2012 were analysed to predict live birth per cycle
started.
Participants/materials, setting, methods: A predictive model of live birth
constructed using latest-technology deep neural networks (DNN) was com-
pared with random forest (RF), decision trees (DT) and Naive Bayes (NB)
machine learning models. Cycles were randomly divided into a training and test-
ing set at a 80:20 ratio. The training set was used to develop the prediction
model and the testing set to validate model performance. Comparisons were
performed using McNemar’s test.
Main results and the role of chance: After exclusions, a total 463,669
cycles were included, of which 99,537 [(21.5% (95% CI: 21.4-21.6%)] resulted
in a live birth. 370,935 and 92,734 cycles were assigned to the training and test-
ing sets, respectively. Variables up to and including the day of embryo transfer
were included in the analysis.
The DNNmodel was associated with signiﬁcantly higher accuracy, speciﬁcity,
positive predictive value (PPV), positive and negative likelihood ratios compared
to other machine learning models. Conversely, sensitivity and negative predict-
ive value (NPV) were lower in DNN compared to other models. All differences
compared to DNN were statistically signiﬁcant (p < 0.0001).
Details of predictive parameters for all machine learning models are shown in
Table 1. ratios and 95/ratios and 95% conﬁdence intervals.
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Table 1
Deep neural
networks
Random
forest
Decision
trees
Naive
Bayes
Accuracy % 76.83
76.59-77.08
74.94
74.66-
75.22
72.90
72.61-
73.18
35.91
35.61-
36.22
Speciﬁcity % 94.86
94.72-95.01
91.16
90.95-
91.36
87.07
86.82-
87.31
18.30
18.02-
18.58
Sensitivity % 11.09
10.71-11.49
16.16
15.65-
16.67
21.53
20.96-
22.11
99.76
99.68-
99.82
Positive
Likelihood
Ratio
2.16
2.07-2.26
1.83
1.76-1.90
1.67
1.61-1.72
1.22
1.22-
1.23
Negative
Likelihood Ratio
0.94
0.93-0.94
0.92
0.91-0.93
0.90
0.89-0.91
0.01
0.01-
0.02
PPV % 37.20
36.16-38.25
33.52
32.65-
34.40
31.48
30.79-
32.19
25.20
25.13-
25.27
NPV % 79.55
79.48-79.63
79.76
79.65-
79.86
80.09
79.96-
80.21
99.63
99.51-
99.72
Limitations, reasons for caution: The anonymised HFEA database holds
no information on the number of cycles performed per patient. Therefore,
necessary adjustments and calculation of cumulative live birth were not pos-
sible. Furthermore, availability of features related to patient demographics,
ovarian reserve, baseline and stimulation characteristics, would likely improve
the models’ predictive ability.
Wider implications of the ﬁndings: The DNN model offered the highest
speciﬁcity and accuracy, efﬁciently predicting cycles not leading to live birth.
Prediction of unsuccessful treatment may be of value for counseling and patient
assessment by clinics and funding bodies. Ongoing research using large datasets
will attempt further improvements of the model’s overall predictive
performance.
Trial registration number:Not applicable
SELECTEDORAL COMMUNICATIONS
SESSION 54: BIOMARKERS FORMALE FERTILITY
Tuesday 3 July 2018 Room 111 + 112 17:00–18:00
O-198 Afamin, a novel human vitamin E-binding glycoprotein, as a
marker of male infertility
R. Nunez-Calonge1, S. Cortes2, R. Kireev3, L.M. Gutierrez4,
J.A. Guijarro5, P. Caballero6
1Clinica Quirurgica Tambre, Reproduction Unit, Madrid, Spain
2Clinica Tambre, ´Reproduction Unit, Madrid, Spain
3Galicia Sur Health Research Institute, Health Research, Vigo, Spain
4University “Alfonso X el Sabio, Research Department, Madrid, Spain
5Hospital Virgen de la Luz, Reproduction, Cuenca, Spain
6Clinica Tambre, Reproduction Unit, Madrid, Spain
Study question: Are afamin levels and single nucleotide polymorphisms in the
5’-untranslated region of the afamin gene associated with male infertility?
Summary answer: Our results show increased afamin levels in the patient
group when compared to controls. Also, suggest that afamin genetic variations
might be associated with infertility.
What is known already: The plasma glycoprotein afamin has been previ-
ously identiﬁed and described as an alternative carrier protein for vitamin E in
extravascular ﬂuids such as plasma, ovarian follicular and seminal ﬂuids. The
role of afamin in male fertility was discovered by the afamin knockout mouse
model. These results from a gene-deleted mouse model indicate a central role
of afamin in fertility possibly due to its vitamin E-binding properties. However,
so far, we have not observed any study which was able to establish a relation-
ship in-between the levels of the protein, polymorphisms and expression of afa-
min genes with male and female infertility.
Study design, size, duration: This observational prospective study evaluates
afamin levels in serum and seminal ﬂuids from infertile men and compares them
with healthy controls Plus, it also studies the association in-between single
nucleotide polymorphisms (SNPs) in the 5‘-untranslated region (5‘-UTR) of the
afamin gene with infertility. The study was performed from samples collected
during the period from May to September 2017.
Participants/materials, setting, methods: Semen samples from 20 oli-
goasthenoteratozoospermic patients attending the Andrology Laboratory were
included in the study. The control was formed by 39 men with normal semen para-
meters. Concentration of afamin was quantiﬁed by sandwich-type ELISA. Peripheral
blood samples were analysed to examine the presence of speciﬁc sequences from
the afamin gene (AFM) by PCR ampliﬁcation followed by direct sequencing. T-
Student test was applied to verify normality distribution of the variables.
Main results and the role of chance: Subjects with low sperm motility or/
and sperm concentration had higher median sperm afamin (18,9 ± 2,9 ng/mg
of proteins) and serum afamin concentrations (24,1 ± 4,0 ng/mg of proteins)
than those without sperm alterations (10,6 ± 1,4 ng/mg of proteins) (p <
0,02); (15,6 ± 1,4 ng/mg of proteins) (p < 0,002).
A total of ﬁve different polymorphisms have been found, these include one
deletion and the remaining four considered as single nucleotide polymorphisms
(SNP).
A new transversion (A/T) (position 4:73481093) was identiﬁed in an OATz
patient and was associated with high levels of afamin in plasma and seminal
ﬂuids. The prevalence of this variant in our study in the case homozygous for
TT is 0.985 (98.5%), whereas in the case heterozygous for TA is 0.015 (1.5%).
5’Upstream single nucleotide polymorphisms rs115041046, rs371710441,
rs35680917, rs72856618 of AFM were polymorphic in both patient and control
groups. However, our data showed that the AG genotype (rs115041046) was
higher among patients compared with controls, and that the TA genotype
(rs371710441) was predominant in the group of male patients.
Limitations, reasons for caution: The main limitation of our study is the
small number of replicates. The results observed in this study should be further
conﬁrmed with a larger sample number.
Wider implications of the ﬁndings: Afamin concentration is higher in the
patient group, potentially due to a compensatory mechanism caused by a pos-
sible decrease in vitamin E levels. Accordingly, these patients could beneﬁt from
an antioxidant therapy. Moreover, these ﬁndings could signiﬁcantly enhance our
understanding of the molecular-genetic causes of infertility.
Trial registration number: FT 115
O-199 combining RNA-seq and proteomic proﬁling in
cryopreserved human sperm exposed to sublethal stress: new
biomarkers for stress-tolerance in sperm
M. Hezavehei1, A. Shahverdi2, G. Hosseini Salekdeh3, M. Mirzaei4,
M. Sharaﬁ5, P. Eftekhari yazdi2, B. Nikmehr6, S. Seiﬁ2,
S. Mirshahvaladi3
1Department of Embryology- Reproductive Biomedicine Research Center- Royan
Institute for Reproductive Biomedicine- ACECR- Tehran- Iran., Reprodactive, Tehran,
Iran
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2Department of Embryology- Reproductive Biomedicine Research Center-, Royan
Institute for Reproductive Biomedicine- ACECR-, Tehran, Iran
3Department of Molecular Systems Biology- Cell Science Research Center-, Royan
Institute for Stem Cell Biology and Technology-ACECR-, Tehran-, Iran
4Macquari University-, Department of Chemistry and Biomoecular Sciences-, Sydney.
NSW-, Austria
5Department of Poultry Sciences-, Faculty of Agriculture- Tarbiat Modares University-,
Tehran-, Iran
6Tehran university of medical sciences, Anatomy department, Tehran, Iran
Study question: What is stress tolerance pathways and changes in the level
of proteome and transcriptome in cryopreserved human sperm exposed to
sublethal stress?
Summary answer: Sub lethal stress induced by nitric oxide(NO) increased
sperm cryoservival by induce expression and modiﬁcations of proteins but, did
not effect on transcriptome level.
What is known already: Stress preconditioning of sperm before cryopreser-
vation is a novel approach for increase sperm cryosurvival. Beneﬁcial effects of
sublethal stress may attributed to the protein response and biosynthesis of
stress-related proteins such as heat shock proteins (HSP) and cellular antioxi-
dant enzymes. These proteins could reduce activation of the apoptotic cascade
and maintain the quality of sperm after freeze. This response may be regulated
at translational or posttranslational levels. Understanding the cellular and
molecular modiﬁcations involved in the offensive controllable strategy by whole
genome sequencing and proteomics could yield valuable information on the
mechanism of cryotolerance in sperm.
Study design, size, duration: This was a control versus treatment study.
We selected 60 semen samples from normozoospermic men, 28-35 years old.
Basic semen analysis performed according to the WHO guidelines, samples
which had not the oxidative stress (ROS-TAC score ≤ 50) were processed by
density gradient centrifugation. Each sample was divided into the following three
subsamples: fresh, freezing without treatment and group exposed to 0.01 μM
NO for 1 h at 37°C and 5% CO2 before cryopreservation.
Participants/materials, setting, methods: Sperm suspensions were cryo-
preserved according to the rapid freezing method and stored for one week.
The post-thaw sperm was evaluated for motility parameters (CASA), percent-
age of apoptosis rate (ﬂow cytometry) and fertilizing ability (heterologous
piezo-ICSI). Protein and transcript proﬁles were investigated between groups
by TMT technology coupled to LC-MS/MS and RNA-seq respectively.
Bioinformatics analyses were performed using DAVID. Candidate proteins and
mRNA were further validated by western blot and Quantitative RT-PCR ana-
lysis respectively.
Main results and the role of chance: Data were analyzed using SPSS soft-
ware and one-way ANOVA. Chi-Square analysis was used for fertilization data,
Level of p < 0.05 was considered statistically signiﬁcant. NO-0.01 group signiﬁ-
cantly increased total motility and progressive motility compared to the cryo-
preserved group. The lowest percentage of apoptotic rate observed in the
NO-0.01 group in compared to the freezing group. In the fertilization trial, the
rate of 2- cell formation was higher in fresh and NO-0.01 groups when com-
pared with the control freezing group. In proteomic analysis,out of 2,912 pro-
teins identiﬁed, 428 proteins were differentially expressed in the fresh, freeze
and NO-0.01 groups. Gene ontology analysis of differentially proteins showed
that the gluconeogenesis pathways, and fertility related proteins such as PLCz
signiﬁcantly down-regulated under cryopreservation condition. whereas in the
NO-0.01 group, HSP70 and redox proteins such as thioredoxin were up-
regulated in compared to cryopreserved group. Using RNA sequencing,
Alignment mapped to the human reference genome (hg19).We determined
that 368 transcripts were differentially expressed (p < 0.05) between fresh and
freeze groups. The main down-regulated genes were PRM1 and PIK3R2,
whereas SPATA family was up-regulated in cryopreserved sperm. We did not
ﬁnd a signiﬁcant differentially in transcript level between NO-0.01 and freeze
groups.
Limitations, reasons for caution: Due to lack of an adequate amount of
protein and RNA for proteomics and RNA-seq analysis,extracted proteins and
RNAs were pooled in each experimental group. Ethical committee not allowed
using human oocytes for research, therefore, for evaluate oocyte activation
capacity,we used mouse oocytes.
Wider implications of the ﬁndings: Cryopreservation effects on the prote-
ome and transcriptome of sperm which may ultimately impair the sperm func-
tion. Stress precondition human sperm before cryopreservation could induce
expression and modiﬁcations of proteins that can increase resistance to cryo-
stress. understand mechanisms of stress-induced stress tolerance might
improve sperm conservation protocols in assisted reproductive techniques.
Trial registration number: not applicable.
O-200 Attenuation of peroxiredoxin activity induce apoptosis in
seminal plasma of men with idiopathic male infertility: striking the
chord for evaluation of a novel biomarker
S. Kanta Goswami1, R. Chattopadhyay2, S. Ghosh2, P. Chakraborty3,
M. Chakraborty2, B. Chakravarty2
1Institute of Reproductive Medicine, ART, Calcutta, India
2Institute of Reproductive Medicine, Assisted Reproductive Technology, Calcutta,
India
3Institute of Reproductive Medicine, Infertility, Calcutta, India
Study question: Is expression of the antioxidant gene panel is altered in sem-
inal plasma of patients with idiopathic male infertility (IMI) compared to normo-
zoospermic men?
Summary answer: Our results show that expression of peroxiredoxin and
glutathione peroxidase was lower in IMI suggesting them as critical oxidative-
stress regulators for fertilization and embryonic development.
What is known already: Most spermatozoa experience DNA repair, add-
itional reactive oxygen species (ROS) being the main cause for DNA injury.
High concentrations of ROS can alter biosynthesis kinetics of stress-related pro-
teins(Heat Shock Protein, intracellular antioxidants etc.). Peroxiredoxin
(PRDX), glutathione peroxidase 6 (GPX6), thioredoxin reductase 1
(TXNRD1) are chief antioxidant genes present in semen and are associated
with various biological processes such as protection against DNA damage,
detoxiﬁcation, oxidative stress and cell apoptosis. Our previous studies have
shown that combination of antioxidants may reduce pregnancy loss by correct-
ing DNA abnormality induced by OS. However, the molecular mechanism
responsible is yet to be explored.
Study design, size, duration: Prospective study; 147 men with IMI served as
study cohort. Normozoospermic men (WHO criteria 2010) were treated as
control (n = 156). The study was carried out from October 2014 to
September 2017and was approved by Institutional Ethics Committee of
Institute of Reproductive Medicine, Kolkata. All participants signed written
informed consent form.
Participants/materials, setting, methods: Sperm parameters (velocity,
motility), apoptosis status, DNA fragmentation, intracellular ROS was evaluated
by Makler’s chamber, ﬂow cytometry, HaloTech DNA assay, and H2DCF-DA
(2’,7’-dichloroﬂuorescein diacetate) ﬂuorescent probe respectively after
freezing-thawing of ~200 spermatozoa. mRNA expression of PRDX, GPX6,
TXNRD1and controls was measured by qRT-PCR using TaqMan probes.
Relative changes in gene expression were calculated using the 2-ΔΔCT meth-
od. Statistical signiﬁcance was set at p < 0.05 as evaluated by Pearson’s correl-
ation test and student’s T-test.
Main results and the role of chance: In comparison with normozoosper-
mic spermatozoa, there was a signiﬁcant decrease (P < 0.03) in motility and vel-
ocity parameters and increase in Caspase+/propidium iodide- (PI-) cells
(P < 0.04) in cryopreserved spermatozoa. As expected, small halo producing
dispersed DNA loops in IMI cohort showed good correlation (r = 1.39;
p < 0.001) with high DNA fragmentation index (DFI) and were signiﬁcantly
higher (P < 0.01) than control. Intracellular ROS levels were signiﬁcantly higher
in samples with increased caspase+ cells compared to normozoospermic men
(p ≤ 0.02) (57 ± 5.5 vs. 16 ± 7.8). We found that increased expression of
PRDX2, PRDX5 and PRDX6 was associated with a signiﬁcant reduction
(r=-0.69, p < 0.02; r=-0.61, p < 0.02; r = 0.55, p < 0.01) in sperm motility
parameters, and viability whereas ROS levels, DNA fragmentation, and loss of
mitochondrial membrane potential as measured by rhodamine 123 were
increased. qRT-PCR analysis revealed that the mean relative levels of mRNA
coding for PRDX2, PRDX5, and PRDX6 were signiﬁcantly decreased in seminal
plasma of men with IMI (PRDX2 p < 0.02; PRDX5 p < 0.05; PRDX6 p < 0.01).
TXNRD1 showed no differential regulation. Attenuation in GPX6 expression,
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although lower than PRDX family, was comparable when correlated with ROS
levels (r = 0.87, p < 0.04).
Limitations, reasons for caution: The results observed in this study should
be conﬁrmed on a larger sample number.
Wider implications of the ﬁndings: The cellular antioxidant defense is
compromised by the attenuation of PRDXs and GPX6 leading to an increase in
oxidative damage thus affecting the fertility potency of patients with IMI. Thus,
current ﬁndings provide a strong platform for new therapeutic strategies
through targeting PRDXs.
Trial registration number:Not applicable.
O-201 Seminal plasma cell-free mitochondrial DNA copy number
is associated with human semen quality
Y. Chen1, T. Liao2, X. Lin1, R.Wu1, L. Jin3
1Reproductive Medicine Center, Zhongshan Boai Hospital, Southern Medical
University
2Reproductive Medicine Center, Afﬁliated Hospital of Guangdong Medical University,
Zhanjiang, China
3Reproductive Medicine Center, Tongji Hospital, Tongji Medical College
Study question:Whether is there association between seminal cell-free mito-
chondrial DNA (mtDNA) copy number and human semen parameters.
Summary answer: Seminal cell-free mtDNA copy number is associated with
semen parameters, which may serve as a novel diagnostic marker of semen
quality.
What is known already: Mitochondria are the major source of ATP through
the electron transport chain and play important roles in sperm function and
spermatogenesis. Recently, it has been suggested that abnormal sperm mito-
chondrial DNA copy number has been associated with defective sperm func-
tion. Despite that the cell-free mtDNA in body ﬂuids has ignited great interest
in exploiting its diagnostic value, there have no report about seminal plasma
cell-free mtDNA and its probable clinical implications.
Study design, size, duration: Semen samples were collected from 205 men
who were undergoing fertility assessment because of idiopathic inability to con-
ceive. The population included men with normal and abnormal semen
parameters.
Participants/materials, setting, methods: Seminal cell-free mtDNA copy
number was measured using Real-time PCR. Seminal reactive oxygen species
(ROS) level was analysed by using the in vitro OxiselectTM assay kit. Sperm
quality was assessed using World Health Organization criteria, while sperm
motility parameters were determined by computer-aided sperm analysis.
Main results and the role of chance: We applied PCR to detect seminal
cell-free mtDNA from infertile men. All seminal plasma samples had mitochon-
drial MTF3212/R3319 gene expression. Average cell-free mtDNA copy num-
bers were 310.3, 199.4, 44.6 and 23.1 in the group of Normal,
Oligozoospermia, Asthenozoospermia and Oligoasthenozoospermia. There
were signiﬁcant differences in mtDNA copy number among the groups of infer-
tile men (P < 0.05). Comparing with the Normal group, seminal cell-free
mtDNA copy numbers were decreased signiﬁcantly in the Asthenozoospermia
group (P < 0.05) and Oligoasthenozoospermia group (P < 0.05). In contrast
with the Normal group, ROS levels were increased signiﬁcantly in the
Asthenozoospermia group (P < 0.05) and Oligoasthenozoospermia group
(P < 0.05). Cell-free mtDNA copy number positively correlated with sperm
concentration (r = 0.345; P < 0.05), motility (r = 0.673; P < 0.05), morphology
(r = 0.291; P < 0.05), curvilinear velocity (r = 0.263; P < 0.05), straight-line vel-
ocity (r = 0.247; P < 0.05), and average path velocity (r = 0.271; P < 0.05).
ROS level negatively correlated with sperm concentration (r = -0.455;
P < 0.05), motility (r = -0.676; P < 0.05), curvilinear velocity (r = -0.273; P <
0.05), straight-line velocity (r = -0.261; P < 0.05), and average path velocity
(r = -0.264; P < 0.05). There was negative correlation between seminal cell-
free mtDNA copy number and ROS level (r = -0.753; P < 0.05).
Limitations, reasons for caution: The results need to be conﬁrmed in
more samples.
Wider implications of the ﬁndings: The strong positive correlation
between cell-free mtDNA and conventional semen parameters suggest seminal
cell-free mtDNA copy number could be used as a novel biomarker in the study
and diagnosis of male infertility.
Trial registration number:N/A.
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O-202 Freezing ovarian tissue and simultaneously obtaining an
average of 8 mature oocytes without ovarian stimulation - is it a
reality?
D. Nikiforov1, C. Junping1, S.E. Pors1, J. Gruhn2, S.G. Kristensen1,
C.Y. Andersen1
1University Hospital of Copenhagen- Rigshospitalet, Laboratory of Reproductive
Biology, Copenhagen, Denmark
2University of Copenhagen, Centre for Chromosome Stability- Department of Cellular
and Molecular Medicine- Faculty of Health Sciences, Copenhagen, Denmark
Study question: Can immature oocytes found in the medium after cortical tis-
sue preparation for fertility preservation, constitute a reliable source of mature
eggs?
Summary answer: GV oocytes released during cortical tissue preparation,
mature to MII stage with an average 23% success rate, resulting in average 8 MII
oocytes per patient.
What is known already: Cryopreservation of ovarian tissue by slow freezing
has become a reliable method of fertility preservation for many groups of the
patients. During the procedure of cortical tissue preparation, many small antral
follicles within the tissue are cut open resulting in release of immature oocytes
into the medium. These oocytes have the potential to develop into mature
oocytes that may be used for fertility purposes. The aim of present study was
to improve the IVM protocol for oocytes deriving from small follicles which was
previously rarely used in the context of fertility utilization.
Study design, size, duration: Oocyte-cumulus complexes (COCs) were
collected into HEPES-buffered medium supplemented with 10 mg/mL of
human serum albumin and cultured following an IVM protocol established in
our laboratory (315 oocytes). After 48 hours oocytes were denudated and
their maturation stage was determined.
Participants/materials, setting, methods: A total of 9 patients aged 21-
36 years (mean age 29) who had one ovary excised for fertility preservation
were included. After collection GV oocytes were divided into one of three
groups: COCs with large amount of cumulus cells, small amount of cumulus
cells and naked oocytes. After maturation measurements of oocyte diameter,
diameter of egg’s cytoplasm and zona pellucida thickness were taken and
related to the maturation status of the oocyte.
Main results and the role of chance: On average, 35 immature oocytes
per patient from one ovary were collected with the range of 13-60 oocytes.
23% (N = 74) of all oocytes matured to the MII stage within 48 hours. On aver-
age each patient had 8,2 mature oocytes. Maturation rate for the oocytes from
large COCs was 37,5%, small COCs matured with the rate of 22,7%, while suc-
cess rate for the naked ones was only 6,3% (p < 0,001). Our morphometric
observations showed how diverse the pool of immature oocytes was. All found
oocytes were within the range of 114-167 μm in diameter (including zona pellu-
cida - ZP). Oocytes matured to MII had a signiﬁcantly larger diameter than MI
and GV ones (p < 0,001). No differences were found in relation between zona
pellucida thickness and different stages. No signiﬁcant relationship was
observed between the number of collected oocytes and the age of patients.
Limitations, reasons for caution:More patients are needed to evaluate the
developmental potential of oocytes obtained by the described method.
Wider implications of the ﬁndings: The unexpected developmental cap-
acity of immature oocytes from small antral follicles is likely to augment chances
for conception in this group of patients in addition to the cortical tissue. The
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use of IVM oocytes collected from small antral follicles during normal IVF treat-
ment may be of interest in the future.
Trial registration number: n/a.
O-203 Recovery of ovarian function after chemotherapy for
Hodgkin lymphoma is limited by age, not pretreatment ovarian
reserve
R. Anderson1, A.M. Kirkwood2, L.A. Clifton-Hadley2, L.I. Stevens2,
P.E. Johnson3
1University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, United
Kingdom
2University College, Cancer Research UK & UCL Cancer Trials Centre, London,
United Kingdom
3Southampton General Hospital, CRUK Centre, Southampton, United Kingdom
Study question: How much do age and pretreatment ovarian reserve impact
on ovarian function recovery after low toxicity chemotherapy with A(B)VD
(doxorubicin, (bleomycin), vinblastine, dacarbazine) for Hodgkin lymphoma?
Summary answer: Anti-mullerian hormone (AMH) showed complete recov-
ery after A(B)VD in women aged <35 but not in those ≥35, whereas recovery
was similar across pretreatment AMH levels.
What is known already: Chemotherapy can be very damaging to the ovarian
reserve, reﬂected in post-treatment amenorrhoea of variable duration, and
reduced AMH levels in those without overt POI. Chemotherapy regimen and
dose, age and pretreatment ovarian reserve have all been implicated in deter-
mining recovery of ovarian function after treatment, but previous studies have
often included women with a range of diagnoses and treatment regimens, pre-
cluding clear interpretation. We have investigated recovery from A(B)VD treat-
ment, regarded as having low gonadotoxicity, in a relatively young adult
population as a more standardised model to investigate the relative contribu-
tions of age and pretreatment ovarian reserve.
Study design, size, duration:Women were recruited from the RATHL trial
of treatment for newly diagnosed advanced Hodgkin lymphoma. Blood samples
from 57 women treated with ABVD or AVD chemotherapy (grouped as A(B)
VD) were taken pretreatment, at the end of treatment and at 1, 2 and 3 years
later and serum stored.
Participants/materials, setting, methods: Women were aged 27.4 ± 0.9
years (range 18-44). Samples were analysed in a single batch for AMH using the
Roche Elecsys automated assay. AMH recovery was calculated as concentration
at 2 years/pretreatment. Spearman correlation coefﬁcients were calculated
and multiple linear regression used to analyse age and pretreatment AMH
against AMH recovery. Groups were compared by Mann-Whitney U test.
Main results and the role of chance: AMH levels fell markedly in all women
during chemotherapy, 13.8 ± 1.8 to 3.5 ± 0.7 pmol/L at end of treatment then
recovered to pre-treatment levels by 1 year (13.1 ± 1.9 pmol/L) with no
decline over the following 2 years. FSH showed opposite changes. There was a
very good correlation between AMH pretreatment and at 2 years (Spearman
r = 0.71, p = 0.0002) but not with AMH recovery (r=-0.02, p = 0.9). There
was no signiﬁcant correlation between age and pretreatment AMH (r=-0.2,
p = 0.1) but there were signiﬁcant negative correlations between age and 2
year levels (r=-0.53, p < 0.0001) and with AMH recovery (r=-0.48,
p = 0.001). This negative impact of age on recovery was supported by mean
AMH recovery in women <35 yrs being complete at 1.27 ± 0.12, whereas it
was markedly reduced at 0.37 ± 0.10 in those ≥35 (p < 0.0001). Analysis by
pretreatment AMH below/above the median value (9.77 pmol/L) showed that
recovery was similar in the 2 groups (low group 1.23 ± 0.21 vs high group 1.03
± 0.09, (p = 0.8). Multiple linear regression analysis also conﬁrmed a signiﬁcant
impact of age (beta -0.43, p = 0.004) but not pretreatment AMH (beta -0.15,
p = 0.3) on AMH recovery.
Limitations, reasons for caution: This analysis may be relevant only to
women treated with this chemotherapy regimen, for Hodgkin lymphoma. It is
unclear whether this impact of age on ovarian recovery can be generalized to
other diagnoses/treatments. The mechanisms through which ageing impacts on
recovery from chemotherapy are unknown.
Wider implications of the ﬁndings: The limiting effect of age on recovery
of growing follicle populations requires further study to more fully understand
the effects of age and chemotherapy on the ovary. This is likely to involve
effects on both on the stroma and vasculature, in addition to depletion of the
ovarian reserve.
Trial registration number:NCT00678327
O-204 Recombinant AMH prevents primordial follicle loss and
long term fertility alteration in cyclophosphamide treatedmice
C. Sonigo1, I. Beau1, M. Grynberg2, N. Binart1
1Inserm U1185, Université Paris Sud, Le Kremlin Bicetre, France
2Hopital Antoine Béclère, Reproductive Medicine and Fertility Preservation, Clamart,
France
Study question: What is the effect of concomitant recombinant Anti-
Müllerian Hormone (rAMH) and cyclophosphamide (Cy) administration on
ovarian reserve and fertility in a mouse model?
Summary answer: Co-treatment of rAMH with Cy preserves primordial fol-
licle (PMF) loss induced by Cy and might improve fertility outcome after
treatment.
What is known already: An endowment of oocytes is established during
fetal development in women. The majority of oocytes are present within non-
growing PMF. This PMF stockpile may decline as a result of age or in some
pathological conditions. Mechanisms controlling the activation of PMF imply a
balance between factors activating the initiation of follicular growth, mainly
actors of the phosphatidyl-inositol-3-kinase (PI3K) signaling pathway, and inhi-
biting factors, such as AMH. Cy induces both the initiation of dormant follicle
growth via an activation of PI3K pathway and the apoptosis of growing follicles
leading to a major depletion of the follicular reserve.
Study design, size, duration: Forty-eight pubertal Swiss female mice
received one intra-peritoneal injection of either vehicle, Cy (150 mg/kg), rAMH
(100 μg) or Cy + rAMH and were sacriﬁced 24 hours or 8 days after treatment.
To assess fertility outcome, a subgroup of pubertal mice was treated with one
weekly intra-peritoneal injection of either vehicle, Cy (75 mg/kg), AMH (10 μg)
or Cy + AMH through 4 weeks and then mated with proven fertile male along
14 weeks. Four weeks after male removing, ovulation tests were performed.
Participants/materials, setting, methods: Ovaries were removed one
week after treatment, serially cut into 4 μm sections and stained with hema-
toxylin eosin. One out of ﬁve sections was analyzed and all follicles were
counted. Western blot analysis of whole ovaries was performed to study PI3K
pathway signaling. Fertility assessment included estrous cycles monitored by
daily vaginal smears, mating experiment, and counting of cumulative pups. At
last the number of ovulated oocytes after superovulation was evaluated.
Main results and the role of chance: The number of PMF into Cy-treated
mice ovaries was signiﬁcantly decreased as compared to controls (597.7 ± 35.9
vs 813.4 ± 68.7 follicles, p = 0.010) and was similar to normal range in Cy
+rAMH mouse ovaries (875.5 ± 83.9 follicles). In addition, the number of early
growing follicles was higher after a single injection of Cy as compared to control
(802.4 ± 64.8 vs 507.7 ± 55.4 follicles p = 0.02). Western blot of ovary homo-
genates analysis showed that Cy increased signiﬁcantly the phosphorylation of
PI3K-pathway key proteins (P70S6K and FOXO3a). Co-administration of
rAMH does not impact PI3K signaling pathway. Nevertheless, phosphorylation
of the transcription factor FOXO3a was signiﬁcantly decreased in ovaries of
mice treated with rAMH alone as compared to control mice suggesting that
AMH via FOXO3a blocks the PMF activation.
Cy-treated mice exhibited a signiﬁcantly reduced number of estrous cycles
when compared to controls (6.5 ± 0.4 vs 9.2 ± 0.3 cycles, p = 0.006). Co-
treatment with AMH did not modify this alteration of cyclicity. The number of
pups was slightly decreased in Cy-group as compared to controls or Cy+
rAMH mice. At last, the mean number of ovulated oocytes was decreased in
the Cy-group as compared to controls and signiﬁcantly increased after AMH
co-administration.
Limitations, reasons for caution: This original study using a mouse model
supports a potential protective role of rAMH against Cy-induced follicular loss.
Further research and clinical studies are needed to conﬁrm these results.
Wider implications of the ﬁndings: PMF activation has been recently
reported as mechanisms for Cy-induced gonadotoxicity. This follicular activa-
tion might not be speciﬁc of Cy and has been described for other drugs.
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Therefore rAMH could become a new option in the therapeutic arsenal of fer-
tility preservation for young women having to undergo chemotherapy.
Trial registration number: not applicable.
O-205 Organotypic culture of fresh and cryopreserved-thawed
human prepubertal and pubertal testis
J. Portela, C.M. DeWinter-Korver, S.K. Van Daalen, A. Meißner,
A.A. DeMelker, S. Repping, A.M. Van Pelt
Academic Medical Center, Center for Reproductive Medicine, Amsterdam, The
Netherlands
Study question: Can organotypic culture of fresh and cryopreserved-thawed
human (pre)pubertal testicular tissue equally maintain spermatogenesis?
Summary answer: Though spermatogonia could be maintained in vitro for 5
weeks, the percentage of tubules containing MAGEA4+ cells decreased inde-
pendently of tissue status and culture condition.
What is known already: Cryopreservation of testicular tissue is increasingly
offered as a fertility preservation method for (pre)pubertal patients prior to
gonadotoxic treatment, whereas strategies for fertility restoration still remain
under development. One of the proposed experimental approaches is to differ-
entiate germ cells in vitro. In fact, this has already been accomplished in mouse
using an organ culture method to both fresh and cryopreserved-thawed testicu-
lar fragments. Despite these encouraging results, the spermatogenic yield is yet
relatively low and could not be successfully applied to cryopreserved human
testis tissue.
Study design, size, duration: Testicular tissue was collected from nine (pre)
pubertal boys (6-14 years) admitted for fertility preservation procedure prior
to gonadotoxic treatment. In all cases, ethical approval was obtained and
informed consent was received from the boys’ parents in order to use a portion
of the testicular biopsy for research purposes.
Biopsies were either immediately processed or cryopreserved-thawed
before organotypic cultured in two different media for a maximum period of 5
weeks, depending on the initial biopsy size.
Participants/materials, setting, methods: Fresh or cryopreserved-
thawed testis fragments (1-2 mm3 pieces) were cultured at a gas-liquid inter-
phase (34°C, 5% CO2) in weekly refreshed α-MEM + 10% KSR media contain-
ing 10-7 M melatonin and 10-6 M retinoic acid, with or without 3IU/L FSH/LH
supplementation. A minimum of 3 cultured pieces were weekly ﬁxed for further
histological and immunohistochemical assessment of spermatogonial survival
and proliferation (MAGEA4/PCNA). Percentage of tubules with MAGEA4
positive spermatogonia was determined in 25-100 tubular cross sections from
each fragment.
Main results and the role of chance: Our data shows that, under the
described conditions, organ culture of human (pre)pubertal tissue supported
spermatogonial maintenance, but no further germ cell differentiation was
detected over a period of 5 weeks. Quantitative analysis revealed a progressive
decrease in the percentage of testicular tubules containing MAGEA4 positive
cells during culture. Nevertheless, spermatogonial survival was comparable
between fresh and cryopreserved-thawed cultured fragments and independent
on culture media (without or supplemented with FSH/LH). Only in a single
case (14 years patient), when elongating spermatids were already present in the
testicular biopsy before culture, the percentage of tubules with MAGEA4 posi-
tive cells increased in fresh cultured tissue.
Depending on patients’ age, spermatogonia remained proliferative active in
the ﬁrst weeks of culture and Sertoli cells regained proliferative ability in vitro.
Limitations, reasons for caution: These results should be interpreted con-
sidering that it is necessary to further optimize the organ culture method for
human testicular tissue, ensuring better spermatogonial survival as well as differ-
entiation potential. Additionally, investigations comprising the supporting som-
atic environment should be performed.
Wider implications of the ﬁndings: Our data suggests that fresh and
cryopreserved-thawed testicular fragments are maintained similarly in vitro.
Therefore, although the culture conditions need to be further optimized, these
results support the concept that cryopreserved testis fragments from (pre)
pubertal cancer survivors could be used for fertility restoration in the future.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 56: BIOLOGYOFOOCYTE ANDCUMULUS
COMPLEX
Tuesday 3 July 2018 Room 117 17:00–18:00
O-206 Mitochondrial DNA sequence variation in human oocytes
by single-cell mtDNA sequencing
Q. Zeng1, S. Cao2, L. Cai1, Z. Xue3, J. Liu1
1First Afﬁliated Hospital- Nanjing Medical University, The Center of Reproductive
Medicine, Nanjing Jiangsu, China
2Nanjing Maternity and Child Health Hospital, The Center of Reproductive Medicine,
Nanjing, China
3Tongji University, School of medcine, Shanghai, China
Study question: Using single-cell mtDNA sequence to explicit variation of
mitochondrial DNA in human oocytes during maturation.
Summary answer: All of the oocytes mtDNA were heteroplasmy. Most of
mtDNA sequence variations were de novo distict to cumulus and located in
MT-RNR1 and MT-RNR2 locus.
What is known already: Mitochondria’s quantity and quality are essential to
oocytes development, fertilization and early embryo development. mtDNA is
unique from the nuclear genome, and mitochondrial inheritance is solely mater-
nally inherited (non-mendelian patterning). And mtDNA shows a higher rate of
mutation than nuclear DNA. It is assumed that most de novomutations accumu-
late through the process of heteroplasmy. However, it is unknown whether
mutations initiated, occur and accumulate early in the oocytes.
Study design, size, duration: Human oocytes were obtained from 8 patients
at our Centers for Clinical Reproductive Medicine through written informed con-
sent and institutional approval. 36 oocytes and its cumulus: Germinal vesicle (GV)
(13), MI (4), and MII (19). After digestion them, oocytes or cumulus were used to
construct mtDNA library and sequence. The whole mitochondrial genome was
sequenced on the Illumina HiSeq platform and haplogroups and mtDNA variants
were identiﬁed through mapping to reference mitochondrial genomes.
Participants/materials, setting, methods: After controlled ovarian hyper-
stimulation, oocytes were collected after 34–36 hours of hCG injection.
Oocytes were treated with Tyrode’s acidic solution to remove zona pellucida
then were used to construct mtDNA library using VariantProTM PCR reaction.
The libraries were sequenced on the Illumina HiSeq 4000 platform. After
removing low quality reads, clean data were analyzed and mapped to the refer-
ence human mitochondrial genomes using MtoolBox toolkit, BWA, GATK
HaplotypeCaller, UniﬁedGenotyper and so on tools.
Main results and the role of chance: It revealed the crucial mtDNA varia-
tions in different stages of oocytes. All samples showed different degree of
mtDNA heterogeneity, and the proportion of heterogeneity and homogeneity
(Het/Hom Ratio) was 0.03 to 0.46. The mitochondrial heteroplasmies were
different among different stages of oocytes from the same patient, and mito-
chondrial heterogeneities were slightly different between the same stages of
oocytes in the same individual.
A total of 196 mitochondrial variations or mutants were detected, and about
30% of them distributed in the non encoding region of (D-loop), e.g. MT-RNR1
and MT-RNR2 locus, which had high mutation rates. All of oocytes had differ-
ent number of 25-50 mutants, and most of them were single nucleotide poly-
morphism (SNP). The types of SNP were different between individuals. It was
found that most of the SNP (75.5%) was common to the oocytes and granulosa
cells, and which was a genetic marker for the patients. But there are also
oocytes and granulosa cells speciﬁc for the SNP, of which there were 22 SNP in
oocytes included 9 missense mutations, and there were 26 SNP mutations in
granulosa cells included 6 missense mutations and 2 synonymous, but most of
the missense mutations with low frequency.
Limitations, reasons for caution: In the study, every stage of human
oocytes was not achieved in natural cycles but induced using a GnRH agonist
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and GnRH antagonist. And extremely-low-level variations were not anaylzed in
this paper.
Wider implications of the ﬁndings: The results provide a valuable
resource to comprehend for mtDNA duplication regulatory mechanisms
underlying progressive development of human oocytes, and our study provides
new insight into mitochondrial genetic disease occurrence and therapy.
Trial registration number: not applicable.
O-207 Transcriptional proﬁle of tubulin post translational
modiﬁcation (PTM) enzymes throughout human oocyte meiotic
progression in vivo and in vitro
P. Karamtzioti1, G. Tiscornia1, M. Barragán1, I. Vernos2, R. Vassena1
1Clínica EUGIN, Assisted Reproduction, Barcelona, Spain
2Center for Genomic Regulation CRG, Cell and Developmental Biology Programme,
Barcelona, Spain
Study question: How do PTM enzyme transcripts in human germinal vesicles
(GVs) change during the process of meiotic progression to the MII stage of
maturation?
Summary answer: 17 PTME transcripts are detectable in GVs, MII oocytes
and GVs cultured in vitro to the MII stage; only 3 PTMEs vary between matur-
ation stages.
What is known already:Oocyte maturation requires the formation of the mei-
otic spindle, mainly composed of tubulin heterodimers (microtubules). Tubulin
PTMs alter microtubule properties, making PTM enzymes potential regulators of
spindle formation and chromosome segregation. Tubulin acetylation, glutamylation,
formation of Δ2- tubulin, and tyrosination have been described in the meiotic spin-
dle. In mice, increased acetylation impairs spindle migration to the subcortical
region. Deacetylase overexpression can compensate for altered spindle formation
and chromosome alignment in aged mouse oocytes. A role for glutamylation and
tyrosination has not yet been deﬁned in oocyte meiosis. Importantly, PTM and
PTM enzymes have not been systematically characterized in human oocytes.
Study design, size, duration: This is a basic research study. GVs or MII stage
oocytes were retrieved from hormonally stimulated oocyte donors aged 20-35
years old. Three experimental groups were deﬁned: GVs (n = 6), in vivo
matured MII oocytes (n = 8) and GVs cultured in vitro (without cumulus cells)
until the MII stage (n = 6). Expression levels of 22 PTM enzymes responsible for
all known tubulin PTMs were determined by single–cell real time quantitative
PCR (qPCR) in the each oocyte.
Participants/materials, setting, methods: All women were stimulated by
GnRH antagonist protocol, with GnRH agonist trigger. Trigger criterion was 2
or more follicles >18 mm, and OPU was carried out strictly 36 h later. Total
RNA was isolated from each oocyte independently, cDNA generated by ran-
dom hexamer priming and ampliﬁed for 24 cycles. qPCR for PTME transcript
detection was performed in triplicate and expression levels were normalized to
ACTB, RPLP1, DNMT1, GADPH, SDHA and UBC, using the ΔΔCt method.
Main results and the role of chance: Out of 22 transcripts measured, 17
transcripts were detected. 14 transcripts out of 17 detected showed no variation
between GVs and in vivo matured MII stage oocytes. NAA50 (acetylation), TTLL4
(monoglutamylation) and TTLL6 (polyglutamylation) showed the highest overall
expression between both groups. In contrast, CCP2 (involved in deglutamylation)
had low expression in both groups. In particular, expression levels of TTLL3 and
TTLL10 (responsible for glycylation) were remarkably low, consistent with the pres-
ence of this modiﬁcation only in exceptionally stable microtubules, such as in cilia
and ﬂagella. All other PTME had intermediate levels of expression. Notably, CCP2,
TTLL4 and TTLL12 (unkown function) were signiﬁcantly lower (Mann-Whitney
test, p < 0.05) in MII oocytes as compared to GVs. PTME expression levels in MII
stage oocytes obtained by culturing GVs in G2-plus medium did not show signiﬁcant
differences when compared to MII oocytes, except in the case of TTLL12 and
TTLL5 (involved in monoglutamylation), which showed signiﬁcantly higher expres-
sion levels than those observed in MII oocytes matured in vivo (Mann-Whitney test,
p < 0.05). SIRT2 (involved in deacetylation) showed a similar tendency but did not
reach statistical signiﬁcance.
Limitations, reasons for caution: Variability may be underestimated by the
relatively low number of samples per group. mRNA and protein expression
levels of PTM enzymes may not be correlated, as transcripts may be stored in
the oocytes in an inactive state, or be left-over from translation during oocyte
growth.
Wider implications of the ﬁndings: This is the ﬁrst characterization of
tubulin PTM enzyme during human oocyte meiosis. Overall, expression levels
of PTM enzymes did not change, with the exception of TTLL4, TTLL12 and
CCP2, which decrease signiﬁcantly during meiotic progression. We hypothesize
that these PTM enzymes may play a role in meiotic spindle regulation.
Trial registration number:Not applicable.
O-208 Dual trigger vs. hCG for ﬁnal oocyte maturation. A
prospective randomized controlled, double blinded study:
preliminary results
J. Haas1, R. Bassil2, R. Casper2
1TRIO fertility clinic, IVF unit, Toronto, Canada
2TRIO fertility partners, IVF unit, Toronto, Canada
Study question: Does co-administration of GnRH agonist and hCG in IVF cycles
improve the number of oocytes and oocyte quality compared to hCG alone.
Summary answer: The dual trigger increases the number of mature oocytes,
and number of top quality blastocysts compared to triggering with hCG alone in
normal responder patients.
What is known already: Human chorionic gonadotropin (hCG) is usually
used at the end of controlled ovarian hyperstimulation as a surrogate LH surge
to induce ﬁnal oocyte maturation. Recently, based on retrospective studies, the
co-administration of GnRH agonist and hCG for ﬁnal oocyte maturation (dual
trigger) has been suggested to improve IVF outcome and pregnancy rates.
Study design, size, duration: A single center, prospective, randomized con-
trolled, double-blinded clinical trial between July 2016 and January 2018.
Participants/materials, setting, methods: Normal responder patients
were randomized either to receive hCG or dual trigger for ﬁnal oocyte maturation.
Data on patients age, BMI, AMH, number of follicles >10mm and >15mm on day
of hCG administration, number of oocytes retrieved, MII, zygotes and blastocysts
were assessed and compared between the dual trigger group and the hCG group.
Main results and the role of chance: One hundred and forty six patients
were included in the study, 73 patients in each arm. The age (35.9 vs. 35.7
p = NS), BMI (23.7 kg/m2 vs. 24 kg/m2, p = NS), AMH (20.7 pmol/l vs. 19.5
pmol/l P = NS) and FSH (6.5 vs. 5.8 p = NS) were comparable between the
two groups. The total amount of gonadotropins, the length of the stimulation and
the number of follicles >10mm and >15mm in diameter on day of hCG adminis-
tration were also similar in the two groups. The number of eggs retrieved (12.9
vs. 10.6, p = 0.02), the number of MII (10.1 vs. 8.6, p = 0.03) and the number of
zygotes (7.9 vs. 6.3, p = 0.04) were signiﬁcantly higher in the dual trigger group
compared to the hCG group. The oocyte recovery rate (oocytes/follicles≥11
mm) was signiﬁcantly higher in the dual trigger group compared to the hCG group
(97% vs. 78% p = 0.001). The number of top quality blastocysts (2.8 vs. 1.8 P =
0.005) was signiﬁcantly higher in the dual trigger group. The clinical pregnancy
rate and the ongoing pregnancy rate were similar in both groups.
Limitations, reasons for caution:None.
Wider implications of the ﬁndings: The co-administration of hCG and
GnRH agonist increases the number of oocytes, and the number of top quality
embryos compared to triggering with hCG alone in normal responder patients.
This increase may improve the outcome of the IVF cycle but a larger study pow-
ered by pregnancy outcome is needed.
Trial registration number:NCT02703584
O-209 Anti-Müllerian hormone promotes granulosa cell
proliferation in the preantral-to-early antral follicles, but induces
granulosa cell apoptosis during the subsequent follicular
development, in the primate ovary
J. Xu1,2, M. Lawson1, L. Liang1,3, C. Bishop1
1Oregon National Primate Research Center Oregon Health & Science University,
Division of Reproductive Sciences, Beaverton- Oregon, U.S.A.
2Oregon Health & Science University, Department of Obstetrics and Gynecology-
School of Medicine, Portland- Oregon, U.S.A.
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3Henan Provincial People’s Hospital, Reproductive Medical Center, Zhengzhou-
Henan, China
Study question: Do granulosa cells in follicles at the different stages of follicu-
logenesis respond differently to anti-Müllerian hormone (AMH) in vivo in the
primate ovary?
Summary answer: AMH may enhance preantral and early antral follicle
growth by promoting granulosa cell proliferation, and prevent subsequent antral
follicle maturation by inducing granulosa cell apoptosis.
What is known already: AMH action in the primate ovary is stage-
dependent, directly promoting preantral follicle survival and growth while inhi-
biting antral follicle maturation in vitro. Blocking AMH actions in vivo interferes
with dominant follicle selection process in nonhuman primates.
Study design, size, duration: Hemi-ovariectomized animals (n = 9) served
as their own controls and were assigned randomly to 6 treatment sequences in a
crossover design. Intraovarian treatments were administered during the follicular
phase (cycle day -2 to mid-cycle estradiol, or E2, surge) of menstrual cycles 1, 3,
5 and 7, with 1 recuperation cycle between treatment cycles. Treatments
included (a) control vehicle, (b) recombinant human AMH (rhAMH; 25 ng/hr),
and (c) neutralizing anti-human AMH antibody (AMH-Ab; 1000 ng/hr).
Participants/materials, setting, methods: Female rhesus macaques (6-10
years) received intraovarian infusions via an osmotic pump. The menstrual cycle
length was recorded. Blood samples were measured daily during treatment cycles
for E2 and progesterone (P4) levels by immunochemiluminescence assays.
Ultrasonography was performed at mid-cycle to assess antral follicle cohorts.
One hour before the ovariectomy at the mid-cycle of the last treatment, animals
received 20mg bromodeoxyuridine (BrdU; iv). Ovaries were evaluated by hema-
toxylin/eosin staining, BrdU immunostaining, and TUNEL assay.
Main results and the role of chance: In the control cycles, only one large (5-
9mm) antral follicle was observed at the mid-cycle E2 surge. However, 3 rhAMH-
treated ovaries displayed multiple medium-sized (2-4mm) antral follicles, while the
other 6 developed a single medium-to-large antral follicle with diameters less than
those of controls (6.1 versus 7.0 mm; P < 0.05). Seven AMH-Ab-treated ovaries
developed multiple medium-to-large (3-10mm) antral follicles. The average serum
E2 levels during the follicular phase decreased following rhAMH infusion, but
increased following AMH-Ab infusion, relative to those of the control cycles
(109.9/167.6 versus 136.1 pg/ml; P < 0.05). There were no differences in the
menstrual cycle length, overall ovarian size at the mid-cycle E2 surge, peak E2 levels,
or average P4 levels during the luteal phase between the control and rhAMH/
AMH-Ab treatment cycles. While the preantral and early antral follicles of the con-
trol and rhAMH-treated ovaries appeared to be healthy, with the rhAMH-treated
follicles containing abundant BrdU-positive granulosa cells, those in AMH-Ab-
treated ovaries exhibited abnormal morphology with TUNEL-positive granulosa
cells. In contrast, healthy medium-to-large antral follicles containing BrdU-positive
granulosa cells were identiﬁed in the control and AMH-Ab-treated ovaries,
whereas those in the rhAMH-treated ovaries contained abundant TUNEL-positive
granulosa cells or became atretic.
Limitations, reasons for caution: The current study was performed in vivo
with follicle cohorts from different developmental stages co-existing in the
macaque ovary. Therefore, effects of the follicle-follicle interactions could not be
ruled out. Hematoxylin/eosin, BrdU and TUNEL staining was descriptive, but
could be quantiﬁed in future studies using cell and follicle counting methods.
Wider implications of the ﬁndings: The ﬁndings are consistent with previ-
ous in vitro data on the stage-speciﬁc actions of AMH in follicle cohorts. The
study provides valuable information relevant to understanding and/or treating
ovarian dysfunction. For example, elevated serum AMH in patients with polycys-
tic ovary syndrome may contribute to the pathology of this endocrine disorder.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 57: APPROACHINGTHE CLINIC: STEMCELLS
TREATMENTS FOR INFERTILITY
Tuesday 3 July 2018 Room 116 17:00–18:00
O-210 Autologous mitochondrial transfer as a complementary
technique to ICSI to improve oocyte and embryo quality in IVF
patients. A Randomized Pilot Study
E. Labarta Demur1, S. Herraiz2, M.J. De los Santos3, A. Marzal1,
M.J. Escribá3, A. Buigues2, A. Pellicer4
1IVI RMA Valencia, Human Reproduction, Valencia, Spain
2IVI RMa, IVI Foundation, Valencia, Spain
3IVI RMA Valencia, IVF Laboratory, Valencia, Spain
4IVI RMA Rome, Human Reproduction, Rome, Italy
Study question: Does Autologous mitochondrial transfer (AUGMENT®
treatment) improve oocyte/embryo quality and pregnancy rates in patients
with previously failed IVF treatments?
Summary answer: AUGMENT does not seem to improve oocyte/embryo
quality in this poor prognosis patients. No differences regarding live birth rates
per embryo cohort were observed.
What is known already: AUGMENT is a proprietary new technology
launched in 2014 by OvaScience℠. Previous clinical use suggested that the add-
ition of autologous mitochondria during IVF is safe, improves embryo quality,
increases the success of IVF and avoids concerns associated to heteroplasmy.
Many studies described the existence of egg precursor cells (EPCs) in the outer
lining of the ovarian cortex, however others have failed to ﬁnd them.
OvaScience reports that mitochondria isolated from EPCs are of high quality
and morphologically like oocyte mitochondria.
Study design, size, duration: Triple blind, randomized, single-center, con-
trolled experimental pilot study.
Study period: October 2015- June 2017.
A biopsy of the ovarian cortex was performed to isolate the EPCs to obtain
their mitochondria. Sibling MII oocytes obtained after stimulation were allo-
cated though computerized randomization to two groups: AUGMENT proto-
col (experimental) and Conventional ICSI (control).
Sample size was calculated to detect a 20% difference (15-35%) in the OPR
between both groups. An interim analysis was performed in 59 patients.
Participants/materials, setting, methods: Infertile patients undergoing an
IVF-PGT-A cycle, aged ≤42, BMI < 30, AMH ≥4 pmol/mL, >5 million/mL
motile sperm, ≥1 unsuccessful previous IVF cycle with ≥5 MII eggs collected
and extremely low embryo quality.
Primary endpoint was ongoing pregnancy rate (>12w).
In the experimental group, ≈1-2 picoliters of mitochondrial suspension were
injected along with the sperm during ICSI. Viable blastocysts from both groups
were biopsied and cryopreserved. The genetic content of the embryos was
evaluated through CGH arrays.
Main results and the role of chance: Two of 59 enrolled patients spontan-
eously conceived (one ended in miscarriage). A total of 57 ovarian cortex biop-
sies were performed. In one case, a suboptimal number of EPCs were isolated;
a second biopsy was performed yielding sufﬁcient EPCs for inclusion in the
study. Twenty-six patients did not undergo embryo transfer for the following
reasons: no blastocysts available for biopsy (n = 16); all aneuploid (n = 8); no
fertilization (n = 1); no survival after thawing (n = 1). A total of 253 MII were
inseminated in the AUGMENT and 250 in the Control group, with a fertilization
rate of 64.0 % and 70.8%, respectively (p = 0.11).
Day 5 blastocyst formation rates were signiﬁcantly reduced in the
AUGMENT group (27.2%) compared to the Control group (43.5%), p = 0.002.
The number of euploid blastocysts/biopsied blastocysts was 42.2% (19/45) in
the AUGMENT and 50% (37/74) in the Control group (p = 0.42). Statistical
differences in euploidy rate/MII oocytes between both groups (7.5% vs. 14.8%,
p = 0.01) were observed.
No differences were observed regarding mtDNA content in euploid
embryos, p = 0.56.
The live birth rate per transferred embryo was 41.2% (7/17) in the
AUGMENT and 39.1% (9/23) in the Control group (p = 0.90).
Limitations, reasons for caution: The technique requires a laparoscopy.
Isolation of EPCs and mitochondrial extraction was performed in a separated
laboratory set up from OvaScience. Data regarding ﬁnal mitochondrial quantity
and quality was not available for this analysis.
Wider implications of the ﬁndings: In this difﬁcult to treat patient popula-
tion, the ratio of euploid embryos obtained per MII was signiﬁcantly lower with
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AUGMENT compared to the Control group. No differences regarding live birth
rates per embryo cohort were seen. Therefore, the study is no longer been
continued.
Trial registration number: The www.clinicaltrials.gov registration number
is NCT02586298
O-211 3D Architecture of endometrial glands in relation to stem
cell organisation
N. Tempest1, A.M. Baker2, M. Jensen3, N.Wright2, D. Hapangama4
1Liverpool Women’s Hospital, Department of Women’s and Children’s Health,
Liverpool, United Kingdom
2Bart’s Cancer Institute, Epithelial Stem Cell Biology group, London, United Kingdom
3Bart’s Cancer Institute, University College London, London, United Kingdom
4Liverpool Women’s Hospital, Women’s and Children’s Health, Liverpool, United
Kingdom
Study question: Is there an epithelial stem cell(s) in the human endometrium
that can regenerate all epithelial cell subtypes and what is the 3D architecture
of endometrial glands?
Summary answer: Epithelial stem cells producing luminal, functional and
basal epithelial subtypes exist in human endometrium; 3D glandular architec-
ture demonstrates region-speciﬁc, horizontal branching and vertical singular
arrangement.
What is known already: Menstrual shedding and repair of the endometrial
functionalis is unique to humans and higher-order primates. The current dogma
is that endometrial epithelium regenerates from endometrial epithelial stem
cells residing in the base of the glands; this theory presumes endometrial glands
to have a single tubular architecture with a blunt end. The precise 3D organisa-
tion of the human endometrial glandular epithelium is unknown. The existence
of a human endometrial epithelial stem cell(s) that can produce the 3 epithelial
regions (luminal, functionalis and basalis) is yet to be directly conﬁrmed.
Study design, size, duration: Prospective observational study examining full
thickness human endometrial samples from 50 normal pre (menstrual/prolif-
erative/secretory) and postmenopausal women undergoing hysterectomy for
benign gynaecological conditions without endometrial pathology.
Participants/materials, setting, methods: The gold standard method,
in vivo cell lineage tracing, detecting unique mitochondrial DNA mutations
(mtDNAm) in laser captured micro-dissected single epithelial cells, was used to
conﬁrm the existence of endometrial epithelial stem cells. 100 consecutive par-
afﬁn sections stained with H&E / cytochrome c oxidase (CCO) were used for
3D reconstruction. Manual drawing of gland boundaries in 2D images were con-
nected along the third dimension. Epithelial subtypes were examined with 10
stains in consecutive endometrial sections.
Main results and the role of chance: CCO deﬁcient patches exist in human
endometrium, ﬁrst appearing in a 27 year old. A unique CCO-mtDNAm, in a
partially mutated gland within a CCO deﬁcient area conﬁrmed a clonal popula-
tion evidently with its origin in a stem cell and suggesting there may be more
than one stem cell responsible for regenerating that gland. Basalis glands inter-
connect (branch) and take a horizontal course along the myometrium; whilst
non-branching single functionalis glands appear to germinate perpendicularly
from these horizontal basal glands. mtDNAm occur in the basalis glands, and
the vertical tracking of such mutations along the functionalis glands, conﬁrmed
that at least one population of endometrial epithelial stem cells resides in the
basalis glands, responsible for endometrial epithelial regeneration. The sequen-
tial tissue sections stained for ten known epithelial cell markers also demon-
strated the existence of all these cell types in a CCO negative clonal patch,
conﬁrming their common origin.
(I have 3D reconstruction videos that look great in a presentation)
Limitations, reasons for caution: Since the different epithelial cell subpopu-
lations with phenotypical and functional differences are not fully characterised in
the human endometrium, the ability of the potential stem cells to produce all
different epithelial cells cannot be conclusively demonstrated.
Wider implications of the ﬁndings: More than one endometrial epithelial
stem cell contributes to the monthly glandular regeneration. The complex 3-
dimentional histo-architectural arrangement, highlights endometrial epithelium
cannot be treated as a single entity. The existence of multiple endometrial
epithelial stem cells with possible functional diversity warrants further interroga-
tion, essential for understanding endometrial pathology.
Trial registration number:NA.
O-212 Human pluripotent stem cell-derived cells expressing
functional follicle-stimulating hormone receptor (FSHR) - a tool for
functional studies and disease modeling
K. Lundin, P. Väyrynen, K. Sepponen, K. Luiro, T. Tuuri,
J.S. Tapanainen
University of Helsinki and Helsinki University Central Hospital, Department of
Obstetrics and Gynecology, Helsinki, Finland
Study question: Can human pluripotent stem cells (hPSCs) be utilized in
modeling FSHR function during early human development, and to study FSHR
expression and function in FSH resistant patients?
Summary answer: hPSC-derived cells expressing human FSHR were derived.
These cells responded normally to FSH while cells from patients with inactivat-
ing FSHRmutation failed normal responses.
What is known already: FSH regulates follicular growth and spermatogen-
esis. FSH bioactivity is exerted through binding to FSHR, where upon intracellu-
lar cAMP synthesis and other downstream signaling pathways are activated.
Besides ovaries and testes, FSHR expression has been reported in extragonadal
tissues including developing placenta and endothelial cells of female reproduct-
ive tract. We have previously shown that the inactivating FSHR mutation
(A189V) leads to arrest of follicular development and infertility in females.
Affected males have reduced sperm counts but are able to father children.
Thus far, the expression or function of the mutated FSHR has not been studied
in cells endogenously expressing the receptor.
Study design, size, duration: The study was conducted in a control human
embryonic stem cell line (hESC H9, 46, XX) and two patient derived human
induced pluripotent stem cell lines (hiPSC HEL127.6 and HEL128.5, 46, XX).
The patient lines contained a A189V mutation in the FSHR gene, known to
inactivate normal receptor function. Generation of patient lines was approved
by Ethics Committee.
Participants/materials, setting, methods: Cells were differentiated with
Activin A, CHIR-99021 and Y-27632 (1d), BMP7 and CHIR-99021 (1d), CHIR-
99021 and dorsomorphin (2d), and B27 supplemented media (4d). Cells at dif-
ferent stages of differentiation were studied by qPCR. At d6 or d8, cells were
stimulated with FSH for ﬂow cytometry, localization, western blotting and
qPCR studies and for cAMP assay. Single-cell sequencing was performed on
control cells. Experiments were repeated at least three times for each cell line.
Main results and the role of chance: hPSCs differentiated by our protocol
endogenously expressed functional FSHR. These cells responded dose-
dependently to FSH stimulation by increasing cAMP production, downregula-
tion of FSHR and inhibin βA (INHBA) mRNA expression and upregulation of
inhibin α (INHA) expression. Patient derived iPSCs carrying A189V mutation
also expressed FSHR, but the receptors did not respond to FSH stimulation by
cAMP production or regulation of FSHR or inhibin gene expressions.
Preliminary qPCR and single cell sequencing results indicate that the cells
resemble extraembryonic cell types. Interestingly, hPSCs differentiated into
trophoblast-like cells with another protocol also expressed FSHR at mRNA
level but did not respond to FSH stimulation. Hence, we have established a
method for differentiating human cells endogenously expressing FSHR that can
be used for studying wild type and mutant receptors. However, the true iden-
tity of these cells is yet to be conﬁrmed.
Limitations, reasons for caution: The cells express functional FSHR and
can thus be used for studying the FSHR biology, but the biological role of these
cells have to be further evaluated. So far, the localization of the receptor on the
cell has not been elucidated due to lack of functional FSHR antibodies.
Wider implications of the ﬁndings: This study presents novel information
about FSHR gene expression patterns during differentiation. The model gener-
ated here provides an efﬁcient method to study the regulation and function of
cells endogenously expressing FSHR obtained from both healthy subjects and
subjects with abnormal FSHR function.
Trial registration number: Translational research, no trial.
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O-213 A novel two-step transplantation procedure using adipose
tissue-derived stem cells increases follicle survival by boosting
angiogenesis in xenografted frozen-thawed human ovarian tissue
D.D. Manavella I.1, L. Cacciottola1, J. Donnez2, C.A. Amorim1,
M.M. Dolmans1
1Institute de Recherche Expérimentale et Clinique- Université Catholique de Louvain,
Gynecology Research Unit, Brussels, Belgium
2Society for Research into Infertility, Fertility Preservation, Brussels, Belgium
Study question: Do adipose tissue-derived stem cells (ASCs) increase follicle
survival by enhancing oxygenation and vascularization in xenografted ovarian tis-
sue using a two-step transplantation approach?
Summary answer: Higher rates of oxygenation and vascularization of ovarian
tissue, as well as increased follicle survival rates, were detected in the early
post-grafting period.
What is known already: ASCs have multilineage differentiation potential,
proangiogenic properties and enhance vascularization in a peritoneal grafting
site. Some studies suggest that using ASCs may improve quality of grafted ovar-
ian tissue by enhancing graft angiogenesis.
Study design, size, duration: In vivo experimental model. A total of 15
severe combined immunodeﬁcient (SCID) mice were intraperitoneally grafted
with frozen-thawed human ovarian tissue from 5 different patients for a short-
term period (7 days). A peritoneal transplantation site had been previously pre-
pared in a ﬁrst step using either empty ﬁbrin (Fi +OT group [n = 5]) or ASC-
loaded ﬁbrin (Fi/ASCs+OT group [n = 5]) 14 days prior to grafting. Five mice
underwent the standard one-step transplantation procedure and served as con-
trols (OT group).
Participants/materials, setting, methods: Prospective experimental study
conducted at the Gynecology Research Unit, Université Catholique de Louvain.
Lithium phthalocyanine (LiPc) crystals were inserted into all grafted human
ovarian tissue before transplantation. On days 3 and 7: pO2 measurements
(EPR oximetry); on day 7: mice were euthanized and samples were collected
for histological (H-E and Masson’s trichrome staining), IHC (anti-mouse and
human double CD34 and anti-human Ki-67) and TUNEL analyses.
Main results and the role of chance: A signiﬁcant increase in pO2 was
observed in all groups between day 3 and 7 (p < 0.001). A signiﬁcantly higher
pO2 level was observed in the Fi/ASCs+OT group compared to the OT group
on day 7 (p = 0.028). Total CD34-positive vessel area on day 7 was greater in
the Fi/ASCs+OT group than in any other group (vs non-grafted group:
p = 0.0014; vs OT group: p = 0.013; vs Fi +OT group: p = 0.018). Follicle sur-
vival rates after grafting were also higher in the Fi/ASCs+OT group compared
to all the rest (vs OT group: p = 0.0059; vs Fi +OT group: p = 0.0138).
TUNEL-positive follicle percentages after grafting were signiﬁcantly lower in the
Fi/ASCs+OT group than in any other grafted tissue (vs OT group: p = 0.045;
vs Fi +OT group: p = 0.0268). Percentages of Ki-67-positive primordial folli-
cles were signiﬁcantly higher in all grafted groups compared to non-grafted tis-
sue controls (p < 0.01). No differences in were observed ﬁbrotic areas.
Limitations, reasons for caution: As demonstrated by our results, the pro-
posed two-step ovarian tissue transplantation procedure using ASCs enhances
vascularization in the early post-grafting period, leading to increased follicle sur-
vival rates and decreased apoptosis. However, mechanisms involved in the
proangiogenic behavior of ASCs remain to be elucidated.
Wider implications of the ﬁndings: Our results suggest that the proposed
transplantation procedure with ASCs is a promising step towards potentially
solving the problem of massive follicle loss after ovarian tissue grafting.
Trial registration number:N/A.
INVITED SESSION
SESSION 58: COCHRANE SESSION: INDUSTRY AND
EVIDENCE IN REPRODUCTIVEMEDICINE: MANAGING
THE CONFLICTS
Wednesday 4 July 2018 Room 211 + 212 08:30–09:30
O-214 Conﬂict of interest and bias: not your problem or is it?
L. Bero
The University of Sydney, D17- The Hub- 6th Floor- Charles Perkins Centre, Sydney
NSW, Australia
Abstract text
Bias in research is a problem that concerns researchers, consumers, policy
makers and other users of evidence. Researchers strive to reduce bias in their
research and make it transparent. A variety of methods have been used to iden-
tify “bias”—the systematic error or deviation from the true results or inferences
of a study—in clinical pharmaceutical research. Bias related to funding sources
or investigator conﬂicts of interest can be introduced throughout the entire
research process (questions asked, design, conduct or publication). Global
transparency initiatives have enabled the detection of previously hidden ﬁnancial
ties between researchers and pharmaceutical companies. I will discuss a num-
ber of ongoing efforts aimed at identifying and reducing bias in clinical research
and practice.
O-215 We need some sunshine - making gifts from industry
Transparent
P. Vercellini
Università degli Studi and Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico- Milan- Italy, Department of Clinical Sciences and Community Health,
Milano, Italy
Abstract text
The collaboration between academic investigators and industry is invaluable for
the advancement of medical knowledge and improvement of health care.
However, whereas the main objective of medicine is to develop increasingly
clinically effective and cost-effective therapeutic options, that of pharmaceutical
industries and medical device manufacturers is to generate proﬁt. Physicians are
accountable to their patients and, more in general, to society. Industry CEOs
and senior executives are accountable to their board of directors and, more in
general, to shareholders. In spite of different main aims, a “convergence of
interests” may arise between medicine and industry when crossing the bound-
aries of science and accepting the weight of ﬁnancial dynamics. Physicians may
desire money for themselves, but also for their research programmes, scientiﬁc
societies, conferences, and medical journals. In an era of scarce public funding,
industry becomes an attractive and abundant source of money for the entire
medical community. In this condition, the risk for medicine would be to favour
the interest of industry to the detriment of that of patients, thus derailing from
its mission, whereas industry can continue to pursue its main interest (i.e., prof-
it) without mission distortion. According to entrepreneurial logic, any industry
ﬁnancial investment should generate revenues, in this case through modiﬁcation
of prescribing patterns. In this regard, scientiﬁc information is crucial to increase
sales of drugs and devices. The way scientiﬁc information is generated, selected,
disseminated, and conveyed to patients is precisely the process that industry
may be tempted to inﬂuence. To accumulate funds for their research pro-
grammes, academicians could accept to conduct trials expressly designed to
systematically favour the experimental drug. The reports of these trials may
appear in prestigious journals that would gain from selling advertisement and
reprints. The publication of these results could inﬂuence the drafting of
guidelines issued by scientiﬁc societies, especially when members of the panel
of experts received industry funds. Annual conferences, which are indispensable
for the ﬁnancial survival of many professional organisations, could be supported
by drug and device manufacturers, provided sponsored symposia including
selected key opinion leaders are strategically positioned within the scientiﬁc
programme. Industry may focus not only on investigators tempted to facilitate
their career and increase their visibility, but also on patient associations, gener-
ally considered by citizens as honest and reliable sources of information.
Awareness campaigns can be organized by façade committees behind which
industries operate. Several stakeholders would proﬁt from this “convergence of
interests”, except patients, their families, and public health services that eventu-
ally would pay the bill. If inﬂuenced scientiﬁc information is the cornerstone of
this ambiguous compromise, then medicine appears much guiltier than industry,
because no distortion of evidence would ever be possible without the active
role of academia. The validity of the shared decision-making process, i.e. the
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currently accepted paradigm of care in chronic medical conditions, is based on
a properly conveyed, complete and truthful information. In case the profes-
sional contract is breached to the beneﬁt of industry, who is more to blame:
the individual physician who accepted meals, gifts, and travels to conferences,
or those academicians with vested interests who, playing several different roles,
generated and disseminated distorted information used to inﬂuence the end-
prescriber? With the objective of limiting the “convergence of interests”, an
open peer-review system could be readily implemented by major journals for
those manuscripts dealing with novel medical interventions with a potential
impact on prescribing patterns. If names of editors and reviewers, as well as
their reports, were publicly accessible, probably the gatekeepers of scientiﬁc
information would be less indulgent toward industry interests.
INVITED SESSION
SESSION 59: NON-GENETIC FACTORS INFLUENCING
EMBRYO VIABILITY
Wednesday 4 July 2018 Room 111 + 112 08:30–09:30
O-216 Inﬂuence of maternal diet on preimplantation embryo
development and long-term potential
T. Fleming
Southampton General Hospital, School of Biological Science\rMailpoint 840- Level D
Lab & Path Block, Southampton, United Kingdom
Abstract text
Epigenetic and physiological mechanisms permit embryos at the onset of devel-
opment to adapt to environmental conditions such as maternal dietary quality,
leading to altered phenotype of both extra-embryonic (placental) and embry-
onic (fetal) cell lineages. Thus, poor maternal diet around the time of concep-
tion in mouse models induces compensatory responses in extra-embryonic
lineages that collectively enhance the capacity for nutrient delivery from the
mother. Peri-conceptional poor diet also causes fetal tissues to coordinate
growth with nutrient availability through control of ribosome biogenesis,
mediated by DNA methylation level of the rDNA promoter. Such adaptations
to peri-conceptional maternal diet appear mediated through nutrient sensing,
particularly levels of select amino acids and insulin, at the blastocyst stage and
modulation of mTOR signalling. Whilst this maternal-embryonic ‘dialogue’ sup-
ports embryo survival, if environmental conditions change, adaptations can
become maladaptive and associate with long-term risk of cardiometabolic and
neurological disease in adult offspring. Evidence of related environmental pro-
gramming of early embryos has been forthcoming across mammalian species
including the human, and can occur in response to diverse conditions, not only
maternal diet but also in vitro embryo techniques as used in assisted concep-
tion. Funding: BBSRC, MRC, EU, NIH, Rosetrees Trust, Kerkut Trust.
O-217 Extrinsic factors disrupting embryo physiology in vivo and
vitro
Y. Menezo1, B. Dale2
1Laboratoire CLEMENT, Paris, France
2CFA centro fecondazione assistita, Assisted reproduction, Napoli, Italy
Abstract text
Hypo fertility or delay/failure to conceive is an increasing multifactorial problem
in western populations. Increasing parental age due to delaying the decision to
have a baby is one problem, while a decrease in sperm quality and premature
ovarian failure (POF) and diminished ovarian reserve (DOR) are today
observed with increasing frequency. Obesity and diabetes are on the increase
and now affect 30% of the population. The link between these chronic patholo-
gies, oxidative stress (OS) and epigenetics and their impact on embryo quality is
now clear. Endocrine disruptors (EDCs) are strong effectors in the contribution
to hypofertility. Pesticides, xenoestrogens, endocrine disrupting chemicals
involved in plastic technology such as polychlorinated bisphenols (PCB), bisphe-
nols (BP), phthalates, alkyl phenols are now present in the environment, food
and even in cosmetics. They induce OS that affects DNA (but not only) quality
via the estrogen (ER) and androgen (AR) receptors leading to hormonal anom-
alies. Via the peroxisome proliferator-activated receptors (PPARs), they per-
turb metabolic signaling and induce endocrine pathologies (obesity). Recent
research suggests that they negatively affect correct DNA methylation in off-
spring tissue and thus epigenesis and imprinting. Epigenetic mechanisms modify
the expression of speciﬁc genes without changing the underlying DNA
sequence: they are involved in important cellular processes: chromosome sta-
bility (and inactivation), transcription and cellular growth and differentiation; all
major effectors for a correct embryonic development. Fetal male and female
gametes are submitted ﬁrst to a methylation/imprinting erasure and then a full
reset of a complete proﬁle. EDCS may affect this resetting as these chemicals
are found in urine of children and adults; they induce ovarian resistance during
pre-implantation development, there is a strong methylation maintenance dri-
ven by the DNA methyltransferase 1 highly expressed in oocytes and early
embryos (Menezo et al. 2011). This maintenance may be affected in vitro as
well as the majority of culture media do not contain methyl donors; these
compounds are the only molecules able to counteract the negative effects of
the EDCs. Recent publications have demonstrated that IVF babies have dif-
ferent DNA methylation proﬁles compared to babies obtained by natural
conception (Katari et al. 2009, Song et al. 2015). All these negative features
may be increased by the endogenous backgrounds affecting methylation
process such as mutations affecting the one carbon cycle (1-CC), such as
MTHFR (methylene tetrahydrofolate reductase) and MS (Methionine syn-
thase) mutations.
In conclusion, many aspects of modern day life have increased the difﬁculty
to conceive. Nutritional backups that support the 1-CC, and therefore
methylation processes, and endogenous protection against oxidative stress
are strongly recommended for men and women before trying to conceive
since avoiding negative factors from environmental pollution now seems
impossible.
INVITED SESSION
SESSION 60: NURSES/MIDWIVES INVITED SESSION:
TOWARDS PARENTHOOD
Wednesday 4 July 2018 Room 113 + 114 + 115 08:30–09:30
O-218 Antenatal care in transition from fertility treatment to
parenthood
C.Warmelink, M. Boekhout, E. Tros, L. Kool
Midwifery Academy Amsterdam-Groningen, Midwifery Academy Groningen,
Groningen, The Netherlands
Study question: What are the antenatal maternity care needs of MAC-
parents in the transition from fertility treatment to parenthood?
Summary answer: The study will be ready in July 2018
What is known already: Nearly ﬁve percent of newborns in the
Netherlands are now born following fertility treatment, Medically Assisted
Conception (MAC), a steadily increasing number. Pregnancies conceived
through MAC are associated with higher risks of complications, such as small
for gestational age, preterm birth, low birth weight, perinatal death and delivery
complications. Next to the medical impact, the fertility treatment and the preg-
nancy after MAC can have psychological and social impact for the MAC-
parents, such as higher levels of anxiety in early pregnancy and perception of
the pregnancy as being more risky and demanding.
Little is known about the antenatal care needs of MAC-parents in transition from
fertility treatment to parenthood. There is a lack of awareness and training for mid-
wives and other maternity care providers on the impact of MAC on the pregnancy.
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Study design, size, duration: Mixed Methods Review – a systematic review
of qualitative, quantitative, and mixed method studies guided by the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist
and methodological quality appraised in accordance with the Mixed Method
Appraisal Tool (MMTA). Data sources such as Medline/PubMed, Cochrane
library, Cumulative Index to Nursing and Allied Health (Cinahl) and Psychology
and behavioral science were searched to ﬁnd eligible studies.
Participants/materials, setting, methods: Two student-midwives research-
ers conducted the searches and selected the studies together and abstracted the
data independently in Winter and Spring 2018. Two researchers (psychologist and
educational scientist) supervised the study.
A PRISMA ﬂowchart present the screening process and results of the biblio-
graphic search.
Main results and the role of chance: In progress.
Limitations reasons for caution: As with all research, the value of this sys-
tematic review depends on what was done, what was found, and the clarity of
reporting. As with other publications, the reporting quality of systematic
reviews varies, limiting readers’ ability to assess the strengths and weaknesses
of those reviews. Even though systematic review and meta-analysis are con-
sidered the best evidence for getting a deﬁnitive answer to a research question,
there are certain inherent ﬂaws associated with it, such as the location and
selection of studies, heterogeneity, loss of information on important outcomes,
inappropriate subgroup analyses, and duplication of publication.
Wider implications of the ﬁndings: The number of women treated with
and babies born after fertility treatments is mounting. Also, there is clear empir-
ical evidence of the postponement of the ﬁrst child in Western societies, which
has implications on the (dis)ability of women to conceive and parents to produce
additional offspring. Subfertility and fertility treatment can be a potential medical,
social and psychologist burden. This places additional and changed demands on
the competence and knowledge of professionals working in maternity care.
The study output can lead to the implementation of innovative interventions,
care models and methods and guidelines for midwives, gynaecologists and other
maternity care takers.
Study funding/competing interests: This work is not funded. All authors
declare s.
Registration number:N/A.
O-219 Focussing on infertile men’s needs
R. Sylvest
Copenhagen University Hospital Hvidovre, Department of Obstetrics/Gynaecology,
Hvidovre, Denmark
Infertile men and their needs
Abstract text
Childlessness concerns both partners in the couple; however until now only
limited focus has been on men’s needs regarding their fertility treatment. Men
with low sperm count are frequently a complex group to treat at the fertility
clinic. Women undergo the majority of the physical aspects of treatment, thus
the focus of the information and physical care is generally directed toward the
women. Even in couples with male factor infertility, men’s role in treatment is
generally limited to providing a semen sample. Research has shown that men
wish to talk about the psychosocial topics and be included more.
Approximately one third of men in heterosexual couples in fertility treatment
have low sperm count. For the individual man this often means that he will con-
sider why his sperm count is low, try to ﬁnd explanations and consequences of
this. Male infertility is a potential severe low-control stressor, and research has
shown that many men with low sperm quality would like to talk about it more
widely. Men, unlike women, rarely express their problems and needs in the
health service or are more reluctant to do so. Mikkelsen et al. found that 72%
of 210 Danish men undergoing fertility care lacked information about the psy-
chological consequences of male infertility.
Previous studies on male fertility patients’ satisfaction with treatment differ in
results. A study among Australian men has shown that the contentment with
the fertility treatment was not inﬂuenced by the outcome of the treatment. A
Danish study among 909 male fertility patients treated in four public clinics and
initiating treatment in 2000-2001 showed higher satisfaction ratings of medical
care and patient-centered care with decreasing social class and if the couple
had achieved a pregnancy after treatment. A Danish qualitative interview study
showed that infertile couples preferred that their treatment took place in a sep-
arate clinic, with few employees, short waiting list and in a setting where the
plan of treatment was known by the doctor and the couple. The patients saw
the fertility treatments as a psychological and emotional strain and they did not
feel that these problems acknowledged by the staff. Further, that the patients
who disclosed their fertility problems to others were the patients who
expected most of the health professionals. These participants wanted detailed
technical assessments along with psychosocial and sexual advice.
We conducted a qualitative study among infertile men who initiated ART with
ICSI-treatment to explore their expectations and needs in order to optimize the
treatment and handling of this patient group. The results showed that men experi-
enced the process of going from diagnosis to treatment like ‘being in a maze’, which
affected their personal life. The men were ready to become fathers and felt impa-
tient because they needed medical assistance to achieve this life goal. The men felt
like they were placed on the sideline but they expressed a desire to have informa-
tion about the treatment plan from medical professionals and they wanted to dis-
cuss the psychological consequences of their low semen quality.
Fertility care and treatment needs to be considered as a couple issue and not
only as a woman issue. Fertility staff needs to focus on involving both the man
and the woman in the treatment, and more focus is needed on the men and
their psychosocial needs.
INVITED SESSION
SESSION 61: ARTHIQS SESSION: THE EVOLVING ROLES
OF COMPETENTAUTHORITIES, PROFESSIONAL
ORGANISATIONS ANDTHE EUROPEAN COMMISSION
IN ART
Wednesday 4 July 2018 Room 117 08:30–09:30
O-220 Introduction: The roots and ﬁndings of ARTHIQS
O-221 Competent authorities: From inspectorates to support
structures
N. Jones
Human Fertilisation and Embryology Authority HFEA, London, United Kingdom
Abstract text
The session will introduce examples of how competent authorities can under-
take their mission. Firstly, by carrying out efﬁcient and effective ‘core’ work in
setting standards and inspecting ART tissue establishments to maintain and
improve standards, doing so in an environment of mutual respect where dia-
logue about practise is engendered; and secondly building on this environment
so policy discussion takes place openly. As such, this may create an opportunity
to ensure that innovation is introduced carefully, together with practices that
would not ordinarily have been introduced – given the country’s context, cul-
ture and history. For example, consultation and discourse on, the treatment of
same sex couples; single woman; pre-implantation genetic diagnosis and other
ethically controversial areas. The two approaches are not mutually exclusive to
a Competent Authority.
O-222 The relationship between competent authorities and the
European Commission
W.N. Strang
Agence de la biomedecine, DPEGH, Saint Denis La Plaine Cedex, France
Abstract text
During and since the preparatory phases of the 2004 EU Tissue and Cells
Directive that created Competent Authorities in all European Union Member
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States, the European Union has worked closely with these Member States and
emerging Competent Authorities in order to align community legislation as
closely as possible to the needs of the different situations found in the different
Member States.
This cooperation occurs within the formal consultations of the advisory
groups, but also via more informal stakeholder consultations and in particular,
through Joint Actions, such as ARTHIQS, where the Commission and its execu-
tive Agency CHAFEA establish frameworks within which the Member State
Competent Authorities can work together, but also with Commission Services
and external organisations such as ESHRE, to share and develop expertise
amongst themselves.
For the European Commission, ARTHIQS was an important Action allowing
the increase of shared knowledge and know-how in the EU-28 Member States
in the ﬁelds of reproductive medicine and haematopoietic stem cell transplant-
ation. These ﬁelds are increasingly important for a large number of EU citizens
in need of treatment for infertility problems on the one hand, and for blood
cancers on the other.
Both these areas are characterised by rapid development. It is therefore of
utmost importance that the national Competent Authorities which oversee
these activities in the 28 EU Member States, keep pace with these develop-
ments and have a minimum and common understanding of how to ensure
safety and quality in these therapies. ARTHIQS built on our European model of
collaboration, bringing together the best expertise in these ﬁelds and making it
available to authorities in all Member States of the European Union.
In domains as complex as reproductive medicine it is essential to create con-
ditions of mutually beneﬁcial synergy whilst deﬁning and developing legislative
and good practice frameworks. As such, the relationships between the
Commission and the Competent Authorities and Professional Societies have
evolved into a quasi-partnership over the last decade. The relationships
between CAs, tissue establishments and professional societies are also devel-
oping and are, overall, positive and constructive. The missions of all these orga-
nisations are aligned with the need to protect donors and patients affected by
assisted reproduction.
O-223 The role of medical societies in promoting good practice
and the scope for reprovigilance
R.G. Farquharson
Liverpool Women’s Hospital, Department of Gynaecolog, Liverpool, United Kingdom
Abstract text
The role of specialist medical societies was historically conﬁned to research,
education and training for the beneﬁt of its membership. A more modern
approach has enlarged that sphere of interest to include core behaviour stan-
dards and patient safeguarding in the belief that collaboration is the gateway to
the future. The European Society of Human Reproduction and Embryology
(ESHRE) has become more involved with relevant competent authorities (CA),
patient organisations and European funded projects in helping to frame policy
making and act as a focus for direction of travel.
With ART speciﬁcally in mind, the journey from gamete to child via preg-
nancy and the newborn requires safety assurance and dialogue with regulatory
agencies to protect patients from harm and to optimise patient outcomes in
achieving a family. Reprovigilance is a term coined by ESHRE that involves moni-
toring of treatment activity and intervention proﬁling that mirrors the ethos of
our core values.
O-224 Closure: Future perspectives for competent authorities’
Cooperation
C. Plancha1,2,3
1CNPMA, Conselho Nacional de Procriação Medicamente Assistida, Lisboa, Portugal
2Instituto de Histologia e Biologia do Desenvolvimento, Faculdade de Medicina -
Universidade de Lisboa, 1649–028 Lisboa, Portugal
3CEMEARE, Centro Médico de Assistência à Reprodução, Lisboa, Portugal
Abstract text
The ARTHIQS Joint Action brought clarity to the diversity of practice and legis-
lation in the ﬁeld of Assisted Reproductive Technologies (ART) within and
between European Union (EU) Member States (MS). It highlighted the speciﬁc
aspects of ART and how ART dedicated Competent Authorities (CA) might
implement regulation in the ﬁeld.
The ARTHIQS Joint Action provided several opportunities of interaction
between different regulators regarding ART, and of these with the profes-
sionals, all recognized as beneﬁcial for the advancement of quality and safety
measures in this sector. The ART dedicated CA have much to learn from each
other, given their different experience in several MS, and need also to work
closely with the healthcare professionals, their representatives and the general
public, given the sensitive and exceptional nature of ART.
How to maintain a close cooperation between CA following the ARTHIQS
Joint Action, emerges as a major organizational challenge. However, this may also
become an opportunity for ART dedicated CA to fertile exchange of experience
and expertise, adoption of shared policies, and to facilitate harmonization of prac-
tices among the different MS, maintaining and enhancing national and European
registers, namely those regarding the safety of patients, donors and recipients.
We defend that a network of ART CA, could conveniently follow the
ARTHIQS Joint Action, in order to provide a forum to bring this experience
together improving quality and safety for the patients, donors and children
born of ART. This could involve proposing joint initiatives, working closely
with the European Commission to analyse amendments to policy and legisla-
tion and resolving difﬁculties encountered in the complex evolving ﬁeld of
ART. The tissues and cells CA could provide the basis for the creation of such
a network, which might be constituted as a speciﬁc working group, with the
support of DG Sante, with transparent declarations of conﬂicts of interest and
adhesion to the EU institutions guidelines. The ART CA network or working
group should call upon the experience of and cooperate with professional and
patient’s organisations, in particular ESHRE. Professional societies play a fun-
damental role in the complex and evolving ﬁeld of ART which continues to be
driven by rapid scientiﬁc progress.
SELECTEDORAL COMMUNICATIONS
SESSION 62: FROMOOCYTEMATURATION IN VIVO TO
BABY BIRTH
Wednesday 4 July 2018 Forum (Auditorium) 10:00–11:45
O-225 Immature oocyte incidence: Contributing factors and
effects on intracytoplasmic sperm injection cycles
B.F. Zanetti1, D.P.A.F. Braga2, R.C.S. Figueira3, A. Iaconelli Jr.4,
E. Borges Jr.4
1Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida,
Scientiﬁc Department, Sao Paulo, Brazil
2Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
3Fertility Medical Group, IVF Laboratory, Sao Paulo, Brazil
4Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
Study question: Which factors contribute to the incidence of immature
oocytes and how this impacts the outcomes of intracytoplasmic sperm injection
(ICSI) cycles?
Summary answer: The immature oocyte incidence is affected by pituitary
blockage regime,gonadotrophin type and dose, and negatively impacts on fertil-
ization rate, embryo quality, implantation and pregnancy outcomes.
What is known already: Oocyte maturation is deﬁned as the restart and
completion of the ﬁrst meiotic division with accompanying cytoplasmic matur-
ation, which includes storage of enzymes, mRNAs, organelles, and substrates
that are necessary for fertilization and early embryo development. Controlled
ovarian stimulation (COS) for IVF apply supra-physiologic gonadotropin doses
to induce coordinately multiple follicular growth and maturation, however up
to 30% of the retrieved oocytes are still immature. The ovarian asynchrony can
be indicative of less responsiveness of ovarian follicles to stimulation, and the
incidence of immature oocytes may reﬂect the competence of the mature
oocytes cohort for proper embryo development.
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Study design, size, duration: This retrospective cohort study included data
from 3,920 ICSI cycles performed from June/2010 to August/2016 of couples
undergoing ﬁrst or second ICSI cycle with fresh embryo transfer performed on
day ﬁve. Immature oocytes rates were deﬁned as the number of Germinal
Vesicle and Metasphase I oocytes by the number of retrieved oocytes in each
cycle. The FSH/oocyte rate was deﬁned as total dose of FSH administered by
the number of oocytes retrieved in each cycle.
Participants/materials, setting, methods: The study was performed in a
private university-afﬁliated IVF center. The inﬂuence of administered FSH doses,
FSH type, pituitary blockage protocol, and E2 peak on the day of hCG adminis-
tration on the incidence of immature oocytes were evaluated by generalized lin-
ear models. The effects of immature oocytes rates on normal and abnormal
fertilization, embryo quality on cleavage stage (days two and three), blastocyst
formation, implantation, pregnancy, and miscarriage rates were analyzed by
regression models.
Main results and the role of chance: The FSH/oocyte rate was positively
correlated with MI/oocyte (β=-0.043, p = 0.014) and GV/oocyte (β=-0.107,
p < 0.001) rates. A higher MI/oocyte rate was observed in patients who
received GnRH agonist and recombinant FSH in relation to GnRH antagonist
and recombinant FSH (13.34 ± 0.09 vs. 10.73 ± 0.28% p = 0.007). Patients
who received recombinant FSH had about 30% increase in GV/oocyte rate in
comparison to urinary FSH, both with GnRH agonist (11.29 ± 0.90 vs. 4.18 ±
4.52 p = 0.048), and antagonist (11.47 ± 0.28 vs. 8.84 ± 1.41 p = 0.021) pro-
tocols. The fertilization rate was negatively correlated to MI/oocyte and GV/
oocyte rates (β=-0.096, p < 0.001; β=-0.059, p < 0.001), while abnormal fer-
tilization rate (1PN or 3PN) was positively correlated with GV/oocyte rate (β
= 0.155, p = 0.049). The incidence of immature oocytes affected negatively the
high-quality embryos rate at day two (MI/oocyte β=-0.102, p < 0.001; GV/
oocyte β=-0.066, p < 0.001), and day three (MI/oocyte β=-0.090, p < 0.001;
GV/oocyte β=-0.087, p < 0.001), as well as the blastocyst rate (MI/oocyte
β=-0.066, p < 0.001.; GV/oocyte β=-0.053, p < 0.001). The negative effect of
the incidence of MI and GV was also noted in the implantation (MI/oocyte
β=-0.074, p < 0.001; GV/oocyte β=-0.042, p = 0.033) and pregnancy
(MI/oocyte B=-0.011 p = 0.002; GV/oocyte B=-0.066, p = 0.013) rates.
Limitations, reasons for caution: The retrospective nature of this analysis
limits the relevance of the study.
Wider implications of the ﬁndings: During COS, pharmacological gonado-
trophins doses creates a supra-physiological environment, which allows the
maturation of oocytes, which under natural conditions, would regress. Our evi-
dence suggests that oocytes derived from a cohort with high incidence of mat-
uration fail may have an inefﬁcient biological machinery, which would have
detrimental effects on clinical outcomes.
Trial registration number:None.
O-226 The inﬂuence of denudation and injection on ICSI outcome
- does timing matter?
M. Carvalho, S. Mota, F. Leal, I. Pereira, C. Rodrigues, A. Aguiar,
S. Sousa, J. Nunes, C. Calhaz-Jorge
Reproductive Medicine Unit, Department of Obstetrics Gynaecology and
Reproductive Medicine - Hospital de Santa Maria, Lisbon, Portugal
Study question:Does the time interval between oocyte retrieval and denuda-
tion or injection have an effect on fertilization and clinical pregnancy rates in
ICSI cycles?
Summary answer:Our ﬁndings suggest that ICSI outcome is improved when
oocytes are cultured for at least 3 hours before denudation and injected 5-6
hours after retrieval.
What is known already: Oocyte maturation is a complex and dynamic pro-
cess involving structural and biochemical modiﬁcations in the cell necessary to
support fertilization and early embryo development. While meiotic compe-
tence is easily identiﬁable by the presence of an extruded ﬁrst polar body, cyto-
plasmic maturation cannot be assessed microscopically. Culturing oocytes with
their surrounding cumulus cells prior to fertilization can enhance the completion
of in vitro cytoplasmic maturation; however, prolonged culture may also induce
cell degeneration. The optimal culture intervals prior to oocyte denudation
and/or injection have not yet been established and may prove relevant for the
improvement of ICSI outcome.
Study design, size, duration: Single-centre retrospective analysis of 1583
ICSI cycles performed between 2002 and 2017 in women <40 years old. All
women performed controlled ovarian hyperstimulation using a long GnRH-
agonist protocol and oocyte retrieval was undertaken 34-36 hours after ﬁnal
ovulation triggering. Time intervals between oocyte retrieval, denudation and
injection of the oocytes were exclusively dependent on laboratory workload.
The effects of these timings on fertilization and clinical pregnancy rates were
compared.
Participants/materials, setting, methods: The effect of oocyte culture
duration prior to injection of the oocytes was considered in two separate ana-
lysis: (i) time interval between oocyte retrieval and denudation (3.2 h±1.0) and
(ii) time interval between oocyte retrieval and injection (5.4 h±0.8). Only cycles
with at least one injected oocyte were included. The effect of the before men-
tioned time intervals on fertilization and clinical pregnancy rates were compared
using multivariable regression adjusted for potential confounding variables.
Main results and the role of chance: 10359 metaphase II oocytes were
injected and checked for the presence of pronuclei. The fertilization rate was
found to be independent of the time interval to denudation and/or injection.
Oocyte degeneration rate after ICSI was also comparable considering different
time intervals to denudation and injection but the abnormal fertilization rate
was signiﬁcantly increased for longer incubation periods before injection, even
after accounting for the time elapsed until denudation (<5 h, 6.1%; 5-6 h, 7.1%;
36, 9.0%, p = 0.01). Extending oocyte culture before denudation signiﬁcantly
improved clinical pregnancy rates, particularly if the time interval comprised of
at least 3 hours (<2 h, 34.5%; 2-3 h, 33.7%; 3-4 h, 41.6%; 34 h; 46.8%,
p < 0.001). Clinical pregnancy was also dependent on time to injection and
optimal results were obtained when ICSI was performed 5-6 hours after
retrieval (<5 h, 35.3%; 5-6 h, 42.3%; 36 h, 39.3%, p = 0.043).
Limitations, reasons for caution: This is a retrospective study, with its
inherent limitations, and restricted to long agonist cycles. Furthermore, the
effect of very short or very long periods of culture before denudation and/or
injection was not evaluated and should not be extrapolated from these results.
Wider implications of the ﬁndings: Our ﬁndings support the importance
of extending oocyte culture with their surrounding cumulus cells, but more
importantly provide new evidence of a correlation between denudation and
injection intervals. Establishing an optimal time window to perform denudation
and ICSI and adjusting laboratory practice may prove beneﬁcial and improve
clinical pregnancy rates.
Trial registration number:Not applicable.
O-227 The impact of intracytoplasmic sperm injection (ICSI) on
embryo development as assessed by Time-Lapse (TL) microscopy
on 4126 embryos
C. Sacha1, G. Christou2, I. Dimitriadis1, M. Brock2, S. McLellan2,
P. Bhowmick2, C. Bormann1, I. Souter1
1Massachusetts General Hospital, Dept of Obstetrics- Gynecology- and Reproductive
Endocrinology and Infertility, Boston, U.S.A.
2Massachusetts General Hospital Fertility Center, Dept of Obstetrics- Gynecology-
and Reproductive Endocrinology and Infertility, Boston, U.S.A.
Study question: Does the utilization of ICSI versus conventional insemination
(CONV) impact either early- or late- morphokinetic parameters in embryos
cultured to blastocyst in a TL-monitored incubator?
Summary answer: Time periods from either pronuclei fading (tPNf) or 5-cell
stage to early blastulation were signiﬁcantly prolonged when usable ICSI
embryos were compared to CONV ones.
What is known already:While some studies suggest that correcting for time
of fertilization by normalizing all times to tPNf may eliminate differences in early
cleavage times between embryos undergoing ICSI versus CONV, other data
suggests a potential effect of fertilization method on early cleavage times. At the
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same time, the potential impact of fertilization method on late-morphokinetic
parameters remains unclear.
Study design, size, duration: Retrospective review of data from 4126
embryos (derived from 364 ICSI and 237 CONV cycles) cultured to the blasto-
cyst stage in TL-monitored incubators. 536 women undergoing ART between
9/2013 and 9/2016 at a large academic fertility center were included in the
analysis.
Participants/materials, setting, methods: Groups were compared in
regard to time periods: i) tPNf to 1st-cytokinesis (P1), ii) 2- to 3-cells (P2), iii) 3-
to 4-cells (P3), iv) 4- to 5-cells (P4), v) 5- to 8-cells, and vi) tPNf and 5-cells to
early blastulation (PSB and P5SB, respectively). Usable (selected either for trans-
fer or cryopreservation) and discarded embryos were sub-analyzed separately.
Generalized ﬁxed and random effects models, Mann-Whitney U-, and χ2-
tests were used as appropriate. P < 0.05 was statistically signiﬁcant.
Main results and the role of chance: Median (interquartile range, IQR)
age, BMI, day-3 FSH and AMH were 34.8(32.3, 37.8) vs. 36.2(33.2-39.4) years,
p < 0.01; 23.1(21.0-26.7) vs. 23.4 (21.6-26.6) kg/m2, p = 0.46; 6.7(5.7-8.0) vs.
7.0(5.9-8.4) IU/L, p = 0.16; and 3.0(1.5-5.1) vs. 2.1(1.1-4.0) ng/ml, p < 0.01;
for ICSI vs. CONV, respectively. Male factor infertility (MFI) was more preva-
lent among ICSI cycles (40.7% vs. 5.0%, p < 0.01 for ICSI vs. CONV,
respectively).
When all embryos were included in the analysis and models were adjusted
for age, BMI, day-3 FSH, AMH, and MFI, P5SB and PSB were found to be signiﬁ-
cantly prolonged in ICSI cycles by 2.4(95%CI: 0.6-4.2) hours, p = 0.01; and 1.8
(95%CI: 0.2-3.3) hours, p = 0.02; respectively. When usable were analyzed
separately from discarded embryos, the impact of ICSI persisted in usable
embryos only [usable: P5SB and PSB: 3.1(95%CI: 1.4-4.7) hours, p < 0.01; and
2.3(0.8-3.7), p < 0.01; respectively; discarded: P5SB and PSB 1.6(-0.9-4.1),
p = 0.20; and 1.2(-0.8-3.3) hours, p = 0.23; respectively].
No impact of ICSI was noted on all other morphokinetic parameters, when
either all embryos were included in the analysis, or usable were analyzed separ-
ately from discarded embryos.
Limitations, reasons for caution: This study is limited by its retrospective
design. Furthermore, all aspects of sperm quality may not have been considered
by adjusting for male factor infertility diagnosis.
Wider implications of the ﬁndings: ICSI did not impact signiﬁcantly early
cleavage times. However, time to early blastulation was prolonged in ICSI
embryos with the impact becoming more prominent from the 5-cell stage and
onward, a ﬁnding suggestive of a possible an interaction between fertilization
method and late paternal genome activation.
Trial registration number:Not applicable.
O-228 Differences in time-lapse practice: is a consensus on
standards needed?
C. Hickman
Imperial College London, IRDB- Faculty of Medicine, Stoke Mandeville, United
Kingdom
Study question: Do clinics differ in how they implement time-lapse technol-
ogy into their processes?
Summary answer: How Time-Lapse is used varies between IVF clinics, par-
ticularly with regards to patient and cross-department involvement, communi-
cation, embryo selection and how process-efﬁciencies are optimised.
What is known already: Time-Lapse incubation involves culturing the
embryo in an incubator that takes regular pictures of the embryos. This has
allowed for embryos to be cultured uninterrupted. With increased observation,
beneﬁts from the technology started to change how embryology was practised,
improving customer service whilst increasing process efﬁciency. However, not
all clinics have experienced these beneﬁts. To our knowledge this is the ﬁrst
study to assess how time-lapse technology is used in different clinics.
Study design, size, duration: In December 2017, 38 experienced time-
lapse embryologists from the UK responded to an anonymous questionnaire
with 20 questions assessing how far they adapted the clinic wide processes to
the time-lapse technology since implementation.
Participants/materials, setting, methods: All participants were
Embryoscope users, 48% with 3+ years experience. The questionnaire was
presented using Mentimeter in a live presentation and anonymity of respon-
dents was maintained.
Main results and the role of chance: 71% did not train non-laboratory
departments in how the Time-Lapse technology affected their processes. 87%
had time-lapse related communication processes between the embryologist
and the patient, a lower proportion involving other departments (23%-51%).
73% provided the patient access to videos of embryos transferred at the time
of transfer with a USB. 52% thought patients would welcome live access to vid-
eos whilst in the incubator, whilst 45% afﬁrmed that irrespective of patient’s
wishes, their clinics would be against giving patients live access. 65% did not
provide patients with written reports. 42% only provided access to time-lapse
incubation to patients willing to pay. 76% did not adapt embryology process
timings to the ﬂexibility provided by time-lapse. 1 clinic adapted the hcg time.
Embryo selection differed: 58% did not review the video. Reliance on algorithm
increased with the number of years experience. Clinics prioritised morphology
on day 5, followed by unusual embryo cleavage, followed by KIDScore. 46% of
the clinics reviewed embryo selection consistency. 19% reviewed efﬁcacy. 52%
annotate daily, followed by morning of ET (32%), and 4 clinics did not annotate
at all. Most clinics reported not having the time required to ensure the annota-
tions are complete, accurate and standardised (56%).
Limitations, reasons for caution: Participants all came from the same
country, and the answers may not be reﬂective of practice in other countries.
Participants were all Embryoscope users, and practice may further differ with
other Time-Lapse systems.
Wider implications of the ﬁndings: This study documents the diversity in
the practice of the time-lapse technology between different IVF clinics, suggest-
ing that there is a need for a formal consensus on standards of time-lapse prac-
tice to ensure patients and clinics beneﬁt fully from time-lapse technology,
irrespective of which clinic they are treated in.
Trial registration number:NA.
O-229 Deconstructing the myth of poor prognosis for fast-cleaving
embryos on Day 3. Is it time to change the consensus?
M.C. Pons Gatell, B. Carrasco, M. Parriego, B. Coroleu, P.N. Barri,
M. Boada, A. Veiga
Women’s Health Dexeus, Reproductive Medicine Service, Barcelona, Spain
Study question: Do fast-cleaving embryos (>8 cells at 68 ± 1hpi) have a low-
er potential to become euploid blastocysts and implant when compared to 8-
cell embryos?
Summary answer: The chance of fast-cleaving embryos on Day 3 (D3) to
give rise to euploid blastocysts and implant is comparable to the one of 8-cell
embryos.
What is known already: The cell number is one of the most predictive mor-
phological parameters for blastocyst formation, implantation and live-birth
rates. The ESHRE-Alpha consensus (2011) established that embryos that cleave
slower or faster than the expected rate (8 cells at 68 ± 1hpi) have a reduced
implantation potential. Likewise, according to the ASEBIR criteria (2015) fast-
cleaving embryos on D3 are included in B or C categories with a lower implant-
ation potential compared to 8-cell embryos classiﬁed as A. Regarding the ploidy
status, higher percentage of chromosomal abnormalities were found in fast-
cleaving embryos compared to 8-cell embryos.
Study design, size, duration: A total of 4028 embryos from 513 PGT-A
cycles performed between July 2014 and June 2017 were included in this obser-
vational retrospective study. Embryos were classiﬁed in groups based on the
number of cells on D3 (from 2-cell to >12-cell and compacted).
Participants/materials, setting, methods: Embryos were cultured in
single-step medium (Global®, LifeGlobal®; GTL™, Vitrolife) and incubated in
Time-lapse incubators (Embryoscope®; Geri®). Embryos were biopsied at the
blastocyst stage followed by vitriﬁcation (Cryotop®, Kitazato). The trophecto-
derm samples were analysed by a-CGH. A generalized linear mixed model
adjusted for confounding factors was performed to assess the chance to
become an euploid blastocyst in each and every group compared to the chance
of 8-cell embryos.
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Main results and the role of chance: In this study, 64.4% of 8-cell embryos
on D3 (875/1358) and 59.3% of fast-cleaving embryos on D3 (863/1454)
reached the blastocyst stage and then were biopsied. After the genetic test,
22.7% of 8-cell embryos (308/1358) and 20.6% of fast-cleaving embryos (299/
1454) were diagnosed as euploid. The statistical analysis showed that the prob-
ability of fast-cleaving D3 embryos to give rise to an euploid blastocyst is not sig-
niﬁcantly different from the chance of 8-cell embryos. The results are valid for
every analyzed fast-cleaving D3 group (from 9-cell group to compacted group)
as demonstrated by the odd ratios (OR): 9-cell group OR (95%CI): 0.76 (0.57-
1.01); 10-cell group OR (95%CI): 0.72 (0.51-1.01); 11-cell group OR (95%CI):
0.95 (0.60-1.51); 12-cell group OR (95%CI): 1.11 (0.75-1.63); >12-cell group
OR (95%CI): 1.35 (0.85-2.15) and compacted group OR (95%CI): 1.19 (0.81-
1.76). Moreover, euploid blastocysts derived from fast-cleaving D3 embryos
and from 8-cell D3 embryos exhibit similar implantation potential (67% vs 55%,
p = 0.25).
Limitations, reasons for caution: This is a retrospective study. The ﬁndings
which originate from a speciﬁc culture environment might not be applicable to
all in vitro culture conditions.
Wider implications of the ﬁndings: Recommendations published by scien-
tiﬁc societies (ASEBIR, ESHRE-Alpha) regarding the poor prognosis of fast-
cleaving embryos on D3 must be reconsidered.
Trial registration number:Not Applicable.
O-230 Pregnancy and neonatal outcomes of embryos achieving
blastulation on day 7: are they of clinical value?
T. Du1,2, Y.Wang1, Y. Fan1, S. Zhang3, B. Mol4, Q. Lyu1, Y. Kuang1
1Shanghai 9th People’s Hospital- Shanghai Jiao Tong University School of Medicine,
Department of Assisted Reproduction, Shanghai, China
2Shanghai First Maternity and Infant Hospital- Tongji University School of Medicine,
Department of Obstetrics and Gynaecology, Shanghai, China
3University of Shanghai for Science and Technology, Shanghai-Hamburg College,
Shanghai, China
4Monash University, Department of Obstetrics and Gynaecology,
Clayton, Australia
Study question: Are embryos achieving blastulation on day 7 of clinical value?
Summary answer: Day 7 blastocysts resulted in a 25.2% live birth rate and
had similar risk of adverse neonatal outcomes with day 5 and day 6 blastocysts.
What is known already: Advantages of blastocyst transfer over cleavage
embryo transfer have led to the shift towards the former in in vitro fertilization
(IVF) practice. However, published data about the pregnancy outcomes of
embryos with a delayed blastulation on day 7 are scarce and controversial.
Moreover, there are few data available on the neonatal outcomes of day 7
embryos. As a result, the clinical value of day 7 embryos cannot be appropri-
ately evaluated.
Study design, size, duration: This was a retrospective cohort study includ-
ing two parts, ﬁrst of which involved 2,908 women undergoing 2,908 frozen-
thawed embryo transfer (FET) cycles of IVF/intracytoplasmic sperm injection
(922, 1,752 and 234 women in day-5, day-6 and day-7 vitriﬁed embryo transfer
groups, respectively) from January 2006 to May 2015. In study part II, 1,518
liveborn infants derived from those women were analyzed.
Participants/materials, setting, methods: Women undergoing day-5,
day-6 and day-7 vitriﬁed embryo transfers were matched into three comparing
cohorts (day 5 vs. day 6, day 5 vs. day 7, and day 6 vs. day 7) by baseline charac-
teristics using propensity score matching. Neonatal outcomes were compared
among liveborn infants derived from day-5, day-6 and day-7 vitriﬁed embryo
transfers. Logistic regressions were performed to investigate risk factors for
implantation failure (among single blastocyst transfers) and congenital malfor-
mations (among liveborn infants).
Main results and the role of chance: The included women were matched
into 921 pairs, 227 triplets and 227 tetrads of cycles in day 5 vs. day 6 (1:1), day
5 vs. day 7 (2:1), and day 6 vs. day 7 (3:1) cohorts, respectively. In study part I,
day-7 vitriﬁed embryo transfers had clinically important but signiﬁcantly lower
rates of intrauterine implantation, clinical pregnancy and live birth than both
day-5 (23.9% vs. 49.9%, p<.001, 31.7% vs. 58.1%, p<.001, and 25.1% vs.
46.5%, p<.001, respectively) and day-6 (24.7% vs. 42.3%, p<.001, 33.0% vs.
53.2%, p<.001, and 25.6% vs. 41.4%, p<.001, respectively) vitriﬁed embryo
transfers. But no statistically signiﬁcant difference was observed among the rates
of biochemical pregnancy, ectopic pregnancy and miscarriage between the
matched cohorts. Female age, year of treatment, developmental stage, mor-
phological grade, and vitriﬁcation day of blastocysts transferred were signiﬁcant
factors affecting implantation rate. In study part II, no statistically signiﬁcant dif-
ference was observed in the rates of low birth weight, congenital malformations
and early neonatal death among the 616, 932 and 68 newborns in day-5, day-6
and day-7 vitriﬁed embryo transfer groups, respectively. Multiples were 5.70
times more likely to experience congenital malformations compared with sin-
gletons (OR: 5.70, 95% CI: 1.42-22.92; P=.014).
Limitations, reasons for caution: This was a single center retrospective
study, and most of the neonatal data were extracted from parent question-
naires. Besides, the amount of day-7 vitriﬁed embryo transfer cycles was still
limited.
Wider implications of the ﬁndings: Vitriﬁcation day of embryos trans-
ferred is an independent risk factor for implantation failure. The compromised
implantation potential in growth-retarded blastocysts might be due to spindle
abnormities. The negative effect of potential defects underlying delayed blastu-
lation may be mostly realized during implantation, and affects less afterwards.
Trial registration number:Not applicable.
O-231 The impact of extremely long term human embryo
cryopreservation: embryonic, obstetric and neonatal outcomes
Y. Yuan, J. Ma, Y. Xu, C. Zhou, G. Zhuang
The ﬁrst afﬁliated hospital of SUN Yat-sen University, The reproductive research
center, Guangzhou, China
Study question: Is extremely long term slow freezing of human embryos do
harm to their embryonic, obstetric and neonatal outcomes?
Summary answer: The embryonic, obstetric and neonatal outcomes follow-
ing long term cryopreserved embryo transfer were encouraging, which met the
common anticipation of embryo freezing.
What is known already: Due to the mature techniques of embryo cryo-
preservation and thawing, the cumulative pregnancy outcomes have greatly
improved.During the ultra-low temperature storage state, the embryos are also
affected by the cosmic background radiation and vibration. The theoretical
cryopreservation span is inﬁnite since the mimic experiment with an equal dose
of 2000 years cosmic radiation on mice embryos gave us a positive result.
While considering future utilization, there is still lacking of solid clinical evidence
to draw conclusions about human embryos.The longest existing storage span of
successful live birth after frozen embryos transfer is 12 years.
Study design, size, duration: This is a retrospective observational study of
128 embryos of 20 patients who seek to have a second child with the utilization
of their long-term cryopreserved embryos (more than 12 years) from March
2012 to April 2017.
Participants/materials, setting, methods: Participants: Patients have
received IVF/ICSI treatments between February 1999 and July 2004 and had
surplus embryos cryopreserved for at least 12 years in our center.
Setting:University teaching hospital.
Methods:We have closely mesured the length of cryopreservation, survival
rate of cryopreserved embryos, blastocyst formation rate, implantation rate,
clinical pregnancy rate, abnormal pregnancy rate, live birth rate, perinatal com-
plications and neonatal development.
Main results and the role of chance: A total of 128 embryos of 20 patients
were observed. The embryo storage duration was 12.00-17.08 yrs, with a
mean of 13.90 ± 1.73 yrs. Among them, 115 embryos were thawed to transfer,
with a survival rate of 73.9%. Sixty embryos were further cultured which
resulted in 20 blastocysts with a blastocyst formation rate of 33.3%. There
were 34 embryos transferred in a total of 23 cycles, which resulted in 1 bio-
chemical pregnancy, 1 ﬁrst trimester miscarriage, 2 ectopic pregnancies, 3 sin-
gletons and 1 case of twins, with a clinical pregnancy rate of 30.4% and live birth
rate of 21.7%. Two out of 4 patients who had live birth developed gestational
diabete mellitus. One out of 5 live births was pre-term delivery. The physical
and psychological development of all live births matched the standard curve in
the ﬁrst 6 months.
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Table I
Cleavage
stage
Blastocyst
stage
Total
Pregnancy Rate 25%(3/12) 45.5%(5/11) 34.8%(8/23)
Implantation Rate 19.0%(4/21) 30.8%(4/13) 23.5%(8/34)
Clinical Pregnancy
Rate
25.0%(3/12) 36.4%(4/11) 30.4%(7/23)
Abnormal Pregnancy
Rate
66.7%(2/3) 25%(1/4) 42.9%(3/7)
Live Birth Rate 16.7%(2/12) 27.3%(3/11) 21.7%(5/23)
Limitations, reasons for caution: Due to the limited sample size, we could
only present the descriptive data. No further statistical analysis was used to
detect the potential correlation factors concerning the clinical outcomes.
Wider implications of the ﬁndings: The reassuring results obtained in the
study show that embryos after extremely long term cryopreservation could be
of great value.
Trial registration number: not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 63: MALE LIFESTYLE AND REPRODUCTIVE
HEALTH
Wednesday 4 July 2018 Room 211 + 212 10:00–11:45
O-232 Has sperm quality been declining for the past 20 years?
C. Huang1, L. Lei2, D. Liu2, X. Yuan2, L. Fan1,W. Zhu2
1Reproductive & Genetic Hospital of CITIC-Xiangya, spermbank, Changsha- Hunan,
China
2Central South University, Institute of Reproductive and Stem Cell Engineering- Basic
Medicine College, Changsha, China
Study question: To evaluate studies of temporal trends in sperm quality in
China.
Summary answer: Sperm concentrations, motility, and morphologies
demonstrated substantial changes in China between 1996 and 2017, and
Geographical differences exist in various regions of China.
What is known already: In recent years, numerous reports have suggested
that semen quality in normal men has been declining. Nevertheless, all of these
reviews showed signiﬁcant changes in sperm quality only in Western countries.
There have been few studies from non-Western countries, and those that do
demonstrate no trends.
Study design, size, duration: We extracted summary statistics on semen
volume, sperm concentration, total sperm count, normal morphology, progres-
sive motile sperm (A + B) and motile sperm (A + B + C), inclusion and exclu-
sion criteria, number of samples per man, and information regarding data
completeness.All data could be derived from 186 studies. Ten of these were
English language studies, and the other 176 studies were not in English.
Participants/materials, setting, methods: The study was excluded if
study participants were selected based on infertile men, genital abnormalities,
or other diseases. We also excluded studies limited to men with exposures that
may affect fertility, such as occupational exposure, post-intervention, smoking,
drinking, and other unhealthy lifestyles. We applied the Cochran–Armitage
trend test for trend to evaluate change over time, and linear regression was per-
formed to evaluate change over time of semen parameters.
Main results and the role of chance: The sperm concentration declined by
1.0% per year, and overall by 21.0% between 1996 and 2017 (P < 0.001). A
similar trend was seen for progressive motile and motile sperm (slope per year
= -0.56% and -0.57%; respectively, P < 0.05), Sperm with normal morphology
declined by 2.4% per year (P < 0.001). Although total sperm count declined by
3.37 million per year, there was no statistical signiﬁcance. Semen volume did
not change signiﬁcantly over the study period (slope per year = 0.005ml; P =
0.69). The Sperm concentrations and progressive motility were greater in the
area of Eastern and Central China than in Northeast China.
Limitations, reasons for caution: First, our ﬁndings may not be based on a
community population, since the study group did not including infertile men and
had a limited age range.Second, our study population lives only in some capital
cities, and does not represent all cities and geographical areas of China.
Wider implications of the ﬁndings: Whether sperm quality is actually
declining in some regions and across time periods remains unknown. The
debate regarding the question continues, but these ﬁndings represent a serious
reproductive health warning. The concerns raised regarding the reproductive
health of men remain urgent.
Trial registration number:None.
O-233 Male reproductive health is a key determinant of unhealthy
aging: results from a longitudinal cohort study
E. Ventimiglia1, P. Capogrosso1,W. Cazzaniga1, L. Boeri1,
F. Pederzoli1, M. Alfano1, N. Frego1, C. Abbate1, F. Chierigo1,
F. Dehò1, F. Gaboardi1, V. Mirone2, E. Montanari3, F. Montorsi1,
A. Salonia1
1Università Vita-Salute San Raffaele, Urology, Milano, Italy
2University of Naples Federico II, Urolgy, Naples, Italy
3University of Milan- Milan- Italy, Urolgy, Milan, Italy
Study question: To inquire reproductive factors associated with health status
decrease in infertile men.
Summary answer: 29% of infertile men had a decrease of the overall health
status. Azoospermic men were those at highest risk of health status decrease.
What is known already: A severe male infertility factor has been associated
with both lower health status and increased mortality in men from infertile cou-
ples. Little is known about the evolution of the health status in infertile men
over time.
Study design, size, duration: Cohort study enrolling 645 infertile men evalu-
ated at baseline between 2003 and 2010. Patients were followed-up yearly
recording any worsening in their health status until 2017.
Participants/materials, setting, methods: Infertility was deﬁned according
to the WHO deﬁnition. Health-signiﬁcant comorbidities were scored with the
Charlson Comorbidity Index (CCI). Cox regression models were used to esti-
mate hazard ratios (HR) and 95% conﬁdence intervals (CI) of CCI score
increase including as covariates age, BMI, CCI, azoospermia, FSH, and duration
of infertility.
Main results and the role of chance: Mean patient age was 37 years (inter-
quartile range, IQR 34-40), median BMI 25 (IQR 23-27), 30 (5%) men had a
CCI≥1, and median duration of infertility was 24 months (IQR 13-30). Median
follow-up was 9 years (IQR 7-11). 186 men (29%) saw an increase of their CCI
score of at least 1 point. The most frequent reason for CCI upgrade was can-
cer, i.e. 43 solid tumors and 5 lymphomas. Compared to patients without a
CCI increase, patients with a CCI increase had a higher proportion of CCI≥1
(9% vs. 3%, p = 0.001) and a higher proportion of azoospermia (32% vs 20%, p
= 0.001) at baseline. Azoospermic men had an increased risk of developing
comorbidities at multivariable analysis (HR 1.88, 95% CI 1.31–2.69; p = 0.001);
along with a basal CCI≥1 (HR 2.61, 95% CI 1.57–4.36; p < 0.001), and with a
longer duration of infertility (HR 1.02, 95% CI 1.01-1.03; p = 0.008) azoosper-
mic men were at higher risk of developing comorbidities during follow-up at
multivariate analysis, after accounting for the aforementioned confounders.
Limitations, reasons for caution: The CCI does not include some condi-
tions (e.g. hypertension) that are important contemporary comorbid
conditions.
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Wider implications of the ﬁndings: Infertility is a proxy of decreased health
status, therefore infertile men must be strictly follow-up to prevent and early
detect the onset of potentially disabling comorbidities.
Trial registration number: not applicable.
O-234 Spermatozoa from patients with seminal alterations and
advanced age show lower reproductive competence in egg donation
cycles
V. Casciani, E. Iovine, V. Zazzaro, A. Pristerà, A. Colasante,
F. Scarselli, M.G. Minasi, A. Ruberti, E. Cursio, S. Muzzì,
M.T. Varricchio, A. Caragia, C. Mencacci, A. Greco, E. Greco
European Hospital, Centre for Reproductive Medicine, Rome, Italy
Study question: Do spermatozoa from men with normal or abnormal semen
and different age perform differently in terms of fertilization and embryo devel-
opment in egg donation cycles?
Summary answer: In presence of abnormal semen, older men spermatozoa
have lower fertilization and embryo development potential. In presence of nor-
mal semen, male age has no effect.
What is known already: The delay in parenthood age observed in the devel-
oped world has brought increasing attention to age-related gametes quality,
embryo development and reproductive outcomes. Whereas the effect of
maternal age has been extensively studied, less is known about the conse-
quences of advanced paternal age. Moreover, no paternal age cut-off value as
been widely accepted. The inverse association between male age and semen
quality has been reported in literature. However little was said about the com-
bined effect of semen quality and paternal age. Oocyte donation cycles are an
ideal model to study the paternal effect on reproductive outcomes.
Study design, size, duration:We retrospectively analyzed 276 egg donation
cycles (OD) performed with 1713 vitriﬁed/warmed oocytes and fresh ejacu-
lated semen between October 2014 and December 2017. Our population was
divided into 4 groups according to sperm quality (WHO, 2010) and male part-
ner’s age. Data are shown as avarage±SD and were analyzed with Chi square
test or Student-t test.
Participants/materials, setting, methods: Groups-1 and -2 included men
with normal semen and respectively <45 yeras old (N = 53 OD; 383 oocytes;
male age 40.5 ± 3.03; donor age 25.7 ± 3.41) or ≥45 yo (N = 50 OD; 363
oocytes; male age 48.9 ± 3.31; donor age 25.8 ± 3.68). Groups-3 and -4
included men with abnormal semen and <45y.o. (N = 84 OD; 580 oocytes;
male age 41.0 ± 2.85; donor age 26.4 ± 3.60) or ≥45y.o (N = 89 OD; 616
oocytes; male age 50.4 ± 5.25; donor age 25.0 ± 3.40). Semen samples distri-
bution was similar in groups-3 and -4.
Main results and the role of chance: The number of surviving and injected
MII, fertilized oocytes and total developed embryos either transferred or frozen
(EC + ET) were, respectively, in group-1, 343, 247 and 202; in group-2, 319,
233 and 198; in group-3, 505, 359 and 307 and in group-4, 546, 359 and 286.
Between groups-1 and -2, no difference was observed in the fertilization rate
(FR 72.0% and 73.0% respectively) and in the rate of available embryos
obtained (EC + ET) calculated either per injected oocytes (58.9% and 62.1%
respectively in groups-1 and -2) or per fertilized oocytes (81.8% and 85.0%).
Between groups-3 and -4, there was a signiﬁcant difference in fertilization rate
(FR 71.1% and 65.8%, respectively, p < 0.05) and in the rate of embryos
obtained (EC + ET) calculated per number of injected oocytes (60.8% and
52.4%, Chi square p < 0.005) or per number of fertilized oocytes (85.5% and
79.7%, Chi square p < 0.05). After fresh embryo transfer, clinical pregnancy
rates (CPR) in groups-3 and -4, were 58.8% (47/80) and 38.8% (31/80) (p <
0.05) and implantation rates (IR) were 38.4% (58/151) and 23.7%(34/144) (p
< 0.005). In groups-1 and -2, CPR and IR were not signiﬁcantly different: CPR
were 49.0% (25/51) and 45.8% (22/48); IR were 41.3% (38/92) and 29.7%
(25/84), respectively.
Limitations, reasons for caution: Since partners’ ages are correlated, in
order to compare clinical outcomes between groups and ascribe the outcomes
decrease to the father, it should be assumed that maternal ageing has no effect.
Additionally, the spermiogram used to categorizes semen is not a clear indica-
tor of male infertility.
Wider implications of the ﬁndings: Spermatozoa from ejaculated sperm
with abnormal parameters (concentration, motility and morphology) show low-
er fertilization potential and embryo development when retrieved from older
patients as compared to younger patients or patients with normal semen. More
oocytes could be necessary in OD cycles with advanced paternal age and poor
sperm quality.
Trial registration number:Not applicable.
O-235 Paternal lifestyle factors and its relationship to semen
quality and in vitro reproductive outcomes
A.S. Setti1, D.P.A.F. Braga2, R.C.S. Figueira3, R.R. Provenza4,
A. Iaconelli Jr.5, E. Borges Jr.5
1Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida,
Scientiﬁc Department, Sao Paulo, Brazil
2Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
3Fertility Medical Group, IVF Laboratory, Sao Paulo, Brazil
4Fertility Medical Group, Andrology Laboratory, Sao Paulo, Brazil
5Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
Study question: Do paternal lifestyle factors inﬂuence semen parameters and
the outcomes of intracytoplasmic sperm injection (ICSI) cycles?
Summary answer: Cigarette smoking and alcohol consumption appear to
reduce semen quality, fertilization and blastocyst formation rates.
What is known already: Seminal parameters have been declining over time
worldwide. This decline is likely multifactorial, and a variety of lifestyle factors
has been proposed to inﬂuence spermatogenesis and reproductive function,
either positively or negatively. It is now known that fertilisation and preimplan-
tation embryo development are inﬂuenced by sperm-derived factors that may
impact ICSI outcomes. Lifestyle factors can be adapted to enhance well-being
and are ultimately under one’s own control, therefore, adjusting for their inﬂu-
ence may yield valuable information for counselling couples submitted to ICSI.
Study design, size, duration: This prospective cohort study included 965
male patients undergoing conventional semen analysis for infertility investigation
from October/2015 to December/2016. The inﬂuences of alcohol consump-
tion, cigarette smoking, environmental and occupation exposure, medications
and physical activity on semen quality were evaluated by regression analyses.
For the investigation of the inﬂuence of lifestyle factors on ICSI outcomes, only
couples with isolated male infertility in which female partner was ≤ 36 y-old
were included in the analysis.
Participants/materials, setting, methods: The study was performed in a
private university-afﬁliated in vitro fertilization center. Prior to semen sample
collection, participants were asked to complete a detailed non-validated ques-
tionnaire containing daily cigarette smoking amount; weekly frequency of alco-
hol consumption; weekly exercise frequency over the past 3 months;
medications used in the past 3 months; exposure to any hazardous agents in
workplace.
Main results and the role of chance: Cigarette smoking negatively inﬂu-
enced semen volume (r: -0.417, slope: 1.5700, p = 0.047), sperm count/mL (r:
-7.363, slope: 52.2981, p = 0.014), total sperm count (r: -4.43, slope: 178.165,
p = 0.023), TMSC (r: - 1.38, slope: 100.276, p = 0.045), and sperm DNA frag-
mentation (r: 0.014, slope: 9.76741, p = 0.033). Total sperm motility, progres-
sive sperm motility and sperm morphology were not signiﬁcantly inﬂuenced by
smoking habit. Alcohol consumption negatively inﬂuenced sperm count/mL (r:
-12.527, slope: 42.2553, p = 0.040) and SDF (r: 5.833, slope: 9.68068, p =
0.002). The other investigated semen parameters were not signiﬁcantly inﬂu-
enced by alcohol consumption. There were no signiﬁcant inﬂuences of other
investigated paternal lifestyle factors on semen quality. Cigarette smoking and
alcohol consumption negatively inﬂuenced fertilization rate (r: -1.349, slope:
21.9506, p-value: 0.039 and r: -3.617, slope: 20.1380, p-value: 0.041, respect-
ively), and blastocyst formation on day 5 (r: -14.244, slope: 28.8513, p-value:
0.025 and r: -34.801, slope: 30.0446, p-value: 0.042, respectively). There were
no signiﬁcant inﬂuences of other investigated paternal lifestyle factors on ICSI
outcomes.
Limitations, reasons for caution: Information on paternal lifestyle factors
was collected through self-completed non-validated questionnaires and we only
assessed lifestyle factors through a few questions, which may have introduced
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under-reporting and underestimation of the true association. The female life-
style were not taken into account, which may have biased the associations with
ICSI outcomes.
Wider implications of the ﬁndings: Cigarette smoking and alcohol con-
sumption appear to reduce semen quality, fertilization and blastocyst formation
rates. Therefore, it would be wise to advise male partners to abstain from
smoking and drinking alcohol to avoid decreased in vitro reproduction
outcomes.
Trial registration number:None.
O-236 The association between glycemic control and semen
parameters
A. Harlev1, Y. Mizrakli2, I. Har-Vardi1, A. Zeadna1, N. Steiner1,
T. Priel1, E. Levitas1
1Soroka University Medical Center- Faculty of Health Sciences- Ben-Gurion Univers,
Fertility and IVF Unit- Department of Obstetrics & Gynecology, Beere Sheva, Israel
2Soroka University Medical Center- Faculty of Health Sciences- Ben-Gurion Univers,
Clinical Research center, Beere Sheva, Israel
Study question: The current study aimed to assess the impact of diabetes
mellitus (DM) and impaired fasting glucose (IFG) on seminal ﬂuid and sperm
parameters.
Summary answer: Interrupted glycemic control, mainly DM, deteriorates
semen volume and sperm morphology, resulting in possible reduced fecundity.
What is known already: The prevalence of diabetes mellitus (DM) and
impaired fasting glucose (IFG) is increasing worldwide. DM is known to deteri-
orate male sexual function, and to affect the endocrine function, a crucial role
player in normal spermatogenesis. The impact of abnormal glycemic control on
semen parameters and consequently on male fecundity is lacking.
Study design, size, duration: A retrospective case-control study including
data from semen analyses of patients undergoing fertility evaluation was con-
ducted. Samples were collected between the years 2009-2017 in a single ter-
tiary hospital. DM and IFG patients were detected according to diagnoses, Lab
criteria and prescribed medications documented in their medical records.
Participants/materials, setting, methods: Patients who were younger
than 18 or older than 65 years, had previous chemotherapy treatment or radio-
therapy, and patients with a diagnosed genetic abnormality (kleinfelter/kallman
etc.) were excluded. Semen analyses were conducted and stratiﬁed according
to the WHO criteria. Multiple regression models were constructed to deﬁne
independent predictors of abnormal semen parameters. A p value of <0.05
was considered statistically signiﬁcant.
Main results and the role of chance: A total of 7,118 semen examinations
of 3,724 patients were included. Of them, 423 had a valid HbA1c result
obtained within ± 90 days of the semen analysis. Comparing DM (n = 336) to
IFG (n = 276) and healthy patients (n = 6679), the DM patients were older
(41.0 ± 10.0, 39.9 ± 9.1, 32.2 ± 7.2, respectively, p < 0.001) with signiﬁcantly
higher smoking rates (47.6%, 36.6, 45.1, respectively, p = 0.013) and had higher
baseline FSH levels (6.6 ± 4.2, 5.5 ± 3.4 and 5.4 ± 3.9, p < 0.001). The BMI of
DM and IFG pateints was signiﬁcantly increased compared to the healthy
patients group (28.8 ± 5.4 and 29.4 ± 6.0 vs. 25.9 ± 6.7 respectively, p <
0.001). Evaluating the semen analysis, the DM group had higher rates of low
semen volume compared to the IFG and non-DM groups (24.1%, 18.1% and
15.3% respectively, p < 0.001), asthenozoospermia (40.2%, 39.1% and 34.2%
respectively, p = 0.035) and teratozoospermia (65.7%, 51.5% and 25.9%,
respectively, p < 0.001). Using multiple logistic regression models, controlling
for confounders including age, BMI and smoking status, DM but not IFG were
found as independent risk factors for low seminal ﬂuid volume (OR 1.57, CI
1.18-2.1, p = 0.002 vs. OR 0.96, CI 0.67-1.37, p = 0.809) and teratozoosper-
mia (OR 1.68, CI 1.23-2.27, p = 0.001 vs. OR 0.96, CI 0.7-1.32, p = 0.791).
Nonetheless, asthenospermia was comparable between the groups.
Limitations, reasons for caution: The study is a retrospective population
based study with its inherited limitation.
Wider implications of the ﬁndings: Glycemic control is a well-known fac-
tor for health in general but as shown in the current study, may alter fecundity
of the male partner. Glycemic control should be advocated as part of the fertil-
ity treatment consultation.
Trial registration number: not applicable.
O-237 The effects of Mycoplasma genitalium infection on semen:
A retrospective study in infertile men of our hospital in China
Z.Wenbing1,2, L.Weina3, S. Lin1, G. Liu1,4
1Central South University, Institute of Reproduction and Stem Cell Engineering,
Changsha, China
2Reproductive and Genetic Hospital of CITIC-Xiangya, Sperm bank, Changsha, China
3Reproductive and Genetic Hospital of CITIC-Xiangya, Andrology Laboratory,
Changsha, China
4Reproductive and Genetic Hospital of CITIC-Xiangya, Clinical Laboratory, Changsha,
China
Study question: Mycoplasma genitalium is an emerging sexually transmitted
infections (STIs) that is associated with genital tract infection. Does Mycoplasma
genitalium infection inﬂuence semen quality?
Summary answer:M.genitalium incidence (2.49%) in infertile men was higher
than in fertile men (0%).It signiﬁcantly reduced sperm concentration, count,
normal morphology, and increased sperm DNA fragmentation.
What is known already: It is estimated that approximately 15% of male
infertility is related to infections in the genital tract. M.genitalium is associated
with male nongonococcal urethritis(NGU), non-chlamydial non-gonococcal
urethritis (NCNGU), but evidence supporting its role in male infertility remains
inconclusive. And to date there are few large infertile men-based studies of
China burden of disease.
Study design, size, duration: The study was performed as a retrospective
survey of 30794 semen specimens from 30094 infertile men between October
2016 and December 2017.
Participants/materials, setting, methods: M.genitalium was detected
using a novel simultaneous ampliﬁcation testing that is RNA-detection based.
Macrolide and tetracycline resistance screening was introduced using PCR and
Sanger sequencing from September 2017. Semen analysis, papanicolaou stain-
ing, and sperm DNA fragmentation detection were performed on semen
samples.
Main results and the role of chance: The incidence (749 of
30094,2.49%;95CI, 2.31%-2.66%) in infertile men was signiﬁcantly higher than
in fertile men (0 of 200, 0%).0.60%(159 of 26627;95CI, 0.50%-0.69%) of infer-
tile couples had concordant infections. There were 123 cases of treatment fail-
ure (13.4%,123/918;95%CI, 11.2–15.6). Macrolide and tetracycline resistance
were detected in 54 samples (98.18%;95%CI,94.54%-101.83%),27 samples
(49.09%;95%CI,35.45%-62.73%) respectively.The most prevalent infection was
in oligozoospermia (5.76%). After treatment, semen volume, sperm concentra-
tion, sperm count and total motile sperm count were signiﬁcantly higher than
those of before treatment(p = 0.046, p < 0.001,p = 0.011,p = 0.024,respect-
ively) in 56 patients. Normal morphology in M. genitalium positive group(n =
50) was signiﬁcantly lower than that of negative group(n = 70) (2.98 ± 0.87%
vs.3.71 ± 0.91%, p < 0.001). Sperm DNA fragmentation (DFI) in M. genitalium
positive group(n = 50) was signiﬁcantly higher than that of negative group(n =
70) (13.72 ± 7.61% vs.8.56 ± 4.81%, p < 0.001). Our study suggested a low
prevalence of M. Genitalium in the infertile men in China. >98% of macrolide
resistance is an likely explanation for high rates of azithromycin treatment failure
(34.48%).M. genitalium infection signiﬁcantly led to a decrease in semen concen-
tration, sperm count, normal morphology, and increased sperm DNA fragmen-
tation(SDF).
Limitations, reasons for caution: A limitation of the study is that we did
not study the pregnancy rates before and after antibiotic treatment. Studying
the pregnancy rates might better support our ﬁndings. And the positive group
sizes followed in this study were relatively small.
Wider implications of the ﬁndings: Since incidence is very low, caution is
required to establish the relationship to M. genitalium and male fertility. These
ﬁndings indicate that M. genitalium infection might ﬁnally affect semen quality.
And there is a need to provide resistance testings, reappraisal the recom-
mended antimicrobial options in China.
Trial registration number:Not applicable.
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O-238 Effect of nut consumption on semen quality and
functionality in healthy males: a randomized controlled trial
A. Salas-Huetos1,2, R. Moraleda1, S. Giardina1,2, E. Anton3,
J. Blanco3, J. Salas-Salvadó1,2, M. Bulló1,2
1Universitat Rovira i Virgili, Human Nutrition Unit, Reus 43201, Spain
2Consorcio CIBER- M.P.- Physiopathology of Obesity and Nutrition CIBERobn,
Instituto de Salud Carlos III ISCIII, Madrid 28029, Spain
3Genetics of Male Fertility Group, Cell Biology Unit- Department of Cellular Biology-
Physiology and Immunology- Faculty of Biosciences- Universitat Autònoma de
Barcelona UAB, Bellaterra Cerdanyola del Vallès 08193, Spain
Study question: Can a chronic consumption of a mixture of nuts improve the
semen quality parameters and the sperm functionality in healthy individuals?
Summary answer: Including nuts in a regular diet signiﬁcantly improved the
sperm count, vitality, motility, and morphology, partly explained by a reduction
of the DNA fragmentation.
What is known already: Human semen quality has declined in industrialized
nations where pollution, smoking, and trends toward a western-style diet are
hypothesized as potential causes. Recently, some studies described that healthy
diets rich in omega-3, antioxidants (e.g. vitamin C and E, selenium and zinc),
carnitines and folate could improve semen quality. Because nuts are nutrient
dense foods containing some of the above-mentioned nutrients, we hypothe-
size that, added to a western-style diet, would beneﬁcially affect semen quality
and functionality.
Study design, size, duration: The study was designed as a 14-week rando-
mized, controlled, parallel two-group trial. 119 healthy male aged 18-35 were
allocated to either following their usual western-style diet supplemented with
60 g/day of a mix of almonds, hazelnuts and walnuts or to follow with their
usual western-style diet free of nuts.
Participants/materials, setting, methods: Sperm and blood samples
were collected at baseline and after 14 weeks of intervention. Dietary informa-
tion was recorded in four visits distributed along the trial. Conventional semen
parameters (WHO, 2010) were determined as primary outcome. To elucidate
at the molecular level the effects of nuts consumption, sperm DNA fragmenta-
tion (TUNEL assay), sperm ROS (chemiluminescence using Luminol), sperm
chromosome stability (FISH for chromosomes X, Y and 18) and total sperm
DNA methylation (ELISA assay) were measured.
Main results and the role of chance: A total of 98 participants completed
the study. General characteristics of the study population (age, weight, height,
BMI, waist circumference, and systolic and diastolic blood pressure) did not dif-
fer between interventions. No signiﬁcant differences were observed in conven-
tional blood biochemical parameters (fasting plasma glucose, total cholesterol,
HDL, LDL and VLDL cholesterol, triglycerides, fasting plasma insulin, C-
reactive protein and folate). In nuts group, we found a signiﬁcant increased
intake of total lipids, MUFA, PUFA, magnesium, vitamin E, omega-3, ALA, and
omega-6. We found an improvement of sperm count (P-value = 0.0043), vital-
ity (P-value = 0.0027), total motility (P-value = 0.0093), progressive motility (P-
value = 0.0207), and morphology (P-value = 0.0073) in the nut group com-
pared to the control. Participants in the nuts group shown a signiﬁcant reduc-
tion of the sperm DNA fragmentation (SDF) (P-value = 0.0018) a parameter
closely related with male infertility. Negative correlations between sperm vital-
ity and SDF (rho=-0.2252; P-value = 0.0266), and between total spermatozoa
and SDF (rho=-0.3170; P-value = 0.0015) were detected. No changes
between interventions were found in ROS (P-value = 0.1996), sperm chromo-
some (X, Y and 18) anomalies (P-value disomies = 0.3336, P-value nullisomies
= 0.9386, and P-value diploidies = 0.0674), and DNA methylation (P-value =
0.8652).
Limitations, reasons for caution: By design, a limitation of this trial is that it
focuses on health, apparently fertile and with western-style diet subjects, and
the results cannot be extrapolated to the general population.
Wider implications of the ﬁndings: Our ﬁndings support a beneﬁcial role
of chronic nut consumption in sperm quality and explore the molecular mech-
anism that could explain our results. Additional efforts to identify male-speciﬁc
dietary recommendations that optimize sperm quality and fertility should be
encouraged.
Trial registration number: The trial was registered in ISRCTN registry with
identiﬁer ISRCTN12857940 (DOI: 10.1186/ISRCTN12857940).
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O-239 Medroxyprogesterone acetate versus ganirelix in oocyte
donation cycles stimulated using GnRH antagonist protocol
triggered with GnRH-agonist: a randomized controlled trial (RCT)
R. Begueria, D. García, R. Vassena, A. Rodríguez
Clínica EUGIN, Assisted Reproduction, Barcelona, Spain
Study question: To evaluate the non-inferiority of oral medroxiprogesterone
acetate (MPA) compared to ganirelix on the number of mature oocytes (MII)
retrieved at ovum pick-up (OPU) in oocyte donation cycles.
Summary answer: MPA is comparable to ganirelix in terms of MII retrieved
at OPU. However, MPA use during ovarian stimulation might decrease preg-
nancy rates in oocytes’ recipients.
What is known already: Oral treatment with MPA inhibits the pituitary LH
surge during ovarian stimulation in infertile patient. Because of its negative effect
on the endometrium, MPA suppression is combined with freeze-all. Published
reports indicate that both the number of MII retrieved and pregnancy rates
from these oocytes are comparable to short protocol of GnRh agonists during
IVF cycles with freeze-all. MPA might allow for more comfortable and cost-
effective ovarian stimulation in oocyte donation cycles.
Study design, size, duration: Randomized clinical trial (RCT), open-label,
conducted from June 2016 to June 2017 to assess the non inferiority of MPA
(10 mg/day) versus a GnRH antagonist protocol with ganirelix (0.25 mg/day)
from day 7 in ovarian stimulation cycles triggered with triptoreline. Trigger cri-
terion was >3 follicles of diameter>18 mm.
Participants/materials, setting, methods: 280 oocyte donors were
selected, 232 randomized and 173 reached OPU: 86 under MPA and 87 under
ganirelix. The main outcome was number of MII at OPU. Secondary outcomes
were: embryological laboratory outcomes and reproductive outcomes in
oocyte recipients. The study was powered to indentify a difference ≥3 MII, with
an alpha risk of 0.05 and beta risk of 0.2. Differences were tested using a two-
sided Student’s t-test or a Pearson’s Chi2 test as applicable.
Main results and the role of chance: All participants were in their ﬁrst cycle
of oocyte donation. On average, donors were 24 ± 4.5 years old and with a
BMI of 23 ± 2.9 kg/m2. Days of stimulation were similar in both groups (11.2),
as well as the total gonadotropin doses up to trigger (2162 IU in MPA and 2163
IU in ganirelix). The number of MII retrieved was no different: 15.1 ± 8.3 with
MPA and 14.6 ± 7.0 with ganirelix (p = 0.69).
Both recipients’ and embryo transfer (ET) characteristics were similar among
groups. The average age of recipients was 42 ± 4.8 years and the BMI was 24
± 4.4 kg/m2. The mean number of MII assigned to each recipients was 6.7 ±
1.1 in MPA and 6.6 ± 1.1 in ganirelix (p = 0.58). MII were fertilized with partner
sperm in 84.9% cycles overall and fertilization rate was 75.7% with MPA vs.
73.9% with ganirelix (p = 0.50). Overall, there was 55.2% of double ET and
44.8% of single ET; 39.1% of ETs were performed in D5. Surprisingly, and in
spite of similar recipients and cycle characteristics, reproductive outcomes
were unexpectedly lower with MPA. Biochemical pregnancy rate was 44.3% vs.
56.2% (p = 0.042); clinical pregnancy rate 29.9% vs. 42.5% (p = 0.026); ongoing
pregnancy rate 27.4% vs. 36.9%, (p = 0.085) and live birth rate 15.4% vs.
26.0%, (p = 0.036).
Limitations, reasons for caution: Although oocyte recipient and ET charac-
teristics are similar among groups, this RCT has been designed under a hypoth-
esis of no-inferiority in the number of MII obtained in two treatment groups,
therefore the reproductive outcomes in recipients should be evaluated with
caution.
Wider implications of the ﬁndings: Ovarian stimulation with MPA yield
comparable results compared to ganirelix in oocyte donation cycles. The unex-
pected ﬁnding in reproductive outcomes should be further investigated.
Trial registration number: EudraCT Number 2015-004328-73
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O-240 Triggering method dramatically alters the cumulus cell
transcriptome in high and normal ovarian reserve patients
B.Wyse1, N. FuchsWeizman1, I. Gat1,2, H. Balakier1,
S. Kenigsberg1, M. Sangaralingam1, S. Russell1, J. Caballero1,
C. Librach1,3,4,5
1CReATe Fertility Centre, Research, Toronto, Canada
2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
3Women’s College Hospital, Department of Gynecology, Toronto, Canada
4University of Toronto, Department of Obstetrics and Gynecology, Toronto, Canada
5University of Toronto, Department of Physiology, Toronto, Canada
Study question: Does triggering oocyte maturation with single vs. dual trigger
(GnRHa & hCG) signiﬁcantly alter the transcriptome of cumulus cells?
Summary answer: Triggering protocol signiﬁcantly alters the cumulus cell
transcriptome; hallmark pathways affected include cell-cycle regulation, ECM
remodeling, and ion-channel activity, all important for folliculogenesis and
ovulation.
What is known already: Cumulus cells (CCs) support the growing oocyte
and their transcriptome could potentially be a valuable non-invasive biomarker
for oocyte quality and competence. The CC transcriptome is inﬂuenced by the
women’s age, BMI, infertility diagnosis (eg. Endometriosis, PCOS, low ovarian
reserve) and stimulation protocol. Previously, using microarray, when triggering
with either GnRHa or hCG, it has been shown that GnRHa enhanced expres-
sion of genes involved in steroidogenesis. Differences in the CC transcriptome
may potentially affect clinical outcomes, including the number of eggs retrieved,
their quality, blastulation rates, aneuploidy, and pregnancy rates.
Study design, size, duration: This study is a part of a larger ongoing RCT
comparing outcomes between single trigger (ST) vs. dual trigger (DT), in differ-
ent patient populations. A total of 21 consented patients (12 with high ovarian
reserve and 9 with normal ovarian reserve) undergoing IVF-ICSI at the CReATe
Fertility Centre (Toronto, Canada) were enrolled in the study. Patients were
matched according to demographic characteristics (age, BMI, etc.), ovarian
reserve parameters (AMH and AFC) and stimulation protocol.
Participants/materials, setting, methods: CCs from expanded MII
oocytes were trimmed, lysed, and RNA was extracted. Sequencing libraries were
prepared (Clonetech SMARTer-v4 and Nextera-XT) and sequenced using a
HiSeq 2500. Sequences were aligned to hg19, differential expression was con-
ducted, and ﬁltered by false discovery rate (FDR < 0.05) and fold change
(logFC<-2 or logFC>2). Pathway analysis using GSEA was performed to elucidate
biologically signiﬁcant genes involved in hallmark processes in the ovary.
Main results and the role of chance: Samples clustered separately by trig-
gering method in patients with both high and normal ovarian reserve. Eight hun-
dred and forty-one genes were differentially expressed between treatment
groups in the high responder cohort, and 2000 genes were differentially
expressed in the normal responder cohort. In the high responders, dual trigger
led to downregulation of ion channel regulators and G-protein receptor binding
pathways when compared with single trigger and upregulation of mesenchymal
development. In the normal responder cohort, dual trigger caused downregula-
tion of immune related pathways (MHC complex, antigen processing, etc.) and
extracellular matrix remodeling, when compared with single trigger and upregu-
lation of cell division related pathways (mitotic spindle, chromosome segrega-
tion, etc.). Furthermore, genes previously associated with live birth were
enriched in the normal responders treated with DT. Blastulation rate was sig-
niﬁcantly higher in normal responders triggered by DT when compared to ST
(3.0 ± 0.37;1.67 ± 0.24 p < 0.01). Triggering method did not affect clinical out-
comes among the high responders.
Limitations, reasons for caution: Our ﬁndings are limited by the sample
size and biological variability. To adjust for this, “signiﬁcant DE” between the
two triggering cohorts was deﬁned with stringent criteria, increasing conﬁdence
in the validity of our ﬁndings. No potential confounding variables were deemed
signiﬁcant (Wilcoxon test).
Wider implications of the ﬁndings: Triggering protocol alters the tran-
scriptome proﬁle of CCs in both high and normal responders and blastulation
rate in normal responders. Hallmark pathways involved in cellular proliferation,
oocyte maturation, and ovulation are affected. This study enhances our under-
standing of the effect triggering has on processes involved in oocyte growth and
maturation.
Trial registration number:Not applicable.
O-241 Daytime variation in serum progesterone during the
mid-luteal phase in women undergoing IVF treatment
T. Haahr1, U.S. Kesmodel2, C.Y. Andersen3, L.H. Thomsen4,
P. Humaidan4
1The Fertility Clinic- Skive- Skive Regional Hospital- Denmark, Department of Clinical
Medicine- Aarhus University- Denmark., Skive, Denmark
2The Fertility Clinic- Herlev Hospital- Herlev- Denmark., Department of Clinical
Medicine- University of Copenhagen- Denmark., Herlev, Denmark
3Laboratory of Reproductive Biology- The Juliane Marie Centre for Women- Children
and Reproduction- University Hospital of Copenhagen- Denmark., University of
Copenhagen- Denmark, Copenhagen, Denmark
4The Fertility Clinic Skive- Skive Regional Hospital- Denmark, Department of Clinical
Medicine- Aarhus University- Denmark., Skive, Denmark
Study question: Does mid-luteal serum progesterone (P4) exhibit clinically
signiﬁcant ﬂuctuations during a 12-hour daytime period in women undergoing
in vitro fertilization (IVF)?
Summary answer: Large P4-ﬂuctuations were seen in patients with median
P4>250 nmol/l whereas patients with P4<60 nmol/l had clinically constant P4-
levels during daytime.
What is known already: Large ﬂuctuations in serum-P4 levels are present in
the mid-luteal phase of the natural cycle, hampering the use of serum-P4 mea-
surements in the evaluation of corpus luteum function. No study so far exam-
ined the possible daytime serum-P4 ﬂuctuations during the mid-luteal phase in a
group of women undergoing IVF treatment.
Study design, size, duration: Observational daytime study of ten women
undergoing IVF treatment at the fertility clinic in Skive, Denmark. Patients were
prospectively enrolled between December 2014 and December 2015.
Participants/materials, setting, methods: Seven days after oocyte pick-
up, patients were admitted to the fertility clinic early in the morning. They had
blood samples drawn every 60 minutes for the subsequent 12 hours, and during
two of these hours every 15 minutes. Patients were selected to represent dif-
ferent stimulation protocols, different modes of triggering of ﬁnal oocyte matur-
ation as well as different regimens of luteal phase support. Serum samples were
analyzed for progesterone, estradiol and LH.
Main results and the role of chance: There was a signiﬁcant positive cor-
relation between median P4-levels and the magnitude of P4-variations – women
with median P4 < 60 nmol/l had clinically stable P- levels throughout the day,
while patients with median P4 > 250 nmol/l exhibited periodic P4-peaks of sev-
eral hundred nmol/l. These endogenous P4-ﬂuctuations were observed irre-
spective of the type of stimulation protocol or mode of triggering of ﬁnal oocyte
maturation and despite the fact that LH was under the detection limit at the
time of measurement. Simultaneously large ﬂuctuations were seen in s-
estradiol. There was no obvious common daytime pattern in the secretion of
P4 in the ten women examined.
Limitations, reasons for caution: Although the sample size was small,
which may limit the validity of general interpretations, this is the ﬁrst study to
explore mid-luteal P4-ﬂuctuations in different types of IVF cycles.
Wider implications of the ﬁndings: When monitoring mid-luteal P4-levels
during IVF-treatment, clinicians should be aware that large P4-ﬂuctuations may
exist when serum-P4 exceeds 250 nmol/l. In contrast, a measured serum
P4<60 nmol/l can be regarded as a true low value – thus, the accuracy of an
individual mid-luteal serum-P4 measurement depends on the median P4-
concentration.
Trial registration number:NCT02673034 (Clinicaltrials.gov).
O-242 Effects of high progesterone in in-vitro fertilization cycle on
DNAmethylation of endometrium receptivity markers during
implantation window
Y. Xiong1, L. Hu2, T. Zhang3, H. Xu1, M.Wang2, Y. Sun2, C.Wang1
1The Chinese University of Hong Kong, Department of Obsetetrics and Gynaecology,
Shatin- New Territories, Hong Kong
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2the First Afﬁliated Hospital of Zhengzhou University, Reproductive Medical Center,
Zhengzhou, China
3Shenzhen Zhongshan Urology Hospital, Shenzhen Key Laboratory of Reproductive
Immunology for Peri-implantation- Fertility Centre, Shenzhen, China
Study question: Does high progesterone level in in-vitro fertilization (IVF)
cycle affect DNA methylation of endometrium receptivity markers during
implantation window?
Summary answer: The endometrium receptivity markers, MUC1, CDH1
and CTNNB1, in patients with high progesterone were highly methylated, while
PAEP was lessly methylated.
What is known already: High progesterone increased endometrium DNA
methylation but how methylation affect the endometrium receptivity during
implantation window is still unclear.
Study design, size, duration: A cohort study including 20 women with high
progesterone level (HP) and 20 women with normal progesterone level (NP)
on the day of human chorionic gonadotrophin (hCG) administration after con-
trolled ovarian hyperstimulation in an IVF cycle.
Participants/materials, setting, methods: Endometrial tissues were col-
lected on 7th day after hCG administration from women with NP or HP on
hCG day. Immunohistochemical staining of DNA methyltransferases (DNMTs)
and receptivity markers (MUC1, CDH1, CTNNB1 and PAEP) was performed.
Methylation level of promotor region of receptivity markers was detected by
Sequenom MassARRAY and/or bisulﬁte-sequencing PCR. RT-qPCR was used
to quantify mRNA expression levels of the receptivity markers. Then methyla-
tion level and expression levels of the receptivity markers were correlated.
Main results and the role of chance: Except for progesterone level on
hCG day, no signiﬁcant demographic difference exists between HP and NP
group. Expression of DNMT3B, but not DNMT1 and DNMT3A, in endomet-
rium from HP group was signiﬁcantly higher than that in NP group. DNA
methylation levels of promotor region of MUC1, CDH1, CTNNB1 in HP group
was signiﬁcantly higher, while the PAEP in HP group was signiﬁcantly lower than
that in NP group. On the contrary, expression levels of MUC1, CDH1 and
CTNNB1 in HP group were signiﬁcantly lower, while PAEP in HP group was sig-
niﬁcantly higher than that in NP group, as detected in RT-qPCR and IHC stain-
ing. The DNA methylation level was negatively correlated with the mRNA
expression level of the receptivity markers.
Limitations, reasons for caution: The sample size was not sufﬁciently large
to permit in depth analysis of confounding variables.
Wider implications of the ﬁndings: Our data demonstrated high proges-
terone affects DNA methylation and gene expression of endometrium receptiv-
ity markers during implantation window, which may contribute the failure of IVF
treatment.
Trial registration number:No.
O-243 Implantation enhancement by elective Cryopreservation of
all viable Embryos (ICE): randomized controlled trial (RCT)
comparing the two safest approaches in IVF/ICSI for
high-responders
S. Santos-Ribeiro1,2, S. Mackens1, B. Popovic1, N.P. Polyzos1,3,4,
A. Racca1,5, P. Drakopoulos1,6,7, M. De Vos1, H. Tournaye1,
C. Blockeel1,8
1Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussels, Belgium
2Santa Maria University Hospital, Department of Obstetrics- Gynaecology and
Reproductive Medicine, Lisbon, Portugal
3Dexeus University Hospital, Department of Reproductive Medicine, Barcelona,
Spain
4Faculty of Health University of Aarhus, Department of Clinical Medicine, Aarhus,
Denmark
5University of Genoa, Academic Unit of Obstetrics and Gynecology, Genova, Italy
6Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy- Department of Surgical
and Clinical Science, Brussels, Belgium
7University of Liège, Departement of Reproductive Medicine, Liège, Belgium
8University of Zagreb-School of Medicine, Department of Obstetrics and
Gynaecology, Zagreb, Croatia
Study question: How does the freeze-all strategy compare to GnRH-agonist
triggering followed by intensiﬁed luteal support and fresh embryo transfer (ET)
in terms of pregnancy/safety outcomes?
Summary answer: Pregnancy rates after either fresh ET or freeze-all did not
vary signiﬁcantly. However, ovarian hyperstimulation syndrome (OHSS)
occurred more frequently after a fresh ET attempt.
What is known already: GnRH-agonist triggering has drastically reduced the
incidence of OHSS. However, the best method to perform an ET after agonist
triggering is still widely unknown. Two strategies (the freeze-all approach and a
fresh ET attempt using a low-dose bolus of hCG followed by intensiﬁed luteal
phase support) have shown to be safer alternatives to conventional hCG trig-
gering with comparable pregnancy outcomes. However, these two strategies
have never been compared head-to-head.
Study design, size, duration: The ICE trial was an RCT designed to recruit
212 women with an excessive response after ovarian stimulation (≥18 follicles
measuring ≥11 mm) for IVF/ICSI in a GnRH antagonist suppressed cycle
between 2014-2017. Our primary outcome was clinical pregnancy at 7 weeks
after the ﬁrst ET. Secondary outcomes included live-birth and the development
of moderate-to-severe early-onset OHSS.
Participants/materials, setting, methods: Following GnRH-agonist trig-
gering, women were randomized to perform either a fresh ET attempt (after a
1500 IU hCG bolus on the day of oocyte retrieval followed by oral estradiol
2 mg bid and vaginal progesterone 200mg tid) or to cryopreserve all good-
quality embryos followed by a frozen ET in a subsequent artiﬁcial cycle.
Main results and the role of chance: The required total of 106 patients in
each study arm were recruited in the study, with 3 patients (1 in the fresh ET
group and 2 in the freeze-all group) later withdrawing their consent to partici-
pate in the study. One patient in the freeze-all group became pregnant spontan-
eously prior to the ﬁrst frozen ET. The study arms did not vary signiﬁcantly in
terms of the number of oocytes retrieved and embryos cryopreserved/trans-
ferred. The intention-to-treat clinical pregnancy rates after the ﬁrst ET did not
vary signiﬁcantly among the fresh ET and freeze-all study arms (49% versus
54%, p = 0.446). However, moderate-to-severe early-onset OHSS occurred
more frequently in the group who had a fresh embryo transfer (9% versus 0%,
p = 0.002).
Limitations, reasons for caution: These preliminary results are limited by
the fact that the accrual of live-births is still ongoing. Furthermore, given that
the RCT was powered for the superiority of one of the arms, smaller differ-
ences among the groups in terms of clinical pregnancy rates may have failed to
reach statistical signiﬁcance.
Wider implications of the ﬁndings: This study offers the ﬁrst comparative
analysis of the two most commonly proposed alternatives for high-responding
women performing IVF/ICSI in modern-day medicine. While pregnancy rates
seemed comparable, a fresh ET may increase the risk of OHSS. Thus, serious
consideration should be made before recommending a fresh ET as ﬁrst-line
treatment.
Trial registration number: ClinicalTrials.gov identiﬁer NCT02148393.
O-244 Oral dydrogesterone is an efﬁcacious and safe alternative to
intravaginal progesterone gel for luteal phase support in IVF: a
randomized, open-label, multicenter, phase III study
G. Griesinger1, C. Blockeel2, A. Patki3, D.Z. Yang4, Z.J. Chen5,
E. Kahler6, C. Pexman-Fieth7, H. Tournaye2
1University Hospital of Schleswig-Holstein, Department of Gynecological
Endocrinology and Reproductive Medicine, Lübeck, Germany
2University Hospital of the Brussels Free University, Center for Reproductive
Medicine, Brussels, Belgium
3Fertility Associates, Mumbai, India
4Sun Yat-Sen University, Department of Obstetrics and Gynecology, Guangzhou,
China
5Shandong University, Department of Obstetrics and Gynecology, Shandong, China
6Abbott Laboratories GmbH, Clinical Development, Hannover, Germany
7Abbott GmbH & Co. KG, Women’s Health Medical Affairs and Clinical
Development, Wiesbaden, Germany
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Study question: Is oral dydrogesterone 30 mg daily non-inferior to 8% intra-
vaginal micronized progesterone gel 90 mg daily for luteal phase support in
in vitro fertilization (IVF)?
Summary answer: Oral dydrogesterone demonstrated non-inferiority to
intravaginal micronized progesterone gel for the presence of fetal heart beats at
12 weeks of gestation (non-inferiority margin 10%).
What is known already: Progesterone therapy for luteal phase support is an
accepted treatment practice for women undergoing IVF. The intravaginal route
of micronized progesterone administration is routinely used in most clinics;
however, it is associated with vaginal irritation, discharge and poor patient com-
pliance. It has been demonstrated that oral dydrogesterone is non-inferior to
micronized vaginal progesterone (MVP) capsules for luteal phase support in IVF
with a similar safety proﬁle (LOTUS I trial; Tournaye et al., Hum Reprod.
2017); In the present study, the efﬁcacy, safety and tolerability of oral dydroges-
terone versus intravaginal micronized progesterone gel (Crinone
®
8%) were
assessed.
Study design, size, duration: Lotus II was a randomized, open-label, multi-
center, phase III clinical study, performed across 37 sites in 10 countries from
August 2015 until May 2017. Subjects were premenopausal women (>18 to
<42 years) with a documented history of infertility who were planning to
undergo IVF. A centralized electronic system was used for randomization to
oral dydrogesterone 10 mg tablets three times daily or 8% intravaginal micro-
nized progesterone gel 90 mg (Crinone
®
) once daily.
Participants/materials, setting, methods: In total, 1034 subjects were
randomized to receive either oral dydrogesterone (n = 520) or intravaginal
micronized progesterone gel (n = 514). Luteal support was started on the day
of oocyte retrieval and continued until 12 weeks of gestation if a positive preg-
nancy test was obtained 2 weeks after embryo transfer and no miscarriage
occurred. The primary outcome measure was the presence of fetal heartbeats
at 12 weeks of gestation as determined by transvaginal ultrasound.
Main results and the role of chance: In the oral dydrogesterone and intra-
vaginal micronized progesterone gel groups, 494 and 489 subjects were
included in the full analysis set (FAS), and 490 and 481 subjects were included in
the per protocol set (PPS), respectively. Pregnancy rates at 12 weeks of gesta-
tion for the oral dydrogesterone and intravaginal micronized progesterone gel
groups were 38.7% and 35.0% in the FAS (difference 3.7%; 95% CI: -2.3–9.7%),
and 36.7% and 34.7% in the PPS (difference 2.0%; 95% CI: -4.0–8.0%), respect-
ively. Thus, in both the FAS and PPS, non-inferiority of oral dydrogesterone ver-
sus intravaginal micronized progesterone gel was demonstrated as the lower-
bound CI was greater than the non-inferiority margin of -10%. Live birth rates in
the FAS were 34.4% and 32.5% (difference 1.9%; 95% CI -4.0–7.8%). The num-
ber of women with multiple newborns was comparable in the two treatment
groups (20.6% versus 17.6% in the FAS for the oral dydrogesterone and intrava-
ginal micronized progesterone groups, respectively). Oral dydrogesterone was
well tolerated, and the incidence of treatment emergent adverse events for
mothers and newborns was comparable to that of intravaginal micronized pro-
gesterone gel in this study.
Limitations, reasons for caution: The analysis of the results was powered
to consider the ongoing pregnancy rate, but a primary objective of greater clin-
ical interest may have been the live birth rate. Conclusions relating to the treat-
ment effects in secondary variables, such as live birth rate, should therefore be
made with caution.
Wider implications of the ﬁndings: The present study conﬁrms the ﬁnd-
ings of the Lotus I trial (Tournaye et al., Hum Reprod. 2017), which already
established oral dydrogesterone as a viable alternative to vaginally administered
micronized progesterone due to its efﬁcacy and comparable tolerability in the
studies.
Trial registration number:NCT02491437 (clinicaltrials.gov)
O-245 FSHR type is a risk factor for developing ovarian hyper
stimulation syndrome during in vitro fertilisation as observed in vivo
and in vitro
H. Nenonen1, I. Lindgren1, E. Henic1, L. Bungum2, Y. Lundberg
Giwercman1
1Lund University, Translational Medicin, Malmö, Sweden
2Copenhagen University Hospital, Department of fertility, Copenhagen, Denmark
Study question: Is the follicle stimulating hormone genotype of importance
when evaluating the risk of ovarian hyper stimulation syndrome (OHSS) in
women undergoing in vitro fertilisation (IVF)?
Summary answer: Women with asparagine in the amino acid 680 of the
FSHR had an OR of 11 (95% CI 1.4-82; p = 0.022) for OHSS compared to
women with serine.
What is known already: A serious and potentially life-treathening complica-
tion to IVF-treatment is OHSS, generally affecting 0.5-5% women undergoing
controlled ovarian hyperstimulation with exogenous FSH, and there are cur-
rently no effective methods to predict the response. It is known that carriers of
NN in aminoacid 680 in the FSHR require lower doses of FSH during controlled
ovarian stimulation compared to women with SS in order to ovulate. Some
cases with mutations in the FSHR and spontaneous OHSS have been reported,
but linking this condition with polymorphisms in the FSHR have shown contra-
dicting results.
Study design, size, duration: Retrospective study. Women undergoing IVF
at Reproductive Center, Malmö hospital, Malmö, Sweden, were enrolled and
genetic variants examined and compared between those who developed OHSS
and those who did not. FSHR variants were studied in monkey kidney cells trea-
ted with rFSH.
Participants/materials, setting, methods: In total n = 586 women were
included in the study and genotyped regarding the polymorphism N680S in the
FSHR gene. A risk allele analysis regarding the association between genotype and
development of OHSS was done. To study receptor activity in vitro, COS-1 cells
were transfected with FSHR variants and response was measured as cAMP amount
produced when stimulated 1 h with 1, 10 or 90 IU follitropin alpha (Gonal-f,
MerckSerono). The experiments were done in duplicates and repeated 3 times.
Main results and the role of chance: The proportion of women who devel-
oped OHSS was 6% (n = 36) in the total cohort. The N680S A > G poly-
morphism in the FSHR was associated with OHSS, ptrend = 0.004 and pallelic
= 0.038. Carriers of an N allele had signiﬁcantly higher OR for OHSS compared
to carriers of S (OR 1.7, 95% CI 1.0 – 2.8, p = 0.04). A higher receptor activity
in cells expressing N compared to the S variant was also evident at all concen-
trations of rFSH tested (p < 0.05 for all).
Limitations, reasons for caution: The number of total OHSS cases is small
in this study but the genotype distribution for all participants is similar to earlier
reports, therefore not indicating selection bias.
Wider implications of the ﬁndings: This study strengthens previous ﬁnd-
ings regarding higher hormonal sensitivity in carriers of N in the FSHR.
Genotyping the FSHR before IVF or egg donation could be a help in identifying
high risk individuals and precaution could be taken regarding hormonal dose to
prevent OHSS in women with this particular genotype.
Trial registration number: not applicable.
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O-246 Vaginal microbiota proﬁle at the time of embryo transfer
does not affect pregnancy in IVF cycles with donated oocytes
P. Vergaro1, G. Tiscornia1, M. Barragán1, D. García1, J. Santaló2,
A. Rodríguez1, R. Vassena1
1Clínica EUGIN, Assisted Reproduction, Barcelona, Spain
2Universitat Autònoma de Barcelona, Unitat de Biologia Cel·lular- Facultat de
Biociències, Barcelona, Spain
Study question:What is the relationship between the vaginal microbiota pro-
ﬁle at the time of embryo transfer and pregnancy rate in women undergoing IVF
with donated oocytes?
Summary answer: The vaginal microbiota proﬁle at embryo transfer in
women receiving donated oocytes does not seem to be related with the preg-
nancy rate in this population.
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What is known already: Vaginal microbiota, i.e. the community of bacterial
species colonizing the vaginal mucosae, plays an important role in the physiology
of the female genital tract. The vaginal microbiota of healthy women is dominated
by lactic-acid producing bacteria, mainly Lactobacillus spp. Dominance of anaer-
obic species such as Gardnerella vaginalis or Atopobium vaginae lead to a dysbiosis
known as bacterial vaginosis (BV). In some reports, such condition has been cor-
related with negative results in IVF, while other authors did not ﬁnd any relation.
It is still unclear whether vaginal microbiota status inﬂuences IVF outcome or not.
Study design, size, duration: 121 Caucasian women receiving donated
oocytes were prospectively included in March-September 2017. Vaginal swabs
were taken immediately before transfer of single blastocysts. Genomic DNA
was extracted with QIAamp DNA mini kit (Qiagen), and bacterial load as well
as the expression of 8 bacterial species was determined by qPCR. The main
outcome was βhCG levels in blood 14 days after single blastocyst transfer.
Univariate analysis was performed to evaluate the association between micro-
biota proﬁles and pregnancy.
Participants/materials, setting, methods: Absolute number of bacterial
genomes per sample was determined by qPCR for 4 species of lactobacilli
(L. crispatus, L. gasseri, L. jensenii, L. iners) commonly found in vaginal microbiota
and 4 species related with BV (Gardnerella vaginalis, Atopobium vaginae,
Mycoplasma hominis and Prevotella spp). Vaginal microbiota proﬁles for each
patient were characterized as Lactobacillus dominated (>50% Lactobacillus spp),
BV associated (>50% BV associated bacteria), or mixed microbiota (dominance
not clear) and correlated with biochemical pregnancy.
Main results and the role of chance: Although bacterial load was variable,
most samples were dominated by a single species. Overall pregnancy rate was
55.4%. A majority of samples (81.8%) were dominated by Lactobacillus spp. In this
group, the pregnancy rate was 52.5%, while in non-Lactobacillus dominated proﬁles
the pregnancy rate was 68.2% (p = 0.238). We further analyzed proﬁles including
Lactobacillus dominated, BV associated and mixed microbiota. The prevalence of
BV associated microbiota was 14.9%, with pregnancy rate of 66.7%. Mixed micro-
biota samples (composed by a combination of Lactobacilli and BV associated spe-
cies) had a very low prevalence (3.3%). Pregnancy rates among the three groups
did not show signiﬁcant differences (p = 0.391). In addition, we determined micro-
biota proﬁles according to the relative expression of bacterial species referred to
human and bacterial load. This approach gave similar results, with no statistically sig-
niﬁcant differences between groups (p = 0.345). Our results suggest that a vaginal
microbiota dominated by BV associated species is not associated to a pregnancy
decrease when high quality embryos derived from donor oocytes are transferred
to a receptive endometrium, in absence of ovarian stimulation. Vaginal microbiota
proﬁle does not seem to be determinant for oocyte recipient cycles success.
Limitations, reasons for caution: Sampling variations cannot be ruled out;
bacterial and human genomic DNA proportion varied slightly between samples.
Our three-way group analysis needs to be conﬁrmed using a higher number of
samples for BV and mixed microbiota categories.
Wider implications of the ﬁndings: Some authors report deleterious
effects of BV on reproductive outcomes. Our data suggest that BV-like vaginal
microbiota at time of embryo transfer does not directly affect endometrial
receptivity and pregnancy rate.
Trial registration number:Not applicable
O-247 Low ovarian response to stimulation in IVF can be related
with activation of the NLRP3 inﬂammasome
L. Rancan1, R. Núñez Calonge2, S. Cortés Gallego2, E. Vara1,
P. Caballero Peregrín2, J.A.F. Tresguerres3
1Facultad de Medicina- Universidad Complutense, Bioquímica y Biología Molecular,
Madrid, Spain
2Clinica Tambre, Scientiﬁc Direction, Madrid, Spain
3Facultad de Medicina- Universidad Complutense, Fisiología, Madrid, Spain
Study question: Does the NLRP3 inﬂammasome play a role in low ovarian
response to stimulation in IVF?
Summary answer: The activation of NLRP3 is higher in patients with low
ovarian response compared to donors. Increased oxidative stress may induce
increased expression of inﬂammatory NLRP3
What is known already: Oxidative stress can stimulate tissue inﬂammation
and induce pyroptosis, a process strongly regulated by inﬂammasomes. The
best-characterized inﬂammasome is NLRP3, whose activation allows the
recruitment of an adaptive ASC protein, which interacts with procaspase-1 and
activates caspase-1, the responsible for maturing pro-IL-1b and pro-IL-18 to
obtain biologically active forms. Parallel to this process, and as a consequence
of caspase activation, apoptosis can be induced too.
It has been also described that large number of miRNAs can bind to coding
mRNAs for proteins in the constituents of inﬂammasome. miR-146, has been
described as one of them.
Study design, size, duration: mRNA expression of NLRP3, ASC, and
Caspase-1 together with the expression of miR-146 were measured in oocyte-
granulose (CGs) complexes and in follicular liquid (FL) retrieved from 8 healthy
fertile oocyte donors (<35 y.o. with at least a previous cycle with pregnancy)
and compared with 8 low responders patients (<35 y.o. who had ≤ 5 oocytes
retrieved after gonadotropic stimulation) whom took part in a prospective
observational study realized from July 2016 to December 2017.
Participants/materials, setting, methods: Participants were stimulated
with the same protocol (FSHr and triggering with GnRH analogues). GCs and
FLs were collected and immediately fresh-frozen. The mRNA expression of
NLRP3, ASC and Caspase-1 was measured by qRT-PCR. Exosomes were
extracted by ultracentrifugation from FL and miR-146 was measured by qRT-
PCR. Relative changes in gene expression were calculated using the 2-ΔΔCT
method. No parametric tests were used to identify any signiﬁcant difference
between groups. Statistical signiﬁcance was set at p < 0.05.
Main results and the role of chance: Inﬂammasome constitutes a high
molecular weight signaling platform that leads to the activation of inﬂammatory cas-
pases. In our study, the mRNA expression of NLRP3, the best-characterized
inﬂammasome, was signiﬁcantly increased in patients with low ovarian response
compared to donors (p = 0.045). Also, the adaptive ASC protein, whom activation
depends on NLRP3, was signiﬁcantly increased in the patients group compared to
the donors one (p = 0.0005). At the same, caspase-1 was found increased in the
patients group compared to the donors one (p < 0.0001). The activation of
caspase-1 can induce the maturing of IL-1b, which has been observed to be
increased in patients with low ovarian response in previous studies from our group.
Although a large number of miRNAs can bind to coding mRNAs for proteins
in the constituents of inﬂammasome, miR-146 seems especially important
because in addition to control inﬂammasome, can also regulate inﬂammation
formation by interaction with RNA encoding for adaptive molecules. In our
study, the expression of miR-146 observed in the exosomes collected from FL
was signiﬁcantly reduced in patients with low ovarian response compared to
donors (p = 0.009).
Limitations, reasons for caution: The main limitation of this study was the
relatively small sample size. Further studies are needed to elucidate the molecu-
lar and cellular mechanisms underlying the relation between the inﬂammasomes
and the oxidative stress observed in relation with infertility as well as their bio-
logical role in follicular function and activity.
Wider implications of the ﬁndings: To observe signiﬁcant differences in
the activation of inﬂammasome in patients with low ovarian response suggests
that, in these patients, there is an inﬂammatory state that could diminish their
antioxidant defenses. These ﬁndings could open up to new therapeutic strat-
egies for the treatment of low ovarian reserve.
Trial registration number: This study received no external funding and
there were no competing interests.
O-248 Do female age and body weight help to identify women who
beneﬁt from individualised gonadotropin dosing in IVF? A secondary
analysis of the OPTIMIST study
H. Torrance1, J.A. Leijdekkers1, M.J.C. Eijkemans2,
S.C. Oudshoorn1, T.C. Van Tilborg1, C.A.M. Koks3, C.B. Lambalk4,
J.P. De Bruin5, K. Fleischer6, M.H. Mochtar7,
W.K.H. Kuchenbecker8, J.S.E. Laven9, B.W.J. Mol10,
F.J.M. Broekmans1, I. On behalf of the OPTIMIST study group
1University Medical Center Utrecht, Reproductive Medicine, Utrecht, The
Netherlands
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2University Medical Centre Utrecht- Utrecht University, Julius Centre for Health
Sciences and Primary Care, Utrecht, The Netherlands
3Maxima Medical Centre Veldhoven, Obstetrics and Gynaecology, Veldhoven, The
Netherlands
4VU University Medical Centre, Centre for Reproductive Medicine, Amsterdam, The
Netherlands
5Jeroen Bosch Hospital, Obstetrics and Gynaecology, ‘s Hertogenbosch, The
Netherlands
6Radboud University Medical Centre, Obstetrics and Gynaecology, Nijmegen, The
Netherlands
7Academic Medical Centre Amsterdam, Centre for Reproductive Medicine,
Amsterdam, The Netherlands
8Isala Clinics, Obstetrics and Gynaecology, Zwolle, The Netherlands
9Erasmus Medical Centre, Obstetrics and Gynaecology, Rotterdam, The Netherlands
10Monash University, Obstetrics and Gynaecology, Clayton, Australia
Study question: Can patient factors, including female age or body weight,
serve as markers to guide individualised gonadotropin dosing in IVF treatment?
Summary answer: In predicted hyper responders, there might be a role for
female age and body weight in identifying women that beneﬁt from a particular
dosing regimen.
What is known already: The OPTIMIST study was a multi-centre prospect-
ive cohort study with embedded randomised clinical trials in 1515 women start-
ing IVF treatment in the Netherlands between 2011 and 2014. This study
revealed that for women starting IVF treatment, no substantial differences exist
between individualised dosing based on the antral follicle count (AFC) (100-450
IU/day) and standard dosing (150 IU/day) in terms of cumulative live birth
rates (LBR). On basis of physiological concepts, female age and body weight
have been suggested as patient characteristics that might have a differential
impact on the effectiveness of individualised gonadotropin dosing.
Study design, size, duration: This was a secondary data-analysis of the
OPTIMIST randomised clinical trials, in which women were categorised in sub-
groups of predicted response according to their AFC, and then randomly allo-
cated to either a standard dose or an AFC based individualised gonadotropin
dose. The primary outcome of the OPTIMIST study was cumulative live birth,
of which the ongoing status was achieved within 18 months of follow-up.
Participants/materials, setting, methods: Logistic regression modelling
with interaction terms was used to investigate whether female age or body
weight interact with the treatment effect of individualised dosing. The primary
outcome was LBR after the ﬁrst complete treatment cycle, and secondary out-
comes were cumulative LBR, safety (deﬁned as any form of OHSS and/or pre-
ventive interventions) and observed response categories. All analysis were
performed separately for predicted poor (AFC < 8), low-normal (AFC 8-10)
and hyper responders (AFC > 15).
Main results and the role of chance: In the predicted hyper response
group (n = 521), a signiﬁcant interaction was found between female age and
the effect of individualised dosing on ﬁrst cycle LBR (p-value for interaction =
0.002). In women under 32 years of age, individualised dosing seemed to nega-
tively affect ﬁrst cycle LBR compared to standard dosing, whereas in women
above 32 years of age this effect was not present.
Also, in the predicted hyper response group, a signiﬁcant interaction was
observed between body weight and the effect of individualised dosing on safety
(p-value for interaction = 0.003). For women with a low body weight (from 50
to 55 kg) lowering the dose did not affect OHSS risks, whereas in women with
higher body weights individualised dosing seemed to reduce OHSS risks.
In the predicted poor (n = 234) and predicted low-normal response group
(n = 277), no signiﬁcant interactions were found between female age or body
weight and the effect of individualised dosing on the predeﬁned outcomes.
Limitations, reasons for caution: Due to the relatively small sample size of
the predicted poor and low-normal response group, the power to detect small
associations in these groups was limited. Lack of blinding in the original trial
might have introduced performance bias, such as selective cycle cancellation,
which could have inﬂuenced our ﬁndings.
Wider implications of the ﬁndings: These preliminary ﬁndings suggest that
for women with a predicted hyper response, female age and body weight could
be possible markers for dose selection in IVF treatment. However, as these
secondary analyses were exploratory and therefore hypothesis generating, con-
ﬁrmation of the validity in a new study is necessary.
Trial registration number: The OPTIMIST study was registered at the
ICMJE-recognized Dutch Trial Registry (www.trialregister.nl). Registration num-
ber: NTR2657.
O-249 The vaginal microbiome as predictor for in vitro
fertilization with or without intracytoplasmic sperm injection
outcome; a prospective study
R. Koedooder1, M. Singer2, D. Budding2, S. Schoenmakers1,
P. Savelkoul3, S. Morré3, J. Laven1
1Erasmus University Medical Centre, Gynaecology & Obstetrics, Rotterdam, The
Netherlands
2VU University Medical Centre, Medical Microbiology and Infection Control,
Amsterdam, The Netherlands
3Maastricht University Medical Centre, Medical Microbiology, Maastricht, The
Netherlands
Study question: Could we use the composition of the vaginal microbiome as
predictor for IVF/IVF-ICSI outcome?
Summary answer: Microbiome proﬁling with IS-pro enables correct predic-
tion of embryo implantation failure prior to an IVF/IVF-ICSI treatment with a
high predictive accuracy.
What is known already: In the last decade, research has shown that besides
the known predictive factors, as duration of subfertility, women’s age, body
mass index, also micro-organisms have a possible impact on assisted reproduc-
tion outcome. Micro-organisms together with their genetic information and the
milieu in which they interact is called the microbiome. One common genus that
habitats the vagina is the Lactobacillus. Studies have shown that the presence of
Lactobacillus during the ART has a positive impact on the outcome. However,
the potential role of using the microbiome as a predictor for outcome has not
been investigated yet.
Study design, size, duration: In a prospective study, we included 301
women from 8 different IVF centres in the Netherlands. These women were
included between June 2015 and March 2016. In total 192 of the 301 women
underwent an embryo transfer (ET) and had a sample that could be analysed.
Participants/materials, setting, methods: Participants were women who
were eligible for their ﬁrst IVF/IVF-ICSI attempt. These women provided a vagi-
nal swab prior to the IVF/IVF-ICSI treatment. Microbiome composition was
analysed with IS-pro. IS-pro is an eubacterial technique based on the detection
and categorisation of 16S-23S rRNA gene interspace regions with lengths that
are speciﬁc for each microbial species. The predictive accuracy of the compos-
ition of the vaginal microbiome for IVF/IVF-ICSI outcome was validated for the
fresh ET.
Main results and the role of chance: The vaginal microbiome of each par-
ticipant was assigned to a community state type based on the dominant micro-
bial species. A low percentage of Lactobacillus had a strong association with
embryo implantation failure. With a combined prediction model based on a
small number of microbial parameters, a subgroup of women (n = 34) who did
not become pregnant could be identiﬁed with a low chance of pregnancy fol-
lowing ET (sensitivity 26%, speciﬁcity 97%). This failure to implant was correctly
predicted in 32 out of 34 women based on the vaginal microbiome, resulting in
a predictive accuracy of 94%.
Limitations, reasons for caution: We analysed the vaginal microbiome to
determine the predictive accuracy of the microbiome for IVF/IVF-ICSI outcome
after the fresh ET. Follow up is needed to investigate whether the predictive
accuracy lasts for the consectutive frozen ETs that may be part of the IVF/IVF-
ICSI treatment.
Wider implications of the ﬁndings: Knowledge of their microbiome proﬁle
may enable couples to make a more balanced decision on whether to continue
with treatment or not. Hence, the unnecessary physical and emotional burden
of an IVF/IVF-ICSI treatment can be avoided.
Trial registration number:Not applicable.
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O-250 Endometrial injury in women with previous in vitro
fertilization and intra-cytoplasmic sperm injection failure: A
systematic review andmeta-analysis
Z. Qiaoli, N. Liu, Y. Liu
Beijing Obstetrics and Gynecology Hospital-Capital Medical University, Department
of Reproductive Medicine, Beijing, China
Study question: Dose endometrial injury (EI) in the cycle preceding ovarian
stimulation improve the pregnancy outcome in women with previous in vitro
fertilization ⁄ intra cytoplasmic sperm injection failure?
Summary answer: In the meta-analysis of published data, EI does not
improve the pregnancy outcome in women with previous unsuccessful IVF/
ICSI.
What is known already: The pregnancy outcome of endometrial injury in
patients with IVF/ICSI failure is still controversial.
Study design, size, duration: A systematic review and meta-analysis were
performed. Main search terms were those related to endometrial injury for the
pregnancy outcome in women with previous IVF/ICSI failure. The ﬁnal compu-
terized database search was performed on 11 october 2017. No language
restriction was placed on the published articles. Two authors independently
performed the literature screening, scrutinized articles of potential interest,
selected relevant studies and extracted data.
Participants/materials, setting, methods: A systematic review was per-
formed in PUBMED, EMBASE, CENTRAL, WEB of SCIENCE, and
CLINICALTRIALS. Overall, 11 randomized clinical trials with a total of 1013
subjects in the intervention group and 1019 subjects in the control fulﬁlled the
inclusion criteria. The dichotomous data for live birth rate, clinical pregnancy
rate and miscarriage rate were expressed as risk ratios with 95% conﬁdence
intervals and were combined in a meta-analysis using the random-effects model
or ﬁx-effects model.
Main results and the role of chance: Funnel plot reveals no evidence of
publication bias. Meta-analysis demonstrated that: live birth: RR = 1.19, 95% CI
0.91 to1.55; P = 0.21; 10 RCTs, 1917 women; I2 = 53%; moderate-quality evi-
dence. Clinical pregnancy rate: RR = 1.25, 95% CI 0.98 to1.60; P = 0.07; 10
RCTs, 1972 women; I2 = 59%; moderate-quality evidence. Sensitivity analysis
excluding the studies at high risk of other bias and subgroup analysis showed
similar estimates. Miscarriage: RR = 1.04, 95% CI 0.73 to 1.49; P = 0.83; 634
women; I2 = 0%; moderate-quality evidence.
Limitations, reasons for caution: Although the trials we included are
RCTs, there still 5 studies at high risk of other bias, 5 studies at unclear risk of
allocation concealment, and 2 study at unclear risk of reporting bias. Sensitivity
analysis excluding the 5 studies at high risk of bias revealed similar estimates.
Wider implications of the ﬁndings: The advantage of our systematic
review is that we only included RCTs, while the most trials included in the
meta-analysis before are non-randomized trials. More future RCTs trials on the
association between EI and pregnancy outcome of women with previous IVF/
ICSI failure are needed.
Trial registration number: not applicable.
O-251 The use of non-donor egg IVF with embryo selection by
morphology is efﬁcient for patients aged 40-43
F. Prados Mondéjar, G. Perez-Bermejo, V. Santos, I. Bruna
Hospital HM Montepríncipe, HM Fertility Center, Madrid, Spain
Study question: Can we counsel 40-43 years old female (AMA) patients to
consider non-donor IVF without selection by PGT-A as their ﬁrst option for
infertility treatment?
Summary answer: AMA patients have a lower than optimum but not negli-
gible 21% probability of delivery per IVF cycle with their own-oocytes and mor-
phological embryo selection.
What is known already: IVF clinics frequently recommend AMA patients to
avoid using their own eggs for the purpose of maximizing success rates.
Reimbursed IVF programs often reject treatment to older patients in order to
optimize the efﬁcient use of their resources. The high incidence of diagnosed
aneuploid embryos in older patients lead to the spread of strategies of routinely
selecting embryos by preimplantation genetic testing for aneuploidies (PGT-A)
in those patients. In conclusion, AMA patients are often derived to private
clinics, submitted to costly PGT-A treatments or advised to accept egg dona-
tion as preferred option in the ﬁrst place.
Study design, size, duration:We analyzed the cumulative (fresh and frozen)
delivery rate per oocyte retrieval of non-donor egg, no PGT-A IVF cycles. The
study group was composed of 424 oocyte retrievals carried out between 2007
and 2016 to women aged 40-43 and which produced 1729 cleaved embryos.
Patients aged 30 to 39 years treated during the same period were studied as
control groups: 30-34, Group A; 35-37, Group B; 38-39, Group C.
Participants/materials, setting, methods: Retrospective analysis of the
delivery rate of non-donor egg IVF cycles in our clinic. Cycles with total fertiliza-
tion failure were excluded. Embryos were selected either for fresh transfer or
cryopreservation at day 2-3 based on classical morphological evaluation. For
the calculation of embryo efﬁciency, the remaining frozen embryos were dis-
counted. Data from egg donation in the Spanish Registry 2015 were used for
comparison of the delivery rate.
Main results and the role of chance: Cumulative delivery rate per oocyte
retrieval was 21,2% for patients aged 40-43 (90/424). In Group A the rate
was 53,3% (519/973); in Group B: 44,5% (394/885); in Group C: 36,3%
(181/498). This means that the study group reached 40%, 48% and 58% of the
delivery rates of control groups A, B and C respectively.
The percentages of transferred embryos that resulted in a live baby born
were: 26,6% (648/2439) in Group A; 22,1% (470/2125) in Group B; 16,1%
(200/1245) in Group C and 10,1% (102/1013) in the study group.
The percentages of cleaved embryos obtained per cycle that resulted in a live
baby born (embryo efﬁciency of the cycles) were: 13,6% (648/4774) in Group
A; 11,9% (470/3966) in Group B; 9,0% (200/2217) in Group C and 6,3%
(102/1616) in the study group.
All differences were statistically signiﬁcant.
The 7 Spanish centers with better results in egg donation according to the
Spanish Registry achieved a 45,7% (501/1096) delivery rate per fresh embryo
transfer in recipients aged > = 40. In our study group, delivery rate per fresh
embryo transfer was 18,1% (70/386) this means 40% of the maximum obtained
with egg donation in same age recipients.
Limitations, reasons for caution: Retrospective observational study.
Lacking a direct comparison of results between egg donation and own oocytes,
the adequacy of the observed delivery rate in the study group was established
by comparison with other age groups and also by benchmarking against the
higher performance Spanish centers with egg donation IVF.
Wider implications of the ﬁndings: A 21,2% delivery rate makes advisable
for patients aged 40-43 to use their own oocytes without PGT-A selection as
ﬁrst option for IVF treatment as this means 40% of the delivery rate in our good
prognosis patients (aged 30-35) or after fresh-embryo transfer with egg-
donation in top-quality centers.
Trial registration number:Not applicable.
O-252 Autologous stem cell ovarian transplant (ASCOT), allowed
5 pregnancies in poor responders (PR) women
N. Pellicer De Castellvi1, S. Herráiz2, M. Romeu1, S. Mártinez1,
A. Buigues2, I. Gómez-Seguí3, J. Martínez4, A. Pellicer5
1Women´s Health Area, La Fe University Hospital, Valencia, Spain
2Fundación IVI, Reproductive Medicine Research Group, Valencia, Spain
3La Fe University Hospital, Hematology Department, Valencia, Spain
4La Fe University Hospital, Radiology Department, Valencia, Spain
5IVI Rome, Reproductive Medicine Research Group, Valencia, Spain
Study question: Can bone marrow (BM)- autologous stem cell ovarian trans-
plantation (ASCOT) improve the impaired ovarian reserve in poor responder
(PR) patients?
Summary answer: ASCOT improved ovarian reserve biomarkers in 81.3%
of aged PR patients. The number of MII-oocytes increased allowing ﬁve preg-
nancies although the low euploidy rate (16.1%).
What is known already: A number of gonadotropin stimulation protocols
have been tested for the clinical management of PR women; nevertheless none
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have been proved to be successful, due to the absence of stimulable antral
follicles.
Competent oocytes can be retrieved, even in women with premature ovar-
ian insufﬁciency (POI), after providing them with an appropriate growth-
supporting ovarian niche following several approaches. BM transplants in
patients with POI, due to chemotherapy or radiotherapy, recovers ovarian
function as demonstrated by several spontaneous pregnancies. BM-derived
stem cells (BMDSC) can reactivate to growth ovarian follicles through paracrine
events occurring in the ovarian niche, as described for other organs.
Study design, size, duration: This is a prospective pilot study developed at
La Fe University Hospital from 2014 – 2017 in which a total of 17 PR women,
according to the ESHRE criteria, were involved. The patients were ≤ 40 [SH1]
years old with 3–5 years of infertility and had[AP2] 24 previous IVF cycles as
PR.
BMDSC were injected in one ovary by intra-arterial catheterization, there-
fore the contralateral ovary served as the control.
Participants/materials, setting, methods: G-CSF was subcutaneously
administered to mobilize BMDSC into peripheral blood. Stem cells were iso-
lated on the ﬁfth day by aphaeresis. Cellular populations and growth factors
related to follicular growth were also determined in aphaeresis.
Intra-arterial catheterization was performed into one utero-ovarian artery,
delivering 50 × 106 non-selected CD133+ cells. After ASCOT, serum AMH
and antral follicular count (AFC) were recorded for up to 5 months. COS
started on the 2nd menstrual cycle day after AFC increase.
Main results and the role of chance: Ovarian reserve biomarkers
enhanced in 81.3% patients. Several patients displayed the AFC increase in both
the treated and control ovary. Presence of circulating FGF-2 and THSP-1 posi-
tively correlated with both AMH and AFC parameters.
ASCOT promoted an increase in total AFC, compared to baseline, from day
2 to 43 after ASCOT, specially on Day 15 (p = 0.031). Some patients also had
an important AMH rise during the ﬁrst 4 weeks.
In the previous 24 COS initiated by 15 PR, a total of 35 MII-oocytes and 24
embryos were obtained; 13 of them were considered as good quality
embryos by morphological criteria and transferred but pregnancy was not
achieved.
After ASCOT, 28 COS cycles were initiated but only 4 in optimal condi-
tions. Ovum pick-up was performed in 85.7% initiated COS, embryos
obtained in 67.8%, and cancellation rate reduced compared to previous
attempts (14.2 vs. 29%. Fifty-one MII were retrieved and 35 embryos
obtained after ICSI (fertilization rate 75.4%) but only 16.1% were euploid.
Five pregnancies were achieved, 2 by ET (1miscarriage) and 3 were spontan-
eous (1ongoing).
When IVF outcomes were compared with previous cycles, the number of
antral follicles (p = 0.001), punctured follicles (p < 0.01) and MII (p < 0.01)
increased after ASCOT.
Limitations, reasons for caution: A pilot study, in which COS and ovum
pick up was not performed in the most favorable conditions. There were con-
founding variables such as the fact that these women do have antral follicles,
and a small increase might not be detected. The ideal population might be
women with POI.
Wider implications of the ﬁndings: ASCOT in PR women may have few
applications, but this study has shown a potential use in POI women. The ﬁnd-
ing of a correlation between certain growth factors and outcomes suggests
potential development of less invasive procedures in the future.
Trial registration number:NCT02240342
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O-253 Relationship between uterine natural killer (uNK) cells
percentage and chronic endometritis in women with recurrent
miscarriage
Y. Zhao, X. Chen, Y. Liu,W.C. Cheung, C.C.Wang, T.C. Li
The Chinese University of Hong Kong, Department of Obstetrics and Gynaecology-
Faculty of Medicine, Shatin, Hong Kong
Study question: Is there any signiﬁcant correlation between uterine natural
killer (uNK) cells count and chronic endometritis in women with recurrent
miscarriage?
Summary answer: A signiﬁcantly (p < 0.01) increased prevalence of chronic
endometritis was observed in high uNK cells group, compared to normal and
low uNK cells groups.
What is known already: Our previous work showed an altered number of
uNK cells in peri-implantation endometrium of women with recurrent miscar-
riage. In addition, chronic endometritis was reported to be associated with
reproductive failure. However, there has not been any study examining the
relationship between uNK cells count and chronic endometritis in recurrent
miscarriage.
Study design, size, duration: It was a retrospective study carried out in a
university center. A total of 102 women with unexplained recurrent miscarriage
were included in this study.
Participants/materials, setting, methods: Endometrial biopsies were
obtained precisely 7 days after luteinization hormone surge in natural cycles.
Endometrial sections were immunostained for CD56 for uNK cells and CD138
for plasma cells, respectively. UNK cell counting was performed by a standar-
dized protocol (Lash et al., 2016) and results were expressed as percentage of
positive uNK cell/ total stromal cells. Chronic endometritis was diagnosed as
the presence > 5.15 plasma cells/0.1mm2 based on our recent work (Liu et al.,
2018).
Main results and the role of chance: Based on our published reference
range for uNK cells percentage, 21 women were classiﬁed into high uNK group,
while 62 women in normal uNK group and 19 women in low uNK group. The
prevalence of chronic endometritis was 8/21(38.1%), 5/62(8.1%), 1/19(5.3%)
in high, normal and low uNK cells percentage group, respectively. A signiﬁcantly
(p < 0.01) increased prevalence of chronic endometritis was observed in high
uNK cells group, when compared with normal and low uNK cells groups.
Limitations, reasons for caution: The role of other immune cells in the
peri-implantation endometrium has yet to be conﬁrmed.
Wider implications of the ﬁndings: Observations on the relationship
between uNK cells and chronic endometritis may improve the understanding of
mechanisms in endometrial immune cells leading to endometrial dysfunction in
recurrent miscarriage.
Trial registration number:N/A.
Funding by the Health and Medical Research Fund in Hong Kong (No.
04152786) and Hong Kong Obstetrical and Gynaecological Trust Fund in 2017.
O-254 Anti-Müllerian Hormone does not predict chance of live
birth in 565 women with recurrent pregnancy loss
S. Bliddal1, U. Feldt-Rasmussen1, A.M. Kolte2, C.H. Nielsen3,
O.B. Christiansen2, L. Hilsted4, E.C. Larsen2, H.S. Nielsen2
1Copenhagen University Hospital Rigshospitalet, Department of Medical
Endocrinology, Copenhagen, Denmark
2Copenhagen University Hospital Rigshospitalet, Recurrent Pregnancy Loss Unit,
Copenhagen, Denmark
3Copenhagen University Hospital Rigshospitalet, Institute for Inﬂammation Research,
Copenhagen, Denmark
4Copenhagen University Hospital Rigshospitalet, Department of Clinical Biochemistry,
Copenhagen, Denmark
Study question: Do low levels of anti-Müllerian hormone (AMH) predict live
birth rate in women with unexplained recurrent pregnancy loss (RPL)?
Summary answer: In women with unexplained RPL, low AMH levels did not
reduce the chance of live birth in the ﬁrst pregnancy achieved after referral.
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What is known already: Recurrent pregnancy loss affects 2% of all women
and in most of these women no explanation can be identiﬁed. In women with
RPL compared to infertile women, previous studies have shown a similar inci-
dence of diminished ovarian reserve as assessed by FSH and estradiol levels.
AMH is cycle day independent and is currently debated as not only a marker of
egg reserve quantity, but also quality. With increasing age, AMH levels
decreases, while the pregnancy loss rate increases. Little is known about AMH-
levels in women with recurrent pregnancy loss.
Study design, size, duration: Cohort study of 565 women with RPL fol-
lowed at the tertiary referral center, RPL Unit, Copenhagen University Hospital
(Rigshospitalet), from 2011-2014.
Participants/materials, setting, methods: All women attending the RPL
unit from 2011-2014. RPL≥3 consecutive losses. AMH drawn more than one
year from referral to the RPL unit were excluded. AMH-levels were measured
with ELISA Generation I (Beckman Coulter, Marseilles, France). According to
our clinical cut-off, low AMH was deﬁned as ≤5 pmol/L. Regression analyses
were adjusted for age, previous number of losses, and smoking status.
Main results and the role of chance: A total of 565 women with RPL had
attended the unit, of which 478 (84.6%) had a measurement of AMH-levels.
Median AMH-levels were 17.5 (interquartile range (IQR), 9.0-30) and AMH
levels were below 5 pmol/L in 55 (11.5%) women. In total 355 (74.3%) women
had a ﬁrst pregnancy after referral. These women did not differ from the
women who did not conceive in terms of median AMH-level (19 pmol/L vs. 16
pmol/L, Mann-Whitney U p = 0.44) or proportion of women with low AMH
(10.7% vs 13.8%, p = 0.41). In women with unexplained RPL, 301 had singleton
intrauterine pregnancies with a last menstrual period of more than nine months
before data extraction. In the 28 women with a low AMH level, live birth rate
was 50% compared to 60.8% in women with an AMH level above 5 pmol/L
(p = 0.31). Having a low AMH level was not a predictor for live birth in adjusted
analyses (adjusted odds ratio (aOR) 0.7 95% conﬁdence interval (CI);0.2-1.8, p
= 0.39). Median AMH level was 20 pmol/L in women who gave live birth com-
pared to 19 pmol/L in those who did not (Mann-Whitney U, p = 0.89). AMH
levels did not predict live birth (aOR 1.0 95%CI:0.88-1.12, p = 0.95).
Limitations, reasons for caution: Although this study to our knowledge is
the largest to date in women with RPL, there may be a lack of power in calcula-
tions of association between live birth rate and AMH levels.
Wider implications of the ﬁndings: AMH levels can serve as a clinical guid-
ance to the chance of achieving pregnancy. However, women with unexplained
recurrent pregnancy loss can be reassured that the chance of live birth in case
of an achieved pregnancy is similar to that of women with normal AMH levels.
Trial registration number:Not applicable.
O-255 The oestro-androgen dehydroepiandrosterone sulphate
(DHEAS) may be a critical intracrine regulator of implantation and
early pregnancy in Eumenorrhic non-PCOS women undergoing
N. Chimote1, B. Chimote2
1Vaunshdhara Clinic & Assisted Conception Centre, Embryology & Reproductive
Endocrinology, Nagpur, India
2Vaunshdhara Clinic and Assisted Conception Centre, Clinical Embryology-
Reproductive Endocrinology, Nagpur, India
Study question: To evaluate the signiﬁcance of endogenous levels of circulat-
ing DHEAS during implantation in predicting implantation failure/early miscar-
riage in eumenorrhic non-PCOS women undergoing IVF.
Summary answer: Maintenance of a steady/balanced rise in serum DHEAS
levels is an early indicator of successful implantation and predicts implantation-
failure/early miscarriage in eumenorrhic women undergoing IVF.
What is known already: Decidualization of endometrial-stroma is necessary
for successful implantation; which if improper, may lead to implantation-failure/
early pregnancy loss. Elevated levels of DHEA are a causative factor for higher
incidences of implantation-failure among PCOS women by inhibiting
endometrial-stromal cell differentiation via prevention of glucose-ﬂux through
the pentose-phosphate-pathway. Contrarily, low DHEA women with dimin-
ished ovarian-reserve, when supplemented with DHEA show signiﬁcant reduc-
tion in early miscarriage rates. Sulphonated-DHEA (DHEAS) is more stable
than DHEA, a major oestro-androgen and most abundant circulating steroid
precursor for estrogen production in humans. However, no study has yet evalu-
ated signiﬁcance of innate DHEAS during implantation in eumenorrhic non-
PCOS women.
Study design, size, duration: Prospective pilot study of n = 85 non-PCOS
eumenorrhic, normo-responder women undergoing conventional antagonist
stimulation protocol IVF from March 2016 to March 2017. Poor-responder/
premature ovarian failure and hyper-androgenic PCOS women (deﬁned as per
Rotterdam consensus) were excluded from the study. All cycles involved day5
fresh, elective single blastocyst transfer (eSBT). Luteal phase support was pro-
vided to all women. Serum DHEAS levels in baseline as well as day7 and day14
post-eSBT were measured by radio-immuno-assay using diagnostic kits.
Participants/materials, setting, methods: Serum estradiol, β-hCG and
progesterone levels were also measured on day7/day14 post-eSBT. β-hCG
measurement on d7 of eSBT was considered early indicator of pregnancy.
Implantation rate and live birth rate were main outcome measures. Cycles
were classiﬁed on the basis of live birth (LB, n = 33), biochemical pregnancy
(BCP, n = 3), early miscarriage (EM, n = 2) and no implantation (NI, n = 47).
Statistical analysis involved Student’s-t test, One-Way ANOVA, ROC analysis,
as applicable, using Graph-pad Prism VI software.
Main results and the role of chance: Overall rates of LB, BCP, EM and NI
were found to be 38.82%, 3.53%, 2.35% and 55.29% respectively. DHEAS
levels depicted a steady rise from baseline to d7 to d14 post-eSBT in women
with LB (165 ± 11.01 vs. 390.3 ± 40.26 vs. 737.9 ± 59.47 respectively).
Although a rising trend was also observed in women with EM, the rise from
baseline to d7 post-eSBT was rather steep (68.5 ± 3.5 vs. 247.5 ± 7.5 vs. 255
± 10). However, the rising pattern was disrupted in BCP cycles where the levels
dropped from baseline to d7 and then increased on d14 post-eSBT (211.7 ±
31.67 vs. 120 ± 5.8 vs. 258.3 ± 10.14); and in NI cycles where a sharp rise on
d7 was followed by a decrease in levels on d14 post-eSBT (201.1 ± 13.95 vs.
1321 ± 134 vs. 791.7 ± 103.4). A signiﬁcant difference in the ratio of d7: base-
line DHEAS levels was observed in LB vs. BCP vs. EM vs. NI cycles (2.59 vs.
0.61 vs. 3.61 vs. 9.65; p = 0.0005). Similarly, the ratio of d14:d7 DHEAS levels
differed signiﬁcantly in LB vs. BCP vs. EM vs. NI cycles (2.23 vs. 2.16 vs. 1.03 vs.
0.8; p < 0.0001). Thus, a twofold rise in DHEAS levels from baseline to d7 and
d7 to d14 is critical for successful implantation leading to a live-birth.
Limitations, reasons for caution: This prospective pilot study signiﬁcantly
implicates endogenously circulating levels of DHEAS in the implantation process
and as a differentiating factor for various categories of implantation. Although
our study has a power of 80%, more systematic studies/RCTs are required to
establish DHEAS as an efﬁcient and robust predictor of implantation.
Wider implications of the ﬁndings: Although the role of various androgens
during pregnancy have been studied, their signiﬁcance in the implantation pro-
cess have received less scrutiny. Previous contradictory results with DHEAS
have been largely due to improper selection of patient populations. This study
underlines the signiﬁcance of optimum levels of endogenous DHEAS for suc-
cessful implantation.
Trial registration number:Not Applicable.
O-256 Endometrial proteomic signature in recurrent implantation
failure
M. Dogan1, I. Demiral2, E. Akgun3, E. Ulgen4, B. Gurel3, B. Sahin3,
A. Nehir Aytan2, B. Yuksel Ozgor2, A.T. Baykal3, U. Sezerman4,
E. Bastu1, F. Buyru1
1Acibadem University School of Medicine, Obstetrics and Gynecology, Istanbul,
Turkey
2Istanbul University School of Medicine, Obstetrics and Gynecology, Istanbul, Turkey
3Acibadem University School of Medicine, Medical Biochemistry, Istanbul, Turkey
4Acibadem University School of Medicine, Biostatistics and Medical Informatics,
Istanbul, Turkey
Study question: How endometrial proteomic proﬁle in patients with recur-
rent implantation failure (RIF) differ from fertile controls?
Summary answer: 6 pathways based on proteomics proﬁle are found to be
different in RIF patients compared to fertile patients.
What is known already: Endometrial changes are important for the develop-
ment of adequate endometrial receptivity and subsequent embryo
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implantation. Recently, mitochondria have been found to play a vital role in fer-
tilization and implantation. It provides ATP to the oocyte for embryo develop-
ment, it affects endometrial receptivity by altering the energy metabolism in the
endometrium. Some studies about Coenzyme Q10 supplement in infertility and
total parenteral nutrition in patients with RIF patients showing good results may
be based on mitochondria’s effect.
Study design, size, duration: For this prospective cohort study, RIF was
deﬁned as failure of pregnancy in ≥ 3 consecutive IVF cycles with ≥1 transfer(s)
of good quality embryo in each cycle. Women with ≥1 live birth(s) and no
other comorbidities were included in the fertile control group. 24 patients were
included in each groups, all 48 patients were recruited during August 2014-
2015.
Participants/materials, setting, methods: From 48 patients recruited in
Istanbul University School of Medicine, endometrial samples were taken during
mid-secretory phase, stored in -80°C following snap freezing with liquid nitro-
gen. Once all tissues were obtained, a LC-MSE-based analyzes of peptides by
mass spectrometry were performed. Protein expression differences were cal-
culated with Gene Ontology enrichment analysis and DAVID functional annota-
tion bioinformatics microarray analysis.
Main results and the role of chance: From 274 proteins found in different
expression in patients with RIF compared to fertile patients, 6 representative
pathways were outlined: pathways in carbon metabolism (p value = 1.63E-06),
pathways in citrate cycle (TCA cycle) (p value = 5,07E-05), spliceosome meta-
bolism (p value = 2,28E-04), protein processing in endoplasmic reticulum (p
values = 3,08E-05), biosynthesis of antibiotics pathway (p values = 6,649E-06)
and ribosome pathway (p value = 2,47E-06).
Limitations, reasons for caution: Endometrial samples were not taken on
the same exact menstrual day for all patients. We chose to be between day 19-
21.
Wider implications of the ﬁndings: Our results revealed a disturbance in
energy metabolism in endometria of patients with RIF. In conjunction with pre-
vious reports, the failure of pregnancy despite good embryos and endometrium
may lie in a lack of appropriate energy that would have supported an implanting
blastocyst and subsequent progression to a viable pregnancy.
Trial registration number: This research received funding from the
Scientiﬁc Research Projects Coordination Unit of Istanbul University (grant no.
47795).
O-257 CRISPR/Cas9 genome editing to reveal the effect of
implantation related genes on speciﬁc cell types which contribute to
implantation process in human andmousemodels
G.N. Sahin1, S. Karahuseyinoglu2, A.C. Taskın3
1koc university graduate of medicine, medicine, istanbul, Turkey
2Koç University School Of Medicine, Histology & Embryology, Istanbul, Turkey
3Koç University Research Center for Translational Medicine, Animal Research
Facilities, Istanbul, Turkey
Study question: Can we manage to reveal the effects of silencing a single
implantation related gene on different cell populations functionally related to
implantation process?
Summary answer: Silencing of one gene in isolated cell populations can be
achieved and the effect can be evaluated successfully in mouse and human 3D
implantation models.
What is known already: Despite all developments in ART, implantation fail-
ure is considerably high due to unexplained molecular, genetic and morpho-
logical interactions affecting the crosstalk between endometrium and embryo.
Complicated nature of this phenomenon still remains obscure as a result of
experimental methods that never can be performed effectively to reveal the
biological functions speciﬁc for each cell type which participates in implantation
process. To interfere with cellular functions, CRISPR/Cas9 genome editing
technology has been shown to be applicable in a wide spectrum of cells, includ-
ing cells of the developing embryo. Same technology can be used to detect and
manipulate molecular interactions of implantation.
Study design, size, duration: Being expressed by both blastocyst and endo-
metrial cells, LIF was chosen to be silenced separately via transfection in mouse
blastocyst, human cell-line derived trophoblastic spheroids and stromal and
epithelial cells of human and mouse endometrium. Three-dimensional culture
was maintained on extracellular matrix(ECM) based gel systems for 48 hours
and implantation parameters related to adherence, invasion and function were
evaluated quantitatively by student’s t test in wild and mutant groups(n = 24/
each group, a total of 192 samples).
Participants/materials, setting, methods: Human and mouse epithelial
and stromal cells were isolated separately. The experimental groups (n = 24
samples/group; 2 blastocysts-spheroids/sample) for human and mouse cells
separately were: i.mutant(gene-edited) epithelia+wild type(wt) stroma +wt
blastocyst/spheroid, ii.wt epithelia+mutant stroma+ wt blastocyst/spheroid,iii.
wt epithelia+wt stroma+mutant blastocyst/spheroid,iv. wt epithelia+wt stro-
ma+wt blastocyst/spheroid. Three-dimensional culture was engaging epithelial
cells onto and stromal cells into the ECM based gel-system. After 48 hours,
implantation parameters (e-cadherin,MMP9, progesterone receptor,invasion
depth) were evaluated by qRTPCR(triple-repeats), WB and IF-multiphoton
microscopy.
Main results and the role of chance:
i. Both mouse and human control groups composed of wild type cells showed
decrease in e-cadherin, increase in MMP9 and PR after 48 hours of culture,
where results with mouse blastocysts were more signiﬁcant (p < 0.05).
Blastocysts showed a better penetration. Survival and implantation parameters
were in acceptable ranges in both control groups, implicating that 3D culture
was efﬁcient enough for this experimental model.
ii. LIF was successfully knocked out in all mutant cells as shown by its absence by
qRTPCR (p < 0.01). In blastocysts trophoblastic cells were silenced more
effectively than ICM, as expected due to transfection.
iii. When mutant groups were compared, implantation parameters were signiﬁ-
cantly affected most in groups with blastocysts/spheroids (p < 0.05) in both
human and mouse; so LIF can be accepted as primarily working through the
embryonic site rather than the endometrial site.
iv. Separate silencing of LIF in epithelial and stromal cells of mouse resulted in
differences regarding implantation parameters, as a deeper decrease of expres-
sion in MMP9 and PR was observed with silenced epithelial cells. Although sig-
niﬁcance was less (p > 0.05), still it shows the behavioral differences between
two cell types. In human however, silencing of stromal cells had a more dra-
matic effect (p > 0.05) on implantation parameters.
Limitations, reasons for caution:
(i) Use of in vitro 3D culture, since a culture totally mimicking in vivo condi-
tions wasn’t maintained.
(ii) Use of human spheroids instead of human blastocysts, since spheroids are
of trophoblastic cells only, ICM effect was not tested in human groups, while
it was taken into account for mouse model.
Wider implications of the ﬁndings:
(i) CRISPR/Cas9 genome editing technology can be utilized for all known
implantation related genes to reveal the cell speciﬁc effects of these genes
during implantation process.
(ii) ECM gel based three-dimensional endometrial co-cultures created for
human and mouse implantation models are successful enough to run
implantation experiments.
Trial registration number: not.
O-258 T helper 1 cell level is associated with reproductive
outcome of women with repeated implantation failures who
received Tacrolimus treatment
K. Nakagawa1, J. Kwak-KIm2, A. Moriyama1, K. Nakao1,
R. Sugiyama1, T. Horikawa1, S. Takamizawa1, K. Kuroda1,
R. Sugiyama1, K. Yamaguchi3
1Sugiyama Clinic Shinjuku, Center for Reproductive Medicine, Tokyo, Japan
2Chicago Medical School at Rosalind Franklin University of Medicine and Science,
Reproductive Medicine- Department of Obstetrics and Gynecology, Chicago, U.S.A.
3National Center for Child Health and Development, Department of Maternal-Fetal
Biology, Tokyo, Japan
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Study question: Is the peripheral blood T helper (Th) 1 cytokine producing
cell level associated with the ongoing pregnancy rate in the repeated implant-
ation failure (RIF) patients treated with tacrolimus?
Summary answer:Women with RIF and increased Th1 cell levels had lower
ongoing pregnancy rate even though they were treated with low dose
tacrolimus.
What is known already: The peripheral blood Th1 and Th2 cells determine
immune inﬂammatory responses at the maternal fetal interface. Previously, we
reported that women with RIF had elevated Th1/Th2 cell ratio. When they
were treated with tacrolimus, immunosuppressive agent, pregnancy rate was
signiﬁcantly improved (Am J Reprod Immunol 2015).
Study design, size, duration: This is a prospective cohort study of 140 RIF
women with elevated Th1/Th2 (CD4+IFN-γ+/ CD4+IL-4+) cell ratios (≥10.3)
from November 2011 to July 2017. All received tacrolimus 1-3 mg per day
based in Th1/Th2 cell ratios. Study populations were grouped according to the
Th1 cell levels; Th1 cell levels <22.8 (Low group), Th1 cell levels
22.8≤Th1<28.8 (Mid group), and Th1 cell levels 28.8≤Th1 (High group).
Participants/materials, setting, methods: All patients received tacroli-
mus, starting 2 days before the ET to the day of pregnancy test. The daily dose
of tacrolimus was depended on the Th1/Th2 ratio as follows; patients with a
mild (≥10.3 and <13.0), moderate (>13.0 and <15.8), and high levels of Th1/
Th2 ratio (>15.8) were treated with 1, 2, and 3 mg of tacrolimus, respectively.
The clinical and ongoing pregnancy rates and miscarriage rates were compared
among three groups.
Main results and the role of chance: Out of 140 patients, 65 women got
pregnant (pregnancy rate, 46.4%). In the pregnant group, 59 women eventually
had a clinical pregnancy, which was documented by the detection of gestational
sac using ultrasound (clinical pregnancy rate, 42.1%). Forty-two patients deliv-
ered healthy babies and 8 are ongoing pregnancy (Ongoing pregnancy/delivery
rate, 35.1%).
The Th1/Th2 cell ratio for the high Th1 group was 18.1 ± 9.0, and this was
signiﬁcantly higher than that in the Low Th1 group (14.5 ± 4.4; p < 0.05). The
pregnancy rates for the Low, Mid and High Th1 groups were 55.3, 46.8, and
37.0 %, respectively, and there were no signiﬁcant differences among the three
groups. The clinical pregnancy rates for the Low, Mid and High Th1 groups
were 48.9%, 44.7%, and 32.6% respectively. The clinical pregnancy rate of the
High Th1 group was lower than those of the Low and Mid Th1 groups, however
the difference was not signiﬁcant. The ongoing pregnancy rate (≥12 weeks ges-
tation) of the Low Th1 group was 46.8%, which was signiﬁcantly higher than
that of the High Th1 group (23.9%, p < 0.05) but not different from that of the
Mid Th1 group (36.2%).
Limitations, reasons for caution: The endometrial changes or peripheral
immune responses after tacrolimus treatment were not evaluated thoroughly.
Further study is needed for tacrolimus effect on both systematic immune
responses and local changes on the uterine endometrium.
Wider implications of the ﬁndings: Adjustment of tacrolimus dosing based
on Th1 cell level may improve clinical efﬁcacy of the treatment. The study is
ongoing, which increases the tacrolimus dose (additional 1 mg) for the patients
who have high Th1 cell level.
Trial registration number:N/A.
O-259 Couples’ perspectives on their need for treatment, support
and follow-up after recurrent pregnancy loss
L. Schmidt1, E. Koert2, G.M.H. Malling1, R. Sylvest3, M.C. Krog2,
A.M. Kolte2, H.S. Nielsen2
1University of Copenhagen, Department of Public Health- Section of Social Medicine,
Copenhagen K, Denmark
2Copenhagen University Hospital- Rigshospitalet, Recurrent Pregnancy Loss Unit-
Fertility Clinic, Copenhagen, Denmark
3Copenhagen University Hospital- Hvidovre, Dept. of Obstetrics and Gynaecology,
Hvidovre, Denmark
Study question:What do couples attending a recurrent pregnancy loss (RPL)
clinic believe they need in terms of treatment, support and follow-up after RPL?
Summary answer: Men and women wish for treatment, support and follow-
up that includes attention to the psychological impact of RPL and includes both
members of the couple.
What is known already: Previous research has highlighted women’s dissatis-
faction with medical care provided post-pregnancy loss (PL) and their desire for
medical professionals to have increased awareness about PL and recognition of
the psychological impact of PL. Less is known about the needs of the male part-
ner, the needs of those experiencing RPL (three or more PL) and if needs
change depending on whether it is the ﬁrst or one of several losses.
Study design, size, duration: This was a qualitative study. Over a two-
month period in 2017-2018, 13 couples who were referred to the RPL program
in Rigshospitalet, Copenhagen, Denmark were interviewed. Interviews were
held at the Rigshospitalet and ranged between 81 and 109 minutes (average
91 minutes).
Participants/materials, setting, methods: Inclusion criteria included: het-
erosexual couples with at least three consecutive PL under 12 weeks gestation
with no children/one child who were willing to be interviewed in English.
Couples were interviewed together in a semi-structured format. Data was ana-
lyzed using thematic analysis.
Thirty invitations were sent to couples who met the inclusion criteria and
indicated an interest in participating and 15 couples contacted the interviewer
to schedule an interview. Due to cancellations, 13 interviews were held.
Main results and the role of chance: On average participants had experi-
enced three PL (range 3-6) and had been on the waiting list for the RPL pro-
gram for six months (range 3-9).
Both men and women described the cumulative effect of RPL with a decrease
in hope and increase in pressure and exhaustion in the third and subsequent
losses. With each PL their dream of having a child felt further from their reach
and they felt a growing sense of dread they would not become parents or not
have the family they pictured. Referral to the RPL clinic often resulted in an
increase in hope. Inclusion of the male partner in consultations and treatment
was seen as important. Couples emphasized medical professionals should rec-
ognize that “every loss counts” when recommending and providing treatment
and comments such as “It’s nature’s way” are unhelpful, given it invalidates their
sense of loss.
Data showed that couples desired reliable and accurate information about
RPL (e.g., common physical/ emotional responses, treatment options). They
desired recognition from the medical community that RPL is not only a physical
experience, but has a signiﬁcant psychological impact as well, and stressed that
effective treatment should include attention to both physical and psychological
aspects of the RPL.
Limitations, reasons for caution: Data was collected until saturation to
enhance the trustworthiness of the ﬁndings. Participants were self-selected thus
ﬁndings cannot be generalized to all couples who have experienced RPL. Single
women and same-sex partners were not included in the study.
Wider implications of the ﬁndings: The ﬁndings suggest that medical pro-
fessionals need to take a holistic approach in their treatment of RPL and include
attention to the psychological impact and cumulative effect of the PL on both
men and women. The results underscore the need for informational resources
psychological support for couples experiencing RPL.
Trial registration number:Not applicable
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O-260 Improved embryo selection: a novel approach for
simultaneous genomic and transcriptomic analysis from a single
trophectoderm (TE) biopsy
N. FuchsWeizman1, B.Wyse2, R. Antes2, Z. Ibarrientos2,
M. Sangaralingam2, V. Kuznyetsov2, S. Madjunkova2, C. Librach2,3,4,5
1University of Toro, OBGYN, Toron, Canada
2CReATe Fertility Centre, Research, Toronto, Canada
3Women’s College Hospital, Department of Gynecology, Toronto, Canada
4University of Toronto, Department of Physiology, Toronto, Canada
5University of Toronto, Department of Obstetrics and Gynecology, Toronto, Canada
Study question: Can RNA and DNA be sequenced simultaneously from the
same trophectoderm biopsy, and be an addition to the clinical preimplantation
genetic screening (PGS)?
Summary answer: The addition of full RNA sequencing to standard PGS did
not alter the quality of the genomic data produced and yielded high-quality
RNA sequencing data.
What is known already: With elective single embryo transfer (eSET)
becoming the leading strategy to avoid multiple gestations, improved embryo
selection is key. PGS reduces time to pregnancy and helps avoid miscarriages,
but it cannot predict the implantation potential of a euploid embryo. Previous
studies attempting to identify genes which are crucial for implantation and fetal
development did not control for ploidy, due to the lack of methods to evaluate
both together. To accurately interrogate the transcriptome, the ability to simul-
taneously sequence DNA and RNA from the same trophectoderm (TE) biopsy,
without impacting the clinical PGS efﬁciency, would be a signiﬁcant advance.
Study design, size, duration: After institutional REB approval, 24 embryos
were collected from consented patients undergoing IVF-ICSI treatment at the
CReATe Fertility Centre. The ﬁrst 3 embryos were used for the initial develop-
ment and optimization of sample processing and sequencing. Thereafter, 21
embryos (3 trisomy-16, 5 monosomy-16, 3 Turner (X0), and 10 euploid, har-
boring a genetic mutation per PGD) were used to demonstrate the clinical
safety and reproducibility.
Participants/materials, setting, methods: Two TE biopsies were taken
from each embryo. The ﬁrst was processed as a clinical sample destined for
PGS only. The second TE biopsy was lysed and split into two fractions: 1) for
genomic analysis with next generation sequencing (NGS) and 2) for transcrip-
tomic analysis. gDNA was ampliﬁed (SurePlex), libraries constructed (VeriSeq),
sequenced on a MiSeq, and analyzed using BlueFuse Multi. RNA was sequenced
on a NextSeq and analyzed using a custom-built pipeline.
Main results and the role of chance: The DNA fraction from both TE
biopsies from each embryo was sequenced using a validated clinical NGS work-
ﬂow and determined ‘clinically acceptable” when the quality control (QC)
metrics met/exceeded the Illumina guidelines (reads post-ﬁltering>250,000
and Noise (DLR) < 0.4). There was no statistical difference in NGS QC
between control and split samples. All split samples met or exceeded this cri-
teria with average post-ﬁltered reads of 559,769 ± 31,121 and DLR of 0.20 ±
0.005. The concordance between PGS results obtained from split and control
samples was 100%, underlining the reliability and safety of our method. High-
quality cDNA and libraries were obtained from all split samples. This yielded
sufﬁcient sequencing data that, after ﬁltering, met/exceeded QC metrics (aver-
age reads 21,563,094 ± 1,636,245; average depth 26.7 ± 3.5; average quality
33.5 ± 0.03) to perform principal component analysis (PCA) and differential
expression (DE). All TE biopsies expressed several speciﬁc TE markers includ-
ing CDX2, GATA2, and TGFBR3, further validating the accuracy of our meth-
od. Using PCA, the samples clearly clustered in euploid and aneuploid
aggregates, highlighting the importance of controlling for ploidy. Euploid
embryos showed downregulation of genes involved in anaerobic metabolism,
oxidative phosphorylation, and fatty-acid oxidation.
Limitations, reasons for caution: This pilot study assessed the feasibility
and safety of adding transcriptomic analysis to the clinical workﬂow of PGS. As
such, clinical outcomes were not collected, impeding our ability to validate the
implications of our ﬁndings. Future clinical trials will be required to correlate
transcriptomic data with outcomes.
Wider implications of the ﬁndings: This is the ﬁrst study to provide full
genomic and transcriptomic proﬁles of a single TE biopsy from human embryos.
The addition of RNAseq did not affect the quality of gDNA or actual results of
PGS. This method has the potential of improving embryo selection in IVF.
Trial registration number: not applicable.
O-261 Pre-implantation genetic screening (PGS) of in vivo
conceived and developed blastocysts recovered by lavage:
Preliminary experience
S. Munne1,2, S. Najmabadi3,4, S. Nakajima5, M.V. Sauer6,
T. Escudero1, J.E. Buster7
1CooperGenomics, Research & Development, Livingston- New Jersey, U.S.A.
2Overture Life, Research & Development, New York, U.S.A.
3Center for Reproductive Health and Gynecology, Reproductive Health and
Gynecology, Punta Mita, Mexico
4Center for Reproductive Health and Gynecology, Reproductive Health and
Gynecology, Beverly Hills, U.S.A.
5Stanford University School of Medicine, Department of Obstetrics and Gynecology,
Stanford, U.S.A.
6Robert Wood Johnson Medical School- Rutgers University, Department of Obstetrics-
Gynecology and Reproductive Sciences, New Brunswick, U.S.A.
7Warren Alpert Medical School- Brown University, Department of Obstetrics and
Gynecology, Providence, U.S.A.
Study question: Can in vivo conceived embryos be reliably recovered by
uterine lavage for diagnostic characterization?
Summary answer: Uterine lavage performed after insemination successfully
recovered blastocysts. Using Next Generation Sequencing (NGS) we per-
formed the ﬁrst chromosomal characterization, where 27.5% were euploid.
What is known already: Early work performed by Buster and colleagues in
1983 recovered embryos from the uterus by lavage in natural cycles. At that
time, genetic testing of embryos was not possible, although approximately 50%
of normal appearing blastocysts conceived. Chromosome abnormalities are
commonly found in embryos after in vitro fertilization (IVF). In contrast, data on
in vivo conceived embryos does not exist. In vivo developed embryos in animal
models, possess different characteristics (i.e. rate of chromosomal abnormal-
ities, higher rates of blastocyst formation, different characteristics in develop-
ment after birth, reduced genetic aberrations) compared toin vitro developed
embryos of similar species.
Study design, size, duration:We performed a single site, prospective, feasi-
bility study in 54 women to evaluate the safety and efﬁcacy of a new uterine lav-
age system (Previvo Genetics, Inc., San Carlos, CA). Patients gave their written
informed consent for the research protocol approved by Western Institutional
Review Board. All lavages were performed in Punta Mita, Mexico during August
2017 to January 2018 by a single investigator. Subjects were followed for 30-
days post-lavage to monitor for complications.
Participants/materials, setting, methods: 54 women were pretreated
with oral contraceptives and stimulated with gonadotropins for 69 cycles.
Ovulation was triggered with either 5,000 IU of human chorionic gonadotropin
(hCG) or Lupron 4 mg and 2,500 IU of hCG, followed by insemination of donor
sperm 36 hours after trigger. Uterine lavage occurred 4-6 days after the insem-
ination. Recovered embryos underwent trophectoderm biopsy, vitriﬁed and
stored in liquid nitrogen. Biopsies were analyzed using the NGS technique.
Main results and the role of chance: This was the ﬁrst study to reliably
demonstrate the feasibility of recovering in vivo derived human blastocysts fol-
lowing ovarian stimulation. Recovered blastocysts were then successfully char-
acterized using comprehensive chromosomal analysis.
A total of 69 uterine lavages were performed in 54 women undergoing
superovulation followed by intrauterine insemination (IUI). After IUI, uterine
lavage recovered embryos in 25 (36.2%) cycles. A total of 48 embryos were
recovered: 18 (37%) multi-cell embryos, 7 (15%) morulas and 23 blastocysts
(48%). Six (12%) morulas progressed to blastocysts, for a total of 29 blastocysts
(60%). All embryos regardless of stage were biopsied, vitriﬁed and cryopre-
served. Of the 29 tested blastocysts, 27.5% were euploid (8/29), 27.5% were
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complex abnormal (8/29), 21% were aneuploidy (6/29), 17% were mosaic (5/
29) and 2 had no result (7%).
The data is observational and the number of participants small making it difﬁ-
cult to assess the impact of ‘chance” on the database. However, our stated
objective was to evaluate the feasibility of using uterine lavage for recovering
blastocysts for analysis and it appears that this goal was met.
Limitations, reasons for caution: The sample size is small, and the lavage
tool and system are not fully optimized. The ovarian stimulation protocol pre-
scribed may inﬂuence the chromosomal proﬁles observed in the recovered
blastocysts. Future experiments are needed to ascertain a potential role in the
observed aneuploidy induced by medications.
Wider implications of the ﬁndings: This study implies uterine lavage is a feas-
ible method to recover embryos in selected patients who desire to bank embryos
or planning for genetic testing (PGS or PGD). Uterine lavage offers a nonsurgical
minimally invasive approach to recovering embryos that is different from IVF.
Trial registration number: The trial has been registered at www.
clinicaltrials.gov and is pending receipt of a trial registration number.
O-262 Comprehensive mitochondrial DNA (mtDNA) analysis and
IVF outcome
B. Lledo1, J.A. Ortiz1, R. Morales1, J. Guerrero2, A. Bernabeu3,
L. Joaquin3, R. Bernabeu3
1Instituto Bernabeu, Molecular Biology, Alicante, Spain
2Instituto Bernabeu, Reproductive Biology, Alicante, Spain
3Instituto Bernabeu, Reproductive Medicine, Alicante, Spain
Study question: Do the mtDNA copy number, heteroplasmy and haplotypes
affect the ongoing pregnancy?
Summary answer: Our study suggests that elevated mtDNA copy number
above a threshold is associated with lower ongoing pregnancy rate, a mutational
load could be an explanation.
What is known already: Mitochondria plays a vital role in cell function and
mtDNA is associated with a number of traits such infertility. Recently, there has
been an increasing focus on research in its potential as biomarker of embryo
implantation. It has been speculated that both mtDNA-heteroplasmy and copy
number contribute to the mitochondrial function but the effects of both factors
in embryo implantation were discussed separately. NGS allows us to study in
depth mtDNA-hetroplasmy and copy-number simultaneously. Moreover, mito-
chondrial genomes can be clustered into groups known as haplotypes/hap-
logroups. mtDNA-haplotypes are responsible for complex diseases and at the
cellular level could inﬂuence expression patterns.
Study design, size, duration: A prospective non-selection study was per-
formed. We included 159 blastocysts biopsies from 142 couples who attended
to our clinic for PGT-A from January 2016 to December 2017. All embryos
were biopsied on day 5 or day 6. The aneuploidy testing was performed by
NGS using Veriseq® kit and the BlueFuse Multi software (Illumina). All blasto-
cysts were diagnosed as euploid non-mosaic and were transferred. The
mtDNA analysis were performed once the diagnosis was known.
Participants/materials, setting, methods: Sequencing reads mapping to
the mtDNA genome were extracted from indexed bam ﬁles to identify copy
number, heteroplasmy and haplotypes. The relative measure of mtDNA copy
number was calculated by dividing the mtDNA reads by the nuclearDNA value
to normalize for technical variants and the number of cells collected at the
biopsy. All the results were subjected to mathematical correction factor
according to the embryo genome. Haplogroups were assigned by HaploGrep
and heteroplasmy by MitoSeek.
Main results and the role of chance: The average of mtDNA was 0.0016
+ 0.0012 with an average depth of 205×. To detect heteroplasmic sites we
consider a sequencing coverage >40 and a minor allele count (MAF)> = 2.
According to this criterion 40 embryos were heteroplasmy carriers (26.32%).
The mtDNA haplogroup of embryos was determined in 94 biopsies, we identi-
ﬁed 8 different haplogroups and 87% belonged to the H2a2a. With respect to
IVF-outcome for mtDNA copy number analysis, due to the fact that mitochon-
drial dysfunction is only revealed when overall mictochondrial function drops
below a threshold, we set 0.003 for the following analysis. The vast majority of
the embryos (142/159) are below the threshold and 17 embryos were
classiﬁed as high mtDNA. We showed a reduction in ongoing pregnancy rate
associated with elevated mtDNA (42.6% vs 17.6%;p < 0.05). This result was
independent of maternal age, day of the biopsy and embryo morphology as
these factors were included as confounding factors. No signiﬁcance differences
were reported for haplotype (43.9% vs 41.7%;p = 0.884) and heteroplasmy
(40.5 vs 37.8;p = 0.77). However, a clear association between heteroplasmy
and mtDNA copy number was reported (0.0013 vs 0.0025;p < 0.001). With
the combination of all the factors a predictive performance of the embryo
implantation score was calculated with 83% of speciﬁcity.
Limitations, reasons for caution: Limitation may be due to the size of the
sample and the high-troughput sequencing technology that might not have
detected heteroplasmy levels lower than 2% and requires high sequence depth.
A clinical randomized trial will be necessary. More research in the mitochondrial
function are needed.
Wider implications of the ﬁndings: Our results have demonstrated that
elevated mtDNA embryos have a lower chance to produce an ongoing preg-
nancy. Moreover, our data suggest a link between mutation of the mtDNA and
the increased mtDNA. Therefore, mitochondrial activity could be a balance
between functional capacity and absolute mtDNA copy number within the cell.
Trial registration number: Conﬂicts of interest and source of funding none
declared.
O-263 Improved concordance rates for aneuploidy detection in
spent culture media compared to trophectoderm biopsies: a step
forward towards non-invasive preimplantation genetic testing
(niPGT-A)
C. Rubio LLuesa1, L. Rienzi2, L. Navarro-Sánchez1, D. Cimadomo2,
C.M. García-Pascual1, L. Albricci2, L. Martínez-Merino1,
A. Capalbo3, F. Ubaldi2, C. Simón4
1IGENOMIX, PGS Research, Paterna Valencia, Spain
2GENERA Centres for Reproductive Medicine, Reproductive Medicine, Rome, Italy
3IGENOMIX, Laboratory Director, Rome, Italy
4University of Valencia- INCLIVA- Igenomix, Obstetrics and Gynecology, Paterna
Valencia, Spain
Study question: Is the embryonic cell-free DNA in the spent culture media
representative of the chromosomal constitution of the blastocysts?
Summary answer: Increased knowledge on the dynamics of embryonic cell-
free DNA has improved aneuploidy detection in blastocysts by the analysis of
spent culture media.
What is known already: Current techniques used for preimplantation gen-
etic testing of aneuploidies (PGT-A) enable the analysis of the full chromosome
content of a single cell with high sensitivity and speciﬁcity. Recent studies have
reported the existence of embryonic cell-free DNA, opening a new era of pos-
sibilities for niPGT-A. However, the percentages of informative samples vary
widely. These discrepancies, could reﬂect the existence of mosaicism and pres-
ence of DNA from granulosa cells or polar bodies in the spent culture media.
Thus, efforts should focus on identifying embryonic cell-free DNA and rule out
maternal DNA contamination to translate this non-invasive technology into
clinical use.
Study design, size, duration: This is a pilot prospective study that includes
analysis of 64 samples of spent culture media from embryos included in a PGT-
A program. These samples correspond to 22 patients with ages ranging from
35-45 years (39.1 ± 2.5), with advanced maternal age, recurrent miscarriage,
or repetitive implantation failure as PGT-A indications. Collection and analysis
of samples were carried out from November 2017 to January 2018. Analysis of
both types of samples from each embryo was performed blindly.
Participants/materials, setting, methods: In the PGT-A cycle, chromo-
some diagnosis from each blastocyst stage embryo was obtained from the
trophectoderm biopsy and the spent culture media. Both, spent culture media
and trophectoderm biopsies have been analysed by Next Generation
Sequencing (NGS). NGS was performed using the Ion ReproSeq PGS Kit
(ThermoFisher Scientiﬁc) using Ion ChefTM plus the Ion S5TM XL SequencerTM.
For the analysis of the spent culture media, the standard protocol has been
modiﬁed to improve ampliﬁcation efﬁciency.
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Main results and the role of chance: Informative results were obtained
from all 64 trophectoderm biopsies and from 60 spent culture media (93.7%
successful ampliﬁcation in spent culture media). Concordance rate between
trophectoderm biopsies and spent culture media in terms of blastocyst diagno-
sis as aneuploid or euploid was 75.0% (45/60). Concordance rate for auto-
somes was 80.0% (48/60). Considering the 15 discrepancies, 3 of them
corresponded to euploid diagnosis in both types of samples, but with discord-
ant gender (5% gender mismatch); 11 discrepancies were classiﬁed as false posi-
tives, with the spent culture media diagnosed as aneuploid and the
trophectoderm biopsy as euploid (18.3% false positive rate); and only 2 discrep-
ancies were false negatives, with spent culture media diagnosed as euploid
and trophectoderm biopsy as aneuploid (3.3% false negative rate). In 4 of
the false positive samples, the spent culture media was diagnosed as chaotic
(40% of the false positives), with multiple chromosomes altered in a pattern
reﬂecting low input of DNA or poor DNA quality. In the 2 false negative sam-
ples, the result in the trophectoderm biopsy was a single uniform monosomy in
one case and, a single low-degree mosaic monosomy in the other one, raising
the question of which sample better represents full blastocyst chromosome
content.
Limitations, reasons for caution: This is a study with limited number of
samples. There is a need to fully discard maternal DNA traces in spent culture
media, to understand the impact of mosaicism in the accuracy of the diagnosis
in PGT-A and niPGT-A and, to unravel why some embryos release more DNA
than others.
Wider implications of the ﬁndings: In this study, the improvements in
methodology and concordance rates prompt us to foresee the possibility of
including niPGT-A in the clinical practice. The niPGT-A approach would help
patient’s access to aneuploidy testing by avoiding the need of invasive biopsy
techniques and by reducing the cost of the procedure.
Trial registration number:Not applicable.
O-264 Concordance rates amongmultiple trophectoderm
samples and ICM remain high proving the efﬁcacy of NGS for
preimplantation genetic screening
R. Anderson1, J.B.Whitney2, C.M. Rios3, A.E. Jones4,
A. Harutunian3, M.C. Schiewe2
1The Southern California Center for Reproductive Medicine, ART Clinic, Newport
Beach, U.S.A.
2Ovation Fertility, ART Lab, Newport Beach CA, U.S.A.
3Ovation Fertility, Genetics, Las Vegas NV, U.S.A.
4Ovation Fertility, Genetics, Nashville TN, U.S.A.
Study question: Are human blastocysts homogeneous for chromosomal
copy number between multiple samples of the trophectoderm and does troph-
ectoderm ploidy accurately predict ICM ploidy?
Summary answer: Upon re-biopsy, trophectoderm homogeneity for full gain
or loss was 97%, while ICM concordance was 100%. Human blastocyst ploidy
proved consistent between cell samples.
What is known already: Blastocyst biopsy and preimplantation genetic
screening (PGS) allows for ploidy status determination before implantation
without adversely impacting embryo competence or baby health and well-
being. The efﬁcacy and invasive nature of the trophectoderm biopsy, as well as
resultant NGS reports of mosaicism, have been scrutinized. The importance of
mosaic proﬁles on PGS outcomes is not well deﬁned and the effect to the off-
spring not fully understood. Importantly, the uniformity of aneuploidy within the
trophectoderm and ICM remains unclear. It has been shown that increased
mosaicism decreases implantation, while low-level mosaics can result in viable
pregnancies, questioning the ICM concordance with trophectoderm.
Study design, size, duration: Nine research consented embryos were
thawed and a minimum of 3 additional trophectoderm samples were taken.
Samples were tubed according to standard NGS ampliﬁcation protocols and
sent blinded to two separate reference labs, including the original testing lab.
Furthermore, both labs were unaware of the experimental plan or cell types
being tested (i.e, double-blinded design). The geneticists performed NGS and
proﬁle examination to produce standard euploid/aneuploid results in accord-
ance with their own established lab guidelines.
Participants/materials, setting, methods: Research consented embryos
possessing single/dual chromosomal aneuploidies were selected and blindly
sampled. MicroSecure vitriﬁed blastocysts were warmed (100% intact) and cul-
tured in LifeGlobal medium (37°C, tri-gas humidiﬁed conditions) for a minimum
of 4 hours. Each blastocyst was biopsied 3-5 times according to standard proto-
cols. A ﬁnal biopsy per embryo attempted to isolate only ICM cells as a separ-
ate sample. A total of 28 re-biopsies were performed for a total of 37 samples.
Main results and the role of chance: A full gain or loss was determined if
the NGS proﬁle reached >95% gain/loss for each chromosome. This cut-off is
contrary to standard calls of ~30%. Of the original samples,7 of the 9 had a sin-
gle full gain or loss, 1 embryo had a full loss and a mosaic loss of >50%, and
another sample had only a mosaic gain of 65%. A total of 36 samples, or 97%
were concordant for the same chromosomes called. A total of 7 ICM samples
achieved 100% concordance with the original trophectoderm sample result.
The one sample not producing concordance was the original 65% mosaic
embryo with all re-biopsies resulting in euploidy. Unfortunately, this embryo did
not have an ICM tubed to determine relevant mosaicism. Additional low-level
mosaics occurred on 3 samples (8%). It is incredibly encouraging that so many
of the proﬁles exhibited mirror images proving the efﬁcacy of NGS repeatability.
Our laboratory has previously reported the importance of biopsy technique, so
every attempt was made to sample healthy cellular masses free of degeneration.
Of note, all mosaic proﬁles had a documented fair to poor cellular mass result
from the biopsy, reinforcing the need for proper technique.
Limitations, reasons for caution: Trophectoderm biopsy with NGS is
heavily reliant on proper technique and geneticist interpretations. Genetic call-
ing policies and deﬁnitions of euploidy/aneuploidy and mosaic embryos can dif-
fer from lab to lab, adding to the growing uncertainty of PGS. Understanding
result interpretation is imperative to improving patient education on the risks of
mosaicism.
Wider implications of the ﬁndings: This study supports that full gain/
losses are extremely reproducible among all cells/types of the human blasto-
cyst. Mosaic proﬁles are potentially detrimental or possibly just artifact. Further
research is needed help alleviate the ambiguity of mosaic proﬁle risks, but this
study has proven NGS efﬁcacy when full aneuploidy is present.
Trial registration number:None.
O-265 What is the genetic signiﬁcance of blastomeres excluded
from the formation of a morphologically normal blastocyst?
C. Pirkevi Cetinkaya, M.A. Tufekci, Y. Kumtepe Colakoglu,
M. Cetinkaya, S. Kahraman
Istanbul Memorial Hospital, Assisted Reproductive Technologies and Reproductive
Genetics Center, Istanbul, Turkey
Study question: Is there a correlation between the ploidy of the blastocyst
and that of the blastomeres excluded from the formation of the blastocyst?
Summary answer: Morphologically normal blastocysts with excluded blasto-
meres were diagnosed with aneuploidy affecting maximum three chromosomes
whereas excluded blastomeres were chromosomally chaotic.
What is known already: Blastomeres that have arisen throughout cleavage-
stage are sometimes excluded from the formation of the blastocyst and are
sequestered either between the zona pellucida and the perivitelline space or
remain internally during blastocyst formation and are sequestered to the blasto-
coel cavity. In both ways, once isolated, those cells do not take part in preim-
plantation development. It has been demonstrated that excluded cells have
poor gap junction communication with the embryo (Hardy et al., 1996). It was
hypothesized that cell surface markers promoting ingestion by neighboring cells
were absent from those isolated cells since phagocytosis is possible in the
blastocyst-stage (Hardy, 1997).
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Study design, size, duration: This observational study was based on 25
good or top-quality blastocysts (at least 4BB) with blastomeres excluded from
the formation of the blastocyst and sequestered between the zona pellucida
and the perivitelline space. They were belonging to 20 patients applying for pre-
implantation genetic screening (PGS) due to advanced maternal age (>37).
Patients with structural abnormalities or a history of abnormal fetal karyotype
were not included in the analysis.
Participants/materials, setting, methods: The 25 trophectoderm biop-
sies were prospectively analyzed and the corresponding excluded blastomeres
(2-5/ blastocyst) samples were in parallel diagnosed either by next generation
sequencing (NGS) (PGM platform, ThermoFisher) or by array Comparative
Genomic Hybridization (aCGH, Illumina). Assisted hatching was done on day-3
and blastocysts having excluded blastomeres in the axis of the zona opening
were included in the analysis to decrease manipulation and most importantly,
not to harm the blastocyst.
Main results and the role of chance: The PGS analysis of the trophecto-
derm biopsies revealed 11 monosomies, 11 trisomies, 3 mosaicisms and 4
euploidies, showing that only 16% of the blastocysts with excluded blasto-
meres were euploid. In 11 blastocysts one chromosome was involved in the
aneuploidy whereas for 8 blastocysts two chromosomes were implicated.
Only two blastocysts were aneuploid for three chromosomes. None but
one of the excluded blastomeres had the same diagnosis with the corre-
sponding embryo (trisomy 4). However, in half of the embryos (12/25) one
chromosomal aneuploidy was shared by both samples; the excluded blasto-
meres having a more complex diagnosis with a mean of four chromosomes
involved in the aneuploidy [for example, a diagnosis of monosomy 7, 14 for
the blastocyst and a diagnosis of trisomy 1q, monosomy (3, 4, 7, 14, 16,
19) for the corresponding excluded blastomeres]. Only one sample of
excluded blastomeres was euploid although the corresponding blastocyst
was aneuploid (monosomy 1). It may be hypothesized that either the
embryo attempts to exclude blastomeres with chaotic aneuploidies from the
blastocyst or that the excluded blastomeres have become chromosomally
chaotic because of apoptotic cell death mechanisms that have been already
initiated in the aneuploid embryo.
Limitations, reasons for caution: Results were obtained in a small group of
blastocysts and in a deﬁned IVF setting. Increasing the number of the study
cohort will undeniably give more reliable results.
Wider implications of the ﬁndings: In the light of the strong association
showed by Munné and colleagues (2017) between center-speciﬁc ART treat-
ment practices and the incidence of chromosome abnormality in human
embryos, it would be interesting to check the validity of the results in an inde-
pendent IVF clinic.
Trial registration number:Not applicable.
O-266 Human in vitro post-implantation culture models reveal the
depletion of aneuploid cells in chromosomally mosaic embryos 12
days post fertilisation
M. Popovic1, A. Dheedene2, L. Dhaenens1, J. Taelman1, P. De
Sutter1, S.M. Chuva De Sousa Lopes1,3, B. Menten2, B. Heindryckx1
1Ghent University Hospital, Ghent-Fertility and Stem cell Team G-FaST- Department
for Reproductive Medicine, Ghent, Belgium
2Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium
3Leiden University Medical Center, Department of Anatomy and Embryology, Leiden,
The Netherlands
Study question: To what extent does genomic instability at the blastocyst
stage affect early post-implantation development in vitro, 12 days post fertilisa-
tion (dpf)?
Summary answer: While aneuploid blastocysts showed reduced develop-
mental potential during extended culture, mosaic embryos generated euploid
outgrowths 12 dpf, indicating no preferential lineage allocation of abnormal
cells.
What is known already: Embryo aneuploidy is associated with implantation
failure and early pregnancy loss. Yet, a proportion of blastocysts are
chromosomally mosaic, containing genomically distinct cell populations.
Although mosaic embryos may lead to live births, the clinical implications of
chromosomal mosaicism on early pregnancy, including foetal and placental
development, remain unknown. The complex nature of genomic instability
coupled with the inaccessibility of research material has inherently limited our
understanding. Newly established embryo culture systems allow blastocyst
attachment, outgrowth formation and extended culture for up to 14 days
in vitro, providing a unique opportunity for investigating chromosomal instability
during early human post-implantation development.
Study design, size, duration: A total of 30 chromosomally abnormal human
blastocysts were included in the study. Embryos were donated following preim-
plantation genetic screening (PGS) and selected based on their original diagno-
sis. Twenty embryos presented with either one (n = 13) or multiple
aberrations (n = 7), while 10 blastocysts showed evidence of mosaicism. The
latter were diagnosed with either one mosaic abnormality (n = 5) or both a uni-
form and a mosaic aberration (n = 5). Vitriﬁed blastocysts were warmed and
cultured to 12 dpf.
Participants/materials, setting, methods:We applied established culture
protocols to generate embryo outgrowths. Outgrowth viability on day 12 was
carefully assessed and correlated to the genomic status of the plated blasto-
cysts. We further selected 13, day 12 embryos for genomic analysis. Of these,
7 outgrowths were separated into two portions, corresponding to inner cell
mass (ICM) and trophectoderm (TE) derived lineages. Taken together, whole
genome ampliﬁcation (WGA), followed by next generation sequencing (NGS)
was performed on 20 samples.
Main results and the role of chance: Of the total embryos plated, 46.7%
remained attached during the extended culture (n = 14). Viable day 12 out-
growths were predominantly generated from blastocysts diagnosed with triso-
mies, structural duplications or mosaic aberrations (13 out of 14, 92.9%).
Conversely, monosomies, deletions and complex aneuploidies signiﬁcantly
impaired in vitro embryo development to 12 dpf (1 out of 14, 12.5%; p = 0.01).
Interestingly, all embryos originally diagnosed with a single mosaic aberration
remained viable at 12 dpf, regardless of the degree of mosaicism originally
reported. Remarkably, of these, all sequenced outgrowths presented with nor-
mal proﬁles (n = 4), including 2 embryos that were separated into ICM and TE
derived portions. All segments were euploid, suggesting a depletion of aneu-
ploid cells in both embryonic lineages. Moreover, we could not conﬁrm mosai-
cism in any day 12 outgrowths generated from blastocysts diagnosed with both
a uniform and mosaic aberration. Here only uniform abnormalities were
detected at 12 dpf. However, within this group, embryos with a higher percent-
age of mosaicism were more likely to detach during culture. Finally, we deter-
mined 100% concordance for uniform aberrations diagnosed at the blastocyst
stage and at day 12. This applied to whole outgrowths and those for which
lineage-speciﬁc proﬁles were obtained.
Limitations, reasons for caution: To thoroughly evaluate genomic instabil-
ity and correlate the degree and type of mosaicism to developmental potential,
expanding our study to include more outgrowths is currently ongoing.
Established models omit the requirement of endometrial tissues, hence do not
account for trophoblast-uterine interactions. The known methodological arte-
facts of WGA warrant careful interpretation.
Wider implications of the ﬁndings: Our ﬁndings echo current prenatal
screening data and further demonstrate the normal developmental potential of
mosaic embryos. Further insights into the impact of chromosomal mosaicism
will contribute to a better understanding of its clinical signiﬁcance. This will
inherently beneﬁt clinical management, particularly when no euploid embryos
are available for transfer.
Trial registration number: not applicable.
INVITED SESSION
SESSION 68: INFERTILITY AROUND THE GLOBE
Wednesday 4 July 2018 Room 211 + 212 12:00–13:00
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O-267 Infertility and assisted reproduction in the muslim world:
Social, cultural, and religious considerations
M. Inhorn
Yale University, Anthropology & International Affairs, New Haven- Connecticut,
U.S.A.
Abstract text
Assisted reproductive technologies (ARTs) to overcome infertility are now
widely available across the Muslim world. Islamic fatwas (religious decrees)
emanating from a variety of Islamic countries have permitted ARTs as a viable
solution to overcome marital infertility. However, in the Sunni Muslim world,
which spans from Morocco to Malaysia, third-party reproductive assistance
(egg, sperm, and embryo donation, plus surrogacy) is religiously disallowed for
a number of reasons having to do with kinship, marriage, and inheritance.
Having said that, religious rulings emanating from Shia Muslim-dominant Iran
have created unique avenues for infertile Muslim couples to overcome their
infertility through third-party reproductive assistance. The opening of Iran, fol-
lowed by Lebanon, to gamete donation has led to reproductive travel across
international borders, especially among Sunni Muslim couples in search of
donor eggs. Having said that, sperm donation remains unpopular among both
Sunni and Shia Muslim men, meaning that they must turn to intracytoplasmic
sperm injection (ICSI) to overcome their male infertility. ICSI has become a
“masculine hope technology” in the Muslim world, despite its many practical
and ethical challenges. In addition, ARTs such as preimplantation genetic diag-
nosis (PGD) for sex selection and multi-fetal pregnancy reduction (MFPR) for
high-order multiple pregnancies (HOMPs) are leading to complex bioethical
conundrums. This presentation reviews the key social, cultural, and religious
issues facing ART-seeking infertile Muslim couples. Despite complex challenges,
ARTs are being used widely and ethically negotiated in novel and unexpected
ways in the Muslim world—a region that has embraced ARTs along with other
forms of high-tech medicine.
O-268 The burden of infertility and childlessness in Sub-Saharan
Africa: how can it be reduced?
T. Gerrits
University of Amsterdam-Faculty of Social and Behavioral Sciences, Amsterdam
Institute for Social Science Research, Amsterdam, The Netherlands
Abstract text
Infertility is highly prevalent in Sub-Saharan Africa, in some areas affecting more
than 15 % of couples of the reproductive-age population, which is mainly due to
a high rate of sexually transmitted infections (STIs) and HIV/AIDS, postpartum
and iatrogenic infections, and post-abortive complications. Often, infertility has
a devastating impact on the people concerned, as in this context parenthood is
‘culturally mandatory’. Infertility does not only have an emotional impact at the
personal level (leading to grief and depression), but it also affects marital rela-
tionships and may result in disrespectful treatment by husbands and/or in-laws,
domestic violence, abandonment, divorce and/or polygamy. Childless women
and men may also suffer from social exclusion and stigmatization and their social
security might be affected as they do not have children to take care of them at
old age or when sick. Further, infertility may lead to economic hardship, as
childless couples often spent their incomes on series of (ineffective) traditional
and/or biomedical treatments. Finally, infertility may lead to additional health
risks because people with fertility problems may be at greater risk of exposure
to HIV and other STIs when they attempt to conceive extramaritally. Despite
the high prevalence of infertility in Sub-Saharan countries and the huge impact
on the daily lives of people concerned, it receives little attention from the public
health system, neither to prevent, nor to treat it. Availability, access and quality
of interventions to address infertility remain largely insufﬁcient. Even basic inter-
ventions such as counselling, medical examinations and information provision
are often scarce. Assisted reproductive technologies are - with a few exceptions
- only offered in private clinics. De-stigmatization of the condition is also not
addressed.
This presentation ﬁrst provides insight in the burden and social suffering of
infertility in the Sub-Saharan African context and subsequently present and dis-
cuss concrete recommendations to reduce this suffering. Clearly, this topic
needs more attention – and funding - of various stakeholders and organizations,
at national and international levels, including also NGOs and donor parties
working in the ﬁeld of Sexual and Reproductive Health and Rights (SRHR).
INVITED SESSION
SESSION 69: CUMULATIVE LIVE BIRTH RATES AFTER
UTILIZATIONOF ALL FRESHAND FROZEN EMBRYOS IN
IVF/ICSI - THEOPTIMAL ENDPOINT
Wednesday 4 July 2018 Room 111 + 112 12:00–13:00
O-269 Howmany oocytes do we need to maximize cumulative live
birth rates after utilization of all fresh and frozen embryos?
S.K. Sunkara
Queens Hospital- Barking- Havering and Redbridge University Hospitals NHSTrust,
Gynaecology and Subfertility Unit, Essex, United Kingdom
Abstract text
Traditionally, IVF success has been reported as live birth rate (LBR) per cycle,
per oocyte retrieval or per embryo transfer. However, advances in controlled
ovarian stimulation (COS) strategies and signiﬁcant improvements in cryopreser-
vation techniques have introduced cumulative live birth rate (CLBR) as a more
robust outcome measure in deﬁning success in ART. There have been steady
increases in frozen-thawed embryo transfers (FET) and resulting live births glo-
bally. Cumulative live birth rate is deﬁned as live births resulting from one initiated
or aspirated ART cycle, including fresh and/or resulting frozen embryo transfers,
until a live birth occurs or until all embryos are used, whichever occurs ﬁrst.
Cumulative live birth rate is a measure of the efﬁciency of COS regimens and
effectiveness of cryopreservation programmes in ART. The aim of COS in ART
is to optimise the number of oocytes to maximise success, efﬁciency, safety and
cost-effectiveness. Ovarian response and number of oocytes retrieved is a sur-
rogate outcome for ART success because of important associations with both
pre-clinical and clinical outcomes. There is a strong relationship between
oocytes retrieved and live birth following IVF, with several studies demonstrat-
ing a non-linear association with the number of oocytes and LBR in fresh IVF
cycles. These studies have demonstrated an initial linear increase in LBR with
increasing number of oocytes up to a consistent threshold of ~15 and a decline
in LBR following fresh transfers with excessive oocyte numbers, >20. Current
evidence of higher LBR following frozen versus fresh embryo transfers in
women with PCOS indirectly concurs with this ﬁnding as these women are
likely to have excessive response. The assumption for this decline is the very
high oestradiol levels affecting the endometrial milieu and implantation in fresh
cycles. This ﬁnding cannot be extrapolated to frozen transfers where hormone
levels are close to physiological range.
Cumulative live birth rate reporting has extended the threshold of oocyte
numbers towards increasing ART efﬁciency. Initial single centre-based studies
reported a positive linear association between number of oocytes and CLBR.
Subsequent multi-centre and registry based studies have demonstrated patterns
of association with CLBR increasing up to 20-24 oocytes and further. This topic
continues to be researched currently. In addition to CLBR, other innovative
measures of success have also been introduced such as the one-and-done
approach. This approach aims to tailor COS to result in successive live births
with embryos from one cycle. Although achieving a live birth is dominant with
ART programmes, safety is paramount and eliminating OHSS is a continued
focus. Large cohort studies have indicated signiﬁcant increases in clinical OHSS
cases with >15, >18, >20 oocytes respectively. However, such studies with
historical data are likely to involve a considerable proportion of GnRH agonist
cycles associated with higher incidence of OHSS. This notion of an OHSS free
clinic could reach near reality with current approaches to COS using the GnRH
antagonist regimen, the GnRH agonist trigger and freeze all strategy. These
strategies could potentially extend the safety limits for oocyte numbers.
Another aspect of safety is the perinatal risks with ART pregnancies and addres-
sing the contribution of ovarian stimulation, ovarian response and number of
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oocytes is of interest. There is a higher incidence of preterm birth (PTB) and
low birth weight (LBW) with excessive response (>20 oocytes) following fresh
transfers. Whilst this could be due to an innate risk for women with PCOS
within this category, high peak oestradiol levels have been shown to be asso-
ciated with risk of LBW.
Understanding important clinical associations is useful for planning COS
regimens. Whilst higher oocyte numbers are positively correlated with high-
er CLBR, maximising CLBR and planning COS should give consideration to
safety.
O-270 Cumulative live birth rates after utilization of all fresh and
frozen embryos in GnRH antagonist versus agonist protocol
INVITED SESSION
SESSION 70: PRECONCEPTIONGENETICS IN CLINICAL
FERTILITY PRACTICE: HOWMUCH INFORMATIONDO
WENEED?
Wednesday 4 July 2018 Room 113 + 114 + 115 12:00–13:00
O-271 Increasing use of mutation screening in fertility clinics
O-272 Genetic carrier screening in gamete donor programs
A. Veiga, M. Boada, A. Abuli
Reproductive Medicine Service, Dexeus Women’s Health, Barcelona, Spain
Abstract text
The data from the ESHRE-EIM Consortium for year 2011 show that more
than 15,000 oocyte donation (OD) cycles have been performed in Spain,
representing 52% of the OD European cycles. Donor screening has always
been an issue that has received utmost attention in Spanish ART centers.
European regulations clearly states that genetic screening for autosomal
recessive genes known to be prevalent in the donor’s ethnic background
and assessment of the risk of transmission of inherited conditions known
present in the family must be carried out according to international scien-
tiﬁc evidence.
Traditionally, in OD programmes, genetic screening has been performed
through karyotype analysis and the screening of diseases most prevalent in the
donor’s country of origin. In the last few years, genetics has experienced
important technological progress allowing the screening for multiple genetic dis-
eases at a reasonable cost. Expanded carrier screening (ECS) panels have now
been implemented to allow a much deeper analysis of the risk of disease trans-
mission during donor evaluation and better matching between donors and reci-
pients shifting from the screening of limited number of conditions with a high
prevalence in speciﬁc groups to the pan-ethnic or universal screening of multiple
recessive conditions.
Since 2010, different panels have been commercially available, with differ-
ent numbers and types of diseases. With the aim to provide with up-to
date risk assessment of oocyte donors and optimised matching between
donors and recipients, we have developed our own ECS panel (qCarrier)
in collaboration with Q Genomics, a technological company that deals with
genomics in human health. For gene selection, consideration has been given
to geographic prevalence, neonatal screening programs and a selection of
mutations associated with severe genetic diseases. The panel has been
based on Next Generation Sequencing (NGS) technology, including com-
plete sequencing of the coding region of genes associated with the most
prevalent diseases and targeted mutational analysis of rare diseases.
Complementary techniques for Fragile X syndrome and some deletions
have been performed.
The results describe the implementation of a carrier screening test for auto-
somal recessive and X-linked diseases in our OD Programme. Donors and
male partners of the recipients were screened for risk assessment and match-
ing. The ECS test covered 200 genes (68 genes by complete sequencing of the
coding region and 132 sequenced by a targeted mutation analysis) associated
with 314 diseases (277 recessive autosomal diseases and 22 ×-linked). Among
participants, 56.4% (761/1350) were identiﬁed as carriers of at least one gene
mutation. Eleven (1.9%) of oocyte donor candidates were identiﬁed as carriers
of X-linked diseases, and as such, were excluded from the OD programme.
The mean carrier burden was 0.84 mutations per sample. With respect to the
matching between oocyte donors and recipients, 26 (3.4%) preassigned
matches were at high risk of transmitting a severe autosomal-recessive genetic
condition to their offspring (cystic ﬁbrosis, classical congenital adrenal hyperpla-
sia, autosomalrecessive non-syndromic sensorineural deafness, alpha thalas-
semia, familial Mediterranean fever, Niemann-Pick disease, thyroid
dyshormogenesis type 6 and cartilage-hair hypoplasia). The ﬁnal matching
between donors and recipients was performed taking into account the ECS
results. A carrier state for an autosomal recessive condition was not an exclu-
sion criterion for oocyte donors, although it implied the assignation of the
donor to a recipient whose male partner was not a carrier for the same reces-
sive condition. When performing ECS in an OD, an appropriate genetic coun-
selling is essential for donors and recipients in order to understand the results,
to decrease anxiety and to give recommendations about own reproductive risk
or that of relatives, when necessary.
INVITED SESSION
SESSION 71: LABORATORY INVITED SESSION: EMBRYO
CULTURE: CHANGING THE ATMOSPHERE
Wednesday 4 July 2018 Room 117 12:00–13:00
O-273 Epigenetic changes by stimulation and culture
A. Sunde
Professor emeritus, Department of Clinical and Molecular Medicine- Faculty of
Medicine- Norwegian University of Science and Technology. Trondheim- Norway.,
Trondheim, Norway
Abstract text
Epigenetic changes means that there is a change in the phenotype of a cell or an
organism without a simultaneous change in the genotype. It is the expression of
genes that are changed. One mechanism of regulation gene expression is trough
adding a methyl-group to a Cytosine in the binding site of a transcription regula-
tor or by methylation or acetylation of histones. These chemical modiﬁcations
of DNA or chromatin can change the likelihood that a gene or sets of genes are
expressed.
Assisted reproduction is associated with shifts in the phenotype of the
embryos, of the placenta and the children born. Interventions like ovulation
induction, in vitro fertilization, embryo culture and cryopreservation of embryos
are associated with changes in gene expression proﬁles methylation patterns in
the placenta and the birth weight of the offspring. In general, the mechanisms
behind the changes in phenotype are unknown, but it is reasonable to assume
that this is mediated epigenetically by modulating gene expression.
From epidemiological data, it is well documented that the nutritional status
of the mother in early pregnancy may have lasting effects on the health of the
offspring. In human IVF, different culture media was shown to induce different
gene expression proﬁles in embryos and a signiﬁcant difference in birth weight
of the children born Similarly, the oxygen concentration in the incubator will
inﬂuence the gene expression in human embryos and this effect was dependent
on the type of culture media used.
Commercially available culture media for ART differ considerably in their
chemical composition and it should not come as a big surprise if embryos show
different epigenetic responses to these differences in the culture environment.
The consequences of these small shifts in phenotype after IVF and embryo
culture is to a large extent unknown, and it is unclear whether this will have an
effect on the long-term health of the ART-offspring. Follow-up studies on ART-
children in relationship to the intervention done both in vivo and in vitro are
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important in order to understand if there is certain interventions that is asso-
ciated with an increase in long term health problems.
O-274 Impact of temperature on embryo culture
R. Janssens
UZ Brussel, IVF Laboratory, Jette- Brussels, Belgium
Abstract text
In ART, the pre-implantation development of human embryos – and their
subsequent ability to implant - depends heavily on the in vitro culture con-
ditions. There is now an increasing understanding that the embryo is
highly adaptive to its environment, the embryo is able to develop to mor-
phologically normal blastocysts even in sub-optimal conditions. These cul-
ture conditions are set to mimic the in vivo conditions as good as
possible and mainly include the culture media, the type of culture system
and the incubator. The primary function of the incubator is to maintain
an appropriate microenvironment (composition of gas phase) and tem-
perature. Temperature can impact gamete and embryo function and mei-
otic spindle stability [1]. Although the developmental plasticity of embryos
permits them to develop over a range of temperatures, from 36.0 to
37.0°C[2], it is know that the micro-environment maintenance ability of
incubators signiﬁcantly inﬂuences the formation of good embryos [3].
Most commercial IVF incubators have important temperature variations
[4],[5] and statistically signiﬁcant associations between incubation shelf and
clinical pregnancy have been reported[6]. Due to these technical limita-
tions, accurate determination of optimal incubation temperature has not
yet been possible. Recent improvements in incubator technology however
now allow accurate temperature regulation and determination of optimal
incubation temperature. Until now, constant incubator settings matching
the core body temperature (37°C) are used, but the optimal culture tem-
perature is yet undeﬁned. Available data on incubation temperature will
be reviewed.
Although modern incubators can now regulate incubation temperature pre-
cise and stable, the temperature control out of the incubator can be problem-
atic. Limited decrease in temperature can alter the cytoskeleton and spindle of
oocytes and there is limited recovery after cooling and rewarming.
Temperature issues can occur during follicle puncture, during manipulations on
heated stages on stereo microscopes and injection microscopes, in incubators
and during embryo transfer. Temperature should be measured in culture dishes
under oil and in tubes with calibrated probes. The choice of measuring probe is
important. Thin, fast responding non shielded type T thermocouples can be
used to detect small temperature gradient and are excellent to detect hot spots
on heating stages while more precise, small probes, ﬁxed in culture dishes are
more suitable for precise temperature measurements in incubators. While the
most stable and accurate sensors are resistance temperature detectors (Pt100,
Pt 1000), they are not easily available in small sizes which allow them to be ﬁxed
inside a culture dish. For this purpose thermistor probes are probably a better
choice. Thermistors with 0.1°C accuracy are now widely available and at a very
reasonable price. They have a fast response time and because of their high sen-
sitivity are ideal for detecting temperature changes in culture dishes. Of course,
accurate temperature measurement is only possible through the use of suitably
calibrated sensors and instruments and the accuracy of these measurements
will be meaningless unless the equipment and sensors are correctly used. Good
knowledge of measurement science is a basic requirement, often lacking in
many laboratories.
SELECTEDORAL COMMUNICATIONS
SESSION 72: NEWHORIZONS IN IVF
Wednesday 4 July 2018 Forum (Auditorium) 14:00–15:15
O-275 Using artiﬁcial intelligence (AI) and time-lapse to improve
human blastocyst morphology evaluation
M. Meseguer Escriva1, N. Zaninovic2, F.G. Nogueira Marcelo3,
O. Oliana4, T.Wilkinson5, L. Benham-Whyte5, S. Lavery4,
C. Hickman4, J.C. Rocha6
1Instituto Valenciano de Infertilidad, IVF Laboratory, Valencia, Spain
2Cornell University, IVF Laboratory, New York, U.S.A.
3Sao Paolo State University-UNESP, Laboratory of Embryonic Micromanipulation,
Sao Paolo, Brazil
4Imperial College of London, Faculty of Medicine, London, United Kingdom
5Oxford University, Reproductive Biology, Oxford, United Kingdom
6Sao Paolo State University-UNESP, Applied Mathematics Laboratory, Sao Paolo,
Brazil
Study question: Following from a bovine study presented at ESHRE 2017, we
compared AI versus ﬁve distinct experienced embryologists in the capabilities to
grade human blastocysts.
Summary answer: As observed in the bovine model, AI outperformed
embryologists who graded human blastocysts using time-lapse images.
What is known already: Morphological grading of blastocysts is clinically
used for embryo selection. Our group demonstrated that blastocyst grading by
embryologists lead to wide inter- and intra-operator variation. We demon-
strated (bovine model) that an image analysis by AI system can reduce variation
in blastocyst grading and acquire additional parameters not detectable by oper-
ator assessment. Human blastocysts present additional challenges for AI image
recognition compared to bovine, given the increased classiﬁcation categories,
diverse trophectoderm thickness, diverse ICM shapes, and lower contrast.
Until now, AI has not demonstrated to improve operator blastocyst grading in
human embryos, which was the focus of the current study.
Study design, size, duration: 394 human embryo time-lapse images taken
at 111.5 hpi were graded for ICM, trophectoderm and expansion using
Gardner grading system by 5 different embryologists from 4 different countries.
Of these, 171 were excluded as blastocysts that were too early (expansion 1 or
earlier), hatched, out of focus or ICM not visible. The mode of the remaining
223 images were used as output for the AI system (70% training, 15% validation
and 15% blind test).
Participants/materials, setting, methods: 29 independent mathematical
variables were extracted from each time-lapse image taken at precisely 111.5
hpi from the central Z-stack and inputted into the AI system. The agreement
was assessed using confusion matrices, ROC curves and Kappa Index.
Embryologists originally trained in the same lab were compared to embryolo-
gists trained in different labs to assess inter- and intra-clinic agreement variation.
Main results and the role of chance: Agreement among the 5 embryolo-
gists was low (Kappa agreement decreasing from Expansion 0.4 to trophecto-
derm and ICM 0.3). There was no difference between the kappa agreement of
embryologists trained in the same clinic to embryologists from different coun-
tries. The low inter-operator agreement is likely to be due to the ﬁxed time
central stack image selection. Previously, we demonstrated that when images
were selected according to focus on ICM, the operator agreement was consid-
erably higher. Improved agreement was observed using AI to predict the mode
of the embryologists with substantial agreement with Expansion (Kappa agree-
ment 0.7) and ICM (0.7) and moderate agreement with trophectoderm (0.4).
The AI’s overall accuracy was almost perfect for prediction of blastocyst expan-
sion (training 93.9% and validation 81.5%) and substantial for prediction of ICM
(training 93% and validation 78.8%) and trophectoderm (training 78.8% and val-
idation 78.3%). The AI system was considerably more predictive of Expansion
(AUC 0.888-0.956) compared to ICM (AUC 0.605-0.854) and trophectoderm
(AUC 0.726-0.769).
Limitations, reasons for caution: Our data suggests that AI is able to cope
better than operators with the challenge of grading three dimensional embryos
from a single ﬁxed two-dimensional image. This technology has now been
demonstrated in two independent centres. Further independent studies are
required to demonstrate reproducibility before establishing its clinical
application.
Wider implications of the ﬁndings: Applying AI to human blastocyst grad-
ing is inexpensive, non-invasive, and more reliable than grading by an operator.
Instead of a human looking at thousands of images, AI faster assesses them and
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continuously learns and quantiﬁes additional information. As demonstrated, this
technology can inherently enhance our capabilities of assessing embryo viability.
Trial registration number: not applicable.
O-276 Optimising Machine Learning Algorithms for the Non-
Invasive analysis of the embryo secretome to enhance informed
decisions imediately prior to embryo transfer
S. Butler1, F. Sharara2, R. Zmuidinaite3, R. Iles3
1MAP Sciences, R&D, Bedford, United Kingdom
2Virginia Centre for Reproductive Medicine, U.S.A.,
3MAP Sciences, Research, Bedford, United Kingdom
Study question: Is it possible to mathematically analyse the secretome of
blastocysts by non-invasive mass spectrometry of spent culture media to pre-
dict viability for embryo selection.
Summary answer: A simple, direct and rapid analysis of mass spectra from
spent blastocyst culture media quickly identiﬁes optimal embryos with the best
chance of viable pregnancy.
What is known already: All available technologies to evaluate successful
implantation, such as PGS, require embryo biopsy. MALDI-ToF MS is success-
fully exploited in microbiology, but has largely been dismissed in assisted repro-
duction. Proteins in media from embryos have been detected using MALDI and
were consistent with gene expression studies and correlate well with positive
pregnancy; however, the ﬁndings were not correlated with all pregnancy out-
comes. This study represents the ﬁrst to use mathematical modeling to correl-
ate the spectral analysis of peptides in the embryo secretome with all
pregnancy outcomes.
Study design, size, duration: A prospective analysis of 500 culture ﬂuid
samples collected at the time of embryo transfer over a three year period which
were compared with eventual outcomes of ongoing viable pregnancy, SAB,
Biochemical pregnancy, negative pregnancy test or evaluation following PGS.
Participants/materials, setting, methods: Over 500 samples of spent
blastocyst culture media were collected from embryos of at the time of transfer
from a single clinic in the US. Just 1 μL of media was analyzed using MALDI ToF
mass spectrometry in a laboratory in the UK. Quantitative characteristics within
the 2000 to 15000 m/z mass range were examined using multiple supervised
machine learning algorithms to predict pregnancy outcome.
Main results and the role of chance: Mathematical analysis of secretome
spectra following MALDI ToF MS analysis shows distinct differences between
high grade embryos which go onto achieve successful pregnancy and those
which do not, either as an SAB, Biochemical Pregnancy, negative pregnancy test
or aneuploidy PGS result. Some analysis of algorithms used for embryos with
negative PGS outcomes samples were able to distinguish different aneuploidies.
Limitations, reasons for caution: More samples tested in a real-time envir-
onment using MALDI ToF in a clinic at the time of embryo transfer would help
validate this study which is limited by the freezing and shipping of samples to the
UK laboratory.
Wider implications of the ﬁndings: Many cycles result in negative out-
comes due to aneuploidies or implantation failure when embryos appear other-
wise viable. Checking for aneuploidies is time consuming, invasive and requires
vitriﬁcation. Implementation of a quick and simple non-invasive mass spectral
analysis could simplify and dramatically improve embryo selection and increase
live births.
Trial registration number:Not Applicable.
O-277 Automation in the IVF laboratory: preliminary results with
a new device able to do both vitriﬁcation/rewarming of mice and
bovine oocytes and embryos
P. Patrizio1, Y. Natan2, P. Levi Setti3, M. Leong4, A. Arav5
1Yale Fertility Center, Obstetrics/Gynecology and Reproductive Sciences, New
Haven, U.S.A.
2FertileSafe Ltd., Experimental Research Laboratory- 11 HaHarash st., Nes-Ziona-
Israel, Israel
3Istituto Clinico Humanitas, Reproductive Medicine unit/ Dept OB/GYN, Rozzano-
Milano, Italy
4The Womens Clinic, Reproductive Medicine Clinic, Hong Kong, Hong Kong
5FertileSafe Ltd, Experimental Research Laboratory- 11 HaHarash st, Nes Ziona,
Israel
Study question: Can both vitriﬁcation and rewarming be standardized using a
unique automated device capable to do both procedures?
Summary answer: The automatic vitriﬁcation/rewarming device (Sarah) pro-
duces high survival rates of oocytes/embryos. This novel device will become
indispensable for standardization and automation in the IVF laboratories.
What is known already: Clinical demand for oocyte vitriﬁcation has been
steadily increasing for women electively postponing motherhood or at iatro-
genic risk of losing their reproductive ability. However, the lack of standardiza-
tion of vitriﬁcation/rewarming protocols produces variable ranges of survival,
pregnancy and live birth rates among ART centers. Currently, most vitriﬁca-
tion/rewarming protocols require manual moving of oocytes or embryos one
at time between various solutions (often 4 or 5) before completing the task.
Study design, size, duration: Experimental research, using mice (40 oocytes
and 242 cleaved embryos) and bovine (234 oocytes and 55 cleaved embryos)
samples in a new automatic vitriﬁcation/warming device (Sarah, FertileSafe,
Ltd).
Participants/materials, setting, methods: Mice oocytes (n = 40) and
embryos (8 cells, n = 35 and blastocysts, n = 165) and bovine embryos (2Pn, n
= 35) and MII oocytes (n = 84) were vitriﬁed using the automated device
(Sarah). A total of 42 (2 cells) mice embryos, 20 (2Pn) bovine embryos, and
150 MII bovine oocytes were used as fresh controls and grown to blastocysts.
Upon rewarming with the same device, all were assessed for viability, cleavage,
blastocyst and hatching rates.
Main results and the role of chance: Up to 5 oocytes/embryos were
loaded into 0.25 ml straws end-closed by special capsules and connected to the
robotic arm. For the mice experiments, the samples were exposed to three ES
(30, 60, 100%) followed by VS (100%). For the bovine experiments, samples
were exposed to six ES (10, 20, 40, 60, 80, 100%) followed by VS (75, 100%).
For rewarming straws were plunged into temperature-controlled 5 ml tubes
containing WS 100, 50, 25 and 12.5%, at RT for 2.5 minutes each, before arrival
to the holding station. 95% (38/40) of the mice MII oocytes regained isotonic
volumes and all (95/95, 100%) were viable. Rewarmed 8 cell mice embryos
had 95% (33/35) blastulation rate and 80% (28/35) hatched. Rewarmed mice
blastocysts had 97% survival rate (160/165) and 81% (135/165) hatched. Fresh
control mice embryos had 100% blastulation rate (42/42) and 73% hatching
(21/42) (p = ns). Bovine embryos survival was 100% with 54 % (19/35) cleav-
age and 9% (3/35) reaching blastocyst stage. Fresh control bovine embryos had
65% (13/20) cleavage and 20% (4/20) blastulation rate. Vitriﬁed/warmed
bovine oocytes had 100% survival, 73% (61/84) cleavage and 7% (6/84) blasto-
cysts rates; fresh control had 83% (125/150) cleavage and 11% (17/150)
blastocyst rate (p = ns).
Limitations, reasons for caution: These successful preliminary results in
animal models need to be replicated in the recently started clinical human IVF
settings.
Wider implications of the ﬁndings: Automation of both vitriﬁcation and
rewarming of oocytes and embryos will drastically reduce the differences in sur-
vival and success rates between ART centers worldwide. Simpliﬁcation and
standardization of protocols will be of great value both for patients requiring
fertility preservation or elective cryopreservation and the whole ART industry.
Trial registration number:N/A
O-278 Single-cell RNA-seq reveals distinct dynamic behavior of sex
chromosomes during human early embryogenesis
Q. Zhou1,2, T.F.Wang1, J.H. Sun1, X. Yang1, Y.R. Xing1, H.X. Chen1,
J.J. Xu1, W.J.Wang1
1BGI-Shenzhen, BGI-Research, ShenZhen, China
2University of Copenhagen, Department of Biology, Copenhagen, Denmark
Study question: For human in vitro fertilization embryos, are there differ-
ences between male and female on the gene expression level during early
development?
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Summary answer: There are imbalanced expression of sexual chromosomes
between gender from the embryonic genome activation (EGA), with a dosage
compensation ﬁrstly occurring in female trophectoderm cells.
What is known already: Several animal studies have demonstrated that the
gender has an effect in the kinetics and metabolism of early embryo develop-
ment. At the stage before implantation, sex-speciﬁc differences in gene expres-
sion become apparent. In rodents, this period of double X chromosome
activation occurs between 4-cell and 16-cell stages, but the equivalent timing is
uncertain in human embryos. Failure to accomplish dosage compensation nor-
mally results in early miscarriage and embryonic lethality. In human, the dosage
compensation is started by silencing the expression of both X chromosomes in
blastocyst embryos, while the exact procedure remains unclear.
Study design, size, duration: We performed global expression analysis
between males and females using single-cell RNA-sequencing data of 1585 indi-
vidual cells from 98 human preimplantation embryos, covering development
stages from 8-cell to late blastocyst.
Participants/materials, setting, methods: We classiﬁed all the cells from
E3 to E7, corresponding to their developmental stages from 8-cell to late
blastocyst. An average of 20 embryos were analyzed per embryonic day. We
determined the sex of each embryo after assessing the expression level of Y-
linked genes for each cell. Then we performed the comparison of expression
between gender for each stage.
Main results and the role of chance: We provide a comprehensive com-
parison of transcriptional atlas between sex of human preimplantation embryos
and reveals the dynamics of sex chromosomes during embryogenesis for the
ﬁrst time. Consistent chromosome-wide transcriptomic level of autosomes was
observed in all stages, while sex chromosomes showed signiﬁcant differences
after EGA. We observed a signiﬁcant enrichment of differentially expressed
genes on X chromosome at the 8-cell stage, on both X and Y chromosomes at
the morula stage, and on Y chromosome at the blastocyst stage(P < 0.001).
Two of the DE genes on Y chromosome, RPS4Y1 and DDX3Y, achieved abun-
dant expression in all male cells immediately beyond the completion of EGA
and could be used as a gender marker in male embryos. For X chromosomes in
female, over 100 signiﬁcantly higher expressed genes were deﬁned in 8-cell
stage and both alleles of most heterozygous sites could be detected in our allelic
analysis. Contrary to constant pattern of Y chromosome, the expression of X
chromosome distinctly dropped at late blastocyst stage, especially in trophecto-
derm cells, revealing the exact time point and details of dosage compensation.
Limitations, reasons for caution: Lack of genomic data to verify the gender
of each embryo is the limitation of this study. In addition, in the allelic analysis,
we still need the variants of embryonic genome to get more informative sites.
Wider implications of the ﬁndings: Studying the sex differences during
human embryogenesis, as well as understanding the procedure of X inactivation
and its correlation with early miscarriage, will build upon the capabilities of
assisted reproductive technology to improve the treatment of infertility and
reproductive health.
Trial registration number: not applicable.
O-279 Parallel single-cell genome and transcriptome sequencing
to study chromosomal instability during human embryonic
preimplantation development
E. Fernandez Gallardo1, A. Sifrim1, S. Debrock2, J.R. Vermeesch1,
T. Voet1
1KU Leuven, Center of Human Genetics, Leuven, Belgium
2UZ Leuven, Leuven University Fertility Centre, Leuven, Belgium
Study question: Is there any transcriptional signature of aneuploidy at single
cell level during human preimplantation embryonic development?
Summary answer: The largest transcriptomic differences between cells are
due to embryonic genome activation. Differences due to aneuploidy become
detectable comparing cells of the same developmental stage.
What is known already: More than 70% of IVF human cleavage stage
embryos are mosaic. Nevertheless, some can potentially develop in healthy
babies after transfer. The causative mechanisms of chromosome instability as
well as the mechanisms of selection and/or correction of aneuploid cells remain
largely unexplored and speculative in the embryo.
Study design, size, duration: All single cells from 31 preimplantation
embryos were subjected to parallel single-cell whole genome and transcriptome
sequencing. Namely, 8 embryos at Day1 (17 cells), 19 embryos at Day2 (62
cells), 2 embryos at Day3 (17 cells) and 2 embryos at Day4 (23 cells). From
each single cell, genome-wide DNA copy number (CNV) and whole transcrip-
tome gene expression levels were determined. The data from this ongoing
cross-sectional study was generated between October 2016 and November
2018.
Participants/materials, setting, methods: Thirty-one zygotes donated for
research from 14 couples were cultured in a time-lapse incubator after surviving
cryopreservation. At a speciﬁc cell stage, embryos were mechanically disso-
ciated into 119 single blastomeres, which were subjected to on-bead separation
and ampliﬁcation of DNA and RNA. Single-cell ampliﬁcation products were
subsequently sequenced with Illumina platforms. Single-cell DNA genome-wide
CNVs were determined by focal read depth analysis. Single-cell gene expression
data was subjected to clustering and principal component analysis (PCA).
Main results and the role of chance: Single-cell DNA CNV analysis
revealed frequent missegregations of whole chromosomes as well as segmental
rearrangements in all embryonic cell stages. Speciﬁcally, 22 out of 31 (70%)
embryos contained at least one genetically abnormal cell. At single cell level, 74
out of 92 cells (80%) that passed sequencing quality control contained at least
one segmental or whole chromosome aneuploidy. The remaining 18 cells
(20%) were normal euploid. Furthermore, using embryonic cell cleavage pheno-
type and the genomic proﬁle of its single cells, we could deduce the origin of
the abnormalities and construct cell lineages.
Single-cell gene expression analysis, classiﬁed the cells according to the
embryonic cell stage and the embryonic genome activation (EGA). Moreover,
we could benchmark our dataset by recapitulating previously described EGA
gene expression patterns. Interestingly, two Day3 blastomeres with heavily
rearranged genomes clustered separately from the rest of the Day3 cells
regardless of the embryo of origin. These results suggest that transcriptomic dif-
ferences due to abnormal genomes might be subtler between cells from differ-
ent embryo stages while more detectable when comparing embryos within the
same developmental stage.
Limitations, reasons for caution: This is a preliminary analysis of an
ongoing study. The current analysis includes a low number of embryos and
unevenly distributed across the preimplantation embryonic stages. Further
RNA-seq computational analysis in a higher number of samples are required to
unravel the effect of CIN in the transcriptome.
Wider implications of the ﬁndings:We deliver proof-of-principle that this
novel, state-of-the-art method for simultaneous genome and transcriptome
sequencing (G&T-seq) of the same single cell can be successfully applied in
human blastomeres. To our knowledge, these are the ﬁrst results of G&T-seq
in human embryos. We foresee a great scientiﬁc potential to study embryo
development.
Trial registration number: not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 73: ART-RELATED COMPLICATIONS
Wednesday 4 July 2018 Room 211 + 212 14:00–15:15
O-280 Oocyte retrieval complications: an update after 23,833
procedures in an academic tertiary care ART referral center
P.E. Levi Setti1, F. Cirillo1, V. Scolaro1, F. Heilbron2, D. Girardello3,
E. Zannoni1, P. Patrizio4
1Humanitas Research Hospital, Humanitas Fertility Center- Department of
Gynecology- Division of Gynecology and Reproductive Medicine, Rozzano Milan, Italy
2Humanitas University, Humanitas University, Rozzano Milan, Italy
3Humanitas Research Hospital, Department of Anesthesiology and Intensive Care,
Rozzano Milan, Italy
4Yale University- School of Medicine- New Haven, Department of Obstetrics-
Gynecology and Reproductive Sciences, New Haven- Connecticut-, U.S.A.
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Study question: The aim of the present study was to assess complications
encountered on the largest single centre series of transvaginal oocyte retrievals (OR).
Summary answer: A signiﬁcant correlation between complications and
women age, BMI, the number oocytes, mean time to complete oocyte retrieval,
clinician experience and presence of risk factors.
What is known already: Ultrasound guided transvaginal OR represents the
most commonly used technique in ART cycles. Several observational studies
evaluating the rates of complications associated with this procedure have
shown it to be safe, with very low rates of serious complications.
Study design, size, duration: This is a retrospective analysis including all the
oocytes retrievals performed at a large teaching hospital from June1996 to
November 2016. The study has been approved by our Institutional Review
Board, all patients signed an informed consent to the use of their data, as long
as their anonymity and conﬁdentiality were assured. February 28th 2016. All
the patients’ data were extracted from the Fertility Center external-audit-
anonymized electronic research query system.
Participants/materials, setting, methods: 23,833 procedures were
included. We did not exclude any patient who performed retrievals during the
period in exam. Complications requiring hospital admission for at least 24 hours
were considered severe complications. Transvaginal ultrasound–guided OR
was performed 34/36 hours after the trigger injection, under deep sedation in
an operating theatre, using a 35 mm, 17-gauge aspiration needle. Antibiotic
prophylaxis was not routinely used except in situation with surgical risk factors.
Main results and the role of chance: A total of 96 out of 12,615 patients
(0.76%) suffered complications, with hospital admission necessary for 71
patients (0.56%). Mean hospital stay was 2.77 ± 2.5 days. When calculated per
retrieval, the overall complication rate was 0.4% while 0.29% was the admission
rate. A surgical procedure was necessary for 24 patients (0.1% per retrieval and
0.19% per patient). Multivariate analysis showed a signiﬁcant correlation
between complications and women age, BMI, the number oocyte retrieved and
mean time to complete oocyte retrieval. The incidence of complications was
signiﬁcantly higher for physicians who had performed fewer than 250 retrievals
as compared to those who had completed more than 250 (OR 0.63; 0.40 –
0.99 – p = 0.0472).
In general, the most important risk factors for the occurrence of a complica-
tion can be identiﬁed in: a) high number of oocytes retrieved; b) a longer dur-
ation of operative time; c) inexperience of the surgeon; d) a low BMI and e) a
history of prior abdominal or pelvic surgery or pelvic inﬂammatory disease.
Interestingly, sixteen of the ﬁfty-four retrievals (29.63%) with hemoperitoneum
had surgical risk factors.
Limitations, reasons for caution: Although the great majority of complica-
tions were treated in our institution (94/96 complications), others could have
been treated in other hospital and not unreported. This could reﬂect a possible
bias with an underestimation of the incidence of complication related to oocyte
retrieval, severe ones are usually reported.
Wider implications of the ﬁndings: OR can be considered a safe proced-
ure, although patients and physicians should understand that this technique is
not without risks. We found that complications were consistently less when the
operator had performed an average of 250 ORs. We can therefore suggest
referring to more experienced surgeons OR at higher risk.
Trial registration number:NCT03282279
O-281 Transfer of two non-top quality embryos increases the risk
of ectopic pregnancy after fresh and frozen-thawed embryo transfer
S. Anzhel1,2, S. Mäkinen3, H. Tinkanen4, T. Mikkilä4, A. Haltia5,
A. Perheentupa3, C. Tomás6, H. Martikainen7, A. Tiitinen1,
J. Tapanainen1, Z. Veleva1
1University of Helsinki and Helsinki University Central Hospital, Obstetrics and
Gynecology, Helsinki, Finland
2University of Varna, Department of Obstetrics and Gynecology, Varna, Bulgaria
3University of Turku, Obstetrics and Gynecology, Turku, Finland
4University of Tampere, Obstetrics and Gynecology, Tampere, Finland
5Felicitas Mehiläinen Turku, Turku infertility clinic, Turku, Finland
6Ovumia and Fertinova Tampere Infertility Clinics, Infertility Clinic, Tampere, Finland
7University of Oulu and Oulu University Hospital, Obstetrics and Gynecology, Oulu,
Finland
Study question: Is embryo quality associated with ectopic pregnancy (EP)?
Summary answer: The odds for EP are elevated after the transfer of two
embryos, even if both are of non-top quality.
What is known already: The incidence of EP after IVF/ICSI varies from 1.6%
to 8.6%, and can be up to four times higher than the rate in spontaneous preg-
nancies. Tubal factor infertility and the transfer of multiple embryos are known
to increase the probability of EP. Nowadays, top quality embryos are mostly
transferred in single embryo transfers (SET). Double embryo transfers (DET)
are therefore performed with non-top quality embryos. The effect of embryo
quality on EP has not been investigated until now. Furthermore, there is no con-
sensus on whether the transfer of fresh vs. cryopreserved embryos has a differ-
ent effect on EP rates.
Study design, size, duration: Retrospective cohort study of 16,891 clinical
pregnancies (diagnosed by ultrasound at 6-8 gestational weeks) after non-
donor IVF/ICSI with fresh (n = 10,255) or frozen-thawed transfer (FET) (n =
6636), performed in 2000-2017 in Finland (LUMI database). In all cases, there
were up to two embryos transferred with known morphological quality.
Presence or absence of tubal factor infertility was also recorded. Heterotopic
pregnancies were classiﬁed as ectopic.
Participants/materials, setting, methods: A single top quality embryo
was transferred in 6634 (39.3%) and a single non-top one in 4206 (24.9%)
cycles. In DET cycles, there were no (3721 cycles, 22.0%), one (1485 cycles,
8.8%) or two (845 cycles, 5.0%) top quality embryos transferred. We analyzed
the effects of female age, the number of embryos transferred, embryo quality,
type of cycle (fresh vs. FET) and tubal factor infertility on EP by logistic
regression.
Main results and the role of chance: EP was observed in 384 (2.3%) cycles.
There was no signiﬁcant difference in EP rate after fresh embryo transfer or FET
(225/10,255, 2.2% vs. 159/6636, 2.4%, P = 0.7). Compared to treatments in
which only top quality embryos were transferred (141/7479, 1.9%), EP rate in
cycles with only non-top quality embryos transferred was higher (219/7927,
2.8%, P < 0.0001). Tubal factor infertility was diagnosed more often in EP than
in intrauterine pregnancies (19.5% vs. 10.2%, P < 0.0001).
Logistic regression revealed that the odds of EP after fresh transfer were simi-
lar to those after FET (odds ratio (OR) for FET 1.06, 95% conﬁdence interval
(CI) 0.86-1.23, P = 0.6). DET increased signiﬁcantly the chance of EP, com-
pared to SET (OR 1.45, 95% CI 1.18-1.78, P < 0.0001). Presence of tubal fac-
tor infertility was associated with EP (OR 2.06, 95% CI 1.59-2.67, P < 0.0001).
In a separate logistic regression analysis, transfer of two non-top quality
embryos (OR 1.49, 95% CI 1.13-1.95, P = 0.004) but not of one (OR 0.79,
95% CI 0.60-1.05, P = 0.1) or two top quality embryos (OR 1.31, 95% CI 0.83-
2.07, P = 0.3) increased the odds of EP, compared to transfer of a single non-
top quality embryo. Female age was not associated with EP (P = 0.3).
Limitations, reasons for caution: The effect of the hormonal environment
in FET (spontaneous vs. hormonally-substituted cycles) was not analized due to
the limited availability of complete data.
Wider implications of the ﬁndings: Transfer of non-top quality embryos
decreases the chances of live birth after IVF/ICSI. The present study found that
DET with two non-top quality embryos is also associated with increased odds
of EP. This is particularly important in tubal factor infertility patients who are
already at risk of EP.
Trial registration number:Not applicable
O-282 Hospitalizations due to OHSS after IVF is not diminished
during the last 15 years despite presumed improvements in ovarian
stimulation - National data from Denmark
L.B. Colmorn1, Ø. Lidegaard2, N. Sopa3, A. Pinborg1, S. Malchau3,
A. Nyboe Andersen1
1Rigshospitalet, Fertilityclinic, Copenhagen, Denmark
2Rigshospitalet, Gynecology, Copenhagen, Denmark
3Hvidovre Hospital, Fertilityclinic, Hvidovre, Denmark
Study question: Do we observe a recent reduction in prevalence of severe
OHSS after change towards antagonist protocols, use of response predictive
factors and agonist triggering?
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Summary answer:National Danish Hospital discharge register data identiﬁed
2.564 OHSS cases after 160.803 ART-cycles and no signiﬁcant prevalence
reduction of severe OHSS from 2001 to 2015.
What is known already: OHSS is a known risk of ovarian stimulation, but it
is known that the numbers directly reported by ART professionals to the regis-
ters are grossly underreported, whereas more accurate numbers may be
obtained from hospital discharge registers. Antagonist protocols that lowers
the risk of OHSS are more commonly used in recent years, agonist triggering
may reduce the OHSS rate, and ovarian response predictive factors like AHM
and AFC have been developed. All these changes in IVF should reduce the
OHSS risk.
Study design, size, duration: This is a retrospective register based study
including 160.803 IVF/ICSI stimulated cycles from all public and private fertility
clinics in Denmark from 2001 to 2015.
Participants/materials, setting, methods: From 2001 to 2015, a total of
2.564 women had at least one hospital admission with an OHSS diagnosis. Data
on OHSS was obtained from the Danish National Discharge Register and the
annual number was compared to the annual number of stimulated IVF/ICSI
cycles, obtained from the ART register of the Danish Fertility Society (www.
fertilitetsselskab.dk). Changes in the prevalence were estimated by Chi-square
test and Cochran-Armitage test for trend.
Main results and the role of chance: The annual number of OHSS ranged
from 151 cases in 2001 to 203 cases in 2009 and 2010 and 169 cases in 2015.
During the same period the number of stimulated IVF/ICSI cycles increased
from 8.805 in 2001 to 12.328 in 2015. The prevalence of OHSS among all sti-
mulated cycles in 2001 was 151/8805 = 1.7% (CI: 1.4 to 1.9) and in 2015 169/
12.328 = 1.4% (CI: 1.2% to 1.9%), with a marginal reduction of 0.3%. The
prevalence varied with the highest ﬁgure in 2005 with 178 /9541 = 1.9% (CI:
1.6 to 2.0), and the lowest in 2007 with 153/11035 = 1.4% (CI: 1.2 to 1.9) and
in 2015 with 169/12.328 = 1.4% (CI: 1.2 to 1.9). We found no signiﬁcant
changes between the annual prevalence of OHSS in Denmark (p = 0.126) as
well as no trend for changes in the prevalence over the 15 years (p = 0.158).
Limitations, reasons for caution: The present analysis was unable to iden-
tify cases of OHSS that may have occurred after ovulation induction for anovu-
lation or intrauterine inseminations. Extensive data sets on those IVF cycles that
did and did not result in OHSS would be needed to analyze why OHSS was not
reduced.
Wider implications of the ﬁndings: We have increased knowledge of risk
factors for OHSS and may adapt treatment regiments towards more antagonist
protocol, agonist triggering, individualized FSH dosing or a freeze all strategy.
However, on a National basis we have not yet seen that the results of such
efforts diminish the risk of OHSS.
Trial registration number: ‘not applicable’
O-283 Pregnancy after frozen-thawed embryo transfer during
hormonal replacement cycle is associated with hypertensive
disorders of pregnancy and placenta accreta
K. Saito1,2,3, A. Kuwahara4, T. Ishikawa3, T. Nakasuji3, M. Miyado1,
K. Miyado5, M. Fukami1, N. Miyasaka3, M. Irahara4, H. Saito2
1National Research Institute for Child Health and Development, Department of
Molecular Endocrinology, Tokyo, Japan
2National Center for Child Health and Development, Department of Perinatal
Medicine and Maternal Care, Tokyo, Japan
3Tokyo Medical and Dental University- Graduate School, Department of
Comprehensive Reproductive Medicine, Tokyo, Japan
4The University of Tokushima Graduate School, Department of Obstetrics and
Gynecology, Tokushima, Japan
5National Research Institute for Child Health and Development, Department of
Reproductive Biology, Tokyo, Japan
Study question: Is there any difference in obstetrical risk between patients
who conceived after frozen embryo transfer (FET) during a hormone replace-
ment cycle (HRC-FET) and during a natural ovulatory cycle (NC-FET)?
Summary answer: The patients who conceived by HRC-FET had an
increased risk of hypertensive disorders and placenta accreta compared with
those who conceived by NC-FET.
What is known already: Previous study has shown that the rate of
Caesarean section in pregnancies conceived through HRC-FET is higher than
those conceived through NC-FET. Little has been clariﬁed regarding an associ-
ation between obstetrical complications and endometrium preparation
methods.
Study design, size, duration: A retrospective cohort study of patients who
conceived after HRC-FET and those who conceived after NC-FET was per-
formed, based on the Japanese assisted reproductive technology registry in
2014.
Participants/materials, setting, methods: Pregnancy outcomes were
compared between the cases of NC-FETs (n = 29,760) and HRC-FETs (n =
75,474). Multiple logistic regression analyses were performed to investigate the
potential confounding factors for mode of delivery and obstetrical
complications.
Main results and the role of chance: The pregnancy rate was signiﬁcantly
lower in HRC-FET cycles than in NC-FET cycles (32.1% vs. 36.1%, p < 0.001).
Among pregnancies, Caesarean section rate was higher (44.5% vs. 33.7%, p <
0.001) for pregnancies conceived through HRC-FET than those conceived
through NC-FET. A multiple logistic regression analysis showed that pregnan-
cies after HRC-FET had increased odds of Caesarean section (adjusted odds
ratio [aOR] 1.736, 95% conﬁdence interval [CI] 1.632–1.847), hypertensive dis-
orders of pregnancy (aOR 1.443, 95% CI 1.231–1.692), and placenta accreta
(aOR 6.817, 95% CI 3.662–12.692) compared to pregnancies after NC-FET.
Limitations, reasons for caution: This study is retrospective, and some
cases were excluded due to missing data. The possible role of residual con-
founding factors and bias must be considered.
Wider implications of the ﬁndings: Pregnancies following HRC-FET have
higher risks of hypertensive disorders of pregnancy and placenta accreta. The
association between endometrium preparation method and these placenta
related obstetrical complications merits further attention.
Trial registration number: not applicable.
O-284 Pregnancy complications following assisted reproductive
techniques - disentangling the role of multiple gestation
S. Oberg1, T. VanderWeele2, C. Almqvist3, S. Hernandez-Diaz2
1Karolinska Institutet, Department of Medical Epidemiology & Biostatistics,
Stockholm, Sweden
2Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston,
U.S.A.
3Karolinska Institutet, Department of Epidemiology & Biostatistics, Stockholm,
Sweden
Study question: Is there a risk of pregnancy complications following ART
among infertile couples, and to what extent is this independent versus mediated
by multiple gestations?
Summary answer: Multiple gestations are responsible for a large proportion
of common pregnancy complications following use of ART, but nearly none of
the risk of placenta previa.
What is known already: Several of the pregnancy complications observed
after use of ART are also common complications of multiple gestation, and
since multiple gestations are more frequent following ART many studies choose
to assess ART risks in singletons and multiples separately. This approach can
induce bias if attention is not paid to potential common causes of the multiple
gestations mediator and the pregnancy complications outcome, and it does not
provide insight into how much of the effect is through the different pathways.
Assessing the inﬂuence of intervention to reduce multiple gestations should be
informative for both clinical practice and public health.
Study design, size, duration: Linkage of national registers allows
population-based cohort studies based on prospectively collected data. The
Medical Birth register consistently covers 96-99% of all births in Sweden. From
the nearly 1.8 million births recorded in the register between 1996 and 2013
we selected the 9.9% (N = 174 067) pregnancies that occurred to couples with
known trouble conceiving (clinical infertility).
Participants/materials, setting, methods: Information regarding infertility
and fertility assistance was available from antenatal self-reports, medical
records, and procedural information from fertility clinics. We used logistic
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regression to estimate odds ratios (OR) and their 95% conﬁdence intervals
(CI), and decomposing the total effect into direct and mediated effects to esti-
mate the proportion mediated by multiple gestations. Sweden’s 2003 imple-
mentation of single-embryo transfer (SET) policy further allowed direct
observation of an intervention to curb the occurrence of multiples following
ART.
Main results and the role of chance: Although the prevalence of multiples
from ART was substantially reduced by SET recommendations (13% in 1996-
2003 to 6% in 2004-2013) it remained 4 times higher than in non-assisted preg-
nancies. Prior to the intervention, pregnancies achieved with ART had higher
odds of all studied complications except gestational diabetes when compared
with non-assisted pregnancies to infertile couples. Associations with placenta
previa (OR 2.91, 95% CI 2.31–3.68) and placental abruption (OR 2.57, 95% CI
1.99–3.33) were found almost entirely independent of multiple gestations. In
contrast, the majority of the associations with preterm birth (OR 2.79, 95% CI
2.28–3.42), cesarean delivery (OR, 1.79, 95% CI 1.54–2.08) and pre-eclampsia
(OR 1.28, 95% CI 1.12–1.46) were mediated by multiple gestations (87%, 84%
and 100% of the effect mediated, respectively). Both direct and mediated path-
ways contributed to the remaining positive associations with chorioamnionitis,
labor induction, and postpartum hemorrhage. While ART remained associated
with all noted complications also after the intervention (2004-2013), the excess
risk dropped markedly for the complications found largely mediated by multiple
gestations (preterm birth, cesarean and pre-eclampsia). In contrast, the excess
risk of placenta previa was largely unchanged.
Limitations, reasons for caution: Some complications may be more likely
detected or recorded in women having undergone ART and/or carrying multi-
ples. Reassuringly, one of the more susceptible such diagnoses, gestational dia-
betes, was not more common in treated pregnancies, nor in pregnancies with
multiples (among infertile) in our study population.
Wider implications of the ﬁndings: Interventions to curb the occurrence
of multiples may greatly reduce the risk of several pregnancy complications fol-
lowing use of ART. Finding some risk independent of multiple gestations, espe-
cially for severe placental complications, demonstrates that pregnancies
achieved after ART may be considered high-risk pregnancies irrespective of
number of fetuses.
Trial registration number:Not applicable.
SELECTEDORAL COMMUNICATIONS
SESSION 74: FACTORS AFFECTING FERTILITY
POTENTIAL PCOSWOMEN
Wednesday 4 July 2018 Room 111 + 112 14:00–15:15
O-285 Endometrial expression of stanniocalcin-1 (STC-1) during
the menstrual cycle in healthy women and in women with polycystic
ovary syndrome (PCOS)
M. Khatun1, M. Kangasniemi2, A. Ahtikoski3, R.K. Arffman2,
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Study question: How is stanniocalcin-1 (STC-1) expressed in normal human
endometrium and is it altered in women with polycystic ovary syndrome
(PCOS)?
Summary answer: STC-1 was dysregulated in PCOS endometrium exerting
lower expression in secretory phase and blunted response to 8-bromo-cyclic
adenosine monophosphate (8-Br-cAMP) and hypoxia compared with controls.
What is known already: STC-1 has been shown to be one of the receptivity
markers but also involved in cancer development. Endometrial STC-1 was
recently reported to be dysregulated in endometriosis, a condition with endo-
metrial progesterone resistance and inﬂammation that characterize PCOS
endometrium. Given that women with PCOS present with subfertility, preg-
nancy complications and increased risk for endometrial cancer, we investigated
STC-1 expression in PCOS endometrium.
Study design, size, duration: Prospective case-control study.
Participants/materials, setting, methods: The material consisted of pro-
spectively collected endometrial tissue biopsies from healthy controls (n = 65)
and in women with PCOS (n = 38). This sample set included endometrial biop-
sies from two clinical trials; 8 endometrial samples from control women using
hormonal contraceptives for nine consecutive weeks and 14 endometrial sam-
ples from over-weight women with PCOS before and after 3-month life style
intervention. The samples were investigated by immunohistochemistry, in situ
hybridization, quantitative RT-PCR and in vitro cell culture.
Main results and the role of chance: In normal human endometrium, STC-
1 was upregulated in glandular epithelium (GE) in early and mid-secretory phase
(ESE and MSE) compared with proliferative phase (PE). Through all cycle
phases, endometrial stromal cells showed the highest STC-1 expression in late
secretory phase (LSE) (P = 0.01) whereas the expression was quiescent during
the use of hormonal contraceptives. Interestingly, in non-PCOS women obesity
seemed to increase the STC-1 expression in secretory phase (P = 0.047).
Women with PCOS had comparable STC-1 expression in proliferative phase
(PE) as controls but the rise in expression towards the secretory phase (SE)
was insigniﬁcant. During induced decidualization in vitro, estrogen or progester-
one (alone or in combination) were not able to trigger STC-1 expression in cul-
tured stromal cells. However, decidualization with 8-Br-cAMP induced high
STC-1 response in control stromal cells, whereas in women with PCOS the
expression was signiﬁcantly lower at mRNA (P < 0.0001) and protein (P <
0.01) levels, despite of the normal levels in classic decidualization markers.
Furthermore, hypoxia triggered high STC-1 protein expression in control stro-
mal cells that was blunted in stromal cells from women with PCOS (P < 0.001).
Limitations, reasons for caution: The study consists of rare endometrial
tissue samples from several cycle phases and from clinical trials. However, the
in vitro testing did not consider the role of hyperandrogenism or hyperinsuline-
mia, common in PCOS. Further studies are also warranted to elucidate the
mechanisms behind the altered endometrial STC-1 expression in PCOS.
Wider implications of the ﬁndings: According to our ﬁndings, despite of
successful decidualization in women with PCOS, aberrant STC-1 expression
was observed possibly reﬂecting impaired and desynchronized endometrial
function during implantation process. Moreover, blunted STC-1 in PCOS endo-
metrium may promote endometrial cancer through defective rescue mechan-
ism related to hypoxia.
Trial registration number: The study of clinical trial testing hormonal con-
traceptives: SYLVI ClinicalTrials.gov Identiﬁer: NCT02352090, Karolinska
Instituet ethical approval number is: IRB 2008/865-32
O-286 Clomiphene citrate or gonadotrophins in women with
WHO type II anovulation and CC failure; a role for EMT?
E. Bordewijk1, N.Weiss1, C. Lambalk2, M. Goddijn1, P. Hompes2,
F. Van der Veen1, B.W. Mol3, M. VanWely1
1Academic Medical Center, Center for Reproductive Medicine, Amsterdam, The
Netherlands
2VU University Medical Center, Center for Reproductive Medicine, Amsterdam, The
Netherlands
3Monash University, Department of Obstetrics and Gynaecology, Melbourne,
Australia
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Study question: Is endometrial thickness (EMT) a biomarker to select women
for clomiphene citrate (CC) or gonadotrophins in women with WHO type II
anovulation and CC failure?
Summary answer: EMT measured in the sixth ovulatory CC cycle can be
used as biomarker to decide on continuing CC or to switch to gonadotrophins.
What is known already: CC has been a long standing ﬁrst line treatment in
women with normogonadotropic anovulation. We recently showed that in
women with normogonadotropic anovulation and CC failure, a switch to gona-
dotrophins increases the chance of live birth over continued treatment with CC
with 10%. This may be due to a thinner EMT after CC compared to gonadotro-
phins. It is unclear if EMT during ovulation induction with CC is a marker to
identify women that beneﬁt from one or the other treatment.
Study design, size, duration: Between Dec 8, 2008, and Dec 16, 2015, 666
women with CC failure (not pregnant after 6 ovulatory cycles) were randomly
assigned to receive an additional six cycles with CC (335) or six cycles with
gonadotrophins (n = 331). The primary outcome was conception leading to
live birth within 8 months after randomisation. In 380 women EMT (n = 190
CC, n = 190 gonadotrophins) was measured before randomisation during their
sixth cycle.
Participants/materials, setting, methods: We randomised women aged
18 years and older with normogonadotrophic anovulation not pregnant after
six ovulatory cycles of CC from 48 Dutch hospitals. EMT was determined in the
sixth cycle of CC before randomisation. An EMT of 8 mm was used as cut-off
value. We evaluated if EMT at baseline had interaction with the treatment
effect. To account for multiple cycles over time we used cox proportional haz-
ard analysis to calculate hazard rates (HR).
Main results and the role of chance: The EMT of the last CC cycle before
randomisation was available in 380 women, of whom 190 were allocated to CC
and 190 to gonadotrophins. Among 169 women (44%) with EMT < 8 mm, the
live birth rates were 33% with CC versus 54% with gonadotrophins, respect-
ively (RR 0.64, 95% CI 0.47 – 0.87), while in 211 women (56%) with EMT >
8 mm, the live birth rates were 53% with CC versus 48% with gonadotrophins,
respectively (RR 1.11, 95% CI 0.83 – 1.50).
Our analysis showed interaction between EMT and treatment success (p =
0.02). The hazard rate (HR) for a live birth in women with CC was 1.37 (95%
CI 1.01–1.84) for EMT > 8 versus EMT < 8. Mean time to live birth were 5.4
and 5.8 cycles for EMT > 8 and EMT < 8 respectively (log rank test p = 0.03).
The HR for live birth in women treated with gonadotrophins was 0.85 (95% CI
0.66–1.10) for EMT > 8 versus EMT < 8. Mean time to live birth were 5.2 and
4.9 cycles for EMT > 8 and EMT < 8 respectively (log rank test p = 0.2).
Limitations, reasons for caution: This was a post-hoc analysis, and EMT
measurements at baseline were not available for all included women. There
were many different doctors that performed the ultrasound measurements.
Wider implications of the ﬁndings: In women with CC-failure and EMT <
8 mm in the sixth cycle, a switch to gonadotrophins improves fertility outcomes
over continuing CC, while in women with CC-failure and EMT > 8 mm continu-
ing CC and switching to gonadotrophins are equally effective. This knowledge
can inform clinical decision making.
Trial registration number:Netherlands Trial Register, number NTR1449
O-287 The expression and regulation of inﬂammatory factor
interleukin-18 in the proliferative phase endometrium of PCOS
X. Long
Peking University Third Hospital, Gynecololgy and Obestetrics, beijing, China
Study question: How does the inﬂammatory factor IL-18 be up regulated in
the endometrium of patients with PCOS and the regulatory pathway that med-
iates this relationship?
Summary answer: SIRT1 interacted with C/EBP-β to activate the SIRT1/C/
EBP-β/IL-18 signaling pathway, resulting in the up-regulation of IL-18 expres-
sion in the endometrium of patients with PCOS.
What is known already: Polycystic ovary syndrome (PCOS) is a multisys-
tem, reproductive-metabolic disorder characterized by polycystic-appearing
ovaries, hyperandrogenism, and irregular menstruation. Recent studies have
indicated that patients with PCOS exhibit chronic inﬂammation, which might be
correlated with the pathogenesis of the disease. According to our previous
studies, the inﬂammatory factor IL-18 is increased both in the serum and the
endometrium of patients with PCOS. CCAAT enhancer-binding protein (C/
EBP) beta is an important transcription factor, and it may up-regulate the
expression of IL-18 in the endometrium. However, the regulatory effects of C/
EBP-β on IL-18 and the signaling pathway mediating these effects have not been
examined.
Study design, size, duration: Endometrial tissue samples of eighteen
women with PCOS and eighteen healthy women were obtained during hystero-
scopic surgery. In the present study, we explored the expression of C/EBP-β
and SIRT1 in the proliferative phase of the endometrium in women with and
without PCOS. We investigated whether C/EBP-β regulates IL-18 expression
and explored the underlying signaling mechanism that IL-18 was up-regulate in
the endometrium of PCOS patients.
Participants/materials, setting, methods: Endometrial tissue samples
were obtained during hysteroscopic surgery.IL-18 protein expression was ana-
lyzed using immunohistochemistry and western blotting, and IL-18 mRNA
expression was analyzed using quantitative real-time polymerase chain reaction.
C/EBP-β and Sirt1 protein combination was veriﬁed with co-
immunohistochemistry. The correlation of C/EBP-β and IL-18 was demon-
strated with Dual-luciferase assay. SIRT1 and C/EBP-β mRNA expression was
analyzed using quantitative real-time polymerase chain reaction.
Main results and the role of chance: IL-18 was signiﬁcantly increased in the
endometrium of women with PCOS compared with normal groups. In over-
weight women, IL-18 was obviously over-expressed in the PCOS group com-
pared with the healthy group. However, in normal weight women, there was
no statistically signiﬁcant difference between the two groups, and there was no
signiﬁcant difference in IL-18 expression in PCOS patients with or without insu-
lin resistance. We demonstrated the interaction of CEBP-β and IL-18 by Dual-
luciferase assay, and we used CO-IP assay demonstrated the combination of
SIRT1 and CEBP-β. Sirt1 and C/EBP-β proteins were over-expression in the
endometrium of PCOS patients.
Limitations, reasons for caution: As we known, PCOS patients have
irregular menstruation, so it’s difﬁcult to obtain the secretary phase endomet-
rium. We only detected and analysed proliferative phase endometrium and lar-
ger sample size was needed to carry on.
Wider implications of the ﬁndings: We detected the up-regulation of C/
EBP-β and SIRT1 in the proliferative endometrium of patients with PCOS.
Additionally, SIRT1 interacted with C/EBP-β to activate the SIRT1/C/EBP-β/
IL-18 signaling pathway, resulting in the up-regulation of IL-18 expression, and
which may related with endometium receptivity abnormality of PCOS patients.
Trial registration number:None.
O-288 Aromatase inhibitors (letrozole) for subfertile women with
polycystic ovary syndrome - A Cochrane Systematic Review
S. Franik1, S. Eltrop1, J. Kremer2, L. Kiesel1, C. Farquhar3
1University hospital Muenster, Obstetrics and Gynaecology, Münster, Germany
2Radboudumc, Obstetrics and Gynaecology, Nijmegen, The Netherlands
3University of Auckland, Obstetrics and Gynaecology, Auckland, New Zealand
Study question: Are aromatase inhibitors (letrozole) superior to other agents
for ovulation induction for subfertile women with anovulatory PCOS?
Summary answer: Letrozole improves live birth and pregnancy rates in sub-
fertile women with anovulatory PCOS, compared to clomiphene citrate.
What is known already: Polycystic ovary syndrome (PCOS) is the most
common cause of infrequent periods (oligomenorrhoea) and absence of peri-
ods(amenorrhoea). It affects about 4% to 8% of women worldwide and often
leads to anovulatory subfertility. Aromatase inhibitors (AIs) are a novel class of
drugs that were introduced for ovulation induction in 2001. Over the last ten
years clinical trials have reached differing conclusions as to whether the AI letro-
zole is at least as effective as the ﬁrst-line treatment clomiphene citrate (CC).
Study design, size, duration: We searched the following sources from
inception to November 2017 to identify relevant randomised controlled trials
(RCTs): the Cochrane Gynaecology and Fertility Specialised Register, the
Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE,
PsycINFO, Pubmed, LILACS, Web of Knowledge, the WHO clinical trials regis-
ter and Clinicaltrials.gov.
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We included all RCTs of aromatase inhibitors used alone or with other med-
ical therapies for ovulation induction in women of reproductive age with
anovulatory PCOS.
Participants/materials, setting, methods: Two review authors independ-
ently selected trials, extracted the data and assessed trial quality. Studies were
pooled where appropriate using a ﬁxed effect model to calculate pooled odds
ratios (ORs) and 95% conﬁdence intervals (CIs) for most outcomes and risk dif-
ferences (RDs) for ovarian hyperstimulation syndrome (OHSS). The primary
outcomes were live birth and OHSS. Secondary outcomes were pregnancy,
miscarriage and multiple pregnancy. The quality of the evidence for each com-
parison was assessed using GRADE methods.
Main results and the role of chance: We included 42 RCTs (7935
women). The aromatase inhibitor letrozole was used in all studies.
Live birth rate was reported in 13 RCTs, including 2954 women. The birth
rate was higher for letrozole compared to clomiphene (with or without
adjuncts) followed by timed intercourse (OR 1.68, 95% CI 1.34 to 1.99, I2 =
0%, NNT = 10).
There was no evidence of a difference in OHSS rates when letrozole (with or
without adjuncts) was compared with clomiphene citrate (with or without
adjuncts) followed by timed intercourse (RR 0.00, 95% CI -0.01 to 0.00, twelve
RCTs, n = 2536).
Pregnanc rate was reported in 25 RCTs, including 4629 women. The preg-
nancy rate was higher for letrozole compared to clomiphene (with our without
adjuncts) (OR 1.56, 95% CI 1.37 to 1.78, I2 = 1%).
Miscarriage rate was reported in 18 studies, including 3754 women. There
was no evidence for a difference between letrozole or clomiphene with or with-
out adjuncts (OR 0.94, 95% CI 0.70 to 1.26, I2 = 0%).
Multiple pregnancy rate was reported in 16 studies, including 3519 women.
There was insufﬁcient evidence to show a difference between letrozole or
clomiphene with our without adjuncts (OR 0.73, 95% CI 0,43 to 1.24, I2 = 0%).
Limitations, reasons for caution: The quality of the evidence was moder-
ate for live birth and pregnancy outcomes. The reasons for downgrading the
evidence were possible publication bias and the tendency for studies that
reported live birth to report higher clinical pregnancy rates in the letrozole
group than studies that failed to report live birth.
Wider implications of the ﬁndings: Our ﬁndings suggest that letrozole is
superior to clomiphene citrate for the treatment of subfertility in women with
PCOS who have had no previous treatment for ovulation induction or are
resistant to clomiphene citrate.
Trial registration number: not applicable.
O-289 Higher probability of pregnancy after frozen-embryo
transfer using a freeze-all policy compared to fresh-embryo transfer
in high, but not in normal responder patients: a meta-analysis
J. Bosdou1, C. Venetis2, B. Tarlatzis3, G. Grimbizis1, E. Kolibianakis1
1Medical School-Aristotle University of Thessaloniki-Greece, Unit for Human
Reproduction-1st Dept of Obstetrics & Gynecology, Thessaloniki, Greece
2University of New South Wales, School of Women’s and Children’s Health UNSW
Medicine, Sydney, Australia
3Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
Study question: Is frozen embryo transfer (ET) using a freeze-all policy asso-
ciated with a higher probability of pregnancy when compared to fresh ET?
Summary answer: A higher probability of pregnancy after frozen ET using a
freeze-all policy compared to fresh ET is present in high, but not in normal-
responder patients.
What is known already: It has been hypothesized that freezing all embryos
in a fresh in-vitro fertilization (IVF) cycle and deferring embryo transfers in sub-
sequent cycles may provide a more physiological endometrial environment for
embryo implantation when compared to fresh ET. Several relevant randomized
controlled trials (RCTs) have recently been published, evaluating the effective-
ness of frozen ET using a freeze-all policy compared to fresh ET either in high or
in normal responder patients without, however, leading to solid conclusions.
Study design, size, duration: A systematic review and meta-analysis was per-
formed aiming to identify RCTs comparing frozen ET, using a freeze-all policy, to
fresh ET. For this purpose, a relevant literature search was carried out until January
2018. Primary outcome measure was achievement of pregnancy, expressed as
ongoing pregnancy/live birth rate after the ﬁrst ET, while severe ovarian hyperstimu-
lation syndrome (OHSS) was evaluated as a secondary outcome.
Participants/materials, setting, methods: Six eligible RCTs were identi-
ﬁed including 4831 patients that evaluated frozen ET using a freeze-all policy
versus fresh ET either in high responder patients (n = 3), or in normal
responder patients (n = 3). Meta-analysis of weighted data using random and
ﬁxed effects model was performed. Results are reported as relative risk (RR)
with 95% conﬁdence interval (CI).
Main results and the role of chance: The eligible RCTs were published
between 1999 and 2018 and the number of patients included in the study ran-
ged from 122 to 2157 patients (median 460). Three studies were conducted in
Asia (4447 patients), two studies in USA (259 patients) and a single study in
Europe (125 patients). In high responder patients, a signiﬁcantly higher ongoing
pregnancy/live birth rate was observed after a frozen as compared to a fresh
ET (RR: 1.16, 95% CI: 1.05 to 1.29; ﬁxed effects model; heterogeneity: I2 = 0%;
n = 1755 patients, respectively). This difference was not present in normal
responder patients (RR: 1.06, 95% CI: 0.90 to 1.23; random effects model; het-
erogeneity: I2 = 51%; n = 3076 patients, respectively), or overall (RR: 1.09,
95% CI: 0.98 to 1.22; random effects model; heterogeneity: I2 = 49%; n = 4831
patients, respectively). The risk of moderate/severe OHSS was signiﬁcantly
lower after a frozen as compared to a fresh ET in high responder patients (RR:
0.19, 95% CI: 0.10 to 0.35; ﬁxed effects model; heterogeneity: I2 = 0%; n =
1633 patients, respectively), in normal responder patients (RR: 0.39, 95% CI:
0.19 to 0.80; ﬁxed effects model; heterogeneity: I2 = 0%; n = 2939 patients,
respectively) as well as overall (RR: 0.25, 95% CI: 0.15 to 0.40; ﬁxed effects
model; heterogeneity: I2 = 9%; n = 4572 patients, respectively).
Limitations, reasons for caution: A considerable heterogeneity was present
in the cryopreservation protocols used in the eligible studies. Moreover,
gonadotrophin-releasing hormone(GnRH) agonist was not used for triggering ﬁnal
oocyte maturation in the freeze-all arm in the eligible RCTs, which might have fur-
ther increased the difference in safety between the freeze-all and fresh ET policies.
Wider implications of the ﬁndings: The results obtained might be
explained by an increased deterioration of endometrial receptivity due to the
more intense ovarian response in high as compared to normal responders.
Concomitantly, the availability of more embryos in high as compared to normal
responders might counteract whatever adverse effect cryopreservation may
exert on embryos.
Trial registration number: not applicable
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O-290 Endometrial receptivity assessment using a transcriptomic
approach for personalized embryo transfer
D. Haouzi1, F. Entezami2, A. Ferrières-Hoa3, L. Delaroche4,
E. Vintejoux3, A. Torre5, S. Hamamah3
1INSERM U1203, IRMB- Hôpital St-Eloi- CHRU Montpellier, MONTPELLIER, France
2Laboratoire Eylau-UNILABS-La Muette- Clinique de La Muette-Ramsay-Générale de
Santé, ART department, Paris, France
3Hôpital Arnaud de Villeneuce- CHU Montpellier, Département de Biologie de la
Reproduction, Montpellier, France
4Laboratoire Eylau-UNILABS-Cherest- Clinique Cherest-Générale de Santé, ART
department, Neuilly sur Seine, France
5Division of Child Health- Obstetrics & Gynaecology, Department of Obstetrics and
Gynecology, Nottingham, United Kingdom
Study question: The aim of this study was to optimize pregnancy outcome
using personalized embryo replacement according to the evaluation of endo-
metrial receptivity.
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Summary answer: Individual evaluation of endometrial receptivity allows a
personalized patient care management and improves pregnancy outcome for
RIF patients.
What is known already: Many approaches for human endometrial receptiv-
ity including microarray has been previously reported. However, efﬁciency of
the tests according to the clinical results is still debated. The aim of this study is
to evaluate the endometrial receptivity (ER) using the Window implantation
Test (Win Test) in RIFs patients who have had at least 3 implantation failures.
The principal of concept which consisting for screening for 13 speciﬁc genes of
implantation window.
Study design, size, duration: Endometrial biopsies are performed during
the implantation windows 7-9 days after the LH surge or 6-9 days after proges-
terone administration under natural cycles and hormone replacement therapy
(HRT), respectively. Then, according to the Win-test result, the transfer strat-
egy was: transfer at the blastocyst stage at the speciﬁc day where endometrium
has been diagnosed as ‘receptive’; transfers at day 2/3 post-fertilization when
endometrium is said ‘partially receptive’. For non-receptive samples, a second
evaluation is proposed later.
Participants/materials, setting, methods: 665 RIF patients with a number
of previous failed attempts and number of non-implanted embryos after fresh
or frozen embryo transfer cycles was 4.3 ± 2.5 and 7.3 ± 4.2, respectively,
were included. RNAs from biopsies were extracted and determination of the
mRNA expression levels of 13 genes predictive of endometrial receptivity
referred in the Win-Test by qRT-PCR. Clinical pregnancy was deﬁned by visual-
ization of a gestational sac with a positive foetal heart beat.
Main results and the role of chance: Analyses of endometrial receptivity
status (n = 1237 biopsies) in a large cohort of 665 RIF patients (age mean ±
SD: 37.5 ± 4.6 years) revealed that a strong inter-patient variability i) of the
moment of the opening of the implantation window with a delay for the major-
ity of RIF patients between 1 to 4 days, as well as ii) of the duration of this
implantation. Then, as soon as the cycle day where endometrium was said
receptive, a personalized embryo transfer can to be perform during a subse-
quent attempt in the respect of the synchronization of the fœto-maternal dia-
logue. 75 % of personalized embryo transfer have been performed under HRT
and 25 % under natural cycles. The implantation rate before and after persona-
lized embryo transfers was 5.5 vs 22.7 %, respectively (p < 0.0001). Using this
strategy, the positive b-hCG and clinical pregnancy rate per cycle in this group
of patients with previous RIFs were 39.4 and 25.5 %, respectively (65 and 27 %
with blastocysts and day-3 embryo transfers).
Limitations, reasons for caution: The beneﬁts of this innovative strategy
will be analyzed in PGS patients.
Wider implications of the ﬁndings: This ﬁnding demonstrated that for the
majority of RIF patients, a delay in their opening implantation window was
responsible for the implantation failure. Personalized embryo transfer according
to the speciﬁc cycle day where endometrium is said receptive improves both
implantation rate and pregnancy outcome in RIF patients.
Trial registration number:Not applicable
O-291 Live birth rate after frozen-thawed embryo transfer
according to endometrial preparation: mild gonadotropin ovarian
stimulation leads to increased success compared to artiﬁcial cycle
S. Epelboin1, X. Ferraretto2, E. Devouche3, S. Gricourt4,
C. Gauche-Cazalis5, J. Lepage6, C. Patrat7, D. Luton8, M. Peigne9
1Assistance Publique Hôpitaux de Paris Bichat-Claude Bernard Hospital, Gynecology
Obstertrics Reproductive Medecine, Paris, France
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Study question: Which endometrial preparation allows a better outcome
after frozen-thawed embryo transfer (FET) between mild stimulated (OS) and
artiﬁcial cycles (AC)?
Summary answer: Despite a similar pregnancy rate, live birth rate (LBR) was
signiﬁcantly higher with mild OS than with AC preparation, even after adjusting
for potential confounders.
What is known already: The best protocol to prepare the endometrium for
FET is still debated. A recent meta-analysis concluded that outcomes with nat-
ural cycles (NC) were similar to those with AC, but that mild OS may be prom-
ising. Some authors described a higher pregnancy rate in AC versus NC, but no
signiﬁcant difference in LBR was found due to higher pregnancy loss rate in AC.
A deﬁcient luteal phase in AC group could explain an asynchronised window of
implantation leading to pregnancy losses. With OS preparation, a secreting cor-
pus luteum leads to more constant progesterone level. Moreover, hCG trigger-
ing can sustain luteotropic effect.
Study design, size, duration:We conducted a retrospective study including
all 1021 FET(issued from 1313 started cycles) performed in one French aca-
demic fertility centre from January 2013 to December 2016. We compared
clinical pregnancy rate (PR), ongoing PR at 12 weeks of gestation (WG), and
LBR, according to mild OS or AC endometrial preparation.
Participants/materials, setting, methods: In OS group, gonadotropins
(37.5 to 75 IU/day) were initiated between Day 2 and 10 followed by r-hCG
triggering. Vaginal micronized progesterone (200 mg/day) was given for 6 WG
if pregnancy. In AC group, estradiol orally (4 or 6 mg/day) or transdermally
(200 μg/3days) started on Day 1. Vaginal micronized progesterone (600 mg/
day) was added to E2 for 12 WG if pregnancy. FET was performed according
to embryos stage. Data were analysed using a multiple regression model.
Main results and the role of chance: Among 1021 FET, 357 (35%) patients
received OS and 664 (65%) AC preparation. No difference in cycle cancellation
rates was observed between both groups. They were comparable for maternal
ages (at transfer and at freezing), body mass index, history of recurrent preg-
nancy losses, viral status and smoking habits. As expected, patients in AC group
suffered more from endometriosis (18.5% vs 12.9%; p = .021) and Polycystic
Ovarian Syndrome (PCOS) (21.7% v 10.9%; p<.0001) than patients in mild OS
group in which masculine infertility was more frequent (49.3% vs 41.1%;
p=.012). There was no difference between groups concerning endometrial
thickness, number of embryos transferred, development stage at FET, cryo-
preservation technique, duration of cryopreservation, number of intact blasto-
meres post thawing for cleaved embryos, embryos’ survival. Despite a similar
clinical PR (24.4% vs 20.8%; p=.189), the ongoing PR at 12WG was signiﬁcantly
increased in the OS compared to AC group (17.9% vs 11%; p=.002), leading to
an increased LBR (17.1%vs 9.8%; p<.001). After adjusting for parameters usu-
ally linked to early pregnancy losses (woman age at freezing, smoking status,
PCOS, endometriosis and previous miscarriages), the results remained
signiﬁcant.
Limitations, reasons for caution: Retrospective design of the study may
potentially have introduced bias, and the size of the cohort, although more than
1000 cycles, could induce a lack of power to analyze subgroups.
Wider implications of the ﬁndings: In the light of LBR results and speciﬁc
concerns about effects of extended hormonal treatment on periconceptional
environment, the ﬁrst intention endometrial preparation for FET should be OS
in most cases. Nevertheless, if AC, a potential defect of luteal phase must be
tracked, and treatment adapted to avoid pregnancy losses.
Trial registration number:Not applicable.
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O-292 Early stop of progesterone supplementation after
conﬁrmation of pregnancy in IVF/ICSI fresh embryo transfer cycles
of poor responders does not affect pregnancy outcome
S.P. Pan1, K.H. Chao1, M.Y.Wu1, M.J. Chen1, C.H. Chang2,
J.H. Yang1, S.U. Chen1
1National Taiwan University Hospital, Department of Obstetrics & Gynecology,
Taipei, Taiwan R.O.C.
2National Taiwan University Hospital, Department of Medical Research, Taipei,
Taiwan R.O.C.
Study question: Does early stop of progesterone supplementation after con-
ﬁrmation of pregnancy affect reproductive outcomes of patients with poor
ovarian response (POR) in IVF/ICSI-embryo transfer (ET) cycles?
Summary answer: Women with POR using hCG as luteal phase support
(LPS) in fresh ET cycles can safely discontinue progesterone supplementation
after positive pregnancy test.
What is known already: Some studies found no signiﬁcant differences in mis-
carriage, ongoing pregnancy and live birth rates between general IVF patients
who underwent early progesterone cessation and those who received proges-
terone until gestational age of 7-9 weeks. However, the usual practice of most
physicians is to continue progesterone supplementation rather than to take a
risk of miscarriage from an earlier stop.
Study design, size, duration: A retrospective cohort study was conducted
for patients in IVF/ICSI and fresh ET cycles in single center between January
2010 and June 2016 (N = 4,320 cycles). Patients with POR using hCG as LPS
were investigated (N = 480 cycles). Those had negative pregnancy test, ectopic
pregnancy or loss of follow-up were excluded (N = 324 cycles). We used the
Bologna criteria to deﬁne POR.
Participants/materials, setting, methods: The pregnant women of POR
were included in this study (N = 156 cycles). They were divided into two
groups: one stopped LPS from day of positive pregnancy test (N = 100 cycles),
and the other kept progesterone supplementation until 7-9 gestational weeks
(N = 56 cycles). We compared implantation, clinical pregnancy, ongoing preg-
nancy and live-birth rates between the two groups. The data were analyzed
with independent t-test, Chi-square test and multivariable logistic regression.
Main results and the role of chance: There were no signiﬁcant differences
in age, body mass index, gravida, parity, causes of infertility, stimulation proto-
cols, hormone data, number of embryos transferred and endometrial thickness
between the early stop group and control group. The adjusted odds ratios
(AORs) with 95% conﬁdence intervals (CI) were calculated by adjusting for the
confounders of stimulation duration and number of oocytes retrieved. After
adjustment with multivariable logistic regression analysis, the implantation per-
centages (81.0% vs. 73.2%, AOR = 1.44, 95% CI: 0.64-3.22), clinical pregnancy
rates (55.0% vs. 57.1%, AOR = 1.72, 95% CI: 0.35-1.45), ongoing pregnancy
rates (47.0% vs. 46.4%, AOR = 0.86, 95% CI: 0.43-1.71) and live-birth rates
(44.0% vs. 46.4%, AOR = 0.75, 95% CI: 0.37-1.50) were not statistically differ-
ent between early stop group and the control group.
Limitations, reasons for caution: Some limitations included the retrospect-
ive nature and somewhat small sample sizes. Whether the early stop of proges-
terone can be applied for every patient or not for patients of POR using
progesterone without hCG for LPS is not studied in this work. This condition
may deserve further research.
Wider implications of the ﬁndings: We may suggest that an early stop
could be based on endogenous activity of corpus luteum by detection of serum
progesterone and estradiol levels on the day of pregnancy test.
Trial registration number:Not applicable
O-293 CSRP2BP is a novel marker in trophoblast development
and preeclampsia pathogenesis
Y. Ma1, Q. Jie2, Z.Wang1, Y.Wei1, P. Long1, C. Tang1, Q. Li1, Y. Yu2
1The Afﬁliated Hospital of Hainan Medical College, Reproductive Medical Center,
Haikou, China
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Gynecology, Guangzhou, China
Study question: What is the potential function of Cysteine-Rich Protein 2-
Binding Protein (CSRP2BP) in the pathogenesis of preeclampsia(PE).
Summary answer: CSRP2BP plays an important role in the pathogenesis of
PE by inﬂuencing the function of the trophoblast cells.
What is known already: PE is the leading cause of maternal and perinatal
mortality and morbidity. The underlying mechanism is still not completely eluci-
dated. Epigenetic abnormalities might be closely related to the pathogenesis of
PE. CSRP2BP is a newly deﬁned histone acetyltransferase, however, the
research of its function in human cells is very limited. It will be interesting to
explore the potential role of CSRP2BP in the process of early trophoblast
development and pathogenesis of PE.
Study design, size, duration: The relationship of CSRP2BP expression and
PE was explored in clinical samples. Meanwhile, Lentivirus systems and
CRISPR/case9 technology were used to generate loss and gain of function
models with trophoblast cell line-HTR8 to study the role of CSRP2BP in the
pathogenesis of PE.
Participants/materials, setting, methods: We examined the expression
of CSRP2BP in placentas from PE patients and normal controls. CSRP2BP loss
and gain of function models were generated in HTR8 cells by using lentivirus
and with CRISPR/case9 technology. Transwell assays, scratch-wound assays,
EDU, cell apoptosis assays and cell cycle assays were used to examine the func-
tion of CSRP2BP in HTR8 cells model. RNA-seq was used to examine the gene
expression panel which might be regulated by CSRP2BP.
Main results and the role of chance: CSRP2BP was enriched in the nucleus
of trophoblast cells from early pregnant stage. It was signiﬁcantly decreased in
placental tissues of PE patients compared with those in control group by qPCR,
western blotting and immunohistochemistry. The current data demonstrated
that knockdown of CSRP2BP in HTR8 dramatically decreased cell proliferation,
cell migration and invasion. It also showed a signiﬁcantly lower plate clone form-
ation rate in CSRP2BP knockdown -HTR8 cells compare with the WT HTR8
cells.
Limitations, reasons for caution: Although we show that CSRP2BP play an
important role in the function of HTR8 by shRNA, the study of working mech-
anism of CSRP2BP in PE is still very limited. More studies will be performed to
explore its underline mechanism.
Wider implications of the ﬁndings: This study was the ﬁrst time to explore
the role of CSRP2BP in PE. It will help us to better understand the pathogenesis
of PE, which might be helpful to discover novel therapeutic targets in diagnosis
and treatment of PE.
Trial registration number: not applicable.
O-294 Reproductive outcome following hyaluronic acid gel
application after D&C in women with at least one previous
curettage; long-term outcomes of a multicenter, prospective
randomized trail
A. Hooker1, R. Leeuw de2, P. Van de Ven3, J. Huirne2
1Zaans Medical Center ZMC, Department of Obstetrics and Gynaecology,
Zaandam, The Netherlands
2VU University medial center, Department of Obstetrics and Gynaecology,
Ansterdam, The Netherlands
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Ansterdam, The Netherlands
Study question: Does intrauterine application of auto-crosslinked hyaluronic
acid (ACP) gel following dilatation and curettage (D&C) for miscarriage in
women with at least one previous D&C improve reproductive outcome?
Summary answer: Reproductive performance was similar in both groups,
with a tendency to a higher pregnancy and live birth rate in women who
received ACP gel.
What is known already: Intrauterine adhesions (IUAs) are reported in 19%
of women after miscarriage; women with more than one D&C have statistically
signiﬁcant more IUAs compared to women with one D&C. Intrauterine applica-
tion of ACP gel following D&C for miscarriage in women with at least one previ-
ous D&C signiﬁcantly reduces the incidence and severity of IUAs. Data on
reproductive performance following application of ACP gel are lacking.
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Study design, size, duration: In the Prevention of Adhesion Post
Abortion (PAPA) trial, a multicentre, prospective randomised controlled
trail 152 women with an (incomplete) miscarriage or retained products of
conception (RPOC) with at least one D&C in history were randomised to
D&C plus ACP gel or D&C alone (control group). The study was con-
ducted between December 2011 and July 2015 in 8 centers in the
Netherlands. Written and signed informed consent was provided by all par-
ticipants at inclusion.
Participants/materials, setting, methods: 149 Participants, 77 assigned to
the intervention group and 72 to the control group received questionnaires
three, six and twelve months after the D&C-procedure. The questionnaire con-
sisted of questions regarding baseline characteristics, current health, interven-
tions received and complications, menstrual pattern, contraceptive use,
conception and reproductive outcomes. In women willingly to conceive, mis-
carriage, ongoing pregnancy and live birth rates were assessed. non-responders
were comtacted to minimize follow-up.
Main results and the role of chance: The overall response rate for the
questionnaires was 94% at twelve months. There was no signiﬁcant difference
in the menstrual characteristic of the responders in both groups. In the inter-
vention group 84.9% (62/73) versus 88.6% (62/70) women in the control
group attempted to conceive. After twelve months 71% conceived in the inter-
vention group compared to 59.7% in the control group, p = 0.56. There was
no statistical difference in the cumulative miscarriage, ongoing and live birth rate
between the two groups. The median time to conception was 5.5 months in
the intervention group versus 7.1 months in the control group, hazard ratio
(HR): 1.40, 95% Conﬁdence interval (CI): 0.92 – 2.14, p = 0.12). Time to con-
ception that resulted in life birth did not reach statistical signiﬁcance (HR: 1.40,
95% CI: 0.76 – 2.57, p = 0.28).
Limitations, reasons for caution: IUAs encountered during follow-up were
treated, it was considered unethical not to perform adhesiolysis because of the
possible negative impact on fertility and pregnancy outcomes. This RCT was
powered to detect differences in occurrence of IUAs between the groups. No
power analysis was performed for reproductive outcomes.
Wider implications of the ﬁndings: Intrauterine application of ACP gel
immediately following D&C for miscarriage reduces the incidence and severity
of IUAs. In this study, we did not ﬁnd any statistical signiﬁcant, probalby due to
the removal of existing IUAs during the routinely planned postoperative hys-
teroscopy and insufﬁcient powerto detect relevant differences.
Trial registration number:NTR3120 (Dutch Clinical Trail Registry).
SELECTEDORAL COMMUNICATIONS
SESSION 76: ART SUCCESS AND ITS FACTORS
Wednesday 4 July 2018 Room 117 14:00–15:15
O-295 Transmission of oocyte DNA damage to preimplantation
embryos after in vivo mouse exposure to daunorubicin and
cytarabine
C. Barral1, R. Castellano2, V. Tassistro3, A. Goubard2, J. Perrin1,4,
B. Courbiere1,4
1Aix Marseille Université- CNRS- IRD- Avignon Université- IMBE UMR 7263- 13397,
Biogenotoxicologie- Santé Humaine et environnement, Marseille, France
2Marseille Cancer Research Center CRCM- TrGET Platform- UMR 1068 Inserm-
UMR 7258 CNRS- Aix Marseille Université- UM 105, Institut Paoli-Calmettes,
Marseille, France
3Aix Marseille Université- CNRS- IRD- Avignon Université- IMBE UMR 7263- 13397,
Marseille, France
4Pôle Femmes-Mères-Enfants- Centre Clinico-biologique d’AMP- AP-HM, Hopital de
la Conception, Marseille, France
Study question: Does oocyte DNA damage induced by a previous in vivo
mouse exposure to chemotherapy agents is transmissible to preimplantation
embryos?
Summary answer: DNA damage was observed in preimplantation embryos
issued from mice previously exposed to daunorubicin and cytarabine.
What is known already: In acute leukemia, the emergency to start a chemo-
therapy don’t allow a fertility preservation at the time of diagnosis. Some
authors have proposed to cryopreserve mature oocytes or embryos after a
controlled ovarian stimulation applied shortly after the induction chemother-
apy, which is mainly composed by daunorubicin and cytarabine, and reputated
to be less gonadotoxic than alkylant agents. We previously observed DNA
damage on mouse oocytes issued from antral follicles exposed in vivo to dauno-
rubicin and cytarabine. Little is known about the risk of transmission of oocyte
DNA damage to preimplantation embryos after fecundation of oocytes recently
exposed to chemotherapy.
Study design, size, duration: By three time, two groups of mice (n = 11)
were exposed for four days to cytarabine (10 mg/kg IP) or every two days to
daunorubicin (1 mg/kg IV). Each group was compared with a negative control
group (n = 11) and with a positive control group (n = 11) injected with cyclo-
phosphamide (75 mg/kg IP). Females were mated one week after exposure
and preimplantation embryos were collected by ﬂushing the oviducts.
Participants/materials, setting, methods: 4 weeks female CD1 mice
were mated one week after exposure for studying embryos conceived from
oocytes exposed to chemotherapy at late pre-antral stage of follicular develop-
ment. Cytotoxicity has been assessed by ovulation and fertilization rates and by
embryo morphology. DNA embryonic damage was assessed by: (i) alkaline
comet assay to quantify the tail DNA (ii) ﬂuorescent immunohistochemical
staining in blastomeres to quantify accumulating γH2AX foci.
Main results and the role of chance: In mouse, a recent exposure to
daunorubicin and cytarabine did not alter the ovarian response to controlled
ovarian stimulation with no adverse impact on the fertilization rate and the
number of embryo conceived. Ovulation and fertilization rates in mice previ-
ously exposed to daunorubicin and cytarabine were similar to those in our
negative control group. One week after exposure, we observed with the comet
assay a signiﬁcant increase of embryonic DNA damage after exposure to
daunorubicin (16.57 ± 1.3, p = 0.0003) and cytarabine (16.46 ± 1.4, p =
0.0003) Vs 26.16 ± 2.5 after cyclophosphamide exposure (p < 0.0001) and
7,01 ± 1,1 in negative control group exposed to an injection of sterile saline
solution. The analysis γ-H2AX on embryos showed a signiﬁcant increase of foci
corresponding to DNA double-strand breaks, after exposure to daunorubicin
(7.97 ± 1.1; p = 0.001), cytarabine (6.47 ± 0.7, p = 0.0039), cyclophospha-
mide (5.92 ± 0.9; p = 0.0148) compared with negative control group (2,8 ±
0,7).
Limitations, reasons for caution: Mouse oocyte DNA is not exactly similar
to human oocyte DNA, and would be more sensitive to genotoxic effects of
chemotherapy agents. After chemotherapy, the kinetic of DNA repair before
and after fertilization has to be studied by further assays in exposed oocyte and
in embryos.
Wider implications of the ﬁndings: DNA damage in preimplantation
embryos conceived from oocytes exposed to chemotherapy at late pre-antral
stage of follicular development lead us to hypothese a transmission of oocyte
DNA damage to preimplantation embryo. In acute leukemia, we strongly advise
to not cryopreserve mature oocytes or embryo early after induction
chemotherapy.
Trial registration number: Experimental protocols and animal handling pro-
cedures were reviewed by the French National Ethics Committee on Animal
Experimentation (N° 2017033010523688).
O-296 Dynamic regulation of germline-soma communication
during oocyte meiotic maturation
L. Abbassi1, Q. Yang2, S. El-Hayek3, H. Clarke4
1Research Institute of McGill University Health Center, Experimental Medicine,
Montreal, Canada
2McGill University, Research Institute of McGill University Health Center, Montreal,
Canada
3Research Institute of McGill University Health Center, Departments of obstetrics and
gynecology- Department of Biology, Montreal, Canada
4Research Institute of McGill University Health Center, Departments of Obstetrics
and gynecology- Experimental Medicine- and Biology, Montreal, Canada
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Study question: What happens to the structures coupling the oocyte to the
surrounding follicular cells during meiotic maturation? If there are changes,
which molecular mechanisms regulate them?
Summary answer: TZPs are lost during the oocyte meiotic maturation under
the regulation of EGF-ERK MAPK-ROCK pathway in the cumulus-cells as well
as nuclear maturation in oocyte.
What is known already: During the oocyte in mammals, cytoplasmic exten-
sions termed transzonal projections (TZPs) emanate from the granulosa cells,
traverse the zona pellucida, and contact the oocyte plasma membrane, enabling
transmission via gap junctions of essential signals and metabolites from the gran-
ulosa cells to the growing oocyte. During maturation, gap junctional communi-
cation is shut off, and TZPs no longer couple the mature metaphase II egg to
the adjacent granulosa cells. These results suggest that a mechanism is activated
during maturation that leads to the loss of TZPs, thus freeing the oocyte from
somatic regulatory signals.
Study design, size, duration: Cumulus-oocyte complexes (COCs) were
obtained from antral follicles of mice and incubated under conditions that pro-
mote maturation. TZP-numbers were assessed at different time-points. Drugs
targeting speciﬁc signaling pathways and developmental progression of the
cumulus granulosa cells and oocyte were used to identify the to identify molecu-
lar mechanisms and relative role of the two cell types in regulating these
changes.
Participants/materials, setting, methods: TZPs were stained using
ﬂuorochrome-conjugated phalloidin, an actin ﬁlament-binding protein, and
imaged using high-resolution confocal microscopy. TZPs numbers were quanti-
ﬁed using customized mathematical function. Pharmacological manipulation of
oocyte meiotic maturation, and ERK MAP kinase and Rho-associated protein
kinase activities was used to identify mechanisms that trigger TZPs loss during
oocyte maturation. All experiments were performed a minimum of three times.
Main results and the role of chance: When COCs were incubated in the
presence of epidermal growth factor (EGF) to reproduce the physiological
mechanism of maturation, TZPs underwent retraction, forming large foci of
actin in the cumulus granulosa cells, such that fewer than 10% remained by 8 hr
after maturation initiation. Strikingly, although β-catenin and E-cadherin were
lost from the oocyte plasma membrane during maturation, EGF-stimulated
retraction of TZPs was unaffected when oocyte maturation was prevented
using inhibitors targeting either cyclin-dependent kinases or phosphodiesterase
3 A, indicating that retraction does not require oocyte maturation. In contrast,
it was almost completely prevented by U0126, an inhibitor of the ERK MAP
kinase signalling pathway. Moreover, cumulus cell-oocyte gap junctional com-
munication was retained in the presence of U0126, indicating that the TZPs
remained functional. EGF-driven loss of TZPs was also blocked by Y-27632, an
inhibitor of Rho-associated protein kinase (ROCK), suggesting that EGF induces
TZPs loss via Rho kinase activity in the cumulus granulosa cells. Altogether, our
ﬁndings suggest that activation of the EGF-ERK MAPK-ROCK signaling pathway
in cumulus granulosa cells triggers the loss of TZPs during oocyte maturation
under physiological conditions.
Limitations, reasons for caution: Mechanisms controlling meiotic matur-
ation and TZP dynamics may differ among species. In vitro studies using drugs
may not recapitulate the conditions of oocyte development in vivo.
Wider implications of the ﬁndings: Inappropriate activation of ERK signal-
ling in the granulosa cells surrounding growing oocytes may trigger precocious
uncoupling between the two cell types prior to the oocyte completing pre-
ovulatory development, resulting in oocytes incapable of being fertilized and giv-
ing rise to a healthy embryo.
Trial registration number: not applicable
O-297 PlasmamicroRNAs identiﬁed as novel markers of successful
implantation
S. Khanjani, R. Islam, S. Lavery, P. Bennett
Imperial College London, Reproductive Medicine, London, United Kingdom
Study question: Can plasma miRNA expression be used as biomarker for
‘receptivity’ to predict IVF treatment outcome?
Summary answer: 3 distinct miRNAs were found to have a statistically sig-
niﬁcant expression between the subsequently pregnant and non-pregnant
groups.
What is known already: MicroRNAs (miRNAs) are small non-coding RNAs
critical for regulating cellular functions. There is growing evidence supporting a
role for microRNAs in embryonic and endometrial cell function. miRNAs are
present within cells and are exported into plasma where their stability makes
them potential biomarkers for health and disease.
Study design, size, duration: This was a prospective cohort study con-
ducted at the IVF unit at Hammersmith Hospital over 6 months. A cohort of 12
patients was used for miRNA analysis selected to exclude confounding factors.
Selected patients i) underwent a fresh cycle of IVF, ii) had AMH 5-25, ii) had no
endometrial disease and iv) had a single top quality blastocyst transferred.
Pregnancy outcomes were recorded.
Participants/materials, setting, methods: Blood samples were collected
at two time points, ﬁrst prior to the start of the IVF treatment cycle and sec-
ondly on the day of embryo transfer prior to the procedure. miRNA was
extracted using Norgen Biotek kit. miRNA expression proﬁle was obtained
using nCounterTM assay. Analysis was performed separately on matching sam-
ples before and after the start of treatment and data from women who went to
to be pregnant was compered to those who didn’t.
Main results and the role of chance: 15 mRNAs were identiﬁed to have
statistically signiﬁcant differential expression following IVF treatment compared
with matching samples before treatment. 3 distinct miRNAs were found to
have a statistically signiﬁcant expression between the subsequently pregnant
and non-pregnant group. Pathway analysis strongly indicated that the identiﬁed
miRNAs are essential for immune and inﬂammatory processes. The results
have been replicated using PCR.
Limitations, reasons for caution: Due to stringent selection criteria we
could only include 12 patients. a replication study is underway and the results
have been replicated using PCR.
Wider implications of the ﬁndings: To our knowledge, this is the ﬁrst
study that has identiﬁed plasma miRNAs as biomarkers of implantation. Once
utility is conﬁrmed in replication cohorts these biomarkers have the potential to
improve IVF success rates by identifying the cycle with best endometrial
receptivity.
Trial registration number: not applicable.
O-298 Progesterone/estradiol (P4/E2) ratio in hormone
replacement cycles can predict ongoing pregnancy rates: a
prospective study
S. Taguchi, M. Funabiki, N. Amano, T. Takano, Y. Okudaira,
N. Suzuki, E. Kawase, L. Young, M. Kobatake, P. Zada, Y. Nakamura
Oak Clinic Infertility Center, Research, Osaka, Japan
Study question: Is progesterone/estradiol (P4/E2) ratio useful for predicting
ongoing pregnancy rates?
Summary answer: Our data indicate that the P4/E2 ratio in hormone
replacement cycles can predict ongoing pregnancy rates.
What is known already: P4/E2 ratio has been suggested as a marker for pre-
diction of clinical pregnancy rates, but the evidence is conﬂicting. Furthermore,
no prospective study evaluating the clinical value of P4/E2 ratio in hormone
replacement cycles has been published.
Study design, size, duration: This prospective study evaluated infertile
patients (n = 500, median age, 37.8 years old) at our clinic in Japan between
July 2016 and December 2017. We evaluated P4/E2 ratio in patients undergo-
ing a hormone replacement regimen (Estrogel
®
: 2.16 mg/day estrogen conver-
sion after 2nd day of menstruation) for thawed blastocyst transfer.
Participants/materials, setting, methods: P4/E2 ratio was calculated as
P4 (ng/ml) × 1,000/E2 (pg/ml). Receiver operating characteristic curve analysis
was performed for P4/E2 cut-off values detrimental to in vitro fertilization (IVF)/
intracytoplasmic sperm injection (ICSI)-embryo transfer (ET) outcome.
Ongoing pregnancy rate was the primary outcome. Mann-Whitney and chi-
square tests were used for statistical analyses. Furthermore, multiple logistic
regression was used to study associations between variables and the P4/E2
ratio. P < 0.05 was considered signiﬁcant. All patients gave informed consent.
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Main results and the role of chance: The optimal cut-off value for P4/E2
ratio in hormone replacement cycles was 14.75. Ongoing pregnancy rates were
signiﬁcantly higher at a cut-off value >14.75 than at ≤14.75 (48.6% vs. 22.4%, P
< 0.001). Furthermore, the P4/E2 ratio in hormone replacement cycles was an
independent predictor of ongoing pregnancy rates (P = 0.001), regardless of
patient’s age (P = 0.53), body mass index (P = 0.17), and endometrial thickness
(P = 0.06) in multiple logistic regression analysis. Moreover, sensitivity was 81%
and speciﬁcity was 70%.
Limitations, reasons for caution: Findings in the present study are limited
to a hormone replacement regimen used in our patient population.
Wider implications of the ﬁndings: P4/E2 ratio in hormone replacement
cycles would be useful as a predictor of ongoing pregnancy rates.
Trial registration number: UMIN000016919
O-299 Progesterone levels but not endometrial thickness
inﬂuence the effectiveness of freeze-only versus fresh embryo
transfer: a prespeciﬁed subgroup analysis of a randomized clinical
trial
T.N.L. Vuong1, T.D. Pham2, V.Q. Dang2, T.M. Ho2, V.N.A. Ho2,
R.J. Norman3,4, B.W. Mol3,5
1University of Medicine and Pharmacy at Ho Chi Minh City, Department of
Obstetrics and Gynecology, Ho Chi Minh, Vietnam
2My Duc Hospital, IVFMD Center, Ho Chi Minh City, Vietnam
3Department of Medicine- University of Adelaide, The Robinson Research Institute,
Adelaide, Australia
4Fertility SA, Fertility SA, Adelaide, Australia
5The South Australian Health and Medical Research Institute, The South Australian
Health and Medical Research Institute, Adelaide, Australia
Study question: Can progesterone level or endometrial thickness be used to
predict whether a freeze-only or fresh transfer strategy will result in a higher
ongoing pregnancy rate?
Summary answer:Women with a serum progesterone >1.14 ng/mL under-
going stimulated IVF will likely beneﬁt from use of a freeze-only approach over a
fresh embryo transfer.
What is known already: Both progesterone level and endometrial thickness
are potential predictors of outcomes during IVF cycles. Higher progesterone
levels at trigger have been associated with lower implantation and ongoing preg-
nancy rates in fresh embryo transfer cycles, and this might be prevented by
using a freeze-only strategy. In addition, thinner endometrium might decrease
the chances of successful pregnancy. However, data on the usefulness of both
biomarkers are not based on randomized comparisons of the two embryo
transfer strategies. We evaluated whether progesterone levels and endometrial
thickness can be used as biomarkers to guide a decision about whether to use
fresh or frozen transfer.
Study design, size, duration: We present a prespeciﬁed secondary analysis
of data from a randomised controlled trial (RCT) performed in a large IVF unit
in Ho Chi Minh City, Vietnam including 782 women undergoing IVF (Vuong LN,
et al. NEJM 2018;378:137-147). The primary endpoint was ongoing pregnancy
after the ﬁrst transfer.
Participants/materials, setting, methods: Infertile women scheduled for
IVF with ≤1 previous IVF cycle were randomised to a freeze-only strategy (n =
391) or fresh embryo transfer (n = 391). IVF was performed using a
gonadotropin-releasing hormone antagonist protocol. Progesterone level was
measured on the day of trigger and endometrial thickness (transvaginal ultra-
sound) on day 3 after ovum pick-up. We explored the impact of both markers
by testing for interaction, and by assessing the treatment effect in four quartiles.
Main results and the role of chance: The initial comparison of all patients
showed the interaction between serum progesterone and treatment group for
ongoing pregnancy after the ﬁrst embryo transfer was of borderline statistical
signiﬁcance (p = 0.051). When serum progesterone levels were in the third
quartile (Q3, 1.14–1.53 ng/mL), ongoing pregnancy rate was signiﬁcantly higher
in the freeze-only versus fresh embryo transfer group (42.9% vs 24.7%, p =
0.01), while in Q4 the ongoing pregnancy rate was numerically, but not statistic-
ally signiﬁcantly, higher in the freeze-only versus fresh transfer group (35.7% vs
26.9%, p = 0.21). Conversely, when serum progesterone was low (Q1,
0.03–0.82 ng/mL), there was a trend towards a lower ongoing pregnancy rate
with freeze-only compared with fresh embryo transfer (33.3% vs 46.6%, p =
0.078). The ongoing pregnancy rate after ﬁrst embryo transfer did not differ sig-
niﬁcantly in the freeze-only and fresh embryo transfer groups across all quartiles
of endometrial thickness, and there was no signiﬁcant interaction between
endometrial thickness and treatment group for ongoing pregnancy rate. In
women with an endometrial thickness below the 10th percentile (<10 mm),
ongoing pregnancy rates were 10/30 (33.3%) in the freeze-only group versus
11/40 (27.5%) in the fresh transfer group (relative risk 1.21, 95% conﬁdence
interval 0.59–2.47).
Limitations, reasons for caution: Although this analysis was included in the
parent RCT protocol, it is a secondary analysis of data. In addition, division of
patients into subgroups based on serum progesterone level or endometrial
thickness quartiles meant that the sample size in each group was reduced,
which affects the power of this analysis.
Wider implications of the ﬁndings: Use of a freeze-only strategy could
maximise ongoing pregnancy and live birth rates in women with a high serum
progesterone level undergoing stimulated IVF. Based on the current ﬁndings,
treatment decisions regarding a freeze-only strategy do not need to be modiﬁed
based on endometrial thickness.
Trial registration number:NCT02471573 (clinicaltrials.gov)
SELECTEDORAL COMMUNICATIONS
SESSION 77: FEMALE FERTILITY FROMGENOMIC
STUDIES TONOVEL THERAPIES
Wednesday 4 July 2018 Room 116 14:00–15:15
O-300 A comprehensive two-centre RNA-seq study reveals
changes in endometrial and bloodmiRNome at mid-secretory
phase in fertile women and in patients with recurrent implantation
failure
A. Velthut - Meikas1, S. Altmäe2, K. Rekker3, M. Suhorutshenko3,
M. Peters3, J.F. Martinez-Blanch4, F.M. Codoñer5, F. Vilella5,
C. Simón6, A. Salumets3
1Tallinn University of Technology, Department of Chemistry and Biotechnology,
Tallinn, Estonia
2University of Granada, Department of Biochemistry and Molecular Biology,
Granada, Spain
3Competence Centre on Health Technologies, Competence Centre on Health
Technologies, Tartu, Estonia
4Lifesequencing SL, Lifesequencing SL, Valencia, Spain
5Igenomix Foundation/INCLIVA, Igenomix Foundation/INCLIVA, Valencia, Spain
6Valencia University, Department of Obstetrics and Gynecology, Valencia, Spain
Study question: Does an RNA sequencing study from endometrium and
blood reveal new endometrial receptivity-related microRNAs in healthy
women and in patients with recurrent implantation failure (RIF)?
Summary answer: Several annotated and one novel microRNA were found
as differentially expressed between early secretory vs. mid-secretory phase
samples in addition to microRNAs dysregulated in RIF.
What is known already: The involvement of miRNAs in mid-secretory
endometrial functions has been shown and aberrant expression of miRNAs in
RIF has been identiﬁed in a few previous studies, but not from whole blood
samples. However, as the analysis settings and platforms have been different
and a small number of samples has been analysed, there is no consensus about
the miRNAs involved in endometrial receptivity and dysfunction.
Study design, size, duration: Our current study recruited 39 fertile women
and 38 infertile RIF patients from Estonia (EST) and Spain (ESP). Paired endo-
metrial and blood samples were collected at early secretory and mid-secretory
phases from fertile women and at mid-secretory phase from infertile RIF
patients. This is the largest miRNA endometrial receptivity study to date with
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novel aspects of combining matched samples of endometrium and blood from
two different population cohorts.
Participants/materials, setting, methods: Samples were subjected to
Illumina small RNA sequencing. Annotated and novel miRNAs were identiﬁed
from sequencing reads by miRDeep2 algorithm. miRNAs with signiﬁcantly
altered levels between the study groups in both EST and ESP datasets were
considered as differentially expressed. Ingenuity Pathway Analysis was applied
for identifying miRNA target genes and canonical pathways from matched
mRNA data. Custom TaqMan Small RNA assay was used for the validation of
novel miRNA expression levels.
Main results and the role of chance: Among fertile women, 91 differen-
tially expressed miRNAs were identiﬁed in mid-secretory vs. early secretory
endometrium, while no differentially expressed miRNAs were found in the cor-
responding blood samples. The comparison of mid-secretory phase samples
between fertile women and RIF patients revealed 21 differentially expressed
miRNAs from endometrium and one from blood samples. miRNA target gene
prediction analysis using our mRNA sequencing data from the matched samples
detected several canonical pathways to be involved in mid-secretory endomet-
rial functions, including JAK/STAT signalling, leptin signalling and growth hor-
mone signalling. Moreover, JAK/STAT signalling pathway was also revealed in
miRNA target analysis of mid-secretory endometrium from RIF patients when
compared to fertile women. Further, our study results highlight the involvement
of miR-30 and miR-200 families in endometrial receptivity, and miR-424-5p in
the development of endometrial dysfunction. We identiﬁed several novel
miRNAs, of which miRNA chr2_4401, being 37-fold up-regulated in mid-
secretory phase, has a potential role in the mid-secretory endometrial func-
tions. From blood samples we identiﬁed miR-30a-5p as a possible marker of
infertility related to RIF.
Limitations, reasons for caution: Our stringent analysis approach of
matching two cohorts and analysing only the common miRNA and mRNA lists
could have resulted in missing some true-positive results. Functional experi-
ments to determine the role of differentially expressed miRNAs were not
performed.
Wider implications of the ﬁndings: In addition to novel ﬁndings, our study
results agree with previously published data implicating that miR-30 and miR-
200 family members are involved in endometrial transition from pre-receptive
to receptive state. Our results together with previous studies indicate that
miRNAs play an important role in the regulation of endometrial receptivity
functions.
Trial registration number: not applicable.
O-301 Sirolimus as a new drug for treatment of RIF patients with
elevated Th17/Treg Ratio: a randomized, double-blind, phase II
clinical trial
M. Ahmadi1, S. Danaii2, K. Berjis3, M. Nouri4, M. Youseﬁ5
1Stem Cell and Regenerative Medicine Institute- Tabriz University of Medical
Sciences- Tabriz- Iran, Department of Immunology, Tabriz, Iran
2Gynecology Department- Eastern Azerbaijan ACECR ART center- Eastern
Azerbaijan branch of ACECR- Tabriz- Iran., Gynecology Department, Tabriz, Iran
3Academic Center for Education- Culture and Research- ACECR- Qom Branch- Qom-
Iran, Gynecology Department, Qom, Iran
4Stem Cell and Regenerative Medicine Institute- Tabriz University of Medical
Sciences- Tabriz- Iran, Department of Biochemistry, Tabriz, Iran
5Department of Immunology- School of Medicine- Tabriz University of Medical
Sciences- Tabriz- Iran, Department of Immunology, Tabriz, Iran
Study question: Can we improve clinical pregnancy and ongoing pregnancy in
recurrent implantation failure (RIF) patients with increased Th17/Treg ratio by
immunosuppressive agent Sirolimus?
Summary answer: Sirolimus treatment in RIF patients can decrease Th17/
Treg ratio and improve clinical pregnancy rate and ongoing pregnancy rate.
What is known already: RIF is clinically deﬁned as the failure of good quality
embryos to implant into the uterus following at least three cycles of IVF/ET.
During pregnancy, a genetically different fetus is allowed to survive within the
uterus despite the maternal recognition of fetal alloantigens. Compared with
normal pregnancy early loss of embryo is associated with systemic lower levels
of Treg cells in IVF. Several lines of evidence have indicated that differentiation
of naive T cells into Th17 is deleterious for normal pregnancy and may cause
implantation failure. Sirolimus as the most common mTOR inhibitor is able to
effectively prevent allograft rejection.
Study design, size, duration: A total 121 patients with a history of at least 3
RIF after IVF/ET cycles that referred to Eastern Azerbaijan ACECR ART center,
Alzahra Hospital of Tabriz University of Medical Sciences and Infertility
Treatment center ACER Qom from July 2016 to June 2017 were selected and
enrolled in this multicenter, randomized, double-blind, phase II study.
Participants/materials, setting, methods: Blood was drawn between
cycle day 5 and 10 of a cycle prior to the index IVF/ET cycle for then assess-
ment of a Th17 and regulatory T cells ratios and functions by ﬂow cytometry,
real-time PCR and ELISA. Normal ranges for Th17/Treg ratios were estab-
lished 0.75 by using 50 normal fertile women. In 76 patients with elevated
Th17/Treg ratios, 43 of them were treated with Sirolimus (Rapamune
®
; Pﬁzer,
UK) and 33 patients were not treated.
Main results and the role of chance: Our results demonstrated a signiﬁ-
cantly higher clinical pregnancy rate (55.81%) in Sirolimus-treated patients com-
pared with control group (20.93%) (P = 0.0005). We also found a signiﬁcantly
increased ongoing pregnancy rate (44.18%) in RIF women who received
Sirolimus compared with control group (16.26%) (P = 0.0005).
Limitations, reasons for caution: We need more research to describe
molecular mechanism of sirolimus in Th17/Treg ratio by focusing to mTOR sig-
naling pathway.
Wider implications of the ﬁndings: The ﬁndings of the current study
revealed the fact that Sirolimus is able to improve reproductive outcome in RIF
women with imbalanced Th17/Treg ratio, thus representing a new approach
for the potential treatment of patients with embryo implantation failure.
Trial registration number: ClinicalTrials.gov Identiﬁer: NCT03161340
O-302 No evidences that implantation of vitriﬁed euploid
blastocysts is inﬂuenced by ovarian stimulation conducted in luteal
vs follicular phase:interim analysis of a prospective multicentre
study
A. Vaiarelli1, D. Cimadomo1, S. Colamaria1, S. Ferrero1,
M. Giuliani1, E. Trabucco2, R. Carmelo2, L. Buffo3, L. Dusi3,
R. Venturella2,4, L. Rienzi1,2,3, F.M. Ubaldi1,2,3
1Valle Giulia Clinic, GENERA Center for reproductive Medicine, Roma, Italy
2Clinica Ruesch, Genera, Napoli, Italy
3Poliambulatorio SALUS, Genera Marostica, Marostica, Italy
4Magna Graecia University, Department of Obstetrics and Gynecology, Catanzaro,
Italy
Study question: Is there any difference in ongoing pregnancy rate after single
embryo transfer (SET) of vitriﬁed euploid blastocysts obtained after luteal-
phase-stimulation (LPS) vs follicular-phase-stimulation (FPS)?
Summary answer: To date, FPS-derived and LPS-derived vitriﬁed euploid
blastocysts did not show any evidence of a different reproductive competence.
What is known already: Multiple follicular waves can arise during a single
menstrual cycle in humans, thereby highlighting a novel folliculogenesis pattern
which overtakes the classic theory. Preliminary studies showed that oocytes
obtained from anovulatory waves seem developmentally-similar to those
obtained from conventional approaches (namely FPS) in terms of fertilization,
blastulation and euploidy rates. These observations led to the introduction of
novel protocols for ovarian stimulation: random-start, luteal phase-only stimula-
tion and DuoStim (FPS plus LPS in the same menstrual cycle).
Study design, size, duration: Multicenter prospective study. 278 poor-
prognosis women (AMH≤1.5 ng/ml and/or AFC≤6 and/or ≤5oocytes
retrieved from a previous cycle and/or ≥35 yr) completed a DuoStim approach
combined with preimplantation-genetic-testing (PGT) between October2015–
July2017. To date, 174 patients obtained and transferred at least 1 euploid
blastocyst either from FPS and/or LPS. Only the ﬁrst SET performed was
included in this study. The primary outcome was the ongoing implantation rate
(>20weeks). Biochemical pregnancy loss (BPL), miscarriage and obstetrical/
perinatal outcomes were also monitored.
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Participants/materials, setting, methods: Both FPS and LPS were per-
formed with gonadotrophins in an antagonist protocol. After the ﬁrst retrieval
from FPS we waited ﬁve days before starting LPS. All embryos were cultured to
blastocyst, underwent trophectoderm biopsy and vitriﬁcation. The samples
from FPS and LPS were analyzed in the same run. In presence of euploid blasto-
cysts from both FPS and LPS, the ﬁrst embryo to be transferred was randomly-
chosen. Frozen-SETs were performed in a modiﬁed-natural or artiﬁcial cycle.
Main results and the role of chance: To achieve 80% power (α = 0.05) to
rule out a 15% difference in ongoing implantation rate between FPS-derived and
LPS-derived euploid blastocysts, we require 174 ﬁrst SETs per arm (348 over-
all). In this interim analysis we reached 50% of this sample size. The positive
pregnancy rates were 57.0% (n = 49/86) and 55.7% (n = 49/88) from FPS-
derived and LPS-derived euploid blastocysts, respectively. The BPL rates were
8.2% (n = 4/49) and 2.0% (n = 1/49), respectively. The miscarriage rates were
11.1% (n = 5/45) and 12.5% (n = 6/48), respectively. The ongoing pregnancy
rates were 46.5% (n = 40/86) and 47.7% (42/88), respectively. To date, 30
FPS-derived and 32 LPS-derived babies have been delivered. Gestational age
(38.1 ± 1.1 weeks, range 36-40 versus 38.0 ± 2.2 weeks, 36-41) and birth-
weight (3308 ± 880 g, 2200-4030 versus 3217 ± 584 g, 2010-4152) were simi-
lar so far between study arms. One FPS-derived euploid blastocyst underwent
spontaneous embryo twinning and resulted in a multiple pregnancy. One and 2
gestational diabetes were reported in the two study groups, respectively. A
FPS-derived pregnancy showed polidramnios and neonatal respiratory distress,
which involved 7 days in the neonatal intensive care unit after birth. No neo-
natal issues have been reported for LPS-derived pregnancies up to now.
Limitations, reasons for caution: This is an interim analysis; therefore, we
are yet underpowered to draw clear conclusions from these data, especially
dealing with obstetrical and perinatal outcomes. Moreover, embryo derived
from LPS are obtainted only after DuoStim approach.
Wider implications of the ﬁndings: LPS in a DuoStim-approach is promis-
ing for poor-prognosis (or oncological) patients that need to collect the highest
number of oocytes in a short timeframe.Although, any stimulation protocol
which exploits anovulatory waves needs a thorough investigation. Here, we
produced clinical data to deﬁne the safety of the pregnancies achieved after
LPS.
Trial registration number:None.
O-303 Age-related gene expression proﬁles of immature human
oocytes
M.A.J. Smits1*, K.M.Wong1*, E. Mantikou1, C. Korver1, A. Jongejan1,
T.M. Breit2, M. Goddijn1, S. Mastenbroek1, S. Repping1
1Academic Medical Center, Center for Reproductive Medicine, Amsterdam, The
Netherlands
2Swammerdam Institute for Life Sciences- Faculty of Science FNWI, MicroArray
Department and Integrative Bioinformatics Unit, Amsterdam, The Netherlands
*Contributed equally
Study question: What is the difference in gene expression proﬁle in human
germinal vesicle (GV) oocytes from women of different ages?
Summary answer: There were no signiﬁcant differences in gene expression
proﬁles of human GV oocytes from women of different ages (range 25-43).
What is known already: It is well established that reproductive capacity
declines as women age. This age-related decline is almost entirely attributed to
oocyte quality, since this decline is counterbalanced in older women receiving
young donor oocytes. Multiple molecular mechanisms explaining the decrease
in oocyte quality with increasing female age have been suggested, but none
have been ﬁrmly demonstrated. Altered gene expression of human oocytes at
different stages of development in relation to female age is one of the suggested
mechanisms for age-related fertility decline.
Study design, size, duration: Between 2012 and 2014, 40 human GV
oocytes of 40 women were obtained during follicular aspiration as part of rou-
tine ICSI treatment. Gene expression proﬁles were determined in four different
age groups: 25-30, 31-35, 36-38 and 39-43 years of age.
Participants/materials, setting, methods: GV oocytes were snap-frozen
shortly after follicular aspiration. Gene expression proﬁle analyses were per-
formed using 4×180 K Agilent arrays containing ~42000 probe-sets. Gene
expression proﬁles were visualized by hierarchical clustering and multidimen-
sional scaling. Transcripts were analyzed in a class comparison between the
four age groups and for indicators of biological age: antral follicle count (AFC)
and the total dosage of follicle stimulating hormone (FSH) used for ovarian
hyper stimulation. Individual transcripts were analyzed using linear regression.
Main results and the role of chance: Visualization of gene expression pro-
ﬁles of GV oocytes with hierarchal clustering and MDS demonstrated no clear
clustering of samples based on female age, AFC or FSH dosage. The gene
expression proﬁle of GV oocytes classiﬁed in four age groups revealed no sig-
niﬁcantly differentially expressed genes between the four different age groups
(FDR < 0.05). There were also no signiﬁcantly differentially expressed genes in
the linear regression analysis for individual transcripts analyses per age year
(FDR < 0.05).
Limitations, reasons for caution: Immature (GV) oocytes obtained after
follicular aspiration in ICSI cycles were used. Findings may be different for
in vivo matured oocytes at other developmental stages, under physiological
conditions. Due to our relatively large, but still limited study sample, we cannot
exclude that there might be smaller age-related gene-expression differences.
Wider implications of the ﬁndings: We did not ﬁnd an effect of age on
gene expression proﬁles of individual human GV oocytes. Other studies have
suggested that gene-expression proﬁles are affected in mature oocytes, which
might implicate that female age affects oocyte maturation. Alternatively, other
mechanisms in human oocytes might affect age-related fertility decline.
Trial registration number: not applicable.
O-304 Age related differences in the translational landscape of
mammalian oocytes
E. Del LLano1, T. Mašek2, A. Tetkova1, D. Jansova1, M. Koncicka1,
L. Gahurova3, A. Šušor1, M. Pospišek2, M. Kubelka1
1Institute of Animal Physiology and Genetics, Laboratory of Biochemistry and
Molecular Biology of Germ Cells, Libechov, Czech Republic
2Faculty of Science- Charles University in Prague, Department of Genetics and
Microbiology, Prague, Czech Republic
3University of South Bohemia, Department of Molecular Biology, České Budějovice,
Czech Republic
Study question: How global translational program differs in mammalian
oocytes after aging of females?
Summary answer: We have identiﬁed several genes with potentially altered
expression in the oocytes of aged females which might contribute to defective
meiosis I and consequent aneuploidy.
What is known already: Oocyte aneuploidy is the result of abnormal
chromosome segregation during meiosis, giving rise to a ready to be fertilized
oocyte which possesses an aberrant number of chromosomes. These anomal-
ies are inherited by the embryo drastically reducing its developmental potential.
Importantly, aneuploidy is not infrequent in mammalian oocytes but rather a
common feature which increases in correlation with female age.
Furthermore, maturing oocytes are transcriptionally silent and rely on the
utilization of mRNAs synthesized and stored during the growth period. To our
knowledge a global analysis of translation in oocytes related to the maternal age
has not yet been performed.
Study design, size, duration: Mouse model for aging: Study group - 1 year
old mouse females / Control 2 months old mouse females.
Samples: 200 oocytes at nuclear envelope break down stage.
Participants/materials, setting, methods: We aim to study age-related
aneuploidy in mammalian oocytes by comparing and analyzing the active tran-
scriptome in oocytes from young and aged mouse females. We have developed
a polysome fractionation protocol to isolate the RNA population involved with
the translational machinery from a minute amount of cells/oocytes. These have
been sequenced by Illumina NextGen to be able to identify differences in the
translational program of the oocytes from young and aged females.
Main results and the role of chance: We have successfully developed a
polysomal fractionation protocol to be used with as low as only 200 oocytes.
Thanks to this method, we have been able to obtain database of actively trans-
lated mRNAs using Illumina NextGen sequencing. After studying the obtained
data, we have found several genes with differences in expression between
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oocytes from young and aged females. These might therefore contribute to the
increased aneuplody characteristic in oocytes from aged females.
Limitations, reasons for caution: Our study samples are oocytes from
aged female mice. This material is scarce due to the time and resources
required to age females. Moreover, these produce only around 5 viable
oocytes.
We used polysome fractionation which is generally performed with high
amounts of material. We reduced the input to 200 oocytes.
Wider implications of the ﬁndings: This project can shed some light upon
the reasons behind the loss of oocyte quality from women of advanced age. It
may help to improve assisted reproduction techniques with a potential develop-
ment of gene therapy to treat the high aneuploidy rates in oocytes of women of
advanced age.
Trial registration number:Not applicable
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P-001 Sperm donors’ opinion towards donation and the release of
identifying information in the Belgian context
F. Mahieu1,W. Decleer2, K. Osmanagaoglu1, V. Provoost3
1AZ Jan Palﬁjn, IVF Laboratory, Ghent, Belgium
2AZ Jan Palﬁjn, IVF Centre, Ghent, Belgium
3Ghent University, Department of Philosophy and Moral Science, Ghent, Belgium
Study question:What is the opinion of sperm donors towards the release of
identifying information in the Belgian context of strict anonymous donation?
Summary answer: One in ﬁve (20,1%; n = 30) of the respondents indicated
they would continue to donate if the legislation would change from anonymous
towards identiﬁable donation.
What is known already: Belgian legislation restricts clinic recruitment adver-
tising. It allows only strictly anonymous gamete donation and known donation
(donation to a recipient known by the donor). Recently an amendment of the
legislation was proposed which would grant donor offspring, as of 18 years old,
the right to claim the identifying information of their donor. International studies
have shown that in countries with anonymous donation programmes, 11% to
50% of the donors would be willing to continue donating upon donor anonym-
ity abolishment. In two Belgian studies, 26% and 28,8% of the candidate donors
and donors would continue donating if legislation would change.
Study design, size, duration: The survey was composed of questions
derived from the international literature. Eight experts validated the survey via a
Delphi procedure. In addition, the survey was examined by two donors to
ensure clarity of wording.
The survey was online from October 27th until December 8th, 2017.
Questions (n = 36) were asked about motivation to donate, attitude towards
anonymous donation and social demographics.
Participants/materials, setting, methods: Al men who were accepted as
sperm donor (n = 242) by Jan Palﬁjn Hospital (Ghent, Belgium), from a period
of 2009 to 2017 were contacted by e-mail and were invited to complete an
anonymous online survey. Two reminder e-mails were sent to the study popu-
lation to maximize the response rate. All statistical analyses were performed
using SPSS. The response rate was 65,5% (150 donors completed the survey;
13 men were not reachable).
Main results and the role of chance: At the time of the survey, the sperm
donors had a mean age of 32 years (20-46; SD 5,97). Half of the respondents
(51,7%; n = 77) also were blood donors. Two thirds of the men (66,4%; n =
99) did not have children of their own. Most (86,6%; n = 129) of them were
motivated by altruism although the majority (59,1%; n = 88) was (also) moti-
vated by the compensation fee and nearly half (45,0%; n = 67) by access to
blood and fertility tests. One in ﬁve (22,8%) would continue to donate without
a compensation fee.
79,2% (n = 118) of the respondents were non-active sperm donors. Of
those men, 68,6% (n = 81) said they were non-active because they thought
that there was enough donor sperm in the sperm bank. The others (31,4%; n
= 37) were non-active for personal reasons, mainly related to lack of time to
donate or a non-supportive partner.
One in ﬁve (20,1%; n = 30) would continue sperm donation upon a legisla-
tion change towards identiﬁable donations whereas 53,7% (n = 80) would no
longer donate. 26,2% (n = 39) were undecided.
No signiﬁcant relationship was observed between the willingness to continue
donating in an identiﬁable system and education (p = 0,724), age (p = 0,725),
having children (p = 0,918), being a blood donor (p = 0,822) or sexual orienta-
tion (p = 0,156).
Limitations, reasons for caution: A limitation of this study is that the data
originate from a single centre and may not represent the opinion of all Belgian
sperm donors.
Wider implications of the ﬁndings: Currently, 40% of donor sperm used
in Belgian ART is of indigenous origin. Consequently, the tendency that only
20,1% of the Belgian sperm donors would continue to donate in an identiﬁable
system, could be detrimental for the future availability of donor sperm in
Belgium.
Trial registration number: The study was approved by the Ethics
Committee of the University Hospital of Ghent.
Belgian Registration Number: B0201733518.
P-002 The effect of unilateral tubal block on clinical pregnancy
rate in intrauterine insemination cycles: Systematic review
&meta-analysis
J. Tan1, S. Tannus2, O. Taskin1, A. Kan1, A.Y. Albert1, M.A. Bedaiwy1
1University of British Columbia, Obstetrics & Gynecology, Vancouver, Canada
2McGill University Health Care Centre, Department of Obstetrics and Gynecology-
Division of Reproductive Endocrinology and Infertility, Montreal, Canada
Study question: What are pregnancy rates after intrauterine insemination
(IUI) among infertile women with unilateral tubal block (UTB) diagnosed by hys-
terosalpingogram (HSG) compared to women with unexplained infertility and
bilateral patent tubes?
Summary answer: Infertile patients with proximal UTB diagnosed by HSG
can expect good pregnancy outcomes after IUI while patients with distal UTB
have lower odds of pregnancy.
What is known already: Fallopian tube occlusion is a common cause of
infertility. For normal fallopian tube function, the tube must be patent, freely
mobile, and in close proximity to the ovary. However, several pathologies are
implicated in distorting this normal physiology, including pelvic infections, endo-
metriosis, and surgical adhesions. Depending on the etiology, tubal pathology
may involve the proximal, distal, or entire tube, and may be transient due to
obstruction or permanent due to occlusion. While bilateral tubal block confers
poor pregnancy rates (PR) after controlled ovarian hyperstimulation and intra-
uterine insemination (COH-IUI), the effect of unilateral tubal block (UTB)
remains controversial.
Study design, size, duration: We systematically searched the Cochrane
Library, EMBASE and MEDLINE databases from inception to September 2017.
Key words included IUI, intrauterine insemination, tubal block, tubal occlusion,
fallopian tube diseases. Original research articles including randomized and non-
randomized controlled trials, cohort studies, patient series and case reports
were included. All included studies reported either pregnancy rates (PR) per
cycle and/or cumulative pregnancy rates (CPR). Additional studies were
extracted from the references in the full text articles.
Participants/materials, setting, methods: Two authors independently
selected trials and extracted study characteristics. Methodological quality was
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assessed using Preferred Reporting Items for Systematic Reviews and Meta-
analysis (PRISMA) guidelines. Clinical pregnancy data were pooled using a
random-effects model to calculate estimated average Odds Ratios (OR). In
order to provide greater weight to larger studies, OR were weighted by the
inverse variance. The I2 metric was calculated to assess study heterogeneity.
Publication bias was assessed by visual inspection of funnel plots.
Main results and the role of chance: 10 observational studies investigating
pregnancy outcomes after IUI in women with unilateral tubal block (UTB) com-
pared to those with bilateral patent tubes and unexplained infertility (control)
were included. All included studies provided diagnostic criteria for assessing
tubal block and screened for appropriate male and female factors through
detailed reproductive history and infertility evaluation. Furthermore, subgroup
analyses were performed among studies that differentiated proximal and distal
tubal blocks. The following comparisons were evaluated based on pregnancy
rate (PR) per IUI cycle and cumulative pregnancy rate (CPR): unilateral tubal
block vs. control, proximal tubal block vs. control, distal tubal block vs. control,
and proximal vs. distal tubal block. Among 2965 patients and 5,749 IUI cycles
across 10 studies, no signiﬁcant difference in PR/cycle (OR = 0.88, CI = 0.69-
1.12) and cumulative PR (OR = 0.80, CI = 0.62-1.04) was observed. Patients
with proximal UTB demonstrated similar PR/cycle (OR = 1.06, CI = 0.68-
1.66) and cumulative PR (OR = 1.10, CI = 0.75-1.62) compared to controls
while patients with distal UTB had signiﬁcantly lower cumulative PR (OR =
0.49, CI = 0.25-0.97, p = 0.04). Patients with proximal block also demon-
strated signiﬁcantly improved cumulative PR compared to patients with distal
block (OR = 2.41, CI = 1.37-4.25, p = 0.002).
Limitations, reasons for caution: All included studies were retrospective
and hence susceptible to confounding. Differences in screening/exclusion cri-
teria and lack of standardized IUI techniques between studies also bias their
comparability. Indeed, differences in sperm quality and processing, cycle timing,
and overall differences in ovarian stimulation treatment have all been shown to
affect IUI outcomes.
Wider implications of the ﬁndings:Our review demonstrates that infertile
patients with proximal UTB diagnosed by HSG can expect good pregnancy out-
comes after COH-IUI while patients with distal UTB have lower pregnancy
odds and may beneﬁt from laparoscopic assessment or IVF. This difference may
reﬂect inherent diagnostic limitations of HSG or differences in underlying
pathologies.
Trial registration number:Not applicable.
P-003 Bilateral versus unilateral cryptorchidism in non-obstructive
azoospermia: outcomes of testicular sperm extraction and ICSI
A.L. Barbotin1, A. Dauvergne2, A. Dumont3, V. Mitchell1,
J.M. Rigot2, F. Boitrelle4, G. Robin3
1Hôpital Jeanne de Flandre, institut de biologie de la reproduction, Lille, France
2Hopital Calmette, Service d’Andrologie, Lille, France
3Hôpital Jeanne de Flandre, Service de Gynécologie Endocrinienne et Médecine de la
Reproduction, Lille, France
4Hôpital de Poissy, Service de Biologie de la Reproduction et de Cytogénétique,
Poissy, France
Study question: How successful is testicular sperm extraction (TESE) in non-
obstructive azoospermia (NOA) in case of unilateral versus bilateral
cryptorchidism?
Summary answer: NOA men with a history of unilateral cryptorchidism
exhibited similar sperm retrieval rate but better clinical pregnancy rate than
those who had bilateral cryptorchidism.
What is known already: Cryptorchidism is a very common genital disorder
affecting almost 3% of male children and it represents one of the most frequent
causes of NOA in adulthood. Although, it is well known that spermatogenesis is
more impaired in bilateral cryptorchidism than in unilateral cryptorchidism, data
available in the literature only refer to small cohorts or inhomogeneous popula-
tion. To date, comparison of testicular sperm extraction and ICSI outcomes in
men with a history of bilateral versus unilateral cryptorchidism is still lacking.
Study design, size, duration: This is a retrospective comparative study per-
formed in the Centre of Reproductive Medicine and Andrology, University
Hospital of Lille. Among the 1274 azoospermic men who underwent TESE
procedure from 1995 to 2014, 314 had a history of cryptorchidism. Out of
these patients, 35 had an additional obstructive cause and were therefore
excluded. In the end, we identiﬁed and included a total of 249 patients with a
history of cryptorchidism as only aetiopathogenetic factor for NOA.
Participants/materials, setting, methods: Patients were divided into two
groups according to the history of cryptorchidism: bilateral (65.1%, 162/249)
or unilateral (34.9%, 87/249). We compared hormonal proﬁles and sperm
retrieval rates (SRR) between the two groups. Additionally, we studied ICSI
outcomes with testicular frozen-thawed sperm.
Main results and the role of chance: This is the largest consecutive crypt-
orchid cohort reported to date. There was no difference in the andrological
phenotype with similar FSH levels (21.7 IU/L vs. 18.8 IU/L; p = 0.17), inhibin B
levels (35.5 pg/mL vs. 37 pg/mL; p = 0.15) and mean testicular volumes
(7.7 mL vs. 7.9 mL, p = 0.71). Similar SRR were observed between the groups
(62.3% vs. 59.8%; p = 0.7,8 respectively). Implantation rate was higher in the
unilateral group (23.7% vs. 10.3%; p = 0.02). Cumulative pregnancy rates per
embryo transfer and cumulative live birth rates were both signiﬁcantly higher in
the unilateral group (28.9% vs. 17.5%; p = 0.04 and 27.6% vs. 17.3%; p = 0.04,
respectively).
Limitations, reasons for caution: This is a retrospective study, which inevit-
ably creates a risk a bias towards the recording of the data. In addition, repro-
ductive outcomes might be interpreted with caution regarding the assessment
of the ovarian reserve, which has changed over time due to the evolution in ser-
um AMH thresholds and ultrasound equipment.
Wider implications of the ﬁndings:We showed for the ﬁrst time that ICSI
outcomes were better in NOA patients with a history of unilateral versus bilat-
eral cryptorchidism, despite similar SRR. This suggests that cryptorchidism
could reﬂect a bilateral testicular impairment, even in unilateral cases, and
should be considered when counseling patients before TESE attempts.
Trial registration number: not applicable.
P-004 Parameters associated with sperm quality prior to
chemotherapy treatment in patients with lymphoma
N. Feigin1, G. Karavani2, T. Tachover2, D. Ben-Yehuda3, D. Lavie3,
A. Ben-Meir2
1Hadassah hospital, General Interns, Jerusalem, Israel
2Hadassah hospital, Obstetrics and gynecology, Jerusalem, Israel
3Hadassah hospital, Hematology, Jerusalem, Israel
Study question: What parameters are associated with poor sperm quality in
lymphoma patients prior to chemotherapy treatment?
Summary answer: The study shows a link between known prognostic factors
of lymphoma (B symptoms, low hemoglobin and albumin levels) and sperm
quality before chemotherapy.
What is known already: Chemotherapy treatment in patients with lymph-
oma may result in reduction in sperm quality. Therefore, patients are strongly
advised to undergo sperm cryopreservation prior to the initiation of treatment.
It is still unknown what factors are associated with increased semen analysis
abnormalities prior to chemotherapy.
Study design, size, duration: Retrospective descriptive analytic study. One-
hundred ninety one lymphoma patients attempting sperm cryopreservation
between 1999 and 2016.
Participants/materials, setting, methods:One hundred and one Hodgkin
lymphoma patients and ninety Non Hodgkin lymphoma patients were included
in the study. Lymphoma prognostic factors (presence of B symptoms, albumin
and hemoglobin levels, stage etc.) were compared between patients with nor-
mal and abnormal sperm (according to World Health Organization 2009
guidelines). Another parameter compared between the groups was the
Prognostic Score Ratio (PSR), an index representing the number of negative
lymphoma prognostic measures that exist in a given patient.
Main results and the role of chance: Among the prognostic factors of
lymphomas, the following factors were found to be associated with reduced
sperm quality: B symptoms (p = 0.021), albumin (p < 0.001) and hemoglobin
(p < 0.001) levels. Logistic regression showed signiﬁcant association of albumin
and hemoglobin indexes with reduced sperm quality (p = 0.013, OR = 2.7 and
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p = 0.015, OR = 13.5, respectively). However, in Hodgkin’s lymphoma specif-
ically, only hemoglobin was found to be statistically signiﬁcant. Another measure
that showed a signiﬁcant relationship was the Prognostic Score Ratio (PSR) (p
< 0.001).
Limitations, reasons for caution: The study included only patients who
were eligible for sperm cryopreservation. Therefore, this study did not include
very ill patients, who started chemotherapy immediately, or older patients who
were not interested in sperm cryopreservation.
Wider implications of the ﬁndings: The prognostic factors mentioned
above are related to a general inﬂammatory state and therefore might affect
sperm production. A further investigation of inﬂammatory factors levels in plas-
ma and seminal ﬂuid is reasonable.
Trial registration number:Not applicable.
P-005 Effects of oral cysteamine on fertility in male mice
A. Reda1, P. Kadam2, C. Camps1, K. Veys1, L. Van Den Heuvel1,
E. Levtchenko1, E. Goossens2
1KU Leuven, Organ system, Leuven, Belgium
2Vrije Universiteit Brussel, Biology of the testis BITE, Brussels, Belgium
Study question: Does oral cysteamine affect fertility in male mice?
Summary answer:Oral cysteamine does not affect fertility in male mice.
What is known already: Cystinosis is a rare autosomal recessive meta-
bolic disease caused by mutations in the lysosomal membrane protein, cysti-
nosin, which leads to intra-cellular accumulation of cystine crystals. The
main clinical presentation is renal Fanconi syndrome, leading to end stage
renal disease (ESRD) by the age of 10, if the patient is left untreated. Female
cystinosis patients could get successful pregnancies. However, male patients
suffer from unexplained infertility. The only available treatment for cystinosis
is the oral cysteamine, which depletes the intra-cellular cystine crystals.
However, the effects of oral cysteamine on male fertility was not investi-
gated thoroughly yet.
Study design, size, duration: C57/BL6J male adult (2 months of age) wild
type mice (n = 24) were randomized into 3 groups (n = 8 each); control group
(fed with normal food), treatment group I (fed with 250 mg cysteamine/kg/day
mixed with normal food), and treatment group II (fed with 500 mg cysteamine/
kg/day mixed with normal food). After two months, mice were sacriﬁced.
Body weights, testis weights, seminal vesicle weights, plasma samples, epididy-
mal sperm, and testicular tissues were collected at sacriﬁce time.
Participants/materials, setting, methods: Plasma levels of testosterone,
luteinizing hormone (LH) and follicle stimulating hormone (FSH) were evalu-
ated, using the appropriate ELISA kit for each hormone. Testicular tissues were
ﬁxed in formalin, embedded in parafﬁn, and sectioned. The sections were
stained by periodic acid-Schiff’s (PAS) staining. Number of seminiferous tubules
at stage VIII were quantiﬁed, relative to the total number of tubules. Results
were compared between the control and treatment groups.
Main results and the role of chance: After two months of treatment, we
found no statistically signiﬁcant differences between groups (control, 250 mg,
and 500 mg) regarding the total body weight (31.6 ± 1.9, 30.6 ± 2.7, and 29.6
± 2.6 g respectively), body weight gain (5.9 ± 0.4, 5.0 ± 1.8, and 6.0 ± 1.8 g
respectively), body weight gain normalized to body weight before treatment
(23.4 ± 2.6, 19.6 ± 6.8, and 25.8 ± 8.0 % respectively), seminal vesicle weight
normalized to total body weight (11.9 ± 1.2, 10.7 ± 1.9, and 10.9 ± 1.1 %
respectively), testis weight normalized to total body weight (3.2 ± 0.2, 3.4 ±
0.3, and 3.3 ± 0.2 % respectively), and epididymal sperm count (2.5 ± 0.9, 3.6
± 1.1, and 3.1 ± 1.2 million respectively), using one-way ANOVA test.
Moreover, there was no statistically signiﬁcant difference between groups in
plasma testosterone (4.4 ± 7.2, 3.4 ± 5.8, and 5.0 ± 7.3 ng/ml respectively)
using Kruskal Wallis ANOVA on ranks test. In addition, after two months of
treatment, plasma LH (4.6 ± 3.5, 4.4 ± 2.2, and 5.6 ± 3.3 ng/ml respectively),
plasma FSH (2.5 ± 0.7, 2.8 ± 1.1, and 2.1 ± 0.5 ng/ml respectively) and num-
ber of tubules at stage VIII normalized to total number of tubules (13.9 ± 2.6,
12.5 ± 1.7, and 11.0 ± 2.1 % respectively) were similar.
Limitations, reasons for caution: The study is performed in wild type
C57/BL6J mice, so the combined effect of cystinosis and cysteamine treatment
was not investigated. Moreover, the effect of treatment is investigated after two
months treatment, while the patients take cysteamine life-long. Hence, the
results should be interpreted cautiously.
Wider implications of the ﬁndings: The results obtained in the study sug-
gest that cysteamine treatment, the only available oral treatment for cystinosis,
may have no negative impact on fertility.
Trial registration number:Not applicable.
P-006 A comparison of reproductive outcome using testicular
sperm Vs. ejaculated sperm in ICSI for patients with abnormal DNA
fragmentation
M. Hozain1, H. Alkhader1, S. Eltanbouly1, H. Zaki2
1Ganin Fertility Center, IVF Laboratory, cairo, Egypt
2Ganin Fertility Center, Gynecology and Obstrics, cairo, Egypt
Study question: Is testicular sperm better than ejaculated sperm in ICSI in
terms of reproductive outcome in men with abnormal DNA fragmentation?
Summary answer: There is no signiﬁcant difference in ICSI clinical outcome
between using Testicular sperm or ejaculated sperm with abnormal DNA frag-
mentation patients.
What is known already: Abnormal levels of DNA fragmentation has nega-
tive impact on embryological parameters (fertilization, cleavage, blast).which
lowers the level of pregnancy rate, ongoing pregnancy rate and increase miscar-
riage rate.
The topographic mapping of sperm DNA fragmentation in male genital tract
represent that testicular sperm have lower DFI than ejaculated sperm which is
better to use in ICSI.Using testicular sperm in ICSI can potentially solve the
problem of abnormal DNA fragmentation and would improve the clinical
outcome.
Study design, size, duration: Prospective cohort study included 111 cou-
ples have abnormal DNA fragmentation levels undergoing ICSI in GFC from
June 2016 to July 2017.Patiens were randomized into two groups; ﬁrst group
was ICSI using testicular sperm and the second group was ICSI using ejaculated
sperm.
Participants/materials, setting, methods: This study included 111 cou-
ples with abnormal DNA fragmentation and randomized into two groups.
Sperm DNA fragmentation test was done by TUNEL assay using bench top
ﬂow cytometry and DFI cutoff value was (20%). Women were eligible to par-
ticipate in the study if they were ≤37 years old and had ≥ 5 (MII)oocytes col-
lected. Embryological data were recorded and results were compared using
IMB SPSS Software Version 22 For Microsoft windows.
Main results and the role of chance: A total 111 cases with abnormal DFI
underwent ICSI and divided into 53 cases injected using testicular sperm and 58
cases injected by ejaculated sperm with no signiﬁcant difference in male or
female age between the two groups. DFI level was (26.7%, 23.8%) in Testi-ICSI
and Ejac-ICSI respectively with (P = 0.7). Fertilization rate was (62.98%,
77.16%) in Testi-ICSI and Ejac-ICSI respectively with (P = 0.1). Blastulation rate
was (38.02%, 65.17%) with (P = 0.004) this signiﬁcant value might be due to
the larger number of D3 ET in Testi-ICSI group vs Ejac-ICSI group. Pregnancy
rate was (50%, 51.02%) in Testi-ICSI and Ejac-ICSI respectively with (P = 0.9).
Implantation rate was(41.4%, 26.7%) in Testi-ICSI and Ejac-ICSI respectively
with (P = 0.1).Ongoing pregnancy was (48%, 42.8%) in Testi-ICSI and Ejac-ICSI
respectively with (P = 0.5) and the miscarriage rate was (7.40%, 16%) in Testi-
ICSI and Ejac-ICSI respectively with (P = 0.16).So there is no signiﬁcant differ-
ence favoring Testi-ICSI over Ejac-ICSI in men with abnormal DNA
fragmentation.
Limitations, reasons for caution: Ten patients vitriﬁed all their embryos in
both groups, and were excluded from the pregnancy rate, implantation rate
and ongoing pregnancy rate. Also there are many factors might affect DFI such
as infertility duration, use of medication, presence of varicocele, elevated ROS
levels and other relevant male factors.
Wider implications of the ﬁndings: More studies are needed with larger
number of cases for more statistically powered ﬁndings, to determine which is
better for ICSI cycles with men who have abnormal DNA fragmentation, the
usage of testicular sperm or ejaculated sperm.
Trial registration number:N/A.
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P-007 Male accessory sexual glands secretion as a potential
predictor of fertilization in conventional IVF
C. Bisioli1, D. Mesquiatti1, I. Paredes2, M. Rolón2, R. Molinas3,
D. Ferrer4, M. Horton1, I. De Zúñiga5, G. Terrado5, F. Sobral5,
M. Gomez Peña1, C. Avendaño6
1Pregna Medicina Reproductiva, Embryology, Buenos Aires, Argentina
2Neolife Medicina y Cirugía Reproductiva, Embriology, Asunción, Paraguay
3Neolife Medicina y Cirugía Reproductiva, Medical, Asunción, Paraguay
4Androlab Cba, Andrology, Cordoba, Argentina
5Pregna Medicina Reproductiva, Medical, Buenos Aires, Argentina
6Androlab Cba / Gynesis, Andrology, Cordoba, Argentina
Study question: Do male accessory sexual glands secretions have a predictive
value on the fertilization outcome in conventional IVF?
Summary answer: Prostatic hyper-secretion may have a negative impact in
the fertilization rate.
What is known already: The use of conventional in vitro insemination (CIVI)
has been declining worldwide while intracytoplasmic sperm injection (ICSI) has
dramatically increased. The main argument supporting ICSI overuse is to pre-
vent fertilization failure. Basic seminal parameters are usually the criteria for
choosing between CIVI and ICSI. Although an association between male acces-
sory sexual glands secretion and fertilization has been shown in animal models,
its evaluation has been sidelined from the basic exam of male fertility due to the
absence of clinical studies.
Study design, size, duration: Eighty ﬁve patients younger than 40 yo, with
more than 4 mature oocytes, with male partners with normal semen para-
meters, undergoing conventional IVF between November 2015 and
October 2016 were included in this controlled, prospective, blinded, multi-
center study. One-way analysis of variance or Kruskall-Wallis analysis was
performed to detect any possible differences between parameter means.
All the categorical variables were compared with a Chi-square test among
groups.
Participants/materials, setting, methods: An aliquot of the IVF semen
sample was centrifuged to keep in the supernatant a free-cell plasma fraction.
Fructose seminal vesicle and citric acid prostate secretions were estimated by
spectrophotometry. Fructose levels between 150-450mg/dL and citric acid of
350-670mg/dL were considered as normal while lower or higher values were
considered as pathological. No differences in patients age, basic seminal para-
meters and number of recovered metaphase II oocytes were observed
between groups.
Main results and the role of chance: No differences were observed in fer-
tilization rates between patients with normal and hyper seminal vesicle secre-
tion (0.79 ± 0.03 vs 0.80 ± 0.05) or normal vs hypo secretions (0.79 ± 0.03 vs
0.80 ± 0.07) were compared. Differences in fertilization rates were found
between normal and hyper prostatic secretions (0.84 ± 0.03 vs 0.70 ± 0.04, p
< 0.01) but not when normal vs hypo secretions (0.84 ± 0.03 vs 0.74 ± 0.04)
were compared.
Limitations, reasons for caution: To determine the true extent of any clin-
ical beneﬁt of these preliminary results a randomized clinical trial will be neces-
sary. Research is needed to understand the putative relationship between
prostatic secretions and fertilization potential.
Wider implications of the ﬁndings: Our data suggest a negative correl-
ation between a pathological prostatic hyper-secretion and sperm fertilization
potential. We have described for the ﬁrst time the use of a simple, inexpensive
and objective method that could be useful to choose the most suitable type of
in vitro insemination between CIVI and ICSI.
Trial registration number:N/A.
P-008 Technical standardization as a ﬁrst step to maximize the
prognostic value of ejaculate related parameters in a homologous
intrauterine insemination programme
L. Van de Velde, D. De Neubourg, H. Van Mulders, I. Goovaerts,
K. Peeters, U. Punjabi
University hospital of Antwerp - CRG, Centre for reproductive medicine, Edegem,
Belgium
Study question: Does standardization of the laboratory procedures help to
evaluate the prognostic value of ejaculate related determinants in an intrauter-
ine insemination (IUI) programme.
Summary answer: When technical parameters were held stable, time-
interval between sample production and insemination signiﬁcantly inﬂuenced
positive hCG outcome, clinical pregnancies and live birth rate after IUI.
What is known already: IUI remains a relatively simple, non-invasive, cheap
treatment option for a well selected population with a sufﬁcient number of
motile spermatozoa. There is a considerable amount of literature on several
prognostic factors either related to patient characteristics, semen sample or the
IUI procedure itself. But, results are controversial due to the lack of technical
standardization and good-quality prospective cohort trials. Although minimum
standards required were deﬁned by WHO and ESHRE Special Interest Group
Andrology, large inter-laboratory variations occur. For example, inseminating
motile count varies between 0.8–5 million to maximize predictive performance
(our own validation was ≥ 2 million).
Study design, size, duration: A prospective cohort study of 1795 homolo-
gous IUI cycles were included from April 2013 to March 2017. Cycles with
cryopreserved semen or with two consecutive semen samples were excluded.
Only complete semen samples prepared by density gradient centrifugation
were included. The IUI procedure was divided into 3 phases to study the inﬂu-
ence of the determinants: pre-analysis (abstinence time); analysis (macroscopic
and microscopic examination and sperm preparation) and post-analysis (after
sample preparation and before insemination).
Participants/materials, setting, methods: Five hundred and eighty one
couples presenting at the Centre for Reproductive Medicine underwent 1447
IUI cycles. Semen samples were analyzed using WHO 2010 recommendations
and prepared with a two-step discontinuous density gradient. Reprotoxicity for
disposables and media was controlled. Staff members were trained in basic
semen analysis and semen preparation and participated regularly in internal and
external quality control. A soft IUI catheter was rinsed with medium and the
inseminating volume was held constant.
Main results and the role of chance: IUI resulted in a positive hCG in
15.3% cycles with 14.5% clinical pregnancies and 12.6% live births per cycle.
Pre-analysis phase: Only complete samples (93.4% of all samples) were con-
sidered for this analysis. Although not signiﬁcantly different, abstinence time of
0-1 days reduced live births from 12.5 to 8.5% as compared to 2-7 days as
recommended by WHO. Analysis phase: Analysis was initiated within 60
minutes (99.2% of all samples) after semen production. Semen viscosity
(>3 cm) reduced live births from 13.0% to 8.6% but not signiﬁcantly. Total
motile sperm count and sperm morphology in the native semen did not inﬂu-
ence clinical IUI outcome. After density gradient, inseminating motile count was
≥2 million (as previously validated). Post-analysis phase: Under standardized
conditions, the time interval between sample production and effective IUI was
signiﬁcantly better if held <110 mins (P = 0.01; 17.1% versus 12.3% positive
hCG; 16.2% versus 11.5% clinical pregnancies; 14.2% versus 9.5% live births,
Receiver operating curve: area under the curve: 0.533; sensitivity 69.6 and spe-
ciﬁcity 42.3).
Limitations, reasons for caution: All participants in this study were already
selected according to initial sperm parameters and reasons of subfertility.
Clinical parameters such as female and male age, indication and lifestyle para-
meters were not taken into account.
Wider implications of the ﬁndings: This is the ﬁrst monocentric study to
standardize the technical aspects for IUI, paving the way to prospective multi-
center approach. With technical determinants under control, attention can
now be drawn to clinical variables inﬂuencing IUI outcome.
Trial registration number: not applicable.
P-009 Effect of varicocele repair on spermDNA fragmentation:
A systematic review
M. Bertoncelli Tanaka1, M. Roque2, A. Agarwal3, S.C. Esteves4
1University of Campinas, Department of Surgery- Division Urology, Campinas, Brazil
2ORIGEN, Center for Reproductive Medicine, Rio de Janeiro, Brazil
3Cleveland Clinic, American Center for Reproductive Medicine-Glickman Urological
and Kidney Institute, Cleveland, U.S.A.
4ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil
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Study question: Does the level of sperm DNA fragmentation decrease after
varicocele repair in patients with male infertility?
Summary answer: Varicocele repair decreases sperm DNA fragmentation
levels in infertile men with clinical varicocele.
What is known already: Varicocele, the leading cause of male infertility, can
impair sperm quality and fertility via various oxidative stress (OS) mechanisms.
Imbalance between excessive reactive oxygen species (ROS) production and
antioxidant protection causes alterations in nuclear and mitochondrial sperm
DNA, thus rendering the spermatozoa less fertile in a subset of varicocele men.
Sperm DNA fragmentation (SDF) is known to be elevated in men with clinical
varicocele in both abnormal and normal semen parameters by the current
World Health Organization criteria. Surgical varicocele repair has been advo-
cated as a means of reducing the oxidative-induced sperm DNA damage in
men with varicocele-associated infertility.
Study design, size, duration: We conducted a systematic search using
MEDLINE/PubMed, Scielo, and Google Scholar to identify all relevant studies
published until December 2017. The search combined terms related to “sperm
DNA fragmentation”, “sperm DNA damage”, “sperm chromatin integrity OR
damage”, “varicocele”, “varicocelectomy OR varicocele repair”, with the ﬁlters
“human” and “English” language. For the advanced search, article types selected
were: clinical study, comparative study, journal article, meta-analysis, observa-
tional study, randomized controlled trial (RCT), case series, and systematic
review.
Participants/materials, setting, methods: Participants were men with
varicocele subjected to varicocele repair in whom sperm DNA fragmentation
had been measured before and after surgery regardless of assay type. The pre-
operative and postoperative levels of SDF in semen were the primary out-
comes. The secondary outcomes were levels of other oxidative stress markers
and pregnancy rates according to postoperative SDF levels.
Main results and the role of chance: We identiﬁed 21 studies (3 RCT, 7
prospective, 7 retrospective, 4 not speciﬁed) including 1,270 infertile men with
varicocele subjected to surgery. Twelve studies included a control group and/
or evaluated other OS markers. The majority of studies included men with clin-
ical varicocele and abnormal semen parameters according to theWHO criteria.
Despite the use of different SDF sperm assays, the mixed design, and variable
sample size, all studies involving infertile men with palpable varicocele unequivo-
cally reported a signiﬁcant postoperative decrease in SDF rates in a follow-up
period ranging from 3 to 12 months. A single report including men with subclin-
ical varicoceles showed that SDF levels remained unchanged after surgery. Of
the 4 studies out of 21 reports providing pregnancy outcomes, the overall post-
operative SDF rates fell in men from couples who had a successful pregnancy
than those who did not. Among studies assessing OS markers, the vast majority
reported higher levels of seminal OS or sperm DNA decondensation in infertile
men with clinical varicocele than healthy fertile counterparts without varicocele
and men with subclinical varicocele. Although these studies (n = 8) unequivo-
cally reported signiﬁcant reductions in SDF after varicocelectomy, two studies
have failed to demonstrate reduction in OS markers after varicocelectomy.
Limitations, reasons for caution: Not all risk factors such as participant
age, use of over the counter medication, and smoking were consistently
reported. These factors may inﬂuence the rates of SDF and varicocele repair
outcomes. Another limitation refers to the quality of included studies, which
also varied.
Wider implications of the ﬁndings: Current evidence based on careful
review of published studies conﬁrms the effectiveness of varicocelectomy as a
means of both reducing oxidatively-induced sperm DNA damage and poten-
tially improving fertility. Varicocele repair should be offered as part of treatment
option for male partners of infertile couples presenting with palpable
varicoceles.
Trial registration number:NA.
P-010 Effects and mechanisms of a heterozygous truncation
mutation in BNC1 onmale subfertility
J. Li1, Y. Liu1, H. Xu2, P. Lv1, D. Zhang1, J. Sheng2, H. Huang2
1Women’s Hospital - School of Medicine - Zhejiang University, Department of
Reproductive Endocrinology, Hangzhou, China
2Zhejiang University, Key Laboratory of Reproductive Genetics, Hangzhou, China
Study question: What is the effects and mechanisms of basonuclin1(BNC1)
gene truncation mutation in male infertility.
Summary answer: BNC1 truncating mutation would lead to impaired sperm-
atogenesis via expression dysregulation of several genes essential for spermato-
genesis including Tex14, Klhl10, Spatc1, Hook1, Tssk6, and Tnp2.
What is known already: Basonuclin (BNC1) is expressed primarily in pro-
liferative keratinocytes and gametogenic cells. However, its role in sperm-
atogenesis is not clear. Previous study reported that BNC1 was present in
spermatogonia, spermatocytes, and spermatids, but absent in Sertoli cells,
and Bnc1-null male mice were sub-fertile, losing germ cells progressively
with age. We recently discovered a novel heterozygous BNC1 truncating
mutation, which led to male subfertility both in mice and human.Yet, the
underlying molecular mechanism of BNC1 mutation on male subfertility
remains unknown.
Study design, size, duration: Transgene mouse model study. Generate
BNC1 truncation mutation mice. Investigate spermatogenesis of wild-type
(+/+), heterozygous (+/tr), and homozygous (tr/tr) BNC1 truncation muta-
tion mice. Assess expression proﬁling and direct binding (ChIP-seq) studies of
wild-type and heterozygous BNC1 truncation mutation mice testis. Explore the
underlying mechanisms of BNC1 on spermatogenesis.
Participants/materials, setting, methods: We generated BNC1 trunca-
tion mutation mice using homologous recombination. Based on the subfertility
phenotype, expression proﬁling study was carried out. Key differentiated genes
were conﬁrmed by RNA extraction and real-time RT-PCR. Furthermore, ChIP-
seq and ChIP-qPCR study with BNC1 in mouse testis was used to identify
spermatogenesis speciﬁc gene promoters targeted by BNC1.
Main results and the role of chance: BNC1 truncation mutation male
mouse model exhibited infertility or subfertility, signiﬁcantly increased serum
FSH and LH levels, lowered testerone level, and decreased testis size. Taken
together, the data from the mouse model indicated BNC1 truncation mice had
impaired spermatogenesis. Go-analysis, pathway-analysis, Gene-act-network,
co-expression network of differentiated expression genes and ChIP-seq bind-
ings were analyzed, and Tex14, Klhl10, Spatc1,Hook1, Tssk6, and Tnp2 were
considered to be the possible genes involved in the mechanisms of BNC1 trun-
cation mutation leading to impaired spermatogenesis.
Limitations, reasons for caution: Further studies performed with germ
cells of different stages may help to explore the entire molecular mechanisms
involved in the function of BNC1 in spermatogenesis.
Wider implications of the ﬁndings: Our ﬁndings describled the ﬁrst time
the effects and mechanisms of BNC1 truncation mutation in spermatogen-
esis disorder, and provided unique evidences that BNC1 was an important
transcription factor involved in spermatogenesis. The testis-speciﬁc role of
BNC1 identiﬁes this regulator as a potential target for male contraceptive
intervention.
Trial registration number:No.
P-011 Efﬁcacy of triple seminal lavage in patients with positive
serology for HIV and HCV
E. Cordts1, I. Yoshida2, E. Vieira2, C. Zulim2, C. Lopes2, P. Beirigo2,
B. Parra2, C. Nogueira2, C. Suganuma2, J. Romanini2, C. Barbosa1
1Instituto Ideia Fertil, Gynecology, Santo André, Brazil
2Instituto Ideia Fertil, Embryology, Santo André, Brazil
Study question: Evaluation of sperm recovery and viral load in samples from
patients affected by HIV and HCV after triple washing and qPCR.
Summary answer: The qPCR for detection of viral load after triple seminal
washing is essential for serodiscordant couples, although it is undetectable in
the blood.
What is known already: Coombs et al., 1998 reported that in 27% of cases,
the theory of compartmentalization occurs: there is a disagreement between
blood viral load and semen. Reproductive and serodiscordant couples for HIV
and HCV can perform in vitro fertilization without risk of transmission of the
disease to descendants. However, seminal washing is recommended in situa-
tions where the man is a carrier of the virus.
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Study design, size, duration: A cross sectional study where 125 seminal
samples from HIV and HCV patients were evaluated from January 2012 to
December 2017.
Participants/materials, setting, methods: A total of 125 seminal samples
from HIV-positive patients were evaluated, 83 of them by HIV and 42 by HCV.
The samples were submitted to triple washing using the techniques of Sperm-
Wash, Density Discontinuous Gradient and Swim up for subsequent quantiﬁca-
tion of viral load by qPCR. Only samples from ejaculate were included. The efﬁ-
cacy and the seminal recovery rate were evaluated after the triple washing.
Main results and the role of chance: An overall recovery of 8% sperm after
triple washing was found. Comparing the serologies, the seminal recovery of
patients with HIV of 7.69% and 8.65% of HCV was observed. The qPCR was
performed and the presence of the virus was found in 1.6% (2/125) of the sam-
ples after the triple washing. Both samples were from men infected with HIV
virus with undetectable viral load in the blood. The clinical decision for these
cases was not to proceed with oocyte fertilization.
Limitations, reasons for caution: More studies are needed with greater
casuistry to conﬁrm the data found in this study.
Wider implications of the ﬁndings: Although patients have undetectable
viral load in the blood, this study demonstrated the need to perform the triple
semen washing associated with quantiﬁcation of the viral load by qPCR to pre-
vent transmission of the virus to the descendants.
Trial registration number:None.
P-012 Male fertility under ﬁre- the association between semen
parameters and armed conﬂict related stress: a population-based
study
Y. Mizrakli1, I. Har-Vardi2, T. Priel2, A. Harlev2, A. Zeadna2,
N. Steiner2, V. Novack1, E. Levitas2
1Soroka University Medical Center and the Faculty of Health Sciences- Ben-Gurion
University of the Negev, Clinical Research Center, Beer-Sheva, Israel
2Soroka University Medical Center and Faculty of Health Sciences- Ben-Gurion
University of the Negev, Fertility and IVF Unit- Department of Obstetrics and
Gynecology, Beer-Sheva, Israel
Study question: Whether the population exposure to the stress, peaking dur-
ing two large military operations (MO), was associated with poor semen quality.
Summary answer: This ecological study showed that acute psychological
stress can potentially impact sperm quality resulting in decreased sperm motility
and reduced normal sperm forms.
What is known already: Psychological stress has been established as having
a negative impact on infertility. However, research examining the association
between psychological stress and semen quality has been inconsistent. Many
studies were small and did not asses stress objectively or dealt with selected
study populations.
Study design, size, duration: An ecological study. The data for 11,195 con-
secutive semen analyses of 6,819 couples between 2009-2017 were analyzed.
Participants/materials, setting, methods: In recent years the civilian
population of Southern Israel experienced multiple alert sirens and rocket ﬁre
on a daily basis, creating a stressogenic environment. MO adjacent samples
were deﬁned as those obtained during the MO and the two subsequent months
following cease-ﬁre. Semen analyses were collected as part of basic fertility
evaluation and conducted according to WHO criteria. Multivariate analysis was
performed using Logistic Regression models.
Main results and the role of chance: Comparison of 659 semen analyses
taken during and adjacent to MO to 10,536 semen samples obtained during the
rest of the time period showed similarity in the mean age (31.8 ± 7.8 vs. 32.1
± 8.1 years, respectively, p = 0.246), BMI (26.1 ± 4.7 vs. 26.1 ± 8.1, p =
0.813) and smoking (44.2% vs. 43.5%, p = 0.320). In the MO adjacent group,
mean total motility was lower (47.4%±22.9% vs. 49.5%±22.0%, p = 0.019), as
well as mean progressive motility (39.7%±21.5% vs. 43.3%±21.5%, p < 0.001)
and mean normal sperm forms (3.4%±1.9% vs. 3.7%±2.3%, p = 0.010).
The prevalence of low progressive motility was higher in the MO group
(37.5% vs. 30.8%, p < 0.001). In multivariate analysis MO adjacency adjusted
for age, BMI and smoking was found to be associated with lower progressive
motility (adjusted O.R = 1.47 C.I 95% 1.16-1.61).
Limitations, reasons for caution: This is an ecological study assigning stress
based on the exposure of the total population. Also, we did not take into con-
sideration the time before the operations when missiles were already ﬁred and
the stress may have been increasing.
Wider implications of the ﬁndings: We detected a negative association
between psychological stress and semen quality. This ﬁnding is of public health
importance, as stress is common and might be a modiﬁable factor. In a clinical
setting, psychological stress should be considered upon the interpretation of
semen analysis data. Future studies should address causality.
Trial registration number: not applicable.
P-013 The impact of male smoking on intracytoplasmic sperm
injection outcomes in In vitro fertilization procedures
Z. Petanovski1, G. Dimitrov2, M. Hadzi Lega3, D. Shushleski4,
V. Matevski5, S. Saltirovski4, S. Stojkovska5, E. Petanovska5,
V. Sotiroska5
1Associate Professor, Medical Faculty, Skopje, Macedonia
2First Private General Hospital ReMedika- Skopje- Macedonia- Medical Faculty-
Goce Delchev University- Shtip- Macedonia, In Vitro Fertilisation Centre-, Skopje,
Macedonia
3First Private General Hospital ReMedika- Skopje- Macedonia, In Vitro Fertilisation
Centre, Skopje, Macedonia
4In Vitro Fertilisation Centre- First Private General Hospital ReMedika- Skopje-
Macedonia, In Vitro Fertilisation Centre-, Skopje, Macedonia
5First Private General Hospital ReMedika- Skopje- Macedonia, In Vitro Fertilisation
Centre-, Skopje, Macedonia
Study question: How does male cigarette smoking inﬂuence in vitro fertiliza-
tion outcomes?
Summary answer: The results suggest that male smoking negatively inﬂu-
ences the IVF outcome resulting in reduced ongoing pregnancy and delivery
rate.
What is known already: Cigarette smoke comprises toxic, mutagenic che-
micals and carcinogens such as cotinine, cadmium, nicotine metabolites, which
were found in the seminal plasma at concentrations proportional to those in
the serum, suggesting that they can cross the blood-testis barrier providing gen-
otoxic environment for germ cells. An evidence based review suggests that oxi-
dative stress and the causing genetic and epigenetic changes that result from
smoking may correlate directly with reduced sperm parameters and reduced
sperm function.
Study design, size, duration: This prospective study encompassed the peri-
od from 2012 to 2013 with 702 performed cycles from which 329 (46.9%) men
were non-smokers and 373 (53.1%) were smokers The exclusion criteria for
women were poor responders (basal FSH greater than 10mIU/ml, less than 5
pre-antral follicles) and patients above 39 years of age. The male exclusion cri-
teria were azozoospermia, severe oligozoospermia, donation, chromosome
alteration, genitourinary infections and operations, chemotherapy treatment
and diabetes mellitus.
Participants/materials, setting, methods: To minimize the bias, only the
ﬁrst IVF cycle was analyzed. Binary logistic regression analysis was used to
study the effect of male smoking on clinical pregnancy and delivery after control-
ling for potential confounding variables, (maternal age, maternal smoking status
and asthenozoospermia). Signiﬁcant differences were considered all values of p
< 0.05
Main results and the role of chance:Our study indicates that male smok-
ing does not have a signiﬁcant inﬂuence on the clinical pregnancy rate (OR
= 1.21, 95%CI 0.89-1.25). After the adjustment for asthenozoospermia
(OR = 1.22,CI 0.91-1.65) and female smoking (OR = 1.21 CI 0.89-1.62),
male smoking was again conﬁrmed to be non-signiﬁcant predictor for reach-
ing clinical pregnancy. These ﬁndings support the observations of ICSI as
preferred fertilization method. The results also demonstrated that male
smoking compromised the quality of the ongoing pregnancy. Signiﬁcant num-
ber of early miscarriages was observed among group of smoker men (18.3%
as opposed to 5.6% p < 0.05 among smokers and non-smokers respect-
ively) resulting in lower ongoing pregnancy rate in this group of patients
(45.9% vs 35.9% p < 0.05). We found that male smoking generally is
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signiﬁcant factor for increasing the chances for not achieving delivery for
1.53 times (CI 1,13-2,07). Women older than 35 years in group of paternal
smoker had 2.27 times (CI 1,39-4,56) higher risk for not achieving delivery.
It is likely that if the oocyte’s repair capacities are inadequate (low oocyte
quality/increased age), a low rate of embryonic development resulting in a
high rate of early pregnancy loss.
Limitations, reasons for caution: Our study should be further investigated.
The data on smoking and male fertility reinforce the preferred preventive
approach of discouraging smoking and eliminating exposure to tobacco smoke
in particular while trying to conceive. Antioxidant supplementation may then be
taken together to improve the patient’s health outcomes.
Wider implications of the ﬁndings: It is also very important to comment
that all smokers are not infertile, which suggests that genetic variations or poly-
morphisms in DNA repair, apoptosis and xenobiotic metabolism genes among
smokers may increase susceptibility to infertility.
Trial registration number:N/A.
P-014 Is “real time” conventional TESE (cTESE) an obsolete
sperm retrieval technique in patients with non obstructive
azoospermia (NOA)?
R. Oses1, P. Medel1, A. Valcarcel2, M. Tiveron2, M. Guidobono2,
M. Felici2, E. Young3
1IFER, Andrology, Buenos Aires, Argentina
2IFER, Embryology, Buenos Aires, Argentina
3IFER, Gynecology, Buenos Aires, Argentina
Study question: How successful is cTESE as a sperm retrieval technique in
patients with NOA when performed in a systematic fashion?
Summary answer: Our results show that “real time” cTESE is a highly efﬁ-
cient sperm retrieval technique in patients with NOA.
What is known already: Recent reports in the literature suggest that there is
a tendency to replace cTESE with mTESE in NOA patients in many centers
around the world. mTESE was introduced as a surgical approach in patients
with very small testicles with the notion of preserving an already diminished tes-
ticular parenchyma but it has not proven to be superior in most cases of NOA.
In order to perform mTESE an operating microscope is required and a highly
trained microsurgeon needs to be always available at the time of egg retrieval, if
done simultaneously.
Study design, size, duration: Retrospective clinical study, January 1996 to
December 2016: all patients who underwent cTESE were included in the study.
All patients were surgically approached in the same fashion by the same team.
In some instances the procedure was carried out at the time of egg retrieval
and in other cases for diagnostic purposes and sperm cryopreservation. The
diagnosis was obtained post operatively in most patients.
Participants/materials, setting, methods: A total of 635 patients under-
went cTESE under local anestesia with IV sedation. A scrotal incision was per-
formed on one side with up to four testicular incisions at random until sperm
were observed. Only if no sperm were present in any of the chosen areas, was
the contralateral testis approached in the same fashion. A small specimen was
separated for histopathological diagnosis and the patient discharged four hours
later.
Main results and the role of chance: Out of 635 patients who underwent
cTESE we were able to identify 388 patients with the histological diagnosis of
NOA who had their ﬁrst testicular biopsy along with sperm retrieval attempt.
In 30 cases the procedure was a repeat, in 20 cases the patients had been
unable to produce a fresh sample the day of oocyte retrieval, in 10 cases the
procedure was undertaken due to absolute asthenospermia/necrospermia or
severe oligospermia, in 28 cases the patients had a single testis, in 100 cases the
diagnosis was obstructive azoospermia (OA), and in 59 cases we were unable
to retrieve their histological reports. All these cases were excluded from our
study. In the 388 patients identiﬁed with the conﬁrmed diagnosis of NOA we
found sperm for ICSI or cryopreservation in 234 (234/388; 60%). In 167 cases
a unilateral procedure was sufﬁcient (167/388; 43%), in 33 cases sperm were
only found in the contralateral testis (33/388; 8%), and in 35 cases (35/388;
9%) a bilateral procedure was needed in order to obtain enough sperm for ICSI
or cryopreservation since only scarce sperm could be harvested from each
testicle. In patients with a single testis the sperm retrieval rate was 28.5%
(8/28).
Limitations, reasons for caution: This is a retropective study. Only one
sperm analysis with centrifugation was performed preoperatively to rule out
cryptozoospermia.
Wider implications of the ﬁndings: Our extensive experience indicates
that “real time” cTESE provides optimal sperm retrieval rates when performed
in a systematic fashion. The procedure is simpler and less invasive than mTESE,
carries less post operative complications and there is no need for an operating
microscope and a trained microsurgeon.
Trial registration number: not applicable.
P-015 Correlation between spermatic dna fragmentation and
spermmotility in infertile subjects
G. Peluso1, A. Palmieri2, P.P. Cozza1, G. Morrone1, P. Verze2,
N. Longo2, V. Mirone2
1Annunziata Hospital of Cosenza, U.O.S.D. of Physiophatology of Human
Reproduction, Cosenza, Italy
2University Federico II°, Urological Clinic, Naples, Italy
Study question: Why the pathophysiology of the testicular damage asso-
ciated with varicocele remains unclear, sperm DNA damage has been identiﬁed
as a potential explanation for this cause of male infertility?
Summary answer: Current study determines the extent of sperm nuclear
DNA damage in patients with varicocele, and to examine its relationship with
parameters of seminal motility.
What is known already: Varicocele is one of the most common adrological
pathologies in the general population and particularly common in infertile men.
The varicocele negatively inﬂuences spermatic function is well documented
although the exact mechanisms are still not understood. In fact, infertility may
be associated to a variety of spermatogenetic conditions ranging from normo-
zoospermia to moderate oligoasthenoteratozoospermia (OAT), to azoosper-
mia. Several authors have suggested that patients with varicocele have a
signiﬁcantly higher DNA fragmentation index. Studies show that varicocele sam-
ples contain a higher proportion of spermatozoa with abnormal DNA and
immature chromatin than those from fertile men as well as infertile without
varicocele.
Study design, size, duration:One hundred and ﬁfty subjects analyzed in this
study ranged in age between 20-50 with the median age of 35 and attending to
Andrology Service for infertility diagnosis and other andrological problems. For
each patient included in the study, the spermatozoon population was deter-
mined. On the basis of the usual seminologic criteria, patients considered in this
phase of the study were characterized by isolated asthenospermia, in according
to WHO 2010
Participants/materials, setting, methods: Semen samples from 60
patients with clinical varicocele and 90 infertile men without varicocele were
examined. Varicocele sperm samples were classiﬁed as normal or pathological
according to the 2010 World Health Organization guidelines. Sperm DNA
damage was evaluated using the Halosperm kit, an improved Sperm Chromatin
Dispersion (SCD) test. All data were calculated as average with standard devi-
ation on experiments which were repeated and analized statistically using the
statistical program SPSS.
Main results and the role of chance: DNA fragmentation index (DFI: per-
centage of sperm with denatured nuclei) values was signiﬁcantly higher in
patients with varicocele, either with normal or abnormal (DFI 25.8 ± 3.2 vs
17.4 ± 2.8- P < 0,01) semen proﬁles. Therefore, most signiﬁcant data of our
study came from the analysis of correlation between the DFI values calculated
and progressive a + b motility values expressed in % and calculated in patients
with varicocele associated with the condition of isolated asthenozoospermia.
Statistical analysis of the data found a semi-empirical correlation of 0,9982
between the index of percentage fragmentation (DFI) and percentage sperm
motility according to the: Eq.1: DFI = 49,48 exp (-0,022 motility)
Limitations, reasons for caution: no limitations took place in the study.
Wider implications of the ﬁndings: Results of our study, on the higher fre-
quency of DNA fragmentation presented in the sperm cells of infertile patients
with varicocele compared to patients suffering from other typologies of
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infertility and the fertile controls, supporting the hypothesis which has been pro-
posed by other authors.
Trial registration number: not applicable.
P-016 Development of sperm searching system using artiﬁcial
intelligence in assisted reproductive technology
T. Takeshima1, S. Kuroda1, M. Yamamoto2, M. Murase2,
Y. Yumura1, H. Sasaki3, T. Hamagami3
1Yokohama City University Medical enter, Department of Urology- Reproduction
Center, Yokohama City- Kanagwa, Japan
2Yokohama City University Medical enter, Department of Gynecology- Reproduction
Center, Yokohama City- Kanagwa, Japan
3Yokohama National University, Faculty of Engineering, Yokohama City, Japan
Study question: This study aims to improve the accuracy of normal sperm
selection and to reduce burden on embryologists by introducing AI incorporat-
ing their skills and experiences to support detection and selection.
Summary answer: Efﬁcient sperm detection and selection, and improving
ART treatment outcome will be expected by development of this AI system.
What is known already: The number of ART cycles in Japan has been
increasing year by year. Detection and selection of morphologically normal and
motile spermatozoa are carried out by the embryologists out of the cell suspen-
sion of prepared semen or testicular tissue. However, the treatment outcome
is greatly dependent on the individual technique and experience, and it takes a
lot of time and labors. It is difﬁcult for all embryologists to detect and select
them with equivalent reproducibility. AI excels in universalizing the elements
such as technology and experience.
Study design, size, duration: We conducted a preliminary experiment as a
collaborative research between our center and the faculty of engineering of
Yokohama National University from 2017. In the training data, 8020 positive
examples (spermatozoa) and 25522 negative examples (non-spermatozoa)
were labeled and AI was made to identify as spermatozoa.
Participants/materials, setting, methods: Embryologists performed label-
ing target cells in selecting spermatozoa during ICSI and then recorded on HDD
and transported to research facilities. Thereafter, we aim to establish the sys-
tem in following 4 steps: (1)detection and indexing of spermatozoa, (2)extrac-
tion of morphology and motility characteristics of spermatozoa, and accurate
reproduction of embryologists’ point of view in combination with multidimen-
sional feature quantities, (3)assessment of spermatozoa by ensemble learning,
(4)collection and evaluation of data by the urological specialists and
embryologists.
Main results and the role of chance: Although the linear discrimination
plane was learned from the histogram for both the learning data and the test
data by the histograms of oriented gradient (HOG) feature extraction method,
and the recall rate 0.99 was obtained, the false positive rate> 0.50 in the test
data.
Limitations, reasons for caution: Limitation is that this system is still in the
development stage.We are now in the stage of conﬁrmation of sperm detection
and grading capability with outlier detection on non-sperm HOG by nonlinear
discrimination, and it is not yet applied to clinical application.
Wider implications of the ﬁndings: Using AI is a new attempt for searching
spermatozoa not reported in the past, and establishing this system make it pos-
sible to search sperm with high accuracy.
Trial registration number: not applicable.
P-017 Ultrasonographic (US) visualization of the scrotal vas
deferens
K. Nakano, G. Sukegawa, Y. Tsuji
Ebisu Tsuji Clinic, Andrology, Tokyo, Japan
Study question: Can the normal scrotal vas deferens be visualized by ultra-
sonography (US)?
Summary answer: US can visualize the normal scrotal vas deferens and may
provide further insights into pathological conditions of the proximal seminal
tract.
What is known already: Obstructive azoospermia results from obstruction
of the seminal tract between the rete testis and the ejaculatory duct.
Determination of the location of the obstruction is extremely important for
selecting an appropriate management. Due to its ﬁrmness, the vas deferens can
be easily palpated through the scrotum. However, subtle changes in the vas def-
erens including luminal dilation are difﬁcult to identify by physical examination.
Although transrectal US clearly reveals the caudal junction of the vas deferens
and seminal vesicles, US visualization of the scrotal vas deferens is considered
to be difﬁcult due to the complex structure of the spermatic cord.
Study design, size, duration: This prospective observational study involved
463 infertile men who visited our andrology outpatient clinic from April to
December 2017. We excluded from the study patients who had any clinical
signs of seminal tract abnormality.
Participants/materials, setting, methods: Because unilateral orchiectomy
had been performed in two patients, a total of 924 vas deferens in 463 patients
aged 25 to 69 years were examined. After physical examination of the scrotum,
we evaluated the testis, rete testis, epididymis and scrotal vas deferens by US
using a 14-MHz linear array transducer.
Main results and the role of chance: Of the 924 normal vas deferens, only
one with very severe varicocele was not visualized by US. The ultrasonographic
features of the normal vas deferens are as follows. Above the proximal tortuous
part connected to the tail of the epididymis, the vas runs linearly up to the
external inguinal ring. The thick muscular wall of the vas appears hypoechoic,
and the lumen is shown as “double-line echoes” at the center of the tube. By
color Doppler US, while the vas itself lacks blood ﬂow signals, pulsatile signals
of the artery of the vas deferens are evident beside the vas.
Limitations, reasons for caution: US does not allow visualization of the vas
deferens from the inguinal canal to just before the ampulla.
Wider implications of the ﬁndings:Our experience provides further infor-
mation for diagnosing anatomical abnormalities of the proximal seminal tract in
certain conditions, including vasal obstruction after inguinal hernia repair.
Trial registration number:Not required.
P-018 Ameliorative effects of Naringenin in altered testicular
ultrastructural and antioxidant activity following use of
antiretroviral therapy in Sprague Dawley rats, a randomised trial
M. Adana1, E. Akang2, E. Naidu2, O. Azu3
1University of Ilorin, Anatomy, Ilorin, Nigeria
2University of KwaZulu-Natal, Clinical Anatomy, Durban, South Africa
3University of Namibia, Anatomy, Windhoek, Namibia
Study question:What is the role of naringenin a bioﬂavonoid on antiretroviral
therapy induced testicular ultrastructural changes and altered fertility potentials
in Sprague Dawley rats?
Summary answer: Antiretroviral therapy induced testicular ultrastructural
changes associated with altered antioxidant activity, impaired semen para-
meters and decline in fertility index which was partly restored by Naringenin.
What is known already: Even though infection with Human Immuno-
deﬁciency Virus (HIV) depresses the health status of men, it does not eliminate
the desire for future fertility yet testicular toxicity has been associated with
Highly Active Antiretroviral Therapy (HAART). HAART induced histopatho-
logical changes in the testes has been linked to increased activity of reactive
oxygen species that ultimately overwhelms the tissue’s total antioxidant status.
The seminiferous tubules has been shown to be particularly sensitive to the
effects of HAART thereby rendering patients oligospermic and even azoosper-
mic. Various ﬂavonoids have been shown to mitigate against free radical/oxida-
tive stress induced tissue damage.
Study design, size, duration: A randomized, controlled animal trial involving
30 male and 18 non- mated female Sprague Dawley rats. Animals were housed
in standard cages under controlled environmental conditions (25oC and a 12-h
light/dark cycle). The study lasted for a period of 10 weeks.
Participants/materials, setting, methods: Thirty male SD rats weighing
200–220 g, were randomly assigned into groups; viz DW: Distilled water, H:
HAART, N40: Naringenin, 40 mg/kg, N80: Naringenin, 80 mg/kg, HN40:
HAART+Naringenin, 40 mg/kg and HN80: HAART+Naringenin, 80 mg/kg.
After treatment, copulation was allowed to take place. The number of
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pregnancies and litters per group were noted. Semen was analysed. Oxidative
enzyme activities were assayed using enzyme linked immunoassay and testicular
ultrastructural changes were noted via electron microscopy.
Main results and the role of chance: Sperm count was signiﬁcantly differ-
ent between the groups. There was a signiﬁcantly lower count in group H com-
pared to DW [p = 0.01] and N40 [p = 0.032]. There were signiﬁcantly lower
progressive sperms in group H when compared to DW [p < 0.0001], N40 [P
= 0.001], N80 [p = 0.00], HN40 [p = 0.00] and HN80 (HAART+Naringenin
80 mg/kg) [p = 0.001]. Group N40 [P = 0.001] and HN40 [P = 0.002] also
displayed signiﬁcantly lower progressive motility when compared to DW.
The testicular glutathione peroxidase levels was higher in the N40 and N80
groups when compared to H group. Lower levels were also observed in groups
DW, HN40 and HN80. The N80 group showed signiﬁcantly higher level of tes-
ticular catalase activity than groups DW (p = 0.024) and H (p = 0.003)
Group H displayed thickening and irregularity in the outline of the basement
membrane. Normal cellular progression in the germinal epithelium was altered.
Spermatids appeared in the basal compartment. There was widening of the
internuclear space between Sertoli cells. Degenerative changes appeared in the
nuclear membrane, abnormally formed spermatid heads and disorganised axo-
nemes were observed the in the midpiece.
The fertility index was higher in the DW group than in the H and N40
groups. The number of pubs per group were also higher.
Limitations, reasons for caution: A larger sample size would have been
more convincing especially in the aspect of fertility index. The study considered
the effect of a FDC of HAART, it is therefore difﬁcult to associate the effects
observed to a single drug in the combination.
Wider implications of the ﬁndings: The study suggests that HAART has
deleterious effects on testicular function and male fertility. This agrees with earl-
ier ﬁndings. Naringenin, a bioﬂavonoid may be a useful adjuvant therapy in pro-
tecting against testicular toxicity.
Trial registration number: The Animal Research Ethical Committee
(AREC), UKZN, South Africa approved this research with a reference number
AREC/046/016D.
P-019 CD147 deﬁciency is associated with impaired acrosome
reaction in patients with asthenozoospermia
E. Fok1, H. Chen2,3, H.C. Chan4
1The Chinese University of Hong Kong, School of Biomedical Sciences, Hong Kong,
Hong Kong
2Guangdong University of Technology, Institute of Biomedical and Pharmaceutical
Sciences, Guangzhou, China
3First Afﬁliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital,
Shenzhen, China
4The Chinese University of Hong Kong, Epithelial Cell Biology Research Centre, Hong
Kong, Hong Kong
Study question: What is the etiological factor underlying the impaired acro-
some reaction in asthenozoospermia infertile patient?
Summary answer: Our study showed that CD147 deﬁciency is associated
with impaired acrosome reaction in patients with asthenozoospermia.
What is known already: Asthenozoospermia, a condition which sperm
exhibit motility lower than the normal threshold, accounts for approximately
18% of all male subfertility and infertility cases. A previous study has shown that
deﬁcient human β-defensin 1, a small antimicrobial peptide released into the
epididymis and female reproductive tract, underlies poor sperm motility
observed in asthenozoospermia patients. Intriguingly, sperm from asthenozoos-
permia patients has been shown to have a signiﬁcantly lowered rate of
ionophore-induced acrosome reaction, suggesting that the infertility outcome
of asthenozoospermia patients could be attributed to multifaceted factors.
However, the molecular mechanisms underlying defects in acrosome reaction
leading to infertility remain incompletely understood.
Study design, size, duration: Sperm from fertile men (n = 36) and astheno-
zoospermia patients (n = 27) were included in the study. The samples were
evaluated for the protein level of CD147 on sperm and used as an in vitro mod-
el to study the effect of soluble CD147 on sperm functions and its underlying
molecular mechanism.
Participants/materials, setting, methods: The level of CD147 on sperm
was assessed by immunoﬂuorescence staining and semi-quantitative Western
blot. Sperm samples were treated with recombinant CD147 proteins or condi-
tioned media containing soluble CD147. Sperm functions were evaluated by
computer-assisted sperm analysis (CASA), ﬂuorescein-Pisum sativum agglutinin
(FITC-PSA) assay, hyaluronan binding assay and oocyte penetration assay.
Calcium imaging was used to examine the mechanism underlying the effect of
CD147 on sperm functions.
Main results and the role of chance: The localization of CD147 was shifted
from the mid-piece to the head region upon capacitation. The expression levels
of CD147 were lower in sperm from asthenozoospermia infertile patients that
exhibited defects in both sperm motility and acrosome reaction. The repro-
ductive female tract-derived soluble CD147 interacted with sperm-bound
CD147. The dimerization of CD147 induced a 2-fold increase in intracellular
calcium level and a 3-fold increase in the percentage of acrosome reaction in
normal capacitated sperm. Soluble CD147 treatment restored the acrosome
reaction from 10% to 37% and enhanced the fertility potential of sperm from
asthenozoospermia patients.
Limitations, reasons for caution: The gain- and loss-of-function in human
sperm were only achieved by neutralizing antibody against CD147 and recom-
binant CD147. A more reliable genetic overexpression or knockout approach
was not possible in human sperm.
Wider implications of the ﬁndings: CD147 deﬁciency may underlie the
acrosome reaction defects in male infertile patients. CD147 is a potential diag-
nostic marker for male infertility and soluble CD147 is a feasible approach to
enhance the fertility outcome of assisted reproductive technologies.
Trial registration number:Not applicable.
P-020 Sperm vitality and DNA fragmentation index (DFI) are good
predictors of progressive spermmotility in oligozooasthenospermic
men treated with metabolic and essential nutrients
S. Micic1, N. Lalic1, D. Djordjevic2, N. Bojanic2, A. Virmani3,
A. Agarwal4
1Uromedica Polyclinic, Andrology department, Belgrade, Serbia
2Clinical Center of Serbia, Urologic Clinic, Belgrade, Serbia
3Sigma tau Helath Science, Innovation- Research and Development, Utrecht, The
Netherlands
4American Center for Reproductive Medicine, Andrology Center, Cleveland, U.S.A.
Study question: The goal of this study was to examine correlation between
sperm vitality and DFI with progressive sperm motility after 6 months therapy
of oligoasthenospermic men.
Summary answer: The increase of the vitality of spermatozoa and decrease
DFI have very good predictive and diagnostic characteristics of progressive
sperm motility after 6 months therapy.
What is known already: Sperm vitality is a reﬂection of the proportion of
live, membrane-intact spermatozoa determined by either dye exclusion or
osmoregulatory capacity under hypo-osmotic conditions. Sperm DNA damage
has been associated with adverse reproductive outcomes and has been increas-
ingly utilised in the management of male infertility in the era of IVF and ICSI. L-
carnitine is essential for the normal mitochondrial oxidation of fatty acids, pro-
tects cell membrane and DNA against damage induced by free oxygen radicals.
Both L-C and acetyl-L-carnitine (ALC) also have important roles in the post-
gonadal maturation of spermatozoa.
Study design, size, duration: The study was randomized, double blind,
placebo controlled (DBPC) and examined the effect of test formulation,
Proxeed Plus, containing L-C 2 g and ALC 1 g, as well as antioxidants, vita-
mins and minerals, in men with idiopathic oligo-asthenozoospermia (age
group18-50 years). The protocol was 2 months wash-out and 6 months
treatment (T-2, T0, T + 3, T + 6), with test formulation (125 patients) or
placebo (50 patients).
Participants/materials, setting, methods: The subjects with oligoasthe-
nozoospermia and history of infertile marriage more than one year, were ran-
domized to receive treatment or placebo in a double blind protocol. Analysis of
ejaculate was done according to WHO 5th guideline. Progressive sperm motility
(A + B grade of rapid) was done manually. DFI was evaluated by Halosperm kit
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(Halotech DNA, S.L) and sperm vitality was done by the one-step eosin-nigro-
sin technique.
Main results and the role of chance: The results of treated group: DFI (%)
was T0 = 38,50 (32,00-48,75), T3 = 35,50 (25,50-44,00) and T6 = 31,00
(25,00-41,00); sperm vitality (%) was T0 = 0.52 (0.43-0.60), T3 = 0.57 (0.46-
0.64) and T6 = 0.56 (0.56-0.65; the progressive sperm motility: T0 = 28.00%
(12.00 ± 38.00), T3 = 30.00%(12.00 ± 39.00) and T6 = 31.00%(20.00 ±
41.00). All showed signiﬁcance of p < 0.001 by Friedman test. The increase of
spermatozoa vitality has the best predictive and diagnostic characteristics. Men
who have increased this parameter by 1% have 1,119 times more likely to have
a progressive motility of spermatozoa greater than 20% after 6 months of ther-
apy. If the spermatozoa vitality after six months of therapy increases by 5.9%
and more (cut off value), the probability that sperm motility will be greater than
10% or 20% is 100% (PPV = 100%). If DFI drops by more than 3% (cut-off),
after 6 months of therapy, it can be expected, with moderate accuracy, that
men have sperm motility greater than 10% (AUC = 0.793; p < 0.001). DFI
reduction (odds ratios = 1.106 with 95% conﬁdence intervals) independently
increases the likelihood that sperm motility is > 10%. Placebo group: no signiﬁ-
cant difference in sperm motility, vitality and DFI, between T0 and T6.
Limitations, reasons for caution:No technical limitations.
Wider implications of the ﬁndings: This analysis showed that the increase
of the vitality of spermatozoa has the best predictive and diagnostic characteris-
tics of progressive sperm motility after 6 months therapy. Further, the percent-
age of change in DFI after therapy can be used with moderate accuracy in the
detection of men with better sperm motility.
Trial registration number: TXT-001-B
P-021 Does replacement of the sperm donor increase the chance
of achieving a pregnancy?
R. Hauser, Y. Cohen, H. Yavetz, S. Kleiman, O. Lehavi, S. Barda
Lis Maternity Hospital, The Institute for the Study of Fertility, Tel Aviv, Israel
Study question: to assess whether replacing a sperm donor affects the
chances of achieving pregnancy via intrauterine insemination treatments.
Summary answer: A sperm donor replacement may increase the chances to
conceive in women who failed to achieve a pregnancy within a few AID
treatments.
What is known already: The primary recipients of donor sperm are single
women, lesbian couples and heterosexual couples suffering from male infertility.
Artiﬁcial insemination by sperm donor (AID) is a widely used treatment to
achieve pregnancy in those cases. There is a common belief among some of the
recipients that replacement of the donor will improve their chances to conceive
in cases of repeated failures.
Study design, size, duration: Study population included 312 women who
conceived using artiﬁcial insemination by sperm donor.
Participants/materials, setting, methods: Group A consisted of 242
women were treated with one donor only and group B of 70 women were treated
with one donor for a few cycles and with a different donor for additional cycles.
Statistical analysis was conducted using a multivariate model, with consideration of
various factors such as age, hormonal treatment, number of inseminations, etc.
Main results and the role of chance: The age of the participants in groups
A and B was similar with mean±SD of 37.02 ± 3.58 and 37.26 ± 3.38, respect-
ively. Baseline FSH levels on day 3 of the cycle was similar in groups A and B.
There was a signiﬁcant difference between the number of AID cycles till preg-
nancy achievement with a single donor (group A) and changed donor (group B,
p < 0.001) with mean number of 3.78 ± 1.90 and 6.07 ± 2.95, respectively.
Further subdivision of groups A and B according to the type of fertility treat-
ment showed signiﬁcant difference between the number of AID cycles of the
ﬁrst and the second donors of group B (p < 0.001).
Limitations, reasons for caution: A retrospective study of women who
achieved pregnancies.
Wider implications of the ﬁndings: Our results suggest that among
women who failed to achieve a pregnancy within a few AID treatments, a
sperm donor replacement may increase their chances to conceive regardless of
ovulation protocol. Further study is needed to provide explanation for this
phenomenon.
Trial registration number: 0726-15-TLV.
P-022 Impact of cigarette smoking on spermDNAmethylation
patterns and gene expression
Y. Alkhaled, M. Laqqan, M.A.D. Jahmani, A. Abu Dayyih,
M. Abd Al-razaq, M.E. Hammadeh
University of Saarland, Gynecology and Obstetrics, Homburg, Germany
Study question: Are there any implicating consequences of cigarette smoking
on sperm DNA methylation level and gene expression?
Summary answer: Cigarette smoking leads to an alteration in the sperm
DNA methylation patterns of PTPRN2 and TYRO3 genes. Besides, an inﬂuence
on gene expression level.
What is known already: Various factors affect the sperm DNA methylation
patterns including, but not limited, to other environmental, social, racial and
biological factors. The effect of cigarette smoking on DNA methylation and
consequently gene expression is still considered a contradictory issue.
Study design, size, duration: This study is a prospective cohort study. A
total of 108 human semen samples were collected during the period of
September 2016 to July 2017. Fifty-nine samples were obtained from fertile
heavy smokers, who smoked ≥ 20 cigarettes per day (as a case), and forty-nine
from fertile non-smokers males (as control).
Participants/materials, setting, methods: All participants came from the
same region without demographic differences such as race. They were all in
reproductive age and normal body mass index. Thirty samples (15 Cases and
15 controls) were subjected to Inﬁnium 450 K BeadChip arrays to identify varia-
tions in sperm DNA methylation between case and control groups.
Furthermore, the local deep bisulﬁte sequencing was applied to 108 samples to
validate CpGs, followed by qPCR to assess the gene expression levels.
Main results and the role of chance: The results of 450 K BeadChip arrays
revealed a signiﬁcant difference in 7 CpGs of the DNA methylation level
between case and control groups. Five of them were overlapped with the anno-
tated SNPs. Therefore, they were excluded from this study. The remaining
CpGs(cg23841288, and cg19169023) were directly linked to the PTPRN2, and
TYRO3 genes and underwent further validation using deep bisulﬁte sequencing.
According to the results of validation, signiﬁcant differences in the methylation
patterns at more than one CpGs and related to PTPRN2 and TYRO3 genes
amplicon in cases compared to control groups were shown. Whereas, nine of
twelve CpG sites in the PTPRN2 gene-related amplicon (p ≤ 0.006, p ≤ 0.004, p
≤ 0.01, p ≤ 0.01, p ≤ 0.01, p ≤ 0.01, p ≤ 0.03, p ≤ 0.006 and p ≤ 0.01
respectively) and three CpGs of four tested CpGs in the TYRO3 gene (p ≤
0.008, p ≤ 0.005, p and p ≤ 0.02 respectively) were found. Furthermore, the
present study demonstrates signiﬁcant differences in the gene expression levels
of the PTPRN2 and TYRO3 genes in the cases compared to controls (P ≤ 0. 01,
and P ≤ 0.04 respectively), with fold change ( 0.6 and 1.2 respectively).
Limitations, reasons for caution: The sample size was a constraint towards
getting a strong outcome. Therefore, more samples are required to demon-
strate the impact of this variation on sperm DNA methylation patterns and the
effect of genes expression on human male fertility.
Wider implications of the ﬁndings: The study results were a concurrent
conﬁrmation towards the drawbacks of cigarette smoking. It should be noted
that signiﬁcant correlations between the variation in the sperm DNA methyla-
tion patterns and semen parameters were found. This was furtherly elucidated
through the positive results of gene expression of the related genes.
Trial registration number:NO.
P-023 Assessment of sperm apoptosis by ﬂow cytometry
technique using 7-Amino-Actinomycin D staining
M. Ben Amor1, A. Sellami1, S. Ben Zarrouk1, S. Daoud1,
F. Hammami1, H. Mnif2, N. Chakroun1, T. Rebai1
1Medical School of Sfax- Histology-Embryology Laboratory and Research Unit- Sfax-
Tunisia
2Regional Center of Blood Transfusion Sfax Tunisia, Sfax, Tunisia
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Study question: Does the analysis of sperm vitality and apoptosis by the ﬂow
cytometry technique offer an interesting sperm biomarker to predict male fertil-
ity potential?
Summary answer: Flow cytometry allows identifying the apoptotic sperm-
atozoa not individualized by classic microscopic evaluation.
What is known already: Conventional sperm analysis is a subjective method
and shows an average prediction of male infertility. New processes can indicate
a more accurate prediction for the state and function of the sperm. Therefore,
ﬂow cytometry has become an important technique in sperm evaluation and is
increasingly used both for routine assessment and for research in human
reproduction.
Study design, size, duration: This basic research study was performed on
semen samples collected from 52 patients attending our center for couple infer-
tility investigation.
Participants/materials, setting, methods: Semen analysis was carried out
according to WHO 2010 guidelines. Sperm vitality was evaluated respectively
by the stain exclusion method (Eosin-Nigrosin) and the ﬂow cytometry tech-
nique using 7AAD (7-Amino-Actinomycin D) a DNA speciﬁc marker witch
label dead spermatozoa. Sperm mitochondrial membrane potential was also
analyzed by the ﬂow cytometry technique using JC1 staining.
Main results and the role of chance: Sperm vitality values assessed by
Eosin-Nigrosin method were signiﬁcantly higher than those noted by cytometry
analysis (74.5% vs 62.3%, p < 0.001). The apoptotic sperm levels were signiﬁ-
cantly correlated with sperm motility (r=-0.283, p = 0.04), sperm mitochon-
drial membrane potential (r = -0.395, p = 0.005) and leukocyte concentrations
(r=+0.434, p = 0.01).
Limitations, reasons for caution: The present study was performed in rela-
tively small number of samples. Further studies with larger sample size are
needed.
Wider implications of the ﬁndings: Active oxygen species produced by
leukocytes cause signiﬁcant damage to sperm membranes with severe altera-
tions of mitochondrial functions inducing sperm apoptosis. Sperm mitochondrial
membrane potential combined with sperm apoptosis level could be interesting
parameters for predicting natural conception and might be used prior to IVF/
ART program.
Trial registration number:No trial registration number.
P-024 The impact of seminal hyperviscosity on sperm parameters
and male fertility
F. Hammami, S. Daoud, M. Ben Abdallah, N. Chakroun, T. Rebai,
A. Sellami
Medical School of Sfax- Histology-Embryology Laboratory and Research Unit, Sfax,
Tunisia
Study question: Is there an effect of increased seminal viscosity on sperm
parameters and does it contribute in male reproduction disorders?
Summary answer: Semen hyperviscosity signiﬁcantly affects sperm para-
meters mainly motility and negatively decreases male fertility rates.
What is known already: Semen hyperviscosity (SHV) is a condition that can
impair the physical and chemical characteristics of seminal ﬂuid, which leads to
an adverse impact on sperm functions. SHV also leads to certain technical difﬁ-
culties in the handling of samples, such as when using different methods of
semen preparation for in vitro fertilization (IVF) programs. Some procedures
used to treat SHV may damage sperm structure and should be revised.
Study design, size, duration: This retrospective study was performed on
semen samples collected over period of 8 years from 2585 patients attending
our center for couple’s infertility.
Participants/materials, setting, methods: Semen analysis was caried out
according to WHO guidelines. Sperm viscosity was estimated by gently aspirat-
ing it into a wide bore pipette, allowing semen to drop by gravity and observing
the lenght of any thread, getting 3 groups: G1 (normal viscosity; n = 2139):
sperm leaves the pipette in seperate drops; G2 (moderate hyperviscosity; n =
56): sperm drop from a thread more than 2 cm long; G3 (severe hyperviscosity;
n = 390): sperm ﬂows very difﬁcult or stays blocked.
Main results and the role of chance: The observed prevalence of SHV was
17.2% (446/ 2585). The mean values of sperm parameters including: volume,
numeration, motility, vitality and normal morphology in G1 group were signiﬁ-
cantly higher than those in G2 and G3 (p = 0.02, p = 0.01, p < 0.001, p <
0.001, p < 0.001; respectively). Asthenospermia associated to SHV would be
related to liquefaction process disturbance secondary to semen kallikreins vari-
ability and the abscence of semenogelins matrix hydrolysis. Hypofunction of the
prostate or seminal vesicles result in the developmet of SHV.
Limitations, reasons for caution: A potential limitation for this study is its
retrospective design. Moreover, semen hyperviscosity does not seem to be
induced by a single pathogenic factor, but rather by several (biochemical,
enzymatic, and genetic) factors that act in synergy. These factors should be
studied further.
Wider implications of the ﬁndings: Biochemical changes on SHV could
impair male fertility linked to a reduce of seminal antioxydant capacity, sperm
membrane lipid peroxidation and sperm nuclear DNA damage. Otherwise, the
mechanism in which the depletion of antioxidants in the seminal plasma of
patients occurs has not been fully elucidated.
Trial registration number: not applicable.
P-025 Genomewide DNAmethylation analysis of ROS-mediated
sperm chromatin integrity damage suffering from idiopathic male
infertility
B. Song, X. He, H.Wu, Z.Wei, Y. Cao
The First Afﬁliated Hospital of Anhui Medical University, Reproductive Medicine
Center, Hefei- Anhui, China
Study question: The objective of this study was to assess genome-wide
sperm DNA methylation alteration between idiopathic male infertility with
ROS-mediated DNA damage and normal fertile males.
Summary answer: The results show that there are signiﬁcant differences in
sperm DNA methylation levels between sperm chromatin integrity damage
patients and fertile males.
What is known already: It is now clear that ROS-mediated sperm
chromatin integrity damage is critical in male infertility. What is not clear is
whether ROS could induce epigenetic alterations that further contribute to
male infertility.
Study design, size, duration: A genome-wide DNA methylation study was
performed using sperm samples of men who were idiopathic infertility with
sever sperm chromatin integrity damage. Human semen samples were col-
lected during the period between July 2017 to September 2017.
Participants/materials, setting, methods: Firstly, Inﬁnium 850 K
Methylation BeadChip arrays were used to determine whether sperm DNA
methylation alterations between 4 infertility males with high sperm DNA dam-
age compared to 4 proven fertile males. Then the top ﬁve sites with highest dif-
ference in methylation levels were underwent to further analysis using deep
bisulﬁte sequencing in a large samples (100 controls and 100 cases).
Main results and the role of chance: We observed signiﬁcantly different
DNA methylation proﬁles for the sperm chromatin integrity damage patients
and fertile controls. The DNA methylation patterns showed that in the cases,
225 of the 445 CpG sites were hypermethylated and 220 hypomethylatedwere
(relative to the fertile controls). Furthermore, we identiﬁed genes that may pro-
vide insight into the mechanism of ROS-mediated idiopathic male infertility. The
top 5 CpGs were found to be directly linked to the genes ZFAT, SOX6,
SCARNA17, RP11-5P22.1 and MIR300. Currently, these results are under val-
idation through local deep bisulﬁte sequencing and are planned to be tested on
a larger sample cohort. Gene Ontology analysis indicated the genes are asso-
ciated with some molecular function and biological process, such as phosphat-
ase binding, DNA binding, nucleic acid binding transcription factor activity, cell
differentiation regulation of metabolic process and RNA polymerase II tran-
scription factor activity. KEGG pathway analysis suggested that the DMRs were
distributed among pathways of ErbB signaling, Gap junction, GnRH signaling and
pathways in cancer, which will lay the theoretical foundation to further excavat-
ing the functional genes of ROS-related DNA damage.
Limitations, reasons for caution: The DNA methylation patterns in sperm
chromatin integrity damage patients should be conﬁrmed with an mRNA
expression analysis and correlated with immunohistochemical data on protein
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expression and localization. More studies are needed to elucidate the mechan-
isms relating to these alterations and to identify their signiﬁcance and conse-
quences on male infertility.
Wider implications of the ﬁndings: The comprehension of mechanisms
leading to epigenetic modiﬁcations associated with ROS may help better
understand the male infertility, as well as aid in the development of potential
biomarkers for better male infertility diagnostics and novel therapeutic
strategies.
Trial registration number:No.
P-026 Evaluating the predictability of oxidation–reduction
potential in male factor infertility in conjunction with semen
analysis: A multicenter study
A. Agarwal1, H. Elbardisi2, M. Arafa2, H. Okada3, K. Suzuki3,
S. Homa4, A. Kileen5, B. Balaban6, A. Ayaz7, R. Saleh8, A. Armagan9,
C. Dorsey10, S. Roychoudhury11, S. Sikka7
1American Center for Reproductive Medicine- Cleveland Clinic, Urology, Cleveland,
U.S.A.
2Hamad Medical Corporation, Urology, Doha, Qatar
3Dokkyo Medical University, Urology, Koshigaya, Japan
4University of Kent, Andrology, London, United Kingdom
5The Doctors Laboratory, Andrology, London, United Kingdom
6American Hospital of Istanbul, Assisted Reproductive Medicine Unit, Istanbul,
Turkey
7Tulane University, Urology, New Orleans, U.S.A.
8Sohag University, Urology, Sohag, Egypt
9Bezmialem Vakif University, Urology, Istanbul, Turkey
10Aytu Bioscience, Medical Diagnostics, Englewood, U.S.A.
11Assam University, Life Science and Bioinformatics, Silchar, India
Study question: Identify if ORP measure could reliably predict semen samples
that meet normal reference range of WHO criteria from those that fail to meet
across fertility centers.
Summary answer: Of the 1644 samples analyzed, the ORP measure pro-
vided the greatest predictability when distinguishing abnormal from normal
semen quality among patients undergoing infertility evaluation.
What is known already: Discrete measures of free radicals, antioxidant
activity, and oxidative damage suggest an ambiguous relationship between
the redox system and male fertility. Oxidation-reduction potential (ORP)
measures the balance between all oxidants and antioxidants providing a
comprehensive status of the redox system. In previous studies, ORP has
been tested in semen samples using the MiOXSYS System as an alternative
method for measuring oxidative stress and distinguishing normal controls
from male factor infertility patients; thus ORP levels may be used to clarify
the relationship between the redox system and semen parameters asso-
ciated with male infertility.
Study design, size, duration: This prospective study was carried out jointly
by nine participating fertility centers on 1644 subjects. The study was approved
by the institutional ethics committee and subjects were consented prior to par-
ticipation. Subjects were grouped into those that had all normal semen para-
meters (concentration, total concentration, total motility, progressive motility,
and morphology) according to WHO 2010 guidelines and those who failed to
meet one or more criteria.
Participants/materials, setting, methods: Exclusion criteria included
azoospermia, presence of sexually transmitted disease or chronic diseases, use
of prescription, OTC medications or antioxidants. Samples were collected and
semen parameters assessed using the WHO 2010 guidelines. ORP was mea-
sured (mV) using the MiOXSYS system and normalized to concentration (mV/
106 sperm/mL). For group comparisons, only those samples with a concentra-
tion >0.999 × 106 sperm/mL were included.
Main results and the role of chance: In the current study, using an ORP
test in conjunction with the semen analysis measures resulted in the detection
of abnormal semen quality with a 98.1% sensitivity, 40.6% speciﬁcity, 94.7%
positive predictive value, and 66.6% negative predictive value. ORP provides a
unique and statistically signiﬁcant contribution in classifying semen quality into
abnormal and normal status. A logistic regression performed on all measures
(six semen analysis parameters and ORP measure) revealed the predictability of
identifying abnormal / normal semen quality within the samples (Table 1).
Measures were categorized according to overall contribution and signiﬁcance.
ORP ranked the highest (beta 2.88, p = 0.01) in terms of predicting abnormal /
normal semen quality, followed by progressive motility (beta 2.29, p = 0.001),
and total motility (beta .494, p = 0.005). Utilizing ORP and semen analysis com-
bined, the overall performance characteristics (Table 2) were 98.1 sensitivity,
40.6 speciﬁcity, 93.3% positive predictive value, and 66.7% negative predictive
value.
Table I
BETA S.E. DF Sig.
(ORP) 2.880 1.152 1 0.012**
(SpermTotal) −0.150 0.202 1 0.458
(PRMot) −2.297 0.211 1 0.001***
(TotalMot) 0.494 0.177 1 0.005***
(NormlMorph) −0.115 0.097 1 0.233
(SpermConc) −0.356 0.186 1 0.055
(Volume) 0.149 0.162 1 0.358
Limitations, reasons for caution: A number of healthy controls with pro-
ven fertility was limited in comparison to the male infertility group. While semen
parameters are an important part of the assessment of the infertile male, the
gold standard is the reproductive outcome. Pregnancy outcomes were not pro-
spectively measured in the infertile group.
Wider implications of the ﬁndings: Abnormal ORP levels will be especially
useful in pinpointing the altered functional status of the sperm in patients with
idiopathic male infertility and thereby directing those men toward accurate
therapeutic management.
Trial registration number: (not applicable) WIRB PRO NUM: 20170761
P-027 Ultrasonographic (US) analysis of seminiferous tubules in
patients with complete deletion of the AZFc region
G. Sukegawa1, T. Sho2, K. Nakano1, S. Nariyoshi2, Y. Tsuji1,2
1Ebisu Tsuji Clinic, Andrology, Tokyo, Japan
2Tenjin Tsuji Clinic, Andrology, Fukuoka, Japan
Study question: Can US ﬁndings regarding seminiferous tubules predict
sperm production in patients with complete deletion of the AZFc region?
Summary answer: Thick seminiferous tubules on US images imply sperm
production in patients with complete deletion of the AZFc region.
What is known already: Microdeletion of the AZF region located on the
long arm of chromosome Y is the most frequent genetic cause of spermato-
genic failure. Complete deletion of the AZFc region causes a variable clinical
phenotype ranging from azoospermia to severe oligozoospermia.
We have previously demonstrated that seminiferous tubules over 200 μm in
diameter can be visualized by US, and thick seminiferous tubules (over 300 μm
in diameter) suggest a high rate of successful sperm retrieval in patients with
non-obstructive azoospermia.
Seminiferous tubules in patients with complete deletion of the AZFc region
have not yet been analyzed by US.
Study design, size, duration: This retrospective study included 802 con-
secutive patients with non-obstructive azoospermia or severe oligozoospermia
who underwent an evaluation for Y chromosome microdeletions at our androl-
ogy clinic from June 2014 to October 2017.
Participants/materials, setting, methods: All of the study patients under-
went a physical examination, endocrine assessment, karyotyping, Y chromosome
microdeletion analysis and US evaluation of the testis, which involved measure-
ment of the testicular volume and the diameter of seminiferous tubules.
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US was performed using a 10- or 14-MHz linear array transducer. To opti-
mize US images for visualization of the seminiferous tubules, gain and contrast
were appropriately adjusted with graphics software.
Main results and the role of chance: Complete deletion of the AZFc
region was identiﬁed in 49 patients. After we excluded 2 patients with chromo-
somal abnormalities and 1 patient with orchitis, 46 patients were included in
this study. Of these patients, 31 had sperm in the ejaculate, whereas 15 were
azoospermic. Microdissection TESE (micro-TESE) was performed in 6 of the 15
patients with azoospermia, and testicular sperm were retrieved in 2 of these 6
patients.
Thick seminal tubules, deﬁned as more than 300 μm in diameter on US
images, were visualized in all patients with sperm in the ejaculate and in both
patients with testicular sperm. In contrast, thick seminal tubules were not
observed in any of the 4 patients in whom sperm was not retrieved by micro-
TESE.
Almost 90% (33/37) of patients with complete deletion of the AZFc region
had sperm in the ejaculate or testis. Thick seminiferous tubules on US images in
patients with complete deletion of the AZFc region indicate sperm production.
Furthermore, a lack of thick seminiferous tubules on US images may suggest a
poor outcome of micro-TESE in patients with complete deletion of the AZFc
region.
Limitations, reasons for caution: Only 6 of 15 azoospermic patients with
complete deletion of the AZFc region underwent micro-TESE, and thick semin-
iferous tubules were not observed in US in any of the 9 patients who did not
choose micro-TESE. More data will be needed before we can draw deﬁnitive
conclusions concerning this small category.
Wider implications of the ﬁndings: US analysis of seminiferous tubules
may be helpful for estimating the potential for sperm production in patients
with various types of genetic disorders.
Trial registration number:Not applicable.
P-028 Adverse effects of Reactive Oxygen Species in semen to the
development of ICSI cleavage embryo
S. Kuroda1, K. Takeshima2, K. Usui1, K. Mori1, T. Asai1, K. Yasuda1,
H. Sanjo1, H. Yamanaka1, T. Takeshima1, T. Kawahara3, Y. Miyoshi3,
Y. Arai2, W. Izumi2, M. Murase2, Y. Yumura1
1Yokohama City University Medical Center, Department of Urology- Reproduction
center, Yokohama, Japan
2Yokohama City University Medical Center, Department of Gynecology-
Reproduction center, Yokohama, Japan
3Yokohama City University Medical Center, Department of Urology and Renal
Transplantation, Yokohama, Japan
Study question:Does Reactive Oxygen Species (ROS) in semen have adverse
effects to the embryo development in ICSI?
Summary answer: The ROS level in semen was signiﬁcantly higher in non-
successfully developed cleavage embryo group compared to successful devel-
oped cleavage embryo group.
What is known already: Reactive Oxygen Species(ROS) in semen is created
from immature spermatozoa and seminal leukocytes. High ROS level results in
lipid peroxidation, DNA damage and induction of apoptosis, which has been
reported to have negative efffect to sperm concentration, motility and male fer-
tile capacity.
Study design, size, duration: This is a retrospective study between March
2013 and December 2016. 887 embryos from 141 cycles were analyzed, which
were divided into to successfully developed group and non-successfully devel-
oped group and the level of ROS was compered between two groups.
Participants/materials, setting, methods: 77 infertile couples who per-
fomed ICSI at our center were enrolled. 887 embryos from 141 cycles were
analyzed.The ROS level were measured by monolight 3010® using whole
semen, which were compared 1) between fertilized group and non fertilized
group, 2) between good cleavage embryo group and non-developed embryo
group. 3) The cut-off ROS level was calculated for the prediction of good cleav-
age embryo development.
Main results and the role of chance: 1) The mean ROS level were 50842
(±178426) relative light unit(RLU) and 50118 (±157274) RLU, respectively.
No signiﬁcant difference was observed between the two groups(p = 0.952). 2)
The ROS level was signiﬁcantly higher in non-developed embryo group com-
pared to good cleavage embryo group(81450 ± 128610 RLU vs 35645 ±
128610 RLU, p = 0.026). 3)The cut off value was 6601 RLU calculated from
receiver operating characteristic curve (Area under the curve = 0.539), and the
embryos were diveded into high ROS group and low ROS group using this cut-
off value. Good cleavage embryo rate was signiﬁcantly lower in high ROS group
compared to low ROS group(51.5% vs 63.8%, p = 0.004).
Limitations, reasons for caution: This is a retrospective and a single-
institute study, prospective and multi center analysis is needed for further inves-
tigation. Anti-oxidant capacity in semen against the ROS were not evaluated in
this study.
Wider implications of the ﬁndings: ROS in semen have adverse effect
under the environment of embryo development in ICSI, especially for the good
cleavage embryo development than for the fertilization. It may help unveiling
the mechanism of cleavage embryo development.
Trial registration number: not applicable.
P-029 Pregnancy rate and infertility in patients with varicocele
and/or oligoasthenoteratozoospermia: evaluation of antioxidant
supplementation effect on sperm parameters
G.M. Busetto1, A. Agarwal2, A. Virmani3, F. Del Giudice1, S. Micic4,
V. Gentile1, E. De Berardinis1
1Sapienza University Policlinico Umberto I, Urology, Roma, Italy
2American Center for Reproductive Medicine, Andrology Center, Cleveland, U.S.A.
3Sigma-tau HealthScience, Nutraceuticals, Utrecht, The Netherlands
4Uromedica Polyclinic, Andrology, Belgrade, Serbia
Study question: Are functional substances able to treat male infertility and
which is the role of varicocele and oligoasthenoteratozoospermia?
Summary answer: The use of functional substances is an efﬁcacious strategy
to handle male infertility. All sperm parameters and pregnancy rate signiﬁcantly
increased in treated subjects.
What is known already: Varicocele has adverse effects on spermatogenesis
and to date is considered as the ﬁrst cause of male infertility. Many factors nega-
tively affecting semen quality act through decreasing energy availability by mito-
chondrial dysfunction and sperm are also vulnerable to reactive oxygen species
because their accumulation leads to membrane damage, instability and func-
tional alterations. However, for normal sperm cell function, a delicate redox
balance of reduction and oxidation is required. Thus, a therapeutic strategy
would need to use supplements to increase sperm energy metabolism, minim-
ize free radical damage and improve the cellular processes connected with the
formation and maturation of sperm.
Study design, size, duration: To evaluate, utilizing a randomized double-
blind placebo controlled trial, the effect of supplementation with selected natur-
ally compounds on pregnancy rate and sperm quality. The effect was evaluated
in subjects with oligo or asthenoteratozoospermia, as well as with or without
varicocele.
Participants/materials, setting, methods: With a block randomization
104 patients were enrolled: 52 had grade I-III varicocele and 52 were not
affected. Patients were further divided in two groups consisting of the supple-
mentation arm and the placebo arm. The supplementation formulation con-
sisted of L-carnitine, fumarate, acetyl-L-carnitine, fructose, citric acid, selenium,
coenzyme Q10, vitamin C, zinc, folic acid and vitamin B12. Spermogram evalu-
ation was done at the beginning of treatment and after 6 months, at the end.
Main results and the role of chance: Adverse events occurred only in the
treatment group: 4 patients had nausea and 3 vertigo or headache. Twelve preg-
nancies occurred during follow-up time: 10 in supplementation group (9 non-
varicocele and 1 varicocele) and 2 in placebo group (1 non-varicocele and 1 vari-
cocele). One spontaneous abortion was reported in placebo arm. Mean changes
of number of sperm (106 × mL) after treatment were 1.7 in the placebo group
and 9.8 in the supplemented group (p = 0.0186). Mean changes of sperm con-
centration (106 × mL) after treatment were 13.0 in the placebo group and 46.9
in the supplemented group (p = 0.0117). Mean changes of progressive motility
of sperm (%) were 1.7 in the placebo group and 5.9 in the supplement group (p
= 0.0088). Mean changes of total motility of sperm (%) were 1.6 in the placebo
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group and 7.3 in the supplement group (p = 0.0120). Analyzing typical and atyp-
ical morphology there was, respectively, a difference of -6.1 and 5.9 in the pla-
cebo group while -6.7 and 3.6 in the supplement group.
Limitations, reasons for caution: We did not compare the effect of this
treatment with surgical treatment of varicocele and we did not evaluate DNA
fragmentation and level of ROS. Furthermore, latest evidences report that
evaluating OS can be a diagnostic tool in predicting the best responders to
supplementation.
Wider implications of the ﬁndings: Oxidative stress is a cause of male
infertility with signiﬁcant negative effect on semen parameters and varicocele is
an additional cause of poor sperm quality. The use of functional substances is
an efﬁcacious strategy to handle male infertility. All sperm parameters and preg-
nancy rate increased in treated subjects.
Trial registration number: PXP-001A
P-030 Novel measures of spermDNA damage increase its
usefulness to diagnose male infertility and predict live births
following both IVF and ICSI
A.J. Vicens-Morton1, T. Yap1, J. Nicopoullos2, S.E.M. Lewis3, K. Lee4,
P. Larsen5, J. Ramsay6, S. Minhas7
1Guy’s and St Thomas NHS foundation trust, Urology-Andrology, London, United
Kingdom
2Lister Fertility Clinic, Reproductive Medicine & Surgery, London, United Kingdom
3Queen’s University Belfast, Andrology, Belfast, United Kingdom
4SpermComet Ltd, Spermcomet, Belfast, United Kingdom
5Cryos International Sperm Bank, Sperm bank, Copenhagen, Denmark
6Charing Cross Hospital / Chelsea & Westminster Hospital / Hammersmith
Hospital, Urology-Andrology, London, United Kingdom
7University College London Hospital, Urology/Andrology, London, United Kingdom
Study question: Predictive power of novel Comet parameters that quantify
damage levels in the semen sample and utility in prediction of ART live birth
rates.
Summary answer: The proportion of sperm with low or high levels of DNA
damage provides discriminatory information for male infertility diagnosis and
treatment outcomes.
What is known already: The Comet assay measures the DNA damage in
individual sperm enabling the degree of heterogeneity of the whole sperm
population to be assessed.
Study design, size, duration: Retrospective study of 381 men of couples
attending a Lister Fertility Clinic for IVF or ICSI treatment were recruited during
2015-2017
Participants/materials, setting, methods: 381 couples attending for IVF
or ICSI. Sperm DNA damage quantiﬁed using the average Comet Score (ACS)
and two novel parameters: the low and the high Comet Score. Sperm from 166
men with idiopathic infertility were compared with those from 76 sperm
donors, using ROC analysis. 79 IVF and 229 ICSI cycles were included to deter-
mine thresholds for each parameter using ROC analysis. Thresholds were used
to compare live birth rates (LBRs) following ART.
Main results and the role of chance: 80% of sperm from fertile men had
less than 33% DNA damage. ACS, HCS and LCS were all highly predictive of
male infertility (ROC > 0.9, p < 0.0001). IVF LBRs declined sharply once sperm
DNA damage exceeded all threshold levels with HCS showing the sharpest
decline. ICSI LBRs were also impacted by sperm DNA damage with highest
LBRs in men whose sperm DNA approached the fertile range. Trends in IVF
and ICSI differed in that IVF LBRs decreased as damage increased whereas in
ICSI, LBRs decreased but then remained stable.
Limitations, reasons for caution: A prospective study choosing IVF or ICSI
based on these thresholds should be performed to conﬁrm this data.
Wider implications of the ﬁndings: The proportion of sperm with low or
high levels of DNA damage provides discriminatory information for male infer-
tility diagnosis and chance of success by IVF compared to ICSI. Implementing
these new test thresholds will enable better selection of ART treatment
pathways.
Trial registration number:None.
P-031 High concentrations of interleukin-18 induce Leydig cell
apoptosis and steroidogenesis disorder
T. Inoue1,2, M. Aoyama-Ishikawa1, M. Uemura3, H. Yamashita4,
Y. Koga4, M. Usami5, J. Kotani6
1Hyogo College of Medicine, Department of Emergency- Disaster and Critical Care
Medicine, Nishinomiya- Hyogo, Japan
2Umeda Fertility Clinic, Department of Gynecology, Osaka, Japan
3Kobe Gakuin University, Faculty of Rehabilitation, Kobe, Japan
4Kobe University Graduate School of Health Sciences, Department of Biophysics,
Kobe, Japan
5Konan Women’s University, Department of Clinical Dietics and Nutrition, Kobe,
Japan
6Kobe University Hospital, Department of Emergency and Critical Care Medicine,
Kobe, Japan
Study question: Do high concentrations of interleukin (IL)-18 inﬂuence a
drop in steroidogenesis by increasing apoptosis of Leydig cells?
Summary answer: High IL-18 concentrations increased apoptosis-related
proteins (cleaved caspase [CC]-8 and -3) and death receptor pathway-related
mRNAs levels but reduced streroidogenic acute regulatory (StAR) protein
levels.
What is known already: IL-18, which is produced by germ cells, Leydig cells
and resident macrophages, is an indispensable cytokine in the maintenance of
testis homeostasis. IL-18 is known to be an inﬂammasome-mediated cytokine,
and IL-18 levels are increased by inﬂammatory stimulation such as lipopolysac-
charide (LPS) in mouse testis. We showed that endogenous IL-18 induced tes-
ticular germ cell apoptosis during endotoxin-mediated inﬂammation when the
plasma IL-18 levels were very high (Inoue T. et al. Reproduction. 2015;150:105-
114).
Study design, size, duration: LPS stimulation: Mouse Leydig cell line TM3
cells and mouse macrophage cell line RAW264.7 cells were stimulated with
200 or 1,000 ng/mL LPS and were sampled at 0, 1, 6, 12, 24 and 48 hours.
Recombinant IL-18 (rIL-18) stimulation: TM3 cells were stimulated with 0.1, 1,
10 and 100 ng/mL rIL-18 and were sampled at 12 h. Vehicle: TM3 or
RAW264.7 cells were incubated in the medium only.
Participants/materials, setting, methods: Cells were cultured on 6-well
microplate (4 × 105 cells) with DMEM-F12 medium for 48 h at 37°C, 5%
CO2. CC-3, CC-8, IL-18 and StAR protein levels were measured by west-
ern blotting. The expression levels of Tnf-α, Il-6, Il-18, Fas, Fas ligand (FasL),
Tnfr1 and Fadd mRNAs were analysed using reverse transcriptional real-
time PCR. Statistical analysis was performed using Student’s t-test or
Welch’s t-test and Tukey-Kramer’s post-hoc test (statistically signiﬁcant: p
< 0.05).
Main results and the role of chance: LPS signiﬁcantly increased Tnf-α and Il-
6 expressions at 1 h (p < 0.01) and Fas and Tnfr1 expressions at 6 h (p < 0.01).
LPS also increased CC-8 and CC-3 expressions at 6 and 12 h, respectively, and
these levels were maintained until 48 h. However, FasL and Fadd mRNA
expressions did not differ signiﬁcantly between the LPS and control groups. LPS
stimulation did not increase IL-18 protein and mRNA expressions in TM3 cells.
The expression of StAR was reduced at 12 h and maintained until 48 h after LPS
stimulation. These results suggest that LPS-induced Leydig cell apoptosis may
lead to steroidogenesis reduction. We hypothesised that IL-18 level increased
in testes after inﬂammation was derived from immune cells. Il-18 expression in
RAW264.7 was signiﬁcantly increased at 6 h (p < 0.01) and maintained at a
high level until 48 h after LPS stimulation. High-concentrated (10 or 100 ng/mL)
rIL-18 increased CC-3, CC-8, Tnf-α, Fas and Fadd expressions. Contrariwise,
high-concentrated rIL-18 reduced the expression of StAR protein. There was
no signiﬁcant difference between control and rIL-18 stimulation on FasL and
Tnfr1 mRNA expressions. These results suggest the overproduction of IL-18
induced Leydig cell apoptosis and reduced steroidogenesis during acute
inﬂammation.
Limitations, reasons for caution: The limitation of this study is that Leydig
cell-macrophage interactions during inﬂammatory condition could not be evalu-
ated. Therefore, even though our results may not completely explain the rela-
tionship between Leydig cell apoptosis/steroidogenesis and immune cell-
derived overproduction of IL-18, they should help to elucidate the underlying
cell-cell interactions.
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Wider implications of the ﬁndings: Our results suggest that the overpro-
duction of IL-18 may induce Leydig cell apoptosis, which may lead to the reduc-
tion of steroidogenesis. Monitoring IL-18 levels and controlling the
overexpression of IL-18 could be a new therapeutic target to prevent
Leydig cell apoptosis and the dysfunction of steroidogenesis during acute
inﬂammation.
Trial registration number:Not applicable.
P-032 Magnetic-activated cell sorting as a complement to swim-up
improves efﬁciency of spermatozoa separation
M. Jeseta, E. Bozenkova, J. Zakova, P. Ventruba, I. Crha, E. Lousova
Faculty of Medicine- Masaryk University Brno and University Hospital Brno,
Gynecology and Obstetrics, Brno, Czech Republic
Study question: Is it beneﬁcial to use swim-up before or after magnetic-
activated cell sorting (MACS) for effective spermatozoa selection for IVF?
Summary answer:Our results showed that the combination of swim-up and
magnetic-activated cell sorting brings better results in sperm selection when the
ﬁrst step is the swim-up.
What is known already: Spermatozoa selection is one of the most import-
ant steps in IVF methods. Magnetic-Activated Cell Sorting (MACS) is a selection
method which reduces apoptotic spermatozoa in sample and improves IVF out-
come. Many reports indicate that MACS is a beneﬁcial technique compared to
classical sperm selection techniques. However, the possible positive effects of
this method in clinical application are still debatable. Although a positive effect
of swim-up and MACS on spermatozoa selection was presented, further studies
are needed to investigate the beneﬁts of using the combination of swim-up and
MACS on separation of spermatozoa.
Study design, size, duration: A prospective study was carried out to investi-
gate the effects of spermatozoa separation procedure on concentration, motil-
ity and DNA integrity after using swim-up and MACS methods and their
combinations. A total of 26 normozoospermic patients were included in this
study from January to December 2017. A sample from each volunteer was
divided into 5 subgroups according to separation procedure as follows: 1)
native 2) swim-up 3) MACS 4) MACS/swim-up 5) swim-up/MACS.
Participants/materials, setting, methods: Semen samples from the volun-
teers were separated by swim-up, MACS or combination of these methods
according to the manufacturer’s instructions (Miltenyi Biotec). The analysis of
sperm concentration and motility was performed both in raw and subgrouped
semen samples according to the WHO manual. Sperm DNA fragmentation
was assessed using sperm chromatin dispersion test (Halosperm G).
Proportion of spermatozoa with fragmented DNA was expressed as DNA
Fragmentation Index (DFI). P value <0.05 was considered statistically
signiﬁcant.
Main results and the role of chance: Compared to spermatozoa concen-
tration in the native sperm samples (average 81.4 mil/ml), this parameter sig-
niﬁcantly decreased in all the other groups. A statistically signiﬁcant decrease
was observed in swim-up (23.2 mil/ml), MACS (29.6 mil/ml) swim-up/MACS
(16.8 mil/ml) and also MACS/swim-up (23.4 mil/ml). Total sperm motility was
signiﬁcantly higher in all the groups where swim-up method was applied (92.7
%), swim-up/MACS (84.5 %) or MACS/swim-up (88.1 %) in comparison with
native ejaculate (52.7 %) and MACS method alone (37.8 %). In the case of
sperm chromatin integrity, no signiﬁcant differences were observed among
native (DFI 30.52 %), MACS (DFI 28.65 %) and MACS/swim-up (DFI 22.7 %).
However, swim-up/MACS signiﬁcantly reduced the proportion of spermatozoa
with fragmented DNA (DFI 13.8 %) as well as swim-up alone (DFI 18.2 %).
Indeed, the combination of swim-up/MACS signiﬁcantly decreased the propor-
tion of spermatozoa with fragmented DNA in comparison with native ejaculate
and also with MACS method alone. Based on our results we recommend to
use swim-up followed by MACS method. This approach brings better results in
sperm selection – lower proportion of spermatozoa with fragmented DNA and
also better gain in terms of total sperm count usable for next IVF or ICSI
methods.
Limitations, reasons for caution: The limitation is the number of semen
samples included and analysed in this study which slightly reduced the power of
the statistical analysis.
Wider implications of the ﬁndings: Combination of the swim-up method
followed by MACS is the most effective. MACS have its limitations regarding
sperm concentration and volume for loading. Indeed, loading of raw semen to
column may reduce the ﬁltering function of MACS, since dead/apoptotic sperm
cells bound to the MACS column compete with motile/non-apoptotic
spermatozoa.
Trial registration number: not applicable.
Supported by MH CZ – DRO (FNBr, 65269705) and fund from Faculty of
Medicine MU to junior researcher Michal Jeseta.
P-033 The impact of semen infections over sperm parameters in
primary infertile men - results of a real-life, cross-sectional study
F. Pederzoli1, E. Ventimiglia1, P. Capogrosso1, L. Boeri2,
W. Cazzaniga1, M. Alfano1, F. Chierigo1, E. Pozzi1, N. Frego1,
F. Dehò1, E. Montanari2, F. Gaboardi1, V. Mirone3, F. Montorsi1,
A. Salonia1
1IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology,
Milan, Italy
2IRCCS Fondazione Ca’ Granda - Ospedale Maggiore Policlinico, Dept. of Urology,
Milan, Italy
3School of Medicine and Surgery- University of Naples Federico II, Dept. of Urology,
Naples, Italy
Study question: To assess the prevalence of urogenital infections and their
impact on sperm and hormonal parameters in Caucasian-European men pre-
senting for primary couple infertility.
Summary answer: Semen infections are highly prevalent in infertile
Caucasian-European men. Non-obstructive azoospermia (NOA) is more fre-
quently found in patients with a positive semen culture.
What is known already: Among the possibly reversible factors associated
with male infertility and abnormal semen parameters, acute and chronic infec-
tions of the male urogenital tract are of great relevance as they account for 15-
20% of all cases. Overall, cellular reactions against the pathogenic agents and
activation of immunity cells present in the seminal ﬂuid can lead to defects of
spermatozoa function, obstruction of the seminal tract and even deterioration
of spermatogenesis. However, the debate about the cause-effect relationship
between genitourinary infections and male infertility is far from over and the
available guidelines do not give clear indications yet.
Study design, size, duration: Real life, cross-sectional study based on a
cohort of 2464 consecutive white-European men assessed at a single academic
centre for couple’s infertility (non-interracial infertile couples only) between
September 2006 and September 2016.
Participants/materials, setting, methods: Demographic, clinical and
laboratory data of the entire cohort were analyzed. Health-signiﬁcant
comorbidities were scored with Charlson Comorbidity Index (CCI; categorized
0 vs. ≥1). Semen analysis was based on WHO 2010. Only patients assessed
with semen culture tests were included in the analysis. Hypogonadism was
deﬁned as a total testosterone level <3.0 ng/ml. Descriptive statistics and logis-
tic regression models tested the association between sperm infection and clin-
ical, seminal, and hormonal characteristics in the entire cohort.
Main results and the role of chance:Overall, 1662 patients (67.5%) under-
went sperm cultures. Of them, semen cultures were positive in 271 patients
(16.3%). Most commonly identiﬁed bacteria were Ureaplasma spp. and
Enterobacteriaceae spp. (32.9% and 14.8%, respectively). A concomitant infec-
tion with 2+ agents was reported in 15.1% cases. Patients with a positive semen
culture had higher mean (SD) BMI [26.1 (4.0) vs. 25.6 (3.3)], lower ejaculate
volume [2.99 (1.6) vs. 3.35 (1.8) ml], lower inhibin B levels [98.1 (74.8) vs.
115.9 (83.3) pg/ml], were more frequently active smokers compared to those
without semen infections (all p≤0.02). No signiﬁcant correlations were found
between the different infectious agents and sperm parameters. Azoospermia
(NOA +OA) was more frequently reported in patients with positive vs. nega-
tive semen cultures (27.7% vs. 17.0%, X2 = 16.29; p < 0.001); semen infections
were more frequently found in NOA patients (X2 = 17.84; p < 0.001) but
not in OA men (p = 0.8). At multivariate analysis, a positive semen culture
achieved independent predictor status for azoospermia (NOA +OA; OR
2.50, p < 0.001) and for NOA (OR 2.59, p < 0.001), after accounting for
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CCI status, genetic abnormalities, history of cryptorchidism and hypogonadal
status.
Limitations, reasons for caution: No comparison with a same-race, age-
matched cohort of fertile individuals. Lack of data regarding potential molecular
alterations in spermatogenesis, which may be important to understand the pos-
sible impact of infections on semen parameters.
Wider implications of the ﬁndings: Infections of the urogenital tract are
thought to be potentially modiﬁable causes of male infertility, so that a detailed
and extensive investigation on them may be advisable to prevent long, poten-
tially unnecessary infertility treatments.
Trial registration number:N/N.
P-034 The effect of autologous platelet-rich plasma on human
sperm parameters: in vitro experimental study
R. Bader1,2, M. Moussa2, A. Mourad3, J. Azoury1, J. Ibrahim4,
G. Raad1, J. Azoury1*, N. Alaaeddine5*
1Mount Lebanon Hospital, Azoury IVF Clinic, Beirut, Lebanon
2Saint-Joseph University, Regenerative Medicine and Inﬂammation Laboratory -
Faculty of Medicine, Beirut, Lebanon
3American University of Beirut Medical Center, Department of Obstetrics and
Gynecology, Beirut, Lebanon
4Lebanese University, Faculty of Public Health II, Beirut, Lebanon
5Saint-Joseph University, Regenerative Medicine and Inﬂammation Laboratory -
Faculty of Medicine, Beirut
*Contributed equally to this work
Study question: Study the effect of autologous PRP (platelet-rich plasma) on
sperm parameters in the presence and absence of oxidative stress.
Summary answer: Autologous PRP improves the quality of the sperm, more
so in the presence of oxidative stress.
What is known already: Around 65 to 80% of infertile men suffer primary
testicular defects in spermatogenesis, detected by abnormal semen analysis. In
addition to standard parameters, specialized tests, such as oxidative stress
measurement and sperm DNA fragmentation test, can help in the diagnosis and
prognosis of infertility. The role of oxidative stress in male infertility is well
established and all sperm parameters are highly affected by its damage.
Recently, a review of growth factors, cytokines, and antioxidants present in PRP
and their effect on sperm parameters have lead to a theoretical conclusion that
PRP might be a novel therapeutic option for male infertility.
Study design, size, duration: Semen samples of 30 healthy men in their
fourth decade attending a fertility clinic, between November 2016 and
December 2017, were enrolled in this cohort study. After obtaining a written
informed consent from all patients, a questionnaire about age, previous diseases
and habits was ﬁlled, and biological samples (blood and sperm) were obtained.
Participants/materials, setting, methods: After establishing H2O2 suit-
able concentration (10 mM) for oxidative stress induction, semen samples were
prepared and cultured in the presence or absence of H2O2. Following prepar-
ation of autologous PRP, semen samples were left untreated or treated with
increasing concentrations of PRP (2%, 5% and 10%). After 24 hours, sperm
motility, morphology, vacuolization, viability, DNA fragmentation, and oxidative
stress assessment were evaluated using light microscopy, Spermoscan kit, eosin-
nigrosine staining, halosperm kit and nitroblue tetrazolium test, respectively.
Main results and the role of chance: This study demonstrated the harmful
effect of oxidative stress on sperm parameters, showing a signiﬁcant increase in
the percentage of vacuolization (p = 0.047) and sperm DNA fragmentation (p
= 0.030), and a signiﬁcant decrease in the percentage of progressive (p =
0.026) and total motility (p = 0.012) in the H2O2 treated group compared to
non-stressed sperm. As expected ROS positive sperm cells were extremely
higher in the H2O2 treated samples. When different concentrations of PRP
were added to all specimens, an improvement of the studied parameters were
noted mainly with PRP 2%, leading to the conclusion that a concentration of 2%
is the best to achieve a positive effect on sperm parameters. As expected the
percentage of dead sperm and the cell morphology didn’t differ between the
group treated with PRP and the untreated group (p > 0.05). However, DNA
fragmentation, and ROS positive cells were signiﬁcantly decreased when PRP
was added to both stressed (p < 0.0001) and non-stressed samples (p = 0.025
and p = 0.008 respectively), and immotile sperm and vacuolization were also
decreased when PRP was added but only for the stressed specimens (p <
0.0001). Finally, the same beneﬁcial effect of PRP was noted with increased per-
centage of progressive and total motility in the stressed group only (p <
0.0001).
Limitations, reasons for caution: Due to ﬁnancial limitations, we could
not be able to include infertile patients in the present study. The correlation
of our ﬁndings with sperm parameters in patients with fertility problems
would give better understanding of the involvement of oxidative stress in
male infertility.
Wider implications of the ﬁndings: Findings from the present study con-
tribute to the understanding of sperm physiology and would have relevance in
the diagnosis and/or treatment of infertile patients.
Trial registration number:Not applicable.
P-035 Effect of paternal age on semen parameters and the live
birth rate of in-vitro fertilization treatment
S.F. Lai, H.W.R. Li, Y. Shu BiuWilliam, H.Y.E. Ng
The University of Hong Kong, Obstetrics and Gynaecology, Hong Kong, Hong Kong
Study question: To determine the effect of paternal age on semen para-
meters and the live birth rate of ﬁrst IVF cycles.
Summary answer: Paternal age is negatively correlated with some semen
parameters but it could not predict the likelihood of a live birth in the fresh IVF
cycle.
What is known already: Two systematic reviews looking at the effect of
paternal age on assisted reproduction outcomes showed conﬂicting results on
both semen parameters and IVF outcomes. The conclusion drawn was that
except for volume and possibly motility, other sperm characteristics such as
concentration and morphology did not alter with age and advancing paternal
age was not associated with adverse IVF outcomes.
Study design, size, duration: This is a retrospective analysis of all ﬁrst IVF
cycles carried out between 2004 and 2014 at the Centre of Assisted
Reproduction and Embryology, The University of Hong Kong - Queen Mary
Hospital. Only those using ejaculated sperms were included for analysis to avoid
any potential bias. Those requiring preimplantation genetic diagnosis and using
donor sperms or surgically retrieved sperms were excluded from the study.
Participants/materials, setting, methods: Women received ovarian
stimulation using either the long gonadotrophin releasing hormone agonist or
antagonist protocol. Embryo transfer was performed two or ﬁve days after the
oocyte retrieval. Up to three embryos were transferred before 2006 and a
maximum of two embryos were transferred after 2006. Luteal phase was sup-
ported with vaginal progesterone pessaries or intramuscular injection of hCG.
Data of all ﬁrst IVF cycles was retrieved from the Assisted Reproduction
Clinical Database of the Centre.
Main results and the role of chance: A total of 3549 ﬁrst IVF cycles fulﬁlling
the inclusion criteria were analysed. In the raw semen, paternal age is negatively
correlated with semen volume, progressive motility, total motility and total
motile count with normal morphology (TNMC) (p < 0.005). It is positively cor-
related with sperm concentration (p < 0.001) but does not correlate with
sperm count, normal morphology and total motile count (TMC). Paternal age
does not correlate signiﬁcantly with fertilization rate, both in the conventional
insemination group, ICSI group and overall (p = 0.786, 0.977 and 0.810
respectively). Paternal age positively correlates with maternal age (Spearman’s
correlation coefﬁcient 0.487, p < 0.001). Paternal age is signiﬁcantly lower in
those who attained pregnancy, ongoing pregnancy and live birth compared with
those who did not (p < 0.001). Logistic regression showed that maternal age,
total numbers of oocytes retrieved and number of embryos transferred, but
not paternal age, were the signiﬁcant factors which independently predicted the
likelihood of live birth in the ﬁrst IVF cycles after controlling for the others (p <
0.001).
Limitations, reasons for caution:We do not have the information on con-
genital abnormalities of the live born and the long term data of the babies born
from IVF/ICSI. The present study examined patients who have undergone IVF
treatment and the results may not be applicable to natural conception.
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Wider implications of the ﬁndings: Infertile couples can be counselled that
although there is a decline in some semen parameters with paternal age, the
live birth rate of IVF depends on the maternal age, the number of oocytes
retrieved and the number of embryos transferred but not the paternal age.
Trial registration number:Not applicable.
P-036 Animal enriched serum contains vitamin E and omega-3
fatty acids; a new suggestion to improve frozen-thawed human
sperm quality
S. Seiﬁ1,2, A. Shahverdi1, A.R. Alizadeh1, H. Choobineh3,
M. Hezavei1
1Department of Embryology, Reproductive Biomedicine Research Center- Royan
Institute for Reproductive Biomedicine- ACECR, Tehran, Iran
2Rouyesh Helal Infertility Treatment Center, Helal Iran Pharmaceutical and Clinical
Complex, Tehran, Iran
3Assisted Professor of School of Allied Medical Sciences, Tehran University of Medical
Sciences, Tehran, Iran
Study question: This study was performed to evaluate the effects of ram
enriched serum contains vitamin E and omega-3 fatty acids on human sperm
cryopreservation.
Summary answer: Low concentration of enriched serum contained vitamin E
and ﬁsh oil + vitamin E in commercially freezing medium improved frozen-
thawed human sperm parameters.
What is known already: Cryopreservation media has crucial role in protec-
tion of sperm against cryo-injuries during freezing-thawing. Therefore, developing
this media can improve the fertility potential of sperm during this process. It
seems that using nutrients in freezing media is leading to improve thawed sperm
parameters. Although effectiveness roles of antioxidants and omega 3 fatty acids
for improvement of sperm quality after freezing are reported, the potential of
dietary enriched serum contains vitamin E is currently unclear. Therefore, the
purpose of this study was to evaluate the addition of enrich serum contains these
nutrients in commercially freezing media for cryopreservation of human sperm.
Study design, size, duration: To produce enriched serum, 16 rams (n = 4)
were fed diets as follows: Control (CTR), vitamin E (VITE; 200 IU/ram/day),
ﬁsh oil (FO; 40 g/ram/day) and ﬁsh oil + vitamin E (FO+VITE). In the second
phase, semen samples were collected from 25 normospermic men and then
were divided into six equal experimental groups for cryopreservation in freezing
media (SpermFreezTM, Fertipro) containing enriched 5% ram serum as men-
tioned above.
Participants/materials, setting, methods: Fetal Bovine Serum (5% FBS)
and commercially freezing media without serum (Control) were used as other
experimental groups. To evaluate the effects of enriched serum on the quality
of frozen-thawed sperm, several parameters such as motion characteristics
(CASA), viability (Eosin-nigrosin), DNA fragmentation (SCSA) and total ROS
(Chemiluminescence assay) were recorded. Data were analyzed using SPSS and
statistical differences among various groups were determined by ANOVA and
Tuckey’s post hoc test.
Main results and the role of chance: The highest signiﬁcant (p < 0.05) per-
centage of sperm motility and viability were observed in groups containing VITE
(49.78 ± 1.96 and 44 ± 8.03) and FO+VITE (51.28 ± 2.71 and 48 ± 7.74) com-
pared to control group (38.66 ± 1.89 and 37 ± 8.47), respectively. Moreover,
FBS produced the lowest signiﬁcant (p < 0.05) percentage of motility and viability
(33.66 ± 1.88 and 30 ± 7.33) compared to control group, respectively.
Interestingly, adding serum contains FO+VITE to freezing media improved curvi-
linear velocity (VCL) than other groups (53 vs. 31, 36, 37, 44, 48 μm/s for FO
+VITE, FBS, FO, control, CTR, VITE, respectively). ROS concentrations were
not signiﬁcantly (p > 0.05) affected by the serum supplementation. Flow cytome-
try parameters in this study conﬁrmed our results related to motility and viability.
Straight linear velocity (VSL) as well as Average path velocity (VAP) were changed
by serum inclusion. This improvement is mostly related to characteristic of anti-
oxidant activity of vitamin E and omega-3 fatty acids. This combination has several
characteristic that may improve the quality of sperm such as membrane ﬂexibility
and improve signal transduction during cryopreservation.
Limitations, reasons for caution: The limitations of the present study
included the limited volume of sample test for more investigations and
functional tests. We cannot test the fertility potential of frozen-thawed sperm
in current study.
Wider implications of the ﬁndings: Our study has clinical relevance and
may result in considerable improvement from a wide range of cryopreservation
procedures and assisted reproductive techniques (ART) which warrants further
studies. Furthermore, this attitude may improve the aspects of sperm freezing
protocols in several species.
Trial registration number:Not applicable.
P-037 Male’s advanced age negatively impacts embryo
development on short-term insemination IVF cycles with younger
female patients
R. Taniguchi, S. Hatakeyama, H. Anakubo, Y. Nagahama, Y. Taga,
S. Shioya, N. Nakasuji, S. Ohgi, A. Yanaihara
Yanaihara Women’s Clinic, Obstetrics and Gynecology, Kamakura, Japan
Study question: Do the couple ages affect short-term insemination conven-
tional in vitro fertilization (c-IVF) results?
Summary answer: Male’s advanced age on short-term insemination c-IVF
has a negative inﬂuence on fertilization and embryo development.
What is known already: Female age has been shown in multiple studies to
be a predictor of poor reproductive success with assisted reproductive technol-
ogy (ART). In addition, the inﬂuence of male age is suggested in undergoing
ART.
Study design, size, duration: This retrospective cohort study included a
total of 3249 c-IVF cycles of infertile couples between January, 2012 and
October, 2017 at Yanaihara Women’s clinic.
Participants/materials, setting, methods: Male and female patients were
divied into two age groups (31-37 years, and 38-44 years), and a male age on
IVF outcomes for short-term insemination was studied. The protocol for all the
cycles was insemination for 3 hours, PB check(two polar body, 2PB) 4-6 houers
later, and fertilization check(two pronuclei, 2PN) 20 hours after insemination.
We compared the rates of fertilization, embryo development, and clinical preg-
nancy on day 5 after ET among different age groups.
Main results and the role of chance: In the 31-37 years age female group
between the same age male partner group and older age male partner group
(38-44 years), the second polar body release rates (80.6% vs 77.5, p < 0.01),
fertilization rates (74.0% vs 70.5% p < 0.05), Day 3 good embryo rates (56.2%
vs 52.0%, p < 0.01) and blastocyst formation rates (57.8% vs 49.2%, p < 0.01)
werer compared, and all the above outcomes were signiﬁcantly lower in the
older male partner group. However, there were showed no signiﬁcant differ-
ences on day 5 good blastocyst rates (53.5% vs 51.6%) and clinical pregnancy
rates (52.9% vs 52.9%) after embryo transfers. Women 38-44 years groups
showed no statistically signiﬁcant differences in the rates among different male
age partner groups (p > 0.05).
Limitations, reasons for caution: Male age affects short-term insemination
IVF outcomes, but female factors outperforms male factor in cases with older
patients.
Wider implications of the ﬁndings:Male age affects c-IVF outcomes, and it
is necessary to think about treatment options with the male age as well as
female age in consideration.
Trial registration number:None.
P-038 The effect of paternal trans fatty acids diet on sperm quality
and expression proﬁle of PPAR genes in the testis of rat offspring
N. Khamehiee1,2,3, G. Javadi1, B. Ebrahimi3, A. Alizadeh
Moghaddam3, M. Shahhoseini2
1Science and research- Islamic Azad University, Department of genetics-, Tehran, Iran
2Reproductive Biomedicine Research Centre- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Genetics-, Tehran, Iran
3Reproductive Biomedicine Research Centre- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Embryology-, Tehran, Iran
Study question: Does the paternal trans fatty acids diet inﬂuence on sperm
quality and expression proﬁle of PPAR genes in testis tissue of rat offspring?
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Summary answer: Paternal intake of trans fatty acids caused to signiﬁcant
decrease in sperm parameters and expression proﬁle of PPARβ and PPARγ genes
in male offspring rats.
What is known already: High fat diets especially trans fatty acids can affect
on the expression of a wide variety of metabolic factors including peroxisome
proliferator-activated receptor, PPAR. PPARs are nuclear receptors that their
normal expression levels in testis tissues of adults are associated with their nor-
mal spermatogenesis. Recently, it has been shown by investigators that subopti-
mal diet during male gametogenesis can inﬂuence the metabolic status of the
offspring.
Study design, size, duration: This study is included 20 adult male Wistar
rats (5 in each groups) that their fathers were fed for 60 days in the following
four diet groups: control diet (C) - control diet with trans fatty acid (CT) - a
diet containing vitamin E (E) and a diet containing vitamin E and trans fatty acid
(ET).
Participants/materials, setting, methods: Epididymal tissue was taken
from male offspring rats and sperm parameters were analyzed by using CASA
computer analysis. On the other hands, total RNA was extracted from testis
tissues and after cDNA synthesis the mRNA expression of PPARα, PPARβ and
PPARγ genes were measured by using quantitative PCR. Data were statistically
analyzed using one-way Anova.
Main results and the role of chance: The results of this study showed stat-
istical signiﬁcant differences between concentration, progressive and total motil-
ity of sperm parameters among groups. Duncan’s test showed that sperm
concentration in group with vitamin E intake was signiﬁcantly higher than other
groups (P < 0.05). Also, the mean of progressive and total motility of sperms in
groups C and E were signiﬁcantly higher than two other groups. The expression
of PPARβ gene in two groups (E and C) was signiﬁcantly higher than other
groups (the CT and ET). Also the expression of PPARγ gene in group E was sig-
niﬁcantly higher than other groups. Eventually, the expression of PPARγ gene in
group C was signiﬁcantly higher than ET group.
Limitations, reasons for caution: The difference in nutrition of fathers
before dietary treatment and also the low sample size of offspring in each group
can be a limited factor in this study.
Wider implications of the ﬁndings: This study showed paternal trans fatty
acid consumption can have negative effects on normal spermatogenesis in male
offspring, resulting to decrease in the quality and quantity of sperms.
Additionally, contrary to our expectations, vitamin E supplement could not neu-
tralize enough the negative effect of trans fatty acids in this regard.
Trial registration number:NA.
P-039 Changes in ultrasonographic (US) images of the
seminiferous tubules during gonadotropin replacement therapy in
men with hypogonadotropic hypogonadism
S. Nariyoshi1, T. Sho1, K. Nakano2, G. Sukegawa2, Y. Tsuji1
1Tenjin Tsuji Clinic, Urology, Fukuoka, Japan
2Ebisu Tsuji Clinic, Urology, Shibuya, Japan
Study question: Are changes in US images of seminiferous tubules during
gonadotropin replacement therapy related to the progression of spermatogen-
esis in men with hypogonadotropic hypogonadism?
Summary answer: The density of thick seminiferous tubules on US images is
related to the extent of spermatogenesis induced by gonadotropin therapy in
men with hypogonadotropic hypogonadism.
What is known already: Gonadotropin replacement therapy using hCG and
rFSH is effective for inducing spermatogenesis in patients with hypogonadotro-
pic hypogonadism. However, the progression of spermatogenesis during hCG
+rFSH treatment in these patients has not been well elucidated. We previously
demonstrated that thick seminiferous tubules on US images suggest a high rate
of successful sperm retrieval in patients with non-obstructive azoospermia
(ESHRE2016 P-014). US analysis of seminiferous tubules may provide valuable
information for determining the extent of spermatogenesis in patients with
hypogonadotropic hypogonadism who are being treated with gonadotropins.
Study design, size, duration: This prospective observational study involved
7 azoospermic patients with male hypogonadotropic hypogonadism who
underwent hCG+rFSH therapy at our outpatient clinic from May 2008 to
November 2017.
Participants/materials, setting, methods: We studied 7 men with hypo-
gonadotropic hypogonadism, aged 34 to 49 years. Of these patients, 6 had idio-
pathic hypogonadotropic hypogonadism, including 2 patients with Kallmann
syndrome and 1 had iatrogenic hypogonadotropic hypogonadism after brain
surgery. Semen analysis and US evaluation of the testis were performed before
and during gonadotropin therapy. To optimize US images for visualization of
the seminiferous tubules, gain and contrast were appropriately adjusted with
graphics software.
Main results and the role of chance: Gonadotropin replacement therapy
induced spermatogenesis in 5 of the 7 patients. The ﬁrst appearance of
sperm in the ejaculate was achieved after a median duration of treatment of
3 months. Although testicular volume in these patients increased from 2.5
to 4.0 mL, there was no further increase in testicular volume 3 months after
the initiation of treatment. Thick seminiferous tubules, deﬁned as more than
300 μm in diameter on the US image, and the ﬁrst sperm in the ejaculate
were detected at almost the same time. Furthermore, an increase in sperm
output was associated with an increase in the density of thick seminiferous
tubules.
In contrast, two patients remained azoospermic 10 and 24 months after the
initiation of treatment, respectively. Neither an increase in testicular volume
nor thick seminiferous tubules on US were observed in these patients.
An increase in testicular volume only suggests the induction of spermatogen-
esis by gonadotropin therapy in patients with hypogonadotropic hypogonadism,
while the extent of spermatogenesis can be assessed by the change in the dens-
ity of thick seminal tubules on US images.
Our results suggest that the appearance of thick seminiferous tubules on US
images may predict a good future response to gonadotropin therapy in hypogo-
nadotropic hypogonadism.
Limitations, reasons for caution: In patients with intrascrotal calciﬁcation
including severe testicular microlithiasis, testicular parenchyma cannot be
assessed by US.
Wider implications of the ﬁndings: The status of spermatogenesis in
patients whose semen is not available for testing due to an ejaculatory disorder
may be estimated by the US analysis of seminiferous tubules.
Trial registration number:Not applicable.
P-040 Dishevelled-associated activator of morphogenesis 1 or
DAAM1: expression and localization in human testicular tissue and
spermatozoa
G. Coppola1, C. Fasano1, M. Venditti2, S. Del Grande1, S. Riccio1,
B. Dale1, L. Di Matteo2
1Centro Fecondazione Assistita, Reproductive Biology, Napoli, Italy
2Università degli studi della Campania “Luigi Vanvitelli”, Department of Medicine,
Napoli, Italy
Study question: Is the protein Dishevelled-associated activator of morpho-
genesis 1 (DAAM1) present in human testicular tissue and spermatozoa and, if
so, where is it located.
Summary answer: DAAM1 is present in both human testicular tissue and
spermatozoa localized in the germ cells and Sertoli cells and in the tail in mature
spermatozoa.
What is known already: DAAM1 is a protein involved in the nucleation of
actin ﬁlaments and in cytoskeletal organization; however, to date it has not
been described in the human male reproductive tract. In a recent study,
DAAM1 has been shown to be expressed in the post-natal development of rat
testis and spermatozoa. The level of expression of DAAM1 in the rat decreases
during development and changes its localization; from the cells near the base-
ment membrane towards the lumen of the tubule. In the spermatozoa it is
found in the tail.
Study design, size, duration: Human testicular tissue was obtained from 15
males, with an average age of 37 years, following Testicular Sperm Extraction
(T.E.S.E.), while human sperm samples were collected from 20 patients under-
going regular sperm analysis, at ‘Centro di Fecondazione Assistita (CFA)” in
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Naples. Only samples with concentration higher than 20 mil/ml, and normal
motility and morphology according to WHO 2010 were used.
Participants/materials, setting, methods: Part of the tissue was frozen
and stored in liquid nitrogen until protein extraction. The proteins were sepa-
rated by SDS-PAGE and identiﬁed by Western Blot. The remaining tissue was
ﬁxed in formalin, embedded in parafﬁn and stained with haematoxylin and eosin
to check the quality of the tissue and identify the cell types. Subsequently
immunoﬂuorescence was performed both on the tissue and spermatozoa.
Main results and the role of chance: Western blot analysis conﬁrmed the
presence of the protein in human testicular tissues. The tissues samples showed
different levels of DAAM1 expression (O.D. DAAM1/Actin ratio ranges from
0,9 – to 2,3). We have also shown the presence of this protein in all sperm sam-
ples studied (O.D. DAAM1/Actin ratio ranges from 0,07 – to 1). In testicular
tissue the protein signal was localized in the cytoplasm of Sertoli cells, gono-
cytes, spermatogonia and spermatids. In spermatozoa, the protein was mainly
detectable inside the ﬂagellum.
Limitations, reasons for caution: Human testicular tissues were obtained
from males following surgical intervention (Testicular Sperm Extraction, TESE)
at ‘Centro di Fecondazione Assistita” of Naples; these men enrolled in the
study were affected by azoospermia. A limit of the study was the absence of
material and experimentation on healthy individuals.
Wider implications of the ﬁndings: This is the ﬁrst report to show the
presence of DAAM1 in human testicular tissues and spermatozoa. Further stud-
ies are needed to elucidate the role of DAAM1 in human spermatogenesis and
male fertility.
Trial registration number: This is basic science.
P-041 Diagnostic value of spermDNA fragmentation for
predicting IVF fertilization failure in males with mild or medium
asthenospermia
S. Zhao, L. Tang, M. Rao
The First Afﬁliated Hospital of Kunming Medical University, Department of
Reproduction and Genetics, Kunming, China
Study question: Is sperm DNA fragmentation (SDF) valuable for predicting
IVF fertilization failure in males with mild or medium asthenospermia?
Summary answer: SDF greater than 31.25% could be associated with higher
probability of IVF fertilization failure in males with mild or medium
asthenospermia.
What is known already: Low levels of natural fertility are detected in cou-
ples with a high percentage of SDF. But studies on effects of SDF on IVF/ICSI
outcomes report controversial results.
Study design, size, duration: Retrospective clinical study.
Participants/materials, setting, methods: Data from a cohort of 116 cou-
ples who underwent their ﬁrst IVF cycle between January 2016 and December
2017 at an University-afﬁliated teaching hospital under criteria as follows: males
with progressive sperm rate between 10% and 32%, woman age < 38 years,
number of oocyte retrieved ≥5. Women diagnosed with PCOS were excluded.
The SDF was detected by chromatin dispersion test.
Main results and the role of chance: The area under the receiver operating
characteristic curve was 0.772 (p = 0.003). A cutoff value for SDF to predict
the IVF fertilization failure is 31.25%. When the SDF exceeded 31.25%, the fer-
tilization rate, number of embryo and number of good embryo were statistically
decreased, but the cleavage rate, good embryo rate and clinical pregnancy rate
were not affected.
Limitations, reasons for caution: A weakness of our study is that SDF was
measured on neat semen samples 1 to 2 months before the initiation of IVF
instead of on sperm collected the day of oocyte retrieval.
Wider implications of the ﬁndings: High rate of SDF may be used as a clin-
ical indication for ICSI in couples with mild or medium asthenospermia.
Trial registration number: not applicable.
This work was supported by the National Natural Science Foundation of
China under grants 81760269, Personnel Training Program of Academic and
Technical Leaders of Yunnan Province (2017HB046), the Applied basic
research projects in Yunnan province (2017FE467(-137)).
P-042 The assessment of clinical intracytoplamic sperm injection
(ICSI) outcome using immotile testicular spermatozoa in non-
obstructive azoospermia (NOA)
T. Ishikawa, S. Mizuta, K. Yamaguchi, Y. Takaya, H. Matsubayashi,
T. Takeuchi, K. Kitaya
Reproduction Clinic Osaka, Reproductive Medicine, Osaka, Japan
Study question: What is the fertilization rate, embryonic development, and
clinical outcome for TESE-ICSI using immotile testicular spermatozoa even after
pentoxifyllin administration among NOA couples?
Summary answer: Better fertilization and embryonic development were
achieved and clinical pregnancy rate per embryo transfer (ET) by motile sperm-
atozoa was signiﬁcantly higher than by immotile spermatozoa.
What is known already: The testicular spermatozoa are often immotile imme-
diately after testicular sperm extraction (TESE) and especially after thawing of frozen
testicular samples and spermatozoa showing reliable signs of vitality are preferred
for ICSI because the use of motile sperm signiﬁcantly increases the efﬁcacy of the
ICSI procedure. To select TESE-retrieved viable spermatozoa for ICSI, pentoxifylline
administration or hypo-osmotic swelling test (HOST) were often used, however,
the testicular sperm from microdissection (micro) TESE and frozen-thawed tissue
are often immotile and we have often observed the NOA patients whose testicular
spermatozoa are immotile only even after pentoxifylline administration.
Study design, size, duration: We performed a retrospective study based
on a reproduction center in Japan and evaluated 966 NOA patinets including
after orchidopexy, Klinefelter syndrome, cryptozoospermia, mumps orchitis,
azoospermia factor (AZF) microdeletion and unexplained NOA and 369 cou-
ples had 646 TESE-ICSI cycles were performed between September 2013 and
December 2017. TESE-ICSI was performed with only motile spermatozoa (268
patients 482 cycles, Mo+), motile/immotile spermatozoa (58 patients 98
cycles, Mo+/-), and immotile spermatozoa only (43 patients 46 cycles, Mo-).
Participants/materials, setting, methods: Sperm preparation medium
with pentoxifylline added (1 mg/mL) was applied to a droplet of testicular cell
suspension in the ratio 1:1 when we could not detect motile spermatozoa.
When immotile spermatozoa was injected even after pentoxifyllin administra-
tion, oocytes were incubated with calcium ionophore (A23187) for 15 minutes.
Two pronuclei (2PN), blastocyst development, good-quality blastocyst, and
clinical pregnancy rates (CPR) were compared. Statistical analysis was per-
formed using unpaired t-tests and chi-squared tests.
Main results and the role of chance: Wives age was not different between
groups. The sperm retrieval rate with micro TESE was 36.5% (353/ 966), in which
motile spermatozoa were retrieved in 79.6% (281/353). Hormonal and any clinical
data did not predict before TESE whether motile spermatozoa could be retrieved.
2PN and blastocyst rates of oocytes injected by motile spermatozoa (57.8% and
50.4%, respectively) were signiﬁcantly higher than by immotile spermatozoa (41.1%
and 15.4%, respectively) (P < 0.001). Good-blastocyst rates of these oocytes were
not observed signiﬁcant differences (42.7% and 47.4%, respectively). CPR per
embryo transfer in embryo by motile spermatozoa was signiﬁcantly higher than by
immotile spermatozoa (35.2% (227/ 644) and 10.6% (7/66), respectively). In all
11 pregnancies of Mo+/- group, all embryo which lead to pregnant were injected
by only motile spermatozoa. Another 5 patients with immotile spermatozoa
injected into oocyte could achieve pregnancy of Mo+/- group (double embryo
transfer using motile and immotile sperm; four from AZFc microdeletion and one
from unexplained NOA. Seven patients with immotile spermatozoa injected into
oocyte achieved pregnancy of Mo- group; four had delivered healthy babies from 2
unexplained NOAs, Klinefelter syndrome, and post orchidopexy and the other
three were ongoing pregnancy from unexplained NOA.
Limitations, reasons for caution: There was a lack of standardization with
respect to the frozen-thaw and fresh cycles. The safety and screening for con-
genital malformations among these children has not been fully investigated. No
study compared the outcome of ICSI with initially immotile and induced motile
testicular sperm.
Wider implications of the ﬁndings: The patients with NOA no longer
should be considered sterile without performing micro TESE-ICSI. Sperm motil-
ity is the most important to deliver a baby in TESE-ICSI. However, embryolo-
gists should not give up when only immotile spermatozoa was injected even
after pentoxifyllin administration.
Trial registration number:Not applicable.
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P-043 Successful clinical outcome of ICSI cycles with sperm of
HIV- positive men after antiretroviral treatment
B. Desmet1, I. Mateizel1, I. Pletincx1, E. Vancutsem2,
A. Van De Vijver1, G. Verheyen1
1UZ Brussel, Centre for Reproductive Medicine, Jette- Brussels, Belgium
2UZ Brussel, Microbiology Department, Jette- Brussels, Belgium
Study question: Does the clinical outcome of ICSI with extensively processed
semen of HIV-positive male patients reach acceptable values?
Summary answer: A high clinical pregnancy rate is obtained after ICSI with
extensively processed sperm of HIV- positive man who underwent antiretro-
viral treatment.
What is known already: HIV men undergo antiretroviral therapy before
undergoing ICSI treatment. However, in ejaculated semen, the HIV virus may still
be present in the cell-free fraction or bound to lymphocytes. Therefore, the prep-
aration of semen for assisted reproduction still requires special attention in order
to reduce the viral load in the ﬁnal sperm fraction. Special devices for the prepar-
ation of sperm samples from HIV-positive men are available in order to improve
safety. Different combinations of sperm preparation techniques can be applied.
Study design, size, duration: A single-centre retrospective analysis was per-
formed on ICSI cycles of HIV-serodiscordant couples with HIV+-male partners,
referred to our unit between August 2009 and December 2017. The male
patients were under antiretroviral therapy and had a blood viral load <40 cop-
ies/ml. The semen samples were tested before and after extensive preparation
for the presence of HIV-virus using COBAS-AmpliPrep/COBAS-TaqMan-HIV-
1 quantitative test. The ﬁnal sperm fraction was frozen and released for later
ICSI if no HIV viruses detected.
Participants/materials, setting, methods: Twenty-ﬁve couples under-
went 45 fresh ICSI cycles and 32 frozen embryo cycles. Based on sperm origin
and quality, different semen preparation protocols were performed: density-
gradient-centrifugation (DGC) combined with swim-up for good-quality semen,
DGC only for fair to low-quality semen, and sperm wash for very low-quality
semen or for testicular sperm. The pro-insert Kit (Nidacon) was used during
DGC procedure. The end-point was clinical pregnancy with fetal heart beat
(CP) per patient.
Main results and the role of chance: From the 45 fresh ICSI cycles, 5 cycles
had no embryo transfer (ET) due to abnormal fertilization (n = 3) or insufﬁcient
embryo quality (n = 2). In 13 cycles, all embryos were frozen for different rea-
sons, while fresh ET was performed in 27 cycles (27/45; 60.0%). In total, 90
embryos were frozen. Regarding the frozen cycles, 43 embryos were thawed in
32 cycles, all resulting in ET. The CP rate per ET was 33.3% (9/27) in cycles with
fresh ET and 25% (8/32) in frozen cycles. The total number of CPs obtained by
the 25 couples who started an ICSI cycle was 17 (68.0%). In total, we report 9
deliveries in the fresh cycles, and 3 deliveries, 3 ongoing pregnancies and 2 miscar-
riages in the frozen cycles. In addition, 42 embryos are still frozen, and have the
potential to increase the cumulative delivery rate. Twenty-one of these embryos
belong to 8 patients who did not get pregnant so far. It can be concluded that the
outcome of ICSI cycles in the present patient population is re-assuring.
Limitations, reasons for caution: The present study is limited by its obser-
vational retrospective nature and by the small number of patients included. The
analysis is restricted to sero-discordant couples with HIV-positive men. A simi-
lar analysis will be performed for HIV-positive women only, and for HIV sero-
concordant couples.
Wider implications of the ﬁndings: Our data show that despite the anti-
retroviral treatment and extensive processing of the semen in cases of HIV-
positive men, the outcome of ICSI treatment in sero-discordant couples is suc-
cessful. Moreover, the use of semen fractions with undetectable HIV virus in
ICSI cycles is reassuring for the patients and clinical staff.
Trial registration number: none.
P-044 Impact of the sperm DNA fragmentation on clinical
outcome in treatments with oocyte donation
F. Giacone, S. Chamayou, E.T. Maniscalchi, D. Lombardo,
E.W. Venti, C. Alecci, A. Liprino, A. Guglielmino
Unità di Medicina della Riproduzione - Centro HERA, Unità di Medicina della
Riproduzione - Centro HERA, Sant’Agata Li Battiati Catania, Italy
Study question: Which is the impact of sperm DNA fragmentation in male
patient on clinical outcomes oocyte donation programs?
Summary answer: The sperm DNA fragmentation of male patient has no
impact on clinical outcome in oocyte donation programs.
What is known already: It has been observed that the high sperm DNA
fragmentation (DNA fragmentation index >30%) in normozoospermic males
could be a cause of infertility. Different studies show a correlation between
high levels of sperm DNA fragmentation and the decrease of the pregnancy
rate in homologous treatments. On the other hand, it is known that oocytes
from healthy young women such as donors have the ability to repair
sperm DNA.
Study design, size, duration: The present retrospective study was per-
formed on 173 couples undergoing cycles of ICSI with cryopreserved donated
oocytes between June 2016 and December 2017.
Participants/materials, setting, methods: The mean age was 42.5 years
for female recipients and 44.5 years for male patients. The donated metaphase
II oocytes were obtained and cryopreserved from donors with a mean age of
age 24.1 years. The sperm DNA fragmentation was evaluated by TUNEL test
and ﬂuorescence microscopy few weeks before ICSI. The percentage of sperm
DNA fragmentation was calculated on fresh sample and sperm preparation
after density gradient treatment.
Main results and the role of chance: The DNA fragmentation of the
spermatozoa resulted to be 14.8%±13.1% (mean±SD) for the fresh sample,
and 7.7%±10.02% (media±SD) after sperm preparation.
No correlation was observed between the two samples and the age of the
patient (in fresh r = 0.13; selected spermatozoa r = 0.03), between the two
samples of spermatozoa and the result of bHCG test (in fresh r = 0.00; selected
spermatozoa: r = 0.05), and the two samples of spermatozoa and clinical preg-
nancy rate (in fresh r = 0.06; selected spermatozoa: r = 0.03).
Limitations, reasons for caution: Limitations might be represented by the
limited number of cases with fragmentation over 30% and by the fact that DNA
fragmentation has been evaluated few weeks before ICSI.
Wider implications of the ﬁndings: Cryopreserved oocytes from young
donors have the ability to repair the sperm DNA. In these cases the valuation
of sperm DNA fragmentation, in the diagnostic phase, couldbe avoided.
Trial registration number:No one.
P-045 Prevalence of HPV infection in potential sperm donors and
in men from infertile couples in the czech republic
H. Jaworek1, I. Oborna2, B. Zborilova3, J. Brezinova4, D. Ruzickova5,
V. Koudelakova1, J. Vrbkova1, M. Hajduch1
1Faculty of Medicine and Dentistry- Palacky University, Institute of Molecular and
Translational Medicine, Olomouc, Czech Republic
2Faculty of Medicine and Dentistry- Palacky University, Dept. of Obstetrics and
Gynaecology, Olomouc, Czech Republic
3Fertimed Ltd., Fertimed Ltd., Olomouc, Czech Republic
4SpermBank International Ltd., SpermBank International Ltd., Olomouc, Czech
Republic
5Arleta IVF Ltd., Arleta IVF Ltd., Kostelec nad Orlici, Czech Republic
Study question:What is the prevalence of hrHPV infection in potential sperm
donors (SD) and men from infertile couples (IM)? Does the presence of hrHPV
inﬂuence the semen parameters?
Summary answer: HrHPV prevalence in SD was 28.9% compared to 35.1%
in IM. Men with hrHPV+semen sample had lower sperm volume, sperm con-
centration, and total sperm count.
What is known already: HPV infection could play a role in human fertility
like other sexually transmitted diseases (STDs). Unlike other STDs, HPV is not
tested obligatorily for gamete donors or infertile couples, although it might
affect fertility and pregnancy outcome.
Study design, size, duration: In this laboratory-based study semen samples
and penile swabs of potential sperm donors (n = 97) and men from infertile
couples (n = 328) were collected between July 2013 and November 2016. All
participants ﬁlled a questionnaire focused on their health status and sexual
behavior.
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Participants/materials, setting, methods: Semen samples were analyzed
for the presence of 14 hrHPV genotypes by cobas 4800 HPV system (Roche)
than genotyped using PapilloCheck HPV-Screening system (Greiner Bio-One)
which detects 18 hrHPVs. Penile swabs were analyzed only by PapilloCheck
HPV-Screening system. The association between hrHPV positivity, sexual
behavior, and semen parameters was assessed using statistical software R.
Main results and the role of chance: The hrHPV prevalence in SD (n = 97)
was 28.9% compared to 35.1% in IM (n = 328, P = 0.312). Penile swabs were
more frequently hrHPV+ than semen samples in both IM (32.3% vs. 11.9%, P
< 0.001) as well as in SD (26.8% vs. 6.2%, P = 0.006).
Men with hrHPV+ semen sample had lower semen volume (median volume
2.5 ml vs. 3 ml, P = 0.009), sperm concentration (median concentration 16 ×
106/ml vs. 31 × 106/ml, P = 0.009) and total sperm count (median count 46 ×
106 vs. 82 × 106, P = 0.009). No association between penile hrHPV positivity
and semen parameters was found.
HPV16 was the most frequent hrHPV genotype in penile swabs in both SD
(6.19% [6/97]) and IM (5.49% [18/328]). The most frequently occurring geno-
type co-infection was HPV42 in SD (5.15% [5/97]) and HPV44/55 in IM
(3.35% [11/328]). In semen samples the single-genotype infection was HPV66
in SD (2.06% [2/97]) and HPV53 in IM (2.13% [7/328]).
Men who tested hrHPV+ in penile swabs from both groups had more sexual
partners than those who tested hrHPV- (in SD median number of 6 vs. 3 [hrHPV
+ vs. hrHPV-] with P = 0.008; in IM, median number of 6 vs. 4 with P = 0.003).
Limitations, reasons for caution: Only penile swabs and semen samples
have been analyzed in this study. No data about female partners, number of
pregnancies and abortion rates were evaluated.
Wider implications of the ﬁndings: HPV positivity of the semen during a
time of donation or use may be of interest for facilities dealing with the treat-
ment of infertility because of the risk of transfer and interference with the fur-
ther development of the pregnancy.
Trial registration number: not applicable.
P-046 Diagnostic evaluation of static oxidation-reduction potential
with MiOXSYS System (Male Infertility Oxidative System) in
normospermic versus teratozoospermic patients: a retrospective
study
F. Scarselli, S. Gatti, E. Cursio, A. Pristerà, V. Zazzaro, M.G. Minasi,
A. Ruberti, S. Muzzì, M.T. Varricchio, A. Caragia, P. Greco,
E. Iovine, V. Casciani, E. Greco
European Hospital, Reproductive Medicine, Rome, Italy
Study question: Does evaluation of static oxidation-reduction potential
(sORP) with MiOXSYS System relate with WHO 2010 (World Health
Organization) sperm parameters and DNA fragmentation in infertile patients?
Summary answer: There is association between sORP and sperm para-
meters: sORP levels are higher in patients with lower concentration, motility
and morphology and with higher DNA fragmentation.
What is known already: Spermatozoa have a physiological equilibrium
between ROS (Reactive Oxygen Species) and anti-oxidants. This equilibrium
assures ordinary functions such as chromatin compaction, lipid membrane
modiﬁcation and sperm-oocyte fusion. When ROS are overproduced this equi-
librium is lost, generating oxidative stress (OS), possible cause of lipid peroxida-
tion, apoptosis and DNA damages or fragmentation. Seminal plasma contains
anti-oxidant factors (enzymatic and non-enzymatic) to prevent post-ejaculation
OS, however many studies demonstrate that in infertile men anti-oxidant levels
are low and ROS are high; these concentrations may be inﬂuenced by both
exogenous and endogenous factors: smoking, alcohol assumption, infection and
inﬂammation of male uro-genital tract.
Study design, size, duration: Semen from 84 infertile men were evaluated,
according to WHO 2010, during June and July 2017. On their ﬁrst visit at
Reproductive Medicine Unit, patients underwent semen analysis and sORP
evaluation and divided in two groups according to semen morphology. Group
A (N = 45) included patients with morphology 3 4 and group B (N = 39)
patients with morphology <4. Men with ejaculatory dysfunction, varicocele,
sexually transmitted diseases and exposed to radiation or chemotherapeutic
agents were excluded.
Participants/materials, setting, methods: Semen samples were produced
after 72-120 hours of sexual abstinence and analyzed after complete liquefac-
tion, evaluating semen parameters and DNA fragmentation with TUNEL
(Terminal deoxynucleotidyl transferase UTP-driven Nick End Labeling) test.
MiOXSYS was used to evaluate sORP (expressed in millivolt/sperm concentra-
tion 106/mL), a ‘snapshot’ of the current balance of the redox system. A higher
sORP level indicates an imbalance in the activity of all available oxidants relative
to all available antioxidants in ejaculates.
Main results and the role of chance: Mean male age was 42.1 ± 6.3 in
group A and 38.2 ± 6.5 in group B (p < 0.05). Semen volume was 3.2 ± 2.3 mL
in group A and 3.0 ± 2.0 in group B (NS). Sperm concentration was 47.2 ±
18.0 mil/mL in group A and 24.7 ± 19.0 mil/mL in group B (p < 0.05). Sperm
motility (progressive plus not progressive) was 66.7 ± 7.4 and 44.3 ± 20.0 in
group A and B respectively (p < 0.05). Morphology was 4.2 ± 0.5 in group A
and 2.1 ± 0.7 in group B (NS). Round cells concentration was 2.3 ± 2.0 and
2.7 ± 2.0 mil/mL in group A and B respectively (NS). DNA fragmentation
measure with TUNEL test resulted to be 7.5 ± 6.4 in group A and 11.0 ± 8.1 in
group B (p < 0.05). sORP level was 1.6 ± 2.5 and 15.5 ± 34.3 in group A and B
respectively (p < 0.05). Statistical analysis was made using Student t-test.
Correlation between sORP level and sperm concentration, motility and DNA
fragmentation resulted statistically signiﬁcant, while there isn’t any statistically
signiﬁcant correlation with morphology, semen volume and round cells concen-
tration. A small concentration of white blood cells in semen, such as poly-
morphonuclear granulocytes and lymphocytes, should contribute to ROS
production, but our study didn’t highlight this correlation and maybe further
studies should be performed to conﬁrm this parameter.
Limitations, reasons for caution:Our study included only infertile patients,
but including a group of men with proven fertility may improve the cutoff values
for sORP and increase the sensitivity of the assay. Another possible limit is
sORP levels are normalized for sperm concentration, leading to an over estima-
tion in men with severe oligozoospermia.
Wider implications of the ﬁndings: Currently available assays for OS
measure only discrete quantity of oxidants (ROS by chemiluminescence assay),
antioxidants (total antioxidant capacity [TAC] assay) or post-hoc damage
(MDA assay) and are tedious, time consuming and expensive. MiOXSYS
System is innovative in measuring ORP level in semen for its easiness and
readiness.
Trial registration number:Not applicable.
P-047 Sperm preparation for Intra-Cytoplasmic Sperm Injection
(ICSI) in cattle
J. Gómez1, R. Alberio1, W.Y. Kwong1, B.J. Woodward1,
C. Kershaw-Young2, K.D. Sinclair1
1University of Nottingham, School of Biosciences, Nottingham, United Kingdom
2Harper Adams University College, Animal Production- Welfare and Veterinary
Sciences, Newport, United Kingdom
Study question: Main aim is to develop improved sperm pre-treatment pro-
cedures required to trigger acrosome reaction (AR) and sperm DNA decon-
densation for bovine ICSI.
Summary answer: Lyshophosphatidylcholine (LPC)/Heparin (Hep) com-
bined with L-glutathione (GSH)/Hep increases the proportion of 2 pronuclei
(PN) after bovine ICSI compare to LPC/Hep or GSH/Hep alone.
What is known already: Bovine ICSI can overcome deﬁciencies of poor
sperm viability and motility, typically associated with frozen-thawed sexed
semen. Unlike human IVP, technical challenges exist with bovine ICSI, leading to
low fertilization rates and poor embryo development. This is may be due to
suboptimal sperm preparation (capacitation, AR), delay in sperm chromatin
decondensation and/or deﬁcient egg activation.
Study design, size, duration: Percoll-gradient separated semen from a sin-
gle frozen-thawed sire were split into three treatments (T): T1, exposure to
Hep (80 μg/ml, 15 min), involved in capacitation followed by LPC (15 min,
100 μg/ml) which induces AR; T2, co-incubation in GSH (15 mM) and Hep
(80 μM) for 20 hours (h) required to facilitate the sperm DNA decondensation;
T3, combination of both treatments. Then, pre-treated spermatozoa were
microinjected into bovine mature oocytes and activated chemically.
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Participants/materials, setting, methods: Sperm viability and AR were
determined simultaneously by a lectin ﬂuorescence staining, counting at least
200 spermatozoa per replicate in four repeated experiments. Decondensed
sperm heads were evaluated under a bright ﬁeld microscope in three replicates.
Microinjected oocytes (n = 175) were exposed to a novel activation proto-
col optimized previously. Calcium ionophore-A23187 (5 μg/ml for 5 min) fol-
lowed by strontium chloride (20 mM) and cyclohexamide (10 μg/ml) for 6 h.
Pronuclear formation (16h-post-activation) and blastocyst quality were
assessed by ﬂuorescent probes.
Main results and the role of chance: We found that sperm pre-treated
with LPC/Hep under the working conditions described before led to 0.81 ±
0.021 of AR spermatozoa over the total sperm population. When, sperm were
exposed to GSH/Hep 0.53 ± 0.054 showed decondensed heads. After the
application of both treatments, slightly lower proportion (0.44 ± 0.008) of
spermatozoa had decondensed sperm heads. However, the majority were AR
(0.97 ± 0.013).
PN assessment 16 hpa following ICSI indicated that LPC/Hep + GSH/Hep
increased (P = 0.012) the proportion of 2PN zygotes relative to LPC/Hep or
GSH/Hep (0.31 ± 0.058, 0.042 ± 0.026, 0.16 ± 0.055, respectively). Finally,
microinjected oocytes using pre-treated sperm with the optimal protocol
(LPC/Hep + GSH/Hep) were cultured until the blastocyst stage (192 hpa).
We observed similar proportions of cleaved (48 hpa) and blastocysts between
the treatment group (0.67 ± 0.059 and 0.09 ± 0.056) and non-treated sperm
(0.61 ± 0.062 and 0), and IVF control (0.81 ± 0.038 and 0.27 ± 0.073). Total
cell number between treatment and controls was similar but LPC + GSH
embryos were less competent than those derived by IVF.
Limitations, reasons for caution: Aggressive sperm treatment (LPC/Hep
+ GSH/Hep) reduced sperm concentration, restricting sperm counting during
the evaluation process.
Wider implications of the ﬁndings:With further development bovine ICSI
has the potential to improve success with sex-sorted semen in bovine in vitro
embryo production. However, the use of sex-sorted semen leads to poor fertil-
isation rates compared to non-sorted semen from the same sire as a result of
the sorting process.
Trial registration number:Not applicable.
P-048 The effects of incubation at two different oxygen
concentrations on oxidation-reduction potential of bull semen of
various breeders
E. Yalcinkaya1, S. Can Celik1, E. Caliskan2, F. Martinez Pastor3
1Private Adatıp Hospital, Assisted Reproduction Unit, Sakarya, Turkey
2Bahcesehir University, Obstetrics and Gynecology, Istanbul, Turkey
3INDEGSAL, University of Leon, Leon, Spain
Study question: Do higher oxygen concentrations in incubation conditions
have a more negative impact on the oxidation reduction potential (ORP) of
thawed bull semen?
Summary answer: This preliminary analysis revealed a nonsigniﬁcant differ-
ence in ORP levels of spermatozoa incubated at two different oxygen
concentrations.
What is known already: High concentrations of reactive oxygen species
have been reported to exert negative effects on sperm quality including
increased DNA fragmentation. Lowering oxygen levels in embryo culture was
also reported to enhance blastocyst development rates. However, there is no
consensus between different IVF laboratories on the incubation conditions of
sperm cells before use for IVF or ICSI.
Study design, size, duration: Thawed bull semen samples were divided into
ﬁve aliquots including one for ORP measurement at zero timepoint, two for the
incubation conditions at 39°C, 5% CO2 and 5% O2 and two for the conditions
at 39°C, 5% CO2 and 20% O2. ORP measurements were done at 0, 4-6 and
18-22 hours. ORP values were normalized and represented as mV/106
spermatozoa.
Participants/materials, setting, methods: Seven cryopreserved bull
semen samples of different breeders were used in the study. Two straws from
each sample were thawed and washed by density gradient centrifugation
(Sperm Grad TM, Vitrolife, Sweden). Total number of spermatozoa was
counted for each and the sample was then diluted with commercial media for
bovine IVF (BO IVF, IVF Bioscience, UK).
Main results and the role of chance: Compared to starting levels, an
increase was observed in ORP values under both oxygen levels at both time
intervals (66.1 vs 70.05 and 80.7 mV/106 (6 h, 5% and 20% O2, respectively);
66.1 vs 87.8 and 90.8 mV/106 (22 h, 5% and 20% O2, respectively) (p > 0.05
for both).
When differences between both oxygen concentrations in time were evalu-
ated, a slight increase was found in 20% compared to 5% at both times, but the
differences were not statistically signiﬁcant (p > 0.05).
Limitations, reasons for caution: The main limitation of our study was bull
variability. Since ORP values were found to be higher in the semen of worst
quality, it might be better to use semen of comparable quality to make a gener-
alized interpretation.
Wider implications of the ﬁndings: Our ﬁndings showed that especially
within 4-6 hours of incubation, higher oxygen level seemed to increase ORP
levels slightly more than lower oxygen concentration, but the difference did not
reach signiﬁcance. However, this ﬁnding may be important to focus on best cul-
ture conditions for human spermatozoa before IVF and ICSI.
Trial registration number:None.
P-049 Impact of spermatozoa origin and quality on fertilization,
pregnancy, miscarriage and live births: a comparative study of
azoospermic, cryptozoospermic, normozoospermic patients and
donors as control
A. Palomar1, I. Molina1, M.J. Soriano1, J.V. Martinez1, S. Balasch2,
J.M. Rubio1
1Hospital Universitari i Politecnic La Fe, Assisted Reproduction Unit, Valencia, Spain
2Universitat Politecnica de Valencia, Departamento de Estadistica e Investigación
Operativa Aplicadas y Calidad, Valencia, Spain
Study question: This study aims to compare reproductive outcomes after
ICSI in a large patient series considering spermatozoa from non-ejaculated ori-
gin and ejaculates of different quality baseline.
Summary answer: Reproductive outcomes, in terms of pregnancy, miscar-
riage and live births, after using non-ejaculated spermatozoa are similar or even
better compared with ejaculated spermatozoa.
What is known already: Azoospermic patients represent 5% to 15% of
infertile males, so they are scarce but not rare. Therefore, it is important to
research in depth clinical outcomes and new treatments to improve manage-
ment of azoospermic patients. Nowadays, the use non-ejaculated spermatozoa
in ICSI when severe male factor is present is still a concern. It is widely discussed
whether different degrees of DNA fragmentation or maturation status of
spermatozoa from non-ejaculate sources impair ICSI outcomes, affecting to fer-
tilization and embryo development. Published studies regarding this issue often
consider limited sample size or they do not include donor and/or ejaculates of
different qualities.
Study design, size, duration: Retrospective cohort study held in HUiP La Fe
(Spain) from April 2010 to April 2017. In total, 2638 ICSI cycles followed by
double fresh embryotransferences of cleavaged embryos were included. Study
groups considered, established according to semen origin and diagnostic. Post-
vasectomy controls and patients currently reporting active sexual transmitted
diseases were excluded. Normal fertilization rate, embryo quality, biochemical
pregnancy, miscarriage rate and live births were reproductive variables con-
sidered to be compared among study groups.
Participants/materials, setting, methods: Study groups comprised tes-
ticular/epididymal spermatozoa (T:183 cycles), fresh cryptozoospermic (C:510
cycles) and normozoospermic (N:1563 cycles) ejaculates and donor sperm
(D:382 cycles) as control group. ANCOVA and Chi-square tests were per-
formed to establish the impact of spermatozoa origin and quality on reproduct-
ive variables. Moreover, spermatozoa origin and quality were studied together
with female age by logistic regressions and ordinal logistic regressions to dem-
onstrate the impact of both effects on the reproductive outcome. P-
values<0.05 were considered signiﬁcant.
Main results and the role of chance: No differences regarding number of
oocytes retrieved or MII oocytes were reported but it was observed, as
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expected, differences in sperm count and progressive motility in fresh and pre-
pared sperm among the groups. Fertilization rate (FR) of testicular/epididymal
spermatozoa (66.49 ± 1.58) was the lowest (p < 0.01) in comparison with
cryptozoospermic patients (71.05 ± 0.94), normozoospermic males (77.89 ±
0.53) and donors (77.67 ± 1.23). However, testicular/epididymal spermatozoa
presented the highest pregnancy rate (PR) (T: 56.29%; C:37.2%; N:36.10;
D:39.84; p = 0.029). In addition, testicular/epididymal spermatozoa presented
the lowest miscarriage rate (MR) although differences did not reach statistical
signiﬁcance (T: 12.94%; C:18.82%; N:19.96; D:18.37; p = 0.493). No differ-
ences were found neither in the quality of embryos transferred (QET), live birth
rate (LBR) nor percentage of singletons/multiplets deliveries. Outcomes
regarding the impact of female age considered together with spermatozoa ori-
gin conﬁrmed that (QET), MR and LBR are inﬂuenced by maternal age (p =
0.01, p < 0.01 and p = 0.04) but not by the spermatozoa’s origin (p > 0.05 in
all cases). It is also revealed that FR was only inﬂuenced by spermatozoa origin
(p < 0.01), not by female age (p = 0.147). Furthermore, PR is not only strongly
inﬂuenced by female age (p < 0.01) but also it is still observed that spermatozoa
origin tends to have an impact on achieving pregnancy (p = 0.08).
Limitations, reasons for caution: Even though only transferences of
embryos at the same development stage were considered to prevent biased
conclusions, further studies could consider a cohort of transferences in other
embryo development stages as blastocysts. Also the current study does not dis-
tinguish about the cause of azoospermia (obstructive or no obstructive).
Wider implications of the ﬁndings: Outcomes derived from this large ser-
ies study are a valuable aid to azoospermic patient counseling. It demonstrates
that the use of non-ejaculated spermatozoa has similar or better likelihood of
success that the use of donor sperm, offering a treatment option for those
azoospermic patients who desire biological offspring.
Trial registration number: This study is not a clinical trial.
P-050 Myoinositol is a good freezing supplement to improve
human semen parameters and DNA fragmentation
A. Vatannejad1,2, N. Varanlou3, F. Mohamadi4, M. Haghighi4,
F. Amjadi4,5, R. Aﬂatoonian6, Z. Zandieh4.5
1Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and
Dietetics, Tehran University of Medical Sciences
2Department of Biochemistry, School of Medicine, Tehran- University of Medical
Science Tehran Iran
3Department of basic sciences, Tehran Central Branch of Islamic Azad University,
Tehran, Iran
4Anatomy Department, School of Medicine, Iran University of Medical Science
5Akbarabadi IVF clinic, Akbarabadi Hospital, Iran University of Medical Science
6Department of Endocrinology and Female Infertility at Reproductive Biomedicine
Research Center, Royan Institute for Reproductive Biomedicine, ACECR
Study question: What is the effect of myoinositol as a supplement on sperm
parameters, DNA fragmentation, total antioxidant capacity, the level of malon-
dialdehyde and reactive oxygen species in human sperm freezing process?
Summary answer: Myoinosito improves sperm motility, morphology, Total
antioxidant capacity and decreases DNA fragmentation and the level of malon-
dealdehyde (MDA).
What is known already: sperm freezing has detrimental effects on sperm
parameters, like motility, morphology, ROS level and sperm DNA. Myoinositol
belongs to the vitamin B complex group and has many phisiological function. It
plays a role in the regulation of calcium intracellular concentration, reproductive
disorders and improve the mitochondrial function.
Study design, size, duration: 40 Fresh semen samples were obtained from
normospermic men. All the samples after primary analysis, were immediately
freezed in two groups, group 1: myoinositol (2 mg per ml) + freezing medium
(Fertipro), group 2: freezing medium. After one month, all samples were
thawed and assessed.
Participants/materials, setting, methods: semen parameters in two
groups were analyzed by CASA for motility and morphology and live ratio.
Also, the level of total ROS, TAC, DNA fragmentation and MDA were evalu-
ated by DCFH(by Fluorimetry), ELISA kit, TUNEL assay by ﬂow cytometry and
ELISA respectively.
Main results and the role of chance: Our data clearly showed that total
motility, morphology and live ratio were higher in myoinositol group. Also,
DNA fragmentation is notably lower in myoinositol than control(20.72 vs
15.28, p = 0.001). TAC is higher (p < 0.0001) and MDA is lower (p = 0.007)
signiﬁcantly in myoinositol than normal.The level of ROS was decreased in
myoinositol group but not signiﬁcant (p = 0.1).
Limitations, reasons for caution: It is better to use this supplement on
freezing process of oligoastenotratospermic (OAT) patients.
Wider implications of the ﬁndings: It seems that the effect of myoinositol
on mitochondria and other parts of the sperm, improve semen parameters
after thawing. So, myoinositol protect normal sperm from detrimental effect of
freezing. This study showed the effective role of myoinositol for the ﬁrst time in
human sperm parameters during freezing process.
Trial registration number:NA.
P-051 Improving effectiveness of a human sperm cryopreservation
program for Assisted Reproduction by testing the effect of different
cryoprotectants and freezing protocols on the post-thawing
outcomes
J. Romero1, A. Palomar1, G. Aida1, J.V. Martinez1, S. Balasch2,
I. Molina1
1Hospital Universitari i Politecnic La Fe, Assisted Reproduction Unit, Valencia, Spain
2Universitat Politecnica de Valencia, Departamento de Estadística e Investigación
Operativa Aplicadas y Calidad, Valencia, Spain
Study question: Evaluate thawing outcomes of two different commercial
cryoprotectants, testing its mode of use in combination with each different
freezing protocol, in a sperm cryopreservation program.
Summary answer: Liquid nitrogen vapors freezing achieves more viable
spermatozoa than slow freezing. Moreover, the effectiveness of a cryoprotect-
ant can be increased by varying its addition method.
What is known already: Sperm freezing is the only method implemented
nowadays in clinical practice to preserve male fertility. In this scenario, it is para-
mount to achieve the best semen quality after thawing since sample’s availability is
limited. Cryoprotectants are needed during the freezing process. However, at
high concentrations, they are toxic. To minimize its toxicity, addition and removal
methods are important. The most common extender of cryoprotectants is egg
yolk. However, it derives from animal origin. Hence, it could be a potential source
of infectious animal diseases. Therefore, more research is needed to ﬁnd new
animal-free extenders that contribute to standardize sperm freezing.
Study design, size, duration: Prospective cohort study held in Hospital La
Fe (Spain) from June to November 2017. In total, 29 normozoospermic males
were considered. Sperm count (SC), progressive (PM) and total sperm motility
(TM) were evaluated using a CASA system. Aliquots from the same sample
were used to test each freezing protocol performed (liquid nitrogen vapors, LN
and slow freezing, SF) using both cryoprotectants (Test Yolk Buffer, TYB and a
commercial cryoprotectant with animal-free extenders, AFE).
Participants/materials, setting, methods: Firstly, 13 samples were mixed
with AFE following provider’s recommendations (ratio cryoprotectant:sample
2:1). In last 16 samples, another addition procedure, consisting on diminishing
the ratio to 1:1, was tested for AFE. In both cases TYB was mixed volume to
volume. Each mix was loaded in two 0.5 ml straws, one used for SF, and the
other used for LN. T-tests of dependent and independent samples were per-
formed to compare cryopreservation outcomes. P-values<0.05 were con-
sidered signiﬁcant.
Main results and the role of chance: LN leads to a higher number of viable
spermatozoa than SF when TYB is used (15.14 ± 4.37 vs 9.24 ± 3.39, p-value
= 0.066) while it is equally effective as SF when AFE is used (1.48 ± 0.82 vs
2.39 ± 3.77, p-value = 0.211). Considering the ﬁrst sample set, use of AFE is
associated with a decreased total motile sperm count (TMSC) when compared
with TYB in both freezing protocols (LN: 1.48 ± 0.82 vs 15.14 ± 4.37, p-value
= 0.003; SF: 2.39 ± 3.77 vs 9.24 ± 3.39, p-value = 0.016), worsening cryo-
preservation outcomes. However, a tendency of increased TMSC is observed
in LN freezing when the mix ratio of AFE is diminished in the second sample set
compared with the ratio used for AFE in the ﬁrst sample set (3.49 ± 1.92 vs
1.48 ± 0.82, p-value = 0.084). Moreover, another comparison considering the
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second sample set in which the mix ratio had been changed was performed.
Interestingly, no signiﬁcant differences were found when comparing the use of
AFE and TYB in LN freezing (p-value = 0.294).
Limitations, reasons for caution: The current study prevents biased con-
clusions since it uses aliquots from the same sample to test freezing protocols
and both cryoprotectants. However, in further studies the sample size should
be increased and other patients apart from normozoospermic males should be
included to validate the results.
Wider implications of the ﬁndings: LN freezing leads to sperm cryo-
preservation program’s optimization due to its equal effectiveness and reduced
operation costs. Moreover, if AFE is going to be used as animal-free extender
cryoprotectant, diminishing the volume of AFE is recommended since out-
comes are improved, so similar results as those associated to TYB are reached.
Trial registration number: This study is not a clinical trial.
P-052 Human SpermAminopeptidase N is related to embryo
development and viability during ART
M. Gianzo1, I. Urizar-Arenaza1, I. Muñoa-Hoyos1, Z. Larreategui2,
J. Irazusta1, N. Subirán1
1University of Basque Country, Department of Physiology, Leioa, Spain
2IVI Bilbao, IVF Laboratory, Bilbao- Leioa-, Spain
Study question: to investigate the association between the levels of amino-
peptidase N (APN) present in human spermatozoa with embryo development
and viability.
Summary answer: Semen samples with less number of Aminopeptidase N
molecules per spermatozoon are related to higher-quality early-embryos, more
evolved blastocysts and blastocyst viability during IVF procedures.
What is known already: 20%-30% of men with normal seminal-parameters
have impaired fertility ability and inability to achieve pregnancy, suggesting that
male infertility can be caused by different deﬁciencies not yet described. One of
the major predictors of ART success is embryo quality, and abnormal embryos
have been linked to poor sperm quality. Sperm molecular features, such as pro-
teins, are involved in fertilization and embryo development. Aminopeptidase N
can be a relevant biomarker due to its high concentration in spermatozoa and
its role in human sperm motility, mussel acrosome reaction and several seminal
pathologies. However, its role in embryo development is not completely
understood.
Study design, size, duration: This prospective cohorts study was conducted
February 2014 to July 2015. Normal and/or pathologic semen samples of cou-
ples undergoing oocytes donation cycles, at Clínica IVI Bilbao, were used to
determine the APN levels in human spermatozoa and to analyze the association
between the APN and human embryo development and viability.
Participants/materials, setting, methods: A total of 81 human semen
samples and 611 embryos were examined. Sperm samples and embryo quality
were examined following WHO and “Asociación Española para el Estudio de la
Biología de la Reproducción” (ASEBIR) guidelines, respectively. APN levels
were measured by semi-quantitative and quantitative ﬂow cytometry assays, in
the same processed sperm sample used for the in vitro techniques. Statistics:
Spearman´s rank correlation, Kruskal-Wallis and Mann-Whitney U-test.
Main results and the role of chance: Sperm samples with higher percen-
tages of APN-positive spermatozoa and lower levels of this enzyme per sperm-
atozoon correlate to sperm samples with better motility. In regard to embryo
quality, embryos with higher implantation potential came from semen samples
with less APN molecules per spermatozoon in early human embryos, at day 2
and 3 of development. Similarly, in the later phase of in vitro development, blasto-
cyst with higher implantation potential, such as fully expanded and hatching
blastocyst, also came from semen samples with less APN molecules per sperm-
atozoon. Furthermore, concerning embryo viability at day 5 and 6 of develop-
ment, we observed similar results, viable human blastocysts came from semen
samples with less number of APN molecules per spermatozoa than non viable
blastocysts.
Limitations, reasons for caution:Duration of the study.
Wider implications of the ﬁndings: APN levels can provide very valuable
information for semen sample quality and embryo development in humans. In
conclusion, the sperm APN could be a potential sperm biomarker to orient
embryologist for embryo selection in IVF procedures in order to obtain a future
embryos with higher implantation potential.
Trial registration number: CEISH/61/2011.
P-053 The impact of sperm chromatin condensation and ploidy on
IVF/ICSI outcome
L. Lazaros1,2, E. Hatzi1, S. Markoula3, C. Kitsou1, K. Zikopoulos1,
G. Vartholomatos4, E. Kanavakis2, I. Georgiou1
1University of Ioannina, Medical School- Department of Obstetrics and Gynecology-
Genetics and IVF Unit, Ioannina, Greece
2Genesis Genoma Lab, Genetic Diagnosis-Clinical Genetics-Research, Athens, Greece
3University of Ioannina, Medical School- Department of Neurology, Ioannina, Greece
4Ioannina University Hospital, Laboratory of Hematology- Molecular Biology Unit,
Ioannina, Greece
Study question: To explore whether sperm chromatin condensation and
ploidy affect the in vitro fertilization (IVF) and intracytoplasmic sperm injection
(ICSI) outcome.
Summary answer: Our data show that sperm nuclear chromatin condensa-
tion and ploidy constitute critical parameters for a successful IVF/ICSI outcome.
What is known already: Fifteen per cent of the couples worldwide face
infertility problems, while half of them are affected by male factor infertility. The
development of medically assisted reproduction technology has allowed infer-
tile couples to achieve a pregnancy. Sperm morphology, concentration and
motility are taken into account for the selection of the appropriate assisted
reproduction procedure. However, noteworthy percentages of IVF/ICSI cycles
remain unsuccessful, suggesting the need of additional parameters for the evalu-
ation of sperm quality, such as sperm nuclear chromatin condensation and ploi-
dy. Sperm ﬂow cytometry (SFC) has been suggested as a reliable method for
the evaluation of these parameters.
Study design, size, duration: The study population was consisted of 280
couples that referred to the Ioannina University Medical School IVF Unit for IVF
or ICSI due to male factor infertility. Men with karyotype abnormalities, Y
microdeletions, hypogonadotropic hypogonadism and seminal tract disorders
were excluded from the study. Furthermore, women suffering from endometri-
osis, polycystic ovary syndrome, ovulatory disorders and reproductive organ
malformations were also excluded so as to analyze the real impact of male fac-
tor infertility on IVF/ICSI outcome.
Participants/materials, setting, methods: Semen analysis was performed
according to World Health Organization guidelines. SFC after Acridine Orange
and Propidium Iodide stainings was used to study the chromatin condensation
and the ploidy of human spermatozoa, respectively. For the ovarian stimulation,
a standard GnRH-antagonist protocol was used. IVF was performed in 130 cou-
ples and ICSI in 150 couples. The fertilization rate, the embryo quality and the
clinical pregnancy rate per cycle begun were the IVF/ICSI outcome measures.
Main results and the role of chance: SFC analysis revealed that 70 ±
20.3% of the spermatozoa in the IVF group and 61.3 ± 19.9% of the spermato-
zoa in the ICSI group had fully condensed chromatin (FCC). Furthermore, 16.3
± 12.2% of the spermatozoa in the IVF group and 18.5 ± 16.7% of the sperm-
atozoa in the ICSI group were aneuploid.
In the IVF group, couples with FCC≥70% presented higher fertilization (p =
0.006) and clinical pregnancy (p = 0.019) rates compared to couples with FCC
< 70%. Furthermore, they were characterized by higher grade A (p = 0.008)
and lower grade C (p = 0.004) embryo rates. As concerns the ICSI group, cou-
ples with FCC≥61.3% were characterized by higher fertilization (p = 0.01) and
clinical pregnancy (p = 0.008) rates compared to couples with FCC < 61.3%.
Additionally, they presented higher grade A (p = 0.009) and lower grade C
(p = 0.03) embryo rates.
In the IVF group, couples with aneuploidy rate<16.3% presented higher fer-
tilization (p = 0.008) and clinical pregnancy (p = 0.017) rates compared to cou-
ples with aneuploidy rate≥16.3%. Moreover, they were characterized by higher
grade A (p = 0.01) and lower grade C (p = 0.005) embryo rates. Regarding the
ICSI group, couples with aneuploidy rate<18.5% showed higher fertilization
(p = 0.01) and clinical pregnancy (p = 0.02) rates compared to couples with
aneuploidy rate≥18.5%. Finally, they were characterized by higher grade A
(p = 0.01) and lower grade C (p = 0.03) embryo rates.
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Limitations, reasons for caution: Our ﬁndings were based on 280 couples
undergoing IVF or ICSI due to male factor infertility. Larger population and mul-
ticenter studies are needed to verify our preliminary results.
Wider implications of the ﬁndings: SFC analysis could provide a better
screening of the male partner’s clinical condition leading to a more appropriate
treatment. The combination of SFC with sperm selection methods could help in
the fractionation/isolation of spermatozoa with normal genetic constitution,
fully condensed chromatin and elevated pregnancy potential post-ICSI from
defective semen samples.
Trial registration number:N/A.
P-054 Metabolomics proﬁles of the seminal plasma in samples
collected following long (4-5 days) and short (2 hours) sexual
abstinence periods
H. Alipour1, F. Dardmeh1, R.K. Duus1, R.Wimmer2, S.S. Du Plessis3,
N. Jørgensen4, O.B. Christiansen5, C. Hnida5, H.I. Nielsen1,
M. Afshani6, G. Van Der Horst7
1Aalborg University, Faculty of Medicine- Department of health science and
technology, Aalborg, Denmark
2Aalborg University, Department of Chemistry and Bioscience, Aalborg, Denmark
3Stellenbosch University, Division of Medical Physiology- Faculty of Medicine and
Health Sciences, Tygerberg, South Africa
4Rigshospitalet, University Department of Growth and Reproduction and International
Center for Research and Research Training in Endocrine Disruption of Male
Reproduction and Child Health EDMaRC-, Copenhagen, Denmark
5Aalborg University Hospital, Dept. of Obstetrics and Gynecology- Fertility unit,
Aalborg, Denmark
6Eastern Mediterranean University, Faculty of Medicine, Famagusta- North Cyprus,
Turkey
7University of the Western Cape, Department of Medical Biosciences, Capetown,
South Africa
Study question: Is there a within-subject variation in Seminal plasma metabo-
lomics proﬁles following long (4-5 days) and short (2 hours) sexual abstinence
periods?
Summary answer: Short ejaculation abstinence was associated with lower
amounts of all detected seminal plasma metabolites, except for pyruvate and
taurine.
What is known already: The metabolome is a dynamic environment and
can be inﬂuenced by genetic or environmental cues. Metabolomic proﬁling of
seminal plasma has been suggested as a possible approach for a fast and non-
invasive diagnosis in the evaluation of male infertility, but the metabolomics pro-
ﬁles in normozoospermic men have not been thoroughly investigated. The
different sperm motility characteristics in samples collected following long and
short abstinence periods have been previously documented but the possible
change of seminal metabolomic proﬁles following different abstinence periods
has not been studied.
Study design, size, duration: Repeated measures study based on seminal
plasma from 31 normozoospermic men who delivered a semen sample after 4-
7 days of abstinence, followed by a second sample 2 hours later. The study was
conducted during 2015–2017.
Participants/materials, setting, methods: Participants included normo-
zoospermic male partners of couples attending IVF treatment at the Fertility
Unit of Aalborg University Hospital (Aalborg, Denmark). All semen samples
were assessed for concentration, total counts and motility characteristics by
using the SCA® (Microptic S.L., Barcelona, Spain) computer aided sperm ana-
lysis system. Metabolite proﬁles of the seminal plasma were determined using
untargeted Nuclear Magnetic Resonance Spectroscopy by a Bruker AVIII-600
NMR spectrometer (Bruker Biospin, Germany and Switzerland).
Main results and the role of chance: 30 metabolites were identiﬁed in the
ejaculates. Among these, the concentration of pyruvate was higher in samples
collected after a two hours abstinence (vs. 4-7 days), and the concentrations of
fructose, acetate, choline, methanol, N-acetylglucosamine, O-acetylcarnitine,
uridine and sn-glycero-3-phosphocoline were lower. There was no difference
for the remaining 21 metabolites. Sperm concentration was also lower in sam-
ples obtained after the short abstinence period. Consequently, the absolute
amounts of pyruvate and taurine per spermatozoa were higher in samples
obtained after the short abstinence (P < 0.001 and P < 0.05 respectively).
Limitations, reasons for caution: The possible physiological explanations
for the ﬁndings cannot be determined by the study, and furthermore we do not
know if the metabolomics patterns we detected are different from those of
men with oligozoospermia. The effect of sperm metabolism after ejaculation
and during liquefaction could not be determined in this study.
Wider implications of the ﬁndings: The concomitant increase in percen-
tages of motile spermatozoa and pyruvate and taurine per spermatozoa might
indicate that these two metabolites are beneﬁcial for sperm motility, which
should be further investigated in future studies.
Trial registration number: -
P-055 Varicocelectomy in patients with elevated serum FSH:
correlation between changes in semen parameters and serum FSH
T. Sho1, S. Nariyoshi1, K. Nakano2, G. Sukegawa2, Y. Tsuji1
1Tenjin Tsuji Clinic, Urology, Fukuoka, Japan
2Ebisu Tsuji Clinic, Urology, Shibuya, Japan
Study question: Can varicocele repair improve semen quality and decrease
serum FSH levels in infertile patients with elevated serum FSH and varicocele?
Summary answer: Even in patients with elevated serum FSH, varicocele
repair can signiﬁcantly improve semen parameters with a substantial decrease
in serum FSH.
What is known already: Varicocele is present in approximately 35% of infer-
tile men and in 81% of those with secondary infertility. Most previous studies
have demonstrated that varicocele repair is associated with a signiﬁcant
improvement in semen parameters as well as spontaneous pregnancy rates.
Furthermore, the beneﬁts of varicocelectomy have been reported even among
patients with non-obstructive azoospermia or hypogonadism. However, the
role of varicocelectomy in patients with severe spermatogenic failure and hor-
monal abnormalities, including those with an elevated serum FSH level, is still
under debate.
Study design, size, duration: We retrospectively reviewed the records of
2,368 consecutive patients who underwent varicocelectomy for subfertility at
our clinics from July 2003 to September 2017.
Participants/materials, setting, methods: Multiple semen analyses were
performed before and after varicocelectomy. The total motile sperm count per
ejaculate was calculated as semen volume x sperm concentration x percent
motility divided by 100. We deﬁned a greater than 50% increase in the total
motile sperm count per ejaculate at three months after surgery as a signiﬁcant
improvement.
Microsurgical subinguinal varicocelectomy was performed under local
anesthesia.
Main results and the role of chance: The serum FSH level was greater
than 10 mIU/mL in 282 patients. After we excluded 43 patients with azoosper-
mia, 5 patients with prior endocrine therapy and 27 patients who were lost to
follow-up, 207 patients were included in this study. After surgery, 135 of these
patients (65.2%) experienced a signiﬁcant improvement of semen parameters.
Preoperative serum FSH levels were not signiﬁcantly different between the
improved patients (14.0 ± 4.3 mIU/mL) and not-improved patients (15.6 ±
5.9 mIU/mL). Serum FSH was measured in 34 improved patients and 15 not-
improved patients after surgery. The decrease in the serum FSH level in the
improved patients (1.8 ± 2.6 mIU/mL) was signiﬁcantly greater than that in the
not-improved patients (−0.6 ± 3.2 mIU/mL).
These data indicate that varicocelectomy in patients with elevated serum
FSH levels and varicocele improves semen quality associated with a decrease in
the serum FSH level.
Limitations, reasons for caution: Because we measured serum FSH only in
selected patients after surgery, further studies with more patients will be
needed to avoid being misled by changes in serum FSH levels induced by varico-
cele repair.
Wider implications of the ﬁndings: In patients with non-obstructive azoo-
spermia, changes in the serum FSH level after varicocele repair may predict the
outcome of microdissection TESE.
Trial registration number:Not applicable.
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P-056 Delayed and impaired development in early mouse embryo
was induced by sperm DNA damage
M. Kobayashi1, A. Yoshida2
1Kiba Park Clinic, Research Center, Tokyo, Japan
2Kiba Park Clinic, Reproductive Medicine, Tokyo, Japan
Study question: Does sperm DNA damage affect to developmental ability
and developmental events such as pronuclear formation, DNA replication, and
cleavage?
Summary answer: DNA damage in spermatozoa induced slowing DNA rep-
lication at the pronuclear stage and delayed time points of early developmental
events.
What is known already: Some studies have indicated that DNA damage in
mammalian spermatozoa could induce some developmental defects such as
low fertilization rates, poor embryo quality, and developmental arrest. Further,
it is suggested that spontaneous miscarriage and childhood disease may be
related to sperm DNA damage. However, the mechanisms of these defects on
embryos with damaged sperm DNA have not yet been cleared.
Study design, size, duration: Spermatozoa obtained from C57BL/6 J mouse
were exposed to 1mM H2O2 for 30min to induce DNA damage (oxidatively
damaged spermatozoa: ODS), and embryos were produced by ICSI with ODS and
normal spermatozoa (control) (n = 70-80 embryos/group). The timing of develop-
mental events (pronuclear formation, DNA replication, syngamy, and cleavage) and
the developmental ability were compared between ODS and control groups.
Participants/materials, setting, methods: Time-lapse monitoring has
been used to examine the developmental events of each embryo. After 4.5-
6.0 hr from ICSI, DNA replication in pronuclei was estimated by using the
DNA replication assay kit with EdU. Further, DNA damages in male pronucleus
and nuclei in developing embryos were detected by immunohistochemical
staining with gamma-H2AX antibody.
Main results and the role of chance: There was no signiﬁcantly difference
in the rate of male and female pronuclear formation between ODS and control
groups. However, DNA replication assay at 5.5 hr after ICSI revealed that the
rate of EdU-positive pronuclei in ODS embryos was signiﬁcantly lower than
that of control (58.8% vs 81.3%, p < 0.05). The time-lapse analysis revealed
that the average time points of syngamy, 1st cleavage, and 3rd cleavage of ODS
embryos were delayed remarkably compared with control (16.9 hr vs 14.7 hr,
20.1 hr vs 17.0 hr, 43.5 hr vs 40.1 hr, respectively, p < 0.01). By immunohistch-
emical staining, male pronucleus and nuclei in embryos with ODS were positive
for gamma-H2AX, and extranuclear DNA fragments were frequently observed
in ODS embryos. In addition, the blastocyst rate of ODS embryos was signiﬁ-
cantly lower than control (15.4% vs 76.7%, p < 0.05).
Limitations, reasons for caution: This study was conducted using a mouse
model with artiﬁcially induced DNA damage by exposing to H2O2. This ﬁnding
does not directly represent human reproductive medicine.
Wider implications of the ﬁndings: This study shows clearly that sperm
DNA damage induced the delay of developmental events and impaired the
developmental ability. Also, our results suggest that damage on sperm DNA
persists during early development. Therefore, this study may provide novel
insights for understanding the relationship between sperm DNA damage and
embryonic development.
Trial registration number:Not applicable.
P-057 Effect of varicocelectomy on oxidation reduction potential
in varicocele associated male infertility
H. Elbardisi1, A. Majzoub1, S. AlSaid1, A. Agarwal2, R. Henkel3,
H. Shehadeh1, K. Alrumaihi1, M. Arafa1
1Hamad Medical Corporation, Urology, Doha, Qatar
2Cleveland clinic, Urology, Ohaio, U.S.A.
3University of the Western Cape, Medical Bioscience, Bellville, South Africa
Study question: Does varicocelectomy improve Oxidation Reduction Potential
(ORP) as an independent measure of oxidative stress (OS) in infertile men?
Summary answer: Elevated oxidative stress is related with poor semen qual-
ity in men with varicocele. Varicocele surgery reduces the ORP levels and
improves sperm count.
What is known already: Patients with varicocele tend to have poor sperm
quality and are at higher risk of being infertile. Although the pathophysiology of
infertility in males with varicocele has been extensively studied, the underlying
mechanism remains unclear. Many reports have shown that oxidative stress is
one of the underlying mechanisms of poor semen quality in infertile men with
varicocele. ORP has been validated as a diagnostic marker of poor semen qual-
ity and oxidative stress in men with infertility.
Study design, size, duration: Prospective, case control study of 43 infertile
patients with clinical grade 2-3 varicocele attending a male infertility clinic during
January to November 2017.
Participants/materials, setting, methods: All patients underwent micro-
surgical subinguinal varicocelectomy. Full medical history and clinical examin-
ation was collected. Semen samples were done using WHO Fifth edition
criteria and ORP levels were measured by MiOXSYS analyzer before surgery
and 3 months post-varicocelectomy. The results were compared by Wilcoxon
rank sum test and Spearman’s correlation test and a P value < 0.05 was con-
sidered signiﬁcant.
Main results and the role of chance: Table 1 compares results of semen
parameters and ORP values before and 3 months after the surgery (n = 43). All
semen parameters (concentration, total motility and normal sperm form)
showed an improvement post- surgery but it was not statistically signiﬁcant.
However, the ORP level was signiﬁcantly reduced after the surgery (10.4 ± 3.3
vs. 4.6 ± 1.1, p value <0.001). Table 2 shows the correlation between semen
parameters and ORP before and after surgery. All semen parameters (concen-
tration, total motility and normal form) were negatively correlated with ORP
pre-operatively. However, only sperm count maintained this signiﬁcant negative
correlation post operatively.
Table 1
Before Surgery After Surgery P value
Sperm Count 25.2 +/− 3.4 29.9 +/− 3.1 0.029
Total Motility 44.8 +/− 3.1 46.1 +/− 2.3 0.645
Progressive Motility 9.3 +/− 1.6 10.3 +/− 1.6 0.64
Normal forms 5.5 +/− 1.6 3.6 +/− 0.4 0.893
sORP 10.4 +/− 3.3 4.6 +/− 1.1 <0.001
Wilcoxon Rank test
Table II
Before Surgery After Surgery
Sperm Count −0.871** −0.827**
Total motility −0.359** −0.288
Progressive motility −0.461** −0.155
Normal forms −0.526** −0.332*
Spearman’s correlation
*p < 0.05
**p < 0.01
Limitations, reasons for caution: The small sample size of this study may
be a limitation. However, we report on a pilot study describing the effect of var-
icocelectomy on oxidative stress measures using the ORP system.
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Wider implications of the ﬁndings: ORP can be used as a prognostic fac-
tor for counselling patients before varicocelectomy.
Trial registration number:Non.
P-058 Oxidation reduction potential is correlated to
spermatogenic testicular function in infertile men
M. Arafa1, A. Majzoub2, A. Agarwal3, R. Henkel4, J. Eliwa5,
S. AlSaid2, A. AlAnsari1, H. Elbardisi1
1Hamad Medical Corporation, Urology/Surgery, Doha, Qatar
2Hamad General Corporation, Urology, Doha, Qatar
3Cleveland Clinic, American Center for Reproductive Medicine, Cleveland, U.S.A.
4University of the Western Cape, Department of Medical Bioscience, Bellville, South
Africa
5University of Kuwait, Faculty of Medicine, Kuwait, Kuwait
Study question: Is oxidative stress a clinical indicator for testicular function in
infertile men?
Summary answer: Oxidative stress measured by oxidation reduction poten-
tial (ORP) can be considered a clinical indicator of spermatogenic and not endo-
crine function of the testis.
What is known already:Oxidative stress plays a major role in the pathogen-
esis of male infertility. ORP is a new marker of oxidative stress that has been
shown to correlate inversely with important semen parameters in infertile men.
ORP levels can be used to discriminate normal fertile men from infertile males.
Besides semen parameters, testicular size and FSH are considered as prognostic
markers of spermatogenesis.
Study design, size, duration: Cross sectional, retrospective study on 660
patients attending a male infertility clinic during January to March 2017.
Participants/materials, setting, methods: Medical records of recruited
patients were reviewed. The data extracted included medical history, clinical
examination, semen analysis (WHO 5th edition), ORP (using MiOXSYS sys-
tem), hormonal assay including FSH, LH, prolactin, testosterone and estradiol
as well as testicular size assessment by scrotal ultrasound. After checking for
normal distribution of the data by the Chi-squared test, Spearman rank test was
used to detect correlations between different parameters. Statistical signiﬁcance
was deﬁned as p < 0.05.
Main results and the role of chance: ORP showed negative correlation
with sperm count (r = -0.793, P < 0.0001), motile sperm count (r = -0.579; P
< 0.0001), progressive motility (r = -0.431; P < 0.0001) and normal sperm
morphology (r = -0.458; P < 0.0001). ORP also correlated with sperm DNA
fragmentation (r = 0.264, P < 0.0001) (Table 1).
ORP levels showed signiﬁcant correlation with the testicular size (r = -0.386;
P < 0.0001), serum FSH (r = 0.273; P < 0.0001) and serum LH concentrations
(r = 0.182; P = 0.0002), but not with testosterone, estradiol and prolactin.
Limitations, reasons for caution: The main limitation is the lack of fertile
controls in this study.
Wider implications of the ﬁndings: ORP can be used as a marker of
spermatogenesis in infertile men. Further studies should be carried out to dem-
onstrate the effect of treating OS on spermatogenesis. Since varicocele patients
show seminal oxidative stress, smaller testes and higher FSH values, ORP could
possibly be used as adjunct indicator of varicocele.
Trial registration number:None.
P-059 Integrity of human spermDNA assessed by the neutral
comet assay and its relationship to oxidative stress and poor
spermatic morphology
A. Oumaima, Z. Ines, A. Tesnim, H.A. Assila, A. Hana, J. Ali,
H. Zohra, M. Meriem
Laboratory of Histology Embryology and Cytogenetic UR 12 ES 10- Faculty of
Medicine University of Monastir- Street Avicenne- Monastir 5019- Tunisia.,
Department of Histology Embryology and Cytogenetic, Monastir, Tunisia
Study question: The current study aimed to determine the extent of sperm
nuclear DNA damage in patients with isolated teratozoospermia and to exam-
ine its relationship with oxidative stress.
Summary answer: Our results may explain the complex biological relation-
ship between teratozoospermia, oxidative stress, and DNA damage.
What is known already: The physiopathology of the morphological abnor-
malities of the spermatozoa has not been completely understood. In the pre-
sent study, we found an impaired seminal antioxidant status and an increased
seminal level of both Lipid peroxidation and Iron can affect sperm nuclear integ-
rity resulting in DNA Breaks and can be associated with poor sperm
morphology.
Study design, size, duration: Semen samples from 60 patients with isolated
teratozoospermia and 30 normozoospermic donors were examined. DNA
damage was evaluated by Comet assay. Seminal antioxidant activities
(Superoxide dismutase; Glutathione peroxidase; Catalase), Iron and malondial-
dehyde concentrations were measured spectrophotometrically.
Participants/materials, setting, methods:Methods and endpoints used:
patients: 60 patients with isolated teratozoospermia and 30 normozoosper-
mic donors,
Methods: Comet assay, spectrophotometer, chemicals reagents.
Main results and the role of chance: Sperm DNA damage; malondialde-
hyde and Iron levels were more elevated in study groups than control groups.
Nevertheless, the antioxidant enzymes activity was signiﬁcantly lower in the
group of patients with teratozoospermia compared to the controls. Sperm
DNA damage was positively correlated to malondialdehyde and seminal Iron
level, While reduced seminal antioxidant status was negatively associated with
sperm DNA Breaks. Interestingly, we noted that sperm DNA damage; lipid
peroxidation, Iron level, and impaired antioxidant status were negatively corre-
lated to normal sperm morphology.
Limitations, reasons for caution: only in vitro study.
Wider implications of the ﬁndings: This work was supported by funds
allocated to the Research Unit of Histology and Genetic UR12ES10 by the
Ministère Tunisien de l’Enseingement Supérieur et de la Recherché Scientiﬁque.
Trial registration number: not applicable.
P-060 Alterations in disease activity and fertility potential in men
with rheumatoid arthritis by yoga based lifestyle intervention
S. Gautam1, U. Kumar2, S. Chandna1, D. Kumar1, R. Dada1
1All India Institute of Medical Sciences, Anatomy, New Delhi, India
2All India Institute of Medical Sciences, Rheumatology, New Delhi, India
Study question: Can a simple lifestyle modiﬁcation program including yoga
bring about positive alterations in fertility potential and reduction in disease
activity in men with Rheumatoid arthritis?
Summary answer: Yoga based lifestyle intervention may not only reduce dis-
ease severity, minimize usage of drugs with minimum side effects especially on
sperm.
What is known already: The complex mechanism of Rheumatoid arthritis
with infertility in men involves interactions between endocrine, immune, and
reproductive systems. Association of autoimmunity with dysregulated androgen
(hypogonadism) levels may cause transient infertility in men. Furthermore,
usage of disease-modifying antirheumatic drugs (DMARDs) like cyclophospha-
mide, methotrexate, sulphasalazine etc. may result into decreased quantity and
quality of sperm, reduced fertility potential and ultimately permanent infertility.
These drugs can cross blood-testis-barrier and induce changes in sperm impair-
ing spermatogenesis. Complementary and alternative medicine like yoga
reduces seminal oxidative stress and its consequences like DNA fragmentation
in sperm nuclear/mitochondrial genome.
Study design, size, duration: Seventy ﬁve males with RA were enrolled in
this 12-week prospective, open-label, single-arm exploratory study, designed to
explore the impact of yoga based lifestyle intervention (YBLI) on disease activity
and fertility potential in men with Rheumatoid arthritis.
Participants/materials, setting, methods: The participants were evalu-
ated for pre (day 0) and post (12th week) levels of C reactive protein (CRP), IL-
6, IL-17A and soluble HLA-G for systemic inﬂammation. Sperm parameters as
per WHO 2010 guidelines and reactive oxygen species (ROS), DNA fragmen-
tation index (DFI), 8-hydroxy-2’-deoxy guanosine (8-OHdG) were estimated.
Parameters of disease activity i.e. disease activity score (DAS28-ESR) and pain
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acuity i.e. visual analogue scale (VAS) and disability quotient i.e. health assess-
ment questionnaire (HAQ) were assessed.
Main results and the role of chance: The mean levels of ROS (p <
0.05***), DFI (p < 0.05**) and 8-OH2dG (p < 0.05**) levels were signiﬁcantly
reduced after 12 weeks of yoga intervention. We observed reduction in mean
levels of CRP (p < 0.05***), IL-6 (p < 0.05**), IL-17A (p < 0.05**) and soluble
HLA-G (p < 0.05**) at 12 weeks compared to base line level (day 0). There
was reduction seen in DAS28-ESR (p < 0.05***), VAS (p < 0.05***) and HAQ
(p < 0.05***) after 12 weeks with respect to the base line levels (day 0).
Limitations, reasons for caution: Compliance of patients for Yoga based
lifestyle intervention was poor, hence we enrolled large number of patients to
achieve the desirable sample size.
Wider implications of the ﬁndings: Adoption of yoga based lifestyle inter-
vention as an integral part of our lifestyle may hold the key to reduce the dis-
ease activity, minimize dosage of DMARDs and its associated consequences
like disabilities associated with physical, mental and reproductive health.
Trial registration number:Not applicable.
P-061 Reproductive potentials of testicular versus ejaculated
sperm for intracytoplasmic sperm injection (ICSI) using sibling
oocytes for men with high sperm dna fragmentation
R. Nayak1, K. Vasanth1, N. Thondehal Math2, G. Deepanjali2,
U. Gayatri2, W.Y. Son3
1Gunasheela Surgical & Maternity Hospital, Andrology, Bangalore, India
2Gunasheela Surgical & Maternity Hospital, embryology, Bangalore, India
3McGill University Health Centre MUHC- Royal Victoria Hospital- Canada,
Embryology, Montreal, Canada
Study question: In couples with high sperm DNA fragmentation (SDF), is
reproductive potential improved with intracytoplasmic sperm injection (ICSI)
using testicular sperm (Testi-ICSI) compared to ejaculated sperm (Ejac-ICSI)?
Summary answer: ICSI with testicular sperm in couples with high SDF
seemed not to have a beneﬁcial effect on reproductive potential compared to
using ejaculated sperm.
What is known already: High SDF may have an adverse impact in repro-
ductive outcomes, reducing the fertilization rate, poor embryo development
and high miscarriages. Although testicular sperm have higher aneuploidy rates,
testicular sperm have lower levels of SDF than ejaculated ones. Therefore,
some studies have been reporting better reproductive outcomes with ICSI
using testicular sperm for men with high levels of SDF. However, these studies
were done on women-based randomization, not on oocyte-based
randomization.
Study design, size, duration: In this prospective pilot study, performed
from November 2016 to November 2017, 29 women (32.2 ± 4.4 years old)
whose male-partners (38.6 ± 4.5 years old) had high sperm DNA fragmenta-
tion (>30% DNA fragmentation index (DFI)) and unsuccessful antioxidant
treatment. This study was performed to compare reproductive potential
between Testi-ICSI (n = 158) and Ejac-ICSI (n = 169) in same patients with
persistently high SDF despite prior antioxidant treatment.
Participants/materials, setting, methods: Sperm DNA damage was
examined by Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay using ﬂow cytometric analysis. All male-partners in this study
had high sperm DNA fragmentation (> 30% DNA fragmentation index (DFI).
Male partners were produced ejaculate sperm and underwent testicular sperm
aspiration (TESA). Approximately half of mature eggs obtained per ICSI cycle
were Testi-ICSI and half with Ejac-ICSI. Fertilization, good-quality blastocyst
development and reproductive outcomes were analyzed between two groups.
Main results and the role of chance: Average seminal DFI of patients was
45.2 ± 12.7%. A total of 327 mature oocytes were injected; 158 with Testi-ICSI
and 169 with Ejac-ICSI. Fertilization rate per oocyte was 65.7 ± 20.5 % and
78.1 ± 20.7 % in Testi-ICSI and Ejac-ICSI, respectively (P < 0.01). Good-quality
blastocyst formation rates (> 4BB) per embryo were 60.2 ± 35.9 % and 65.5
± 32.4 % in Testi-ICSI and Ejac-ICSI, respectively (NS). Seventeen cycles out of
29 ICSI cycles had fresh embryo transfer (ET), twelve cycles cancelled because
of high risk of developing OHSS. In Testi-ICSI, 11 blastocysts were transferred
in 7 ET cycles resulting in 3 clinical pregnancy rate (CPR) of 42.9% and an
implantation rate (IR) of 27.3% (N = 3). It resulted in one live birth, one
ongoing and one miscarriage. In Ejac-ICSI, 10 ET cycles were performed trans-
ferring 17 blastocysts obtaining the CPR and IR of 50 % (5/10) and 35.3% (6/
17). One of the clinical pregnancies of this group resulted in an abortion. The
other 4 pregnancies had live births.
Limitations, reasons for caution: Sample size is still too low and it should
be enlarged; furthermore a high number of mature oocytes available for the
injection per patient is needed. Finally, frozen embryos have still to be trans-
ferred before drawing ﬁnal conclusions.
Wider implications of the ﬁndings: Due to variable factors between
patients, study on sibling oocytes might be the actual valid method to see useful-
ness of Testi-ICSI. Our study implies that more studies are necessary before
changing clinical practice for the couples with high SDF because of potential
known/unknown risks of using testicular sperm.
Trial registration number:Not applicable.
P-062 Effect of paternal high values of spermDNA fragmentation
on the outcomes of PGT-A programs in couples with different age
groups of female patients
I. Ushakova, A. Kirillova, J. Kiseleva, T. Kodyleva, T. Volodjaeva,
O. Golubeva, N. Mishyeva, A. Ekimov, A. Abubakirov
Federal State Budget Institution “Research Center for Obstetrics- Gynecology and
Perinatology” Ministry of Helthcare of the Russian Federation- Moscow- Russia,
Department of preservation and restoration of reproductive function- Moscow-
Russia., Moscow
Study question: Does the maternal age inﬂuence the outcomes of the PGT-A
programs with high levels of partner’s DNA fragmentation?
Summary answer: A high level of DNA fragmentation does not affect the
frequency of clinical pregnancy in women under 30 years of age in the PGT-A
programs.
What is known already: High sperm DNA fragmentation in couples under-
going assisted reproductive technologies is associated with lower live birth rate.
Sperm DNA damage has a close inverse relationship with live-birth rates
after IVF.
Study design, size, duration: Retrospective, experimental study of 126 cou-
ples, undergoing IVF treatment with the evaluation of functional semen para-
meters (concentration, motility, morphology), and sperm DNA fragmentation
from January 2016 to January 2017
Primary endpoints:
The fertilization rates groups.
The rates of blastocyst formation in groups.
The rates of clinical pregnancy in groups.
Participants/materials, setting, methods: Sperm DNA fragmentation
was evaluated using the TUNEL assay (the normal level of DNA fragmentation
is < 15%).
ICSI+PGT-A program, fertilization and embryo culture according to the
manufacturers recommendations of William A. COOK (Australia).
Array CGH (Agilent, USA) was used for 24-chromosome embryonic gen-
ome analysis.
The rates of fertilization, rates of blastocyst formation, and rates of implant-
ation were evaluated.
Main results and the role of chance: 126 women who were enrolled in the
study were distributed according to their age as followed: under 30 years old
(30 patients); 31-34 years old (35 patients); 35-40 years old (45 patients); older
than 40 years old (16 patients).
Our results showed that there are lower fertilization rates (71,1% vs. 83,4%,
p < 0.05) and signiﬁcantly lower rates of blastocyst formation (23,7% vs. 53,2%,
p < 0.05) in the group with high values of sperm DNA fragmentation in com-
parison with the group with normal values of this parameter.
Our data demonstrated that for couples with a female partner under 30
years there is no difference in the rates of clinical pregnancies between the
group with high values of paternal sperm DNA fragmentation and the group
with normal values of this parameter (63% and 63%, respectively). On the
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contrary, for couples with female partners older than 31 the rates of clinical
pregnancies were higher for groups with normal values of paternal sperm DNA
fragmentation compared to the groups with high values of this parameter: 53%
vs. 44% for women 31-34 years old; 32% vs.24% for wome 35-40 years old and
25% vs.0% for women > 40 years.
Limitations, reasons for caution: Our study didn’t include a large number
of couples, and new bigger studies with extra criteria’s of comparison are
required.
Wider implications of the ﬁndings: Our study shows that high values of
sperm DNA fragmentation do not inﬂuence the outcomes of the IVF programs
only when a female partner is younger than 30 yours old. Thus, we can specu-
late that oocytes of younger women have an ability to compensate the sperm-
atozoa damaged DNA.
Trial registration number: not applicable.
P-063 Clinical outcomes of microdissection testicular sperm
extraction (micro tese) and intracytoplasmic sperm injection (ICSI)
in non-obstructive azoospermia (NOA) with the history of
cryptorchidism
A. Ishida1, S. Mizuta1,2, H. Matsubayashi1,2, T. Takeuchi2, K. Kitaya1,
T. Ishikawa1,2
1Reproduction Clinic Osaka, Reproductive Medicine, Osaka, Japan
2Reproduction Clinic Tokyo, Reproductive Medicine, Tokyo, Japan
Study question: To assess the prevalence and signiﬁcance including SRR by
micro TESE and ICSI outcomes with embryonic development in NOA couples
with the history of cryptorchidism.
Summary answer: Micro TESE is particularly helpful for sperm retrieval in
UT cases and ICSI outcomes in NOA with UT are equivalent to OA and unex-
plained NOA.
What is known already: Undescended testis (UT) is associated with impair-
ment of germ cell maturation and subsequent infertility in adulthood because
the UT is exposed to a higher temperature compared with the scrotal tempera-
ture and there is progressive Leydig and Sertoli cell atrophy. There have been
very few studies of ICSI with a focus on, or large enough numbers to examine,
the speciﬁc outcomes associated with male factor infertility including NOA with
the history of cryptorchidism.
Study design, size, duration: This study was conducted in 50 NOA patients
post cryptorchidism, 526 unexplained NOA patients without past history
(unexplained NOA; not including after orchidopexy, Klinefelter syndrome,
cryptozoospermia, mumps orchitis, etc), and 141 OA patients and the ICSI out-
comes of their wives are retrospect assessed between September 2013 to
December 2017.
Participants/materials, setting, methods: We evaluated SRR of micro
TESE, two pronuclei (2PN) oocyte rates, blastocyst development rates, good-
quality blastocyst (Grade 3BB and above on day 5 by the Gardner scoring)
rates, and clinical pregnancy rates per embryo transfer (ET) in 25 cases the his-
tory of UT, 94 cases of unexplained NOA, and 107 cases of OA. The wives age
at ICSI after cryptorchidism, Unexplained NOA, and OA were 34.1 ± 3.5
years, 34.6 ± 4.6 years, and 34.9 ± 3.9 years, respectively.
Main results and the role of chance: SRR of micro TESE NOA with the his-
tory of cryptorchidism (32/50 = 64.0%) was higher than unexplained NOA
(107/526 = 20.3%) (p < 0.001). No correlation was found between serum
FSH, LH, and T level with the success of sperm retrieval. Testicular volume and
patient age at orchidopexy also did not affect the SRR for micro TESE. 2PN
oocytes, blastocyst development, and good-quality blastocyst rates were
54.8%, 46.6%, and 38.2% in NOA with the history of cryptorchidism, 55.7%,
34.2%, and 40.9% in unexplained NOA with the history of cryptorchidism, and
62.7%, 37.7%, and 42.6% in OA, respectively (no signiﬁcant differences).
Clinical pregnancy rates per ET were 31.6% in unexplained NOA with the his-
tory of cryptorchidism, 30.8% in unexplained NOA, and 40.4% in OA, respect-
ively (no signiﬁcant differences).
Limitations, reasons for caution: In the present series, we could not assess
whether the children born had a cryptorchidism or not. It would be worthwhile
evaluating, in a larger series, the prevalence of cryptorchidism in boys born
from fathers with an undescended testis.
Wider implications of the ﬁndings: However testicular function is con-
sidered to be severely impaired, orchidopexy for undescended testes in even
adulthood could be considered to have any effect on spermatogenesis.
Objective counselling of the NOA patinets with the history of cryptorchidism
for the chance of having a healthy baby is of utmost importance.
Trial registration number:N/A.
P-064 Raman spectroscopical assessment of human sperm
capacitation in vitro
A. De Angelis1, G. Coppola2, A.C. De Luca3, N. Angiolelli2,
M.A. Ferrara4, L. Siani2, G. Coppola4, B. Dale2
1CNR, Institute of Protein Biochemistry, Naples, Italy
2Centro Fecondazione Assistita, Biology or Reproduction, Naples, Italy
3Italy National Research Council, Institute of Protein BiochemistryCNR, naples, Italy
4Italy National Research Council, Institute of Protein BiochemistryCInstitute for
Microelectronics and Microsystems, Naples, Italy
Study question: Is it possible to assess human sperm function using a label-
free and non-destructive method.
Summary answer: Raman microspectroscopy (RM) can enables label-free,
non-invasive, accurate and reproducible assessment of sperm function, includ-
ing the discrimination of capacitated from un-capacitated spermatozoa.
What is known already: Current methods for evaluating sperm function
are indirect and of limited clinical applicability since they render the analysed
spermatozoon unﬁt for IVF. We applied RM as a spectroscopic method to
provide detailed biochemical maps of cells, including spermatozoa, without
affecting their viability, revealing DNA fragmentation, nuclear composition
(such as discrimination of X and Y-bearing bovine sperm cells) and protein/
lipid oxidation. Can RM could be used for the biochemical assessment of
sperm physiology?
Study design, size, duration: Raman spectra and images of capacitated
versus untreated human spermatozoa were analysed. A concentration of 10
million of sperm/ml was divided into four aliquots: the untreated serving as
a control; the others were added with a 100 mg/ml of heparin and incu-
bated at 37°C for different times: 1, 2, 3 and 4 hours. A totality of 5 samples
from 5 different patients were analysed through CTC assay and Raman
spectroscopy.
Participants/materials, setting, methods: Semen samples were obtained
from men (age: 35-48 years) attending the Centre for Assisted Fertilization
(Naples). The ejaculates were collected after 3–5 days of sexual abstinence and
processed. Following a routine spermiogram and washing on a Percoll density
gradient, capacitation was induced in vitro using heparin, and the percentage of
capacitated spermatozoa was evaluated using a CTC staining assay. Finally, con-
trol and treated samples were analysed by RS at the Institute of Protein
Biochemistry (Naples).
Main results and the role of chance: The average spectra acquired from
different regions of the human sperm head (acrosome, middle region) for both
control cells and those treated at different timeswith heparin were analysed.
Capacitated spermatozoa reveal important spectral variation in the Raman
bands associated with proteins and lipids content (1200-1600 cm-1), reﬂecting
the protein/lipid migration and scrambling especially in the acrosoma region.
On the contrary, the average spectra from the mid-head region (mainly
nucleus) did not show any signiﬁcant changes in lipid peak intensity, as
expected. Interestingly, the Raman peaks at 2850 cm-1 and 2885 cm-1, assigned
to cholesterol decreases in the Raman spectra of capacitated spermatozoa,
coinciding with the cholesterol efﬂux that triggers capacitation. All these varia-
tions increase with increasing the incubation time with heparin. Finally, multi-
variate statistical analysis (PCA, principal component analysis) was used for
revealing the main speciﬁc Raman biomarkers associated with capacitation, and
to use them for the efﬁcient identiﬁcation and sorting ofcontrol and capacitated
sperm cells.
Limitations, reasons for caution: Raman analysis was performed on ﬁxed
spermatozoa. The results demonstrated only proof of principle of using RS as a
method to study sperm function without clinical validation. The complexity in
interpreting our results make the translation of RS technique into clinical prac-
tice challenging.
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Wider implications of the ﬁndings: Assessment and classiﬁcation of male
infertility based on sperm function, useful for choosing the best technique for
ART.
Complete sperm quality assessment for selecting a fertile spermatozoon for
IVF.
Evaluating or comparing media or conditions used to handle sperm in vitro
or in cryopreservation processes.
Trial registration number: This in basic science.
P-065 Amulticenter study to evaluate oxidative stress by
oxidation–reduction potential, a reliable and reproducible method
A. Agarwal1, R. Chandrakumar1, M. Arafa2, H. Elbardisi2, H. Okada3,
K. Suzuki3, S. Homa4, A. Killeen5, B. Balaban6, A. Ayaz7, R. Saleh8,
A. Armagan9, S. Roychoudhury10, S. Sikka7
1The Cleveland Clinic Foundation, American Center for Reproductive Medicine-
Department of Urology- Cleveland Clinic, Cleveland- Ohio, U.S.A.
2Hamad Medical Corporation, Urology, Doha, Qatar
3Dokkyo Medical University, Urology, Koshigaya, Japan
4University of Kent, Andrology, London, United Kingdom
5The Doctor’s Laboratory, Andrology, London, United Kingdom
6American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey
7Tulane University, Urology, New Orleans, U.S.A.
8Sohag University, Urology, Sohag, Egypt
9Bezmialem Vakif University, Urology, Istanbul, Turkey
10Assam University, Life Science and Bioinformatics, Silchar, India
Study question: Investigate the reproducibility and reliability of the ORP
measurement as a marker of sperm quality across different fertility centers.
Summary answer: ORP provided equal or less variability than the current
semen analysis measures across 9 different fertility centers.
What is known already: Discrete measures of free radicals, antioxidant
activity, and oxidative damage suggest an ambiguous relationship between
the redox system and male fertility. Static oxidation-reduction potential
(sORP) measures the balance between all oxidants and antioxidants provid-
ing a comprehensive status of the redox system. In a previous study, ORP
and semen analysis data were compared between two andrology laborator-
ies, in which ORP remained consistent in both datasets individually or in
combined data.
Study design, size, duration: This prospective study was carried out jointly
by nine participating fertility centers on 1644 subjects. The study was approved
by the institutional ethics committee and subjects were consented prior to par-
ticipation. Subjects were grouped into those that had all normal semen para-
meters (concentration, total cell, total motility, progressive motility, and
morphology) according to WHO 2010 guidelines and those who failed to meet
one or more criteria. ANOVA/t-test measures were used to determine signiﬁ-
cant differences.
Participants/materials, setting, methods: Exclusion criteria included
azoospermia, presence of sexually transmitted disease or chronic disease, use
of prescription, OTC medications or antioxidants. Samples were collected and
semen parameters assessed using the WHO 2010 guidelines. ORP was mea-
sured (mV) using the MiOXSYS system and normalized to sperm concentration
(mV/106 sperm/mL). For group comparisons, only those samples with a con-
centration >0.999 × 106 sperm/mL were included.
Main results and the role of chance: The results of ORP reﬂects the oxida-
tive relationship between the sperm cell and its environment - the expulsion of
oxidants, a by-product of cellular metabolism, into the seminal environment
and the deactivation of them by extracellular antioxidants. The resulting ORP
measurement reﬂects the average of the ﬁnal ten (10) seconds (or twenty read-
ings) of the sample. Of the 1644 samples, 138 were found to have normal
semen parameters and 1506 were found to have abnormal semen parameters.
The mean ORP value (mV/106 sperm/mL) in the semen of the abnormal group
was 5.07 mV/106 sperm/mL whereas that of the normal group was 0.88 mV/
106 sperm/mL (p = 0.001). The SD for ORP was equal to or better than most
measures, with exception to morphology. However, it should be noted that
morphology is the parameter with the highest variability typically found
between laboratories.
Table 1 Sperm parameters and ORP values (mv/106
sperm) in patients with at least one abnormal semen
parameter (n = 1506) versus patients with normal
semen parameters (n = 138) [values are presented as
mean ± SEM].
Group Mean SEM
ORP Normal 0.88 0.14
Abnormal 5.07 0.37
Progressive Motility Normal 48.08 0.93
Abnormal 15.81 0.39
Normal Morphology Normal 6.76 0.30
Abnormal 4.87 0.19
Limitations, reasons for caution: Study enrollment of an even number of
healthy controls with proven fertility was limited in comparison to the male
infertility group.
Wider implications of the ﬁndings:ORP remains stable even with measur-
able differences in sperm parameters, and it therefore can be used as a supple-
mentary test to semen analysis to conﬁrm oxidative stress and poor semen
quality.
Trial registration number: There are no competing interests.
P-066 Protein Kinase Amodulation by nitric oxide during human
sperm capacitation
F.D. Staicu1, J.C. Martinez-Soto2, C. Matas1
1Veterinary Faculty- University of Murcia, Animal Physiology, Murcia, Spain
2IVI-RMA, Andrology laboratory, Murcia, Spain
Study question: To further examine how nitric oxide (NO) modulates
Protein Kinase A (PKA) activity during the in vitro capacitation of human
spermatozoa.
Summary answer: We provide further evidence that NO plays a role in
regulating speciﬁc phosphorylation events during human sperm capacitation.
What is known already: Several studies have identiﬁed important factors
involved in the regulation of sperm capacitation, a physiological process neces-
sary to achieve the fertilization ability. Reactive Oxygen Species such as NO are
generated during this process and are beneﬁcial in low concentrations for its
progress. It has been reported that NO can modulate PKA-dependent phos-
phorylation events linked to the capacitation in different species. NO can acti-
vate the sAC-cAMP-PKA pathway either directly or by increasing the cGMP
levels. A rise in the cGMP concentration may inhibit cAMP degradation, which
subsequently leads to PKA activation.
Study design, size, duration: Semen samples were obtained from
normozoospermic donors (n = 7) by masturbation after 3–5 days of sexual
abstinence. Spermatozoa were incubated for 4 hours in capacitating and non-
capacitating conditions. The media were supplemented with 100 μM S-
Nitrosoglutathione, a NO donor, and two inhibitors of NO synthesis: 10 mM
NG-Nitro-L-arginine Methyl Ester Hydrochloride and 10 mM Aminoguanidine
hemisulfate salt. The experiments were performed in absence and presence of
10 mM L-Arginine monohydrochloride, the substrate for NO production.
Participants/materials, setting, methods: The protein phosphorylation
pattern on Serine and Threonine residues (i.e. PKA activity) was evaluated by
Western blotting (WB). Proteins were separated by electrophoresis on 4-15%
SDS-polyacrylamide gels and electrotransferred to PVDF membranes. The lat-
ter were treated with the following antibodies: rabbit monoclonal antibody
anti-protein kinase A (1:2000) and goat anti-rabbit IgG-HRP (1:10000). The
relative amount of signal in each membrane was quantiﬁed using the
ImageQuant TL v8.1 software (GE Healthcare, Life Sciences, Buckinghamshire,
UK).
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Main results and the role of chance:Our results indicated that in the pres-
ence of Nitric Oxide Synthase inhibitors, spermatozoa showed a lower Serine
and Threonine phosphorylation pattern than those capacitated with the NO
donor (p < 0.05) when quantifying the signal corresponding to the whole WB
lane. Moreover, we observed a speciﬁc phosphorylation pattern for two PKA
substrate species, ~ 87 and ~ 62 kDa, which showed a higher degree of phos-
phorylation in the presence of S-Nitrosoglutathione (p < 0.05). The inhibitory
effect on PKA activity when blocking NO synthesis was again evident in the ~
87 and ~ 62 kDa species.
Our data showed that the presence of L-Arginine had no signiﬁcant effect
when analyzing the signal corresponding to the whole WB lane. However, simi-
larly to the experiment where L-Arginine was not used, the ~ 62 kDa species
showed a lower amount of phosphorylation when using NOS inhibitors (p <
0.05).
These effects were not observed under non-capacitating conditions.
Limitations, reasons for caution: The number of samples is small and
should be increased. Also, the study should include infertile men in the future.
Wider implications of the ﬁndings: We identiﬁed speciﬁc PKA substrates
such as the species of approximately 87 and 62 kDa, which show a distinct
Serine and Threonine phosphorylation pattern. These bands might include key
proteins in modulating the events downstream of NO-mediated signaling and
could be differently regulated in infertile men.
Trial registration number:Not applicable.
P-067 Determination of aneuploidy in spermatozoa by ﬂow
cytometry and its relationship on reproductive results
R. Lafuente1, K. Lattes2, S. Brazal3, D. García3, R. Vassena3,
M. Brassesco2
1CIRH, Andrology Lab, Barcelona, Spain
2CIRH, Medical Dpt., Barcelona, Spain
3Clínica EUGIN, Research Dpt., Barcelona, Spain
Study question: Is it possible to link the determination of semen aneuploidy
by ﬂow cytometry to the reproductive results of IVF?
Summary answer: The degree of semen aneuploidy is not related to repro-
ductive outcomes and should not be routinely included before IVF.
What is known already: Previous studies have conﬁrmed an inverse correl-
ation between aneuploidy in sperm and conventional seminal parameters.
Furthermore, the presence of aneuploidy in sperm is associated with failed
spermatogenesis, and may cause oligospermia or azoospermia. The study of
semen aneuploidy can be performed quickly and sensitively by ﬂow cytometry.
This technique allows to determine sperm subpopulations with different DNA
contents and, therefore, with different aneuploidy levels. This methodology
analyzes a greater number of cells than in a conventional FISH and takes into
account the entire DNA content of the cell.
Study design, size, duration: This is a prospective cohort study of 481 cou-
ples who have undergone a ﬁrst IVF cycle with embryo transfer between 2014
and 2017. The patients underwent a semen analysis and a study of sperm DNA
using propidium iodide staining (PI/RNase, BD Pharmingen) by ﬂow cytometry
(MACSQuant Analyzer, Miltenyi Biotec).
Participants/materials, setting, methods: Sperm populations were classi-
ﬁed according to ﬂuorescence intensity as: subhaploid, haploid, diploid and
polyploid. A univariate analysis has been carried out in which the different
results obtained from the sperm analysis and the study of ploidies have
been compared according to the reproductive results (positive / negative):
clinical pregnancy, ongoing pregnancy and live birth. The statistical analysis
were carried out by Student’s t-tests, considering p < 0.05 as statistically
signiﬁcant.
Main results and the role of chance: No statistically signiﬁcant differences
were observed in the levels of subhaploidies between patients with positive and
negative reproductive results for clinical pregnancy (35.0% vs. 65.0%, p = 0.77),
ongoing pregnancy (22.5% vs. 77.5%, p = 0.79), or live birth (22.2% vs. 77.8%,
p = 0.83). There were also no differences in the haploidy rate (35.0% vs.
65.0%, p = 0.45, 22.5% vs. 77.5%, p = 0.21, 22.2% vs. 77.8%, p = 0.25); nor in
the diploidy rate (35.0% vs. 65.0%, p = 0.42, 22.5% vs. 77.5%, p = 0.29, 22.2%
vs. 77.8%, p = 0.32). However, in the polyploidy percentage, statistically
signiﬁcant differences were detected for ongoing pregnancy and live birth
(35.0% vs. 65.0%, p = 0.21, 22.5% vs. 77.5%, p = 0.01, 22.2% vs. 77.8%, p =
0.02), as the percentage of polyploidies was somewhat higher in the group of
pregnant patients, but without clinical relevance.
Limitations, reasons for caution: The population included in this study was
part of infertile couples at their ﬁrst IVF cycles; caution should be exerted when
extending these results to other populations with a longer infertility history.
Wider implications of the ﬁndings: The degree of semen aneuploidy does
not seem to be related to reproductive outcomes; a more conservative
approach to semen analysis seems to be best suited for routine assessment
before IVF.
Trial registration number:None.
P-068 Characterization of somatic testicular cells in fetal,
prepuberal and adult testis. The role of StAR in Leydig cells
A. Garcia1, L. Herrera1, C. Rodriguez1, M.A. Vesga1,
M. Diaz-Nuñez2, A. Exposito2, R. Matorras2, B. Prieto2,
S. Chuva de Sousa Lopes3, C. Eguizabal1
1Centro Vasco de Transfusiones y Tejidos Humanos Hospital de Galdakao, Cell
Therapy and Stem Cells Group, Galdakao Bizkaia, Spain
2Cruces University Hospital, Human Reproduction Unit, Barakaldo, Spain
3Leiden University Medical Center, Department of Anatomy and Embryology, Leiden,
The Netherlands
Study question: Is StAR protein present in somatic cells of male fetal gonads
in the ﬁrst trimester?
Summary answer: No StAR expression in Leydig cells from 9-10 weeks of
gestation, whereas a weak expression at 12 weeks and high expression at 14
weeks.
What is known already: In humans, StAR protein is known to be express in
adult Leydig cells, but also in Leydig cells of fetal testes from 14.5-19 gestational
weeks, however there is no data about the expression of StAR in ﬁrst trimester
fetal male gonads.
Study design, size, duration: We collected fetal, prepuberal (Klinefelter
Syndrome patients) and adult testis samples to perform immunoﬂuorescence
for studying the presence of speciﬁc testicular somatic cell markers as StAR,
GATA4 and SOX9 during the human development of the male gonads.
Participants/materials, setting, methods: Human fetal samples from 9 to
21 weeks postconception (wpc) were obtained from Leiden Universitary
Medical Center (LUMC) (The Netherlands). Human prepuberal patient sam-
ples diagnosed with Klinefelter Syndrome and human adult samples diagnosed
with azoospermia were obtained from Cruces University Hospital (Spain). Oral
and written information was given and informed consent was obtained from all
patients. We performed immunoﬂuorescence for detecting VASA,OCT4,
SOX9, GATA4 and StAR markers on parafﬁn sections of the samples previ-
ously mentioned.
Main results and the role of chance: StAR expression in male fetal gonads,
there was no presence of StAR at 9 and 10 weeks of gestation, however, a
weak expression is observed at week 12, being very signiﬁcant at week 14 up to
21 weeks. As expected, StAR expression only appeared between the seminifer-
ous tubules, in the interstitial space, where Leydig cells are located. GATA4
was clearly present in the Sertoli cells but also in some interstitial cells. SOX9
expression, it was present only in the nucleus of Sertoli cells.
In testis of Klinefelter Syndrome prepuberal patients, StAR expression is in
Leydig cells with a spotty pattern. GATA4 was express in somatic cells inside
the seminiferous tubules, but also in cells between tubules.
SOX9 expression is present in the nucleus of somatic cells inside the tubules.
Adult patients were separated in two different groups, depending on the
presence or lack of spermatozoa (azoospermia). In general there was no signiﬁ-
cant difference between both groups and was detected StAR protein in the
interstitial cells with spotty pattern. GATA4 positive cells were inside seminifer-
ous tubules and in the interstitial space. SOX9 expression was observed only
nuclear staining in Sertoli cells.
Limitations, reasons for caution: Due to the limited and difﬁculty in the
obtention of material used in this study, we used few samples of gonads from
several gestational stage and few samples of prepuberal testis.
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Wider implications of the ﬁndings: The results obtained in this study will
help to understand the early development of the fetal somatic cells, especially
the Leydig cells and the role of StAR protein in steroidogenesis during this fetal
development.
Trial registration number:NONE.
P-069 Association of the sperm telomere length and telomerase
activity with semen quality and fertilization in IVF
Y. Li, R. Li, S. Ou, K. Dai, W.Wang
Sun Yat-sen Memorial Hospital, Department of Obstetrics and Gynaecology,
Guangzhou- Guangdong, China
Study question: Whether the sperm telomere length(STL) and sperm tel-
omerase activity(STA) are related to semen quality and pregnancy outcomes in
IVF?
Summary answer: The STA gradually decreased with age. Better semen
quality and fertilization outcomes are observed in patients with longer STL or
higher levels of STA.
What is known already: Telomeres are functional DNA-protein structures
located at the end of the chromosome and maintain the chromosome stability
as well as genome integrity. Telomerase is an critical enzyme for maintaining the
telomere length(TL). The sperm TL(STL) has been reported to be associated
with idiopathic male infertility and early embryo development in IVF.
Study design, size, duration: 42 samples from men with normal semen
examination were collected and divided into the group A(≤36 years old, n =
16), group B(36-40 years old, n = 12), group C(41-45 years old, n = 7) and
group D(≥45 years old, n = 7).
Participants/materials, setting, methods: The STL was measured using
quantitative real-time PCR and STA was detected by a modiﬁed quantitative-
telomeric repeat ampliﬁcation protocol assay.
Main results and the role of chance: STA levels differed signiﬁcantly among
four groups(P = 0.010). The STA was highest in group B(between 0.009 to
0.33) and decreased in group A(between 0.002 to 0.05), group C(between
0.005 to 0.029) and group D(between 0.001 to 0.011). No obvious differences
were observed in the STL, sperm density, fertilization rate, normal fertilization
rate, available embryos or good quality embryos among these groups(P >
0.05). Sperm density was positively correlated to the STL(r = 0.325, P = 0.044)
in our study population(n = 42). The non-progressive sperm motility was nega-
tively correlated to STL(r=-0.361, P = 0.024) and STA(r=-0.318, P = 0.033).
The normal IVF fertilization rate was positively correlated to STL(r = 0.365, P
= 0.021). There were no signiﬁcant differences in STL or STA between the
pregnant samples and non-pregnant samples(P > 0.05).
Limitations, reasons for caution: Our sample size is not that large enough
to see the signiﬁcant differences of STL among four groups. Further studies with
larger sample size are needed to explored the differences of STL as well as
other clinical features among these groups.
Wider implications of the ﬁndings: Patients with longer STL or higher
levels of STA might have better semen quality and fertilization outcomes in IVF.
Men who aged over 46 are more likely to have a very low level of STA.
Trial registration number:Not applicable.
P-070 Effect of leucospermia on sperm parameters and
Intracytoplasmic Sperm Injection outcomes
K. Kacem Berjeb1, S. Mnallah1, N. Ben Brik1, M. Braham2,
M. Ben Mefteh2, D.Wahbi1, S. Chtourou1, A. Fadhlaoui2,
F. Zhioua2, A. Zhioua1
1Aziza Othmana Hospital, IVF Laboratory, Tunis, Tunisia
2Aziza Othmana Hospital, Departement of Gynecology and Obstetrics, Tunis, Tunisia
Study question: Is there an association between seminal leucocytes levels,
sperm parameters and ICSI outcomes in a large population of infertile patients?
Summary answer: Leucocytospermia had a harmful effect on sperm para-
meters, including sperm concentration, morphology and chromatin maturity of
spermatozoa, but do not inﬂuence ICSI outcomes.
What is known already: Leucospermia is highly prevalent among infertile
patients even those with negative semen culture. The role played by leukocytes
in the human sperm is not totally understood. Activated leucocytes generate
excessive reactive oxygene species (ROS) which have been negatively corre-
lated with fertility and semen quality. In fact, there is consensus that leucocytos-
permia, deﬁned by leukocytes exceeding 1 × 106 cells/mL, impaires sperm
quality. In the other hand, there is still much controversy about its correlation
with ICSI outcomes.
Study design, size, duration: Prospective observational study including 157
patients who underwent ICSI cycles between February and May 2017, in a uni-
versity hospital. Patients were divided into two groups according to sperm leu-
cocytes levels: Group 1 (n = 33) ≥ 1 × 106/ml and Group 2 (n = 124) < 1 ×
106/ml.
Participants/materials, setting, methods: Only patients with negative
semen culture were included in our study. Patients with azoospermia or crypto-
zoospermia were excluded. Sperm parameters were evaluated according to
World Health Organization 2010 guidelines. The peroxidase method was used
to quantify leucocytes, when round cell concentration exceeded 1 × 106/ml on
fresh semen. Sperm chromatine condenstation was assessed by aniline blue
staining.
The main parameters compared between the two groups were sperm para-
meters(volume, concentration, motility, morphology and chromatin maturity)
and ICSI outcomes.
Main results and the role of chance: The mean age of the patients was
comparable in groups 1 and 2 respectively (39.21 years VS 40.86; p = 0.1445).
The clinic and paraclinic characteristics, the stimulation parameters and the
ovarian response, were similar in both groups.
The number of leucocytes had a statistically signiﬁcant negative inﬂuence on
sperm concentration, morphology and sperm maturity when comparing groups
1 and 2 respectively (30,5 ± 26,0 VS 40,5 ± 37,7; p = 0.02); (3,3 ± 1,0 % VS
4,6 ± 1,7 % p = 0.00); (57,6 % ± 14,1 % VS 73,2 ± 11,8%; p = 0.0001)
In contrast, sperm volume and progressive motility were comparable in both
groups.
In the other hand, leucospermia has not signiﬁcantly inﬂuence ICSI outcomes.
The fertilization rate and the cleavage rate were comparable between the two
groups (81.22 VS 83.82%, p = 0.59); (91.37 vs 95.66%, p = 0.25). We also
didn’t found any signiﬁcant difference in top embryo rate and blastulation rate.
The pregnancy rate were also comparable (37.03 VS 44.76%; p = 0.51).
Limitations, reasons for caution: The observational character of the study,
and the reduced size of the samples studied constitute major limitations. In add-
ition, measurement of sperm leucocytes in routine semen analysis appears to
be of little prognostic value with regard to male fertilizing potential.
Wider implications of the ﬁndings: Further studies are needed to deﬁne
other factors that increase the risk of sperm damage through elevated number
of leucocytes in semen.
Trial registration number:Not applicable.
P-071 Lifestyle and semen variables: a prospective cohort study of
men referring to an Italian Fertility Clinic
S.A. Noli1, E. Ricci2, S. Ferrari2, I. La Vecchia1, S. Cipriani2,
V. De Cosmi3, E. Somigliana1, F. Parazzini1
1Università degli Studi di Milano- Milan- Italy, Department of Clinical Sciences and
Community Health, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dipartimento Madre-
Bambino-Neonato, Milan, Italy
3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intensive
Care Unit, Milan, Italy
Study question: We designed a prospective cohort study to investigate the
relation between lifestyle and semen quality in men of subfertile couples under-
going assisted reproductive procedures.
Summary answer: In our study moderate alcohol intake was related to a
beneﬁcial effect on semen quality in male partners of infertile couples undergo-
ing ART cycles.
What is known already: Although the causal link between environmental
factors and impaired male fertility is still weak, there is growing evidence
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suggesting that semen quality may be inﬂuenced by lifestyle habits; in particular,
smoking, overweight, physical activity, dietary factors and alcohol intake have
been suggested to play an important role but evidence is not always consistent.
According to a recent meta-analysis of 15 cross-sectional studies, an occasional
consumption does not adversely affect semen parameters, whereas daily con-
sumption has a negative association with semen volume and normal morph-
ology. However, these ﬁndings could not be controlled for confounders such as
smoking and age.
Study design, size, duration: From September 2014 subfertile couples,
presenting for evaluation to the Fertility Unit of Fondazione IRCCS Ca’
Granda, Ospedale Maggiore, Policlinico, Milan, and eligible for assisted
reproduction technologies (ART), were invited to participate to an ongoing
prospective cohort study on the role of lifestyle habits and diet on ART out-
come. The present study reported exclusively on evidence obtained from the
male partner. From September 2014 to December 2016, 327 men were
enrolled.
Participants/materials, setting, methods: Men of couples who agreed to
participate were interviewed to obtain information on: BMI, smoking, caffeine
intake, occupational and leisure physical activity (PA) and usual alcohol intake.
Information on diet were obtained using a validated food frequency question-
naire (FFQ). Couples were interviewed on the day of oocyte retrieval. On the
same day, a semen sample was collected and analyzed to proceed with ART.
Semen volume, total sperm count and sperm concentration and motility, were
determined.
Main results and the role of chance:We distinguished 3 categories of alco-
hol intake: a low intake group, who drank ≤ 4.3 g of alcohol per day; an inter-
mediate intake group, who drank 4.4-13.3 g per day; a high intake group, who
consumed ≥13.3 g per day. At univariate analysis, sperm volume was signiﬁ-
cantly associated with age, alcohol intake and leisure PA; sperm concentration
with a history of ROD (reproductive organ diseases); total sperm count with a
history of ROD and alcohol intake; sperm motility with age, history of ROD
and leisure PA. We analyzed the association between alcohol intake and semen
variables in a general linear model including age, history of ROD, leisure PA
(associated with at least 1 semen parameter), smoking status, caffeine con-
sumption, calories intake (associated with alcohol intake). After accounting for
these variables, alcohol intake showed a signiﬁcant beneﬁcial relation with
semen volume, total sperm count and sperm concentration. In analyses per-
formed in strata of age, ROD and leisure PA showed that the positive nonlinear
association between alcohol and semen volume was consistently observed in all
subgroups, whereas the signiﬁcant effects on concentration, total count and
motility were limited to men who performed less than 2 hours per week of leis-
ure PA.
Limitations, reasons for caution: Study limitations: ﬁndings should be
referred only to patients of infertile couples, information regarding alcohol
use was self-reported. Study strengths: large sample size, analysis of the role
of alcohol in men with or without other conditions associated with
infertility, adjustment for potential biases reported to be associated with semen
quality.
Wider implications of the ﬁndings: A moderate alcohol intake exerts a
beneﬁcial effect on semen quality. These ﬁndings are in line with results of a
recent meta-analysis, supporting that opposite effects might be exerted by alco-
hol on semen parameters and according to the amount consumed. The
mechanisms underlying these effects need to be further investigated.
Trial registration number:No trial registration number needed.
P-072 Clinical predictors for selection of surgical sperm retrieval
techniques in non-obstructive azoospermia patients
A. Majzoub1, M. Arafa2, S. AlSaid2, K. Khalafalla2, H. Burjaq3,
M. Albader3, T. Al-Marzooqi4, H. Elbardisi2
1Hamad Madical Corporation, Urology, Doha, Qatar
2Hamad Medical Corporation, Urology, Doha, Qatar
3Hamad Medical Corporation, Assisted conception unit, Doha, Qatar
4Hamad Medical Corporation, Obstetrics and Gynecology, Doha, Qatar
Study question: Can the clinical ﬁndings of patients with non-obstructive
azoospermia (NOA) aid in selecting the most appropriate surgical sperm
retrieval (SSR) method prior to invitro fertilization (IVF)?
Summary answer: Clinical ﬁndings such as testicular size, initial and post-
treatment hormone levels and testicular tissue histopathology can aid in select-
ing the sperm retrieval technique.
What is known already: Testicular sperm retrieval has been practiced over
the past few decades as a mean of providing patients with NOA the chance to
father their biologic children through IVF. While microsurgical testicular sperm
extraction (mTESE) yields higher SSR rates when compared to testicular sperm
extraction (TESA), it can also be considered a more invasive procedure with, at
times, detrimental effects on testicular spermatogenic and endocrine functions.
Study design, size, duration: This was a retrospective study of 439 patients
presenting with NOA who underwent surgical sperm retrieval at a tertiary
medical center over a period of 5 years. Data regarding patient demographics,
clinical ﬁndings, serum hormone levels before and after medical stimulation
therapy, chromosomal abnormality, type/outcome of the sperm retrieval pro-
cedure and histopathology results was collected.
Participants/materials, setting, methods: All participants received hor-
monal stimulation prior to a staged SSR procedure starting with TESA (needle
aspiration biopsy technique) and progressing to mTESE when no sperm were
retrieved after 4 aspirations from each testicle. Collected variables were exam-
ined against the sperm retrieval outcome and the method of SSR utilized. X2
and Kruskal-Wallis tests were used to analyze categorical and numerical values,
respectively. A p value < 0.05 was considered statically signiﬁcant.
Main results and the role of chance: Overall, SSR rate was 42.1%. Sperm
were retrieved through TESA and mTESE from 99(22.5%) and 140(42.6%)
patients respectively. Patients with a positive SSR were divided into 2 groups
according to the SSR method used. Testes size, initial LH and FSH levels, post-
treatment LH, FSH and testosterone levels and histopathology results signiﬁ-
cantly varied between the study groups (table 1). Patients with a positive sperm
retrieval through TESA had a statistically signiﬁcant larger right and left testicular
size, lower initial and posttreatment LH and FSH levels, and higher posttreat-
ment testosterone levels. The SSR rate with mTESE was higher than TESA in all
testicular histopathologies (p < 0.001). However, the highest SSR rate in
patients who underwent TESA was found in hypospermatogenesis, followed by
maturation arrest, tubular atrophy and Sertoli cell only syndrome.
Table I
TESA +ve
(n = 99)
mTESE +ve
(n = 140)
Age 37.6 ± 0.8 36.6 ± 0.6
Left testis size 8.8 ± 0.5* 6.8 ± 0.4*
Right Testis Size 9.6 ± 0.6* 7.2 ± 0.4*
(i)Testosterone 15.9 ± 0.7 16.2 ± 0.8
(i)LH 4.4 ± 0.2** 7.5 ± 0.5**
(i)FSH 8.1 ± 0.7** 14.8 ± 1.1**
(i)Estradiol 104.1 ± 4.1 121.7 ± 5.4
(t)Testosterone 23.3 ± 3.6* 17.3 ± 1.04*
(t)LH 8.1 ± 1.4 10.8 ± 0.8
(t)FSH 11.4 ± 1.1 19.9 ± 1.5
(t)Estradiol 134.7 ± 10.8 213.8 ± 87.1
Histopathology
Hypospermatogenesis 36.4%** 41.5%**
Maturation arrest 15.2%** 29.6%**
Sertoli cell only 4.6%** 30.2%**
Atrophy 14.8%** 51.8%**
Abnormal Karyotype 11.5% 34.6%
Y-chromosome microdeletion 8.3% 8.3%
(*pvalue<0.05, **pvalue<0.01); (i)initial, (t)post-treatment
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Limitations, reasons for caution: This was a single center study. Results
need to be validated across different centers and study population.
Wider implications of the ﬁndings: It is important to recognize the predic-
tors for successful SSR in different SSR methods to aid in selecting the most
appropriate technique that can be effective and at the same time least invasive.
Trial registration number:NA.
P-073 Association between bloodmetal concentrations and
human semen quality: a cross-sectional study in Hong Kong
X. Shi, M. Zhao, C. David, L. Tin-Chiu
Department of Obstetrics and Gyneacology- Prince of Wales Hospital, The Chinese
University of Hong Kong- Hong Kong., New Territories, Hong Kong
Study question: Does heavy metal exposure, including essential and non-
essential heavy metals, associated with the decline of semen quality and sperm
function?
Summary answer: Although high blood lead and mercury level may be asso-
ciated with poor semen quality, heavy metal exposure may not affect the sperm
fertilisation function signiﬁcantly.
What is known already: Exposure to metals, including essential and non-
essential elements, is widespread and may be associated with altered semen
quality. However, evidence from previous reports was contradictive.
Moreover, there was lack of investigation regarding the effect of heavy metal
exposure on sperm function.
Study design, size, duration: This is a cross-sectional study, which included
298 men who underwent routine fertility assessment between November 2015
and June 2016 in Hong Kong.
Participants/materials, setting, methods: Blood and semen samples
were collected from participants at the teaching hospital of the Chinese
University of Hong Kong. Routine semen analysis and sperm functional test
(sperm vitality, sperm DNA fragmentation and acrosome-reaction test) were
performed. Thirteen metals (As, Cd, Co, Cr, Cu, Fe, Hg, Mn, Mo, Ni, Pb, Se,
and Zn) were measured in whole blood samples by inductively coupled plasma
mass spectrometry. Multivariable logistic regression models were employed in
data analysis.
Main results and the role of chance: After adjusting for age, abstinence
time, current cigarette smoking habits and alcohol drinking habits in the multiple
logistic regression analyses, we found blood lead level was signiﬁcantly and
negatively associated with sperm motility (Ptrend = 0.048). Moreover, we
found signiﬁcant dose-dependent trends of blood lead and mercury quartiles
with sperm DNA fragmentation (Lead: Ptrend = 0.006; Mercury: Ptrend =
0.009). Furthermore, we found signiﬁcantly dose-dependent trends of increase
blood selenium with increase sperm morphology (Ptrend = 0.001). There were
no signiﬁcant associations between blood metal level and sperm vitality and
acrosome reaction after adjustment for multiple demographic and lifestyle
factors.
Limitations, reasons for caution: Our study is a cross-sectional study, the
association found in our study is not causation between heavy metal exposure
and semen quality, which is a common limitation to cross-sectional studies.
Wider implications of the ﬁndings: Environmental exposure to lead may
be associated with lower sperm motility, and exposure to lead and mercury
may associate with higher sperm DNA fragmentation; whereas selenium may
have a protective effect for sperm morology. However, heavy metal exposure
may not signiﬁcantly affect the sperm fertilisation function.
Trial registration number:N/A.
P-074 Assessment of the impact of CryoFlex tubing on sperm
cryopreservation outcome
T. Said1, I. Kuznyetsova2, A. Rajput1, A. Del Valle1
1The Toronto Institute for Reproductive Medicine - ReproMed, Andrology Laboratory
and Reproductive Tissue Bank, Toronto, Canada
2The Toronto Institute for Reproductive Medicine - ReproMed, IVF Laboratory,
Toronto, Canada
Study question: Does wrapping cryovials with CryoFlex tubing prior to
immersion in liquid nitrogen (LN) impact sperm cryopreservation outcome and
the post-thaw recovery of motile sperm?
Summary answer: The use of CryoFlex tubing can negatively impact the out-
come of sperm cryopreservation. The tubing should be removed prior to thaw-
ing to prevent such outcome.
What is known already: Cryovials are widely used to store cryopreserved
semen samples. Nevertheless, they are not considered to provide effective bio-
containment. Thus, LN penetration in addition to contamination of samples
and LN tanks remain a concern. It has been suggested that wrapping cryovials
in heat-shrinkable tubing prior to immersion in LN could reduce these risks.
The tubing is made of a safe plastic resin polymer, however it has a poor tem-
perature capability, which could affect cryopreservation-thawing protocols. It is
not yet known if the use of CryoFlex tubing will impact the outcome of sperm
cryopreservation, speciﬁcally, cryosurvival rates.
Study design, size, duration: Semen samples (n = 34) were included in this
cross-sectional study. Following dilution with cryoprotectant media, each sam-
ple was split into 2 equal aliquots: 1) sample with CryoFlex wrapping, and 2)
control without CryoFlex wrapping. The CryoFlex tubing remained wrapped
during the thawing in 20 samples; while it was removed prior to thawing in 14
samples. All trials were conducted over the course of 3 months.
Participants/materials, setting, methods: Samples were provided by
healthy donors. All aliquots were cryopreserved in vials with internal threading
and silicon gasket (Nunc CryoTubes, Thermo Scientiﬁc). Heat-sealable wrap-
ping (Nunc CryoFlex, Thermo Scientiﬁc) was applied to the sample aliquots,
vials without wrapping served as controls. Thereafter, aliquots were placed in
liquid nitrogen vapor for 20 minutes followed by plunging in liquid nitrogen.
Thawing was performed after a minimum of 24 hours by immersion in 37 C
water bath for 4 minutes.
Main results and the role of chance: Cryosurvival rates were calculated by
dividing total motile sperm post-thaw by total motile sperm pre-freeze X 100.
Statistical analysis was conducted using paired t-test with two-tailed test of sig-
niﬁcance. In samples thawed with the CryoFlex wrapping, the post-thaw sperm
percentage motility and cryosurvival rates were signiﬁcantly lower compared to
controls (26.4 ± 6.1 vs. 30.9 ± 8.2, P = 0.003 and 60.6 ± 11.7 vs. 70.2 ± 12.8,
P = 0.007, respectively). In samples where CryoFlex wrapping was removed
prior to the thawing, no signiﬁcant differences were noted in post-thaw sperm
percentage motility and cryosurvival rates (32.1 ± 12.9 vs. 32.9 ± 12.8 and
69.0 ± 20.4 vs. 71.0 ± 12.5, respectively). Overall, the results showed that
whenever the CryoFlex tubing is kept wrapped around the vials during the
thawing process, a signiﬁcant decline in the recovery of cryopreserved sperm-
atozoa post-thaw will occur. No such decline was seen when the CryoFlex tub-
ing was removed prior to thawing.
Limitations, reasons for caution:Our results are solely based on the evalu-
ation of semen samples from healthy donors with normal semen parameters
using a single cryopreservation protocol. It cannot be assumed that semen sam-
ples with lower quality parameters or the use of other cryopreservation proto-
col will yield with the same results.
Wider implications of the ﬁndings: This pilot provides new insights into
the impact on CryoFlex tubing on sperm cryopreservation outcome. While it
may alleviate some of the safety concerns associated with the use cryovials in
sperm cryopreservation, CryoFlex can also negatively impact the outcome of
sperm cryopreservation unless removed prior to thawing.
Trial registration number:Not applicable.
P-075 Nrf2 signaling in experimental cryptorchid mice
M. Baazm1, H. Fallah asl1, F. Jalali Mashayekhi2, A. Zendedel3
1Arak University of Medical Sciences, Anatomy, Arak, Iran
2Arak University of Medical Sciences, Biochemistry and Genetics, Arak, Iran
3Institute of Neuroanatomy, RWTH Aachen University, Aachen, Germany
Study question:Whether Nrf2 signaling activates in experimental cryptorchid
mice?
Summary answer: The Nrf2 signaling fails to develop in the cryptorchid
testis.
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What is known already: The nuclear factor erythroid 2 (Nrf2), a tran-
scription factor, involve in cellular protection against oxidative stress. During
cryptorchidism, heat stress induces destructive oxidative stress in testis by
following deleterious impact on gonadal function which ﬁnally can result in
decreasing sperm quality and infertility. Several studies report that Nrf2
plays an important role in inhibition the progress of oxidative stress in
spermatogenesis. It has shown that the expression level of Nrf2 target
genes decrease in men which suffer from low sperm motility. These ﬁndings
spurred our interest to investigate the role of Nrf2 signaling in experimental
cryptorchidism mice.
Study design, size, duration: 48 male mice at the age of 6 weeks were
used. Cryptorchidism was induced by pushing left testis via inguinal canal into
the abdominal cavity and ﬁxing the testis to the abdominal wall, then gubernacu-
lum was cut and inguinal canal was closed. After cryptorchidism-induction, mice
were scariﬁed on one day, one, four and eight eight weeks post operation.
Sperm parameters and the expression of Nrf2 target genes such as HO1 and
NQO1 were assessed.
Participants/materials, setting, methods: Sperm parameters including
count, motility, morphology and viability were analyzed. Total RNA was
extracted from the left testis of each mouse. The cDNAs were synthesized.
For real time PCR reactions, primers were adapted from other primers
(designed by the NCBI website). The quality of each reaction was conﬁrmed
by melting curve analyses. Efﬁciency was determined for each gene using a
standard curve. For each sample, the target genes were normalized to a ref-
erence gene.
Main results and the role of chance: According to our statistical analysis,
in all groups sperm parameters were reduced after cryptorchidism induc-
tion. The expression levels of studied genes were time dependent. One
day and one week after surgery had similar gene expression pattern, except
about the Keap1 expression (no change one day after surgery and decrease
one week after cryptorchidism). In the mentioned time, the expression
levels of Nrf2 and NQO1 were raised signiﬁcantly (p≤ 0.05), but the level
of HO1 expression declined (p≤ 0.05). Two weeks after cryptorchidism
induction, Nrf2 expression level increased signiﬁcantly, but the expression
of Keap1 and HO1 signiﬁcantly decreased (p≤ 0.05) and the expression of
NQO1 showed any changes. Four and eight weeks after surgery, we could
not detect any changes at the level of mRNA expression of the studied
genes.
Limitations, reasons for caution: The limitation of research is that only
gene expression is not strong tool for assessing the signaling and it needs sup-
plementary studies.
Wider implications of the ﬁndings: In this study for the ﬁrst time we
showed Nrf2 signaling is activated during cryptorchidism, but it is not enough
strong to prevent deleterious effect on the testis tissue.
Trial registration number:N/A.
P-076 Prevalence of Mycoplasma genitalium among infertile men
and sperm donors consulting in a French center for Assisted
Reproduction
L. Ferreux1, A. Chargui1, J. Loubinoux2, J. Raymond2, C. Jean3,
C. Chalas3, V. Drouineaud3, C. Poyart2, C. Patrat1, J.P.Wolf1,
E. Dulioust1
1Hopitaux Universitaires Paris-Centre CHU Cochin, Service d’Histologie Embryologie
Biologie de la Reproduction, Paris, France
2Hopitaux Universitaires Paris-Centre CHU Cochin, Service de bactériologie, Paris,
France
3Hopitaux Universitaires Paris-Centre CHU Cochin, Service d’Histologie Embryologie
Biologie de la Reproduction CECOS, Paris, France
Study question: Is the prevalence of Mycoplasma genitalium (MG) higher in
infertile men than in sperm donors? Does MG affect semen parameters?
Summary answer: MG prevalence in infertile men is signiﬁcantly lower than
in fertile men. No signiﬁcant impact of MG on sperm parameters was
evidenced.
What is known already: Mycoplasma genitalium is a bacterium, hard to iso-
late. Its prevalence is estimated between 1% and 3% in the general population.
It is likely to cause a sexually transmitted infection and is responsible for 10 to
25% of non gonoccocal urethritis. Mycoplasma genitalium infection is usually
asymptomatic. The impact of this emerging bacterium on semen parameters is
still unknown as well as its role in male infertility.
Study design, size, duration: This study included 5208 infertile men and
162 sperm donors consulting between March 2012 and December 2016 in our
Reproduction Center (Cochin hospital, AP-HP). A systematic search for
Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium was
performed on the ﬁrst urinary stream by a highly sensitive and speciﬁc PCR
technique (Test Dx CT/NG/MG®, Bio-Rad). This testing was systematically
associated to semen parameters analysis.
Participants/materials, setting, methods: Prevalence of MG was calcu-
lated for each sub-group. Concomitant ejaculated semen was analyzed accord-
ing to the 2010 WHO references. Semen parameters (sperm numbers, vitality,
progressive motility and leucospermia) of infertile infected with MG were com-
pared to those of infertile men free of any infection and matched according to
the age, the abstinence period and date of analysis, using a student test.
Main results and the role of chance: The prevalence of MG was signiﬁ-
cantly lower in men consulting for infertility than men willing for sperm dona-
tion, already fathers (58/5208 1.1%, versus 7/162 4.3% p < 0.01). This
prevalence among infertile men is similar to that reported in literature among
the general population. The proportion of Chlamydia trachomatis infection was
comparable in both populations (2/162, 1,2% versus 26/5208, 0,5% p > 0,5).
Four of the 56 men consulting for infertility with a positive detection of MG
(7.1%) exhibited genital-urinary symptoms. No signiﬁcant difference was found
between the sperm parameters of infertile men with or without MG consulting
in our university center considering total sperm count (M) 162.6 ± 182.0 for
MG+ versus 188.7 ± 215.5, p > 0.5, progressive motility (%) 34.6 ± 15.0 ver-
sus 34.4 ± 16.5 in MG-, p > 0.5, vitality 56.8 ± 15.8 versus 58.4 ± 17.3, p >
0.5, or leucospermia (M/mL) 0.8 ± 2.4 versus 0.4 ± 1.1, p > 0.5.
Limitations, reasons for caution: The semen parameters of infertile men
with a positive PCR for Mycoplasma genitalium were not systemically controlled
after an efﬁcient antibiotic treatment to evidence a possible improvement of
the parameters and eventually the pathogenic role of Mycoplasma genitalium on
male fertility.
Wider implications of the ﬁndings: These ﬁndings need to be conﬁrmed
taking into account the prevalence and impact of Mycoplasma genitalium among
the female partners of these patients and the outcomes of Assisted
Reproduction therapies in couples carrying MG.
Trial registration number:Not applicable.
P-077 Euploid rate of embryos derived from aspirated and
ejaculated sperm
A. Miller1, C. Rios2, M. VerMilyea3, K. Silverberg4
1Texas Fertility Center, Embryology, Austin- Texas, U.S.A.
2Ovation Fertility, Genetics Laboratory, Henderson- Nevada, U.S.A.
3Ovation Fertility, Embryology, Austin- Texas, U.S.A.
4Texas Fertility Center, Physician, Austin- Texas, U.S.A.
Study question:What is the euploid rate relationship between aspirated and
ejaculated sperm-sourced embryos?
Summary answer: TESE sperm may be more effective to treat male patients
with azoospermia.
What is known already: Micro-surgical sperm aspiration procedures TESE
(testicular sperm aspiration) and PESA (Percutaneous Epididymal Sperm
Aspiration) followed by ICSI and PGS are all suitable approaches for treating
azoospermia (Weng, 2014). The choice of surgical procedure is based on the
cause of azoospermia: non-obstructive azoospermia (NOA) or obstructive
azoospermia (OA). NOA often requires extracting testicular spermatozoa,
which are fragile, non-motile, and have not undergone chromatin condensation.
OA can be treated with a less invasive procedure to extract sperm from the
epididymis, which are more durable, mostly motile, and have completed or are
currently undergoing meiotic maturation.
Study design, size, duration: This is a retrospective cohort study that spans
from 1/2016 until 12/2017. Overall 992 embryos were biopsied and analyzed
for this study. High quality blastocyst embryos exhibiting tightly bound inner
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cellular mass (ICM) and good quality trophectoderm were subsequently biop-
sied. Trophectoderm biopsy and PGS screening were performed on Day 5, 6
and 7 embryos. Chi-square statistical analysis was performed to determine sig-
niﬁcant differences between groups.
Participants/materials, setting, methods: Trophectoderm biopsy and
PGS screening were performed on Day 5, 6 and 7 of high quality blastocyst
embryos. Overall 992 embryos were biopsied (751 ejaculated sperm, 114 TESE,
and 127 PESA sperm-sourced embryos). Biopsied embryos were segregated into
based on sperm source: ejaculated sperm, TESE, or PESA. Biopsied samples
were analyzed using next generation sequencing (NGS) to determine euploid sta-
tus. Embryos were vitriﬁed using Vit Kit (Irvine Scientiﬁc) for subsequent transfer.
Main results and the role of chance: Euploid rates per group were 50%
(374/751) for ejaculated sperm, 57% (65/114) for TESE and 43% (54/127) for
PESA. Chi-square statistical analysis displayed that PESA sperm embryos
resulted in signiﬁcantly lower euploid rate when compared to TESE sperm rates
(p = 0.0246). Ejaculated sperm euploid rate was not found to be signiﬁcantly
different between TESE and PESA. Complex abnormal rates were 9% (18/196)
for ejaculated sperm, 7% (5/67) for TESE, 14% (15/104) and for PESA; these
results were not signiﬁcantly different from each other. Embryos sourced from
testicular sperm resulted in a signiﬁcantly higher euploid rate than those from
epididymal sperm. These data suggest that, in some patients, maturation of
sperm through the epididymis may alter DNA during chromatin condensation.
This, in turn, can cause an abnormal random assortment during fertilization
causing a potential higher propensity of aneuploidy in the developing embryo.
Our ﬁndings suggest that sperm retrieved prior to further maturation in the epi-
didymis may be more effective to treat male patients with azoospermia.
Limitations, reasons for caution: This study was limited by not grouping
age of female patient providing the oocytes, which can impact euploid rate. It
also does not provide speciﬁc reasons for requiring aspirated sperm.
Wider implications of the ﬁndings: Literature suggests that ejaculated sperm
would have a higher euploid rate than that of aspirated sperm and no difference
between TESE and PESA. This data completely contradicts published literature in
that TESE sperm had a signiﬁcantly higher euploid rate than that of PESA.
Trial registration number: not applicable.
P-078 Is human semenmore sensitive than blood for assessing
environmental impact on health? EcoFoodFertility Project
L. Montano1, P. Bergamp2, M.G. Volpe3, M.G. Adreassi4, C. Vecoli4,
S. Lorenzetti5, A. Mantovani6, T. Notari7
1Andrology Unit of the “San Francesco d’Assisi” Hospital- Local Health Authority ASL
Salerno- EcoFoodFertility Project Coordination Unit- via M. Clemente- 84020 Oliveto
Citra SA- Italy, Urology, Acerra, Italy
2Institute of Food Sciences- National Research Council CNR-ISA- via Roma 64-,
National Researh Council, Avellino, Italy
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Study question: The aim of this study is to evaluate if human semen can be
considered more than blood early biomarker of environmental pollution expos-
ure and useful for innovative prevention program.
Summary answer: Semen RedOx status, motility, DFI and sperm telomere
length (STL) can be considered as an early markers of environmental pollution,
more sensitive than blood.
What is known already:High environmental pressure may impair male infer-
tility by affecting semen quality, but the real effects remains controversial. Some
studies have supposed that speciﬁc factors present in some areas, but not in
other, might cause a reduction of semen quality. In a previous EcoFoodFertility
study, we have demonstrated that sperm DNA fragmentation is signiﬁcantly
higher in men who live in high environmental polluted areas respect of those
who live in low polluted areas and, others studies, have hypothesized that air
pollution could be affects the length of sperm telomeres.
Study design, size, duration: Pilot biomonitoring study (EcoFoodFertility
Project) conducted in Campania (Italy) on blood and semen of clinically healthy
men living in the ‘Land of Fires” (High Environmental Impact-HEI) and, as con-
trol group, in ‘Alto-Medio Sele” (Low Environmental Impact-LEI), to assess
environmental impact on fertility and human health. 220 men were recruited,
from July to December 2015, for analysis of: 22 trace elements, sperm DNA
fragmentation (DFI), total antioxidant capacity (TAC), antioxidant enzyme
activity and telomere length (TL).
Participants/materials, setting, methods: Partecipants were divided into
two groups:
Group A: 110 males from HEI (n = 60) and LEI (n = 50);
Group B: 112 males from HEI (n = 57) and LEI (n = 55).
In group A 22 trace elements were analyzed in blood and semen by optical
emission spectrometry, DFI by Sperm Chromatin Dispersion test, TAC by
Glutathione peroxidase/reductase (GPX-GSR).
In group B telomere length (TL) was assessed by quantitative Real-Time PCR
on genomic extracted from leukocytes (LTL) and sperm (STL).
Main results and the role of chance: In Group A, HEI subjects showed sig-
niﬁcantly higher values (p < 0.05) for Al, Mn, Cr, Mg, Li, Co, Ca in blood, as
well as for Cr, Cu, Zn in semen, while Fe was lower in semen (p < 0.05).
Immotile sperms and DFI were both higher (p < 0.026 and p < 0.01 respect-
ively) in HEI-group. TAC in blood showed no differences, while TAC, GPX and
GSR in the seminal plasma were signiﬁcantly lower in the HEI-group (p < 0.05).
In group B, a signiﬁcant negative correlation was found between age and LTL
(r=-0.024, p = 0.01), as aspected, but no correlation was found between STL
and age (p = 0.7). No signiﬁcant LTL differences was observed between low
and high exposure groups (0.99 ± 0.33vs 0.90 ± 0.38, p = 0.2), while STL was
signiﬁcantly higher in HEI-group compared to LEI-group (1.15 ± 0.51vs 0.90 ±
0.26, p = 0.04). Age-adjusted analysis conﬁrmed a higher STL in HEI-group
compared to control group LEI (1.10 ± 0.36vs 0.90 ± 0.32, p = 0.05). When
STL was analyzed according to the 75th percentile distribution, HEI-group
emerged as a signiﬁcant risk predictor of longer STL (Odds Ratio: 3.1, 95% con-
ﬁdence intervals: 1.1-10.2; p = 0.02).
Limitations, reasons for caution: Several limitations need to be con-
sidered: no direct ambient measures of air pollution were available and some of
the differences in the associations could be due to the relatively small sample
size of the groups. Even if analysis were adjusted for potential covariates, we
cannot exclude other unidentiﬁed confounding factors.
Wider implications of the ﬁndings: Semen RedOX status, DFI and STL
can be considered as early markers of environmental pollution and human
semen seemed a more early sensitive source of biomarkers than blood to
monitor high environmental pressure on human health, hence useful for innov-
ation prevention programs and health surveillance, especially in risk areas.
Trial registration number: This work was supported by institutional funds.
The authors declares.
Not required because it is a pilot biomonitoring observational study.
P-079 Oxytocin expression in spermatozoa is positively associated
with their motility, whereas expression of oxytocin receptor is
negatively associated with their morphology
E. Neofytou1, S. Lymperi2, C. Vaitsopoulou3, M.G. Bazioti2,
K. Chatzimeletiou3, A. Lambropoulos3, E.Y. Kolibianakis3,
B. Tarlatzis3
1Newlife IVF, IVF Unit, Thessaloniki, Greece
2Private Diagnostic Laboratory Agias Soﬁas, Andrology Laboratory, Thessaloniki,
Greece
3Aristotle University of Thessaloniki, 1st Department of Obstetrics and Gynecology,
Thessaloniki, Greece
Study question: Is oxytocin (OXT) and oxytocin receptor (OXTR) mRNA
expression in spermatozoa different between normal sperm samples and sam-
ples with at least one abnormal parameter?
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Summary answer: Compared to normal sperm samples, OXT mRNA
expression is signiﬁcantly lower, whereas OXTR mRNA expression is signiﬁ-
cantly higher in abnormal samples (at least one parameter).
What is known already: OXT is synthesized in the penis, testis, epididymis
and prostate, whereas its receptor has been detected throughout the male
reproductive tract. Furthermore, OXT promotes the conversion of testosterone
into dihydrotestosterone. During orgasm, a burst of OXT is released into the sys-
tematic circulation to stimulate contractions of the reproductive tract. Various
studies have shown that exogenous administration of OXT increases the sperm-
atozoa concentration of ejaculated sperm. OXT seminal plasma levels have been
shown to be lower in fertile men compared to men with oligoasthnoteratozoos-
permia. However, OXT and OXTR has never been assessed in spermatozoa.
Study design, size, duration: A prospective study was performed in 2016-
2017, including a total of 105 samples for OXT and 70 samples for OXTR. All sam-
ples had > 1*106 spermatozoa/ml and <1*106 leukocytes/ml. Sperm samples’
analysis was performed according to WHO 2010 criteria and mRNA was
extracted to assess the mRNA expression levels of OXT and OXTR. mRNA
expression levels were compared between different categories of sperm samples,
classiﬁed according to their concentration, total number, motility and morphology.
Participants/materials, setting, methods: All sperm samples were sub-
jected to mRNA extraction, cDNA synthesis and quantitative Real-Time PCR (RT-
PCR) for the expression of the OXT and OXTR genes. The relative standard curve
method was selected as the most appropriate due to the nature of human spermato-
zoa. Each sample was run in duplicate and normalized to β2-microtubulin.
Differences in mRNA expression levels were analyzed between different sperm cat-
egories using the generalized linear model. Values are expressed as median (95% CI).
Main results and the role of chance: Compared to normal samples, sam-
ples with at least one abnormal sperm parameter had statistically signiﬁcant lower
OXT mRNA expression levels [5.27(1.69-13.98) vs. 0.93(0.53-1.64), p = 0.019]
and higher OXTR mRNA expression levels [0.91(0.42-3.3) vs. 4.79(1.02-8.43),
p = 0.000). Compared to samples with total number of spermatozoa >39 ×
106/ml, oligozoospermic samples had statistically signiﬁcant higher OXT mRNA
expression levels [1.64(0.99-2.94) vs. 0.65(0.24-2), p = 0.002] and lower OXTR
mRNA expression levels [3.3(0.86-4.71) vs. 16.03(0.07-63.89), p = 0.047). In
addition, compared to samples with normal motility, asthenozoospermic samples
had statistically signiﬁcantly lower OXT mRNA expression levels [1.96(1.15-4.4)
vs. 0.4(0.21-0.79), >60% immotile spermatozoa, p = 0.000 and 1.97(1.16-4.6)
vs. 0.32(0.09-0.75), progressive motility <32%, p = 0.000]. Furthermore, terato-
zoospermic samples had statistically signiﬁcant lower OXT mRNA expression
levels [4.19(1.66-9.5) vs. 0.79(0.52-1.59), p = 0.049] and higher OXTR mRNA
expression levels [0.94(0.44-3.3) vs. 5.46(1.22-10.16), p = 0.000]. Interestingly,
OXT mRNA expression was positively associated with the rapid progressive (a)
(spermatozoa with a speed >25μm/sec at 37oC, p = 0.008), the slow progres-
sive (b) (spermatozoa with a speed <25μm/sec at 37oC, p = 0.021) and the total
progressive (a + b) motility (p = 0.000), and negatively associated with the per-
centage of immotile spermatozoa (p = 0.001). On the contrary, OXTR mRNA
expression was negatively associated with the percentage of normal forms (p =
0.000) and positively associated with the percentage of head defects (p = 0.01).
Limitations, reasons for caution: Given that the method used for the ana-
lysis was the relative standard curve method, it would be interesting to deﬁne
the absolute levels of OXT and OXTR in spermatozoa and conﬁrm the results
with the protein expression of both genes.
Wider implications of the ﬁndings:We have shown for the ﬁrst time that
OXT mRNA is downregulated in samples with lower motility and OXTR is
upregulated in samples with abnormal morphology compared to normal sperm
samples. OXT and OXTR mRNA expression in spermatozoa could be used as
novel and unbiased diagnostic tool of male infertility.
Trial registration number:NOT APPLICABLE.
P-080 Paternal age and semen quality: Does the association of
those two factors affect the embryo development?
P.A. Monteleone1,5, P. Peregrino2,5, S. Gonçalves2, P. Petersen2,
J. Miorin2, D.Wajman2,5, M. Fugii3, H. Martin3, T. Bonetti4,
A. Gomes3
1Centro de Reproducao Humana Monteleone, Clinical director, Sao Paulo / SP,
Brazil
2Monteleone Centro de Reproducao Humana, Clinical, Sao Paulo, Brazil
3Monteleone Centro de Reproducao Humana, Embriology, Sao Paulo, Brazil
4Universidade Federal de São Paulo – Escola Paulista de Medicina UNIFESP-EPM,
Gynecology, Sao Paulo, Brazil
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Study question: Does the association of advanced paternal age and low
sperm count affect the embryo development?
Summary answer: The paternal age, sperm count or association of them do
not affect blastocyst formation rate or clinical pregnancy rate in ICSI cycles.
What is known already: Many studies exist on the impact of female age on
fertility and success of ART. More recently, male age has been highlighted and
there are reliable scientiﬁc data, which conﬁrm decline of fertility related to
advancing male age and in the risk of genetic diseases for the offspring. The age
at which men are often classiﬁed as advanced age is commonly after age 50
years, although many of the risks continue to increase with age. Semen analysis
remains a standard component of a male fertility evaluation, and several studies
have reported general decline of semen parameters with advancing age.
Study design, size, duration: We hypothesized the association of advancing
paternal age and decreased sperm count can affect the embryo development
potential. Then, we developed a retrospective cohort study, which reviewed
3063 ICSI cycles using ejaculated sperm performed during the last 15 years in a
private ART center. Semen analysis were performed following World Health
Organization manual and controlled ovarian stimulation used standard protocols.
Participants/materials, setting, methods: Cycles were split into four
groups according to paternal age and sperm count: (1) young men (age < 50
years) and normal sperm count (≥15 × 106 sperm/ml) (Group young-normal,
n = 2101); (2) young men (age < 50 years) and low sperm count (<15 × 106
sperm/ml) (Group young-oligo, n = 796); (3) ageing men (age ≥50 years) and
normal sperm count (≥15 × 106 sperm/ml) (Group old-normal, n = 87); and
(4) old men (age ≥50 years) and low sperm count (<15 × 106 sperm/ml)
(Group old-oligo, n = 79).
Main results and the role of chance: Men age varied from 21 to 84 years
old (young-normal: 38.4 ± 4.8; young-oligo: 38.4 ± 5.1; old-normal: 54.4 ± 5.4;
old-oligo: 56.7 ± 7.0; p < 0.001). Sperm concentration were similar for young-
normal (50.0 ± 33.3 million/ml) versus old-normal (52.6 ± 37.6 million/ml; p =
0.490) and for young-oligo (5.9 ± 4.4 million/ml) versus old-oligo (5.4 ± 4.5 mil-
lion/ml; p = 0.351). There was not a correlation between men age and sperm
concentration (Pearson’s correlation: r=-0.013, p = 0.469). For the 1127 cycles
in which the embryos were cultured until blastocyst stage, the blastocyst forma-
tion rate was not affected by the men age (young-normal: 29.8%; young-oligo:
27.4%; old-normal: 32.8%; old-oligo: 28.3%; p = 0.457). The association of men
age or sperm concentration or interaction of both on the clinical pregnancy was
evaluated by multiple regression analysis adjusted to women age and we did not
ﬁnd any signiﬁcant association (men age: OR = 0.995, p = 0.432; sperm count:
OR0.998, p = 0.162; interaction of both: OR = 0.648, p = 0.254). The clinical
pregnancy rates of groups were: young-normal: 32.7%; young-oligo: 34.8%; old-
normal: 26.7%; old-oligo: 22.8% (p = 0.080).
Limitations, reasons for caution: Retrospective design is a limitation of this
study. Despite of large casuistic of this study, the number of cycles included in
the group of age ≥50 years is small. The multiple regression model was used to
adjust the outcomes for the women age; however, other female factors were
not considered.
Wider implications of the ﬁndings: We investigated the association of
men age and sperm count in outcomes of ICSI cycles and showed no associ-
ation. Our ﬁndings are in line with those authors presenting the paternal age is
not a determinant factor of the ICSI cycles, even if the sperm count is declined.
Trial registration number: not applicable.
P-081 The impact of isolated teratozoospermia on the outcome of
intrauterine insemination after ovarian stimulation with
gonadotropin
M. Jeong1, S. Kim1, C.W. Choo2, S.K. Kim3, S.H. Kim1
1Seoul National University Hospital, Obstetrics and Gynecology, Seoul, Korea- South
2Seoul Maria Fertility Hospital, Obstetrics and Gynecology, Seoul, Korea- South
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Study question: What are pregnancy outcomes after intrauterine insemin-
ation (IUI) in couples with isolated teratozoospermia (<4% of normal form with
normal count and motility)?
Summary answer: Clinical pregnancy rate and abortion rate after IUI in cou-
ples with isolated teratozoospermia are comparable with those in couples with
normozoospermia.
What is known already: Decreased sperm count and motility before and
after sperm preparation are known to be associated with IUI outcomes, but the
impact of sperm morphology on IUI outcomes are still controversial.
Study design, size, duration: A retrospective study was conducted using
data from 466 couples who underwent 858 stimulated IUI cycles from January
2015 to December 2016.
Participants/materials, setting, methods: Couples with endometriosis
and tubal factor infertility were excluded. All couples showed normal count and
motility in the semen analysis. Ovarian stimulation was performed by gonado-
tropin injections. The couples were divided according to the percentage of nor-
mal form; group A(<1.0%), group B(1.0–1.9%), group C(2.0–2.9%), group
D(3.0–3.9%), and group E(≥4.0%). Subgroup analysis was performed in women
with normal ovarian reserve(serum AMH level 1.5–4.0 ng/mL, female age ≤40
years).
Main results and the role of chance: Overall clinical pregnancy rate was
15.3% (131/858). Clinical pregnancy rate was 13.0% (32/247) in group A,
24.0% (44/183) in group B, 13.0% (16/123) in group C, 10.4% (8/77) in group
D, and 13.6% (31/228) in group E. Clinical pregnancy rate was signiﬁcantly high-
er in group B compared with group E (P <.05). In women with normal ovarian
reserve, clinical pregnancy rate was similar among ﬁve groups; 16.0% (13/81) in
group A, 18.3% (11/60) in group B, 15.9% (7/44) in group C, 3.8% (1/26) in
group D, and 11.1% (8/72) in group E.
Limitations, reasons for caution: Size and numbers of mature follicles at
triggering day was not included.
Wider implications of the ﬁndings: These results suggest that IUI which is
less invasive and cost-effective may be the ﬁrst-line option in couples with iso-
lated teratozoospermia before moving on to in vitro fertilization/
Intracytoplasmic sperm injection (IVF/ICSI).
Trial registration number:Not applicable.
P-082 Human sperm lipid proﬁling in men with asthenospermia
Y.S. Cho1, S. Lobasso2, R. Vitale2, P. Lopalco2, P. Totaro1,
A. Corcelli2
1Ospedale Santa Maria, Assisted Procreation Unit, Bari BA, Italy
2University of Bari Aldo Moro, Department of Basic Medical Sciences- Neuroscience
and Sense Organs, Bari, Italy
Study question: Is sperm lipid proﬁle in asthenospermia different from
normozoospermia?
Summary answer: Asthenospermic semen samples showed an alteration in
cholesterol sulphate/seminolipid ratio.
What is known already: Lipid composition of spermatozoa is important in
determining the functional characteristics of the spermatozoa, in particular on
motility, acrosomal exocytosis or fusogenic properties of the sperm.
Study design, size, duration: Sperm samples from 33 men undergoing IVF/
ICSI treatment were collected of which 9 with normozoospermia (group A;
control) and 11 with asthenospermia (group B) were included in this study. The
total progressively motile sperm cells/ejaculate were 166.4 + 44.3 millions and
6.4 + 5.9 millions in group A and B respectively. Semen samples were collected,
frozen, and stored at -80 °C until processed.
Participants/materials, setting, methods:We used Matrix Assisted Laser
Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF/MS) in
the negative ion mode combined with Thin Layer Chromatography (TLC) to
elucidate the lipid composition.
The signals of the MALDI mass spectra (3 replicates/sample) were exported
in a ﬁnal matrix in a compatible format for the multivariate analysis with
ClinProTools 3.0 software and t-test was used to conﬁrm signiﬁcant differences
between the two lipid patterns. Peaks with P < 0.05 were considered statistic-
ally signiﬁcant.
Main results and the role of chance: Our data on the lipid composition of
whole ejaculate give novel information on lipid molecular species and compo-
nents. In contrast to previous literature reports, we have found only traces of
cardiolipin; the only cardiolipin species found in sperm has four palmitic acid
chains (corresponding to the MS peak at m/z 1352.3). The mass spectrometry
and chromatographic (TLC) comparative analyses of control and asthenosper-
mic samples suggest an alteration in cholesterol sulphate/seminolipid ratio. As
regards sulfolipids, TLC and MALDI-TOF mass spectra replicates showed
that the content of the cholesterol sulphate (corresponding to the MS peak
at m/z 465.4) and of the sulphoquinovosyl acylalkyl glycerol (namely S-
QDG or seminolipid corresponding to the MS peak at 795.8) were signiﬁ-
cantly different between the two groups (P < 0.05). The mean intensity of
the cholesterol sulphate MS peak and of the seminolipid MS peak were
40.0 ± 6.8 and 278.9 ± 70.6 in group A and 156.4 ± 53.9 and 59.7 ± 25.5
in group B respectively.
The speciﬁc lipid composition of seminal plasma and of spermatozoa is under
investigation.
Limitations, reasons for caution: The seminolipid is exclusively present in
the spermatozoa whereas the cholesterolsulphate is a component of the sem-
inal ﬂuid and of blood, too. In future studies, it may be interesting to measure
the cholesterol levels as well as its derivative cholesterolsulphate in the blood in
order to verify patient speciﬁc differences.
Wider implications of the ﬁndings: Our results suggest that the MALDI-
TOF/MS lipid proﬁle of sperm may represent a diagnostic tool for the assess-
ment of asthenospermic conditions in the clinical practice.
Trial registration number:None.
P-083 Fibronectin and human sperm selection
M. Heidari, M. Darbandi, S. Darbandi, M.R. Sadeghi
Avicenna Research Institute Shahid Beheshti University- Evine, Endocrinology
Reproductive & Embryology, Tehran, Iran
Study question: Does Fibronectin protein as a new biomarker can be used
for human sperm selection in ART?
Summary answer: Fibronectin can be used for selection of sperm with suit-
able quality.
What is known already: Detection of these molecules on the sperm surface
and separation of sperm according to them are dependent on the availability of
a speciﬁc ligand for designing a commercial test. Todays, hyaluronic acid as the
PICSI dish is the only speciﬁc ligand available for sperm selection. In addition
speciﬁc antibodies, as powerful ligands for detection, separation and measure-
ment of other suggested biomarkers were used in different studies. Fibronectin
(FN) is a multifunctional diametric glycoprotein on the surface of sperm plays
an important role in sperm-oocyte interaction and fertilization process.
Study design, size, duration: Amount of FN and the sperm quality were
assessed in normozoospermia (N) (42 men) and asthenoteratozoospermia
(AT) (72 men) groups through Sperm chromatin dispersion (SCD), sperm
chromatin structure assay (SCSA) and chromatin maturation index (CMI).
Semen samples were collected after 48–72 h of sexual abstinence and assessed
according to World Health Organization guideline (WHO)
Participants/materials, setting, methods: Polyclonal antibody against
human FN was produced in rabbit. Its quality, purity and immune reactivity
were assessed by SDS-PAGE and western blotting (WB). Also presence of FN
on sperm surface was assessed through immunocytochemistry (ICC) and ﬂow
cytometry (FCM).
Main results and the role of chance: The results showed the FN distribu-
tion on the equatorial region of human sperm. Statistically signiﬁcant differences
were found in the FN levels of sperm surface between two groups with 24.64
± 9.08% in N and 16.90 ± 7.27% in AT (p≤0.0001). Also, FN level correlated
negatively with SCD (p≤0.0001), SCSA (p≤0.0001), and CMI (p≤0.001). A
threshold of FN level and DFI percentage respectively were 16 and 30, were
identiﬁed as a cut-off value to determine N with speciﬁcity 83.3% and 81.0%,
and sensitivity of 16.8% and 19.0%. A speciﬁcity and sensitivity of FN-DFI were
91.2% and 8.8%.
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Limitations, reasons for caution: This study implied that the FN levels in
sperm could be potentially used as a biomarker in sperm selection and assessing
the quality of sperm in ART.
Wider implications of the ﬁndings: Our study suggests that FN can be
used for selection of sperm with suitable quality although future studies are
recommended.
Trial registration number:N.A.
P-084 Prognostic factors of ICSI-success rates in azoospermic male
patients
J. Rehnitz1, S. Roesner1, J. Harsch1, T. Bruckner2, T. Strowitzki1,
A. Germeyer1
1Universitäts-Frauenklinik, Gynecological Endocrinology and Fertily Disorders,
Heidelberg, Germany
2University Hospital, Institute of Medical Biometry and Informatics, Heidelberg,
Germany
Study question: Identiﬁcation of prognostic factors affecting success rates in
infertile couples undergoing ICSI procedure after TESE (testicular sperm
extraction).
Summary answer: High embryo quality and lower male BMI positively affect
ICSI success rate after TESE. In case of tubular-atrophy ≥SIGG4 no pregnancy
could be achieved.
What is known already: Azoospermia is deﬁned as complete absence of
sperms in male ejaculate leading to infertility. Azoospermia can be divided into
obstructive azoospermia, where the vas deferens is affected and non obstruct-
ive azoospermia, where spermatogenesis itself is impaired. Testicular atrophy
can be classiﬁed histologically after its severity into categories after SIGG.
Azoospermic men are often recommended to undergo TESE to evaluate, if
mature sperms can be found and ICSI-procedure is feasible. To our knowledge
little is known about further clinical factors that can affect ICSI success rates in
those couples undergoing ICSI treatment after sperm-positive testicular
biopsie.
Study design, size, duration: Retrospective analysis of 118 cycles of ICSI-
treatment after TESE-procedure because of male azoospermia. Clinical data
were selected from our medical records. Statistical analysis including Wilcoxon,
Fishers Exact and Chi-Square-Test were carried out with SAS statistic software;
statistical signiﬁcance was set as p≤0.05.
Participants/materials, setting, methods: 118 cycles of couples undergo-
ing ICSI procedure after TESE with sperm-positive result were analyzed. Of
those 66 cycles were the ﬁrst, 35 the second and 17 the third ICSI attempt. To
avoid statistical bias only the ﬁrst 66 cycles of 66 different couples are demon-
strated here. We evaluated, if potential prognostic factors, such as male/female
age, male/female BMI, male/female nicotine abuse and histological result affect
ICSI-pregnancy-rates (HCG-positivity 14 days after embryo transfer).
Main results and the role of chance: Pregnancy rate of couples with two
good quality embryos were 47.62% and 38.1% with one good quality embryo,
whereas only 14.29% in case of poor quality embryos. So embryo quality was
positively associated with pregnancy chance (p = 0.0278), as seen in conven-
tional IVF/ICSI. Males whose mates conceived after TESE/ICSI were signiﬁ-
cantly leaner than men whose partners did not get pregnant (p = 0.023). BMI
of women and age of men and women had no effect on pregnancy rate in our
population; as well as nonsmoking was not positively correlated in men and
women with ICSI-success - maybe due to small numbers of smokers in both
groups (only 12 men and 9 women in total). Women whose partners had tubu-
lar atrophy ≥ SIGG4 did not conceive in our population even if mature sperms
were bioptically found, regardless of the number of cycles that were
performed.
Limitations, reasons for caution: Analyzed cycle number (total 118) was
low. Prospective analysis of more patients are needed to improve prognostic
statements for couples undergoing ICSI procedure after TESE.
Wider implications of the ﬁndings: Similar to situation in conventional
IVF/ICSI embryo quality is highly relevant for success-rate in ICSI/TESE.
Additionally, men´s weight seems to have an effect and weight reduction in
overweight men can be discussed before TESE. In case of tubular-atrophy
≥SIGG4 couples should be informed about their low chances conceiving with
ICSI-procedure.
Trial registration number: not applicable.
P-085 Investigating the expression of sperm-speciﬁc microRNAs in
a mousemodel of obesity
M. Khalid Abdulkareem Al-Gazi1, S. Bradburn1, S. Sugden2,
M. Ahmed2, A. Greenstein2, C. Murgatroyd1, M. Carroll1
1Manchester Metropolitian University, School of Healthcare Science, Manchester,
United Kingdom
2University of Manchester, Institute of Cardiovascular Sciences, Manchester, United
Kingdom
Study question: To investigate the relative expression and the epigenetic
control of sperm-speciﬁc microRNAs in high fat diet (HFD) mice and aged
matched controls (AMC).
Summary answer: Sperm-speciﬁc MicroRNAs from HFD mice are upregu-
lated, with miR-21a-5p being highly signiﬁcant. miR-21a-5p expression is regu-
lated by methylation of CpG islands on VMP1 promoter.
What is known already: MicroRNAs (miRNAs) are small non-coding sin-
gle-strand RNA molecules (17-26 nucleotides). miRNAs are encoded in the
genome and transcribed by RNA polymerase II to form long primary miRNA
transcripts. After post-transcriptional processing, the mature miRNAs can
targets mRNA transcripts inhibiting gene expression through disruption of
ribosomal attachment, or via degradation of the mRNA transcript. Sperm
contain a unique family of miRNAs, which are responsible for spermatogen-
esis, sperm function and embryogenesis. Several reports have implicated
dysregulation of sperm speciﬁc miRNAs in male infertility. High fat diet can
alter the expression of miRNAs in sperm, which may impair sperm function
and fertility.
Study design, size, duration: C57BL/6 mice were fed on rodent diet with
60% kcal% fat (HFD, n = 12) and rodent diet with 10% kcal% fat (AMC, n =
12) for 24-28 weeks post weaning. After sacriﬁce, the testes were removed
and the sperm were extracted form the epididymis and processed for total
DNA and RNA extraction. A panel of 84 sperm-speciﬁc microRNA was
assessed in addition to the methylation status of the VMP1 promoter.
Participants/materials, setting, methods: Epididymal sperm were
removed and isolated by the swim-up method. Total RNA was extracted using
the Norgen biotek kit and used for qPCR for 84 sperm-speciﬁc miRNAs using
custom miScript miRNA PCR array (Qiagen-UK). Sperm DNA was isolated by
cell lysis and ethanol precipitation. The methylation status at two CpG sites on
the VMP1 promoter region was carried out by bisulﬁte pyrosequencing using
PyroMark Q24 system (Qiagen, UK).
Main results and the role of chance: This study revealed an increase in the
relative expression of 28 miRNAs (p = 0.05) in the sperm of HFD mice. With
miR-883a-3p expression been signiﬁcantly lower in HFD nice (p = 0.05). The
remaining miRNAs assessed on the miRNA PCR array showed no signiﬁcant
difference in relative expression in HFD and AMC mouse sperm. After applying
a Bonferroni correction, it was demonstrated that miR-21a-5p relative expres-
sion was highly signiﬁcant in the HFD mouse sperm relative to AMC (p =
0.0006). We were then interested in the epigenetic regulation of miR-21a-5p.
The sequence responsible for the expressions of the pre-miR-21a-5p overlap
with the upstream 3’UTR end of the VMP1 gene. Using bisulﬁte pyrosequencing
we showed increased methylation at CpG sites in this region in AMC mice.
These data indicate the epigenetic control of miR-21a-5p expression in sperm
in relation to high fat diet.
Limitations, reasons for caution: A limited panel of miRNAs were analysed
and only mature sperm were assessed.
Wider implications of the ﬁndings: This study links obesity with altered
expression of sperm miRNAs in a mouse model. In addition, there was a
change in the methylation status and expression of miR-21a-5p. These data
indicate the impact that paternal high fat diet has on sperm miRNA expression
and DNA methylation.
Trial registration number:None.
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P-086 Sperm quality affects fertilization but not embryo cleavage
and pregnancy rates after intracytoplasmic sperm injection
F. Imbimbo1,3, G. Coticchio2, G. Patria1, G. Intra1,
M.R. Campitiello3, A. Borini1,2,3
1Policlinico San Marco- 9puntobaby Family and Fertility Center Osio Sotto- Bergamo,
Ospital, Osio di Sotto- Bergamo, Italy
29puntobaby Family and Fertility Center Bologna - Medicine of reproduction - Via
Dante, 15 - Bologna - Italy,
3Tortorella Clinic - 9puntobaby Family and Fertility Center Salerno - Via Nicola
Aversano, 1 - Salerno - Italy,
Study question: This study deals with correlations between sperm quality
and fertilization rate, early embryos development, pregnancy and implantation
rates in patients undergoing Intra-Cytoplasmic Sperm Injection (ICSI).
Summary answer: Sperm quality signiﬁcantly affects fertilization rate but not
embryo cleavage in patients who underwent ICSI.
What is known already: Several studies have suggested that differences in
sperm quality (i.e., azoospermic, sever oligoasthenoteratozoospermic and nor-
mozoospermic) reﬂect on oocyte fertilization, zygotes and embryos quality dur-
ing cleavage stages. Also, pregnancy and implantation rates are believed to be
independent from sperm quality.
Study design, size, duration: This study considered 1049 ICSI cycles
between April 2016 and December 2017. The study excluded those cases with
freeze-all embryos and couples with sever female factor (i.e., endometriosis
and uterine factor). Sperm quality was classiﬁed into four groups according to
WHO2010: Group1 - Normozoospermic (sperm/ml≥15M); Group2 -
Moderate Male Factor (5≤sperm/ml<15 M); Group3 - Severe
Oligoasthenoteratozoospermia (0<sperm/ml≤5 M); Group4 – Azoospermia
(sperm/ml = 0).
Participants/materials, setting, methods: Partner age for the four groups
was respectively: Female - 34.71 ± 5.8; 37.72 ± 3.75; 36.73 ± 4.47; 36.38 ±
4.45. Male – 40.3 ± 5.8; 40.1 ± 5.75; 39.97 ± 5.73; 41.24 ± 8.57. A total of
5849 MII oocytes were inseminated. Average value of inseminated oocytes for
each group was 5.16 ± 2.89, 5.14 ± 2.76, 5.50 ± 3.15, 6.45 ± 3.55 respect-
ively. Data analysis was carried out using correlation study and ANOVA, which
was set with a statistical signiﬁcance threshold of P < 0.05. The statistical
Matlab toolbox was adopted for the study.
Main results and the role of chance: Fertilization rate decreased with
increasing severity of male factor across the groups. The difference was not
statistically signiﬁcant among Group1, 2 and 3 (77%, 73% and 73% respectively)
but was signiﬁcant (P-value 0.00043) between Group1-3 and Group4 (59%).
Instead, no trend was observed for cleavage rate both on day 2 and 3. The dif-
ference was not statistically signiﬁcant among groups (97%, 96%, 99%, 96%, P-
value 0.07 on day 2) (87%, 86%, 84%, 85%, P-value 0.128 on day 3). Embryo
quality, expressed as number of grade 1-2 and 4-cell embryos on day 2, was
not affected by sperm quality. In fact, the difference was not statistically signiﬁ-
cant (P-value 0.507) among groups (90%, 86%, 87%, 84%). The same trend was
observed for embryo quality on day 3 (78%, 75%, 80%, 73%, P-value 0.67).
Finally, no signiﬁcant differences were observed in the pregnancy and implant-
ation rates (16%, 11%, 17%, 19%) (10%, 8%, 11%, 12%) (P-value 0.527)
respectively.
Limitations, reasons for caution: Although a very large cohort of patients
was enrolled, the study is retrospective. In addition, groups are different in size.
Therefore, controlled, randomized and well-designed studies are needed to
conﬁrm data.
Wider implications of the ﬁndings: Sperm quality impacts fertilization but
it does not affect ICSI outcome. Therefore, all measures should be taken to
assure maximal performance of ICSI in cases of severely compromised sperm
quality.
Trial registration number:Not applicable.
P-087 Peak retrograde ﬂow in adolescents with varicoceles
inﬂuences spermDNA integrity
G. DeWin1, S. Stuer2, E. Coeck2, S. DeWachter1,
D. De Neubourg3, U.R. Punjabi3
1Universitair Ziekenhuis Antwerpen, Department of Urology, Edegem, Belgium
2University of Antwerp, Faculty of Medicine and Health Sciences, Edegem, Belgium
3Universitair Ziekenhuis Antwerpen, Centre for Reproductive Medicine, Edegem,
Belgium
Study question: Does varicocele diagnosed in adolescents using the peak
retrograde ﬂow inﬂuence sperm DNA integrity?
Summary answer: The presence of varicocele, particularly with a PRF ≥
38 cm/sec, tends to increase both total and vital DNA fragmentation as com-
pared to healthy adolescents.
What is known already: Correct indication for varicocele repair in adoles-
cents remains a subject of ongoing debate. Some researchers advocate the
use of a high peak retrograde blood ﬂow (PRF > 38.4 cm/s) in combination
with a 20% testicular atrophy index (TAI) as criteria for treatment. Currently,
there is a growing interest in the measurement of the supine PRF in the varico-
cele vessels. Conventional semen parameters are evaluated in varicocele
studies but the signiﬁcance is weakened due to lack of standardization.
However, the true signiﬁcance of the presence of the harbinger regarding
standard sperm parameters and sperm DNA fragmentation in adolescents is
still unclear.
Study design, size, duration: This study was a prospective, cross-sectional
observational study. Between February 2017 and January 2018, sixty seven
volunteers (mean age 21.5 years) were recruited. A total of 62 participants met
the inclusion criteria.
Participants/materials, setting, methods: Every participant had a scrotal
ultrasound to calculate testicular volumes (using the Lambert formula) and TAI.
If varicocele was present, the grade and PRF in supine position was measured.
All participants provided semen samples. Standard semen parameters were
analyzed according to the WHO 2010 guidelines, and sperm DNA fragmenta-
tion test was performed using TUNEL assay in total and vital fractions of the
semen. For statistical analysis, primarily ANOVA, Kruskall-Wallis, t-tests and
Mann-Whitney tests were performed.
Main results and the role of chance: Of the 62 participants included, 35
were without (56.5%) and 27 (43.5%) with a varicocele. There was no signiﬁ-
cant difference in the semen parameters (sperm concentration, motility and
morphology) and sperm DNA integrity between these two groups. Taking into
account the 20/38-harbinger criteria, progressive and total sperm motility was
signiﬁcantly (p = 0.009 and p = 0.027, respectively) lower than in those who
did not meet the harbinger-criterium. Sperm concentration, morphology and
sperm DNA were not signiﬁcantly different. The varicocele group was subdi-
vided into one with a low PRF (21/27, 77.7%) and those with a high PRF (6/27,
22.2%). The descriptive semen parameters were not signiﬁcantly different in
the healthy control and in the varicocele group with high/low PRF. Total sperm
DNA fragmentation was signiﬁcantly higher (p = 0.021) with high PRF than with
low PRF as compared to the controls. Vital sperm DNA fragmentation was
higher in high PRF group than in the low PRF group (p = 0.029). TAI and differ-
ent grades of varicocele did not inﬂuence semen parameters and sperm chro-
matin integrity.
Limitations, reasons for caution: Study is still ongoing. Results are prelimin-
ary observations on a limited number of participants.
Wider implications of the ﬁndings: The ﬁndings in this study might have
implications in proving the presence of the 20/38-harbinger in varicocele
patients as a valid criterium for surgical treatment.
Trial registration number: B300201730926
P-088 Severe male factor infertility – is there a role for
pre-implantation genetic screening (PGS)?
K.C. Mantravadi1, D.R. Gedela2
1Oasis Centre for Reproductive Medicine, EMBRYOLOGY, Hyderabad, India
2Oasis Centre for Reproductive Medicine, Infertility, Hyderabad, India
Study question: Will male factor infertility bring about higher incidence of
Embryo Aneuploidy? Will PGS help us pick euploid embryo and optimize repro-
ductive outcome in cases with severe male factor infertility?
Summary answer: Severe male factor does’nt bring about higher incidence
of embryo aneuploidy and there seems positive trend for use of PGS to opti-
mize reproductive outcomes.
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What is known already: Sperm has an equal contribution in reproductive
outcomes. Severe male factor is shown to affect reproductive outcomes.
There is an increasing concern that lower sperm counts, advancing paternal
age and use of testicular sperm might increase embryo aneuploidy and
negatively affect the reproductive outcomes. There is also a potential risk
for epigenetic changes in the off spring with severe male factor infertility.
Hence, we wanted to look for incidence of aneuploidy in severe male fac-
tor cases through PGS and justify the role of PGS to optimize reproductive
outcomes in such cases.
Study design, size, duration: This was a retrospective study of all of couples
in the year 2014-2016 with severe male factor infertility and undergoing PGS
for failed implantation as an indication.
All couples during study period with two-failed IVF/ICSI attempts (fresh or
frozen transfers) were offered PGS at our centre.
All couples were subjected to trophectoderm biopsy on day 5-post insemin-
ation. All embryos were vitriﬁed post biopsy. Biopsied tissue was subjected to
comprehensive chromosomal screening with Next Generation Sequencing.
Participants/materials, setting, methods: Male partners were divided
into three groups based on age (<40 yrs (n = 43) and >40 yrs age (n = 20)),
sperm counts (<5millions/ml (n = 14) & >5millions/ml (n = 31)) and source of
sperm (Ejaculate (n = 31) &Testicular sperm (n = 33)).
Mean aneuploidy was calculated. Only couples with female age < 35years
were included to ensure we do not have bias with advanced maternal age.
Euploid embryos were transferred in a frozen embryo replacement cycle. Live
birth rate in all groups were calculated.
Main results and the role of chance: Mean aneuploidy and Live birth rates
in each group respectively were as follows:
<40 yrs age – 54.58% & 68.75%
>40 yrs age – 56.66% & 25% (p = 0.0013)
<5millions/ml -52.63% & 50%
>5millions/ml – 54.45% & 59%
Testicular sperm- 56.41% & 64%
Ejaculate sperm – 54% & 59%
All the groups of severe male factor infertility showed similar incidence of
aneuploidy and there was no statistical signiﬁcance. LBR across all groups was
comparable except advanced paternal age group – 25% (p = 0.0013).
Young couples seem to have the highest LBR compared to advanced age.
Though the advanced paternal age group had similar aneuploidy rates, still LBR
were statistically low. Sperm counts and source of sperm for IVF/ICSI seem to
have comparable aneuploidy rates and LBR.
Limitations, reasons for caution: Retrospective data, Small sample size.
Wider implications of the ﬁndings: Advanced Paternal age and reproduct-
ive outcomes needs further research. Use of testicular sperm for IVF/ICSI
seems encouraging. Advanced techniques seem to offer better reproductive
outcomes in severe male factor infertility. Third party reproduction using donor
sperm should not be offered as a ﬁrst line of treatment in such cases.
Trial registration number:Not Applicable.
P-089 Protective effects of Cinnamtannin B-1 (CINB-1) on human
sperm cryostorage
P.J. Soria Meneses1, J. Bartolomé García1, L. Luque2, I. Ochando2,
A.J. Soler3, R. Bernabeu2, F. Martinez-Pastor4, J.J. Garde3,
M.R. Fernández-Santos1
1University of Castilla La Mancha, Faculty of Pharmacy, Albacete, Spain
2Instituto Bernabeu, Instituto Bernabeu, Alicante, Spain
3University of Castilla La Mancha, Ciencia y Tecnología Agroforestal y Genética,
Albacete, Spain
4University of León, Bioquímica, León, Spain
Study question: Could the antioxidant CINB-1 protect sperm during cryo-
preservation and preserve its physiological parameters after thawing?
Summary answer: CIN B-1 at 100 μM preserves sperm viability and mito-
chondrial activity during sperm cryopreservation.
What is known already: The process of sperm freezing and thawing may be
related to an excessive production of reactive oxygen species (ROS), resulting
in adverse changes in membrane lipid composition, acrosomal status, motility
and viability. Adding antioxidants to the freezing extender could reduce these
negative effects. CINB-1 is a natural A-type of proanthocyanidin that is present
in few plants, which has a large number of cellular actions, mostly derived from
its antioxidant properties. The protective ability of CINB-1 in thawed sperm
samples from deer has been demonstrated before.
Study design, size, duration: Forty four amples were evaluated from eleven
sperm healthy young donors. Sperm was collected with a period of abstinence
between 48-72 h. Samples were cryopreserved following the WHO manual
(2010) guidelines, supplementing with 0, 10 and 100 μM of CNB-1. Samples
were evaluated after thawing and after incubation (37 °C, 4 h). Motility was
evaluated by CASA. Viability, mitochondrial membrane potential, acrosomal
status, lipoperoxidation, intracellular ROS and DNA integrity were assessed by
ﬂow cytometry.
Participants/materials, setting, methods: Sperm donors were selected
according to ESHRE guidelines for gamete donation. After liquefaction, we
washed the sperm samples with PBS and diluted them in freezing medium
(Irvine Scientiﬁc). Extended spermatozoa were loaded into 0.25-mL plastic
straws and cooled down, equilibrated to 5 °C (40min) and frozen in nitrogen
vapours. The straws were thawed at 37 °C for 7 min. Data were analyzed by
linear mixed-effects models using R (http://www.r-project.org).
Main results and the role of chance: CNB-1 did not affect sperm motility
parameters. There were signiﬁcant effects in sperm viability, CINB-1 100 μM
showing a positive effect (p < 0.05) on the percentage of live sperm cells at 0 h
(19.27% ± 1.26) comparing to the control (15.11% ± 1.38) and CNB-1
(10 μM) (16.23% ± 0.74). Our results also show that the highest concentration
of CNB-1 (100 μM) preserved better the mitochondrial activity after 4 h of
incubation (10.60% ± 0.48) than the control (8.27 ± 0.54) (p < 0.05). There
were no effect of CINB-1 on the rest of sperm parameters evaluated (p ≥
0.05). There were no signiﬁcant effects of CINB-1 on other sperm parameters,
including DNA integrity, either after thawing or after 4 h of incubation (p ≥
0.05).
Limitations, reasons for caution: We believe that sample size might be a
limitation of this study as well as the use of normozoospermic samples. Further
studies should be carried out to verify CINB-1 protective effect during cryo-
preservation in samples of low seminal quality.
Wider implications of the ﬁndings: Given the beneﬁcial effect of
Cinnamtannin B-1 in vitro, its use could also be considered as a feeding supple-
ment especially in infertile men.
Trial registration number: not applicable.
P-090 Ability of SOD1 and SOD3 in seminal plasma to distinguish
between two different azoospermic subgroups (mixed testicular
atrophy and Sertoli cell-only syndrome)
E. Savadi Shiraz1, A. Pilatz2, W.Weidner2, D. Fietz3, L. O’Donnell4,
M. Bergmann3, T. Diemer2, P. Stanton4
1Department of Urology- Pediatric Urology and Andrology- Justus Liebig University-
Giessen- Germany, Department of Urology- Pediatric Urology and Andrology- Justus
Liebig University- Giessen- Germany, Giessen, Germany
2Justus Liebig University, Department of Urology- Pediatric Urology and Andrology.,
Giessen, Germany
3Justus Liebig University, Institute for Veterinary Anatomy- Histology and Embryology.,
Giessen, Germany
4Monash University, Hudson Institute of Medical Research. Department of Molecular
and Translational Science., Melbourne, Australia
Study question: Are there marker proteins in seminal plasma that can predict
the presence of testicular sperm before an invasive surgery in men suffering
from non-obstructive azoospermia?
Summary answer: SOD3 (Superoxide dismutase 3) protein in seminal plas-
ma has potential to predict the success of micro-dissection sperm retrieval in
non-obstructive azoospermia men (NOA).
What is known already:Men with NOA have zero sperm in the ejaculate.
Testicular sperm suitable for assisted reproductive technology (ART) could
be present in NOA patients.
Sperm is collected by micro-testicular sperm extraction (M-TESE). However,
no diagnostic test exists to predict the presence of sperm in the testis biopsy
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before surgery. About 50% of azoospermic men are unable to have sperm
retrieved at M-TESE and therefore have surgery unnecessarily. The ability to
predict the presence of sperm in the testis prior to TESE would improve sperm
retrieval rates and avoid unnecessary surgery.
Study design, size, duration: Identiﬁcation of speciﬁc proteins related to
spermatogenesis in seminal plasma(SP) could provide a novel proteomics assay
for sperm presence prior to biopsy. SP is a rich, easily-accessible and promising
source of spermatogenesis biomarkers. This study was designed to compare
the SP proteomes of two different groups of NOA.
(1) Men with mixed-testicular atrophy(MA) with a positive sperm retrieval at
M-TESE.
(2) Sertoli-cell-only(SCO) patients with a negative sperm retrieval at M-TESE.
Results also compared with the control-group.
Participants/materials, setting, methods: SP was collected from MA and
SCO patients (n = 8/group). Samples were compared by label-free Liquid
chromatography-mass spectrometry/MS proteomics. Differentially expressed
proteins were deﬁned as those with a fold-change >2.0 and a signiﬁcant differ-
ence between the groups(p < 0.05).
Among the signiﬁcant proteins identiﬁed, SOD3 and SOD1 were selected
for further validation by 3 different methods:Western blotting, immunohisto-
chemistry and ELISA (n = 15/group). To compare with SP, the protein concen-
trations of SOD3 and SOD1 were measured in the blood-serum of
participants.
Main results and the role of chance: SOD3 immunoreactivity (ELISA) in
SP from SCO men was 2.3 fold lower than controls (p < 0.05), and SP
from MA men was 4.6 fold lower than controls (p < 0.0001). The SOD3
MA/SCO protein ratio was 0.49 (p < 0.05) by ELISA and 0.16 (p < 0.01)
by mass spectrometry. SOD3 gave the expected band of 30 kDa by
Western blot of SP samples, but no signiﬁcant difference between MA and
SCO groups was observed.
In normal human testis, SOD3 staining was predominantly observed in Sertoli
cells, while in the testis of azoospermic patients staining was more variable.
SOD1 immunoreactivity (ELISA) in SP from SCO and MA men was
decreased signiﬁcantly compared with controls (p < 0.05). The MA/SCO ratio
of SOD1 was signiﬁcantly different by mass spectrometry but not by ELISA or
quantitative Western blot. In normal human testis, SOD1 was predominantly
localized in spermatogonia, while in the testis of azoospermic patients variable
SOD1 staining was noted.
There were no signiﬁcant differences in the levels of SOD1 and SOD3 in the
blood-serum of MA compared to SCO patients.
Limitations, reasons for caution: Two different antibodies were used for
quantitation of protein (in both cases of SOD1 and SOD3) by Western-blotting
compared to ELISA which may explain the variation in results. Moreover, the
selected antibodies may not target the same sequence region that was detected
by the mass spectrometry.
Wider implications of the ﬁndings: SOD3 was signiﬁcantly different in SP
from MA versus SCO azoospermic patients by at least 2 different proteomics-
methods (mass spectrometry and ELISA), and thus has the potential to predict
the presence of sperm in the testis prior to biopsy.
Trial registration number: The trial registration number for this project is
IRTG-62280541.
P-091 Predictors of positive sperm retrieval in azoospermic men
M. Esbert Algam1, J.M. Pomerol2, A. Gimenez1, M. Florensa1,
A. Ballesteros3, N. Garrido4
1IVI Barcelona, IVF laboratory, Barcelona, Spain
2IVI Barcelona, Andrology, Barcelona, Spain
3IVI Barcelona, Gynecology, Barcelona, Spain
4IVI Foundation, Research/Innovation, Valencia, Spain
Study question: Are there reliable factors able to predict the sperm retrieval
rate (SRR) after conventional testicular sperm extraction (c-TESE)?
Summary answer: Testicular volume and histopathological diagnosis are
related with the SRR while age, months of infertility, FSH level and body mass
index are not good predictors.
What is known already: Obtaining sperm from the testis in combination
with ICSI has become a routine in the assisted reproduction technology.
However, it is still controversial which is the most effective sperm retrieval
technology, the accuracy of different factors in predicting the SRR and if
uncoupled TESE/oocyte pick-up (OPU) should be considered to prevent pos-
sible unnecessary ovarian stimulation and OPU when no sperm cells are
detected.
The ability to predict those patients with a high probability of achieving a suc-
cessful sperm retrieval would be of great value in counselling the patient and his
partner.
Study design, size, duration: This is a retrospective cohort study which
includes 96 consecutive azoospermic patients, 17 with obstructive azoospermia
(OA) and 79 with non-obstructive azoospermia (NOA) who underwent c-
TESE between 2004 and 2017.
The origin of the obstructive azoospermia was epididimal obstruction (n =
13), vas deferens obstruction (n = 3) or vasectomy (n = 1).
Participants/materials, setting, methods: All patients, whose azoosper-
mia was conﬁrmed by two semen analyses, underwent c-TESE by the same sur-
geon. The specimens were examined by an embryologist, where all the tubules
were teased and analysed for the presence of sperm. A histopathology speci-
men was sent for analysis.
Factors such as male age (years), duration of infertility (months), FSH level
(mUI/mL), body mass index (BMI), testicular volume (mL) and the histopatho-
logical diagnosis were correlated with the presence of sperm.
Main results and the role of chance: OA patients were older than NOA
males (39.5 (95%CI 34.3-43.8) vs. 36.03 (95%CI 35.0-37.0)) (p = 0.015).
However, the infertility duration (27.5 (95% CI 20.5-34.4) vs. 32.35 (95%CI
27.2-37.5)) (p = 0.028) and FSH levels (5.6 (95%CI 4.2-7.1) vs. 16.8 (95%CI
14.0-19.7)) (p = 0.001) were lower.
The SRR was 100% in the OA patients and 29.1% in the NOA group. No
complications after the surgery were seen.
In the NOA group, the area under the ROC curve of male age, months of
infertility, FSH level and body mass index respect the chance of ﬁnding sperm
after c-TESE were 0.59, 0.51, 0.36, 0.45, respectively.
In 45.6% of the NOA patients, the volume of the biopsied testicle was dimin-
ished (<14 mL). The chance of positive SRR was higher in normal vs. low vol-
ume testicles (73.9% vs. 26.1%, p = 0.03).
Histopathological ﬁndings included four patterns: hypospermatogenesis
(reduced number of normal spermatogenetic cells), MA (maturation arrest,
only spermatogonia, spermatocytes and spermatids were detected), SCO
(Sertoli cell only) and tubular sclerosis. The incidence of each pattern in
NOA patients with negative SRR was 7.1%, 39.3%, 44.6% and 9.3%,
respectively. That means that in 92.9% of the cases where the embryologist
did not found any spermatozoa, the histopathological diagnosis conﬁrmed
the absence.
Limitations, reasons for caution: A low number of patients were analyzed
because most of the azoospermic males visiting in our center are foreigners and
their diagnostic TESE is performed abroad.
Our SRR is in the low range of what has been published, but the absence of
sperm was mostly conﬁrmed with the testis histopathology.
Wider implications of the ﬁndings: Although the testicular size seems to
be related to the SRR, the most reliable parameter predicting the presence of
sperm is the histopathological examination of testicular fragments. Despite hav-
ing higher predictive value, it would not prevent the patient from undergoing a
testicular biopsy.
Trial registration number:Not available.
P-092 Impaired fertility in a rat model of spinal cord injury and the
role of inﬂammasome complex
B. Nikmehr1, F. Abolhassani1, G. Hassanzadeh1, A. Shahverdi2,
M. Bazrafkan1, M. Hezavehei2, S. Berenjian1
1Tehran University of Medical Sciences, Department of Anatomy, Tehran, Iran
2Royan Institute for Reproductive Biomedicine- ACECR, Department of Embryology-
Reproductive Biomedicine Research Center, Tehran, Iran
Study question: Activation of inﬂammasome complex affects male fertility fol-
lowing spinal cord injury.
i182 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Summary answer: We found that there is a relationship between inﬂamma-
some activation in rat testis and low sperm parameters.
What is known already: Infertility is a common feature of men with spinal
cord injury (SCI). Inﬂammation is one of the most important abnormalities in
semen of these patients. Previous studies showed some inﬂammasome compo-
nents in semen of SCI men. Inﬂammasome activation pattern was found in
many tissues and disease but about testis is still unclear.
Study design, size, duration: There are 20 Wistar male rats in this study.
They were divided into four groups (n = 5): spinal cord injury was induced at
T10 level of the spine, at three groups and one group remained intact (control
group). Rats in SCI groups were sacriﬁced at three different time points: one
day, three days, and 7 days after surgery. Testes were removed and protein
analysis was done.
Participants/materials, setting, methods: In this experiment, Male
Wistar rats weighing 200-250 g were used. Testis sampling was done at three
speciﬁc time points (1, 3 and 7 days after injury). Protein expression (Caspase-1
and ASC) was assessed by immunoﬂuorescence (IF). Data were analyzed by a
parametric test of One-way ANOVA, and the comparison between the groups
was taken by the Tukey post hoc test (p < 0.05).
Main results and the role of chance: Immunoﬂuorescence showed a sig-
niﬁcant increase of inﬂammasome complex components from day 1 after injury.
The protein level of Caspase-1 increased signiﬁcantly on day 1, 3 and 7 after
injury in comparison to control (p < 0.001).The peak of Caspase-1 expression
was on day 7. ASC protein was raised signiﬁcantly on day 1, 3 and 7 after injury,
versus the control group (p < 0.001). The highest level of ASC protein was on
day 3
Limitations, reasons for caution: We had some ethical considerations
about the number of rats used in the study. Our data are experimental and
should be proven in human studies.
Wider implications of the ﬁndings: The reason of diminished sperm
parameters in patients with spinal cord injury is not clearly deﬁned. Our
data revealed a pattern for inﬂammasome activation in the rat testis
following spinal cord injury. In later step, Inﬂammasome antagonists should
be used to eliminate inﬂammasome complex and improve sperm
parameters.
Trial registration number: not applicable.
P-093 Novel mutations in the CFTR gene associated congenital
absence of vas deferens in China
Y. Gao1, Y. Xu1, Y. Liu1, C. Deng2, Y. Xu1, C. Zhou1
1The First Afﬁliated Hospital of Sun Yat-sen University, Reproductive Medicine
Centre, Guangzhou, China
2The First Afﬁliated Hospital of Sun Yat-sen University, Department of Andrology,
Guangzhou, China
Study question: What are the novel cystic ﬁbrosis transmembrane conduct-
ance regulator (CFTR) gene mutations and mutation spectrum in Chinese
patients with congenital bilateral absence of vas deferens (CBVAD)?
Summary answer: 23 novel CFTR mutations were detected in 192 Chinese
patients with CBAVD. 66% (127/192) patients have CFTR mutations.
What is known already: CBAVD is an autosomal recessive disease and
occurs in 1–2% of infertile men. CFTR mutations or IVS8-5T polymorphism
were the most common causes of CBAVD. The most common CFTR mutation
in many populations is a deletion named F508del. The 5 T variant in intron 8
(IVS8-5T) is common in the different populations, but a higher than normal fre-
quency of this allele has been found in CBAVD patients.
Study design, size, duration: A total of 192 male probands of congenital
bilateral absence of the vas deferens were collected from the Andrology Clinic
of the Reproductive Medicine Center in the First Afﬁliated Hospital of Sun Yat-
sen University between 2014 and 2016. Twenty males with normal vas defer-
ens were included as a control.
Participants/materials, setting, methods: CFTR mutations were
searched for using Sanger sequencing to analyze genomic DNA samples from
192 probands with CBAVD. The primers used to amplify the 27 coding exons,
the adjacent intronic regions, and the promoter. Potential pathogenic variants
were ﬁltered by the multiple-step bioinformatics analysis and further evaluated
in 20 normal controls by Sanger sequencing.
Main results and the role of chance: 66% (127/192) patients have CFTR
mutations. 35% (67/192) patients have two or more mutations (common
CFTR mutations or IVS8-5T polymorphism). 31% (60/192) have a single
detectable CFTR mutation. Of these detected mutations, 23 mutations were
novel. 7 novel mutations were detected in promoter. 11 of 16 novel mutations
in exons were predicted to be pathogenic by bioinformatic analysis. 30 (16%)
homozygous and 73 (38%) heterozygous IVS8-5T polymorphism were found.
But it was not found in controls. The most common CFTR mutation (F508del)
in many populations were not found in our subjects. This suggested the IVS8-5T
polymorphism was the major effect for Chinese male patients with CBAVD.
The other frequent mutation in the studied cohort, G970D, was found in 9 pro-
bands. This mutation was on shared haplotype and thus evidence of a founder
effect in the population. Furthermore, the severity of phenotypes may affect by
the number or type of CFTR mutations in those patients.
Limitations, reasons for caution: Over 34% (65/192) of the patients with-
out identiﬁed mutations might carry other pathogenic variants in the intron of
CFTR, or may be caused by mutations in novel genes yet to be identiﬁed.
Wider implications of the ﬁndings: This study analyzed the relation
between genotype and phenotype in Chinese CBAVD patients with CFTR
mutations. A comprehensive analysis of the CFTR gene expanded the mutation
spectrum in Chinese patients with CBAVD, and supplied the clues for discover-
ing novel causative CBAVD genes and the foundation for gene therapy.
Trial registration number: not applicable.
P-094 Improvement of ICSI outcome using sperm selection by
thermotaxis
S. Perez-Cerezales, R. Fernandez-Gonzalez, A. Chacon de Castro,
B. Rodriguez-Alonso, M.J. Sanchez-Calabuig, R. Laguna-Barraza,
A. Gutierrez-Adan
INIA, Reproducción Animal, Madrid, Spain
Study question: We tested if human and mice spermatozoa selected by
thermotaxis show higher quality than spermatozoa selected by swim-up.
Summary answer: We found that spermatozoa selected by thermotaxis
show much higher quality than those selected by swim-up and that mice
thermotaxis-selected spermatozoa improved ICSI outcome.
What is known already: Sperm selection occurring in vivo within the female
reproductive tract is bypassed when some artiﬁcial reproductive techniques
(ART) are used, such as in vitro fertilization or intracytoplasmic sperm injection
(ICSI). This could be in part behind the relative low success of fertility treat-
ments. Thus, improving sperm selection has been pointed as primary strategy in
order to improve ARTs outcome. Processes operating within the oviduct to
guide the spermatozoa to the fertilization site are candidates as mechanisms of
selection. This is the case of thermotaxis that guides the spermatozoa in
response to a temperature gradient stablished within the Fallopian tube.
Study design, size, duration: Mice and human spermatozoa were selected
by swim-up or by thermotaxis and the DNA integrity of the spermatozoa after
both selections was analyzed (n = 5 for mouse and n = 8 for human, 50-100
spermatozoa per determination). ICSI was conducted with mice spermatozoa
selected by swim-up or by thermotaxis (260 total ICSIs per sperm type).
Resultant embryo were cultured in vitro up to two cells or blastocyst stage and
transferred to recipient females.
Participants/materials, setting, methods: Sperm samples from B6D2
mice and 15 normospermic patients were used. Swim-up was performed fol-
lowing a standard procedure and thermotaxis using a method of sperm migra-
tion between two drops of medium connected by a capillary. Between the two
drops a temperature gradient was stablished in a way that one drop was at
35°C (were spermatozoa were loaded) and the other at 37°C (were spermato-
zoa were collected after 1 h). DNA quality was analyzed by comet assay.
Main results and the role of chance: In both species we clearly observed
lower DNA fragmentation in spermatozoa selected by thermotaxis. Thus, mice
swim-up showed 12 ± 0.6% and thermotaxis 3 ± 0.5% (P = 0.0001, Student’s
t-test) of DNA fragmentation and human swim-up showed 15 ± 3% and
thermotaxis 5 ± 0.8% (P = 0.001, Student’s t-test). Using spermatozoa selected
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by thermotaxis for ICSI we produced higher percentage of embryo reaching to
blastocysts stage (expanded and hatched) than using swim-up spermatozoa
[73 ± 6% vs 40 ± 11% respectively (P = 0.01, Student’s t-test)]. Furthermore,
signiﬁcantly higher implantation rates (analyzed 15 days after ICSI) were
recorded for thermotaxis-derived than swim-up-derived embryos both when
two cell embryos (75 ± 8% vs 27 ± 7%, P = 0.01, Student’s t-test) or blasto-
cysts (77 ± 9 vs 43 ± 18, P = 0.03, Student’s t-test) were transferred. For trans-
fers with 2-cell embryo, we also recorded higher rates of development to term
for the spermatozoa selected by thermotaxis (5 and 13 pregnancies to term
out of 24 transfers per group for swim-up–ICSI and thermotaxis–ICSI respect-
ively) and higher rates of born pups for the thermotaxis-ICSI derived embryos
(12 ± 2 and 29 ± 4% for swim-up- and thermotaxis separated spermatozoa
respectively; P = 0.027 two-tailed Student’s t-test).
Limitations, reasons for caution: Our results of ICSI are limited to mice
and are a proof of concept. At this stage we cannot conclude that sperm selec-
tion by thermotaxis would improve ICSI outcome in humans. Clinical trials with
human patients are being done now.
Wider implications of the ﬁndings: Sperm selection by thermotaxis repre-
sents the ﬁrst approach available to isolate a speciﬁc subpopulation of capaci-
tated spermatozoa for their characterization. This would allow to reveal basic
aspects of sperm biology and seed light on the contribution of the spermatozoa
in the process of fertilization and on early embryo development.
Trial registration number: not applicable.
P-095 Predictive value of static oxidation-reduction potential in
detecting high levels of spermDNA fragmentation in infertile men
A. Lee1, B. Yee1,2, A. Qu1,3, S. Shahani1, S. Moskovtsev1,4,
C. Librach4,5,6
1CReATe Fertility Center, Andrology, Toronto, Canada
2University of Toronto, Physiology, Toronto, Canada
3University of Toronto, Medicine, Toronto, Canada
4University of Toronto, Obstetrics and Gynaecology, Toronto, Canada
5CReATe Fertility Center, Reproductive Endrocrinology, Toronto, Canada
6Women’s College Hospital, Gynaecology, Toronto, Canada
Study question: Can sperm oxidative stress, measured as static oxidation-
reduction potential (sORP), predict high levels of sperm DNA damage?
Summary answer: sORP was positively correlated (p = 0.002) to DNA
damage and a sORP cut-off of 2.37 mV/106 sperm/mL was predictive of high
levels of DNA damage.
What is known already: High levels of sperm DNA damage have been asso-
ciated with decreased pregnancy rates and an increased risk of miscarriage.
While the causes are multifactorial, sperm oxidative stress has been shown to
play a key role in the etiology of DNA damage. The MiOXSYS system uses
sORP, a global measure of the balance between oxidants and reductants, to
determine oxidative stress.
Study design, size, duration: This prospective, institutional REB approved
cross-sectional study was performed on 52 male, infertile patients presenting to
the Andrology laboratory for routine semen analysis after 2-5 days of abstin-
ence at the CReATe Fertility Center between July 2017 and January 2018.
Participants/materials, setting, methods: Male infertility patients with
leukocytospermia or sperm concentration <1 million/mL were excluded.
Semen analysis was conducted as per WHO 2010 guidelines. sORP was mea-
sured using the MiOXSYS system. DNA damage was evaluated by standard
ﬂow cytometric acridine orange-based assay as DNA Fragmentation Index
(DFI). sORP was compared between a high DFI (≥30%) and low DFI (<30%)
group and correlated to semen parameters. Receiver Operator Curve (ROC)
analysis determined the sORP cut-off predictive of high DFI.
Main results and the role of chance: The mean paternal age was 39.2 ±
6.1 years (age range: 28 – 54 years). The mean sperm concentration was 43.0
± 37.2 M/mL, total motility was 55.2 ± 14.5 %, morphology was 6.5 ± 4.2 %,
and DFI was 21.7 ± 10.1 %. A signiﬁcant positive correlation was found
between sORP and DFI (r = 0.43, p = 0.002). A signiﬁcant negative correlation
was found between sORP and concentration (r=-0.46, p = 0.0006) and
between sORP and morphology (r=-0.33, p = 0.02). Mean sORP was signiﬁ-
cantly higher (p = 0.03) in the high DFI group (4.29 ± 2.52 mV/106 sperm/mL)
compared to the low DFI group (1.87 ± 2.17 mV/106 sperm/mL). ROC ana-
lysis indicated that a sORP cut-off of 2.37 mV/106 sperm/mL had a sensitivity
of 75.0%, a speciﬁcity of 77.2%, a positive predictive value (PPV) of 37.5% and a
negative predictive value (NPV) 94.5%. The area under the ROC (AUROC)
was 0.84 (95% CI: 0.72 – 0.96, p = 0.003) and the diagnostic accuracy was
76.9%.
Limitations, reasons for caution: No additional conﬁrmatory DNA dam-
age methodologies were assessed. The DNA damage assay used in this study is
generally considered the gold standard, however several alternatives are also
routinely used. Larger standardized studies are needed to conﬁrm the perform-
ance characteristics of sORP in predicting high DFI.
Wider implications of the ﬁndings: Requiring as little as 5 minutes to com-
plete and a drop (30 uL) of semen, the MiOXSYS system provides a rapid,
cost-effective measure of global oxidative stress easily integrated into clinical
workﬂows. It can be used to speciﬁcally identify patients with oxidative stress
induced DNA damage for anti-oxidant therapy.
Trial registration number: not applicable.
P-096 Vitamin D levels and sperm parameters
P. Navarro1, L. Luque2, A. Fabregat3, J.A. Ortíz4, J.C. Castillo5,
B. Lledó4, J. Llácer5, R. Bernabeu5
1Instituto Bernabeu Alicante, Endocrinology, Alicante, Spain
2Instituto Bernabeu Albacete, Reproductive Medicine, Albacete, Spain
3IB Bioctech Alicante, Andrology, Alicante, Spain
4IB Bioctech Alicante, Molecular Biology, Alicante, Spain
5Instituto Bernabeu Alicante, Reproductive Medicine, Alicante, Spain
Study question: Is it possible to evaluate a potential impact of vitamin D on
male fertility through the measurement of routine sperm parameters?.
Summary answer: Routine seminal parameters are not a good predictor of
the possible deleterious effects of low levels of vitamin D on male fertility.
What is known already: Vitamin D has physiological functions beyond those
related to bone metabolism. As far as male fertility is concerned, it has been
shown that vitamin D receptors are expressed in germ cells, ejaculatory duct
and mature sperm cells. Vitamin D deﬁcit has been described to a greater or
lesser extent in all human populations studied. Deleterious reproductive effects
of such deﬁcit have been shown in animals. There is, however, contradictory
evidence in humans, which makes this a controversial issue.
Study design, size, duration: Prospective observational study carried out in
males coming to our institute between April 2013 and May 2015, seeking sub-
fertility testing, who accepted to participate in the study. Vitamin D levels were
tested and routine sperm parameters were recorded from the same sample
used in the fertilization cycle.
Participants/materials, setting, methods: Caucasian males were included
in the study. Subjects with systemic diseases were excluded. Vitamin D serum
levels were tested and routine semen quality parameters were recorded.
Semen samples were obtained by masturbation after an abstinence of 2-5 days.
They were analyzed following 2010WHO criteria. Association among variables
was analyzed using linear regression and a Student´s t-test.
Main results and the role of chance: The study included 175 subjects (18
were smokers), with an average age of 39,7 ± 5,8 years. Average BMI was
26,3 ± 3,6. Average vitamin D was 25,6 ± 8,9 ng/ml (51% of the samples were
collected between May and September). All semen parameters (volume, con-
centration/count and % progressive motile) showed a trend towards values
indicating better quality with higher vitamin D levels. However, when correla-
tions among vitamin D and the different semen parameters were analyzed a sig-
niﬁcant positive correlation was found only with sperm counts (p = 0,045). This
correlation was lost after adjusting for confounding factors (age, BMI, seasonal-
ity and smoking). From 122 subjects with vitamin D levels< 30 ng/ml, 43 (35%)
had alterations in semen. This proportion diminished to 28% (14 out of 53) in
males with vitamin D levels ≥ 30 ng/ml (p = 0,25).
Limitations, reasons for caution: Age was relatively high in our study sub-
jects, so that results may not be extrapolated to younger populations.
Wider implications of the ﬁndings: Our population included a few males
with vitamin D levels≥ 30 ng/ml, above which the pleiotropic effects are evi-
dent. Studies with comparable subject samples with adequate/deﬁcient vitamin
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D levels are needed. Longitudinal studies comparing sperm quality in males with
vitamin D deﬁcit before and after supplement ill be useful.
Trial registration number:Not applicable.
P-097 Levels of p53 protein in human spermatozoa, embryo
quality and pregnancy rate. EcoFoodFertility project (preliminary
data)
S. Raimondo1, T. Notari2, M. Gentile3, M. Cirmeni2, T. Gentile1,
L. Montano4, G. Borsellino2
1°Gentile s.a.s°- Gragnano NA, Field of research of the Laboratory °Gentile s.a.s°,
Gragnano, Italy
2Polydiagnostic Center Check Up - Day Surgery, Lab - GEA - Ginecology- Embryology
- Andrology, Salerno, Italy
3°Gentile s.a.s°- Gragnano NA, Field of research of the Laboratory °Gentile s.a.s°,
Gragnano, Italy
4ASL Salerno °San Francesco d°Assisi° Hospital, Andrology Unit, Oliveto Citra SA,
Italy
Study question: The aim of this study is to evaluate if different concentrations
of p53 protein in human spermatozoa could inﬂuence embryo quality and preg-
nancy rate.
Summary answer: High concentrations of p53 in human spermatozoa is
associated to low percentage of embryos at 6-8 cells stage in third day and low-
er pregnancy rate.
What is known already: Frequently seminal ﬂuids with normal parameters
of evaluation, according to the WHO laboratory manual for examination and
processing of human semen ( 2010), show variations on the capacity to fertilize
oocytes and also the quality of obtained embryos is very variable.
Protein p53 is well known as “The guardian of genome”; it changes its con-
centration in human spermatozoa DNA in relation to the damage of the latter.
It has been suggested that the role of the p53 ancestral gene was to ensure the
integrity of the genomic germline and the ﬁdelity of the development process.
Study design, size, duration: From July 2013 to June 2017 we have exami-
nated retrospectively 79 couples with 2-5 years of infertility history.
We have divided the couples on the basis of p53 levels:
Group A: 0,35–1,65 ng/mil (21 males);
Group B: 1,66–3,57 ng/mil (32 males);
Group C: 3,58-14,53 ng/mil (26 males).
We have evaluated the number of embryos at stage of 6-8 cells, obtained at
the third day of embryo development, in these three different groups.
Participants/materials, setting, methods: Male partners of examinated
couples had an average age of 27 ± 7,5 years, sperm concentration of 33,8 ±
6,2 mil/ml, progressive motility of 41,4 ± 8,3% and a typical morphology of
16,5 ± 3,5% according to Kruger’s method.
In order to evaluate the concentration of p53 protein, we ﬁrst proceeded to
a DNA extraction with forensic method and then to a quantiﬁcation p53 pro-
tein with ELISA-immunoenzymatic assay, expressed in ng/million of
spermatozoa.
Main results and the role of chance:We have observed different percent-
age of embryo development at stage of 6-8 cells in the third day and different
pregnancy rate (PR):
Group A: 101 embryos at 6-8 cells/ 147 total number of obtained embryos
in this group (68,4%) and PR = 52,38%
Group B: 128/240 (53,5%); PR = 37,50%;
Group C: 79/216 (36,1%); PR = 7,69%.
These results support the hypothesis that an high concentration of p53 in
human sperm DNA is associated to a low percentage of embryos able to reach
the stage of 6-8 cells in the third day of development and also to a lower preg-
nancy rate.
So p53 levels can be considered as a predictive value to embryo develop-
ment and pregnancy rate.
Limitations, reasons for caution: This study is preliminary. The number of
couples examinated is limited. Some unknown confounding factors could not
be considered. Further data are necessary.
Wider implications of the ﬁndings: Protein p53 is a sequence-speciﬁc
transcription factor that responds to a wide variety of stress signals. Particularly
quantitative research of p53 could be considered as a novel biomarker of sperm
quality, able to predict the success of ART techniques, and could open a new
road for infertility diagnosis.
Trial registration number: JHRS-01-18
P-098 Redox potential in human semen: validation and
qualiﬁcation of a quantitative electrochemical assay for
measurement of oxidative stress
S. Homa1, A. Vassiliou2, C. Martin3, A. Killeen3, A. Dawkins3, T. Yap4
1Andrology Solutions, Andrology, London, United Kingdom
2University of Kent, Department of Biosciences, Canterbury, United Kingdom
3The Doctors Laboratory, Department of Andrology, London, United Kingdom
4Guy’s Hospital, The Urology Centre, London, United Kingdom
Study question: Does an electrochemical assay using the MiOXsys CE-
marked analyser, consistently meet the requirements and speciﬁcations to reli-
ably measure static oxidation reduction potential (sORP) in human semen?
Summary answer: The MiOXsys assay is robust, performing according to
expectations and has been standardised and validated to reliably and accurately
measure sORP in human semen.
What is known already: Low levels of reactive oxygen species (ROS) are
prerequisite for sperm function. Physiological levels of ROS are maintained by
antioxidants (reductants) in the local environment. A disturbance in the balance
between oxidants and antioxidants leads to oxidative stress (OS), impairing
sperm function and genetic integrity. A novel method for assessing OS in semen
involves measuring sORP using the MiOXsys galvanostat-based technology ana-
lyser. ORP measures levels of oxidants and reductants, providing a more com-
prehensive measure of OS than measurement of ROS alone. Although the
MiOXsys assay effectively measures sORP in semen, it has yet to be fully
validated.
Study design, size, duration: This study was a technical validation of an
assay for measuring sORP using the MiOXsys CE-marked analyser. It included
40 replicate measurements of control samples on different days and on two
separate analysers. Intra- and inter-technician variability was determined from
40 replicates. The characteristics of sORP in semen and the effects of independ-
ent variables were measured in 6 replicate samples from 19 men. Variables
included time from ejaculation, temperature, mechanical agitation and freeze-
thaw action.
Participants/materials, setting, methods: The assay requires applying
30 μl sample onto a disposable sensor which is inserted into the MiOXsys ana-
lyser and a current is applied. sORP is displayed in mV after 2-4 min. Values
were recorded for different operators, days and analysers using multipurpose
handling medium (Irvine Scientiﬁc, CA, USA) as a control. Semen samples were
obtained from consenting men attending for routine semen analysis to deter-
mine the stability of seminal ORP under different conditions.
Main results and the role of chance: Measurement of sORP (mV) using
the CE-marked MiOXsys platform (Aytu Bioscience, CO, USA) demonstrated
repeatability between 40 replicates of the same control sample with no signiﬁ-
cant difference between measurements (mean sORP (mV) ± SEM = 281.5 ±
4.8; CV = 0.1). Readings remained consistent across multiple operators (p =
0.67), separate analysers (p = 0.95) and on different days (p = 0.09).
Additionally, there was no signiﬁcant difference between sORP values for 40
replicates of a single semen sample (mean sORP (mV) ± SEM = 45.1 ± 1.0;
CV = 0.1). Although readings remain relatively stable in semen up to 45 min
post ejaculation (p = 0.06), there are signiﬁcant variations in seminal sORP
values across all samples by 60 min post ejaculation (p < 0.005). sORP in semen
remains stable after freezing and thawing as values do not change signiﬁcantly
(p = 0.47). This was demonstrated across biological replicates (n = 6). There
was a signiﬁcant difference between sORP in semen after mechanical agitation
using a bench-top vortex (p = 0.005) and between samples incubated at differ-
ent temperatures (2-6°C, 20-24°C and 36 + 1°C; p = 0.003).
Limitations, reasons for caution: The validation of the MiOXsys platform
was carried out in one laboratory only. A multicentre validation would assist in
conﬁrming the reproducibility and reliability of the test.
Wider implications of the ﬁndings: This simple to use, cost effective assay
could be implemented in conjunction with semen analysis providing a welcomed
i185Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
addition to routine diagnostic testing for male infertility. It may be particularly
relevant to men with unexplained infertility, whose partners experience a delay
in conception, multiple assisted conception failures or miscarriages.
Trial registration number:Not applicable.
P-099 The addition of porcine oviductal ﬂuid (OF) in swim-up
media improves the selection and modiﬁes motility patterns and
capacitation potential of boar spermatozoa
S. Navarro-Serna, S. García-Martínez, E. Paris-Oller, P.O. Calderon,
J. Gadea
University of Murcia., Physiology, Murcia, Spain
Study question: Could the OF improve the sperm selection in swim-up and
modify sperm parameters?
Summary answer: Porcine OF improve sperm selection, modulates motility
patterns and increase the percentage of spermatozoa with high calcium
response after incubation in capacitated media.
What is known already: Previous studies have demonstrated that the use of
porcine OF from late follicular phase or speciﬁc OF proteins provides sperm
membrane changes modulating capacitation process and motility pattern (Coy
et al, 2010 Theriogenology).
When OF was added to swim-up procedure and the oocytes were incubated
in OF before IVF, embryo development was improved, DNA methylation and
gene expression patterns were closer to in vivo embryos (Cánovas et al, 2017
eLife). However, the speciﬁc role of the OF addition in swim-up media on
sperm parameter is not well known.
Study design, size, duration: NaturARTsPIG sperm swim-up media
(Embryocloud, Murcia, Spain) were supplemented with different amounts of
BSA and OF. As a control we used swim-up medium with 5 mg/ml of BSA
(5BSA) and was compared to 1 mg/ml of BSA (1BSA), 1 mg/ml of BSA plus 1%
of Porcine OF (NaturARTsPOF-LF, Embryocloud) (1BSAPOF) or 1% Porcine
OF (POF). Then we analysed sperm recovery, morphology, motility and vitality
and calcium levels as capacitation signal after samples were incubated in a cap-
acitating media.
Participants/materials, setting, methods: Swim-up was prepared adding
1 ml of NaturARTsPIG sperm swim-up medium in a conical tube and 1 ml of
sperm sample of boar with proven fertility at the bottom of the tube. After
incubation 500 μl from the top were recovered. Sperm recovery rate and
morphology were evaluated. Motility and motion parameters were assessed by
CASA and simultaneously sperm vitality and calcium levels were measured by
ﬂow cytometer with propidium iodide and Fluo-3AM (14 replicates).
Main results and the role of chance: Swim-up resulted in a suitable sperm
selection, increasing normal morphology from 83,5 ± 1,3% before swim-up to
>90% after. Morphology selection was worse in 5BSA (90.6 ± 2.2%) than other
groups (1BSA: 96.4 ± 1.5%; 1BSAPOF: 96.3 ± 0.9%; POF: 95.7 ± 1.1%, p =
0.02). In addition, changing BSA concentration and adding OF modiﬁed motility
patterns and calcium response. These motility differences have been found in all
motility parameters which were represented in a study of motility subpopula-
tion, with lower values for OF groups than others (motility %, velocities). In this
sense, after a subpopulation analysis, the POF group showed a lower percent-
age of high motility population than others (5BSA: 14.1%, 1BSA: 9.4%,
1BSAPOF: 9,9%, POF: 4,5%). On the other hand, sperm vitality (mean 68.1 ±
2.4%) was not affected by groups (p = 0.50). Regarding the calcium response
after incubation in a capacitating medium, the percentage of spermatozoa with
high calcium level was higher in groups with OF (1BSAPOF: 32.2 ± 3.3%; POF:
34.6 ± 3.4%) than without OF (5BSA: 20.8 ± 2.7%; 1BSA: 26.7 ± 2.4%) with
signiﬁcative differences (p = 0.01). These results conﬁrmed OF can modulate
sperm function, leading to a better status for fertilizing after the swim-up
procedure.
Limitations, reasons for caution: Modulating capacity of the OF could be
affected by concentration of some proteins in the system and further studies
are necessary to optimize the sperm selection procedure, in terms of viably and
healthy embryos after IVF.
Wider implications of the ﬁndings: Our results agree with other studies
demonstrating that OF reduces motility parameters and protect spermatozoa
from early capacitation. The control capacitation patterns could be involved in
the improved embryo development. This information could be used as a model
to improve fertilization rate and embryo quality in humans.
Trial registration number: not applicable.
P-100 The effects of melatonin on possible damage that will be
occured on epididymis and sperm parameters with the
coadministration of fructose and bisphenol a (BPA)
S.Ö. Akarca Dizakar1, S. Ömeroğlu1, D. Erdoğan1, T. Peker2,
N. Coşkun3, İ. Türkoğlu1, M.A. Eşmekaya4
1Medical Faculty of Gazi University, Histology and Embryology, Ankara, Turkey
2Medical Faculty of Gazi University, Anatomy, Ankara, Turkey
3Medical Faculty of Hacettepe University, Obstetrics and Gynecology, Ankara,
Turkey
4Medical Faculty of Gazi University, Biophysics, Ankara, Turkey
Study question: Does melatonin have effects on epididymis and sperm
morphology with the coadministration of fructose and BPA?
Summary answer: Administration of BPA, fructose, and concurrently both of
these causes damaged to epididymis and sperm samples and melatonin were
partially successful in preventing this damage.
What is known already:Nowadays, it is notable that the increase in the inci-
dence of metabolic syndrome (MetS) and related clinical cases correlated with
the increased of fructose rich food consumption and environmental and oral
exposure to chemical substances known as endocrine disruptors. Fructose feed
has recently increased and higher fructose consumption has associated with the
increased of diseases such as dyslipidemia, insulin resistance, hypertension,
hyperuricemia and infertility. BPA exhibits estrogen-like activity that cause tox-
icity in reproductive organs suppresses spermatogenesis, decreases sperm pro-
duction and fertility rates.
Study design, size, duration: We used 42 adults, Sprague Dawley rats that
were divided into seven groups. The groups were arranged as follows, Group 1
(n = 6, Control), Group 2 (n = 6, 10 % fructose), Group 3 (n = 6, only with
25 mg/bw/day BPA), Group 4 (n = 6, fructose 10% + 25 mg/bw/day kg BPA),
Group 5 (n = 6, fructose 10 % +20 mg/bw/day melatonin), Group 6 (n = 6,
25 mg/bw/day BPA + 20 mg/bw/day melatonin), Group 7 (n = 6, fructose 10
%+ 25 mg/bw/day BPA + 20 mg/kg/day melatonin.
Participants/materials, setting, methods: After 8 weeks epididymal tissue
was removed and analyzed by using histochemical (Hematoxylen-eosin,
Masson’s Trichrome and Silver impregnation stain) immunohistochemical
(Zonula occludens-1 (ZO-1), Occludin (Occ) and Claudin-1 (Cl-1)) procedure.
Sperm samples were counted, sperm morphology, motility and viability were
investigated with Diff-quick and Eosin-Nigrosin stains. The apoptotic sperm
cells were determined by ﬂow cytometry.
Main results and the role of chance: Histopathologic changes were
observed on the epididymis in BPA and BPA + Fructose groups and it was
observed that melatonin has a protective effect on the histologic structural and
morphological alterations of epididymis and sperm. When we semi-
quantitatively compared the groups, ZO-1, Occ and Cl-1 immunostaining were
decreased in BPA and BPA+Fructose groups compared to the control group,
and these expression increased after melatonin administration. The total sperm
count was not signiﬁcantly different between the all groups (p = 0.069). Sperm
motility increased signiﬁcantly in the BPA + melatonin group compared to the
BPA group (p = 0.049). Viability percentage of BPA + Fructose group was sig-
niﬁcantly lower than the control group (p = 0.001). The percentage of apop-
totic sperm with Annexin V-FITC/PI staining in the BPA+Fructose+Melatonin
group was lower than BPA+Fructose group (P = 0,04). Moreover, BPA and
BPA+Fructose induced anomalies of the head and tail of sperm (p < 0.05). The
anomalies head and tail of sperm were signiﬁcantly lower in the BPA+Fructose
+Melatonin group than BPA+Fructose group (p = 0.018, p = 0.02,
respectively).
Limitations, reasons for caution: The limitations of the study are being an
experimental animal model and immunohistochemical results should be sup-
ported quantitatively by using advanced molecular techniques.
Wider implications of the ﬁndings: Fructose and BPA have adverse effects
on epididymis and sperm parameters. The decreased in immunoreactivity on
epididymal tight junction proteins suggests that BPA and fructose can disrupt
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the regular mechanism of blood-epididymis barrier and affect sperm matur-
ation. This study have shown that melatonin can reduce the negative effects.
Trial registration number: not applicable.
P-101 Identiﬁcation of seminal plasma proteins as potential
biomarkers in men with primary infertility
A.D. Martins1,2, A. Agarwal1, L. Samanta3, R. Sharma1, B. Gopalan4,
B.Willard5, Z. Cui6, D. Durairajanayagam7, E. Sabanegh8
1Cleveland Clinic, American Center for Reproductive Medicine - Department of
Urology, Cleveland, U.S.A.
2Instituto de Ciências Biomédicas Abel Salazar - Universidade do Porto, Dep.
Microscopia- Lab. de Biologia Celular and Unit for Multidisciplinary Research in
Biomedicine, Porto, Portugal
3Ravenshaw University, Department of Zoology, Odisha, India
4Yorg Corporation, Bioinformatics, Plano, U.S.A.
5Cleveland Clinic, Research Core Services- Proteomics, Cleveland, U.S.A.
6Southwest University, College of Pharmaceutical Sciences, Chongqing, China
7Universiti Teknologi MARA, Discipline of Physiology- Faculty of Medicine, Selangor,
Malaysia
8Cleveland Clinic, Department of Urology, Cleveland, U.S.A.
Study question: To identify molecular mechanism(s) and potential biomar-
kers of male infertility by comparing the seminal plasma proteome proﬁle of fer-
tile donors and men with primary infertility.
Summary answer: Altered protein expression proﬁle in the seminal plasma
of men with primary infertility may affect spermatozoa function, its use as a bio-
marker can be explored.
What is known already: Male factor is estimated to contribute to approxi-
mately 50% of all infertility cases. Primary infertility is the inability to father a
child after 12 months of regular unprotected sexual intercourse. Basic semen
analysis is the ﬁrst step in the assessment of male potential. However, men with
normal semen parameters can be infertile. There is a need for advanced meth-
ods to evaluate male fertility. Seminal plasma is a unique biological ﬂuid that
contains secretions from sex accessory glands. Therefore, the analysis of sem-
inal plasma can serve as a great source for identiﬁcation of key biomarkers of
primary infertility.
Study design, size, duration: This study included seminal plasma samples
from 13 men with primary infertility (without any female factor) and 13 proven
fertile men. Following the basic semen analysis, seminal plasma was separated
from the spermatozoa by high-speed centrifugation. For the proteomic study a
pooled sample (n = 5) for each group was analyzed, and differentially expressed
proteins (DEPs) identiﬁed. Validation of 7 selected proteins was carried out by
Western blot (n = 8).
Participants/materials, setting, methods: Seminal plasma proteins were
extracted and quantiﬁed. Following LC-MS/MS, Mascot, SEQUEST and X!
Tandem tools were used to search the human reference database for protein
identiﬁcation. DEPs were identiﬁed based on normalized spectral abundance
factor. Functional annotations, pathways and enrichment analysis were per-
formed using GO, UniProtKB, Reactome, MetacoreTM and DAVID. Network
analysis was performed using both IPATM and MetacoreTM software databases.
DEPs were selected for validation by Western blot and compared with prote-
omic analysis.
Main results and the role of chance: A total of 515 proteins were identi-
ﬁed in the two groups, 48 were differentially expressed in primary infertility
compared with proven fertile donors. In the primary infertility group, proteins
related to diseases such as male infertility (p < 0.0001), azoospermia (p =
0.005), and oligozoospermia (p = 0.02) were underexpressed. Cellular assem-
bly and organization, cell morphology and cell-to-cell signaling and organization
were the main biological functions identiﬁed as dysregulated in primary infertility
group. Proteins involved in cellular movement, free radical scavenging and cell-
to-cell signaling and interaction such as: annexin-A2 (p = 0.02), cell division
control protein 42 (p < 0.0001), peroxiredoxin-2 (p = 0.03), CD63 (p =
0.005) and transferrin (p < 0.0001) were overexpressed in the primary infertil-
ity group. On the other hand, proteins such as semenogelin-1 (p = 0.001) and
semenogelin-2 (p < 0.00001), implicated in liquefaction and regulation of ﬂagel-
lated sperm motility, were underexpressed in the primary infertility group. The
aforementioned DEPs were chosen to be validated by Western blot, however
only annexin-A2 (p = 0.03) showed overexpression in the primary infertility
group. This protein is a calcium regulated membrane-binding protein with high
afﬁnity to calcium. Dysregulation of calcium levels can be detrimental for key
sperm processes such as capacitation, hyperactivation, acrosome reaction, and
motility, which in turn may result in a failure of fertilization.
Limitations, reasons for caution: The number of samples used in this study
is a major limitation. The use of only 13 different samples for each group is not
enough to overcome the biological variability seen in the fertile and infertile
male population.
Wider implications of the ﬁndings: The different seminal plasma prote-
omic proﬁle of proven fertile men versus men with primary infertility suggests
the important role of these proteins in the impairment of fertility. These pro-
teins could be developed as biomarkers for diagnostic purposes. However, lar-
ger cohort studies are needed to justify their value as biomarkers.
Trial registration number: ‘not applicable’
P-102 Exosomes, a bio-compatible delivery platform for
mammalian sperm cells: A non-invasive approach for the transfer of
therapeutic compounds
T. Vilanova1, C. Plow2, C. Jones3, R. Dragovic2, K. Coward2
1PhD Student, Nufﬁeld Department of Women’s and Reproductive Health, Oxford,
United Kingdom
2University of Oxford, Nufﬁeld Department of Women’s and Reproductive Health,
Oxford, United Kingdom
3University of Oxford, Nufﬁeld Departmen of Women’s and Reproductive Health,
Oxford, United Kingdom
Study question: Can naturally-synthesised exosomes rival the efﬁcacy of engi-
neered nanoparticles to mediate the delivery of compounds into gametes for
potential clinical use?
Summary answer: In vitro exposure of sperm to in vivo-synthesised exo-
somes did not signiﬁcantly affect motility. Thus, exosomes may represent an
effective delivery-tool for compounds into sperm.
What is known already: Over recent years, exosomes have become widely
utilised as an efﬁcient tool to mediate directed delivery of nucleic acids, pep-
tides, antibodies, ﬂuorescent compounds and other small molecules into cells
and tissue in a non-invasive manner. However, the potential application of exo-
somes for the delivery of therapeutic compounds to mammalian gametes has
not yet been elucidated.
Study design, size, duration: This study aimed to develop a mammalian cell
line (HEK293T cells) from which exosomes can be synthesised, isolated and
characterised for their ability to deliver compounds to mammalian sperm. A
ﬂuorescent dye (BODIPY) was used to test the efﬁciency of association
between exosomes and sperm and to evaluate internalisation and safety
aspects.
Participants/materials, setting, methods: BODIPY-labelled exosomes
were synthesised and characterised by Nanoparticle Tracking Analysis (NTA)
and Western blotting. Different exposure times (1 h, 2 h and 4 h) were tested
by incubation with pre-activated boar sperm (n = 3). Sperm motility was then
assessed by Computer Assisted Sperm Analysis (CASA), sperm-exosome asso-
ciation was quantiﬁed by Metafer-4 analysis and localisation/internalisation was
assessed by confocal microscopy.
Main results and the role of chance: NTA showed that synthesised exo-
somes had a mean diameter of 152.5 ± 5 nm and concentration of 4.55 × 108/
mL. Furthermore, Western blotting showed bands of the expected sizes for the
characteristic exosome markers: Alix, syntenin and CD9. The association rate
of BODIPY-exosomes incubated with boar sperm increased in a time depend-
ent manner (1 h, 19.0%; 2 h, 24.9%; 4 h, 26.8%). Moreover, a consistent trend
was observed for both internalisation and multiple association to the sperm
with increased incubation (internalisation: 1 h, 12.5%; 2 h, 18.0%; 4 h, 55.0%;
multiple association: 1 h, 0.83%; 4 h, 1.63%). Association to the tail declined
progressively (tail association: 1 h, 50%; 2 h, 46%; 4 h, 35%). Interestingly, no
exosome-surface head attachment was observed after 4 h. Metafer-4 analysis
indicated a relationship between association and the length of incubation (1 h,
5.33%; 2 h, 6.6%; 4 h, 7.38%). Finally, exposure to labelled-exosomes did not
signiﬁcantly inﬂuence sperm motility after 2 h of incubation (p = 0.244).
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Limitations, reasons for caution: The data presented here is preliminary in
nature and derived from only a small sample size, thus limiting statistical analysis.
Furthermore, Metafer-4 analysis is unable to quantify sperm tail association, and
association rates may have been under-represented.
Wider implications of the ﬁndings: Our preliminary data demonstrated
the successful synthesis, labelling and characterisation of exosomes. In vitro
exposure of labelled-exosomes to mammalian sperm showed encouraging pat-
terns of association and did not affect sperm motility. An exosome delivery-
platform represents a multifaceted tool for reproductive biology with which to
investigate gamete structure, physiology and preservation.
Trial registration number: not applicable.
P-103 The diet quality of couples undergoing IVF
T. Boedt1, E. Dancet2, K. Peeraer2, S. Lie Fong2, C. Spiessens2,
C. Matthys1
1KU Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven,
Belgium
2KU Leuven, Department of Development and Regeneration, Leuven, Belgium
Study question: Is the diet quality of men and women undergoing IVF
adequate and is it correlated between partners?
Summary answer: The average diet quality of couples undergoing IVF does
not meet Belgian dietary recommendations and is highly correlated between
partners.
What is known already: Evidence on the association between reproductive
health and dietary patterns of infertile men or infertile women is increasing.
Infertility is a couples’ condition. Yet, little is known on the correlation between
the diets of partners undergoing IVF. Multiple methods to evaluate diets exist.
Using a diet quality index has the added value of considering the complexity of
food consumption patterns. It is an overall index to assess compliance with
food-based dietary recommendations based on the quality, balance and variety
of foods consumed.
Study design, size, duration: A cross-sectional observational survey was
conducted between October 2016 and October 2017. Valid and reliable food
frequency questionnaires (FFQ’s) were disseminated online through the hos-
pital e-platform to 396 Dutch speaking heterosexual couples about to start an
IVF-cycle at a Belgian University fertility clinic. A total of 105 couples visited the
e-platform. No reminders for ﬁlling out the questionnaire were sent.
Participants/materials, setting, methods: A total of 57 couples fully com-
pleted the FFQ, assessing portions and frequencies of foods consumed and
their quality, balance and variety. Diet quality was described with an overall
score between 0-100 and a cut-off <70/100 warranting need for dietary advise.
Spearman correlations described inter-partner correlations. Clinical pregnancy
(with fetal heartbeat) after one IVF and corresponding cryo-cycles was regis-
tered. Logistic regressions evaluated if the diet quality of couples was associated
with their clinical pregnancy rate.
Main results and the role of chance: Participating men had a mean age of
36 (±6.7) and mean body mass index (BMI) of 26.6 kg/m2 (±4.8). Participating
women had a mean age of 33 (±4.8) and mean BMI of 23.6 kg/m2 (±4.3). The
overall diet quality was 70.5/100 (±12.7) for men and 73.2/100 (±10.1) for
women. The diet quality of partners was positively correlated (r = .537, p
= .001). On food (group) level, subfertile men and women did not meet the
Belgian dietary recommendations. The vegetable intake (recommendation of
300 g/day) was inadequate, respectively on average 154 g/day in men and
146 g/day in women. The intake of processed foods (i.e. cookies, soft drinks,
fast food) exceeded the recommendation of 10% of daily food intake, respect-
ively 23.4% in men and 20.4% in women. One in three couples achieved a clin-
ical pregnancy. After controlling for BMI and age, the average couples’ diet
quality of this small sample was not associated with their clinical pregnancy rate
(OR 1.12, 95% CI .88-1.57).
Limitations, reasons for caution: Selection bias by health conscious cou-
ples is likely, which means that the diet of the average couple might be even
more suboptimal. The small sample size and cross-sectional nature of this study
does not allow causal inference.
Wider implications of the ﬁndings: Subfertile couples are in need of diet-
ary advise, as was already reported for the general Belgian population. It would
be interesting to examine whether advise improves reproductive health in large
scale randomized controlled trails, which should include couples as partner’s
diet quality is correlated.
Trial registration number:Not applicable.
P-104 Impact of male partner chlamydia trachomatis
seropositivity on infertility in unselected subfertile population
P. Joki-Korpela1, T. Rantsi1, H. Öhman2, M. Puolakkainen3,
J. Paavonen4, H.M. Surcel5, A. Tiitinen1
1Helsinki University Central Hospital- Womens hospital, Reproductive medicine,
Helsinki, Finland
2The National Institute for Health and Welfare- Oulu- Finland, Immunology, Oulu,
Finland
3University of Helsinki, Department of Virology, Helsinki, Finland
4University of Helsinki, Department of Obstetrics and Gynecology, Helsinki, Finland
5University of Oulu, Faculty of Medicine, Oulu, Finland
Study question: Does C. trachomatis infection affect male fertility and preg-
nancy outcome? Is there association in lifestyle factors of male partners and
female fertility?
Summary answer: We found a link between male chlamydial seropositivity
and tubal factor infertility (TFI) in the female partner but no signiﬁcant associ-
ation in male semen parameters.
What is known already: The study results on the role of C. trachomatis and
male fertility have been variable. C. trachomatis persistent infection might cause
scarring of the ejaculatory ducts and loss of stereocilia or induce an autoimmune
reaction inducing antisperm antibodies or autoantibodies. DNA fragmentation
in sperm caused by C. trachomatis could affect the quality of the embryo and
implantation. Fragmented DNA is a common ﬁnding in couples having a history
of recurrent miscarriage. It has been reported that C. trahcomatis IgA and IgG
but not heat shock protein 60 antibodies in male serum correlate negatively
with semen characteristics and lower pregnancy rates.
Study design, size, duration: Altogether 224 subfertile couples were
recruited in the Department of Obstetrics and Gynecology, Helsinki University
Hospital, Finland, between July 2007 and December 2010 and follow-up contin-
ued until June 2014. Infertility work-up was performed according to our stand-
ard protocol after at least one year of unprotected intercourse. Data on
lifestyle factors (smoking, alcohol consumption), previous illnesses, and medica-
tion was collected.
Participants/materials, setting, methods: Humoral immune responses to
C. trachomatis were studied by measuring C. trachomatisMOMP speciﬁc IgG and
IgA and CHSP60 speciﬁc IgG antibodies using ELISA kits (Medac Diagnostika,
Hamburg, Germany) according to manufacturer’s instructions. Results were
obtained as a mean absorbance of duplicated samples at 450 nm. Less than
10% variation was seen in doublets (OD > 0.2). Semen samples of the male
partners were analyzed according the criteria of World Health Organization
(WHO).
Main results and the role of chance: The age of all male participants ranged
from 21 to 49 (median 32) years with no difference between C. trachomatis sero-
positive or seronegative males. The prevalence of C. trachomatis IgG in male
population was 10.3% (23/224), IgA 8.5% (19/224) and CHSP60 IgG 16.1%
(36/224). The duration of infertility was signiﬁcantly longer in couples with IgA
seropositive males (p = 0.04) when compared to seronegative males. History of
miscarriage was more common in couples with CHSP60 and IgA antibody posi-
tive male partners than antibody negative male partners (p = 0.04 and p = 0.05,
respectively. No signiﬁcant difference on live birth rate or need for IVF occurred
between couples of chlamydial seropositive and seronegative males. There was
no signiﬁcant association in male semen parameters and chlamydial seropositiv-
ity. Male seropositivity correlated with TFI in the female partner (p = 0.007), but
not with male factor infertility (p = 0.43). Alcohol consumption by a male part-
ner was associated with a history of C. trachomatis infection (p < 0.001) and with
TFI of the female partner (p = 0.003), while male smoking was associated with
unexplained infertility of the couple (p = 0.01).
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Limitations, reasons for caution: The rate of C. trachomatis antibodies
were low in our study population leading to small study groups. The results on
semen parameters were based on one sample. Knowing that the quality of
semen can vary within the same individual this can have effect on the results.
Wider implications of the ﬁndings: In our study, we found signiﬁcant asso-
ciation between male lifestyle factors and TFI, thus couples should be informed
on the effect of healthy lifestyle on fertility. According to our results, not only
female but also male chlamydial infection has an important effect on fertility of
the couple.
Trial registration number: not applicable.
P-105 Open testicular mapping: a new and less invasive testicular
sperm extraction (TESE) procedure
M. Vieira1, S. Glina1, J. Leite Marques2, F. Elia Mizrahi2
1Aliança dos Laboratórios de Fertilização Assistida, Urology, São Paulo, Brazil
2Aliança dos Laboratórios de Fertilização Assistida, Embriology, São Paulo, Brazil
Study question: The aim of this study was to evaluate the successful sperm
recovery rate (SSR) of open testicular mapping (OTEM) in non-obstructive
azoospermic men.
Summary answer: Testicular sperm viable for Intracitopalsmic Sperm
Injection (ICSI) was found in 50 (54%) of 92 azoospermic men.
What is known already: In 1999, Schlegel et al. reported on novel microsur-
gical techniques for TESE.
In Schlegel’s hands this technique of microdissection resulted in an improve-
ment of sperm retrieval rates (SRR) from 45 to 63%
Despite initial good results, the wide opening of the tunica albuginea and
potential vascular damage are the controversial aspects of this technique.
Testicular microdissection SSR range from 34% (Japanese Nationwide
Survey) to 63% (initial Schlegel results)
Study design, size, duration: Retropective study of laboratory ﬁles from
patients presenting with non obstructive azoospermia from 2008 to 2016 evalu-
ating 92 patients submited to OTEM for ICSI or cryopreservation.
Participants/materials, setting, methods: After delivered, the testis were
mapped for sperm production without albuginea opening.
Patients were divided in two groups according to sperm recovery for pur-
pose of analysis: group I (G I), men with sperm found, and group 0 (G 0), men
with no sperm recovered.
Age, FSH level and testicular volume (TV) were compared between groups I
and 0 using the Statistical Package for Social Sciences (SPSS), 21.0 version, with
signiﬁcant values below ﬁve percent (p < 0.05)
Main results and the role of chance: SSR was 54% (50/92). Statistical dif-
ference was found for male age, mean 38 years for G I and 34 for G 0. FSH and
TV had no statistical difference between the groups.
Limitations, reasons for caution: Histologic evaluation and laboratory
exams were done in different laboratories may leading to non uniform readings
and a wide range of normal values.
Wider implications of the ﬁndings: We present a new and less invasive
option for sperm retrieval for patients presenting with non obstructive azoo-
spermia with similar results to testicular microdissection.
Trial registration number: not applicable.
P-106 Differential expression of exosome-associated proteins in
seminal plasma of infertile men with unilateral varicocele
M.K. Panner Selvam1, A. Agarwal1, L. Samanta2, R. Sharma1,
S. Gupta1, D. Durairajanayagam3, Z. Cui4, A. Ayaz5, B. Gopalan6,
B.Willard7, E. Sabanegh8
1Cleveland Clinic, American Center for Reproductive Medicine- Department of
Urology, Cleveland, U.S.A.
2Ravenshaw University, Department of Zoology, Odisha, India
3Universiti Teknologi Mara, Discipline of Physiology- Faculty of Medicine, Selangor,
Malaysia
4Southwest University, College of Pharmaceutical Sciences, Chongqing, China
5Tulane Medical Center, Department of Urology, New Orleans, U.S.A.
6Yorg Corporation, Bioinformatics, Plano, U.S.A.
7Cleveland Clinic, Research Core Services - Proteomics, Cleveland, U.S.A.
8Cleveland Clinic, Urology, Cleveland, U.S.A.
Study question: Does compromised delivery of sperm maturation factors by
defective seminal exosomes cause sperm dysfunction in infertile men presented
with unilateral varicocele?
Summary answer: Altered expression of seminal plasma proteins involved in
the exosome-sperm fusion pathway may be a contributory factor for infertility
in patients with unilateral varicocele.
What is known already: Exosomes are cell-derived vesicles that are either
released from the cell upon fusion of an intermediate endocytic compart-
ment (the multivesicular bodies) with the plasma membrane or directly from
the plasma membrane. Seminal plasma provides a favorable environment for
spermatozoa and exosomes released from the epididymis, prostate and
seminal vesicles. Seminal exosomes carry a distinctive repertoire of small
non-coding RNAs with potential regulatory functions. Though proteins asso-
ciated with exosome function are involved in energy pathways, protein
metabolism, cell growth and maintenance, there is paucity of information on
the role of seminal exosomes on sperm function in general and varicocele in
particular.
Study design, size, duration: Semen samples were collected from 33 infer-
tile patients with unilateral varicocele from March 2012 to April 2014 and from
10 proven fertile healthy male volunteers. Proteomic proﬁling of seminal plasma
was carried out in Finnigan LTQ linear ion trap mass spectrometer LC-MS/MS
system. Differentially expressed proteins (DEP) in the unilateral varicocele
patients to that of the fertile controls were evaluated.
Participants/materials, setting, methods: We compared the proteome
of seminal plasma from unilateral varicocele patients (n = 5) with that of fertile
men (n = 5). Relative quantiﬁcation of proteins was estimated by spectral
counts (SC) and their abundance determined based on the normalized spectral
abundance factor. In silico analysis was done using Cytoscape and Metacore
platforms to identify the top-most enriched pathways and DEPs involved in
regulating the upstream transcription receptors respectively. Exosome-
associated DEPs were validated by Western blot (WB) analysis.
Main results and the role of chance:Of the 47 DEPs identiﬁed in the sem-
inal plasma, three were unique to the unilateral varicocele group and one to
the fertile donor group. Network analysis predicted 13 DEPs (APOD,
SERPINF2, ORM1, TSPAN1, CRISPLD2, Rab-27A, CD13, MME, KLK11,
TMPRSS2, DPP4, TGM4 and GLOI) to be under the regulation of Androgen
receptor affecting normal sperm function. Other transcription factors YB-1
(associated with fertility), SP1 (related with reproductive processes) and
NRF2 (antioxidant gene expression) were the principal upstream regulators
of most DEPs. Bioinformatic analysis revealed the altered expression of vital
proteins involved in regulation of vesicle fusion and positive regulation of
endocytosis related to exosomes. We demonstrated the presence of exo-
somes in the seminal plasma of both, the patients and the control group by
WB expression of CD63 (exosomal marker). Annexin A2 (ANXA2), a
calcium-regulated binding protein responsible for fusion of exosomes was sig-
niﬁcantly upregulated (2.49-folds; P = 0.0016) and transferrin (TF), involved
in positive regulation of endocytosis showed a 1.19-fold (P = 0.1257) increase
indicating impaired fusion of exosomes with spermatozoa in varicocele
patients. Therefore, it is suggested that exosomes were unable to deliver the
regulatory factors/elements resulting in impaired maturation of spermatozoa
in varicocele patients.
Limitations, reasons for caution:
• We did not purify the exosomes for proteomic studies, thus decreasing the
speciﬁcity of the technique.
• Samples were pooled to overcome the biological variation in high-
throughput experiments.
Wider implications of the ﬁndings: Aberrant expression of exosome func-
tion associated proteins hinders the transfer of exosomal elements/factors to
the spermatozoa essential for maturation process. Validation of additional
DEPs may further strengthen our hypothesis. These ﬁndings could help clini-
cians identify the exosomal dysfunction as one of the causes of infertility in
patients with unilateral varicocele.
Trial registration number:Not Applicable.
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P-107 Taste receptors expression in human sperm: possible
chemosensors for sperm-oocyte attraction
A. Luddi, C. Marrocco, L. Governini, A. Capaldo, B. Semplici,
V. Pavone, L. Boschi, V. De Leo, P. Piomboni
University of Siena, Molecular and Developmental Medicine, Siena, Italy
Study question: Are taste receptors (TAS) implicated in the capacitation and
reprogramming of spermatozoa during their successful trip toward the oocyte?
Summary answer: Human spermatozoa express a number of taste receptors
and their localization is modiﬁed by sperm capacitation and ligand interaction.
What is known already: Recent studies showed the expression of several
TAS in mammalian testis and sperm, suggesting their possible role in fertility.
The taste receptor ligands are single amino acids, nucleotides, sugars, proteins,
acids and other molecules; their presence in the female genital tract imply a
possible role for taste receptors as chemosensor during the journey of sperm
towards the fertilization site. To this regard, it has been demonstrated that glu-
tamate concentration is very high in the uterus but it decreases in the fallopian
tube, thus suggesting the possibility that taste receptors may use this gradient to
guide the sperm towards the oocyte.
Study design, size, duration: We enrolled for this study a total of 30
patients referring to our Centre for Couple Sterility (median age 36 years;
range18–58) undergoing semen evaluation during an infertility diagnostic
screening, from October 2016 to February 2017, at the Centre of Couple
Sterility, Siena University Hospital.
Participants/materials, setting, methods: Patients have been enrolled
after signing an informed consent. Ejaculated sperm were collected and seminal
parameters were monitored according to WHO 2010 guidelines. Taste recep-
tor expression/localization was conﬁrmed at the protein level by western blot
and immunoﬂuorescence. We analysed, by quantitative RT-PCR, in ejaculated
sperm the gene expression proﬁle of the genes involved in the transduction cas-
cade elicited by TAS. Finally, we also evaluated the TAS expression/localization
after exposure to TAS ligands, agonist/antagonist.
Main results and the role of chance: In ejaculated human sperm we
demonstrated the expression of several taste receptors: TAS1R1, TAS1R2,
TAS2R3, TAS2R4, TAS2R14, TAS2R19 and TAS2R43. Immunoﬂuorescence
showed a different localization of these receptors in basal and capacitated con-
ditions; the modiﬁcation of their expression pattern seems to be compatible
whit motility hyperactivation and predisposition to acrosomal reaction. Indeed,
during their journey through the female genital tract, sperm are subjected to
modiﬁcations that induce a functionally reprogramming or capacitating enabling
the sperm to became able to fertilize. Western blot analysis conﬁrmed these
modiﬁcations in basal and capacitated conditions, with different protein iso-
forms detected. Since the molecules involved in sperm capacitation and che-
moattraction are still widely unknown, we in vitro tested some TAS ligands
selected from the literature, such as genistein, daidzein and trihydroxyﬂavone.
Our data demonstrated a time and dose-dependent signiﬁcant impact on sperm
parameters, such as motility and vitality. Therefore, investigations on these
molecular pathway could be interesting for increasing the outcome of ART
procedures.
Limitations, reasons for caution: In this pilot study we analyzed only nor-
mozoospermic patients. The inclusion of patients with altered semen para-
meters (oligozoospermic, astenozoospermic) is mandatory in order to validate
these ﬁndings.
Wider implications of the ﬁndings: Further studies might contribute in
better understanding the physiologic role of taste receptors in sperm-oocyte
attraction and recognition. This should be crucial to clarify the mechanism
underlying fertilization, thus to provide a chance for ameliorating the in vitro
conditions, in order to improve IVF outcome.
Trial registration number:Not applicable.
P-108 To evaluate outcome of methylxanthine theophylline in
frozen thawed testicular sperm in intra cytoplasmic sperm injection
cycles
G. Kant, K.D. Nayar, M. Singh, N. Sharma, R. Gahlot, K. Nayar
Akanksha IVF Centre, Reproductive Medicine, New Delhi, India
Study question: To evaluate whether methylxanthine theophylline can be
used routinely in frozen thawed testicular sperm in intra cytoplasmic sperm
injection (ICSI) cycles.
Summary answer: Theophylline increases sperm motility, which may con-
tribute towards higher fertilization, improved embryo formation and better
pregnancy rates.
What is known already: Cryopreserved thawed spermatozoa are used to
avoid further damage to the testis. While reduced motility of extracted sperm
and affect of cryopreservation represent a persistent problem in ﬁnding a viable
sperm for ICSI. Over the years, many chemical agents have been tried to over
come this problem like: caffeine and other methylxanthines. Pentoxifylline
turned out to be an effective tool in stimulating motility in fresh and cryopre-
served human sperm. Interestingly, theophylline, a closely related molecule, has
been investigated for this purpose to a much lesser extent and no randomised
control study is reported to its show beneﬁt.
Study design, size, duration: A randomized controlled study was con-
ducted from 1st January 2015 to 31st September 2017 where normal
responder women undergoing frozen testicular sperm ICSI cycles were rando-
mized using computer generated list and closed opaque envelops into 2 groups,
group (A) sperm treated with theophylline and group (B) not treated with theo-
phylline. All A grade embryos were vitriﬁed at day 3 (7–9 cells) or day 5
(Blastocyst) and transferred in the subsequent frozen embryo transfer cycle.
Participants/materials, setting, methods: Eighty women were rando-
mised in group A (n = 36) and B (n = 34),rest 10 women were excluded due to
<4 oocyte retrieved or left the cycle. All A grade embryos in both groups were
vitriﬁed and warmed using same protocol by same embryologist on 7-9 cells
and blastocyst stage.Primary outcome of the study was clinical pregnancy rate
and secondary outcome was fertilization rate. Statistical analysis was performed
using SPSS for Windows version 20.
Main results and the role of chance: Descriptive characteristics of the
patient in group A and group B like Age, BMI, total dose of FSH, total dose of
HMG, days of stimulation, Metaphase II oocytes were found to be comparable.
The sperm selection was easier in the group A than group B due to increased
motility in thawed testicular sperm. The fertilization rate in group A were
67.2% vs. group B 46.4% (95% CI 13.6–27.7%, p < 0.001) and mean Grade-A
embryo formation rate in group A were 2.97 ± 1.424 vs. group B 2.24 ± 0.741
( 95% CI 0.191–1.283, p = 0.023) were signiﬁcantly higher in group A com-
pared to group B. Results were comparable for both the groups for clinical
pregnancy rate 44.4% vs. 29.4% (95% CI -7.4% - 35.4%, p = 0.193) however, it
was higher in the group A than group B.
Limitations, reasons for caution:Need large sample size.
Wider implications of the ﬁndings: Theophylline increase selection of
viable sperm due to increased motility. This may contribute towards higher fer-
tilization, improved embryo formation and increased clinical pregnancy rate.
This can also reduce the burden on embryologist for ﬁnding viable sperm.
Further studies may be required for better understanding of potency of
theophylline.
Trial registration number:MCDH/2015/7.
P-109 The relevance of Annexin A5 in male fertility
H. Lavorato1, A. Markoff2, N. Bogdanova2, F. Tüttelmann2,
S. Schlatt1
1Muenster University, Center of Reproductive Medicine and Andrology, Münster,
Germany
2University Clinics Muenster, Institute of Human Genetics, Münster, Germany
Study question: The study aimed to investigate the relationship of the haplo-
type M2/ANXA5 and male fertility parameters.
Summary answer: Our study does not show any biologically relevant effect
of lower levels of annexin A5 on male fertility parameters.
What is known already: Annexin A5, which functions as an anti-
coagulation protein, is coded by the ANXA5 gene. The haplotype M2/
ANXA5 decreases the ANXA5 gene promoter region activity and mRNA
expression. The carrier status of the haplotype M2/ANXA5 is an important
risk factor for recurrent pregnancy loss during the early stages of pregnancy.
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In rabbits, annexin A5 is the main protein of the seminal plasma and inﬂu-
ences all sperm parameters. Yet, the role of annexin A5 in men is currently
underresearched.
Study design, size, duration: This study consists of a retrospective selection
and analysis of the clinical data from our patient cohort (n = 340; 165 severe
oligozoospermic and 175 normozoospermic), taking into consideration a new
genetic diagnostic evaluation.
Participants/materials, setting, methods: Genomic DNA from blood
was sequenced with Sanger sequencing. The frequency of the haplotype
M2/ANXA5 was then compared between the groups and compared with
the general population. The clinical data from the patient groups was evalu-
ated according to their genetic variant of the promoter region for ANXA5.
The hormonal parameters were FSH, LH, testosterone, SHBG, free-
testosterone, prolactin and estradiol. Sperm parameters evaluated were eja-
culated volume, concentration, total count, motility, morphology, vitality and
accessory glands markers.
Main results and the role of chance: Association of M2 carrier status with
oligozoospermia was ﬁrst assessed in the two comparably sized groups of oligo-
zoospermic and normozoospermic patients. Both groups were in HWE at p =
0.773 and p = 1.000, respectively. The M2 carrier rate was 24.2% for oligo-
zoospermic and 17.7% for the normozoospermic patients (table 1). The com-
parison of both groups yielded an OR of 1.5 (95%CI 0.9 to 2.6), not achieving
signiﬁcance. When comparing the oligozoospermic patients with the general
population control group, the OR was 1.8 (95% CI 1.1 to 2.8), p = 0.009. The
only statistically signiﬁcant differences between the carriers and non-carriers of
the haplotype M2/ANXA5 could be observed in the prolactin and α-glucosi-
dase levels when looked in the normozoospermic patients. The prolactin levels
mean in the non-carriers and M2 carriers was 196 mU/l and 167 mU/l,
respectively. The α-glucosidase levels mean was 78.3 mU and 113 mU in the
non-carriers and M2 carriers group, respectively. In the oligozoospermic
patients, there is also a decrease in prolactin levels and an increase in α-glucosi-
dase levels. However, these variations are small and not statistically signiﬁcant.
Selection of patient cohorts may account for the observed differences or lack of
them.
Limitations, reasons for caution: The study was carried out with patients
attending a human reproduction service, thus the results may not reﬂect the dif-
ferences present in the general population.
Wider implications of the ﬁndings: The patients carrying the haplotype
M2/ANXA5 do not present a clinical proﬁle, so genetic screening is advisable
to avoid recurrent pregnancy loss.
Trial registration number: not applicable.
P-110 Timing of intrauterine insemination in relation to human
chorionic gonadotropin trigger following superovulation with
clomiphene citrate
P. Chung1, M. Irani2, S. Elder3, V. Ramnarine4, J. Wan5,
Z. Rosenwaks2
1Weill Cornell Medical College, Reproductive Medicine, New York- N.Y., U.S.A.
2Weill Cornell Medicine, Center for Reproductive Medicine, New York, U.S.A.
3Cornell University, Weill Cornell Medicine, New York, U.S.A.
4Jamaica Hospital Medical Center, Obstetrics and Gynecology, New York, U.S.A.
5Columbia Univervisty, Columbia University Medical Center, New York, U.S.A.
Study question: Does the timing of intrauterine insemination in relation to
ovulation trigger with human chorionic gonadotropin (hCG) affect the out-
comes of clomiphene citrate cycles?
Summary answer: Intrauterine insemination (IUI) performed 19–23 hours
after the administration of hCG has comparable clinical pregnancy rates with
those performed 24–36 hours after trigger.
What is known already: Several factors affect IUI outcomes, including
female age, total number of inseminated motile spermatozoa (TM), number of
recruited follicles, and infertility diagnosis. The timing of IUI is also important
given the limited fertilization window of the ovulated oocyte(s). Yet, the optimal
insemination timing is not well deﬁned.
Study design, size, duration: It is a retrospective cohort study at an aca-
demic medical center. All IUI cycles performed between 2004 and 2013 were
reviewed. To control for female age and stimulation protocol, we included only
clomiphene citrate cycles of women ≤35 years old with normal uterine cavity
and patent fallopian tubes.
Participants/materials, setting, methods: A total of 741 clomiphene cit-
rate/IUI cycles were included. Cycles were divided into two groups based on
the number of motile inseminated spermatozoa (<15 × 106 and ≥15 × 106).
Within each group, the clinical pregnancy rates (CPRs) were compared
between IUI performed within the ﬁrst 23 hours after hCG to those who had
their IUI ≥24 hours after hCG. χ2 and Fisher’s exact tests were used for cat-
egorical variables. Values were expressed as mean ± standard deviation.
Main results and the role of chance: Within the group of patients with an
adequate number of motile inseminated spermatozoa (≥15 × 106) (n = 618
cycles), the CPRs were comparable between those who underwent IUI within
the ﬁrst 23 hours after hCG (range: 19–23 hours) (n = 71 cycles) and those
≥24 hours (range: 24–36 hours) (n = 547 cycles) (15.5% vs. 20.2%, respect-
ively, P = 0.3). There was no signiﬁcant difference in terms of female age (32.4
± 2.9 vs. 31.8 ± 2.7 years old, P = 0.2), number of dominant follicles larger
than 18 mm at the time of trigger (1.7 ± 0.8 vs. 1.8 ± 0.1, P = 0.1), or peak
endometrial thickness (7.9 ± 2.3 vs. 7.9 ± 2.3 mm, P = 0.9) between cycles of
the two timing groups. Similarly, among the cycles in which the number of inse-
minated spermatozoa was <15×106, IUI performed within the ﬁrst 23 hours
after hCG had comparable CPR with those ≥24 hours (7.6% vs. 14.4%, P =
0.3). Female age (31.7 ± 2.1 vs. 31.7 ± 2.7 years old), number of dominant folli-
cles (1.8 ± 0.8 vs. 1.9 ± 0.9), and peak endometrial thickness (7.5 ± 2.1 vs. 7.8
± 2.3 mm, P = 0.6) were not signiﬁcantly different between the two timing
groups.
Limitations, reasons for caution: Although this is a retrospective study, the
adjustment for all potential confounding factors such as female age, number of
dominant follicles, stimulation protocol, peak endometrial thickness, and num-
ber of inseminated motile spermatozoa strongly supports the accuracy of our
ﬁndings in investigating the inﬂuence of IUI timing on pregnancy outcomes.
Wider implications of the ﬁndings: Timing the IUI as early as 19 hours
after hCG administration yields comparable clinical pregnancy rates with IUI
performed as late as 36 hours after ovulation trigger. This reassuring wide range
of IUI timing grants providers and patients more ﬂexibility when scheduling IUI
without impairing the outcomes.
Trial registration number:N/A.
P-111 Differential sperm proteomic proﬁle between sperm
samples achieving pregnancy or not in intracytoplasmic sperm
injection (ICSI) cycles in oocyte donation program
R. Rivera Egea1, N. Sota1, M. Meseguer2, F. Dominguez3, J. Remohi4,
N. Garrido3
1IVIRMA, Andrology, Valencia, Spain
2IVIRMA, IVF laboratory, Valencia, Spain
3IVI Foundation, Research, Valencia, Spain
4IVIRMA, gynecologist, Valencia, Spain
Study question: Are there any differences between sperm samples that failed
vs. those achieving pregnancy regarding the sperm proteomic proﬁle after ICSI
cycles?
Summary answer: This study reveals a differential protein proﬁle between
sperm samples that failed vs. those achieving pregnancy, able to be used as
sperm fertility biomarkers.
What is known already: There is a lack of sperm fertility markers, and sev-
eral studies demonstrated that idiopathic male infertility is multifactorial.
Although is believed that sperm are cells translational and transcriptionally
silent, their functionality can be studied using proteomic approaches. Many pro-
teins have been already identiﬁed having an important role in sperm motility,
sperm-oocyte’s zona pellucida interaction, metabolism, apoptosis, cellular
cycle, meiosis, membrane transport, and ribonucleotide acid regulation.
Furthermore, some previous works from our group described differential
molecular factors in sperm samples from which a pregnancy was obtained com-
pared with those failing, deﬁning molecular characteristics for physiologically
competent sperm.
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Study design, size, duration: Descriptive, prospective and non-randomized
biomedicine study evaluating the proteomic proﬁle of spermatozoa from
patients’ ejaculates where pregnancies were (Group pregnant (P), n = 4) or
were not (Group non-pregnant (NP), n = 4) achieved after ICSI in an oocyte
donation program aiming to standardize female factor. Aliquots from the same
samples employed in ICSI procedures were collected, frozen until the repro-
ductive results were known, and then assigned to their corresponding group
and analysed.
Participants/materials, setting, methods: Eight sperm samples from
infertile males undergoing ICSI cycles in oocyte donation program with normal
sperm parameters and total progressive motility >5mill were included in our
study, 4 of them failed to achieve pregnancy and 4 who succeeded. Proteins
were separated and analysed by means of SWATH-MS (Sequential Windowed
Acquisition of All Theoretical Fragment Ion Mass Spectra). Proteins are avail-
able via ProteomeXchange: identiﬁer PXD006309. All proteins abundances
were compared statistically between P and NP groups.
Main results and the role of chance: We identiﬁed 2228 proteins, 53 of
them were found in different abundance between sperm samples, being 37 sig-
niﬁcantly more abundant in sperm samples in P group, and 16 less abundant in
this same group compared with NP. We applied Elastic-Net statistic method to
identify the 27 proteins best performing to differentiate both groups. Also, we
use PLS-DA analysis (Partial Least Squares Discriminant Analysis) verifying that
the samples are classiﬁed accordingly to their group. Finally, we applied a VIP-
score test over Elastic-Net and PLS-DA, in order to determine which proteins
have more importance in achieving pregnancy. We obtained 27 proteins with
high VIP-score in Elastic-Net, and 300 in PLS-DA.
Then we applied functional analysis over the proteins obtained in the analysis
PLS-DA+vip-score, obtaining 5 proteins more abundant in P group with repro-
duction functions (NME5, SPATA20, DNAI1, ARMC4 and AK7) and 10 less
abundant in NP group (GNB2L1, PDIA4, YWHAZ, SYNGR1, FNTB, LCP1,
NDUFS4, COG3, STOM and GIT1) with metabolic functions.
Finally, we identiﬁed 11 proteins present in PLS-DA+VIP-score analysis,
located in membrane, susceptible to be selected by MACS (Magnetic-activated-
cell-sorting) to develop a new system to select the best spermatozoon.
Limitations, reasons for caution: Other molecular factors not included
within this analysis could be involved in sperm fertility given that sperm function
has been demonstrated multifactorial.
The low number of samples studied make us be cautious about our ﬁndings,
but lead us to design a focused research on the main ﬁndings with bigger
sample-sizes.
Wider implications of the ﬁndings: The description of proteins linked to
sperm fertility, open new possibilities regarding the development of male fertil-
ity diagnostic tools, culture media formulations, or, to design new sperm selec-
tion tools based on these molecular traits, using MACS of spermatozoa
exhibiting speciﬁc proteins associated with the best reproductive results.
Trial registration number: This study is not considered as a trial study.
P-112 SpermDNA fragmentation index (DFI) does not increase
with increasing number of treatment cycles
A. Prahl1, A. Giwercman2, S. Malic Voncina2, A. Stenqvist2,
Y. Lundberg Giwercman1
1Molecular genetic reproductive medicine, Department of Translational Medicine,
Malmo, Sweden
2Reproductive medicine, Department of Translational Medicine, Malmo, Sweden
Study question: Do men undergoing numerous IVF cycles have higher
amount of sperm DNA strand breaks than those who experience only one
cycle?
Summary answer: Men in couples who have undergone numerous cycles do
not have higher mean DFI then those who have undergone one.
What is known already: Sperm DNA strand breaks, measured as DNA frag-
mentation index (DFI) by sperm chromatin structure assay (SCSA) is a clinically
useful marker of male infertility, and a couple’s chance of pregnancy. However,
it is still unclear if high DFI is more common in men going through many IVF
treatment cycles compared to those achieving pregnancy in the ﬁrst.
Study design, size, duration: Prospective, clinical study, in which n = 2968
men were consecutively enrolled during the period 2007–2018, at
Reproductive Medicine Centre, Malmö, Sweden. Sperm samples were col-
lected and analysed before each cycle. In total, DFI from 4894 fresh treatment
cycles ranging from cycle number 1-7 were included.
Participants/materials, setting, methods: Approximately 5000-10 000
sperm cells were analyzed by SCSA. Analysis of the ﬂow cytometric data was
carried out using dedicated software.
Main results and the role of chance: In the ﬁrst cycle there were 2460 DFI
values, second cycle 1402 DFI values, third cycle 755 DFI values, fourth cycle
190 DFI values, and in cycles 5-7 87 DFI values were available. The mean DFI
value for the ﬁrst, second and third cycle was 16%, respectively, the fourth cycle
19%, and the 5th-7th 17%. There was no statistically signiﬁcant difference in DFI
between the cycles (p trend = 0.058).
Limitations, reasons for caution: The number of men was decreasing with
numbers of IVF cycles completed.
Wider implications of the ﬁndings: Men who have undergone many IVF/
ICSI are not presenting with higher DFI than those who enter the assisted
reproduction treatment.
Trial registration number:Not applicable.
P-113 Intrauterine insemination: predictive factors regarding
pregnancy outcomes for women aged 35 and over
M. Bendayan1, N. Swierkowski-Blanchard1, A. Oppenheimer2,
L. Alter1, L. Caceres-Sanchez1, J. Selva1, A. Torre1, G. Robin3,
F. Boitrelle1
1CHI de Poissy-St-Germain-En-Laye, Service d’Assistance Médicale à la Procréation -
Biologie de la Reproduction -, Poissy, France
2Hôpital Antoine Béclère, Service d’Assistance Médicale à la Procréation, Clamart,
France
3CHRU de Lille, Service de Médecine de la Reproduction, Lille, France
Study question: From what age pregnancy rates in intrauterine insemination
(IUI) decrease? Among these women, what sperm parameters are necessary to
get pregnancy in IUI?
Summary answer: There is an interest of IUI in women aged 35 and over
when spermatic parameters allow to reach the needed thresholds.
What is known already: As women’s age increases, specialists of assisted
reproductive technologies (ART) tend to offer an in vitro fertilization (IVF)
whereas the necessary conditions for an IUI were sometimes reunited. There is
no threshold concerning women’s age. Furthermore, the number of insemi-
nated motile spermatozoa deﬁnitely has an impact on the pregnancy outcome
after IUI, but with variable thresholds. The sperm morphology impact of is
more questionable, and only the initial morphology (on total sperm) has been
studied.
Study design, size, duration: We have performed a prospective study in
Poissy Hospital Center, between January 2015 and June 2017. A multivariate
logistic regression analysis was used to determine the predictive value of each
parameter in clinical pregnancy outcome after 12 weeks. A p value of 0.05 was
considered as statistically signiﬁcant.
Participants/materials, setting, methods: We have studied couples
with primary infertility and beneﬁts from an IUI cycle after ovarian stimula-
tion with follicle-stimulating hormone (FSH) and mono-follicular answer. For
each IUI, sperms count and motility of post-wash sperm preparation
(sperm preparation for IUI) were performed with computer-assisted meth-
od. A smear of this preparation was stained to establish percentage of typ-
ical spermatozoa (David classiﬁcation). The number of inseminated motile
spermatozoa (NIMS) and the number of inseminated normal spermatozoa
(NINS) were calculated.
Main results and the role of chance: 433 couples with 990 IUI cycles were
included in the study. The clinical pregnancy per cycle was 11.8%. According to
a multivariate logistic regression analysis, women’s age is the only predictive fac-
tor of clinical pregnancy (p <0.004) in this population. A 35-year threshold was
shown to be predictive for success, with higher rates of pregnancy among
women under 35 (14.1% vs. 8.1%, p = 0.0038).
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The second part of the study focuses on women 35 years and older (383
cycles). According to the multivariate logistic regression analysis, the NIMS and
the NINS are the only predictive factors of the occurrence of a clinical preg-
nancy in women over 35 years-old. In this population, regardless of women’s
age, women’s body mass index (BMI), and the number of attempts, the rates of
clinical pregnancies are statistically higher:
– if NIMS > 7.25 million (11.4% vs. 5.3%, OR adjusted 2.21 [1.04, 4.93], p =
0.04)
– or if NINS > 1.56 million (10.6% vs. 4.8%, OR adjusted 2.33 [1.05, 5.69], p
= 0.04)
– and if NIMS and NINS are above the previously described thresholds (3.9%
vs. 10.7%, OR adjusted 3.37 [1.22, 7.97], p = 0.02).
Limitations, reasons for caution: It’s a monocentric study, and we only
included mono-follicular cycles. Only a few centers use David classiﬁcation to
improve sperm morphology.
Wider implications of the ﬁndings: We demonstrated the value of IUI in
women aged 35 and over when spermatic parameters allow to reach the
thresholds previously found, with rates of progressive pregnancy per cycle high-
er than 10%, which is the equivalent of pregnancy rates, reported in the general
population in IUI, regardless of the age.
Trial registration number: not applicable.
P-114 New computational approach for the analysis of quantitative
proteomics: Identiﬁcation of patient-speciﬁc altered pathways in
seminal ﬂuid from infertile men
D. Delgado-Dueñas1, F. Barrachina1, A. Soler-Ventura1,
J.L. Ballescà2, R. Oliva1, M. Jodar1
1Molecular Biology of Reproduction and Development Research Group- Department
of Biomedical Sciences- Faculty of Medicine- University of Barcelona- Institut
d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- Barcelona- and
Biochemistry and Molecul
2Hospital Clinic, Clinic Institute of Gynaecology- Obstetrics and Neonatology-,
Barcelona, Spain
Study question: Could novel computational methods to analyze quantitative
proteomic data be designed to seek for patient-speciﬁc altered pathways in
seminal ﬂuid?
Summary answer: Patient-speciﬁc altered protein pathways in seminal ﬂuid
were determined in individual infertile patients, by identifying deregulations in
the stable-correlated proteins established in the control population.
What is known already: The current classiﬁcation of infertile men is limited
to the evaluation of seminal parameters. However, a wide range of factors
alters both sperm and seminal ﬂuid compositions, leading to a high heterogen-
eity within patients sharing the same phenotype. Quantitative proteomics ana-
lyses provide a valuable tool in the ﬁeld of male reproduction to identify
proteins in semen as biomarkers to better stratify the different subgroups of
infertile patients. Nevertheless, no candidates were validated to date, probably
due by the misclassiﬁcation of the patient groups. Novel approaches for data
analysis are demanded to overcome these limitations.
Study design, size, duration: Quantitative proteomic data derived from the
TMT-10Plex isobaric labeling followed by mass spectrometry identiﬁcation of
16 samples of seminal plasma were used for this computational methodology.
The samples were separated in four groups according to the World Health
Organization criteria: 4 normozoospermic patients with normal seminal para-
meters (NZ), 4 oligozoospermic patients with low sperm concentration (OZ),
4 asthenozoospermic patients with altered sperm motility (AS) and 4 azoosper-
mic patients (AZ) without presence of sperm cells.
Participants/materials, setting, methods: Stable-correlated proteins
were determined in each group of patients by applying the following statistical
principle: 2 proteins (with more than 1 peptide quantiﬁed each) were highly-
correlated when ≥90% of their peptides has a Pearson correlation coefﬁcient
≥0.9. The repetition of this analysis with control group samples (NZ) by adding
a case sample once a time allows determining changes on the control proﬁle of
stable-correlated proteins, leading to the identiﬁcation of deregulated pathways
in individual samples.
Main results and the role of chance: A total of 1175 correlations compris-
ing 78 different proteins were identiﬁed in the control population (NZ).
Interestingly, BASP1, a protein required for the activation of the oocyte,
showed the highest number of correlations with other proteins (58). In con-
trast, the number of identiﬁed stable-correlated proteins was drastically
reduced in patients presenting altered seminal parameters (126 in AS, 0 in OZ
and 6 in AZ). These results reﬂect the high heterogeneity present in infertile
patients, as well as the multiple causes that might be affecting to the seminal
parameters. To overcome these limitations we used the methodology men-
tioned above to assess potential speciﬁc-altered pathways in individual patients.
The repetition of the analysis after adding patient AS-2 to the control group
resulted in few changes in the stable-correlated proteins proﬁle. This suggests
that AS-2 contains a seminal plasma protein signature similar to the control
group. Interestingly, this patient was taking MACA, an herbal supplement con-
sidered to improve male fertility. In contrast, when this analysis is repeated by
adding other patients one by one, deregulations in speciﬁc pathways are
revealed: glycolysis for AS-1, OZ-1, AZ-1 and AZ-2, the response of oxygen
reactive species for AS-4, and the complement system for OZ-3 and AZ-4.
Limitations, reasons for caution: This computational statistical study has
been conducted with a small sample size. It is considered a ﬁrst pilot study to
design the algorithms that will be used in a wider sample population.
Wider implications of the ﬁndings: This study represents the ﬁrst step for
the generation of new methodologies leading to the identiﬁcation of patient-
speciﬁc molecular deregulations. This would contribute to an improvement in
the classiﬁcation of the infertile patients, as well as to the achievement of a per-
sonalized medical care in the treatment of infertility.
Trial registration number:N/A.
P-115 Comparison of ICSI outcomes with hypo-osmotic swelling
(HOS) reactive sperm andmotile sperm on sibling oocytes in
patients with severe asthenospermia
C. Çakır1, I. Kasapoglu2, S. Saribal1, G. Uncu2, B. Avci1
1Uludag University Faculty of Medicine, Histology and Embryology, BURSA, Turkey
2Uludag University Faculty of Medicine, Obstetric and Gynecology, Bursa, Turkey
Study question: Is there any difference between motile sperm and immotile
HOS reactive sperm from fresh/frozen and ejaculate/testicular sperm samples
in terms of embryo development?
Summary answer: Since the effect of using HOS reactive or motile sperm on
fertilization rates, HOS reactive sperm can be used in asthenospermic patients.
What is known already: Considering that the prevalence is approximately
18% for isolated asthenospermia and abouth 63% for asthenospermia asso-
ciated with oligospermia or teratospermia; this cases have a great importance
for ART centers. It is known that the motility and viability of spermatozoa and
their origin from ejaculate or testicular biopsies are important predictors in
terms of fertilization, pregnancy and live birth rates. In order to improve the
outcome of ICSI in these cases, various methods have been described for the
selection of the immotile but viable spermatozoa.
Study design, size, duration: A retrospective cohort study was performed
using database of University afﬁliated Assisted Reproductive Technology
Center from 2011 to 2017. The inclusion criteria were patients with isolated
male infertility etiology (total motile sperm count<10% from ejaculate or tes-
ticular biopsies) under the age of 39 (male/female) and ICSI cycles in which the
total number of oocytes was higher than the total motile sperm counts in order
to compare both motile and immotile sperm results in sibling oocytes.
Participants/materials, setting, methods: 491 oocytes obtained from the
49 cycle were evaluated. Considering that the injected sperm was motile
(Group 1) or immotile HOS reactive(Group 2) study groups were formed.
Each groups divided in 4 subgroups according to sperm sample type (fresh or
frozen) and origin (ejaculate or TESE). If the absence of motile sperm, HOS
reactive sperm had to chosen for ICSI. Fertilization, implantation, live birth,
cleavage (CQS) and blastocyst quality score (BQS) were compared throughout
individual embryos.
Main results and the role of chance: The total fertilization rate was 43.1%
(n = 211) and there was no differences in group 1 (47.5%, n = 105) compared
with group 2 (39,4%, n = 106) including comparison between ejaculate and
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TESE subgroups. When fresh or frozen sperm samples in Group 2 were con-
sidered, the fertilization rate of fresh ejaculate sperm was signiﬁcantly higher
than frozen ejaculate sperm (46.2% vs 10.0%, p = 0.02), while there was no sig-
niﬁcant difference in the fertilization rates between fresh and frozen testicular
sperm (50.4% vs 43.3%, p = 0.42). When quality scores of embryos obtained
by using motile or immotile HOS reactive sperm with randomized sibling
oocytes were evaluated, there was no signiﬁcant difference between day2
CQS, day3 CQS and day5 BQS between the two groups. According to the
number of transferred embryos (n = 74), there was no difference between
group 1 (51.4%, n = 38) and group 2 (48.6%, n = 36) (p = 0.26). The implant-
ation and live birth were only achieved when fresh testicular sperm had been
used. 4 live birth were achieved with fresh/immotile HOS reactive/TESE sperm
and 1 pregnancy was achieved with fresh /motile /TESE sperm.
Limitations, reasons for caution: The limitations of the study were the
small sample size and HOS test could not be conﬁrmed with different methods
of selecting viable sperm from among immotile sperms. The main disadvantages
of HOS test is related to false positive as well as false negative results.
Wider implications of the ﬁndings: There is no difference between motile
sperm and HOS reactive sperm in terms of clinical outcome in ICSI cycles. In
contrast to testicular sperm, HOS test could not predict spermatozoa viability
following freezing / thawing procedure of ejaculate sperm.
Trial registration number: The study is not a clinical trial.
P-116 Human sperm protein extraction for proteomic analysis:
Effect of different lysis buffer on quality and quantity of extracted
proteins
T. Rezaei Topraggaleh1, S.M.J. Taher Mofrad1, P. Rahimizadeh1,
S. Mirshahvaladi2, N. Ziarati1, A. Shahverdi1, G. Hosseini Salekdeh2
1Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Embryology, Tehran, Iran
2Cell Science Research Center- Royan Institute for Stem Cell Biology and Technology-
ACECR, Department of Molecular Systems Biology, Tehran, Iran
Study question: Are there quantities and qualities variation in human sperm
proteins extracted with different lysis buffer?
Summary answer: Lysis buffer containing Urea/triton yielded higher levels of
the proteins with better quality in human sperm cell.
What is known already: Molecular studies in protein level of sperm is
increasing due to the crucial role of proteins in normal functions of spermato-
zoa. High purity and concentration of extracted protein is essential for protein
analyses. Based on the types of the cells and intended proteomic approaches,
proper lysis buffer must be selected. The speciﬁc lysis buffer should be con-
sidered for sperm protein extraction because of the special features of sperm
such as high amounts of membrane associated proteins and intensive nuclear
compaction.
Study design, size, duration: In this experimental study, the semen samples
of 70 normozoospermic men who referred to Royan institute for assisted
reproductive treatments were collected between April 2017 and November
2017.
Participants/materials, setting, methods: This study comprised two
experiments. At the ﬁrst, the pooled semen samples were divided to the seven
equal groups and diluted in urea/ thiourea, urea/ nonidet P-40 (NP40), urea/
sodium dodecyl sulfate (SDS), urea/triton, RIPA, Trizol and Qiagen kit lysis buf-
fers. The extracted proteins were quantiﬁed through the Bradford assay and
SDS-PAGE. In second experiment, the subcellular localization of speciﬁc pro-
teins which extracted with high yielded lysis buffers, were quantiﬁed by western
blotting.
Main results and the role of chance: In the ﬁrst experiment, the protein
concentration was signiﬁcantly high in urea/ thiourea, urea/ NP 40, urea/
SDS and urea/triton lysis buffers in compared to the others. The highest
yield of the proteins was related to urea/triton which was not signiﬁcantly
different between four mentioned lysis buffers. In the second experiment,
the expression of cytoplasmic (β actin, α tubulin, GAPDH, Lactate dehydro-
genase C, heat shock protein 60) and mitochondrial (Malate dehydro-
genases, and ATP synthetize 5 A) proteins were not signiﬁcantly different,
although the expression level of nuclear protein such as histone H3 and
membrane associated protein like pan cadherin were higher in urea/SDS
and urea/triton lysis buffers respectively.
Limitations, reasons for caution: Lower concentration of the extracted
proteins in some lysis buffers such as urea/SDS, was a limited factor for the
number of possible replicates in the western blot technique.
Wider implications of the ﬁndings: According to our results, urea/triton
lysis buffer could be a proper suggestion for extraction of whole sperm pro-
teins. However, other lysis buffers would be suitable for extraction of speciﬁc
proteins that are localized in the particular subcellular regions.
Trial registration number: 0
P-117 Testicular sperm retrieval in azoospermic male cancer
survivors
F. Adenubi, E.Williamson, M. Davies
University College London Hospital- UCLH, Reproductive Medicine Unit, London,
United Kingdom
Study question: Can testicular sperm extraction offer azoospermic cancer
survivors a chance for fertility and a possible route to biological fatherhood?
Summary answer: Successful sperm retrieval can be achieved in men who
have received intensive chemotherapy treatment, however larger studies are
required to determine predictors of success.
What is known already: Sperm cryopreservation is routinely offered to men
with cancer prior to undergoing gonadotoxic treatments such as chemotherapy.
For children, young adolescents and azoospermic men, cryopreservation prior
to treatments may not be possible, and hopes for biological children rest on
recovery of sperm following treatments. Azoospermia in adults following treat-
ment modalities can be treated with surgical sperm retrieval techniques (TESE),
however success rates in this patient group are unknown and there is not
enough data to conﬁrm patient selection for this invasive procedure. We pre-
sent our experience.
Study design, size, duration: A retrospective case note analysis of 28
patients with a history of past cancer treatment who underwent surgical sperm
retrieval for azoospermia at a tertiary fertility clinic within a 3 year period.
Participants/materials, setting, methods: Patients with a history of past
cancer treatment who underwent TESE for azoospermia at a tertiary Fertility
clinic.
Main results and the role of chance: 28 patients aged 22-66 years (median
37) underwent TESE. The diagnoses included 11 patients with testicular can-
cers, 6 patients with lymphomas, 3 patients with leukaemia and the remaining 8
patients had other types of cancers. 11/28 (39.2%) had mature sperm success-
fully retrieved, 16/28 (57.1%) were unsuccessful and 1/28 (3.6%) had partial
success (2 grossly abnormal sperm seen). In the testicular cancer group 5/11
(45%) had successful TESE with 3 showing normal spermatogenesis, 1 showing
maturation arrest and 1 showing sertoli cell only syndrome (SCOS) upon histo-
logical analysis. In lymphoma group, 2/6 (33%) had successful TESE, with hist-
ology showing 1 patient with SCOS and 1 with normal spermatogenesis. None
of the 3 patients with history of acute leukaemia, total body irradiation and
bone marrow transplant had successful TESE. However, 1 patient with history
of rhabdomyosarcoma had a successful procedure, indicating the potential for
fertility in men surviving intensive treatment modalities. Testicular histology in
all unsuccessful TESE showed SCOS in all but 2 patients, the remaining having
ﬁbrotic or totally sclerosed tissue. 4 patients with normal spermatogenesis and
1 with maturation arrest indicates that azoospermia in the post-chemotherapy
male may be attributed to complications of cancer treatment other than
gonadotoxicity.
Limitations, reasons for caution: Although TESE is widely used for patients
with cancer, there is little published research studying the outcome of TESE in
azoospermic men following chemo/radiotherapy. Larger studies will be
required to help in deﬁning the determining predictors of success. Outcome
data for use of retrieved sperm in fertility treatments were unavailable.
Wider implications of the ﬁndings: Our data shows 39.2% success with
TESE for this patient group. This signals an opportunity for this patient group to
achieve fertility, including those who have received intensive treatments.
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Prospective patients should be counselled for the undetermined success rates,
which may remain low in some groups.
Trial registration number: not applicable.
P-118 Adipokines expression in seminal ﬂuid of normal-weight
men
A. Bongrani1, Y. Elfassy2, C. Ramé3, N. Mellouk4, P. Froment5,
I. Berthaut2, S. Fellahi6, J.P. Bastard7, R. Levy2, C. Vasseur8,
J. Dupont3
1INRA Centre VAl de Loire, Indre et Loire, Tours, France
2Service de Biologie de la Reproduction et UF Biomarqueurs inﬂammatoires et
métaboliques- Hôpital Tenon- AP-HP- UPMC Université Paris 06- Inserm UMRS 938-
Centre de Recherche Saint-Antoine- IHU ICAN- Paris- France., Biology of
reproduction, Paris, France
3UMR 85 Physiologie de la Reproduction et des Comportements- Centre INRA Val de
Loire, Physiologie de la Reproduction et des Comportements, Nouzilly - Tours, France
4UMR 85 Physiologie de la Reproduction et des Comportements- Centre INRA Val de
Loire- 37380 Nouzilly., Physiologie de la Reproduction et des comportements,
Nouzilly- Tours, France
5UMR 85 Physiologie de la Reproduction et des Comportements- Centre INRA Val de
Loire- 37380 Nouzilly., Physiologie de la Reproduction et des Comportements,
Nouzilly - Tours, France
6Service de Biologie de la Reproduction et UF Biomarqueurs inﬂammatoires et
métaboliques- Hôpital Tenon- AP-HP- UPMC Université Paris 06- Inserm UMRS 938-
Centre de Recherche Saint-Antoine- IHU ICAN- Paris- France., Biologye of
reproduction, Paris, France
7Service de Biologie de la Reproduction et UF Biomarqueurs inﬂammatoires et
métaboliques- Hôpital Tenon- AP-HP- UPMC Université Paris 06- Inserm UMRS 938-
Centre de Recherche Saint-Antoine- IHU ICAN- Paris- France., Biochemistry, Paris,
France
8Pôle Santé Léonard de Vinci, Centre AMP, Chambray-lès-Tours, France
Study question: The aim of the study was to investigate expression proﬁle of
adipokines in seminal ﬂuid of normal-weight men and compare their seminal
and plasmatic concentrations.
Summary answer: Adipokines proﬁle expression in seminal and blood plas-
ma is different: many adipokines, including some inﬂammatory markers, are pre-
sent in seminal ﬂuid in higher concentrations.
What is known already: Infertility affects 14% of childbearing-age couples
and a male causal factor is involved in 20-50% of cases. Unlike women, little
data is available about relation between body-mass index and spermatic para-
meters. It is however known that obesity is associated with impaired male fertil-
ity through a decrease of sperm quality. We hypothesized that adipokines,
produced by adipose tissue, could interfere with gonadal function. Leptin’s role
in the interaction between energy metabolism and male reproductive system is
well-known. Recently, some novel adipokines have been identiﬁed in seminal
ﬂuid and their seminal concentration is likely to be correlated with some
morpho-functional spermatic parameters.
Study design, size, duration: Seminal and blood samples from 70 healthy
men consulting for couple infertility were collected in two Assisted
Reproductive Centers (Tours, FERTIPROTECT protocol, n = 32, and Paris,
METASPERME protocol, n = 38) between 2015 and 2017. Subjects aged
between 20 and 40 years, had normal BMI (20-24,5 kg/m2) and normal semen
analysis according to 2010 World Health Organization guidelines. Men with
metabolic disorders were excluded. Informed consent was signed by each
participant.
Participants/materials, setting, methods: Adipokines were analysed in
seminal ﬂuid and blood plasma using three different methods. First, human
adipokine-arrays, testing simultaneously 58 adipokines, were performed on
seminal and blood samples from 6 patients enrolled in Tours. The identiﬁed adi-
pokines of interest were then quantiﬁed by enzyme-linked immunosorbent
assay (ELISA) and Western-Blot analysis in the samples from Paris Centre (n =
38) and Tours Centre (n = 20), respectively.
Main results and the role of chance: Preliminary adipokine-arrays (n = 6)
showed that blood concentrations of adiponectin, leptin, chemerin and resistin
were signiﬁcantly higher than seminal ones. Interestingly, others adipokines,
such as visfatin, vaspin, ﬁbrinogen, IL-8, CCL-2, FGF-19, calgranulin and
angiopietin-1, were signiﬁcantly more expressed in seminal ﬂuid than in blood
plasma. These results were conﬁrmed by successive analyses. Western-Blot
analysis evidenced that visfatin, FGF-19, VEGF, IL-8, HGF and CCL-2 concen-
trations were signiﬁcantly higher in seminal ﬂuid than in blood plasma
(p<0,0001). Similarly, signiﬁcantly higher visfatin and IL-6 concentrations in
seminal ﬂuid were conﬁrmed by using ELISA assay (p<0,0001). On the other
hand, adiponectin, leptin, chemerin and resistin were predominantly expressed
in blood plasma (p<0,0001 for all adipokines, except for resistin, p = 0,01),
then conﬁrming different adipokines proﬁle expression in seminal ﬂuid and per-
ipheral blood.
Limitations, reasons for caution: Our study shows that adipokine expres-
sion in seminal ﬂuid is different from blood plasma. However, the meaning of a
predominant expression of some adipokines in seminal ﬂuid, notably including
inﬂammatory markers, remains to be elucidated. We can only speculate that
adipokines may play a role in male fertility.
Wider implications of the ﬁndings: Different adipokines proﬁle expression
in seminal and blood plasma suggests the possibility of a gonadal production or
a compartment-speciﬁc regulation of adipokines in reproductive tract and per-
ipheral blood. Immunohistochemistry characterisation of adipokines, currently
in progress in spermatozoa and different testicular cellular types, could allow us
to elucidate adipokines metabolism.
Trial registration number: METASPERME Protocol: AOM 10020 – NI
10033 – ID-RCB 2011-A01052-3
FERTIPROTECT Protocol: approved by Ethical Committed of Leonard de
Vinci Clinic.
P-119 Association between spermDNA damage extent,
fertilisation and cumulative live birth rates among infertile couples
undergoing assisted reproduction treatments
S. Malic Voncina1, A. Stenqvist1, M. Bungum2, A. Giwercman1
1Lund University, Dept. of Translational Medicine, Malmö, Sweden
2Skåne University Hospital, Reproductive Medicine Centre, Malmö, Sweden
Study question: Is there any association between sperm DNA Fragmentation
Index and cumulative live birth rate (CLBR) following up to three IVF/ICSI
cycles?
Summary answer: If the ﬁrst treatment was IVF, couples with DFI ≥320% at
initiation of treatment had statistically signiﬁcantly lower CLBR as compared to
those with DFI<20%.
What is known already: Several studies have shown that high DFI is asso-
ciated with lower chance of live birth, mainly in IVF and, to a less degree in
ICSI cycles. However, these observations are made on single IVF/ICSI
cycles. From a clinical point of view, it seems most relevant to look at the
CLBR following all treatments offered to a couple. In many countries where
the IVF/ICSI treatment is supported by the public health service, the cou-
ples are offered up to 3 fresh cycles and frozen embryo transfers emerging
from these treatments.
Study design, size, duration: The study is a large cohort longitudinal analysis
of retrospective data from August 2007 to August 2017 in a tertiary medical
centre, at the Reproductive Medicine Centre at the Skåne University Hospital,
Sweden. In total 5443 cycles in 2730 eligible consecutively included couples
with 1280 children born were analysed.
Participants/materials, setting, methods: All IVF/ICSI treatments (up to
3 fresh plus frozen) offered by the public health care were included. DFI value
used for analysis was, assessed by SCSA at the initiation of the treatment. The
couples were divided into them starting with IVF and those with ICSI as ﬁrst
treatment. Switching between IVF and ICSI, during the treatment course, were
based on standard laboratory parameters, sperm number after gradient centri-
fugation and fertilisation/good quality embryo in previous cycle(s).
Main results and the role of chance: Using linear regression we found
negative association between DFI and fertilization rate for IVF (p<0.0001) but
not for ICSI (p = 0.89).
Using Kaplan-Meier analysis with subsequent log rank test, adjusted for the
female age, we found statistically signiﬁcantly higher CLBR for those with
DFI<20% at initiation of treatment as compared to couples with DFI3 ≥20%, if
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the ﬁrst method used was IVF (56% vs 51%; p<0.02), whereas it was not case if
the ﬁrst treatment was ICSI (54% vs 53%, p = 0.97).
These calculations based on the assumption that patients who did not return
for IVF/ICSI cycles would have the same chance of a pregnancy resulting in a
live birth as patients who continued treatment. were conﬁrmed by calculations
based on assumption that none of the women who did not return for a subse-
quent cycle would have had a live birth.
Limitations, reasons for caution: Despite our robust methodological
approach, the presence of biases related to retrospective design cannot be
excluded.
Wider implications of the ﬁndings: Our results, demonstrate that selec-
tion of the ﬁrst method for assisted reproduction, based on the results of SCSA
analysis, has a statistically signiﬁcant impact on the CLBR.
Trial registration number:Not relevant.
P-120 Is fertility preservation justiﬁed in male patients with
congenital adrenal hyperplasia (CAH)?
T. Chougar1, M. Laanani2, L. Ferreux3, J. Dulon4, C. Chalas3,
P. Tourraine4, J.P.Wolf3, C. Patrat3, V. Drouineaud3
1CECOS Cochin- Service d’Histologie-Embryologie-Biologie de la Reproduction-
Centre Hospitalier Universitaire Cochin- Assistance Publique - Hôpitaux de Paris AP-
HP- Bâtiment Port-Royal- 123 Boulevard de Port Royal- 75014 Paris- France, PARIS,
Boulogne-B
2Université de Biostatistique et d’Epidémiologie- Hôtel Dieu- Assistance Publique –
Hôpitaux de Paris AP- HP- 1 Place du Parvis Notre-Dame- 75004 Paris- France,
Paris, Paris, France
3CECOS Cochin- Service d’Histologie-Embryologie-Biologie de la Reproduction-
Centre Hospitalier Universitaire Cochin- Assistance Publique - Hôpitaux de Paris AP-
HP- Bâtiment Port-Royal- 123 Boulevard de Port Royal- 75014 Paris- France, Paris,
Paris, France
4Service d’Endocrinologie et Médecine de la Reproduction- Hôpital Pitié Salpêtrière-
IE3M-ICAN- Equipe du Centre des Maladies Endocriniennes Rares de la
Croissance- Equipe du Centre de Pathologies Gynécologiques Rares- Equipe
européenne ENDO-ERN- 83 Bd
Study question: Is sperm cryopreservation relevant in patients with congeni-
tal adrenal hyperplasia (CAH), especially in those having testicular adrenal rest
tumours (TARTs)?
Summary answer: Men with CAH should beneﬁt from a sperm cryopreser-
vation at the onset of puberty, before the occurrence of TART and/or before
alteration of sperm parameters.
What is known already: CAH is a genetic autosomal recessive defect in
the adrenal steroidogenesis pathway. 21-hydroxylase deﬁciency is the most
common form, leading to glucocorticoid and in more severe cases, min-
eralocorticoid deﬁciency associated with androgen excess. The clinical
phenotype is classiﬁed classic (with or without salt-wasting) for the severe
form or non-classic for the mild form. In men with CAH, infertility is an
important complication in which (TARTs) are the most frequent cause.
TARTs can strongly contribute to the occurrence of oligospermia or azoo-
spermia through an obstructive or a deleterious paracrine effect. Therefore,
several authors have recommended sperm cryopreservation in patients with
CAH.
Study design, size, duration: This was a retrospective and observational
study including CAH male patients, addressed to the CECOS (sperm bank) of
Paris Cochin Hospital between 2008 and 2017 for sperm cryopreservation.
Clinical, hormonal and testicular ultrasound data were collected as well as
sperm parameters before freezing and after thawing.
Participants/materials, setting, methods: Twenty CAH patients between
15 and 37 years old, with or without TARTs were included. Initial sperm ana-
lysis was performed in all patients. Sperm cryopreservation was performed in
15 men and sperm parameters before and after freezing were analysed. Data
were compared between the group of patients with TARTs or without TARTs.
All samples were analysed according to the WHO 2010 recommendations.
The potential use of straws in assisted reproductive technology (ART) was
evaluated.
Main results and the role of chance: Mean age of the patients was 22.1
+/- 5.6 years old. 85[i1] % of them had a 21-hydroxylase deﬁciency, and
75% classiﬁed as salt-wasting TARTs were present in 65% of the patients.
Median total sperm count (33.8 × 106) and sperm concentration (12.1 ×
106 /ml) was low according to the WHO criteria. 25% (5/20) of the
patients showed azoospermia and 25% (5/20) showed oligospermia while
50% (10/20) had normal sperm. All patients who were azoospermic had
TARTs (5/5). Severe oligozoospermia (<5 M/ml) was signiﬁcantly more fre-
quently observed than moderate oligozoospermia (between 5 and 15 M/ml)
or normozoospermia (>15M/ml) in patients with TARTs compared to
patients without TARTs (p = 0 .04). Sperm concentration and total sperm
count were signiﬁcantly lower in patients with TARTs than in patients with-
out TART (respectively p = 0.02 and p = 0.03). The[DV2] post-thawing
sperm progressive motility was signiﬁcantly lower in all patients (p = 0.001)
and particularly in patients with TARTs compared to sperm progressive
motility before freezing (p = 0.01). The mean total number of motile sperm-
atozoa per straw was low, at 0.7 × 106, allowing their use only in ICSI in
73% of the patients in case of a future fertility project and regardless to the
fertility check-up in the female partner.
Limitations, reasons for caution: CAH is a rare disorder, explaining the
low number of patients included. The same id observed in the scientiﬁc littera-
ture. Our study was a retrospective observational study and a prospective lon-
gitudinal study with a larger sample would be necessary to conﬁrm these ﬁrst
results about sperm cryopreservation in CAH patients.
Wider implications of the ﬁndings:We have conﬁrmed that patients with
CAH and especially those with TARTs, could have severe altered sperm para-
meters, with high rate of azoospermia. Sperm cryopreservation should be pro-
posed as soon as possible, before the occurrence of TARTs and/or alteration
of sperm parameters, in order to improve their chance to procreate.
Trial registration number:Not applicable.
POSTER VIEWING
Embryology
P-121 Effects of the oral oxytocin receptor antagonist nolasiban on
early embryonic development
O. Pohl1, D. Perks2, R. Sisti3, J.P. Gotteland1
1ObsEva SA, Research and Development, Plan-les-Ouates Geneva, Switzerland
2Covance Laboratories Ltd, Reproductive toxicology, Harrogate, United Kingdom
3Research Toxicology Centre S.p.A., Reproductive toxicology, Pomezia, Italy
Study question: Nolasiban, an oral oxytocin receptor antagonist, may
increase rates of implantation and live-births among patients undergoing ART.
The embryonic safety of nolasiban was demonstrated using rat and rabbit
models.
Summary answer: Nolasiban showed no teratogenic or embryotoxic effects
in rats and rabbits, nor effect on postnatal development and learning abilities of
rats at the doses tested.
What is known already: Antagonism of oxytocin receptors may enhance
uterine receptivity by decreasing uterine contractions and by improving endo-
metrial perfusion. A meta-analysis of 7 studies showed signiﬁcant improvements
in clinical pregnancy rate after administration of oxytocin receptor antagonist
(OTR) atosiban. To enable safe clinical testing of nolasiban, a novel, oral OTR,
it is critical to evaluate its effects on early embryonic development.
Study design, size, duration:We administered nolasiban to rats and rabbits
from implantation and throughout embryonic development at doses of 0, 37.5,
75 and 125 mg/kg/d and of 0, 125, 200 and 300 mg/kg/day, respectively, to
assess fetal safety.
Participants/materials, setting, methods: Purpose-bred pregnant rats
(50/group) and rabbits (20/group) were treated daily from gestation day (GD)
6-17 and 7-19, respectively. Females underwent cesarean section before term
and external, visceral and skeletal examinations of fetuses were performed.
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Additional rat groups were allowed to litter and offspring was assessed for mor-
tality, behavior, learning abilities and reproductive performance.
Main results and the role of chance: Nolasiban had no effect on preg-
nancy parameters of pre- and post-implantation loss or the number of
implantations or live fetuses per female. There were no effects on fetal
weight or fetal sex ratio and no malformations. Treatment had also no
effect on clinical observations including body weight, food intake develop-
mental hallmarks such as vaginal opening and testes descent, behavior and
learning abilities and mating and reproductive performance. The number of
observed litters were sufﬁcient to exclude nolasiban effects and in line with
international testing guidelines.
Limitations, reasons for caution: The translation of animal ﬁndings to man
should be made with caution.
Wider implications of the ﬁndings: In addition to previously reported
peri-implantation safety data, these studies conﬁrm the absence of harmful
nolasiban effects on early fetal development, paving the way for developing
nolasiban for use in ART. Our ﬁndings raise a potential to administer nolasiban
beyond the current single-dose administration on the day of embryo transfer.
Trial registration number:N/A.
P-122 Time intervals from the hCG trigger: analysis of different
checkpoints and their impact on embryo development,
implantation and pregnancy
M. Papayannis1, A. Demarco2, G. Terrado Gil2, C. Bisioli1, J. Serna1,
M. Gomez Peña1, M. Rocha2, I. De Zuñiga2, L. Kopcow2, F. Sobral2,
A. Oubiña2, M. Horton2
1Pregna Medicina Reproductiva, IVF Lab, Buenos Aires, Argentina
2Pregna Medicina Reproductiva, Department of Gynaecology and In Vitro Fertilisation
Unit, Buenos Aires, Argentina
Study question: To analyse the impact on reproductive outcome of different
time intervals at each stage of an ART procedure, from triggering of ﬁnal oocyte
maturation.
Summary answer: In ICSI cycles, we observed better pregnancy and implant-
ation rates when interval between oocyte retrieval and denudation was <
2.5 hours.
What is known already: Previous reports have observed a greater number
of available embryos and a signiﬁcant increase in fertilization and clinical preg-
nancy rates when oocyte collection was close or even after 36 h from the hCG
trigger. Other authors have also proposed delaying oocyte retrieval to optimize
oocyte maturation.
Modifying oocyte incubation time could also affect reproductive outcomes
and synchronise nuclear and cytoplasmic maturation. Some authors concluded
that the incubation of oocytes approximately 1.5-2 hours between collection
and denudation signiﬁcantly inﬂuences the implantation rate.
Study design, size, duration: An initial set of 843 patients performing ART
treatment with their own oocytes during a one-year period was reviewed.
After exclusion of 145 patients with less than 3 oocytes retrieved, a cohort of
679 patients was analysed. Among them, 336 underwent ICSI and 343 conven-
tional IVF insemination. We analysed the number of oocytes retrieved, the
maturity rate, fertilisation rate, and blastulation rate, as well as implantation and
clinical pregnancy rates at different time intervals.
Participants/materials, setting, methods: Patients were grouped into the
following time-intervals:
(1) hCG trigger to oocyte retrieval (<35 and >35 h; early and late retrieval)
(2) oocyte retrieval to denudation (<2.30 and >2.30 h)
(3) denudation to ICSI (<10 and >10 min)
(4) oocyte retrieval to IVF (<2 and >2 h) and.
(5) administration of hCG to IVF or ICSI (<38 and >38 h).
Continuous variables were compared by T-test; categorical variables were
compared by X2 test.
Main results and the role of chance: One hundred and eighty seven
patients (early retrieval group) and 492 (late retrieval group) were compared,
showing similar age (37.7 ± 4.0 vs. 37.3 ± 3.8, p = 0.17) and total number of
eggs retrieved (8.4 ± 6.2 vs. 9.2 ± 6.1, p = 0.12). In ICSI cycles, we observed a
higher number of good quality embryos on day 3 (54.2% vs. 63.1% p = 0.002),
and better blastocyst development (41.4% vs. 48.9% p = 0.0006) in the late
retrieval group, which also showed a trend towards better oocyte maturity
rate, although not signiﬁcant (p = 0.06). Also in ICSI cycles, there was an
increase in clinical pregnancy (42.3% vs. 23.2%, p = 0.005), ongoing pregnancy
(34% vs. 19.6%, p = 0.03) and implantation rates (28% vs. 16%, p = 0.007)
when time between oocyte collection and denudation was less than 2 h 30 min.
These differences between groups were not present in IVF cycles, were both
groups showed comparable outcomes. This could be related to the fact that
the exact timing of fertilisation events and gamete fusion are difﬁcult to evaluate
and cannot be determined precisely.
Limitations, reasons for caution: This is an analysis of time intervals in an
unselected population, where most retrievals were done in a narrow window
between 35 and 36 hours of hCG trigger. Subtle differences between patients
or undetected premature luteinization could affect these results.
Wider implications of the ﬁndings: Even a slight ﬂexibilization of the trigger
timing can have a substantial impact on treatment outcome because it has an
inﬂuence on oocyte maturation and quality. Nonetheless, extending the culture
of the oocytes prior to ICSI could have a negative effect, potentially linked to
the premature ageing of the oocyte.
Trial registration number:Not applicable.
P-123 Comparing early embryomorphokinetics between patients
with lower and normal ovarian response by using time-lapse
microscopy in assisted reproductive technology
E. Alexopoulou1, A. Bisgaard Pinborg2, A. Zedeler1
1Hvidovre Hospital, 455 Fertility Clinic, Hvidovre, Denmark
2Hvidovre Hospital, Department of Obstetrics/Gynaecology, Hvidovre, Denmark
Study question: Are there differences on early embryo morphokinetic para-
meters and cleavage stage patterns between patients with a low and normal
ovarian response to controlled ovarian stimulation?
Summary answer: We did not ﬁnd any statistically signiﬁcant difference in
early morphokinetic parameters and cleavage patterns between the two
patients groups.
What is known already: In the era of time-lapse microscopy (TLM) and
elective single embryo transfer, early embryo morphokinetic parameters seem
to play a signiﬁcant role to select the embryo with the highest implantation
potency. Patients with a low ovarian response have fewer fertilized oocytes
hence fewer embryos for transfer than the normal responders. Little is known
about embryo developmental patterns in low responders compared with
patients with a normal ovarian response and if a similar morphokinetic model
can be applied in both groups.
Study design, size, duration: Retrospective study on early embryo morpho-
kinetics and cleavage patterns in 606 oocytes, where 435 oocytes derived from
47 patients with a normal ovarian response and 171 oocytes derived from 47
patients with a low ovarian response. Data were collected from May 2015 to
November 2017 and extracted from our Embryoscope database.
Participants/materials, setting, methods: Number of aspirated oocytes
and AMH were used to allocate patients into two groups. Low responders had
AMH ≤ 7.8 pmol/L and less than 7 oocytes, while normal responders had
AMH 10-35 pmol/L and 8-15 oocytes. Time of PN fading (tPnf), time to two
cells (t2), three cells (t3), four cells (t4), asynchrony in 2nd cell cycle (S2), frag-
mentation, multinucleation, direct cleavages from 1-3 cells, reversed cleavage,
rolling and non-tetrahedral shape were recorded.
Main results and the role of chance: Student’s t-test was used to compare
the timings between the groups and Chi-square test to compare proportions.
The parameters that did not follow the normal distribution were analyzed with
Mann- Whitney U-test. The timings of the early cell divisions did not differ stat-
istically (p-value >0.05) between the low and normal responder group (t2:
29.0 h vs 28.1 h, t4: 40.4 h vs 39.6 h). Additionally, no statistically signiﬁcant dif-
ference was observed for irregular cleavage patterns (26.5 % vs 35.1 %), multi-
nucleation (53.8 % vs 53.4 %), fragmentation and non-tetrahedral shape rate at
the 4-cell stage. The groups did not differ regarding fertilization and cleavage
rate as well as the number of embryos that fulﬁll the ESHRE criteria for top qual-
ity characteristics on Day 2.
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Limitations, reasons for caution: The retrospective nature of the study
and the small number of patients limit the potential power. Prospective studies
are required to conﬁrm the validity of our results.
Wider implications of the ﬁndings: It is reassuring for patients with lower
ovarian response and for clinicians to know that embryos derived from these
patients are not prone to more prolonged and abnormal cleavages than the
embryos from normal responders. Also, the use of a similar time-lapse mor-
phokinetic model for both groups is possible.
Trial registration number:Not applicable.
P-124 Comparison of neonatal outcomes of births conceived from
day 1 rescue ICSI and conventional ICSI cycles
M. Li, F. Xue
Peking University Third Hospital, Center of Reproductive Medicine, Beijing, China
Study question: Are the neonatal outcomes of births conceived from day 1
rescue ICSI different from births generated during conventional ICSI cycles?
Summary answer: neonatal outcomes of births conceived from day 1 rescue
ICSI were comparable with the births generated during conventional ICSI treat-
ment, including the incidence of abnormalities.
What is known already: A limited number of reports on day 1 rescue ICSI
children are currently available; the available data and a systematic study are
lacking.
Study design, size, duration: The study was a retrospective analysis of 74
singletons born from day 1 rescue ICSI cycles in fresh cleavage-stage embryos
transfers, 38 singletons in frozen-thawed cleavage-stage embryo and 71 single-
tons in frozen-thawed blastocyst-stage embryo.To evaluate day 1 rescue ICSI
on neonatal outcome, comparison groups (conventional ICSI) were used: 148
singletons born in fresh cleavage-stage embryos transfers 56 singletons in
frozen-thawed cleavage-stage embryo and 142 singletons in frozen-thawed
blastocyst-stage embryo.
Participants/materials, setting, methods: Conventional ICSI cycles were
chosen as a control group to exclude possible inﬂuences of the insemination
technique. To eliminate the effects of age, the female ages were matched
between rescue ICSI cycles and conventional ICSI cycles (one rescue ICSI cycle
was matched with two conventional ICSI cycles).
Main results and the role of chance: No signiﬁcant differences were found
between rescue ICSI cycles and conventional ICSI cycles with respect to the
birth weight of singletons (3334.99 ± 338.59 g vs. 3331.52 ± 511.70 g) and ges-
tational age (39.04 ± 1.44 vs. 38.61 ± 1.86 weeks) in fresh cleavage-stage
transfers, and there were no signiﬁcant differences with respect to the birth
weight of singletons (3352.14 ± 599.33 g vs. 3406.21 ± 474.17 g) and gesta-
tional age (38.69 ± 1.47 vs. 39.09 ± 1.32 weeks) in frozen–thawed transfers
and no signiﬁcant differences with respect to the birth weight of singletons
(3526.06 ± 434.15 g vs. 3505.90 ± 421.43 g) and gestational age (39.23 ± 1.54
vs. 38.88 ± 1.54 weeks) in blastocyst-stage transfers. Rate of congenital birth
defects of the rescue ICSI group were similar to those in the conventional ICSI
groups.
Limitations, reasons for caution: Additional cases are in need of study,
especially with respect to the long-term health and development of day 1 res-
cue ICSI children.
Wider implications of the ﬁndings: The current study showed that the
neonatal outcomes of births conceived from day 1 rescue ICSI are comparable
with conventional ICSI treatment. Additional cases are in need of study, espe-
cially with respect to the long-term health and development of day 1 rescue
ICSI children.
Trial registration number: The study was approved by the Ethics
Committee of Peking University Third Hospital (reference no. 20080612) and
all patients signed written informed consent.
P-125 Identifying general markers of human cumulus cells enables
precise analysis for predicting human oocyte quality
M. Tsuneto, K. Yumoto, J. Yamauchi, S. Miyazaki, M. Nakaoka,
I. Matsumoto, H. Moriwaki, Y. Kai, K. Iwata, Y. Mio
Mio Fertility Clinic, Reproductive centre, Yonago, Japan
Study question: Are ﬂow cytometric analyses useful in detecting the bio-
logical features of cumulus cells relevant to predicting oocyte quality?
Summary answer: We successfully identiﬁed several general markers of
human cumulus cells that could be used to sort and characterize these cells.
What is known already: Many studies have tried to predict oocyte quality
by analyzing the surrounding human cumulus cells. For example, transcriptomic
analyses identiﬁed candidate genes expressed in cumulus cells that were related
to oocyte quality. However, the results of such studies remain controversial. As
proposed by us in 2017 at the annual ESHRE meeting, several speciﬁc markers
of cumulus cells must be identiﬁed for precise analysis and quality assessment of
oocytes to avoid irrelevant information from contaminating peripheral blood
cells and dead cells.
Study design, size, duration: From June 2016 to October 2017, cumulus
cells were collected from intracytoplasmic sperm injection-treated patients
who provided informed consent. The total number of patients was 26.
Participants/materials, setting, methods: The age of patients ranged
from 30 to 47 years. After hyaluronidase treatment of the cumulus-oocyte
complexes (COCs), cumulus cell samples were collected for staining with anti-
bodies and analysis by ﬂow cytometry (Gallios, Becton-Dickinson, USA). In
cases where patients provided more than 2 COCs, the cumulus cells derived
from the COCs were pooled. Alternatively, to compare the character of cumu-
lus cells from individual COCs, cumulus samples from each COC were separ-
ately prepared.
Main results and the role of chance: The cumulus cell samples collected
included 63.1% ± 15.95% dying/dead cells, indicated by staining with propidium
iodide (PI). The PI-negative living cells contained10.7% ± 9.52% CD45-positive
blood cells and CD235a-positive erythrocytes, suggesting contamination of the
suspension by surrounding blood cells during oocyte retrieval. After screening
out the blood cells by ﬂow cytometry, the remaining non-hematopoietic cells
expressed CD49a, activated leukocyte cell adhesion molecule, CD49f, and
CD56 on the cell surface.
By further isolating the PI-CD45/CD235a-/dullCD49f+ cells, cumulus cells
were puriﬁed and conﬁrmed by expression the Cyp19a1 gene using real time
RT-PCR. Expression comparisons of these surface proteins on cumulus cells
from individual COCs showed no remarkable differences, even in the presence
of distinct oocyte developmental outcomes. Furthermore, by using JC-1 dye as
a mitochondrial potential sensor, we could stain mitochondria in the cumulus
cells.
These results suggest that ﬂow cytometry and cell sorting are useful for pre-
cise analyses of cumulus cells.
Limitations, reasons for caution: The current work involves only a small
number of samples, and large-scale analyses of cumulus cells should be done in
the future.
Wider implications of the ﬁndings: Puriﬁcation of human cumulus cells
hold the promise of enabling precise transcriptomic analysis. In addition, ﬂow
cytometric analysis itself could provide simple screening of the condition of
human cumulus cells associated with prediction of oocyte quality.
Trial registration number:Not applicable
P-126 Laboratory factors affecting the occurrence of
multinucleated blastomeres
N. Aono1,2, E. Sagara2, Y. Ogura2, N. Okuyama2, N. Oka2, R. Obata2,
T. Hashimoto2, K. Kyono1,2
1Kyono ART Clinic, Obstetrics and Gynecology, Sendai, Japan
2Kyono ART Clinic Takanawa, Obstetrics and Gynecology, Tokyo, Japan
Study question: Do clinical and laboratory factors have an inﬂuence on the
occurrence of multinucleation?
Summary answer: The occurrence of multinucleation among human
embryos may be affected by laboratory factors such as culture media.
What is known already: Multinucleated blastomere (MNB) is a nuclear
abnormality, and has been reported to be associated with poor embryo devel-
opment and low implantation rates. Accordingly, embryos with MNB are usu-
ally not the ﬁrst choice for embryo transfer. Furthermore, it has been reported
that the frequency of MNB is high in human embryos cultured in vitro, and it
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may have an effect on the development of aneuploidy among human embryos.
However, it is unclear what kinds of factors have an impact on the development
of MNB. We aimed to investigate whether clinical and laboratory factors may
affect the occurrence of MNB embryos.
Study design, size, duration: This is a retrospective observational study
conducted at Kyono ART clinic Takanawa in Japan from January 2015 to
April 2017. A total of 1509 embryos from 302 cycles of 189 patients were
included in this study. All embryos were monitored by time-lapse
cinematography.
Participants/materials, setting, methods: We compared the back-
grounds of the embryos which had at least one MNB between day 1 to day 3
embryo culture for age factor, fertilization method (c-IVF or ICSI), ovarian
stimulation protocol (GnRH antagonist, agonist long, agonist short and others)
and culture media (two different single culture media). Chi-squared and Fisher’s
test were used for statistical analysis. A P value of less than 0.05 was considered
statistically signiﬁcant.
Main results and the role of chance: The overall incidence of MNB was
33.7% (509 / 1509). MNB embryos showed lower blastulation rates
(50.7%) compared to non-MNB embryos (55.9%), although this was not
statistically signiﬁcant (P = 0.055). The good morphology blastocyst
(Gardner’s grade 3BB or more) formation rate in the MNB embryos was
signiﬁcantly lower (18.3%) than that of the non-MNB embryos (25.1%) (P =
0.003). There was no signiﬁcant difference in the MNB occurrence rate in
terms of age factor (patients aged under 40 y.o. vs over 40 y.o.; 35.5% vs.
31.2%), and fertilization method (c-IVF vs ICSI; 33.6% vs. 33.8%). Also,
there was no signiﬁcant difference in MNB rate in terms of ovarian stimula-
tion protocols. Culture media tended to have an impact on MNB incidence
rate (media A vs B; 16.2% vs. 27.5%, P = 0.067) although this was not stat-
istically signiﬁcant.
Limitations, reasons for caution: The small sample size may have inﬂu-
enced these results. The details of culture media which have affected MNB is
unclear.
Wider implications of the ﬁndings: MNB affects subsequent developmen-
tal potential of embryos, and these events may be affected by laboratory factors
such as culture media. MNB formation may be related to an increase in aneu-
ploidy rate and mosaic formation rate by using different culture media.
Trial registration number: not applicable.
P-127 Blastocyst development rates of embryos with
morphokinetic variables and the effect of morphokinetic variables
on clinical pregnancy rates in vitriﬁed-warmed single blastocyst
transfers
Y. Hur1, E.K. Ryu1, S.H. Yoon2, K.S. Lim1,W.D. Lee1, J.H. Lim1
1Maria Fertility Hospital, IVF-ET Center 2, Seoul, Korea- South
2Maria Research Center, Research center, Seoul, Korea- South
Study question: How many embryos exhibiting morphokinetics variables
could develop up to blastocyst stage? And how much the blastocysts were
affected by morphokinetics variables on pregnancy?
Summary answer: The blastocyst development rates of embryos with mor-
phokinetic variables were more than 40% and the clinical pregnancy rates of the
blastocysts vitriﬁed-warmed were adversely affected.
What is known already: In time-lapse cultures, morphokinetic variables are
used to refer to two concepts; morphological assessment parameters and mor-
phokinetic assessment parameters. Morphological assessment parameters
include uneven pronuclei, blastomere, and multinucleation etc. Morphokinetic
assessment parameters include direct division, reverse division, and rapid div-
ision etc. Morphokinetic variables generally have a fatal inﬂuence on the embryo
development, implantation and pregnancy rates in fresh cycles. There are a few
reports on the impact of various morphokinetic variables on blastocysts devel-
opments; and, there are a few reports on the effect of morphokinetic variables
on vitriﬁed-warmed blastocyst transfer cycles.
Study design, size, duration: Morphokinetic variables include uneven pro-
nuclei, blastomere, multinucleation, and direct division, rapid and irregular div-
ision. Regularly developed embryos which are not observed in any kind of
morphokinetic variables were compared with the embryos observed in
morphokinetic variables. We conducted a review between January 2014 and
November 2017. During the same period, the clinical pregnancy rates of the
single blastocysts vitriﬁed-warmed were determined and the effects of each
type of morphokinetic variables on pregnancy rates were observed.
Participants/materials, setting, methods: Embryos were monitored in a
time-lapse incubation system (embryoscope). Embryos were selected for
transfers on day 3 or day 5, and surplus embryos were cultured for blasto-
cyst development. The blastocysts were evaluated according to the blasto-
cyst scoring system, and blastocysts graded 3BB or higher were
cryopreserved. Vitriﬁcation and thawing processes were performed as lab
protocols. In thawed blastocysts, they were graded CC or higher and were
used for embryo transfers.
Main results and the role of chance: The blastocyst development rate
and freezing rate of regularly developed embryos were 56.6% (2116/3739)
and 45.1% (1687/3739) respectively. Uneven pronuclei were 43.4% (189/
435) and 31.7% (138/435) respectively. Uneven blastomere were 55.9%
(137/245) and 42.4% (104/245) respectively. Multinucleation were 53.5%
(423/790) and 40.1% (317/790) respectively. Direct division were 40.2%
(146/363) and 27.0% (98/363) respectively. Rapid division were 56.8%
(162/285) and 39.3% (112/285) respectively. And, irregular division were
43.9% (94/214) and 24.3% (52/214) respectively. The blastocyst develop-
ment rates of embryos with morphokinetic variables were lower than regu-
larly developed embryos, but the blastocyst development rates of embryos
with morphokinetis variables were more than 40%. The clinical pregnancy
rate of regularly developed single blastocyst that vitriﬁed-warmed was
37.7% (60/159). Uneven pronuclei were 20.0% (2/10). Uneven blasto-
meres were 10% (1/10). Multinucleation were 18.8% (6/32). Direct div-
ision was 6.3% (1/16). Rapid division was 0.0% (0/9). And, irregular
division was 0.0% (0/5). The clinical pregnancy rates of single blastocyst
with uneven pronuclei, blastomere and multinucleation were lower than a
regularly developed single blastocyst. The clinical pregnancy rates of single
blastocyst with direct, rapid and irregular divisions were much lower than a
regularly developed single blastocyst.
Limitations, reasons for caution: In this study, it was possible to assess the
effect of morphokinetic variables on pregnancy rates. However, further studies
will be required to accumulate sufﬁcient data to determine the effects of each
type of morphokinetic variables on pregnancy, delivery, and congenital anomaly
rates.
Wider implications of the ﬁndings: More than 40 percent of embryos
exhibiting morphokinetic variables could develop up to blastocyst stages in
the time-lapse system. Therefore, it was important that freezing the
embryos were to be done carefully, because the embryos with morphoki-
netic variables were not easy to implant, even if morphology was good
after thawing.
Trial registration number: not applicable.
P-128 A prediction model powered by a Group Method of Data
Handling (GMDH) algorithm for selecting patients of a single frozen
embryo
X. Zhang, T. Dineen, A. Kovacs, R. Mihart, J. O’Callaghan,
J. Culligan, A. Tocado, N. Daly, R. Mendez-Vega, D. McAuliffe,
M.Walsh, J. Waterstone
Waterstone Clinic, Laboratory, Cork, Ireland
Study question: As frozen embryo transfer (FET) cycles become more com-
mon, policies regarding the number of embryos to transfer need to be formu-
lated for individual patients.
Summary answer: Using the most relevant factors relating to patients,
embryos and fresh cycle outcomes, this GMDH predictive model can reason-
ably predict the occurrence of implantation.
What is known already: The introduction of vitriﬁcation has improved
both embryo survival and FET success and has led to a large increase in
routine embryo freezing. The improvement of embryo cryopreservation
signiﬁcantly increases the overall success for superovulation cycle. But a
high proportion of twins results after transfer of 2 frozen embryos. Studies
from fresh cycles suggested that acceptable pregnancy rates could be
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achieved after transfer of a single frozen embryo in selected groups of
patients.
Study design, size, duration: A retrospective analysis of all FET cycles
carried out at Waterstone clinic between Feb 2012 and Dec 2017 was
conducted.
Participants/materials, setting, methods: All embryos in the study had
been vitriﬁed on day 5 or day 6. Success rates were compared after transfer of
either one or two embryos. SET cycle outcomes were also analysed with the
factors which most strongly predicted success after FET. Two statistical models
were used: the logistic regression and the GMDH algorithm.
Main results and the role of chance: From Feb 2012 to Dec 2017, a
total of 1535 out of 1601 vitriﬁed embryos survived after warming 95.9%
and were transferred in 1205 cycles. Two embryos were transferred in
327 FET cycles and one embryo was transferred in 878 cycles. The clinical
pregnancy (fetal heart activity at 8/40) rates were 41.9%/ transfer and
33.3%/ transfer for 2-ET vs. 1-ET cycles. The overall implantation rate was
31.4%. The proportion of pregnancies which were twins in the 2-ET group
was 37.2%.
A logistic analysis was performed based on SET events to investigate the
relationship between the implantation of embryos and different prognostic
factors. We identiﬁed three prognostic factors that made the most signiﬁ-
cant contributions to the success of implantation: the woman’s age, the
quality of the inner cell mass (ICM) and the success or failure of the fresh
cycle from which the frozen embryos derived. The predictive ability of the
model measured by the area under the receiver operating characteristic
(ROC) curve was 0.61 when using logistic analysis. Prediction ability was
signiﬁcantly improved by application of a GMHD algorithm which increased
the ROC to 0.67 with the negative and positive predictive value of 70.5%
and 76.9%.
Limitations, reasons for caution: This prediction model may be beneﬁted
by including uterine factors. Prospective studies are now required to conﬁrm
the clinical validity of the model.
Wider implications of the ﬁndings: Application of this GMHD algorithm
may help in the decision making by accurately predicting success. It should iden-
tify patients for whom single embryo transfer is indicated and a smaller number
of patients for whom a 2-embryo transfer would be wiser.
Trial registration number: na.
P-129 Polar body transfer in a mousemodel to overcome
transmission of mitochondrial diseases
M. Tang, R.R. Guggilla, P. Stamatiadis, M. Ferrer-Buitrago, V. Thys,
M. Van der Jeught, P. De Sutter, B. Heindryckx
Ghent University Hospital Ghent Fertility and Stem cell Team, Department for
Reproductive Medicine, Gent, Belgium
Study question: Can polar body transfer (PBT) serve as an efﬁcient type of
germline nuclear transfer (NT), to overcome mitochondrial diseases?
Summary answer: This mouse model study supports the efﬁcient use of ﬁrst
(PB1) polar body transfer for overcoming mitochondrial DNA (mtDNA)
disorders.
What is known already: Since mtDNA diseases are difﬁcult to treat and
manifest with life-threatening consequences, their prevention is a priority.
Different germline NT have recently been proposed as novel technologies for
preventing mtDNA mutations transmission, including germinal vesicle transfer
(GVT), spindle transfer (ST), pronuclear transfer (PNT) and even PBT. Previous
mouse studies have revealed full potential of PB1/2 genomes for embryonic
development, by replacing female genome of oocytes/zygotes with PB1/2.
However, PB2T requires female PN identiﬁcation in zygotes, which is arduous
in human. Therefore, we tested if MII oocytes can be used for both PB1/2 T
and compared its efﬁciency with ST and PNT.
Study design, size, duration: In a ﬁrst set, PB1/2T were carried out in
B6D2F1 mice, by introducing PB1/2 into enucleated oocytes (spindle removal,
PB1T/novel PB2T) or zygote (female pronucleus removal, PB2T). For controls,
ST, PNT and ICSI groups were implemented. In a second set, ST, PNT and rou-
tine PB2T were performed between NZB/OlaHsd and B6D2F1 mice for evalu-
ating effect of heterologous NT on embryonic developmental potential.
Oocytes/zygotes from B6D2F1 mice served as recipients, while karyoplasts ori-
ginated from NZB/OlaHsd mice.
Participants/materials, setting, methods: Oocytes/zygotes were from
superovulated B6D2F1 and NZB/OlaHsd female mice (6-8 weeks). NT
was performed in KSOM-HEPES (2 μg/ml cytochalasin D, 1 μg/ml nocoda-
zole). Karyoplasts were exposed to Sendai virus for fusion with enucleated
oocytes/zygotes. One part of ST-, PB1T- and novel PB2T-oocytes were
fertilized (ICSI) and exposed to cytochalasin D (only for novel PB2T) to
prevent PB2 extrusion. Another part were examined for de novo spindle
formation through polarized microscopy, and spindle morphology assess-
ment via confocal analysis.
Main results and the role of chance: For homologous NT between
B6D2F1 mice, after ICSI, novel PB2T-oocytes showed signiﬁcantly lower two-
cell formation rates compared to ST and PB1T groups (50.0%, 83.8% and
90.0%), but not different with ICSI control (70.6%). For routine PB2T, blasto-
cyst rates (52.2%) were comparable with PB1T group and ICSI control (77.8%
and 75.0%, respectively), but these were signiﬁcant lower than ST- and PNT-
embryos (80.6% and 100%, p<0.05 and p<0.005 respectively). Remarkably,
no blastocyst formation could be achieved in the novel PB2T group. Polarized
microscopy showed most reconstructed oocytes after novel PB2T contained a
visible spindle (22/27, 81.5%) similar to PB1T-reconstructed oocytes (12/17,
70.6%). Confocal analysis, however, revealed that 61.5% of novel PB2T-
oocytes displayed an abnormal spindle-chromosome-complex compared to
33.3% in PB1T-oocytes showing aberrant spindles. After heterologous NT
from NZB/OlaHsd to B6D2F1 mice, following fertilization, 38.5% of ST-
oocytes developed to blastocysts, signiﬁcantly lower than ICSI control
(B6D2F1-oocytes) (72.7%, p<0.05) and the homologous ST group (80.6%,
p<0.05). In heterologous routine PB2T and PNT groups, two-cell rates were
similar (69.2% and 83.3%, respectively), whereas PNT-embryos yielded higher
blastocyst rates (27.8% vs 100%, p<0.001).
Limitations, reasons for caution: Further investigation is currently ongoing
to determine whether these NT techniques would alter the genetic and tran-
scriptomic landscape of resulting blastocysts and to assess the mitochondrial
carry over level.
Wider implications of the ﬁndings: Intra-strain NT in B6D2F1 mice, rou-
tine PB1/2T, ST and PNT, did not compromise embryonic development.
Novel PB2T could not support blastocyst formation, probably owing to embry-
onic aneuploidy. Inter-strain NT between NZB/OlaHsd and B6D2F1 mice
resulted in declined development in routine PB2T and ST groups contrast with
PNT and ICSI controls.
Trial registration number:Not applicable.
P-130 Predictive value of total number of normal morphology and
progressively motile sperm on the fertilization failure of short-term
insemination in in vitro fertilization
P. Chen, H. Zhang, G. Li, Q. Sun, F. Xiong, J. Huang, Y. Zeng,
C.Wan
Shenzhen Zhongshan Urology Hospital, Fertility Center/Institute for Reproduction
and Genetics/Shenzhen Key Laboratory for Reproductive Immunology of
Preimplantation-, ShenZhen, China
Study question: To investigate the predictive value of total number of normal
morphology and progressively motile sperm (TNNPS) on the fertilization failure
of short-term insemination.
Summary answer: TNNPS may be considered as a potential parameter for
predicting the failure of short-term insemination.
What is known already: Short-term insemination combined with early-
rescued ICSI has some advantages in decreasing the incidence rate of fertiliza-
tion failure. However, some studies suggested that short-term insemination can
lead to increase the abnormal fertilization. For the patients treated by short-
term insemination and early rescue ICSI, they had to withstand greater eco-
nomic and mental stress. Therefore, it is necessary to predict the rate of fertil-
ization failure of short-term insemination. TNNPS contains numerous
information of semen and has shown to closely related with fertilization failure
in IVF and IUI. Therefore, it is potential to be a parameter to predict the failure
of short-term insemination.
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Study design, size, duration: 2 768 cycles of short-term insemination in our
fertility center from January 1, 2013 to March 31, 2016 were retrospectively ana-
lyzed. All cycles were divided into four groups by the 25th, 50th, and 75th percen-
tiles of TNNPS, and then the cycles whose TNNPS≤3.0×106 were divided into six
groups according to the difference of TNNPS and the intercept was 0.5×106.
Participants/materials, setting, methods: Comparing the differences of
basic medical recording information (such as female age, male age, infertility
years, average number of oocytes retrieved and female BMI) and fertilization
failure rate among the different groups. Logistic regression was used to deter-
mine the inﬂuence of female age, male age, infertility years, average number of
oocytes retrieved,female BMI and TNNPS≤1.0×106 on fertilization failure.
Main results and the role of chance: For all the cycles, no signiﬁcant differ-
ences were found in the basic medical record information(P>0.05)among 4
groups. However, the insemination failure rate of group 1(23.27%,
TNNPS:0~2.76×106) was signiﬁcantly higher than that in group 2(9.83%,
TNNPS:2.76~7.21×106), 3(9.83%, TNNPS:7.21~16.31×106), and 4(5.92%,
TNNPS:16.31~149.61×106) (P<0.05). For the cycles that TNNPS≤3.0×106,
no signiﬁcant difference was found in the basic medical record information
(P>0.05) among 6 groups. However, both the insemination failure rate of group
I (43.31%, TNNPS:0~0.5×106, n = 157)and group II (28.79%,
TNNPS:0.5~1.0×106, n = 132)were signiﬁcantly higher than that in group III
(12.84%, TNNPS:1.0~1.5×106, n = 148), IV (14.04%, TNNPS:1.5~2.0×106, n
= 114), V (16.50%, TNNPS:2.0~2.5×106, n = 103) and VI (11.34%,
TNNPS:2.5~3.0×106, n = 97)(P<0.05). Analysis of logistic regression demon-
strated that TNNPS≤1.0×106(OR: 25.422; 95% CI: 17.702-36.508) had signiﬁ-
cance differences for predicting the fertilization failure of short-term insemination.
Limitations, reasons for caution: If patients with TNNPS≤1×106 treated
by short-term insemination, they may have a higher risk of fertilization failure.
Thus, it may be more favorable if those patients would be beneﬁted by changing
treatment program from IVF to ICSI. However, currently we lack the relevant
data to support our conjecture.
Wider implications of the ﬁndings: TNNPS may be regarded as an index
for predicting the failure of short-term insemination. For the patients treated by
short-term insemination with TNNPS≤1.0×106, they have a higher risk of fertil-
ization failure.
Trial registration number:None.
P-131 Comparative effectiveness of a universal warming/dilution
approach to blastocyst vitriﬁcation using two different solutions: A
randomized trial
M.C. Schiewe1, S. Zozula2, R. VanTol2, A. Jones3, R. Anderson4
1Ovation Fertility, ART, Newport Beach, U.S.A.
2Ovation Fertility, Assisted Reproductive Technologies, Newport Beach, U.S.A.
3Ovation Fertility, Assisted Reproductive Technologies, Nashville, U.S.A.
4Southern California Center for Reproductive Medicine, Clinic, Newport Beach, U.S.A.
Study question: Is the efﬁcacy of vitriﬁed human blastocyst post-warming
dilution using a universal sucrose dilution approach comparable to standard
manufacturer procedures?
Summary answer: Human blastocysts vitriﬁcation is equally effective using a
simple sucrose step down dilution approach independent of the type of cryo-
protective agent used.
What is known already: Blastocyst vitriﬁcation is a global standard in the IVF
industry. Numerous vitriﬁcation systems are being marketed and successfully
used. Each commercial company has its own recommended thawing solution.
As more patients move their cryopreserved embryos between laboratories, it
has become increasingly difﬁcult and cost inefﬁcient to maintain a stock of differ-
ent thaw solutions. Although proprietary in formulation, it is safe to assume
that all manufactured thaw solutions have one thing in common, declining
sucrose concentrations. Sucrose is an effective non-permeating solute that
safely removes intracellular cryoprotective agents (EG, DMSO, Glycerol) and
allows for isotonic equilibration by gradual rehydrating dilution steps.
Study design, size, duration: Research consented, discard slow frozen
(SF) embryos (N = 363; n = 328 cleavage stage, n = 35 blastocysts) were
thawed, cultured and fair-good quality blastocysts were randomly assigned
within batch groups to 1 of 2 vitriﬁcation treatments: 1) control Glycerol/
EG solution, I.C.E. >7.9 M;or 2)15% DMSO/15% EG solution. All vitriﬁed
blastocysts were warmed rapidly according to standard operating proce-
dures (SOP) then randomly assigned to either stepwise SOP dilution or
universal sucrose step down dilution (n = 31 embryos/group; 2×2 factorial
arrangement of treatments).
Participants/materials, setting, methods: All vitriﬁed blastocysts were rap-
idly cooled (>1500°C/min) and warmed (>6000°C/min) in an aseptic closed sys-
tem. All warmed embryos underwent stepwise dilutions by manufacturer SOP or a
universal 4-step sucrose dilution (21°C) of 1.0M for 5min and 0.5M, 0.25M and
0.125M for 3min each before isotonic equilibration for 5min at 37°C. Embryo sur-
vival and development was determined and differences in % survival and continued
development were statistically compared by Chi-square analysis (p<0.05).
Main results and the role of chance: Sucrose diluted, SF embryos yielded
124 (34.2%) fair to good quality blastocysts for study revitriﬁcation, whether
derived from cleaved embryos (n = 113, 34.5%) or blastocysts (n = 14; 40%).
Day 5 SF blastocysts had superior sustained development (67%, n = 10 of 15)
in contrast to Day 6 (20%, n = 4 of 20), as deﬁned by blastocoele re-expansion
and cellular fullness/growth. There were no differences in survival or sustained
development of vitriﬁed blastocysts between the combined dilution treatments,
whether SOP thawing (93.5%) or standard sucrose dilutions (90.3%) was
applied. Interestingly, cryoprotective agent treatments were signiﬁcant, with
98.4% (n = 61) of the Glycerol/EG treated blastocysts being viable post-
dilution and culture compared to 86.9% for DMSO/EG exposure (n = 53).
Only a single I.C.E.-sucrose treated embryo degenerated, whereas degener-
ation occurred in 4 DMSO/EG-SOP and 5 DMSO/EG-sucrose dilution treated
embryos. Although some DMSO/EG treated blastocysts appear to be more
sensitive to osmotic injury, the overall viability of the intact blastocysts was
excellent based on cellular fullness, clarity and growth/re-expansion.
Limitations, reasons for caution: Possible differences in blastocyst quality
may have contributed to VTF survivability of blastocyst exposed to the EG/
DMSO vitiriﬁcation solutions, as DMSO exposure to the lipid bilayer of vulner-
able trophectoderm cells may be more sensitive to osmotic stress.
Alternatively, 30%EG/DMSO solutions may be unstable under closed vitriﬁca-
tion/warming conditions, being less reliable.
Wider implications of the ﬁndings: This study has demonstrated that a
cost-effective “universal” approach involving stepwise sucrose dilutions is an
acceptable thawing method for vitriﬁed blastocysts independent of the vitriﬁca-
tion solution used. This standardized procedure allows for continuity of patient
care within and between laboratories vitrifying embryos by different methods.
Trial registration number: none.
P-132 Effect of l-carnitine supplementation during vitriﬁcation of
mouse oocytes: a RNA-seqtranscriptome proﬁling and validation
Y.Wang1, H. Shen2, M. Zhang3, Y. Kuang1
1Shanghai Ninth people’s hospital afﬁliated Shanghai Jiao Tong University, Assisted
reproduction department, Shanghai, China
2Obstetrics & Gynecology Hospital of Fudan university- Shanghai- China, Department
of gynecology, Shanghai, China
3Renji Hospital afﬁliated Shanghai Jiao Tong University, Assisted reproduction,
Shanghai, China
Study question: To investigate the protedctive effects of L-carnitine on cell
damage of oocytes following cryopreservation-warming
Summary answer: Our data are consistent with L-carinitine enhancing the
developmental potential of when used as a supplement during the course of
oocyte vitriﬁcation in murine model.
What is known already: Supplementation of L-carnitine(LC) during in vitro
muturation (IVM) is reported to improve cryotolerance of mammalian oocytes.
However, potential side effects of these supplements on transcriptional regula-
tion during cryopreservation are not well understood.
Study design, size, duration: Oocytes collected from C57 female mice (8
to 10-week-old), were divided into 4 groups: LMXB-1 (n = 30, fresh and non-
vitriﬁed), LMXB-2 (27 oocytes, vitriﬁed), LMXB-3 (29 oocytes, vitriﬁed +1 mg/
ml LC) and LMXB-4 (29 oocytes, vitriﬁcation +2 mg/ml LC).
Participants/materials, setting, methods: RNA sequencing and in silico
pathway analysis were used to identify differentially expressed genes (DEGs) that
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involved in oocyte viability after vitriﬁcation. DEGs were also analyzed by con-
structing regulatory networks and protein-protein interaction (PPI) networks,
transcription factor (TF)-miRNA-target, and drug-gene interaction analysis.
Main results and the role of chance: Following parthenogenetic activation,
a reduction in apoptosis marker expression in the L-carnitine treated group
that was not observed in control groups. Protective effects of LC were also
observed in RT-PCR mRNA studies, ATP measurements, and morphology con-
ﬁrming beneﬁcial effects of LC indicated bioinformatics analyses.
Limitations, reasons for caution: The research is only in murine model.
Female preservation ﬁnially need to be used on human being. The study got the
data that L-carnitine could enhance the oocyte’s devolopmental potential fol-
lowing cryopreservation-warming.
Wider implications of the ﬁndings: Next step, more discarded human
oocytes could go through the silimar research to see whether it could be the
same results or not. If L-carnitine could enhance human oocyte’s developmen-
tal potential following cryopreservation-warming, this research could be really
beneﬁcial to human being, especially women.
Trial registration number: HKDL 2017-389 from trial experimental ethical
inspection Shanghai Ninth people’s Hospital afﬁliated to Shanghai Jiao Tong
University, School of medicine.
P-133 Impact of vitriﬁcation on human oocytes before and after
in vitro maturation (IVM): a systematic review andmeta -analysis
M. Mohsenzadeh1, M.A. Khalili2, N. Tabibnejad2,
A. Salehi-Abargouei3, M. Karimi-Zarchi4
1Gerash University of Medical Sciences, Gerash Research Center, Gerash, Iran
2Research and Clinical Center for Infertility- Shahid Sadoughi University of Medical
Sciences- Yazd- Iran., Research and Clinical Center for Infertility, Yazd, Iran
3Department of Nutrition- Faculty of Health- Shahid Sadoughi University of Medical
Sciences- Yazd- Iran, Department of Nutrition, Yazd, Iran
4Department of Obstetrics and Gynecology- Faculty of Medicine- Shahid Sadoughi
University of Medical Sciences- Yazd- Iran., Department of Obstetrics and
Gynecology, Yazd, Iran
Study question: What is the impact of vitriﬁcation on human oocytes before
and after in vitro maturation?
Summary answer: Oocyte vitriﬁcation neither before nor after in vitro mat-
uration (IVM) has not a signiﬁcant effect on matutration rate, survival rate, fertil-
ization rate and cleavage rate.
What is known already: There are controversies regarding IVM procedure,
the time of storing frozen oocytes and maturation stage of vitriﬁed oocytes and
its impact on oocytes fertilization capability.
Study design, size, duration: A systematic review with meta-analysis was
undertaken. Main search terms were those related key words. We searched
Medline, Embase, Scopus and ISI web of science to detect English-language
studies. The ﬁnal search was performed on 27 January 2018.
Participants/materials, setting, methods: The original articles which stud-
ied ART outcomes after vitriﬁcation of MII or GV oocytes before or after IVM
were included. Studies that compared the combination of vitriﬁcation and IVM
with fresh oocytes were also included. Exclusion criteria were animal trials and
the studies that performed cryopreservation using slow-freeze method. Oocyte
maturation, survival, fertilization and cleavage rates were assessed. Bias and
quality assessments were applied.
Main results and the role of chance: 1102 articles and ﬁfteen studies were
included for analysis. Five studies compared laboratory outcomes between
oocytes that vitriﬁed at the GV stage and those ﬁrstly matured in vitro, and then
vitriﬁed. MA showed that vitriﬁcation of oocytes at GV stage had a negative
impact on maturation rate (RR = 0.78, CI: 0.59-1.04); cleavage rate (RR =
0.93, 95% CI: 0.61-1.42); but not on fertilization rate(RR = 1.01, 95% CI: 0.88-
1.18) and survival rate(RR = 0.99, 95% CI: 0.95-1.04). Eight studies compared
outcomes between the oocytes that vitriﬁed at GV stage before maturation and
oocytes which were matured in vitro without vitriﬁcation. MA indicated that
oocyte vitriﬁcation at GV stage had a signiﬁcant negative impact on maturation
rate (RR = 0.77, 95% CI: 0.65-0.91) and cleavage rate (RR = 0.65, 95% CI:
0.54-0.78). Fertilization rate did not differ between vitriﬁed oocytes at GV stage
and directly in vitro matured oocytes without vitriﬁcation (RR = 0.99, 95% CI:
0.87-1.11). Only one study compared vitriﬁed in-vivo matured oocytes versus
vitriﬁed in-vitro matured oocytes. According to the results, survival rate (RR =
0.94, 95% CI: 0.81-1.09), fertilization rate (RR = 0.83, 95% CI: 0.70-0.98) and
cleavage rate (RR = 0.91, 95% CI: 0.82-1.02) were signiﬁcantly lower in vitriﬁed
IVM oocytes. No evidence of publication bias was seen using asymmetry tests
with regards to outcomes.
Limitations, reasons for caution: However exact inclusion criteria were
used in the design of the systematic review, the included studies are heteroge-
neous in culture media and laboratory technique.
Wider implications of the ﬁndings: In general, oocyte vitriﬁcation
decreases the consequent maturation rate by 23%. However, maturation rate,
survival rate and fertilization rate as well as cleavage rates did not signiﬁcantly dif-
fer between the oocytes vitriﬁed before IVM versus oocytes vitriﬁed after IVM.
Trial registration number: CRD42017054372
P-134 Clinical utility of decorin in follicular ﬂuid as a biomarker of
oocyte potential
Y. Sawada, T. Sato, C. Saito, F. Ozawa, Y. Ozaki,
M. Sugiura-Ogasawara
Nagoya City University Graduate School of Medical Sciences, Obstetrics and
Gynecology, Nagoya city, Japan
Study question: This study investigated whether decorin (DCN) is useful as a
biomarker for outcomes of assisted reproductive technology (ART).
Summary answer: The concentration of DCN in follicular ﬂuid (F-DCN) has
a possibility to be a biomarker indicating the quality of oocytes collected from
the corresponding follicle.
What is known already: In the ovary, previous studies have shown that
DCN presents in the connective tissue, follicular thecal compartments, follicular
ﬂuid (FF) of ovulatory follicles, and corpus luteum, and plays roles in some
important processes such as follicle growth, ovulation, and keeping corpus
luteum by regulating growth factors. However the association between DCN
and the outcomes of infertility treatment has not been discussed.
Study design, size, duration: A retrospective cohort study involving 88
patients treated with ART because of unexplained infertility was performed at
Nagoya City University Hospital between April 2010 and March 2016. Serum,
FF and oocytes were collected at ovum pick-up (OPU). FF and oocytes were
aspirated and collected from the ﬁrst punctured follicle of each ovary. Some FF
were layered over a Ficoll-Paque gradient. The cell samples in the mononuclear
cell layer were cryopreserved as the granulosa cells (GCs).
Participants/materials, setting, methods: F-DCN and the concentration
of DCN in serum (S-DCN) was measured by ELISA. The relation between F-
DCN and patient’s age, Perfusion Index (PI) of the blood ﬂow around the fol-
licle at OPU, the total dose of gonadotropin administered, S-DCN, the concen-
tration of IGF-1 in FF, fertilization, and quality of embryo were analyzed. In
addition, immunostaining and western blotting were performed using the granu-
losa cells to identify existence and localization of DCN.
Main results and the role of chance: A total of 130 oocytes and the cor-
responding FF and serum samples from 88 patients. F-DCN was 39.26 ng/
ml (median value); it was higher than that in serum. Correlations were not
observed between F-DCN and patient age, the total dose of gonadotropin
administered, IGF-1 concentration in FF, and PI of the blood ﬂow around
the follicle. However, F-DCN showed a weak negative correlation with S-
DCN (R = −0.189; P = 0.031). F-DCN of the oocytes fertilized by intracy-
toplasmic sperm injection (ICSI) was signiﬁcantly lower than that of oocytes
that were not fertilized (33.24 ng/ml vs 40.18 ng/ ml; P = 0.043). When a
cut-off level of 34.5 ng/ml was set according to the receiver-operating char-
acteristic curve, the fertilization rate of the oocytes from the follicles in
which F-DCN was lower than the cut-off level tended to be good com-
pared to that of the oocytes with F-DCN higher than the cut-off level (P
= 0.052). S-DCN of the good embryos was signiﬁcantly higher than that of
the poor embryos only for those oocytes fertilized by ICSI. DCN is less
likely to be produced by GCs, because it was not detected in GCs by
immunostaining and western blot analysis.
Limitations, reasons for caution: The sample size was relatively small,
which made it difﬁcult to analyze the association between DCN and pregnancy
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or birth rate. As the reason for that, our study was limited to patients treated
with ART only because of unexplained infertility and FF samples were collected
from the ﬁrst punctured follicles.
Wider implications of the ﬁndings: The fertilization rate of oocytes from
follicles in which F-DCN was less than 34.5 ng/ml was high, indicating that it is
possible to predict the potential of oocytes to be fertilized by examining F-
DCN of the corresponding follicle during ICSI. Therefore, it is useful for plan-
ning embryo transfer and cryopreservation.
Trial registration number: This study is not registered.
P-135 Morphologic status and angulation of meiotic spindle in
vitriﬁcation-warmed oocytes of donor bank: effects on the ICSI
outcomes
T.H. Chuang, Y.C. Huang, M.J. Lee, H.H. Lai, H.L.Wang, C.L. Hsieh
Stork Ladies Clinic, Stork Fertility Center, Hsinchu, Taiwan R.O.C.
Study question: Do the morphology and angulation of meiotic spindle correl-
ate with the fertilization outcomes after ICSI in vitriﬁcation-warmed oocytes of
donor bank?
Summary answer: The correlation exists between the spindle morphology
and fertilization outcomes, while it does not show between the spindle angula-
tion and fertilization outcomes in vitriﬁcation-warmed oocytes.
What is known already: The meiotic spindle is crucial for the fertilization
process, including completion of meiosis, second polar body extrusion, forma-
tion of pronuclei, and the following mitosis. Since the structure of spindle is
dynamic depending on the timeline of oocyte, temperature, and physical stress,
characteristics of spindle in the vitriﬁcation-warmed oocytes may show different
phenomenon with that in the fresh oocytes.
Study design, size, duration: Between June and September of 2017, ﬁve hun-
dred and twenty-ﬁve oocytes from donor bank were included in the analysis. A
total of 37 egg donors were involved: mean age 24.7 ± 3.5 years; body mass index
(BMI) 19.7 ± 1.8 kg/m2; anti-mullerian hormone (AMH) value 7.0 ± 4.2 ng/mL.
Participants/materials, setting, methods: All the metaphase II (MII)
oocytes were cryopreserved by vitriﬁcation (Cryotech®, Japan) at the bank.
Once being matched to the appropriate recipients, the oocytes were warmed
and cultured in standard conditions for at least 2.5 hours following with image
taken for spindle (Oosight®, Hamilton Thorne). The spindle presence, morph-
ology, and angle to polar body (PB) were measured. The correlation between
the outcomes of ICSI and post-warmed spindle status were estimated.
Main results and the role of chance: The overall survival rate of
vitriﬁcation-warmed oocytes was 92.4% (485/525), and two-pronuclei (2PN)
rate was 75.1%. The morphology of post-warmed spindle was classiﬁed into
normal, translucent, no-visible, and telophase; the 2PN rate in each group was
as below (p-value was compared to the normal group): normal = 79.4%, trans-
lucent = 73.2% (p = 0.30), no-visible = 48.6% (p<0.05), and telophase =
37.5% (p<0.05). Of the 2PN rates in oocytes with different angulation, no cor-
relation was found: 0–30° = 79.8%; 31-60° = 76.1%; 61-90° = 82.1%;
91-120° = 80.0%; >120° = 90.0%.
Limitations, reasons for caution: Individual biases in manipulation of spin-
dle microscopy cannot be completely avoided.
Wider implications of the ﬁndings: Unlike the biological representative-
ness of spindle angulation in fresh oocytes, the correlation between the spindle
angulation and fertilization outcome was not observed in vitriﬁcation-warmed
oocytes. The displacement of spindle in vitriﬁcation-warmed oocytes could be
caused by the physical effects during the freezing-thawing procedures.
Trial registration number:Not applicable.
P-136 Antioxidants in IVF and culture media signiﬁcantly
improve human embryo development: A prospective randomised
multi-centre trial
A. Yoshida1, T. Kuramoto2, M. Tanaka3, S. Mitzumoto4, M. Montag5,
D.K. Gardner6
1Kiba Park Clinic, Reproductive Medicine, Tokyo, Japan
2Kuramoto Women’s Clinic, Reproductive Medicine, Fukuoka, Japan
3Kiba Park Clinic, VF Laboratory, Tokyo, Japan
4Kuramoto Women’s Clinic, IVF Laboratory, Fukuoka, Japan
5ilabcomm GmbH, Eisenachstr, Sankt Augustin, Germany
6University of Melbourne, School of BioSciences, Melbourne, Australia
Study question: What is the effect of combined antioxidants Acetyl-L-
Carnitine (ALC), N-Acetyl-L-Cysteine (NAC) and α-Lipoic Acid (ALA) on
human embryo development, when present in IVF culture media?
Summary answer: Combined antioxidants present in G-Series media signiﬁ-
cantly increased the percentage of good quality embryos on day 3 and showed
a trend to higher pregnancy rates.
What is known already: The combination of the antioxidants ALC, NAC
and ALA in IVF media and/or culture media has a signiﬁcant beneﬁcial effect on
mouse embryo development and viability.
Study design, size, duration: A sibling oocyte study, where oocytes were
randomly distributed to the control or test group at the time of pick up. Day 3
embryo and day 5/6 blastocyst quality were assessed. Good embryo quality on
day 3 was deﬁned as 8 to 10-cells with even cells and low fragmentation; good
quality blastocysts as equal or greater than 3BB. Clinical outcome was assessed
on transfers of a single vitriﬁed-warmed embryo on day 5.
Participants/materials, setting, methods: The study was conducted in 2
IVF centres in Japan. 115 patients were included in the study, generating a total
of 1,350 MII oocytes. IVF/ICSI and embryo culture (G-1 and G-2 PLUS) were
conducted in 5% oxygen in the presence or absence of antioxidants (10 μM
ALC /10 μM NAC /5 μM ALA). Controls were oocytes and embryos that
were not exposed to antioxidants in the medium.
Main results and the role of chance: The fertilization rate in the control
and test group was 75% and 76% respectively. Of the resultant 2PN, 19.6% and
26.1% resulted in good quality embryos on day 3 (P<0.05). Good quality
blastocyst rate was 25.4% vs 26.5% for the control and test group, respectively,
and these results were not signiﬁcant. 42 single embryo transfer cycles were
performed in the control group and 45 in the test group. The ongoing clinical
pregnancy rate, as determined by cycles with fetal heart beat was 52.4% vs
60.0%, however, the study was not powered for signiﬁcance of clinical outcome
data.
Limitations, reasons for caution: Transfers are mostly performed after vit-
riﬁcation/warming of embryos, which is why clinical outcome data are still not
complete.
Wider implications of the ﬁndings: The presence of antioxidants during
IVF and embryo culture imparts signiﬁcant beneﬁts on day 3 embryo quality.
Hence, supplementation of antioxidants to IVF and culture media may improve
the viability of human embryos in ART, plausibly through the reduction of oxi-
dative stress.
Trial registration number:NCT02999958
P-137 Prolonged blastomere movement induced by the delay of
pronuclear fading and ﬁrst cytokinesis adversely affects pregnancy
outcomes in human embryo
K. Ezoe1, K. Ohata1, A. Yabuuchi1, S. Ueno2, K. Uchiyama2,
T. Okimura2, T. Kobayashi3, K. Kato3
1Kato Ladies Clinic, R&D division, Tokyo, Japan
2Kato Ladies Clinic, Embryology Laboratory, Tokyo, Japan
3Kato Ladies Clinic, Department of Gynecology, Tokyo, Japan
Study question: Does the prolonged blastomere movement post ﬁrst cyto-
kinesis inﬂuence the pregnancy outcomes in human embryo?
Summary answer: The Prolongation of blastomere movement induced by
the delay of pronuclear fading and ﬁrst cytokinesis adversely affects pregnancy
outcomes.
What is known already: Time-lapse monitoring systems allow consecutive
observation of embryonic development and have been increasingly used for the
selection of viable embryos. Morphokinetics during the ﬁrst and second cytokin-
esis is an effective biomarker of developmental competence to high quality blas-
tocysts in human. In a preliminary study using time-lapse imaging we
characterized different patterns of blastomere movement between the ﬁrst and
second cytokinesis in human embryos. However, it is still unknown how
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blastomere movement inﬂuences clinical pregnancy outcome and which factors
inﬂuence the duration of blastomere movement.
Study design, size, duration: A total of 708 embryos from 708 patients
(36.4 ± 0.2 years) were cultured in EmbryoScope+® time-lapse system and
subjected to single fresh cleaved embryo transfer from April to July 2017 and
retrospectively analyzed. Blastomere movement was observed between the
ﬁrst and second cytokinesis. First, the correlation between the duration of
blastomere movement and clinical pregnancy was evaluated. Second, the asso-
ciation of the blastomere movement duration with patient characteristics and
developmental speed until second cytokinesis was examined.
Participants/materials, setting, methods: Retrieved oocytes were inse-
minated either by conventional in vitro fertilization or intracytoplasmic sperm
injection. Fertilized oocytes were cultured in time-lapse incubator and the time
from insemination to pronuclear (PN) alignment (tPNa), PN fading (tPNf), ﬁrst
cytokinesis (t2), and second cytokinesis (t3) was annotated. Duration of blasto-
mere movement (BMov) between t2 and t3 (dBMov) was monitored and the
ratio of dBMov over the period of 2-cell stage (t3-t2) was calculated (dBMov/
(t3-t2)).
Main results and the role of chance: The mean value of dBMov/(t3-t2)
was 0.347 ± 0.008 (range: 0.033–1.000). Logistic regression analysis revealed
that the increasing value of dBMov/(t3-t2) was statically associated with
decreasing clinical pregnancy rate (Odds ratio: 0.193 [95% conﬁdential interval:
0.081–0.480], P<0.01). The value of dBMov/(t3-t2) was not correlated with
patient characteristics, including female age (P = 0.49), male age (P = 0.34),
female body mass index (P = 0.68), number of previous cycles (P = 0.20),
cause of infertility (P = 0.44), insemination methods (P = 0.73), total number of
spermatozoa (P = 0.35), number of motile spermatozoa (P = 0.36), and num-
ber of abnormal spermatozoa (P = 0.19). No correlation between tPNa and
the value of dBMov/(t3-t2) was found. On the other hand, the period of PN
alignment (tPNf-tPNa) was positively associated with the value of dBMov/(t3-
t2) (Spearman’s rank correlation coefﬁcient (SC): 0.097, P = 0.01). In addition,
the period of PN fading (t2-tPNf) was signiﬁcantly correlated with the dBMov/
(t3-t2) value (SC: 0.178, P<0.01).
Limitations, reasons for caution: The limitation of this study was that the
pregnancy outcomes after a single fresh cleaved embryo transfer were exclu-
sively analyzed. Further studies are required to examine whether the blasto-
mere movement affects the blastocyst development and subsequent pregnancy
outcomes after blastocyst transfer.
Wider implications of the ﬁndings: The chance for a clinical pregnancy
after single fresh cleaved embryo transfer is adversely affected by the prolonged
blastomere movement which is associated with the delay of PN fading and ﬁrst
cytokinesis. These results support the possibility that blastomere movement
can be used as a predictive parameter for pregnancy outcomes.
Trial registration number:None.
P-138 The proportion of monopronuclear zygote (1PN) after
intracytoplasmic sperm injection (ICSI) is signiﬁcantly higher in
frozen-thawed oocytes than fresh oocytes
M.F. Chuang1, Y.M. Peng1, M.J. Lee2, H.H. Lai2, H.L.Wang2,
C.L. Hsieh2, Y.C. Huang1
1Stork Fertility Center, Assisted Reproductive Technology, Hsinchu, Taiwan R.O.C.
2Stork Fertility Center, Reproductive Endocrinology & Infertility, Hsinchu, Taiwan
R.O.C.
Study question: Is there different distribution of pronuclear types between
fresh and frozen-thawed oocytes after ICSI?
Summary answer: The proportion of monopronuclear zygote (1PN) in
frozen-thawed oocytes is signiﬁcantly higher than fresh oocytes, irrespective of
recipient or infertile group.
What is known already: In in vitro fertilization (IVF), the ﬁrst check point is
to conﬁrm the appearance of pronuclei, including shape and number, around
16-18 hours after insemination. The formation of two pronuclei is deﬁned as a
successful and normal fertilization; however, the other pronuclear types such as
more or less than two pronuclei or uneven pronuclei are considered as abnor-
mal fertilization. Nevertheless, blastocysts derived from abnormal fertilized
oocytes have been referred to have potential to develop into normal chromo-
somal status and produce a healthy baby.
Study design, size, duration: A retrospective cohort study was conducted
at Stork Fertility Center, between January 2017 to December 2017. Total 1155
cycles were included in the study and divided into oocytes recipient (N = 458)
and infertility (N = 697) groups. Total 14615 mature oocytes (MII) were col-
lected from recipient (n = 7603) and infertility (n = 7012) groups. The further
analysis including pronuclear types and embryo development were evaluated
only against the MII fertilized by ICSI.
Participants/materials, setting, methods: The recipient and infertility
groups were subsequently categorized into two subgroups: fresh (N = 166 and
569, respectively) and frozen-thawed oocytes (N = 292 and 128, respectively)
inseminated cycles. Moreover, all frozen-thawed oocytes were preserved by
vitriﬁcation in this study. Total 6039 fresh and 5589 frozen-thawed oocytes
were performed by ICSI, and the proportion of pronuclear types and following
embryo development were observed.
Main results and the role of chance: In the recipient group, the mean age
of the fresh and frozen-thawed subgroups were 23.86 and 24.42 years old, and
2031 and 4582 MII were performed ICSI respectively; the fertilization rate (FR),
good embryo rate (GER) and good blastocyst rate (GBR) of the fresh and the
frozen-thawed subgroups were 82.32% vs. 77.48%, 62.14% vs. 55.80%, and
63.10% vs. 54.33%. In the infertility group, the mean age of the fresh and
frozen-thawed subgroups were 36.36 and 36.80 years old, and 4008 and 1007
MII were performed ICSI respectively; the FR, GER and GBR of the fresh and
the frozen-thawed subgroups were 79.89% vs. 70.04%, 64.08% vs. 55.52%, and
57.87% vs. 42.63%. The different proportion of pronuclear types was found
between fresh and frozen-thawed oocytes. The 1PN rate in frozen-thawed was
signiﬁcant higher than the fresh oocytes, which was showed in both recipient
(10.83% vs. 5.61%, p<0.01) and infertility (12.1% vs. 5.39%, p<0.01) groups.
This phenomenon might be a clue to explore the effect of frozen-thawed pro-
cess and fertilization mechanism.
Limitations, reasons for caution: The difference between fresh and frozen-
thawed oocytes such as spindle structure, protein expression proﬁle, chromo-
somal constitution, mitochondria activity and cytoskeleton conformation should
be distinguished to illuminate the causes of the different distribution of pro-
nuclear formation. This phenomenon is restricted to ICSI since frozen-thawed
oocytes could not be performed conventional IVF.
Wider implications of the ﬁndings: The exact factors of abnormal fertiliza-
tion and the impact of frozen-thawed process have not been elucidated yet.
This study might provide an additional aspect to investigate the crucial part of
these issues and rescue the abnormal fertilized oocytes for further clinical
applications.
Trial registration number:N/A.
P-139 Irregular oocyte swelling time in thawing solution (TS)
highly correlates with the subsequent survival rate
Y.M. Peng1, M.F. Chuang1, M.J. Lee2, H.H. Lai2, H.L.Wang2,
C.L. Hsieh2, Y.C. Huang1
1Stork Fertility Centre, Assisted reproductive technology, Hsinchu, Taiwan R.O.C.
2Stork Fertility Centre, Reproductive Endocrinology & Infertility, Hsinchu, Taiwan
R.O.C.
Study question: Whether irregular oocyte thawing time in thawing solution
correlates with following oocyte survival rate?
Summary answer: Irregular oocyte swelling time in thawing solution (TS)
highly correlates and dramatically increases the mortality after thawing.
What is known already: Vitriﬁcation is an optimal method employed for
oocyte preservation to prevent intracellular and plasma membrane molecules
such as enzymes, structural protein and mRNA damage from ice crystals. The
critical process of oocyte vitriﬁcation is considered to exchange water and cryo-
protectant between intracellular and extracellular environments. Membrane
integrity is supposed to be one of the major reasons inﬂuencing water/cryopro-
tectant exchange rate and following survival rate after thawing.
Study design, size, duration: A retrospective cohort study throughout June
2017 to November 2017, total of 2144 oocytes in 162 cryopreservation/thaw-
ing cycles were included. The timing of swelling, ﬂattening and recovering time
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in thawing solution were recorded and analyzed to reveal the effects on the
thawing outcomes.
Participants/materials, setting, methods: Every oocyte undergone thaw-
ing procedure were recorded with the individual timing of swelling, ﬂattening
and recovering (swelling combined with ﬂattening). All the oocytes were classi-
ﬁed according to the (1. thawing outcomes-survival or mortal to reveal the tim-
ing diversity; or (2. regular (>30 s) or irregular (≤30 s) swelling time in thawing
solution (TS) to compare the mortality.
Main results and the role of chance: Based on the thawing outcome,
ﬁrstly, oocytes were grouped into survival and mortal groups for comparing the
swelling, ﬂattening and recovering time of the two groups. The results indicated
that the mean time of swelling (44.3 s vs. 28.9 s, p<0.05) and recovering (57.2 s
vs. 39.9 s, p<0.05) in survival group was signiﬁcantly higher than the mortal
group. The primary disparity of recovering time were mainly derived from the
swelling time, although the average ﬂattening (12.9 s vs. 10.9 s, p<0.05) time of
survival group was also signiﬁcant higher than the mortal group. Secondly, in the
contrary, thawed oocytes were classiﬁed according to swelling time (regular,
>30 s or irregular, ≤30 s). Mortality of the regular group revealed signiﬁcantly
lower than the irregular group (2.97% vs. 26.9%, p<0.05). Taken together, the
two aspects indicated that the swelling time is a critical indicator correlating to
the mortality of oocyte thawing. These observations implicated that osmotic
potential plays a critical role affecting the thawing survival rate. Furthermore,
membrane permeability and surface molecular proﬁle might inﬂuence cell resist-
ant from osmotic potential, which accounts for the dramatically increasing
mortality.
Limitations, reasons for caution: Vitriﬁcation strategy was adopted in all
the frozen-thawed oocytes in this study. Vitriﬁcation Kit 101 (Cryotech) and
Warming Kit 102 (Cryotech) were employed for performing frozen-thawed
procedures. The phenomenon should be observed in other vitriﬁcation strategy
but might fail to refer to other frozen-thawed methods such as slow freezing
process.
Wider implications of the ﬁndings: The present study implies that swelling
time in TS is correlated with oocyte mortality. The considerable increase of
mortality in irregular group implies that membrane constitution such as inappro-
priate lipids/cholesterol ratio and suboptimal water/ion channels, might play a
critical role in regulating the water/cryoprotectant exchange between intracel-
lular and extracellular environments.
Trial registration number:N/A.
P-140 Revisiting a controversial topic: The vitriﬁcation-warming
procedure does not induce zona pellucida hardening in human
blastocysts
H. Iwayama1, M. Ishiyama1, M. Shimoda1, A. Nakatani1, A. Hayashi2,
M. Yamashita2
1Yamashita Ladies’ Clinic, Section of Human Gamete & Embryo Manipulation, Kobe,
Japan
2Yamashita Ladies’ Clinic, Section of Human ART, Kobe, Japan
Study question: Should the variation in zona pellucida (ZP) thickness during
blastocoel expansion be considered an important factor of ZP hardness in
vitriﬁed-warmed blastocysts?
Summary answer: Unlike during the vitriﬁcation warming procedure, a
reduction in ZP thickness during the physiological expansion of the blastocoel is
a potential confounder of ZP hardness.
What is known already: Previous studies have demonstrated ZP hardening
in cryopreserved blastocysts, resulting from improved clinical outcomes follow-
ing assisted hatching and small experiments focused on the enzymatic digestibil-
ity of the zonae. However, to date, the regulatory pathways such as cortical
reaction during oocyte ZP hardening remain unclear. Moreover, the main point
of discussion regarding the multivariate associations of ZP hardening with
respect to the vitriﬁcation-warming procedure and ZP thinning during blasto-
cyst expansion was not addressed by these studies.
Study design, size, duration: This experimental study included fresh (n =
61) and vitriﬁed-warmed (n = 36) blastocysts that were discarded during the
treatment of patients. These blastocysts were harvested from IVF or ICSI cycles
(n = 50) between March 2010 and May 2011.
Participants/materials, setting, methods: Two types of ZP hardness
were estimated based on the response to enzymatic digestion and elastic
behavior of ZP. Dissolution time was assessed by ZP disappearance in 0.1%
protease solution. Elasticity was calculated from the maximum expansion rate
in a sham-expansion model, which was micro-injection of Fluorinert™ ﬂuid
below ZP layer. The mean ZP hardness indexes were compared between fresh
and vitriﬁed-warmed blastocysts of each ZP thickness categories (>15, ≤15 to
>7.5, and ≤7.5 μm).
Main results and the role of chance: Regarding the response of ZP to
enzymatic digestion, the digestion time negatively correlated (r = 0.67, p <
0.01) with the reduction of ZP thickness during blastocyst expansion. The
mean digestion time of vitriﬁed-warmed ZP was similar to that of fresh ZP
(405 vs. 390 s). The mean digestion time derived for the >15, ≤15 to
>7.5, and ≤7.5 μm categories, i.e., 493, 375, and 334 s, respectively, were
signiﬁcantly (p < 0.05) decreased depending on the ZP thickness.Regarding
the elastic behavior of ZP, the maximum expansion rate negatively corre-
lated (r = 0.92, p < 0.01) with the reduction of ZP thickness during blasto-
cyst expansion. The mean maximum expansion rate of vitriﬁed-warmed ZP
was similar to that of fresh ZP (24 vs. 28%). The mean maximum expan-
sion rate derived for the >15, ≤15 to >7.5, and ≤7.5 μm categories, i.e.,
40, 28, and 11%, respectively, were signiﬁcantly (p < 0.05) decreased
depending on the ZP thickness.
Limitations, reasons for caution: In this study, the results of molecular biol-
ogy are absent.
Wider implications of the ﬁndings: The present study indicates that ZP
softening might be induced by the reduction of ZP thickness during blasto-
coel expansion. Failure to evaluate the ZP thickness as a potential confoun-
der might have led to biased results and conclusions, i.e., the
demonstration that the vitriﬁcation-warming procedure induces ZP harden-
ing in blastocysts.
Trial registration number: The authors declare no potential.
P-141 Is there a difference in embryomorphokinetics between
ejaculated and non-ejaculated spermatozoa?
G. Raad, C. Nader, J. Azoury, K. Rizk, E. Dahdouh, M.C. Zayat,
R. Bader, J. Azoury, J. Azoury
Azoury IVF clinic, ivf, Beirut, Lebanon
Study question: Does sperm origin (ejaculated, epididymal, and testicular)
affect pre-implantation embryo morphokinetics and morphodynamics?
Summary answer:Non-ejaculated spermatozoa negatively affect all develop-
mental stages of preimplantation embryos.
What is known already: Spermatozoa undergo biochemical and physio-
logical modiﬁcations during their transit in the epididymis. However, the inﬂu-
ence of the testicular extracted spermatozoa on embryo developmental
competence did not reach a ﬁrm consensus.
Study design, size, duration: A retrospective study was conducted at
Azoury IVF clinic, from August 2013 until August 2017. It was performed on 86
couples, who have undergone only intracyoplasmic sperm injection (ICSI)
cycles. The infertile couples were divided into four groups: normozoospermia
group (n = 23 couples, n = 133 embryos); oligozoospermia group (n = 22 cou-
ples, n = 109 embryos); percutaneous epididymal sperm aspiration (P.E.S.A.)
group (n = 21 couples, n = 119 embryos), and testicular biopsy group (n = 23
couples, n = 123 embryos).
Participants/materials, setting, methods: The couples where the females
had 38 years old or less at the time of ICSI, were selected and divided into four
study groups according to sperm quality and source. Only the data of the
embryos with normal fertilization and cultured for 5 consecutive days without
interruption was included. In addition, embryos that were subjected to embryo
biopsy were excluded. Subsequently, embryo morphokinetics and morphody-
namics were analysed through time-lapse microscopy (Embryoscope) using the
Embryoviewer software.
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Main results and the role of chance: During the pre-compaction stage, the
embryos of the P.E.S.A and testicular biopsy groups showed a signiﬁcant delay
in the ﬁrst embryonic cell cycle (ECC1) when compared to the embryos of the
normozoospermia group (p<0.05 and p<0.01, respectively). In addition, the
third embryonic cell cycle (ECC3) was signiﬁcantly delayed in both non-
ejaculated sperm groups compared to the normozoospermia group (p<0.01
and p<0.001, respectively). Interestingly, this delay in the development contin-
ued through the post-compaction stage. Particularly, the embryos of the tes-
ticular biopsy group had signiﬁcant delay in the time of starting blastulation
(p<0.05) and in the time to reach a full blastocyst (p<0.001) in comparison to
those derived from the normozoospermia group. Regarding the morphody-
namic parameters, a lower percentage of blastocysts showed blastocyst con-
traction in the P.E.S.A and testicular biopsy groups compared to the
normozoospermia group (p<0.05 and p<0.05, respectively).
Limitations, reasons for caution: A very important limitation of this study
is its retrospective nature itself. A randomized controlled trial (RCT) should be
conducted to conﬁrm the ﬁndings of this study.
Wider implications of the ﬁndings: The present study clearly shows a
negative impact of non-ejaculated sperm on early embryo development.
Hence, recommending the use of testicular sperm in case of repetitive IVF fail-
ure and high sperm DNA fragmentation should be taken with caution.
Trial registration number:Not applicable.
P-142 Characteristics of human single pronucleated zygotes
derived from conventional in vitro fertilization, considering the
genome composition, chromosomal distribution and morphological
assessment
H. Moriwaki, Y. Kai, K. Yumoto, K. Iwata, Y. Mio
Mio Fertility Clinic, Reproductive Centre, Yonago, Japan
Study question: Do human single pronucleated (1PN) zygotes derived from
conventional in vitro fertilization (c-IVF) have developmental potential as nor-
mal fertilized zygotes leading to newborns?
Summary answer: Although approximately 80% of 1PN zygotes in c-IVF pro-
cedures were diploid, not all distributed their genome normally during the 1st
cleavage.
What is known already: Cytogenetic and genetic composition based on his-
tone modiﬁcation analysis has revealed that many 1PN zygotes are diploid in c-
IVF procedures. Some of them are able to develop to the blastocyst stage and
result in normal deliveries in humans.
Study design, size, duration: We used 1PN zygotes obtained from
February 2015 to September 2017 from c-IVF procedures (n = 60). Fresh or
frozen/thawed zygotes were provided for cell biological and morphological
analysis. Three normal two-pronuclear zygotes were also used as controls.
Participants/materials, setting, methods: Donated and ethically-
approved zygotes derived from c-IVF were used in this study. 1PN zygotes
were obtained more than 22 hours post insemination. We analyzed the gen-
ome composition by DNA and histone methylation status, chromosome distri-
bution, pronucleus diameter, and the time-course from syngamy to the 1st
cleavage. Immunoﬂuorescence was performed using antibodies against 5mC,
5hmC, H3K9me3, alpha-tubulin and pericentrin. Live-imaging analysis was per-
formed using TagGFP2-H2B mRNA and FusionRed-MAP4 mRNA.
Main results and the role of chance: Analysis of DNA methylation status
by immunoﬂuorescence for 5mC and 5hmC revealed that 80% of the 1PN
zygotes (n = 10) showed a mixed 5mC/5hmC-positive genome in a single pro-
nucleus, and analysis of histone methylation by immunoﬂuorescence for
H3K9me3 revealed that 78% of zygotes (n = 9) had a non-uniform H3K9me3-
positive pronucleus or chromosomes. Analyses of spindle formation and
chromosome segregation by immunoﬂuorescence revealed that 45% of zygotes
(n = 20) formed bipolar spindles at metaphase. At telophase, one zygote
showed an unequal distribution of paternal and maternal genomes. In live-
imaging analysis which visualized histone H2B (chromosomes) and MAP4
(microtubules), one zygote showed a tripolar spindle formation leading to
abnormal chromosomal distribution during the 1st cleavage, while 56% of
zygotes (n = 9) showed bipolar spindles and even chromosomal distribution.
The average pronucleus diameter of zygotes which showed pronucleus
disappearance and 1st cleavage was slightly bigger than the defectively-
developed zygotes (n = 14, overlapped with live-imaging data). The time-
course from pronucleus disappearance to 1st cleavage was almost the same as
in normally-fertilized zygotes (n = 6, overlapped with live-imaging data).
Limitations, reasons for caution: This study was conﬁned only to the peri-
od from zygote stage to 1st cleavage, so further developmental stages need to
be analyzed.
Wider implications of the ﬁndings: Although we showed it is possible to
select the diploid 1PN zygotes with developmental potency based on pro-
nucleus diameter assessment, not all have the ability to distribute chromosomes
normally during the 1st cleavage. Our ﬁndings may help in the selection of use-
able 1PN zygotes for clinical applications.
Trial registration number:Not applicable.
P-143 High-resolution nuclear magnetic resonance based proﬁling
of spent human embryo culture media for assessment of in vitro
embryo quality
M. Vilches1, F.D.L.N. Ignacio2, R.D.A. Ana Cristina3, G.G. Ana4,
A.S. Luis Manuel2, A.C. Francisco Manuel2, S.F. Encarnacion1
1Complejo Hospitalario Torrecardenas, Unidad de Reproduccion Asistida Humana,
Almeria, Spain
2Universidad de Almería, Departamento de Física y Química, Almeria, Spain
3Universidad de Almeria, Departamento de Física y Química, Almeria, Spain
4Hospital Universitari Vall Hebron, Unidad de Reproducción Asistida Humana,
Barcelona, Spain
Study question: Over recent years, there has been much interest in the use
of metabolomics to detect biomarkers of embryo viability, which might help
embryologists to successfully increase implantation rates.
Summary answer: The aim of this study was to identify biomarkers from
embryo metabolome that would allow us to predict and differentiate embryos
of the best quality.
What is known already: The metabolic proﬁle in the culture media used can
be investigated using non-invasive metabolic techniques, such 1H-NMR. This
noninvasive quantiﬁcation of embryonic metabolism can be a useful predictor of
pregnancy outcome after embryo transfer, a potential supported by recent clin-
ical studies that work with speciﬁc classes of metabolites such as glycolytic inter-
mediates and amino acids (Singh, 2007).
Study design, size, duration: Multidisciplinary_study of several institutions
which compass a highly analytical component, with random selection and
assignment of the samples. The sample size (Perduzzi’s formula [n = 10 * (k +
1)] and prevalence of poor quality embryos of 54%, p <0.005) included 185
embryo cultures, assuming losses of 20%, being the ﬁnal size of 222. The
chronogram has combined embryonic selection tasks with NMR
measurement periods with the aim of obtaining metabolic proﬁles and identify-
ing biomarkers.
Participants/materials, setting, methods: The inseminated MII oocytes
and were individualized in G1-Plus_medium (Vitrolife) left in culture during 48
hours (D+3). After embryo selection and transfer, embryo culture medium
was collected and cryopreserved at -80 °C. The media for NMR measurements
were prepared in a solution of NaCl in D2O and were carried out on a
Bruker_Avance_III_600 spectrophotometer equipped with a cryoprobe. The
spectra were acquired using a 1H CPMG sequence and processed through the
TOPSPIN 3.2 software.
Main results and the role of chance: Schematically, the experimental pro-
cedure was carried out as follows: a) Collection of the samples, b) Analysis of
the samples by NMR, c) Application of multivariate analysis techniques to the
1H NMR data to identify the biomarkers that were associated with a better
morphological kinetics and embryonic implantation. The Principal Component
Analysis (PCA) model obtained so far allowed to discriminate between the
embryo culture samples of the embryos that had an optimal development of
those that did not. At the same time, the quantiﬁcation of the metabolites that
contribute most to the discrimination of the model was obtained, observing
that the embryos with optimal development showed a higher consumption of
metabolites such as pyruvate, glutamate, citrate, tryptophan (which means that
they are metabolically more active). The worst embryonic development was
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associated mostly to a lower consumption of pyruvate, the energy source, and
of tryptophan, used in protein biosynthesis. The formate/acetate ratio signiﬁ-
cantly decreased in media samples belonging to embryos of type A (according
to ASEBIR classiﬁcation criteria), while it increased in embryo medium samples
with worst development (types C and D).
Limitations, reasons for caution: Limitations: 1) rate of embryo fertiliza-
tion; 2) the high operational cost associated with NMR measurements could be
a limitation for routine prediction; and 3) the possibility that the tool is not sen-
sitive enough to detect differences in metabolic embryos and does not achieve
sufﬁcient differentiation power is another weak point.
Wider implications of the ﬁndings: A large population size (> 200, average
36 years) from different geographical areas, as well as the use of mass spec-
trometry and separation methods in parallel to NMR spectroscopy, will try to
give solidity to the study, although the preliminary results agreement with previ-
ous studies found in the bibliography.
Trial registration number: not applicable.
P-144 Does blastocyst re-expansion one hour post-warming
predict clinical pregnancies?
C. Shaw Jackson1, A. Tubbing2, L. Ameye3, B. Becker4,
A.L. Thomas2, S. Rozenberg2, C. Autin2
1CHU Saint-Pierre, FIV, Brussels, Belgium
2CHU St Pierre, Gynaecology, Brussels, Belgium
3Jules Bordet Institute, Data centre, Brussels, Belgium
4CHU Saint-Pierre, Gynaecology, Brussels, Belgium
Study question: Is it possible to predict a clinical pregnancy based on early
conventional warmed blastocyst re-expansion analysis?
Summary answer: We demonstrate statistically higher clinical pregnancy
rates for blastocysts that displayed re-expansion in the ﬁrst hour after warming,
as opposed to those that did not.
What is known already: A few studies have demonstrated that post warm-
ing blastocyst expansion is a predictor of implantation. However, most studies
focus on expansion at one time point several hours after warming with no infor-
mation on the method of expansion evaluation. Moreover, the stage of blasto-
cyst development is not always taken into account. Time lapse technology was
very recently used in two studies and demonstrated that early onset of re-
expansion and duration of re-expansion were predictors of pregnancy.
Study design, size, duration: A retrospective analysis of 264 single vitriﬁed-
warmed blastocyst transfers that took place between January 2014 and
December 2016 were included in this study. Photographs of the warmed blas-
tocysts were taken at 0 – 30 and 60 minutes post warming and were prospect-
ively analyzed by two methods.
Participants/materials, setting, methods: Blastocyst post-warming
behavior was evaluated by the means of morphological measurements taken by
a computer program, as well as independently by three biologists based on
photographs at 0-30 and 60 minutes post warming. Four main groups were
established based on the ability of the blastocyst to compact and re-expand.
Survival and clinical pregnancy rates were compared between groups for differ-
ent stages of blastocyst development.
Main results and the role of chance:We observed different post-warming
behavioral patterns depending on the stage of blastocyst development.
Blastocysts (stage 3) showed a lesser amplitude of compaction/re-expansion
by computer analysis and no signiﬁcant difference was observed between
expanding and non-expanding groups in terms of clinical pregnancy rates (23%
versus 27% p = 0.76) despite increased survival for re-expanding blastocysts
(93% versus 88% p = 0.01). For combined expanded and hatching blastocysts
(stages 4 and 5) showing re-expansion within 30-60 minutes after warming, sig-
niﬁcantly higher survival (99% versus 79% p<0.001) and clinical pregnancy rates
(33% versus 13% p = 0.02) were observed compared to embryos that did not
show signs of re-expansion. No signiﬁcant difference in clinical pregnancies was
observed between embryos showing fast and slow re-expansion (35% versus
31%, p = 0.064). Nine percent of all vitriﬁed-warmed blastocysts showed atyp-
ical behavior without any signs of compaction directly post warming, or during
the 60-minute observation period. The overall clinical pregnancy rate for these
embryos was 35%. Globally, the biologist’s method conﬁrmed the computer
analyses though this method was better suited to detect a larger cavity without
an overall increase of the size of the embryo.
Limitations, reasons for caution: Expanded and hatching blastocysts that
did not re-expand post warming had reduced pregnancy rates. Nevertheless,
the decision to discard them should be done with caution. Further investigation
between slow and fast re-expansion groups need to be carried out, focusing on
the method and timing of re-expansion analysis.
Wider implications of the ﬁndings: This study is the ﬁrst to demonstrate
different post-warming behavior depending on the stage of blastocyst develop-
ment and to investigate various methods of blastocyst re-expansion analysis.
Early decisions concerning the fate of the warmed embryos can be made with-
out the need for sophisticated time-lapse technology.
Trial registration number: not applicable.
P-145 Correlation between euploid blastocysts expansion/
morphology and clinical outcomes in cycles with single frozen
embryo transfer
M. Nicolielo1, M. Piccolomini1, N. Nobrega1, M. Fanelli1, A.P. Reis1,
T. Bonetti2, E. Motta3, P. Seraﬁni4, J.R. Alegretti1
1Huntington Medicina Reprodutiva, Embryology Department, Sao Paulo / SP, Brazil
2Federal University of São Paulo, Gynecology Department, São Paulo- SP, Brazil
3Huntington Medicina Reprodutiva/Federal University of São Paulo, Clinical Medicine
Department/Gynecology Department, Sao Paulo / SP, Brazil
4Huntington Medicina Reprodutiva/University of São Paulo, Clinical Medicine
Department/Department of Gynecology and Obstetrics, Sao Paulo / SP, Brazil
Study question: How much the morphology of euploid blastocyst determines
the clinical outcomes in frozen-thawed transfers after preimplantation genetic
screening (PGS)?
Summary answer: The morphology of frozen-thawed euploid blastocyst
does not affect the clinical outcomes in single embryo transfer (SET) cycles.
What is known already: Blastocysts are routinely evaluated with regard to
the expansion of the blastocoel and the number of cells in the Inner Cell Mass
(ICM) and in the Trophoectoderm (TE). However, the literature is not clear in
euploid blastocysts evaluated by PGS, how much the morphology affects clinical
outcomes. While some authors suggested that morphology was not associated
with the chance of ongoing pregnancy, and ‘poor” quality euploid blastocysts
fared just as well as higher graded blastocysts, others believe that blastocyst
morphology grading and particularly ICM is a useful predictor of ongoing preg-
nancy rate per biopsied euploid embryos.
Study design, size, duration: This is a retrospective cohort study including
data from 270 SET of frozen-thawed euploid blastocysts performed between
January 2016 and July 2017. Blastocysts were morphologically classiﬁed accord-
ing with Gardner for expansion grade (EG), ICM and TE. Blastocysts were biop-
sied for PGS analysis by using NGS and then vitriﬁed. Euploid blastocysts were
warmed and single embryo transfers were placed after endometrial
preparation.
Participants/materials, setting, methods: Blastocyst were classiﬁed as
grade 3, 4, 5 or 6 for EG. The ICM and TE were classiﬁed as A, B and C, as
grade A is best grade and C is poorer grade. Clinical pregnancy rate was ana-
lyzed according with each morphological classiﬁcation of blastocysts and the
multivariate analysis was performed to evaluate the association of EG, ICM, TE
and the interaction among then in the clinical pregnancy rates, adjusted for
confounders.
Main results and the role of chance: Patients included were 37.8 ± 3.6
years of age and the indications for PGS were implantation failure, recurrent
miscarriage, advanced maternal age, severe male factor or patients’ choice. The
most of blastocysts were classiﬁed as EG grades 4 (40.4%) or 5 (47.5%), ICM
grades A (43.3%) or B (40.4%) and TE grades A (32.9%) and B (38.8%). In the
univariate analysis, we observed the clinical pregnancy rates yielded no statistic-
ally difference when blastocysts were classiﬁed by EG (3: 33.3%; 4: 46.6%; 5:
44.4%; 6: 35.7%, p value = 0,438), by ICM (A: 43.8%; B: 34.5%; C: 29.7%, p
value = 0,258). When blastocysts were classiﬁed by TE morphology, the clinical
pregnancy rate (A: 39.8%; B: 48.3%; C: 27.3%) was higher when TE=B (48.3%)
compared to TE=C (27.3%; p = 0.008). The multivariate analysis did not show
any association of EG (OR = 1.19; p = 0.250), TE (OR = 1.24; p = 0.190) or
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ICM (OR = 1.35; p = 0.106) individually or the interaction of them (OR =
0.984; p = 0.223) with clinical pregnancy rate, adjusted to confounders.
Limitations, reasons for caution: This is a retrospective study including a
relatively low number of samples and higher cohorts of cycles should be studied
to conﬁrm the outcomes. All patients included received SET; however not all
cycles were elective SET, as some of them had only one euploid blastocyst
available.
Wider implications of the ﬁndings: Our ﬁndings suggested that once the
blastocyst is euploid after PGS evaluation, it morphology does not affect the
clinical pregnancy rates. Based on that, we can speculate that high morphology
grade and low morphology grade euploid blastocysts have same implantation
potential and can be transferred arbitrarily.
Trial registration number:Not applicable.
P-146 ICSI procedure impairs the development of embryos to the
blastocyst stage in patients with a slight degree of
teratozoospermia: a prospective study
M. Stimpfel, I. Verdenik, J. Kmecl, L. Bacer-Kermavner, J. Mivsek,
B. Valentincic-Gruden, K. Ferk, E. Vrtacnik-Bokal, I. Virant-Klun
Univerzitetni Klinicni Center Ljubljana, Department of Obstetrics and Gynaecology,
Ljubljana, Slovenia
Study question: Is intracytoplasmic sperm injection (ICSI) the wrong method
of choice in infertile couples with a slight degree of teratozoospermia deﬁned
by the strict Kruger criteria?
Summary answer: Classical IVF insemination resulted in better embryo
development than ICSI procedure in infertile couples with a slight degree of
teratozoospermia.
What is known already: ICSI procedure enables the fertilization of oocytes
with a low quality sperm or even, in extreme cases, with only a few spermato-
zoa available. Although, the overuse of ICSI is observed, since it is also per-
formed in couples with normal sperm quality and female indications of
infertility. It has already been shown that the overuse of ICSI does not improve
or may even impair the outcome of IVF/ICSI cycles (Grimstad et al., 2016;
Tannus et al., 2017) but it is still not clear at which percentage of normal sperm-
atozoa ICSI is beneﬁcial, if sperm concentration and motility are normal.
Study design, size, duration: Our prospective sibling-oocyte study included
27 couples who were treated in y. 2017 because of male infertility with a slight
degree of teratozoospermia (7-14% of morphologically normal spermatozoa),
deﬁned by strict Kruger criteria, and with normal sperm concentration and
motility. In each couple approx. half of oocytes were fertilized with ICSI (ICSI-
group) and the remaining half of oocytes with classical IVF (IVF-group). The aim
was to elucidate, which procedure results in a better clinical outcome.
Participants/materials, setting, methods: The female partners were aged
26-43 years and had at least 6 cumulus-oocyte complexes to express a normal
ovarian reserve. Up to two optimal embryos were transferred into the uterus
regardless the procedure. The IVF and ICSI-groups were compared in terms of
fertilization rate, quality of day 3 and day 5 embryos, and pregnancy rate. To
determine the differences between the two groups, a multivariate analysis was
performed. Statistical signiﬁcance was set at P<0.05.
Main results and the role of chance: The mean age of included patients
was 35.6 ± 4.7 years for females and 36.0 ± 4.8 years for males. Mean numbers
of oocytes included in each group were: 6.3 ± 3.6 for ICSI and 7.9 ± 6.1 for
IVF- group. The fertilization (ICSI vs. IVF; 56.7% vs. 63.9%), cleavage (100% vs.
98.4%), and good quality day 3 embryo rates (55.0% vs. 63.9%) did not differ
signiﬁcantly between the two groups. Nevertheless, a signiﬁcantly higher blasto-
cyst (35.3% vs. 63.9%; P = 0.019) and good quality blastocyst rates (14.5% vs.
33.5%; P = 0.049) were observed in the IVF-group than in ICSI-group on day 5.
The multivariate regression analysis showed that other factors such as female/
male age and sperm quality parameters did not inﬂuence the difference
between the two groups. The embryo transfer was performed in 24 cycles
(without 2 cycles with ‘freeze all” blastocyst freezing due to hyperstimulation).
In 5 cycles embryos only from ICSI-group were transferred (number of ET
embryos 1.0 ± 0) with 40% pregnancy rate and in 15 cycles embryos only from
IVF-group were transferred (number of ET embryos 1.1 ± 0.3) with 66.7%
pregnancy rate. None of these differences were signiﬁcant.
Limitations, reasons for caution: The limitations of the study are in the
relatively low number of included couples but the study is still in a progress. A
further prospective study is needed. Achieved pregnancies need to be followed
to evaluate the miscarriage and live birth rates according to the procedure (IVF,
ICSI).
Wider implications of the ﬁndings: The results of this study show that the
IVF procedure is optimal in couples with a slight degree of teratozoospermia
along with normal sperm concentration and motility. In these couples the ICSI
procedure may even impair the development of embryos to the blastocyst
stage and a chance to get pregnant.
Trial registration number: not applicable.
P-147 Impact of embryo density on ICSI outcomes
S. Chtourou1, K.F. Kacem1, M. Braham2, S. M’nallah1,
M. Ben Meftah2, H. Bellil1, F. Anis2, F. Zhioua2, A. Zhioua1
1Hôpital Aziza Othmana, Center of Reproductive Medecine, Tunis, Tunisia
2Hôpital Aziza Othmana, Gynecology and Obstetrics, Tunis, Tunisia
Study question: Does embryo density have an impact on embryo cleavage or
development and does it enhance Intra-Cytoplasmic Sperm Injection (ICSI)
outcomes?
Summary answer: The grouped cultured embryos with a density of 10 μl cul-
ture medium per embryo seems to promote embryo development and slightly
improve ICSI outcomes.
What is known already: Among all culture methods, many authors agreed
that group culture seemed to be beneﬁcial to embryos through growth factors
deposited in the droplet of culture medium. Though, not only growth factors
but also toxic substances (such as ammonium and oxygen-derived free radicals)
can be secreted by embryos in a group culture. Embryo density appears to be
one of the most important settings in group culture to guarantee a better
embryo development without exposing the embryos to an increased concen-
tration of negative factors.
Study design, size, duration: It is a monocentric, prospective and rando-
mized study, which lasted for one year, from June2015 to June2016.
Patients who had 2 or 3 fertilized oocytes were included in the study, which
made a total number of 169 ICSI cycles.
Embryos were cultured either individually, or in a group of 2 or 3 embryos
per droplet, which yielded to an embryo density of 30 μl, 15 μl, or 10 μl of cul-
ture medium per embryo for the three groups respectively.
Participants/materials, setting, methods: ICSI cycles were randomized,
according to oocyte retrieval day, in three groups of different embryo density:
– Group A: Individual culture (1embryo per droplet: 30 μl of medium per
embryo) (91 cycles)
– Group B: Group culture (2 embryos per droplet: 15 μl of medium per
embryo) (43 cycles)
– Group C: Group culture (3 embryos per droplet: 10 μl of medium per
embryo) (35 cycles)
Embryo transfer took place on day2 or day3, and sequential culture medium
was used for the culture pursuit.
Main results and the role of chance: Group culture in an embryo density
of 15 μl (GroupB) yielded to better cleavage rates than GroupA or C (96.% vs
95.2% vs 91% respectively, p = 0.08). Though, among the three groups,
GroupC had the best embryo quality with a signiﬁcant difference in the mean
number of TOP quality embryos obtained (1.1 vs 0.73 vs 0.74 for GroupC, A
and B respectively, p = 0.023).
Pregnancy rates were higher for GroupC compared with the two other
groups (41.1% vs 33.3% vs 31.4% for GroupC, B and A respectively, p = 0.22).
Implantation rates were also greater after transferring embryos cultured in a
density of 10 μl than the two other groups (22% vs 21% vs 17.8% for GroupC,
B and A respectively, p = 0.44). Nevertheless, those differences were not stat-
istically signiﬁcant.
Same ﬁndings were noticed for live birth rates from embryos of GroupC,
which were greater than the two other groups with no statistical difference
(18.6% vs 13% vs 10% for GroupC, A and B respectively, p = 0.29).
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Our results suggest that embryo density of 10 μl seems to be suitable for
obtaining a better embryo quality and for enhancing ICSI outcomes in terms of
pregnancy, implantation and live birth rates after transfer of day2 or day 3
embryos.
Limitations, reasons for caution: Adopting day5 embryo transfer could
provide more proofs of the beneﬁts of culturing embryos with a 10 μl embryo
density rather than other tested densities.
Wider implications of the ﬁndings: Culturing embryos in high density
could generate some assessing and selection difﬁculties. That is why some
authors brought the idea of culture systems, such as the Well-Of-the-Well sys-
tem, in which embryos are cultured in a cone shape well to increase growth fac-
tor concentration while diluting negative ones.
Trial registration number:
P-148 Development of a chemically deﬁned protein supplement
for in vitro embryo culture
S. Lin, M.K. Villafuerte, H.T. Ni
Irvine Scientiﬁc, Research & Development, Santa Ana, U.S.A.
Study question: Development of an effective, improved chemically deﬁned
protein supplement for IVF by identifying functional proteins found in the female
reproductive tract and commercially serum-derived supplements.
Summary answer: A chemically deﬁned protein supplement containing
recombinant proteins identiﬁed in the female reproductive tract, HSA, and glo-
bulins, improved mouse and bovine blastocyst development in vitro.
What is known already: Commercially available protein supplements for
embryo culture are used worldwide to effectively promote blastocyst develop-
ment in IVF clinics. However, they generally consist of plasma derived human
serum albumin (HSA) and globulin fraction IV, which lead to lot-to-lot variation.
As a result, there is a need for the development of a chemically deﬁned protein
supplement that eliminates variability and delivers high quality blastocysts con-
sistently. Recent studies have reported various biologic, functional proteins,
including growth factors not only found in the female reproductive tract, which
is the natural environment where embryos develop, but also in serum-derived
protein supplements used in IVF labs.
Study design, size, duration: ELISAs were used to determine the presence
and concentration of candidate factors in multiple lots of HSA and globulins.
Mouse and bovine embryo assay (MEA/BEA) experiments were conducted to
evaluate the effect of the identiﬁed factors on blastocyst development. ≥25
embryos were used per test group in both embryo assays. Embryos were cul-
tured continuously in microdroplets overlaid with light mineral oil, and blasto-
cyst rates were graded after 5 (mouse) or 7 (bovine) days of incubation.
Participants/materials, setting, methods: Frozen mouse zygotes from
EmbryoTech were thawed and cultured in Continuous Single Culture Medium
(CSCM®-NX) complemented with chemically deﬁned protein supplement pro-
totypes containing different deﬁned protein compositions. All embryos were
cultured in 5% CO2 incubators at 37°C in 98% humidity. BEA experiments
were performed at Applied Reproductive Technology, and all test samples pro-
vided were blinded to prevent biased evaluation and an internal control was
always performed using speciﬁc bovine embryo culture media.
Main results and the role of chance: ELISA results demonstrated the pres-
ence of biological protein regulators, such as insulin in both the HSA and globu-
lin/fraction IV, and concentrations were consistently higher in the fraction IV
than in the HSA. These growth factor (GF) proteins, as previously reported,
were also found in the oviduct and the endometrium. Test media prototypes
were developed containing different combinations of these proteins. Even
under more stressful and stringent embryo culture conditions of one embryo
per droplet, MEA results showed that medium containing only insulin, per-
formed equally well as control medium containing 10% Serum Substitute
Supplement (HSA + globulin/fraction IV). In addition, test medium containing
insulin and selected factors consistently improved blastocyst rate (≥80%) when
compared to the control. Additional studies were done using the more sensitive
BEA system, and these experiments also demonstrated that presence of
deﬁned protein supplement improved blastocyst rate as well as rate of fertiliza-
tion, in vitro. Replacement of serum-derived components with recombinant
proteins in IVF culture supplements not only eliminated inconsistencies and
demonstrated improved performance, but it also removes the negative factors
in human biological samples that may present toxic effects to the cultured
embryos.
Limitations, reasons for caution: Present study of the newly developed,
chemically deﬁned protein supplement does not include human embryo devel-
opment data. Human studies are in progress for full evaluation of the GF bene-
ﬁts to human embryo growth.
Wider implications of the ﬁndings: GF were shown to exist in the female
reproductive tract as well as commercially available supplements that IVF
laboratories have used for years. Therefore, GF in the chemically deﬁned pro-
tein supplement will bring consistency in blastocyst development and can be
considered safe as GF were present in previously accepted products.
Trial registration number:Not Applicable.
P-149 Early rescue ICSI has good clinical results - Record of 14
years at our clinic
S.Watanabe1, R. Matsunaga1, M. Miura1, Y. Kobayashi1,
N. Yamanaka1, M. Kamihata1, T. Maeda1, H. Makino1, M. Ochi1,
T. Horiuchi2
1Ochi Yume Clinic Nagoya, ART Lab., Nagoya, Japan
2Prefectural University of Hiroshima, Faculty of life and emvironmental science,
Shobara, Japan
Study question: Long-term clinical performance of early rescue ICSI.
Summary answer: Early rescue ICSI can result in clinically valuable outcomes,
producing normal rates of fertilization, blastocyst formation, pregnancy, and
production.
What is known already: Although the outcome of early rescue ICSI has
been reported in the past, there have been no reports that describe experi-
ences over a prolonged period (14 years in this presentation).
Study design, size, duration: We performed a retrospective analysis of
5171 oocytes in which early rescue ICSI was performed, among 29,776 oocytes
taken from 10,750 cases undergoing IVF in 2004-2017. The fertilization rate,
blastocyst rate, pregnancy rate, and production rate were examined. As a con-
trol, we used 30,114 oocytes taken from 12,815 cases who underwent conven-
tional ICSI during the same period. The stimulation methods used in this study
were natural cycle, letrozole cycle, or clomiphene cycle.
Participants/materials, setting, methods: Cumulus cells were removed 5
hours after insemination, and oocytes were observed.
(1) After stripping, release of the second polar body was observed.
(2) Fertilization cone or cytoplasmic ﬂare was observed.
(3) Although not applicable to 1-2, spindle body was not observed in the egg
by observation with the spindle visualization system (PolScope).
Observations were carried out until 7 hours after insemination, and early rescue
ICSI was performed when none of 1-3 was applicable.
Main results and the role of chance: The normal fertilization rate of early
rescue ICSI was 81.8% (4232/5171), and the 3PN rate (which indicates the
possibility of multisperm fertilization) was 4.8% (249/5171). The good blasto-
cyst rate was 36.2% (1140/3149), the pregnancy rate was 56.3% (429/762),
and the production rate was 67.9% (248/365).
The normal fertilization rate of conventional ICSI conducted during the same
period was 80.9% (24344/30097) and the 3PN rate was 3.2% (972/30097).
The good blastocyst rate was 33.0% (6879/20839), the pregnancy rate was
48.9% (2489/5088), and the production rate was 66.6% (1426/2141).
There was no signiﬁcant difference in normal fertilization rate. The 3PN rate, the
good blastocyst rate and the pregnancy rate were signiﬁcantly higher in the early
rescue ICSI group (P < 0.05). There was no signiﬁcant difference in production rate.
Good blastocysts were deﬁned as those with a diameter of 160 μm or more
and a recognizable ICM. All embryo transfers were performed using the freeze-
thaw single embryo transfer protocol, and production rates were based on
embryo transfers up to 2016.
Limitations, reasons for caution: In Japan, some patients do not like ICSI
(due to concerns over health of the resulting children), and there are institu-
tions that perform IVF as much as possible and only carry out early rescue ICSI
where fertilization fails.
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Wider implications of the ﬁndings: The clinical outcome of embryos ferti-
lized by early rescue ICSI is equal to or higher than that of conventional ICSI
and is a useful technique for patients who do not like ICSI. Because the 3PN
rate was higher than conventional ICSI, more effective multispermic fertilization
prevention measures are necessary.
Trial registration number:Not applicable.
P-150 Clinical value of embryos with three or more blastomeres at
the ﬁrst division (direct cleavage embryos) but with nuclei in only
two blastomeres
K. Isobe1, S.Watanabe1, M. Miura1, Y. Kobayashi1, R. Matsunaga1,
N. Yamanaka1, M. Kamihata1, T. Maeda1, H. Makino1, M. Ochi1,
T. Horiuchi2
1Ochi Yume Clinic Nagoya, ART Lab., Nagoya, Japan
2Prefectural University of Hiroshima, Faculty of Life and Environment sciences,
Shobara, Japan
Study question:Does the clinical outcome differ between direct cleavage embryos
with two and three or more nucleus-bearing blastomeres at the ﬁrst division?
Summary answer:Direct cleavage embryos with two nucleus-bearing blasto-
meres had a signiﬁcantly higher rate of blastocyst formation than embryos with
three or more nucleus-bearing blastomeres.
What is known already: There are many reports that the rate of develop-
ment to the blastocyst stage is markedly decreased in direct cleavage embryos,
and that these embryos have an increased risk of aneuploidy during develop-
ment into blastocysts. However, few reports have investigated whether the
number of blastomeres with nuclei in direct cleavage embryos affects their
developmental outcomes.
Study design, size, duration: We performed a retrospective analysis of
embryos that were cultured in the period 2013 to 2015 and that had been
recorded using a time lapse monitoring system (EmbryoScope, Vitlolife).
In total, 1135 embryos with three or more blastomeres at the ﬁrst division
were included in the study. Cells with a diameter of 40 μm or more were
deﬁned as blastomeres.
Participants/materials, setting, methods: The ﬁrst division of embryos
cultured within the target period was observed with a time lapse monitoring
system. Embryos with a nucleus in only two blastomeres (two nucleus group)
and embryos with a nucleus in three or more blastomeres (three or more
nucleus group) were classiﬁed among 1135 direct cleavage embryos. The rates
of good blastocyst formation (a diameter of 160 μm or more and a recognizable
ICM), pregnancy, and production were compared.
Main results and the role of chance: The rates of formation of good blas-
tocysts were 26.0% (159/611) for the two nucleus group and 5.2% (27/524)
for the three or more nucleus group; the rate in the two nucleus group was sig-
niﬁcantly higher (P < 0.05). After freezing, thawing and transplantation by single
embryo transplantation, a pregnancy rate of 46.9% (38/81) was achieved in the
two nucleus group and of 40.0% (6/15) in the three or more nucleus group;
production rates were 65.8% (25/38) and 83.3% (5/6), respectively, for the
two groups, which was not signiﬁcantly different.
Limitations, reasons for caution: In Japan, PGS has not been approved,
and a method for conﬁrming euploidy of the embryos on the basis of morph-
ology and developmental kinetics during culture is required.
Wider implications of the ﬁndings: The two nucleus group is presumed to
have a normal chromosome distribution (blastomeres without a nucleus may
be fragments). Although an abnormal distribution of chromosomes is expected
in embryos with three or more nuclei, these embryos can produce successful
pregnancies. The reasons for this will be studied in the future.
Trial registration number:Not applicable.
P-151 Clinical outcomes of metaphase II oocytes with the
presence of refractile bodies in patients undergoing
intracytoplasmic sperm injection treatment
H. Takahashi1, J. Otsuki2, R. Hirata1, H. Saito1, T. Habara3,
N. Hayashi3
1Okayama couple’s clinic, laboratory, Okayama, Japan
2Okayama university, Assisted reproductive technology center, Okayama, Japan
3Okayama couple’s clinic, Physician, Okayama, Japan
Study question: Does the presence of refractile bodies (RF) negatively affect
fertilization, embryo development and implantation rates following intracyto-
plasmic sperm injection (ICSI)?
Summary answer: Oocytes with RFs showed lower embryo development
and implantation rates than those without RFs, however there were no signiﬁ-
cant negative effects on fertilization rates.
What is known already: RFs are a one of the main morphological abnormal-
ities that can be observed in the cytoplasm of human oocytes. RFs consist of a
mixture of lipids and dense granular materials, having a yellow autoﬂuorescence
which is consistent with the typical autoﬂuorescence of lipofuscin. Lower fertil-
ization rates and lower embryo development rates have been consistently
reported among oocytes with RFs when compared with those without RFs.
However, the implantation potential of embryos derived from oocytes with RFs
still remains unclear.
Study design, size, duration: To have the background of patients compar-
able and know whether RFs have negative impact on clinical outcomes, RF posi-
tive cycles which had both RF positive (RF(+)) and negative (RF(-)) oocytes
were subjected into this study. A total of 316 ICSI cycles performed between
January 2013 and June 2016 were retrospectively analyzed regarding fertilization
and embryo development rates and 438 single frozen embryo transfers per-
formed prior to January 2017 were analyzed to compare the implantation rates.
Participants/materials, setting, methods: MII oocytes with the presence
of RFs ≥5 μm in diameter were recorded as RF(+). Retrieved oocytes were
morphologically classiﬁed into RF(+) and RF(-) oocytes at the time of ICSI. A
comparison of the fertilization and the blastocyst formation rates on Day 5 was
made between the two groups. Implantation rates were assessed in frozen-
thawed single embryo transfer cycles. Statistical signiﬁcance was determined by
Chi-Square test.
Main results and the role of chance: A total of 3,085 oocytes were
retrieved. Of these, 648 (21.0%) were RF(+). Fertilization rates in RF(+) and RF
(-) were 76.5% and 77.2% respectively and no signiﬁcant differences were
detected (Odds Ratio (OR) = 0.96; 95% CI: 0.79-1.18, P = 0.730). The blasto-
cyst formation rates on Day 5 in RF(+) and RF(-) were 45.8% and 52.2%
respectively and were signiﬁcantly lower in RF(+) oocytes than those in RF(-)
oocytes (OR = 0.77, 95% CI: 0.63-0.94, P = 0.011). Implantation rates in RF
(+) and RF(-) were 24.2% and 42.2% respectively and were also signiﬁcantly
lower in RF(+) oocytes than those in RF(-) oocytes (OR = 0.44, 95% CI: 0.26-
0.73, P = 0.001). Furthermore, the implantation rates in RF(+) oocytes when
high quality blastocysts were transferred was 28.6%, which was also signiﬁcantly
lower than that of 46.1% in RF(-) oocytes (OR = 0.47, 95% CI: 0.26-0.86, P =
0.011). However, no signiﬁcant differences were found regarding miscarriage
rates (16.7% vs. 30.1%) (OR = 0.47; 95% CI: 0.15-1.44, P = 0.158).
Limitations, reasons for caution: As the presence of RFs was only
recorded at the time of ICSI, the presence of RFs in immature oocytes could
not be analyzed. Since this study only focused on the differences between RF
(+) and RF(-) oocytes from RF(+) cycles, comparisons with RF(-) cycles have
yet to be done.
Wider implications of the ﬁndings: Our results suggest that oocytes with
the presence of RFs have a lower potential to develop into blastocysts and even
when they develop into high quality blastocysts, the chances of implantation are
reduced. Further study is required to elucidate the causes of RF formation and
thus improve implantation rates.
Trial registration number:Not applicable.
P-152 A higher incidence of smooth endoplasmic reticulum
clusters in patients treated with a regimen of aromatase inhibitors
H. Saito1, J. Otsuki2, R. Hirata1, H. Takahashi1, T. Habara3,
N. Hayashi3
1Okayama couple’s clinic, laboratory, okayama, Japan
2Okayama university, Assisted reproductive technology center, Okayama, Japan
3Okayama couple’s clinic, Physician, okayama, Japan
Study question: Can a regimen of aromatase inhibitor (AI) reduce the occur-
rence of smooth endoplasmic reticulum clusters (sERCs) in oocytes?
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Summary answer: Contrary to expectations, the occurrence of sERCs was
signiﬁcantly higher in oocytes from patients treated with AI than in those trea-
ted with clomiphene citrate (CC).
What is known already: sERC is one of the dysmorphic phenotypes found
in human oocytes and signiﬁcantly reduces pregnancy rates. A comparatively
higher number of abnormities in live-births appear to be associated with the
presence of sERCs in oocytes, although healthy babies can be born from
embryos derived from sERC(+) oocytes. sERC formation is related to the high-
er levels of serum E2 detected in sERC(+) cycles. It has recently been reported
that embryos derived from sERC(+) oocytes are prone to a higher frequency of
aberrant spindle formation and mitotic cleavage. The levels of serum estradiol
are known to be lower in patients with AI.
Study design, size, duration: This was a retrospective cohort study of patients
whose AMH levels were ≦1.0 ng/ml, involving a total of 598 cycles between July
2014 and December 2016. The choice of ovarian stimulation protocol was
dependent on serum AMH levels and age. Patients treated with AI and CC were in
the same classiﬁcation and the choice of AI or CC was according to the patients’
preferences, therefore the two regimens, AI and CC are comparable.
Participants/materials, setting, methods: All of the participants were
infertile women who were being treated by ICSI. When there was at least one
sERC positive oocyte among the retrieved oocytes the cycle was deﬁned as a
sERC(+) cycle. The rates of sERC occurrence were calculated for each regimen
of ovarian stimulation. The AI and CC regimens were compared regarding the
sERC(+) rates and the serum estradiol and progesterone levels on the date of
hCG administration.
Main results and the role of chance: The average age and AMH(ng/ml)
level were 41.4 ± 3.5 and 0.38 ± 0.3 respectively for patients treated with AI
and 41.3 ± 3.5 and 0.41 ± 0.29 for those with CC. The two regimens were
comparable regarding age and AMH level (Age: OR 1.01, 95% CI 0.96-1.06, P
= 0.79; AMH: OR 0.75, 95% CI 0.41-1.36, P = 0.35). The occurrence of sERCs
was found to be 13.2% (23/174) in oocytes from patients treated with AI which
was signiﬁcantly higher than that of 3.8% (16/424) in oocytes from those trea-
ted with CC (OR 3.88, 95% CI 2.00-7.55, P<0.0001). Among the patients trea-
ted with AI, serum estradiol(pg/ml) and progesterone(ng/ml) levels on the
date of hCG were 549.1 ± 388.2 and 1.20 ± 0.72 in sERC (+) and 366.0 ±
276.0 and 0.75 ± 0.55 in sERC(-) cycles. Both the estradiol and the progester-
one levels were signiﬁcantly higher in sERC(+) than in sERC(-) cycles (E2: OR
1.18, 95% CI 1.01-1.39, P = 0.033; P4: OR 3.10, 95% CI 1.57-6.37, P = 0.001).
With regard to the CC cycles, the serum estradiol and progesterone levels on
the date of hCG were 1305.4 ± 443.1 and 0.83 ± 0.51 in sERC(+) and 994.8
± 491.6 and 0.71 ± 0.46 in sERC(-) cycles. Conversely, no signiﬁcant differ-
ences were detected (E2: OR 1.12, 95% CI 0.97-1.27, P = 0.12; P4: OR 1.64,
95% CI 0.58-3.83, P = 0.32).
Limitations, reasons for caution: The comparison was limited to two ovar-
ian stimulation protocols. Other stimulation protocols, such as long, short, and
antagonist protocols, could not be compared with AI in this study, as the
patients’ backgrounds (age and levels of AMH) were all different.
Wider implications of the ﬁndings: As AI did not reduce the occurrence
of sERCs, the elevation of estradiol may not be the cause of sERC occurrence,
but a consequence. Considering the higher levels of progesterone in sERC(+)
cycles, the negative effects of premature luteinization on oocytes, which fre-
quently occur with AI protocol, require further study.
Trial registration number:Not applicable.
P-153 Male Factor is the most important factor inﬂuencing the
frequency of unequal direct cleavage events as visualized by
time-lapse during early embryo development
S. Davies1, C. Karamolegos2, A. Karagianni2, P. Sisi2, C. Mendorou2,
M. Mastrominas3
1c/o Embryogenesis, embryology, Maroussi- Athens, Greece
2embryogenesis, embryology, athens, Greece
3embryogenesis, Clinical, athens, Greece
Study question: To study Irregular Direct Cleave (DC) events under differing
Infertility causes, IVF protocols and age groups to identify sub-groups with
increased prevalence.
Summary answer: Irregular direct cleavage events were observed with a
consistent regularity in all groups studied. Only male factor patients showed sig-
niﬁcant increase in occurrence.
What is known already: Irregular divisions during initial cleavage stage of
embryo development generate low viability embryos which either arrest at
cleavage stage or have elevated aneuploidies or mosaicism. The events are very
speciﬁc, appear to occur at random, but with a consistent regularity, are not an
artefact of stimulation, and the underlying mechanism is not clearly understood.
Study design, size, duration: A retrospective study over the period of
2012-2017 with all embryos incubated in Embryoscope and all annotations per-
formed by the same person, and irregular direct cleavages deﬁned as DC1,
DC2 & DC3 (referring to direct cleave 1st cycle, 2nd cycle and 3rd cycle).
Embryos were incubated for 3-5 days in Sage-1-step media. All embryos were
sub characterised into Stimulated IVF cycle, Natural cycle, PGS (RIF, RM,
Altered Karyotype), Age, & male factor (Ejaculated, TESE, Ionophore).
Participants/materials, setting, methods: A total of 7052 embryos were
included. Patients included, (a) IVF with ICSI (2998 embryos); (b) PGD-AS:
Implantation Failures RIF (n = 706), Recurrent Miscarriages (RM) (n = 894), &
Translocations (n = 448); (c) Male: Ejaculated (n = 786), TESE (n = 278) &
ionophore-enhanced fertilisation (n = 204); & (d) Natural Cycle IVF (n = 738).
Only 1-3 cell cleavages were included, all ambiguous cleavages excluded.
Setting, private IVF facility.
Main results and the role of chance: Irregular cleavages DC1, DC2 & DC3
occurred with regular frequency across all groups studied irrespective of age,
aetiology, or if embryos were generated with ovarian stimulation or natural
cycle. The overall proportion of embryos with irregular direct cleavage up to 8
cell stages were 1692 / 7052 (23.9%), with a distribution: DC1, 955/7052
(13,5%), DC2, 700 / 7052 (9,9%), & DC3, 37 / 7032 (0,5%). The proportion
of embryos showing multiple direct cleavages DC1 + DC2, DC2 + DC2,
DC1/2 + DC3 were only 40 / 7032 (0,5%).
Male factor patients showed a signiﬁcant increase (p>0,01) in direct divisions
DC1 with respect to all the other groups studied, and there was increasing fre-
quency of DC1 with decrease in sperm quality (+ ionophore (37/204, 18,1%)
> TESE (47/278, 16,9%) > Ejaculate (122/786, 15,5%). There were no signiﬁ-
cant differences in DC2 or DC3 for any of the groups studied.
All the DC1 embryos arrested at cell stages of development. DC2 embryos
developed to blastocyst but with much lower frequency than non-DC embryos.
Limitations, reasons for caution: Great care was taken to standardise all
timings and annotations to include any comparable irregular direct cleavage
events and avoid pseudo-cleavage events. Natural cycles are primarily non-
elective and include older patients (>40 years) and poor responders. DFI was
not used as criteria for male factor.
Wider implications of the ﬁndings: Decoupling of visible events of time
lapse analysis is an important task in trying to understand the underlying cause
or mechanism. The observation that sperm quality can increase DC1 but not
DC2/3 implies independent mechanisms. Multinucleation may play more
important role in DC2/3.
Trial registration number:None.
P-154 Effectiveness of≥170-μmdiameter criterion for blastocyst
cryopreservation
T. Kyoya, H.Watanabe, H. Hasegawa, R. Suzuki, K. Tsukamoto,
M. Kobayashi, S. Saito, J. Kobayashi
Kanagawa Ladies Clinic, ivf, yokohama- kanagawa-, Japan
Study question: Does setting a ≥170-μm diameter criterion for blastocyst
cryopreservation inﬂuence clinical outcomes following implantation of frozen-
thawed embryos?
Summary answer: Pregnancy rates following frozen-thawed embryo transfer
were constant, irrespective of blastocyst diameter.
What is known already: Frozen blastocyst transfer is known to yield higher
pregnancy rates than fresh blastocyst transfer due to embryo–endometrium
synchronization.
We previously froze good-quality blastocysts at stage 3, and then thawed
them on the day before transfer. Blastocysts were developed to stage 4 on the
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following day and then implanted, and we reported a resultant improvement in
post-freeze-thaw pregnancy rate over thawing on the day of transfer.
Based on this, we changed our cryopreservation criterion to stage 4 (blasto-
cyst diameter ≥170 μm) in 2017.
Study design, size, duration: We targeted 547 cycles subject to single
frozen-thawed blastocyst transfer between January and October 2017 for ana-
lysis in this study. Only good-quality blastocysts with diameter ≥170 μm at days
5 and 6 were eligible for analysis. Blastocyst diameter was measured from images
taken immediately prior to cryopreservation, using an EmbryoScope system.
Participants/materials, setting, methods: Blastocysts were classiﬁed by
diameter into Categories A (170 to 179 μm), B (180 to 189 μm), C (190 to 199
μm), and D (≥ 200). We compared pregnancy rates between the four blasto-
cyst categories after 5- and 6-day incubation periods.
Main results and the role of chance: Pregnancy rates achieved with trans-
ferred blastocysts after 5-day incubation showed no signiﬁcant differences
between the 4 diameter categories, at 41.8% (64/153) for Category A, 39.5%
(45/114) for Category B, 47.6% (30/63) for Category C, and 41.6% (32/77)
for Category D.
Pregnancy rates achieved with transferred blastocysts after 6-day incubation
showed no signiﬁcant differences between the 4 diameter categories, at 29.5%
(13/44) in Category A, 21.4% (9/42) in Category B, 45.5% (10/22) in
Category C, and 46.9% (15/32) in Category D; however, the rates in
Categories C and D tended to be high.
Limitations, reasons for caution: This study is limited to its retrospective
design and small sample size.
Wider implications of the ﬁndings: Pregnancy rates showed no signiﬁcant
difference between transferred blastocyst categories irrespective of incubation
periods; therefore, we considered that the cryopreservation criterion setting
investigated in this study did not inﬂuence pregnancy outcome. Accordingly, we
suggest that a criterion of diameter ≥170 μm is effective for blastocyst
cryopreservation.
Trial registration number:Not applicable.
P-155 SCF in follicular ﬂuid and granulosa cells is positively
associated with oocyte developmental potential in humans
J. Tan1, Y. Zou2, X.W.Wu1, X.J. Wan1, Q.F.Wu1
1Jiangxi Provincial Maternal and Child Health Hospital, Reproductive Medicine
Center, Nanchang, China
2Jiangxi Provincial Maternal and Child Health Hospital, Key Laboratory of Women’s
Reproductive Health of Jiangxi Province, nanchang, China
Study question: To explore whether the levels of SCF in follicular ﬂuid (FF)
and GCs can be used as a potential marker for predicting oocyte developmental
potential.
Summary answer: The levels of SCF in FF and GCs might be considered as a
new marker for predicting oocyte developmental potential.
What is known already: Stem cell factor (SCF), which is derived from granu-
losa cells (GCs), plays a key role in the process of follicular development and
oocyte maturation.
Study design, size, duration: Follicular ﬂuid and GC samples from 150
female patients undergoing intracytoplasmic sperm injection were collected in
this study.
Participants/materials, setting, methods: The SCF concentrations in FFs
and SCF messenger RNA (mRNA) in GCs were evaluated by using enzyme-
linked immunosorbent assay and real-time polymerase chain reaction,
respectively.
Main results and the role of chance: The results showed that the levels of
SCF protein and mRNA were signiﬁcantly associated with oocyte maturation,
normal fertilization, cleavage, and embryo quality. Moreover, the levels of SCF
protein and mRNA in pregnancy group were also higher than those in the non-
pregnancy group. The cutoff value of SCF in FF for predicting high-quality
embryo was 1.346, with a sensitivity of 57.8% and a speciﬁcity of 72.4%, and
the cutoff value of SCF in GCs for predicting high-quality embryo was 6.650,
with a sensitivity of 64.4% and a speciﬁcity of 78.1%.
Limitations, reasons for caution: The number of samples is the limitation
in this present. Further study need to comﬁred this results.
Wider implications of the ﬁndings: Our results showed a positive and
statistically signiﬁcant relationship between SCF level and oocyte maturation,
normal fertilization, cleavage, embryo quality, and clinical pregnancy.
Trial registration number: not applicable.
P-156 A newmeta-analysis about an unclear topic in ART: Fresh
embryo versus freeze-all embryo transfer strategies
J.G. Franco Jr.1,2, F. Dieamant1,2, C.G. Petersen1,2, A.L. Mauri1,2,
M.C. Mattila1, V.A. Comar1, L. Vagnini2, A. Renzi2, B. Petersen2,
C. Zamara1, J.B.A. Oliveira1,2, R.L.R. Barufﬁ1,2
1Centre for Human Reproduction Prof. Franco Jr, Research, Ribeirao Preto, Brazil
2Paulista Center for Diagnosis Research and Training, Research, Ribeirao Preto, Brazil
Study question: Can cryopreservation of all embryos with subsequent
embryo transfer (Freeze-all) promote improvements in the clinical ART out-
comes compared with fresh embryo transfer (Fresh-ET)?
Summary answer: Freeze-all does not improve clinical outcomes when the
mean number of oocytes retrieved is <15. It seems be useful when >15
oocytes are collected.
What is known already: Freeze-all has been hypothesized as the preferred
way to avoid the potential deleterious effects of controlled ovarian stimulation
(COS) on endometrial receptivity in fresh cycles of IVF/ICSI. It has been sug-
gested that the supra-physiologic hormonal levels during COS promote a sub-
optimal uterine environment, impairing clinical outcomes in ART cycles. There
are few randomized controlled trials demonstrating higher pregnancy rates with
frozen-embryo transfer than with Fresh-ET. A previous meta-analysis has
shown more favourable clinical outcomes with Freeze-all than with Fresh-ET.
However, with the randomized trials published recently, a new meta-analysis is
essential to guide the scientiﬁc community on this issue in reproductive
medicine.
Study design, size, duration: A systematic review based on electronic
searches of databases(PubMed, EMBASE, Web of Science, SCOPUS, and
Cochrane Central Register of Controlled Trials; key-words:Freeze-all; Fresh-
embryo; pregnancy rates; oocytes-retrieved) up to January 2018 was con-
ducted to identify randomized controlled trials(RCTs) comparing the ART out-
comes of fresh versus elective frozen-embryo transfer. The primary outcome
was live birth rate (per woman randomized). Secondary outcomes included
ongoing pregnancy rate(per woman randomized), clinical pregnancy rate(per
patient randomized) and miscarriage rate(from clinical pregnancies).
Participants/materials, setting, methods: Six RCTs were included as tar-
gets for data extraction and meta-analysis. Most of the trials did not allow the
clear identiﬁcation of the study subjects(e.g,PCOS). Data were combined for
meta-analysis using the StatsDirect statistical software. Dichotomous data are
expressed as Relative Risk (RR) with a 95% conﬁdence interval (CI). The
amount of heterogeneity was evaluated using Cochran’s Q and I2. Study data
were combined using a random-effects model. P-values <0.05 were considered
statistically signiﬁcant.
Main results and the role of chance: The results of this meta-analysis are
divided into three parts, based on the mean number of oocytes retrieved.
Part I: mean number of oocytes retrieved >12 and < 21
1. Live birth rates(4-trials): Freeze-all: 46.9%(1081/2305) versus Fresh-
ET:43.9%(1020/2321) with no statistical signiﬁcant differences(RR = 1.13;
95%CI = 0.97-1.32; P = 0.12). Heterogeneity:I2 = 77.4%; CochranQ = 13.2,
P = 0.04.
2. Ongoing pregnancy rates(6-trials): Freeze-all:49.7%(1209/2435) versus
Fresh-ET:48.0%(1177/2450), with no signiﬁcant differences(RR = 1.11;
95%CI = 0.98-1.25; P = 0.1). Heterogeneity: I2 = 67%; CochranQ = 15.1,
P = 0.01.
3. Clinical pregnancy rates(5-trials): Freeze-all:54.5%(1278/2344) versus
Fresh-ET: 53.7%(1269/2362), with no signiﬁcant differences(RR = 1.04;
95%CI = 0.96-1.14; P = 0.35). Heterogeneity: I2 = 47.5%; CochranQ =
7.62, P = 0.10.
4. Miscarriage rates(5-trials): Freeze-all: 10.3%(132/1278) versus Fresh-ET:
12.1%(154/1269), with no signiﬁcant differences(RR = 0.85; 95%CI =
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0.65-1.12; P = 0.25). Heterogeneity:I2 = 23.8%; CochranQ = 5.25, P =
0.26.
Part II: mean number of oocytes-retrieved was >12 and <15
1. Live birth rates(3-trials): Freeze-all: 46.2%(1025/2214) versus Fresh-ET:
44.1%(985/2233), with no signiﬁcant differences(RR = 1.07; 95%CI = 0.93-
1.22; P = 0.36). Heterogeneity: I2 = 72.2%; CochranQ = 7.2, P = 0.03.
2. Ongoing pregnancy rates(4-trials): Freeze-all: 48.8%(1114/2284) versus
Fresh-ET: 48.1%(1107/2300), with no signiﬁcant differences(RR = 1.04;
95%CI = 0.93-1.16; P = 0.47). Heterogeneity: I2 = 59.3%; CochranQ =
7.30, P = 0.07.
3. Clinical pregnancy rates(4-trials): Freeze-all: 54.2%(1239/2284) versus
Fresh-ET: 53.7%(1235/2300) with no signiﬁcant differences(RR = 1.03;
95%CI = 0.94-1.13; P = 0.50). Heterogeneity: I2 = 53.8%; CochranQ =
6.5, P = 0.09.
4. Miscarriage rates(4-trials) Freeze-all: 10.3%(128/1239) versus Fresh-ET:
12.1%(149/1235), with no signiﬁcant differences(RR = 0.87; 95%CI = 0.63-
1.20; P = 0.39). Heterogeneity: I2 = 41.8%; CochranQ = 5.15, P = 0.16.
Part III: mean number was ≥15 and <21
1. Ongoing pregnancy rates(2-trials): Freeze-all: 62.9%(95/151) versus Fresh-
ET: 46.7%(70/150), with statistical signiﬁcant differences(RR = 1.33; 95%CI
= 1.01-1.76; P = 0.04). Heterogeneity: CochranQ = 1.75, P = 0.18.
Limitations, reasons for caution: Most of the trials included did not deﬁne
the population studied as PCOS/non-PCOS, so we cannot rule out the pres-
ence of ovulatory/anovulatory patients in the same study. Therefore, the mean
number of oocytes retrieved was considered in the present meta-analysis.
Some studies had high heterogeneity, thus high risk of bias.
Wider implications of the ﬁndings: Freeze-all could be favourable when a
high number of oocyte is collected (≥15), suggesting an association between
higher COS and impairment of endometrial receptivity. However, when the
mean number of oocytes collected is <15, Freeze-all does not appear to be
advantageous. RCTs on this topic are required.
Trial registration number:Not applicable.
P-157 Failure of cytokinesis and its higher incidence during ICSI
procedures and in oocytes containing smooth endoplasmic
reticulum clusters
J. Otsuki1, T. Iwasaki2, Y. Katada2, Y. Tsutsumi2, Y. Tsuji2,
K. Furuhashi2, M. Yamamoto3, S. Kokeguchi2, M. Shiotani2
1Okayama University, ART Center, Okayama, Japan
2Hanabusa Women’s Clinic, Reproductive Medicine, Kobe, Japan
3Okayama University, Graduate School of Environmental and Life Science, Okayama,
Japan
Study question: Can the failure of cytokinesis be attributed to ICSI proce-
dures and oocytes which contained smooth endoplasmic reticulum clusters
(sERCs)?
Summary answer: Embryos fertilized by the ICSI have a higher incidence of
meiotic failure and oocytes containing sERCs have a higher incidence of meiotic
and mitotic failure.
What is known already: sERCs are one of the dysmorphic phenotypes
that have been reported in human oocytes. Signiﬁcantly reduced pregnancy
rates and a comparatively higher number of abnormities in live births appear
to be associated with the presence of sERCs in oocytes. However, some
reports have shown that healthy babies can be born, without reduced preg-
nancy rates, from oocytes observed to contain sERCs. In ESHRE 2017 we
reported a higher incidence of cleavage failure among embryos derived from
sERC(+) oocytes in contrast to their sERC(-) siblings. However, the inci-
dence of cleavage failure among embryos in sERC negative cycles has been
under investigation.
Study design, size, duration: This was a retrospective observational
cohort study, involving a total of 1,415 oocytes, evaluated between January
2011 and December 2015. Oocytes were obtained from 43 sERC(+) cycles,
which had at least one sERC(+) oocyte among the retrieved oocytes, and
143 sERC(-) cycles. During the course of this study, time-lapse recording
was restricted to patients aged between 30 and 40 years of age who
yielded 4 or more oocytes.
Participants/materials, setting, methods: The presence of sERCs was
evaluated by careful observation of 7 focal planes using an EmbryoScope®Time-
lapse system while studying the dynamic changes within oocytes and embryos.
Statistical analysis was carried out to explore the nature of the abnormalities.
Logistic regression analysis was carried out to explore the independent vari-
ables for meiotic and mitotic cleavage failure. Independent variables included
fertilization procedure (ICSI or IVF), cycle occurrence of sERCs and oocyte-
based occurrence of sERCs.
Main results and the role of chance: Among 1,415 oocytes, sERCs were
found in 5.7% of the oocytes (81/1415) using a time-lapse observation sys-
tem. The occurrence of mitotic cleavage failure after the IVF procedure
among sERC(+) oocytes in sERC(+) cycles, sERC(-) oocytes in sERC(+)
cycles, and sERC(-) oocytes in sERC(-) cycles was 22.9% (8/35), 8.7% (10/
115) and 7.7% (31/404) respectively. By comparison, the occurrence of
mitotic failure after the ICSI procedure across the same categories was
33.3% (7/21), 20.4% (11/54) and 5.5% (15/274) respectively. The occur-
rence of meiotic cleavage failure after the IVF procedure among these cat-
egories was 8.9% (4/45), 0.7% (1/141) and 0.8% (4/506) respectively,
while the occurrence of meiotic cleavage failure after the ICSI procedure
across these categories was 4.0% (1/25), 3.0% (2/67) and 2.9% (10/340)
respectively. The incidence of mitotic cleavage failure in oocytes with sERCs
was found to be signiﬁcantly higher than that in oocytes without sERCs
(OR = 2.560, 95% CI: 1.210-5.410, P = 0.014). The incidence of meiotic
cleavage failure during the second polar body extrusion in oocytes with
sERCs was also signiﬁcantly higher than that in oocytes without sERCs (OR
= 5.140, 95% CI: 1.190-22.200, P = 0.028). Furthermore, ICSI was found to
have a greater frequency of meiotic failure than IVF (OR = 0.413, 95% CI:
0.174-0.981, P = 0.045).
Limitations, reasons for caution: The mechanism of the frequent failure of
cytokinesis in embryos derived from sERC(+) oocytes is still unknown. This
requires further investigation, as the appearance of sERCs could be a conse-
quence rather than a cause of cleavage failure.
Wider implications of the ﬁndings: Our current data, showing that aber-
rant cleavage frequently occurs in sERC(+) oocytes during meiosis and mitosis
and in ICSI cases during meiosis, suggests that abnormal embryo development
could be related to disturbed Ca2+ distribution patterns. Regarding cytokinetic
failure, an embryonic cell could become tetraploid, which may induce abnormal
chromosomal conﬁgurations.
Trial registration number: not applicable.
P-158 Annual variation in ICSI cycle outcome in temperate zones
is related to weather-temperature not calendar - seasons nor
day-light duration as proved by regression analysis
M.E. Ghanem1, L.A.H. Al-Boghdady1, A.G. El-Metwally2, M. Emam1,
M. Hassan2, A. Helal2, A. Shababan3, H. Abdel- Fattah2, A. Zayed2,
M. Elzayaat1
1Miﬁc, IVF, Mansoura, Egypt
2Mansoura faculty of medicine, ob/gyn, Mansoura, Egypt
3Al-Azhar faculty of medicine, ob/gyn, Cairo, Egypt
Study question: If the annual variation of ICSI outcome in our geolocality is
related to meteorological year seasons (winter –spring-summer –autumn) or to
weather temperature?
Summary answer: Weather temperature ≥ the 50th -centile, not calendar
season in our geolocation independently predicts better IR and CPR in ICSI as
shown by regression analysis.
What is known already:Whereas many studies reported signiﬁcant seasonal
variation in the outcome of IVF/ICSI cycles few studies denied the presence of
such seasonality. The mechanisms underlying periodicity of human in vitro con-
ception however are still unclear. While many authors attributed the annual
variation in ICSI outcome to daylight length, others linked it to temperature
changes. Peak natural fertility times vary from one latitude and climate to
another and geographical discrepancies reﬂect differences in the mix of daylight
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and temperature that most closely approximates ideal conditions for human
conception. Are the same mechanisms apply to in vitro human conception?
Study design, size, duration: We retrospectively analyzed 3586 fresh ﬁrst
completed ICSI cycles performed in our center, geolocation -N 31.044183, E
31.378584300000057,by the same team of clinicians and embryologists over 6
years (2011-2016). We included all female ages and all ICSI indications. The
cycles were assigned to one of 4 calendar- seasons (winter-spring-summer-
autumn) then 2 temperature- centiles ( November-_April) < & (May-
October)≥ 50th centile: 20 °C) depending on date of ovum pick-up (OPU).
Participants/materials, setting, methods: We compared ages, infertility
duration, eggs retrieved (ER), dose/ER, fertilization rate (FR), number of
embryos-transferred ( NET), blastocyst –ratios (RBL), clinical pregnancy rate
(CPR) implantation rate (IR) in 4 calendar and 2 temperature seasons. Binomial
logistic (BNLR) and multiple regression (MR) analysis were used to compare
the predictive values of age, NET, RBL, calendar-season, temperature-centile, day-
light duration-centile) for, IR, CPR.
Main results and the role of chance: No statistically signiﬁcant differences
were found between cycle features nor cycle outcome in the 4 calendar sea-
sons: winter (888- ET), spring (843- ET),summer ( 840-ET), autumn ( 887 -ET)
respectively (IR: 13.8, 13.1, 14.1, 13.2) (p = 0.68)#, CPR: 41.5, 40.6, 42.3, 40.5
(p = 0.86) #.Comparing the 2 temperature- centiles ( November-April temp
< 20° C, 1747 ET) & (May-October temp ≥ 20 ° C – 1718 ET) respect-
ively): age 29.38 ± 5.6, 29.83 ± 5.6 (p = 0.02) *, Infertility-Duration
5.69 ± 4.26, 5.51 ± 3.975 (0.268) *, ER 11.16 ± 6.3, 11.02 ± 6.4 (p =
0.52) *, Amps/ER 3.92 ± 4.09, 3.94 ± 4.81(p = 0.92) *, FR 76.61 ±
22.02, 76.63.52 ± 22.0 (0.97) * mean NET 2.73 ± 0.83, 2.72 ± 0.85 (p
= 0.9) *, RBL 36.2%, 38.9% (p = 0.11), total number of transferred
embryos 4749, 4683, Total number of Sacs 601, 679, IR 12.7%, 14.5%
(P = 0.0098) #, number of clinical pregnancies 690, 753, CPR 39.8%
,43.8% ( P = 0.0026) #. ( * T-test, # χ 2-test) Using MR for IR & BNLR
for pregnant outcome employing the 6 variables signiﬁcantly pre-
dicted both IR and CPR (p < .000) but, day- light duration, calendar-
season did not signiﬁcantly add to prediction (p>0.05). Absolute RR
= 4 and Relative RR = 9.%, Number-Needed -to -Treat = 25
Limitations, reasons for caution: The large sample size ﬂagged minor dif-
ferences in age (mean-29) and infertility duration (mean-5) as signiﬁcant which
is difﬁcult to defend. The assignment to one calendar season or temperature
centile by date of OPU does not exclude effects of other seasons when ET is
done in subsequent season.
Wider implications of the ﬁndings: Patients in our geolocation should be
counseled about the relatively better outcome in warmer weather compared
to cold weather.This recommendation is only valid in locations which share us
the weather temperature centiles.
Trial registration number: enter ‘not applicable.
P-159 Re-biopsy combined with double vitriﬁcation during
preimplantation-genetic-testing cycles: comprehensive description
of blastocysts rescued after failing the ﬁrst round of diagnosis
D. Cimadomo1, L. Rienzi1, F.M. Ubaldi1, C. Patassini2, V. Romanelli2,
E. Alviggi3, L. Dusi4, E. Albani5, N. Barnocchi6, F. Benini7, P.E. Levi
Setti5, A. Capalbo2
1Clinica Valle Giulia, G.EN.E.R.A. centers for reproductive medicine, Roma, Italy
2Igenomix, Igenomix Italia, Marostica, Italy
3Clinica Ruesch, G.en.e.r.a. centers for reproductive medicine, Naples, Italy
4Clinica Salus, G.en.e.r.a. centers for reproductive medicine, Marostica, Italy
5Humanitas Research Hospital, Humanitas Fertility Center, Rozzano, Italy
6G.en.e.r.a. Umbria, G.en.e.r.a. centers for reproductive medicine, Umbertide, Italy
7Demetra, Centro di procreazione medicalmente assistita, Firenze, Italy
Study question: Which are the technical and clinical results of re-biopsied
blastocysts that failed the ﬁrst round of qPCR-based aneuploidy testing on
trophectoderm biopsies?
Summary answer: The risk of inconclusive diagnoses is <3%.Re-biopsied
blastocysts after double vitriﬁcation show similar survival, euploidy and implant-
ation rates as blastocysts diagnosed at the ﬁrst analysis.
What is known already: The implementation of multicellular trophectoderm
biopsy approach has signiﬁcantly reduced the risk for ampliﬁcation failure and
inconsistent results during preimplantation-genetic-testing cycles. Yet, to date
few reports deﬁned the rate of re-biopsy procedures required, as well as their
related technical and clinical results. On average, 2-6% of the blastocysts were
reported to result in an inconclusive diagnosis after comprehensive-
chromosome-testing (CCT), of which 1-2% due to DNA ampliﬁcation failure.
The technical and clinical outcomes seem comparable to blastocysts with a con-
clusive result after the ﬁrst biopsy.
Study design, size, duration: 8991 blastocyst biopsy procedures were con-
ducted between April 2013 and September 2017 at 7 IVF centres in Italy and
analysed by qPCR at a single genetic lab. 206 blastocysts were successfully re-
biopsied after warming and re-expansion, and then re-vitriﬁed. 41 frozen
single-embryo-transfers (SETs) of blastocysts diagnosed euploid after troph-
ectoderm re-biopsy were performed to date. Logistic regression analyses were
performed to investigate the parameters associated with an inconclusive
diagnosis.
Participants/materials, setting, methods: Only preimplantation-genetic-
testing-for-aneuploidies (PGT-A) cycles with a freeze-all approach were
included. Vitriﬁcation was performed within 30 min from trophectoderm biopsy
on collapsed blastocysts. qPCR-based CCT method was adopted.
Ampliﬁcation failure or nonconcurrent molecular data resulted in an inconclu-
sive diagnosis. Only frozen euploid SETs were performed ≈2 hr after warming.
Clinical pregnancy, miscarriage (<20weeks) and ongoing pregnancy rates were
monitored.
Main results and the role of chance: 8991 blastocysts were included (3244
PGT-A cycles conducted from 2687 couples, mean maternal age: 38.5 ± 3.9,
25-45). 2.6% of the trophectoderm biopsies resulted in an inconclusive diagno-
sis (n = 228/8991, 95%CI:2.2%-2.9%), of which 2% (n = 176/8991) due to
ampliﬁcation failure and 0.6% (n = 52/8991) due to nonconcurrent results. The
only parameters signiﬁcantly associated with the risk of obtaining an inconclu-
sive diagnosis were the IVF centre (OR = 1.13, 95%CI:1.1-1.2 from the one
performing the highest to the one performing the lowest number of proce-
dures; p<0.01) and the day-of-biopsy (OR = 0.55, 95%CI:0.43-0.69 from day 5
to day7; p<0.01).
213 blastocysts were warmed to be re-analysed. The survival rate after
warming was 98.1% (n = 209/213) and the survival rate after re-biopsy was
98.6% (n = 206/209). All the re-biopsied blastocysts resulted in a conclusive
diagnosis, among them the euploidy rate was 51.9% (n = 107/206) (The
euploidy rate of blastocysts biopsied only once was 45.7% (n = 4000/4778)).
41 blastocysts diagnosed euploid after re-biopsy have been warmed to date.
All of them survived (100%, n = 41/41) and were transferred. 51.2% clinical
pregnancy (n = 21/41), 9.5% miscarriage (n = 2/21) and 46.3% ongoing preg-
nancy (n = 19/41) rates were reported.
Limitations, reasons for caution:Only targeted-qPCR-based CCT method
was adopted in this retrospective analysis. A more powered report of the clin-
ical (and possibly obstetrical and perinatal) outcomes after frozen euploid SET
of re-biopsied blastocysts requires a larger sample size. Ideally, these clinical
data should be clustered also per blastocysts’ quality and day of full-blastulation.
Wider implications of the ﬁndings: Trophectoderm biopsy approach is
conﬁrmed technically-consistent and clinically-secure. The residual risk for
inconclusive diagnoses (2.6%) seems related to day-of-biopsy (possibly the
number/volume of retrieved cells) and IVF centres’ expertise. Yet, it is worth
re-biopsying undiagnosed blastocysts since the survival, euploidy and ongoing
implantation rates seem comparable to the control.
Trial registration number:None.
P-160 Blastocyst culture using G-TL single-step versus Origio
sequential medium: a semi-randomized approach
M. Abraham, A. De Vos, I. Mateizel, H. Tournaye, G. Verheyen
UZ Brussel, Centre for Reproductive Medicine, Jette, Belgium
Study question: Does human blastocyst formation and clinical outcome after
IVF differ when using a single-step medium or sequential culture media?
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Summary answer: Signiﬁcant differences were observed for fertilization and
embryo development in favour of the sequential medium. However, clinical
pregnancy rate was not different.
What is known already: Embryo culture conditions represent a key part of
IVF success. The development of culture media is based on two distinct
approaches. 1) “Back to nature” in which the embryos are exposed to stage-
speciﬁc media, designed to reﬂect the physiological changes in nutrient concen-
trations in the fallopian tube and the uterus (sequential media). 2) “Let the
embryo choose” in which the embryos select the nutrients they require from a
medium that provides them all at once (single media). At present, insufﬁcient
evidence exists to prefer sequential or single-step media for the culture of
human embryos to the blastocyst stage.
Study design, size, duration: A preliminary sibling oocyte study (50 ICSI
cycles) did not reveal differences in fertilization and embryo quality between the
single-step medium (G-TL, Vitrolife) and the sequential media (Origio
Sequential, Origio). In order to focus on the clinical outcome, a semi-
randomized controlled trial including unselected ICSI cycles was performed
between July 2016 and December 2016. In total, 2012 ICSI cycles were
assigned to G-TL single-step medium (n = 1007) or Origio sequential media (n
= 1005) on alternate days.
Participants/materials, setting, methods: In the G-TL single-medium
group, injected oocytes were individually cultured in the same 25 μl droplet until
day 5/6. In the cycles with Origio sequential media, injected oocytes were indi-
vidually cultured in 25 μl cleavage medium and replaced to 25 μl blastocyst
medium on day 3 until day 5/6. Fertilization, embryo development, embryo
utilization rate (embryos transferred and vitriﬁed per fertilized oocyte) and clin-
ical pregnancies (with FHB) per intended transfer were compared between the
two media.
Main results and the role of chance: Mean female age was 35.1 (±4.9 SD)
in the G-TL single-step medium group and 35.4 (±5.1 SD) years in the Origio
sequential media group. On average, 7.0 (±0.2 SD) and 7.1 (±0.2 SD) mature
oocytes were available for ICSI. Fertilization rates in G-TL single-step medium
(67.5%) and Origio sequential media (71.9%) were signiﬁcantly different (p =
0.0006). Embryo development (top and good quality embryos) was signiﬁcantly
in favour of Origio sequential media, both on day 3 (74.8% versus 69.8%, p =
0.0008) and on day 5 (47.6% versus 40.5%, p = 0.0005). Likewise, the embryo
utilization rate in Origio sequential media (44.8%) was signiﬁcantly higher than
in G-TL single-step medium (40.1%, p = 0.0013). Nevertheless, no signiﬁcant
difference was observed in the clinical outcome between the two media. In
some cycles, freeze all policy was applied (236 cycles in the G-TL single-step
group and 256 cycles in the Origio sequential group). Clinical pregnancy rate
with FHB per intended transfer was 25.4% in G-TL single-step medium and
24.5% in Origio sequential media (p = 0.708).
Limitations, reasons for caution: In the present comparison between a
single-step and a sequential medium clinical pregnancy rate was used as end-
point. However, in view of the signiﬁcant differences in embryo development
and embryo utilization rate, it might be worthwhile to look at cumulative live
births.
Wider implications of the ﬁndings: The present study contributes to
evaluate the performance of single-step versus sequential media in terms of
embryo development and clinical outcome. In a smaller sibling oocyte study the
present ﬁndings remained unnoticed. Differences in embryo development
between media might also depend on speciﬁc laboratory conditions.
Trial registration number: not applicable.
P-161 Correlation among pAKT, pERK1/2 and DNA
fragmentation index in human cumulus cells to determine oocyte
competence
L. Bosco1, M.C. Roccheri1, C. Luparello1, D. Matranga2,
A. Ferrigno1, S. Cuomo3, G. Ruvolo4
1University, Dip di Scienze e Tecnologie Biologiche- Chimiche e Farmaceutiche,
Palermo, Italy
2University, Dip di Scienze per la Promozione della Salute e Materno Infantile
“G.D’Alessandro” Via del Vespro- PALERMO, Palermo, Italy
3Centro Internazionale di Procreazione Assistita Via Clemente Maraini 8-, ProCrea,
Lugano, Swaziland
4Centro di Biologia della Riproduzione- Via Villareale, Centro CBR, Palermo, Italy
Study question: The aim was to correlate speciﬁc biological aspects of cumu-
lus cells isolated from individual cumulus-oocyte complexes (COCs) with the
clinical outcome of the related embryos.
Summary answer: In case of positive clinical outcome, pERK1/2 nuclear
localization in cumulus cells was correlated positively with pAKT expression
levels and negatively with the DFI value.
What is known already: It is widely acknowledged that the activated
pERK1/2 and pAKT factors play a key role in supporting the survival pathway,
exerting an anti-apoptotic effect; it is also known that pERK1/2 translocates
into the nucleus to interact with transcription factors and the DNA itself to pro-
mote cell viability and proliferation. Previous results demonstrated that in the
cumulus cells of the oocytes able to produce blastocysts, the pAKT/DFI ratio
was higher than in cumulus cells of embryos arrested during the in vitro culture.
In addition, a signiﬁcant direct correlation was found between pAKT and
pERK1/2, suggesting a cooperative action as survival factors.
Study design, size, duration: The study had the duration of 24 months and
involved 26 patients after informed consent. For each follicle containing a
mature oocyte, the levels of pAKT, the nuclear localization of pERK1/2 and the
DNA fragmentation index (DFI) in cumulus cells of single COCs were evaluated
and put in correlation with the positive or negative clinical outcome of the
related embryos according to the ability to reach blastocyst stage and the
results assessed for statistical signiﬁcance.
Participants/materials, setting, methods: Normo-responder patients of
ART procedures were selected. The cumulus cells were harvested after hyalur-
onidase treatment of the individual COCs and centrifugation. The oocytes
were transferred to the culture medium until used for ICSI. The DFI was evalu-
ated via TUNEL assay. The levels of pAKT and the nuclear localization of
pERK1/2 were assessed via immunoﬂuorescence microscopy and densitomet-
ric analysis of the images using the appropriate software. The statistical signiﬁ-
cance was evaluated via the non-parametric Kruskall-Wallis test.
Main results and the role of chance:Out of 126 MII oocytes, 91 were ferti-
lized and the derived embryos had the following evolution: 53 were transferred
“in utero”, 8 were arrested during “in vitro” culture and 30 were cryopreserved.
In case of the positive clinical outcome, we found that in cumulus cells of the cor-
responding COCs the nuclear localization of pERK1/2 showed a signiﬁcant
inverse correlation with the DFI value, which is an apoptosis hallmark, (rs
= -0.39, p = 0.007), and a signiﬁcant direct correlation with the intracellular accu-
mulation of pAKT (rs = 0.477, p < 0.001). These results were not obtained with
cumulus cells of COCs related to negative clinical outcome of the arrested
embryos. In addition, all the cumulus cells examined showed a signiﬁcant inverse
correlation between the intracellular accumulation of pAKT and the DFI value (rs
= -0.37, p < 0.001), conﬁrming its role as a survival factor also in this cell type.
Therefore, our results suggest that high levels of nuclear pERK1/2 accumulation
coupled with an increase of pAKT and a low DFI value in the cumulus cells of the
corresponding COCs might be considered as a marker of oocyte competence
leading to the development of embryos of presumed good quality.
Limitations, reasons for caution: The present results are preliminary and
further investigation is needed to improve their signiﬁcance level and to gain fur-
ther insights into the involvement of the biological aspects under study in the
acquisition of oocyte competence.
Wider implications of the ﬁndings: Our results suggest that the nuclear
localization of pERK1/2 coupled to an enhanced intracellular accumulation of
pAKT may play an anti-apoptotic role and increase cell viability thereby provid-
ing a novel marker tool to facilitate the choice of the best oocyte to be fertilized
and submitted to an ICSI cycle.
Trial registration number: The trial is an observational study and no regis-
tration is needed.
P-162 Degree of blastocoel re-expansion is the single most
determinant factor for enhanced live birth rates in vitriﬁed-warmed
single blastocyst transfer cycles
N. Shaikh1, B. Chimote2, N. Chimote3
1Vaunshdhara Clinic and Assisted Conception Center, Biochemistry- Embryology and
Endocrinology, Nagpur, India
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2Vaunshdhara Clinic and Assisted Conception Center, Embryology- Reproductive
Endocrinology- Biochemistry, Nagpur, India
3Vaunshdhara Clinic and Assisted Conception Center, Embryology and Reproductive
Endocrinology, Nagpur, India
Study question: To evaluate the independent effects of Inner-cell-mass
(ICM), trophectoderm (TE), and degree of blastocoel re-expansion on live-
birth rate in vitriﬁed/ warmed single blastocyst transfer cycles.
Summary answer: Re-expansion of blastocoel with degree of 3-4 is imperi-
ous to ICM and TE cell gradation for better live-birth rates in vitriﬁed-warmed
single blastocyst transfer cycles.
What is known already: The relevance of blastocoel expansion for clinical
outcomes in blastocyst transfer cycles has been documented. However recent
studies have presented contradictory results regarding signiﬁcance of ICM grad-
ation, TE gradation and degree of blastocoel expansion/re-expansion for
increased live-birth rates in fresh as well as vitriﬁed-warmed blastocyst transfer
cycles. There is no consensus yet on which of these is the most signiﬁcant pre-
dictor for live-birth. Moreover, few studies have reported combined results
from fresh/frozen and single/double transfer cycles. Therefore, we aimed at
verifying the relevance of each of these three parameters in predicting live-birth
rates exclusively in vitriﬁed-warmed cycles involving single-blastocyst transfer.
Study design, size, duration: Retrospective study of vitriﬁed-warmed cycles
involving women (n = 216) undergoing elective / non elective single blastocyst
transfer from February 2014 to November 2016 at our private ART centre.
Oocyte donation, Embryo-donation, assisted hatching and preimplantation gen-
etic diagnosis cycles were excluded. Ethics Committee of the centre approved
this retrospective study. All blastocysts were graded as per Gardner and
Schoolcraft method of classiﬁcation as 1-6 for degree of expansion and grades
A/B/C for ICM and TE.
Participants/materials, setting, methods: Natural-cycle endometrial
preparation was done with hormone supplementation followed by luteal-phase
support with micronized progesterone. Endometrial response (thickness and
homogeneity) was noted by ultrasound. Elective/non-elective single blastocyst-
transfer was done 3 hours after warming of vitriﬁed blastocyst. Warmed blasto-
cyst was compared with pre-vitriﬁed blastocyst for degree of expansion, grad-
ation of ICM/TE. β-hCG level measured on day8 of transfer indicated
pregnancy. Positive cardiac activity at sixth week conﬁrmed clinical pregnancy.
Live-birth was the primary outcome measure.
Main results and the role of chance: Women were classiﬁed into Live-
birth (LB; n = 74) and non-pregnant (NP; n = 142) groups. Age, BMI, infertility
period as well as number of oocytes retrieved, rate of formation of good quality
cleavage-stage and blastocyst-stage embryos and survival rates post-warming
did not differ signiﬁcantly between the two groups. Same brand of embryo-
transfer catheter and same brand and volume of media was used for transfer.
However, the degree of re-expansion was signiﬁcantly higher in LB group than
in NP group (Mean ± SD: 3.6 ± 1.0 v 3.2 ± 0.94, P = 0.0068). The Fisher-Exact
test odds ratio for achieving a live-birth with 3-4 degree of re-expansion was
2.78 (p = 0.0016) whereas the odds ratio was much lower (0.36) with any
other degree of re-expansion. Although ICM grade was higher/better in Live-
birth group than in non-pregnant group, the difference remained statistically
non-signiﬁcant (Odds ratio 1.25, p = 0.82). No signiﬁcant difference was
observed in the TE grades between the two study groups (p = 0.17). A notable
difference was also observed in the endometrial echopattern (p = 0.03)
although the endometrial thickness remained comparable between the two
groups. Thus, post-warming degree of re-expansion is the single most promising
predictive factor for live birth rates in such cycles.
Limitations, reasons for caution: Although the results are promising, this is
a retrospective study with a relatively small sample size. A multicentric/rando-
mized trial with much larger sample size is essential to generate a strong power
for degree of re-expansion to be predictive of live-birth.
Wider implications of the ﬁndings: A good experimental design catering
exclusively to vitriﬁed-warmed cycles involving single blastocyst transfer is a
strong point of this study. Therefore, even a relatively small sample size leaves
no ambiguity regarding the signiﬁcance of selection of best blastocyst on the
basis of degree of re-expansion in predicting live birth rates.
Trial registration number:Not Applicable.
P-163 Morphokinetic analysis of euploid blastocysts: searching for
non-invasive criteria of embryo implantation additional to
chromosomal assessment
R. Maggiulli1, M. Stoppa1, D. Cimadomo1, G. Fabozzi1, A. GIancani1,
L. Dovere1, L. Albricci1, A. Capalbo2, F.M. Ubaldi1, L. Rienzi1
1Clinica Valle Giulia, GENERA centers for reproductive medicine, Rome, Italy
2Igenomix, Italia, Marostica, Italy
Study question: Can we deﬁne any morphokinetic parameter able to
increase our predictive power upon implantation potential of euploid blasto-
cysts cultured in time-lapse?
Summary answer: Blastomeres’ symmetry at 4 cell-stage and blastocyst
morphological quality after full-expansion were signiﬁcantly correlated with the
implantation of euploid blastocysts.
What is known already: To date, the assessment of a normal chromosomal
constitution through comprehensive-chromosome-testing techniques repre-
sents a powerful predictive parameter upon blastocyst’s reproductive potential.
However, ≈50% of euploid blastocysts fail to implant.
The study of preimplantation embryonic development, via morphokinetic
parameters in time-lapse, do not provide to date solid evidence of correlation
with the clinical outcomes after IVF. Although, the additional predictive value of
morphokinetic in preimplantation-genetic-testing (PGT-A) cycles conducted in
time-lapse is yet to be assessed.
Study design, size, duration: Retrospective exploratory study. All trans-
ferred euploid blastocysts obtained after consecutive PGT-A cycles conducted
in a time-lapse system between March 2014-March 2017 were included (n =
320). All morphokinetic parameters of embryo evaluation were compared
among implanted and not implanted euploid blastocysts. Logistic regression
analyses and receiver operating curve (ROC) analysis were conducted. Power
calculations for signiﬁcant differences were performed with the software
G*Power v3.1.
Participants/materials, setting, methods: 130 implanted and 190 not
implanted euploid blastocysts were included and confronted for the following
timings: tPB2(2ndPolar-Body extrusion), tPNf (pronuclei formation), t2,t3,t4,t5,
t8 (2-,3-,4-,5- and 8-cell division), cc1(t3-t2), cc2(t4-t3), cc3(t5-t4), tM(mor-
ula), tSB(starting-blastulation), tB(full-expansion). Furthermore, blastomeres’
symmetry and fragmentation at t4, and blastocyst’s quality at tB were evaluated
and blindly-conﬁrmed by two independent operators. The results were cor-
rected through univariable and multivariable logistic regression analyses for all
putative confounders including maternal age.
Main results and the role of chance: Signiﬁcant differences were reported
between implanted and not implanted euploid blastocysts for cc2 (1.3 ±
2.3 h,0-12.6 h versus 2.5 h±4.3 h,0-26.5 h, p<0.01), cc3 (12.4 ± 5.2 h,0.3-
45.5 h versus 10.7 ± 6.5 h,0-43.4 h, p = 0.02) and tM (88.7 ± 10.5 h,66.9-
121.7 h versus 91.4 ± 10.0 h,61.3-123.1 h, p = 0.03). Furthermore, low-
fragmentation (<10%; n = 111/243, 45.7%) at t4 resulted in higher ongoing
implantation rates after euploid blastocyst transfer than high-fragmentation
(≥10%; n = 9/77,24.7%; p<0.01 and power = 92%). Similarly, even blasto-
meres’ symmetry (n = 114/241, 47.3%) at t4 resulted into a better reproduct-
ive outcome than uneven one (n = 16/79,20.3%; p<0.01 and power>99%). At
last, blastocysts’ quality at tB was also correlated with a positive ongoing
implantation (excellent: n = 86/184,46.7%; good: n = 21/49,42.9%; average:
n = 17/51,33.3% and poor: n = 6/36,16.7%; p<0.01 and power = 95%). The
univariable logistic regressions conﬁrmed these data. Conversely, the multivari-
able logistic model outlined only blastomeres’ symmetry (even/uneven, OR =
0.36, 95%CI:0.19-0.67; p<0.01) and blastocyst’s quality (excellent/good/aver-
age/poor, OR = 0.77, 95%CI:0.61-0.98; p = 0.04) as predictive of implantation
success/failure. The ROC curve analysis deﬁned an area under the curve
(AUC) for this model of 0.65, 95%CI:0.60-0.71, p<0.01.
Limitations, reasons for caution: The main limitations of this study are its
retrospective nature and the subjectivity of blastomeres’ symmetry deﬁnition at
t4. Possibly, these data should be conﬁrmed through a computational/mathem-
atical assessment. Moreover, the extension of the sample size may allow the
evaluation also of anomalous patterns of development, such as direct/reverse
cleavage.
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Wider implications of the ﬁndings: A model including blastomeres’ sym-
metry at 4cell-stage and blastocyst’s quality at full-blastulation may
represent a valuable selection tool to predict euploid blastocysts’ repro-
ductive competence for any PGT-A cycle, regardless the adoption of a
time-lapse system. Nonetheless, these data should be conﬁrmed from a
prospective study.
Trial registration number:None.
P-164 Does embryonic culture environment affect ploidy rates
R. Ahmed-Odia1, E. Drew1, H. Exeter1, X. Vinals-Gonzalez1,
W. Saab2, P. Serhal2, V. Seshadri2
1Center for Reproductive and Genetic Health CRGH, Embryology, London, United
Kingdom
2Center for Reproductive and Genetic Health CRGH, Clinician, London, United
Kingdom
Study question: Does culture condition affect the chances of detection of an
euploid embryo in a benchtop incubator (BT) compared to Time lapse moni-
toring incubator (TLM)?
Summary answer: This study demonstrates that uninterrupted controlled
culture environment (TLM) has an increased probability of detection of an
euploid embryo in a PGT-A cycle.
What is known already: Most aneuploidies are meiotic in origin and mater-
nal age related. Aneuploidies do not always impair embryo development and
blastocyst formation can be achieved. Studies suggest several factors may
adversely affect the incidence of chromosomal anomalies. Additionally, environ-
ment is known to affect outcome through epigenetic modulation. A recent
study concluded that the incidence of mosaicism and euploid rates differed
amongst labs, thought to be due to screening methods, culture conditions and
biopsy stage and unknown indication for PGT-A. Our study explores the poten-
tial impact of culture environment on ploidy, evaluated by comparing two differ-
ent incubator types in the same laboratory.
Study design, size, duration: Retrospective single centre cohort study, a
total of 732 blastocysts were biopsied on D5/6 between May 2017 to
December 2017. The genetic testing was performed using Next Generation
Sequencing Technique (NGS) at a single reference centre (cooperge-
nomics-UK). The euploid rate in embryos cultured in BT incubator, inter-
rupted single-step medium (n = 349 blastocysts) vs those cultured in a TLM
incubator, uninterrupted single-step medium (n = 383 blastocysts) were
compared.
Participants/materials, setting, methods: Patients undergoing PGT-A
cycle with at least two failed previous IVF attempts, advanced maternal age,
recurrent miscarriage, or previous aneuploidy pregnancy. Study was con-
ducted at a single centre IVF unit CRGH London. The average female age
was 38.1 ± 4.3. Post ICSI, oocytes were either cultured in a BT incubator or
TLM incubator. Trophectoderm biopsy was performed on D5/6 removing
between 6-8 cells. The ploidy rates were subsequently compared between
groups.
Main results and the role of chance: Age was normally distributed and
comparable (p = 0.229) in both incubators. Fertilisation rate in the TLM was
signiﬁcantly higher (77 ± 17.3 vs 71 ± 14.9, p = 0.047) when compared to the
BT Incubator. The blastulation rate was signiﬁcantly higher in the TLM group
versus BT group (64.8 ± 36.5 vs 63.4 ± 36.1, p = 0.000) respectively. The
Euploid rate obtained from both groups showed a higher proportion of euploid
embryos in the TLM incubator 25.5% (98/383) compared to those cultured in
the BT incubator 20.6% (72/349) (p = 0.04).
Limitations, reasons for caution: Further PGT-A cycles resulting in
increased number of biopsied blastocysts to be evaluated in a different centre
to observe this ﬁndings in both culture environment.
Wider implications of the ﬁndings: First single centre study to directly
compare euploid rates in two different culture conditions. Studying the algo-
rithm patterns in euploid embryos could provide the means for non-invasive
PGT-A screening. Further evaluate how culture conditions at a cellular level
could affect epigenetic mechanism in embryo/s resulting in a higher aneuploid
rate.
Trial registration number: not applicable.
P-165 The effects of 2-APB on the intracellular calcium
concentration and ultra structure damage of vitriﬁcation oocyte
C. Junping1, X.Wang2, Y. Xue2, W. Tan1, B. He1, X. Mao1, J. Qin1
1The People’s Hospital of Guangxi Zhuang Autonomous Region, The Center of
Human Assisted Reproduction, Nanning, China
2Guangxi University, The department of animal’s science and technology, Nanning,
China
Study question: Can the change of calcium concentration of oocyte induced
by cryoprotectant be regulated to reduce the damages of ultra structures?
Summary answer: IP3 receptor inhibitor 2-APB can effectively inhibit the
increase of calcium concentration of oocytes and relieve the damages induced
by freezing.
What is known already: Vitriﬁcation can effectively preserve human oocytes
with high survival rate about 90-95%,Which was accompanied by compromised
developmental potential and ultra structure damage of oocyte induced by cryo-
protectants and low temperature. The increase of intracellular calcium concen-
tration of oocyte induced by cryoprotectants was supposed mediating the
injury happening in oocyte cryopreseving process. 2-APB which was known as
IP3 receptor inhibitor can effectively inhibit calcium releasing from intracellular
calcium store of endoplasmic reticulum for many different non excitatory cells.
Study design, size, duration: More than 500 cumulus-oocyte-complexes
(COCs) were collected from 15 mice. The total of 478 MII oocytes with ﬁrst
polar body and normal morphology was used in subsequent calcium detection,
vitriﬁcation and ultra structure analysis. The oocytes derived from the same
mouse were allocated into 3 different groups at random: control, croprotectant
without or with 2-APB. 60 oocytes were used for calcium labeling and other
oocytes were vitriﬁed and thawed with different treatment for subsequent
analysis.
Participants/materials, setting, methods: A Total of 15 mice and 478
oocytes was included in present study. The oocytes were divided into 3 groups
at random: control, croprotectant without or with 2-APB, in which the oocytes
were treated with culture medium, cryoprotectants, and cryoprotectants with
0.1umol/l 2-APB respectively, following with analysis of intracellular calcium
concentration by laser scan confocal microscope, ultra structures of freeze-
thawing oocytes by transmission electron microscope.
Main results and the role of chance: Exploring the calcium transients
demonstrated that cryoprotectant(n = 15) induced instantaneous increasing of
Ca2 + in oocyte, and the concentration at steady state was also higher than that
of fresh oocyte in control group(n = 15)(123.59 ± 4.73 vs.94.75 ± 3.54)
(P<0.05); However the 2-APB treatment (n = 15) can effectively stabilize cal-
cium level, the calcium transient peak and steady-state levels were lower than
that cryoprotectants induced, and the concentration of calcium at steady-state
was similar with that of the control group(92.76 ± 4 .22 vs.94.75 ± 3.54)
(P>0.05). Undergoing freezing,the calcium concentration of 2-APB group was
lower than that without 2-APB group(122.21 ± 4.33 vs.139.70 ± 6.00)
(P<0.05). Examination by transmission electron microscope indicated that
microvilli shortened and deﬁciency, cortical granule reduced in the cortex area
in cryoprotectant, mitochondrial swelled, intermediate ﬁlament disassembled,
edge of lipid drop blured, and a large number of vacuoles in matrix formed in
vitriﬁcation group without 2-APB comparing with that in control group.
Treatment with 2-APB relieved the injuries of the microvilli, cortical granule,
mitochondria and lipid drops etc, which was partly resulted by vitriﬁcation. But
the damages were still severer than that of control group.
Limitations, reasons for caution: More studies are needed to evaluate the
developmental potential of oocytes treated by IP3 receptor inhibitor.
Wider implications of the ﬁndings: Our ﬁndings suggest a possibility to
relieve the oocyte injuries induced by cryoprotectant and low temperature for
oocytes which undergo cryopreservation.
Trial registration number: n/a.
P-166 High pressure freezing: A potential method for improving
oocyte cryopreservation
K. Reader1, J. Juengel2, D. Morbeck3
1University of Otago, Department of Anatomy, Dunedin, New Zealand
2AgResearch, Reproduction, Mosgiel, New Zealand
i217Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
3Fertility Associates, Department of Obstetrics and Gynaecology, Auckland, New
Zealand
Study question: Do oocytes frozen under high pressure survive and exhibit
better ultrastructural preservation than those frozen by standard vitriﬁcation
methods?
Summary answer:Oocytes frozen under high pressure have improved ultra-
structural preservation and survive freezing if cryoprotectants are used.
What is known already: Current vitriﬁcation methods are able to pre-
serve oocyte viability but cause molecular and structural changes to both
the nuclear and cytoplasmic compartments, which may compromise quality.
Cortical granule release can occur during the cryopreservation process
causing premature hardening of the zona pellucida (ZP) and necessitating
the use of ICSI. High pressure freezing (HPF) is known to provide superior
ultrastructural preservation, and potentially improved molecular preservation
of cells. Some cell types survive this process. However, it is not known
whether high pressure freezing can be used to preserve viability of oocytes
or embryos.
Study design, size, duration: Grade 1 or 2 immature cumulus-oocyte com-
plexes (COC) were collected from adult sheep ovaries. Groups of 16 to 24
COC or in vitro matured oocytes (MO) underwent HPF or vitriﬁcation, with or
without cryoprotectants (CP) and were stored in liquid nitrogen for a minimum
of one week. Three frozen oocytes from each group were examined by trans-
mission electron microscopy following freeze substitution, embedding and sec-
tioning. Thawed oocytes were matured, fertilised and cultured.
Participants/materials, setting, methods: COC and MO were frozen and
thawed either without CP in H199 with 10% FBS or with CP as follows.
Oocytes were equilibrated in base medium (H199 with 20% FBS; BM) with
7.5% each DMSO and ethylene glycol (5 to 15 min), then frozen within 60 sec
in BM with 0.5 M sucrose and 15% each DMSO and ethylene glycol. Oocytes
were thawed in BM with 1 M sucrose (1 min) then 0.5 M sucrose (3 min) and
BM (5 min).
Main results and the role of chance: None of the HPF oocytes, without
CP, survived thawing. However, the ultrastructure of these oocytes, following
freeze substitution, was superior to those HPF or vitriﬁed with CP, and conven-
tionally ﬁxed oocytes. 44% of the HPF and 21% of the vitriﬁed COC, and 50%
of the HPF and 43% of the vitriﬁed MO underwent cleavage following IVF,
though numbers were too low to perform meaningful statistics. None devel-
oped to morula stage. Oocytes vitriﬁed with CP all had irregularly structured
ZP containing pores of variable size. Oocytes frozen with HPF and CP had
superior ultrastructural preservation of the ZP, with four out of the 6 oocytes
examined having ZP with a uniform structure and no pores.
Limitations, reasons for caution: This was a pilot study to assess the
potential of HPF for oocyte cryopreservation and low numbers of oocytes
were examined. Polyspermy was not assessed in the fertilised oocytes.
Wider implications of the ﬁndings: High pressure freezing appears to pro-
vide improved ultrastructural preservation, particularly of the ZP, which may
avoid the need for ICSI. The use of ICSI bypasses natural sperm selection pro-
cesses and may also be associated with an increase in epigenetic defects in the
resulting embryo.
Trial registration number:Not applicable.
P-167 Let-7bmicroRNAmodulates attachment of trophoblastic
cells and integrin β3 expression of endometrial cells
J. Kim1, Y.E. Lee2, Y.J. Choi3, J.E. Park2, E. Kim1, J.W. Lee4, J.H. Jun2
1Fertility Center of CHA Bundang Medical Center, Laboratory of Reproductive
Medicine, Seongnam-si, Korea- South
2Graduated School- Eulji University, Dept. of Senior Healthcare- BK21 Plus Program,
Seongnam-si, Korea- South
3Graduate School- Eulji University, Dept. of Senior Healthcare- BK21 Plus Program,
Seongnam-si, Korea- South
4Eulji University, Dept. of Biomedical Laboratory Science, Seongnam-si, Korea- South
Study question: Does let-7b microRNA (miRNA) modulate attachment of
trophoblastic cells and expression of integrin (ITG) family in endometrial cells?
Summary answer: Transfection of let-7b miRNA inhibitor decreases the
attachment of trophoblastic spheroids, whereas transfection of let-7b miRNA
mimic increases the expression of ITG-B3 in endometrial cells.
What is known already: Several miRNAs are known to be involved in regu-
lating the implantation process, there is incomplete understanding of how let-7
family controls implantation. Expression of let-7b miRNA was signiﬁcantly
increased in outgrowth and peri-implantation embryos compared to pre-
implantation embryos. ITG family expression levels in uterine biopsy samples
suggested as a biomarker for evaluating uterine receptivity and determining the
optimal time for embryo transfer. The ITG is an important molecule involved in
attachment and invasion of trophoblasts and endometrial cells.
Study design, size, duration: Our previous studies have focused on the
expression and function of let-7 family in blastocysts, outgrowth embryos and
endometrial cells for successful implantation. This study was performed to
evaluate the regulatory function of let-7b miRNA in human trophoblastic JAr
cells and endometrial Ishikawa and ECC-1 cells.
Participants/materials, setting, methods: The expression proﬁle of let-
7b was clariﬁed in a series of developing mouse embryos, and the target gene
was conﬁrmed by bioinformatics. Inhibitor or mimic of let-7b miRNA was trans-
fected into human trophoblastic and endometrial cells, respectively. To investi-
gate the effects of the let-7b on attachment and implantation process,
transfected trophoblastic spheroids were co-cultured on endometrial cells.
Expression patterns of integrin family after transfection of miRNAs were evalu-
ated by immunoblot analysis in endometrial cells.
Main results and the role of chance: Expression of let-7b miRNA was sig-
niﬁcantly increased in outgrowth embryos on 7.5 days post coitum compared
to pre-implantation embryos. When let-7b inhibitors were transfected into
trophoblastic JAr cells, attachment rate of trophoblast spheroids onto endo-
metrial cells was signiﬁcantly decreased in both Ishikawa and ECC-1 cells. We
found that ITG-B3 could be directly targeted by let-7b miRNA by in silico ana-
lysis. There were no signiﬁcant differences of ITG-B4 and ITG-A5 expression
after transfection of let-7b inhibitor and mimic transfection in endometrial cells.
However, expression of ITGB3 was upregulated when mimic let-7b miRNA
was transfected into Ishikawa endometrial cells.
Limitations, reasons for caution: Functional approaches were carried out
by analyzing transient expressions of transfected microRNA modulators using
in vitro model. The consequence of the let-7b miRNA on implantation process
still remains to be determined in physiological in vivo model. Other target genes
of let-7b in embryo implantation should be further elucidated.
Wider implications of the ﬁndings: Our ﬁndings indicate that the let-7b
miRNA plays an important role in embryo implantation as a regulator of ITG-B3
expression. These results could provide a valuable understanding of the regulation
involved in the miRNA-mediated implantation between trophoblastic and endo-
metrial cells. It could subsequently improve outcome in human ART program.
Trial registration number:Not applicable.
P-168 Reproductive outcomes after vitriﬁcation of oocytes
generated from human chorionic gonadotropin (hCG)-primed
in vitro maturation cycles
Y. Cohen1,2, A. St-Onge-St-Hilaire1, S. Tannus1, G. Younes1,
M. Dahan1, W. Buckett1, W.Y. Son1
1Reproductive Centre. McGill University Health Centre, Obstetrics and Gynecology,
Montreal, Canada
2Tel Aviv Sourasky Medical Center, Obstetrics and Gynecology, Tel Aviv, Israel
Study question: What is the effect of cryopreservation of oocytes that
matured in vitro (vIVM) on reproductive outcomes compared to fresh in vitro
maturation (fIVM) cycles?
Summary answer: Lower fertilization, embryo cleavage and good embryo
rates were found in vIVM cycles. Live birth rates were signiﬁcantly lower in
vIVM compared to fIVM.
What is known already: Although two successful live births and one ongoing
pregnancy from cancer survivors were reported after cryopreservation of IVM
embryos obtained, there is no report of a live birth from the cryopreservation
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of oocytes produced by IVM of immature oocytes for cancer patients. In previ-
ous studies, lower reproductive potentials were found in vIVM cycles compared
to oocyte vitriﬁcation in IVF cycles.
Study design, size, duration: This is a retrospective cohort study conducted
at a university hospital afﬁliated IVF unit. Fifty-six cycles of vIVM and 263 fIVM
cycles in women diagnosed with polycystic ovarian syndrome ovaries (PCOS)
were included in the analysis. All women underwent a human chorionic gona-
dotropins (hCG) primed IVM cycle.
Participants/materials, setting, methods: The study group included
PCOS patients who failed ovulation induction with intrauterine insemination
and were offered IVM cycle followed by oocyte vitriﬁcation and warming. The
embryological aspects and clinical outcomes of vitriﬁcation/warming were com-
pared to controls undergoing fresh IVM cycles during the same period. The
main outcome measure was the live birth rate.
Main results and the role of chance: From 1070 oocytes that were col-
lected (56 patients) a total of 68 MII and 1,002 GV oocytes were retrieved;
645 oocytes (64.4%) matured in vitro and underwent vitriﬁcation/warming.
In the fIVM group, 485 MII and 4,296 GV oocytes were retrieved; 2,630
(61.2%) matured to MII. Survival rate after warming was 59.8% (416/713).
Fertilization and embryo cleavage rates per oocyte were signiﬁcantly lower
in the vIVM. Clinical pregnancy (10.7% vs. 36.1%) and live birth rates (8.9%
vs. 25.9%) per cycle were signiﬁcantly lower in the vIVM group than in the
fIVM group (P = 0.005 and P<0.001, respectively). Five healthy singleton
babies were born in the vIVM group, and 80 babies including 18 twins and
1 triplet were born following fIVM cycle. Furthermore, the association
between live birth and vitriﬁcation, age, number of in vitro matured
oocytes, AFC and number of embryo transferred was analyzed using a
stepwise logistic regression analysis. Vitriﬁcation of IVM oocytes was asso-
ciated with a lower likelihood of a live birth (adjusted odds ratio, 0.3 95%
conﬁdence interval 0.1 to 0.7).
In our fertility preservation program, 6 cancer survivors underwent a transfer
of embryos from vitriﬁed IVM oocytes that resulted in 2 chemical pregnancies.
Limitations, reasons for caution: The retrospective nature of this study.
Wider implications of the ﬁndings: Our results suggest that although vitri-
ﬁcation of IVM oocytes is an alternative for women who cannot pursue IVF
oocyte vitriﬁcation for fertility preservation, the reproductive potential of these
oocytes is impaired.
Trial registration number:NA.
P-169 A new approach to reduce thermal and oxidative stress
during vitriﬁcation procedure
M. Dashtizad1, P. Kazemi2, F. Sarmadi1, S. Fayazi1, E. Hashemi1,
S. Molaeiyan1
1National Institute of Genetic Engineering and Biotechnology, Department of Animal
Biotechnology, Tehran, Iran
2Mcgill University, Biology, Montreal, Canada
Study question: Determine whether suspended graphene can be used
instead of sucrose to reach higher thermal conductivity while maintaining the
efﬁciency of vitriﬁcation solution.
Summary answer: Graphene can be proposed as a conductive cryoprotect-
ant, leading to a more moderate expression of apoptosis, oxidative and thermal
stress-related genes.
What is known already: The most effective characteristic of vitriﬁcation is
high cooling/warming rate, which helps to reduce ice crystal formation and cel-
lular damage. In recent years, the ultra-rapid cooling rate has been achieved
using small volumes of vitriﬁcation solution along with various cryodevices.
However, the heat conductivity of vitriﬁcation solutions as an effective param-
eter on the cooling/warming rate has received less attention.
Study design, size, duration: To determine the optimal concentration of
graphene, 100 blastocysts in each group were vitriﬁed using different graphene-
based solutions (vitriﬁcation solution: 0.5, 1, 1.5, 3, 7 M; thawing solution: 2, 3,
4 M; dilution solution: 1, 1.5, 2 M), evaluated in terms of survival and hatching
rate. The optimal solution was then compared with sucrose-based one in order
to analyze all the aspects described below.
Participants/materials, setting, methods: In vivo produced mouse blas-
tocysts were vitriﬁed using Cryotop as described by Kuwayama (Kuwayama
et al., 2005), with slight modiﬁcations. After 12 h, vitriﬁed blastocysts were
compared with fresh blastocysts in terms of survival, hatching and implant-
ation rate, cellular peroxide levels and expression level of genes related to
thermotolerance (Hspa1a) oxidative stress (Sod1, Sod2) and apoptosis
(Trp53, Bax, Bcl2).
Main results and the role of chance: The optimum concentrations of 1.5,
2 and 4 M were ﬁrst selected for vitriﬁcation, thawing and dilution solutions,
respectively. According to our results, natural honey as a cryoprotectant could
be as efﬁcient as sucrose in terms of survival, hatching and implantation rate.
The real-time RT-PCR analysis also revealed a reduction in the expression of
Hspa1a, Sod1, Sod2 and Trp53 transcripts in the graphene group compared to
the sucrose group; the abundance of Bax and Bcl2, however, did not change.
Furthermore, there was a lower cellular peroxide level in the graphene-based
group compared with sucrose-based one.
Limitations, reasons for caution: Further studies are necessary to evaluate
development-related genes expression and live birth rate in blastocysts vitriﬁed
using graphene-based solution to assess long-term safety outcomes.
Wider implications of the ﬁndings: Our ﬁndings highlight the importance
of heat conductivity of vitriﬁcation solutions, demonstrating that graphene can
act as a cryoprotectant as well as a heat transfer agent.
Trial registration number:None.
P-170 Effects of resveratrol, GM-CSF, and DCA on the
development of embryos in agedmice
K.M. Juhn1, J. Yoon1, E.H. Jung1, H.J. Park1, H.Y. Choi2, J.Y. Kim2,
C.Y. Hur2, S.H. Yoon1, J.H. Lim2
1Maria Fertility Hospital, Maria research center, Seoul, Korea- South
2Maria Fertility Hospital, Maria Fertility Hospital, Seoul, Korea- South
Study question: To determine whether supplementation of culture media
with resveratrol, GM-CSF, and DCA inﬂuence embryo development and preg-
nancy rates in aged mice.
Summary answer: Resveratrol signiﬁcantly increased pregnancy and implant-
ation rates even though there were no differences in fertilization and develop-
ment rates.
What is known already: Major implications of older patients are low fertil-
ization rate, poor embryonic development, and increased rate of chromosomal
aberrations, which leads to an increased miscarriage and aneuploidy. It is asso-
ciated with several molecular mechanisms contributing to ovarian aging such as
alterations in gene expression and mitochondrial dysfunction. There were some
reports that resveratrol has a positive effect on embryo development through
improving mitochondria function. Moreover, addition of dichloroacetic acid
(DCA) to culture media improved blastocyst development and mitochondrial
output in embryos produced from aged mice. Granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) had signiﬁcant effect on ongoing implantation
rate in women with previous miscarriage.
Study design, size, duration: BD F1 female mice at 58-62 weeks of age
were used for this study. MII oocytes obtained by super-ovulating mice were
fertilized and cultured in MRC media with or without resveratrol (0.5 uM), GM-
CSF (2 ng/ml), and DCA (1.0 mM). Blastocysts from each group were trans-
ferred into 2.5 days post-coitum (dpc) pseudo-pregnancy ICR mice using non-
surgical embryo-transfer device.
Participants/materials, setting, methods: Fertilization and embryo devel-
opment rates were monitored. To assess pregnancy and implantation rates,
expanded or hatching blastocysts from each groups were transferred into
pseudo-pregnant ICR mice. The pregnancy rate was measured as the number
of pregnant mice as a proportion of the total transfer mice. Implantation rates
were calculated as the number of live pups as a proportion of the total number
of embryos transferred.
Main results and the role of chance: A total of 673 MII oocytes were ferti-
lized in vitro (control: 186; Resveratrol: 177; GM-CSF: 158; DCA: 152). There
were no statistically differences in fertilization rates among groups (control:
94.6%; Resveratrol: 97.2%; GM-CSF: 96.2%; DCA: 97.4%, respectively). The
addition of resveratrol, GM-CSF, and DCA (92.4%, 92.1%, and 95.9%,
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respectively) tended to increase the blastocyst rate, but only DCA group was
signiﬁcantly higher than control group (86.9%, P<0.05). After blastocyst transfer
to recipient females, there was no signiﬁcant increase in pregnancy and implant-
ation rates when embryos were fertilized and cultured in the presence of GM-
CSF (50.0% and 22.3%) and DCA (53.8% and 16.7%) as compare to the control
(52.6% and 19.2%). However, supplement of resveratrol signiﬁcantly increased
pregnancy and implantation rates (75.0% and 33.8%) compared to the other
three groups (P<0.05).
Limitations, reasons for caution: In this study, only development and preg-
nancy rates were measured in order to examine the effect of each factor in
aged mice. Further investigations on the mechanism are needed to conﬁrm the
effect of each factor.
Wider implications of the ﬁndings: Resveratrol added to the media
enhanced pregnancy and implantation rates, although there was no difference
in fertilization and blastocyst rates. It suggests that the addition of resveratrol to
embryo culture media for patient with advanced maternal age may potentially
increase IVF outcomes.
Trial registration number:None.
P-171 Effect of resveratrol supplement during in vitro culture on
the mitochondrial membrane potential and histone acetylation of
embryos from agedmice
J. Yoon1, K.M. Juhn1, E.H. Jung1, H.J. Park1, H.Y. Choi2, J.Y. Kim2,
C.Y. Hur2, S.H. Yoon1, J.H. Lim2
1Maria Fertility Hospital, Maria Research Center, Seoul, Korea- South
2Maria Fertility Hospital, Maria Fertility Hospital, Seoul, Korea- South
Study question: Does resveratrol supplementation of culture media affect
mitochondrial membrane potential and histone acetylation of embryos from
aged mice?
Summary answer: The addition of resveratrol to embryo culture media
improves mitochondrial membrane potential and inhibits abnormal histone
acetylation of embryos from aged mice.
What is known already: Advanced maternal age affects the quality of
oocytes and blastocysts. Reproductive aging pathologies are frequently asso-
ciated with mitochondrial dysfunction and gene expression of histone deacety-
lase, which may be involved in the process of epigenetic modiﬁcation. There
were some reports that resveratrol has the ability to prevent age-related dis-
eases by improving mitochondria function. In addition, resveratrol activates sir-
tuin 1 (SIRT1), an NAD+-dependent histone-deacetylase, which is able to
remove the acetyl group from histone H4 at lysine 12 (H4K12) in somatic cell.
It was reported that level of H4K12 acetylation in oocytes increased during the
aging process in human and mouse.
Study design, size, duration: BD F1 female mice at 58-62 weeks of age
were used for this study. As a control, 6-8 weeks old female mice were used
for young group. MII oocytes obtained by super-ovulating mice were fertilized
and cultured in MRC media with or without resveratrol (0.5 uM). Their embry-
onic development rates were monitored. On the other hand, mitochondrial
membrane potential and level of histone acetylation were examined at different
developmental stages (2-cell, 4-cell, morula, and blastocyst).
Participants/materials, setting, methods: Mitochondrial membrane
potential throughout the pre-implantation embryo development was analyzed
by 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl-carbocynanine iod-
ide (JC-1) staining. The acetylation pattern of H4K12 was examined by
immunoﬂuorescence staining using an anti-acetylated H4K12 antibody.
Main results and the role of chance: Fertilization rates were no statistically
differences among three groups (Young: 98.1%, Old: 94.6%, Old-res: 97.2%,
respectively). However, blastocyst rate in young group (99.4%) was signiﬁcantly
higher than that in old group (86.9%) (P<0.05). The addition of resveratrol
(Old-res group) increased the blastocyst rate (92.4%), but there was no statis-
tical differences compared to the other two groups. The average mitochondrial
membrane potential in young group was higher than that in old groups, but
there was a statistical signiﬁcant difference at 2-cell and 4-cell stages (P<0.05).
Resveratrol supplement increased the level of mitochondrial membrane poten-
tial throughout the stages of pre-implantation embryo in aged mice. These
increases were signiﬁcantly greater than either young or old groups (P<0.05).
The acetylation levels of H4K12 were examined and compared among three
groups. Immunocytochemistry with speciﬁc antibody against AcH4K12 showed
that the ﬂuorescence signal was statistically higher in old group than in young
group throughout the pre-implantation embryo development. The acetylation
levels of H4K12 tended to decrease with the addition of resveratrol and it was
statistically signiﬁcant only at the 4-cell stage.
Limitations, reasons for caution: In the preliminary study, 0.5 uM resvera-
trol enhanced embryo development and mitochondrial membrane potential of
embryos from aged mice. Therefore, 0.5 uM resveratrol was used in this
experiment. However, the dose of resveratrol should be determined carefully
because the appropriate dosage reported by researchers were varied.
Wider implications of the ﬁndings: Poor development of embryo in aged
mice was associated with mitochondrial dysfunction and abnormal histone
acetylation. In addition, resveratrol added to the media may result in an
improvement of mitochondria membrane potential and stabilization of histone
acetylation. Addition of resveratrol to culture media for aged women may
increase IVF outcomes.
Trial registration number:None.
P-172 Embryo culture medium based on the composition of
human oviductal ﬂuid contributes to improving the viability of
mouse embryos
T. Yao1, Y. Asayama1, Y. Sugiyama1, Y. Kumasako2, T. Utsunomiya3
1Fuso Pharmaceutical Industries- Ltd., Research and Development Center, Osaka,
Japan
2St. Luke Clinic, IVF Labolatory, Oita, Japan
3St. Luke Clinic, Dept. of Ob/Gyn, Oita, Japan
Study question: Does a culture medium reﬂecting the inorganic salts, carbo-
hydrates, organic acids, and amino acid concentrations of human oviductal ﬂuid
improve the viability of mouse embryos?
Summary answer: Embryo culture media based on human oviductal ﬂuid
composition with modiﬁed potassium and phosphate concentrations improve
the hatching rate and cell numbers of mouse blastocysts.
What is known already: Commercially available HTF medium based on six
components of human oviductal ﬂuid and sequential media based on three
components of human oviductal/uterine ﬂuid have been used clinically in
human assisted reproductive technology. However, information on the com-
position of female reproductive tract ﬂuids is far from complete because of the
limited volumes available for analysis. There is no medium with almost all of the
components (more than 30) similar to human oviductal ﬂuid.
Study design, size, duration: We developed a high-sensitivity multicompo-
nent analysis system and analyzed human oviduct ﬂuid. In a prospective study,
mouse embryo culture media based on this analysis were compared with con-
ventional culture medium. In vitro fertilized 1-cell mouse embryos were cul-
tured in the media and observed every day until day 4. Blastocysts were
analyzed to assess their viability. In total, 780 fertilized oocytes and 725 blasto-
cysts were examined.
Participants/materials, setting, methods: Human oviductal ﬂuid samples
aspirated laparoscopically from 28 women aged 26–39 years were analyzed to
determine the concentrations of 31 components by liquid chromatography
with tandem quadrupole mass spectrometry and ion chromatography. Zygotes
from ICR strain mice were cultured in control medium, KSOMAA, or test media
for 4 days to assess blastocyst formation and hatching rates. Blastocysts were
analyzed by TUNEL staining to measure total cell numbers and the percentages
of apoptotic cells.
Main results and the role of chance: Because the apoptosis rate of blasto-
meres cultured in media based on human oviductal ﬂuid was higher than in
KSOMAA medium (3.8% vs 5.2%), the potassium and/or phosphate levels in
the new media were reduced from the levels found in human oviductal ﬂuid
levels to levels in conventional media (potassium, from 15.3 to 5.5 mmol/L;
phosphate, from 2.5 to 0.3 mmol/L). As a result, using a potassium-modiﬁed
medium or a potassium- and phosphate-modiﬁed medium, the hatching rate
was improved (from 73.1% to 86.5% and 88.5%, respectively; p < 0.05) and the
numbers of blastomeres increased (from 80.2 ± 1.5 to 95.8 ± 2.0 and 90.2 ±
2.0; p < 0.01) compared with the KSOMAA medium. In the phosphate-
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modiﬁed medium, the numbers of blastomeres increased (from 80.2 ± 1.5 to
90.7 ± 2.2, p < 0.01) compared with the KSOMAA medium.
Limitations, reasons for caution: Oviductal ﬂuid samples were collected
from ampullae after ovulation from patients suspected of infertility. The analyt-
ical values might differ if the donor and collection times or sites differ. This was
a study using mouse embryos and their performance in such deﬁned culture
media might differ from human embryos.
Wider implications of the ﬁndings: We analyzed more than 30 compo-
nents of human oviductal ﬂuid for the ﬁrst time and clariﬁed that it was effective
in helping to formulate new embryo culture media. We believe that these
results have the potential to lead to the development of an ideal culture envir-
onment for human embryos.
Trial registration number:Not applicable.
P-173 Aremorphology of ﬁrst polar body related to embryo
quality and euploidy rate in couples?
H. Jang1, J. Jung1, T. Kim1, J. Woo1, J. Eum1, D. Lee2, J. Ko2, H. Park1,
J. Kim1,W. Lee1
1CHA fertility center, CHA Gangnam medical center, Seoul, Korea- South
2CHA University, Biomedical Science, Seoul, Korea- South
Study question: What is the parameter of an oocyte that indicates the
embryo quality and euploidy rate?
Summary answer: Morphology of ﬁrst polar body has a relationship with the
euploidy rate especially in under 38 years old maternal group.
What is known already: Previous studies have reported that morphology of
ﬁrst polar body (1st PB) affects oocyte viability and embryo quality.
Furthermore, it has been reported that morphology of 1st PB is correlated with
chromosome abnormality of embryos.
Study design, size, duration: This retrospective study was carried out to
investigate the difference of euploidy rate and embryo quality according to
morphology types of 1st PB in couples with advanced maternal age.
Morphological classifying of 1st PB was evaluated in 676 MII oocytes of 101 PGS
cycles using array-CGH. During the period from January 2016 to November
2017, this study was performed in couples suffering from recurrent implantation
failure or repeated spontaneous abortion over 2 times.
Participants/materials, setting, methods: Observation of 1stPB was per-
formed using an inverted microscope during Intracytoplasmic Sperm Injection
(ICSI). Morphology of 1st PB is classiﬁed into 4 different groups: Type 1: ovoid
1st PB with smooth surface; Type 2: ovoid 1st PB with rough surface; Type 3:
fragmented 1st PB; Type 4: large 1st PB. All embryos were biopsied at day 3
and day 5, and then analyzed by array-CGH.
Main results and the role of chance: The highest day2 and day3 good qual-
ity embryo (GQE) rate is type1 among four types (70.6 % and 58.1 %), with no
statistically signiﬁcant difference. However, the euploidy rate of type1 was
observed signiﬁcant difference with among each type2 and type4 (33.1% vs.
23.3%, p<0.05 and 33.1% vs.3.8%, p<0.05). Groups were divided to under 38
and over 38 years old, type1 and type2 of under 38 years of age group have
higher euploidy rate than over 38 years old group with statistically signiﬁcant dif-
ference (40.5% vs. 22.8%, p<0.05 and 29.2% vs. 16.2%, p = 0.05).
Limitations, reasons for caution: This study has numerical differences with
each type which needs to be further validated. More studies should be per-
formed to demonstrate these signiﬁcant differences.
Wider implications of the ﬁndings: We found a relationship between the
morphology of 1st PB and the euploidy rate in PGS cycles. Study suggests that
the morphology of 1st PB can be one of the indicators of embryo euploid.
Trial registration number:N/S.
P-174 Comparison of clinical pregnancy and live birth rates among
fresh day 5 and frozen-thawed day 5, day 6 blastocyst transfer
A. Konkova, V. - Apryshko, E. Shalamova, A. Naumova,
A. Klepukov, M. Kharitonova, A. Bolt, K. Kirienko, A. Mironova,
I. Ermilova, S. Yakovanko
AltraVita IVF Clinic, Embryology, Moscow, Russia C.I.S.
Study question: Is there a signiﬁcant difference in outcome of IVF pro-
grammes with fresh day 5(d5ET), frozen day 5(d5FET) and frozen day 6(d6FET)
blastocyst transfer?
Summary answer: According to our data based on 9671 fresh and frozen
blastocyst transfers the highest pregnancy and live birth rates are in IVF pro-
grammes with d5FET.
What is known already: Blastocyst cryopreservation in IVF cycles is used to
accumulate embryos in poor-responder patients, allows time to perform gen-
etic testing, provides the opportunity to postpone a transfer away from the
non-physiologic endometrium, which occurs during a stimulation cycle, and
may improve pregnancy rate (PR) and fetal outcome. Some studies show higher
ongoing pregnancy and live birth rate (LBR) following d5FET compared with
d6FET.
Study design, size, duration: We performed retrospective comparative
study of PR and live birth rate/transfer among 3 groups of ICSI-ET cycles: 3254
with d5ET (average woman age 34 ± 4,5 years), 3969 with d5FET (average
woman age 34 ± 4,0 years) and 2448 with d6FET (average woman age 34 ±
4,7 years). All patients underwent IVF and ET from 2009 to 2016 at AltraVita
IVF clinic, Moscow. Cycles with a single ET of a good and high quality blastocyst
were included in the study.
Participants/materials, setting, methods: Vitriﬁcation method by
Cryotech and Kitazato, Japan, was used for vitriﬁcation/thawing of blastocysts.
Embryos were evaluated before transfer and were assigned grades according to
Gardner blastocyst grading scale. For our investigation analysis cases with
blastocyst transfer grades (1-4) AA, AB, BA, BB were chosen. Ongoing preg-
nancy after ET was conﬁrmed by one fetal sac and heart beat. PR and LBR were
statistically analyzed using Chi-square test.
Main results and the role of chance: Outcome results in the group of
d5FETwere 36.6 % PR and 26.3 % LBR, which is signiﬁcantly higher com-
pared to 26,5 % PR (P<0.01; OD 1.64, 95% Cl, 1.49-1.82) and 18.5 % LBR
(P<0.01, OD 1.12, 95% Cl, 1.05-1.37) in the group with d5ET and 27,5 %
PR (P<0.01, OD 1.53, 95% Cl, 1.37-1.70) and 18.1 % LBR ( P<0.01,
OD1.2, 95% Cl, 1.06-1.36) in the group with frozen d6FET. There were
no signiﬁcant differences in the pregnancy rate 26,5% versus 27,5 % (OD
0.95, 95% Cl, 0.84-1.07) and LBR 18.5% versus 18.1% (OD 1.01; 95%
Cl, 0.88-1.18) between groups with fresh d5ET and frozen d6FET,
respectively.
Limitations, reasons for caution: ICSI-ET cycles groups contain data on all
types of stimulation protocols without exceptions.
Wider implications of the ﬁndings: We’ve analyzed a high number of ET
cycles in our study. The pregnancy and life birth potential of good and high qual-
ity frozen-thawed day 5 blastocysts is higher than fresh day 5 blastocysts and
frozen-thawed day 6 blastocysts. D5FET may be considered as a preferable
strategy during the IVF treatment.
Trial registration number:N/A.
P-175 Moving towards individualized embryo transfer-Guidelines
for number of embryos to be transferred based on key performance
indicators
U.N. Jindal1, S. Kumar2, S. Maheshwari3
1Jindal IVF & Sant Memorial Nursing Home, ART, Chandigarh, India
2Jindal IVF & Want Memorial Nursing Home Chandigarh, Assisted Reproduction
Techniques, Chandigarh, India
3Jindal IVF & Sant Memorial Nursing Home, Assisted Reproduction Techniques,
Chandigarh, India
Study question: Can key performance indicators (KPIs) help in formulating
guidelines for number of embryos to be transferred?
Summary answer: Single embryo transfer (SET) should be considered in
donor oocyte cycles and in women < 30 years if cleavage rate (CR) is above
95%
What is known already: KPIs in the Assisted Reproduction Techniques
(ART) laboratory act as early warning signs. The Vienna Consensus Statement
of July, 2017 of the European Society of Human Reproduction and Embryology
(ESHRE) deﬁnes competency (COMP) and benchmark (BENCH) levels of vari-
ous KPIs. Globally, there is a recommendation to shift to SET to avoid
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complications of multiple pregnancies. However, it is a common practice at
most of the centres in several countries including in India to transfer two
embryos in routine and three in poor prognosis cases to increase the pregnancy
rate.
Study design, size, duration: This study reported an analysis of 3-year data
of 699 in-vitro fertilization (IVF) cycles with fresh embryo transfer at a tertiary
IVF centre. KPIs analysed included: metaphase II (MII), fertilization (FR), CR and
embryo quality rates (EQR), which were compared with COMP and BENCH.
Outcomes compared included clinical pregnancy rate (CPR) and implantation
rate (IR). Statistical analysis was done with one way ANOVA and Chi Square
test methods for comparison using SPSS-21.
Participants/materials, setting, methods: The IVF cycles were divided in
four groups based on age: Group I, ≤ 30 years; group II, age 31-35 years; group
III, age > 35 years; and group IV, donor oocyte irrespective of recipient’s age.
Each group was subdivided into two sub-groups based on CR: A with CR <
95% (COMP level) and B with CR > 95 %. The CPR, IR and multiple pregnancy
rates were compared amongst groups and within sub groups.
Main results and the role of chance: The mean CPR and IR rates respect-
ively: Group I were 36.92% & 22.31%; group II, 33.05% & 18.53%; group III;
21.57 % & 11.44 %,and group IV; 43.79% & 27.02%. The CPR and IR were the
highest in donor oocyte group, decreased as the age increased. Women above
35 years’ age performed worst. These differences were statistically signiﬁcant
amongst various groups. In sub groups, CPR and IR were higher with cleavage
rate > 95 % than CR < 95%, but the difference was statistically insigniﬁcant.
Multiple pregnancy rate was the 11.83 % in group IV, followed by group I with
9.23 %, group II 7.73% and in group III 3.92%. Thus, a clear recommendation
for SET can therefore be made for Group-IV. Similarly in group I with CR
>95%, a policy of SET can be preferred over double embryos transfer (DET).
Group II with age 31-35 years should be given DET due to a lower IR. In group
III, all cases should be transferred three embryos to improve CPR.
Limitations, reasons for caution: KPI like MII, FR and EQR, being above
BENCH were not considered. Any dip in an individual case will affect decision.
The other variables which may affect the IVF outcome like endometrium, day of
ET, previous failures were not taken into consideration. Moreover patient’s
choice has also to be considered.
Wider implications of the ﬁndings: Mathematical modelling based on clin-
ical and laboratory KPIs can help individualize the number of embryos to be
transferred.
Trial registration number: Since it was a retrospective analysis of data, trial
registration number was not sought.
P-176 Enhancing blastocyst quality by priming spermatozoa with
cumulus mass fragments for human ICSI cases
R. Dunn1, V. Pham2, G. Grunert1, E. Kovanci1, S. Chauhan1,
L. Schenk1, R. Mangal1, Y. Anaya1, W.S.Wun2
1Houston Fertility Specialists, Fertility Clinic, Houston, U.S.A.
2Houston Fertility Specialists, IVF lab, Houston, U.S.A.
Study question: Does priming spermatozoa with cumulus mass before ICSI
enhance developmental speed and quality of blastocysts?
Summary answer: ICSI with cumulus primed sperm not only increases devel-
opmental speed but also enhance the quality of blastocysts.
What is known already: By using big data set from US Society of Assisted
Reproductive Technology (SART), it has found that application of ICSI for
non-male factor cases signiﬁcantly decrease pregnancy outcomes. In mouse
model, ICSI with acrosome intact sperm has severe negative impact upon egg
survival. Induce acrosomal reaction before ICSI can prevent this negative
impact.
Study design, size, duration: The study is a cross sectional -control vs.
treatment design. Totally 1447 eggs from 97 ICSI cases during September 1 -
December 23, 2017 included in the study.
Participants/materials, setting, methods: The study population was with
mean age 33.5 and median age at 33 in a fertility clinic. All ICSI cases with at
least 6 oocytes and 5 million motile sperm/sample included in the study. In
each case, half number of mature eggs assigned as control (ICSI with swim up
sperm; Standard ICSI) and the other half number of mature oocytes ICSIed
with autologous cumulus primed sperm (Primed ICSI). Generalized Estimation
Equation used for statistical analysis.
Main results and the role of chance: For convenience, Standard ICSI is
brief as Standard. Primed ICSI is brief as Primed. For fertilization, Standard has
482 fertilized out of 713 ICSIed eggs (67%) vs. Primed ICSI 546/764 71%)(not
signiﬁcant); Day 5 blastocyst quality > = 3BB, Standard 61/482 (12.6%) vs
Primed 102/546 (18.6%) p<0.01); Total good quality blastocyst (> = 3BB)
rate: Standard 254/482 (52.6%) vs. Primed 324/546 (59.3%) p<0.05;
Biopsiable rate (at exapnded blastocyst stage): Standard 193/254 (75.9%) vs.
Primed 246/324 (75.9%) not signiﬁcant; euploid rate: Standard 80/193 (41.4%)
vs. Primed 103/246 (41.8%) not signiﬁcant.
Limitations, reasons for caution: The statistical power is limited due to
small sample size.
Wider implications of the ﬁndings: There are reasons for worldwide ele-
vation of ICSI utilization. To alleviate the negative impact of ICSI, the couple’s
autologous cumulus mass fragments show promising improvement. If conﬁrmed
by big data power, the cumulus priming procedure may will be the standard
ICSI protocol worldwide.
Trial registration number: not applicable.
P-177 Blastocyst diameter is an important parameter for
predicting live birth in frozen single blastocyst transfer cycles
R. Hirata, S. Inoue, K. Taguchi, H. Toshihiro, H. Nobuyoshi
Okayama Couple’s Clinic, Gynecology, Okayama, Japan
Study question:Which morphological parameter is most important to select
the best blastocyst for transfer?
Summary answer: The blastocyst diameter on Day 5, rather than inner cell
mass (ICM) or trophectoderm (TE) grade, is the most signiﬁcant predictor of
live birth.
What is known already: To assess the blastocyst, three morphological para-
meters have routinely been used: degree of blastocoele expansion, size and
compactness of the ICM and number of TE. Although blastocysts with the high-
est scores for all three parameters achieve high implantation rates (IRs), there is
controversy over which parameter is the strongest predictor of live birth. In
addition, even for the same expansion grade, the range of embryo diameters is
wide.
Study design, size, duration: This study is a retrospective analysis of 1107
vitriﬁed/warmed Day 5 single embryo transfers of good morphology blasto-
cysts (≥3BB) between 2012 and 2015. Exclusion criteria included patients with
≥38 years of age, repeated implantation failure (≥6 embryo transfer) and hatch-
ing/hatched blastocyst. Blastocysts were divided by their diameter, ICM and TE
grade. Implantation and live birth rates (LBRs) were compared.
Participants/materials, setting, methods: The blastocysts were observed
at 114-116 hours after insemination. The blastocyst diameter was measured
between the outside borders of the TE. Blastocysts were classiﬁed according to
their diameters (<140μm, 140-160μm, 160-180μm, ≥180 μm), ICM (A, B) and
TE (A, B). Adjusted odds ratios (AOR) were calculated by multivariate logistic
regression.
Main results and the role of chance: The mean patient age was 32.4 ± 3.4
years. Univariate regression analysis showed blastocyst diameter and TE grade
to be correlated with IR and LBR. The IRs for blastocyst diameter groups
(<140μm, 140-160μm, 160-180μm, ≥180μm) were 37.1%, 53.9%, 59.1% and
61.3% respectively; while the LBRs were 28.2%, 38.6%, 46.5% and 48.6%,
respectively (P<0.05). The IRs for TE grade (A, B) were 56.9% and 50.0%,
respectively (P<0.05); while the LBRs were 44.4% and 37.3%, respectively
(P<0.05). However, there was no signiﬁcant association between ICM grade
and LBR. LBRs were 42.8% and 37.2% for ICM grades A and B, respectively.
Furthermore, multivariate logistic regression analysis showed that only
blastocyst diameter was signiﬁcantly associated with live birth (<140μm versus
140-160μm: AOR 1.56 95%Cl 1.08-2.27; <140μm versus 160-180μm: AOR
2.12 95%Cl 1.47-3.06; <140μm versus ≥180μm: AOR 2.26 95%Cl 1.50-3.43).
Limitations, reasons for caution: Only high-quality embryos used in frozen
transfer were considered in this study. In addition, hatching/hatched embryos
were excluded because an accurate diameter was not measureable.
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Wider implications of the ﬁndings: Our data show a strong correlation
between blastocyst diameter on Day 5 and probability of live birth. More indivi-
dualized timing of embryo transfer in frozen embryo cycles may be needed to
improve implantation rates, especially for blastocysts that are <140μm.
Trial registration number:Not applicable.
P-178 What stage of in vitro embryo development is affected by
oxygen tension? A randomized clinical trial (RCT)
P. Maurin1, C. Herbemont1, I. Cedrin-Durnerin2, J. Boujenah3,
B. Dagher-Hayeck2, S. Sarandi1, J. Calvo2, A. Seroka2, M. Comtet2,
C. Vinolas2, M. Grynberg2, C. Sifer1
1Hôpital Jean Verdier, Histologie-Embryologie-Cytogénétique-CECOS, Bondy, France
2Hôpital Jean Verdier, Médecine de la Reproduction, Bondy, France
3Hôpital Jean Verdier, Maternité-Gynécologie-Obstétrique, Bondy, France
Study question: Is embryo development inﬂuenced by oxygen tension
applied during culture? If yes, are both cleavage and blastocyst stages vulnerable
to oxidative stress (OS)?
Summary answer: Hypoxia during embryo culture improves embryo quality
and development ability. However, late pre-implantation embryo development
seems to be less vulnerable to oxidative stress.
What is known already: In mammals, uterine environment is at low oxygen
concentration (2-8% O2). Thus, human embryo culture under 2-8% O2 is
recommended by ESHRE revised guidelines for good practices in IVF labs.
Indeed, hypoxia (5% O2) seems to improve embryo quality at cleavage and
blastocyst stages, presumably by reducing damages of OS. Nevertheless, recent
meta-analyses concluded with a very low evidence to a superiority of hypoxia
on IVF/ICSI outcomes. Furthermore, a study on mouse embryos suggested a
negative impact of OS only at cleavage stage. This hypothesis has still never
been investigated in humans.
Study design, size, duration: From 01/2016 to 12/2017, 721 IVF/ICSI
cycles were included in this RCT. At Day-0 (D0), cycles were randomized using
a 1:2 allocation ratio: group “20%-O2” (n = 241); group “5%-O2” (n = 480).
Extended culture (EC) was performed when ≥5 D2-good-quality-embryos
were available (n = 83 in subgroup A (“20%-O2”)). In subgroup “5%- O2”, 175
EC cycles were randomized again at D3 (using 1:1 ratio): group B: 5%-O2 until
D6 (n = 88); or C: switch to 20%-O2 from D3 to D6 (n = 87).
Participants/materials, setting, methods: Inclusion criteria were: intra-
couple IVF/ICSI using fresh/frozen ejaculate; female age <40 years; absence of
hydrosalpinx; ≥8 cumulus-oocyte complexes retrieved. Oocytes were fertilized
and cultured in similar benchtop incubators, under 5 or 20% O2. Fertilization
rate, cleavage-stage quality (D2-top-quality-embryo (D2-TQE): 4 blastomeres,
<20% cytoplasmic fragmentation), blastocyst quality when necessary (D5-top-
quality-blastocyst (D5-TQB): ≥B4AA/AB/BA (Gardner and Schoolcraft’s clas-
siﬁcation)) and implantation rate (IR) were compared between groups “20%”
and “5%” (=cleavage-stage analysis), or A(20%), B(5%) and C(5%-to-20%)
(=EC analysis).
Main results and the role of chance: In cleavage-stage analysis, all charac-
teristics were similar between groups “20%” and “5%” O2. A total of 6 304
embryos were analyzed. A signiﬁcantly higher number of early-cleaved embryos
was obtained under 5%-O2 (3.3 vs. 2.4 under 20%; p = 0.0009). A trend
towards higher D2-TQE rate was achieved under 5%-O2 (40.8% vs. 37.0%; p
= 0.067). Then, overall IR was comparable whatever the culture condition
applied from D0 to D3 (“5% O2”: 29.7% vs. “20% O2”: 27.8%). Considering EC
analysis, both demographic and clinical parameters of the cycles were also com-
parable. Blastulation rates were similar in groups A, B and C (68.1%, 70.4% and
71.6%, respectively). Regarding blastocyst quality, embryo culture under 20%-
O2 from D0 to D6 (group A) resulted in signiﬁcantly lower D5-TQB rates/
blastocyst (15.2%), than in both groups B (23.4%; p = 0.0029) and C (20.1%, p
= 0.04). Furthermore, blastocyst quality was statistically equivalent between
groups B and C. Finally, blastocysts IR were similar in groups A, B and C (43.4%
vs. 39.4% vs. 42.7%, respectively).
Limitations, reasons for caution: Embryos were not analyzed using mor-
phokinetic parameters, which could have made the interpretation less
subjective.
Wider implications of the ﬁndings: If conﬁrmed, these results would
encourage to systematically culture embryos under hypoxia during only early
development stages, since OS might be detrimental exclusively before embry-
onic genome activation.
Trial registration number: ID-RCB: 2015-A02019-40
P-179 Functionally active extracellular vesicles are released and
taken up by zona-intact bovine embryos produced in vitro
K.C. Pavani1, A. Hendrix2, B. Leemans1, A. Van Soom1
1Ghent University, Department of Reproduction- Obstetrics and Herd Health,
MERELBEKE, Belgium
2Ghent University, Department of Radiation Oncology and Experimental Cancer
Research, Ghent, Belgium
Study question: Are extracellular vesicles (EVs), as putative autocrine factors,
released into the culture medium by bovine embryos and are they able to cross
the zona pellucida?
Summary answer: Extracellular vesicles were isolated from EV-free media
conditioned by bovine embryos and were, after ﬂuorescent labeling, taken up
and internalized by zona-intact embryos.
What is known already: Group culture of bovine embryos in medium con-
taining bovine serum albumin (BSA) is currently the most successful method to
produce embryos in vitro. Autocrine factors play a key role in group culture,
with EVs being possibly important autocrine mediators. Moreover, EVs are pre-
sent in various body ﬂuids including serum, suggesting that BSA may support
bovine embryo development by enriching medium with extracellular vesicles.
Theoretically, EVs (50-300 nm) can pass through the pores of the bovine zona
pellucida (mean diameter 200 nm). We hypothesize that EVs are released and
taken up by embryonic cells, serving as positive mediators in group culture.
Study design, size, duration: In vitro maturation and fertilization was per-
formed using routine methods. For in vitro culture, presumed zygotes were
allocated to Synthetic Oviduct Fluid (SOF) containing insulin, transferrin and sel-
enium (ITS) and supplemented with 0.4% BSA. To assess the presence of
embryo secreted-EVs, both standard and ultracentrifuged (EV-depleted; centri-
fuged at 100,000 g for 18 h at 4°C) media were tested. At day 8, blastocysts
were recorded and quality was evaluated by differential staining.
Participants/materials, setting, methods:One ml of embryo-conditioned
medium was pooled at day 8 and subsequently subjected to Optiprep® density
gradient ultracentrifugation and size exclusion chromatography to isolate EVs.
Identiﬁcation and characterization of EVs was performed by nanoparticle track-
ing analysis, transmission electron microscopy and western blotting (CD9,
TSG101,CD63). Next, EVs were pre-labeled by PKH67 dye and subsequently
co-incubated with day 6 embryos for 48 hours to assess EV passage through
the zona pellucida. The uptake was analyzed by confocal microscopy.
Main results and the role of chance: Blastocyst development and hatching
rates were not signiﬁcantly different comparing standard and EV-depleted
embryo culture medium (40 ± 3.43 % vs 38.88 ± 1.48 %; 25.20 ± 1.16 % vs
24.0 ± 0.83%; normal medium vs EVs free medium; P>0.05). In contrast, a signiﬁ-
cant difference between culture media was observed in total cell number of
expanded and hatched blastocysts (151.0 ± 1.95 vs 126.8 ± 1.74; 209.6 ± 1.31
vs 162.12 ± 2.29; normal medium vs EV-depleted medium; P<0.05). Moreover,
apoptotic cell ratio was signiﬁcantly higher in expanded blastocysts cultured in
EV-depleted compared to standard medium (8.7 ± 0.35 vs 6.1 ± 0.50; P<0.05).
Based on this data, EV-depleted culture medium had an signiﬁcant adverse effect
on embryo quality. Moreover, embryos cultured in EV-depleted medium
secreted EVs in the culture medium. At day 8, EVs sizing from 25 to 250 nm were
isolated, which indicates the secretion of EVs through the pores of the zona pellu-
cida. By nanoparticle tracking analysis, the concentration of EVs extracted from
1ml of conditioned medium was 1.36 × 108 particles/ml. Western blotting ana-
lysis demonstrated the presence of CD9, TSG101, CD63 markers in embryo-
derived EVs. Co-incubation of PKH67 prelabeled EVs and embryos demon-
strated the uptake of embryo-derived EVs by zona-intact embryos. We conclude
that functionally active EVs can cross the zona pellucida.
Limitations, reasons for caution: The major limitation in the current study
was the collection of high volumes of embryo conditioned medium, as it
requires 400-500 in vitro produced embryos to obtain 1 ml conditioned
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medium. To counteract this limitation we were obliged to make use of pooled
embryo conditioned medium.
Wider implications of the ﬁndings: Our data demonstrated that EVs are
secreted by in vitro cultured bovine embryos in the medium, cross the zona pel-
lucida and can be taken up by embryos. These facts indicate the potential role
of EVs as mediators in embryo development, also with possible implications for
human embryo culture.
Trial registration number:Not Applicable.
P-180 A role of E-cadherin-Wnt/β-catenin-lin28/let7 pathway in
epithelial-mesenchymal transition (EMT) during extravillous
trophoblast differentiation
Q. LI
The university of hong kong, obstetrics & gynaecology, hong kong, China
Study question: How dose E-cadherin change in embryo trans-activate
canonical Wnt/β-catenin signaling pathway and its downstream target lin28(a/
b)/let7 affect extra-villous trophoblast EMT during normal implantation.
Summary answer: E-cadherin bound β-catenin release feeds into Wnt signal-
ing pathway and promote trophectoderm EMT through up-regulation lin28a/b
as well as suppression mir-let-7.
What is known already: Wnt/β-catenin signaling is one of the several path-
ways that involve in EMT, E-cadherin associated with β-catenin on the cellular
membrane to prevent β-catenin participate in signaling pathway. Our own data
showed that up-regulation of lin28a is required for the activation of mouse blas-
tocysts and mir-let 7 was up-regulated in dormant embryo but lower expressed
in implantation competent embryo in our microarray analysis.
Study design, size, duration: The expression of EMT related marker,
lin28a,b, mir-let-7 family was detected in Wnt/β-catenin activated and inhibited
human trophectoderm cell line, HTR-8/SVneo and Jeg-3. The function of E-
cadherin disassociation with β-catenin in activate Wnt pathway was conﬁrmed.
The in vivo and in vitro effect of Wnt/β-catenin-lin28/let7 on embryo EMT was
examined.
Participants/materials, setting, methods: Human trophectoderm cell line
HTR-8/SVneo and Jeg-3 was used for in vitro assay. Pregnancy was produced
by natural mating between female and male ICR mice, and C57BL6/J mir-let-7g
overexpression transgenic mouse for in vivo assay. The expression of active β-
catenin, E-cadherin, EMT marker, lin28a,b, mir-let-7 was detected in both cell
line and mouse embryo in Wnt induced EMT by QPCR, Western blot, and
immunostaining.
Main results and the role of chance: E-cadherin dissociation from adhesion
junction (AJ) with β-catenin cause β-catenin gain the ability to be translocated
into nucleus and activate Wnt signaling in Jeg-3 cell. Wnt/β-catenin activation
trans-activate lin28a/b in Jeg-3 and HTR-8/SVneo in E-cadherin dissociated
cell. Lin28 functionally regulates the expression of mir-let-7 family in Jeg-3 and
HTR-8/SVneo. E-cadherin dissociation from AJ, Wnt/β-catenin activation,
Lin28 overexpression and mir-let-7 knockdown cause Jeg-3 and HTR-8/SVneo
cell EMT in vitro and also increase the invasion and migration rate. In the
embryo in vitro co-culture process, from 24 h attachment to 48 h invasion, E-
cadherin was down-regulated in invasive trophectoderm but active-β-catenin
was increased, mesenchymal related markers were upregulated. In vivo, the
implantation rate and embryo EMT of let-7g overexpressed mouse was
decreased.
Limitations, reasons for caution: E-cadherin dissociation from AJ with β-
catenin cause β-catenin and E-cadherin both translocated into nucleus, and
Wnt activation, how the speciﬁc regulatory mechanism of E-cadherin affect
Wnt activation still do not know.
Wider implications of the ﬁndings: Our ﬁndings indicate that trophecto-
derm cell experience Wnt/β-catenin pathway activation as E-cadherin dissoci-
ation from AJ, and supression its down-stream target mir-let-7 by lin28, thus
promote EMT. This information contribute to a better understanding of the
mechanisms that the miRNA-mediated regulation of embryo implantation, and
subsequently improve treatments for infertility.
Trial registration number: no.
P-181 Embryo cryopreservation is associated with signiﬁcantly
higher birth weight compared with sibling cohort fresh embryo
transfer: a bicenter cohort
A. Margaux1, S. Phillips2, A. Ferrieres-Hoa1, A. Gala1, A. Fournier1,
C. Vincens3, E. Vintejoux3, F. Bissonnette2, I.J. Kadoch2,
S. Hamamah1
1human reproductive biology, art/pgd, Montpellier, France
2Ovo fertilité, Department of Obstetrics and Gynecology, Montreal, Canada
3Gynecology and Obstetrics, art/pgd, Montpellier, France
Study question: To determine if the freeze-thaw procedure itself is involved
in birth weight difference between singletons born after fresh embryo transfer
and those born after frozen embryo transfer.
Summary answer: Birthweight after frozen embryo transfer (slow freezing or
vitriﬁcation) was signiﬁcantly higher (215.6 g) than after fresh embryo transfer
(3487.4 g vs 3271.8 g, p = 0.0001).
What is known already: It is well established that the frozen embryo transfer
(FET) is associated with a change of birth weight in comparison with fresh
embryo replacement even after taking into consideration relevant confounding
factors. However, no study has compared the birth weight of consecutive sib-
lings conceived using the same oocyte/embryo cohort but different transfer
procedures (fresh vs frozen embryos).
Study design, size, duration: Retrospective bicenter cohort study. The
cohort included 145 sibling pairs where the older sibling was born after fresh
embryo transfer and the second after embryos frozen-thawed replacement
from the same in vitro fertilization (IVF) cycle.
Participants/materials, setting, methods: The cohort included all IVF
cycles where fresh embryo transfer that resulted in a singleton live birth (fresh
group n = 145) was followed by FET that led to a singleton live birth (FET group
n = 145). Twin pregnancies and stillbirths were excluded. The embryos were
frozen either by slow freezing or after vitriﬁcation. Birth weight were adjusted
for gestational age and the mean adjusted birth weight in the two groups were
compared with the Wilcoxon test.
Main results and the role of chance: The mean adjusted birth weight of
the FET group was signiﬁcantly higher (by 215.6 g) than that of the fresh
group (3487.4 g vs 3271.8 g respectively, p = 0.0001). These result were
also signiﬁcant for transfer at the blastocyst stage (3513.5 g vs 3290 g, p =
0.0074) but not at the cleaved stage (3448.7 g vs 3258 g, p = 0.1074).
Concerning the number of embryos transferred, when one embryo was
transferred, the birth weight was, indeed higher after FET than after fresh
embryo transfer (3494.2 g vs 3296.9 g, p = 0.0044) but the results were not
signiﬁcant when two embryos were transferred (3452.8 g vs 3186.7 g, p =
0.3123). A signiﬁcantly higher risk of being large for gestational age (LGA) >
90ème percentile or >97ème percentile after FET versus fresh embryo
transfer was revealed: RR, 1.13 (95% CI, 1.03-1.23) and RR, 1.1 (1.02-1.19)
respectively. As both embryos (fresh and frozen) were from the same IVF
cycle to avoid confounding factors and the only difference between groups
was the absence/presence of the cryopreservation step, our results strongly
suggest that the cryopreservation procedure affects the birth weight of sib-
ling embryo cohort.
Limitations, reasons for caution: The main limitation of this study, is the
retrospective design.
Wider implications of the ﬁndings: ART techniques, such as cryopreserva-
tion procedure, alter birth weight, possibly through epigenetic modiﬁcations in
FET (freezing/thawing procedure, cryoprotectants).
Trial registration number:Not applicable.
P-182 Clinical validation of a non-invasive embryo selection
algorithm combining time-lapse morphokinetics and the oxidative
status of spent embryo culture media
R. Del Gallego Bonilla1, L. Alegre1, T. Cnaani2, S. Shnizer2,
J. Remohí1, M. Meseguer1
1IVI Valencia, IVF Laboratory, Valencia, Spain
2Carmel Diagnostics, Thermochemiluminiscence, Kiryat Tiv’on, Israel
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Study question: Determine if novel embryo selection technique based on
spent´s embryo culture media oxidative proﬁle combined with time-lapse mor-
phokinetic analysis could predict implantation potential.
Summary answer: Implanting transferred embryos showed a more extensive
oxidative metabolism which, when combined with morphokinetic data, led to
the development of a predictive algorithm.
What is known already: Despite IVF’s (in vitro fertilisation) widening applica-
tion and technological progress, it remains associated with two main weak-
nesses that derive partly from our inability to adequately assess embryo quality:
low implantation rates and high multiple pregnancy rates. Novel non-invasive
strategies based on spent culture media analysis provide additional valuable
data to current morphology and morphokinetic analysis performed by time-
lapse technology. In particular, the assessment of the embryo’s oxidative proﬁle
with the Thermochemiluminescence (TCL) AnalyzerTM (Carmel Diagnostics,
Israel) suggests a new approach in determining embryo’s quality or viability and
subsequent implantation potential.
Study design, size, duration: A retrospective cohort study was performed
with a total of 505 spent embryo culture media, including 205 single-embryo
transfers (SET) with known implantation, from 390 IVF cycles. Embryos were
cultured and monitored in independent-well slides in the time-lapse system
incubator Embryoscope® (Vitrolife) and were subsequently transferred at
blastocyst stage. Implantation potential and embryo quality at day 5
(Transferred+Vitriﬁed vs. Discarded embryos) were considered, in terms of
oxidation, to ﬁnd a predictive proﬁle of pregnancy success.
Participants/materials, setting, methods: Oxidative status of 15 μl/
embryo of Blastocyst medium (Cook) samples were assessed by the
Thermochemiluminescence (TCL) AnalyzerTM, based on the heat-induced oxi-
dation of biological ﬂuids, leading to the production of light energy counted as
photons emitted per second (cps). TCL parameters recorded were cps ampli-
tude after 55 seconds (H1), 155 seconds (H2) and 255 (H3), in a 300-second
period. Oxidative data was normalized with a smoothing algorithm (sm) and
analyzed by the statistical test ANOVA.
Main results and the role of chance: Regarding day 5 embryo quality,
transferred and vitriﬁed embryos showed signiﬁcantly higher values (sig.
<0.05) for the oxidative parameters H1sm, H2sm and H3sm. In addition,
out of 205 transferred embryos, 54.1% succeeded at implantation showing
again higher signiﬁcant values (sig. <0.05) in the oxidative parameters. This
therefore implies high quality embryos have a more extensive oxidative
metabolism exerting an oxidative load on their surrounding media. A com-
bined assessment algorithm, including morphology, morphokinetics and the
embryo’s culture media oxidative status was subsequently developed as a
predictive clinical tool of embryo selection, prior to transfer. Motato et al.
(2016) morphokinetic model based on blastocyst expansion (tEB; optimal
range ≤ 112.9 hours) and timing of transition from 5-blastomere embryo
until 8-blastomere embryo (t8–t5; optimal range ≤ 5.67) was combined
with TCL parameter H2sm (optimal range ≤ 92.96). A hierarchical classiﬁ-
cation was generated with six embryo categories (A - F) according to their
implantation potential (76.5–29.2%).
Limitations, reasons for caution: The present retrospective study and its
developed selection algorithm require an additional prospective validation for
its routine clinical use. Oxidative status database will increase while using TCL
to pursue a more accurateH2sm optimal range.
Wider implications of the ﬁndings: The fair correlation between TCL oxi-
dative results, embryo quality and implantation potential proves its application
as a clinical biomarker. Its combination with morphokinetic data aims for the
improvement of our current selection criteria. A more accurate selection of the
best embryo, especially in good-quality embryo cohorts, would determine IVF
success.
Trial registration number:
P-183 Detection of multinucleated trophectoderm cells by
time-lapse microscopy: Implications for PGT-A biopsy results
Q. Zhan, Z. Rosenwaks, N. Zaninovic
Weill Cornell Medicine, Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Is the nuclear status of trophectoderm (TE) cells uniform? If
multinuclear TE (MNT) cells are used for PGT-A analysis, will they impact the
aneuploid results?
Summary answer: MNT cells can be identiﬁed in human blastocysts. Biopsy
and analysis of these cells using current PGT-A techniques may yield invalid
results.
What is known already: Detection of triploidy and polyploidy using current
chromosomal testing techniques (NGS or PCR) is limited. Bovine embryos con-
tain polyploidy cells in the TE. So far, multinuclear cells in the human TE of
preimplantation-stage blastocysts have not been reported. In contrast, poly-
ploid multinuclear cells have been identiﬁed in the human trophoblast and syn-
cytiotrophoblast. Day 11 human embryos contain single nucleated TE cells in
cells adjacent to the epiblast compared to those in peripheral TE, which contain
multinucleated cells. The chromosomal status of single multinucleated blasto-
meres on day 3 indicated polyploidy and/or aneuploidy. The chromosomal sta-
tus of MNT cells is unknown.
Study design, size, duration: This is an observational study of IVF embryos
cultured under time-lapse microscopy (TLM) incubation until the blastocyst
stage.
Participants/materials, setting, methods: Embryos were cultured and
monitored in a TLM incubator (EmbryoScope, Vitrolife, Sweden). At the blasto-
cyst stage, the embryos were carefully monitored for the presence of binu-
cleated and/or multinucleated cells in the TE. If MNT cells were detected, a
retrospective analysis of TLM videos was performed to identify their origin.
Main results and the role of chance: Multinuclear blastomeres were posi-
tively identiﬁed with high speciﬁcity during the ﬁrst three embryo cleavages. In
addition, we observed the existence of MN cells in the TE during blastocyst
development. This novel observation can be easily identiﬁed by TLM in fully
expanded blastocysts where TE cells are stretched out. We observed MNT
cells at various stages of blastocyst development, usually as single cells, an
observation which appeared to be independent of the quality of the blastocyst
or density of TE cells. We observed that MNT cells can be formed de novo dur-
ing TE development by the fusion of two or more single nucleated TE cells.
Interestingly, these MNT cells can subsequently cleave to two daughter cells
with single nuclei. The chromosomal analysis may be altered if MNT cells or
their progeny are used during TE biopsy. The chromosomal status of a single
MNT cell and its descendant cells is unknown. The occurrence of MNT cells
can be a normal event during blastocyst development, and it may indicate the
plasticity of TE formation. It is possible that the quantity, quality, and nuclear
status of TE cells could have an impact on the accuracy of PGT-A.
Limitations, reasons for caution: This is an observational study. The
chromosomal status of individual MNT cells cannot be performed.
Wider implications of the ﬁndings: During TE biopsy, it is imperative to
assess the nuclear status of the TE. MNT cells should not be used for biopsy, as
they might cause an incorrect diagnosis of the embryo.
Trial registration number:N/A.
P-184 Does the transfer of a poor quality embryo together with a
good quality embryo affect the In Vitro Fertilization (IVF) outcome?
L. Yang1,2, S. Zhang2,3,4, C. Lu2,4,5, J. Dai2,6, F. Gong2,4,6, G. Lu2,4,
G. Lin2,4,6
1Central South University, Basic Medicine College, Changsha, China
2National Health and Family Planning Commission, Key Laboratory of Reproductive
and Stem Cell Engineering, Changsha, China
3Central South University, Institute of Reproducitve and Stem Cell Engineering- Basic
Medicine College, Changsha, China
4Reproductive and Genetic Hospital of CITIC-XIANGYA, Reproductive and Genetic
Hospital of CITIC-XIANGYA, Changsha, China
5Central South University, Institute of Reproducitve and Stem Cell Engineering- Basic
Medicine College-, Changsha, China
6Central South University, Institute of Reproducitve and Stem Cell Engineering- Basic
Medicine College, Changsha, China
Study question: Whether a poor quality embryo has a negative effect on a
good quality embryo when transferred along with a good quality embryo.
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Summary answer: A poor quality embryo does not negatively affect a good
quality embryo, when transferred together in a double embryo transfer.
What is known already: Embryo quality is one of the main predictors of suc-
cess in IVF cycles. Many studies have shown a strong association between
embryo morphology, implantation, and clinical pregnancy rates. In theory, the
poor quality embryo has potential for a successful pregnancy, and may lead to
higher spontaneous abortions and overall decreased clinical pregnancies and
live birth rates. IVF cycles which result in only one good quality embryo, and a
second poor quality embryo present a dilemma when the decision involves
transferring two embryos.
Study design, size, duration: This single-center, retrospective cohort study
involved patient who had only one good quality embryo in fresh cleavage stage
embryo transfer using non-donor oocytes at the Reproductive and Genetic
Hospital of CITIC Xiangya in the years 2010–2016. The analysis involved 409 of
418 enrolled cycles in patients who were included in the study group and 409
control cycles in patients who were identiﬁed by propensity matching from a
cohort of 1339 cycles.
Participants/materials, setting, methods: We enrolled patients who had
only one good quality embryo in the cleavage stage(D3), and involving double
embryo transfers(DET) with one good quality embryo and one poor quality
embryo(study group) or single good quality embryo transfers(SET)(control
group). Propensity matching was used to identify a propensity matched control
group from a cohort of 1339 cycles based on age, BMI, basical FSH, endometrial
thickness on the day of hCG, number of oocytes retrieved, and quality embryo.
Main results and the role of chance: 818 cycles were included in the study.
409 cycles in women who had DET with one good quality embryo and one
poor quality embryo [study group (G + P)], and 409 cycles in women who had
SET with one good quality embryo [control group (G)]. There was no differ-
ence in patient baseline and cycle characteristics between the two groups. The
clinical pregnancy rate (39.9% vs. 34.2%, P > 0.05), implantation rate (21.3% vs.
17.5%, P > 0.05), and live birth rate (28.6% vs. 26.2%, P > 0.05) were no differ-
ence between study and control groups respectively. The early abortion rate
(17.8% vs. 17.1%, P > 0.05) and ectopic pregnancy rate (0.6% vs. 1.4%, P >
0.05) were no difference between study and control groups respectively. The
twin pregnancy rate of the study group (G + P) (6.7%) was slightly higher than
that of the control group (G) (2.1%) (P = 0.096), without reaching statistical
signiﬁcance.
Limitations, reasons for caution: The extrapolation of the results is limited
by the retrospective nature of the study.
Wider implications of the ﬁndings: A poor quality embryo does not nega-
tively affect a good quality embryo, when transferred together in a double
embryo transfer.
Trial registration number:No.
P-185 Double biopsy at the blastocyst stage by retrieving
blastocoelic ﬂuid and trophectoderm cells does not affect embryo
viability
G. Terzuoli1, M.C. Magli1, A. Pomante1, S. Mascaretti2,
M. Dell’Aquila1, I. Camera1, A.P. Ferraretti1, L. Gianaroli1
1S.I.S.Me.R., Reproductive Medicine Unit, Bologna, Italy
2S.I.S.Me.R. Servizi Abruzzo, Reproductive Medicine Unit, L’Aquila, Italy
Study question: Does the procedure of double biopsy affect embryo viability?
Summary answer: The simultaneous biopsy of blastocoelic ﬂuid (BF) and
trophectoderm (TE) cells does not decrease embryo viability, whereas double
biopsy at previous stages negatively affects implantation.
What is known already: The current trend in Preimplantation Genetic
Testing (PGT) programs is to perform biopsy of TE cells. This gives several
advantages including the high probability of having informative results when
compared to cases in which genetic analysis is done on polar bodies (PBs) or
blastomeres. Consequently, the need to perform re-biopsy is not a common
event following TE biopsy, but it can be necessary when biopsy is done at previ-
ous stages.
Study design, size, duration: This retrospective study includes 450 PGT
cycles from September 2009 to September 2017. According to the clinical indi-
cation, biopsy was performed on PBs (n = 131 cycles), blastomeres (n = 227
cycles) or TE cells (n = 80 cycles). In cases of non-informative results, re-biopsy
was performed. Only single embryo transfer were included in the study to
evaluate the effect of double biopsy on ongoing pregnancy rate (>16 weeks).
Participants/materials, setting, methods: Indications to PGT were
monogenic diseases (PGT-M, n = 93) or aneuploidy (PGT-A, n = 357).
Following biopsy, Whole Genomic Ampliﬁcation (WGA) was immediately per-
formed and, after positive ampliﬁcation, embryos were cryopreserved at the
blastocyst stage to complete the genetic analysis. In case of negative ampliﬁca-
tion, re-biopsy was performed at the cleavage stage after PB biopsy and after
blastomere biopsy. For blastocysts, the BF was used as back-up sample.
Main results and the role of chance: PGT-M and PGT-A cycles were
equally distributed in the three biopsy groups (PBs, blastomeres, TE cells). Re-
biopsy was performed in 14.5% of PB cycles, 9.8% of blastomeres cycles and
5% of TE cycles. The ongoing pregnancy rate in PB group was 14.2% after re-
biopsy and 29.5% after single biopsy, while after blastomere biopsy it was
14.2% and 25% respectively. When pooling these two groups, the difference
between re-biopsy and controls was signiﬁcantly different (14.3% vs. 27%,
P<0.05). For blastocysts, the ongoing pregnancy rate was 50% after biopsy of
both TE and BF compared with 39% after biopsy of TE only. A signiﬁcant differ-
ence was found when relating the ongoing pregnancy rate after re-biopsy that
was signiﬁcantly lower when done at the cleavage stage and the double biopsy
at the blastocyst stage (P<0.001). Finally, a difference was also found when
comparing the controls of single biopsies done at earlier stages (PB and cleavage
stage) with blastocyst biopsy (P<0.025) conﬁrming the clinical advantage
related to blastocyst transfer.
Limitations, reasons for caution: The limited number of cases in the three
biopsy groups is probably softening differences that are suggested by the
observed trend.
Wider implications of the ﬁndings: Biopsy at the blastocyst stage is the
preferable option either alone or combined with removal and storage of the BF.
The last approach could provide a back-up sample to be used in case of non-
informative genetic results. In addition, artiﬁcial blastocyst collapsing could pos-
sibly improve the results after vitriﬁcation.
Trial registration number:Not applicable.
P-186 High oxygen tension during in vitro maturation of human
oocytes improves developmental competence
M. Miura1, R. Matsunaga1, K. Isobe1, Y. Ohnuki1, W. Mita1,
Y. Kobayashi1, N. Yamanaka1, M. Kamihata1, S.Watanabe1,
T. Maeda1, H. Makino1, M. Ochi1, T. Horiuchi2
1Ochi Yume Clinic Nagoya, IVF laboratory, Nagoya, Japan
2Prefectural University of Hiroshima, Department of Life Science-, Shobara, Japan
Study question: Is it advantageous to culture cumulus-oocyte complexes
(COCs) under high oxygen tension (20%) during in vitro maturation?
Summary answer: Culturing COCs under high oxygen tension (20%) during
in vitro maturation increased the rate of blastocyst development.
What is known already: Previous studies have investigated whether oxygen
tension during in vitro culture of oocytes affects clinical outcome. However,
there are few reports on the optimum oxygen level for in vitro maturation. It
has been suggested that oxygen concentration during in vitro maturation (IVM)
affects murine blastocyst cell numbers and fetal development. It is thought that
oxygen tension inﬂuences reactive oxygen species levels in oocytes matured
in vitro and it is also known to inﬂuence the normal fertilization rates of bovine
oocytes in IVF. However the inﬂuence of oxygen tension on embryo develop-
mental competence after human oocytes maturation is unknown.
Study design, size, duration: The study was performed from March to
December 2017. We collected immature COCs from IVF patients undergoing
letrozole stimulation and divided them into two groups. 188 COCs from 59
patients were cultured with 5% O2 and 133 COCs from 47 patients were cul-
tured with 20% O2.
Participants/materials, setting, methods: COCs were cultured in
TCM199 supplemented with FSH and EGF in 5% O2 or 20% O2. ICSI was per-
formed on these oocytes which where then cultured in a one step medium for
six days in 5% O2, 6% CO2 and 89% N2. We measured oocytes maturation
rate, normal fertilization rate and blastocyst formation rate.
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Main results and the role of chance: Oocytes maturation rate in 5% O2
was 55.3% and in 20% O2 was 53.4% (P > 0.05). There was no signiﬁcant differ-
ence in normal fertilization rate between the two groups (5% O2 = 73.8% vs.
20% O2 = 78.6%). The blastocyst development rate following oocyte matur-
ation in the 20% O2 group (47.3%) was signiﬁcantly higher than that in the 5%
O2 group (25.2%, P < 0.05).
Limitations, reasons for caution: This study is limited to immature oocytes
obtained from patients undergoing IVF.
Wider implications of the ﬁndings: This is the ﬁrst study to demonstrate
the effectiveness of high oxygen tension during IVM in human oocytes. Our
results show that oocytes cultured in 20% O2 during IVM exhibit enhanced
developmental competence.
Trial registration number: none.
P-188 Artiﬁcial oocyte activation improves pre- and post
implantation development of ICSI embryos irrespectively of sperm
origin
K. Sasamine1, T. Takeuchi2, S. Mizuta1,2, K. Kitaya1,
H. Matsubayashi1,2, T. Ishikawa1,2
1Reproduction Clinic Osaka, Reproductive Medicine, Osaka, Japan
2Reproduction Clinic Tokyo, Reproductive Medicine, Tokyo, Japan
Study question: Is the effect of artiﬁcial oocyte activation (AOA) on embry-
onic development and pregnancy outcome associated with sperm origin?
Summary answer: Regardless of sperm origin, AOA effectively improved fer-
tilization and pre- and post-implantation development by increasing the quantity
and the quality of blastocysts available for transfer.
What is known already: AOA has been a therapeutic option for patients
with a history of ICSI fertilization failure.
In earlier studies, it has been shown that AOA is effective in improving not
only the fertilization rate, but also the pregnancy rate in cases where impaired
fertilization was observed in preceding cycles.
However, whether sperm origin has any impact on the development of AOA
embryos is not well understood.
Study design, size, duration: In order to examine the effect of AOA on late
embryonic development, we compared ICSI outcome between non-AOA and
AOA cycles in patients with various fertilization rates and different sperm origin,
ejaculated (EJ) and testicular spermatozoa (TESE).
Between October 2013 and November 2017, total of 153 infertile couples
with EJ and 48 with TESE ICSI were involved in the study.
All patients gave written consent, and institutional review board approval
was granted.
Participants/materials, setting, methods: Consenting patients were
grouped according to the sperm origin as well as fertilization rates in initial non-
AOA cycles.
For AOA, ICSI inseminated oocytes were exposed to 10 μM calcium iono-
phore (A23187) for 15 minutes.
Developed embryos were all vitriﬁed, and warmed-replaced in subsequent
embryo transfer cycles, while no fresh embryo transfers were elected.
The rates of fertilization, blastulation, good blastocyst, clinical pregnancy, and
on-going pregnancy were compared between non-AOA and AOA cycles.
Main results and the role of chance: The couples initially underwent 341
non-AOA cycles (280 with EJ and 61 with TESE), followed by 427 AOA cycles
(328 EJ and 99 TESE, respectively). Both EJ and TESE groups were further
divided into three subgroups according to initial non-AOA fertilization rates,
i.e., low (<30%), sub-optimal (30-60%), and satisfactory (>60%). Semen para-
meters were comparable among the three groups. In both EJ and TESE groups,
the rates of fertilization after AOA were signiﬁcantly improved from non-AOA
cycles in all (P<0.001), but satisfactory group as expected. We deﬁned good
blastocyst rate as the proportion of blastocyst with good quality per embryo
reached the blastocyst stage. Interestingly, AOA treatment remarkably
increased blastulation and good blastocyst rates in sub-optimal group with EJ
sperm (38.4 vs 62.0 and 14.0 vs 43.3%, P<0.01), and satisfactory group with
TESE sperm (22.2 vs 40.0%, N.S. and 12.5 vs 62.5%, P<0.05). More import-
antly, overall clinical pregnancy rates and on-going pregnancy rates after AOA
were obviously improved regardless of sperm origin (15.8 vs 31.5 and 12.1 vs
27.0% with EJ, 16.6 vs 52.3 and 11.4 vs 38.8% with TESE, respectively, P<0.01).
Limitations, reasons for caution: We included only cycles with motile
sperm. Further investigations are needed to assess the effect of AOA in cases
with severely compromised sperm quality. Long-term follow-up of children
born after AOA with calcium ionophore has not been well studied yet.
Wider implications of the ﬁndings: AOA was effective for improving fertil-
ization as well as late embryonic development irrespective of sperm maturity.
Considering the beneﬁcial effect observed in TESE cases with satisfactory fertil-
ization, our ﬁndings indicate potential use of AOA even at ﬁrst attempts once
the safety is warranted.
Trial registration number:None.
P-189 Should we vitrify the early blastocyst? Retrospective study
on 851 warming cycles with single embryo transfer
F. Entezami1,2, B. Gonzalez-Marti2, C. Davy3, S. Alvarez3,
D. Delafontaine3, D. Cornet3, A.M. Junca2
1Clinique Internationale du Parc Monceau, Paris, France
2Eylau-Unilabs, IVF Department, Paris, France
3Eylau-La Muette, IVF Department, Paris, France
Study question: To optimize the outcome of frozen-thawed cycles with single
embryo transfer (SET), survival rate after thawing and ongoing pregnancy rates
were compared between early and non collapsed full blastocysts.
Summary answer: Survival rate after thawing is not affected by the blastocyst
expansion while early blastocyst transfers (B1-B2, Gardner classiﬁcation) yield
signiﬁcantly less clinical pregnancies.
What is known already: Extended embryo culture to blastocyst stage allows
better embryo selection and higher implantation rates. Since a couple of years
SET policy is widely used to reduce the risk of multiple pregnancies and freeze
all strategy is routinely performed in order to transfer embryos in a more
physiological environment and to overcome ovarian hyperstimulation conse-
quences. Studies have shown the superiotity of vitriﬁcation of blastocysts com-
pared to cleavage stage.
Lately extensive research was done around the best vitriﬁcation/thawing
protocol and techniques: closed vs open system, media, shrinkage prior to vitri-
ﬁcation, blastocyst stage at vitriﬁcation, automation.
Study design, size, duration: Observational retrospective study on 851 fro-
zen cycles with SET during 2016-2017. Blastocysts were divided in four groups
based on Gardner’s classiﬁcation: 1 early (B1-B2, 251 embryos), 2 full (B3, 233
embryos), 3 expanded (B4, 301 embryos) and 4 hatching/hatched (B5-B6, 66
embryos). All blastocysts were transferred on monitored natural cycles under
ultrasound control 6/7 days after LH surge. Survival rate after thawing (SR) and
ongoing pregnancy rate (OPR) were compared between the groups.
Participants/materials, setting, methods: Study was performed in a pri-
vate IVF center.
Blastocysts were scored at day 5 according to the classiﬁcation of Gardner.
No shrinkage was done before vitriﬁcation of expanded blastocysts.
Vitriﬁcation/thawing were performed using closed high security straws
(CryoBioSystem) in combination with Irvine Scientiﬁc® Freeze/Thaw kit.
After thawing the blastocysts were cultured for two hours (Sage 1-Step®,
Origio) in order to assess survival and reexpansion. Damaged and non-
reexpanded blastocysts were discarded.
The transfer catheters were loaded with EmbryoGlue® (Vitrolife).
Main results and the role of chance: Patients mean age and infertility indi-
cations were comparable between the four groups (p>0.05). Ovarian stimula-
tion protocols at retrieval (antagonist with recombinant FSH) were the same
for all the patients.
Survival rates were similar between 4 groups (p>0.05): B1-B2 97.2%, B3
97.8%, B4 98.3%, B5-B6 96.9%.
OPR per transfer in B1-B2 (20.5%) was signiﬁcantly lower compared indi-
vidually to each group: B3 (32.0%, p = 0.029), B4 (38.2%, p = 0.001), B5-B6
(35.9%, p = 0.049). Furthermore, the OPR per transfer of full-expanded-
hatched blastocysts were signiﬁcantly higher than early blastocysts (37.8% vs
20.5%, p = 0.0008).
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Limitations, reasons for caution: The study was undertaken to evaluate
D5 blastocysts at vitriﬁcation. D6 blastocysts were not included. Blastocysts
obtained at D6 must be evaluated in order to decide if one extra day of culture
may beneﬁt to early blastocysts before undergoing vitriﬁcation.
Wider implications of the ﬁndings: Our two years experience of blasto-
cyst SET in frozen cycles shows that OPR are signiﬁcantly lower with early blas-
tocysts even if SR are comparable to late blastocysts. Therefore, our
vitriﬁcation policy has been moved to one extra day of culture for blastocysts
that are not expanded on D5.
Trial registration number:Not applicable.
P-190 Increased scrutiny of NGS proﬁles / ranking does not
improve eSET implantation of euploid blastocysts: A randomized
comparative trial
C.M. Rios1, J.B.Whitney2, M. VerMilyea3, A.E. Jones4, A. Picou3,
K. Balloch2, N.L. Nugent2, K. Silverberg5, R.E. Anderson6,
M.C. Schiewe2
1Ovation Fertility, Genetics, Henderson, U.S.A.
2Ovation Fertility, ART Lab, Newport Beach CA, U.S.A.
3Ovation Fertility, ART Lab, Austin TX, U.S.A.
4Ovation Fertility, Genetics, Nashville TN, U.S.A.
5Texas Fertility Center, ART Clinic, Austin TX, U.S.A.
6Southern California Center for Reproductive Medicine, ART Clinic, Newport Beach
CA, U.S.A.
Study question: Can NextGeneration sequencing (NGS) proﬁle ranking of
euploid embryos better predict eSET implantation potential of top quality blas-
tocysts in contrast to morphological grading alone?
Summary answer: When blastocysts are both top quality and euploid, the
lack of noise on a NGS proﬁle adds no beneﬁt for eSET compared to embryo
grading.
What is known already: Blastocyst morphology assessment is the primary
determinant for embryo transfer selection. Preimplantation genetic screening
(PGS) now provides patients the ability to know the ploidy status of embryos
before being transferred, which increases the implantation potential of eSETs.
NGS provides every embryo a unique genetic proﬁle which gives geneticists
more information on genetic “noise” and low-level mosaicism that remains
inconsistent between samples, patients, technicians and labs. Transferring
mosaic embryos of differing proﬁle levels has resulted in viable pregnancies, fur-
ther questioning the clinical relevance of mosaic proﬁles. Furthermore, the risks
to the offspring of a mosaic embryos is relatively unknown.
Study design, size, duration: Prospective randomized multicenter trial,
initiated April 2016 and ended December 31, 2017. A total of 61 patients quali-
ﬁed for randomization by producing ≥ two top quality euploid day 5 or day 6
blastocysts. Upon enrollment, eSET selection was randomized between two
pre-determined, double blinded ranking groups: Group 1 - embryologists
ranked euploid blastocysts based on morphologic grade; and Group 2 - geneti-
cists ranked transfer selection based on their interpretation of the NGS
proﬁles.
Participants/materials, setting, methods: The study was performed at
two locations (Clinic A: Newport Beach, CA; and Clinic B: Austin, TX) involving
6 physicians and differing embryology lab management and protocols. A single
genetics lab performed NGS analysis using MiSeq (Illumina), with genetic noise/
rank evaluated by a geneticist’s interpretation. All embryos were cultured
through day 6, and trophectoderm biopsy and vitriﬁcation performed according
to individual lab procedures. Implantation was measured by a visual sac and all
pregnancies documented.
Main results and the role of chance: Eighty patients agreed to participate
in this IRB approved study, however 19 (23.8%) failed to achieve inclusion cri-
teria. Fifty-seven eSET’s have been performed to date. Group 1 (Morphology)
achieved a 75.9% implantation and 62.1% ongoing pregnancy rate. Group 2
(Genetics) produced a 78.6% implantation and a 71.4 % ongoing pregnancy
rate. There was no statistical difference (p>0.05) between either group for
implantation, spontaneous abortion and/or ongoing pregnancy rate. Between
clinics, clinic A accomplished a combined 96.7% implantation rate and 87.1%
ongoing pregnancy, while clinic B had a 53.8% and 42.3% implantation and
pregnancy rate, respectively. Clinic A exhibited no trends (p<0.1) between
morphology and genetics, whereas clinic B revealed a preference for Group 2
(Genetics) for ongoing pregnancy. The latter ﬁnding that genetic proﬁle ranking
is associated with reduced miscarriage rates, warrants further investigation with
a larger sample population. There were no signiﬁcant differences between labs
regarding fertilization rates, blastocyst yields or euploid rates. Patient age was
not different between clinics, with a mean of 34 years old for qualifying partici-
pants. Clinic A had a single physician perform all stimulation and transfers,
whereas Clinic B involved a rotation of 5 physicians for treatment.
Limitations, reasons for caution: Although sample size was low, it is
important to note that patient selection was not biased, with study qualiﬁcation
requiring two top quality euploid blastocysts, not achievable for all IVF patients.
Levels of mosaicism under 30% were classiﬁed as euploid and further scrutiny
of extremely low levels was not performed.
Wider implications of the ﬁndings: Morphological grading has long been a
standard for improving IVF success rates. With the adoption of NGS testing,
more scrutiny of the PGS results has placed further importance on the role of
the evaluating geneticist. This study indicates to the contrary, the embryologist
is still vital for eSET embryo selection.
Trial registration number:None.
P-191 Development of a Mouse Embryo Assay with enhanced
sensitivity for detection of peroxides in mineral oil samples
E. Mestres1, M. Garcia-Jimenez1, L. Faes2, I. Vanrell1, V. Bogaert2,
I. Jonckheere2, A. Casals1, C. Llop1, N. Costa-Borges1, G. Calderon1
1Embryotools S.L., R&D, Barcelona, Spain
2FertiPro N.V., R&d, Beernem, Belgium
Study question: How can culture conditions alter the sensitivity and reliability
of the Mouse Embryo Assay (MEA), used for detection of toxicity in mineral oil
samples?
Summary answer: Culture conditions can greatly alter the sensitivity of the
MEA and must be carefully optimized to ensure a reliable detection of embryo-
toxic mineral oil samples.
What is known already: Mineral oil has been a key component in IVF since
Brinster described its use for oocyte/embryo culture in 1963. Overlaying cul-
ture medium micro-droplets with mineral oil helps stabilizing temperature, pH
and osmolarity during culture, as well as protecting against external contami-
nants. However, as a petroleum-derived product, mineral oil can harbor
undesired components (e.g. peroxides) that may adversely affect fertilization
and embryo development. Peroxides can originate during oil manufacturing,
and its inadequate storage/handling can result in an increase of peroxides over
time. Thus, it is essential to develop quality control assays with enhanced sensi-
tivity to detect toxicity in mineral oil samples.
Study design, size, duration: Mineral oil samples, produced by an ART-
medium manufacturer (FertiPro), were exposed to UV-light for different time-
periods to induce peroxide formation. Peroxide levels after exposure were
determined by potentiometric titration (detection limit <0.1mEq/kg), and sam-
ples were MEA tested in our laboratory (Embryotools). Different culture condi-
tions (concentration and type of protein supplement, individual vs. group
embryo culture, culture dish design) were tested on each oil sample, and results
compared to establish optimal parameters for sensitive toxicity detection.
Participants/materials, setting, methods: Experiments were performed
with one-cell freshly collected mouse embryos (n = 2066). Three replicates
were performed on each oil sample with the different culture conditions estab-
lished: medium protein supplement type (HSA+Globulins, HSA or BSA) and
concentration (5 mg/ml, 0.5 mg/ml), embryo density (individual vs. group cul-
ture), and culture dish design (Petri vs. time-lapse dish). Embryo development
was followed and registered daily until the end-points (Day 5 or Day 6).
Blastocysts obtained were ﬁxed and stained for total cell counts.
Main results and the role of chance: A minimum of 80% of expanded blas-
tocysts was obtained in oil with peroxide levels <0.1mEq/kg, regardless of the
type and concentration of protein used. By contrast, no blastocysts formed in
oil samples with high peroxide concentrations (0.198, 0.503, 0.756mEq/kg).
Interestingly, when an oil sample with peroxide levels close to the detection
limit was used (0.128mEq/kg), culture conditions showed a strong inﬂuence on
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the assay’s sensitivity. High embryo density (group culture) and medium supple-
mentation with BSA resulted in higher blastocyst formation rates, indicating a
lower capacity to detect embryotoxicity than individual culture and HSA or
HSA+Globulins supplements. In HSA and HSA+Globulins groups, lower pro-
tein concentrations (0.5 mg/ml) also yielded more blastocysts (p = 0.0013)
than higher protein concentrations (5 mg/ml), reducing the assay’s sensitivity.
By contrast, lower concentrations of BSA resulted in diminished blastocyst
formation, compared to higher concentrations (p = 0.0018). Total cell number
was signiﬁcantly decreased in HSA and HSA+Globulins (p<0.005) groups, but
not with BSA, once again demonstrating the reduced sensitivity of the latter.
Culturing in a time-lapse dish (Embryoslide®, Vitrolife) improved develop-
mental rates in all protein groups (p≤0.005), possibly because its design entails
less contact surface between the culture medium and the oil overlay, hence
reducing its sensitivity for mineral oil embryotoxicity detection.
Limitations, reasons for caution: This study conﬁrms that culture condi-
tions must be carefully optimized to successfully detect low concentrations of
peroxides in mineral oil. Medium supplementation with BSA, as well as group
embryo culture, signiﬁcantly improved embryo development and can com-
promise the sensitivity of MEA testing, resulting in undetected embryotoxicity
in mineral oil samples.
Wider implications of the ﬁndings: Culture conditions signiﬁcantly modu-
late embryo development, hence playing a major role in quality control testing.
Inappropriate testing of mineral oil derives in diminished sensitivity for embryo-
toxicity detection. As previously reported, even low traces of peroxides in min-
eral oil could dramatically affect clinical human IVF outcomes.
Trial registration number:N/A.
P-192 Systematic single embryo transfer after preimplantation
genetic screening improves overall results (in terms of “normal”
ongoing pregnancies) and should be widely implemented
G. Barrenetxea Ziarrusta1, E. Martínez2, M. De Las heras2,
G. Ohiane2, J.I. Arambarri3, J. Barrenetxea4
1REPRODUCCION BILBAO, Gynecolgy & Assisted Reproduction, BILBAO, Spain
2Reproducción Bilbao, Lab. Embriology, Bilbao, Spain
3Reproducción Bilbao, Gynecology & Obstetrics, Bilbao, Spain
4Complejo Hospitalario de Navarra, Gynecology & Obstetrics, Pamplona, Spain
Study question: Why do most of specialists transfer 2 (or more) embryos in
most of the assisted reproduction procedures, even knowing that multiple preg-
nancies constitute a real (and sometimes hazardous) complication?
Summary answer: The transfer of a genetically screened embryo after sys-
tematic application of blastocyst culture allows the achievement of high preg-
nancy rates and reduction of multiple pregnancies.
What is known already: Even knowing the complications of multiple preg-
nancies (MP), 2 (even 3) embryos are transferred in most assisted reproduction
procedures in many countries. The main reason for such a policy is to try to
achieve high pregnancy rates per transfer even though multiple pregnancies
represent a risk both for women and offspring. PGS along with the blastocyst
culture allows the selection of the embryo with the highest odds to implant and
to become an ongoing, normal and successful.
Study design, size, duration: Retrospective cohort analysis of a total of 530
embryos genetically screened from 117 successive PGS cycles performed during
one year period (June,2016-May,2017) at a University associated ART center
were analyzed.
Cycles involving PGD for monogenic disease or chromosomal abnormalities
were excluded. Also, cycles in donor eggs were used were not included.
Participants/materials, setting, methods: Due to previously reported
results (ESHRE Geneva) systematic single embryo transfer (SET) is offered to all
patients at our center. After being informed, each patient gave informed con-
sent form for the procedure.
Rates of euploidy depending on the day of embryo biopsy and age of patients
were assessed. Efﬁciency of treatment was deﬁned as the ongoing pregnancy
rate (OPR) per transferred embryo and was analyzed depending on age of
patients.
Main results and the role of chance: The mean number of microinjected
MII microinjected was 12,99. After the fertilization of 766 oocytes, a total of
530 embryos were genetically screened (4,53 per cycle). Euploidy rates were
different depending on the day of embryo biopsy: 17,78%, 44,68% and 21,69%
of the assessed embryos were genetically normal after embryo biopsies per-
formed on days 3, 5 and 6 respectively (p = 0,032). As expected, aneuploidy
rates increased with advanced age of patients. Almost half of the embryos
(46,94%) from women aged 30-35 were genetically normal, whereas only
26,32% and 8,82% of embryos from women aged 36-40 and 41-45 respectively
were euploidic (p = 0,021).
Irrespective of the day of the biopsy, the OPR after single embryo transfer of
genetically selected embryos was high either among fresh or frozen-thawed
embryo transfers. Overall ongoing pregnancy rate per transfer was 67,09%. In
the cleavage stage biopsy setting, 12 out of 22 fresh embryo transfers (54,55%)
and 8 out 12 frozen-thawed embryo transfers (66,67%) resulted in ongoing
pregnancies. Among embryos biopsied at blastocyst stage, the ongoing preg-
nancy rate was 73,33% (33 out of 45 transferred embryos).
No multiple pregnancy was suffered during the study period.
Limitations, reasons for caution: The number of patients included and the
retrospective nature of the study should make us cautious regarding the results.
Randomized trials would be needed to corroborate the results shown in the
present study.
Wider implications of the ﬁndings: As specialists, we should not accept
multiple pregnancies as an “unavoidable” side effect of assisted reproduction in
the 21st Century. Furthermore, improvements in embryo culture systems,
freezing-thawing procedures and genetic assessment of embryos, among
others, should be fully (and really) incorporated into practice.
Trial registration number:Not applicable.
P-193 Safety of ﬂuorescence lifetime imaging microscopy (FLIM)
as a non-invasive assessment of embryometabolism
M. Venturas Pedro1, T. Sanchez1, E. Seidler2, D. Sakkas2,
D. Needleman1
1Harvard University, Molecular and Cellular Biology, Cambridge, U.S.A.
2Boston IVF, Reproductive Endocrinology and Infertility, Waltham, U.S.A.
Study question: Is the illumination from FLIM-based metabolic imaging safe
for embryos?
Summary answer: Using two assays, we found that excessive FLIM illumin-
ation dosages caused a transient perturbation to embryos, whereas a limited
clinical dosage had no measurable effect.
What is known already: Embryo mitochondrial health is known to be essen-
tial for viability. Metabolic imaging uses FLIM to measure autoﬂuorescence of
the endogenous molecules, NADH and FAD, which are essential for cellular
respiration. We have show that this technique is an effective tool for quantita-
tively measuring metabolic state; but in order to develop it into a clinical appli-
cation, we must understand the effects of the technique’s illumination on
embryos. The primary cause for potential damage using FLIM illumination is the
generation of ROS due to the photochemical absorption of light, hence we
investigated whether FLIM produced elevated ROS levels.
Study design, size, duration: We conducted a prospective observational
study. Mouse embryos were illuminated using carrying degrees of photo
dosages (intended clinical dose and varying excessive dosages) and were com-
pared to control groups that received no illumination. We tested four illumin-
ation conditions with a total of 155 illuminated embryos and 122 non-
illuminated control embryos. Embryo ROS levels were then measured, and
metabolic measurements using FLIM were also taken to determine whether illu-
mination had affected metabolic state.
Participants/materials, setting, methods: We used an on-stage incuba-
tion system to culture embryos from the 2-cell stage until blastoscyt. During
this period, we took metabolic measurements of the embryos at regular inter-
vals. To vary photodosage, we performed this experiment with varying intervals
of illumination, from 2 hours to 24 hours. Control embryos were cultured in
the same chambers but were not illuminated. After FLIM illuminations, we used
an ROS reporter dye (HC-DCFDA) to measure intracellular ROS levels.
Main results and the role of chance: ROS levels were quantiﬁed by taking
a simple measure of HC-DCFDA intensity, using custom units. According this
measure, none of the illumination conditions resulted in signiﬁcant differences
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compared to non-illuminated control groups of embryos (p values < 0.05). The
following dosages produced these mean values (± SD). For 44 metabolic mea-
surements: 6.65 ± 1.81 (n = 39) for control and 6.59 ± 1.83 (n = 37) for
experimental group; 24 measurements: 5.69 ± 1.22 (n = 32) for control and
5.58 ± 0.7(n = 36) for the experimental; 3 measurements: 4.42 ± 1.07 (n =
33) for control and 4.18 ± 0.80 (n = 33) for experimental group; 1 measure-
ment: 4.42 ± 0.71 (n = 33) for control and 4.18 ± 0.80 (n = 33) for experi-
mental group. We validated our assay by comparing to the positive control of
adding H2O2 to embryos, which produced a mean value of 11.76 ± 1.97.
Additionally, we performed several experiments in which we took a single
metabolic measurement of illuminated and non-illuminated groups.
Interestingly, we found our method performed with superior sensitivity, as
there were signiﬁcant, yet transient, shifts for the metabolic parameters for
excessive dosages between the illuminated and the control group. These effects
where reversed after 24 hours.
Limitations, reasons for caution: Although we did not observe signiﬁcant
increases in ROS levels, our data showed large variations in ROS measure-
ments. We concluded that this popular assay has limited sensitivity to subtle
ROS differences. Also, safety data must be obtained using human embryos to
further validate this technique for clinical application.
Wider implications of the ﬁndings: These data complement previous
safety studies showing that FLIM illumination affects neither blastocyst develop-
ment nor live birth rates in mouse. Together, these results support the safety of
using metabolic imaging as a potential embryo selection tool. Future experi-
ments on human embryo samples are planned in the clinic.
Trial registration number:Not aplicable.
P-194 Reproductive outcomes in patients with severe
oligospermia undergoing intracytoplasmic sperm injection using
testicular versus ejaculated sperms
S. Hebisha1, H. Saleh2, B. Aboelazm1, M. Sakr3, N. Abdellatif4,
S. Zakaria5
1Faculty of Medicine-Alexandria University, OBGYN, Alexandria, Egypt
2Faculty of medicine-Alexandria Uinversity, obgyn, Alexandria, Egypt
3Faculty of Medicine-Alexandria University, urosurgery, Alexandria, Egypt
4Medical Research Institute- Alexandria University, pathology, Alexandria, Egypt
5Pharos University, science, Alexandria, Egypt
Study question: To compare intracytoplasmic sperm injection (ICSI) out-
come in patients with severe oligospermia using testicular versus ejaculated
sperms.
Summary answer: In patients with severe oligospermia,TESE should be con-
sidered as it offers higher pregnancy rates.
What is known already: In infertile men with severe oligospermia (sperm
concentration <5 million/mL) undergoing ICSI the choice between using
repeatedly ejaculated sperm or recommending use of testicular sperm remains
controversial.
Testicular sperm have shown lower levels of DNA damage compared with
ejaculated spermatozoa from the same individuals, however testicular sperm
exhibit higher rates of chromosomal abnormalities.
Study design, size, duration: Retrospective cohort study.
Patients with severe oligospermia who underwent ICSI cycles with either tes-
ticular or ejaculated sperm between January 2014 and December 2016 were
included in this study.
205 couples met the study criteria after exclusion of cycles with mixed sperm
sources.
Participants/materials, setting, methods: Patients were divided into 2
groups (Group A) included 104 patients in which ejaculated sperms were
obtained while (Group B) included 101 patients where fresh testicular sperms
were extracted (TESE).
The medical records of the included couples were reviewed and tabulated
regarding demographic data, hormonal proﬁles and different semen
parameters.
After micro injection; fertilization rate, cleavage rates, embryo quality,
implantation and pregnancy rates were evaluated and compared in both
groups.
Main results and the role of chance: There was no signiﬁcant difference in
the fertilization rate between the two subgroups (group A 67.93%, group B
68.01%, p = 0.960), however the cleavage rate of day 2 embryos was signiﬁ-
cantly higher when testicular sperm cells were used (47.37% vs 42.77%, p =
0.024*).
Implantation rate was slightly lower in group A compared to group B but
without statistical signiﬁcance (25.23% and 29.77% respectively, p = 0.292).
There were no statistically signiﬁcant differences between both subgroups
regarding number and quality of day 3 and day 5 embryos.
Pregnancy rate was signiﬁcantly higher in group B where testicular sperm cells
were used (54.45% vs 40.38, p = 0.044*).
Limitations, reasons for caution: Prospective randomized studies involving
larger number of cases are needed to establish whether TESE should be per-
formed as a routine step in infertile males with severe oligospermia or should it
be limited to cases with previous ICSI failure.
TESE remains a surgical intervention with possible associated risk.
Wider implications of the ﬁndings: Sperm source can lead to better ICSI
outcome in this certain group of patients; such ﬁnding may extend to include
infertile males with abnormal DNA fragmentation testing.
Trial registration number: The study was revised and approved by the ofﬁ-
cial ethical committee of Faculty of Medicine, Alexandria University, Egypt.
P-195 Sequential low oxygen culture improves blastocyst rate and
morphokinetics in a randomised controlled study onmouse embryo
assays (MEA)
T.N.Q. Nguyen1, B. Greene2, I. Bardua3, C.Wrenzycki4,
U.Wagner3, M. Kalffsuske3, V. Ziller3
1Universitätsklinikum Gießen und Marburg GmbH, Klinik für Frauenheilkunde und
Geburtshilfe, Marburg, Germany
2Philipps University Marburg, Institut of medical biometry and epidemiology,
Marburg, Germany
3University hospital Giessen and Marburg, Department of gyn. endocrinology and
reproductive medicine, Marburg, Germany
4Jutus-Liebig-University Giessen, Clinic for obstetrics- gynecology and andrology of
large and small animals, Giessen, Germany
Study question: Does the sequential low oxygen concentration have better
results in embryo development and morphokinetics than the commonly used
cell culture condition on mouse model?
Summary answer: Sequential low oxygen concentration signiﬁcantly
improves blastocyst rate and morphokinetics compared to constant low and
high oxygen tension on mouse model.
What is known already: Mammalian fertilization and early embryonic devel-
opment occur in oviduct and uterus. In both organs, oxygen tension rises from
day 1 to 3 between the eight-cell-morula stage and blastocyst formation, and
then drops when the blastocysts are fully developed and implantation begins.
Therefore, this study used time-lapse technique as a tool to investigate the
effects of this sequential low oxygen concentration (7% from day 1 to day 2, 2%
from day 3 to day 5) in mouse embryo development and morphokinetic analysis
of cell division compared to low (5%) and high (20%) oxygen tension, giving
insight into potential improvement in ART.
Study design, size, duration: To determine the best oxygen concentrations
which have the most beneﬁcial results in ART, we designed a randomized study
employing mouse embryos. 314 zygotes were arranged randomly into three
parallel groups consisted of high atmospheric oxygen concentration (20%) (n =
93), low oxygen (5%) (n = 129), and mixed (7% from day 1 to 2 and 2% from
day 3 to 5) (n = 92). Blastocyst rate and morphokinetic analysis of cell division
were recorded using a Primovision-System.
Participants/materials, setting, methods: Hybrid Bl6/CBAca MEA was
used to identify morphokinetic cleavage parameters derived from time-lapse
imaging. Female mice were sacriﬁced and zygotes were isolated 20-hours post-
insemination. They were cultured in Primovision micro-well culture dishes using
GTL Medium (Vitrolife) and observed in the Primovision system that integrates
a digital inverted microscope into a standard high volume Memmert IVF incuba-
tor. Pictures of embryos were taken at 10 minute intervals for 5 days. Statistical
analyses were performed using R program.
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Main results and the role of chance: Blastocyst rate at 120 hours in mixed
group (91,3%) was signiﬁcantly increased compared to high (76,34%) and low
group (74,42%), p = 0.009 and 0.001, respectively. Moreover, cell division of
mixed group was signiﬁcant faster in almost every cleavage stages comparing to
the other groups, including p = 0.014 at 2 pronuclei stage (2PN) (mixed vs
high), p = 0.002 at 2-cells stage (2 C) (mixed vs low), p = 0.005 at 5-cell stage
(5 C) (mixed vs high), p = 0.009 at 8-cell stage (8 C) (mixed vs high), p = 0.031
and p = 0.034 at morula stage (mixed vs low, and mixed vs high, respectively),
p = 0.001 at early blastocyst formation (mixed vs high), p = 0.005 at hatching
stage (mixed vs low). Notably, the interim events was also signiﬁcantly different
between the groups, such as p = 0.022 (mixed vs low) and p = 0.002 (mixed vs
high) from 3 C to 4 C, p = 0.001 (mixed vs low) and p < 0.001 (mixed vs high)
from 3 C to 5 C, p = 0.032 (mixed vs low) and p < 0.001 (mixed vs high) from
4 C to 5 C, and p < 0.001 (mixed vs high) from 2 C to 5 C.
Limitations, reasons for caution: This in-vitro study used surrogate para-
meters as morphokinetics and blastocyst rates. No data on pregnancy or birth
rates can be provided as blastocysts were not transferred due to German law
restrictions. The results may differ on embryo development in different labora-
tory settings such as types of incubator and laboratory procedures.
Wider implications of the ﬁndings: If further research shows improved
ART outcome in sequential low oxygen culturing, this should enter clinical ART
management.
Trial registration number:N/A.
P-196 Female age affects DNA repair gene expression in mouse
GV oocytes from stimulated and unstimulated cycles and in MII
oocytes matured in-vivo and in-vitro
A. Ravichandran1, F. Horta1, S. Catt1, B. Vollenhoven1,2,
P. Temple-Smith1
1Monash University, Obstetrics and Gynaecology, Melbourne, Australia
2Monash IVF, Reproductive Medicine, Melbourne, Australia
Study question: Does female age affect DNA repair gene expression in GV
oocytes from stimulated and unstimulated mice and MII oocytes matured in-
vivo and in-vitro?
Summary answer: Age has a major impact on DNA repair genes during the
GV-MII transition in stimulated and unstimulated cycles.
What is known already: Gene expression patterns in germinal vesicles (GV)
and metaphase II (MII) oocytes change with age. Oocyte maturation involves
extensive degradation of maternal transcripts suggesting that GVs would have a
larger number of mRNA transcripts than MII oocytes. Nevertheless, GVs from
aged females show a decrease in numbers of transcripts compared to young
GVs, and likewise in old MII oocytes compared to young MII oocytes. DNA
repair gene expression patterns may give clearer links to repair competency
during early embryo development. Understanding molecular signatures that
predict genetically stable oocytes with higher developmental competency may
result in better prognosis for reproductive treatments.
Study design, size, duration: GVs were collected from 4 stimulated and 4
unstimulated young (5-8 weeks) and old (42-45 weeks) mice respectively. From
the stimulated cycles 20 GVs (stim-GVs) and 20 MIIs (in vivo-MII) were collected
for each age groups. For unstimulated cycles 20 GVs (unstim-GVs) were used
for analysis and a further cohort were matured in order to collect 20 MIIs for
analysis (IVM-MIIs). Expression proﬁles were determined in all 4 groups per
female age.
Participants/materials, setting, methods: C57BL6 female mice were
used. Unstimulated GVs were in vitromatured in culture for 18hrs, and resulting
MIIs collected. Oocytes for each treatment were pooled (n = 5), snap frozen
and stored at -80C for later cDNA synthesis. cDNA synthesis was performed
using the Single Cell-to-Ct Kit (Ambion, Life technologies) and cDNA samples
were tested for DNA repair gene expression of 90 DNA repair genes using the
Fluidigm Biomark HD system GE 96×96 Standard v2 Biomark Protocol.
Main results and the role of chance: Comparing MII oocytes to GV
oocytes in both age groups, signiﬁcant differences in gene expression were
observed between in vivo-MII and IVM-MII oocytes (95% Conﬁdence Interval,
95%-IC). The number of signiﬁcantly down-regulated genes in IVM-MIIs from
younger females, were greater than in vivo-MII (Young IVM-MII: 38 genes;
Young in vivo-MII: 25 genes, 95%-IC). In aged oocytes, the expression pattern
was reversed, with more DNA repair genes signiﬁcantly up-regulated in IVM-
MII and in vivo-MII oocytes than GVs (Old IVM-MII: 22 genes; Old in vivo-MII: 12
genes, 95%-IC). Also, in older females more DNA repair genes were down-
regulated in IVM-MII oocytes than in in-vivo-MIIs (Old IVM-MII: 13 genes; Old in-
vivo-MII: 4 genes, 95%-IC), suggesting that IVM has a different effect on MII
repair genes than in vivo maturation in stimulated oocytes, with potential reper-
cussions on oocyte quality. The key DNA damage response gene, H2AFX, was
always down-regulated in MII oocytes compared to GV oocytes irrespective of
maturation type (95%-IC). Conﬁdence intervals were used to establish differen-
tial expression in DeltaDeltaCt analysis while Mann-Whitney was used to test
relative expression of DeltaCt analysis.
Limitations, reasons for caution: The two age groups in this study were
selected to represent women at either end of their reproductive lives, but clin-
ical studies are required to conﬁrm this effect in women. However, challenges
in obtaining either unstimulated and/or stimulated MII oocytes for research
may limit studies to human GVs.
Wider implications of the ﬁndings: Our results show DNA repair gene
expression in oocytes is affected in older females, suggesting that this may also
be linked with decreased DNA repair capacity in both GV and MII oocytes.
These ﬁndings will direct future research to develop novel methods to assess
the effects of aging on fertility.
Trial registration number:N/A.
P-197 Embryos derived from late maturing oocytes show no
increased risk of chromosomal aneuploidy as assessed by Next
Generation Sequencing (NGS) and can achieve clinical pregnancies
M. Cooney, J. Mullen
Monash IVF, Embryology, Clayton, Australia
Study question: Are oocytes that are immature at cumulus removal but
mature by the time of insemination capable of normal fertilization and develop-
ment into chromosomally euploid embryos?
Summary answer: Late maturing oocytes, inseminated by intraplasmic sperm
injection (ICSI), if fertilized, can form chromosomally euploid embryos and are
capable of establishing clinical pregnancies.
What is known already: Approximately 20% of retrieved oocytes from con-
trolled ovarian stimulation cycles are found to be immature as either metaphase
I (MI) or germinal vesicle (GV) stage at the time of cumulus cell removal.
Debate exists as to whether these immature oocytes should be utilised if, after
further evaluation, they are observed to extrude a polar body during the period
of in vitro culture prior to insemination. The chromosomal constitution and
developmental competence of these in vitro matured oocytes has not been
adequately explored, with conﬂicting views on the rates of multinucleation and
aneuploidy in the resulting embryos.
Study design, size, duration: A retrospective study was undertaken for
1902 autologous ICSI cycles performed between January-August 2017. Fresh
or frozen spermatozoa were used for ICSI insemination.
Participants/materials, setting, methods: Autologous ICSI cycles that
had one or more MI oocyte at the time of cumulus cell removal (38 hours post
trigger) were included in the study. Embryos were cultured in Vitrolife sequen-
tial media and COOK mini-incubators. After laser ablation of the zona on day
3, 5-10 trophectoderm cells were biopsied on day 5 or 6 and embryos immedi-
ately vitriﬁed. Genetically euploid embryos were warmed and transferred indi-
vidually. PGS cycles were performed only at patient request.
Main results and the role of chance: In total 21,138 oocytes were col-
lected from 1902 ICSI cycles. Of these, 75.2% were mature (metaphase II, MII)
at the time of cumulus removal and 14.4% were MI. Of the MI oocytes, 42.6%
progressed to mature to MII 4-6 hours after oocyte collection and were insemi-
nated via ICSI. Overall, the fertilisation rate after ICSI of the late maturing
oocytes was lower than those that were MII at the time of initial cumulus cells
removal (41.9% v 64.8%, p<0.05). In total 80 transfers were performed (34 at
day 3, 46 at day 5/6) with 51 fresh and 28 frozen embryos resulting in 18
ongoing pregnancies with to date, 2 live births.
A sub-group of embryos resulting from late maturing oocytes were ana-
lysed by NGS to assess their chromosomal composition. Thirty one
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blastocysts were biopsied and vitriﬁed. Seventeen of the thirty-one embryos
(54.8%) were found to be euploid and deemed suitable for embryo transfer
in future frozen embryo transfer cycles. To date, six singleton embryo trans-
fers have occurred resulting in four ongoing pregnancies (4/6, 66.7%) in
patients aged 44, 43, 39 and 34. These results refute previous reports that
suggest late maturing oocytes are more likely to produce embryos with
chromosomal aneuploidies.
Limitations, reasons for caution: This study looks at patients of all ages
and aetiology. Genetic testing was limited to patients who had selected to
undergo a PGS cycle.
Wider implications of the ﬁndings: The maturation status of oocytes at
the time of cumulus removal does not indicate an increased risk of chromo-
somal aneuploidy in the resulting embryos. Late maturing oocytes should be uti-
lised for patients undergoing ICSI as they can result in genetically tested euploid
embryos and clinical pregnancies.
Trial registration number:Not applicable.
P-198 Optimal timing of trophectoderm biopsy for
preimplantation genetic screening (PGS)
E.A. Park1, R. Kim2, B.Y. Kim1, J.Y. Lee1, S.Y. Moon1, K.H. Choi1,
H.H. Kang1, J.I. Baek1, H.J. Jeong1, J.J. Ko3, J.H. Lee1,3, Y.S. Kim2,
M.K. Koong2, I.S. Kang2, T.K. Yoon2
1CHA Fertility Center Seoul Station, Research, Seoul, Korea- South
2CHA Fertility Center Seoul Station-CHA University, Department of Obstetrics and
Gynecology, Seoul, Korea- South
3CHA University, Department of Biomedical Science- College of Life Science,
Pocheon, Korea- South
Study question: Is the timing of trophectoderm biopsy associated with suc-
cessful pregnancy after the embryo transfer of blastocyst subjected to preim-
plantation genetic screening (PGS)?
Summary answer: Trophectoderm biopsy(PGS) before or after the cryo-
preservation may be the optimal strategy for the better clinical outcomes com-
pared to the fresh trophectoderm biopsy without cryopreservation.
What is known already: Embryo biopsy and fresh embryo transfer are trad-
itionally performed in the PGS cycle. However, before embryo transfer, the
time allowed for genetic analysis of the specimens is restricted, particularly after
blastocyst biopsy. Cryopreservation of blastocysts after biopsy instead of fresh
transfer permits more sufﬁcient time for performance of molecular diagnosis.
The effect of cryopreservation and thawing/warming procedures on clinical
outcomes in PGS cycle has not been effectively studied.
Study design, size, duration: This retrospective study included women that
underwent IVF with PGS from January 2016 to December 2017. 1469 blasto-
cyst from 306cycles were subjected to trophectoderm biopsy for performing
array comparative genomic hybridization (CGH) test. Embryos were cultured
to expanded blastocyst stage and underwent trophectoderm biopsy on day 5
to day 6 of embryo development.Cycles with complete PGS diagnosis were
306, 161 of which had embryo transfer. The performance of different groups of
PGS patients was evaluated.
Participants/materials, setting, methods: The groups were divided into
three; ﬁrst group (n = 46 transfer/168 cases) contained fresh blastocysts that
biopsied for PGS without cryopreservation followed by embryo transfer. In the
second group (n = 34 transfer/56 cases), the cryopreserved blastocysts were
warmed and biopsied prior to ET. The last group (n = 81 transfer/82 cases),
the blastocysts were initially biopsied then proceeded with vitriﬁcation and
warming before the embryo transfer.
Main results and the role of chance: The total pregnancy rate of fresh
blastocyst biopsied group was 47.8% (22/46), the cryopreserved-warmed-
biopsied blastocyst group showed 70.6% (24/34) and ﬁnally biopsied and
cryopreserved-warmed group showed 55.6% (45/81), respectively. First group
is signiﬁcant higher pregnancy rate than second group.(p = 0.043). Also, The
second(cryopreserved-warmed –biopsied) group showed slightly higher
numerical pregnancy rate than third (biopsied and cryopreserved-warmed)
group.
Limitations, reasons for caution: This is a retrospective study and had
some limited case numbers for analysis.
Wider implications of the ﬁndings: Using currently available data, when
faced with the option of fresh embryos, before or after trophectoderm biopsy
for PGS, our result supported performing the biopsy before or after embryo
cryopreservation and thawing.
Trial registration number: not applicable.
P-199 Synchrony or morphology: embryo-endometrial synchrony
is more important than embryomorphology as a predictor of
in vitro fertilization outcomes
I. Park1, H. Sun1, J. Kim1, K. Lee2, C. Sim2, Y. Jeung2, H. Chi2,
S. Kim2, J. Park2, S. Kwak2, C. Yoo2
1Liora fertility center, Busan, Korea- South
2Mamapapa & baby Hospital, obstetrics and gynecology, Ulsan, Korea- South
Study question: Which one is better as a predictor of in vitro fertilization
(IVF) outcomes, synchrony or morphology?
Summary answer: Embryo-endometrial synchronization, represented by
proper embryo developmental speed, could be a better predictor of IVF suc-
cess than good morphology.
What is known already: Embryo morphology including blastomere sym-
metry and fragmentation is well-known and most commonly used as a predictor
of IVF outcomes. Therefore, transferred embryos are usually selected by mor-
phological assessment. Embryo-endometrial synchronization which is repre-
sented by developmental speed coincident with embryo stage is also an
important predictor of IVF outcomes.
Study design, size, duration: This was retrospective study with fresh
embryo transfer on day 3 between January 2015 and December 2016. This
study included 428 women who had two transferred embryos of same blasto-
mere number.
Participants/materials, setting, methods:Women transferred two slowly
developing day 3 embryos with good morphology embryo were divided into 2
groups by blastomere number.
S1 – two 4 cell embryos with good morphology.
S2 – two 6 cell embryos with good morphology.
Women transferred two properly developed 8 cell day 3 embryos were
divided into 3 groups by grade.
G1 – two grade 1 8cell embryos.
G2 – two grade 2 8cell embryos.
G3 – two grade 3 8cell embryos.
Main results and the role of chance: In each group, age and AMH level
reﬂected no differences. Pregnancy rate (PR) of S1 [7.4%(2/27)] was signiﬁ-
cantly lower than PR of G1[69.3%(138/199), P<0.01] and G2[54.0%(81/
150), P<0.01]. It was also signiﬁcantly lower that of G3[35.7%(10/28), P =
0.02]. PR of S2 [37.5%(9/24)] was signiﬁcantly lower than PR of G1[69.3%
(138/199), P<0.01]. However, it did not show signiﬁcant difference as com-
pared with that of G2[54.0%(81/150), P = 0.198] or G3[35.7%(10/28), P
= 0.876].
Limitations, reasons for caution: This is a retrospective study. The sample
size of each group shows difference among groups.
Wider implications of the ﬁndings: Implantation potential of slowly devel-
oping embryos with good morphology is lower than properly developed low
grade embryos. It is probably that slowly developing embryos do not synchron-
ize endometrial implantation window. Therefore, properly developed low
grade embryos rather than slowly developing good morphology embryos
should be selected for fresh embryo transfer.
Trial registration number:None.
P-200 Testicular sperm of severe oligo-cryptozoospermia patient
may expect to improve clinical outcomes compared with ejaculated
sperm
K.Y. Kang1, B.Y. Kim1, J.W. Park1, E.B. Joe1, K.H. Choi1, H.H. Kang1,
E.A. Park1, J.H. Lee1,2, J.J. Ko2, Y.J. Hur3, D.K. Kim4, Y.S. Kim3,
M.K. Koong3, I.S. Kang3, T.K. Yoon3
1CHA Fertility Center Seoul Station, Fertility laboratory, Seoul, Korea- South
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........................................................................................
2CHA University, Department of Biomedical Science- College of Life Science,
Pocheon, Korea- South
3CHA Fertility Center Seoul Station- CHA University, Department of Obstetrics and
Gynecology, Seoul, Korea- South
4CHA Fertility Center Seoul Station- CHA University, Department of Urology, Seoul,
Korea- South
Study question: The purpose was to compare clinical outcomes of in vitro
fertilization-intracytoplasmic injection (IVF-ICSI) between sperm retrieved from
severe male factor (oligozoospermia, cryptozoospermia, TESE -sperm)
patients.
Summary answer: In case of severe male factors, patients with cryptozoos-
permia showed low fertilization and signiﬁcantly low clinical pregnancy rates
compare to patients with oligozoospermia and TESE-sperm.
What is known already: Sperm from severe male factor contains more
DNA damage than sperm from fertile patients as this is due to Reactive
Oxygen Species. Several studies reported that sperm are susceptible to dam-
age during passage through the male reproductive tract. When increased
DNA damaged sperm is used for assisted reproduction, this sperm may be
able to fertilize an oocyte, however, this may result in poor embryo develop-
ment, implantation and pregnancy rates. The sperm quality may be related to
unexplained recurrent pregnancy loss. Some reports states that patients using
testicular sperm showed higher implantation and pregnancy rates than patients
with severe oligoasthenoteratozoospermia syndrome.
Study design, size, duration: From January 2016 to December 2017, our
IVF center performed 9707 IVF-ICSI cycles. Among them, only 299 cycles with
severe male factor were analyzed in this retrospective study. The clinical out-
comes including fertilization and pregnancy rate were compared and the age of
couple was also evaluated in severe male factor groups. Statistical analysis was
performed using ANOVA and chi-squared tests.
Participants/materials, setting, methods: Oligozoospermia was deﬁned
as spermatozoa under 15 × 106/cc; and cryptozoospermia was deﬁned as
spermatozoa observed only in the pellet with sperm concentration under 104
after centrifugation (WHO 2010). However, in this study, we considered oligo-
zoospermia as over 0.1×106/cc to under 15 × 106/cc. TESE sperm was con-
sidered as sperm retrieved from azoospermia patients. In the study, the IVF-
ICSI cycles were divided into three groups. Group 1: Oligozoospermia, Group
2: Cryptozoospermia, Group 3: TESE sperm.
Main results and the role of chance: This study showed a signiﬁcant low
fertilization rate in patients with cryptozoospermia (Group 2) compare to
other groups (Group 1: 81.67%(820/1004), Group 2: 74.45%(303/407),
Group 3: 79.02%(1134/1435); p = 0.009). Furthermore, pregnancy rate
was also signiﬁcantly low in cryptozoospermia patients (Group 1: 40.19%
(43/107), Group 2: 17.78%(8/45), Group 3: 46.27%(62/134); p = 0.003)
than others. However, there was no signiﬁcant difference in fertilization
rate and pregnancy rate between Group 1 and Group 3. In addition, there
was no signiﬁcant difference in both the wife’s age (Group 1: 36.14 ± 4.09
(n = 107), Group 2: 35.04 ± 4.08(n = 45), Group 3: 35.37 ± 4.35(n = 134);
p>0.05), and the husband’s age (Group 1: 38.25 ± 5.10(n = 107), Group 2:
37.60 ± 5.73(n = 45), Group 3: 37.54 ± 5.66(n = 134); p>0.05) in all three
groups.
Limitations, reasons for caution: This is a retrospective study and a limited
number of severe male factor in IVF-ICSI cycles were used for analysis.
Wider implications of the ﬁndings: The ﬁndings of this study indicate that
cryptozoospermia patients, using several cryo-sperms with repetitive IVF-ICSI
cycle failure and pregnancy failure may need to consider an alternative strategy
of using TESE sperm for improved clinical outcomes.
Trial registration number:Not applicable.
P-201 The inﬂuence of blastocyst formation time on the
pregnancy outcomes of vitriﬁed-warmed blastocyst transfer
according to the number of embryo transferred
S.H. Shin, J.H. Cha, J.W. Lee, Y.J. Kim, S.K. Lee, H.J. Cha, J.H. Kim,
D.H. Kim, E.H. Kang, J.H. Ahn, H.Y. Kim, K.A. Pak, J.S. Yoon,
S.Y. Park
Agaon Fertility Clinic, IVF center, Seoul, Korea- South
Study question: Does the blastocyst formation time before vitriﬁcation affect
the pregnancy outcomes in single or double vitriﬁed-warmed blastocyst transfer
(SET or DET)?
Summary answer: Day 5-DET resulted in similar the pregnancy outcomes
compared to day 6-DET while day 5-SET yielded signiﬁcantly higher the preg-
nancy outcomes compared to day 6-SET.
What is known already: Zygotes can reach the blastocyst on day 5 or day 6
after insemination. Many studies on fresh IVF cycles have reported higher the
pregnancy outcomes with the transfer of day 5 blastocyst compared with day 6.
However, it is still unclear whether the blastocyst formation time in vitriﬁed-
warmed blastocyst transfer with studies yielding conﬂicting results affects the
pregnancy outcomes.
Study design, size, duration: A retrospective cohort study of 405 SET or
DET cycles was performed from January 2013 to September 2017. The
cycles with frozen sperm, surgical retrieved sperm, genetic diagnosis, oocyte
donation, poor responder, and advanced maternal age (≥38 years) were
excluded. We compared the rates of good-quality embryos, clinical preg-
nancy, ongoing pregnancy, and implantation between day 5 and day 6
vitriﬁed-warmed blastocyst transfer according to the number of embryo
transferred.
Participants/materials, setting, methods: The cycles were divided into
4 groups based on the blastocyst formation time and the number of
embryo transferred (SET: day 5, n = 107 vs. day 6, n = 104 and DET: day
5, n = 128 vs. day 6, n = 66). The classiﬁcation of warmed blastocysts
quality was evaluated refer to the criteria for classiﬁcation by Gardner and
Schoolcraft.
Main results and the role of chance: Characteristics of the cycles had
no statistically signiﬁcant difference in the female age, male age, infertil-
ity diagnosis, number of embryo thawed, survival rate, good quality
(≥BB) embryos rate, with the exception of male factor infertility, which
was signiﬁcantly more common in the DET (14.1% vs. 25.8%, p =
0.045). Rates of clinical pregnancy, ongoing pregnancy, and implant-
ation in day 5-SET was higher than those of day 6-SET (Table 1).
However, the pregnancy outcomes were not signiﬁcantly different
between day 5-DET and day 6-DET.
Table 1 Comparison of the pregnancy outcomes
between day 5 and day 6 vitriﬁed-warmed blastocyst
transfer according to the number of embryo
transferred.
Day
5-SET
Day
6-SET
P-value Day
5-DET
Day
6-DET
P-value
Cycles (n) 107 104 128 66
Clinical
pregnancy
rate (%)
43.0 20.2 0.000 50.8 43.9 0.366
Ongoing
pregnancy
rate (%)
36.4 17.3 0.002 45.3 37.9 0.321
Implantation
rate (%)
43.9 22.1 0.001 35.2 29.5 0.266
Limitations, reasons for caution: This is a retrospective study. The number
of day 6-DET group was smaller than day 5-DET group. Prospective, further
studies are needed in order to support our results.
Wider implications of the ﬁndings: The blastocyst formation time could
be an independent predictor of the pregnancy outcomes. Although the transfer
of blastocyst derived from day 6 remains a viable treatment option, giving pre-
cedence to blastocyst derived from day 5 could allow opportunity to successful
pregnancy outcomes in SET.
Trial registration number:Not applicable.
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P-202 Morphokinetic differences of human embryo development
according to the type of morphological defects of sperm
M. Ryu, S. Jeong, S. Bark, J. Kim, M. Kim, M. Chung
Seoul Rachel Fertility Center, Fertility Center, Seoul, Korea- South
Study question: Does type of morphological defects of sperm and fertilization
method have an impact on morphokinetics of embryo development?
Summary answer: Morphokinetics of embryo development showed various
difference according to the type of morphological defects of sperm and fertiliza-
tion method, such as IVF and ICSI.
What is known already: Sperm morphology is the important parameter
for evaluation in predicting male fertility potential. Time-lapse monitoring sys-
tem offers evaluation criteria of embryo development that can chance to
select embryos with higher implantation. In recent years, many studies have
been reported that sperm affected in embryo development. But, not well
known about the relation between morphokinetics of embryo development
and type of morphological defects of sperm according to fertilization method.
Study design, size, duration: We performed a retrospective cohort study
on patients undergoing IVF and ICSI cycle from October 2013 to May 2017. A
total of 422 zygotes obtained from 60 patients. Exclusion criteria; A women
who was over 40 years old or an anti-Mullerian hormone (AMH) less than
1.0 ng/㎖. Sperm parameters were evaluated according to 2010WHO criteria.
Correlation between type of morphological defects of sperm and morphoki-
netics of embryo development were analyzed.
Participants/materials, setting, methods: Patients were divided into
three categories; normozoospermatozoa (≥15 million/㎖, motility ≥40% and
normal morphology ≥4%) (Group1), teratozoospermatozoa (normal morph-
ology <4%) with head defects (Group 2), and teratozoospermatozoa with head
and tail defects (Group 3). Zygotes were cultured with the time-lapse monitor-
ing system (Primo vision). Morphokinetics were evaluated as below; time of cell
division (tS-t8) and interval of cell cycle (tS-tSC, cc1: tSC-t2, cc2; t2-t3, cc3; t3-
t5, t2-t5 and s2; t4-t3).
Main results and the role of chance: Time points and durations of cell
cycle in the ICSI embryos were similar in Group1 (n = 76) and Group2 (n =
73) except the times of syngamy to ﬁrst division (tS-tSC) (2.1 ± 0.6, 2.0 ± 0.4,
p = 0.0476) and Group1 and Group3 (n = 55) except synchrony in division
from 3 to 4 cells (s2) (2.0 ± 3.1, 4.3 ± 5.3, p = 0.0143). There were no signiﬁ-
cant differences between Group2 and Group3. In IVF embryos, there were sig-
niﬁcant differences between Group 1 (n = 119) and Group 2 (n = 62)
embryos; tS (27.7 ± 3.6, 30.1 ± 4.9, p = 0.0002), tSC (29.5 ± 3.7, 32.2 ± 5.4,
p = 0.0001), t4 (41.4 ± 5.0, 43.6 ± 6.2, p = 0.0230) and t8 (57.1 ± 6.8, 61.1
± 8.9, p = 0.0099). Signiﬁcant differences were shown between Group 1 and
Group 3 (n = 32) embryos; t8 (57.1 ± 6.8, 62.6 ± 9.9, p = 0.0012) and cc3
(11.9 ± 4.1, 14.1 ± 3.3, p = 0.0093). Also, there were signiﬁcant differences
between Group 2 and Group 3 embryos; tS (30.1 ± 4.9, 27.6 ± 3.7, p =
0.0135), tSC (32.3 ± 5.4, 29.5 ± 3.7, p = 0.0122) and t2 (31.6 ± 3.5, 29.9 ±
3.8, p = 0.0466).
Limitations, reasons for caution: This study was conducted with using
cleavage stage embryos. Because the remaining embryos after transfer were
cultured to blastocyst stage, we excluded it from this study. Based on the this
study, more data will be collected in future prospective studies.
Wider implications of the ﬁndings: We found that type of morphological
defects of sperm affected embryo development in IVF than ICSI. This is prob-
ably due to the high probability that ICSI will select the normal sperm. Our
results suggest that morphological defects is may be an important factor to con-
sider in the morphokinetics of embryo.
Trial registration number:None.
P-203 Effects of tocotrienol-rich fraction supplementation on the
expression of DNA damage response genes in ovary and oocytes
quality in mice exposed to corticosterone-induced oxidative
damage
A.S. Nuraliza1, W.A.R. Zaid2, A. Norrabiatul Adawiyah2,
A. Nasibah1, M. Mudiana3
1Faculty of Medicine- UiTM- Sg Buloh Campus, Physiology, Sg Buloh, Malaysia
2Faculty of Medicine- UiTM- Sg Buloh Campus, Institute of Medical Molecular
Biotechnology, Sg Buloh, Malaysia
3Faculty of Medicine- UiTM- Sg Buloh Campus, Biochemistry & Molecular Medicine,
Sg Buloh, Malaysia
Study question: Does tocotrienol-rich fraction (TRF) supplementation acti-
vate the DNA damage response genes in ovary and improves the quality of
oocytes in mice exposed to exogenous corticosterone that induced oxidative
damage.
Summary answer: Expression of CHEK1 gene that detects DNA damage in
ovary is low and oocytes quality improves following TRF supplementation in
mice exposed to exogenous corticosterone.
What is known already: Chronic exposure to exogenous corticosterone
(CORT) induced-oxidative DNA damage in cells. Female reproductive system
is susceptible to the detrimental effects of oxidative DNA damage leading to a
decline in biological function of ovaries, deteriorate oocytes quality and eventu-
ally contributes to infertility. Tocotrienol-rich fraction (TRF), an antioxidant
plays a protective role in oxidative stress-induced damage thus prevent infertil-
ity in female. The proposed mechanism of action TRF in protecting female
reproductive system from various oxidative damage is by lowering plasma levels
of malondialdehyde (an oxidative stress biomarker), reducing DNA damage in
embryos and upregulating the expression of anti-aging gene in mouse ovary.
Study design, size, duration: Thirty-two (six-week-old) female mice (Mus
musculus) were equally divided into four groups. Group 1: vehicle control was
given via intraperitoneal (i.p) injection, Group 2: CORT (10 mg/kg body weight
(BW) was administered intraperitoneally, Group 3: vehicle controls were given
via i.p injection and oral gavage while Group 4 were administered with CORT
(10 mg/kg BW, i.p injection) and concurrently supplemented with TRF (oral
gavage) at the dose of 150 mg/kg BW for two weeks.
Participants/materials, setting, methods: At the end of the supplementa-
tion period, mice were superovulated and euthanized. The ovaries were col-
lected for total cellular RNA isolation and oocytes were collected for zona
pellucida (ZP) thickness measurement to assess its quality. The gene expression
analysis of ATM, MPG, CHEK 1, CHEK 2 and MLH3 genes was performed using
QuantiGene Plex 2.0 Assay kit.
Main results and the role of chance: Expression of CHEK1, the gene
responsible for the detection of DNA damage was signiﬁcantly higher in the ovary
of mice exposed to exogenous CORT as compared to the control group. The
expression level of CHEK1 gene in CORT group supplemented with TRF on the
other hand was found to be normalized towards control value. However, expres-
sion of other DNA damage response genes was not signiﬁcantly different in all
groups as compared to its respective control. The ZP thickness of oocytes in
mice exposed to exogenous CORT increased signiﬁcantly as compared to its
control. Conversely, TRF supplementation reduced ZP thickness of oocytes in
mice exposed to exogenous CORT towards control. Upregulation of DNA dam-
age response genes play a signiﬁcant role in the maintenance of cell by activating
various signalling network that detect and repair the oxidative stress induced-
DNA damage in mice ovary exposed to exogenous CORT thus protect the
ovary and maintain the production of good quality oocytes.
Limitations, reasons for caution: Gene expression analysis can only be
done using ovarian tissue and not using oocytes as large quantity of oocytes is
required for gene expression analysis.
Wider implications of the ﬁndings: Tocotrienol-rich fraction supplementa-
tion blocks the adverse effect of exogenous CORT in inducing oxidative DNA
damage, as indicated by the low expression of CHEK1 gene that detects DNA
damage in mice ovary. Consequently, by protecting ovary from oxidative damage,
TRF maintain the quality of oocytes and hopefully will potentially improve fertility.
Trial registration number:N/A.
P-204 Is vitriﬁcation-warming of embryos developed from vitriﬁed
oocytes (double vitriﬁcation) an effective procedure for
heterologous IVF program with egg donation?
R. Picone, F. Bertocci, P. Evangelisti, R. Fucci, C. Giachini,
E. Borrani, P. Falcone, L. Badolato, F. Rizzello, C. Cozzi,
C. Romanelli, M.G. Servidio, L. Criscuoli, M.E. Coccia
Careggi University Hospital, assisted reproduction technology, Florence, Italy
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Study question: To evaluate the efﬁcacy of transfer of vitriﬁed-warmed (V-W)
embryo derived from V-W oocyte (double vitriﬁcation) in heterologous IVF pro-
grams with egg donation.
Summary answer: Transfer of V-W embryo derived from V-W oocyte
allows to obtain results statistically comparable to those obtained with fresh
embryo derived by V-W oocytes.
What is known already: Advances in reproductive techniques, i.e. the intro-
duction of oocytes vitriﬁcation, have provided opportunity to conceive from
oocytes banks. The vitriﬁcation of oocytes and embryos is the gold standard
method used worldwide for cryopreservation in infertility management and fer-
tility preservation. The IVF outcome, in terms of pregnancy and implantation
rate, are comparable with those obtained with fresh oocytes/embryos.
Study design, size, duration: This is a prospective study aimed to evaluate
the efﬁcacy of double vitriﬁcation in heterologous IVF cycles with oocytes dona-
tion at the IVF clinic of Careggi University Hospital of Florence, from 2016 to
2017. We compared pregnancy and implantation rates of transfer of V-W
embryos derived from V-W oocytes (double vitriﬁcation) with transfer of fresh
embryos derived from V-W oocyte (single vitriﬁcation), that represent our con-
trol population.
Participants/materials, setting, methods: From January 2016 to
December 2017 we performed 49 transfer of V-W embryos derived from V-W
oocytes; as controls we included 329 transfer of fresh embryos obtained from
V-W oocytes within our egg donation program. We used the Kitazato
vitriﬁcation-warming protocol; embryo transfers were performed in day 3 or
day 5.
Main results and the role of chance: The pregnancy rate per ET cycle was
40,0% in the double vitriﬁcation group and 37,0% in the control group (p =
0,751). The implantation rate was similar in the double vitriﬁcation group and in
the control population (29,7% and 24,7% respectively; p = 0,562).
Limitations, reasons for caution: The age of recipients in our oocytes
donation program is usually advanced (even if less than 50 years old), so this
could inﬂuence uterine receptivity due to several age-related pathologies (such
as ﬁbroids, menopause, endometritis).
Wider implications of the ﬁndings: Our ﬁndings conﬁrmed the efﬁcacy of
the double vitriﬁcation-warming procedure (at oocytes and embryos stage) that
could be used for supernumerary embryos or to postpone embryo transfer
when the endometrial pattern is suboptimal.
Trial registration number:Not Applicable.
P-205 Cell-lineage speciﬁc effects of granulocyte macrophage
colony-stimulating factor (GM-CSF) in mouse blastocysts
T. Pock1, K. Schulte2, S. Schlatt1, M. Boiani3, V. Nordhoff1
1Centre of Reproductive Medicine and Andrology, Experimental embryology,
Münster, Germany
2Central Animal Facility of the Faculty of Medicine, Experimental embryology,
Münster, Germany
3Max Planck Institute for Molecular Biomedicine, Mouse embryology, Münster,
Germany
Study question: Does GM-CSF induce cell lineage speciﬁc differences during
pre-implantation development?
Summary answer: Embryos cultured in medium supplemented with GM-
CSF show signiﬁcantly increased numbers of cells in the pre-implantation state.
The effect is strongest in the trophectoderm.
What is known already: GM-CSF is a cytokine inﬂuencing the maternal-fetal
interface and supporting placental development in mouse and human. It is
expressed in epithelial cells of the endometrium under regulation of estrogens.
A large clinical trial showed that GM-CSF supplemented medium leads to an
increased survival of transferred embryos up to week 12. Especially in women
with previous miscarriages GM-CSF supplementation of culture medium may
improve ongoing implantation rates. However, a research study in mice found
that high concentrations of GM-CSF may have a negative impact on blastocyst
development and total cell numbers of the preimplantation embryo.
Study design, size, duration: Thirty female mice (5-10 weeks pp) were sti-
mulated for zygote isolation. After 4.5 days of culture in deﬁned concentrations
(1, 2 or 5 ng/ml) of GM-CSF a total of 277 embryos were collected and
subjected to immunohistochemical staining. Markers against the three cell lines
trophectoderm (CDX2), epiblast (NANOG) and primitive endoderm
(SOX17) enabled selective counting of cell numbers. 244 embryos were eligible
for further analysis.
Participants/materials, setting, methods: Female mice (B6C3F1) were
superovulated by injection of 5 IU PMSG and 10 IU hCG and mated to males
(C57BL/6 J). Zygotes were isolated on day 0.5 post coitum, pooled and ran-
domly distributed to KSOM(aa) without GM-CSF and medium supplemented
with increasing concentrations of GM-CSF. Zygotes were cultivated until blasto-
cyst stage with a medium refreshment step at day 2.5.
Main results and the role of chance: Total cell numbers of blastocysts
showed signiﬁcant differences between KSOM(aa) without GM-CSF and KSOM
(aa) containing 2 or 5 ng/mL GM-CSF (mean: KSOM(aa): 81.7 cells; KSOM(aa)
+1 ng/mL GM-CSF: 84.5 cells; KSOM(aa)+2 ng/mL GM-CSF: 90.9 cells;
KSOM(aa)+5 ng/mL GM-CSF: 91.4 cells). These differences were mainly due
to changes in trophectoderm cell numbers; we found signiﬁcant differences in
the number of CDX2 positive cells between embryos cultured without GM-
CSF and the two groups containing 2 and 5 ng/mL GM-CSF (mean: KSOM(aa):
65.6 cells; KSOM(aa)+1 ng/mL GM-CSF: 69.5 cells; KSOM(aa)+2 ng/mL GM-
SCF: 74.1 cells; KSOM(aa)+5 ng/mL GM-SCF: 73.8 cells; p ≤ 0.01).
Additionally, more positive primitive endoderm (SOX17) cells were found at
higher concentrations of GM-CSF (mean: KSOM(aa): 9.21 cells; KSOM(aa)
+5 ng/mL GM-CSF: 11 cells p>0.5).The amount of epiblast (NANOG positive)
cells showed almost no variance at different concentrations of GM-SCF.
However, the proportion of trophectoderm, epiblast and primitive endoderm
cell numbers did not change among the embryos of the different groups (80-
82% trophectoderm; 11-12% primitive endoderm; 7-8% epiblast).
Limitations, reasons for caution: This study was performed in a mouse
model and would need further investigation in other animal models or experi-
ments with human embryos to elucidate and validate the inﬂuence of GM-CSF
on trophectoderm cell numbers during preimplantation development.
Wider implications of the ﬁndings: GM-CSF increases the number of
trophectoderm cells which may lead to an improvement in the implantation
process and embryo or placental development and also may increase survival
rates of transferred embryos in a clinical application.
Trial registration number:DFG NO 413/3-3 and BO2540/4-3
P-206 A prospective sibling oocyte study; do sequential and single
stepmedia perform comparably
K. Rennison, P. Knaggs, A. Storey, F. Heath
Abertawe Bro Morgannwg University Health Board, Wales Fertility Institute, Cardiff,
United Kingdom
Study question: Do sequential and single step media perform comparably in
terms of blastocyst formation, quality and pregnancy rates when using sibling
oocytes?
Summary answer: There is an increase in blastocyst formation with single
step media, however this does not appear to translate to an increase in clinical
pregnancy rate.
What is known already: Recent years have seen the increased utilisation of
culture in time lapse systems. Associated with this is the rise in the use of Single
Step media for IVF culture. Using sibling oocytes we are validating the use of
Sage Single Step (SS) media alongside Sage Sequential (SQ) media, with the
eventual aim of introducing SS with the use of time lapse culture.
Study design, size, duration: From August 2017 until Decmeber 2017 103
patients who were being treated with IVF or ICSI who had 4> normally ferti-
lised oocytes were included in the study. 85 patients reached transfer (the
remainder had freeze all). Embryo selection for transfer is based on develop-
ment and quality only not on media type. Decision to transfer on day 3 or cul-
ture on is based on embryo development and quality on the morning of day 3.
Participants/materials, setting, methods: The fertilised oocytes are
divided between Sage Single Step (SS) media and Sage Sequential (SQ) media;
Cleavage media, that is changed to Blastocyst media at approximately 68 hours
post insemination. 50% that are cultured in Sage SS media that is refreshed at
approximatley 68 hours post insemination. Our programme aimed to transfer a
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single embryo unless patient history or embryo quality indicate a beneﬁt from
double embryo transfer.
Main results and the role of chance:Our inital analysis of the data suggests
an increase of blastocyst formtion rate in SS embryos compared to SQ (68% vs
54% P<0.05). This is reﬂected in the increase seen in SS cultured embryos being
selected for transfer over SQ derived embryos (50.5% vs 44.7%) the remaining
4.8% of transfers reﬂects a mix of SQ and SS embryos. Top quality blastocyst
rates (SS 44% vs SQ 47%) and number of embryos frozen (SS 40% vs SQ 42%)
are comparable. An increase is seen in positive pregnancy test for SQ transfers
(53% vs 60% per embryo transfer), on going clinical pregnancy rates are com-
parable (SS 44% vs SQ 45%) and per embryo transferred (SS 34% vs SQ 32%).
Limitations, reasons for caution: The limitations of this study are the num-
bers of patients who have so far been recruited. As this is an ongoing study we
hope to provide more data to increase its power.
Wider implications of the ﬁndings: This ongoing study indicates an
increase in blastocyst formation for embryos cultured in SS media over SQ
media. This increase does not currently translate into an increase in quality or
clinical pregnancy outcome or increase in the number of embryos frozen.
Trial registration number: not applicable.
P-207 Embryo secretome proﬁle from infertile patients
undergoing assisted reproductive techniques can be affected by
infertility factors
T. Bonetti1, D. Hadad2, T. Domingues1,3, J.R. Alegretti4, E. Motta1,3,
K. Seeley5, I. Silva1
1Universidade Federal de Sao Paulo - Escola Paulista de Medicina UNIFESP-EPM,
Gynecology, São Paulo- SP, Brazil
2Universidade Federal de Sao Paulo - Escola Paulista de Medicina UNIFESP-EPM,
Urology, São Paulo- SP, Brazil
3Huntington Centro de Medicina Reprodutiva, Clinical, Sao Paulo, Brazil
4Huntington Centro de Medicina Reprodutiva, Embryology, Sao Paulo, Brazil
5University of South Florida, Proteomics and Mass Spectrometry Facility- Center for
Drug Discovery and Innovation CDDI, Tampa, U.S.A.
Study question: Does the embryo secretome vary in according with infertility
factor of women undergoing assisted reproductive techniques (ART), as endo-
metriosis, polycystic ovarian syndrome or tubal factor?
Summary answer: Embryonic secretome from patients presenting deep inﬁl-
trating endometriosis (DIE), polycystic ovarian syndrome (PCOS), and tubal
factor (TF) presented divergent protein proﬁles evaluated through proteomics
approach.
What is known already: The ﬁeld of human ART would beneﬁt from more
quantitative methods of determining embryo viability and implantation poten-
tial. It is known that soluble ligands and it receptors mediate human pre-
implantation embryo development and implantation. A number of researchers
has been used proteomics approach related to human reproduction in several
subareas. Various proteins has been investigated as embryo biomarker in the
spent culture media, given the embryo culture medium secretome reﬂect the
embryo development. We hypothesize that protein proﬁles are affected
according with infertility factors, which can be responsible for detrimental
oocyte and embryonic developmental, ensuing on lower IVF success rates.
Study design, size, duration: We studied embryo culture media from
patients presenting DIE (n = 14) and PCOS (n = 7), which are the most fre-
quent female factors of infertility. The control group was constituted by TF (n
= 6) patients. It were included in the study embryo culture media samples
obtained from patients submitted to IVF cycle. Patients underwent IVF treat-
ment as routine and oocytes were fertilized by ICSI. The embryos were group
cultured until D3 and after transfer, the culture media were collected.
Participants/materials, setting, methods: For the proteomics analysis,
two pools of samples were prepared for groups CONTROL and PCOS, and 4
pools for group DIE. Samples were prepared to deplete high abundant proteins
and followed evaluated by high throughput proteomics approach. Raw data
acquired were searched against the European Bioinformatics Institute’s (EBI)
universal protein resource database (UniProt) using Mascot (version 2.2).
Peptide and protein validations were performed using the Scaffold platform
(version 3.00.08).
Main results and the role of chance: From 2904 proteins identiﬁed, decoy
proteins that are considered false identiﬁcation were excluded. Two sets of
analysis were carried out with remaining proteins using the Ingenuity Pathway
Analysis Software. In the DIE group, 17 proteins were exclusively expressed,
and two were over expressed compared to CONTROL. The canonical path-
ways identiﬁed were associated with calcium metabolism (calcium signaling and
transport and calcium induced T –lymphocyte apoptosis) and EGF signaling.
The PCOS group presented 284 proteins exclusively expressed and one over-
expressed compared to CONTROL, which were associated with the following
canonical pathways: Protein Kinase A signaling and calcium signaling were
downregulated, and GADD45 signaling, hydrocarbon receptor signaling and
GDP-L fucose biosynthesis II were upregulated. Based on proteins identiﬁed,
the CONTROL group had the following cellular and molecular function high-
lighted: cellular development, cellular movement, amino acid metabolism, small
molecule biochemistry, cellular assembly and organization, which were function
associated to general cellular development. Also, the embryonic, organ and tis-
sue development were physiological functions activated based on proteins iden-
tiﬁed in the three study groups.
Limitations, reasons for caution: We did not correlate proteins with the
embryo characteristics, as samples come from group cultured embryos. Also,
due to high concentration of contaminants in the culture media, samples were
submitted to a number of process which might depleted other less abundant
proteins. The validation of proteins found is necessary.
Wider implications of the ﬁndings: The DIE group present a high calcium
activity while PCOS showed a decreased calcium action, which may be related
to embryo developmental competence or plasticityEmbryonic secretome will
advance our knowledge and could lead to improved selection of embryos for
transfer warrants further investigation.
Trial registration number: not applicable.
P-208 Oviduct-embryo interaction in cattle: Effect of asynchrony
between the embryo and the oviduct on subsequent embryo
development
B. Rodriguez Alonso1, J.M. Sánchez1, M. Hamdi2, U. Besenfelder3,
V. Havlicek3, P. Lonergan1, D. Rizos2
1University College Dublin UCD, School of Agriculture and Food Science, Dublin,
Ireland
2National Institute for Agriculture and Food Research and Technology INIA, Animal
Reproduction, Madrid, Spain
3University of Veterinary Medicine, Biomedical Sciences, Vienna, Austria
Study question: Does maternal-embryonic asynchrony in the oviduct have an
impact on subsequent development?
Summary answer: Asynchrony between the developing embryo and the ovi-
duct has a negative impact on embryo survival and development.
What is known already: In cattle, which share a similar chronology of early
embryo development with humans, while fertilisation of the oocyte occurs suc-
cessfully in the majority of cases, a large proportion of embryos die subse-
quently, mostly in the ﬁrst 2-3 weeks. Using state-of-the-art assisted
reproduction techniques, this study aims to determine the inﬂuence of
maternal-embryonic asynchrony in the oviduct on embryo development using
the bovine model. Speciﬁcally, we investigated how the oviductal environment
affects early development up to 8- to 16-cell stage embryos (Day 4, embryonic
genome activation), blastocyst stage (Day 7, cell differentiation) and Day 15
conceptus stage (maternal recognition of pregnancy).
Study design, size, duration: Day 1 in vitro-produced bovine zygotes
(IVF=Day 0) were endoscopically transferred to the oviducts of heifers (40
cross-bred beef heifers) which were either (i) synchronous with the embryos
(i.e., at Day 1 after ovulation) or asynchronous and ahead of the embryo (i.e.,
at Day 3 after ovulation). A proportion of the heifers were slaughtered in a
commercial abattoir 3, 6 and 14 days after transfer to assess embryo develop-
ment at key embryo developmental stages.
Participants/materials, setting, methods: Fifty presumptive zygotes were
transferred endoscopically into the oviduct ipsilateral to the corpus-luteum of
heifers (n = 40, total of 2000 zygotes) which were synchronous or asynchron-
ous with the embryo. Embryos on Day 4, 7 and 15 were recovered and
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assessed; location within the reproductive tract, survival (based on morph-
ology) and developmental stage (cell count by ﬂuorescence microscopy or con-
ceptus size in Day 15 embryos) were recorded. Data were analysed by Chi
square and Student’s t-test analysis.
Main results and the role of chance: Overall recovery rates were: Day 4
(83.5% vs 57.0%; p<0.05), Day 7 (70.0% vs 71.3%) and Day 15 (4.0% vs 12.0%)
for asynchronous vs synchronous transfer, respectively. Transfer of an embryo
to an advanced oviduct (asynchrony) resulted, on Day 4, in fewer embryos at
the expected location (oviduct) (6.0% vs 42.2%), more degenerated (95.2% vs
74.4%) and less developed (8- to 16-cells: 9.7% vs 22.7%) embryos with a lower
total cell number (10.8 ± 0.8 vs 13.7 ± 0.8) compared to synchrony group
(P<0.05).
On Day 7, the recovery rate at the expected location (uterus) was lower fol-
lowing asynchronous transfer (86.7% vs 98.1%) with more degenerated (96.7%
vs 84.1%) and less developed embryos (morula/ blastocyst stage: 14.8% vs
33.2%) compared to the synchrony group (p<0.05). However, in terms of qual-
ity the total embryo cell number was similar among asynchrony (78.3 ± 5.9)
and synchrony (77.3 ± 3.6) groups.
On Day 15, only 50% of the asynchronous heifers yielded conceptuses vs
100% in the synchrony group. Day 15 conceptuses were longer following asyn-
chronous tranfers (33.7 ± 4.4 vs 17.2 ± 1.9 mm, P <0.01), likely due to a
progesterone-mediated effect in the uterus rather than an oviduct effect.
Limitations, reasons for caution: While the transfer of multiple embryos
has been successfully used to study early embryo-maternal communication in
the past, it should be noted that the presence of 50 embryos in the bovine ovi-
duct is not the physiological norm.
Wider implications of the ﬁndings: Understanding how the early embryo
interacts with the the oviduct will improve our knowledge of the factors regulat-
ing embryo development and survival and may lead to improved in vitro culture
systems. Also, results may provide valuable information regarding the correct
timing for embryo transfer.
Trial registration number: Project authorised by the Health Products
Regulatory Authority (www.hpra.ie). Project Authorisation Number:
AE18982/P120.
P-209 Laboratory and clinical outcome with embryos cultured in
continuous single step media containing reduced lactate: A
prospective sibling oocyte study
T. Aksoy1, N. Findikli1, B. Ozturk1, I.O. Olcay1, F.K. Boynukalin2,
E. Oral3, M. Bahceci2
1Bahceci Fulya IVF Centre, IVF Laboratory, Istanbul, Turkey
2Bahceci Fulya IVF Centre, Infertility Clinic, Istanbul, Turkey
3Istanbul University Cerrahpasa School of Medicine, Obstetrics and Gyneocology,
Istanbul, Turkey
Study question: Does embryo culture media with reduced lactate create any
disturbances/beneﬁts in terms of human embryo development and clinical out-
come in comparison to conventional single step media?
Summary answer: Simultaneous comparison of two single step embryo cul-
ture media containing control and low lactate on sibling oocytes shows compar-
able and acceptable laboratory and clinical outcomes.
What is known already: Pyruvate, lactate and glucose are the primary
energy substrates for human preimplantation embryos. Although its concentra-
tion greatly varies in vivo during the course of preimplantation embryo develop-
ment, lactate concentration in commercially available human single step
embryo culture media is usually kept between 4-10 mM. Recent studies indicate
that blastocyst development and viability can be improved in environments hav-
ing low lactate concentrations (<5 mM). Also, high lactate concentration in the
culture media has previously been shown to change pyruvate uptake and may
cause metabolic disturbances during zygote and early cleavage stages.
Study design, size, duration: This study is a prospective sibling oocyte
study, performed between February – November 2017, including 1101 mII
oocytes of 55 freeze-only ICSI cycles. After hyaluronidase treatment, mII
oocytes of each case were equally (where available) allocated in two commer-
cially available complete culture media, namely Continuous Single Culture
Media (CSCM) and CSCM-NX (Low lactate) from the same producer (Irvine
Scientiﬁc). They were individually cultured before and after vitriﬁcation/warm-
ing under 6% CO2 and low O2 (5%) conditions.
Participants/materials, setting, methods: Mean female age and oocytes
collected per case were 31,6 ± 5,6 and 22,8 ± 6,1 respectively. A total of 546
and 555 mII sibling oocytes were inseminated by ICSI and cultured in either
CSCM or CSCM-NX. In all cycles, developing embryos were cryopreserved by
vitriﬁcation on either day 3 or day 5 of embryo development and subsequently
warmed/cultured until ET. Fertilization, early embryo cleavage, blastocyst
development as well as clinical pregnancy/delivery outcomes were compared
between the groups.
Main results and the role of chance: Data regarding main laboratory KPIs
such as fertilization rate, percentage of slow (<6 cells) and fast (>8 cells) devel-
oping embryos on day 3 as well as blastocyst development on day 5 were
76.9%, 19.5%, 19.0% and 44.0% for CSCM Group and 78.4%, 16.1%, 24.3%
and 46.9% for embryos in CSCM-NX Group respectively. Although a slight
increase in cleavage rates towards blastocyst stage was observed in CSCM-NX
Group, no statistically signiﬁcant differences were observed for all laboratory
variables documented and compared in the current study (p>0.5). Of 55
freeze-only cycles, a subsequent FET was performed in 47 cycles by utilizing
embryos from either CSCM Group (n = 21) or CSCM-NX Group (n = 26).
Clinical pregnancy, ongoing pregnancy and implantation rates in each group
were 66,6%, 57,1% and 64% for CSCM Group and 69,2%, 65,4% and 69,7% for
CSCM-NX Group respectively.
Limitations, reasons for caution: Since this study mostly included good
responder patients, our preliminary results should not be generalized for other
patient groups with varying degree and spectrum of infertility indications. More
studies with larger sample sizes are needed to compare these results in general
patient population.
Wider implications of the ﬁndings: Lowering the lactate concentration in
routine single step culture media displays similar embryo cleavage and develop-
mental kinetics during early as well as post-compaction embryo development
on embryos generated from sibling oocytes of good responder patients.
Trial registration number:None.
P-210 Spindle transfer can enhance the potential of
developmentally compromised human oocytes to reach the
blastocyst stage: proof of concept with donor oocytes
N. Costa-Borges1, E. Nikitos2, I. Miguel-Escalada K. Rink1, K. Spath3,
D.Wells4, I. Zervomanolakis2, I. Vasilopoulos2, D. De Ziegler S
Grigorakis2, G. Kontopoulos2, T. Prokopakis2, K. Dimitropoulos2,
P. Polyzos N. Vlachos2, K. Kostaras2, P. Psathas2, G. Calderón1
1Embryotools S.L., Embryotools, Barcelona, Spain
2Institute of Life, IVF center, Athens, Greece
3CooperGenomics, CooperGenomics, Oxford, United Kingdom
4University of Oxford, Nufﬁeld Department of Women’s and Reproductive Health,
Oxford, United Kingdom
Study question: Can spindle transfer represent a valuable strategy to enhance
the potential of developmentally compromised human oocytes?
Summary answer: Spindle transfer can overcome embryo development
arrest and enhance the potential of human oocytes with compromised quality
to reach the blastocyst stage.
What is known already: Spindle transfer (ST) is a mitochondrial replacement
therapy that has been proposed to prevent the transmission of maternally
inherited mitochondrial diseases. In a recent study, we showed that ST could
also be successfully used to overcome embryo development arrest and
improve implantation rates in a mouse model with an intrinsic poor reproduct-
ive performance. The feasibility of using this technique for the purpose of treat-
ing infertility problems should be further explored, as it could offer patients with
poor oocyte quality a last chance of having a child genetically related to them.
Study design, size, duration: Experiments were authorized by the Greek
National Authority of Assisted Reproduction and approved by the IRB of the
IASO Maternity Hospital. Informed consent was obtained from the 18 donors
participating in the study, which was carried out at the Institute of Life (Athens)
between June and December 2017. Experimental design aimed to compare the
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efﬁciency of two membrane fusion methods and explore the feasibility of the
technique using donor oocytes with different developmental competence.
Participants/materials, setting, methods: Micromanipulation procedures
were performed on a heated stage under an inverted microscope (Olympus-
IX73) equipped with an image birefringence system to conﬁrm spindle removal.
Karyoplast-cytoplast fusion was induced by exposure of the reconstructed
oocytes to either a chemical solution or an inactivated protein extract (HVJ-E).
Manipulated and non-manipulated control oocytes were inseminated by ICSI
with a donor’s sperm sample and cultured (Embryoscope+, Vitrolife) in single
medium (LifeGlobal) until Day6. Blastocysts were used for molecular analysis.
Main results and the role of chance: After careful optimization, enucle-
ation of MII-oocytes was 100% in all oocytes presenting a birefringent spindle.
The volume of cytoplasm removed was estimated in <1%(judged by micro-
scopic measurements). In the ﬁrst set of experiments, aimed at comparing two
fusion methods, a total of 54 oocytes were used. HVJ-E-mediated fusion rates
were signiﬁcantly higher (98.2%) than those in the chemical method (71.7%,
p<0.01). Fertilization rates were similar between the control (70%), HVJ-E
(75%) and chemical-fusion (66.7%) groups. No differences (p>0.05) were
found in blastocyst rates between controls (85.7%), HVJ-E (73.3%) and
chemical-fusion (60.2%) groups. In the second set of experiments, ST was per-
formed in 104 donor oocytes with differing developmental competence col-
lected from normal and high responder donors, which included: fresh, vitriﬁed,
‘PCO-like”-morphology and in vitro matured oocytes. Overall, fertilization and
blastocyst formation rates varied greatly depending on the quality of the recipi-
ent cytoplasm. When spindles were transferred from in vitro matured or PCO-
like morphology oocytes into good quality cytoplasts, fertilization (66.7%-
71.4%) and blastocyst (75.0%-60.0%) rates were signiﬁcantly (p<0.05)
improved compared to those of the corresponding non-manipulated controls
(50.0%-33.3% and 0.0%-0.0%, respectively) or the reciprocally reconstructed
(25.0%-0.0% and 37.5%-33.3%, respectively) oocytes. Preliminary molecular
analyses from 8 ST-reconstructed blastocysts resulted in euploidy rates >60%.
Limitations, reasons for caution: Spindle transfer is a technically demand-
ing procedure with multiple steps that need to be carefully optimized and valid-
ated to ensure its effectiveness. Genetic analyses are currently being performed
to determine the aneuploidy rates and mtDNA carryover levels in a larger num-
ber of blastocysts.
Wider implications of the ﬁndings: This study shows the feasibility of ST
to enhance the potential of compromised oocytes to develop up to the blasto-
cyst stage. These promising preliminary results prompt further investigation
under regulated controlled trials to conﬁrm the effectiveness of the technique
and identify groups of patients that could beneﬁt from its application.
Trial registration number:Not applicable.
P-211 Embryonic exposure to Mono-2-ethylhexyl phthalate
(MEHP) inhibits invasion and alters metabolism in mouse
blastocysts
Y.Y. Ma1, L. Guan Lin2, C. Xiao Pan3, S. Jing3, C. Ya Ching4,
T. Chii Reuy4
1Center for Reproductive Medicine & Sciences, Department of Obstetrics &
Gynecology, Taipei City, Taiwan R.O.C.
2College of Medicine- Taipei Medical University Taipei- Taiwan, Department of
Obstetrics & Gynecology, Taipei City, Taiwan R.O.C.
3Department of Reproductive Endocrinology- Zhejiang Provincial People’s Hospital-
158 Shangtang Road- Hangzhou- Zhejiang- 310014- China., Department of
Reproductive Endocrinology, Zhejiang, China
4Taipei medical university hospital Taipei- Taiwan, Department of Obstetrics &
Gynecology, Taipei City, Taiwan R.O.C.
Study question: MEHP is lipophilic, tends to accumulate in adipose tissue and
disturbs energy metabolism. Here we aim to investigate the inﬂuence of MEHP
on embryonic metabolism and mitochondrial function.
Summary answer: Exposing to MEHP could negatively affect embryo
implantation potential and viability by inhibits invasion and alters metabolism,
suggesting possible risks for female reproductive health.
What is known already: In Human studies and animal exposure experi-
ments, there is increasing evidence showing that exposure to PAEs elicits
adverse effects on female reproduction.
Study design, size, duration: A prospective RCT of experimental animal
study in a university hospital.
Participants/materials, setting, methods: The 2-cell mouse embryos
were cultured in HTF supplemented with MEHP at range levels (0-50 μM) for
48 h (blastocyst stage) then blastocysts were collected from each groups. The
expression levels of proteins involved in antioxidant enzyme (MnSOD), implant-
ation (MMP-2 and MMP-9) and metabolism (lipin 1 and Glut3) were validated
by Immunoﬂuorescence analysis. The Lipid droplet abundance, ATP content
and mitochondrial activity also assessed by sting BODIPY and MitoTracker,
respectively.
Main results and the role of chance: Lipid droplet and antioxidant enzyme
(MnSOD) was signiﬁcantly increased (P< 0.05) in blastocyst by exposure MEHP
(50 μM) than control. Moreover, MEHP were up- regulation of lipin 1 expres-
sion in dose-dependent manner (in 25 and 50 μM, P< 0.05). Meanwhile, ATP
content and MMP-9 were signiﬁcantly decreased in MEHP-treated blastocysts
(P< 0.05).
Limitations, reasons for caution: Our study was based in mouse model
and further studies on implantation or birth rate are required to conﬁrm our
ﬁndings.
Wider implications of the ﬁndings: This study provided new evidence of
PEAs negative impact on embryo implantation and metabolism. It may contrib-
ute to early pregnancy loss in women.
Trial registration number:NA.
P-212 Aberrant expression of ribosomal proteins results in the
developmental failure of human preimplantation embryo
C.Q. Zhang1, L.Z. Leng1, S.P. Zhang1, L. Zhao2, P.Y. Xie1,3,
C.F. Lu1,2, F. Gong1,2, G. Lin1,2,3
1Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
Science- Central South University, Changsha, China
2Reproductive and Genetic Hospital of CITIC-Xiangya, Reproductive center,
Changsha, China
3National Engineering and Research Center of Human Stem Cells, National
Engineering and Research Center of Human Stem Cells, Changsha, China
Study question: To investigate the underlying molecular mechanism of 8-cell
arrested embryos without chromosomal abnormalities and morphokinetic
abnormalities.
Summary answer: The decreased expression of ribosomal proteins (RPs)
genes activate p53 pathway by nucleolar stress, which induced human embryo
arrest at 8-cell stage.
What is known already: During in vitro fertilization (IVF) treatment, about
50-70% of normally fertilized human embryos cannot form blastocyst.
Chromosomal abnormalities including uniformly aneuploid, polyploid, haploid,
mosaicism chaotic chromosomal complement, and morphological abnormal-
ities, such as multinucleation, cytoplasmic fragmentation, and unequal cleavage
are the main causes of early embryonic development block. However, a small
number of embryos with normal chromosome and morphological features still
cannot reach the blastocyst stage.
Study design, size, duration: A total of 26 in-vitro matured metaphase
(MII) oocytes were collected to perform ICSI. Then 8-cell embryos with normal
cleavage in the ﬁrst three times cleavages were collected, and single blastomere
from 8-cell embryos was biopsied for transcriptome sequencing. According to
whether the 8-cell embryos form blastocyst, they were divided into two groups,
the blastocyst and the arrested embryo. Test the chromosomal constitution
and compare the gene expression differences between the two groups.
Participants/materials, setting, methods: Monitor the morphological fea-
tures and kinetic parameters of the two groups embryos via time-lapse technol-
ogy, and analyze gene expression of single blastomere from 8-cell embryos by
single-cell RNA-SEQ. Trophectoderm (TE) of the blastocysts and the arrested
embryos were biopsied and detected the chromosomal makeup by next-
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generation sequencing. And then the remaining of blastocyst were stained by
immunoﬂurescence for SOX17 and NANOG.
Main results and the role of chance: A total of 3 embryos were collected
in the blastocyst and the arrested group, respectively. 6 embryos are high-
quality embryo at day 3 which graded 8cell-I or 8cell-II, and they had normal
chromosome compositions at day 5. In the blastocyst group, all embryos had a
signiﬁcant expansion blastocoelic cavity and inner cell mass (ICM), and the aver-
age cell number of TE and ICM are 226 and 33, respectively. In the arrested
group, 3 embryos arrested at 8-cell stage, with compaction of a few of cells and
embryo fragmentation.
The average of total gene number for the blastocyst and arrested group
were 15785 and 13907, respectively. 420 genes of 675 differentially expressed
genes (DEGs) were identiﬁed as downregulated genes, and 255 DEGs were
upregulated. The majority of 420 downregulated genes had a low level of
expression, except RPs. And KEGG pathway analysis showed the most appar-
ent enriched pathway was ribosome, including 80 genes, 23 of which were RPs.
Likewise, the PRAME family genes were the higher expression among the 255
upregulated genes. Meanwhile, MDM2 related to nucleolar stress was upregu-
lated. This indicates the decreased expression of RPs induces nucleolar stress
indispensable for p53 activation, resulting in human embryo arrest.
Limitations, reasons for caution: A limitation is the sample size of this
study. In addition, the preliminary results of the analysis will need to be further
investigated by the more arrested embryos experiment.
Wider implications of the ﬁndings: During IVF/ICSI, 8-cell high-quality
embryo without morphokinetic abnormalities may not have a capable of
implantation at day 3 and it is necessary to perform more studies for accurate
evaluation. And that besides the primary ribosome biogenesis, ribosomal pro-
teins could regulate early human embryo development.
Trial registration number:NA.
P-213 Editing of the coatomer protein complex subunit alpha gene
in bovine blastocysts using CRISPR/Cas9
M. Poirier, D. Miskel, F. Rings, M. Hoelker, K. Schellander
Institute of Animal Science, Animal Breeding and Husbandry, Bonn, Germany
Study question: Is CRISPR/Cas9-mediated editing of the coatomer protein
complex subunit alpha (COPA) gene possible in bovine zygotes?
Summary answer: Microinjection of CRISPR/Cas9 in presumptive zygotes
led to gene edited bovine blastocyst stage embryos.
What is known already: Successful genome editing to term has been accom-
plished in cattle by somatic cell nuclear transfer (SCNT). CRISPR/Cas9 micro-
injection of zygotes has been done in a limited number of attempts in ruminant
species, mostly using RNA. Here we report successful editing of the COPA
gene through plasmid delivery of CRISPR/Cas9 in bovine zygotes.
Study design, size, duration: Presumptive zygotes (n = 350) were microin-
jected with a CRISPR/Cas9 plasmid. Injected embryos were put in in vitro cul-
ture until blastocyst stage. At day 8, embryos were selected based on GFP
ﬂuorescence and frozen individually for sequence analysis. A separate IVF run
with identical parameters was used as negative control without microinjection
to compare development rates.
Participants/materials, setting, methods: Presumptive zygotes derived
from slaughterhouse oocytes by in vitro maturation and fertilization were micro-
injected with the pX458 plasmid (Addgene #48138) containing a guide RNA
recognition sequence for the 6th exon of the COPA gene. GFP positive struc-
tures at day 8 were selected as candidates for successful editing. Editing was
assessed through T7 endonuclease assay, subsequently followed by Sanger
sequencing.
Main results and the role of chance: Compared to the control (32.3%),
the injected group showed a day 8 blastocyst rate of 27.7%. Fluorescence rate
at day 8 was 7.6%. GFP positive blastocyst rate was 2.5%, totaling 7 blastocysts.
T7 endonuclease assay revealed editing in blastocysts and morulae as well.
Structures that were selected for editing through T7 assay showed a high vari-
ability of editing events neighboring the guide RNA target site. Deletions as long
as 94 base pairs were found in blastocysts, as well as the absence of editing.
Multiple editions found in structures as well as wild-type sequences suggest
mosaic editing of blastocysts. This implies that editing of the COPA gene is pos-
sible in bovine zygotes and did not affect embryo development in vitro.
Limitations, reasons for caution: Editing of the COPA gene in bovine
embryos is possible with plasmids but limited because of mosaic editing.
Observation of genome editing without wild-type sequences persisting through
development is crucial to imply that complete editing of COPA is not lethal.
Wider implications of the ﬁndings: This research sheds light on how
CRISPR-Cas9 plasmid delivery in zygotes behaves and how it could circumvent
cloning of edited cells. Results also indicate that the COPA gene may not be
required for early embryo development.
Trial registration number: This study was funded by project number 309-
70102 of the University of Bonn. The authors declare.
P-214 Effects of sperm direction (head ﬁrst injection, tail ﬁrst
injection) in Piezo-ICSI on oocyte survival, fertilization and embryo
morphokinetics in humans
K. Hiraoka1, Y. Otsuka2, K. Kawai1, T. Harada3, T. Ishikawa4
1Kameda Medical Center, ART Center, Chiba, Japan
2Kameda Medical Center, Department of Laboratory Medicine, Chiba, Japan
3Kameda IVF Clinic Makuhari, ART Center, Chiba, Japan
4Tokyo Medical and Dental University, Comprehensive Reproductive Medicine,
Tokyo, Japan
Study question: Does the sperm direction (head ﬁrst injection, tail ﬁrstinjec-
tion) in Piezo-ICSI have an effect on oocytes survival, fertilization and embryo
morphokinetics in humans?
Summary answer: Sperm’s tail ﬁrst injected oocytes showed signiﬁcantly
higher fertilization as compared to the sperm’s head ﬁrst injected oocytes, but
the fertilized embryo morphokinetics were similar.
What is known already: For the application of ICSI to human oocytes, it is
believed that the sperm should be injected head ﬁrst into the cytoplasm for fer-
tilization because the internalization of sperm in the cytoplasm is initiated from
the sperm head during natural fertilization. However, in the ICSI procedure,
sperm are directly injected, bypassing the internalization of the sperm head in
the cytoplasm; accordingly, oocytes could be fertilized if the sperm is injected
tail ﬁrst into the cytoplasm. However, little is known about the effect of the
sperm direction on ICSI results, including embryo morphokinetics.
Study design, size, duration: We retrospectively investigated 75 mature
oocytes retrieved from 26 patients were microinjected from sperm’s head ﬁrst
(H-ﬁrst) and 145 mature oocytes retrieved from 40 patients were microin-
jected from sperm’s tail ﬁrst (T-ﬁrst) between May 2016 and April 2017. Of
these. Only metaphase II oocytes with a visible meiotic spindle at the time of
ICSI were microinjected to minimize the potential inﬂuence for fertilization
(Heindryckx B et al. Hum Reprod. 2011: 26: 535-44).
Participants/materials, setting, methods: The survival, fertilization and
good-quality day-3 embryo rates after Piezo-ICSI by H-ﬁrst injection group and
tail T-ﬁrst injection group were compared. In addition, the time of second polar
body emission, vanishing the two pronucleus and the ﬁrst cleavage of fertilized
oocytes were monitored by a time-lapse microscopy system (CCM-iBIS).
Times were expressed as mean ± SD hours post-insemination and analyzed,
where appropriate, by Unpaired T Student or Fisher’s exact tests.
Main results and the role of chance: The survival rates of H-ﬁrst and T-
ﬁrst groups were 97% (73/75) and 99% (143/145). No signiﬁcant difference
was observed. The fertilization rates of H-ﬁrst and T-ﬁrst groups were 85%
(64/75) and 95% (137/145). A signiﬁcantly higher fertilization rate was achiev-
ing in T-ﬁrst group (P = 0.0397). The 0PN (no pronucleus) rates of H-ﬁrst and
T-ﬁrst groups were 11% (8/75) and 2% (3/145). A signiﬁcantly lower 0PN rate
was achieved in T-ﬁrst group (P = 0.0087). The 1PN (mono pronucleus) rates
of H-ﬁrst and T-ﬁrst groups were 0% (0/75) and 1% (1/145). No signiﬁcant dif-
ference was observed. The 3PN (three pronucleus) rates of H-ﬁrst and T-ﬁrst
group were 1% (1/75) and 1% (2/145). No signiﬁcant difference was observed.
The good quality day-3 embryo rates per microinjected oocytes of H-ﬁrst and
T-ﬁrst groups were 52% (39/75) and 68% (98/145). A signiﬁcantly higher good
quality day-3 embryo rate was achieving in T-ﬁrst group (P = 0.0280). Among
the H-ﬁrst and T-ﬁrst groups, there were no signiﬁcant differences when com-
paring the time of second polar body emission (2.6 ± 0.8 vs. 2.8 ± 0.7 h), two
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pronucleus vanishing (23.0 ± 2.9 vs. 22.5 ± 2.7 h) and ﬁrst cleavage (25.4 ± 2.9
vs. 25.1 ± 2.8 h) of fertilized oocytes.
Limitations, reasons for caution: The morphokinetic parameter of ﬁrst
cleavage assessed in this study may require better deﬁnition to reduce inter-
operator annotation variability.
Wider implications of the ﬁndings: Sperm tail ﬁrst injection associated
with higher fertilization and good quality day-3 embryo rates as compared to
sperm head ﬁrst injection without detrimental effect on embryo morphoki-
netics. Interestingly, sperm tail ﬁrst injection might be used as a new technique
for human ICSI to improve the effective utilization rate of oocytes.
Trial registration number:Not applicable.
P-215 A prospective study of oocyte Zona Pellucida mechanics as a
predictor of embryo implantation: a novel tool for embryo selection
I. Har-Vardi1, T. Priel1, Y. Perets2, A. Harlev1, A. Zeadna1,
N. Steiner1, E. Levitas1, E. Priel3
1Soroka University Medical Center, Dept. of Obstetrics & Gynecology, Beer - Sheva,
Israel
2Faculty of Health Sience Ben-Gurion University of the negev, School of Medical
Laboratory Sciences, Bear-Sheva, Israel
3Shamoon College of Engineering and Rotem Industries LTD, Department of
mechanical engineering, Beer-Sheva, Israel
Study question: Does the zona pellucida’s ability to resist shape change
(shear modulus) predict embryo implantation potential?
Summary answer: Zona pellucida (ZP) shear modulus can predict implant-
ation rate, regardless of ZP thickness, embryo diameter or patient’s age.
What is known already: The ZP undergoes extensive mechanical deform-
ation at the time of blastocyst expansion and hatching. To the best of our
knowledge, no study examined the effect of mechanics properties of the ZP on
embryo hatching and implantation ability. Furthermore, most studies assume
that the ZP can be described as a linear elastic material and employ analytical
models that mimic the oocyte deformation. This assumption may be applicable
to small deformations but not to extensive ones when ICSI is performed.
Although ZP hatching is at least partly a mechanical phenomenon, oocyte
mechanics is not taken into consideration during embryo selection.
Study design, size, duration: A non-randomize prospective study per-
formed during 2015 – 2017 designed to examine the deformation of the ZP
during the ICSI procedure. One hundred and sixty-four oocytes were aspirated
from 28 IVF patients. The patients were tested for ZP mechanical properties.
Thirty nine embryos were transferred and the implantation rate was measured.
Participants/materials, setting, methods: The study was conducted at an
IVF unit and the mechanical engineering department. Images from ICSI proce-
dures were used to construct computational models using a non-linear model
applicable to large deformations. The computed ZP deformation was com-
pared to deformation observed in ICSI during oocyte suction. This comparison
enabled the determination of ZP-shear modulus which represents the ability to
resist shape change. Implanted embryos were compared to non-implanted
embryos regarding the shear modulus using chi-square test.
Main results and the role of chance: The data show that a great variance
exists in the shear modulus of oocytes aspirated from the same patient
(0.0001-0.00065 Mega Pascale-MPa). A signiﬁcant correlation was found
between the value of the ZP shear modulus and implantation rate. The total
implantation rate of the transferred embryos in the study was 30.7% (12/39). A
signiﬁcant difference was found when comparing implantation rate inside and
outside of a speciﬁc shear modulus range (0.0002-0.0004 MPa). Ten out of the
16 (62.5%) implanted embryos, displayed shear modulus values in the speciﬁc
range, with only 2 implanted embryos out of 23 were outside the range (8.7%)
P = 0.037. No correlation was found between ZP shear modulus and embryo
quality regarding blastomere’s number and morphological index. The age of the
patients inside and outside the range of the ZP shear modulus was comparable.
Other mechanical properties such as the thickness of the ZP and oocyte diam-
eter were not associated with implantation rate.
Limitations, reasons for caution: The limitations of the study: a small sam-
ple size.
Wider implications of the ﬁndings: The ZP shear modulus which is deter-
mined early at the time of sperm injection can be used as a novel method for
embryo selection, consequently leading to a higher embryo implantation rate.
Our methodology can be implemented with no major changes in the current
ICSI procedure.
Trial registration number: 0041-14-SOR.
P-216 Human blastocyst development and implantation rate with
human recombinant growth factors supplementation of culture
media
V. Kazarinov, T.V. Ovsyannikova
Center of New Medical Technologies CNMT Institute of Chemical Biology and
Fundamental Medicine Siberian Branch of the Russian Academy of Sciences,
Laboratory of Reproductive Problems, Novosibirsk, Russia C.I.S.
Study question: Could growth factors promote early embryonic develop-
ment and implantation in IVF treatment?
Summary answer: Growth factors promote blastocyst quality; this may help
choosing embryo for transfer and improve implantation chance.
What is known already: Early studies using animal models demonstrated
enhanced early embryonic development and survival when culture media were sup-
plemented with individual growth factors (GF), including insulin-like growth factor-I
(IGF-I), granulocyte-macrophage colony-stimulating factor (GM-CSF), epidermal
growth factor (EGF) and others. Supplementation of culture media with key auto-
crine/paracrine growth factors promoted the development of tripronuclear human
zygotes to blastocyst, promoted blastocyst formation of day 3 cryopreserved
embryos and increased the proportion of high quality blastocyst. Also, growth fac-
tors could improve normally fertilized hatching blastocysts outgrowth in vitro.
Study design, size, duration: Patients undergoing IVF treatment were ran-
domly divided into two groups (Group 1, n = 44, 34.2 ± 4.4 years; Group 2, n =
58, 34.1 ± 4.0 years). All obtained two-pronuclear zygotes were cultivated without
GF (group 1, 196 embryos) or with recombinant human growth factors mix (group
2, 247 embryos) to blastocyst stage. Received good and high quality embryos were
transferred or cryopreserved on ﬁfth day. Both groups treatment, cultivation and
embryo transfer (ET) were used with informed consent of the patients.
Participants/materials, setting, methods: After fertilization embryos
were cultivated in one-step media with human serum albumin (Global total,
LifeGlobal, US) individually in 30 ml microdrops without or with IGF-I and GM-
CSF mix (each at 5 ng/ml) at equal conditions (37°C, 6.5% CO2, pH 7.2-7.25).
Blastocyst were assigned scoring based on the Gardner blastocyst grading scale
(AA blastocyst were scored 5; AB, BA and BB - 4; CB, BC, CC - 3; and arrested
blastocyst were scored 2) for statistical analysis.
Main results and the role of chance: Group 1 and 2 has no difference in
blastocyst formation (50 ± 45% and 51 ± 44% to zygotes quantity, respectively,
p = 0.82) but in the group with GF high quality blastocyst proportion was sig-
niﬁcant increased (morphological score was 3.6 ± 0.9 in group 1, and 4.0 ± 0.9
in group 2, p = 0.0035). In group 1 was 42 transfers (1.38 embryo on ET) and
56 ET were in group 2 (1.46 embryo on ET) inclusion of growth factors mix
showed rising trends in implantation rate without signiﬁcantly differences in
groups (14 ± 5% and 22 ± 5% to the number of transferred embryos, respect-
ively, p = 0.20). The ET success was evaluated at 8-9 gestation week by ultra-
sound screening with a heart rate examination. Two miscarriages cases were in
group 1 (one frozen pregnancy and one trisomy 22) and an anembryonic preg-
nancy in group 2. All miscarriages were not included in success ET cases. All
samples in groups were compared by T-test for Independent Samples, and
values were showed in Mean±SD format.
Limitations, reasons for caution: Although this experimental design is
based on the supplementation of recombinant growth factors diluted during
embryo cultivation, future studies on the potential side effects of these factors
on chromosomal numbers, genomic integrity, proteomic changes, and epigen-
etic modiﬁcations are essential for wide clinical use.
Wider implications of the ﬁndings: Though, growth factors not inﬂuence
on the blastocyst formation rate, but increase proportion of high quality embryos.
Probably GF using not evaluate on blastocyst quantity, but assist to grow and
choose better morphological grade blastocyst for ET, this ﬁnding could potentially
increase implantation chance for every one transferred embryo.
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Trial registration number:Not applicable.
P-217 The effect of changing culture media on aneuploidy rates
seen in preimplantation embryos
B. Behr1, R. Lathi2, C. Cinnioglu3, J. Kort4
1Stanford University, Reproductive endocrinology and infertiliity, Stanford, U.S.A.
2Stanford University, Reproductive endocrinology and infertility, Stanford, U.S.A.
3Ivigen, Genetics, Torrance, U.S.A.
4Stanford University, OB/GYN, Stanford, U.S.A.
Study question: To examine the effect of two different embryo culture media,
in the same clinic using the same reference lab, on blastocyst ploidy.
Summary answer: Aneuploidy rates vary with different culture media for
speciﬁc patient populations. However, this may be a manifestation of different
blastulation rates.
What is known already: Aneuploidy screening of embryos has been pro-
posed to increase implantation rates and decrease miscarriage rates in women
undergoing IVF. While maternal age is the strongest predictor of embryonic
aneuploidy, these and mosaicism rates have been observed to vary between
clinic and reference labs. These variations have been seen in donors and cannot
be explained by maternal age alone. The embryo culture system was changed
from sequential media to a single step medium in our lab in 2017.
Study design, size, duration: This was a retrospective cohort study compar-
ing aneuploidy rates between two ﬁve month periods in a single clinical lab in
which the culture system was different (Period I: Sage sequential plus 10% SPS,
Period II: Sage 1-step media). All patients undergoing PGS during these periods
were included, consisting of 212 patients and 465 blastocysts cultured in sequen-
tial media, and 176 patients and 476 blastocysts cultured in 1-step media.
Participants/materials, setting, methods: Patient age, blastocyst develop-
ment rates and pre-implantation genetic screening results were compared
between two periods during which different culture media were used. CO2
levels were adjusted to maintain the same media pH of both media and no
other changes in culture SOP were made between these two periods. All biop-
sies were performed at the blastocyst stage on day 5-6 and sent to a single ref-
erence lab for aneuploidy testing using NGS.
Main results and the role of chance: A total of 212 patients and 465 blasto-
cysts biopsied over a 5 month period after culture in sequential media. A total of
176 patients and the corresponding 476 blastocysts were biopsied after culture in
single step media. Mosaicism rate was< 2% in all groups throughout the study peri-
od and therefore no statistical analysis was possible. There were signiﬁcantly more
usable blastocysts in the single step medium (Sequential Media 48 % usable Blast/
2PN vs. Single Step: 56 % usable blastocysts/2PN, p<0.05). Euploid/Aneuploidy
rates were similar between media groups for patients in age groups <30, 30-35,
36-37, 38-39. There were signiﬁcantly higher euploidy rates for blastocysts cultured
in single step media for patients age 40-41 (54% vs. 32%, p<0.05) than blastocysts
cultured in sequential media, and a similar trend approaching signiﬁcance for
patients ≥42 (6% vs. 0%, p<0.05) favoring blastocysts cultured in single step media.
Limitations, reasons for caution: This studies retrospective design and the
difference in blastulation rates between culture systems prevents concluding
whether the media affects embryo ploidy rather than changing the number of
embryos available for biopsy.
Wider implications of the ﬁndings: There was an increase in euploidy rate
after culture in single step media compared to sequential media for women
>40. This ﬁnding suggests that culture conditions may inﬂuence aneuploidy
rates, directly or indirectly by increasing the number of blastocysts available for
biopsy or other less understood mechanisms.
Trial registration number:Not applicable.
P-218 Investigating the efﬁcacy of non-invasive pre-implantation
genetic testing for aneuploidy (NI-PGT-A) using spent culture
media as a source of embryonic DNA
D. Babariya1, S. Sarda2, A. Manoharan2, A. Coates3, M. Large4,
J. Barritt5, T. Escudero2, S. Sawarkar2, S. Munne2, D.Wells2
1University of Oxford and Reprogenetics UK, Nufﬁeld Department of Women’s and
Reproductive health, Oxford, United Kingdom
2CooperGenomics, CooperSurgical, New Jersey, U.S.A.
3Oregon Reproductive Medicine, Oregon Reproductive Medicine, Oregon, U.S.A.
4CooperGenomics, CooperSurgical, Houston, U.S.A.
5ART Reproductive Center, ART Reproductive Center, Beverly Hills, U.S.A.
Study question: Are spent media samples, derived from different culture sys-
tems/ conditions, a reliable non-invasive source of embryonic DNA for the
purpose of NI-PGT-A?
Summary answer: Spent media samples contain embryonic DNA but the
nature and content of that DNA varies according to their corresponding culture
conditions.
What is known already: Currently, analysis of DNA from trophectoderm
biopsy is the gold standard for comprehensive chromosomal screening (CCS)
as well as pre-implantation genetic diagnosis for monogenic disorders.
However, this approach is invasive and necessitates highly skilled personnel
along with expensive micromanipulators to perform the biopsies. In recent
years, non-invasive sources of embryonic DNA such as blastocoel ﬂuid and
spent culture media have been explored with the ultimate aim of developing
non-invasive chromosomal screening and genetic diagnosis methods.
Study design, size, duration: Standard DNA ampliﬁcation methods, includ-
ing Sureplex and multiple displacement ampliﬁcation (MDA), along with a modi-
ﬁed MDA method were used to explore genetic content of 84 spent culture
media samples derived from either fresh embryo cultures (n = 51) or vitriﬁed-
warmed embryo cultures (n = 33).The samples were subjected to next gener-
ation sequencing (NGS) and subsequently analysed for chromosomal copy
number. Results were compared to those obtained using well-established inva-
sive methods involving trophectoderm (TE) biopsy followed by CCS.
Participants/materials, setting, methods: For spent media samples from
fresh embryo cultures (n = 51), a changeover of media was performed on Day-
3 post fertilisation to a new 3 μl culture droplet (Sage Quinn) and the samples
were subsequently collected on Day5/6 post fertilisation. Previously vitriﬁed
blastocysts (n = 33) were warmed in ~3-5 μl of culture media and collected
after overnight incubation. The samples were subjected to whole genome amp-
liﬁcation (either Sureplex, MDA or modiﬁed MDA) and subsequently
sequenced using Illumina’s Miseq platform.
Main results and the role of chance: Overall, the DNA ampliﬁcation rates
were superior in the samples ampliﬁed with the modiﬁed MDA method com-
pared to those ampliﬁed by Sureplex and MDA methods: 93.48% (43/46) versus
47.37% (9/19) and 15.78% (3/19) respectively (P<0.05). Of note, the media sam-
ples which failed to amplify mainly belonged to a cohort frozen (at -20°C) for over
a month before ampliﬁcation. The aneuploidy/euploidy concordance rate
between spent media samples and the corresponding embryo biopsy was found
to be 95.35% (42/43) for modiﬁed MDA samples, 88.8% (8/9) for Sureplex amp-
liﬁed samples and 33.34% (1/3) for MDA samples. There was 99.3% concordance
at the individual chromosome level for modiﬁed MDA samples (over 1000 chro-
mosomes assessed), 99.1% for Sureplex samples and 94.4% for MDA samples.
For spent media samples ampliﬁed using modiﬁed MDA, all the female embryos
were correctly identiﬁed with respect to gender of the corresponding TE biopsy
(female embryos concordance: 27/27; 100%). However, one male embryo was
misidentiﬁed as a female embryo (male embryos concordance: 15/16; 94%).
Limitations, reasons for caution: The sample size for present study is rela-
tively small and the results need to be veriﬁed on a larger sample population.
The ploidy status of the spent media samples was compared with a TE biopsy
from the corresponding embryo and not the entire embryo.
Wider implications of the ﬁndings: The results conﬁrm that the analysis of
spent media represents a promising strategy for non-invasive PGT-A, frequently
yielding genetic material which is representative of the embryo when appropri-
ately ampliﬁed. While further experiments need to be performed to verify this
data on larger sample sizes, the preliminary results are encouraging.
Trial registration number:Not applicable.
P-219 Determination of c-Abl tyrosine kinase and mTERT
catalytic subunit of telomerase expression level during mouse
prenatal and postnatal gonadal development
E. Yıldırım, A. Yaba Ucar
Yeditepe University School of Medicine, Histology and Embryology, Istanbul, Turkey
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Study question: Do c-Abl tyrosine kinase and mTERT catalytic subunit play
an important role in a successfull gonadal development?
Summary answer: c-Abl tyrosine kinase and mTERT telomerase catalytic
subunit may have curriciale role during mouse prenatal and postnatal gonadal
development.
What is known already: c-Abl is a non-receptor tyrosine kinase that plays
an important role including cell adhesion, cell proliferation, growth and develop-
ment. Telomerase is a ribonucleoprotein complex and a part of this complex as
telomerase catalytic subunit telomerase reverse transcriptase (TERT). The
maintenance of telomerase activity is necessary for the survival of proliferating
cells. c-Abl and mTERT have important role in regulation of telomerase func-
tion. We aimed to compare and demonstrate the localization of c-Abl tyrosine
kinase and mTERT telomerase catalytic subunit during periods of known pre-
natal and postnatal ovary-testis development.
Study design, size, duration: Gonads were dissected from prenatal 10.5,
11.5, 12.5 and 13.5 embryonic days and dissection was performed on days
determined from different mothers. Ovary and testis tissues from postnatal
days 1, 3, 5 and 9 were dissected by accepting the day when the pups were
born. Additionally, 12-week old adult ovary and testis were removed from
female and male mice, respectively.
Participants/materials, setting, methods: Hematoxylin-eosin staining was
performed to compare ovarian and testicular morphology in prenatal and post-
natal developmental periods in mice. Subsequently, localization of c-Abl and
mTERT were detected by immunoﬂuorescence staining with confocal microscope.
c-Abl and mTERT expressions were detected at the mRNA level by qRT-PCR.
Main results and the role of chance: The morphological evaluation was
completed with hematoxylin and eosin staining and gonadal areas were
detected under a light microscope. c-Abl and mTERT protein localization were
observed in germ cells and somatic cells in gonads. In the embryonic 10.5, 11.5,
12.5 and 13.5 days, c-Abl and mTERT expression were observed in germ cells
and follicular cells surrounding germ cells. c-Abl expression in postnatal day 1,
3, 5, and 9-day ovaries was observed in only oocyte cytoplasm while it was
observed in both oocyte and granulosa cells in adult ovaries. mTERT expression
was weakly observed on days 1, 3, and 5, whereas a signiﬁcant increase expres-
sion was observed in granulosa cells on day 9 in testicular tissue. c-Abl immu-
noreactivity detected in Sertoli cells. PN 1, 3, 5 ve 9 days. c-Abl
immunoreactivity seen in Leydig cells on day 5. mTERT expression was not
observed on days 1 and 3 in the testes, whereas expression was observed in
Sertoli cells and Leydig cells on days 5 and 9. In the adult testis, c-Abl and
mTERT expression were seen in spermatid cells found in the seminiferous
tubule lumen.
Limitations, reasons for caution: Additional studies related inhibition of c-
Abl gene expression might conﬁrm the association between c-Abl and mTERT
during gonadal development.
Wider implications of the ﬁndings: Interaction between c-Abl and mTERT
genes can contribute to the explanation of gonadal developmental
abnormalities.
Trial registration number: not applicable.
P-220 Elective frozen over fresh blastocyst transfer highly
increases pregnancy rate in patients over 35 years-old
R. Pella1, F. Escudero2, P. Orihuela2, Y. Pérez2, M. García2,
I. Zorrilla3, P. Berrío3, S. Romero4
1Centro de Fertilidad y Reproducción Asistida CEFRA, Dirección de Laboratorios de
Andrología y Embriología, Lima, Peru
2Centro de Fertilidad y Reproducción Asistida CEFRA, Dirección Médica, Lima, Peru
3Centro de Fertilidad y Reproducción Asistida CEFRA, Laboratorio de Embriología,
Lima, Peru
4Centro de Fertilidad y Reproducción Asistida CEFRA, Dirección de Investigación,
Lima, Peru
Study question: Is elective frozen blastocyst transfer an advantageous strat-
egy for patients of all ages?
Summary answer: Chance of pregnancy in female patients, over 35 years-
old, is increased by performing frozen embryo transfer.
What is known already: Researchers have recently focused on understand-
ing endometrial receptivity, providing tools that are meant to evidence the best
moment to perform embryo transfer, however oocyte and embryo quality are
key factors that are not to be disregarded.
Due to the success on embryo vitriﬁcation, discrepancy has been raised over
the point of whether the strategy of freeze-all embryos and subsequent frozen
embryo transfers are meant for all cases.
In this study, we analyze our data of the past 6 years, trying to provide an
answer on which patients may beneﬁt of a freeze-all policy and a subsequent
frozen embryo transfer.
Study design, size, duration: This retrospective cohort study includes
infertile patients aged 30 to 41 years old, without previous history of
recurrent failure of ART (including recurrent miscarriages). Enrolments
took place between January 2012 and December 2017 and cycles with
oocyte donation were excluded. Patients were transferred with either 1)
embryos from a fresh cycle (ET) or 2) embryos that were frozen in a
freeze-all policy (FET).
Participants/materials, setting, methods: Only patients with transfer of 1
or 2 blastocysts were included. PGD cycles were excluded. Moreover, follow-
ing a freeze-all policy, pregnancy rate of the ﬁrst FETs was compared to the out-
come of the ETs. Transfers of Top and/or good quality embryos were included
in the study.
The number of patients complying with the inclusion criteria were: 391
patients in 403 ICSI cycles (ET); and 216 patients in 220 transfers of frozen
embryos (FET).
Main results and the role of chance: Mean age of patients with ET or FET
was similar (35.0 ± 3.9 years-old vs 35.7 ± 3.9; mean ± SD; respectively).
Pregnancy rate was 47.6% and 58.6% (ET and FET, respectively). Based on
our own observations and what has been reported in literature, pregnancy
rate, following ET, undergoes a progressive decline at 35 years-old, therefore
our patient population was stratiﬁed in four age ranges (30-32, 33-35, 36-38,
39-41 years-old).
No differences between ET vs FET were observed among 30-32 and 33-35
groups (45.7% vs 60% and 58.0% vs% 58.5%, respectively). However, FET sig-
niﬁcantly increased pregnancy rate in the 36-38 group (68.5% vs 48.6%), non-
signiﬁcant in the 39-41 group (54.1% vs 41.7%). These contrasting results were
attributed to the population size in the oldest group (n = 37 for FET).
This latter result led us to further re-stratify the population in two groups
(30-35 & 36-41 years-old).
In the group 30-35, no difference was observed between ET and FET.
However, pregnancy rate was signiﬁcantly lower following ET vs FET for the 36-
41 group (46.0% vs 62.6%, respectively) (odds ratio 1.97; 95% CI 1.19-3.27).
This result translates into a 36% higher chance of pregnancy when choosing FET
over ET for the 36-41 group.
Limitations, reasons for caution: Although the authors consider that the
patient population is of optimal size, a detailed analysis of the stimulation proto-
col and hormonal values (estradiol and progesterone) during treatment, and its
potential relation to the outcomes, should follow.
Wider implications of the ﬁndings: Considering the discrepancy on
whether applying a freeze-all policy to all patients or not, our data suggests that
elective frozen embryo over fresh transfer is advantageous for the older patient
population (advanced maternal age); enhancing the chances to pregnancy in
36%.
Trial registration number: not applicable.
P-221 Spectroscopic characterization of Granulosa Cells
correlates with oocyte fate
G. Gioacchini1, V. Notarstefano1, E. Sereni2, C. Zaca2, E. Giorgini1,
L. Vaccari3, O. Carnevali1, A. Borini2
1Università Politecnica delle Marche, Department of Life and Environmental Sciences,
Ancona, Italy
29.baby, Family and Fertility Center, Bologna, Italy
3Elettra Syncrhotron, SISSI Beamline, Trieste, Italy
Study question: Is it possible to outline the fate of an oocyte by analysing the
corresponding granulosa cells?
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Summary answer: By evaluating spectral Granulosa Cells biomarkers, here iden-
tiﬁed and validated, it is possible to outline the fate of the corresponding oocyte.
What is known already: In ART, oocyte selection is mainly based on the
subjective observation of its morphological features; however, the success rate
of this practice is still unsatisfactory.
Granulosa Cells (GCs) play a key role in regulating oocyte development and
in maintaining the appropriate microenvironment for the acquisition of its com-
petence. GCs produce estradiol and progesterone, together with essential
nutrients for oocyte development.
Fourier Transform Infrared (FTIR) spectroscopy is a well-established vibra-
tional technique, applied in life sciences for the study of the biomolecular build-
ing and composition of cells. Recently, FTIR was applied to evaluation of oocyte
quality in several experimental models including human.
Study design, size, duration: The study has been conducted between
March 2016 and September 2017 on 55 women undergoing a COH for IVF
treatment at 9.baby, Bologna Italy. Inclusion criteria: age <40 years; no ovarian
infertility diagnosis (only tubal, idiopathic and male infertility); regular ovulatory
menstrual cycles (25-30 days) with FSH < 10 IU/I on day 3 of the menstrual
cycle; sperm sample with a total motility count after treatment ≥ 300.000; num-
ber of oocytes retrieved ≥ 8; non-smokers.
Participants/materials, setting, methods: GCs from single-follicle
aspirates were classiﬁed based on the clinical outcome of the corresponding
oocyte: clinical pregnancy(A), fertilization failure(B), embryo development fail-
ure(C), and implantation failure(D). FTIR analysis provided a set of macromol-
ecular data characterising GCs; then, feature selection procedures were applied
to derive the spectral biomarker signature for different oocyte fates. ANOVA,
PERMANOVA, Factorial Discriminant Analysis, FDA, and Canonical Analysis of
Principal Coordinates, CAP statistical tools were applied to validate the identi-
ﬁed spectral biomarker signature.
Main results and the role of chance: An innovative FTIRM-based method
was developed to characterize GCs macromolecular ﬁngerprint and to retro-
spectively relate this FTIR information to the corresponding oocyte clinical out-
come. Several feature selection procedures (‘Leave-one-out’ method on FDA,
Variable Characterization method, and Logistic Regression method; signiﬁcance
set P<0.0001) let identify 17 FTIR-biomarkers, singularly analyzed by univariate
statistics and validated by multivariate tools.
ANOVA (P<0.05) analysis pinpointed that each experimental group showed
speciﬁc macromolecular traits, ascribable to different biological and metabolic
characteristics of GCs, and that not only the correct amount of macromolecule
supplied by the GCs but also the quality could make the difference for the fate
of the surrounding oocyte.
By applying multivariate tools, we validated the ability of the 17 FTIR-
biomarkers to segregate GCs samples in the four experimental groups. FDA
showed a clear separation along F1-axis (62.75% of discrimination) between GCs
from oocytes able (A,Dgroups) or not (B,Cgroups) to develop into embryos; F2-
axis (24.14% of discrimination) segregated the embryos that gave pregnancy (A)
from those that failed implantation (D). The confusion matrix (total percentage of
correctness = 80.25%) obtained from this analysis pinpointed that GCs from
oocytes unable to develop into embryos (B,C) were better characterized than
those from oocytes able to give viable embryos (A,D).
Limitations, reasons for caution: This study was conducted on a cohort of
patients selected based on tight inclusion/exclusion criteria. Further analyses should
also include elder women and/or presenting with ovarian infertility diagnosis.
Wider implications of the ﬁndings: The 17 identiﬁed and validated bio-
markers could be the basis for the development of a data standardization sys-
tem based on machine learning techniques, with the ﬁnal scope to establish a
reliable, non-invasive and objective tool to predict oocyte fate by analysing the
biochemical composition of the surrounding GCs.
Trial registration number:Not requested as Basic Study.
P-222 Sperm derived from testicular sperm extraction is
associated with differences in time-lapse morphokinetics of
resulting human embryos
E. Van Marion, G. Van der Heijden, J. Speksnijder,W. Boellaard,
J. Hoek, J. Laven, R. Steegers-Theunissen, E. Baart
Academisch Ziekenhuis Rotterdam, Wytemaweg 80, Rotterdam, The Netherlands
Study question: Is there a difference in developmental kinetics between
embryos resulting from intracytoplasmic sperm injection (ICSI) with testicular
derived sperm compared to ejaculated sperm?
Summary answer: The ﬁrst cell cycle, from pronuclear appearance to dis-
appearance, is signiﬁcantly longer in embryos fertilized by testicular sperm,
whereas the second cell cycle is faster.
What is known already: Embryo selection based on time-lapse morphoki-
netics is a promising method to improve implantation rates and time-to-
pregnancy. However, morphokinetics can be inﬂuenced by culture conditions
and patient characteristics. So far, little is known about the impact of the origin
of the sperm cell used for fertilization on embryo morphokinetics. One earlier
study showed that embryos from testicular sperm reached the 3- and 8 cell
stage signiﬁcantly later than embryos from epididymal sperm. Another study
showed a delayed morula formation and blastocyst hatching in embryos derived
from surgically retrieved sperm compared to ejaculated sperm. The clinical rele-
vance of these observations is unclear.
Study design, size, duration: This is a retrospective study of couples (n =
299) undergoing their ﬁrst intracytoplasmic sperm injection (ICSI) cycle with
frozen-thawed testicular sperm (TESE-ICSI; n = 112) or fresh ejaculated sperm
(normal ICSI; n = 187) between 31 January 2012 till 4 August 2017 at the
Erasmus MC. A total of 798 oocytes were injected with testicular sperm and 978
oocytes with ejaculated sperm. Only transferred and cryopreserved embryos
were annotated in the TESE-ICSI group (n = 310) and ICSI group (n = 496).
Participants/materials, setting, methods: All patients underwent ovarian
stimulation, ICSI, TESE-ICSI and embryo transfer according to standard proto-
cols. After injection, fertilized oocytes were cultured in the EmbryoScopeTM
time lapse incubator in either Vitrolife G-series culture media (from January
2012 to 15 November 2014) or Sage 1-step (after 17 November 2014).
Transfer was performed on Day 3 and embryos were frozen on Day 4.
Embryos were annotated for pronuclear appearance and –fading, and for time-
points in reaching the 2-8-cell stage.
Main results and the role of chance: Signiﬁcant differences were observed
between the group that underwent normal ICSI vs. TESE-ICSI in female age
(median age of 33.0 vs 31.6 years; p-value 0.045) and culture medium used
(55.1% vs 97.3% Sage1, 44.9% vs 2.7% Vitrolife G-series; p-value <0.001). TESE-
ICSI resulted in signiﬁcantly less fertilized oocytes than ejaculated sperm (respect-
ively 57% vs 75%; p-value <0.001). Implantation and live birth rates were com-
parable between normal ICSI and TESE-ICSI ( 41.2% vs 41.1% and 24.6% vs
24.1%, respectively). A linear mixed model was used to correct for clustering of
embryos from one patient and for differences in age. TESE-ICSI embryos needed
more time from pronuclear appearance to disappearance compared to embryos
from normal ICSI (beta 0.74 h, 95% CI [-0.07 to 1.55]; p-value 0.073). These
results suggest that embryos from TESE-ICSI need more time before nuclear
envelope breakdown, possibly due to repair of DNA damage or changes in epi-
genetic proﬁles. Remarkably, despite the initial delay, TESE-ICSI embryos reached
the six cell stage signiﬁcantly earlier (beta -2.68 h, 95% CI [-4.10 to -1.25]; p-value
<0.001). Also, the interval between pronuclear fading and the 3-cell stage (t3-
tPNf), was shorter (-1.25 h 95% CI [-1.97 to -0.53]; p-value 0.001), an important
parameter in morphokinetic selection models.
Limitations, reasons for caution: When adding culture medium to our
mixed model analysis results become less signiﬁcant. More research is needed
on the speciﬁc effect of culture medium on morphokinetics. The testicular
sperm cells were frozen, whereas the ejaculated sperm cells were fresh.
However, freezing was previously not observed to have an effect.
Wider implications of the ﬁndings: Prediction models based on time-lapse
annotations become a more common tool for embryo selection. In our study
TESE-ICSI embryos developed signiﬁcantly faster without impacting on implant-
ation potential. However, using the previously published KIDscore Day 3 selec-
tion model would lead to signiﬁcantly more unjustly discarded embryos in the
TESE-ICSI group.
Trial registration number: not applicable
P-223 Importance of multinucleation at the two-cell stage on
embryo development
S. Arrones1, C. Olmedo2, I. Martinez-Rodero3, S. Marín3, M. Barea3,
I. Cuevas Saiz4
1MasVida Reproducción, Reproduction, Sevilla, Spain
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2Hospital General Universitario de Valencia, Medicina Reproductiva, Valencia, Spain
3Hospital General Universitario de Valencia, Unidad de Medicina Reproductiva,
Valencia, Spain
4Hospital General Universitario de Valencia, Unidad de Medicina Reproductiva,
Chiva, Spain
Study question: To study the impact of multinucleation at the 2-cell stage in
human embryos regarding development, implantation and abortion rate.
Summary answer: In our study no correlation was found between multinu-
cleation at two-cell stage and embryo development, implantation status or
abortion.
What is known already: According to literature, multinucleation is related
to aneuploidies, detrimental effect on implantation and higher abortion risk.
However, time-lapse technology has shown that an important number of the
cultured embryos are multinucleated at the 2-cell stage. This has led to recon-
sider the impact of this event in normal embryo development.
Study design, size, duration: A retrospective morphokinetical analysis of
323 Known Implantation Data (KID) embryos was performed. Analysis con-
sisted in comparing KID and abortion relative to 2-cell stage multinucleated ver-
sus non-multinucleated embryos. Here, both clinical and biochemical abortions
were considered.
Participants/materials, setting, methods: We retrospectively analyzed
the implantation data of 323 embryos which were cultured at MIRI-TL® incuba-
tor with Continuous Single Culture Media (Irvine®). This analysis consisted in
comparing embryo implantation and abortion rates according to whether they
had multinucleation in 2-cell state. Data were analyzed by Student´s t-test using
SPSS 22.0 v. statistics software.
Main results and the role of chance: From the 323 KID embryos, 76 were
multinucleated at the 2-cell stage (23,5%). Among them, 26 were KID+ and 50
KID- (34,2% vs. 65,8% respectively). The other 247 embryos (76,5%), showed
no multinucleation, 61 were KID+ (24,7%) and 186 were KID- (75,3%). No sig-
niﬁcant differences were found between implantation status (KID+/KID-) of
multinucleated and non-multinucleated embryos. Regarding abortion, no signiﬁ-
cant statistical differences were found between multinucleated (26,9%) and no
multinucleated (27,9%) 2-cell embryos.
Limitations, reasons for caution: It would be necessary to increase the
number of analyzed embryos to conﬁrm this hypothesis.
Wider implications of the ﬁndings: According to these results it is reason-
able to consider multinucleation at the two-cell stage as not informative or pre-
dictive for implantation potential or abortion risk.
Trial registration number:No
P-224 Lipid and antioxidant supplements improve cryotolerance
and embryonic quality of Metaphase II mouse oocytes undergoing
vitriﬁcation
I. Viana1, A. Vireque2, P. Navarro3
1Universidade de São Paulo - Faculdade de Medicina de Ribeirão Preto, Ginecologia
e Obstetrícia, Ribeirão Preto-Brazil e Semear Fertilidade
2Invitra - Assisted Reproduction Technology LTDA, Pesquisa e Desenvolvimento,
Ribeirão Preto, Brazil
3Universidade de São Paulo - Faculdade de Medicina de Ribeirão Preto, Ginecologia
e Obstetrícia, Ribeirão Preto, Brazil
Study question: May lipid and antioxidant added to vitriﬁcation media
improve cryotolerance and embryonic quality of blastocyst originating from
metaphse II (MII) mouse oocytes that underwent vitriﬁcation?
Summary answer: Short-term exposure of MII mouse oocytes to lipid and
antioxidant biomolecules during vitriﬁcation safeguards blastocyst inner cell
mass (ICM), which improve safety of oocyte cryopreservation.
What is known already: Clinical application of oocyte vitriﬁcation was
approved only in 2013. Preservation of oocytes by vitriﬁcation had signiﬁcantly
higher survival rate, clinical pregnancy, and implantation rates than slow freez-
ing. Although recently there has been a consistent improvement in efﬁciency of
vitriﬁcation with live birth rates similar to fresh oocytes, safety remains obscure.
The scientiﬁc literature anticipates that lipids, serum derivatives and antioxi-
dants added to sperm freeze medium have improved sperm viability and preg-
nancy rates. However, the state-of-the-art does not yet contemplate the
development of new cryoprotective media for human oocytes containing lipids
and antioxidants with greater biosafety and efﬁcacy.
Study design, size, duration: The total number of vitriﬁed MII oocytes was
484. Three cryoprotectant formulations were investigated: Tvitri-4 (control/
standard vitriﬁcation media n = 127), Tvitri-4-AX (T4-Antioxidants n = 133),
Tvitri-4-LIPID-AX (T4-LIPIDS-Antioxidants n = 111) and Tvitri-4-LIPID-AX-PL
(T4-LIPIDS-Antioxidants-Phospholipids n = 113). IVF was performed with
oocytes surviving the thawing process: CT (191), Tvitri-4 (127), Tvitri-4-AX
(129), Tvitri-4-LIPID-AX (107) and Tvitri-4-LIPID-AX-PL (109) and blastocysts
rates were analyzed. ICM cells, TE (trophectoderm) and total cells were com-
pared from a total of 20 blastocysts per group.
Participants/materials, setting, methods: Females from 8-12-week-old
C57Bl/6 were submitted to superovulation with pregnant mare’s serum
gonadotropin and human chorionic gonadotropin (hCG) for obtaining of in vivo
matured oocytes. The oocytes were distributed in following groups: Fresh con-
trol; Tvitri-4; Tvitri-4-AX; Tvitri-4-LIPID-AX and Tvitri-4-LIPID-AX-PL. After
devitriﬁcation, oocyte survival rates were observed and in vitro fertilization was
performed. Blastocyst rates and embryonic quality evaluated by ICM, TE and
total cell number were compared among groups using ANOVA and Tukey’s
multiple comparisons.
Main results and the role of chance: The blastocyst formation rate from
CT oocytes was 58%. The survival rates (p = 0.2275) and blastocyst rates
(0.4274) of the vitriﬁed eggs in Tvitri-4, Tvitri-4-AX, Tvitri-4-LIPID-AX, Tvitri-
4-AX-LIPID-PL were 100% and 48%, 96.7 and 47.4%, 96 and 57% and 96.9 and
51.3%, respectively. The number of ICM cells, TE and total cells of the blasto-
cysts were: CT (19.5 ± 3.48, 51.45 ± 6.56, 70.95 ± 9.63), Tvitri-4 (14.85 ±
2.28, 33.0 ± 5.78, 47.85 ± 6.76), Tvitri-4-AX (16.05 ± 4.11, 34.7 ± 8.01,
50.75 ± 11.4), Tvitri-4-LIPID-AX (17.85 ± 3.95, 34.95 ± 7.48, 52.80 ± 9.78),
Tvitri-4-LIPID-AX-PL (17.80 ± 3.69, 35.6 ± 7.11, 53.4 ± 9.75). The mean
number of ICM cells was similar among CT and lipid plus antioxidant-
supplemented media (Tvitri-4-LIPID-AX, and Tvitri-4-LIPID-AX-PL groups)
(p>0.05). Inversely, ICM cells of CT were higher than Tvitri-4 and Tvitri-4-AX
(p = 0.0009). Regarding the number of TE and total cells, blastocyst from CT
have better parameters than others experimental groups (p<0.0001).
Limitations, reasons for caution: The clinical applicability of these ﬁndings
is challenged by the small sample size but positively affected by highly consistent
and reproducible in vitro outcomes, with excellent survival of vitriﬁed-thawed
oocytes and blastocyst rates in a mouse model widely used in pre-clinical stud-
ies and quality control in ART laboratory.
Wider implications of the ﬁndings: Adequate lipid supplementation during
vitriﬁcation seems to be crucial to embryo development of cryopreserved
oocytes. The primary endpoints were concluded and reinforced the potential
for efﬁcacy and safety of the new cryoprotectant formulation containing lipid
and antioxidant biomolecules, which would have clinical applicability by improv-
ing the safety of this technique.
Trial registration number: Ethics committee on the use of animals -
Medical School of Ribeirão Preto - University of São Paulo - 233/2014
P-225 The proportion of immature/compromised oocytes impairs
ooplasmic maturity of the mature cohort retrieved
S. Chow, A. Parrella, M. Irani, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Can the performance of the retrieved mature oocytes be
inﬂuenced by the fraction of immature and/or compromised cohort retrieved?
Summary answer: An increasing share of immature/compromised oocytes
among the retrieved cohort may foretell embryo developmental competence
and subsequent live birth rate.
What is known already: The achievement of complete oocyte maturation is
a prerequisite to accomplish fertilization ability and yield conceptuses capable
of implanting. The meiotic progression and ooplasmic maturity are integral
events allowing the attainment of oocyte competence. While oocyte nuclear
maturity is assessed by the extrusion of the ﬁrst polar body, indeed ooplasmic
readiness is a subtle phenomenon that has been known for some time but has
still been poorly detected.
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Study design, size, duration: Couples treated by ICSI between 1993 and
2017 involving young female partners (≤ 35 years old) and men with adequate
semen parameters were included. Cycles were divided into four groups accord-
ing to the proportion of MII oocytes at time of retrieval: Optimal (76-100%),
adequate (51-75%), partial (26-50%), and minimal (0-25%). Ovarian stimulation
and ICSI were performed in a standard fashion. Fertilization and pregnancy
characteristics was compared between the four groups.
Participants/materials, setting, methods: The average maternal age was
31.9 ± 3 years while paternal age was 35.1 ± 5 years. A total of 8,861 ICSI
cycles in which 87,029 MII oocytes were injected using ejaculated spermatozoa
were included. T-test was used to compare the mean values of the number of
injected oocytes. Chi-squared test was used to compare the percentages of cat-
egorical variables.
Main results and the role of chance: Cycles were allocated into the follow-
ing four oocyte maturity ratio groups: optimal (n = 5516), adequate (n = 2599),
partial (n = 635), and minimal maturation (n = 111). Maternal age was compar-
able among the four groups (31.9 ± 2, 31.9 ± 2, 32.0 ± 2, and 31.8 ± 2 years,
respectively). The mean numbers of injected oocytes were 11, 8.9, 4.8, and
1.4, respectively (P<0.0001). The decreasing proportion of MII oocytes was
associated with a signiﬁcant increase of germinal vesicle (GV) from 5.5% to 48%
(P<0.0001). The number of degenerated oocytes at time of retrieval increased
from 1% to 10.3% (P<0.0001). Consequently, the minimal group presented the
lowest rates of normal fertilization (2-pronuclei) (78.6% to 63.2%, P<0.0001)
and corresponding highest rates of abnormal fertilization (digynic 3-pronuclei)
(2.7% in the optimal group versus 4.3% in the minimal group, P = 0.03). The clin-
ical pregnancy rates (52.2 to 32.0%, P<0.0001), and live birth rates (49.1% to
30.0%, P<0.0001) were also affected by the decreasing proportion of MII
oocytes among the total cohort retrieved.
Limitations, reasons for caution: To control for the confounding effect of
oocyte aneuploidy, this study only included young female partners. In this study,
while we prove the obvious synergy between nuclear and ooplasmic maturity
required for optimal outcomes, we did not provide a direct marker of the latter
but only an indirect evidence.
Wider implications of the ﬁndings: This study indicates that cytoplasmic
component needs to complement nuclear maturity to achieve successful ART
outcomes. It provides guidance toward superovulation protocols aimed at
achieving lower proportion of MI, GV, and degenerated oocytes in order to
yield a higher fraction of more competent MII sibling oocytes.
Trial registration number:N/A.
P-226 Era of frozen blastocyst embryo transfer might replace that
of fresh blastocyst embryo transfer—A large retrospective cohort
study
W. Saab1, V. Seshadri1, A. Alchami1, S. Cawood2, C. Heath2,
R. Odia2, B. Sowry2, X. Vinals Gonzalez2, P. Serhal1
1Centre for Reproductive and Genetic Health, Clinicians, London, United Kingdom
2Centre for Reproductive and Genetic Health, Embryologists, London, United
Kingdom
Study question: Does frozen blastocyst transfer have a better clinical out-
come compared to fresh blastocyst transfer in all patients undergoing IVF/ICSI
treatment across all age groups?
Summary answer: This study demonstrates that frozen blastocyst on (day
5/6) compared to a fresh blastocysts transfer resulted in signiﬁcantly better
pregnancy outcome irrespective of age.
What is known already: Elective frozen-embryo transfer has been shown to
result in a higher live-birth rate than fresh-embryo transfer among anovulatory
women with the polycystic ovary syndrome. The hormonal effect of ovarian
stimulation on the endometrial lining has been attributed as one of the possible
causes for the lower pregnancy rates during fresh transfer in this subcategory of
patients. Pregnancy and perinatal outcomes of frozen embryos have shown to
have similar outcome to that of fresh in women. In addition, Day 5 blastocyst
transfer result in a better pregnancy rates compared to day 6 blastocyst
transfers.
Study design, size, duration: Retrospective single centre cohort study
evaluating the pregnancy outcome of total of 4049 blastocyst embryo transfers
(fresh and frozen D5/6) between January 2014 to December 2017, was per-
formed. During that period 2272 frozen embryo transfers and 1777 fresh
embryo transfers were done.
Participants/materials, setting, methods: Patients undergoing fresh and
frozen blastocyst transfers were included. Study was conducted at a single UK
centre, CRGH London. Clinical pregnancy rates were calculated for fresh day 5,
fresh day 6, frozen day 5 and frozen day 6 blastocyst transfers from January
2014 to December 2017. Live birth rates for the above categories were also
calculated from January 2014 to December 2016. Results were compared.
SPSS version 23 was used for analysis.
Main results and the role of chance: Age was normally distributed and
comparable between fresh day 5 and frozen day 5 transfer (p = 0.095). It was
also comparable between fresh day 6 and frozen day 6 transfers (p = 0.622).
The number of embryos transferred per cycle was signiﬁcantly more in the fresh
compared to the frozen embryo transfers irrespective if the blastocyst was day
5 (1.6 ± 0.5 vs 1.3 ± 0.4, p = 0.000) or day 6 (1.8 ± 0.5 vs 1.3 ± 0.48, p =
0.000) respectively. Pregnancy rates were signiﬁcantly higher for frozen embryo
transfers compared to fresh transfers irrespective if the blastocyst was day 5
(65.8% vs 62.9%, p = 0.048) or day 6 (48.5% vs 35.2%, p = 0.011). Similarly,
better outcome was seen in the clinical pregnancy rates for frozen compared to
fresh transfers. Clinical pregnancy rates for day 5 frozen vs fresh (61.8% vs 58.1
%, p = 0.027) and those for day 6 transfers ( 45.1% vs 34.1%, p = 0.039) irre-
spectively. Live birth rate was signiﬁcantly higher with frozen embryos com-
pared to fresh embryos irrespective if the blastocyst was day 5 or 6. Live birth
rate for day 5 frozen vs fresh blastocyst (51.1% vs 49.2%). Live birth rates for
day 6 transfer frozen vs fresh (33.8% vs 31.1%).
Limitations, reasons for caution: Embryo quality was not analysed to check
if there is any difference between the grade of the frozen vs the fresh embryos
which could have attributed to the better pregnancy outcome in the frozen
group.
Wider implications of the ﬁndings: This is the ﬁrst large prospective study
to compare outcome of frozen blastocyst with fresh blastocyst transfer relating
to the day of blastocyst development. The results are very reassuring suggesting
a possible beneﬁt of freeze all policy at the blastocyst stage and transfer
embryos on a frozen cycle.
Trial registration number:Not applicable.
P-227 Is Day 3 (D3) Laser Assisted Hatching Better than Day 1
(D1) Laser Assisted Hatching in PGS/PGDCycles?
V. Reddy1, J. Dasig1, O. Badamjav1, Q. Zhao1, J.H. Moon1, Y. Qin1,
A. Masoudi1, B. Behr2
1Lucile Packard Childrens Hospital- Stanford Fertility and Reproductive Health,
Obstetrics and Gynecology, Sunnyvale, U.S.A.
2Stanford University, Obstetrics and Gynecology, Palo Alto, U.S.A.
Study question: The goal of this study was to evaluate whether there is a dif-
ference in the blastocyst development rate between embryos that were
hatched using a laser on D1 versus D3.
Summary answer: There was no statistically signiﬁcant difference in the
blastocyst rate between the 2PN hatched on D1 versus cleavage stage embryos
hatched on D3.
What is known already: D3 assisted hatching of some patients’ embryos in
non-PGS/PGD cycles is standard in embryology practice. However, due to an
increase in blastocyst biopsy cycles, our lab adopted the policy to hatch on D3
to enhance the trophectoderm hatching potential on day 5 for easier biopsy.
Study design, size, duration: This study was carried out between May and
October 2017 at Stanford Fertility and Reproductive Health, USA. Total of 261
2PN from 24 patients were prospectively randomized to be hatched on D1 or
D3.
Participants/materials, setting, methods: Total of 130 2PN on D1 and
131 embryos on D3 were hatched using a 1460 nm, 300 mW diode laser. The
hatching was performed on the outer edge of the zona pellucida using only a
single 470-μs pulse. The embryos were cultured in the same single step medium
from day 1 to day 6.
Main results and the role of chance: There was no signiﬁcant difference in
the blastocyst rates between the two groups (p > 0.05). There were a total of
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123 and 122 embryos ≥5 cell grade 2 on D3 in the cohorts that were hatched
on D1 and D3, respectively. Blastocyst rate was 66.9% (87 total blastocysts,
with 37 on day 5) and 61% (80 total blastocysts, with 41 on day 5) with a grade
≥3BB in the D1 and D3 cohorts, respectively. Fisher’s exact test with two tails
was used.
Limitations, reasons for caution: This was a pilot study. IVF and ICSI were
not equal as 20% 2PN that were hatched on D1 and 22% embryos that were
hatched on D3 came from IVF. The study is limited to laser assisted hatching
only.
Wider implications of the ﬁndings: By hatching on D1, embryos for PGS/
PGD cases can be cultured uninterrupted in the incubator until the blastocyst
stage to harness the full potential of single step culture media. This is especially
useful for clinics that do not use time-lapse technologies.
Trial registration number:NA.
P-228 Oocytes cryoconservation and reproductive outcome:
evaluation of embryometabolomiic proﬁles
M. Santonastaso, F. Caprio, R. Ianniello, M.D. D’ Eufemia,
A. Natella, N. Colacurci
Seconda Università degli Studi di Napoli, Dpt. of Woman-Child and General and
Special Surgery, Naples, Italy
Study question: Does oocyte cryopreservation change the metabolism of the
embryo obtained?
Summary answer: Oocyte cryopreservation determines a greater activation
of embryo metabolism.
What is known already: The oocytes vitriﬁcation is successfully applied to
maximize the safety and efﬁcacy of ovarian stimulation cycles in an IVF treat-
ment, proving to be an effective approach also for the preserving female fertil-
ity.Oocyte vitriﬁcation showed a fertilization and implantation rates comparable
to those of fresh oocytes, even if it is lack the possible effects of vitriﬁcation on
metabolic status of the developed embryos. Recent data prove that the culture
media of embryos that were positive or negative for successful implantation
showed speciﬁc metabolomic signatures. However,there is some weak evi-
dence that metabolomics technologies studying culture media of embryo devel-
oped from vitriﬁed oocytes.
Study design, size, duration: Spent embryo culture media (ECM) were col-
lected on day 3 before transfer from April 2017 to November 2017
Participants/materials, setting, methods: The control group was the
ECM obtained from fresh oocyte (n = 9).The study group was composed
of culture media of embryos developed from vitriﬁed oocytes (n = 7). The
oocyte vitriﬁcation-thawing was conducted in accord to the manufac-
turer’s instructions. After the embryos were removed from the culture,
the spent culture media were collected and we analyzed metabolomic pro-
ﬁle by 1H-NMR. Embryo quality was assessed by Gardner morphological
classiﬁcation. The data were analyzed using the unpaired Student’s t-test
(p-value≤0.05)
Main results and the role of chance: The IVF outcomes (fertilization,
embryo quality and implantation rate) were statistically signiﬁcant less in study
group compared to control group. Our 1H-NMR analysis evidenced that in cul-
ture media of embryos developed from vitriﬁed oocytes the levels of formate,
albumin, H-Cα lactate, H-Cβ lactate, glucose and endotoxin were lower in
comparison to embryo obtained from fresh oocyte. The reduced embryo qual-
ity observed in study group can be certainly correlated to the different levels of
these molecules.
Limitations, reasons for caution: Study limitation is the low number of
samples analyzed.
Wider implications of the ﬁndings: Our study showed that quantitative
and qualitative modiﬁcations of metabolites were linked to embryo develop-
ment. We can suggest to integrate embryo analysis through the study of meta-
bolomic parameters on culture medium. Detecting embryo with greater
capacity for development and implantation will increase the oocyte cryopreser-
vation success.
Trial registration number:None.
P-229 Can the distribution of morphokinetic parameters help
predict pregnancy viability in women undergoing In-Vitro
Fertilization/Single Embryo Transfer (IVF/SET)? A time lapse (TL)
study
I. Souter1, G. Christou2, I. Dimitriadis3, C. Sacha4, N. Piekarski2,
J. Diemick2, C.L. Bormann3
1Massachusetts General Hospital-Harvard Medical School, Obstetrics/Gynecology-
Reproductive Endocrinology and Infertility, Dover- MA, U.S.A.
2Massachusetts General Hospital Fertility Center, Obstetrics/Gynecology-
Reproductive Endocrinology and Infertility, Boston, U.S.A.
3Massachusetts General Hospital-Harvard Medical School, Obstetrics/Gynecology-
Reproductive Endocrinology and Infertility, Boston, U.S.A.
4Massachusetts General Hospital and Brigham and Women’s Hospital-Harvard
Medical School, Obstetrics/Gynecology-Reproductive Endocrinology and Infertility,
Boston, U.S.A.
Study question: Is there an association between the distribution of early-
and/or late-morphokinetic parameters (as assessed by TL-microscopy) and
pregnancy viability following IVF/SET?
Summary answer: Neither early- nor late-morphokinetic parameters
predicted pregnancy viability in IVF/SET cycles. However, most embryos
successfully implanting reached early blastulation within a deﬁned time
range.
What is known already: TL-monitoring is a novel tool widely used to predict
an embryo’s developmental and implantation potential. Several morphokinetic
parameters, either static and/or interval, in early and/or late stages of embry-
onic development have been assessed as predictors of reproductive outcomes
and appear promising. However, it remains unclear whether blastocysts result-
ing in successful pregnancies differ in all or some of these morphokinetic para-
meters from those of morphologically normal embryos that fail to implant or
establish a viable pregnancy.
Study design, size, duration: Retrospective cohort of 191 women undergo-
ing IVF/SET at a major academic center between 9/2013 and 4/2016. Women
with embryos cultured to the blastocyst stage in a TL-monitored incubator and
selected for fresh SET were eligible. Embryos resulting in viable pregnancies
(progressing to ≥20 weeks gestation) were compared to those from unsuccess-
ful transfers in regards to the distribution of certain early- and late-
morphokinetic parameters.
Participants/materials, setting, methods: The primary outcome was
time-period from pronuclei fading (tPNf) to early-blastulation (PSB). Secondary
outcomes were time-periods from i) tPNf to 1st-cytokinesis (P1), ii) 2- to 3-cells
(P2), iii) 3- to 4-cells (P3), iv) 4- to 5-cells (P4), and v) 5- to 8-cells (P8).
Statistics: Mann-Whitney U-, χ2-tests, multiple logistic-regression to calculate
odds ratio (OR), 95% conﬁdence interval (95%CI) controlling for potential con-
founders (maternal age, body mass index (BMI), basal-FSH, fertilization
method).
Main results and the role of chance: Groups did not differ in baseline char-
acteristics (basal FSH, AMH, antral follicle counts). In 58.1% of cycles ICSI was
utilized.
Following IVF/SET, 58.1% (111/191) of the patients conceived a viable
pregnancy. When all embryos were included in the analysis and morphoki-
netic parameters from viable-pregnancies were compared to those from
unsuccessful transfers in regard to PSB distribution, no difference was noted
[median (95% range): 68.78(59.78-77.81) vs. 69.26(59.28-79.81), p = 0.43;
for viable pregnancy vs. unsuccessful SETs, respectively). Similarly, none of the
remaining morphokinetic parameters’ distributions differed between groups
[median (95% range): 2.53(1.93-3.24) vs. 2.50(1.83-3.34), p = 0.42; 10.97
(2.94-12.67) vs. 10.97(2.11-13.40), p = 0.81; 0.69(0.00-8.51) vs. 0.58(0.00-
8.32) hours, p = 0.18; 11.62(0.68-14.81) vs. 11.58(2.20-14.71), p = 0.72; and
4.34(0.83-18.55) vs. 4.67(1.28-15.93) hours, p = 0.71] for P1, P2, P3, P4 and
P8, respectively].
However, for the vast majority (80%) of embryos resulting in viable pregnan-
cies, the time to reach early blastulation ranged between 61.96-75.72 hours.
When PSB remained in that range, the odds of a viable pregnancy were
increased by 166% overPSB durations slower or faster than that [adjusted OR
(95%CI): 2.66 (1.17, 6.04); p = 0.02]. No other time period affected the odds
of achieving a viable pregnancy.
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Limitations, reasons for caution: The study was limited by its retrospective
design. Moreover, only morphokinetic parameters thought to predict blastocyst
formation were studied and algorithms taking into consideration standard mor-
phologic criteria and/or genetic composition of embryo were not included.
Wider implications of the ﬁndings: Among women undergoing IVF/SET,
no single morphokinetic parameter predicted pregnancy. However, the odds
for a viable pregnancy were signiﬁcantly higher among embryos that reached
early blastulation within a deﬁned time range. Additional studies taking into con-
sideration morphologic criteria and ploidy status are needed to develop algo-
rithms helpful in embryo selection.
Trial registration number:Not applicable.
P-230 Simple embryo selection for vitriﬁed-warmed blastocyst
transfer cycles: blastocyst derived from 4-cell embryo at 40-42 hours
after insemination has the potential to improve clinical outcomes
J.H. Cha, J.W. Lee, S.H. Shin, Y.J. Kim, S.K. Lee, H.J. Cha, J.H. Kim,
D.H. Kim, E.H. Kang, J.H. Ahn, H.Y. Kim, K.A. Pak, J.S. Yoon,
S.Y. Park
Agaon Fertility Clinic, IVF center, Seoul, Korea- South
Study question: Does blastocyst derived from 4-cell embryo at 40-42 hours
after insemination (Bla-4c) has the potential to improve clinical outcomes in
vitriﬁed-warmed blastocyst transfer cycles?
Summary answer: Bla-4c has signiﬁcantly higher clinical outcomes compared
to the blastocyst derived from non-4-cell embryo at 40-42 hours after insemin-
ation (Bla-n4c).
What is known already: The number of cells is the morphological marker
strongly associated with implantation potential. Optimal results are achieved
when 4-cell embryos are transferred on day 2. Implantation potential
decreases when the number of cells is other than four. Developments of
extended embryo culture and cryopreservation techniques have allowed IVF
programs to offer patients the chances of embryo transfer without ovum-
pick-up.
Study design, size, duration: A total of 880 vitriﬁed-warmed blastocyst
transfer cycles were retrospectively analyzed from June 2014 to September
2017. The cycles with frozen sperm, surgical retrieved sperm, genetic diagnosis,
oocyte donation, poor responder, and advanced maternal age (≥38 years)
were excluded.
Participants/materials, setting, methods: Cycles were divided into 2
groups based on the origin of blastocyst (Bla-4c, n = 336 vs. Bla-n4c, n = 544).
4-cell stage embryos were separated from non-4-cell stage embryos at 40-42
hours after insemination and culture them to blastocyst stage. Vitriﬁcation was
performed for cryopreservation of blastocyst. The quality of warmed blastocyst
was evaluated by Gardner and Schoolcraft’s classiﬁcation. The number of
embryos transferred was less than or equal to two.
Main results and the role of chance: There were no differences between
Bla-4c and Bla-n4c regarding female age (33.1 ± 2.3 vs. 33.4 ± 2.5, p = 0.136),
the number of embryos transferred (1.5 ± 0.5 vs. 1.5 ± 0.5, p = 0.499), and
abortion rate (14.4% vs. 18.5%, p = 0.354). However, Bla-4c achieved signiﬁ-
cantly higher rates of survival (99.2% vs. 97.5%, p = 0.022), good quality (≥BB)
embryos (66.1% vs. 47.1%, p = 0.000), biochemical pregnancy (47.9% vs.
41.0%, p = 0.044), clinical pregnancy (39.3% vs. 28.9%, p = 0.001), ongoing
pregnancy (33.6% vs. 23.5%, p = 0.001), and implantation (31.5% vs. 24.1%, p
= 0.004) than those of Bla-n4c.
Limitations, reasons for caution: This study was based on static observa-
tion. The assessment of 4-cell embryo development was done at given time
point (40-42 hours after insemination). Further studies are required pro-
spectively to conﬁrm our ﬁndings with respect to the rates of live birth
outcomes.
Wider implications of the ﬁndings: Pre-selection of 4-cell embryo at 40-
42 hours after insemination can eliminate inappropriately developed embryo
and increase the chance to transfer appropriately developed embryos to the
patients. Bla-4c has the potential to improve clinical outcomes in vitriﬁed-
warmed blastocyst transfer cycles.
Trial registration number: not applicable.
P-231 Non-invasive biomarkers for embryo quality in sterile
patients
I. Martínez Rodero1, J. Marí-Alexandre2, J.M. Moreno-Moya3,
S. Marín-Real1, M. Barea1, C. Olmedo-Illueca1, I. Cuevas-Sáiz1
1Hospital General de València, Reproductive Medicine Unit, Valencia, Spain
2Health Research Institute La Fe, Unit of Hemostasia- Thrombosis- Atherosclerosis
and Vascular Biology-, Valencia, Spain
3Oslo University Hospital, Reproductive Department, Oslo, Norway
Study question: To improve reproductive prognosis in sterile patients sub-
jected to IVF, especially in endometriosis, by means of measuring miRNAs in
CCs (Cumulus Cells) through quantitative RT-PCR.
Summary answer: For the ﬁrst time, miRNAs expression has been measured
in CCs endometriosis patients, where snU6 has been found downregulated
compared to control group.
What is known already: Considering the need of selecting embryos with
the highest implantation potential, morphological selection could be
improved with the use of new methodologies. Among them, cumulus cells
transcriptomics is a less invasive technique, since the analysis is not per-
formed to the embryo but to cells removed prior to ICSI procedure. To
our knowledge, there is no previous study of miRNAs expression in CCs
of endometriosis patients. However, there are previous results of CCs
miRNA proﬁle sequencing. To notice is report by Tong et al., who using
RNA-seq and validation by RT-qPCR identiﬁed hsa-miR-16-5p, hsa-miR-
26a-5p and hsa-miR-101-3p in CCs.
Study design, size, duration: This preliminary work retrospectively analyzed
miRNA expression of single-oocyte CCs from 34 patients undergoing ICSI and
single embryo transfer, from 2015 until 2016. Exclusion criteria were Polycystic
Ovary Syndrome, severe male factor and patients without Known Implantation
Data (KID). Only CCs corresponding to the transferred embryo were included.
Four clinical groups were deﬁned according to endometriosis and KID. Control
group was KID+ without endometriosis.
Participants/materials, setting, methods: From 34 total patients, 6 suf-
fered from endometriosis and 28 did not. From endometriosis, 2 were KID+
and 4 KID-. From non-endometriosis group, 15 were KID+ (control group) and
13 KID-. The expression of 6 miRNA plus presumptive normalizer (snU6) was
measured in CCs by rt-qPCR: hsa-miR-101-5p, hsa-miR-223-5p, hsa-miR-16-
5p, hsa-miR-26b-5p, hsa-miR-124-3p, hsa-miR-335-5p. They were measured
from microdrops where CCs were contained when total RNA was isolated.
RefFinder software was used to select normalizer.
Main results and the role of chance: miRNAs of study were quantiﬁed
below detection limit in blank culture media where CCs had been collected and
stored, so they did not interfere in our results. 4 miRNAs and snU6 were suc-
cessfully detected, while 2 did not (miRNA-101-5p and miRNA-124-3p).
RefFinder output pointed at miR-26b-5p as better normalizer than snU6. The
robustness of miR-26b-5p expression in our samples could be liked to its target,
which is a cell cycle gene. When comparing miRNAs fold-change values
between KID+ and KID- groups, no statistical differences were found.
However, when we compared miRNAs expression data in endometriosis vs.
non-endometriosis patients, snU6 was statistically signiﬁcant (p<0,05). Allegra
and colleagues are the unique reference of CCs transcriptome in endometriosis
context, where they found genes related to inﬂammation, such as TNF-α,
down-regulated in endometriosis. Interestingly, snU6 serum levels have been
signiﬁcantly correlated with established serum markers of inﬂammation, such as
TNF-α, suggesting snU6 is speciﬁcally downregulated in inﬂammatory diseases
(Benz et al., 2013). Surprisingly, in our study snU6 levels were lower in CCs of
endometriosis patients, pointing that snU6 is also downregulated here. In line
with that, exacerbated inﬂammation has been postulated to play an important
role in endometriosis (Stilley et al., 2012).
Limitations, reasons for caution: Among limitations is reduced sample
size. This is a frequent situation in IVF units performing less than 500 cycles
per year, since samples are considerable reduced when non-KID cases are
discarded. Another limitation is the methodology for selecting miRNAs of
study.
Wider implications of the ﬁndings: For future insights, we consider using
single-cell technology in CCs with a larger number of patients, including endo-
metriosis. It is important to continue trying to improve reproductive chances of
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these type of patients. Also, it would be interesting to validate miR-26-5p as
normalizer gene for RT-qPCR in CCs.
Trial registration number: not-applicable
P-232 Single embryo transfers in frozen-thawed cycles may help to
lower twin pregnancies and complications when compared to
double embryo transfers without compromising outcomes
H.K. Yelke, Y. Kumtepe Colakoglu, C. Pirkevi Cetinkaya,
S. Kahraman
Istanbul Memorial Hospital, Assisted Reproductive Technologies and Reproductive
Genetics Center, Istanbul, Turkey
Study question: Is the cumulative live birth rate of subsequent frozen-thawed
cycles similar to that of double embryo transfers?
Summary answer: The cumulative pregnancy rate of patients with a potential
OHSS risk is not compromised when good or top-quality blastocysts are trans-
ferred in FET cycles.
What is known already: IVF success has generally been measured based on
live birth rates after a single episode of treatment resulting in the transfer of a
ﬁrst fresh or frozen thawed embryo. This fails to capture the real chance of hav-
ing a baby after a number of complete cycles-each involving the replacement of
remaining frozen-thawed embryos. Therefore, cumulative rate of live birth is
more important since it better summarizes the chance of a live birth over an
entire treatment period.
Study design, size, duration: This retrospective cohort study includes
patients whose blastocysts were “all-frozen” between January 2015 and January
2016. The cumulative pregnancy rate was calculated for all patients whose live
birth data was available until October 2017. For comparison, a patient group
under 35 who have received a double blastocyst in a FET cycle in the same peri-
od were included in the analysis.
Participants/materials, setting, methods: The cumulative pregnancy rate
was calculated by dividing the total number of births by the number of fresh
cycles. The mean female age in the elective single embryo transfer (eSET; n =
486) group and in the double embryo transfer (DET; n = 457) group was 29.7
and 30.3, respectively.
Main results and the role of chance: The live birth data was available for
427 out of 486 patients who came to our clinic for a FET cycle and whose blas-
tocysts were frozen because of a potential OHSS risk. 45.2% of ﬁrst FET cycles
(n = 193) resulted in a live birth. From the patients who did not get pregnant in
their ﬁrst FET and came for a second FET (n = 225) 39 resulted in a live birth
(17.3%). When outcomes were calculated cumulatively, with a relative increase
of 20.1%, the cumulative live birth rate of the eSET group has been calculated
as 54.3%. The live birth rate of the DET group which has been transferred in
the same period, was 55.1%. The statistical comparison of the live births of
both groups gives a non-signiﬁcant p value. Moreover, the multiple pregnancy
rate was 1.2% and 38.5% in the cumulative eSET and DET groups, respectively
(p<0.0001). When term pregnancies were analyzed, 84% of singleton pregnan-
cies were found to be delivered after the 37th week of pregnancy whereas only
29.4% of twin pregnancies achieved term (p<0.0001).
Limitations, reasons for caution: Cumulative pregnancy outcomes are cal-
culated as the number of pregnancies per initiated cycle, therefore the rate vary
depending on patients who come forward to use their remaining frozen
embryos over time.
Wider implications of the ﬁndings: In recent years, improvements in labora-
tory conditions and embryo-endometrium synchronization have resulted in higher
pregnancy rates with the transfer of blastocyst-stage embryos in FET cycles.
Therefore, a cumulative eSET strategy is advisable with the additional beneﬁt of
reducing multiple pregnancy risks and consequently neonatal complications.
Trial registration number:Not applicable.
P-234 Can assisted reproduction technologies decide
unintentionally the sex of the babies?
C. Olmedo Illueca, I. Cuevas Saiz, I. Martíínez Rodero, S. Marín Real
Hospital General Universitario de Valencia, Reproductive Medicine Unit, Valencia,
Spain
Study question: The main objective is evaluating the possible effect of
assisted reproductive technologies (ARTs) on the sex ratio of the offspring.
Summary answer: We found statistical signiﬁcance in sex ratio when trans-
ferring embryos at blastocyst stage, while there is no correlation when embryos
are transferred at cleavage stage.
What is known already: Sex ratio calculated as male proportion is 1.7 times
higher than female under natural conception. However, at birth, this sex ratio
diminishes to 1.05 caused by abortion and other reasons. Under in vitro condi-
tions this proportion could be modiﬁed. Studies using preimplantation genetic
diagnosis (PGD) shown sex ratio at cleavage stage embryos is lower than those
at blastocyst stage. In addition, sex ratio at birth was signiﬁcantly higher in IVF
compared to ICSI embryos. Recently, a group of researchers found correlation
between male’s BMI during treatment and higher probability of giving male
singletons.
Study design, size, duration: This retrospective study included all live birth
from IVF cycles between 2005 and 2017. During this period 399 babies were
born from IVF or ICSI fresh and frozen cycles.
Participants/materials, setting, methods: A total of 333 patients were
included in our study. All the analysis was carried out with Statistical Package
for the Social Science software (SPSS version 21.0). Pearson χ2 test was used to
compare the distribution of categorical variables in different groups. We com-
pare sex ratio at birth with the day of embryo transfer (Cleavage-stage or
blastocyst-stage) in singletons and twins, the ART employed (conventional IVF
or ICSI) and embryos from fresh or frozen cycle.
Main results and the role of chance:When we compare the sex ratio with
the day of embryo transfer we found statistically signiﬁcant differences towards
the males when we transfer the embryos at blastocyst stage (2.57). At
cleavage-stage the ratio at birth is maintained at 1.08 towards males, very simi-
lar to natural conditions (1.05). However, we did not ﬁnd any association
between sex ratio and ART employed nor the fresh/ frozen groups.
Our results suggested that the day of embryo transfer is directly related with
the sex ratio at birth towards males. Blastocyst embryos are selected because
male embryos grow faster than female embryos. Furthermore, there is a higher
mortality in female embryos that may be caused by inactivation of one of the X
chromosomes. Our ﬁndings agree to other investigators results. The transfer of
Blastocyst-stage embryos seems to be directly related with sex ratio at birth
both singletons and twins.
Limitations, reasons for caution: This study had also limitations. The num-
ber of cases included in IVF group is lower than ICSI group. Furthermore, we
do not know if our twins are monozygotic or dizygotic twins.
Wider implications of the ﬁndings: Since ARTs landscape is increasingly
moving to day 5 transfer, this result should be considered, so we could be unin-
tentionally selecting embryos towards male children. In that line, blastocyst
selection criteria may be revised.
Trial registration number:Not applicable.
P-235 Exploring the use of mid-infrared spectroscopy to detect
development and implantation biomarkers in spent culture media
of human embryos
J. Sousa Emídio dos Santos1, C. Calado2, L. Ramalhete2,
M. Gallardo1, L. Montero1, A. Braula1
1Malo Clinic - Ginemed, IVF unit, Lisbon, Portugal
2ISEL, Instituto Superior de Engenharia de Lisboa-, Lisbon, Portugal
Study question: Can the mid-infrared spectra of spent embryo culture media
predict the ability of an embryo to develop into blastocyst and implant?
Summary answer:Distinct spectra features have been observed in the meta-
bolomic proﬁle of media of embryos that developed into good quality blasto-
cyst compared to those that arrested.
What is known already: There is great interest in detecting a biomarker
with enough sensitivity and speciﬁcity to predict embryo development and
implantation potential in order to select the best embryo from a cohort, for a
single embryo transfer, reducing time to pregnancy and the economic and psy-
chological burden of unsuccessful attempts. Approaches like single metabolite
quantiﬁcation by mean of high performance liquid chromatography and less
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informative near-infrared spectroscopy haven’t provided a reliable predictor.
Mid-infrared spectroscopy is a powerful tool that provides richer spectra.
Study design, size, duration: Spent embryo culture media from embryos
undergoing extended culture to the blastocyst stage was collected, frozen and
subsequently used for the mid-infrared spectroscopy (MIR) analysis. A cohort
of 101 embryos were analyzed in this pilot study. Data regarding embryo quality
and development was collected retrospectively.
Participants/materials, setting, methods: Embryos were cultured from
day 1-3 in 30 microliters drops of sequential media (G1Plus, Vitrolife, Sweden),
with an oil overlay, at 37 °C, 6% CO2, 5% O2, and 90% humidity. Embryos
were transferred to another culture dish by careful and individual pipetting and
the media was collected within an hour and frozen at -20 °C. Sample processing
and optimization of MIR spectral acquisition conditions, quality control indica-
tors (ICQ) as the signal to noise ratio.
Main results and the role of chance: The processed MIR spectrum (e.g.
the 2nd derivative) was analyzed and retrospectively evaluated for its association
with embryo quality and development to blastocyst and embryo implantation.
The high speciﬁcity and sensitivity of the technique is evidenced by statistically
signiﬁcant differences of diverse ratios of spectral bands between spent culture
of embryos that developed poorly with those that produced good quality
blastocysts.
Limitations, reasons for caution: The potential confounding factor of vari-
ables that can inﬂuence the analysis outcome, such as media type, volume of
the culture drops, culture conditions, among others, has to be identiﬁed.
Wider implications of the ﬁndings: The informative MIR spectra shows
potential to be used as a predictor of embryo development to blastocyst stage,
and eventually, for the selection of the ﬁttest embryo with highest implantation
potential within a cohort.
Trial registration number: not applicable.
P-236 Increased anti-oxidative capacity of follicular ﬂuid HDL is a
positive predictor of embryo quality in modiﬁed natural cycle IVF
R. Nagy1, A. Van Moontfoort2, H. Groen3, I. Homminga2,
D. Andrei4, R. Mistry4, J. Anderson4, A. Hoek2, U. Tietge4
1University Medical Center Groningen, Pediatrics and Obstetrics & Gynecology,
Groningen, The Netherlands
2University Medical Center Groningen, Obstetrics & Gynecology, Groningen, The
Netherlands
3University Medical Center Groningen, Epidemiology, Groningen, The Netherlands
4University Medical Center Groningen, Pediatrics, Groningen, The Netherlands
Study question: Is anti-oxidative function of follicular ﬂuid (FF) high density
lipoproteins (HDL) associated with embryo quality in modiﬁed natural cycle
in vitro fertilization (MNC-IVF)?
Summary answer: A higher FF-HDL anti-oxidative function is associated
with increased development of a top quality embryo on day two after
fertilization.
What is known already: HDL are the main cholesterol carriers in FF. Thus
far, FF-HDL have been mainly studied in the context of steroid hormone
synthesis.
Study design, size, duration: For the present cross sectional study,
between August 2013 and April 2017 FF and plasma samples were collected
during 561 consecutive MNC-IVF cycles of 249 consenting patients in a single
academic infertility treatment center.
Participants/materials, setting, methods: The anti-oxidative function of
HDL, measured as the capacity to prevent native LDL oxidation in vitro, was
determined in (i) 19 matched plasma and FF samples from randomly selected
patients and (ii) FF from 375 MNC-IVF cycles, where one oocyte was retrieved
and minimum FF blood contamination was present. The association between
HDL anti-oxidative function and oocyte and embryo quality as well as occur-
rence of a viable pregnancy were assessed statistically by general estimating
equations.
Main results and the role of chance: The anti-oxidative function of FF-
HDL was signiﬁcantly higher than that of matching plasma-HDL (84 [79.2-87.1]
versus 67.2 [63.8-70.1]; p <0.001); more than 80% of the total FF anti-
oxidative capacity was attributable to the presence of HDL. A higher FF-HDL
anti-oxidative function was associated with higher odds of development of top
quality embryos, association that persisted after adjustment for BMI and smok-
ing (OR 2.04, 95%CI 1.18-3.53, p = 0.011). However, the anti-oxidative func-
tion of FF-HDL was not associated with the occurrence of an ongoing
pregnancy.
Limitations, reasons for caution: The present study did not ﬁnd an associ-
ation between the anti-oxidative function of FF-HDL and ongoing pregnancy,
possibly as a consequence of low power. Only patients from a single center
participated.
Wider implications of the ﬁndings: More research on the oxidative
stress/anti-oxidant balance of FF in relation to oocyte development and fertility
outcomes is warranted. Further, deﬁnition of lifestyle interventions to increase
the anti-oxidative capacity of FF-HDL holds potential to increase the success
rates of IVF procedures and of natural conceptions.
Trial registration number:Nederlands Trial Register number NTR4409.
P-237 Cleavage stage versus blastocyst stage embryo transfer in
oocyte donation cycles
G. Kontopoulos1, P. Psathas2, C. Dimitropoulos2, I. Vasilopoulos2,
S. Grigorakis2, T. Mantzavinos2, E. Dedoulis2, K. Agapitou2,
N. Vlahos1
1Institute of Life- National Kapodestrian University of Athens, Institute for Life ART
unit -Iaso Maternity Hospital, Athens, Greece
2Institute of Life, Institute for Life ART unit -Iaso Maternity Hospital, Athens, Greece
Study question: Is there a difference in implantation and clinical pregnancy
rates between day 3 cleavage stage and day 5 or blastocyst stage embryo trans-
fer in frozen-thaw oocyte donation cycles.
Summary answer: Embryo transfers on day 5 are associated with signiﬁcant
improvement on implantation and clinical pregnancy rates in oocyte donation
cycles.
What is known already: During the last few years a shift has occurred for
transfer of embryos at the blastocyst stage. It has been shown that embryo
transfer at the blastocyst stage following COH /ET has been associated with
improved implantation rates and clinical pregnancy rates as compared to cleav-
age stage transfers. So far, there is no study evaluating this notion in oocyte
donation cycles.
Study design, size, duration: This is a retrospective evaluation of all trans-
fers performed after oocyte donation in our center during the period between
January 2017 to December 2017. Oocyte donors is a unique populations in
terms that they represent a good prognosis group, more homogeneous as com-
pared to infertile patients. The study was approved by the ethics committee of
the IASO maternity hospital and the scientiﬁc board of the IOLIFE fertility
center.
Participants/materials, setting, methods: 303 oocyte donation cycles
performed. From January 2017 to December 2017.
Donor ovarian stimulation was performed using a short GnRHantagonist
protocol with rFSH. ICSI was performed in all donors. All embryos were cryo-
preserved either on cleavage or blastocyst stage.
Recipient endometrial preparation was standardized. Progesterone was
initiated 3days prior to cleavage stage embryo transfers and 5-6 days prior to
blastocyst stage transfers.Statistical analysis was done using SPSS, v25. A p value
< 0.05 was considered signiﬁcant.
Main results and the role of chance: Three hundred and one (301) frozen-
thaw transfers from oocyte donation cycles where ﬁnally included in the study.
There were 171 day 3 transfers out of which there were 92 clinical pregnancies
(53.8%). In 123 day 5 transfers there were 75 clinical pregnancies (60.9%) In
7 day 6 transfers ,4 clinical pregnancies were reported (57%).
Overall there was no difference between the two groups in terms of the age
of the donors, day 2 FSH, antral follicle count, number of MII oocytes and num-
ber of good quality embryos. There was no difference between the groups in
terms of type of catheter use and documented difﬁculty during the transfer.
Embryo transfers performed on day 3 were compared to transfers performed
on blastocyst stage in terms of clinical and ongoing pregnancy rates. Day 5 and
day 6 transfers were evaluated in the same group. Overall embryo transfers at
the blastocyst stage were associated with signiﬁcantly improved pregnancy rates
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(60.7%) as compared to cleavage stage transfers (53,8%) p = 0.012. The risk of
multiple pregnancies (mainly twins) was similar in the two groups (data not
shown)
Limitations, reasons for caution: There is no complete information on the
obstetrical outcome on a signiﬁcant proportion of those pregnancies.
Wider implications of the ﬁndings: These ﬁndings suggest that in oocyte
donation cycles embryo transfer at the blastocyst stage is associated with a sig-
niﬁcant improvement in pregnancy rates and should be adopted as a standard
practice.
Trial registration number:Not applicable.
P-238 Canmetabolomics provide information about blastocyst
development?
I. Cuevas-Sáiz1, C. Olmedo-Illueca1, S. Marín-Real1,
I. Martínez-Rodero1, S. Arrones2, M. Barea1
1Hospital General Universitario de Valencia, Reproductive Medicine Unit, Valencia,
Spain
2MASVIDA Reproduccion- Sevilla, IVF laboratory, Sevilla, Spain
Study question: Is blastocyst´s culture media metabolic proﬁle correlated
with other embryo selection criteria?
Summary answer: Metabolic proﬁle is not correlated to implantation, nor to
women’s age or morfokinetic parameters but may be linked with expansion
degree and cryoresistance of blastocyst.
What is known already: With the aim of improving Assisted Reproductive
Techniques (ARTs) outcome, new methods for embryo selection have
appeared in the last few years. One of them is metabolomics of embryo culture
media. Up to now, metabolic proﬁle is not able to predict clinical outcome, so
there is controversy about its applicability to clinical context. Nevertheless, it is
true that metabolomics provide valuable information about embryo metabol-
ism. It has been demonstrated that embryo at blastocyst stage changes its meta-
bolism to glycolysis, which generates lactate. Furthermore, lipids metabolism
has been studied in other animal species, and it has been related to
cryoresistance.
Study design, size, duration: This study included 48 blastocysts from 38
patients, whose transfer ended in Know Implantation Data (KID). All patients
performed an IVF treatment with fresh transfer at the blastocyst stage between
September of 2016 until March of 2017.
Participants/materials, setting, methods: Embryos culture media
(Continuous Single Complete, Irvine) were stored after transfer in day 5 was
performed. All embryos were cultured in MIRI-TL (ESCO- Medical Ò) incuba-
tor, so that morphokinetical data was available for study. Culture media was
analysed by Magnetic Nuclear Resonance (MNR). Spectrum obtained were
processed and analysed by Principal Component Analysis (PCA) and Partial
Least Squares Regression (PLS-DA) using MATLAB. T-student test was per-
formed using SPSS 15.0 v and signiﬁcance was set as 0,05.
Main results and the role of chance: The 48 spectrum of culture media
were signiﬁcative separated in two groups based on its composition. More spe-
ciﬁcally, three regions of spectrum: lactate region (0.075 ± 0.003 in group 1 vs
0.05 ± 0.01 in group 2), lipids HDL+LDL+VLDL region (0.15 ± 0.03 in group 1
vs 0.72 ± 0.30 in group 2) and mobile lipids (0.09 ± 0.03 in group 1 vs. 0.82 ±
0.40 in group 2). Although the difference was not signiﬁcant, blastocyst from
group 1 tended to be more expanded than blastocyst from group 2 (p-
value>0,05). No correlation was found between the two groups and KID, nor
with patient’s age and morphokinetic parameters (p-values>0,05).
With these results, metabolic proﬁle of embryos cultured until blastocyst
stage may not be related with implantation status. Nevertheless, two groups of
blastocysts were differentiated in terms of its metabolism, particularly in lactate
and lipids content of their culture media. This differentiation is independent
from patient’s age and morphokinetic parameters measured until day 5.
Limitations, reasons for caution: To conﬁrm these preliminary results, it
would be necessary to increase the number of culture media samples.
Wider implications of the ﬁndings: Metabolic differences found could be
linked with grade of blastocyst expansion. Lactate differences between two
groups refer to glucose intake in glycolysis, since results indicate there is more
lactate production in more expanded blastocyst. Furthermore, we found less
lipid content in more expanded blastocyst, which could be related to
cryoresistance.
Trial registration number:Not applicable
POSTER VIEWING
Endometriosis, endometrium and fallopian tube, and benign
disorders of the endometrium and fallopian tube
P-239 Preimplantation genetic screening in endometriosis and
non-endometriosis patients in a single institution
S.J. Chon1, B.H. Yun2, Y.S. Jung3, Y.J. Cho1, S.Y. Jung1
1Gil Hospital, Obstetrics and Gynecology, Incheon-si, Korea- South
2Severance Hospital, Obstetrics and Gynecology, Seoul, Korea- South
3Wonju Severance Hospital, Obstetrics and Gynecology, Wonju, Korea- South
Study question: Is there any difference in between prevalence of aneuploidy
embryos in endometriosis and non-endometriosis patients using preimplanta-
tion genetic screening?
Summary answer:No.
What is known already: Endometriosis is deﬁned as the presence of endo-
metrial tissue outside the uterine cavity and it leads to chronic inﬂammation
with oxidative stress, and genetic variations which eventually decrease preg-
nancy rates and live birth rates. Among these various factors, meiotic spindle
alterations have been reported disturbing on chromosomal segregation and
organization in endometriosis patients which could cause aneuploidy. As ART
increases striving for higher pregnancy rate, it is believed that majority of aneu-
ploidy embryos might cause lower live birth rates. Therefore people were
recommended for PGS patients who are considered to be at high risk of having
aneuploidy embryos.
Study design, size, duration: Cross sectional study.
Retrospective chart reviews.
Patients who have undergone IVF and PGS from August, 2014 to July, 2017.
PGS was recommended to couples who have at least one of these criteria;
woman’s age ≥37 years old, ≥ one parent has chromosomal mosaicism, spon-
taneous abortion ≥ 2 times, implantation failure ≥ 2 times.
Patients who were diagnosed with endometriosis were 19 people and who
were not diagnosed with endometriosis were 93 people.
Participants/materials, setting, methods: Eighty two embryos from 19
patients with endometriosis and 371 embryos from 93 non-endometriosis
women were enrolled. All of them were indicated for IVF with PGS. A
cleavage-stage embryo biopsy was performed on Day 3 of embryo develop-
ment by extruding one blastomere from embryos reaching at least the six-cell
stage, and samples were taken for analysis on the same day.
Main results and the role of chance: Aneuploidy rates in between the two
groups according to age groups in both endometriosis and non-endometriosis
groups consistently tended to increase when they were calculated according to
embryos. Among patients less than 35 years old, the aneuploidy rates were
52.6 %, 72.9 %, and among patients equal to greater than 41 years old, the
aneuploidy rates were 89.6 %, 87.7 % in both endometriosis and non-
endometriosis groups.
We saw whether age, abnormal karyotype, history of recurrent pregnancy
loss, history of recurrent implantation failure, serum AMH, number of retrieved
oocytes have signiﬁcant impact on abnormal PGS. Among these factors, other
than history of recurrent pregnancy loss and number of retrieved oocytes, they
were signiﬁcantly related to aneuploidy embryos that they were set for con-
founding factors and associations in between presence of endometriosis and
aneuploidy embryos were re-analyzed. Presence of endometriosis was not sig-
niﬁcantly associated with abnormal PGS result (Exp(B) = 0.766, 95% CI =
0.401-1.465, P-value = 0.420).
Limitations, reasons for caution: The number of cases of endometriosis
was small and endometriosis stages are missing. Also, we cannot say non-
endometriosis patients do not have endometriosis. Lastly, PGS was done in
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blastocyst staged embryos that we cannot say that abnormal chromosomal seg-
regation and organization of embryos were thoroughly analyzed.
Wider implications of the ﬁndings: Although the sample size is small, we
certainly are sure that the results of this study would be meaningful in recognizing
that the aneuploidy rates in between the endometriosis and non-endometriosis
groups are not much different in certain groups of Korean population.
Trial registration number: not applicable.
P-240 Factors affect the outcome of IVF and the recurrence of the
endometrial disease of patients with atypical endometrial
hyperplasia (AEH) and early well-differentiated endometrial
adenocarcinoma (EC)
H. Li, X. Song, R. Li, J. Qiao
Peking University Third Hospital, Department of Obstetrics and Gynecology-
Reproductive Medical Center, Beijing, China
Study question: When to initiate IVF is safe and effective for patients with
atypical endometrium hyperplasia(AEH) and early well-differentiated endomet-
rial adenocarcinoma (EC) after fertility-sparing treatment?
Summary answer: It is safe and effective to start IVF immediately
after achieving ﬁrst complete response (CR) for patients with AEH and early EC.
What is known already: The available data support the relative safety and
efﬁcacy of progestin therapy and allow fertility-sparing patients to achieve their
fertility goals in a short window of disease resolution.More and more women
with AEH and EC after fertility-sparing treatment have to receive IVF treatment.
Although some literatures report that IVF is safe to these patients, the number
of the cases is small. The factors that affect the outcome of IVF and the recur-
rence of the disease are still not clear.
Study design, size, duration: A total of 60 patients with AEH and early
well-differentiated EC after fertility-sparing treatment were included. All these
patients received IVF treatment in Reproductive medical center of Third hos-
pital,Peking university between May 2011 and May 2017. Data of the results
was retrospectively analysis.
Participants/materials, setting, methods: According to the time to start
IVF after the ﬁrst time to CR, 60 patients were divided into within 3 months
(group A) and after 3 months (group B).The implantation rate, clinical preg-
nancy rate,spontaneous abortion rate and recurrence rate were compared
between the two groups.
Main results and the role of chance: A total of 60 patients were included,
45 with AEH and 15 with EC. The follow-up time from the ﬁrst CR was 39.6
± 26.9 months. Ninety-ﬁve ovum pickup cycles were performed. There were
67 fresh embryo transfer cycles and 54 FET cycles. A total of 36 patients
achieved 47 pregnancies, and 25 patients gave 32 babies. The pregnancy rate
per cycle in fresh cycle was 38.8%(26/67),and the pregnancy rate per cycle in
FET cycle was 25.93%(14/54). The pregnancy rate of fresh cycles in Group A
and B was 39.1% and 38.6%, respectively(P = 0.969).In FET cycles,the preg-
nancy rate was 50% and 24% in Group A and B,respectively (P = 0.583). The
total recurrence rate was 30% (18/60) during the follow-up period. It was sig-
niﬁcantly higher in the group B than the group A (17.1% vs 48%, P = 0.022).
Limitations, reasons for caution: This study is nonrandomized,as the pro-
portion of such patients in IVF is low, and the number of cases was relatively
small, so some statistical results may be limited by the smal sample size.
Wider implications of the ﬁndings: From the results of the paper, the
recurrence of the endometrial disease is associated with the initiation of IVF
after the ﬁrst CR, and the outcome of IVF is not related to the starting time of
IVF. It is recommended that IVF should be started as soon as possible.
Trial registration number: none.
P-240 Factors affect the outcome of IVF and the recurrence of the
endometrial disease of patients with atypical endometrial
hyperplasia (AEH) and early well-differentiated endometrial
adenocarcinoma(EC)
H. Li, X. Song, R. Li, J. Qiao
Peking University Third Hospital, Department of Obstetrics and Gynecology-
Reproductive Medical Center, Beijing, China
Study question: When to initiate IVF is safe and effective for patients with
atypical endometrium hyperplasia(AEH) and early well-differentiated endomet-
rial adenocarcinoma (EC) after fertility-sparing treatment?
Summary answer: It is safe and effective to start IVF immediately after
achieving ﬁrst complete response (CR) for patients with AEH and early EC.
What is known already: The available data support the relative safety and
efﬁcacy of progestin therapy and allow fertility-sparing patients to achieve their
fertility goals in a short window of disease resolution.More and more women
with AEH and EC after fertility-sparing treatment have to receive IVF treatment.
Although some literatures report that IVF is safe to these patients, the number
of the cases is small. The factors that affect the outcome of IVF and the recur-
rence of the disease are still not clear.
Study design, size, duration: A total of 60 patients with AEH and early
well-differentiated EC after fertility-sparing treatment were included. All these
patients received IVF treatment in Reproductive medical center of Third hos-
pital,Peking university between May 2011 and May 2017. Data of the results
was retrospectively analysis.
Participants/materials, setting, methods: According to the time to start
IVF after the ﬁrst time to CR, 60 patients were divided into within 3 months
(group A) and after 3 months (group B).The implantation rate, clinical preg-
nancy rate,spontaneous abortion rate and recurrence rate were compared
between the two groups.
Main results and the role of chance: A total of 60 patients were included,
45 with AEH and 15 with EC. The follow-up time from the ﬁrst CR was 39.6 ±
26.9 months. Ninety-ﬁve ovum pickup cycles were performed. There were 67
fresh embryo transfer cycles and 54 FET cycles. A total of 36 patients achieved
47 pregnancies, and 25 patients gave 32 babies. The pregnancy rate per cycle in
fresh cycle was 38.8%(26/67),and the pregnancy rate per cycle in FET cycle
was 25.93%(14/54). The pregnancy rate of fresh cycles in Group A and B was
39.1% and 38.6%, respectively(P = 0.969).In FET cycles,the pregnancy rate was
50% and 24% in Group A and B,respectively( P = 0.583). The total recurrence
rate was 30% (18/60) during the follow-up period. It was signiﬁcantly higher in
the group B than the group A (17.1% vs 48%, P = 0.022).
Limitations, reasons for caution: This study is nonrandomized,as the pro-
portion of such patients in IVF is low, and the number of cases was relatively
small, so some statistical results may be limited by the smal sample size.
Wider implications of the ﬁndings: From the results of the paper, the
recurrence of the endometrial disease is associated with the initiation of IVF
after the ﬁrst CR, and the outcome of IVF is not related to the starting time of
IVF. It is recommended that IVF should be started as soon as possible.
Trial registration number: none.
P-241 Chronic endometritis: Prevalence using hysteroscopy and
CD138 immunohistochemistry and impact on reproductive
outcome in patients with previous IVF/ICSI failure
S. Anis Hebisha1, N. Mashaly2, N. Elbadawy3
1Faculty of Medicine-Alexandria University, OBGYN, Alexandria, Egypt
2Faculty of Medicine-Alexandria University, Pathology, Alexandria, Egypt
3Research Institute- Alexandria University, Pathology, Alexandria, Egypt
Study question: To evaluate the prevalence of CE in women with previous
IVF/ICSI failure using hysteroscopy and CD138 immunohistochemistry and
whether subsequent antibiotic treatment positively impacts implantation.
Summary answer: In women with previous IVF/ICSI failure the diagnosis and
treatment of chronic endometritis CE, signiﬁcantly improves implantation and
pregnancy rates in subsequent attempts.
What is known already: A healthy receptive endometrium is essential for
embryo implantation.Recently, the relationship between chronic endometritis
(CE) and infertility-related conditions such as previous implantation failure has
emerged as an area of inquiry. CE is diagnosed by endometrial biopsy, and the
presence of plasma cells in the endometrial stroma is the generally accepted
histological diagnostic criterion for CE.Recently, an immunohistochemical (IHC)
stain capable of detecting CD38 and CD138 plasma cellspeciﬁc surface antigens
was introduced for the conﬁrmation of the presence of plasma cells inside the
endometrium.The hysteroscopic evaluation of endometrial inﬂammatory dis-
ease showed a good sensitivity for detecting CE.
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Study design, size, duration: Design: prospective cohort study.
145 women aged between 25 and 38 years with history of previous IVF/ICSI
failure included in the study during three years.
Participants/materials, setting, methods: women underwent hystero-
scopy and endometrial sampling for CD138 immunohistochemistry. Women
diagnosed with CE were treated with antibiotics until follicular phase biopsy
showed no CE. Patients were placed in two groups based on presence or
absence of CE (group A and B, respectively). Primary outcome was sensitivity,
speciﬁcity and accuracy of hysteroscopy in relation to immunohistochemistry
(as a gold standard) in diagnosis of CE. Secondary outcomes were implantation
and pregnancy rates in the post-treatment IVF/ICSI attempt.
Main results and the role of chance: Primary outcome was sensitivity, spe-
ciﬁcity and accuracy of hysteroscopy in relation to immunohistochemistry (as a
gold standard) in diagnosis of CE. Secondary outcomes were implantation and
pregnancy rates in the post-treatment IVF/ICSI attempt.
Prevalence of CE was 23.4% (34/145) using hysteroscopy and 19.3% (28/
145) using immunohistochemistry (golden standard) showing 78.6%, 89.7%,
and 87.5% sensitivity, speciﬁcity and accuracy respectively.
Implantation rate in subsequent cycles was signiﬁcantly higher in group A vs.
B (35.16% vs 16.43%, p = 0.001*). Group A also showed higher pregnancy rate
compared to group B (57.14% vs 34.18%, p = 0.076*).
Limitations, reasons for caution: larger number of study cases is needed.
Wider implications of the ﬁndings: In women with previous IVF/ICSI fail-
ure the diagnosis and treatment of CE signiﬁcantly improves implantation and
pregnancy rates in subsequent attempts therefor hysteroscopy and endometrial
sampling should be considered in evaluation of the endometrium in infertile
women and specially before starting assisted reproductive technique ART.
Trial registration number:
• Informed consent was obtained from all participants.
• The study was approved by Alexandria University ethical
committee.
• The study was performed at Alexandria University, Egypt.
P-242 Naturally occurring endometriosis in the cynomolgus
macaque: effects of analgesics on pain-related behavior and brain
activation
I. Hayashi5, A. Matsuda2, T. Natsume3, M. Yano2, S. Ogawa4, Y.
Awaga4, A. Hama1, H. Takamatsu4
1Hamamatsu Pharma Research- Inc., Research Plannning, Hamamatsu, Japan
2Hamamatsu Pharma Research- Inc., Animal Care, Hamamatsu, Japan
3Hamamatsu Pharma Research- Inc., Contract Research, Hamamatsu, Japan
4Hamamatsu Pharma Research- Inc., Pharmacology, Hamamatsu, Japan
5Hamamatsu Pharma Research USA- Inc., Business Development, Hamamatsu,
Japan
Study question: Can pain and brain activation be observed in cynomolgus
macaques with endometriosis?
Summary answer: Macaques with endometriosis demonstrate marked
abdominopelvic pressure hypersensitivity and thalamic and insula activation,
which were reduced with morphine and dienogest treatment.
What is known already: The mechanism of abdominopelvic pain associated
with endometriosis is poorly understood, as reﬂected by the lack of effective
treatments that offer signiﬁcant pain relief for endometriosis patients. While
more preclinical studies are needed, one potential barrier to translating preclin-
ical ﬁndings to clinical application is that rodents, a species with a reproductive
system that is distinct from that of humans, are most frequently used as the spe-
cies to model clinical endometriosis. By contrast, the cynomolgus macaque is
anatomically and phylogenetically closer to humans than rodents.
Study design, size, duration: This was an observational, preclinical study
utilizing cynomolgus macaques (Macaca fascicularis) diagnosed with naturally
occurring endometriosis. During abdominal pressure pain assessment, maca-
ques were restrained and awake and during brain imaging, macaques were
anesthetized with propofol. Following acute dosing with morphine, meloxicam
and acetaminophen, macaques were treated for eight weeks with dienogest.
Participants/materials, setting, methods: Five macaques with endometri-
osis (10-18 yo) and three healthy controls (10 yo) were used. Responsiveness
to pressure in the abdominopelvic area was measured using a pressure alg-
ometer and the effects of morphine, meloxicam, acetaminophen and dienogest
on pressure sensitivity were determined. Non-noxious abdominopelvic
pressure-induced brain activation was visualized with functional magnetic reson-
ance imaging (fMRI; 3.0 T MRI Signa HDxt (GE)) and the effects of drug treat-
ment on brain activation were observed with fMRI.
Main results and the role of chance: Macaques with endometriosis dis-
played signiﬁcantly decreased abdominopelvic pressure thresholds compared
to healthy macaques (P < 0.05), suggestive of pressure hypersensitivity.
Morphine (P < 0.05) but not meloxicam or acetaminophen acutely ameliorated
pressure hypersensitivity. Dienogest treatment ameliorated pressure hypersen-
sitivity beginning on the second week of treatment (P < 0.05) which persisted
for at least four weeks following termination of dienogest treatment (P < 0.01).
Abdominal pressure also induced bilateral activation of the insular cortex and
thalamus, which was reduced with an acute dose of morphine and eight weeks
of dienogest treatment. Interestingly, while the mean endometrioma volume
tended to decrease over time in dienogest-treated macaques, this was not stat-
istically signiﬁcant compared to the pre-treatment volume (P = 0.09).
Limitations, reasons for caution: The current study utilized a small sample
size with possibly differing stages of endometriosis for each macaque. Whether
it is possible to measure ‘spontaneous pain” in the macaques with endometri-
osis, whether through behavior or brain activity, has yet to be determined.
Wider implications of the ﬁndings: The current macaque ﬁndings suggest
that endometriosis patients could have signiﬁcant pain-related brain activation.
If so, then brain activation in the macaque could be utilized as a preclinical bio-
marker against which to develop treatments that not only reduce symptoms
but modify the underlying disease.
Trial registration number:N/A.
P-243 Antifertility effectiveness of a novel copper-containing
intrauterine device material and its inﬂuence on the endometrial
environment in rats
S. Hu1,W. Xia1, C. Zhu1, Q. Yu2
1Family Planning Research Institute- Tongji Medical College, Huazhong University of
Science and Technology, Wuhan- Hubei, China
2Reproductive Medicine Center- Tongji Medical College-Tongji Hospital, Huazhong
University of Science and Technology, Wuhan- Hubei, China
Study question: This study was designed to investigate the antifertility effect-
iveness of a novel copper-containing intrauterine device (Cu-IUDs) material
and its effect on the endometrial environment in rats.
Summary answer: This study demonstrates that micro-Cu/LDPE/MVQ
exhibits satisfactory contraceptive efﬁcacy and causes fewer side effects than
Cu.
What is known already: Cu-IUDs have excellent contraceptive efﬁcacy, the
existing Cu-IUDs are associated with undesirable side effects, such as menor-
rhagia, intermenstrual bleeding, pelvic pain, and spotting.
Study design, size, duration: One hundred sixty healthy female rats were
randomly divided into four groups of 40 each: (a) a sham-operated control
group (SO group); (b) the Cu/LDPE/MVQ group; (c) the LDPE/MVQ group;
and (d) the Cu group.
Participants/materials, setting, methods: Twenty rats in each group
were mated with male rats of proven fertility, from 30 days after insertion, and
the antifertility rates (ATs) were observed at Day 12 of pregnancy. The patho-
logical changes and factors associated with bleeding, pain, and inﬂammation in
the endometrium of the remaining rats in each group were then investigated 90
days after insertion, and the surface condition of the implants was analyzed 90
days after insertion.
Main results and the role of chance: The contraceptive effectiveness was
100% in both the bulk Cu group and the micro-Cu/LDPE/MVQ group, and
that in the LDPE/MVQ group was 30%. On day 90 after insertion, histopatho-
logical observation and the ultrastructural changes of the endometrium showed
that the damage caused by bulk Cu was much more severe than that caused by
the Cu/LDPE/MVQ microcomposite and that the surface of the Cu/LDPE/
MVQ microcomposite was much smoother than that of the bulk Cu.
Furthermore, compared with the sham-operated control group, the
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concentrations of tissue plasminogen activator and prostaglandin E2 were sig-
niﬁcantly increased 90 days after insertion in all experimental groups except for
the LDPE/MVQ group (P < 0.05), and the parameters in the Cu/LDPE/MVQ
group were signiﬁcantly lower than those in the Cu group (P < 0.05). In add-
ition, the expression levels of matrix metalloproteinase 9, tissue inhibitor of
metalloproteinase 1, plasminogen inhibitor 1, CD34, vascular endothelial
growth factor, substance P, and substance P receptor in the endometrium in all
experimental groups were signiﬁcantly lower than those in the Cu group 90
days after insertion (P < 0.05).
Limitations, reasons for caution: We chose rats for the antifertility effect-
iveness and safety. We did not use other animals to show that the novel
copper-containing composite are the most promising materials.
Wider implications of the ﬁndings: The micro-Cu/LDPE/MVQ may be
useful in intrauterine contraceptive devices.
Trial registration number: not applicable.
P-244 Impact of long term pretreatment with GnRH agonist
before standard GnRH agonist protocol for IVF/ICSI on cumulative
live birth rates of infertile women with adenomyosis
M.H. Chen,W. Qiong, G. Jun, L. Lu, Z. YIngying, Z. Canquan
The First Afﬁliated Hospital of Sun Yat-sen University, Reproductive medicine center,
Guangzhou-Guangdong, China
Study question: Can long term pretreatment with GnRH agonist before
standard GnRH agonist protocol improve cumulative live birth rates (CLBRs)
for infertile women diagnosed as adenomyosis compared with standard agonist
protocol alone?
Summary answer: CLBRs per IVF/ICSI ovarian stimulation cycle were lower
in long term GnRH agonist pretreatment group than without pretreatment
group for infertile women with adenomyosis.
What is known already: GnRH agonist can cause hypoestrogenism there-
fore reduce uterine size in adenomyosis. Long term use of GnRH agonist is
shown to improve pregnancy outcomes in women with adenomyosis in frozen
embryo transfer cycle. However, it is unknown whether long term pretreat-
ment with GnRH agonist before standard GnRH agonist protocol for IVF/ICSI
can improve CLBRs of infertile women with adenomyosis.
Study design, size, duration: This is a retrospective cohort study; A total of
232 ovarian stimulation cycles and 201 women diagnosed as adenomyosis who
underwent ovarian stimulation for IVF/ICSI with standard GnRH agonist proto-
col with or without long term GnRH agonist pretreatment at our hospital from
January 2010 to March 2017 were identiﬁed and reviewed.
Participants/materials, setting, methods: Infertile women with adeno-
myosis who attempted ovarian stimulation for IVF or ICSI were categorized
into two groups (standard GnRH agonist protocol with or without long term
pretreatment with GnRH agonist). CLBR was deﬁned as the ﬁrst live birth per
ovarian stimulation cycle including fresh and frozen cycles and evaluated by
group. Binary logistic regression was used to assess the association between
controlled ovarian hyperstimulation (COH) protocol and cumulative live birth
after adjusting for confounding factors.
Main results and the role of chance: Oocyte retrieval was cancelled in 14
cycles. Baseline characteristics including female and male age, female BMI, grav-
idity and times of previous miscarriage, basal FSH, proportion of patients com-
plicated with endometriosis as well as insemination method were similar in the
two groups. Stimulation outcome including number of retrieved oocytes and
mature oocytes, number of transferred embryos, high quality embryos and fro-
zen embryos were similar in the two groups. Cumulative live birth rates were
lower in standard GnRH agonist protocol with long term GnRH agonist pre-
treatment than without pretreatment (32.4% vs 46.6%, P = 0.044). The CLBRs
is associated with female age (OR 0.923, 95% CI 0.852-0.994, P = 0.035),
standard GnRH agonist protocol without long term pretreatment (OR 2.299,
95% CI 1.124-4.705, P = 0.023) and number of high quality embryos (OR
1.833, 95% CI 1.508-2.227, P<0.001) after adjusted for basal FSH, proportion
of patients complicated with endometriosis.
Limitations, reasons for caution: As a retrospective study, our analysis
depended on previously recorded data; therefore, certain variables such as ser-
um CA125 level could not be collected.
Wider implications of the ﬁndings: Long term pretreatment of GnRH
agonist may be not necessary for infertile women with adenomyosis who
undergo IVF/ICSI with standard GnRH agonist protocol.
Trial registration number: not applicable.
P-245 Adenomyosis down regulates endometrial L-selectin ligands
at the mid-secretory phase during menstrual cycle
F.W. Chang1, T.H. Lai2,3,4, J.J. Lin3,5, Q.D. Ling4,5
1Department of Obstetrics and Gynecology, Tri-Service General Hospital, National
Defense Medical Center
2Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan
3Fu Jen Catholic University School of Medicine, New Taipei City, Taiwan
4Institute of Systems Biology and Bioinformatics, National Central University, Taoyuan
City, Taiwan
5Cathay Medical Research Institute, Cathay General Hospital, New Taipei City,
Taiwan
Study question: Does adenomyosis impair L-selectin ligand (LSL) expression
in human endometrium?
Summary answer: Adenomyosis decreases LSL expression in the luminal
epithelium of the endometria at the mid-secretory phase during the menstrual
cycle.
What is known already: The relationship between adenomyosis and infertil-
ity is still unclear, but severe adenomyosis has a negative impact on pregnancy
rate in clinical observation. One of the possible pathophysiology is impaired
endometrial receptivity. LSL is a biomarker for endometrial receptivity. Defects
in LSL expression leading to implantation failure were reported in women with
endometriosis, PCOS and unexplained infertility. However, LSL expression in
adenomyosis is still unknown.
Study design, size, duration: This is a retrospective, experimental study.
Forty-two endometrial samples from reproductive-aged women with adeno-
myosis underwent hysterectomy were obtained at Cathay General Hospital,
Taipei, Taiwan from Aug 2008 to July 2009. Twelve samples were collected
from the proliferative phase, 10 from the early-secretory phase, 9 from the
mid-secretory phase, and 11 from the late-secretory phase. Another 11 endo-
metrial samples were collected from menopausal women as controls.
Participants/materials, setting, methods: The inclusion criteria of the
participants were: (1) 35 < age < 50 years; (2) regular menstrual cycle; (3) BMI
< 28; (4) no hormone therapy at least 2 months before surgery; (5) no known
endometrial pathologies. Immunohistochemistry with MECA-79 Ab, western
blotting and RT-PCR were performed to evaluate LSL expression. The intensity
of immunostaining was analyzed by HSCORE. Non-parametric Kruskal-Wallis
one-way analysis of variance with multiple comparisons was performed to
examine differences among phases.
Main results and the role of chance: In luminal epithelium, MECA-79
reactivity increased from the proliferative to late-secretory phase but decreased
at the mid-secretory phase. The mean HSCOREs among the proliferative,
early-secretory and late-secretory phase were signiﬁcant differences (P<0.05).
Five LSL genes were detected in adenomyotic endometria: PODXL, EMCN,
CD300LG, GLYCAM1, and CD34. The mRNA expression of LSL genes
occurred differentially among phases. Especially, PODXL differed signiﬁcantly
among phases (P<0.05). Comparison with the mRNA expression in the prolif-
erative and mid-secretory phase, all the LSL genes totally increased in the mid-
secretory phase then that in the proliferative phase. The mRNA expressions of
CHST2 and CHST4 genes, which involved in the generation of LSL epitopes
and LSL activity, were expressed without signiﬁcant differences among phases.
Limitations, reasons for caution: The small number of samples could limit
the power of the study. The heterogeneity of the samples could impact the
results. Finally, because of ethical considerations, normal endometrial samples
cannot be obtained from healthy women as controls.
Wider implications of the ﬁndings: Adenomyosis may cause abnormalities
in the production of LSL, which may contribute to impaired endometrial recep-
tivity and implantation failure. Further studies via in vitro and in vivo are
required to determine the mechanisms related to the decrease of LSL expres-
sion in adenomyosis.
Trial registration number:None.
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P-246 Defecation associated (dys)functions after surgical resection
of (recto)sigmoid inﬁltration by deep inﬁltrating endometriosis
A. Al-Saidi1, E.R. Klinkert2, H.S. Hofker1, M. Trzpis1, P.M.A. Broens1
1University Medical Center Groningen, Surgery, Groningen, The Netherlands
2University Medical Center Groningen, Obstetrics & Gynaecology, Groningen, The
Netherlands
Study question: Do the defecation associated outcomes in patients after sur-
gical resection of (recto)sigmoid inﬁltration due to Deep Inﬁltrating
Endometriosis (DIE) resemble the outcomes of healthy women?
Summary answer: Constipation, fecal incontinence (FI), Irritable Bowel
Syndrome (IBS) and their symptoms have a signiﬁcantly higher prevalence in
patients after (recto)sigmoid resection of DIE than healthy women.
What is known already: Patients with DIE are known to experience fecal
problems, such as constipation and FI. It is also known that patients with DIE
tend to have more IBS related problems and hypertonia of the pelvic ﬂoor mus-
cles. Further, vaginal delivery is known to inﬂuence fecal problems. (Recto)sig-
moid resection performed for DIE has been reported to improve the
defecation associated outcomes.
Study design, size, duration: For this cross-sectional study we included 181
adult women who had been treated with a (recto)sigmoid resection for DIE
between January 2005 and December 2015. Of these women 132 ﬁlled in the
questionnaire. The data of the control group, i.e. 680 women from the general
Dutch population, were collected in 2015, and we used them retrospectively.
Patients and controls with comorbidities which are known to inﬂuence defeca-
tion and fecal continence were excluded (n = 2 and n = 119 respectively).
Afterwards, 130 patients were age-matched with female controls from the
Dutch population in a 1:2 ratio. The afore described steps resulted in a data
base which consisted of 130 patients and 260 controls.
Participants/materials, setting, methods: All patients and controls com-
pleted the validated Groningen Defecation and Fecal Continence questionnaire
(DeFeC). Constipation, FI and IBS were deﬁned according to the Rome IV
criteria.
Main results and the role of chance: The prevalence of constipation, FI
and IBS in the patients was signiﬁcantly higher than in the control group (50.8%
versus 26.2%, p<0.001, 15.4% versus 5.0%, p = 0.001, and 14.6% versus 5.4%,
p = 0.002, respectively). Patients also used laxatives and other forms of conser-
vative treatment more often (OR = 2.780, p<0.001). In addition, constipated
patients experienced the co-existence of FI more often than their healthy coun-
terparts (9.2% versus 1.5%, p<0.001). Surprisingly, women who have had less
vaginal deliveries did suffer more from FI (p = 0.011). Furthermore, multivariate
analysis showed that women who underwent (recto)sigmoid resection for DIE
were more likely to be constipated or fecally incontinent (respectively p<0.001
and p = 0.002), independently of history of vaginal birth.
Limitations, reasons for caution: In this cross-sectional study we included
only patients who had already undergone surgery; the occurrence of these
symptoms before surgery is therefore unknown. Moreover, functional tests
could indicate the pathophysiological factors behind the increased fecal
problems.
Wider implications of the ﬁndings: The prevalence of fecal problems is
signiﬁcantly higher in patients who underwent (recto)sigmoid resection for DIE
than in healthy controls. Further research is important to improve the com-
plaints of patients.
Trial registration number:METc 2014/516
P-247 The human fallopian tube vs endometrium: can differences
in function and steroid hormone receptor expression be explained
by differential hormone responsiveness?
A. Maclean, E. Bunni, S. Makrydima, A.Withington, J. Drury,
D. Hapangama
University of Liverpool- Liverpool Women’s Hospital- Crown Street- Liverpool- L8 7SS,
Centre for Women’s Health Research, Liverpool, United Kingdom
Study question: Are there spatial and temporal differences in cellular prolifer-
ation and steroid hormone receptor expression in the human fallopian tube
(FT), as there are in the endometrium?
Summary answer: The premenopausal FT does not show cyclical changes in
cellular proliferation, with a similar steroid hormone receptor expression pat-
tern to the quiescent postmenopausal endometrium.
What is known already: The human FT epithelium exists as a continuum of
the endometrium. Both tissues share the same embryological origin. The endo-
metrium is widely accepted as the main target organ for the ovarian steroid hor-
mones, and undergoes a well-described monthly cycle of proliferation,
differentiation, shedding, and regeneration throughout a woman’s reproductive
life. Hormonal regulation is exerted through the cognate ovarian steroid hor-
mone receptors (ERa, ERb, PR, and AR), which are expressed in endometrial
cells. Although the steroid hormone dependent cyclical changes are well
described in the endometrium, the effect of the same hormones on the FT epi-
thelium has not been comprehensively studied.
Study design, size, duration: A prospective observational study, analysing
matched full thickness human endometrial and FT samples, from 38 healthy
women undergoing hysterectomy for benign conditions, including 28 samples
from premenopausal women, and 10 from postmenopausal women. Full thick-
ness samples were obtained to allow investigation of the three compartments
of the endometrium: the luminal epithelium, the functionalis, and the basalis.
The FT samples were taken from both the isthmic and the ﬁmbrial areas.
Participants/materials, setting, methods: Matched endometrium and FT
samples were analysed by immunohistochemistry, for proliferative marker Ki-
67, and steroid hormone receptors AR and PR (n = 38). Gene expression of
AR and PR was examined by qPCR in matched endometrial and FT samples (n
= 5). Primary human endometrial and FT epithelial cells were treated with E2
and DHT in short term cultures, and the expression of Ki-67, AR, and PR ana-
lysed by IHC and qPCR (n = 7).
Main results and the role of chance: The FT displayed low levels of prolif-
eration throughout the menstrual cycle in all compartments, whereas the pre-
menopausal endometrium was highly proliferative, particularly the functionalis
(p = 0.03).
Interestingly, AR expression was high in the FT, and was weak in the matched
premenopausal endometrium (p = 0.004). There was no signiﬁcant difference
in AR expression between the FT and the postmenopausal endometrium. PR
expression in the FT and endometrium was not signiﬁcantly different. AR and
PR expression showed no correlation in the FT.
As both AR and PR are thought to be regulated by oestrogen in the endo-
metrium, the matched FT and endometrial cell cultures with E2 and DHT
in vitro, to explore the steroid hormone receptor response to ovarian hor-
mones. In the FT, E2 treatment increased AR protein expression in the glands,
and increased AR mRNA expression. There was no effect of E2 treatment on
PR expression in the FT. DHT treatment increased protein AR expression in
the FT glandular epithelium, and increased AR mRNA expression in the FT.
There was no effect of DHT treatment on PR protein expression in the FT or
endometrium, but there was an increase in PR mRNA expression in the FT.
Limitations, reasons for caution: This is a descriptive study with short-
term culture of primary human endometrial and tubal epithelial cells in vitro,
with a small sample size of matched endometrium and FT samples.
Wider implications of the ﬁndings: The FT does not undergo cyclical pro-
liferation, and shares similarities in steroid hormone receptor expression with
the postmenopausal endometrium. These ﬁndings contribute towards under-
standing the physiology of the FT. Further research in this area will enable
research into disorders of the FT, such as ectopic pregnancy, infertility, and FT
cancer.
Trial registration number: This work was funded by the ITM/Department
of Women’s Health at the University of Liverpool. All authors have to declare.
P-248 Comparison of IVF results in cases of severe endometriosis:
after or without previous surgery
M. Camus1, A.S. Gremeau2, C. Valdeyron2, L. Dejou-Bouillet2,
N. Bourdel2, F. Brugnon3, M. Canis2, J.L. Pouly2
1CHU Estaing, ob gyn, Clermont-Ferrand - France, France
2CHU Estaing, ob gyn, Clermont-Ferrand, France
3CHU Estaing, Clinical Biology, Clermont-Ferrand, France
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Study question: Does surgery before in-vitro fertilization (IVF) improve the
results of assisted reproductive technologies (ART) in patients with severe
endometriosis?
Summary answer: There is evidence that IVF without previous surgical treat-
ment results in a decreased delivery rate per cycle and per patient.
What is known already: Whether to operate severe endometriosis or not
to improve ART results remains a debate. There is still no international consen-
sus about the management of infertile patients with severe endometriosis. A
recent french study demonstrated among a 110 patients cohort that IVF results
were lower without previous surgery. But some others studies provided oppos-
ite conclusions.
Study design, size, duration: A 190 patients cohort was analysed (retro-
spective analysis on prospective recorded datas). All patients presented severe
endometriosis with rectovaginal nodule and/or multiple endometriomas and/
or major adhesions. The decision to operate or to move directly to IVF was
taken by trained laparoscopic surgeons according to the expected chance of
pregnancy after surgery and the potential risk of surgery.
Participants/materials, setting, methods: We could include 41 patients
in the no surgery group (group NS) and 149 patients in the surgery group
(group SU). All data were prospectively recorded. Main outcomes were clinical
delivery rates per cycle (fresh+frozen transfers) and crude and actuarial cumula-
tive rates to obtain the ﬁrst delivery. A complementary analysis was done for
attempts to obtain a second delivery. All outcomes are provided in terms of
delivery.
Main results and the role of chance: The delivery rate per attempt to
obtain the ﬁrst child was 18.6 % in group NS versus 28.6 % in the group SU (p
= 0.051).
The crude delivery rates after 5 attempts were respectively 43.9 % versus
54.4 % (p = 0.23).
The actuarial delivery rates after 5 attempts were respectively 52.2 % and
71.3 % (p = 0.021).
The delivery rate per attempt to obtain a second child was 75 % in the NS
group versus 32.3 % in the SU group (p = 0.09).
A step by step analysis of IVF results among the attempts to obtain the ﬁrst
delivery shows a difference in defavour of the non operated group for the risk
to collect no oocyte (10.3 % versus 4.6 %- p = 0.003), the mean number of
oocytes (5.8 versus 7.4 – p<0.008) and the risk for miscarriage ( 35 % versus
17% -p = 0.04).
Limitations, reasons for caution: Retrospective study, subjective decision
to operate or not and unicentric study.
Wider implications of the ﬁndings: This study suggests that operating
severe endometriosis improves IFV results. On the other hand, if surgery is con-
sidered to be too risky, ﬁrst-line IVF results seem to be acceptable. Surgery
should thus be the ﬁrst step because it is the only way to judge on operability.
Trial registration number:No object.
P-249 Aberrant ER stress induction in response to progesterone
enhances endometriotic stromal cell invasiveness
D. Choi1, J. Choi1, M. Jo2, E. Lee1, D.Y. Lee1
1Sungkyun Kwan University Samsung Medical Center, Dept. of Ob/Gyn, Seoul,
Korea- South
2Samsung Biochemical Research Institute, Center for Clinical Research, Seoul, Korea-
South
Study question: Whether endoplasmic reticulum (ER) stress is involved in
the regulation of human endometrial cell invasiveness through AKT/mTOR
pathway, and is this associated with the altered invasiveness in endometriotic
cells?
Summary answer: Abnormal ER stress induction in response to progester-
one was observed in endometriotic stromal cells, which led to the alteration of
invasiveness via AKT/mTOR pathway.
What is known already: ER stress is a common cellular stress response,
which is known to reduce invasiveness in some cell types including ovarian and
breast cancer cells through inhibiting AKT/mTOR pathway. Recent studies
have shown that ER stress is suppressed by estrogen in human endometrial
cells, which suggests that estrogen may promote endometrial cell
invasiveness by down-regulating ER stress. Therefore, aberrant ER stress in
response to progesterone may contribute to the altered invasiveness found in
endometriotic tissues.
Study design, size, duration: Normal endometrial stromal cells (NESCs)
and endometriotic cyst stromal cells (ECSCs) were cultured with tunicamycin
to induce ER stress. To evaluate the effects of estrogen and progesterone on
ER stress, AKT/mTOR pathway and invasion, NESCs and ECSCs were cultured
with estrogen and/or progesterone. In addition, to evaluate the cycle-
dependent induction of ER stress and invasion, normal endometrial and endo-
metriotic tissues were collected according to menstrual cycle.
Participants/materials, setting, methods: The expression level of
glucose-regulated protein 78 (GRP78) was measured by Western blot to evalu-
ate ER stress induction. As ER stress-mediated C/EBP homologous protein
(CHOP)/tribbles homologue 3 (TRIB3) pathway is a negative regulator of AKT,
CHOP and TRIB3 expression was measured to evaluate the effects of ER stress
on AKT/mTOR pathway. In addition, cell invasiveness was evaluated by meas-
uring the expression of invasion associated proteins (MMP2 and MMP9) and by
performing invasion assay.
Main results and the role of chance: The expression levels of GRP78,
CHOP and TRIB3 protein were markedly increased in NESCs treated with tuni-
camycin compared with control cells, which was accompanied by decreased
AKT, mTOR activity and cellular invasiveness. Similarly, progesterone treat-
ment signiﬁcantly increased CRP78, CHOP, TRIB3 expression in NESCs.
Subsequently, cellular invasiveness decreased through the inhibition of AKT and
mTOR activity. This progesterone-induced decrease in cellular invasiveness
was reversed by the inhibition of ER stress using either mifepristone (progester-
one receptor modulator) or salubrinal (ER stress inhibitor). These results sug-
gest that progesterone increases ER stress, which then is directly involved in
regulation of NESC invasion. In contrast, progesterone had no signiﬁcant effects
on CRP78, CHOP, TRIB3 expression, AKT, mTOR activity and cellular inva-
siveness in ECSCs. Furthermore, in contrast to normal eutopic endometrium,
endometriotic tissues showed constant CHOP, TRIB3, MMP2 and MMP9
expression throughout the menstrual cycle.
Limitations, reasons for caution: Only primary human endometrial and
endometriotic stromal cell cultures were used in this study.
Wider implications of the ﬁndings: Our results reveal new insights into
the pathogenesis of ovarian endometriotic cyst, and it may also allow the devel-
opment of new therapeutic strategies based on the modulation of endometrio-
tic cell invasiveness.
Trial registration number: not applicable.
P-250 The new strategy of dydrogesterone protocol as progestin
primed ovarian stimulation is effective for patients with ovarian
endometriosis undergoing in vitro fertilization
N. Iwami, H. Kamiya, N. HIrayama, Y. Kobayashi, M. Kawamata,
N. Ozawa, T. Yamamoto, E.Watanabe, O. Moriwaka
Kamiya Ladies Clinic, Center of reproduction, Sapporo, Japan
Study question: Is dydrogesterone (DYG) regimen as progestin primed ovar-
ian stimulation (PPOS) effective for patients with endometriosis during con-
trolled ovarian stimulation(COS), compared to GnRH antagonist protocol?
Summary answer: Higher number of oocytes could be retrieved in DYG
protocol than in GnRH antagonist protocol. The pregnancy rates were compar-
able between the two groups.
What is known already: A Large number of women with endometriosis
eventually seek IVF/ ICSI to achieve pregnancy, but endometriosis is an
estrogen-dependent chronic inﬂammatory condition that affects the pregnancy
rate compared to women with other causes of infertility.Some progestin have
been used for endometriosis therapy for more than 40 years, the use of proges-
terone may improve the embryo quality of women with endometriosis.
Recently, PPOS using DYG was reported as very convenient regimen for
patients during COS.
Study design, size, duration: This was prospective controlled study of 133
women with endometriosis (aged <41) undergoing COS for IVF/ICSI and frozen
embryo transfer (FET) at our private infertility clinic from June 2016 through
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October 2017. The patients were allocated alternately into two groups, one with
DYG protocol (n = 68) and the other with GnRH antagonist protocol (n = 65).
Participants/materials, setting, methods: In DYG protocol, dydrogester-
one (20 mg/day) was administered simultaneously with HMG (150-225IU)
beginning on day 2 or 3. Ovulation was triggered with GnRH agonist and HCG
(1000IU) when the leading follicle matured. All high quality embryos were cryo-
preserved for later transfer. The primary outcome measure was the number of
retrieved oocytes. The secondary measure was the clinical pregnancy rate.
Statistical analysis was performed using unpaired t-test and chi-square
contingency.
Main results and the role of chance: Patient characteristics: the age, body
mass index, basal hormone proﬁle, duration of infertility, and AMH level were
similar in the two groups. None of the patients experienced a premature LH
surge in both groups. No signiﬁcant difference was found between the two
groups for the HMG dose and the stimulation duration of HMG. In DYG group,
the number (mean±SD) of retrieved oocytes (10.71 ± 6.97 vs. 7.45 ± 4.71,
P<0.01), and the number of mature oocytes (8.68 ± 5.74 vs. 6.18 ± 4.12,
P<0.01) were signiﬁcantly higher than in GnRH antagonist group. Other para-
meters such as fertilization rate, viable embryo rate, and the cycle cancellation
rate due to no viable embryos were similar (P> 0.05). During the follow-up per-
iod of FET, a total of 120 patients completed 182 FET cycles, and single embryo
transfer was performed in 93.6% of the patients. No signiﬁcant difference was
found in the clinical pregnancy rate (DYG group; 43.3% vs. GnRH antagonist
group; 38.8%, P = 0.541), respectively (difference 4.48%; 95% conﬁdence inter-
val (CI): -9.86 − 18.8%), and ongoing pregnancy rate (DYG group; 38.1% vs.
GnRH antagonist group; 31.8%, P = 0.369), respectively (difference 6.38%;
95% CI: -7.52 – 20.3%).
Limitations, reasons for caution: Patients affected of all stage of endomet-
riosis have been included and the number of patients was small, because of
single-center setting. A large sample size is needed to draw a ﬁrm conclusion.
Wider implications of the ﬁndings: This study shows that DYG regimen is
feasible to improve the number of oocyte collected, and DYG has the advan-
tages of oral administration, user convenience and cost reduction, so possibly
providing a new choice for women with endometriosis undergoing IVF/ICSI
treatment in combination with FET.
Trial registration number:Not applicable.
P-251 The expression of microRNA in uterine leiomyoma cell:
submucosal versus subserosal leiomyoma
Y.J. Kim1, Y.Y. Kim2, S.Y. Ku2, S.M. Lee1, J.H. Shin1, T. Kim3, J.
Y. Hur1
1Korea University Guro Hospital, Obstetrics & Gynecology, Seoul, Korea- South
2College of Medicine- Seoul National University, Departments of Obstetrics and
Gynecology, Seoul, Korea- South
3Korea University Anam Hospital, Obstetrics & Gynecology, Seoul, Korea- South
Study question: To compare the expression of microRNA (miR)s in leiomyo-
ma cells according to their location in the uterus.
Summary answer: The expression proﬁle of miR in leiomyoma cells was dif-
ferent according to their location in the uterus.
What is known already: The expression proﬁle of miR in uterine leiomyoma
cells is different from that of normal uterine myometrial cell. Although the
impact of uterine leiomyoma on uterine receptivity to embryos has been known
to vary according to their location in the uterus, the difference of miR expres-
sion in submucosal versus subserosal leiomyoma cells is still rare known.
Study design, size, duration: To analysis of expression of miR and target
gene, 18 of matched sample of leiomyoma and myometrium tissue were
obtained from 9 of women with subserosal leiomyoma and 9 of women with
submucosal leiomyoma by pelviscopic myomectomy.
Participants/materials, setting, methods: The relative expressions of
miRs related leiomyoma and the candidate target genes in leiomyoma cells
were compared to the related myometrial cells by RT-PCR. The target gene
expression was analyzed after in vitro culture of leiomyoma cells with transfec-
tion of miR analogues. All experiments were repeated more than 3 times with
more than 3 different portion of samples.
Main results and the role of chance: The relative expressions of miR-29
(0.633-fold, P = 0.031) in leiomyoma cells were downregulated compared to
the myometrial cells and the relative expressions of estrogen receptor β
(2.121-fold, P<0.001) and matrix metalloproteinase-1 (1.923-fold, P<0.001)
were upregulated in leiomyoma cells compared to myometrial cells. After trans-
fection with mimic of miR-29 into leiomyoma cells in-vitro-cultured, the expres-
sion of estrogen receptor β and matrix metalloproteinase-1 were
downregulated (0.215-fold and 0.105-fold, P<0.001 in all). After transfection
with mimic and inhibitor of miR-29 into leiomyoma cells in-vitro-cultured, the
expression of estrogen receptor β and matrix metalloproteinase-1 were down-
(0.215-fold and 0.105-fold, P<0.001 in all) and up-regulated (8.354-fold and
4.721-fold, P<0.001 in all). The expressions of miR-29 in submucosal leiomyo-
ma relative to myometrium was upregulated compared to the subserosal leio-
myoma relative to myometrium (1.213 ± 0.562 vs. 0.412 ± 0.214, P<0.001).
The expression of estrogen receptor β (1.515 ± 0.467 vs. 2.124 ± 0.870, P =
0.041) and matrix metalloproteinase-1 (1.484 ± 0.230 vs. 2.221 ± 1.021, P =
0.021) in submucosal leiomyoma cells were downregulated compared to sub-
serosal leiomyoma cells.
Limitations, reasons for caution: To fully understanding the regulatory
roles of miRs on leiomyoma growth, further extended study with the other
miRs related to leiomyoma should be necessary.
Wider implications of the ﬁndings: The difference in proﬁles of miR
expression between submucosal and subserosal leiomyoma may implicate that
miRs relate the growth of leiomyoma to alter the biomechanics of the uterus.
Trial registration number: Not available/This study was supported by
grants of Ministry of Education, Republic of Korea (2016R1D1A1A02937287).
P-252 Comparison of uterine natural killer (uNK) cells count in the
peri-implantation endometrium between natural cycles and
hormone replacement therapy cycles
W.J. Yang1, X. Chen2, Y. Zhao2, T.C. Li2
1Taiwan IVF Group Center, Department of Infertility and Reproductive Medicine,
Hsinchu City, Taiwan R.O.C.
2The Chinese University of Hong Kong, Department of Obstetrics and Gynecology,
Shatin, Hong Kong
Study question: Is there any difference in uNK cells count between natural
cycles and hormonal replacement therapy (HRT) cycles in women undergoing
IVF-ET treatment around the time of implantation?
Summary answer: There is no signiﬁcant difference in uNK cells count
between natural cycles and HRT cycles in the peri-implantation period.
What is known already: Our previous study, using a standardized method
for uNK cells counting, has established a reference range for uNK cells count in
natural cycles. However, the number of uNK cells may be inﬂuenced by the
hormone level and the ﬁndings may not apply to HRT cycles in women under-
going IVF-ET treatment.
Study design, size, duration: A total of 163 women from two IVF centres
participated in the study, including 55 women in natural cycles and 108 women
in HRT cycles. All endometrial biopsies were collected precisely on the putative
day of blastocyst transfer, that is seven days after LH surge (LH+7) of the nat-
ural cycles or ﬁve days after initiation of progesterone (P+5) of the HRT cycles.
Participants/materials, setting, methods: Endometrial sections were
immunostained for CD56 to identify uNK cells. Image capture and cell counting
were performed by a standardised protocol agreed and published by the par-
ticipating centres. Results were expressed as percentage of positive uNK cells/
total stromal cells.
Main results and the role of chance: There is no signiﬁcant difference
(p>0.05) in uNK cells count between natural cycles (median 2.28%, range 0.99-
4.78%) and HRT cycles (median 2.55%, range 0.69-5.02%) in women undergo-
ing IVF-ET treatment on the putative day of blastocyst transfer. Using our
established reference range from 1.2% to 4.5% for uNK cell percentage, there
is no signiﬁcant difference in high uNK cell rate between natural cycles (9.1%,
5/55) and HRT cycles (10.2%, 11/108).
Limitations, reasons for caution: The prognostic value of uNK cells meas-
urement has yet to be conﬁrmed.
i256 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Wider implications of the ﬁndings: Observations on uNK cells in natural
cycles may be applicable to those in HRT cycles. Further studies may be con-
sidered whether the same conclusion applies to other receptivity markers.
Trial registration number: non.
P-253 The effect and mechanisms of GM-CSF on endometrial
regeneration
J. Liu1, Y. Ying1, J. Li1, S.Wang1, R. Zhang1, J. Xu1, P. Lv1, C. Zhou2,
J. Chen2, Y. Liu1, Y.Wu1, Y. Huang1, Y. Chen1, L. Chen1, D. Zhang1
1Women’s Hospital- School of Medicine-Zhejiang University, Key Laboratory of
Reproductive Genetics Ministry of Education and Department of Reproductive
Endocrinology, Hangzhou, China
2Women’s Hospital- School of Medicine-Zhejiang University, Department of
Pathology, Hangzhou, China
Study question: Does granulocyte macrophage colony-stimulating factor
(GM-CSF) play a role in endometrium and can it be used as a new application
for treating thin endometrium?
Summary answer: GM-CSF might play a key role in endometrium and could
provide new ideas for improving endometrial condition.
What is known already: GM-CSF is a cytokine normally expressed in the
female reproductive tract and has key roles in embryo implantation and subse-
quent development. GM-CSF receptor in human endometrium suggests that
epithelial-derived GM-CSF may inﬂuence various endometrial biological activ-
ities and local inﬂammatory response. However, the role and mechanism of
GM-CSF on the endometrium have not been investigated.
Study design, size, duration: A total of 57 female ICR mice (aged 8 weeks)
were used to generate thin endometrium model and assess the effect of GM-
CSF. Human endometrial tissues were obtained from patients who underwent
hysterectomy for uterine myomas, and patients who underwent hysteroscopy
and endometrial biopsy for infertility examination.
Participants/materials, setting, methods: We established thin endomet-
rium mice model by uterine perfusion with 20 μL 90% ethanol. GM-CSF were
intraperitoneal injected and then the endometrial thickness by HE staining, Ki67
expression by immunohistochemistry and the number of embryo implantation
after mating were evaluated, comparing to the control group. The effects of
GM-CSF on primary cultured human endometrial glandular and stromal cells
were examined by BrdU assay, transwell assay, followed by exploring protein
signaling pathway by Western Blot.
Main results and the role of chance: 90% ethanol caused distinct endo-
metrial injury in mice, with observably thinner endometrial thickness,
decreased expression of Ki67 in endometrial glandular cells, and reduced
number of embryo implantation. Compared with the saline group, GM-CSF
injection was signiﬁcantly beneﬁcial for rescuing the thickness of impaired
mice endometrium, improving the expression of Ki67 in endometrial glandular
cells, and increasing the number of embryo implantation. GM-CSF signiﬁcantly
promoted the proliferation of primary cultured human endometrial glandular
cells and the migration of stromal cells. GM-CSF signiﬁcantly activated p-Akt
and increased the expression of p70S6K and c-Jun protein, which could be
blocked by LY294002, the PI3K/Akt pathway inhibitor.Our study found that
GM-CSF is beneﬁcial for regeneration of injured endometrium in mice, and
can promote the proliferation of primary human endometrial glandular cells
and the migration of endometrial stromal cells. The effect of GM-CSF on
endometrial glandular cell proliferation is via activating the PI3K/Akt signaling
pathway.
Limitations, reasons for caution: I.p. injection of GM-CSF in mice can not
totally simulate human uterine perfusion.
Wider implications of the ﬁndings: We found that GM-CSF can improve
endometrial regeneration and it has potential application in clinical therapies to
improve reproduction. It provides new ideas for the treatment of infertile
patients, who have difﬁculty in endometrial proliferation, with thin endomet-
rium or severe intrauterine adhesion.
Trial registration number:Not applicable.
P-254 Treatment outcomes in women with endometrioma at
time of IVF/ICSI treatment. An analysis of 4416 fresh and frozen
treatment cycles using mainly SET
M. Feichtinger1,2,3,4, J.I. Olofsson5, E. Nordenhök1,
N. Hadziosmanovic6, K.A. Rodriguez-Wallberg1,3
1Karolinska University Hospital, Obstetrics and Gynecology- Division of Reproductive
Medicine, Stockholm, Sweden
2Medical University of Vienna, Obstetrics and Gynecology, Vienna, Austria
3Karolinska Institutet, Oncology/Pathology, Stockholm, Sweden
4Wunschbaby Institut Feichtinger, Wunschbaby Institut Feichtinger, Vienna, Austria
5Karolinska Institutet, Division of Obstetrics and Gynecology- Department of
Women’s and Children’s Health, Stockholm, Sweden
6Uppsala University, Uppsala Clinical Research Center, Uppsala, Sweden
Study question: Do IVF/ICSI outcomes differ between patients with pres-
ence of ovarian endometrioma versus patients with infertility from other
causes?
Summary answer: Women with endometrioma had a signiﬁcantly reduced
ovarian response compared to controls and required higher gonadotropin
stimulation doses; however, treatments resulted in similar cumulative live-birth.
What is known already: Single-embryo transfer (SET) with subsequent
frozen-embryo transfer was shown to result in similar cumulative live-birth rates
compared to double-embryo transfer in patients <36 years. Some studies sug-
gested a negative effect of endometrioma on oocyte yield and number of
embryos cryopreserved, which maintain live-birth rate in the fresh cycles
although cumulative live-birth rate might be reduced.
Study design, size, duration: Single-center, retrospective cohort study of
patients treated between January 2009 - December 2013. A total of 2651
patients underwent 4416 treatment cycles (2426 fresh and 1990 frozen). In 66
cases, the women presented with endometrioma at time of IVF/ICSI treatment
(cases) and they were compared to infertile women without endometriosis
(controls N = 2585).
Participants/materials, setting, methods: Seventy percent of patients
underwent IVF/ICSI followed by SET and single FET in consecutive frozen-
thawed cycles. Primary outcome measures: Oocyte and embryo yield, ovarian
sensitivity index and live birth rate in fresh and frozen cycles as well as cumula-
tive. Multivariable GEE models were applied including all subsequent treatment
cycles, controlling for age, stimulation protocol and IVF/ICSI.
Main results and the role of chance: Women with endometrioma were
similar to controls as regards to age (33.56 vs. 34.05 years, p = 0.31) or BMI (p =
0.97), however, they required higher gonadotropin doses for stimulation (3081 vs.
2370 IU FSH; p = 0.03) and their treatments resulted in reduced oocyte yields
(7.64 vs. 9.54 retrieved oocytes, p = 0.0055) and number of frozen embryos (1.86
vs. 2.51; p = 0.0042). In fresh or frozen cycles, live-birth rates were similar
between women with endometrioma vs. controls (25.0% vs. 25.5% per OPU,
respectively, p = 0.94, and 27.5% vs. 28.4% per ET, respectively, p = 0.78, and
FET per ET 25.0% vs. 26.2%, respectively, p = 0.86). The cumulative live-birth per
OPU did not differ between the groups (38.4% vs. 34.7%, respectively, p = 0.39).
Limitations, reasons for caution: Retrospective character of the study.
Endometrioma might be un- or misdiagnosed.
Wider implications of the ﬁndings: Elective SET and consecutive frozen-
thawed cycles can be encouraged also in patients with endometrioma. Women
with endometrioma had a reduced ovarian sensitivity to gonadotropins resulting
in lower oocyte yields and less frozen embryos but similar live-birth rates per
ET when compared to controls.
Trial registration number:Not applicable.
P-255 Impact of endometrial thickness on IVF/ICSI outcome
S. Suhail, H. Latif Khan, Y. Latif Khan
Lahore Institute of Fertility & Endocrinology, LIFE, Lahore, Pakistan
Study question: To determine any existing correlation among endometrial
lining thickness (ELT) and pregnancy out come in patient’s undergone IVF/ICSI
cycle.
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Summary answer: ELT was found to be an independent positive prognostic
factor for clinical pregnancy outcome.
What is known already: Receptivity of endometrium is a pre-requisite for
initiation of a thriving pregnancy during IVF/ICSI treatment. Endometrium pro-
liferates under hormonal inﬂuence especially estrogen and progesterone,
involved in the control of endometrial thickness measured through trans-vaginal
ultrasonic scanning (TVS).
Study design, size, duration: A retrospective cohort study was conducted
on the available clinical data of 1500 patients, since from January 2015 to
December 2017 at the Lahore institute of fertility and endocrinology, Hameed
Latif Hospital Lahore, Pakistan.
Participants/materials, setting, methods: Fifteen hundreds cycles were
divided into three groups based on ELT on the hCG day; First Group with ELT
< 7-8 mm, Second group 2 ELT 8-14 mm and third group ELT > 14 mm.
A logistic regression analysis was conducted using a stepwise procedure to
identify the variables which were signiﬁcantly associated with the outcome of
clinical pregnancy. Furthermore, ROC (Receiver-operating Curve analysis) and
Chi-square test were used to validate the whole model.
Main results and the role of chance: Our primary outcome is that thicker
endometrial lining associated with positive beta-hCG and clinical pregnancy.
First group had signiﬁcantly decreased pregnancy rate, embryo implantation and
live birth rates than 2nd and 3rd group (p <0.001). However, no signiﬁcant dif-
ference was found among spontaneous abortion and miscarriage rate in
between the three groups. A higher clinical pregnancy rate was observed when
ELT > 15 mm.
Limitations, reasons for caution: not applicable.
Wider implications of the ﬁndings: the ranges of endometrium deﬁnes in
the abstract. the endometrium range divided into three categories.
Trial registration number: not applicable.
P-256 Inﬂuence of the microRNA let-7d on epithelial-to-
mesenchmal transition in endometriosis
C. Brandhorst1, L. Kiesel1, B. Greve2, M. Götte1
1Münster University Hospital, Gynecology and Obstetrics, Münster/Westf., Germany
2Münster University Hospital, Radiotherapy-Radiooncology, Münster/Westf.,
Germany
Study question: Does the microRNA let-7d have an impact on epithelial-to-
mesenchymal transition in endometriosis?
Summary answer: Let-7d differentially affects the expression of mesenchy-
mal markers in epithelial endometriotic and endometrial stroma cells.
What is known already: MicroRNAs are small noncoding RNAs that regu-
late gene expression at the posttranscriptional level. A dysregulation of
miRNAs is observed in endometriosis, and may be functionally linked to the
pathogenetic process. Let-7d is implicated in regulating EMT in malignancies.
Let-7d is downregulated in the serum of endometriosis patients during the pro-
liferative phase.
Study design, size, duration: In vitro study on the endometriotic epithelial
cell line 12Z and the endometrial stroma cell line ST-T1b.
Participants/materials, setting, methods: Cells were transiently trans-
fected with let-7d precursors to study the effects of miRNA upregulation
in vitro. The impact of let-7d on cell viability and cell cycle progression was stud-
ied by MTT assay and ﬂow cytometry, respectively, whereas invasiveness was
assayed in matrigel invasion chambers. Predicted targets of let-7d were identi-
ﬁed by microRNA.org database analysis, and target regulation was conﬁrmed
by quantitative real-time PCR andWestern Blotting.
Main results and the role of chance: Let-7d upregulation had no signiﬁcant
effect on cell viability, whereas cell cycle analysis revealed a shift to the gap
phases (G1/G2/M) in let-7d-transfected St-T1b cells. Data in the invasion assay
were highly variable. A differential effect of let-7d upregulation was observed in
endometrial stroma cells and endometriotic epithelial cells: In St-T1b cells, let-
7d induced downregulation of the mesenchymal markers ﬁbronectin and N-
cadherin (n>3, p<0.05), whereas a panel of mesenchymal markers
(Fibronectin, Snail1, Snail2, Vimentin, Twist and ZEB2) was upregulated upon
let-7d transfection in 12Z cells (n>3, p<0.05).
Limitations, reasons for caution: This is an in vitro study based on a transi-
ent transfection approach in immortalized cell line models. Additional targets
may be involved in the phenotypic changes.
Wider implications of the ﬁndings: Let-7d differentially affects the expres-
sion of mesenchymal markers in endometrial stroma and epithelial endometrio-
tic cells, and may be implicated in regulating EMT as a contributing factor to
locally invasive growth of endometriotic cells. Further exploration of this
hypothesis in primary cells and animal models is worthwhile.
Trial registration number:Not applicable.
P-257 Caesalpinia sappan induces apoptosis of ectopic endometrial
cells through inhibition of pyruvate dehydrogenase kinase
J.K. Joo1, K. Ha2, B. Kim2, K. Lee3, S. Han3, K. Yun3, E. Jeun3, J. Park3,
E. Ryu3, H. Yoon3
1Pusan National University Hospital, OB/GY, Busan, Korea- South
2Pusan National University, Korean Medicine, Busan, Korea- South
3Pusan National University Hospital, obstetrics and gynecology, Busan, Korea- South
Study question:We thought that if we returned the Warburg-like metabolic
reprogrammed metabolism of endometriosis to normal metabolism, we could
induce apoptosis of endometriosis.
Summary answer: The expression of TGF-β, PDK-1, PDK-2, PDK-4 and lac-
tate production were increased in 12Z cells. Activated oxidative phosphoryl-
ation decreased mitochondrial membrane potential and increased ROS.
What is known already: Endometriosis has similar characteristics to cancer.
It has been reported lactate production was elevated in endometriosis patients,
and previous studies have also suggested that Warburg-like metabolic repro-
gramming may be associated with endometriosis. Heartwood of Caesalpinia
sappan(CS) have been a medicinal herb used for improving blood circulation,
accelerating hemostasis, removing of extravasated blood and reducing swelling.
Especially, heartwood of CS was used for treating gynecological symptoms
including algomenorrhea and amenorrhea. Recently, it has been reported that
treatment of cisplatin with CS components arrests cell cycle and increases
apoptosis in colon cancer. However, the effect of CS on endometriosis was not
studied.
Study design, size, duration: Heartwood of CS was crushed and extracted
with distilled water. The extract was ﬁltered and concentrated using a rotary
evaporator and lypophilized using a freeze dryer to yield of powder. The pow-
der was dissolved in DMSO to prepare a stock solution and was diluted with
culture medium prior to use in the in vitro experiments. Immortalized normal
human endometrial (HES cells) and endometriotic epithelial cells (12Z) were
used.
Participants/materials, setting, methods: The cytotoxicity of CS was
examined using a MTT assay and lactate production of 12Z cells were mea-
sured with ﬂuorometric assay kit. LDH activity was determed by measuring the
decrease of absorbance at 340 nm. Also, in vitro pyruvate dehydrogenase
kinase assay was done. Total RNA and protein was isolated from HES and 12Z
cells and measured by RT-PCR and western blot analysis. Apoptotic cells trea-
ted with CS in12Z cells were examined.
Main results and the role of chance: The lactate production of 12Z cells
was further increased higher than that of HES cells. There was no change in
LDHA expression in between HES and 12Z cells. However, the phosphoryl-
ation of PDH was increased in 12Z cells. TGF-β expression was higher in 12Z
cells than in HES cells. 12Z cells were more sensitive to CS-induced cytotoxicity
compared with HES cells. CS reduced lactate production but not inhibited activ-
ity nor expression of LDHA. CS inhibited the phosphorylation of PDH through
suppressing PDKs expression. CS produced ROS production in endometriotic
cells.). In addition, cell viability reduced by CS is reversed by NAC treatment.
CS induced apoptosis in endometriotic cells. In previous studies, endometriosis
was resistant to apoptosis. These anti-apoptotic cells develop into endometri-
osis of endometrial cells reﬂuxed into the abdominal cavity. Experiments were
conducted to determine whether apoptosis of endometriotic cells was induced
by CS treatment. 12Z cells were identiﬁed by FACS in that apoptotic cells were
increased by CS treatment. The apoptosis signals were also increased in cleaved
caspase 3 and cleaved PARP, conﬁrming the occurrence of apoptosis.
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Limitations, reasons for caution: In this study, CS treatment did not inhibit
the downstream of TGF-β signaling pathway, but decreased PDK expression.
Therefore, it is necessary to elucidate the mechanism responsible for suppres-
sing PDK expression by CS treatment. The dose of CS should be determined
by further in vivo studies.
Wider implications of the ﬁndings:We suggest that CS can be a candidate
for development of novel drug treating endometriosis through inhibiting aerobic
glycolysis and inducing ROS-mitochondria mediated apoptotic cell death.
Trial registration number: not applicable.
P-258 Extended doxycycline treatment versus salpingectomy in
the management of patients of hydrosalpinx undergoing IVF-ET
H. El-Shaer, U. Fouda, M. Taymour, A.Wali, F. Darweesh
Cairo university, Obstetrics and Gynecology department, Giza, Egypt
Study question: Is treatment with doxycycline before and after oocyte
retrieval as effective as salpingectomy in minimizing the detrimental effect of
hydrosalpinx on the outcomes of IVF-ET?
Summary answer: Salpingectomy is more effective than extended doxycyc-
line treatment before and after oocyte retrieval in improving the outcomes of
IVF-ET in patients with hydrosalpinx undergoing IVF-ET.
What is known already: Several prospective and retrospective studies
revealed that hydrosalpinx has a detrimental effect on the outcomes of IVF-ET.
A Cochrane review revealed that laparoscopic salpingectomy improves the out-
comes of IVF-ET. A small retrospective study revealed that extended doxycyc-
line treatment before and after oocyte retrieval was as effective as
salpingectomy in improving the outcomes of IVF-ET.
Study design, size, duration: A retrospective analysis of the outcomes of
the fresh IVF-ET cycles for patients with hydrosalpinx who were treated with
salpingectomy prior to IVF cycle ( n = 260) or extended doxycycline treatment
(n = 45) in Riyadh fertility and reproductive health center during the period
between 2012 and 2017. Laparoscopic salpingectomy or ultrasound guided
aspiration of hydrosalpingeal ﬂuid were offered to patients. Patients who
declined surgery and aspiration of hydrosalpingeal ﬂuid received doxycycline
treatment.
Participants/materials, setting, methods: In doxycycline group, doxycyc-
line (100 mg/ 12 h) was started one week before anticipated oocyte retrieval
and continued for one week after oocyte retrieval. In salpingectomy group, lap-
aroscopic salpingectomy was performed two months before IVF-ET cycle. The
ﬁrst attempt IVF-ET cycles after treatment were included in the analysis.
Patients with age ≥ 37 years, anti-Müllerian hormone (AMH) ≤ 0.66 ng/ml,
antral follicle count (AFC) < 6 and previous IVF cycles were excluded from the
study.
Main results and the role of chance: The implantation, clinical pregnancy,
ongoing pregnancy and live birth rates were signiﬁcantly higher in the salpingec-
tomy group ( 20.91% Vs. 9.91%, P value = 0.007, 44.62% Vs. 20% P value =
0.002, 39.62% Vs. 17.78%,P value = 0.005 and 37.31%Vs. 15.56% P value =
0.005 respectively) The abortion rate was comparable between both groups (
11.21% Vs. 11.11 %, P value = 0.993). No signiﬁcant differences were detected
between both groups in age, basal FSH, AFC, AMH level, retrieved oocytes,
fertilization rate, quality of embryos transferred and number of embryos trans-
ferred. None of the patients in salpingectomy group had peri-operative
complications.
Limitations, reasons for caution: The retrospective design and the small
sample size are the main limitations of the study.
Wider implications of the ﬁndings: The data presented in the current
study suggest that extended doxycycline treatment before and after oocyte
retrieval is not effective in minimizing the detrimental effect of hydrosalpinx on
the outcomes of IVF-ET. Further, larger well designed randomized controlled
trials should be conducted to conﬁrm the ﬁndings of this study.
Trial registration number:Not applicable.
P-259 Exploring the RNA landscape of uterine ﬂuid extracellular
vesicles
P. Vigano1, E. Giacomini1, G.M. Scotti2, S. Makieva1, F. Simeoni2,
E. Papaleo3, J. Ottolina3, P. Giardina3, I. Molineris2, G. Tonon2,
D. Lazarevic2
1IRCCS San Raffaele Scientiﬁc Institute, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology, Milan, Italy
2IRCCS San Raffaele Scientiﬁc Institute, Center for Translational Genomics and
BioInformatics, Milan, Italy
3IRCCS San Raffaele Scientiﬁc Institute, Obsterics and Gynecology Unit, Milan, Italy
Study question: Can RNA species present in uterine ﬂuid (UF)-derived extra-
cellular vesicles (EVs) represent a potential noninvasive proxy of respective
endometrial tissue transcripts?
Summary answer: RNA species in UF-derived EVs mirror the transcriptome
of endometrial tissue, can discriminate between the menstrual phases and are
enriched in molecules involved in migration.
What is known already: The human endometrium is a highly dynamic tissue
that is cyclically shed, repaired, regenerated and remodelled, primarily under
the orchestration of ovarian-derived hormones. Studies addressing the dynam-
ics of phase transition and tissue abnormal remodelling have been based so far
on endometrial sampling analysis that is unfortunately associated with several
problems. EVs of uterine origin has been recently identiﬁed. Selective packaging
of RNA/miRNA proﬁle into uterine EVs has been demonstrated using cell lines.
Data on the comparative RNA proﬁle between the endometrial tissues and the
corresponding UF-derived EVs are very limited.
Study design, size, duration: Endometrial tissues and UF samples were sim-
ultaneously obtained from proven fertility women (n = 10). Endometrial tissues
were obtained with the use of a pipelle while UFs were obtained with a balloon
hysterosonosonography catheter to avoid vaginal contamination. Based on the
histological dating, 5 samples were in proliferative and 5 in secretory phase of
the cycle. EVs have been isolated by differential ultracentrifugations.
Participants/materials, setting, methods: For RNAseq analysis, libraries
were synthesized using Lexogen 3’UTR mRNA kit, starting from total RNA. In
average, 10 M reads of 75 nt length were produced by Illumina NextSeq 500 via
SBS technology. Two parallel differential expression (DGE) analyses were per-
formed comparing RNA presence in proliferative and secretory phase on cor-
respondent tissues and EVs. RNAs in EVs were ranked according to the
normalized cpm counts. The Webgestalt platform was used for enrichment
analysis.
Main results and the role of chance: Biotype composition of RNA species
for each sample recognized most of them as derived from protein coding genes
(86% in tissues and 77% in EVs), but fractions of Mt_rRNA (6% in tissues and
15% in EVs) and lincRNA (5% in tissues and 6% in EVs) were also present.
Considering as ‘expressed’ those genes that showed at least 1 cpm on at least 5
samples, 15268 genes deﬁned tissue samples transcriptional proﬁle, while only
4132 were found in UF-derived EVs. Even if ‘expression’ in EVs was generally
more unstable, it correlated well with that observed in tissues, especially con-
sidering mean values (Spearman coefﬁcient 0.81). DGE analysis could identify
139 genes up-regulated in UF-derived EVs in the secretory phase (p<0.01) and
none up-regulated in the proliferative phase. Nine genes (TMEM37, TNS2,
RIMKLB, PABPN1, ITGB8, ALDH1A3, SNHG25, DCDC2, MECOM) varied
simultaneously in tissues and UF-derived EVs according to phases. Among the
biological processes enriched in the 20% RNAs with the greatest difference in
ranking of secretory versus proliferative phase, those involved in cell migration
regulation were identiﬁed. Of 57 meta-signature genes recently identiﬁed as
human receptivity transcriptomic biomarkers (Scie Rep 2017), 18 (31%) were
found to be present in UF-derived EVs.
Limitations, reasons for caution: UF-EVs samples showed an overall great-
er variability in cpm means among samples compared to those found in corre-
sponding endometrial tissues. Therefore, the deﬁnitive RNA proﬁle should be
evaluated in a greater number of samples.
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Wider implications of the ﬁndings: UF-derived EVs might be used as non-
invasive endometrial biopsy to predict endometrial normal functions and dys-
functions becoming an advancement in the molecular medicine era.
Trial registration number: not applicable.
P-260 Extended doxycycline treatment versus aspiration of
hydrosalpingeal ﬂuid at the time of oocyte retrieval in the
management of patients with ultrasound visible hydrosalpinx
undergoing IVF-ET
U. Fouda, H. Elshaer, M. Taymour, F. Darweesh, A.Wali
Cairo university, Obstetrics and Gynecology department, Cairo, Egypt
Study question: Is treatment with doxycycline before and after oocyte
retrieval as effective as ultrasound guided aspiration of hydrosalpingeal ﬂuid in
minimizing the detrimental effect of hydrosalpinx on the outcomes of IVF-ET?
Summary answer: Ultrasound guided aspiration of hydrosalpingeal ﬂuid is
more effective than extended doxycycline treatment in improving the outcomes
of IVF-ET in patients with ultrasound visible hydrosalpinx.
What is known already: The negative impact of the hydrosalpinx on the out-
comes of IVF-ET has been conﬁrmed by several retrospective and prospective
studies. Several randomized controlled trials revealed that ultrasound guided
aspiration of hydrosalpingeal ﬂuid is effective in improving the outcomes of IVF-
ET. A small retrospective study revealed that extended doxycycline treatment
before and after oocyte retrieval was effective in minimizing the detrimental
effect of hydrosalpinx on the outcomes of IVF-ET. Till now, no studies have yet
compared the effectiveness of ultrasound guided aspiration of hydrosalpingeal
ﬂuid with extended doxycycline treatment in the management of patients with
ultrasound visible hydrosalpinx undergoing IVF-ET.
Study design, size, duration: A retrospective analysis of the outcomes of
the IVF-ET cycles for patients with ultrasound visible hydrosalpinx who were
treated with ultrasound guided aspiration of hydrosalpingeal ﬂuid ( n = 61) or
extended doxycycline treatment (n = 36) in Riyadh fertility and reproductive
health center during the period between 2012 and 2017. Laparoscopic salpin-
gectomy or aspiration of hydrosalpingeal ﬂuid were offered to patients. Patients
who declined surgery and aspiration of hydrosalpingeal ﬂuid received doxycyc-
line treatment.
Participants/materials, setting, methods: In doxycycline group, doxycyc-
line (100 mg/12 hours) was administered one week before the expected time
of oocyte retrieval and continued for one week after oocyte retrieval. In aspir-
ation group, aspiration of hydrosalpingeal ﬂuid was performed under ultrasound
guidance at the time of oocyte retrieval. The analysis included the ﬁrst attempt
IVF-ET cycles after treatment. Exclusion criteria were age ≥ 37 years, anti-
Müllerian hormone (AMH) ≤ 0.66 ng/ml, and antral follicle count (AFC) < 6.
Main results and the role of chance: The implantation, clinical pregnancy
and live birth rates were signiﬁcantly higher in the aspiration group ( 16.35% Vs.
6.52 %, P value = 0.024, 36.07% Vs. 16.67% P value = 0.042, and 32.79% Vs.
13.89 %,P value = 0.039 respectively). The abortion rate was comparable
between both groups (9.09% Vs. 16.67%, P value = 0.595). The age, basal FSH,
AFC, AMH level, duration of infertility, percentage of patients with bilateral
hydrosalpinx, retrieved oocytes, fertilization rate, quality of embryos trans-
ferred and number of embryos transferred were comparable between both
groups. None of the patients in the aspiration group had ﬂaring of infection or
peritonitis.
Limitations, reasons for caution: The main limitations of the current study
are the retrospective design and the small sample size. The results of this study
should be conﬁrmed by larger well designed randomized controlled trials.
Wider implications of the ﬁndings: Extended doxycycline treatment
before and after oocyte retrieval should not be used in the management of
patients with ultrasound visible hydrosalpinx who declined salpingectomy prior
to IVF-ET. Ultrasound guided aspiration of hydrosalpingeal ﬂuid is a simple, safe
and effective option for those patients.
Trial registration number:Not applicable.
P-261 Fertility preservation outcomes in endometriosis patients:
A Pilot Study
S. Mokhtar1, S. Ansaripour1, A. Mohazab2, N. Madadi1,
A. Mohammadzade1
1Avicenna infertility treatment center, Infertility, Tehran, Iran
2Avicenna infertility treatment center, Endometriosis, Tehran, Iran
Study question: Does endometriosis affect ART outcomes for fertility
preservation?
Summary answer: The size of endometrioma inversely affects the number
and quality of oocytes and embryos, the clinical pregnancy rate is not related to
the endometriosis characteristics.
What is known already: Fertility preservation may be of interest for
women with endometriosis, particularly whom with bilateral un-operated
endometriomas and those who previously had excision of unilateral endo-
metriomas and require surgery for a contralateral recurrence. However, we
should consider the probability of low successful outcomes and complica-
tion of the ovarian stimulation and ovum pick up in endometriosis patients.
the feasibility and potential beneﬁts of fertility preservation procedures in
women with endometriosis are warranted prior to implementing its use in
routine clinical practice.
Study design, size, duration: This cross-sectional study has conducted since
March 2017 to January 2018, 52 patients with endometriosis who were
referred for fertility preservation via ART, have been studied. They underwent
controlled ovarian stimulation and ART results including number and quality of
oocytes and embryos and also clinical pregnancy rate were obtained.
Endometriosis characteristics such as presence, size, laterality, the number of
endometriomas, the coexistence of DIE and previous history of endometriosis
surgery were registered.
Participants/materials, setting, methods: 57 controlled ovarian stimula-
tion cycles with GnRH antagonist protocol have been studied, and ovarian
puncture were performed, then ART results were followed. The number and
quality of oocytes and embryos were assessed and the clinical pregnancy rate
was calculated in patients who underwent embryo-transfer (18 patients).
Multivariate regression analysis, bi variate correlations and Chi-square test
were applied for evaluation of impressive factors on ART results. The level of
signiﬁcance was considered 0.05.
Main results and the role of chance: Controlled ovarian stimulation and
ovum pick up were performed for 52 patients, 10 patients had repeated COH
cycles and embryo cryopreservation has performed, except 5 patients who had
Oocytes cryopreservation. COH cycles were canceled for 5 cases due to poor
ovarian responses. 18 patients had 23 embryo transferred cycle. Age and BMI
mean and SD of cases were 33.11 ± 4.72 and 23.87 ± 3.9 respectively. From
46 patients who have previously suffered from infertility, there was mild to
moderate male factor in16 cases. There was an inverse relation between the
size of endometrioma and number of oocytes(P-value = 0.011), the quality of
oocytes (P-value = 0.002), the number of embryos (Pvalue = 0.004), the qual-
ity of embryos(Pvalue = 0.007). The number and quality of oocytes and
embryos have related to age and AMH levels signiﬁcantly. Although these
effects were not signiﬁcant for clinical pregnancy rate (26% per embryo trans-
fer) and there is no statistical relationship between those ART outcomes and
endometriosis characteristic such as DIE, laterality and number of endometrio-
ma and previous surgery history.
Limitations, reasons for caution: The cases of the study are more severe
than total endometriosis population due to referral nature of Avicenna infer-
tility clinic and endometriosis clinic. Because of rare cases of fertility preser-
vation in normal population, selection of a standard control group seems
unavailable.
Wider implications of the ﬁndings: Age, AMH level and the size of endo-
metrioma signiﬁcantly affect the number and quality of oocytes and embryos in
endometriosis patients who were referred for fertility preservation.Our intrest-
ing ﬁndings offer further study to ﬁnd which endometriosis patients beneﬁt from
fertility preservation via ART.
Trial registration number: This study is not clinical trial.
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P-262 The gametotoxic effects of the endometrioma content:
insights from a parthenogenetic humanmodel
A. Paffoni1, V. Bolis2, S. Ferrari2, L. Benaglia2, L. Restelli2,
E. Somgiliana3
1Azienda Ospedaliera Sant’Anna - Presidio di Cantù, Procreazione medicalmente
assistita, Cantù, Italy
2Fondazione IRCCS Ca’ Granda, Infertility Unit, Milan, Italy
3University of Milan, Department of Clinical Sciences and Community Health, Milan,
Italy
Study question: To evaluate the effect of exposure of human cryopreserved
oocytes to endometriotic ﬂuid using a validated experimental model of human
parthenogenesis.
Summary answer: Exposure of human oocytes to endometriotic ﬂuid has a
negative effect on the morphology of deriving embryos/parthenotes mainly due
to an excess of cellular fragmentation.
What is known already: Exposure to the content of endometriotic cysts
may be harmful to the oocyte and may alter its subsequent developmental
potential as an embryo due to the presence of several potentially toxic sub-
stances such as growth factors and interleukins, matrix metalloproteinases,
catalytic iron and lipid peroxide. The great amount of free iron in endometriotic
cysts is a matter of concern because of the risk of local production of the highly
toxic reactive oxygen species. However, experimental data supporting these
concerns are scanty both in humans and in animal models.
Study design, size, duration: A randomized in vitro study conducted
between January 2016 and July 2016. A three-folds decrease in the rate of day
3 good quality parthenotes for exposed oocytes compared to unexposed ones
was considered important (from 37% to 12%, based on previuos data).
Considering a survival rate of 80% after warming, the total number of oocytes
to be used for the study were 140 (type I and II errors equal to 0.05 and 0.20,
respectively)
Participants/materials, setting, methods: Oocytes used for the study
protocol were donated by consenting women aged <42 years. After thawing,
oocytes belonging to every single patient were randomly (1:1) allocated to fer-
tilization medium containing endometriotic ﬂuid (exposed oocytes) or to the
fertilization medium (control). After 3 minutes of culture, oocytes were rinsed
and activated using ionomycin followed by 3-hours incubation in 2 mM 6-
DMAP. Parthenotes were cultured until day 5 and embryological parameters
were registered daily.
Main results and the role of chance: Twenty-three women donated a total
of 147 vitriﬁed oocytes (range 2-17). After warming, 121 intact oocytes were
randomized in 13 sets of experiments. A total of 60 oocytes were randomized
to the exposure group while 61 oocytes were randomized to the non exposure
group. The day after treatment and activation, 42 parthenotes (70%) among
exposed oocytes and 46 parthenotes (75%) among unexposed oocytes were
observed (p = 0.51). The developmental rates on day 3 and day 5 did not sig-
niﬁcantly differ between the two groups. The RRs (95%CI) of exposed oocytes
for activation, cleavage on day 3 and blastulation on day 5 were 0.93 (0.75-
1.16), 0.88 (0.65-1.19) and 0.47 (0.19-1.15), respectively. Conversely, data on
morphology tend to support a detrimental effect of endometrioma ﬂuid expos-
ure. The rate of day 3 good quality parthenotes was 22% (13/60) and 41%
(25/61) in exposed and unexposed oocytes, respectively (RR = 0.53; 95%CI:
0.30-0.93, p = 0.031). A trend was observed also in the development of good
quality-expanded blastocysts on day 5, 5% (3/60) and 13% (8/61) of oocytes,
respectively (RR = 0.39, 95%CI: 0.11-1.37). A signiﬁcantly higher proportion of
parthenotes failing to develop to the blastocyst stage showed cellular fragmen-
tation in the exposed compared to unexposed parthenotes (RR = 0.64, 95%CI:
1.04-2.57; p = 0.024).
Limitations, reasons for caution: We used a ﬁxed experimental model
that cannot mimic all the variability of every possible clinical conditions.
Endometriotic ﬂuids from three different patients were used; even though we
did not observed differences based on the donor of the endometriotic ﬂuid, we
cannot exclude possible different biological effects.
Wider implications of the ﬁndings: Even if robust inferences cannot be
drawn, because our ﬁndings were obtained in an experimental context, we
believe that our study has some potential clinical implications and can be
interpreted as a scientiﬁc support of the common dogma that ovarian endome-
triomas should not be punctured or aspirated during oocytes retrieval.
Trial registration number: not applicable.
P-263 High mobility group box-1 increases cell proliferation,
expression of adhesion molecules, and secretion of cytokines in
human endometrial stromal cell in endometriosis
J. Yun, J.H. Lee, S.K. Seo, S. Cho, Y.S. Choi, B.S. Lee, B.H. Yun
Severance Hospital- Institute of Women’s Life Medical Science- Yonsei University
College of Medicine, Division of Reproductive Endocrinology- Department of
Obstetrics and Gynecology-, Seoul, Korea- South
Study question: Does endogenous ligands such as High mobility group box-1
(HMGB-1) signaling may play a pathogenic role developing endometriosis?
Summary answer: HMGB-1 is important in establishment of endometriosis
through inﬂammatory pathway, which leads increase of inﬂammatory cytokines
and change adhesion molecules in ectopic endometrial stromal cell.
What is known already: Oxidative stress and chronic inﬂammation play
important roles in the pathophysiology of endometriosis. A representative
Damage-associated molecular pattern (DAMP), HMGB-1 has previously shown
increased release from the endometrial stromal cell at oxidative stress.
Moreover, recombinant HMGB-1(rHMGB-1) stimulated cell proliferation and
increased expression of Toll like receptor 4(TLR4) in human endometrial stro-
mal cell(HESC), suggesting altered pathologic endometrium according to oxida-
tive stress and chronic, endogenous inﬂammation.
Study design, size, duration: In-vitro, experimental study using primary cell
culture and molecular biologic methods.
Participants/materials, setting, methods: HESC culture was done using
ectopic endometrium from the surgical specimen. HESCs were examined to
see cell proliferation and HMGB-1 release according to H2O2 treatment. Then,
HESCs were treated with rHMGB-1 by dose dependent fashion. The superna-
tants acquired during the rHMGB-1 treatment were examined to measure
inﬂammatory cytokines such as TNF-a, IL-1b, IL-6 and IL-10. Adhesion mol-
ecule, angiogenic marker, DAMP receptors were measured by RT-PCR and
western blotting from HESCs treated with rHMGB-1.
Main results and the role of chance: HESCs showed decreasing cell viabil-
ity and increasing HMGB-1 release according to H2O2 treatment. Cell prolifer-
ation and invasion was signiﬁcantly increased according to the treated dose of
rHMGB-1. Expression of mRNA and the protein expression of TLR4, RAGE,
VEGF, ICAM-1 increased signiﬁcantly according to the treated rHMGB-1 con-
centration. E-Cadherin showed decrease in mRNA and protein by increase of
rHMGB-1 treatment. Inﬂammatory cytokines from the supernatants of HESC
during rHMGB-1 treatment showed signiﬁcant increase.
Limitations, reasons for caution: Our study is limited in that we only per-
formed in vitro analysis using HESCs. Therefore, in vivo studies are required.
Wider implications of the ﬁndings: Our results support that the progres-
sion of endometriosis may be guarded by oxidative stress and endogenous stim-
uli results in chronic inﬂammatory pathway.
Trial registration number:NRF-2012R1A1A1013167
P-264 Circulating Cf-DNA quantiﬁcation according to the location
of the endometriotic lesions
S. Hamamah1, A. Torre2, S. El Moghrabi3, F. Entezami4, P. Santulli5,
C. Chapron5, D. Haouzi3
1Hôpital Arnaud de Villeneuve, Service de Biologie et de Médecine de la
Reproduction B, Montpellier Cédex 5, France
2Division of Child Health- Obstetrics & Gynaecology, Department of Obstetrics and
Gynecology- University of Nottingham, Nottingham, United Kingdom
3Inserm U1203, Hôpital St-Eloi- IRMB- CHU MOntpellier, Montpellier, France
4Laboratoire Eylau-UNILABS-La Muette- Clinique de La Muette-Ramsay-Générale de
Santé, ART department, Paris, France
5Université Paris Descartes- Sorbonne Paris Cité- Faculté de Médecine- Assistance
Publique - Hôpitaux de Paris AP-HP- Groupe Hospitalier Universitaire GHU Ouest-
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Centre Hospitalier Universitaire CHU Cochin, Department of gynecology Obstétrics II
and Rep,
Study question: Is there an association between the circulating Cf-DNA
(CCf-DNA) and the location of the endometriotic lesions?
Summary answer: CCf-DNA concentrations was higher in the deep pelvic
endometriosis compared with control and other types of endometriosis.
What is known already: Circulating Cf-DNA are present in the bloodstream
and their quantiﬁcation is already used as a biomarker for gynaecological disor-
ders such as ovarian and endometrial cancer. To date, only one study reported
the potential role of CCf-DNA as potential biomarker for minimal and mild
endometriosis. However, no studies analyzed the CCf-DNA according to the
location of the endometriotic lesions.
Study design, size, duration: This was an retrospective study using serum
prospectively collected from non-pregnant patients from the Cochin Hospital
who were between 18 and 41 years of age (mean ± sem: 31.5 ± 0.6 years),
and who underwent surgery for symptomatic benign gynecological conditions
between January 2011 and December 2013.
Participants/materials, setting, methods: Surgery was performed on 76
patients available preoperative MRIs. After a thorough surgical examination of
the abdomino-pelvic cavity, 55 women with histologically proven endometriosis
and/or adenomyosis were allocated to the endometriosis group and 21 symp-
tomatic women without evidence of endometriosis with or without adenomyo-
sis to the endometriosis free group. CCf-DNA was extracted from 200 μl of
serum and quantiﬁed by qPCR using primers amplifying ALU115 sequences in
both groups and according to surgical endometriosis phenotypes.
Main results and the role of chance: CCf-DNA concentrations were simi-
lar in the endometriosis free group with or without adenomyosis (245 ± 70 vs
200 ± 29 fg/μL respectively, p = 0.6). The concentration of CCf-DNA was sig-
niﬁcantly higher in the endometriosis group than in the control group (342 ± 66
vs 215 ± 38 fg/μL, p = 0.1). In addition, accordingly to the location of the endo-
metriotic lesions, the CCf-DNA concentrations was higher in the deep pelvic
endometriosis (359 ± 110 vs 215 ± 38 fg/μL) compared with control group,
superﬁcial peritoneal and ovarian endometriosis.
Limitations, reasons for caution: These ﬁndings must be validated in a
large cohort of patients to judge of the relevance of the CCf-DNA quantiﬁca-
tion as potential biomarker of endometriosis.
Wider implications of the ﬁndings: These ﬁndings of signiﬁcantly increased
concentrations of CCf-DNA in serum of patients with endometriosis suggests
that CCf-DNA might be a potential biomarker for developing non-invasive diag-
nostic test in endometriosis.
Trial registration number:Not applicable.
P-265 The use of home remedies and complementary health
approaches in endometriosis
B. Leeners1, E. Gross1, K. Geraedts1, M. Rauchfuss2, M.Wölﬂer3,
F. Haeberlin4, S. Von Orelli5, M. Eberhard6, P. Imesch7, D. Fink7,
B. Imthurn1, A. Kohl Schwartz1
1Department of Reproductive Endocrinology, University Hospital Zürich, Zürich,
Switzerland
2Charité Berlin- University Hospital, Department of Psychosomatics, Berlin, Germany
3University Hospital Graz, Gynecology and Obstetrics, Graz, Australia
4Canton hospital St. Gallen, Gynecology and Obstetrics, St. Gallen, Switzerland
5Triemli hospital Zürich, Gynecology and Obstetrics, Zurich, Switzerland
6Canton Hospital Schaffhausen, Gynecology and Obstetrics, Schaffhausen,
Switzerland
7University Hospital Zurich, Gynecology, Zurich, Switzerland
Study question: How do endometriosis-affected women use complementary
health approaches (CHA) and home remedies (HR)?
Summary answer: Persisting disease symptoms and dissatisfaction with med-
ical support are key factors for the use of CHA and HR in women with
endometriosis.
What is known already: Endometriosis is characterized by pain symptoms
such as dysmenorrhea, dyspareunia and chronic pelvic pain. The physiology of
nociception and pain syndromes is not yet fully understood, but it is assumed
that somatic mechanisms interact with psychological factors and are further
modiﬁed by individual differences in pain perception. Surgical treatment of
endometriosis lesions followed by hormonal and/or analgesic therapies are typ-
ical approaches to alleviate pain symptoms. However, these conventional treat-
ments are often associated with adverse effects and endometriosis pain
symptoms may reoccur despite treatment.
Study design, size, duration: Retrospective cross-sectional data analysis of
574 women with endometriosis, recruited in hospitals and associated private
practices and self-help groups in Switzerland, Germany and Austria between
2010 and 2016. Primary outcome measures were frequency and perceived efﬁ-
cacy of the use of CHA and HR. The secondary outcome was the analysis of
confounders such as duration of disease, stage of disease, disease symptoms, as
well as satisfaction with conventional health care.
Participants/materials, setting, methods: Included were women aged 18
to 59 with surgically conﬁrmed endometriosis. Data was acquired with a ques-
tionnaire focusing on endometriosis in general, including questions on surgical
and hormonal therapies. The use of CHA and HR was assessed. The pain was
investigated with a modiﬁed version of the validated standard questionnaires
such as the Brief Pain Inventory and Pain Disability Index. Outcome measures
were compared for the hospital recruited and the self-help recruited group.
Main results and the role of chance: A total of 359 (62.5%) from 574
included women with conﬁrmed diagnosis of endometriosis, applied any form
of CHA/HR. The approaches “topical heat” (by 48.6%) and “repose” (by
43.0%) were applied most often, followed by “movement/massage” (by
25.4%), “homeopathy/phytotherapy” (by 22.8%) and “acupuncture/traditional
Chinese Medicine (TCM)” (by 22.6%) of the women. Therapeutic effect was
assigned high (80.3% for “topical heat”, 70% for “repose”, 69.2% for “move-
ment/massage”, 44.3% for acupuncture/TCM ans 42% for “homeopathy/ phy-
totherapy”. Women suffering from chronic fatiguing disease symptoms selected
more often alternative therapies (odds ratio 3.14, 95% conﬁdence interval
1.39–7.11, p = 0.006) compared to women without these characteristics. In
total 18.9% (109/574) of women felt well supported by their physician in deal-
ing with endometriosis-associated pain, while 13.8% (79/574) did not at all.
Women in the self-help group were signiﬁcantly more frequently dissatisﬁed
with the treatment provided by their physicians (p<0.001). Furthermore,
women dissatisﬁed with the treatment provided by their physicians used signiﬁ-
cantly more often complementary approaches. Our study shows that the
majority of women with endometriosis seek additional treatment strategies
such as CHA/HR to deal with and/or cure symptoms of the disease, as they
seem to provide a good symptom alleviation than hormonal therapies.
Limitations, reasons for caution: Data analysis was based on questionnaire
information of a non-standardized questionnaire. Apart from reports on
endometriosis-related surgery, no other medical records were reviewed. As
we asked for lifetime use of medication, we cannot give any information on
time relations between conventional and complementary approaches.
Wider implications of the ﬁndings:Women dissatisﬁed with medical sup-
port and persisting disease symptoms frequently used CHA and HR. Gaining
control and actively participating in the treatment motivates them to seek add-
itional options. Women’s’ needs should be respected while counselling and a
more active role should be offered in developing individual treatment strategies.
Trial registration number: ClinicalTrials.gov NCT 02511626.
P-266 Fatigue – an underestimated symptom in endometriosis
A. Ramin-Wright1, A.S. Kohl Schwartz2, K. Geraedts1,
M. Rauchfuss3, M.M.Wölﬂer4, F. Haeberlin5, S. Von Orelli6,
M. Eberhard7, B. Imthurn1, P. Imesch8, D. Fink8, B. Leeners1
1University Hospital Zurich, Reproductive Endocrinology, Zurich, Switzerland
2University Hospital Bern, Gynecology- Gynecological Endocrinology and
Reproductive Medicine, Bern, Switzerland
3Charité Berlin, Psychosomatics, Berlin, Germany
4University Hospital Graz, Gynecology and Obstetrics, Graz, Austria
5Canton Hospital St. Gallen, Gynecology and Obstetrics, St. Gallen, Switzerland
6Triemli Hospital Zurich, Gynecology and Obstetrics, Zurich, Switzerland
7Canton Hospital Schaffhausen, Gynecology and Obstetrics, Schaffhausen, Switzerland
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8University Hospital Zurich, Gynecology, Zurich, Switzerland
Study question: Is fatigue a frequent symptom of endometriosis which should
be given more consideration?
Summary answer: Fatigue is an underestimated symptom of endometriosis
as it affects numerous women with endometriosis, but is not widely considered
clinically or discussed in literature.
What is known already: Along with pain, fatigue can be a symptom of endo-
metriosis which may cause major distress and further reduce the quality of life
of women with endometriosis. However, few studies with large sample sizes
have investigated prevalences and confounders of fatigue as a symptom of
endometriosis.
Study design, size, duration: The study was designed as a multi-center
matched case-control study. Recruitment took place at hospitals and private
practices in Switzerland, Germany, and Austria between 2010-2016. Data was
collected from 1120 women, 560 of them with endometriosis.
Participants/materials, setting, methods: Age +/- 3 years and ethnic
background were chosen as matching criteria. Endometriosis diagnosis of 560
women was surgically and histologically conﬁrmed while 560 controls were
selected by surgical exclusion or absence of symptoms. More women showed
an advanced disease stage (61.9% rASRM III or IV). Materials included surgical
and histological reports as well as data retrieved from a self-administered ques-
tionnaire. Variable relationships were established by regression analysis and
associations were quantiﬁed as odds ratios.
Main results and the role of chance: Severe fatigue is a very frequent
symptom in women diagnosed with endometriosis (50.7% versus 22.5% in con-
trol women, p<0.001). Fatigue in endometriosis is associated with insomnia
(OR: 10.37, CI: 6.83-15.75, p<0.001), chronic pain (OR: 2.56, CI: 1.81-3.62,
p<0.001), and occupational stress (OR: 1.53, CI: 1.10-2.13, p = 0.012), but it
is independent of age, time since ﬁrst diagnosis, and stage of the disease.
Limitations, reasons for caution: Women with asymptomatic endometri-
osis cannot be excluded in the control group which would lead to underestima-
tion of our results. The data was retrieved from a self-administered
questionnaire, therefore, answers are at risk for recall biases. The study’s design
allows no evaluation of causal effects.
Wider implications of the ﬁndings: Our study is the ﬁrst to systematically
investigate fatigue in endometriosis in a large study population. High fatigue pre-
valences demonstrate the need of addressing it when managing the disease. In
addition to treating endometriosis, it would be beneﬁcial to reduce insomnia,
pain, and occupational stress to better manage fatigue.
Trial registration number: ClinicalTrials.gov, NCT 02511626
P-267 A speciﬁc serum cytokines proﬁle determines disease
phenotype in adenomyosis-affected women
M. Bourdon1,2, P. Santulli1,2, S. Chouzenoux2, K. Bailly2,
C. Maignien1, L. Marcellin1,2, L. Doridot2, F. Batteux2, C. Chapron1,2
1Cochin - Port Royal, Service de Gynécologie Obstétrique II and Reproductive
Médicine Professor Chapron, Paris Cedex 14, France
2Institut Cochin- INSERM U1016- Université Paris Descartes- Sorbonne Paris Cité,
Laboratoire d’immunologie, Paris, France
Study question: Is there a speciﬁc serum cytokines proﬁle in adenomyosis
women according to the adenomyosis phenotype, as compared to disease-free
counterpart?
Summary answer: A decrease in serum interleukin (IL)23, IL31, IL25, IL33
levels was identiﬁed adenomyosis women with associated diffuse and focal form
as compared to disease-free counterpart.
What is known already: Adenomyosis is a benign uterine disorder charac-
terized by the presence of heterotopic endometrial stroma and glands deeply
into the myometrium associated with hypertrophy of adjacent uterine smooth
muscle cells. Different forms of adenomyosis can be distinguished: Diffuse ade-
nomyosis (DIF-ADE), Focal adenomyosis (FOC-ADE) and the association of
diffuse and focal lesions (DI/FOC-ADE). The origin of ectopic endometrial
implants within the myometrium is still debated and could be multiple.
Abnormal immune phenomena have been described trying to understand
adenomyosis physiopathology. However, the immune imbalance in adenomyo-
sis is still poorly understood.
Study design, size, duration: This cohort study, conducted in a tertiary care
university hospital, included 80 women who have received a pelvic magnetic
resonance imaging (MRI) performed by one senior radiologist during the pre-
operative work-up.
Participants/materials, setting, methods: According to MRI ﬁndings
women were allocated to two groups: Adenomyosis (ADE) group (n = 60) and
the control group of women without any criteria for ADE at MRI (n = 20).
Women in the ADE group were further sub-divided according to adenomyosis
phenotypes: DIF-ADE, FOC-ADE and FOC/DIF-ADE. For all women, blood
samples were obtained prior to a surgical procedure and serum cytokine levels
were assayed by multiplex immunoassay.
Main results and the role of chance: Serum levels of interleukin (IL)23
(237.77 pg/ml ± 70.97 in ADE-group versus 1855.04 ± 1411.33 in control-
group, p = 0.019), IL25 (31.98 ± 8.54 vs. 222.08 ± 170.90 respectively, p =
0.006), IL31 (10.13 ± 3.83 vs. 91.51 ± 71.21 respectively, p = 0.034), IL33
(3.77 ± 1.23 vs. 17.86 ± 11.49 respectively, p = 0.016) and IL17F (16.29 ±
2.35 vs. 30.12 ± 8.29 respectively, p = 0.042) were signiﬁcantly decreased in
adenomyosis-affected women as compared to controls. In DIF/FOC –ADE
group, a signiﬁcant decrease of serum IL23, IL31, IL25, IL33 levels were identi-
ﬁed as compared to controls.
Limitations, reasons for caution: Diagnostic of adenomyosis was based
only on strict imaging criteria and no correlation with local adenomyotic lesions
has been performed.
Wider implications of the ﬁndings:Our results may provide new clues for
understanding the pathogenesis of adenomyosis, potentially associated with an
immunotolerant process more pronounced in associated diffuse and focal
forms of adenomyosis.
Trial registration number:None.
P-268 Comparison of effect of Silymarin and Cabergoline on
experimental model of endometriosis
S. Jouhari1, M.M. Naderi2, A. Mohamadzade1, S. Khazali3,
S. Zafardoust1, F. Fatemi1, Z. Mohamadi4, H. Soltanghoraee2
1Avicenna Research Institute- ACECR, infertility, Tehran, Iran
2Avicenna Research Institute- ACECR, Reproductive Biotechnology Research Center,
Tehran, Iran
3Ashford and St. Peter’s Hospital NHS Foundation Trust-, Centre for Endometriosis
and Minimally Invasive Gynaecology CEMIG, Chertsey, United Kingdom
4Avicenna Research Institute- ACECR, Nanobiotechnology Research Center, Tehran,
Iran
Study question:What is the effects of Silymarin and Cabergoline on induced
endometrial lesion in experimental model of endometriosis?
Summary answer: Silymarin and Cabergoline administration resulted in
decreased size and hystopathological grade of the induced endometrial lesions
in experimental endometriosis model of rat.
What is known already: Previous lines of evidence suggest that cabergoline
(dopamine agonist) is effective in treatment of patients with endometriosis
(reducing size and symptoms). But less is known regarding the effects of silymar-
in (a natural compound with antioxidant effects).
Study design, size, duration: Twenty four female Sprague-Dawley mature
rats.
were used for an experimental study in the Avicenna Research Institute.
Participants/materials, setting, methods: Endometriosis was surgically
induced in 24 rats.animals were randomized into three groups. Group I was
administered 100 mg/kg Silymarin S.C, group II was given 0.5 mg/kg
Cabergoline S.C and group III had no medication.The rats medicated 3 weeks.
Then rats were sacriﬁced and size and histopathological grade of the endome-
triotic implants and biochemical parameters were evaluated.Serum and periton-
eal levels of vascular endothelial growth factor (VEGF), total antioxidant
capacity(TAC) and tumor necrosis (TNF)-α were compared between groups.
Main results and the role of chance: All the animals had comparable base-
line characteristics. We found that the size of endometrial lesions decreased
signiﬁcantly in cabergoline (p<0.001) and silymarin (p<0.001) groups. The
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histopathology grade was signiﬁcantly lower in cabergoline (p<0.001) and sily-
marin (p<0.001) groups compared to controls. There was no signiﬁcant differ-
ence between study groups regarding serum levels of VEGF, TNF-α and
peritoneal levels of TAC. Those receiving silymarin had signiﬁcantly higher TAC
compared to control after 21 days of therapy (p<0.001).
Limitations, reasons for caution: The study was performed on animal sub-
jects.Endometriosis studies in humans are challenging to perform as the mea-
sured effect of the treatment on the actual peritoneal lesion will necessitate
surgical interventions. The second weakness of the current data is the knowl-
edge regarding the administration route of the treatment for human patients.
Wider implications of the ﬁndings: cabergoline and silymarin administra-
tion resulted in decreased size and histopathologic grade of the induced endo-
metrial lesions in animal model of rat. Silymarin appear to be a virtual novel
therapeutic agent for treatment of endometriosis probably due to its potent
anti-oxidative properties.
Trial registration number:Not applicable.
P-269 The effect of endometriosis on the antimüllerian hormone
level in patients with infertility
P. Romanski1, P. Brady1, A. Thomas1, L. Farland1,2, M. Hornstein1
1Brigham &Women’s Hospital/Harvard Medical School, Department of Obstetrics-
Gynecology and Reproductive Biology, Boston, U.S.A.
2Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston,
U.S.A.
Study question: Among patients with infertility, is endometriosis associated
with differences in baseline antimüllerian hormone (AMH) levels?
Summary answer: Patients with endometriosis, regardless of prior ovarian
cystectomy, were observed to have lower AMH values and higher incidence of
diminished ovarian reserve at infertility evaluation.
What is known already: Patients with moderate to severe endometriosis
experience an accelerated decline in AMH levels following ovarian cystectomy
which may lead to a decreased reproductive life span. It is unclear whether
women with endometriosis have lower AMH levels at baseline. Conversely,
polycystic ovarian syndrome is associated with higher AMH levels and a longer
time to menopause compared to normo-ovulatory controls.
Study design, size, duration: This retrospective cohort study included three
groups of women who presented for infertility evaluation at our tertiary care
center from 04/27/2015 to 05/31/2017: 29 women with endometriosis and a
history of ovarian cystectomy (EndoOC), 29 women with endometriosis with-
out a history of ovarian cystectomy (Endo), and 240 women with male factor
infertility (MFI; control group).
Participants/materials, setting, methods: AMH levels (ng/mL; using
Ansh Labs Ultra-Sensitive assay) were measured as part of the routine infertility
evaluation. Patients diagnosed with endometriosis were surgically staged per
the revised American Society for Reproductive Medicine scoring system. Linear
regression using robust standard errors and logistic regression models were
adjusted a priori for age, body mass index, race, and smoking status to estimate
adjusted beta coefﬁcients (aβ) and adjusted odds ratios (aOR) with 95% conﬁ-
dence intervals (CI).
Main results and the role of chance: The mean ± standard deviation of
age (years) and body mass index (BMI; kg/m2) was similar across groups:
EndoOC age = 33.4 ± 3.5, BMI = 25.2 ± 5.9; Endo: age = 33.9 ± 3.9, BMI =
25.8 ± 5.7; MFI: age = 34.0 ± 3.6, BMI = 25.4 ± 5.9. Compared to the MFI
group (4.0 ± 3.1 ng/mL), a lower mean AMH level was observed in the
EndoOC group (3.1 ± 2.9; aβ -1.12, 95% CI [-2.2, -0.05]) and in the Endo
group (2.7 ± 2.3; aβ -1.30, 95% CI [-2.17, -0.43]). The mean AMH level was
similar for the Endo group compared to the EndoOC group (aβ -0.09, 95% CI
[-1.34, 1.16]). Women were more likely to have an AMH <1 in the EndoOC
group (24.1%; aOR 3.53, 95% CI [1.22–9.25]) and in the Endo group (24.1%,
aOR 2.71, 95% CI [1.00–7.40]), compared to women in the MFI group
(10.8%). The proportion of women with an AMH <1 was similar for the Endo
group compared to the EndoOC group (aOR 1.00, 95% CI [0.27 – 3.65]).
Limitations, reasons for caution: The generalizability of these results to
women with endometriosis and normal fertility may be limited. Given our small
sample, we have limited power to detect differences in AMH levels between
different stages of endometriosis which may represent important disease
heterogeneity.
Wider implications of the ﬁndings: Lower baseline AMH levels in infertility
patients with endometriosis could suggest an increased rate of decline in ovar-
ian reserve over time in this population. Early referral for fertility assessment
and treatment in patients with known endometriosis may be prudent.
Trial registration number: not applicable.
P-270 Oral contraceptive use in women with pelvic pain and
endometriosis: history of ineffectiveness or discontinuation due to
side-effects
N. Alsowayan, M. Bedaiwy, P. Yong, C. Allaire, C.Williams,
S. Lisonkova
University of British Columbia, Faculty of Medicine- Department of Obstetrics and
Gynaecology, Vancouver, Canada
Study question: To investigate the relationship between failure of combined
oral contraceptive pill (COC) regimens due to ineffectiveness or side effects,
and pelvic pain severity and quality-of-life in women with endometriosis.
Summary answer: Discontinuation of COC due to ineffectiveness for pain
or due to side-effects, was associated with more severe pelvic pain and poorer
quality-of-life in endometriosis.
What is known already: COCs are regarded as the ﬁrst line of therapy in
treating endometriosis associated chronic pelvic pain. Although several studies
were performed to evaluate their effectiveness, many has reported patient dis-
continuation of treatment because of side effects intolerability or lack of symp-
tomatic control without expanding this trend.
Study design, size, duration: Analysis of a prospective patient registry from
a tertiary care referral center for patients with endometriosis and pelvic pain
between December 2013 to and April 2015.
Participants/materials, setting, methods: 656 patients in reproductive
age who were prospectively consented for the registry. Patients had to ﬁll the
online questionnaire which included eleven point numeric rating scale (0-10) for
pain symptoms, Endometriosis Health Proﬁle 30 “EHP-30”, Patient Health
Questionnaire “PHQ-9” for depression assessment, and Generalized Anxiety
Disorder “GAD-7” questionnaire for anxiety assessment.
Main results and the role of chance: Prior cyclical COC use was reported
by 362 (55.2%) women, of which 167 (25.5%) stated it was ineffective for their
pain and 139 (21.2%) stated they discontinued due to side effects. Previous con-
tinuous COC was reported by 267 (40.7%) women, of which 110 (16.8%) stated
it was ineffective and 80 (12.2%) stated they discontinued due to side effects.
Worse chronic pelvic pain severity in the last 3 months was associated with a his-
tory of ineffectiveness of COC use whether cyclical (p<0.008) or continuous
(p<0.001). Worse dysmenorrhea and poorer quality-of-life was present in
women who reported a history of COC discontinuation due to side effects.
Limitations, reasons for caution: Retrospective analysis potentiates for
selection and information bias. However, our data was collected prospectively
through online patient questionnaire, thus it was dependent on the accuracy of
subject’s input.
Wider implications of the ﬁndings: Further research is needed to identify
novel treatment approaches for women with endometriosis who are non-
responders to COC.
Trial registration number: not applicable.
P-271 Reciprocal changes of H3K27ac and H3K27me3 at the
promoter regions of the critical genes for endometrial
decidulaization
N. Katoh1, K. Kuroda2, J. Tomikawa1, H. Ogata-Kawata1, R. Ozaki2,
A. Ochiai2, M. Kitade2, S. Takeda2, K. Nakabayashi1, K. Hata1
1National Center for Child Health and Development, Department of Maternal=Fetal
Biology, Tokyo- Setagaya-ku, Japan
2Juntendo University, Obstetrics and Gynecology, Bunkyo-ku, Japan
Study question: To capture the epigenetic dynamics and to understand its
roles during decidualization, we conducted transcriptome and epigenome pro-
ﬁling for endometrial stromal cells and decidualized cells.
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Summary answer: We discovered that the promoter regions of the genes
critical for decidualization are often associated with the reciprocal changes of
H3K27ac and H3K27me3 marks.
What is known already: Decidualization, the transformation of endometrial
stromal cells (ESCs) into secretory decidual cells, is essential for embryo
implantation and placental development, and is dependent on the postovula-
tory increases in progesterone and local cyclic AMP production levels in
humans. The responsiveness of ESCs to the hormonal cues is thought to be
potentiated by genome-wide chromatin remodeling followed by the coordi-
nated action of decidua-speciﬁc transcriptional networks. However, informa-
tion for such epigenetic alterations has been limited.
Study design, size, duration: Endometrial biopsies were obtained from the
uterine fundus from two women of reproductive age without endometriosis
who underwent laparoscopic cystectomy. The tissues were processed for pri-
mary endometrial stromal cell culture. The primary cells remained untreated
(D0), or decidualized for 4 days (D4) and 8 days (D8) in the presence of 8-
bromo-cAMP and progesterone. Genomic DNA, total RNA, and
formaldehyde-ﬁxed chromatin were prepared from cells.
Participants/materials, setting, methods: The resultant endometrial stro-
mal (D0) and decidualized cells (D4, D8) from two donors were subjected to
transcriptome and methylome proﬁling as well as chromatin immunoprecipita-
tion followed by next-generation sequencing (ChIPseq) for H3K27ac (an active
chromatin mark), and for H3K9me3 and H3K27me3 (repressive chromatin
marks). DNA methylation, gene expression, and histone enrichment proﬁles
were compared between untreated (D0) and decidualized (D4 and D8) cells to
search for differential gene expression and epigenetic modiﬁcations upon
decidualization.
Main results and the role of chance: Although the H3K27ac and
H3K27me3 proﬁles have already been reported previously, our data for these
histone modiﬁcations enabled us to have detected larger numbers of peaks and
differentially enriched regions upon decidualization. Among the epigenetic modiﬁ-
cations examined (DNA methylation, H3K27ac, H3K9me3, and H3K27me3),
the H3K27ac patterns changed most dramatically, with a moderate correlation
with gene expression changes, upon decidualization. We revealed that subsets of
up- and down-regulated genes upon decidualization were associated with recip-
rocal changes of H3K27ac and H3K27me3 modiﬁcations at their promoter region
and were enriched with genes essential for decidualization. The top 23 genes
most extremely up-regulated were found to contain four genes (namely, WNT4,
ZBTB16, PROK1, and GREB1) that have been shown to be essential for decidua-
lization. The top 8 genes most extremely down-regulated also contained two
genes, CRABP2 and PTHLH, whose down-regulation has been shown to be crit-
ical for decidualization. These results demonstrate a central role of epigenetic
regulation in the coordinated gene expression changes required for decidualiza-
tion. We minimized the role of chance in our results by obtaining and assessing
datasets from two independent donors. Our dataset is useful to elucidate further
the molecular mechanisms underlying decidualization.
Limitations, reasons for caution: It should be noted that all results were
obtained through the analysis of in vitro decidualized cells from donors without
abnormality in endometrium. It is important to obtain epigenome proﬁles of
ESCs and decidualized cells from donors with endometriosis and compare such
datasets with those obtained in this study.
Wider implications of the ﬁndings: siRNA knockdown screening for the
genes with the reciprocal changes of H3K27ac and H3K27me3 at their pro-
moter region will help identifying additional critical genes for decidualization.
Such genes represent novel targets for the development of therapeutic drugs to
recover the implantation and the pregnancy rates of recurrent miscarriages.
Trial registration number: not applicable.
P-272 A comparison of Toll-like receptors and cytokine proﬁles in
the endometrium around the time of implantation between women
with and without chronic endometritis
Y. Liu1, G.C.W. Man1,2, X. Chen1, F.Wu1,W.C. Cheung1, Y. Zhao1,
J. Huang1, C.C.Wang1, T.C. Li1
1The Chinese University of Hong Kong, Obstetrics and Gynaecology, Shatin- New
Territories, Hong Kong
2The Chinese University of Hong Kong, Orthopaedics and Traumatology, Shatin- New
Territories, Hong Kong
Study question: Does the presence of chronic endometritis (CE) affect the
expression of Toll-like receptors (TLR) and inﬂammatory cytokine proﬁles in
endometrial tissues around the time of implantation?
Summary answer: The expression of TLR1, 2, 3, and 4 and Interferon gam-
ma (IFN-γ) in the endometrial tissues of women with CE was higher than with-
out CE.
What is known already: The prevalence of CE has been found to be higher
in women with recurrent miscarriage and recurrent implantation failure.
However, the exact mechanism whereby implantation is affected in women
with CE is largely unknown. One earlier study showed the expression of TLR4
was increased in women with CE. Another study showed the alteration of cyto-
kine proﬁles in CE patients. However, in these earlier studies, the validity of the
observations has been questioned because the specimens were not precisely
timed, and because it is well recognized that TLRs and cytokine proﬁles change
throughout the cycle.
Study design, size, duration: This is a non-interventional observational
study on the expression of 10 TLRs and 17 different inﬂammatory cytokines in
precisely timed endometrial tissue collected from 83 women with reproductive
failure.
Participants/materials, setting, methods: Endometrial tissue was col-
lected from participants seeking treatment for infertility. All specimens were
collected on day LH+7. Chronic endometritis was deﬁned as plasma cell dens-
ity above normal range established from a fertile control population (> 5.15
CD138+ plasma cells/0.1 mm2, Liu Y et al., in press). TLRs 1-10 were stained
by conventional immunohistochemistry for each speciﬁc antibody. In addition,
17 different inﬂammatory cytokines were analysed with the Luminex technique
(Millipore, Billerica, MA) following protein extraction.
Main results and the role of chance: Among 83 patients studied, 19 were
found to have CE, and the other 64 did not have CE. There was no difference
in age, duration of infertility, and the number of miscarriage between these two
groups.
In women with CE, the endometrial expression of some TLRs was signiﬁ-
cantly altered. In particular, stronger expression of TLR 1, 2, 3, and 4 were
observed in endometrial epithelial and glandular cells when compared with
women without CE.
Among the 17 cytokines examined, the expression of IFN-γ in women with
CE was 3.69 pg/mL, which was signiﬁcantly higher (p = 0.034) than that of in
women without CE, 3.47 pg/mL. However, there was no statistically signiﬁcant
difference found among the other 16 cytokines and chemokines (EGF, G-CSF,
GM-CSF, IL-10, IL-12P40, IL-12P70, IL-13, IL-1α, IL-1β, IL-2, Il-4, IL-5, IL-6,
MCP-1, MIP-1β and TNF-α) studied. The data indicate that altered amount of
IFN-γ in human endometrium with CE may be a result of higher expression of
TLR 1, 2 3, and 4.
Limitations, reasons for caution: The relative small sample size of this
study precludes the analysis of the relationship between conception and preg-
nancy outcome.
Wider implications of the ﬁndings: It appears that adverse effect of CE on
reproduction is mediated via the IFN-γ pathway. Further study should be con-
ducted to explore how alteration of IFN-γ leads to implantation failure with the
regulation of TLRs.
Trial registration number: Chinese Clinical Trials Registry Number:
ChiCTR-IOC-16007882
Funding by Hong Kong Obstetrical and Gynaecological Trust Fund in 2016
and 2018. The authors have s.
P-273 Ovarian Endometriosis: deciphering the underlying
mechanisms using a genomic approaches
Ö. Okutman1,2, K. Boynukalin3, M. Ben-Rhouma2, M. Gultomruk4,
N. Findikli5, M. Bahceci3, J. Muller6,7, S. Viville1,2
1Hôpitaux Universitaires de Strasbourg- Nouvel Hôpital Civil, Laboratoire de
Diagnostic Génétique- UF3472 Infertilité, Strasbourg, France
2Université de Strasbourg- Institut de Parasitologie et Pathologie Tropicale, EA 7292-
Fédération de Médecine Translationelle, Strasbourg, France
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3Bahceci Health Group, IVF Department, Istanbul, Turkey
4Bahceci Health Group, Research and Development, Istanbul, Turkey
5Bahceci Fulya IVF Center, Embryology Laboratory, Istanbul, Turkey
6Université de Strasbourg- Laboratoire de Génétique Médicale, INSERM U1112-
Fédération de Médecine Translationnelle de Strasbourg FMTS, Strasbourg, France
7Hôpitaux Universitaires de Strasbourg, Laboratoire de Diagnostic Génétique,
Strasbourg, France
Study question: Endometriosis has long been suspected of familial tenden-
cies. Our goal is to identify genes involved in the pathogenesis of ovarian endo-
metriosis by using genomic approach.
Summary answer: Whole exome sequencing (WES) on a large consanguin-
eous Turkish family revealed a possible causative gene mutation segregating
with ovarian endometriosis phenotype in the family.
What is known already: Endometriosis is a common gynecologic disease
deﬁned as the growth of endometrial tissue outside the uterine cavity.
Laparoscopic visualization of endometriotic lesions remains the ‘gold standard’
in diagnostic tests. Though, only 70–75% of visually diagnosed lesions are con-
ﬁrmed histologically. Despite its high prevalence and incapacitating symptoms,
the etiology of endometriosis remains unclear. A number of chromosomal loci
have been found to be associated with endometriosis in selective populations;
however genes that play a role in endometriosis remain to be identiﬁed.
Study design, size, duration: This study has been performed at the
Strasbourg University, France in collaboration with the Bahceci Health Group,
Istanbul, Turkey. A large, consanguineous Turkish family having six affected
women in two generations as well as more than two unaffected women was
available for the study. 19 well-deﬁned individual ovarian endometriosis cases
and 20 endometriosis free women were also included for further validation.
Participants/materials, setting, methods: Saliva samples, not pathological
samples, have been used for the WES in order to avoid possible accumulation
of mutations in the pathological samples. Genomic DNA was extracted from
saliva according to the manufacturer’s instructions (DNAGenotech, Ottowa,
Canada). WES was performed on four affected and two non-affected samples
by the Institute of Genetics and Molecular and Cellular Biology microarray and
sequencing platform, member of the ‘France Génomique programme’.
Suspected mutations were conﬁrmed via Sanger sequencing.
Main results and the role of chance:We identiﬁed a heterozygous 3’-UTR
variation in an autosomal gene which is co-segregating with the ovarian endo-
metriosis phenotype in the family. The gene in question is located on chromo-
some 19, belongs to protein family that regulates endometrial epithelial cell
adhesion, trophoblast motility and invasion during implantation. The variation is
predicted to be deleterious via different prediction tools. In order to validate
the identiﬁed mutation and check for other possible mutations in the gene, all
exons and exon/intron boundaries of the identiﬁed gene were ampliﬁed and
sequenced in 19 ovarian endometriosis patients and 20 controls. The analysis is
still on going.
Limitations, reasons for caution:Our study contains only a limited number
of Turkish patients. Mutation screening should be continued on larger groups of
ovarian endometriosis patients, including women of other ethnicities. Also for
obvious ethical reasons, no in-vivo works were possible.
Wider implications of the ﬁndings: In long term, results will help us to
deﬁne potential non-invasive test for ovarian endometriosis. Understanding the
fundamental molecular mechanisms in ovarian endometriosis pathogenesis is
the ﬁrst step to develop novel therapeutic approaches, to eliminate endometri-
osis lesions and to prevent recurrence.
Trial registration number:Not applicable.
P-274 Assisted Reproductive Techniques (ART) and their possible
effect on the progression of endometriosis symptoms
M. Mathiasen1, A.G. Egekvist2, U.S. Kesmodel3,
U. Breth Knudsen4,5, M. Seyer-Hansen2
1Aarhus University and Aarhus University Hospital- Denmark, Department of
Obstetrics and Gynecology, Aarhus, Denmark
2Aarhus University Hospital AUH, Department of Obstetrics and Gynecology, Aarhus,
Denmark
3Herlev and Gentofte University Hospital, Department of Obstetrics and Gynecology,
Herlev, Denmark
4The Regional Hospital in Horsens, The Fertility Clinic, Aarhus, Denmark
5Aarhus University, Institute of Clinical Medicine, Aarhus, Denmark
Study question: Do women with endometriosis experience worsening in
endometriosis symptoms (quality of life, pain, bowel symptoms) when undergo-
ing controlled ovarian stimulation (COS) during assisted reproductive techni-
ques (ART)?
Summary answer: This study did not ﬁnd worsening in the abovementioned
parameters during ART, which supports ART as a suitable therapeutic option
for infertile women with endometriosis.
What is known already: 10-25% of women with endometriosis require ART
to conceive. During COS levels of estrogen increases, hence in theory increas-
ing the risk of progression of symptoms related to endometriosis. Anaf et al.
identiﬁed four cases of rapidly growing sigmoid endometriosis during ovarian
stimulation resulting in cessation of ART and bowel surgery. Ten similar cases
have occurred in our department since 2007. Moreover, isolated cases with
severe worsening of endometriosis during COS have been reported.
Study design, size, duration: Prospective cohort study carried out from
February 2016 to October 2017 with a total of 177 women recruited.
Participants were excluded during the study if they were lost to follow-up, or if
egg retrieval was cancelled. This study is based on questionnaires containing the
Endometriosis Health Proﬁle (EHP-30), and pain and bowel habits were evalu-
ated on the numerical rating scale (NRS). Questionnaires were administered
before and after COS in one cycle of ART.
Participants/materials, setting, methods: Patients < 40 years old were
recruited from three fertility clinics and the endometriosis unit, Aarhus
University Hospital (AUH). Depending on endometriosis diagnosis (conﬁrmed
by previous laparoscopy, transvaginal ultrasound or magnetic resonance
imaging) and ART, patients were assigned one of three groups (endometriosis
with or without ART, or no endometriosis undergoing ART). According to
power calculations each group should include 48 women. Median and mean
changes in pain and quality of life scores are reported.
Main results and the role of chance: 52 women with endometriosis under-
going ART (+Endo/+ART), 50 not undergoing ART (+Endo/-ART), and 52
without endometriosis undergoing ART (-Endo/+ART), answered two
questionnaires.
The three groups differed signiﬁcantly on all pain parameters (general and
worst non-menstrual pelvic pain, dyschezia, dyspareunia, and dysuria) at base-
line, women without endometriosis had a signiﬁcantly better score in all EHP-
30® modules (pain, control and powerlessness, social support and emotional
well-being) except self-image where the groups did not differ. Bowel para-
meters (constipation, diarrhea, nausea, vomiting and bloating) were compar-
able between the groups, except that +Endo/-ART indicated worse bloating.
Changes from 1st to 2nd questionnaire indicated that -Endo/+ART experi-
enced a one NRS point greater worsening in the parameters ‘tired” and ‘general
non-menstrual pelvic pain” compared to women with endometriosis (p =
0.003, and p<0.001). Regarding worst non-menstrual pelvic pain, the median
changes were 1, 2.5, and 0 for +Endo/+ART, -Endo/+ART, and +Endo/-
ART, respectively (p<0.001). Women with endometriosis, undergoing ART or
not, experienced a slight improvement in EHP-30
®
modules during ART com-
pared to -Endo/+ART who worsened in all modules except ‘self-image”. None
of the three groups changed in bowel parameters except bloating where both
ART groups experienced an increase of one NRS point compared to +Endo/-
ART (p = 0.020).
Limitations, reasons for caution: Women with endometriosis were
included regardless of stage, which caused disease heterogeneity. +Endo/-ART
was recruited from a tertiary referral center. Hence, this group may have par-
ticularly severe endometriosis stages. In the group of women without endomet-
riosis subclinical disease might have been present without the clinicians’
knowledge.
Wider implications of the ﬁndings: Our results are in line with previous
studies (Benaglia et al. and Coccia et al.) which further supports ART as a suit-
able therapeutic option for infertile women with endometriosis. Our two refer-
ence groups added new information by allowing differentiation between
changes in parameters caused by ART and endometriosis individually.
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Trial registration number: The Danish Data Protection Agency:
Registration number 2012-58-006). ClinicalTrials.gov: NCT02762461.
P-275 Molecular characterization of PRM associated endometrial
changes (PAEC) followingmifepristone treatment
N.R. Boggavarapu1, C. Berger1, S. Queckbörner1, E. Norlin1,
K. Hornaeus2, A. Falk2, M. Engman1, L. Pgl1, K. Gemzell-Danielsson1
1Karolinska University Hospital, Women and children health, Stockholm, Sweden
2Uppsala University, Analytical chemistry, Uppsala, Sweden
Study question: Does endometrium displaying PAEC after mifepristone
treatment have a characteristic gene and protein expression?
Summary answer: Molecules signiﬁcantly altered in PAEC after mifepristone
exposure are mainly involved in the structural architecture of tissue, which may
explain the morphological features of PAEC.
What is known already: The non-physiological endometrial changes caused
by the progesterone receptor modulator mifepristone, PAEC, have previously
been morphologically described but not explored at molecular level in regards
to both gene and protein expression.
Study design, size, duration: A comparative analysis of gene and protein
expression between endometrium displaying PAEC (n = 7) and endometrium
that did not develop PAEC (n = 6) after three months of mifepristone treat-
ment was performed. The current observational cross-sectional study is part of
a previous randomized, placebo-controlled clinical trial at Karolinska University
Hospital in Stockholm, Sweden.
Participants/materials, setting, methods: Endometrial biopsies, obtained
from pre-menopausal women treated with mifepristone prior to surgery due
to uterine leiomyoma, were evaluated regarding occurrence of PAEC and a
comparative analysis of molecular expression between endometrial samples
displaying PAEC and non-PAEC endometrial samples was performed.
Methods used include microarray analysis, real time PCR, Ingenuity Pathway
Analysis and Proteomics Analysis with Mass Spectrometry and
Immunohistochemistry.
Main results and the role of chance: Combinations of characteristic non-
physiological features were observed in 53.8% of collected endometrial sam-
ples. We observed non-decidualized stroma and both inactive and secretory
active glands as well as extensively apoptotic glands, mitotic glands and apop-
totic degeneration and atrophy.
Microarray analysis showed 181 differentially regulated genes by a minimum
of two-fold in PAEC samples compared to non-PAEC samples. 142 genes were
upregulated and 39 were downregulated. Microarray ﬁndings were validated by
real time PCR for nine genes, three of them, THY1 (p = 0.02, fold change (FC)
= 3.18), ADAM12 (p = 0.04, FC = 3.28) and TN-C (p = 0.04, FC = 3.21)
reported in endometrial function were differentially regulated with PAEC. The
proliferation marker MKi67 was not statistically signiﬁcantly altered between
the groups.
Mass spectroscopic analysis showed 25 proteins upregulated and 5 downre-
gulated in endometrium with PAEC compared with non-PAEC and most of the
proteins including TUBA4A (p = 0.002), MYOF (p = 0.006), TPM4 (0.013),
RRBP1 (p = 0.021) and CSRP1 (p = 0.001), DPYSL3 (p = 0.012), FMOD (p =
0.045) are involved in tissue morphology. Mass spectrometry ﬁndings were val-
idated with immunohistochemistry and were found to be in accordance with
mass spectrometry results, but none of the tested antibodies were statistically
signiﬁcant by immunohistochemistry.
Limitations, reasons for caution: Although most of the endometrial sam-
ples from the clinical trial were used for analysis in this study, the main limitation
is the small sample size. 14 women were randomized to receive mifepristone in
the pilot study.
Wider implications of the ﬁndings: Our study has generated new knowl-
edge on the molecular proﬁle of endometrium displaying PAEC after 3 months
of mifepristone treatment due to symptomatic leiomyoma. This knowledge is
of great importance as the application of progesterone receptor modulators
(PRMs) for the medical management of benign gynecological conditions is
increasing.
Trial registration number: www.clinicaltrials.gov:NCT00579475
P-276 Endometriosis pathogenesis: role played by the oxidative
stress due to MTHFRmutations
A. Clement1, D. Cornet2, P. Neveux1, P. Clement1, Y. Menezo1
1Laboratoire Clement, Laboratoire Clement, PARIS, France
2Clinique de la Muette, Paris, Paris, France
Study question: Can endometriosis in infertile patients be linked to the oxida-
tive stress due to methylenetetrahydrofolate reductase (MTHFR) mutations?
Summary answer: A clear relationship has been established between
MTHFR mutations and the pathogenesis of endometriosis. Treating patients to
by-pass MTHFR mutations consequences improves ART outcomes.
What is known already: Endometriosis pathogenesis is unclear and its eti-
ology is complex. Recent studies mention the role of oxidative stress implicated
in the pathophysiology of endometriosis by causing a general inﬂammatory
response in the peritoneal cavity (Augoulea, 2009).
MTHFR is a key enzyme involved in folate metabolism and in the genesis of
major antioxidant molecules (gluthatione, hypotaurine). Oxidative stress can be
induced by polymorphisms of MTHFR through the increased homocysteine
level (Guo, 2016).
To our knowledge, no study in the literature analyzed the role played by
MTHFR in the endometriosis genesis of infertile patients.
Study design, size, duration: From January 2016 to january 2018, we fol-
lowed 30 infertile patients suffering from endometriosis and having had at least
1 ART (Assisted Reproductive Technologies) cycle failure.
At ﬁrst, we compared the MTHFR mutations distribution in our population.
The patients carrying a MTHFR mutation were afterwards treated and we
compared the pregnancy rates obtained before and after treatment.
Participants/materials, setting, methods: All the infertile patients
involved in this study were diagnosed with endometriosis according to the
ESHRE 2013 guidelines.
The presence of MTHFR C677T was determined from a venous blood sam-
ple, using real time PCR with the RealFastTM assay (ViennaLab Diagnostic
GMBH, Vienna, Austria).
The infertile patients with recurrent ART failures (2 to 7) and carrying
MTHFR mutations were treated with 5MTHF (5 Methylene Tetrahydrofolate),
a treatment by-passing the problems linked to MTHFR impaired activity.
Main results and the role of chance: Among the endometriosis population
of our study, 60% of the patients are carrying the MTHFR mutation (46.7% in a
heterozygous state, 13.3% in a homozygous state). This proportion is signiﬁ-
cantly more important (p<0.05) than the proportion of patients carrying
MTHFR mutations in the general population: 50.5% (Zappacosta, 2009).
Furthermore, after we treated infertile couples with endometriosis and
recurrent ART failures (2-7) carrying MTHFR mutations, we signiﬁcantly
improved their ART outcomes (average ongoing pregnancy rate per cycle:
23.4% before treatment; 29.6% after treatment, p<0.05).
Limitations, reasons for caution: Our results needs to be conﬁrmed on a
larger population. The genetic analysis of the MTHFR gene needs to be enlarged
to other mutations related to the one carbon cycle in order to screen all the
patients in which fertility could be affected by oxidative stress due to MTHFR
mutations.
Wider implications of the ﬁndings: Endometriosis can be explained by
MTHFR mutations. The resulting oxidative stress impairs the fertility of the
female patients.
Therefore, by improving the methylation and decreasing the oxidative stress,
treating MTHFR mutation carriers improves the quality of the gametes and their
ART outcomes.
Trial registration number:None.
P-277 Functional genomic meta-analysis identiﬁes similarities
between endometrial-related subfertilities
A. Devesa-Peiro1, P. Sebastian-Leon2, F. Garcia-Garcia3, V. Arnau4,
A. Pellicer5, P. Diaz-Gimeno2
1University of Valencia / IVI-RMA Fundación IVI. Genomic & Systems Reproductive
Medicine, Valencia, Spain
2IVI-RMA Fundación IVI. Instituto de investigación sanitaria INCLIVA- University of
Valencia, Research. Genomic & Systems Reproductive Medicine, Valencia, Spain
i267Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
3Centro de Investigación Príncipe Felipe CIPF, Unit of Bioinformatics and Biostatistics,
Valencia, Spain
4University of Valencia-CSIC, ETSE. Institute for Integrative Systems Biology I2SysBio,
Valencia, Spain
5IVI-RMA Fundación IVI. Instituto investigación sanitaria La FE- University of Valencia.,
Reproductive Medicine. Pediatrics- Obstetrics and Gynecology, Valencia, Spain
Study question: Are there relevant enriched functions shared both within
and between endometrial-related subfertilities as endometrial adenocarcinoma,
endometriosis, Recurrent Implantation Failure (RIF) and Recurrent Pregnancy
Loss (RPL)?
Summary answer: Speciﬁc enriched functions were common between all
considered endometrial-related subfertilities. RIF and endometriosis were the
most similar, and RPL differed from all others.
What is known already: Endometrial-related pathologies are complex,
multifactorial conditions affecting female fertility. Prior studies described endo-
metrial adenocarcinoma, endometriosis, RIF, and RPL through transcriptomics
analysis using case vs control approaches to identify altered genes and functions.
However, the underlying mechanisms linking these conditions to endometrial
subfertility remain controversial due to small sample sizes and differing experi-
mental designs. Functional meta-analysis techniques provide a more robust
method to highlight the most important functions associated with a set of indi-
vidual studies. The objective of this research was to identify enriched shared
functions within and between endometrial-related subfertilities studies for
robustly underlaying the common molecular basis.
Study design, size, duration: An in-silico study involving systematic review,
transcriptomic analysis, and functionally integrative meta-analysis was applied to
selected case vs control experiments associated with endometrial-related path-
ologies. From 613 datasets, we included 3 from endometrial adenocarcinoma,
2 from RIF, 2 from RPL, and 2 from eutopic endometrium of endometriosis.
Functional meta-analysis techniques were employed to a) separately identify
shared functions and pathways related to each single condition; and b) to deter-
mine altered functions common between endometrial-related conditions.
Participants/materials, setting, methods: Raw data were downloaded
from Gene Expression Omnibus (GEO). Selected datasets were pre-
processed, normalized using quantile method (Limma R-package), and explored
through principal component and clustering analysis. Gene Set Enrichment
(mdgsa R-package) was performed on differential expression analysis results
(Limma R-package). Functional meta-analysis was performed using Der-
Simonian & Laird random-effects model to identify signiﬁcant shared functions
(False Discovery Rate (FDR) < 0.05). Functional databases consulted were
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes.
Main results and the role of chance: Functional meta-analysis allowed us to
identify functional connections within studies related to each endometrial-related
pathology. Functions such as cell junctions, p53 signaling pathway, endoplasmic
reticulum, and cell adhesions (3.9412e-07<=FDR< = 0.00016) were associated
with adenocarcinoma; proteasome complex, amine transport, apical part of cell,
and chromosome-related functions (7.2107e-06<=FDR< = 0.04849) with RIF;
DNA replication and ribonucleoprotein complex (0.00035<=FDR< = 0.04281)
with RPL; and proteasome, mitochondria, and microtubule-related processes
(0.00434<=FDR< = 0.04823) with endometriosis. Results from integrating all
endometrial subfertilities (adenocarcinoma, RIF, RPL, endometriosis) identiﬁed 8
shared functions related to cell projections (0.00282<=FDR< = 0.03690), chro-
matin DNA binding (FDR = 0.0440), and organelle assembly (0.00053<=FDR<
= 0.0336). Furthermore, when RPL, RIF, and endometriosis were integrated by
pairs, RPL was the least similar, having only one common function with RIF
(FDR = 0.0484) and 8 with endometriosis (1.0609e-05<=FDR< = 0.04390).
RIF and endometriosis were the most similar, sharing 21 functions (1.1262e-
08<=FDR< = 0.04823). Finally, those pathologies involving tissue growth
(endometrial adenocarcinoma and endometriosis) were found to have a higher
number of altered genes and functions than RIF or RPL.
Limitations, reasons for caution: Despite including good-quality GEO
datasets, this study is limited by available endometrial-related subfertilities and
the heterogeneity between studies. However, all datasets were transcriptomi-
cally analyzed using the same methodology and the applied meta-analysis incor-
porates the variability of each study, robustly integrating them at a functional
rather than at a gene level.
Wider implications of the ﬁndings: Due to functional alteration similarities
between endometriosis and RIF, there is evidence that eutopic endometrium is
affected, supporting the controversial idea that endometriosis affects endomet-
rial function. Shared detected functions between all considered endometrial
subfertilities could enable development of a common method to diagnose all of
them.
Trial registration number: not applicable.
P-278 Interventions for endometriosis related infertility: a
systematic review and networkmeta-analysis
R. Hodgson1, H.L. Lee2, R.Wang3, B.W.J. Mol3, N. Johnson3
1Cairns Hospital, Women’s Health, Cairns, Australia
2Adelaide University, School of Medicine, Adelaide, Australia
3Robinson Research Institute, University of Adelaide, Adelaide, Australia
Study question: What is the comparative effectiveness of different treat-
ments for women with endometriosis associated subfertility?
Summary answer: More research is required to clarify the relative effective-
ness of treatments for endometriosis-related infertility.
What is known already: Most recognised therapies have not been directly
compared in randomised controlled trials, therefore there is no direct evidence
to inform clinical decision-making, hence selection of the most effective treat-
ment is difﬁcult. NMA compares multiple treatments in one statistical model. It
is possible to guide treatment decision-making through the provision of a hier-
archy of effectiveness of the treatment options. In the setting of subfertility
related to endometriosis, the ability to apply this model is invaluable, as it is an
area where there are numerous intervention options, and it has the potential to
promote selection of the optimal therapy.
Study design, size, duration: A systematic review and network meta-
analysis of relevant randomised control trials (RCTs) was performed. We
searched electronic databases including, MEDLINE, Embase and the Cochrane
Central Register of Controlled Trials (CENTRAL), as well as reference lists to
identify eligible studies.
Participants/materials, setting, methods: We included RCTs comparing
any medical or surgical interventions to each other or placebo/ no treatment in
couples with endometriosis associated subfertility. The primary effectiveness
outcome is a composite of clinical pregnancy.
Main results and the role of chance: 4,252 titles/abstracts were identiﬁed
through the literature search, of which we included 27 trials reporting on 2,195
women with endometriosis associated subfertility. We included 14 different
interventions in NMA. The most frequent direct comparisons were surgical
laparoscopy versus surgical laparoscopy plus gonadotrophin releasing hormone
analogues (GnRHa) (7 studies, 686 women), surgical laparoscopy versus pla-
cebo (3 studies, 483 women), GnRHa versus danazol (4 studies, 127 women)
and danazol versus placebo (2 studies, 99 women). All 27 studies reported on
clinical pregnancy. In vitro fertilisation (IVF) and intrauterine insemination (IUI)
could not be included in the NMA, as RCTs compared only different stimulation
protocols for IVF and for IUI and none of the RCTs compared IUI or IVF versus
no treatment, placebo or other interventions.
Network meta-analysis showed that compared to placebo, Lipiodol (OR
7.56, 95% CI 1.95-29.37) and surgical laparoscopy plus pentoxifylline (OR 3.44,
95 CI 1.08-10.93) resulted in more clinical pregnancies; GnRH-a (OR 1.54, 95%
CI 0.93-2.56) and surgical laparoscopy OR 1.43, 95% CI 0.93-2.56) were likely
to result in more clinical pregnancies. Dydrogesterone (OR 3.00, 95%CI 0.69-
13.30), pentoxifylline ( OR 1.98, 95%CI 0.55-7.17) and laparoscopy plus dana-
zol ( OR 1.72, 95%CI 0.34, 8.78) showed imprecise effect sizes.
Limitations, reasons for caution: The CIs in most interventions with large
ORs were imprecise and therefore should be exercised with caution. The value
of the NMA was limited as IVF and IUI could not be included. Live birth was
reported in only 5 studies in the network meta-analysis.
Wider implications of the ﬁndings: The most important conclusion is that
more RCTs are needed to clarify the relative effectiveness of treatments for
endometriosis-related infertility, in particular RCTs comparing IVF or IUI to other
treatments including surgical laparoscopy and lipiodol to other treatments.
Trial registration number:N/A.
i268 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
P-279 The role of reproductive tract microbiome in infertility
V. Gota, M.R. Mitropoulou, S. Arkouli, G. Basios, T. Arkoulis
IVF Mitosi, Embryology Lab, Pireaus, Greece
Study question: How the microbiome of the endometrium of asymptomatic
women with a history of infertility inﬂuences IVF techniques?
Summary answer: The molecular investigation of endometrium tissue from
infertile women for common microbes unravels “silent” infections that may
affect on Assisted Reproductive Technologies (ART).
What is known already: The human microbiome has gained much attention
recently for its role in health and disease. Sexually transmitted infections are a
major concern to clinicians and researchers in the ﬁeld of reproductive medi-
cine especially if the inﬂammation concerns the endometrium. An untreated
inﬂammation caused by those agents, can lead to serious consequences, includ-
ing miscarriages, tubal obstruction, preterm birth, chronic pelvic pains and
unexplained infertility. The most common used method for microbe detection
is based on culture results of cervicovaginal secretions. However, this diagnostic
method is insufﬁcient since it is difﬁcult to detect any kind of infection in the
upper genital tract.
Study design, size, duration: The aim of our study is to use the endomet-
rium as a study material for the molecular detection -using real time PCR- of
Chlamydia trachomatis, Ureoplasma sp, Mycoplasma hominis, Mycoplasma genital-
lium and Herpes I/II. In order to subtract cervicovaginal secretions and to
detect microbes directly from the endometrium, we used a pipelle suction to
retrieve the material. In the present study, endometrium tissue samples of
Greek women were collected from January 2013 till December 2017.
Participants/materials, setting, methods: The study group was a total of
358 Greek women of age 36.4 ± 4,8 (Mean ± St.Dev) with fertility problems.
Endometrium samples were collected with endometrial biopsy under hystero-
scopy with mild sedation of the women and were screened for the presence of
Chlamydia trachomatis, Ureoplasma sp, Mycoplasma hominis, Mycoplasma genital-
lium and Herpes I/II by real time PCR. The procedure of sample collection try-
ing to mimic the embryo transfer technique.
Main results and the role of chance: In the overall study group, the preva-
lence of Chlamydia trachomatis was 1.1%, Ureoplasma sp was 7.26%,
Mycoplasma hominis was 0.83%, Mycoplasma genitalium was 0.27% and Herpes
I/II was 0.27%. There is a prevalence of Ureoplasma sp infection in the upper
genital tract of infertile women. These ﬁndings suggest that microbiome present
in the upper genital tract and could be detected efﬁciently by molecular techni-
ques (real time PCR).
Limitations, reasons for caution: The sample collection occurs under mild
sedation of the women.
Wider implications of the ﬁndings:Our study suggests that there is a pos-
sible correlation with uterus microbiome and infertility. In addition, our results
demonstrate that the investigation of endometrium tissue for infectious
microbes by using real time PCR, could be used as an alternative technique,
unraveling a “silent infection”.
Trial registration number:Not applicable.
P-280 Effect of endometriosis on spermmotility and organization
of the tail microtubules
P. Lorca1, I. Velasco2, P. Sáez3, M.I. Acien2, M.J. Gomez3
1Universidad Miguel Hernández de Elche, Medicina Clinica, San juan de alicante,
Spain
2Universidad Miguel Hernández de Elche, Salud Pública- Historia de la Ciencia y
Ginecología, San Juan de Alicante, Spain
3Universidad de Alicante, Biotecnología, Alicante, Spain
Study question: To evaluate in vitro the effect of peritoneal ﬂuid (PF) from
women with endometriosis on sperm motility and organization of the sperm ﬂa-
gellar structure.
Summary answer: In vitro exposure of sperm to endometriosis PF is asso-
ciated with an early decrease of progressive motility and an alteration of the tail
microtubules.
What is known already: Endometriosis is a hormone-dependent disease
associated with infertility in 30% of patients. The peritoneal ﬂuid (PF) of women
with endometriosis decreases sperm function and interfere with the correct
oocyte-sperm interaction. The clinical relevance of sperm motility is evident,
but the molecular mechanisms involved in this process have not yet been fully
understood.
Study design, size, duration: Experimental study. 36 patients were
recruited for the study obtaining the sample of PF during surgery (18 patients
with endometriosis and 18 with other benign ovarian cysts).
Participants/materials, setting, methods: Human donor sperm was incu-
bated during 24 and 48 hours in absence (control group) or presence of PF
diluted at 20% from women with (n = 18) and without endometriosis (n = 18).
Sperm motility was assessed by optical microscopy and the organization of the
sperm tail microtubules was evaluated by ﬂuorescence microscopy (alpha-tubu-
lin immunostaining) in all experimental conditions, evaluating three types of
patron after staining: 1) continuous tail; 2) discontinuos tail; and 3) not stained
tail.
Main results and the role of chance: Sperm motility decreased signiﬁcantly
along the time of culture in all conditions. The greatest difference was observed
at 24 hours, being a higher decrease in endometriosis group compared to non-
endometriosis group (p = 0.004) and control (p = 0.001). Regarding to the
alpha-tubulin distribution, the greatest difference was observed at 48 hours of
culture in all patrons: 1) continuous tail, p = 0.008; 2) discontinuos tail, p =
0.002; and 3) not stained tail, p = 0.046, comparing endometriosis versus non-
endometriosis group.
Limitations, reasons for caution: The main limitation of our study is the
introduction of a possible variability in the basal cell properties because of the
selection of four different human sperm donors. Moreover the sample size
must be increased in order to establish deﬁnitive conclusions.
Wider implications of the ﬁndings: Previous studies have described
altered sperm motility comparing PF from endometriosis patients to healthy
women. In our study, we compared the condition of endometriosis to other
ovarian pathologies, showing that quality sperm is more affected by factors pre-
sent in the endometriosis PF.
Trial registration number:NA.
P-281 Comparing the clinical efﬁcacy of intrauterine cook balloon
and contraceptive device in preventing adhesion reformation and
improving pregnancy outcomes after hysteroscopic adhesiolysis in
IVF/ICSI
H. Chen1, Y. Li2, H. Guo3, G.X. Lu2, G. Lin2, F. Gong2
1Reproductive and Genetic Hospital of CITIC-XIANGYA, Reproductive center,
Changsha, China
2Institute of Reproductive and Stem Cell Engineering- Basic Medicine College- Central
South University-Reproductive and Genetic Hospital of CITIC-XIANGYA, China,
3Reproductive and Genetic Hospital of CITIC-XIANGYA, China,
Study question: Are the intrauterine cook balloon effective for preventing
adhesion reformation and improving pregnancy outcomes?
Summary answer: The long term intrauterine cook balloon placement for 2
months with hormone replacement therapy are efﬁcacy in preventing adhesion
reformation and improving clinical outcomes.
What is known already: There are many strategies now available to prevent
adhesion recurrence and restoring endometrium. Previous studies have
described that intrauterine cook balloon and IUD are of similar efﬁcacy in the
prevention of adhesion reformation. But both devices were removed only after
1 week. The recurrence of adhesion rate is 10-30%, and the study did not
report the pregnancy outcomes following the treatment. Limited dates are
available whether to increase days of cook balloon stents can decrease the
recurrence of adhesion rate and remove the balloon in the FET cycle can pro-
mote endometrial proliferation and improve the clinical pregnancy rate.
Study design, size, duration: This retrospective analysis involved 566 infer-
tile women with moderate to severe intrauterine adhesion and received the
frozen thawed embryo transfer (FET) cycle at the Reproductive and Genetic
Hospital of CITIC-Xiangya between October 2016 and July 2017.
Participants/materials, setting, methods: The patients in the cook bal-
loon group were matched by 1:2 with IUD controls. At the end of the hystero-
scopy procedure the patients were ﬁtted with cook balloon or IUD for 2
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months. In all cases hormone replacement therapy was commenced since the
third day of menstrual cycle that the ﬁrst hysteroscopy were carried out, until
FET cycle which second-look hysteroscopy was carried out in the proliferative
phase 2 months after the ﬁrst surgery.
Main results and the role of chance: According to the inclusion criteria
and exclusion criteria, there were 76 cook balloon patients and 152 IUD con-
trol patients.
The hysteroscopy outcomes suggested that there was no statistical different in
adhesion grade( P = 0.647), American Fertility Society (AFS) score before
operation(6.8 ± 1.31vs 6.58 ± 1.28, P = 0.233) in two groups. But compared
to IUD group, the AFS score after operation(P = 0.00) and recurrence of adhe-
sion(1.32%vs 20.4%, P = 0.00) were signiﬁcantly decreased in cook balloon
group. It is comparable to the endometrial thickness on embryo transfer (ET)
day(9.65 ± 1.12vs 9,66 ± 1.66,P = 0.963), number of embryo transferred
(1.30 ± 0.61vs 1.36 ± 0.58, P = 0.527), high quality embryo rate(55,71%vs
51.38%, P = 0.552) and cancellation rate(7.89% vs 5.26%, P = 0.435) between
cook balloon group and IUD group. The clinical outcomes suggested that the
implantation rate(32.32% vs 19.43%;P = 0.013), clinical pregnancy rate(44.28%
vs 25%;P = 0.004), ongoing pregnancy rate(40% vs 20.83%;P = 0.003) in cook
balloon group are higher than IUD group.
Limitations, reasons for caution: Lack the evaluating of the bacterial colon-
ization or infection in the uterus after 2 months with cook balloon stent. Well-
designed, adequately powered random controlled trials are needed.
Wider implications of the ﬁndings: Long term intrauterine cook balloon
placement can improve the pregnancy outcomes of infertile women with mod-
erate to severe intrauterine adhesion.
Trial registration number: none.
P-282 A long-term pretreatment with GnRH agonists prior to IVF/
ICSI does not improve the clinical pregnancy rate in patients with
endometriosis: a systematic review
A.A. Marino1, S. Gullo2, A. Volpes1, F. Sammartano1, A. Maiorana3,
A. Allegra1
1ANDROS Day Surgery Clinic, Reproductive Medicine Unit, Palermo, Italy
2ANDROS Day Surgery Clinic, Medical Statistics Unit, Palermo, Italy
3A.R.N.A.S. Civico Hospital, Department of Obstetrics and Gynecology, Palermo,
Italy
Study question: Does a long-term pituitary suppression with GnRH agonists
prior to IVF/ICSI improve the clinical pregnancy rate (CPR) in patients with
endometriosis?
Summary answer: In endometriosis, a long-term pituitary suppression does
not improve the CPR, increases the stimulation duration and total gonadotro-
pins dose, reducing the number of retrieved oocytes.
What is known already: The mechanisms of endometriosis-associated infer-
tility have been debated for years and they are still unclear. Excluding altered
pelvic anatomy, these mechanisms include: abnormal folliculogenesis, elevated
oxidative stress, altered immune function. In IVF, these factors lead to poor
oocyte quality, impaired fertilization and implantation. In order to increase
pregnancy rates in patients with endometriosis, various approaches have been
proposed. A meta-analysis (Sallam et al., 2006) demonstrated that a down-
regulation for 3-6 months with GnRH agonists prior to IVF/ICSI increases the
odds of clinical pregnancy by >4-fold. This meta-analysis was included in the
ESHRE guidelines published in 2014 (grade of recommendation B).
Study design, size, duration: A systematic review, based on PubMed, ISI-
Web, Cochrane CENTRAL, EMBASE, was conducted to verify the effective-
ness of the long-term pretreatment with GnRH agonists in patients with endo-
metriosis. According to PICO format, inclusion criteria were: Population,
endometriosis patients; Intervention, long-term pretreatment with GnRH ago-
nists; Control, no long-term pretreatment; Outcome, clinical pregnancy in
patients undergoing IVF/ICSI. Secondary outcomes were: duration of stimula-
tion, total dose of gonadotropins, oocytes retrieved, fertilization rate (FR),
embryos transferred, ongoing pregnancy rate (OPR).
Participants/materials, setting, methods: A bibliographic search was
undertaken from 2006 to 2017, yielding 54 studies. Three researches (A.M., S.
G., A.V.) reviewed independently the studies, excluding 36 studies after the ﬁrst
screening (title and abstract) and 10 studies after the second screening. The
Mantel-Haenszel method was used to calculate odds ratios (OR) and hetero-
geneity among studies (I2). The results were expressed as OR with 95% conﬁ-
dence intervals (CI). Standardized mean differences (SMD) between groups
were used for continuous outcomes.
Main results and the role of chance: Eight studies were included. Three
were RCTs; the remaining studies were cohort/case-control.
In two studies (Söritsa et al., 2015, Decleer et al., 2016), stage I-II endometri-
osis was considered; in three studies (Ma et al., 2008; Tamura et al., 2014; van
der Houwen et al., 2014), stage III-IV endometriosis; in two studies (Surrey
et al., 2010; Rodriguez-tarrega et al., 2016) all stages. In one case (Gong et al.,
2009), the endometriosis was not classiﬁed.
The female age was comparable among the studies.
CPR was not signiﬁcantly different in women receiving the long-term pre-
treatment compared with the control group (OR 1.25, 95% CI 0.82 to 1.91, I2
= 0%). No differences in FR (OR 0.83, 95% CI 0.51 to 1.35, I2 = 0%), number
of embryos transferred (t=-1.26, p = 0.21, SMD -0.19, 95%CI -0.49 to 0.11, I2
= 64%) and OPR (OR 1.36, 95% CI 0.80 to 2.31, I2 = 0%) were observed. The
patients pretreated had a lower number of oocytes retrieved in comparison
with control group (t = -2.53, p = 0.01, SMD -0.20, 95%CI -0.35 to -0.04, I2 =
36%), such as a longer duration of stimulation (t = 2.49, p = 0.01, SMD 0.41,
95%CI 0.09 to 0.73, I2 = 76%), and a higher total dose of gonadotropins (t =
2.40, p = 0.07, SMD 0.48, 95%CI 0.09 to 0.88, I2 = 84%).
Limitations, reasons for caution: In selected studies, patients with different
stages of endometriosis were included. The couples’ basal characteristics (AFC,
AMH, FSH, BMI, seminal parameters, previous surgery) were not indicated in
all the studies. Although the duration of the pretreatment with GnRH agonists
was comparable among the studies, the formulations and dosages were
different.
Wider implications of the ﬁndings: This review indicates no improvement
in terms of IVF/ICSI success when the endometriosis patients are pretreated
with GnRH agonists. We believe that diagnosis of endometriosis is not a critical
parameter in the choice of treatment protocol.
Further well-designed studies are needed to corroborate our results.
Trial registration number:Not applicable.
P-283 Impact of endometriosis on assisted reproduction
cumulative outcome
A. Bazzocchi, C. Zacà, M. Cattoli, M.A. Bonu, A. Borini
9.baby Family and Fertility Center, Assisted Reproduction, Bologna, Italy
Study question: Is cumulative live birth rate (CLBR) impaired in endometri-
osis patients?
Summary answer: Cumulative birth rate is overall signiﬁcantly lower in endo-
metriosis patients, compared to idiopathic infertility, but the signiﬁcance disap-
pears when adjusted for number of oocyte retrieved.
What is known already: Endometriosis can cause adhesive disease that
alters pelvic anatomy and may yield an inﬂammatory altered immune environ-
ment that has the potential to impact oocyte quality, embryogenesis and
implantation.
Several studies, including systematic reviews and meta-analyses, have yielded
conﬂicting results regarding the impact of endometriosis on ovarian reserve and
IVF outcomes; some suggest comparable ART outcomes between women with
and without endometriosis, whereas others suggest that the presence of endo-
metriosis negatively affects ART success, but cumulative success rates have not
yet been analyzed.
Study design, size, duration: This is a retrospective cohort study. 1672
patients diagnosed with idiopathic infertility and 387 endometriosis patients
who underwent IVF between 2009 and 2012, were included.
Participants/materials, setting, methods: CLBR has been calculated by
adding up births resulting from fresh embryotransfer and births from thawing
embryo cycles, per number of oocyte retrievals.
CLBR was evaluated in idiopathic group and endometriosis group. A further
analisys included stratiﬁcation per age and per number of oocytes retrieved.
Patiens aged < 37 years and 38-45 years, with more than 8 oocytes retrieved
were analyzed in the two groups.
i270 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Main results and the role of chance: Number of oocytes retrieved was
overall statistically lower in endometriosis group (6.3 vs 8.1; p< 0.001), as well
as CLBR (16.5 % vs 21.8; P< 0.001).
In patients younger than 37 years old, with more than 8 oocytes retrieved
(respectively 13.2 and 11.9 on average, in idiopathic and endometriosis; p =
ns), CLBR was comparable between the two groups, with a tendency towards
worse results in endometriosis group (41.5 % and 32.9%, p = ns)
In patients aged 38-45 years old, with more than 8 oocytes retrieved
(respectively 12.5 and 13.8 on average, in idiopathic and endometriosis; p =
ns), CLBR was comparable between the two groups, with even a tendency
towards better results in endometriosis group (23.6 % and 29.2%, p = ns).
Therefore, the cumulative outcomes of assisted reproduction seem to be
impaired by endometriosis, mainly by reducing the number of oocytes
retrieved. When the number of oocyted retrieved is the same, cumulative birth
rate is not statistically reduced in endometriosis patients, not even in older
patients.
Limitations, reasons for caution: The study groups are quite small. The
endometriosis group includes all endometriosis stages.
Wider implications of the ﬁndings: Given the importance of the number
of oocytes retrieved in endometriosis, ovarian reserve should be preserved
from radical surgery and ovarian stimulation should be personalized and
improved, in order to obtain a good number of oocytes.
Trial registration number:Not applicable.
P-284 The sensitivity of DNA damage response target ovarian gap
junction proteins in granulosa cells in women with advanced
endometriosis
R. Chattopadhyay1, S. Ghosh2, S.K. Goswami2, G. Bose2, K. Jana3,
G. Ganguly Mukherjee4, P. Chakraborty4, B. Chakravarty2
1Institute of Reproductive Medicine, ART, Calcutta, India
2Institute of Reproductive Medicine, Assisted Reproductive Technology, Calcutta,
India
3Bose Institute, Molecular Medicine, Kolkata, India
4Institute of Reproductive Medicine, Infertility, Calcutta, India
Study question: What is the impact of DNA damage response (DDR) on
granulosa cells (GC) in women with advanced endometriosis?
Summary answer: Double strand breaks (DSBs) trigger ATM/ATR/Chk1
axis to activate DDR suppressing ovarian gap junction protein (GJP) expression
in GCs in advanced endometriosis.
What is known already: Endometriosis is a disease associated with elevated
reactive oxygen species (ROS), both in follicular environment and systemically.
DSBs are the most critical type of DNA damage which activate signal transduc-
tion by ataxia telangiectasia mutated (ATM), ataxia telangiectasia (ATR) and
Rad3-related proteins to promote DNA repair and arrest cell cycle. However,
recent data document other factors besides DDR proteins responsible for
detection of DSBs in mouse granulosa cell DNA. Attenuation of ovarian GJP
(connexins (Cx)) involves decreased follicular development and growth retard-
ation in oocytes. There is little information whether DDR target Cx proteins to
alter follicular growth in advanced endometriosis.
Study design, size, duration: Experimental study; Samples of follicular ﬂuid
(FF) and GC were obtained from February 2016 to October 2017 from 48
infertile women, 14 with early endometriosis, 23 with advanced endometriosis
and 11 with tubal or male factors of infertility as control group, who underwent
ovarian stimulation for IVF at our Assisted Reproduction unit. FF was obtained
during oocyte retrieval and MGC were isolated from the follicular ﬂuids of each
woman through a Histopaque gradient.
Participants/materials, setting, methods: GCs were exposed to FF to
estimate ROS production by ﬂow-cytometry. DNA damage was assessed by
immunoﬂuorescence to quantify histone-H2AX phosphorylation (γH2AX) foci.
DDR (pATM, ATR, Chk1, GADD45G) and ovarian GJP expression (Cx 37, 43)
were evaluated by immunoblot in MGCs. Effect of DDR on Cxs in endometrial
epithelial cell line (RL95-2) was evaluated with addition of 10 mm ATM,ATR,
Chk1,and GADD45 inhibitors by immunoblot. P <0.05 was considered to be
signiﬁcant as evaluated by Student’s t-test.
Main results and the role of chance: GCs exposed to 50 μl/ml FF for up
to 24 hours led to a signiﬁcant increase in ROS production in both early and
advanced endometriosis. No signiﬁcant difference was observed between GCs
in early endometriosis and controls in γH2AX foci assay; however, induction of
DSBs was noted in advanced endometriosis showing more γH2AX foci
(P<0.01). Increased levels of ROS and cell death induced by γH2AX accumula-
tion result in the activation of DDR components in early and advanced endo-
metriosis; pATM (NS, P<0.01), ATR (NS, P<0.01), Chk1 (NS, P<0.025), and
GADD45G (P< 0.05, P<0.03). Moreover, a signiﬁcant diminution was
observed in Cx 37 (NS, P<0.01) and 43 (NS, P<0.03) protein expressions of
GCs in early and advanced endometriosis. To evaluate the effect of DDR on
Cxs in vitro, we observed addition of ATM inhibitor, ATR inhibitor and Chk1
inhibitor ameliorated the protein expression/s in the culture system consider-
ably (P<0.001). However, a combination of all four inhibitors demonstrated no
extra advantage. Taken together, the ﬁndings suggest that a reduction in both
Cx protein expressions in advanced endometriosis after DSBs requires ATM/
ATR/Chk1 activity, suggesting possible arrest in early pre-antral and antral folli-
cles impeding folliculogenesis leading to production of incompetent oocytes.
Limitations, reasons for caution: Small sample size; Signals emitted from
GCs is solely due to an increase in ROS was not evaluated by a ROS inhibitor
either in early or advanced endometriosis. In addition, no positive control has
been used for the experimental set-up/s.
Wider implications of the ﬁndings: DDR induced by increased ROS alter
oocyte-granulosa cross talk to inﬂuence follicular growth and maturation in
women with advanced endometriosis in GCs. Identiﬁcation of other gap junc-
tional proteins and elucidation of their physiological functions within the follicle
must be research priorities of the future.
Trial registration number:Not applicable.
P-285 Systemic inﬂammation and coagulation status in stage 3-4
endometriosis
A. Vural1, M. Dizdar2, S. Sahin2, B. Ergin2, R. Arısoy3,
B. Mohammadi4, G. Kıran2
1Ümraniye EAH, Obstetrics and gynecology, İstanbul, Turkey
2Health Sciences University- Umraniye Research and Education Hospital, Obstetrics
and Gynaecology, Istanbul, Turkey
3Memorial Atasehir Hospital, Department of Obstetrics and Gynecology, İstanbul,
Turkey
4University College of London - EGA Institute for Women’s Health, Prenatal Genetics
and Fetal Medicine, London, United Kingdom
Study question: Do the coagulation and inﬂammation status differ in women
with surgically conﬁrmed Stage III- IV endometriosis?
Summary answer: Neutrophil count and mean platelet volume are higher in
women with stage-III/IV endometriosis and activated partial thromboplastin
time is shortened compared to benign gynecologic pathologies.
What is known already: Local inﬂammatory process has a pivotal role in the
pathogenesis of endometriosis. However, the role of systemic inﬂammation in
the pathogenesis of endometriosis is unclear.
Study design, size, duration: This retrospective cohort study used data
from a single medical center from 2012 to 2017.
Participants/materials, setting, methods: A total of 321 women who
underwent surgery were evaluated. The case group (n: 220) included patients
with a surgical diagnosis of stage III-IV endometriosis. The control group (n:
101) consisted of women with a surgical diagnosis of benign gynecologic path-
ology. The routine preoperative tests including complete blood count para-
meters, activated partial thromboplastin time, prothrombin time and
International Normalized Ratio (INR) were obtained at a maximum of 1 month
before surgery.
Main results and the role of chance:Mean platelet volume (MPV) and neu-
trophil count were higher in patients with endometriosis when compared to
controls (8,63 ± 5,32 vs. 7,95 ± 1,45; p = 0,012) and (4,96 ± 2,58 vs 4,33 ±
1,34; p = 0,004) respectively. Although in the normal range, women with endo-
metriosis had signiﬁcantly shortened activated partial thromboplastin time
(aPTT) (29,86 ± 3,19 vs 28,72 ± 2,69; p = 0,002) than controls. Conversely,
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no difference was found for protrombin time, INR, platelet count, lymphocyte
count between women with endometriosis and controls.
Limitations, reasons for caution: This study has some limitations: (1) the
retrospective design of the study that could have inﬂuenced the interpretation
of our ﬁndings and (2) the presence of only one type of controls, the surgical
population. Therefore the results should be taken with caution.
Wider implications of the ﬁndings: Elevated neutrophil count and MPV
and shortened aPTT in patients with Stage III-IV endometriosis may reﬂect an
inﬂammatory and/or procoagulant systemic status in these patients. Further
studies are warranted to conﬁrm our ﬁndings and to assess the role of systemic
inﬂammatory and coagulation markers in the pathophysiology of endometriosis.
Trial registration number:Not applicable.
P-286 Inﬂuence of peritoneal ﬂuid from patients with
endometriosis on sperm glycocalyx
P. Saez Espinosa1, P. Lorca2, I. Velasco1,3, M.I. Acién3,4,
M.J. Gómez-Torres1,5
1Universidad de Alicante, Departamento de Biotecnología, Alicante, Spain
2Universidad Miguel Hernández de Elche, Medicina clínica, San Juan de Alicante,
Spain
3Hospital Universitario San Juan De Alicante, Ginecología y Obstetricia, San Juan de
Alicante, Spain
4Universidad Miguel Hernández de Elche, Salud Pública- Historia de la Ciencia y
Ginecología, San Juan de Alicante, Spain
5Cátedra Human Fertility, Universidad de Alicante, Alicante, Spain
Study question: Can peritoneal ﬂuid (PF) from women with endometriosis
affect the redistribution of glycoconjugates in human sperm membrane?
Summary answer: Sperm cultured with PF from women with and without
endometriosis presented different distribution of sugar residues in the
glycocalyx.
What is known already: Endometriosis is a chronic gynaecological condition
that affects around 10% of women of reproductive age and it is associated with
infertility in 40% of the cases. Studies report that endometriosis signiﬁcantly
reduces oocyte quality, embryonic development and percentage of implant-
ation. Also, it has been shown that PF from patients with endometriosis
decreases sperm motility, acrosome reaction and the ability to penetrate the
oocyte, hindering the correct interaction between oocyte and sperm.
However, additional studies are necessary to know how the presence of endo-
metriosis affects the disposition of glycocalyx sugars involved in sperm-oocyte
recognition.
Study design, size, duration: We conducted a double-blind prospective
study. A total of 30 PF were collected from patients with endometriosis (EP) (n
= 15) and non-endometriosis (NEP) (n = 15) from November 2015 to
September 2017. Semen samples were obtained from normozoospermic men
(n = 5) as assessed according to World Health Organization criteria 2010.
Participants/materials, setting, methods: PF was collected by laparos-
copy from EP and NEP. Sperm were capacitated by density gradients and cul-
tured with 20% of PF during 0 h, 24 h, 48 h and 72 h (37°C and 5% CO2).
Controls were performed with commercial culture medium. Sperm cells were
ﬁxed in paraformaldehyde and carbohydrates were evaluated by ﬂuorescent
lectins: Aleuria aurantia agglutinin (AAA), Concanavalin A (ConA), Peanut agglu-
tinin (PNA) and Wheat germ agglutinin (WGA). Results were observed by ﬂuor-
escence microscopy and statistically evaluated.
Main results and the role of chance: Results showed signiﬁcant differences
in the location of certain sperm membrane carbohydrates depending on the PF.
When we compared the results obtained in controls with cultures performed
with PF from EP, signiﬁcant differences (p<0.05) in the disposition of all sugars
recognized by the AAA, ConA, WGA and PNA lectins at 24 h, 48 h and 72 h
were found. On the other hand, these differences were reduced when compar-
ing controls against FP cultures from NEP, since only signiﬁcant differences were
found in the distribution of carbohydrates identiﬁed by lectins ConA and AAA
at 24 h and 48 h. In the same way, when contrasting the results obtained from
the cultures using PF from patients with and without endometriosis, we found
signiﬁcant differences just in the location of the carbohydrates bound to the
ConA and WGA lectins at 24 h. Therefore, these results allow mentioning that
both the PF from EP and that of NEP inﬂuenced the distribution of sperm mem-
brane sugars. However, as indicated by the results these glycocalyx differences
are more marked when the sperm were cultured with PF of EP.
Limitations, reasons for caution: A relative small number of peritoneal
ﬂuids would be the main limitation of our study.
Wider implications of the ﬁndings: The high rate of signiﬁcant differences
found between the sugars glycocalyx location of sperm cultured with PF from
EP and controls could negatively affect sperm-oocyte recognition and therefore
be associated with infertility in endometriosis.
Trial registration number:Not applicable.
P-287 Role of TGF-b on endometriotic stem cells and its
differentiation into cells with cancer phenotype
L.L.K. Parameswaran Grace, S. Vignesh-Srinivasan,
M. Saare, J. Retkowski, A. Iyengar, C. Garcia Pascual,
K. Gemzell-Danielsson
Karolinska Institute, Women’s and Children’s Health, Stockholm, Sweden
Study question: Does high levels of TGF-b reduce the invasiveness of endo-
metriotic stem cells (EndoSC) and their differentiation into cells with cancer
phenotype?
Summary answer: Treatment with TGF-b reduced invasion of EndoSC at
doses and positively alters the expression of genes that are highly expressed in
pre-cancerous cells.
What is known already: In a previous study, high mRNA levels of TGF-b1
was observed in stem cells derived from endometriotic tissue. High levels of
TGF-b is seen in peritoneal ﬂuid (PF) of endometriosis patients and is positively
correlated to the severity of endometriosis.
Study design, size, duration: Tissues from endometrioma were collected
after the planned surgical excision of endometrioma from women (n = 16)
underwent surgery for endometriosis.
Participants/materials, setting, methods: EndoSC were isolated from
endometriotic tissue using stem cell markers CD73, CD90, and EpCAM.
Spheroids (50 m) were generated from EndoSC and the effect of TGF-b (2 ng/
ml; 250 ng/ml; with/without TGF-b inhibitor Ly2109761) on cell invasion was
studied by invasion assay. Molecules involved in epithelial-mesenchymal trans-
ition (SNAI1) and 20 genes over expressed in pre-cancer cells (SDC1, SDC4,
ESR1, CTNNB1, BMI1, ARIDA1 ect.) were studied by real time PCR.
Main results and the role of chance: Treatment with TGF-b reduced the
invasion of EndoSC spheroids. Addition of TGF-b inhibitor Ly2109761 reversed
this effect in a dose dependent manner with the up regulation of SDC -1 and -4
indicating a direct link with Syndecan family and cell invasion process. Analysis
of gene expression data by heat-maps with supervised hierarchical cluster and
principle component analysis showed few samples clustered together with simi-
lar expression of molecules (TGF-b, ESR1, CTNNB1, BMI1, ARIDA1 and
SDC4) known to be involved in pre-malignant conditions.
Limitations, reasons for caution: This study is limited by a small sample
size and results will need to be conﬁrmed in a larger study.
Wider implications of the ﬁndings: Results from this study if conﬁrmed in
a larger sample may help in developing treatment strategies to reduce the risk
of endometriosis-associated cancer by using TGF- b inhibitor.
Trial registration number:NA.
P-288 Wnt signaling as a target for the treatment of
endometriosis
R. Assaf1, O. Farah2, T. Tulandi3, D. Dufort3
1McGill University, Medicine- Division of Experimental Medicine, montreal, Canada
2University of California San Diego, Pathology, San Diego, Canada
3McGill University Health Centre, Obstetrics and Gynecology, Montreal, Canada
Study question: We ultimately aim to assess Wnt signaling as a target for
treatment of endometriotic lesions in vivo and in vitro.
Summary answer: We have shown that Wnt signaling is auto-activated in
endometriotic lesions and appears to play a role in the development of endo-
metriosis lesions.
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What is known already: Endometriosis is a chronic condition deﬁned by the
presence of endometrial tissue outside the uterine cavity. It affects about 15%
of women of reproductive age and can cause severe pain and infertility. The
painful symptoms are only treated with hormonal treatments that achieve
amenorrhea. Our lab has shown that Wnt signaling plays a role in the develop-
ment of endometrial glands and in stromal cell proliferation and this pathway
appears to be aberrantly activated in lesions of endometriosis patients.
Study design, size, duration: For in vivo experiments, we used 5 control and
5 mutant mice for each of the 3 time-points of disease development, and 10
mice for the in vitromouse experiments.
For the in vitro patient study, we are in the process of obtaining endometri-
osis samples from 30 patients and treating them with different Wnt signaling
inhibitors. We are measuring proliferation rates and investigating gene expres-
sion changes and expect to observe a reduction in proliferation following
treatment.
Participants/materials, setting, methods: We are using the established
auto-transplantation mouse model with a Wnt reporter strain to look at Wnt
signaling activation in vivo, as well as a uterine-speciﬁc Porcupine conditional
knock-out strain to study the role of Wnt signaling in endometriosis. We are
comparing the in vitro proliferation of endometriotic cells in controls and
mutants.
Peritoneal endometriosis lesions are obtained by physicians from the
MUHC-RVH Department of OBGYN from women of reproductive age pre-
senting with the condition.
Main results and the role of chance:We observed canonical WNT signal-
ing activation in the lesions of reporter mice, but not in Porcupine knock-out
mice, during the intermediate stages of the disease. Since these mutant mice do
not express Wnt ligands in their reproductive tract, the activation of Wnt sig-
naling must be due to uterine Wnt ligands, and not WNTs produced by other
tissues. Additionally, mutant mice developed smaller lesions 3 and 6 weeks after
the induction of endometriosis. This suggests that Wnt signaling is involved in
endometriosis this mouse model. We are now looking to verify this in vitro in
mouse endometriotic cells and patient samples.
Limitations, reasons for caution: Other mouse models exist, and some
model the initiation of the disease more accurately, but the auto-
transplantation model allows us to evaluate the development of endometriosis.
Wider implications of the ﬁndings: Understanding the function of Wnt sig-
naling in the development and maintenance of endometriosis could lead to the
identiﬁcation of a new treatment to induce regression of the disease. The
upstream signaling component Porcupine could be targeted to treat endometri-
osis, which our lab is currently testing in vitro and in vivo.
Trial registration number: not applicable.
P-289 Outcomes of conventional IVF versus ICSI in infertile
women with endometriosis: a retrospective cohort study
A. Chargui1, M. Bourdon2, L. Ferreux1, C. Maignien2, A. Sallem1,
A.S. Gille1, C. Patrat1, J.P.Wolf1, P. Santulli2, K. Pocate-Cheriet2
1Hôpital Cochin - Assistance Publique des Hôpitaux de Paris, Service d’Histologie
Embryologie Biologie de la Reproduction, PARIS, France
2Hôpital Cochin - Assistance Publique des Hôpitaux de Paris, Service de Gynécologie-
Obstétrique II et de Médecine de la Reproduction, Paris, France
Study question: Are biological and clinical outcomes in infertile women with
endometriosis better after ICSI than after conventional IVF?
Summary answer: Fertilization rate is signiﬁcantly higher in ICSI cycles versus
conventional IVF. Secondary outcomes are similar in the two groups.
What is known already: Endometriosis is a benign chronic gynaecological
disease, deﬁned as the presence of endometrial tissue outside the uterus.
Prevalence is estimated to reach 15% of reproductive-aged women and 25-50%
of infertile women. ART are commonly offered for managing endometriosis-
related infertility. However it has been showed that peritoneal ﬂuid from
women with endometriosis inhibits the binding of spermatozoa to the zona-
pellucida. One previous study concluded that ICSI is a better option than IVF in
endometriosis because of a higher rate of fertilization leading to more embryos.
There nonetheless remains a lack of knowledge concerning the optimal treat-
ment between IVF and ICSI.
Study design, size, duration: Retrospective cohort study including 538
cycles (341 IVF and 197 ICSI) in infertile women with endometriosis performed
between October 2012 and October 2017 at a tertiary care center (Cochin
Hospital, APHP-Paris). Among the 538 cycles, fresh embryo transfer (FET) at
Day 2/3 was performed for a total of 238 women (157 IVF and 81 ICSI).
Participants/materials, setting, methods: IVF and ICSI cycles were per-
formed in women under 42 years having at least ﬁve cumulus-oocyte com-
plexes (COC) after oocyte retrieval with ejaculated sperm. Primary outcome
(fertilization rate) was compared between IVF and ICSI for the studied popula-
tion and in FET subgroup. Secondary outcomes (number of embryo D2/D3,
blastocyst formation) and clinical outcomes (implantation, miscarriage and
ongoing pregnancy rates) were compared for FET subgroup. Statistical analysis
was conducted using univariate and multivariate logistic regression models.
Main results and the role of chance: For the baseline characteristics
between women undergoing IVF or ICSI, only AMH and AFC were signiﬁcantly
lower in ICSI group (p-values were respectively: 0.01 and 0.006). A signiﬁcantly
higher fertilization rate was reported in the studied population and FET sub-
group (62.97 ± 22.12 % for IVF versus 69.11 ± 22.99% for ICSI p = 0.001 and
62.98 ± 22.16 for IVF versus 69.27 ± 19.30 for ICSI p = 0.03, respectively). No
signiﬁcant difference in the number of retrieved oocytes was found.
In the FET subgroup, no signiﬁcant difference was shown when comparing
the mean number of embryos at Day2/3 for IVF versus ICSI (7.2 ± 3.16 and
5.79 ± 2.77; p = 0.074), the mean number of embryos per transfer (p =
0.825) and blastocyst formation rate (42.0 ± 51.5% versus 36.0 ± 32 95%; p =
0.85). Clinical outcomes (implantation, miscarriage and ongoing pregnancy
rates) were similar between the two groups.
Limitations, reasons for caution: Histological proof of endometriosis was
not available for all the patients. Cumulative pregnancy rate was not evaluated
because couples are still having frozen blastocysts not yet transferred.
Wider implications of the ﬁndings: These ﬁndings need to be conﬁrmed
by further prospective studies taking into account the stage of endometriosis.
Yet, it brings a new insight in the complex task of dealing with infertile deep inﬁl-
trating endometriosis patients and might help physicians to choose between IVF
and ICSI to optimize ART outcomes.
Trial registration number: No funding was sought for this study. Authors
declare no competing interests.
P-290 Endometrial receptivity: Expression proﬁle of candidate
genes in endometriosis
C. Marrocco, A. Luddi, L. Governini, A. Capaldo, B. Semplici,
V. Pavone, L. Boschi, V. De Leo, P. Piomboni
Siena University, Molecular and Developmental Medicine, siena, Italy
Study question: Are the genes involved in endometrial receptivity differen-
tially expressed ineutopic compared to healthy endometrium? Does the hor-
monal hyperstimulation modulates thisproﬁle?
Summary answer: There is a different gene expression proﬁle in tissues from
healthy and eutopicendometrium. The in vitro hormonal hyperstimulation may
affect this speciﬁc ﬁngerprinting.
What is known already:Many pathologies affecting endometrial functionality
should alterimplantation process and, as a consequence, cause infertility.
Among others, endometriosis has anegative impact on embryo implantation
and pregnancy rate and, for these reasons, it is consideredas one of the major
causes of women infertility. Really, despite the great progress achieved byas-
sisted reproductive techniques, implantation represents one of the most crucial
stage. Moreover,several evidences suggest that controlled ovarian hyperstimu-
lation may alters endometrialphysiology thus impairing receptivity, with possible
negative effects on the embryo implantation.
Study design, size, duration: For this study, we have collected 6 endomet-
rial tissue biopsies from healthy subjects and fromwomen with endometriosis,
who underwent surgical interventions starting from January to October2017.
Gene expression analysis of 24 genes involved in endometrial receptivity was
carried out intissue biopsies and in primary HESC untreated or treated with
FSH in combination with LH orhCG.
Participants/materials, setting, methods: The primary HESCs prepared
from endometrium ofhealthy or endometriotic women, collected during
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implantation window, were treated for 24 h withFSH in combination with LH
or hCG, in order to reproduce hormonal hyperstimulation conditions.mRNA,
extracted from both endometrial tissue and HESC was subjected to qRT-PCR
in order toevaluate the expression levels of 24 selected genes involved in endo-
metrial receptivity.
Main results and the role of chance: The investigated genes resulted differ-
entially expressed inhealthy compared to eutopic endometrium, both in tissue
and in stromal endometrial cells. Inaddition, we observed that in vitro hormonal
stimulations signiﬁcantly affect the gene expressionproﬁle of stromal endomet-
rial cells. In particular, the expression of LIF and LIF receptor (LIFR)resulted dif-
ferently modulated in healthy and eutopic endometrial tissue, whereas in HESC
both LIFand its receptor have the same trend of expression. Noteworthy, the
hormonal treatmentsigniﬁcantly reduced the expression of LIF in stromal cells,
whereas signiﬁcantly increased theexpression of its receptors. Among other
genes, PAEP mRNA levels are signiﬁcantly increased ineutopic compared to
healthy tissue HESC, whereas its expression was extremely low in botheutopic
and healthy HESCs, becoming undetectable upon hormonal treatment.
Limitations, reasons for caution: Different parameters may inﬂuence the
response tohyperstimulation protocols, therefore larger study needs to be car-
ried out in order to deﬁnitivelyvalidate these ﬁndings.
Wider implications of the ﬁndings: This approach allowed us to identify
key genes whose expression is signiﬁcantly modulated ineutopic compared to
healthy HESC, also in response to hormonal hyperstimulation. This study, ifre-
plicated in a larger population, might contribute in understanding impact of the
ovarianhyperstimulation protocols used in ART cycles.
Trial registration number:NONE.
P-291 Endometriosis is associated with a lower number of oocytes
during IVF independently of serum AMH level
D. Albu1, A. Albu2
1Carol Davila University of Medicine and Pharmacy, Gynecology, Voluntari, Romania
2Carol Davila University of Medicine and Pharmacy, Endocrinology, Voluntari,
Romania
Study question: Does the serum anti-mullerian hormone level (AMH) over-
estimate the oocytes yield in infertile patients with endometriosis undergoing
in vitro fertilization (IVF)?
Summary answer: In infertile patients, endometriosis is an independent pre-
dictor of a lower number of oocytes retrieved during IVF after adjustment for
serum AMH and other confounders.
What is known already: AMH is a member of TGF-ß superfamily recognized
as a biomarker of ovarian response and as a reliable tool for controlled ovarian
stimulation (COS) for IVF. Endometriosis is a hormonally-mediated inﬂamma-
tory condition, being hypothesized that the members of TGF-ß family, including
AMH, are increased, affecting its ability to reﬂect the ovarian reserve. However,
data showing the predictive value of AMH for IVF outcome in endometriosis
are limited.
Study design, size, duration: We performed a retrospective study which
included 376 infertile female patients undergoing controlled ovarian stimulation
for IVF between June 2016 –June 2017
Participants/materials, setting, methods: The study group included 94
patients with endometriosis and 282 patients with other causes of infertility. All
the patients were evaluated and treated for infertility with IVF in a private out-
patient clinic. Only patients with endometriosis, tubal causes, idiopathic infertil-
ity and male factor were included. Patients with polycystic ovary syndrome
were excluded from the study. The following data were recorded: age, body
mass index (BMI), AMH, gonadotrophins dose, number of oocytes retrieved
during IVF protocol.
Main results and the role of chance: The mean age of the study group was
34.23 ± 3.5 years, mean BMI 22.1 ± 3.81 kg/m2, mean AMH value 2.57 ±
0.78 ng/mL. The two groups of patients were similar in terms of age, BMI and
gonadotrophins dose used during COS. Patients with endometriosis had signiﬁ-
cantly lower AMH serum level (2.13 ± 0.99 versus 2.95 ± 1.1 ng/mL, p<0.05)
and obtained a lower number of oocytes during IVF (6.24 ± 4.6 versus 7.84 ±
4.9, p<0.005) in comparison with control group. After adjustment for confoun-
ders (including AMH level) in a model of multivariate linear regression, both
endometriosis (beta=-0.117, p = 0.019) and AMH (beta = 0.519, p<0.001)
independently predicted the number of oocytes retrieved during IVF.
Limitations, reasons for caution: The limitations of the study are its retro-
spective design and the lack of data about the subtypes of endometriosis.
Moreover, our study did not include patients with an increased level of AMH
(possibly as a consequence of inﬂammation) and our results can not be applied
to these patients.
Wider implications of the ﬁndings: The results of our study suggest that
patients with endometriosis could have decreased response to COS in com-
parison with patients with other causes of infertility with similar AMH level.
Therefore, AMH serum level might not have the same predictive value in
patients with endometriosis.
Trial registration number:NA.
P-292 Telomerase component, Dyskerin (DKC1), is expressed and
hormonally regulated in healthy endometrium: implications for
endometrial pathologies
R. Al-Nafakh1, M. Adishesh1, J. Drury1, G. Saretzki2, D. Hapangama1
1Institute of Translational Medicine- University of Liverpool- Liverpool Women’s
Hospital, Department of Women’s and Children’s Health, Liverpool, United Kingdom
2Institute for Cell and Molecular Biosciences and the Ageing Biology Centre, Campus
for Ageing and Vitality- Newcastle University, Newcastle, United Kingdom
Study question: Is dyskerin expressed in the healthy endometrium, altered in
proliferative endometrial conditions and is it regulated by ovarian steroid
hormones?
Summary answer: Healthy human endometrium expresses dyskerin, signiﬁ-
cantly lower dyskerin protein levels are observed in endometrial cancer and the
expression is regulated by oestrogen, progesterone and dihydrotestosterone
(DHT).
What is known already: Telomeres are maintained and elongated by the
specialized enzyme telomerase. Telomerase activity is important for endomet-
rial epithelial proliferation, dynamically regulated by ovarian steroid hormones
and is implicated in endometrial proliferative conditions such as endometriosis
and endometrial cancer. Although two of the core subunits of telomerase holo-
enzyme, the RNA Component, hTERC and the catalytic component, hTERT
have been extensively studied in human tissues including the human endomet-
rium, the 3rd component, dyskerin protein is not well described. The effect of
ovarian steroid hormones on dyskerin in human cells is not yet known.
Study design, size, duration: A prospective observational study, included
endometrial samples collected from 240 women in total. They were 52 healthy
premenopausal (29 proliferative phase; 23 secretory phase); 32 postmenopau-
sal women; 29 women with endometriosis (18 eutopic secretory phase; 11
ectopic endometriotic samples). 109 women with endometrial cancer. A fur-
ther 18 women using a Mirena IUCD were also recruited.
Participants/materials, setting, methods: Endometrial samples were ana-
lysed with immunohistochemistry and western blotting for dyskerin protein,
qPCR for DKC1 gene expression. Telomerase activity was measured by TRAP
assay, hTERC mRNA levels with qPCR. The hormone receptor expression in
the endometrial samples were measured using immunohistochemistry and a
four-tiered Liverpool endometrial steroid quick score. Ki67 proliferative index
was evaluated as the percentage of immunopositive cells. Endometrial cancer
cell line, Ishikawa was used to examine in-vitro hormonal regulation.
Main results and the role of chance: Healthy human endometrium showed
a dynamic spatio-temporal expression pattern of dyskerin. The expression of
dyskerin protein and mRNA was signiﬁcantly increased in healthy postmeno-
pausal endometrium, compared with the premenopausal endometrium (P =
0.0022 and P = 0.0021 respectively). Secretory endometrium had the lowest
DKC1 mRNA expression levels compared with the postmenopausal endomet-
rium (P = 0.01).
We did not see a signiﬁcant difference in dyskerin protein or DKC1 mRNA
levels in the eutopic secretory endometrium of women with endometriosis
compared with secretory phase from healthy women.
This was in contrast to hTERC which was signiﬁcantly upregulated in secre-
tory endometrium of women with endometriosis compared with healthy secre-
tory endometrium (p = 0.0199).
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Dyskerin immunoscores were signiﬁcantly low in endometrial cancer samples
compared with the healthy postmenopausal endometrium (P = 0.0002).
DKC1 mRNA levels were up regulated by oestradiol (E2) and DHT and
down regulated by progesterone in vitro in Ishikawa cells. Progesterone induced
downregulation of DKC1 was counteracted by E2. However, in our in vitro
study, ovarian steroid hormones did not have an obvious effect on telomerase
activity measured by TRAP assay.
Limitations, reasons for caution: This is an observational study. The sam-
ple size that we have used to evaluate DKC1mRNA and telomerase activity was
relatively small.
Wider implications of the ﬁndings: The observed in vivo and in vitro data
showed that dyskerin is hormonally regulated and its immunoexpression was
signiﬁcantly lower in endometrial cancer compared with healthy postmenopau-
sal endometrial tissue. That suggests that dyskerin might be a new target in
developing treatments for endometrial proliferative disorders such as endomet-
rial cancer.
Trial registration number: not applicable
P-293 Interactions between GSTs genes polymorphisms and trace
metals are associated with endometriosis
G.L. Lai1, C.R. Tzeng2, C.Y. Yeh1
1Taipei Medical University, School of Public Health, Taipei, Taiwan R.O.C.
2Taipei Medical University and Hospital, Center for Reproductive Medicine and
Sciences, Taipei, Taiwan R.O.C.
Study question: Are there interactions between GSTs genes polymorphisms
and trace metals for endometriosis.
Summary answer: Yes, null genotype of GSTs genes may modify the effect
of blood zinc and lead for endometriosis.
What is known already: The women with null types GSTs genotypes may
associate with risk of endometriosis. Besides blood metal levels such as lead
and cadmium are also associated with risk of endometriosis.
Study design, size, duration: This is a cross-sectional study design. From
2008 through 2010, this study included 181 women who visited the infertility
clinic at Taipei Medical University Hospital. 64 endometriosis women and 117
non-endometriosis women were included.
Participants/materials, setting, methods: Blood samples were taken
from each woman. Trace metal levels in blood were measured by inductively
coupled plasma mass spectrometry (ICP-MS). The genotypes for GSTM1 and
GSTT1 genes were identiﬁed by PCR.Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) were calculated using multiple logistic regression models adjusted
for probable confounders.
Main results and the role of chance: In stratiﬁcation analysis, the null type
GSTM1 group is with an OR = 0.34 (3rd tertile vs. 1st tertile, 95% CI,
0.13–0.86) for a reversed association between zinc levels and endometriosis
and OR = 2.22 (3rd tertile vs. 1st tertile, 95% CI, 1.05-4.73) for an association
between lead levels and endometriosis. The null type GSTT1 group is with an
OR = 0.26 (3rd tertile vs. 1st tertile, 95% CI, 0.09–0.75) for a reversed associ-
ation between zinc levels and endometriosis. In present type GSTM1 and
GSTT1 group are with non-signiﬁcant OR for associations between both these
metal levels and endometriosis.
Limitations, reasons for caution: Because of the hospital-based design,
generalization of these results to the general Taiwanese population and to other
ethnic groups needs caution.
Wider implications of the ﬁndings: The GST family genes are known to be
involved in the metabolism of environmental chemical agents. Women with null
type GSTM1 and GSTT1 genotypes may be sensitive to zinc and lead exposure
for having endometriosis.
Trial registration number: not applicable
P-294 No treatment versus surgical management of
endometrioma on the IVF outcomes
V. Trindade1, M.R. Hentschke2, M. Badalotti2, A. Petracco2,
J.D.R. Michelon2
1Medical Resident in Human Reproduction, Fertilitat - Center for Reproductive
Medicine, Porto Alegre, Brazil
2Doctor in Medicine, Fertilitat, Porto Alegre, Brazil
Study question: Does surgery have a positive impact on the IVF outcome of
patients with endometrioma?
Summary answer: Surgery for endometrioma showed to favor pregnancy
rate and live birth rate per cycle, but this was not statiscally signiﬁcant.
What is known already: Two meta-analyses have assessed the impact of
endometrioma resection on IVF outcomes. One demonstrated no signiﬁcant
differences in clinical pregnancy rates, comparing surgical resection to no treat-
ment. Other suggested that surgical management of endometrioma resulted in
no beneﬁts for a subsequent IVF cycle. Also, some studies suggested a decrease
in ovarian reserve in women with endometrioma, and some studies suggested a
further decrease in ovarian reserve after surgery.
Study design, size, duration: Retrospective case-control study, performed
at Fertilitat - Reproductive Medicine Center, from 2001-2017, including 252 IVF
cycles. Patients included were referred to IVF due to endometriosis. Group 1
was composed by patients who had laparoscopic excision of endometriomas
by cystectomy or cauterization of the cyst. Group 2 was composed by patients
who had an image of endometrioma conﬁrmed by an ultrasound exam, and did
not receive surgical treatment.
Participants/materials, setting, methods: We found 76 IVF cycles on
group 1 and 176 IVF cycles on group 2. Number of oocytes retrieved, preg-
nancy rate and live birth rate was compared between groups. Summary data
were presented as mean and standard deviation. Student’s t-test or chi-square
test were used. The null hypothesis was rejected when p <0.05
Main results and the role of chance: Group 1 was composed by 76 IVF
cycles. Group 2, by 176 IVF cycles. The maternal age between group 1 and 2
was: 35.1 ± 3,5 vs 35.8 ± 3.7 year-old, p = 0,15. The number of oocytes
retrieved between group 1 and 2 was: 5,5 ± 3,7 vs. 6,0 ± 5,1, p = 0,25. From
76 IVF cycles in Group 1, there were 47 embryo transfer cycles. From 176 IVF
cycles in Group 2, there were 107 embryo transfer cycles. The number of
embryo transferred per cycle was 2.0 ± 0.7 vs 2.1 ± 0.8 p = 0,66, between
Group 1 and 2 respectively. The pregnancy rate between Group 1 and 2 was
21 (44,68%) vs. 41 (38,31%), p = 0,45. The live birth rate between Group 1
and 2 was 15 (31,91%) vs 29 (27,10%), p = 0,54.
Limitations, reasons for caution: Group 1 had fewer patients. On Group
1, there were different surgical techniques.
Wider implications of the ﬁndings: In patients with endometrioma, sur-
gery seems to improve pregnancy and live birth rate, but this was not statiscally
signiﬁcant. It is important to assess the surgery risks of ovarian intervention,
when current evidence suggests that women treated with surgery have similar
cycle outcomes compared to those not treated.
Trial registration number:Not applicable.
P-295 Results from a case-control study comparing mean
aneuploidy rates and pregnancy outcomes in women with and
without endometriosis undergoing In Vitro Fertilization (IVF) cycles
R. Venturella1, A. Vaiarelli2, D. Lico1, D. Cimadomo2, L. Rienzi2,
B. Laura3, C. Gentile3, E. Alviggi4, S. Alfano4, P. D’Alessandro4,
F. Zullo1, A. Conforti5, F. Ubaldi2
1University Magna Graecia, Chair of Obstetrics and Gynecology, Catanzaro, Italy
2Valle Giulia Clinic, GENERA center for Reproductive Medicine, Roma, Italy
3Poliambulatorio SALUS, GENERA Marostica, Marostica, Italy
4Clinica Ruesch, GENERA Napoli, Napoli, Italy
5University Federico II, Obstretics and Gynecology, Napoli, Italy
Study question: Do women with and without endometriosis undergoing IVF
with Pre-implantation genetic test for aneuploidies (PGT-A) before blastocysts
transfer differ for aneuploidy rates and reproductive outcomes?
Summary answer: Endometriosis patients do not differ from their age and
MII obtained oocytes-matched healthy peers for mean aneuploidy rates and for
pregnancy outcomes in IVF cycles.
What is known already: It has been estimated that 30-50% of women with
endometriosis can’t conceive naturally and affected IVF patients have worse
outcomes than women without endometriosis, such as lower number of
oocytes retreived, reduced fertilization, implantation and pregnancy rates.
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Several pathways have been exploited to explain the endometriosis-related
subfertility, both at ovarian than at the endometrial side. The evidence that peri-
toneal higher levels of reactive oxygen species and inﬂammatory cytokines can
cause oocyte microtubule and chromosome instability has suggested that even
the rate of embryo aneuploidy could be increased in these patients, contributing
to the poorer IVF outcomes of endometriosis patients.
Study design, size, duration: This study retrospectively evaluated data of
women producing at least one blastocyst subjected to PGT-A after
Intracytoplasmic Sperm Injection from November 2008 to March 2017. To limit
the potential bias of the analysis, a case-control study design was adopted. Age
at pick-up, number of previous IVF failures and number of MII oocytes were
chosen as matching criteria, since they are reported among the strongest suc-
cess predictors in IVF. Every case was matched with two controls.
Participants/materials, setting, methods: Data available from the entire
PGT-A population were reviewed and the study population was divided into
two groups, according to the presence or the absence of endometriosis.
Demographic (age, previous miscarriage, previous failed IVF) and IVF-related
information (number of MII, injected and fertilized oocytes, of blastocysts, of
euploid blastocysts, of single embryo transfers, of positive beta-Human chori-
onic gonadotropin, biochemical pregnancy, clinical pregnancy loss, miscarriage
and live birth rates) were collected and compared between groups.
Main results and the role of chance: In this study, 249 women affected by
endometriosis were matched with 498 women without the disease, according to
maternal age at pick-up (38.1 ± 2.9 years), previous IVF failure (0.6 ± 0.8 cycles)
and number of MII oocyte retrieved (7.1 ± 3.8 per pick-up). In our population,
the percentage of fertilized oocytes per number of MII oocyte was signiﬁcantly
lower in women with endometriosis than in control groups (77 vs 74%).
Percentage of blastocysts obtained per fertilized oocytes (51.0 vs 53.3%),
mean blastocyst rate per fertilized oocyte per cycle (56.5 ± 25.2% vs 58.3 ±
26.8%), percentage of euploid blastocysts per biopsied embryo (49.4 vs 50.1%)
and mean euploidy rate per blastocyst per cycle (46.8 ± 38.7% vs 43.7 ±
37.3%) did not differ between control patients and women with endometriosis.
Moreover, no signiﬁcantly differences in terms of percentage of positive preg-
nancy tests per Single Euploid Embryo Transfer (eSET) (52.4 vs 57.7%), per-
centage of Biochemical Pregnancy Loss per positive pregnancy test (11 vs
10.6%), percentage of miscarriages per clinical pregnancy (12.3 vs 12.9%) and
percentage of ongoing implanted blastocysts or babies born per SET (41.0 vs
44.9%) were detected between group. According to Post-hoc power calcula-
tion, we had 80% power to detect a 10% difference in the mean euploidy rate
per cycle between groups.
Limitations, reasons for caution: This is a ﬁrst retrospective analysis per-
formed in 3 IVF Italian centers undergoing PGT-a cycles and eSET. Prospective
studies could allow better stratiﬁcation of endometriosis type and stage.
Moreover, only patients which obtained at least one blastocysts have been
included in the ﬁnal analysis.
Wider implications of the ﬁndings: Our preliminary data demonstrate
that the rate of aneuploidy and the pregnancy outcomes are not statistically sig-
niﬁcantly different between women with endometriosis as compared with age-
matched controls in the IVF population. Aneuploidy therefore could not be
related to the poorer IVF outcomes of endometriosis patients.
Trial registration number: not applicable.
P-296 RCT of intra-uterine administration or subcutanious
injection of GCSF (granulocyte colony-stimulating factor) before
embryo-transfer on resistant thin endometrium in IVF
R. Singh1, M. Singh2
1Bhopal Test Tube Baby Centre, Infertility, Bhopal, India
2Bhopal Test-Tube-Baby Centre, Infertility, Bhopal, India
Study question: Does intrauterine administration Or Subcutanious injection
of G-CSF (granulocyte colony-stimulating factor) prior to Embryo Transfer in
patients with resistant thin endometrium improve endometrial thickness and
pregnancy rate in IVF?
Summary answer: Subcutanious injection OR Uterine perfusion with G-CSF
represents a promising new tool for the currently mostly intractable problem of
inadequate, thin endometrium.
What is known already: In 2009, GCSF was successfully used in patients
with recurrent abortions (Scarpellini & Sbracia 2009),and later another study
reported promising results by using GCSF in four women undergoing IVF who
had demonstrated highly inadequate endometrium(Gleicher et al. 2011). Since
then, several studies with controversial results have evaluated the effect of
GCSF on endometrial thickness and IVF success ( Kunicki et al. 2014, Li et al.
2014,Xu et al. 2015). The implantation and pregnancy rates were signiﬁcantly
higher (Scarpellini & Sbracia 2012,et al.2015), whereas did not affect endomet-
rial thickness, implantation, or pregnancy rates (Barad et al. 2014, Li et al.
2014).
Study design, size, duration: The study group (n = 56) received either
intrauterine infusion of 300 microgramme /1ml of G-CSF, or subcutanious
injection of GCSF and control group (n = 56) underwent either placebo-saline
infusion or placebo subcutanious multivitamin injection before Embryo
Transfer.
Participants/materials, setting, methods: The study group (n = 56)
received either intrauterine infusion of 300 microgramme G-CSF, or SC injec-
tion of GCSF and control group (n = 56) underwent either placebo-saline infu-
sion OR placebo subcutanious injection before ET.
G-CSF was administered per intrauterine catheter on the day of hCG admin-
istration. If the endometrium had not reached at least a 7-mm within 48 h, a
second infusion was given following oocyte retrieval and same was for
Subcutanious route.
Main results and the role of chance: The endometrial growth was signiﬁ-
cantly different within the two groups. An improvement was shown between
the control and G-CSF groups. Endometrial expansion to minimal thickness
occurred within approximately 48–72 hour from G-CSF infusion./ SC injection.
In all the subjects at the time of infusion of G-CSF, endometrial thickness was
6.23 ± 1.45 mm, and,after infusion /SC injection it increased signiﬁcantly to
8.46 ± 1.27 mm. The IR and PR were statistically signiﬁcantly higher in the
group that received intrauterine infusion of G-CSF/ SC injection (24% and 34%,
respectively) as compared with the control group (11% and 16%, respectively).
Optimal endometrial thickness reﬂects an adequate maturation, which is a
key factor for embryo implantation.
Limitations, reasons for caution: The main strengths of our study were its
randomized,controlled design and to evaluate for the ﬁrst time the efﬁcacy of
both systemic subcutaneous and local intrauterine GCSF administration on IVF
success.
Further more RCT are required to establish the best route and dose of
GCSF administration in IVF patients.
Wider implications of the ﬁndings: Uterine perfusion or SC injection with
G-CSF represents a promising new tool for intractable problem of thin endo-
metrium. Proliferative and secretory changes in the endometrial lining are the
result of a complex intrauterine environment where sex steroid hormones and
different local factors play an important role for endometrial thickening.
Trial registration number:NOT APPLICABLE.
P-297 Optimising for patients with endometriosis and reducing the
time of the gynaecological examination with a new concept of a
pelvic examination chair
G. Edelstam1, M. Hagmar2, L. Makdessi3
1Obstetrics & Gynecology, Obstetrics & Gynecology, Stockholm, Sweden
2Clinical Sciences- Danderyd Hospital, Department of Obstetrics & Gynaecology-
Danderyd Hospital, SE 182 88- Stockholm-, Sweden
3Obstetrics & Gynecology, Obstetrics & Gynecology- Vrinnevi Hospital, 603 79
Norrköping, Sweden
Study question: Is it possible to improve the pelvic examination and particu-
larly for patients with pain due to endometriosis?
Summary answer: The intrusive examination process was compensated by
improved comfort and respect for the patients’ integrity which also signiﬁcantly
reduced the examination time.
What is known already: Most women with endometriosis have an unpleas-
ant expectancy on gynaecological examinations. If an examination has been
unpleasant, the patient will be hesitant to future pelvic examinations and vaginal
ultrasounds. Awkward examination positions may cause psychological stress
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for the patients with a subsequent risk of generating or magnifying a negative
experience. The gynaecological chair with stirrups has had the same design for
many years. One reason for the lack of development could be that the examin-
ation products are designed from the medical perspective. Human-oriented
innovations for comfort irrespective of age and gender should be developed in
collaboration with the patients.
Study design, size, duration: A prototype of a gender neutral pelvic exam-
ination chair was constructed without stirrups and with built-in heating in the
soft upholster. The new technical solution provided improved integrity for the
patient with the perineum only exposed during the examination procedure.
The patients and the gynaecologists who performed the examination, answered
131 questionnaires concerning experiences after the examinations in the trad-
itional examination chair and in the new prototype, respectively. The examin-
ation time was registered.
Participants/materials, setting, methods: The protypes of pelvic examin-
ation chairs were evaluated at outpatient gynaecological wards of two different
university hospitals. The investigation was carried out by 13 gynaecologists who
examined 131 patients in two subgroups with and without endometriosis. The
questionnaires were ﬁlled out after the examinations were coded and collected
feedback on an easy 5 graded scale on 9 questions.
Main results and the role of chance: The questionnaires demonstrated sig-
niﬁcance (p<0.01) in favour of the new concept on a majority of the aspects
evaluated. The new pelvic examination chair with heating and without stirrups
was rated signiﬁcantly more comfortable and respectful for the patient’s integ-
rity. There were no differences between the groups in their attitude towards
going through a pelvic examination, neither in any experience of pain during the
examination. A question concerning the experience of examination without
stirrups was rated 3.8 on the ﬁve graded scale. The gynaecologists were signiﬁ-
cantly more positive on all questions comparing the pelvic examination chairs
with and without stirrups. Measuring the examination time demonstrated a sig-
niﬁcantly shorter procedure without stirrups. The time saved (average 1.6
minutes per patient) during a day on an outpatient gynecological clinic can per-
mit that one patient more can be examined per day. The patients were not ran-
domised to examination in the different pelvic examinations chair but the
number of patiens and gynaecologists participating reduces the role of chance.
Limitations, reasons for caution: The questionnaires were coded but the
investigation was for practical reasons not randomised. The patients were ran-
domly invited to participate before the examination. There were no differences
between the groups in the patients´ attitude towards going through a gynaeco-
logical examination, neither in any experience of pain during the examination.
Wider implications of the ﬁndings: The results in the present study
demonstrated that minor adjustments of a gynaecological chair can generate a
signiﬁcantly more positive examination experience for the patients in a majority
of the aspects investigated. This might have a positive impact on the drop-out
rate from fertility treatments.
Trial registration number: not applicable.
P-298 IVF or ICSI:Which is better in women with endometriosis
associated infertility requiring ART?
L.Y. Tan1, K. Brown2, H. Dhanani2, L. Hughes1, F. Tekpetey1,
B. Abu Rafea1
1The Fertility Clinic- Victoria Hospital- Western University, Department of Obstetrics
and Gynaecology, London, Canada
2Schulich School of Medicine and Dentistry, Western University, London, Canada
Study question: Does IVF or ICSI improve reproductive outcomes in women
with endometriosis associated infertility compared to infertile women with no
endometriosis?
Summary answer: The ﬁndings of this study seem to suggest that there is no
added beneﬁt and it is potentially detrimental to recommend ICSI in women
diagnosed with endometriosis associated infertility especially in moderate to
severe (Stage III & IV) endometriosis.
What is known already: Endometriosis is associated with infertility.
Between 25–50% of infertile women have endometriosis and 30 – 50% of
women with endometriosis are infertile. Many of these women will have to
undergo IVF. Abnormal folliculogenesis, impaired oocyte and embryo quality
due to radical oxidative stress and imbalances in the levels of cytokines and
interleukins have been described as potential contributors to infertility in
women with endometriosis. We wondered if utilising ICSI may overcome these
stressors and improve fertilisation rate and pregnancy rate in women with
endometriosis associated infertility.
Study design, size, duration: A retrospective cohort study was performed
and included 262 conventional IVF cycles and 260 ICSI cycles from 2006 – 2016
at the Fertility Clinic in London, Ontario, Canada.
Participants/materials, setting, methods: The study group included
women with endometriosis associated infertility who were surgically staged
according to the ASRM revised classiﬁcation of endometriosis: 1996. They
were classiﬁed as no endometriosis (control group), minimal to mild (Stage I &
II) endometriosis or moderate to severe (Stage III & IV) endometriosis.
Women aged > 40 years old, male factor infertility, donor gametes and gesta-
tional surrogates were excluded.
Linear and logistic regression analyses were performed to examine the asso-
ciation between stages of endometriosis and method of fertilisation on various
reproductive outcomes. The primary outcome was live birth rate. The second-
ary outcomes included number of oocytes retrieved, percent of oocytes ferti-
lised, number of embryos transferred, number of embryos that developed to
blastocyst, biochemical pregnancy rate and clinical pregnancy rate. Outcomes
were adjusted for age, BMI, FSH, and number of embryos transferred.
Main results and the role of chance: No statistically signiﬁcant differences
in reproductive outcomes were noted between women with no endometriosis
and those with minimal to mild (stage I & II) endometriosis whether conven-
tional IVF or ICSI was utilised. However, ICSI was associated with a 71%
decrease in clinical pregnancy rate (OR = 0.29, p = 0.046) and approached
statistical signiﬁcance for a 69% decrease in live birth rate (OR = 0.31, p =
0.0796) for women with moderate to severe (stage III & IV) endometriosis.
Limitations, reasons for caution: The small sample size of this study may
result in the possibility of observations occurring by chance alone.
Wider implications of the ﬁndings: Further study with a larger sample size
will need to be done to further delineate the relationship between ICSI and
endometriosis associated infertility. However, at this time caution should be
practiced against recommending ICSI when there is no clear indication of failed
fertilisation with conventional IVF or male factor infertility, especially in women
diagnosed with endometriosis associated infertility.
Trial registration number:Not applicable.
POSTER VIEWING
ETHICS AND LAW
P-299 A comparative analysis of marketing materials used to
recruit egg donors in Belgium, Spain and the United Kingdom
V. Provoost1, C. Coveney2, L. Culley2, C. Herbrand2, S. Lafuente3,
V. Pavone3, G. Pennings4, N. Hudson2
1Bioethics Institute Ghent BIG Ghent University, Vakgroep Wijsbegeerte en
Moraalwetenschap, Gent, Belgium
2De Montfort University, Centre for Reproduction Research, Leicester, United
Kingdom
3Spanish National Research Council, Institute of Public Goods and Policies, Madrid,
Spain
4Ghent University, Bioethics Institute Ghent BIG- Department of Philosophy and
Moral Sciences, Ghent, Belgium
Study question: How is egg donation framed in clinic marketing material used
to recruit and/or inform potential egg donors in (Dutch speaking) Belgium,
Spain and the UK?
Summary answer: In Belgium, egg donation (ED) was constructed as an
engagement that required considerable investment and entailed clear risks in
contrast to Spain and the UK.
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What is known already: Across Europe, ED recruitment is performed in dif-
ferent ways. Some countries permit a range of advertising methods while others
limit or completely prohibit any form of advertising relating to human bodily
material (e.g. Belgium). Much of the existing research on recruitment of gamete
donors comes from the US where market forces shape practice more directly.
This paper focusses on Belgium, Spain and the UK - three countries that hold a
stake in the growing global reproductive bio-economy and share features of
technological innovation and expertise, but have adopted different regulatory
positions in relation to the governance and marketing of ED.
Study design, size, duration: An interdisciplinary team of researchers (bio-
ethics, political economy, sociology) conducted a content analysis (including
high frequency words analysis) as well as a comparative thematic analysis to
consider ‘framing’ of egg donation in the data. Interdisciplinary auditing was
used to challenge constructed categories and the conceptual framework at sev-
eral points in the analysis. The ﬁndings were compared with country laws and
informed consent rules and the implications for informed consent were studied.
Participants/materials, setting, methods: In Belgium, all Dutch language
websites of centres were included compared to around 20 clinic websites in both
Spain and the UK. For the latter countries, maximum variation sampling was used
taking into account geographical location, number of cycles, and sector (public/
private). In Belgium, ED is almost entirely situated in the publicly funded system
whereas in Spain and the UK it is mainly performed in the private sector.
Main results and the role of chance: In all three countries, ED recipients
were presented as women whose fertility problems were no fault of their own,
constructing a clear need for the donor to fulﬁl. Descriptions of medical proﬁles
included ‘early menopause’ while natural menopause was absent. With regard
to the act of donating, in Spain and the UK, words such as ‘sharing’, and ‘help-
ing’ were considerably more frequently used compared to the Belgian data.
Especially in Spain, ED was constructed as a form of solidarity between women
nonetheless with a clear emphasis on the compensation. In Belgium, where
clinic advertising is strictly regulated, ED was presented as requiring a consider-
able investment of time and energy from the donor. Potential egg donors in
Belgium were repeatedly warned that the act was ‘not straightforward’ and
‘something to reﬂect about very carefully’. The Belgian material also appeared
to be more focussed on risks and side effects than the Spain and UK material.
The data were analysed within the policy context of the countries. We will dis-
cuss the possible impact of the public/private sector setting and of the Belgian
ban on advertising for the way ED is framed and the implications of the differ-
ences in marketing material for informed consent.
Limitations, reasons for caution: The results are limited to three countries,
and to a (well considered) selection of clinics, therefore precluding generalisa-
tion to whole countries. Further research will be needed on the effects of
recruitment discourses on potential donors in order to generate more general
conclusions and recommendations.
Wider implications of the ﬁndings: These results can contribute to a
more complete understanding of the recruitment of egg donors as a practice
that depends on speciﬁc discourses and is embedded in particular policy con-
texts. The identiﬁcation of problematic framing of marketing material is crucial
in terms of safeguarding true informed consent of donors.
Trial registration number:Not applicable.
P-300 Attitudes and opinions towards gestational surrogacy
among physicians working within reproductive medicine and
obstetrics in Sweden
K.Wånggren1, C. Stenfelt2, G. Armuand3, A. Skoog Svanberg4,
G. Sydsjö5
1Karolinska University Hospital and Karolinska Institutet- Huddinge, Reproductive
medicine and CLINTEC, Stockholm, Sweden
2Karolinska Institutet, Department of Clinical Science Intervention and Technology,
Stockholm, Sweden
3Linköping University, Department of Clinical and Experimental Medicine- Faculty of
Health Sciences, Linköping, Sweden
4Uppsala University, Department of Women’s and Children’s Health, Uppsala, Sweden
5Linköping University, Linköping & Department of Clinical and Experimental
Medicine- Faculty of Health Sciences, Linköping, Sweden
Study question: What attitudes and opinions do physicians working within
obstetrics and reproductive medicine in Sweden display towards gestational
surrogacy?
Summary answer: The physicians were relative positive towards surrogacy
being introduced in Sweden, however they had concerns about the risk of coer-
cion or emotional pressure and exploitation.
What is known already: Gestational surrogacy is not allowed in Sweden,
however about 50 children are born annually to Swedish citizens through cross-
border surrogacy. Very sparse investigations suggest that there is no evidence
of harm for the surrogate, her family or the child, but there is an ongoing debate
about the ethical aspects and medical and psychological risk for the surrogate
and for the child in the future.
Study design, size, duration: A cross sectional survey study was conducted
in 2016. Questionnaires was sent to 141 physicians working within obstetrics
and reproductive medicine.
Participants/materials, setting, methods: This was a Swedish nationwide
study including all physicians working with assisted reproduction technology
(ART) at both public and private IVF units as well as obstetricians heading
maternity clinics and all delivery departments in the hospitals. The study-
speciﬁc questionnaire measured attitudes and experiences in three domains:
Attitudes towards surrogacy, Assessment of prospective surrogate mothers,
and Obstetric and delivery care for surrogate mothers.
Main results and the role of chance: A total of 103 of the physicians
returned the questionnaire yielding a response rate of 74%. While 63% of the
physicians were positive or neutral towards altruistic surrogacy being intro-
duced in Sweden, only 28% thought that it should be publically ﬁnanced. The
majority of the physicians agreed that surrogacy involves risk of exploitation of
women’s bodies (60%). They also expressed concerns about potential surro-
gate mothers not being able to fully understand the risks of entering pregnancy
on behalf of someone else, and agreed that there was a need that a clear legal
contract to be written stating the responsibilities of all involved. They also
expressed concern that there is a risk that the commissioning couple might pay
‘under the table’ to the surrogate mother (82%). As concerns the attitudes of
speciﬁc professional groups, ART-physicians were more positive towards legal-
ization as well as public ﬁnancing compared to those working within maternity
and delivery care. Severe gestational problems, depression, and preeclampsia in
potential surrogate mothers were all regarded as criteria for rejection.
Limitations, reasons for caution: The attitudes and opinions reported here
are based on hypothetical situations. It is possible that physicians would think
differently if surrogacy were to be allowed in Sweden. Due to the anonymous
design we were not able to identify non-responders in order to assess the
representativeness.
Wider implications of the ﬁndings: The study ﬁndings provide important
knowledge about attitudes towards surrogacy among the ART-physician and
obstetricians who would be the ones to implement surrogacy if it were to be
allowed in Sweden. Further discussions about legalization of surrogacy should
include views from a wide ﬁeld of different medical professions and laymen.
Trial registration number:Not applicable.
P-301 Ethical evaluation of informing relatives of premature
menopause (PM) patients
M. Rasekh1, S.R. Ghaffari2, M. Rafati3, F. Ameri1
1Avicenna Research Institute Shahid Beheshti University- Evine, Bio. Law and Ethics
Department- Nano-Biotechnology Research Center, Tehran, Iran
21-Avicenna Research Institute Shahid Beheshti University- Evine- 2- Fetal Health
Research Center- Hope Generation Foundation, Reproductive Biotechnology Research
Center, Tehran, Iran
31- Avicenna Research Institute Shahid Beheshti University- Evine- 2- Fetal Health
Research Center- Hope Generation Foundation, Reproductive Biotechnology Research
Center, Tehran, Iran
Study question: As PM has genetic origins, is it morally right to require the
PM patient to inform her relatives so as to receive ATRs?
Summary answer: In general, it is morally right and justiﬁable to require a PM
patient to inform her relatives who are in reproductive age.
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What is known already: Genetic science has enabled us to identify genetic
causes of PM. Chromosome disorders and cases of advanced mutation of
FMR1 (fragile X Syndrome) are known as the most prominent genetic causes of
PM. Genetic techniques of Next-Generation Sequencing help growing identiﬁ-
cation of single-gene causes of PM in recent years.
There is an up to 50% PM risk for patient’s relatives. Also, 6% of cases of
sporadic PM and 13% of familial PM disease is a result of FMR1 Pre-mutation
and Fragile-X Syndrome carriage. Therefore, informing relatives at risk of PM
saves their natural reproduction and helps preventing unhealthy reproduction.
Study design, size, duration: Firstly, the cases available in the Avicenna
ARTs Clinic over the last ﬁve years are studied. Secondly, based on the empir-
ical data, ethical arguments for and against informing the PM patients’ relatives
are considered. Thirdly, we conclude with the moral stance of our research to
the defence of a general rule of necessity of informing, as this would be condu-
cive to a natural healthy reproduction and prevention of giving birth to children
with severe illnesses.
Participants/materials, setting, methods: Experts in the area genetics,
law and philosophy are involved in this study. Materials are taken from the data
existing in the Clinic relating to the issue at hand, and also analytical substance
derived from the related areas. All ethical requirements for research are met.
The research is conducted on the basis of a combined method. That is, it is
based both on empirical and analytical (moral) methods.
Main results and the role of chance: Notwithstanding the advantages PM
patients gain from ARTs services, conﬁdentiality of certain information may be
violated. In this regard, there exist two obligations which may ﬂy in the face of
each other: 1. patients’ or geneticists’ obligation to let the patients’ relatives
know the possibility of PM and exigency of genetic screening; and 2. an obliga-
tion to keep information of child conceived through ARTs conﬁdential.
The are two radical approach on this issue: 1. taking conﬁdentiality as an
absolute value and plan all other actions on this basis; and 2. profound signiﬁ-
cance of obligation to inform people on the basis of the principle of no harm
and taking all measure on this basis.
Given the above, if PM patients do not inform their relative they may inﬂict
harm on them, especially where the relatives could have taken measures to util-
ize the awareness of their genetic situation.
On the other hand, informing the relatives has to be morally set in tune with
the conﬁdentiality of information of children resulted from ARTs, as this may
amount to disclosure of the conception methods of such children and in the
end damage their quality of lives. How can we make a balance here?
Limitations, reasons for caution: As the study is taking place in a traditional
and heavily religious context, cautions have to be taken on the airing and pub-
lishing of the results of the study.
Wider implications of the ﬁndings: Given the context of the study, imple-
mentation of the results of the study has to be well thought and cautiously
initiated.
Trial registration number: n/a.
P-302 Reproductive Endocrinology Infertility (REI) specialists’
utilization and attitudes towards expanded carrier screening for
oocyte donors
S.R. Lindheim1, T. Glenn1,2, O. Obiako1, J. Madeira3, N. Pereira4,
H. Mertes5, G. Pennings5
1Wright State University Boonshoft School of Medicine, Dayton, OH
2Department of OB/GYNWright Patterson AFB/ Dayton, OH,
3Maurer School of Law, Indiana University, Bloomington, IN
4Weill Cornell Medicine, New York, NY
5Bioethics Institute Ghent, Ghent University, Department of Philosophy and Moral
Science
Study question: To report REIs’ current utilization and attitudes towards ECS
for OD in clinical practice.
Summary answer: Data suggests disagreement concerning the utilization and
dissemination of ECS. Standardized guidelines are needed to clarify ECS applica-
tion and provide guidance regarding ethical quandaries.
What is known already: ECS has become an increasingly important compo-
nent of preconception and prenatal care, however its use for OD remain
unclear globally. Currently, American Society for Reproductive Medicine
(ASRM) advises that genetic screening should be performed based on the
donor’s ethnic background and family history, while European Society of
Human Reproduction and Embryology (ESHRE) recommends it based on
effectiveness and proportionality.1,2
Study design, size, duration: An IRB approved qualitative survey study
from February to December 2017. A total of 83 responses were obtained.
Participants/materials, setting, methods: A 33-question qualitative sur-
vey was distributed through SurveyMonkey® to all Society for Reproductive
Endocrine Infertility (SREI) members.
Main results and the role of chance:Of 83 surveys, 81 (97.6%) were com-
pleted. Based on current ASRM recommendations, 86.7% of REIs request
donors to update their medical history, particularly after identifying a heritable
condition. While 60.2% of respondents discuss ECS with recipients, only 26.5%
of recipients request it. ECS for ODs is utilized by 51.5% prior to acceptance,
while 54.7%. responded that ODs could also decline ECS or request informa-
tion not be disclosed. However, 75% felt that OD agencies and sperm banks
have a responsibility to obtain ECS on all their donors. From a practice stand-
point, REI physicians (46.7%), nurses (12.0%), and geneticists (34.8%) counsel
those with positive carrier status. Overall, 57.8% agreed that ECS should not be
offered until the clinical signiﬁcance is understood for rare diseases. Moreover,
30.6% believed that ECS could lead to a genetically selected population. In con-
trast, 58.1% felt screening should be performed regardless of clinical signiﬁ-
cance. Interestingly, only 20.5% excluded carriers with heritable conditions
from their OD pool.
Limitations, reasons for caution: Limitations of this survey-based study
include varying interpretation of the questions, ability to skip questions, and low
response rate. The sensitive nature of the questions may have deterred indivi-
duals from replying honestly or at all, even considering the anonymous nature
of the survey.
Wider implications of the ﬁndings: ECS is becoming customary practice
for third party reproduction. However, varying responses have been reported
concerning who/what to test, counseling patients, and notifying individuals of
positive carrier status. Our data suggests the necessity of standardizing
guidelines including the inclusion and exclusion of third party gamete donors
with a positive carrier status especially as genetic testing advances and a wider
array of genetic aberrations are discovered.
References.
1. Practice Committee of American Society for Reproductive Medicine;
Practice Committee of Society for Assisted Reproductive Technology.
Recommendations for gamete and embryo donation: a committee opinion.
Fertil Steril 2013;99(1):47-62.
2. Dondorp W, De Wert G, Pennings G, Shenﬁeld F, Devroey P, Tarlatzis B,
et al. ESHRE Task Force on Ethics and Law 21: genetic screening of gamete
donors: ethical issues. Hum Reprod 2014;29(7):1353-9.
Trial registration number:Not applicable.
P-303 The ethics of commercialization: a temporal analysis of
newspaper coverage of IVF add-ons in the UK
A. Geampana, M. Perrotta, A.S. Giraud, J. Hamper
Queen Mary University of London, School of Business and Management, London,
United Kingdom
Study question:What changes have occurred in recent reporting on IVF add-
on treatments in the UK?
Summary answer: During the past year, the public conversation has shifted
from concerns about perceived low-rates of success to issues surrounding add-
on costs and patient ﬁnancial strain.
What is known already: Most media analyses of assisted reproductive tech-
nologies have focused on the North American context (Campbell 2011;
Markens 2012; Orr et al. 2017). Although the UK provides a unique case where
public debates about the cost of IVF treatments have been prominent, there
have been few systematic media reviews to clearly identify temporal changes in
how public concerns have been framed in recent years.
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Study design, size, duration:We performed a search of all newspaper arti-
cles published in the last four years (2013-2017) using the Factiva database. The
key words used were “IVF” and “Add on.” We included all articles that were:
1) focused on IVF and add-ons and 2) published in the UK media. In total, we
retrieved 93 articles. After further screening, we selected 67 records, as some
were duplicates, while others were on topics outside of our inclusion criteria.
Participants/materials, setting, methods: Data were analyzed using con-
tent analysis based on similar work in health-related areas (Graneheim and
Lundman 2004; Forman and Damschroder 2007). Codes were developed both
deductively and inductively according to standard qualitative methods used in
the social sciences (Strauss and Corbin 1997). Articles were then coded in
order to analyze emerging themes.
Main results and the role of chance: This study aimed to explore recent
changes in public debates on IVF add-ons. The term “add-ons” is usually
referred to additional treatments offered – often at an additional cost – to IVF
patients on top their main treatment. However, as fertility professionals have
pointed out, even the term “add-on” itself can be misleading as it can some-
times include routine treatments. We found that the UK public debate signiﬁ-
cantly changed in the wake of a BBC Panorama special on IVF add-ons.
Although ﬁndings suggest that the UK media’s focus has always been on com-
mercialization issues, newspaper articles published before the BBC special
mainly talked about the costs paid by older women undergoing IVF given their
low chances of conceiving. However, starting with the end of 2016, the public
debate has focused particularly on add-ons and the lack of evidence for their
effectiveness. Such treatments are now represented mostly and indiscriminately
as a scientiﬁcally unjustiﬁable cost for patients, focusing on the lack of evidence
of their efﬁciency, safety and cost-effectiveness, and assuming a tacit and uncrit-
ical understanding of what “sufﬁcient” and “robust” evidence is. Additionally,
we found that the most commonly critiqued add-ons are PGS and intralipid
infusion.
Limitations, reasons for caution: This study is limited to media coverage
and does not include surveys or interviews with members of the public.
Wider implications of the ﬁndings: Previous authors have shown that
media coverage can inﬂuence behaviours and health service utilization (Howe
et al., 2002; Leask et al. 2010). The ways in which news reports are framed can
affect policy initiatives in public health as well as the general public’s understand-
ing of IVF add-ons.
Trial registration number: not applicable
POSTER VIEWING
FEMALE FERTILITY
P-304 The anogenital distance can be a response biomarker in
patients undergoing controlled ovarian stimulation for IVF
F. Fabregues Gasol1, I. Gonzalez-Foruria2, P. Joana1, G. Sandra3,
C. Francisco1
1Hospital Clinic, Institut Clinic of Gynecology- Obstetrics and Neonatology, Barcelona,
Spain
2Hospital Clinic /I. Dexeus, Institut Clinic of Gynecology- Obstetrics and Neonatology,
Barcelona, Spain
3I. Dexeus, Unitat de Reproduccio Asistida, Barcelona, Spain
Study question: Is the length of the anogenital distance (AGD) a biomarker
of ovarian reserve and response to controlled ovarian stimulation (COS)?
Summary answer: Shorter AGD is associated with presence of poor ovarian
response.
What is known already: Organ development during prenatal life is inﬂu-
enced by the prevailing intrauterine environment, and it has been suggested
that nutritional, environmental and toxic factors could affect ovarian reserve set
prenatally. AGD is a biomarker of prenatal-hormonal environment and
observational studies have shown an association between its length and repro-
ductive parameters in both sexes.
Study design, size, duration: This was a prospective cohort study of 437
women treated with IVF/ICSI conducted in a tertiary-care university hospital
between January and December 2016.
Participants/materials, setting, methods: Patients were divided into
three groups: poor responders (<3 oocytes) (n = 50), normoresponders (4-15
oocytes) (n = 332) and high responders (>15 oocytes) (n = 55).Clinical charac-
teristics, ovarian reserve markers, total doses of gonadotropins used and ovar-
ian sensitivity index (OSI) were recorded. Patients with previous pregnancies,
polycystic ovary syndrome (PCOS), endometriosis and previous ovarian or
genital surgery were excluded. AGDAC (anus-clitoris) and AGDAF (anus-four-
chette) were measured before proceeding to oocyte pick-up. Multiple linear
regression and logistic regression analyses were used.
Main results and the role of chance: Baseline FSH, AMH, AFC and age
were signiﬁcantly different among the three groups of ovarian response, as
were the units of gonadotropin used, and the ovarian sensitivity index (OSI)
(P< 0.001). Both AGDAC and AGDAF measurements were positively corre-
lated with AMH levels (r = 0.38 and r = 0.21; P< 0.05), AFC (r = 0.41 and r =
0.20; P< 0.05), the OSI (r = 0.24 and r = 0.19; P< 0.05) and the number of
oocytes retrieved (r = 0.29 and r = 0.28, respectively; P< 0.05). Conversely,
there was a negative correlation between both AGD measurements and the
doses of gonadotropins used (r = -0.19 and r = -0.15; P< 0.05). The area
under the curve (AUC) for prediction of poor response of AGDAC was 0.70
(95%CI 0.66-0.75), which was comparable to the classic ovarian reserve mar-
kers, such as AFC and AMH. AGDAF showed a signiﬁcantly worse predictive
capacity for poor ovarian response (AUC 0.60 [95% CI 0.55-0.60]) than AMH
and AFC.
Limitations, reasons for caution: As this was an observational study, causal
inference cannot be ruled out.
Wider implications of the ﬁndings: The ﬁndings of this study suggest that
in utero exposure to certain hormonal environments could affect the ovarian
reserve set prenatally.
Trial registration number:No.
P-305 Non steroidal anti-inﬂammatory drugs (NSAID) such as
ibuprofen have only a limited effect on on the intrafollicular milieu of
pre-ovulatory follicles
I. Bienz, N. Bersinger, M. Eisenhut, A. Kohl, M. VonWolff
University Women’s Hospital, Division of Gynaecological Endocrinology and
Reproductive Medicine- Inselspital, Bern, Switzerland
Study question: What is the impact of NSAID, speciﬁcally ibuprofen, on the
intrafollicular milieu of naturally matured pre-ovulatory follicles?
Summary answer: Ibuprofen slightly decreases cytokine and estradiol but
not matrix metalloprotease concentrations in the ﬂuid of naturally matured pre-
ovulatory follicles.
What is known already: NSAID are not recommended around ovulation in
women trying to conceive spontaneously. In contrast, in Natural Cycle IVF
(NC-IVF) NSAIDs are used in daily routine to reduce the risk of premature
ovulation. NSAID inhibit cyclooxygenases (COX2) that catalyse the synthesis
of PGE2, a key prostaglandin in the inﬂammatory cascade of ovulation.
Ibuprofen, at a dosage of 3×400 mg/day, is a frequently used analgesic in
women.
Study design, size, duration: Prospective, within-subjects study, performed
at a University based infertility centre between 2014 and 2017 and including 19
women undergoing NC-IVF. Patient age was 26-44 years; menstrual cycles
were regular. If an early onset of an LH-surge (10-20 IU/L) was diagnosed the
women were administered ibuprofen (3×400 mg/day), and follicle aspiration
was performed 36 hours after HCG injection. If no LH-surge was detected no
ibuprofen was taken.
Participants/materials, setting, methods: Follicular ﬂuid was collected
from the 19 women, undergoing one cycle with and one cycle without ibupro-
fen. The concentrations of follicular cytokines (IL-1β, IL-6, IL-8, IL-12, GM-CSF,
TNFα, VEGF), prostaglandin E2, matrix metalloproteases-2 and -9 and hor-
mones (LH, FSH, estradiol, total testosterone, AMH) were determined by
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single or multiplexed immunoassays and compared in matched cycles with and
without ibuprofen administration.
Main results and the role of chance: In the follicular ﬂuid of ibuprofen trea-
ted women, IL-8 was signiﬁcantly (P<0.05) decreased and IL-6 and PGE2
showed a trend towards reduced concentrations compared to controls (IL-8,
170 pg/mL vs. 218 pg/mL, P<0.05; IL-6, 2.2 pg/mL vs. 3.3 pg/mL; PGE2,
5.4 ng/mL vs. 6.3 ng/mL). Estradiol concentration was also lower in patients
with Ibuprofen (2293nmol/L vs. 3047nmol/L, P<0.05). However, other cyto-
kines, matrix metalloproteases and hormones, including IL-1β, TNFα, VEGF,
MMP-2, MMP-9, LH, FSH, total testosterone and AMH, were unchanged
between cycles with or without ibuprofen. Our study revealed that NSAIDs,
speciﬁcally ibuprofen, had some but limited impact on the follicular physiology.
It also showed that ibuprofen can postpone ovulation in most women for sev-
eral hours.
Limitations, reasons for caution: The number of included women was lim-
ited due to the strict, within-patient inclusion criteria.
Wider implications of the ﬁndings: As the effect of ibuprofen on prosta-
glandin and cytokine concentrations in follicular ﬂuid is small, the treatment with
this medication around ovulation should be safe in the analysed dosage in
women trying to conceive spontaneously as well as under IVF treatment.
Trial registration number:Not applicable.
P-306 Dynamic culture of human ovarian tissue in a perfusion ﬂow-
through bioreactor enhances follicle progression as compared to
static culture in gas-permeable dishes
R. Talevi1, G. Catapano2, M. Di Nardo1, V. Costanzo1, V. Barbato1,
S. Braun1, A. Merolla1, R. Ferraro3, R. Gualtieri1
1Università degli studi di Napoli Federico II, Dipartimento di Biologia, Napoli, Italy
2University of Calabria, Dept. of Environmental & Chemical Engineering, Cosenza,
Italy
3Iatropolis, Centro Genesis, Caserta, Italy
Study question: Can in vitro continuous perfusion of human ovarian tissue
strips improve follicle progression and viability of follicles over culture in gas-
permeable dishes (PD)?
Summary answer: Culture in dynamic perfusion ﬂow-through bioreactors
(PB) vs static gas-permeable dishes signiﬁcantly increased follicle progression to
the secondary stage.
What is known already: In vitro culture of strips of human ovarian tissue in
static PD enhances follicle viability and progression over conventional gas-
impermeable dishes by improving oxygen availability in situ. However, progres-
sion to the secondary stage is not yet optimal for subsequent follicle isolation
and culture until complete oocyte maturation. This is possibly due to subopti-
mal control of culture conditions and the absence of physiological biomechan-
ical cues in static culture dishes. Dynamic continuous perfusion bioreactors may
enable the physiological availaibility of solutes as well as the application of
physiological ﬂuid mechanic stresses to tissue.
Study design, size, duration: This paper reports on a comparative study of
static versus dynamic bioreactors for the culture of human ovarian biopsies.
Tissue strips 1×1×0.5 mm from each patient (n = 4) were cultured in static
oxygen permeable dishes (PD) and in dynamic perfusion ﬂow-through bioreac-
tors (PB) for 6 days. Follicle quality, progression and viability were respectively
assessed through histology and live/dead assay under confocal microscopy.
Participants/materials, setting, methods: Ovarian biopsies, collected
from consenting patients (age <35) during laparoscopic surgery for benign gyne-
cologic conditions, were cut with a tissue chopper and cultured in PB and PD
for 6 days in alpha-MEM medium plus supplements at 37°C, 5% CO2 and 95%
humidity in air. Fresh (D0) and cultured strips (D6) were ﬁxed and stained for
histological analysis or labelled with live-dead far red and Hoechst 33342 for via-
bility assessment at the confocal microscope.
Main results and the role of chance: Overall 1349 follicles were analysed.
Data showed that ovarian strips at day 0 mainly contain follicles at the primor-
dial stage (primordial, 72.5%; primary, 24.3%; secondary, 3.2%) characterized
by a good quality (grade1, 42.5%; grade2, 27.3%; grade3, 30.2%). Culture for 6
days in PB generally yielded signiﬁcantly higher follicle progression (primordial,
24.4%; primary, 46.2%; secondary, 29.4%), viability (64.4%), and quality
(grade1, 28.4%; grade2, 38.6%; grade3, 33%) than in PD (primordial, 34.5%
(p<0.05); primary, 47.9% (NS); secondary, 17.6% (p<0.01) - viability, 64.3%
(NS) - grade1, 22.5% (NS); grade2, 31.7% (NS); grade3, 45.8% (p<0.01)). The
results suggest that dynamic culture of human ovarian tissue strips in the perfu-
sion ﬂow-through bioreactor for 6 days enhances follicle progression as com-
pared to static culture in gas-permeable dishes in the patients under
investigation.
Limitations, reasons for caution: Due to the high heterogeneity of ovarian
tissue structure and follicle density and the limited number of patients, this pre-
liminary study needs to be validated on a higher number of tissue strips and in a
larger cohort of patients.
Wider implications of the ﬁndings: In perfusion ﬂow-through bioreactors,
oxygen perfusion, nutrients availability and biomechanical cues have a key role
in the health and progression of cultured follicles. This approach may increase
the yield of secondary follicles and enhance the efﬁciency of two-step protocols
for human in vitro folliculogenesis.
Trial registration number: not applicable.
P-307 Thyroid autoimmunity is associated with higher risk of
premature ovarian failure - A nationwide Health Insurance
Research Database study
J.Y.P. Ho1, Y.T. Hsieh2
1China Medical University Hospital, Center for Reproductive Medicine, Taichung City,
Taiwan R.O.C.
2China Medical University Hospital, Department of Chinese Medicine, Taichung City,
Taiwan R.O.C.
Study question: Is thyroid autoimmunity associated with higher risk of low
ovarian reserve and premature ovarian failure?
Summary answer: Thyroid autoimmunity have a signiﬁcantly higher risk of
premature ovarian failure.
What is known already: Premature ovarian failure is closely related with
autoimmune disease and thyroid autoimmunity may account for diminished
ovarian reserve in some studies. However, there is no large scale cohort study
to demonstrate the association between thyroid autoimmunity and premature
ovarian failure.
Study design, size, duration: A population-based retrospective cohort
study on the foundation of the National Health Insurance Research Database
was designed in a longitudianl-time-course fashion. National Health Insurance
(NHI) program in Taiwan since March1, 1995 and included 99.9% of the 23 mil-
lion population of Taiwan. Patients between January 1, 2000 to December 31,
2013 were eligible for recruitment.
Participants/materials, setting, methods: An autoimmune thyroid dis-
ease cohort was composed of patients with autoimmune thyroid disease older
than 25 years of age and younger than 40 years of age. The comparison cohort
consisted of patient in the National Health Insurance Research Database with-
out autoimmune thyroid disease matched by age at a ratio of 1:3.95.
Main results and the role of chance: Overall, 2736 autoimmune thyroid
disease patients and 10821 comparison patients were followed-up until a diag-
nosis of ovarian failure, amenorrhea or menopausal syndrome had been made.
Compared with the comparison cohort, patients with autoimmune thyroid dis-
ease presented a 78% higher risk for ovarian failure (95% CI = 1.44-1.97) and a
49% higher risk of ovarian failure after adjustment (95% CI = 1.08-2.07). The
cumulative incidence of amenorrhea or ovarian failure in thyroid autoimmunity
group were signiﬁcantly higher than in comparison group.
Limitations, reasons for caution: This is a retrospective study with ICD-9
disease code analysis for the statistical association between two diseases.
Wider implications of the ﬁndings: Given that the autoimmune thyroid
disease is highly associated with early diminished ovarian reserve or even pre-
mature ovarian failure, the option for infertility treatment may be re-directed to
more efﬁcient methods in infertile patients diagnosed with autoimmune disease.
Trial registration number: non-clinical trials.
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P-308 Possibilities of preimplantation genetic screening (PGS) in
overcoming the impact of age on assisted reproductive technologies
(ART) results
V. Lokshin, R. Valiev, S. Karibaeva, A. Rybina, A. Malik, Y. Tyugay,
I. Khoroshilova
The international clinical reproductive center “PERSONA”., Reproductology, Almaty,
Kazakhstan
Study question: Does PGS increase pregnancy rate in advanced age women?
Is there a relationship between AMH level and the frequency of aneuploidy?
Summary answer: A strong correlation between AMH and aneuploidy was
found. The frequency of clinical pregnancy is signiﬁcantly higher in women of
older reproductive age after CGH.
What is known already: The inefﬁciency of assisted reproductive technolo-
gies can be as a result of many factors. Aneuploidy is directly depends on the
maternal age and rarely associated with the morphological characteristics of the
embryos. PGS are used for diagnosis chromosomal rearrangements and selec-
tion balanced or healthy embryos. Consequently PGS can increase pregnancy
rate and prevent transmission of unbalanced rearrangements to offspring.
Study design, size, duration: Since November 2016 to December 2017 the
retrospective open comparative study of 282 embryos from 99 couples was
conducted in the international clinical reproductive center “PERSONA”.
Participants/materials, setting, methods: All couples were undergone
IVF and FET programs. Embryos were undergone biopsy of trophoectoderm
on day 5 or 6 with examination by a-CGH to diagnose chromosomal abnormal-
ities. All 99 women were divided into two groups at different ages. The ﬁrst
group included 32 women under 35 years old, the average age was 29.7 years.
The second group included 67 women over 36 years and older (average age
41.6 years).
Main results and the role of chance: In the ﬁrst group 460 oocytes and 85
embryos were obtained. In the second group 559 oocytes and 197 embryos
were obtained. Chromosomal abnormalities of embryos in both groups were
identiﬁed: 45.8% and 56.3% respectivly. There was a strong correlation
between the level of AMH and the probability of obtaining an euploid embryo,
r = 0.99. An average AMH in group 1 was 4.79+ 2.2, the level of euploidy was
54.2%. An average AMH level in group 2 was 2.98 + 2.9, the level of embryo
euploidy was 43.7%, p<0.05. Pregnancy occurred in 57.1% in group 1, in the
2nd group pregnancy occurred in 64.5%, p<0.05.
Limitations, reasons for caution:Non.
Wider implications of the ﬁndings: Applying of PGS allows to increase the
pregnancy rate up to 65% for embryo transfer to reduce the risk of a chromo-
somal pathology with a probability of up to 95%. There is a direct relationship
between AMH level and the probability of receiving an euploid embryo.
Trial registration number: 1 PK.
P-309 Themost accurate approach for reproductive tract
microbiome analysis
M. Díaz1, A. Bernabeu2, B. Lledo3, J. Ortiz3, A. Masbou4, D. Keefe4,
J. Llacer2, R. Bernabeu2
1Instituto Bernabeu, IVF laboratory, Alicante, Spain
2Instituto Bernabeu, Reproductive Medicine, Alicante, Spain
3Biotech, Molecular Biology Department, Alicante, Spain
4New York University, Langone Fertility Centre, New York, U.S.A.
Study question: Does primer selection have any effect on vaginal and endo-
metrial microbiome analysis?
Summary answer: V3V5 primers sets are better suited to identify microor-
ganisms at genus and species abundance. Thus, experimental design is essential
when examining the vaginal/endometrium microbiome.
What is known already: The human microbiome is tightly related to health
in disease states as well as the reproductive system. Its analysis using a marker
gene and NGS became in a powerful tool. The 16S-rRNA contains nine hyper-
variable regions (V1V9) ﬂanked by conserved regions, which makes an ideal tar-
get of bacterial classiﬁcation. However, most NGS-platforms are not capable of
covering the full-length gene. Thus, short regions have been prioritized.
Currently, there is no consensus of which region best reﬂects the vagina/
endometrium microbiome. The aim was to investigate if the reproductive-tract
microbiome proﬁle will have subtle variations by virtue of the primer set used.
Study design, size, duration: A prospective study was performed. Patients
attenting to our clinic were recruited from May to December 2017. In order to
detect different diversity in the microbiome, samples were taken at different
stages from the same patient (n = 22): luteal phase in the previous cycle, the
day of the embryo transfer, the day of the BHCG sample and the day of the
ultrasound in the case of getting pregnant.
Participants/materials, setting, methods: In order to avoid confusion fac-
tors that can affect the variability and diversity in the microbiome proﬁle we
included patients that performed a frozen embryo transfer. DNA was extracted
using the PureLink Microbiome DNA Puriﬁcation kit. To evaluate biases intro-
duced by primer selection V3V4 and V3V5 were used. Sequencing and bioinfor-
matics analysis were performed according to Illumina Metagenomics protocol
using the NexteraXT library on the Miseq instrument.
Main results and the role of chance:Overall, the average classiﬁcation rate
at genus level was 90.2% and at species level 74.32% for all samples. Regarding
the sample collection, differences were shown when we compared the endo-
metrium and the vaginal samples, for genus and species classiﬁcation results
(60.0 + 25.6 vs 98.7 + 0.6, p<0.05; 44.0+ 21.0 vs 81.1+4.1, p<0.05). For pri-
mer set used, no differences were reported in the classiﬁcation rates for V3V4
and V4V5 at genus and species level when we consider all the samples.
However, when we consider the subset of vaginal samples, higher numbers of
classiﬁed microorganisms at genus level were obtained when we used V3V5
(99.0+0.1 vs 98.3+ 0.7, p<0.05). Regarding the diversity studies 35 different
genus and 13 species at top frequencies were detected among samples, sug-
gesting that genus studies give us more information about the microbiome
diversity, revealing more than unique Lactobacillus OTU. Species identiﬁcation
of Lactobacillus is more difﬁcult using a V3V4 primer set. Thus, V3V5 provides
both breadth and depth of communities dominated by these genera, V3V5
amplicons will reveal either lactobacilli-dominant or lactobacilli-diminished
groups. Because the reproductive tract microbiome is a Lactobacilli dominant,
experimental design is essential for a broad species detection when examining
the vaginal/endometrium microbiome.
Limitations, reasons for caution: The study is limited due to the sample
size. A higher sample size should be used in future studies to corroborate the
current ﬁndings. The lack of a standardized workﬂow has led to uncertainties
regarding the transparency and reproducibility of microbiome studies.
Wider implications of the ﬁndings: In conclusion, the microbiome proﬁle
will have subtle variations by virtue of the primer set used. V3V5 will distinguish
more accurate species in Lactobacillus predominant communities.The uniﬁca-
tion of analysis procedures and the implementation of standardized workﬂows
may be done in order to minimize variation introduced in the results.
Trial registration number:Not applicable.
P-310 Melatonin attenuates aging of post-ovulatory mouse oocytes
via a SIRT1-MnSOD dependent pathway
Q. Yang, S. Dai, X. Luo, S. Yingpu
The First Afﬁliated Hospital of Zhengzhou University, Reproductive medcine centor,
Zhengzhou, China
Study question: The underlying mechanisms of how melatonin improves the
quality of post-ovulatory aged oocytes remain largely unclear.
Summary answer: melatonin delays post-ovulatory mouse oocyte aging via a
SIRT1-MnSOD-dependent pathway.
What is known already: The quality of post-ovulatory metaphase II oocytes
undergoes a time-dependent deterioration as a result of the aging process.
Melatonin is considered an anti-aging agent.
Study design, size, duration: In vitro aged MII oocytes were used in experi-
ments at 0, 6, 12 and 24 h. For the melatonin treatment, the treated oocytes
were incubated in the IVF medium with a ﬁnal concentration of 10-7, 10-5, or
10-3 M melatonin.
Participants/materials, setting, methods: To collect the metaphase-II
(MII) oocytes, mice were stimulated by an intraperitoneal injection of 7.5 IU of
Pregnant Mares Serum Gonadotropin (PMSG), and 7.5 IU human Chorionic
Gonadotropin (hCG) was injected to induce superovulation. The mice were
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sacriﬁced 12-14 h after the hCG was used. The cumulus-oocyte complexes
(COCs) were obtained by breaking the oviductal ampullae.
Main results and the role of chance: In this study, we found that there
were elevated ROS levels and impaired mitochondrial function demonstrated
by reduced mitochondrial membrane potential (ΔΨm) and increased mito-
chondrial aggregation in oocytes aged 24 h, accompanied by an increased num-
ber of meiotic errors, unregulated autophagy-related proteins and early
apoptosis, which led to decreased oocyte quality and disrupted developmental
competence. However, all of these events can be largely prevented by supple-
menting the oocyte culture medium with 10-3 M melatonin. Additionally, we
found that the expression of sirtuin family members (SIRT1, 2, 3) was dramatic-
ally reduced in aged oocytes. In addition, in vitro supplementation with mela-
tonin signiﬁcantly upregulated the expression of SIRT1 and antioxidant enzyme
MnSOD, but this action was not observed for SIRT2 and SIRT3. Furthermore,
the protective effect of melatonin on the delay of oocyte aging vanished when
the SIRT1 inhibitor EX527 was used to simultaneously treat the oocytes with
melatonin. Consistent with this ﬁnding, we found that the post-ovulatory
oocyte aging process was markedly attenuated when the oocytes were treated
with the SIRT1 activator SRT1720.
Limitations, reasons for caution: This study was done only in vitro.
Wider implications of the ﬁndings: Melatonin can be used in IVF for pre-
vents oocyte aging.
Trial registration number: none.
P-311 Peripheral bloodmononuclear cells in IVF practice: 2 years
experience
E. Zhylkova1, O. Feskov2, V. Feskov3, O. Blazhko4
1Centre of Human Reproduction Sana-Med, Genetic laboratory, Kharkiv, Ukraine
2Clinic of Professor Feskov A.M. Sana-Med Ltd., Administration, Kharkov, Ukraine
3Sana-Med Ltd., IVF department, Kharkov, Ukraine
4Clinic of Professor Feskov A. M. Sana-Med Ltd., IVF Department, Kharkov, Ukraine
Study question: Do the application of intrauterine transfer of peripheral
blood mononuclear cells (PMBC) improve embryo implantation rates in IVF?
Summary answer: The IVF success rates were higher in the PBMC-treated
group (P <0.01) comparing with the non-treated group in “cryo” IVF cycles.
What is known already: A human endometrium is able to accept embryos
only during some limited period. Endometrium should be prepared to embryo
transfer to achieve embryo implantation. There is a suggestion that maternal
immune cells are able to support the process of embryo implantation.
Study design, size, duration: The aim of the work was to examine the inﬂu-
ence of intrauterine peripheral blood mononuclear cells application on embryo
implantation rates for infertile patients in “fresh” and “cryo” IVF cycles. The
study’s protocol was approved by the Center’s IRB.During January 2016 -
December 2017, a total of 890 infertile couples were subjected to IVF treat-
ment. All the infertile patients were divided into two groups: with application of
PBMC and without one.
Participants/materials, setting, methods: PBMC were applied for 401
patient – 216 “fresh” IVF cycles and 165 ET after blastocysts cryopreservation.
Non-PBMC group consisted of 489 patients – 240 “fresh” IVF cycles and 249
“cryo” IVF protocols. Two high quality blastocysts were transferred in each
case. PBMC were applied after previous culture before the ET. Veriﬁcations of
associations of PBMC application with implantation rates were accomplished by
the Chi-square test (χ2 test).
Main results and the role of chance: The implantation rate was signiﬁcantly
higher in PBMC-treated group in “cryo” IVF protocol comparing with ETs of vit-
riﬁed blastocysts without PBMC (df = 1, χ2 = 9.852, χ2critical = 6.635, P <0.01).
There was no signiﬁcant difference in implantation rates in both groups after
“fresh” IVF attempts. We haven’t considered the age of the patients in the pre-
sent study. But out previous investigations showed the PBMCs affects in “fresh”
IVF cycles in patients after 38 years old.
Limitations, reasons for caution: ET and vitriﬁcation of the blastocyst can
be carried out for the embryos with the high quality of morphology.
Wider implications of the ﬁndings: More detailed investigations in this
ﬁeld could explain the role of immune system in the implantation process and
early pregnancy control. PBMC therapy could improve implantation rates in
patients with recurrent IVF failures with the high quality embryos.
Trial registration number: -
P-312 Use of granulocyte colony-stimulating factor during an
assisted reproductive treatment does not increase the risk of birth
defects
M. Cruz1, D. Alecsandru2, J.A. García-Velasco3, A. Requena3
1IVI Madrid, IVF Lab, Madrid, Spain
2IVI Madrid, Immunology, Madrid, Spain
3IVI Madrid, Reproductive Medicine, Madrid, Spain
Study question: To assess the effect of administration of granulocyte colony-
stimulating factor (G-CSF) in newborns resulting from an assisted reproductive
treatment.
Summary answer: Administration of G-CSF during the ﬁrst steps of preg-
nancy does not imply a higher risk of perinatal complications or malformations
in offspring.
What is known already: G-CSF illustrates the scope of reproductive immun-
ology, as they act on reproductive function at different levels such ovulation,
embryo implantation and embryo development. Despite their growing interest
in the reproductive ﬁeld, actions of G-CSF have still not been explained con-
cerning its effects on the early stages of embryo development. Information avail-
able up to date indicates that administration of G-CSF is safe in terms of risk of
perinatal complications on offspring, although further studies are needed to
show the harmlessness of this drug in newborns.
Study design, size, duration: Retrospective study performed in 11 private
clinics belonging to IVI-RMA group from January 2014 to December 2016. Our
study group included 33 live-born children from a pregnancy in which G-CSF
was administered compared to the control group, which contained 3798 chil-
dren from couples also undergoing an assisted reproductive treatment in the
same clinics and in whose pregnancy this drug was not ordered. Couples were
called a month after delivery date to obtain perinatal information.
Participants/materials, setting, methods: G-CSF is essential in the utero-
placental cytokine network needed to establish and maintain pregnancy.
Patients with KIR-HLA-C mismatch and recurrent miscarriage as the study
group were treated as off label and after a signed informed consent, with a daily
subcutaneous administration of 13 mUI of ﬁlgrastim (Neupogen, Amgen, USA)
from the embryo transfer until the end of the ninth week of pregnancy.
Statistical analysis was performed by ANOVA and Chi-squared where
applicable.
Main results and the role of chance: There were no statistical differences
in mother’s age (40.9 ± 0.1 vs. 38.9 ± 1.8, p = 0.055), body mass index (23.2
± 0.2 vs. 22.6 ± 1.5, p = 0.503), children’s weight (2952 ± 200 g vs. 3145 ±
270 g, p = 0.184), gestational age (38 ± 1 w vs. 37 ± 1 w, p = 0.926) and length
(50.7 ± 2.1 cm vs. 50.0 ± 1.3 cm, p = 0.969) between control group and
women treated with G-CSF respectively. According prematurity rate, we did
not also observe relevant variances in the percentage of births before week 36
(10.0% vs. 9.5%, p = 0.783) and week 32 (2.2% vs. 0.0%, p = 0.585) for the
control and the study group respectively. Finally, we also analyzed the percent-
age of children under 2500 g (19.6% vs. 11.8%, p = 0.570) and under 1500 g
(2.5% vs. 0.0%, p = 0.454) and as the previous data, we did not ﬁnd signiﬁcant
differences for non-treated and ﬁlgrastim treated women.
According adverse perinatal outcomes, we did not ﬁnd any birth defect in
children included in the study group compared to a 2.1% of children affected by
some congenital anomaly.
Limitations, reasons for caution: A limitation of our study is the small sam-
ple size, which makes difﬁcult to draw conclusive results. Moreover, a conse-
quence of a retrospective study is that not all pertinent risk factors are likely to
have been identiﬁed and subsequently recorded. Therefore, only association
can be inferred from the results.
Wider implications of the ﬁndings: The above analysis of the effect of G-
CSF of in vitro fertilization perinatal outcomes in infertile women suggest the
safety of G-CSF use in pregnancy, as no neonates complications have been
observed. Even though, this treatment should be used carefully.
Trial registration number:Not applicable.
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P-313 Control of actin nucleators by maturation regulating factors
in mouse oocytes
F. Tepekoy Ozcelik1, G. Akkoyunlu2
1Istinye University Faculty of Medicine, Histology and Embryology, Istanbul, Turkey
2Akdeniz University Faculty of Medicine, Histology and Embryology, Antalya, Turkey
Study question: Does MAPK/ERK kinase (MEK) inhibition and maturation
promoting factor (MPF) activation affect actin nucleators Spire-1 and Spire-2 in
mouse oocytes?
Summary answer: MEK inhibition and MPF activation results in elevated
levels of Spire-1 and Spire-2 at different stages of oocyte meiotic maturation.
What is known already:Meiotic resumption of the oocyte is mainly driven
by MPF. During meiotic arrest, MPF is inhibited by protein kinase A (PKA),
thus inactivated PKA leads to meiotic resumption. Resumption of meiosis
results in two inequivalent cells: the polar body and oocyte. Chromosome
migration regulated mainly by actin nucleators, takes place to achieve this
asymmetric division. Actin nucleators Spire-1 and Spire-2 are known to have
roles in asymmetric division of oocytes. MAPK signaling, known to regulate
MPF, is also associated with asymmetric division of oocytes, though it is
unclear whether it directly affects actin nucleators, or through the activation
of MPF.
Study design, size, duration: The oocytes retrieved from 10 mice were
pooled and divided into 4 groups for in vitro culture: MEK inhibitor PD98059
(1), PKA inhibitor H89 for MPF activation (2) and combination of these inhibi-
tors (3), DMSO only as vehicle (4). The oocytes were analyzed at germinal ves-
icle breakdown (GVBD) (2 hours), spindle formation (5 hours), spindle
migration (7 hours) and polar body extrusion (PBE) stages as wells as at germi-
nal vesicle (GV) stage without culturing process.
Participants/materials, setting, methods: MEK inhibitor PD98059 and
PKA inhibitor H89 for MPF activation was applied during IVM to the GV
oocytes retrieved from preovulatory ovarian follicles of 3-5 weeks old female
BalbC mice after follicle activation. GVBD and PBE rates of the oocytes were
determined. The localizations of Spire-1 and Spire-2 were detected through
immunoﬂuorescence. Spire-1, Spire-2, pERK1/2 and pCREB protein levels
were determined via Western blot for oocytes at different stages. All experi-
ments were repeated 3 times.
Main results and the role of chance: MEK inhibitor at a concentration of
50 μM signiﬁcantly reduced pERK1/2 (MEK phosphorylation target) levels of
the oocytes. pCREB, the downstream target of PKA was signiﬁcantly reduced
at 10 μM concentration of PKA inhibitor. The inhibitors were applied at these
doses during IVM of the oocytes.
GVBD rates were similar in different groups, while PBE rates were lower in
MEK inhibition group. Cortical localization of Spire-1 and Spire-2 was
detected in oocytes by IF at all stages of meiotic maturation. In control group,
both cortical and total Spire-1 level was signiﬁcantly the lowest at spindle
migration stage, though Spire-2 cortical localization was the lowest in GV
oocytes. MEK inhibition resulted in a decrease both in cortical Spire-1 and
Spire-2 levels in PBE oocytes. PKA inhibition (MPF activation) led to increase
in cortical Spire-1 levels in spindle migration stage oocytes, while it resulted in
increase of cortical and total Spire-2 levels in PBE oocytes. Application of
MEK inhibition and MPF activation at the same time caused an increase in
Spire-1 levels at PBE oocytes, pointing out a compensation of the decreasing
effect of MEK inhibition. However, Spire-2 levels remained low with no com-
pensation of MEK inhibition in PBE oocytes.
Limitations, reasons for caution: This study only includes the inhibition of
a particular member of MAPK signaling and a certain regulator of MPF.
However, the relation of actin nucleators with MAPK and MPF might also be
through their upstream or downstream regulators.
Wider implications of the ﬁndings: The factors affecting actin nucleation
contribute to correct positioning of the meiotic spindle during oocyte matur-
ation. Proper manipulation of actin nucleators by chemical inhibitors or activa-
tors during IVM of oocytes might enhance the development potential of the
embryo leading to an increased success rate in fertility treatments.
Trial registration number: This work was supported by The Scientiﬁc and
Technological Research Council of Turkey (TUBITAK).
P-314 Anti-Müllerian hormonemay have a rebound effect in long-
term human ovarian tissue grafts co-transplanted with Endothelial
Cells
L. Man1, L. Park1, G.L. Schattman1, Z. Rosenwaks1,2, D.J. James1,2
1Weill Cornell Medical College, Center for Reproductive Medicine and Infertility, New
York, U.S.A.
2Weill Cornell Medical College, Tri-Institutional stem cell Derivation Laboratory, New
York, U.S.A.
Study question: Will co-transplantation of human ovarian tissue with Anti-
Müllerian hormone (AMH) producing endothelial cells (ECs) keep a larger
cohort of quiescent follicles in long-term grafts?
Summary answer: Co-transplantation of human ovarian tissue with AMH
producing ECs in long-term grafts may create a rebound effect and cause follicu-
lar requirement.
What is known already: AMH has been suggested to exert a repressive
input on activation and/or growth during normal folliculogenesis. We have pre-
viously shown that direct paracrine delivery of AMH via lentivirally engineered
exogenous endothelial cells (exECs) reduced premature follicular mobilization
and growth upon co-transplantation at 2-weeks post grafts (Man, et al., 2017).
Another group, using continuous administration of AMH via osmotic pump or
intraperitoneal injection of lentivirally encoded AMH in a murine model showed
similar results (Kano, et al., 2017).
Study design, size, duration: Cross-sectional study, xenograft of human
ovarian tissue into NOD scid gamma (NSG) mice with co-transplantation of
control exECs (n = 7) or exECs ectopically expressing human AMH (n = 8).
Grafts were harvested at 14 weeks and the ratio of follicles in each treatment
was assessed in histologic sections using light and confocal microscopy.
Participants/materials, setting, methods: Human ovarian tissue, originat-
ing from 2 patients, was co-transplanted with ECs or AMH-ECs; patient-
matched ovarian tissue was used in control and experimental groups. Both con-
trol and AMH expressing ECs were transduced with lentiviral vectors encoding
Red ﬂuorescent protein (RFP). Grafts were harvested at 14 weeks and a ratio
of follicles in each treatment was assessed in histologic sections.
Main results and the role of chance: AMH-ECs grafts revealed a shift in
the follicular pool away from quiescence with a decreased percentage of prim-
ordial follicles. In contrast, grafts co-transplanted with ECs showed a signiﬁcant
retention of primordial follicles at 14 weeks. In these long-term grafts, we found
a two-fold increase in primordial follicles median percentage with AMH-ECs;
10.84 ± 6.98 vs. ECs 22.51 ± 7.15, P = 0.05. We found a 2-fold decrease
between a median ratio of primordial to growing follicles with AMH-ECs; 8.23
± 3.62 vs. ECs 3.44 ± 1.07, P = 0.05.
Limitations, reasons for caution: Human ovarian tissue available for
research is restricted, repeating the experiment at different time points may
shed more light on the phenomenon we have described here.
Wider implications of the ﬁndings: As auto-transplantation of ovarian tis-
sue becomes more widely practiced, resolution of mechanisms mediating fol-
licular activation and growth are increasingly relevant. Our unexpected ﬁnding,
given previous results indicating a suppressive input of AMH, suggests that tran-
sient AMH overexpression may initially suppress activation, but ultimately
induces a rebound effect via negative feedback.
Trial registration number: not applicable.
P-315 Effect of Ulipristal Acetate (UPA) on the gene expression
proﬁling of endometrial cells in culture
M.J. Munuce1, M. Jiménez Guerrero2, D. Cotán2, A. García2,
A.M. Caille1, P. Cuasnicú3, L. Bahamondes4, J. Horcajadas2,
D. Cohen3
1Laboratory of Reproductive Medicine- School of Biochemical and Pharmaceutical
Sciences- National University of Rosario, Biochemical Chemistry, Rosario, Argentina
2Andalusian Center for Developmental Biology- University Pablo de Olavide-SINAE,
Genetics Department, Seville, Spain
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3Instituto de Biología y Medicina Experimental IBYME, CONICET-Buenos Aires,
Buenos Aires, Argentina
4School of Medical Sciences- University of Campinas UNICAMP, Family Planning
Clinic- Department of Obstetrics and Gynecology, Campinas, Brazil
Study question: To assess the effect of UPA, in concentrations compatible
with emergency contraception (EC), on gene proﬁle expression of an endomet-
rium cell line in culture.
Summary answer: The presence of UPA modiﬁes the transcriptomic signa-
ture of endometrial cells in culture.
What is known already: Emergency contraception consists in the use of
drugs or devices to prevent pregnancy after unprotected sexual intercourse.
Considering the fundamental role that progesterone has throughout the pro-
cess ranging from ovulation to implantation and embryo development, UPA has
been developed as a selective progesterone receptor modulator (SPRM) with
agonist/antagonist activity and pharmacological applications in EC.
The principal mechanism of action of UPA is the inhibition or delay of follicu-
lar rupture when administered previous to LH peak. However, given its high
effectiveness in the prevention of pregnancy (up to 5 days after intercourse),
post-ovulatory effects related to endometrial receptivity, cannot be excluded.
Study design, size, duration: This basic research work was conducted in
2017 and designed as a prospective study. Epithelial cells of human endomet-
rium carcinoma cell line (HEC-1A) were exposed 24 and 48 h to UPA (100,
250, 500 ng/ml) in triplicates. Total RNA was extracted and 192 genes asso-
ciated with endometrial receptivity were evaluated by quantitative PCR.
Participants/materials, setting, methods: Fluidigm Microﬂuidic technol-
ogy combines microarrays with real time PCR, where 192 genes are analyzed.
This selected panel was analyzed after 24 and 48 h in culture. From normalized
Cqs with respect to the constituent genes, Fold-Change (FC ≥ 0,5 in absolute
value) was calculated to determine the differential gene expression between
samples treated with UPA and controls. Gene Ontology was performed to
identify the biological function of those representative genes.
Main results and the role of chance: Data showed that by 24 h of incuba-
tion, there are no signiﬁcant changes of transcriptomic proﬁle in those cells
exposed to UPA (100, 250, 500 ng/mL) respect to controls cultured without
the drug. However, by 48 h of incubation, there is a signiﬁcant (p<0,05)
increase in total transcriptomic proﬁle in those cells exposed to UPA (at all con-
centration assayed) compared to controls. To determine which genes are dif-
ferentially expressed after 48 h of culture, FC of the 192 genes related to
endometrial receptivity were analyzed. Absolute value of FC increases with the
concentration of UPA in culture, suggesting a dose-dependent trend of down-
regulation of gene expression in the panel of genes analyzed. Considering those
genes with FC ≥ 0,5 in absolute value, a Gene Ontology (DAVID) was per-
formed to identify the biological function of those representative genes as well
as the possible effects of UPA on those genes. Genes related to cellular adhe-
sion and proliferation, signal transduction, growth factors, cytokine activity and
estradiol response seem to be down regulated after UPA exposure.
Limitations, reasons for caution: Our study was carried out in vitro with a
human endometrium carcinoma cellular model that expresses estrogen, pro-
gesterone, molecular adhesion receptors and proteases This could limit the
extrapolation of results to the UPA effects on endometrial tissue.
Wider implications of the ﬁndings: The present study suggests that there
are changes in gene expression of endometrial cells exposed to UPA at concen-
trations compatible with EC. Our data brings new evidence for the study of the
molecular mechanisms of action of UPA, used for contraceptive proposal, on
endometrium receptivity associated with embryo implantation.
Trial registration number: This study was supported by SINAE, University
of Rosario (BIO 486 Res. 1480/2016), São Paulo Research Foundation
(FAPESP) 2015/20504-9, CONICET and ANPCyT (PICT 2016-1057).
P-316 An increase of intracellular cyclic AMP improves
mitochondrial function of bovine immature oocytes
S. Hashimoto1, M. Yamanaka2, T. Yamochi1, H. Iwata3,
R. Kawahara-Miki4, Y. Nakaoka5, Y. Morimoto6
1Osaka City University Graduate School of Medicine, Reproductive Science Institute,
Osaka, Japan
2IVF Namba Clinic, Research, Osaka, Japan
3Tokyo University of Agriculture, Department of Animal Science, Atsugi, Japan
4Tokyo University of Agriculture, Nodai Genome Research Center, Tokyo, Japan
5IVF Namba Clinic, Medical ofﬁce, Osaka, Japan
6HORAC Grandfront Osaka Clinic, Medical ofﬁce, Osaka, Japan
Study question: How does a transient increase of cAMP prior to in vitro mat-
uration (IVM) improves oocyte competence?
Summary answer: An increase of intracellular cAMP improved oocyte qual-
ity by enhancement of its mitochondrial function. On the other hand, nuclear
maturation did not proceed during treatment.
What is known already: IVM of oocytes is an important technology for
assisted reproduction (ART) with a wide range of research and clinical applica-
tions. However, it is generally accepted that the development of embryos pro-
duced using IVM oocytes are lower than their in vivo counterparts probably
due to inappropriate status of cytoplasm. It has been also shown that an artiﬁ-
cial increase of intracellular cAMP before IVM signiﬁcantly improves oocyte
developmental competence in cattle and mice. However, the precise mechan-
ism by which cAMP improves oocyte competence during an increase of cAMP
remains to be elucidated.
Study design, size, duration: The changes of gene expression in bovine
oocytes and surrounding somatic cells following FSK and IBMX treatment were
investigated by transcriptome analyses. A total of 458 COCs were exposed to
pre-IVM treatment. As references, 491 COCs without culturing to pre-IVM
were also used. Time-dependent change of nuclear maturation of oocytes and
mitochondrial function in oocytes following FSK and IBMX treatment were also
assessed.
Participants/materials, setting, methods: Total RNA was extracted using
the RNAqueous-Micro Kit (Thermo Fisher Scientiﬁc, CA, USA) from oocytes
or cumulus cells separately after isolations of oocytes and cumulus cells. RNA
of Clusters were generated on a cBot (Illumina), and two lanes for the four
groups were sequenced as 50-bp reads (single end) on a HiSeq 2500 (Illumina).
The oxygen consumption rates (OCRs), cytochrome c oxidase (CCO) activity
in mitochondria and ATP contents of oocytes were also measured.
Main results and the role of chance: Although the expression of several
genes related with the progress of meiotic maturation was up-regulated, the
key gene for MPF activation, Cdc25 was down-regulated (p < 0.01). As a result,
the duration required for meiotic maturation of oocytes treated with FSK and
IBMX was the same as that of control oocytes. Meiotic resumption was
arrested during FSK and IBMX treatment.
The expression of genes encoding proteins which compose beta-oxidation,
glycolysis, mitochondrial electron transport system, lipase maturation, and
transportation of fatty acids signiﬁcantly increased in oocytes following FSK and
IBMX treatment (p<0.01). The OCRs, the proportion of mitochondria with
high CCO activity and ATP content in oocytes signiﬁcantly increased (p<0.01).
Genes involved in glycolysis and ovarian steroidogenesis were signiﬁcantly
upregulated in cumulus cells following FSK and IBMX treatment (p<0.01).
Limitations, reasons for caution: Further studies should be required to
assess whether the data obtained from bovine oocytes is applicable to human
ART.
Wider implications of the ﬁndings: The data of the present study revealed
that FSK and IBMX treatment at prophase stage induced the gene expression of
glycolysis, fatty acid degradation and mitochondrial functions in oocytes, and
accordingly improved mitochondrial functions and ATP levels in oocytes.
Trial registration number:Not applicable.
P-317 Vitamin B2 and B6 deﬁciency and overgrowth of intestinal
candida adversely affect fertilized embryos
S. Idei1, F. Yachiyo2,W. Harimura2, N. Shiozawa3
1Omiya Ladies Clinic, Gynecology, Saitama, Japan
2Omiya Ladies Clinic, Embryologist, Saitama, Japan
3Omiya Ladies Clinic, Nurse, Saitama, Japan
Study question: Could most favorable embryos be created by organic acid
testing capable of realistic evaluation of nutrition deﬁciency and metabolism?
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Summary answer: Vitamin B6 deﬁciency decreased the antral follicle count
(AFC) and normal fertility rate. With intestinal candida overgrowth, signiﬁcant
decrease in good blastocyst count was observed.
What is known already: Apparently, metabolism of egg mitochondria deter-
mines the egg quality; however, most studies were based on dietary composi-
tions with unclear nutrition details. In contrast, our study was based on organic
acid testing, which can precisely assess both excess and deﬁciency of nutrition
from metabolic products of nutrients after digestion and absorption.
Study design, size, duration:Of the patients who underwent an in vitro fer-
tilization procedure (short or antagonist protocol) between November 2016
and December 2017, 82 patients (age: 26–45 years; mean: 38.2; 2 SD: ±8.62)
who exhibited poor ovum count, fertilization rate, division rate, and/or blasto-
cyst reach rate were subjected to organic acid testing. In this study, we retro-
spectively examined these patients. Of 82 patients examined, the number of
patients suffering from candida overgrowth was abnormally high at 70 (80%).
Participants/materials, setting, methods: We categorized the subjects
into the excessive deﬁciency group (<−2 SD) and normal group (>−2 SD) for
vitamin B2, B6, B12, and folic acid, which are frequent and signiﬁcant items
among the test items, and the candida overgrowth group (>+2 SD) and normal
group (<+2 SD) regarding intestinal bacteria. We assessed the AFC, ovum
count, fertilization rate, and blastocyst reach rate of each group and compared
by t-test.
Main results and the role of chance: Compared to the normal group, vita-
min B2 deﬁciency group (<−2 SD) exhibited a signiﬁcant decrease in the AFC
(P = 0.0056; odds ratio, 0.73). The vitamin B6 deﬁciency group (<−2 SD)
exhibited a signiﬁcant decrease in the AFC (P = 0.023; odds ratio, 0.62) and
normal fertility rate (P = 0.0195; odds ratio, 0.48) compared to the normal
group. Although not statistically signiﬁcant, we also observed a decline in two
other items: the ovum count (P = 0.0537; odds ratio, 0.61) and day 3 good
embryo count (P = 0.063; odds ratio, 0.49). Regarding intestinal bacteria, the
candida overgrowth group demonstrated a signiﬁcant decline in the blastocyst
reach rate (P = 0.0245; odds ratio, 0.54) and good blastocyst reach rate (P =
0.027; odds ratio, 0.14) compared to the normal group. Although not statistic-
ally signiﬁcant, a decrease was also observed in three other items: the day 3
good embryo count (P = 0.087; odds ratio, 0.70), good blastocyst reach rate
(P = 0.059; odds ratio, 0.23), and used embryo count (P = 0.0819; odds ratio,
0.71).
Limitations, reasons for caution: The study cohort comprised only 82
patients; therefore, further investigation with larger sample size is warranted. In
addition, the novelty of this study necessitates an additional examination by
other institutes.
Wider implications of the ﬁndings: Improvement in the pregnancy rate
can be anticipated by adequate supplementation of vitamin B2 and B6 and inhib-
ition of candida overgrowth.
Trial registration number: none.
P-318 Granulosa cells provide elimination of apoptotic oocytes
through unconventional autophagy-assisted phagocytosis
M. Yeﬁmova1, N. Bourmeyster2, A. Bashamboo3, C. Eozenouo3,
A. Burel4, M.T. Lavault4, C. Pimentel5, S. Veau5, S. Sun5, S. Jaillard5,
B. Jégou6, C. Ravel7
1Sechenov Institut of Evolutionary Physiology and Biochemistry, Russian Academy of
Sciences, St-Petersburg, Russia C.I.S.
2Univ-Poitiers- CHU Poitiers, STIM ERL 7003 CNRS Pole Biologie-Santé-, Poitiers,
France
3Institut Pasteur, Unit of Human Developmental Genetics, Paris, France
4Univ-Rennes, Plateforme Biosit- MRIC, Rennes, France
5Univ-Rennes, CHU Rennes, Rennes, France
6Univ Rennes- Inserm- EHESP- Irset, Inserm, Rennes, France
7Univ Rennes- CHU Rennes- Inserm- EHESP- Irset-, CHU Rennes, Rennes, France
Study question: Granulosa cells manifest a strong gonadotropin-dependent
autophagy activity during folliculogenesis, which correlates with apoptosis.
There was no data on the ability of granulosa cells to clean apoptotic oocytes.
Summary answer: Granulosa cells eliminate apoptotic oocytes and other
apoptotic substrates through unconventional autophagy-assisted phagocytosis.
What is known already: The insufﬁciency to clean the tissues from apoptotic
substrates strongly perturbs tissue homeostasis and causes autoimmunity.
Premature ovarian failure (POF) is often associated with the presence of auto-
antibodies against ovarian proteins. The role in elimination of apoptotic oocytes
during follicular atresia is commonly attributed to macrophages, which are
found within the granulosa cell layer only in the most advanced stages of atresia.
Living granulosa cells are known to clean their apoptotic counterparts in atretic
follicles through autophagy-related mechanism. No data on the role of granulo-
sa cells for disposal of apoptotic oocytes has been reported.
Study design, size, duration: Cultured human granulosa cells were used to
study main phagocytosis (binging, ingestion, degradation) and autophagy (initi-
ation, elongation, docking and fusion, degradation) steps after loading with
apoptotic oocytes and other apoptotic substrates.
Participants/materials, setting, methods: Analysis of primary cultures of
human granulosa cells and human granulosa cell line (KGN), for the presence of
speciﬁc molecular markers and end-products characteristics for different steps
of phagocytic and autophagic machineries by immunocytochemistry, confocal
and electron microscopy and Western-blotting before and after loading with
apoptotic substrates.
Main results and the role of chance: Granulosa cells manifest a strong abil-
ity to eliminate apoptotic substrates of different origin. As demonstrated kinetic
studies, the rate of elimination of apoptotic substrates by granulosa cells is high-
er comparing with other phagocyte cells (Sertoli cells, retinal pigmented epithe-
lium cells). The process of apoptotic cleaning by granulosa cells is strongly
supported by autophagy in the process resembling LC3-associated phagocyt-
osis (LAP). This indicates that granulosa cells should be considered as one of
the most powerful non-professional phagocytes in the body, endowed with the
ability to combine phagocytic and autophagy degradative pathways for ovarian
homeostasis maintenance.
Limitations, reasons for caution: Thorough analysis of different steps
(binding and ingestion, initiation, elongation, degradation) of both phagocytic
and autophagic degradative processes depending on gonadotropin status merits
to be performed.
Wider implications of the ﬁndings: Cleaning of apoptotic oocytes by sur-
rounding granulosa cells seems likely to be a physiological mechanism involved
in follicular atresia. Proper functioning of this mechanism may be a new strategy
for the treatment of POF syndrome.
Trial registration number: GMR 2018-03
P-319 In vitro embryo development outcomes of DuoStim ovarian
stimulation
K. Ozgur1, M. Berkkanoglu1, H. Bulut2, E. Basol1, K. Coetzee3
1Antalya IVF, Clinic, Antalya, Turkey
2Antalya IVF, Clinic, Antalaya, Turkey
3Antalya IVF, laboratory, Antalya, Turkey
Study question: To investigate in vitro embryo development outcomes fol-
lowing DuoStim in patients with poor follicular phase (FP) ovarian response.
Summary answer: Luteal phase (LP) ovarian stimulation not only contributes
to oocyte number, but also to blastocyst number, blastocyst quality, and the
chance of freeze-all.
What is known already: Studies have shown that it is possible to cumula-
tively increase the retrievable oocyte number in poor ovarian response patients
by consecutively performing FP and LP ovarian stimulation in the same men-
strual cycle.
Study design, size, duration: The study is a retrospective observational
study being performed at a private IVF center. Poor ovarian response patients
undergoing blastocyst freeze-all IVF cycles are prospectively being included in
the study, as of May 2017. All ovarian stimulations are being performed using
gonadotropin releasing-hormone (GnRH) antagonist co-treatment protocols,
using combinations of recombinant follicle stimulating hormone (rFSH) and
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human menopausal gonadotropin (hMG), with or without clomiphene citrate
(CC) priming for follicular stimulation.
Participants/materials, setting, methods: Patients with poor response
(≤5 oocytes) after FP ovarian stimulation who have at least two follicles of
>5 mm at oocyte retrieval are eligible for inclusion. Indomethacin is being admi-
nistered from the day of trigger to the day of oocyte retrieval. Follicles <10 mm
at FP oocyte retrieval are not being aspirated, with LP ovarian stimulation com-
mencing on or after the day of FP oocyte retrieval. The primary outcome meas-
ure is oocyte number.
Main results and the role of chance: Twenty-three eligible patients have
thus far been included in the study. Two patients have had their LP ovarian
stimulation discontinued, as the result of poor follicular development. Two
patients did not undergo LP oocyte retrieval, because of premature ovulation.
From a median day2-3 antral follicle count of 4.7, 1.8 oocytes have been
retrieved at FP oocyte retrieval, increasing to 3.7 after LP oocyte retrieval.
Similarly, the number of blastocysts increased from 0.52 to 1.1. Eight patients
had blastocysts for cryopreservation after FP oocyte retrieval, increasing to 11
after LP oocyte retrieval. Four (4/12; 33.3%) good quality blastocysts (>2CC)
were obtained from the FP and eight (8/13; 61.5%) from the LP.
Limitations, reasons for caution: The use of DuoStim prevents the use of
fresh embryo transfer, necessitating effective cryopreservation and frozen
embryo transfer protocols. While DuoStim may improve in vitro embryo devel-
opment outcomes of patient with cycle dependent poor response, this may not
include Bologna poor response patients.
Wider implications of the ﬁndings: LP ovarian stimulation increases the
chances of patients having blastocyst freeze-all. Developing effective DuoStim
protocols may beneﬁt patients with reduced ovarian reserve, as well as, normal
ovarian reserve patients wishing to cumulatively increase their reproductive
chances or expedite effective treatment outcomes.
Trial registration number:N/A.
P-320 Neuropeptide phoenixin (PNX) and its novel receptor
GPR173 induce COX-1/COX-2 expression and PGE2 production
through the CREB signaling pathway
X.P. Nguyen, A. Iwase, T. Murase, U. Ganieva, Y. Qin, B. Bayasula,
K. Shimizu, S. Osuka, T. Nakamura, M. Goto, F. Kikkawa
Nagoya University Graduate school of Medicine, Obstetrics and Gynecology, Nagoya,
Japan
Study question: Can phoenixin in human granulosa cells has a direct effect on
ovulation?
Summary answer: Phoenixin acts through its novel receptor GPR173 to
induce COX-1, COX-2 expression, and PGE2 production by activating the
CREB signaling pathway in human granulosa cells.
What is known already: Phoenixin is a recently discovered neuropeptide
involved in regulating the reproductive system. Phoenixin activates the cAMP/
PKA/CREB pathway through its receptor GPR173, a part of SREB (Super con-
served Receptor Expressed in Brain) family. GPR173 also was detected at high
level in the ovary. Studies have linked the CREB signaling pathway to induce
COX-2 expression. Besides, cyclooxygenase (COX) enzyme is the key enzyme
that controls the rate-limiting step of prostaglandin E2 (PGE2) synthesis, which
has been recognized as a key mediator of ovulation. Whether the direct effect
of phoenixin on PGE2 biosynthesis and ovulation is still unknown.
Study design, size, duration: In vitro studies utilizing the human non lutei-
nized granulosa cells line (HGrC1) was performed to investigate the effects of
PNX on COX-1/COX-2 expression and PGE2 production.
Participants/materials, setting, methods: HGrC1 was cultured with
PNX-20 at 10 nM, 100 nM concentration with different time points, 1 hour, 3
hours, 6 hours, 12 hours and 24 hours. The levels of mRNA and protein were
examined by RT-quantitative real-time PCR and western blotting. The PGE2
concentrations in the culture medium were measured by ELISA. siRNA target-
ing GPR173 was used to observe the inﬂuence of GPR173 receptor.
Main results and the role of chance: Our previous studies demonstrated
that PNX and GPR173 present in human oocytes, granulosa cells and theca
cells in various stages of development. Interestingly, GPR173 expression in
granulosa cells from primary follicle and increases according to the stage of
follicle development. We also conﬁrmed the expression of PNX and GPR173
mRNA in HGrC1 cells. PNX-20 signiﬁcantly induced the mRNA levels of
COX-1 (2.25 ± 0.04-fold, P < 0.001) and COX-2 (2.76 ± 0.06-fold, P <
0.001) in a dose-dependent manner. The level of COX-1 and COX-2 were
induced with the maximal effect observed after 3 hours treatment with PNX-
20. PGE2 production in culture medium was signiﬁcantly enhanced by PNX-20
administration in a dose-dependent manner. We assessed CREB mRNA levels
and found increased CREB mRNA upon PNX-20 100 nM treatment (1.44 ±
0.07, P < 0.01). In addition, our Western blotting results reveal that PNX-20
increased Phospho-CREB in 15 and 30 minutes of treatment (3.66-fold and
8.42-fold, respectively). Moreover, the silencing of GPR173 markedly reduced
the PNX-induced increase in COX-1, COX-2 mRNA expression.
Limitations, reasons for caution: Although HGrC1 share common charac-
teristics and are functionally similar to primary human granulosa cells, there are
many differences between the primary granulosa cells and HGrC1 cells such as
karyotype and the response to the stimulating factors.
Wider implications of the ﬁndings: Our results show that phoenixin act
through GPR173 to induce COX-1, COX-2 expression and PGE2 production
in human granulosa cells, by activating the CREB signaling pathway. Overall,
these ﬁndings demonstrated that phoeinxin may participate in regulating human
ovulation through the induction of cyclooxygenase-mediated PGE2 production.
Trial registration number:None.
P-321 CHK2 controls the oocyte pool in mammals
A. Martinez Marchal1,2, A. Guixé1,2, M.T. Guillot1,2, M. García-
Caldés1,2, I. Roig1,2
1Universitat Autònoma de Barcelona, Cell Biology- Phisiology and Immunology,
Cerdanyola del Vallès, Spain
2Institut de Biotecnologia i de Biomedicina, Genome Integrity and Instability,
Cerdanyola del Vallès, Spain
Study question: Is the CHK2-dependent checkpoint responsible for the peri-
natal loss of oocytes? Does it control oocyte pool and mammalian female
fertility?
Summary answer: CHK2 has a role in the pachytene checkpoint controlling
the oocyte number in fetal ovaries. It also regulates the number of oocytes in
adult females.
What is known already: During mammalian oogenesis, oogonia proliferate
forming the so-called germinal cysts. They progress through meiotic prophase I
and cysts break down due to massive perinatal oocyte death. During meiotic
prophase I, double strand breaks (DSBs) are formed throughout the genome
and repaired by homologous recombination. In response to errors in this pro-
cess, the DNA damage response kinase CHK2 is activated promoting cell cycle
arrest or even apoptosis. Contrary to what occurs in spermatocytes, oocytes
present high numbers of unrepaired DSBs at pachynema, at the time of the
massive oocyte death and cyst breakdown.
Study design, size, duration: We studied the number of oocytes and folli-
cles present in control and Chk2 mutant ovaries at different time points of ani-
mal development. We collected ovaries from Chk2+/- and Chk2+/+ (control),
and Chk2-/- (mutant) mice from 16 and 18 days post coitum (dpc), 0, 1, 2, 3, 40
and 400 days post-partum (dpp). For the fetal mice, the females were breed and
timing was counted from the day when the vaginal plug was observed.
Participants/materials, setting, methods: For perinatal mice the ovaries
were collected, ﬁxed in 4% Paraformaldehyde, processed and sectioned at
7 μm. Every second section was stained by immunoﬂuorescence against the
germinal cell marker DDX4 with DAPI as counterstaining. The DDX4-positive
cells were scored and classiﬁed. For adult females the ovaries were collected,
ﬁxed in Bouin solution, processed and sectioned at 7 μm. Every ﬁfth section
was stained with PAS-Hematoxylin and only the oocytes with visible nucleus
were counted.
Main results and the role of chance: Control and mutant ovaries present
the same number of oocytes at 16 dpc. However, at 18 dpc there is a signiﬁcant
two-fold increase in mutants compared to controls. This difference is still signiﬁ-
cant at 0 dpp, but is overturned during the following postnatal days. This data
suggests that CHK2 regulates the number of oocytes in fetal ovaries, but there
must be an alternative mechanism capable of levelling the number of oocytes
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during the perinatal phase. Interestingly, while in young adult mice (40 dpp) we
see no difference in the number of oocytes present in control and mutant ovar-
ies, elder mutant mice (400 dpp) have three times more oocytes than control
mice. In particular, this increase is due to an accumulation of primordial follicles,
which represent the pool of oocytes available to use during the fertile period of
a female. Therefore, our results show that CHK2 regulates the pool of oocytes
present in adult mouse ovaries. We propose these data reﬂects how many
oocytes may accumulate DNA damage and are naturally eliminated by a
CHK2-dependent checkpoint. Thus, these ﬁndings suggest that CHK2 inhibition
may extend the reproductive life of mammalian females.
Limitations, reasons for caution: The number of oocytes present in peri-
natal ovaries was highly variable between individuals and even between ovaries
from the same mouse.
Wider implications of the ﬁndings: We found evidences that show that
CHK2 controls the oocyte numbers both around birth and in adult females.
Our results in elder mice suggest that inhibition of CHK2 could extend mamma-
lian female fertility.
Trial registration number: not applicable.
P-322 Dual triggering in antagonist ICSI cycles
K. Yildiz, D. Deniz, R. Pabuccu, M.U. Ucar
Private Dogufertil IVF Center, Assisted Reproductive Technology Department,
MALATYA, Turkey
Study question: Is it beneﬁcial dual triggering with 0,1 mg/ml triptorelin
asetat and 250 μcg recombinant hCG together in GnRH antagonist cycles.
Summary answer: It seems to be that dual triggering does’nt have superior
effect over only rhCG triggering group in GnRH antagonist ICSI cycles.
What is known already: Final oocyte maturation is induced by human chori-
onic gonadotropin (hCG) after the controlled ovarian hyperstimulation (COH).
According to some studies, dual triggering with a GnRH agonist and recombin-
ant hCG does have improved oocyte maturation rates and pregnancy rates in
IVF cycles compared to hCG alone groups.
Study design, size, duration: Single center, prospective, randomized clinical
study.
Participants/materials, setting, methods: Two groups allocated as
Group A (GnRH analog+ rhCG 56 patients) and Group B (only rhCG 66
patients) according to the triggering method. 0,1 mg/ml triptorelin asetat
was used for GnRH analog and Ovitrelle for 250 μcg recombinant hCG
(rhCG). Severe male infertility factor (<15 million sperm/ml) and poor
ovarian reserve patients (<5 antral folicule count) were excluded from the
study.When at least 3 follicules >17 mm the triggering was made randomly.
P value set >0.05
Main results and the role of chance: Groups were comparable in terms of
age, gonadotropin start dosage,total amount of gonadotropins, duration of
stimulation (Table I)
Table I
Parameters Group A
(n = 56)
Group B
(n = 66)
P value
Age 32.79 ± 5.71 34.09 ± 4.9 0,17 NS
Gonadotropin start dosage 212 ± 44 209 ± 46 0,71 NS
Total amount of gonadotropins 1948 ± 459 1991 ± 617 0,66 NS
Duration of stimulation (day) 9,39 ± 0,78 9,42 ± 0,90 0,83 NS
As main outcome of this study, collected total oocyte numbers, maturation
and fertilization of oocytes and pregnancy rates were compared between the
groups (Table II).
Table II
Parameters Group A Group B P Value
Collected total
oocyte numbers
11,13 ± 5,41 9,68 ± 4,17 0,09 NS
Mature Oocytes 8,5 ± 3,67 8,11 ± 3,46 0,54 NS
Fertilised Oocytes 6,23 ± 3,12 6,15 ± 2,52 0,87 NS
Pregnancy rates 28/56 (%50) 31/66 (%46,9) 0,73 NS
According to these results there isn’t any signiﬁcant difference between two
groups in all parameters. We didn’t see OHSS in any group.
Limitations, reasons for caution:None.
Wider implications of the ﬁndings: Dual triggering is alternative to classic
only hCG trigger. Whether some studies mentioned as an signiﬁcant increase in
total collected oocyte number, mature oocyte number and pregnancy rates we
didn’t ﬁnd any signiﬁcant difference with these parameters. It seems that large-
scale collaborative studies needed for future aspects.
Trial registration number:None.
P-323 Unravelling the molecular pathways responsible for sex
determination in humans
J. Taelman1, M. Popovic1, L. Tilleman2, M. Van der Jeught1,
D. Deforce2, P. De Sutter1, F. Van Nieuwerburgh2, B. Heindryckx1,
S. Chuva De Sousa Lopes3
1Ghent University Hospital, Department of Reproductive Medicine, Ghent, Belgium
2Ghent University, Faculty of Pharmaceutical Sciences, Ghent, Belgium
3Leiden University Medical Center, Department of Anatomy and Embryology, Leiden,
The Netherlands
Study question: What are the molecular signals governing sex determination
in human fetal gonads?
Summary answer:While the antagonizing sex determination mechanisms of
WNT and FGF signaling appear to be conserved between humans and mice,
the key determining factors are different.
What is known already: Sex determination and germ cell maturation
mechanisms vary widely between species. In female mice, upregulation of
WNT4 initiates a signaling cascade, leading to the development of ovaries.
Conversely in males, WNT4 signaling is repressed by SOX9 and its target
FGF9, shortly after activation of the male fate determining SRY gene, resulting in
the formation of testes. Human (partial) sex reversal case studies suggest that
the antagonistic role of WNT and FGF signaling is conserved between mice and
humans. Transcriptomic analysis of human fetal gonads may provide valuable
insights into the underlying mechanisms of sex determination and maturation in
humans.
Study design, size, duration: Single cell sequencing data, from human fetal
gonads of both female and male samples, were analyzed in R (version 3.4.2).
Developmental age ranged from week (W)5 to W26 of development for
female, and W4 to W25 for male cells. Data were ﬁltered to include only cells
with cell types validated through marker gene expression, retaining a ﬁnal data-
set of 992 female and 852 male cells of various ages from 17 female and 12
male embryos.
Participants/materials, setting, methods: Genes fromWNT and FGF sig-
naling pathways, from Gene Ontology databases, were queried in the datasets
to identify age- and cell type-speciﬁc genes of interest (GOI). Heatmaps were
generated of those GOI to visualize differences between various developmental
clusters of germ cells and somatic cells. Differentially expressed genes (DEGs)
between germ cell and somatic clusters of speciﬁc ages were identiﬁed.
Volcano plots were generated to visualize signiﬁcant DEGs.
Main results and the role of chance: The analysis of DEGs between W4
and W9-W10 male fetal gonadal cells (FGCs) and Sertoli cells showed that,
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similar to mouse, SOX9 was differentially upregulated in human Sertoli cells.
Furthermore, comparison between W5 and W7-W8 FGCs and granulosa cells
in female, revealed elevated expression of multiple WNT signaling genes.
Markedly, unlike mouse, the female determining factor WNT4 was not differ-
entially expressed in somatic cells compared to FGCs at the time of sex deter-
mination. However, we observed a signiﬁcant increase in WNT6 expression at
W7-W8. This suggests that although similar sex determining mechanisms exist
between human and mouse, other WNT genes may fulﬁl differing key roles in
humans. Furthermore, we have identiﬁed WNT-antagonizing factors, such as
SOX10 and SOX11 in both W9-W10 male and W7-W8 female somatic cells.
These genes may perform undescribed regulatory functions during sex speciﬁ-
cation, in humans. Surprisingly, we also identiﬁed FGF9, a male determining fac-
tor, to be elevated in female human somatic granulosa cells, thus further
highlighting interspecies differences in the underlying mechanisms of sex
determination.
Limitations, reasons for caution: DEGs were identiﬁed from existing in sili-
co databases from human fetal gonadal cells. To further validate the expression
of the GOI, immunoﬂuorescence analysis in freshly isolated human gonadal
material from 7-12W is currently ongoing.
Wider implications of the ﬁndings: Deﬁning the key regulatory players of
WNT and FGF signaling during sex determination in humans will greatly con-
tribute to elucidating the role of these pathways during germ cell development
and maturation. Adaptation of culture conditions based on this knowledge may
ultimately advance efforts to derive sex-speciﬁc germ cells in vitro.
Trial registration number: not applicable.
P-324 Oral Vitamin D supplementation impacts luteinized
granulosa-cell transcriptomics
S. Makieva1, F. Bonesi1, E. Giacomini1, A. Paffoni2, V. Sarais1,
S. Ferrari2, L. Pagliardini1, E. Papaleo1, E. Somigliana2, P. Viganò1
1IRCCS San Raffaele Scientiﬁc Institute, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology, Milan, Italy
2Ospedale Maggiore Policlinico, Infertility Center- Fondazione Ca’Granda, Milano,
Italy
Study question: Can oral administration of Vitamin D (VD) to infertile
women undergoing in vitro fertilization (IVF) inﬂuence luteinized granulosa-cell
(GCs) gene expression?
Summary answer: Surprisingly, oral administration of VD manifests at the
gene expression level in luteinized GCs, which were isolated during an oocyte
retrieval procedure for IVF.
What is known already: There is evidence that circulating VD concentration
in infertile women is associated with successful Assisted Reproductive
Technology (ART) treatment. It is unclear whether this association is causal and
no randomized clinical trial to date addressed this notion. We launched (2017)
the ﬁrst multi-centre controlled double-blinded randomized clinical trial to
assess whether supplementation of VD will improve IVF clinical pregnancy rate.
Herein we addressed one of the secondary objectives, whereby the indirect
effect of VD supplementation on oocyte prognosis is explored. Speciﬁcally, we
investigated the effect of the intervention on GCs transcriptomic machinery,
critical regulator of oocyte maturation.
Study design, size, duration: The clinical trial aims to recruit 600 women
with a baseline VD serum level <30 ng/ml, who are administered either
300,000 IU of 25-OH-vitamin D (VD group) or placebo (PL group) in a single
oral shot. The duration of the study is set on three years.
Participants/materials, setting, methods: Follicular ﬂuid (FF) samples
were aspirated during the procedure of oocyte retrieval and GCs were isolated.
Pilot transcriptomic analysis with RNAseq utilizing a subset of participant sam-
ples (n = 3 per group) and RT-PCR (n = 19 VD, n = 22 PL) was employed to
scrutinize the differences between the two groups.
Main results and the role of chance: RNAseq analysis conﬁrmed that GCs
derived from the VD group owned a different transcriptomic signature com-
pared to the PL group. The impact of VD on pathways involved in the GC-
oocyte interaction was thoroughly explored and a number of genes were found
differentially expressed between the VD and PL groups. The action of VD in
GCs is plausibly mediated via the Vitamin D Receptor (VDR), the gene expres-
sion of which was 3.3 fold higher (±1.33, p = 0.046) in GCs of the VD group
(n = 19) compared to PL group (n = 22). Notably, the expression of GC-
speciﬁc genes traditionally associated with oocyte regulation, such as HAS2,
VCAN, 3βHSD, AMHR-2, FSHR, PTGS2, GREM-1, CCND1, STAR, did not
signiﬁcantly change. Non-traditional GC-gene expression patterns reﬂecting
GC-oocyte interaction following administration of Vitamin D warrant further
investigation and promise to provide insight into the pathophysiology of oocyte
maturation and inform future strategies for the improvement of IVF outcomes.
Limitations, reasons for caution: RNAseq validation on the protein level is
pending for full interpretation of gene expression data.
Wider implications of the ﬁndings: Vitamin D supplementation may be
inﬂuencing IVF outcomes via indirect control of GC-gene expression. The latter
is critical for the GC-oocyte interaction and, hence, expected to impact oocyte
quality.
Trial registration number: EUDRACT 2015-004233-27
P-325 Impact of the fresh cycle outcome on the subsequent
frozen-thawed blastocyst transfer in medicated vs natural cycle
M. Bhaduri, N. Lee, Y. Khalaf, T. El Toukhy, J. Kopeika
Guy’s and St Thomas’ Hospital, Assisted Conception Unit, London, United Kingdom
Study question: Does the endometrial preparation regimen inﬂuence the
outcome of frozen embryo transfer when preceding fresh transfer was
unsuccessful?
Summary answer: Our study suggests that medicated frozen cycle is super-
ior to natural cycle for patients where the preceding fresh cycle didn’t result in a
live birth.
What is known already: Currently, there is still no agreement whether dif-
ferent regimens of endometrial preparations in frozen embryo transfer cycles
have equal effectiveness. It remains unclear whether hormonal preparation with
estrogen and progesterone may enhance likelihood of pregnancy, when com-
pared with a natural cycle environment.
Study design, size, duration: Between May 2015 and May 2017 the live
birth rate of all naturals cycles was assessed in a case-controlled matched study
with medicated frozen replacement cycles in a tertiary center.
Participants/materials, setting, methods: A total of 208 natural frozen
cycles were case-matched by age, indication for ART, number of previous
cycles and number of transferred thawed blastocysts with 528 medicated fro-
zen cycles. Patients were offered natural frozen cycle if they had regular ovula-
tory menstrual cycle. Assuming α = 0.05 and 80% power it was calculated that
722 frozen-thawed cycles were required to demonstrate a difference of 10% in
live birth rate.
Main results and the role of chance: A total number of 981 embryos was
transferred in 736 cycles were included. The mean age of patients who had nat-
ural and medicated cycles was 34.3 ± 3.8 and 33.7 ± 4.2 respectively (P =
0.07). The mean endometrial thickness was 8.7 ± 1.9 mm in natural and 9.5 ±
1.85 mm in medicated frozen cycles (P = 0.2). The mean number of transferred
embryos was 1.3 ± 0.5 in the former and 1.4 ± 0.5 in the latter (P = 1.12). The
live birth rate per frozen embryo transfer, was signiﬁcantly lower in the natural
(35/150, 23%) cycle in comparison with medicated frozen cycle (117/354 –
33%), RR 1.4, 95% CI 1.02-1.96, P = 0.036), if preceding fresh cycle did not
result in a live birth. However, if fresh cycle resulted in live birth, there was no
signiﬁcant difference in subsequent frozen cycle whether it had natural (22/47 –
46%) or medicated (51/148–34%) preparation (RR 1.3, 95% CI 0.93 – 1.98, P
= 0.11).
Limitations, reasons for caution: Although important variables such as age,
indication for ART and previous attempts of transfer number of transferred
embryos were comparable some bias could arise from the fact that allocation
of frozen cycle was not random.
Wider implications of the ﬁndings: This study suggests that medicated
cycle might be more preferential for patients in whom the fresh transfer did not
result in live birth. This is a ﬁrst study to report such observation and a rando-
mised controlled study is needed to explore this hypothesis further.
Trial registration number: non-applicable.
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P-326 Collagen, type I, alpha 1 (COL1A1) as potential molecular
marker of ovarian aging and reproductive success in cumulus
oophorus cells (CCs)
M.Â. Esteves Ribeiro1, M. Pardalejo2, R. Magalhães1, A. Gomes1,
E. Silva Moura3, J.L. Silva Carvalho4, H. Almeida5
1CETI, Centro de Estudo e Tratamento da Infertilidade, Porto, Portugal
2ICBAS and FCUP - Universidade do Porto, Department of Biomedicine- Faculdade
de Medicina- Universidade do Porto, Porto, Portugal
3IBMC- Instituto de Biologia Molecular e Celular and I3S Instituto de Investigação e
Inovação em Saúde - i3S- Universidade do Porto, Department of Biomedicine-
Faculdade de Medicina- Universidade do Porto, Porto, Portugal
4CETI- Centro de Estudo e Tratamento da Infertilidade- Porto, Department of
Obstetrics & Gynaecology- Faculdade de Medicina- Universidade do Porto- CUF Porto
Hospital- IBMC- Instituto de Biologia Molecular e Celular and I3S Instituto de
Investigação e I,
5IBMC- Instituto de Biologia Molecular e Celular and I3S Instituto de Investigação e
Inovação em Saúde - i3S- Universidade do Porto- Department of Biomedicine-
Faculdade de Medicina- Universidade do Porto, CUF Porto Hospital- CETI - Centro de
Estudo e T,
Study question: Could the expression of some Transforming Growth Factor
(TGF)-beta family members in CCs be related to reproductive aging and/or
Assisted Reproductive Technology (ART) outcomes?
Summary answer: Molecular analysis combined with a multiple endpoint
evaluation in ART allows the identiﬁcation of transcripts and proteins in CCs
that seemingly reﬂect reproductive success/treatment outcome.
What is known already: Success rates in ART are still unsatisfactory, partly
because of insufﬁcient oocyte quality. As this property worsens with aging, it
suggests that an age-related regulatory imbalance is likely to occur in the grow-
ing ovarian follicle of reproductively aged women. Due to their prominent role
in follicular growth and oocyte maturation, abnormal CCs regulation appears as
an important contributor to such imbalance. Apart from producing compounds
that nurture the oocyte, CCs are important interveners in a set of reciprocal
interactions with the oocyte that involve different members of the varied TGF-
beta family of proteins.
Study design, size, duration: CCs pools were prepared for different
molecular analysis performed in the Biomedicine Department of the Faculty of
Medicine-Porto University, after women undergoing ART at CETI-Centro de
Estudo e Tratamento da Infertilidade (Porto, Portugal) gave their informed con-
sent. Collection was performed intermittently over 3 years, as the work pro-
gressed, following a strict methodology based on clinical and laboratory
parameters, 118 samples were grouped using multiple criteria, including cell
morphology assessment and data obtained during treatment.
Participants/materials, setting, methods: CCs were mechanically dis-
sected from CCs-oocyte complexes after ovarian puncture of women aged
between 27 to 43 years old. Upon proper morphological evaluation and sam-
pling, they were washed and preserved in liquid nitrogen until RNA extraction,
followed by its ampliﬁcation and quantiﬁcation by quantitative PCR (qPCR),
transcription levels were measured and statically analyzed. Other samples were
preserved at -20oC for protein assay, they were completely lysed and analyzed
by Western Blotting followed by normalized quantiﬁcation.
Main results and the role of chance: The work established a methodology
for grouping CCs samples, based on multiple and speciﬁc criteria, aiming to
increase groups homogeneity and biomarkers reliability. Gene expression ana-
lysis used qPCR arrays to allow simultaneous quantiﬁcation of 84 transcripts
linked to the TGF-beta family. Major changes in expression levels were subse-
quently conﬁrmed by conventional qPCR. Comparing the medians of quantiﬁca-
tions with Mann-Whitney’s test (p < 0,05 was established for signiﬁcance level),
one of the transcripts - col1a1 – corresponding to alpha-1 type I collagen, was
found to be signiﬁcantly expressed in younger women (p = 0,041) compared to
the older group and in CCs associated to better prognosis (p = 0,036), i.e.
pools of cells retrieved from apparently mature complexes, which evolved to
good quality embryos, resulting in a successful treatment outcome (clinical
pregnancy). Interestingly, transposing this study to the protein level and using
the same statistical methodology, a refractory tendency was observed,
COL1A1 appeared more abundant in CCs corresponding to poorer prognosis
samples, classiﬁed with less morphological quality and linked to unsuccessful
treatment outcome (p = 0,007), being also more expressed in CCs from older
women (p = 0,003). These results lead us to investigate the importance of
COL1A1 and its regulatory effects on CCs.
Limitations, reasons for caution: The reduced amount of CCs collected in
each sampling procedure limits the use for both analytical methods of gene
expression proﬁling and western blotting. Moreover, women biological variabil-
ity limits the homogeneity of the samples. The employment of multiple end-
points of analysis was meant to minimize this obstacle.
Wider implications of the ﬁndings: Both in physiological and in-vitro aging,
CCs often exhibit modiﬁcations in the compaction grade of their extracellular
matrix; interestingly COL1A1 is one of its major structural constituents. As this
molecule is likely to become a biomarker, its assessment should become rele-
vant during oocyte selection in the setting of ART.
Trial registration number:Not applicable.
P-327 Themotility and localization of mitochondria related with
the maturation of advanced age oocytes
K.H. Choi1, H.R. Lee2, D.W. Suh2, H.H. Kang2, M.K. Koong2,
Y.S. Kim2, T.K. Yoon2, K.A. Lee3, J.J. Ko3, H.T. Lee4, J.H. Lee2,3,
S.J. Lee5
1CHA fertility center, Research, Seoul, Korea- South
2CHA fertility center Seoul- Station, Fertility laboratory, Seoul, Korea- South
3CHA University, Department of biomedical Science, Pochen, Korea- South
4Konkuk University, Department of Animal Biotechnology, Seoul, Korea- South
5Sahmyook University, Department of Animal Biotechnology, Seoul, Korea- South
Study question: What functional properties of mitochondria are induced to
chromosomal error and poor quality in the maturation of advanced aged
oocytes?
Summary answer: Poor motility and its movement of mitochondria could be
related to chromosomal error and its poor quality in advanced aged oocytes.
What is known already: The major role of mitochondria is supported
through bio-energy for oocytes’ maturation and chromosomal meiosis.
Advanced age oocytes have high aneuploidy ratios with poor quality, which is
associated with low mitochondrial activity. However, there are still some ques-
tions about why advanced age oocytes have low functional activity in the
mitochondria.
Study design, size, duration: This study is designed for motility and the
localization of mitochondria with young (n = 80) and advanced age oocytes (n
= 60). All experiments were repeated three times. The statistical differences
were analyzed with SPSS.
Participants/materials, setting, methods: We performed confocal live
imaging of young and advanced age oocytes stained with mitochondria speciﬁc
staining dye from the GVBD to MII phase. Young oocytes were treated with
Cytochalasin-B (CB), which is well known as a microtubule unstable agent.
Next, we compared the localization and motility of mitochondria in young, old
age and CB treated oocytes. In addition, we checked the speed and maturation
ratio of oocytes in each group.
Main results and the role of chance: In this study, we found that young age
oocytes showed dynamic mitochondrial motility gathering to the nuclear region
during oocytes’ maturation, whereas advanced age oocytes did not.
Furthermore, the dynamic motility of mitochondria might be related with
microtubule stability in oocytes. Unstable microtubules in young age oocytes
showed a similar phenotype in advanced age oocytes, such as low dynamic
motility of the mitochondria and slow maturation ratios from the GV to MII
phase.
Limitations, reasons for caution: This is an animal study. Therefore, we
needed more studies with human oocytes regarding mitochondrial activity, in
order to see whether or not the motility and localization of mitochondria was
related to oocyte aging in human samples.
Wider implications of the ﬁndings: Mitochondrial movement could be
associated with oocyte maturation through microtubule stability, which
depends on aging in mice. Therefore, these ﬁndings could contribute to rejuven-
ation of advanced age oocytes, such as young age oocytes. It can be a possible
application to treat infertility for old women in the human reproductive
medicine.
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Trial registration number: not applicable.
P-328 Fertilization and embryonic development of eggs from
naturally-aged mice
S.Y. Yoon1, J.H. Eum1, H.M. Jang1, J. Kim2, M. Lee2, J.J. Ko1,
W.S. Lee1, D.R. Lee2
1CHA University, Fertility Center of CHA Gangnam Medical Center, Seoul, Korea-
South
2CHA University, Biomedical Science, Seoul, Korea- South
Study question: According to recent paper, the major mechanism of egg acti-
vation, Ca2+ oscillations at fertilization is largely unchanged by advancing
maternal ages. How about fertilization and embryonic development is?
Summary answer: Fertilization and embryo development of eggs from natur-
ally aged mouse are not affected by the age of maternal ages at least in well care
condition.
What is known already: Female fecundity decreases with age, and the
decline accelerates rapidly after 35 years. The main age-dependent decline is in
the number and quality of eggs. The quality of eggs mostly due to an increase of
chromosomal aneuploidy with advanced maternal age. The ooplasm could be
affected by ageing. According to recent paper, the major mechanism of egg acti-
vation, Ca2+ oscillations at fertilization is largely unchanged by advancing
maternal ages. Here we investigate the ability of fertilization and further embry-
onic development in eggs from naturally aged mouse from 7 weeks to 90 weeks
old.
Study design, size, duration: MII eggs were collected from B6D2F1 mice
7weeks, 62~65 weeks, 65~68 weeks, 77~80 weeks, 89~92 weeks. Naturally
aged mice were acquired at 30 weeks from commercial breeders and housed
for a further periods.
Participants/materials, setting, methods: At 14 hr post hCG injection,
both ovaries and oviducts were collected MII-cumulus mass. In older than 65
weeks, MII eggs were obtained from antral follicles by puncture with 29 G nee-
dles. Collected MII eggs were fertilized sperm from 12 weeks male mice.
Fertilization rate was calculated by two pronucleus at 8 hr post insemination.
Further embryo culture were performed for 5 days for blastocyst formation.
ICM/TE counts were performed by immunostaining with anti-Oct 4 and DAPI
staining.
Main results and the role of chance: Number of eggs in oviducts was
decline in 62 weeks female mouse (P<0.001). No ovulated eggs were observed
in more than 65 weeks. However, preovulatory healthy MII eggs were collected
from antral follicles in those mouse ovary using needle puncture. The number
of eggs were decreased from 62 weeks female mouse. Chromosomal abnor-
mality was not seen in eggs from old eggs. Fertilization rate of these preovula-
tory eggs from 62 weeks to 90 weeks old was no difference compared to those
from 7 weeks mouse. Also, most of the fertilized eggs developed blastocysts
in vitro, and the total cell count of these blastocyst was no difference compare
to those from 7 weeks mouse.
Limitations, reasons for caution: This study was designed to investigate
the effects of natural aging on experimental animals raised in a well-maintained
environment. However, it is difﬁcult to interpret patients with pathological
causes.
Wider implications of the ﬁndings: The aging of the ovaries as a result of
natural aging does not affect the quality or fertilization of the eggs, and subse-
quent embryonic development. Nutritional and growing environments are
important for the maturation and development of eggs. This research was sup-
ported by NRF-2017R1D1A1B03028155.
Trial registration number: non-clinical trials.
P-329 Downregulation of long non-coding RNAMALAT1 inhibits
granulosa cell proliferation in endometriosis by activation of p21/p53
and ERK/MAPK signaling pathways
Y. Li, S.L. Chen
Nanfang Hospital- Southern Medical University, Center for Reproductive Medicine-
Department of Gynecology and Obstetrics, GuangZhou, China
Study question: We want to explore the role of metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1), as an extensively expressed and evo-
lutionarily conserved lncRNA, in endometriosis-associated infertility.
Summary answer: MALAT1 may play an important role in regulating the
function of granulosa cells (GCs), proceeded to affect the growth and develop-
ment of oocytes in endometriosis.
What is known already: Our ﬁndings ﬁrst reported that MALAT1 was sig-
niﬁcantly down-regulated in endometriosis GCs and was associated with AFC.
MALAT1 was primarily localized in the nuclei of GCs. Knockdown of MALAT1
in KGN cells obviously inhibited cell proliferation through restraining cell-cycle
at G1/S phase, caused by p21/p53-mediated cell cycle arrest, and the activa-
tion of the ERK/MAPK pathway participates in this process.
Study design, size, duration: 80 GC samples were collected from endo-
metriosis patients (38) and non-endometriosis women (42) undergoing in vitro
fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment in the
period of March 2014 to December 2015. All endometriosis patients were
diagnosed by laparoscopy or laparotomy. The inclusion criteria for control
women were as follows: regular menstrual cycles occurring every 25-35 days,
antral follicle count (AFC) > 5, and were limited to male factor or tubal disease.
Participants/materials, setting, methods: We used human GCs and
KGN cell line to investigated the potential role of MALAT1 in the endometri-
osis women undergoing assisted reproductive technology (ART). Quantitative
reverse transcription PCR (qRT-PCR) was used to compare the expression of
MALAT1 in GCs from 42 endometriosis patients and 38 controls. Then, we
knocked down MALAT1 with locked nucleic acid (LNA) GapmeRs and per-
formed CCK-8, EdU and Western blot to explore the role of MALAT1 in regu-
lating cell proliferation.
Main results and the role of chance: MALAT1 was signiﬁcantly downregu-
lated in endometriosis GCs as compared with controls (P<0.001), statistical
analyses indicated signiﬁcant correlations between MALAT1 expression and
AFC (r = 0.343, P = 0.005). The result of qRT-PCR to analyze RNA from
nuclear and cytoplasmic fractions indicated that MALAT1 was predominately
distributed in the nucleus. Knockdown of MALAT1, a signiﬁcant increase in the
protein levels of p21 and p53, and a decrease in cyclin D1 and CDK2 were
observed, which are key regulators that is required for G1/S phase, however,
no detectable changes were observed in apoptosis-related proteins. Moreover,
MALAT1 knockdown signiﬁcantly increased the levels of phosphorylated
ERK1/2, while no detectable changes were observed in the total levels of
ERK1/2, p38 MAPK, JNK, PI3K and AKT, as well as the levels of p-JNK, p-p38
MAPK, p-AKT and p-PI3K. With the presence of U0126 (a MAPK/ERK kinase
inhibitor that inhibits MEK1/2 for downregulation of p-ERK), the upregulation
of phospho-ERK1/2, p21 and p53 by the knockdown of MALAT1 was
attenuated.
Limitations, reasons for caution: GCs were obtained from preovulatory
follicles after Gn stimulation. The hormonal treatment used in IVF may alter the
gene expression. These cells may not behave in the same way as GCs from
small antral follicles. The isolation of primary cells inevitably causes contamin-
ation with other tissues, such as blood cells.
Wider implications of the ﬁndings: ERK/MAPK pathway is often aber-
rantly activated in human cancers and contributes to enhanced cell prolifer-
ation, however, in our study, the activation of ERK/MAPK pathway, conversely,
contributes to suppress cell proliferation. Therefore, the direct link between
the ERK/MAPK pathway and proliferation remains unclear and requires further
study.
Trial registration number: not applicable.
P-330 Extracellular vesicles from human follicular ﬂuid inhibit
coagulation
R. Togawa1, R. Nieuwland2, C.M. Hau2, N. Hajji2, B. Toth3
1Heidelberg University Women’s Hospital, Department of Gynecologic Endocrinology
and Fertility Disorders, Heidelberg, Germany
2Academic Medical Centre of the University of Amsterdam, Department of Clinical
Chemistry and Vesicle Observation Centre, Amsterdam, The Netherlands
3Medical University Innsbruck, Department of Gynecological Endocrinology and
Reproductive Medicine, Innsbruck, Austria
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Study question: Do extracellular vesicles from human follicular ﬂuid promote
coagulation?
Summary answer: For the very ﬁrst time, extracellular vesicles from a human
body ﬂuid are shown to inhibit coagulation.
What is known already: Extracellular vesicles (EVs) are small, cell-derived
particles which are abundantly present in body ﬂuids. EVs in human body ﬂuids
promote and/or trigger coagulation by exposing phospholipids and/ tissue fac-
tor. Although it is known that follicular ﬂuid (FF) contains EVs, it is unknown
whether these EVs promote coagulation.
Study design, size, duration: FF was collected from patients undergoing
hormonal stimulation for IVF/ICSI. The ability of FF and isolated EVs from FF to
trigger clotting was measured in a plasma clotting test, the ﬁbrin generation test
(FGT). This study was approved by the ethical committee and informed con-
sent was obtained from each volunteer.
Participants/materials, setting, methods: FF was fractionated by ultra-
centrifugation, and by size exclusion chromatography (SEC). The latter sepa-
rates EVs from soluble components such as proteins. We measured the clotting
activities of FF, FF fractionated by ultracentrifugation, and of EVs isolated by
SEC.
Main results and the role of chance: Surprisingly, FF or ultracentrifugation
fractions of FF did not trigger coagulation. In fact, when EVs were isolated by
SEC, these EVs even delayed the clotting of plasma. For example, when clotting
was triggered with thromborel (extrinsic coagulation), the clotting time (CT)
increased from 654-813 seconds in the absence to 1214-1609 seconds in the
presence of EVs. Similarly, clotting initiated by kaolin plus phospholipid (intrinsic
coagulation) increased from 656-783 seconds without EVs to 913-1280
seconds in the presence of EVs. When EVs were pretreated with heparinase,
the CTs increased 120 seconds and >500 seconds for extrinsic and intrinsic
coagulation, respectively. Taken together, human FF contains EVs exposing or
more heparinase-sensitive factors that inhibit the common pathway of
coagulation.
Limitations, reasons for caution: Additional studies are needed to eluci-
date the role of anticoagulant EVs in the uptake of oocytes and fertilisation.
Wider implications of the ﬁndings: Follicular EVs may play a role in the
uptake of oocytes by the fallopian tube.
Trial registration number:None
P-331 Cumulus cells GPX4 expression levels are higher in patients
with successful embryo implantation
L. Von MengdenMeirelles1, M.A. De Bastiani1, L. Grun1, L. Arruda2,
C.A. Link3, M. Pozzer2, F. Barbé-Tuana1, F. Klamt1
1Universidade Federal do Rio Grande do Sul, Biochemistry, Porto Alegre, Brazil
2Clínica ProSer, Embriology, Porto Alegre, Brazil
3Clínica ProSer, Clinic, Porto Alegre, Brazil
Study question: Do the redox enzyme GPX4 mRNA expression levels in
cumulus cells relate to embryo implantation rates?
Summary answer: Implantation rates shows to be higher in patients with
higher cumulus cells GPX4 expression levels, regardless of patient’s clinical
characteristics.
What is known already: Cumulus oophorus cells (CCs) represent the ﬁrst
interface of the gamete with the ovarian environment. Therefore, they can pro-
vide valuable information concerning the viability and genetic constitution of the
oocyte and its environment. CCs are responsible for protecting oocytes from
oxidative stress. GPX4 encodes GPx protein GPX4 isoform, that acts preferably
reducing lipid hydroperoxides and protects cells against membrane lipid peroxi-
dation and cell death. It is possible that oocytes protected by CCs with better
defense mechanisms against oxidative stress during oocyte maturation present
greater chances of becoming a good quality oocyte.
Study design, size, duration: Pooled CCs samples were collected from
23 patients submitted to ICSI procedure and subsequent embryo transfer.
Patients were analyzed for B-HCG detection at day 14 after transfer, and
samples were divided between Positive (n = 8) and Negative (n = 15)
groups accordingly to B-HCG result. Patients clinical characteristics, as Body
Mass Index (BMI), age, stimulation protocol and infertility diagnosis were
considered in the analysis.
Participants/materials, setting, methods: Total RNA was extracted from
CCs samples and submitted to reverse transcriptase quantitative polymerase
chain reaction (RT-qPCR). Oligonucleotides were selected to be RNA speciﬁc
and complementary to the human sequence of Glutathione Peroxidase 4
(GPX4). The relative expression (real quantitative [RQ]) of the genes analyzed
was calculated for each sample by the 2-ΔΔCT method. For the multiple
regression analysis, clinical and experimental data were combined.
Main results and the role of chance: A baseline model were built using B-
HCG result as the dependent variable and age, diagnosis, stimulation protocol
and BMI as independent variables. We compared test models composed of the
four clinical variables and RT-qPCR assay data against the baseline model. With
the results being submitted to the regression model considering the clinical
data, GPX4 has shown to be a potential pregnancy biomarker. A signiﬁcant
model (P = 0. 010541996), containing four variables indicated that GPX4
expression levels are overexpressed in Positive group, and this signiﬁcance is
independent of the clinical variables of each patient.
Limitations, reasons for caution: For validation, this result need to be
tested in a larger cohort, with best interest in analyzing individually collected
CCs samples from patients submitted to single embryo transfer.
Wider implications of the ﬁndings: Our study revealed that GPX4 mRNA
expression levels are related to embryo implantation potential, and therefore
are promising candidates for identifying oocyte quality independently of patient
clinical proﬁle.
Trial registration number: This study was approved by ethics comittee of
Universidade Federal do Rio Grande do Sul under the approval number
68081017.2.0000.5347.
P-332 The effect of recent contraceptive use on the probability to
conceive: A comparison between hormonal contraceptives and a
fertility awareness-based method
O. Lundberg1, E. Berglund Scherwitzl2, H. Kopp Kallner3,
J. Trussell4, K. Gemzell Danielsson5, R. Scherwitzl2
1Natural Cycles, Science, Stockholm, Sweden
2Natural Cycles Nordic AB, Science, Stockholm, Sweden
3Karolinska Institutet, Department of Clinical Sciences at Danderyd Hospital,
Stockholm, Sweden
4Princeton University, Ofﬁce of Population Research, Princeton, U.S.A.
5Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm,
Sweden
Study question: Are there differences in short- and long-term conception
probabilities between women who recently used a fertility awareness-based
contraceptive method and women who recently used hormonal
contraceptives?
Summary answer: Results in this study suggest that FAB methods used for
contraception increase short-term pregnancy rates with respect to hormonal
contraceptives, but not ong-term pregnancy rates.
What is known already: Previous studies have indicated that the use of techni-
ques associated with fertility awareness-based methods for contraception may
enhance pregnancy rates for women trying to conceive. Such studies have so far
mainly treated various verisons of the so-called Billings method and the sympto-
thermal method. Several previous studies also show that the use of hormonal con-
traceptives may instead reduce the short-term probabilities to conceive. Most stud-
ies do not ﬁnd any long-term effect of hormonal contraceptives on fecundity.
Study design, size, duration: The study is a real-life prospective observa-
tional study of women who use a mobile fertility monitoring application (Natural
Cycles) in attempting to become pregnant. A total of 2934 women planning a
pregnancy using the mobile application Natural Cycles between August 2014 and
June 2016 were included. Of these women 1638 were previous users of hormo-
nal contraceptives and 1296 had previously used the fertility awareness-based
method provided by the Natural Cycles application to prevent pregnancies.
Participants/materials, setting, methods: Users were included if they
registered as users of the mobile contraceptive app with the intent of planning a
pregnancy between August 2014 and June 2016. Comparisons were performed
using two complementary methods: We calculated the average Time to
Pregnancy (TTP) for all women who became pregnant during the time of the
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study, and performed Kaplan-Meier life-table analysis to analyze the cumulative
probabilities of pregnancy including all women who entered the study.
Main results and the role of chance: We found an average Time To
Pregnancy of 2.3 (95%CI: 2.1-2.4) cycles for the women who had used Natural Cycles
to prevent pregnancies, compared to 3.7 (95% CI: 3.4-3.9) for women who used hor-
monal contraceptives prior to attempting to become pregnant.We used Kaplan-Meier
life-table analysis to compare the time to reach 30% cumulated pregnancy probability
for the two groups and found the time for women previously on hormonal contracep-
tives to be 1.6 (95%CI: 1.5-1.8) times longer than the time for women previously using
Natural Cycles. When comparing 13-cycle cumulated pregnancy probabilities there
were no signiﬁcant differences between the two groups.
Limitations, reasons for caution: The results do not provide a comparison of
neither method to other non-hormonal method of contraception. The study popu-
lation only contains women who decided to use an application for fertility monitor-
ing, which may lead to a selection bias compared to the average population.
Wider implications of the ﬁndings: The result is likely widely applicable to
women who uses fertility awareness methods prior to planning a pregnancy.
The results presented in this study may be of interest to women planning to
become pregnant in the near future as well as for healthcare professionals coun-
seling women on contraception and fertility.
Trial registration number:Not applicable.
P-333 Epigenetic changes in human cumulus cells during
reproductive aging
E. Molinari1, S. Horvath2, D.T.S. Lin3, M.S. Kobor4, P. Patrizio5
1New England Fertility Institute, Embryology Lab, Stamford, U.S.A.
2UCLA, Dept of Human Genetics, Los Angeles, U.S.A.
3UBC, Department of Medical Genetics, Vancouver, Canada
4UBC, Department of Medical Genetics, Department of Medical Genetics, Canada
5Yale University, Obstetrics and Gynecology, New Haven, U.S.A.
Study question: Oocyte aging is a common cause of infertility and still the
mechanisms involved are unknown. Could age-related changes in DNA methy-
lation (DNAmAge) of cumulus cells explain the reproductive decline?
Summary answer:We found suggestive evidence that chronological age cor-
relates with DNAmAge (r = 0.38, p = 0.074). Epigenetic age acceleration
exhibited moderately high correlations with variables measuring fertility.
What is known already: The study of the epigenetic proﬁle of a tissue has
been proven to reliably provide information regarding the age of the derived
organ, through the analysis of 353 CpG islands across the entire human gen-
ome. The epigenetic clock algorithm identiﬁes the discrepancies between
chronological age and biological age, so called age acceleration rate (AgeAccel).
Conditions such as chronic diseases, viral infection and chromosomal anomalies
show an increased AgeAccel compared to healthy individuals. Our study aimed
at deciphering AgeAccel in follicles of women undergoing in vitro fertilization.
Study design, size, duration: Thirty-two women undergoing IVF/ICSI were
selected for the study (exclusion criteria: endometriosis, PCOS, use of PGD).
Cumulus cells were removed from oocytes and pooled for each individual
patient. Patient’s ages ranged 24-45 y.o. (mean 36.8)
Participants/materials, setting, methods: Total DNA from cumulus cells
was extracted and used for bisulﬁte conversion (Zymo Research).
Genomewide DNA methylation proﬁling was carried out with 160 ng bisulﬁte
converted DNA, using the Inﬁnium Methylation BeadChips (Illumina) and hybri-
dized to the Illumina Inﬁnium 450 K Human Methylation Beadchip.
Main results and the role of chance: AgeAccel is inversely correlated to
good markers of patient’s prognosis, such as AMH (r = -0.24), number of
oocytes collected (r = -0.33), oocyte maturity (r = -0.31), fertilization (r
= -0.22) and cleavage (r = -0.25) and positively correlated to amount of admi-
nistered gonadotropins (r = 0.19)
Limitations, reasons for caution: This study focused almost exclusively on
assessing the epigenetic differences in CC across a population of patients under-
going IVF/ICSI. These epigenetic ﬁndings were not correlated with embryonic
development and clinical outcome.
Wider implications of the ﬁndings: Our data conﬁrms the hypothesis of a
link between follicle senescence, cumulus cells and oocyte aging. The use of the
age acceleration clock could, on a larger and more diverse cohort of patients,
predict weather also other conditions, such as endometriosis and PCOS could
be associated with follicular aging.
Trial registration number:N/A.
P-334 Effects of dietary AGE (Advanced Glycation End product) on
ovarian microenvironment and oocyte quality
G. Di Emidio, G. Rossi, M. Placidi, S.J. Santini, A.M. D’Alessandro,
S. Falone, F. Amicarelli, C. Tatone
University of L’Aquila, Dept. of Life- Health and Environmental Science, L’Aquila, Italy
Study question: Does the ovary activate an effective adaptive response to
counteract the toxicity derived from dietary AGEs?
Summary answer: The ovary activates an adaptive response, which counter-
acts AGE accumulation but does not prevent toxic effects of dietary AGE on
growing follicles and mature gamete.
What is known already: The levels of advanced glycation end products
(AGEs) are increased during aging and under conditions of impaired glucose meta-
bolism and/or oxidative stress (OS), promoting insulin resistance and other endo-
crine abnormalities. AGE deposition may be also ascribed to exogenous factors,
such as tobacco smoking and diet. In the ovary, AGE formation has been associated
to reproductive aging and polycystic ovarian syndrome (PCOS). In vitro exposure
to methylglyoxal (MG), the main precursor of AGE, severely affects oocyte matur-
ation, whereas in vivo ovarian and oocyte toxicity of MG is still unknown.
Study design, size, duration: To study the effects of dietary AGE (dAGE),
4-week-aged female CD1 mice received water (n = 9) or 100 mg/kg MG (n =
9) by gastric administration for 28 days. This treatment induces increased serum
MG levels (Ghosh et al., 2006). Six mice per group were sacriﬁced 48-h after
the last administration and ovaries were collected for further analysis. Three
mice were sacriﬁced 15-h after induction of superovulation by PMSG-hCG
protocol and MII oocytes were isolated from ampullae.
Participants/materials, setting, methods: The number of ovarian follicles
was recorded in ovaries stained by ematossilin/eosin. The abundance of MG-
AGEs, sirtuins (SIRT1, SIRT3), catalase (CAT), mitochondrial superoxide dis-
mutase (SOD2), PGC1α, glyoxalase 1 (GLO1) were analysed by Western blot
(WB). Spindles and chromosomes of MII oocytes were stained by immuno-
ﬂuorescence and digital images were analysed by ImageJ to obtain measure-
ments of spindle dimensions (length, equator and pole width). Statistical
analysis was performed by Sigma-Stat software.
Main results and the role of chance: Analysis of follicle population revealed
a reduced number of primary and secondary follicles in dAGE group.
Biochemical investigation demonstrated similar levels of ovarian MG-AGEs in
the two groups. Nevertheless dAGE ovaries displayed an increase of SIRT1, an
OS sensor, together with up-expression of CAT and SOD2. Expression of the
mitochondrial sirtuin SIRT3 and PGC1α, the main regulator of mitochondrial
biogenesis, was also increased. Finally, enhanced protein expression of GLO1,
the main ovarian AGE detoxifying enzyme, was observed in dAGE group.
Although similar ovulation rate were recorded in control and dAGE mice, spin-
dle analysis showed that dAGE oocytes exhibited abnormal spindle size resem-
bling those previously found in low quality oocytes (Sanﬁns et al, 2003).
Limitations, reasons for caution: The results on this animal model may not
fully extrapolate to humans.
Wider implications of the ﬁndings: Present results suggest that AGE intake
induces ovarian oxidative stress and triggers an adaptive response, which pre-
vents ovarian AGE accumulation. Nevertheless, dAGE leads to loss of growing
follicles and production of low quality oocytes. These results contribute to the
knowledge of mechanisms underlying the reduced fertility in PCOS and diabetes.
Trial registration number: not required.
P-335 Bisphenol S (BPS) affects meiotic spindle formation and
causes DNA damage: Implications for female infertility
J. Nevoral1, M. Jeseta2, T. Zalmanova3, K. Hoskova3, P. Klein1,
S. Prokesova4, M. Stiavnicka1, J. Moravec1, P. Hosek1, J. Zakova2,
E. Koutna1, J. Petr3, M. Kralickova1
1Faculty of medicine in Plzen- Charles University in Prague, Biomedical Center, Plzen,
Czech Republic
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2University Hospital and Masaryk University- Obilni trh 11- 602 00 Brno- Czech
Republic, Department of Obstetrics and Gynecology-, Brno, Czech Republic
3Institute of Animal Sciences- Prague-Uhrineves- Czech Republic, Biology of
reproduction, Prague, Czech Republic
4Czech University of Life Sciences Prague- Czech Republic, Department of Veterinary
Sciences, Prague, Czech Republic
Study question: Does BPS occur in human follicular ﬂuid? If yes, is BPS able to
inﬂuence chromosome alignment and spindle formation in mouse oocyte?
Summary answer: BPS was measured in follicular ﬂuid of women underwent
ART. Accordingly, BPS in vivo treatment of mice impairs the quality of the
matured oocyte.
What is known already: BPS represents the main substituent of earlier
widely-used bisphenol A (BPA). In accordance with BPA detection in human
follicular ﬂuid and negative effects of both BPA and BPS is known so far, we
assumed BPS presence in human follicular ﬂuid and its negative effect on oocyte
quality. Detrimental effects of BPS on oocytes were described on pig model
in vitro only. On the other hand, BPS levels in human follicular ﬂuid were not
determined and inﬂuence of BPS on oocytes in vivo remains unknown.
Study design, size, duration: 35 samples of human follicular ﬂuid were
obtained from April to November 2017. Subsequently, eight-week-old ICR
mice (n = 25) were treated with BPS in four different concentrations for 7 days
per os. When the experiment was terminated, oocytes were isolated and
matured in vitro. In total, the experiments included 127 matured oocytes.
Participants/materials, setting, methods: The samples of follicular ﬂuid,
obtained from patients of ART clinic were digested by β–glucuronidase and sub-
jected to derivatization by 1-methylimidazol-2-sulfonyl chloride, followed by
BPS measurement by LC-MS. Eight-week-old ICR mice were exposed to
0.001–100 ng BPS/g BW/day per os for 7 days. Isolated oocytes were in vitro
maturated followed by TUNEL assay or spindle α-tubulin immunostaining.
Oocytes were analysed by confocal microscope (Olympus, Germany) and sig-
nal intensity measurement (ImageJ, NIH, USA).
Main results and the role of chance: BPS levels were detected in samples
of human follicular ﬂuid of patients of the ART clinic, with values 3.5 ± 0.77 ng.
ml-1 (median ± S.E.M.; LOD: 0.19 ng/ml, LOQ 0.65 ng/ml). The additional
experiment, using mouse in vivo exposure, proved the negative impact on
female reproduction. BPS treatment of mice disrupted DNA stability of
matured oocytes. There was observed 4.7, 7.0 and 5.8-fold TUNEL signal
intensity in metaphase chromosomes after dosing 0.001, 0.1, 100 ng BPS/g
BW/day, respectively. Moreover, BPS exposure showed signiﬁcantly increased
the incidence of malformed spindle microtubules and chromosome misalign-
ment. Individual BPS doses seemed to have a speciﬁc pattern of spindle abnor-
malities, such as extended shapes and barrel-shaped spindle in 0.001 and 10 ng
BPS/g BW/day, respectively.
Limitations, reasons for caution: With respect to the observation of BPS
levels in the follicular ﬂuid, we analysed the oocyte quality after mouse in vivo
exposure. Considering the results of decreasing oocyte quality arise from an ani-
mal model, it would be appropriate to evaluate the BPS effect in human oocytes.
Wider implications of the ﬁndings: Currently, the BPS exposure on man-
kind rise as the BPS becomes widely used, as shown with detection of BPS in
follicular ﬂuid. Moreover, concentrations of BPS closely resemble those of
harmful BPA. Our ﬁndings show that these low doses of BPS signiﬁcantly impact
female reproduction.
Trial registration number: The sample colection and experiments with
mice were performed in accordance with the Ethical Committee at Faculty
Hospital in Brno and Act No 246/1992 Coll.
P-336 Circadian rhythm disruption in polycystic ovary syndrome
F.Wang1, Y.Wu1, F. Qu2
1Women’s Hospital-School of Medicine-Zhejiang University, Department of
Obstetrics and Gynecology, Hangzhou, China
2Women’s Hospital-School of Medicine-Zhejiang University, Department of
Traditional Chinese Medical Gynecology, Hangzhou, China
Study question: Is circadian rhythm disruption involved in the pathogenic
mechanism of polycystic ovary syndrome (PCOS)?
Summary answer: The chronodisruption, typically attributable to shift work,
may contribute to the development of PCOS.
What is known already: Although the underlying etiology remains unclear,
aberrant light–dark cycles greatly impair the ovarian function.Despite emerging
evidence of a high prevalence of sleep disorders in patients with PCOS, there is
limited epidemiological data concerning the association between PCOS risk and
circadian disruption by sleep disturbances or night shift work.
Study design, size, duration: We performed a multicenter, questionnaire-
based survey to explore the link between night shift work and PCOS risk in 436
PCOS cases and 715 controls between June 2016 and May 2017.Moreover, we
conducted a series of experiments to investigate the roles of ovarian circadian
disruption in PCOS pathogenesis.
Participants/materials, setting, methods: Firstly, the survey was con-
ducted over twelve hospitals in mainland China. Only women aged 21–45 with-
out any sleep disorders, caused by neurological, psychiatric or respiratory
disorders etc., were recruited. Patients were diagnosed with PCOS according
to the Rotterdam Consensus.The controls were healthy women who had parti-
cipated in a health screen in these hospitals. Secondly, PCOS patients and
women with tubal blockage undergoing in vitro fertilization (IVF) were
recruited, GCs and follicular ﬂuids were collected.
Main results and the role of chance: After adjusting for potential confoun-
ders, night shift workers had a signiﬁcantly increased risk of PCOS compared
with day workers (OR = 1.80; 95%CI = 1.18–2.75; Table 2). This association
was also observed among those with rotating, but not permanent, night shifts
(OR (Rotating vs. day work) = 2.00, 95%CI = 1.16–3.44; OR (Permanent vs. day work) =
1.54, 95% CI = 0.80–2.95). Compared with day workers, participants that
worked night shifts for a longer period of time (more than 2 years) had a higher
PCOS risk (OR = 2.08; 95%CI = 1.15–3.73). However, those that had worked
night shifts for a shorter period of time (less than 2 years) did not have an
increased risk of PCOS (OR = 1.56; 95%CI = 0.86–2.80). In addition, we found
that in GCs of PCOS women, the overexpression of core clock gene PER1 sup-
pressed the transcriptional activity of AR through combination, and altered
androgen metabolism in GCs contributing to AR-associated hyperandrogenism.
Limitations, reasons for caution: Our survey is a retrospective investiga-
tion, further veriﬁcation is required, particularly studies that evaluate indivi-
duals of different ethnicities using a prospective observational technique.The
GCs used in the present study were collected from patients undergoing IVF,
thus it is of signiﬁcance to further conﬁrm our ﬁndings in unstimulated and
non-luteinized GCs.
Wider implications of the ﬁndings: Understanding the role of circadian
rhythm disruption in PCOS could help to intervene the infertility resulted from
irregular light–dark cycles common to modern-day 24-hour society.
Trial registration number:Not applicable.
POSTER VIEWING
Female infertility
P-337 Estrogen receptor 1 polymorphism (A&gt;G, rs12199722) is
associated with recurrent implantation failure
L. Vagnini1, A. Renzi1, B. Petersen1, C.G. Petersen1,2, A.L. Mauri1,2,
M.C. Mattila2, V.A. Comar2, J. Ricci2, F. Dieamant1,2,
J.B.A. Oliveira1,2, R.L. Barufﬁ1,2, J.G. Franco Jr1,2
1Paulista Center for Diagnosis Research and Training, Research, Ribeirao Preto, Brazil
2Centre for Human Reproduction Prof. Franco Jr, Research, Ribeirao Preto, Brazil
Study question: Is there an association between any Single Nucleotide
Polymorphism (SNP) in the estrogen receptor 1 (ESR1) gene and recurrent
implantation failure (RIF)?
Summary answer: ESR1 polymorphism (A>G, rs12199722) is associated
with RIF. Women with A/G genotype had a 60% decrease in the chance of
being included in RIF group.
i294 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
. . . . . . . . . . . . . . . . . . . . . . . . . . . . ...............
........................................................................................
........................................................................................
What is known already: Estrogen, as a crucial hormone during pregnancy,
acts through its receptors alpha and beta, which are encoded by the ESR1 and
ESR2 genes, respectively. These receptors are involved in reproduction and
may play important roles in RIF. The uterus is a primary target of oestrogen for
various functions during the reproductive cycle and pregnancy. Estrogen binds
to the receptor alpha, which modulates uterine events preparing the endomet-
rium for embryo ﬁxation and implantation. Since genetic factors appear to be
highly associated with RIF, SNPs in the ESR1 gene encoding the receptor alpha
can be used to predict RIF.
Study design, size, duration: A cross-sectional study was performed between
2015 and 2017, comparing 48 women presenting RIF (two or more failed IVF/
ICSI attempts and at least ﬁve or more good-morphological-quality embryos trans-
ferred) versus 2 control groups: 63 women who became pregnant in the ﬁrst IVF/
ICSI attempt (control group I) and 68 fertile women who had at least 2 live births
and no history of miscarriage or infertility treatment (control group II).
Participants/materials, setting, methods: Genomic DNA was extracted
from peripheral blood samples taken from RIF and control groups. DNA was
sequenced on MiSeq(Illumina) to search for SNPs in the ESR1 gene. SNPs found
by Next-Generation Sequencing were analysed to ﬁnd a possible association
with RIF. The A>G polymorphism (rs12199722) was identiﬁed and subse-
quently validated by Real Time PCR. Frequencies of genotypes and alleles were
compared using Fisher’s exact test. An association with RIF was calculated by
logistic regression analysis.
Main results and the role of chance: Our results showed an association
between A/A genotype of ESR1 gene (rs12199722) and women presenting
RIF. Patients with A/A genotype had 3.0-fold increase in the chance of being
included in the RIF group. On the other hand, the presence of A/G genotype
was associated with a 60% decrease in the chance of being included in the RIF
group. A comparison of genotype and allele frequencies of ESR1 polymorphism
(A>G, rs12199722) among women with RIF and two control groups are shown
in Table 1. The association between each genotype and RIF is in Table 2.
Table 1 Genotype and allele frequencies of ESR1
polymorphism(A>G, rs12199722).
ESR1
(rs12199722)
RIF
(%)
Control
group I (%)
P RIF
(%)
Control
group II (%)
P
n = 48 n = 63 n = 48 n = 68
Genotype
AA 64.6 39.7 0.02 64.6 35.3 0.008
AG 29.2 55.5 29.2 50.0
GG 6.2 4.8 6.2 14.7
Allele
A 79.2 67.5 0.05 79.2 60.3 0.002
G 20.8 32.5 20.8 39.7
Table II Logistic Regression between ESR1
polymorphism(A>G, rs12199722) and RIF.
ESR1 (rs12199722) OR (95% CI) P
AA 3.0 (1.53-6.08) 0.002
AG 0.4 (0.18-0.75) 0.006
GG 0.6 (0.16-2.22) 0.45
Limitations, reasons for caution: Since the basic idea of performing a test
is to increase the chance of obtaining a correct diagnosis, further validation of
the ESR1 polymorphism (A>G, rs12199722) is required (e.g., increasing the
number of cases, expanding to different ethnic groups) to provide more infor-
mation regarding its potential use to predict RIF.
Wider implications of the ﬁndings: Our results, based on two control
groups, showed for the ﬁrst time evidence that ESR1 polymorphism(A>G,
rs12199722) can be used as a genetic marker to predict RIF allowing physicians
to provide a better risk analysis for each patient, helping to make assertive deci-
sions, improving the chances of a woman becoming pregnant.
Trial registration number: Merck Grant for Fertility Innovation (GFI-2014-
16). The funders had no role in study design, data collection and analysis, or
preparation of the abstract.
P-338 Analysis of 215,212 ovulation induction (OI) and intrauterine
insemination (IUI) cycles reveals the high rate of multiple gestations
in patients across age groups and diagnoses
K. Hunter Cohn1, C.Wellock1, B.T. Miller2, M. Hinckley3,
J.N. Gutmann4, C. Benadiva5, J.C. Nulsen5, G. Letterie6,
J. Hirshfeld-Cytron7, P. Yurttas Beim1
1Celmatix Inc., Research and Development, New York, U.S.A.
2Reproductive Medicine Associates of Michigan, Reproductive Endocrinology, Troy,
U.S.A.
3Reproductive Science Center of the San Francisco Bay Area, Reproductive
Endocrinology, San Ramon, U.S.A.
4Reproductive Medicine Associates of Philadelphia, Reproductive Endocrinology,
Philadelphia, U.S.A.
5University of Connecticut School of Medicine, The Center for Advanced Reproductive
Services, Farmington, U.S.A.
6Seattle Reproductive Medicine, Reproductive Endocrinology, Seattle, U.S.A.
7Fertility Centers of Illinois, Reproductive Endocrinology, Highland Park, U.S.A.
Study question: What are the ongoing pregnancy rates (OPR) and multiple
gestation rates (MGR) associated with different non–in vitro fertilization (non-
IVF) treatments?
Summary answer: Non-IVF treatment yielded OPR of 3.4%–19.0% and
MGR of 3.5%–25.5%, with higher-order multiple (HOM) rates of 3.3%–6.4% in
patients younger than 40 using gonadotropins.
What is known already: Non-IVF treatments with OI using oral medications
(clomiphene citrate or letrozole) or injectable gonadotropins with IUI or timed
intercourse (TI) are frequently used as ﬁrst-line fertility treatments because of
lower up-front costs compared to IVF. Since non-IVF treatments often lead to
multiple birth and consequently high neonatal costs, characterization of preg-
nancy and multiples rates resulting from non-IVF treatments is needed to prop-
erly evaluate the cost-effectiveness of these treatment options. A study of this
magnitude has been hindered to date by the lack of outcome tracking for non-
IVF treatments in data registries in both the United States and Europe.
Study design, size, duration: We performed a retrospective analysis of
cycles that used the OI medications clomiphene citrate or letrozole (Orals)
and/or injectable FSH or hMG (Gnd) with IUI or TI with partner semen. We
included 215,212 cycles from 77,303 patients treated at 13 fertility centers
located within the United States. Cycles were performed between 2002 and
2017.
Participants/materials, setting, methods: We included all women who
were treated with OI or IUI that were 18–45 years old, and excluded cycles
utilizing donor sperm. Patients were treated according to standard clinic proto-
cols for OI and IUI. Ongoing pregnancy outcomes were determined by the
presence of a fetal heartbeat (FH) upon discharge to obstetrical care. Multiple
gestations were determined by the number of FHs detected by ultrasound, and
classiﬁed as either twins or HOMs (3 or more FHs).
Main results and the role of chance: The overall OPR was 11.1%, with
10.7% twin and 1.5% HOM. The OPR and MGR by age and treatment type are
shown in Tables 1 and 2. Notably, the HOM rate was as high as 3.3%–6.4% in
patients younger than 40 who used Gnd.
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Table 1 Ongoing pregnancy % (N of cycles)
<30 30–34 35–39 40–45
Orals+TI 11.2%(7831) 10.1%(16,113) 6.9%(11,922) 3.4%(5902)
Orals+IUI 11.7%(10,842) 11.1%(36,850) 9.7%(33,053) 4.9%(12,738)
Gnd+Orals+TI 14.6%(623) 12.9%(1472) 8.9%(1401) 3.9%(908)
Gnd+Orals+IUI 15.9%(2751) 14.8%(10,271) 12.6%(11,793) 6.9%(7553)
Gnd+TI 18.1%(867) 18.2%(1566) 11.4%(1257) 5.3%(1122)
Gnd+IUI 19%(3059) 17.3%(10,767) 14.2%(12,927) 6.9%(11,624)
Table II Multiple gestation % of ongoing pregnancies
(N of cases)
<30 30–34 35–39 40–45
Orals+TI: Twins 8.6%(75) 7.7%(126) 7.3%(60) 3%(6)
Orals+TI: HOM 0%(0) 0.7%(11) 0.6%(5) 0.5%(1)
Orals+IUI: Twins 7.9%(100) 8.9%(365) 8.7%(279) 6.8%(42)
Orals+IUI: HOM 0.9%(12) 0.6%(23) 0.7%(24) 0.3%(2)
Gnd+Orals+TI: Twins 17.6%(16) 13.7%(26) 11.3%(14) 14.3%(5)
Gnd+Orals+TI: HOM 2.2%(2) 1.1%(2) 1.6%(2) 2.9%(1)
Gnd+Orals+IUI: Twins 14.8%(65) 12.7%(194) 13.1%(194) 8.9%(46)
Gnd+Orals+IUI: HOM 1.4%(6) 1.7%(26) 0.9%(14) 1.2%(6)
Gnd+TI: Twins 19.1%(30) 13.7%(39) 11.9%(17) 11.7%(7)
Gnd+TI: HOM 6.4%(10) 5.3%(15) 4.2%(6) 1.7%(1)
Gnd+IUI: Twins 16.6%(96) 16.9%(315) 16.6%(306) 12.4%(100)
Gnd+IUI: HOM 3.6%(21) 4%(74) 3.3%(61) 1.6%(13)
Limitations, reasons for caution: This retrospective dataset included a var-
iety of treatment and monitoring protocols used at multiple clinics over a large
time range. In addition, the observed rates were of all treated patients, so com-
parison of rates between treatments, in particular TI to IUI, should be the sub-
ject of a subsequent investigation.
Wider implications of the ﬁndings: This is the ﬁrst large scale study to
date of the health burden associated with non-IVF fertility treatments. We
observed that these treatments result in a signiﬁcant rate of multiple births,
including HOMs. This study sets the foundation for future cost-effectiveness
studies that can improve policy-making around fertility care.
Trial registration number:N/A.
P-340 External validation of a dynamic prediction model for
repeated predictions of natural conception
R. Van Eekelen1, D.J. McLernon2, M. VanWely1, M.J.C. Eijkemans3,
S. Bhattacharya4, F. Van der Veen1, N. Van Geloven5
1Academic Medical Center, Centre for Reproductive Medicine, Amsterdam, The
Netherlands
2University of Aberdeen, Medical Statistics Team, Aberdeen, United Kingdom
3University Medical Center Utrecht, Department of Biostatistics and Research
Support, Utrecht, The Netherlands
4Unversity of Aberdeen, Institute of Applied Health Sciences, Aberdeen, United
Kingdom
5Leiden University Medical Center, Department of Biomedical Sciences, Leiden, The
Netherlands
Study question: How well does a previously developed dynamic prediction
model perform in an external, geographical validation in terms of predicting the
chances of natural conception at various points in time?
Summary answer: The dynamic prediction model performs well in an exter-
nal validation on a Scottish cohort.
What is known already:We developed a dynamic prediction model for nat-
ural conception that is able to update predictions of natural conception when
couples return to their clinician after a period of unsuccessful expectant man-
agement. However, it is not known how well this model performs in an external
population for clinical use.
Study design, size, duration: A record-linked registry study including the
long term follow up of all couples who were considered unexplained subfertile
following a fertility work up at the Aberdeen Fertility Clinic in the Grampian
region of Scotland between 1998 and 2011. Couples with anovulation, uni/
bilateral tubal occlusion, mild/severe endometriosis or impaired semen quality
according to WHO criteria were excluded.
Participants/materials, setting, methods: The endpoint was time to nat-
ural conception, leading to an ongoing pregnancy. Follow up was censored at
the start of treatment, at the change of partner or at the end of study (31st of
March, 2012). The performance of the van Eekelen model was evaluated in
terms of calibration and discrimination at various points in time. Additionally,
we assessed the clinical utility of the model in terms of the range of the calcu-
lated predictions.
Main results and the role of chance: Of a total of 1214 couples with a
median follow up of 14 months after the fertility workup, 397 (33%) couples
conceived naturally leading to an ongoing pregnancy. Using the dynamic predic-
tion model, the mean probability of natural conception over the course of the
ﬁrst year after the workup was estimated at 25% (observed: 22%), After half a
year, one year and one and a half years of expectant management after comple-
tion of the fertility workup, the average probability of conceiving naturally over
the next year was estimated at 18% (observed: 15%), 14% (observed: 14%) and
11% (observed: 12%).
Calibration plots showed good agreement between predicted chances and
the observed fraction of ongoing pregnancy within risk groups. Discrimination
was moderate with c statistics similar to those in the internal validation, ranging
from 0.60 to 0.64. The range of predicted chances was sufﬁciently wide to dis-
tinguish between couples having a good and poor prognosis with a minimum of
zero at all times and a maximum of 55% over the ﬁrst year after the workup,
which decreased to maxima of 43% after half a year, 34% after one year and
29% after one year and a half after the workup.
Limitations, reasons for caution: The primary analysis showed a slight
overestimation of conception by approximately 3 percentage points on group
level in the ﬁrst year post fertility workup and after half a year of expectant man-
agement. This is likely attributable to the difﬁculty in identifying the exact date
of completion of the fertility workup.
Wider implications of the ﬁndings: The van Eekelen model is a valid tool
in clinical practice to counsel couples with unexplained subfertility on their indi-
vidualised chances of conception at various points in time, notably when cou-
ples return to the clinic after a period of unsuccessful expectant management.
Trial registration number:Not applicable.
P-341 Effects of Vitamin D supplementation on Assisted
Reproduction Technology (ART) outcomes: an interim analysis of a
randomized double-blind multicenter placebo-controlled trial
V. Sarais1, S. Ferrari2, M. Reschini2, A. Paffoni2, G. Cermisoni3,
S. Signorelli4, E. Papaleo4, P. Viganò3, E. Somigliana5
1IRCCS San Raffaele Scientiﬁc Institute, Centro Scienze Natalità, MILANO MI, Italy
2Infertility Unit- Fondazione IRCCS Ca’ Granda- Ospedale Maggiore Policlinico- Via
M. Fanti 6- 20122- Milan-Italy, Infertility Unit, milano, Italy
3Division of Genetics and Cell Biology- IRCCS San Raffaele Scientiﬁc Institute- 20132
Milan- Italy, Infertility Unit, milano, Italy
4Centro Scienze Natalità- IRCCS San Raffaele Scientiﬁc Institute- 20132 Milan- Italy-,
Infertility Unit, milano, Italy
5Infertility Unit- Fondazione IRCCS Ca’ Granda- Ospedale Maggiore Policlinico- Via
M. Fanti 6- 20122- Milan-Italy - University of Milan- Via della Commenda 10-
20122- Milan- Italy, Infertility Unit, milano, Italy
Study question: Does vitamin D supplementation affect clinical pregnancy
rate (CPR) per started cycle in women undergoing ART procedures?
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Summary answer: No signiﬁcant differences were found in CPR. A signiﬁ-
cantly higher top quality embryo rate was observed in women allocated to vita-
min D.
What is known already: Several observational data from IVF cycles suggest a
possible beneﬁcial effect of vitamin D on the rate of success of the procedure.
According to a recent metanalysis, the ORs of clinical pregnancy in vitamin D
sufﬁcient women was 1.33 (95%CI: 1.08-1.65) (Chu et al., 2018). However, a
causal relation remains to be demonstrated and interventional studies are war-
ranted. To date, only one randomized controlled trial on the potential beneﬁt
of vitamin D for IVF has been published (Aﬂatoonian et al., 2014). No signiﬁcant
beneﬁts emerged but the sample size (n = 106) was insufﬁcient for meaningful
conclusions.
Study design, size, duration: Eligible women with a serum vitamin D level
<30 ng/ml were recruited. The sample size (630 women) was calculated con-
sidering a 10% difference in CPR between the supplemented and not supple-
mented populations. The ﬁrst visit for recruitment was 10/10/2016. Recruited
women received 600,000 IU of Vitamin D or placebo (in a single oral adminis-
tration) at the time of randomization. Ovarian hyperstimulation initiated within
three months after randomziation.
Participants/materials, setting, methods: All participants and physicians
managing the patients were blinded to trial intervention allocation. The alloca-
tion sequence was computer-generated and blinded to the investigators and
participants. Inclusion criteria of women were: age 18-39 years, less than 3 pre-
vious ART attempts, body mass index between 18 m2/Kg and 25 m2/Kg.
Exclusion criteria were: poor responders according to Bologna criteria, ART
freezing-cycles. Eligible women signed an informed consent and provided a
blood sample for vitamin D assessment.
Main results and the role of chance: Since the start of the study, 267
women were recruited (n = 136 women were administered vitamin D and n =
131 women placebo). No differences were observed in duration of ovarian
hyperstimulation (p = 0.29) and total dosage of gonadotropins administered (p
= 0.21) between the two groups. The mean (±SD) number of retrieved
oocytes was 8.7 ± 6.4 in vitamin D group and 7.6 ± 4.6 in the placebo group
(p = 0.09). No signiﬁcant differences were found in the total number of follicles
> 16 mm (p = 0.24), oocytes used (p = 0.46) and fertilization rate (p = 0.84).
Cleavage rate and number of total embryos on day 3 were not different
between vitamin D and placebo group (respectively p = 0.27 and p = 0.97). A
statistically signiﬁcant higher top quality day 3 embryos rate was found in the
supplemented group (respectively 60% compared to 43%, p = 0.03).
Blastulation rate was not different between the two groups (vitamin D treat-
ment 50% and placebo 44%, p = 0.72). Due to the increased strategy to freeze
embryos for clinical conditions, clinical pregnancy rate was calculated on a low-
er number of women (vitamin D supplemented n = 77 and placebo group n =
82) and was not different between the groups (p = 0.74).
Limitations, reasons for caution: This is a planned interim analysis per-
formed in order to evaluate preliminary results mostly on embryological out-
comes. The sample size is not powered enough to detected differences in CPR
per started cycle.
Wider implications of the ﬁndings: This study can potentially inﬂuence the
clinical practice of infertility treatment. Vitamin D supplementation is a simple
and cheap intervention and is free of relevant side effects. It may also have
beneﬁcial effects on pregnancy outcome.
Trial registration number: EUDRACT 2015-004233-27
P-342 Only patient age - and not stimulation or relationship
status - affects IUI outcome in 13-year single-centre series of 8995
consecutive cycles
E. Linara, J.J. Wang, G. Lamanna, S. Nair, N. Macklon, K. Ahuja
The London Women’s Clinic, Embryology, London, United Kingdom
Study question: Are clinical outcomes in donor insemination cycles affected
by patient age, ovarian stimulation, or relationship status?
Summary answer: Clinical outcomes are strongly associated with patient
age. Ovarian stimulation, or relationship status did not signiﬁcantly affect preg-
nancy outcomes in almost 9000 consecutive IUI cycles.
What is known already: It is well known that age affects fertility in both nat-
ural and assisted conception, with patient age to be inversely and signiﬁcantly
associated with positive pregnancy outcomes. Despite the improvements in
semen preparation methods and controlled ovarian stimulation, the success of
IUI is still lower than what is reported for other assisted reproduction proce-
dures and we know that it is affected by many factors. Important prognostic
indicators of success with IUI include the patient’s age, the cause and duration
of infertility, methods of ovarian stimulation, number of cycles, ovarian reserve
and male factor infertility.
Study design, size, duration: Our analysis is a retrospective observation
study of data collected from 8995 consecutive treatment cycles of intrauterine
donor insemination performed at the LondonWomen’s Clinic between January
2004 and December 2016. The aim of the study was to examine the efﬁcacy of
IUI effectiveness in relation to patient age, ovarian stimulation, and relationship
status. Statistical analysis was performed using STATA.
Participants/materials, setting, methods: Between 2004 and 2016, 3406
women attended the London Women’s Clinic (LWC) for donor insemination.
1018 women were in heterosexual relationship, 4265 were in same-sex rela-
tionship, and 3712 were single. 58% of cycles were natural; the remainder sti-
mulated (42%). The cross-section of patients - with a high number of lesbian
and single women - reﬂects a clinical focus of the LWC and socio-legal change
in the acceptance and parental rights of individuals in the UK.
Main results and the role of chance: The highest live birth rate (LBR) was
found in women aged <35 years (n = 2948 cycles) with a LBR of 12.6% per
cycle. Women aged 35-37 years (n = 2204 cycles) had a LBR of 10% per cycle
and those aged 38-39 years (n = 1544 cycles) had a LBR of 8% per cycle. In
women aged 40-42 years (n = 1621 cycles) LBR declined to 5% per cycle, while
no pregnancy was observed in women aged ≥45 years.
LBRs were affected by relationship status with single women having signiﬁ-
cantly different results compared with the other groups, but this difference was
fully explained after adjustment for age (p<0.000).
Single women (n = 3712) had a mean age of 39 years and a LBR per cycle of
7%, women in heterosexual relationships (n = 1018) a mean age of 34 years
and a LBR of 10% per cycle, and those in same-sex relationships (4265) a mean
age of 35 years and a LBR of 11% per cycle.
There was a fairly even distribution of non-stimulated (n = 5212) and stimu-
lated cycles (n = 3783) and we found no statistically signiﬁcant difference in the
outcome (p = 0.70). LBR was 8.7% in non-stimulated natural cycles and 9.4% in
stimulated cycles.
Limitations, reasons for caution: This study uses a large sample size of
patients and is adequately powered to detect medium-size effects. The data are
observational and were retrospectively analysed though so unknown confoun-
ders were not assessed. Throughout the study period stimulation protocols
were modiﬁed and LBRs were calculated in varying numbers of cycles.
Wider implications of the ﬁndings: Our study has implications for clinical
practice and patient counselling, with outcome following IUI dependent mainly
on patient age and only marginally on ovarian stimulation and relationship
status.
Trial registration number: not applicable.
P-343 Vascular endothelial growth factor polymorphism (C&gt;T,
rs3025010) can predict recurrent implantation failure
A. Renzi1, L. Vagnini1, B. Petersen1, C.G. Petersen1,2, A.L. Mauri1,2,
M.C. Mattila2, V.A. Comar2, J. Ricci2, F. Dieamant1,2,
J.B.A. Oliveira1,2, R.L.R. Barufﬁ1,2, J.G. Franco Jr1,2
1Paulista Centre for Diagnosis- Research and Training, Research, Ribeirao Preto,
Brazil
2Centre for Human Reproduction Prof Franco Jr, Research, Ribeirao Preto, Brazil
Study question: Is it possible single nucleotide polymorphisms (SNPs) of the
vascular endothelial growth factor (VEGF) gene to predict recurrent implant-
ation failure (RIF)?
Summary answer: VEGF polymorphism (C>T, rs3025010) can predict RIF.
Women with T/T genotype had a 60% decrease in the chance of being included
in RIF group.
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What is known already: VEGF is involved in embryonic development, decid-
ual vascularization, fetal and placental angiogenesis and blastocyst invasion. This
gene located on chromosome 6, contain eight exons and seven introns, which
can form different isoforms by alternative splicing. There are several reports
showing that polymorphisms in this gene can affect the expression and function
of the protein, as well as serum levels of VEGF that could lead to implantation
failure. The rs3025010 VEGF polymorphism site located in the intron region
has been reported to be associated with another SNP in the promoter region
(rs1570360), both related to implantation.
Study design, size, duration: A cross-sectional study was performed
between 2015/2017 comparing 48 women presenting RIF (two or more failed
IVF/ICSI attempts and at least ﬁve or more good morphological quality embryo
transferred) (RIF group) with 68 fertile women who had at least 2 live births
and no history of miscarriage or infertility treatment (control group).
Participants/materials, setting, methods: Genomic DNA was extracted
from peripheral blood samples taken from RIF and control groups. The genomic
DNA was sequenced on MiSeq system (Illumina) to search for SNPs in VEGF
gene. The SNPs found by Next Generation Sequencing were analysed to ﬁnd
possible association with RIF. The C>T polymorphism (rs3025010) was identi-
ﬁed and conﬁrmed by Real Time PCR using the allelic discrimination method.
Differences in genotype were compared using Fisher’s exact test and logistic
regression.
Main results and the role of chance: Our results showed an association
between VEGF C/C genotype (rs3025010) and increased prevalence of RIF as
well as T/T genotype and fertile women. Distribution of genotype and allele
frequencies of RIF and control groups are represented in Table 1. These ﬁnd-
ings have been corroborated by logistic regression analysis where patients with
C/C genotype had 2.8-fold increase in the chance of being included in the RIF
group and patients with T/T genotype had a 60% decrease in the chance of
being included in the RIF group (Table 2).
Table 1 Genotype and allele frequencies of VEGF
polymorphism (C>T,rs3025010).
VEGF
(rs3025010)
RIF group
(%)
Control
group
(%)
P-value
n = 48 n = 68
Genotype
CC 27.1 1.8 0.03
CT 39.6 32.3
TT 33.3 55.9
Allele
C 46.9 27.9 0.003
T 53.1 72.1
Table II Logistic Regression between VEGF
polymorphism (C>T,rs3025010) and RIF.
VEGF (rs3025010) OR (95% CI) P-value
CC 2.8 (1.05-7.38) 0.04
CT 1.4 (0.63-2.96) 0.42
TT 0.4 (0.18-0.85) 0.02
Limitations, reasons for caution: Since the basic idea of performing a test
is to increase the chance of attaining a correct diagnosis, further validation of
the VEGF polymorphism (C>T, rs3025010) is required (i.e., increasing the
number of cases; expanding to different ethnic groups) to provide more infor-
mation regarding its potential use to predict RIF.
Wider implications of the ﬁndings: The ability to predict RIF using the
VEGF polymorphism (C>T, rs3025010) can enable physicians to provide a bet-
ter risk analysis to each patient, helping make assertive decisions, improving the
chances of a woman to get pregnant, encouraging her to undergo additional
cycles of ART.
Trial registration number: Merck Grant for Fertility Innovation (GFI-2014-
16). The funders had no role in study design, data collection and analysis, or
preparation of the abstract.
P-344 A new biochemical approach to detect oxidative stress in
infertile women undergoing assisted reproductive technology
procedures
R. Fucci1, C. Giachini2, M. Becatti2, A. Mannucci2, R. Picone1,
F. Bertocci1, P. Falcone1, E. Borrani1, M.G. Servidio1, L. Badolato1,
L. Criscuoli1, C. Fiorillo2, M.E. Coccia2
1Careggi University Hospital, Assisted Reproductive Technology, Florence, Italy
2University of Florence, Experimental and Clinical Biomedical Sciences “Mario Serio”,
Florence, Italy
Study question: To compare blood and follicular ﬂuid (FF) redox status in
infertile women versus age-matched controls undergoing in vitro fertilization
(IVF) and to establish its connection with the IVF outcome.
Summary answer: Blood oxidative stress reﬂects FF oxidative stress; it is sig-
niﬁcantly increased in infertile women compared to controls and correlates
with IVF outcomes.
What is known already: Studies performed so far indicate that oxidative
stress – characterized by an overabundance of reactive oxygen species (ROS)
or/and a deﬁciency of antioxidants – negatively affects reproductive potential.
The inﬂuence of oxidative stress (OS) on ART outcome is related to its negative
impact on gamete quality and early embryo development, as reported by sev-
eral studies. However, a clinically reliable, biologically accurate indicator of oxi-
dative stress condition does not yet exist and is still difﬁcult to identify.
Antioxidant therapy can restore the redox balance and therefore potentially
improve implantation, pregnancy and live birth rate and time to pregnancy.
Study design, size, duration: The study population included 45 women
with female factor infertility (excluding tubal factor) and 45 age-matched con-
trols (women from couples with pure male factor or tubal factor) undergoing
ART. The biological samples used for the planned investigations were: i) blood
(both plasma and leukocyte subpopulations); ii) follicular ﬂuid (FF), including
granulosa cells.
Participants/materials, setting, methods: ROS assessment (blood/gran-
ulosa cells) was performed by Cytoﬂuorimetric analysis. OS markers (plasma/
FF) were assessed by ﬂuorometric lipid peroxidation markers (MDA) estima-
tion. Total antioxidant capacity (plasma/FF) was performed by ﬂuorimetric
ORAC assay. Measurements of outcomes were based on the evaluation of:
rate of retrieved MII oocytes, fertilization, implantation and pregnancy rates.
Statistical analysis were used to correlate OS markers between blood and fol-
licular samples and its association with embryo development and ART
outcome.
Main results and the role of chance: In this study we assessed redox status
in blood, follicular ﬂuid (FF) and granulosa cells from 45 infertile women and 45
controls undergoing ART. Oxidative stress markers in blood and in granulosa
cells resulted signiﬁcantly (p<0.001) increased in infertile patients compared to
controls. Moreover, we observed: i) a signiﬁcant increase of OS markers in
blood and in granulosa cells in infertile patients compared to controls
(p<0.001); ii) a signiﬁcant correlation between blood and FF redox markers,
indicating that blood oxidative stress reﬂects FF oxidative stress; iii) an associ-
ation between oxidative stress parameters and the considered IVF outcomes
(rate of oocyte at metaphase II and fertilization rate).
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Limitations, reasons for caution:Not applicable.
Wider implications of the ﬁndings: The non-invasive evaluation of oxida-
tive stress will allow the selection of patients who could beneﬁt from antioxi-
dant therapy to restore redox balance before starting the IVF treatment. The
improved redox environment would increase the ART efﬁciency, allowing the
quicker achievement of a successful pregnancy.
Trial registration number:Not applicable.
P-345 Reproductive outcomes in patients with a history of
retained products of conception after delivery versus abortion
H. Ganer Herman, Z. Kogan, D. Tairy, M. Ben Zvi, R. Kerner,
S. Ginath, J. Bar, Y. Mizrachi, R. Sagiv
Edith Wolfson Medical Center, Obstetrics & Gynecology, Holon, Israel
Study question: In the assessment of infertile patients - does a history of
retained products of conception (RPOC) entail a similar prognosis following
delivery and abortion?
Summary answer: Following hysteroscopy for RPOC after delivery and
abortion similar reproductive outcomes were observed. However, following
delivery, subsequent pregnancies entailed a higher rate of abnormal
placentation.
What is known already: RPOC are associated with the formation of intra-
uterine adhesions and subsequent infertility, while hysteroscopic treatment is
associated with less adhesions as compared to curettage. A single study to date
compared post-partum and post abortion RPOC, and noted no difference in
fertility and pregnancy outcomes between cases following delivery and ﬁrst tri-
mester abortion. However, study patients were not uniformly treated with hys-
teroscopy, now the gold standard for RPOC.
Study design, size, duration: This is a cohort of operative hysteroscopies
performed between 2011-2015 for suspected RPOC. Variables were com-
pared between cases following delivery (n = 85), and following abortion (n =
96).
Participants/materials, setting, methods: Patients included underwent an
operative hysteroscopy at our university hospital due to RPOC, during which
conﬁrmed trophoblastic tissue was removed. Computerized ﬁles were
reviewed. For patients who did not deliver at our institution following the hys-
teroscopy – a telephone survey was performed, during which we inquired
regarding infertility or subsequent pregnancies.
Main results and the role of chance: A history of infertility following hys-
teroscopy, deﬁned as at least one year of failure to conceive, was noted in 11
patients (11.8%) in the post abortion group, four of whom were receiving
assisted reproductive treatment, as compared to two patients (2.3%) in the
post-delivery group, one of whom was receiving assisted reproductive treat-
ments (p = 0.01). None of the cases were attributed to mechanical female fac-
tor (intrauterine adhesions). A similar rate of patients in both groups had
experienced an abortion since their hysteroscopy. In the post-delivery group –
34 patients delivered following hysteroscopy (40.0%) for a total of 36 deliveries,
while in the post-abortion group 37 delivered (39.7%) a total of 42 deliveries.
Deliveries in the post-delivery group were notable for a higher rate of abnormal
placentation – 30.5% - including low lying placenta and placenta accreta. A sig-
niﬁcant rate of vaginal deliveries in both groups entailed manual removal of the
placenta or manual exploration of the uterine cavity (23.5% and 10.5%, p =
0.20).
Limitations, reasons for caution: The study is retrospective and data
obtained was that available in patient ﬁles and through telephonic survey. In
addition, the post abortion group included missed abortion and termination of
pregnancy, and medically and surgically treated cases. These entities may entail
different outcomes, but were not powered for seperate analysis.
Wider implications of the ﬁndings: In the assessment of infertility patients,
a history of past RPOC following delivery or abortion entails a similar prognosis,
and warrant a similar suspicion for intrauterine adhesions. During pregnancy fol-
low up – cases of RPOC following delivery necessitate careful attention to
placentation.
Trial registration number:Not applicable.
P-346 Predicting the cumulative chance of live birth over multiple
complete cycles of in vitro fertilization (IVF): an external validation
study
J. Leijdekkers1, M.J.C. Eijkemans2, H.L. Torrance1, S.C. Oudshoorn1,
T.C. Van Tilborg1, D.J. McLernon3, B.W.J. Mol4, S. Bhattacharya5,
F.J.M. Broekmans1
1University Medical Centre Utrecht- University Utrecht, Reproductive Medicine,
Utrecht, The Netherlands
2University Medical Centre Utrecht- University Utrecht, Julius Centre for Health
Sciences and Primary Care, Utrecht, The Netherlands
3Institute of Applied Health Sciences- University of Aberdeen, Medical Statistics
Team, Aberdeen, United Kingdom
4Monash University, Obstetrics and Gynaecology, Clayton, Australia
5University of Aberdeen, Institute of Applied Health Sciences, Aberdeen, United
Kingdom
Study question: Are the published pre-treatment and post-treatment
McLernon models, predicting cumulative live birth rates (LBR) over multiple
complete IVF cycles, valid in a different context?
Summary answer: With minor recalibration of the pre-treatment model,
both McLernon models accurately predict cumulative LBR in a different geo-
graphical context and a more recent time period.
What is known already: Previous IVF prediction models have estimated the
chance of live birth after a single fresh embryo transfer, thereby excluding the
important contribution of embryo cryopreservation and subsequent IVF cycles
to cumulative LBR. In contrast, the recently developed McLernon models pre-
dict cumulative LBR over multiple complete IVF cycles at two certain time
points: a) before initiating treatment using baseline characteristics (pre-treat-
ment model) and b) after the ﬁrst IVF cycle adding treatment related informa-
tion to update predictions (post-treatment model). Before these models are
used in clinical practice, their predictive performance needs to be validated in
an independent cohort.
Study design, size, duration: External validation study in an independent
prospective cohort of 1515 Dutch women who participated in the OPTIMIST
study (NTR2657) and underwent their ﬁrst IVF treatment between 2011 and
2014. Participants underwent a total of 2882 complete treatment cycles,
deﬁned as all fresh and frozen thawed embryo transfers resulting from one epi-
sode of ovarian stimulation. The follow up duration was 18 months after inclu-
sion, and the primary outcome was ongoing pregnancy leading to live birth.
Participants/materials, setting, methods: Model performance was evalu-
ated up to three complete treatment cycles, using the linear predictor as
described by McLernon to calculate the probability of live birth. Discrimination
was expressed by the c-statistic and calibration was depicted graphically in a
calibration plot. In contrast to the original model development cohort, antimul-
lerian hormone (AMH), antral follicle count (AFC) and body weight were avail-
able in the OPTIMIST cohort and evaluated as potential additional predictors
for further model improvement.
Main results and the role of chance: Applying the McLernon models to
the OPTIMIST cohort, the c-statistic of the pre-treatment model was 0.62 (95%
CI 0.59-0.64) and of the post-treatment model 0.71 (95% CI 0.69-0.74). The cali-
bration plot of the pre-treatment model indicated slight overestimation of the
cumulative LBR. To improve calibration, the pre-treatment model was adjusted
by subtracting 0.40 from the intercept. The post-treatment model calibration plot
revealed accurate cumulative LBR predictions. After addition of AMH, AFC and
body weight to the McLernon models, the c-statistic of the updated pre-
treatment model improved slightly to 0.66 (95% CI 0.64-0.68), and of the
updated post-treatment model remained at the previous level of 0.71 (95% CI
0.69-0.73).
As example for clinical application, using the recalibrated pre-treatment
model, a woman aged 30 years with 2 years of primary infertility who starts
ICSI treatment for male factor infertility has a probability of success of 0.39 in
the ﬁrst ICSI cycle, increasing to 0.71 over 3 complete cycles. Then using the
post-treatment model, if this woman had 10 oocytes retrieved in the ﬁrst cycle,
embryos cryopreserved and a single fresh cleavage stage embryo transfer, the
cumulative probability of success rises to 0.83 over 3 cycles.
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Limitations, reasons for caution: The OPTIMIST study contained two ran-
domized controlled trials (RCT) evaluating the effectiveness of gonadotropin
dose individualization on basis of the AFC. The strict dosing regimens, the RCT
in- and exclusion criteria and limited follow up time of 18 months might have
inﬂuenced model performance in this independent cohort.
Wider implications of the ﬁndings: The McLernon prediction models can
be introduced in clinical practice, after local recalibration, to inform patients
and to complement clinical reasoning. These new counselling tools are the ﬁrst
to offer an objective and personalized estimate of the cumulative probability of
live birth over multiple complete IVF cycles.
Trial registration number:Not applicable.
P-347 Pretreatment with coenzymeQ10 improves ovarian
response and embryo quality in low-prognosis young women with
decreased ovarian reserve: a randomized controlled prospective
study
Y. Xu, X. Zhen
Peking University Third Hospital, Reproductive Center, Beijing, China
Study question: Is there any effect of anti-oxidant treatment with coenzyme
Q10 (CoQ10) on ovarian response and embryo quality in young low-prognosis
patients with POR?
Summary answer: Women in CoQ10 group had more retrieved oocytes,
higher fertilization rate and more high-quality embryos, less cancelled embryo
transfer, more available cryopreserved embryos.
What is known already: It has been suggested that poor responders could
assist in evaluation of optimal management strategies for these patients.
CoQ10 acts as an antioxidant by inhibiting lipid peroxidation and DNA oxida-
tion, Several animal studies have demonstrated that CoQ10 protects ovarian
reserve, counteracts physiological ovarian ageing by restoring mitochondrial
function In the clinical setting, led to better response to ovulation induction and
decreased odds of fetal aneuploidy in 35–43-year-old women. To date, how-
ever, no study has investigated whether CoQ10 pretreatment could improve
the ART treatment outcomes in young subpopulation of poor responders in a
randomized setting.
Study design, size, duration: A prospective, randomized controlled study
included 186 consecutive patients with POR stratiﬁed according to the
POSEIDON classiﬁcation group 3 (age < 35, poor ovarian reserve parameters).
The participants were randomized to the CoQ10 pre-treatment for 60 days
preceding IVF-ICSI cycle or no pre-treatment. The number of high quality
embryos was a primary outcome measure.
Participants/materials, setting, methods: This was a prospective rando-
mized controlled study conducted at the Reproductive Medical Center of the
Peking University Third Hospital, a tertiary university hospital and a center of
excellence in Reproductive Medicine in China. The study is reported according
to the CONSORT guidelines.
Main results and the role of chance: A total of 169 participants were eval-
uated (76 CoQ10 and 93 controls) and 17 women were excluded due to low
compliance with CoQ10 administration. The baseline demographic and clinical
characteristics were comparable between the groups. CoQ10 pretreatment
resulted in signiﬁcantly lower gonadotrophin requirements and higher peak E2
levels. Women in CoQ10 group had increased number of retrieved oocytes (4,
IQR 2-5), higher fertilization rate (%) and more high-quality embryos (1, IQR 0-
2); p<0.05. Signiﬁcantly less women treated with CoQ10 had cancelled embryo
transfer because of poor embryo development than controls (8.33% vs.
22.89%, p = 0.04) and more women from treatment group had available cryo-
preserved embryos (18.42% vs. 4.3%, p = 0.012). The clinical pregnancy and
live birth rates per embryo transfer and per one complete stimulation cycle
tended to be higher in CoQ10 group, but did not achieve statistical signiﬁcance.
Limitations, reasons for caution: The important limitation of our study
was its small sample size and we were unable to detect signiﬁcant differences in
clinical outcomes.
Wider implications of the ﬁndings: Pretreatment with CoQ10 improves
ovarian response to stimulation and embryological parameters in young women
with poor ovarian reserve in IVF-ICSI cycles. Further work is required to deter-
mine whether there is an effect on clinical treatment endpoints.
Trial registration number: Chinese Clinical Trial Registry (trial registration
number: ChiCTR-IPR-17010945).
P-348 Investigating the effect of lifestyle risk factors upon the
number of aspirated andmature oocytes in in vitro fertilization
cycles: interaction with antral follicle count
L. Joelsson1, E. Elenis1, K.Wanggren2, A. Berglund3, A. Nyman
Eliadou4, C. Cesta4, S. Mumford5, R.White6, T. Tyden1,
A. Skalkidou1
1Department of Women’s and Children’s Health, Obstetrics/gynecology- Uppsala
university, Uppsala, Sweden
2Karolinska institute, Department of Clinical Science- Intervention and Technology-
Obstetrics and gynecology-, Stockholm-, Sweden
3National Centre for Knowledge on Men’s Violence, National Centre for Knowledge
on Men’s Violence, Uppsala, Sweden
4Karolinska institute, Inst of Medical Epidemiology & Biostatistics, Stockholm-,
Sweden
5Eunice Kennedy Shriver National Institute of Child Health and Human
Development- National Institutes of Health, Epidemiology Branch- Division of
Intramural Population Health Research, Bethesda- Maryland-, U.S.A.
6Norwegian Institute of Public Health, Norwegian Institute of Public Health, Oslo,
Norway
Study question: Is there a cumulative effect of smoking and Body mass Index
on the reproductive outcomes after the ﬁrst completed IVF cycle. Is there any
possible interaction with antral follicle count.
Summary answer: There is an independent and a cumulative effect of smok-
ing and BMI on the number of aspirated oocytes and mature oocytes in fresh
IVF treatment-cycles.
What is known already: There is evidence demonstrating that lifestyle fac-
tors have a detrimental effect on fertility, however the data examining the
effects of lifestyle changes on fertility treatment outcomes are limited.
Furthermore, little is known about the cumulative impact of these unhealthy
factors. Despite the lack of clear preconception guidelines intended for people
seeking fertility treatment, most patients undergoing IVF treatment are willing
to modify their lifestyle behavior. It is therefore crucial that they are aware of
the precise lifestyle changes they can implement in order to enhance the likeli-
hood of IVF success.
Study design, size, duration: Cohort study based on 2 different prospective
cohorts. In total, 242 participants (hypothesis generating cohort) from the
‘Lifestyle study cohort” in which data collection started in May 2013 and ended
in September 2015. In addition, 432 participants (validation cohort) from the
‘UppSTART cohort” starting their ﬁrst fresh IVF cycle between September
2011 and December 2013 were included. Both public and private fertility clinics
in mid-Sweden region were included in both studies.
Participants/materials, setting, methods: Number of aspirated oocytes,
number of mature oocytes, number of embryos created, number of utilizable
embryos and proportion of mature oocytes were the main outcome measures.
The lifestyle factors considered were age, body mass index (BMI), smoking,
alcohol consumption, daily caffeine consumption, physical activity score and his-
tory of depression. A regression model were performed to identify potential
risk factors in the ‘Lifestyle study cohort”. The results were then validated in
the UppStART cohort.
Main results and the role of chance: The median age of the population at
cycle start was lower in the ‘Lifestyle study” cohort 31.1 (IQR = 6.8) years
compared to the ‘UppStART study” validation cohort 34.0 (6.0) years.
However, there were more women with university education in the
‘UppStART study” validation cohort compared to the ‘Lifestyle study” cohort.
Signiﬁcant risk factors were identiﬁed in the ‘Lifestyle study cohort”: smoking
and BMI. Women with both risk factors had (on average) 25% less aspirated
oocytes than women without risk factors (IRR of 0.75,95% CI 0.61–0.94).
Women with these risk factors had also an IRR of 0.78 (95% CI: 0.62–0.98) for
the proportion of mature oocytes (in relation to the total number of aspirated
oocytes), meaning that they would (on average) have 22% fewer mature
oocytes than women with no risk factors. For the outcome of proportion of
mature oocytes (in relation to the total number of aspirated oocytes), the num-
ber of risk factors was found to have a borderline signiﬁcant interaction with
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AFC (p = 0.099): the larger the value of AFC, the less harmful the effect of the
risk factors.
Limitations, reasons for caution: The relatively small sample size, especially
in the ‘Lifestyle study”, might introduce some problems with statistical power.
This might be reﬂected in the borderline statistical signiﬁcance of some of the
results, where, on the other hand, notable and stable trends are demonstrated.
Wider implications of the ﬁndings: These negative lifestyle factors are
easy to detect at an early stage of the assessment process and might allow for
optimization of the treatment outcome. The results provide evidence on the
signiﬁcance of preconception guidance for the optimization of the treatment.
Trial registration number:Not relevant.
P-349 Outcome of Progestin-primed ovarian stimulation protocol
vs. ultra-long protocol in patients with a ﬁrst IVF/ICSI cycle: a
randomized clinical trail
X. Qianwen, K. Yanping
Shanghai ninth hospital afﬁliated to jiaotong University, Department of Assisted
Reproduction, Shanghi, China
Study question: Could Progestin-primed ovarian stimulation protocol or
ultralong protocol be a preferred alternative for infertile women during IVF/
ICSI.
Summary answer: Both regimens can get similar top-quality embryos with
good developmental potential. They all have their beneﬁts and are
irreplaceable.
What is known already: Ultralong protocol with fresh embryo transfer is a
typical ovarian stimulation regimen using a depot of long acting GnRH agonist. It
is well recognized and widely used. Progestin-primed ovarian stimulation
(PPOS) based on a freeze-all strategy is a new ovarian stimulation regimen that
uses progestin as an alternative to a GnRH-a for preventing a premature LH
surge. Ultralong protocol has some weakness of being increased procedure
complexity, higher fees, and greater risk of ovarian hyperstimulation syndrome
(OHSS) in addition to its beneﬁts. There is an unmet need for new ovarian
stimulation protocols with improved efﬁcacy and user convenience.
Study design, size, duration: A prospective RCT including 260 patients was
performed between 1 July 2017 to 31 December 2017. Computerized random-
ization was conducted to assign participants at a 1:1 ratio into two treatment
groups: PPOS (130 patients) or ultralong protocol (130 patients) followed by
their ﬁrst IVF/ICSI with fresh/frozen embryo transfer. The primary outcome
was the number of top-quality embryos. The sample size was chosen to detect
a difference of two oocytes with a power of 85%.
Participants/materials, setting, methods: Patients with normal ovarian
reserve undergoing their ﬁrst IVF/ICSI procedure were included. MPA and
HMG was simultaneously administered at menstrual cycle 3 in PPOS group.
Oocyte maturation was co-triggered by a GnRHa and hCG(1000IU). In the
ultralong protocol group, pituitary down-regulation was obtained in early follicle
phase, Ovarian stimulation started after 35 days and hCG(5000IU) was used to
trigger. Only the ﬁrst embryo transfer cycle was followed-up. The embryo-
logical and clinical outcomes were measured.
Main results and the role of chance: Basic characteristics, such as age, BMI
and infertility duration, in both groups were comparable. There was no signiﬁ-
cant difference in the number (mean ± SD) of top-quality embryos [3.9 ± 3.0
for PPOS vs 3.4 ± 2.5 for ultralong protocol] or the number of oocytes
retrieved [11.8 ± 6.5 for PPOS vs 11.1 ± 5.7 for ultralong protocol] between
the groups. During the whole process of ovarian stimulation, the LH level in the
PPOS group was always higher than that in the ultralong protocol group but
lower HMG dosage was administrated in the PPOS group [2027.9 ± 333.9 for
PPOS vs 2689.0 ± 624.9 for ultralong protocol, P = 0.00]; however, no patient
from either group experienced a premature LH surge. Besides, there was no
moderate or severe ovarian hyperstimulation syndrome during the ovarian
stimulation in PPOS group while three patients suffered it in the ultralong proto-
col group. No signiﬁcant difference was found in the clinical pregnancy rate of
the ﬁrst embryos transfer cycle between the two groups (P = 0.89): 56.5% for
the PPOS group (65/115) versus 57.4% for the ultralong protocol group
(70/122).
Limitations, reasons for caution: Patients and physician were not blinded
to the study. Moreover, some patients had not ﬁnish their ﬁrst embryo transfer
cycle at the end of the trial. It would be better if the live birth rates were
observed in the follow up period and the result could be demonstrated.
Wider implications of the ﬁndings: PPOS effectively reduces the HMG
dosage and the incidence of moderate and severe OHSS during COH while
having a weakness to use freeze-all strategy only. It can be an alternative of the
treatments for infertile woman undergoing IVF as well as traditional protocols.
Trial registration number: ChiCTR-INR-17012089.
P-350 Arterial stiffness during controlled ovarian hyperstimulation
and early pregnancy in women exposed to assisted reproduction
P. Saldeen1, E. VonWowern2, P. Olofsson3
1Nordic IVF Malmö, Nordic IVF Malmö, Limhamn, Sweden
2Institution of Clinical Sciences Malmö- Lund University, Department of Obstetrics
and Gynecology- Skåne University Hospital, Malmö, Sweden
3Institution of Clinical Sciences Malmö- Lund University, Cura Mödravård, Malmö,
Sweden
Study question: To study the effects of controlled ovarian hyperstimulation
(COH) for in vitro fertilization (IVF), and early pregnancy, on arterial stiffness
determined by digital pulse wave analysis (DPA).
Summary answer: We found an increased systemic arterial stiffness,
assessed by DPA, in luteal phase of IVF but no change during ovarian stimulation
or in early pregnancy.
What is known already: Among female sex hormones, estrogen has a vaso-
dilatory effect whereas the vascular effect of progesterone is not yet fully deter-
mined. A person’s vascular condition can be expressed in terms of arterial
stiffness, as measured by pulse wave analysis. Photoplethysmographic DPA is
an operator-independent method to estimate arterial stiffness and endothelial
function in large and small arteries, and changes in DPA parameters towards
increased stiffness have shown good correlations with age and cardiovascular
pathology and morbidity. To our knowledge, there are no previous studies
investigating the effects of IVF and COH on arterial stiffness.
Study design, size, duration: Prospective observational longitudinal study
including 68 women, starting before conception and performed during COH
and IVF treatment until the seventh gestational week.
Participants/materials, setting, methods: 68 women planned for IVF
treatment were asked to participate. The women were examined with DPA at
ﬁrst visit to the clinic (baseline), during IVF stimulation, after embryo transfer,
and in early pregnancy. Heart rate, mean arterial pressure (MAP) and DPA vari-
ables cardiac ejection elasticity index (EEI), b/a, dicrotic index (DI), d/a, and the
global variable aging index (AI), were measured. The ovarian response to
gonadotropin stimulation was estimated with ovarian stimulation index (OSI).
Main results and the role of chance: Heart rate was signiﬁcantly increased
at all measuring points (p≤0.003) but MAP only at embryo transfer (p = 0.007).
DPA variables representing large arteries (EEI, b/a) and peripheral arteries (DI,
but not d/a), and AI, all indicated increased arterial stiffness at embryo transfer
compared with baseline (p≤0.035). No DPA variable was signiﬁcantly changed
during stimulation or at pregnancy measurements. Independent of the inﬂuence
of age, basal measurements of b/a and AI indicated higher arterial stiffness in
poor ovarian responders.
Limitations, reasons for caution: The stimulation measurements, which
showed no signiﬁcant DPA variable changes, may have been performed too
early during the stimulation (stimulation day 7), before the full effect of stimula-
tion had been reached. Baseline measurements were obtained without consid-
ering the menstrual cycle.
Wider implications of the ﬁndings: We expected a vasodilatory effect of
COH since estrogen is a vasodilator, but found the opposite. The unexpected
ﬁndings could be a progesterone effect, or activation of the renin-angiotensin-
aldosterone-system (RAAS), eclipsing the estrogen effects. The association
between arterial stiffness and poor ovarian response, independent of age,
deserves further exploration.
Trial registration number: The study was approved by Regional Research
Ethics Committee in Lund, Sweden, Dnr 2014/648.
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P-351 Identiﬁcation of empty follicles or oocyte-containing follicles
by ultrasound images using K-means method and principal
component analysis assessing several parameters with artiﬁcial
intelligence
H. Matsubayashi1, K. Kitaya1, Y. Takaya1, R. Nishiyama1,
K. Yamaguchi1, N. Kim1, K. Sakaguchi2, M. Doshida2, T. Takeuchi2,
T. Ishikawa1
1Reproduction Clinic Osaka, Obstetrics and Gynecology, Osaka, Japan
2Reproduction Clinic Tokyo, Obstetrics and Gynecology, Tokyo, Japan
Study question: To investigate whether we can identify the existence of
oocytes from ovarian follicles by ultrasound images using artiﬁcial intelligence
(AI).
Summary answer: We can retrospectively classify ovarian follicles with or
without oocytes by ultrasound images using K-means method and principal
component analysis assessing several parameters with AI.
What is known already: We cannot distinguish follicles with or without
oocytes using ultrasound, because a diameter of oocyte is below minimum
detection levels of usual ultrasound devices. When we choose 8 MHz as a fre-
quency of ultrasound, minimum detection levels are estimated to be 0.2 mm
and 0.48 mm with a simple calculation and in consideration with distance-based
resolution, respectively. Therefore, physicians and patients cannot speculate
how many oocytes could be retrieved before oocyte retrieval, or whether a fol-
licle would be empty in a cycle with timed intercourse or intrauterine insemin-
ation. New idea to detect oocytes by ultrasounds has been desired.
Study design, size, duration: We hypothesized the follicles with oocyte
might be more rigid (i.e. less elastic) than those without oocytes, because the
former has thicker follicle membrane as cumulus-oocyte-complex. If they were,
deformity patterns with or without oocytes might be different when a needle
was going to insert into the follicles. With a similar concept, elastography has
been utilized for prediction of breast cancer. We performed a pilot study in a
single center on October in 2015.
Participants/materials, setting, methods: With informed consent, 3
patients participated in the study. Ultrasound (B-mode) moving images were
recorded throughout the oocyte retrieval under anesthesia, each follicle was
aspirated separately using different syringe followed by conﬁrmation with
microscopy. Aspirated follicles and moving images were numbered in numerical
order. The image data of 16 follicles (11 contained oocytes, 5 did not) were
analyzed with AI in order to distinguish the differences with or without oocytes
using several parameters, retrospectively.
Main results and the role of chance: We chose six parameters from the
moving images when a needle was going to insert into the follicles: #1:
Circularity of outline of the follicles (C = 4πS/L2, where S is the area sur-
rounded by the outline of the follicles and L is the perimeter of the outline),
#2: Angle formed between the two lines deﬁned by the two points just
before piercing the follicles (θ1/√2 = D1/√2, where D is the distance
between the convex hull and the outline for each angle, and D1/√2=Dmax x
1/√2), #3: θ0.01 = D0.01 where D = 0.01 mm, #4: Dmax difference between
just before piercing the follicles and 1 mm in front of piercing the follicles
(Dmax
diff), #5: θ1/√2 difference between just before piercing the follicles
and 1 mm in front of piercing the follicles (θ1/√2 diff), #6: θ0.01 difference
between just before piercing the follicles and 1 mm in front of piercing the
follicles (θ0.01 diff). By K-means method and principal component analysis
with AI, oocytes-containing follicles can be predicted in 8/10 and empty fol-
licles can be predicted in 5/6.
Limitations, reasons for caution: This was a retrospective pilot study with
a sample size, and was a single-center study. Moreover, this method requires
needle aspiration. Further prospective studies in large samples size without nee-
dles are needed.
Wider implications of the ﬁndings:We can retrospectively classify ovarian
follicles with or without oocytes by ultrasound images with AI. If we could pro-
spectively recognize ovarian follicles with or without oocytes by ultrasound
image only (without needles), we could predict retrieval oocyte number and
locations of empty follicles at daily ofﬁce gynecology.
Trial registration number:N/A.
P-352 Is the follicular ﬂushing usefull for poor ovarian response, a
prospective controlled randomised trial
C. Calabre1, E. Schuller1, C. Celebi1, N. Meyer2, I. Lichtblau1,
O. Pirrello1
1CMCO Schiltigheim, Strasbourg fertility unit- CMCO, Schiltigheim, France
2Faculté de medecine de Strasbourg, Laboratoire de biostatistiques, strasbourg,
France
Study question: Does follicular ﬂushing with a double-lumen needle improve
the number of oocytes collected in a poor responder population?
Summary answer: Follicular ﬂushing does not improve, number of oocytes
collected, numbers of top embryos, oocyte quality and pregnancy rate and
could decrease the number of oocytes collected.
What is known already: Follicular ﬂushing in poor ovarian response is a usual
practice but beneﬁt is unproved. No strong statistical power prospective rando-
mised study has been produced at this time.
Study design, size, duration: A monocentric controlled randomised pro-
spective study leaded in Strasbourg fertility unit from March 2011 to June 2016.
We compared two technics of oocyte retrieval: direct aspiration with a single
lumen aspiration needle vs ﬂushing method with a double lumen aspiration nee-
dle (EchoTip® Cook® Double Lumen Aspiration Needle K-OPSD-1735-B-L).
Participants/materials, setting, methods: Patients with 4 or less follicles
bigger than 14 mm on ovulation induction day in IVF cycle were included.
Patients were randomized between a FLUSH group with a double-lumen nee-
dle with ﬂushing and a NO FLUSH group with a classic single-lumen needle
without ﬂushing. The primary outcome was the number of oocyte collected.
The secondary criteria was the pregnancy rate and the number of embryos.
Main results and the role of chance: 250 patients were included: 125
patients were included in the FLUSH group and 125 in the NO FLUSH group.
The two groups were comparable about Age, BMI, FSH and AMH before
stimulation and number and follicle and oestradiol on ovulation induction day.
The number of oocytes retrieval was highest in the NO FLUSH group ( 2.35 in
the ﬂush group versus 3.43 in the non ﬂush group, p<0,001), as the number of
meta II oocytes ( p = 0,003).
Limitations, reasons for caution: Several operators participated to this
study, each one had some differences in their own practice of ﬂushing even if
the amont of ﬂushing medium was standardised. Those differences of practice
could be a bias to interpret our results.
The volume of ﬂushing ﬂuid was limited that’s why for some patients included
in FLUSH GROUP, few oocytes were not collected by ﬂushing procedure.
Wider implications of the ﬁndings: Follicular ﬂushing with double-lumen
needle for poor responder patients doesn’t increase the number of oocyte
collected.
Trial registration number: PRI 2010 HUS n°4781 2010-A00589-30
P-353 Circulating microRNAs as biomarkers for controlled ovarian
stimulation
M.G.F. Mulato1, R.C.S. Figueira2, D.P.A.F. Braga3, B.F. Zanetti4,
A.S. Setti4, M.V. Geraldo1, E. Borges Jr.5
1Universidade Estadual de Campinas, Departamento de Biologia Estrutural e
Funcional- Instituto de Biologia, Campinas, Brazil
2Fertility Medical Group, IVF Laboratory, Sao Paulo, Brazil
3Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
4Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida,
Scientiﬁc Department, Sao Paulo, Brazil
5Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
Study question: Are circulating microRNAs (miRNAs) able to predict the
response to controlled ovarian stimulation (COS) in patients undergoing
assisted reproduction cycles?
Summary answer: The presence of speciﬁc miRNAs in serum may be a tool
to predict the ovarian response to COS.
What is known already: Most assisted reproduction cycles use COS before
oocyte pick up, to increase the number of embryos. However, the optimal
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stimulation protocol has not been established. The need for COS individualiza-
tion to attain an optimal oocyte yield while minimizing the risk of an excessive
response, has been recognized. Therefore, the development of tolls to predict
the response to COS is extremely important. MiRNAs are small non-coding
RNAs that can be detected in the extracellular environment. Circulating
miRNAs emerged as diagnostic and prognostic markers of several diseases;
however, its utility as a biomarker of response to COS is still unknown.
Study design, size, duration: This study included 15 serum samples split
into three groups, and polled together, according with the response to COS:
poor response: < 4 retrieved MII oocytes (Poor, n = 5), normoresponse: ≥ 4
and < 25 retrieved MII oocytes (NR, n = 5), and hyper response: ≥ 25 oocytes
(Hyper, n = 5).
Participants/materials, setting, methods: Serum samples were collected
from patients < 36 years-old, body mass index (BMI)>18,5 and <25 Kg/m2,
prior to the COS for intracytoplasmic sperm injection (ICSI), in a private
university-afﬁliated IVF center, between January/2017 and June/2017. Patients
presenting endometriosis grades III and IV were excluded. Circulating RNA was
extracted, cDNA was synthesized and large-scale analysis of miRNA was per-
formed (miScript miRNome qPCR Array, QIAGEN). The cel-miR-39 was
spiked-in to calibrate the gene expression analysis.
Main results and the role of chance: A total of nine miRNAs were differen-
tially detected in serum from the pool of patients who presented hyper
response, in comparison with the pool of patients who responded normally
(NR). Four miRNAs were exclusively detected in patients on the Hyper group,
with undetectable levels in the NR and Poor groups. On the other hand, ﬁve
miRNAs were differentially detected in patients with poor response, four of
them exclusively detected in patients from Poor group. Moreover, we identiﬁed
the absence of one miRNA in Poor group, with normal detection levels in NR
and Hyper groups. These ﬁndings suggest these miRNAs could be explored as
speciﬁc serum predictive markers for poor or hyper response to COS.
Limitations, reasons for caution: These analyses were performed in pooled
samples. The next step includes the validation of these candidate miRNAs in a
larger cohort of samples and the correlation with clinical data from the patients.
Wider implications of the ﬁndings: Individual heterogeneity in ovarian
response limits the implementation of individualized COS protocols. Currently,
there is no consensus regarding the factors to be considered when determining
the gonadotropin dose in individualized protocols. Detection of speciﬁc circu-
lating miRNAs prior to the treatment could guide the COS and improve the
outcomes of IVF.
Trial registration number:None.
P-354 Vitamin D deﬁciency leads to increased insulin resistance
and advanced glycation end-product (AGE) accumulation and
decreased DHEA-S levels and oocyte maturation rates
T. Nishihara1, T. Inoue2, Y. Morimoto3
1HORAC Grand Front Osaka Clinic, Department of culture environment, Osaka,
Japan
2HORAC Grand Front Osaka Clinic, Medical doctor, Osaka, Japan
3HORAC Grand Front Osaka Clinic, Chief Executive Ofﬁcer, Osaka, Japan
Study question: Is vitamin D deﬁciency associated with hormone levels, oxi-
dative stress, insulin resistance, advanced glycation end-products (AGEs), and
the outcome of IVF-ET in infertile patients?
Summary answer: Vitamin D deﬁciency has been associated with increased
insulin resistance and AGE accumulation and decreased DHEA-S levels and
oocyte maturation rates.
What is known already: Vitamin D is necessary for maintaining calcium
homeostasis and promoting bone metabolism. However, vitamin D deﬁciency
is still common in the general population, particularly in women of reproductive
age. Vitamin D receptors are expressed in a number of tissues including the
skeleton and parathyroid glands as well as reproductive tissues. Vitamin D has
been shown to exert effects on female reproduction.
Study design, size, duration: The present study enrolled 510 infertility
women who received IVF treatment at the HORAC Grand Front Osaka Clinic
between July 2016 and August 2017. Patients were divided into two groups
based on their serum 25-hydroxyvitamin-D3 [25(OH)D] levels: Group A <
20 ng/ml and Group B ≥ 20 ng/ml, and follicular ﬂuid 25(OH)D levels: Group
C < 20 ng/ml and Group D ≥ 20 ng/ml. This study was approved by the local
Ethics Committee.
Participants/materials, setting, methods: Vitamin D insufﬁciency and deﬁ-
ciency corresponded to 25(OH)D levels < 30 and < 20 ng/ml, respectively.
Serum 25(OH)D, AMH, basal FSH, testosterone, and DHEA-S were measured
at a commercially available laboratory. Reactive oxygen metabolite (d-ROM) and
biological antioxidant potential (BAP) levels were measured as indicators of the
degree of oxidative stress. AGEs were measured using the AGE Reader. A follicu-
lar ﬂuid sample was obtained from preovulatory follicles ≥ 18mm in diameter.
Main results and the role of chance: The numbers (%) of women with a
vitamin D deﬁciency and insufﬁciency were 337 (66.1%) and 141 (27.6%),
respectively. No signiﬁcant differences were observed in age (38.4 ± 4.7 vs.
38.1 ± 5.0 years) or BMI (21.1 ± 4.1 vs. 21.0 ± 3.8 in kg/m2) between groups
A (n = 337) and B (n = 173). DHEA-S was signiﬁcantly lower in group A than in
group B (165.9 ± 90.4 vs. 188.1 ± 115.4 μg/dL, p < 0.05). HOMA-R was sig-
niﬁcantly higher in group A than in group B (1.81 ± 1.5 vs. 1.28 ± 0.6, p <
0.01). AGEs were signiﬁcantly higher in group A than in group B (213.6 ± 60.5
vs. 192.9 ± 29.4 AU, p < 0.01). However, no signiﬁcant differences were
observed in AMH, testosterone, basal-FSH, PRL, d-ROM, or BAP. Oral vitamin
D supplementation increased follicular ﬂuid 25(OH)D levels in deﬁciency and
insufﬁciency cases (from 16.0 ng/mL to 29.7 ng/mL, p < 0.01). Oocyte matur-
ation rates were signiﬁcantly lower in group C than in group D (73.7 vs. 83.1%,
p < 0.05). However, no signiﬁcant differences were observed in the rate of fer-
tilization, good quality embryos, blastocysts, or good quality blastocysts.
Limitations, reasons for caution: The vitamin D status ﬂuctuates and may
be inﬂuenced by several external factors such as sun exposure, seasonality, and
diet. Therefore, the limitation of the present study is that vitamin D levels may
have varied.
Wider implications of the ﬁndings: The present results demonstrated that
serum vitamin D levels are increased by oral vitamin D supplementation and
this may have a signiﬁcant impact on insulin resistance, DHEA-S levels, AGE
accumulation, and oocyte maturation. A vitamin D deﬁciency may be involved
in the pathogenesis of infertility.
Trial registration number:Not applicable.
P-355 Factors associated with livebirth in couples undergoing their
ﬁrst ICSI cycle: an internally validated predictionmodel
E. Kalafat, B. Berker, A. Gokce, E. Sukur, B. Ozmen, M. Sonmezer,
C. Atabekoglu, R. Aytac
Ankara University, Obstetrics and Gynecology, Ankara, Turkey
Study question:What factors are associated with livebirth in couples without
children undergoing ICSI cycles for the ﬁrst time?
Summary answer: Our seven-parameter model shows good precision and
calibration for the prediction of live birth and can be reliably used for estimation
and counseling.
What is known already: Predictive models are useful for counseling patients
and guiding treatment decisions. Most prediction models rely on demographic
and ovarian reserve parameters without incorporating cycle speciﬁc information
which can be vital. The precision of the existing models is most often subopti-
mal for clinical use. Also, there is a paucity of information about the variables
which are most useful predicting success in the ﬁrst ICSI cycles.
Study design, size, duration: This was a cohort study including ICSI cycles
managed at Ankara University, Department of Reproductive Health and
Infertility between years 2010 and 2017. A total of 488 women were included.
Participants/materials, setting, methods: Couples with no prior children
undergoing their ﬁrst ICSI cycles using fresh embryos were included in the
study. Exclusion criteria consisted patients with secondary infertility, younger
than 45 years, and cycles in which more than two embryos were transferred.
The cohort was partitioned for model building (n:305) and internal validation
via bootstrapping. The prediction model was built using a variable selection
approach, and parameter estimates were obtained using Bayesian logistic
regression with a vague prior.
Main results and the role of chance: A total of 488 women with a live birth
rate of 27.9% were included. The model variables consisted female age ≥38
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years (OR:0.05,95% CrI:0.00-0.44), baseline luteinizing hormone (LH) levels
above 6mIU/mL (OR:2.46,95% CrI:1.33-4.52) and antral follicle count below 5
(OR:0.13,95% CrI:0.02-0.60), duration of induction cycle longer than 10 days
(OR:2.31,95% CrI:1.18-4.61), endometrial thickness at the day of transfer
greater than 9 mm (OR:2.16,95% CrI:1.02-4.75), transferred embryo grade
and count. The model showed good precision (AUC: 0.76) and good calibra-
tion (Hosmer-Lemeshow test, P = 0.624) in the internal validation cohort. The
baseline model without using cycle speciﬁc information also showed modest
precision (AUC:0.68).
Limitations, reasons for caution: Our cohort size is smaller than optimal,
and some parameter estimates may be unreliable despite using a Bayesian
framework with Markov Chain Monte Carlo simulations. An external validation
study is required for the generalization of these results to broader populations.
Wider implications of the ﬁndings: Our model uses variables which are
easily obtained and widely recorded during ICSI cycles worldwide. If proven to
be stable in external validation studies, our model offers the highest precision
reported up to date.
Trial registration number:Not applicable.
P-356 Cheaper, simpler, better: oral desogestrel versus antagonist
injections for LH suppression in corifollitropin-stimulated cycles in
the same oocyte donor. A crossover study
F. Martinez, D. Rodriguez, E. Clúa, J. Rodriguez-Purata,
I. Rodríguez, P.N. Barri, B. Coroleu
Hospital Universitario Dexeus, Obstetrics- Gynaecology and Reproduction, Barcelona,
Spain
Study question: Is the ovarian response to Corifollitropin (CFT) among
oocyte donors (OD) different when treated with oral Desogestrel (DSG)or
subcutaneous injections of antagonist (ANT) for LH suppression?
Summary answer: Donors response to CFT-DSG compared to CFT-ANT
was similar in number of oocytes and pregnancy rates in recipients, with less
injections and lower medication costs.
What is known already: A single injection of CFT replaces the ﬁrst seven
daily injections of any rFSH preparation. Initiating CFT seven days after discon-
tinuation of the oral combined contraceptive pill (OCP) instead of 5 days,
results in a signiﬁcant reduction of the additional consumption of rFSH in oocyte
donors(OD) on an antagonist protocol. Patients showed high degree of satis-
faction and preference for this preparation. A new form of controlling the
endogenous LH peak has been put forward: the so-called “progesterone proto-
cols”. DSG is a progestogen-only pill (POP) that at a dose of 75 mcg inhibits
ovulation by suppressing endogenous LH peak.
Study design, size, duration: An observational cross-over study, including 35
donors treated at a private, university-based IVF centre between Feb’15 and
May’17. Recruited donors had undergone two stimulation cycles within <20
months under CFT. Exclusion criteria: AFC >20, hypersensitivity to CFT, presence
of ovarian cysts or enlarged ovaries, risk or history of ovarian hyperstimulation syn-
drome (OHSS). Fifty-four corresponding recipients of freshly donated oocytes
were analysed (29 in the CFT-ANT group and 25 in the CFT-DSG group).
Participants/materials, setting, methods: Healthy donors, pre-treated
with OCP and CFT. On stimulation day 8, daily FSH doses were added if
needed. In CFT-ANT cycles, daily antagonist was administered since follicle
>14 mm until trigger. Subsequently, in CFT-DSG cycles, donors received daily
DSG starting right after OCP until trigger. All donors were triggered with a
GnRH agonist bolus. Outcomes of both cycles and clinical pregnancies among
corresponding recipients were compared. Paired statistical test was used to
compare variables.
Main results and the role of chance: Mean donors age was 25.94 ± 5.37
years, mean basal AMH was 3.57 ± 2.07 ng/mL, and mean AFC was 19.35 ±
5.07. Interval between both treatment cycles was 0.91 ± 0.70 months.
Compared to CFT-ANT cycles, cycles under CFT-DSG received less num-
ber of injections (10.34 ± 2.83 vs 5.03 ± 2.12, p<0.05), a lower total supple-
mentary rFSH dose (497.4 ± 338.9 IU vs 442.9 ± 332.8 IU, p<0.05); all this
translated in a lower total cost of medication (1018.6 ± 191.0€ vs. 813.8 ±
145.9€, p<0.05).
Compared to CFT-ANT, donors treated with CFT-DSG had signiﬁcantly
higher mean serum estradiol at trigger (1505.4 vs 2406.0 pg/ml, p<0.05).
There were no differences in the total number (17.4 ± 7.5 vs 18.6 ± 89.0) and
mature oocytes retrieved (14.1 ± 6.9 vs. 15.9 ± 8.1). There were no cycles
cancelled due to low ovarian response or premature LH rise prior to GnRH
trigger. There were no cases of OHSS.
The average number of embryos transferred was 1.3 ± 0.7 in the CFT-ANT
group vs. 1.1 ± 0.6 in the CFP-DSG group(p> 0.05). Clinical pregnancy rate/
embryo transfer was similar between groups: 52.0% vs. 58.6% respectively
(p>0.05).
Limitations, reasons for caution: No cycles were cancelled due to low
ovarian response and it should be interpreted with caution. Given that included
patients were OD that had undergone both treatment cycles, with good ovar-
ian reserve markers, and none previous cancelled cycles.
Wider implications of the ﬁndings: In OD programs, treatment cost sav-
ings are important, but so are patient safety, comfort and compliance, and clin-
ical results among recipients. The main advantage of this strategy is its
simplicity, an aspect of utmost importance in the management of ODs. This
information could be useful for PGS and fertility preservation.
Trial registration number: The study was in clinicaltrials.gov (Trial number:
NCT03354494).
P-357 Amultivariate logistic regression model for embryo
selection improves pregnancy outcomes in frozen-thawed embryo
transfer
T. Habara1, Y. Miyagi2, R. Hirata3, N. Yoshioka3, S. Terada3,
N. Hayashi3
1Okayama Futari Clinic, Private Clinic, Okayama, Japan
2Medical Data Labo, Private Clinic, okayama, Japan
3Okayama Couple’s Clinic, Private Clinic, Okayama, Japan
Study question: Can a validated model, based on biological variables, be
developed to predict successful pregnancy outcomes in frozen-thawed embryo
transfer (FET)?
Summary answer: Our logistic model with six variables shows good per-
formance on validation of the values for the prediction of pregnancy in single-
blastocyst transfers.
What is known already: Although three morphological parameters have
routinely been used to select the best blastocyst for transfer (degree of blasto-
coele expansion and appearance of the trophectoderm (TE) and the inner cell
mass (ICM)), their independent ability to predict pregnancy outcomes remains
unclear. A simple scoring system derived from a mathematical model that can
be easily implemented in clinical practice has not been previously described for
the prediction of ongoing viability.
Study design, size, duration: We performed a retrospective cohort study.
Retrospective evaluation of data extracted from implantation data originating
from 4717 blastocyst transfers conducted at a single clinic between January
2012 and December 2015 in phase I. Data from 490 FETs were collected
between January 2016 and February 2017 in phase II.
Participants/materials, setting, methods: We obtained the regression
functions for the establishment of pregnancy for each factor of the ASEBIR
embryo assessment system (Hum Reprod, 2011) and of conventional clinical
information, which were statistically related to the establishment of pregnancy
conﬁrmed by univariate analysis. A multivariate logistic regression was con-
ducted, which was not affected by multicollinearity, which provided the prob-
ability of the establishment of pregnancy with calculated values from actual data
from the regression functions.
Main results and the role of chance: In phase I of the study, 4717 single-
blastocyst transfers were performed that resulted in 1826 pregnancies (38.7%
of the women). The prediction model, built after multivariable logistic regres-
sion analysis, demonstrated that blastocyst diameter (odds ratio (OR) 271.03,
95% conﬁdence interval (CI): 62.93-1167.34), ICM (OR 4.36, 95% CI: 1.22-
15.59), and TE (OR 3.03, 95% CI: 1.12-8.22) were predictive factors for
successful pregnancy outcomes. Cryopreservation day (OR 14.40, 95% CI:
2.03-102.18), ET attempt (OR 11.18, 95% CI: 2.06-60.63), and female age (OR
11.16, 95% CI: 4.89-25.51) were predictive for unsuccessful pregnancy
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outcomes. The area under the receiver operating characteristic curve for the
model for successful pregnancy outcomes was 0.692 (95% CI: 0.669-0.716).
Sensitivity and speciﬁcity were 0.611 and 0.667, respectively; positive and nega-
tive predictive values were 0.540 and 0.729, respectively. In phase II, a valid-
ation study (n = 490) showed that the application of this logistic model was
associated with a signiﬁcantly higher ongoing clinical pregnancy rate (54.2% ver-
sus 43.4%) with an odds ratio of 1.62 (95% CI: 1.12-2.36, P = 0.011).
Limitations, reasons for caution: In this study, the morphokinetic variables
provided by time-lapse incubators could not be assessed, and embryo evalu-
ation was limited to distinct time-point observations. The interpretation of our
ﬁndings is limited by the retrospective nature of the analysis and the potential
for unmeasured confounding.
Wider implications of the ﬁndings: This prediction model incorporates
readily available data that are routinely collected in clinical practices and have
been shown to signiﬁcantly improve pregnancy outcomes. Further study is
required to add morphokinetic information and thereby improve implantation
rates.
Trial registration number:Not applicable.
P-358 Patients with Inﬂammatory Bowel Disease (IBD) have
similar reproductive outcome compared to the general infertile
population
C. Hernandez-Nieto1, L. Sekhon1, D. Gounko1, J. Lee1, M. Luna1,
E. Cervantes1, A. Copperman1,2, B. Sandler1,2
1Reproductive Medicine Associates of New York, Reproductive endocrinology and
Infertility, New York, U.S.A.
2Icahn School of Medicine at Mount Sinai Hospital, Reproductive endocrinology and
Infertility, New York, U.S.A.
Study question: Is reproductive outcome compromised in patients with IBD
who undergo IVF with transfer of single euploid blastocyst?
Summary answer: IBD Patients who pursue a single euploid embryo transfer
have similar odds of implantation, clinical pregnancy and pregnancy loss com-
pared to the general infertile population.
What is known already: Often, women with IBD experience challenges to
family building throughout the course of their reproductive years. Patients may
encounter decreased fertility and fecundity associated with pelvic adhesive dis-
ease from surgery and/or by the disease itself. IBD has been postulated to
cause infertility due to an adverse autoimmune inﬂuence on embryo quality
and/or endometrial receptivity. Currently, there is limited data assessing the
implantation rate in IBD patients following IVF. This study aims to evaluate
embryo transfer outcome in IBD patients who undergo transfer of screened
embryos.
Study design, size, duration: This was a retrospective cohort study of
patients who underwent IVF with preimplantation genetic testing and subse-
quent euploid single embryo transfer (SET) of a vitriﬁed-warmed blastocyst in a
synthetically prepared endometrial cavity from Jan 2012 to January 2018.
Trophectoderm biopsies (Day 5-6) were analyzed by Next-Generation
Sequencing or quantitative Polymerase Chain Reaction (qPCR). A sample size
of 36 patients per group was needed to detect a 25% difference in implantation
rates with 80% power (alpha = 0.05).
Participants/materials, setting, methods: Natural language processing
was used to identify from the electronic medical records a cohort of women
with the diagnosis of IBD. A matched 3:1 ratio cohort of control subjects were
identiﬁed using a propensity-score matching algorithm based on oocyte age,
BMI, and ovarian reserve markers. Cases involving the transfer of fresh and/or
multiple embryos were excluded. Also, uterine factor infertility, ovum donation,
recurrent pregnancy loss, recurrent implantation failure and severe male factor
infertility were excluded.
Main results and the role of chance: Of 3274 euploid, single, vitriﬁed-
thawed blastocyst transfers included, 38 patients with an IBD diagnosis were
compared to 114 control patients. IBD and control patients had a similar
implantation rate (71.0% vs. 78.0% (p = 0.68)), clinical pregnancy rate (50.0%
vs 60.5% (p = 0.68)) and pregnancy loss rate (37% vs 25.8% (p = 0.25))
respectively. An IBD diagnosis was not found to signiﬁcantly modify the odds of
implantation (adjusted OR = 0.6 [CI 95% -1.2–0.8]) after the data was
evaluated using a GEE model that accounted for patients who underwent mul-
tiple cycles and controlled for oocyte age, body mass index, anti-müllerian hor-
mone, basal antral follicle count and endometrial thickness at embryo transfer.
Additionally, the odds of implantation were not altered by IBD patients having
an ulcerative colitis or Crohn’s disease diagnosis. (OR = 0.4 CI95% 0.1 – 1.9).
Limitations, reasons for caution:We acknowledge the potential weakness
of this study. The retrospective nature of the study might create a possible
selection bias. The study’s current results must therefore be considered with
some caution. Larger, well-controlled studies are needed to verify the study’s
ﬁndings.
Wider implications of the ﬁndings: Patients who suffer from Inﬂammatory
bowel disease have comparable embryo transfer outcomes to the general infer-
tile population when pursuing a euploid, single, cryo-thawed embryo transfer.
Patients and physicians can be reassured that an IBD diagnosis does not appear
to adversely impact embryo quality and endometrial receptivity.
Trial registration number: This study was approved by the Western
Institutional Review Board (Study Number: 1167398).
P-359 Association of follicular ﬂuid levels of adrenomedullin 2,
vascular endothelial growth factor and its soluble receptors with
ICSI outcome
Z. Latiﬁ1, H.R. Nejabati2, A. Ranjbaran1, T. Ghasemnejad3,
K. Hamdi1, H. Hajipour1, N. Raffel4, Z. Bahrami-asl1, P. Hakimi1,
A. Mihanfar2, A. Ghasemzadeh1, L. Farzadi1, M. Nouri1, A. Fattahi1
1Tabriz University of Medical Sciences, Department of Reproductive Biology, Tabriz,
Iran
2Tabriz University of Medical Sciences, Department of Biochemistry and Clinical
Laboratories, Tabriz, Iran
3Tabriz University of Medical Sciences, Department of Medical Genetic, Tabriz, Iran
4Erlangen University Hospital- Friedrich-Alexander University Erlangen-Nuremberg,
Department of Obstetrics and Gynecology, Erlangen, Germany
Study question: Association between follicular ﬂuid (FF) levels of adrenome-
dullin 2 (ADM2), vascular endothelial growth factor (VEGF) and its soluble
receptors with ICSI outcome.
Summary answer: The FF ADM2 could be a potential predictive marker for
ovarian non-responders with cutoff value of 348.55 (pg/ml).
What is known already: ADM2 and VEGF are involved in ovarian function
especially angiogenesis, follicular development, and ovulation. VEGF action
could be antagonized by its soluble receptors, soluble fms-like tyrosine kinase-1
(sFlt-1) and soluble VEGF receptor 2 (sVEGFR-2), via decreasing its free form,
thereby decreasing angiogenesis. It has been reported that sFlt-1 and sVEGFR-2
have low expression in post-selected follicles (POF) compared with preselected
follicles (PRF). However, after dominant follicle selection, sVEGFR-2 expression
increases while sFlt-1 expression reduces along with the days of cycle.
Study design, size, duration: Ninety non-smoker women aged from 20-40
years with fallopian tube obstruction, idiopathic infertility and male factor infer-
tility (varicocele and oligospermia) were enrolled in this study. The long GnRH
agonist–recombinant FSH protocol was used for all patients and a single FF
aspiration without blood was done. All patients were treated with ICSI and
were categorized as non-, poor-, normo- and high-responders according to the
retrieved oocytes number.
Participants/materials, setting, methods: The fertilization rates were
determined by dividing the number of fertilized oocytes with the number of
mature oocytes and the clinical pregnancy was evaluated by existence of the
intrauterine gestational sac via transvaginal ultrasound. Implantation rate was
deﬁned as the quantity of visible sacs per number of transferred embryos. FF
ADM2, VEGF, sFlt-1 and sVEGFR-2 levels were determined by ELISA kits and
the VEGF/sFlt-1 and VEGF/sVEGFR-2 ratios were also calculated.
Main results and the role of chance: In the present study, for ﬁrst time
existence of ADM2 in FF was reported; its mean level was 62.2 ± 66.86 pg/ml.
Also, it was found that age of the patients was signiﬁcantly correlated with
ADM2 (r = 0.268, p = 0.049). ADM2 level was positively correlated with
VEGF and sVEGFR-2 levels (r = 0.586, p = 0.001 and r = 0.482, p = 0.001,
respectively). Our results showed that the levels of ADM2 in FF were signiﬁ-
cantly higher in ovarian non-responders in comparison to patients with poor-,
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normo- and high- ovarian responses (p<0.05). Also, the FF levels of VEGF, and
sVEGFR-2 were signiﬁcantly higher in the non-responders than in poor-
responder patients (p<0.05). We found no signiﬁcant association between FF
levels of ADM2, VEGF and sVEGFR-2 with clinically pregnant. Based on receiver
operating characteristic (ROC) analyses, cutoff value for ADM2 as a non-
responder predictor was 348.55 (pg/ml) with sensitivity and speciﬁcity of 67.7
% (CI, 67.21–68.25%) and 94.6% (CI, 94.11–95.08%), respectively.
Limitations, reasons for caution: It is a preliminary report covering exist-
ence of ADM2 in FF and further studies are required to clarify mode of action of
ADM2 in ovarian angiogenesis. The number of subjects was almost low and there
may have been other confounding factors that we were unable to account for.
Wider implications of the ﬁndings:We found higher FF levels of ADM2 in
non-responder women and proposed ADM2 as a potential predictive marker
for non-responders. Besides, positive correlations of ADM2 with VEGF and
sVEGFR-2 were obtained, what could be considered as an important clue
regarding the roles of ADM2 in ovarian angiogenesis.
Trial registration number:Not applicable.
P-360 Bacterial infection other than Chlamydia associated to tubal
factor of infertility suggests new approach
R. Piscopo1,2, J. Ueno3,4, R. Guimaraes2, F. Ikeda4,5,
Z. Jarmy-Di Bella6, M. Girão6, M. Samama5,6
1Clínica Camargo& Piscopo, Gynecology, Araras, Brazil
2Instituto Gera de Medicina Reprodutiva, Post-graduation, Sao Paulo, Brazil
3Instituto Gera de Medicina Reprodutiva, Clinical Head, Sao Paulo, Brazil
4Hospital Sirio Libanes, Hysteroscopy, Sao Paulo, Brazil
5Instituto Gera de Medicina Reprodutiva, Clinical, Sao Paulo, Brazil
6Universidade Federal de São Paulo – Escola Paulista de Medicina UNIFESP-EPM,
Gynecology, Sao Paulo, Brazil
Study question: Is the presence of endocervical bacteria associated to hyster-
osalpingography outcomes in patients screened for infertility?
Summary answer: Endocervical bacterial is associated to tubal factor infertil-
ity and most prevalent etiologic agents were Ureaplasma and Mycoplasma, sug-
gesting that not only Chlamydia must be screened.
What is known already: It is known that microorganisms infecting vaginal
ﬂora as Chlamydia trachomatis and Neisseria gonorrhoeae cause pelvic inﬂam-
matory disease (PID) in at least 50% of cases. A strong association exists
between chlamydia infection and tubal factor infertility, leading PID-related
morbidity (i.e., infertility and ectopic pregnancy) and is a substantial public
health problem worldwide. Considering the uterine and tubal factors are
responsible for 20% of infertility causes, the hysterosalpingography is part of
infertility investigation. Besides that, in developing countries, the female infertil-
ity by infection as Chlamydia trachomatis is highly prevalent and correlated to
tubal alterations.
Study design, size, duration: Cross sectional study reviewed 156 clinical
charts of women who underwent infertility investigation during 2016 and 2017
in a private reproductive medicine center in Brazil. The inclusion criteria were
women who had hysterosalpingography realized and collected endocervical
secretion for bacteria screening.
Participants/materials, setting, methods: Women had complete infertil-
ity investigation including anamneses, serum hormone measurements, transva-
ginal ultrasound, hysteroscopy and biopsy if necessary, hysterosalpingography
and endocervical bacteria screening. The hysterosalpingography results were
classiﬁed as normal tubal or abnormal tubal and endocervical bacteria’s
screened were Chlamydia Trachomatis, Neisseria Gonorrhea, Ureaplasma
Urealíticum, Mycoplasma Hominies and Gardnerella by using PCR. Patients
with bacteria positive received antibiotic treatment before IVF cycle.
Main results and the role of chance: Patients were 22 to 48 years of age
(36.3 ± 4.6), had a mean of 4.3 years of infertility time, basal FSH of 9.4 ± 14.5
and anti-mullerian hormone of 2.2 ± 2.0. The hysterosalpingography was
abnormal in 53.2% of patients, which determined tubal factor of infertility. The
prevalence of endocervical bacteria’s was 20.5%, as Chlamydia Trachomatis
3.2%, Neisseria Gonorrhea 0.0%, Ureaplasma Urealíticum 7.7%, Mycoplasma
Hominies 5.1%, Gardnerella 2.6%, other bacteria 9.6% (Staphylococcus
Epidermidis, Streptococcus Agalactiae, Enterococcus Faecalis, and Escherichia
Coli). Patients presenting abnormal hysterosalpingography had a higher preva-
lence of endocervical bacteria (27.7%) compared to normal hysterosalpingogra-
phy (12.3%; p = 0.014), independently of the type of bacteria. From women
with endocervical bacteria positive (n = 32), 34.4% presented more than one
type of bacteria positive, and from those, 81.8% (9/11) had tubal factor of
infertility.
Limitations, reasons for caution: The number of cycles included in this
study is relatively small and larger prospective studies should be carried out to
conﬁrm the results. The prevalence of each bacteria individually analyzed in this
study was low and it was not possible to correlate each one with hysterosalpin-
gography outcomes.
Wider implications of the ﬁndings: The prevalence of endocervical bacter-
ial infection was higher among patients with tubal factor infertility, supporting
the association between bacterial infection (other than Chlamydia) and tubal
factor. The prevention of complications associated with bacterial infection is an
indication for screening at the time of IVF and even at gynecological routine.
Trial registration number: not applicable.
P-361 Progesterone dose adjustment and transfer postponement
in patients with low progesterone levels following hormonal
replacement therapy for frozen thawed embryo transfer
I. Cedrin - Durnerin1, L. Laup1, M. Comtet1, C. Vinolas1, A. Seroka1,
B. Dagher Hayeck1, C. Herbemont2, C. Sifer2, M. Grynberg1
1Hôpital Jean Verdier, Service médecine de la reproduction et préservation de la
fertilité, Bondy, France
2Hôpital Jean Verdier, Laboratoire de biologie de la reproduction, Bondy, France
Study question: Is progesterone (P) dose adjustment and postponement of
frozen thawed embryo transfer (FET) effective to improve outcome in patients
with low P levels following hormonal replacement therapy?
Summary answer: Dose adjustment to obtain serum P levels >10 ng/ml and
transfer postponement accordingly gave similar outcome to those of normal P
and ‘in phase” transfers.
What is known already: Several studies have demonstrated that, in HRT
cycles, low serum P levels on the day of FET were associated with decreased
pregnancy and live birth rates. However, in our hands, P dose adjustment after
ET to obtain P levels >10 ng/ml was ineffective to correct impaired outcome.
Therefore, we decided to measure serum P levels and adjust P dose to obtain a
serum P level >10 ng/ml prior to ET and to postpone ET by one or two days
accordingly.
Study design, size, duration: This retrospective study included data from
March to October 2017 obtained in a cohort of 139 patients, undergoing FET
following HRT. Endometrial preparation was achieved by sequential administra-
tion of vaginal estradiol until endometrial thickness >7 mm, followed by trans-
dermal estradiol combined with 600 mg/day vaginal micronized P (200 mg
three times a day).
Participants/materials, setting, methods: This study was conducted in a
university hospital. Serum P was measured on D2 following exogenous P intro-
duction in the evening (referred as D0). When P levels were >10 ng/ml, ET
was performed on D2, D3 or D5 depending on embryo stage at cryopreserva-
tion. When P levels were <10 ng/ml, P dose was increased to 1200mg/day.
Serum P level was checked one day later and the next day if necessary. ET was
postponed accordingly.
Main results and the role of chance: Mean serum P level on D2 was 12.1
+ 3.52 ng/ml and serum P <10 ng/ml were observed in 28% of cycles. Cycles
were cancelled in 11 patients because of inability to obtain P >10 ng/ml despite
increased progesterone supplementation (n = 5) or failure in performing P
measurement timely (n = 6). ET was postponed in 26 patients after P dose
adjustment until reaching serum P values beyond 10 ng/ml. This strategy led to
similar positive pregnancy test (42.3 % vs 43.1 %, NS), heartbeat activity at 6
weeks (30.7 % vs 27.5 %, NS) and ongoing pregnancy rates at 12 weeks (26.9
% vs 25.7 %, NS) when compared with 102 ‘in phase” transfers performed in
patients with P >10 ng/ml at ﬁrst evaluation.
Limitations, reasons for caution: The number of treated patients has to be
extended to conﬁrm these preliminary data.
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Wider implications of the ﬁndings: These results suggest that serum P
measurement prior to ET and further adjustment of exogenous P dose and
postponement of transfer might optimise the outcome of FET cycles performed
using HRT.
Trial registration number: not applicable.
P-362 Mitochondrial function in granulosa cells of preovulatory
follicles may be diminished in infertile women with polycystic ovary
syndrome
C.H. Kim1, J.W. Moon2, H.J. Kim1, S.H. Kim1, H.D. Chae1,
B.M. Kang1
1Asan Medical Center- University of Ulsan, Dept. of Ob/Gyn, Seoul, Korea- South
2M fertility center, Gynecology, Seoul, Korea- South
Study question: Could polycystic ovary syndrome (PCOS) affect the mito-
chondrial function in granulosa cells (GCs) of preovulatory follicles?
Summary answer: Mitochondrial function in GCs of preovulatory follicles
may be diminished in infertile women with PCOS.
What is known already: Several problems in patients with PCOS undergoing
IVF have been reported including decreased fertilization rates, abnormal embryo
development, high incidence of miscarriage and increased likelihood of ovarian
hyperstimulation syndrome (OHSS). In addition, Infertile women with PCOS fre-
quently have higher concentrations of inﬂammatory cytokines such as tumor
necrosis factor (TNF)-alpha and androgens in follicular ﬂuid (FF). These unfavor-
able intrafollicular environment may have a negative effect on the mitochondrial
function in GCs. However, the study on the mitochondrial activity in GCs of infer-
tile patients with PCOS undergoing COS for IVF has not been reported.
Study design, size, duration: This retrospective study included 51 infertile
patients with PCOS (PCOS group) and 95 infertile patients with normal ovula-
tory cycle (control group) who underwent IVF/ICSI in controlled ovarian stimu-
lation (COS) cycles between June 2015 and December 2016.
Participants/materials, setting, methods: IVF cycles in which GnRH
antagonist protocol was used for controlled ovarian stimulation (COS) were
included for this study. FF from at least 2 follicles (range 17-21 mm) at oocyte
retrieval was collected. IVF results and relative amounts of succinate dehydro-
genase complex subunit A (SDHA) and peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1alpha) mRNA in GCs were com-
pared between the two groups. The expression of SDHA and PGC-1alpha
mRNAs was analyzed by realtime RT-PCR.
Main results and the role of chance: Patients’ age and infertility duration
were similar in the two groups. In the PCOS group, total dose of recombinant
human FSH (rhFSH) used for COS was signiﬁcantly lower and the number of
oocytes retrieved was signiﬁcantly higher than in the control group. However,
number of embryos fertilized was comparable between the two groups. FF
TNF-alpha and IL-6 concentrations at oocyte retrieval were signiﬁcantly higher
in the PCOS group (P<.001, P<.001). Relative amount of SDHA mRNA in GCs
was signiﬁcantly lower in the PCOS group of 4.58 ± 2.87 compared with 9.62
± 3.90 in the control group (P<.001). Relative amount of PGC-1alpha mRNA in
GCs was also signiﬁcantly lower in the PCOS group (P<.001).
Limitations, reasons for caution: This study have limitations to evaluate
the mitochondrial function due to a small numbers of sample available and
marker genes investigated and its retrospective nature. Therefore these results
should be taken with caution until well-designed controlled studies will be
presented.
Wider implications of the ﬁndings: Mitochondrial function in GCs may be
impaired in infertile women with PCOS and these results may be associated
with the unfavorable intrafollicular environment including higher levels of FF
pro-inﬂammatory cytokines.
Trial registration number:None.
P-363 Expression of various genes in granulosa cells derived from
women undergo IVF procedures
M.Wasserman1, I. Har-Vardi2, E. Levitas2, E. Priel1
1Ben Gurion University of the Negev, Microbiology- Immunology & Genetics- Faculty
of Health Sciences, Beer-Sheva, Israel
2Ben Gurion University of the Negev, - Faculty of Health Sciences- Fertility and IVF
unit- Obs/Gyn- Soroka University medical center, Beer-Sheva, Israel
Study question: Do telomerase and topoisomerase expression and activity in
luteinized granulosa cells derived from woman undergoing IVF treatments cor-
relate with woman infertility?
Summary answer: The results show variations and correlations between
enzymes activities and expressions with women’s age, cause of infertility and
estrogen levels with/without telomerase activating compounds.
What is known already: Telomerase (Telo) and topoisomerase (Topo) are
nuclear enzymes with essential activities needed for maintaining the normal
functions and survival of cells and tissues in organisms.
Granulosa cells ( GCs) are somatic cells, surrounding each developing
oocyte, required for the development and functionality of ovarian follicle
in vivo. These enzymes exist in all living organisms, in which they play a crucial
role in genomic stability. Little is known about in their functions and activities in
developing GCs. Thus, deep understanding of the enzymes participating in the
maintenance of oocytes and GCs quality and functionality is important for
improving human fertility.
Study design, size, duration: GCs were collected from 80 IVF patients fol-
lowing oocyte retrieval and formal consent. The GCs were immediately sub-
jected to protein or RNA extract procedures or incubated for various intervals
with/without AGS (telomerase activating compounds).
The extend of the activity and expression of the enzymes and other genes (mar-
kers of GCs) in the GCs of each woman were correlates to various parameters
including woman age, cause of infertility, number of oocytes and estrogen levels.
Participants/materials, setting, methods: GCs were collected and iso-
lated from follicular ﬂuids of patients undergoing IVF treatments. In some
experiments GCs were treated with telomerase activating compounds (AGS)
Telomerase activity was determined in whole cells (WC) and DNA bound
(DB) extracts using TRAP assay. Topoisomerase I activity was assayed by the
relaxation of supercoiled DNA plasmid. The expressions of the enzymes and
other relevant genes were examined by RT-PCR using speciﬁc primers.
Main results and the role of chance: Variations in telo and topo I activities
in the GCs derived from the examined women were detected. A negative correl-
ation between topo I or telo activities and blood estrogen levels was observed.
The patients were divided into two groups according to the cause of infertility.
Low but not signiﬁcant, telo activity was observed within the group diagnosed as
“female infertility” and not in “male infertility” group. An increase in Telo expres-
sion with AGS, was shown in older women–in female infertility group, while in
male infertility group, the increase in Telo expression was determined in all ages.
Speciﬁc GCs genes expression (known as markers for GCs: CAMTA1,
UNC-5, 3bhsd, B4galt 2), showed different expression pattern due to the pres-
ence/absence of AGSs. We found that the expression pattern of CAMTA and
B4galt 2 in correlation with woman age, was the opposite to that observed for
telo, but 3bhsd expression was very similar to Telo expression. No dependency
with woman age was observed for the expression of Unc5 and STAR genes in
GCs. Generally, Telo expression decreases with woman’s age, but in the pre-
sense of AGS’s, Telo expression was increased, especially in older women.
Limitations, reasons for caution: The Gcs in our experiments were
derived from woman exposed to gonadotropins and maturating oocyte agents
therefore they represent the state of luteinized GSc.
Wider implications of the ﬁndings: Telomerase and topoisomerase are
nuclear enzymes.
Deep understanding of the enzymes participating in maintenance of oocytes
and GCs quality and functionality is important for the design of strategies to
treat human infertility. Identiﬁcation of GCs response to AGS compounds,
could provide a new and promising insights into IVF procedures.
Trial registration number: All the human samples used in this study were
approved by Helsinki committee no. 0003-15-SOR
P-364 Anti-Mullerian hormone can predict pregnancy, live birth
and miscarriage?
T. Inoue1, N. Nakayama2, N. Terawaki1, R. Kawabe1, Y. Asai1,
T. Himeno1, Y. Morimoto1
1HORAC GRAND FRONT OSAKA CLINIC, medical, Osaka, Japan
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2HORAC Grand Front Osaka clinic, reproductive technology, Osaka, Japan
Study question: Is the serum Anti-Mullerian hormone (AMH) level in infertile
women associated with the outcome of fertility treatment?
Summary answer: AMH cannot be a predictive value for pregnancy, live
birth or miscarriage 1 to 1.5 years after starting fertility treatment.
What is known already: AMH is an established marker of ovarian reserve
and a good predictor of ovarian response for controlled stimulation, and previ-
ous research has shown that AMH is associated with implantation and clinical
pregnancy rate effectuated from assisted reproductive medicine treatments.
However, it is still uncertain whether AMH can predict the ﬁnal outcome of
every type of fertility treatment.
Study design, size, duration: This retrospective cohort study was designed
to identify the correlation between serum AMH levels and fecundity by review-
ing infertile couples’ medical records. Four hundred and eighty-one women had
the AMH test at their ﬁrst consultation visit from January 2015 until June 2016.
The history of 477 women who received any kind of fertility care was examined
only if the couples reached clinical pregnancy, live birth, or miscarriage by June
2017.
Participants/materials, setting, methods: This study was performed at a
private fertility clinic located in Japan’s second city, Osaka. AMH was measured
by an enzyme-linked immunosorbent assay (gen II). The couples suffered from
various causes of infertility and underwent different fertility treatments includ-
ing, timed intercourse direction, intrauterine insemination, assisted reproduct-
ive technology, and/or alternative medicine. The data was analyzed with the
Games-Howell multiple comparisons procedure.
Main results and the role of chance: The average age of the women was
38.9 (SD = 4.6, range 25-49), and the average AMH was 2.4 (SD = 2.4, 0-33.8)
ng/mL. Two hundred and forty-one were younger than 40 years old (group I),
and two hundred and thirty-six women were in their forties (group II). The data
was analyzed according to their AMH levels, a: <0.1, b: 0.1-0.49, c: 0.5-0.99, d:
1.0-1.49, e: 1.50-1.99, f: 2.0-2.49, g: 2.5-2.99, h: 3.0-3.99, i: 4.0-4.99, j:
≥5.0 ng/mL. The pregnancy rate, the live birth rate including the ongoing preg-
nancy rate after the 12th week of gestation, and the miscarriage rate were com-
pared among different AMH sub-groups (a-j) at the point of 1 to 1.5 years after
their ﬁrst visit. The pregnancy rate in group I was a: 0.31, b: 0.53, c: 0.46, d:
0.52, e: 0.57, f: 0.62, g: 0.60, h: 0.77, i: 0.59, j: 0.66. The live birth rate was a:
0.23, b: 0.40, c: 0.38, d: 0.41, e: 0.54, f: 0.58, g: 0.47, h: 0.65, i: 0.53, j: 0.58. No
signiﬁcant difference was found among the AMH dependent subgroups. This
trend was the same in the elderly group (II). The analysis on miscarriage rates
showed no relation between AMH and miscarriage development.
Limitations, reasons for caution: Small sample size. There is possible dis-
persion of the cause of infertility, the patients’ back ground and treatment
policy.
Wider implications of the ﬁndings: AMH is not associated with the out-
come of fertility treatment. Low AMH doesn’t necessarily mean a poor progno-
sis of fertility treatment. With adequate management for poor ovarian
responders we anticipate just under 40% of infertile couples can achieve
conception.
Trial registration number: not applicable.
P-365 A personalizedmaturation trigger administered 36 hours
before IUI improves the pregnancy rates
T. Horikawa, K. Nakagawa, A. Moriyama, R. Sugiyama, K. Nakao,
K. Kuroda, S. Takamizawa, R. Sugiyama
Sugiyama Clinic Shinjuku, Reproductive Medicine, Tokyo, Japan
Study question: If a maturation trigger of human chorionic gonadotropin
(hCG) is administered 36 hours before intrauterine insemination (IUI), will this
improve the pregnancy rate?
Summary answer: A maturation trigger of hCG administered 36 hours
before intrauterine insemination (IUI) improves the pregnancy rate.
What is known already: In ART treatment, 36 hours is accepted as the opti-
mal duration between a maturation trigger and oocyte pick-up (OPU) in order
to obtain mature oocytes. With a shorter duration, the chances for immature
oocyte obtainment rate are higher; when the duration is longer, the ovulation
rate becomes higher. Therefore, approximately 36 hours following the matur-
ation trigger could be a suitable duration for both ovulation and fertilization nat-
urally without ART. In our country, self-injection kits with a preﬁlled syringe
containing either recombinant-human chorionic gonadotropin (r-hCG) syringe
or Gonadotropin-releasing hormone agonist (GnRH-a) are available as matur-
ation triggers.
Study design, size, duration: This was a retrospective cohort study of total
425 patients who received IUI form the husband’s semen in our clinic between
January and April 2017. The patients were classiﬁed into one of three groups:
the r-hCG group included 73 patients who received r-hCG 36 hours before IUI;
the u-hCG group included 233 patients who received urinary-hCG 24 hours
before IUI; and, the GnRH-a group included 119 patents, who received GnRH-
a 36 hours after IUI.
Participants/materials, setting, methods: Some patients were received
Clomiphen citrate or recombinant follicle stimulating hormone (r-FSH) as ovar-
ian stimulation, but others received no drugs for stimulation. Luteal support
was not performed for all participants. Factors that included male infertility and
advanced maternal age of the female partner were excluded in this study. A
clinical pregnancy was deﬁned as the conﬁrmation of a gestational sac via ultra-
sound. The clinical pregnancy and miscarriage rates were evaluated for the
three groups.
Main results and the role of chance: The mean age of the patients in the r-
hCG, u-hCG and GnRH-a groups were 36.5, 36.1 and 35.7, respectively, and
there were no signiﬁcant differences. The mean number of previous IUI
attempts (times) and the percentage of stimulated cycles in the r-hCG, u-HCG
and GnRH-a groups were 1.2 and 19.2%, 1.4 and 15.5%, and 1.6 and 20.2%,
respectively, with no signiﬁcant differences among the three groups. The clinical
pregnancy rate in the r-hCG group was 16.4%, which was signiﬁcantly higher
than that for the u-hCG group (8.2%, p<0.05). But there were no signiﬁcant dif-
ferences between the r-hCG and GnRH-a groups (20.2%). The miscarriage
rates for the r-hCG, u-hCG, and GnRH-a groups were 0, 26.7, and 36.8%,
respectively, with no other signiﬁcant differences among the three groups.
Limitations, reasons for caution: This study was not a randomized con-
trolled trial. The r-hCG has only been available since March 2017. Prior to that,
u-hCG wss the only agent available for hCG preparation.
Wider implications of the ﬁndings: The miscarriage rate in the GnRH-a
group tended to be higher than that in the r-hCG group. One of the reasons
could involve the half-life of each agent, because r-hCG shows a longer half-life
than GnRH-a. Nobody received luteal support, which suggested that r-hCG
might support the luteal phase.
Trial registration number: This study had no RCT status, and was not
assigned a trial registration number.
P-366 Impact of yoga- and meditation-based lifestyle intervention
on depression and quality of life in infertile couples: a randomized
controlled trial
M. Tolahunase1, R. Kumar2, R. Sagar3, R. Dada1
1All India Institute of Medical Sciences, Lab for Molecular Reproduction and Genetics-
Department of Anatomy, New Delhi -110029, India
2All India Institute of Medical Sciences, Department of Urology, New Delhi -110029,
India
3All India Institute of Medical Sciences, Department of Psychiatry, New Delhi
-110029, India
Study question: What is the impact of yoga- and meditation-based lifestyle
intervention (YMLI) on depression severity, quality of life, and accelerated cellu-
lar aging in infertile couples with major depressive disorder (MDD)?
Summary answer: A brief 12-week YMLI signiﬁcantly decreases depression
severity, increases the quality of life, and reverses the biological aging in infertile
couples with major depressive disorder.
What is known already: Depression and Infertility are comorbid and signiﬁ-
cantly affect pregnancy outcomes. Modern lifestyle factors, including the psy-
chological stress of infertility and treatment failures, contribute to depression.
The depression-related accelerated cellular aging that includes neurodeﬁcits,
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regulatory feedback dysfunctions, affect reproductive functions and quality of
life in both infertile men and women. In addition, it can lead to poor quality
gametes and severe complications in the offspring like neurodevelopmental dis-
orders and cancers. Targeted interventions are needed to increase the success
of pregnancy and healthy offspring.
Study design, size, duration: A randomized clinical trial of 12−week YMLI
for infertile couples (n = 80 couples) with MDD was designed to evaluate the
impact on depression severity, quality of life, and systemic biomarkers of cellular
aging.
Participants/materials, setting, methods: Infertile couples with MDD
were randomly assigned to a 12−week yoga intervention group (n = 40) or to
a control group (n = 40). Clinical parameters and blood samples were collected
before and after the intervention.Assessment of depression severity was by
Beck Depression Inventory–II scale (BDI-II)], and quality of life was by abbre-
viated 26 item version of World Health Organization Quality-of-Life Scale
(WHOQOL−BREF). Systemic biomarkers of cellular aging were assessed as
per manufacturer protocols.
Main results and the role of chance: YMLI led to a signiﬁcant decrease [dif-
ference between means, (95% CI)] in BDI-II score [-5.83 (-7.27, -4.39), p < 0.
001]. There was signiﬁcant improvement in all domains of the quality of life:
physical [11.3 (4.2 to 21.3), p < 0. 001]; psychological [13.2 (3.9 to 22.4), p <
0. 001]; social [4.6 (1.6 to 12.3), p < 0. 033]; and environment [3.4 (1.1 to 7.8),
p < 0. 039]. There were signiﬁcant improvements in the 12-week levels of the
systemic biomarkers of accelerated aging in yoga group compared to control
group [decrease in ROS, 8OH2dG, cortisol, and IL-6, and, increase in TAC,
COX2 activity, telomerase activity, BDNF, serotonin, melatonin, and sirtuin 1)
(all P<0.05). Although YMLI did not differentially improve telomere length (P =
0. 084), telomere length was maintained. These ﬁndings were in parallel with
the signiﬁcant reduction in BDI-II scores and increase in WHOQOL-BREF
scores.
Limitations, reasons for caution: Interpretation of the study ﬁndings will be
more precise only after further studies of the impact of YMLI on pregnancy out-
comes in infertile couples with MDD and their future offspring become avail-
able. It should also be noted that chronological age is an independent risk for
infertility.
Wider implications of the ﬁndings: Reversal of depression associated
accelerated aging by YMLI in infertile couples with MDD improve all domains of
the quality of life. YMLI induced improvement in neural networks and integra-
tive mechanisms contribute to improvement in both male and female repro-
ductive systems, gametes, pregnancy outcomes, and future offspring.
Trial registration number: Clinical Trial Registry of India (CTRI) REF/
2014/09/007532
P-367 Live birth rate in Turner syndrome patients after oocyte
donation: a matched-cohort study over a 10-years period
E. Milego1, D. García2, P. Giménez-Bonafé1, R. Vassena2,
A. Rodríguez2
1Barcelona University, Faculty of Medicine, Barcelona, Spain
2Clínica EUGIN, Assisted Reproduction, Barcelona, Spain
Study question: Is the live birth rate in Turner syndrome women after oocyte
donation (OD) comparable to that of oocyte recipients without Turner
syndrome?
Summary answer: The live birth rate in Turner syndrome patients after IVF
with donated oocytes (OD) is 35.4%, comparable to other women accessing
this treatment.
What is known already: Turner syndrome is one of the most common
female chromosomal abnormalities with gonadal dysgenesis, due to a total or
partial (mosaicism) absence of one X chromosome. Turner syndrome usually
causes infertility and gestational complications, thus spontaneous pregnancies in
these women are rare, and pregnancy outcomes involve an increased risk of
miscarriage and stillbirths. Assisted reproduction techniques, especially OD,
can give women with Turner syndrome the possibility to become pregnant and
delivery healthy children.
Study design, size, duration: Retrospective matched (1:2) cohort study
including 252 OD patients. The exposed group (“Turner”, n = 84) were
women affected by Turner syndrome performing their ﬁrst fresh embryo trans-
fer (ET) between 2010 and 2017. The non-exposed group (“no-Turner”; n =
168) were women without chromosomal alterations also performing their
ﬁrst ET in the same time period. Endometrial preparation was performed
with estrogens, administered either orally or transdermally, while oocyte
donors were stimulated using GnRH antagonist protocol triggered with GnRH-
agonist.
Participants/materials, setting, methods: Turner women in this study
had different karyotypes: 45,X (4 women, 4.8%) and several mosaics such as
45,X/46,XX and 45,X/46,XY. No-Turner women required OD mainly due to
age. Cases and controls were matched by date of ET, number of embryos
transferred, and developmental stage of the embryo at the time of ET.
Differences in reproductive outcomes between groups were assessed using
Chi-square tests. Additionally, we analyzed the subset of 147 cycles with single
ET (SET).
Main results and the role of chance:Women in the Turner group were on
average 32.2 years old (SD 4.8, range 22-43), while women in the no-Turner
group were 41.8 (SD 4.3, range 25-50). All other parameters were similar in
both groups: mean BMI was 23.9 (SD 4.2), mean number of mature oocytes
(MII) assigned to each woman was 7.3 (SD 1.5, range 4-14), and they were fer-
tilized with partner’s sperm in 86.8% of cases. ET was performed on day 2-4 in
165 (66.7%) cases, with 1 embryo transferred in 147 (58.3%) of cycles.
Reproductive outcomes were slightly higher in the Turner group, although
not statistically signiﬁcant. Biochemical pregnancy rate was 54.9% vs. 47.2% (p
= 0.28). Clinical pregnancy rate was 39.5% vs. 37.7% (p = 0.82). Ongoing preg-
nancy rate was 36.3% vs. 30.6% (p = 0.38), and live birth rate was 35.4% vs.
29.6% (p = 0.36). Comparable results were obtained when analyzing the subset
of SET: biochemical pregnancy rate was 57.5% vs. 50.5% (p = 0.44); clinical
pregnancy rate 43.5% vs. 38.3% (p = 0.56); ongoing pregnancy rate 40% vs.
30.4% (p = 0.27); live birth rate 38.6% vs. 29.7% (p = 0.30).
Limitations, reasons for caution: Women in the Turner group were on
average 10 years younger; however reproductive outcomes are not affected by
the patient’s age when donated oocytes are used, and the mean donor age was
26 in both groups.
Wider implications of the ﬁndings: OD is an assisted reproduction tech-
nique that offers excellent results in women with Turner syndrome, especially
in single ET, which is the recommended treatment option for these patients.
Trial registration number:Not applicable.
P-368 National U.S. utilization patterns and live birth rates of
various ovarian stimulation protocols for IVF
S. Darmon, D. Barad, N. Gleicher, V. Kushnir
Center for Human Reproduction, n/a, New York- NY, U.S.A.
Study question: How does the U.S. utilize various ovarian stimulation proto-
cols for in vitro fertilization (IVF) and what are resulting live birth rates?
Summary answer: Paradoxically, minimal stimulation, natural cycles and
in vitro maturation (IVM) are utilized primarily in poor prognosis patients, where
their utility is the lowest.
What is known already: Alternative ovarian stimulation protocols for IVF
have grown in popularity. Yet, patient populations best suited for these proto-
cols have not been deﬁned.
Study design, size, duration: This is a retrospective study of aggregate data
published by the Society for Assisted Reproductive Technologies (SART) for
autologous IVF cycles performed in the U.S. during 2014 and 2015.
Participants/materials, setting, methods: IVF cycles were stratiﬁed based
on ovarian stimulation protocols and included 205,705 conventional stimula-
tions, 4,397 minimal stimulations, 2,785 natural cycles and 514 in vitro matur-
ation (IVM) cycles. The main outcome measures were utilization patterns and
age-speciﬁc live birth rates for the different ovarian stimulation protocols.
Main results and the role of chance:With advancing female age, utilization
of conventional stimulation protocols decreased, while minimal stimulation and
natural cycle IVF increased. LFOR diagnoses were in all age groups less preva-
lent in patients undergoing conventional stimulation than with all other proto-
cols. Live birth rates were uniformly the highest with conventional stimulation
at 42.4%, 33.1%, 22.1%, 11.7% and 3.9% for ages <35, 35-37, 38-40, 41-42 and
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>42, respectively. Moreover, pars in live birth rates between conventional
stimulation and other protocols widened with advancing age from 1.6-3.9-fold
among women <35 years to 4.4-6.6-fold among women > 42 years.
Limitations, reasons for caution: Current U.S. national IVF outcome
reporting allows for only limited interpretation of data: One such limitation is
absence of a standardized deﬁnition of what represents minimal stimulation.
Another limitation is that SART reports only present aggregate data. Our ability
to adjust for confounding patient characteristics was, therefore, limited.
Wider implications of the ﬁndings: Conventional stimulation protocols
still represent the gold standard of care. Alternative protocols should only be
used in younger patients with normal FOR if speciﬁc indications exist which neg-
ate lower pregnancy and live birth chances but should be avoided in older
women and in younger patients with LFOR.
Trial registration number: not applicable.
P-369 Is there a difference between blastocyst formation and
cumulative pregnancy rates between cycles of recipients who
received fresh or vitriﬁed eggs from the same donor?
B. Barros1, A.P. Aquino2, R. Mazzeto3, T. Bonetti4,
A.R. Lorenzon-Ojea5, E. Motta6, T. Domingues2
1Huntington Medicina Reprodutiva, Embryology Department, Sao Paulo / SP, Brazil
2Huntington Medicina Reprodutiva, Clinical Medicine Department, São Paulo- SP,
Brazil
3Huntington Medicina Reprodutiva, Embryology Department, São Paulo- SP, Brazil
4Federal University of São Paulo, Gynecology Department, São Paulo- SP, Brazil
5Huntington Medicina Reprodutiva, Scientiﬁc Coordination, São Paulo- SP, Brazil
6Huntington Medicina Reprodutiva/Federal University of São Paulo, Clinical Medicine
Department/Gynecology Department, São Paulo- SP, Brazil
Study question: Do frozen-thawed oocytes affect the blastocyst formation
and pregnancy rate compared to fresh oocytes from the same donor in in vitro
fertilization (IVF) cycles?
Summary answer: Frozen-thawed oocytes do not affect blastocyst formation
and pregnancy rates in donation cycles when compared to fresh oocytes from
the same donor.
What is known already: An efﬁcient oocyte cryopreservation method is
mandatory to establish a successful egg-banking program. There are increasing
reports showing good clinical outcomes after oocyte cryopreservation, but
there is still a lack of large controlled studies evaluating the effectiveness of
oocyte cryo-banking. Although previous studies suggest that vitriﬁed oocytes
result in similar pregnancy rates when compared to fresh oocytes, no data is
available regarding blastocyst formation and pregnancy rates from the same
oocyte donor.
Study design, size, duration: Cross-section study from an oocyte donation
program, including 20 oocyte donors, that obtained ≥14 MII oocytes/cycle and
divided into 49 different recipient’s, 20 receiving fresh and 29 frozen eggs, from
2013 to 2017.
Participants/materials, setting, methods: All oocyte donors (23.5 ± 2.91
years old) were stimulated using the same protocol. Recipient’s patients (42.04
± 4.14 years old) received at least 07 mature oocytes from fresh (n = 20) or
frozen-thawed (n = 29) cycles, according to uterine synchronization. For all
recipients, fertilization were carried out with ICSI and the embryos produced
within the cycle were transferred on blastocyst stage (2.02 ± 0.59).
Main results and the role of chance: There was no difference between
fresh and frozen-thawed oocyte cycles rates for fertilization (83.21% vs 81.57%,
p = 0.6765), D3 embryo formation (93.44% vs 94.42%, p = 0.6038), top qual-
ity D3 embryo (total TQ D3/total D3 embryos: 46.24% vs 42.14%, p =
0.3719), blastocyst formation (55.78% vs 54.59%, p = 0.8324), top quality
blastocyst (total TQ Blastocyst/total Blastocyst: 67.69% vs 62.99%, p =
0.5945), pregnancy (75.86% vs 65.52%, p = 0.5648) and implantation (48.15%
vs 44.44%, p = 0.7074). Paired T-test or Fisher´s test was applied as
appropriated.
Limitations, reasons for caution: The egg donation is usually performed by
healthy and young woman (≤29 years) and could be speculated that oocytes
from women below 30 years old may be more resistant to vitriﬁcation than
those from women of advanced age. Moreover, male factor was not
considered.
Wider implications of the ﬁndings: Using eggs from the same donor to
fresh or frozen-thawed cycles produce an excellent clinical outcome.
Moreover, a consistent egg vitriﬁcation program could be extended to accumu-
late oocytes from successive stimulations from the same donor, decreasing risk
of ovarian hyperstimulation and improving fertility preservation and/or oocyte
donation program outcomes.
Trial registration number:Not applicable.
P-370 Dual triggering with GnRH agonist plus hCG versus
triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist
cycles
C.H. Chen1, C.R. Tzeng1, P.H.Wang2,W.M. Liu1, H.Y. Chang3,
H.H. Chen1, C.H. Chen1
1Taipei Medical University Hospital, Department of Obstetrics and Gynecology,
Taipei, Taiwan R.O.C.
2Taipei Veterans General Hospital, Department of Obstetrics and Gynecology,
Taipei, Taiwan R.O.C.
3Taipei Medical University, Department of Biochemistry and Molecular Cell Biology-
School of Medicine- College of Medicine, Taipei, Taiwan R.O.C.
Study question: Is dual triggering with GnRH agonist plus hCG as efﬁcacious
as hCG triggering in terms of oocyte and pregnancy outcomes?
Summary answer: Results indicate comparable or signiﬁcantly improved out-
comes with the use of GnRH agonist plus hCG as compared with hCG alone
for triggering of oocyte maturation.
What is known already: Final oocyte maturation triggering in in vitro fertiliza-
tion cycles using GnRH antagonist protocols is conventionally achieved with
hCG, which is associated with an increased risk of ovarian hyperstimulation syn-
drome (OHSS). Triggering with GnRHa has been used as an alternative to
hCG; however, previous ﬁndings indicate poorer pregnancy outcomes with this
method.
Study design, size, duration: A comprehensive literature search was per-
formed to identify randomized controlled trials comparing IVF outcomes
between women receiving combined administration of hCG with GnRHa and
those receiving hCG alone for triggering of ﬁnal oocyte maturation.
Participants/materials, setting, methods:Meta-analysis.
Main results and the role of chance: Four studies including 527 patients eli-
gible for inclusion in meta-analysis were identiﬁed. No signiﬁcant difference in the
number of mature oocytes or fertilized oocytes retrieved was found between
groups. Clinical pregnancy rate with dual triggering was signiﬁcantly higher as
compared with hCG-alone triggering (pooled OR = 0.48, 95% CI: 0.31 to 0.77,
P = 0.002), but there was no signiﬁcant difference in the ongoing pregnancy rate
between groups (pooled OR = 0.88, 95% CI: 0.29 to 2.66, P = 0.826).
Limitations, reasons for caution: Only 4 studies were eligible for inclusion
and the quality of the studies was only moderate overall.
Wider implications of the ﬁndings:None.
Trial registration number:None.
P-371 Relationship between pregnancy rate and post spermwash
motile sperm count in IUI cycles: perspective from a developing
country
J. Sneha1, A. Sadashivan2
1NU Hospitals- Bangalore, Reproductive Medicine, Bengaluru, India
2Nu Hospitals- Bengaluru, Reproductive Medicine, Bengaluru, India
Study question:What is the least total Motile sperm count in a post wash IUI
semen sample for a reasonable pregnancy rate?
Summary answer: No pregnancies occured when the total motile sperm
count of the post wash semen sample was < 10million.
What is known already: IUI is an efﬁcacious, cost effective treatment of
infertility. In developing country like India where IVF is not covered by health
insurance, the affordability of common man for IVF is low. Also there are vari-
ous societal taboos associated with IVF. Hence, we are expected to offer IUI
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for those with higher degrees of male factor infertility. The quality of sperms is
an important determinant of outcome. KoyunOk et al, suggested that an aver-
age post-wash total motile sperm count of 10×106 may be a useful threshold
value for IUI success, but more studies are needed to determine a cut-off value.
Study design, size, duration: It was a prospective observational study car-
ried out between November 2015 and November 2017. The sample included
422 consecutive IUI cycles. All IUI cycles using husband sperm were included
and those using donor sample were excluded. Post sperm wash motile sperm
count(PMSC) was calculated as Post sperm wash (Total sperm count x
Percentage motility)
Participants/materials, setting, methods: The patients underwent stand-
ard protocol of ovulation induction using clomifene and gonadotropins as per
institutional protocol. Follicular monitoring was done using Mindray Resona 6
using 7.5 MHz transvaginal probe.Ovulation trigger with puriﬁed urinary HCG
10,000 units was given and IUI done 36-40 hours later. The ovulation was
checked prior to IUI and done only if follicles had ruptured. Semen sample was
collected by masturbation and processed by WHO prescribed density gradient
method and IUI done.
Main results and the role of chance: In the 422 patients included in the
study, the range of female partner age and male partner age (mean) was 18-
38 yrs(29.8) and 23-42 yrs(31.3) respectively.312 and 110 patients had primary
and secondary infertility respectively. The number of patients with PMSC
<10,10-20,20-30,30-40,40-50,>50 million was 43,51,77,103,80,68 respectively
and number of pregnancies(pregnancy rate) was 0(0%),17(33.3%),15
(19.4%),21(20.3%),17(21.3%),24(35.2%) respectively. Out of the 422 patients
who underwent IUI, 94 conceived, making pregnancy rate 22.2%.
There were no pregnancies when the total motile sperm count of the insemi-
nated sample was < 10million. However, the motile sperm count >10 million
gives good pregnancy rate. This can be used to explain prognosis to patients
undergoing IUI and counsel them for other options such as IVF/ICSI in the sub-
sequent cycle.
Limitations, reasons for caution: The study has a low sample size and is an
observational study. It is a single centre study.
Wider implications of the ﬁndings: Further multicentre studies with larger
number including the combined impact of post wash motility/morphology must
be carried out. This can be used to deﬁne criteria for explaining the limitations
of IUI treatment and next step to offer after IUI fails: whether to go ahead with
IUI or offer IVF/ICSI.
Trial registration number: RM003
P-372 Pain scores during oocyte retrieval: a retrospective cohort
study comparing three different protocols
I. Roest1, E. Buisman2, J. Smeenk3, J.W. Van der Steeg2, C. Koks1
1Maxima Medical Centrum, Gynaecology, Veldhoven, The Netherlands
2Jeroen Bosch Hospital, Gynaecology, ‘s-Hertogenbosch, The Netherlands
3Elisabeth-TweeSteden Hospital, Gynaecology, Tilburg, The Netherlands
Study question: Pain scores during oocyte retrieval in three Dutch clinics: a
comparison of oral analgesics with intravenous or intramuscular opioids.
Summary answer: The lowest pain scores were achieved by intramuscular
administration of alfentanil, followed by intravenous fentanyl and, ﬁnally, non-
sedative oral analgesics.
What is known already: No particular method is superior in providing
effective conscious sedation and analgesia for pain relief during oocyte retrieval,
as described in a 2013 Cochrane review (Kwan, et al.). Conscious sedation is
most commonly used for pain relief in the USA and UK, whereas pain protocols
in the Netherlands vary from oral analgesics to various administration methods
of opioids or a paracervical block. Comparison of these methods has never
been done before. We aimed to compare these methods and thereby identify
the most effective and convenient pain relief protocol, ultimately enabling the
creation of a uniform protocol across the Netherlands.
Study design, size, duration: A retrospective cohort study was conducted
in three hospitals in the Netherlands. A total of 2.134 oocyte retrievals
between May 2012 and May 2017 were included in the analysis. Each clinic has
a different protocol for pain relief during oocyte retrieval: clinic 1. oral analgesics
(1000 mg paracetamol and 500 mg naproxen), clinic 2. intramuscular opioids
(0.01 mg/kg alfentanil), clinic 3. intravenous opioids (50ug fentanyl). We
excluded patients where pain relief was not given according to local protocol.
Participants/materials, setting, methods: In all three clinics, pain scores
were registered during every oocyte retrieval on a scale from 0 to 10. Clinic
one and three used the numerical rating scale, clinic two used the visual ana-
logue scale. Pain scores and additional variables, such as female demographics,
treatment type and cycle (in vitro fertilisation or intracytoplasmic sperm injec-
tion) and oocyte number were recovered from the national electronic fertility
database or from the local electronic ﬁle.
Main results and the role of chance: A mixed linear model was performed,
since some patients had had multiple follicle punctures. Mean pain scores and
their 95% conﬁdence intervals were: 5.6 (5.3-5.8) in the oral analgesics group,
5.1 (5.0-5.3) in the intravenous opioids group and 4.0 (3.9-4.2) in the intramus-
cular opioids group. Furthermore, age, number of oocytes and number of previ-
ous retrievals had a signiﬁcant effect on pain scores. A lower age, higher
number of follicles and having undergone a retrieval in the past were associated
with higher pain scores. The largest effect was found on having undergone a
previous oocyte retrieval, the mean pain score increases with 0.28 (95% CI
0.17-0.38) per previous puncture. In view of the large size of the participant
population it is unlikely that outcomes are the result of chance.
Limitations, reasons for caution: Potential limitations of this study include;
the retrospective design, the use of only one type of analgesia per centre for
comparison and the use of verbal and visual pain scores (although both using a
scale from 0 to 10 with whole numbers).
Wider implications of the ﬁndings: Acceptable pain scores were demon-
strated following intramuscular administration of opioids during oocyte
retrieval. The use of intramuscular alfentanil is unaccustomed for this procedure
worldwide, but could be a cost effective and less invasive alternative for con-
scious sedation. Further research is needed to compare post-procedure pain,
side effects and patient satisfaction.
Trial registration number: N17.059, trial registration number from the
local Medical Ethical Committee.
P-373 Embryo implantation failure as a prognostic factor of ART
outcomes: An evaluation of 3315 ART cycles
R.L. Barufﬁ1,2, C.G. Petersen1,2, A.L. Mauri1,2, L. Vagnini2, A. Renzi2,
B. Petersen2, M.C. Mattila1, V.A.A. Comar1, A. Nicoletti1,
F. Dieamant1,2, J.B.A. Oliveira1,2, J.G. Franco Jr1,2
1Centre for Human Reproduction Prof Franco Jr, Research, Ribeirao Preto, Brazil
2Paulista Center for Diagnosis Research and Training, Research, RIibeirao Preto,
Brazil
Study question: Can the number of previous implantation failures (NIF) alone
be a useful tool for predicting the outcomes of ART cycles?
Summary answer: An increase in NIF is associated with a worsening of ART
outcomes but is closely related to patient age.
What is known already: As one of the main reasons for the high rate of
abandoning ART programmes, implantation failure (IF) is a challenging condi-
tion. Adjuvant treatments and diagnostic investigations to improve the chances
of pregnancy have been proposed. However, the use of IF alone as a prognostic
factor for ART outcomes has not been evaluated.
Study design, size, duration: A single-centre prospective-cohort study on
data from 3315 couples submitted to IVF/ICSI cycles (one per couple) was
conducted. Only fresh embryo transfers were considered. The couples were
categorized into three groups according to female age: ≤35 years, 36–39 years
and ≥40 years. The NIF of each couple was recorded at the ﬁrst appointment.
Exclusion criteria included abnormal karyotype, uterine defects, evidence of
hydrosalpinx, infections, endocrine problems, coagulation defects or thrombo-
philia and autoimmune defects.
Participants/materials, setting, methods: Potential confounding factors,
including age, aetiologies, duration/type of infertility, type of ovarian stimula-
tion, endometrial thickness, and number/quality and development stage of the
transferred embryo, were included as variables. NIF was correlated with the
presence or absence of clinical pregnancy (CP) and live birth (LB). Simple logis-
tic regression (considering only the independent variable NIF), multiple logistic
i311Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
................................. ...............................
........................................................................................
regression (considering other cycles variables together with NIF) and ROC
curve analysis were used to evaluate the results.
Main results and the role of chance: Simple logistic regression revealed
that the likelihoods of CP and LB were signiﬁcantly (P<0.0001) associated with
NIF. Multiple logistic regression conﬁrmed this results, although to a smaller
degree. However, this inﬂuence of NIF seemed to be important only in younger
women (≤35 years). In older age groups, an inﬂuence of NIF on clinical preg-
nancy and live birth was not observed (Table 1). In the younger group (≤35
years), for the probability of CP and LB occurrence, the ROC curve set the
threshold at ≤1 for the best prognostic value.
Table 1 Regression analysis. OR:odds ratio CI:
conﬁdence interval.
Simple Regression Multiple Regression
Total (3315) OR 95%CI P OR 95%CI P
CP (n: 1091) 0.88 0.85-0.92 <0.0001 0.94 0.90-0.98 0.007
LB (n: 840) 0.86 0.82-0.90 <0.0001 0.94 0.89-0.98 0.01
≤35 years (n: 1572)
CP (n:651) 0.88 0.82-0.94 0.0004 0.90 0.84-0.97 0.005
LB (n:547) 0.87 0.81-0.93 0.0004 0.90 0.84-0.97 0.008
36-39 years (n:1049)
CP (n: 321) 0.97 0.91-1.0 0.40 0.97 0.91-1.04 0.43
LB (n: 227) 0.96 0.88-1.0 0.30 0.96 0.89-1.0 0.34
≥40 years (n: 694)
CP (n: 119) 0.96 0.88-1.04 0.31 0.94 0.86-1.03 0.19
LB (n: 66) 0.99 0.90-1.10 0.94 0.98 0.88-1.10 0.78
Limitations, reasons for caution: Including the number of transferred
embryos can change the results.
Wider implications of the ﬁndings: This study highlights the importance of
NIF alone in the prognosis of clinical outcomes after IVF/ICSI cycles. Changes
in therapy with inclusion of procedures that may enhance the results (e.g.,
increasing the number of embryos transferred, PGS, time lapse) would be advis-
able in young patients with ≥2 IF.
Trial registration number: The local ethics committee authorised this study.
P-374 In vitro fertilization (IVF) outcomes after dramatic weight
loss linked to bariatric surgery: a case-control study
V. Grzegorczyk Martin1, A. Finet de Bantel2, E. Bonnet3,
I. Cédrin-Durnerin4, M. Merzouk5, J. Roset1, C. Avril1, R.Wainer5,
P. Landais6
1Clinique Mathilde, Centre d’Assistance Médicale à la Procréation, rouen, France
2Clinique Mathilde, Centre d’Assistance Médicale à la Procrétaion, rouen, France
3Montpellier Universite, clinical Research University Institute Montpellier, Montpellier,
France
4Hôpital Jean Verdier, Centre d’Assistance Médicale à la Procréation, Bondy, France
5CHI poissy Saint germain, Médecine de la reproduction, Poissy, France
6Universite Montpellier, Clinical research university Institute, Montpellier, France
Study question: Do women having undergone bariatric surgery achieve simi-
lar IVF outcomes as compared to women matched at the ﬁrst IVF for age and
body mass index?
Summary answer: Cumulative live birth rates are comparable, even after
adjustment for confounding variables. Smaller weight for gestational age was
observed in newborns of bariatric surgery group.
What is known already: Bariatric surgery leads to long term signiﬁcant
weight loss, improves spontaneous fertility, obstetrical and neonatal prognosis
but increases incidence of newborn’s small weight for gestational age. So far,
articles concerning IVF outcomes after bariatric surgery are sparse; they
included small cohorts, ranging from 5 to 40 cases, comparing IVF results both
before and after surgery, or cases to obese and normal-weight patients. This is
the ﬁrst and the largest study matching bariatric surgery patients undergoing IVF
to patients of similar Body Mass Index (BMI) and age and without a history of
signiﬁcant weight loss.
Study design, size, duration: This case-control study was performed from
the retrospective analysis of three IVF center databases. Data from 10,287 IVF/
ICSI cycles between January 1st, 2012 and December 31st, 2016 were
extracted and analyzed, and all patients were followed until the pregnancy issue
including newborn’s state of health. Inclusion criteria for all cases were women
aged 18 to 43 years old with a previous history of bariatric surgery and undergo-
ing their ﬁrst IVF cycle during this time frame.
Participants/materials, setting, methods: Each case was matched with
two following controls of the same IVF centre, of similar BMI (±2 kg/m2) and
age (±2 years) and without a history of signiﬁcant weight loss. A total of 249
women were included: 83 cases and 166 controls.The main outcome measure
was the cumulative live birth rate after the ﬁrst IVF cycle; secondary outcomes
were number of mature oocytes and embryos obtained in the ﬁrst IVF cycle
and neonatal outcomes.
Main results and the role of chance:No signiﬁcant difference in cumulative
live birth rates was found between cases and controls (22.9% vs. 29.5%,
respectively, p = 0.339), nor was any signiﬁcant difference observed in cumula-
tive pregnancy rates (36.1% vs. 38.6% respectively p = 0.817). Average number
of mature oocytes (6.9 ± 4.9 vs 7.4 ± 4.9, p = 0.189) and embryos (4.4 ± 4.2
vs. 4.9 ± 3.8, p = 0.239) were similar between both groups. A lower BMI and
higher number of good-quality embryos appeared to have a signiﬁcant positive
impact on the occurrence of live birth in both groups. However, multivariate
conditional logistic regression analysis showed no signiﬁcant difference in cumu-
lative live birth rates after adjustment for potential confounding factors.
Additionally, miscarriage rates were found to be 41% in cases and 33% in
controls (p = 0.613), and a signiﬁcantly smaller weight for gestational age was
observed in newborns of cases versus controls (2849 g±687 vs 3170 g±863; p
= 0.002).
Limitations, reasons for caution: This is the largest study concerning live
birth results in IVF bariatric surgery patients and the ﬁrst to match IVF patients
having undergone bariatric surgery to patients of similar BMI and age.
Nonetheless, the sample size remains limited and further studies, with pro-
spective inclusion, are needed to conﬁrm these conclusions.
Wider implications of the ﬁndings: Bariatric surgery allowed IVF prognosis
of patients with previously morbid obesity to be similar to that of comparable
age and BMI women. Higher BMI negatively impacts live birth occurrence.
Smaller weight for gestational age necessitates investigations concerning impact
of surgery types and fresh versus frozen embryo transfers on neonatal
outcomes.
Trial registration number: This study was approved by our Institutional
Review Board (IRB) and registered in clinicaltrial.gouv under the number
NCT02884258
P-375 Pregestational thyrotropin level and reproductive outcome
of in vitro fertilisation in healthy euthyroid women
D. Grove-Laugesen1, E. Ebbehøj1, C. Aaskov2, U.B. Knudsen3
1Aarhus University Hospital, Department of Endocrinology and Internal Medicine,
Aarhus C, Denmark
2Aarhus University, Clinical Institute, Aarhus, Denmark
3Regionshospitalet Horsens, The Fertility Clinic, Horsens, Denmark
Study question: Does pregestational thyrotropin (TSH) level above 2.5 mIU/
L predict delivery rates in euthyroid healthy women undergoing ﬁrst in vitro fer-
tilization (IVF)?
Summary answer: In euthyroid women TSH above as compared to below
2.5 mIU/L was associated with lower odds for clinical pregnancy and delivery.
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What is known already: Thyroid hormones (TH) are vital for achieving and
maintaining pregnancy. Pregnancy inﬂicts a vast increase in demands for TH.
This impact is even greater in the setting of fertility treatment due to ovarian
hyperstimulation. Elevated TSH in early pregnancy is associated with increased
risk of miscarriage. Current guidelines recommend levothyroxine supplementa-
tion in women with elevated TSH undergoing IVF procedures, aiming at TSH
2.5 mIU/L. However, data on impact of pregestational TSH above 2.5 mIU/L
in euthyroid women on success of IVF is sparse.
Study design, size, duration: This is a retrospective cohort study of 623
women comparing success of ﬁrst IVF according to pregestational level of TSH
above or below 2.5 mIU/L.
Participants/materials, setting, methods: Women with ﬁrst referral for
fertility treatment at Aarhus University Hospital, Denmark, January 1st 2012
until March 31th 2014 were included. Exclusion criteria were chromosomal
abnormalities, comorbidity, prior levothyroxine (LT4) treatment, and lack of
TSH measurement. TSH and anti-thyroperoxidase-antibodies (TPOab) were
measured as part of infertility work-up. Impact on success of IVF was assessed
using logistic regression adjusted for BMI, smoking, age, fertility status, and initi-
ation of LT4. P-values of <0.05 were considered signiﬁcant.
Main results and the role of chance: Overall live birth rate was 27.0 % (n
= 168). 14.5 % (73) miscarried, 24.5 % (59) before week 8 of gestation. 18.3 %
(114) had TSH above 2.5 mIU/L. Baseline demographics according to grouping
of TSH showed no differences in age, BMI, history of smoking, fertility status or
infertility diagnosis. However, women with TSH above 2.5 mIU/L had lower
change of clinical pregnancy (21.1 % vs 31.0 %, p = 0.035) and delivery (18.4 %
vs 28.9%, p = 0.023), despite comparable chance of conception (22.2% vs
39.9%, p = 0.19). These associations were conﬁrmed in the adjusted analysis
with odds ratio for clinical pregnancy 0.49 (95% CI: 0.27-0.90, p = 0.022) and
odds ratio for delivery 0.54 (95% CI: 0.29-1.00, p = 0.049), comparing TSH
above vs below 2.5 mIU/L. In crude analysis odds for any pregnancy loss was
signiﬁcantly higher among women with TSH above2.5 mIU/L, but not in the
adjusted analysis.
TPOab was only available in a subcohort. In subanalysis adding TPOab to the
adjusted regression analysis, the adverse impact of TSH on success of IVF
remained regarding clinical pregnancy. In line with this ﬁnding, odds for early
pregnancy loss was higher in women with TSH above 2.5 mIU/L (OR 3.43
(95% CI:1.03-11.40, p = 0.044).
Limitations, reasons for caution: TPOab are associated with increased risk
of miscarriage. TPOab were available only in a subcohort. However women
with or without available sample were comparable, and a subanalysis adjusted
for TPOab displayed similar adverse impact of TSH above 2.5 mIU/L as in our
main analysis indicating validity of our ﬁndings.
Wider implications of the ﬁndings: RCTs show improved IVF outcome
when treating pregestational TSH above 4.0 or 4.5 mIU/L with LT4. Our data,
though retrospective, suggests adverse IVF outcomes with TSH above 2.5
mIU/L. Future intervention studies should clarify whether additional improve-
ment of reproductive success in IVF is obtainable treating pregestational TSH
above 2.5 mIU/L.
Trial registration number:None.
P-376 Double embryo obtaining using the 1st polar body transfer
technique: is it a fact or a myth?
I. Ilyin1, N. Buderatskaya2, J. Gontar3, O. Parnitskaya2, E. Ilyina4,
E. Kapustin4, S. Lavrynenko2, Y. Lakhno3, M. Yaroshyk3,
N. Kazachkova3
1Reproductive Genetics Institute, IVF Department, Kyiv, Ukraine
2Medical Center IGR, Embryology, Kyiv, Ukraine
3Medical Center IGR, Diagnostic Laboratory, Kyiv, Ukraine
4Medical Center IGR, ART department, Kyiv, Ukraine
Study question: Could transfer of the patient’s 1st polar body (PB) to donor
oocyte cytoplasm be used to obtain viable embryos?
Summary answer: The 1st PB transfer technique can be used to double the
number of embryos suitable for embryos transfer.
What is known already: Mainly the increase of oocytes number in patients
with poor response are conducted in stem cells studies. But the 1st PB transfer
technique, which is mainly applied in case of oocyte cytoplasm donation, could
be used to double oocyte number for further fertilization.
Study design, size, duration: The study was performed in the Medical
Centre IGR from March 2017 to January 2018. It involved 60 oocytes in each
group (groups A and B) obtained from 16 patients and 11 donors, respectively.
The mean age of oocyte donors and patients was 28.2 ± 2.4 and 40.4 ± 3.9
years, respectively. We evaluated embryos’ euploidy and the number of
zygotes and viable embryos at 48, 72, 96 and 120 hours after fertilization.
Participants/materials, setting, methods: Oocytes obtained from 16
patients with poor response. Donor oocytes had been pre-enucleated and
modiﬁed by the transfer of patient’s 1stPB with further fertilization. The proced-
ure was carried out using Nikon Ti Eclipse(Japan) inverted microscope, Saturn
3 laser console(UK). Blastocyst biopsy was performed for the preimplantation
genetic screening (PGS), samples were diagnosed using Ion S5 by Thermo
Fisher Scientiﬁc(USA). Statistical analysis was carried out using Shapiro-Wilk
test for normality, Chi-square test.
Main results and the role of chance: The number of normal fertilized
oocytes in both groups was comparable and reached 46 (76.7%) zygotes in
group A and 45 (75.0%) zygotes in group B. Nine oocytes (15.0%) in group A
had abnormal fertilization pattern and 5 oocytes (8.3%) degraded after ICSI,
whilst 14 oocytes (23.3%) in group B had abnormal fertilization and 1 oocyte
(1.7%) degraded after sperm injection. Then embryos developed as follows: in
48 hours after fertilization there were 41 (68,3%) and 49 (81.7%) embryos, in
72 hours - 39 (65.0%) and 47 (78.3%), in 96 hours - 33 (55.0%) and 40 (66.7%),
in 120 hours – 27 (45.0%) and 30 (50.0%) embryos, where 16 (59.3%) and 20
(66.7%) blastocysts were of high quality (5AA) in group A and group B, respect-
ively, and there was no statistically signiﬁcant difference between the groups
(p>0.05). Embryos distribution by euploidiy/aneuploidy was as follows: group
A –1:1 (12 euploid and 12 aneuploid embryos), group B – 1:2 (8 euploid and 16
aneuploid embryos). Next combinations of embryos’ chromosome sets
(obtained from patients oocytes and modiﬁed donor oocytes) were detected:
euploidy/euplody (5 pairs), euploidy/aneuploidy (4 pairs), euploidy/mosaic (2
pairs), euploidy/polyploidy (1 pair), aneuploidy/euploidy (3 pairs), aneuploidy/
polyploidy (2 pairs), aneuploidy/aneuploidy (7 pairs).
Limitations, reasons for caution: The 1st PB chromosome set corresponds
to the oocyte nucleus and and unequal meiosis-I will result in two aneuploid
embryos But the availability of two euploid oocytes obtained by transfer doesn’t
guarantee the presence of a normal embryo’s chromosomal set, since two dif-
ferent spermatozoa are used for fertilization.
Wider implications of the ﬁndings: The 1st PB transfer is useful to increase
the patient’s chances of having a biologically native child and avoiding the
oocytes donation. Also the use of this technique makes it possible to detect
quantitative chromosomal abnormalities of embryos introduced by spermato-
zoa, in particular polyploidy and mosaicism, without any additional analyses.
Trial registration number:Not applicable.
P-377 Predictive factors for pregnancy after controlled ovarian
stimulation and intrauterine insemination: A retrospective analysis
of 4146 cycles
A. Michau1, H. El Hachem2, J. Galey1, S. Le Parco1, S. Perdigao1,
B. Guthauser1, A. Rousseau1, M. Dahoun1, C. Guillaume1,
N. Tabchouri1, I. Hammoud1
1ART Center, Institut Mutualiste Montsouris (IMM) 42 boulevard Jourdan, 75014
Paris, France
2Department of Obstetrics and Gynecology, Clemenceau Medical Center, Lebanon
Study question: What are the predictive factors for clinical pregnancy (CP)
and live birth (LB) in intrauterine insemination (IUI) cycles following controlled
ovarian stimulation (COS)?
Summary answer: Age <38, anovulatory infertility, ≥2 preovulatory follicles,
total motile sperm count ≥5 million, and IUI cycle rank ≤3 are associated with
a good outcome.
What is known already: IUI is a widely used infertility treatment in various
indications, and is frequently offered ﬁrst-line because it is simple, non-invasive,
has a low cost and minimal risk of complications. However, its overall efﬁciency
remains questioned, whether in natural cycles or following COS. Despite being
i313Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
recommended by many international societies, it is sometimes overlooked in
favor of in vitro fertilization (IVF), which offers higher success rates, but at a con-
siderably higher cost. Studies have shown that many factors can affect out-
comes, such as age and cause of infertility, but the impact of many other
variables remains unknown.
Study design, size, duration: A retrospective unicentric study at the depart-
ment of reproductive medicine of Institut Mutualiste Montsouris, a university
afﬁliated private IVF center in Paris, France, between January 2009 (date when
patient data became computerized) and December 2016.
Participants/materials, setting, methods: Patients aged 18 to 43 years
who had an IUI following COS with gonadotropins were included. Donor cycles
were excluded. Cycles were monitored by transvaginal ultrasounds and hor-
mone assays. Ovulation was triggered with hCG when 1-3 follicles reached
>16 mm with an endometrial thickness >7 mm, and insemination performed
36 h later. When serum LH was >10 IU/L, IUI was performed the day after
hCG. Statistical analysis was performed using Chi square and logistic regression.
Main results and the role of chance: 4146 cycles (1312 couples) were
included. Mean age was 34.7 ± 4 years. CP rate (CPR) and LB rate (LBR) were
11.5% and 8.1%, respectively. CPR/cycle was signiﬁcantly higher in women <38
years compared to ≥38 years (12.6% versus 8.3%, p = 0.0001), in cycles with
≥2 preovulatory follicles (>16 mm) compared to 1 follicle (14.4% versus 11%,
p = 0.01), and when TMSC was ≥5 million compared to <5 million (12.4% ver-
sus 7.7%, p = 0.0002). LBR/couple was 39% for anovulatory infertility (WHO
group II), signiﬁcantly higher (p<0.05) than unexplained infertility (28.6%),
mixed (23.4%), male factor (20.1%), unilateral tubal (14.2%), low ovarian
reserve (13.2%), and endometriosis (stage I and II) (11.1%). However, it was
comparable to cervical factor infertility (29.3%, p = 0.11). Multivariate analysis
showed the following factors were associated with CP: Cycle rank ≤3 (Odds
ratio (OR) = 1.5, 95% CI: 1.2-1.9, p<0.001), age <38 years (OR = 1.5, 95%
CI: 1.2-2, p<0.001), ≥2 preovulatory follicles (OR = 1.4, 95% CI: 1.1-1.8, p =
0.004), TMSC ≥5 million (OR = 1.8, 95% CI: 1.3-2.4, p<0.001). Compared to
anovulatory infertility, endometriosis, low ovarian reserve, unilateral tubal, and
male factor were associated with a lower CPR (OR = 0.3, 95% CI: 0.1-0.5,
p<0.001; OR = 0.4, 95% CI: 0.3-0.7, p<0.001; OR = 0.5 95% CI: 0.3-0.9, p =
0.01; OR = 0.6, 95% CI: 0.4-0.8, p = 0.002 respectively).
Limitations, reasons for caution: The main limitation of our study is the
unicentric retrospective design, although the large number of cycles and the fact
that only COS with gonadotropins was included make the ﬁndings interesting.
Moreover, a cost analysis would have been relevant in order to compare the
efﬁcacy of IUI and IVF.
Wider implications of the ﬁndings: Our study conﬁrms that IUI can be an
efﬁcient treatment in selected indications. Young patients with anovulatory
infertility seem to be the ideal candidates, with a 39% LBR per couple. These
data need to be validated in prospective trials, but can be used to council
patients on the treatment choice.
Trial registration number:Not applicable.
P-378 In vivo conceived embryos recovered by nonsurgical uterine
lavage: Preliminary experience
S. Nakajima1, S. Najmabadi2, S. Munné3, M. Sauer4, M. Angle5,
C. Nezhat6, S. Carson7, J. Buster8
1Stanford University, Obstetrics and Gynecology, Sunnyvale- CA, U.S.A.
2Center for Reproductive Health and Gynecology, Obstetrics and Gynecology, Punta
de Mita, Mexico
3CooperGenomics, Genomics Laboratory, Livingston- NJ, U.S.A.
4Robert Wood Johnson Medical School, Obstetrics- Gynecology and Reproductive
Sciences, New Brunswick- NJ, U.S.A.
5Laurel Fertility Center, Embryology Laboratory, San Francisco- CA, U.S.A.
6Center for Special Minimally Invasive and Robotic Surgery, Research Laboratory,
Palo Alto- CA, U.S.A.
7American Congress of Obstetricians and Gynecologists, Education Department,
Washington- DC, U.S.A.
8Warren Alpert Medical School of Brown University, Obstetrics and Gynecology,
Providence- RI, U.S.A.
Study question: After controlled ovarian hyperstimulation (COH) and intra-
uterine insemination (IUI), can embryos be recovered by uterine lavage using an
automated programmable lavage catheter?
Summary answer: In a series of 69 cycles of superovulation followed by IUI,
uterine lavage recovered 48 embryos in 25 (36.2%) of cycles.
What is known already: Early work performed by Buster and colleagues in
1983 recovered embryos from the uterus by lavage in natural cycles. Prior
attempts performing lavage after COH and IUI failed to recover embryos con-
sistently and resulted in unintended pregnancies in the ovum donors. The cur-
rent uterine lavage catheter prior to its use in this study underwent extensive
bench and in vivo testing for ﬂuid dynamics and the ability to recover known
numbers of implanted artiﬁcial and human tissue (discarded oocytes and in vitro
conceived embryos). Subjects gave their consent for any embryo recovered to
be donated to research.
Study design, size, duration:We performed a single site, prospective, feasi-
bility study in 54 women to evaluate the safety and efﬁcacy of a new uterine lav-
age system (Previvo Genetics, Inc., San Carlos, CA). Subjects gave their written
informed consent for the research protocol approved by Western Institutional
Review Board. All lavages were performed in Punta Mita, Mexico during August
2017 to January 2018 by a single investigator. Subjects were followed for 30-
days post-lavage to monitor for complications.
Participants/materials, setting, methods: 54 women were pretreated
with oral contraceptives and stimulated with gonadotropins for 69 COH cycles.
Ovulation was triggered with either 5,000 IU of human chorionic gonadotropin
(hCG) or leuprolide acetate 4 mg and 2,500 IU of hCG, followed by IUI of
donor sperm 36 hours after trigger. Uterine lavage occurred 4-6 days after the
IUI. After lavage, uterine curettage performed and a GnRH antagonist injection
(0.25 mg/day) was given for 3 days.
Main results and the role of chance: A total of 69 lavages were performed
in 54 women with a mean age of 25.7 years (range 19-38) and 44% were nul-
liparous. Mean subject BMI was 25.4 kg/m2 (range 17.8-36.7). In the COH
cycles, subjects were mildly stimulated an average of 9.2 days of gonadotropins
(mean rFSH 733 IU total dose, mean hMG 722 IU total dose). Ovulation trigger
was given when there was at least 2 dominant follicles ≥18 mm. After IUI, uter-
ine lavage recovered embryos in 25 (36.2%) cycles (range 0-4/cycle). A total of
48 embryos were recovered: 18 (37%) multi-cell embryos, 7 (15%) morulas
and 23 blastocysts (48%). Six (12%) morulas progressed to blastocysts, for a
total of 29 blastocysts (60%). Blastocysts were of high quality, 79% (23/29)
were 3BB or higher. All embryos regardless of stage were biopsied, vitriﬁed and
cryopreserved. All subjects menstruated after the GnRH antagonist injections.
Eight cycles (11.6%) had detectable hCG levels (>2 mIU/mL) after their men-
ses, that regressed spontaneously in two, declined after curettage in one and
persisted after curettage in ﬁve. Persistent hCG levels (highest level 2,652 mIU/
mL) were treated with one dose of methotrexate (50 mg/m2) in 3 cycles and
two doses in 2 cycles.
Limitations, reasons for caution: Although sample size is small, there were
progressive increases in embryo recovery due to improvements in lavage tech-
nique. It is difﬁcult, however, to determine the efﬁciency of each lavage, because
we are unable to verify the number of oocytes ovulated and number of
embryos available for recovery.
Wider implications of the ﬁndings: Uterine lavage offers a nonsurgical
minimally invasive approach to recovering embryos in patients at risk for a mul-
tiple gestation after IUI or desire preimplantation genetic screening or diagnosis
for genetic conditions without IVF.
Trial registration number: Trial registration number is pending.
P-379 Frozen-thawed embryos generated from a successful fresh
IVF cycles have higher potential for favorable outcome than frozen-
thawed embryos obtained from unsuccessful fresh cycles
A. Simon, S. Herzberg, A. Ben-Meir, B. Reubinoff, G. Karavani
Hadassah Hebrew University Medical Center, Department of OB/GYN - P.O. Box
12000, Jeruzalem, Israel
Study question: Whether a successful fresh in-vitro fertilization (IVF) cycle
correlates with better outcomes of frozen-thawed embryo transfers (FT-ET)
from same ovum pick-up.
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Summary answer: Frozen-thawed embryos generated from successful fresh
embryo transfer cycles have a higher potential to implant when compared to
frozen-thawed embryos obtained from unsuccessful fresh cycles.
What is known already: Many variables, including woman’s age, embryo
quality and endometrial receptivity, inﬂuence the success rate of either fresh
embryo transfer (ET) or FT-ET cycles. Patients frequently ask whether previous
successful fresh IVF attempt is a positive prognostic factor for their FT-ET.
Study design, size, duration: A retrospective cohort study comprised of
2218 patients that underwent IVF treatment in a single IVF unit between 1997
and 2017.
Participants/materials, setting, methods: Patients who underwent fresh
ET and at least one consecutive FT-ET cycle at Hadassah Medical center IVF
unit were included in the study. Comparison of FT-ET cycles details and out-
comes were assessed in relation to the outcome of the preceding fresh ET
cycles. Statistical analyses were performed to evaluate the correlation between
the outcome of fresh ET attempt and its consecutive FT-ET cycle.
Main results and the role of chance: Six hundred and seven out of 2218
patients achieved clinical pregnancies in their fresh ET (27.4%). No difference
was found in the number of retrieved oocytes, maturity rates, fertilization rates
and embryo quality distribution between fresh cycles resulting in clinical preg-
nancy and failed fresh cycles. When the outcome of the consecutive frozen
cycles were compared between patients with successful and unsuccessful fresh
ET cycles, a signiﬁcant higher pregnancy rates were observed, for either per
patient or per treatment cycle (37.2% vs. 32.1% and 26.6% vs. 21.8%; p = 0.01
and p = 0.026, respectively). This was substantiated by the McNemar test
which showed a signiﬁcant association between a successful fresh cycle and
positive outcome in the consecutive FT-ET cycle (P<0.001).
Limitations, reasons for caution: The retrospective design of our study
makes it more prone to bias. Assessment is performed for a long period of time
where culture condition and laboratory work might be differing between
patients and for each particular patient.
Wider implications of the ﬁndings: A successful fresh IVF-ET attempt that
resulting in a clinical pregnancy can serve as a positive prognostic factor for the
subsequent FT-ET cycle. Among other parameters, this ﬁnding provides an
important information for the clinician when counseling patients before carrying
out their frozen thawed ET cycle.
Trial registration number:Not applicable.
P-380 Results from a novel transnational fresh egg donation
program based on frozen sperm and embryos shipping
A. La Marca1, M. Dal Canto2, M. Valerio1, R. Fadini2, S. Brazal3,
R. Vassena3, A. Rodriguez3, M. Mignini Renzini2
1Clinica Eugin, Clinic, Modena, Italy
2Biogenesi, Reproductive Medicine Center, Monza, Italy
3Clinica Eugin, Clinic, Barcelona, Spain
Study question: To investigate the clinical efﬁcacy of a novel fresh oocyte
donation program based on transportation of semen and embryos between
two countries.
Summary answer: This novel fresh-egg donation program based on inter-
national transportation of frozen embryos is highly effective. When blastocysts
are available, the success rate is very high.
What is known already: Despite several advantages of oocyte vitriﬁcation in
donation cycles, recent large cohort studies suggest that oocyte vitriﬁcation
may lead to lower live birth rates compared with fresh gametes. On the con-
trary, increasing evidence suggest comparable outcomes with frozen compared
to fresh embryo transfer. Hence, a new strategy could be to treat recipient in
countries with limited availability of oocyte donors: the shipping of frozen sperm
of the partner to the center where the donor will undergo pick up, insemination
of fresh oocytes, the vitriﬁcation and shipment of the resulting embryos and to
the country of origin.
Study design, size, duration: A retrospective cohort study of donor oocyte
IVF cycles with elective vitriﬁed-thawed embryo transfer and shipping from
December 2015 to July 2017 between two IVF clinics in different European
countries. All donors were stimulated with a GnRH antagonist protocol with
GnRH agonist trigger; oocytes were inseminated by ICSI with frozen/thawed
semen. Recipients’ endometrium was prepared with a standard dose of 6 mg
estradiol valerate and 800 mg vaginal progesterone in the last days before the
transfer.
Participants/materials, setting, methods: A total of 630 patients were
available for statistical analysis. In 11% of cases the semen used was from a
donor, in the remaining 89% it was from the male partner and was frozen and
transported to the oocyte donation clinic. Resulting embryos were vitriﬁed
between with an open system on day +2 or on +5, and shipped back to the ori-
ginal clinic for transfer.
Main results and the role of chance: The main reasons for treatment were
female age (40%), reduced ovarian reserve or menopause (25%) and previous
IVF failures (21%). The mean (±SD) age of the patients was 42.3 ± 4.2 years.
The oocytes were obtained from healthy donors aged 26.2 ± 4.4 years. The
number of mature oocytes assigned to each recipient was 6.8 ± 1. The mean
number of 2PN and viable frozen embryos per patient was 4.9 ± 1.56 and 4.17
± 1.5, respectively. For the 630 patients, a total of 1066 embryos were
warmed; the survival rate was 98.5% (n = 1051). After the ﬁrst embryo trans-
fer, the clinical pregnancy rate (CPR) and ongoing pregnancy rate (OPR) were
43 and 31.9% respectively. The embryos were transferred at the cleavage stage
(day 2 or 3) in 476 patients (75.5%) and the OPR was 30.6%. The single and
twin pregnancy rates were 73 and 27%, respectively. Vitriﬁed blastocysts were
available for 154 patients and the CPR and OPR were 44 and 37%, respectively.
The median number of days between donor oocyte pick up and the frozen
embryo transfer was 63.
Limitations, reasons for caution: Limitations include the retrospective
design, sample size and data from a single institution.
Wider implications of the ﬁndings: This study reports an oocyte donation
program based on transfer of frozen embryos transported between countries.
This system eliminates the need to align the timing of donor oocyte retrieval
with the embryo transfer to recipients, while using fresh oocytes for treatment.
Trial registration number:Not Applicable.
P-381 The effect of the oocyte donor’s and recipient’s ages the on
cumulative live birth rate: a population-based cohort study
R. Hogan1, A.Wang1, Z. Li1, L. Johnson2, K. Hammarberg3,
E. Sullivan1
1University of Technology Sydney, Faculty of Health, Sydney, Australia
2Victorian Assisted Reproductive Treatment Authority, Chief Executive Ofﬁcer,
Melbourne, Australia
3Monash University, School of Public Health and Preventative Medicine, Melbourne,
Australia
Study question: What is the impact of the donor’s and recipient’s ages on
the cumulative live birth rate (CLBR) in oocyte donation cycles?
Summary answer: Recipients using oocytes from donors aged 35 years and
older had a signiﬁcantly lower CLBR compared to recipients using oocytes from
donors aged <35 years.
What is known already: Cycle-based statistics show that the donor’s age is
a major determinant of success in oocyte donation/recipient programmes and
that the age of the oocyte recipient has less impact on pregnancy and live birth
rates. There is no existing evidence about the impact of the donor’s and the
recipient’s ages on CLBR in oocyte donation cycles.
Study design, size, duration: A population-based retrospective cohort
study used data from the Victorian Assisted Reproductive Treatment Authority
in Victoria, Australia. This study included 1,490 women commencing assisted
reproductive technology using donated oocytes between 2009 and 2016.
Demographic characteristics, treatment type and resulting pregnancy and birth
outcomes were recorded for the stimulated cycle and associated thaw cycles
until 30 June 2016, or until a live birth was achieved, or until all embryos from
the stimulated cycle had been used.
Participants/materials, setting, methods:Women using donated oocytes
in Victoria, Australia from 2009-2016 were included. The association between
the donor’s/recipient’s ages and CLBR was measured by adjusted hazard ratio
(AHR) in multivariate Cox regression. The following covariates were included:
cause of infertility, parity and number of embryos transferred (1 or 2). Donor
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age was grouped as <30, 30-34, 35–37, 38-40, and 41+ years and recipient age
as <35, 35–37, 38–40, 41-42, 43-44 and 45+ years.
Main results and the role of chance: The mean age of the oocyte donors
was 33.7 years (range 21 to 45 years) with 64.9% under 35 years. The mean
age of the oocyte recipients was 41.4 years (range 19 to 45 years) with 60% of
the oocyte recipients aged under 40 years and 25.4% aged 45+ years.
There was a signiﬁcant relationship between donor’s age and CLBR. The
CLBR for recipients with donors aged <30 years and 30-34 years was 44.7%
and 43.3% respectively. This decreased to 33.6% in donors aged 35-37 years,
22.6% in donors aged 38–40 years and 5.1% in donors aged 41+ years.
Compared with recipients with donors aged <30 years, recipients with donors
aged 38-40 years had 22.1% less chance to achieve a live birth (AHR 0.60, 95%
CI 0.43–0.86) and recipients with donors aged 41+ years had 39.6% less
chance to achieve a live birth (AHR 0.14, 0.04–0.44). The multivariate analysis
showed no signiﬁcant differences in the success by recipient’s age. Advanced
male age was not associated with a decrease in the likelihood of live birth.
Limitations, reasons for caution: The use of data from one state in
Australia limits the generalizability of the results. Number of cycles was used as
the time variable in Cox regression, which does not account for the time differ-
ence between cycles among recipients.
Wider implications of the ﬁndings: These estimates can be used when
counselling women about their likelihood of having a baby using donated
oocytes, and to inform public policy as currently there are no national
Australian recommendations on the age of women who donate their oocytes.
Trial registration number:Not applicable.
P-382 Fully automated assay assessment of intra- and inter-cycle
variation for Anti-Müllerian hormone during the natural cycle
L. Melado Vidales1, B. Lawrenz1, J. Sibal2, E. Abu2, A. Navarro3,
H. Mousavi Fatemi1
1IVI Middle East Fertility Clinic, Medical department, Abu Dhabi, United Arab
Emirates
2IVI Middle East Fertility Clinic, Laboratory department, Abu Dhabi, United Arab
Emirates
3IVI Foundation., Statistical Department, Valencia, Spain
Study question: Does Anti-Müllerian Hormone (AMH) have important intra-
and inter-cyclic variations during the natural cycle when a fully automated assay
is used for the sample analysis?
Summary answer:With the use of a fully automated assay, AMH shows sig-
niﬁcant intra- and intercycle variations during the natural cycle, not caused by
analytical variability.
What is known already: AMH has emerged as one important clinical marker
for ovarian reserve. Fully automated assays reduce analytical variability and
enables more accurate evaluation of biological variations. The hormone shows
strong correlation to the number of antral follicles and provides an important
baseline assessment for individualizing of the therapeutic strategy in assisted
reproductive techniques (ART). AMH has been considered a reliable test to be
measured any day of the cycle without substantial variation. However, recent
data have pointed towards important inter- and intra-cycle ﬂuctuations and
questioned whether a single AMH measurement is sufﬁcient for decision-
making in ART.
Study design, size, duration: Prospective study including 22 volunteers
from April to December 2017. Blood samples for AMH, FSH, LH, estradiol,
and progesterone were obtained by venous puncture during the natural cycle
on day 2/3, day 10, day of LH surge (LH surge was deﬁned as LH concentration
rise by 180% above the latest serum value), luteal phase (conﬁrmed by elevated
progesterone levels 8 days after LH surge), and day 2/3 of the subsequent
bleeding.
Participants/materials, setting, methods: Healthy volunteers between
18–37 years of age were included, with regular menstrual cycles and a BMI
between 18-28 kg/m2. Exclusion criteria: Intake of hormonal contraceptives
for two previous months, pregnancy, breastfeeding, previous conditions with
possible impact on the ovarian reserve (ovarian surgery, chemotherapy, radi-
ation of the pelvis, …). Blood for AMH-evaluation was stored at -20°C. For
batch analysis, two kits of Elecsys® AMH automated (Roche for Cobas 601
platform®) were used.
Main results and the role of chance: A total of 99 samples from 22 women
with a median age of 30,7 ± 4,11 years and a BMI of 23,2 ± 3,63 were analysed.
A substantial longitudinal ﬂuctuation in AMH levels was found, expressed as
coefﬁcient of variation (CV) intra-cycle of 0,207, calculated for all individual
readings per cycle day. Clinically, AMH value varied 20,7% throughout the cycle
from the ﬁrst serum analysis obtained at the beginning of the cycle with no clear
pattern of ﬂuctuation. Serum AMH levels were signiﬁcantly altered by BMI and
age (p<0,001), both negative correlated with AMH values. A positive correl-
ation between LH and AMH concentrations was found (p = 0,01), but not to
other hormones. Absolute intra-individual inter-cyclic variability of AMH (cycle-
day 2-3 in two consecutive cycles) was 0,75 ng/mL (range: 0,03 ng/mL –
2,81 ng/mL) and inter-cycle CV was 0,28 (Conﬁdence interval: 0,16-0,39;
p<0,0001). No differences were found comparing variability of AMH between
the assays used. The observed AMH ﬂuctuations across the cycle are noticeably
higher than expected from the assay imprecision and therefore seem more
likely to be caused by biologic variability.
Limitations, reasons for caution: This study reports limited number of
study subjects. However, an average of 4.5 blood-samples study subject were
assayed in one run, eliminating inter/intra-assay bias in the normal cyclic
women included. Further studies will have to investigate, whether AMH-
ﬂuctuations are also present in other subgroups of population.
Wider implications of the ﬁndings: The large intercycle and intracycle
AMH ﬂuctuations in the same woman during her natural cycle using an auto-
mated assay keeps the question open on the best time to measure AMH for
decision-making in daily practice. Further RCTs evaluating AMH dynamics and
its correlation with treatment outcomes should be conducted.
Trial registration number: This trial has been registered for clinical.trials.
gov: NCT03106272.
P-383 Can “patient-friendly” salivary hormonemeasurements
replace serummonitoring of IVF patients? An Europeanmulti-
center assessment
D. Sakkas1, L. Atkinson2, A. Borini3, E.A. Bosch2, C. Bryce4,
M. Cattoli3, A. Finet de Bantel5, B. French6, S. Gaitonde4, J. Gerris7,
S. Granger4, V. Grzegorczyk-Martin5, C. Howles8, S. Somers7,
M. Alper6
1Boston IVF, Waltham- MA, U.S.A.
2IVI-RMA Valencia, Clinic, Valencia, Spain
3Tecnobios Procreazione S.r.l., Clinic, Bologna, Italy
4Salimetrics LLC, Research, Carlsbad, U.S.A.
5Clinique MATHILDE, Laboratoire d’Assistance Médicale à la Procréation, Rouen,
France
6Boston IVF, Clinic, Waltham- MA, U.S.A.
7Gent University Hospital, Vrouwenkliniek, Gent, Belgium
8Preglem S.A., Medical Affairs, Geneva, Switzerland
Study question: Can a saliva based Estradiol (E2) assay replace the use of
blood monitoring during a controlled ovarian stimulation (COS) cycle for IVF/
ICSI?
Summary answer: Salivary E2 based hormone testing provides an equivalent
alternative to serum based assessment and may become the preferred method
of COS monitoring in the future.
What is known already: Salivary diagnostic testing is emerging as a less inva-
sive, inexpensive alternative to serum analyte measurements with proven diag-
nostic accuracy in clinical settings. This study aimed to determine the
performance of a salivary hormone competitive immunoassay for monitoring
patient E2 levels during monitored cycles for infertility treatment. Such treat-
ments encompass: Undergoing monitored infertility treatment employing con-
trolled ovarian stimulation (COS) with oral agents or gonadotropins for
Ovulation induction/ IUI and COS for IVF/ICSI.
Study design, size, duration: The prospective study was performed at 4 dif-
ferent European clinics (Italy, Spain, Belgium, France), between 9/2016-11/
2017, whereby at each venipuncture appointment, subjects also collected a sal-
iva sample via passive drool according to the assay speciﬁcations. In total 152,
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214, 184 and 104 samples were collected from 59, 122, 40 and 40 patients
respectively. Between 1 and 6 samples were collected from each individual
patient. 122 patients collected ≥3 samples in an individual cycle.
Participants/materials, setting, methods: Saliva samples were coded, de-
identiﬁed and stored frozen. They were then run blinded in a separate facility.
Saliva and serum correlation were calculated using the matched mean saliva and
serum assay results for all E2 data points collected. Pearson product moment
correlations of the serum and saliva were conducted using the natural log trans-
formed data. Data was assessed per clinic and overall taking into account the
different serum E2 testing platforms used per clinic.
Main results and the role of chance: One to six salivary E2 samples were
analyzed for each patient. In the four clinics the correlation coefﬁcients of Saliva
E2 to serum values were Italy: r = 0.69, p < 0.001; France: r = 0.53, p <0.001;
Belgium: r = 0.75, p < 0.001; Spain: r = 0.79, p <0.001. Mean (±SD) serum E2
values (pg/ml) differed between clinics reﬂecting different demographics and
approaches to patient stimulation [Italy: 803 ± 760, France: 862 ± 892;
Belgium: 1174 ± 933; Spain: 1276 ± 1026. The respective mean (±SD) saliva
values (pg/ml) were 17 ± 9, 26 ± 15, 24 ± 14 and 24 ± 14. When examining
individual patients who collected ≥3 samples in one cycle, more than 75% of
patients showed an individual within cycle correlation of >0.7 and 62% a correl-
ation of >0.9. Patients with discolored saliva samples generally showed poor
correlations, indicating that they failed to collect according to protocol. Patient
surveys have also shown that saliva based hormone testing is associated with
improved patient satisfaction and decreased stress.
Limitations, reasons for caution: The results could be limited as the study
was conducted in an unselected population of all patients performing IVF. A fur-
ther limitation was that although patients were informed on collection proto-
cols it was evident that some patient saliva samples may have been sub
optimally collected which inﬂuences the assay outcome.
Wider implications of the ﬁndings: Rapid, salivary E2 based hormone test-
ing provides an equivalent alternative to serum based assessment. The ease of
saliva sampling allows a reduction in treatment burden, improved patient satis-
faction and decreased stress. Saliva based hormone tests may become the pre-
ferred method of hormone monitoring for fertility treatments in the future.
Trial registration number:NCT03162809.
P-384 Premature progesterone elevation is associated with
decreased uterine artery blood ﬂow and clinical pregnancy rate
C. Kim1, J.W. Moon2, H.J. Kim1, B.M. Kang1
1Asan Medical Center- University of Ulsan, Obstetrics Gynecology, Seoul, Korea-
South
2M Fertility Center, Gynecology, Seoul, Korea- South
Study question: Could premature progesterone elevation (PE) affect the
uterine artery (UA) perfusion and IVF outcome?
Summary answer: PE on the day of hCG is associated with decreased UA
blood ﬂow and clinical pregnancy rate (CPR) in infertile patients undergoing IVF.
What is known already: Controlled ovarian stimulation (COS) is correlated
with premature PE and it is generally believed to have an adverse effect on preg-
nancy outcome in infertile patients undergoing IVF. Although many possible
mechanisms of decreased pregnancy rate by premature PE have been dis-
cussed, the causes has not been completely elucidated. Moreover, the study on
the effect of premature PE on UA blood perfusion has not been reported.
Study design, size, duration: This retrospective study included 108 infertile
patients who had their blood taken for measurement of serum progesterone
on the day of hCG in stimulated IVF cycles between February 2015 and January
2017.
Participants/materials, setting, methods: The association of serum pro-
gesterone levels (group 1: ≤ 1.5 ng/ml, group 2:1.5-2.0 ng/ml, group 3: >
2.0 ng/ml) measured on the day of hCG with IVF outcome and resistance index
(RI) and pulsatility index (PI) of UA on the day of embryo transfer (ET) was eval-
uated in 108 cycles corresponding to 108 patients who underwent IVF in COS
cycles using GnRH antagonist protocol.
Main results and the role of chance: Patients’ characteristics were com-
parable among three groups. Total days of gonadotropins used for COS was
signiﬁcantly longer in group 1 than in group 2 or 3 (P=.012 vs group2, P=.040 vs
group 3, respectively). The number of oocytes retrieved was signiﬁcantly higher
in group 3 than in group 1 (P=.029). However, there were no differences
among three groups with respect to the numbers of mature oocytes, fertilized
oocytes and good quality embryos. RI of UA was signiﬁcantly higher in group 3
than in group 1 or 2 (P<.001, P<.001). PI of UA was also signiﬁcantly higher in
group 3 than in group 1 or 2 (P<.001, P<.001). CPR seemed to be lower in
group 3, but this difference did not attain the statistical signiﬁcance (P=.076
between group 1 and 3, P=.087 between group 2 and 3). When CPR was com-
pared between the two groups with each progesterone levels ≤ 2.0 ng/ml and
> 2.0 ng/ml, CPR was signiﬁcantly lower in the group with PE (P=.034).
Limitations, reasons for caution: This study has a limitation to evaluate the
impact of premature PE on UA blood ﬂow and IVF outcome due to a retro-
spective nature and small number of sample available. The effect of premature
PE should be investigated according to the different responders to COS in a big-
ger patient pool.
Wider implications of the ﬁndings: Premature PE (especially > 2.0 ng/ml)
can result in a decrease of UA blood ﬂow and it can be one of contributing fac-
tors of decreased CPR by premature PE in IVF cycles.
Trial registration number:None.
P-385 Does the effect of body mass index on in vitro fertilization
with GnRH-antagonist protocol in polycycstic ovary syndrome vary
with the level of androgen?
W. Yang, R. Yang, J. Zhang, T. Pang, F. Deng, Y.Wang, J. Qiao
Peking University Third Hospital, Center for Reproductive Medicine- Department of
Obstetrics and Gynecology, beijing, China
Study question: Does the effect of body mass index on in vitro fertilization
with GnRH-antagonist protocol in polycycstic ovary syndrome vary with the
level of androgen?
Summary answer: Economic beneﬁts were achieved in hyperandrogenism-
PCOS patients with less cost and more available embryos. Overweight and
hyperandrogenism both have signiﬁcantly negative effects on pregnancy
outcomes.
What is known already: Endocrine disturbances are complicated in poly-
cycstic ovary syndrome (PCOS) patients. hyperandrogenism (HA), and obesity
interact with each other and promote PCOS progression. However, few stud-
ies to date have investigated body mass index (BMI) and androgen level
together. Moreover, there are limited literatures that investigate the clinical
phenotype of PCOS patients that can beneﬁt most from the GnRH-antagonist
protocol during in vitro fertilization (IVF). Therefore, the present study was
designed to evaluate whether the effect of BMI in PCOS varies with the level of
androgen on IVF with GnRH-antagonist protocol.
Study design, size, duration: A total of 583 infertile women between 20
and 35 years of age who underwent IVF using the conventional GnRH antagon-
ist protocol at a single center between January 1, 2013, and December 31,
2015, were included in this retrospective cohort study.
Participants/materials, setting, methods: Patients were divided into 4
groups: BMI<25 kg/m2 with normal androgen level (group 1, n = 218),
BMI<25 kg/m2 with hyperandrogenism (group 2, n = 152), BMI≥25 kg/m2
with normal androgen level (group 3, n = 117), BMI≥25 kg/m2 with hyperan-
drogenism (group 4, n = 96).
Main results and the role of chance:Number of retrieved oocytes was sig-
niﬁcantly higher in lean PCOS patients compared with overweight PCOS
patients. Available embryos were signiﬁcantly higher whereas Gn stimulation
days and total Gn dosage were signiﬁcantly lower in the HA PCOS group, com-
pared with non-HA PCOS patients. Clinical pregnancy rate was of no signiﬁcant
difference among four groups. Live birth rates in overweight PCOS groups
were signiﬁcantly lower when compared with group 1 (23.9%, 28.4% vs. 42.5%,
P<0.05). Abortion rate in group 4 was signiﬁcantly higher than group 1 (45.2%
vs. 14.5%, P<0.05). Logistic regression analysis revealed that BMI and androgen
level both acted as signiﬁcant inﬂuence factors for abortion rate.
Limitations, reasons for caution: One major limitation of our study is the
retrospective design. hyperandrogenism, obesity, and hyperinsulinemia are the
mainly endocrine disturbances in PCOS patients. Prospective studies should
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investigate the effects of hyperinsulinemia and BMIs on IVF outcomes in patients
undergoing the GnRH-antagonist protocol to determine their impact on HA.
Wider implications of the ﬁndings: Economic beneﬁts were achieved in
HA-PCOS patients with less cost and more available embryos. Due to the high
abortion rate and low live birth rate, a freeze-all approach might be a preferable
option for HA-PCOS patients so as to create a buffer for reducing androgen
levels before transferring freeze-thawed embryos.
Trial registration number:None.
P-386 Excessive intrauterine interventions negatively affect
in vitro fertilization (IVF) outcomes in women with repeated IVF
failure
E. Usoltseva1, L.K. Dzhemlikhanova2, D.A. Niauri3, I.Y. Kogan4,
A.M. Gzgzyan4
1D.O.Ott Research Institute of Obstetrics and Gynecology RAMS, Assisted
Reproductive Technologies Department, Saint Petersburg, Russia C.I.S.
2Saint-Petersburg State University, Department of Obstetrics- Gynecology and
Reproductology, Saint Petersburg, Russia C.I.S.
3Saint-Petersburg State University, Department of Obstetrics- Gynecology and
Reproductology, Saint-Petersburg, Russia C.I.S.
4D.O.Ott Research Institute of Obstetrics- Gynecology and Reproductology, Assisted
Reproductive Technologies Department, Saint Petersburg, Russia C.I.S.
Study question: Does the number of performed intrauterine interventions
have an impact on IVF outcomes in women with repeated IVF failure?
Summary answer: The previous history of an excessive number of intrauter-
ine interventions appears to have an adverse effect on IVF outcomes in women
with repeated IVF failure.
What is known already: The necessity for comprehensive assessment of
endometrial morphology and function in women with repeated IVF failure along
with the lack of the non-invasive assessment methods oblige us to perform an
invasive intrauterine procedure to get endometrial samples. However, even the
minimally invasive intrauterine procedures carry a slight risk of infection and can
cause destruction of the endometrium right through to its basal layer. The
damaged endometrial basal layer can be responsible for residual fertility impair-
ing changes. However, there is still a lack of systematic analysis to assess the
number of intrauterine interventions as a risk factor for IVF outcomes.
Study design, size, duration: A retrospective observational cohort study
includes 131 women with previously repeated IVF failure undergoing fresh IVF
or cryo cycle in a single University-afﬁliated infertility clinic. The study was con-
ducted from September 2011 to February 2014.
Participants/materials, setting, methods: The female patients with
repeated implantation failure (after at least two previous attempts of embryo
transfer) under the age of 40 years with two or more high-quality embryos
were enrolled for the study. The history of previously performed intrauterine
interventions (both diagnostic and curative, not only a uterine curettage but
also minimally invasive procedures) was taken into account.
Main results and the role of chance: On average each woman included in
the study had 5,32 ± 0,23 intrauterine interventions (1,85 ± 0,10 uterine curet-
tage procedures and 4,29 ± 0,21 minimally invasive procedures). The number
of performed uterine curettage procedures didn’t correlate to the IVF outcome
(R = 0,031, p = 0,76), while there was a moderate, but signiﬁcant negative cor-
relation between the number of minimally invasive intrauterine procedures and
the implantation rate (R=−0,21, р = 0,013). A logistic regression analysis
demonstrated that more than three previously performed intrauterine proce-
dures in women with repeated IVF failure were associated with subsequent
implantation failure (OR 2,20; 95%CI 1,06-4,56).
Limitations, reasons for caution: In the retrospective study not all pertin-
ent risk factors could be identiﬁed and subsequently recorded. So only associ-
ation, and not causation, can be inferred from the results. These data for the
risk factor analysis were received just from one center. It should be validated
using the dataset from other centers.
Wider implications of the ﬁndings: These data may provide information
for the development of an effective strategy of preconceiving care in women
with repeated implantation failure with reasonable rejection of excessive
uninformative ineffective intrauterine procedures. The data also could be con-
sidered for explanatory and prognostic purposes.
Trial registration number:Not applicable.
P-387 The correlation between oocyte diameter and blastocyst
quality
R. Bassil1, J. Haas1, Z. Eran1, M. Chaula1, C. Robert2
1University of Toronto- Trio fertility center, ObGyn, Toronto, Canada
2University of Toronto- Trio fertility center- Lunenfeld Research Institute, ObGyn-
Physiology, Toronto, Canada
Study question: Is there an association between the diameter of the oocyte
and the quality of its corresponding blastocyst?
Summary answer:When comparing the ratios of oocyte diameters, the low-
er the ratio the higher the chance of developing to better quality blastocyst.
What is known already: The reproductive capacity of females decreases sig-
niﬁcantly in the fourth decade which is directly correlated to an age-related
decrease in oocyte quality and quantity. The fact that the live birth rates from
oocyte donation in older women is consistent suggests that oocyte quality is
the major factor responsible for infertility. Decreased substrate for ATP pro-
duction and increased mitochondrial deoxynucleic acid (mtDNA) mutations
might be involved in increased loss and decreased quality of ovarian follicles in
older women. An association between low mitochondrial DNA copy and the
ability of the oocyte to become fertilized has been described.
Study design, size, duration: It is a retrospective study conducted at Trio
Fertility Center in Toronto, Ontario, Canada afﬁliated with University of
Toronto. We collected all the data from the IVF cycles conducted in 2015 in
which an embryoscope was used to visualize the progression of the embryos.
Participants/materials, setting, methods: We retrospectively analyzed
the cycles of 470 women where the embryoscope was used which gave us a
total of 1914 embryos. The embryoscope’s diameter function was used to
measure the mature oocytes’ (M IIs) diameter at the stage where the ﬁrst polar
body is visible. Two measurements were taken for each oocyte and the average
diameter as well as the ratio were calculated.
Main results and the role of chance: We didn’t ﬁnd any correlation
between the diameter of the oocyte and the development to a top quality
embryo. The diameter of oocytes that developed to a top quality blastocyst
compared to the diameter of the oocytes that did not develop to the blastocyst
stage was similar ( 112.3 vs. 112.5 micro)
We did ﬁnd a correlation between the ratio of the oocytes’ two diameters
and the development to a top quality blastocyst. The oocytes with a ratio below
1.1 had higher probability to develop to a top quality blastocyst compared to
oocytes with ratio above 1.2 ( 15% vs 5% p <0.001).The probability of oocytes
to arrest prior to the blastocyst stage was increased in the group of oocytes
with a ratio above 1.2 compared to the oocytes with the ratio below 1.1 ( 80%
vs. 66% p< 0.01)
Limitations, reasons for caution:None.
Wider implications of the ﬁndings: The study shows that as the ratio of
the oocyte diameters increases, the chances of it developing to a good quality
embryo decreases. In other words, the lower the ratio, meaning the more
spherical the shape of the oocyte the more likely it will develop to a good qual-
ity blast.
Trial registration number:Not applicable.
P-388 Age stratiﬁed Anti-Müllerian Hormone (AMH) reference
range evaluation in polycystic ovary syndrome women at
reproductive age using an automated AMH assay
L. Sun1, S. Retka1, C. Lejeune2, D. Broyles3
1Beckman Coulter- Inc., Product Management, Chaska, U.S.A.
2Beckman Coulter- Inc., Research & Development, Marseille, France
3Beckman Coulter- Inc., Clinical Affairs, Carlsbad, U.S.A.
Study question: Do AMH levels differ signiﬁcantly between age groups in
PCOS women?
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Summary answer: The AMH levels in PCOS women are substantially higher
compared to age-matched healthy controls and decrease signiﬁcantly with
increased age.
What is known already: AMH has been proposed as a surrogate test for fol-
licular count in the diagnosis of PCOS. Although there has been interest to
deﬁne a universally agreed threshold of serum AMH in PCOS women, studies
have shown AMH levels and age have a negative correlation in PCOS women.
The age stratiﬁed AMH reference ranges for PCOS women at reproductive age
has not been determined using the automated AMH assays.
Study design, size, duration: This study was a multi-center, prospective,
cross-sectional study of 146 PCOS women enrolled from March 2016 to
August 2016. The study used four geographically diverse sites in the United
States.
Participants/materials, setting, methods: The study included PCOS
women aged 18–45 years who met the Rotterdam criteria. The age stratiﬁed
AMH reference ranges were established, and the difference of AMH distribu-
tions between age groups were further analyzed using the Kruskal-Wallis test.
A comparison of PCOS reference ranges was made to age-matched healthy
adult females. Serum samples were measured at a separate, single site using the
Beckman Coulter Access 2 immunoassay system and the Access AMH assay.
Main results and the role of chance: Age stratiﬁed AMH reference ranges
were established in 146 PCOS women with AMH levels ranging from 0.03 to
34.6 ng/mL. Age was categorized as 18-25 (n = 16), 26-30 (n = 51), 31-35 (n-
41), 36-40 (n = 23), and 41-45 (n = 15) years. Median AMH levels categorized
by age for PCOS women demonstrated a decreasing trend (7.11, 7.35, 6.77,
3.95 and 1.63 ng/mL, respectively) with increased age, but were statistically sig-
niﬁcantly higher than apparently healthy age-matched adult women. Overall,
median AMH level for PCOS women was 3 times higher than apparently
healthy adult women with a statistical signiﬁcance (6.02 vs. 1.83 ng/mL,
respectively, p-value<0.0001). Kruskal-Wallis test showed substantial differ-
ence in AMH distributions between the age groups (p-value = 0.0022) in PCOS
women, and the Pearson’s correlation analysis conﬁrmed a negative relation-
ship between AMH levels and age (r=-0.229, 95%CI=-0.379 – -0.069, p-value
= 0.0054).
Limitations, reasons for caution: The small sample size represents a
limitation.
Wider implications of the ﬁndings: To our knowledge, this is the ﬁrst
study that established the age stratiﬁed AMH reference ranges using the auto-
mated AMH assay in PCOS women. AMH distributions in PCOS women differ
signiﬁcantly between age groups, questioning the use of one universal AMH
threshold for PCOS women at all ages.
Trial registration number:Not Applicable.
P-389 Mitochondrial DNA copy number in peripheral blood: a
potential non invasive biomarker for female subfertility
A. Busnelli1, D. Lattuada2, A. Paffoni3, E. Somigliana1
1IRCCS Ospedale Maggiore Policlinico Regina Elena, Obstet-Gynecol, Milano, Italy
2Fondazione IRCCS Ca’ Granda- Ospedale Maggiore, Department of Obstetrics and
Gynaecology-, Milan, Italy
3Fondazione IRCCS Ca’ Granda- Ospedale Maggiore, Department of Obstetrics and
Gynaecology, Milan, Italy
Study question: Does the mitochondrial DNA copy number (mtDNAcn) in
peripheral blood have the potential to serve as a non invasive biomarker for
female subfertility?
Summary answer: A mtDNA peripheral blood level below 105 mtDNAcn
resulted associated with a ﬁve-folds increased risk of subfertility, providing a
possible way of predicting this condition.
What is known already: Low mtDNA content in oocytes and in cumulus
cells is a signiﬁcant indicator of poor oocyte quality and may prevent the oocyte
from completing the process of fertilization and embryo development.
Furthermore, and of utmost relevance, is the recent evidence showing a correl-
ation between mtDNA content in cumulus cells and mtDNAcn in peripheral
blood cells.
Study design, size, duration: This is a nested case-control study drawn
from a prospective cohort of pregnant women referred for routine ﬁrst trimes-
ter screening for aneuploidies (from 11+0 to 12+6 weeks of gestation)
between January 2012 and March 2013 at the “Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico” of Milan, Italy.
Participants/materials, setting, methods: Cases were subfertile women
who attempted to become pregnant for 12–24 months. Controls were the two
subsequently age-matched women who became pregnant in less than one year.
Blood samples were obtained from all participating women. MtDNA was quan-
tiﬁed using real time PCR and normalized to nuclear DNA.
Main results and the role of chance: One hundred and four subfertile
women and 208 matched fertile controls were selected. The median (inter-
quartile range) mtDNAcn was 95 (73-124) and 145 (106-198), respectively
(p<0.001). The area under the receiver operating characteristic (ROC) curve
was 0.73 (95% Conﬁdence Interval-CI: 0.67-0.79) (p<0.001). The Youden
index was 105 mtDNAcn. The crude odds ratio for subfertility in women with
mtDNAcn below this threshold was 5.72 (95%CI: 3.43-9.55). We repeated
these analyses in different age groups: the accuracy of mtDNAcn assessment in
peripheral blood resulted higher in younger women and progressively
decreased with increasing age.
Limitations, reasons for caution:We did not perform an infertility diagnos-
tic work-up of the couples and we are thus unable to rule out other potential
causes of subfertility. However, severe concomitant causes of infertility can be
conﬁdently ruled out since all women conceived within two years.
Wider implications of the ﬁndings: MtDNAcn assessment in peripheral
blood appears to have all the features of the much sought non-invasive bio-
marker of female fertility. Noteworthy its performance resulted very good in
young women. Our results may thus have future clinical applications. However,
further independent studies including non-pregnant women undergoing high
throughput screening are warranted.
Trial registration number:Not applicable.
P-390 Prognostic of IUI depends of the number of motile
spermatozoa inseminated and patient age, however high
concentrations are always detrimental: an analysis of 9618 cycles
C. Grysole1, S. Phillips1,2, M.P. Velez3, R. Antaki1,2, F. Bissonnette1,2,
I.J. Kadoch1,2
1Faculty of Medicine- University of Montreal, Obstetrics and Gynecology, Montreal,
Canada
2OVO Clinic, OVO Fertility, Montreal, Canada
3Queen’s University, Obstetrics and Gynecology, Kingstone, Canada
Study question: What is the impact of the number of motile spermatozoa
inseminated (NMSI) on clinical pregnancy rates (CPR) in intrauterine insemin-
ation (IUI) according to patient age?
Summary answer: The NMSI positively inﬂuences the CPR of IUI for women
between 30 and 40 years, while not for women under 30, or older than 40.
What is known already: Many authors have studied the effects of the NMSI
on the success of IUI, but a real consensus has not yet been achieved. A min-
imum of 1 M (million) motile spermatozoa inseminated is often quoted as
required to optimize IUI but several authors question this threshold. Some
studies have shown that the pregnancy rates were higher if the NMSI exceeds
2 M or 5 M. However, according to a recent study, female age is the only vari-
able signiﬁcantly correlated with IUI success rates. NMSI and female age have
rarely been studied together.
Study design, size, duration: This is a retrospective cohort study, in which
4394 couples completed 9618 IUI cycles with partner sperm, between January
2011 and December 2015, at a University-afﬁliated private ART clinic in Montreal.
Participants/materials, setting, methods: All couples had been trying to
conceive without success for at least 1 year. Indications for IUI included moderate
male factor, dysovulation and unexplained infertility. IUI was performed after a
natural cycle (n = 180) or an ovarian stimulation by clomiphene citrate or letro-
zole (n = 7611) or gonadotropins alone (n = 218) or in addition to letrozole (n
= 1609). The outcome measure was clinical pregnancy rates deﬁned by an intra-
uterine gestational sac with heartbeat visible with ultrasonography at 7 weeks.
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Main results and the role of chance: The 9618 cycles were divided into
four groups based on the NMSI as follows: group 1, <1 M; group 2, 1 to 4 M;
group 3, 5 to 10 M; group 4, ≥10M. In women younger than 30 years (n =
1814 cycles), CPR between the four groups were not signiﬁcantly different
(6.4%, 14.8%, 13.7% and 14.1%, respectively; p = 0.20). Nevertheless, the CPR
appeared clinically lower in group 1. In women 30 to 34 (n = 3499 cycles), CPR
were signiﬁcantly different between groups (2.9%, 10.2%, 15.6%, and 15.0%,
respectively; p<0.001). In women 35 to 39 (n = 3083 cycles), CPR were also
different between the groups (5.5%, 10.5%, 8.0%, 14.2%, respectively; p =
0.001). Thus, better results are observed if the NMSI is ≥5 M between 30 and
34 years, and if the NMSI is ≥10M between 35 and 39 years. For patients ≥ 40
years (n = 1222 cycles), CPR were not different by groups of NMSI (4.7%,
5.4%, 6.3%, 9.7%, respectively; p = 0.21), although the CPR seemed to double
between groups 1 and 4. Less pregnancies in the older age group could explain
the lack of signiﬁcance. Interestingly, we noted that an NMSI ≥150 M had a det-
rimental effect on CPR any age combined (10.0%, p<0.001).
Limitations, reasons for caution: Our population was heterogeneous; all
indications of inseminations combined. Ovulation stimulation treatments varied
and the therapeutic strategy was physician-dependent. However, the very high
number of cycles adds strong value to our study and the NMSI is a standardized
data.
Wider implications of the ﬁndings: The only study analyzing the NMSI by
age category reported no difference in CPR in women older than 25, possibly
due to a lack of statistical power. Our study suggests that in women 30-39 years
with NMSI<5 M, IUI results in lower CPR, thus IVF should be considered a ﬁrst
option.
Trial registration number:Not applicable.
P-391 The effect of weight intervention on obstetric and neonatal
outcome in obese women scheduled for IVF treatment
S. Einarsson1, B. Christina2, L. Kluge2, A. Thurin-Kjellberg2
1Livio Reykjavik, Reproductive medicine, Reykjavik, Iceland
2University of Gothenburg, Reproductive Medicine, Gothenburg, Sweden
Study question:What is the effect of a low calorie diet weight intervention in
obese women prior to IVF on maternal and neonatal outcome?
Summary answer: No differences in maternal and neonatal outcomes
between the study groups were found and most pregnancies were successful
with healthy children and few maternal complications.
What is known already: Fertility, obstetric and neonatal outcome are nega-
tively affected in obese women. A recent Dutch randomized trial of infertile
women and lifestyle weight intervention with a weight loss of 3,3 kg, found no
difference in live birth rate, obstetric or neonatal outcomes. In previously pub-
lished data from our trial no effect on live birth rates were found despite large
weight loss (9,44 kg). A difference was found in spontaneous pregnancies lead-
ing to live birth and was in favor of the weight intervention, 10,5% (16/152) ver-
sus 2,6% (4/153) in the control group.
Study design, size, duration: This is a secondary analysis of a prospective,
multicenter, randomized controlled trial that was performed between 2010 and
2016 in the Nordic countries. 305 women were randomized to one of two
groups; weight reduction intervention followed by IVF-treatment or IVF-
treatment only. The weight reduction included 12 weeks of a low-calorie liquid
formula diet (LCD), of 880 kcal per day followed by two to ﬁve weeks of diet
re-introduction and weight stabilization before IVF treatment started.
Participants/materials, setting, methods: Nine infertility clinics in
Sweden, Denmark and Iceland participated. Women under 38 years of age
planning for IVF, and having a body mass index (BMI) ≥30 and <35 kg/m2 were
randomized to two groups: an intervention group (152 patients) with weight
reduction before IVF, starting with 12 weeks of a low calorie liquid formula diet
of 880 kcal/day and thereafter weight stabilization for 2-5 weeks, or a control
group (153 patients) with IVF only.
Main results and the role of chance: There were 87 live births; 45 single-
tons in the intervention group and 41 singletons and one twin birth in the con-
trol group. The characteristics of the women having a live birth were
comparable in the two groups. The mean age and infertility length were 31,4
years and 35,3 months in the intervention group and 30,7 years and 36,6
months in the control group. The infertility diagnoses were comparable. None
of the maternal and neonatal outcomes differed signiﬁcantly between the inter-
vention and the control group: cesaerean section 28,9% vs. 24,4%, OR: 1.14
(CI: 0.45; 2.94); preeclampsia 11,1% vs. 9,8%, OR: 1.19 (CI: 0.30; 4.76); gesta-
tional diabetes 2.2% vs. 4.9%, OR: 0.45 (CI: 0.04; 5.21); postpartum hemor-
rhage >1000ml 4.4% vs. 12.2%, OR: 0.34 (CI: 0.06; 1.88); preterm birth <37
weeks 4.4% vs. 2.4%, OR: 1.95 (CI: 0.17; 22.36); low birth weight <2500 g
4.4% vs. 2.4%, OR: 1.95 (0.17; 22.36). No children within the study were trea-
ted in a neonatal intensive care unit or had a major malformation observed
within the ﬁrst week of life. When comparing the women who achieved a live
birth through a spontaneous pregnancy in the different randomization groups
no signiﬁcant differences were found for any variables.
Limitations, reasons for caution: The study was not designed or powered
to detect differences in maternal or neonatal outcome nor was it blinded for
patients or physician. Further, the intervention group had longer time to achieve
a spontaneous pregnancy, but was slightly older than the control group at IVF.
Wider implications of the ﬁndings:Maternal and neonatal outcomes were
satisfactory in both groups. Although estimates of absolute values and OR indi-
cated no differences between groups in any outcomes, the 95% CI were gener-
ally wide meaning that clinical important differences may exist.
Trial registration number: ClinicalTrials.gov number, NCT01566929
P-392 The predictive value of pulsatility index for pregnancy after
assisted conception: a systematic review
M. Eyo1, P. Smith2, J. Chu3, A. Coomarasamy4
1Tommy’s National Centre for Miscarriage Research Institute of Metabolism and
Systems Research -, Academic Department - Third Floor - BirminghamWomen’s
Hospital NHS Foundation Trust University of Birmingham- Metchley Park Road -
Edgbaston- Birmingham-,
2Tommy’s National Centre for Miscarriage Research - Institute of Metabolism and
Systems Research - University of Birmingham -, Academic Department - Third Floor -
BirminghamWomen’s Hospital NHS Foundation Trust - Metchley Park Road -
Edgbaston- B15 2TG,
3Tommy’s National Centre for Miscarriage Research - Institute of Metabolism and
Systems Research - University of Birmingham -, Academic Department - Third Floor -
BirminghamWomen’s Hospital NHS Foundation Trust - Metchley Park Road -
Edgbaston- Birming,
4Tommy’s National Centre for Miscarriage Research - Institute of Metabolism and
Systems Research - University of Birmingham - Academic Department - Third Floor -
BirminghamWomen’s Hospital NHS Foundation Trust - Metchley Park Road -
Edgbaston- Birmingh
Study question: Is there a difference between the uterine vascularity of
women who get pregnant and the uterine vascularity of women who do not
become pregnant after assisted conception.
Summary answer: The pregnant group had a signiﬁcantly lower uterine pul-
satility index when compared with the non-pregnant group [WMD -0.14; 95%
conﬁdence interval (CI): -0.22,-0.06; p = 0.000].
What is known already: Angiogenesis is critical for the development of the
endometrium to enable successful embryo implantation. Pulsatility index is a
marker of resistance to blood ﬂow which can be used to quantify and compare
downstream blood ﬂow to tissues. Our study is the ﬁrst systematic review to
investigate whether the vascularity of the endometrium correlates with assisted
conception outcomes.
Study design, size, duration: The electronic databases EMBASE and
MEDLINE Were systematically searched, up to October 2017, for publications
that studied the differences in pulsatility index measurements between women
who became pregnant and women who did not become pregnant after assisted
conception. Twenty-nine papers met the inclusion criteria, which included 4022
participants in total.
Participants/materials, setting, methods: Participants included infertile
women who were undergoing either IVF, frozen embryo transfer or intrauter-
ine insemination. 1292 became pregnant and 2730 did not become pregnant
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after assisted conception. Causes of infertility included a range of male and
female factors. The studies were performed in the fertility clinic setting.
Pulsatility index measurements were taken using transvaginal ultrasound at vari-
ous points prior to embryo transfer.
Main results and the role of chance: The search produced a total of 758
studies which were all retrieved. A total of 29 cohort studies were included
in the review. A raised mean PI (>3) was present in 1 study within the
group of pregnant women and present in three studies within the group of
non-pregnant women. Overall the pregnant group had a signiﬁcantly lower
uterine pulsatility index when compared with the non-pregnant group
[WMD -0.14; 95% conﬁdence interval (CI): -0.22,-0.06; p = 0.000; 29 stud-
ies]. Pulsatility index measurements taken within a day of embryo transfer
most reliably correlated with the primary outcome after assisted conception
[WMD -0.18, 95% CI 0.26, -0.10); p = 0.065; 10 studies), however this
could be due to chance. There was a high degree of heterogeneity (I2 =
44%).
Limitations, reasons for caution: There was signiﬁcant heterogeneity
between studies, with variation in population characteristics and the treatment
protocols given to participants. Using the Newcastle-Ottawa scale for assessing
quality, the included studies were considered “satisfactory”.
Wider implications of the ﬁndings: This review suggests that women with
a lower uterine pulsatility index are more likely to achieve pregnancy, after
assisted conception. Further research is required to determine whether there is
a cut-off pulsatility index above which pregnancy is not possible and to deter-
mine the most reliable test of endometrial vascularity.
Trial registration number: CRD42017059529
P-393 Comparison of Cap-Score™, TUNEL, and semen analysis in
couples undergoing timed intercourse and IUI
P. Xie1, A. Parrella1, A. Travis2, D. Keating1, Z. Rosenwaks1,
G. Palermo1
1Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
2Cornell University, College of Veterinary Medicine, Ithaca, U.S.A.
Study question: What relationships exist among Cap-Score™ (test of sperm
capacitation), TUNEL (test of DNA fragmentation) and traditional semen ana-
lysis parameters?
Summary answer: Cap-Score™ didn’t correlate with semen analysis or
TUNEL. However, TUNEL had a strong negative correlation with motility,
making determination of cause of fertilization failure difﬁcult.
What is known already: High sperm DNA fragmentation and diminished
capacitation response may impair conception with timed intercourse or intra-
uterine insemination (IUI). Terminal deoxynucleotidyl transferase dUTP Nick
End Labeling (TUNEL) is widely used to assess breaks within sperm DNA. Cap-
ScoreÔ measures the proportion of sperm that respond to capacitation stimuli
by assessing localization changes in GM1, a key regulator of capacitation and
acrosome exocytosis. One prior study showed no relationship between Cap-
Score™ and semen analysis, whereas multiple conﬂicting reports exist on the
relationship of TUNEL and semen analysis. No one has previously assessed the
potential correlation of Cap-Score™ and TUNEL.
Study design, size, duration: In the past 3 months, ejaculates were obtained
from 41 consenting men for infertility screening. Preliminary pregnancy out-
comes were also collected. Statistical relationships among semen analysis,
TUNEL and Cap-Score™ were assessed. Potential linear associations between
Cap-Score™ or TUNEL and traditional semen parameters were assessed by
Pearson’s Product-Moment Correlation. Any potential relationship between
TUNEL and Cap-Score™ was evaluated similarly, and “normal vs abnormal”
Cap-Score™ and TUNEL were examined by Chi-Square.
Participants/materials, setting, methods: To control for female con-
founding factors, inclusion criteria consisted of couples with female partners ≤
35 years old with normal uterine cavity and patent fallopian tubes. Semen sam-
ples were processed by density gradient centrifugation according to WHO 2010
criteria. Post-wash specimens were sent to Androvia LifeSciences for Cap-
Score™ assessment. Cap-Scores™ ≥27.6% were considered “normal”. DNA
strand breaks were assessed by TUNEL on at least 500 spermatozoa under
ﬂuorescent microscopy. TUNEL scores £15% were considered “normal”.
Main results and the role of chance: Cap-Score™ was independent of
ejaculate volume (r = 0.075; p = 0.571), concentration (r=-0.032; p = 0.810),
percentage of motile sperm (r = 0.005; p = 0.967) and percentage of sperm hav-
ing strict normal morphology (r = 0.010; p = 0.942). No relationship was
observed between Cap-Score™ and TUNEL, either linearly (r=-0.091; p =
0.571), or when grouped into normal or abnormal bins and evaluated by Chi-
Square (p = 0.524). Conversely, a very strong negative relationship was observed
between TUNEL and the percentage of motile sperm (r=-0.930; p<0.001), mean-
ing that as DNA fragmentation increased, motility decreased. Of the 41 men,
TUNEL was abnormal in 11 (26.8%) and Cap-Score was abnormal in 19 (46.3%).
In the 11 patients with abnormal TUNEL (mean = 24.1), no natural conceptions
were yet reported, nor in the 2 cycles of IUI for which outcomes are known. Of
the 30 having normal TUNEL, there were 3 natural conceptions and 5 concep-
tions out of 9 cycles of IUI for which outcomes are known. In the 22 men having
normal Cap-Scores™, 3 natural conceptions occurred, whereas none occurred in
the 19 men with low Cap-Scores™. In couples pursuing IUI with normal Cap-
Scores™, there were 3 pregnancies out of 6 cycles for which outcomes are
known; 2 of 5 cycles with a low result achieved pregnancy with IUI.
Limitations, reasons for caution: These data clearly indicate that the ability
of the sperm to capacitate does not correlate with sperm DNA strand breaks.
Clinical outcomes represent preliminary data from a limited number of couples.
More clinical outcomes data are needed to determine the efﬁcacy of either test
at predicting conception by different means.
Wider implications of the ﬁndings: This is the ﬁrst report showing that
Cap-Score™ and DNA fragmentation are not related. As assessed by TUNEL,
high DNA fragmentation correlated with decreasing motility. To better test and
inform infertile couples, the addition of proven biomarkers to the standard
semen analysis would help to identify those who can conceive.
Trial registration number:N/A.
P-394 A novel maternal age and blastocyst cohort size-based
prediction model estimating the probability of obtaining at least one
euploid blastocyst for transfer in IVF/ICSI cycles
S. Esteves1, J.F. Carvalho2, C. Martinhago3, A.M. Dias3,
P. Humaidan4, C. Alviggi5, A. Conforti5, F. Ubaldi6, R. Fischer7,
K. Bühler8, C.Y. Andersen9
1Androfert - Center for Male Reproduction, Male Infertility, Campinas, Brazil
2Statistika Consulting, Statistics, Campinas, Brazil
3Chromosome, Center for Genomic Medicine, São Paulo, Brazil
4Faculty of Health- Aarhus University, Fertility Clinic Skive- Skive Regional Hospital,
Skive, Denmark
5University of Naples Federico II, Department of Neuroscience- Reproductive Science
and Odontostomatology, Naples, Italy
6GENERA, Center for Reproductive Medicine, Rome, Italy
7Fertility Center, Hamburg, Hamburg, Germany
8Center for Gynecology- Endocrinology, and Reproductive Medicine, Stuttgart,
Germany
9University Hospital of Copenhagen- Faculty of Health and Medical Sciences,
Laboratory of Reproductive Biology, Copenhagen, Denmark
Study question: Can a statistical prediction model estimate the probability of
achieving at least one euploid blastocyst as a function of female age and embryo
cohort size?
Summary answer: Our novel predictive model estimates the minimum
blastocyst cohort size needed to achieve at least one euploid blastocyst for
transfer given a speciﬁed probability.
What is known already: Array comparative genomic hybridization data
indicate a negative correlation between female age and embryo euploidy.
Aneuploidy rates do not differ signiﬁcantly by cohort size in women of
same age, and the proportion of women with at least one euploid blasto-
cyst is increased when more embryos are available. An individualized esti-
mate of the couple’s probability of having a euploid blastocyst and the
number of blastocysts needed to achieve this goal before treatment can be
used for counseling and treatment planning. Also, estimation of this
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probability after the embryos are generated may aid doctors to set patient
expectations.
Study design, size, duration: Retrospective analysis of 1,220 trophecto-
derm biopsy results from 436 infertile couples undergoing assisted reproductive
technology (ART) cycles and preimplantation genetic testing for aneuploidy
(PGT-A) between 2016 and 2017. PGT-A was used for reasons of advanced
maternal age, severe male factor infertility, recurrent miscarriage, repeated
implantation failure, as well as patients who were concerned about the euploidy
status of their embryos.
Participants/materials, setting, methods: Biopsied trophectoderm cells
were subjected to next-generation sequencing (NGS) analysis using the Ion
PGM™ platform. Logistic regression was ﬁt to the dataset, with female age as
the predictor and the status of the embryos (euploid or aneuploid) as the
response. The best model was chosen and validated by randomly splitting two
portions of the data, 80% for training and the remaining 20% for testing.
Computations were carried out using JMP 13 (www.jmp.com).
Main results and the role of chance: Given a blastocyst cohort, the num-
ber of euploid blastocysts (M) is a random variable with a binomial distribu-
tion. The quadratic model on female age was signiﬁcant (Prob>ChiSquare
= 0.028). A model-independent veriﬁcation by aggregating the data in age
bins revealed that the estimated probability distribution was veriﬁed in the
validation dataset. The model was not biased as there was linearity in the
relationship between the ﬁtted probabilities and empirical data. The min-
imum number of blastocysts needed for obtaining at least one euploid
blastocyst for transfer can be computed for different probabilities. At the
age of 28 years, the model estimates that a total of three blastocysts is
required to obtain at least one euploid blastocyst with 90% probability,
whereas it is 4, 5, 6, 9, 16 and 29 for ages 35, 37, 39, 41, 43, and 45,
respectively. Furthermore, an embryo cohort size of 2, 3, 5, 7, and 11 are
required to obtain at least one euploid blastocyst with 80% probability for
ages 28, 35, 39, 41, and 43, respectively.
Limitations, reasons for caution: External validation is currently being per-
formed. Other covariates that could affect embryo genetic status were not ana-
lyzed. Furthermore, the model is not intended to be generalized to IVF patients
undergoing cleavage-stage embryo transfer and should not be used for making
decisions about whether or not patients should undergo treatment.
Wider implications of the ﬁndings: This novel resource will aid clinicians
counsel and plan treatment of couples regarding the embryo cohort size
needed to obtain at least one euploid blastocyst for transfer.
Trial registration number:Not applicable.
P-395 Women with polycystic ovary syndrome are at increased
risk of postnatal depression
M. Davies,W. March, M.Whitrow, R. Fernandez, V. Moore
The University of Adelaide, The Robinson Institute, Adelaide, Australia
Study question: Are women with polycystic ovary syndrome (PCOS) at ele-
vated risk for postnatal depression (PND)?
Summary answer: For women with PCOS, a history of miscarriage and
assisted conception interacted (p = 0.06 and p < 0.05, respectively), with 56%
having PND.
What is known already: Maternal depression associated with pregnancy and
childbirth, known as postnatal depression (PND), is a debilitating condition that
can have a signiﬁcant impact on the health and wellbeing of the woman, her
child and her wider family. PND is likely to be under-diagnosed but is estimated
to affect 10-20% of mothers in western countries.
Women with PCOS have increased susceptibility to depression and anxiety,
which is an identiﬁed risk factor for PND. The potential for a link between
PCOS and PND has not previously been published.
Study design, size, duration: The Lucina study is a community based retro-
spective birth cohort of female births from 1973-75 at a single maternity hos-
pital in Adelaide, South Australia. Participants were traced and enrolled at age
30-31, with n = 566 providing data for the current study.
Participants/materials, setting, methods: Details of reproductive history,
pregnancy, birth, and PND were obtained through structured face to face inter-
view with study participants. PCOS was diagnosed using the Rotterdam criteria.
Comparisons were made between women with and without PCOS using logis-
tic regression analysis including the investigation of interactions.
Main results and the role of chance: Compared to their counterparts,
women with PCOS were substantially more likely to have difﬁculty conceiving
(OR = 5.2, 95% CI 2.9-9.4), to have conceived with medical assistance (OR =
11.6, 95% CI 5.5-24.4), and to have pregnancy complications (gestational dia-
betes, pregnancy-induced hypertension, or pre-eclampsia, OR = 2.0, 95% CI
1.1-3.5). A positive but statistically non-signiﬁcant association was observed
between PCOS and PND (OR = 1.6, 95% CI 0.9-2.9) for the overall group.
However, where women with PCOS had a history of miscarriage or conceived
with medical assistance, the combination interacted (p = 0.06 and p < 0.05,
respectively), with 56% of these women having PND.
Limitations, reasons for caution: Susceptibility to PND for women with
PCOS could be due to either their perturbed hormonal and metabolic proﬁles,
or to distress created by PCOS symptoms and their management. Due to lim-
itations in power, the study was not able to calculate risks for speciﬁc PCOS
sub-phenotypes or treatments received.
Wider implications of the ﬁndings: As the ﬁrst study to investigate post-
natal depression (PND) in women with polycystic ovary syndrome, ﬁndings
point to vulnerability inherent in PCOS being ampliﬁed, or by speciﬁc fertility
treatment regimens. This highlights a potential need for targeted postnatal
follow-up of women with PCOS.
Trial registration number:Not applicable.
P-396 Comparison of the treatment outcomes in women with
unicornuate uterus undergoing ART versus controls with normal
uterine anatomy: a nested case-control retrospective analysis
Y. Chen1, V. Nisenblat2, C. Ma2
1Peking University Third Hospital, 49 North Garden Rd.-Haidian District Beijing -P.R.
China, Beijing, China
2Peking University Third Hospital, Center of Reproductive Medicine- Department
Obstetrics and Gynecology, Beijing, China
Study question: Are the ART outcomes different in women with unicornuate
compared to normal uterus and whether culture to blastocyst improves the
outcomes in unicornuate uterus group?
Summary answer: In unicornuate uterus implantation rate following fresh
embryo transfer and cumulative live-birth rate are lower than in normal uterus.
Blastocyst transfer signiﬁcantly improved clinical outcomes.
What is known already: Unicornuate uterus have been associated with a
decreased risk of obstetrics complications with lower birth rate, mainly due to
an increased risk of miscarriage and very preterm birth. It remains unclear,
whether women with unicornuate uterus who undergo IVF-ICSI have different
response to ovarian stimulation and whether implantation and pregnancy rates
in these women are different from those in women with normal uterus.
Study design, size, duration: A retrospective nested case-control study
was conducted at the Reproductive Medical Center of Peking University Third
Hospital. The participants were recruited from the cohort of women who
underwent IVF-ICSI cycles between 2012 and 2016, identiﬁed by using centra-
lized computer database. Consecutive women diagnosed with unicornuate
uterus and randomly selected controls with normal uterus were included. The
controls were matched 1:3 by age, cause of infertility and number of embryos
transferred.
Participants/materials, setting, methods: The study population com-
prised 342 women with unicornuate uterus (study group) and 1026 patients
with normal uterus (control group). Demographic and clinical information was
retrieved from the electronic records. Cumulative live birth rate upon one com-
plete IVF cycle, including all resulting embryos was considered as a primary out-
come measure. Other outcomes included number of oocytes retrieved,
endometrial thickness, implantation rate, number of embryos obtained, clinical
pregnancy, multifetal gestation, miscarriage rate.
Main results and the role of chance: The demographic characteristics, dur-
ation and causes of infertility were comparable between the groups. There was
higher rate of primary infertility in unicornuate uterus group. Unicornuate
uterus was associated with signiﬁcantly lower endometrial thickness on day of
hCG (p<0.001) and lower number of oocytes retrieved (p = 0.016), although
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peak E2 levels did not differ between the groups. The number of embryos
transferred per cycle, day-3 or blastocysts was similar between the study and
control groups. Transfer of day-3 embryos in fresh cycle was associated with
lower implantation rate (23.7% vs. 32.5%, p<0.001) and lower live-birth rate
(26.9% vs. 34.4%, p = 0.031) per transfer. On contrast, frozen embryo transfer
(FET) of day-3 embryos did not result in different implantation and live birth
rate between the groups (p = 0.288 and p = 0.686, respectively). Blastocyst
transfer led to comparable rates of implantation and live birth between the two
groups in either fresh and frozen cycles. The cumulative live birth rate following
one complete IVF-ICSI cycle including all the resulting FET was 42.4% in women
with unicornuate uterus vs. 52.8%; p = 0.001 in controls. Subgroup analysis
revealed that blastocyst transfer in women with unicornuate uterus led to sig-
niﬁcantly higher live birth rate than cleavage transfer (40% vs. 53%, p = 0.045).
Limitations, reasons for caution: Retrospective nature and no information
on the obstetrics and neonatal outcomes are the main limitations of this study.
Not all women treated in 2016 utilized their available embryos from the index
stimulation cycle and were not included in estimation of cumulative live birth
rate.
Wider implications of the ﬁndings: Lower implantation and pregnancy
rates following fresh but not frozen cleavage embryo transfers and signiﬁcantly
improved outcomes with blastocyst culture were observed in unicornuate com-
pared to normal uterus. This suggests considering blastocyst transfer or freeze
all policy in women with unicornuate uterus, which warrants evaluation in pro-
spective randomized setting.
Trial registration number: not applicable.
P-397 Should couples with low sperm count in the ﬁrst
intrauterine insemination (IUI) cycle continue IUI treatment?
S. Huang1, R.Wang2, R. Li3, H.Wang4, B.W.J. Mol5, J. Qiao6
1Center of Reproductive Medicine- the Third Hospital of Peking University,
Department of Obstetrics and Gynecology, Beijing, China
2Robinson Research Institute, Department of Obstetrics and Gynaecology, Adelaide,
Australia
3Centre of Reproductive Medicine- Peking University Third Hospital-, - Department of
Obstetrics and Gynaecology-, Beijing, China
4Centre of Reproductive Medicine- Peking University Third Hospital-, Department of
Obstetrics and Gynaecology, Beijing, China
5Monash Medical Centre- Monash Health and Monash University, Department of
Obstetrics and Gynaecology, Clayton, Australia
6Centre of Reproductive Medicine- Peking University Third Hospital, Department of
Obstetrics and Gynaecology, Beijing, China
Study question: Should couples with low post-wash total motile count
(TMC) in the ﬁrst intrauterine insemination (IUI) cycle continue IUI treatment?
Summary answer: Couples with low post-wash TMC in the ﬁrst IUI cycles
can continue IUI treatment without compromising their fertility outcomes.
What is known already: IUI is the treatment of ﬁrst choice for couples with
unexplained or mild male infertility. The post-wash TMC in the ﬁrst IUI cycle can be
used to predict pregnancy, and at present many couples switch to IVF after a ﬁrst
poor post-wash semen analysis. However, it is unknown if a poor post-wash TMC
in the ﬁrst IUI cycle is predictive for future IUI outcomes. To study the association
between post-wash TMC and outcomes of future IUI cycles, we compared live
birth rates in women undergoing IUI in relation to their post-wash semen analysis.
Study design, size, duration: We performed a retrospective cohort study
in the Reproductive Medicine Centre of Peking University Third Hospital.
Participants/materials, setting, methods: We included couples with
unexplained or mild male infertility treated with IUI in two consecutive cycles
with similar protocols. Women with polycystic ovary syndrome were not
included. We compared live birth rates in the second cycle according to differ-
ent groups in post-wash TMC in the ﬁrst cycle.We also compared the baseline
characteristics and clinical pregnancy between groups with different post-wash
TMC. ANOVA and Chi square analysis were conducted in SPSS 19.0.
Main results and the role of chance:We studied 4,496 IUI cycles in 2,248
couples, of which 2,732 were unstimulated cycles and 1,764 were cycles stimu-
lated with CC, letrozole or gonadotropins. We sorted data according to their
post-wash TMC in the ﬁrst cycle in ascending order and then divided all patients
into eight equal groups. Medians of sperm count were 0.6, 1.3, 2, 3, 4, 5, 7, and
13. Live birth rates in the second cycle were 6.1%, 6.4%, 7.5%, 8.9%, 6.1%,
7.8%, 6.1%, and 7.5%, respectively. Likelihood ratios for various categories of
the post wash TMC varied between 0.68 and 1.41, with most likelihood ratios
being close to 1, indicating no predictive performance of the post-wash TMC in
the ﬁrst cycle for subsequent pregnancies.
Limitations, reasons for caution: Our study was retrospective, and we
included only cycles in which the insemination was performed.
Wider implications of the ﬁndings: Our study shows that in couples trea-
ted with IUI, the post-wash semen analysis should not be used to select women
who should continue IUI or switch to IVF.
Trial registration number:Not applicable.
P-398 Prediction models for IUI success incorporating male age
are more accurate among older women
K. Shlush1, J. Julia2, S. Moskovtsev2, L. CliffordLibrach2
1Rabin Medical Center Petah Tikva- Israel., OBGYN, Herzliy, Israel
2CReATe Fertility Centre, IVF unit, Downtown Toronto, Canada
Study question: What factors are important to predict who will not beneﬁt
from IUI and who should be recommended for IVF directly.
Summary answer:We identiﬁed clinical and laboratory parameters that pre-
dicted a low probability for pregnancy with IUI. These are patients who should
be move directly to IVF.
What is known already: The decision of which assisted reproductive technol-
ogy (ART) method is most suitable for speciﬁc subfertile couples is complicated.
Intrauterine insemination (IUI) with or without ovulation induction is commonly
offered to subfertile couples without bilateral mechanical factor or severe male
factor. On average after three to six IUI cycles without pregnancy, couples will be
recommended to undergo IVF. IUI success rate predictors have been suggested
to be moderately accurate in the past, however older studies did not include
ovarian reserve parameters and modern male factor parameters.
Study design, size, duration: In the current study we evaluated the predict-
ive capacity of different parameters in predicting IUI success, and constructed a
generalized linear regression model (LRM). A total of 467 patients (1342 IUI
cycles) were studied retrospectively.
Participants/materials, setting, methods: Clinical and laboratory para-
meters signiﬁcantly different between patients with clinical pregnancy and with-
out clinical pregnancy were identiﬁed. The following parameters were
signiﬁcantly different: male age, duration of infertility, AMH, antral follicle count
(AFC), DNA fragmentation index (DFI), number of follicles and E2 levels at
HCG trigger, and total motile sperm count (TMC). These parameters were
used to construct a two-step predictive model.
Main results and the role of chance: Our prediction model was able to
identify couples with low probability for pregnancy upfront (less than 5%
chance) that should be referred directly to IVF without any IUI cycle. This pre-
diction could have saved going through failed IUI for 20.5% of patients. Later
after the ﬁrst IUI cycle a second predictive score was calculated and identiﬁed
couples with low pregnancy probability who should be referred to IVF after one
IUI cycle (26% of patients). Our predictive model was most accurate for
females older than 40 years old (AUC = 0.775), with number of follicles before
HCG trigger, male age, and DFI being the most important factors.
Limitations, reasons for caution: This is a single center retrospective study
that should be validated prospectively.
Wider implications of the ﬁndings: Altogether, based on these results we
conclude that after the ﬁrst IUI cycle a predictive score can be calculated.
Couples with a low score (pregnancy probability <5%) should be referred to IVF.
Trial registration number: REB #20120043-E.
P-399 Fresh or vitriﬁed: comparing the number of oocytes
necessary to achieve reproductive success in egg donation
programme
H. Visnova, R. Huttelova
IVF CUBE, Reproductive Medicine, Prague 6, Czech Republic
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Study question: Does egg banking provide comparable outcome to fresh egg
donation cycles, what are the oocyte-to-blastocyst and oocyte-to-baby rates
per fresh and vitriﬁed oocyte?
Summary answer: Compared to vitriﬁed, fresh oocytes gain more available
blastocysts, higher implantation rates and more babies born, higher number of
surplus blastocysts increases cumulative success rate.
What is known already: Vitriﬁcation of oocytes represents an effective
method resulting in pregnancy rates per embryotransfer similar to usage of
fresh oocytes. Vitriﬁcation and banking of oocytes offers an advantage for both
clinics and recipients in terms of management, timing and lesser treatment can-
celations. However, due to losses during warming and fertilization failures, the
number of available blastocysts declines. Metric methods calculating success
rates per oocyte provide more accurate picture of the biological efﬁciency than
standard pregnancy rate per embryotransfer. According to available data, the
live birth rate per fresh donated oocytes, even with the best-prognosis group of
young donors, is only 7.3%.
Study design, size, duration: A retrospective comparative analysis of 266
fresh egg donation cycles and 63 cycles using vitriﬁed donor oocytes performed
from January 2016 to December 2016.
Comparison parameters included age of oocyte donors, age of recipients,
total gonadotrophin dose and average duration of stimulation. Total oocyte
number and number of metaphase II oocytes, survival rate, fertilization rate,
blastocyst rate, implantation rate and ongoing pregnancy rates per ET and per
oocyte were calculated.
Participants/materials, setting, methods: All donors underwent gonado-
trophin stimulation in antagonist protocol. Antagonist administration was
initiated from day 6 of stimulation. GnRH-a (triptorelin 0.2) was used as a trig-
ger and egg collection was performed 35–36 hours later. Oocytes were vitriﬁed
using Sage media and closed system. Both fresh and warmed oocytes were inse-
minated using ICSI. Both groups of fertilized oocytes underwent identical cul-
ture and handling conditions.
Main results and the role of chance: There was no statistically signiﬁcant
difference noted for age of donors, body weight or BMI, nor total gonado-
trophin dose, duration of stimulation, no difference in age of recipients between
both groups. There was no difference observed in terms of fresh oocytes and
vitriﬁed oocytes per recipient’s treatment cycle (10,89 ± 2,00 vs 11,36 ± 3,14,
p = 0,14).
Fertilization rate of fresh oocytes was higher (84,81% vs 72,97%, p<0,001),
we have achieved signiﬁcantly higher oocyte-to-blastocyst rate (32,11% vs
13,36%, p<0,001), Signiﬁcantly higher numbers of fresh oocytes (6,11% vs
5,07%, p<0,001) increased implantation and live birth rate, oocyte-to-baby rate
for fresh oocytes was 5,81% compared to 3,76%, p<0,001.
Average number of blastocyst per embryotransfer was 1,56 ± 0,56 for fresh
oocytes and 0,81 ± 0,79 for vitriﬁed ones, p<0,001. Pregnancy rate of 68,05%
was signiﬁcantly higher for fresh oocytes in comparison to 42,86% pregnancy
rate for cycles using vitriﬁed eggs (p<0,001).
Signiﬁcantly higher number of surplus blastocysts per treatment cycle (1,93
± 1,82 vs 0,60 ± 1,19, p<0,001) favors fresh vs frozen oocytes. Cumulative
chance of reproductive success was estimated. If all available surplus blastocyst
were used in the future and resulted to similar pregnancy rates, hypothetical
cumulative oocyte-to-baby rate for fresh eggs would be 13,06% vs 6,87% for
vitriﬁed, p<0,001
Limitations, reasons for caution: Our results might be biased by legally
enforced usage of close system for vitriﬁcation as majority of studies have
included open vitriﬁcation systems. Contrary to published results, we have not
conﬁrmed the number of 8–10 vitriﬁed eggs per ongoing pregnancy.
Cumulative chance of success was based only on hypothetical estimation.
Wider implications of the ﬁndings: We assert that oocyte-to-blastocyst
and oocyte-to-baby rates offer more equal methods for evaluating fresh and
frozen egg donation programmes. Such data are easily interpreted to patients
and help to understand better the efﬁcacy of egg banking compared to fresh
donation programmes from perspective of providers and patients.
Trial registration number: not applicable.
P-400 Odds and predictors for achieving successful pregnancy at
two years follow-up in a cohort of treated and untreated subfertile
couples in a secondary care hospital
S. Owen1, P. Dube2, S. Amer2, B. Shah2, K. Jayaprakasan1,2
1University of Nottingham, School of Medicine, Nottingham, United Kingdom
2Royal Derby Hospital, Derby Fertility, Derby, United Kingdom
Study question: To estimate the chances of achieving live birth/ongoing preg-
nancy beyond twenty weeks for couples within two years and determine pre-
dictive factors for a successful pregnancy.
Summary answer: 60% in treated and 35% in the untreated cohorts achieved
successful pregnancy in two years. Age and duration of subfertility were the
most signiﬁcant predictors.
What is known already: With fertility declining globally, more couples are
seeking fertility treatment. Initial clinic investigation is key to determine the
cause and future treatment regimen. A large cohort study across all UK in-vitro
fertilisation (IVF) clinics identiﬁed key factors predicting success in assisted
reproductive technology were younger maternal age and shorter duration of
subfertility, with younger women being 66% more likely to achieve success.
Reduced ovarian reserve, the primary measure of which is age, causes signiﬁ-
cantly decreased rates of treatment success. National statistics state that live
birth rates following IVF and IUI treatment for women under 35 is 32% and
13% respectively.
Study design, size, duration: This observational cohort study evaluated all
newly referred patients to a secondary care hospital Fertility Clinic of the UK
between January 2013 and December 2015. These patients were followed up
for 2 years using electronic records. This included 1257 couples, 1142 of which
matched inclusion criteria and 1136 of whom were suitable for analysis.
Participants/materials, setting, methods: Inclusion criteria were hetero-
sexual couples, with no prior fertility treatment. 677 patients were offered
treatment based on the National Health Service (NHS) funding criteria. Data
collected from electronic records was collated onto an excel database.
Statistical analysis was carried out using IBM SPSS, reporting the median (IQR)
as the data were skewed. MannWhitney U Test or Chi Square Test and logistic
regression analysis were done as appropriate.
Main results and the role of chance: The overall success rate was 50%
among women who were referred. Patients offered treatment (N = 677)
achieved 60% success, compared to 35% in untreated patients (N = 459).
Across treated patients, those successful were younger (Median (IQR) = 31
(28-34) vs 32 (29-36), P<0.05), had higher rates of primary infertility (86.8% vs
80.6%, P<0.05) and shorter duration of subfertility (P = 0.001). Univariate
regression analysis (OR, 95% CI) showed that younger patients (0.95, 0.92-
0.98) with a reduced duration of subfertility (0.82, 0.75-0.91), and suffering
from primary infertility (1.58, 1.04-2.40) were most successful. Anti-Mullerian
Hormone (AMH) and Follicle Stimulating Hormone (FSH) levels were not pre-
dictive of successful outcome. Multivariate analysis (OR, 95% CI) showed that
age (0.95, 0.90-0.99), duration of subfertility (0.85, 0.75-0.95) and primary
infertility (2.03, 1.10-3.72) were still signiﬁcant factors after adjusting for con-
founders. The most common cause was unexplained (44%), the least common
was uterine factors (1.4%). The best success rates were with ovulatory cause
(58%), the worst was uterine factors (25%). While 49% of successful outcomes
were following IVF, ovulation induction, intrauterine insemination and spontan-
eous conception contributed to the success by 24%, 19% and 7.8%
respectively.
Limitations, reasons for caution: While data of the treated patients were
robust, some of the untreated patients may have been followed up for treat-
ment elsewhere. Although difﬁcult to quantify, this number is assumed to be
low because of adherence to local patient referral pathways.
Wider implications of the ﬁndings: This study provides realistic chances of
success for subfertile couples within two years and demonstrates that age and
duration of subfertility are the most signiﬁcant baseline predictors in achieving
live birth/ongoing pregnancy at two years. These results are useful to explain
success rates and counselling couples seeking fertility treatment.
Trial registration number:Not Applicable.
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P-401 Oocytes quality in women with thalassaemia major
L. Mensi1, M. Reschini2, R. Borroni3, E. Cassinerio4, M.D. Cappellini5,
E. Somigliana6
1Università degli Studi di Milano- Via. Festa del Perdono- 7 20122 Milano- Milan-
Italy, Obstetric and Gynecology Department- Fondazione Ca’ Granda- Ospedale
Maggiore Policlinico- Via M Fanti- 6- Milan 20122- Italy., Milan, Italy
2Università degli Studi di Milano- Via. Festa del Perdono- 7 20122 Milano- Milan-
Italy, Infertility Unit- Fondazione Ca’ Granda- Ospedale Maggiore Policlinico- Via M
Fanti- 6- Milan 20122- Italy., Milan, Italy
3Fondazione Ca’ Granda- Ospedale Maggiore Policlinico- Via M Fanti- 6- Milan
20122- Italy.- Milan- Italy., Infertility Unit- Fondazione Ca’ Granda- Ospedale
Maggiore Policlinico- Via M Fanti- 6- Milan 20122- Italy.- Milan- Italy., Milan, Italy
4Università degli Studi di Milano- Via. Festa del Perdono- 7 20122 Milano- Milan-
Italy, Centre for rare diseases - Fondazione Ca’ Granda - Ospedale Maggiore
Policlinico- Milan- Italy, Milan, Italy
5Università degli Studi di Milano- Via. Festa del Perdono- 7 20122 Milano- Milan-
Italy, Department of Internal Medicine- Universita’ di Milano- Ca Granda Foundation-
IRCCS- Milano- Italy., Milan, Italy
6Università degli Studi di Milano- Via. Festa del Perdono- 7 20122 Milano- Milan-
Italy, Obstetrics and Gynecology Department- Fondazione Ca’ Granda- Ospedale
Maggiore Policlinico- Via M Fanti- 6- Milan 20122- Italy., Milan, Italy
Study question: Is the quality of the oocytes affected in women with thalas-
saemia major undergoing IVF-ICSI cycles?
Summary answer: The quality of oocytes obtained from women with thalas-
saemia major is not affected.
What is known already: Women with thalassaemia major commonly face
reproductive disorders. The iron overload that is consequent to the lifelong
transfusional therapy typically produces a toxic effect on the anterior pituitary,
leading to hypogonadotropic hypogonadism, a condition that can be overcome
with exogenous gonadotropins. However, recent studies showed that affected
women have also reduced levels of AMH and AFC, suggesting that ovarian
reserve may be damaged. Moreover, the elevated peripheral levels of free iron
may directly harm the quality of primordial follicles and could perturb folliculo-
genesis. Evidence to support a detrimental effect on oocytes quality is however
lacking.
Study design, size, duration: A retrospective case-control study was con-
ducted in women with thalassaemia major referred to our infertility unit
between January 2008 and December 2017 and undergoing at least one IVF or
ICSI cycle. Controls were matched to cases in a 5:1 ratio by age and study peri-
od. Both cases and controls were included only for the ﬁrst treatment cycle.
Participants/materials, setting, methods: Thirty-ﬁve infertile women
with thalassaemia major were referred during the study period, of whom 21
(60%) underwent IVF-ICSI. These 21 cases were matched to 105 controls.
Participants underwent IVF-ICSI according the local standardized protocols.
Compared to controls, cases also received LH in a 1:2 ratio compared to FSH.
The primary outcome was the proportion of top quality embryos per oocytes
used.
Main results and the role of chance: The baseline clinical characteristics of
the two study groups did not signiﬁcantly differ, with the exception of serum
AMH and AFC which were signiﬁcantly lower among women affected. The
medians (Interquartile-IQR) in cases and controls were 0.6 (0.2-1.8) and 1.5
(0.7-3.5) ng/ml (p = 0.05) and 4 (1-7.5) and 11 (5.5-16) (p<0.001),
respectively.
Considering the IVF-ICSI cycle, despite the expected longer duration of
stimulation and higher total doses of gonadotropins used for cases, the number
of developed follicles and oocytes retrieved did not differ. Live births were 4
(19%) and 34 (32%), respectively (p = 0.30). Fertilization rate and cleavage rate
were even higher in women with thalassaemia major. The medians (IQR) in
cases and controls were 100% (76-100%) and 75% (50-100%) (p = 0.03) and
75% (39-100%) and 50% (29-64%) (p = 0.04), respectively. In contrast, the rate
of top quality embryos (the main outcome of the study) did not differ. The
median (IQR) was 20% (0-76%) and 25% (5-50%), respectively (p = 0.98).
Finally, we correlated serum ferritin and the duration of transfusional therapy
with the rate of top quality embryos but failed to detect any signiﬁcant
correlation.
Limitations, reasons for caution: Thalassaemia major is a rare condition
and the sample size is inevitably small: a type II error cannot be excluded for
some outcomes. Moreover, the primary outcome chosen is a surrogate marker
of oocytes quality. Live birth rate would be more informative but would require
a signiﬁcantly larger sample size.
Wider implications of the ﬁndings: Fertility preservation in young age is
not justiﬁed in affected women since the quality of the oocytes does not appear
to be compromised. This conclusion is also strengthened by the recent pro-
gresses of iron chelation therapies that can reduce the injury to the pituitary,
thus potentially consenting natural conception.
Trial registration number:Not applicable.
P-402 Freeze-all versus conventional approach in normal
responders: comparison of cumulative live birth in a multicenter
cohort study
C. Zaca’1, A. Bazzocchi2, G. Coticchio3, M.A. Bonu3, A. Borini4
1Tecnobios Procreazione, IVF laboratory unit, Bologna, Italy
29-Baby Family and fertility center, Reproductive medicine IVF, Bologna, Italy
39.baby Family and fertility center, IVF laboratory unit, Bologna, Italy
49.Baby Family and fertility center, Reproductive Medicine IVF, Bologna, Italy
Study question: Does freeze-all assure a better outcome in terms of cumula-
tive live birth rate (CLBR) in normal responder patients?
Summary answer: In the present analysis, freeze-all is not superior to the
conventional strategy in terms of CLBR.
What is known already: To date some studies have suggested that cryo-
preservation of the entire embryonic cohort derived from a single cycle is asso-
ciated with a higher live birth rate in selected patient categories, such as women
at risk of developing ovarian hyperstimulation syndrome (OHSS), patients
awaiting results of genetic tests or in cycles with supra-physiological levels of
estrogen and progesterone. Since the experience with freeze-all has been lim-
ited to selected typologies of patients, this approach should be tested in a wider
context in order to evaluate whether it can be proposed as the gold standard
for IVF treatments.
Study design, size, duration: This is a retrospective matched cohort study
involving completed IVF cycles conducted between 2012 and 2016, in 5 fertility
centres. Cycle data were analyzed according to approach (fresh cycle or freeze-
all) and then stratiﬁed according to the number of oocytes retrieved, age and
embryo transfer day.
Participants/materials, setting, methods: This study analysed 564 com-
pleted IVF cycles in which 12-18 oocytes were retrieved[1]. In 435 cycles the
conventional strategy was applied, involving ﬁrst transfer of fresh embryo(s) and
afterwards use of cryopreserved embryos; in 129 cycles the freeze all approach
was performed, with elective cryopreservation of all viable embryos. Only
patients who had transferred all available embryos and/or achieved a live birth,
were included.
Main results and the role of chance: Our analysis showed a higher CLBR,
but not statistically signiﬁcant, in the freeze-all group (53.5% vs 45.5%, p =
0.11). Data stratiﬁcation on the basis of age and number of oocytes retrieved
suggested a trend towards a higher CLBR in the freeze-all group, although again
in the absence statistical signiﬁcance. In the sub-analysis focusing on the day of
embryo transfer, no difference was found in the cleavage stage data segment,
whereas in cycles where embryo transfer was carried out at the blastocyst stage
the CLBR was signiﬁcantly higher in the freeze-all group (p<0.05).
Limitations, reasons for caution: Since this is a retrospective study, the
information obtained is based on previously recorded data. Consequently, cer-
tain parameters that could inﬂuence the outcome, such as BMI, markers of
ovarian reserve and others, were not included in the analysis.
Wider implications of the ﬁndings: Our analysis ofCLBRshows that the
freeze-all approach is not superior to the conventional strategy.However,its
performance appears at least as competitive as the conventional modality of
use of fresh and cryopreserved embryos.The statistically signiﬁcant difference in
CLBRin treatments where embryo transfer was carried out at the blastocyst
stage warrants further investigation.
Trial registration number:Not applicable.
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P-403 Atosiban Infusion (Oxytocin Receptor Antagonist) is
effective in improving the pregnancy outcome of Blastocyst
Transfer cycle in a Younger population (&lt;35 yrs)
R. Angik1, A. Chimote2, N. Chimote3, N. Chimote3
1Vaunshdhara Fertility Centre Pvt. Ltd., OBGYN, Nagpur, India
2Vaunshdhara Fertility Centre Pvt. Ltd., Obgy, Nagpur, India
3Vaunshdhara Fertility Centre Pvt. Ltd., Clinical Embryology, Nagpur, India
Study question: Is Atosiban Effective in reducing myometrial contraction dur-
ing Blastocyst transfer and improving pregnancy rate in a general population?
(18-45 yrs)
Summary answer: Atosiban is more effective in younger population of
women undergoing ART cycle (age<35 yrs)
What is known already: Implantation and pregnancy rates are inversely cor-
related with the frequency of uterine contractions. Supraphysiological concen-
tration of oestradiol following ovarian stimulation has been shown to increase
uterine contractility. Atosiban infusion prior to embryo transfer is known to
reduce the uterine contraction but its effectiveness in a particular subset of age
group is not known.
Study design, size, duration: This prospective non randomised study of
infertile women (n = 150) undergoing Blastocyst transfer divided into two
group A (Atosiban infusion) & B (no Atosiban) and further divided into sub-
groups of i (<35 yrs.) ii (>35 yrs.). Both groups received similar quality of
blastocyst & were evaluated for myometrial contraction and clinical pregnancy
rates by Transvaginal Ultrasound (TVS). Study was conducted between
December 2016 and December 2017 at our private ART clinic.
Participants/materials, setting, methods: Group A(n = 75) received
total dose of 22.5 mg atosiban in (100 ml Normal saline) @ 32 drops per min
half hour before Blastocyst transfer while Group B(n = 75) received no
Atosiban infusion. Group A evaluated for myometrial contraction (contraction
/2 min) before transfer and after infusion and group B evaluated before trans-
fer. Clinical pregnancy determined by presence of Foetal cardiac activity on TVS
in both the groups and subgroups.
Main results and the role of chance: women undergoing Blastocyst trans-
fer in group A and group B were subjected to student T test to determine the
pregnancy rates, a signiﬁcant difference was noted student t test p value 0.0013
between the two groups. A signiﬁcantly higher rate of pregnancy was noted in
subgroup i, student t test p value 0.0211. While there was no signiﬁcant differ-
ence in group ii student t test p Value 0.780 in. There was an extremely signiﬁ-
cant decrease in the myometrial contraction in group A as compared to group
B (p value <0.0001). Contingency analysis for group i (< 35 yrs) Fischer exact
test p value was 0.048(signiﬁcant), odds ratio 2.33, 95 % CI 1.001 to 5.7 sensi-
tivity 21.8 %, speciﬁcity 89.2 %, Positive predictive value (PPV) 70 %, Negative
predictive value (NPV) 50%, LR 2.04 while for group ii, Fischer exact test p
value was > 0.999( non-Signiﬁcant), odds ratio 1, 95 % CI 0.4002 – 2.499,
Sensitivity 10.7%, speciﬁcity 89.2 %, PPV 50%, NPV 50% likely hood ratio of 1.
Limitations, reasons for caution: This prospective non randomized study
has a small sample size which may cause bias in the Atosiban group hence a
multicentre randomized control trial with a large sample size with follow up till
delivery is to be done to determine the live birth rate and effectiveness of
Atosiban.
Wider implications of the ﬁndings: Atosiban used at the time of blastocyst
transfer in young age group(<35 yrs.) gives a favourable outcome in an ART
cycle as compared to older age group patients in terms of decreased myome-
trial contraction and higher clinical pregnancy rates.
Trial registration number: not applicable.
P-404 Application of seminal plasma to female genital tract prior
to embryo transfer in assisted reproductive technology cycles (IVF,
ICSI and frozen embryo transfer)
B. Ata1, A. Abou Setta2, A. Seyhan3,W. Buckett4
1Koc University, Obstetrics & Gynecology, Istanbul, Turkey
2University of Manitoba, Knowledge Synthesis Platform- George and Fay Yee Centre
for Healthcare Innovation-, Winnipeg, Canada
3American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey
4McGill University, Obstetrics and Gynecology, Montreal, Canada
Study question: Does application of seminal plasma (SP) to the female genital
tract prior to embryo transfer improve ART cycle outcome?
Summary answer: We found low quality evidence that SP application may
increase clinical pregnancy rate. There was insufﬁcient evidence for live birth or
ongoing pregnancy rates.
What is known already: The female genital tract is not exposed to SP during
standard assisted reproductive technology cycles. However, it is thought that
the inﬂammatory reaction triggered by SP may be beneﬁcial by inducing mater-
nal tolerance to paternal antigens expressed by the products of conception,
and may increase the chance of successful implantation and live birth. Studies
have revealed inconsistent results.
Study design, size, duration: Systematic review and meta-analysis of rando-
mised controlled trials (RCTs) comparing SP application versus no SP exposure
were identiﬁed from Cochrane Gynaecology and Fertility Group Specialised
Register of Controlled Trials, Cochrane Central Register of Studies Online,
MEDLINE, Embase, CINAHL and PsycINFO, trial registers for ongoing trials,
Web of Knowledge, OpenGrey, LILACS, PubMed, Google Scholar and the ref-
erence lists of relevant articles.
Participants/materials, setting, methods: Eleven RCTs (3215 women)
were included.
Main results and the role of chance: SP may increase clinical pregnancy
rates (RR 1.15, 95% CI 1.01 to 1.31; participants = 2768; studies = 10; I2 =
0%). If clinical pregnancy rate following standard ART is 22.0% it will be
between 22.2% and 28.8% with SP application.
SP application makes little or no difference in live birth rates (RR 1.10, 95%
CI 0.86 to 1.43; participants = 948; studies = 3; I2 = 0%). If the live birth rate
following standard ART is 19% it will be between 16% and 27% with SP
application.
SP application makes little or no difference in live birth or ongoing pregnancy
rates (RR 1.19, 95% CI 0.95 to 1.49; participants = 1178; studies = 4; I2 = 4%).
If the live birth or ongoing pregnancy rate following standard ART is 19.5% it
will be between 18.5% and 29% with SP application.
There was insufﬁcient evidence to determine whether there was a difference
in miscarriage rate between the groups (RR 1.01, 95% CI 0.57 to 1.79; partici-
pants = 1209; studies = 4; I2 = 0%). If the miscarriage rate following standard
ART is 3.7%, the miscarriage rate following SP application will be between 2.1%
and 6.6%.
Limitations, reasons for caution: The quality of the evidence ranged from
very low to low. The main limitations were risk of bias (associated with poor
reporting of allocation concealment and other methods) and imprecision for
the primary outcome of live birth rate.
Wider implications of the ﬁndings: We conclude that seminal plasma
application is worth further investigation, focusing on live birth and miscarriage
rates.
Trial registration number:N/A.
P-405 Reproductive strategy in young women with critical ovarian
reserve
G. Damiano1, E. Porcu1, L. Cipriani1, S. Rossi1, F. Fabbri1,
F. Sacilotto1, G.M. Cillo1, L. Notarangelo1, P.M. Ciotti1, N. Calza1,
L. Vaccarella2
1University of Bologna, Human Reproductive Medicine unit, Bologna, Italy
2University of Luigi Vanvitelli Naples, Human Repdroductive Medicine unit, Naples,
Italy
Study question: Is Assisted Reproductive Technology (ART) indicated in
young women aged ≤34 years old when ovarian reserve is critical?
Summary answer: After ART, the pregnancy rate in young patients with crit-
ical ovarian reserve (29.4%) is comparable to ≥35 years old women (30.7%)
with normal ovarian reserve.
What is known already: The ovarian reserve reﬂects the oocyte quality and
number. Anti-Müllerian hormone (AMH) and antral follicle count (AFC) are the
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best predictive markers of the ovarian reserve and constantly decrease with
age. AMH levels play a key role in the proper counselling of the infertile patients
and allow the clinician to elect a personalized controlled ovarian stimulation
(COS) protocol. AMH and AFC are the most important factor predicting ovar-
ian stimulation response based on retrieved oocytes number. Pregnancy rate
also depends on oocyte quality which is strictly related to age.
Study design, size, duration: Retrospective study: 2289 patients undergoing
a COS cycle at the University of Bologna infertility and IVF center, from 2011 to
2017. Two groups were considered: Group A with 833 women aged ≤34, and
group B with 1465 women aged ≥35. Both groups were divided based on AMH
levels into Critical Ovarian Reserve (COR) AMH ≤ 0.5 ng/ml, Diminished
Ovarian Reserve (DOR) AMH 0.5–1 ng/ml and Normal Ovarian Reserve
(NOR) AMH ≥ 1 ng/ml.
Participants/materials, setting, methods: In group A there were 208
(25%) patients with COR, 51(6.16%) patients with DOR and 574(68.9%)
patients with NOR. In group B there were 379(25.9%) patients with COR, 189
(12.9%) patients with DOR and 897(61.2%) patients with NOR. 3227 cycles of
COS were performed. Duration of stimulation, total amount of gonadotropins
used, number of retrieved oocytes, percentage of cycle cancellation and preg-
nancy rate were considered.
Main results and the role of chance: Patients of group A-COR compared
to group A-NOR had a longer stimulation (11.4 ± 3.4 days vs 10.7 ± 2.8 days,
p<0.0001) and a higher dose of gonadotropins used (2721 ± 1021 U.I. vs
1799 ± 927 U.I., p<0.0001). The number of retrieved oocytes decreases with
the reduction of AMH level (3.4 ± 2.2 A-COR vs 5.3 ± 3.6 A-DOR vs 7.8 ±
4.6 A-NOR, p<0.0001), whereas the percentage of cycle cancellation was high-
er in group A-COR compared to group A-NOR (12.2% vs 0.5%, p<0.0001).
The pregnancy rate in group A-COR was lower than in group A-NOR (29.4%
vs 42,3%, p<0.0001).
Pregnancy rate of group A-COR was higher than that of group B-COR
(29.4% vs 20,6% p<0.0001) but similar to that of group B-NOR (29.4% vs
30.7%, p=n.s.)
Limitations, reasons for caution: The scientiﬁc community has not deter-
mined a standardized cut off to deﬁne normal, diminished or critical ovarian
reserve. There is not a recognized method to dose AMH level, therefore is not
possible to compare values measured with different techniques. The cut-off
used in this study are based on literature review.
Wider implications of the ﬁndings: Despite critical ovarian reserve, young
patients seem to compensate the low number of oocytes with good quality
gametes resulting in a satisfactory pregnancy rate.
Trial registration number: \
P-406 Oocyte accumulation as a strategy to optimize clinical
outcomes in infertile poor ovarian responders meeting the Bologna
criteria: A real-life non-randomized prospective study
C. Herbemont1, S. Sarandi1, M. Comtet2, A. Seroka2, C. Vinolas2,
J. Calvo2, B. Dagher-Hayeck2, J. Boujenah3, I. Cedrin-Durnerin2,
M. Grynberg2, C. Sifer1
1Hôpital Jean Verdier, Histologie-Embryologie-Cytogénétique-Biologie de la
Reproduction-CECOS, Bondy, France
2Hôpital Jean Verdier, Medecine de la Reproduction, Bondy, France
3Hôpital Jean Verdier, Gynécologie-Obstétrique, Bondy, France
Study question: Does oocyte accumulation offer reasonable chances of preg-
nancy in infertile poor ovarian responders (PORs)?
Summary answer: Oocyte accumulation in PORs appears as a successful
strategy for both treating their infertility as well as while preserving their fertility
potential through embryo cryopreservation.
What is known already: In Assisted Reproductive Technology (ART),
chances of live birth are highly correlated to the number of retrieved oocytes.
PORs are particularly affected by this issue, since recent studies have set a
threshold of 3 oocytes as a predictive factor of live birth. Moreover, repeating
ART cycles in such patients represents a high risk of repeated failure, associated
to an elevated drop-out rate. Hence, the management of PORs remains quite
challenging, and the strategy of oocyte accumulation might constitute an
interesting option to optimize clinical outcomes in these patients. However,
data on this topic are still scarce.
Study design, size, duration: This single-center, prospective study has been
in progress since January 2014. A total of 40 infertile couples have been
enrolled in an oocyte accumulation program when female partner was diag-
nosed as POR according to Bologna criteria (2 out of the 3 following criteria:
<4 oocytes in a previous cycle, abnormal markers of ovarian reserve, age >40
years) associated to any other infertility cause (male, female or both).
Participants/materials, setting, methods: Enrollment in the program
required patients’ written informed consent. Metaphase-2 (M2) oocytes were
accumulated by vitriﬁcation during ≥1 controlled ovarian hyperstimulation cycle
(s) (n = 85 cycles). Then, all vitriﬁed oocytes were warmed and inseminated
using ICSI simultaneously with fresh M2-oocytes retrieved during a last cycle of
ovarian stimulation. Twenty-four couples underwent the whole procedure
(oocyte-vitriﬁcation cycles, followed by oocyte warming +/- simultaneous fresh
ICSI cycles). Biological and clinical outcomes of these cycles were analyzed.
Main results and the role of chance: Brieﬂy, median patients’ age was 36.0
years [28-42]. Their median serum AMH and FSH levels as well as antral follicle
count were 1.2 ng/mL [0.2-2.8], 7.6 IU/L [3.2-15], and 6 follicles [3-14],
respectively. Each couple underwent an average of 2.6 previous IVF/ICSI
attempts before entering our program of oocyte accumulation. During the
oocyte accumulation period, a mean of 2.3 cycles/couple (in total, 55 cycles)
were performed, leading to the vitriﬁcation of 6.2 M2-oocytes/couple (stand-
ard deviation (SD) = 3.0). A total of 149 M2 oocytes were warmed (survival
rate = 81.2%), and 121 M2-oocytes were micro-injected simultaneously with
81 fresh M2-oocytes (8.4 M2-oocytes injected/couple; SD = 4.6). Number of
oocytes retrieved, maturation, fertilization rates and embryo quality were com-
parable between oocyte accumulation and fresh cycles. So far, oocyte accumu-
lation strategy resulted in 23 embryo transfers (ET) (mean number of
transferred embryos = 2.4): 10 ET arose from warmed oocytes only (43.5%), 4
from fresh oocytes (17.4%) and 9 from both warmed and fresh oocytes
(39.1%). Furthermore, supernumerary embryos were cryopreserved for 10
couples (41.7%). Finally, clinical pregnancy rate (CPR) of 33.3%/cycle (8/24),
and cumulative CPR of 37.5%/cycle (9/24) were achieved. Interestingly, sur-
plus embryo cryopreservation was performed for 55.5% of pregnant patients
and only 33.3% of non-pregnant ones.
Limitations, reasons for caution: This preliminary study lacks statistical
power, and further investigations are required to conﬁrm the efﬁciency of
oocyte accumulation in the management of infertile PORs. Then, cost-
effectiveness issues will have to be considered.
Wider implications of the ﬁndings: This study highlighted acceptable CPR
for poor-prognosis patients. Thus, enrollment of infertile PORs in oocyte accu-
mulation programs might optimize their success rates. Moreover, this strategy
could offer an opportunity of fertility preservation for women whose ovarian
reserve is inexorably decreasing, and enhance their chances of achieving a sub-
sequent pregnancy.
Trial registration number:Not applicable.
P-407 Physical activity and sedentary time before and during
in vitro fertilization: a longitudinal study exploring the associations
with infertility treatment outcomes
D. Sõritsa1,3, S. Läänelaid2, E. Lätt4, N. Margit5, M. Jarek4,
J.H. Migueles6, A. Ehrenberg5, A. Sekavin5, A. Sõritsa3,
A. Salumets1.7, F.B. Ortega8,9, S. Altmäe9,10
1Competence Centre on Health Technologies, not applicable, Tartu, Estonia
2University of Tartu, Institute of Family Medicine and Public Health, Tartu, Estonia
3Elite Clinic, not applicable, Tartu, Estonia
4University of Tartu, Institute of Sport Sciences and Physiotherapy, Tartu, Estonia
5Tartu University Hospital’s, Women’s Clinic, Tartu, Estonia
6University of Granada, Department of Physical Education and Sports, Granada,
Spain
7University of Helsinki and Helsinki University Hospital, Department of Obstetrics
and Gynecology, Helsinki, Finland
8University of Granada, Department of Physical Education and Sports-, Granada,
Spain
9Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden
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10University of Granada, Department of Biochemistry and Molecular Biology,
Granada, Spain
Study question: Do physical activity (PA) and sedentary lifestyle inﬂuence
controlled ovarian stimulation (COS) and embryo implantation and pregnancy
outcomes in in vitro fertilization (IVF) treatment?
Summary answer: Physically more active women obtained higher number of
oocytes and embryos after COS, while PA and inactivity levels did not inﬂuence
embryo implantation in IVF.
What is known already: Regular PA has positive effects on human health
and several epidemiologic studies indicate an association between self-reported
PA and fertility. There are studies demonstrating that physically more active
women during IVF have higher probability of pregnancy, while others, on the
contrary, report negative impact of PA on IVF. All these studies have assessed
PA using self-reported questionnaires, which give only a rough estimate of PA.
Only one published study has measured objectively PA, with accelerometry, in
infertile women after embryo transfer, where no effect of PA was detected.
We still are lacking objective recommendations of PA for women undergoing
IVF.
Study design, size, duration: This longitudinal study was carried out among
108 infertile women receiving fresh embryo transfer (ET) in their ﬁrst IVF cycle.
The study was carried out at the Reproductive Unit at the University Hospital
between 2013 and 2016.
Participants/materials, setting, methods: Each woman provided three
objective measurements of PA using accelerometry (ActiGraph GT2X+) of 2
weeks: 1) the baseline PA level, 1-6 months before IVF; 2) embryo implantation
period, from the day embryo was transferred; 3) early pregnancy establishment
period, from the day of pregnancy test. Lifestyle questionnaire, body compos-
ition and IVF treatment outcomes were recorded for each patient.
Main results and the role of chance: In general, the group of infertile
women undergoing IVF treatment signiﬁcantly reduced their PA levels and
increased sedentary time. Physically more active and less inactive women
obtained signiﬁcantly higher number of oocytes and embryos after COS, while
PA and sedentary lifestyle did not seem to have any effect on embryo implant-
ation and early pregnancy establishment in IVF. Further, we found that those
women with a high screen time during the weekends (>3 h per day) have 4.7
oocytes and 2.8 embryos less after COS than women with low screen time.
Furthermore, isotemporal analysis demonstrated that if a woman would
increase her daily light PA for 1.5 h and thus by reducing their daily sedentary
time for 1.5 h, she would obtain 2 more oocytes and 1 more embryo after
COS.
Limitations, reasons for caution: Regardless of the clear results of PA
effects on ovarian stimulation, bigger sample size would increase the power of
the study.
Wider implications of the ﬁndings:We can suggest recommendations for
infertile women undergoing IVF indicating that light and moderate PA is beneﬁ-
cial for ovarian stimulation outcomes, while sedentary lifestyle clearly is not.
Additionally, IVF patients could continue with their normal lifestyle and there is
no need to reduce PA levels after embryo transfer procedure.
Trial registration number:Not applicable.
P-408 Euploidy rates in donor egg cycles are signiﬁcantly
inﬂuenced by the number of accumulated ovarian stimulations
I. Jurado1, M. Enciso1, J. Sarasa1, C. Real2, B. Rodriguez Estrada1,
I. Vilella1, J. Luna Romero1, S. Rogel2, J. Aizpurua2
1Integrated Genetic Lab Services SL, Genetic, Alicante, Spain
2IVF-SPAIN, Ginecology, Alicante, Spain
Study question: Could ovarian stimulation protocols inﬂuence oocyte quality,
embryo developmental potential and the euploidy status?
Summary answer: The total number of previous ovarian stimulations in
donor egg cycles positively correlates with embryo aneuploidy rates.
What is known already: The presence of chromosome aneuploidy is one of
the most signiﬁcant causes of embryo loss. Studies performed in the last two
decades reveal these abnormalities affect a remarkable number of ART pro-
duced human embryos (over 50%). Although the majority of aneuploidies are
known to be maternal age related, this phenomenon has also been observed in
young patients and donors at a considerable and wide ranged frequency (20-
60%). Apparently, range dependent from center and/or doctors involved sug-
gesting stimulation and/or culture conditions as possible explanations. To date,
no detailed analysis of such factors has been performed.
Study design, size, duration: This observational retrospective study
includes data from 102 donor-oocyte cycles undergoing Preimplantation
Genetic Testing for Aneuploidy (PGT-A) between January 2017 and January
2018. A total of 2850 oocytes and 569 embryos were studied. Only cycles
from couples who showed no clear male factor infertility (normozoospermic
sperm according to WHO) were selected. The inﬂuence of donor characteris-
tics, ovarian stimulation protocol, dose and number on oocyte count and qual-
ity and on embryo competence and ploidy was assessed.
Participants/materials, setting, methods: 67 donors aged 18-34 (24.86
± 3.87) participated in the study. Donors followed a protocol for ovarian stimu-
lation with rFSH (Puregon®, Merck) with variable doses (AMH, folliculometry
and weight dependant). Oocytes collected were in-vitro fertilised, embryos cul-
tured to blastocyst stage (equal conditions), biopsied and PGT-A tested by
NGS (VeriSeq protocol, Illumina). Oocyte count and quality, fertilization rate,
blastocyst formation rate, embryo quality and chromosome status depending
on donor age, BMI, stimulation dose and number were statistically explored.
Main results and the role of chance: A signiﬁcant positive correlation was
found between donor age and the number of oocytes retrieved (Pearson cor-
relation, R=-0.294 p = 0.008). Young donors ≤27 tend to produce signiﬁcantly
higher number of oocytes compared to older (>27) donors (28.74%±1.46 vs
22.35%±1.83, Student´s t-test, p = 0.011). No such age inﬂuence was found in
embryo competence neither in terms of blastocyst formation rate, good quality
blastocyst rate or euploidy rate. No correlation between oocyte count and
BMI, stimulation dose or number of ovarian stimulation cycles was identiﬁed.
Interestingly, embryonic aneuploidy rates in the donor egg cycles studied
were associated with the number of stimulation cycles performed by the donor.
The number of previous stimulations negatively inﬂuenced embryonic euploidy
rates (Spearman correlation, R=-0.222, p = 0.036). A signiﬁcant increase in the
proportion of embryos presenting chromosome abnormalities was found in
donors that had undergone more than 5 stimulation cycles compared to donors
experiencing 5 or less stimulation cycles (31.93%±3.64 vs 24.40%±2.78, U-
Mann Whitney, p = 0.037). Neither age, BMI or r-FSH stimulation dose or hor-
mone levels showed such an impact on embryo ploidy.
Limitations, reasons for caution: The retrospective and unicentric design
of this study may be a reason of caution. The number of donors and donor egg
cycles was limited; this should be increased to conﬁrm the results ob-tained.
Further prospective studies are needed to validate our results.
Wider implications of the ﬁndings: Our results show a strong association
between the number of previous stimulation cycles and embryo aneuploidy in
oocyte donors. These data indicate that other factors like age, previous stimula-
tions or ovarian damages of oocyte maturation and genetic competence, may
inﬂuence chromosome abnormalities in IVF embryos.
Trial registration number: not applicable.
P-409 Nodal deletion increases susceptibility to inﬂammation-
induced preterm birth in mice and human
T. Ayash
Mcgill, Expreimental medicine, Montral, Canada
Study question: How does inﬂammation combined with reduced Nodal gene
expression increase susceptibility to Preterm Birth in mice and humans.
Summary answer: Nodal heterozygous mice are senstive to LPS which
causes preterm birth. In humans,Nodal revealed that Nodal SNPs correlate
with increased susceptibility to inﬂammation-induced preterm birth.
What is known already: Potential risk factors prior to conception, during
pregnancy genetic predisposition have been identiﬁed to correlate with increase
susceptibility to preterm birth. Our lab has been studying the role of Nodal sig-
naling during pregnancy. Nodal is belonging to the Transforming Growth
Factor-beta superfamily. Previously we have demonstrated that Nodal signaling
is active in uterus during early pregnancy and required both for embryo implant-
ation and for the timing of parturition. We have a uterine speciﬁc deletion using
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a progesterone receptor-Cre system and observed a 75% reduction in preg-
nancy, 25% of Nodal mutant gave birth two days prior to term.
Study design, size, duration: In mouse we have injected a low dose of LPS
(1.4 mg/kg) which resulted in 50% of pregnant Nodal heterozygous mice to give
birth preterm. Furthermore, we have also veriﬁed the protein and RNA levels
of several pro-inﬂammatory cytokines using immunoﬂuorescence and real time
PCR. In the human study, 613 women (189 preterm and 424 term) from the
Montreal Prematurty Study were genotyped for NODAL polymorphisms and
assessed for bacterial vaginosis and placental inﬂammation.
Participants/materials, setting, methods: We are using an RT2 Proﬁler
PCR Array, we examined the expression of 84 genes involved in innate and
adaptive immunity. Critical cytokines in the parturition cascade were signiﬁ-
cantly up-regulated in maternal decidua tissue of Nodal heterozygous mice at
day 16.5 of pregnancy. We have also used different antibodies to look to differ-
ent immune cells in placental tissue in our mouse model.
Main results and the role of chance: Our mouse study demonstrated that
absence of one allele of Nodal leads to increased susceptibility to preterm birth
in response to low doses of LPS. We also provide evidence that NODAL may
regulate the immune system during late pregnancy and labor. We suggest that
the Nodal heterozygous knockout mouse is a suitable model to study gene-
environment interactions in human preterm birth. Future experiments will
address the mechanism of how NODAL affects the immune system.
In human, we identiﬁed 12 known SNPs in the NODAL gene of participants in
the study population. Of these, four had VAF > 1%, three of the NODAL poly-
morphisms were not associated with preterm birth.in more details, the
rs2231947 variant allele was associated with increased risk for preterm birth
among women with bacterial vaginosis. Among women without placental
inﬂammation, the rs1904589 variant allele was associated with increased risk of
preterm birth. Among women with placental inﬂammation, the rs10999338
variant allele was associated with reduced risk of preterm birth.
Limitations, reasons for caution: Experiments were performed on a
mouse model and the implication of the Nodal signaling pathway in humans is
still unclear.
Wider implications of the ﬁndings: As Nodal appears to be involved in
the timing of parturition, manipulation of its activity or of its downstream signal-
ing components may lead to effective treatments in the prevention of preterm
birth.
Trial registration number: Funded by March of Dimes Grant, Toronto
Dominion Bank Post-Doctoral Fellowship for Child Health Research Excellence
and The Ministry of Higher Education of Saudi Arabia.
P-410 BMI adversely affect embryo quality andmorphokinetics
G. Shrem1, M. Michaeli2, D. Poltov2, N. Asliha2, N. Rotfarb2,
E. Shoshan-Karchovsky2, O. Ruzov2, Y. Atzmon2, E. Shalom-Paz3
1Hillel - Yaffe medical center, IVF unit, Hadera, Israel
2Hillel Yaffe Medical Center, IVF unit, Hadera, Israel
3Hillel Yaffe Medical Center, IVF unit, Hadera, Iceland
Study question: What is the effect of BMI on embryo’s morphokinetics as
reﬂected by timelaps scores with regard to treatment protocol IVF cycle
outcome.
Summary answer: Obesity has adverse effect on IVF treatment represented
by less TOP quality embryo and a trend of lower pregnancy rate.
What is known already: It is well established that there is a strong correl-
ation between obesity and reproductive pathology including anovulation, infer-
tility and obstetrical complication.
Study design, size, duration: A retrospective cohort study.
179 infertile women, total of 2280 oocytes.
January 2016 to December 2017
Participants/materials, setting, methods: Records of all fresh cycles that
their embryos were cultured in a time-laps incubator were evaluated. Embryos
were scored by EmbryoScope™ and correlated with patients BMI and clinical
pregnancy rates.
Main results and the role of chance: 179 infertile women, total of 2280
oocytes were divided according to their BMI into 3 groups: BMI < 25, BMI 25-
29, and BMI ≥30. The duration of treatment was signiﬁcantly longer for the
BMI≥30 (10.2 ± 1.6 days vs. 9.3 ± 2.2 days, respectively). The endometrium
was signiﬁcantly thicker in the BMI≥30 group (10.2 ± 1.6 vs. 9.8 ± 2.4). The
Estradiol level on ovulation induction day, the number of oocyte retrieved, the
number of oocytes at the M2 phase and the number of the normal fertilization
oocyte were signiﬁcantly higher at the BMI<25 group. We found signiﬁcantly
more TOP quality embryos in the BMI< 25 compared with the other groups
(58% vs 52%). Pregnancy and clinical pregnancy rate demonstrated a trend
towards higher pregnancy in the BMI<25 group vs. the BMI≥30 group (49% vs
32%, NS and 46% vs 32%, NS; rspectively).
Limitations, reasons for caution: Since it is a retrospective cohort study,
the results shoud be interprated with cuation.
Wider implications of the ﬁndings: Understanding the adverse effects of
obesity, may contribute to infertility couples education and may contribute to
the understanding of adverse effect of obesity on oocyte developement.
Trial registration number:N/A.
P-411 Association of weight change since age 18 years and
probability of live birth among women undergoing assisted
reproduction
M. Arvizu1, M.C. Afeiche2, R. Hauser3, P. John C4, C. Jorge E5,
G. Audrey J6
1Harvard University, Nutrition, Boston, U.S.A.
2Harvard T.H. Chan School of Public Health, Nutrition, Boston, U.S.A.
3Harvard T.H. Chan School of Public Health- Massachusetts General Hospital and
Harvard Medical, Nutrition- Environmental Health and 3Vincent Obstetrics and
Gynecology, Boston, U.S.A.
4Massachusetts General Hospital and Harvard Medical School, Vincent Obstetrics
and Gynecology, Boston, U.S.A.
5Harvard T.H. Chan School of Public Health and Brigham and Women’s Hospital
and Harvard Medical School, Nutrition- Epidemiology- Channing Laboratory, Boston,
U.S.A.
6Brigham and Women’s Hospital and Harvard Medical School- Harvard T.H. Chan
School of Public Health, Nutrition and Channing Laboratory, Boston, U.S.A.
Study question:What is the association between female weight change from
young adulthood (age 18) to time of ART and the probability of live birth?
Summary answer: Greater weight gain in adulthood was associated with
lower probability of live birth following ART, particularly among women who
were ≥22.5 kg/m2 at age 18.
What is known already: Pre-pregnancy overweight and obesity in adulthood
has been associated with lower natural fertility and lower success rates in ART.
While short-term weight loss trials have not demonstrated improved live birth
rates among obese women undergoing ART, the impact of longer-term weight
change on ART outcomes, particularly throughout early adulthood has yet to
be studied.
Study design, size, duration: Our analysis included 448 women (767 ART
cycles) enrolled in the Environment and Reproductive Health (EARTH) study -a
prospective cohort study- recruited between 2005-2016 at the Massachusetts
General Hospital Fertility Center.
Participants/materials, setting, methods: At study entry, women were
asked to recall their weight at age 18 and trained research nurses measured
women’s current height and weight. ART outcomes were abstracted from
medical records. We used multivariate generalized linear mixed models with
random intercepts to account for repeated observations adjusted for age,
smoking status, race, height, and BMI at age 18.
Main results and the role of chance: At time of study entry, 62% of women
had gained > 5 kg since age 18 and 33% were overweight or obese. The
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adjusted percentage of initiated ART cycles resulting in live birth (95% CI)
among women who gained 0-5 kg, 5-9.9 kg, 10-14.9 kg, and ≥15 kg since age
18 was 57.2% (49.8%, 64.2%), 58.9% (51.4%, 66%), 54.6% (45.2%, 63.7%), and
48.1% (40.5%, 55.9%), respectively (p-trend = 0.08). There was no difference
in the probability of live birth between women who lost weight versus those
who remained relatively weight stable (gained 0-5 kg). The inverse association
between adult weight gain and probability of live birth was more pronounced
among women who were ≥22.5 kg/m2 at age 18 (p-interaction = 0.09).
Speciﬁcally, among women who were ≥22.5 kg/m2 at age 18 the adjusted dif-
ference in percentage of initiated ART cycles resulting in live birth was 17.6%
(95% CI 2.9%, 28.0%) comparing women who remained weight stable versus
those who gained ≥15 kg in adulthood. This similar comparison in women
<22.5 kg/m2 at age 18 was 6.6% (95% CI -2.5%, 14.6%).
Limitations, reasons for caution: Weight at age 18 was self-reported by
participants, which may lead to misclassiﬁcation. There were very few women
who lost weight since young adulthood which limited the statistical power of
those comparison. Despite our adjustment for a variety of confounders,
residual confounding is possible.
Wider implications of the ﬁndings: Women who gained ≥15 kg in adult-
hood have lower probability of live birth per initiated ART cycle, particularly
among women who were heavier at age 18. These results add to the growing
literature supporting the beneﬁts of minimizing weight gain in adulthood on
female fertility.
Trial registration number:None.
P-412 Predictive models for pregnancy outcomes with non-IVF
treatments reveal that protocol choice, not patient-speciﬁc factors,
are the primary risk for multiple gestations
K. Hunter Cohn1, C.Wellock1, B.T. Miller2, M. Hinckley3,
J.N. Gutmann4, C. Benadiva5, J.C. Nulsen5, G. Letterie6,
J. Hirshfeld-Cytron7, A.B. Copperman8, P. Yurttas Beim1
1Celmatix Inc., Celmatix, New York, U.S.A.
2Reproductive Medicine Associates of Michigan, Reproductive Endocrinology, Troy,
U.S.A.
3Reproductive Science Center of the San Francisco Bay Area, Reproductive
Endocrinology, San Ramon, U.S.A.
4Reproductive Medicine Associates of Philadelphia, Reproductive Endocrinology,
Philadelphia, U.S.A.
5University of Connecticut School of Medicine, The Center for Advanced Reproductive
Services, Farmington, U.S.A.
6Seattle Reproductive Medicine, Reproductive Endocrinology, Seattle, U.S.A.
7Fertility Centers of Illinois, Reproductive Endocrinology, Highland Park, U.S.A.
8Reproductive Medicine Associates of New York, Icahn School of Medicine at Mount
Sinai, New York, U.S.A.
Study question: Which factors are predictive of ongoing pregnancy and risk
of multiple gestation with non–in vitro fertilization (non-IVF) treatment?
Summary answer: Personalized predictive models for OPR (ongoing preg-
nancy rate) and MGR (multiple gestation rate) highlight an increased risk of mul-
tiple gestation with non-IVF treatment using gonadotropins.
What is known already: Non-IVF treatments with OI using oral medications
(clomiphene citrate or letrozole) or injectable gonadotropins with IUI or timed
intercourse (TI) are frequently used as ﬁrst-line fertility treatment due to the
lower physical and ﬁnancial burden. Treatments vary in pregnancy rate as well
as MGR, and thus in associated maternal and fetal risks. Although previous stud-
ies have looked for factors predictive of pregnancy, they did not analyze the
multiple gestation rate. Patient-speciﬁc predictions for both pregnancy and risk
of multiples across treatment options and cumulatively over multiple cycle
attempts can help with patient counseling and allow for informed treatment
decisions.
Study design, size, duration: Predictive models were built using retrospect-
ive data collected from 173,916 cycles from 69,003 patients at 13 fertility cen-
ters in the United States between 2002 and 2017. We included cycles that
received the OI medications clomiphene citrate or letrozole (Orals) and/or
injectable FSH or hMG (Gnd) with or without IUI. We excluded cycles that uti-
lized donor sperm.
Participants/materials, setting, methods: Outcomes evaluated were
OPR (presence of fetal heartbeat upon discharge to obstetrical care) and MGR
(presence of multiple fetal heartbeats relative to ongoing pregnancy). Patient
data were divided into a training set (2/3) and a validation set (1/3). The OPR
and MGR models were logistic regression models and used inverse probability-
of-censoring weighting to compensate for informative censoring. Continuous
patient factors were evaluated for nonlinear spline terms.
Main results and the role of chance: In a multivariate model for OPR, sig-
niﬁcant nonlinear patient factors included age, anti-Müllerian hormone, body
mass index, basal antral follicle count, and day 3 FSH, estradiol, and luteinizing
hormone. In addition, endometriosis (odds ratio [OR] 0.48), tubal factor (OR
0.57), and sperm total motile count <10 million (OR 0.55) and morphology
<4% Kruger (OR 0.82) (p<0.001 for all) had a negative impact on OPR.
Notably, we found that inclusion of Gnd or IUI in the protocol led to increased
OPR (OR: Gnd+IUI, 2.80; Gnd+Orals+IUI, 2.13; Orals+IUI, 1.40; Gnd+TI,
2.04; Gnd+Orals+TI, 1.37; Orals+TI, 1.0). Modeling OPR over multiple cycles,
we observed that the incremental probability with each additional cycle varied
by treatment protocol, with a greater decrease for cycles including Gnd.
Additionally, a multivariate model for MGR showed that risk primarily
depended on protocol choice, with Gnd inclusion signiﬁcantly increasing risk of
multiple gestation (OR: Gnd+IUI, 3.34; Gnd+TI, 3.09; Gnd+Orals+IUI, 1.86;
Gnd+Orals+TI, 1.45; Orals+IUI, 1.23; Orals+TI, 1.0; p<0.001). The MGR was
independent of cycle attempt number.
Evaluating the OPR model against a holdout validation dataset, we observed
an AUC of 0.65 and a Brier score of 0.091. The MGR model had an AUC of
0.65 and a Brier score of 0.079.
Limitations, reasons for caution: The described predictive models were
built and validated on retrospective data and should be independently validated
using a prospective dataset. In addition, differences in clinic treatment and mon-
itoring protocols may inﬂuence both OPR and MGR.
Wider implications of the ﬁndings: Personalized probabilities for both
OPR and the associated MPR are important for helping patients make treat-
ment choices to maximize their likelihood of a healthy outcome. The >3-fold
increase in MGR with Gnd compared to oral medications highlights the import-
ance of balancing this signiﬁcant risk with the incremental increase in OPR.
Trial registration number:N/A.
P-413 Comparative study of the Poseidon subgroups 1a and 1b low
responder IVF cycles
N. Massiah, P. Fedorcsak
Oslo University Hospital, Reproduction Medicine, Oslo, Norway
Study question: What are the comparative trends of the Poseidon group 1a
and group 1b low responder IVF cycles?
Summary answer: Low responder cycles increased with time and age with
group 1a carrying a signiﬁcantly higher no embryo transfer rate and lower clin-
ical pregnancy rate.
What is known already: The 4 group Poseidon stratiﬁcation of low respon-
ders was introduced in 2016. Unexpected poor or suboptimal responders, 34
years and younger with a normal ovarian reserve are classiﬁed as Poseidon
group 1. Subgroups 1a and 1b are based on the number of oocytes retrieved
after standard ovarian stimulation. Low responders with fewer than 4 oocytes
are classiﬁed as subgroup 1a. Those with 4-9 oocytes are classiﬁed as subgroup
1b. Since this is a new classiﬁcation, there is a need for fertility centres to apply
it to their own population of women to enable the development of reprodu-
cible and comparable research.
Study design, size, duration: Retrospective comparative study of 777 IVF
cycles of Poseidon subgroups 1a and 1b low responders. The IVF cycles were
undertaken between Jan 2007 to Dec 2017.
Participants/materials, setting, methods: First IVF cycle low responders,
34 years and younger with normal ovarian reserve parameters (AFC >5,
AMH>1.2 ng/ml). This group was divided into subgroups 1a and 1b. Subgroup
1a were low responders with fewer than 4 retrieved oocytes. Subgroup 1b
were low responders with 4-9 retrieved oocytes. The data was extracted from
an electronic register of IVF cycles that were undertaken at a university hospital
fertility centre. Chi square test for statistical analysis. Signiﬁcance: p <0.05.
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Main results and the role of chance: There was a 4-fold and 7-fold
increase in Poseidon subgroup 1a and subgroup 1b ﬁrst IVF cycles respectively.
Poseidon subgroup 1a consisted of 114 women (14.6%) and subgroup 1b con-
sisted of 663 women (85.4%). An upward trend with age was found in both
subgroups. The mean (SD) number of oocytes retrieved per cycle was 2.2 ±
0.8 in subgroup 1a, and 6.7 ± 1.7 in subgroup 1b. The mean (SD) number of
embryos transferred per cycle was 1.1 ± 0.5 in subgroup 1a and 1.1 ± 0.6 in
subgroup 1b.
Embryo transfer was not achieved in 111 women. The no embryo transfer
rate was signiﬁcantly higher in subgroup 1a (29.8% v/s 11.6%, p<0.05). Of the
111 women, 18 (16.2%) undertook further IVF treatment. Of these 18 women,
there was a cumulative pregnancy rate of 44.4% over three cycles.
The clinical pregnancy rate of subgroup 1b was signiﬁcantly greater than sub-
group 1a (41.8% v/s 22.8%, p<0.05). A sub-analysis of single embryo transfers
found that the clinical pregnancy rate of subgroup 1a was lower than subgroup
1b (30.1% v/s 47.1%, p<0.05). For double embryo transfers, the clinical preg-
nancy rate in subgroup 1a was signiﬁcantly higher than subgroup 1b (57.1% v/s
40.0%, p<0.05).
Limitations, reasons for caution: This was a retrospective study which is
historically known for its limitations. However, there was no missing data in this
study.
Wider implications of the ﬁndings: Research is warranted to determine
parameters that can identify Poseidon type 1 women prior to ovarian stimula-
tion. This will enable optimisation of treatment and reproductive outcomes.
Double ET can be considered for group 1a women based on low oocyte num-
bers, difﬁculty creating embryos and low pregnancy rates with single ET.
Trial registration number:Not applicable.
P-414 Antibodies to chlamydial heat shock protein 60 kDa in sera
and follicular ﬂuid of women undergoing IVF
V. Muller1, I. Kogan2, A. Savicheva3, A. Gzgzyan2
1D.O.Ott Research Institute of Obstetrics- Gynecology and Reproductology, IVF,
Saint-Petersburg, Russia C.I.S.
2D.O.Ott Research Institute of Obstetrics- Gynecology and Reproductology, In vitro
fertilization, Sankt-Petersburg, Russia C.I.S.
3D.O.Ott Research Institute of Obstetrics- Gynecology and Reproductology,
Microbiology, Sankt-Petersburg, Russia C.I.S.
Study question: To determine whether past or persistent chlamydial infec-
tion is associated with the results of infertility treatment with in vitro fertilization
(IVF)
Summary answer: No relation between antibody positivity to chlamydial
heat shock protein 60 kDa (cHSP60) and IVF outcome was found.
What is known already: Recent studies have shown that serum antichlamy-
dial antibodies are found in almost every second woman seeking treatment for
tubal infertility with IVF. However, seropositivity of follicular ﬂuid to chlamydial
antigens and its diagnostic value is described only in several publications. Even
more limited is the knowledge on the prevalence of persistent infection with
Chlamydia trachomatis, deﬁned by anti-cHSP60 antibody positivity, in women
undergoing infertility treatment.
Study design, size, duration: A prospective comparative cohort study of
242 women with tubal factor of infertility was conducted at the IVF department
of a state institution between January 2012 – January 2016.
Participants/materials, setting, methods: Serum (obtained at the ﬁrst
day of stimulation) and follicular ﬂuid (aspirated at the day of oocyte pick-up)
samples were analyzed using enzyme-linked immunosorbent assay for immuno-
globulins (Ig) to major chlamydial antigens (IgG, IgA) and for anti-cHSP60 IgG.
Study participants were divided to 2 groups according to the results of serum
anti-C.trachomatis IgG test: 122 seropositive (main) and 120 seronegative sub-
jects (comparison). Primary study outcome was clinical pregnancy rate.
Main results and the role of chance: Prevalence of anti-C.trachomatis IgG,
IgA and anti-cHSP60 IgG was 50.4%, 10.7% and 5.8% in sera; 37.1%, 4.6% and
5.6% – in follicular ﬂuid. Major stimulation and in vitro stage parameters did not
differ between the study groups. ‘Poor response’ to ovarian stimulation was
found to be 2 times more frequent in the main group (22.9% vs. 13.3%, p =
0.039), however was not associated with anti-cHSP60 antibody detection both
in sera (ОR: 2.56, 95%CI 0.87-3.34) and follicular ﬂuid (ОR: 1.93, 95%CI 0.99-
3.87). Seropositive and seronegative women demonstrated similar clinical preg-
nancy (20.5% vs. 25.0%) and life birth rates (13.1% vs. 20.0%). Incidence of
missed abortion after IVF was higher in the main group (28.0% vs 3.3%, p =
0.018) and showed no relation with anti-cHSP60 antibody positivity.
Limitations, reasons for caution: Despite the relatively sufﬁcient initial size
of the study, the subpopulation of anti-cHSP60 positive women appeared to be
rather small. In addition, only women with tubal factor of infertility were
assayed during the trial. All of this expectedly limits the generalizability of the
obtained results.
Wider implications of the ﬁndings: The possibility of Chlamydia trachomatis
persistence in women with tubal factor of infertility should be investigated with
the employment of additional microbiological methods. Further trials may esti-
mate the diagnostic and prognostic value of antichlamydial antibody testing for
women undergoing IVF.
Trial registration number:Not applicable.
P-415 Acquisition of a next baby using a frozen sibling embryo(s): a
proposal for advanced aged infertility couples to build a desired
family
R. Uekusa1, H. Ando1, T. Shimaya1, M. Kawai2
1Toyohasi Municipal Hospital, Center for Reproductive Medicine and Surgery,
Toyohashi, Japan
2Toyohasi Municipal Hospital, Department of Obstetrics and Gynecology, Toyohashi,
Japan
Study question: To evaluate the predictability of the acquisition of a next
baby using a frozen sibling embryo(s) from the successful single embryo transfer
(SET) cycle.
Summary answer: Our data indicate that 38.8% couples that keep at least
one sibling embryo for the next baby may have another success without add-
itional oocyte retrieval.
What is known already: The essential aim of ART is the birth of one single
healthy child. SET has been introduced to avoid multiple pregnancy that is a
major complication of ART. However, in advanced ages, usually from the latter
half of 30’s, pregnancy rate is gradually decreasing, and miscarriage rate is mark-
edly increasing. Thus, it is difﬁcult for advanced aged subfertility couples to build
a desired family using high potential embryos with safety. Improvement of cryo-
preservation of embryos may contribute to maintain the reproductive results at
the age of the embryo freezing.
Study design, size, duration: This is a retrospective clinical study in our
institute from 2007 to 2017. We included 121 patients who gave birth to a
baby through a timelapse-conﬁrmed embryo transfer, keeping a sibling frozen
embryo(s) and used the frozen embryo(s) for another baby.
Participants/materials, setting, methods: Patients were divided into
acquisition and non-acquisition group (AG and non-AG) according to the ﬁnal
results of the new baby acquisition through the sibling embryo transfer(s). Main
outcome was the ratio of AG. Furthermore, we newly deﬁned the original
embryo score based on the quality of the embryo at any developmental stage.
The total score of the frozen embryos at the time of cryopreservation (F score)
was evaluated.
Main results and the role of chance: The number of AG and non-AG
were 47 (38.8%) and 74 (61.2%), respectively. There was one monozygotic
twining in AG. No sibling embryo was remained in non-AG. Female age (32.3
± 2.8 vs. 32.3 ± 3.5; P = 0.85) and body mass index (21.3 ± 2.2 vs. 21.4 ± 4.2;
P = 0.15) were similar between the two groups. Common etiological factors of
subfertility were also similar between the groups. The number of retrieved
oocytes (15.9 ± 7.4 vs. 13.4 ± 7.4; P = 0.03), that of MII oocytes (12.5 ± 5.9
vs. 9.8 ± 5.2; P = 0.006), that of fertilized oocytes (10.4 ± 4.7 vs. 8.0 ± 4.4; P
= 0.002), that of frozen embryos (6.4 ± 4.1 vs. 4.2 ± 3.3; P = 0.0003), F score
(9.9 ± 6.5 vs. 5.6 ± 4.1; P < 0.0001) were higher in AG. The total amount of
administrated FSH/HMG and the peak estradiol concentration of each group
(AG vs. non-AG) were 2,210 ± 1,007 IU vs. 1,965 ± 915 IU (P = 0.06) and
3,680 ± 2,262 pg/ml vs. 2,956 ± 2,627 pg/ml (P = 0.009), respectively.
i331Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Limitations, reasons for caution: Limitations of this study include the smal-
ler sample size and the retrospective study from a single institute.
Consideration for the next baby was not given into the stimulation protocol in
this study.
Wider implications of the ﬁndings: This study indicate that much higher
acquisition rate for the next baby may be expected if we utilize information on
the number of children of couple’s desire, and if more precise developmental
prognosis of each embryo is available in the near future.
Trial registration number:Not applicale.
P-416 Does starting day of progesterone intake really matter in
frozen blastocyst transfer cycles?
S. Cavkaytar1, N. Fındıklı2, M. Gultomruk3, G. Karlıkaya4,
M. Kavrut4, R. Abalı4, B. Erzik4, K. Boynukalın4, M. Bahceci4
1Bahceci Umut IVF Center, Infertility Clinic, İstanbul, Turkey
2Bahceci Fulya IVF Centre, IVF Laboratory, İstanbul, Turkey
3Bahceci Fulya IVF Centre, R&D Laboratory, İstanbul, Turkey
4Bahceci Fulya IVF Centre, Infertility Clinic, İstanbul, Turkey
Study question: This study aims to evaluate whether a 1-day delay in the
starting day of progesterone intake can change the clinical outcome in frozen
blastocyst transfers.
Summary answer: Both P+0 and P+1 can be taken as the starting day of pro-
gesterone supplementation resulting in similar clinical outcome in frozen blasto-
cyst transfers.
What is known already: Due to recent improvements in human embryo
cryopreservation, deferred embryo transfer strategies involving frozen cleavage
and blastocyst-stage embryos are increasingly adopted in IVF clinics worldwide.
On the other hand, this continuous increase in the number of frozen embryo
transfer (FET) cycles also necessitates successful endometrial preparation.
Although encouraging clinical outcomes have been reported in the literature,
optimal timing of progesterone intake during FET cycles still need to be estab-
lished. Since serum progesterone levels start to rise before ovulation, it can be
argued that progesterone administration before FET should also start earlier.
Study design, size, duration: This retrospective study consisted of 1407
consecutive FET cycles involving single blastocysts performed between
September 2013 - August 2017. In all cycles, same endometrial preparation
strategy was used except the starting day of progesterone which was either P
+0 or P+1 depending on the clinician’s preference. All embryos were warmed
in the morning of embryo transfer day and FET was performed in the
afternoon.
Participants/materials, setting, methods: In 749 FET cycles, progester-
one intake was found to be started as P+0 (Group I) and in 658 cycles, it was
commenced as P+1 (Group II). During the study period, embryo culture media
as well as vitriﬁcation/warming media were purchased and used from the same
producer (Irvine Scientiﬁc). FETs were performed either on the ﬁfth or sixth
day of progesterone supplementation, which was given either from vaginal or
intramuscular route.
Main results and the role of chance: In both groups, general patient- and
cycle-related demographics and distributions such as female age, BMI, number
of previous ART trials, reason of infertility as well as quality scores and distribu-
tion of transferred embryos scores were found to be similar (p>0.05).
Comparison analysis also displayed high but similar biochemical pregnancy
(74.2% vs. 69.6%) and clinical pregnancy rates (68.6% vs. 65.3%; p>0.05).
Twenty-eight percent of these pregnancies have already resulted in live birth in
Group I and 30.2% in Group II respectively.
Limitations, reasons for caution: The main limitation of our study was its
retrospective design. Also, patients were not blinded about the exact duration
of progesterone supplementation.
Wider implications of the ﬁndings: Our study shows that setting of start-
ing time of progesterone intake either as P+0 or p+1 does not create any sig-
niﬁcant difference in clinical outcomes in frozen single blastocyst transfer cycles.
Further randomized studies involving single euploid blastocysts with a single
progesterone supplementation route are needed to conﬁrm these results.
Trial registration number:Not applicable.
P-417 Impact of Body Mass Index on outcome of the ﬁrst
pregnancy after referral among women with recurrent pregnancy
loss
M. El Issaoui1, M.C. Krog1, O.B. Christiansen2, A. Kolte1,
H.S. Nielsen1
1Copenhagen University Hospital- Rigshospitalet, Recurrent Pregnancy Loss Unit,
Copenhagen, Denmark
2Aalborg University Hospital, Gynecology and Obstetrics, Aalborg, Denmark
Study question: Does Body Mass Index (BMI) impact outcome of the ﬁrst
pregnancy after referral among women with recurrent pregnancy loss (RPL)
referred to a tertiary center?
Summary answer: BMI is not a prognostic factor for the chance of live birth
among women with RPL referred for evaluation and treatment in tertiary center.
What is known already:Obesity has been reported to affect the chance of a
live birth in women with RPL. One study reported that BMI, maternal age, num-
ber of previous losses, and ethnicity were associated with pregnancy outcome.
They found an increased risk of another pregnancy loss in in obese women with
unexplained RPL but not in overweight women. We have previously reported
that BMI is not a signiﬁcant prognostic factor for live birth in women with RPL
and a normal menstrual cycle. As concluded in the new ESHRE guideline the
impact of BMI on the prognosis of live birth has not been determined.
Study design, size, duration: A retrospective cohort study including 1068
Danish women with RPL, deﬁned as three consecutive pregnancy losses,
referred for evaluation and treatment at the National Danish RPL Unit between
2000-2010
Participants/materials, setting, methods: Anonymized data on age, num-
ber of pregnancy losses prior to referral, outcome of ﬁrst pregnancy after refer-
ral, BMI and menstrual cycle (normal vs. oligomenorrhea) were retrieved from
the Danish National RPL database. Chi-square testing and logistic regression
analysis were performed. A p-value of <0,05 was considered signiﬁcant.
Women, whose ﬁrst pregnancy outcome after referral were ectopic pregnancy
or induced abortion, were excluded from the analysis.
Main results and the role of chance: Normal weight women with BMI
between 18.5–24.9 kg/m2 constituted the largest group (n = 623, 59.4%) fol-
lowed by overweight women with BMI between 25.0-29.9 kg/m2 (n = 242,
23.1%), obese women with BMI ≥30 kg/m2 (n = 165, 15.7%), and the smallest
group being underweight women with BMI <18.5 kg/m2 (n = 18, 1.7%). Live
birth rates in the BMI groups were 60.3% (n = 356); 58.6% (n = 136); 55.3%
(n = 89); 64.7% (n = 11), respectively. There was no impact of BMI on chance
of a live birth, neither as a grouped variable (<18.5; 18.5-24.9; 25-29.9; ≥30),
OR 0.93 (CI 0.79-1.09), p = 0.37, nor as a continuous variable OR 0.992 (CI
0.97-1.02), p = 0.56 adjusted for menstrual cycle (normal vs. oligomenorrhea),
maternal age, and number of previous pregnancy losses. We did not ﬁnd a
poorer prognosis for live birth among obese women compared with non-obese
women (% live birth 55.3 vs. 60.2, p = 0.26). Maternal age ranged from 20 to
45 years (mean age 33 years). Increasing maternal age reduced the chance of a
live birth, OR 0.97 (95% CI 0.94-1.00) p = 0.05, as did number of prior losses
(OR 0.80 95% CI 0.69-0.92), p = 0.002.
Limitations, reasons for caution: We did not adjust for ethnicity, karyo-
type, autoimmune and endocrine diseases. Especially karyotyping of prior losses
could change our results as a higher number of euploid losses are found when
BMI >25 kg/m2, suggesting that high BMI or associated conditions could be the
cause in overweight and obese women.
Wider implications of the ﬁndings: Our study in women with RPL cannot
conﬁrm that high BMI is a negative prognostic factor for birth in the ﬁrst preg-
nancy after referral. We conﬁrm that maternal age and number of losses are
important prognostic factors. These ﬁndings merit further scrutiny and add-
itional studies are needed.
Trial registration number:N/A.
P-418 The inﬂuence of subfertility, type of counsellor and
educational level on women’ choices regarding ﬁrst trimester
prenatal screening
S. Al-Nasiry
azM, Obstetrics & Gynecology, Maastricht, The Netherlands
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Study question: Does subfertilit, type of counsellor and education level inﬂu-
ence the choice for ﬁrst trimester prenatal screening?
Summary answer: subfertility and type of counsellor have limited impact on
the choice of women for prenatal screening, while education level does.
What is known already: Prenatal screening is performed between 11 and 14
weeks of gestation and provides a risk assessment concerning congenital abnor-
malities. Since 2017 a non-invasive prenatal test is accessible to all pregnant
women, screening for trisomy 13, 21 and 18. In case of an increased risk for
congenital abnormalities, termination of pregnancy is permitted till 24 weeks of
gestation.
In the Netherlands parental counselling is practiced by both midwives and
gynaecologists. Women with healthy pregnancies, deﬁned as a low-risk preg-
nancy without co-morbidities, are counselled by a midwife. Women with
high-risk pregnancies (i.a. previous preeclampsia) are counselled by a
gynaecologist.
Study design, size, duration: For a period of 10 months, a questionnaire
regarding prenatal screening was given to all women with a new pregnancy, by
midwives and gynaecologist in Maastricht, the Netherlands. Prior to the ques-
tionnaire, women were informed about the prenatal screening, impact of out-
comes). Survey questions focused on social and medical maternal
characteristics, socioeconomic. status and choice and motivation for prenatal
screening. A total of 82 questionnaires were completed and returned.
Participants/materials, setting, methods: The questionnaire consisted of
three parts. The ﬁrst part focused on the choice of ﬁrst trimester screening, the
second part on screening at 20 weeks of gestation (ultrasound) and the third
part on paternal inﬂuence regarding (shared)decision making. Questions were
formatted into statements and provided with an answer scale from 0 till 4 (0 =
no inﬂuence, 4 = highly inﬂuential). Data on maternal, obstetric and socio-
economic status were recorded in an electronic database.
Main results and the role of chance: In total 258 women returned a
completed questionnaire The average age was 31 ± 4 years and 56% of all
women were multiparous. Subfertile were 10%. Neither subfertility itself,
nor factors related to it (type, cause, duration) affected the choices women
made regarding prenatal screening, there was a non-signiﬁcant trend among
subfertile women to more towards NIPT 4% vs 1%, and less towards com-
bined test 43% vs 59%, and invasive tests (0% vs 5%), compared to control
women. The type of counsellor did not affect the choice for FTS, 68.6% in
the midwife-counselled group vs 69.2% in the gynaecologist-counselled
group (p = 0.66). Education level was deﬁned as “low educated” (completed
primary school), “secondary trained” (completed any secondary education)
and “high educated” (bachelor’ or masters’ degree) according to the Dutch
Statistic Registry. The percentage of women that declined versus those that
choose FTS were 5% vs 9%, 64% vs 25% and 32% vs 66%, respectively. A
signiﬁcant difference was found between the “low educated” and “high edu-
cated” group with a p-value of 0.006.
Limitations, reasons for caution: The educational level of the subjects
does not match the Dutch society, more low educated people compared to
this study. Furthermore, counselling was not performed in a controlled setting.
Wider implications of the ﬁndings: These results show that subfertility
and type of counsellor have limited impact on the choice of women for prenatal
screening, while education level does Further research should focus on the rea-
son for this difference and eventually may lead to more intensive counselling in
lower educated women.
Trial registration number:NA.
P-419 RCT of Single versus double intrauterine insemination in
ovarian hyperstimulation cycles
A. Jindal1, R. Singh2, M. Singh2
1Bhopal Test Tube Baby Centre, Infertility, Bhopal, India
2Bhopal Test-Tube-Baby Centre, Infertility, Bhopal, India
Study question: To ﬁnd out any difference in sucess rates between single and
double IUI groups in Ovarian Hyperstimulation cycles with multi-follicular
development?
Summary answer: Double IUI offers no clear beneﬁt in the overall clinical
pregnancy rate in Ovarian Hyperstimulation cycles with multi-follicular
development.
What is known already: Correct timing of intrauterine insemination (IUI)
might optimize the success rate in infertile couples.
Nonetheless, timing of ovulation varies and might depend on the ovarian
stimulation protocol used.
Away to bypass this problem in IUI cycles is to increase the frequencyof IUI
in the same treatment cycle.
Early randomized trials revealed higher clinical pregnancy rates during
double IUI treatmentcycles. IUI is an evidence-based, ﬁrst-step approach for
the management of patients with unexplained infertility (Verhulst et al.,
2006), and it is a generally preferred treatment for mild male factor infertil-
ity, ovulatory dysfunction,cervical factor infertility and endometriosis (Duran
et al., 2002).
Study design, size, duration: 426 women who underwent IUI from 2015 to
2017.under age of 40 yrs.
Women were randomly assigned to single (n = 213) or double (n = 213) IUI
groups.
Women in the single group underwent IUI performed 36-38 hours after
human chorionic gonadotropin (HCG) administration.
Women in the double group underwent two IUIs performed 18–20 and 40-
42 hours after HCG administration. The main outcome was clinical pregnancy
Rate by evidence of fetal cardiac activity.
Participants/materials, setting, methods: 426 women who underwent
IUI from 2015 to 2017.under age of 40 yrs. Women were randomly assigned to
single (n = 213) or double (n = 213) IUI groups. Women in the single group
underwent IUI performed 36-38 hours after human chorionic gonadotropin
(HCG) administration. Women in the double group underwent two IUIs per-
formed 18–20 and 40-42 hours after HCG administration.
The main outcome was clinical pregnancy Rate.
Data were analyzed by SPSS software.
Main results and the role of chance: Pregnancy rate was 10.2% in the sin-
gle IUI group and 11.4 % in the double IUI group. difference between the two
groups was not statistically signiﬁcant.
There were no signiﬁcant difference between the groups regarding women’s
age, their husbands’ age, women’s BMI,duration of infertility, causes and types
of infertility, the level of AMH, FSH and LH, the number of dominate follicles,
endometrial thickness, endometrial pattern, and the sperm character (P >
0.05)
Limitations, reasons for caution: Despite the 36th hour being the pre-
ferred timing for IUI, there was no difference regarding pregnancy rates
between single and double inseminations.
Wider implications of the ﬁndings: There is consensus that controlled
ovarian hyperstimulation(COH) combined with an IUI is a much more effective
treatment for infertility than single applications of IUI or COH. Limited data
exist on the optimal timing of an IUI and the number of inseminations needed
to improve pregnancy rates.
Trial registration number:Not applicable.
P-420 The clinical potential of “random start” ovarian stimulation
of fertility preservation for Japanese breast cancer patients
K. Nakamura, S. Takae, Y. Suzuki, S. Sawada, H. Iwahata,
Y. Sugishita, Y. Horage, N. Suzuki
St. Marianna University School of Medicine, Obstetrics and Gynecology, 2-16-1
Sugao- Miyamae-ku- Kawasaki- Kanagawa 216-8511, Japan
Study question: Is “Random start” ovarian stimulation for Japanese breast
cancer patients effective?
Summary answer: The “Random start” ovarian stimulation protocol is effect-
ive method for breast cancer patients who need to start their cancer treatment
immediately.
What is known already: The traditional approach of ovarian stimulation as
fertility preservation depends on their menstrual cycle. As a result, some of the
patients may give up fertility preservation, because there are the possibilities of
a signiﬁcant delay of cancer treatment and increasing psychologic stress for the
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patients. For that reason, to prevent any delay in cancer treatment, the
“Random start” ovarian stimulation has been reported as effective for cryo-
preservation at any point during the menstrual cycle in 2013.
Study design, size, duration: Data were retrospectively obtained from the
clinical records of 44 breast cancer patients who were referred to the
Oncofertility Unit at the Center for Reproductive Medicine of St. Marianna
University Hospital from March 2014 to December 2017.
Participants/materials, setting, methods: The breast cancer patients
who hope to preserve own fertility were received controlled ovarian hypersti-
mulation regardless menstruation cycle for oocyte or embryo cryopreservation.
We checked back the clinical records of patients and ﬁgured out their back-
grounds, the way of stimulation, the phase of menstruation (follicular, peri-
ovulatory, luteal), and the level of serum anti-Müllerian hormone (AMH), the
number of oocytes per cycle and the mature oocytes rates.
Main results and the role of chance: Mean age of 44 participants was 34.9
(±3.8) years-old, and 18 of them were unmarried. They had normal menstrual
cycles prior to treatment and their average level of serum AMH was 5.1 (±2.8) ng/
ml. The period from consultation to the ﬁrst visit to our hospital was 7.4 (±5.1)
days. And the surplus period, which was period for fertility preservation from visiting
our hospital to starting the cancer therapy, was around 1.4 (±0.6) months.
Nineteen of them used GnRH antagonist for ovarian stimulation, 24 of them were
stimulated with short protocol. In addition, 33 of them used aromatase-inhibitor
combined FSH agents. Altogether 8.9 (±6.8) oocytes per cycle were retrieved, the
mature oocytes rate was 0.86(±0.2), which outcomes were comparable to previous
reports. The phase of menstruation did not affect either the number of oocytes
extracted (p = 0.34) or maturation oocytes (p = 0.10). Also, no complications (e.g.
OHSS, infection,etc.) resulted from the procedure.
Limitations, reasons for caution: This study was only data which are the
numbers of oocytes per cycle and the mature oocytes rates, but the fertilization
rates, pregnancy rates are not evaluated enough, because we have few embryo
transfer cases. Therefore, they are needed to evaluate, intend for veriﬁcation
the efﬁcacy of “Random start” method.
Wider implications of the ﬁndings: Present research outcome which is
consistent with published data may promote “Random start” ovarian stimula-
tion for fertility preservation in Asian countries, too.
Trial registration number: This study received Institutional Review Board
approval from St. Marianna University of Medicine. (approval No. 1588 2873
3464 3486)
P-421 Asymptomatic bacterial colonization during embryo
transfer and its impact on ICSI pregnancy rate
M. Braham1, M. Hamdoun2, K. Kacem3, A. Fadhlaoui1, S. Mnallah3,
M. Bouyahia1, M. Ben Meftah1, G. Merdassi3, H. Hannachi2,
O. Bahri2, A. Zhioua3, F. Zhioua1
1University of Medicine Of Tunis. Aziza Othmana Hospital, Gynecology- obstetrics
and Reproductive Medicine, Tunis, Tunisia
2University of Medicine of Tunis. Aziza Othmana Hospital, biochemistry laboratory,
Tunis, Tunisia
3University of Medicine of Tunis. Aziza Othmana Hospital, Reproductive Medicine
Laboratory, Tunis, Tunisia
Study question: What’s the effect of bacterial contamination of the embryo
transfer catheter and the vagina on ICSI outcomes.
Summary answer: This study shows that the contamination of the embryo
transfer catheter by cervical-vaginal bacteria is associated with signiﬁcantly
decreased pregnancy rates during ICSI.
What is known already: As the procedure of ICSI involves the replacement
of embryos into the uterine cavity using a catheter that passes through the cer-
vix, bacterial contamination during embryo transfer is possible. Studies have
demonstrated a 50% reduction in pregnancy rate when a contamination of the
embryo catheter tip occured. Furthermore, a decreased live birth rate has been
reported in patients in whom pathogenic bacteria were isolated from the
embryo transfer catheter tip. Dominant microorganisms involved were B and D
groups Streptococci, E.coli and Enterococcus.
Study design, size, duration: A prospective, longitudinal and analytical study
during eight months (from February 1st to October 31st, 2017)
Participants/materials, setting, methods: The study included patients
who attended the ART center for embryo transfer and who matched the fol-
lowing criteria: age ≤ 40, normal uterine ultrasound and hysteroscopy, ﬁrst or
second attempt of ICSI, use of fresh semen and transfer of at least one good
quality embryo. At the time of embryo transfer, three samples were done for
microbiological analysis: a vaginal swab, a cervical mucus sample and the tip of
the transfer catheter.
Main results and the role of chance: The study included 40 patients. The
overall pregnancy rate was 52.5%. Catheter contamination occurred in nine
cases (22.5%). The most frequently isolated bacteria were Streptococcus angi-
nosus (37%), Gardnerella vaginalis (27%) and Streptococcus agalactiae (18%).
In all cases of contamination, the same isolated bacteria were also found at in
the vagina and in the cervical mucus. In cases of contamination with Gardnerella
vaginalis, the study of vaginal ﬂora based on the calculation of the Nugent score
showed bacterial vaginosis. No cases of pregnancy have been obtained when a
contamination of the transfer catheter occurred. However, in the absence of
contamination, the success rate was 61.2% (ρ = 0.001). Patients’ characteris-
tics, stimulation protocols, embryology, number and quality of embryos trans-
ferred and partners sperm parameters did not vary signiﬁcantly between the
two groups (patients with catheter contamination and patients without catheter
contamination). We can then speculate that the presence of these bacteria on
the cervix at the time of embryo transfer could affect the pregnancy rate during
ICSI.
Limitations, reasons for caution: Even if the results of this study were stat-
istically signiﬁcant, they need to be conﬁrmed on large scale since the popula-
tion size was relatively small.
Wider implications of the ﬁndings: If the negative effects of bacterial con-
tamination during embryo transfer are conﬁrmed on larger population, system-
atic antibiotic prophylaxis may be effective to limit this impact. After the
inclusion of additional subjects, we could study the cervical vaginal ﬂora before
and after antibiotic administration.
Trial registration number: not applicable.
P-422 Embryo development, aneuploidy and clinical outcome in
different isolated female infertility indications: Do our expectations
meet the reality?
M. Gultomruk1, N. Findikli2, F.K. Boynukalin3, M. Kavrut3, E. Oral4,
M. Bahceci3
1Bahceci Fulya IVF Centre, R&D Laboratory, Istanbul, Turkey
2Bahceci Fulya IVF Centre, IVF Laboratory, Istanbul, Turkey
3Bahceci Fulya IVF Centre, Infertility Clinic, Istanbul, Turkey
4Istanbul University Cerrahpasa Faculty fo Medicine, Obstetrics & Gyneocology,
Istanbul, Turkey
Study question: This study aims to evaluate the realistic contribution of
female infertility on embryonic development, aneuploidy and clinical outcome
in non-male infertility couples undergoing PGD-A cycles.
Summary answer: Our results show that embryonic development, aneu-
ploidy and clinical outcome are all variably affected by the nature of female
infertility diagnosis.
What is known already: It is nowadays well-known that female age and the
severity of male infertility are one of the biggest and direct contributors of
human embryonic aneuploidy leading to poor clinical outcome. Although selec-
tion and uterine replacement of euploid embryos by preimplantation genetic
diagnosis (PGD-A) greatly contributes in successful clinical outcome, recent
studies show that its efﬁciency and possible beneﬁts in IVF are usually hindered
by biological and technical limitations related to the complex nature of infertility
diagnosis, making it very difﬁcult to predict or assess the true impact and suc-
cess of the approach.
Study design, size, duration: This retrospective study includes 668 patients
undergoing 755 PGD-A and 348 subsequent euploid frozen embryo transfer
(FET) cycles performed between January 2016 - August 2017. All PGD-A cycles
involved trophectoderm biopsy of developing blastocysts on day 5 or day 6 and
subsequent vitriﬁcation. Embryonic aneuploidy was analyzed by next generation
sequencing (NGS). All embryo transfers were performed as FET.
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Participants/materials, setting, methods:Only cycles with a single female
infertility diagnosis and non-male infertility were included in the study and
grouped as follows: Group I consist of cases with diminished ovarian reserve
(DOR; 257 patients/311 cycles), Group II includes cases with endometriosis
(55 patients/61 cycles); Group III includes cases with PCOS (66 patients/69
cycles). Group IV consists of unexplained infertility cases (UEI; 290 patients/
314 cycles). Laboratory and clinical outcome were compared among groups.
Main results and the role of chance: Female age, laboratory parameters
such as mean number of oocytes collected, fertilized and mean number of
embryos biopsied in Group I was signiﬁcantly lower than the others (p<0.01).
Although blastocyst development rate was found to be comparable among
groups (50.9%, 53.4%, 46.9% and 40.6%), the rate of embryo euploidy was
found to be signiﬁcantly lower in Group I than the others (34.0%, 52.4%, 57.4%
and 52.2% respectively; P<0.01). Cases in Group III and IV had the lowest cycle
cancellations compared to Group I and II (13.0%, 29.9%, 58.8% and 36.1%
respectively). Once an euploid embryo was found and transferred in the uterine
environment, Group I, III and IV resulted in comparable clinical pregnancy rates
(64.1%, 61.9% and 67.2% respectively). Although the highest clinical pregnancy
rate (90.9%) and lowest miscarriage rate (6.9%) were observed in cycles involv-
ing endometriosis (Group II), the differences were not found to be statistically
signiﬁcant (p>0.05).
Limitations, reasons for caution: The main limitations in our study were
the number of cases included and its retrospective design. Prospective studies
with higher number of cases included are needed in order to validate these
ﬁndings.
Wider implications of the ﬁndings: Our results ﬁrst show that transfer of
a euploid embryo results in successful clinical outcome in all non-male infertility
groups evaluated in the study. However, quantitatively poor laboratory out-
come prior to embryo biopsy is found to be the major determinant which leads
in high cycle cancellations (>50%) in DOR cases.
Trial registration number:None.
POSTER VIEWING
Implantation and early pregnancy
P-423 Oxidative stress induced autophagy dysfunction in human
decidual cells: a novel mechanism involved in early pregnancy loss
T. Yu1, L. Jin1, H. Huang1.2
1International Peace Maternal and Child Health Hospital, Shanghai Jiao Tong
University, School of Medicine
2Institute of Embryo-Fetal Original Adult Diseases, School of Medicine, Shanghai Jiao
Tong University
Study question: To examine whether autophagy is associated with the patho-
genesis of early pregnancy loss(EPL)?
Summary answer: We found in EPL decidual cells, endoplasmic reticulum
stress-induced(ER stress) autophagy through increasing Ca2+ release and acti-
vating of CaMKKβ-AMPK signaling pathway.
What is known already: Our previous study ﬁrst reported that ER stress
existed in maternal-fetal interface, and sustained ER stress could cause decidual
cells apoptosis. Autophagy as an essential, conserved lysosomal degradation
pathway, is involved in pathological processes including neurodegenerative dis-
eases, infection and cancer. Many studies have demonstrated that ER stress trig-
gers autophagy. And the possible mechanism of ER stress induced autophagy
might be the release of Ca2+ from the ER into the cytosol, which can subse-
quently activate various kinases and proteases involved in autophagy signaling.
Study design, size, duration: Normal and EPL decidual tissues were col-
lected from patients with normal pregnancies undergoing elective termination
of gestation, and from patients with EPL, respectively.
Participants/materials, setting, methods: From January 2015 to may
2016, 15 pregnant women with a diagnosis of EPL and 30 age-matched women
with normal pregnancy were selected in the international peace maternity and
child health hospital, school of medicine, shanghai Jiao tong university. The tech-
nology of western blot, immunohistochemical and transmission electron micro-
scopic were performed on deciduas from women with EPL, and then ER stress
markers, autophagy associated protein and autophagic features were analyzed
in decidual cells (DCs).
Main results and the role of chance: This present study found that EPL
deciduas were characterized by up-expression of microtubule-associated pro-
tein (MAP) 1 light chain 3II(LC3II), extensive dilation of ER, and morphological
features of autophagosome. To explore the function and regulation mechanism
of autophagy in the pathogenesis of EPL, we developed a cell model of oxidative
stress(OS) using hydrogen peroxide(H2O2) administrated normal decidual cells.
In normal decidual cells, we found that H2O2-induced ER stress could lead to
autophagy through increasing Ca2+ release and activation of CaMKKβ-AMPK
signaling pathway. However, vitamin E could reverse the concentration of cyto-
solic Ca2+ and the expression of LC3II. These ﬁndings indicated the occurrence
of ER stress-induced autophagy in EPL decidual cells, which might play an
important role in the development of EPL.
Limitations, reasons for caution: This study focused on the function of
LC3II in EPL, however, numerous other autophagy related proteins may also be
responsible for the pathogenesis of EPL. Therefore, further studies are required
to elucidate the mechanism in EPL.
Wider implications of the ﬁndings: Our ﬁndings indicate that autophagy
may contribute to the development of EPL, and the inhibition or disruption of
autophagy may be a potential therapeutic target to prevent EPL in the future.
Trial registration number: no.
P-424 A systematic review andmeta-analysis of chronic
endometritis and recurrent miscarriage
M. Rimmer, K. Fishwick, J. Brosens, S. Quenby
University of Warwick, Reproductive Health, WARWICK, United Kingdom
Study question: Is their an association between chronic endometritis (CE)
and recurrent miscarriage (RM)? Does CE predict miscarriage? Do antibiotics
reduce CE and prevent miscarriage?
Summary answer:Despite a high prevalence of CE in RM, there is insufﬁcient
evidence to recommend screening for and treating CE in recurrent miscarriage.
What is known already: Chronic Endometritis (CE) is deﬁned as long-term
inﬂammation of the endometrium and possibly driven by infection. The diagno-
sis is based on the identiﬁcation of plasma cells within the endometrium by
morphology with Haematoxylin and Eosin or mere recently using immunohis-
tochmestry to CD138 or hysteroscopy. CE has been associated with potential
pathogenic organisms, bacterial dysbiosis. Numerous studies have reported a
high prevalence of CE in the recurrent reproductive failure population and anti-
biotics have been used to reduce CE and prevent miscarriage. A systematic
review of these studies is needed to provide clarity as to the status of the cur-
rent evidence.
Study design, size, duration: Search terms were identiﬁed and searches
were run in the MEDLINE, EMBASE, Web of Science, CINAHL and Cochrane
databases. Studies were excluded if large potential bias existed. Two independ-
ent reviewers selected 17 studies, which met predeﬁned criteria. Manuscript
quality and analysis of bias were assessed using the Critical Appraisal Skills
Programme.
Participants/materials, setting, methods: Studies were included if they
included women with RM and/or; investigated a link between CE and RM,
investigated CE prevalence in women with and without RM, compared treat-
ment of women with RM with antibiotics or no antibiotics, looked for an out-
come of live birth rate, tested for CE using endometrial biopsy or hysteroscopy.
There were no language restrictions. 173 studies were identiﬁed of which 17
met the inclusion criteria.
Main results and the role of chance: Several studies reported a high inci-
dence of CE in recurrent miscarriage, up to 57%. However, there were no stud-
ies with adequate controls to establish the prevalence in the general population.
Two studies found a higher live birth rate in women with RM and CE than
without CE (OR 3.34 (1.67, 6.87) N = 159).
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Based on assessment of a repeat endometrial biopsy, a single course of
Doxycycline was reported to “cure” CE deﬁned histologically in 92%, 94%, 75%
and 70% of patients (4 studies). Although no randomised controlled trials were
identiﬁed, non-randomised observational studies found that:
• Published comparisons of livebirth rate in women with untreated CE com-
pared to treated CE were small OR 1.12 (0.27,4.67) N = 71
• An increase in livebirth rate in CE patients who responded to antibiotic
treatment compared to those who did not. OR 12.40 (6.74, 22.81) N =
244
• A comparable livebirth rate in women with CE who were actively treated
with antibiotics compared to subjects without CE OR 1.48 (0.83, 2.65) N =
540.
Limitations, reasons for caution: The incidence of CE in the normal popu-
lation was not published. No randomised control trials were identiﬁed assessing
the efﬁcacy of antibiotics in the prevention of miscarriage for women with CE
and RM.
Wider implications of the ﬁndings: This review has found insufﬁcient evi-
dence to recommend screening for and treating CE in recurrent miscarriage at
the present time. However, the data do suggest that CE may be a treatable
cause of recurrent miscarriage. Randomised, controlled trials are urgently
needed.
Trial registration number:NA.
P-425 Lipidomic proﬁle as a non-invasive tool to predict
endometrial receptivity in freeze-all cycles
D.P.A.F. Braga1, E. Borges Jr.2, A.T. Godoy3, G.P. Oliveira3,
M.N. Eberlin3, D.A. Montani4, A.S. Setti5, B.F. Zanetti5, E. Ono5,
E.G. Lo Turco4
1Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
2Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
3Universidade de Campinas, Laboratorio ThoMSon de Espectrometria de Massas,
Campinas, Brazil
4Universidade Federal de Sao Paulo, Departamento de Cirurgia, Sao Paulo, Brazil
5Instituto Sapíentiae - Centro de Estudos em Reprodução Assistida, Scientiﬁc
Department, Sao Paulo, Brazil
Study question: Is the endometrial ﬂuid lipidomic an useful approach to pre-
dict endometrial receptivity in freeze-all cycles?
Summary answer: The endometrial ﬂuid lipidomic is a valuable tool to pre-
dict endometrial receptivity in freeze-all cycles.
What is known already: The embryo implantation depends on the proper
embryo development and the acquisition of a receptive endometrium. The
embryo is unable to adhere to it through most of the menstrual cycle, except
during a short, self-limited period, the window of implantation (WOI).
Inadequate uterine receptivity has been estimated to contribute to one third of
implantation failures, whereas the embryo itself is responsible for two thirds of
them. Predictors of the uterine receptive are needed to better understand the
causes of endometrial-based infertility, and help women with recurrent implant-
ation failure (RIF) due to possible dyssynchrony, between embryo and endo-
metrium, to achieve pregnancy.
Study design, size, duration: For this prospective cohort study, endometrial
ﬂuid samples, were collected immediately before embryo transfer, using a soft
catheter, attached to a 5mL-syringe, with which a slight suction was made to
bring the ﬂuid into the catheter. Samples (n = 41) collected between Jan/2015
and Dez/2016 were split into two groups depending on the pregnancy out-
come: Positive-Group (n = 24) and Negative-Group (n = 17). The study
included exclusively freeze-all cycles in which one or two top quality blastocysts
were transferred.
Participants/materials, setting, methods: Collections were performed in
university-Afﬁliated IVF-center. Lipid extraction was performed according with
the Bligh and Dyer method and spectra were acquired in the positive mode by
MALDI-TOF mass spectrometer method. The principal component analysis
(PCA) and Partial Least square discriminant Analysis (PLS-DA) were applied to
the dataset. A list of potential ions ratios biomarker was obtained, the values
were used to build a ROC curve to predict pregnancy success, and the lipid cat-
egories were identiﬁed.
Main results and the role of chance: Patient’s and cycle’s characteristics
did not differ among the groups. The raw data was processed and 265 ions
were used for statistical analysis. Twenty ions ratios were established according
with their correlations and those variables were used for the further analysis.
The fold-change analysis detected 13 ratios with two-fold increased representa-
tion in the Positive and 84 in the Negative-Group. According with the t-test, 16
ratios were differentially represented among the groups (p<0.05), and the vol-
cano plot analysis detected ﬁve ratios two-fold differentially represented among
groups with statistical signiﬁcance. The PCA analysis showed a tendency of sep-
aration between the studied groups, while the PLS-DA was able to clearly dis-
tinguish the groups. Fifteen ratios (13 hyper-represented in the Negative and
two in the Positive-Group) were selected considering their importance for the
model prediction. These ratios were used to build the ROC curve, which pre-
sented an area under the curve of 81.8% (CI 95%: 62.7–94.7%, p = 0.009).
Ions identiﬁed by the lipidmaps database were: phosphoethanolamine,
phosphatidic-acid, diacylglycerol, triacylglycerol, glycosyl diacylglycerol, phos-
phatidylcholin, neutral-sphingolipidium, lysophosphatidylglycerol. Functional
enrichment analysis revealed that increased triacylglycerol and phospholipids
ratio leads to low density lipoproteins remodeling, which may be associated
with changed steroid syntheses, and therefore, WOI displacement.
Limitations, reasons for caution: The model was not validated because the
MS/MS experiment was not yet performed.
Wider implications of the ﬁndings: Our ﬁndings demonstrated that endo-
metrial ﬂuid lipidomics may be a powerful approach to deﬁne the exact time of
the WOI. This would be extremely important for determination of the right
time for embryo transfer and, consequently, diminish the incidence of RIF, a
substation challenge in assisted reproduction.
Trial registration number:None.
P-426 Endometrial thickness and oocyte quality affect perinatal
outcomes in intracytoplasmic sperm injection cycles
A. Iaconelli Jr.1, B.F. Zanetti2, D.P.A.F. Braga3, A.S. Setti2,
R.C.S. Figueira4, E. Borges Jr.1
1Fertility Medical Group, Clinical Department, São Paulo, Brazil
2Instituto Sapientiae - Centro de Estudos em Reprodução Assistida, Scientiﬁc
Department, Sao Paulo, Brazil
3Fertility Medical Group, Scietiﬁc Department, São Paulo, Brazil
4Fertility Medical Group, IVF Laboratory, São Paulo, Brazil
Study question: Which factors affect perinatal outcomes in intracytoplasmic
sperm injection (ICSI) cycles?
Summary answer: Perinatal outcomes are positively affected by embryo
quality and endometrium thickness and negatively affected by the presence of
oocyte polar body fragmentation.
What is known already: Pregnancies derived from assisted reproduction
techniques (ART) cycles have been correlated with worse perinatal outcomes,
such as preterm birth, low birth weight, small size for gestational age, and peri-
natal mortality. Although these complications are commonly attributed to the
higher rate of multiple births with ART, assisted singleton pregnancies had also
worse perinatal results than natural ones. Nevertheless, the role of ART itself
on poorer obstetric and perinatal outcomes has not been demonstrated con-
vincingly and is still to be determined which aspects of ART pose greater risks
of perinatal complications and how these risks can be minimized.
Study design, size, duration: This cohort study included 402 babies born to
307 patients undergoing ICSI cycles from January/2014 to December/2015.
The number of gestational weeks (GW), baby weight (BW) and length (BL) at
birth were correlated with: number of follicles and retrieved oocytes, mature
and immature oocytes, fertilization rate, number of high-quality embryos, trans-
ference stage and endometrial thickness using linear regression models. In single
embryo transfer (SET) cycles, oocyte dysmorphisms and embryo quality were
also evaluated.
Participants/materials, setting, methods: The study was performed in a
private university-afﬁliated in vitro fertilization center. After childbirth, the GW,
BW, BL, baby sex, and presence of malformations at birth were recorded by
the patient gynecologist and a written reported. All analysis were adjusted for
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mother’s age, body mass index (BMI), number of transferred embryos, gesta-
tional sacs, and born infants.
Main results and the role of chance: The endometrial thickness was posi-
tively correlated with GW (95%CI OR: 0.069; 0.327 p = 0.003) and BW (95%
CI OR: 0.770; 55.932 p = 0.044). Blastocyst transference was negatively corre-
lated with the GW in comparison to cleavage-stage embryo transfer (95%CI
OR: -1.899; -0.057 p = 0.037). The number of follicles (95%CI OR: -0.127;
-0.012 p = 0.018), that of mature oocytes (95%CI OR: -0.175; -0.001 p =
0.050), and that of immature oocytes (95%CI OR: -0.668; -0.141 p = 0.003)
were negatively correlated with BL. In SET cycles, the transfer of embryos clas-
siﬁed as high-quality was positively correlated with the number of GW (95%CI
OR: 0.633; 5.685 p = 0.014) and BW (95%CI OR: 56.394; 720.323 p = 0.022).
The only oocyte dysmorphism that negatively impacted all the perinatal out-
comes was the presence of polar body fragmentation. Babies born from
oocytes with this dysmorphism were characterized by a lower GW (95%CI
OR: -2.907;-0.083 p = 0.038), a lower BW (95%CI OR: -814.697; -85.140 p =
0.016), and a smaller BL (95%CI OR: -5.801; -2.346 p<0.001).
Limitations, reasons for caution: Although the analysis was adjusted for a
number of important confounders, the dataset included no information on edu-
cation level, ethnicity, and medical history of the women before and during
pregnancy to allow for additional adjustments. Moreover the small samples size
may limit the relevance of the study.
Wider implications of the ﬁndings: Ovarian stimulation, oocyte and
embryo quality may impact perinatal outcomes. Better perinatal outcomes may
be achieved through the transfer of high-quality embryos to a proper endomet-
rium. The presence of polar body fragmentation highly impacts the perinatal
outcomes, suggesting that the fertilization of oocytes with this dysmorphism
must be further evaluated.
Trial registration number:None.
P-427 Embryo transfer medium containing granulocyte
macrophage colony-stimulating factor improved implantation and
ongoing pregnancy rates in patients who have experienced
miscarriage
H. Tomari, K. Kunitake, K. Uchimura, N. Aramaki, S. Kuhara,
K. Nishimura, N. Hidaka, K. Honjo, Y. Nagata
IVF NAGATA Clinic, ART Lab, Fukuoka, Japan
Study question: How does embryo transfer medium containing granulocyte
macrophage colony-stimulating factor (GM-CSF) affect clinical outcomes in
vitriﬁed-warmed embryo transfer cycles in patients who have experienced
miscarriage?
Summary answer: Embryo transfer medium containing GM-CSF produced
high implantation and ongoing pregnancy rates in vitriﬁed-warmed embryo
transfers in patients who had experienced miscarriage.
What is known already: Human embryonic development and implantation
in vivo is regulated precisely by various cytokines including growth factors.
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that
plays an important role in reproductive function. Previous studies have reported
that GM-CSF is increased in normal pregnancy and is very low during pregnancy
before abortion. It suggests that increasing the concentration of GM-CSF in
implantation environment may be beneﬁcial for previous miscarriage patient.
However, the effect of GM-CSF on the cleavage stage in vitriﬁed-warmed
embryo transfer in patients who have experienced at least one miscarriage
remains unclear.
Study design, size, duration: A prospective quasi-randomized controlled
study was performed in a single in vitro fertilization (IVF) center between January
2015 and December 2017. This study included patients with nulliparity who
had experienced at least one miscarriage. All study participants provided
informed consent, and the study design was approved by the ethics committee
of IVF Nagata Clinic, Fukuoka, Japan.
Participants/materials, setting, methods: We examined 243 cycles of
vitriﬁed-warmed embryo transfer. Embryos were vitriﬁed at the 4-cell stage
(day 2). Warmed embryos were cultured for 24 hours and transferred on day
3. Patients were allocated at random to two groups. Embryos were cultured
and transferred to control medium containing no GM-CSF (Global; Lifeglobal)
(control group) or to test medium containing 2 ng/ml GM-CSF (EmbryoGen;
ORIGIO) (test group). Embryo transfer was performed at hormone replace-
ment therapy cycle.
Main results and the role of chance: Clinical pregnancy, implantation, mis-
carriage and ongoing pregnancy rates after embryo transfer were compared
between the two groups. The mean patient age was 38.8 ± 4.1 years (± SD;
range 23–45). There were no signiﬁcant differences in patient characteristics
(age, endometrial thickness, number of miscarriages, and number of embryos
transferred) between the two groups. Among the 243 vitriﬁed-warmed embryo
transfer cycles, 120 were allocated to the control group and 123 to the test
group. The clinical pregnancy rate in the test group was higher than that in the
control group (p = 0.10, 30.9% vs. 21.7%). The implantation rate in the test
group was higher than that in the control group (p = 0.09, 20.3% vs. 13.9%).
The miscarriage rate in the test group was lower than that in the control group
(p = 0.269, 28.9% vs. 42.3%). The ongoing pregnancy rate in the test group
was higher than that in the control group (p = 0.05, 22.0% vs. 12.5%).
Limitations, reasons for caution: The study was limited by the study size
and lack of data about live birth rates after embryo transfer. In addition, the
mechanism of action of GM-CSF on implantation is unknown. Further functional
studies are needed to explain the molecular mechanism of GM-CSF.
Wider implications of the ﬁndings:Our ﬁndings indicate that medium con-
taining GM-CSF improves implantation and ongoing pregnancy rates. The
results suggest that the use of embryo transfer medium containing GM-CSF
may be effective as a treatment strategy not only for patients who have experi-
enced miscarriage but also for patients with repeated implantation failure.
Trial registration number:Not applicable.
P-428 Lipidomic analysis reveals increased TXA2 presence in non-
receptive endometrium of recurrent miscarriage and repeated
implantation failure patients
E. Bastu1, I. Demiral2, E. Ulgen3, M.B. Erkan4, S.E. Celik5, Y. Aydin4,
A.N. Onem5, B. Yuksel Ozgor2, M. Dogan2, R. Apak5, U. Sezerman3,
F. Buyru2
1Acibadem University Faculty of Medicine, Department of Obstetrics and
Gynecology, Istanbul, Turkey
2Istanbul University School of Medicine, Department of Obstetrics and Gynecology,
Istanbul, Turkey
3Acibadem University, Department of Biostatistics and Medical Informatics, Istanbul,
Turkey
4Istanbul University Faculty of Science, Department of Biology, Istanbul, Turkey
5Istanbul University Faculty of Engineering, Department of Chemistry, Istanbul,
Turkey
Study question: Would the endometrial prostanoids proﬁle of unexplained
infertility, recurrent miscarriage (RM) and repeated implantation failure (RIF)
patients differ from fertile controls?
Summary answer: We have identiﬁed the increased endometrial presence
of TXA2 in RM and RIF patients; TXA2 is a prostanoid linked with platelet
aggregation and vessel contraction.
What is known already: The endometrium is a dynamic tissue that under-
goes growth, differentiation, and regression periods throughout the menstrual
cycle in response to hormonal regulation to prepare the uterus for embryo
implantation. In recent years, several studies in animal models have shown the
importance of lipids at the time of embryo implantation. Lipidomics studies
have enabled the identiﬁcation and characterization of these lipids at the time of
endometrial receptivity. Lipid molecules such as prostaglandins are some of the
most widely studied mediators of embryo implantation. Prostaglandins modu-
late the activity of endometrium and their functional role can be appreciated
through tissue concentration of prostanoids.
Study design, size, duration: In this prospective cohort study, endometrial
samples were collected from 18 unexplained infertility patients, 16 RM patients,
15 RIF patients and 23 fertile controls during the window of implantation (LH
+7 to LH+10) at gynecology and infertility clinics of Istanbul University School
of Medicine. Tissue samples were homogenized and extracted. Then lipidomic
analysis of prostanoids were carried out by LC-ESI-MS/MS in the analytical
chemistry laboratory of the Istanbul University.
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Participants/materials, setting, methods: 18 prostanoids were identiﬁed
according to literature: 6-keto 6-keto PGF1α, PGF3α, TXB2, PGE3, PGD3,
PGF1α, PGF2α, PGE2, PGE1, 13,14-dihydro-PGF2α, PGD1, PGD2, 13,14-dihy-
dro-PGF1α, 13,14-dihydro PGE1, 13,14-dihydro-15-keto PGF2α, 13,14-dihy-
dro-15-keto PGE2, 13,14-dihydro-15-keto-PGE1, 15-deoxy-Δ 12,14 PGJ2.
Unexplained infertility was deﬁned as normal hormone panel, hysteroscopic
ﬁndings and sperm parameters. RM was deﬁned as at least 2 miscarriages at 20
weeks or less. RIF was deﬁned the failure to conceive after at least 2 cycles of
IVF.
Main results and the role of chance: When prostanoid concentration in
endometrium samples of unexplained infertility patients were compared with
fertile controls, there was no statistically signiﬁcant differences (p>0.05). When
prostanoid concentration in endometrium samples of RM patients was com-
pared with fertile controls TXA2 (measured as TXB2 in line with literature due
to the unstable nature of TXA2) was signiﬁcantly higher (p<0.001). Similarly,
TXB2 was higher in endometrium samples of RIF patients again in comparison
to fertile controls (p<0.001). Median values of TXB2 are as follows: in fertile
controls 133.5 pg/mg; in RM patients 858.7 pg/mg; in RIF patients 843.1 pg/
mg. When TXB2 was further compared between samples of RM and RIF
patients, there was no statistically signiﬁcant difference (p>0.05).
Limitations, reasons for caution: Recent studies have used lipidomic ana-
lyses to study pregnancy outcome, but receptive versus non-receptive endo-
metrium in humans were not analyzed. For the ﬁrst time in literature, we
attempted to compare receptive versus non-receptive endometrium using lipi-
domic approach via 18 chosen prostanoids. However, a comprehensive map of
prostaglandin expression is lacking.
Wider implications of the ﬁndings: Using lipidomic analysis we have identi-
ﬁed the increased endometrial presence of TXA2 in RM and RIF patients, while
no such presence in unexplained infertility patients. Interestingly, TXA2 has
well-recognized platelet aggregating and vessel-contracting activities. This is clin-
ically relevant because it may shed light on events leading to successful embryo
implantation.
Trial registration number: not applicable.
P-429 Ectopic pregnancy and endometrial thickness in assisted
reproduction cycles: is there a link?
S. Mattar1,2, L. Lapensée1,2, C. Sylvestre1,2, A. Eberle3, S. Phillips1,2,
R. Antaki1,2
1Université de Montréal, Obstetrics & Gynecology- division of Reproductive
Endocrinology & Infertility, Montreal, Canada
2Ovo Clinic, Ovo Fertility, Montreal, Canada
3Université de Montréal, Faculty of Medicine, Montreal, Canada
Study question: Can a thick endometrial lining measured prior to embryo
transfer be considered a protective factor against ectopic pregnancy (EP)?
Summary answer: An endometrial thickness (ET) of > 12 mm is associated
with a 68% decreased chance of EP in assisted reproduction technology (ART)
cycles.
What is known already: EP is more common in pregnancies resulting from
ART compared to those from spontaneous conception, with some peculiar risk
factors like number and day of embryos transferred, volume and depth of trans-
ferred material, among others. However only one study so far assessed the link
between ET and EP.
Study design, size, duration: This is a retrospective case-control study
comparing all cases (n = 45) of EP (study group) to 119 cases of documented
viable intra-uterine pregnancies (control group) between August 2009 and
December 2016 at a private fertility clinic (OVO clinic, Montreal, Canada).
Pregnancies resulting from both fresh embryo transfer and frozen embryo
transfer (FET) were included.
Participants/materials, setting, methods: The study group consisted of
29 EP in the fresh cycles and 16 in the FET cycles. The control group cases
were selected based on a random number generator model on a year-to-year
basis. Bivariate analysis was conducted to assess the effect of all collected vari-
ables on EP. A multivariate analysis was then used to calculate the odds ratio
(OR) for EP with an ET > 12 mm, adjusted for known confounders.
Main results and the role of chance: The two groups did not differ signiﬁ-
cantly in factors traditionally associated with EP (previous EP, endometriosis,
tubal disease, history of pelvic infection, and abdominal surgery). Patients with
EP were more likely to have a thinner endometrium (9.7 vs 10.2 mm, p =
0.009), had day 3 rather than a day 5 transfer (p <0.001), had double rather
than a single embryo transfer (p <0.001), and ﬁnally were more likely to have
had a difﬁcult transfer (p = 0.002).
When analyzed separately, the association between a small ET and EP was
preserved in FET cycles (8.9 vs 9.8 mm, p = 0.015) but not in fresh cycles (10.0
vs 10.4 mm, p = 0.116).
In multivariate analysis, ET > 12 mm was found to be a signiﬁcant protective
factor against EP with an OR of 0.32 (95% CI 0.12-0.84). However, difﬁcult
transfer and day 3 embryo transfer remained as statistically signiﬁcant independ-
ent risk factors for EP with OR’s of 18.04 (95% CI 2.36-137.62) and 7.07 (95%
CI 2.62-19.07) respectively.
Limitations, reasons for caution: The retrospective nature of the study
and the inter-observer variability in the measurement of the ET might weaken
the conclusion. It is also possible that some other confounders have not been
accounted for.
Wider implications of the ﬁndings: It is the ﬁrst study to show that a high-
er ET could have a risk-reducing effect on EP, which if conﬁrmed by future pro-
spective observations, can act as a counseling cornerstone by providing
reassurance for patients at risk undergoing ART.
Trial registration number:Not applicable.
P-430 Danaparoid is effective and safe for patients with obstetric
antiphospholipid syndrome
H. Yoshihara, M. Sugiura-Ogasawara, C. Bannno, T. Kitaori,
Y. Ozaki, K. Katano, N. Suzumori
Nagoya City University -Gradeate School of Medical Science, Obstetrics and
Gynecology, Nagoya, Japan
Study question: It was unclear whether danaparoid sodium (OrgaranR) is
effective in improving the live birth rate in patients with obstetric antiphospholi-
pid syndrome (oAPS).
Summary answer: The live birth rate in patients who received danaparoid
was similar to that in patients who received unfractionated heparin.
What is known already: Unfractionated heparin and low-dose aspirin (LDA)
is known to improve the live birth rate in patients with oAPS. Alternatively,
anticoagulation with danaparoid was reported to be effective and safe in 83
patients with a history of thrombophilia and/or intra-uterine growth retard-
ation complicated by HIT or intolerance or resistance to low molecular weight
heparins.
Study design, size, duration: A case-control study was conducted between
2006 and 2017. It examined 86 pregnancies in 62 patients with oAPS diagnosed
according to criteria of the International Congress on APS. Patients who suf-
fered two miscarriages were included based on ESHRE recurrent pregnancy
loss guidelines.
Participants/materials, setting, methods: APS was diagnosed by measur-
ing lupus anticoagulant (LA), by the activated partial thromboplastin time and
Russell’s viper venom time and/or the presence of b2glycoprotein I dependent
anticardiolipin antibodies. Live birth rates, and adverse pregnancy and perinatal
outcomes were compared among patients given danaparoid and LDA (dana-
paroid group), unfractionated heparin and LDA (heparin group) and LDA and/
or prednisolone (LDA group).
Main results and the role of chance: Live birth rates were 63.6 % (14/22)
for the danaparoid group, 79.5 % (31/39) for the heparin group and 56.0 %
(14/25) for the LDA group. After excluding 11 miscarriages with abnormal
embryonic chromosomes and one ectopic pregnancy, live birth rates were 87.5
% (14/16) for the danaparoid group, 86.1% (31/36) for the heparin group and
63.6 % (14/22) for the LDA group. Frequencies of abnormal embryonic karyo-
types were 75.0% (6/8), 25.0% (2/8), 33.3% (3/9), respectively, because the
mean (SD) age of the danaparoid group tended to be higher (p = 0.014). The
live birth rate of patients given danaparoid and unfractionated heparin was simi-
lar and tended to be higher than that of patients given LDA (OR 4.0, 95%
i338 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
conﬁdence interval 0.72-22.2 and 3.5, 0.98-12.8). One patient given unfractio-
nated heparin developed HIT and this case resulted in stillbirth.
Limitations, reasons for caution: This study was not a randomized control
trial (RCT). The sample size of patients with danaparoid was relatively small
because Japanese medical insurance could cover only treatment with unfractio-
nated heparin. Further RCTs are necessary to conﬁrm these results.
Wider implications of the ﬁndings: Danaparoid is safe and effective in
improving the live birth rate in patients with oAPS.
Trial registration number: UMIN000031012
P-431 Serum 17-alpha-hydroxyprogesterone (Sr. 17-α-OHP): a
precocious early indicator of implantation and gestational status in
double embryo-transfer fresh IVF cycles
B.N. Chimote1, N. Chimote2
1Vaunshdhara Clinic & Assisted Conception Centre, Embryology- Endocrinology,
Nagpur, India
2Vaunshdhara Clinic and Assisted Conception Centre, Endocrinology- Embryology,
Nagpur, India
Study question: To evaluate if serum level of 17-alpha-hydroxyprogesterone
(17-α-OHP) in the peri-/post-implantation period may be early indicator of
gestational status in double embryo-transfer fresh IVF cycles.
Summary answer: Ratio of Day of Embryo-transfer(dET):d7ET serum 17-α-
OHP and its pattern of rise/fall post-ET is a robust marker of implantation and
gestational status in IVF cycles.
What is known already: The complications of maternal morbidity and neo-
natal care associated with high-risk multiple-gestations that often occur in IVF
cycles due to transfer of supernumery embryos has prompted the practice of
single embryo-transfer. However, several countries, with no IVF funding/insur-
ance cover, continue to transfer ≥2 embryos on day3/day5 to enhance preg-
nancy rates in minimal number of cycles and to complete family structure (one
boy/one girl) in single cycle. Under such circumstances, it is imperative and
advantageous to know gestational status well in advance so that necessary care
and precautions may be taken. Currently, no such early indicator of gestational
status is available.
Study design, size, duration: Prospective cohort study of IVF cycles (n =
780) carried out from July 2014 to March 2017 in consenting women undergo-
ing antagonist stimulation protocol followed by double embryo-transfer on
either day3 or day5 in a suitably prepared endometrium. Similar luteal phase
support was provided to all women. Serum 17- α-OHP level was measured on
dET and subsequently on days 7,11,14,19,23 post-ET. Serum estradiol, β-hCG
and progesterone levels were also measured on all these days using diagnostic
kits.
Participants/materials, setting, methods: β-hCG measurement on d7ET
was considered indicator of pregnancy. Implantation was main outcome meas-
ure with singletons (n = 131), twins (n = 43), miscarriages (n = 18), ectopic
pregnancy (n = 9) and biochemical pregnancy (n = 70) as offshoot measures of
implantation. Ratio of 17-α-OHP levels on dET:d7ET in no-implantation cycles
(n = 509) were compared with those in different categories of implantation.
Statistical analysis involved Student’s-t test, Chi-square test, Correlation, One-
Way ANOVA/Post-test, ROC analysis, as applicable, using Graph-pad Prism
VI software.
Main results and the role of chance: The ratio dET: d7ET serum 17-α-
OHP levels differed signiﬁcantly between no-implantation (3.2 ± 0.16) versus
singletons (1.18 ± 0.05;p<0.0001,), twins (0.67 ± 0.05;p<0.0001), early mis-
carriages (1.23 ± 0.1;p = 0.02), ectopic pregnancy (0.82 ± 0.1;p = 0.04) and
biochemical pregnancy (1.87 ± 0.1;p = 0.002).
Day7 serum 17-α-OHP levels strongly correlated with implantation
(Spearman r = 0.63,p<0.0001, 95%CI 0.58-0.67). The likelihood for all kinds of
pregnancies increased above the D7 17-α-OHP median value of 3.2 ng/ml;
whereas likelihood of singletons and twins was high above the 75th percentile
value of 5.4 ng/ml and 95th percentile value of 9.98 ng/ml respectively. Post-
test for linear trend in 17-α-OHP levels serially every 4 days from day7 to
day23 post-ET showed a linear rise in singleton and twins cycles (Slope 0.77,
p<0.0001 and 2.3, p = 0.0002 respectively); displayed non-signiﬁcant steep rise
in ectopic cycles (slope 4.97,p = 0.33) whereas declined in biochemical
pregnancies (Slope -0.06, p = 0.45). Indication for IVF, day of ET (Day3/Day5),
endometrial thickness and echo-pattern on ultrasonography, all remained non-
signiﬁcantly comparable throughout the study population.
Thus, transition from dET to d7ET and thereafter maintenance of linear rise
in 17-α-OHP levels decides the fate of implantation/gestational-status.
Minimum sample size of 108 was required for 17-α-OHP to have >85% pre-
dictive power for no-implantation versus 5 different types of implantation/ges-
tational status. The power of our study (n = 780) is therefore very strong and
predictive.
Limitations, reasons for caution: Not exactly a limitation but although the
sample size of this study is sufﬁciently large with robust results and strong pre-
dictive power; a multi-centric Randomized Controlled trial is warranted for
establishing serum 17-α-OHP as an early indicator and a gold standard for
implantation/ gestational status in multiple embryo-transfer IVF cycles.
Wider implications of the ﬁndings: This study assumes immense signiﬁ-
cance especially in Asian sub-continent where multiple-embryo-transfer is done
for various reasons. Risks associated with multiple-gestations/ectopics are well
documented and it is often too late to take necessary steps. An early indicator
can facilitate timely clinical management and help circumvent the complications
to a large extent.
Trial registration number:Not Applicable.
P-432 Endometrial transcriptomic pathways analysis in recurrent
miscarriages and unexplained infertility
I. Demiral1, E. Gumusoglu2, E. Ulgen3, M. Hosseini2, B. Yuksel
Ozgor1, M. Dogan4, A. Nehir Aytan1, U. Sezerman3, T. Gunel2,
E. Bastu4
1Istanbul University School of Medicine, Obstetrics and Gynecology, Istanbul, Turkey
2Istanbul University, Molecular Biology and Genetics, Istanbul, Turkey
3Acibadem University School of Medicine, Biostatistics and Medical Informatics,
Istanbul, Turkey
4Acibadem University School of Medicine, Obstetrics and Gynecology, Istanbul,
Turkey
Study question:Would endometrial genes and their transcriptomic pathways
in patients with recurrent miscarriage (RM) and unexplained infertility (UI) differ
from fertile controls?
Summary answer: In RM and IU, respectively 8 and 20 pathways based on
730 and 2171 differentially expressed genes are signiﬁcantly altered when com-
pared to fertile controls.
What is known already: The endometrium is a complex structure undergo-
ing signiﬁcant transcriptomic transformations during menstrual cycle. This con-
stantly changing feature support the adherence, then invasion and growth of an
embryo. Any disturbance in this fragile system results with infertility or negative
pregnancy outcomes. Beginning with Carson’s paper in 2002, genomic analysis
have been broadly used in different subgroups of infertility. RM and UI have
been studied in many papers using microarray analysis in order to ﬁnd ‘target’
genes responsible of the disease. Despite the high number of microarray stud-
ies, a consistency between results is still lacking, making this topic still interesting
for researchers.
Study design, size, duration: This prospective cohort study involved 24
patients in each group: RM, UI and control. Recruited between August 2014-
August 2015, all patients were <35 years old. RM was deﬁned as ≥2 consecu-
tives pregnancy losses in women with normal RM workup (hormon proﬁle at
Day 3, hysterosalpingogram, spermiogram, karyotype, antiphospholipid syn-
drome antibodies, inherited trombophilias). Women with no evident reason
for infertility were in UI group. Women with ≥1 live birth(s) and no other
comorbidities were controls.
Participants/materials, setting, methods: Endometrial samples were
taken in Istanbul University School of Medicine, during the window of implant-
ation (LH+7 to LH+10). They were put in RNAlater for one night at +4°C, and
then snap frozen in liquid nitrogen. In our molecular biology and genetics
laboratory, RNA extraction and hybridization with microarray slides were per-
formed. Slides were scanned and hybridization signals were extracted using a
sotfware program. R10 package limma and PANOGA were used for statistical
analysis.
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Main results and the role of chance: Analysis for RM compared to controls
revealed 730 differentially-expressed genes (DEGs) clustered in 8 representa-
tive pathways: pathways in cancer (p value = 3.11E-12), regulation of actin
cytoskeleton ( p = 2.81E-09), NF-kappa B signaling pathway (p = 5.89E-11),
adherens junction (p = 9.99E-09), complement and coagulation cascades (p =
6.23E-09), SNARE interactions in vesicular transport (p = 5.60E-06), citrate
cycle (TCA cycle) (p = 2.98E-07) and sulfur relay system (p = 1.90E-06).
Analysis for UI compared to controls revealed 2171 DEGs clustered in 20
representative pathways: complement and coagulation cascades (p = 1.22E-
19), morphine addiction (p = 6.49E-19), PI3K-Akt signaling pathway (p =
3.25E-14), SNARE interactions in vesicular transport (p = 2.33E-13), adherens
junction (p = 4.43E-11), p53 signaling pathway (p = 6.15E-11), spliceosome (p
= 3.02E-10), endocytosis (p = 3.02E-10), TGF-beta signaling pathway (p =
3.15E-10), amyotrophic lateral sclerosis (ALS) (p = 2.30E-09), notch signaling
pathway (p = 5.36E-09), viral myocarditis (p = 1.76E-08), renin-angiotensin sys-
tem (p = 2.64E-08), maturity onset diabetes of the young (p = 4.40E-08), pro-
teasome (p = 4.97E-06), dilated cardiomyopathy (p = 1.08E-05), non-
homologous end-joining (p = 3.28E-05), basal transcription factors (p = 3.83E-
05), folate biosynthesis (p = 5.74E-05) and amoebiasis (p = 6.03E-05).
Limitations, reasons for caution: Some limitations should be addressed:
endometrial samples were not taken on the exact same menstrual day for all
patients, the commercially available microarray slides used in our study can
have differences from other brands, and complete disclosure of genes in others
studies is lacking making a fair literature comparison difﬁcult.
Wider implications of the ﬁndings: Instead of being limited to one gene or
a group of genes, pathways analysis provides us a better understanding of the
ethiology beneath RM and UI. Different genes may impact one common path-
way: this could be the reason why a consistency can not be achieved across
microarray studies.
Trial registration number: not applicable.
P-433 Prostaglandin E2 receptor 3 (EP3) signaling is induced in
placentas of patients with unexplained recurrent pregnancy losses
(uRPL)
Y. Ye1, A. Vattai1, N. Ditsch1, C. Kuhn1, M. Rahmeh1, S. Mahner1,
M. Ripphahn2, R. Immler2, M. Sperandio2, U. Jeschke1,
V. Von Schönfeldt1
1Ludwig-Maximilians-University of Munich- Germany, Department of Obstetrics and
Gynecology, Munich, Germany
2Ludwig-Maximilians-University of Munich- Germany, Department of Cardiovascular
Physiology and Pathophysiology, Munich, Germany
Study question: Is prostaglandin E2 receptor 3 (EP3) signaling involved in the
mechanism of unexplained recurrent pregnancy losses (uRPL)?
Summary answer: Elevated expression of EP3 signaling in ﬁrst trimester pla-
centas plays an important role in the fetal-maternal interface of patients with
uRPL.
What is known already: An inﬂammatory microenvironment is required for
successful implantation, however an inﬂammatory overreaction is one of the
main causes for uRPL. Prostaglandin E2 (PGE2) plays a pivotal role in regulating
immune balance and angiogenesis during early pregnancy and it is able to stimu-
late inﬂammatory reactions via EP3.
Study design, size, duration: A total of 19 women with uRPL and 19 healthy
pregnancies were included. For in vitro studies, JEG-3 and HTR-8/SVneo cells
were used and stimulated by PGE2, sulprostone (an EP1/EP3 agonist) and L-
798,106 (an EP3 antagonist) with different concentrations.
Participants/materials, setting, methods:We analysed the expression of
cyclooxygenase-2 (COX-2), EP3 and G protein alpha inhibitor 1 (Gi1) in ﬁrst tri-
mester placentas of women with uRPL and healthy pregnancies via immunohis-
tochemistry and double immunoﬂuorescence. The production of β-hCG,
progesterone and plasminogen activator inhibitor type 1 (PAI-1) in JEG-3 and
HTR-8/SVneo cells was examined by enzyme-linked immunosorbent assay
(ELISA). The expression of EP3 and Gi1 of JEG-3 and HTR-8/SVneo cells was
evaluated by western blotting.
Main results and the role of chance: The expression of COX-2, EP3 and
Gi1 was upregulated in the placenta of women with uRPL in comparison to
healthy controls. Sulprostone inhibited the secretion of β-hCG and progester-
one in JEG-3 cells and the secretion of β-hCG in HTR-8/SVneo cells, while it sti-
mulated the expression of PAI-1 in JEG-3 cells in vitro. In addition, PGE2/
sulprostone was able to induce the expression of Gi1 in JEG-3 and HTR-8/
SVneo cells, respectively. L-798,106 (an EP3 speciﬁc antagonist) suppressed
EP3 expression in both trophoblast cell lines.
Limitations, reasons for caution: Further studies are required to under-
stand the role of the additional membrane receptors of PGE2 (EP1, 2 and 4)
and other members of the Gi family (Gi2 and Gi3) in the placenta of uRPL
patients.
Wider implications of the ﬁndings: These mechanisms give a better
understanding of how PGE2 may regulate placental inﬂammatory status in uRPL
patients. As an EP3 antagonist, L-798,106 might quantify a ‘potential therapeutic
candidate’ for the treatment of uRPL.
Trial registration number:NA.
P-435 Utilization of dydrogesterone in programmed FET cycles
allows the determination of serum progesterone of exclusively
trophoblastic origin in pregnancy- an update on the luteoplacental
shift
K. Neumann, M. Depenbusch, A. Schultze-Mosgau,
T. Osterholz-Zaleski, G. Griesinger
Universitäre Kinderwunschzentren Lübeck/Manhagen, Department of Gynecological
Endocrinology and Reproductive Medicine, Lübeck, Germany
Study question:What are the precise kinetics of placental progesterone pro-
duction in early pregnancy and how do these relate with the type and course of
pregnancy?
Summary answer: Progesterone remains virtually undetectable until the
+16-22 days (d) after embryo transfer. The increase is nonlinear, depends on
the type of pregnancy and predicts miscarriage.
What is known already: The onset of placental progesterone production is
termed the luteo-placental shift (LPS). Previous studies on pregnancies after
oocyte donation in ovarian failure patients map the LPS to around the 5th
(Devroey et al. 1990) or 9th gestational week (GW) (Scott et al. 1991), whereas
the classical oophorectomy studies of Csapo et al. report the LPS between the
8th and 9th GW. Dydrogesterone does not cross-react with antibodies in
ELISAs. The utilization of dydrogesterone in a programmed frozen-thawed
embryo transfer cycle (in which no corpus luteum is present) therefore allows
the determination of serum progesterone of exclusively trophoblastic origin in
pregnancy.
Study design, size, duration: Prospective analysis of pregnancies resulting
from programed FET cycles with oral E2 (6 mg/d for minimal intake 13 days)
followed by E2 (6 mg/d) and 30 mg/d oral dydrogesterone up to the 12th GW.
The sample collection started in 7/2015 and is currently ongoing. Progesterone
levels are expressed in μg/l (±standard deviation).
Participants/materials, setting, methods: All patients were transferred
one (singletons) or two embryos. Patients were divided into groups by preg-
nancy type (singletons, n = 17; dichorionic twins, n = 7; triplets, n = 1, abor-
tion, n = 20). The type of pregnancy was determined by ultrasound starting
+16-22d following embryo transfer (ET). Progesterone, E2 and hCG was mea-
sured in serum samples by the Roche Elecsys ELISA before dydrogesterone
intake on day 13-15 (to conﬁrm absence of ovulation) and weekly in early preg-
nancy up to +65-71d following ET.
Main results and the role of chance: Endogenous progesterone was not
increased in all groups on ﬁrst blood analysis on day 9-15 days following ET
compared to baseline levels on day 13-15 (singletons after eSET: 0.25 ± 0.20;
n = 16; twins: 0.25 ± 0.15; n = 6, triplet: 0.33; n = 1) and increased only mar-
ginally up to +16-22d post ET independently from the type of pregnancy
(singleton: 0.33 ± 0.11; n = 13; twins: 0.51 ± 0.27; n = 6, triplet: 0.33).
Progesterone levels started to rise above 1.0 μg/l within 23-29d post ET
(singleton: 1.43 ± 0.89; n = 16; twins: 1.96 ± 0.83; n = 6, triplet: 3.44). From
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+30-36d on the twin group and the triplet pregnancy (n = 1) showed an ele-
vated progesterone increase versus singleton pregnancies (singleton: 3.67 ±
1.53; n = 14; linear slope: y = 2.8465× - 6.912; twins: 6.45 ± 2.29; linear slope:
y = 4.6047× - 10.821; n = 6, triplet: 11.9; linear slope: y = 6.5007× - 15.602)
which was aggravated even further on following analysis and resulted in mark-
edly enhanced progesterone levels on last analysis during +65-71d (singleton:
23.33 ± 7.51; n = 11; twins: 36.57 ± 6.57, n = 4; triplet: 60.9;) in parallel with
estradiol levels. While hCG plateaus around +37-43d, placental progesterone
production steadily increases throughout the ﬁrst trimester. Miscarriage was
reliably predicted by progesterone levels measured +23-29d after embryo
transfer (ROC analysis AUC = 0.85, 95% CI: 0.69–1.00, p = 0.004).
Limitations, reasons for caution: Minimal cross-reaction of the antibodies
used in the Roche ELISA between endogenous progesterone and dydrogester-
one may have slightly distorted the values. The sample size is too small to reli-
ably establish the predictive performance of endogenous progesterone values
for miscarriage or adverse events related to abnormal early placental
development.
Wider implications of the ﬁndings: For the ﬁrst time in human reproduc-
tion, early pregnancy trophoblastic progesterone production was assessed
without the background “noise” caused by either a corpus luteum graviditate or
exogenous progesterone supplementation. The ﬁndings ﬁre new studies on the
LPS, prediction of pregnancy viability, placental activity/pathology with wide
implications (fetal growth etc.).
Trial registration number: n.a.
P-436 Local Endometrial injury before frozen-thawed embryo
transfer (FTET) cycles? A review andmeta-analysis
E. Theodorou, J. Ben Nagi, O. Ozturk, P. Serhal
The Centre for Reproductive and Genetic Health CRGH, Reproductive Medicine,
London, United Kingdom
Study question: Does endometrial injury before a frozen-thawed embryo
transfer (FTET) cycle increases chances of pregnancy or live birth?
Summary answer: Currently there is limited evidence to recommend endo-
metrial injury before FTET cycles.
What is known already: Randomised studies and meta-analysis suggest that
local endometrial injury (LEI) in the cycle preceding IVF treatment appears to
increase pregnancy rate particularly in women with recurrent implantation fail-
ure. A further meta-analysis concluded that while results must be interpreted
with caution due to low quality evidence, endometrial injury before intrauterine
insemination or when trying for a natural conception could be associated with
higher live birth rate. It is not known whether the same beneﬁt could be
observed after endometrial injury for FTET cycles.
Study design, size, duration:We searched the MEDLINE, EMBASE and the
Cochrane Central Register of Controlled Trials (CENTRAL), as well as refer-
ence lists of relevant reviews and included studies. We performed the search
from inception to January 2018. We included randomised controlled trials
(RCTs) that evaluated any kind of intentional endometrial injury in women plan-
ning to undergo a FTET compared to no intervention or a mock intervention.
The risk of bias was judged according to Cochrane Handbook’s
recommendations.
Participants/materials, setting, methods: We identiﬁed 4 RCTs that
included in total 476 FTET cycles; three studied patients who had FTET with
hormone replacement treatment (HRT) and one patients during a natural cycle.
In all studies the intervention group had endometrial injury with an endometrial
biopsy catheter (Pipelle, Pipette or an Endocyte® sampler) while the control
group in one of the three studies had endocervical manipulation and in the
remaining three no uterine manipulation.
Main results and the role of chance:Meta-analysis of two RCTs that evalu-
ated LEI in women undergoing FTET showed no signiﬁcant difference in preg-
nancy rate between the LEI and control group (OR 0.89; 95% CI 0.41-1.94; p
= 0.77).
Studies that investigated FTET during natural and HRT cycles were pooled
due to evidence suggesting the outcome is similar and also due to the small
number of studies.
Four RCTs evaluated the role of LEI in women undergoing FTET (1 with nat-
ural cycles and 3 studies with HRT) showed no difference rate in clinical preg-
nancy rate and ongoing/live birth rate versus the control group (OR 1.17; CI
0.68-2.01; p = 0.57 and OR 1.40; CI 0.63-3.11; p = 0.40, respectively).
A subgroup analysis of two RCTs including unselected women for FTET and
two RCTs including women with at least 2-4 failed embryo transfers didn’t sug-
gest a higher LBR for women having EI for either of the two subgroups (OR
0.95; CI 0.54-1.66; p = 0.85 and OR 2.61; CI 0.44-15.51; p = 0.29,
respectively).
Limitations, reasons for caution: This is the ﬁrst attempt to systematically
review the evidence for endometrial injury before FTET. However, this was
based on a small number of RCTs, which did not allow for the analysis of sub-
groups such us natural vs HRT or number of previous failed embryo transfers
for all outcomes.
Wider implications of the ﬁndings:While there is evidence to suggest that
endometrial injury could increase the success rate for women having fresh IVF
treatment, IUI or when trying to conceive naturally, there is currently limited
evidence to indicate that LEI could improve FTET outcome.
Trial registration number:Not applicable.
P-437 Identiﬁcation of the human uterine acetylome
M. Taggart1, M. Karolczak-Bayatti2, R.Watson1, A. Treumann3,
G.N. Europe-Finner1, P. Palmowski1
1Newcastle University, Institute of Genetic Medicine, Newcastle upon Tyne, United
Kingdom
2Manchester University, School of Health Sciences, Manchester, United Kingdom
3Newcastle University, Newcastle Proteome and Protein Analysis, Newcastle upon
Tyne, United Kingdom
Study question: Can we identify the breadth of lysine residues modiﬁed by
acetylation in the human uterine proteome?
Summary answer: Almost 2,000 lysine residues were acetylated in the
human myometrium proteome. >300 were potentially modulated by treatment
with a lysine deacetylase inhibitor TSA.
What is known already: There are many possibilities for post-translationally
modifying proteins and regulating uterine cell function during menstruation,
early and established pregnancy - e.g, acetylation of lysine residues, regulated
by acetyltransferases (KATs) and deacetylases (KDACs), plays a prominent
role in cellular biology via modiﬁcation of histones and non-nuclear proteins.
We have previously shown that protein acetylation is important for regulating
human uterine contractility. Treatment of ex vivo biopsies with KDAC inhibi-
tors changed the acetylation of selected proteins – e.g. the cytoskeletal protein
HSPB6 - and altered contractility. These observations suggest protein acetyl-
ation to be a potential mechanism for initiation/regulation of uterine function.
Study design, size, duration: Uterine biopsies were obtained, following
written informed consent, from pregnant women undergoing elective
Caesarean section (38 subjects in total). 20 samples were treated with TSA and
18 were used as controls. To reach the required amount of material per repli-
cate, samples were randomly pooled into 5 treated and 6 control pools.
Participants/materials, setting, methods: The collected tissues were
immediately treated with 3.3uM TSA for 6 hours and stored frozen. Tissues
were homogenized, digested to peptides with tripsin/endolyse C and subjected
to immunoprecipitation with anti-Acetyl Lysine Antibody. The eluates, contain-
ing enriched acetylated peptides, were analysed using LC-MS based approach
(Thermo Q-Exactive). The individual peptides and acetylated residues were
identiﬁed and quantiﬁed using MaxQuant 1.5.3.8 comparisons to a Uniprot–
derived human proteome database.
Main results and the role of chance:We identiﬁed (with FDR<0.01) 1951
acetylation sites (localization probability >0.75) related to 821 protein groups.
342 acetylation sites were uniquely identiﬁed in TSA-treated samples.
Acetylation of 1254 sites was quantiﬁable between experimental conditions, of
which 127 differed signiﬁcantly (t-test, FDR<0.05) and 45 were increased by
TSA treatment. A combination of quantitative (t-test and clustering) and inter-
rogative analysis allowed us to identify that many of the acetylated proteins
were involved in cellular processes related to energy utilisation (TCA cycle and
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oxidative phosphorylation), cell motility (MYH9, MYH10, ACTB, TPM4) and
adhesion (COL6, ZYX, VCL) and chromatin structure (histones).
Limitations, reasons for caution: The process of immunoprecipitation tar-
geted for acetylated lysine residue-containing peptides enriches a small pool of
total digested peptide and cautions the interpretation of subsequent
quantiﬁcations.
Wider implications of the ﬁndings: This study provides a platform of iden-
tiﬁcation of almost 2,000 protein lysine acetylation sites in human uterine tissue.
Future experiments designed to expand the breadth of acetylated protein iden-
tiﬁcation (the acetylome) will facilitate the examination of the regulatory inﬂu-
ences of protein acetylation on human uterine function.
(Supported by MRC grant MR/L0009560/1)
Trial registration number: not applicable.
P-438 Is Endometrial Receptivity Array (ERA) screening relevant
to increase pregnancy rates in patients with failed IVF cycles?
G. Teles1, R. Lacordia2, T. Bonetti3, A.R. Lorenzon-Ojea4, E. Motta5
1Huntington Medicina Reprodutiva, Clinical Medicine Department, São Paulo, Brazil
2Huntington Medicina Reprodutiva, Clinical Medicine Department, São Paulo- SP,
Brazil
3Federal University of São Paulo, Gynecology Department, São Paulo- SP, Brazil
4Huntington Medicina Reprodutiva, Scientiﬁc Coordination, São Paulo- SP, Brazil
5Huntington Medicina Reprodutiva/Federal University of São Paulo, Clinical Medicine
Department/Gynecology Department, São Paulo- SP, Brazil
Study question: Is Endometrial Receptivity Array (ERA) screening relevant to
increase pregnancy rates in patients with previous negative IVF results?
Summary answer: There is no difference in pregnancy rates for patients with
previous fails followed by personalized ERA embryo transfer if compared to
controls with standard preparation.
What is known already:Onset of pregnancy is given when a proper embryo
has the ability to attach in a receptive tissue. Endometrial receptivity is accom-
plished on day 19-21 in normal cycle, also known as window of implantation
(WOI). Usually, endometrial thickness and progesterone serum levels are para-
meters considered to evaluate the endometrium receptivity, but it remains a
lack of accurate methods. The endometrial receptivity array (ERA) is a tran-
scriptomic signature test aiming to provide proﬁles of biopsied tissue in pre/
post non-receptive or receptive endometrium. According to this proﬁle, an
adjustment in endometrial stimulation protocol could be performed to better
synchronize an embryo transfer.
Study design, size, duration: A retrospective study, including 418 patients
divided into two groups: 209 had at least 1 previous IVF fail, followed by an
ERA biopsy, proceeded to a frozen embryo transfer (FET) where the endomet-
rial stimulation was adjusted according to the ERA result in a later cycle (perso-
nalized embryo transfer, pFET), named ERA group, and 209 age-matched
controls, at the same time, not-biopsied for ERA with a FET with a standard
endometrial preparation, named non-ERA group.
Participants/materials, setting, methods: Endometrial biopsies samples
were obtained after 120 hours of progesterone introduction and classiﬁed into
Receptive, Pre-Receptive, Post-Receptive or Non-Receptive by ERA. In both
groups, transfers were performed on blastocyst stage (embryo day 5-6).
Patients from pFET and FET groups (38 ± 5.26 years old) were also subdivided
into 2 subgroups: those with euploid biopsied embryos (ERA/PGD and Non-
ERA/PGD, n = 92 each, CGH or NGS) and those with no biopsied embryos
transferred (ERA/non-PGD and non-ERA/non-PGD, n = 117 each).
Main results and the role of chance: The majority of patients, with at least
one IVF fail and submitted to an ERA test, were found to displace a receptive
endometrium (n = 137, 65.55%) followed by pre-receptive (n = 53, 25.35%),
non-receptive (n = 11, 5.26%) or post-receptive (n = 8, 3.82%). The average
pregnancy rates were similar comparing both groups (51.67% vs 47.85%, p =
0.4935; ET number 1.75 ± 0.62 vs 1.56 ± 0.52, p = 0.0011). Either in euploid
biopsied embryos or not biopsied embryos subgroup: ERA/PGD vs Non-ERA/
PGD (48.91% vs 43.47% p = 0.5561; ET number: 1.60 ± 0.50 vs 1.43 ± 0.57,
p = 0.02), ERA/No PDG vs Non-ERA/No PGD (55.55% vs 51.28% p =
0.6002; ET number: 1.88 ± 0.72 vs 1.65 ± 0.51 p = 0.009). Receptive and pre-
receptive endometrium showed similar pregnancy rates (54.01% vs 49.05%, p
= 0.6274, ET number: 1.77 ± 0.68 vs 1.72 ± 0.49, p = 0.8607). Non-receptive
and post-receptive patients were in low numbers for relevant purpose (n = 11
and 8 respectively). For statistical analysis, paired T-test or Fisher´s test was
applied as appropriated.
Limitations, reasons for caution: In the cases where ERA result was pre,
post or non-receptive, adjusted endometrial stimulation protocol was applied
in a later cycle as suggested, but the array was not repeated to conﬁrm the
adjusted receptivity. Male factor and primary infertility reason were not con-
sidered in this study.
Wider implications of the ﬁndings: Using ERA adjustment indiscriminately,
is not relevant to increase patient’s pregnancy rates when compared to stand-
ard endometrial stimulation protocol. However, ERA should be considered for
patients with speciﬁc cause of infertility, such as repeated implantation failure.
Trial registration number:Not applicable.
P-439 The inﬂammatory response during the implantation period:
association with the Reticular Stress and the Unfolded Protein
Response
R.E. Ramhorst1, E. Grasso1, S. Gori1, E. Soczewski2, L. Fernánez2,
L. Gallino2, T. Lobo3, S. Daher3, M. Irigoyen4, G. Martínez4,
C. Ruhlmann4, C. Pérez Leirós2
1CONICET- UNIVERSIDAD DE BUENOS AIRES, Laboratorio de Inmunobilogía de la
Reproducción, Buenos Aires, Argentina
2CONICET- Uinversidad de Buenos AIres, Laboratorio de Inmunobilogía de la
Reproducción, Buenos Aires, Argentina
3Universidade Federal de São Paulo- São Paulo- Brazil, Department of Obstetrics-,
Sao Pablo, Brazil
4Instituto Feritilidad San isidro, Instituto Feritilidad San isidro, Buenos Aires, Argentina
Study question: Could the decidualization program of endometrial cells
induce a sterile inﬂammatory response through the induction of reticular stress
(RS) and unfolded protein response (UPR)?
Summary answer: Decidualized cells display a physiological RS and UPR that
induce the inﬂammasome activation generating a sterile inﬂammatory response
with production of IL-1b.
What is known already: Embryo implantation in humans requires the gener-
ation of a sterile inﬂammatory response for blastocyst invasion; however, it is
still unclear how it could be induced. During decidualization, endometrial stro-
mal cells suffer RS and trigger UPR, allowing the expansion of the endoplasmic
reticulum and the production of immunomodulators. The physiological RS gen-
erates the activation of sensing proteins, which induces kinase/Rnase-TXNIP
expression, activating the inﬂammasome. This multiprotein system allows
caspase-1 activation, which catalyzes the cleavage of inactive pro-form IL-1b to
secretory mature IL-1b. This pro-implantaoty cytokine is associated with an
inﬂammatory response that should be control in favor of a tolerogenic
microenvironment.
Study design, size, duration: Human endometrial stromal cell line (HESC)
was decidualized or not with medroxiprogesterone+dbcAMP during 8 days,
and was used to evaluate RS and UPR. An in vitro implantation model based on
co-culture of blastocyst-like spheroids (BLS) from Swan-71 trophoblast cells
line over decidualized-HESC cells was used to evaluate decidual functionality.
Finally, we evaluated the UPR-inﬂammatory pathway in endometrial biopsies
obtained from fertile women, with recurrent spontaneous abortions (RSA) or
with in vitro fertilization failures (RIF).
Participants/materials, setting, methods: RS sensors (IRE1a, ATF6 and
PERK) and UPR markers (sXBP1 and CHOP) were evaluated by RT-qPCR.
Inﬂammasome activation was measured by TXNIP and NLRP3 expression.
Caspase-1 activity was evaluated by the ﬂuorescent inhibitor probe FAM-Flica
and IL-1b production by FACS analysis, ELISA and Western Blot. Assays were
performed also in the absence/presence ofSTF083010 (an Ire1α inhibitor) and
Thapsigargin, Tg (RS-inducer). These pahtways were evaluated in endometrial
samples from RSA, RIF and fertile women by RT-qPCR.
Main results and the role of chance: The decidualized cells (Dec)
increased the expression of RS-sensors (ATF6, PERK and IRE1a) and UPR mar-
kers (sXBP1 and CHOP) in comparison with non-Dec cells. Tg-treated non-
Dec cells were used as RS +control. Then, we evaluated the UPR inﬂammatory
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pathway, which activates the inﬂammasome. Interestingly, while TXNIP expres-
sion remains unchanged, we oberved an increased NLRP3 expression in Dec
cells compared with non-Dec cells, while STF083010 prevented this increase.
Downstream, we detected increased levels of active caspase-1 on Dec cells
compared with non-Dec uding the ﬂuorescent inhibitor probe-FAM-Flica
Caspase-1, suggesting the NLRP3 inﬂammasome activation. According to this,
decidualized cells signiﬁcantly increased IL-1b protein expression compared
with non dec cells. This multiprotein complex increases IL-1b production in
Dec cells. In fact, the inhibition of IRE1α-UPR by STF083010 treatment pre-
vented IL-1b increase in Dec cells and decreased the invasion index evaluated
in the in vitromodel of implantation, suggesting that the induction of IL-1b is par-
tially dependent of a RS-UPR process. Finally, the present results were validated
using endometrial samples. We found an increase expression of IRE1α, sXBP1,
TXNIP, NLRP3 and lL-1b on RSA-endometrial biopsies in comparison with fer-
tile women; while biopsies from RIF patients showed a signiﬁcantly lower
expression than fertile women.
Limitations, reasons for caution: The present results were obtained using
immortalized cell lines and in vitro decidualization and implantation models.
Even the results were validated in endometrial samples from fertile women,
recurrent spontaneous abortions and in recurrent in vitro fertilization failures,
further studies are necessary to elucidate whether these mechanisms operate
similarly in vivo.
Wider implications of the ﬁndings: The present results suggest that
human decidualization process is accompained by a physiological RS/UPR,
which induces a physiological and sterile inﬂammatory response associated with
an increase of IL-1b production. These processes were differentially affected in
RSA and RIF patients in comparison with fertile women, suggesting their rele-
vance on reproductive pathologies.
Trial registration number: n/A.
P-440 HLA-C haplotypes distribution among gametes donors in
our population
D. Alecsandru1, C. Iglesias1, A. Pacheco2, A. Barrio1, N. Garrido3,
J.A. García-Velasco4
1IVI Madrid, Department of inmunology and department of reproductive
endocrinology and infertility, Madrid, Spain
2IVI Madrid, Andrology department, Madrid, Spain
3IVI Foundation Director, Research administration and innovation, Valencia, Spain
4IVI Madrid. Rey Juan Carlos University. Hospital Universitario La Paz- Madrid.,
Department of inmunology and department of reproductive endocrinology and
infertility, Madrid, Spain
Study question: HLA-C haplotypes distribution among gametes donors in
Caucasian population.
Summary answer: Among oocyte donors, 37.5% have an HLA-C1C1 haplo-
type, and very similar among sperm donors 32%.
What is known already: Increased risk of recurrent miscarriage (RM), pre-
eclampsia and fetal growth restriction has been described in mothers KIR AA
when the fetus has more HLA-C2 genes than the mother with a higher inci-
dence in oocyte donation pregnancies compared to spontaneous conception
or IVF pregnancies. In oocyte donation, the oocyte HLA-C behaves as the
paternal HLA-C increasing the number of non-self-antigens presented to the
mother´s uterine immune cells. This KIR-HLA-C combination is still not con-
sidered nowadays in the process of donor selection. KIR AA patients have low-
er live birth rates (LBR) after double embryo transfer (DET) oocyte-donation,
especially with HLA-C2 partner.
Study design, size, duration: Between April 2015 and October 2017, we
performed a prospective study that included 783 gametes donors matched for
couples with recurrent miscarriage or recurrent implantation failure of unknown
etiology. We performed HLA-C typing for 683 oocytes donors and for 100
sperm donors.
Participants/materials, setting, methods: All the donors were selected
from IVIRMA Clinics, and showed a normal karyotype, negative serology and
fulﬁlled our standards for gamete donation. We did genetic typing for HLA-C
after obtaining signed informed consent. HLA-C haplotype distribution among
oocytes and sperm donors in our Caucasian Spanish population was analyzed.
Main results and the role of chance: In our cohort of 683 oocytes donors,
we observed a 37.5% HLA-C1C1 haplotype (N = 256), 47.7% HLA-C1C2 and
14.8% HLA-C2C2. Among the sperm donor cohort, HLA-C haplotype distribu-
tion was 32% for HLA-C1C1, 50% for HLA-C1C2 and 18% for HLA-C2C2.
Knowing the HLA-C distribution in our gametes donors might be helpful as
LBR is lower when women KIR AA received a C2 donor, especially when they
have a HLA-C2 partner and the embryo has more HLA-C2 antigens than the
mother. This ﬁrst study, observed a 32-37% of HLA-C1C1 frequency among
gametes donors in our population. Those KIR-HLA-C mismatched couples
affected by recurrent miscarriage or recurrent implantation failure may beneﬁt
from this approach.
Limitations, reasons for caution: The study’s objective was to describe the
HLA-C distribution among our donors cohort and the frequency of what we
may consider the “best” haplotype, HLA-C1C1. This is the ﬁrst study observing
the HLA-C distribution among gametes donors and represent useful data.
Wider implications of the ﬁndings: It’s believed that completing a normal
pregnancy is possible only for KIR AA mothers who carry a baby with a least
one non-–self HLAC1. During oocyte donation, the KIR-HLA-C mismatch
increases compared to own oocytes. Therefore, selecting HLA-C1 among
donors could be more efﬁcient and safer, for speciﬁc couples.
Trial registration number: not applicable.
P-441 In-cycle prediction of the outcome after fresh embryo
transfer in IVF/ICSI: a molecular analysis of follicular endometrial
biopsies
S. Mackens1, S. Santos-Ribeiro1, C. Blockeel1, A. Racca1, A. Koch2,
W. Essahib1, A. Aberkane1, I. Van Riet3, C. Bourgain1,
W. Verpoest1, J. Brosens4, H. Tournaye1, Y.H. Lee5, H. Van de Velde1
1UZ Brussel, Centre for Reproductive Medicine, Jette- Brussels, Belgium
2Maastricht University Medical Center, Pathology, Maastricht, The Netherlands
3UZ Brussel, Blood transfusion/Immunology/stem cells, Jette- Brussels, Belgium
4University of Warwick, Division of Biomedical Sciences- Clinical Science Research
Laboratories, Warwick, United Kingdom
5KK Research Centre, Department of Reproductive Medicine, Singapore, Singapore
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Study question: Can molecular analysis of an endometrial biopsy harvested
during ovarian stimulation (OS) predict the outcome of fresh embryo transfer
(ET) in that cycle?
Summary answer: Early follicular phase endometrium harvested during OS is
signiﬁcantly different in patients having a live birth compared to an implantation
failure after fresh ET.
What is known already: The endometrium adapts from cycle to cycle
thanks to tissue renewal and decidualization. Endometrial biopsies taken during
OS have been shown not to harm the chances of implantation in case of fresh
ET. At the molecular level, differential gene expression (DGE) has been
reported between women that achieve pregnancy versus those who do not. In
luteal phase endometrial biopsies, a transcriptional signature predictive for
repeated implantation failure (RIF) was shown to be associated with reduced
cell proliferation, an essential function of the proliferative phase. Furthermore, a
disordered endometrial stromal cell (EnSC) secretome has been linked to failed
implantation.
Study design, size, duration: This study was part of a RCT investigating the
effect of scratching during OS on clinical pregnancy rates after IVF/ICSI.
Patients in the intervention arm underwent an endometrial biopsy in the early
follicular phase of OS. Of the 85 biopsies available for this study, after matching
to minimize the risk of potential confounding, 18 (9 versus 9) were used for
transcriptome analysis and 9 (5 versus 4) for EnSC isolation and in vitro decid-
ualization (IVD).
Participants/materials, setting, methods: RNA-sequencing was per-
formed for individual endometrial biopsies on an Illumina HiSeq1500 machine
(BrightCore, Brussels). DGE was analyzed using 3 software systems (DESeq2 in
R, EdgeR, Wilcoxon rank-sum test) and gene set enrichment analysis (GSEA)
was performed using the GOrilla tool.
EnSC isolation and IVD (for 2 and 4 days) was performed, after which media
from undifferentiated and decidualized cultures were harvested, stored at
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-80°C and later assayed using a multiplex suspension bead immunoassay
(Ebioscience, Singapore).
Main results and the role of chance: After correction for multiple hypoth-
esis testing, DGE analysis of whole tissues revealed no differences between
patients having a live birth and patients having an implantation failure after fresh
ET (lowest adjusted p-value = 0.15). However, after GSEA (false discovery rate
< 0.05) several enriched ontologies were identiﬁed, the most affected biological
process being protein targeting to the endoplasmic reticulum and the cell
membrane.
Secretome analysis after EnSC isolation and culture, analyzed by partial least
squares regression modelling, showed 2 distinct clusters that corresponded to
the two clinical groups. Increased secretion of MCP-1, LIF and eotaxin in undif-
ferentiated EnSC was associated with implantation failure. Upon IVD, the secre-
tome proﬁle clearly shifted from that of undifferentiated cells, although it
remained different between the 2 groups. VEGF-A was highly secreted in the
live birth group whereas a preponderance of IL-8 secretion characterized the
implantation failure group. The differences in secretomes between the groups
became muted upon prolonged IVD, suggesting convergence of cytokine pro-
ﬁles upon full differentiation.
Limitations, reasons for caution: Caution is warranted because of the lim-
ited sample size of the study and the in vitro nature of the second part of the
experiment.
Wider implications of the ﬁndings: If conﬁrmed on a larger scale, an in-
cycle predictive test could be developed to guide clinical decision-making
between a fresh ET immediately after OS or a freeze-all approach with a frozen
ET in a subsequent cycle, possibly linked to higher success rate in case of a sub-
optimal test result.
Trial registration number: This study was part of a clinical RCT: the
REFRESH trial, NCT02061228.
P-442 Serum vitamin D and calcium levels in ectopic pregnancies
P. Yalcin bahat1, B. Yuksel ozgor2, B. Aslan cetin1, N. Koroglu1,
N. Arslan1
1Istanbul Kanuni Sultan Suleyman Training and Research Hospital, obstetric and
gynecology, istanbul, Turkey
2istanbul university medical faculty, obstetric and gynecology, istanbul, Turkey
Study question: what is the place of vitamins and calcium metabolism in
ectopic pregnancy?
Summary answer: this is the ﬁrst study that reports the decreased serum
levels of vitamin D, calcium and magnesium in patients with ectopic pregnancy.
What is known already: According to recent evidences, vitamin D was
found to have important roles in female reproductive system, both in physio-
logical and also pathological mechanisms. Since vitamin D is tightly related with
calcium metabolism, both molecules were reported to be associated with some
pregnancy complications including preeclampsia, gestational diabetes, low birth
weight, preterm delivery, and cesarean section. The aim of the present study
was to evaluate the vitamin D levels in ectopic pregnancies, which may have
clinical importance in the etiology of this disorder.
Study design, size, duration: Between October 2015 and June 2017,50
women with ectopic pregnancy and 61 women with normal 1st trimester preg-
nancy were included. Blood samples were taken for biochemical analyses
including vitamin D, calcium, magnesium, parathormone, thyroid stimulating
hormone (TSH), T3, T4, hemoglobin, hematocrite, thrombocyte, C-reactive
protein, beta-human chorionic gonadotropin, and procalcitonin. Study groups
were compared for these biochemical markers.
Participants/materials, setting, methods: In the study, 50 women with
ectopic pregnancy and 61 women with normal 1st trimester pregnancy were
included. Blood samples were taken for biochemical analyses including vitamin
D, calcium, magnesium, parathormone, thyroid stimulating hormone (TSH),
T3, T4, hemoglobin, hematocrit, thrombocyte, C-reactive protein, beta-human
chorionic gonadotropin, and procalcitonin. Study groups were compared for
these biochemical markers.
Main results and the role of chance: The distribution of the serum levels
of vitamin D, calcium, thyroid hormones, magnesium, and hemoglobin are pre-
sented in Table 1. Accordingly, vitamin D (p = 0.006), Ca++ (p<0.001), T3 (p
= 0.003), magnesium (p = 0.001), and hemoglobin (p = 0.040) levels were sig-
niﬁcantly lower in the ectopic pregnancy group than those in the normal preg-
nancy group. On the other hand, TSH (p = 0.029) and thrombocyte (p =
0.018) levels were signiﬁcantly lower in the normal pregnancy group than those
in the ectopic pregnancy group.
Limitations, reasons for caution: study was conducted in a single center
and with low number of participants. Te number should be extended for the
future studies.
Wider implications of the ﬁndings: This study reports the decreased ser-
um levels of vitamin D, calcium and magnesium in patients with ectopic preg-
nancy. The molecular interactions at ultrastructural level, altered tubal ﬂuid
content, or an inﬂammatory process that affects ciliary motility might all play a
role in the etiology of tubal implantation of the fetus.
Trial registration number: ‘not applicable.
P-443 Chemokines in relation to human Choriogonadotropin
(hCG) after four weeks of gestation are signiﬁcantly altered in
women with miscarriage
A. Freis1, J. Schlegel1, D. Volker2, J. Jauckus1, T. Strowitzki1,
A. Germeyer1
1Universitäts-Frauenklinik, Department of Gynecologic Endocrinology and Fertility
Disorders, Heidelberg, Germany
2Transplantation-Immunology, Institute of Immunology- University Hospital
Heidelberg-, Heidelberg, Germany
Study question: Are chemokine levels at the time of pregnancy testing rela-
tive to human Choriogonadotropin (hCG) altered in patients who will experi-
ence a miscarriage in this pregnancy?
Summary answer: Chemokines in relation to hCG after four weeks of gesta-
tion are signiﬁcantly altered in women with miscarriage, promising potential as a
prognostic biomarker.
What is known already: Miscarriage is one of the most common complica-
tions in early pregnancy and affects 10-20% of all pregnancies. A predictive test
to identify women who will experience a miscarriage even before ﬁrst symp-
toms occur is not established. Activation of maternal immunological tolerance
seems to be essential for early fetal development and various cytokines have
been described in different stages of pregnancy. However, none of these cyto-
kines alone has been described as a useful biomarker in asymptomatic women.
To screen for promising biomarkers, we tent to enhance the possible predictive
effect for later abortion by examining a chemokines/hCG correlation in mater-
nal plasma.
Study design, size, duration: The prospective pilot study was approved by
Heidelberg University Ethical Committee (protocol S-243/2015). Blood sam-
ples were obtained at the time of pregnancy testing after informed consent
from women who underwent ovarian hyperstimulation to perform in vitro fer-
tilization by IVF or ICSI during the period 05/15-05/16 at the University
Hospital in Heidelberg, Germany. Exclusion criteria were autoimmune diseases,
essential hypertonia, diabetes mellitus or the intake of confounding medication.
Participants/materials, setting, methods: We obtained blood samples
from n = 39 women. Dependent on the follow-up, patients with a positive
pregnancy test were subsequently divided in two groups: ongoing pregnancy (n
= 22, group 1) and 1st trimester miscarriage (n = 17, group 2) in this pregnancy.
Immunological and endocrine proﬁling of maternal blood was performed using
Multiplex and ELISA assays. Statistical analysis using student’s t-test was per-
formed with SPSS® Version 24, IBM, Armonk, USA. p ≤ 0.05 was considered
to be signiﬁcant.
Main results and the role of chance: There was no signiﬁcant difference in
age (33.64 ± 6.49 years vs. 33.94 ± 4.4 years), body mass index with 23.81 ±
4.29 kg/m2 in group 1 vs. 26.48 ± 5.27 kg/m2 in group 2 or transfer day. hCG
levels, despite normal overall levels, were signiﬁcantly decreased in patients
with abortion compared to those with ongoing pregnancy (151.75 ± 25.29 IU/l
vs. 351.27 ± 111.02 IU/l, p<0.05) whereas levels of IL-1ra (655.80 ±
78.80 pg/ml vs. 398.69 ± 32.73 pg/ml, p<0.01), MIP-1a (73.74 ± 9.91 pg/ml
vs. 34.20 ± 8.25 pg/ml, p<0.01) and TNF-alpha (5.11 ± 0.40 pg/ml vs. 4.00 ±
0.26 pg/ml, p<0.05) were signiﬁcantly increased. GCSF/ IL-1ra-ratio was 1.66-
fold increased in patients with ongoing pregnancy. TGF-beta /MIP1a-ratio was
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signiﬁcantly 3,45-times higher in patients with miscarriages. Comparing patients
with ongoing pregnancy to patients experiencing a miscarriage, we could dem-
onstrate signiﬁcant alterations of the ratios MIP1a/hCG (0.16 ± 0.04 pg/mIU
vs. 1.02 ± 0.38 pg/mIU, p<0.05), IL-1ra/hCG (2.22 ± 0.72 pg/mIU vs. 7.83 ±
2.30 pg/mIU, p<0.05), TNFalpha/hCG (0.02 ± 0.01 pg/mIU vs. 0.07 ±
0.02 pg/mIU, p<0.05), MCP1/hCG (0.50 ± 0.16 pg/mIU vs. 1.44 ± 0.40 pg/
mIU, p<0.05), IL-6/hCG (0.0681 ± 0.002 pg/mIU vs 0.016 ± 0.003 pg/mIU,
p<0.05), TPO/hCG (2.50 ± 0.70 pg/mIU vs 5.47 ± 1.31 pg/mIU, p<0.05)
and TGF-beta1/hCG (68.04 ± 22.37 pg/mIU vs. 149.35 ± 33.89 pg/mIU,
p<0.05). The strongest effects were seen for the ratio MIP1a/hCG, IL-1ra/
hCG and TNFalpha/hCG.
Limitations, reasons for caution: The limitations of this study are its small
sample size and the fact, that we only detected protein in maternal plasma with
no further validation technique.
Wider implications of the ﬁndings: Biomarkers screening for an upcoming
miscarriage in asymptomatic women of the ﬁrst trimester can be a helpful
instrument to reassure patients with expected normal pregnancy outcome. We
think that these established ratios are better predictors for pregnancy outcome
than cytokine levels alone.
Trial registration number: na.
P-444 Impact of resveratrol supplementation on implantation and
early pregnancy during embryo transfer cycles: a cross-sectional
study
K. Kuroda1,2, A. Ochiai2, Y. Ikemoto2, A. Matsumoto2,
K. Nakagawa1, S. Nojiri3,4, R. Sugiyama1
1Sugiyama Clinic Shinjuku, Division of Reproductive Medicine, Tokyo, Japan
2Juntendo University Faculty of Medicine, Department of Obstetrics and
Gynaecology, Tokyo, Japan
3Juntendo University, Medical Technology Innovation Center-, Tokyo, Japan
4Juntendo University Hospital, Clinical Research and Trial Center, Tokyo, Japan
Study question: To determine whether resveratrol supplementation impacts
on implantation and early pregnancy following transfer of morphologically com-
petent embryos.
Summary answer: Resveratrol supplementation during the luteal phase was
associated with lower implantation and clinical pregnancy rates and higher mis-
carriage rate following embryo transfer.
What is known already: Resveratrol is a polyphenolic compound and nat-
ural activator of SIRT1. Based on animal experiments, resveratrol has been
mooted as a potentially therapeutic agent preventing infertility associated with
ovarian aging due to its inhibition of senescence. Recent reports have shown a
relationship between decidualization of human endometrial cells and cell senes-
cence. Furthermore, inhibition of decidual senescence had also been reported
to suppress decidual changes in the endometrium. However, clinical trials
involving resveratrol supplementation for infertility treatment have not been
performed in humans.
Study design, size, duration: The present study was approved by the local
ethics committee. This single-centre, cross-sectional retrospective study (2012
to 2014) was designed to compare the outcomes of ET between women
receiving resveratrol supplementation (200 mg/d) during the luteal phase (RES
group) and a control group (non-RES).
Participants/materials, setting, methods: Of 8,686 ET cycles, we
excluded 1,097 cycles with poor prognostic factors, including those from
women ≥44 years old and those with poor-quality embryos (Veeck grade 4–5
or Gardner grade CC). The RES group (205 cycles, 102 women) was then com-
pared with the non-RES group (7,382 cycles, 3024 women). Odds ratios (OR)
and 95% conﬁdence intervals (CIs) were calculated using multivariate logistic
regression after controlling for potential confounders; patient age, embryo
grade and cleavage speed.
Main results and the role of chance: After adjusting for age and embryo
quality, statistical analysis showed a lower hCG positivity rate (OR = 0.68; 95%
CI: 0.46–1.00), lower clinical pregnancy rate (OR = 0.51; 95% CI: 0.32–0.80)
and higher miscarriage rate (OR = 2.68; 95% CI: 1.11–6.51) in the RES group
compared to the non-RES group.
Limitations, reasons for caution: We focused on ET cycles with morpho-
logically competent embryos. However, resveratrol supplementation may have
a positive impact on the development of follicles and production of high-quality
embryos.
Wider implications of the ﬁndings: In line with the adverse effects of sen-
escence inhibitors on endometrial decidualization in vitro, resveratrol supple-
mentation during the luteal phase appears to be detrimental for pregnancy
outcomes during IVF treatment. Nonetheless, analysis of the supplementation
period and additional studies are required.
Trial registration number:None.
P-445 Mid-luteal serum progesterone levels determine the
reproductive outcome following controlled ovarian stimulation. A
prospective study of 602 IVF/ICSI cycles
L. Thomsen1, U.S. Kesmodel2, K. Erb3, P. Humaidan1
1Department of Clinical Medicine- Aarhus University- Denmark., The fertility Clinic-
Skive Regional Hospital- Denmark., Skive, Denmark
2Department of Clinical Medicine- University of Copenhagen- Denmark., The fertility
Clinic- Herlev Hospital- Denmark., Herlev, Denmark
3Odense University Hospital- Denmark., The Fertility Clinic. Odense University
Hospital- Denmark., Odense, Denmark
Study question: Is the chance of on-going pregnancy following IVF treatment
and fresh embryo transfer affected by early and mid-luteal serum progesterone
(P4) levels?
Summary answer: Low as well as high s-P4 levels during the early and mid-
luteal phase reduce the chance of on-going pregnancy following IVF-treatment
and fresh embryo transfer.
What is known already: Data from non-human studies and studies of fro-
zen/thawed embryo transfer cycles indicate that low as well as high P4-levels
during the early/mid-luteal phase decrease the chance of pregnancy. A subopti-
mal P4-level may disrupt the endometrial maturation and lead to asynchrony
between embryonic development and the endometrial receptivity, thereby
compromising implantation and early pregnancy development.
Study design, size, duration: Prospective multicenter cohort study of 602
women undergoing IVF treatment. Patients were recruited from four Danish
public Fertility Centers from May 2014 to June 2017. The study population was
unselected, thus representing a normal everyday Danish patient cohort.
Patients were treated in a long GnRH-agonist protocol or a GnRH-antagonist
protocol and triggered for ﬁnal oocyte maturation with either hCG or a GnRH-
agonist. The same vaginal luteal support regime was applied in all patients.
Participants/materials, setting, methods: Serum P4 levels on luteal day
2/3 or luteal day 5 were correlated to the rate of positive hCG and to on-going
pregnancy rates (> gestational week 10). Patients were divided into four P4-
groups based on raw data of P4-concentrations and reproductive outcome on
luteal days 2/3 (P4<60 nmol/l, P4 60-100 nmol/l, P4 101-400 nmol/l and
P4>400 nmol/l) and luteal day 5 (P4<150 nmol/l, P4 150-250 nmol/l, P4 251-
400nmol/l and P4>400 nmol/l).
Main results and the role of chance: The optimal chance of pregnancy was
achieved with s-P4 levels 60-100 nmol/l on luteal day 2/3 whereas the optimal
P4-level on day 5 was 150-250 nmol/l. Below, but most distinctly above these
levels, the chance of pregnancy was consistently reduced. Following cleavage-
stage embryo transfer and an early luteal P4-level of 60-100 nmol/l, the chance
of a positive hCG- test was 65%, CI [51; 77%]. In contrast, with a cleavage-
stage embryo transfer and a P4-level > 400 nmol/l, the chance of a positive
hCG-test was signiﬁcantly reduced to 34%, CI [17; 56%], thus, a reduction of
-31%, CI [-54;-10%]. A similar negative association between early luteal P4 and
on-going pregnancy rate was found, although it did not reach statistical signiﬁ-
cance. Following blastocyst transfer and a mid-luteal P4 level of 150-250 nmol/l,
the chance of on-going pregnancy was 57%, CI [41;73%] compared to 38%, CI
[20;59%] with a P4-level > 400 nmol/l, thus, a reduction in chance of -19%, CI
[-40;2%], p = 0.078. With blastocyst transfer and P4 < 150 nmol/l, the chance
of an on-going pregnancy was reduced to 41%, CI [43;59%]. All estimates were
adjusted for maternal age, BMI, smoking, ﬁnal follicle count and late follicular P4
levels.
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Limitations, reasons for caution: This study is the ﬁrst to explore a thresh-
old and ceiling level for luteal P4 following IVF treatment and fresh embryo
transfer, and the optimal P4-ranges found in this study must be corroborated in
future clinical trials.
Wider implications of the ﬁndings: Future studies need to be performed to
establish whether additional exogenous luteal P4-supplementation in the low P4
-group could increase the chance of on-going pregnancy following fresh embryo
transfer and whether patients with luteal P4-levels > 400 nmol/l would beneﬁt
from segmentation followed by subsequent transfer in frozen/thawed cycles.
Trial registration number:NCT02129998 (Clinicaltrials.gov).
P-446 The role of sub-chorionic blood ﬂowmeasured by 3D power
Doppler ultrasonography in the prediction of pregnancy outcome: a
preliminary study
J. Huang1,2, W. Cheung2, X. Chen2, Y. Liu2, S. Saravelos2,3, T.C. Li2
1The First Afﬁliated Hospital of Chongqing Medical University, Obstetrics and
Gynaecology, Chongqing, China
2The Chinese University of Hong Kong, Obstetrics and Gynaecology, Hong Kong,
Hong Kong
3Hammersmith Hospital- Imperial College Healthcare NHS Trust, IVF Unit, London,
United Kingdom
Study question: Does sub-chorionic blood ﬂow at 6 weeks of gestation ana-
lyzed by 3D power Doppler ultrasonography predict pregnancy outcome?
Summary answer: The sub-chorionic blood ﬂows at 6 weeks of gestation
analyzed by 3D power Doppler ultrasonography have the potential of predict-
ing miscarriage.
What is known already: Transvaginal ultrasound has been considered as a
reliable technique to monitor early pregnancy. Present ultrasonography features
at the time of 6-8 weeks of gestation have been applied as a diagnostic tool of
early pregnancy; while the predictive role of pregnancy outcomes were seldom
developed.
Study design, size, duration: This is a prospective cross sectional prelimin-
ary study in a setting of assisted reproductive technology (ART) center. So far,
37 cases were recruited, in which 4 lost follow up of pregnancy outcome, 5
excluded from this study for twin pregnancy, and 2 excluded for biochemical
pregnancy loss. Therefore, in total, there were 21 term live birth and 5 miscar-
riages (miscarried during 7-12 weeks of gestation) included in the analysis.
Participants/materials, setting, methods: After embryo transfer and
positive hCG test, transvaginal ultrasound scan was scheduled for conﬁrmation
of clinical pregnancy for patients recruited for this study on the day of 6 weeks
of gestation. After the routine conﬁrmation of clinical pregnancy by 2D ultra-
sound, a 3D power Doppler dataset were taken and stored for VOCAL®
(Virtual Organ Computer-Aided Analysis) histogram analysis to measure the
gestational sac volume and indices of sub-chorionic blood ﬂows.
Main results and the role of chance: There seems no difference in the com-
parison of the miscarriage and term live birth group in demographic information
and general pregnant conditions, including patient age, body mass index, embryo
quality, hormone levels (hCG and P4). It is also not signiﬁcant different in the com-
parison of 2D ultrasound parameters between the two groups, including crown-
rump length, diameters of gestational sac, yolk sac and presentation of heart beat.
For 3D power Doppler VOCAL analysis, vascularization index (VI), and vasculariza-
tion ﬂow index (VFI) were likely higher in the live birth group compared with those
of the miscarriage group (3.02 ± 1.03 vs 0.74 ± 0.58, p = 0.08; 1.26 ± 0.23 vs
0.23 ± 0.10, p = 0.07, respectively); whilst ﬂow index (FI) might be not different
between the two groups (32.92 ± 2.14 vs 28.60 ± 2.41, p = 0.14).
Limitations, reasons for caution: This is a preliminary prospective study with
a current small group of patients. As our clinical routine monitoring of patients con-
ceived by ART were scheduled in 6 weeks of gestation, we are recruiting more
cases in this cohort for a more robust interpretation of the 3D parameters.
Wider implications of the ﬁndings: VI is considered to indicate the vascu-
larity in the sub-chorionic area; FI indicating the average intensity of blood ﬂow;
while VFI is a combination of vascularity and ﬂow intensity. Our preliminary
data suggested that miscarriage may have some angiogenesis abnormalities early
on, before the miscarriage occur.
Trial registration number:None.
P-447 Reference intervals of gestational sac, yolk sac, embryonic
length, embryonic heart rate at 6-10 weeks after in vitro
fertilization-embryo transfer
Y. Ouyang, X. Li, Y.Wen
Reproductive and Genetic Hospital of Citic-Xiangya, Imaging department, Changsha,
China
Study question: What are the ultrasound reference intervals of early preg-
nancies after in vitro fertilization-embryo transfer (IVF-ET)?
Summary answer: Reference intervals and centile charts for early pregnancy
biometry after IVF-ET have been established in this study.
What is known already: To accurately determine the normal range of early
pregnancy biometry was the basis for predicting adverse pregnancy outcomes.
Some studies have constructed such kind of reference intervals, mostly,
depending on natural conceptions. However, the ovulation day were change-
able even in regular menstrual cycle, which makes the uncertainty of the accur-
acy for reference intervals in natural pregnancies. While during the IVF-ET
procedure, the days of oocytes retrieval and ET were certain, and thus, the
gestational age (GA) was accurate. Then, we speculate the reference intervals
deriving from IVF-ET data would be more accurate than natural conceptions.
Study design, size, duration: The data of 3763 singleton pregnancies,
including embryonic length (or crown-rump length, CRL), embryonic heart rate
(HR), gestational sac diameter (GSD) and yolk sac diameter (YSD) at 6–10 ges-
tational weeks from January 2014 to December 2015 after IVF-ET were retro-
spectively analyzed. The ultrasound measurements conformed to uniform
standards by experienced sonographers. The GA was calculated by subtracting
the date of embryo transfer from the date of birth and the addition of 17 days.
Participants/materials, setting, methods: This study was conducted at
the Reproductive and Genetic Hospital of CITIC-Xiangya (Changsha, China).
All included patients conceived singleton pregnancies via IVF-ET and resulted in
phenotypically normal live neonates after 36 complete gestational weeks, with
birth weight above the 5th centile for GA. All patients had full records of early
ultrasound measurements of CRL, HR, GSD and YSD. Regression analysis was
used to establish normal ranges of CRL, HR, GSD and YSD with gestation.
Main results and the role of chance: At 6–10 weeks, there were signiﬁcant
quadratic associations between CRL, HR, GSD, YSD and GA. The correspond-
ing quadratic models were CRL = -0.445–0.559GA + 0.015GA2 (R2 = 0.986, F
= 128300.664, P < 0.001); HR = -382.279 + 16.623GA - 0.123GA2, R2 =
0.927, F = 23740.394, P < 0.001); GSD = -26.547 + 0.991GA + 0.001GA2,
R2 = 0.851, F = 10768.859, P < 0.001); YSD = 1.709 + 0.079GA + 0.000GA2,
R2 = 0.986, F = 128300.664, P < 0.001). The normal ranges of CRL, HR, GSD
and YSD were successfully derived from these models.
Limitations, reasons for caution: This study was conﬁned to a reproduct-
ive center, territorial limitation may exist. A future study with multi-center sam-
ples are necessary to establish a nationwide or worldwide reference interval. In
addition, whether the references coming from IVF population are suitable for
natural conceptions needs further elucidation.
Wider implications of the ﬁndings: The normal ranges of early pregnancy
biometry provide clinicians a reliable reference to analyze the development of
early embryos after IVF-ET and also give a possibility for predicting pregnancy
outcomes at an early stage.
Trial registration number:None.
P-448 Virtual screening andmolecular dynamics of FDA drugs into
the beta-2-glycoprotein I’s ﬁfth domain for treatment of pregnancy
complications with antiphospholipid antibody syndrome
S. Mahdian1, M. Movahedi1, M. Zarrabi2, M. Shahhoseini3, A. Moini4
1Faculty of life Sciences- Islamic Azad University- Tehran North Branch, Department
of Cellular and Molecular Biology, Tehran, Iran
2biological faculty- alzahra university, Department of biotechnology, Tehran, Iran
3Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- Academic Center for Education Culture and Research, Department of
Genetics, Tehran, Iran
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4Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- Academic Center for Education Culture and Research, Department of
Endocrinology and Female Infertility, Tehran, Iran
Study question:What drugs can be used for treatment of pregnancy compli-
cations with antiphospholipid antibody syndrome?
Summary answer: Some drugs prescribed for recurrent miscarriage, RIF and
preeclampsia and some FDA drugs might be useful candidates for pregnancy
complications with antiphospholipid antibody syndrome.
What is known already: Antiphospholipid antibody syndrome (APS or
APLS), is an autoimmune disease, caused by antiphospholipid antibodies. APS is
associated with pregnancy complications, including preeclampsia, thrombosis,
fetal growth restriction, fetal loss and recurrent implantation failure. B2GPI is
the major antigen for APL antibodies and associated with thrombosis. B2GPI
exists in different conformations, an open J-shaped conformation, a circular
conformation and a S-shape conformation. B2GPI is a glycoprotein by a single
polypeptide chain of 326 amino acids with ﬁve repeated domains. B2GPI’s ﬁfth
domain is highly effective in binding to negative charge phospholipids and bind-
ing to oxidized LDL in inﬂammatory and blood clotting reactions.
Study design, size, duration: In this study calculation of binding free-energy
change (ΔG) of drugs that are prescribed during pregnancy, and especially
recurrent miscarriage, RIF, preeclampsia and all of the FDA drugs, were evalu-
ated using virtual screening to b2GPI’s ﬁfth domain. The starting coordinates of
b2GPI were obtained from PDB (PDB code: 1C1Z). The next step were
Molecular dynamics simulation studies of protein and drugs/ protein complex
using gromacs software in the Linux environment.
Participants/materials, setting, methods: Bioinformatics software, such
as, auto dock vina, molegro virtual docker, pyrx 0.8, linux, gromacs software
and online resources like NCBI, RCSB and Drug bank were used in this study.
The best drugs were chosen based on binding free energy value and hydrogen
bonding interaction. Regarding the mechanism of action for vorapaxar and
antrafenine, as well as the optimal ΔG for these two drugs, vorapaxar and
antrafenine were selected for more accurate studies using molecular dynamics.
Main results and the role of chance: In this study calculation of binding free-
energy change (ΔG) of drugs that are prescribed during pregnancy, and especially
recurrent miscarriage, RIF and preeclampsia, were evaluated using the Auto
Dock Tools method on b2GPI’s ﬁfth domain. Heparin, folate and warfarin have
highestΔG. Also in the present study, the molecular docking and MD simulations
were performed to explore the possible binding mode of beta-2-glycoprotein I’s
ﬁfth domain with FDA drugs. The best drugs were chosen based on binding free
energy value and hydrogen bonding interaction. The conclusion drawn from the
docking analysis was that eight FDA drugs had the highest binding afﬁnity with
b2GPI. Vorapaxar and antrafenine are anti-platelet and anti-inﬂammatory drugs.
Regarding the mechanism of action for vorapaxar and antrafenine, as well as the
optimal ΔG for these two drugs, vorapaxar and antrafenine were selected for
more accurate studies using molecular dynamics. B2GPI exists in different confor-
mations, an open J-shaped conformation, a circular conformation and a S-shape
conformation. In this study using molecular dynamics for protein, it was shown
that the J-shaped was transformed into a s-shaped during the 10 ns. RMSD,
RMSF, and H-bond results reveal that two complexes were stable.
Limitations, reasons for caution: Findings of this study is based on in silico
method. Studies in vitro and in vivo can help us complete this study.
Wider implications of the ﬁndings: This study for the ﬁrst time evaluated
the effect of FDA Drugs on antiphospholipid antibody syndrome (APLS) based
on in silico method. Vorapaxar and antrafenine might be useful candidates for
antiphospholipid antibody syndrome and pregnancy complications with APLS.
Trial registration number: This investigation is based on in silico method.
P-449 Novel insights into 3D endometrial tissue and cellular
architecture during preimplantation, in women with recurrent
miscarriage
J. Pearson-Farr1, R. Lewis2, Y. Cheong1
1University of Southampton, Obstetrics & Gynaecology, Southampton, United
Kingdom
2University of Southampton, Institute of Developmental Sciences, Southampton,
United Kingdom
Study question: Can whole-mount confocal microscopy be used to analyse
three-dimensional spatial relationships between multiple endometrial cell types,
providing a platform to individualise reproductive health diagnostics?
Summary answer: 3D endometrial tissue provides informative insight on the
interaction between cell populations and tissue architecture in women with
recurrent miscarriage versus controls.
What is known already: The endometrium forms the ﬁrst point of contact
for a conceptus during implantation, acting as the barrier between the uterine
tissue and uterine cavity milieu. Immunohistochemistry is widely used to study
the role endometrial cell types with respect to reproductive health. However,
the 2D nature of these samples means that much of the information about the
relationships between these cells is lost.
Study design, size, duration: An observational study comparing three main
patient groups; (1) egg donor controls, (2) recurrent miscarriage patients with
≤ 4 consecutive miscarriages and (3) ≥ 4 consecutive miscarriages.
Participants/materials, setting, methods: Endometrial biopsy samples
were collected at mid-luteal phase (LH +7-10). Patients were excluded if they
were on hormonal contraceptives, had a history of subfertility or uterine path-
ology. Multi-marker whole mount immunohistochemistry was carried out for all
endometrial samples, including markers for uterine natural killer cells (CD56),
macrophages (CD163+), and endometrial ﬁbroblasts (anti-vimentin).
Quantiﬁcation methods were developed to investigate inter and intra-cellular
relationships.
Main results and the role of chance: An informative approach to imaging
the endometrium in 3D has been developed. Uterine natural killer cells
(CD56), macrophages (CD163+) and ﬁbroblasts were imaged simultaneously
in 3D endometrium, and the relationship between these cells identiﬁed at the
mid-luteal phase. Tissue and cellular morphology was quantiﬁed in relation to
uterine glandular structures and the luminal epithelial surface. With regard to
patient groups, results are indicative of differences in morphological spatial
relationships.
Limitations, reasons for caution: This is an observational study with a small
sample size, larger studies are required. Further, 3D analysis of endometrial
samples is currently time consuming in comparison to traditional 2D immuno-
histochemistry, thus more applicable for research studies.
Wider implications of the ﬁndings: This 3D approach can be later applied
to answer questions in reproductive health and implantation.
Trial registration number: not applicable REC ref: 08/H0502/162
P-450 Interaction among embryos in blastocyst double embryo
transfer: better alone than in bad company
C. Jacobs1, M. Piccolimini1, D. Garcia2, R. Vassena2, E. Motta3,4,
T. Bonetti4.5
1Huntington Medicina Reprodutiva, Embriology, Sao Paulo, Brazil
2Clinica EUGIN, Scientiﬁc, Barcelona, Spain
3Huntington Medicina Reprodutiva, Clinical Director, Sao Paulo, Brazil
4Universidade Federal de São Paulo – Escola Paulista de Medicina UNIFESP-EPM,
Gynecology, Sao Paulo, Brazil
5Huntington Medicina Reprodutiva, Scientiﬁc, Sao Paulo, Brazil
Study question: How does the quality of an additional blastocyst transferred
with a top-quality one affect pregnancy rates?
Summary answer: The addition of a good-quality blastocyst to a one top-
quality blastocyst transfer does not increase substantially pregnancy rates, while
increasing twin gestations.
What is known already: It is well stablished that increasing the number of
transferred embryos increases pregnancy rate; this is however associated with
a substantial rise in multiple pregnancies. The morphology of transferred
embryos is linked to IVF success and, combined with extended culture to
blastocyst stage, it has been considered effective in selecting top-quality (TQ)
blastocysts for transfer. Double embryo transfer (DET) is commonly used as a
strategy to increase pregnancy rates. On the other hand, it is not clear how the
morphological scores of any additional embryo affects the implantation and
pregnancy rates of each embryo transfer.
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Study design, size, duration: Retrospective cohort study of 1149 fresh IVF-
cycles with single (SET) or double embryo transfer (DET) between 2014-2016.
Cycles with donated oocytes and PGS cycles were excluded. Blastocysts were
classiﬁed as good-quality (GQ; B and C scores according to Gardner) or top-
quality (TQ; at least one A score). Patients received one TQ blastocyst (1-TQ,
n = 62), one GQ (1-GQ, n = 158), two TQ (2-TQ, n = 235), two GQ (2-GQ,
n = 488) or one TQ and one good blastocysts (1-TQ+1-GQ, n = 206).
Participants/materials, setting, methods: Ovarian stimulation, oocyte
pickup and embryo culture followed routine protocols. Fresh blastocyst trans-
fers were done at day 5 following routine protocols, and clinical pregnancy (CP)
was conﬁrmed by the presence of gestational sac with fetal heart-beat.
Student’s t-test and Chi-square were used as appropriate. Multivariate analysis
was performed to evaluate the effect of transferring additional embryo, of same
or different quality, on clinical pregnancy, adjusted for women age. Differences
were considered signiﬁcant if p<0.05.
Main results and the role of chance: The groups were comparable in
women age (1-TQ:34.0 ± 3.6, 1-GQ:36.0 ± 4.2, 2-TQ:33.6 ± 3.9, 2-GQ:34.5
± 4.0, 1TQ+1GQ:33.7 ± 3.8; p<0.001), number of MII oocytes recovered (1-
TQ:7.1 ± 4.7, 1-GQ:5.2 ± 3.4, 2-TQ:10.2 ± 4.2, 2-GQ:8.3 ± 3.8, 1TQ
+1GQ:8.1 ± 3.9; p<0.001), and of blastocysts available for transfer (1-TQ:2.6
± 2.8, 1-GQ:1.3 ± 1.1, 2-TQ:5.3 ± 2.4, 2-GQ:2.9 ± 1.6, 1TQ+1GQ:3.5 ±
2.0; p<0.001). Both CP (1-TQ: 41.9%, 1-GQ: 18.4%, 2-TQ: 61.3%, 2-GQ:
43.9, 1TQ+1GQ: 51.5%; p<0.001) and multiple pregnancy rate (1-TQ: 3.8%,
1-GQ: 0.0%, 2-TQ: 40.3%, 2-GQ: 20.6%, 1TQ+1GQ: 26.4%; p<0.001) were
much higher when two TQ blastocysts were transferred compared to all other
categories. When 1TQ+1GQ were transferred, the CP was still satisfactory
and multiple pregnancy rate was approximately half of that observed in 2-TQ.
Multivariate analysis adjusted for woman age was performed to evaluate the
interaction between different quality embryos and its effect on CP. Compared
to a SET of 1-GQ embryo (OR = 1.0), having a SET of a TQ embryo increases
the CP threefold (OR = 3.0). A second TQ embryo would give an OR = 6.3
and a second GQ embryo an OR = 3.96; this difference is due to the lower
quality and the moderate negative interaction of the GQ embryo, meaning that
when transferring 1-TQ, the addition of 1-GQ embryo only improve CP 4%.
Since multiple PR is still high, SET of 1-TQ should be preferred.
Limitations, reasons for caution: The main limitations of this study reside
in the fact that most SET were not elective, and in the small size of the 1-TQ
group. Nevertheless, the multivariate and interaction analysis allows for gener-
alizable results.
Wider implications of the ﬁndings: The higher clinical pregnancy rate was
observed in the 2-TQ group, as did multiple pregnancy. However, the presence
of a second GQ blastocyst didn’t signiﬁcantly improve the clinical pregnancy,
but signiﬁcantly increased multiple gestations. When at least one TQ-blastocyst
is available, SET should be considered.
Trial registration number: not applicable.
P-451 Non-classical progesterone signaling may be sufﬁcient to
induce decidualization in Human Endometrial Stromal Cells (ESC)
S. Salsano1, A. Quiñonero1, S. Pérez1, R. Gonzalez1, C. Simón2,
F. Domínguez3
1IVI Foundation-RMA Global, Research, Valencia, Spain
2Igenomix Academy, Research, Valencia, Spain
3IVI Foundation-RMA Global- INCLIVA Biomedical Research Institute- Valencia- Spain,
Research, Valencia, Spain
Study question: Is it progesterone (P4) entry into the human endometrial
stromal cells (ESC) necessary to produce a correct decidualization?
Summary answer: P4 entry in ESC is not necessary to induce in vitro decid-
ualization as long as PGRMC1 is inhibited by AG205.
What is known already: PGRMC1 is a membrane receptor that mediates
non-genomic action of P4.It has been implicated in a diversity of biological
events,including apoptosis and folliculogenesis(1,2).PGRMC1 mediates non-
classical P4 signaling in endometrium but its mechanism of action is still
unknown.PGRMC1 protein is down-regulated in receptive endometrium but its
expression is higher in stromal compartment compared to epithelial cells(3).
We previously published that it localizes in membrane, cytosol and nucleus of
non-decidualized ESC,but accumulates in the nucleus of decidualized ESC
(dESC).Its overexpression inhibits in vitro decidualization,co-localizing with
SERPINE 1 mRNA binding protein(SERBP1) throughout the menstrual cycle
and in the cytosol of non-decidualized and decidualized ESC(4).
Study design, size, duration: Endometrial biopsies were obtained from
donors (n = 7) and ESC were isolated. In vitro decidualization was induced by a
long protocol using P4/E2 (Estradiol) (8 days) and a short protocol using cyclic
adenosine monophosphate/Medroxyprogesterone (cAMP/MPA) (4 days). To
activate only membrane progesterone receptors we used a membrane-
impermeable P4 (P4-BSA) that avoids P4 entry in the cell. Also, we employed
AG205, a PGRMC1 antagonist that blocks PGRMC1 activation.
Participants/materials, setting, methods: We induced in vitro deciduali-
zation by long protocol with P4(1uM)/E2 (10 nM) or P4-BSA(1uM)/E2 in com-
bination with AG205 (50uM) (PGRMC1 antagonist), and by short protocol with
MPA/cAMP or P4-BSA/cAMP+AG205. Decidualization was checked by
IGFBP1 and Prolactin (PRL) secretion by ELISA and F-actin staining with phal-
loidin in each condition (n = 7). Classic progesterone receptor (PRAB) and
PGRMC1 localization was performed in non-decidualized ESC (ndESC) and
decidualized ESC (dESC) of both protocols by immunoﬂuorescence (n = 4).
Main results and the role of chance: PRL secretion signiﬁcantly decreased
in the presence of P4-BSA/E2 compared to dESC P4/E2 group (p<0.05).
Nevertheless, PRL levels were signiﬁcantly increased in the presence of P4-
BSA/E2+AG205 compared to ndESC and dESC P4-BSA/E2 group (p<0.05).
However, when we use the short protocol, all groups were able to secrete high
levels of PRL included the P4-BSA/cAMP and P4-BSA/cAMP+AG205 groups.
F-actin staining showed a lack of cytoskeleton reshaping in P4-BSA dESC group
compared to the typical polygonal shape observed in decidualized controls. The
F-actin ﬁlaments disposition of a dESC were restored in P4-BSA group in the
presence of AG205. Again, dESC of all groups showed a correct F-actin struc-
ture when we induced decidualization with the short protocol, also in the P4-
BSA/cAMP and P4-BSA/cAMP +AG205 groups. Immunocytoﬂuorescence
assay revealed a clear PGRMC1 perinuclear and nuclear sublocalization in P4/
E2 and P4/E2+AG205 dESC groups, while it persisted at the membrane and
cytosol in P4-BSA/E2 and P4-BSA/E2+AG205 dESC groups. Surprisingly,
PRAB, continued translocating to the nucleus in P4-BSA/E2 dESC group as in
the control (P4/E2). However, PRAB signal strongly decreased in P4-BSA/E2
+AG205 dESC group. Finally, immunocytoﬂuorescence of PR receptors using
the short protocol did not show localization differences between all the groups
in both receptors.
Limitations, reasons for caution: Due to the variability between human
endometrial samples and the low number of experiments performed, results
should be taken with caution.
References
(1)J.J.Peluso et al.,Biol.Reprodb 88(1)2013
(2)M. Guo, et al.,Sci. Rep. b 16(6)2016
(3)T.Garrido-Gómez et al.,Hum.Reprod 29(9)2014
(4)S. Salsano et al.,Fertil.Steril. 108(5)2017
Wider implications of the ﬁndings: According to our results, we demon-
strated that in absence of the P4 entry into the stromal cell, the activation of P4
membrane receptors in concomitance with PGRMC1 inhibition, is sufﬁcient to
achieve in vitro decidualization. Further molecular experiments are needed to
understand the underlying mechanisms.
Trial registration number:Not applicable.
Supported by IVI Foundation (1405-FIVI-024-FD),the Spanish Ministry of
Economy, and Competitivenessthrough the Miguel Servet programme (CP013/
0450)(F.D.)co-founded by FEDER and by aSantiago Grisolia (S.S.) grant.
P-452 Sufﬁcient vitamin D supplementation regulates maternal
T-helper cytokine production in women suffering from infertility
S. Yamashita1,2, Y. Ikemoto1, A. Ochiai1, K. Nakagawa3,
K. Murakami1, R. Ozaki1, K. Nakao3, A. Matsumoto1, K. Kuroda1,3,
R. Sugiyama3
1Juntendo University Faculty of Medicine, Obstetrics and Gynecology, Tokyo, Japan
2Oita University Faculty of Medicine, Obstetrics and Gynecology, Oita, Japan
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Study question: To determine the impact of vitamin D (VD) supplementation
on maternal immune tolerance in vivo, as well as decidualisation of human
endometrial stromal cells (HESCs) in vitro.
Summary answer: VD supplementation suppressed T-helper (Th)1 cell
levels in vivo and secretion of interferon (IFN)-γ in decidual HESCs in vitro.
What is known already: Maternal immune tolerance during pregnancy has
been associated with the balance between Th1 (IFN-γ production) and Th2 (IL-
4 production) cells in favour of the latter. An imbalance in the Th1/Th2 cell
ratio has been associated with reproductive failure, such as implantation failure
and miscarriage. VD plays a signiﬁcant role in regulating the immune system,
including Th and other cells. However, the impact of VD on successful preg-
nancy and optimal preconception levels of VD have not been clearly
understood.
Study design, size, duration: The present study was approved by the local
ethics committee. This prospective intervention study was designed to deter-
mine the impact of VD supplementation on Th cell immune response. Various
Th cell tests before and after VD supplementation (vitamin D3 1,000 IU/day)
for 3 months were compared. In primary culture, HESCs were decidualised
using 8-bromo-cAMP and progesterone with or without 1,25(OH)2VD for 4
days. Molecular analysis was then used to examine the cells and condition
media.
Participants/materials, setting, methods: Out of 28 patients aged 40 or
below suffering from infertility and low 25(OH)VD levels (<30 ng/ml), ﬁve
were excluded (one was lost to follow-up and four had received immunosup-
pressive drugs for post-liver transplantation or collagen disease). Twenty-three
women suffering from infertility underwent various Th cell tests before and after
VD supplementation. We then examined the effects of VD on HESC deciduali-
sation using real-time quantitative PCR, ELISA and immunohistochemical
staining.
Main results and the role of chance: Among the 23 patients, 22 (95.7%)
had increased 25(OH)VD (p < 0.0001). Moreover, VD supplementation signiﬁ-
cantly decreased the Th1/Th2 cell ratio (14.8% ± 4.0% to 13.1% ± 4.1%, p =
0.015). Sufﬁcient VD levels [25(OH)VD level ≥30 ng/ml] had been found in 11
patients (47.8%), among whom signiﬁcantly decreased Th1 cell levels and Th1/
Th2 cell ratios had been observed (p = 0.032 and 0.010). However, no signiﬁ-
cant differences in Th cell levels had been observed in patients who did not
reach sufﬁcient VD levels after supplementation. No complications or adverse
effects were identiﬁed in all patients.
Basic research has suggested that co-treatment of decidualising cultures with
1,25(OH)2VD increased the expression of vitamin D receptor (VDR) in decid-
ual cells, leading to the upregulation of IGFBP1 expression, a marker of decidua-
lisation. Moreover, 1,25(OH)2VD treatment of decidual cells in parallel
cultures showed nuclear accumulation of VDR, unlike cells not treated with
1,25(OH)2VD. In a cytokine assay of decidualised HESCs in culture media with
or without 1,25(OH)2VD, IFN-γ levels were signiﬁcantly lower in cells treated
with 1,25(OH)2VD compared to those without 1,25(OH)2VD (p = 0.008),
but not IL-4.
Limitations, reasons for caution: Considering that VD levels can be
affected by exposure to sunlight and diet, supplementation may not be the only
factor affecting VD levels. We recognise that signiﬁcant seasonal changes had
not been observed in the present study.
Wider implications of the ﬁndings: Optimal Th1/Th2 cell balance is
important during implantation and maintenance of pregnancy. Aberrantly high
population of Th1 cells has been associated with embryonic rejection, leading
to repeated reproductive failure and complications during pregnancy. Sufﬁcient
preconception VD levels may prevent maternal immune rejection of the
embryo, leading to a successful pregnancy.
Trial registration number:None.
P-453 The effect of maternal BMI on the development of human
fetal kidney
S. Banh1, J. Mulhern1, N.Walker1, M. Bellingham2,
P.J. O’Shaughnessy2, H.M.Wilson1, P. Filis1, P. Brown3, P.A. Fowler1
1University of Aberdeen, Institute of Medical Sciences, Aberdeen, United Kingdom
2University of Glasgow, Institute of Biodiversity- Animal Health and Comparative
Medicine, Glasgow, United Kingdom
3Aberdeen Royal Inﬁrmirary, Department of Pathology, Aberdeen, United Kingdom
Study question: How does maternal BMI affect development of the human
fetal kidney?
Summary answer: High maternal BMI affects fetal kidney development and
dysregulates development of the renin-angiotensin system.
What is known already: The obesity epidemic worldwide currently affects
one-third of women in reproductive age, giving rise to higher prevalence of
obesity in pregnancy. Children born to overweight or obese mothers (BMI
≥25) are at an increased risk of developing childhood obesity and type 2 dia-
betes, which in turn predisposes individuals to chronic kidney disease (CKD).
Although clear associations have been demonstrated between maternal obesity
and long-term consequences on offspring health, the mechanisms underlying
the effects remain largely unknown.
Study design, size, duration:We aimed to characterize and identify pheno-
typic and molecular changes to the human fetal kidney in relation to maternal
BMI status. A total of 112 human fetal kidneys were collected from elective ter-
minations of normally-progressing pregnancies (7-20 weeks of gestation,
Scottish Advanced Fetal Research Study, REC 15/NS/0123). 53 from mothers
of BMI <25 and 59 from overweight or obese mothers of BMI ≥25.
Participants/materials, setting, methods: All 112 kidneys were weighed
before sample processing. Whole kidney extracts were prepared from 58
fetuses. 23 transcripts of key renal developmental genes, renin-angiotensin sys-
tem (RAS), and kidney injury markers were quantiﬁed by qPCR. 27 whole kid-
neys were processed for histomorphological analysis to assess gross phenotype
and podocyte density. Statistical analysis was done by ANOVA, linear regres-
sion and non-parametric tests as appropriate.
Main results and the role of chance: High maternal BMI signiﬁcantly
increases the relative ratio of kidney weight to total fetal body weight in male
fetuses (p < 0.02), but maternal BMI has no signiﬁcant association with overall
podocyte density in fetuses.
Expression of 11/23 transcripts (5 renal developmental genes, 4 components
of RAS, 1 kidney injury marker and 1 hypoxic marker) signiﬁcantly increased
with fetal age, while the erythropoietin (EPO) transcript was undetectable in all
groups. The renal renin encoding gene, REN, involved in blood pressure and
ﬂuid balance control was signiﬁcantly increased in fetal male kidneys if maternal
BMI was ≥25 (p < 0.04).
These ﬁndings are suggestive of altered kidney development, particularly the
renin-angiotensin system in male fetuses carried by women with high maternal
BMI. This study is currently being expanded by analysis of the RAS and kidney
damage markers in fetal human plasma.
Limitations, reasons for caution: Human nephrogenesis begins from 4
weeks of gestation and continues into the late fetal period (gestation week 34-
35). Our population sample includes fetuses up to 20 weeks of gestation, hence
the ﬁnal stages of podocyte development cannot be quantiﬁed in our study.
Wider implications of the ﬁndings: Disturbance of the fetal renal renin-
angiotensin system is a major contributor to the development of hypertension
and kidney diseases in later life. Insight into mechanisms underlying effects of
maternal BMI on fetal kidney development may provide key data to prevent
progression of kidney damage and reduce CKD complications in adulthood.
Trial registration number:Not applicable.
P-454 Clusterin, CXCL1 and MUC1may play important roles in
improving endometrial receptivity with local injury of endometrium
in unexplained recurrent implantation failure patients
K. Huang1, Q. Mai1, Y. Luo2
1The First Afﬁliated Hospital of Sum Yat-sen University, Reproductive Medical Center,
Guangzhou, China
2The First Municipal Hospital of Foshan, Reproductive Medical Center, Foshan, China
Study question: How endometrial scratch improves endometrium receptivity
in unexplained recurrent implantation failure (RIF) patients.
Summary answer: Endometrial scratch might be related to the up-regulation
of the expression of CLU and MUC1 and the down-regulation of CXCL13 after
the scratch.
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What is known already: The effectiveness of endometrial scratch on
improving endometrial receptivity in unexplained RIF patients has been
reported in multiple clinical studies, but the molecular and genetic mechanism
of this appearance remain unclear.
Study design, size, duration: It was a self-contrast designed study, 27
patients diagnosed as unexplained RIF were included. Patients diagnosed with
intrauterine adhesions, poor ovarian response, autoimmune disease were
excluded. Expression of 14 genes regulating the process of the response to
wounding and 8 gene reported to be related to endometrial receptivity were
analyzed in the endometrium sample before and after scratching. The immuno-
histochemistry tests were performed to further testify expression and distribu-
tion of deferential expression genes.
Participants/materials, setting, methods: Included RIF patients were
monitoring by ultrasonic and endometrium samples were obtained on the ﬁfth
day after ovulation as control group. Scratches were performed on day 5 of fol-
lowing menstrual cycle with biopsy catheters and endometrium sample were
taken on the ﬁfth day after ovulation as test group. The expression levels of tar-
geted genes were assessed by RT-qPCR tests, then immunohistochemistry
(IHC) tests were performed to analyze the expression status of the signiﬁcantly
regulated genes.
Main results and the role of chance: We select 14 genes that have been
reported as genes regulating the process of the response to wounding, including
C4BPA, HPSE, FGB, SCYE1, CXCL14, THBD, CXCL13, BCL6, SERPING1,
CLU, CFD, C3, PROS1 and AOX1. Meanwhile, 8 gene symbols reported to be
related to endometrial receptivity were also tested, including TP53, COX2,
CPLA2, MUC1, SGK1, LIF, ITGAV, and ITGB3. Our RT-PCR data demonstrate
that there are no signiﬁcant changes of the expression levels of most detected
genes except for CXCL13 (fold change: 0.91), MUC1 (fold change: 1.42) and
CLU (fold change: 2.19). Immunostaining endometrium were observed and ana-
lyzed with average positive staining method. The CXCL13 positive cells area per-
centage (PCA%) is 4.89% vs 2.78% (p = 0.10), showing reduction after the
scratch but without statistical signiﬁcance. On the other hand, MUC1 was specif-
ically stained in the cytoplasm of endometrial glandular epithelial cells before and
after the scratch, and the PCA% is signiﬁcantly higher after the scratch (15.18%
vs 33.20, p = 0.01). Unlike MUC1, CLU stained mostly in the cytoplasm of
endometrial stromal cells, and the PCA% also elevated after the scratch but the
difference is no statistical signiﬁcance (15.51% vs 19.43%, p = 0.37).
Limitations, reasons for caution: This is an observation study and the regu-
lating mechanism of MUC1 on human endometrium receptivity should be fur-
ther evaluated by gene knock-out model.
Wider implications of the ﬁndings: Endometrial receptivity defect is a
major factor that’s hampering the embryo implanting and endometrial scratch is
one of the most applied procedure in clinical practice on RIF. With the revealing
of its detail, we are aiming for more targeted examination and therapy to
improve endometrial receptivity for unexplained RIF patients.
Trial registration number: not applicable.
P-455 Pregnancy loss rates (PLR) in IVF patients as an overlooked
topic
M. Murtinger1, B.Wirleitner2, P. Vanderzwalmen3, M. Schuff2
1IVF-Centers Prof. Zech Endocrinology- IVF Centers Prof. Zech, Bregenz, Austria
2IVF-Centers Prof. Zech, Bregenz, Bregenz, Austria
3Centre Hospitalier Inter Régional Edith Cavell CHIREC, Braine-l’alleud, Bruxelles,
Belgium
Study question: Are IVF patients of increased risk for pregnancy loss com-
pared to natural conception and is there a beneﬁt of pre-implantation genetic
screening (PGS)?
Summary answer: Interestingly, PLR were not increased in sub-fertile IVF-
patients compared to spontaneous conception. No signiﬁcant improve with
PGS questions aneuploidy as major early PL factor.
What is known already: Human reproduction is characterized by a high
embryo-wastage. The majority of embryos are already lost before implantation
with chromosomal imbalance suggested as the most important cause for this
phenomenon. Major concern in IVF was turned on implantation failure, includ-
ing the implementation of PGS. Less interest was drawn on PL after successful
implantation of the embryo. While several studies focused on PL in natural con-
ception, e.g. the pioneering work of Wilcox et al.,1988, PL in IVF-patients and
especially in PGS remains under-investigated.
Study design, size, duration: A retrospective study single center study was
conducted including 1.383 vitriﬁed/warmed blastocyst transfers between 01/
2010 and 12/2016 to insure a standardized optimal endometrial preparation.
Clinical data were extracted by using the DynaMed® software; statistics were
performed using SPSS statistics.
Participants/materials, setting, methods: All patients with a positive
pregnancy test after blastocyst transfer in the test period were included. Mean
female age at the time-point of cryopreservation was 35 years. In PGS-cycles
trophectoderm biopsy was performed with aCGH or NGS analysis. We com-
pared outcomes of single or double blastocyst transfers with or without PGS by
analyzing implantation rate (IR), pregnancy loss rate (PLR) and birth rate (BR).
Obtained data were compared with data published on natural conceptions.
Main results and the role of chance: After positive hCG-test a PLR before
detection of embryonic heart-beat of 22.8% was observed in IVF-cycles, no
statistically signiﬁcant difference between conventional and PGS cycles was seen
(22.6% vs. 30.0%, respectively). Thirteen pregnancy losses (0.94%) occurred
due to ectopic implantation. Distinctly higher IRs were found in single blastocyst
transfer (SBT) compared to double BT (DBT) in both, conventional and PGS
cycles (SBT 79.7% and 70.8% vs. DBT: 50.0% and 33.3%, respectively). SBTs
resulted in a 1.5% monozygotic twin rate; DBTs in 28.8% twin pregnancies. PLR
after implantation and detection of embryonic heart-beat was 13.7% after fro-
zen/warmed BT in conventional IVF-cycles and 9.5% in PGS-cycles with not
statistically signiﬁcant difference. These observed PRL in sub-fertile IVF patients
were close to natural embryo loss after detection of fetal heart beat (assumed
6-12%). No statistically signiﬁcant difference was detected between singleton
and twin pregnancies. In this line, similar BRs/BT were detected in both groups:
66.7% in conventional vs. 63.3 % in PGS cycles.
Limitations, reasons for caution:Only vitriﬁed/warmed BT were included,
thus results might be not applicable for fresh BT. Further limitations are the
small data set of PGS BTs. Larger data analysis are needed to further conﬁrm
our data.
Wider implications of the ﬁndings: Our data show increased risk of non-
implantation for embryos in DBT. However, PLR after embryonic heart-beat in
both, conventional IVF and natural conception are similar, potentially due to the
beneﬁt of an optimal luteal phase support. The beneﬁt of PGS in PRL remains
to be proven.
Trial registration number: ‘not applicable’
P-456 Human chorionic gonadotropin improves endometrial
receptivity by increasing the expression and enhancing
phosphorylation of HOXA10
M. Zhu, S. Yi, X. Huang, J. Meng, Y. Cai, W. Shen, H. Sun, J. Zhou
Nanjing University Medical School, Reproductive Medicine Center- Drum Tower
Hospital, Nanjing, China
Study question: Does hCG affect endometrial receptivity by regulating the
expression of homeobox A10 (HOXA10)?
Summary answer: hCG activates endometrial decidualization by reducing
expression and concomitant DNA methylation of HOXA10 and enhancing
phosphorylation of HOXA10.
What is known already: HOXA10 has emerged as an important molecular
marker of endometrial receptivity. Recent evidence suggested that hCG may
inﬂuence the endometrial milieu thereby enhancing receptivity and implantation
success, but the exact underlying mechanism of this phenomenon remained
elusive.
Study design, size, duration: Endometrial samples were collected from nor-
mal cycling women during the mid-secretory phase for endometrial stromal
cells (ESCs) isolation used to investigate the molecular mechanisms in vitro.
Blastocyst-like spheroid(BLS) implantation models were performed to examine
the roles of hCG during embryo expansion on hESCs. This is an experiment
study lasted nine months.
Participants/materials, setting, methods: Endometrial stromal cells
(ESCs) and JAR cells were used as study models. Western blotting, real-time
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RT-PCR and BLS expansion assay were used to determine the mechanism of
endometrial receptivity changes induced by hCG. All experiments were con-
ducted using at least three different cell culture preparations in triplicate.
Main results and the role of chance: Western Blot analysis revealed that
addition of 0.2IU/mL hCG to ESCs induced the increase of HOXA10 and
decrease of DNA methyltransferases 1 (DNMT1) at 48 h (both p<0.01 versus
control). Increase of mammalian sterile20-like kinase1(MST1) in ESCs treated
with 0.2IU/mL hCG at 20 min ( p = 0.043 versus control). HOXA10 mRNA
levels were signiﬁcantly increased by hCG 0.2IU/mL treatment for 48 h
(p<0.01) and DNMT1 mRNA levels were decreased by hCG 0.2IU/mL treat-
ment for 48 h. hESCs treated with hCG 0.2IU/mL up to 48 h showed a good
decidual response, mainly characterized by increased BLS expansion.
Limitations, reasons for caution: This is an in vitro study utilizing hESCs
and JAR cells. The changes of DNA methylation of HOXA10 and phosphoryl-
ation of MST1 should be further evaluated. Furthermore, the results obtained
should be conﬁrmed in mice with hCG intrauterine perfusion treatment in vivo.
Wider implications of the ﬁndings:Our results suggest that hCG activates
endometrial decidualization not only by reducing expression and concomitant
methylation of HOXA10 also enhancing phosphorylation of HOXA10. These
ﬁnding may subsequently provide novel potential therapeutic regimens for
patients with poor decidualization.
Trial registration number: This work was supported by the National
Natural Science Foundation of China (81571504).
P-457 Increased NK-cell subsets with inhibitory cytokines and
surface receptors in patients with recurrent miscarriage
R.J. Kuon1, L. Zhu2, M. Aly2, K. Vomstein3, T. Strowitzki1, B. Toth3,
V. Daniel2
1University Hospital, Department of Gynecological Endocrinology and Fertility
Disorders, Heidelberg, Germany
2University of Heidelberg, Department of Transplantation- Immunology, Heidelberg,
Germany
3Medical University Innsbruck, Gynecological Endocrinology and Reproductive
Medicine, Innsbruck, Austria
Study question: How do the counter-regulating inhibitory mechanisms of
NK-cell subsets differ in patients with recurrent miscarriage compared to
healthy controls?
Summary answer: Patients with recurrent miscarriage show abnormally high
NK-, NKT- and T- cells in the blood which express inhibitory cytokines and
inhibitory surface receptors.
What is known already: NK-cells are in the focus of debate as potential
immunologic markers and targets in recurrent miscarriage. There is increasing
evidence for immunoregulatory NK cells that might mediate immune responses
by secretion of IL10, IL4, and TGFß. Patients with recurrent miscarriage show
upregulated cytotoxic NK cells that are suspected to play a causal role in the
pathogenesis. Further elevated NK-cells are associated with decreased uterine
blood ﬂow in early pregnancy, possibly leading to hypertension, preeclampsia,
and fetal growth restriction.
Study design, size, duration: Prospective cohort study, in total n = 31
patients with recurrent miscarriage and n = 37 healthy controls were recruited
between 01/2016 and 09/2017.
Participants/materials, setting, methods: NK-, NKT- and T-cell subsets
were analyzed in the peripheral blood of n = 31 patients with idiopathic recur-
rent miscarriage and n = 37 healthy controls using eight-color ﬂuorescence
ﬂow cytometry. Patients had a history of 3 and more consecutive miscarriages
and were screened for anatomical disorders (vaginal ultrasound and hystero-
scopy), endocrine dysfunctions, autoimmune disorders, deﬁciencies in coagula-
tion factors, inherited haemostatic changes and parental chromosomal
abnormalities. All analyses were performed at least 3 months after the last
pregnancy.
Main results and the role of chance: Compared with healthy controls,
patients with recurrent miscarriage showed signiﬁcantly higher absolute num-
bers of CD56+ NK-cells co-expressing the phenotype IFNyR+, IL4+, TGFβ+,
IL4+HLADR+, TGFβ+HLADR+, IL4+TGFβ+, IL4+TGFβ-, IFNy+ and/or
IL10- IFNy+ (all p≤0.01), more IL17+CD56bright (p = 0.028) NK-cells, and
more CD56dimCD16+ NK-cells co-expressing IFNyR, IFNy, IL4 and/or TGFβ
(all p≤0.01). Further, patients with recurrent miscarriage showed signiﬁcantly
higher absolute numbers of CD158a-CD158e+, CD158a+, CD158b+ (all
p<0.05), NKG2D+NKG2A+, NKG2D+NKG2A-, NKG2D+ and/or NKG2A
+ (all p≤0.01) CD56+ NK-cells and higher CD158a+, CD158b+ (all p<0.05),
NKG2D+ and/or NKG2A+ (all p<0.01) CD56dim+CD16+ NK-cells than
healthy controls.
Limitations, reasons for caution: This data needs to be conﬁrmed in a lar-
ger cohort of patients.
Wider implications of the ﬁndings: Compared to healthy controls,
patients with recurrent miscarriage have abnormal high circulating NK-cells
expressing inhibitory cytokines and inhibitory surface receptors which might
contribute to the pathogenesis. This immune proﬁle might be used to identify
patients that beneﬁt from therapies that inhibit cytotoxic immune response in
clinical trials.
Trial registration number: not applicable.
P-458 Recurrent implantation failure: should we refuse from
scanning electronmicroscopy
I. Gyulmamedova1, T. Tatarchuk2, O. Nosenko3,
E. Gyulmamedova2, P. Bazanov4, S. Khabarov5, O. Babenko6
1VitroKlinik, IVF, Moscow, Russia C.I.S.
2Institute of Pediatrics- Obstetrics and Gynecology-, Department of Endocrine
Gynecology, Kyiv, Ukraine
3Odessa National Medical University, Department of Obstetrics and Gynecology,
Odessa, Ukraine
4VitroKlinik, In vitro fertilisation, Moscow, Russia C.I.S.
5VitroClinik, Gynecology, Moscow, Russia C.I.S.
6Medical Center “Mother Child-”, gynecology, Kyiv, Ukraine
Study question: To evaluate clinical outcome of scanning electron micros-
copy (SEM) usage for Personalized Embryo Transfer (PET) algorithm in women
with recurrent implantation failure (RIF).
Summary answer: Determination of the implantation window via SEM helps
improve the strategy of PET, as well as pregnancy rate in women with RIF.
What is known already: Recurrent implantation failure is a challenge of
modern reproductive medicine. The endometrium acquires the ability to
implant a hatched blastocyst only within a speciﬁc time termed the receptive
phase. Pinopodes have been suggested as the markers of uterine receptivity.
Endometrial pinopodes formation can be detected by SEM. Controversial data
are published on SEM as an efﬁcient method of endometrial receptivity deter-
mination. Implementation of endometrial receptivity array (ERA) test for
«Implantation Window» determination (IW) limited SEM usage. However, in
recent years interest to SEM has revived, given its availability, reproducibility
and informative value.
Study design, size, duration: A prospective study of 66 cycles in patients
with recurrent implantation failure was conducted between 2012 and 2016.
Patients with RIF who had euploid embryos according to PGD results were
included in the study after Informed Consent was obtained. Hysteroscopy was
performed for all patients to exclude intrauterine pathology. Patients were
divided in two groups. 1.89 ± 0.05 embryos were transferred in the ﬁrst group
and 1.94 ± 0.06 - in the second, (p> 0.05).
Participants/materials, setting, methods: Patients were divided in two
groups. 1 group - 36 patients - transfer of frozen-thawed euploid embryos on
day (P+7) after initiation of progesterone therapy in hormone replacement
cycle (HRС). 2 group - 30 patients - Pipelle endometrium sampling was per-
formed on day (P+6) and day (P+8). SEM was performed for pinopodies
imaging. Frozen-thawed euploid embryos in this group were transferred
depending on the IW according to results of SEM.
Main results and the role of chance: There were no differences in age,
BMI, reproductive and gynaecological history, as well as in the number of previ-
ous IVF cycles in the groups. Analysis of SEM results on day P+6: lack of pino-
podes in 24 (80,00%) patients, sites of scant pinopodes around the uterine
gland in 4 (13,33%), plenty of developing pinopodes – in 2 (6,67%). On Day P
+8 we found lack of pinopodes in 5 (16,67 %) participants. Scant, moderate
and abundant amounts of developing pinopodes - in 8 (26,67%); 6 (20,00%); 4
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(13,33%) respectively. The abundance of developing and single developed ones
in 4 (13.33%); and scant, moderate and abundant quantity of regressed pino-
podes in 1 (3.33%), 1 (3.33%), 1 (3.33%) respectively. Transfer of frozen-
thawed embryos was performed according to the IW: on day P+5–1 (3,33%);
P+6–6 (20,00%); P+7–5 (16,67%); P+8–10 (33,33%); P+9–6 (20%). In 2 cases
was performed double transfer. Endometrial thickness on the day of ET was
9,35 ± 0,31 mm and 9,34 ± 0,3 mm (P>0.05). Pregnancy rate was 4 (11,11 %)
in the ﬁrst group and 18 (60%) in second (P <0.05). Live birth incidence on ET
was 3 (8.33%) and 16 (53.33%) (P <0.05).
Limitations, reasons for caution: For the effectiveness of the proposed
approach it is necessary to know the exact day of administration of exogenous
or secretion of endogenous progesterone. The IW formation is different in
women in the natural cycle, in cycle with HRT, and in the cycle with controlled
ovarian stimulation.
Wider implications of the ﬁndings: Knowledge of IW in patients with RIF
helps to obtain pregnancy in this complex category of patients. Along with the
modern transcriptomic genetic investigation of IW, SEM remains an informative,
reproducible, accessible method.
Trial registration number: Not trial; this prospective study was approved
by Ethics Committee.
P-459 Systematic review andmeta-analysis of variants in cytokine
genes emphasizes their clinical validity with respect to recurrent
pregnancy loss
E. Parﬁtt, C. Clementi, T. Hu-Seliger, B. Burnett, P. Yurttas Beim
Celmatix Inc., Research and Development, New York, U.S.A.
Study question: Is existing evidence sufﬁcient to conclude that testing variants
in cytokine genes is not useful in the context of recurrent pregnancy loss (RPL)?
Summary answer: Systematic assessment of all association studies to date,
followed by meta-analysis, reveals that 5 variants in 3 cytokine genes are signiﬁ-
cantly associated with RPL.
What is known already: Although immunological cytokines are involved in
establishing and maintaining pregnancy, studies testing the association of var-
iants in cytokine genes with RPL have yielded mixed results. Indeed, the ESHRE
Early Pregnancy Guideline Development Group (2017) recommends against
testing for cytokine polymorphisms because ‘meta-analyses have not been able
to ﬁnd polymorphisms in relevant cytokine genes associated with RPL.”
However, only one of the studies cited to support this recommendation is a
meta-analysis, covering 3 variants in 3 genes (Medica et al., 2009). Moreover,
since the publication of this analysis, at least 26 studies of cytokine variants and
RPL have been published.
Study design, size, duration: Natural language processing algorithms were
used to identify articles in NCBI PubMed pertaining to genetics and RPL. Of the
1,599 articles identiﬁed, 684 were found to be true positives after manual evalu-
ation. The evaluation also uncovered articles cited as references that were not
identiﬁed algorithmically. Reported gene associations were ranked using an
adaption of the Clinical Genome (ClinGen) Gene-Disease Clinical Validity
Classiﬁcation Framework. Data was extracted upstream of meta-analysis fol-
lowing PRISMA guidelines.
Participants/materials, setting, methods: Variants in genes that met
ClinGen-adapted criteria for ‘strong” evidence of clinical association with RPL
were statistically validated using random-effects model meta-analyses. Variants
were excluded from analysis if there were <2 published studies or evidence of
overlapping cohorts, or if an article’s presentation of information precluded the
determination of the risk allele. p<0.05 was considered statistically signiﬁcant,
equivalent to a false discovery rate cutoff of approximately 0.10.
Main results and the role of chance: We found no genes demonstrating
100% penetrance with RPL over multiple independent studies, which is
required for a “deﬁnitive” association ranking based on the adapted ClinGen
framework. Our analysis revealed that 39 genes, including the cytokines IFNG,
IL1B, IL6, IL10, IL18, and TNF, currently satisfy guidelines for strong evidence of
association with RPL. This ranking requires at least 2 independent demonstra-
tions of statistically higher prevalence of variants in affected individuals than in
controls, as well as supporting experimental data (e.g., from mouse models or
human gene expression studies). Of the variants within these genes, 62 had
sufﬁcient experimental evidence for inclusion in meta-analysis, including 19 in 6
cytokine genes. Five of these variants were found to be signiﬁcantly associated
with RPL after meta-analysis. Three of these 5 lie within TNF and include the c.-
488G>A variant (OR = 1.43, 95%CI:1.09-1.76, p = 0.003), previously
observed to have no association with RPL after meta-analysis. Notably, the TNF
variants c.-1211T>C and c.-556G>A have an even higher effect size, with ORs
of 2.64 (95%CI:1.77-3.50, p<0.001) and 2.29 (95%CI:1.07-3.51, p = 0.002),
respectively, which emphasizes the importance of assessing different variants in
the same gene. We observed a similarly high effect for the c.-887T>G variant in
IL18 (OR = 1.92, 95%CI:1.58-2.27, p<0.001).
Limitations, reasons for caution: We only included studies in which
patients had experienced ≥2 losses in our analyses. Heterogeneity introduced
by other factors, such as age, population stratiﬁcation, stage of loss, whether or
not losses were consecutive, and the wide variety of exclusion criteria, were
not adjusted for.
Wider implications of the ﬁndings: The association of genetic biomarkers
with RPL cannot be discounted without objective, systematic, and standardized
analysis. While the signiﬁcant variants identiﬁed here may not be causative by
themselves, such markers may enable physicians to distinguish molecular sub-
types of RPL, leading to treatment strategies that help mitigate inherent,
patient-speciﬁc risk factors.
Trial registration number:N/A.
P-460 Which one is more effective on Recurrent Implantation
Failure,innate or adaptive immunity?
F. Amjadi1, Z. Zandieh1, M. Mehdizadeh1, S. Aghajanpour2,
R. Aﬂatoonian2
1Iran University of Medical Sciences, Department of anatomy, tehran, Iran
2Royan Institute for Reproductive Biomedicine- ACECR-, Department of
Endocrinology and Female Infertility at Reproductive Biomedicine Research Center-,
Tehran, Iran
Study question: Which one is more effective on Recurrent Implantation Failure,
innate or adaptive immunity?
Summary answer: adaptive immunity play more important role in recurrent
implantation failure patient.
What is known already: The immune system is required for maternal
immune tolerance, protecting the fetus, and regulating the placentation process.
In RIF patients, Many factors may contribute to implantation failure as inappro-
priate immune responses at the time of embryo introduction is one of the rea-
son for unsuccesful implantation. So, evaluation of innate and addaptive
immune syatem in RIF patients seems valued.
Study design, size, duration: This study was a basic genomic analysis of
human endometrial biopsies taken from 10 patients with repeated implantation
failure and 6 healthy fertile women in the secretory phase. All participants are in
reproductive age with normal menstrual cycles.
Participants/materials, setting, methods: Total mRNA were extracted
from endometrial tissues of women with repeated implantation failure (on day
3-5 after ovulation, n = 12) and healthy fertile individuals (on day 3-5 after ovu-
lation, n = 10) during luteal phase. The expression proﬁle of 84 genes related
to innate and adaptive immunity was investigated using qRT-PCR array.
Informed consent was obtained from patients. All measurements were per-
formed in triplicates on independent biological replicates.
Main results and the role of chance: Our data clearly showed that cyto-
kines expressions like IL6, IL-2, IFN gamma, IL17, IL23 and IL13 are higher in
RIF group than normal. The innate immunity pathways as, pattern recognition
receptors and their pathways like TICAM1, TICAM2, IRAK1, TRAF, MYD88
expression are lower or not signiﬁcant in RIF than normal group, also the
expression of NFKBIA (IκBα, MAD3) as an inhibitor of NFKB1 are higher in RIF
group. The adaptive immunity markers like T cell activation,Thelper1 and
Thelper17 like CD86, ICAM1, CXCR3, TBX21 and FASLG (TNFSF6) expres-
sions are higher in RIF than normal.
Limitations, reasons for caution: The results need to be conﬁrmed in
more cases and in protein level.
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Wider implications of the ﬁndings: Results showed more proinﬂammatory
environment than anti-inﬂammatory in RIF. Apparently, the source of inﬂamma-
tory cytokines production are Tcells not PRR pathways. For example, MYD88,
an important factor downstream of PRR was decreased in RIF patients. So, it
seems adaptive is more contributing factor than innate immunity in pathophysi-
ology of RIF.
Trial registration number:N/A.
P-461 Patient acceptability and perception of randomisation in a
trial of Scratch in Recurrent Miscarriage (SiM trial)
V. Kandavel1, S. Quenby2
1Sub specialty trainee in reproductive medicine and surgery, Complete Fertility centre,
southampton, United Kingdom
2Professor of Obstetrics, UHCW NHS Trust- University of Warwick, coventry, United
Kingdom
Study question: 1. Would women be prepared to be randomised to scratch
vs sham examination?
2. Will patients be aware of endometrial biopsy compared to sham
procedure?
Summary answer: Women were accepting to the randomisation process
within the trial.
Women were not aware whether they had the endometrial biopsy or the
sham procedure.
What is known already: The Cochrane meta-analysis of the effects of endo-
metrial scratch in women undergoing assisted reproductive conceptions, sug-
gested that obtaining endometrial biopsy in the luteal phase prior to the
treatment improves the clinical pregnancy and live birth rates. This was particu-
larly so in women with previous failed IVF’s.
The trials in the review compared endometrial scratch vs endometrial injury
by other methods such as hysteroscopy.
In the Endoscratch trial for women prior to their ﬁrst IVF, women are rando-
mised to scratch vs no examination.
The ESHRE RPL guideline acknowledges the gap in the evaluation of endo-
metrial scratch in women with recurrent miscarriage.
Study design, size, duration: Evidence from trials in recurrent miscarriage
(RM) patients suggests good outcomes in the placebo group. The presence of a
sham arm was important methodologically, in the trial. However patient
acceptability was unknown.
The SiM trial is a pilot randomised controlled trial of endometrial scratch vs
sham procedure, in the luteal phase, on the pregnancy outcomes in RM.
109 women were recruited over a 2 year period (2015-2017). Ethics
approval was obtained for trial, questionnaire collation.
Participants/materials, setting, methods: Women (age 18-42) were
approached in the recurrent miscarriage clinic to participate in the SiM trial.
There were given trial explanation and PIS by the research midwife and clinical
fellow. The questionnaire was provided in a self addressed envelope at their
randomisation visit, to be completed and returned within 4 weeks.
The questionnaire contained objective measures quantifying pain, bleeding,
duration- to assess the difference between the groups and free text box for
comments and feedback.
Main results and the role of chance: Of the 226 women screened, 150
women were eligible. 133 patients were consented and 109 women were ran-
domised. The acceptance rate was 72.66 %.( 10/24 women were excluded as
pregnant before randomisation). 109 Questionnaires were given at randomisa-
tion. The response rate was 62.38 %( 68/109), with similar numbers in both
groups-(33 and 35), with most responses within 2 weeks from randomisation
(76.5%, 52/68). There were no reported infection following the procedures.
More bleeding was reported in the biopsy group (28/33) compared to the
control group (8/35), which was mild in 80% of the women. A signiﬁcant pro-
portion of women in both the groups experienced pain, but more women in
the biopsy group (30/33) reported pain than the control group (20/35).
However the pain score was reported as mild by the majority of women in
both the groups. Interestingly 7of 20 women who reported pain in the control
group described it as moderate pain. 1 in 10 patients experienced severe pain
in the biopsy group.30/68 patients had prior analgesia intake. The duration was
short lasting (< 10 minutes) in most women.
Women who experienced pain in the sham group thought they had the inter-
vention and those painfree in the biopsy group vice-versa.
Limitations, reasons for caution: The numbers are small as this is a pilot
trial. There is a possibility of recall bias especially when the response has been
delayed. The inﬂuence of the procedure expectations and experience leading
upto the randomisation may have contributed to the recall bias.
Wider implications of the ﬁndings:
• Women with recurrent miscarriage accepted to randomisation in
the trial with a sham group.
• More women experienced bleeding in the biopsy group.
• As some women in both groups experienced pain and others did
not during the procedure, they were not aware of the allocation
group and so blinding occurred.
Trial registration number: The trial is registered on clinicaltrials.gov.
The trial registration number is NCT02681627
P-462 The effect of uterine cavity irrigation with ofﬁce
hysteroscopy during antagonist cycle 0varian stimulation on IVF
outcome
M. Ghasemi1, A. Aleyasine2, M. Aghahosseini2
1Pregnancy Health Research Center-Zahedan University of Medical Sciences-
Zahedan-Iran, obstetric and gynecology -IVF center, Zahedan, Iran
2Tehran University of Medical Sciences, obestetric and gynecology and Ivf center-
Tehran University of Medical Sciences, Tehran, Iran
Study question: Dose uterine cavity irrigation with ofﬁce hysteroscopy in the
day 5-7 during antagonist cycle ovarian stimulation in the IVF cycle improve the
endometrial receptivity and ivf outcome.
Summary answer: hysteroscopy could not improve the IVF outcome in the
same cycle but could enhance the cumulative pregnancy rate.
What is known already: Although many studies were done about the effect
of routine hysteroscopy prior to the ﬁrst IVF cycle, there is still no agreement
about the effect of hysteroscopy on IVF outcomes.
Study design, size, duration: This prospective randomized clinical trial was
conducted in the shariati hospital infertility ward, Tehran university of medical
sciences from June 2015 to June 2016.
250 women who were less than 40 years, with primary infertility and without
the history of prior hysteroscopy examination in the ﬁrst IVF cycle, and also
with normal transvaginal sonography and hysterosalpingography were entered
to the study.
Randomization was done with web-based concealed allocation and patients
were randomly entered to each group.
Participants/materials, setting, methods: Controlled ovarian hyperstimu-
lation was done by using antagonist regimen with r-FSH in two groups.
Hysteroscopy was performed in the early mid-follicular phase of a stimulation
cycle (day 5-7) with a vaginoscopy approach in hysteroscopy group. Embryo-
transfer was done in the same cycle. The primary outcomes were clinical preg-
nancy rate and secondary outcome was live birth rate.
also we followed all patients without live births through the second freeze
embryo transfer cycle for secondary outcome.
Main results and the role of chance: From June 2015 to June 2016 we ran-
domly assigned 250 women in one of the two groups: hysteroscopy (case
group) or without hysteroscopy (control group) and ﬁnally 228 patients ﬁnished
the study. clinical pregnancy rate was 47% in the case group and 40% in the con-
trol group. (p-value = 0.396, RRR = 13.8% [-5.9% to 35.9%], NNT = 15 [-16
to 5])
Live birth rate was 41.28% in the hysteroscopic group and 31.9% in the control
group (p-value = 0.18, RRR = 22.7% [-9.2% to 45.2%], NNT = 11 [-32 to 5]).
When the patients were followed for 2 months for an additional embryo
transfer, LBR was 78% in the hysteroscopic group and 47.5% in the control
group (p-value = 0.039, RRR = 26.9% [3-44.9%] and NNT = 8 [4-85]).
Limitations, reasons for caution: conduction in just one center and small
sample size were two limitations in this study.
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Wider implications of the ﬁndings: in order to decide about the generalis-
ability to other populations, more robust RCTs must be coducted.
Trial registration number: IRCT2016011022795N2
P-463 The relationship between angiogenic markers in peri-
implantation endometrium and hypertensive disorder in pregnancy
in women with reproductive failure
X. Chen,W.C. Cheung, Y. Liu, Y. Zhao, C.C.Wang, T.C. Li
The Chinese University of Hong Kong, Department of Obstetrics and Gynaecology,
Hong Kong, China
Study question: Do angiogenic markers in peri-implantation endometrium
predict hypertensive disorder in pregnancy in women with reproductive failure?
Summary answer: Micro vessel density (MVD) in the peri-implantation
endometrium may have a predictive value for hypertensive disorders in a subse-
quent pregnancy in women with reproductive failure.
What is known already: Vascular endothelial dysfunction in the placenta
bed has an important role in the pathogenesis of gestational hypertension and
preeclampsia. Barker hypothesis proposed that early intrauterine events might
have a long-term effect on the later on pregnancy or even after birth. We aimed
to examine the relationship between angiogenesis at the peri-implantation peri-
od and hypertensive disorders in the subsequent pregnancy in this study.
Study design, size, duration: This is a retrospective study including 110
women with a history of reproductive failure, including 58 women with recur-
rent miscarriage, 38 infertile women and 14 women with recurrent implantation
failure.
Participants/materials, setting, methods: Endometrial biopsies were
obtained precisely 7 days after luteinization hormone surge in natural cycles.
Immunohistochemistry was used to determine expression of VEGF-A, VEGF-C
and PLGF and micro blood vessels were identiﬁed by von Willebrand factor
(vWF). A semi-quantitative analysis was performed by using H-score analysis of
staining intensity for VEGF-A, VEGF-C and PLGF in the luminal epithelium, glan-
dular epithelium and stroma, separately. The number of vWF-positive endo-
metrial micro vessels were counted by Image J software.
Main results and the role of chance: Nineteen out of the 110 women
were diagnosed as gestational hypertensive disorders in the subsequent preg-
nancy, including 16 women with gestational hypertension and 3 women with
preeclampsia. The mean±SD number of micro blood vessels/mm2 in women
with gestational hypertensive disorders (15.2 ± 5.1/mm2) was found to be sig-
niﬁcantly (P = 0.041) higher than those with normal gestational blood pressure
(9.8 ± 3.1/mm2). However, there was no signiﬁcant difference in the expres-
sion intensity of VEGF-A, VEGF-C and PLGF in any endometrial compartments
(luminal epithelium, glandular epithelium and stroma) between women with or
without gestational hypertensive disorders.
Limitations, reasons for caution: Immunohistochemistry and H-score ana-
lysis for staining intensity are semi-quantitative methods to determine the
amount of protein expression. The study could potentially be strengthened by
other quantitative measurements.
Wider implications of the ﬁndings: Observations of relationship between
MVD in peri-implantation endometrium and gestational hypertensive disorders
may indicate the long-term effect of peri-implantation events on the later-on
pregnancy. Further studies may be considered whether the same conclusion
applies to other markers or other pregnancy complications.
Trial registration number:N/A.
P-464 Reduced adrenomedullin expression leads to aberrant
macrophage activities in human oviduct: implications for the
pathophysiology of tubal ectopic pregnancy
X.Wang1, C.L. Lee1,2, M. Vivijian1, R.H.W. Li1,2, Y.L. Lee1,
S.B. Liao1, K.F. Lee1,W.S.B. Yeung1, Y. Zhang3, P.C.N. Chiu1,2
1Department of Obstetrics & Gynecology, The University of Hong Kong,
2Shenzhen Key Laboratory of Fertility Regulation, Department of Obstetrics and
Gynecology, The University of Hong Kong-Shenzhen Hospital, Hong Kong
3Department of Obstetrics and Gynecology, Reproductive Medicine Center,
Zhongnan Hospital of Wuhan University
Study question: Does adrenomedullin (ADM) play a role in the pathogenesis
of tubal ectopic pregnancy (tEP) by modulating tubal macrophage activities?
Summary answer: ADM inhibits tubal implantation by suppressing the pro-
inﬂammatory activities of tubal macrophages.
What is known already: tEP accounts for ~2% of all pregnancies in the west-
ern world and is the major cause of maternal morbidity and mortality in the ﬁrst
trimester of pregnancy. The most important predisposing condition of tEP is sal-
ingitis. ADM is an immune-modulatory molecule with anti-inﬂammatory activ-
ities. Its expression in human oviduct is steroid dependent and peaked in a
steroid environment simulating the early luteal phase, a phase when embryo
transport occurred. We have demonstrated lower plasma and oviductal ADM
levels in patients with tEP than in normal pregnancy. Macrophages is the pre-
dominant leukocyte populations in the oviduct with tEP.
Study design, size, duration:Women undergoing salpingectomy due to tEP
were recruited as tEP group (n = 19). Non-pregnant women undergoing
hystero-salpingectomy for benign diseases were also recruited and divided into
control (n = 11) or salpingitis group (n = 19) according to their clinicopatholo-
gical diagnosis.
Participants/materials, setting, methods: Oviducts were collected from
the patients. ADM and implantation-related molecules expressions were deter-
mined by RT-qPCR and immunohistochemistry. Tubal macrophages were iso-
lated and cultured with or without ADM treatment. Their conditioned medium
(CM) were collected for inﬂammatory cytokine level determination by cytokine
array and ELISA. The effect of CM form macrophages on the implantation-
related molecules expressions and implantation capacity of tubal epithelial cells
was also studied by RT-qPCR and trophoblastic spheroid attachment model
respectively.
Main results and the role of chance: There was a reduced oviductal ADM
levels and an elevated implantation-related molecules levels in patients with sal-
pingitis and tEP when compared to the normal patients. Interestingly, ADM
treatment signiﬁcantly suppressed the stimulatory effects of tubal macrophages
on the implantation-related molecules expressions and implantation capacity of
tubal epithelial cells. These observations were associated with a decreased pro-
inﬂammatory cytokines secretion of tubal macrophages after ADM treatment.
Since Implantation is widely accepted to be associated with local inﬂammatory
event, the results indicated that reduced oviductal ADM level in tEP patients
may contribute to exacerbating pro-inﬂammatory activities of tubal macro-
phages, leading to a permissive environment for the embryo-tubal ectopic
implantation.
Limitations, reasons for caution: Our study only focused on the role of
ADM on tubal macrophage-derived pro-inﬂammatory cytokines production.
Further studies are required to illustrate whether there are other factors from
tubal macrophages can be modulated by ADM and thereby affecting implant-
ation process.
Wider implications of the ﬁndings: Our study provides a new insight on
the microenvironment change leading to tEP, as well as promote our under-
standing on the immunopathological mechanism of tEP.
Trial registration number:Not applicable.
P-465 Personal frozen-thawed embryo transfer in unexplained RIF
patients according to the blinded histological dating of endometrial
biopsies
Li1, Gan2, J. Song2, J.N. Liao3, G.X. Lu1, G. Lin1, F. Gong1
1Institute of Reproduction and Stem Cell Engineering- Basic Medicine College- Central
South University-Reproductive and Genetic Hospital of CITIC-XIANGYA, China,
2Reproductive and Genetic Hospital of CITIC-XIANGYA, China,
3Institute of Reproduction and Stem Cell Engineering- Basic Medicine College- Central
South University, China,
Study question: To determine the clinical effect of blinded endometrial histo-
logical dating in RIF patients.
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Summary answer: Personal frozen-thawed embryo transfer(pFET) according
to more accurate endometrial histologic dating (ovulation monitoring by ultra-
sound) may improve clinical outcomes in unexplained RIF patients.
What is known already: Many endometrial markers, such as pinopods,
immunohistochemical biomarkers, endometrial blood ﬂow, have been used to
determine the receptivity. They may interact transiently with the embryo at
implantation but appear not to be reliable markers of receptivity as the preci-
sion clinical diagnostic tools. The morphological changes observed on histology
for each speciﬁc day after ovulation were described by Noyes in 1950’.
Endometrial biopsy that shows a difference of more than 2 days between the
histologic dating and actual day after ovulation is considered to be “out of
phase”. But such pFET studies according to the Noyes criterion are relatively
lacking.
Study design, size, duration: From July 2017 to December 2017,
altogether 205 infertility patients were recruited in the prospective intervention
study.
Participants/materials, setting, methods: A total of 50 patients in con-
trol group and 155 RIF patients underwent endometrial biopsy. In phase I,
control group patients with PGD-CCS were recruited before their ﬁrst FET
cycles in luteal phase (postovulatory +3/+5/+7/+9/+11) (ovulation moni-
toring by ultrasound). Endometrial histological dating were evaluated in con-
trol patients who were ongoing pregnancy in next natural FET cycle. In
phase II, according to the results of endometrial dating, pFET were per-
formed in the RIF group.
Main results and the role of chance: In the phase I, criteria for endometrial
dating according to the Noyes dating criteria was developed in different time
(postovulatory +3, postovulatory +5, postovulatory +7, postovulatory +9,
postovulatory +11). And all the blinded endometrium dating (n = 205) was
evaluated by two experienced pathologists. The agreement between patholo-
gist A and pathologist B was determined to be good (weighted kappa = 0.672;
95% CI 0.606–0.737; P < 0.001). In the phase II, the rate of out of phase in the
day of postovulatory +7 was signiﬁcantly higher (31.61% vs 8.0%, P = 0.015) in
RIF group than control group.The ongoing pregnancy rate(OPR) was dramatic-
ally high in the pET RIF group (61.70%).
Limitations, reasons for caution: We didn’t design randomized controlled
study in RIF group which the endometrial dating was out of phase. Because the
RIF patients who have experienced multiple IVF failure were mostly reluctant to
try routine treatment protocol.
Wider implications of the ﬁndings: Provide a new insight for the unex-
plained RIF patients with individualized treatment.
Trial registration number:NCT03222830
P-466 Usefulness of hysteroscopic intrauterine perfusion in frozen-
thawed embryo transfer (FET) cycles
K. Takeuchi, T. Iwakawa, Y. Nagai, K. Hazeyama, C. Uchimura,
A. Ogawa, C. Kondo, N. Mori, M. Takeuchi
Takeuchi Ladies Clinic / Infertility Center, Infertility, Aira-shi- Kagoshima-, Japan
Study question: Patients who did not become pregnant after initial FET
underwent hysteroscopic intrauterine perfusion. Its usefulness was examined
by comparing pregnancy status.
Summary answer: Intrauterine perfusion with 500 ml of saline solution sig-
niﬁcantly increased the pregnancy rate even in women without macroscopic
abnormalities in hysteroscopy.
What is known already: FET is now being performed more often in the
world. FET is also what has mainly been performed at our hospital. Although
the involvement of endometrial thickness in pregnancy is widely known, there
are few reports on the other intrauterine environments.
Study design, size, duration: Between January 2013 and December 2017,
the pregnancy rate in FET was 46.3% (1545/3337). Subjects comprised 710
women who did not become pregnant after initial FET. Conditions of
embryo transfer limited materials strictly to an endometrial thickness of
more than ≧8 mm and good-quality embryos (Veeck’s classiﬁcation for Day
3 embryos ≧6 cell G II, Gardner’s classiﬁcation for blastocysts ≧3BB) in this
study.
Participants/materials, setting, methods: Subjects were classiﬁed into
three groups: Group I (women who underwent FET without hysteroscopy),
Group II (women who received treatment for polyps and inﬂammation
detected by hysteroscopy and then underwent FET) and Group III (women
who had no macroscopic abnormalities in hysteroscopy and underwent FET
immediately after intrauterine perfusion). A comparison of the pregnancy rate
was made between the three groups.
Main results and the role of chance: The pregnancy rate was 40.5% (85/
210) in Group I, 57.9% (168/290) in Group II and 59.0% (124/210) in Group
III, respectively. In terms of pregnancy rate, a more signiﬁcant increase was
recognized in Group II and Group III than in Group I (Group I vs Group II
P<0.01, Group I vs Group III, P<0.01). Even in the women without any macro-
scopic abnormal hysteroscopic ﬁndings, the pregnancy rate increased signiﬁ-
cantly after intrauterine perfusion.
Limitations, reasons for caution:None.
Wider implications of the ﬁndings: It is suggested that intrauterine perfu-
sion with saline solution during hysteroscopy might improve conditions for
implantation. Further examination is underway to clarify differences in bacteria
and endometrial microbiota before and after intrauterine perfusion.
Trial registration number:None.
P-467 Novel binding partners with serine protease A differentially
expressed in recurrent pregnancy loss
K.H. Baek1, C.Z. Pei1, J.H. Park1, L.A. Li1, I.K. Oh2, B. Choi2
1CHA University, Department of Biomedical Science, Seongnam, Korea- South
2Creative and Love Hospital, Gwangju, Korea- South
Study question: Could the role of serine protease A in regulating its matrix
proteins be related to the pathophysiology of recurrent pregnancy loss (RPL)?
Summary answer:We identiﬁed novel binding partners of serine protease A
and found that the regulation of this protease has an important role in women
with RPL.
What is known already: In humans, serine proteases are responsible for
various cellular processes including reproduction, immune response, and blood
coagulation. In a previous study, a novel serine protease gene was identiﬁed to
be more expressed in chorionic villi from the normal controls than in those
from the RPL patients.
Study design, size, duration: The serine protease A was investigated to
identify putative substrates using yeast two-hybrid screening. 22 different genes
encoding proteins, which may interact with the novel serine protease A, were
identiﬁed. The serine protease A and its putative binding proteins may play a
role in the occurrence of RPL.
Participants/materials, setting, methods: The full-length serine protease
A and human cDNA library were used for yeast two-hybrid Matchmaker GAL4
Two-Hybrid System 3. The novel serine protease A gene was transfected into
HeLa cells, and cellular lysates from these cells were separated on SDS-PAGE,
and proteins in these lysates were immunoblotted with diverse antibodies. In
addition, bioinformatics tools were employed to identify putative substrates of
the novel protease A.
Main results and the role of chance: In a previous study, we identiﬁed
eight differentially expressed genes in chorionic villi between the normal
control and RPL groups. Of these, a novel serine protease A gene was less
expressed in chorionic villi from RPL patients than in those from controls.
By performing yeast two hybrid screening, 22 different genes encoding pro-
teins, which interacted with the novel serine protease A, were identiﬁed. In
addition, we tried to identify the interaction between the novel serine pro-
tease A and known substrates through the bioinformatics tools.
Immunoprecipitation assay revealed that putative substrates including
immunoglobulin transporter (IGT) and inhibitor of apoptosis (IOA) inter-
acted with the novel serine protease A. Exogenous and endogenous expres-
sion levels of substrates were decreased by the novel serine protease A in
a dose-dependent manner.
Limitations, reasons for caution: The results of this study can only indicate
the limitations of serine protease A function in vitro.
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Wider implications of the ﬁndings: This is to explain the pathogenesis of
RPL from a new perspective, and will be the cornerstone of the development
for diagnostic reagents and the treatment of drugs.
Trial registration number: not applicable.
P-468 Effect of intrauterine perfusion of granulocyte colony
stimulating factor on endometrial parameters, implantation and
pregnancy rate in women undergoing IVF cycles: randomised
controlled trial
A. Kriplani1, S. Jain2, R. Mahey2, N. Malhotra2, N. Singh2,
M. Kalaivani2
1All India Institute of Medical Sciences- New Delhi- India, Obstetrics Gynaecology,
New Delhi, India
2All India Institute of Medical Sciences- New Delhi, Obstetrics & Gynaecology, New
Delhi, India
Study question: Whether there is any beneﬁt of intrauterine perfusion of
Granulocyte- Colony Stimulating factor (G-CSF) on Endometrial parameters,
implantation and pregnancy rate in women undergoing IVF-ICSI cycles?
Summary answer: Intrauterine perfusion of G-CSF had no beneﬁt in terms
of clinical pregnancy rate and implantation rate in women undergoing fresh IVF-
ICSI cycles.
What is known already: Implantation is the rate limiting step in ART cycles.
The interaction between a good quality embryo and a receptive endometrium
at the time of implantation determines the success of ART cycles. A lot of
research has been directed towards studying the factors that inﬂuence endo-
metrial receptivity, measures to assess and possibly improve endometrial
receptivity. Role of G- CSF is being investigated in increasing endometrial thick-
ness and pregnancy rate in women undergoing ART. Few studies have shown
that it increases implantation in women with poor endometrial thickness. Its
beneﬁt in women undergoing IVF with normal endometrial thickness is
unknown.
Study design, size, duration: A randomised controlled trial was conducted
among 150 women undergoing IVF/ICSI treatment at ART Centre after taking
approval from Institute Ethics Committee.
According to inclusion/exclusion criteria, 76 patients were randomised to
the intervention group (I) and 74 patients were randomised to the control
group (II). IVF protocol was decided according to age, BMI hormonal para-
meters and previous response. Primary outcome was clinical pregnancy rate.
Secondary outcome were effect endometrial parameters, implantation rate and
ongoing pregnancy rate.
Participants/materials, setting, methods: Patients in the intervention
group received intrauterine perfusion of 300μgm (0.5 ml) of G-CSF on the day
of ovulation trigger. Control group was administered intrauterine perfusion of
0.5 ml of normal saline. Endometrial thickness, volume and vascularity was
assessed by TVS on trigger day and embryo transfer day. The IVF protocol was
started according to age, BMI, previous IVF response, ovarian reserve, AMH
and FSH levels. Clinician and participants both were blinded about the group
allocation.
Main results and the role of chance: Baseline demographic parameters
and IVF characteristics were comparable between the two groups. Endometrial
thickness on day of ovulation trigger was 9.3 ± 1.6 mm in group I and 9.4 ±
1.6 mm in group II and was comparable ( p value 0.660). Endometrial volume
on day of trigger was 5.4 ± 1.7 ml in group I and 5.3 ± 1.8 ml in group II and
was comparable.Endometrial thickness on day of embryo transfer (ET) was
comparable in group I (11.3 ± 2.0 mm) and group II 11.2 ± 1.8 mm ( p value
0.697). Endometrial volume was also comparable. Only parameter which
showed signiﬁcant improvement in intervention group was endometrial vascu-
larity on day of embryo transfer (CI 1.67 (1.24, 2.24); p-0.001). Though there
were more clinical pregnancies in group I (21/76; 27.6%) as compared to group
II (14/74; 18.9%), but the difference was statically signiﬁcant (CI-1.25 (0.9,
1.74) p value- 0.207). Implantation rate was also comparable between the two
groups. Ongoing pregnancy rate (pregnancy beyond 12 weeks) was 20/76
(26.3%) in group I and 12/74 (16.2%) in group II. But the difference was not
statically signiﬁcant ( p value 0.131).
Limitations, reasons for caution: Main limitation of this study was small
sample size. Further large number data is required to document the role of
intrauterine perfusion of G-CSF on clinical pregnancy rate and implantation rate
in women undergoing IVF-ICSI cycles with normal endometrial thickness.
Wider implications of the ﬁndings: As published previously, our study also
did not ﬁnd any beneﬁt of intrauterine perfusion of G-CSF on clinical pregnancy
rate and implantation rate in women undergoing IVF cycles with normal endo-
metrial thickness.
Trial registration number: CTRI/2017/10/010310
P-469 Mutations in the sperm-activating factor PLCZ1 causing
fertilization failure after ICSI lead to partial hydatidiformmoles
R.R. Guggilla1, M. Ferrer-Buitrago1, D. Bonte1, L. Dhaenens1,
J. Parrington2, P. De Sutter1, P. Coucke3, B. Heindryckx1
1Ghent University Hospital Ghent Fertility and Stem cell Team, Reproductive
Medicine, Gent, Belgium
2University of Oxford, Department of Pharmacology, Oxford, United Kingdom
3Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium
Study question: Is the occurrence of partial hydatidiform moles (PHMs)
related to a sperm-related activation deﬁciency, caused by mutations in the
phospholipase C zeta (PLCZ1) gene?
Summary answer: Mutational screening of the PLCZ1 gene revealed three
distinct point mutations in male partners of three women with a previous his-
tory of PHMs.
What is known already: PHMs are aberrant pregnancies characterized by
trophoblastic proliferation and may contain embryonic tissues. PHMs mostly
contain one maternal and two paternal chromosomes, in 90% of cases due to a
dispermic fertilization. PLCZ1 is a sperm-related oocyte activating factor which
is required to induce normal calcium oscillations after fertilization. Aberrant pat-
terns of Ca2+oscillations caused by sperm of infertile men have been associated
with deﬁcient oocyte activation and failed fertilization. Genetic predisposition
for PHM in females have been described (e.g. NLRP7), but none are studied in
males. We therefore investigated the possible.
new role of PLCZ1 mutations in males causing PHMs.
Study design, size, duration: Three couples with a history of PHMs and
failed fertilization after ICSI were enrolled in this study. The mouse oocyte acti-
vation test (MOAT) was performed to reveal sperm-related activation deﬁcien-
cies. Mouse and human oocyte calcium analysis were performed to evaluate
the activation capacity of sperm. Male and female partners were screened for
mutations in the PLCZ1 and NLRP7 genes respectively. Patients were coun-
seled to undergo assisted oocyte activation (AOA) during ICSI to overcome
fertilization failure.
Participants/materials, setting, methods: Mutation screening included all
coding exons of the PLCZ1 gene. After PCR ampliﬁcation, products were
sequenced using Illumina MiSeq. Mouse oocyte assays were carried out with
piezo-drilled microinjection. Human ICSI was performed following standard
procedures. For Ca2+ imaging, oocytes were loaded with a Ca2+ sensitive dye
before ICSI. For ICSI-AOA treatment, a sperm was injected into the oocyte
together with 0.1 mol/l CaCl2 followed by a double exposure to ionomycin
(10 mM) 30 minutes after ICSI.
Main results and the role of chance:While two patients showed high acti-
vation rates after the MOAT, one patient showed a slightly reduced activation
rate (78%). Remarkably, all sperm samples induced abnormal Ca2+ oscillatory
patterns in mouse oocytes. This was even more pronounced when calcium ana-
lysis was performed using human oocytes, with most of the oocytes failing to
show calcium rises. However, in accordance with the hypothesis of dispermic
fertilization causing PHM, when two spermatozoa were injected into human
oocytes, an increase in the number of oocytes showing normal calcium oscilla-
tions was observed. Sequencing of the three patients revealed three different
heterozygous mutations in the PLCZ1 gene which include two missense muta-
tions: D46N and H233L, and a splice mutation: c.136-1 G>C.RT-PCR on the
cDNA of the patient sperm revealed that the c.136-1 G>C mutation leads to
loss of exon 4, subsequently leading to a truncated protein. No mutations in
NLRP7 were found in their female partners, thus excluding its role in these
PHM. To overcome fertilization failure after routine ICSI, ICSI-AOA was
i356 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
successfully employed for two couples, resulting in a total of 5 healthy children.
The other couple conceived spontaneously while waiting to start an ICSI-AOA
cycle, this pregnancy did develop normally, and a healthy child was born.
Limitations, reasons for caution: More studies conﬁrming this new role of
PLCZ1 in causing PHMs are needed. The functional effect of the mutations
identiﬁed has to be studied by making recombinant protein with these muta-
tions and look at their effect on activation rate, the pattern of Ca2+ signals, and
embryonic developmental potential.
Wider implications of the ﬁndings: This study shows for the ﬁrst time the
involvement of mutations in the sperm-related oocyte activating factor causing
PHMs in vivo, instead of an oocyte-related deﬁciency, as previously thought.
PLCZ1 gene screening may contribute to better understanding of the patho-
physiological mechanisms in PHM, thus improving clinical management of these
cases.
Trial registration number: not applicable.
P-470 A comparison of miscarriage and live birth rates between
hormone replacement treatment cycle versus natural cycle for
frozen embryo transfer
S. Abdul Mubarak1, S. Acharyya2, V. Viardot-Foucault3, H.H. Tan3,
J.W.L. Phoon3
1General Hospital Kuala Lumpur - Ministry of Health - Malaysia, Obstetrics and
Gynaecology Unit, kuala lumpur, Malaysia
2Centre for Quantitative Medicine, Duke-NUS Medical School -The Academia-,
Singapore 229899, Singapore Rep. of
3KK Women’s and Children’s Hospital, Department of Reproductive Medicine,
Singapore 229899, Singapore Rep. of
Study question: Primary objective is to compare miscarriage rates for frozen
embryo transfer cycles, between the hormone replacement treatment (HRT)
thaw cycle and the natural thaw cycle.
Summary answer: A signiﬁcant increase in miscarriage rates in frozen
embryo transfer(FET) cycles for patients who underwent the HRT thaw cycles
compared to the natural thaw cycle.
What is known already: The FET protocol is easy to perform and can be
accomplished in a shorter period of time than repeated in-vitro fertilization or
intracytoplasmic sperm injection cycles. FET can result in extra work on week-
ends for both clinicians and laboratory staff. This is more likely to happen with
natural thaw cycles, as the ovulation timing is not predictable.The recent
Cochrane database stated that there is no difference in the outcome with the
various methods of endometrial preparation used for FET.Thus we embarked
on this study to evaluate if it will be worthwhile to continue performing natural
thaw cycles at our centre.
Study design, size, duration: Design: Retrospective analysis of hospital
records.
Setting: KK Women’s and Children’s Hospital, Singapore. An Academic
Hospital with reproductive care.
Patient(s): Women undergoing frozen embryo transfer cycles either with
HRT thaw cycle or the natural thaw cycle from 1st January 2011 till 31st
December 2015.
Sample size:We would need 957 subjects in each arm to achieve a power
of 90% to detect the difference at 5% statistical signiﬁcance level in a two-sided
chi-squared test after applying continuity correction.
Participants/materials, setting, methods: We had a large sample size of
2752 subjects.To exclude any pelvic pathology, all women included in our study
had a recent endometrial cavity assessment within the last 6 months to exclude
any pelvic pathology.Patients with regular menstrual cycles were mostly
selected for true natural thaw cycle and irregular menstrual cycles were
selected for HRT thaw cycle.Statistical analysis was carried out using R version
3.1.1. All tests were done at 5% statistical signiﬁcance level.
Main results and the role of chance: A total of 2752 FET cycles were
included in this retrospective study analysis.A total of 81 (6.6%) and 171
(11.2%) women suffered from miscarriage in the natural and HRT thaw group,
respectively (p value 0.004). The live birth rate per transfer was signiﬁcantly
higher in the natural thaw group (22.8%) compared to the HRT thaw group
(17.3%) with p value <0.001. Multivariable logistic regression models were
used to control for factors that might be potentially associated with the risk of
both the miscarriage and live birth rates as well as the choice of FET cycles. We
adjusted for the patient’s age at which the embryo was cryopreserved, race,
BMI, main indication for IVF, number of embryo transferred, the type of embryo
transferred and the type of protocol used for the FET cycle (either natural cycle
or HRT cycle). The natural thaw group was considered as reference group to
estimate the odds ratios. The protocol type used was independently
associated with the risk of miscarriage (odds ratio 1.55; 95% conﬁdence interval
1.15 to 2.08; p value 0.004) and live birth rates (odds ratio 0.69; 95% conﬁ-
dence interval 0.56 to 0.84; p value <0.001) after adjusting for potential
covariates.
Limitations, reasons for caution: The limitation is that this is a retrospect-
ive study and the patients included were those with ovulatory and anovulatory
menstrual cycles. Patient allocation to the different type of endometrial prepar-
ation based on their menstrual cycle characteristics can pose as a bias as patient
characteristics differ in both the groups.
Wider implications of the ﬁndings: As the protocol type used for FET
cycles was independently associated with miscarriage rates, patients with regu-
lar menstrual cycles should be offered natural FET cycles for better outcomes in
live birth rates and reducing the miscarriage rates in the future.
Trial registration number: The Centralized Institutional Review Board at
SingHealth Services approved this study (CIRB/2014/033/D).
P-471 The effect of low oxygen concentration on gene expression
of potassium channels in human secretory endometrium
H. Al-Ahwany, S. Amer, C. Tufarelli, R. Khan
Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
University of Nottingham
Study question: Does changing in vitro partial oxygen pressure affect
the molecular expression of potassium ion channels in the human
endometrium?
Summary answer: A signiﬁcant difference was observed on the expression
of potassium channels in cells cultured in normal oxygen and low oxygen
concentration.
What is known already: There is a known functional signiﬁcance of intra-
uterine acute oxygen concentration changes in relation to both gamete viability,
embryo implantation and development. Potassium channels have been shown
shown to play an important role in implantation but the effect of oxygen con-
centration on potassium channels is not yet clear.
Study design, size, duration: This is a lab based study investigating the effect
of oxygen concentration on potassium channel in normal human secretory
endometrium (n = 6) and Recurrent implantation failure (RIF) human secretory
endometrium (n = 4).
In each group we are comparing the potassium channels gene expression of
KCNK9, KCNK10, KCNK17 and KCNMA1 under 2 different oxygen concen-
trations (atmospheric and 5% low oxygen concentrations). The experiment
were carried out using qPCR and ﬂow cytometry.
Participants/materials, setting, methods: Human endometrial samples
are collected after consenting the patients. Samples are washed from blood in
HBSS media and cultured in media supplemented with 10% fetal bovine serum
(FBS) and incubated for 24 hours, half of sample in atmospheric oxygen incuba-
tors and other half in 5% low oxygen tri-gas incubator. After 24 hours, RNA is
extracted, cDNA synthetized and qPCR carried out. Also same samples were
prepared for ﬂow cytometry.
Main results and the role of chance: Expression of all potassium channels
(KCNK9, KCNK10, KCNK17 and KCNMA1) in all samples are tested. After
the oxygen tension is modiﬁed, two of the channels showed signiﬁcant altered
expression (P<0.05). Translation to protein for the potassium channels was
conﬁrmed by ﬂow cytometry.
Limitations, reasons for caution: Larger (n) number of samples is needed
in order to apply two oxygen conditions on same patient sample.
The criteria of target group is so precise not allowing a high recruitment ﬂow.
The heterogeneity of the tissue makes it difﬁcult to identify which cell types
showed the expression.
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Wider implications of the ﬁndings: The ﬁndings from this study will
provide new knowledge on the role of potassium channels contributing to
normal and RIF endometrial function and may have future application in
improving implantation rates and identifying novel targets for fertility
regulation.
Trial registration number: ‘not applicable’
P-472 Exosomal proﬁle of the receptive endometrium: a source of
non-invasive biomarkers for guiding of a successful embryo
implantation
P. Piomboni1, A. Luddi1, C. Marrocco1, A. Capaldo1, V. Pavone1,
L. Boschi1, V. De Leo1, V. Cappelli1, L.A. Quintero2, F. Loria3,
N. Zarovni3
1Siena University, Molecular and Developmental Medicine, Siena, Italy
2IMER Valencia, Spain
3Exosomics Siena, Siena, Italy
Study question: Is endometrial ﬂuid exosomal proﬁle is a non-invasive source
for biomarker for guiding a successful embryo implantation in order to reduce
the time to pregnancy?
Summary answer: Exosomes playing key roles during embryo implantation,
should be used to drive a single embryo transfer in the proper time with the
highest endometrial receptivity.
What is known already: Accurate timing of embryo transfer is a critical clin-
ical need in reproductive medicine. Several factors secreted by the endometrium
in uterine ﬂuid control implantation by directly affecting blastocyst development
and/or by modulating the expression of key epithelial adhesion molecules and
embryo-endometrial cross talk. Some of these molecules may be sorted from
cytoplasmic endosomal compartments into secretory exosomes/Ev which
selectively interact with speciﬁc target cells, delivering their biologically compe-
tent cargo of lipids, proteins and RNAs. Hence, Exosomes/Evs act at the same
time as effectors of endometrium/embryo cross talk and as indicators of the
speciﬁc molecular proﬁle distinctive of the implantation window.
Study design, size, duration: Uterine ﬂuid samples were collected from
women undergoing hormonal stimulation for assisted reproductive techniques.
The uterine ﬂushing was collected at different times after the LH surge, from
women volunteers with proven fertility (n = 14). All samples were taken with
prior informed consent and exosome isolation and analysis were performed by
researchers blinded to the study protocol. The study has been carried out dur-
ing 12 months.
Participants/materials, setting, methods: Uterine washings, obtained by
using a disposable catheter for histerosalpingography, were scheduled in LH
+1/LH+3/LH+5/LH+7/LH+9, from women volunteers with proven fertility
(n = 14) at the Centre for Couple Sterility, Siena University Hospital. EXs/MV
were isolated by ultracentrifugation and precipitation and counted with NTA.
Conventional technologies for RNA quantiﬁcation and analysis have been used,
including in-house optimized LNA PCR assays, and TaqMan miRNA arrays.
Main results and the role of chance: Two fractions of the uterine ﬂushes,
mucus (M) and supernatant (UF), were analyzed for overall vesicles content by
NTA (Nanoparticle Tracking Analysis). Despite very low protein content UF
appears rich in particles as measured by NTA and ELISA. Conversely, M,
although rich in overall proteins, is very poor in vesicles. This drives us to con-
clusion that exosomes largely contribute to a proteome of UF while are not
contained in its mucous fraction. By confronting the protein content and the
particle number we can appreciate that protein equivalent of UF has about 16-
fold more particles with respect to M. This is even more striking when we con-
front total proteins and exosome associated CD9 levels in ELISA, where the
fold of exosomal protein enrichment of UF versus M is >2*106. To trace the
portion of endometrial EVs in totals recovered from each sample we have
assessed a small set of genes speciﬁc of the endometrium. Their assessment in
EVs/exosomes recovered from healthy volunteer’s raises the possibility that
some of these genes, PAEP and PGR, are conﬁned to, or increased in UF frac-
tion, and their expression ﬂuctuates along the phases of the cycle.
Limitations, reasons for caution: All ﬁndings have to be validated in a larger
cohort. Moreover, Embryo implantation involves a complex crosstalk have to
be established between the embryo and human endometrium. Therefore, our
data regarding the maternal contribution must be interpreted with caution and
integrated with data resulting from embryo derived exosomes.
Wider implications of the ﬁndings: Our study allows the identiﬁcation of
the informative biomarker pannel, with the potential to drive a single embryo/
blastocyst transfer during the highest endometrial receptivity. This clinical
approach would be widely applied not only in ART cycles, but also in treatment
of uterine pathology negatively inﬂuencing the beginning of the pregnancy.
Trial registration number:None.
P-473 Effect of N-acetyl cysteine on expression of oxidation-
reduction genes during implantation window in Recurrent
Implantation Failure: a double blinded randomized placebo
controlled trial, phase II
B. Salmani1, E. Teimoorbakhsh2, M. Shahhoseini1, A.A. Akhlaghi3,
A. Moeini4,5, P. Afsharian1
1Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- ACECR-, Department of Genetics, tehran, Iran
2Faculty of Science- East Tehran Branch- Islamic Azad University-, Department of
Genetics, Tehran, Iran
3Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- ACECR-, Department of Epidemiology and Reproductive Health,
tehran, Iran
4Reproductive Biomedicine Research Center- Royan Institute for Reproductive
Biomedicine- ACECR-, Department of Endocrinology and Female Infertility, Tehran,
Iran
5Faculty of Medicine- Tehran University of Medical Science, Department of Obstetrics
and Gynecology, Tehran, Iran
Study question: Is N-acetyl cysteine (NAC) effective on the Expression of
genes NRF2, GPX3, GSTM1, GSTM2, GSTM5 and PRDX6 in recurrent implant-
ation failure (RIF)?
Summary answer: our preliminary results have demonstrated no signiﬁcant
differences in expression level of studied genes in comparing pre-treatment
NAC-supplementation and placebo administered groups in RIF patients.
What is known already: Assisted reproductive techniques help infertile cou-
ples to conceive, however, the implantation rate is one of the limiting factors in
assisted reproductive techniques. Endometrial receptivity plays an important
role in embryo implantation. NAC as a nutritional supplement is a precursor of
glutathione-biosynthesis, therefore, it has been greatly applied as an antioxidant.
Since recent studies that showed high expression of genes which involved in
oxidation-reduction pathway effect on successful implantation rate, thus we
examined the expression of Oxidation-Reduction genes of NRF2, GPX3,
GSTM1, GSTM2, GSTM5, PRDX6 in NAC supplementation during implantation
window in women with Recurrent Implantation Failure.
Study design, size, duration: A single center, double-blinded, placebo con-
trolled, randomized trial was performed over one year with 40 women (age:
22-40 years) with at least two RIF history who were undergoing IVF cycle (long
protocol for their ovarian stimulation). Subjects received either NAC or pla-
cebo with both effervescent tablets having similar color, size and appearance.
Expression of genes NRF2, GPX3, GSTM1, GSTM2, GSTM5, PRDX6 were evalu-
ated on the day of Window of Implantation biopsies from the endometrium.
Participants/materials, setting, methods: forty RIF patients were rando-
mized to receive NAC 1200mg/day or placebo for at-least 6 weeks before
starting ovarian stimulation. Their tissue took (Pipelled based biopsy from
endometrium) on 19-21 day of their cycle, the day of WOI. Then patients were
undergone ovarian stimulation (using NAC) ended to IVF. Total RNA-
extraction and cDNA synthesis were performed from samples. Real Time PCR
was conducted to evaluate Expression of genes NRF2, GPX3, GSTM1, GSTM2,
GSTM5, PRDX6.
Main results and the role of chance: mean (SE) of the fold change of
expression NRF2, GPX3, GSTM1, GSTM2, GSTM5, PRDX6 were 2.62 (0.69),
14.83 (7.4), 19.82 (9.23), 9.73 (4.5), 7.40 (2.36), 1.74 (0.2) in drug group
respectively and were 1.85 (0.3), 8.93 (5.4), 8.38 (3.7), 2.09 (0.7), 3.82(1.7),
1.75(0.3) in placebo group. No statistical signiﬁcant difference between gene
expression two arm were detected.
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Limitations, reasons for caution:Owning the strict selection criteria in this
late phase trial caused limitation to achieve enough patients participation in lim-
ited period of time (one year). Thus, to overcome this issue and also for the
purpose of getting more experimental data, a larger number of RIF patients is
needed.
Wider implications of the ﬁndings: There are no signiﬁcant differences in
expression of evaluated genes in comprising two NAC supplementation (as
scavenging free radicals) and placebo groups during IVF protocols for RIF
patients.
Trial registration number:Not Applicable.
P-474 Can we increase the Live-Birth predictive value of early
beta-hCG level: A simple proposal for clinical practice
P. Arvis1, A. Guivarch-Leveque1, M. Bidet1, F. Jaffre1, P. Lehert2
1Clinique La Sagesse, Amp Department, Rennes, France
2The University of Melbourne and Melbourne IVF, Faculty of Medicine- Psychiatry
Department, East Melbourne VIC, Australia
Study question: Can the Live birth (LB) predictive value from serum concen-
trations of beta-hCG level (bHCG) in early pregnancy be enhanced in adding
other simple predictors?
Summary answer: Early Single bHCG level remains a strong predictor of
pregnancy outcome after embryo transfer. However, maternal age signiﬁcantly
increases the precision of prediction.
What is known already: bHCG rapidly increases during normal early preg-
nancy, however with a high inter-individual variation. bHCG blood level possibly
dependent on the volume of distribution in the mother’s body, and thus on
maternal age and BMI, Eskild and al. (Fertil Steril. 2012) suggested that bHCG
were negatively associated with maternal BMI, and Haavaldsen and al. (ACOG,
2014) found the same negative association with maternal age. In parallel, Age
and BMI are predictors of live birth (Arvis et al 2012).
Study design, size, duration: In this non-interventional, retrospective,
observational, single-centre cohort study, 3,077 live-births (LB) followed
16,105 embryo transfers after IVF or frozen-thawed embryo (FTE) cycles during
2000-2016 period. Intent to treat principle was used, no inclusion or exclusion
criteria were applied. Luteal phase was supported by vaginal progesterone only.
Serum bHCG were measured on day 14 after oocytes retrieval, or on day 14
embryo in FTE.
Participants/materials, setting, methods: The association between LB
and maternal age, BMI and log-transformed bHCG was estimated by a linear
mixed model, patient considered as random factor, Log-Transformed (or not)
BHCG, BMI and age as ﬁxed covariates. Main effects and Interaction with
bHCG were tested. The ﬁnal model was obtained through a backward strategy
based on likelihood ratio.
Main results and the role of chance: The determination coefﬁcient based
on Log-transformed BHCG was higher (R2 nagelkerke=.67) than its untrans-
formed value BHCG (R2=.56). The backward process identiﬁed a simple model
where only log(bHCG) and its interaction with age remained the only signiﬁcant
predictors. Area under the ROC curves with this model reached a value of c
= .91 95%CI [.86,.93] compared with the bHCG only (C=.82 95%CI [.79,.86]
with a signiﬁcant difference, p=.015).
Predicting values of this model are illustrated by a curve, providing LB prob-
ability according to bHCG level and age.
As a conclusion, although bHCG remains a strong predictor of LB, adding
age adds important precision. Neither BMI, nor other predictors, inﬂuence sig-
niﬁcantly this probability. However bHCG exhibit a non-linear variation: the age
effect is not constant with bHCG, the difference being the largest for intermedi-
ate values of bHCG. For example, for a bHCG level of 50 UI/L, probability of
LB is 72% at the age of 20, 55% at 30 and 37% at 40. Above 200, the probability
is closed to 100% for youngest patients.
Limitations, reasons for caution: This was a Retrospective uni-center
study, needing external validation, and the assessment of other potential predic-
tors of live birth.
Wider implications of the ﬁndings: Such result remains simple to used for
clinical practice, while signiﬁcantly increasing the precision of prediction.
Trial registration number: not applicable.
P-475 Mucin1 (MUC1) localization and quantitative study in
luminal epithelium during implantation window
F.Wu, Y. Liu, D. Mao, X. Chen, H. Xu, T.C. Li, C.C.Wang
Department of Obstetrics and Gynaecology- The Chinese University of Hong Kong-
Shatin Hong Kong, Obstetrics and Gynaecology, HONG KONG, Hong Kong
Study question: Are MUC1 differentially expressed among different develop
stage of pinopodes in fertile and recurrent implantation failure (RIF) patients?
Summary answer: MUC1 only expressed on the surface of ciliated cell, and
showed no relationship with pinopode. Its expression level was signiﬁcantly
decreased in RIF patients.
What is known already: MUC1 has long been supposed as an anti-adhesion
molecule during embryo implantation because of its molecule structure. But its
expression level signiﬁcantly increased in human endometrium during implant-
ation window. The exact function of MUC1 in early development of pregnancy
is still unknown. Endometrium is made up by ciliated cell and microvilli cell.
During implantation window, microvilli cell lost its microvilli and developed as
pinopodes. Animal and in vitro study have showed that pinopodes provided the
implant site for embryo. However, the relationship between MUC1 expression
concentration and different develop stage of pinopodes have not be studied.
Study design, size, duration: Twenty-ﬁve fertile control and 25 RIF patients
were recruited in this study. All participants underwent daily urine test from
day 9 of the cycle onwards to identify the LH surge, and endometrial biopsy
was obtained at LH+7 day.
Participants/materials, setting, methods: Recurrent implantation failure
was deﬁned as failure to achieve a clinical pregnancy after at least 4 good-quality
embryos have been transferred in 3 or more transfer cycles. Infertile patients
who got ongoing pregnant result from a FET cycle were recruited as fertile con-
trol, and the endometrial biopsy was conducted just one cycle preceded
embryo transfer. Scanning immunoelectron microscope and double immuno-
ﬂuorescence staining have been used to determine MUC1 expression on
luminal epithelium.
Main results and the role of chance: MUC1 expressed mainly on the sur-
face of ciliated cell. There was no MUC1 expression on developing, developed
and regressing pinopodes. Double immunoﬂuorescence staining showed that
ciliated cell counting and MUC1 expression level were signiﬁcantly decreased in
RIF patients (P <0.05).
Limitations, reasons for caution: The main limitation of this study is its
only one-time point biopsy study, which cannot demonstrate MUC1 dynamical
change as menstrual cycle proceeding. And this is only an observational study,
research into the mechanism of MUC1 and pinopodes in embryo implantation
is needed.
Wider implications of the ﬁndings: This investigation reveals that MUC1 is
not expressed on the surface of potential implantation site. Its anti-adhesion
function need to be further discussed. And ciliated cells maybe played a role in
embryo implantation.
Trial registration number:NO.
P-476 Capturing the physiological characteristics of early
pregnancy using wrist worn wearables
M. Shilih1, B. Goodale2, L. Falco2, F. Kuebler2, F. Dammeier2,
B. Leeners1
1University Hospital Zurich, Department of Reproductive Endocrinology, Zurich,
Switzerland
2Ava AG, Research and Development, Zurich, Switzerland
Study question: Could wrist worn wearable sensors capture the physiological
changes associated with early pregnancy?
Summary answer: We observed signiﬁcant differences in heart rate variabil-
ity, pulse rate, breathing rate, perspiration, temperature, and susceptance (of
the wrist skin).
What is known already: The physiological changes associated with the
reproductive hormones are well studied and widely reported (e.g., the increase
of temperature associated with post-ovulatory progesterone rise). The onset of
pregnancy is known to impart signiﬁcant endocrinological changes. The
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hormonal proﬁle of the late luteal phase is therefore signiﬁcantly different when
comparing conceptive cycles to non-conceptive cycles. Consequently, it is
plausible that these physiological changes could be captured by wrist worn
wearables.
Study design, size, duration: This study is an interventional longitudinal
observational study conducted at the University Hospital Zurich. The study is
planned to run from the fourth quarter 2016 to the second quarter of 2018,
with 430 participants. The participants are requested to measure the speciﬁed
parameters for 6 months, and if they conceive, to term.
Participants/materials, setting, methods: We included healthy, eume-
norrheic women, 20-40 years old, who are trying to conceive. Participants
wore Ava bracelet which measures temperature, pulse rate, and heart-rate-
variability ratio among other parameters. An LH home-urine test was used to
estimate the ovulation day. The late luteal phase was deﬁned as ovulation+7 to
the end of the cycle for the non-conceptive cycles, ovulation+10 to ovulation
+18 for conceptive cycles. Associations were evaluated using linear-mixed-
effects models with random intercepts for each participant.
Main results and the role of chance: We included 49 conceptive cycles
and 560 non-conceptive cycles from 253 women in the analysis. In comparison
to the late luteal phase of non-conceptive cycles, conceptive cycles were char-
acterized by: an increase in pulse rate+, breathing rate***, perspiration+. In add-
ition, non-conceptive cycles were more likely to have lower wrist skin
temperature***, heart rate variability ratio***, and wrist skin susceptance*.
Overall, the physiological parameters trends in conceptive cycles had steeper
rises and falls, and more pronounced peaks and troughs, compared to non-
conceptive cycles. This suggests that the underlying hormonal dynamics (which
are responsible for the physiological changes) in conceptive cycles are similarly
steeper in rising and falling, and have higher peaks and lower troughs.
Note: +p<.10, *p<.05, **p<.01, ***p<.001
Limitations, reasons for caution: The limited number of conceptive cycles
limits the generalization of the results and the development for a pregnancy rec-
ognition classiﬁer. Pregnancy tests are known to have limited sensitivity at the
beginning of the pregnancy, hence, some conceptive cycles could be labeled as
non-conceptive.
Wider implications of the ﬁndings: Wirst worn wearables are capable of
capturing known and novel early-pregnancy associated physiological changes.
Wearables represent a useful and non-invasive research tool to monitor
women’s health, and given sufﬁcient data could allow for the continuous moni-
toring of early-pregnancy.
Trial registration number:NCT03161873.
P-477 What is the real length of the window of implantation
(WOI) in humans?
A. Rincon1, M. Clemente-Císcar2, E. Gomez1, C. Marin1,
D. Valbuena3, C. Simon4,5,6,7
1Igenomix SL, Endometrial Receptivity Department, Valencia, Spain
2Igenomix SL, Bioinformatics Department, Valencia, Spain
3Igenomix SL, Medical Department, Valencia, Spain
4Igenomix SL, Scientiﬁc Director, Valencia, Spain
5University of Valencia / INCLIVA, Department of Obstetrics and Gynecology,
Valencia, U.S.A.
6Stanford University, Department of Obstetrics and Gynecology, California,
U.S.A.
7Baylor College of Medicine, Department of Obstetrics and Gynecology, Texas, U.S.A.
Study question: How long the human window of implantation (WOI) last?
Summary answer: Using endometrial receptivity analysis (ERA) in paired
samples (same patient), the WOI last from 29-36 hours, exceptionally shorter
WOI than 24 hours are found.
What is known already: The window of implantation (WOI) is a transient
functional state when the endometrium became receptive for the implantation
of the blastocyst. The endometrium is a hormonally regulated organ, progester-
one (P) induces the acquisition of endometrial receptivity that theoretically last
from LH+6 to LH+9 of the menstrual cycle or from P+4 to P+7 in a hormonal
replacement therapy (HRT) cycle. Currently, it is possible to determine the
molecular diagnosis of the WOI analyzing the transcriptomic signature known.
But, the length of the WOI has never been previously determined.
Study design, size, duration: From the paired-biopsy dataset (n = 3,616)
from patients who underwent ERA to test their endometrial receptive status, a
selection of 2,874 endometrial samples from 1,437 patients were analyzed. The
inclusion criteria was that the ﬁrst biopsy was taken in the time interval of 120
+12 hours (P+5). Samples were collected from the same patient and HRT on P
+5 and P+7 (n = 627 pairs) or on consecutives HRT cycles with the second
biopsy made at P+6 toP+7 (n = 810 pairs).
Participants/materials, setting, methods: ERA results were reported as
1 day pre-receptive, 12 hours to Receptive, receptive (R), 12 hours late R and
24 hours or more post-receptive.
A cross-tabulation analysis of time between biopsies (10-hours intervals) was
performed for each combination of paired-samples. A descriptive analysis of
the obtained percentages for each time-interval was used for describing the
length of WOI. Average time between paired-biopsies of main stages combina-
tions was studied and a conﬁdence interval was computed.
Main results and the role of chance: In general, we stablished the opening
of the WOI at early-receptive stage and the closing at late-receptive stage. The
average length of the WOI between these two stages was 32.8 hours (95% IC,
[29.2, 36.3] (n = 47 patients).
The average length of the WOI between early-receptive to post-receptive
was 48.2 hours (95% IC, [45, 51.4] (n = 94 patients), indicating the WOI was
already closed. Although few patients passed from early-receptive to post-
receptive stages in less than 24 hours (n = 4 patients), indicating that they have
a narrowWOI (<24 hours).
When analysis was performed from previous non-receptive stages to our ref-
erence (late-receptive stage), the average time between 1 day pre-receptive
and late-receptive was 41.7 hours (95% IC, [39.4, 44], n = 201 patients).
However, some patients last less than 30 hours from 1 day pre-receptive to
late-receptive (n = 46 patients) or less than 40 hours to post-receptive (n = 13
patients), showing narrowWOI.
Limitations, reasons for caution: This study has been performed using a
retrospective descriptive approach. An increase sample size is needed.
Wider implications of the ﬁndings: This study suggests that using molecu-
lar diagnosis, theWOI length varies from 29 to 36 hours, although exceptionally
few cases have shorter WOI.
Trial registration number: not-applicable
P-478 Changes in human chorion gonadotropin as a predictor of
live birth outcome among Danish women with recurrent pregnancy
loss
S. Landersø1, A.M. Kolte2, M.S. Kroman3, M. El Issaoui2,
H.S. Nielsen2
1Rigshospitalet, Fertility Clinic, KØBENHAVN Ø, Denmark
2Rigshospitalet, Recurrent Pregnancy Loss Unit, Copenhagen, Denmark
3Rigshospitalet, Fertility Clinic, Copenhagen, Denmark
Study question: Are changes in serum-human chorion gonadotropin (hCG)
levels in early pregnancy a reliable predictor of live birth in women with recur-
rent pregnancy loss (RPL)?
Summary answer: A daily hCG increase of 20% and 40%, respectively, can
predict a 65% and 70% chance of live birth among women with recurrent preg-
nancy loss.
What is known already: The increase of hCG in early pregnancy is used to
clinically differentiate between viable and non-viable early pregnancies
(ectopic/biochemical pregnancies and miscarriages). However, the evidence
behind this practice is limited. A small study (n = 20) from 1990 showed a
doubling time of 2 days for intrauterine pregnancies and this rate is often used
in the clinic. Other studies have addressed the change in hCG according to the
pregnancy outcome, but often only on symptomatic women (bleeding/pain) or
IVF-patients – with inconsistent results.
No studies have evaluated the change in hCG in RPL patients, despite this
being a crucial part of RPL care.
Study design, size, duration: This was a large retrospective cohort study at
a national tertiary Recurrent Pregnancy Loss Unit.
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In total 409 women were included between 2008 and 2016.
Inclusion criteria: ≥3 consecutive pregnancy losses; known outcome of the
pregnancy; minimum two hCG samples in early pregnancy.
Exclusion criteria: Extra-uterine pregnancies (due to too small a number for
the purpose of the statistics), pregnancies after donation of an ovum, and miss-
ing data on pregnancy outcome.
Participants/materials, setting, methods: The ﬁrst pregnancy after refer-
ral to the RPL-Unit was included. Serum-hCG was measured in at least two
blood samples few days apart during gestational week 4-7. Logistic regression
analyses were used to investigate the change in hCG according to pregnancy
outcome. Results were adjusted for maternal age, number of prior losses, and
the between-sample interval.
When viability was uncertain, serial hCGs were performed until a ﬁnal diag-
nose could be made.
P-values <0.05 was considered signiﬁcant.
Main results and the role of chance: Pregnancy outcome was: 261 live
births; 100 miscarriages; 38 biochemical pregnancies, not counting 10 excluded
observations due to missing data/extreme outliers. In the ﬁnal sample the
mean age was 35.0 years (SD = 4.4), mean number of prior pregnancy losses
was 3.8 (SD = 1.8), mean time of the ﬁrst hCG sample was 4+4 weeks of gesta-
tion (SD = 5.7 days), and hCG samples were on average collected 3.1 days
apart (SD = 2.0). The lowest initial hCG that subsequently led to a live birth
was 12.
Main results: A 20% daily increase in hCG predicted a 65% chance of a live
birth whereas a 40% increase predicted a live birth in 70% of the cases.
The association between change in hCG and live births was weaker for
women with more than three losses, and was strongest for age <30years. The
probability of a live birth decreased with increasing number of losses.
In summary, a daily increase in hCG between 20 and 40% is a strong indica-
tor of live birth together with low maternal age and a lower number of losses.
Increases above 40% did not add signiﬁcantly to prognostic value.
All abovementioned results are signiﬁcant at a 5% level. We therefore assess
that the ﬁndings are not due to chance.
Limitations, reasons for caution: This study is limited by uncertainties
regarding e.g. ovulation date, implantation date and the timing of both urine and
blood testing depending on patient preferences. However, all measurements
are related to the menstrual cycle and the date of last menstrual period was
known for all except two women.
Wider implications of the ﬁndings: For women with RPL the uncertainty
about whether a pregnancy is viable or not causes a lot of psychological distress.
By this study clinicians can become better equipped to predict which pregnan-
cies will lead to live births and thereby – hopefully – diminish the amount of dis-
tress for these women.
Trial registration number: not applicable.
P-479 Screening for pre-eclampsia: toward the development of a
non-invasive repaid clinical mass spectrometry pregnancy urine test
M. Naase1, S. Butler1, R. Zmuidinaite1, S. Keshavarz1, F. Sharara2,
R. Iles1
1MAP Sciences-, Research and Development, Bedford- UK, United Kingdom
2Virginia Centre for Reproductive Medicine, Embryology, Reston, U.S.A.
Study question: Can Matrix Assisted Laser Desorption Ionisation Time of
Flight (MALDI ToF) Mass Spectrometry of early pregnancy urine be used to
predict the likelihood of preeclampsa?
Summary answer: It is possible to use the analysis of data, following MALDI-
ToF MS of maternal urine, to generate risk screening algorithms for subsequent
development of pre-eclampsia.
What is known already: Identifying pregnant women who will develop pre-
eclampsia is one of the last remaining grand challenges in obstetric medicine
and pre-eclampsia occurs in around 1 in 50 pregnancies. The ability to do so
non-invasively and at low cost in early pregnancy would dramatically impact
maternal obstetric care worldwide. Recently proteomic and metabolomic ana-
lysis of maternal urine have been proposed as a possible route to an inexpen-
sive and truly non-invasive screening test for Downs Syndrome. Using a similar
approach it should be possible to achieve a risk score for preeclampsia.
Study design, size, duration: In this diagnostic test study to determine the
analytical process and corrections needed to develop a clinical maternal urine
screening test for risk of subsequent pre-eclampsia; we examined the spectral
proﬁling of maternal urine at 15-17 weeks of gestation by MALDI ToF mass
spectrometry from pregnant women being monitored for PE.
Participants/materials, setting, methods: A retrospective collection of
40 urine samples at 15-16 weeks of pregnancy 28 women (12 developed pre-
eclampsia). Samples were examined by MALDI-ToF mass spectrometry in the
mass/charge range between 1000 and 100,000 m/z. The spectral masses
between 2000 and 11,000m/z were speciﬁcally examined and a method was
developed by mathematical algorithm to normalise spectral data in mass bins of
100 m/z and express as a percentage of the total mass spectra.
Main results and the role of chance: Of the ninety 100 m/z bins, forty-six
were identiﬁed as m/z bins at which statistically signiﬁcant spectral differences
occurred between those who developed pre-eclampsia and control samples
where pre-eclampsia was not subsequently diagnosed. Based on the differences
and variance, for values at these bins, weighted scores of the probability of
developing pre-eclampsia were assigned. Comparative algorithms consisting of
various mass bins were tested for ability to distinguish those who developed
pre-eclampsia as the pregnancy progressed. A change in pattern was evident
from the raw and normalized spectra of pregnancy urine from women who
developed pre-eclampsia and those who did not. Interestingly the changes seen
were different to those found previously in screening for Downs syndrome by
this same methodology. In this cohort decrease of signal intensity in the proﬁle
at 6000 and 7000m/z were associated with those pregnancies that developed
pre-eclampsia. An algorithms based on these changes had a sensitivity of 91.7%
and speciﬁcity of 85.7%.
Limitations, reasons for caution: This study is limited by cohort size.
Wider implications of the ﬁndings: Using a simple, non-invasive screening
tool such as MALDI ToF MS of early pregnancy urine could potentially improve
pregnancy outcomes. Targeted maternal and fetal monitoring would lead to
earlier detection of the clinical signs and, where necessary, intervention planned
for those individuals at increased risk.
Trial registration number: not applicable.
P-480 Improved pregnancy rates following endometrial receptivity
analysis and personalized embryo transfer in patients with previous
failed implantation after euploid embryo transfer
M. Leondires1, A.L. Akopians2, T. Stankewicz3, E. Gomez4,
A. Snider5, G. Harton6, D. Valbuena Perilla7, C. Simon8,9,10,11
1RMA of Connecticut, Medical Department, Connecticut, U.S.A.
2Southern California Reproductive Center, Medical Department, Los Angeles, U.S.A.
3Igenomix SL, USA ERA Department, New York, U.S.A.
4Igenomix SL, ERA Department, Paterna- Valencia, Spain
5Igenomix SL, Genetic Counceling Department, New York, U.S.A.
6Igenomix SL, Operations Department, New York, U.S.A.
7Igenomix SL, Medical Department, Paterna- Valencia, Spain
8Igenomix SL, Scientiﬁc Director, Paterna- Valencia, Spain
9University of Valencia/INCLIVA, Department of Obstetrics and Gynecology,
Valencia, Spain
10Stanford University, Department of Obstetrics and Gynecology, California, U.S.A.
11Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston,
U.S.A.
Study question: Does Endometrial Receptivity Analysis (ERA) with persona-
lized embryo transfer (pET) of euploid embryos improve the reproductive out-
come in patients with previous failed euploid embryo transfer?
Summary answer: Patients who experienced failed euploid embryo transfer
had improved reproductive outcome combining pET of euploid embryos guided
by ERA.
What is known already: Recurrent implantation failure (RIF) is a frustrating
condition for patients and clinicians. The two most likely candidates implicated
are embryo chromosomal abnormalities and/or alterations/desynchrony of
endometrial receptivity. Preimplantation genetic testing for aneuploidy (PGT-A)
identiﬁes euploid embryos for selective ET improving reproductive outcomes in
RIF due to embryo abnormalities (Rubio et al., 2013). The Endometrial
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Receptivity Analysis (ERA) is based on the transcriptomic signature of 236
genes used to diagnose the receptive status of the endometrium guiding a pET.
Increased reproductive outcome following pET guided by ERA has been
demonstrated in patients with RIF of endometrial origin (Ruiz et al., 2013).
Study design, size, duration: In this prospective pilot study, ﬁfteen patients
with previous failed euploid embryo transfer after PGT-A in a hormone replace-
ment therapy cycle (HRT) underwent ERA to assess the endometrial receptivity
status. In a subsequent cycle, a pET guided by ERA with euploid embryo(s) was
performed. This study was done in two independent reproductive centers from
December 2016 to November 2017.
Participants/materials, setting, methods: Women of reproductive age
(34.5+4), who have never achieved clinical pregnancy following at least one
failed euploid ET in a HRT cycle were enrolled in this study. An endometrial
biopsy for ERA was obtained in a HRT cycle identical to one carried out in the
failed euploid ET cycle. Once a receptive result was obtained, the patient
underwent a pET with the remaining euploid embryo(s). Pregnancy rates and
follow-up data were collected from participating sites.
Main results and the role of chance: Thirteen of the ﬁfteen patients with
failed euploid ET were diagnosed with a non-receptive (NR) endometrium
(86.7%), from those, four were early-receptive and nine were pre-receptive.
The other two patients had receptive result (R). At this time, we have clinical
follow-up data from all patients who have undergone pET of remaining euploid
embryo(s). All ﬁfteen patients (100%) achieved pregnancy (+hCG) when pET
was performed based upon their personalized Window of Implantation (WOI)
guided by ERA, one had a biochemical pregnancy (6.7%), three presented clin-
ical miscarriages (20%) and the other eleven are ongoing or have delivered, cor-
responding to 73.3% ongoing pregnancy rate (OGP). The implantation rate was
87.5%.
Limitations, reasons for caution: The main limitation for this study is the
number of patients included due to pilot nature. Further clinical validation in a
Randomized Clinical Trial (RCT) is underway.
Wider implications of the ﬁndings: Our study demonstrates that patients
with previous failed euploid embryo transfer could have WOI displacements in
high proportion (86.7%) and it may beneﬁt from ERA testing to guide pET
when a displacedWOI is the cause of their failed implantation.
Trial registration number:Not applicable.
P-481 The inhibitory T cell co-receptor molecule B7-H4 (VTCN1)
regulates major histocompatibility complex class I expression in a
stem cell-derived model of primitive human trophoblast
development
J. Zhou1, R. Karvas1, L. Schulz1, T. Ezashi2, R.M. Roberts2, D. Schust3
1University of Missouri, Obstetrics- Gynecology and Women’s Health, Columbia, U.S.A.
2University of Missouri, Animal Sciences, Columbia, U.S.A.
3University of Missouri, Obstetrics and Gynecology, Columbia, U.S.A.
Study question: Could the isolated expression of the inhibitory T cell co-
receptor B7-H4 on human trophoblast cells during the ﬁrst half of pregnancy be
important in maternal-fetal immune interactions?
Summary answer: Downregulation of B7-H4 in an in vitro stem cell-derived
model of primitive human trophoblast development dramatically increases
HLA-A and –B, but not HLA-G protein levels.
What is known already: Downregulation of the classical MHC class I mole-
cules, HLA-A and HLA-B on trophoblast cells in direct contact with maternal
immune cells is thought to aid in the escape of the semiallogenic fetus from
maternal immune rejection. B7-H4 is a co-receptor in MHC/T cell interactions
and decreases T cell activities. Increases in B7-H4 expression correlate directly
with cancer invasion and severity and increases in MHC class I expression.
We have demonstrated that B7-H4 is expressed in ﬁrst and second trimester
placenta and in an in vitro human embryonic stem cell-derived model of early
placental development (hESCBAP), but not in term placenta.
Study design, size, duration: In vitro B7-H4 knockdown study of human
embryonic stem cell (hESC)-derived trophoblast cells.
Participants/materials, setting, methods: The human embryonic stem
cell line, H1, was treated with BMP4, A83-01 and PD173074 (BAP treatment)
to create an established in vitro model for peri-implantation trophoblast
development. Cells were transfected with silencing B7-H4 siRNA or control
siRNA on day 3 or 4 of differentiation. Proteins were collected on day 6 and
expression of B7-H4 and MHC class I proteins compared to that of a house-
keeping protein (GAPDH) using western immunoblotting.
Main results and the role of chance: In direct contrast to ﬁndings in cancer
cell lines, downregulation of B7-H4 expression in cells representing the earliest
stages of placental development dramatically increased the expression of HLA-
A and HLA-B molecules at the protein level. Interestingly, knockdown of B7-H4
had little effect on the expression of HLA-G, a non-classical MHC class I mol-
ecule whose normal tissue expression is restricted to a subset of invasive pla-
cental cells called extravillous cytotrophoblast cells.
Experiments were repeated at least three times and after 3 days as well as
after 4 days of differentiation. Endpoints were assayed at 48 and 72 hours after
knockdown, all with consistent results. Comparison to experiments using a
scrambled siRNA control limits the chance that the effects noted are the result
of exposure to gene silencing methods. No differences in cell proliferation or
cell viability were observed between the B7-H4 knockdown and control cells
across the time period studied. This is consistent with equivalent protein
expression of the control housekeeping gene, GAPDH.
Mechanism identiﬁcation using comparisons of RNAseq datasets from knock-
down and control cell lines is ongoing.
Limitations, reasons for caution: The cell system used is an in vitro system
and may not directly mimic in vivo occurrences. Unfortunately, ethical and logis-
tical factors limit access to human tissues directly post-implantation and before
clinical detection of a pregnancy is possible. In vitro surrogates remain our best
methods to study early post-implantation events.
Wider implications of the ﬁndings: Discrepancies between HLA
responses to B7-H4 knockdown in cancer cells and in early trophoblast cells
suggest the B7-H4 pathway regulates the unique transplantation antigen expres-
sion patterns found in the human placenta. This exposes opportunities to ﬁll the
pronounced knowledge gap in our understanding of HLA regulation in the
human placenta.
Trial registration number: not applicable.
P-482 The uterine cavity in patients with recurrent pregnancy loss
(RPL)
L.H.J. Andersen1, K.J. Hare2, H.S. Nielsen3
1Hvidovre Hospital- University hospital of Copenhagen- Denmark, Department Of
Gynecology and Obstetrics, Copenhagen, Denmark
2Hvidovre Hospital- University hospital of Copenhagen - Denmark, Department Of
Gynecology and Obstetrics, Copenhagen, Denmark
3Rigshospitalet and University of Copenhagen - Denmark, Consultant Fertility Clinic
and Recurrent Pregnancy Loss Unit, Copenhagen, Denmark
Study question: What is the frequency of uterus pathology and histological
analysis in a consecutive cohort of well characterized RPL patients, and is evalu-
ation justiﬁed?
Summary answer:We report lower incidence of intrauterine adhesions and
chronic endometritis compared to previous reports. However, 14.3% of the
patients had intrauterine pathology justifying sensitive investigation.
What is known already: RPL patients have often had several uterine evacua-
tions (medical (with Misoprostol) or D&C), which increases the risk of chronic
endometritis (CE) and intrauterine adhesions (IUA). A meta-analysis from 2014
found that 19.7 % of women with one pregnancy loss had IUA, the incidence
increases signiﬁcantly with further pregnancy losses. Other studies evaluating
biopsies from the uterine cavity suggests: that CE is as high as 10–30 % in
patients with RPL.
We aimed to evaluate the uterine cavity in a well characterized group of RPL,
and compare our incidences of CE and IUA to international ﬁndings.
Study design, size, duration: The study design is a macroscopic and histo-
logical description of the uterine cavity and endometrium in a cohort of women
with RPL. We recruited a cohort of 70 women with RPL, over a time period of
19 month from May 2016 to December 2017. Inclusion criteria: three consecu-
tive ﬁrst- or second trimester miscarriages and no known uterine abnormalities
or pathologies.
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Participants/materials, setting, methods: All the included patients had a
diagnostic ofﬁce hysteroscopy (OH) with biopsies. The OH was performed by
trained gynecologists; ﬁxated biopsies were evaluated by pathologists. We
compared the macroscopic description with the histologic diagnoses. The OH
was performed during the proliferative phase of the menstruation cycle to
standardize biopsies, as the numbers of immune cells change during the men-
struation cycle. We conﬁrmed the timing by measuring peripheral Oestrogen-
and Progesterone levels at the examination day.
Main results and the role of chance: Seventy patients with RPL had an
ofﬁce hysteroscopy with biopsy during the study period. One patient was
excluded due to the formalities. Histological diagnoses: 1/69 had signs of
inﬂammation, with the presence of plasmacells, and was diagnosed with CE.
Macroscopic diagnosis: 3/69 had IUA, 3/69 had placenta remnants, 1/69 had a
polyp, 1/69 had a septum and 2/69 had intrauterine leiomyomas, macroscopic
pathology in total 10/69.
These data diverse from earlier published data. We describe a much lower
incidence of IUA (only 4% compared to 19.7 %) and only one patient were diag-
nosed with CE (1.4 % compared to 10 % - 30 %) in our clinical setting/cohort.
Although we do not describe the same incidence of IUA and CE, we describe
intrauterine pathology in 14.5 % of the women with RPL. All women were
examined with TVUS, none were suspected to have the positive ﬁndings subse-
quently found at OH, despite a high incidence of earlier interventions
(Misoprostol or D&C). Hereby we suggest that standard OH is a highly sensi-
tive diagnostic tool for evaluating women with RPL.
Limitations, reasons for caution: This is a descriptive study on a large
cohort of well characterized RPL patients. The study is not powered or
designed to study the prognostic impact of uterus pathology or histology.
Wider implications of the ﬁndings:We describe low incidence of IUA and
CE compared to historic data. We hope this conﬁrm a trend towards higher
quality in treatment of pregnancy loss. Further, we suggest OH as frontline
examination elucidating the uterine cavity; reducing uterine pathology in women
may increase the chance of a successful pregnancy.
Trial registration number:NCT02746588
P-483 Global Gene Expression Analysis of Blastocyst Implantation
on 2D and 3D Implantation Models: Towards a Comprehensive and
Inclusive Research
K. Sarı1, S. Karahuseyinoglu2, D. Yucel3
1MSc. Student, Graduate School of Health Sciences- Reproductive Biology, ıstanbul,
Turkey
2Koç University, Research for Translational Medicine KUTTAM, Istanbul, Turkey
3Acıbadem University, School of Medicine- Department of Histology- Embryology,
Istanbul, Turkey
Study question: Does the use of mesenchymal stem cells or endometrial cells
on 2D and 3D implantation models enough for demonstrating large scale
molecular regulation?
Summary answer: Endometrial and mesenchymal stem cells can be used for
constructing implantation models with gel or polymer-based carriers to analyse
differential expression of implantation related markers.
What is known already: Implantation is complex series of events; appos-
ition, adhesion and invasion; that happens during a well-deﬁned period with
competent embryo and receptive endometrium. Since the process takes place
in 3D environment, it is difﬁcult to mimic implantation process in vitro. To
examine invasion, human trophoblast cells and embryos have been cultured
with human endometrial stromal cells. Endometrial cells cultured in collagen
matrices to create a 3D model with different layers of trophoblast spheroids
and embryos. The pregnancy is balanced with fetal decidual defense against
pathogens therefore; immunomodulatory properties of MSCs could have posi-
tive effects on implantation and embryo development.
Study design, size, duration: Effects of 2D and 3D implantation models;
designed with gel or polymer-based carriers with endometrial and mesenchy-
mal stem cells; were analysed to reveal differential expression of 24 different
implantation related markers; LIF, Hoxa10, Hoxa11, Wnt4, IHH, E-cadherin,
Trophinin, Fibronectin, L-selectin, Laminin, Entactin, Integrin, MMP9,TIMP3,
HBEGF,ErbB1, ErbB2, HBEGF, Progesteron and Estrogen Receptor and
Collagen I,III,IV,V. Comparative analysis at 48 and 96 hours were performed by;
IF, WB, qRTPCR and by multiphoton microscopy (for invasion depth)
quantitavely.
Participants/materials, setting, methods: Mouse blastocysts were cul-
tured in four groups as: i. routine IVF drop culture, ii.blastocysts on collagen
coated bioﬁlm, iii. blastocysts on gel matrices over bioﬁlm decorated with endo-
metrial cells, iv.blastocysts on collagen coated bioﬁlm with human mesenchymal
stem cells.Groups were compared in terms of structure, function and invasion
by several signalling molecules, including cytokines, growth- transcription factors
together with hormone receptors. Live/dead cell assay was also performed.
Statistical analysis was performed by student’s t-test.
Main results and the role of chance: Two very effective gel and polymer
based 3D in-vitro implantation models, supported by either mesenchymal stem
cells or endometrial cells,were constructed successfully and efﬁcacy of new sys-
tems were compared with control group which is of routine-IVF culture. Both
can be used to see the in-vitro development and survival of the blastocyst
together with the newly differentiating trophoblasts. Comparative analysis was
made between groups and also within groups from 48 to 96 hours. There is
increase in LIF, trophinin, entactin, integrin expression of all groups.
Additionally; LIF, MMP9 and PR showed signiﬁcant increase with approximate
p-value of 0,02. HOXA10 and HOXA 11 showed increase with tissue remodel-
ling enzymes; MMP9 and TIMP3 in expression on 3D implantation models. E-
cadherin and ﬁbronectin expression decreased signiﬁcantly (p ≤0,04) in 3D
models consistent with extracellular matrix remodeling process in vivo and sug-
gest modulation of endometrial stroma during implantation. Among collagen
types, collagen V was detected the most increasing type during implantation
(p≤ 0.05). Endometrial co-cultures supported the blastocyst to invade horizon-
tally under the implantation area as depicted by the increase of dead cells, and
human MSC also supported the blastocysts for invasion, implicating that human
MSC can be used for generation of 3D endometrial co-cultures.
Limitations, reasons for caution: This study is based on use of mouse
endometrial epithelial and stromal cells and human MSCs.The limitation is the
inter-species implantation differences between of mouse and human. Human
blastocysts were intentionally not used for such trial, since there is a major eth-
ical concern.
Wider implications of the ﬁndings: There is a clear need to develop 3D
in vitro models to investigate embryo implantation.The methods proposed
here are based on mouse blastocyst implantation, they provide information
about different implantation models with the effects of human mesenchymal
stem cells and endometrial cells to reveal extensive analysis of implatation
markers.
Trial registration number:Not applicable.
P-484 Cripto is required for normal uterine remodeling,
decidualization and development of placental vasculature
S. Shaﬁei1, D. Dufort2
1Research Institute of the McGill University Health Center, Experimental Medicine,
Montreal, Canada
2Research Institute of the McGill University Health Center, Obstetrics and
Gynecology, Montreal, Canada
Study question:What is the role of CRIPTO, a member of the TGFβ super-
family, in female reproduction?
Summary answer:Deletion of uterine Cripto causes defective uterine remod-
eling, decidualization and placental development resulting in subfertility, fetal
intrauterine growth restriction (IUGR) and fetal loss in mouse.
What is known already: Cripto, a member of the TGFβ superfamily,
encodes for a cell surface receptor whose role in embryonic development and
stem cell maintenance has been studied. Cripto mRNA and protein have been
detected in the human uterus at all stages of the menstrual cycle with moder-
ately higher levels of expression during the secretory phase and its dysregulation
has been found in placenta creta and endometriosis in humans. To date, there is
not much known on Cripto’s role in female reproduction.
Study design, size, duration: As Cripto null Knockout (KO) is embryonic
lethal, we created a conditional KO (cKO) mouse model in which Cripto is
deleted only in the reproductive tissues using a Cre-loxP system. We assessed
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major reproductive events necessary for the establishment and maintenance of
pregnancy (e.g. ovulation, fertilization, implantation, decidualization and placen-
tal development) in Cripto cKO versus control mice. For every studied stage, 8
to 10 mice were included in each of cKO and control groups.
Participants/materials, setting, methods: Cripto deletion in cKO mice
was conﬁrmed by PCR and insitu hybridization. Pregnancy rate and number of
pups/litter were evaluated as general fertility indices. To determine the under-
lying causes of the observed subfertility, these approaches were used: embryo
ﬂushing and retrieval, dissections and histology of uterus and placenta at several
time points during pregnancy, measuring blood Progesterone level, size and
weight of decidua, placenta and fetus, artiﬁcial decidualization, quantitative
PCR, immunoﬂuorescence staining and western blot.
Main results and the role of chance:We observed a signiﬁcant decrease in
pregnancy rate (cKO 62% vs Control 100%) and litter size (cKO 7.68 vs
Control 9.51 pup/litter) with loss of uterine Cripto. Even though no signiﬁcant
effects were detected in the pre-implantation period, assessment of the post-
implantation period showed that 20% of cKO females fail to establish pregnancy
and an additional 20% of females undergo full litter loss after implantation
(between day 5.5 postcoitum and d8.5). By means of histology (d5.5, d7.5),
quantitative PCR (d5.5) for assessing expression of important uterine remodel-
ing and decidualization factors (Wnt4, Bmp2, Hoxa10, components of notch
signaling pathway, etc.) and artiﬁcial induction of decidualization, we showed
this is due to defects in uterine decidualization and remodeling/luminal closure.
During placental development, we observed that decidual area (d10.5) and
fetal weight (d16.5) were signiﬁcantly lowered, while the number of fetal deaths
was signiﬁcantly increased in cKOs. Histological examination of the placenta
revealed abnormal labyrinth development; showing increased cellular density.
The surface area of fetal vasculature in the labyrinth of the developing placenta
on d12.5 was signiﬁcantly reduced in the cKOs compared to controls.
Interestingly, surface area of maternal blood sinuses, however, doesn’t show
any signiﬁcant difference. (Where indicated signiﬁcant: P<0.05 or p<0.01)
Limitations, reasons for caution: Limitations in in vivo research on uterine-
embryo interactions in humans has led to relying primarily on animal models.
Although there are considerable similarities between reproductive processes in
mouse and humans, there are some differences which should be kept in mind
when extrapolating data obtained from mouse model studies to humans.
Wider implications of the ﬁndings: While the major physiological events
associated with female reproduction have been characterized, there are still
many molecular pathways that have yet to be uncovered in order to open new
windows toward overcoming and managing infertility and pregnancy associated
complications which place both mother and fetus’s health at risk.
Trial registration number: not applicable.
P-485 The roles of let-7 contained in extracellular vesicles (EV) in
embryo implantation in human
W. Liu1, Z. Niu2,W. Yeung2
1University of HongKong, O&G, HongKong, China
2University of HongKong, Dept. O&G, HongKong, China
Study question: human uterine ﬂuid contained plenty of EVs, the precise
functions are still not clear.
Summary answer: let-7 contained in EVs decreased embryo implantation
potential in human and mouse.
What is known already: embryonic diapause is an evolutionarily conserved
phenomenon across mammals. The expression of Let-7 family members was
signiﬁcantly higher in dormant mouse embryos than estradiol-activated
embryos. Human ULF contained EV and Let-7 was highly expressed in EV of
human endometrial cell line ECC1. To investigate if EVs have regulatory func-
tions in human blastocyst, we collected EV from non-receptive endometrial cell
line, HEC-1B, which were transfected with pre-let-7a
Study design, size, duration: ﬁrstly, we detected the expression patterns of
small RNA in EVs of dormant and activated uterine ﬂuid in mice; secondly, we
demonstrated the functions of EV-containing let-7 in embryo implantation and
dormancy in mice; ﬁnally, we tested the potential roles of EV-containing let-7 in
embryo attachment in human.
Participants/materials, setting, methods: morphology of EVs was
observed by electron microscopy, identiﬁcation of EVs was done by western
blotting, small RNAs were detected by RNA-seq, targeted miRNAs were valid-
ated by Q-PCR
Main results and the role of chance: electron microscopy showed the
presence of EV-like structures in the mouse uterine lumen. CD63 immnoreac-
tivities were also localized to the endometrial epithelium during dormancy, on
Day 4 of pregnancy and after E2-activation of delayed implanting mice. To
determine if blastocysts internalized EV from ULF, scanning electron micros-
copy showed binding of EV-like particles to the trophectoderm of in vivo iso-
lated blastocysts. RAN-seq and Q-PCR results showed that the expression of
let-7 family was signiﬁcantly increased in EVs of dormant uterine ﬂuids com-
pared to that of activated uterine ﬂuids. EVs-containing let-7 induced blasto-
cysts diapause-like state in mice. Let-7 of dormant embryos was mainly derived
from uterine ﬂuids. To investigate if EVs have similar functions in human blasto-
cyst, we collected EV from non-receptive endometrial cell line, HEC-1B, which
were transfected with pre-let-7a. EDU incorporation assay showed that DNA
synthesis was signiﬁcantly decreased in blastocysts co-cultured with let-7a-EV
for 2 days. To further demonstrate if EVs contained let-7 regulate human
blastocyst implantation potential, attachment rates of BAP-EB (surrogate of
human embryos) were detected in the presence of let-7-EVs. After 48 h of
treatment by let-7-EVs, attachment rates of BAP-EB were signiﬁcantly
decreased compared to Crtl-EV (65% vs 95%)
Limitations, reasons for caution: BAP-EB is not human embryos although
spheroids expressed many markers which are similar human embryos and have
cavity after 72 h of differentiation.
Wider implications of the ﬁndings: small RNAs are differentially expressed
in uterine ﬂuid EVs during menstrual cycles. EVs of uterine ﬂuid are used as
marker of receptive endometrium.
Trial registration number: embryos were collected from 8 IVF patients.
P-486 Odds and predictors of monozygotic twinning in a
multi-centre cohort of 25,794 IVF cycles
G.Woodhead1, L. Kellam1, A. Campbell2, K. Jayaprakasan1,3
1CARE Fertility Nottingham, Embryology, Nottingham, United Kingdom
2CARE Fertility, Embryology, Nottingham, United Kingdom
3Derby Fertility Unit, Royal Derby Hospital, Derby, United Kingdom
Study question: To estimate the incidence of monozygotic twinning (MZT) in
In-Vitro Fertilisation (IVF) and embryo transfer (ET; Single–SET and double
DET) cycles and to determine the predictive factors of MZT.
Summary answer: MZT following SET and DET were 0.47% and 0.16%
respectively with its odds being highest with fresh, blastocyst SET and lowest
with frozen, cleavage DET.
What is known already:While the single best intervention to decrease mul-
tiple pregnancy rate is elective single embryo transfer (SET), the risk is not com-
pletely eliminated. The incidence of MZT from SET is up to around 2%, the
risks are reported to increase with ICSI insemination, assisted hatching or
blastocyst transfers. Some smaller studies reported frozen embryo transfers
and advanced age increase the incidence of MZT. The data on MZT with dou-
ble embryo transfers (DET) are limited.
Study design, size, duration: This observational study involved analysis of
prospectively collected data of all consecutive IVF treatment cycles of seven ter-
tiary fertility units in the UK between 2013 and 2017. Out of 26,347 embryo
transfer cycles, 25,794 cycles matched inclusion criteria and were suitable for
analysis. 16,845 cycles were SET and 8,949 were DET.
Participants/materials, setting, methods: All fresh IVF and intra-
cytoplasmic injection (ICSI) cycles and frozen embryo transfer (FET) resulting in
SET and DET were included. As per the unit protocol, all women were advised
not to have unprotected intercourse during the treatment cycles. MZT was
conﬁrmed if two foetal hearts were detected for SET at the 8 week post
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embryo transfer scan and three or more foetal hearts for DET. Data analysed
by Chi square tests and logistic regression analysis.
Main results and the role of chance:While the over all risk of MZT was
0.37% (96/25794), the risks following SET and DET were 0.47% (82/
16845) and 0.16% (14/8949) respectively. The risk of MZT in all SET
cycles was signiﬁcantly higher with blastocyst transfer compared to cleavage
stage embryos (OR; 95% CI: 3.2; 1.01-10.1). But on subgroup analysis the
increased risk persisted only with fresh SET cycles (OR 8.4; 1.16-60.9), but
not with frozen transfers (OR 0.65; 0.16-2.67). With DET, there was no
difference in the risks of MZT between blastocyst transfer and cleavage
stage transfer regardless of whether the cycles were fresh or frozen. The
risk of MZT was higher with SET than with DET (OR 3.12; 1.77-5.42) with
the same effect seen with blastocysts only (OR 3.15; 1.58-6.26), but not
with CSE (OR 1.18; 0.28-4.93). Both fresh and frozen SET had signiﬁcantly
higher MZT rates compared with DET (OR 3.15; 1.6-6.2 and OR 2.88;
1.02-8.1 respectively). On regression analysis women’s age was not a sig-
niﬁcant predictor for MZT. There was no difference in MZT risks between
IVF and ICSI cycles whether the cycles were fresh, frozen, SET, DET,
blastocyst or cleavage stage embryo transfer cycles.
Limitations, reasons for caution:MZT was diagnosed if the number of foe-
tal hearts seen on ultrasound scan were higher than the number of embryos
transferred. While the chances of concurrent natural conception from unpro-
tected sexual intercourse during treatment leading to dizygotic and higher order
pregnancies with SET and DET respectively, such risk is low.
Wider implications of the ﬁndings: The study provides data to counsel
couples undergoing IVF/ICSI treatment about the risks of MZT following SET
and DET. The study agrees with the previous reports of increased risk of MZT
with blastocyst SETs. However, no relationship between age, IVF or ICSI and
frozen ET with MZT risks were observed.
Trial registration number: not applicable.
P-487 Effect of embryomorphology on maternal serum β-hCG
level in pregnancies resulting from a fresh single cleavage embryo
and a fresh single blastocyst
G. Kuspinar1, I. Kasapoglu2, S. Saribal1, G. Uncu2, B. Avci1
1Uludag University Faculty of Medicine, Histology and Embryology, Bursa, Turkey
2Uludag University Faculty of Medicine, Obstetric and Gynecology, Bursa, Turkey
Study question: Is there any effect of early embryonic factors on serum β-
hCG levels in biochemical pregnancy resulting after a single fresh cleavage
embryo or blastocyst transfer?
Summary answer: The day 12 serum β-hCG levels has no association with
early embryonic factors and similar between a single fresh cleavage embryo and
blastocyst transfer.
What is known already: Results of studies comparing β-hCG levels after the
transfer of cleavage stage or day blastocyst stage have been mixed, with some
studies reporting higher β-hCG levels after the transfer of blastocysts and
others reporting higher levels after the transfer of cleavage-stage embryos. A
limited numbers of studies have evaluated relation β-hCG levels with embryo
quality parameters resulted with biochemical pregnancy from single fresh cleav-
age ETs or blastocyst ETs.
Study design, size, duration: In this retrospective cohort study, we
reviewed all fresh single ET (sET) cycles performed between September 2011
and December 2016 at the University afﬁliated Assisted Reproductive
Technology Center. Positive serum β-hCG levels (>5mIU/ml 12 days after ET,
biochemical pregnancy) resulting from transfer of a fresh cleavage-stage embryo
(day 2 or 3 after oocyte retrieval) and those of a fresh blastocyst transfer (day 5
after oocyte retrieval) were compared.
Participants/materials, setting, methods: Four thousand ﬁfty-ﬁve fresh
single ETs were analyzed, 82 biochemical pregnancies from single blastocyst
transfer and 60 biochemical pregnancies from a single cleavage ET were
included.
Main results and the role of chance: The median β-hCG levels resulting
from a single fresh blastocyst stage transfer was 173.4 (88.8-476.0) IU/L and
similar with hCG levels resulting from a cleavage-stage transfer (140.8 [66.5-
448.3] IU/L) (p=.70). In the simple correlation analysis, the median β-hCG
levels resulting from a cleavage-stage transfer or blastocyst transfer and early
embryonic factors had no associations. The threshold value predicting a clinical
pregnancy for a cleavage stage-embryo was 127.1 IU/L, and for a blastocyst
transfer was 173.5 IU/L. The proposed optimal thresholds predictive for live
birth were 129.4 IU/L and 178.5 IU/L for cleavage-stage and blastocyst stage
ETs, respectively.
Limitations, reasons for caution: The limitations of our study include its
retrospective nature and the ability to include only resulted with biochemical
pregnancy from single fresh cleavage ETs or blastocyst ETs for avoiding missin-
terpretion of early embryonic factors on serum β-hCG levels.
Wider implications of the ﬁndings: The threshold value predicting a clin-
ical pregnancy and live birth for a cleavage-stage embryo and blastocyst transfer
provides information regarding the outcome of pregnancy.
Trial registration number: This study is retrospective cohort study, not
clinical trial.
P-488 RCT depicting favourable IVF outcomes following ATT
(anti-tubercular treatment) either on abnormal endoscopy ﬁndings
or history of contact of tuberculosis
P.C. Jindal1, R. Singh2, M. Singh3
1Bhopal Test Tube Baby Centre, Infertility, Bhopal, India
2Bhopal Test- Tube- Baby Centre, Infertility, Bhopal, India
3Bhopal Test-Tube-Baby Centre, Infertility, Bhopal, India
Study question: Genital Tuberculosis is a major cause of infertility in India.
Does Anti-Tubercular Treatment on the sole basis of abnormal endoscopy
ﬁndings OR history of contact yield better IVF-Result?
Summary answer: Prior treatment of abnormal Endoscopy ﬁndings OR his-
tory of contact of Tuberculous Mycobacterial infection cases with no other
demonstrable cause improves the ART results.
What is known already: The morbidity and mortality due to tuberculosis
(TB) is high worldwide, and the burden of disease among women is signiﬁcant,
especially in developing countries. Mycobacterium Tuberculosis bacilli reach the
genitaltract primarily by haematogenous spread and dissemination from foci
outside the genitalia with lungs as the common primary focus. Genital TB in
females is a chronic disease with low-grade symptoms.
The fallopian tubes are affected in almost all cases of genital TB, and along
with endometrial involvement, it causes infertility in patients.
More research is needed on the changing trends in the prevalence and on the
appropriate methods for diagnosis and management.
Study design, size, duration: 423 infertile patients below 40 years were
evaluated by laparoscopy and hysteroscopy between 2010 to 2017. Out of
these, 108 patients having abnormal hysteroscopic ﬁndings or history of con-
tacts only, were prospectively randomised into Anti-Tuberculosis treatment
and Non-treatment groups by a computer generated list, before undergoing
IVF.
History of contact of Tuberculosis and Screening for genital TB needs to be a
part of evaluation of infertility and menstrual abnormalities.
Participants/materials, setting, methods: 423 infertile patients below 40
years were evaluated by laparoscopy and hysteroscopy between 2010 to 2017.
Out of these, 108 patients having abnormal hysteroscopic ﬁndings or history of
contact only, were prospectively randomised into Anti-Tuberculosis treatment
and Non-treatment groups by a computer generated list, before undergoing
IVF.
The primary outcome measured was cumulative pregnancy rate following
IVF, and secondary outcome was the miscarriage rate.
Main results and the role of chance: There was a statistically signiﬁcant dif-
ference between the two groups, the cumulative pregnancy rate being higher
following IVF in the group who took prior anti tubercular treatment - 34% ver-
sus 16%. Although the miscarriage rate was lower in the treatment group, it
was not statiscally signiﬁcant ( 9% Vesrsus 13%).
Most of the patients present in advanced stage with scarring, severe ﬁbrosis
and adhesions and treatment outcomes, especially with regard to infertility, are
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poor. Hence, early diagnosis and correct treatment is vital to avoid complica-
tions and to restore fertility.
Clinicians need to be aware of this important cause of infertility and men-
strual dysfunction in women and major cause of poor IVF results.
Limitations, reasons for caution: Genital TB is a major cause of infertility
inwomen, and prevalence is generally under stimated because of the asymp-
tomatic nature of the infection and diagnostic challenges. Large multicentric
studies are needed to estimate the magnitude of FGTB and to identify the most
sensitive test for diagnosis.
Wider implications of the ﬁndings: In resource poor developing countries
where IVF cycles are self-funded and difﬁcult to afford, prior treatment of
abnormal hysteroscopic ﬁndings or history of contact of tuberculous mycobac-
terial infection cases with no other demonstrable cause improves the ART
results. Genital Tuberculosis is a major cause of infertility in developing
countries.
Trial registration number: no trial number.
P-489 Bed rest after embryo transfer might affect embryo
implantation, clinical pregnancy and spontaneous miscarriage rates:
a prospective cohort analysis
H. Asakura, K. Nishio, Y. Nakahara, M. Nagaike
Ohgimachi ART Ladeis’ Clinic, Reproductive Medicine, Osaka, Japan
Study question: Bed rest after embryo transfer has been routinely advised
without clear clinical evidence and beneﬁt. We investigated whether abolishing
the practice would negatively affect the clinical outcomes of ART.
Summary answer: Routine bed rest after embryo transfer appeared detri-
mental to the clinical outcomes including clinical pregnancy and embryo
implantation rates, and spontaneous miscarriage rate after ART.
What is known already: There are several routine measures for embryo
transfer to maximize its efﬁciency since inception of ART. Bed rest after embryo
transfer has been historically practiced without clear medical beneﬁt and evi-
dence by meta-analysis (Cochrane Review, 2014: CD006567). Other recent
publications suggested bed rest for long duration after embryo transfer might
lower implantation as well as ongoing pregnancy rates. Even short 10 minutes’
bed rest after embryo transfer using donor oocytes had negative impact on
ART delivery rate (Gaikuwad et al. Fertil. Steril, 2013;100:729).
Study design, size, duration: A prospective non-randomized cohort study:
clinical outcomes of frozen embryo transfers were compared before (86 cycles)
and after (83 cycles) abandoning routine bed rest in July, 2015. Ethics commit-
tee approved the study protocol and consent was obtained from each
participant.
Participants/materials, setting, methods: Females under age 43 receiving
autologous frozen embryos were recruited for the study at a single private ART
institution. The endometrium was prepared using transdermal estradiol and
vaginal progesterone was administered until 8 weeks’ gestation. The vitriﬁed
embryos were thawed at cleavage or blastocyst stage and transferred. Bed rest
group spent 30 minutes’ in supine or prone position after embryo transfer, and
no bed rest group was ambulatory immediately after embryo transfer.
Main results and the role of chance: Between the two groups with and
without bed rest, the average female age (38.3 vs. 38.3 y.o.) and the order of
transfer (2.8 vs. 2.9) and the number of embryos transferred (1.4 vs. 1.5) were
similar. There was tendency of higher clinical pregnancy rate (38.6% vs. 27.9%,
OR 1.6 (p = 0.14)), implantation rate (27.6% vs. 22.8%, OR1.3 (p = 0.38)) and
lower miscarriage rate (45.8% vs. 28.1%, OR 0.46 (p = 0.17)) for the group
without bed rest. These trends were similarly observed despite the stage of
thawed embryos (cleavage or blastocyst), and the uterine positions (anterior or
posterior). Further analysis with fresh embryo transfer had the same ﬁndings
though not statistically signiﬁcant.
Limitations, reasons for caution: Lack of study power due to relatively
small sample size, and non-randomized and non-blinded nature of the study
design are the major limitations.
Wider implications of the ﬁndings: Abolishing routine bed rest after
embryo transfer increased pregnancy and implantation rates, and lowered
chance of miscarriage. The effects were unrelated to the stage of thawed
embryos, or uterine positions. The uterine condition or higher sense of self efﬁ-
ciency with early ambulation after transfer might be related to the ﬁndings.
Trial registration number:Not applicable.
P-490 Relationship between gestational age and the observed
protein patterns of ﬁrst trimester maternal urine analysed by
maldi-tof mass spectrometry
R. Zmuidinaite1, F. Sharara2, S. Butler3, S. Keshavarz3, R. Iles3
1Employee of MAP Sciences, Research and Developement, Mill Hill, United Kingdom
2Virginia Centre for Reproductive Medicine, Embryology, Reston, U.S.A.
3MAP Sciences Ltd, Research, Bedford, United Kingdom
Study question: Does mass spectral patterns of healthy pregnancy maternal
urine analysed by MALDI-ToF MS represent the gradual and directional changes
associated with increasing gestational age?
Summary answer: The observed difference in maternal urine of different ges-
tational age show a consistent pattern at selected regions corresponding to pro-
tein peak areas.
What is known already: Urinalysis by MALDI-ToF MS has been shown to
be a useful tool for identiﬁcation of pregnancy related diseases including pre-
eclampsia screening, downs syndrome screening and assessment of pregnancy
viability in case of threatening miscarriage. Furthermore it is also recognised, by
both biochemical testing and MALDI-ToF MS technique, that gestational age is
a very important factor affecting maternal urine protein levels. Therefore, this is
likely to have an effect on any methods which involve the study relative protein
in the urine of women during pregnancy.
Study design, size, duration: Retrospective longitudinal study analysing a
total of 633 urine samples at an average of 8 weeks of gestation from four USA
IVF clinics collected between May 2014 and August 2016. Samples were cate-
gorised into ﬁve groups for gestational weeks from six to ten (n = 187, 127,
162, 103 and 54). Pregnancy losses were excluded and only MALDI ToF MS
proﬁles from healthy pregnancies were assessed for changes relating to gesta-
tional age.
Participants/materials, setting, methods: Subsequent to the mass spec-
tral analysis all data was subject to meticulous pre-processing to render data
comparable and the region between 2000 to 12000m/z was subject to further
testing. There were 274 peaks identiﬁed to be representative throughout the
data and were quantiﬁed by summing the ion count in the peak regions. Non-
parametric test for trend was applied to medians of ﬁve groups for all 274
peaks. Analysis was performed using R.
Main results and the role of chance: Total of 274 peaks were tested for
upward or downward trends, each one representing the upregulated or down-
regulated proteins present during the ongoing pregnancy. Visual assessment of
the 274 peaks by scatter plots and boxplots led to the conclusion that such
trends both positive and negative are present in about quarter of the peaks ana-
lysed. Twenty (7.3%) of the observed peaks had a strong (>0.8) negative cor-
relation and forty two (15.4%) peaks had a strong positive linear correlation for
gestational weeks. These signiﬁcant peaks were further examined for trends by
removing the categories and analysing the raw data by day, giving more cer-
tainty to the results and to conﬁrm the existing trends. Furthermore, the
increase of human chorionic gonadotropin (hCG) during ﬁrst weeks of gestation
was represented by the increase of ion counts in the mass region of 9425 m/z
to 9847m/z which corresponds to the hCG β subunit core fragment. The con-
sistent presence of this peak provides additional conﬁdence in the reliability of
the data. Additionally, this has conﬁrmed the previously observed pattern
(unpublished data) for maternal urine in Downs screening data.
Limitations, reasons for caution: Urine samples were not analysed fresh
and were subject to at least one freeze – thaw cycle.
Wider implications of the ﬁndings: The study furthers the understanding
of maternal pregnancy urine analysed by MALDI-ToF MS which has several
potential applications for diagnostic testing including pre-eclampsia and aneu-
ploidies screening. This new knowledge will allow improvements to the diag-
nostic algorithms by adjusting predictive models to particular gestational ages.
Trial registration number: n/a.
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P-491 Towards the development of rapid, ﬁrst trimester, maternal
urine maldi-tof ms screening tests for Downs syndrome
S. Keshavarz1, S. Butler2, J. Iles1, R. Zmuidinaite1, F. Sharara3,
R. Iles2
1Employee, Research, Bedford, United Kingdom
2MAPSciences Director, Research, Bedford, United Kingdom
3Virginia Centre for Reproductive Medicine, Embryology, Reston, U.S.A.
Study question: Question - Can the examination of mass spectral data from
maternal urine obtained from 12 to 14 week high risk pregnancies predict a risk
of Downs syndrome?
Summary answer: Mass spectral examination of maternal urine, in the range
of 2,000 to 11,000m/z, gives rise to gestational age speciﬁc testing algorithms
for Downs syndrome screening.
What is known already: The established methods of antenatal screening
test for Down’s syndrome are based on a panel of maternal serum biomarkers
measured by immunoassay together with ultrasound markers. Recently, a
method based maternal plasma cell free (cf)DNA has begun to be used but it
has a number of limitations including excessive turn-around time and cost. We
aimed to develop an alternative method based on urinalysis which is simple,
affordable and accurate.
Study design, size, duration: A retrospective collection of 20 Down
Syndrome and 100 non-aneuploid pregnancy urines collected in 2007-2008
from high risk pregnancy cohorts.
Participants/materials, setting, methods: Samples were thawed and
examined by MALDI-ToF mass spectrometry in the mass/charge range
between 1000 and 100,000 m/z. The spectral masses between 2000 and
11,000m/z were speciﬁcally examined and a method has been developed by
which data was collected and analysed. Normalisation of spectral data was
deﬁned using mass bins of 100 m/z expressed as a percentage of the total mass
spectra from 2,000 to 11,000m/z.
Main results and the role of chance: Of the ninety 100 m/z bins, nineteen
of them, covering the maximum amount of variation were selected, all demon-
strating statistically signiﬁcant difference between Downs and control/non-
aneuploid samples as veriﬁed by Mann-Whitney test. Based on the differences
and variance, for values at these spectral regions, weighted scores of the prob-
ability of being Downs were assigned. Comparative algorithms consisting of
various mass peak regions were tested for ability to distinguish Downs syn-
drome from non-aneuploid pregnancy. Although various algorithms could dis-
tinguish Downs from non-aneuploid controls, it was found that gestational age
was a confounding factor and that if separated into gestational age matched
cohorts the ability to distinguish the groups improved dramatically e.g. whilst an
algorithm consisting of nineteen measured bin spectral regions separated a
100% of Downs for non-Downs for 10% false positive in the mixed gestational
ages cohort; a two mass peak algorithm distinguished 100% of Downs for 6%
false positive rate for a cohort of 12 weeks gestation samples.
Limitations, reasons for caution: This study is limited by the cohort num-
ber and samples which have been stored for a considerable time.
Wider implications of the ﬁndings: Implementation of simple screening
programmes based on rapid analysis of urine from women in early pregnancy
would provide an economical alternative to complex screening programmes
and costly genetic NIPT. This will be of particular use in countries with large
and widespread populations.
Trial registration number:N/A.
P-492 Duration of medicated frozen embryo transfer cycles. Is
length of estradiol supplementation having a role in outcomes? A
retrospective study
A. Tsironis, S. Priyanka, S. Campbell, G. Nargund
Create Fertility Ltd, St Paul’s London, LONDON, United Kingdom
Study question: Is the length of estradiol supplementation affecting outcomes
in frozen embryo transfer cycles?
Summary answer: Our data suggest that clinical pregnancies are signiﬁcantly
increased with duration of estradiol supplementation of twelve or more days.
What is known already: According to data presented in the recent ASRM1,
estradiol duration n does not have an impact on pregnancy rates. Other studies
suggest that prolonging estradiol supplementation may have negative effects on
pregnancy outcomes2.
1. Sekhon L, Endometrial preparation for FET: Does the duration of estradiol
supplementation matter? (2017) ASRM P675
2. Sunkara SK., The impact of the duration of estrogen supplementation on
the outcome of medicated frozen-thawed embryo transfer (FET) cycles (2011)
Fertil Steril, Vol96, Issue 3, S43
Study design, size, duration: Retrospective analysis of medicated frozen
embryo transfer cycles in our unit from January 2016 until December 2017. We
reviewed 378 consecutive medicated frozen embryo transfer cycles. Cycles
were divided into 2 groups A. those with duration of estradiol supplementation
of 11 days or less (duration varied between 5 and 11 days) and B. those with
estradiol supplementation of 12 days or more (duration varied between 12 and
28 days)
Participants/materials, setting, methods: Group A consisted of 154
cycles frozen embryo transfer cycles and Group B of 224. Egg recipients were
not included in the study. Five PGS cycles were included in the study (1 in
Group A and 4 in Group B but their inclusion does not affect the signiﬁcance of
results). Main outcomes off the study were implantation (as deﬁned by positive
pregnancy test) and clinical pregnancy rates (presence of heartbeat in the 7th
week scan).
Main results and the role of chance: Age and AMH were similar in the 2
groups (p: 0.22 and p: 0.385 respectively). BMI was signiﬁcantly higher in Group
A 23.9 vs 23.2 in Group B (p: 0.039). Endometrial thickness was signiﬁcantly
higher in Group A (8.7 mm vs 8.1 mm, p:0.002). Endometrial morphology was
recorded as triple layer endometrial lining in the majority of cycles. Implantation
rates were similar in both groups (40.25% vs 43.7%) but clinical pregnancy rates
were signiﬁcantly higher in Group B (30.8% vs 22.7%, p: 0.03). In the subgroup
analysis, the increase involves mainly blastocyst transfers with cleavage stage
transfers demonstrating similar results in both groups. More speciﬁc, for cleav-
age stage transfers implantation (Group A 35.5% vs Group B 33%) and clinical
pregnancy rates (Group A 21% vs Group B 22.3%)were similar in both groups.
In blastocyst transfers implantation was higher in Group B (52,9% vs 43.5%) but
did not reach signiﬁcance. Clinical pregnancies were signiﬁcantly higher in
Group B (38% vs 23.9%, p:0.012).
Limitations, reasons for caution: The major limitation of the study is its
retrospective design. BMI and endometrial thickness were signiﬁcantly different
in both groups but it is difﬁcult to quantify the effect of these features on the
outcomes as in both groups BMI and endometrial thickness are within normal
limits.
Wider implications of the ﬁndings: Improved endometrial maturity and
receptivity are possible key factors implicated in lenght of estradiol supplemen-
tation of 12 or more days. Our ﬁndings are in contrast with current literature
suggesting that length does not have a role or increased length may have a nega-
tive impact on outcomes.
Trial registration number: not aplicable.
P-493 Minimally-invasive RNA-Seq proﬁling of the endometrium
during stimulated in vitro fertilization cycles to identify predictive
markers of endometrial receptivity
C. Chan1, T. Li1, E.J. Shin1, N. Stickle2, C. Virtanen2,
N.Winegarden3, T. Brown1, E. Greenblatt1
1Mt Sinai Hospital, Obstetrics and Gynaecology, Toronto, Canada
2University Health Network, Bioinformatics and HPC Core, Toronto, Canada
3Princess Margaret Cancer Centre, Genomics Centre, Toronto, Canada
Study question:What genes are differentially expressed by the endometrium
at the time of embryo transfer in stimulated cycles and how does this compare
to natural cycles?
Summary answer: A distinct gene expression signature distinguishes the
receptive phase endometrium in stimulated cycles, with 58 genes overlapping
with the natural cycle.
What is known already: Several groups, including ours, have characterized
the gene expression of the endometrium in natural cycles and identiﬁed
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transcripts that are differentially expressed during the receptive phase (LH+7)
versus the pre-receptive phase (LH+2). Most investigators have used invasive
endometrial biopsy to sample the endometrium, which must be performed in a
‘mock” cycle as the biopsy may disrupt implantation. Therefore, molecular
characterization of the endometrium in stimulated IVF cycles and same-cycle
correlation of gene expression to pregnancy outcome are lacking. We previ-
ously developed a minimally-invasive technique of uterine ﬂuid aspiration (UFA)
that allows for transcriptomic proﬁling during an active conception cycle.
Study design, size, duration: Healthy women ≤ 40 years of age with regular
cycles and normal uterine cavities, undergoing their ﬁrst or second IVF cycle,
were recruited with informed consent. UFA sampling was performed at the
time of oocyte retrieval (hCG+2), classiﬁed as ‘pre-receptive” samples (N =
40). UFA sampling was also performed in the same women at the time of fresh
day 5 embryo transfer (hCG+7), classiﬁed as ‘receptive” samples (N = 26).
Participants/materials, setting, methods: Total RNA was extracted from
samples and RNA-Seq analysis was performed. Reads from each sample were
mapped to the human reference genome (UCSC hg19) using HISAT2.
Transcript assembly and abundance estimation was performed using StringTie,
and R statistical software with the Ballgown package was used to determine dif-
ferentially expressed transcripts between timepoints (fold change ≥ 4, false dis-
covery rate q<0.05). These transcripts were cross-referenced with our
previously published data from natural cycles (LH+2 and LH+7).
Main results and the role of chance: Statistical analysis showed 11,152
genes were differentially regulated between hCG+2 and hCG+7 samples.
Hierarchical clustering of the samples using these genes revealed a clear segre-
gation of samples into two major sub-groups: the ﬁrst consisting almost exclu-
sively of hCG+2 samples and the second of hCG+7 samples. The differentially
expressed genes between hCG+7 and hCG+2 were then compared to a list of
245 genes showing ≥ 4-fold change from our previous natural cycle data (LH+7
versus LH+2). Of those 245 genes, 58 overlapped with the stimulated cycle
data (q<0.05). The RNA-seq data for these genes were then clustered using a
divisive analysis clustering method (DIANA) and showed two major sub-groups
that correspond to hCG+2 and hCG+7. Of the patients that underwent fresh
embryo transfer, 7 conceived. No statistically signiﬁcant differences were identi-
ﬁed between the samples from pregnant vs. non-pregnant patients.
Limitations, reasons for caution: This translational study focused on dis-
covery of candidate biomarkers of endometrial receptivity in stimulated cycles.
The main limitation is a small sample size. The gene expression proﬁle requires
further validation through prospective clinical trials with more patients to deter-
mine the transcripts that may have predictive value for implantation.
Wider implications of the ﬁndings: This is the ﬁrst whole-genome tran-
scriptomic study on the stimulated endometrium, with direct correlation to
embryo transfer outcomes. Prospective studies using this signature will allow
identiﬁcation of predictive markers of pregnancy. Overlapping transcripts
between stimulated and natural cycles imply conserved pathways involved in
endometrial receptivity that are of particular interest.
Trial registration number:Not applicable.
P-494 Clinical pregnancies achieved after embryo transfer date
adjustment based on novel endometrium receptivity test
A. Lukaszuk1, R. Lenckowski2, W. Sieg1, G. Jakiel3,4,
W. Kuczynski5,6, K. Lukaszuk1,7,8
1Invicta Sp. z o.o., Fertility Clinic, Gdansk, Poland
2Invicta Sp. z o.o., Diagnosic Laboratory, Gdansk, Poland
3Invicta Sp. z o.o., Fertility Clinic, Warsaw, Poland
4Center of Postgraduate Medical Education, Department of Obstetrics and
Gynecology, Warsaw, Poland
5Centre for Reproductive Medicine KRIOBANK, Fertility Clinic, Bialystok, Poland
6Medical University of Bialystok, Department of Gynecology, Bialystok, Poland
7Medical University Warsaw, Department of Gynecological Endocrinology, Warsaw,
Poland
8Gdansk Medical University, Department of Nursing, Gdansk, Poland
Study question: Does the embryo transfer (ET) date adjustment based on
the new endometrium receptivity test lead to increased clinical pregnancy rate?
Summary answer:We can report encouraging preliminary results in patients
who had their embryo transfer date adjusted based on the results of the simple
endometrium receptivity test.
What is known already: Embryo implantation is a crucial step in the in-vitro
fertilization. The so called “window of implantation” is a 4-5 days usually
between cycle day 20 and 24. This, however, can vary depending on the cycle
type and on individual basis. Analysis of the reasons for implantation failure in
cases of top quality embryos showed that a common cause is the lack of syn-
chronization of embryonic development with endometrial maturation.
There are commercial and non-commercial tests available that assess endo-
metrial receptivity based on expression levels of genes linked to the status of
endometrial receptivity, using RNA sequencing.
Study design, size, duration: This is an ongoing study initiated in April 2017.
Study will include 160 patients with 3 previous implantation failures after a
transfer of top quality embryos (with a total number of transferred embryos
being at least 4), who are planning a frozen embryo transfer (FET). Patients are
divided equally into study group that undergoes endometrium receptivity test-
ing and the control group of those patients who do not opt for the test.
Participants/materials, setting, methods: To date 68 patients were quali-
ﬁed and underwent endometrial biopsies. Endometrial biopsies on day 5 and 7
after ovulation or after start of progesterone supplementation, depending on
the planned preparation for FET. Endometrial biopsy material was processed
with immunohistochemical staining to evaluate presence of the following pro-
tein: estrogen receptor (ER), progesterone receptor (PR), BCL-6, interleukin
15 (IL-15), osteopontin, beta-3 integrins, HOXA10.
Main results and the role of chance: 58.2% of patients had a normal result
for both biopsy samples - day 5 and day 7. 38.2% had at least one of the results
showing endometrium as delayed in development, prematurely developed or
showing mixed development. There were 2 non-diagnostic results (due to poor
sample quality) where D5 result was Normal and D7 was non-diagnostic.
D5 samples were Normal in 88.1% cases (59 patients), Delayed - 6.0% (4),
Premature - 3.0% (2) and Mixed - 3.0% (2). For the day 7 samples the results
were as follows: Normal - 64.2% (43), Delayed - 9.0% (6), Premature - 11.9%
(8), Mixed - 11.9% (8), Non-diagnostic - 3.0% (2).
It is worth noting that in 11.9% of cases D7 biopsy results showed mixed
endometrium development, i.e., party delayed and party premature develop-
ment. In those cases other mRNA based tests may show misleading results.
24 patients have already undergone an FET. 15 of those had a normal recep-
tivity test result and 9 an abnormal one. In the normal result subgroup there are
4 clinical pregnancies (26.7%). For patients in the abnormal subgroup the FET
date was adjusted based on the receptivity test result. In that group there are 5
clinical pregnancies (55.6%)
Limitations, reasons for caution: These are preliminary results and the
group of patients that had already underwent the FET is relatively small.
Wider implications of the ﬁndings: This test may provide a simple and
cost effective method of determining endometrial receptivity. The preliminary
results are encouraging. It appears that when endometrial receptivity is deter-
mined the be the cause of implantation failure adjustment of transfer date helps
in achieving clinical pregnancies.
Trial registration number:Not applicable.
P-495 Frozen Embryo Transfer Protocols:Which one is best?
J. Joy, P. Lowe
CARE Manchester, Reproductive Medicine, Manchester, United Kingdom
Study question: Is there a difference in live birth rates between frozen
embryo transfer (FET) protocols?
Summary answer: In under 36 year olds having FET with single vitriﬁed top
quality blastocyst, live birth rates are signiﬁcantly higher after natural cycle com-
pared to medicated.
What is known already: Currently, there is no deﬁnitive evidence that there
is a superior protocol for frozen embryo transfer. Several studies have com-
pared natural cycle, modiﬁed natural cycle and medicated cycles including both
with down regulation and with out. Whilst pregnancy rates have been shown to
be higher in some groups in some studies, the live birth rates have not shown
i368 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
any signiﬁcant differences. Most of these studies have not be carefully selected
with heterogeneity and confounding factors affecting reliability.
Study design, size, duration: This was a retrospective study, from July 2011
to Dec 2016. 1933 FET cycles were included.
Participants/materials, setting, methods: Inclusion criteria: ≤36 years,
vitriﬁed top quality blastocysts, elective single embryo transfers, own eggs, no
assisted hatching, at least 75% recovery of embryos at FET, patients with over
two previous failed embryo transfers.
Exclusion criteria: egg recipients, double embryo transfer, age over 36 yrs,
embryos cryopreserved by slow freeze.
1933 FET cycles that complied with inclusion criteria during study period
were categorised into 3 groups based on treatment protocol and live birth rates
were compared.
Main results and the role of chance: 746 had down regulation protocol, 981
had non downregulation protocol and 206 had natural cycle. (There were no sig-
niﬁcant differences between three protocols ( Down regulation protocol (DR),
Non downregulation protocol (NonDR) and natural cycles) in positive pregnancy
rates (58.7%, 56.7%, 60.2%, p = 0.54). The clinical pregnancy rates (44.1%, 43%,
53.9%, p = 0.16) and live birth rates (38.5%, 36.7%, 46.1%, p = 0.008) were how-
ever signiﬁcantly higher in the NC group. This can be attributed to a signiﬁcantly
lower biochemical pregnancy loss and miscarriage rate in natural cycle group. The
number of natural cycle protocols are less than the medicated and so perhaps
there is the role of chance which can be conﬁrmed by further prospective analysis.
Limitations, reasons for caution: The main draw back is the retrospective
design.
Wider implications of the ﬁndings: Natural cycle FETs can be unpredict-
able and hence may increase workload over weekend. This can be particularly
unsuitable for planning clinic timings.
Trial registration number: not applicable.
P-496 CCS-STR analysis as standard of care for loss of pregnancy
has advantages over traditional culture and karyotype
K. Bauckman, T. Escudero
CooperGenomics, Laboratory, Livingston, U.S.A.
Study question: Does CCS-STR analysis of pregnancy loss products have
advantages over traditional culture and karyotype analysis?
Summary answer: CCS-STR analysis has several advantages over culture and
karyotyping as a method to determine cause of early pregnancy loss.
What is known already: Simpson (1990) summarized the results of culture
and karyotyping studies of pregnancy loss products.
Study design, size, duration: 516 pregnancy loss products were analyzed
over a 5 year period using CCS technology (array-CGH and NGS sequencing)
with follow-up STR analysis when appropriate.
Participants/materials, setting, methods: SurePlex whole genome ampli-
ﬁcation products from dissected pregnancy loss products that were previously
performed in a clinical setting were analyzed.
Main results and the role of chance: Unlike traditional karyotyping, CCS-
STR analysis is able to conﬁrm the presence of fetal tissue being analyzed due to
unique STRs found in the purported fetal tissue compared to the maternal tis-
sue. We found that the proportion of “normal” results in the karyotyping study
(51%) was comparable to combining both the normal and maternal contamin-
ation results using the CCS-STR method (31.4% diagnosed normal, 23.3% diag-
nosed as maternal contamination, total 54.7%).
CCS-STR analysis is able to be accurately identify monosomic lines and abnor-
malities involving 2-3 or more chromosomes. Simpson identiﬁed no losses involv-
ing both a monosomy and a trisomy or three or more abnormalities, while CCS
+STR analysis found 1.2% and 0.2% of losses in those categories, respectively.
In addition, karyotyping involves use of the subcategory “G”, when the oper-
ator has difﬁculty differentiating chromosomes 21/22. CCS-STR analysis is able
to conﬁdently distinguish even small chromosomes accurately, including 21/22.
While culture and karyotype and CCS+STR identiﬁed the same proportion of
losses involving trisomy 21 (2.1% vs 2.3%), CCS+STR identiﬁed almost double
the proportion of trisomy 22 losses (5.2% vs 2.3%).
Limitations, reasons for caution: CCS-STR is not able to identify certain forms
of polyploidy, including high-order polyploidy and mitotically-derived polyploidy.
Wider implications of the ﬁndings: CCS+STR analysis is a highly accurate
way to determine cause of pregnancy loss without many of the drawbacks
involved in culture and karyotyping. Shifting pregnancy loss testing towards SNP
array + STR analysis should maintain the advantages of CCS+STR in addition to
being able to identify more types of polyploidy.
Trial registration number:Not applicable.
POSTER VIEWING
Male and female fertility preservation
P-497 Small or large ovarian tissue fragment.Which is the ideal
size for fertility preservation?
A. Mikich1, Á. Dupont1, E. Sanguinet1, E.T. Massignam2, B. Iser1,
M. Ferreira1, F. Klamt2, N. Lothhammer1, N. Frantz3
1Federal University of Rio Grande do Sul, Morphological Sciences, Porto Alegre, Brazil
2Federal University of Rio Grande do Sul, Department of Biochemistry, Porto Alegre,
Brazil
3Nilo Frantz Fertility Center, Assisted Reproduction, Porto Alegre, Brazil
Study question: Does the size of the ovarian fragment affect stromal and fol-
licular morphology and tissue physiology after vitriﬁcation?
Summary answer: Electron microscopy and Gomori´s staining show normal
follicular morphology, collagen ﬁbers and ﬁbroblasts in small and large samples
and similar lactate dehydrogenase production in culture.
What is known already: Reports describe the use of small and large frag-
ments and slow freezing. Ovarian tissue vitriﬁcation is gaining attention, however,
effects of the size of the fragment on stroma morphology and tissue physiology
were not reported. Larger samples may reduce mechanical damage caused by
dissection. Fibroblasts and extracellular matrix present in the stroma play a critical
role in folliculogenesis and angiogenesis through microenvironment remodeling
and growth factors delivery, two processes involved in successful grafting and pre-
vention of necrosis. Gomori´s staining and electron microscopy reveal details of
stromal components and lactate dehydrogenase (LDH) represents a signature of
necrotic cells pos-cryopreservation and culture.
Study design, size, duration: Fresh small (S, 1 × 1 × 2mm) and large (L, 1 ×
1 × 5) fragments of bovine ovaries were ﬁxed for light (LM) and electron micros-
copy (EM) observations, or vitriﬁed. Fresh and rewarmed fragments were cul-
tured for 48hrs. Next, tissues were ﬁxed and processed for LM and EM. LM,
sections were stained with Gomori´s trichrome for connective tissue and collagen
ﬁbers. Culture media was collected for LDH assay. Experiments were performed
in triplicates.
Participants/materials, setting, methods: S and L fragments from 4-6
ovaries were ﬁxed for LM and EM observations or vitriﬁed using 15% DMSO,
15% ethylene glycol and 0,5 M sucrose in human tubal ﬂuid. Fixed S and L tis-
sues were prepared according to standard LM and EM protocols.
Morphological analysis included: collagen ﬁbers, ﬁbroblasts, follicle and blood
vessel structures. LDH activity was measured by enzymatic colorimetric assay.
LDH measurements were compared by ANOVA. P value was considered sig-
niﬁcant when <0.05
Main results and the role of chance: Gomori´s trichome staining of S and L
vitriﬁed tissue sections showed that interstitial matrix, collagen ﬁbers and ﬁbro-
blasts maintain a similar structure to that found in fresh tissues. However, S frag-
ments presented a looser matrix structure, than L samples. Follicles in S and L
fragments show no major alteration in relation to ﬁndings observed in fresh tis-
sues. These observations were conﬁrmed by EM micrographs, where collagen
ﬁbers in vitriﬁed samples appear as continuous structures, with no interstitial gaps
between them. In addition, it is possible to observe the normal fusiform morph-
ology of ﬁbroblasts, intact blood vessel wall and endothelium. Ultrastructural
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analysis of primordial follicles demonstrated well-preserved integrity of the
oocyte and the surrounding follicular cells. No differences in LDH activity
were found between fresh and vitriﬁed, S and L fragments after 48 hours
culture (P = 0,347).
Limitations, reasons for caution: The main limitation of our study refers to
the fact that results were shown for ovarian tissue collected from one species,
bovine. Further studies with human ovarian samples are necessary to conﬁrm
our ﬁndings. Also, EM micrographs show detailed structures within limited
areas of tissue, not the whole fragment morphology.
Wider implications of the ﬁndings: The present study provides evidence
that vitriﬁcation does not induce major morphological and physiological changes
in the stroma and follicles of S and L ovarian tissue fragments. Thus, it is recom-
mended to use L ovarian fragments for tissue banking.
Trial registration number: Basic animal research.
P-498 Luteal phase stimulation, the future of fertility preservation?
Retrospective cohort study of luteal phase stimulation versus
follicular phase stimulation
F. Jochum1, N. Sananes1, I. Lichtblau2, M. Teletin2, C. Rongieres1,
O. Pirrello1
1University hospital of Strasbourg, Department of Obstetric and Gynaecology,
Strasbourg, France
2University hospital of Strasbourg, Reproduction laboratory, Strasbourg, France
Study question: Is luteal phase stimulation capable of improving fertility
preservation?
Summary answer: Luteal phase stimulation appears to be a promising alter-
native to conventional protocols in view of the number of mature oocytes
obtained.
What is known already: Ovarian stimulation with cryopreservation of
oocytes / embryos is today the most widely used technique for fertility preser-
vation in women. Usually, ovarian stimulation starts early in the follicular phase.
However, this method requires, depending on the day of the cycle of the
patient on the day of consultation, between 2 and 6 weeks of implementation.
This can delay the beginning of cancer treatment. In this context, luteal phase
stimulation appears as a solution. It would indeed reduce the time of comple-
tion so the cancer treatment can start quickly as possible.
Study design, size, duration: We performed a retrospective cohort study
of consecutive ovarian stimulations, during January 2012 and October 2017 in
the University Hospital of Strasbourg.
Participants/materials, setting, methods: Were included all patients
under 40 who were referred to our centre for fertility preservation. All
included patients had regular cycles and normal ovulation. Non-inclusion cri-
teria are a low expected ovarian response deﬁned by AMH<0.75 μg/l, poly-
cystic ovarian syndrome, amenorrhea, history of infertility or hypofertilization
treatment. The primary endpoint is the number of mature oocytes (meta-
phase II) obtained.
Main results and the role of chance: A total of 87 patients were included:
19 in luteal phase and 68 in follicular phase. A larger number of mature
oocytes was obtained in luteal phase versus follicular phase (12.4+/-8.8 ver-
sus 7.9+/-5.6 with p = 0.046). A greater amount of total (mature and imma-
ture) oocytes was obtained in luteal phase versus follicular phase with a
signiﬁcant difference (15.5+/-10.0 versus 10.2+/-6.9 with p = 0.041). No dif-
ference was found for the initial and total doses of gonadotropin.
Limitations, reasons for caution: One of the issues of our study was to
determine the progesterone level to deﬁne the beginning of the luteal phase. In
our study, a progesterone level above 2 ng/ml arbitrarily deﬁned the luteal
phase, while many studies have used a higher rate.
Wider implications of the ﬁndings: Luteal phase stimulation has the
advantage of a better ﬂexibility with positives results as to the number of
oocytes obtained. It is easy to imagine a future for this new protocol, par-
ticularly in the preservation of fertility, where it is essential to reduce the
delay in achieving stimulation.
Trial registration number:Not applicable.
P-499 An existing tool in a new concept: Retrieval of immature
oocytes during laparoscopy/hysteroscopy followed by in vitro
maturation as a strategy for oocyte banking
C. Lu, X.L. Song, X.Y. Zheng, J. Qiao
Center for Reproductive medicine, Department of Obstetrics and Gynecology- Peking
University Third Hospital, Beijing, China
Study question: The feasibility of performing transvaginal retrieval of imma-
ture oocytes and subsequent in vitro maturation (IVM) in adjunct with gynaeco-
logical surgery for women themselves or donation.
Summary answer: IVM-surgery is simple, safe and associated with good
results, which allows embryo or oocyte cryopreservation utilised by treated
women or donation of spare oocytes.
What is known already: n contrast to conventional in vitro fertilization (IVF),
IVM offers several advantages. It may be performed without ovarian stimulation
with gonadotrophins, thus avoiding ovarian hyper stimulation syndrome (OHSS),
and requires shorter treatment time. IVM also involves less complexity associated
with planning and monitoring of the cycle, and incurs lower costs, which is expected
to be more acceptable to the patients and to expand access to fertility treatments.
It’s common that women undergo non- assisted reproduction technologies (ART)
procedures, such as hysteroscopy or laparoscopy prior or during their fertility treatment.
Study design, size, duration: To assess the feasibility and the efﬁcacy of
IVM treatment when oocyte retrieval was performed in adjunct with laparos-
copy/ hysteroscopy in infertile women. To evaluate the outcomes of the ART
cycles with both fresh and vitriﬁed-warmed fertilised IVM oocytes and the efﬁ-
ciency of this technique compared with conventional IVM in our center. In add-
ition, we examined the safety of the technique including ovarian function.
Participants/materials, setting, methods: We included 158 consecutive
women with PCOS who underwent laparoscopy or hysteroscopy had concomi-
tant transvaginal oocyte retrieval followed by IVM between June 2014 and May
2016. Matured IVM oocytes were either fertilised (n = 46) or vitriﬁed (n = 112)
and then warmed and inseminated (n = 33). Women with PCOS who under-
went conventional IVM and women who underwent gynaecological surgery
without IVM served as controls. The analysis of outcomes included embryo-
logical data, clinical outcomes, and ovarian function 6 months post-procedure.
Main results and the role of chance: The number of oocytes retrieved per
patient was 14.5 (9.0, 20.0), the average maturation rate was 47.4% ±16.5%.
Fertilisation rate of fresh-inseminated oocytes was 64.6% and of vitriﬁed-warmed
oocytes was 50.0% with oocyte survival 83.0%. Vitriﬁed blastocysts were avail-
able for 41.3% patients (2.4 ± 1.641). Vitriﬁed-warmed oocytes resulted in high-
quality cleavage embryos in 63.6% patients [32.5 (0.0, 50.0)]. Clinical pregnancy
and live birth rates per single blastocyst transfer cycle in vitriﬁed blastocyst group
were 63.6% and 54.6%, respectively and per single or double day-3 cleavage
transfer cycle in vitriﬁed oocyte group were 31.8% and 22.7%, respectively. No
adverse neonatal outcomes were recorded in either group.
IVM-surgery resulted in comparable oocyte yield and maturation rate as con-
ventional IVM. The fertilisation rate and high-quality cleavage embryos from
fresh-inseminated oocytes were also similar to those of conventional IVM.
IVM-surgery added 30 minutes to operative time, but was not associated
with postoperative complications or longer hospital stay and did not seem to
affect ovarian function compared with those of surgery alone group.
Limitations, reasons for caution: We included only women with PCOS
because PCOS patients have larger follicle pool and were more likely to beneﬁt
from IVM cycle.
Sample size limited our ability for meaningful conclusions regarding perinatal
outcomes.
The ﬁndings need to be conﬁrmed in a larger population and in different
phenotypic groups of women.
Wider implications of the ﬁndings: Combined IVM-surgery is a simple and
safe procedure. It carries minimal risk of OHSS and is associated with accept-
able live birth rate. Importantly, this approach provides additional avenue for
social fertility preservation in treated women and allows utilising excess vitriﬁed
oocytes for oocyte donation program or for research.
Trial registration number: The study was retrospectively registered with
the Chinese Clinical Trial Registry on 04.07.2017; clinical trial registration ID
ChiCTR-ONC-17011861.
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P-500 Effect of letrozole added to gonadotropins in controlled
ovarian stimulation protocols for fertility preservation on the yield
and maturity of retrieved oocytes
A.Wertheimer1,2, E. Klochendler2, O. Sapir1,2, Y. Shufaro1,2,
G. Oron1,2, A. Ben-Haroush1,2
1Helen Schneider Hospital for Women- Rabin Medical Center-Beilinson Hospital-, IVF
and Infertility Unit, Petach-Tiqva, Israel
2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
Study question: Does the co-administration of letrozole and gonadotropins
during ovarian stimulation inﬂuence oocyte yield and maturation in breast can-
cer patients prior to chemotherapy?
Summary answer: In apparently normal responders with breast cancer, the
addition of letrozole to gonadotropins does not increase the number of
retrieved oocytes or maturation rate.
What is known already: Ovarian stimulation with letrozole and gonadotro-
pins is effective in patients with breast cancer and spares them exposure to high
estradiol levels in fertility preservation cycles. Adjunctive letrozole administra-
tion in poor-responder patients decreased the rate of cycle cancelation with
increased oocyte yield, perhaps due to increased endogenous gonadotropins
secretion or increased follicular androgens concentration.
Study design, size, duration: A retrospective cohort design was used com-
paring oocyte cryopreservation cycles among patients with breast cancer
patients with other oncological indications and women undergoing elective
oocyte cryopreservation at a single tertiary medical center between 2007 and
2017. All patients were treated with GnRH antagonist protocol using GnRH
agonist for ﬁnal oocyte maturation. The breast cancer group was additionally
treated with letrozole (5 mg/day) from the ﬁrst day of treatment until the day
of oocyte retrieval.
Participants/materials, setting, methods: The cohort included 418
patients: 145 breast cancer patients, 168 with other oncological indications, and
105 patients who chose to undergo elective oocyte cryopreservation.
Main results and the role of chance: There were no signiﬁcant differences
among the groups in number of retrieved oocytes (13.1 ± 11.9 vs. 14.4 ± 11.0
vs. 13.6 ± 10.8, respectively, p = 0.593) or proportion of mature oocytes (85
± 16% vs. 81 ± 22% vs. 80 ± 20%, respectively, p = 0.125). On multivariate lin-
ear regression models, co-treatment with letrozole was not a signiﬁcant factor
for the number of retrieved oocytes (p = 0.408) or for oocyte maturation rate
(p = 0.127) after controlling for age, body mass index, and FSH dose.
Limitations, reasons for caution: Our study has several limitations, includ-
ing the fact that the groups were not evenly distributed, age differences, and the
BRCA status was not available for all breast cancer patients.
Wider implications of the ﬁndings: The suspected biological effect of aro-
matase inhibitors and increased intrafollicular androgens level reported in poor
responders is probably unique to that speciﬁc population and was not found in
apparently normal responders.
Trial registration number: 0163-16-RMC
P-501 Oocyte vitriﬁcation for elective Fertility preservation. An
excellent tool for fertility counseling
F. Lorenzo1, F. Macarena2, A. Valcarcel2, T. Caballero3, V. Taquini4,
E. Young4
1IFER, Reproduction, Buenes Aires, Argentina
2IFER, Embriologyst, Buenos Aires, Argentina
3IFER, Reproductive Medicine, Buenos Aires, Argentina
4IFER, Reproductive Medicine, Buenos Aires, Argentina
Study question: Is the number of oocytes obtained for vitriﬁcation in an elect-
ive fertility program a good tool for fertility counseling?
Summary answer: Our results show that vitriﬁcation of oocytes for elective
fertility preservation is an excellent tool to be use for fertility counseling.
What is known already: Vitriﬁcation has superior post-thaw survival and fer-
tilization outcomes compared with oocytes frozen with the slow-freeze tech-
nique.Oocyte vitriﬁcation is being offered to healthy women to extend their
reproductive options,providing similar results to fresh oocytes.Currently,
delayed maternity is most motivated by career aspiration, relationship
instability, breakdown and late marriage.Age is strongly related to the probabil-
ity of having a child with better chances when they do younger than 35,and
between 10-12 oocytes would be the ideal number to obtain good results in
terms of live birth rates and cost effectiveness.Obteining less oocytes than
expected make us provide an strict reproductive counseling.
Study design, size, duration: Retrospective study, September 2008 to
December 2017
Participants/materials, setting, methods: A total of 280 patients (37.4 ±
2,8 years), in 327 cycles, vitriﬁcated 1584 MII oocytes, All patients had normal
values of FSH, AHM and E2. The length of stimulation was 11.2 ( 10.1 12.3),
Mean FSH dose (IU) 1445.85(1408.5-1483.2), E2 on day of hcg (pg/ml) 1636
(1548.3-1725.4).
Main results and the role of chance: A total of 280 patients, vitriﬁcated
1584 MII oocytes, the mean age was 37 ± 2,8, ( <35 y: 45(16.07%), 35-37 y: 67
(23.92%), 38-40 y: 122 (43.57%), >40 y: 46(16.42%), E2 on day of hcg (pg/ml)
1636 (1548.3-1725.4) ( <35 y 1404 ± 1244, 35-37 y: 1479 ± 1074, 37-40
y:1209 ± 911, >40 y: 905 ± 674, Number of oocyte obtained/patient age: < 3:
87 ( < 35 y: 9, 35-37 y:19, 38-40 y: 37, >40: 22), 4-6: 87 (<35 y: 15, 35-37 y:
17, 38-40 y: 43, >40 y: 22), 7-10: 57( <35 y: 11, 35-37 y: 15, 38-40 y: 21, >40:
10), > 11: 49 (<35 y: 10, 35-37 y: 15, 38-40 y: 21, >40 y: 2).This retrospective
analysis, shows that the 67.5% of patients were between 35 and 40 years old,
even more the 43,57% were between 38 and 40 years old.The 62.14% of
patient vitriﬁed 6 oocytes or less, in patients younger than 35 years old 53,3%
vitriﬁed 6 or less oocytes (<3:9 patients,4-6:15 patients, 7-10:11 patients,
>11:10 patients).The probability of having a baby according to N*of oocytes
used is: oocytes/CLBR(95%CI) 5: 14.7 (6.2-23.1), 8: 30.9 (19.1-42.7), 10: 37.9
(24.9-51.0)
Limitations, reasons for caution: This is a retrospective study. Although
the size of our sample is small, our data provides useful information regarding
convenient reproductive counseling, even more when the amount of oocytes
obtained is less than expected.( empty follicles,poor response) with normal
values of serum estradiol at the day of HCG.
Wider implications of the ﬁndings: Oocyte vitriﬁcation is an efﬁcient tool
which can be helpful In women who delay child bearing,we should inform
women about their speciﬁc probabilities according to their age and number of
oocytes at vitriﬁcation,is important to counsel women that elective oocyte
cryopreservation can increase future reproductive chances but cannot guaran-
tee success.
Trial registration number:Not applicable.
P-503 Optimising ovarian stimulation protocol for oncology
patients
E. Yasmin1, E. Parker1, G.Williams1, S. Sheth2
1University College London Hospital, Women’s Health, London, United Kingdom
2UCLH, Women’s Health, London, United Kingdom
Study question: Do timing of start and dose of gonadotrophin stimulation
effect oocyte yield in oncology patients.
Summary answer: The timing of the start of stimulation in menstrual cycles
does not appear to affect oocyte yield but the starting dose does.
What is known already: Oocyte number is a good predictor of live birth
when using cryo-preserved oocytes. Time is of essence in oncology patients as
the ovarian stimulation cycle needs to be completed swiftly to enable oncology
treatment to commence without delay. This may make conventional early folli-
culr phase stimulations difﬁcult or incur time delay. There is concern about
oocyte yield in late follicular or luteal phase stimultion starts as it may affect
quality and number of eggs. There is also concern about using high dose of
gonadotrophin due to risk of OHSS.
Study design, size, duration: A retrospective analysis was carried out in 78
patients having 78 cycles having ovarian stimulation and oocyte collection for
fertility preservation prior to oncological treatment.
The study period was 2014-2017
Participants/materials, setting, methods: An analysis of 78 cycles was
performed.
Demographic characteristics like age and BMI were evaluated.
Ovarian reserve was assessed with AMH and AFC.
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Oncology diagnosis was taken.
Start time of stimulation, dose pf gonadotrophin used and number of oocytes
collefted were evaluated.
Any adverse events like OHSS or haemorrhage was noted.
Duration of treatment to oocyte collection was assessed.
All patients had antagonist cycles with agonist trigger.
The study was perfomed in a tertiary care reproductive medicine unit.
Main results and the role of chance: There were 8 late follicular and luteal
phase starts and 70 early follicular starts. An average of 13.75 (9-17) oocytes
were collected in the late follicular and luteal phase with an average of 10.25
metaphase 2 eggs. The average oocyte yield in the early follicular phase start
was 12.45 (2-31).
AMH of <5pmol/l was associated with a lower egg yield as expected (7.25).
AMH of <1 were noted in some of the pill users which did not affect oocyte
yield.
An analysis of oocyte yield with AMH>15pmol/l revealed fewer than 10
eggs when start dose of gonadotrophin was 150units. Average oocyte yield was
15 (11-30) with starting dose of 225-300 units in the same group. In an analysis
of 12 cases with an oocyte yield of <5neggs, 5 were in young women with
AMH >20pmol/l started on 150 units of gonadotrophin. There was no signiﬁ-
cant difference in oocyte yield between different diagnosis and no signiﬁcant dif-
ference in those patients who came to freeze oocytes after chemotherapy.
There were no cases with OHSS. Patients did not have to delay oncological
treatment in any case.
The late follicular/luteal phase start group was small and the absence of
effect could be due to chance.
Limitations, reasons for caution: The retrospective nature of the study
and low numbers are limitations.
Luteal phase starts need more numbers.
Wider implications of the ﬁndings: AMH is not lways reliabe as a measure
of ovarian reserve prior to fertility preservation.
Conventional stimulation protocols are not always suitable for oncology
patients.
Trial registration number: not applicable.
P-504 Long term cumulative rate of use of frozen sperm in cancer
patients
M. Reschini1, S. Ferrari1, C. Guarneri1, S. Noli2, A. Paffoni3,
E. Somigliana2
1Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Infertility Unit, Milano, Italy
2Università degli Studi di Milano, Department of Clinical Sciences and Community
Health, Milano, Italy
3ASST Lariana, Infertility Unit, Cantù, Italy
Study question: What is the long-term cumulative use rate of frozen sperm
in men who storage the semen before cancer therapies?
Summary answer: The cumulative usage rate is 11%.
What is known already: Cancer therapies are frequently aggressive and
unwanted side effects are common, including threats to fertility. Affected
patients should be aware of the risk of permanent infertility and on the possible
options for fertility preservation. Currently, the only way to efﬁciently preserve
the reproductive potential in men remains sperm cryopreservation. However,
the economical validity of this intervention has been questioned because of the
low rate of use. A recent review reported a mean percentage of use of only 8%.
Unfortunately, evidence on the long-term cumulative rate of use, which is far
more signiﬁcant than the crude rate, is scanty.
Study design, size, duration: The analysis includes all males cancer patients
who cryopreserved semen from 1986 to 2009 at the Infertility Unit of the
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan.
Information were obtained from patients’ charts. Moreover, men with incom-
plete information were actively contacted by phone and interviewed using a
standardized questionnaire.
Participants/materials, setting, methods: The analysis focussed on the
following information: age at semen preservation, semen parameters at the
time of preservation, oncological diagnosis, use of frozen samples and time of
use, duration of follow-up, disposal of samples and reasons for their removal.
Main results and the role of chance: We included 1524 cancer patients
cryopreserving at least one sperm sample. Most frequent classes of malignan-
cies among patients were testicular cancers (n = 660, 43%) and lymphatic-
haematological cancers (n = 651, 43%). Mean age at the time of sperm banking
was 30.0 ± 7.5 years (range, 14–66 years) and the median time from storage to
use or to the last follow-up was 12 years (range 0–28 years). Out of 1524
patients, 137 (9%) used their cryopreserved sperm sample to perform ART.
The cumulative rate of use for the whole cohort at 10 and 20 years follow-up
was 9% and 11%, respectively. We then evaluated predictive factors of use.
The Cox regression analysis identiﬁed two factors that were signiﬁcantly asso-
ciated with the chances of use: 1) age at the time of cryostorage (B = 1.033,
95%CI: 1.011-1.056, p = 0.003), and 2) cancer diagnosis (haematological ver-
sus testicular tumours B = 1.808, 95%CI: 1.234-2.648, p = 0.002; other diag-
noses versus testicular B = 1.675, 95%CI: 0.996-2.818, p = 0.052).
Limitations, reasons for caution: Duration of follow-up is insufﬁcient to
draw information regarding young adults. Distribution during the duration of
the program is unlikely to be uniform because interest in fertility preservation
has grown during the last two decades.
Wider implications of the ﬁndings: Using these data, the cumulative rate
of men banking and subsequently using their semen is 11%. On this basis, one
should claim in depth economical analyses to investigate the economical validity
of sperm banking programs in cancer male patients.
Trial registration number:Not applicable.
P-505 Comparison of conventional and random start ovarian
stimulation for fertility preservation in oncological patients
N. Jancar, E. Vrtacnik Bokal, I. Virant Klun, M. Stimpfel, L. Bacer
Kermavner, V. Salamun
University Medical Center Ljubljana, Department of Human Reproduction- Division of
Obstetrics and Gynecology, Ljubljana, Slovenia
Study question: To compare the number of retrieved oocytes in oncological
patients, when ovarian stimulation started in early follicular, late follicular or
luteal phase of menstrual cycle.
Summary answer: The number of retrieved oocytes was similar when the
ovarian stimulation was initiated in early follicular, late follicular or luteal phase
of the cycle.
What is known already: Chemotherapy and pelvic irradiation for malig-
nant or autoimmune disease have improved survival of patients but may
lead to premature ovarian failure and infertility. Therefore, young onco-
logical patients should be referred to Reproductive medicine subspecialist
for counselling and procedures to preserve their chances to be parents
with their own genetic material. With the usage of short antagonist proto-
cols the ovarian stimulation requires no important delay in systemic oncolo-
gic treatment.
Study design, size, duration:We included all women who were referred to
the Department of Human Reproduction of the Division of Obstetrics and
Gynecology of the University Medical Centre Ljubljana for fertility preservation
before gonadotoxic treatment from January 2013 to the end of December
2017.
Participants/materials, setting, methods: A total of 127 female patients
were referred to our Department for counselling in this period. Our
Department is the only one offering genetic material preservation for onco-
logical patients in Slovenia. If the time available for stimulation was > 1 month,
the ovarian stimulation started in early follicular phase, otherwise it was initiated
immediately or ovarian tissue cryopreservation was offered.
Main results and the role of chance: Out of 127 patients, 54 (42.5%)
had breast cancer, 36 (28.3%) had lymphoma, 7 (5.5%) had leukaemia, 7
(5.5%) had borderline ovarian tumour, 6 (4.7%) had autoimmune disease, 5
(3.9%) had sarcomas, 3 (2.4%) had colon cancer and 9 (7%) had other
rear malignant disease such as brain tumour, disgerminomas and vaginal
cancer. The median age of included women was 29 ± 2.3 years (range 3 to
43 years). In 41 (31.5%) patients we did not preserve any material due to
variety of reasons. In 67 (52.7%) patients oocytes were vitriﬁed, in 14
(11%) patients embryos were vitriﬁed, in 3 (2.4%) patients oocytes and
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embryos were vitriﬁed, in 6 (4.7%) patients ovarian tissue was cryopre-
served. When the stimulation started in early follicular phase (N = 58), the
mean number of retrieved oocytes was 10 (range 1-31 oocytes); 8.56
oocytes were mature at aspiration. With the start in late follicular phase
(N = 11) the mean number of oocytes was 11.3 (range 1-35 oocytes);
10.2 were mature at aspiration. With the start in luteal phase (N = 14) the
mean number of oocytes was 12.6 (range 1-30 oocytes); 9.6 oocytes were
mature at aspiration.
Limitations, reasons for caution: The majority of patients had breast can-
cer and time interval to the initiation of systemic treatment was 6 to 8 weeks.
Therefore, majority of patients had conventional start of stimulation in early fol-
licular phase. The number of patients in other two groups is quite small, so fur-
ther studies are needed.
Wider implications of the ﬁndings: It has already been published, that ran-
dom start stimulation can be used in oncological patients with good results.
Our study also showed that numbers of retrieved and numbers of mature
oocytes were similar when the ovarian stimulation was started in early follicular,
late follicular or luteal phase of menstrual cycle.
Trial registration number: not applicable.
P-506 Does oxygen tension inﬂuence in vitro maturation of human
oocytes in a fertility preservation program? Preliminary results of a
prospective auto-controlled study
M. Dahoun1, C. Herbemont1, N. Sermondade1, A. Seroka2,
B. Dagher-Hayeck2, M. Comtet2, C. Vinolas2, I. Cedrin-Durnerin2,
M. Grynberg2, C. Sifer1
1Hôpital Jean Verdier, Histologie-Embryologie-Cytogénétique-CECOS, bondy, France
2Hôpital Jean Verdier, Médecine de la reproduction, bondy, France
Study question: Are human oocyte (i) maturation rate (MR) and (ii) morpho-
logical score enhanced by low oxygen (O2) tension applied during in vitromatur-
ation (IVM) cycles?
Summary answer: Oocyte MR was similar whatever the O2 tension applied
during IVM, whereas morphologic Total Oocyte Score (TOS) was signiﬁcantly
higher under low oxygen tension.
What is known already: O2 tension within the mammalian female genital
tract is low, (2-8%), contrary to culture conditions applied in most of Assisted
Reproductive Technology laboratories (20%O2). Hypoxia might reduce oxida-
tive stress commonly triggered by atmospheric O2 tension, further allowing a
more physiological process. Besides, the latest recommendations state that
embryos should be cultured under hypoxia. However, several randomized
studies in mammals have reported controversial ﬁndings concerning in vitro MR
and subsequent embryo development when oocytes were matured under
either 5% O2 or atmospheric conditions. To date, no study has ever evaluated
the impact of O2 tension on human oocyte matured in vitro.
Study design, size, duration: prospective, observational, monocentric,
auto-controlled study on sibling oocytes was performed from November 2016
to July 2017. Fifty-nine patients candidates for fertility preservation (FP) using
vitriﬁcation of metaphase 2 (M2) oocytes from IVM cycles were included when
at least 2 cumulus-oocyte complexes (COCs) were retrieved. Each COC
cohort was randomly split into two equal groups: group 1=culture under 20%
O2; and group 2=culture under 5% O2.
Participants/materials, setting, methods: COCs were incubated for 48 h
using an appropriate media, in similar benchtop incubators (G-210, K-
Systems®), either under 5 or 20%O2. After 24 h and 48 h of culture, every
oocyte was assessed for maturity and morphology, using 6 parameters (shape,
size, ooplasm, perivitelline space, zona pellucida and polar body characteristics)
each graded as -1, 0 or +1, giving a TOS ranging from -6 to +6 (Lazzaroni-
Tealdi et al., 2015). MR and TOS were compared using paired-sample analysis.
Main results and the role of chance: We analyzed our preliminary data.
Brieﬂy, patients’ mean age was 30.6 years. Their mean serum AMH levels and
antral follicle count were 3.62 ng/mL and 33.2 follicles, respectively. On aver-
age, 13.13 COCs per cycle were retrieved, leading to 7.5 M2 oocytes vitriﬁed
(global MR = 58.01% (449 M2/774 COCs)). Respectively 383 and 391 COCs
were included in groups 1 and 2. In group 1 (20% O2), MR after 48 h of culture
yielded 56.14% of M2 oocytes (215/383), which was comparable to MR
achieved in group 2 (5% O2) (59.85%; 234/391; p = 0.21). Considering M2
oocyte morphology, the mean TOS was signiﬁcantly higher under low O2 ten-
sion (3.44 per oocyte in group 2 versus 3.16 in group 1; p = 0.014). Finally, a
subgroup analysis outlined a signiﬁcantly higher number of high-grade oocytes
(TOS ≥ 4) in group 2 than in group 1 (2.24 versus 1.64, respectively; p =
0.032).
Limitations, reasons for caution: This study, still in progress, needs to be
continued to clarify the impact of O2 tension on human IVM oocyte and their
morphology. Furthermore, analysis of subsequent warming cycles would com-
plete these data, in terms of survival, fertilization rates, embryo quality and clin-
ical outcomes according to IVM culture conditions.
Wider implications of the ﬁndings: Although these preliminary results
failed to highlight any increase in MR under hypoxia, oocyte morphology has
been improved. Therefore, further analysis is needed to investigate whether
oocyte maturation under 5% O2 increases the chances of pregnancy after
thawing.
Trial registration number:N° ID RCB: 2017-A02264-49
P-507 Spermatogonial quantities in untreated prepubertal cancer
patients are comparable to normative prepubertal spermatogonial
values
I. Masliukaite1, E. Ntemou2, M. Van deWetering3, A. Meißner1,
L. Kremer3, S. Repping1, K. Jahnukainen4,5, E. Goossens2,
A. Van Pelt1
1Academic Medical Center AMC, Center for Reproductive Medicine, Amsterdam,
The Netherlands
2Vrije Universiteit Brussel VUB, Biology of the Testis- Department of Reproduction-
Genetics and Regenerative Medicine, Brussels, Belgium
3Academic Medical Center AMC, Department of Pediatric Oncology- Emma
Children’s Hospital, Amsterdam, The Netherlands
4Karolinska Institutet and University Hospital, Department of Women’s and
Children’s Health- Pediatric Endocrinology Unit, Stockholm, Sweden
5University of Helsinki and Helsinki University Central Hospital, Children´s Hospital,
Helsinki, Finland
Study question: Does cancer affect spermatogonial quantity in the the testes
of prepubertal boys?
Summary answer: Spermatogonial quantities in prepubertal boys with hema-
tologic, solid cerebral, or solid extra-cerebral cancer were comparable to those
in healthy prepubertal boys.
What is known already: The incidence of pretreatment azoospermia in
adult men diagnosed with cancer is known to be ten-fold higher compared to
the general population, with the highest rates among hematologic and testicular
malignancies (9-13% and 10-15%, respectively). It has been hypothesized, that
such fertility impairments are caused by disease-related effects on the body,
including hormone and metabolic imbalances, and immune response. However,
no studies have thus far investigated the effect of different types of cancers on
the numbers of germ cells in prepubertal boys. If numbers are reduced, these
cancer survivors may face sub-/infertility without the possibility to use fertility
preservation treatments.
Study design, size, duration: In this study, we collected data on cancer diag-
nosis in 83 prepubertal boys, who underwent testicular biopsy for fertility pres-
ervation prior to cancer treatment between 2011 and 2017. We classiﬁed their
diagnoses into three cancer categories (hematologic, solid cerebral and solid
extra-cerebral) and examined histology of the testicular biopsies by immunohis-
tochemistry. Patients with the history of testicular torsion or cryptorchidism,
able to ejaculate spermatozoa, or with malignancies in the testes were excluded
from the study.
Participants/materials, setting, methods: Patient data were identiﬁed
through records of the Academic Medical Center in Amsterdam, the
Netherlands, and included patient age at the time of testicular biopsy and can-
cer diagnosis. A small part of the testicular biopsies were ﬁxed, parafﬁn embed-
ded, and labelled for MAGE-A4, a biomarker for human spermatogonia. The
amount of spermatogonia per tubular cross-section (S/T) was determined
using bright-ﬁeld microscopy and compared with the normative reference
values. Polynomial regression was used for data analysis.
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Main results and the role of chance: In the analyzed cohort of 83 pre-
pubertal boys diagnosed with cancer, median age at diagnosis was 9 years
(range 0.5-16 y). Altogether, 15.7%, 27.7%, and 56.6% of boys had hemato-
logic, solid cerebral, and solid extra-cerebral malignancy, respectively. The
average S/T in the total cohort was 4.4 (SD = 5.29), with 6.59 (SD =
7.34) in hematologic cancer, 3.10 (SD = 4.54) in solid cerebral cancer, and
4.43 (SD = 4.87) in solid extra-cerebral cancer patients. No signiﬁcant dif-
ferences or associations between S/T and cancer categories were found.
The amount of spermatogonia per tubular cross-section in all three patient
groups was within the range of the normative reference values for healthy
prepubertal boys.
Limitations, reasons for caution: These results should be interpreted in
the context of the small sample size per cancer category, as well as the high
variance between patients’ general health condition within each group.
Wider implications of the ﬁndings: Our data suggest, that in each cancer
category the size of the spermatogonial pool in prepubertal boys was compar-
able to the normative values. Therefore, all pediatric cancer patients who might
face high risk of spermatogonial depletion due to gonadotoxic treatment can be
referred for fertility preservation.
Trial registration number:Not applicable.
P-508 NewmiRNAs to evaluate ovarian reserve in patients with
breast cancer
S. El Moghrabi1, C. Decanter2, P. Pigny3, D. Haouzi1, S. Hamamah4
1Inserm U1203, Institut de Médecine Régénérative et Biothérapies IRMB- Hôpital
Saint Eloi- CHU Montpellier, Montpellier, France
2Service d’Assistance Médicale à la Procréation et de préservation de la fertilité-
Hôpital Jeanne de Flandre- CHRU Lille, EA 4308 Gamétogénèse et qualité du
gamète- Centre Hospitalier Universitaire de Lille, Lille, France
3Laboratoire de Biochimie Hormonologie HMNO- Centre de Biologie Pathologie-
CHRU Lille, Inserm- UMR-S 1172, Lille, France
4Service de Biologie de la Reproduction- Hôpital Arnaud de Villeneuve- CHU
Montpellier, ART/PGD Department, Montpellier, France
Study question: The aim of this study is to identify a new non invasive strat-
egy to evaluate the ovarian reserve in patients with breast cancer.
Summary answer:We found 4 deregulated miRNAs as a potential target for
fertility preservation in patients with breast cancer.
What is known already: Anti-Müllerian hormone (AMH) is a reliable quanti-
tative biomarker of the ovarian reserve, but not after chemotherapy treat-
ments. Indeed, young breast cancer patients have signiﬁcantly lower AMH after
chemotherapy than age-matched controls. In addition, AMH solely is not able
to determine the quality and the fertilization capacity of oocytes containing in
the resting follicles from patients who wish to conceive after breast cancer
treatment. Indeed, the necessity to quantify the ovarian reserve in patients after
chemotherapy treatment remains a major medical issue.
Study design, size, duration: 21 serum samples were obtained from three
breast cancer patients aged between 35 and 37 years old (mean age±SD: 35.7
± 1.1 years) with chemotherapy treatment. All patients were prospectively
recruited before initiation of the chemotherapy.
Participants/materials, setting, methods: Serum miRNAs and AMH
quantiﬁcation were performed at baseline, 15 days after and before the ﬁrst
chemotherapy treatment and every 3 months after the end of chemotherapy
until time + 18 months.
We used Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) that allows to
study a total of 178 miRNAs.
Main results and the role of chance: Our preliminary results revealed that
four miRNAs (miR144-5p, miR186-5p, miR34-5p and miR21-5p) were over-
expressed during chemotherapy treatment compared with both before and
after the chemotherapy treatment although these differences were not signiﬁ-
cant. Meanwhile, serum AMH concentration dramatically decreased 6 months
after chemotherapy treatment in breast cancer patients compared at baseline
measure (3 ± 0.03 vs 10.3 ± 3.5 ng/ml), and thus, until 18 months post-
treatment. One of these miRNAs, miR 21-5p was suggested to affect follicular
development. These four miRNAs could be a potential target for fertility pres-
ervation in patients with breast cancer.
Limitations, reasons for caution: This result is issue from few samples and
the study is in progress.
Wider implications of the ﬁndings: This ﬁnding opens new perspectives in
the patient care management of patients with breast cancer.
Trial registration number: CHACRY-1501.
P-509 A follow-up survey on the reproductive intentions and
experiences of women who underwent “social freezing” or elective
oocyte cryopreservation
A.Waﬁ, J. Nekkebroeck, C. Blockeel, N. De Munck, H. Tournaye,
M. De Vos
Universitair Ziekenhuis Brussel- Vrije Universiteit Brussel- Brussel- Belgium., Centre for
Reproductive Medicine, Brussel, Belgium
Study question: What are the reproductive attitudes and experiences in
women who previously underwent elective oocyte cryopreservation for antici-
pated gamete exhaustion (AGE)?
Summary answer:Women who previously underwent elective oocyte cryo-
preservation perceive fertility preservation as a useful procedure to enhance
the probability of motherhood.
What is known already: Elective oocyte cryopreservation is available to
women who prefer to or have to defer and delay motherhood until the right
time or the right partner arrives. A previous survey has shown that women are
highly satisﬁed with their decision to cryopreserve oocytes. However, follow-
up data documenting their reproductive outcomes, and their beliefs and expec-
tations regarding the utilisation of cryopreserved oocytes are limited.
Study design, size, duration: Cross-sectional Survey.
Participants/materials, setting, methods: Women who had stored
oocytes in a tertiary university-based fertility clinic between January 2009 and
September 2016 were invited to complete an anonymous questionnaire about
their reproductive intentions and expériences.
Main results and the role of chance: Of the 342 potential respondents,
138 (40.3%) returned completed questionnaires. The average age of respon-
dents was 40.2 y and the reported age at ﬁrst cycle of cryopreservation was
35.8 y. Eighty-three % had been single when they underwent oocyte cryo-
preservation while 44% of respondents still were. Almost two-thirds (65%)
anticipated to use their cryopreserved oocytes and were planning to do so
before the age of 45 y (range 38-55 y). Sixty-six respondents (48%) had already
tried to achieve a pregnancy, of which 69% had succeeded (79% spontaneously
and 21% using their cryopreserved oocytes). Sixty-ﬁve percent would consider
adoption, whereas only 31,4% would turn to oocyte donation if they failed to
become pregnant with their vitriﬁed oocytes. When asked if they would ever
consider to remain childless 50.4% answered yes.
Limitations, reasons for caution: The results of this survey may have been
biased by the limited response rate and potential misinterpretation of ques-
tions. National and international registries of larger numbers of women who
undergo elective oocyte cryopreservation as a prevention for age-related fertil-
ity decline would offer the best prospect of generating wide-reaching qualitative
data.
Wider implications of the ﬁndings: After a mean follow-up of four years,
“past social freezers” report an overall high degree of satisfaction with their pre-
vious decision. Even if only a subset achieved a pregnancy using these vitriﬁed
oocytes so far, the majority of respondents still have the intention to use their
oocytes to realise motherhood.
Trial registration number:Not applicable.
P-510 Professionals’ barriers in female oncofertility care and
strategies for improvement
M. Van den Berg1, Ö. Baysal1, I. Beerendonk1, D. Braat1,W. Nelen1,
R. Hermens2
1Radboud University Medical Centre, Obstetrics and Gynaecology, Nijmegen, The
Netherlands
2Radboud University Medical Centre, IQ Healthcare, Nijmegen, The Netherlands
Study question:What are Dutch healthcare professionals’ barriers and strat-
egies for improvement in female oncofertility care?
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Summary answer: Professionals particularly perceive barriers in knowledge,
attitude and organization towards fertility preservation and are open to
improve oncofertility care.
What is known already:One of the most important undesirable side effects
of cancer treatment in young women is the potential loss of fertility. Guidelines
recommend to discuss the potential loss of fertility with all female cancer
patients and, if desired, offer a referral to and counseling by a fertility specialist.
Unfortunately, studies have shown that not all patients receive information on
their fertility risks and options to preserve fertility and only a small proportion
of these women is referred. A study on barriers for discussing fertility preserva-
tion and appropriate referral in a country with structural reimbursement has
not yet been performed.
Study design, size, duration: Semi-structured in depth interviews were con-
ducted with a total of 24 healthcare professionals. Thereafter, a selection of
improvement strategies was performed with an expert panel consisting of
patients and healthcare professionals to overcome these barriers.
Participants/materials, setting, methods: Oncological professionals
working in Dutch female oncofertility care were recruited out of the three
Dutch expertise hospitals for female fertility preservation and their afﬁliated
hospitals. In the Dutch setting ﬁnancial aspects do not play a role in oncofertility
care. Professionals were asked for their barriers and improvement suggestions
in individual interviews. A meeting with an expert panel was held to select
improvement strategies and reach consensus on an oncofertility program.
Main results and the role of chance: In total 31 barriers and 23 facilitators
were identiﬁed. Barriers have been revealed distributed over three domains;
patient, professional and organization. On the patients’ domain a focus on sur-
viving cancer and starting treatment and not a focus on their fertility have been
identiﬁed as barriers. On the professionals’ domain a lack of awareness and a
lack of knowledge, and on the organization domain no written information avail-
able, no time and FP is not discussed at multidisciplinary meetings have been
identiﬁed as main barriers. The expert panel selected different strategies to
improve oncofertility care. These include provision of written and online infor-
mation, education of professionals, reminders for professionals, fertility should
be a standard discussion item on the agenda of multidisciplinary oncology meet-
ings and specialized oncology nurses should play a role in informing patients in
oncofertility care and patient navigators at the fertility department to facilitate
referral and counseling.
Limitations, reasons for caution: Selection bias could have occurred
because it is likely that only professionals who are interested in oncofertility
care were willing to participate. However this means that we underestimated
the barriers.
Wider implications of the ﬁndings: This study was a preview for a multifa-
ceted oncofertility program which should be developed in order to increase
adherence to the national clinical guideline.
Trial registration number:Not applicable.
P-511 IVM before vitriﬁcation induces alterations of maturation
rates and deleterious effects on actin and tubulin architecture of
human oocytes
A. Metchat, H. Pons-Rejraji, S. Vorilhon, S. Mestres, S. Lusho,
L. Chaput, S. Dollet, A.S. Grémeau, J.L. Pouly, F. Brugnon
Université Clermont Auvergne-CHU Clermont-Ferrand, Biologie de la Reproduction-
AMP-CECOS, Clermont-Ferrand, France
Study question: Is it better to vitrify oocytes before or after in vitro
maturation?
Summary answer: Since we observed alterations of maturation and deleteri-
ous effects on actin and tubulin architecture in oocytes vitriﬁed before IVM,
IVM should be performed before vitriﬁcation.
What is known already: Human oocyte cryopreservation is routinely used
for fertility preservation of women who will be exposed to gonadotoxic treat-
ments. After ovarian stimulation, matured oocytes are vitriﬁed. However, this
strategy cannot always be used, particularly for hormone-sensitive cancer or
when ovarian stimulation is not possible. An approach including immature
oocytes and in vitro maturation (IVM) could be considered in these cases.
While some qualitative analyses of oocytes vitriﬁed before or after IVM suggest
that vitriﬁcation should be performed after IVM, little is known about vitriﬁca-
tion effects on actin and tubulin cytoskeleton and on maturation of human
oocytes.
Study design, size, duration: To answer to this question, we performed
quantitative analyses comparing matured oocytes from three different groups:
(i) oocytes vitriﬁed before IVM, (ii) oocytes vitriﬁed after IVM, and (iii) fresh
immature oocytes. Non-vitriﬁed (fresh) in vitro matured oocytes were used as
controls. Kinetic of maturation and subcellular structures were analysed during
maturation and in matured oocytes. 160 immature oocytes were collected
from women without ovulation troubles from March 2017 to January 2018.
Participants/materials, setting, methods: A total of 160 immature
oocytes were collected from 63 patients (≤37 years old, without ovulatory dis-
eases) who underwent ICSI. Oocytes were matured in vitro with IVM medium
(Origio) for 36 hours and vitriﬁed in a closed system, Rapidi with RapidVit
Omni and RapidWarm Omni (Vitrolife). Kinetics of maturation were analysed
by PrimovisionTM (Vitrolife). The actin and spindle organisation were studied by
immunostaining techniques, confocal microscopy (Leica SP6), and quantitative
analyses (Imaris® and Fiji).
Main results and the role of chance: While the kinetics of maturation
were similar for oocytes vitriﬁed before or after IVM (17:27 before IVM versus
17:53 after IVM; p>0.05; h:min), a lower rate of oocytes vitriﬁed before IVM
extruded polar body (78% after IVM versus 56% before IVM, p = 0.003). Then,
the cytoskeletal organisation of matured oocytes vitriﬁed before or after IVM
was quantitatively analysed. Using biophysical methods, our analysis revealed
that spindle length and shape were signiﬁcantly altered in oocytes vitriﬁed
before IVM, while oocytes vitriﬁed after IVM appeared normal compared with
fresh oocytes. By high-resolution imaging, we characterised for the ﬁrst time the
actin organization in human matured oocytes. Actin exhibits a complex organ-
isation with a dense cytoplasmic network and cortical actin. Cortical actin thick-
ness and actin ﬁlament lengths were measured in both conditions. Our results
showed that the cortical actin thickness was signiﬁcantly higher in oocytes vitri-
ﬁed before IVM compared with fresh oocytes; while it was not affected in
oocytes vitriﬁed after IVM. Analysis of actin ﬁlaments indicated that the average
of ﬁlament lengths diminished similarly in both conditions compared with fresh
oocytes. All these alterations observed in oocytes vitriﬁed before IVM suggests
that IVM should be performed before vitriﬁcation.
Limitations, reasons for caution: Since, we used oocytes from women
without cancer; our data should be completed with an analysis of the effect of
vitriﬁcation combined with IVM in oocytes from women diagnosed with a can-
cer. Moreover, homologous chromosome segregation during the ﬁrst meiotic
division should be investigated in order to detect aneuploidy.
Wider implications of the ﬁndings: Our preliminary data shows clearly
that IVM should be performed before vitriﬁcation. After chromosome segrega-
tion analysis and validation on immature ovocytes from women with cancer,
the protocol that we provide here, will be applied, with immature oocytes for
fertility preservation.
Trial registration number: Clinical trial registration: NCT03416400.
P-512 Assessment of a sensitive and speciﬁc method to detect
Ewing sarcomaminimal residual disease in testicular and ovarian
tissue by RT-qPCR
L. Chaput1, V. Grèze2, P. Halle3, A. Tchirkov4, L. Véronèse4,
N. Robin5, B. Pereira6, H. Lejeune7, P. Durand8, G. Martin8,
A.S. Grémeau1, M. Canis1, F. Brugnon1
1CHU Clermont-Ferrand- Site Estaing, Biologie et Médecine de la Reproduction-
AMP-CECOS, Clermont-Ferrand, France
2CHU Clermont-Ferrand- Site Estaing, Service d’Hématologie et d’Oncologie
Pédiatrique, Clermont-Ferrand, France
3CHU Clermont-Ferrand- Site Estaing, Centre de Biothérapie d’Auvergne, Clermont-
Ferrand, France
4CHU Clermont-Ferrand- Site Estaing, Service de Cytogénétique Médicale, Clermont-
Ferrand, France
5Centre Jean Perrin CLCC de la région Auvergne, LBM OncoGènAuvergne- Unité
Pathologie, Clermont Ferrand, France
6CHU Clermont Ferrand, Unité de Biostatistiques- Délégation à la Recherche Clinique
et l’Innovation, Clermont Ferrand, France
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7CHU Lyon Hôpital Femme Mère Enfant, Service de Médecine de la Reproduction,
Lyon, France
8Ecole Normale Supérieure de Lyon, Kallistem, Lyon, France
Study question: The aim of this study was to assess the sensitivity and speciﬁ-
city method to detect Ewing sarcoma minimal residual disease in human germi-
nal tissue.
Summary answer: The detection of EWS-FLI1 (RT-qPCR) enables sensitive
and speciﬁc detection of Ewing sarcoma cells which may be contained in frozen
germinal tissues for fertility preservation.
What is known already: Ewing sarcoma is a frequent solid tumor in children
with high metastatic potential and high risk of infertility due to the potential
toxic treatments for reproductive functions. Since the high survival rate of
patients and deleterious effects of intensive chemotherapy, the cryopreserva-
tion of ovarian tissue or testicular tissue is recommended. However the risk to
reintroduce cancer cells should be evaluated to ensure safety of fertility restor-
ation with these tissues. The assessment of this minimal residual disease could
be performed with frozen tissues by slow freezing or immediately after tissue
collections by snap freezing.
Study design, size, duration: Ovarian tissues (OT) and testicular tissues
(TT) were frozen (slow and snap freezing). After thawing, each fragment was
contaminated with increasing amount of human Ewing sarcoma cells (RD-ES).
The expression of EWS-FLI1 mRNA was measured. To evaluate the invasive
potential of RD-ES cells, cocultures (OT or TT / RD-ES cells) were performed.
OT and TT from metastatic patients were analyzed once the high sensitivity
and speciﬁcity of the detection method by RT-qPCR was demonstrated.
Participants/materials, setting, methods: OT: women with ovarian cyst
(n = 12). TT: Non-obstructive azoospermia men (n = 14).
Tissues were frozen (slow/snap freezing). After thawing, they were contami-
nated with RD-ES cells (10, 100, 1000 cells). The expression of EWS-FLI1 was
quantiﬁed by RT-qPCR. The invasive potential of RD-ES cells was evaluated by
cocultures and RT-qPCR, FISH and immunochemistry. Minimal residual disease
was assessed in OT and TT of children with Ewing sarcoma once the efﬁciency
of our in vitromodel was demonstrated.
Main results and the role of chance: Yields of RNA extraction from OT
(median weight: 39.2 mg [15.2 – 62.0]) and TT (median weight: 28.8mg [16.6 –
48.0]) did not differ between slow or snap freezing (p = 0.54) method. The expres-
sion of EWS-FLI1 transcript was positive in OT and TT samples contaminated with
10, 100 and 1000 RD-ES cells and was negative in uncontaminated samples. There
was a strong correlation between the amount of RD-ES cells and the expression of
EWS-FLI1 mRNA (OT: r = 0.93 and TT: r = 0.96 with p < 0.001) whatever freezing
method. The sensitivity and speciﬁcity to detect the expression of EWS-FLI1 tran-
script by our method was respectively 97% IC 95% [0.92-1.00] for OT and 99% IC
95% [0.98-1.00] for TT. After cocultures, we observed in germinal tissues the pres-
ence of Ewing cells by standard histology (HES coloration) and by immunohisto-
chemistry with a diffuse nuclear pattern of ERG staining. Moreover, the expression
of EWS-FLI1 mRNA (qPCR) and the expression of t(11;22)(FISH) were clearly
shown in the germinal tissues after cocultures. In OT and TT from children with
Ewing sarcoma, we did not detect the expression of EWS-FLI1 mRNA and did not
observe Ewing cells by the histology methods.
Limitations, reasons for caution: The assessment of the method was per-
formed by an in vitromodel. An in vivomodel by xenografting could be necessary
to ensure the accuracy.
Wider implications of the ﬁndings: By our study, we demonstrated the
high sensitivity and speciﬁcity of RT-qPCR to detect Ewing sarcoma minimal
residual disease in human testicular tissue (TT) and ovarian tissue frozen by
snap or slow freezing for fertility preservation. This is the ﬁrst study to assess
this measurement in TT.
Trial registration number: Clinical trial: NCT 02400970.
P-513 Texture proﬁle analysis reveals a stiffer ovarian cortex after
testosterone therapy
C. De Roo1, K. Tilleman1, C. Vercruysse2, H. Declercq2, G. T’Sjoen3,
S.Weyers1, P. De Sutter1
1University Hospital Ghent UZ, Division of Reproductive Medicine- Department of
Gynaecology, Ghent, Belgium
2Ghent University, Bioprint Core Facility- Tissue Engineering and Biomaterials,
Department of Basic Medical Science- Faculty of Medicine and Health Science,
Ghent, Belgium
3Ghent University Hospital, Department of Endocrinology and Center for Sexology
and Gender, Ghent, Belgium
Study question: Does prolonged testosterone administration induce stiffness
in the ovarian cortex?
Summary answer: An increased cortical stiffness in the most outer part of
the ovarian cortex could be documented following prolonged testosterone
administration in trans men.
What is known already: The importance of ovarian stroma in the develop-
ment and maturation of follicles has recently gained attention. The ovarian stro-
ma does not only contribute to the structural support of the growing follicle,
but also to the bidirectional paracrine communication between the oocyte and
surrounding somatic cells, thereby inﬂuencing folliculogenesis. An aberrant
extracellular matrix has been described in ovaries of patients with polycystic
ovary syndrome (PCOS) where a more rigid structural environment, possibly
induced by endogenous testosterone, impairs normal folliculogenesis. In this
context, the effect of prolonged administration of testosterone on the ovarian
cortex in female to male transgender persons was studied.
Study design, size, duration: Texture proﬁle analysis (TPA) was performed
on ovarian cortex of oncological (N = 3) and transgender patients (N = 3). A
total of 34 frozen-thawed cortical strips (5 × 5 mm,) were subjected to TPA in
order to measure stiffness, hardness, cohesiveness and springiness of the ovar-
ian cortex (LRXplus universal testing system). Statistical analysis was performed
using repeated measurements mixed models and the Spearman’s rank order
correlation test (IBM SPSS Statistics 23).
Participants/materials, setting, methods: Ovarian tissue was obtained of
3 oncology patients (25.00 + 3.61 years) (11 strips) and 3 transgender men
(22.67 + 2.08 years) (23 strips). Oncological indications for fertility preservation
comprised acute lymphoblastic lymphoma, breast cancer and acute myeloid leu-
kemia. All trans men received intramuscular testosterone undecanoate 1000mg
every 12 weeks during 80.72 + 32.24 weeks. Cortical strips were compressed
over a distance of 50% of the original sample thickness during 2 cycles.
Main results and the role of chance: A typical TPA double compression
curve of ovarian cortex is characterized by a slower upstroke in the toe region,
where increasing compression resulted in a steeper upstroke prior to the peak.
Release of the maximum compression causes an immediate drop in the TPA curve.
Typically a bigger ﬁrst curve was noted, when compared to the second curve (Peak 2
< Peak 1), reﬂecting an incomplete recovery of the tissue post compression, prob-
ably as a result from the breaking points seen in the ﬁrst upstroke. There was no dif-
ference in fragment thickness comparing tissue fragments originating from
transgender (1.43 + 0.46mm) and oncology (1.38 + 0.38mm) patients (p = 0.826).
The most outer part of cortex fragments of ovaries originating from transgender per-
sons (fragments < 1.4mm; N = 10) were signiﬁcantly stiffer compared to the super-
ﬁcial area of ovarian cortex derived from oncology patients (N = 7) (p = 0.036).
Limitations, reasons for caution: TPA is applied in biomaterial industry to
determine textural properties of foods, gels and pharmaceutical matrices. This
is the ﬁrst application of TPA in ovarian tissue, requiring optimization of the
compression protocol. Future experiences in TPA on human tissue samples
might contribute to optimization and lead to a standardized setup.
Wider implications of the ﬁndings: If increased cortical stiffness impairs folli-
culogenesis, it is advisable to interrupt testosterone prior to fertility preservation.
Also, if aiming for in vitro follicle activation through Hippo signaling disruption, an
adapted technique for tissue preparation is necessary. Last, these TPA parameters
enable to optimize biomaterial characteristics in artiﬁcial ovary engineering.
Trial registration number: UZ Ghent reference: 2012/780 – Belgian regis-
tration number: B670201 21 5468
P-514 Controlled ovarian stimulation applied before ovarian
cortex cryopreservation does not impact tissue histological aspect
V. Puy1, M. Bendayan1, A. Mayeur1, L. Hesters1, S. Prevot2,
M. Grynberg3, N. Frydman1
1University hospital Antoine-Béclère- AP-HP, Reproductive Biology Unit, Clamart,
France
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2University hospital Antoine-Béclère- AP-HP, Pathology, Clamart, France
3University hospital Antoine-Béclère- AP-HP, Reproductive medecine & fertility
preservation, Clamart, France
Study question: Is there an impact of controlled ovarian stimulation (COS)
on the histological aspect of ovarian tissue cryopreserved for fertility preserva-
tion (FP)?
Summary answer: COS applied before ovarian tissue cryopreservation
(OTC) allows optimizing the number of metaphase 2 oocytes vitriﬁed when
compared with IVM, without detrimental histological effect.
What is known already: Vitriﬁcation of in vitro matured oocytes (IVM) has
been proposed in combination with OTC as a method for urgent female fertility
preservation. However, both IVM and ovarian tissue transplantation remains
experimental contrary to oocytes vitriﬁcation following COS. When COS is feas-
ible in contexts of highly gonadotoxic treatment, vitriﬁcation of in vivo matured
oocytes may be considered before OTC. However, the impact of ovarian stimu-
lation on histological aspects of the ovary has never been described.
Study design, size, duration: This observational retrospective study con-
ducted from 2009 to 2016 aimed to compare the histological aspect of ovarian
tissue removed on the day of oocyte retrieval performed on stimulated (group
1, n = 13) or unstimulated (group 2, n = 12) ovaries. The number of metaphase
2 oocytes vitriﬁed was also analyzed in both groups.
Participants/materials, setting, methods: Twenty-ﬁve cancer patients
referred in our center for OTC before highly gonadotoxic chemotherapy were
prospectively studied. Ovarian tissue was removed laparoscopically immedi-
ately after oocyte retrieval. The latter was performed after COS when feasible
or from unstimulated small antral follicles. A sample of ovarian tissue was sys-
tematically addressed for pathological analysis.
Main results and the role of chance: Patient’s age was similar between
groups 1 and 2 (24.0 ± 6.2 versus 27.4 ± 6.3 respectively; p = 0.18). Histological
aspects of ovarian tissue as well as the number of primordial follicles per mm2
were similar between both groups. The total number of cumulus-oocyte com-
plexes (COC) obtained in group 1 was 155 (mean 11.9 ± 5.7) and 122 (mean
8.6 ± 7.8) were vitriﬁed. In group 2, 103 COCs were recovered (mean 9.4 ±
4.4), leading to 66 vitriﬁed oocytes (5.5 ± 6.2) after an IVM rate of 64%.
Limitations, reasons for caution: Although our preliminary results are
reassuring, histological data after thawing and further outcome after transplant-
ation are lacking.
Wider implications of the ﬁndings: The competence of frozen-thawed
ovarian tissue removed following COS constitutes an important issue. If it
remains intact, oocytes vitriﬁcation after ovarian stimulation will have to be sys-
tematically considered before OTC, since this method is dramatically superior
to IVM in terms of chances of pregnancy.
Trial registration number:Not required.
P-515 Dual In Vitro Maturation (Dual-IVM): an innovative fertility
preservation strategy to increase the total number of cryopreserved
oocytes when ovarian stimulation is unfeasible
N. Sermondade1, C. Sonigo2, C. Valdelièvre2, M. Comtet2, C. Sifer1,
M. Grynberg2
1Hôpital Jean Verdier, Histologie-Embryologie-Biologie de la Reproduction-CECOS,
Bondy, France
2Hôpital Jean Verdier, Médecine de la Reproduction et Préservation de la Fertilité,
Bondy, France
Study question: Is it feasible to perform within a short time frame two suc-
cessive immature oocyte retrievals for fertility preservation (FP), especially dur-
ing the same menstrual cycle?
Summary answer: Dual-IVM can be performed within a few days of interval
to increase the total number of mature oocytes cryopreserved for urgent FP.
What is known already: Oocyte vitriﬁcation after IVM may constitute an
alternative option for FP when controlled ovarian stimulation (COS) is unfeas-
ible. Recent data reported that 8 to 20 cryopreserved oocytes are required to
achieve reasonable success in healthy women. Since the competence of IVM
oocytes is unknown, it is likely that the number of oocytes needed to obtain a
pregnancy would be higher than that after COS. Combination with OTC has
been proposed as an option to improve FP effectiveness. However, in women
rejecting OTC, the strategy to be adopted for increasing the total number of
cryopreserved oocytes can be questioned.
Study design, size, duration: Eighteen breast cancer patients, candidates
for FP and presenting contraindication to COS for oncologic reasons, were pro-
spectively included. All were offered ovarian tissue cryopreservation (OTC)
combined with oocyte vitriﬁcation following IVM, and chose IVM only. They
were systematically advised on reconsidering OTC and on the possibility of a
second IVM cycle (IVM2), if these procedures did not require chemotherapy
postponement.
Participants/materials, setting, methods: We hereby report a case-
series of 18 breast cancer patients having undergone 2 successive cycles of IVM
before initiation of chemotherapy. Cumulus-oocyte complexes (COC) were
recovered under ultrasound guidance, and incubated 24-48 hours for IVM.
Metaphase II oocytes were vitriﬁed. When OTC was associated with IVM2,
transvaginal oocyte retrieval was performed prior to laparoscopy. Outcomes of
ﬁrst and second IVM cycles (IVM1 and IVM2) were compared using Wilcoxon
matched-paired signed rank test.
Main results and the role of chance: Median time interval between both
IVM cycles was 24.5 days (ranging from 3 to 92 days). The mean number of
COCs retrieved did not differ signiﬁcantly between IVM1 and IVM2 (6.7 ± 2.9 vs.
7.1 ± 5.4 oocytes, respectively, NS). Maturation rates were not different (62 ±
23 % vs. 51 ± 34%, NS), leading to a similar number of metaphase II oocytes
cryopreserved during IVM1 and IVM2 cycles (3.8 ± 2.6 vs. 4.0 ± 4.2, respectively,
NS). IVM2 outcomes did not differ when it was performed during the same (n =
11/18) or different (n = 7/18) menstrual cycle than IVM1. No complication was
reported during IVM1 or IVM2. Finally, performing IVM1 + IVM2 signiﬁcantly
increased the total number of oocytes vitriﬁed per patient when compared with
IVM1 alone (7.7 ± 5.7 vs. 3.8 ± 2.6, respectively, p < 0.001).
Limitations, reasons for caution: This study was conducted in a limited
number of patients and further analysis will be required to conﬁrm our prelimin-
ary results. In addition, the outcome of in vitro matured oocyte after thawing
remains unknown.
Wider implications of the ﬁndings: Threshold values of cryopreserved
IVM oocytes to achieve a live birth should be deﬁned in order to assess the rele-
vance of iterative oocyte collections.
Trial registration number:N/A.
P-516 Are Adolescents and young adults lymphoma patients less
susceptible to chemotherapy than patients over 25 years old?
Results of systematic prospective AMH levels follow-up
J. Bertrand-Delepine1, G. Robin2, D. Dewailly2, F. Morschhauser3,
P. Pigny4, C. Decanter2
1Hopital Jeanne de Flandre, Service de Médecine de la Reproduction et de
Préservation de la fertilité, Lille, France
2University Hospital, Reproductive Medicine Center and Fertility Preservation, Lille,
France
3University Hospital, Department of hematology, Lille, France
4University Hospital, Laboratory of endocrinology- Parc Eurasanté, Lille, France
Study question: To prospectively evaluate the inﬂuence of age and chemo-
therapy regimen on the longitudinal blood AMH variations in young lymphoma
patients to elaborate fertility preservation strategies.
Summary answer: Adolescents and young adults (AYA) (15-24 years old)
are less susceptible to chemotherapy than non-AYA (25-35 years old) even in
case of alkylating regimen.
What is known already: Anti-Müllerian hormone (AMH) is now well-
recognized to be a real-time indicator of growing follicle depletion and recovery
in women treated by chemotherapy. Its longitudinal variations may discriminate
between strong and soft protocol regarding the ovarian toxicity. It has been
shown, mainly in breast cancer patients, that age, type of chemotherapy regi-
men and pre-treatment AMH levels are the main predictor of the ovarian
recovery. Data on lymphoma are scarce but gives the opportunity to investigate
the longitudinal AMH variations under chemotherapy at a younger age than
breast cancer patients.
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Study design, size, duration: Prospective monocentric observational study in
the Fertility Observatory of the Lille University Hospital. Data were collected
between 2007 and 2014. Non-Hodgkin or Hodgkin lymphoma patients (n = 122)
between 15 to 35 years old were prospectively recruited before commencing
chemotherapy. Patients were treated either by a non-alkylating protocol (non-
alkylating group, ABVD; n = 67) or by an alkylating one (alkylating group; n = 55)P.
Participants/materials, setting, methods: Serial AMH measurements
were performed at baseline (AMH0), 15 days after the start of chemotherapy
(AMH1), 15 days before the last cycle (AMH2) and every 3 months from the
end of chemotherapy until time + 24 months.
AMH variations were studied by ANOVA in the overall population according
to the chemotherapy protocol. Then the study population was divided into 2
groups according to age: 65 AYA and 57 non-AYA.
Main results and the role of chance: Ovarian recovery in the non-
alkylating group was complete and fast whereas no patients in the alkylating
group recovered their initial pre-treatment value. There was no difference
between the AYA and non-AYA groups regarding AMH 0 and the pattern of
follicular depletion.
During the recovery phase, AMH levels re-increased more rapidly in the
AYA group than non-AYA-group.
In AYA-group, the recovery phase is very fast and complete in non-alkylating
group but progressive and partial in alkylating group. Only AMH+12 and AMH
+24 were statistically different from AMH2 and all the serum AMH levels after
chemotherapy remained different from AMH0 (p<0,0001).
In the non-AYA-group, the recovery phase is more progressive in the non-
alkylating group. In alkylating group, serum AMH levels after chemotherapy
remain low and not statistically different from AMH2.
AYA and non-AYA patients who received an alkylating protocol never recov-
ered pre-treatment AMH values unlike those treated by a non-alkylating one.
AYA patients treated by alkylating protocol highlighted higher levels of AMH
during the recovery phase than non-AYA patients.
Limitations, reasons for caution: Large disparity in chemotherapy proto-
cols in the alkylating group. The average duration of chemotherapy for patients
treated with alkylating protocol was longer than treated with non-alkylating
protocol.
Wider implications of the ﬁndings: These results allow for the ﬁrst time
developing evidence-based strategies for fertility preservation according to age
and type of protocol in a large series of young lymphoma patients.
Trial registration number:DEC2015-112 and DC-2008-642
P-517 Identiﬁcation and efﬁciency assessment of potential
miRNAs targets for developing new pharmacological drugs against
chemotherapy induced ovarian damage using mice model
C. Alexandri1, I. Demeestere2, B. Stamatopoulos3, F. Rothe4
1University Hospital Erasme, Research laboratory in human reproduction, Brussel,
Belgium
2Université Libre de Bruxelles- Belgium- Hospital Erasme, Research Laboratory in
Human Reproduction, Brussels, Belgium
3Université Libre de Bruxelles- Belgium, Laboratory of Clinical Cell Therapy, Brussels,
Belgium
4Université Libre de Bruxelles- Belgium, Heuson Breast Cancer Translational
Research Laboratory, Brussels, Belgium
Study question: Can miRNA replacement approaches be used to develop a
new adjuvant protective therapy to reduce chemotherapy induced ovarian
damage?
Summary answer: Amongst several identiﬁed miRNAs that rapidly response
to chemotherapy exposure, replacement of the selected miRNA, let-7a is feas-
ible and efﬁcient to reduce chemotherapy-induced ovarian damage.
What is known already: Cancer treatments as cyclophosphamide and its
active metabolite, 4- hydroxycyclophosphamide can cause primordial follicle
activation, apoptosis and ovarian reserve depletion. As these therapies nega-
tively inﬂuence the ovarian function, fertility preservation is recommended.
Today, several miRNA-based therapeutics have reached clinical trials, in oncol-
ogy landscape. Several studies also indicate that miRNAs have a key role in fol-
licle development as they can regulate the follicular growth, atresia and
steroidogenesis. Last, miRNAs are involved in DNA-damage response, apop-
tosis and they can be themselves modulated during chemotherapy exposure
which contributes to minimize the off-target toxicity.
Study design, size, duration: Postnatal day 3 ovaries (PND3) from
C57blxCBAF1 hybrid mice were cultured under control and treated conditions-
exposed to 4-hydroxycyclophosphamide (4-HC, 20μΜ, 1 or 24 h). Six ovarian
samples (3/condition) were used for the miRNA expression proﬁling while 20
and 24 samples were used for the validation of miRNA levels after 1 and 24 h
exposure to 4-HC respectively. Forty ovarian samples were used in mimic
transfection experiments (10/condition: control, control with mimic-miRNA-
transfected, 4-HC alone, 4-HC with mimic-miRNA-transfected).
Participants/materials, setting, methods: TaqMan Low Density Arrays
were used for miRNA expression proﬁling. Custom Cards and QPCR -assays
validated the differently expressed miRNAs. A functional annotation clustering
was performed on DAVID database. A liposome-based system was used to
deliver selected mimic-let7a into ovaries. After 48 h of mimic-transfection (plus
1 h exposure to 4-HC in treated samples), the efﬁciency was conﬁrmed by
ﬂuorescence microscopy. The expression of the target genes was evaluated by
QPCR. The apoptosis was also assessed.
Main results and the role of chance: The expression proﬁling of 384
miRNas in PND3 ovaries, revealed that miRNAs are differently expressed after
chemotherapy exposure. Amongst 245 expressed genes, 74 stayed stable, 81
were upregulated and 40 downregulated after 1 h/4-HC/20 μM exposure. A set
of these miRNas was selected for further validation. We found that mir-10a-5p,
mir-146a-5p, mir-34a-5p, miR-494 and let-7a were signiﬁcantly expressed. Then,
we chose to focus on miR-10a and let-7a because they presented a stable and
profound downregulated proﬁle in all miRNA proﬁling assays. Moreover, their
target genes are involved in DNA damage response, apoptosis and cell prolifer-
ation, based on functional annotation clustering results. As the let-7a is downre-
gulated, we used a liposome-based system to deliver a mimic-let7a in PND3
ovaries in vitro. We evaluated the safety and efﬁciency of this transfection system
and we found that we can successfully deliver the mimic-miRNA without causing
signiﬁcant apoptosis in the ovaries. The overexpressed let-7a was conﬁrmed after
transfection and was able to prevent the upregulation of the selected mRNA tar-
gets in response to chemotherapy, as genes involved in apoptosis (FASL, Bax)
and in cell growth (STAT3). The potential protective effect of mimic-let7a will be
conﬁrmed by follicular count-follicle activation, DDR and apoptosis analysis.
Limitations, reasons for caution: The mimic-miRNA was delivered in vitro
using the Lipofectamine/RNAiMAX in whole ovaries, avoiding dissection which
could trigger the spontaneous follicle activation. Efﬁciency of the transfection
could vary from one experiment to the other. Results must be conﬁrmed
in vivo using appropriate delivery system.
Wider implications of the ﬁndings: We identiﬁed several miRNAs target
molecules involved in crucial cellular pathways during chemotherapy damage.
By reducing chemotherapy-induced apoptosis, the mimic-let7a could be used
for ovarian protection during treatment. Let-7a, may also affect pathways
involved in follicle activation like PI3K/AKT, opening a new research area in fer-
tility preservation by pharmacological protection.
Trial registration number:Not applicable.
P-518 Factors associated with the reproductive potential of
vitriﬁed-warmed, autologous oocytes derived from elective oocyte
cryopreservation cycles
L. Sekhon1, C. Hernandez-Nieto2, D. Gounko2, M.C.Whitehouse2,
J.A. Lee2, M.J. Duke2, C. Briton-Jones2, B. Sandler1,
A.B. Copperman1
1Reproductive Medicine Associates of New York / Icahn School of Medicine at Mount
Sinai, Reproductive Endocrinology and Infertility, New York, U.S.A.
2Reproductive Medicine Associates of New York, Reproductive Endocrinology and
Infertility, New York, U.S.A.
Study question: What clinical factors are associated with optimal cryopre-
served oocyte survival, fertilization, embryo culture, and transfer outcomes?
Summary answer: The outcome of autologous oocyte vitriﬁcation-warming
cycles is optimized in younger patients who undergo transfer of blastocyst-stage
embryos.
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What is known already: In order to protect against the age-related fertility
decline, women electively undergo oocyte cryopreservation to enhance their
ability to conceive when they are ready. While enhancements in cryopreserva-
tion methodology, including vitriﬁcation techniques, have demonstrated the efﬁ-
cacy of elective oocyte cryopreservation as a means of fertility preservation, a
relatively small proportion of women have returned to utilize their vitriﬁed
oocytes. Current data related to efﬁcacy is limited to extrapolations from hypo-
thetical models and case series. Given the paucity of experience, physicians
seek prognostic information to guide and counsel patients and manage expecta-
tions regarding the likelihood of success from vitriﬁed-warmed oocytes.
Study design, size, duration: This retrospective cohort study includes 1197
patients who underwent 1396 oocyte vitriﬁcation cycles, from 2010 to 2017.
One hundred and eleven patients (9.3%) returned for oocyte warming (n =
118) and treatment. Fresh (n = 52) and frozen (n = 39) transfers of cleavage (n
= 37) or blastocyst stage (n = 54) embryos were observed. Over half of the
patients (52.3%) who warmed their oocytes were successful in creating
embryos eligible for preimplantation genetic testing (PGT), that were then vitri-
ﬁed for future use.
Participants/materials, setting, methods: Patients presented to a private
IVF clinic for elective oocyte cryopreservation. Cycles in which autologous, vitri-
ﬁed oocytes were warmed (n = 118) were analyzed using multivariate linear
and binary logistic regression models to assess patient demographics (age, BMI,
and AMH); and treatment related factors (number of oocytes cryopreserved)
associated with oocyte survival and clinical outcome. The inﬂuence of these fac-
tors and the treatment approach (i.e. PGS, frozen embryo transfer (FET)) on
embryo transfer success was determined.
Main results and the role of chance: One thousand and ﬁfteen oocytes
were thawed and fertilized using ICSI. Of the fertilized oocytes, 63.3% reached
the cleavage stage, and 39.0% reached the blastocyst stage. Chemical and clin-
ical pregnancies were achieved in 52.7% (n = 48/91) and 41.8% (n = 38/91) of
cycles, respectively. Increased oocyte age (b = -0.6, p = 0.0003) and decreased
AMH (b = -1.4, p<0.0001) reduced the number of oocytes available for warm-
ing, but not the rate of survival. Controlling for age, each additional oocyte
warmed was associated with an increase in the rate of oocyte survival (b =
0.007, p = 0.04), embryos reaching the cleavage (b = 0.008, p = 0.01) and
blastocyst stage (b = 0.008, p<0.0001) and being amenable to PGT (OR 1.182
[95% CI 1.051-1.33], p = 0.005) and vitriﬁcation (OR 1.212 [95% CI 1.048-
1.403], p = 0.009). Oocyte age (b=-0.02, p = 0.02) and AMH (b = 0.05, p =
0.03) modiﬁed the rate of blastulation. The odds of having an embryo available
for fresh transfer was independent of age, AMH or the number of oocytes
warmed. Controlling for confounders (age, AMH, BMI, oocytes warmed,
embryo stage, PGT, FET, embryos transferred and endometrial thickness), clin-
ical pregnancy rate was negatively impacted by increased oocyte age (OR 0.78
[95% CI 0.60-1.01], p = 0.059) and transfer of cleavage embryos (OR 0.10
[95% CI 0.01-1.05], p = 0.05).
Limitations, reasons for caution: This analysis is retrospective and subject
to confounding bias. Prospective randomization of patients to various treatment
approaches (ie. transfer of day 3 vs. day 5 and screened vs. unscreened
embryos) would ultimately validate our ﬁndings and deﬁne the optimal strategy
for patients utilizing vitriﬁed-warmed oocytes.
Wider implications of the ﬁndings:Women desiring elective fertility pres-
ervation should be encouraged to vitrify their oocytes at a younger age to
increase their probability of future pregnancy. When possible, zygotes from
warmed oocytes should undergo extended culture and be transferred at the
blastocyst stage to optimize embryo selection and improve clinical outcome.
Trial registration number: This study was approved by the Western
Institutional Review Board (Study Number: 1167398).
P-519 Effects of natural honey, as a new cryoprotectant, on
viability and genes expression of vitriﬁedmouse blastocysts
P. Kazemi1, M. Dashtizad2, F. Sarmadi2, S. Fayazi2, S. Esfandiari 2,
P. Tirgar Bahnamiri3, L. Sotoodeh2
1McGill University, Department of Biology, Montreal, Canada
2National Institute of Genetic Engineering and Biotechnology NIGEB, Animal
Biotechnology, Tehran, Iran
3McGill University, Biological and Biomedical Engineering, Montreal, Canada
Study question: To investigate if natural honey can be used instead of sucrose
to optimize the vitriﬁcation procedure of mouse blastocysts.
Summary answer:Natural honey with a wide range of monosaccharides, dis-
accharides and antioxidants can be proposed as a cryoprotectant to reduce the
cellular stress caused by vitriﬁcation.
What is known already: Profound understanding of cryobiology has led to
novel protocols for vitriﬁcation of blastocysts in terms of media composition. It
has been demonstrated that a combined presence of permeating and non-
prmeating cryoprotectants, both monosaccharides and disaccharides, can
effectively increase the viability of vitriﬁed embryos. Although these improve-
ments resulted in high survival rates, other analyses on post warming blastocysts
with normal morphology demonstrated a wide range of cellular and molecular
impairments.
Study design, size, duration: The ﬁrst part of the experiment was con-
ducted to determine the optimum concentration of honey in vitriﬁcation (0.5,
1, 2 M) and warming solutions (thawing: 1, 2, 3 M; dilution: 0.5, 1, 1.5 M). The
second part was designed to compare the effects of honey-based selected solu-
tions and sucrose-based one on embryo quality.
Participants/materials, setting, methods: In vivo produced mouse blasto-
cysts were vitriﬁed as described by Kuwayama (Kuwayama et al., 2005) using
mentioned solutions. After 12 h, vitriﬁed blastocysts were compared with fresh
blastocysts in terms of survival and hatching rate as well as the expression level
of genes related to apoptosis (Trp53, Bax) and oxidative stress (Sod2).
Main results and the role of chance: The optimum concentrations of 1, 2
and 1 M were chosen for vitriﬁcation, thawing and dilution solutions, respect-
ively. Our results showed a high survival rate for both treatment groups and
control one. The hatching rate of vitriﬁed blastocysts was signiﬁcantly lower
than fresh blastocysts (58.47%). However, no signiﬁcant difference was found
between sucrose-based and honey-based mediums (40.8% and 38.3%, respect-
ively). Furthermore, real-time RT-PCR analysis data showed a reduction in the
expression of Trp53, Bax and Sod2 transcripts in the honey group (1.8-, 2.15-
and 1.1-fold, respectively) compared to the sucrose group (6.15-, 2.83- and
4.05-fold, respectively).
Limitations, reasons for caution: The implantation and live birth rates are
necessary to give a complete picture of natural honey effects during vitriﬁcation
procedure.
Wider implications of the ﬁndings: Our study considered antioxidant
properties of vitriﬁcation solutions as a new parameter for the success of the
procedure.
Trial registration number:None.
P-520 Slow passive freezing for ovarian tissue shows comparable
in vitro activation of primordial follicles with no difference in
apoptosis compared to traditional controlled slow freezing
S. Lierman1, K. Tilleman1, R. Cornelissen2, P. De Sutter1
1Ghent University Hospital Ghent Fertility and Stem cell Team, Department for
Reproductive Medicine, Gent, Belgium
2Faculty of Medicine and Health, Department of Basic Medical Science, Ghent,
Belgium
Study question: Is slow passive freezing (PSF) an alternative to the standard
controlled slow rate freezing (CSF) of human ovarian tissue?
Summary answer: The PSF showed no loss on primordial follicle count, acti-
vation, apoptosis and cell proliferation compared to the traditionally CSF.
What is known already: Fertility preservation is an important issue in regard
to the long-term quality of life. Cryopreservation of OT fragments is a strategy
for fertility preservation for cancer patients. For the moment, CSF is the estab-
lished method used to freeze cortical fragments of ovarian tissue. CFS requires
expensive computerized equipment and the process is time-consuming.
Moreover, there is a risk for technical failures with the potential loss of precious
material. Several publications reported passive slow freezing (PSF) to be suc-
cessful for testicular tissue of different animal species including for human tes-
ticular tissue (Goossens et al., 2013).
Study design, size, duration: OT strips (n = 50) from transgender patients
(n = 10) were divided in 3 groups: (1)Fresh tissue; (2)CSF and (3)PSF. DMSO
i379Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
(1.5 M) was used as cryoprotectant in both freezing protocols. CSF was per-
formed with a programmable freezer including a manual seeding. For PSF, cryo-
vials were placed in an isopropyl alcohol container in the -80°C freezer
overnight allowing a cooling rate »-1°C/min. Samples were stored in LN. Strips
were thawed, cultured for 2 h and for 2days (2d).
Participants/materials, setting, methods: OT strips were cultured indi-
vidually in 24-well plates containing supplemented McCoy’s 5a medium for 2 h
and 2d at 37°C (6%O2, 5%CO2). The strips were ﬁxed in 10% paraformalde-
hyde and embedded in parafﬁn. Histological sections were made for follicle
count, apoptosis and cell proliferation analysis. Light microscopic evaluation
was performed to study apoptosis by TUNEL en capsase-3 and cell prolifer-
ation PCNA and Ki67-staining. Statistical analysis (Wilcoxon Signed Ranks Test)
was performed (SPSS vs23).
Main results and the role of chance: Both freezing procedures, PSF versus
CSF, showed no loss in number of primordial follicle after 2 h of warming (54.6
± 24.0% versus 64.1 ± 16.4%). The PSF technique, showed a signiﬁcant higher
amount of primary follicles when comparing the amount after 2 h and 2d of cul-
ture (30.3 ± 24.2% versus 66.1 ± 11.2% (P = 0.013)), indicating a clear activa-
tion of the follicles. This was also observed in the SRF (18.1 ± 11.2% versus
60.2 ± 15.5% (P = 0.005)). This activation shift was not signiﬁcantly different
between both techniques (Fisher’s Exact p = 0.24). The PSF and CSF technique
did not affect the apoptosis level of the oocyte nor the granulosa cells after 2d
culture. There was no statistical difference in caspase-3 negative follicles after
2d of culture between PSF and CSF respectively (36.1 ± 27.4% versus 51.7 ±
33.7% for primordial follicles and 73.5 ± 22.1% versus 77.7 ± 19.9% for pri-
mary follicles). Likewise for the late apoptosis PSF versus CSF (89.2 ± 13.2%
versus 73.4 ± 21.1% (TUNEL negative primordial follicles) and 80.2 ± 16.6%
versus 77.9 ± 20.6% (TUNEL negative primary follicles)). For the cell prolifer-
ation PSF and CSF method showed comparable results after 2d of culture
(14.5 ± 23.6% versus 13.7 ± 19.9% (PCNA positive primordial follicles and
23.1 ± 30.8% versus 18.4 ± 17.4% PCNA positive primary follicles)) and the
ki67 positive staining (34.4 ± 34.1% versus 33.5 ± 35.3% (primordial) and 41.9
± 22.1% versus 45.3 ± 24.3% (primary).
Limitations, reasons for caution: Further studies should be conducted to
evaluate the true activation and maturation potential by xenotransplantation. It
is also important to note, that these experiments should be repeated using OT
from oncological patients as tissue characteristics might be affected by long
term testosterone treatment in the OT of trans persons.
Wider implications of the ﬁndings: PSF could be an easy and cost-
effective alternative to CSF for fertility preservation of ovarian tissue.
Trial registration number: This research is conducted with the approval of
the local ethics committee 2015/0124 – B670201523543).
P-521 Autologous oocyte vitriﬁcation: outcomes assessment
D. Montjean, C. Geoffroy-Siraudin, M.J. Gervoise-Boyer,
A. Amar-Hoffet, P. Boyer
Hopital Saint Joseph, Médecine et Biologie de la Reproduction, Marseille, France
Study question: Do maternal age and number of collected mature oocyte
affect post-warming biological and clinical outcomes?
Summary answer: Oocyte survival and fertilization rates after vitriﬁcation
and warming are not impaired in older patients and in patients with large num-
ber of mature oocytes collected.
What is known already: Autologous oocyte vitriﬁcation is widely proposed
to women receiving ICSI treatment in our fertility centre in order to limit the
number of embryos created. So far, few data have been published regarding
post-warming outcomes of autologous oocytes as main studies on oocytes vitri-
ﬁcation were conducted on donated eggs from young women. As both the
number of oocytes collected at pick-up and patient age are known to affect
oocyte quality, there is a need to evaluate the impact of these factors on bio-
logical and clinical outcomes after autologous oocyte vitriﬁcation and warming.
Study design, size, duration: This is a retrospective study conducted over a
6-year period. A total of 1217 autologous oocytes vitriﬁcation cycles were per-
formed. This program allowed the cryopreservation of 8926 oocytes. To date,
1080 oocyte warming cycles were performed including 5153 oocytes.
Participants/materials, setting, methods: 970 women receiving ICSI
treatment were proposed to vitrify a part of mature oocytes concomitantly to
ICSI procedure on sibling oocytes. Oocytes were vitriﬁed and warmed using
Kitazato vitriﬁcation media and system. Post-warming oocyte survival rate
(Number injected oocytes/Number of warmed oocytes), fertilization rate
(Number of zygotes displaying 2PN/Number of injected oocytes) and early
pregnancy rate per transfer (βHCG blood measurement>100UI/l) were
assessed and compared between groups of age and number of collected
mature oocytes.
Main results and the role of chance: The mean age of women included in
the study is 32.8 years. They were divided into age groups and 3 groups based
on the number of mature retrieved oocytes. Our data show that maternal age
at vitriﬁcation doesn’t affect post-warming survival rate (<30years: 84.3%, 30-
35years:83.8%, >35years: 84.8%, p>0.05), nor fertilization rate
(<30years:64.2%, 30-35years: 65.7%, >35years: 63.1%, p>0.05). However, as
expected, women above 38 years have signiﬁcantly lower chances to achieve a
pregnancy than women under 30years (28.0% vs 16%, p = 0.003) but the differ-
ence observed between the other age group is not statistically signiﬁcant (30-
35years: 22.7%, >35years: 21.3%, p>0.05). The number of mature oocytes
available after pick-up doesn’t change survival rate (≤10: 83.9%, 11-15:84.6%,
>15: 83.7%, p>0.05), fertilization rate (≤10: 62.8%, 11-15:64.5%, >15:63.8%,
p>0.05), nor early pregnancy rate per transfer ((≤10: 22.4%, 11-15:20.8%,
>15:19.6%, p>0.05). Finally, when looking at the different age groups described
above, no correlation was found between survival/fertilization rates and num-
ber of mature oocyte at pick-up.
Limitations, reasons for caution: The major limitation of the study is
potential confounding factors such as infertility factor, ovarian stimulation
protocol and treatment used for endometrial preparation for oocyte warming
cycle couldn’t be taken into account.
Wider implications of the ﬁndings: Since we have shown that critical fac-
tors like maternal age and number of oocytes have no impact on post-warming
biological outcomes, one can suggest that the cryopreserved oocytes that are
not intended to be used could be allocated to oocyte donation program with
the consent of the couple.
Trial registration number: Clinical Trials Registration number: 209 R02
P-522 UV irradiation of freeze-dried human sperm shows high
DNA integrity as compared to conventionally frozen sperm
A. Arav1, Y. Natan2, P. Levi Setti3, M. Leong4, P. Patrizio5
1Fertilesafe Ltd., R&D, Nes-Ziona, Israel
2Fertilesafe Ltd., Research and Development, Nes-Ziona, Israel
3Humanitas Fertility Center- Humanitas Research Hospital, Department of
Gynaecology, Milan, Italy
4The Women’s Clinic, The Women’s Clinic, Hong Kong, Hong Kong
5Yale Fertility Center & Fertility Preservation, Obstetrics- Gynecology & Reproductive
Sciences, New Haven, U.S.A.
Study question: Is freeze-dried human sperm more resistant to UV irradi-
ation than conventionally frozen?
Summary answer: Freeze-dried human sperm maintained a high DNA integ-
rity compared to conventionally frozen sperm after UV irradiation.
What is known already: Recently, it was shown that mice sperm preserved
in the dry state for 9 months in a space station and exposed to cosmic irradi-
ation showed only minor DNA damages which were repaired by oocytes cyto-
plasm and resulted in normal offspring.
Study design, size, duration: Basic human experimental research using
human sperm allocated to four different groups: (1) Fresh (2) Freeze-dried and
rehydrated cells (3) Freeze-dried and irradiated prior rehydration. (4)
Conventionally frozen and irradiated prior thawing. Each group contained 4 vials
with a minimum of 10 drops. Drying duration was 48 hours. Dried samples
were stored in vials at 4°C prior rehydration, and frozen samples were stored
in vials in liquid nitrogen prior thawing.
Participants/materials, setting, methods: Sperm diluted 1:1 in lyophiliza-
tion solution (LyoS). Freezing done by pipetting 10 μL drops into sterile liquid
air (CLair, Fertilesafe, Israel). Freeze-drying done using a sterile drying device
(Darya, FertileSafe, Israel) having a shelf temperature of -35°C and vacuum of
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........................................................................................
10mtorr. Samples were irradiated 30 min under a UV lamp. Rehydration was
done using 0.2 mL/vial LyoS at 37°C, thawing was done on warm (37°C)
microscopic slides. DNA integrity was evaluated using Halosperm G2kit
(Halotech, Spain).
Main results and the role of chance: Fresh sperm concentration was
10•106 cells/ml, motility was > 50% and DNA integrity was 81.06%±9.2%.
Post thaw motility (after conventional freezing) was 65-80% of the fresh (nor-
malized) same specimens. Rehydrated freeze-dried irradiated human sperm
showed no signiﬁcant cell loss 5•106 cells/ml and no decrease in DNA integrity
84%±8.1%. After freeze-drying and rehydration cells concentration was
5.375•106 cells/ml and DNA integrity was 81.3%±3.5%. The DNA integrity of
the irradiated but conventionally frozen sperm was signiﬁcantly lower, 9%±15%
(P<0.05) and concentration was slightly lower 4.5•106 cells/ml. Morphological
analysis of irradiated conventionally frozen sperm was much different than the
irradiated freeze-dried sperm displaying loss of tails and membranes and DNA
showing larger halos. These results show that there was no cell loss and no add-
itional damage to the DNA integrity due to the drying process and irradiation
while at the dry state. Human sperm freeze-drying is a revolutionary technology
that will allow long-term storage of sperm at room temperature and protection
from UV irradiation.
Table 1 Summarizes the results of human sperm
following freeze-drying, freeze thawing and irradiation.
Group Sperm Concentration
(cells/ml)
DNA
integrity
Fresh control
(undiluted)
10 • 106 81.06% ± 9.2%
Freeze-dried
rehydrated
5.375 • 106 81.3% ± 3.5%
Freeze-dried
irradiated
5 • 106 84% ± 8.1%
Frozen thawed
irradiated
4.5 • 106 9% ± 15%*
*(p<0.05)
Limitations, reasons for caution: Small number of samples and lack of data
on embryonic development following ICSI.
Wider implications of the ﬁndings: These ﬁndings suggest that freeze-
dried human sperm is more resistant to UV irradiation than frozen sperm. This
may be due to a lesser amount of reactive oxygen species created in the dry
state compared to the frozen state. Thus, freeze-drying may be preferred when
storage conditions are less than optimal.
Trial registration number:N/A.
P-523 Follow-up of elective oocyte cryopreservation for
age-related reasons: utilisation of vitriﬁed oocytes and reproductive
outcomes of women who return
E. Maes, J. Nekkebroeck, H. Tournaye, N. De Munck, M. De Vos
Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussels, Belgium
Study question: What is the come-back rate and what are the reproductive
outcomes of women who previously had their oocytes cryopreserved to antici-
pate age-related fertility decline?
Summary answer: Of all women who underwent elective oocyte cryo-
preservation, only 7.6% have so far returned to use these oocytes. Of those,
32.6% had an ongoing pregnancy.
What is known already: Oocyte vitriﬁcation has become an established and
efﬁcient technology, which has facilitated the practice of elective oocyte cryo-
preservation for women who defer motherhood and wish to anticipate age-
related fertility decline, for various reasons. Little is known about the utilisation
of the vitriﬁed oocytes of these “social freezers” and their reproductive out-
comes. Follow-up data of reproductive behavior and outcomes in these women
are needed for a comprehensive appraisal of social freezing.
Study design, size, duration: We performed a retrospective observational
single-centre follow-up study in a cohort of 563 women who underwent elect-
ive cryopreservation of oocytes to anticipate age-related fertility decline
between January 2009 and November 2017.
Participants/materials, setting, methods: A total of 563 women under-
went 902 ART cycles for oocyte vitriﬁcation. Data were collected from compu-
terised clinical charts. We evaluated reproductive treatment choices in social
freezers who returned, warmed oocyte survival rates, fertilisation rates,
embryo quality, the use of donor sperm, pregnancy rates, and live birth rates.
Main results and the role of chance: Mean age at oocyte vitriﬁcation was
36.5 y [95% conﬁdence interval (CI) 36.3–36.6]. A mean number of 8.5 [95%
CI 8.1 –8.8] oocytes were vitriﬁed per cycle. Seventy-two women (12.8%)
returned to the clinic for reproductive treatment at the moment of writing. In
43% of them (31/72), donor sperm was used for artiﬁcial insemination or ICSI.
7.6% (43/563) of women requested to have their vitriﬁed oocytes warmed for
ART, at a mean age of 42.1 y [95% CI 41.5-42.7]. Their oocytes had been vitri-
ﬁed at a mean age of 38 y. They underwent 72 warming cycles in total; overall
survival rate of warmed oocytes was 73.4 %. The fertilisation rate was 66.8%
and 64 warming cycles resulted in a fresh embryo transfer. In total, 25.6% (11/
43) patients had an ongoing pregnancy after oocyte warming and fresh embryo
transfer; the ongoing pregnancy rate (OPR) was 32.6% (14/43). Of women
who returned, 32 underwent ≥1 ART cycles with oocyte retrieval (69 cycles in
total), at a mean age of 38.9 y [95% CI 37.9-39.9] and the OPR was 34.4%.
Nineteen patients underwent artiﬁcial insemination (15 with donor sperm), of
whom 26.3% (5/19) had a live birth. Three patients had a live birth after oocyte
donation.
Limitations, reasons for caution: Due to the limited follow-up period, the
return rate of social freezers is low and utilisation rates of cryopreserved
oocytes are incomplete. Hence, the reproductive outcome of only a subset of
social freezers is currently known. Of patients who returned for reproductive
treatment, 40.3% have not used their vitriﬁed oocytes.
Wider implications of the ﬁndings: The majority of social freezers who
returned have found a suitable partner to pursue motherhood. Whether their
previous decision to undergo oocyte cryopreservation has enhanced the prob-
ability of a live birth will require conﬁrmation in larger follow-up studies.
Trial registration number:Non applicable.
P-524 SerumAMH as predictor of ovarian stimulation outcome
among women undergoing oocyte cryopreservation prior to breast
cancer treatment
I. Wikander1, K.A. Rodriguez-Wallberg2
1Karolinska UNiversity Hospital, Reproductive Medicine, Stockholm, Sweden
2Karolinska University Hospital and Karolinska Institutet, Department of
Reproductive Medicine and Oncology-Pathology, Stockholm, Sweden
Study question: Can AMH determination before hormonal stimulation in
emergency fertility preservation for breast cancer help to evaluate the ovarian
reserve and optimize the chance of a successful response?
Summary answer: AMH might not correlate with the ovarian reserve in
patients with breast cancer prior to chemotherapy treatment, and novel bio-
markers should be investigated.
What is known already: AMH is associated with the size of the follicle pool.
In some studies AMH has shown to be predictive of the woman’s ovarian
reserve and the number of oocytes collected after hormonal stimulation. A suc-
cessful fertility rescue treatment can be crucial for the woman´s future possibil-
ity of having biologically related children.
Study design, size, duration: Prospective cohort study between January
2012 and May 2016 of women with breast cancer that underwent a fertility res-
cue hormonal stimulation cycle in an antagonist protocol, with or without letro-
zole supplement, depending on their tumor estrogen receptor status, prior to
chemotherapy. Stimulation started any day of their menstruation cycle, serum
AMH was sampled before cycle start.
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Participants/materials, setting, methods: A total of 124 women diag-
nosed with breast cancer were included, mean age 32,8 (range 21-42), mean
BMI 23,0 (range 18-35). The mean AMH concentration was within normal
ranges for age (mean 2,32 microgram/L, range 0,16-9,6). The majority of
women were nulliparous. More than half (70 out of the 124 patients,56%) were
on contraceptive pills at time of diagnosis.
Main results and the role of chance: There were only modest, non-
signiﬁcant correlations between age and AMH levels or between AMH levels
and oocyte yield in the whole group. Possible explanatory variables were thus
investigated. In the subset of 70 patients who had complete data on use of
contraceptive pills at time of breast cancer diagnosis, sub-analysis indicated that
patients who were on contraceptive pills and discontinued them at time of can-
cer diagnosis presented with signiﬁcantly lower AMH levels than women who
had not had contraceptives previously. However, women who were previously
on contraceptive pills had a similar oocyte yield as women who were not on
contraceptives.
Limitations, reasons for caution: Several clinicians planned and performed
the stimulation of the patients and the retrieval of the oocytes. The time of the
stimulation treatments varied between the patients and in some cases could
not be prolonged due to planned chemotherapy initiation.
Wider implications of the ﬁndings: The predictive value of AMH deter-
mination before hormonal stimulation in emergency fertility preservation for
women in breast cancer is still debatable. Measurements of serum AMH con-
centrations to evaluate ovarian reserve previously to fertility preservation might
not correlate with the outcome in all patients with breast cancer.
Trial registration number: non-applicable
P-525 Serial serum cell- free DNA (cfDNA) quantiﬁcation in
lymphoma and breast cancer patients before and after
chemotherapy: is there a link with the ovarian function?
C. De Canter1, P. Pigny2, S. El Moghrabi3, D. Haouzi3, S. Hamamah4
1Hopital Jeanne De Flandre, reproductive medicine, Lille Cedex, France
2Laboratoire de Biochimie Hormonologie HMNO- Centre de Biologie Pathologie-
CHRU Lille, Inserm- UMR-S 1172- F-59000 Lille, Lille, France
3Inserm U1203- IRMB, Hôpital St-Eloi- CHU Montpellier, Montpellier, France
4Service de Biologie de la Reproduction- Hôpital Arnaud de Villeneuve- CHU
Montpellier, ART/PGD Department, Montpellier, France
Study question: Can longitudinal study of serum cf-DNA levels serve to pre-
dict the recovery of the ovarian function after chemotherapy in different type of
cancer?
Summary answer: Serum cf-DNA level can be used as a non-invasive prom-
ising prognostic biomarker to evaluate and predict ovarian reserve in hodgkin
lymphoma and breast cancer patients.
What is known already: cf-DNA can be quantiﬁed in small amounts in ser-
um resulting from the release of genetic materials from apoptotic/necrotic cells.
Serum cf-DNA can serve to cancer diagnosis but also in predicting response to
treatment. It still unclear the oocyte quality during fertility preservation proce-
dures in the cancer area. Recently, cf-DNA has been shown to be signiﬁcantly
correlated to the oocyte as well as the embryo quality, suggesting that it may
serve as an innovative and a non-invasive objective biomarker of the micro-
follicular environment and oocyte quality.
Study design, size, duration: 46 and 37 serum samples were obtained from
ﬁve hodgkin lymphoma patients (mean age: 24.3 ± 1.8 years) and ﬁve breast
cancer patients (mean age: 36.5 ± 1.8 years) respectively. All patients were
prospectively recruited before initiation of the chemotherapy. Serum cf-DNA
quantiﬁcation and AMH measurements were performed at baseline, 15 days
after the ﬁrst cycle, 15 days before the last cycle and every 3 months after the
end of chemotherapy until time 24 months.
Participants/materials, setting, methods: We performed cf-DNA qRT-
PCR using Alu-115 (detecting both necrotic and apoptotic DNA) primers to
evaluate serum cf-DNA level.
Main results and the role of chance: Our preliminary results revealed that
the cf-DNA concentration was signiﬁcantly higher in serum from breast cancer
compared with Hodgkin lymphoma patients (Alu-115 mean ± SEM: 788.9 ±
129.5 vs 383.7 ± 99.6 fg.μl-1, t-test p = 0.08). At baseline, serum AMH
concentrations were 33.1 ± 9.8 and 24 ± 13.9 ng/ml (mean ± SEM) in hodgkin
lymphoma and breast cancer patients, respectively. AMH concentration
decreased signiﬁcantly 15 days and 6 months after the ﬁrst chemotherapy cycle
in hodgkin lymphoma (6.7 ± 2.1 ng/ml, p = 0.03) and breast cancer patients
(3 ± 0.03 ng/ml, p = 0.05), respectively. 18 months pos-chemotherapy treat-
ment, AMH concentration remained stable in breast cancer patients (2.3 ±
0.9 ng/ml) while a tendency toward an increase of AMH concentration was
observed (13.1 ± 5 ng/ml) in hodgkin lymphoma patients. Meanwhile, Cf-DNA
concentration dramatically decreased 15 days after chemotherapy treatment in
hodgkin lymphoma patients compared at baseline measure (441.2 ± 141.6 vs
1031.9 ± 719.7 fg.μl-), and thus, until 18 months post-treatment (295 ± 141.6
fg.μl-) although the tendency was not signiﬁcant. In the breast cancer patients,
there is no signiﬁcant or tendency before, during and after chemotherapy treat-
ment. As cf-DNA concentration has been reported to be negatively correlated
to follicular size and embryo quality, our cf-DNA results question about cryo-
preserved oocytes quality in breast cancer and hodgkin lymphoma patients.
Limitations, reasons for caution: The few number of samples and patients
and the heterogeneity of chemotherapy regimen in lymphoma patients.
Wider implications of the ﬁndings: This ﬁnding opens new perspectives in
cancer patient care especially for fertility preservation program and counselling.
cf-DNA may serve as a non-invasive objective biomarker of cryopreserved
oocytes quality.
Trial registration number: CHACRY-1501.
P-526 Preliminary human application of optical coherence
tomography for quantiﬁcation and localization of primordial follicles
aimed at effective ovarian tissue transplantation
S. Takae1, K. Tsukada2, Y. Sato1, N. Okamoto1, I. Maeda3,
Y. Motani2, Y. Takahashi1, S. Sawada1, H. Iwahata1, C. Nishijima1,
N. Yoshioka1, Y. Sugishita1, Y. Horage1, N. Suzuki1
1St. Marianna University School of Medicine, Obstetrics and Gynecology, Kawasaki-
Kanagawa, Japan
2Keio University, Graduate School of Fundamental Science and Technology,
Kawasaki city, Japan
3St. Marianna University School of Medicine, Pathology, Kawasaki- Kanagawa, Japan
Study question: Is it possible to apply optical coherence tomography (OCT)
intend for effective ovarian tissue transplantation with assessment numbers and
localization of follicles on ovarian tissue?
Summary answer: OCT may detect primordial follicles non-invasively on
fresh human and mice ovary coincident with ovarian reserve test.
What is known already: Primordial follicles in ﬁxed and embedded human
and bovine ovarian tissue could be detected using the current full-ﬁeld OCT
(FF-OCT) system. Although, in terms of effect for viability, non-invasiveness of
near-infrared ray (NIR) used for OCT was indicated by glucose uptake assay
and neutral red staining with bovine ovarian tissue, there are no reports about
affect of OCT for oocyte to prove the reproductive ability including outcome of
in vitro fertilization (IVF).
Study design, size, duration: To assess of NIR irradiation effect for oocytes,
day3 mice were assigned to 4 groups: control (n = 3), 60 mW (n = 3),
110 mW (n = 4), 250mW (n = 5). Also, to assess the affect of OCT for IVF,
day 3 mice ovaries were assigned to with/without OCT group (n = 15, n = 10
respectively). The clinical study was conducted in four patients who received
ovarian tissue cryopreservation from May 2016 to February 2017. Present stud-
ies were performed with informed consent and IRB approval.
Participants/materials, setting, methods: Fresh ovaries from each life
stage mice were examined. And to conﬁrm non-invasiveness of OCT, out-
comes of IVF were compared among follicles from mice ovaries irradiated step-
wise NIR. Also, day3 mice ovaries with/without OCT were transplanted under
kidney capsule of host mice. Two weeks later, outcome of IVF with trans-
planted ovaries were examined. Additionally, newborns were bred and mated.
Finally, OCT examination was performed using human ovary tissues. And fol-
licle count using OCT was performed.
Main results and the role of chance: The standard OCT images were
established including primordial follicle. And stepwise NIR irradiation (60-
250 mW/cm2) did not affect for IVF outcome (fertilization rate p = 0.86-1.00,
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Blast cyst rate p = 0.86-1.00). Also, OCT examination did not affect for IVF
outcome of transplanted ovaries (number of extracted oocytes p = 0.29, fertil-
ization rate p = 0.35). Furthermore, all of newborns were shown normal
appearances including reproductive ability. In the clinical study, three patients
were received ovarian tissue cryopreservation for hematological disease as fer-
tility preservation, and a patient received ovary extraction for in vitro activation
intend for childbearing. Finally, OCT images of human ovary were well-
accorded with histological images and ovarian reserve test on adult patients.
While, OCT imaging detected primordial follicles fresh ovarian tissue from child
patients (15 and 11 years-old) with unevaluable ovarian reserve by anti-
Müllerian hormone and follicle stimulating hormone levels. As the result of fol-
licle count, there were no signiﬁcant differences between histology and OCT
(p = 0.98).
Limitations, reasons for caution: The scanning area of commercial optical
coherence tomography equipment is too small, and the scanning depth is insuf-
ﬁcient. Therefore, it is presently difﬁcult to assess actual ovarian reserve and fol-
licle distribution using existing instrumentation. For the application for ovarian
tissue transplantation, optimization of the OCT system is needed.
Wider implications of the ﬁndings: OCT holds the possibility for assess-
ment of actual ovarian reserve and follicle distribution on each ovarian tissue.
The selection of most suitable ovarian tissue using OCT may promote the
development of effective ovarian tissue transplantation.
Trial registration number: The registraion numbers of present studies
were No. 470 and 471(animal study) and UMIN000023141- No.3311 (clinical
study) under IRB of St. Marianna University.
P-527 Towards fertility preservation for prepubertal boys – The
role of gonadotrophins on functional maturation of Leydig and
Sertoli cells in immature human testis xenografts
M. Hutka1, P. Kadam2, D. Van Saen2, E. Goossens2, R. Mitchell1
1University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, United
Kingdom
2Vrije Universiteit Brussel, Biology of the Testis- Research Laboratory for
Reproduction- Genetics and Regenerative Medicine, Brussels, Belgium
Study question: We investigated whether gonadotrophin (hCG + FSH)
administration promotes germ, Sertoli, and Leydig cell development in xeno-
transplanted immature human testis tissue for purposes of fertility preservation.
Summary answer: Sertoli cell maturation was induced or maintained in
xenografts, whilst induction of steroidogenesis required gonadotrophin adminis-
tration. Germ cell differentiation did not occur in xenografted tissues.
What is known already: For prepubertal boys facing gonadotoxic (e.g.
chemotherapy, radiotherapy) treatments that are likely to result in sub/infertil-
ity, there are no established options to preserve their fertility. Whilst testicular
tissue may be obtained and cryopreserved prior to treatment, no clinical appli-
cations have been developed to use this tissue to restore fertility.
Transplantation of immature testis tissue into adults of several species has pro-
vided a proof of principle that grafting of tissue can generate gametes capable of
producing progeny. However, the factors required to functionally mature
immature human testis tissue to produce gametes have not yet been
determined.
Study design, size, duration: Prospective laboratory study using immature
human testis tissue obtained from boys (n = 3) undergoing testicular biopsy
prior to gonadotoxic treatment for fertility preservation. Tissue was obtained
with informed consent for clinical cryostorage and research purposes. Ethical
approval was obtained from the Local Research Ethics Committee. Host mice
xenografted with testicular tissue pieces were exposed to vehicle or treatment
for 12wks prior to analysis by immunohistochemistry with quantiﬁcation of cel-
lular development and function.
Participants/materials, setting, methods: Testicular tissues from three
boys (8, 13 and 14 yrs) were xenografted intratesticularly into immunocom-
promised castrate mice (n = 12). Hosts received subcutaneous injections of
vehicle or gonadotrophins (hCG, 20IU, FSH, 12.5IU), 3× weekly for 12wks.
Retrieved grafts were double immunostained for VASA, MAGEA4 (germ cell),
SOX9 (Sertoli cell), Androgen Receptor (AR, mature Sertoli cell), Anti-
Mullerian Hormone (AMH, immature Sertoli cell), CYP11a1 (Leydig cell -
steroidogenic marker) and Ki67 (proliferation marker). Results analyzed by
two-factor ANOVA.
Main results and the role of chance: Testicular tissue structure and histo-
logical appearance was maintained in xenografts. Administration of hCG/FSH
was required to induce steroidogenesis (CYP11A1) in Leydig cells of xeno-
grafted tissue from one patient (8 yrs), whilst for the two remaining patients (13
and 14 yrs), steroidogenesis was maintained only in the hCG/FSH-exposed
xenografts. Maturation of Sertoli cells (as indicated by AR expression) was
induced (8 yrs) or maintained (13 and 14 yrs) in the xenografts, however, there
was no difference in the number of Sertoli cells expressing AR between vehicle
and hCG/FSH-exposed xenografts (2247.48/mm2 vs 2411.13/mm2, p>0.05).
Sertoli cell number was signiﬁcantly reduced in hCG/FSH-exposed xenografts,
compared to vehicle control (3015.56/mm2 vs 2548.92/mm2, p = 0.01), and
Sertoli cell proliferation was reduced although not signiﬁcantly (7.65/mm2 vs
1.35/mm2, p>0.05). Germ cells were maintained in xenografts and germ cell
numbers were lower in vehicle-, compared to gonadotrophin-exposed xeno-
grafts, although this was not signiﬁcant (115.46/mm2 vs 517.68/mm2, p>0.05).
Interestingly, for the youngest patient (8 yrs), whilst germ cell numbers were
maintained in vehicle-exposed xenografts, there was a complete loss of germ
cells in those exposed to hCG/FSH. Taken together, these results indicate
xenografting immature testis tissue induces and maintains Sertoli cell matur-
ation, whilst exogenous hCG/FSH promotes steroidogenesis in xenografted
tissues.
Limitations, reasons for caution: Prepubertal human testis tissue is a ﬁnite
resource limiting the number of samples in these studies. Inter-individual vari-
ation between patients is also a factor. Experimental design involving direct
comparison of vehicle versus treatment for each sample and statistical analysis
using two-factor analysis can account for some of these limitations.
Wider implications of the ﬁndings: These ﬁndings suggest that endogen-
ous or exogenous gonadotrophins stimulate development and function of som-
atic cells in transplanted immature human testicular tissues. However, further
work is required to determine the factors required to generate functional
gametes from this tissue in order to develop viable options for fertility preserva-
tion in prepubertal boys.
Trial registration number:Not applicable.
P-528 Impact of breast cancer prognostic factors on the response
to controlled ovarian stimulation in patients undergoing fertility
preservation
F. Zeghari, C. Sonigo, M. Comtet, N. Sermondade,
I. Cedrin-Durnerin, M. Grynberg
Hospital Jean Verdier, Department of Reproductive Medicine and Fertility
Preservation, Bondy, France
Study question: Do breast cancer (BC) prognostic factors inﬂuence ovarian
function and response to controlled ovarian stimulation (COS) in patients seek-
ing fertility preservation (FP)?
Summary answer:Neither SBRIII grade, high Ki67 expression, HER2 overex-
pression nor triple negative status inﬂuence COS outcomes in pre-
chemotherapy BC patients undergoing FP.
What is known already: Since the development of FP, concerns about the
potential impact of cancer status on ovarian reserve, function and response to
COS have been raised. Studies evaluating COS outcomes before chemotherapy
in FP context have reported conﬂicting results. On the other hand, BC tumor
markers such as Scarff-Bloom-Richardson (SBR) grade, high Ki67, HER2 overex-
pression or triple negative status represent well established prognostic factors
which might inﬂuence the treatment strategy. However, the potential impact of
these factors on ovarian reserve or COS outcomes in BC patients undergoing
FP has never been investigated.
Study design, size, duration: A total of 151 BC patients undergoing COS
for FP were prospectively included between November 2013 and December
2016. COS was initiated regardless of the phase of the cycle, with or without
letrozole supplementation. Matured oocytes and/or embryos obtained were
vitriﬁed. COS characteristics and outcomes were analyzed in all women.
Participants/materials, setting, methods: BC prognostic factors con-
sidered in the present study were SBRIII grade, Ki 67> 20%, HER2
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overexpression and “triple negative” tumor. Univariate and multivariate analysis
were performed to determine their impact on ovarian reserve markers (serum
Anti-Müllerian Hormone (AMH) and antral follicle count (AFC)) as well as on
ovarian response to exogenous FSH. Less than 8 mature oocytes vitriﬁed, mat-
uration rate under 70% or Follicle Output RaTe (FORT) under 35% were con-
sidered as poor COS outcomes.
Main results and the role of chance: A total of 154 COS cycles were per-
formed and analyzed in BC patients 33.4 ± 4.1 years of age were analyzed.
Mean AMH and AFC were 3.2 ± 4.5 ng/mL and 20.2 ± 14.3 follicles, respect-
ively. HER2 overexpression was observed in 18.9% and 34.7% of tumors
expressed estrogen or progesterone receptors. Triple negative status charac-
terized 25% of tumors. BRCA1/2 mutation was found in 22.4% of patients. A
mean of 9.2 ± 7.4 mature oocytes were cryopreserved per cycle.
After multivariate analysis, only serum AMH levels, AFC and smoking status
were signiﬁcantly associated with the number of mature oocytes obtained fol-
lowing COS. BC prognostic factors did not appear to have a signiﬁcant inﬂuence
on ovarian reserve markers, number of retrieved oocytes, maturity rate or on
ovarian response to exogenous FSH assessed by FORT index, deﬁned as the
ratio of the number of pre-ovulatory follicle (16-22 mm) count on the triggering
day X100 to the antral follicle (3-8 mm) count at baseline.
Limitations, reasons for caution: The main limitation is related to the
patients themselves referred for FP, who usually have early stage disease.
Therefore, these results cannot be generalized to patients with advanced
tumoral stage. Since oocytes were not thawed, the actual impact of BC prog-
nostic factors on live birth rate remains unknown.
Wider implications of the ﬁndings: BC prognostic factors probably have
no or low impact on ovarian function in terms of ovarian reserve and response
to COS. Further analysis, in particular after oocyte thawing will be needed to
clarify a possible impact egg quality.
Trial registration number:Not applicable.
P-529 Effects of cancer on ovarian reserve and ovarian response to
stimulation
E. Porcu1, G. Damiano1, L. Cipriani1, S. Rossi1, F. Fabbri1,
G.M. Cillo1, F. Sacilotto1, L. Notarangelo1, P.M. Ciotti1, N. Calza1,
L. Vaccarella2
1University of Bologna, Human Reproductive Medicine Unit, Bologna, Italy
2University of Luigi Vanvitelli Naples, Human Reproduction unit, Napoli, Italy
Study question: This study investigates differences in ovarian reserve and
stimulation response in a group of cancer patients and in a control group.
Summary answer: Despite their reduced ovarian reserve, cancer patients
did not show lower number of oocytes retrieved and oocyte cryopreserved
when compared to healthy control group.
What is known already: Premature ovarian failure is a well recognized con-
sequence of chemotherapy. Therefore counseling plays a critical role for these
patients. A proper counsel should include fertility preservation options.
Oocytes cryopreservation is a procedure accepted as non-experimental tech-
nique. The debate on the negative inﬂuence of cancer on ovarian stimulation is
still open. Many studies compared oncological patients with a control group but
reports are still in conﬂict. It is assumed that cancer can damage ovarian granu-
losa cells affecting their sensibility to exogenous FSH. Another theory recog-
nizes cancer as responsible for generating a catabolic state that can increase
oxidative stress.
Study design, size, duration: Retrospective study: 212 oncological patients
aged 30.5 ± 6.1 years (16 to 40 years old) undergoing a fertility preservation
treatment at the University of Bologna IVF Center were considered from 1997
to 2017. These patients have been compared with a control group of 733
women aged 30.6 ± 2.3 years, undergoing ovarian stimulation because of tubal
or male infertility.
General characteristic and ovarian stimulation aspects were analyzed.
Participants/materials, setting, methods: Out of the 212 oncological
patients, 96 had hematologic cancer, 61 had breast cancer, 35 had gyneco-
logical neoplasms and 20 had other tumors (brain, thymic, melanoma and
colon). All patients were stimulated with FSH-r and GnRH antagonist or antag-
onist. Aromatase inhibitors were used in hormone-sensitive neoplasm. In the
control group 733 women were considered. Abnormal Ovarian reserve was an
exclusion criteria. Only mature oocytes were cryopreserved. T-student test
was used to analyze the data.
Main results and the role of chance: Both groups presented comparable
age (30.5 ± 6.1 versus 30.6 ± 2.3 P=NS) and FSH levels (6.7 ± 4.3 versus 6.6
± 2.0 P=NS). However oncological patients showed lower AMH levels (2.18
± 2.65 versus 3.5 ± 2.6 P<0.0001) and AFC (8.42 ± 3.9 versus 10.5 ±
3.3 P<0.0001).
No differencies in duration of ovarian stimulation in oncological patients and
in healthy patients were detected (11 ± 3.4 versus 11.2 ± 2.4 P=NS).
Cancer patients needed signiﬁcantly higher doses of FSH-r compared with
controls (2182.5 ± 1235.3 UI versus 2025 ± 783 UI, P<0.05)
Oncological patients and controls produced a similar number of total follicles.
(12.13 ± 6.7 versus 12 ± 5.2 P=NS)
On the other hand, cancer patients presented lower estradiol peak than con-
trols (1148.65 ± 1235.38 versus 1913 ± 1490 P<0.0001).
There was no statistical difference in the number of oocytes retrieved (8.92
± 6.24 vs 8.3 ± 4.8 P=NS) and mature oocytes cryopreserved (7.24 ± 4.75 vs
6.8 ± 4.4 P=NS) between cancer patients and control.
Limitations, reasons for caution: The estradiol peak reached during the
ovarian stimulation is inﬂuenced by the use of the Aromatase inhibitors in breast
cancer hormone-sensitive tumor patients.
Wider implications of the ﬁndings: Present study shows a reduced ovarian
reserve in cancer patients. However, despite low AMH and AFC values, onco-
logical women can produce the same number of oocytes suitable for cryo-
preservation as observed in non cancer patients.
Trial registration number: \
P-530 Protective effect of visnagin on doxorubicin-induced
follicular apoptotic activation in ovarian tissue of rat
A. Ozbay, B. Avci
Uludag University Faculty of Medicine, Histology and Embryology, Bursa, Turkey
Study question: Is there any efﬁcacy of viscagin treatment to prevent tissue
damage at cellular level in doxorubicin-induced ovarian toxicity?
Summary answer: Visnagin reduces the loss of follicles and protects the
ovarian reserve against the gonadotoxic effect of doxorubicin.
What is known already: Chemotherapy causes loss of primordial follicles
and impaired follicular maturation. Invitro studies suggest that apoptotic
changes in pregranulosa cells lead to follicular damage. As a result of
doxorubicin-induced toxicity, oocytes exhibit chromosome condensation,
altered gene expression and oxidative stress. Oxidative stress at the cellular
level causes DNA damage. There is an increase in apoptotic activation and an
increase in follicular atresia and a decrease in ovarian reserve. Visnagin is an
organic chemical compound and a furanochromone. It was reported that visna-
gin protects against doxorubicin-induced apoptosis in cultured cardiomyocytes.
Study design, size, duration: Experimental study conducted at Uludag
University School of Medicine, the department of Histology and Embryology
between 2016-2017 in master’s thesis and licensed by the local ethics com-
mitte. A total of 24 Wistar albino adult female rats were used in the study.
Ovarian toxicity was established with doxorubicin treatment in rats.
Therapeutic effect of visnagin on ovarian toxicity was evaluated light microscop-
ically and immunohistochemically.
Participants/materials, setting, methods: Female Wistar Albino rats that
were six months of age (n = 24) divided 4 groups: GroupI: intraperitoneal (ip)
saline, GroupII: ip doxorubicin (21 mg/kg), GroupIII: ip visnagin (30 mg/kg),
GroupIV: ip doxorubicin+visnagin injected groups for 7 days. Vaginal smear was
performed on all rats before application for drug administration and ovarian dis-
section. Parafﬁn tissue sections were stained with hematoxylin&eosin to mor-
phological analysis. Apoptotic activation of ovarian follicles at different stages of
development was assessed by the TUNEL assay.
Main results and the role of chance: In the doxorubicin group, there was a
decrease in the numbers of primordial (p = 0,001), secondary (p = 0,002) and
graaﬁan follicles (p = 0,001) compared to the control, visnagin and doxorubicin
+ visnagin groups, and a signiﬁcant increase in atretic follicle counts (p = 0,001),
but there was no statistically signiﬁcant difference unilaminar and multilaminar
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primary follicles between groups. In the doxorubicin+visnagin group, the num-
bers of the secondary and graaﬁan follicles were similar to those of the control
and visnagin group, and the atretic follicle numbers decreased signiﬁcantly com-
pared to the doxorubicin group (p = 0,002). In vivo administration of doxorubi-
cin resulted in an increase in the apoptotic granulosa cells poured into the
antral ﬂuid as a morphological indicator of atretic follicles. It was observed that
the connections between the granulosa cells and the oocyte were deteriorated
and inclusions were formed in the follicular cells. In granulosa cells of the sec-
ondary and graaﬁan follicles, degeneration ﬁndings were observed in all follicles,
with the pyknotic nuclei more prominent in the secondary follicles. The treat-
ment of visnagin following the doxorubicin has a protective effect against the
gonadotoxicity caused by doxorubicin. This effect showed protection in the
number of primordial and developing follicles and decrease in the number of
atretic follicles.
Limitations, reasons for caution: The limitations of the study is an experi-
mental study and apoptotic activation could not be conﬁrmed with different
method.
Wider implications of the ﬁndings: This is the ﬁrst study to show the pro-
tective effect of visnagin against the toxic effect of doxorubicin on the ovary.
Visnagin therapy following chemotherapy is effective in protecting both of the
primordial follicle pool and the developing ovarian follicles.
Trial registration number: The study is not clinical trials.
P-531 Social egg freezing in Israel –Do women take advantage of
their opportunities?
R. Segal, M. Dviri, S. Avraham, D. Ben-yosef, F. Ezam
Sackler Faculty of Medicine- Tel-Aviv University- Israel, Institute of Reproduction and
Racine IVF Unit- Lis Maternity Hospital Tel-Aviv Sourasky Medical Center, tel aviv,
Israel
Study question: Do women utilize their legal privilege to perform up to
4 elective retrievals in order to maximize their chances for a future live
birth?
Summary answer:Most women will undergo only one oocyte retrieval, even
though the number of cryopreserved oocytes is less than optimal to ensure a
live birth.
What is known already: In Israel, oocyte freezing has been approved in
2011, allowing women between the ages of 30-40 years to self-ﬁnance up to 4
retrievals or until 20 eggs are obtained (whichever comes ﬁrst).
Previous studies indicate that 15 metaphase II oocytes will result in 90%
cumulative live birth rate in women ≤35 years old, compared to 35% for
women >35 years old.
Limited data has been published regarding this intervention results in Israel.
Study design, size, duration: A retrospective cohort study performed at a
single academic center between January 2011 and December 2017.
Computerized medical records of all fresh IVF/ICSI cycles during the study peri-
od were screened to identify patients undergoing social egg freezing.
Participants/materials, setting, methods: Patient’s and cycle’s data were
collected and analyzed including age at ﬁrst cycle, marital status, superovulation
protocol, ovarian reserve markers, number of treatment cycles, number of
retrieved oocytes, and number of oocytes/embryos frozen.
Main results and the role of chance: During the study period, 47 women
underwent a total of 61 social fertility preservation cycles (22% of preservation
cycles during the study period). A total of 19 cycles were performed during
2017, as compared to only one cycle in 2011.
Seventy ﬁve percent of women were > 35 years old when the ﬁrst cycle was
performed, mean age at ﬁrst cycle was 36.4 ± 2.1 years.
The majority of women (89%) were single, 95% of them had no children and
23.3% had ovarian reserve markers indicating reduced ovarian reserve prior to
the ﬁrst cycle.
Seventy percent of the women underwent only one cycle, 12% had two
cycles and 8% ≥ 3 cycles.
Antagonist protocol was used in 95% of patients.
The mean number of retrieved oocytes at ﬁrst cycle was 14.8 ± 11.9, with a
mean of 11.9 ± 9.9 oocytes being frozen. Four women choose embryo freezing
rather than egg freezing.
Only 21% of women at ﬁrst cycle, yeilded ≥ 20 frozen eggs.
One woman, 34 years old, yeilded 39 frozen eggs.
25% of the cycles ended in freezing less than 5 oocytes.
Limitations, reasons for caution: The main limitation is the retrospective
nature of the study and the small sample size, which may limit its power.
Wider implications of the ﬁndings:Women do not exploit their full elect-
ive preservation options, most probably due to economic burden. Women
who wish to perform social freezing should be encouraged to do so prior to 35
years old, and preferably more than one cycle, in order to maximize the
chances for a future live birth.
Trial registration number: not applicable.
P-532 Assessing the effects of ovarian tissue ultra-rapid
cryopreservation by vitriﬁcation on primordial-stage oocytes
N. Panagiotopoulou1, J. Stewart2, M. Herbert3
1Newcastle University, Institute of Genetic Medicine/ Newcastle Fertility Centre at
Life, Aberdeen, United Kingdom
2Newcastle Fertility Centre at Life- Newcastle Hospitals NHS Foundation Trust,
Fertility Centre, Newcastle upon Tyne, United Kingdom
3Institute of Genetic Medicine- Newcastle University and Newcastle Fertility Centre at
Life- Newcastle Hospitals NHS Foundation Trust, Institute of Genetic Medicine,
Newcastle upon Tyne, United Kingdom
Study question: Is immediate post-thaw assessment of the effects of ovarian
tissue vitriﬁcation on primordial-stage oocytes accurate?
Summary answer: Assessing ovarian tissue immediately after thawing does
not reveal the full extent of cryodamage caused to primordial-stage oocytes by
ultra-rapid cryopreservation procedures.
What is known already: To date, the optimal laboratory protocol for ovar-
ian tissue cryopreservation remains unclear. Although slow freezing is the cur-
rently standard procedure for ovarian tissue cryopreservation, there is a need
to further develop cryopreservation techniques in order to reduce the degree
of cryodamage. Ultra-rapid cryopreservation by vitriﬁcation has signiﬁcantly
advanced in the last decade and recent studies have suggested equivalent or
even better results for ovarian tissue preservation. However, high concentra-
tion of cryoprotectants used in vitriﬁcation may cause high oocyte toxicity.
Observing the effects of vitriﬁcation on the primordial-stage oocyte level is
important in designing vitriﬁcation protocols that will minimize cellular damage.
Study design, size, duration: This was an in vitro mouse model study. Six
intervention groups were employed, namely fresh, no in vitro culture group;
fresh, 24 hours in vitro culture group; cryo-group 1, no in vitro culture; cryo-
group 1, 24 hours in vitro culture; cryo-group 2, no in vitro culture; and cryo-
group 2, 24 hours in vitro culture.
Participants/materials, setting, methods: Rec8 transgenic mice were
used to develop an assay to assess primordial-stage oocytes damage following
ovarian tissue vitriﬁcation. All animal procedures were approved by the UK
Home Ofﬁce and were carried out in accordance with ‘3Rs’ principle – replace-
ment, reduction and reﬁnement. Cell death – using TUNEL assay and immuno-
ﬂuorescence analysis of activated Caspase 3 –was assessed at two time points:
immediately after thawing and after 24-hours in vitro culture of thawed ovarian
tissue strips.
Main results and the role of chance: Assessment of cell death was deter-
mined by a Staurosporine-validated assay that involved TUNEL and
Caspase-3 labelling. We found that the proportion of primordial-stage
oocytes staining positive for TUNEL and/ or Caspase-3 was higher in vitri-
ﬁed/ thawed ovarian strips analyzed immediately after thawing than in
untreated (control) ovarian strips. This increase in the number of apoptotic
primordial-stage oocytes was noted regardless of the cryopreservation med-
ia used and was evident in all biological repeats. Similar results were noted
following 24 hours in vitro culture of untreated and treated ovarian strips.
Comparison of the binomial proportion of primordial-stage oocytes staining
negative for TUNEL and Caspase-3 and positive for TUNEL and/ or
Caspase-3 showed a statistically signiﬁcant difference among the six
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intervention groups; χ2(5) = 93.14, p<0.0005. Post-hoc analysis showed that
after 24 hours in vitro culture of vitriﬁed/ thawed ovarian tissue strips, there
was a statistically signiﬁcant increase in the total number of primordial-stage
oocytes that stained positive for TUNEL and/ or Caspase-3 for cryo-group
2 but not for cryo-group 1 nor for the untreated group. This ﬁnding was
further supported by quantitative analysis of primordial-stage oocyte DNA
fragmentation using the TUNEL assay for each of the six intervention
groups; Kruskal-Wallis test: χ2(5) = 326.749, P<0.001.
Limitations, reasons for caution: Although our model allows cellular
assessment of vitriﬁcation effects, the use of a mouse in vitro model constitutes
a study limitation. Signiﬁcant species differences limit the transferability of our
ﬁndings beyond the mouse model. Moreover, protection mechanisms available
from the mouse organism were eliminated due to the in vitromethodology.
Wider implications of the ﬁndings: To improve the effectiveness of ovar-
ian tissue cryopreservation, cryodamage caused to primordial-stage oocytes
should be minimized. Our in vitro mouse model and validated cell death assay
could be used as a prototypes for a human ovarian tissue model that will allow
optimization of ovarian tissue freezing for fertility preservation.
Trial registration number:N/A.
P-533 Inﬂuence of breast cancer prognostic factors on in-vitro
maturation outcomes in patients seeking urgent fertility
preservation
M. Grynberg1, J. Raad2, N. Sermondade3, A. Benoit3, C. Sifer3,
C. Sonigo2,4
1Department of Reproductive Medicine and Fertility Preservation- Hôpital Jean
Verdier, Ile de France, Bondy, France
2Department of Reproductive Medicine and Fertility Preservation- Hôpital Jean
Verdier, Seine-Saint-Denis, Bondy, France
3AP-HP- Service de Cytogénétique et Biologie de la Reproduction- Hôpital Jean
Verdier, Seine-Saint-Denis, Bondy, France
4Inserm U1185- Univ Paris-Sud- Université Paris Saclay, Val de Marne, Le Kremlin
Bicêtre-, France
Study question: Do the prognostic and predictive factors for breast cancer
(BC) inﬂuence in-vitro maturation of immature oocytes (IVM) outcomes in
patients undergoing fertility preservation (FP)?
Summary answer: Patients with SBRIII tumors had signiﬁcantly less cryopre-
served oocytes and HER2 overexpression was correlated with a decreased risk
to cryopreserve less than 5 mature oocytes.
What is known already:Overexpression of HER2, Scarff-Bloom-Richardson
(SBR) grade, triple negative status as well as high Ki67 expression represent
prognosis factors for BC and are involved in the management of BC patients.
On the other hand, concerns exist about the potential impact of cancer status
on ovarian reserve and function. Previous studies analysing Controlled-Ovarian
Stimulation results for FP in cancer patients have shown conﬂicting ﬁndings.
Nevertheless, there is no data on the potential impact of BC status and prog-
nostic factors on IVM outcome in women undergoing urgent FP.
Study design, size, duration: From November 2013 to December 2016,
we prospectively studied 321 BC patients, aged 18-41 years, and candidates for
oocyte cryopreservation following IVM. Number of oocytes recovered, matur-
ation rate and total number of cryopreserved oocytes were assessed.
Participants/materials, setting, methods: Ovarian reserve markers
(Antral-Follicle Count (AFC) and serum Anti-Mullerian Hormone (AMH) levels)
and IVM outcomes were compared according to BC prognostic factors (Ki67 >
20%, progesterone and/or estrogen receptors status, HER2 status and SBR
grade). Then, logistic regression analysis was performed to determine the vari-
ables that could be independently associated with poor IVM outcomes deter-
mined as maturation rate < 60 % or number of mature oocytes cryopreserved
< 5.
Main results and the role of chance: Overall, the mean age of the popula-
tion was 32.3 ± 4.1 years. Mean AFC and serum AMH levels were 22.8 ± 13.9
follicles and 3.8 ± 3.1 ng/ml, respectively. AMH serum level was signiﬁcantly
lower in case of triple-negative BC as compared to ER/PR/HER2 status posi-
tive cancer (3.1 ± 2.6 ng/ml vs 4.0 ± 3.3 ng/ml, p = 0.02).
The mean number of recovered oocytes was 10.2 ± 9.1. After a mean mat-
uration rate of 58 ± 26%, 5.8 ± 5.3 matured oocytes were cryopreserved per
cycle. The number of retrieved and cryopreserved oocytes were signiﬁcantly
decreased in patients presenting SBRIII tumor as compared with SBRI or II (9.6
± 8.7 vs 11.7 ± 9.8, p = 0.02 and 5.4 ± 5.4 vs 6.0 ± 5.8 p = 0.02 respectively).
Multivariate statistical analysis showed that HER2 positive status was posi-
tively correlated with a mean maturation rate < 60 % (OR: 0.54; 95% CI (0.30-
0.97)). Ki67, SBR classiﬁcation or hormonal status was not correlated with poor
IVM outcomes.
Limitations, reasons for caution: The main limitation of our study is the
lack of data concerning the true competence of these cryopreserved oocytes
and subsequently the impact of BC prognostic factors on pregnancy rates fol-
lowing utilization IVM oocytes remains unknown.
Wider implications of the ﬁndings: BC prognostic factors could play a role
in IVM outcome. Moreover, HER2 is likely to be involved in oocyte maturation
process. Further investigations are needed to better understand these mechan-
isms and to objectively assess the real potential of IVM oocytes after
cryopreservation.
Trial registration number:N/A.
P-534 Determination of ovarian primordial/primary follicle density
in 1002 ovarian tissue biopsies and amh concentrations in 824
serum-samples for a better reﬂection of the ovarian reserve
J. Liebenthron1, J. Reinsberg2, R. Fimmers3, N. Sänger4, K. Van der
Ven2, H. Van der Ven2, P. Stute5, M. VonWolff5
1University Gynaecological Clinic- UniCareD, Department Reproductive Medicine and
Fertility Protection, Düsseldorf, Germany
2University Gynaecological Clinic, Department for Endocrionology and Reproductive
Medicine, Bonn, Germany
3University Clinic Bonn, Department for Medical Biometry- Informatics and
Epidemiology IMBIE, Bonn, Germany
4University Gynaecological Clinic, Department for Endocrionology and Reproductive
Medicine, Frankfurt, Germany
5Inselspital- University Clinic, Department of Obstetrics and Gynaecology, Bern,
Switzerland
Study question: Enables the follicle density of primordial/primary follicles a
better reﬂection of the ovarian reserve in cortex pieces of patients who under-
went cryopreservation of ovarian tissue in terms of fertility protection?
Summary answer:Nomograms of follicle density FD and Anti-mullerian hor-
mone AMH are similar in adulthood but different in childhood, as well the over-
all correlation of both parameters.
What is known already: Several parameters are suggested to estimate the
ovarian reserve. These include the female age, the concentrations of FSH and
Inhibin B, the antral follicle count AFC and the concentration of Anti-mullerian
hormone AMH. Comparative studies have shown that AMH and AFC best
reﬂect the response to gonadotropins. However, the antral follicles are only a
small fraction of the total amount of ovarian follicles and AMH is already known
to be a poor prognostic factor for the ovarian reserve in childhood.
Study design, size, duration: This retrospective observational study
included 1.002 females (28,1 y ±6.9, 3-45 y) with malignant (n = 955) and
benign (n = 47) diseases who cryopreserved tissue in a single center as part of
a national fertility preservation program. Patients with ovarian surgery or gen-
etic predispositions for a reduced ovarian reserve had been excluded. Follicle
densities (FD) (n = 1.002) and AMH concentrations (n = 824) were evaluated
from 03.2011 to 09.2016.
Participants/materials, setting, methods: Three standardized 2-mm
biopsies, obtained from different areas of prepared ovarian cortex were col-
lected, FD analysis was performed after tissue digestion and calcein staining
(counting of ﬂuorescent/viable PROF/PRIF follicles). Serum AMH was mea-
sured (before gonadotoxic therapy starts) using the AMH Gen II ELISA Kit.
Statistical nomograms of FD/AMH were drawn in relation to age as well statis-
tical correlation analyses of FD and AMH in two age groups (≤ 25 y/≥ 25 y).
Main results and the role of chance: First-time that a nomogram of FD as
a function of age and in correlation with the AMH concentration in serum-
blood is published. Thus, the cortex ovary reserve was analyzed directly and
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not on the basis of known surrogate parameters. AMH concentrations were
lower in childhood, increased to a peak in early adulthood and decreased after-
wards. In contrast, FD were highest in childhood and decreased with increasing
age. Our correlation analysis of FD with AMH, the marker with the highest
prognostic prediction probability for an ovarian response, allowed us to esti-
mate to what extent the AMH concentration correlates with the density of
PRIF/PROF follicles. In the age group ≥ 25 y there was a signiﬁcant better cor-
relation of AMH and the FD (r = 0.3199, p < 0.0001) compared to the younger
group (≤ 25 y), r = 0.0539, p = 0.4022, probably due the fact that the ovarian
volume and surface area are lower in childhood.
Due the limited prognostic value of AMH for the FD, it should be questioned,
if in terms of transplantation of ovarian tissue the evaluation of the individual FD
is a more valid tool to estimate the amount of ovarian tissue needed for
transplantation.
Limitations, reasons for caution: This study showed the FD in single cor-
tical biopsies. Although the analysis and averaging of three biopsies increases
the accuracy of the analysis, it is still not possible to accurately determine a het-
erogeneous FD.
Wider implications of the ﬁndings: The analysis of ovarian reserve by FD
rather than surrogate parameters is one of the strengths of this study.
Nevertheless, as ovarian FD was measured, an estimation of total concentra-
tion of follicles requires a surface correction regarding small size ovaries in child-
hood and the larger size ovaries in young adulthood.
Trial registration number: not applicable.
POSTER VIEWING
Nursing and midwifery
P-535 Fertility nursing education and career progression
framework
F. Steyn1, J. Wilson2, F. Pringle3, J. Denton4, C. Bagness5, H. Miller6,
Y.Wedden7, A. Denga8, K. Best9, J. Mutch10
1The Centre for Reproductive and Genetic Health, Nursing, London, United Kingdom
2Care Fertility Birmingham, Nursing, Birmingham, United Kingdom
3IVI uk, Nursing, London, United Kingdom
4Multiple Births Foundation, Nursing, London, United Kingdom
5The Royal College of Nursing, Midwifery and Women’s Health, London, United
Kingdom
6Bath Fertility Centre, Nursing, Bath, United Kingdom
7BirminghamWomen’s Fertility Centre, Nursing, Birmingham, United Kingdom
8Assisted Conception Unit- Guy’s and St Thomas’s NHS Foundation Trust, Nursing,
London, United Kingdom
9Gateshead Fertility Unit, Nursing, Gateshead, United Kingdom
10Hewitt Fertility Centre, Nursing, Liverpool, United Kingdom
Study question: Fertility nursing is a specialist area of practice where nurses
are at the forefront of an emerging care setting, do we need to provide an edu-
cational framework to support this?
Summary answer: Fertility nursing encompasses the care and practices
undertaken by any registered nurse/midwife providing fertility care, an educa-
tional framework is paramount for those individuals.
What is known already: Fertility nurses have increased levels of responsibility.
Political drivers, workforce requirements and nursing care require multidisciplin-
ary collaboration; whilst it is recognised that not every nurse/midwife will aspire
to masters level advanced practice, all are expected to reach the maximum
potential expected of their role in the context of competence and knowledge.
Equally the need for nurses to become specialists in their particular ﬁeld of
practice, to enhance overall service provision, through clinical leadership and be
recognised as expert practitioners includes understanding the socio economic
and political dimensions to delivering care, and ensuring service meets the
needs of those seeking fertility care.
Study design, size, duration: A career progression and education frame-
work has been constructed by senior fertility nurses, professional stakeholders
and peers. The framework has been published and shared with professional sta-
keholders for review. The framework is a publication and booklet for fertility
nurses and Health care assistants throughout the UK and contains tools for self
assessment for competency. The project was the focus of the group for 2017
and has taken a total of 5 months to complete.
Participants/materials, setting, methods: The project group consisted of
12 core contributors, 3 external advisers and a wider group of stakeholders.
The work was mainly constructed by individuals of the core group and for-
warded to the group chair for amalgamation and prooﬁng. Teleconferences and
face to face meetings took place to discuss project content and for any amend-
ments to be made. Each member of the core group were responsible for separ-
ate parts of the document.
Main results and the role of chance: This Fertility Nursing Education and
Career Progression Framework is intended to facilitate a conversation, and
enable the building of a career pathway for all nurses and healthcare assistants
in fertility services. The aim is to ensure development and progression of knowl-
edge and expertise towards enhancing the quality of service provision in
Fertility Nursing Care.
This framework could also be used by individual nurses to assess their
ongoing competence, and prepare for re validation.
All newly appointed nurses and HCA’s should have an identiﬁed mentor to
support their continuing professional development.
This Fertility Nursing Education and Career Progression Framework is
intended to inspire individual nurses and HCA’s to progress their career to con-
tinue to provide a quality service for those seeking fertility advice and manage-
ment across the care provision.
Limitations, reasons for caution: This project serves as a reminder that
anyone providing care should not undertake a procedure unless competent to
do so, whilst considering how they can best ensure competence and conﬁdence
to carry out activities that expands their scope of practice.
Wider implications of the ﬁndings: Negative - Professional bias from other
members of the MDT, increased costs for employers and increased training needs.
Positive - Improves patient care and satisfaction, Morale boosting, better skill
mix, provides a key pathway for career progression.
Trial registration number: not applicable.
P-536 Development of a quality of life causal model for men
undergoing fertility treatment
K. Asazawa1, A. Mori2, M. Jitsuzaki3, T. Ichikawa4, K. Shinozaki5
1Tokyo Healthcare University, Department of Nursing, Tokyo, Japan
2Women’s Health and Midwifery, Graduate School, St. Luke’s International University
3University of Occupational and Environmental Health, Department of Nursing,
Fukuoka, Japan
4Graduate School of Medicine, Chiba University, Chiba, Japan
5Graduate School of Health and Welfare Science, International University of Health
and Welfare, Fukuoka, Japan
Study question: The purpose of this study was to create a QOL (Quality of
Life) cause-and-effect model for male patients undergoing infertility treatment
in Japan.
Summary answer: The QOL was inﬂuenced by psychological Distress, lack
of Spousal Support, prolonged infertility period as well as the male factor in a
QOL cause-and-effect model.
What is known already: Patients undergoing infertility treatment become
stressed from the physical burden of treatment, and their QOL also declines.
An overview of 73 studies revealed that even though the mental health pro-
blems among the men were no higher than the general population, infertile men
experienced infertility-speciﬁc anxiety and socially isolated men were more vul-
nerable to severe anxiety. Researchers from the USA identiﬁed life stress as a
factor in reducing men’s fertility; two or more stressful life events in the past
year negatively affected men’s sperm motility and morphology however, they
found that job strain had no impact on sperm parameters.
Study design, size, duration: A descriptive quantitative cross-sectional
questionnaire survey.
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During the study period April to August 2016, we distributed 411 question-
naires to clients eligible for participation. A total of 332 (80.8%) were returned,
and 321 were usable for analyses.
Participants/materials, setting, methods: This quantitative cross-
sectional survey used a self-report questionnaire for 411 infertile male patients
with and without male factor infertility from four human reproductive clinics in
Japan. The four scales measured the main outcomes: FertiQoL (Japanese ver-
sion), Psychological Distress, Social Support (spousal and workplace). The data
were analyzed with descriptive statistics, multiple regression analyses and struc-
tural equation modeling.
Main results and the role of chance: Returned questionnaires were 332
(80.8%). Male factor cause of infertility was signiﬁcantly associated with the
FertiQoL scale score (F = 5.174, p < 0.001). The QOL was signiﬁcantly lower
in those with male factor infertility than in other causes or unknown cause. The
three signiﬁcant predictors of QOL were: (i) distress (β = - 0.53, P < 0.001);
(ii) Spousal Support (β = 0.25, P < 0.001) and (iii) infertility period (β = - 0.09,
P < 0.05). The structural equation modeling revealed the same factors were
related to QOL.
Limitations, reasons for caution: Of the 600 fertility clinics in Japan
only four urban facilities for data collection were used and were selected by a
convenience sample instead of a random sample. The diagnosis and the details
of the disease condition of infertile men with male factors were not
investigated.
Wider implications of the ﬁndings: Infertile male factors, mental anguish,
less spousal support, and longer period of infertility were associated with
poorer quality of life for infertile men. These results suggested that focusing on
infertility causes, distress conditions, length of infertility period, and support for
couples’ partnership are needed to maintain QOL during treatment.
Trial registration number: not applicable.
P-537 Evaluation of psychological distress in male patients
undergoing assisted reproductive technologies (ART) treatments
M. Mandas, D. García, S. Franci, R. Vassena, A. Rodríguez
Clínica EUGIN, Assisted Reproduction, Barcelona, Spain
Study question: Are men undergoing ART treatment more emotionally dis-
tressed, in comparison to a reference population?
Summary answer: ART male patients seem to present lower emotional mal-
adjustment and higher resources to cope with infertility than the reference
population.
What is known already: The psychological characteristics of men coping
with infertility and ART are understudied. A previous report analyzed men using
an online infertility support group and found that they were feeling sidelined and
marginalized in the process and in the way fertility professionals responded to
them. DERA is a validated instrument of 48 questions with a 5-point Likert scale
format developed to measure maladjustment and resources to affront mal-
adjustment in both women and men. The validation study was performed in
490 patients, including 220 infertile men. We now investigate emotional distress
and coping resources in heterosexual men undergoing ART with their partner.
Study design, size, duration: Cross-sectional study performed on 33 men
between May 2017 and January 2018. Participants completed the DERA ques-
tionnaire at the end of their treatment. We evaluated the emotional maladjust-
ment as well as the individual and interpersonal adaptive resources men may
have for coping with ART. The sum of personal and interpersonal resources
indicates the adaptive resources. The sum of the remaining answers indicates
the emotional maladjustment.
Participants/materials, setting, methods: Participants were Spanish male
patients undergoing IVF (n = 22) or IUI (n = 11) with their partner. In 6 cases
donor sperm was used (1 IVF and 5 IUI). The study was proposed to each
patient by an ART nurse. The participants ﬁlled in the questionnaire on the day
of the ET or IUI.
Main results and the role of chance: The mean age of participants was
36.2 ± 4.7 (range 29-52). The age of their female partner was 35.4 ± 3.5 (range
28-41). For 8 patients (75.8%) it was their ﬁrst ART cycle, while 2 participants
(6%) had children at the time of treatment. The sub-score of maladjustment
was, on average, 51.3 ± 14.7 (range 27-90), with P50 = 49; the sub-score of
personal resources 41.7 ± 4.7 (range 30–54), with P50 = 42.0; the sub-score of
interpersonal resources 45.1 ± 4.7 (range 35-55), with P50 = 45.5 and the
adaptive resources 86.7 ± 7.7 (range 70-109), with P50 = 86. Overall, our
results (P50) indicate lower maladjustment and higher resources to cope than
those of the reference population of the questionnaire (54-55, 41-42, 43 and
84 for, emotional maladjustment, personal resources, interpersonal resources
and adaptive resources, respectively).
When focusing on patients who needed donor sperm for their treatment,
we observed a slightly higher maladjustment (53.0 ± 8, P50 = 49.5), and lower
personal, interpersonal and adaptative resources (37.5 ± 4.7, P50 = 35, 40.8 ±
5.0, P50 = 41.5, and 78.3 ± 6.7, P50 = 81.0, respectively); these results should
be however conﬁrmed in a bigger cohort.
Limitations, reasons for caution: The main limitation of this study resides
in the relatively low number of patients included, in line however with several
studies regarding male ART patients.
Wider implications of the ﬁndings: Male patients accessing ART might
beneﬁt from individual psychological counseling and support; the impact of using
donated sperm on male patients’ emotional distress should be explored further
in future investigations.
Trial registration number:Not applicable.
P-538 Self-care (behavioral intention) during pregnancy and
postnatal depression in females who conceived with in vitro
fertilization (IVF)
D. Matsuura1, S. Okuhara2, S. Oguma2, Y. Kato2, N. Sato2,
N. Ogawa2, Y. Nojiri2, K. Kuroda3, S. Hayashi3, H. Furuhashi1,
T. Awa3, A. Tsuboi4, S. Takikawa4, M. Nomura4, K. Furui4
1Clinic Mama, Counseling, Gifu, Japan
2Clinic Mama, Embryo culture, Gifu, Japan
3Clinic Mama, Nurse, Gifu, Japan
4Clinic Mama, Medical Ofﬁce, Gifu, Japan
Study question: This study compared the incidence of postnatal depression
between patients conceiving with in vitro fertilization (IVF; IVF group) and nat-
urally (natural pregnancy group).
Summary answer: At 1 month after delivery, the IVF group showed a more
marked tendency to develop postnatal depression compared with the natural
pregnancy group.
What is known already: Using the Edinburgh Postnatal Depression Scale
(EPDS) (full score: 30) developed by Cox et al. (1987), Okano et al. (1996)
deﬁned females showing a score of 9 or higher at 1 month after delivery as
EPDS-positive, with a cut-off point of 8/9. Manabe et al. (2001) developed the
Self-care Scale for Pregnant Females (full score: 160), consisting of 4 subscales:
<prevention and early discovery of abnormalities in pregnancy (40)>, <prepar-
ation for delivery and mothering (40)>, <dietary habits (40)>, and <care in dai-
ly life (40)>.
Study design, size, duration: Among the 529 patients who had delivered in
our facility within the period between May and December 2017, 457 and 72
were classiﬁed into the natural pregnancy and IVF groups, respectively. At one
month after delivery, we evaluated the 529 patients using the 30-point EPDS
revised by Okano. Furthermore, at week 12 of pregnancy, we examined the
self-care consisting of 4 subscales in the Self-care Scale for Pregnant Females of
Manabe.
Participants/materials, setting, methods: In both groups, those showing
an EPDS score of 8 or lower and that of 9 or higher were deﬁned as EPDS-
negative and -positive, respectively. Subsequently, in the IVF group (12), scores
from the Self-care Scale for Pregnant Females (<prevention and early discovery
of abnormalities in pregnancy>, <preparation for delivery and mothering>,
<dietary habits>, and <care in daily life>) during pregnancy (at week 12 of
pregnancy) were compared between EPDS-negative (5) and -positive (7)
members.
Main results and the role of chance: Compared with the natural pregnancy
group, the IVF group showed signiﬁcantly higher EPDS scores, with a markedly
higher rate of being EPDS-positive. Furthermore, on comparing EPDS-positive
and -negative members of the IVF group, the former showed signiﬁcantly higher
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<care in daily life>-related scores from the Self-care Scale for Pregnant
Females, suggesting that they faced more marked stress when performing
<care in daily life> as part of self-care during pregnancy. In addition, the dur-
ation of outpatient treatment was longer among EPDS-positive than -negative
members, although the difference was non-signiﬁcant. There were no signiﬁcant
differences in parity or a history of miscarriage.
Limitations, reasons for caution: The presence/absence of postnatal
depression represents the psychological status of patients who conceived nat-
urally or with IVF at 1 month after delivery. Similarly, their scores from the Self-
care Scale for Pregnant Females represent their psychological status at week 12
of pregnancy. Stress assessment is based on an individual’s perception.
Wider implications of the ﬁndings: Compared with the natural pregnancy
group, the IVF group showed a more marked tendency to develop postnatal
depression (higher EPDS scores). Furthermore, on comparing scores from the
Self-care Scale for Pregnant Females, EPDS-positive of the IVF group showed
signiﬁcantly higher scores related to <care in daily life>.
Trial registration number:None.
P-539 Multidisciplinary gestational surrogacy care in absence of a
legal framework
E. Van Moer1, L. Leunens1, V. Schutyser1, S. Van Ginderdeuren1,
L. Gucciardo2, H. Tournaye1
1UZ Brussel, Centre for Reproductive Medicine, Jette- Brussels, Belgium
2UZ Brussel, Centre for Obstetrics and Prenatal Medicine, Jette- Brussels, Belgium
Study question: How to setup gestational surrogacy care at a medical setting,
in the absence of a legal framework?
Summary answer: In absence of legislation for surrogacy, thorough criteria,
evaluation by and cooperation within psychology, reproductive medicine, mid-
wifery and obstetrics are necessary to limit related risks.
What is known already: In many European countries, surrogacy is not ofﬁ-
cially allowed nor prohibited. Consequently, the persons involved are not legally
protected and are exposed to several risks.
The woman who gives birth is recognized as legal mother until an adoption
procedure is completed and approved in court. This implicates that theoretic-
ally the surrogate may claim motherhood and intended parents can abandon
their child.
Furthermore obstetrical and fetal complications and emotional distress may
occur.
Partially due to the absence of a legal framework, hospitals have a responsi-
bility to ensure a successful outcome. Legislating gestational surrogacy is
strongly adviced by fertility centres to diminish risks and responsibilities.
Study design, size, duration: In 2014, a core surrogacy team was installed
at an academic fertility centre. The team consists of a gynecologist, psychologist
and a midwife, all with a fertility subspecialisation. In order to implement a ges-
tational care program, at ﬁrst a literature study was conducted, secondly team
visits to other surrogacy providers were scheduled and ﬁnally the team con-
sulted a lawyer specialised in family law.
Participants/materials, setting, methods: Our research indicated that
surrogacy care requires a broader approach than just conventional fertility care.
Therefore, gynecologists and midwives, subspecialised in obstetrics joined the
team to ensure a complete approach and follow-up, from screening to handing
over of the newborn. The surrogacy-program includes a thorough screening
procedure, based on clear criteria for acceptance, a clinical pathway and a
detailed description of the role of each stakeholder, in order to reduce possible
risks.
Main results and the role of chance: We provide a program based on
altruistic surrogacy by performing IVF-treatment using only gametes of the
intended parents and single embryo transfer. Only surrogacy projects where a
long-standing history of friendship or kinship with the surrogate is observed are
accepted.
First both intended parents and surrogate are referred to a lawyer specialised
in family law where the absence of a legal framework, all risks and rights, and
the adoption procedure are fully explained.
The reproductive gynecologist analyses medical indication and fertility status
and is responsible for medical care and IVF-treatment.
During several consultations, the psychologist evaluates resilience, stability,
motivation, interpersonal and marital relationships, coping strategies, indica-
tions of psychopathology and personality measures of intended parents, surro-
gate and her partner.
An obstetrician performs an obstetrical screening of the surrogate aiming to
exclude any potential risk during pregnancy or childbirth.
When screening is completed, a report is submitted to the hospital’s ethical
committee for approval of the surrogacy treatment.
During the entire process, psychological support is provided by the psycholo-
gist assisted by the midwife. The midwife is responsible for navigating and coun-
seling the patients, discussing the birth plan, obstetrical care and guidance
during handing over after birth.
Limitations, reasons for caution:Not applicable.
Wider implications of the ﬁndings: Surrogacy is a complex process
demanding a structured approach. A team coordinator who acts as single per-
son of contact and manages all communication and cooperation is primordial to
maintain patient centered care. Therefore, a midwife with reproductive and
obstetrical background is best placed in order to achieve a favourable outcome.
Trial registration number:Not applicable.
POSTER VIEWING
Psychology and counselling
P-540 Religion, spirituality and faith:What is the real impact on
assisted reproduction?
E. Ono1, D.P.A.F. Braga2, B.F. Zanetti1, R.M.M. Melamed3,
A. Iaconelli Jr.4, E. Borges Jr.4
1Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida,
Scientiﬁc Department, Sao Paulo, Brazil
2Fertility Medical Group, Scientiﬁc Department, Sao Paulo, Brazil
3Fertility Medical Group, Psychology department, Sao Paulo, Brazil
4Fertility Medical Group, Clinical Department, Sao Paulo, Brazil
Study question: Is there any impact of the patient’s faith, religion and spiritu-
ality on the outcomes of intracytoplasmic sperm injection (ICSI) cycles?
Summary answer: There is a signiﬁcant relationship between patient’s reli-
gion, spirituality and faith on ICSI outcomes.
What is known already: Worldwide, more than eight in ten people identify
with a religious group. Many patients seek religion or spirituality to relieve suf-
fering and ﬁnd a source of strength to cope with the disease. It has long been
documented a positive association between religious involvement and better
adaptation to medical illness as well as increased level of well-being and quality
of life. Lately, there has been considerable interest in exploring the impact of
the spiritual and religious issues on the health of people with infertility diagnosis,
however nothing is known about the inﬂuence of these factors on the results of
Assisted Reproduction.
Study design, size, duration: This prospective study included 877 patients
undergoing intracytoplasmic sperm injection (ICSI) cycles from April/2016 to
June/2017. Patients ﬁlled a questionnaire with information on faith, religiosity,
and spirituality. The results of the questionnaires were correlated with: patient’s
age, number of retrieved oocytes, fertilization rate, number and rate of high
quality embryos, cycle’s cancelation, and pregnancy result using One way
ANOVA, followed by Bonferroni post hoc test and linear regression models.
Participants/materials, setting, methods: The study was performed in a
private university-afﬁliated in vitro fertilization center. Women were asked
about their religion; if they attend meetings of their religions, and in which fre-
quency; if they keep in touch with leaders of their religions or if they pray, and
in which frequency; whether their faith contributed to the decision to go
through the treatment; and in a scale, from 0 to 10, how did they believe in the
treatment success.
Main results and the role of chance: Patients were divided into: Catholics
(n = 457), Spiritists (n = 114), Evangelicals (n = 138), Other (n = 52), and No
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religion (n = 98). Eighty patients were not willing to respond to the question-
naire. The signiﬁcant effects of the religions on ICSI outcomes are described in
Table 1. An increased pregnancy rate was observed in patients who reported
including infertility diagnosis and treatment in their prayers (31.4% vs. 5.5%, p
= 0.039). The high-quality embryos rate increased among patients who
answered that their faith contribute to their decision to undergo infertility treat-
ment (38.,9% vs. 28.4% p = 0.012) and those who belief in the treatment’s suc-
cess (RR: 0.001–0.0013, p = 0.022), while it decreased if they afﬁrmed that
their faith was affected by their infertility diagnosis (29.9% vs. 39.2% p = 0.050)
or that religiousness had negatively affected the decision to undergo infertility
treatment (8.24% vs. 36.8%, p = 0.010).
Limitations, reasons for caution: This questionnaire is subjective and may
not reliably reﬂect the actual potential of the patient’s faith and degree of religi-
osity/spirituality. Further bias may come from how prayer, spirituality and faith
are understood, duration or types of prayer, or conditions in which prayers,
contact with leaders, or religious meetings are performed.
Wider implications of the ﬁndings: Spirituality plays a role in adjusting psy-
chological aspects of an infertile patient. Given that prayer or other spiritual
approaches are safe and low-risk strategies, ART professionals need to be
aware of the use of these strategies as non-pharmacological, non-invasive
adjunct therapies.
Trial registration number:None.
P-541 The unwillingness to be in contact with the painful
experience of infertility: experiential avoidance as a mediator in
relationship between infertility-related stress and depressive
symptoms
A. Galhardo1, J. Alves2, M. Moura-Ramos3, M. Cunha1
1Instituto Superior Miguel Torga- CINEICC-Faculty of Psychology and Educational
Sciences of the University of Coimbra, Psychology, Coimbra, Portugal
2Instituto Superior Miguel Torga, Psychology, Coimbra, Portugal
3CINEICC-Faculty of Psychology and Educational Sciences of the University of
Coimbra, Psychology, Coimbra, Portugal
Study question: Does experiential avoidance play a mediating role in the rela-
tionship between infertility related stress and depressive symptoms?
Summary answer: Representations about parenthood were associated with
depressive symptoms indirectly, throughout the association with the impact of
infertility in women’s life and use of experiential avoidance.
What is known already: Experiential avoidance or psychological inﬂexibility
is described as encompassing two related components: unwillingness to remain
in touch with aversive private experiences (including bodily sensations, emo-
tions, thoughts, memories, and behavioral predispositions), and action to
change aversive experiences or the events that trigger them. It has been suggest
that experiential avoidance can be seen as a vulnerability factor for the develop-
ment and maintenance of psychopathology. Studies addressing experiential
avoidance in people dealing with infertility are scarce but couples with an infer-
tility diagnosis pursuing medical treatment presented signiﬁcantly higher scores
of experiential avoidance when compared to fertile couples and couples apply-
ing for adoption.
Study design, size, duration: Cross sectional study. Data were collected
online through self-report instruments between February 2016 and June 2016.
Inclusion criteria were age (18 years or older), and an infertility medical diagno-
sis. The study was conducted in a sample of 124 infertile women pursuing med-
ical treatment.
Participants/materials, setting, methods: A sample of 124 infertile
women pursuing medical treatment completed online the following standar-
dized self-report measures: Fertility Problem Inventory (FPI), Acceptance and
Action Questionnaire (AAQ-II), and the depression scale of the Depression,
Anxiety and Stress Scale (DASS-21). Patients were invited to participate
through a post on the national patients association, gave their informed consent
and were asked to ﬁll in the questionnaires. The mediation model analysis was
tested with the SPSS Process macro.
Main results and the role of chance: The model examined the direct and
indirect effect of representations about parenthood on depressive symptoms,
by modeling the mediation effects of representations about the importance of
parenthood on the impact of infertility on participants’ life domains and of this
on experiential avoidance. The direct effect of representations about parent-
hood on depressive symptoms was nonsigniﬁcant (effect = .04, SE = .02, p
= .127). The indirect effect of representations about the importance of parent-
hood on depressive symptoms, while modeling the inﬂuence of the intervening
variables, was statistically signiﬁcant (Indirect effect = 0.03, 95%CI: [.015; 050]).
An alternative model considering that people facing infertility that highly value
parenthood tend to avoid situations and feelings related to children and this
may be associated with higher impact of infertility on life domains (e.g. social
isolation, poor sexual relationship), which would be associated with depressive
symptoms was also tested. The result on the indirect effect of this serial mul-
tiple mediation model included 0 and therefore was not signiﬁcant (Indirect
effect = 0.01, 95%CI: [.00; 03])
Limitations, reasons for caution: The ﬁndings rely on cross-sectional and
self-report data. Even though a sequential mediation effect was tested, the
framework to establish the sequence of the variables is a theoretical one, and
not a temporal one. The online recruitment tends to recruit more educated
participants, with easy access to online platforms.
Wider implications of the ﬁndings: Results suggest that the tendency of
infertile women to avoid thoughts, emotions and situations associated with par-
enthood, as a way of trying to escape from the infertility painful experience,
induces higher suffering. Consequently, the core emotional regulation process
of experiential avoidance should be addressed by psychologists in the clinical
context.
Trial registration number:Not applicable.
P-542 The implications of the religious/spiritual beliefs and
practices among commercial gestational carriers in the United
States for international surrogacy arrangements
M. Riddle
The Pennsylvania State University, Psychology Department, University Park, U.S.A.
Study question: What are the implications of the religious/spiritual beliefs
and practices of commercial gestational carriers (GCs) in the United States for
mental health evaluations in international surrogacy arrangements?
Summary answer: Discussing religion/spirituality within a mental-health
evaluation serves a GC’s psychological best interests and may help to match
them with intended parents (IPs) from other countries/cultures/religions.
............................................................................................................................
.............................................................................................................................................................................................
Table 1 The effect of patient’s religion on ICSI outcomes, controlled for patient’s age.
Patient’s religion
Catholic Spiritist Evangelical Other No religion p
Fertilization Rate 82.0 ± 1.7a 89.9 ± 9.3b,c 87.0 ± 3.5e 72.4 ± 3.7b,d,f 70.6 ± 3.5b,d,f 0.007
High quality embryos 2.6 ± 0.2a 3.6 ± 0.4b 3.0 ± 0.3b,d 0.9 ± 1.3c 1.2 ± 0.6c 0.043
High quality embryos rate 32.6 ± 2.3a 47.1 ± 3.3b 45.1 ± 4.3b 36.3 ± 9.7c 43.1 ± 5.1b 0.043
Pregnancy Rate 32.9%a 58.0% b 33.9%c 31,2.%a 23,0%d 0.047
a≠b, c≠d, e≠f
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What is known already: Religious customs and beliefs inﬂuence both the
practice and prohibition of surrogacy around the globe. It has been theorized
that religious and spiritual themes are more likely to emerge among altruistic
(unpaid) surrogates. Little is known about the religious/spiritual beliefs and
practices of commercial surrogates in the United States (US) and how these
beliefs inﬂuence the process of surrogacy. No studies to date have examined
how incorporating a discussion on religious/spiritual beliefs and practices might
contribute to both the psychological evaluation process of potential GCs and
the matching process with IPs who are coming from other countries and
cultures.
Study design, size, duration: This is a qualitative research study using a
grounded theory approach. 17 GCs raised in diverse denominations of faith
were recruited via an ad posting from across the United States to participate in
this study. GCs were interviewed using in-depth, semi-structured interviews
that were conducted via Skype. Interviews lasted between 60-90 minutes and
took place over a 4-month period (January through April, 2017).
Participants/materials, setting, methods: 17 GCs had a total of 28 surro-
gate pregnancies (36 surrogate children). 76% (n = 13) of participants worked
with international IPs. Participants came from a variety of religious backgrounds
(Mornon/LDS, Catholic, Baptist, Christian). GCs were recruited via an ad post-
ing on websites frequented by carriers and through surrogacy agencies. In-
depth, semi-structured interviews were conducted via Skype. Interviews were
audiotaped and transcribed verbatim. Grounded theory of analysis of data
included line-by-line coding and emergent themes were identiﬁed.
Main results and the role of chance: Themes emerging from the narrative
data included Gestational Surrogacy as a Religious/Spiritual “Calling”;
Motivation for Surrogacy Rooted in Faith Beliefs; Gestational Surrogacy as
Providing Existential Meaning and Purpose to Life; Role of Religious/Spiritual
Beliefs in Relationships with IPs. Some GCs felt their surrogacy experiences
were part of “God’s plan” that shaped their future trajectory providing existen-
tial meaning to life. GCs felt that their decision to become a surrogate was
“doing the will of God” and that they were “furthering God’s kingdom”. GCs
felt they were providing a positive role model for their children by modeling
Christian values. In the words of one GC (when asked whether it was important
for mental health professionals to ask about religious/spiritual issues in the psy-
chological evaluation): “My religion is very important to me - it’s part of who I
am - it’s part of who I’ve become - I deﬁnitely think this is something that should
be talked about.”
Unexpected ﬁndings included reticence on the part of some GCs in sharing
their belief system in their psychological evaluation for fear of being excluded
based on their beliefs or feeling that their beliefs would be seen as
psychopathology.
The role of chance in these results is minimal.
Limitations, reasons for caution: This is a qualitative study and, therefore,
the generalizability of the ﬁndings should be treated with caution.
Wider implications of the ﬁndings: Findings suggest that religious/spiritual
narratives are not the exclusive domain of altruistic surrogates. Discussing reli-
gion and spirituality can enhance the psychological evaluation and counseling of
potential GCs and may also help in matching GCs to IPs, particularly when they
are international arrangements representing diversity in religious beliefs and
practices.
Trial registration number:Not Applicable.
P-543 Somatising the desire toward a child among Hong Kong
Chinese women undergoing IVF: Themediating role of anxiety
C.H.Y. Chan, M.Y.J. Tam, B. Lau, Q.S.Wong
The University of Hong Kong, Department of Social Work and Social Administration,
Hong Kong Island, Hong Kong
Study question: Does anxiety mediate the effect of importance of childbear-
ing on physical symptoms among Hong Kong Chinese women undergoing IVF?
Summary answer: Anxiety fully mediates the effect of importance of child-
bearing on physical symptoms among women undergoing IVF after controlling
for demographic and clinical factors.
What is known already: Anxiety is a common emotional reaction among
women undergoing IVF. The unpredictable and uncontrollable nature of IVF
fuels anxiety toward its process and outcome. Anxiety could be somatised and
manifested in physical symptoms such as fatigue, headache, insomnia, and mus-
cle pain. The stake and therefore the anxiety toward the IVF treatment could
be heightened if the couple regards having a child as essential to themselves,
their relationship and the family. Hence, this study examined whether perceived
importance of childbearing escalates physical symptoms of somatization, and
whether anxiety mediates the relationship between such attitude and physical
distress.
Study design, size, duration: This analysis utilized the baseline data of a ran-
domized controlled trial that compared the effectiveness of a body-mind-spirit
intervention in reducing the anxiety of women during the two-week wait before
pregnancy test against two control conditions (health education and spiritual
intervention). 225 participants who provided complete response to the items
required in this analysis was included. The baseline data was collected in
between 2015 and 2017 from the Queen Mary Hospital, Hong Kong.
Participants/materials, setting, methods: Women who were going to
undergo IVF were recruited. The importance of childbearing was measured by
a 4-item scale; anxiety was assessed by the State-Trait Anxiety Inventory (State
scale); physical symptoms were evaluated by the 14-item physical distress scale
of Body-Mind-Spirit Well-Being Inventory. The mediation analysis was con-
ducted with PROCESS macro in SPSS with 5000 bootstrapped samples, and
with women’s and husbands’ age, previous ART treatment, subfertility years,
subfertility type, and causes of subfertility controlled.
Main results and the role of chance: Perceived importance of childbearing
was positively correlated with state anxiety (r=.31; p<.001) and physical dis-
tress (r=.20, p<.001), and physical distress was positively correlated with state
anxiety (r=.35, p<.001). After controlling for demographic and clinical charac-
teristics, childbearing importance was signiﬁcantly associated with physical dis-
tress in the total effect model, B = 0.69, SE = 0.23, [95%CI of B = 0.22-1.15],
p=.0038. However, when state anxiety was added to the model, state anxiety
was signiﬁcantly related to physical distress, B = 0.70, SE = 0.14, [95%CI of B
= 0.42-0.98], p<.001, and the association between childbearing importance
and physical distress was no longer signiﬁcant (p>.05). The indirect effect was
statistically signiﬁcant, B = 0.36, SE = 0.10, [95%CI of B = 0.20-0.59]. In other
words, full mediation by state anxiety was found in the effect of childbearing
importance on physical distress. The analysis was repeated by interchanging the
role of physical distress and state anxiety, such that physical distress became
the mediator. However, although the indirect effect was statistically signiﬁcant,
the mediation was partial as the direct effect from childbearing importance to
state anxiety continued to be signiﬁcant too. Hence, the former model was
regarded as a more parsimonious representation of the relationship among
childbearing importance, state anxiety and physical distress. Statistical signiﬁ-
cance was indicated by a p-value below 0.05.
Limitations, reasons for caution: Physical distress was evaluated by self-
report of the participants. Recall bias and self-selection bias may reduce the
generalizability of the ﬁndings.
Wider implications of the ﬁndings: Interventions that aim at reducing anx-
iety during IVF treatment should take into account personal value and expecta-
tions attached to childbearing and the somatization of such concerns. Our
ﬁndings also highlight the interaction among values, emotions and physical dis-
tress, and provide empirical foundation for multi-component interventions that
address these aspects.
Trial registration number: HKUCTR-1984
P-544 Typology of family involvement and fertility-speciﬁc Quality
of Life among Chinese couples with infertility: A cluster analysis
Y. Sylvia Hong1, C.H.Y. Chan1, Y.J. Hou2, R. Li3, W. Shang4,
C.L.W. Chan1
1University of Hong Kong, Social Work and Social Administration, Hong Kong, Hong
Kong
2Renmin University of China, School of Sociology and Population Studies, Beijing,
China
3Peking University Third Hospital, Obstetrics and Gynecology, Beijing, China
4Navy General Hospitcal, Obstetrics and Gynecology, Beijing, China
i391Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Study question: To identify subgroups of Chinese infertile couples based on
their experiences with family emotional supports, economic supports and
interference.
Summary answer: Four relatively distinct subgroups regarding family involve-
ment were identiﬁed, namely, intrusive, detached, emotionally responsive, and
economically supportive categories.
What is known already: Family involvements, largely divided into supports
and interference were found to have mixed effects on wellbeing of married cou-
ples. As the primary social support reservoir, family supports served as protect-
ive factors for couples to overcome psychosocial distress caused by infertility.
However, overwhelming interferences and unwanted inquiries from social net-
works could turn into detrimental stressors for married couples, especially dur-
ing experiences of infertility. There are limited evidences regarding the typology
of family involvements experienced by infertile couples, which constraint the
development of family-oriented psychosocial services.
Study design, size, duration: A cross-sectioned study was implemented
during October to December 2016. Current study recruited 429 infertile cou-
ples in a reproductive center afﬁliated to a public hospital in Beijing, China.
Eligibility criteria for inclusion were couples who were (1) legally married; (2)
medically diagnosed with infertility and (3) undergoing assisted reproductive
treatments. After obtaining written consents, infertile couples were invited to
take questionnaires separately and independently to avoid dyadic interference.
Participants/materials, setting, methods: Despite demographic informa-
tion, family involvement scale and Fertility-speciﬁc Quality of Life were used to
measure key variables. Mean age of wives and husbands were 34.21 ± 6.22 and
32.50 ± 5.12, respectively and couples had been married for six years approxi-
mately. More than half of participants received tertiary education (62.9%) and
69.4% had a full-time job. In terms of the infertility etiology, there are 252
female factor, 250 male factor, 170 both factor and 148 unexplained factor
infertility.
Main results and the role of chance: Cluster analysis identiﬁed four sub-
groups regarding emotional responsiveness, economic supports and interfer-
ence, namely, intrusive (44 pairs), detached (92 pairs), emotionally responsive
(107 pairs), and economically supportive (178 supports) groups. There were
signiﬁcant between-group differences regarding FertiQoL scores (F = 3.09,
P<0.05 for husbands; F = 4.58, P<0.01 for wives). Multiple comparison results
indicated wives in intrusive subgroups show signiﬁcant lowest emotional QoL,
social QoL and total FertiQoL scores comparing to their counterparts in other
three subgroups. For social QoL, husbands in detached subgroups show signiﬁ-
cantly lower scores than husbands in emotionally and economically supportive
subgroups. Moreover, husbands in emotionally supportive subgroups show
higher emotional QoL and total FertiQoL scores than husbands in intrusive and
detached subgroups. In terms of relational QoL, both wives and husbands in
emotionally and economically supportive subgroups reported signiﬁcantly high-
er scores than their counterparts in detached and intrusive subgroups. No sig-
niﬁcant between-group differences on mind-body QoL for couples.
Limitations, reasons for caution: Current study carried several limitations.
First of all, measures used to evaluate family supports and interference was uni-
versal, rather than being speciﬁc to infertility. Secondly, cross-sectional research
design adopted by current study was constrained to draw causal inferences.
Finally, self-selection bias might limit generalizability of results found in this
study.
Wider implications of the ﬁndings: Despite person-centered and dyadic
approach in infertility counseling, family-oriented interventions should be
designed to improve quality of life for couples during experiences of infertility.
Given the signiﬁcance of emotional supports, it is extremely important to
extend the therapeutic alliance through educating extended families regarding
emotional competence and skills.
Trial registration number:Not applicable.
P-545 Themediating role of self-compassion between parental
interference and quality of life among Chinese infertile couples: An
actor-partner interdependence model
S.H. Yao1, C.H.Y. Chan2, H. Ya Jie3, R. Li4, C.L.W. Chan5
1The University of Hong Kong, Faculty of Social Science, Hong Kong, China
2University of Hong Kong, Social Work and Social Administration, Hong Kong, China
3Renmin University of China, School of Sociology and Population Studies, Beijing,
China
4Peking University Third Hospital, Obstetrics and Gynecology, Beijing, China
5University of Hong Kong, Social Work and Social Administration, Hong Kong, Hong
Kong
Study question: This study aims to test the mediating role of self-compassion
between the relationships between parental interference and quality of life
(QoL) among Chinese infertile couples.
Summary answer: Self-compassion partially mediated the negative relation-
ships between in-law/family-of-origin interference and QoL for both husbands
and wives. No partner effects have been found in current study.
What is known already: Infertility, as a collective family crisis, could involve
actions of the entire family. Studies conducted in Chinese context found the
overwhelming attentions and unwanted inquiries from the extended families
could cause psychosocial distress for infertile couples. Parental interference
became a risk factor for the wellbeing of infertile couples, though differences
between in-law and family-of-origin interference wellbeing still remained inad-
equate. Moreover, a dearth of studies has identiﬁed self-compassion as a medi-
ating factor between family supports and psychological wellbeing; however, few
studies explore its mediating role between interference as the opposite of sup-
ports, and psychosocial outcomes, particularly in infertility context.
Study design, size, duration: A cross-sectioned study was implemented
during October to December 2016. Current study recruited 431 infertile cou-
ples in a reproductive center afﬁliated to a public hospital in Beijing, China.
Eligibility criteria for inclusion were couples who were (1) legally married; (2)
medically diagnosed with infertility and (3) undergoing assisted reproductive
treatments. After obtaining written consents, infertile couples were invited to
take questionnaires separately and independently to avoid dyadic interference.
Participants/materials, setting, methods: Despite demographic informa-
tion, family involvement scale and Fertility-speciﬁc Quality of Life were used to
measure key variables. Mean age of wives and husbands were 34.23 ± 6.21 and
32.49 ± 5.11, respectively and couples had been married for six years approxi-
mately. More than half of participants received tertiary education and 69.9%
had a full-time job.
Main results and the role of chance: Current study adopted actor-partner
interdependence mediation model (APIMeM) to investigate the mediating role
of self-compassion in the negative relationships between parental interference
(in-law/family-of-origin interference) and QoL among infertile couples. For the
in-law interference, APIMeM results conﬁrmed two signiﬁcant mediation effects
of self-compassion in the negative relationships between in-law interference
and QoL for both husbands and wives (b=-0.057, p<0.01). In terms of family-
of-origin interference, APIMeM results also showed two signiﬁcant actor effects
for both husbands and wives (b=-0.07, p<0.001). However, no partner effects
have been found in all APIM models. These signiﬁcant actor effects indicated
that the mediating effects of self-compassion on the associations between par-
ental interference and QoL only existed at the individual level, rather than the
intra-couple level.
Limitations, reasons for caution: Current study carried several limitations.
First of all, measure used to evaluate family interference was universal, rather
than being speciﬁc to infertility. Secondly, cross-sectional research design
adopted by current study was constrained to draw causal inferences. Finally,
self-selection bias might limit generalizability of results found in this study.
Wider implications of the ﬁndings: To mitigate the negative effects of fam-
ily interference, family-oriented psychosocial education should be developed to
prepare extended families to support in a way that suited infertile couples’
needs. Given the mediating role of self-compassion, counseling and interven-
tions should aim at awaking and improving couples’ inner strengths during
experiences of infertility.
Trial registration number:Not applicable.
P-546 Effects of infertility on quality of life in Greek infertile
women
M. Souropani1, M. Konstadoudaki2
1Institute of Life -IVF- IASO CLINIC -ATHENS, Institute of Life -IVF -IASO CLINIC
-ATHENS, ATHENS, Greece
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2Institute of life, Iaso clinic, athens, Greece
Study question: Can the infertility and its treatment affect the quality of life of
infertile women?
Summary answer: The experience of infertility is highly stressful for women.
In general, women have lower levels of fertility -related to quality of life.
What is known already: Infertility inﬂuences all the dimension of women life.
Social and family pressure, well-being,change in marital relationship and in sex-
ual satisfaction can lead to impairment in quality of life.Attention to their quality
of life guarantees stability and satisfaction with life and establish an effective rela-
tionship between patient and her treatment team.Quality of life has become
one of the most crucial issues nowadays and is seen as one of the measurable
criteria for evaluation of treatment.Promotion of quality of life in infertile
women requires a deep understanding of their problems from different aspects.
Study design, size, duration: We included 192 infertile women,who were
attended the clinic Institute of Life, under at any stage of treatment, at the
beginning of treatment and at the day of embryo transfer, from April to
November 2017.
Participants/materials, setting, methods: This is a cross- sectional study
in which 192 infertile women were (aged 30-45) participated.The subjects,who
visited the Institute of life clinic, were selected through random sampling.Data
were collected using a questionnaire which had two sections:demographic
information and FertiQol questionnaire which measured the quality of life. The
collected data were analyzed using SPSS version 16.
Main results and the role of chance: The result showed that were no sig-
niﬁcant difference between quality of life of infertile women and socio-
demographic factors. A regression analysis was conducted and showed that age
is characterized as a predictor of infertility.Age has be noted as a factor which is
signiﬁcant with infertility, on the other hand education of infertile women has be
noted as a non signiﬁcant factor that affects infertility in accordance with regres-
sion analysis of the present study.
Limitations, reasons for caution: We have only included women who
were undergoing in vitro fertilization (IVF) treatment in the study.Due to prac-
tical reasons their partners did not participate.The result of the study may be
inﬂuenced by the small sample size.
Wider implications of the ﬁndings: Data were obtained only from one
clinical site. The present study would has a huge interest if also record couples
or even men opinion about infertility.
Trial registration number: non clinical trial.
P-547 Health and wellbeing of adults conceived by IVF: a
comparison of those who do and don’t participate in a follow up
study
J. Halliday1, R. McLachlan2, S. Farrow1, J. Kennedy1,
K. Hammarberg3, D. Burgner4, L. Doyle5, J. McBain6, D. Amor7,
M. Juonala8, M. Cheung9, S. Ranganathan10, L.Welsh10, S. Lewis1
1Murdoch Children’s Research Institute, Public Health Genetics, Melbourne, Australia
2Hudson Institute of Medical Research, Department of Molecular and Translational
Sciences, Melbourne, Australia
3Monash University, School of Public Health and Preventive Medicine, Melbourne,
Australia
4Murdoch Children’s Research Institute, Susceptibility to Paediatric Infection,
Melbourne, Australia
5The Royal Women’s Hospital, Department of Obstetrics and Gynaecology,
Melbourne, Australia
6Melbourne IVF, Reproductive Services, Melbourne, Australia
7Murdoch Children’s Research Institute, Developmental Disability and Rehabilitation
Research, Melbourne, Australia
8University of Turku, Department of Internal Medicine, Turku, Finland
9The Royal Children’s Hospital, Department of Cardiology, Melbourne, Australia
10The Royal Children’s Hospital, Department of Respiratory and Sleep Medicine,
Melbourne, Australia
Study question: Will there be measurable differences in characteristics of
participants and non-participants that could bias the results of a clinical review
follow up study?
Summary answer: Based on questionnaire data obtained by telephone sev-
eral years before, factors inﬂuencing participation in the current clinical review
were not major confounders.
What is known already: As there is wide belief that common adult health
problems have their origins in early life, the IVF population might be at an
increased risk through epigenetic mechanisms. In our earlier telephone
interview-based study of this cohort, differences between the IVF and a spon-
taneously conceived control group were found, i.e. increased respiratory condi-
tions, such as asthma and hay fever, and increased hospital admissions in
childhood and adolescence. In terms of clinical review, there have been few
studies to date of adults conceived by ART but a small number report on cardi-
ometabolic outcomes and suggest a difference.
Study design, size, duration: This retrospective cohort of 24-35 year olds
was recruited for clinical follow up in 2016-2017. 530 IVF-conceived and 490
age and sex-matched, spontaneously conceived controls were invited to
participate.
Participants/materials, setting, methods: Participants were those who
had completed a telephone interview in an earlier study in Victoria, Australia,
and who were willing to come to the hospital for a clinical review, which took
approximately three hours, encompassing assessments of cardiovascular struc-
ture and function, cardiometabolic proﬁle, respiratory function and growth. A
comparison of characteristics (e.g. health, sociodemographic, psychosocial) of
participants with non-participants was possible using the questionnaire data col-
lected in the initial telephone interview study.
Main results and the role of chance: Of the 179 (33.8%) IVF-conceived
and 81 (16.5%) controls who participated in the follow up study, females were
more likely to participate than males (58% of IVF and 69% of controls). Active
decline occurred in 21% of both groups and the remaining proportion did not
respond to three invitations to participate. The following key variables demon-
strated no signiﬁcant differences between participants and non-participants
within both the IVF and control study groups: number of hospitalisations in
childhood, chronic illness, asthma, allergies, mental health, gestation at birth,
mother’s age and parity, BMI, perceived age at sexual maturity, fertility con-
cerns, quality of life, ﬁnancial status, educational attainment (level of schooling).
In the IVF group, participants were younger than non-participants when initially
interviewed (61% <20 years compared with 48%, p = 0.01) and fewer worked
>37 hours/week (36% vs 46%, p = 0.05). In the control group, participants had
more allergies than non-participants (26% vs 19.3%, p = 0.03), were less likely
to be in a relationship (41% vs 58%, p = 0.03), and had more anxiety/behaviour
problems (32% vs 21.5%, p = 0.04). In both groups, among those who had
completed school, non-participants had a lower ﬁnal average education score
than participants (p = 0.01).
Limitations, reasons for caution: Comparisons are based on self-reported
data without validation, but the same errors in reporting are likely to be seen
across all groups. Also, there has been a time lag between the telephone inter-
view and clinical review (5-6 years) and we have no knowledge of that interven-
ing period in non-participants.
Wider implications of the ﬁndings: Although participation was lower than
expected, the similarity of characteristics between participants and non-
participants reduces concern about selection bias. Furthermore, knowing what
the few differences between participants and non-participants are, enables sen-
sitivity analyses. We therefore expect that the clinical review will contribute
substantially to knowledge of long-term safety of IVF.
Trial registration number: not applicable.
P-548 Yoga as an adjuvant to enhance the outcome of IVF
treatment
P. Nayar, K.D. Nayar, M. Singh, N. Aggarwal, M. Gupta, R.A. Gupta,
G. Kant, R. Gahlot, K. Nayar
Akanksha IVF Centre- Mata Chanan Devi Hospital, Reproductive Medicine, new
delhi, India
Study question: To study the effect of Yoga on clinical pregnancy rates in
women undergoing frozen embryo transfer.
Summary answer: This study suggests Yoga can be an adjuvant to improve
the pregnancy rates in couples undergoing frozen embryo transfer.
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What is known already: The distress of the diagnosis and the treatment of
infertility is a known, well established fact. It can be confounding variable which
can lead to poor treatment compliance, and hence outcome. Yoga is system of
neuromuscular retraining which helps the organism to learn the relaxation
response and a faster regaining of homeostasis after stress. Utilization of the
techniques may help woman to cope with the roller coaster of psychophysio-
logical states accompanying diagnosis and management of infertility.
Study design, size, duration: The study was conducted from 01.01. 2016
to 31.12.2017 at a private infertility centre. 150 women were randomly allo-
cated to two groups. Group A (N = 77) attended 3 months of Yoga, thirty ses-
sions- involving asana (exercises) and pranayama (regulated breathing) before
undergoing frozen embryo transfer and Group B (N = 73) underwent frozen
embryo transfer after 3 natural cycle without any Yoga adjuvant. Primary out-
come was clinical pregnancy rates. Secondary outcomes were change in psy-
chological test scores.
Participants/materials, setting, methods:Women with primary infertility
> 5 years, who did not conceive in the ﬁrst IVF cycle and were to undergo fro-
zen embryo transfer in subsequent cycle were enrolled.Age > 38 years, Fibroid
> 5 cm, either side hydrosalpinx, adenomyosis were excluded. Psychological
assessment was done at baseline (S1) and after 3 months (S2) before ET using
Hamilton Depression Rating Scale (HAM- D), Hamilton Anxiety Rating Scale
(HAM-A) and FertiQol.
Main results and the role of chance: The Clinical Pregnancy rates were sig-
niﬁcantly better in Group A compared to Group B( 49.35% vs 32.87%: p =
0.04). There was a signiﬁcant S1 to S2 reduction after YOGA therapy in
Hamilton Depression rating Scale (HAM- D), Hamilton Anxiety Rating Scale
(HAM-A) ( p< 0.001 for HAM-D and p<0.001 for HAM-A).The improvement
in quality of life as seen on FertiQol but not statistically signiﬁcant.
Limitations, reasons for caution: The study was done on a single centre,
replication with more subjects and in different centres is needed.
Yoga encompasses a heterogeneity of techniques, there is a need to develop
a standardised protocol suitable for the infertility patients which is simple, safe
and effective.
Wider implications of the ﬁndings: Integrating yoga as an adjuvant to
infertility treatment management may provide a simple, economic non invasive
method which can enhance the outcome of the IVF treatment. It is cost effect-
ive and safe.
Trial registration number:MCDH/2016/54.
P-549 Fertility knowledge of Japanese university students who
aspire to be schoolteachers in the future
Y. Akizuki1, S. Kusunoki2
1Kumamoto university, educational department, Kumaomto-shi-, Japan
2Kumamoto University, Graduate School of Education, Kumamoto-shi, Japan
Study question: The aim of this study was to clarify the fertility knowledge of
Japanese students who just entered the education department of one
university.
Summary answer: Fertility knowledge among education students is insufﬁ-
cient, except for questions related to aging and smoking as risk factors.
What is known already: It is obvious that aging, STDs, obesity and smoking
have a negative inﬂuence on fertility. Many previous studies reported that
knowledge about fertility, reproduction and infertility among high school and
university students is insufﬁcient. Very limited research investigating fertility
knowledge and attitudes toward fertility education among Japanese schooltea-
chers has been conducted. One study showed that the majority of teachers do
not have enough fertility knowledge and are not conﬁdent in teaching this topic
to students. However, the fertility knowledge of younger people who aspire to
become schoolteachers in the future has not been clariﬁed.
Study design, size, duration: We conducted a quantitative, cross-sectional
questionnaire survey of ﬁrst-year education department students in April 2017
at one university in the Kyusyu area. Questionnaires were distributed to all 291
students in an introductory psychology class that is required for all ﬁrst-year
education students. Only those who consented to participate in the survey
were asked to complete the questionnaire.
Participants/materials, setting, methods: Although the response rate
was 100%, those who were not ﬁrst-year education students were excluded,
leaving 252 participants.
The questionnaire asked about sociodemographic variables, desire to have a
child, life planning experience, and daily life habits. To measure fertility knowl-
edge, including the reproduction system and infertility, the Cardiff Fertility
Knowledge Scale (13 items) and six original questions were used. To assess the
relationship between fertility knowledge, gender and other variables, chi-square
analysis was conducted.
Main results and the role of chance: 96.1% (242) of participants were 18-
19 years old and 60.3% (152) were women. Although only 8.7% (22) currently
had a sex partner, nearly 90% desired to have a child in the future.
Approximately 70% experienced life planning in the past and almost 60% were
interested in their own fertility.
The accuracy of knowledge about the effects of aging and smoking on fertility
was comparatively high (71-90%). On the other hand, less than half answered
the question about STDs as a risk factor of fertility correctly. As for questions
concerning infertility (deﬁnition, frequency, gender ratio of cause), accuracy was
not high (39-52%). The accuracy of the timing of pregnancy during the men-
strual cycle was under 30%. Although over 60% correctly answered the ques-
tion concerning the frequency of sperm production, only 4% correctly
answered the question about the frequency of primordial egg generation.
As for fertility knowledge and gender, the accuracy of the question ‘A woman
who never menstruated is still fertile’ among women was signiﬁcantly higher
than men. For the question about the frequency of sperm production, men had
a higher accuracy rate than women. However, men’s accuracy rate for the
question about menopause was signiﬁcantly lower than women.
Limitations, reasons for caution: The limitation of this study is that all par-
ticipants were selected from only one university in the Kyusyu area in Japan.
Therefore, caution should be taken when generalizing the results to the general
population of Japanese university education department students.
Wider implications of the ﬁndings: From the present results, in order for
younger people to have a child in the future when they desire, it is essential to
give them accurate fertility knowledge. Therefore, ﬁrst, schoolteachers should
have accurate fertility knowledge to teach students. This might contribute to
decreasing infertile patients due to age.
Trial registration number: not applicable.
P-550 Psychological inﬂuence of azoospermic male infertility
diagnosis amongmen about to start in-vitro fertilization (IVF)
treatment using donor sperm
M. Sharma, K.D. Nayar, P. Nayar, N. Agarwal, M. Singh, M. Gupta,
G. Kant, R.A. Gahlot, K. Nayar
Akanksha Ivf Centre- Mata Chanan Devi Hospital, Reproductive Medicine, New
Delhi, India
Study question: To compare psychological stress among men undergoing
assisted reproductive technology (ART) with donor sperm compared to stress
among men undergoing ART with own sperm.
Summary answer: The depression scores among males with donor sperm
used as compared to males using their own sperm were signiﬁcantly higher.
The marital satisfaction was same.
What is known already: Studies comparing women and men found that
women react more strongly overall to infertility. Some studies also suggest that
men’s experience of infertility is connected to threats to their masculinity. So, it
was thus anticipated that even after donor sperm ART, male factor infertility
could inﬂuence men’s psychological well being. The aim of this study was to
investigate whether a diagnosis of male azoospermic infertility had any inﬂuence
on their experience of anxiety, depression and spousal relationship well being
as compared to male partner in couples where the diagnosis was male, female,
mixed or unexplained infertility.
Study design, size, duration: A cross sectional study was conducted with
100 couples attending the Out Patient Department of Akanksha IVF, Delhi for
the ﬁrst IVF cycle from January 2017 up to December 2017. 50 of these were
diagnosed with azoospermic male infertility requiring donor sperm (Group 1),
while the remaining 50 were diagnosed with other causes of male infertility,
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female infertility, mixed or unexplained infertility using husband sperm (Group
2). Data were analyzed using SPSS software version 20.
Participants/materials, setting, methods: The study population com-
prised of 100 male partners who consented to participate in the study. A ques-
tionnaire was given to male partners at start of the ART cycle. They were asked
to answer without communicating with their partners. They ﬁlled question-
naires on Beck’s Anxiety Inventory (BAI), Beck’s Depression Inventory (BDI)
and Couple Satisfaction Index-16 (CSI-16). Data was analyzed. Means, standard
deviation and ranges were used in descriptive statistics. Mann-Whitney test was
performed for the scores.
Main results and the role of chance: The age and duration of infertility
were analyzed in both the groups and the following values were ascertained.
The mean age in the group of males requiring donor sperm (Group 1) was
36.86 ± 4.40 years and the mean age in the other group, (Group 2) was 36.76
± 5.10 years. The mean value of duration of infertility in the donor treated
sperm was 6.20 ± 3.07 years while the duration of infertility in Group 2 was
5.52 ± 3.79 years. The p-value of comparisons of age and duration of infertility
in both the groups is 0.917 and 0.664 respectively. So, the demographic vari-
ables of both the groups were comparable.
The Mann-Whitney test was performed on the Beck’s Anxiety Inventory
score, Beck’s Depression Inventory score and the Couple Satisfaction Index-16
scores of both the groups. The U score was 931.5 for the comparison of the
Beck’s Depression Inventory in the two groups, with a p-value of 0.028, signify-
ing greater depression scores in the donor sperm usage group. The anxiety
levels, analyzed by BAI, were concluded to be non signiﬁcantly different (U =
1065.5, p = 0.203). The CSI-16 scores depicting marital relationship was also
comparable (U = 1202.5, p = 0.743).
Limitations, reasons for caution: The infertility treatment are not covered
under insurance in India, so, the study included subjects who were ﬁnancially
secure, well educated and from an urban background, a wider study in a public
setup would be more descriptive of the general population.
Wider implications of the ﬁndings: The psychological state of men with
azoospermic infertility needs to be given more consideration and may need
counseling.
Trial registration number:MCDH/ 2017/6
P-551 Canmen’s dyadic coping strategies make the difference?
The role of man’s dyadic coping strategies for his and his partner’s
adjustment to infertility
C. Chaves1, M.C. Canavarro1, M. Moura Ramos2
1University of Coimbra, Faculty of Psychology and Educational Sciences, Coimbra,
Portugal
2Centro Hospitalar e Universitário de Coimbra, Reproductive Medicine unit, Coimbra,
Portugal
Study question: Does the association between the impact of infertility stress
and marital and emotional adjustment is mediated by dyadic coping (DC) by
oneself and by partner?
Summary answer: Signiﬁcant indirect effects were found between infertility
stress impact and marital adjustment through DC strategies by the self, for
men, and by partner, for women.
What is known already: In previous literature, emotional and marital adjust-
ment to infertility showed great variability. Research is now focused in examin-
ing factors that predict a better adjustment. Individual coping strategies were
found to explain partially this variability in infertile individuals’ adjustment.
Nevertheless, in other ﬁelds of expertise, DC strategies were associated with
dyadic adjustment and distress levels, being even a stronger predictor of rela-
tionship quality than individual coping strategies. As infertility is a dyadic experi-
ence, it seems plausible that strategies triggered inside the relationship to cope
with stressors (DC strategies) inﬂuence couples’ adjustment, but until now this
association has not been studied.
Study design, size, duration: The study was cross-sectional and included 67
heterosexual couples with infertility (n = 134 participants). Participants were
recruited in a public fertility treatment unit.
Participants/materials, setting, methods: Participants are 67 couples that
were referred to a reproductive medicine unit for fertility problems. They were
consecutively recruited by the researcher. Written informed consent was
obtained. Self-report measures assessing sociodemographic data, infertility-
related stress (Fertility Problem Inventory), dyadic coping (Dyadic Coping
Inventory), dyadic adjustment (Dyadic Adjustment Scale – Revised) and depres-
sion and anxiety symptoms (Hospital Anxiety and Depression Scale) were ﬁlled
out by participants.
Main results and the role of chance: The ﬁnal sample was composed by
67 couples, with a response rate of 73%. Couples were on average in a relation-
ship for approximately 6 years (M = 5.98; SD = 3.10) and were trying to con-
ceive for approximately 3 years (M = 3.01; SD = 1.67). Mean age of
participants was 34.67 and 32.73, for males and females, respectively. Most par-
ticipants were highly educated and had medium socio‐economic status. There
is an indirect effect of the impact of infertility in one’s life on marital adjustment
through men’s perceived dyadic coping efforts employed by the self (Estimate:
.181; 90% BCCI -.356, -.061) and women’s perceived dyadic coping efforts of
the partner (Estimate: -.236; 90% BCCI -.422, -.126). These models explained
38% and 30% of marital adjustment variance for women and men, respectively.
Regarding the emotional adjustment of infertile couples, infertility stress impact
had an indirect effect only on depressive symptoms through men’s dyadic cop-
ing by oneself.
Limitations, reasons for caution: Due to the small sample size and the
cross-sectional design, the results must be analysed with caution. Moreover,
the sample comprised mainly highly educated individuals, from urban areas,
which restrain the generalization of ﬁndings to all infertile couples’ population.
Wider implications of the ﬁndings: The results highlight the importance of
men’s dyadic coping strategies for the marital adjustment of couples, as well as
for men’s emotional adjustment. Findings emphasize the importance of involving
men in the fertility treatment process, reinforcing the dyadic nature of infertility
processes.
Trial registration number: not applicable.
P-552 Endometriosis and/or wish for a child: Implications on
partnership, sexuality and psychological well-being
M. Schick1, A. Germeyer2, S. Hecht2, S. Rösner2, T. Strowitzki2,
B. Ditzen1, T.Wischmann1
1Institute of Medical Psychology, University Hospital Heidelberg, Heidelberg,
Germany
2Department of Gynecologic Endocrinology and Fertility Disorders, Heidelberg
University Women’s Hospital, Heidelberg, Germany
Study question: Goal was to investigate the relationship between psycho-
logical well-being and partnership of women with and without endometriosis
and/or wish for a child and their partners.
Summary answer: Study emphasizes the importance of partnership for psy-
chosocial well-being. Participants having EM and no desire for children scored
the highest on stress, depression and anxiety.
What is known already: Endometriosis (EM) is a common, gynecological,
inﬂammatory disorder, often associated with severe dysmenorrhea, pelvic pain,
dyspareunia and infertility. It is well known that partnership positively inﬂuences
the course of various diseases. Furthermore, a positive relationship between
partnership and perceived stress can be found in infertility treatment, with part-
nerships being able to buffer high levels of stress associated with treatment.
However, there are still few studies on the reciprocal effects of endometriosis
on partnership and sexuality.
Study design, size, duration: A quantitative study was devised, approved by
the Ethics Committee of the Heidelberg Medical Faculty. The study took place
from September 2016 to December 2017 with N = 108 participants.
Participants/materials, setting, methods: Participants completed a ques-
tionnaire with items regarding endometriosis (EHP-5, Endometriosis Health
Proﬁle), wish for a child (Screen-IVF), partnership (SHP, Swiss Household
Panel), sexuality (FSFI, Female Sexual Function Index), psychosocial well-being
(DASS, Depression Anxiety Scales), pain (DSF, German Pain Questionaire) and
sociodemographic items. All women undergoing laparoscopy during their treat-
ment at Heidelberg University Women’s Hospital and their partners were
invited to participate in the study. Data were analyzed using independent t-test
analysis and ANOVA.
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Main results and the role of chance: In total, N = 58 women (Ø age:
30.9) and N = 50 men (Ø age: 35.0) participated in the study. 93.4% lived in
partnership (Ø 7.0 years) and 9.3% already had children. 87.6% had a present
wish for a child, on average since 3.1 years. EM was clinically conﬁrmed in N =
78 (72.2%) participants respective their partners. Of all subjects, 57.5% had
high school or university graduation. The sample was split in three groups:
Participants with EM and wish for a child (EM+C+; N = 63), participants with
EM and without wish for a child (EM+C-; N = 15) and participants with no EM
but wish for a child (EM-C+; N = 30). Sociodemographic variables did not differ
between the groups, besides group EM+C- was younger than the other groups
(p≤.001). The groups differed signiﬁcantly from each other in terms of partner-
ship satisfaction (p≤.080), with group EM+C+ having the highest and the men
of group EM+C- the lowest partnership satisfaction (p≤.001). Group EM-C+
had the highest intercourse frequency (p≤.034) and group EM+C- reported
most dyspareunia (p≤.001). Satisfaction with sexual intercourse was compar-
ably high in all groups. Furthermore, the groups differed in terms of perceived
stress (p≤.004), anxiety (p≤.002) and marginal in depression (p≤.068), with
group EM+C- reporting the highest scores.
Limitations, reasons for caution: Generalization of ﬁndings is limited due
to small sample and the unequal distribution of groups, based on the difﬁculty
of diagnosing women with endometrioses outside of family planning.
Furthermore, participants in this sample had an above-average high educational
background.
Wider implications of the ﬁndings: The study highlights the importance of
partnership for psychosocial well-being. Participants with EM and no desire for
children showed lower partnership satisfaction, but higher scores on stress,
depression and anxiety, compared to participants with EM and desire for chil-
dren. The causal relation of these factors needs to be explored further.
Trial registration number:None.
P-553 Mothers to be without a partner - current data on a
German-wide documentation on issues raised by single women in
fertility counselling
B. Mayer-Lewis1, P. Thorn2, M. Schick3, T.Wischmann3
1Staatsinstitut für Familienforschung an der Universität Bamberg, Familienforschung,
Bamberg, Germany
2Practice for Couple and Family Therapy, Infertility Counselling- German Society for
Fertility Counselling, Moerfelden, Germany
3Heidelberg University Medical School, Center for Psychosocial Medicine- Institute for
Medical Psychology, Heidelberg, Germany
Study question: What do we know about women without a partner seeking
fertility counselling in Germany?
Summary answer: Our study shows that of all documented fertility counsel-
ling sessions with individuals approx. a quarter (26%) were used by women
without a partner.
What is known already: Delaying child birth is a common phenomenon in
many industrial countries. In Germany in 2015, 51% of all ﬁrst-time-mothers
were 30 years or older. In order to fulﬁl their wish for a child, an increasing
number of women decide to build a family even though they lack a partner. So
far, there is only little international data regarding women considering solo
mothership and there are no studies in Germany.
Study design, size, duration: After the development of evaluation instru-
ments, a ﬁrst German-wide online assessment of counselling sessions was car-
ried out between 2015 and 2017. The study included 517 valid documentations
from psychosocial fertility counsellors and 197 feedback forms from women
and men with the desire for a child who took up professional counselling.
Participants/materials, setting, methods: The study was conducted in
cooperation between the State Institute for Family Research at the University
of Bamberg, the Institute of Medical Psychology at Heidelberg University
Hospital and the German Society for Fertility Counselling. Data was collected
via an online questionnaire addressed to all German professionals offering psy-
chosocial fertility counselling and to all men and women who sought
counselling.
Main results and the role of chance: In 26% of all counselling sessions with
individuals (n = 282), women stated that childlessness was the result of a lack
of partner. These women were aged between 26 and 48 yrs. with a mean age
of 38 yrs. 79% of them planned pregnancy with the assistance of medical treat-
ment and sperm donation. Though most intended to use sperm donation only,
approx. 5% already had concrete plans for using either both egg and sperm
donation or solely embryo donation. Nearly 14% of the women who had
already worked out concrete plans for using reproductive assistance, or had
already started treatment, took advantage of treatment possibilities abroad.
However, during counselling, nearly 33% of all single women discussed the pos-
sibility of treatment abroad. 61% of all women without partner were interested
in speciﬁc forms of medical treatment of which 33% were egg or embryo dona-
tion and 2.5% social freezing. The most important issues during counselling
were as follows: 84% managing future parenthood; 75% managing emotional
distress; and 61% information regarding legal regulations. This data shows the
need for comprehensive counselling addressing both current (such as legal
information and emotional distress during treatment) and future issues (such as
parenting a child after donor conception).
Limitations, reasons for caution:We only report on those women without
partner who took up counselling; other single women may have different needs
and perspectives. We also only examined those opting for medical treatment
and not for private solutions. Some women of the target group may not have
been addressed by an online survey.
Wider implications of the ﬁndings: The data shows that approx. a quarter
(26%) of individuals seeking fertility counselling are women without a partner.
Analysing the collected data enables counsellors to develop needs-orientated
offers for women planning solo motherhood.
Trial registration number: not applicable.
P-554 Effects of family-centered postpartum care for postpartum
depression among previously infertile couples
S.H. Lee1,2,3, L.S. Huang1,4, M.C. Lee2,5,6, M.S. Lee2,4
1Chung Shan Medical University, School of Nursing, Taichung, Taiwan R.O.C.
2Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan R.O.C.
3Chung Shan Medical University Hospital, Department of Nursing, Taichung, Taiwan
R.O.C.
4Lee Womens’ Hospital, ART center, Taichung, Taiwan R.O.C.
5Chaoyang University of Technology, College of Management, Taichung,
Taiwan R.O.C.
6Taichung Hospital- Ministry of Health and Welfare, Family Medicine, Taichung,
Taiwan R.O.C.
Study question: The purpose of this study was to develop and evaluate a
family-centered postpartum care for postpartum depression among previously
infertile couples.
Summary answer: For husbands, the mean score of EPDS in the experimen-
tal groups had signiﬁcantly lower than that of the control groups after
intervention.
What is known already: Postpartum depression (PPD) is a signiﬁcant mental
health problem that occurs more frequently in the ﬁrst 4 weeks postpartum
and also may occur later or during the ﬁrst postpartum year. The correlation
between paternal and maternal depression was positive, but little is known
about the effects of family-centered postpartum care for postpartum depres-
sion among couples receiving assisted reproductive technology.
Study design, size, duration: This is a randomized controlled trial for previ-
ously infertile couple who will be divided into experimental group and control
group based on Edinburgh Postpartum Depression Scale (EPDS≧10 points,
either husband or wife)checked 4 weeks after delivery. There were 180 couples
recruited in the screening stage. Forty-nine couples were randomized assign
into two groups. The experimental group consists 21 couples and the control
group consists 19 couples in the ﬁnal stage.
Participants/materials, setting, methods: Experimental group will
receive health education CD/booklet at the 5th week, and telephone con-
sultation for 20 minutes during 6th-9th weeks after delivery. The self-
administer questionnaire is composed of subjects’ proﬁles, Edinburgh post-
partum depression scale, self-esteem questionnaire, Brief parenting stress
questionnaire and social support questionnaire. Generalized estimating equa-
tion(GEE) will be used for multi-variant time-series data analysis by SPSS/PC
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window 19.0 to evaluate the effects and difference of long-term change with
the intervention.
Main results and the role of chance: For husbands, the mean score of
EPDS in the experimental groups had signiﬁcantly lower than the control groups
after intervention(Exp(B) = 0.12, 95%c.I. = 0.025-0.569, p<0.05). But, for
wives, the mean score of EPDS in the experimental groups had not signiﬁcantly
lower than the control groups after intervention(Exp(B) = 0.457, 95%c.I. =
0.165-1.268, p>0.05). The couples still had high demand for information of
postpartum care during 3 to 6 months after delivery. The most helpful educa-
tion method perceived by husbands in 3th and 6th months was booklet(86%),
and then telephone consultation(62%) and booklet(62%). The most helpful
education method perceived by wives in 3th and 6th months was telephone con-
sultation(86%), and then telephone consultation(72%).
Limitations, reasons for caution: The study was performed by a self-
administered questionnaire which might involve a recognition problem in mean-
ing or deﬁnition of questions asked.
Wider implications of the ﬁndings: Through this study, a family-centered
postpartum care for postpartum depression in previously infertile couple model
can be developed as a reference for care and policy.
Trial registration number: not applicable’ for non-clinical trials
P-555 Cortisol diurnal proﬁle in women with high anxiety may be
associated with progesterone levels in infertile women
M. Moura-Ramos1, M.C. Canavarro2, A.P. Sousa1, S. Antunes3,
H. Lopes1, T. Almeida Santos4
1Centro Hospitalar e Universitário de Coimbra, Serviço de Reprodução Humana,
Coimbra, Portugal
2University of Coimbra, Faculty of Psychology and Educational Sciences, Coimbra,
Portugal
3Centro Hospitalar e Universitário de Coimbra, Serviço de Patologia Clínica, Coimbra,
Portugal
4University of Coimbra, Faculty of Medicine, Coimbra, Portugal
Study question: Can anxiety be associated with an impaired reproductive
function in women with infertility?
Summary answer: Women with anxiety symptoms above the normal range
may have altered diurnal cortisol rhythm, especially in the situations where pro-
gesterone levels are low.
What is known already: The effect of stress in infertility has been addressed
in previous studies, but ﬁndings are still inconsistent. In large cohort of couples
trying to conceive, it was found that preconception stress, assessed by alpha
amylase, was associated with a longer time to pregnancy, but the mechanism of
this effect remains unclear. Also, it has been suggested that ovulation may be
linked with stress, although this hypothesis needs further research.
Study design, size, duration: This study is part of a prospective study evalu-
ating biopsychological correlates in couples with infertility. The design of the
current study was cross-sectional. Participants were women from heterosexual
couples attending a reproductive medicine unit for infertility diagnosis. Written
informed consent was obtained from all participants.
Participants/materials, setting, methods: Women were consecutively
recruited by the researcher at their ﬁrst visit at the unit. Progesterone was mea-
sured at the 23rd day of the cycle. Five samples of saliva were collected in the
previous day for determination of salivary cortisol, to obtain the diurnal proﬁle:
at awakening, +30’, +45’, at 16 h and by bedtime. In the same day, symptoms
of anxiety were assessed using the Hospital Anxiety and Depression scale.
Main results and the role of chance: The ﬁnal sample was composed by
44 women. Mean age of participants was 31.31 (SD = 3.17). Most participants
were highly educated and had medium socio‐economic status.
Women were grouped in “low” and “high” anxiety according to the cutoff
score for the HADS for the anxiety scale (7). Groups based upon the progester-
one level were dividing using the cut off value of 9 ng/ml (<9=likely inadequate
luteal function, ≥9=suggestive of adequate luteal function). Results showed that
there was a signiﬁcant interaction effect between the diurnal cortisol proﬁle,
levels of anxiety (low vs. high) and progesterone level (<9=likely inadequate
luteal function, ≥9=suggestive of adequate luteal function) (F = 2.848; p = 0.05).
Further analysis revealed differences across the groups (F = 4.750, p=.038). The
diurnal proﬁle of the cortisol was equal across the two groups of progesterone
levels in women with low anxiety. In the group of high anxiety, the group with
progesterone levels suggestive of inadequate luteal function had a different pro-
ﬁle, with peaked cortisol values at the third cortisol measurement.
Findings highlight that women with anxiety symptoms above the normal
range may have altered diurnal cortisol rhythm, especially in the situations
where progesterone was low.
Limitations, reasons for caution: Main limitation was the small of number
of patients that were included in the ﬁnal sample. In addition, the study was
cross sectional, and therefore no causal inference can be established. Finally,
the absence of absolute cut off scores for deﬁning ovulation may affect the con-
sistency of the ﬁndings.
Wider implications of the ﬁndings: The ﬁndings challenge the notion that
there is a linear association between stress and infertility. Our ﬁndings suggest
that psychobiological stress is associated with the progesterone output,
although future prospective should clarify the predictive effect of psychobio-
logical stress in ovulation.
Trial registration number:
P-556 Preliminary data on communication to parents of donor-
conceived offspring regarding the risks of inherited diseases
E. Buyse1, G. Verheyen2, I. Pletincx3, B. Andrea4, H. Tournaye2,
M. Bonduelle5, J. Nekkebroeck6
1UZ Brussel, Centre for Medical Genetics/ Centre for Reproductive Medicine,
Brussels, Belgium
2UZ Brussel- Vrije Universiteit Brussel, Centre for Reproductive Medicine, Brussels,
Belgium
3UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium
4UZ Brussel, Centre for Medical Genetics, Brussels, Belgium
5UZ Brussel- Vrije Universiteit Brussel, Centre for Medical Genetics, Brussels, Belgium
6UZ Brussel- Vrije Universiteit Brussel, Centre for Medical Genetics/ Centre for
Reprodcutive Medicine, Brussels, Belgium
Study question: How to manage the communication of genetic risks to par-
ents? What’s the impact of this risk on the desire for other children using donor
gametes?
Summary answer: Description of our experience on communication of gen-
etic risks to parents with donor-conceived offspring and how this information
inﬂuences the wish for a consecutive child.
What is known already: Little is known about the communication of newly
identiﬁed genetic risks in donor-conceived offspring and the preferences and
needs of their parents. More studies on risks of inherited diseases in donor-
conceived offspring focus on medical evaluation and genetic screening and their
limitations and challenges. Studies show an international variability in genetic
evaluations, education and informed consent processes (Sims et al., 2010; Isley
& Callum, 2013; Dondorp et al., 2014; Isley et al., 2016).
However, there is limited knowledge about the wish for a second child using
the same donor with a (minor) genetic risk (Squires & Simoglou, 2013).
Study design, size, duration: Between June 2015 and December 2017, a
qualitative study was performed with 27 parents who have one or more chil-
dren, conceived using gametes from anonymous sperm donors (n = 23),
oocyte donors (n = 3) or both (n = 1). The genetic risk presented after the
donors had been qualiﬁed for donation. All parents were treated in our fertility
unit with gametes from our internal or from an external bank. Twenty two par-
ents had a wish for a second child.
Participants/materials, setting, methods: Semi-structured interviews
were performed with the parents at our Medical Genetics unit, asking them
about: (1) the way they were informed about the genetic risk, (2) their
perceptions of the communication by health-care providers, (3) their perceived
risk, and if applicable (4) how they would like to realise their wish for a second
child.
Main results and the role of chance: Twenty one parents were informed
about a minor genetic risk by the fertility department when seeking treatment
to conceive a second child, 4 parents without seeking treatment, and 2 parents
received an e-mail from an external sperm bank. Both parents informed by
e-mail, were upset and preferred being informed face-to-face. In the group with
the wish for a second child, 2 parents were aghast and worried that they would
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never know the risk if they didn’t ask for the treatment. Eleven parents (40%)
experienced the risk-communication as emotionally taxing, 10 parents (37%)
felt comfortable during this contact. Two parents (7%) regarded the communi-
cation as unnecessary; both of them have a wish for a second child.
Independent of the medical risk, 55% perceived the risk as high, 14% as moder-
ate and 33% as low.
Of the parents wishing for a second child who perceived the risk as high, 7
had doubts (58%) about the way to fulﬁl their wish, 3 (25%) asked for a different
donor, while 2 (17%) asked for the same donor. With a low risk-perception, 6
(67%) wanted to use the same donor, 2 (22%) had doubts and 1 (11%) wanted
to use a different donor.
Limitations, reasons for caution: The small sample size undermines the
representability of the results to a whole population. Variation in how future
parents were counselled upon intake may affect how they experienced the
communication. Because of the descriptive study-design ﬁndings may be open
for interpretation.
Wider implications of the ﬁndings: This research may be a pre-cursor to
future research. The issues reported can be used to achieve a higher quality of
care. These ﬁndings may be a starting point for developing guidelines on coun-
selling, exploring the (ir)relevance of minor genetic risks for parents with
donor-offspring and the impact on secrecy.
Trial registration number:No randomized controlled trial.
P-557 Obsessive symptoms and the need of gamete donation as
predictors of treatment dropout in infertile patients
L. Jurkowski1, J.M. Gómez Penedo2, N. Bossi3, C. Granados3,
E. Polak de Fried3
1CER Medical Institute, Psychology, Buenos Aires, Argentina
2Conicet UBA, Psychology, Buenos Aires, Argentina
3CER Medical Institute, Human Reproduction, Buenos Aires, Argentina
Study question: Can psychological symptoms and medical diagnosis be a pre-
dictor of dropout in infertile patients?
Summary answer: In infertile patients high scores of obsessivity and the need
of gamete donation could predict the possibility of dropout.
What is known already: Infertility diagnosis and treatment is a burden for
some patients and this relates to psychological symptoms that have an impact
on their quality of life and medical treatments. There is an agreement in the lit-
erature that psychological burden is referred as one of the reason of treatment
dropout but there are no studies about speciﬁc symptoms related to this aban-
donment. As far as we know, there are no publications regarding treatment dis-
continuation and the need of gamete donation.
Study design, size, duration: Prospective and relational study part of a
wider research program in psychology and infertility from the CER Medical
Institute from Buenos Aires, Argentina. Over a period of six months, from
March-August 2017, 187 patients completed a questionnaire.
Participants/materials, setting, methods: 187 new patients from infertile
couples, 120 women(Age: x̄ 38.21 +/-5.18 years) and 67 men(Age: x̄ 39.61
+/-7.42 years) agreed to complete the Symptom Checklist-90-R(SCL-90-R)
(Derogatis, 1994), a self-reported questionnaire, in the waiting room before
their ﬁrst appointment at the fertility clinic.The SCL-90-R is a standardized
instrument that assesses a wide range of current psychological symptoms.
Medical data is obtained from clinical records. Logistic regression was made
with the SPSS 24. Statistical signiﬁcance = p< 0.05.
Main results and the role of chance: In the total sample, the likelihood of
the patient dropping out was signiﬁcantly predicted by: a) levels of obsessivity,
β = 1.32, SE=.66, Wald(1) = 6.157, p < .05, and, b) gamete donation (female
or male), β = 1.26, SE=.48, Wald(1) = 6.96, p < .01. Both higher levels of
obsessive symptoms and the need for a gamete donation increase the odds of
dropping out. When looking at women, the need effect of gamete donation
remain signiﬁcant, β = 1.32, SE=.62, Wald(1) = 4.58, p = .03. On the other
hand, in the men sample, obsessivity signiﬁcantly predict drop out, β = 6.13, SE
= 2.99, Wald(1) = 4.19, p = .04.
Limitations, reasons for caution: It was a small sample and limited in time
so results should be generalized with caution.
Wider implications of the ﬁndings: This study shows that the impact of
knowing the need of gamete donation and obsessive symptoms could predict
treatment discontinuation in infertile patients.It would be helpful to be aware of
this in fertility clinics in order to incorporate a psychopathological screening to
provide patients with help and improve treatment adherence.
Trial registration number:N/A.
P-558 The evaluation of patients’ experience with manual vacuum
aspiration: Comparison with other methods of miscarriage
managements and infertility procedures
W.C. Cheung, G.W.S. Kong, A.K.W. Yiu, A.S.Y. Hui, J.P.W. Chung,
T.C. Li
The Chinese University of Hong Kong, Department of O&G 1 F, Shatin- New
Territories, Hong Kong
Study question: How do women perceive manual vacuum aspiration (MVA)
in comparison with other methods of miscarriage management and infertility
procedures?
Summary answer: Even though MVA was associated with the highest pain
score in comparing with infertility procedure, women highly accepted MVA
procedure.
What is known already: Previous studies reported that MVA was as effect-
ive as electric vacuum aspiration and it had fewer side effects than the use of
misoprostol. However, it is not known the efﬁcacy and acceptability of MVA in
comparing with three other measures of ﬁrst trimester miscarriage.
Study design, size, duration: This comparative cohort study took place in a
university based teaching hospital with recruiting 55 women underwent MVA
over a 12 months period. The data of women underwent suction curettage (n
= 53), medical evacuation (n = 59) and expectant management (n = 58) were
retrieved from our previous randomized controlled trial.
Participants/materials, setting, methods: Patient’s psychological status
was systematic assessed through various instruments including impact of event
(IES), state-trait anxiety inventories (STAI), Beck depression inventory (BDI),
general health questionnaire (GHQ), and client satisfaction scale (CSQ).
Women were asked to rate their pain score of (1) MVA, (2)oocyte retrieval
(OR), (3) hysterosalpingogram (HSG), (4) embryo transfer (ET). The number
of days of bleeding and abdominal pain was recorded by a symptom log sheet.
Main results and the role of chance: As regarding the pain experience of
infertility procedures, women at MVA procedure (6.4 ± 1.7) had signiﬁcantly
higher (p = 0.000) pain level than HSG (5.1 ± 2.8), OR (4.5 ± 3.0) and ET (0.9
± 1.8). However, there was no difference in client satisfaction level. Among all
groups, there was no difference in IES, BDI, GHQ and CSQ scores. In compris-
ing the 4 different methods of miscarriage management, the anxiety score in
women who underwent MVA (54.9 ± 9.4) was signiﬁcantly lower (p = 0.041)
than that in the expectant group (60.8 ± 13.0), and found similar to suction cur-
ettage (58.5 ± 10.6) and medical management group (59.7 ± 12.9). The dur-
ation of bleeding (in days) of MVA group (9.7 ± 4.1) was signiﬁcantly shorter
than the medical (15.1 ± 6.6) and expectant (12.8 ± 5.8) management group,
but there was no difference from suction curettage group (10.7 ± 5.8). Four
groups of women had no difference in the duration (in days) of abdominal pain.
The complete evacuation rate of MVA group (94.5%) was signiﬁcantly higher
than medical (71.2%) and expectant (79.3%) management group, but there was
no signiﬁcantly difference between MVA and suction curettage group (98.1%).
Limitations, reasons for caution: Due to the comparative cohort study
design, the ﬁnding should be interpreted with caution.
Wider implications of the ﬁndings: Even though MVA group had similar
client satisfaction level compared with other methods of miscarriage manage-
ment, it was also associated with the highest pain score. Therefore, further
study is required to examine methods to reduce the pain during MVA is
deemed desirable.
Trial registration number: not applicable.
i398 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
P-559 Counselling in decision making by couples for assisted
reproductive technology –A key role in quality care
N. Agarwal, K.D. Nayar, P. Nayar, R. Gahlot, M. Singh, M. Gupta,
G. Kant, D. Nayar
Akanksha IVF Centre- Mata Chanan Devi Hospital, Reproductive Medicine, New
Delhi, India
Study question: How couples decide for fertility treatment and what is the
role of counselling?
Summary answer: Key factors in deciding for fertility treatment are ﬁnance,
society pressure and prognosis. Counselling can help couples to choose the
appropriate treatment.
What is known already: Coping with the emotional challenges of infertility
can be difﬁcult for couples. More stressful is the task of decision making in seek-
ing fertility treatment. When they embark on assisted reproductive treatment
(ART) they may experience many different emotions, from joy and excitement
to grief and disappointment. This can be emotionally and physically challenging,
Clinicians need to develop the skills to communicate about the treatment
modalities available to be able to reduce the emotional suffering, to prepare
them for fertility treatments, and explore the options and implications when
making decisions about starting, changing or stopping treatments.
Study design, size, duration: Longitudinal study was performed at fertility
centre in Delhi, India where 900 patients were interviewed during the year,
January 2017 - December 2017, who consented to participate in study. They
were divided into two groups: Group A (n = 348) who were ready for ART
and Group B (n = 552) who did not accept ART due to factors like ﬁnance,
social pressure and prognosis explained for the ART. Data were analyzed using
SPSS software version 20.
Participants/materials, setting, methods: Group B was counselled for
accepting ART. 333 patients accepted ART after counselling while 219 did not
accept ART. Chi square test was applied to ﬁnd out the role of counselling and
extent to which ﬁnance, social pressure and prognosis inﬂuence the decision of
couple for accepting or rejecting ART treatment.
Main results and the role of chance: Chi-square test for independence
was calculated comparing frequency for accepting ART treatment in patients
with social pressure. A signiﬁcant interaction was found (X2 [1] = 12.83,
p<0.05) and Cramér’s phi coefﬁcient = 0.476 which shows strong association
that is 71.43% of them accepted ART treatment after counselling as compared
to 28.57% who did not accept.
Similarly signiﬁcant interaction was found between prognosis of ART and
accepting ART after counselling (X2 [1] = 5.79, p<0.05). In Patient with good
prognosis ,79.17% of them accepted ART treatment after counselling as com-
pared to 20.83% who did not accept and patient with poor prognosis ,44.45%
still opted for ART after counselling and Cramér’s phi coefﬁcient = 0.34 which
shows moderate association.
Chi-square test for independence was calculated comparing non- modiﬁable
factor ﬁnance with accepting or rejecting ART after counseling. Although
patients accepted ART after counseling but was found to be not signiﬁcant.
In Conclusion, we found in our study counselling helped signiﬁcantly in cou-
ples for accepting ART treatment when they were effected by peer pressure
and worried about ﬁnal outcome of ART. Counselling may have a role in
patients with ﬁnancial problems also but ﬁnance is limiting factor for accepting
ART.
P<0.05 was considered signiﬁcant.
Limitations, reasons for caution: Although it is prospective study, it has
limitation of small sample size.
Wider implications of the ﬁndings:When couples ﬁrst meet with special-
ist, most of them have not made any decisions and are seeking information and
advice. Understanding how couples reach consensus about accepting repro-
ductive treatment and counseling appropriately holds promise to improve qual-
ity of care and increase long-term decisional satisfaction for patients and their
partners.
Trial registration number:MCDH/ 2017/7
P-560 Fertility- and early menopause-related information needs of
young breast cancer survivors
E.M. Sparidaens1, I. Beerendonk2, D. Braat2,W. Nelen2
1Radboud university medical center, Obstetrics and Gynaecology, Tilburg, The
Netherlands
2Radboud university medical center, Obstetrics and Gynaecology, Nijmegen, The
Netherlands
Study question:What are the fertility- and early menopause-related informa-
tion needs and preferences of Dutch young breast cancer survivors?
Summary answer: Extensive information about fertility is desired by young
breast cancer survivors, especially on the risk of infertility, possible treatments
and long-term consequences of early menopause.
What is known already: Approximately 10-15% of women diagnosed with
breast cancer are in their reproductive age. Treatment can impair their fertility,
which is disturbing since half of them desire to have a subsequent pregnancy
after treatment. Current guidelines focus on informing breast cancer patients
on the possibility of reduced fertility mainly prior to treatment, because this is
the moment to decide about fertility preservating options. However, it is
equally important to address information needs on fertility and possible early
menopause after treatment has been completed and the wish to conceive
becomes topical.
Study design, size, duration: A qualitative study consisting of semi-
structured in-depth interviews with professionals and patients. In May 2015 13
professionals (oncologists, surgeons, gynaecologists, nurses) were interviewed
about their experiences with information provision concerning fertility during
follow-up. Based on these results a topic guide has been developed, which was
used in 18 interviews with patients between April 2016 and December 2017.
Furthermore, after each interview, patients composed a priority list with the
ﬁve most important items of information provision.
Participants/materials, setting, methods: Interviewed professionals were
active in the Radboud university medical center (Radboudumc) and four periph-
eral hospitals in the Netherlands. Interviewed patients were treated in the
Radboudumc or Rijnstate Hospital. Eligible for participation were women
between 20-45 years at the time of the interview who had completed their ini-
tial treatment, i.e. surgery and chemo- or radiotherapy. The number of inter-
views was determined by data saturation. Data were analyzed in accordance
with grounded theory.
Main results and the role of chance: The risk of infertility was discussed
with most of the women before starting treatment, although half of them wer-
en’t satisﬁed with the information they received. After treatment had ended,
also the majority of participants indicated that they received too little informa-
tion and many reported having brought up the topic themselves. Most women
looked up fertility and early menopause online and described struggling to ﬁnd
reliable information speciﬁc to their situation. They expressed the need for an
information tool on fertility and early menopause aimed at young breast cancer
survivors. Among other items, this tool should include information such as the
chance of still being fertile and when to expect their menstruation cycle to
resume. They want to know the risks of pursuing a pregnancy, for themselves
as well as for the future child. When is the best moment to do so and what
contraception should be used in the meantime? They seek advice on how long
they should try to conceive before approaching a fertility specialist. With regard
to early menopause, they want to know which symptoms to expect and espe-
cially what the long term risks are for their general health. They value advice on
dealing with these problems.
Limitations, reasons for caution: Limitations include focusing on breast
cancer survivors and a shortage of quantitative data. We started to provide
quantitative data through patients’ priority lists, but given the sample size statis-
tic measurements couldn’t be performed. It would be interesting to conﬁrm
data in a larger population also including other types of cancer.
Wider implications of the ﬁndings: In-depth insight in the information
needs of young breast cancer survivors concerning fertility and early menopause
was obtained. In the following months information materials will be developed
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and subsequently tested within this population. This supports professionals to
improve information provision to meet the needs and preferences of their
patients.
Trial registration number: not applicable.
P-561 Impact of infertility diagnosis on male sexuality and self
esteem
L. Leis1, M. Vieira2, C. Busso3, M. Cassará3, C. Glina3, L. Tso3,
R. Romano4, S. Glina2
1Projeto Alfa, Psicology, São Paulo, Brazil
2Projeto ALFA, Urology, São Paulo, Brazil
3Projeto ALFA, Reproductive Medicine, São Paulo, Brazil
4Projeto Alfa, Reproductve Medicine, São Paulo, Brazil
Study question: Does infertility diagnosis impact on male sexuality and self
esteem?
Summary answer: Diagnosis of infertility does not seem to affect male self
esteem. However, in couples presenting with combined infertility factors, male
partners showed orgasmic dysfunctions.
What is known already: Studies show that the diagnosis of infertility, spe-
cially male infertility, negatively interferes in male auto esteem, conﬁdence and
sexuality.
Study design, size, duration: Cross sectional, descriptive study.
Participants/materials, setting, methods: One hundred twenty two men
during in vitro fertilization were included, between March 2017 and December
2017. Sexual Quotient- male version- (SQ-M) was used to evaluate sexuality
and Rosenberg Self-Esteem Scale to evaluate self esteem. In associations involv-
ing diagnosis, ﬁxed factor analysis of variance was used. In associations involving
sexual dysfunctions, Fisher’s exact test was used. Adopted p = 0.05 statistically
signiﬁcant.
Main results and the role of chance: 27% of couples presented male, 50%
female and 22,1% combined infertility factor. There was no association
between self esteem and infertility factor (P = 0.851). In couples presenting
with combined infertility, male partner had difﬁculties in achieving orgasm (P =
0.043). In couples with male infertility, male partner showed higher self conﬁ-
dence in sex (P = 0.045) than in couples with female or combined factors. No
associations were found between sexuality/auto esteem and duration of infer-
tility, previous pregnancies or education.
Limitations, reasons for caution: I n our sample, the majority of the cou-
ples presented female infertility, what might have generated a sample bias.
Wider implications of the ﬁndings: Diagnosis of infertility has a negative
impact on male sexuality. In those couples psychological follow up should be
encouraged.
Trial registration number:Not applicable.
P-562 ‘myFertiCare’: quantitative evaluation of an online
application for infertile couples
K. Fleischer1, E.M. Sparidaens2, D. Braat2, J. Logger2,W. Nelen2
1Radboud University Medical Center, Department of Obstetrics and Gynaecology,
Nijmegen, The Netherlands
2Radboud university medical center, Obstetrics and Gynaecology, Nijmegen, The
Netherlands
Study question: Is it feasible to develop and successfully implement an online
application to support couples undergoing ICSI with surgically retrieved sperm
during their treatment trajectory?
Summary answer: myFertiCare, an online application providing personalized
and interactive features has been quantitatively evaluated. Since it meets
Human, Organizational en Technological aspects, successful implementation is
concluded.
What is known already: The Internet is an important and low threshold
source of information and support for couples undergoing ART. We hypothe-
sized that an online application can be a suitable instrument to support couples
during their full treatment trajectory. By providing personalized information and
offering the opportunity of communication, it is possible to decrease infertility-
speciﬁc anxiety and stress, increase knowledge and enhance patient-centred
care.
Study design, size, duration: A quantitative study in which 314 couples
were invited to evaluate ‘myFertiCare’. A questionnaire was based on the
HOT-ﬁt framework, assuming a ‘ﬁt’ between Human, Organizational and
Technological factors is needed to successfully implement an eHealth tool.
Therefore, it consisted of validated questionnaires covering these domains.
Moreover, attention was payed to the effect on patient knowledge, experi-
enced patient-centeredness and treatment burden. Non-users of myFertiCare
received an adjusted questionnaire, to discover motivations for not using.
Participants/materials, setting, methods: The questionnaires were dis-
tributed between June and August 2017 in the Radboud university medical cen-
ter in Nijmegen, the Netherlands. Eligible for participation were couples
undergoing ICSI with surgically retrieved sperm, who had had the opportunity
to use myFertiCare during their treatment trajectory. Each couple received one
questionnaire together. Both couples that did and did not actually use
myFertiCare could participate. Furthermore, user statistics were analyzed.
Main results and the role of chance: Response rate was 48%. After exclu-
sion, 142 questionnaires were included for analysis. Participants appreciated
myFertiCare on human, organizational, as well as technological aspects. At the
human and technology domain, myFertiCare showed good system usability,
high user satisfaction and good information and interface quality. The visualized
treatment trajectory was the most appreciated functionality of the application.
At the organizational domain, the information provided to patients about the
application appeared to be complete. Unfortunately, non-users of the applica-
tion often didn’t recall receiving information about the possibility to use
myFertiCare. Among the health care providers, knowledge about all opportun-
ities myFertiCare offers to couples could be improved.
myFertiCare turned out to improve knowledge about treatment of infertility,
to increase the degree of experienced patient centered fertility care and to
decrease the experienced treatment burden.
User statistics showed that myFertiCare was mainly used by the female part-
ner, and most activity was seen at the beginning of treatment.
Limitations, reasons for caution: Although we conclude that myFertiCare
has been successfully implemented, we also assessed some pitfalls. This pro-
vides us the opportunity to further develop the application based on patients’
needs and preferences and to improve the infrastructure surrounding
myFertiCare, so that all couples are optimally aware of the opportunities
myFertiCare offers them.
Wider implications of the ﬁndings: Since myFertiCare has been success-
fully implemented, the use of the application can possibly be expanded to other
fertility treatments, and also to other fertility clinics, both in the Netherlands
and abroad. Further research can be done to explore possibilities of using the
application format in other medical departments.
Trial registration number: not applicable.
P-563 Factors affecting the disclosure management of infertility of
expatriate women in Hong Kong
D.A. Niederberger, H.Y.C. Chan, L. Liu
The University of Hong Kong, Social Work and Social Administration, Hong Kong,
China
Study question: What are the emotional and socio-cultural factors affecting
women’s decisions to disclose their infertility to various members of their social
support network?
Summary answer: Various Infertility-related stigmas affected women’s dis-
closure decision. Women tended to consider their infertility disclosure from a
two-pronged approach – protection and productivity.
What is known already: Infertility affects up to 15% of reproductive-aged
couples worldwide with negative psychological, physical, social and economic
impacts. Women experienced the higher stress as well as feelings of shame and
guilt due to their infertility. Studies showed that higher perceived social support
could ameliorate the emotional distress for women with infertility. However,
existing evidence has revealed a perplex relationship between social support
and women’s disclosure patterns as social stigma associated with infertility
would negatively inﬂuence women’s decision of disclosure. Therefore, this
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study explored the complex relationship between a woman’s social support
network and the extent to which infertility-related information was disclosed.
Study design, size, duration: This study employed a qualitative design with
semi-structured individual interviews. As a methodological innovation, this
study applied Infertility Disclosure Map (IDM) to enact a visual, tangible
representation of woman’s social support network and the extent of their dis-
closure of infertility-related information. Six participants were recruited. The
interviews were conducted between March 2015 and March 2016.
Participants/materials, setting, methods: Participants were English-
speaking expatriates living in Hong Kong aged 18 or above. They were diag-
nosed of primary infertility and were undergoing ART procedures in Hong Kong
at the time of the study. Exclusion criteria included inability to give written
informed consent, condition with cognitive impairment or major psychiatric dis-
orders. Participants were recruited from a locally-based, online social network-
ing forum, targeting English-speaking expatriates in Hong Kong. The interviews
were audio-taped, transcribed and thematically analysed with NVivo.
Main results and the role of chance: Six female participants aged between
33 and 40 were recruited. They had varies ethnic backgrounds including
Caucasian, Chinese and Latin/Asian. Three of them had one children and the
other had no children. The duration of infertility ranged from 1.75 to 6.5 years.
Consistent with existing ﬁndings indicating that many women have experienced
stigmatization from their infertility, ﬁve of the six participants experienced some
forms of stigmatization. However, perceptions of stigma among participants
were divergent, which included: infertility is the woman’s fault; infertility is a dis-
ease; voluntary childlessness is shameful; and age discrimination on the desire
for biological children. Extending the existing models that explain women’s dis-
closure decision-making, the ﬁndings illustrated a two-pronged approach uti-
lized by participants in deciding whether to conceal or disclose information
about their infertility – protection and productivity. Protection of self, spouse
and even the recipients of the information so as to avoid pain, worry and
embarrassment was a signiﬁcant consideration that prompted participants to
withhold information. Productivity, namely the usefulness of the disclosure to
participants was the other key component in participants’ decision-making pro-
cess. The usefulness includes emotional support from others, tangible support
to facilitate treatment, information gathering, and altruistic purpose of helping
others with infertility.
Limitations, reasons for caution:Major limitations include the small sample
size and insufﬁcient representation from individuals from different cultural
backgrounds.
Wider implications of the ﬁndings: With a deeper understanding of the
complex reasons and emotions inﬂuencing women’s decisions to disclose their
infertility to various members of their social support network, counsellors and
other helping professionals could better assist the women to manage their infer-
tility treatment as well as improving their psychological wellbeing.
Trial registration number:Not applicable.
P-564 Psychological wellbeing and relational stress of women with
a predicted poor ovarian response at the start of IVF treatment
Z. Donarelli1, S. Gameiro2, G. Lo Coco3, L. Salerno1, S. Gullo4,
A. Volpes5, A. Allegra5, J. Boivin2
1Andros Day Surgery Clinic, Psychology Unit, Palermo, Italy
2Cardiff University, School of Psychology, Cardiff, United Kingdom
3University of Palermo, Department of Psychology and Educational Sciences,
Palermo, Italy
4Andros Day Surgery Clinic, Medical Statistic Unit, Palermo, Italy
5Andros Day Surgery Clinic, Reproductive Medicine Unit, Palermo, Italy
Study question: Do women predicted to have a poor ovarian response
(POR) at the start of IVF treatment report higher psychological and relational
stress, than non-POR women?
Summary answer: Prior to IVF treatment the predicted POR group showed
higher psychological difﬁculties (relational stress) than women without a pre-
dicted poor ovarian response.
What is known already: The Bologna Criteria are used to predict a poor
response to ovarian stimulation based on age, ovarian response and number of
oocytes retrieved in a previous cycle. It is estimated that between 5.6% and
35.1% of women undergoing ART will exhibit a POR. Although it is known that
poorer prognosis is associated with higher stress during treatment, suggesting
that women with POR may need additional/tailored psychosocial support, to
date no studies have examined associations between a POR classiﬁcation/diag-
nosis and psychological adjustment.
Study design, size, duration: This cross-sectional case-control study is part
of a longitudinal study of infertile couples undergoing IVF in a private clinic
between February 2013 and September 2015.
Participants/materials, setting, methods: 257 women (POR = 50; non-
POR = 207, based on the Bologna criteria) ﬁlled out questionnaires (response
rate 65%) on well-being (FertiQoL and FPI) and relational stress (ECR,
Commitment Inventory, ENRICH), after physicians informed patients about
POR. 16 out of 50 of the cases reported a history of POR. The two groups
were compared on well-being and relational stress using multivariate analysis of
covariance, controlling for cause and duration of infertility. Effect size was
expressed by partial eta squared.
Main results and the role of chance:Wilks’s λ was signiﬁcant, F (1, 241) =
2.34, P < 0.01, ηp2=.10, showing a difference between the two groups.
Contrast analyses revealed that patients with POR reported lower quality of life
on the relational domain (z = 9.35, p < .01, ηp2=.04); lower level of commit-
ment on couple identity and relational agenda (z = 4.76, p < .05, ηp2=.02; z =
3.94, p < .05, ηp2=.02, respectively); higher anxiety and avoidance in close rela-
tionships (z = 6.48, p < .05, ηp2=.03; z = 4.27, p < .05, ηp2=.02, respectively);
and higher FPI sexual stress (z = 8.13, p < .01, ηp2 = 0.03), than non-PORs
women.
The group difference remained signiﬁcant after controlling for cause and dur-
ation of infertility, F (1, 241) = 1.99, P = 0.02, ηp2=.09.
Limitations, reasons for caution: The questionnaires were completed
immediately after the POR diagnosis and the inﬂuence of preexisting levels of
infertility stress cannot be excluded. Moreover, uncontrolled factors explaining
the association between POR status and distress could have been relevant.
Finally, no measures of mental health disorders, such as anxiety or depression,
were collected.
Wider implications of the ﬁndings: POR status is associated with higher
relational stress and the cause of this association could be due to the awareness
of their risk of a POR. The ﬁndings provide support for the importance to
address speciﬁc relational issues in women with POR at the early stage of ART
treatment.
Trial registration number:Not required.
P-565 A pregnancy loss in the ﬁrst fertility treatment is a postitive
predictor of birth in the following treatment
M.C. Krog1, S.S. Malchau2, A. Pinborg3, A.M. Kolte4, H.S. Nielsen4
1Copenhagen University Hospital- Rigshospitalet, Recurrent Pregnancy Loss Unit- The
Fertility Clinic 4071, Copenhagen Ø, Denmark
2Copenhagen University Hospital Hvidovre, Department of Obstetrics and
Gynecology, Hvidovre, Denmark
3Copenhagen University Hospital- Rigshospitalet, The Fertility Clinic 4071,
Copenhagen, Denmark
4Copenhagen University Hospital- Rigshospitalet, Recurrent Pregnancy Loss Unit- The
Fertility Clinic 4071, Copenhagen, Denmark
Study question:What is the chance of a birth in the second treatment after a
pregnancy loss (PL) compared to no pregnancy in the ﬁrst treatment?
Summary answer: The chance of a birth in the second treatment is signiﬁ-
cantly higher after a PL compared to a negative pregnancy test after the ﬁrst
treatment.
What is known already:When infertile couples experience an early PL dur-
ing fertility treatment, it is generally considered to be a positive predictor of
future birth because the couple were able to achieve a pregnancy. Previous
studies on this topic in the ART population are conﬂicting. A study in 12,174
Chinese patients found no difference in birth rate in the second treatment after
a PL compared to negative pregnancy test. In contrast, a PL in the ﬁrst treat-
ment was a positive predictor of a birth among 112,549 UK patients in the two
following treatments (compared to no pregnancy in the ﬁrst treatment).
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Study design, size, duration: A Danish national cohort study of 32,975
infertility patients including total register data on their ﬁrst two fertility treat-
ments. We used data from the mandatory Danish ART register and included
treatments from 1994 to 2012. Both intra-uterine inseminations and ART treat-
ments were included and treatments with egg-donation were excluded.
Participants/materials, setting, methods: Detailed data from the ﬁrst and
second treatment in every Danish patient attending both public and private
Danish fertility clinics were retrieved. An accurate registration of births was
obtained by cross-linking treatments with the Danish National Birth Register by
the personal social security number. A positive s-hCG without a resulting birth
was categorized as a pregnancy loss. Data is presented as percentages and dif-
ferences were accessed using the Pearson chi-square test and one-way
ANOVA.
Main results and the role of chance: Outcome of the ﬁrst treatment was
devided into three groups; 1) no pregnancy (n = 26,852, 81.4%), 2) pregnancy
loss (n = 3092, 9.4%) and 3) birth (n = 3031, 9.2%). Mean maternal age differed
at time of ﬁrst treatment between the groups 1) 32.9 years, 2) 32.9 years and
3) 31.2 years, respectively (p<0.0001). In the second treatment, only 17.3 %
(n = 4640) in group 1 achieved a birth compared to 22.7 % (n = 702) and 23.8
% (n = 722) in group 2 and 3, respectively, which also was signiﬁcantly different
( p<0.0001). The reoccurrence of another pregnancy loss in the same couple
(group 2) in the second treatment was 11.7% (n = 362) compared to the ﬁrst
occurrence of a pregnancy loss in the second treatment in group 1) 8.6% (n =
2304) and 3) 11.0% (n = 333), (p<0.0001).
Limitations, reasons for caution: This is a nationwide study and the ana-
lyses are restricted to the ﬁrst encounter with fertility treatment, irrespective of
type of treatment. Current results are not reﬂecting the treatment regime as a
whole.
Wider implications of the ﬁndings: Our study conﬁrms that a pregnancy
loss compared to a negative pregnancy test is a positive predictor of birth in the
following treatment. The ﬁndings can not be explained by maternal age and will
be useful when counselling patients who experience a pregnancy loss in their
ﬁrst treatment.
Trial registration number:Not applicable.
P-566 Stress and depression among couples with recurrent
pregnancy loss - focusing both on the male and the female partner
S. Hedegaard1, A.M. Kolte1, M.C. Krog1, L.R. Olsen2, H.S. Nielsen2
1Recurrent Pregnancy Loss Unit, Fertility Clinic 4071, Copenhagen University
Hospital
2Child and Adolescent Mental Health Center, Mental Health Services, Capital Region
of Denmark
Study question: What is the prevalence of psychological stress and moder-
ate/severe depression in couples with recurrent pregnancy loss (RPL)?
Summary answer: Male partners revealed no increased frequency of stress
and depression, but we conﬁrmed our previous ﬁnding of signiﬁcantly increased
frequencies among female partner with RPL.
What is known already: In a previous large study of women with RPL, we
have shown that psychological stress and major depression are signiﬁcantly
more common among women with RPL than other pregnancy planners.
Emotional distress among male partners is much less studied, but one study
investigated 76 male partners of RPL using the Beck Depression Inventory and
found that 14,9% of the men were considered mildly depressed.
Study design, size, duration: The study is a cross-sectional study, where we
compared the prevalence of stress and depression among 226 men and 342
women in RPL couples referred for evaluation and treatment at the Danish
national RPL Unit from 2015-2018. We deﬁned RPL as three or more preg-
nancy losses before 12 weeks’ gestation. Results among men were compared
to a Danish population study performed in 2000.
Participants/materials, setting, methods: From March 2015, all couples
have been asked to complete the Major Depression Index (MDI) and Cohen’s
Percived Stress Scale (PSS) as part of standard evaluation before ﬁrst consult-
ation. Of the invited patients, 226 men (57%) and 342 women (80%)
participated.
Main results and the role of chance:Of the men in the RPL couples 5/226
(2.2%) had a score on the MDI corresponding to moderate/severe depression,
as did 27/342 (7.9%) of the participating women.
In a Danish population study from 2000 using the same psychometric scales,
2.2% of the men aged 20-79 years reported symptoms corresponding moder-
ate/severe depression. The prevalence of moderate to severe depression
among men in RPL couples was not different from the Danish background
population (P = 0.96).
The prevalence of moderate/severe depression among the female partners
of RPL couples is comparable to our previous results in a different cohort of
RPL women (8.6%) (P = 0.73). In our previous study the response rate was 69
% compared to 80 %.
Among the men in the RPL couples 26/226 (11.5%) reported a high stress
level (deﬁned as ≥ 19 on the PSS scale), as did 97/338 (28.7%) of the women.
When compared to the stress levels reported in our previous study on a RPL
female cohort we ﬁnd a signiﬁcantly lower frequency of high stress level (P <
0.001). The lower occurrence of high stress level in the most recently collected
cohort maybe explained by selection.
Limitations, reasons for caution: The response rate among men is rela-
tively low compared to women; this may bias the results. We are unaware if
some of the non-responders suffer from depression or high stress level.
Furthermore, the comparison group is a population sample and we are thus
unaware if they suffer from reproductive problems.
Wider implications of the ﬁndings: To our knowledge, this is the ﬁrst lar-
ger scale questionnaire study of emotional distress among men with RPL. We
did not ﬁnd a high prevalence of neither stress nor moderate/severe depres-
sion. Furthermore, we conﬁrmed previous ﬁndings regarding stress and depres-
sion among women with RPL, highlighting the emotional toll of RPL.
Trial registration number:N/A.
P-567 Quality of life of transgender women andmen during
hormonal treatment
S. Feigl, J. Wegscheider, K. Feil, K.Winkler-Crepaz, B. Böttcher,
B. Toth
University Hospital Innsbruck, Dept. for gynecological endocrinology and reprod.
medicine, Innsbruck, Austria
Study question: Does quality of life change during cross-sex hormonal treat-
ment in transgender individuals and are quality of life aspects comparable with
non-transgender individuals?
Summary answer: Quality of life in transgender individuals improves during
cross-sex hormonal treatment.
What is known already: Social understanding and support for transgender
individuals have steadily improved, but knowledge about their socio-
psychological development is scarce. There are few studies that show better
physical and mental health after hormonal treatment or sexual reassignment
surgery but aspects such as socio-economic integration, self-perception and
acceptance have been neglected.
Study design, size, duration: Since no suitable questionnaire was available,
we developed a transgender questionnaire. Validation of the questionnaire was
performed by repeated completion after one week. The questionnaire includes
demographic data, 45 questions about trans-identity, physical, mental and sexual
wellbeing as well as social background and acceptance. Validation of the question-
naire was performed with item-total correlation, internal consistency (Cronbach’s
α) and test-retest reliability (intraclass correlation coefﬁcient). Chi2Test,
Wilcoxon- test and independent sample t-tests were used for statistical analysis.
Participants/materials, setting, methods: Transgender individuals receiv-
ing hormonal treatment in the University hospital of Innsbruck and matched
controls were included. Transgender individuals answered the questions twice,
representing the time point before and after start of treatment whereas the
controls answered it once except those who validated the questionnaire.
Main results and the role of chance: So far 26 transgender individuals and
44 controls were included. Median age of transgender individuals was 25,8
(min-max: 18-50) years, 26,7 (min-max: 18-52) years in controls. Quality of life
improved during hormonal treatment in transgender individuals. This was
mainly true for self-conﬁdence and physical perception. We also observed less
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discrimination and more support from the social environment after at least 6
months of hormonal treatment.
Limitations, reasons for caution: Our study was conducted by a limited
number of participants. Transgender individuals may already experience a dif-
ferent quality of life due to social acceptance and access to medical facilities.
Wider implications of the ﬁndings:Hormonal treatment options for trans-
gender individuals raise the urge to better understand and support trans-
persons. Our study shows a possible way to monitor and optimize quality of life
and psychosocial aspects during hormonal treatment.
Trial registration number: not applicable.
P-568 Remote access to embryo images and video during their
cycle enhances a patients In Vitro Fertilisation (IVF) experience
D. Bui, E. Debenham, N. Hesketh, S. McArthur, K.Waite,
M. Bowman
Genea, Embryology, Sydney, Australia
Study question: Does providing patients remote access to images and video
of their embryos developing during an IVF cycle enhance their experience?
Summary answer: The majority of patients surveyed indicated that viewing
their embryo images during cycle enhanced their experience of IVF treatment.
What is known already:With the advent of online self-diagnosis and in turn
patients understanding and expecting certain service standards during their
treatment, there is a shift in how medical providers are adjusting their interac-
tions and delivery of treatment to patients. Patients who have a tangible image
from ultrasound scans respond better and feel more informed about their treat-
ment options than those without an image (Carlin et al 2014). The advent of
time-lapse imagery of embryo development allows not only scientists to view in
great detail the growth of an embryo but opens up opportunities for patients to
have access to this information.
Study design, size, duration: Patients undertaking an oocyte retrieval were
recruited on a voluntary basis over an 8 month time period from May-2017 to
January-2018. Patients who participated were sent an optional survey to com-
plete after embryo culture but before pregnancy outcome. A total of 149
responses were collated from 358 patients who participated in the trial. The
survey consisted of a number of questions on usability, enhancement of IVF
experience and communication using a 5 level Likert scale.
Participants/materials, setting, methods: Participants were recruited on
a voluntary basis to trial an embryo viewing portal through a phone or PC appli-
cation (GrowTM, Genea Sydney). This app allows patients to log on and view
their embryos growing in-situ via a direct link with image collating software Geri
Connect using the Geri embryo monitoring incubator (Genea Biomedx,
Sydney). Still and time-lapse video were uploaded at speciﬁc time points and
patients received ongoing communications from embryologists regarding their
embryo development.
Main results and the role of chance: 149 patients took part in the trial and
completed the survey. The average age of the recruited cohort was 35.9, with
62% of patients falling into the <38 age group and 38%in the > = 38 age group.
First cycle patients accounted for 39% of the recruited cohort and the remaining
61% had at least one previous cycle either at Genea or elsewhere. Overall, 85%
of participants either strongly agreed or agreed that their IVF experience was
enhanced by having access to their embryo images during treatment. Technical
issues in the usage of the application and a requirement for greater information
were the main contributors to the 15% of either neutral or negative scores.
Feedback collected during the survey collation pointed towards a variety of rea-
sons for this enhancement with inclusion of partner in the cycle, giving greater
understanding and education, feeling more connected with treatment and also
provides an element of feeling more in control during treatment. Patient feed-
back continues to be collected and assessed to improve the patient experience
whilst undergoing treatment for infertility.
Limitations, reasons for caution: The cohort of patients that elected to
take part in the trial may have been a positively biased group. No data has yet
been collected to determine if negative pregnancy outcomes would impact the
score of enhancement.
Wider implications of the ﬁndings: The introduction of an application for
patients to view their developing embryos enhances the delivery of information
by providing greater education and allowing patients to feel more involved
across their treatment as well as providing a more personal experience thereby
aligning IVF with trends in medical management of patients.
Trial registration number:Not applicable.
POSTER VIEWING
Reproductive (epi)genetics
P-569 Is mitochondrial DNA quantiﬁcation (NGS) a useful tool for
embryo viability assessment?
D. Lorenzi1, M. Bilinski1, M. Fabbro2, V. Rovera3, S. Gonzalez
Klikailo3, F. Noblia3, S. Papier1,3, F. Nodar1,3
1NOVAGEN, Reproductive Genetics, Ciudad Autónoma de Buenos Aires, Argentina
2NOVAGEN, Bioinformatics, Ciudad Autónoma de Buenos Aires, Argentina
3CEGYR, Reproductive Medicine and Genetics, Ciudad Autónoma de Buenos Aires,
Argentina
Study question: Is there a relationship between human blastocyst mitochon-
drial DNA (mtDNA) content and female age, embryo chromosome ploidy and
clinical pregnancy?
Summary answer: This study demonstrates no association among mtDNA
score, female age and pregnancy outcome. However, a relationship between
mtDNA score and embryo ploidy was observed.
What is known already: Recently, there are controversial publications about
the clinical relevance of mtDNA quantiﬁcation in human blastocysts. The
increase of mtDNAmay be a sign of elevated metabolism related to high energy
requirements in stressed embryos.
Some studies found no association between this parameter and chromo-
somal ploidy, maternal age or pregnancy outcome. However, some laborator-
ies, based on their evidence, apply this quantiﬁcation as an implantation
potential biomarker between euploid embryos.
Different methodologies have been used for mtDNA assessment, principally
next generation sequencing (NGS) platforms and real-time polymerase chain
reaction (qPCR), with consistent results between them.
Study design, size, duration: A cohort of 384 blastocysts obtained from
144 couples, with an average female age of 35 years old (21-45), undergoing
preimplantation genetic testing for aneuploidies (PGT-A) were retrospectively
included. The data was collected between April 2016 and December 2017
from a single center. Mosaic embryos (between 20%-80%) were excluded from
this analysis.
Participants/materials, setting, methods: Trophectoderm biopsies from
384 blastocysts (PGT-A) using NGS (Veriseq-Illumina) were assessed.
For each sample, reads were aligned to the human reference genome (hg19)
and the mtDNA genome separately. Reads mapped to the mtDNA were
divided by the number of reads that mapped to the nuclear DNA. The resulting
values were mathematically adjusted by correction factors previously reported
for embryo ploidy and gender.
mtDNA scores were analyzed regarding embryo aneuploidy, maternal age
and clinical pregnancy (T-test).
Main results and the role of chance: Regarding all blastocysts analyzed,
189 (49%) were euploid and 195 (51%) aneuploid. The amount of mtDNA was
signiﬁcantly higher in aneuploid embryos (P = 0.002). However, the amount of
mtDNA was not different between embryos from younger (<38 years, n =
147) and older women (≥38 years, n = 41) (P = 0.2161).
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During the period covered, 46 normal embryos were transferred after thaw-
ing, resulting in 25 ongoing pregnancies (54%). The mtDNA score from euploid
blastocysts that achieved a clinical pregnancy was no signiﬁcantly different from
those that did not result in an ongoing pregnancy (P = 0.4118).
A mathematical adjustment was performed in order to correctly normalize
the relative mtDNA content regarding embryo gender and chromosome
ploidy.
From our in-house data, mtDNA score was only statistically associated with
chromosomal aneuploidy suggesting that high levels of mtDNA may have a
negative impact resulting in an inadequate chromosome segregation.
Limitations, reasons for caution: This is a retrospective study. Despite
NGS approach for mtDNA quantiﬁcation has been validated by others method-
ologies, these techniques should be applied in order to conﬁrm these results.
Wider implications of the ﬁndings: This study contributes evidence that
mtDNA quantiﬁcation in euploid embryos have no clinical impact in pregnancy
outcome. The results demonstrate that mtDNA levels are independent to
female age. However, mtDNA score reveals a strong association with embryo
aneuploidies.
Trial registration number:Not applicable.
P-571 Impact of microﬂuidic sperm sorting on embryo quality and
comprehensive chromosome screening outcomes of couples with
repeated implantation failure
E. Pabuccu1, R. Pabuccu2, S. Sertyel3, D. Demirkıran3, H. Gunes3,
S. Dogan4, A.H. Haliloglu5, Ö. Şahin1
1Ufuk University School of Medicine, Obstetrics and Gynecology, Ankara, Turkey
2Ufuk University School of Medicine- Centrum Clinic IVF Center, Obstetrics and
Gynecology, Ankara, Turkey
3Centrum Clinic IVF Center, Embryology, Ankara, Turkey
4Centrum Clinic IVF Center, Andrology, Ankara, Turkey
5Ufuk University School of Medicine, Urology, Ankara, Turkey
Study question: What is the impact of the microﬂuidic sperm selection tech-
nique for IVF/ICSI on embryo quality and euploidy rates in couples with
Repeated Implantation Failure (RIF)?
Summary answer: When microﬂuid chip-sorted spermatozoa is used for
IVF/ICSI, a higher number of top quality blastocysts and better euploidy rates
were observed compared to standard selection.
What is known already: Aneuploidy is the most common type of chromo-
some abnormality and the leading cause of implantation failure in humans.
Oocyte and spermatozoa equally contribute to embryonic aneuploidy however,
womens’ age is the well-known factor. We are still unable to modify the quality
of oocytes, however several sperm selection techniques have gained attention.
Being one of those, microﬂuidic sorting technology has been proposed in order
to pick the best spermatozoas with better genomic integrity and physiological
quality. It is of interest whether utilizing this technique will reveal better embryo
morphology and euploidy rates in couples with RIF undergoing pre-implantation
genetic screening (PGS).
Study design, size, duration: This was a retrospective analysis of assisted
reproductive technology (ART) cycles performed at the Centrum Clinic IVF
Center located in Ankara, Turkey between 2016 and 2017. In total, data from
171 patients were obtained for the analysis that accounts for 491 embryos. In
group 1 (STANDARD), a total of 127 cycles and 366 embryos, in group 2
(CHIP) 44 cycles and 125 embryos were evaluated in terms of embryology data
and euploidy rates.
Participants/materials, setting, methods: Only patients with complete
patient records on clinical, IVF/ICSI cycle characteristics, and PGS (Next
Generation Sequencing) analysis could be included in the retrospective analysis.
Main indication for PGS was RIF history of couples. Women with age > 43, BMI
> 35, with documented uterine abnormalities, trombophilia and azoospermic
males were excluded. In CHIP group, microﬂuid sorted spermatozoas were
obtained for IVF/ICSI. On the day of biopsy, 5–10 trophectoderm cells were
sent to the laboratory.
Main results and the role of chance:
Table 1 Basal characteristics, stimulation outcomes
and embryologic data.
STANDARD
(N = 127
cycles, 366
embryos)
CHIP
(N = 44
cycles, 125
embryos)
p
value
Female age (years) 37.3 ± 4.8 37.4 ± 4.9 NS
AMH (ng/ml) 1.69 ± 1.4 1.8 ± 1.6 NS
FSH (mIU/mL) 8.8 ± 4 7.8 ± 2 NS
TSH (IU/mL) 2.06 ± 0.9 2.1 ± 1.2 NS
Sperm concentration
(mil./ml)
22 (1-130) 29 (1-120) 0.03
Total motility (A+B+C) % 46.8 ± 19 48.5 ± 17 NS
DFI % (TUNNEL Assay) 23.5 ± 14 17.1 ± 7.9 NS
Total duration (days) 11.2 ± 2 11.3 ± 1 NS
M2 oocytes (n) 4 ± 2.7 5.4 ± 6.5 NS
2PN (n) 3.7 ± 2.6 4.3 ± 3.5 NS
No of cleavage embryos 3.6 ± 2.4 4.1 ± 3.1 NS
No of blastocysts 3.0 ± 2.1 3.5 ± 2.7 NS
No of top quality
blastocysts (5AA, 5AB,
5BA, 4AA)
0.8 ± 1.4 1.6 ± 2.7 0.04
Euploid blastocyt % 7 23 <0.001
Mosaic embryos % 2.7 4 NS
Cost USD (excluding IVF/
ICSI, including PGS and/or
chip-sorting)
864.5 ± 557 1436 ± 645 <0.001
According to the univariate linear regression analysis;
– female age (β: 0.09, p = 0.24)
– sperm concentration (β: 0.09, p = 0.23)
– collected oocytes (β: 0.2, p = 0.008
– top quality blastocyst formation (β: 0.2, p = 0.001)
– microﬂuidic chip sorting (β: 0.35, p<0.001) parameters were found to inﬂu-
ence (p<0.25) embryo euplodiy (%, dependent variable).
When backward multivariate linear regression analysis was performed, chip
sorting was the only signiﬁcant parameter (p = 0.002), whereas top quality blast
formation did not reach enough signiﬁcance (p = 0.06).
Limitations, reasons for caution: Major limitations are retrospective
design, limited patient number, lack of DFI data following chip sorting and preg-
nancy outcomes of the groups. Chip-sorting is not a routine in our center and
offered to those with RIF history only, because it comes with a signiﬁcant cost.
Moreover, literature data is very limited.
Wider implications of the ﬁndings: Successful euploid-blastocyst forma-
tion is the consequence of a perfect fertilization and mitosis. When compar-
able women age and number of oocytes are considered, chip sorted
spermatozoas may inﬂuence our results in terms of better blastocyst forma-
tion and euploidy when DFI is relatively high (>15% in both groups). Cost
should be considered.
i404 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Trial registration number:Not applicable.
P-572 Role of male factor in embryo aneuploidy
B. Rodriguez-Estrada1, J. Sarasa1, M. Enciso1, I. Vilella1, I. Jurado1,
J. Luna-Romero1, L. Ortega2, J. Aizpurua2
1iGLS, Genetic laboratory, Alicante, Spain
2IVF Spain, IVF laboratory, Alicante, Spain
Study question: Are sperm quality parameters relevant predictors of embryo
aneuploidy?
Summary answer: Sperm apoptosis levels and male age are signiﬁcantly cor-
related with different types of embryo aneuploidy in egg donor cycles.
What is known already: Embryonic chromosomal aneuploidy plays an
important role in human reproduction causing implantation failures, miscar-
riages and a wide variety of genetic syndromes. While contribution to embryo
aneuploidy has been largely attributed to female factor, focusing on maternal
age, male role keeps uncertain. Infertile men often display unconventional
semen parameters, nonetheless, wider implications in relation to aneuploidy
have not been clariﬁed. There are few studies in which sperm parameters are
considered to be involved with embryo aneuploidy. To our knowledge, there is
an absence of female factor-controlled studies.
Study design, size, duration: This is a retrospective observational study
including data from a total of 102 egg donation cycles undergoing
Preimplantation Genetic Testing for Aneuploidy (PGT-A) at blastocyst stage
and comprehensive analysis of sperm quality parameters between January and
October 2017. Egg donor cycles are optimal to study male factor avoiding
maternal effect. Paternal inﬂuence on embryo aneuploidy and clinical outcomes
were explored in all cases.
Participants/materials, setting, methods: 102 male patients aged 25-64
(41,74 ± 6.9) undergoing egg donation cycles with PGT-A participated in the
study. Comprehensive sperm analysis including volume, concentration, total
count, motility, morphology, vitality, proportion of apoptotic spermatozoa and
DNA integrity was performed in all cases. All embryos were cultured to blasto-
cyst stage, biopsied and PGT-A tested by Next Generation Sequencing (Illumina
VeriSeq protocol). Analysis of the association between the different male para-
meters studied, embryo aneuploidy and clinical outcomes was performed.
Main results and the role of chance: In the study group, no inﬂuence of
conventional semen parameters on embryo aneuploidy was found. Differences
in sperm total count, motility, morphology, vitality, sperm DNA integrity did
not impact embryo aneuploidy levels.
Interestingly, in normozoospermic samples, sperm apoptosis signiﬁcantly
correlated with the proportion of aneuploid embryos presenting sex pair
abnormalities. Sperm presenting high levels of live apoptotic spermatozoa pro-
duced a signiﬁcantly increased number of embryos with aneuploidies affecting
the sex-chromosomes (Spearman Test, R = 0.348, p = 0.044).
Additionally, male age was found to inﬂuence the presence of complex aneu-
ploid embryos, i.e. with 2 or more chromosomes affected (Spearman correl-
ation Test, R = 0.246, p = 0.044). Men over 40 y.o. showed 1.5× more
embryos with several aneuploidies than younger men (46.46%±6.39 vs. 31.15%
±5.98, U-MannWhitney, p = 0.0037).
Finally, a signiﬁcant inﬂuence of sperm apoptosis was also observed beyond
preimplantation embryo development, affecting the likelihood of pregnancy
after single euploid embryo transfer. The group of males that failed to achieve
pregnancy presented signiﬁcantly higher levels of live apoptotic spermatozoa
compared to the ones who accomplished a positive beta (13.40%±1.25 vs.
9.04%±0.972, Student’s t-test, p = 0.004), and an ongoing 12-weeks pregnancy
(12.61%±1.19 vs. 8.15%±1.02, Student’s t-test, p = 0.004)
Limitations, reasons for caution: The retrospective and unicentric design
of this study may be a reason for caution. It is important to note that the num-
ber of patients included was limited and should be increased to conﬁrm the
results. Further prospective studies are needed to validate our ﬁndings.
Wider implications of the ﬁndings: Evidence shown raises the question of
whether male age and sperm apoptosis should be taken into account as predict-
ive markers for cases at risk of embryo aneuploidy and whose outcomes may
be improved through PGT-A. Corrective methods are strongly recommended
to palliate sperm apoptosis even if levels are not pathological.
Trial registration number: not applicable.
P-573 Haplotyping and copy-number proﬁling of single cells by
massive parallel sequencing
H. Masset1, M. Zamani Esteki2, E. Dimitriadou3, C. Melotte3,
S. Debrock4, K. Peeraer4, A. Ardeshirdavani5, D. Alcaide5,
A. Sifrim2, J. Aerts5, Y. Moreau5, T. Voet2, J.R. Vermeesch1
1Laboratory for Cytogenetics and Genome Research, Department of Human
Genetics, Leuven, Belgium
2Laboratory of Reproductive Genomics, Department of Human Genetics, Leuven,
Belgium
3University Hospitals Leuven, Center for Human Genetics, Leuven, Belgium
4University Hospitals Leuven, Leuven University Fertility Center, Leuven, Belgium
5STADIUS Center for Dynamical Systems- Signal Processing and Data Analytics
Department, Department of Electrical Engineering ESAT, Leuven, Belgium
Study question: Provide a high-throughput and comprehensive methodology
for haplotyping and copy-number proﬁling single cells to overcome the limita-
tions of SNP arrays by using massive parallel sequencing.
Summary answer: Genotyping-by-sequencing allows for accurate concurrent
haplotyping and copy-number proﬁling of single cells and can be used for preim-
plantation genetic testing (PGT).
What is known already: PGT embodies not only the diagnosis of disease
alleles for Mendelian disorders (PGT-M), but also allows detection of aneuploi-
dies and structural rearrangements genome-wide, PGT-A and PGT-SR,
respectively. Genome-wide haplotyping of single cells became feasible through
karyomapping. We recently developed haplarithmisis that enables concurrent
haplotyping and copy-number proﬁling of single cells using SNP arrays. These
methodologies are being implemented as a generic method for PGT-M in many
IVF laboratories. SNP arrays come at a stable cost and the resolution is limited.
To provide comprehensive screening of a single cell whole-genome sequencing
is necessary, which is currently too expensive and computationally heavy.
Study design, size, duration: To address the limitations of SNP array and
the cost of sequencing, we exploit a reduced representation sequencing strat-
egy on a single cell by performing genotyping-by-sequencing (GBS). Proof-of-
principle experiments were performed on single cells from HapMap cell lines.
For all embryo samples informed consent was given.
Participants/materials, setting, methods: Three different restriction
enzymes were tested to digest DNA and reduced representation libraries were
generated. Sequencing was performed on an Illumina HiSeq2500 system.
Downstream analysis was evaluated and optimized to allow haplotyping with
the interactive web application HiVA, which is based on haplarithmisis.
Subsequently, an internal validation was performed by comparing GBS with
SNP array. Furthermore, nine embryos in three families with different PGT-M
indications were analysed.
Main results and the role of chance: For the HapMap samples, a total of 7
single cells of two individuals was used to assess genome-wide haplotype accur-
acy. Haplotypes from both GBS and SNP array data were generated through
HiVA. The concordance rate reached 99% for both maternal and paternal hap-
lotypes. In the internal validation, for a total of 9 embryos from three families
with different indications for PGT-M, we obtained 100% accuracy.
Limitations, reasons for caution: This study is limited by the sample size.
Wider implications of the ﬁndings:We present a novel NGS-based meth-
odology for haplotyping single cells through massive parallel sequencing. By
applying a reduced representation sequencing methodology and the advancing
sequencing technologies, we envision that this methodology will a valuable
alternative to SNP array technology for genotyping, haplotyping and copy num-
ber proﬁling of single cells.
Trial registration number: not applicable.
P-574 Feasibility of artiﬁcial intelligence for predicting live birth
from a blastocyst image
Y. Miyagi1, T. Habara2, R. Hirata2, N. Hayashi2
1Medical Data Labo, Department of artiﬁcial intelligence, Okayama, Japan
2Okayama Couple’s Clinic, Infertility, Okayama, Japan
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Study question: Can artiﬁcial intelligence (AI) applied toward blastocyst
images have strong potential to predict the probability of becoming an alive
neonate?
Summary answer: Classiﬁers using AI applied toward a blastocyst image
have strong potential to show the probability of an alive neonate being the
outcome.
What is known already: None of the features of morphological structures
have been conclusively assessed as having prognostic value for the further
developmental competence of oocytes. Preimplantation genetic testing for
aneuploidy to examine chromosomal proﬁles is an invasive technique for the
embryo, which bring with it considerable ethical arguments. The chromosomal
proﬁle of the biopsy specimen does not always represent the proﬁle of the rest
of the embryo.
Study design, size, duration: Logistic regression, naive Bayes, neural net-
work, random forest, nearest neighbors and deep learning were examined as
machine learning method of AI. The images of the blastocyst of live birth (n =
80) and of abortion because of chromosomal abnormalities (n = 80) were used
in retrospective study. The 10-fold ross validation method was used for making
classiﬁers.
Participants/materials, setting, methods: We developed a system for
using the machine learning approach of AI to predict the probability of live birth
from a blastocyst image. An image was obtained from the ﬁfth day after oocyte
retrieval. The off-line images of which training data were augmented were trans-
ferred to the AI, then the classiﬁer by the AI was made as the accuracy was
higher and the variances were lower as much as possible.
Main results and the role of chance: The logistic regression with L2 regu-
larization was the best among the above mentioned machine learning methods.
Only a few seconds are needed to complete analysis of each image. The accur-
acy, sensitivity, speciﬁcity, positive predictive value and negative predictive value
for predicting those in the abortion category were 0.619, 0.600, 0.638, 0.626
and 0.629, respectively. Area under the curve of the receiver operator curve
was 0.594 ± 0.045 (mean ± standard error). Estimated probability of belonging
to the live birth category was found signiﬁcantly related to the probability of live
birth (P<0.02).
Limitations, reasons for caution: Though the logistic regression showed
the best result among the six machine learning methods examined, further
investigation in the future might prove other machine learning methods
superior.
Wider implications of the ﬁndings: This method does not harm the
embryo, which can be transferred after establishing the prediction. It offers eco-
nomic and time savings for patients and/or clinical institutes, gives quick and
efﬁcient diagnosis of the classiﬁcation.
Trial registration number: not applicable.
P-575 Preimplantation genetic screening (PGS) with next
generation sequencing (NGS) in recurrent spontaneous abortion
patients (RSA); does it help?
B.C.F.K. Brunet1, M.B. Toorabally2, J. Shen1, J. Wang1, L. Cai1,
J. Xie1, Y. Cui1, J. Liu1,W.Wu1
1The State Key Laboratory of Reproductive Medicine- Clinical Center of Reproductive
Medicine- First Afﬁliated Hospital- Nanjing Medical University, Gynecology and
obstetrics, Nanjing, China
2First Afﬁliated Hospital- Nanjing Medical University, Cardiology, Nanjing, China
Study question: Does PGS using NGS increase the live birth rate in recurrent
spontaneous abortion patients?
Summary answer: PGS using NGS successfully increases the live birth rate in
recurrent spontaneous abortion patients.
What is known already: Advances in PGS with the newest NGS technology,
considered the main technique for selecting embryo to result in healthy preg-
nancy, has the ability to accurately know the ploidy status and select an embryo
prior to implantation thereby removing aneuploidy, which is one of the most
common cause of recurrent spontaneous abortion, as the cause of spontaneous
abortion in the equation for RSA. RSA patients are considered the best candi-
dates for PGS however, limited data exist about the effectiveness of this
technique.
Study design, size, duration: This retrospective study included a total of
161 patients with a history of recurrent spontaneous abortion undergoing
artiﬁcial reproductive technology at our hospital from the year 2015 to
2017. We included 67 patients in the PGS group and 94 patients in the control
no PGS group. The comprehensive chromosome screening was done using
NGS.
Participants/materials, setting, methods: All patients underwent con-
trolled ovarian stimulation and oocytes retrieval. In the PGS group, ICSI, troph-
ectoderm biopsy and blastocyst cryopreservation was performed before single
frozen balanced/euploid embryo transfer detected by NGS molecular cytogen-
etic analysis. For the no PGS group, IVF or ICSI was followed by single or double
embryo transfer with fresh or frozen embryos. The primary outcome was live
birth.
Main results and the role of chance: After 209 cycles on 161 patients, a
total of 70 embryos were transferred (0.97 per cycle) in the PGS group, of
which 37 (53.6%) implanted, resulting in a live birth rate of 47.8%. In the no
PGS group a total of 166 embryos were transferred (1.21 per cycle), of which
48 (28.9%) implanted, resulting in a live birth rate of 26.5%. The higher live birth
rate in the PGS group was statistically signiﬁcant (p<0.05). The analysis revealed
aneuploidy in 123/240 (51.25%) of blastocyst tested in the PGS group, among
which 31(12.9%) had single chromosome loss (monosomy), 24 (10.0%) dis-
played single chromosome gain (trisomy), 21/240 (8.75%) had dual chromo-
somal abnormality, 13 (5.42%) showed complex chromosomal abnormality and
34/240 (14.2%) were observed with mosaicism.
Limitations, reasons for caution: This study is a single center retrospective
study with a small study population. Any ﬁndings can only be indicative and the
improved live birth rate after PGS with NGS should further be investigated in a
larger population.
Wider implications of the ﬁndings: Our ﬁndings show that PGS with NGS
improves the live birth rate in recurrent spontaneous abortion patients. If con-
ﬁrmed, these results could encourage the routine use of PGS with NGS to
reduce the time to achieve pregnancy and avoid the physical and emotional bur-
den of a miscarriage.
Trial registration number:Not applicable
P-576 Whole exome sequencing identiﬁed of MEI1 mutation
causing human non-obstructive azoospermia
Y. Tan1,2, C. Tu2, L. Meng1, S. Yuan1,W. He1,2, A. Luo2, J. Du1,2,
G. Lin2, G. Lu1,2
1Reproductive & Genetic Hospital of CITIC-Xiangya, Genetic Center, Changsha-
Hunan, China
2Central South University, Institute of Reproductive and Stem Cell Engineering,
Changsha, China
Study question:What’s the genetic etiology of non-obstructive azoospermia
(NOA) in a consanguineous Han Chinese family?
Summary answer: A novel homozygous missense mutation in MEI1 gene,
c.1585 T>A, might be the genetic cause of NOA in this family.
What is known already:Mei1 knockout mice have been reported to present
with NOA and only two polymorphic alleles (SNP3 (C1791A) and SNP4
(C2397T)) of the human MEI1 gene were associated with azoospermia. No
causative mutation has been identiﬁed inMEI1 in men with NOA.
Study design, size, duration: Genomic DNA samples from a consanguin-
eous Han Chinese family, 50 sporadic NOA patients (with normal 46, XY kar-
yotype and no Y-chromosome microdeletions) and 200 fertile male controls
with randomly matched age (32 ± 2.7 years) who had at least one child were
obtained.
Participants/materials, setting, methods: Whole exome sequencing was
performed to identify the genetic cause of NOA in two affected brothers of a
consanguineous Chinese family. Histological analysis was performed for the
biopsied testicle sample in the proband. Mutation screening was performed
using Sanger sequencing for 50 NOA patients and 200 fertile male individuals,
and in silico analysis was conducted for functional characterization of the muta-
tion. Expression analysis of various tissues of human and mouse was performed
by using RT-PCR.
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Main results and the role of chance: We identiﬁed a homozygous mis-
sense mutation (NM_152513.3: c.1585 T>A, p.Phe529Ile) in a new gene,
MEI1, which co-segregated with the NOA phenotype in this family. The identi-
ﬁed missense mutation results in the substitution of a conserved phenylalanine
residue with isoleucine in the SCOP domain of MEI1, which might resulted in
protein misfolding. Histological analysis demonstrated a lack of spermatozoa in
the proband’s seminiferous tubules due to meiotic arrest. Expression analysis
showed thatMEI1 is expressed speciﬁcally in adult human and mouse testis. For
mutation screening, we only detected one heterozygous mutation of the
c.1585 T>A in MEI1 in a cohort of 200 fertile controls. We did not ﬁnd any
association between the two polymorphic alleles (SNP3 (C1791A) and SNP4
(C2397T)) of the humanMEI1 gene and NOA.
Limitations, reasons for caution: All novel putative disease-causing muta-
tions may only be clinically reported as ‘variants of uncertain signiﬁcance’ (VUS),
unless and until the mutation is functionally characterized and more patients
with a similar phenotype are discovered with the same mutation.
Wider implications of the ﬁndings: To the best of our knowledge, this is
the ﬁrst report of the identiﬁcation of MEI1 as a new causative gene with an
autosomal recessive mode of inheritance for human NOA.
Trial registration number:Not applicable.
P-577 Novel inactivating mutations in the FSH receptor cause
premature ovarian insufﬁciency with resistant ovary syndrome
W. He1,2, J. Du1,2, X.W. Yang1, W. Li1,2, W.L. Tang2, G.X. Lu1,2,
G. Lin1,2, F. Gong1,2, Y.Q. Tan1,2
1Central South University, Institute of Reproductive and Stem Cell Engineering,
Changsha, China
2Reproductive and Genetic Hospital of CITIC-Xiangya, Genetic Center, Changsha,
China
Study question: What is the genetic aetiology of three resistant ovary syn-
drome (ROS) pedigrees from thirteen Chinese Han families with non-
syndromic premature ovarian insufﬁciency (POI)?
Summary answer: Four novel mutations of the FSHR gene were the genetic
aetiology of these three ROS families, respectively.
What is known already: To date, only 15 FSHR-inactivating mutations have
been described in women affected by POI, each of them is a missense
mutation.
Study design, size, duration: Thirteen Han Chinese families with POI were
recruited from the Reproductive and Genetic Hospital of CITIC-Xiangya.
Genomic DNA samples from the thirteen portends and their family members
were obtained.
Participants/materials, setting, methods: To identify the genetic cause of
POI in the affected women from these families, the proband in each family was
subjected to whole-exome sequencing and the putative disease-causative varia-
tions were conﬁrmed by Sanger sequencing. Bioinformatic and in vitro func-
tional analyses were performed for the functional characterization of the FSHR
mutations, which aimed to address the clinical relevance of the three novel
point mutations.
Main results and the role of chance: Four novel mutations, two homozy-
gous mutations (c.419delA(p. Lys140Argfs*16), c.1510 C>T(p. Pro504Ser)),
and a compound heterozygous mutation (c.44 G>A(p. Gly15Asp) and deletion
of exons 1 and 2) of FSHR gene were identiﬁed in the three non-syndromic
POI-with-ROS families. A donor splice site mutation in STAG3 (c.1573
+5 G>A) and a missense mutation in DMC1 (c.106 G>A) were identiﬁed in
two of the thirteen families, one in each family. Bioinformatic analysis predicted
that the three novel point mutations in FSHR are deleterious and are associated
with POI in the three families, which was conﬁrmed by in vitro functional ana-
lysis in which FSH-induced cAMP production was abolished for all receptors.
Limitations, reasons for caution: All novel putative disease-causing muta-
tions may only be clinically described as ‘variants of uncertain signiﬁcance’ unless
and until more patients with a similar phenotype are discovered in the same
mutation.
Wider implications of the ﬁndings: To the best of our knowledge,
c.419delA is the ﬁrst report of a truncation mutation of FSHR, and c.44 G>A is
the ﬁrst missense mutation in the signal peptide-encoding region of FSHR
causing POI. Our ﬁndings expand the mutational spectrum of FSHR and are
valuable for the genetic diagnosis of POI.
Trial registration number: not applicable.
P-578 The effect of paternal trans fatty acid diet on expression
pattern of PPAR genes in the ovary of rat offspring
F. Nanavakenari1,2,3, G. Javadi1, B. Ebrahimi2, A. Alizadeh
M. Masouleh2, M. Shahhoseini3
1Science and Research Branch- Islamic Azad University, Biology, Tehran, Iran
2Royan Institute for Reproductive Biomedicine- ACECR, Embryology- Reproductive
Biomedicine Research Centre, Tehran, Iran
3Royan Institute for Reproductive Biomedicine- ACECR, Genetics- Reproductive
Biomedicine Research Centre, Tehran, Iran
Study question: Does the intake of trans fatty acids in paternal diet affect on
body weight index and also expression pattern of PPAR metabolic genes in the
ovary of rat offspring?
Summary answer: Paternal intake of trans fatty acids will increase the female
offspring’s body weight in rats and decrease the expression of PPAR genes in
their ovary.
What is known already: Studies on maternal exposures and the risk of dis-
eases in the offspring is growing. But paternal associations are often not con-
sidered. Trans fatty acids in industrial oils have harmful effects on human health
and cause to signiﬁcant changes in expression pattern of several metabolic
genes. PPARs are nuclear receptors that involve in many metabolic functions in
different organs including ovary.
Study design, size, duration: The study included 20 adult female Wistar
rats (5 in each groups) that their fathers were fed in the following groups for 60
days. C: Standard diet group (control group), CT: The trans fatty acid group, E:
The group contains vitamin E, ET: The group containing vitamin E + trans fatty
acid.
Participants/materials, setting, methods: ovary of rat offspring was iso-
lated. Total RNA was extracted from ovary using TRIzol reagent. A Nanodrop
(Thermo Fischer) was used to quantify total RNA extraction and cDNA synthe-
sis was performed. Using designed primers the mRNA expression of PPAR fam-
ily genes were measured by real time polymerase chain reaction. Expression
data was analyzed by SPSS- one way ANOVA.
Main results and the role of chance: There was a signiﬁcant difference
between the mean body weight of the groups under study (F(3,36) = 10.24;
p<0.001). According to the ﬁndings, the mean body weight of the CT and ET
groups were signiﬁcantly higher than the E and C groups from 5 and 10 wk of
age, respectively. The mRNA expression levels of PPAR genes were decreased
in ovary tissue in group CT, and increased in group E, although these differential
expressions were only signiﬁcant for the PPARγ member gene in group E
(p<0.05). There were no signiﬁcant differences in PPARs in group ET.
Limitations, reasons for caution: In order to have robust data concerning
the effect of trans fatty aicds on expression of metabolic genes, an even larger
dataset would be required.
Wider implications of the ﬁndings: We imply that excessive consump-
tion of trans fatty acids can have bad genetic/epigenetic effects on human
reproduction, and vitamin E can diminish this consequence by its antioxidant
function.
Trial registration number:NA.
P-579 Next-generation sequencing (NGS) based preimplantation
genetic testing for products of reciprocal translocation (PGT-TR)
improves diagnosis of the patients by veriﬁcation of their classical
karyotyping results
S. Pukszta1, C. Cybulska1, M. Mickiewicz1, M. Zborowska1, J. Liss2,
K. Lukaszuk2
1Invicta Sp. z o.o., Molecular Biology Laboratory, Gdansk, Poland
2Invicta Sp. z o.o., Reproduction and Fertility Centre, Gdansk, Poland
Study question: Can results of next-generation sequencing based preimplan-
tation genetic testing for products of reciprocal translocation (PGT-TR) be use-
ful for veriﬁcation patient’s postnatal karyotype result?
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Summary answer: Molecular karyotyping of embryos provides information
that helps to localize the breakpoints more accurately, leading to veriﬁcation of
classical karyotype results of the patients.
What is known already: Classical banding karyotype and ﬂuorescence in situ
hybridization (FISH) are classical techniques used for detection and description
of reciprocal translocations. The application of molecular techniques, e.g.
aCGH and NGS allows for description of unbalanced products of chromosomal
rearrangements in higher resolution. The patients who are carriers of balanced
reciprocal translocations routinely are identiﬁed by classical karyotype and
results are provided to the laboratory conducting preimplantation genetic test-
ing during course of IVF treatment. These results serve as the reference infor-
mation in the prediction of localization and size calculation for putative
products of translocations.
Study design, size, duration: Study was performed from December 2016
to January 2018 and included 352 cases of reciprocal translocations. PGT-TR
outcomes were analyzed for presence and localization of the breakpoints based
on patients’ classical karyotype results provided to the laboratory.
Participants/materials, setting, methods: Biopsy samples were subjected
to whole genome ampliﬁcation (WGA) and whole genome library were con-
structed. Ion Personal Genome Machine System was used for whole genome
sequencing. The Torrent Suite Software was used to generate BAM ﬁles. The
BAMs ﬁles were uploaded to the Ion Reporter Software used for genotyping.
Results with MAPD value (the Median of the Absolute values of all Pairwise
Differences) less than 0.2 were qualiﬁed for further interpretation.
Main results and the role of chance: The localization of breakpoints in
molecular karyotyping were overlapped with classical karyotyping in 668 out
of 704 positions. Remaining 36 spots, which is 5.1% of all breakpoints ana-
lyzed, were subjected to further investigation speciﬁcally. The differences in
localization ranged from 5 to 26 mega bases (Mb). In case when data
derived from two or more embryos and re-localization of the breakpoint’s
coordinates affected of classical band descriptions laboratory ask the clinics
for veriﬁcation provided result of postnatal karyotype. All veriﬁcations
resulted in new description concordant with molecular coordinates obtained
during preimplantation testing.
Limitations, reasons for caution: The reliability of this technique may be
lower in case of rearrangements where the breakpoints are located near telo-
meres or centromeres what may have effect on precision of established
coordinates.
Wider implications of the ﬁndings: The application of next generation
sequencing in preimplantation genetic testing for chromosomal rearrangements
enhances the quality of diagnosis in the infertility clinics and have potential effect
on reproductive risk calculation and prognosis to the patients.
Trial registration number:Not applicable.
P-580 Comparison of mitochondrial DNA content in euploid and
aneuploid embryos at cleavage stage and blastocyst stage with NGS
A. Liñán Tegedor1, A. Bayram2, A. Arnanz1, I. Elkhatib3, C. Rubio4,
C. Rupali5, N. Garrido6, H. Fatemi7, B. Lawrenz8
1IVI Middle East Fertility Clinic LLC, IVF Laboratory, Abu Dhabi, Spain
2IVI Middle East Fertility Clinic LLC, IVF Laboratory, Abu Dhabi, Turkey
3IVI Middle East Fertility Clinic LLC, IVF Laboratory, Abu Dhabi, Jordan
4Igenomix Foundation- Valencia- Spain, Genetic laboratory, Valencia, Spain
5Igenomix Dubai- United Arab Emirates., Genetic laboratory, Dubai, India
6IVI Valencia, IVI Foundation, Valencia, Spain
7IVI Middle East Fertility Clinic LLC, Medical Director, Abu Dhabi, Iran
8IVI Middle East Fertility Clinic LLC, Scientiﬁc Director, Abu Dhabi, Germany
Study question: Is the mitochondrial DNA-content (mtDNA) and its dynam-
ics in cleavage stage and blastocyst stage embryos different in euploid and aneu-
ploid embryos when measured with NGS?
Summary answer: mtDNA-content is comparable in euploid and aneuploid
embryos at cleavage stage, however, it is signiﬁcantly higher in aneuploid
embryos at blastocyst state.
What is known already: Mitochondria and their DNA (mtDNA) are lately
increasingly investigated regarding their ability as a potential marker for embryo
viability and implantation chances and an increased number of mtDNA-copies
in the blastocyst seems to be associated with decreased implantation-rates.
Replication of mtDNA is not initiated during the ﬁrst 3 days of embryo develop-
ment and because of cell division, mtDNA-content is expected to decline from
cleavage to blastocyst stage biopsy. Increased mtDNA-numbers at blastocyst
stage are found with advanced female age and in aneuploid embryos. However,
so far, data on the mtDNA-content in euploid and aneuploid embryos at cleav-
age stage is rare.
Study design, size, duration: Retrospective, blinded, observational study
including 35 patients (118 embryos) which underwent preimplantation genetic
testing (PGT-A) from August 2016 to January 2017. This study validated the
chromosomal status of D5 embryos previously diagnosed on D3 and deter-
mined the mtDNA-content. Double biopsy (D3 and D5) was performed to all
embryos that reached blastocyst stage on D5 and were not selected for trans-
fer (including surplus euploid embryos that could not be vitriﬁed according to
the UAE law).
Participants/materials, setting, methods: Infertile patients with normal
karyotype undergoing preimplantation genetic screening with fresh oocytes and
with ≥5 MII or more than 4 embryos to biopsy on D3. For embryo biopsies at
D3, only embryos with ≥5 nucleated blastomeres and < 25 % fragmentation
and for blastocyst biopsy, only hatching blastocyst were evaluated. Relative
values of mitochondrial DNA were directly obtained from the software and
were analyzed using IGenomix algorithm for day 3 and day 5 biopsies.
Main results and the role of chance: After genetic screening at cleavage
stage, there were 70 aneuploid and 48 euploid embryos. In the group of aneu-
ploid embryos, mean mtDNA-content on D3 was 50.8 with a range from 31.7
to 99.4, a 95% conﬁdence interval from 47.1 to 54.4 and a standard deviation
(SD) of 15.3. In the group of euploid embryos, mean mtDNA on D3 was 51.1
with a range from 35.2 – 99.6, a 95% conﬁdence interval from 47.3 to 54.8 and
SD of 13.0. No signiﬁcant correlation between mtDNA on D3 and the chromo-
somal status of the embryos was found (p = 0.628).
After blastocyst biopsy, the results of the genetic screening revealed 51 aneu-
ploid and 62 euploid embryos. In the group of aneuploid embryos, mtDNA-
content was 22.8 with a range of 12.2 – 48.4, a 95% conﬁdence interval of 20.8
to 24.9 and SD of 7.3. In the euploid embryos, the results were 20.6 for the
mean mtDNA-content with a range of 12.8 to 45.4, a 95% conﬁdence interval
of 19.0 – 22.2 and SD of 6.2. A signiﬁcant difference in mtDNA on D5 between
aneuploid and euploid embryos (p = 0.034) was found with Mann-Whitney
test.
Limitations, reasons for caution: It is a bivariate analysis (aneuploidies ver-
sus mtDNA-content), and not controlled by other covariates that could poten-
tially bias the relationship we are studying. At blastocyst stage, 5 embryos with
trophectoderm Mitoscore values above 1.000 were considered as “outliers”
and therefore excluded from the comparison between euploid and aneuploid
embryos.
Wider implications of the ﬁndings: The fact that mtDNA-content is simi-
lar in euploid and aneuploid cleavage stage embryos, however signiﬁcantly high-
er in aneuploid blastocysts supports the idea that mtDNA-content might have a
direct impact on chromosome segregation during embryo development. It
seems that embryos under energetic stress are forced to increase the biogen-
esis as compensation.
Trial registration number: not applicable.
P-581 Whole-genomemethylomic proﬁling of iPSC-derived
granulosa-like cells and adult granulosa cells implicates novel
pathophysiological pathways of polycystic ovarian syndrome
C.C. Huang1, M.J. Chen1, S.U. Chen1, H.N. Ho1, Y. Yu-Shih1,2
1National Taiwan University Hospital, Obstetrics and Gynecology, Taipei City, Taiwan
R.O.C.
2Fu Jen Catholic University Hospital, Department of Obstetrics and Gynecology, New
Taipei City, Taiwan R.O.C.
Study question: Were the epigenetic aberrations (esp. DNA methylation)
involved in the pathophysiology of polycystic ovarian syndrome (PCOS)?
Summary answer: Common differentially methylated pathways were found
between iPSC-derived granulosa-like cells (GLCs) and adult granulosa cells
(GCs), which might be related to the pathophysiology of PCOS.
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What is known already: Although the heritability of PCOS is considered as
high as 70% from the twin study, there is no deﬁnite candidate gene found.
Epigenetic aberrations had been found to be involved in the pathogenesis of
metabolic disorders such as type 2 diabetes and could possibly also contribute
to the etiology of PCOS.
Study design, size, duration: This is a case-control study conducted from
2014-2016. Eleven patients of PCOS and 4 control subjects who underwent in-
vitro fertilization treatment were recruited for the collection of ovarian GCs.
Another 2 patients of PCOS and 2 control subjects were recruited for the col-
lection of skin ﬁbroblasts.
Participants/materials, setting, methods: Luteinized ovarian GCs were
collected during oocyte retrieval and were puriﬁed by Ficoll gradient and cell
culture. Patient-speciﬁc iPSC were established from skin ﬁbroblasts and were
then differentiated into GLCs using multistep approaches with cocktails of
growth factors. Whole-genome DNA methylation proﬁles were obtained using
Inﬁnium Methylation EPIC Beadchip in both adult GCs and iPSC-derived GLCs.
Other validation methods included real-time PCR, western blotting, immuno-
ﬂuorescence, ﬂow cytometry, and in vivo and in vitro differentiation assays.
Main results and the role of chance:We demonstrated a successful deriv-
ation of PCOS-speciﬁc iPSCs from ﬁbroblasts of women with PCOS by applying
the safer, non-viral episomal reprogramming and differentiate them into ovarian
GLCs through a cocktail of growth factors. Gene expression analyses revealed
the GC speciﬁc markers including anti-Mullerian hormone (AMH), type 2 AMH
receptor, follicle-stimulating hormone (FSH) receptor, luteinizing hormone
(LH) receptor and estrogen synthetase cytochrome P450 19A1 (CYP19A1) all
expressed in differentiated GLCs derived from PCOS and non-PCOS iPSCs.
When integrating the results of whole-genome DNA methylomic analysis in
iPSC-derived GLCs and adult GCs, a commonly overexpressed cAMP-
response element binding protein (CREB) pathway in the PCOS group was
found. Western blot also revealed a higher expression of CREB binding protein
in the iPSC-derived GLCs and adult GCs in the PCOS group. The aberration of
DNA methylation could explain the hereditary trait and the susceptibility to
environmental inﬂuence of PCOS. The methylomic aberrations existed after
cell reprogramming and re-differentiation, and this might suggest that the devel-
opment origin of PCOS could start from very early stage.
Limitations, reasons for caution: The population of PCOS is highly hetero-
geneous and our case number is small. Further validation in a larger cohort is
necessary.
Wider implications of the ﬁndings:Our ﬁndings not only provide new per-
spectives on the pathophysiology and therapeutic choices of PCOS, but also
provide new knowledges on the stem cell and epigenetic research.
Trial registration number:Nil.
P-582 Optimized NGS based protocol for the detection of small
duplications/deletions in preimplantation embryos from carriers of
balanced translocations and inversions
C.M. Garcia Pascual1, L. Navarro-Sánchez1,
L. Martínez-Merino1, L. Rodrigo2, C. Simón3, C. Rubio1
1Igenomix, PGS Research, Valencia, Spain
2Igenomix, PGD Molecular Cytogenetics, Valencia, Spain
3University of Valencia- INCLIVA- Igenomix, Obstetrics and Gynecology, Valencia,
Spain
Study question: Is it possible to develop an accurate, automated and fast
Next Generation Sequencing (NGS) based Preimplantation Genetic Testing for
structural rearrangements (PGT-SR) protocol?
Summary answer: NGS can be applied to identify duplications and deletions
≥6 Mb in carriers of balanced translocations/inversions offering high sensibility
and speciﬁcity in trophectoderm biopsies.
What is known already: Chromosome translocations are the most fre-
quent structural chromosomal abnormalities in humans. In carriers of
balanced translocations and inversions, small duplications and deletions can
arise because of adjacent meiotic segregation. The presence of inter-
chromosomal effect has been described inducing a higher risk of aneuploi-
dies for chromosomes not involved in the rearrangement. Array-CGH (com-
parative genomic hybridization) and FISH (ﬂuorescence in-situ hybridization)
have been used to detect these alterations. Currently, NGS is widely
applied in PGT for aneuploidy (PGT-A) and to increase the resolution for
its application in PGT-SR, improved NGS protocols are needed to detect
deletions/duplications ≥6 Mb.
Study design, size, duration: From July to January 2017, an optimized NGS
protocol to detect unbalances ≥6 Mb was developed and validated using 10
Coriell cell lines with deletions of known sizes (5.8-20 Mb). To test the sensibil-
ity and speciﬁcity of the protocol a set of experiments using pools of 4-6 cells
mimicking trophectoderm biopsies was set up (n = 38). Then, 136 trophecto-
derm biopsies with unbalances of expected sizes according to the reported kar-
yotype ranging from 6.4-57.8 Mb were analysed.
Participants/materials, setting, methods: In the cell lines experiments, a
total of 38 samples, with a minimum of three samples per cell line were ana-
lyzed. A modiﬁed Reproseq protocol was employed for genome ampliﬁcation,
library preparation and puriﬁcation, using Ion ChefTM and S5 sequencer
(Thermoﬁsher). A customized workﬂow was developed using the Ion Reporter
software version 5.4 for analysis and interpretation of the sequencing data.
Afterwards, 136 trophoblast biopsies were analysed following the protocol
developed with cell lines.
Main results and the role of chance: Using the pools of cells with deletions
of different sizes, we set the detection limit of our protocol in 6 Mb. The per-
centage of detection was 100%. In trophoblast biopsies from 35 patients, we
analysed 136 embryos and 99.3% of them were informative. The percentage of
unbalanced embryos was 44.8% (61/136). Full chromosome aneuploidies for
chromosomes not involved in the rearrangements were observed in 38.9%
(53/136) of the biopsies: 16.9% (23/136) of them in unbalanced biopsies and
22.1% (30/136) in balanced biopsies. Additionally, this protocol can be com-
pleted in 12-13 hours, from the preparation of the sample (lysis, preampliﬁca-
tion, ampliﬁcation, puriﬁcation, pooling and quantiﬁcation) to the release of the
results.
Limitations, reasons for caution: It could be variability in the number of
cells retrieved in the biopsy and their integrity accounting for potential ampliﬁ-
cation failures or non-informative results. Also, the whole genome ampliﬁcation
could result in false positives/ negatives. Nevertheless, in the validation study
no false positives/negatives were observed.
Wider implications of the ﬁndings: Formerly, FISH or array-CGH were
the techniques used for PGT-SR. These techniques have disadvantages. Here
in, we describe an improved, mostly automatized, fast, and accurate protocol
for detecting small del/dup up to 6 Mb. An additional advantage is that PGT-A
and PGT-SR could be performed with similar equipment.
Trial registration number:Does not apply.
P-583 Exome sequencing in a consanguineous family including
spontaneous ovarian hyper-stimulation cases with unknown triggers
S. Viville1,2, E. Yagmur3, F. Mantar4, M. Ben-Rhouma2,
M. Gultomuk5, N. Findikli6, M. Bahceci7, J. Muller8,9, O. Okutman1,2
1Hôpitaux Universitaires de Strasbourg- Nouvel hôpital civil, Laboratoire de
diagnostic génétique- UF3472 Infertilité, Strasbourg, France
2Université de Strasbourg- Institut de Parasitologie et Pathologie Tropicale, EA 7292-
Fédération de Médecine Translationelle, Strasbourg, France
3Erbil Yagmur Infertility Clinic, Infertility, Istanbul, Turkey
4Bahcesehir University, Department of Endocronology and Metabolism, Istanbul,
Turkey
5Bahceci Health Group, Research and Development, Istanbul, Turkey
6Bahceci Fulya IVF Center, Embryology Laboratory, Istanbul, Turkey
7Bahceci Health Group, IVF Department, Istanbul, Turkey
8Université de Strasbourg- Laboratoire de Génétique Médicale, INSERM U1112-
Fédération de Médecine Translationnelle de Strasbourg FMTS, Strasbourg, France
9Hôpitaux Universitaires de Strasbourg, Laboratoire de Diagnostic Génétique,
Strasbourg, France
Study question: Ovarian hyper-stimulation can rarely occur spontaneously in
patients not undergoing ovulation induction therapies. Could we determine
underlying factors via high throughput sequencing?
Summary answer: By using whole exome sequencing, a homozygous auto-
somal mutation has been identiﬁed in two affected sisters in the family.
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What is known already: Spontaneous ovarian hyper-stimulation syndrome
(sOHSS) is a rare case of OHSS, deﬁned as OHSS appearing in patients with no
history of stimulatory infertility treatment. Cases of sOHSS have been reported
in women with severe primary hypothyroidism, polycystic ovary syndrome
while pregnant, gonadotroph pituitary adenoma, and normal pregnancy. So far,
mutations in FSH receptor (FSHr) have been identiﬁed only in cases of sOHSS
triggered by pregnancy, no causative mutation has been identiﬁed for non-
pregnant sOHSS cases with unknown triggers.
Study design, size, duration: This is a case control study carried on a con-
sanguinous Turkish family comprising four siblings in which 2 sisters showing
well-documented recurrent sOHSS with no currently known triggers. Affected
sisters had sOHSS sporadically without pregnancy, TSH levels are normal, no
tumors or pituitary adenomas have been detected.
Participants/materials, setting, methods: Saliva samples have been col-
lected from parents and all siblings. Genomic DNA was extracted from saliva
using Oragene DNA self-collection kit (DNA genotek, Ottowa, Canada)
according to the manufacturer’s instructions. Whole exome sequencing of par-
ents and four sisters was performed by the Institute of Genetics and Molecular
and Cellular Biology microarray and sequencing platform, member of the
‘France Génomique programme’. Suspected mutations were conﬁrmed via
Sanger sequencing.
Main results and the role of chance: A homozygous autosomal mutation
on chromosome 10 has been identiﬁed in two affected sisters. Parents and one of
the fertile sisters are carrier while the third fertile sister is wild type. Results were
conﬁrmed with Sanger sequencing. The identiﬁed mutation alters the wild type
donor site and most probably affecting splicing. Functional studies are planned in
order to highlight underlying mechanism related to the identiﬁed mutation.
Limitations, reasons for caution: Our study contains only one family pre-
senting this very rare form of female infertility.
Wider implications of the ﬁndings:Our results provide a new understand-
ing for the pathogenesis of sOHSS and help us to identify underlying trigger in
our patients. It may help to deﬁne novel therapeutic approach to patients with
similar symptoms.
Trial registration number:Not applicable.
P-584 Comprehensive comparison of trophectoderm (TE) and
inner cell mass (ICM) by next generation sequencing (NGS)
I. Elkhatib1, B. Lawrenz2, A. Linan1, A. Arnanz1, A. Bayram1,
H. Fatemi2
1IVI Middle East Fertility Clinic LLC, IVF laboratory, ABU DHABI, United Arab
Emirates
2IVI Middle East Fertility Clinic LLC, IVF Clinic, Abu Dhabi, United Arab Emirates
Study question: Does the chromosomal information of trophectoderm
(TE) accurately predict the chromosomal information of the inner cell
mass (ICM)?
Summary answer: The observed discordance rate between TE and ICM was
15.9%. Hence, further exploration on the implication of mosaicism due to
mitotic errors is mandatory.
What is known already: The most important cause for implantation failure
is chromosomal imbalance in the embryo. Identiﬁcation of a chromosomally
normal embryo is possible due to current techniques available; however,
mosaicism can complicate interpretation of the result. Whereas meiotic
errors of the oocyte result in uniform aneuploidies, errors occurring during
the ﬁrst three mitotic division of the embryo might lead to mosaicism. TE
biopsy is commonly used to infer the chromosomal status of the ICM,
hence in case of mosaicism, TE biopsy might not represent the correct
chromosomal status of the ICM and could therefore lead to a misdiagnosis
of embryo´s chromosomal status.
Study design, size, duration: Observational, blinded study, including 88
embryos, that underwent PGS prior embryo transfer, between August 2016
and January 2017. NGS technique used to compare the chromosomal status of
the trophectoderm and the inner cell mass in blastocysts on embryos that were
not selected for transfer (including surplus euploid embryos that could not be
cryopreserved according to the UAE law).
Participants/materials, setting, methods: Infertile couples with normal
karyotype undergoing PGS with fresh oocytes, female partner with age 18 to 45
years and a body mass index of 19 to 30. Only expanded blastocyst with distin-
guishable ICM were biopsied. The genetic laboratory was blinded regarding the
identity of the couple and the origin of the sample.
ICM biopsy was performed as described in the validated procedure by
Capalbo et al. 2013.
The patients were counseled and consents were obtained.
Main results and the role of chance: Out of the 88 embryos, in which
trophectoderm and ICM biopsy could be performed, 14 embryos (14/88 =
15.9%) had a discrepant chromosomal status between ICM and
trophectoderm.
In depth analysis of the embryos with discordant ﬁndings of trophectoderm
and ICM, in 4 embryos (4/14 = 28.57%; 4/88 = 4.54%) ICM revealed an
euploid ﬁnding and trophectoderm an aneuploid ﬁnding ( = false-positive for
trophectoderm biopsy). In 3 embryos (3/14 = 21.42%; 3/88 = 3.41%), ICM
reported an aneuploid ﬁnding and trophectoderm an euploid ﬁnding ( = false-
negative of trophectoderm biopsy). Therefore in total 7 discrepancies (7/14 =
50%; 7/88 = 7.95%) regarding the embryo diagnosis (euploid / aneuploid;
aneuploid / euploid) for whole chromosome analysis. The other 7 embryos (7/
14 = 50%; 7/88 = 7.95%) had different chromosomal abnormalities in ICM and
trophectoderm.
Limitations, reasons for caution: To thoroughly identify the exact rate of
mosaicism, more embryos should be included in future studies.
Moreover, the well known methodological artefacts linked to the
whole-genome ampliﬁcation, warrant careful interpretation of the current
ﬁndings.
Wider implications of the ﬁndings: Mosaicism in the embryo results from
mitotic errors during the ﬁrst cleavage divisions and different proportions of the
embryo can be affected. Our results of false-positive TE biopsy question the
accuracy of aneuploidy results from TE biopsy in regards of being representative
for the whole embryo.
Trial registration number:Not applicable.
P-585 Segmental aneuploidy (SA) in oocytes and preimplantation
embryos
A. Pomante1, M.C. Magli1, C. Albanese1, M.C. Fasolino1, A. Crippa1,
A.P. Ferraretti1, L. Bernardini2, L. Gianaroli1
1S.I.S.Me.R., Reproductive Medicine Unit, BOLOGNA, Italy
2Presidio Ospedaliero Levante Ligure, U.O. OstGin Materno Infantile, La Spezia, Italy
Study question: Does the detection of SA reﬂect a real event or is it an
artifact?
Summary answer: Sequential biopsies of the same oocyte or embryo indi-
cate that SA most probably are a real event.
What is known already: SA, the loss or gain of chromosomal fragments, has
been detected in ~6% of spontaneous abortions. Some are compatible with life
and the affected children carry a range of congenital abnormalities. The current
cytogenetic techniques used in preimplantation genetic testing for aneuploidy
(PGT-A) have shown that SA occur at appreciable frequencies. However, the
possibility exists that whole genome ampliﬁcation (WGA) may induce artifacts
resulting in SA.
Study design, size, duration: This retrospective study includes 285 PGT
cycles from January 2014 to December 2017. According to clinical indications,
biopsy was performed on polar bodies (PB, n = 66 cycles), blastomeres (n =
169 cycles) or trophectoderm cells (TE, n = 50 cycles). In cases of SAs involving
loss or gain in excess of 15 Mb, embryos were excluded from transfer and,
depending upon the patients’ consent, re-biopsy was performed. The aim was
to evaluate the repeated occurrence of SA in following biopsies.
Participants/materials, setting, methods: Whole genome ampliﬁcation
and array comparative genomic hybridization (a-CGH) (Illumina) was done on
cells biopsied from oocytes and / or embryos of IVF patients with normal kar-
yotype from our PGT-A program. The chromosome analysis of sequential biop-
sies was performed at later stages, after the conclusion of the treatment cycle.
Re-biopsies was done in 48 cases and included sequential blastomere biopsy,
TE and BF.
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Main results and the role of chance: The occurrence of SAs was signiﬁ-
cantly lower in oocytes (4.5%; 13 oocytes over 288 analyzed), compared with
13% in blastomeres (105/821; P<0.001), 11% in TE cells (P<0.005), and 15%
in BF (P<0.001). The analysis of sequential biopsies revealed that in 6 of 13
oocytes (46%), SA occurred repeatedly: 2 were reciprocal in PB1 and PB2,
while 4 were also detected in the following stages. In blastomeres, SA were
conﬁrmed in 11 of 16 samples (69%): 5 had the same SA, 4 had the opposite
SA, and 2 cases involved the whole chromosome. In TE cells, we had 19 sets of
sequential biopsies, of which 15 were conﬁrmed (79%): 3 had the same SA plus
4 case involving the whole chromosome, and 5 had the opposite SA plus 3
cases involving the whole chromosome. In all, 32/48 SAs detected in one
biopsy occurred also in subsequent biopsies as the same anomaly (n = 8),
opposite anomaly (n = 15) or involving the whole chromosome (n = 9).
Excluding the 9 re-biopsies involving the whole chromosomes, SAs were con-
ﬁrmed in 23/48 subsequent biopsies (48%). The highest incidence of SA was
found in chromosomes 1, 2, 9 and 16.
Limitations, reasons for caution: The cytogenetic analysis on blastomeres
and TE cells did not take into consideration the occurrence of mosaicism for
which each biopsy might be not representative of the whole embryo.
Wider implications of the ﬁndings: These data could be relevant for PGT-
A, where the detection of de novo SA seems to reveal an event that has either
meiotic or mitotic origin. The transfer of embryos carrying SA should be strictly
followed-up to gain knowledge on implantation and on the genetic status of any
resulting fetus.
Trial registration number:Not applicable.
P-586 MiNtagSNP: A tagSNPs selection algorithm for
informativity maximization in Preimplantation Genetic Diagnosis
(PGD) through the use of Single Nucleotide Polymorphism (SNP)
N. Castejon Fernandez1, D. Amoros2, S. Gonzalez-Reig3, H. Blanca4,
V. Penacho3, F. Galan5, M. Fernandez4, L.A. Alcaraz6
1Bioarray, Bioinformatic, ELCHE ALICANTE, Spain
2Bioarray, Bioinformatic, Elche, Spain
3Bioarray, Sequencing, Elche, Spain
4Bioarray, Pgd/pgs, Elche, Spain
5Bioarray, Medical counseling, Elche, Spain
6Bioarray, Technical direction, Elche, Spain
Study question: Could a tagSNP-algorithm be used for ﬁnding usefull inform-
ative SNPs for a PGD case?
Summary answer: MiNtagSNp is an application for designing single and
multi-population genotyping panels based on the linkage disequilibrium of SNPs
and additional constraints imposed by the user.
What is known already: PGD has become a standard of care when dealing
with stopping the transmission of heritable-diseases. At ﬁrst sight it seems that
the directly sequencing of the disease locus is the best option to discard sick
and carrier embryos, but because of the Allele drop-out effect (ADO) the dis-
ease allele could be present but silent.
Ancient methods aimed the ampliﬁcation of polymorphic Short Tandem
Repeats (STRs) to detect mutant and wild allele. However, even when the tech-
nology has evolved quickly is still deﬁcient to face these kind of problems.
Study design, size, duration: We performed a new tagging-approach that
combines the correlation calculations of Linkage Disequilibrium criteria in order
to select informative SNPs (Informative success: heterozygous in one of the
both parents and homozygous in the other one)
Number of tagSNP selected and the number of informative-tagSNP ﬁnding
were calculated to evaluate our algorithm.
TagSNPs were obtained for three regions-of-interest and compared with the
results obtained by a STRs approach. Time execution, sensitivity and speciﬁcity
were also evaluated.
Participants/materials, setting, methods: In-silico and in-vitro approaches
were achieved in order to evaluate our algorithm.
For the In-silico set, phased SNPs were obtained for the 404 individuals of the
European super-population registered in 1000Genomes db.
Sequencing data from 15 trios (parent couple + child) obtained from the
Coriell Institute and 15 trios (appropriately informed) from our own laboratory
were used to perform two in-vitro sets.
Main results and the role of chance: An SNP is a genetic variation when a
single nucleotide in the DNA-sequence is altered and kept through heredity
thereafter. A tagSNP is a polymorphic site that represent others in a DNA-
region; using tagSNP we could ensure that disease embryos may be discard for
the transferred phase because not onlythose that shows the disease allele are
discard, even those with thehaplotype associated to it. But there is no software
specially designed for accurately use them for PGD till now.
MiNtagSNp automates the design of tagSNP genotyping panels with max-
imum likelihood of informative success, while minimizing the number of tagSNP
to assay. This approach makes MiNtagSNP different from other applications
that only considers if one SNP can be tag of a region, block, or set of SNPs,
without considering if the informativity problem solution is maximized or not.
An extensive experimental study on various datasets including three regions
of interest of the evaluation approach shows that MiNtagSNP uses fewer
tagSNPs than the state-of-the-art methods, maximizing the prediction accuracy
and the informativity problem solution.
Limitations, reasons for caution: Consanguineous couples may have large
homozygous regions due to the heritance of the same alleles; these regions
could interfere with MiNtagSNP approach.
Wider implications of the ﬁndings:We develop an efﬁcient computational
framework for tagSNP selection that is able to identify smaller tagSNP sets,
than the other studied algorithms, usefull for PGD cases and always outperform
in terms of the tagSNP size and number of choosen informativity-SNPs.
Trial registration number: none.
P-587 Aneuploidy rescue in preimplantation embryos
C. Albanese, M.C. Magli, A. Pomante, A. Crippa, S. Azzena,
I. Camera, A.P. Ferraretti, L. Gianaroli
S.I.S.Me.R., Reproductive Medicine Unit, Bologna, Italy
Study question: How do human embryos try to rescue an aneuploid
condition?
Summary answer: One possible mechanism involved in aneuploidy rescue
includes the active extrusion of aneuploid cells into the blastocoelic ﬂuid (BF).
What is known already: Embryos try to rescue aneuploidy, although the
majority of chromosomal errors are probably unlikely to be corrected, espe-
cially if they involve many chromosomes. Accordingly, most of arrested
embryos carry multiple chromosomal errors, suggesting that chromosomal
abnormalities are tightly related to embryonic arrest. Some embryos with total
or partial aneuploidy can form blastocysts that are morphologically indistin-
guishable from those with a euploid status. Their implantation potential
depends on the proportion of aneuploid cells. Several processes can contribute
to the self-correction of aneuploidy, including the formation of micronuclei, cel-
lular fragmentation, and apoptosis.
Study design, size, duration: This retrospective analysis includes a subset of
156 embryos from 71 patients with normal karyotype that underwent PGT-A
from January 2010 to December 2017. Embryos were biopsied at the blasto-
cyst stage by removing 6-8 trophectoderm (TE) cells and the BF. The aim of the
study was to compare the number of chromosome errors in TE-DNA and in
the corresponding BF to verify whether the BF could be a sort of collector of
aneuploid DNA.
Participants/materials, setting, methods: Whole genome ampliﬁcation
and array comparative genomic hybridization (a-CGH) (Illumina) was done on
TE cells. Before vitriﬁcation, the BF was collected and stored for later analysis
that was performed by operators blinded to the results of the corresponding
TE cells. Results were reported on a per-chromosome basis, but cases of seg-
mental aneuploidy (SA) involving loss or gain of chromosomal fragments in
excess of 15 Mb were also described.
Main results and the role of chance: Chromosomal results from the ana-
lysis of 156 BFs and TEs from the same embryo showed a ploidy concordance
of 93.6%, namely 104 cases of total concordance (66.6%), and 42 of partial con-
cordance (27%). The remaining 10 blastocysts (6.4%) had a ploidy discordance.
The overall mean number of aneuploid chromosomes was signiﬁcantly higher in
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BFs than in TE cells (1.9 versus 1.3 respectively, P = 0.01). In the cases of partial
concordance, this ﬁgure was 4.0 versus 2.2 respectively (P = 0.002). Both
values were signiﬁcantly more frequent in the group of partial concordance in
comparison to the group of total concordance (1.1; P<0.001). In the 10 dis-
cordant cases, 4 were aneuploid for TE cells and euploid for BF, while the
remaining 6 blastocysts had the opposite condition. SA were found in 19
embryos (11.4%). In 7 cases they were present in both TE and BF, while in the
remaining 15 cases, 8 were in BF (TE was either normal or aneuploid for the
whole chromosome) and 4 in TE cells (BF was aneuploid for the whole
chromosome).
Limitations, reasons for caution: A higher number of observations is
necessary to support the hypothesis that the embryo actively tries to extrude
aneuploid cells into the BF.
Wider implications of the ﬁndings: The higher incidence of chromosome
abnormalities including SA in BFs could reﬂect a mechanism that embryos have
against aneuploidy. The following outcome depends on the grade of mosaicism
in the embryo, but also on its capacity to activate a rescue system to gain a
euploid, or prevalently euploid, condition.
Trial registration number:Not applicable.
P-588 Presence of genomic dna in extracellular vesicles (EVs)
secreted from human embryos: a new source for non-invasive
pre-implantation diagnosis?
L. Corti1, F. Spinella2, E. Giacomini3, S. Makieva1, A.M. Sanchez3,
M. Surdo2, A. Biricik2, F. Fiorentino2, P. Viganò3
1IRCCS San Raffaele Scientiﬁc Institute, Obstetrics and Gynaecology Department,
Milan, Italy
2GENOMA Group, Molecular Genetics Laboratory, Rome, Italy
3IRCCS San Raffaele Scientiﬁc Institute, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology, Milan, Italy
Study question: To investigate the nature of DNA contained in embryo-
derived EVs and to study whether it could predict the genetic status of the
embryo.
Summary answer: Parental mutated and healthy alleles can be detected in
embryo-derived EVs using direct and indirect DNA analysis.
What is known already: EVs are heterogeneous populations of endogenous
nano- and micro-sized cell-derived membrane vesicles that are released by dif-
ferent cell types and their cargo can affect the phenotype and activity of target
cells. Previously we demonstrated, for the ﬁrst time, that conditioned media
from human embryos cultured in vitro between day 3 and 5 of development
contain EVs with predominant exosomal nature. The embryonic origin of EVs
was conﬁrmed by the presence of speciﬁc proteins and RNAs.
Study design, size, duration: This study was conducted to characterize the
genetic cargo of EVs released from embryos during in vitro culture. Initially, we
characterized the presence of genomic DNA in embryo-derived EVs.
Subsequently, we studied the utility of the ampliﬁable vesicular DNA in the con-
text of non-invasive pre-implantation diagnosis (PGD).
Participants/materials, setting, methods: Embryos undergoing PGD ana-
lysis were cultured up to blastocyst stage and underwent trophectoderm
biopsy. The spent medium was collected at day 5 of embryo culture, EVs were
isolated, lysed and subjected to DNA ampliﬁcation. The DNA fragmentation
and coverage were assessed with TapeStation and Short Tandem Repeats
(STR)/Next Generation Sequencing (NGS) analysis. The parental STR-
mutation associated analysis and direct gene mutation detection were per-
formed on EV-ampliﬁed DNA. Concordance between trophectoderm biopsy
and EV-analyses was deduced.
Main results and the role of chance: In EVs derived from grouped embryo
culture (n = 4 pools of 50 embryos), STR analysis conﬁrmed the presence of 8
common markers. The DNA in EVs was less fragmented and more enriched
compared to the free DNA in the medium. In single embryo culture, only
11out of 24 samples were analysed due to DNA ampliﬁcation issues. NGS ana-
lysis conﬁrmed a good DNA coverage and parental STRs used in PGD linkage
analysis were identiﬁed. In 11 of samples suitable for analysis, the only maternal
allele was detected in 6 out of 11 (54.5%), the only paternal allele was detected
in 3 out of 11 (27.3%), whereas both maternal and paternal alleles were present
in 2 out of 11 (18.2%) cases. Allele drop-out might be an explanation for these
ﬁndings possibly due either to the high rate of DNA fragmentation or the lim-
ited DNA ampliﬁed. In one case, the presence of the maternal mutated allele
causing congenital deafness was conﬁrmed in the EV-DNA by the direct analysis
of 35delG in CX26 gene.
Limitations, reasons for caution: Improvement of DNA ampliﬁcation and
analyses when utilizing EV-cargo is needed to increase the efﬁcacy of the meth-
odology. Additional clinical data must be obtained before this approach can be
evaluated for routine integration into PGD programs.
Wider implications of the ﬁndings: The detection of mutated or healthy
alleles (maternal and/or paternal) in embryo-derived EVs is encouraging in a
non-invasive PGD context.
Trial registration number: not applicable.
P-589 Monopronuclear embryos derived from testicular sperm
extraction followed by intra cytoplasmic sperm injection revealed
extremely high euploidy rate with next generation sequencing
S. Mizuta1, H. Matsubayashi1, Y. Tamura2, M. Santo2, Y. Araki2,
T. Takeuchi3, K. Kitaya1, T. Ishikawa1
1Reproduction Clinic Osaka, Reproductive Medicine, Osaka, Japan
2Nippon Reprogenetics Inc., Lab, Maebashi, Japan
3Reproduction Clinic Tokyo, Reproductive Medicine, Tokyo, Japan
Study question: To investigate the incidence and euploidy rate of monopro-
nuclear (1PN) embryos derived from testicular sperm extraction (TESE) fol-
lowed by intra cytoplasmic sperm injection (ICSI).
Summary answer: TESE-ICSI derived 1PN embryos showed signiﬁcantly
higher incidence than those with ejaculated sperms, however the euploidy rate
of TESE-ICSI derived 1PN embryos was extremely high.
What is known already: It has been reported that 1PN embryos were
observed around 5% both from in vitro fertilization (IVF) and ICSI, and that
blastocyst formation rate of 1PN embryos was signiﬁcantly lower than that of
two nuclear (2PN) embryos (especially in ICSI). Embryos derived from 1PN
may be considered abnormal which are unsuitable for embryo transfer.
However, a recent study revealed that 1PN embryos contained normal
embryos similar to those of 2PN embryos by preimplantation genetic screening
(PGS). We asked whether 1PN embryos derived from TESE-ICSI showed simi-
lar euploidy rate as ejaculated sperms by next generation sequencing (NGS)
because of their immaturity.
Study design, size, duration: A single-center retrospective study was per-
formed. Patients who generated 1PN embryos were asked to participate in this
study, and gave written informed consent for the study between April 2016 and
November 2017. All 1PN embryos were cultured until blastocyst stage fol-
lowed by NGS. Finally, embryos reached blastocyst and performed NGS were
from TESE-ICSI (n = 5), IVF (n = 20) and ejaculated sperm-ICSI (n = 12). Rates
of 1PN and euploidy were compared among three groups.
Participants/materials, setting, methods: The average age of patients
who provided embryos was 39.7 years. Trophectoderm biopsy was performed
using laser system (Saturn 5 ActiveTM, RI Ltd., Falmous, UK). Whole genome
ampliﬁcation was carried out using the SurePlex DNA Ampliﬁcation System
(Illumina Inc., San Diego, USA), and further chromosome proﬁles were ana-
lyzed by VeriSeq-PGS kit (Illumina). The Chi-squared tests were performed to
analyze differences in distribution between the two groups. Statistical signiﬁ-
cance was deﬁned as P < 0.05.
Main results and the role of chance: The incidence of 1PN embryos by
TESE-ICSI (10.1%, 402/3982) was signiﬁcantly (P<0.001) higher than that of
IVF (4.0%, 413/10374) or ejaculated sperm-ICSI (4.2%, 756/18009), while
2PN rate on ejaculated sperm-ICSI (70.7%) was signiﬁcantly (P<0.001) higher
than that of IVF (54.7%) or TESE-ICSI (53.5%). Polypronuclear (3PN or more)
incidence in IVF (8.8%) was signiﬁcantly (P<0.001) higher than that of ejaculated
sperm-ICSI (3.5%) or TESE-ICSI (2.5%). Blastocyst formation rate of 1PN
embryo was 27.8% (97/349) in IVF, which was signiﬁcantly (P<0.001) higher
than that of ejaculated sperm-ICSI (10.6%, 61/578) or TESE-ICSI (14.2%, 48/
337). Trophectoderm biopsy can successfully be performed from 1PN embryos
with similar rate among three groups; 100% (20/20) in IVF, 92.3% (12/13) in
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ejaculated sperm-ICSI, and 100% (5/5) in TESE-ICSI. The euploidy rate of 1PN
embryos was 30.0% (6/20) in IVF, 41.7% (5/12) in ejaculated sperm-ICSI and
100.0% (5/5) in TESE-ICSI. Of all 1PN embryos, female embryos were signiﬁ-
cantly (P<0.05) higher (62.2%, 23/37) than in male embryos (37.8%, 14/37).
The male/female embryo ratio was 9/11 in IVF, 5/7 in ejaculated sperm-ICSI,
and 0/5 in TESE-ICSI, respectively. We did not perform embryo transfer of
these euploid embryos because these embryos were to be discarded (allowed
to be used for this study).
Limitations, reasons for caution: Since this study is a single center retro-
spective observational study with a small sample size, multi-center larger scale
studies are needed to conclude. Since we did not perform other tests to track
biparental inheritence of the 1PN embryos, uniparental diploidy owing to
endoreduplication of a haploid oocyte cannot be excluded.
Wider implications of the ﬁndings: We, for the ﬁrst time, revealed that
TESE-ICSI derived 1PN embryos showed signiﬁcantly higher incidence and high-
er euploidy rate than those with ejaculated sperms. Although several mechan-
isms have been proposed to account for normal 1PN embryos, we speculate
premature pronuclear breakdown by immature testicular sperm might occur in
the embryo.
Trial registration number:N/A.
P-590 Chromosomal mosaicism in spontaneous abortions: a
case-control molecular cytogenetics study of 1280 specimens by
interphase FISH
S. Vorsanova1, O. Kurinnaia1, Y. Yurov2, A. Kolotii1, I. Demidova1,
V. Kravets1, M. Zelenova2, K. Vasin2, M. Gordeeva1, S. Fedorenko2,
I. Iourov2
1Academician Yu.E. Veltishchev Research Clinical Institute of Pediatrics- N.I. Pirogov
Russian National Research Medical University- Ministry of Health of the Russian
Federation- Moscow, Laboratory of molecular cytogenetics of neuropsychiatric
diseases,
2FSBSI «Mental Health Research Center»- Moscow, Laboratory of cytogenetics,
Moscow, Russia C.I.S.
Study question: What is the contribution of mosaic aneuploidy and poly-
ploidy to spontaneous abortion (SA)?
Summary answer: Aneuploidy/polyploidy was found in 52,8% of 1280 SA
specimens; chromosomal mosaicism was observed in 49,1% of abnormal cases.
What is known already: Numerical chromosomal abnormalities are the
most common genetic cause of SA during the ﬁrst trimester. Classical cytogen-
etic methods have shown that chromosomal abnormalities are found in
approximately 15% of SA. Many previous studies have indicated that chromo-
somal mosaicism frequently contributes to SA and can be potentially associated
with intrauterine mortality.
Study design, size, duration: Using interphase FISH with chromosome-
speciﬁc DNA probes selected according to the involvement in causative
chromosome imbalances, we have performed a case-control study of chromo-
somal mosaicism in spontaneous abortions.
Participants/materials, setting, methods: We have analyzed 1280 chori-
onic villus samples of SA (ﬁrst trimester) by interphase multiprobe FISH using
DNA probes for chromosomes 1, 9, 13/21, 14/22, 15, 16, 18, X and Y.
Main results and the role of chance: Numerical chromosomal abnormal-
ities were detected in 676 cases (52.8%) of 1280 SA samples. Multiple aneu-
ploidy/polyploidy were observed in 7.5% of abnormal samples (51 samples) or
in 4.0% of all the SA samples. Autosomal trisomy was found in 46.5% of abnor-
mal samples (314 samples) or in 24.5% of all the samples. Chromosome X
aneuploidy was found in 21.3% of abnormal samples (144 samples) or in 11.2%
of all the samples. Polyploidy was found in 20.4% of abnormal samples (138
samples) or in 10.8% of all the samples. In 4.3% of abnormal samples, mosaic
autosomal monosomy was observed. Among all the cases of chromosomally
abnormal SA, mosaicism was detected in 49.1%. Consequently, mitotic non-
dissociation and/or anaphase lagging causing mosaic chromosomal pathology is
likely to be one of the most frequent genetic causes of fetal death. Beside high-
lighting the role of chromosomal mosaicism in intrauterine fetal death, it is
shown that chromosomal mosaicism uncovered by interphase mFISH signiﬁ-
cantly contributes to SA.
Limitations, reasons for caution: Current study is limited to numerical
chromosomal abnormalities of chromosomes 1, 9, 13/21, 14/22, 15, 16, 18, X
and Y.
Wider implications of the ﬁndings: These data demonstrate that chromo-
somal mosaicism is highly frequent in SA. Furthermore, interphase FISH seems
to be a valid approach towards uncovering chromosomal mosaicism in large
scale case-control studies.
Trial registration number:Not applicable.
P-591 Application of SMRT Sequencing in preimplantation genetic
testing (PGT) for reciprocal translocation carriers
L. Hu1, J. Zhou2, D. Cheng3, K. Luo4, F. Gong4, Y. Tan4, P. Xie5,
D.Wang2, G. Lu6, K.Wang7, G. Lin4
1Institute of Reproductive and Stem Cell Engineering- School of Basic Medical
Science, Central South University, Changsha, China
2Nextomics Biosciences, Nextomics Biosciences, Wuhan, China
3Reproductive and Genetic Hospital of Citic-Xiangya, Genetic Center, Changsha,
China
4School of Basic Medical Science- Central South University, Institute of Reproductive
and Stem Cell Engineering, Changsha, China
5National Engineering and Research Center of Human Stem Cells, R&D department,
Changsha, China
6National Engineering and Research Center of Human Stem Cells, National
Engineering and Research Center of Human Stem Cells, Changsha, China
7Columbia University, Institute for Genomic Medicine, New York, U.S.A.
Study question: Can SMRT sequencing be used in in preimplantation genetic
testing (PGT) for balanced reciprocal translocation carriers?
Summary answer: Although it is still needed to be optimized and evaluated,
SMRT Sequencing could be another option for PGD, especially for balanced
reciprocal translocation carriers.
What is known already: Fluorescence in situ hybridization (FISH)-PGD and
comprehensive chromosome screening have been used to identify unbalanced
embryos and prevent recurrent spontaneous abortion for reciprocal transloca-
tions carriers. Array CGH, MicroSeq, and MaReCs were successfully applied
for discrimination of normal embryos and balanced embryos. However, detec-
tion of both copy number variants (CNVs) and structural variants (SVs) during
PGT in a single sequencing testing remains unsolved. Single Molecule, Real-
Time (SMRT) Sequencing enables accurate localization of CNVs and SVs simul-
taneously with long-read whole genome sequencing. However, its application in
PGT is rarely tested.
Study design, size, duration: This proof-of-principle study included totally 2
couples with balanced reciprocal translocation in CITIC-XIANGYA. Besides
regular PGT with next-generation sequencing (NGS) and MicroSeq, we per-
formed SMRT sequencing for both translocation carriers and all 6 Day-6
blastocysts.
Participants/materials, setting, methods: Two patients with balanced
translocation participated in the study after signing informed consent. We per-
formed SMRT Sequencing on gDNA of the carriers to identify the translocation
breakpoints with about 6× coverage. SMRT Sequencing (~10× coverage) and
NGS were then performed with the MDA-ampliﬁed whole genome ampliﬁca-
tion (WGA) products. Speciﬁc primers spanning the breakpoints were designed
to verify the SMRT sequencing results. Results of SMRT sequencing were com-
pared to those of NGS to evaluate its efﬁciency.
Main results and the role of chance: We successfully detected the break-
points of the two reciprocal translocations. For SMRT sequencing of the six
embryos, both CNVs and target breakpoint could be detected by using blasr-
PBhoney. The results of CNVs detected by SMRT sequencing was comparable
to that of NGS. The existence of the breakpoints in the embryos was validated
by PCR. However, there are numerous SVs are derived from artiﬁcial noise in
low coverage, e.g. Blunt ligation could induce target DNA self-ligated before
adapter ligation; adapter was not recognized in sequencing process. BAMsplit
was developed for reads selection and SVs could be screened by using CNV.
Each family has 1 unbalanced embryo, 1 balanced embryo, and 1 normal
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embryo. The two normal embryos were transferred. Both patients got preg-
nant. By prenatal diagnosis, 2 babies were conﬁrmed normal without balanced
translocation, which consisted with our breakpoint analysis.
Limitations, reasons for caution: Due to current costs of the SMRT
sequencing, it is hard to sequencing the whole genome with a high coverage,
which may inﬂuence the accuracy of PGT. Besides, artiﬁcial noise affect the efﬁ-
ciency of SVs detection. This limitation may be solved by developing new meth-
odology of both sequencing and bioinformatics.
Wider implications of the ﬁndings: This proof-of-principle study suggest
that SMRT Sequencing could be another option for PGD, especially for
balanced reciprocal translocation carriers. However, there are still a lot of pro-
blems remain to be solved before future clinical application.
Trial registration number: not applicable.
P-592 Comparison of euploid embryo formation after natural or
mild stimulation
M. Terribile, M.Wilding, I. Parisi, T. Pehlivan, V. Hall, G. Nargund
Create Fertility, Embryology, London, United Kingdom
Study question: To compare the efﬁciency of euploid embryos analysed with
next-generation sequencing (NGS) after natural and mild stimulation in a preim-
plantation genetic screening program.
Summary answer: Our study on patients undergoing NGS cycles suggests
that natural modiﬁed stimulation did not lower the likelihood of euploidy in
developing embryos.
What is known already: Mild stimulation cycles aim to achieve multiple fol-
licular recruitment balancing the quantity and quality of oocytes with reduction
of health risks to the patient in normoresponder patients. Natural modiﬁed
protocols assist the production of a single, high quality follicle and therefore egg
in low responders. Some papers have suggested that the cumulative pregnancy
rate is comparable between natural modiﬁed and mild stimulation, however
this has not been demonstrated at the present time. In this work, we test the
effectiveness of these protocols by examining the percentage of production of
normoploid embryos diagnosed with PGS-NGS.
Study design, size, duration: In this retrospective observational research
study we included 96 patients undergoing PGS at Create Fertility St Pauls,
London. Between 2015 and 2017 in a PGS-NGS program 550 eggs were col-
lected resulting in 136 embryos biopsied. Data related to the stimulation type
(natural modiﬁed or mild stimulation) was retrospectively analyzed. The out-
come measures were fertilization rate, blastocyst formation and euploid rate.
Participants/materials, setting, methods: Patients with normal karyotype
undergoing PGS with fresh oocytes, aged between 25 and 49 years old, with a
body mass index between 19 and 30 were included. Blastocysts were scored
according to the standard Gardner grading system and laser-assisted trophecto-
derm biopsy was performed on day 5/6 post oocytes retrieval. Pre-
implantation genetic screening was performed with next-generation sequen-
cing. Chi-squared test was used for statistical analysis with P<0.05 considered
signiﬁcant.
Main results and the role of chance: A total of 550 oocytes were col-
lected, 132 “natural modiﬁed” vs 418 “mild” respectively. No statistical differ-
ence was observed in fertilization rate between the two groups (82 vs 260,
NS). A better blastocyst formation was observed in the natural modiﬁed group,
(27% vs 46% respectively, p<0.001). After 5 or 6 days of culture, 136 embryos
were analyzed with PGS-NGS (49 vs 87, NS). In 10 samples no results were
obtained (3 vs 7, NS). On a total of 126 biopsies with results 18 embryos were
euploid (4 vs 14, NS) and 108 were abnormal (42 vs 66, NS) with a euploid
rate of 4.88% for natural modiﬁed and 5.38% for mild stimulation.
Our results suggest that more embryos are able to grow to blastocyst stage
in the natural modiﬁed group, in equivalent culture conditions. Secondarily, the
percentage of the euploid embryos between the two groups is not statistically
different.
These data suggest that natural modiﬁed cycles are as effective in producing
high quality eggs than mild cycles in their distinctive patient groups, leading to
lower embryo wastage and a more efﬁcient use of embryos in IVF cycles.
Limitations, reasons for caution: This study was limited by its retrospect-
ive design. Prospective data on the outcomes of embryo transfers is needed to
determine their true implantation potential.
Wider implications of the ﬁndings: This study showed that euploid rates
for blastocysts are not signiﬁcantly different in natural or mild stimulation cycles.
This suggests that the natural modiﬁed stimulation approach is an efﬁcient and
safe protocol in a program of assisted reproduction.
Trial registration number: not applicable.
P-594 Novel loss of function mutations of follicle-stimulating
hormone receptor in a patient with premature ovarian insufﬁciency
identiﬁed by infertility gene panel using next generation sequencing
S. Van Dooren1, A. Sassi2, J. Désir3, S. Costagliola4, V. Janssens5,
M. Bonduelle6, A. Gheldof6, D. Daneels6, A. Delbaere2
1UZ Brussel, Centre for Medical Genetics & BRIGHTcore, Jette- Brussels, Belgium
2Erasme Hospital- Université Libre de Bruxelles, Fertility Clinic- Department of
Obstetrics and Gynecology, Brussels, Belgium
3Erasme Hospital- Université Libre de Bruxelles- Brussels- Belgium, Department of
Genetics, Brussels, Belgium
4Université Libre de Bruxelles, IRIBHM- Institute of Interdisciplinary Research in
Human and Molecular Biology-, Brussels, Belgium
5Université Libre de Bruxelles -, IRIBHM- Institute of Interdisciplinary Research in
Human and Molecular Biology, Brussels, Belgium
6UZ Brussel- Vrije Universiteit Brussel, Centre for Medical Genetics- Reproduction and
Genetics- Reproduction and Genetics and Regenerative Medicine, Brussels, Belgium
Study question: Can an infertility gene panel (GP) approach uncover genetic
etiology of premature ovarian insufﬁciency (POI) in a patient with primary
amenorrhea (PA) and hypergonadotropic hypogonadism?
Summary answer: Analysis of GP using next generation sequencing (NGS)
identiﬁed two new rare inactivating mutations of FSHR which are very likely
responsible for the POI phenotype.
What is known already: Inactivating mutations of FSHR are an extremely
rare cause of POI. Sixteen inactivating mutations of the receptor have been
reported so far in POI patients affecting either the extracellular domain (ECD)
or the transmembrane domain (TMD) of the FSHR whether in homozygous or
compound heterozygous state. In patients with previously characterized FSHR
mutations, the phenotype varied depending on the level of inactivation of the
receptor. In most cases, patients presented with a primary amenorrhea and
streak ovaries. Some mutations were associated with partial or normal breast
development, secondary amenorrhea and normal sized ovaries containing pre-
antral and even small antral follicles.
Study design, size, duration: Analysis of a panel of 31 genes implicated in
POI was performed in a 32 years old Belgian patient presenting an idiopathic
POI with PA diagnosed at the age of 17 and normal breast development. This
patient consulted our fertility clinic for assisted reproduction with oocyte dona-
tion and gave her written informed consent to be tested for a genetic etiology
of POI.
Participants/materials, setting, methods: We performed GP using NGS
@ BRIGHTcore in a patient with POI. FSH and AMH levels were respectively
74UI/L and 1.4ug/L. Karyotype and array CGH were normal. Transvaginal pel-
vic ultrasound and laparoscopy showed small ovaries with no antral follicles.
Transient transfection of COS7 cells was performed with a plasmid containing
wild-type FSHR cDNA as well as the two novel FSHR variants identiﬁed by GP
analysis. Cell surface expression of FSHR variants was tested by FACS.
Main results and the role of chance: NGS identiﬁed the presence of two
new compound heterozygous FSHR missense mutations: c.646 G>A
(Gly216Arg) in exon 8 (ECD) and c.1313 C>T (Thr438Ile) in exon 10 (TMD)
of the receptor. Both mutations were predicted to be deleterious and/or prob-
ably damaging by in silico analysis. The in vitro functional study showed that the
expression of both FSHRs variants was barely detectable at the cell surface of
transfected COS7 compared to wildtype FSHR. Two experiments showed simi-
lar results.
Limitations, reasons for caution: Mutations segregation in patient’s family
was not evaluated. As FACS experiments used antibodies that recognize an epi-
tope located in the ECD of FSHR, it is possible that the c.646 G>A mutation
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alters the epitope recognition by the antibodies without altering the cell surface
expression of the receptor.
Wider implications of the ﬁndings: FSHR mutations are found in less than
1% of POI patients rendering the single gene analysis approach inefﬁcient. We
report new FSHR inactivating mutations in a patient presenting PA and hypergo-
nadotropic hypogonadism demonstrating the interesting contribution of a spe-
ciﬁc GP using NGS to uncover genetic etiologies of idiopathic POI cases.
Trial registration number: P2016/196/CCB B406201628264
P-595 Higher resolution aneuploidy screening with targeted NGS
may increase the pool of transferrable embryos despite inclusion of
segmental and mosaic range diagnostic categories
S. Morin1, A. Tiegs2, C. Jalas3, Y. Zhan3, J. Landis3, S. Neal2,
J. Franasiak2, R. Scott- Jr.2
1IVI/RMA Northern California, Reproductive Endocrinology and Infertility, San
Francisco, U.S.A.
2IVI/RMA New Jersey, Reproductive Endocrinology and Infertility, Basking Ridge,
U.S.A.
3Foundation for Embryonic Competence, Genetics, Basking Ridge, U.S.A.
Study question: How does the higher resolution of next generation sequen-
cing based aneuploidy screening, inclusive of segmental error and mosaic range
diagnostic categories, inﬂuence the proportion of transferrable embryos in
PGT-A cycles?
Summary answer: The higher resolution capability of targeted NGS (tNGS)
for PGT-A produces fewer whole chromosome aneuploidy calls. If mosaics/
segmentals are considered transferrable, more embryos are available.
What is known already: Euploid embryos, screened with qPCR, have been
prospectively demonstrated to produce higher implantation rates than
unscreened embryos. Early reports suggest that an embryo diagnosed as
euploid with higher resolution NGS platforms produce even higher implantation
rates than lower resolution approaches. However, some concern has been
raised that inclusion of additional diagnostic categories (segmental and mosaic
range) in NGS reports may signiﬁcantly limit the pool of transferable embryos
by reducing the number of euploids available. Given lack of quality data regard-
ing the reproductive potential and long term safety of these embryos, some
have suggested limiting their inclusion on clinical reports.
Study design, size, duration: This was a retrospective cohort study of
13,465 embryos from 2,830 cohorts utilizing tNGS based aneuploidy screening
at a single IVF center between July 2016 and November 2017. This represented
all PGT-A cycles at the center after the reference laboratory switched from
qPCR based PGT-A to a tNGS platform. Aneuploidy screening results were
compared to a large, published retrospective cohort of 15,169 embryos ana-
lyzed with qPCR based PGT-A in 2014 by our group.
Participants/materials, setting, methods: Targeted NGS embryos were
placed into one of four categories: aneuploid (whole chromosome aneuploidy
present), segmental (only abnormality was deletion/duplication), mosaic range
(no other whole chromosome or segmental aneuploidy), euploid. Diagnostic
results were compared to published 2014 cohort using qPCR / SNP microarray
with respect to 1) Percentage aneuploid diagnoses per embryo and 2)
Percentage of cohorts with at least 1 euploid available. Relationship between
age and each diagnostic category was evaluated by logistic regression.
Main results and the role of chance: The age of the female partners ranged
from 21 to 46 years. The percentage of the 13,495 embryos with aneuploid
calls was signiﬁcantly reduced with tNGS compared to qPCR/SNP microarray
(32.4% vs. 41%, p<0.001). Mosaicism and segmental rates in tNGS cohorts
were 3.6% and 7%, respectively. The no result rate was signiﬁcantly lower with
tNGS than the qPCR/SNP microarray cohort (1.2% vs. 2.8%, p<0.001).
A total of 80.7% of the 2,830 tNGS cohorts featured at least one euploid
embryo for transfer. The likelihood that a cohort produced all aneuploid
embryos increased as the age of the female partner increased (p<0.001).
However, more than 90% of cohorts produced at least one euploid embryo for
transfer for all ages <35 years; 80% of cohorts did so through age 38. It wasn’t
until age 42 that the majority of cohorts produced no euploid embryos for
transfer. The percentage of cohorts in which the only available embryo for
transfer was segmental or mosaic was 1.3 and 2.5%, respectively. Thus, 96.2%
of cohorts produced a clear clinical strategy (euploid available or all aneuploid
embryos).
Female age was strongly associated with whole chromosome aneuploidy.
However, there was no association between age and segmental or mosaic
range diagnoses.
Limitations, reasons for caution: These data reﬂect the experience of one
PGT-A strategy. While NGS-based methods are now widely used, the ampliﬁ-
cation strategy, opportunity for concomitant genotyping, bioinformatic custom-
ization, and thresholds for intermediate calls can vary widely. This may explain
wide variation in reported prevalence of mosaicism. Higher mosaicism rates
may alter these conclusions.
Wider implications of the ﬁndings: If segmental and mosaic range
embryos are considered for transfer, the pool of eligible embryos is increased
with tNGS (despite inclusion of additional abnormal diagnostic categories), as
whole chromosome aneuploidy calls are less frequent. Data from nonselection
studies are needed to deﬁne reproductive potential and health outcomes of
these embryos.
Trial registration number:Not applicable.
P-596 Clinical implementation of a POI gene panel in idiopathic
patients
A. Gheldof1, S. Van Dooren2, K. Stouffs2, A. Sassi3, D. Daneels2,
J. Désir4, M. Bonduelle2, A. Delbaere3
1Centrum Medische Genetica, Centrum Medische Genetica, Brussel, Belgium
2Centrum Medische Genetica, Reproduction and Genetics, Brussel, Belgium
3Erasme Hospital- Université Libre de Bruxelles- Fertility Clinic, Department of
Obstetrics and Gynecology, Brussels, Belgium
4Erasme Hospital- Université Libre de Bruxelles- Fertility Clinic, Department of
Human Genetics, Brussels, Belgium
Study question: Can a small NGS based gene panel be clinically incorporated
in order to identify the genetic cause in idiopatic POI patients?
Summary answer:We have developed a gene pannel consisting of 21 litera-
ture evidence based genes which has allowed us to investigate 32 idiopathic
POI women.
What is known already: Premature ovarian insufﬁciency (POI) has been
shown to occur in 1% of all women under 40 years old. Already known etiolo-
gies are mainly karyotype abnormalities, X fragile premutation, auto-immunity
and iatrogenic factors. During recent years, genetic causes, ranging from
chromosomal aberrations to single nucleotide alterations, have been shown to
contribute to POI, as 31% of POI patients have a familial history. To date, differ-
ent genetic tools have been used in order to the uncover genetic etiology of
POI, but few reports have focused on the contribution of a speciﬁc female infer-
tility gene panel in the POI assessement.
Study design, size, duration:We have performed a speciﬁc female infertility
gene panel by NGS. This GP is restricted to 21 genes implicated in POI and
selected according to the evidence based literature ﬁndings. Genes where only
limited associations have been reported were excluded. This approach allows a
more accurate diagnostic route, and an easier clinical workﬂow in terms of data
interpretation.
Participants/materials, setting, methods: We have applied our GP to a
cohort of 32 idiopathic POI cases recrutted prospectively from our hospital
since june 2016. These patients presented a normal caryotype, no fragile X pre-
mutation, no pathogenic nor likely pathogenic CNV at array CGH and no
adrenal nor ovarian antibodies. The GP analysis was performed (Capturing
Based) on an Illumina HiSeq1500 machine.
Main results and the role of chance:We have identiﬁed six rare variants at
the heterozygous state (HTs) and one variant at the homozygous state (HOs).
Two of them are likely pathogenic and probably responsible for the POI pheno-
type as they implicate NOBOX and DIAPH 2 genes which inheritance is domin-
ant. The remaining ones are of uncertain signiﬁcance (VUS): One is
homozygous in the XPNPEP2 gene (X-linked dominant inheritance) while the
remaining ones implicate the STAG3, HFM1, FOXO1 and MCM8 genes in which
the inheritance is recessive.
Limitations, reasons for caution: The implication of the identiﬁed variants
in the POI physiopathology needs to be further documented by familial
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segregation of mutations and phenotypes, as well as functional studies are
required. Furthermore, the limited gene set of our panel has to be taken into
account.
Wider implications of the ﬁndings: Our data shows that a speciﬁc GP
restricted to a relative small number of genes is useful and rapid genetic tool
identiﬁng rare variants in 21,8% of patient. This GP should be integrated as a
ﬁrst line assessment of idiopathic POI idiopathic cases before large GP and
Exome sequencing.
Trial registration number: P2016/196/CCB B406201628264
P-597 Preliminary analysis of chromosome abnormalities in
inversion preimplantation genetic diagnosis cycles using
comprehensive chromosome screening
P. Xie, L. Hu, Y. Tan, S. Zhou, G. Lu, G. Liin
1National Engineering and Research Center of Human Stem Cell- Changsha
410078- China
2Institute of Reproduction and Stem Cell Engineering- Central South University-
Changsha- Hunan 410078- China-
3Reproductive and Genetic Hospital of Citic-Xiangya- Ch
Study question: To determine the factors associated with unbalanced chromo-
somal rearrangement in blastocysts originating from the parental inversion.
Summary answer: The risk of generating unbalanced blastocysts originating
from the parental inversion is affected by the inversion segment proportion and
gender of pericentric inversions carriers.
What is known already: Inversion carriers have an increased risk of having
fertility problems, recurrent miscarriages or an abnormal chromosomal off-
spring. Previous studies in spermatozoa suggested the probability of generating
unbalanced spermatozoa is affected by many factors including, e.g. the length of
the inverted segment, the position of the breakpoints. Study in translocation
carriers suggested sperm FISH cannot be used as a reliable predictor of blasto-
cysts and preimplantation genetic diagnosis (PGD) outcome. However, there is
few studies analyzed the PGD outcome of inversion carriers.
Study design, size, duration: A retrospective study from October 2011 to
October 2017, a total of 482 blastocysts originating from 145 oocyte retrieval
cycles from 128 couples with one of the partners carrying inversion were inves-
tigated. The mean maternal age was 32.08 years (20–44 years). Meanwhile, a
total of 1228 blastocysts from 406 age-matched patients with normal karyotype
were analyzed as control group.
Participants/materials, setting, methods: Trophectoderm biopsy of blas-
tocysts was performed on the 5th or 6th day of development. Whole genome
ampliﬁcation (WGA) was performed on all samples, and the WGA was ana-
lyzed with SNP array or NGS. The inversion was classiﬁed into two categories:
paracentric and pericentric inversions. Further, the blastocysts from pericentric
inversions carriers were analyzed according to inversion segment proportion of
the length of the inversion over the length of the whole chromosome and the
gender.
Main results and the role of chance: For paracentric inversions, we
detected chromosome abnormalities in 44/162 embryos (27.16%) while 117
showed a normal chromosome (72.22%). Seven embryos (5/162, 3.08%) with
unbalanced rearrangement originating from the parental inversion were identi-
ﬁed. For pericentric inversions, ﬁrst, the pericentric inversions were divided
into 3 groups according to the inversion segment proportion (<30% group, 30-
50% group, >50% group), the normal embryo proportion was 58% (56/99),
69.23% (57/84), 7.37% (63/133). The unbalanced rearrangement originating
from the parental inversion was 3/99 (3.03%), 9/84(10.71%), 44/133(33.08%)
respectively in three groups, with signiﬁcant difference (p<0.01). Second, we
analyzed the unbalanced rearrangement from maternal and paternal inversion,
interesting, the unbalanced rearrangement proportion originating from paternal
inversion was higher than maternal inversion in >50% group (43.64%(24/55) vs
25.64%(20/78), P<0.05. Further, In order to determine whether an interchro-
mosomal effect (ICE) occurred in blastocysts obtained from inversion carriers.
Aneuploidies unrelated to inversion chromosome were identiﬁed in both inver-
sion carriers and control group. In the samples from inversion carriers, a total
of 20768 chromosomes were examined and 182(0.88%) aneuploidies were
identiﬁed. In the control group, 54032 chromosomes were assessed and 510
(0.94%) aneuploidies were identiﬁed. There was no apparent ICE detected in
blastocysts of inversion carriers.
Limitations, reasons for caution: Due to the difﬁculty in recruiting patients
with inversion, the sample size of this study is moderate and more cases should
be added.
Wider implications of the ﬁndings: Our results indicate the risk of gener-
ating unbalanced embryos is low for paracentric inversions, however, the risk is
affected by inverted segment proportion and gender for pericentric inversions.
There was no apparent ICE detected in blastocysts of inversion carriers. This
study may provide data for genetic counseling of inversion carriers.
Trial registration number: not applicable.
P-598 Non-invasive preimplantation genetic testing – aneuploidy
screening (PGT-A) using spent culture medium (SCM)
Q.S.Y. Yeung, Y.X. Zhang, J.P.W. Chung, T.C. Li, G.W.S. Kong,
K.W. Choy
The Chinese University of Hong Kong, Obstetrics & Gynaecology, Hong Kong, Hong
Kong
Study question: Could the same genome proﬁle be identiﬁed if spent culture
media (SCM) instead of trophectoderm (TE) were used for aneuploidy screen-
ing (PGT-A)?
Summary answer: PGT-A using SCM was capable but not as efﬁcient as
using TE in euploid identiﬁcation.
What is known already: By comprehensively screening all 24 chromosomes,
PGT-A has been shown to increase implantation and ongoing pregnancy rates.
However, the current practice of PGT-A requires an invasive biopsy procedure
on the embryo, usually at the blastocyst stage. While the embryologists per-
forming this delicate procedure are usually skilled, the long term effect of laser
ablation at the site of biopsy and the removal of a small cell mass from a preim-
plantation embryo remains unknown for the babies born. It would be ideal if
euploid embryos could be accurately identiﬁed via a non-invasive approach.
Study design, size, duration: This is a prospective study comparing PGT-A
results of SCM samples to the routine results based on TE of the same
embryos. Couples undergoing PGT-A cycles were recruited from a university
hospital infertility centre. The study is still ongoing, and this interim review is
consisted of 70 blastocysts from 24 PGT-A cycles between March 2017 and
September 2017.
Participants/materials, setting, methods: All recruited cycles underwent
intracytoplasmic sperm injection (ICSI). Normally fertilized embryos were indi-
vidually cultured in sequential media, with change of simple to complex media
on day 3. Blastocysts were biopsied on day 5 or day 6. The complex media in
which these embryos were cultured since day 3 were collected. After whole
genome ampliﬁcation (WGA), TE samples were analysed by array comparative
genomic hybridization (aCGH) and SCM samples were analysed by next gener-
ation sequencing (NGS).
Main results and the role of chance: All TE samples were subjected to
routine PGT-A by aCGH (GenetiSure Pre-Screen 8×60 K microarray, Agilent),
from which 69 (98.6%) produced an interpretable result. For SCM from the 70
corresponding embryos, 60 samples (85.7%) had cell free DNA that were suc-
cessfully ampliﬁed. These WGA products were then subjected to NGS
(Veriseq, Illumina), with 39 of them (65.0%) giving an interpretable result.
There was an 88.2% concordance rate in sex determination. When SCM results
were classiﬁed into euploid and aneuploid, the concordance rate with TE results
was 71.8%. Overall, 12 euploids were identiﬁed by SCM, in which 6 were also
euploids based on TE biopsy, 3 contained low level of mosaicism, 1 involved a
segmental error on one chromosome, and 2 false negatives probably due to
presence of cumulus cells in the SCM. Interestingly, there were 3 aneuploids
identiﬁed by SCM which were euploids by TE biopsy. These three embryos
were already transferred based on their euploid status as established from TE,
resulting in 2 miscarriages and 1 ongoing pregnancy.
Limitations, reasons for caution: Our study was limited by the small sam-
ple size. While sperm contamination could be eliminated by using ICSI, further
care might be needed in oocyte denudation to avoid maternal contamination.
Several rinsing could be incorporated into the media change on day 3 of embryo
development.
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Wider implications of the ﬁndings: Spent culture media from embryos
have the potential to become the ﬁrst non-invasive method in euploid identiﬁ-
cation and gender determination. Gamete and embryo handling may be reﬁned
to allow better accuracy and consistency. Much research is needed to elucidate
the origin of cell free DNA found in SCM.
Trial registration number: Research Licence R3004 by the Council on
Human Reproductive Technology of Hong Kong.
P-599 Model ensembling and synthetic features in PGS cycles with
single embryo transfer
O.O. Barash, K.A. Ivani, S.P.Willman, N. Huen, M.V. Homer,
L.N.Weckstein
Reproductive Science Center of the San Francisco Bay Area, U.S.A.,
Study question: Can model ensembling and synthetic features be used to
evaluate the impact of the wide range of clinical, as well as morphological and
kinetic parameters of embryo development in vitro on the clinical pregnancy
rates in autologous IVF PGS cycles with single embryo transfer.
Summary answer: Model ensembling and synthetic features can be used
evaluate the impact of factors affecting clinical outcomes in IVF PGS cycles with
high accuracy and superior predictive performance.
What is known already: Comprehensive chromosomal screening has been
proven as the best option to increase clinical outcomes in autologous IVF cycles
for advanced maternal age patients. Recent advances in statistical learning (also
known as Machine learning or Artiﬁcial Intelligence) coupled with a steady
increase in the number of IVF cycles with PGS has created a background for
effective, non-bias and reproducible data analysis via model ensembling.
Study design, size, duration: 1029 cycles of IVF PGS treatment with single
embryo transfer between January 2013 and November 2017 were included in
the study (average age 35.5 ± 4.8). 175 clinical factors (age, BMI, AMH, FSH,
AFC, stimulation protocol, stimulation duration, gonadotropin dosage, gravidity
history, diagnosis, etc.) and 145 morphological and kinetic parameters of
embryo development (number of eggs retrieved, number of 2PN, blastulation
rate, embryo morphology, euploidy rate per cycle, number of embryos biop-
sied on day 5 and day 6, number of euploid embryos per cycle, fertilization rate,
etc.) were recorded for each IVF PGS cycle. Clinical pregnancy rate (PR) was
deﬁned by the presence of a fetal heartbeat at 6-7 weeks of pregnancy. To ﬁnd
the optimal combination of prediction algorithms loss-based supervised learning
method was employed.
Participants/materials, setting, methods: From 320 original features
3247 synthetic features were created (by Weight of Evidence for columns,
Encoding of categorical levels of the feature, Cross Validation Target Encoding,
Time series, etc), tested and 609 features were selected for each IVF PGS cycle.
104 statistical models were trained and ensembled in the ﬁnal model. Predictive
accuracy was evaluated by 5-fold cross-validation and AUC value (ROC curve).
Main results and the role of chance: Combined predictions from multiple
weak learners (generalized logistic regression, random forest, gradient boosting,
etc.) processed by Generalized Model Stacking produced a predictive perform-
ance of AUC = 0.8047. The probability of positive clinical outcome was calcu-
lated for each IVF PGS cycle and ranged from 0.239 to 0.850 (baseline
prediction – 0.63). A number of previous biochemical pregnancies, blastocysts
morphology and time when embryo became available for biopsy had highest
variable importance in the ensembled model (0.82, 0.52 and 0.43, respectively).
These results were conﬁrmed by univariate analysis: the statistically signiﬁcant
difference in ongoing PR was detected between the groups of patients with and
without a history of previous biochemical pregnancies (72.36% (479/662) and
43.88% (136/310), respectively, χ2 = 73.72, OR = 3.349, CI 2.527-4.438).
Similarly, signiﬁcant difference in ongoing PR was detected between embryos
biopsied on day 5 versus day 6 (69.34% (405/584) and 54.28% (241/444),
respectively, χ2 = 24.53, OR = 1.906, CI 1.475-2.463) and between PGS
cycles where good versus fair embryos were transferred (67.95% (422/621)
and 57.62% (208/361), respectively, χ2 = 10.61, OR = 1.560 CI 1.193-2.040).
Limitations, reasons for caution: Retrospective study and heterogeneity of
patients included.
Wider implications of the ﬁndings: Analysis of the data proved that history
of previous biochemical pregnancies, embryo morphology and timing of blasto-
cyst biopsy have the biggest impact on clinical pregnancy rates in IVF PGS cycles
with SET. Ensemble methods of statistical learning offer superior performance
over their singleton counterparts and essentially help to transform medical
records into medical knowledge.
Trial registration number:Not applicable.
P-600 Low progression of spermmotility kinetics related
aneuploidy ratios of a fertilized embryo
E. Lee1, T.E. Shin1,2, J. Park1,2, H. Kwon1, B. Jeon1, H. Kang1,
K.Y. Kang1, Y.J. Cho1, D.K. Kim3, Y.S. Kim4, I.S. Kang4, M.K. Koong4,
T.K. Yoon4, J.J. Ko5, J.H. Lee1,2
1CHA Fertility Center Seoul Station, Fertility Laboratory, Seoul, Korea- South
2CHA University, Biomedical Science- College of Life Science, Pocheon, Korea- South
3CHA Fertility Center Seoul Station- CHA University, Uro – Colleage of Medicine,
Seoul, Korea- South
4CHA Fertility Center Seoul Station- CHA University, Ob/Gyn – Colleage of Medicine,
Seoul, Korea- South
5Institute of Reproductive Medicine, Biomedical Science- College of Life Science, Pan-
Gyo, Korea- South
Study question: Does the sperm motion kinetic proﬁle have an effect to
aneuploidy ratios of in-vitro fertilized embryos?
Summary answer: We found that there is a speciﬁc relationship between
aneuploidy ratios of in-vitro fertilized embryos and the Computer Assistant
Sperm Analysis (CASA) proﬁling of sperm.
What is known already: Sperm motion kinetics is related to the sperm cen-
trioles complex, which is involved in sperm directional movement. This is
because a sperm’s centriole complex is related to the microﬁlament of sperm
motility. But the sperm motion kinetics proﬁle has not reported that there is a
co-relationship with aneuploidy ratios of embryos.
Study design, size, duration: We performed a retrospective study about
the relationship between the sperm motion kinetics analysis data and the pre-
implantation genetics screening data. We tried to set up a prediction model for
aneuploidy ratios of fertilized embryos. Total number of analysis sampleanalysis’
sample number is 1504 and the sample was collected from March 2017 to
December 2017.
Participants/materials, setting, methods:We performed the sperm pro-
ﬁle analysis using the CASA system before conducting in-vitro fertilization with
the ICSI. Then we analyzed sperm kinetics proﬁles and the PGS outcome (nor-
mal and abnormal ratios). We calculated sperm speed (VSL, VCL and VAP) and
its progression (LIN = VSL/VCL, STR=VSL/VAP, WOB=VAP/VCL, ALH and
BCF). Then, normal and abnormal PGS ratios were compared to each of the
sperm’s speed and progression ratios.
Main results and the role of chance: Straight of sperm kinetics proﬁling
showed a signiﬁcantly high normal PGS ratio compared to the curved sperm
kinetics proﬁling. This was especially true when a sperm’s head balance in
movement had a stronger relationship with the PGS abnormal outcome ratios.
Therefore, the abnormal embryo of PGS had a different chromosomal desegre-
gation pattern, just like having a high population of large chromosomal aneu-
ploidy ratios, such as 1 to 10 chromosomes. The spindle of the sperm is
localized at the sperm neck region. The moving direction of the sperm is asso-
ciated with the sperm neck connection and the tail microﬁlament is associated
with the rolling movement to move forward. Then after fertilization, sperm
nuclear and spindle changed into a paternal nuclear formation and was distribu-
ted as chromosomal segregation. It is possible that a speciﬁc moving pattern of
a has some effect to chromosomal segregation in the fertilized embryo.
Limitations, reasons for caution: This is a retrospective study and a limited
number of normal IVF-ICSI cycles were used for analysis.
Wider implications of the ﬁndings: Low straightness proﬁle of sperm
kinetics for male patients may be recommended to perform PGS analysis before
embryo transfer, in order to save IVF cycles and time.
Trial registration number: It is no application trial registration.
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P-601 Validation of using the mitochondrial genome for clinical
embryo identiﬁcation
S. Myers1, M. Barry2, M. Jasper1
1RHS Ltd, RHS Ltd, Thebarton, Australia
2Fertility SA, Fertility SA, Adelaide, Australia
Study question: Can analysis of PG-Seq™ low pass next generation sequen-
cing data for PGT-A also provide genetic information for the identiﬁcation of
embryos in a clinical scenario?
Summary answer: RHS’ PG-Seq™ and Embryo ID Single Nucleotide Variant
(SNV) Panel readily generates a unique embryo signature providing a simple
novel identiﬁcation protocol.
What is known already: PG-Seq™ with DOPlify® WGA provides superior
ampliﬁcation of the mitochondrial genome. The mitochondrial genome contains
single nucleotide variants (SNVs) that can be used to differentiate individuals.
Additionally, mitochondrial DNA (mtDNA) is maternally inherited, providing a
novel opportunity for DNA-based conﬁrmation of maternal origin of embryo
biopsies. During Preimplantation Genetic Testing for Aneuploidy (PGT-A) by
Next Generation Sequencing (NGS), biopsies from different patients are often
processed together. The mitochondrial genome is sequenced during PGT-A
and has the potential to be used to differentiate the maternal origin of the ana-
lysed embryos.
Study design, size, duration: A large putative panel of mitochondrial SNVs
was compiled from published literature and by comparative analysis of PG-
Seq™ data in IGV. Any SNVs associated with disease-related markers, that
were monomorphic or that were in regions of low depth of coverage using
DOPlify®, were excluded. Two panels comprising 14 and 33 SNVs were
assessed using multiple patient embryos and a large in silico dataset.
Participants/materials, setting, methods: Embryos from 50 PGT-A
patients and a dataset of 380 publicly available human mtDNA sequences
representing the global population was compiled. PG-Seq™ analyses 48
embryo biopsies in a single NGS run. Combinations of mtDNA sequences
modelling 4 embryos per patient (ie 12 mtDNA genomes), 2 embryos per
patient (ie 24 mtDNA genomes), or 1 embryo per patient (ie 48 patients) were
tested. Ten thousand randomly selected mtDNA genome combinations were
run for each scenario.
Main results and the role of chance: A total of 47 SNVs were assessed.
Using the 380 mtDNA sequences, 177 SNV signatures were observed, with
125 being unique to one individual and 52 being shared by 2 or more indivi-
duals. Using the embryo biopsy data, all 47 SNVs were conserved within a
patient’s cohort. The 14 SNV panel differentiated 20 of 50 patients’ embryos.
The 34 SNV panel differentiated 28 of 50 patients’ embryos. In combination,
the 47 SNVs differentiated 48 patients’ embryos. In the 10,000 simulated cases
using the 380 mtDNA genome database and modelling embryos from 12
patients, on average, the 14 SNV panel differentiated 83.7% of embryos, and
the 47 SNV panel differentiated 86.7% of embryos. In the simulated cases with
embryos from 24 patients, on average, the 14 SNV panel differentiated 71.4%
of embryos, and the 47 SNV panel differentiated 75.2% of embryos. In simu-
lated cases with embryos from 48 patients, on average, the 14 SNV panel differ-
entiated 55.9% of embryos, and the 47 SNV panel differentiated 61% of
embryos. Should embryo signatures match in a clinical setting, the rest of the
mtDNA genome can be used to further differentiate samples.
Limitations, reasons for caution: Maternally-related patients will share
mtDNA genomes. In this case, it will not be possible to distinguish between
embryos from these patients using the Embryo ID panel or the rest of the mito-
chondrial genome. De novo mutations within the SNVs are rare but possible,
which may result in matching errors.
Wider implications of the ﬁndings: RHS’ Embryo ID panel has the poten-
tial to improve PGT-A practice by providing a DNA-based conﬁrmation of
maternal origin and sibling embryo identiﬁcation. This could be used for sample
tracking within an IVF or genetic service provider laboratory. Embryo ID will be
incorporated into a future release of PG-Seq™ software.
Trial registration number: -
P-602 The optimal time and whole genome ampliﬁcationmethod
for spent culturemedia in pre-implantation genetic testing
Z. Shuang1, X. Pingyuan1,2, L. Ping3, L. Guangxiu2,4, L. Ge1,2,4
1Institute of Reproductive & Stem Cell Engineering, Research Department, Changsha-
Hunan, China
2China and National Engineering and Research Center of Human Stem Cell,
Research department, Changsha-Hunan, China
3BGI- BGI-Shenzhen, Research Department, Shenzhen-Guangdong, China
4Reproductive and Genetic Hospital of Citic-Xiangya, Research Department,
Changsha-Hunan, China
Study question: What is optimal time to collect samples and whole genome
ampliﬁcation (WGA) method for spent culture media in pre-implantation gen-
etic testing (PGT)?
Summary answer: The media from Day5-6 has the highest DNA concentra-
tion and the highest speciﬁcity and sensitivity for comprehensive chromosome
screening (CCS) combined with the PicoPLEX ampliﬁcation.
What is known already: Recently, in order to reduce costs associated with
biopsy and minimize the possibility of damage, blastocoels ﬂuid and spent culture
media are being explored for non-invasive PGT (NI-PGT). But the extensive use
of NI-PGT has been hotly debated due to the accuracy of the procedure, particu-
larly regarding the possible of cumulus-corona radiate cells contamination. Also
the degraded cell free DNA in spent culture media is difﬁcult to ampliﬁcation and
may fail to test. For embryonic genetic screening of spent IVF media to become
reliable, several steps must be optimized. These include improving DNA collec-
tion methods, DNA ampliﬁcation, and screening techniques.
Study design, size, duration: This was an experiment study including 9
donated intracytoplasmic sperm injection (ICSI) embryos. Each embryo was
cultured in a separate single 25 μl droplet of sequential media (G1 and G2,
Vitrolife) to the blastocyst stage. About 20 μl spent culture media was collected
at 9 am of Day3/4/5/6 separately and the blastocoel ﬂuid was aspirated before
the biopsy. In general, each embryo had four spent culture medium samples, a
blastocoel ﬂuid and a TE biopsy sample.
Participants/materials, setting, methods: All the spent culture medium
and blastocoels ﬂuid samples were used quantitative-PCR to qualify the amount
of DNA. For the non-invasive PGT, all the samples were subject to three WGA
methods (PicoPLEX, MALBAC, DOP-PCR) separate and sequencing in BGI-
500 with about 15 Mb total reads (36 bp+10 bp barcodes). The TE biopsies
underwent the conventional PGS procedure, and concordance of TE biopsies
and spent culture media results was assessed.
Main results and the role of chance: The average DNA concentration was
0.58, 0.10, 0.3, 0.71, 0.43 pg/μl by q-PCR in Day1-3, 3-4, 4-5, 5-6 and BF sam-
ples. For WGA, we have modiﬁed the methods to eliminate the effects of
degraded DNA, and the mean concentration after ampliﬁcation was 21.16,
21.12, 25.52, 28.41, 23.31 ng/μl (PicoPLEX); 20.65, 10.41, 24.12, 43.23,
20.58 ng/μl (DOP-PCR); 6.63, 6.12, 9.02, 9.51, 10.35 ng/μl (MALBAC) in
Day1-3, 3-4, 4-5, 5-6 and BF samples. For the 45 NI-PGT samples, the ampliﬁ-
cation rate for each methods were 77.78% (35/45) (PicoPLEX), 64.44% (29/
45) (DOP-PCR) and 80% (36/45) (MALBAC) separately. But the results
showed that PicoPLEX had the highest reproducibility than the other two meth-
ods. And the ampliﬁcation rate was much higher in Day4-5 (92.59%) and Day
5-6 (96.29%) than Day 3-4 (74.07%), Day 1-3 (44.44%) and BF (62.96%) sam-
ples. Though Day 4-5 and Day 5-6 have higher ampliﬁcation rate, the concord-
ance rate of genetic screening results compare to TE samples were much
higher in Day 5-6 (76.92%, 20/26) samples than Day 4-5 (52%, 13/25). And it
should be noted that some media sample from Day 1-3 and Day 4-5 were
euploidy female while the corresponding TE samples were male. These results
indicated the cumulus-corona radiate cells contamination.
Limitations, reasons for caution: At the time of writing the sample size is
relatively modest and is need recruiting more populations to the further pro-
spective controlled study. Even though, we have explored the optimal process
for NI-PGT, the sensitivity and speciﬁcity are still to improve in NI-PGT com-
pare to conventional PGS.
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Wider implications of the ﬁndings: This is the ﬁrst study to compare dif-
ferent WGA method and DNA collection methods in different culture stage.
And the results of the study might help to reduce maternal contamination and
improve the accuracy of the NI-PGT in clinical application.
Trial registration number:NA.
P-603 The interval between human chorionic gonadotropin (hCG)
priming and oocyte retrieval effects euploidy rate in PGS cycles
C.C. Huang1, C.I. Lee3, M.S. Lee2, H.H. Chen1, C.H. Chen1,
T.H. Lee3
1Division of Infertility, Lee Women’s Hospital, Taichung, Taiwan
2Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
3Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital,
Taichung, Taiwan
Study question: Does the interval between hCG priming and oocyte pick up
(hCG-OPU interval) affect the euploidy rate in preimplantation genetic screen-
ing (PGS) cycles?
Summary answer: The hCG-OPU interval affects euploidy rate in PGS
cycles.
What is known already: The optimal time interval of hCG-OPU has been
encountered controversy, whether prolonged interval (>36 h) has any inﬂuence
on the euploidy rate of blastocyst. In most IVF programs, the commonly prac-
ticed interval was 32 to 36 h. However, several studies had shown that ideal IVF
performance can be obtained when oocyte retrieval was done more than 36 h
(up to 39 h) after hCG priming to increase more high quality oocyte or cleaving
embryos.
Study design, size, duration: This is a retrospective study. The next-
generation sequencing (NGS) - PGS outcome data from blastocysts biopsied was
conducted to identify differences in euploidy rate. This study included 2090
biopsied embryos from 499 patients undergoing PGS between January 1, 2016
and October 31, 2017.
Participants/materials, setting, methods: All blastocysts were analyzed
by the hCG-OPU interval (34-35, 35-36, 36-37, 37-38 and 38-39 hours),
women age (≤38 and > 38 years) and the infertility groups (oocyte donor,
normal-responders, poor-responders and hyper-responders). Logistic regres-
sion analysis was performed to identify whether the hCG-OPU interval is asso-
ciated with the euploidy rate. Our primary outcome was the effect of the hCG-
OPU interval in euploidy rate by women age and the infertility groups.
Main results and the role of chance: According to logistic regression ana-
lysis, the hCG-OPU interval (OR: 1.102, 95% CI: 1.010-1.202, p = 0.028) and
women age (OR: 0.931, 95% CI: 0.916-0.947, p<0.001) were associated with
the euploidy rate. In the patients with age ≤38 years, the euploidy rate within
the group of hCG-OPU interval 34-35 hours (32.1%, 37/138) was statistically
lower than that in groups of interval 35-36 (42.3%, 113/331; P = 0.046), 36-37
(43.6%, 207/594; P = 0.017) and 38-39 hours (47.2%, 42/122; p = 0.011). In
the older patients (age > 38 years), the euploidy rate in group of interval 34-35
hours (9.8%, 12/44) was signiﬁcantly lower than that in groups of interval 35-36
(24.0%, 36/150; p = 0.048) and 38-39 hours (27.3%, 12/44; p = 0.039). In all
infertility groups, the interval 34-35 hours showed the lowest euploidy rates
(oocyte donor: 37.5%, poor-responders: 18.2%, hyper-responders: 31.3% and
normal-responders: 23.6%). However, the interval of 38-39 hours in all infertil-
ity groups showed higher euploidy rates (oocyte donor: 52.6%, poor-
responder: 41.2%, hyper-responders: 35.8% and normal-responders: 44.2%)
than that in 34-35 interval. Furthermore, in normal-responders, the euploidy
rates of interval 38-39 (44.2%, 42/95) and 37-38 hours (36.7%, 94/256) were
signiﬁcantly higher than that in interval 34-35 hours (23.6%, 21/89; p = 0.003
and 0.024, respectively).
Limitations, reasons for caution: Retrospective study of patients included.
Wider implications of the ﬁndings: Our ﬁndings indicate that hCG-OPU
interval in PGS is associated with euploidy rate regardless with different groups
of women age or infertility groups. Especially 34-35 interval shows a adverse
effect on euploidy rate. This is a importance ﬁnding as embryo biopsy in the
forms of PGS is increasingly applied.
Trial registration number: No formal funding has been received for this
study.
P-604 Is it the best choice for balanced translocation-carrier
couples to get children by PGDmethod?
X. Lu, Y. Feng
Shanghai Jiao Tong University School of Medicine- Ruijin Hospital, Center for
Reproductive Medicine- Department of Obstetrics and Gynecology, Shanghai, China
Study question: If it is the best way that balanced translocation-carrier cou-
ples should get children with preimplantation genetic diagnosis(PGD) method.
Summary answer: IVF-ET with PGD may not the best choice for
translocation-carrier couples to get healthy babies.
What is known already: In order to reduce the high miscarriage rate of
balanced translocation-carrier couples, PGD is the most recommended way.
But some other studies reported that the cumulative live birth rate of natural
pregnancy cycles is as high as 60-80% in couples with structural chromosome
rearrangements, and balanced translocation-carrier couples obtained high
implantation rate per blastocyst and delivery rates in IVF-ET without PGD
cycles.
Study design, size, duration: A retrospective analysis of 441 couples with
balanced translocation-carrier was performed. The patients come to our gen-
etic counseling clinic from Oct. 2002 to Oct. 2012. And we obtained their preg-
nancy outcomes when they made return visits or by phone and e-mail follow-
up way.
Participants/materials, setting, methods: Patients were grouped
according to different preferences as expectant management, intrauterine
insemination, regular in-vitro fertilization and embryo transfer (IVF-ET) with-
out preimplantation genetic diagnosis (PGD), IVF-ET with PGD, or gametes
donation. Pregnancy loss rate, pregnancy success rate deﬁned as delivery of
at least one healthy child or an ongoing pregnancy in the third trimester,
cumulative pregnancy rate, and average cost of per pregnancy success were
calculated.
Main results and the role of chance: The couples for expectant manage-
ment, IVF-ET without PGD, IVF-ET with PGD may gain a successful preg-
nancy out of every 1.64, 3.22, and 4.66 times per treated cycle (p<0.01).
The pregnancy loss rate of couples for expectant management, IVF-ET with-
out PGD, IVF-ET with PGD were 39.13%, 25% and 25%, while the cumula-
tive pregnancy rate of couples were 67.74%, 39.13%, and 23.07% (p<0.01),
and the average cost of per pregnancy success were about ¥3286,
¥116,000, and ¥238,000.
Limitations, reasons for caution: This study relied on retrospectively inves-
tigate and survey, which may have led to some degree of recall bias.
Wider implications of the ﬁndings: If the doctors tell the balanced
translocation-carrier couples the detail information of these different ways to
get pregnant, it may help them choose a suitable method to get healthy babies.
Trial registration number:No.
P-605 Filling the gap of short-read next generation sequencing in
PGD by long-read approach
D.N.Y. Ho1, C.H. Au1, J. Lau1, E.Y.L.Wong1, K.A. Rocha2, L. Xue2,
T.W. Shum2, Y.C. Law2, Y.Y. Ng2, I.H. Lok2, O.S. Tang2,
S.T.S. Lam3, T.L. Chan1, E.S.K. Ma1
1Hong Kong Sanatorium & Hospital, Division of Molecular Pathology- Department of
Pathology, Hong Kong, Hong Kong
2Hong Kong Sanatorium & Hospital, IVF Centre, Hong Kong, Hong Kong
3Hong Kong Sanatorium & Hospital, Clinical Genetic Service, Hong Kong, Hong
Kong
Study question: Structural chromosomal abnormality is a common pheno-
type in PGD cases. A cost effective strategy to distinguish the disease chromo-
some from the wild-type is challenging.
Summary answer: The uprise of long-read next generation sequencing
(NGS) provides a direct and cost effective approach to identify the precise
breakpoint for non-carrier embryo selection.
What is known already: In the past, haplotype reconstruction could be the
way to access the carrier status of individual embryo in PGD cases with struc-
tural chromosomal abnormality, including balanced translocation, inversion,
deletion and/or duplication. However, a signiﬁcant drawback is the
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unpredictable recombination events. Currently, the advances in long-read NGS
create the opportunity to identify the exact breakpoint at a relatively lower
cost, but it has never been used in the preparation of PGD.
Study design, size, duration: Two PGD cases were studied so far using
long-read NGS. The ﬁrst patient was an ectrodactyly male with a 610 kb
pathogenic duplication identiﬁed by aCGH. The second patient diagnosed
with karyotype 46,XX,t(2;13)(q33.3;q12.1) and already went through the
PGD cycle. After breakpoint identiﬁcation, speciﬁc PCR primers were used
to target the mutations. The breakpoint was validated by Sanger sequencing.
The whole-genome-ampliﬁed biopsy samples were subjected to the break-
point analysis. Haplotype reconstruction was performed by microsatellite
markers.
Participants/materials, setting, methods: We performed PCR-free
whole genome sequencing on peripheral blood DNA using MinION sequencing
(Oxford Nanopore Technologies). The data was obtained within a 48-hour
sequencing run and aligned. The speciﬁc genomic breakpoints have been
revealed and PCR primer pairs were designed for breakpoint ampliﬁcation and
Sanger Sequencing. Day5/6 trophectoderm biopsies were subjected to whole
genome ampliﬁcation (SurePlex DNA Ampliﬁcation System, Illumina) and the
products were used for PGD analysis.
Main results and the role of chance: In the ectrodactyly case, we identi-
ﬁed the genomic breakpoint by nanopore whole-genome sequencing and
the duplication was found to be exactly 683.9 kb. The breakpoint was con-
ﬁrmed by PCR and Sanger sequencing. In family study, the breakpoint was
completely linked to the ectrodactyly phenotype and concordant with haplo-
types of 5 microsatellite markers ﬂanking the duplication. Trophectoderm
biopsies were collected for in vitro fertilization PGD and the patient speciﬁc
breakpoint PCR assay was performed on the WGA products. Three out of
seven embryos were identiﬁed to inherit the duplication, hence carrier of
the disease chromosome. The carrier status of all embryos was further con-
ﬁrmed by haplotyping. A similar strategy was used to detect the breakpoint
of the t(2;13) translocation in the trophectoderm biopsy samples. The long-
read sequencing came across the aberration site on derivative chromosome
13 and gap PCR were used to deﬁne the embryos with or without balanced
translocation. Overall, the result of breakpoint PCR analysis and the haplo-
type reconstruction were concordant.
Limitations, reasons for caution: The limitation of nanopore whole-
genome sequencing is the fact that it is PCR-free and may require micrograms
of DNA. Multiple MinION runs may be required to identify the target disease
sites.
Wider implications of the ﬁndings: Long read next generation sequencing
is an emerging technology for whole-genome structural variant detection with
single base pair resolution. We demonstrated its potential to accurately deter-
mine the genomic breakpoint in the ectrodactyly and t(2;13) patients and may
represents a novel strategy for PGD of unknown structural aberration.
Trial registration number: not applicable.
P-606 Excluded cells during blastocyst formation: is aneuploidy the
reason?
M. Parriego, L. Coll, M. Devesa, M. Boada, B. Coroleu, A. Veiga
Dexeus University Hospital, Department of Gynaecology- Obstetrics and
Reproduction, Barcelona, Spain
Study question: Is the exclusion of cells at compaction during blastocyst
formation due to aneuploidy?
Summary answer: No higher aneuploidy rate is observed in excluded cells
when compared to the corresponding trophectoderm biopsies. The ploidy sta-
tus among them is highly concordant.
What is known already: Time-lapse technology has allowed the detection of
developmental anomalies that could not be properly assessed with single obser-
vations. The exclusion of cells from compaction during the blastocyst formation
is occasionally observed.
The incidence of chromosomal abnormalities decreases through embryo
development. While some aneuploidies are compatible with the blastocyst
stage and onwards, developmental arrest during culture is the main mechanism
against severe chromosomal abnormalities. Embryo self-correction of
chromosomal abnormalities has also been proposed. Aneuploidy rescue
through the exclusion of the abnormal cells from the developing embryo could
be one of the potential mechanisms for self-correction.
Study design, size, duration: Retrospective observational study performed
from July 2016 to November 2017. Chromosome content of 17 pairs of troph-
ectoderm biopsies and excluded cells from blastocysts of PGT-A patients were
analysed.
Participants/materials, setting, methods: Cells excluded from compac-
tion during blastocyst formation and the corresponding biopsied trophecto-
derm cells from 15 PGT-A patients were analysed to determine their
chromosomal constitution. Only fully hatched blastocysts with left over cells in
the zona pellucida were considered. Excluded cells as well as trophectoderm
biopsies from hatched blastocysts were separately processed by a-CGH or
NGS.
Results regarding ploidy concordance were evaluated. The speciﬁc chromo-
somal constitution of the sample pairs was analysed.
Main results and the role of chance: Seventeen pairs of trophectoderm
biopsies and excluded cells were analysed. In 3 cases there was no DNA ampli-
ﬁcation of the excluded cells.
Ploidy concordance was observed in 13 of the 14 pairs that could be ana-
lysed. Discordant results were found in one blastocyst diagnosed as a mosaic
that showed euploidy in the corresponding excluded cells.
Five of 14 trophectoderm samples were diagnosed as euploid. All their com-
plementary excluded cells showed the same euploid chromosomal constitution.
In 8 of 9 cases diagnosed as aneuploid after trophectoderm biopsy, the
excluded cells were also aneuploid. Full concordance of the chromosomal con-
stitution was observed in 4 of them while certain differences were detected in
the remaining 5. There seems to be a tendency for more severe chromosomal
abnormalities in the excluded cells.
A high ploidy concordance is observed among trophectoderm cells and cells
excluded from compaction in biopsied PGT-A blastocysts.
Limitations, reasons for caution: Retrospective observational study with
limited sample size.
Wider implications of the ﬁndings: According to our results, exclusion of
certain cells during blastocyst development does not seem to be related to
aneuploidy rescue.
Trial registration number:Not applicable.
P-607 Polymorphic variants of chromosomes decrease cleaved
embryos rate in vitro fertilization and embryo transfer treatment
L. Saijiao, Z. Danni, Z. Ying, Y. Jing, L. Ao
Renmin Hospital of Wuhan University, Department of Reproductive Medicine Center,
Wuhan, China
Study question: This retrospective study comprehensively analyzed the cor-
relation between chromosome polymorphisms and the outcome of IVF–
embryo transfer treatment for infertile couples.
Summary answer: Polymorphic variants of chromosomes affect the embryo
cleaved rate of in vitro fertilization and embryo transfer treatment.
What is known already: Studies indicate that chromosome polymorphisms
may cause certain clinical effects, such as infertility and spontaneous miscarriage.
Little report has studied whether chromosomal variation, other than Y chromo-
some variation, affects the outcome of IVF–embryo transfer treatment.
Study design, size, duration: During the period from October 2014 to
November 2017, 1415 infertile couples who had received their ﬁrst IVF–
embryo transfer treatment cycle in our hospital were selected for this retro-
spective study, and the frequency of chromosomal polymorphic variations was
calculated.
Participants/materials, setting, methods: 1415 infertile couples were
divided into four groups: 1182 couples with normal chromosomes (Group 1).
129 couples with 1qh+/-, 9qh+/- or 16qh+/- (Group 2) ;56 couples with ps+,
pss or pstk+ of the acrocentric chromosomes (Group 3); And 48 couples with
pericentric inversion of chromosomes 9 (Group 4).The fertilized rate, embryo
cleaved rate, good quality embryos rate, clinical pregnancy rate(CPR), implant-
ation rate and early stage miscarriage rate after IVF-embryo transfer treatment
were compared.
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Main results and the role of chance: There were no statistically signiﬁcant
differences among the four groups in patient’s fertilization rate, good quality
embryos rate, clinical pregnancy rate(CPR) and implantation rate. But the
chromosomal polymorphism groups (Group 2, Group 3 and Group 4) had low-
er cleaved embryos rate comparing with control group (Group 1) (95.83,
95.05, 89.90 and 97.5% respectively, P<0.05). The ﬁrst trimester pregnancy
loss rates in Group 4 patients were higher than in control group (25% versus
4.4%, P<0.05), but not in Group 2 and Group 3.
Limitations, reasons for caution: The limitations are the number of hetero-
morphism carriers was insufﬁcient. Furthermore, the chromosome analysis
method in the present study had a 400-550 BPHS banding resolution; some
potential variations could not be distinguished from common polymorphism
variations. Therefore, a greater number of samples and more sensitive techni-
ques are needed.
Wider implications of the ﬁndings: Chromosomal polymorphism carrier
could decrease cleaved embryos rate. chromosome 9 pericentric inversion may
increase ﬁrst trimester pregnancy loss and impact IVF outcomes. We should
afford individual genetic counseling suggestion according to the polymorphism
types.
Trial registration number: not applicable.
P-608 Level of embryonic mosaicism do not seem to be inﬂuenced
by extrinsic features: analysis of 298 mosaic embryos
M.G. Minasi1, F. Fiorentino2, A. Ruberti1, A. Biricik2, E. Cursio1,
S. Bono2, A. Colasante1, E. Cotroneo2, V. Casciani1, F. Scarselli1,
R. Polese1, M.T. Varricchio1, M. Baldi2, F. Spinella2, E. Greco1
1European Hospital, Center for Reproductive Medicine, Rome, Italy
2GENOMA Group, Molecular Genetics Laboratories, Rome, Italy
Study question: Is the percentage of embryo mosaicism related to culture
and/or patient characteristics?
Summary answer: The rate of mosaic cells detected in an embryo does not
seem to be correlated to different culture conditions nor to patient’s origin.
What is known already: Embryonic mosaicism is deﬁned as the contempor-
ary presence of two or more genetically different cell lines in the same embryo.
It is a common phenomenon in human embryos due to mitotic errors after fer-
tilization and could have an impact on embryo developmental and implantation
potentials. It has been reported that mosaic embryos hold the potential to
implant, leading to the birth of healthy babies. Anyway, the extent of mosaicism
can inﬂuence the success rate. Lower aneuploidy percentage has been demon-
strated to maintain higher chances of resulting in the birth of healthy babies
compared to embryos with higher mosaicism levels.
Study design, size, duration: In this preliminary study, only cycles where at
least one mosaic embryo was found, were enrolled. In 195 IVF cycles per-
formed in 185 patients, 298 mosaic embryos were obtained. Mean female and
male ages were 35.39 ± 4.22 and 38.83 ± 5.79 years old, respectively. All biop-
sies were performed at blastocyst stage and diagnosed with either array-CGH
or NGS-based PGS. Single embryo cultures were performed in standard or
time-lapse incubators at 37°C, 6%CO2, 5%O2 in sequential or 1-step media.
Participants/materials, setting, methods: Embryos were divided in two
groups on the basis of their mosaicism percentage: ≤40% (N = 160) and >40%
(N = 138). Differences among culture systems (culture media and incubators),
embryo quality (morphological grade at embryo and blastocyst stages, day of
biopsy and morphokinetic development) and patient’s characteristics (female
body mass index [fBMI], FSH dose, female and male ages, antral follicle count
[AFC] and seminal parameters) were analyzed in the two groups.
Main results and the role of chance: One-step and sequential media were
employed for 20.0% and 80.0% and for 16.7% and 83.3% of the embryos in
≤40% and >40% groups, respectively. Time-lapse and standard incubators
were used for culturing 58.8% and 41.2% and 63.0% and 37.0% of the embryos
in ≤40% and >40% groups, respectively. The rates of day-3 excellent, good and
poor morphology grades were 72.3%, 22.7% and 5.0% in ≤40% group and
73.9%, 20.1% and 6.0% in >40% group, respectively. The rates of excellent,
good and poor blastocyst grades were 31.9%, 28.1% and 40.0% in ≤40% group
and 32.6%, 32.6% and 34.8% in >40% group, respectively. Biopsies were per-
formed on day-5, day-6 or day-7 in 57.5%, 38.7%, 3.8% and in 61.6%, 34.8%,
3.6% of the blastocysts in ≤40% and >40% groups, respectively.
Normospermic, oligoastenoteratospermic and testicular men were 26.9% and
27.4%, 39.8% and 38.5%, 33.3% and 34.1% in ≤40% and >40% groups, respect-
ively. None of these values reached a statistical signiﬁcance. The morphokinetic
development did not show statistical differences at any time-points, neither at
embryo nor at blastocyst level. No differences were found between the two
groups according to the distribution of the fBMI, the dose of FSH, the AFC and
the female/male ages.
Limitations, reasons for caution: The number of mosaic embryos enrolled
in the study need to be enlarged. It should be reasonable to test also other dif-
ferent mosaicism level cut-offs. A comparison with both euploid and aneuploid
blastocysts obtained in the same cycles could better clarify the role of embry-
onic mosaicism.
Wider implications of the ﬁndings: To date, a lot of different culture sys-
tems are available and the decision about which of them should be preferred is
extremely subjective. Our study suggests that the level of embryonic mosaicism
is not ascribable to culture conditions or to patient’s origin.
Trial registration number:Not applicable.
P-609 Cryptic complexity identiﬁed by whole-genomemate-pair
sequencing in complex chromosomal rearrangements: implications
on preimplantation genetic diagnosis and reproductive genetic
counseling
C. Aristidou1, E. Constantinou1, A. Alexandrou1, A. Theodosiou1,
M. Mehrjouy2, M. Bak2, N. Tommerup2, C. Sismani1
1The Cyprus Institute of Neurology and Genetics, Department of Cytogenetics and
Genomics, Nicosia, Cyprus
2University of Copenhagen, Wilhelm Johannsen Centre for Functional Genome
Research- Department of Cellular and Molecular Medicine, Copenhagen, Denmark
Study question: Two Complex Chromosomal Rearrangement (CCR) cases
were characterized in detail in order to provide more precise abnormal preg-
nancy risk estimations and better genetic counseling.
Summary answer: Cryptic rearrangement complexity increases abnormal
pregnancy risk in couples with CCRs and reproductive problems.
What is known already: CCR carriers are at high risk for chromosomally
unbalanced pregnancies, which may lead to recurrent miscarriages or affected
offspring. The nature of each rearrangement, including the number of chromo-
somes and breakpoints involved, have signiﬁcant implications on the percentage
of unbalanced gametes following meiotic segregation of CCRs. As a result,
reproductive risk in CCR carriers may remain underestimated with the use of
conventional, low-resolution methods. Detailed characterization of CCRs is
therefore crucial to unravel potential higher rearrangement complexity, and
subsequently, aid in better prenatal preimplantation genetic diagnosis (PGD)
and reproductive genetic counseling in couples with reproductive problems.
Study design, size, duration:Non applicable.
Participants/materials, setting, methods: In the present study, whole-
genome mate-pair sequencing (WG-MPS) was used to further characterize and
delineate the breakpoints of a rare, paternally-transmitted t(6;7;10) CCR in a
phenotypically normal father and daughter, and a de novo t(6;7;8;12) CCR in a
female patient with mild intellectual disability. Results were validated with
Sanger sequencing and Fluorescence In Situ Hybridization (FISH).
Main results and the role of chance: WG-MPS allowed accurate recon-
struction of all derivative (der) chromosomes involved, and interestingly, cryptic
complexity was revealed in both cases.
In the rare, paternally-transmitted CCR, WG-MPS detected an additional
cryptic translocation breakpoint on der(6). FISH using a chromosome (chr) 6
custom-designed probe and a chr10 control probe conﬁrmed that the intersti-
tial chr6 segment, created by the two chr6 breakpoints, was translocated onto
der(10). Previous sperm-FISH investigations in the father analyzing the possible
segregation patterns revealed that only two combinations out of sixty-four
(3.1%) are balanced. Identiﬁcation of a cryptic breakpoint in this study and
accurate delineation of the full CCR complexity, suggest that the number of
possible segregation patterns is even higher, and concurrently, the percentage
of balanced gametes becomes even lower.
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In the de novo t(6;7;8;12) CCR, WG-MPS revealed a chromothripsis
rearrangement involving thirty-eight translocation breakpoints and two hetero-
zygous deletions. Haploinsufﬁciency of the SOX5 gene, disrupted by two break-
points and a heterozygous chr12 deletion, most probably underlies intellectual
disability in the patient. Since it has been generally estimated that there is an
additional ~3.5% risk per breakpoint for unbalanced gamete production, it is
expected that this massively complex rearrangement will have a signiﬁcant
impact on the patient’s reproduction risk.
Limitations, reasons for caution: Even though WG-MPS can successfully
delineate the full complexity of CCRs, an applicable strategy for PGD still
remains very challenging.
Wider implications of the ﬁndings: In concordance with available litera-
ture, this study highlights the importance of investigating CCRs using a combin-
ation of conventional and next generation sequencing-based methods in order
to delineate their full complexity, and thus provide better abnormal pregnancy
risk estimations and reproductive genetic counseling in CCR couples.
Trial registration number:Non applicable.
P-610 Introducing direct CGG repeat analysis in preimplantation
genetic diagnosis (PGD) for fragile X syndrome: an overview of
clinical outcomes for 116 patients
R. Cabey1, D. Nusblat1, J. Gay1, E. Armenti1, B. Chu2, N. Goodall2,
R. Prates2, M. Konstantinidis2
1CooperGenomics, genetic counseling, Livingston- New Jersey, U.S.A.
2CooperGenomics, laboratory, Livingston- New Jersey, U.S.A.
Study question: Does incorporating analysis of CGG repeat number in PGD
embryos have a signiﬁcant effect on the clinical outcomes for fragile X premuta-
tion carriers?
Summary answer: Performing CGG repeat analysis for embryos provides
patients with an additional layer of information that can assist with the embryo
transfer decision making process.
What is known already: Fragile X mental retardation gene (FMR1) CGG
repeat testing has been the routine method of analysis on living individuals and
prenatal samples. Historically, PGD for fragile X syndrome has been performed
via linkage analysis alone. While differentiating between the normal allele and
the expanded allele has been extremely beneﬁcial for patients, it lacks the ability
to further distinguish between intermediate, premutation and full mutation
embryos. As a result, patients and physicians have been making decisions con-
cerning embryos without potentially impactful clinical information.
Study design, size, duration: Outcome data was obtained on 116 patients,
who underwent PGD for fragile X syndrome via a linkage-based technology
(Karyomapping; Illumina, USA), and direct CGG repeat analysis, between 01/
2014 and 12/2017. Trophectoderm biopsy samples from 852 embryos were
received from 194 IVF cycles.
Participants/materials, setting, methods: This cohort of patients carried
either an intermediate, premutation, or full mutation FMR1 allele and the aver-
age maternal age was 34.03 ± 0.32 (standard error of the mean). As 33 patients
banked embryos from multiple IVF cycles, a total of 160 PGD tests were per-
formed; 148 of these included aneuploidy screening via aCGH or NGS
(Illumina, USA). Following exclusion of embryos with no diagnosis, sex aneu-
ploidy, or that were untested, results were obtained in 771 embryos.
Main results and the role of chance: CGG repeat results were obtained in
756/771 samples (98.05%). Overall, the maternal normal allele was inherited in
48.59% of embryos. Of the embryos that inherited the expanded allele, 70.97%
remained in the premutation or intermediate range. The following rates of
expansion from premutation to full mutation in embryos were observed: 0%
(0/74) in the maternal premutation group of 55-59 CGG repeats, 7.78% (7/
90) in the 60-69 group, 9.52% (4/42) in the 70-79 group, 30.30% (10/33) in
the 80-89 group, 91.67% (22/24) in the 90-99 group, and 100% (47/47) in the
100-199 group. Notably, 3.02% (12/397) of embryos contracted from the
maternal expanded allele size (ranging from 57 to >200). The number of
embryos per PGD test increased to (6.73 ± 0.71) when patients banked
embryos, compared to those who did not (4.91 ± 0.29). There was a signiﬁcant
increase in the average number of embryos available for transfer from 1.33 ±
0.11 (euploid and normal FMR1 alleles) to 2.07 ± 0.17 when including
premutation embryos (P<0.001). Follow up from patients revealed that 70 nor-
mal allele embryos, 8 premutation, and 2 normal or premutation embryos were
transferred; resulting in 38 live births and 6 ongoing pregnancies. Subsequent
conﬁrmatory testing was pursued by 5 patients revealing concordant results
with PGD.
Limitations, reasons for caution: A little over 100 patients were evaluated
in this study, but clinical outcomes were not obtained on all. In addition, a large
portion of patients did not pursue prenatal or postnatal conﬁrmatory testing via
outside laboratories. Continued follow up will aid in providing additional
analysis.
Wider implications of the ﬁndings: This data set presents useful ground-
work for understanding the clinical implications of CGG repeat testing in PGD
embryos. The differentiation between premutation and full mutation PGD
embryos provides more complete diagnostic information; therefore highlighting
the need for counseling regarding options for embryo transfer.
Trial registration number: not applicable.
P-611 External veriﬁcation of the Agilent Technologies OnePGT
solution for PGT-M on blastomere and trophectoderm biopsies
fromUZ Leuven
C. Melotte1, E. Dimitriadou1, M. Zamani Esteki2, H. Masset3,
K.O. François4, J. Allemeersch4, R. Richards4, S. Moeys4, J. Theuns4,
J.R. Vermeesch1
1Leuven University Hospital, Center for Human Genetics, Leuven, Belgium
2Center for Human Genetics- KU Leuven, Laboratory of Reproductive Genomics,
Leuven, Belgium
3Center for Human Genetics- KU Leuven, Laboratory for Cytogenetics and Genome
Research, Leuven, Belgium
4Agilent Technologies, Agilent Technologies, Leuven, Belgium
Study question: To assess the level of concordance between OnePGT
(Agilent Technologies) and Gold Standard reference data of embryo biopsies
for preimplantation genetic testing for monogenic disorders (PGT-M).
Summary answer: A conclusive result was obtained for 113/118 (95.8%)
embryos analyzed for PGT-M, with a concordance of 100% between the results
of OnePGT and the Gold Standard.
What is known already: OnePGT is an innovative next-generation sequen-
cing (NGS)-based solution for all-in-one Preimplantation Genetic Testing (PGT)
of in vitro fertilized (IVF) embryo biopsies. OnePGT can be used to genetically
proﬁle IVF embryos by testing a single- or few-cell biopsy to 1) identify those
free of a speciﬁed Mendelian disorder or translocation and/or 2) prioritize
chromosomally normal i.e. euploid embryos for transfer in a single workﬂow.
This enriched level of information can hence improve success rate of implant-
ation and live birth.
Study design, size, duration: A total of 118 whole genome ampliﬁed-
embryo biopsies previously analyzed with SNParray and the siCHILD algorithm
were submitted for analysis with the OnePGT solution. These samples,
together with gDNA from the parents and reference family member(s), origi-
nated from 16 families encompassing 15 unique single gene disorders. Both
affected and unaffected embryos were included. Data analysis and interpret-
ation was kept blinded and concordance with SNParray/siCHILD results was
conducted only after the OnePGT results were recorded.
Participants/materials, setting, methods: Twelve families segregated a
dominant, 1 family an X-linked and 3 families an autosomal recessive disorder.
In 5 families, the phasing reference was a child of the IVF-parents while for the
other families the parents of the carrier IVF-parent were available as phasing
references. DNA-samples were library prepped with OnePGT reagents and
sequenced on a NextSeq 500 instrument (Illumina). The NGS data was ana-
lyzed with the proprietary OnePGT software tool, in particular the PGT-M
pipeline.
Main results and the role of chance: The library preparation was success-
fully performed on a total of 189 samples (including embryo’s and respective
family members). A conclusive call was achieved for 113 embryonic samples
from a total of 118 (95.8%), with 5 embryos receiving an inconclusive call
(4.2%). The root cause of these inconclusive calls included cross-over or break-
points in close proximity of the disease locus (4/5), and nullisomy of the
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chromosome of interest (1/5). For two of the inconclusive cases, the Gold
Standard result was also inconclusive indicating a biological reason for failure. In
addition, one embryonic sample inconclusive in the Gold Standard protocol
received a conclusive result in OnePGT. For concordance analysis, both the
inconclusive results from OnePGT and Gold Standard were excluded. A 100%
concordance was obtained for the 112 embryo samples analyzed with OnePGT
when compared with the Gold Standard result, of which 50 unaffected embryos
were correctly called as unaffected and 62 affected embryos were correctly
called as affected.
Limitations, reasons for caution: This study is limited by the population
size which is not sufﬁcient to calculate % speciﬁcity, % sensitivity or positive pre-
dictive value. For Research Use Only. Not for use in diagnostic procedures.
Wider implications of the ﬁndings: The results of this study indicate that
the OnePGT solution is able to accurately determine the disease status of
embryo biopsies, both from blastomere and trophectoderm sample types, for a
wide range of single gene disorders.
Trial registration number: not applicable.
P-612 A proposedmethod to minimize male gamete contribution
to aneuploidy in the embryo cohort
A. Melnick, A. Parrella, S. Cheung, P. Xie, Z. Rosenwaks,
G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Can a new method to select spermatozoa enhance the gen-
omic competence of the male gamete and yield euploid embryos in couples
with all abnormal conceptuses?
Summary answer: Microﬂuidic selection yields spermatozoa with high pro-
gressive motility and genomic integrity, enabling the generation of chromoso-
mally normal embryos despite history of recurrent, total aneuploid
conceptuses.
What is known already: The presence of a male factor can negatively impact
embryo cleavage and chromosomal status. In addition, dysfunction of the male
genital tract increases sperm chromatin fragmentation that, particularly in cases
of double strand breaks, can lead to aneuploidy of the male gamete. Thus, in
couples with a relatively young female partner, the recurrent appearance of
aneuploid embryos may reﬂect the contribution of the male gamete.
Study design, size, duration: In a 16-month period, 4 couples with history
of high Sperm Chromatin Fragmentation (SCF) and embryo aneuploidy after
several ART attempts underwent a successive cycle of ICSI where semen speci-
mens were processed in a microﬂuidics chamber. Fertilization and clinical preg-
nancy rate were assessed and compared between different sperm preparation
methods. SCF was assessed by TUNEL and sperm aneuploidy by FISH analysis.
Chromosomal analysis was carried out by preimplantation genetic testing for
aneuploidy (PGT-A) on conceptuses.
Participants/materials, setting, methods: Consenting men had their eja-
culates screened by standard semen analysis according to WHO 2010 criteria.
Ejaculate specimen were processed by density gradient and MFSS. SCF was
measured by TUNEL utilizing a commercial kit (In Situ Cell Death Detection
Kit, Roche). At least 500 spermatozoa were counted under ﬂuorescent micros-
copy with an adopted threshold of 15%. FISH analysis was carried out on at
least 1000 spermatozoa by 9 chromosome probes.
Main results and the role of chance: In a total of 18 cycles, the average age
for the men was 44.5 ± 15 years. The average semen parameters were: con-
centration of 14.9 ± 23.5×106/mL, motility of 26.3 ± 17%, 2.0 ± 0% normal
morphology. The SCF was 34 ± 12% and the sperm aneuploidy rate was 4 ±
2%. In 13 cycles, after selection by density gradient, the total motility rose to
48.7 ± 9%. The mean of oocytes injected was 7.1 ± 4 with a fertilization rate of
68.7%. The euploidy rate was 3 embryos out of 30 (10%). These euploid
embryos were transferred in two patients and two clinical pregnancies were
established, both resulting in miscarriages. In 5 cycles, where the sperm was
processed by MFSS, the total motility increased to 98.3%±2 (P<0.0001). The
sperm morphology became 4% and the SCF reduced to 1.8 ± 1 (P<0.001). The
average number of injected oocytes was 5.7 ± 3 with a subsequent fertilization
of 78.1%. Following MFSS processing, there were 7 euploid blastocysts out of
14 (50%) that, after transfer, yielded a pregnancy in all four patients (100%)
(P<0.001).
Limitations, reasons for caution: This is a pilot study on a small number of
subjects. However, this microﬂuidic method is capable of selecting spermatozoa
with better morphology, higher chromatin integrity, and presumably lower
sperm aneuploidy, which may likely yield euploid embryos in couples with sub-
tle male factor infertility.
Wider implications of the ﬁndings: According to this study, the selection
of a genomically competent male gamete may enhance the euploidy of the con-
ceptus. Couples with a relatively young female partner and recurrent aneuploid
embryos may beneﬁt from MFSS selection to improve reproductive outcome
due to an occult male factor.
Trial registration number:N/A.
P-613 Genomic proﬁling of spermatogenetic function in
azoospermic men
B. Chin, S. Cheung, C. O’Neill, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Can sequencing of the genome shed light on the genes
involved in the spermatogenic function of the seminiferous tubules of azoosper-
mic men?
Summary answer: Men with secretory azoospermia have a mutated set of
genes with compromised function responsible for the impaired meiotic
process.
What is known already: Azoospermia represents about 1% of all men in the
fertile age and about 15% of the infertile men. Azoospermia is seldomly due to
pre-testicular factors, but the most common forms are testicular and post-
testicular. While the post-testicular type is due to obstruction, whether con-
genital or acquired, the most puzzling type remains the secretory azoospermia
where scattered dysfunctional seminiferous tubules strive to proceed through
the germline meiotic process toward the generation of spermatozoa.
Study design, size, duration: Over a period of 2 years, NGS assessment
was carried out on surgically retrieved spermatozoa from 9 azoospermic men,
who were categorized as obstructive (OA) or non-obstructive (NOA) based
on their spermatogenetic proﬁle. Speciﬁc gene mutations and ICSI pregnancy
outcomes were assessed and compared between the two groups.
Participants/materials, setting, methods: Consenting men being treated
at our center for infertility provided their specimens. DNA extraction was car-
ried out from at least 500 spermatozoa followed by PCR-based random hexam-
er ampliﬁcation (average DNA concentration 395 ± 217 ng/ul and quality of
1.7 ± 0.1 nm). Following DNA sequencing of the specimens by NGS, gene
mutations, including duplications and deletions, were detected by CASAVA and
VarScan2 software programs.
Main results and the role of chance:Our analysis included a total of 9 con-
senting men with an average age of 45.2 ± 8 yrs. Six OA patients were treated
by epididymal aspiration or testicular biopsy with an average concentration of
2.0 ± 3×106/ml and a motility of 0.5 ± 1%. In all OA cases, the reason for the
obstruction was a prior vasectomy. Also these men underwent 6 cycles with a
pregnancy and delivery rate of 50%. Three NOA men underwent testicular
biopsies that yielded spermatozoa in all cases. They were treated by ICSI in 3
cycles with a pregnancy and delivery of 66.7%. NGS reported no difference in
aneuploidy of spermatozoa from the OA and NOA groups. The sequencing of
DNA was carried out on 70,000 genes of which only 2 were mutated in the
obstructive patients, while non-obstructive azoospermic men had 123 genes
mutated (P<0.0001). Among the genes mutated, the most represented were
related to mRNA transcription (n = 26) followed by genes involved in sperm-
atogenesis (n = 15), DNA repair (n = 14), centrosomal function (n = 13), and
apoptosis (n = 12).
Gene expression analysis by RNA sequencing reported 12 genes, of which 9
were signiﬁcantly underexpressed (P<0.001). Their functions included calcium
mobilization (CXCL16), acrosomal integrity (ACR), and overall regulatory
genes of spermatogenesis (ZMYND15).
Limitations, reasons for caution: This is still a limited number of observa-
tions carried out on men being screened for infertility. Moreover, testicular
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specimens were donated by patients with specimens that yielded spermatozoa
and it should be extended to include men with spermatogenic arrest and germ
cell aplasia.
Wider implications of the ﬁndings: NGS screening of infertile men will
help characterize the spermatogenic function of the seminiferous tubule. This
will help designate patients who beneﬁt from testicular sampling versus those
who would not. Moreover, querying the genome and the epigenome will help
shed light on the etiology of this severe form of infertility.
Trial registration number:N/A.
P-614 Reassessing the prevalence of aneuploidy in sperm retrieved
from different levels of the male genetic tract
S. Cheung, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question:We questioned the notion that sampling epididymal and tes-
ticular tissues yields spermatozoa with higher incidence of aneuploidy than
those found in the ejaculate.
Summary answer:With the adoption of advanced molecular genetic techni-
ques, we conﬁrmed that surgically retrieved spermatozoa have at least compar-
able incidence of aneuploidy compared to ejaculated spermatozoa.
What is known already: Previous studies, including our own, evidenced, in a
few men and by only 4 chromosome probes on about 100 cells, that these tes-
ticular spermatozoa have a remarkably higher (13%) occurrence of aneuploidy.
This notion, however, did not translate into a higher incidence of miscarriages
nor a lower rate of pregnancy. Moreover, ICSI offspring generated from surgi-
cally retrieved gametes did not suffer from an increased aneuploidy than those
generated from ejaculated specimen. In light of the availability of more accurate
molecular genetic techniques, we have decided to challenge this dogma.
Study design, size, duration: Nine chromosome FISH was carried out on 2
donor controls, the ejaculates of 67 men, and surgical specimens of 9 azoosper-
mic men. DNA sequencing technology was carried out on the ejaculates and
surgical samples of 20 men. A combined assessment was performed on non-
azoospermic (non-NOA) men with high DNA fragmentation in their ejaculate.
ICSI pregnancy outcome was also recorded and compared. Additionally, an
analysis was carried out to compare obstructive (OA) and non-obstructive
(NOA) men.
Participants/materials, setting, methods: Consenting men treated for
infertility provided their specimens. FISH was performed on at least 1000
spermatozoa with a threshold of >1.6% with 2-3% FISH error. DNA was
extracted and ampliﬁed from a comparable number of spermatozoa by PCR-
based random hexamer ampliﬁcation (average DNA concentration 610 ±
102 ng/ul and quality of 1.7 ± 0.1 nm). By NGS, duplications and deletions by
Copy Number Variants (CNVs) were then calculated for all chromosomes by
CASAVA and VarScan2 software programs.
Main results and the role of chance: A total of 76 couples were included
in our study (maternal age 35.8 ± 4 yrs and paternal age 39.4 ± 8 yrs).
Aneuploidy by FISH yielded 0.9% for the donor control but rose in the study
group to 3.6% in the ejaculated, 1.2% for the epididymal, and 1.1% for testicular
spermatozoa. NGS yielded 1.2% for the control while in the study was 11.1%
for the ejaculated specimen and decreased to 1.8% in the epididymal and 1.9%
for the testicular (P<0.0001). The ICSI pregnancy rate for the ejaculated speci-
men was 47.2% and 55.5% for the surgically retrieved.
Paired aneuploidy assessment in the same individual (non-NOA) on the eja-
culated and testicular samples evidenced a sperm chromatin fragmentation
(SCF) of 20% in the ejaculate while on the testicular spermatozoa was only 8%.
Aneuploidy assessment by FISH evidenced 2.8% in the ejaculated and 1.2% in
testicular biopsy while with NGS became 8.4% and 1.3% in testicular biopsy (P
= 0.02), respectively. The pregnancy rate was 0% with ejaculated while 100%
with the testicular spermatozoa.
An additional aneuploidy assessment by NGS in exclusively azoospermic
men evidenced, in the OA 6.7% while in the NOA 5.1%.
Limitations, reasons for caution: This is still a limited number of observa-
tions carried out on men screened for infertility. If conﬁrmed, this study may
suggest that testicular sampling is safe in terms of retrieving euploid
spermatozoa and may be considered in non-azoospermic men in order to
obtain cells with lower SCF.
Wider implications of the ﬁndings: This study challenges the dogma that
testicular spermatozoa conceal a higher proportion of aneuploidy. This implies
that testicular gametes do not contribute to chromosomally related pregnancy
losses. Moreover, this may explain why offspring from testicular biopsy do not
evidence higher autosomal or gonosomal aneuploidy than those resulting from
ejaculated spermatozoa.
Trial registration number:N/A.
P-615 Differential expression of testicular function can shed light
on why someNOAmen successfully yield spermatozoa
L. Zimmerman, C. O’Neill, A. Parrella, M. Irani, Z. Rosenwaks,
G. Palermo
Weill Cornell Medicine, CRMI, New York, U.S.A.
Study question: Can RNA-sequencing analysis of testicular biopsy samples of
NOA men indicate a spermatogenic defect and identify the best candidates for
surgical retrieval?
Summary answer: By sequencing transcripts of NOA men, we identiﬁed dif-
ferential gene expression proﬁles suggesting maturation arrest in NOA men
who failed to yield spermatozoa after TESE.
What is known already:Men with non-obstructive azoospermia (NOA) can
typically be categorized into three varying degrees of impaired testicular func-
tion: hypospermatogenesis, maturation arrest, or germ cell aplasia (sertoli cell–
only syndrome). Although it can be difﬁcult to analyze these conditions during a
targeted testicular biopsy, a detailed assessment is of great importance, as the
likelihood of retrieving no spermatozoa via testicular aspiration occurs in 50%
of NOA cases. To supplement histology assessment of testicular tissue, RNA-
sequencing can be utilized to differentiate gene expression proﬁles of NOA
men with spermatozoa from men without spermatozoa.
Study design, size, duration:Over 9 months, surgical samples from 5 NOA
men undergoing testicular sperm extraction (TESE) were assessed for differen-
tial expression by RNA-sequencing and grouped for comparison based on the
presence of spermatozoa in their respective samples. Gene expression proﬁles
of these men were compared to a control group with acquired obstructive
azoospermia (OA).
Participants/materials, setting, methods: Among the NOA study group
(n = 5), 2 patients had spermatozoa in their surgical samples, whereas 3
patients did not possess any spermatozoa, even after an extensive search of the
samples (71 ± 10 minutes) by several embryologists. Samples were processed
for RNA isolation and sequenced by Illumina HiSeq at 2×150 bp conﬁguration
per lane with ~58 M reads per sample. A log fold change of >2 and a FDR
P<0.05 were considered signiﬁcant.
Main results and the role of chance: Quantitative analysis of RNA
extracted from the samples averaged a concentration of 41.1 ± 29 ng/μL and
an RNA integrity number of 4.6 ± 1. Upon differential expression analysis, gene
ontology enrichment analysis indicated a differential expression of genes related
to spermatogenesis, with 30.8% of genes related to a compromised spermato-
genic function signiﬁcantly under-expressed in NOA patients with no spermato-
zoa identiﬁed, and 16.7% of spermatogenesis-related genes signiﬁcantly under-
expressed in NOA patients with spermatozoa, compared to an OA control.
Most interestingly, differentially expressed genes unique to NOA patients with-
out spermatozoa were related to the regulation of meiosis (TEX11; P =
0.0002) and were signiﬁcantly under-expressed, with 77.8% of genes involving
synaptonemal complex assembly affected (HORMAD1, SYCE1, SYCE3,
SYCP1, SYCP2, and TRIP13; P<0.0001), as well as processes related to the
regulation of chromosome organization (MEIOB; P<0.00001) and chromosome
segregation (STAG3; P<0.01). These gene families were normally transcribed in
NOA patients from whom spermatozoa were successfully retrieved as com-
pared to the control. These ﬁndings suggest a maturation arrest of germ cells in
NOA patients who failed to yield spermatozoa via TESE.
Limitations, reasons for caution: This study would beneﬁt from an
increased sample size to conﬁrm ﬁndings. Although it is currently difﬁcult to
query the epigenome and gain consistent and predictive information on the
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infertility status of these men, this method represents a way to identify novel
markers to understand the etiology of this condition.
Wider implications of the ﬁndings: While the etiologies of NOA are not
fully understood, RNA-sequencing may help gauge the spermatogenetic pro-
gress of male germ cells, potentially enabling reproductive urologists to select
the best candidates for successful sperm retrieval. This may also serve to better
counsel severe male factor patients and provide realistic expectations for
procreation.
Trial registration number:N/A.
P-616 Factors affecting the probability of ﬁnding at least one
euploid embryo
M.A. Tufekci1, S. Kahraman2, C. Pirkevi Cetinkaya3, Y. Kumtepe3,
C. Cinar Yapan1, M. Cetinkaya1
1Memorial Hospital Sisli, Reproductive Genetics Diagnostic Laboratory, Istanbul,
Turkey
2Memorial Hospital Sisli, ART and Reproductive Genetics Diagnostic Centre, Istanbul,
Turkey
3Memorial Hospital Sisli, Embryology Laboratory, Istanbul, Turkey
Study question: What clinical factors affect the probability of ﬁnding at least
one euploid embryo?
Summary answer: The number of biopsied blastocysts and female age were
found to be signiﬁcantly associated with the probability of ﬁnding at least one
euploid embryo.
What is known already: It is well known that the number of embryos avail-
able for transfer is signiﬁcantly lower in patients undergoing preimplantation
genetic screening (PGS) compared to regular IVF simply because of chromo-
somal selection. Thus, the clinical evaluation of a patient applying for PGS is
important in order to maximize the probability of ﬁnding at least one euploid
embryo for transfer. There have been various studies investigating factors which
might affect the probability of ﬁnding euploid embryos, such as the number of
generated embryos, the number of oocytes and AMH (Ata et al., 2012.,
Kahraman et al.,2016, La Marca et al., 2017).
Study design, size, duration: This retrospective cohort study was con-
ducted in a private IVF center between September 2011 and December 2017.
A total of 2001 PGS cycles were analysed and 5952 trophectoderm samples
were diagnosed either by array Comparative Genomic Hybridization (aCGH)
and by next generation sequencing (NGS).
Participants/materials, setting, methods: The probability of ﬁnding at
least one euploid embryo per cycle was evaluated according to maternal age,
body mass index (BMI), AMH, number of cumulus-oocyte complexes (COCs),
and number of biopsied blastocysts using multivariate analysis as a generalized
linear mixed model. Four categories were deﬁned for COCs: <4; 4-9; 10-15;
>15.
Main results and the role of chance: Maternal age, body mass index (BMI),
AMH, the number of cumulus-oocyte complexes (COC), and the number of
biopsied embryos were introduced in the multivariate analysis as independent
factors. The probability of ﬁnding at least one euploid embryo per cycle was
deﬁned as the target variable. The analysis showed that the generated model
was statistically signiﬁcant (F:57.155, p<0.001). Female age and the number of
biopsied blastocysts were found to be statistically signiﬁcant in the multivariate
analysis. With a one unit (year) increase in female age, the likelihood of ﬁnding
at least one euploid embryo decreased by 18.6% [OR (95%CI): 0.814 (0.789,
0.840), p<0.001)]. With a one unit increase in the number of biopsied blasto-
cysts, the likelihood of ﬁnding at least one euploid embryo increased by 78.9%
[OR (95%CI): 1.780 (1.627, 1.948), p<0.001)]. The number of trophectoderm
biopsies was found to be the most signiﬁcant variable affecting the probability of
ﬁnding at least one euploid embryo after adjustment for age.
Limitations, reasons for caution: The study population is limited to a single
IVF setting, results may show variation with different IVF clinics. This study is
based on trophectoderm biopsy samples, cleavage stage biopsies have been
shown to have higher aneuploidy rates.
Wider implications of the ﬁndings: The estimated probabilities of ﬁnding
at least one transferable embryo based on age and number of biopsied embryos
enables more accurate counselling of patients.
Trial registration number:Not applicable.
P-617 Querying gene expression to proﬁle human
spermatogenesis in infertile men
N. Pereira, A. Parrella, C. O’Neill, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question:We question whether gene products isolated from men with
different categories of infertility may shed light on their seminiferous tubule
function and gamete competence.
Summary answer: Loss of expression of DNA repair and apoptotic genes
provide information on the ability to successfully treat couples by assisted
reproductive technology (ART).
What is known already: The limitation of evaluating human semen charac-
teristics, even according to the most stringent criteria, is known to provide lim-
ited information on the performance of spermatozoa even when used for ART.
Standard semen analysis is ill-deﬁned in predicting reproductive outcome in
men with unexplained infertility. For this purpose, attempts have been made to
detect ploidy, DNA integrity, highly detailed morphology and maturational sta-
tus of the spermatozoon. Epigenetic assessment by proﬁling RNA transcripts in
the sperm cell has been proposed as an alternative method to screen the male
partner for infertility and predicts pregnancy outcome.
Study design, size, duration: In an 18-month period, we assessed the
expression of genes in relation to spermatogenesis and reproductive outcome.
RNA-Sequencing (RNA-Seq) was carried out on the specimens of 19 consent-
ing men. By sequencing the genome, we assessed ejaculated specimens of 5
infertile couples that were compared to 5 fertile and 3 donors acting as con-
trols. Additionally, 5 non-obstructive azoospermia (NOA) men were compared
to one obstructive azoospermia (OA) control.
Participants/materials, setting, methods: Ejaculated spermatozoa and
testicular biopsy tissue was used to isolate total RNA using a spin column com-
mercial kit. The nucleic acid quality and spermatozoal RNA concentration was
assessed. The RNA samples were then made into paired-end libraries. Pilot
paired-end 76 bp RNA-Seq using an Illumina platform (NextSeq 500) was car-
ried out and expanded to 60 M reads. Expression values were calculated in
Fragments Per Kilobase Of Transcript Per Million Fragments Mapped reads
(FPKM) and normalized read counts.
Main results and the role of chance: The study group (N = 19) had a
mean age of 35.9 ± 3 and normal sperm parameters, RNA concentration was
14.3 ± 6 ng/μL (9.1-21.3) with an RNA integrity number of 5.9 ± 1.7. The con-
trol couples (n = 3) with a female age of 38.3 ± 5 and male age of 33.6 ± 7
years evidenced normal semen parameters and delivered 3 healthy offspring.
Five men underwent ICSI with their female partner (mean age of 35.6 ± 3
years) and achieved a fertilization of 79.3% (30/42), and all delivered.
Additionally, 5 men underwent ICSI (female partner with a mean age of 34.8 ±
1 years) and achieved a fertilization rate of 71.4% (30/42), however, they failed
to obtain a pregnancy. A total of 86 genes were differentially expressed
(P<0.001) between the infertile and control cohorts. Of them, 24 genes were
overexpressed and 62 under-expressed. Speciﬁcally, DNA repair genes (APLF,
CYB5R4, ERCC4 and TNRFSF21) and apoptotic modulating genes (MORC1,
PIWIL1 and ZFAND6) were remarkably under-expressed (P<0.001) in study
cohort. MORC1 and PIWIL1 were also signiﬁcantly under-expressed in NOA
men (P<0.0001). Additional 26 genes DNA repair related, were unique to
NOA men. Among those, 8 genes were linked to specimens that yielded
spermatozoa while the remainder 18 were speciﬁc of men with spermatogenic
arrest.
Limitations, reasons for caution: This study proﬁles men with various
stages of spermatogenesis and must be conﬁrmed in a larger cohort. While the
contribution of the female partner cannot be excluded, gene expression proﬁl-
ing of infertile men may serve as an assay to measure reproductive potential of
the male gamete and seminiferous tubule function.
Wider implications of the ﬁndings: Deep sequencing of sperm RNA is a
reliable and reproducible technique that may aid in the diagnosis and screening
of infertile men. Epigenetic analysis evidenced that DNA repair and apoptosis
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genes are linked to seminiferous tubules function indicating their involvement in
meiosis and apoptosis typical of germ cells.
Trial registration number:N/A.
P-618 The karyotype of the blastocoel ﬂuid demonstrates low
concordance with both trophectoderm and inner cell mass
O. Tšuiko1, D. Zhigalina2, T. Jatsenko3, N. Skryabin2,
O. Kanbekova4, V. Artyukhova5, A. Svetlakov5, K. Teearu6,
A. Trošin7, A. Salumets3, A. Kurg6, I. Lebedev2
1University of Tartu, Department of Biomedicine, Tartu, Estonia
2Tomsk National Research Medical Center of Russian Academy of Science, Research
Institute of Medical Genetics, Tomsk, Russia C.I.S.
3Competence Centre on Health Technologies, Competence Centre on Health
Technologies, Tartu, Estonia
4Tomsk Regional Perinatal center, Department of Assisted Reproductive Technology,
Tomsk, Russia C.I.S.
5Krasnoyarsk Center for Reproductive Medicine, Department of Embryology,
Krasnoyarsk, Russia C.I.S.
6University of Tartu, Department of Biotechnology, Tartu, Estonia
7East-Tallinn Central Hospital, Women’s Clinic, Tallinn, Estonia
Study question: Is blastocoel ﬂuid (BF) karyotype comparable to inner cell
mass (ICM) and trophectoderm (TE) cells derived from the same blastocyst?
Summary answer: BF has an increased karyotype discordance rate between
ICM and TE and does not adequately represent the status of the rest of the
embryo.
What is known already: In assisted reproductive technology (ART) different
biopsy methods are used to obtain embryonic material for genetic analysis.
Recently, the discovery of ampliﬁable cell-free DNA in blastocoel ﬂuid (BF)
made it the object of attention by representing a potentially less invasive way of
obtaining DNA for preimplantation genetic screening (PGS). However, the use
of BF-DNA for PGS still remains questionable, as few of the preliminary studies
showed contradictive results regarding aneuploidy detection rates and karyoty-
pic concordance between BF and different biopsied samples. Therefore, add-
itional studies are warranted to investigate the potential use of BF-DNA for
diagnostic purposes.
Study design, size, duration: In the present study we utilized the most
widely used VeriSeq™ PGS (Illumina Inc, USA) platforms for next generation
sequencing (NGS)-based comparative chromosome analysis of BF-DNA and
TE and ICM cell populations from 16 cryopreserved blastocysts, donated for
research by patients who have undergone IVF treatment. The study was
approved by the Bioethics Committee of the Biological Institute of the National
Research Tomsk State University. All the patients have signed an informed
consent.
Participants/materials, setting, methods: All BF, TE and ICM samples
derived from a single blastocyst were whole-genome ampliﬁed and analysed fol-
lowing the Illumina next-generation sequencing (NGS) VeriSeq™ PGS protocol.
Data analysis and genome-wide proﬁle visualization was performed by applying
standard settings on Illumina BlueFuse Multi v4.3 Software with embedded
aneuploidy calling algorithm. Prior to embryo analysis, mixing experiments were
performed in three replicates using aneuploid cell lines to mimic embryonic
mosaicism and evaluate NGS sensitivity in mosaic aneuploidy detection.
Main results and the role of chance: Internal validation of mixing experi-
ments revealed that Veriseq™ PGS NGS-platform is able to distinguish mosaic
losses and gains that are present in at least 20% of cells. Next, after WGA of
embryo samples, a sufﬁcient amount of DNA was detected in all of ICM and TE
samples (16/16), but only in 14 out of 16 BF biopsies (87.5%). Following
sequencing and quality control, genomic proﬁles were obtained for 10 BF sam-
ples (10/16, 62.5%) and compared to corresponding TE and ICM, while the
karyotypes of TE and ICM were obtained and compared in 14 embryos out of
16 (87.5%). The analysis revealed that BF-DNA was burdened with mosaic
aneuploidies and the total number of affected chromosomes in BF was signiﬁ-
cantly higher compared to the TE and ICM (P < 0.0001), while no difference
was observed between TE and ICM. Thus, only 40.0% of BF-DNA karyotypes
(4/10) were fully concordant to TE or ICM, compared to 85.7% between TE
and ICM (12/14), making TE more representative of embryonic chromosomal
status than BF (P<0.03).
Limitations, reasons for caution: The major limitation was the number of
embryos analyzed. Additionally, BF aspiration was performed after embryo
thawing, which can potentially affect DNA quality and subsequent results.
Finally, we sequenced the whole trophectoderm cell population, which is
opposite to TE biopsy, when only a small number of cells are analyzed.
Wider implications of the ﬁndings: Using BF-DNA as a single source of
DNA for PGS can potentially lead to an increased rate of false positive ﬁndings,
at least using current approach. Blastocentesis cannot be ruled out in the future,
although the improvement of current sample handling protocols and aneuploidy
calling algorithm may be warranted.
Trial registration number: not applicable.
P-619 Comparison of the times to achieve an ongoing pregnancy in
advancedmaternal age patients with PGS and young IVF patients
without PGS
M. Cetinkaya, M.A. Tufekci, C. Cinar Yapan, Y. Kumtepe Colakoglu,
H. Yelke, S. Kahraman
Istanbul Memorial Hospital, Assisted Reproductive Technologies and Reproductive
Genetics Center, Istanbul, Turkey
Study question: Do young IVF patients achieve an ongoing pregnancy earlier
than older patients applying for PGS?
Summary answer: Kaplan-Meier survival analysis based on the number of
frozen embryo transfers showed that PGS patients achieved an ongoing preg-
nancy with signiﬁcantly less number of transfers.
What is known already: It has been shown that more than 40% of the blas-
tocysts are aneuploid increasing with advanced maternal age (Schoolcraft et al.,
2010). These chromosomal abnormalities adversely affect IVF outcomes even
in younger patients (Munne, 2012). Transfer of euploid embryos have been
shown to result in higher implantation rates especially when trophectoderm
biopsy was used (Scott et al., 2013). Evaluation of the time between pick-up
and transfer as days may be inﬂuenced by many patient and clinical factors, thus
misrepresenting the interpretation of survival analysis. To overcome this bias,
each embryo transfer cycle is used as a time unit.
Study design, size, duration: This retrospective cohort study includes 2400
frozen-thawed embryo transfer cycles (FET) of 1956 couples whose embryos
were frozen, thawed and transferred between August 2011 and December
2017. Blastocysts of young patients with a good ovarian reserve were frozen
and transferred later (freeze-all group; n = 1456). Aneuploidy screening was
routinely applied for advanced maternal age (>37), patients with an history of
abnormal fetal karyotype and with repeated implantation failures (>2) (PGS
group; n = 914).
Participants/materials, setting, methods: The mean female age was 29.8
± 4.2 and 35.1 ± 4.9 for the freeze-all and the PGS groups, respectively
(p<0.0001). The mean number of cumulus oocyte complexes and metaphase II
oocytes was 21.6 ± 10.5 and 17.3 ± 8.7 for the freeze-all group and 14.6 ± 9.7
and 12.1 ± 7.9 for the PGS group, respectively (p<0.0001). The mean number
of frozen blastocysts was 6.7 ± 3.9 and 4.9 ± 3.5 for the freeze-all and the PGS
groups, respectively (p<0.0001). PGS was done either with aCGH or NGS.
Main results and the role of chance: In the Kaplan-Meier survival analysis
performed, at most four subsequent FET cycles were taken into consideration
for each patient. However, once a patient reached an ongoing pregnancy, any
further FET cycles were not cumulatively counted since the purpose of the
study was to determine the number of FET cycles required to obtain an ongoing
pregnancy. When survival curves were compared in the Kaplan-Meier analysis,
it revealed that achieving an ongoing pregnancy was one cycle earlier in the PGS
group than the freeze-all group (p<0.0001). The overall ongoing pregnancy rate
of FET cycles with PGS was signiﬁcantly higher when compared to transfers
without PGS (49.3% vs. 44.1%, respectively (p<0.05)), despite a higher average
age in PGS cycles (29.8 ± 4.2 and 35.1 ± 4.9, respectively) and a signiﬁcantly
lower AMH level in the PGS group (5.6 ± 3.9 and 3.2 ± 2.9, respectively).
Additionally, FET cycles with PGS were 1.19 (1.0589 to 1.3527 95 %CI) fold
more likely to result in an ongoing pregnancy when compared to non-PGS FET
cycles with signiﬁcantly less frozen embryos (6.7 ± 3.9 and 4.9 ± 3.5*, respect-
ively) [*number before aneuploidy screening].
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Limitations, reasons for caution: Self-evidently PGS patients received an
euploid blastocyst transfer. The number of embryo transfers is directly related
with the number of vitriﬁed blastocysts and therefore with ovarian reserve.
Wider implications of the ﬁndings: PGS may be offered to young IVF
patients with a good ovarian reserve to decrease the time to achieve an ongoing
pregnancy.
Trial registration number: not applicable.
P-620 Alterations in global epigenetic proﬁle (DNAmethylation
and histonemodiﬁcations) of cumulus cells in women with
endometriosis
E. Hosseini1, E. Hosseini2, M. Shahhosseini3, P. Afsharian4,
L. Karimian5, M. Ashraﬁ6, F. Mehraein2, R. Aﬂatoonian6
1IVF center- Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
2Department of Anatomy- School of Medicine- Iran University of Medical Sciences-,
Department of Anatomy, Tehran, Iran
3Department of Genetics- Reproductive Biomedicine Research Center- Royan
Institute for Reproductive Biomedicine- ACECR–, Royan Institute, Tehran, Iran
4Department of Genetics- Reproductive Biomedicine Research Center- Royan
Institute for Reproductive Biomedicine- ACECR, Royan Institute, Tehran, Iran
5Department of Embryology- Reproductive Biomedicine Research Center- Royan
Institute for Reproductive Biomedicine- ACECR-, Royan Institute, Tehran, Iran
6Department of Endocrinology and Female Infertility- Reproductive Biomedicine
Research Center– Royan Institute for Reproductive Biomedicine- ACECR, Royan
Institute, Tehran, Iran
Study question: This study aimed to evaluate global DNA methylation and
histone methylation/ acetylation levels in cumulus cells of infertile patients with
endometriosis.
Summary answer: Differential epigenetic changes (DNA methylation and
acetylation/ methylation of lysine 9 of histone3 (H3K9ac and H3K9me2) in
cumulus cells were detected in endometriosis patients.
What is known already: Two epigenetic mechanisms, DNA methylation
and post-translational modiﬁcations of histone residues (H3K9ac and
H3K9me2 as the markers of gene activation and silencing, respectively), are
known to regulate the gene expression and their modiﬁcations being the main
reasons of human diseases.
Although the precise etiology of endometriosis is poorly understood, several
evidences recommend that epigenetic factors are associated with the molecular
aspect underlying endometriosis. Ovarian cells such as cumulus cell, which sur-
rounds oocyte is one of the main cells that inﬂuence by endometriosis.
Study design, size, duration: This study was conducted on 12 infertile
endometriosis patients and 12 normo-ovulatory patients with tubal factor infer-
tility or egg donors). All women, who were diagnosed with endometriosis
either by laparoscopy or pathological examination, constituted the study group.
Endometriosis was categorized according to the revised American Fertility
Sterility classiﬁcation. Cumulus-oocyte complexes were obtained from follicles
during ovarian puncture. Only cumulus cells with metaphase II oocytes were
selected for this study.
Participants/materials, setting, methods: Chromatin extracts from
cumulus cells were prepared following ﬁxation with formaldehyde and then
shearing into fragments by sonication. Nucleosome ELISA was performed on
chromatin fractions using antibodies against H3K9ac (activating mark),
H3K9me2 (repressing mark) and MeCP2 (as a marker of DNA methylation).
Relative assay level for incorporation of MeCP2, H3K9me2 and H3K9ac pro-
teins in chromatin fractions were calculated by normalizing ELISA signals (after
background subtraction) to core histone H1 content.
Main results and the role of chance: Our data revealed that cumulus cells
of endometriosis patients were globally DNA hypermethylated compared to
the cells from controls (P = 0.03). Furthermore, a signiﬁcant hyperacetylation
as well as hypermethylation at histone H3K9 (P = 0.04 and P = 0.01, respect-
ively) was observed in endometriosis samples compared to the control group.
Limitations, reasons for caution: For getting more comprehensive infor-
mation, we need to analyze epigenetic alterations in cumulus cells that are
involved in the ovarian functions in infertile endometriosis patients.
Wider implications of the ﬁndings: These results clearly show that epigen-
etic proﬁle such as DNA methylation and histone acetylation/methylation were
signiﬁcantly altered in cumulus cells of endometriosis patients and these altera-
tions may be responsible for infertility in such patients.
Trial registration number: not applicable.
P-621 Customising the limit of detection for PGT-A and PGT-SR
using NGS
K.Warren, S. Myers, M. Jasper
RHS Ltd, RHS Ltd, Thebarton, Australia
Study question:What is the lower limit of detection for segmental copy num-
ber variations by Next Generation Sequencing using PG-Seq™?
Summary answer: Whilst aneuploidy detection can be achieved from
300,000 reads, detection of a 100 kb microdeletion requires over 13 million
reads, or sequencing 1-2 samples per run.
What is known already: Next generation sequencing platforms provide a
highly ﬂexible and customizable workﬂow to attain a variety of levels of reso-
lution for the detection of segmental aberrations unlike other DNA analysis
platforms previously used for preimplantation genetic testing (PGT). In simple
terms higher resolution for the detection of smaller genetic aberrations can be
achieved by reducing the number of samples in a single sequencing run to
increase the total reads for each sample available for analysis.
Study design, size, duration: Library Preparation and 48 sample multiplex
NGS was performed according to standard PG-Seq™ protocol (RHS Ltd).
Initially, to evaluate the minimum number of mapped reads required to detect a
7 Mb segmental loss and 31Mb gain, PG-Seq™ NGS ﬁles were randomly
downsampled to produce ﬁles containing reads ranging from approximately
500,000 to 100,000 reads. The minimum number of reads required to detect
incrementally smaller chromosome aberrations was determined in silico.
Participants/materials, setting, methods: Individually sorted 5-cell ali-
quots from a segmental deletion and duplication cell line (GM14485, Coriell
Institute) were analysed using PG-Seq™ according to manufacturers
instructions.
Main results and the role of chance: Downsampling and analysis of
sequencing read data showed the detection of both the 7 Mb deletion and
31 Mb duplication indicated that detection was still possible using 100,000
mapped reads. However, the PG-Seq™ quality control score increased as
mapped reads declined from approximately 300,000 to 100,000 mapped reads
per sample. In silico modelling indicated the detection of a 100 kb segmental
copy number variation would require 6-19 million mapped sequencing reads
per individual sample. To achieve >6 million reads for a single sample would
require no more than 3 samples to be sequenced on a MiSeq sequencer. A
higher level of conﬁdence for reporting would be achieved for samples with
mapped reads of 13-19 million, and no more than 1-2 samples could be
sequenced in a single MiSeq run.
Limitations, reasons for caution: In silico data analysis does not replace
the need for validation of NGS workﬂows using cell line or clinical samples to
determine the resolution of the chosen workﬂow.
Wider implications of the ﬁndings: In silico analysis of sequencing data
highlights the technical limitations and ﬁnancial implications for the detection of
small segmental aberrations by NGS.
Trial registration number: -
P-622 OnePGT proof of concept for PGT-M and PGT-SR on
blastomere and trophectoderm biopsies
E. Coonen1, A. Paulussen1, J. Dreesen1, J. Dumoulin2, C. Van Uum1,
M. Drusedau1, E. John1, K. Derks1, R. Van Golde1, M. Zamani
Esteki1, C. De Die-Smulders1
1Maastricht University Medical Centre, Clinical Genetics, Maastricht, The
Netherlands
2Maastricht University Medical Centre, Center for Reproductive Medicine,
Maastricht, The Netherlands
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Study question: Investigating the OnePGT product as a single assay for pre-
implantation genetic testing for monogenic disorders (PGT-M) and preimplanta-
tion genetic testing for aneuploidies (PGT-SR) for blastomere and
trophectoderm embryo (TE) biopsies.
Summary answer: OnePGT accurately determined the single gene disorder
status of 48/48 embryos for PGT-M, and the presence of an unbalanced trans-
location in 33/33 embryos for PGT-SR.
What is known already: OnePGT is a next-generation sequencing (NGS)
haplarithmisis-based solution for Preimplantation Genetic Testing (PGT) of
in vitro fertilized (IVF) embryo single-cell or TE biopsies. OnePGT is a wet- and
dry lab solution allowing concurrent PGT-M, PGT-SR of whole-genome ampli-
ﬁed (WGAed) products biopsied from IVF embryos in a single assay. This
innovative product provides a sample-to-answer solution, from wet lab to
cloud-based analysis software, which has haplarithmisis in its heart.
Study design, size, duration: To test the performance of Agilent’s OnePGT
solution, we performed a blinded clinical veriﬁcation study on 109 embryos (32
couples) donated to Maastricht UMC+ for research purposes. For PGT-M, 67
embryos (20 couples) that are previously analyzed with conventional STR-PCR
PGD as well as phasing reference (a close relative) samples (PGT-M) were pro-
cessed in our facility. For PGT-SR a total of 36 embryos (11 couples), previously
analyzed with FISH or arrayCGH PGD, were tested.
Participants/materials, setting, methods: In total 36 couples (109 spare
embryos unsuitable for uterine transfer) were participated in this study. These
embryos were affected with monogenetic disorder, unbalanced translocation
or had poor morphology. All embryos were re-biopsied, WGAed and pro-
cessed according to the OnePGT library preparation protocol. Subsequently,
NGS libraries were sequenced and analyzed via the PGT-M or PGT-SR pipeline
in the OnePGT software in a blinded fashion. The onePGT diagnoses were
then compared with the conventional PGD method.
Main results and the role of chance: For the 36 embryos for which both
OnePGT and the conventional PGD methods gave a conclusive result, 100%
concordance was demonstrated. The main reason for inconclusive results were
loss-of-heterozygosity-like regions in the reference family members, affecting 10
embryos. Another 14 samples were found to be affected by the common
chromosome instability (CIN) phenomenon, such that the copy number dis-
crepancies between OnePGT and STR-PCR were conﬁrmed by SNP-array ana-
lysis supporting the OnePGT results. The quality control module of the
OnePGT software identiﬁed 8 samples with no genomic DNA but with a high
mitochondrial DNA content.
Regarding the PGT-SR analysis, a conclusive result was obtained for all sam-
ples (36/36, 100%). Of the 36 embryos, 3 were found to be with CIN, as
shown by copy number discrepancies between OnePGT and FISH/arrayCGH,
which were further conﬁrmed by an orthologous method (Agilent GenetiSure
PreScreen). Overall, the OnePGT diagnoses on 33 embryos were 100% con-
cordant with the gold standard conventional PGD.
Limitations, reasons for caution: Although the sample-size (number of
embryos) in this study is not sufﬁcient to reach to the 0.9 statistical power, we
have increasingly expanded the samplesize in collaboration with UZ Leuven.
Wider implications of the ﬁndings: OnePGT is a single-assay solution for
both PGT-M and PGT-SR, applicable on single-cell or TE WGAed genomes
derived from cleavage-stage or blastocyst-stage IVF embryos, respectively.
Trial registration number: The study was funded by Agilent Technologies.
P-623 Clinical impact of reporting embryomosaicism for
preimplantation genetic testing for aneuploidy (PGT-A)
K. Xu, C. Zhang, J. Wei, X. Qin, S. Lee, M. Mason, Z. Rosenwaks
Cornell University Medical College, The Center for Reprod. Medicine & Infertility -
IVF/PGD, New York, U.S.A.
Study question: Reporting mosaicism allows prioritizing embryo transfer.
This study examines the clinical impact of reporting mosaicism in PGT-A
practice.
Summary answer:Of 813 PGT-A patients, about 5% (43) had only euploidy-
mosaic embryos. Those embryos, accounted for 6.6% of analyzed embryos, are
transferrable but with caution.
What is known already: Mosaicism in early preimplantation embryos is
recognized as a common phenomenon and it appears to be readily detectable
in D5/6 biopsied specimens with next generation sequencing platform.
Transfer of mosaic embryos may result in healthy babies (Greco et al., NEJM,
2015). Although it is generally believed that the results of chromosomal ploidy
and mosaicism detected in biopsied specimens are likely correlated to the
healthy status of the embryos, controversy exists as to whether or not to
report mosaicism due to insufﬁcient knowledge on this biological or artefactual
phenomenon.
Study design, size, duration: PGS data were collected from 813 cycles and
4423 embryos from January 1 to December 31, 2017. Patients (average age =
38.4) were divided into three groups: ≤34, 35 to 40, and ≥41. Embryo biopsies
were performed on D5 or D6. Illumina’s VeriSeq PGS platform was used for
sequencing and data analysis.
Participants/materials, setting, methods: Euploidy was deﬁned as no
gain/loss detected in any chromosomes screened. Euploidy-mosaic (Eup-M)
was deﬁned as an absence of whole chromosome gain/loss, but with low conﬁ-
dence combined with a proﬁle of one or more whole chromosome(s) or seg-
mental region(s) that showed 25 to 80% gain or loss. Embryos with mosaic
chromosomes coupled with the presence of one or more whole chromosomal
gain/loss were excluded from this classiﬁcation since those were deﬁned as
aneuploidy.
Main results and the role of chance: Of 813 patients, 205 (25.2%) have all
aneuploidy embryos. In 569 patients at least one or more euploid embryos
were available for transfer. An overall of 396 embryos were identiﬁed as Eup-
M. The distribution of euploidy, euploid-mosaic and aneuploidy embryos in
three age groups are tabulated below:
Ch. Status/
Age
≤34 (#) 35-40 (#) ≥41 (#) Overall (#)
Euploidy 53.4% (639) 36.1% (812) 13.8% (135) 34.0% (1586)
EUP-M 13.1% (157) 8.8% (197) 4.3% (42) 6.6% (396)
Aneuploidy 33.5% (401) 55.1% (1240) 81.9% (800) 55.2% (2441)
Total #
embryos
1197 2249 977 4423
More euploid-mosaic embryos were present in younger women than that in
older women because the latter had more aneuploid embryos which also had
mosaic chromosomes. Frequently, only one (32.9%, 187/569) or two (10.4%,
59/569) mosaic embryos were detected in PGT-A cases, up to 6 mosaic
embryos were observed in one patient. In 43 patients (7.6%, 43/569), only
mosaic embryos were available for transfer.
Limitations, reasons for caution: In patients (~8%) who have only euploid-
mosaic embryos available for transfer, extensive genetic counseling should be
recommended to assist in decision making. Further study is warranted to follow
the pregnancy results from transfers of those embryos.
Wider implications of the ﬁndings: The frequencies of mosaicism appears
to be relatively low as indicated in this study. However, mosaicism will affect
embryonic development and may create real issues for PGT-A where biopsied
specimens may not precisely reﬂect the inner cell mass and/or the whole
embryos, thus may lead to false-negative or false-positive results.
Trial registration number:N/A.
P-624 Paternal factors in recurrent pregnancy loss: a proteomic
insight
G. Mohanty1, S. Kar2, L. Samanta1
1Ravenshaw University, Redox Biology Laboratory- Department of Zoology, Cuttack-
Odisha, India
2Kar Clinic And Hospital, Obstetrics and Gynaecology, Bhubaneswar- Odisha, India
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Study question: Do differential protein expression lead to aberrant embryo
development leading to loss of foetus in idiopathic recurrent pregnancy loss
(iRPL)?
Summary answer: Differential protein expression in spermatozoa of part-
ners may be the contributing factor towards impaired embryo development
and pregnancy loss in patient with iRPL.
What is known already: Defective paternal genome has been attributed to
be an important cause for spontaneous recurrent pregnancy loss (RPL).
Controlled level of reactive oxygen species (ROS) is essential for normal sperm
function while elevated levels results in increase in oxidative damage to sperm
chromatin, induce mutations, oxidize proteins, and membrane lipids. There is
enhanced ROS generation in spermatozoa of partners of iRPL resulting in aug-
mented lipid peroxidation, protein carbonylation and thionylation.
Study design, size, duration: This prospective study consisted of male part-
ners of iRPL patients (n = 16) with no female factor abnormality as revealed by
gynaecologic investigation including karyotyping and age matched fertile healthy
volunteers (n = 20). All samples were collected during 2013-2015 after getting
institutional ethical approval and written consent from the participants.
Participants/materials, setting, methods: Seminal ejaculates were col-
lected by masturbation after 2-3 days of sexual abstinence and analysed accord-
ing to World Health Organization criteria. Samples from each group after
separation by 2D-DIGE were subjected to mass spectrophotometric analysis to
identify differentially expressed proteins (DEPs).STRING and Cytoscape soft-
wares were used for pathway analysis.Two key proteins, HSPA2 and GPx4 of
the identiﬁed pathways were validated by Western blot analysis.
Main results and the role of chance: Based on the relative abundance of
the common protein spots 27 were overexpressed and 9 were underex-
pressed, while 18 proteins spots were identiﬁed with low abundance. A fold
change >2 was considered as overexpressed or underexpressed. A total of 6
spots were picked for protein sequencing analysis owing to their abundance
and position on the gel. This included GPx4, JIP4, ZN248 to be overexpressed
while HSPA2,GSTM5, TF3C1, CC74A was underexpressed in RPL group.
Owing to its greater coverage, HSPA2 was subjected to single nucleotide poly-
morphism (SNP) analysis wherein of 444 SNPs were synonymous and 56 were
found to be nonsynonymous SNPs. It was found that 18 SNPs were deleterious
using a combinatorial servers-SIFT, Polyphen, Provean, nsSNP analyser and
SNPs and GO. Protein structural analysis with these amino acid variants was
performed by using HOPE, ConSurf, Swiss PDB viewer, Chimera and
NOMAD-Ref servers to check their solvent accessibility, molecular dynamics
and energy minimization.
Limitations, reasons for caution: 2D-DIGE though a robust technology in
terms of reproducibility, has a limitation because all the identiﬁed differential
protein spots needs to be subjected to mass spectrophotometry to identify all
DEPs. Secondly, increasing the sample size would augment the biological vari-
ability and statistical power of the study.
Wider implications of the ﬁndings: This pilot study showed that in case of
iRPL paternal factors play a role which can be further analysed to develop bio-
markers for iRPL. Additionally, our in silico analysis suggests that screening of
SNP variants of HSPA2 such as V106E, D55Y, T301R, R314P,S343Pmay be
useful for predicting outcome.
Trial registration number:Not applicable.
POSTER VIEWING
Reproductive endocrinology
P-625 The effect of the duration of elevated progesterone during
the late-follicular phase of ovarian stimulation on live birth rates
following IVF/ICSI
C. Roelens1, S. Santos-Ribeiro1,2, A. Racca1,3, S. Mackens1,
P. Drakopoulos1,4,5, H. Tournaye1, C. Blockeel1,6
1Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Jette, Belgium
2Santa Maria University Hospital, Department of Obstetrics- Gynecology and
Reproductive Medicine, Lisbon, Portugal
3University of Genoa, Academic Unit of Obstetrics and Gynecology, Genova, Italy
4Centre Hospitalier Universitaire de Liège, Department of Reproductive Medicine,
Liège, Belgium
5Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy - Department of
Surgical and Clinical Science, Brussels, Belgium
6University of Zagreb - School of Medicine, Department of Obstetrics and
Gynecology, Zagreb, Croatia
Study question: Does a longer exposure to late-follicular elevated progester-
one (LFEP) hinder live birth rates (LBRs) after fresh embryo transfer?
Summary answer: LBRs are only weakly affected by the duration of LFEP.
What is known already: The overproduction of progesterone (P) during
ovarian stimulation has been associated with endometrial genetic/epigenetic
changes in the luteal phase and, most importantly, lower LBRs after a fresh
embryo transfer. Therefore, in daily clinical practice, P levels on the day of
human chorionic gonadotrophin (hCG) administration are often measured and
a freeze-all strategy is adopted whenever LFEP (>1.50 ng/ml) occurs.
However, a recent retrospective analysis has concluded that also the duration
of LFEP >1.00 ng/ml prior to hCG administration may affect clinical pregnancy
rates. We assessed whether this result was reproducible, namely when using
LBR as the primary outcome.
Study design, size, duration:We performed a retrospective cohort analysis
including all women undergoing ovarian stimulation for IVF/ICSI in a university-
afﬁliated tertiary referral centre between January 2010 and March 2015. A total
of 4312 cycles were included. To minimize potential confounding, only patients
with GnRH antagonist pituitary suppression who underwent fresh embryo
transfer using autologous oocytes were included. Couples with planned embryo
biopsy, managed natural cycles or in-vitro maturation were excluded from the
analysis.
Participants/materials, setting, methods: The primary outcome was live
birth, deﬁned as a live born delivery after 24 weeks. LBRs were compared
among different P elevation duration groups (0 days, 1 day, 2 days or ≥3 days)
using multivariable regression analysis to account for potential confounders.
This analysis was repeated using two cut-offs of LFEP: 1.00 and 1.50 ng/ml.
Main results and the role of chance: The average female age of the cohort
was 34.0 ± 5.0 years. The mean number of oocytes retrieved was 9.3 ± 5.7
and 64.7% of the fresh embryo transfers were performed at cleavage stage (day
3), with a single embryo being transferred in 51.0% of all cases.
In the univariable analysis, the duration of LFEP >1.00 ng/ml was not asso-
ciated with a signiﬁcant decrease in LBR. Speciﬁcally, LBRs were 25.8%, 24.1%,
23.6% and 24.2% according to whether the patient had LFEP >1.00 ng/ml last-
ing for 0, 1, 2 or ≥3 days respectively (p = 0.259). However, LBR for the same
LFEP durations, but using LFEP >1.50 ng/mL as the threshold, lowered signiﬁ-
cantly as the duration of LFEP increased: 25.8%, 18.4%, 15.1% and 13.8%,
respectively (p<0,001).
Although the duration of LFEP >1.50 ng/mL predicted LBR independently in
the univariable analysis, the relative frequency of having such LFEP levels for 2
or ≥3 days was exceedingly rare (1.2% and 0.2%, respectively). Moreover, the
duration of LFEP >1.50 ng/ml was no longer a statistically signiﬁcant LBR pre-
dictor in the multivariable regression analysis performed (which accounted for
female age, number of preceding IVF/ICSI cycles, type/dose of exogenous
gonadotrophins, endocrine proﬁle at hCG administration, number of oocytes
retrieved, embryo stage, number and quality at transfer).
Limitations, reasons for caution: Although this study includes a large sam-
ple set and adjusts for multiple potential confounding, the results are limited by
its retrospective nature and the inability to include all relevant potential con-
founders (e.g. smoking habits). Better extrapolation could be obtained by valid-
ating these results prospectively.
Wider implications of the ﬁndings: Although LBRs were discretely lower if
LFEP >1.50 ng/ml lasted for more than 1 day, such an event seemed rare and
was no longer signiﬁcant when accounting for potential confounding. Therefore,
one may postulate that the clinical value of measuring P prior to hCG adminis-
tration is limited.
Trial registration number: not applicable.
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P-626 Efﬁcacy of metformin therapy to reduce pregnancy-induced
hypertensive disorders in women with silent impaired
insulin-sensitivity
J. Romero1, E. Spinedi2
1Perinat Clinic, Reproductive Endocrinology, La Plata, Argentina
2La Plata Medical School, CENEXA UNLP-CONICET, La Plata, Argentina
Study question: Could metformin therapy, throughout pregnancy, be effect-
ive to reduce the risk of late pregnancy-induced hypertensive disorders (PIHD)
in women with defective insulin-signaling system function?
Summary answer: Metformin therapy, throughout pregnancy, reduced the
development of third trimester gestation-induced hypertensive disorders in
women with silent defective insulin-signaling system function from 23.6% to
13.8%.
What is known already: Pregnant women with impaired insulin sensitivity
are at a high risk for developing pregnancy-induced hypertensive disorders
(PIHD). Previous data support that 2 h-insulinemias greater than 215.25 pM
after 75 g-glucose overload could be a predictor for detecting women at high
risk of developing PIHD. Indeed, compared with pregnant women at low risk (2
h-insulinemias lower than 215.25 pM), those at high risk displayed a 4-fold high-
er occurrence of gestational hypertension and pre-eclampsia. Additionally, it is
accepted that metformin (MTF) therapy is able to prevent poor pregnancy out-
come in women diagnosed for gestational diabetes mellitus (GDM).
Study design, size, duration: We performed a 2-year-prospective study in
226 multiparous women that became spontaneously pregnant either under oral
MTF therapy (2 g/day; n = 29) or not (n = 198). During gestational week 25-
26, women were subjected to an oral glucose tolerance test (OGTT) measuring
insulinemias on both sample-times. Thereafter, women were classiﬁed at low
(being the 2 h-insulinemias lower than 215.25 pM) or at high (being the 2 h-
insulinemias greater than 215.25 pM) risk for developing PIHD (LR-PIHD and
HR-PIHD, respectively.
Participants/materials, setting, methods: Overnight fasting pregnant
women (age 29-37 years) were bled before (sample time-zero) and 2 h after 75
g-oral glucose load (OGTT). Glucose (enzymatic-colorimetric assay) and insulin
(chemiluminescence) plasma concentrations were determined in samples times
zero and 2 h from the OGTT. Finally, HOMA-IR score (glucose in mM x insulin
in mIU/mL x 0.044) and Glucose (in mg/dL) to Insulin (in mIU/mL) ratio (G:Ir)
were calculated for both time-samples. Anthropometric data were recorded
throughout pregnancy.
Main results and the role of chance: Biochemical data indicate that 125
and 101 women were at LR-PIHD and HR-PIHD, respectively, MTF-treated
women pertained to the HR-PIHD group. Comparing data from HR-PIHD
MTF-treated (n = 29) versus MTF-untreated women (n = 72), although time-
zero glycemias were similar, time-2 h glycemias were signiﬁcantly (P<0.05) low-
er in MTF-treated than in MTF-untreated women. Plasma insulin and HOMA-IR
values were statistically similar in both groups, regardless of the sample-time
examined. Finally, G:Ir values were signiﬁcantly (P<0.05) higher in MTF-treated
than in MTF-untreated women although in sample-time zero only. While 17/72
MTF-untreated women developed any PIHD, conversely, PIHD was noticed in
4/29 MTF-treated women. Starting woman body mass index, weight-gain
throughout pregnancy, gestational length, multiparity and, the appearance of
polihydramnios and newborn respiratory distress were similar among groups;
none stillbirth was noticed. Although mean values of weight at birth were similar
among groups, macrosomic babies were born to MTF-untreated mothers only
(3/72). Finally, while PIHD (hypertension/pre-eclampsia) were developed by
17/72 (23.6%) MTF-untreated women, a better pregnancy outcome was
noticed in MTF-treated women because only 4/29 (13.8%) developed PIHD.
Data indicate that pregnancy outcome in women at HR-PIHD, due to their
impaired insulin sensitivity (2h-insulinemias >215.25 pM), could be highly bene-
ﬁced if treated with MTF throughout pregnancy.
Limitations, reasons for caution: Data emerging from this prospective
study need to be corroborated by studying the beneﬁcial effect of MTF therapy
throughout gestation, on poor pregnancy outcome in a larger sample-
population of pregnant women at high risk of developing PIHD, deﬁned as hav-
ing 2 h-insulin values greater than 215.25 pM during an OGTT.
Wider implications of the ﬁndings: We have established that by applying
the simple criterion ¨2-h insulinemia > 215.25 pM during an OGTT¨, pregnant
women with silent impaired insulin sensitivity are at high risk of developing
PIHD, however, such increased risk could be reduced when these women are
treated with MTF throughout pregnancy.
Trial registration number:Not applicable.
P-627 Expression of reproductive hormone receptors and
contraction-associated genes in porcine uterus during the estrous
cycle
K.S. Lee1, J.K. Joo2, M.S. Jo2, G.Y. Yun2, S.E. Han2
1Pusan Nat. University School of Medicine, Dept. of Ob/Gyn, Pusan, Korea- South
2Pusan National University Hospital, Obstetrics and Gynecology, Busan, Korea- South
Study question: What is mechanism of uterus contraction activity in a por-
cine model?
Summary answer: hormonal receptors and contraction-associated proteins
were dynamically regulated depending on the estrous cycle.
What is known already: Contraction of uterus tissue frequently occurs
throughout the estrous cycle and is regulated by several endogenous factors,
including estradiol, progesterone, luteinizing hormone, follicle-stimulating hor-
mone, oxytocin (OXT) and contraction-associated proteins (CAPs).
Study design, size, duration: Experimental study.
Participants/materials, setting, methods: mRNA and protein expression
levels of reproductive hormonal receptors, including estrogen receptors, pro-
gesterone receptor and luteinizing hormone/choriogonadotropin receptor in
addition to CAPs including OXT, OXT receptor (OXTR), hydroxyprostaglan-
din dehydrogenase 15-(NAD) and gap junction α-1 protein, were examined in
the porcine uterus according to the follicular and luteal phases.
Main results and the role of chance: hormonal receptors and CAPs were
dynamically regulated depending on the estrous cycle. In conclusion, genes
associated with uterine contraction and its regulatory hormonal receptors in
the porcine uterus were differently regulated in the follicular and luteal phases.
Limitations, reasons for caution: These experiments were limited to only
mRNA measurements, these result differ from those of the current study due
to the distinct environmental conditions for other animals.
Wider implications of the ﬁndings: Genes associated with uterine con-
traction and its regulatory hormonal receptors in the porcine uterus are critic-
ally involved in the remodeling and contraction of uterine tissue and may be
required to modulate the physiological status of the uterus.
Trial registration number: not applicable.
P-628 Effects on body weight and waist/hip circumference during a
1-year three-component lifestyle RCT in obese PCOS women
L. Jiskoot1, R. Timman2, A. Beerthuizen2, J. Busschbach2, J. Laven1
1Erasmus Medical Center, Department of Reproductive medicine room HS416,
Rotterdam, The Netherlands
2Erasmus Medical Center, Section of Medical Psychology and Psychotherapy,
Rotterdam, The Netherlands
Study question: Is a multidisciplinary one-year cognitive-behavioural lifestyle
treatment more effective to decrease weight and waist/hip circumference than
usual care?
Summary answer: A three-component lifestyle program for women with
PCOS achieved a weight loss of 5%. A self-induced weight loss by publicly avail-
able services is less effective.
What is known already: Obesity in women with polycystic ovary syndrome
(PCOS) negatively affects all clinical features. There is a large number of small
uncontrolled (two-component) trials demonstrating that losing 5 to 10% of ini-
tial body weight has shown promising results on reproductive, metabolic and
psychological level. Weight loss programs seem to be effective in the short
term; however, most of the initial weight loss is regained within 1 year. The big-
gest challenge is to achieve a reasonable and sustainable weight loss. More
intensive (three-component) trials are needed to enhance adherence and
achieve a sustainable weight-loss of 5 to 10%.
Study design, size, duration: The present study is a longitudinal randomized
controlled trial (RCT) to study the effectiveness of a three component 1-year
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cognitive-behavioural lifestyle intervention in overweight/obese women with
PCOS. A total of 209 participants are randomly assigned to three groups: 1)
CBT provided by the multidisciplinary team or; 2) CBT provided by the multi-
disciplinary team and Short Message Service (SMS) or; 3) usual care: encourage
weight loss through publicly available services (control group).
Participants/materials, setting, methods: Women with menstrual cycle
disorders are systematically screened using a standardised protocol. Data of
209 women diagnosed (according this protocol) with PCOS according to the
Rotterdam criteria, a Body Mass Index above 25 kg/m2 were included between
September 2009 and August 2016. Outcome variables were measured at the
start of the study, at three, six, nine and twelve months. Mixed modelling is
applied for longitudinal analyses of the data.
Main results and the role of chance: The reduction in BMI within one year
was -2.18 kg/m2, 95% conﬁdence interval (CI) [-2.72, -1.64] in the lifestyle
intervention group (P<0.001), and -0.91 kg/m2, 95% CI [-1.59, -0.23] in the
control group (P<0.009), a difference of -1.27 95% CI [-2.14, -0.41] (P<0.004).
The mean weight loss in the lifestyle intervention group was -6,39 kg, 95% conﬁ-
dence interval (CI) [-7.93, -4.85] (P<0.001) and -2,44 kg 95% CI [-4,37, -0,50],
in the control group (P = 0.014), a difference of 3.96 kg, 95% CI [-6.43, -1.49]
(P<0.002). Body Mass Index at baseline was no predictor for weight loss. The
chance of a 5% BMI reduction was 7.19 times larger in the lifestyle intervention
group than in the control group.
Waist circumference signiﬁcantly decreased in both groups: - 4.84%, 95% CI
[-6.48, -3.21] and -4.75%, 95% CI [-6.98, -2.51] respectively, but there was no
difference between the lifestyle intervention and controls (P .944). Hip circum-
ference also decreased signiﬁcantly: -4.17%, 95% CI [-5.04, -3.31] versus
-2.14%, 95% CI [-3.30, -0.97] and signiﬁcantly more (P .006) in the lifestyle
intervention group.
Limitations, reasons for caution: All PCOS patients with a BMI > 25 kg/
m2 and eligible for ovulation induction treatment are obligated to follow the life-
style modiﬁcation protocol prior to fertility treatment. After inclusion of 150
patients, we applied an interim power analysis to the complete cases.
Wider implications of the ﬁndings: These ﬁndings support that three-
component multidisciplinary cognitive- lifestyle interventions should be incorpo-
rated in daily practice to support women with PCOS to achieve a healthy
weight loss of at least 5%.
Trial registration number: Registered at the Netherlands National Trial
Register with number NTR2450 on August 2nd, 2010.
P-629 The inﬂuence of cadmium, copper, lead, selenium, and zinc
concentrations in follicular ﬂuid on embryo developmental
dynamics by time-lapse microscopy
A.Wdowiak1, M. Artur2, B. Szymon2
11Medical University of Lublin- Poland, Diagnostic Techniques Unit- Faculty of Health
Sciences, Lublin, Poland
2Medical Center Ovum, Embryology Department, Lublin, Poland
Study question: This study investigated the inﬂuence of cadmium (Cd), cop-
per (Cu), lead (Pb), selenium (Se), and zinc (Zn) in follicular ﬂuid (ff) on the
dynamics of embryo development.
Summary answer: Zinc concentrations in ff affect the dynamics of embryo
development from tC to t4. Pb impede the dynamics of embryo development
from tF to t4
What is known already: The negative impact of the environment in which
the oocyte grows affects the quality of the embryo and the time at which subse-
quent developmental stages are reached. The oocyte can probably be damaged
by a toxic microenvironment during the primordial stage of follicle development
and at the time of oocyte maturation. One suggested cause of egg-cell damage
is the deleterious effects of excess amounts of heavy metals.
Study design, size, duration: The present study was conducted in medical
center ‘Ovum” between March 2016 and April 2017. The study involved 220
women undergoing ICSI treatment for the ﬁrst time. The inclusion criteria
were: age below 35 years, FSH level ≤ 10 mIU/mL, AMH level ≥ 1.5 ng/mL,
and Body Mass Index (BMI) ≤ 30 kg/m2. Women with severe endometriosis,
metabolic disease, or leiomyoma were excluded from the study.
Participants/materials, setting, methods: The ovarian stimulation was
carried out according to the short protocol: injections of gonadotropin-
releasing hormone analogue were followed by human (group A,n = 110) and
recombinant (groupB,n = 110) FSH administration. The growth of embryos
was monitored with time-lapse system.The trace metals measurements were
performed by the electrothermal-atomic absorption spectrometry method.
After six weeks, the presence of the embryo cardiac activity were assessed via
ultrasound. The relationship between concentrations of trace metals and
embryo kinetic data were analyzed.
Main results and the role of chance: Pregnancy was achieved in 57 women
– 29 (26,36%) of them were stimulated with hFSH and 28 (25.45%) were stimu-
lated with rFSH.No statistically signiﬁcant difference was found between the
two groups with regards to the type of gonadotropins used (Chi2 = 0.278, df
= 1, p = 0.575).Comparing time of embryo development in groups A and B it
was noted that almost all successive stages of embryo development (except tF)
occurred earlier in women who achieved pregnancy than in women in whom
pregnancy was not achieved.In both groups possitive correlations were found
between mean level of Zn and the embryonic development periods: tC-t2, t4
and negative correlations occurred for the Pb levels with times tF–t4.In regards
to other trace metals, we have observed no signiﬁcant relationships. ROC
curve analysis showed no statistically signiﬁcant differences between accuracy of
using FSH and trace metals levels to predict pregnancy after IVF.
Limitations, reasons for caution: The results of this study where ICSI was
performed with ejaculated sperm and for male-factor infertility cannot be gen-
eralized to all ICSI offspring because the indications for ICSI have nowadays
been extended and ICSI is also being performed with non-ejaculated sperm and
reported differences may thus either decrease or increase.
Wider implications of the ﬁndings: It has been hypothesized that zinc sup-
plementation may improve achivement pregnancy in patients undergoing ICSI.
It raises the need for further research into this problem by larger research
groups.
Trial registration number: 8/07/2016
P-630 Non-invasive detection of dominant follicle metabolite
composition in PCOS women receiving rFSH, clomiphene citrate or
aromatase inhibitor for ovarian stimulation
M. Acet1, N. Celik2
1private, obstetric and gynecology, İstanbul, Turkey
2Department of Biochemistry- Behcet Uz Children’s Hospital- Izmir-Turkey,
Biochemistry, Izmir, Turkey
Study question: Does metabolite composition of dominant follicle change in
women with PCOS receiving rFSH, clomiphene citrate (CC) or aromatase
inhibitor (AI).
Summary answer: While CC use changes the developing follicle metabolite
content negatively rFSh or AI will not cause any change.
What is known already: Although conventional ovarian stimulation drugs
used in assisted reproductive technology cycles allow selection and maturation
of oocytes they may lead to retrieving of compromised quality oocyte that may
cause fertilization failure or compromised embryo development. rFSH, CC and
AI are the three most commonly used drug groups for ovulation stimulation.
Although a number of studies have looked at the metabolites compostion of
reproductive tissues MRS-based approach to identify the impact of drugs used
for ovarian stimulation on human follicular ﬂuid has not been carried out.
Study design, size, duration: This is a case controlled study, enrolled 26
women who undergoing IVF/ICSI due to PCOS.
Participants/materials, setting, methods: A total of 21 infertile PCOS
women equally assigned to three groups consisting of women receiving rFSH or
CC or aromatase inhibitor. Each group of women underwent MR spectroscopy
of a dominant follicle before hCG injection as soon as the detection of a follicle
with a mean diameter of at least 16-18 mm. N-acetylaspartate (NAA), lactate
(Lac), creatine (Cr), and choline (Cho) content of follicle were measured as
ppm.
Main results and the role of chance: Four fold decrease in Cho signal was
detected in subjects receving CC compared to fertile subjects. Cho signal of
subjects taking rFSH or AI were signiﬁcantly higher than in the CC group.
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Signiﬁcantly increased Lac signal was detected in the dominant follicle of sub-
jects taking CC. Three-fold higher Cr signals was detected in fertile subjects
compared to CC group. Likewise, Cr peak of subjects taking rFSH or AI were
signiﬁcantly higher than in Cr signal of CC group.
Limitations, reasons for caution: The low number of patients being studied
is the basic limitation of our study.
Wider implications of the ﬁndings: Prediction of the developmental cap-
acity of egg before OPU with spectroscopy may increase the accuracy of best
quality embryo selection. Thus, it may be possible to see the developmental
defects of the growing oocyte before OPU and to take treatment steps for
improving oocyte developmental potential.
Trial registration number:NA.
P-631 Experimental study of rat bonemarrow stem cell on
polycystic ovary syndromemodel of rattus norvegicus decreasing fas
ligand expression and apoptotic index
S. Siahaan1, B. Santoso1,W.Widjiati2
1Faculty of Medicine- Universitas Airlangga, Obstetrics & Gynecology, Surabaya,
Indonesia
2Faculty of Veterinary Medicine- Universitas Airlangga, Veterinary Anatomy,
Surabaya, Indonesia
Study question: This study aims to compare Fas ligand expression and apop-
totic index in rat ovaries with or without the administration of Rat Bone
Marrow Stem Cell.
Summary answer: There was a decrease of Fas ligand expression and apop-
totic index in the administration of rat bone marrow stem cell in rat with PCOS
model.
What is known already: Hiroyuki et al. conducted further research by com-
paring ovarian expression and localize of FAS and Fas Ligan (FasL), caspace-9.
This study found TdT-mediated dUTP-Biotin nick-end-labeling (TUNEL) which
indicates positive result, highly increase in Polycystic Ovary Syndrome (PCOS)
ovaries compared with healthy ovaries (p<0,005), FasL level and caspace-8
increase.
Study design, size, duration: This study used experimental design with
post-test only control group design conducted on rats with PCOS model. The
large sample of the study, based on Federer’s formula with the amount of 27
rats. The study was conducted on January to May 2016.
Participants/materials, setting, methods: The large sample of the study,
based on Federer’s formula with the amount of 9 rats/group, was then divided
into three groups which are rats without treatment, PCOS model rats, and
PCOS model rats with stem cell. The dependent variables in this study were
Fas ligand expression and apoptotic index. If the distribution is normal, the data
analysis used ANOVA test. If it is not normal, the data analysis used non-
parametric Kruskal Wallis test.
Main results and the role of chance: The characteristics of the research
subjects (age and weight) of rats were in normal distribution. It was found that
there was no signiﬁcant difference in the weight of rats (P = 0.924) and the age
of rats (p = 0.556). There was no signiﬁcant difference on Fas ligand expression
in the three groups (p = 0.002). There was no signiﬁcant difference on apop-
totic index for three groups (p = 0.002). The comparison of Fas ligand expres-
sion and apoptotic index between the untreated rats and PCOS model rats was
1.6000 + 1.126 vs 3.377 + 1.065, p = 0,001; 2.533 + 1.322 vs 5.822 + 2.892,
P = 0.001. There was signiﬁcant difference on Fas ligand expression and apop-
totic index in PCOS model rats and PCOS model rats with stem cell (3.377 +
1.065 vs 0.933 + 0.529, p<0,0001; 5.822 + 2.892 vs 1.400 + 0.812,
p<0,0001). There was no signiﬁcant difference between the untreated rats and
PCOS model rats with stem cell (1.6000 + 1.126 vs 0.9333 + 0.529, p = 0.148;
2.533 + 1.322, p = 0.148 vs 1.400 + 0.812, p = 0.217). There was strong cor-
relation between the decreased Fas ligand expression and apoptotic index (R
= 0.94286).
Limitations, reasons for caution: The use of rats as samples could not
represent women with PCOS as a whole.
Wider implications of the ﬁndings: The result of the study is in line with
the previous literature regarding beneﬁt of stem cell in PCOS. Stem cells have
the effect on Fas ligand and apoptotic index at PCOS cases.
Trial registration number:Not applicable.
P-632 Cumulative live birth rate after in vitro maturation (IVM) in
patients with polycystic ovary syndrome (PCOS): retrospective
analysis of 1,110 cycles
N.A.V. Ho1, D.T. Pham1, H.A. Le1, M.T. Ho1, N.L. Vuong2
1IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam
2Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at
Ho Chi Minh City, Ho Chi Minh City, Vietnam
Study question: What is the cumulative live birth rate after IVM in patients
diagnosed with PCOS?
Summary answer: The cumulative live birth rate after IVM is satisfactory,
and similar to that achieved after IVF.
What is known already: IVM is an emerging assisted reproductive technol-
ogy technique that eliminates risk of ovarian hyper-stimulation syndrome in
patients with PCOS. However, there is a lack of data on the effectiveness and
safety of IVM cycles.
Study design, size, duration: This retrospective cohort study included
1,110 PCOS patients (1,110 IVM cycles, 1,206 transfers). The most common
indication for IVM was ovulation induction failure (93.5%). Mean age, body
mass index (BMI), and anti-Müllerian hormone levels were 28.8 ± 3.5 years,
21.9 ± 3.2 kg/m2, and 12.5 ± 3.6 ng/mL, respectively. The majority of patients
had primary infertility (81%); mean infertility duration was 3.6 ± 2.5 years.
Participants/materials, setting, methods: Women who were diagnosed
with PCOS (Rotterdam criteria) underwent IVM at a large center in Ho Chi Minh
City, Vietnam between 2014 and 2016. Human chorionic gonadotropin (hCG)
priming was used in 921 patients. Exclusion criteria included uterine abnormalities,
donor or pre-implantation genetic screening/diagnosis, loss to follow-up cycles
and cycles without embryo transfer. Data on the number of live births 12 months
after initiation of IVM were used to calculate the cumulative live birth.
Main results and the role of chance: Mean number of immature oocytes
retrieved per patient was 15.9 ± 10.2. Maturation and fertilization rates were
69.0 ± 23.9% and 68.7 ± 22.5%, respectively. First embryo transfer was fresh in
76.5% of patients and frozen in 20.4%. No case of ovarian hyperstimulation syn-
drome (OHSS) was reported. The ongoing pregnancy rate and live birth rate per
embryo transfer were 33.6% and 26.8%, respectively, and the 12-month cumula-
tive live birth rate was 29.1% (66% in singleton and 34% in twins). Median time
to ongoing pregnancy and live birth were 2.4 and 8.8 months, respectively. The
cumulative live birth rate was the same with or without hCG-priming (30.1% vs
24.3%, p = 0.13), but median time to live birth was shorter in hCG-priming vs
non hCG-priming cycles (8.7 vs 9.6 months, p<0.001) since a freeze-only strat-
egy was used when hCG-priming was not given. Multivariate logistic regression
analysis revealed that BMI, number of IVF attempts and number of good
embryos were signiﬁcant independent predictors of live birth after IVM.
Limitations, reasons for caution: The retrospective design of this study
was the most important limitation. In addition, pregnancy-related complications
(e.g. pre-eclampsia and diabetes mellitus) were not documented.
Wider implications of the ﬁndings: Cumulative live birth rate after IVM in
PCOS women was acceptable and similar to that after IVF. IVM is a convenient,
low cost option in these patients and has been shown to eliminate the risk of
ovarian hyper-stimulation; therefore, IVM may be an alternative to IVF in PCOS
women.
Trial registration number: not applicable.
P-633 Natural cycle cryopreserved embryo transfer: is a washout
period needed after a failure of fresh embryo transfer?
Y. Mizrachi, E. Horowitz, A. Ravhon, A. Shalev, S. Allouche, E. Gold,
M. Finkelstein, Z. Steinfeld, J. Farhi, A. Raziel, A.Weissman
IVF Unit, Department of Obstetrics and Gynecology- Edith Wolfson Medical Center-
and Sackler Faculty of Medicine- Tel Aviv University., Tel-Aviv, Israel
Study question: Does delaying modiﬁed natural cycle (mNC) frozen embryo
transfer (FET) after a failed fresh embryo transfer (ET) improve the live birth
rate (LBR)?
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Summary answer: In mNC FET cycles, delaying FET after a failed fresh cycle
does not improve the LBR.
What is known already: The optimal timing of FET after a failed fresh IVF-ET
cycle is controversial. While some studies suggest that a “washout” period is
unnecessary, others support the postponement of FET after a failed fresh cycle
for at least one menstrual cycle, out of concern that there may be residual
effects of the controlled ovarian stimulation, which may interfere with the sub-
sequent cycle. Until now, published studies included only artiﬁcial FET cycles,
and the use of the natural cycle, which is a popular and effective method for
FET, has not been investigated.
Study design, size, duration: A retrospective cohort study reviewing all ﬁrst
FET cycles performed after failed fresh ET attempts, between 2009 and 2016
(n = 212).
Participants/materials, setting, methods: The study included patients
aged 18-45, who underwent FET in a single university-afﬁliated IVF unit. Only
mNC FET cycles were included, where hCG was used for ovulation triggering,
and vaginal progesterone was given as luteal support. Cycles were divided
according to the time interval between oocytes retrieval and FET into immedi-
ate FET group (<50 days) and delayed FET group (≥50 days). Clinical preg-
nancy was deﬁned as fetal heart activity on ultrasound.
Main results and the role of chance: Overall, 127 patients had an immedi-
ate FET and 85 patients had a delayed FET. Mean age was 32.6 ± 5.1 and 34.0
± 5.6 respectively (p = 0.06), and mean number of previous failed cycles was
3.3 ± 2.6 and 4.0 ± 3.0, respectively (p = 0.09). The immediate and the delayed
FET groups did not differ with regard to LBR (22.8% vs. 14.1%, respectively, p =
0.11) or clinical pregnancy rate (27.6% vs. 20.0%, respectively, p = 0.21). On
multivariate regression analysis, delaying mNC FET was not associated with live
birth (aOR 0.56, 95%CI 0.25-1.22) or clinical pregnancy (aOR 0.61, 95%CI 0.30-
1.24), after controlling for woman’s age, infertility diagnosis, fresh ET protocol,
and the number of embryos transferred. The study was powered to detect a 2-
fold increase in the LBR, with alpha of 0.05 and power of 80%.
Limitations, reasons for caution: The study limitations include its retro-
spective design and small sample size. It was not sufﬁciently powered to detect
a small difference in LBR.
Wider implications of the ﬁndings: These data should reassure patients
and clinicians who desire to proceed with FET immediately after fresh IVF
failure.
Trial registration number: IRB reference number 0220-17-WOMC
P-634 iTRAQ-based proteomic proﬁle of ovarian granulosa cells
fromwomen with PCOS undergoing IVF/ICSI
H. Zhongying,W. Fan, Q. Ma,W. Huang
West China Second University Hospital Sichuan University, Department of Obstetrics
and Gynecology, Chengdu, China
Study question: To investigate the differences of protein expression in ovar-
ian granulosa cells between women with PCOS and the controls patients
receiving IVF/ICSI.
Summary answer: This study reveals the differences of protein expression in
granulosa cells from PCOS women and the controls undergoing IVF/ICSI.
What is known already: The pathogenesis of PCOS, the most common
cause of ovulatory disturbance leading to infertility, is not clear, particularly with
regard to proteins expressed in the ovarian granulosa cells from PCOS women.
Proteomic analysis is a powerful technological tool for investigations of human
diseases. iTRAQ is a quantitative method that has frequently been used in
proteomic studies and demonstrated to be effective and accurate in character-
izing various diseases. However, iTRAQ has not been applied in the proteomics
proﬁle of granulosa cells proteins from PCOS women undergoing IVF.
Study design, size, duration: Eight women undergoing IVF/ICSI with tube
factor or male factor infertility were enrolled in this study. Four patients with
PCOS and insulin resistance were included in PCOS group. The other four with
regular ovulatory cycles, normal basal FSH and LH levels, and with 15 or more
antral follicles were included as the control. Standard long GnRH agonist proto-
col was used in both groups. The dose of gonadotropin for ovarin stimulation is
FSH 100-150IU/d.
Participants/materials, setting, methods: The granulose cells were col-
lected soon after oocyte retrieval. The protein expression proﬁle of each sam-
ple was detected by isobaric tags for relative and absolute quantitation
(iTRAQ) technique coupled with liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). The up- and down-regulated proteins were analyzed
based on Gene Ontology and KEGG enrichment pathway. The proteins were
analyzed in terms of molecular function, cell location and biological processes
for ﬁnding the key protein molecules.
Main results and the role of chance: The estradiol levels in serum on hCG
administration day were comparable in PCOS group and the controls. There
was no difference in the number of ooccytes retrieved between the two
groups. A total of 3556 protein were identiﬁed, among which 486 differentially
expressed, including 406 up-regulated and 80 down-regulated protein in granu-
losa cells from women with PCOS. Gene ontology analysis showed that most
differentially expressed proteins were located in the extracellular region.The
differential expression proteins in PCOS groups and the controls were mainly
related to the protein binding and catalytic activity of some enzymes, and play
important role in the cellular process, metabolic process, biological regulation
and regulation of biological process. KEGG enrichment analysis linked 373 dif-
ferentially expressed protein to 27 different metabolic pathways, with most
proteins involved in the metabolic pathways, biosynthesis of secondary metabo-
lites, ribosome, and microbial metabolism in diverse environments.
Limitations, reasons for caution: The differentially expressed protein need
to be veriﬁed byWestern blot.
Study funding:This study was supported by grants from the National Natural
Science Foundation of China (81200453), Science & technology department of
Sichuan Province (2014KJT062-2014SZ0001), and Chengdu science and
Technology Bureau (2015-HM01-00494).
Wider implications of the ﬁndings: These iTRAQ results provides new
insights into the pathogenesis of PCOS, which may facilitate the discovery of
novel therapeutic targets to treat female infertility associated with PCOS.
Trial registration number:None.
P-635 To compare the effect of metformin plus myoinositol vs
metformin alone in terms of clinical pregnancy rate in infertile
PCOS women
R. Mahey1, A. Agrawal2, G. Kachhawa2, I. Kriplani3, V. Kulshrestha2,
R. Kumari2, R. Khadgawat2, A. Kriplani4
1All India Institute of Medical Sciences-, Obstetrics & Gynaecology, Delhi, India
2All India Institute of Medical Sciences- New Delhi, Obstetrics & Gynaecology, New
Delhi, India
3All India Institute of Medical Sciences- New Delhi- India, Obstetrics & Gynaecology,
New Delhi, India
4All india Instate of Medical Sciences- New Delhi, Obstetrics & Gynaecology, New
delhi, India
Study question: Whether combination of metformin and myoinositol is bet-
ter as compared to metformin alone in improving clinical pregnancy rate in
infertile PCOS women undergoing ovulation induction.
Summary answer: Clinical pregnancy was signiﬁcantly higher due to synergis-
tic effect of metformin and mho-inositol as compared to metformin alone in
infertile PCOS women undergoing ovulation induction.
What is known already: Polycystic ovary syndrome is the most common
cause of anovulatory infertility. Metformin has been used for decades as either
primary therapy or after failed ovulation induction in infertile PCOS women.
Mechanism of action of metformin is through improving peripheral insulin resist-
ance. Recently there is literature on use and function of inositols in PCOS
women which have been shown to act at the ovarian level where it improves
insulin resistance and improves oocyte quality. Myo-Inositol is the main type
required for improving oocyte quality. But there is no consensus on dose, dur-
ation and any beneﬁt of combining the two drugs.
Study design, size, duration: A randomised controlled trial was conducted
with 120 infertile PCOS women ( January 2016 to May 2017). Group I was the
intervention group and received Metfromin 500 mg+ Myoinositol 600 mg TDS
and Group II (n = 60) received Tab Metformin 500 mg TDS. The therapy was
continued for total 6 months and couples were advised to try for natural
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conception. Those who didn’t conceive after 3 months, were given ovulation
induction and intrauterine insemination.
Participants/materials, setting, methods: Baseline clinical and hormonal
proﬁle and infertility work up was done and patients were recruited according
to inclusion criteria. Clinical and hormonal parameters were repeated at 3
months. Improvement in HOMA-IR was calculated after 3 months of therapy.
Primary outcome was clinical pregnancy rate at the end of 6 months. Secondary
objective was ovulation rate, ongoing pregnancy rate, OHSS, abortion rate,
multiple pregnancy rate and improvement in clinical / metabolic proﬁle of
patients.
Main results and the role of chance: Baseline characteristics were compar-
able in two groups.After 3 months therapy, improvement in clinical and hormo-
nal parameters were comparable in two groups except for improvement in
menstrual cycle length and HOMA-IR index, which were signiﬁcantly better in
group I. more patients (14/60; 23.3%) conceived spontaneously in group I as
compared to group II (8/60;13.3%), though the difference was not statistically
signiﬁcant(p = 0.15). Overall conception rate was signiﬁcantly higher in group I
(38/60; 63.3%)) as compared group II (20/60; 33.3%) in Group II with p =
0.001. Five patients in group I and 1 patient in group II had multiple pregnancy.
one patient in group I had early onset ovarian hyper stimulation syndrome
(OHSS) and 4 had late onset OHSS. All late onset OHSS were due to multiple
pregnancies. Group II had no case of OHSS. The ongoing pregnancy rate
(POG>20 weeks) was 55% (33/60) in Group I and 26.67% (16/60) in Group II
which was signiﬁcantly higher in Group I (p = 0.002).
Limitations, reasons for caution: The main limitation was small sample
size. Serum progesterone were not done on day 21 of cycles to document ovu-
lation. More data on large sample size is required to document the synergistic
effect of metformin and myo-inositol in terms of live birth rate in infertile PCOS
women.
Wider implications of the ﬁndings: This was the ﬁrst study to document
better efﬁcacy of combined use of metformin and my-inositol over metformin
alone in infertile PCOS women. The two can be used to improve clinical preg-
nancy and ongoing pregnancy rate in infertile PCOS women undergoing ovula-
tion induction cycles.
Trial registration number: CTRI/2017/07/009021
P-636 Convenience and efﬁcacy of treatments for endometrial
preparation prior to frozen embryo transfer (FET): a randomised-
controlled trial comparing stimulated cycle (SC) vs natural cycle
(NC)
A. Lobersztajn1, M. Pasquier1, C. Piétin-Vialle1, C. Villette1,
A.L. Dessapt1, H. Bry1, C. Jung2, M. Brussieux2, N. Massin1
1Intercommunal Hospital- University Paris XII, Dpt of Gynecology- Obstetrics and
Reproductive Medecine, Creteil, France
2Intercommunal Hospital- University Paris XII, Clinical Research Center CRC, Creteil,
France
Study question: Can ovarian stimulation with rec-FSH used for endometrial
preparation for women undergoing FET be more convenient (number of visits
reduced) than natural cycle?
Summary answer: Endometrial preparation with rec-FSH decreases signiﬁ-
cantly the number of visits needed to schedule the FET, without impairing the
ongoing pregnancy rate.
What is known already: Before frozen embryo transfer, it is necessary to
ensure that the transfer is carried out at a time when the endometrium is recep-
tive, deﬁned as the “implantation window”. Endometrial preparation can be
performed by hormone replacement therapy, FSH stimulation, or close moni-
toring of a natural cycle. The natural cycle may appear more physiological but
more burdensome as it needs more monitoring, and reduces ﬂexibility for
patients and the organization of centers. To date, no study compares the con-
venience of FSH stimulation compared to natural cycle for FET.
Study design, size, duration: Prospective open-labeled randomised con-
trolled study in a public IVF center from may 2015 to oct 2017. To demonstrate
a decrease of one visit with SC compare to NC, the sample size was calculated
as 48 patients per group (two-sided alpha-error 0.05, power 90%), increased
by 30% for cancellation rate, ie 62 patients per group and 124 patients in total.
Participants/materials, setting, methods:Women aged 18 to 38 y under-
going their ﬁrst or second FET (day 2/3 embryos) were randomized to either
NC with close monitoring by ultrasound and hormonal measurements begin-
ning at day 12, or stimulation with rec-FSH 75 IU/day from day 6 to 11 and
HCG triggering when leading follicle > 17 mm. The study compares number of
visits (ultrasound and blood tests), progesterone levels before FET, HCG posi-
tive and ongoing pregnancy rates and spontaneous miscarriages.
Main results and the role of chance: 124 women were included, 62 in
both groups. Mean age (+SD) 32.8+4.0 vs 33.9+3.3 (p 0.11) for SC and NC
respectively, and other baseline characteristics, were comparable. The primary
outcome, number of visits, was signiﬁcantly lower in the SC group (3.7+0.9 vs
4.5+1.1, p<0.05). The number of blood tests (2,7+0.9 vs 3.5+1.1, p<0.05) as
well as the number of ultrasound performed (1.1+0.4 vs 1.4+0.6, p<0.05)
were also signiﬁcantly lower in the SC group compared to NC. The number of
FET during “non-opening” hours was lower in SC compared to NC but not
statistically different (21.1% vs 28.3%, p = 0.38). The cancellation rate was also
lower in SC compared to NC but not statistically different (8.1% vs 14.5%, p =
0,26). The mean progesterone level was signiﬁcantly higher in SC 4.2+1.7 vs
NC 3.2+1.2 ng/ml (p<0.05), measured 72 h before FET. The number of
embryo transferred was comparable in SC and NC (1.30+0.5 vs 1.38+0.5, p
= 0.40). The HCG positive rate and ongoing pregnancy rate per transfer were
higher in SC compared to NC but not statistically different (31.6% vs 24.5%, p
= 0.41 and 22.8% vs 20.7%, p = 0.79, respectively). The miscarriage rate was
higher in the SC vs NC but not statistically different (21.7% vs 13.3%, p = 0.51).
Limitations, reasons for caution: Monitoring cycles with strict criteria in
both groups limits the potential bias. The power does not allow us to conclude
on pregnancy and cancellation rates. A medico-economic study will be provided
as the higher cost with rec-FSH is balanced by the cost and constraints of more
visits and cancellation.
Wider implications of the ﬁndings: Burden of treatment is a major issue
for infertile patients. For women reluctant to have injections, NC is a good
option but women must be aware of increased monitoring. SC enables to
reduce monitoring and cancellation rates, and offers more ﬂexibility for patients
and IVF centers.
Trial registration number: N° EUDRACT: 2015-A00088-41 ClinicalTrials.
gov ID: NCT02834117
P-638 Function of Lin28a/Akt/mTOR in regulating premature
ovarian failure
J. Chen
the University of Hong Kong, Obestrics & Gynaecology, Hong Kong, Hong Kong
Study question: Does Lin28a play a role in regulating premature ovarian
failure?
Summary answer: Overexpression of lin28a in oocyte can enhanced the
activity of Akt/mTOR pathway, which may play a role in regulating premature
follicle activation.
What is known already: Infertility is a prevalence of disease that besets 15%
of couples in childbearing age around the world. Premature ovarian failure
(POF), deﬁned as primary ovarian defection and characterized as cessation of
menstruation or absent function of ovarian follicles in women under the age of
40, accounts for approximately 1% of infertility disease in women at childbear-
ing age. The study on the speciﬁc mechanism of how premature ovarian failure
occurs remained further exploration. Lin28a is mRNA binding protein and
highly expressed in embryogenesis. Akt/mTOR pathway is also widely
reported to be involved in regulating follicologenesis.
Study design, size, duration: Litter size, oocyte number and follicle number
of 2-month, 3-month, 4-month and 5-month old Lin28a and wild type mice
were counted (n = 6). 100 Oocyte that can be visualized under the microscope
was isolated from 3-month (n = 4) and 4-month (n = 4) Lin28a transgenic and
wild type mice, and the expression of proteins downstream of the Akt/mTOR
pathway including phosphorylated AKT (Ser 473), phosphorylated ribosomal s6
and phosphorylated S6K1 were analyzed by Western blotting and normalized
by beta-actin.
Participants/materials, setting, methods: Mice: wild type (ICR), lin28a
transgenic mice, female, the age is from 2-month old to 5-month old.
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The superovulation result was determined by pregnant mare’s serum
gonadotropin (PMSG)
Mouse Vasa homologue (Mvh) was used as marker when performing immuo-
histochemistry to identify oocyte during follicle counting.
western blot was conducted to detect the protein level.
Main results and the role of chance: Lin28a transcripts were found to be
highly expressed in the Lin28a mice ovaries. The immunoﬂuorescent staining
showed that Lin28a was mainly expressed in the cytoplasm of oocyte.
Consistent with the decrease of oocyte number and litter size at 4-month old
Lin28a transgenic mice, there was a decrease of primordial follicle and increased
primary follicle number of Lin28a transgenic mice from 4-month old compared
with wild type control. Expression of downstream molecule of Akt/mTOR
pathway-phosphorylated S6 and p-Akt (Ser473) in the oocyte was signiﬁcantly
increased in 3-month and 5-month old Lin28a transgenic mice, which indicated
that there may be an interplay of Lin28a/Akt/mTOR in regulating POF.
Limitations, reasons for caution: The technique for in vitro culture of prim-
ordial follicle is not available.
The human sample is not easy to be achieved.
Wider implications of the ﬁndings: Premature ovarian failure is an import-
ant factor that causes women infertility. However, current therapy for POF
patient is estrogen treatment. In this study, we explore the functional roles of
Lin28a and Akt/mTOR pathway to restore the ovarian reserve and open new
treatment strategy to patient who suffered from POF.
Trial registration number:Not applicable.
P-639 Hyperglycemia creates an optimal environment for
endometrial cells to exhibit resistance to metformin effects
A. Machado, T. Strowitzki, A. Germeyer
Universitätsfrauenklinik Heidelberg, Abt. für gynäkologische Endokrinologie und
Reproduktionsmedizin, Heidelberg, Germany
Study question: Evaluate the antiproliferative effect of therapeutic metformin
doses on endometrial cells when exposed to normal and hyperglycemic envir-
onment, imitating PCOS and diabetes.
Summary answer: Endometrial cells exposed to high glucose levels exhibit
resistance to anti-proliferative metformin effects, an effect potentially related to
estrogen receptors expression.
What is known already: Endometrial hyperplasia predisposes for the devel-
opment of endometrial cancer (EC). Women with PCOS are prone to endo-
metrial hyperplasia due to anovulatory cycles with chronic elevated estrogen
serum levels and an increased incidence of adipositas, knowns as an additional
risk factor for EC development. Metformin, an insulin-sensitizing agent com-
monly used in the treatment of type II diabetes, is also used off-label in women
with PCOS for ovulation induction. Recently, metformin treatment has been
suggested as therapy to inhibit cellular overgrowth and hyperplasia in several tis-
sues, however detail analysis of endometrial tissues under various conditions
remain to be examined.
Study design, size, duration: This study is an in vitro experimental study
using endometrial cell lines treated with metformin under different conditions
for 7 days.
Participants/materials, setting, methods: Two different endometrial
adenocarcinoma type I human cell lines (Ishikawa and HEC-1A cells) with differ-
ent estrogen receptors expression were treated long-term (7 days) with low
metformin doses (0 mM, 0.01 mM, 0.1 mM, 0.5 mM, 1 mM and 5 mM) cultured
in an environment with normal or high glucose concentrations. Moreover, all
groups were treated in the presence of 10-9 mM estradiol. The proliferation
rate and colony formation were performed using crystal violet assay.
Main results and the role of chance: Metformin treatment shows dose-
dependent manner effects in the colony formation of both cell lines, decreasing
the number and size of colonies independent of the glucose levels present in
the medium. Nevertheless, 5 mM metformin treatment showed expressive
inhibition effect (demonstrative data). Additionally, in a normal glucose environ-
ment 0.5 mM, 1 mM and 5 mM metformin doses decreased the proliferation
rate of HEC-1A cells 32% (P = 0.05), 38% (P = 0.02) and 55% (P<0.01),
respectively. However, in the presence of high glucose levels, only the highest
metformin treatment dose (5 mM) was able to decreased the proliferation rate
of this cells (40 %; P<0.01), showing signiﬁcant 15% (P<0.01) lower effect when
compared to the cells treated in an environment with normal glucose levels.
Moreover, this resistance was not observed in Ishikawa cells, where the range
between 0.5 mM to 5 mM metformin dose decreased signiﬁcantly the prolifer-
ation rate of this cells in normal (12%; P<0.01, 25%; P = 0.04 and 55%; P =
0.02 respectively) and high (18%; P<0.01, 37%; P<0.01 and 62%; P<0.01) glu-
cose levels. In addition Ishikawa cells did not show different response to metfor-
min effect when compared to cell cultured in normal glucose levels, suggesting
that this resistance may be driven by estrogen receptors expression.
Limitations, reasons for caution: These results are regarding to in vitro cell
line culture, therefore patient viability response are not measured.
Wider implications of the ﬁndings: Our data suggest that metformin may
be a long-term treatment strategy for anovulatory patients at risk, such as
PCOS women, preventing EC development. Furthermore, our results showed
the importance of glucose metabolism for the EC treatment response.
Trial registration number:Not applicable.
P-640 The axis and location of male and female pronuclei affect
both the determination of ﬁrst cleavage plane and further
development in human embryos
M. Nakaoka, K. Yumoto, K. Iwata, Y. Kai, T. Shimura, Y. Mio
Mio Fertility Clinic, Reproductive Centre, Yonago, Japan
Study question: Are the axis and location of male and female pronuclei
involved in both forming the ﬁrst cleavage plane in human embryos and their
further development?
Summary answer: Both the axis and location of male and female pronuclei
are involved in determining the ﬁrst embryonic cleavage plane and affecting fur-
ther development.
What is known already: Several studies have investigated how the site of
the second polar body (2nd PB) might be involved in plane formation in the ﬁrst
cleavage, with suggestions that the 2nd PB position deﬁnes the ﬁrst cleavage
plane in human embryos. Thus far, these studies remain controversial.
Recently, time-lapse monitoring has been used to monitor and analyze early-
stage embryonic development in a clinical setting.
Study design, size, duration: From January to July 2015, we conducted
time-lapse imaging (EmbryoScope®) for 40 hours under culture after intracyto-
plasmic sperm injection (ICSI) of 672 oocytes from couples with severe male
factor or fertilization failure. Of the oocytes, 485 were normally fertilized,
showing extrusion of the second polar body (2ndPB) with male and female pro-
nuclei (2PN); 361 of these that formed the ﬁrst cleavage plane and developed
to the 2-cell stage were analyzed for this study.
Participants/materials, setting, methods: Oocytes after ICSI were cul-
tured in an EmbryoScope® and images were acquired every 15 minutes for 40
hours to analyze the relationship between axis and location of the cytoplasmic
pronuclei and the ﬁrst cleavage plane. A straight line connecting the pronuclei
was deﬁned as the ‘2PN axis”. Based on the direction of ﬁrst cleavage relative
to the 2PN axis, embryos were further classiﬁed into two groups, parallel and
perpendicular, for evaluation of further development.
Main results and the role of chance: First, we analyzed the relationship
between the cytoplasmic 2PN location and the ﬁrst cleavage plane. Of the 361
fertilized embryos, 208 produced suitable imaging, with 198 (95.2%) forming a
cleavage furrow through or close to the 2PN location at ﬁrst cleavage.
Second, we investigated the relationship between 2PN axis and the ﬁrst
cleavage plane in 315 of the 361 embryos showing suitable images; 275 (87.3%)
formed a cleavage furrow parallel to the 2PN axis at the ﬁrst cleavage, while the
remainder (n = 40) formed a cleavage furrow perpendicular to the axis.
Third, we analyzed the relationship between 2PN axis and the ﬁrst cleavage
plane in the 24 (6.7%) of 361 embryos with pronuclei located at the cytoplasmic
margin. Of those, 20 image sets were suitable for analysis, with 18 (90.0%)
forming a cleavage furrow parallel to the 2PN axis at ﬁrst cleavage.
Finally, the quality of embryos was determined based on the modiﬁed
Istanbul Consensus. There were signiﬁcantly more poor-quality embryos in the
perpendicular group than in the parallel group (50.0% vs. 25.5%, P < 0.01).
Furthermore, clinical utility rate was signiﬁcantly lower in the perpendicular
group than in the parallel group (42.5% vs. 69.1%, P < 0.001).
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Limitations, reasons for caution: Since only ICSI zygotes were analyzed in
this study, we could not investigate the inﬂuence of fertilization methods on
subsequent development. Further studies including molecular biological ana-
lyses would help to deﬁne the mechanisms underlying determination of the ﬁrst
cleavage plane in human embryos.
Wider implications of the ﬁndings:We suggest that both the axis and the
location of pronuclei are essential for determining the ﬁrst cleavage plane and
ongoing embryonic development because the 2PN axis might be involved in
positioning the mitotic spindle poles.
Trial registration number:Not applicable.
P-641 Comparison of the effect of two combinations of
myo-inositol and D-chiro-inositol in women with polycystic ovary
syndrome who undergo ICSI
P. Llaneza1, M. Aragon2, V. Maldonado3, J. Lorente4, M.J. Bravo5,
J. Fonolla6, M.P. Diaz6, M. Olivares6, N. Mendoza7
1HUCA, Obstetrics and Gynecology, Oviedo, Spain
2Torrecardenas Hospital, Obstetrics and Gynecology, Almería, Spain
3Hospital of Jaén, Obstetrics and Gynecology, Jaén, Spain
4Reina Sofía Hospital, Obstetrics and Gynecology, Córdoba, Spain
5El Ángel Hospital, Obstetrics and Gynecology, Málaga, Spain
6Biosearch Life, Research, Granada, Spain
7Margen Clinic, Obstetrics and Gynecology, Granada, Spain
Study question: Do high doses of D-chiro-inositol (DCI) in combination with
myo-inositol (MIO) have any effect on pregnacy rate (PR) in women with
PCOS who undergo ICSI?
Summary answer: The combination of MIO with high dose of DCI achieved
a higher PR in women with PCOS who undergo ICSI.
What is known already: A recent meta-analysis indicates that MIO supple-
mentation is not sufﬁcient to improve oocyte or embryonic quality or the per-
centage of pregnancies in women with PCOS who undergo ICSI, opening the
possibilities to the combination with DCI. On the other hand, the evidence
with the use of DCI is scarce and heterogeneous, especially in relation to the
dose.
Study design, size, duration: A multicenter controlled, randomized,
double-blind, parallel-group study with two MIO-DCI formulations for 12
weeks. Study group (SG): 550 mg MIO + 150 mg DCI (Caronositol®) twice dai-
ly; Control group (CG): 550 mg MIO + 13.8 mg DCI 2 times daily.
Participants/materials, setting, methods: Inclusion criteria were: women
meeting Rotterdam criteria for PCOS with BMI <30 who undergo ICSI. Sixty
women with PCOS were recruited, four women were excluded after random-
ization and ﬁfty six started the treatment. Three of them did not complete the
intervention, two due to personal reasons (one in each group), and one woman
in the CG did not complete the study due to an accident. No baseline differ-
ences were observed between the two groups.
Main results and the role of chance: At the end of the 12-week study,
number of MII oocytes and percentage of good-quality embryos were also simi-
lar in both groups. However, the pregnancy and live birth rates were signiﬁ-
cantly higher in the SG than in the CG (65.5 vs 25.9, p = 0.003 and 55.2 vs
14.8, p = 0.002). Respect testosterone and insulin sensitivity, a signiﬁcant
improvement was found from baseline to end of the study in both groups.
Limitations, reasons for caution: Results should be taken with caution due
to the short sample size.
Wider implications of the ﬁndings: A combination of 550 mg MIO +
150 mg DCI twice daily could improve pregnancy and live birth rates in women
with PCOS who undergoing ICSI.
Trial registration number:NCT03201601
P-642 All you need to you know about resistant ovary syndrome: a
systematic review and foundation for future research
C. Zundel, C.B. Lambalk
VU University Medical Center, Department of Obstetrics and Gynaecology,
Amsterdam, The Netherlands
Study question: What is the current standpoint in research and clinical man-
agement of resistant ovary syndrome (ROS)?
Summary answer: ROS presents a heterogeneity of etiologies (mutations
and antibodies) and phenotypes. Hormonal therapies and in-vitro maturation
(IVM) have led to pregnancies resulting in live-births.
What is known already: ROS is a rare disorder characterized by a normal
amount of follicles that are arrested in development despite a high level of FSH.
Patients thus have a resistance to FSH. This leads to infertility. According to
Grynberg (2013), ROS is frequently misdiagnosed as premature menopause.
This is because ROS is largely unknown to physicians. Indeed, there are over a
hundred papers reporting ROS cases but, remarkably, there is no review on the
presentation of ROS and its treatment options. Multiple hypotheses on the eti-
ology of ROS have been made. But an overview of these hypotheses and the
evidence found lacks.
Study design, size, duration:We conducted a systematic review of all pub-
lished articles discussing ROS. We searched for papers on PubMed, Cochrane
and Embase. The ﬁnal search was performed on 26 January 2018. We also
identiﬁed articles through cross-referencing. We then critically reviewed all the
publications found.
Participants/materials, setting, methods: We included all articles ever
published concerning women with the characterizing features of ROS, namely
oligo- or amenorrhea, post-menopausal FSH level, a normal amount of follicles
and an arrest in folliculogenesis. All papers regarding FSH receptor (FSH-R)
mutations in women were also included. We excluded cases of subjects with a
karyotype other than 46-XX. We also excluded all articles in which neither the
abstract nor the text was in English, French, Dutch, Spanish or German.
Main results and the role of chance: From the articles that we found, we
drew the typical clinical picture of ROS. Along with the characterizing features
of ROS, patients have normal internal and external genitalia. Besides, most
patients have normal secondary sex characteristics that developed on time. At
the time of diagnosis, patients mostly have either primary or secondary amen-
orrhea, which is often preceded by oligomenorrhea. Accompanying elevated
FSH, LH is often increased and estradiol is usually decreased. Multiple papers
reported treatment attempts. Outcomes varied from absence of ovarian
response to pregnancies resulting in at-term births of healthy babies. The most
promising treatments used were clomiphene, estrogen, hMG with or without
hCG, combinations of estrogen and progesterone, and, recently, IVM. ROS
could be explained by a mutation in the FSH-R gene or in a molecule regulating
the FSH-R or involved in the pathway downstream of FSH-R activation.
Another possible cause is antibodies against FSH, against FSH-R or against a
molecule involved in its regulation or the downstream pathway. The absence or
presence of several of these causative factors, along with the associated cellular
disturbances, has been shown in multiple ROS patients. The heterogeneity in
causes and phenotypes and in particular the relationship between these two is
fascinating.
Limitations, reasons for caution: It is likely that many cases were not pub-
lished, especially those who did not respond to treatment (Vaitukiatis 1986).
Additionally, the search and analyzing work of this review were performed by
only one person. Finally, a few articles could not be taken into account due to
our language restrictions.
Wider implications of the ﬁndings: This study is the only existing review
on ROS. It provides a clear view on the current standpoint in clinical manage-
ment of ROS. It also reports what is known on the etiology of ROS and sets the
path for future research, which must aim for treatment improvement.
Trial registration number: not applicable.
P-643 Higher menopausal age but no differences in parity in
women with polycystic ovary syndrome as compared to controls
M. Forslund1, K. Landin-Wilhelmsen2, J. Schmidt3, M. Brännström1,
P. Trimpou2, E. Dahlgren1
1Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg
2Institute of Medicine, Sahlgrenska Academy, University of Gothenburg
3Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg
Study question: To study the menopausal age in women with polycystic
ovary syndrome (PCOS) as compared to women without PCOS.
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Summary answer: Menopause is clearly delayed in women with PCOS and
that is also reﬂected in lower FSH levels.
What is known already: Models with anti-Müllerian hormone predict a later
menopause in women with PCOS. A cross-sectional study using questionaires
showed a later menopause in women stating that they have PCOS diagnosis.
Study design, size, duration: A prospective cohort study of women with
PCOS compared to age-matched, randomly selected controls. Twenty-seven
women, diagnosed with PCOS in 1992 were re-examined in 2016. Of the initial
cohort of thirty-three, ﬁve had died and one declined participation. Controls
were recruited from another study, these women were initially examined 1995
and re-examined in 2008. 94 controls were included.
Participants/materials, setting, methods: The PCOS women (mean age
52.4 years, range 42-60 years) were diagnosed 24 years ago. They all met
Rotterdam criteria. Age-matching was used to derive a control group from
women randomly selected from the same geographic area. PCOS n = 27.
Controls n = 94. The women were examined using structured interviews,
anthropometric measures, blood pressure, and blood tests.
Main results and the role of chance: Among women with PCOS, 37% sta-
ted that they were postmenopausal, compared to 57% of the controls (ns). The
mean menopausal age in women with PCOS (53.3 years, n = 7) was signiﬁ-
cantly (p<0.01) higher than in controls (49.3 years n = 52). Serum-FSH levels
were signiﬁcantly (p = 0.02) lower in PCOS (31.7 IU/L) than in controls (50.1
IU/L). There was no difference in parity between women with PCOS (1.9 ±
1.3 children) compared to controls (1.7 ± 1.0 children).
Limitations, reasons for caution: The numbers of women that could state
their menopausal age were lower in the PCOS group, mainly because a bigger
proportion of them had not yet become postmenopausal as compared to con-
trols despite the age-matchning.
Wider implications of the ﬁndings: The results supports previous predic-
tion models. The prolonged ovarian hormonal activity might be a protective fac-
tor for cardiovascular events later in life in women with PCOS.
Trial registration number: not applicable.
P-645 Comparative analysis of structural differences of Ovaleap
and GONAL-f: site-speciﬁc glycosylation mapping and cell signaling
activation
M. Lispi1, R. Mastrangeli2, E. Galano3, A. Palmese3, F. Cutillo2,
L. Casarini4, L. Riccetti4, S. Longobardi1, M. Simoni4
1Merck Serono S.p.A, Fertility Medical Affairs, Roma, Italy
2Merck Serono S.p.A, Biotech Development Programme, Roma, Italy
3Merck Serono S.p.A, Protein Chemistry, Roma, Italy
4University of Modena and Reggio Emilia, Unit of Endocrinology- Dept. Biomedical-
Metabolic and Neural Sciences, Modena, Italy
Study question: Could differences in site-speciﬁc glycosylation between biosi-
milar (Ovaleap
®
) and originator (GONAL-f
®
) recombinant-human follicle-stimu-
lating hormone (r-hFSH) impact calcium (Ca2+)-mediated cell signalling
activation with these treatments?
Summary answer: Site-speciﬁc glycosylation differences between Ovaleap
and GONAL-f, including greater N-glycolylneuraminic acid content with
Ovaleap, may impact FSH-mediated intracellular Ca2+ increase and the poten-
tial for immunogenicity.
What is known already: It is well known that the glycosylation proﬁle of FSH
can affect the molecule’s receptor-binding efﬁcacy, half-life and clearance, all of
which have an effect on the overall biological activity of FSH. In particular, the
glycosylation proﬁle at asparagine 52 of the alfa chain (αAsn-52) is known to
affect FSH receptor binding and signal transduction. Differences in manufactur-
ing processes can lead to differences in the glycosylation patterns between bio-
similar and originator recombinant FSH preparations, including the amount of
non-human N-glycolylneuraminic acid that is incorporated, which may have
safety implications because N-glycolylneuraminic acid can increase the risk of
immunogenicity in humans.
Study design, size, duration: Glycopeptide mapping and Ca2+-mediated
cell-signaling activation were assessed in three batches of Ovaleap (S06622,
S27266, R38915) and three batches of GONAL-f (199F005, 197F049,
197F051). The Ovaleap batches had 4–11 months until expiry and the
GONAL-f batches had 5–7 months until expiry.
Participants/materials, setting, methods: Glycopeptide mapping was
performed after chymotryptic digestion and separation with 0.1% TFA in aceto-
nitrile/water on a hydrophilic interaction liquid chromatography column using
Acquity UPLC coupled to a Xevo G2-S QTof Mass Spectrometer (Waters,
Milford, MA, USA). Intracellular Ca2+ increase with 10 nM or 100 nM of the
three batches of Ovaleap was compared with the increase with equimolar
doses of GONAL-f in FSH receptor-transfected HEK293 cells using a biolumin-
escence resonance energy transfer assay.
Main results and the role of chance: Site-speciﬁc glycosylation mapping
revealed differences in glycosylation patterns between Ovaleap and GONAL-f.
In particular, the batches of Ovaleap had greater sialylation at all N-
glycosylation sites than GONAL-f (Z-number range (Ovaleap vs. GONAL-f):
αAsn-52: 178.1–183.8 vs. 173.9–176.0; αAsn-78: 183.7–188.5 vs.
175.6–178.6; βAsn-7: 305.6–311.0 vs. 284.7–290.9; βAsn-24: 211.6–219.5 vs.
184.9–189.2). N-glycolylneuraminic acid content was also higher in batches of
Ovaleap, with only trace amounts of N-glycolylneuraminic acid present on
GONAL-f (ranges Oveleap vs. GONAL-f: 2.6–4.7% vs. 0.0–0.4%). Differences
in the potential for Ca2+-mediated cell-signaling activation were observed
between Ovaleap and GONAL-f. Although 10 nM and 100 nM GONAL-F, as
well as the positive control thapsigargin, induced a 200–300-fold increase of
intracellular Ca2+ compared with baseline, equimolar doses of all the three
batches of Ovaleap failed to induce an increase in Ca2+. It can be speculated
that the differences in Ca2+-mediated cell-signaling activation may be the result
of the differences in the glycosylation proﬁles observed between the FSH
preparations.
Limitations, reasons for caution: These analyses were performed in-vitro.
The potential impact and clinical relevance of the glycosylation differences on
efﬁcacy and risk of adverse events cannot be conﬁrmed from these ﬁndings.
Wider implications of the ﬁndings: Differences in glycosylation among
FSH preparations have the potential for profound effects on the efﬁcacy and
safety of this treatment and these require further investigation using in vitro
models and clinical settings.
Trial registration number:Not applicable.
P-646 Further characterization of a newly described
hypo-androgenic PCOS-like phenotype based on adrenal and
ovarian hormone proﬁles
N. Gleicher1, S. Soldin2, V. Kushnir1, D. Barad1, S. Darmon1,
D. Albertini1, C. Stratakis3
1Center for Human Reproduction, n/a, New York- NY, U.S.A.
2Clinical Center, Department of Laboratory Medicine, Bethesda- MD, U.S.A.
3NICHD, Section of Endocrinology and Genetics, Bethesda- MD, U.S.A.
Study question: How do hormone proﬁles in women with the recently
described hypo-androgenic PCOS-like phenotype (H-PCOS) differ from
controls?
Summary answer: They differ signiﬁcantly in almost all hormones of adrenal
and ovarian origins.
What is known already: Women with H-PCOS are lean, characterized by
excessively high AMH values for age and/or in comparison to FSH levels, by
low testosterone (T), low dehydroepiandrosterone-sulfate (DHEAS) and high
prevalence of autoimmunity (Gleicher et al; J Steroid Biochem Mol Biol
2017;167:144-152). They at young ages are hyper-androgenic and, likely, dem-
onstrate mild hyper-cortisolism but in late 20 s to early 30 s, suddenly, become
hypo-androgenic and, often, show mild hypo-cortisolism (Gleicher et al.,
Endocrine 2018; doi:10.1007/s12020-017-1498-8).
Study design, size, duration: This was a prospective study involving 7 H-
PCOS patients and 9 controls.
Participants/materials, setting, methods:We prospectively investigated 3
young oocyte donors deﬁned as H-PCOS, 4 control donors, 4 older H-PCOS
infertility patients undergoing IVF, and 5 control patients in early follicular phase
for cortisone, cortisol, corticosterone, 11-deoxycortisol, androstenedione, T, 17-
OH-progesterone, progesterone, DHEA and Cyp17(17-0 P/P). Bloods were
obtained and frozen at CHR, and transported de-identiﬁed and coded to the
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NICHD for analyses by ultra-ﬁltration LCMS/MS (Stolze et al., J Steroid Biochem
Mol Biol 2016;162:110-116). Statistical analyses were performed at CHR.
Main results and the role of chance: H-PCOS donors and patients were of
similar ages as controls (24.0 ± 2.6 vs. 26.8 ± 7.6 and 39.5 ± 7.6 vs.37.8 ± 6.1
years), had signiﬁcantly higher AMH than controls (8.2 ± 1.9 vs.2.6 ± 07 and
8.1 ± 3.3 vs.1.2 ± 0.9 ng/mL). In non-parametric statistical analyses, H-PCOS
donors did not differ from control donors in any of the other hormones. H-
PCOS patients, however, demonstrated lower cortisol (P = 0.02), cortico-
sterone (P = 0.04) and 11-deoxicortisol P = 0.04). Comparing H-PCOS donors
to older H-PCOS patients no hormonal differences were apparent, while com-
paring normal control donors and patients, androstenedione was lower in
patients than donors (P = 0.02), as was testosterone (P = 0.04) and DHEA (P
= 0.04). Adjusting for AMH values, H-PCOS donors had higher corticosterone
(P = 0.007), 11-deoxicortisol (P = 0.003), progesterone (P = 0.007 and Cyp17
(P = 0.021), while older H-PCOS patients demonstrated lower cortisol (P =
0.045), corticosterone (P = 0.046) but higher androstenedione (P<0.0001),
higher testosterone levels (P = 0.0002) and higher Cyp17 (P = 0.04).
Comparing young H-PCOS donors with older H-PCOS patients, donors had
higher cortisone (P = 0.03), cortisol (P<0.0001), testosterone (P = 0.01), 17-
OHP (P = 0.04) and DHEA (P = 0.02), while among controls, donors had high-
er cortisone than patients (P = 0.03), cortisol (P<0.0001), androstenedione (P
= 0.001), testosterone (P = 0.03) but lower corticosterone (P = 0.03), 11-
deoxicortisol (P = 0.04).
Limitations, reasons for caution: Considering the small number of study
subjects, the data presented here have to be viewed as preliminary.
Wider implications of the ﬁndings: These data reafﬁrm at all ages signiﬁ-
cant differences in adrenal and ovarian function between H-PCOS-like pheno-
types and controls, supporting a previously reported strong interdependence
between adrenal and ovarian steroid hormone secretion (Gleicher et al; J
Steroid Biochem Mol Biol 2017;167:144-152; Gleicher et al., Endocrine 2018;
doi:10.1007/s12020-017-1498-8).
Trial registration number: not applicable.
P-647 SerumAMH concentration has limited prognostic value for
follicle density of primordial and primary follicles questioning AMH
as a parameter for the real ovarian reserve
M. VonWolff1, M. Roumet2, J. Reinsberg3, H. Van der Ven3,
N. Sänger4, J. Liebenthron3
1University of Bern - Inselspital, Department of Endocrinology & Reproductive
Medicine, Bern, Switzerland
2CTU Berne- Institute of Social and Preventive Medicine ISPM, University of Berne,
Berne, Switzerland
3Medical University of Bonn, Department of Gynaecological Endocrinology and
Reproductive Medicine, Bonn, Germany
4Universirty of Frankfurt, Universirty Women’s hospital, Frankfurt, Germany
Study question: What is the prognostic value of Anti mullerian hormone
(AMH) to estimate the ovarian density of ovarian primordial and primary
follicles?
Summary answer: The prognostic value of AMH to estimate ovarian follicle
density is low due to poor correlation of both parameters.
What is known already: AMH is a predictor for ovarian response in IVF
therapies. AMH is also used as a marker of ovarian reserve to predict the risk
of premature ovarian insufﬁciency (POI) in gonadotoxic therapies and to esti-
mate the amount of cryopreserved ovarian tissue needed for transplantation.
However, the accuracy of AMH to estimate the ovarian response is limited.
Furthermore, the concentration of AMH poorly correlates with the risk of
developing POI after gonadotoxic therapies. The reasons for the limited use of
AMH as a prognostic factor are poorly understood.
Study design, size, duration: 823 females (29.5 y [23.3; 33.1]) underwent
ovarian tissue freezing before gonadotoxic therapy within the network
FertiPROTEKT 09/2011 – 08/2016. Based on the analysis and correlation of
histologically determined follicle density (three standardized biopsies per ovary,
analysed after tissue digestion) and serum AMH concentrations (analysed by
the same ELISA assay) the prognostic accuracy of AMH to estimate ovarian fol-
licle density was evaluated.
Participants/materials, setting, methods: Women with ovarian surgery
and genetic causes of low ovarian reserve were excluded. First, the crude and
adjusted associations between AMH and follicle density were assessed using
regression analysis, adjusting for age and disease category. Second, regression
models were used to predict follicle density as a function of (i) AMH concentra-
tion, (ii) AMH concentration and women age. In order to discuss the
accuracy of the derived predictions the 50 and 95% prediction intervals were
calculated.
Main results and the role of chance: AMH concentrations and follicular
density are signiﬁcantly correlated (P<0.001). However, the correlation coefﬁ-
cient of 0.26 reveals an only moderate relationship between the two variables.
Accordingly, the prediction intervals of follicle density are rather wide.
Regression analysis did not reveal a signiﬁcant effect of disease category on
follicle density whereas a relationship was found between age and follicle dens-
ity in a quadratic regression analysis. Modelling the follicle density as a function
of both AMH and age the predicted follicle density of women aged 10, 20, 30
and 40 y and the associated 50 and 95% prediction intervals were derived:
log10(follicle density) ~ 1.62 + 0.247 × log10(AMH) - 0.049 × age/10 –
0.067 × (age/10)2
For instance, in women with an AMH concentration of 2.0 ng/ml, the pre-
dicted density was 38.2 per mm3 at the age of 10 y (50% prediction interval
(PI): 18.7;78.1). The density decreased to 21.4 follicles per mm3 at the age of
20 y (50% PI: 10.6;43.4), to 8.8 at the age of 30 y (50% PI: 4.4;17.9) and to 2.7
at the age of 40 y (50% PI: 1.3;5.4). The large prediction intervals highlight the
fact that knowing the patient’s age and AMH value is not sufﬁcient to reliably
predict the follicle density.
Limitations, reasons for caution: Even though three biopsies were taken
from each ovary to increase the accuracy of the analysis, some inaccuracy can-
not be excluded.
Wider implications of the ﬁndings: As the data provide evidence for the
limited prognostic value of AMH for the density of primordial and primary folli-
cles, AMH as a parameter for the real ovarian reserve has to be questioned.
Ovarian biopsies might be a better tool to estimate the amount of ovarian tis-
sue needed for transplantation.
Trial registration number:Not applicable.
P-648 Centrosome and spindle organization variations in mouse
oocytes matured in vitro under different conditions do not correlate
with developmental competence after fertilization
F. Peris1, S. Alonso1, J. Santaló1, M.T. Paramio2, E. Ibanez1
1Universitat Autònoma de Barcelona, Biologia Cel·lular- Fisiologia- Immunologia-
Facultat de Biociències, Bellaterra, Spain
2Universitat Autònoma de Barcelona, Ciència Animal i dels Aliments- Facultat de
Veterinaria, Bellaterra, Spain
Study question: Is maturation, fertilization and development of mouse
oocytes differentially affected by addition of follicular ﬂuid from adult (AFF) or
prepubertal (PFF) goats to maturation medium?
Summary answer: In vitro maturation conditions resulted in signiﬁcant
variations in centrosome-spindle organization in metaphase-II oocytes, but
embryonic development after fertilization was not correlated with these
variations.
What is known already: Addition of intraspeciﬁc follicular ﬂuid to matur-
ation medium improves both nuclear and cytoplasmic maturation of oocytes in
most species, but the effect of interspeciﬁc follicular ﬂuid has not been investi-
gated in mouse oocytes. In this species, centrosome and spindle organization
has been shown to differ between in vivo and in vitro matured oocytes and
among oocytes matured under different in vitro conditions. These variations
have been suggested to be related to differences in developmental competence
among these oocyte populations. This led to the proposal that centrosome-
spindle organization characteristics could be considered as potential biomarkers
for oocyte quality.
Study design, size, duration: We analyzed spindle and centrosome organ-
ization in metaphase-II mouse oocytes matured in vitro (IVM) for 16-18 h in the
presence of 10% fetal bovine serum (FBS, n = 97), AFF (n = 106) or PFF (n =
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96), using in vivo ovulated oocytes (IVO) as controls (n = 70). Fertilization and
development to the blastocyst stage were also recorded after in vitro fertiliza-
tion for 3 h and culture for 120 h (IVO n = 123, IVM-FBS n = 114, IVM-AFF n
= 96, IVM-PFF n = 114).
Participants/materials, setting, methods: Mouse B6CBAF1 cumulus-
oocyte complexes matured in the presence of FBS, AFF or PFF and control IVO
oocytes were ﬁxed, immunostained for alpha-tubulin, pericentrin and chroma-
tin, and observed under an epiﬂuorescence microscope to evaluate nuclear
maturation status, spindle dimensions and morphology, and number and conﬁg-
uration of cytoplasmic and spindle-pole centrosomes. In a second set of experi-
ments, IVM and IVO oocytes were fertilized in vitro and fertilization and
blastocyst rates were determined.
Main results and the role of chance: Nuclear maturation rates were
equivalent among IVM groups (70-82%). In contrast to fusiform spindles
with pointed poles and solitary pericentrin foci found in IVO oocytes, IVM-
FBS and IVM-AFF oocytes exhibited barrel-shaped spindles with wider poles
(p<0,0001) and multiple pericentrin foci in 91-96% of them (p<0,0001).
IVM-PFF oocytes showed an intermediate phenotype between IVO and the
other two groups of IVM oocytes, displaying rhomboid-shaped spindles with
an intermediate pole width and multiple pericentrin foci in 70% of them
(p<0,0001). Overall, a signiﬁcant decrease in spindle length (except for IVM-
FBS), and a signiﬁcant increase in spindle width and area (except for IVM-
PFF) was evident as a result of IVM. Regarding cytoplasmic centrosomes,
IVM oocytes consistently exhibited lower numbers of cytoplasmic pericentrin
foci (9-10) than IVO oocytes (15; p<0,001) and a more frequent presence
of pericentrin-positive foci in the polar body (22-25% vs 3%; p = 0,0001).
Despite the differences in centrosome-spindle organization among the IVM
groups and between IVO and IVM oocytes, fertilization rates were equiva-
lent among all of them (90-93%) and blastocyst rates were consistently low-
er in IVM (41-47%) than in IVO oocytes (90%; p<0,0001). Thus, the
differential effect of AFF and PFF in centrosome-spindle organization was
not correlated with developmental potential.
Limitations, reasons for caution: Although morphological and morphome-
trical characteristics of the spindle and spindle-pole centrosomes in IVM-PFF
oocytes more closely resembled those of IVO oocytes, compared with IVM-
AFF or IVM-FBS oocytes, the spindle-centrosome organization of IVO oocytes
was not fully recapitulated. Moreover, other maturation deﬁciencies may
account for their lower developmental potential after fertilization.
Wider implications of the ﬁndings: Our data support previous results
showing that IVM conditions affect centrosome-spindle organization in mouse
oocytes. However, contrary to some of these reports, partial recapitulation of
this organization did not translate into an improved development after fertiliza-
tion. Thus, centrosome-spindle organization characteristics alone may not con-
stitute suitable biomarkers for oocyte quality.
Trial registration number:Not applicable.
P-649 Comparison of oocyte morphology and embryo quality
among women with different polycystic ovary syndrome phenotypes
A. UK1, C. Grysole2, L. Keller1, H. Behal3, C. Decanter2,
D. Dewailly2, G. Robin2, A.L. Barbotin1
1lille university hospital, reproductive biology, Lille, France
2Lille university hospital, Department of Endocrine Gynecology and Reproductive
Medicine, Lille, France
3Lille university hospital, Department of biostatistics, Lille, France
Study question: Does polycystic ovary syndrome (PCOS) phenotype inﬂu-
ence oocyte morphology and embryo quality?
Summary answer: Women with different PCOS phenotypes exhibited
similar oocyte and embryo quality following controlled ovarian stimulation.
What is known already: In PCOS, phenotype A (or full phenotype com-
bining hyperandrogenism (HA), oligo-anovulation (OA) and polycystic
ovarian morphology (PCOM)) and phenotype B (HA+ OA) are con-
sidered as the more severe phenotypes. Indeed, these phenotypes are
associated with higher risk of comorbidities. Additionally, it has recently
been demonstrated that PCOS phenotype A and B are associated with
lower clinical pregnancy rate (CPR) as compared to control patients in
IVF/ICSI cycles.
Consequently, oocyte quality is suspected to be impaired in cases of combin-
ation of OA and HA. However, little is known about oocyte quality and embryo
quality among women with different PCOS phenotypes.
Study design, size, duration: In this retrospective study, we have ana-
lyzed data collected from women undergoing ICSI cycles between 2006
and 2015. We identiﬁed 109 PCOS patients. According to their phenotype,
patients were split into 4 subgroups: PCOS A (PCOM + HA + OA, n =
41); PCOS C (PCOM + HA, n = 31); PCOS D (PCOM + OA, n = 37).
As only one patient was diagnosed with PCOS phenotype B, therefore the
patient was excluded.
Participants/materials, setting, methods:Oocyte quality was the primary
outcome and was assessed using morphological criteria. The following abnor-
malities (fragmented ﬁrst polar body, abnormal zona pellucida, large perivitelline
space, material in perivitelline space, abnormal shape of oocyte, granular cyto-
plasm and intracytoplasmic vacuoles) were recorded. A total of 602 metaphase
II (MII) oocytes for the phenotype A, 462 MII for the phenotype C and 432 MII
for the phenotype D were compared. Secondary outcomes included embryo
quality and reproductive outcomes.
Main results and the role of chance: After controlling for confounders in
logistic regression analysis, our results show that the mean numbers of
total and MII oocytes rates did not differ signiﬁcantly between the three
phenotypes. No signiﬁcant difference was found in the oocyte quality
between the three groups. Fertilization rates were similar between PCOS
women with phenotype A, C and D (61.8%, 59.1% and 59.2% respect-
ively, p = 0.93). In addition, the percentage of top quality embryos
obtained on day 2-3 did not signiﬁcantly differ regardless of the PCOS
phenotype (49.8%, 50.9% and 51.7% respectively, p = 0.86). No differ-
ence was found in the implantation rate (31.5%, 28.8% and 32.1%
respectively, p = 0.84), CPR (49.1%, 51.3% and 45.5% respectively, p =
0.73) and live birth rate (35.8%, 41.0 and 39.4% respectively, p = 0.51)
between the 3 groups. Altogether, our ﬁndings suggest that PCOS pheno-
types have no impact on the oocyte and embryo quality or the repro-
ductive outcomes following ICSI attempts.
Limitations, reasons for caution: This is a retrospective study with inher-
ent limitations. The main bias is represented by the phenotypic distribution in
our study population with only one patient diagnosed with PCOS phenotype B.
Indeed, an excessive serum anti-Müllerian hormone level is used as a surrogate
for PCOM criterion in our centre.
Wider implications of the ﬁndings: In this novel retrospective study,
we compared oocyte morphological quality and embryo quality in three
different phenotypes of PCOS patients. These ﬁndings suggest for the ﬁrst
time that different PCOS phenotypes have no impact on oocyte and
embryo quality.
Trial registration number: not applicable.
P-650 Women’s perceptions regarding early menopause eHealth
resources to facilitate self-care
L. Yeganeh, A.J. Vincent, M. Gibson-Helm, H. Teede, J.A. Boyle
School of Public Health and Preventive Medicine- Monash University, Monash Centre
for Health Research and Implementation, Melbourne, Australia
Study question: What are women’s needs and perspectives regarding early
menopause (EM) eHealth resources?
Summary answer: Most women with EM have access to multiple electronic
devices and are supportive of a comprehensive co-designed EM eHealth web-
site or App with multiple features.
What is known already: Provision of evidence based information and
resources are integral to high quality collaborative patient centred care,
improved patient experience, promotion of best practice and optimal health
outcomes. Consumer and health professional knowledge gaps regarding EM
exist and potentially contribute to the observed delayed diagnosis, variation
in management, dissatisfaction with care, non-compliance with cancer treat-
ment, poor risk perception and poorer outcomes. With continuing increases
in digital device ownership, women are seeking electronic resources to
i439Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
facilitate knowledge access and enhance self-health management, yet current
EM related eHealth resources are either lacking or are inadequate for
women’s needs.
Study design, size, duration: A cross-sectional study of 386
Australian women with EM recruited between May and November 2017.
The study was approved by the Monash Health Human Research Ethics
Committee.
Participants/materials, setting, methods: Women with a self-reported
diagnosis of EM, recruited from hospital clinics or the community, completed an
online or paper survey. Exclusion criteria were no formal EM diagnosis or non-
Australian residence (n = 123). Data collection included: demographics, med-
ical history, current use of electronic resources to manage health/EM, support
for an App, desired features of the ideal App and EM information topics. Data
analysis included descriptive statistics (mean ±standard deviation) and logistic
regression.
Main results and the role of chance: Of 263 women, the mean age was
53.81(±10.68) with EM diagnosed at age 38.54 (±5.27). Most participants
were diagnosed with EM ≥5 years ago (78%), lived in metropolitan areas
(55%) and had post-school qualiﬁcations (71%). Reported cause of EM was
surgical removal of ovaries (30%), unknown (29%), cancer therapy (26%), or
autoimmune/genetic/metabolic (14%). Most women had a smartphone
(84%) and 98% of those owned multiple electronic devices. Women
reported they would prefer a website (59%) to an App (38%) to manage
EM with only 37% reporting current App use to manage health and 2% to
manage EM. However, 67% women thought an App would be helpful and
45% would be likely to use it. Future menopause App use was less likely
with increasing age (OR, 0.96; CI, 0.93-0.99, p = 0.008) but there were no
signiﬁcant associations with residential location, education, time since diagno-
sis, or cause of EM. Features considered very important/essential to include
in an EM App were: evidence-based information (81%), question prompt list
(78%), opportunities to ask an expert (76%) and ability to record symp-
toms/ health measures (67%). EM topics rated very important/essential to
include (>80% respondents) were: diagnosis, symptoms, physical/psycho-
logical effects, long term implications, hormonal/non-hormonal management
and lifestyle changes.
Limitations, reasons for caution: Potential response bias in relation to
age/self-reported diagnosis of EM. These ﬁndings may be less relevant to non-
English speakers, women with lower literacy/ educational attainment and those
without internet access.
Wider implications of the ﬁndings: The results of this study will help
development of high quality eHealth resources aiming to improve self-care and
health outcomes. Further research is required to address limitations, and co-
develop resources, including user testing and evaluation.
Trial registration number:Not applicable.
P-651 AMH variability and its implications for the number of
oocytes retrieved following individualized dosing with follitropin
delta
S. Nelson1, P. Larsson2, B. Mannaerts3, A. Nyboe Andersen4,
B.C. Fauser5
1University of Glasgow, School of Medicine, Glasgow, United Kingdom
2Ferring Pharmaceuticals, Biometrics – Global Clinical R&D, Copenhagen, Denmark
3Ferring Pharmaceuticals, Reproductive Health – Global Clinical R&D, Copenhagen,
Denmark
4Copenhagen University Hospital Rigshospitalet, Fertility Clinic, Copenhagen,
Denmark
5University Medical Center Utrecht, Reproductive Medicine & Gynaecology, Utrecht,
The Netherlands
Study question: Does AMH intra- and inter-menstrual cycle variability inﬂu-
ence the number of oocytes retrieved after individualised follitropin delta dosing
based on AMH and body weight?
Summary answer: For 95% of women, the implication of AMH variability on
ovarian response using individualized follitropin delta dosing is limited to ±1
oocyte.
What is known already: The intra-class correlation coefﬁcient for AMH (age
adjusted ICC 0.89, 95%CI 0.84-0.94) was higher when compared to antral fol-
licle count (ICC 0.71, 95%CI 0.63-0.77) when measured across four cycles
(Van Disseldorp et al 2010). Within the menstrual cycle AMH exhibits minimal
variation. The dose of follitropin delta (Rekovelle
®
) is based on AMH and body
weight where AMH is measured on a random day of the menstrual cycle.
Whether variability in AMH across and between menstrual cycles has a clinically
relevant impact on the number of oocytes retrieved is unknown.
Study design, size, duration: Cohort study of 1,326 women (aged 18-40
years) participating in a prospective randomised controlled trial undertaken in
11 countries and 37 participating IVF centres, with central AMH measurements
(Nyboe Andersen and Nelson et al, 2017).
Participants/materials, setting, methods:Women had serum AMH mea-
sured twice: at a random day at screening and at cycle day 2-3 prior to stimula-
tion by centralised laboratory using the Elecsys AMH Plus immunoassay. The
variability across the cycle was assessed by analysis of variance with log-
transformed AMH ratio. The model underlying the dosing algorithm was used
to calculate the predicted number of oocytes based on the doses determined
by the AMH values at screening and start of stimulation.
Main results and the role of chance: There was a strong correlation
between AMH measured on a random day of the cycle up to 3 months previ-
ously (screening AMH) and at the start of stimulation (cycle day 2-3) (r = 0.92).
The variation in AMH within-subjects between screening and start of stimula-
tion was limited (coefﬁcient of variation 0.23). This variability was not attribut-
able to measurement on a random day of the menstrual cycle. There was no
evidence that AMH varied across the menstrual cycle (p = 0.08). If the dose of
follitropin delta had been based on the AMH at start of stimulation instead of
AMH at screening this would have had a minor impact on the predicted number
of oocytes retrieved. For those women with an anticipated lower response
(AMH<15pmol/l) the number of oocytes retrieved would be identical in 97%
of women, and for those with an anticipated higher response (AMH≥15pmol/
l) the number of oocytes would be at most ± 1 oocyte in 90% of women, with
a further 9% attaining ± 2 oocytes. Overall for 95% of women, the implications
of AMH variability on ovarian response using individualized follitropin delta dos-
ing is limited to + 1 oocyte.
Limitations, reasons for caution: A centralised AMH measuring laboratory
was used which may give rise to reduced AMH variability. AMH measurements
were compared with samples taken within 3 months prior to ovarian stimula-
tion, longer time intervals may have shown different variability due to the age-
related decline in AMH.
Wider implications of the ﬁndings: An AMH measured on a random day
of a menstrual cycle prior to commencing ovarian stimulation can be used to
individualise the dose of follitropin delta. The variability in AMH within and
between menstrual cycles does not have a clinically important impact on the
number of oocytes retrieved.
Trial registration number:NCT01956110
P-652 The Bologna criteria patient and dual stimulation for IVF
using long-acting FSH - a cohort study
B. Alsbjerg1,2, T. Hahr1,2, H.O. Elbaek1, R. Laursen1, B.B. Povlsen1,
P. Humaidan1,2
1The Fertility Clinic, Skive Regional Hospital, Denmark
2Health, Aarhus University, Aarhus, Denmark
Study question: What is the clinical outcome of a patient friendly double
stimulation with corifollitropin alfa in a cohort of poor responders, fulﬁlling the
Bologna criteria.
Summary answer: Signiﬁcantly more oocytes were retrieved during luteal
phase stimulation (DuoStim 2) compared to follicular phase stimulation
(DuoStim 1).
What is known already: Bologna criteria poor responder patients have a
reported live birth rates ranging from 5.5% to 11.7% per cycle started and the
crucial parameter is the number of oocytes available. Different combinations of
follicular and luteal phase stimulation have been suggested and the overall
advantage of the double stimulation is the possibility of retrieving more oocytes
within a short period of time having a lower risk of no oocytes retrieved or no
embryos available for a consecutive frozen embryo transfer.
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Study design, size, duration: In this retrospective cohort study 81 patients
were identiﬁed in the prospective clinical database from August 2015 to
December 2017 planned for DuoStim. Fifty-four patients completed both
DuoStim 1 and DuoStim 2 fulﬁlling the Bologna criteria.
Participants/materials, setting, methods: Patients were treated in a pub-
lic fertility clinic. Both stimulations were ﬁxed GnRH-antagonist protocol start-
ing on the second or third cycle day using 150 mg corifollipin-α. GnRH-
antagonist 0.25 mg daily was introduced on the 5th stimulation day and contin-
ued until the day of ovulation trigger. Additional exogenous gonadotropin was
added from the 5th or 6th stimulation day and ovulation was triggered with
GnRH-agonist followed by “freeze-all”. Between the two stimulations there
was a four-day pause.
Main results and the role of chance: The average age of the cohort was
36.7 years (SD 3.6; range 24-42) with a mean antral follicle count of 4.4 (SD
1.9). A total of 52 (96%) patients had previously performed at least one oocyte
retrieval with less than four oocytes retrieved. Prior to DuoStim 1, patients had
a mean number of 2.8 (SD 1.6) failed cycles. Besides the diagnosis of POR, a
total of 45 patients (83%) also had a secondary fertility diagnosis.
The mean number of oocytes retrieved in DuoStim 1 and DuoStim 2 was 2.4
(SD 2.1) and 3.7 (SD 2.6) respectively, hence, a total of 1.2 (95% CI 0.46 –
1.96) more eggs were retrieved in DuoStim 2 compared to DuoStim 1, P =
0.002. Neither the number of embryos frozen nor the cancellation rate was sig-
niﬁcantly different comparing DuoStim 1 to DuoStim 2.
Only 6% (3/54) patients did not have any oocytes retrieved at all. The overall
cancellation rate after retrieval was 41% (22/54) meaning that no top-quality
embryo was frozen after both stimulations.
A total of 32 patients went through at least one embryo transfer. The overall
ongoing pregnancy rate of the cohort was 20 % (11/54). Four patients still have
spare embryos in the freezer.
Limitations, reasons for caution: The drawbacks of this study are the
retrospective nature, the small number of patients and differences in the add-
itional gonadotrophins and dose. Whether the results can be related to older
Bologna criteria patients is uncertain.
Wider implications of the ﬁndings: The results of this study corroborate
the results of previous studies, showing that dual stimulation might be an alterna-
tive treatment concept with more oocytes retrieved within a shorter time; for
the ﬁrst time long-acting FSH was used for stimulation. Collectively this protocol
reduces the treatment burden of the Bologna criteria poor responder patient.
Trial registration number: The study was approved by the Regional Ethical
Committee. The study carries no Trial registration number due to its retro-
spective nature.
P-653 Critical role of HOTAIR long non coding RNA as an
epigenetically master regulator of HOX loci genes in Cumulus Cells
of patients with PCOS
S.Z. Tabatabaei1,2, P. Eftekharyazdi3, M. Hafezi4, S. Zarei Moradi1,
M. Shahhoseini1,2
1Reproductive Biomedicine Research Centre- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Genetics, Tehran, Iran
2Faculty of Basic Sciences and Advanced Technologies- University of Science and
Culture- ACECR, Department of Genetics, Tehran, Iran
3Reproductive Biomedicine Research Centre- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Embryology, Tehran, Iran
4Reproductive Biomedicine Research Centre- Royan Institute for Reproductive
Biomedicine- ACECR, Department of Endocrinology and Female Infertility, Tehran,
Iran
Study question: To assess relationship between HOTAIR expression asso-
ciated with HOXC & HOXD clusters and determine functional epigenetic marks
in women with PCOS.
Summary answer: Aberrant correlative expression of HOXC & HOXD clus-
ters and HOTAIR gene in alliance with regulatory epigenetic marks of PCOS
patients vs. healthy women was observed.
What is known already: Poly Cystic Ovary Syndrome (PCOS) is the most
common endocrinal disorder affecting anovulatory infertility. HOX family are
genes that have altered expression in human reproductive system disorder.
Previous researches have shown that long non coding RNAs do epigenetic
regulation of gene expression and play important roles in proliferation, apop-
tosis and metastatic capacity of cancers. Recent studies revealed HOX
Transcript Antisense Intergenic RNA (HOTAIR) as lncRNA which has
estradiol-dependent activation and epigenetically regulatory functions. HOTAIR
which is located in HOXC genes cluster, could bind with histone modiﬁer com-
plexes and direct to speciﬁc HOXD cluster that prone to cause their expression
switching.
Study design, size, duration:Our study consist of 20 patients with PCOS as
a case and 20 fertile women with male infertility problems referred to the
Royan Institute to get ICSI under GnRH antagonist protocol as a control popu-
lation. Cumulus cells (CC) were collected from PCOS patients and fertile.
Informed consents were obtained from the participants. Thirty six hours after
hCG injection, ovaries were punctured and cumulus oocyte complexes were
dissected.
Participants/materials, setting, methods: Total RNA was extracted
from CCs and cDNA was synthetized by whole transcriptome ampliﬁcation
kit. Quantitative real-time PCR was performed by use of speciﬁc primer for
target genes. For the epigenetic evaluation, soluble chromatin was extracted
from CCs and chromatin immune precipitation (ChIP) coupled with real-
time PCR was performed to quantify both activator (H3K27 methylation)
and suppressor (H3K4 demethylation) epigenetic histone modiﬁcation
marks on regulatory regions of HOXD10 gene as a main target of
HOTAIR.
Main results and the role of chance: Obtained data showed signiﬁcant
increase of HOTAIR (P<0.05), HOXC6 (P<0.05), HOXC9 (P<0.05), HOXC10
(P<0.05), HOXC11 (P≤0.01), HOXC12 (P<0.05), gene expression in PCOS vs.
control group but there were no signiﬁcant changes in PCOS vs. PCOD group.
On the other side, there was a signiﬁcant decrease in expression of HOXC8
(P<0.05), HOXC13 (P<0.05), HOXD8 (P<0.05), HOXD9 (P<0.05), HOXD10
(P<0.05), HOXD11 (P<0.05), HOXD12 (P<0.05). Interestingly there was no
signiﬁcant changes in HOXD13 (P<0.05) contrary to HOTAIR impression on
HOXD cluster. All above expression proﬁles was conﬁrmed by epigenetic evalu-
ation in subsequent.
Limitations, reasons for caution: Due to the small number of participant
limitation, larger studies should be needed for the conﬁrmation.
Wider implications of the ﬁndings: Current study suggest that there is sig-
niﬁcant correlation between altered expression of HOX family genes, HOTAIR
lncRNA as an epigenetic regulator in PCOS disorder. This project provides new
insights to understand the pathogenesis of PCOS.
Trial registration number:Not Applicable.
P-654 Role of measuring serum LH levels 12 hours post agonist
trigger and administration of rescue HCG trigger
R.G. Patel, V. Mehta, H. Dayma, D.G. Patel
Sunﬂower Women’s Hospital, Reproductive Medicine, Ahmedabad, India
Study question: Does measurement of serum LH levels 12 hours after agon-
ist trigger and administration of rescue HCG trigger( if LH level <50 IU/L)
improve oocyte recovery rate and maturity rate?
Summary answer: This kind of approach does not signiﬁcantly improve
oocyte recovery rate and maturity rate.
What is known already: With advent of antagonist protocol in IVF stimula-
tion it has become common to administer agonist trigger for ﬁnal oocyte matur-
ation to decrease the risk of OHSS. Even though pregnancy rates are lower and
miscarriage rates are higher with fresh embryo transfer in agonist triggered
cycles, not much has been published about efﬁcacy of agonist trigger in terms of
oocyte recovery rate(eggs retrieved/mature size follicles on day of trigger
administration) and maturity rate( metaphase II/eggs retrieved). There are few
studies reporting lower oocyte recovery rate with agonist trigger if serum LH
level < 15IU/L 12 hours post trigger administration.
Study design, size, duration: Retrospective study of 100 patients undergo-
ing IVF-ICSI freeze all cycles with own eggs on ﬂexible antagonist protocol at
our centre between April –May 2016 and April- May 2017
Participants/materials, setting, methods: Group 1–50 patients triggered
with agonist and serum LH levels not performed (April –May 2016)
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Group 2–50 patients triggered with agonist and serum LH levels performed
approximately 12 hours after trigger. If levels were below 50 IU/L, injection
HCG 2000 units was administered immediately, and ovum pick up was per-
formed 36 hours post agonist trigger. (April- May 2017)
Group 2 A (LH < 15IU/L)
Group 2B (LH 15-30IU/L)
Group 2 C (LH 30-50IU/L)
Group 2D (LH >50IU/L)
Main results and the role of chance:On an average 20 eggs were retrieved
per patient in group 1 and 21 eggs were retrieved per patient in group 2( p
value – 0.15). There was no signiﬁcant difference in oocyte recovery rate
(oocytes retrieved/follicles > 14 mm on day of trigger administration) between
the two groups. ( 87% in group 1 and 83.9% in group 2, p value- 0.26). There
was only one patient with empty follicle syndrome in group 1 and none in group
2. Oocyte maturity rate (metaphase II / eggs retrieved) was also similar
between both groups. (Group 1 – 71%, Group 2 – 72.3%, p value- 0.46). No
patient had LH levels <15IU/L in our study, 2 patients(4%) had LH level meas-
uring 15-30 IU/L and 10 patients(20%) had LH level measuring 30-50 IU/L. In
group 2B(LH <30IU/L), oocyte retrieval rate was lower than remaining 2
groups (Group 2B-59.5%, Group 2C- 90.3%, Group 2D- 90.6%). We had no
incidence of OHSS in any of the patients.
Limitations, reasons for caution: Retrospective nature of the study and
participants selected over 2 different time spans. Administration of HCG may
pose a patient at risk of OHSS. Majority of the participants were hyper-
responders undergoing all freeze cycles to avoid risk of OHSS( results cannot
be extrapolated to all).
Wider implications of the ﬁndings: Measuring LH levels 12 hours post
agonist trigger and administration of rescue HCG trigger does not improve
oocyte recovery rates even if LH level was<30 IU/L(Incidence 4%). This kind
of approach will just add to patient inconvenience, cost and pose them at risk of
OHSS.
Trial registration number: not applicable.
P-655 FSH exposure between day 8 and day of hCG administration
is an independent predictor of serum progesterone rise
H.M. Fatemi1, G. Griesinger2, V. Valerie Teal3, N.P. Polyzos4,
E. Bosch5, B. Johnson6, B. Lawrenz7, S. Dos Santos Ribeiro8,
J. Garcia Velasco9, D. Stoop10
1IVI, Middle east, Abu Dhabi, United Arab Emirates
2Lubeck university hospital, repr med, Lubeck, Germany
3MSD, art, New Jersey, U.S.A.
4Dexeus, art, barcelona, Spain
5IVI, art, valencia, Spain
6MSD, asia paciﬁc, adelaid, Australia
7ivi me, art, abu dhabi, United Arab Emirates
8uzbrussel, Crg, brussels, Belgium
9ivi, art, madrid, Spain
10msd, art, brussels, Belgium
Study question: What is the effect of additional recFSH administration after
one dose of corifollitropin alfa (CFA) on the progesterone rise on the day of
ﬁnal oocyte maturation?
Summary answer: While little increase in progesterone levels is observed
after seven days of CFA stimulation, post-CFA recFSH dosing is the strongest
determinant of subsequent progesterone rise.
What is known already: Late-follicular progesterone (LFP) increase is
related to both ovarian response and the intensity of FSH exposure during con-
trolled ovarian stimulation (COS). CFA-treated patients who reach the hCG
triggering criteria without need for additional daily recFSH (<8days) have a low-
er incidence of elevated progesterone >1.5 ng/ml when compared to daily
recFSH treated controls. This suggests that the pharmacokinetic proﬁle of CFA,
with its progressively declining FSH activity, also may reduce the progesterone
rise. However, it remains unclear why favourable progesterone levels on the
day of hCG administration are not observed in patients who need additional
recFSH after CFA (>8days).
Study design, size, duration: A post-hoc subgroup data-analysis of three
previously published trials; ENGAGE, ENSURE and PURSUE was performed.
All were randomized double-blind trials comparing the efﬁcacy of ovarian stimu-
lation with 150 μg (ENGAGE/PURSUE) or 100 μg (ENSURE) CFA versus a
recFSH control group. In both arms, recFSH doses were adjusted according to
ovarian response. Cycles with a duration of ovarian stimulation >8 days, which
includes all CFA cycles requiring additional recFSH (n = 1234) and their daily
recFSH controls (n = 1026), were included.
Participants/materials, setting, methods: The studies included women
aged 18–42 years with a regular menstrual cycle (24–35 days), and an indi-
cation for ovarian stimulation for IVF/ICSI. All trials were multicentre and
multinational involving centres in Europe, North America and Asia.
Treatment cycles <8 days were excluded. Progesterone levels were
obtained on days 1, 8 and the day of hCG administration. Linear regres-
sion analysis was performed to assess the factors contributing to the ser-
um progesterone levels.
Main results and the role of chance: Patient’s demographics and baseline
characteristics were comparable between groups. Mean progesterone levels on
day 8 of stimulation were signiﬁcantly lower in the CFA group when compared
to the recFSH arm (0.6 ± 0.3 ng/ml vs. 0.9 ± 0.4 ng/ml; p<0.001), with a four-
fold lower incidence of progesterone levels >1.5 ng/ml (2.2% vs. 8.7%;
p<0.001). However, progesterone levels on day of hCG were comparable
between groups (1.1 ± 0.7 ng/ml vs. 1.2 ± 0.6 ng/ml; p = 0.18), owing to a sig-
niﬁcantly sharper increase in progesterone levels between day 8 and the day of
hCG administration in CFA-stimulated cycles (0.5 ± 0.5 ng/ml vs. 0.3 ± 0.3 ng/
ml; p<0.001). Multivariable linear regression analysis, controlling for age and
progesterone on Day 8, showed that the post-CFA progesterone increase was
independently associated with the number of days of recFSH stimulation from
day 8 onwards (0.10 ng/ml per day; 95% CI 0.08-0.12; p<0.001), the daily
dose of post-CFA recFSH (0.08 ng/ml per 50 IU; 95% CI 0.05-0.11; p<0.001)
and the number of oocytes retrieved (0.02 ng/ml per oocyte; 95% CI 0.01-
0.02; p<0.001).
Limitations, reasons for caution: Although this post-hoc analysis is of
importance to generate hypotheses on strategies to minimize progesterone
rise, prospective randomized trials are needed to conﬁrm whether reduced
post-CFA recFSH dosing could prolong the favourable effect of CFA on proges-
terone levels without a clinically relevant impact on the ovarian response.
Wider implications of the ﬁndings: This study found that CFA treatment
has a lower incidence of elevated progesterone during the ﬁrst week of treat-
ment compared to a daily recFSH regimen. Moreover, it suggests that lower
daily recFSH doses following CFA could signiﬁcantly contribute to maintaining
these favourable progesterone levels until the day of hCG.
Trial registration number: Engage NCT00696800; Ensure NCT00702845;
Pursue NCT01144416
P-656 The Effect of Alpha Lipoic Acid on expression of IRS-1,
GLUT-4, and folliculogenesis in Polycystic Ovary Syndrome with
insulin resistance
R. Rusnaidi
Dr. Soetomo General Hospital- Surabaya, Obstetrics & Gynecology, Surabaya,
Indonesia
Study question: This study aimed to prove the effect of Alpha Lipoic Acid on
expression of IRS-1, GLUT-4 and folliculogenesis of PCOS model rats with insu-
lin resistance.
Summary answer: After administering ALA, expression of IRS-1 and GLUT-
4 were higher. There was no difference in folliculogenesis but there was signiﬁ-
cant difference in de Graff follicles.
What is known already: Polycystic Ovary Syndrome (PCOS) is a frequent
endocrine disorder in women of reproductive age where insulin resistance plays
an important role. Insulin resistance complicates optimal treatment of infertility.
Administration of Alpha Lipoic Acid (ALA) is expected to be an alternative
therapy in clomiphene citrate resistant PCOS and in PCOS which has side
effects on metformin.
Study design, size, duration: This study used randomized post-test only
control group design. The sample size was 30 female rats (rattus norvegicus).
This study was conducted in February until May 2017 in Faculty of Veterinary,
Universitas Airlangga, Surabaya.
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Participants/materials, setting, methods: 30 female rats were given
100 mg/kg B testosterone propionate injection for 28 days to form PCOS
model with insulin resistance. Then, they were divided into 3 groups ran-
domly. Group I was negative control, group II got placebo, and group III got
ALA. The expression of IRS-1 and GLUT-4 were assessed by Immuno
Reactive Score (IRS) on immunohistochemical examination. Folliculogenesis
was assessed by counting the number of follicles at each stage through
Hematoxylin Eosin (HE).
Main results and the role of chance: The mean expression of IRS-1 in mus-
cle of treatment group (4.28 + 1.05) was signiﬁcantly higher than placebo (3.02
+ 1.03) (p = 0.01). The mean expression of IRS-1 in ovary of treatment group
(7.78 + 1.10) was signiﬁcantly higher than placebo (3.06 + 1.56) (p <0.01). The
mean expression of GLUT-4 in muscle of treatment group (4.28 + 0.91) was
signiﬁcantly higher than placebo (3.20 + 1.14) (p = 0.01). The average number
of primary follicles in treatment group (58,00 + 13,11) was signiﬁcantly lower
than placebo (66,00 + 19,81) (p = 0,55). The average number of secondary fol-
licles of the treatment group (18.00 + 4.62) was signiﬁcantly lower than placebo
(27.00 + 10.82) (p = 0.10). The average number of tertiary follicles of the treat-
ment group (2.00 + 1.56) was signiﬁcantly lower than placebo (4.00 + 1.89) (p
= 0.13). The average number of de Graff follicles of the treatment group (5.00
+ 3.37) was signiﬁcantly higher than placebo (2.00 + 0.82) (p <0.01). The aver-
age number of corpus luteum of the treatment group (9.00 + 3.37) was signiﬁ-
cantly higher than placebo (6.80 + 3.58) (p = 0.13).
Limitations, reasons for caution: This study has limitation that it did not
use normal rats control.
Wider implications of the ﬁndings: ALA can be used as an alternative
therapy in PCOS patients with clomiphene citrate resistance, especially for
women who cannot tolerate the side effects of metformin.
Trial registration number:Not applicable.
P-657 Among Bologna poor responders, does the type of GnRH
analogue play any role when corifollitropin alfa is used?
J. Errazuriz1,2, P. Drakopoulos1, D. Pening1,3, A. Racca1,4,
N. De Munck1, M. De Vos1, H. Tournaye1, C. Blockeel1,5
1Universitair Ziekenhuis Brussel- Vrije Universiteit Brussel, Center for Reproductive
Medicine, Brussels, Belgium
2Clínica Alemana, Center for Reproductive Medicine, Santiago, Chile
3Université libre de Bruxelles, Faculté de Médecine, Brussels, Belgium
4University of Genoa - IRCCS AOU San Martino, Academic Unit of Obstetrics and
Gynecology, Genoa, Italy
5University of Zagreb-School of Medicine, Department of Obstetrics and Gynecology,
Zagreb, Croatia
Study question: Does the type of GnRH analogue in different stimulation
protocols affect cumulative live birth rate (CLBR) in Bologna poor responders
treated with corifollitropin alfa (CFA)?
Summary answer: CLBR remains similar in different stimulation protocols
using corifollitropin alfa in poor responders. However, the GnRH antagonist
protocol results in more supernumerary embryos cryopreserved.
What is known already: In normal responders, CFA may increase the num-
ber of oocytes retrieved compared to recombinant FSH (rFSH). Preliminary
studies using CFA in poor responders have also shown promising results in this
poor prognosis population. However, it remains unclear which protocol
(GnRH-antagonist, long GnRH-agonist or short GnRH-agonist) represents the
ideal therapeutic approach when using CFA in poor responders.
Study design, size, duration: This is a large retrospective analysis including
poor responder patients fulﬁlling the Bologna criteria and undergoing their ﬁrst
ICSI cycle with CFA, between 2011 and 2017. The study population was
divided according to the ovarian stimulation protocol into three categories: long
GnRH-agonist, short GnRH-agonist and GnRH-antagonist. The starting dose of
CFA was 150 μg. CLBR was deﬁned as the delivery of a live born resulting from
fresh and all subsequent frozen embryo transfers.
Participants/materials, setting, methods: In the GnRH-antagonist ﬁxed
protocol, CFA was started on day2 (D2) of the cycle and GnRH-antagonist was
initiated on D6. In the long GnRH-agonist, patients started the agonist from
D21 of the previous cycle and CFA was initiated following conﬁrmation of
ovarian suppression. For the short protocol, GnRH-agonist was administered
from D2 of the cycle and CFA from D3. If necessary, daily injections of hp-
HMG (300 IU) were given from D8, until hCG-trigger.
Main results and the role of chance: A total of 757 cycles were divided
into 3 groups: group A (antagonist protocol, n = 437), group B (long-agonist
protocol, n = 231) and group C (short-agonist protocol, n = 89). There were
no differences in baseline characteristics among the groups, including age and
ovarian reserve markers. Days of additional hp-HMG following CFA were sig-
niﬁcantly different between group A, B, and C (3 vs 5 vs 3; p=<0.001). There
were no differences among the groups in terms of number of mature oocytes,
fertilization rate, embryo quality on day 3 and day of embryo transfer. CLBR
were 21.0%, 20.8% and 16.9% (p = 0.68), respectively, for the three study
groups.
Limitations, reasons for caution: The main limitation of our large study is
its retrospective design which is inherent to risk of bias.
Wider implications of the ﬁndings: This is the largest analysis including
Bologna poor responders stimulated with CFA. Based on our results, different
CFA protocols do not increase CLBR. However, the antagonist protocol may
result in more supplementary frozen embryos.
Trial registration number: not applicable.
P-658 Effect of simvastatin on improvement of polycystic ovary
syndrome (PCOS) induced by Dehydroepiandrosterone (DHEA) in
rats
M.H. Bahadori1, E. Mirzajani2, R. Habibi2, M. Balani2
1Gilan University of Medical Sciences, Cellular and Molecular Research Center,
Rasht, Iran
2Guilan university of medical sciences, Cellular and molecular research center, Rasht,
Iran
Study question: What is the role of simvastatin to protect polycystic ovary
syndrome (PCOS) induced with Dehydroepiandrosterone (DHEA)
Summary answer: Its seems simvastatin decrease the damaging inﬂuence of
Dehydroepiandrosterone (DHEA) on rat polycystic ovary syndrome model.
What is known already: Polycystic ovarian syndrome (PCOS) is the most
common endocrine disorders in women and the most common diagnostic cri-
teria are hyperandrogenism, ovulatory dysfunction, and polycystic ovarian
morphology. Also Pro-inﬂammatory cytokines, such as tumor necrosis factor
alpha (TNF-α), have been conﬁrmed to be elevated in at least a subcategory of
women with PCOS. On the other hand, statins (including simvastatin) not only
improve lipid proﬁles, but also decrease inﬂammatory markers, ovarian size,
and oxidative stress. Moreover, the aim of this study was to investigate the pro-
tective effect of simvastatin against polycystic ovarian syndrome (PCOS)
induced by Dehydroepiandrosterone (DHEA) in the female rats.
Study design, size, duration: A total of 60 Wistar female rats were ran-
domly distributed into control, DHEA and DHEA + simvastatin (n = 20 per
group) groups. The PCOS rat model was developed by the injection of DHEA
(6 mg/100 g body weight diluted in 0.4 ml/rat sesame oil) for each animal dur-
ing 20 days subcutaneously. Control group received only oil. After then each
animal daily received simvastatin (10 mg/100 g orally) during 4 weeks or saline
solution as control.
Participants/materials, setting, methods: In all groups, ovarian tissue was
evaluated by morphological observation and the follicular theca ﬁbrosis was
recorded using trichrome Masson staining and morphometric technique. Serum
level of anti-Mullerian hormone (AMH) was analyzed by ELISA. Furthermore,
tissues were analyzed by immunohistochemistry to detect TNF-alpha and
apoptosis. Data were analyzed by one-way ANOVA followed by Tukey’s test
using SPSS version 16 software. The p<0.05 was considered signiﬁcant.
Main results and the role of chance:Our result indicated that PCOS group
showed a signiﬁcant increase in serum levels of anti-Mullerian hormone (AMH)
compare to control groups (p <0/05). It also increases the follicular theca
ﬁbrosis and thickness of theca and decrease body loss in PCOS group signiﬁ-
cantly (p <0/05). In comparison with the control and PCOS groups, there was
a signiﬁcant increase in the apoptosis index and TNF-α expression (p <0/05).
Also Simvastatin (10 mg/100gr) decreases serum anti-Mullerian hormone
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(AMH) in the experimental group compare PCOS group signiﬁcantly (p <0/
001). Moreover, compared with the PCOS group, both follicular theca ﬁbrosis
and thickness of theca decreased but it’s not signiﬁcant. The apoptosis index
was lower (p<0.05) and TNF-α expression was lower (p<0.05) in the
simvastatin-treated groups.
Limitations, reasons for caution: It’s in only one species and further data
are required to better deﬁne the polycystic ovarian syndrome.
Wider implications of the ﬁndings: We concluded simvastatin could be
useful to prevent the harmful effects of PCOS in polycystic ovarian syndrome
(PCOS) induced by Dehydroepiandrosterone (DHEA) in the female rats.
Trial registration number: The results of this study indicated that Master of
Science thesis in Guilan University of medical sciences with No: 102 and.
P-659 Occurrence and characteristics of recombinant human
follicle-stimulating hormone (r-hFSH) dose adjustments during
ovarian stimulation in a real-world US database study of 33,962 IVF
patient cycles
M. Mahony1, B. Hayward2, K. Richter3, T. D’Hooghe4
1EMD Serono- Inc., Medical Affairs - Endocrinology/Reproductive Health, Rockland-
MA, U.S.A.
2EMD Serono- Inc., Global Biostatistics & Epidemiology, Rockland- MA, U.S.A.
3Shady Grove Fertility Reproductive Science Center, Research, Rockville, U.S.A.
4Merck KGaA, Global Medical Affairs Fertility, Darmstadt, Germany
Study question: What is the real-world occurrence of r-hFSH dose adjust-
ments during IVF cycles and what are the demographics and baseline character-
istics of patients with dose adjustments?
Summary answer: Dose adjustments were observed during 40.7% of cycles
analysed and there were clinical differences in patients whose dosing was con-
stant versus those with dosing adjustments.
What is known already: Standard practice during individualized ovarian
stimulation with r-hFSH is to tailor the starting dose according to a variety of
biomarkers (age; BMI; previous ovarian response; ovarian reserve markers like
antral follicle count [AFC], anti-Müllerian hormone [AMH], FSH level). In add-
ition, many physicians adjust FSH dose depending on individual ovarian
response during ovarian stimulation. Although this is considered common prac-
tice, it has been proposed that it is sufﬁcient to maintain the starting dose of
FSH without dose adaptation. There is a lack of real-world data documenting
the prevalence of dose adjustments and the characteristics and demographics
of patients receiving dose alterations.
Study design, size, duration: Non-randomized, observational, retrospect-
ive analysis of a large, US, real-world, electronic de-identiﬁed medical records
database (IntegraMed America, Inc.), including data from >15 ART clinics serv-
ing patients from all 50 states. Data for patients receiving any GONAL-f presen-
tation (r-hFSH; EMD Serono, Inc., Rockland, MA, USA) during IVF cycles
between Jul 2009 and Dec 2016 were analysed.
Participants/materials, setting, methods: Outcomes evaluated included:
overall number of cycles with a constant dose; number with at least one dose
adjustment; number with a dose increase; number with a dose decrease; and
the subset with both decreases and increases; the mean (standard deviation
[SD]) start, end and total r-hFSH (GONAL-f) doses; and patient baseline char-
acteristics according to dosing pattern. Dosing data were evaluated per cycle.
The ﬁrst cycle per patient was evaluated for patient demographics and baseline
characteristics.
Main results and the role of chance: A total of 23,582 patients undergoing
33,962 IVF cycles included 13,823 cycles (40.7%) with r-hFSH dose adjust-
ments; 40.0% (5524) of these involved more than one dose change. Among
cycles with dose changes, ≥1dose increase was observed in 7939 (57.4%)
cycles, ≥1 dose decrease in 8639 (62.5%) cycles and both increases and
decreases in 2755 (19.9%) cycles. The mean (SD) starting dose (IU) was higher
in cycles with constant dose (292[133.2]) compared with those with dose
adjustments (238[122.6], 258[133.3] and 231[149.9] for cycles with ≥1 dose
increase, ≥1 decrease and both increases/decreases, respectively; all
p<0.0001). The median dose adjustment in all three dose adjustment groups
was 75 IU. Patients treated with a constant dose were signiﬁcantly older (35.9
[4.60] years), had a lower AFC (12.8[7.83]), had a lower AMH (2.2[2.90] ng/
mL) and a higher day 3 FSH (8.2[4.81] mIU/mL) compared with cycles with
dose adjustments (increases, decreases and both increases/decreases).
Patients with constant dosing were more likely to have a diagnosis of diminished
ovarian reserve (25.2%) versus those with dose adjustments (20.1%, 15.9% and
14.0%) and were less likely to have ovulatory disorders (10.6% versus 15.2%,
18.3% and 19.2%) for dose increases, decreases and both increases and
decreases.
Limitations, reasons for caution: This was a retrospective, observational
study of US real-world data, not speciﬁcally collected for research purposes,
and may not reﬂect clinical practices in other parts of the world. In addition,
diagnostic and drug use information may not always be validated or complete.
Wider implications of the ﬁndings: Individualized r-hFSH dose adaptation,
depending on ovarian response, is highly prevalent during ovarian stimulation
for ART in real world practice in the USA. These dose adjustments are used for
all patient types, and more frequently in younger patients with higher ovarian
reserve and diagnosis of ovulation disorders/PCOS.
Trial registration number:N/A.
P-660 Long-term health related quality of life (HRQoL), life
satisfaction and health status in women with PCOS–a
population-based follow-up analysis at ages 31 and 46
S. Karjula1, L. Morin-Papunen1, J. Auvinen2, S. Franks3,
M.R. Järvelin4, J. Tapanainen5, J. Jokelainen6, J. Miettunen2,
T. Piltonen1
1Oulu University Hospital- University of Oulu- Medical Research Center Oulu and
PEDEGO Research Unit, Obstetrics and Gynecology, Oulu, Finland
2University of Oulu- Medical Research Center Oulu and Oulu University Hospital,
Center for Life Course Health Research, Oulu, Finland
3Imperial College, Institute of Reproductive and Developmental Biology, London,
United Kingdom
4Imperial College, Department of Epidemiology and Biostatistics- Medical Research
Council-PHE Public Health England Centre for Environment & Health- School of
Public Health, London, United Kingdom
5Oulu University Hospital- University of Oulu- Medical Research Center Oulu-
PEDEGO Research Unit Oulu- University of Helsinki and Helsinki University Hospital,
Obstetrics and Gynecology, Oulu- Helsinki, Finland
6University of Oulu, Faculty of Medicine, Oulu, Finland
Study question: Do the health-related quality of life (HRQoL), life satisfaction
and self-estimated health status in PCOS change over time between ages 31
and 46 years?
Summary answer: Women with PCOS presented with decreased HRQoL
and poor life satisfaction and health status up till age 46 independent of hyper-
androgenism and BMI.
What is known already: PCOS is a common syndrome affecting 5-18% of
women at reproductive age. The syndrome is mainly characterized as repro-
ductive and metabolic disorders, however, it has become evident that the
women also often have psychological problems. Obesity, diabetes, metabolic
syndrome, irregular cycles, infertility, psychological distress and aesthetic con-
cerns like acne and hirsutism burden these women, decreasing their HRQoL.
As some of the syndrome-related issues and symptoms become untimely
(infertility) or they resolve (menstrual irregularities) over time, it would be of
interest to assess how HRQoL, life satisfaction and self-estimated health status
change over time in these women.
Study design, size, duration: In a prospective, general population-based fol-
low-up birth cohort (n = 5889 females), postal questionnaires were sent at
ages 14, 31 and 46 yrs with respective answer rates of 95, 81 and 72%.
Questionnaires on PCOS symptoms (31 yrs), 15D HRQoL, life satisfaction and
self-estimated health status (31 and 46 yrs) and BMI (14, 31 and 46 yrs) were
analyzed. Clinical examination and testosterone measurement were performed
at age 31 (3115 women) and 46 (3280 women).
Participants/materials, setting, methods: According to questionnaires,
331 women (11.2%) presented isolated oligoamennorrhea (OA) and 323
(10.9%) isolated hirsutism (H) and 125 (4.2%) presented both symptoms
(PCOS), whereas 2188 asymptomatic women where considered as controls.
The 15D scores were analysed with Kruskal-Wallis H-test, life satisfaction and
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self-estimated health status with chi-square analysis. The risks related to PCOS
symptoms were estimated using a logistic regression model.
Main results and the role of chance: In all four study groups HRQoL
decreased over time. In women with PCOS and in women with isolated H the
HRQoL was decreased both at ages 31 and 46 compared with controls
whereas there was no difference in the sum score in women with isolated OA.
The individual HRQoL that differed between PCOS and controls were at age
31: vitality, mobility, breathing, sleeping, excretion, discomfort and complaints
and at age 46: vitality, mobility, vision, hearing, sleeping, excretion, usual activ-
ities, discomfort and complaints and depression. Women with PCOS presented
3.8-fold risk for being in the lowest HRQoL quartile at age 31 and 2.5 –fold risk
at age 46. The risk remained signiﬁcant after adjusting for BMI, testosterone,
infertility and marital and socioeconomic status. Women with isolated H or
PCOS also associated with risk of low life satisfaction at age 31 (H: OR1.57
95% CI [1.06, 2.34], PCOS: 2.64 [1.59, 4.39]) and PCOS group at age 46 (2.11
[1.59, 3.84]) compared with controls. Moreover, PCOS also associated with
risk of poor self-reported health status age 31 (3.60 [1.84, 7.05]) and 46 (3.85
[1.89,7.85]).
Limitations, reasons for caution: The symptoms of PCOS were self-
reported and no ultrasound examinations were available. The study population
was relatively young for assessing some items included in the 15D tool.
Wider implications of the ﬁndings: PCOS and isolated H associates with
low HRQoL from fertile age until late reproductive years. As women with
PCOS are at risk for reporting poor life satisfaction and health status at age 31
and 46, more studies aiming to improve HRQoL in these women are
warranted.
Trial registration number: not applicable.
P-662 Co-administration of GnRH-agonist and a standard dose of
hCG (dual trigger) for improving IVF outcome in patients with low
proportion of mature oocyte
L.Wang, Y.Wang
Peking University Third Hospital, Department of Obstetrics and Gynecology, Beijing,
China
Study question:Whether the Co-administration of GnRH-agonist and stand-
ard hCG (dual trigger) can be used for improving IVF outcome in patients with
low proportion of mature oocyte?
Summary answer: For patients who have normal ovarian response but low
proportion of mature oocytes, dual trigger can help improving their IVF
outcome.
What is known already: Oocyte maturation occurs after the luteinizing
hormone( LH) surge during the menstrual cycle. As a surrogate LH surge,
GnRH-agonist and Human chorionic gonadotropin(hCG) are usually used at
the end of controlled ovarian hyperstimulation(COH) to induce ﬁnal follicu-
lar maturation. Patients who have low oocyte maturity or the inability to
retrieve mature oocytes have poorer IVF outcomes compared with those
who have more mature oocyte obtained. Now it is more frequent to see
that normal responding patients with an apparently normal follicular devel-
opment and E2 levels on the day of HCG injection result in low proportion
of mature oocyte.
Study design, size, duration: Retrospective study was preformed to com-
pare the stimulation characteristics of 366 IVF cycles from March 2016 to
August 2017. Patients were given combination of Group A (dual trigger group,
n = 123), Group B(Group A’s patients’ previous IVF attempt, triggered with
hCG-only, n = 123), Group C (different patients form Group A, triggered with
hCG-only, n = 120).
Participants/materials, setting, methods: Patients who were eligible for
this study must be normal response and have a prior IVF cycle with low propor-
tion of MII oocytes(<66%) per number oocytes retrieved. During the previous
cycle, patients underwent various IVF stimulation protocols and were triggered
with hCG only (5,000IU or 10,000IU). For the dual trigger cycle, patients
underwent a GnRH antagonist COH protocol and dual trigger( 0.2 mg GnRH-
agonist plus 250ug rhCG) was preformed 36 hours prior to OPU.
Main results and the role of chance: The basic characteristic date including
age, ART indications, duration of infertility, based hormonal level between the
three groups were not statistically signiﬁcant. The number of metaphase-II (MII)
oocyte in the dual trigger group is signiﬁcantly higher than Group B and Group
C (6.9vs 3.4vs 4.0, p<0.05). In addition, patients who received dual trigger
(group A) had a signiﬁcantly higher number of top quality embryos (TQE) (
1.6vs 0.7vs 0.6, p<0.05), number of embryos transferred(1.1vs 0.5vs 0.5,
p<0.05), rate of clinical pregnancy ( 0%vs 18%vs 2%, p<0.01) while lower rate
of cycle cancellation (10.2%vs 28.1%vs 20.3%, p<0.05) than the other two
groups.
Limitations, reasons for caution: Our study suggested a higher pregnancy
rate in the study group( dual trigger). However, this is biased due to our study
design which offered this protocol to patients who had failed their previous IVF
attempt. Further multicenter prospective studies are needed to strengthen our
current ﬁndings.
Wider implications of the ﬁndings: This study is based on a large sample
of data which may provide some new insights to treat patients who appear to
have normal ovarian response and follicular development but low proportion of
mature oocyte.
Trial registration number: not applicable.
P-663 Relevance of prednisolone treatment in patients with
multipronuclear embryos caused by anticentromere antibodies:
improvement of fertilization, blastocyst formation and pregnancy
rates
M. Inoue1, S. Mizuta1,2, H. Matsubayashi1,2, T. Takeuchi2, K. Kitaya1,
T. Ishikawa1,2
1Reproduction Clinic Osaka, reproductive medicine, Osaka, Japan
2Reproduction Clinic Tokyo, reproductive medicine, Tokyo, Japan
Study question: To investigate whether prednisolone treatment may improve
fertilization, blastocyst formation and pregnancy rate in patients with multipro-
nuclear embryos caused by anticentromere antibodies.
Summary answer: We retrospectively conﬁrmed prednisolone signiﬁcantly
improved fertilization, blastocyst formation and pregnancy rate in patients with
multipronuclear embryos caused by anticentromere antibodies compared to
no prednisolone.
What is known already:Women with anticentromere antibodies have been
reported to show impaired oocyte maturation, fertilization, embryo cleavage
and pregnancy rates. Sometimes their embryos showed increasing amount of
multipronuclear embryos (3 pronuclei or more). Based on mouse studies, injec-
tion of anticentromere antibodies interfered with meiosis and mitosis by attach-
ment of anticentromere antibodies to the centromeric region of a
chromosome. Those embryos showed impaired oocyte maturation, fertiliza-
tion, embryo cleavage and blastocyst formation rates as shown in human obser-
vations. However, the precise mechanism caused by anticentromere antibodies
needs further investigation. To the best of our knowledge, no therapeutic stud-
ies have been reported.
Study design, size, duration: A single-center retrospective study was per-
formed. All patients gave written informed consent for this study. Patients who
performed in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
between May 2014 and December 2017 were included in the study. Serum
anticentromere antibodies were measured using CLEIA method by a clinical
laboratory company, and positive anticentromere antibodies were deﬁned as
more than 10 IU/mL. Of 4651 women, 45 women had anticentromere anti-
bodies (0.97%), performing 94 IVF/ICSI cycles.
Participants/materials, setting, methods: The average age of the positive
anticentromere antibodies was 38.5 ± 3.6 years. We divided 94 cycles into two
groups with or without prednisolone (64 and 30 cycles), and compared fertiliza-
tion, blastocyst formation and pregnancy rates between two groups.
Prednisolone (15 mg/day) was administered orally from the ﬁrst day of ovarian
stimulation to the day before oocyte retrieval. Ovarian stimulation protocols
were similar between two groups, because those were set according to
patients’ age and AMH levels.
Main results and the role of chance: In the ICSI group, two pronuclear
(2PN), multipronuclear, cleavage, and blastocyst formation rates with pred-
nisolone group were signiﬁcantly (P<0.05) better than those without pred-
nisolone (41.2% vs. 20.2%, 28.1% vs. 39.4%, 62.4% vs. 41.4%, 24.1% vs.
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0%), respectively. In the IVF group, however, no signiﬁcant differences were
observed between the two groups (20.0% vs. 19.8%, 45.3% vs. 42.3%,
40.0% vs. 29.2%, 31.3% vs. 15.4%), respectively. The titer of the anticentro-
mere antibodies was not related to 2PN or multipronuclear rate. Clinical
pregnancies were conﬁrmed in 6 patients from prednisolone group only; 3
patients had live births and 2 patients are ongoing pregnancies. Implantation
rate with prednisolone group was signiﬁcantly (P<0.05) higher than that
without prednisolone (7/39 vs. 0/32). Seven patients experienced both
cycles with or without prednisolone. In the ICSI group of these patients,
2PN rate with prednisolone (44.3%, 47/106) signiﬁcantly increased com-
pared with that without prednisolone (20.6%, 13/63). The titer of the antic-
entromere antibodies in patients who improved fertilization rate with
prednisolone was signiﬁcantly lower than that in patients who did not
(P<0.001). Patients who may beneﬁt from prednisolone might be low titer
of the anticentromere antibodies.
Limitations, reasons for caution: Since this study is a single center retro-
spective observational study, multi-center prospective randomized studies are
needed to conclude the relevance of prednisolone treatment in patients with
multipronuclear embryos caused by anticentromere antibodies. To the best of
our knowledge, however, there are no studies for treatment strategies in these
patients.
Wider implications of the ﬁndings: We, for the ﬁrst time, revealed rele-
vance of prednisolone treatment in patients with multipronuclear embryos
caused by anticentromere antibodies. Oral prednisolone (15 mg/day) success-
fully improved fertilization, blastocyst formation rates and may improve preg-
nancy rate in patients with positive anticentromere antibodies in our limited
study population.
Trial registration number:N/A.
P-664 The serum ProAMH/totalAMH ratio is linked to metabolic
status but not to Polycystic Ovary Syndrome (PCOS) per se
M. Peigné1,2,3, P. Pigny4, D. Dewailly2,3, P. Giacobini2,
S. Catteau-Jonard2,3
1Bichat Claude Bernard Hospital, Department of Gygecology Obstetrics and
Reproductive Medicine, Paris, France
2INSERM U1172 Team 2, JPARC- Univ. Lille-, F-59000 Lille, France
3CHU Lille, Department of Endocrine Gynecology and Reproductive Medicine- Univ.
Lille 2, F-59000 Lille, France
4CHU Lille, Service de Biochimie et Hormonologie- Centre de Biologie Pathologie-,
Lille, France
Study question: Is the ProAMH/totalAMH ratio decreased in Polycystic
Ovary Syndrome or obese women?
Summary answer: Serum ProAMH/totalAMH ratio is not signiﬁcantly differ-
ent between PCOS and control women but is decreased in obese women ver-
sus controls.
What is known already: Anti Mullerian Hormone (AMH) is known to inhibit
initial and cyclic follicular recruitment. Compared to controls, serum AMH level
is higher in PCOS women and is supposed to act in the follicular arrest.
Different molecular forms of AMH exist: one inactive (proAMH) and two active
which can bind the AMHRII receptor and induce AMH speciﬁc actions. The
active forms are obtained after proAMH cleavage: AMHC (C-term domain) and
AMHN,C (non-covalent association of N-term and C-term domains). In blood,
proAMH and AMHN,C are found, whereas the presence of AMHC is debated.
Different AMH molecular forms ratio are described in different populations.
Study design, size, duration: Cross sectional study using 72 biobanked ser-
um samples collected between 2014 and 2017 in one Academic Hospital.
Participants/materials, setting, methods: In a database prospectively
constituted from 2014 to 2017, 39 PCOS women according to Rotterdam cri-
teria (21 obese and 18 lean) and 33 controls (14 obese and 19 lean) were
selected. Their biobanked serum were tested for total AMH and pro AMH
(after desoxycholate treatment) using a Beckman Coulter Dxi automatic ana-
lyser. Relative levels of pro AMH were expressed as a proAMH ratio:
[proAMH]/[totalAMH]x100.
Main results and the role of chance: PCOS and control women had similar
BMI. Total AMH and Pro AMH levels were higher in women with PCOS
compared to controls (p<0.001). They were not signiﬁcantly different between
obese and lean women (p = 0.427 and p = 0.96, respectively). ProAMH/
totalAMH ratio was not signiﬁcantly different between control and PCOS
women (38.2 % vs 35.9%; p = 0.38). However, it was signiﬁcantly decreased in
obese (PCOS and control) women compared to lean ones (34.7% vs 39.4%;
p<0.001). In the subgroups analysis, ProAMH/totalAMH was different
between lean and obese women with PCOS (p = 0.001) but not between lean
and obese controls (p = 0.15). With univariate analysis, ProAMH/totalAMH
was negatively correlated to weight, BMI, waist circumference and fasting insuli-
nemia. No correlation was found with androgens, LH or ovulation disorders.
Limitations, reasons for caution: Small sample size, limiting statistical
power in subgroup analysis.
Wider implications of the ﬁndings: Metabolic status may have an impact
on proAMH cleavage enzymes leading to an increased rate of circulating active
AMH forms in obese women (with or without PCOS). Further studies on larger
populations are required to study whether they may contribute to ovulation
disorders in PCOS women and control obese women.
Trial registration number:Not Applicable.
P-665 Long-Antagonist protocol; single luteal use of long-acting
GnRH-antagonist Degarelix can efﬁciently downregulate LH during
ovarian stimulation for IVF. A proof of concept
E. Papanikolaou1, H. Yarali2, E. Timotheou3, P. Tatsi3,
T. Chartomatsidou3, M. Grynberg4, O. Zafeiratis1, C. Vlachou5,
I. Asouchidou6, H. Tournaye7, R. Najdecki1
1Assisting Nature- IVF Centre, Medical Department, Thessaloniki, Greece
2Anatolia IVF Centre, Medical Department, Ankara, Turkey
3Assisting Nature- IVF Centre, Embryology Lab, Thessaloniki, Greece
4Hôpital Antoine Béclère, Department of Reproductive Medicine & Fertility
Preservation, Paris, France
5Assisting Nature- IVF Centre, Midwifery Department, Thessaloniki, Greece
6Medical Department, Aristotle University of Thessaloniki, Greece
7Centre for Reproductive Medicine, Department Gynecology-Fertility, Brussels,
Belgium
Study question: Does a single luteal dose of long-acting GnRH-antagonist efﬁ-
ciently downregulate hypophysis during ovarian stimulation for IVF?
Summary answer: A single dose of long-acting antagonist Degarelix, during
luteal phase, down-regulates LH resulting in no LH rise and production of
mature oocytes and implantable embryos.
What is known already: Contrary to GnRH-agonist treatment, GnRH-
antagonists block GnRH receptors by competitive binding. Therefore,
GnRH-antagonist eliminates various disadvantages observed when using
GnRH-agonists especially reducing Ovarian Hyperstimulation Syndrome risk
(OHSS), without decreasing the likelihood of live birth. Nevertheless, limited
ﬂexibility in cycle programming and asynchrony of the follicular cohort are con-
sidered drawbacks. Consequently, despite the beneﬁts of antagonist protocols,
long-agonist protocol is still the preferred treatment in the majority of IVF
clinics. We hypothesized whether a single luteal dose of long-acting antagonist
causes prolonged suppression of LH rise allowing thus ﬂexibility in the starting
day of gonadotropins later in the follicular phase.
Study design, size, duration: This proof of concept randomized control trial
studied the efﬁcacy of a single dose of long-acting antagonist, Degarelix. The
study was performed during January-October 2017. Two groups of patients
were compared. Group A (control group) consisted of 10 women, who fol-
lowed a classic ﬁxed day-6 GnRH-antagonist protocol whereas, Group B (study
group) involved 10 women undergoing the new long-antagonist protocol. Both
groups involved infertile women prepared to undergo IVF treatment in
Assisting Nature Centre.
Participants/materials, setting, methods: According to the protocol, in
late luteal phase (day-24) a bolus injection of 0,5 ml Degarelix was admini-
strated subcutaneously to control LH surge in the follicular phase. After men-
ses, ovarian stimulation with gonadotropins was initiated from cycle-day-2 to
10. Different gonadotropin starting days were tested to observe LH level and
whether ovarian response is affected by the proximity of stimulation initiation
to the day of degarelix injection.
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Main results and the role of chance: The mean age of participants was not
different (32,1 vs. 32,6) among groups. Stimulation ranged from 9-10 days in
control group A, whether in the Long Antagonist group ranged from 10-11
days. Similar number of blastocysts produced in both groups (5.8 vs. 7.0). No
LH rise was noticed in any groups. Especially, in the Long Antagonist group one
patient was triggered with HCG on cycle-day-22. After fresh embryo transfer,
pregnancy efﬁcacy and possible negative effect on endometrium receptivity
were assessed. All patients (except one who followed Freeze-all strategy)
underwent blastocyst transfer. Clinical pregnancy was 40% in classic antagonist
(group A) and 50% in the new Long Antagonist (group B).
Limitations, reasons for caution: The limitation of this study is the small
size of the groups, however this is a proof of concept trial. Additionally, other
doses of Degarelix could be tested to investigate differences in ovarian
stimulation.
Wider implications of the ﬁndings: This is a pure novel concept for IVF
couples combining security and ﬂexibility. This new Long-Antagonist protocol
addresses cycle programming that was missing, with antagonist protocols and
almost zeros OHSS as it allows also the triggering with GnRH-agonist.
However, larger studies are required to conﬁrm the success of this protocol.
Trial registration number:NCT03240159
P-666 Real-life experience with follitropin delta (FD): dosing
inconsistencies based on short AMH changes and treatment
outcome in patients of the higher AMH spectrum
M. Depenbusch, K. Neumann, A. Schultze-Mosgau,
T. Osterholz-Zaleski, G. Griesinger
University Hospital of Schleswig-Holstein- Campus Lübeck, Department of
Gynecological Endocrinology and Reproductive Medicine, Lübeck, Germany
Study question: How often will short-term changes of AMH imply a dosage
change? What is the ovarian response to an individualized dose in hyper-
response risk patients?
Summary answer: Short term AMH (and body weight) changes occur and
affect dose choice. The utility of FD in higher AMH level patients needs further
study.
What is known already: Dosing of follitropin delta (FD), which was intro-
duced to the market in 2017, is based on body weight and serum AMH levels
(measured in one distinct ELISA within 12 months before treatment). In the
phase-III trial (ESTHER-1), excessive ovarian response was less frequent in
patients receiving individualized FD doses. There is short-term intra-individual
variation in body weight and AMH levels, which may lead to inconsistencies
between the dose being prescribed at treatment planning (and drug prescrip-
tion) and the later time point of actual FD utilization. Furthermore, in the
ESTHER-1 trial patients with cycle irregularities and BMI >32.0 kg/m2 were
excluded.
Study design, size, duration: Retrospective analysis of all patients undergo-
ing controlled ovarian stimulation with FD for who, at the outset of FD utiliza-
tion in our center, it had prospectively been decided to repetitively measure
body weight and AMH. The target ovarian response was deﬁned as 8-14 COCs
(in line with the primary outcome parameter in the ESTHER-1 trial). FD was
used according to the posology. Weight and AMH is expressed ±standard devi-
ation (SD). This study is still ongoing.
Participants/materials, setting, methods: For the initial dosing of FD,
recent AMH levels and ad-hoc body weight was used. On day of the ﬁrst folli-
tropin delta injection, AMH and weight was re-assessed and compared. In two
cases, AMH was re-assessed later in the follicular phase under ongoing FD
administration. The number of COCs in follitropin delta and previous and/or
following stimulation cycles using conventional FSH were analysed. AMH
assessment was conducted using the Roche Elecsys ELISA AMH assay.
Main results and the role of chance: To date, 20 patients have been
included in this analysis. The mean body weight was 71 ± 12 kg on ﬁrst assess-
ment and 72.6 ± 14.4 kg on second assessment. Mean AMH was 7.1 ± 3.8 ng/
ml and 6.0 ± 2.4 ng/ml on ﬁrst and second assessment, respectively. This
change resulted in a dose adjustment in ﬁve patients (25%, 95%CI: 11-47%). In
the two patients with another AMH value generated during FD administration,
the AMH was approximately halved as compared to pre-treatment values.
Individual dosing with follitropin delta achieved a target response in COC num-
ber in seven patients (35%, 95%CI: 18-57%), whereas 13 (65%, 95%CI: 43-
82%) patients responded off-target. Of the off-target patients, two patients
with pre-treatment AMH of 8.4 and 7.4 ng/ml showed an aresponse which led
to cycle cancellation, the patient with AMH 8.4 having had produced more than
20 COCs in two previous cycles with conventional FSH dosing. A hyperre-
sponse with GNRH-agonist and freeze-all strategy was observed in six patients
(30%, 95%CI: 14-52%). A clinical pregnancy was achieved in six patients out of
a total of 11 patients undergoing fresh embryo transfer after using follitropin
delta for ovarian stimulation.
Limitations, reasons for caution: Short term AMH changes will not neces-
sarily affect dosing in high AMH women, since the minimum dose still remains
to be prescribed. Of note, the patient numbers presented herein are still small.
Wider implications of the ﬁndings: The implications of short term AMH
and body weight changes on the performance of the individualized dosing algo-
rithm needs to be studied further. Furthermore, the performance characteris-
tics of FD may be modulated by AMH, with a risk of underexposure with the
minimal dose.
Trial registration number: n.a.
P-667 Rescue protocol and fresh embryo transfer after trigger
with analogs of GnRH
F. Cirillo1, R. De Cesare1, V. Scolaro1, P. Persico1, V. Canevisio1,
V. Immediata1, E. Morenghi2, P.E. Levi Setti1
1Humanitas Research Hospital, Humanitas Fertility Center- Department of
Gynecology- Division of Gynecology and Reproductive Medicine, Rozzano Milan, Italy
2Humanitas Research Hospital, Biostatistics Unit, Rozzano Milan, Italy
Study question: Do GnRH agonists (GnRHa) trigger and fresh embryo trans-
fer preserve live birth rate in high responder (HR) patients during in vitro fertil-
ization (IVF) cycles?
Summary answer: In HR patients trigger with GnRHa and the rescue proto-
col seems to reduce the risk of ovarian hyperstimulation syndrome (OHSS)
since ensuring excellent pregnancy outcomes.
What is known already: GnRHa trigger is effective in the induction of oocyte
maturation and prevention of OHSS during IVF treatment. The trigger with ana-
logue seems to increase the Abortion Rate (AR) and reduce the Live Birth Rate
(LBR), due to the supposed luteal phase dysfunction and impaired endometrial
receptivity. Some authors afﬁrm that the solution could be the intensive support
of the luteal phase; other authors suggest that the best strategy is the “freeze
only” policy.
Study design, size, duration: This is a single center retrospective observa-
tional study performed in a tertiary care academic Fertility Center. We analyzed
a total of 732 antagonist IVF protocols with GnRHa trigger in the period
between 1/03/2013 and 31/12/2016. Among these cohort, 271 patients
underwent “rescue protocols” and fresh embryo transfer. The rest underwent
a freeze only policy.
Participants/materials, setting, methods: In HR patients (AMH> 3.5 ng /
ml and more than 18 follicles with diam. ≥ 12 mm) the trigger was obtained
with triptorelin 0.2 mg / sc. In patients considered to be at intermediate risk of
OHSS (< 18 oocytes retrieved) a rescue protocol has been applied: HCG 1500
IU / sc. at retrieval + estradiol 4 mg + vaginal progesterone 400 mg a day) and
fresh embryo transfer on day 3 or 5.
Main results and the role of chance: Patients included in the study were
good prognosis women with a mean age of 34.13 ± 4.42 years and good ovar-
ian reserve (FSH mean baseline of 6.29 ± 1.85 and AMH of 4.85 ± 3.34 ng /
mL). The retrieved oocytes were 13.71 ± 4.26 with a recovery rate of 75.6 ±
18.84% and a percentage of M2 oocytes of 79.41 ± 15.30%. The percentage of
patients with a recovery rate less than 75% was 30.33% and less than 50% of
was 6.15%. A total of 548 embryos were transferred, with an implantation rate
of 26% and a pregnancy rate of 39.11%. We stratiﬁed patients for transfer: 239
women performed the transfer at cleavage stage and 31 on blastocyst stage on
day 5. The pregnancy rate were respectively 38% and 48%. Analyzing the evolu-
tion of the 106 pregnancies obtained, our results show: 9 abortions in the ﬁrst
trimester and 2 in the second trimester (10.38% abortion rate), 2 therapeutic
abortions (1.8%) and 1 ectopic pregnancy (0.9 %). We had 92 deliveries (LBR
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39.49%). We observed 8 cases of OHSS (2.95%): 4 cases (1.48%) were admit-
ted to hospital for observation and medical therapy.
Limitations, reasons for caution: Although this is a single center study with
an homogenous population, the retrospective nature of the analysis has wide
range of biases, and although limited a risk condition for the patients.
Wider implications of the ﬁndings: In HR patients with intermediate risk
of OHSS, a GnRHa trigger and rescue protocol allows fresh ET with a relative
low risk of OHSS, excellent results in terms of LBR and a reduced time to preg-
nancy compared to a freeze only policy.
Trial registration number:NA.
P-668 The resting metabolic rate in women with polycystic ovary
syndrome and its relation to the hormonal milieu, insulin
metabolism and body fat distribution
V. Versace1, D. Romualdi1, V. Tagliaferri2, S. De Cicco1,
V. Immediata1, R. Apa1, M. Guido2, A. Lanzone1
1Università Cattolica del Sacro Cuore, Department of Obstetrics and Gynaecology,
Roma, Italy
2Ente Ecclesiastico Ospedale Generale Regionale “F. Miulli”, Department of
Obstetrics and Gynaecology, Acquaviva delle Fonti, Italy
Study question: Is resting metabolic rate (RMR), a major determinant of
energy expenditure, altered in women with polycystic ovary syndrome (PCOS)
compared with age- and BMI-matched controls?
Summary answer: PCOS women do not seem to have an abnormal basal
metabolism, as their RMR resulted comparable to control women.
What is known already: PCOS women have a higher prevalence of obesity
compared to the general population, moreover women with PCOS struggle in
their attempt to obtain weight loss and encounter more difﬁculties in weight
control compared with the age and BMI-matched general population. Both gen-
etic and environmental factors seem to be involved in this predisposition. Some
authors explored the hypothesis that the energy expenditure capacity could be
intrinsically reduced in PCOS, but results deriving from studies with indirect cal-
orimetry and Doubly Labeled Water are still inconsistent.
Study design, size, duration: This is a monocentric observational prospect-
ive cohort study. It was conducted for two consecutive years from January
2013 to January 2015 and included 138 subjects.
Participants/materials, setting, methods: 107 Caucasian subjects diag-
nosed with PCOS, according to Rotterdam Consensus diagnostic criteria and
31 healthy, age-BMI matched control women were enrolled in the study.
Energy expenditure evaluation, expressed as RMR, was obtained through the
SenseWear Armband (SWA), a reliable and validated metabolic holter, never
previously used in the PCOS population to this purpose. Hormonal assessment,
insulin metabolism evaluated by HOMA-IR and OGTT, anthropometric fea-
tures (BMI and WHR) were also assessed.
Main results and the role of chance: In accordance with the study design,
age and BMI were similar in the two cohorts: median age was 26.0 ± 9.2 years
in PCOS women and 25.5 ± 8.5 years in controls (p = 0.524); median BMI
26.4 ± 9.4 kg/m2 in PCOS women and 27.2 ± 12.8 kg/m2 in controls (p =
0.330). Nonetheless, the body fat distribution resulted signiﬁcantly different
between the two groups, suggesting a tendency towards central body fat accu-
mulation in the PCOS population (WHR 0.79 ± 0.10 vs 0.75 ± 0.10; p =
0.020).
Median RMR resulted similar in PCOS and control women: 1520.0 ± 248.00
kcal/day vs 1464.0 ± 332.70 kcal/day (p = 0.472), even after adjusting for
obesity, fat distribution, hyperinsulinemia and insulin resistance (respectively p
= 0.164, p = 0.317, p = 0.377, p = 0.232). RMR resulted directly correlated
with BMI, WHR, estradiol, total cholesterol, triglycerides, basal blood glucose,
basal insulin, AUC insulin 240’ and HOMA, while inversely with SHBG. In the
subgroup of patients with WHR>0,85, PCOS women showed a signiﬁcantly
lower RMR compared with controls.
Limitations, reasons for caution: The relatively small number of controls
might unbalance the sample size, even if an appropriate statistic was carried
out. WHR is not considered an accurate estimation of body fat distribution.
Wider implications of the ﬁndings: Our results strengthen the scientiﬁc
evidence regarding the normal capacity of consuming energy of women with
PCOS. The ﬁnding of a signiﬁcantly lower RMR rate among PCOS women with
WHR>0.85 compared with controls requires further investigation about the
role of body fat distribution in the metabolic homeostasis of PCOS population.
Trial registration number: clinicaltrials.gov Identiﬁer NCT03132545
P-669 Childhood and adolescence body mass index associates with
impaired reproductive function - a prospective, population-based
cohort study
J. Laru1, R. Nedelec2, M. Ojaniemi4, M.R. Järvelin2, J.S. Tapanainen1,
S. Franks9, S. Sebert2, T.T. Piltonen1, L. Morin-Papunen1
1University of Oulu and Oulu University Hospital, Department of Obstetrics and
Gynocology- Medical Research Center- PEDEGO Research Unit, Oulu, Finland
2University of Oulu, Center for Life Course Health Research, Oulu, Finland
3University of Oulu, Biocenter Oulu, Oulu, Finland
4University of Oulu and Oulu University Hospital, Department of Children and
Adolescents- Medical Research Center- PEDEGO Research Center, Oulu, Finland
5Imperial College London, Department of Epidemiology and Biostatistics- MRC-PHE
Centre for Environment and Health- School of Public Health, London, United
Kingdom
6Oulu University Hospital, Unit of Primary Health Care, Oulu, Finland
7Brunel University, Department of Life Sciences- College of Health and Life Sciences,
London, United Kingdom
8University of Helsinki and Helsinki University Hospital, Department of Obstetrics
and Gynaecology, Helsinki, Finland
9Imperial College London, Institute of Reproductive and Developmental Biology,
London, United Kingdom
10Imperial College London, Department of genomic of complex diseases- School of
Public Health, London, United Kingdom
Study question: What is the contribution of the prenatal environment, birth
weight, as well as childhood, adolescence and adulthood body mass index
(BMI) for reproductive capacity?
Summary answer: Children and adolescent girls with obesity have increased
risk of infertility and childlessness in adulthood. The association seems to be
partly independent of adult BMI.
What is known already: Previous studies have shown inverted J-shaped rela-
tionship between BMI during adolescence and the number of children later in
life. Furthermore, obese girls (BMI95thpercentile) display more menstrual
irregularities and can be more affected with infertility problems and inability to
become pregnant compared to their normal weight (NW, BMI:5-85thpercen-
tile) counterparts. Timing of adiposity peak (AP, maximum infant BMI at around
9 months) and of adiposity rebound (AR, second rise of BMI at 5-7years) is
associated with obesity and unfavorable metabolic proﬁle in adulthood.
However, follow-up studies through the whole reproductive life span on the
relationship between growth patterns and fertility/parity are limited.
Study design, size, duration: We study data from 5889 women born in
1966 and followed-up from gestational week 24 to age 46.
Postal questionnaires at ages 31 and 46 (answer rates 81% and 72%)
addressed questions on infertility problems and treatment. The fecundability
ratio (FR) was deﬁned as the probability of pregnancy within 12 months of preg-
nancy attempt. Self-reported infertility at age 46 (‘Have you ever had infertility
problems?”) and/or self-reported infertility treatments at both ages were
asked.
Participants/materials, setting, methods: Prenatal and BMI data were
collected by trained personnel at all stages. AR and AP were assessed using
REED1 model (infancy, N = 2858, and childhood, N = 3471, separately). BMI
Z-scores (for 17 time-windows from ages 2 to 31) were used to model devel-
opmental trajectories. Four latent BMI categories were identiﬁed. Deliveries
were collected from the Finnish birth register. All models were adjusted for
education level, marital and socioeconomic status, and smoking.
Main results and the role of chance: Mother’s BMI or weight gain during
pregnancy as well as birthweight, age at AP, AR or menarche were not asso-
ciated to problems of infertility or number of deliveries. Compared with NW,
obesity at adrenarche and menarche was associated with decreased FRs at age
31 (12.5% vs. 20.6%, OR:1.77, 95% CI [1.04-3.02] and 12.8% vs. 20.4%,
OR:1.74 [1.07-2.82], respectively). In comparison to NW group, obesity at
menarche, but not at adrenarche, positively associated with more self-reported
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infertility (15.4% vs. 28.4%, OR:1.48[1.05-2.08]) and nulliparity (18.3% vs.
23.9%, OR:1.47[1.01-2.13]), but not with self-reported infertility treatments.
Women with obesity at menarche and at age 31, but not at age 46, had less
deliveries than their NW counterparts (1.80 vs. 2.07, p = 0.023; 1.87 vs. 2.06,
p = 0.048, respectively). All those results remained statistically signiﬁcant after
adjusting.
The women in the two highest BMI trajectory groups (Group 3: ‘slow weight
gainers’; 14.0%) Group 4: ‘constant high’; 2.3%) exhibited higher risk for low
FRs compared to NW control group (Group 4: OR:3.03[1.22-7.56]); Group 3:
OR:1.49[0.97-2.31]). They also tend to have increased risk of self-reported
infertility (Group 4 OR:1.64[0.79-3.41]; Group 3: OR:1.49[1.02-2.05]) and nul-
liparity (Group 4:OR:1.90[1.13-3.19]; Group 3:OR:1.40[1.08-1.81]) and had
fewer children (Group 4:1.76 (p = 0.056); Group 3:1.84 (p = 0.002) vs.
NW:2.09).
Limitations, reasons for caution: Despite high participation rates through-
out all collection points, children’s growth data was not available for all partici-
pants due to delay in digitalization of hand written healthy records.
Wider implications of the ﬁndings: This study reveals that girls affected by
obesity during childhood and at adolescence might display reduced fertility cap-
acity in adulthood, partly independently of adulthood obesity. These results
support the importance of an active prevention and treatment of obesity
already in early childhood.
Trial registration number: not applicable.
P-670 Evaluating the impact of ovarian stimulation on endometrial
receptivity and reproductive outcome - A sibling oocyte study
D.K. Kumar1, P. Gopinath1, N. S1, R. R2, B. John1, G. Kannoly1
1Cimar Cochin Hospital, Infertility, Cochin, India
2cimarcochin hospital, infertility, cochin, India
Study question: Does “ freeze all “ policy improve pregnancy rate?
Summary answer: No, fresh transfer has equal or even better results than
frozen transfer.
What is known already: Clinical observations that frozen embryo transfer
(FET) reduces the risk of ovarian hyper stimulation syndrome and improves
endometrial receptivity has been supported by literature. Evidence which has
tilted the balance strongly in favor of deferring fresh transfer. Before we make
‘freeze all” a norm, it is important to evaluate its effectiveness.
Study design, size, duration: A sibling oocyte study provides a unique win-
dow of opportunity to test this hypothesis by comparing outcomes in ESP (Egg
Sharing patient) & ERP (Egg Receiving Patient). This is a prospective study con-
ducted at a tertiary level infertility centre during June 2015 - June 2017.the study
include 203 ESP and 276 ERP.
Participants/materials, setting, methods: In this study, the data from
oocyte sharing of 203 patients (ESP), all stimulated by conventional long proto-
col (GnRH agonist) and followed by controlled ovarian stimulation with HMG
(150IU-300IU) were included. The oocytes were shared among ESP and 276
anonymous recipients (ERP) after endometrial preparation with HRT.
Main results and the role of chance: This study revealed that pregnancy
rate was statistically higher (p = 0.0003) in fresh transfer in ESP than fresh trans-
fer in ERP (70.9% vs 53.2%). The pregnancy rate was statistically higher (p =
0.028) in fresh transfer in ESP than frozen transfer in ESP (70.9% vs 55.7%) with
no signiﬁcant difference (p = 0.588) in mean E2 between positive and negative
pregnancy rate. It was observed that pregnancy rate was statistically higher (p
= 0.03) in frozen ERP than fresh ERP (67.6% vs 53.2%). The pregnancy rate
between fresh ESP and fresh transfer deferred ESP (70.9% vs 78.6%) was similar
( p = 0.540).The incidence of OHSS in ESP was mild (4.4%), moderate (1.47%)
and severe (0.98%).
Limitations, reasons for caution: The study group was small in no. We
require larger groups for better comparison. Also other confounding factors in
ERP were not taken into account during the study.
Wider implications of the ﬁndings: The statistical analysis of this study
showed a better pregnancy rate among fresh transfer in ESP than in ERP or with
frozen transfers ESP there by disproving the concept of endometrial afﬂiction in
cases of stimulated cycles and alleviating the need to freeze all.
Trial registration number: not applicable.
P-671 Random-start Ovarian Stimulation in Egg donors (ROSE
trial). A self-controlled randomized pilot study
J.C. Castillo, A. Bernabeu, J. Guerrero, B. Moliner, J. Llacer,
R. Bernabeu
Instituto Bernabeu, Reproductive Medicine, Alicante, Spain
Study question: Can we expect a similar oocyte yield after randomly initiating
ovarian stimulation during the follicular phase when compared to conventional
protocols performed in the same oocyte donors?
Summary answer: The number of total and MII oocytes from random-start
protocols initiated during the follicular phase appears similar to conventional
ovarian stimulation start protocols in egg-donors.
What is known already: Random-start ovarian stimulation protocols has
been well studied in women with cancer for fertility preservation and, more
recently, in women who desire ‘elective” cryopreservation of oocytes, resulting
in optimal outcomes. In the context of an egg donation program, if ovarian
stimulation can be initiated irrespective of the phase of the menstrual cycle
without adversely impacting oocyte yield or quality, the approach may facilitate
schedules.
Study design, size, duration: Single center, prospective, randomized, clinical
trial performed in egg donors during year 2017. The study group (15 partici-
pants) started ovarian stimulation randomly at different moments throughout
the follicular phase, according to a list of random allocation of treatments start-
ing at day 5,7,9,11 or 13 of the menstrual cycle (three participants allocated to
each day). Controls: each patient served as her own control comparing previ-
ous cycle within 6 months under conventional initiation of stimulation.
Participants/materials, setting, methods: The study group started ovar-
ian stimulation randomly at days 5,7,9,11 or 13 of the cycle. Participants
received urinary FSH (Fostipur®) 150-225 IU/d, cetrorelix 0.25 mg/d
(Cetrotide®) started ﬁve days after ovarian stimulation and triptorelin 0.2 mg
(Decapeptyl®) induced the ﬁnal follicular maturation. Controls: previous cycle
by the same egg donor under conventional initiation of stimulation (cycle day
2/3), using the same gonadotrophin and dose. 28 cycles in total were included
in the analysis. There was 01 drop-out.
Main results and the role of chance: As a whole, among young egg donors
(mean age: 24.8 ± 4.5 y.o.); the results were comparable between study group
vs controls with regards to: number of days of stimulation (9.2 ± 1.3 vs 10 ±
1.5 p = 0.2); gonadotrophin (IU) consumption (1898 ± 457 vs 2065 ± 808 p
= 0.5); number of collected eggs (19 ± 9.2 vs 21 ± 12.2 p = 0.6) and propor-
tion (%) of mature eggs (82 ± 10 vs 85.8 ± 5.5; p = 0.2) respectively.
Additionally, the fertilization rate (ICSI%) was also similar (71 ± 7.8 vs 69.6 ±
8.7 p = 0.3).
Limitations, reasons for caution: Small number of donors included per
speciﬁc day of started stimulation. These results might be extrapolated to other
group of IVF patients (e.g. young women with tubal or male factor infertility)
although caution is warranted since laboratory outcomes beyond fertilization
were not analyzed. Future trials should address this point.
Wider implications of the ﬁndings: As ovarian stimulation can be initiated
regardless of the day during the follicular phase of the menstrual cycle without
adversely impacting oocyte yield or fertilization rate in egg donors, the
approach may facilitate schedules in egg donation programs.
Trial registration number:NCT02821819.
P-672 Validation of a novel ELISA assay for serumAMH
determination
A. Schultze - Mosgau1, K. Neumann2, M. Depenbusch2,
T. Osterholz-Zaleski2, G. Griesinger2
1University of Schleswig-Holstein- Campus Luebeck, Section of Reproductive
Medicine, Lübeck, Germany
2Section of Gynecologic Endocrinology and Reproductive Medicine, University
Hospital of Schleswig-Holstein Campus Luebeck, Lübeck, Germany
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Study question: Validation of the novel Euroimmun MRH/AMH ELISA using
the Gen II ELISA by Beckmann Coulter (GenII-BC) as a standard.
Summary answer: The novel EU AMH ELISA achieves adequate perform-
ance as compared to established GenII-BC ELISA and is suitable for broader
utilization in clinical and research settings.
What is known already: Serum Anti-Mullerian Hormone (AMH) levels cor-
respond to ovarian function and reserve. Clinically, AMH levels are routinely
assessed in infertility treatment to estimate the prognosis and risk proﬁle of a
given woman.
Different assays have been developed for serum AMH assessments. Several
studies demonstrated signiﬁcant variations of AMH values depending on the
ELISA kit used, casting doubts on the validity of AMH measurements in a clinical
scenario.
Recently, the company Euroimmun (Luebeck, Germany) developed a novel
MRH/AMH ELISA, based on a combination of two highly speciﬁc antibodies,
different from the antibodies utilized for the GenII-BC
Study design, size, duration: This was a prospective, single-center study.
AMH values were generated with/without buffer pre-mixing. Furthermore, dif-
ferent lots of the GenII-BC were tested as reference. The novel Mullerian-duct
repression hormone (MRH/AMH) ELISA from Euroimmun (referred to as EU
AMH ELISA herein) is based on the combination of two highly speciﬁc anti-
bodies. Quantitative measurement is performed at 450 nm wavelength. Results
are expressed as nanogrammes per milliliter (ng/ml).
Participants/materials, setting, methods: Frozen serum samples from
121 infertile female patients were analysed by the Euroimmun AMH ELISA and
GenII-BC assay, respectively. To study assay agreement, a Passing-Bablok
regression model and a Bland-Altman analysis were performed.
Main results and the role of chance: There is no difference between the
AMH values generated with or without pre-mixing of probes with assay buffer
in either the GenII-BC (Passing-Bablok equation: y = 1.13 + 0.03×, 95% conﬁ-
dence intervals (CI): 1.10. - 1.18, intra class correlation coefﬁcient (ICC) =
0.98, 95% CI: 0.88–0.99, Rc = 0.97, 95% CI: 0.96–0.99; n = 24) or in the EU-
AMH ELISA (Passing-Bablok equation: y = 1.06 + 0.04×, 95% CI: 1.03. - 1.10,
ICC = 0.99, 95% CI: 0.97–0.99, Rc = 0.99, 95% CI: 0.98–0.99; n = 19).
The Passing-Bablok equation shows adequate performance of the EU-AMH
ELISA (y = 1.17–0.05×, 95% CI: 1.12–1.23; n = 121) compared to GenII-BC
ELISA. The analysis conﬁrms a linear association (p = 0.51 for non-linear associ-
ation) and prove adequate correlation of the assays (ICC = 0.96, 95% CI:
0.92–0.98 and Rc = 0.93, 95% CI: 0.90–0.95; n = 121).
Limitations, reasons for caution: It is in the nature of a comparison of two
different ELISA assays that an inﬂuence of the GenII-BC ELISA on assumed out-
liers measured by the EU-AMH ELISA cannot be excluded without comparison
of these values with those of further ELISA assays.
Wider implications of the ﬁndings: The EU-AMH ELISA shows good per-
formance in measuring serum AMH levels. Assessing the intra-assay variation
the ELISA revealed a high reproducibility between different standard- and kit-
lots. The present study could not reveal an inﬂuence of pre-mixing on the
reproducibility of measured AMH values which is in contrast to previous
investigations.
Trial registration number: not applicable.
P-673 Is there any predictive factor of resistance to clomiphene
citrate (CC) for ovulation induction in polycystic ovarian syndrome
(PCOS)?
L. Huyghe1, A. Dumont2, O. Calistru3, S. Catteau-Jonard4,
G. Robin2, D. Dewailly5
1Medical Gynecology Resident, Endocrine Gynecology and Reproductive Medicine
Department- CHRU, LILLE, France
2Medical Gynecology Doctor, Endocrine Gynecology and Reproductive Medicine
Department- CHRU, Lille, France
3Obstetrician Gynecologist Doctor, Obstetrics and Gynecology Department, Lille,
France
4Medical Gynecology Professor, Endocrine Gynecology and Reproductive Medicine
Department- CHRU, Lille, France
5Endocrinology Professor, Endocrine Gynecology and Reproductive Medicine
Department- CHRU, Lille, France
Study question: To study whether clinical, biological or ultrasonic characteris-
tics of PCOS patients with ovulation disorder can predict total or partial resist-
ance to ovulation induction by CC.
Summary answer: Only BMI was weakly predictive. No other factor could
discriminate patients with total or partial resistance to CC from sensitive
patients.
What is known already: PCOS is the most common endocrine disorder in
women of childbearing age. It can be responsible for ovulation disorder and
infertility. The Thessaloniki consensus deﬁnes CC as the ﬁrst-line treatment for
ovulation induction in PCOS patients seeking a pregnancy. It is an efﬁcient, easy
and low cost treatment. The cumulative pregnancy rate was 70 % after 6 cycles.
20 % of the patients are resistant to CC, either at the starting dose (50 mg) or
100 mg (partial resistance) or at the maximum dose of 150 mg (total resist-
ance). Literature is still conﬂicting about factor(s) predicting total/partial resist-
ance to CC.
Study design, size, duration: This large retrospective study was conducted
between March 1999 and November 2017 in a single academic department of
Reproductive Medicine. Patients included were diagnosed with PCOS, as
deﬁned by the Rotterdam consensus. Only patients with ovulation disorder
(phenotypes A, B, D) and undergoing CC treatment for ovulation induction
were included.
Participants/materials, setting, methods: 312 patients were included
(1,012 cycles). To determine if the treatment was effective, an ultrasound was
performed on D12, looking for a dominant follicle. A progesterone assay was
conducted on D24 and ovulation was attested if progesterone was ≥ 5 ng/mL.
Resistance to CC was deﬁned by absence of ovulation. Four groups were
formed according to CC resistance proﬁl: no resistance, resistance to 50 mg,
resistance to 100 mg, resistance to 150 mg (total resistance).
Main results and the role of chance: Compared to the group “no resist-
ance” (n = 153), partially and totally CC-resistant patients (n = 249) were
more likely to be amenorrheic (p<0.02), and had ranks of higher BMI
(p<0.005) and waist circumference (p<0.005). Biologically, in the latter group,
baseline serum AMH levels were signiﬁcantly higher (p<0.02), as well as D4-
androstenedione (p<0.02) and fasting insulin levels (p<0.01). SHBG levels were
signiﬁcantly lower (p<0.001). All those parameters increasingly varied between
the 3 groups of resistance, although not signiﬁcantly. By discriminant analysis,
only one model including only BMI could signiﬁcantly (p<0.0001) distinguish
between sensitive and resistant patients. By ROC analysis including either BMI,
AMH or D4-androstenedione, no discriminating threshold could be obtained to
predict CC resistance with satisfactory sensitivity and speciﬁcity.
Limitations, reasons for caution: The main limitation of our study was its
retrospective design, responsible for bias and missing data. But to our knowl-
edge, this is the largest cohort of PCOS patients monitored for CC in the same
hospital, making the evaluation more reliable.
Wider implications of the ﬁndings: Our data conﬁrm that no parameter
can be used to decide whether skipping or not the step of CC treatment or to
choose the starting dose in anovulatory patients with PCOS. However, the
association between BMI and CC resistance should encourage the management
of obesity before and during treatment.
Trial registration number:Not applicable.
P-674 The ovarian response after follicular versus luteal phase
stimulation with a double stimulation strategy
P. Santulli, M. Bourdon, Y. Chen, J. Gonnot, C. Cervantes,
V. Blanchet, C. Maignien, K. Pocate-Cheriet, L. Marcellin,
C. Chapron
Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-
obstétrique et médecine de la reproduction II, Paris, France
Study question: Is the ovarian response after stimulation performed during
the follicular phase (FP) versus the luteal phase (LP) with a double stimulation
strategy equally efﬁcient?
Summary answer: Stimulation during the LP in a double-successive stimula-
tion strategy results in a lower ovarian response as compared to the FP equiva-
lent daily dose stimulation.
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What is known already: Double ovarian stimulation is an option for enhan-
cing oocyte recruitment when a single stimulation is not sufﬁcient, or when
there is limited time for assisted reproductive technology, such as with fertility
preservation. It is also a viable option for dealing with an insufﬁcient ovarian
response that can sometimes be encountered with ART, notably in poor
responders. Nonetheless, there is still controversy regarding the equivalence
and effectiveness of luteal phase controlled ovarian stimulation (COS) as com-
pared to the previous follicular phase stimulation with a double stimulation
strategy.
Study design, size, duration: This was an observational cohort study using
data collected in a continuous series of patients scheduled for a double stimula-
tion protocol between March 2014 and June 2017 at our institution.
Participants/materials, setting, methods: Women starting a FP (COS1)
and a LP stimulation (COS2) in a double-stimulation protocol were enrolled.
Both the COS1 and the COS2 used equivalent daily doses of gonadotropins in
combination with GnRH-antagonist. Ovulation was triggered using GnRH-
agonist. The number of oocytes retrieved, the oocyte maturation rate, the dur-
ation of stimulation, the total dose of injected gonadotropin, and the estradiol
level at triggering were collected so as to compare the extent of the ovarian
response.
Main results and the role of chance: A total of 77 patients were included
in the analysis. The number of oocytes retrieved (5.25 ± 3.38 for COS 1 versus
3.83 ± 3.14 for COS 2; p = 0.001), as well as the number of MII oocytes (4.49
± 3.05 for COS 1 versus 3.25 ± 2.86 for COS 2, p = 0.003) after COS 1 were
signiﬁcantly higher than after the COS 2. There were no signiﬁcant differences
in regard to the oocyte maturation rate between the two stimulations. The dur-
ation of the stimulation was signiﬁcantly shorter (9.71 ± 1.46 days for COS 1
versus 11.25 ± 1.82 days for COS2; p < 0.001), the total dose of injected gona-
dotropins was signiﬁcantly lower (2,916.23 ± 439.68 for COS 1 versus
3,374.03 ± 546.62 for COS 2; p < 0.001,) and the estradiol level on the trigger
day was signiﬁcantly higher (1,135.99 ± 824.28 pg/mL for COS 1 versus
661.42 ± 477.74 pg/mL, for COS 2; p < 0.001) with COS 1 as compared to
COS 2.
Limitations, reasons for caution: The present study suffers from the limita-
tion of its design involving a retrospective analysis of a prospective cohort.
However, in this cohort study, numerous epidemiological variables were col-
lected prospectively through face-to-face interviews before stimulation.
Wider implications of the ﬁndings: The two phases (FP and LP) were not
equally efﬁcient with a double stimulation strategy. Aside from in an emergency
situation, a double stimulation strategy does not appear to be more effective
than two separate conventional follicular phase stimulations. Further investiga-
tions are required, however, to conﬁrm these ﬁndings.
Trial registration number:None.
P-675 A randomized, controlled trial (RCT) of AMH-based
individualized ovarian stimulation for in vitro fertilization
J.F. Petersen1, E.C.L. Løkkegaard1, L.F. Andersen1, K. Torp1,
L. Hedegaard2, D.R. Nysom2, A.N. Egeberg2, A.N. Andersen2
1North Zealand Hospital, Obstetrics and gynecology, HIllerød, Denmark
2Rigshospitalet, The Fertility Clinic, Copenhagen, Denmark
Study question: Does an individualized Anti-Müllerian hormone (AMH)
based follicle stimulating hormone (FSH) dosing in an antagonist protocol
increase the proportion of patients with an optimal number of oocytes?
Summary answer: The AMH-based individualized dosing algorithm did not
optimize the number of oocytes mainly due to insufﬁciency of 100 IU/day of
FSH in predicted hyper-responders.
What is known already: Individualizing FSH dosing for ovarian stimulation
can theoretically improve the balance between beneﬁts and risks. Current data
suggest a reduced risk of ovarian hyperstimulation syndrome (OHSS), but no
evidence of increased pregnancy or live birth rates. AMH is known as a good
marker of ovarian response, but data are limited on how to implement the use
of this predictive factor into clinical practice. Only a few RCTs have used AMH-
based algorithms to optimize the FSH dosing in ovarian stimulation.
Study design, size, duration: A dual-center open-label RCT conducted
January 2013 – November 2016. Eligibility was assessed in 269 women and 221
were randomized 2:1 between study and control in an antagonist cycle.
Women with high AMH (≥25 pmol/L) had minimal stimulation (rFSH 100 IU/
day); women with medium AMH (12 – 24 pmol/L) standard stimulation (rFSH
150 IU/day), and low AMH (<12 pmol/L) had maximum stimulation (corifolli-
tropin). The control group had 150 IU/day of FSH irrespective of pretreatment
AMH.
Participants/materials, setting, methods: All women had a presumed
normal ovulatory menstrual cycle, were aged 25–38 years, weighed <75 kg,
had 1st IVF or ICSI with pretreatment AMH ranging from 4–40 pmol/L and
had two ovaries accessible to oocyte retrieval. Recruitment was conducted
from both participating sites. Women with anovulatory PCOS, endometri-
osis grade III/IV, hydrosalpings on ultrasound, recurrent miscarriages (≥3)
and FSH > 12 IE/L were excluded. All transfers were single blastocyst
transfers.
Main results and the role of chance: After randomization 149 women
comprised the study group and 72 the control group. The groups had a similar
distribution of basal AMH levels. The primary outcome of predeﬁned optimal
number of 5-14 oocytes was achieved in 72% of the study and 78% of the con-
trols. This difference was not signiﬁcant. In the high AMH stratum of the study
group given 100 IU rFSH/day 38% had an insufﬁcient (<5) number of oocytes,
compared with 6% among the controls given 150 IU rFSH/day (p = 0.03). In
the low AMH stratum the study group given corifollitropin had a nonsigniﬁcant
tendency towards more optimal responses of 73% compared with 53%in the
control group. Dose reduction was needed in 2 women (one in each study
arm) and cycle cancellation due to insufﬁcient response occurred in 3 (2 in the
study and 1 in the control).OHSS was diagnosed in 4 women (2 in each group).
Participants answered a daily questionnaire during the luteal phase describing
subjective well-being in terms of abdominal distention, abdominal pain, dyspnea
and weight. No differences were found between groups. The live birth rates
per started cycle were similar (28% and 29%) in the study vs. control group.
Limitations, reasons for caution: This study was powered to determine
differences in the distribution of number of oocytes retrieved in the study and
control groups, but not to assess possible risk reductions of OHSS as larger
data sets would be needed.
Wider implications of the ﬁndings: In the high AMH stratum expected to
be at risk for excessive responses, 100 IU/day of rFSH seems insufﬁcient when
using the antagonist protocol. Further studies should investigate whether 125
IU/day would be better to balance beneﬁts in terms of number of oocytes ver-
sus OHSS risk.
Trial registration number: EUDRACT number 2012-004969-40
P-676 Telomere length and telomerase activity in cumulus cells of
women with Polycystic Ovarian Syndrome
D.C.C. Pedroso1, C.L. Miranda-Furtado1, M.C. Picinato1,
F.S. Donaires2, R.C. Giorgenon1, V.P. Santana1, B.A. Santana2,
D.L. Keefe3, R.A. Ferriani1, R.D.T. Calado2, R.M. Reis1
1Ribeirao Preto Medical School- University of Sao Paulo, Gynecology and Obstetrics,
Ribeirao Preto, Brazil
2Ribeirao Preto Medical School- University of Sao Paulo, Internal Medicine, Ribeirao
Preto, Brazil
3New York University Langone Medical Center, Gynecology and Obstetrics, New
York, U.S.A.
Study question: What are the implications of Polycystic Ovarian Syndrome
(PCOS) on telomere length and telomerase activity in cumulus cells?
Summary answer: Telomere length in cumulus cells did not differ between
PCOS and controls. However, telomerase activity in cumulus cells was higher in
the PCOS.
What is known already: Women with PCOS, despite responding well to
Assisted Reproduction Treatments (ART), the oocytes usually have low
quality and reproductive capacity, which is correlated to oocyte interaction
with cumulus cells, in the cumulus-oocyte complex. The low oocyte quality
may be related to loss of genomic stability of oocytes, or even cumulus
cells, and may lead to a reduction of female fertility. The telomere length
and telomerase activity play a fundamental role in maintaining genomic sta-
bility, which is considered an important molecular marker of cell viability,
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whose alterations are related to apoptosis and/or senescence, maybe also
an indicative of oocyte quality.
Study design, size, duration: A prospective case-control study, in which 38
women with PCOS and 61 controls were included from September 2015 to
June 2017.
Participants/materials, setting, methods: Age, body mass index (BMI)
were measured. Follicle stimulating hormone (FSH), luteinizing hormone (LH),
estradiol, prolactin, insulin, androstenedione, testosterone, free androgen index
(FAI), c-reactive protein and homocysteine were evaluated. Telomere length in
cumulus cells from immature (ICC) and mature (MCC) oocytes, and leukocytes
were evaluated by quantitative real-time polymerase chain reaction (qPCR).
Telomerase activity from cumulus cells was evaluated by TRAPeze® XL Kit.
Statistical analyses were determined by Wilcoxon test and Spearman
correlation.
Main results and the role of chance: Age mean was 33.74 (±4.12) in
PCOS and 34.33 (±3.63) in controls (p=.509). The variables BMI (p=.001), LH
(p=.015), estradiol (p=.004), insulin (p=.002), testosterone (p<.0001), andro-
stenedione (p=.001), FAI (p<.0001) and c-reactive protein (p=.003) was
increased in PCOS group. FSH (p=.0002) was smaller in PCOS group. Prolactin
and homocysteine were not different between the groups. The telomeres
length in ICC did not differ between PCOS and control groups (1.60 ± 0.56 vs
1.58 ± 0.33; p=.649, respectively). The telomeres length in MCC did not differ
between PCOS and control groups (1.61 ± 0.47 vs 1.70 ± 0.43; p=.378,
respectively). However, in leukocytes reduced telomeres were observed in the
PCOS (p=.025), respectively. The telomerase activity in ICC was higher in the
PCOS group than in the control group (1.62 ± 1.49 vs 0.30 ± 0.42; p=.003,
respectively). The telomerase activity in MCC was higher in the PCOS group
than in the control group (1.39 ± 1.63 vs 0.55 ± 0.84; p=.022, respectively). A
positive correlation between telomerase activity and telomere length in the
ICC was observed in control group (p=.051). PCOS also presented a positive
correlation between telomerase activity and telomere length in MCC (p=.048).
Telomere length of leukocytes, ICC and MCC were a positive correlated in
both groups.
Limitations, reasons for caution: The limited number of cases of the study
group. An increase of sample size is recommended to make the data more
robust and conﬁrm the results.
Wider implications of the ﬁndings: PCOS seems not to affect telomere
content in ICC and MCC, only leukocytes telomeres were reduced in this syn-
drome. On the other hand, higher telomerase activity ICC and MCC may be
required for telomere maintenance in the PCOS.
Trial registration number:N/A.
P-677 HECTD1 inﬂuences endocytosis of EGFR through APPL1
C. De Geyter1, X.Wang2, H. Zhang2
1University of Basel, Reproductive Medicine and Gyn. Endocrinology RME, Basel,
Switzerland
2Department of Biomedicine DBM, University Hospital- University of Basel-
Switzerland, Basel, Switzerland
Study question: Whether HECTD1, a newly identiﬁed E3-ligase, inﬂuences
endocytosis of membrane-bound hormone receptors (such as the epidermal
growth factor-receptor, EGFR) and how is it regulated?
Summary answer: HECTD1 inhibits degradation of EGFR and thereby inﬂu-
ences EGF-signalling pathway. It regulates the recycling pathway through APPL1
What is known already: HECTD1, also known as EULIR, denominates a
HECT domain containing E3 ubiquitin ligase. HECTD1 interacts with several
membrane receptors, including LH-receptor, FSH-receptor and EGFR. APPL1 is
a subpopulation of early endosomes, which regulates the endocytosis pathway.
Study design, size, duration: prospective experimental study, lasting 2
years.
Participants/materials, setting, methods: In HeLa cells HECTD1 expres-
sion level is downregulated by HECTD1-speciﬁc shRNA. The stable cell lines
were selected by puromycin. Immunoﬂuorescence and FACS were used to
study the receptor trafﬁcking. EGF receptor degradation and EGF signalling
pathway activation were examined by Western blot. Immunoﬂuorescence was
used to localize APLL1.
Main results and the role of chance: Our studies demonstrated that
HECTD1-knockdown inhibits degradation of EGFR and inﬂuences signalling of
EGF. Activated MAPK signalling pathway is prolonged. APPL1 localizes in the
cytoplasm, under the plasma membrane and in the centrosome. HECTD1 co-
localizes with APPL1 6 minutes after EGF-stimulation. After HECTD1-
knockdown, APPL1 co-localizes with EGF less in cytoplasm but appears close
to the plasma membrane.
Limitations, reasons for caution: Basic experimental research results may
not be fully appreciated in complete systems.
Wider implications of the ﬁndings: Understanding the regulation of endo-
cytosis of membrane-bound receptors through HECTD1 may help to under-
stand local and temporal differences in sensitivity to endocrine regulation.
Trial registration number:None.
P-678 Cumulative live birth rates (CLBR) after in vitro maturation
(IVM) of oocytes in patients with polycystic ovary syndrome (PCOS):
does PCOS phenotype have an impact?
T. Deckers1, L. Mostinckx1, R. Buyl2, I. Segers1, E. Anckaert3,
C. Blockeel1, M. De Vos1
1Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussels, Belgium
2Vrije Universiteit Brussel, Department of Biostatistics and Medical Informatics-
Faculty of Medicine and Pharmacy, Brussels, Belgium
3Universitair Ziekenhuis Brussel, Laboratory of Clinical Chemistry and
Radioimmunology, Brussels, Belgium
Study question: Which parameters are predictive of CLBR after non-hCG
triggered serum-free IVM and is there an impact of the PCOS phenotype?
Summary answer: After IVM, CLBR do not vary signiﬁcantly between PCOS
phenotypes. Calculated free testosterone (FTc) and number of fertilised
oocytes are independently correlated with CLBR.
What is known already: In patients with PCOS undergoing conventional
assisted reproductive technology (cART), PCOS phenotype is an independent
predictor of CLBR. Hyperandrogenic phenotypes of PCOS have signiﬁcantly
poorer cumulative outcomes compared to their normoandrogenic counter-
parts and compared to patients with polycystic ovarian morphology (PCOM).
IVM is a mild-approach, OHSS-free ART alternative and can be offered to
patients with polycystic ovaries. Whether clinical outcomes of IVM treatment
are inﬂuenced by the PCOS phenotype is currently unknown.
Study design, size, duration: Retrospective cohort study of all patients who
underwent their ﬁrst IVM cycle in a university-based tertiary clinic between
April 2014 and December 2016. Patients who underwent fertility preservation
or preimplantation genetic diagnosis were excluded. In total, 258 cycles were
analysed, in 240 of which the cumulative outcome was known.
Participants/materials, setting, methods: Patients with PCOM, PCOS
A (hyperandrogenism + ovulatory dysfunction + polycystic ovaries), C
(hyperandrogenism + polycystic ovaries) and D (ovulatory dysfunction +
polycystic ovaries) between 20-41 years-old underwent non-hCG triggered
IVM (30 h) after a short HP-hMG course. Fresh blastocyst transfer was
planned if ≥4 good-quality d3-embryos were available. Otherwise, embryos
were vitriﬁed at cleavage-stage and transferred in an artiﬁcial cycle.
Androgens and SHBG levels were measured at intake and cumulative live
birth rates were calculated.
Main results and the role of chance: Mean age, body mass index, and
antimüllerian hormone concentration were 28.7 ± 3.3 years, 25.0 ± 5.2 kg/
m2, and 10.3 ± 6.2 ng/mL, respectively. Mean amount of COCs retrieved,
metaphase II oocytes after IVM and 2PN oocytes after ICSI were 20.2 ± 13.0,
9.1 ± 6.4 and 6.0 ± 4.9, respectively. A total of 77 infants were born, all of
which were singletons. Overall, CLBR per started cycle was 32.1% (77/240)
and CLBR did not vary signiﬁcantly between PCOS phenotypes, ranging from
23.1% (3/13) in PCOS-C, 31.8% (35/110) in PCOS-D to 37.1% (36/97) in
PCOS-A (p = 0.2). In patients with PCOM, CLBR was only 15% (3/20). None
of the patients developed OHSS.
Multiple binary logistic regression analysis showed that serum FTc levels and
number of 2PN oocytes, with unstandardized coefﬁcients (95% CI) of 0.732
(0.613–0.874) (P = 0.001) and 1.183 (1.076–1.299) (P<0.001), respectively,
are strong independent predictors of cumulative live birth.
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Limitations, reasons for caution: The relative small sample size of PCOS
phenotype C and PCOM may preclude robust conclusions regarding CLBR
after IVM in these subpopulations. Other variables, such as needle type, aspir-
ation technique and IVM culture system may also contribute to IVM outcome.
Wider implications of the ﬁndings: Cumulative outcomes after HP-hMG
primed, non-hCG triggered IVM in selected patients with PCOS are strongly
inﬂuenced by the endocrine proﬁle of the patient. Whether medical or lifestyle
interventions that result in reduced free testosterone levels could improve IVM
success rates in hyperandrogenic patients merits further scrutiny.
Trial registration number: not applicable.
P-679 Artiﬁcial frozen embryo transfer cycles: how important are
the circulating estradiol (E2) levels for live birth rates?
E. Orinx, S. Mackens, S. Santos-Ribeiro, N. DeMunck, A. Racca,
B. Popovic-Todorovic, H. Tournaye, C. Blockeel, M. De Vos
UZ Brussel, Centre for Reproductive Medicine, Jette, Belgium
Study question: Do artiﬁcial frozen embryo transfer (FET) cycles require
endocrine monitoring for E2 prior to commencing exogenous P administration?
Summary answer:We found no association between late-proliferative phase
serum E2 levels and livebirth rates in artiﬁcial FET cycles.
What is known already: The use of FET has progressively increased and the
need for endocrine monitoring during the proliferative phase in artiﬁcial cycles
remains unclear. In several studies, late-proliferative phase serum E2 and lutein-
izing hormone (LH) levels did not seem to predict outcome, however, others
have found elevated proliferative serum E2 may negatively impact live birth
rates after artiﬁcial FET.
Study design, size, duration: All artiﬁcial FETs performed in a tertiary cen-
tre between 2010-2015 were included in this retrospective study (n = 1341).
The same artiﬁcial protocol was performed in all cases and blood sampling with
a hormone measurement essay was performed 1 or 2 days before exogenously
inducing the luteal phase. These cycles were subdivided into 4 groups according
to the 25%, 50% and 75% percentiles for late-proliferative serum E2 levels:
≤190 pg/ml (n = 341), 191-257 pg/ml (n = 331), 258-355 pg/ml (n = 338)
and ≥356 pg/ml (n = 331).
Participants/materials, setting, methods: We performed mixed-effects
multilevel multivariable regression to assess the potential effect of late-
proliferative E2 on livebirth rates while adjusting for the following potential con-
founders: female age, prior livebirths, IVF/ICSI cycle rank, body mass index
(BMI), presence of irregular cycles, number of good quality embryos produced,
blastocyst versus cleavage stage transfer, total number of days of E2 supplemen-
tation, endometrial thickness, need to step-up the administration of E2, and the
late-proliferative serum LH and progesterone levels.
Main results and the role of chance: There were no signiﬁcant differences
between these groups in terms of age (31.9 ± 4.7), IVF/ICSI cycle rank (1.8 ±
1.3), number of oocytes retrieved (15.4 ± 9.2), BMI (25.2 ± 5.2), number of
prior livebirths (0.4 ± 0.6), blastocyst vs cleavage stage transfer (65.1% vs
34.9%), total dose of E2 administered (76.1 ± 36.1 mg of estradiol valerate)
and endometrial thickness (8.5 ± 2.2 mm). There were, however, statistically
signiﬁcant differences among the 4 study groups in terms of number of embryos
produced after the fresh cycle (5.2 ± 2.9, 5.3 ± 3.2, 5.6 ± 3.2, 5.7 ± 2.9,
p<0.001), the presence of irregular cycles (59.1%, 61.2%, 53.6%, 50.2%, p =
0.016), the need for a exogenous E2 administration step-up (21.7%, 13%,
14.8%, 19.9%, p0.015) and the total number of days of E2 supplementation
(14.4 ± 3.7, 13.8 ± 3.2, 13.7 ± 2.8, 14.2 ± 3.3, p = 0.023). Following both uni-
variable and multivariable regression analysis, the level of late-proliferative circu-
lating E2 showed no signiﬁcant difference in terms of livebirth rates after FET
(15.2%, 16.7%, 18.8% and 16%, p = 0.662).
Limitations, reasons for caution: The interpretation of the ﬁndings of this
study is limited by the retrospective nature of the analysis and the potential for
unmeasured confounding.
Wider implications of the ﬁndings: According to this large retrospective
dataset, the late-proliferative circulating levels of E2 in artiﬁcial FET cycles are
not associated with the subsequent livebirth rates and, thus, monitoring these
levels and using them to guide clinical decision-making (e.g. medication step-up,
cycle prolongation or cancelation) is of questionable value.
Trial registration number:NA.
P-680 Changes in the management of poor-responders patients
after internal analysis of IVF outcomes according to the Poseidon
criteria
P. Oger1, L. Delaroche2, C. Yazbeck1, N. Kazdar2, F. Lamazou1
1CMC Pierre Cherest, ART Center, neuilly sur seine, France
2Unilabs-Laboratory, ART Center-CMC Pierre Cherest, Neuilly sur seine, France
Study question: How did the internal analysis of IVF outcomes in poor-
responders patients according to the Poseidon criteria help us to change our
management?
Summary answer: Management of poor responders consists to start ovarian
stimulation with high-dose of FSH and to cancel the cycle if less than 4 follicles
are obtained.
What is known already: The chances of achieving a live birth in the poor
responders are low. The deﬁnition of poor ovarian responders according to the
Bologna criteria is unclear because it mixes different ovarian proﬁles. That is
why the Poseidon group has proposed a new classiﬁcation deﬁning 4 categories
of patients. To our knowledge, no study has reported so far the IVF outcomes
according to this new classiﬁcation.
Study design, size, duration: This is a single-center observational study per-
formed from January 2016 to 2017. 2519 cycles from patients aged between 18
and 42 years old were included. The exclusion criteria were extreme oli-
goasthenoteratospermia and genetic diseases; classiﬁcation according to the 4
groups described by the Poseidon classiﬁcation.
Participants/materials, setting, methods: Ongoing pregnancy (OPR) and
miscarriage rates were analyzed according to Poseidon classiﬁcationGroup 1
(<35 years, AMH > 2 ng/mL) 498 cycles: 1 A (<4 oocytes) 23 cycles; 1B (4 to
9 oocytes) 165 cycles Group 2 (> 35 years, AMH > 2 ng/mL) 638 cycles: 2 A
(<4 oocytes) 64 cycles; 2B (4 to 9 oocytes) 181 cyclesGroup 3 (<35 years,
AMH <1.2 ng/mL and AFC<5): 99 cyclesGroup 4 (> 35 years, AMH <1.2 ng/
mL and AFC <5): 730 cycles.
Main results and the role of chance: In the good prognosis groups (Group
1 and 2), the pregnancy rate was low in case of few oocytes collected (group
1 A, the OPR is 28.5% (2/7), no miscarriage was reported. In group 2 A, we
had no evolutive pregnancy (0/30) and the miscarriage rate was 100% (2/2)).
When 4 to 9 oocytes were obtained, the OPR was better in younger group
(group 1B, OPR was 28.4% (35/123), miscarriage rate 20.5% (9/44); In group 2B,
OPR was 21.4% (28/131), miscarriage rate 39.1% (18/46)). In the worst progno-
sis groups (Group 3 and 4), regardless of age, OPR was low (group 3, OPR was
7.7% (5/65), miscarriage rate 55% (6/11); group 4, OPR was 16.1% (37/230),
miscarriage rate 35.1% (13/37)). in these groups, OPR was not improved by nat-
ural cycles compared to high stimulated cycles in the older patients (Group 3: 73
stimulated cycles, OPR was 7.4% (4/54), miscarriage rate 60% (6/10);12 natural
cycles, OPR was 25% (1/4), no miscarriage. Group 4: 615 stimulated cycles, 468
pick-up, OPR 16.1% (30/186), miscarriage rate 43.3% (13/30); 115 spontaneous
cycles, 96 pick-up, OPR 15.9% (7/44), no miscarriage).
Limitations, reasons for caution: This is an observational retrospective
study and the protocols and strategies were speciﬁc to each clinician. Some
subgroups are too small.
Wider implications of the ﬁndings: The Poseidon classiﬁcation allows to
modify medical practice: a maximum number of oocytes is essential because
rate of euploid oocytes is constant; the cancellation of a poor cycle allows to
propose a stronger appropriate stimulation to recover as many oocytes as pos-
sible. Couples can be informed on the expected results.
Trial registration number: not applicable.
P-681 Does the change in needle diameter effect oocyte quality
and embryomorphokinetics? A prospective randomized pilot study
with sibling oocytes
Y. Atzmon, M. Michaeli, N. Aslih, G. Shrem, O. Ruzov, N. Rotfarb,
E. Shoshan-Karchovsky, E. Shalom-Paz
Ruth and Bruce Rappaport School of Medicine- Technion- Haifa- Israel., Hillel Yafe
Medical center IVF, Hedera, Israel
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Study question: Does the change in needle diameter along the 17-20 G dur-
ing oocyte collection effect oocyte quality and embryo morphokinetics in com-
pare to 17 G needle?
Summary answer: Beside higher negative value in oocyte score in 17 G nee-
dle, no other differences were demonstrated in terms of fertilization, embryo
quality or morphokinetics.
What is known already: A smaller diameter needles yielded signiﬁcant
improvement in recovery after ovum pick-up, as well as minimizing bleeding
during the procedure and reducing pain afterwards, various needles are avail-
able in the ﬁeld of in vitro fertilization, with the aim of creating a needle that
reduces pain without diminishing its stability and ease of operation, a variable
diameter 20-17 G needle was introduced to the market (Vitrolife Sweden AB,
Goteborg, Sweden). And was found signiﬁcant decreases in pain and vaginal
bleeding compared to the 17 G needle, without affecting the oocyte recovery
rate, damaging oocytes or affecting fertilization and clinical pregnancy rates.
Study design, size, duration: Prospective, randomized, blinded pilot study
comparing sibling oocytes. 20 patients were prospectively enrolled from August
2016 through January 2017.
Participants/materials, setting, methods: Women undergoing IVF-ICSI,
21 to 39 years old, FSH≤10 IU/l and antral follicular count (AFC) >10 follicles.
Comparing oocyte collected with 2 different aspiration needles (17 G/35 mm
and 20-17 G/35mm) in the same patients-Sibling oocytes). Oocyte quality
(judged by 5 parameters based on previous publication) and embryo grading
including morphology and morpho-kinetics were evaluated. The embryologist
was blinded to the needle used for each ovary.
Main results and the role of chance: A total of 256 oocytes were col-
lected, 118 oocytes in the 17 G needle group and 116 in the 20-17 G group.
Aspirating with the 17 G needle yielded more oocytes with higher negative
score per oocyte compared with the oocytes collected with the 20-17 G needle
(2.2 ± 1.39 vs. 1.87 ± 1.69; P = 0.02). Oocytes collected in the cohort with
degenerative oocytes (DEG group) immediately after OPU had poorer per-
formance compared to their sibling oocytes from the cohort with no degenera-
tive oocytes(nonDEG group).the DEG group had poorer oocyte scores
compared to the nonDEG group(-2.4 ± 1.73 vs. -1.87 ± 1.48; P = 0.02; 95%CI
-1.02 to -0.09). Overall fertilization rate was poorer for the DEG group of
patients 56.1% versus 70.7% for the nonDEG group (P = 0.05).
However, the amount of good quality embryos were comparable between
the DEG vs nonDEG (65.6% vs. 66.4%, respectively).
Furthermore, sub analyzing the cohort with the degenerative oocyte accord-
ing to the aspiration needle size did not affect fertilization rates or morphoki-
netic scores (KIDS and alfa ESHRE).
A logistic regression found that the presence of degenerative oocyte in the
cohort of sibling oocytes increased the total negative score of the rest of the
oocytes in the cohort, ß=-1.3 (95%CI: -1.8 to -0.79); p<0.0001.
Limitations, reasons for caution: Pilot study, small number of participant.
Wider implications of the ﬁndings: Our results conﬁrm previous ﬁndings
that showed no difference in embryo quality and morphokinetics, regardless of
the needle used for OPU. This study evaluated embryo quality using morphoki-
netics parameters after comparing the use of different needle diameters on sib-
ling oocytes.
Trial registration number:NIH number NCT02749773
P-682 Lean PCOSmay be a genetically distinct from obese PCOS:
lean women with polycystic ovary syndrome and their relatives have
no increased risk of T2DM
E. Johnstone1, L. Cannon-Albright2, C.M. Peterson1, K. Allen-Brady2
1University of Utah, Obstetrics and Gynecology, Salt Lake City, U.S.A.
2University of Utah, Genetic Epidemiology, Salt Lake City, U.S.A.
Study question: Do lean women with polycystic ovary syndrome (PCOS)
and their ﬁrst, second, and third degree relatives have the same risk of type 2
diabetes (T2DM) as obese women with PCOS?
Summary answer: T2DM risk is increased in obese PCOS women and their
ﬁrst, second, and third degree relatives, but not in lean PCOS women or their
relatives.
What is known already: PCOS is a strong risk factor for T2DM, with an
approximately 2-fold increase in risk. Heritability of PCOS has been demon-
strated in numerous studies, but mode of inheritance has not ﬁt a single model.
First degree relatives of women with PCOS appear to share the increased risk
of T2DM, suggesting shared susceptibility alleles. However, studies of the
T2DM and insulin resistance in relatives of women with PCOS have primarily
included overweight and obese probands and relatives.
Study design, size, duration: This cohort study used the Utah Population
Database (UPDB), which contains demographic and genealogy data, and med-
ical records from the second largest health caresystem in Utah from 1994
through 2015. PCOS and T2DM cases were identiﬁed by ICD-9 codes. Body
mass index (BMI) was obtained from drivers’ licenses. Lean was deﬁned as BMI
<25, and obese as BMI ≥ 30. All ﬁrst, second, and third degree relatives of
PCOS probands in the database were identiﬁed.
Participants/materials, setting, methods: PCOS cases were diagnosed at
ages 10-54, and had least 3 generations of genealogical data in the UPDB.
Controls were matched for sex, birth place, birth residence (urban/rural), and
5-year birth cohort. 463 lean PCOS women and their 1369 ﬁrst degree, 2179
second degree, and 4612 third degree relatives and 367 obese PCOS women
and their 1008 ﬁrst degree, 1760 second degree and 3422 third degree relatives
with linked hospital data were included.
Main results and the role of chance: In the lean PCOS cohort, 13 of 463
probands, 36 of 1369 ﬁrst degree relatives, 150 of 2179 second degree rela-
tives, and 232 of 4612 third degree relatives had T2DM. The relative risks (95%
conﬁdence intervals) for T2DM among lean PCOS women were 1.71 (0.91-
2.93) for probands, and 0.77 (0.54-1.06), 1.01 (0.86-1.19), and 1.04 (0.91-
1.18) for ﬁrst, second, and third degree relatives, respectively. In the obese
PCOS cohort, 50 of 367 probands, 74 of 1008 ﬁrst degree relatives, 151 of
1760 second degree relatives, and 219 of 3422 third degree relatives had
T2DM. The relative risks (95% conﬁdence intervals) for T2DM among obese
PCOS women were 6.85 (5.08-9.03) for probands, and 1.72(1.35-2.16), 1.39
(1.18-1.63), and 1.21 (1.05-1.38) for ﬁrst, second, and third degree relatives,
respectively.
Limitations, reasons for caution: This study includes those who received
an ICD-9 diagnosis of PCOS and/or T2DM, and thus those with health insur-
ance may be overrepresented. Details of diagnostic criteria are not available,
and so there may phenotypic variability between the lean and obese PCOS
cohorts beyond BMI.
Wider implications of the ﬁndings: This study suggests that the lean
PCOS phenotype is genetically distinct from the obese phenotype, and neither
lean PCOS probands nor their relatives share the increased risk of T2DM found
in obese PCOS families. BMI should be used for stratiﬁcation in studies of genes
associated with PCOS and T2 DM.
Trial registration number:None.
P-683 Estrogen regulates proliferation of mouse female bone
marrow-derived stromal cells
Y.J. Kim1, I.J. Chang1, Y.Y. Kim2, S.Y. Ku2, S.M. Lee1, J.H. Shin1,
T. Kim1, J.Y. Hur1
1Department of Obstetrics and Gynecology, College of Medicine, Korea University
2Departments of Obstetrics and Gynecology, College of Medicine, Seoul National
University
Study question: To assess the effects of estradiol on the proliferation of the
murine bone marrow-derived stromal cells (BMdSCs) according to its
concentration.
Summary answer: Estradiol may have a role in the regulation of proliferation
of murine BMdSCs by dose- and time- dependent manners.
What is known already: BMdSCs has been known to demonstrate different
responses to sex hormones according to gender difference or reproductive
aging. Although estradiol has been known to play a major endocrine role on
various cells in vivo to female, dose-dependent effect of estradiol on prolifer-
ation of BMdSCs has been rarely known.
Study design, size, duration: Femurs of 6-week-old female C57BL/6 mice
(n = 20) were collected and washed using fresh media (DMEM).
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Participants/materials, setting, methods: The marrow suspension from
collected femurs was ﬁltered through sterile Nitex mesh, and retrieved
BMdSCs were cultured in in-vitro-conditioned with estradiol at 10-5 to 10-7 M
and estrogen antagonist (ICI-1640), added for 24, 48, and 72 hours. FACS assay
for isolated BMdSCs using markers (CD90 and CD105) and RT-PCR for target
gene (FSH receptor and LH receptor) were performed after culture.
Main results and the role of chance: Isolated BMdSCs demonstrated
enhanced proliferative activity and positively expressed CD90 and CD105. The
expression of FSH receptor and LH receptor genes was increased after estra-
diol treatment and the peak response was observed at 48 hours. This prolifera-
tive effect was slightly suppressed by treatment of estrogen antagonist.
Limitations, reasons for caution: To fully understanding the regulatory
roles of hormonal effect on proliferation of BMdSCs, further extended study
with androgen and corticosteroids should be necessary.
Wider implications of the ﬁndings: This experiment implicates hormonal
factors could regulate the cell cycles and regenerative capacity of BMdSC popu-
lation with dose- and time- dependent manners.
Trial registration number: Not available / This study was supported by
grants of Ministry of Education, Republic of Korea (2016R1D1A1A02937287
and 2016R1E1A1A01943455).
P-684 Bax-DUB expression regulated by formaldehyde in ovarian
cells
C.Z. Pei1, S.Y. Kim1, D.H. Lee1, K. Lee2, B.S. Yun3, K.H. Baek1
1Department of Biomedical Science, CHA University, Gyeonggi-Do, Korea- South
2Department of Obstetrics and Gynecology, Ewha Mokdong Hospital, Seoul, Korea-
South
3Department of Obstetrics and Gynecology, Gangnam CHA Hospital, Seoul, Korea-
South
Study question: Could the role of Bax-DUB on formaldehyde-induced apop-
tosis be implicated in premature ovarian failure (POF)?
Summary answer: Bax-DUB expression is upregulated by formaldehyde in
ovarian cells, and Bax-DUB interacts with Bax, participating in deubiquitination
of Bax.
What is known already: It has been known that formaldehyde, a ubiquitous
environmental pollutant, has a harmful effect on the ovary and may cause POF.
Formaldehyde increases oxidative damage and mitochondrial dysfunction that
induces mitochondrial apoptosis. DUBs can reverse protein degradation by
cleaving the peptide or isopeptide bond between ubiquitin and its substrate
proteins.
Study design, size, duration: The expression levels of Bax-DUB were
determined by the treatment of ovarian cells with different concentrations of
formaldehyde, and the protein-protein interaction along with biological roles of
Bax-DUB in ovarian cells was investigated.
Participants/materials, setting, methods: Ovarian cells were treated
with formaldehyde in a dose-dependent manner, and it was found that Bax-
DUB was upregulated by formaldehyde. We studied the protein-protein inter-
action through yeast two-hybrid, GST pull-down, immunoprecipitation, and
immunocytochemical assays. Ubiquitination and deubiquitination assays were
performed to investigate cellular functions of Bax-DUB in ovarian cells.
Main results and the role of chance: The expression level of Bax-DUB was
increased by formaldehyde in ovarian cells. Bax is known as a pro-apoptotic fac-
tor to initiate mitochondrial apoptosis and is increased by formaldehyde.
Therefore, we investigated relationship between Bax-DUB and Bax, and identi-
ﬁed that Bax-DUB binds to Bax directly. Moreover, the ubiquitination level of
Bax is decreased by Bax-DUB.
Limitations, reasons for caution: The results of this study were limited by
the conduct of a cell line.
Wider implications of the ﬁndings: This is the ﬁrst attempt to explain the
pathogenesis of POF in the ubiquitin-proteasome system. The results of this
study suggest that Bax-DUB may enhance the effect of mitochondrial mediated
apoptosis by regulating the function of Bax, and deplete ovarian cells as early as
possible to cause POF.
Trial registration number: not applicable.
P-685 Negative progesterone elevation threhold level on trigger
day is different in subclasses of patients
R. De Cesare1, F. Cirillo1, P. Persico1, V. Canevisio1, V. Immediata1,
E. Morenghi2, M. Monari3, P.E. Levi Setti1
1Humanitas Research Hospital, Humanitas Fertility Center- Department of
Gynecology- Division of Gynecology and Reproductive Medicine, Rozzano Milano,
Italy
2Humanitas Research Hospital, Biostatistic Unit, Rozzano Milano, Italy
3Humanitas Research Hospital, Clinical Investigation Laboratory, Rozzano Milano,
Italy
Study question: Inﬂuence of progesterone elevation (PE) and different pro-
gesterone threshold values at trigger day in different groups of fresh cleavage or
blastocyst stage embryo transfer.
Summary answer: In good prognosis patients the progesterone impact starts
when the serum level is > 1 ng/ml. In other women when it is > 1,75 ng/ml.
What is known already: Endometrial receptivity play a substantial role in
implantation and a serum PE measured on the day of human chorionic gonado-
trophin (hCG) administration has been associated with a lower pregnancy rate
in fresh cycles, although threshold levels and percentage of success reduction
are still objects of debate. There is not an optimal PE threshold to predict the
IVF cycle outcome, although most studies indicate a value ≥ to 1.5 ng/ml to
reduce the pregnancy rate. Several studies indicate that embryo transfer at the
blastocyst stage can at least partially reverse the negative impact of high proges-
terone levels.
Study design, size, duration: This study is a single-center retrospective
study, performed in a tertiary care academic Fertility Center. We analyzed all
fresh embryo transfer, at cleavage (CS) and blastocyst (BS) stage, performed
from January 2012 to December 2015. We, therefore, separately analyzed all
the ﬁrst thawing transfer performed after cancelled transfer cycles for any rea-
son and elevated progesterone values (≥1.5 ng/ml).
Participants/materials, setting, methods: We report of 6,484 fresh
embryo transfers performed during the study period: 6,098 cleavage, 386
blastocyst stage transfers and We included 108 thawing cycle. For each cycle,
we analyzed serum progesterone level at trigger day. Progesterone assay was
performed by a Chemiluminescent Micro particle Immunoassay (CMIA) with an
analytical sensitivity ≤ 0.1 ng/mL. The impact of progesterone level on clinical
pregnancy rate (CPR) and live birth rate (LBR) were explored using multiple
logistic regression.
Main results and the role of chance: After the adjustment for maternal
age, number of retrieved oocytes and transferred embryos, in CS transfers
CPR shows the ﬁrst signiﬁcant decrease at progesterone ≥1 ng/ml (OR 0.83
95%CI 0.69-0.99 P = 0,039). An additional CPR decrease is observed with
levels ≥1.75 ng/ml (OR 0.50 95% CI 0.36–0.68 P<0.001). This difference was
conﬁrmed by a statistically lower LBR in PE cycles. In good prognosis patients
(<38 years and retrieved oocytes >8) the adverse effects of elevate proges-
terone is already evident when progesterone reaches 1 ng/ml (38.2% vs
30.7%, OR 0.72 95%CI 0.58–0.88 P = 0.001). In patients >38 years or <8
retrieved oocytes the inﬂuence of progesterone level become evident only
from 1.75 ng/ml (23.1% vs 13.1% OR 0.50 95%CI 0.32–0.78 P = 0.002). In
the BS group, only a progesterone level over 1.75 ng/ml halved the CPR (OR
0.43 95%CI 0.19-0.98 P = 0.045) and LBR (OR 0.41 95%CI 0.16-1.05, P =
0.062). In the ﬁrst frozen embryo transfer after PE freeze only cycles, the CPR
(OR 1.19 95%CI 0.78-1.82 p = 0.407) and LBR (0.80 95%CI 0.48-1.34, p =
0.401) appeared not signiﬁcantly different than in low progesterone level fresh
transfers.
Limitations, reasons for caution: This is a retrospective analysis, with all
the inherent limitations and bias of such a study. The results of vitriﬁed-warmed
freeze only cycles need to be conﬁrmed in a larger sample.
Wider implications of the ﬁndings: Our data show that PE at trigger day
is signiﬁcantly inversely related to the fresh cycle outcome in CS and BS
transfers, although the PE threshold appear to be higher in BS. Our data con-
ﬁrm that elective freezing strategy rescue the negative effect of PE on cycle
outcome.
Trial registration number:N/A.
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P-686 Cross-talk between Bcl2l10 and Aurka in regulation of
meiotic spindle assembly
S.Y. Lee, E.Y. Kim, K.H. Kim, K.A. Lee
CHA University, Department of Biomedical Science- College of Life Science,
Gyeounggi-Do, Korea- South
Study question: How does Bcl2l10 regulate expression and activity of Aurka
(Aurora kinase A)?
Summary answer: Bcl2l10 and Aurka regulate each other for their expres-
sion and activity via transcription factor of Aurka expression and PP1 (protein
phosphatase 1) in mouse oocytes.
What is known already: Previously, we ﬁrstly identiﬁed the non-apoptotic
function of Bcl2l10, a member of Bcl-2 gene family, that Bcl2l10 was expressed
in meiotic spindle and RNAi (RNA interference)-based Bcl2l10 silencing caused
meiotic arrest at Metaphase-I with abnormal spindle assembly. Aurka is a piv-
otal kinase that required for centrosome maturation and spindle assembly in
mitosis as well as meiosis. Expression of Aurka decreased at transcription and
translation levels, whereas phospho-Aurka increased by depletion of Bcl2l10 in
mouse oocytes. In addition, activity of Aurka was also reduced by Bcl2l10
RNAi. Consequently, we ﬁrstly found that Bcl2l10 is an upstream regulator of
Aurka in oocytes.
Study design, size, duration: Phospho-Aurka can be dephosphorylated by
PP1. Because Bcl2l10 RNAi increased auto-phosphorylation of Aurka on
Threonine 288, we conﬁrmed whether changes in PP1 activity mediated that
increase in Aurka phosphorylation after Bcl2l10 RNAi. Oocytes were collected
from C57BL/6 mice. Changes in PP1 activity were conﬁrmed by western blot
analysis using phospho-PP1 speciﬁc antibody. For inhibition or activation of
Aurka activity, we treated oocytes with MLN8054 or okadaic acid, respectively.
Participants/materials, setting, methods: Bcl2l10 RNAi-treated MI
oocytes were obtained by microinjection of Bcl2l10 double-stranded RNA and
non-treated MI-oocytes were used as control. MLN8054 or okadaic acid were
added to culture medium and oocytes were incubated for 16 hours. RT-PCR
was carried out by using cDNAs equivalent to that of single-oocyte. For west-
ern blot analysis, 200 oocytes of each group were used.
Main results and the role of chance: As a result of RT-PCR, transcripts of
E4TF1, TRAP220/MED1 and HIF-1α decreased by Bcl2l10 RNAi. In addition,
protein expressions of E4TF1 and HIF-1α were decreased whereas TRAP220/
MED1 was not detected. Phosphorylation of PP1 at Threonine 320, an inactive
form of PP1, increased after Bcl2l10 RNAi treatment indicating that PP1 activity
was inhibited by Bcl2l10 RNAi. It suggests that Bcl2l10 regulates the phosphor-
ylation of Aurka through regulation of PP1 activity. By treatment MLN8054
(Aurka inhibitor) or okadaic acid (Aurka activator) during in vitro oocyte matur-
ation, phosphorylation of Aurka at Threonine 228 decreased or increased,
respectively. Interestingly, Bcl2l10 expression was enhanced by MLN8054 and
was reduced by okadaic acid. Therefore, our data suggests that a novel form of
reciprocal regulation exists between Aurka activity and Bcl2l10, forming a feed-
back loop in mouse oocytes.
Limitations, reasons for caution: This study was performed with mouse
oocytes and results need to be validated for human oocytes.
Wider implications of the ﬁndings: In the present study, we ﬁrstly identi-
ﬁed the association between Bcl2l10 and Aurka in meiotic spindle assembly. It
is known that defects in spindle assembly are the major contributor to aneu-
ploidy in oocytes. Therefore, this study may provide new theoretical basis
about high rates of aneuploidy in human eggs.
Trial registration number:No required.
P-687 Does endometriosis inﬂuence the embryo quality and/or
development? Insights from a retrospective study
A.M. Sanchez Garcia1, L. Pagliardini2, L. Privitera3, G.C. Cermisoni3,
A. Bartolacci3, E. Papaleo3, M. Candiani3, P. Vigano’2
1Università Vita-Salute San Raffaele, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology- IRCCS San Raffaele Scientiﬁc Institut, Milano, Italy
2IRCCS San Raffaele Scientiﬁc Institute, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology, Milan, Italy
3IRCCS San Raffaele Scientiﬁc Institute, Department of Obstetrics and Gynecology,
Milan, Italy
Study question: To evaluate the impact of endometriosis on embryo devel-
opment at cleavage stage.
Summary answer: We did not ﬁnd differences in the number/quality of day
3 embryos but we detected a lower ongoing pregnancy rate in women with
endometriosis.
What is known already: The impact of endometriosis on fecundity and IVF
outcomes is still controversial. Some studies suggested that endometriosis
could inﬂuence IVF outcomes since oocytes may be more difﬁcult to be
retrieved and fewer embryos could be obtained compared to women without
endometriosis. Poor oocyte and embryo quality has been as well postulated.
Moreover, endometriosis has been not consistently associated with lower
implantation rates and lower pregnancy rates. Nevertheless, the reasons to
explain the suboptimal performance of IVF in endometriosis patients are poorly
understood and can only be hypothesized.
Study design, size, duration: This is a retrospective study including patients
undergoing IVF at the San Raffaele Hospital from 2013 to 2017. Endometriosis
were laparoscopically diagnosed in all patients before IVF treatment.
A total of 430 cycles from women with endometriosis were studied and
matched with cycles of women without the disease (n = 854) according to age,
number of oocytes retrieved and time period of the treatment. A total of 3818
embryos at cleavage stage (day 3) have been analyzed.
Participants/materials, setting, methods: Embryo quality at day 3 in
terms of number of cells, cell fragmentation and symmetry was evaluated.
Principal components summarizing baselines variables (age, BMI, seminal para-
meters, number of oocytes retrieved, number of oocytes available) were used
as covariates. Student’s test, Mann-Whitney U test and logistic regression mod-
el were used as appropriate. All the results are presented as mean ± SD, OR
(95% CI) or median (interquartile range)
Main results and the role of chance: The number of oocytes retrieved in
both groups were similar (5.8 ± 4.4 controls vs 5.8 ± 4.6 endometriosis, p =
0.84). We did not ﬁnd as well any statistically differences in the percentage of
MII oocytes [80% (56-100%) controls vs 75% (50-100%) endometriosis
patients, p = 0.25] and in fertilization rate [80% (57-100%) controls vs 80% (61-
100%) endometriosis patients, p = 0.29]. Overall, in cycles from endometriosis
women we did not ﬁnd any difference regarding the number of embryos
obtained at cleavage stage (3.5 ± 2.6 controls vs 3.7 ± 2.6 endometriosis
patients, p = 0.47). In addition, the percentage of top/good quality embryos
was as well similar [56% (25-100%) controls vs 50% (17-88%) endometriosis
patients, p = 0.20]. Besides, we did not ﬁnd any difference in the blastulation
rate, excluding cycles in which transfers were performed or embryos were fro-
zen in day 3. Despite similar fertilization rate and number/quality of embryos
obtained, we found a reduction in ongoing pregnancy rate in women with endo-
metriosis compared with the control group (24.2% in controls vs 17.7% in
endometriosis group, corrected OR = 0.60; 95% CI 0.40-0.90, p = 0.014) after
adjusting for the number and quality of transferred embryos, the day of transfer
(cleavage or blastocyst stage) and principal components.
Limitations, reasons for caution: The main limitation of our study is its
retrospective design; however, no clinical decision/intervention has been done
between the time of fertilization and day 3 so that this study may be compar-
able to a prospective one. In both groups, the effect of other causes of infertility
cannot be excluded.
Wider implications of the ﬁndings: These results indicate that women with
endometriosis undergoing IVF treatments may expect a similar embryo quality
than women without the disease. The results of this study could help in under-
standing whether embryo or endometrial factor represents the main cause for
the poor success in ART in patients with moderate/severe endometriosis.
Trial registration number: not applicable.
P-688 GnRH antagonist administration in the luteal phase for the
prevention andmanagement of severe OHSS: a systematic review
andmeta-analysis
T.G. Lainas1, G. Lainas1, I. Sfontouris1, A. Prodromidou1,
C. Venetis2, I. Zorzovilis1, B. Tarlatzis3, E. Kolibianakis3
1EUGONIA, Dept. of IVF, Athens, Greece
2University of New South Wales, School of Women’s and Children’s Health UNSW
Medicine, Sydney, Australia
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Study question: Is luteal GnRH antagonist administration effective for the
prevention and management of severe OHSS?
Summary answer: Luteal GnRH-antagonist administration is not effective for
the prevention of severe OHSS, while appropriate trials evaluating its use for
outpatient management of OHSS are lacking.
What is known already: Despite the increasing use of GnRH agonist trigger
in high risk for OHSS patients, hCG administration remains the most popular
triggering option, and as a result a signiﬁcant proportion of high-risk women (9-
38%) will still develop severe OHSS. Luteal GnRH-antagonist administration has
been used as a method of OHSS prevention, as well as tertiary management of
established severe OHSS at an outpatient level via a luteolytic mechanism.
Study design, size, duration: Medline, Scopus, Google Scholar, Cochrane
and Clinicaltrials.gov databases were systematically searched for articles pub-
lished up to December 2017, along with the references of all articles that were
retrieved in full text. Trials referring to prevention or treatment of OHSS by
administering GnRH antagonists in the luteal phase of women undergoing ART
who were either at risk for developing OHSS or were diagnosed with severe
OHSS were considered eligible for inclusion.
Participants/materials, setting, methods: Fourteen studies with a total
1029 patients were considered eligible for inclusion. Pooled odds ratios (OR)
and 95% conﬁdence intervals (CI) were calculated using random effects model
due to signiﬁcant heterogeneity in the methodological characteristics of the
included studies. Higgin’s Ι2 was utilized for statistical heterogeneity assessment.
Statistical meta-analysis was performed using RevMan 5.3.
Main results and the role of chance: Prevention of early OHSS: Four eli-
gible studies (1 RCT, 1 case-control, 2 retrospective) with 409 high-risk patients
(GnRH-antagonist n = 197 versus control n = 212) were included in the meta-
analysis. GnRH-antagonist was administered from Day 0 or Day 1 for 3-5 days.
The incidence of OHSS was not affected by GnRH-antagonist administration
(Mild OHSS: OR = 1.58%, 95% CI:0.49-5.15, p = 0.44, Ι2 = 79%; Moderate
OHSS: OR = 0.92%, 95% CI:0.41-2.05, p = 0.84, Ι2 = 56%; Severe OHSS: OR
= 0.39%, 95% CI:0.05-3.16, p = 0.37, Ι2 = 54%). Clinical pregnancy rates were
similar (229 patients; OR 1.33 95% CI 0.71 to 2.51, p = 0.37; Ι2=%, p = 0.56)
in GnRH-antagonist and control group.
Management of established early severe OHSS (tertiary management): Ten stud-
ies: 3 prospective observational, 2 retrospective and 5 case-series; 620 patients)
were considered eligible. GnRH-antagonist was administered from the day of
severe OHSS diagnosis for 2-4 days. The studies used different methodology and
inclusion criteria, rendering a meta-analysis not feasible. In the systematic review
conducted, the majority of studies supported that luteal GnRH-antagonist adminis-
tration prevented patient hospitalization and resulted in rapid regression of estab-
lished severe OHSS. OHSS resolution was demonstrated by a signiﬁcant decline of
ovarian volume, ascites, haematocrit, white blood cell count, serum oestradiol and
progesterone, making patient management on an outpatient basis feasible.
Limitations, reasons for caution: The retrospective nature of most of the
included studies, their high heterogeneity and low quality, as well as the limited
number of patients treated constitute signiﬁcant limitations. Furthermore, the
deﬁnition of OHSS and the therapeutic protocol of GnRH- antagonist adminis-
tration varied both for prevention and for treatment of OHSS studies.
Wider implications of the ﬁndings: Although available evidence is insufﬁ-
cient, luteal GnRH-antagonist administration does not appear to be effective for
the the prevention of severe OHSS. On the other hand, GnRH-antagonist
appears to result in rapid regression of established severe OHSS, but appropri-
ate trials evaluating its use for outpatient management of OHSS are lacking.
Trial registration number:Not applicable.
P-689 Follicular ﬂushing is associated with a signiﬁcantly higher
oocyte recovery rate compared to no ﬂushing: a randomized
controlled trial
G. Lainas1, I. Sfontouris2, T. Lainas2, A. Makris2, C. Venetis3,
I. Zorzovilis2, G. Petsas2, B. Tarlatzis4, E. Kolibianakis4
1Barts and The London NHS Trust - Royal London Hospital, Obstetrics and
Gynaecology, London, United Kingdom
2EUGONIA, Eugonia Unit of Assisted Reproduction, Athens, Greece
3University of New South Wales, School of Women’s and Children’s Health UNSW
Medicine, Sydney, Australia
4Aristotle University of Thessaloniki Medical School, Unit for Human Reproduction -
1st Dept of Obstetrics and Gynecology, Thessaloniki, Greece
Study question: Is follicular ﬂushing associated with a higher oocyte recovery
rate compared to no ﬂushing?
Summary answer: Follicular ﬂushing is associated with signiﬁcantly higher
oocyte recovery rates compared to no ﬂushing.
What is known already: There is an ongoing debate regarding the effective-
ness of follicular ﬂushing during oocyte retrieval. Current evidence suggests that
follicular ﬂushing does not seem to improve live birth rate, clinical pregnancy
rate or the number of oocytes retrieved, but to signiﬁcantly increase the dur-
ation of oocyte retrieval compared to no ﬂushing. Nevertheless, follicular ﬂush-
ing continues to be a routine procedure in many IVF centres.
Study design, size, duration: In this randomized controlled trial, conducted
from November 2017 until January 2018, the right and left ovary from each
patient were randomized (with a computer-generated randomization list) to be
aspirated using either follicular ﬂushing or no ﬂushing. The primary outcome
was oocyte recovery rate deﬁned as the number of oocytes retrieved/number
of follicles aspirated (>11 mm). Assuming a 10% difference in recovery rate, a
sample size of eighteen patients was required to yield 80% power.
Participants/materials, setting, methods: Patients aged <42 years, with
intact ovaries, each containing at least four follicles > 11 mm on the day of hCG
administration were included in the study. Patients with endometriotic cysts
were excluded. Oocyte retrieval was performed 35–36 h after hCG by transva-
ginal ultrasound-guided aspiration using the same double lumen needle (16 G,
Casmed International Ltd, UK) and the same digitally adjusted aspiration vac-
uum for both ovaries. Outcomes were analyzed using paired t-test.
Main results and the role of chance: A total 20 patients were included in
the study. Baseline characteristics, expressed as mean (SD), were: age 34.6
years (4.7), BMI 24.1 kg/m2 (5.2), duration of infertility 4.1 years (3.0), number
of previous attempts 1.0 (1.1), AFC 8.8 (5.8), AMH 3.1 (2.7), basal FSH 7.2
(1.9), basal LH 5.1 (1.9), basal oestradiol 43.8 (13.8) and basal progesterone
0.7 (0.6).
Oocyte recovery rates [mean (95% CI)] [74.2% (65.0-83.4) versus [42.7%
(30.0-55.5), p<0.0001], number of COC retrieved [7.7 (5.1-10.2) versus 4.1
(1.7-6.5), p<0.0001], number of metaphase-II oocytes [6.8 (4.6-8.9) versus 4.0
(1.7-6.3), p<0.0001] and number of fertilised oocytes [4.1 (2.9-5.4) versus 2.2
(1.2-3.1), p = 0.001] were signiﬁcantly higher using follicular ﬂushing compared
to no ﬂushing. Maturation rates [90.2% (82.5-97.9) versus 87.8% (75.6-99.9)],
fertilization rates [64.5% (53.4-75.6) versus 65.3% (45.5-85.1)], proportion of
embryos transferred [34.1% (6.4-61.9) versus 25.8% (-3.4 – 55.1)] were similar
in the ﬂushing and no ﬂushing groups. There were no cases of bleeding in either
group of the present study.
Limitations, reasons for caution: A double-lumen needle was used in both
“ﬂushing” and “no-ﬂushing” groups. The use of a single-lumen aspiration needle
in the non-ﬂushing group might have altered the results obtained, although this
is not supported by the published literature. The current study was powered to
compare retrieval rates but not pregnancy achievement.
Wider implications of the ﬁndings: Follicular ﬂushing was associated with
a signiﬁcantly higher oocyte recovery rate, number of COCs retrieved, number
of metaphase-II oocytes, number of 2PNs but with similar oocyte maturation,
fertilization rates and proportion of embryos transferred compared to no ﬂush-
ing in normal/high responders.
Trial registration number:NCT03354858
P-690 The acceleration of reproductive aging in MMTV-TGF-alpha
mice
T. Önel1, E. Yildirim2, S. Dogan3, A. Yaba Ucar2
1Yeditepe University Institute of Health Science, Histology and Embryology, İstanbul,
Turkey
2Yeditepe University School of Medicine, Histology and Embryology, İstanbul, Turkey
3Yeditepe University School of Medicine, Medical Biology, İstanbul, Turkey
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Study question: Does MMTV-TGF-alpha mice present diminished ovarian
reserve during reproductive lifespan and does TGF-alpha gene interfere with
mTOR signal pathway during ovarian aging?
Summary answer: Protein and mRNA expression levels of mTOR and P-
mTOR were gradually decreased from 10 to 18 week, but increased at 50
week in MMTV-TGF-alpha ovary.
What is known already: TGF-alpha is an important growth factor regulating
follicle development and tumorigenesis. TGF-alpha detected in granulosa cells
of developing follicles, atretic follicles and theca-lutein cells. mTOR is a key
regulator for proliferation, growth, differentiation, and apoptosis. Previously,
we have shown that mTOR has regulatory role during follicular development
and inhibition of mTOR induced a reduction in granulosa cell proliferation and
follicle growth. mTOR signaling also plays a major regulatory role in aging since
suppression of this pathway extends lifespan in model organisms.
Study design, size, duration: Total of 24 MMTV-TGF-alpha female mice
which overexpreses TGF-alpha were used. Animals were ad-libitum fed and
sacriﬁced and then, ovaries were removed at 10, 18, 50 and 82 weeks of mouse
age.
Participants/materials, setting, methods: Ovaries of 10, 18, 50 and 82
week old MMTV-TGF-alpha mice were dissected and ﬁxed in 4% paraformalde-
hyde and embedded in parafﬁn. 5 μm slides were taken from parafﬁn blocks
and stained with hematoxylin and eosin staining in order to examine the mor-
phological changes in ovaries. mTOR and P-mTOR protein and mRNA expres-
sion levels were detected using western blot and q-RT-PCR,respectively, for
each experimental group.
Main results and the role of chance: 10 week old MMTV-TGF-alpha
mouse ovary presented numerous developing follicles from different follicular
developmental stage. However, compared to the usual healthy mouse ovary,
MMTV-TGF-alpha ovary had smaller antrum spaces in secondary follicles and
did not exhibit a healthy follicular structure. The number of inﬁltration of lutei-
nized cells were higher, while the number of developing follicles were lower at
18 week old ovaries. Compared to the other groups (10, 18, and 82 week), 50
week old ovary had decreased number of developing follicle and increased
number of atretic follicles. In addition, diminished number of developing folli-
cules and increased number of atretic follicles were detected in 82 week old
mouse ovary. Protein and mRNA expression levels of m-TOR and P-mTOR
were gradually decreased from week 10 to 18 week, but they were increased
at 50 week. Then, expression levels were decreased again towards to week 82
of mouse age. Therefore we suggest that TGF-alpha may have relation with
mTOR signal pathway during ovarian aging and over-expression of TGF-alpha
may cause acceleration of diminished ovarian reserve and premature ovarian
failure.
Limitations, reasons for caution: The best way to explain interaction
between TGF-alpha and mTOR signal pathway might be use TGF-alpha homo-
zygote/heterozygote knock-out mouse ovary.
Wider implications of the ﬁndings: TGF-alpha and/or mTOR might be
targets for developments of drug which could be used in infertility.
Trial registration number: Embryology/(female (in) fertility)
P-691 Altered endometrial receptivity in infertile females with
polycystic ovarian syndrome (PCOS) as compared to fertile
counterparts: analogy of protein expression proﬁles
N. Rashid1, A. Nigam2, S.K. Jain3, S.Wajid1
1Jamia Hamdard, Biotechnology, Delhi, India
2Hamdard Institute of Medical Sciences and Research, Gynecology and Obstetrics,
Delhi, India
3Hamdard Institute of Medical Sciences and Research, Biochemistry, Delhi, India
Study question: To unravel the proteins involved in compromising the recep-
tivity and hampering the decidualization process in the endometrium of females
with polycystic ovarian syndrome.
Summary answer: Proteins involved in cell proliferation, differentiation,
development, signaling, mitochondrial metabolism, DNA repair, apoptosis and
post-transcriptional modiﬁcation may play key roles in endometrial program-
ming for receptivity.
What is known already: Various expression studies have revealed the pro-
ﬁles of genes underlying unique cellular and molecular mechanisms involved in
endometrial shedding, repair, regeneration and remodelling. Endometrium in
PCOS females is known to be compromised for receptivity due to progester-
one resistance with elevated levels of androgens and/or insulin. However dys-
regulation of speciﬁc downstream pathways and involved proteins need to be
elucidated in detail for the development of biomarkers related to infertility and
pregnancy disorders in PCOS women.
Study design, size, duration: 12 infertile PCOS and 12 healthy fertile sub-
jects within reproductive age group (24–36 years) were recruited from
Gynecology and Obstetrics OPD of HAH Centenary Hospital, Jamia Hamdard,
during the period (june 2015 to august 2016) after approval of JHIEC for clinical
studies. Endometrial biopsies were collected during secretory phase in oligo-
ovulatory PCOS, anovulatory PCOS (progesterone withdrawal bleeding) and
normal subjects after written informed consent was taken from all subjects
enrolled in the study.
Participants/materials, setting, methods: Tissue was lysed and protein
proﬁles were generated though two-dimensional gel electrophoresis (GE
Lifesciences) and analyzed with PD-QUEST analysis software (Bio-Rad).
Differential protein spots were identiﬁed through MALDI-TOF MS protein
mass ﬁngerprinting (Ultraﬂex III instrument). This was followed by RNA isola-
tion (MiniSure Spin total RNA isolation kit, Nucleopore) and cDNA synthesis
using RevertAidTM H Minus ﬁrst strand cDNA synthesis kit (Thermo Fisher
Scientiﬁc). Relative expression analysis was performed using real time-PCR
(Light cycler 480, Roche)
Main results and the role of chance: Relative expression of 13 genes was
calculated with reference to GAPDH (reference gene). Altered expression in
genes UCHL1, MYO3A, TGM1, CCNB1, AR6P1, PARP6, CRBB2, PIGX,
DUS2L, THIL, ZNHI1, RAM and P2YP12 was found to be associated with infer-
tile endometrial grounds in PCOS females. Besides basic cellular processes like
proliferation, differentiation and development; cell cycle regulatory, DNA repair
and apoptotic processes seemed to be involved in decreased endometrial
receptivity in case of PCOS females. Mitochondrial metabolism, cell signaling
and cellular transport were some other key affected processes. Regulation at
post transcriptional level also seem to control many important downstream
processes. The observed differences in gene expression proﬁles provide a road-
map into the intricacies involves in endometrial remodelling and receptivity.
Limitations, reasons for caution: Small sample size and unicentric nature of
the study are the main limitations.
Wider implications of the ﬁndings: These ﬁndings have important diagnos-
tic and prognostic implications in case of infertile PCOS females. Moreover the
study also provide insights into endometrial cancer risk in infertile PCOS sub-
jects. Further studies are required to establish the role of these proteins in the
regulation of pathways associated with endometrial programming and
remodeling.
Trial registration number:None.
P-692 Increased apoptosis and inﬂammation are key factors in
endometrial dysfunction of PCOS patients
N. Daei-farshbaf1, F. Amjadi1, Z. Zandieh1, M. Mehdizadeh2,
M. Ashraﬁ3, R. Aﬂatoonian4
1School of medicine- Iran university of medical science, Department of Anatomy,
Tehran, Iran
2School of medicine- Iran university of medical science, Cellular and Molecular
Research Center and Department of Anatomy, Tehran, Iran
3School of medicine- Iran university of medical science, Obstetrics and Gynecology
Department, Tehran, Iran
4Royan Institute for Reproductive Biomedicine- ACECR, Department of Endocrinology
and Female Infertility at Reproductive Biomedicine Research Center, Tehran, Iran
Study question: Which phenomena could result in impaired endometrial
function in women with PCOS?
Summary answer: Apoptosis and inﬂammation pathways play important
roles in endometrial dysfunction of PCOS patients.
What is known already: Increased cytokine expression and inﬂammatory
responses due to intense leukocyte immigration could impede endometrial
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preparation and manifest implantation failure and recurrent miscarriage.
Besides, overexpression of p53-dependant apoptosis genes demonstrated
excess cell death in endometrial cell in PCOS patients which could be caused
by higher inﬂammation and following ROS production. Generally, it seems that
reduced implantation rate in PCOS might be due to insufﬁcient endometrial
preparation caused by more intense inﬂammation and apoptosis than normal
proliferative phase endometrium.
Study design, size, duration: This study was genomic analysis that 10
human endometrial biopsies taken from pcos patients and 10 from healthy fer-
tile women in the proliferative phase. All participants are in reproductive age
with normal menstrual cycles.
Participants/materials, setting, methods: Total mRNA were extracted
from endometrial tissues from pcos patients (n = 10) and healthy fertile indivi-
duals (n = 10) during proliferative phase. The expression proﬁle of female infer-
tility was investigated using qRT-PCR array.Informed consent was obtained
from patients. All measurements were performed in triplicates on independent
biological replicates.
Main results and the role of chance: Data of PCR array demonstrated high
expression of apoptosis inducing factors such as IL1B, TNF and TNFRSF and
apoptosis promoting factors like TP53, BAX and Bcl2 in PCOS group, while the
expression of CASP3 was not different signiﬁcantly in both groups. Beside apop-
tosis genes, cytokine genes expression was higher in PCOS group. overexpres-
sion of inﬂammatory factors like CCL5, CXCL12, CLDN4 and ICAM1
conﬁrmed leukocyte immigration in endometrial tissue and inﬂammation. In
inﬂammation, TNF, IL6 and IL1 activate NF-kB which could enhance DNA
hypermethylation and chromosomal instability. Following DNA hypermethyla-
tion, epigenetic inactivation of tumour suppressors and overexpression of Bcl2
which suppresses DNA repair might reduce endometrial cell quality and impair
its function in implantation.
Limitations, reasons for caution: The main limitation of this study is a low
number of human endometrial samples for array analysis.
Wider implications of the ﬁndings: This study provide novel data about
impeded endometrium preparation in proliferative phase of PCOS patients as
compared to normal women which might affect endometrial receptivity in
women with PCOS.
Trial registration number:N/A.
P-693 Effect of maternal separation stress and use of
antidepressants on rat ovarian reserve
H.K. Parlaktaş1, E. Yıldırım1, T. Onel1, H. Zortul2, F. Arıcıoğlu2,
A. Yaba Ucar1
1Yeditepe University School of Medicine, Histology And Embryology, İstanbul, Turkey
2Marmara University, Department of Pharmacy, İstanbul, Turkey
Study question: does maternal separation and consequent antidepressant
use effect ovarian reserve in rat ovaries?
Summary answer: Maternal separation may cause diminish of ovarian
reserve. Afterwards antidepressants use have different effects on ovary
depending on Agmatine treatment or Imipramine treatment.
What is known already: Premature ovarian insufﬁciency (POI) occurs when
primordial follicle pool of a female is depleted early in her reproductive life lead-
ing to the cease of menstrual cycle and fertility. The premature activation of
primordial follicles can occur due to many reasons such as genetic background,
diseases, drug use or exposure to harmful materials. There might be a relation-
ship between the use of antidepressants and the premature depletion of ovar-
ian reserve in female rats using a depression model. Therefore, we aimed to
determine the follicle reserve of the ovaries in the depression model created by
maternal separation in rats with antidepressants used.
Study design, size, duration: Totaly 20 pups were used in this study. Pups
separated from their mother on their second postnatal day for 4 hours every
day for 15 days and when they were grown to 60 days old they were given anti-
depressants Agmatine and Imipramine for 15 days until dissection. Dissected
ovaries were processed, embedded in parafﬁn and sectioned using microtome.
The sections were then stained with hematoxylin and eosin for morphological
analyzes and imaged using light microscope.
Participants/materials, setting, methods: Dissected ovary tissues were
processed and sectioned at 5 μm. Sections were stained using hematoxylin and
eosin for morphological analyzes and follicle counting. Afterwards mTOR and
P-mTOR expression were detected in serial sections using immunoﬂuores-
cence staining.
Main results and the role of chance: Morphological results presented that
maternal separation may cause diminish of ovarian reserve. Rats were sepa-
rated from their mother as pups but not treated with antidepressants later in
life would have smaller ovaries and more corpus luteum then control ovaries
that were kept together with mother. Afterwards antidepressants use have dif-
ferent effects on ovary depending on Agmatine treatment or Imipramine treat-
ment. Agmatine treatment helps decrease corpus luteum numbers so may
maintain follicles from reserve in each ovarian cycle in rats. In addition to that
decreased number of Graaﬁan follicle numbers in Agmatine treated group could
indicate that, activation of oocytes decrease along with their full maturation
therefore number of Graaﬁan follicles decrease and ovarian reserve is main-
tained. mTOR expression was detected in oocyte and granulosa cells in rat
ovary from each experimental group. P-mTOR expression observed speciﬁcally
in oocyte nucleus and in mitotic dividing granulosa cells in rat ovaries. Even
though no signiﬁcant change is observed in mTOR and P-mTOR levels in
immunoﬂuorescence staining, Imipramine has detrimental effects on ovarian
reserve as it increases corpus luteum numbers. Therefore, further functional
studies will provide an insight into whether mTOR signal pathway have relation
with Agmatine and Imipramine treatment in model of depression.
Limitations, reasons for caution: Anti-mullerian hormone level might show
as indicator of diminished ovarian reserve. We will conﬁrm mTOR and P-
mTOR expression results with western blot and qRT-PCR.
Wider implications of the ﬁndings: Tricyclic antidepressant Imipramine
has more severe effects that Agmatine on ovarian reserve.
Trial registration number: not applicable.
P-694 Does early respons on ovarian stimulation using
corifollitropin alfa versus hp-hMG inﬂuence live-birth rates in a
GnRH antagonist protocol?
S. De Rijdt1, J. Errazuriz1,2, S. Santos-Ribeiro1, P. Drakopoulos1,
A. Racca1, A. Galvao1,3, N. De Munck1, M. Camus1, H. Tournaye1,
C. Blockeel1
1Universitair Ziekenhuis Brussel, Center for Reproductive Medicine, Brussels, Belgium
2Clinica Alemana, Center for Reproductive Medicine, Santiago, Chile
3Centro Materno Infantil do Norte - Centro Hospitalar do Porto, Department of
Obstetrics and Gynecology, Porto, Portugal
Study question: Does early respons on ovarian stimulation using either cori-
follitropin alfa (CFA) or highly puriﬁed human postmenopausal gonadotrophin
(hp-hMG) in an antagonist protocol inﬂuence live-birth rates?
Summary answer: No statistically signiﬁcant difference in terms of clinical
outcomes between early versus normal responders after ovarian stimulation
with CFA or hp-hMG was found.
What is known already: A single injection of CFA for the ﬁrst 7 days of ovar-
ian stimulation provides similar clinical outcomes when compared to daily injec-
tions of rFSH, namely with respect to the number of oocytes and live-birth
rates. A retrospective analysis has also shown that early responders (women
who fulﬁll the ﬁnal maturation hCG trigger criteria prior to or on stimulation
day 8) have comparable number and size of pre-ovulatory follicles, oocytes,
good-quality embryos and ongoing pregnancy rates, when compared to those
who perform stimulation for >8 days. However, comparative information
between early and late responders following CFA versus hp-hMG is lacking.
Study design, size, duration: This is a retrospective analysis of a cohort of
fresh IVF/ICSI cycles in GnRH antagonist protocol performed in a single tertiary
IVF center, during the period comprised between January 2011 and January
2017.
Participants/materials, setting, methods: Patients (aged ≥35 to ≤42
years) received either a single dose of 150 μg CFA or daily 300IU of hp-HMG
for the ﬁrst 7 days of stimulation. From day 8 on, treatment continued with a
daily dose of hp-hMG (300IU/d) until the day of trigger. We categorized
patients as “early responders” if they reached at least three follicles ≥17 mm
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before day 8 of stimulation and as “normal responders” those that reached the
criteria after 8 days.
Main results and the role of chance: A total of 916 cycles were divided in
4 groups: group A (CFA early responders, n = 116), group B (CFA normal
responders, n = 344), group C (hp-hMG early responders, n = 127) and group
D (hp-hMG normal responders, n = 309). There were no differences in demo-
graphic characteristics among the groups regarding age, AFC and BMI. Patients
who needed 8 or more stimulation days needed on average 3 extra days until
triggering in both groups (CFA-group 10.1 total days vs hp-hMG-group 9.5 total
days; p = 0.2). There were no differences among the four groups in terms of
total number of retrieved oocytes (6.0 ± 5.3, 5.7 ± 3.3, 5.6 ± 4.9, 5.7 ± 3.7, p
= 0.9), number of mature oocytes (4.4 ± 4.3, 4.7 ± 2.7, 4.0 ± 3.0, 4.4 ± 3.2;
p = 0.22), and number of embryos transferred (1.5 ± 0.8, 1.6 ± 0.6, 1.5 ± 1.0,
1.5 ± 0.9; p = 0.3). Live-birth rates were 22.4%, 20.4%, 17.3% and 15.6% (p =
0.28) respectively, for the four study groups.
Limitations, reasons for caution: We acknowledge that this is a retro-
spective data analysis. Although a large dataset was analyzed, prospective stud-
ies are needed to conﬁrm these results.
Wider implications of the ﬁndings: The duration of ovarian stimulation to
reach the criteria for triggering ﬁnal oocyte maturation did not seem relevant
for the clinical outcome.
Trial registration number: not applicable.
P-695 NLRP3 expression is upregulated in ovarian granulosa cells
in a mousemodel of polycystic ovary syndrome
B.Wang1, P. Hong2, G. Yuping1, L. Bin1
1Xinhua Hospital- School of Medicine- Shanghai Jiaotong University, Department of
Reproductive Medicine, Shanghai, China
2The International Peace Maternity and Child Health Hospital- School of Medicine-
Shanghai Jiao Tong University, reproduction center, Shanghai, China
Study question: TLR3 and NLRP3 inﬂammasome contribute to the patho-
genesis of Type 2 diabetes in functioning as sensors for metabolic stress.
Whether TLR3 and/or NLRP3 are involved in the pathogenesis of PCOS.
Summary answer: By immunohistochemical analysis, expressions of TLR3
and NLRP3 are increased in granulosa cells in the PCOS mice.
What is known already: Elevated TLR3 is involved in dysfunction of pancre-
atic β-cells. NLRP3 inﬂammasome activation is upregulated in type 2 diabetes.
TLR3 activation is one of the most important signals that can activate NLRP3
inﬂammasome. Most PCOS women are suffering from insulin resistance. High
fat diet (HFD) and letrozole (LET) treatment have successfully induced repro-
ductive and metabolic phenotype of PCOS in mice.
Study design, size, duration: Four week-old, C57BL/6N female mice were
implanted subcutaneously with a placebo or 3 mg LET pellet with or without
HFD (60% calories from fat) feeding (n = 8 for control and HFD group, n = 6
for LET and LET plus HFD group). Seven weeks after treatment, the mice were
anesthetized with chloral hydrate, blood was collected via retro-orbital bleed-
ing, the parovarian fat pad, the ovaries were dissected, ﬁxed in 4%
paraformaldehyde.
Participants/materials, setting, methods: The mice were weighed
weekly. A glucose tolerance test was performed on the mice 3 weeks after the
treatment. Blood triglyceride, total cholesterol were measured. Parafﬁn-
embedded fats and ovaries were sectioned and stained with hematoxylin and
eosin. Expression of TLR3 and NLRP3 in the ovaries were evaluated by immu-
nohistochemical staining. Numbers of follicle and corpus luteal in each ovary
were recorded, and diameters of fat cells were measured by using the CellSens
software.
Main results and the role of chance: From 3 weeks after treatment, the
LET + HFD and LET mice exhibited signiﬁcantly more weight gain than control
and HFD mice (P < 0.05). LET + HFD and LET mice contained more large
antral follicles than HFD and control mice. The number of corpora lutea was
signiﬁcantly lower in LET and LET + HFD mice than in control and HFD mice (P
< 0.01). Fasting glucose levels in LET and LET + HFD mice were signiﬁcantly
higher than control mice (P < 0.05). LET + HFD mice resulted in markedly
increased serum glucose levels at 60, 120 and 180min after administration of
glucose compared with control and LET mice (P < 0.01). LET + HFD mice
exhibited signiﬁcantly higher serum triglyceride and total cholesterol levels than
control, HFD, and LET mice (P < 0.05). The average diameter of adipocytes
was signiﬁcantly larger in LET + HFD mice than control and LET mice (P <
0.01). Integral optical density (IOD) of TLR3 in ovary section of LET and LET +
HFD mice was higher than HFD and control (P > 0.05). IOD of NLRP3 in LET
and LET + HFD mice was signiﬁcantly higher than control (P < 0.05).
Limitations, reasons for caution: In this study, expression of TLR3 and
NLRP3 in the ovary was shown only in mouse species evaluated by immunohis-
tochemistry. Further study needs to be carried out in human beings. Whether
increased NLRP3 correlates with activation of caspase-1 then results in pyrop-
tosis of granulosa cell still need to be clariﬁed.
Wider implications of the ﬁndings: The signiﬁcant body weight gain, dysli-
pidemia and ovarian morphology change in mice is caused mainly by LET. TLR3
and NLRP3 mediated inﬂammation might involved in the pathogenesis and eti-
ology of PCOS. NLRP3 might be used as potential therapeutic target in this
disease.
Trial registration number: basic research, no trial registration number.
P-696 Dual trigger with gonadotropin-releasing hormone agonist
(GnRHa) and standard dose of human chorionic gonadotropin
(hCG) to improve oocyte maturation rate (MR)
I. Elkouhen1, C. Herbemont1, A. Brax2, M. Comtet2, S. Sarandi1,
A. Seroka2, B. Dagher-Hayeck2, J. Boujenah3, C. Vinolas2,
M. Grynberg2, I. Cedrin-Durnerin2, C. Sifer1
1Hôpital Jean Verdier, Histologie-Embryologie-Cytogenetique-CECOS, Bondy, France
2Hôpital Jean Verdier, Medecine de la Reproduction, Bondy, France
3Hôpital Jean Verdier, Gynecologie-Obstetrique, Bondy, France
Study question: Does dual trigger with GnRHa and standard dose of hCG in
IVF/ICSI cycles increase MR in patients with a history of >25% of immature
oocytes?
Summary answer: The proportion of mature oocytes retrieved was signiﬁ-
cantly higher after a dual trigger in comparison with the patient’s previous cycle.
What is known already:Oocyte maturation for IVF/ICSI cycles is commonly
induced by hCG to mimic natural luteinizing hormone (LH) surge. After con-
trolled ovarian hyperstimulation (COH), few oocytes are arrested at immature
stages. If >25% of retrieved oocytes are immature, affected patients have
poorer IVF outcomes than those with <25%. GnRHa has been explored in
many clinical scenarios, primarily to prevent ovarian hyperstimulation syn-
drome. One advantage of using GnRHa to trigger oocyte maturation is the
induction of a more physiological release of LH/FSH (Follicle-Stimulating-
Hormone). Recently, a dual trigger has been proposed as a potential treatment
in patients with a history of immature oocytes retrieved.
Study design, size, duration: This is a retrospective, case-control study per-
formed between December 2008 and December 2017. A total of 70 patients,
who experienced high oocyte immaturity rate (>25%) during their ﬁrst IVF/
ICSI cycle (analyzed as control group) and received a dual trigger for their sub-
sequent cycle (dual trigger group), were involved in the study. Only patients
with at least one oocyte retrieved were included.
Participants/materials, setting, methods: Initial COH cycle was per-
formed using agonist/antagonist protocols, and ovulation was triggered with
hCG. During the subsequent cycle, patients received antagonist protocol and
dual trigger using triptorelin 0.2 mg and hCG. Primary endpoint was MR (num-
ber of metaphase-2 (M2) oocytes/ retrieved oocytes). Secondary endpoints
were (i) fertilization (ii) D2-top-quality-embryo (D2-TQE: 4 blastomeres,
<20% cytoplasmic fragmentation) and (iii) cumulative clinical pregnancy rates
(including fresh and frozen-thawed transfers during the study period).
Outcomes were compared using paired-sample analysis.
Main results and the role of chance: Brieﬂy, patients’ mean age was 32.9
(control group) versus (vs.) 34.3 years (dual trigger group) (p<0.0001). A mean
of 11.3 and 12.3 oocytes were retrieved in control and case groups, respect-
ively (p = 0.26). A signiﬁcant increase in number of M2 oocytes and conse-
quently MR was achieved in case of dual trigger (8.9; 73.0%) when compared to
control group (6.0; 50.3%: p<0.0001). Hence, numbers of fertilized oocytes
(6.2 vs. 3.8; p<0.0001) and D2-TQE (2.2 vs. 1.6; p = 0.015) were signiﬁcantly
higher after dual trigger. However, fertilization (61.3 vs. 68.0%; p = 0.19) and
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D2-TQE rates (33.5 vs. 36.7%, p = 0.4) per mature oocyte were statistically
similar when compared between control and dual trigger groups, respectively.
During the study period, cumulative clinical pregnancy rate yielded 50% (35/
70) in control group vs. 64.3% (45/70) in dual trigger group (p = 0.08).
Limitations, reasons for caution: Cases of high oocyte immaturity rate are
rare, explaining the long inclusion period in this retrospective study. Besides,
baseline characteristics of patients were heterogeneous; especially antagonist
and agonist protocols were included in control group. Only randomized studies,
analyzing both biological and clinical outcomes, would conﬁrm the efﬁciency of
this strategy.
Wider implications of the ﬁndings: Dual trigger seems efﬁcient for man-
aging patients with high oocyte immaturity rate. Moreover, oocyte ability to be
fertilized and develop into TQE might not be impaired by this treatment. If
these results were conﬁrmed, dual trigger, permitting to obtain more M2-
oocytes, might optimize the chances of pregnancy in such patients.
Trial registration number:Not applicacable.
P-697 Oocyte quality in patients with polycystic ovary syndrome
(PCOS): impact on the extended culture and live birth rates
L. Delaroche1, C. Dupont2, N. Kazdar3, F.X. Aubriot4, P. Oger4,
F. Lamazou4, C. Yazbeck4
1Laboratoire d’AMP Eylau Unilabs de la clinique Pierre Cherest, AMP, Neuilly sur
seine, France
2University Hospital Tenon, Reproductive Medecine, Paris, France
3Laboratoire d’AMP Eylau Unilabs de la clinique Pierre Cherest, Reproductive
Medecine, Neuilly sur seine, France
4CMC Pierre Cherest, Reproductive Medecine, Neuilly sur Seine, France
Study question: Does the oocyte quality in patients with PCOS affect the
extended culture and live birth rates?
Summary answer: PCOS does not seem to affect the rate of useful blasto-
cysts when compared to normo-ovulatory patients.
What is known already: PCOS and its subsequent fertility disorders cause
difﬁculties in the management of the assisted reproductive technologies. Some
authors have hypothesized that PCOS patients have a lower oocyte and
embryo quality due to modiﬁcations of intra- and extra-ovarian factors.
Nonetheless, few studies have investigated the biological parameters in PCOS
patients after IVF attempts and speciﬁcally the extended culture.
Study design, size, duration: This is a single-center cohort study performed
from October 2015 to December 2017. Patients with PCOS (Rotterdam cri-
teria) and control normo-ovulatory patients (deﬁned as patients presenting
tubal, male or idiopathic infertility, with regular cycles and AMH basal level
between 2 and 4 ng/ml), who underwent IVF with extended culture to day 6
were included. Were exclude: woman’s age > 37 years, severe endometriosis,
cycle rank > 3 and severe male factor (<1 million/mL).
Participants/materials, setting, methods: 59 PCOS and 114 control
patients were included. The main endpoint was the rate of useful blastocysts
obtained (transferred and/or frozen) and secondaries were the oocyte matur-
ity rate and the cumulative live birth rate per ovum pick up.
Results were compared using chi-square test and Student t-test.
Confounding factors were evaluated by a logistic regression model. The P value
was considered signiﬁcant when <0.05. The results were expressed by mean ±
standard deviation or percentage.
Main results and the role of chance: The mean age of the patients was
31.5 ± 3.1 and 32.4 ± 3.0 years old, respectively, for the PCOS and the control
groups (p = 0.06). While the total dose of FSH administered and the number of
days of stimulation were similar, the average number of oocytes retrieved was
signiﬁcantly higher in the PCOS group compared with controls (15.7 ± 7.3 ver-
sus 12.9 ± 7.1, p = 0.02). The oocyte maturity rate was statistically lower in
the PCOS group compared to controls (74.3% versus 83.1%, p = 0.005). The
rate of useful blastocysts was similar between the PCOS and the control groups
(50.1% versus 53.6%, p = 0.62). The cumulative live birth rates per ovum pick
up were not statistically different (31.7% in the PCOS group versus 37.2% in
the control group, p = 0.50; Odds Ratio = 0.78; 95% Conﬁdence Interval
[0.38; 1.59]).
Limitations, reasons for caution: This preliminary results need to be con-
ﬁrmed by larger studies and prospective randomized controlled trials.
Wider implications of the ﬁndings: Our study conﬁrms that PCOS
patients have signiﬁcantly more retrieved oocytes but a lower maturity rate
thus leading to a similar number of mature oocytes compared to normo-
ovulatory patients and the chances of obtaining useful blastocysts were similar.
Pregnancy and birth rates were comparable to those of the normo-ovulatory
patients.
Trial registration number: I certify that there is with any ﬁnancial organiza-
tion regarding the material discussed in the study.
P-698 To compare clinical and metabolic effects of metformin
versus combined therapy with metformin and myoinositol and
D- chiro-inositol in PCOS women: A randomized control trial
A. Bahadur, H. Arora, J. Chaturvedi, A. Raj, L. Chawla, A. Gaurav,
K. Khoiwal, R. Kuncham, O. Kumari, N. Bhattacharya, A. Yadav,
S. Kumari
All India Institute of Medical Sciences, Obstetrics & Gynaecology, Rishikesh, India
Study question: Does addition of Inositols have a role in improving clinical
and metabolic parameters in women with PCOS?
Summary answer: Inositols have shown to reduce insulin resistance, it
improves insulin sensitivity of target tissues and positively affects clinical and
metabolic parameters in women with PCOS.
What is known already: PCOS is one of the most common endocrine disor-
ders (6-10%) affecting women of reproductive age. Insulin resistance plays a piv-
otal role in etiopathogenesis of PCOS. To prevent long term health
consequences of PCOS, besides life style modiﬁcations, use of insulin sensitizers
has been proposed. Metformin has been commonly used. Recently, inositols-
Myoinositol (MI) and D-chiro-inositol (DCI) have shown to be an efﬁcient and
safe alternative in PCOS management.
Study design, size, duration: This randomized controlled trial was con-
ducted in Gynae OPD at All India Institute of Medical Sciences, Rishikesh from
January 2017 till December 2017. Patients with PCOS were randomized into
two groups, 30 in group I (Metformin) and 32 in group II (Metformin and MI
and DCl).
Participants/materials, setting, methods: Group 1 received Metformin
500 mg twice a day for 3 months & in Group 2 received metformin with Myo-
inositol 550 mg + D-chiro-inositol 150 mg twice daily for 3 months. Clinical
parameters like menstrual cycle regularity, acne, hirsutism, BMI, waist & hip cir-
cumference were compared at baseline and after 3 months of therapy. Similarly
fasting blood sugar, fasting insulin levels and HOMA-IR index was compared at
baseline and after 3 months of therapy.
Main results and the role of chance: Baseline characteristics were similar
in two groups. Mean age was 28.35 +/- 2.74 & 27.12 +/- 3.34 years in Group I
and II respectively. Mean BMI was 27.71 +/- 3.60 & 27.38 +/- 3.92 kg/m2 in
Group I and II respectively. There was no improvement in acne score.
However, after receiving treatment for 3 months statistically signiﬁcant
improvement was seen in Group 2 (metformin + MI +DCI) in their clinical
parameters like weight (p < 0.02), waist circumference (p < 0.0155) & hip ratio
(p < 0.00045). A signiﬁcant improvement was seen in menstrual cycle length
and bleeding days in Group II (p < 0.01). HOMA-IR index also showed a statis-
tically signiﬁcant improvement after 3 months of therapy in Group II (2.83 +/-
1.29 vs 1.62 +/- 0.59, p < 0.03).
Limitations, reasons for caution: Main limitation of this study is small sam-
ple size. Large randomized control trials are required to explore above
hypothesis.
Wider implications of the ﬁndings: Using a comprehensive, detailed
assessment of clinical parameters our study has shown a beneﬁcial effect of
Metformin in combination with MI + DCI in women with PCOS & insulin resist-
ance. Combined therapy may have a role in PCOS patients.
Trial registration number: Applied for.
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P-699 Impaired follicular development and ovulation in PCOS
mousemodel can rescued by rapamycin treatment
A. Yaba1, M.Ş. Aydin2, S. Agus3, E. Gunalan3, E. Yildirim1, B. Yilmaz3
1Yeditepe University School of Medicine, Histology and Embryology, Istanbul, Turkey
2İstanbul Medipol University School of Medicine, Histology and Embryology, İstanbul,
Turkey
3Yeditepe University School of Medicine, Physiology, Istanbul, Turkey
Study question: Does Rapamycin (Inhibitor of mTOR) treatment suppress
proliferation of granulosa cells and decrease LH level in treatment of PCOS?
Summary answer: Rapamycin may have important role in treatment of
PCOS.
What is known already: Polycystic ovary syndrome (PCOS) is a complex
reproductive and endocrine disorder. The target of rapamycin (TOR) gene
product has been implicated in the control of cell growth and proliferation, pro-
tein synthesis, and autophagy. mTOR consist of 2 different protein complex as
TOR complex 1 (mTORC1) and TOR complex 2 (mTORC2). Rapamycin is an
inhibitor of mechanistic target of rapamycin pathway. Phosphorylation of serine
residue 2448 in mTOR has been shown to correlate with the activation status
of mTOR and proliferation of granulosa cells, and mTOR has functional role in
granulosa cells during successful folliculogenesis and ovary with PCOS.
Study design, size, duration: 5 groups were mainly designed: Control (no
treatment), PCOS (injection of DHEA (6 mg/100 g BW in 0.1 ml of sesame oil)
(s.c) for 20 consecutive days), Vehicle (daily (s.c) sesame oil alone injection),
Rapamycin (5 mg/kg in DMSO), Rapamycin Vehicle (daily (s.c) DMSO alone
injection).
Participants/materials, setting, methods: We used hematoxylin-eosin
staining for morphological eveluation to show the effect of Rapamycin treat-
ment on PCOS mouse ovary. 17-Beta estradiol, progesterone and Luteinizing
hormone levels detected by using ELISA. Additionally TUNEL and follicle count-
ing methods were used for determine of follicle reserve in each experimental
groups. mTOR signal pathway proteins and genes were presented with western
blot and quantitative Real Time PCR, respectively.
Main results and the role of chance: it is the ﬁrst time mTOR pathway
(TORC1 ve TORC2) and activation products are presented at protein and
mRNA levels in Rapamycin treated-PCOS mouse model. We detected that
Rapamycin treatment can improve follicular development, decreased LH level
and provide ovulation, and corpus luteum structure can occur again in PCOS
mouse ovary (p<0.05). Additionally, we detected decrease number of atretic
follicle and save primordial follicle reserve (p<0.05) after Rapamycin treatment.
Therefore Rapamycin may be use as a potential therapeutic strategy for the
treatment of PCOS.
Limitations, reasons for caution: Different treatment dosages might use
for treatment model of POCS.
Wider implications of the ﬁndings: We suggested that Rapamycin may
have a new approach to PCOS treatment and understanding the mechanism of
dominant follicle selection and anovulatory female infertility.
Trial registration number: not applicable.
P-700 Cumulative live birth rates in women with low ovarian
reserve are higher with conventional IVF stimulation than after
repeated natural cycle IVF attempts
M. Gaudoin1, P. Sim2, H. Smith3, R. Fleming1, L. Zujovic3,
N. Raine-Fenning3
1GCRM- Glasgow Centre For Reproductive Medicine, IVF Unit, Glasgow, United
Kingdom
2University of Glasgow, Medical School, Glasgow, United Kingdom
3Nurture, IVF Unit, Nottingham, United Kingdom
Study question: To determine the comparative efﬁcacy of stimulated IVF
(stimIVF) versus natural cycle IVF (ncIVF) in women with predicted poor ovar-
ian reserve (POR).
Summary answer: The stimIVF group had fewer visits, fewer cycles cancelled
and higher egg yield (all P<0.001) and higher cumulative live birth rate (18.2%
vs. 10.3%, P<0.03).
What is known already: The conveyor belt of follicle recruitment in POR,
and how many follicles might develop in any one treatment cycle, is unpredict-
able and variable. Such women have a poor prognosis and clinics are often
reluctant to treat them because of the perceived effect on the clinic’s success
rates. In the UK, ncIVF is not counted in a clinic’s pregnancy results so it offers
an alternative, also avoiding expensive FSH injections and the possibility of
back-to-back treatment cycles if a cycle is unsuccessful. However, a maximum
of 2 oocytes is achievable.
Study design, size, duration: Simultaneous, parallel 2-centre cohort study
in cycles from January 2015 – December 2016.
501 women underwent 699 stimIVF cycles (ﬂare protocol with Gonal-F) at
GCRM (Glasgow), and 55 women underwent 116 ncIVF cycles at Nurture
(Nottingham).
The number of visits required, the cycle cancellation rate, the egg yields, live
birth rates (LBR) per fresh cycle and cumulative LBR were determined.
Participants/materials, setting, methods: Both centres are private IVF
units but take a different approach to treatment of poor ovarian responders.
GCRM (Glasgow) favours conventional stimulation ﬂare protocol with Gonal-F
(225 IU/day if weight < 80Kg, 300 IU/day if weight > 80Kg). Nurture
(Nottingham) favours ncIVF with no FSH but starting Cetrotide and daily ultra-
sound scans when the lead follicle is greater than 13 mm diameter. Both trigger
using Ovitrelle and oocyte retrieval is performed 35-37 hours post-trigger.
Main results and the role of chance: There was no difference in BMI between
the groups but the stimIVF patients were one year younger (P<0.01). They had a
higher AMH level (P< 0.001) but were more likely to smoke (P<0.001).
The stimIVF group had fewer treatment cycles per patient (1.4 vs. 2.1, P <
0.01). Furthermore, they had fewer scans (and hence fewer clinic visits), fewer
cycles cancelled, higher egg yields per egg retrieval (3.6 ± 2.7 vs. 0.9 ± 0.5)
with more embryos available for transfer (all P<0.001). Only 4% of the stimIVF
patients retrieved no eggs compared to 18% in the ncIVF group although this
was not statistically signiﬁcant (P = 0.11).
The fresh live birth rate (LBR) per cycle start was not different (16.6% v.
10.3%, P = 0.09). However, the stimIVF group had a greater chance of having
frozen embryos and when subsequent frozen embryo transfers were taken into
account, the cumulative LBR was higher (18.2% vs. 10.3%, P<0.03).
Limitations, reasons for caution: This was neither a matched nor rando-
mised study. The stimIVF group were more likely to smoke but had a higher
AMH. However, the difference in AMH does not account for the difference in
the egg yields between the groups.
Wider implications of the ﬁndings: This is a poor prognosis group and
both approaches have their merits. The avoidance of FSH injections in ncIVF
must be balanced against the need for more scans (the increased burden of
more clinic visits), the psychological impact of greater likelihood of cycle cancel-
lation and the lower cumulative LBR.
Trial registration number:N/A.
P-701 Optimal number of oocytes need to complete family per
retrieval
R.A. Gupta, K.D. Nayar, G. Kant, N. Sharma, M. Singh, D. Nayar,
Kapil Dev Nayar
Akanksha IVF centre, Mata Chanan Devi Hospital, New Delhi, India
Study question: To determine the optimal number of oocytes per retrieval
needed to obtain at least two live births while practicing safe and effective
stimulation.
Summary answer: Retrieving12-16 oocytes per cycle is optimal for complet-
ing family without wastage of surplus embryos as compared to retrieving more
than16 or less than 8 oocytes.
What is known already: The practice is globally shifting to mild stimulation
and elective single embryo transfer claiming to attain pregnancy rates similar to
conventional stimulation and embryo transfer, but the desire to complete family
and need for multiple retrieval cannot be overlooked. Aggressive stimulation to
obtain too many oocytes, is associated with risk of OHSS, diminished receptiv-
ity because of high estradiol levels. On the other hand mild stimulation with
multiple stimulation cycles, associated surgical and anaesthetic risks, ﬁnancial
and emotional burden.Too many cryopreserved embryos burden the lab and
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couples ﬁnancially. Generally they are written off by couples after achieving two
live births.
Study design, size, duration: A prospective cohort study conducted in an
IVF centre of tertiary hospital. All women less that 36 years with primary infer-
tility undergoing IVF between 1st January 2016 and 31st December 2016.
Participants/materials, setting, methods: Women were stimulated with
conventional antagonist protocol. All the participants meeting the inclusion cri-
teria were divided in 3 groups Group A: 8-12, Group B: 12–16 and Group C
with ≥ 16 oocytes. Women with < 8 retrieved oocytes or with single embryo
transfer were excluded. The primary outcomes cumulative pregnancy rate
(CPR) and family completion rate (≥ 2 live births) were calculated for each
group. Statistics done using chi square test.
Main results and the role of chance: A total of 782 women meeting the
inclusion criteria were divided in Group A (N = 186) Group B (N = 308) Group
C ( N = 288) based on number of oocytes as described. The number of fresh
cycles were least in Group C (39%) due to elective freezing to prevent OHSS.
The family completion rate was comparable in group B and Group C which was
signiﬁcantly more than that in Group A ( 23%, 26%, 13% respectively p =
0.0005,0.0007, 0.34). There would be signiﬁcantly more number of patients with
unused embryos in group C compared to Group B ( 15% vs 9% p = 0.03).
N = 782 Group A
8-12N =
186 (%)
Group B
12-16N =
308(%)
Group C
> = 16N
= 288 (%)
Fresh ET cases 162 (87%) 211 (89%) 112 (39%)
Retrievals leading to a 1 Live
Birth
87(47%) 179 (58%) 184 (64%)
Retrievals leading to 2 Live
Birth
20(11%) 52 (17%) 55(19%)
Patients with 1 live birth
with frozen embryos
remaining
14 (8%) 74 (24%) 83 (29%)
Patients with 2 live birth
with frozen embryos
remaining
3 (2%) 29 (9%) 43(15%)
Expected no. patients to
achieve a 2nd child from
their remaining frozen
embryos
4(2%) 18 (6%) 20 (7%)
Family Completion Achieved 24(13%) 70(23%) 75(26%)
Limitations, reasons for caution: A better design would be comparison of
multiple stimulation cycles in women with low oocyte yield. Small sample size
and short follow up too are limitations.
Wider implications of the ﬁndings: Stimulate mildly to retrieve 12-16
oocytes as LBR are better in fresh cycles with just sufﬁcient number of frozen
embryos needed for family completion compared to too many oocytes posing
risk of OHSS and high cost of unused cryopreservation embryos without any
increase in number of women with completed family.
Trial registration number: Trial registration number: MCDH/2015/58
P-702 The impact of polycystic ovary syndrome (PCOS) on
early- and late-morphokinetic parameters: a retrospective analysis
of 3938 time-lapse (TL) monitored embryos
G. Christou1, I. Dimitriadis2, C.R. Sacha2, J.B. Bakkensen2,
K.A. Dickinson1, C. Veiga1, A. Blanchard1, C.L. Bormann3, I. Souter3
1MGH Fertility Center, Obstetrics and Gynecology, Boston- MA, U.S.A.
2Massachussets General Hospital, Obstetrics and Gynecology, Boston- MA, U.S.A.
3Massachussets General Hospital/Harvard Medical School, Obstetrics and
Gynecology, Boston- MA, U.S.A.
Study question: Is there an effect of PCOS on either early- and/or late-
morphokinetic parameters obtained during embryonic culture to blastocyst
stage in a TL-monitored incubator?
Summary answer: When comparing embryos derived from PCOS patients
with those from other diagnoses no signiﬁcant effect of PCOS on either early-
and/or late-morphokinetic parameters was noted.
What is known already: PCOS contributes to both anovulation and poor
embryonic quality, as well as an increased risk for early pregnancy loss.
Emerging TL studies have raised suspicions that PCOS may inﬂuence certain
TL-morphokinetic parameters, such as the duration of the 4th cleavage division
and the time to reach the morula stage. Whether PCOS affects the timing of
additional early- and/or late-morphokinetic parameters thought to predict
blastocyst formation and implantation remains unclear.
Study design, size, duration: Data from 3938 embryos, derived from 579
IVF cycles taking place at a major academic center between 9/2013 and 9/
2016, were retrospectively reviewed. All embryos were cultured to the
blastocyst in a TL-monitored incubator. Embryos derived from PCOS were
compared to i) those from patients with all other diagnoses (225 and 3713
embryos, respectively), and ii) in a sub-analysis to those with either idio-
pathic or tubal factor infertility (TFI), in regards to certain morphokinetic
parameters.
Participants/materials, setting, methods: Groups were compared in
regards to the following TL-morphokinetic parameters: time-period from i)
pronuclei fading (tPNf) to 1st-cytokinesis (P1), ii) 2- to 3-cells (P2), iii) 3- to 4-
cells (P3), iv) 4- to 5-cells (P4), v) tPNf to early-blastulation (PSB).
Mann-Whitney U-, χ2-tests, and multilevel mixed-effects regression models
[adjusted for potential confounders: age, body mass index (BMI), basal-FSH, fer-
tilization method] were used to assess mean differences [AMD (95% CI)]
between groups. P<0.05 was considered signiﬁcant.
Main results and the role of chance: Median (interquartile range) age,
BMI, basal-FSH were 33.1(31.6-36.6) vs. 35.6(32.9-38.8) years, p = 0.01;
24.5(22.3-28.1) vs. 23.1(21.2-26.5) kg/m2, p = 0.06; 5.4(5.0-6.5) vs. 7.0(5.9-
8.3) IU/L, p<0.01 for PCOS vs. non-PCOS diagnosis, respectively. When all
embryos were included in the analysis, no difference was noted in any of the
morphokinetic parameters between the groups [AMD (95% CI) in hours: 0.1
(-0.2-0.3), p = 0.54; -0.3(-1.3-0.7), p = 0.53; -0.4(-1.4-0.6), p = 0.46; -0.3
(-1.8-1.1), p = 0.66; 1.3(-1.6-4.3); p = 0.38; for P1, P2, P3, P4 and PSB,
respectively]. Furthermore, when usable (selected for either transfer or cryo-
preservation) were analyzed separately from discarded embryos, the results
did not change.
Similarly, in a sub-analysis comparing PCOS-embryos to those derived
from couples with idiopathic infertility, no signiﬁcant differences were noted
in any of the studied morphokinetic parameters [AMD (95% CI) in hours:
0.10(-0.18-0.38), p = 0.48; -0.3(-1.3-0.7), p = 0.53; -0.4(-1.4-0.6), p =
0.46; -0.3(-1.8-1.1), p = 0.66; 1.3(-1.6-4.3), p = 0.38; for P1, P2, P3, P4 and
PSB, respectively]. However, when comparing PCOS to TFI-embryos (no
oocyte factor infertility), P1 duration was signiﬁcantly longer and P2 signiﬁ-
cantly shorter in the former subgroup [AMD (95%CI): 0.36(0.07-0.66)
hours, p = 0.02; 1.25(0.44-2.06) hours, p<0.01, respectively]. Differences
persisted for the most part, even when analyzing usable embryos separately
from discarded ones. All other morphokinetic parameters did not differ
between PCOS and TFI groups.
Limitations, reasons for caution: Limitations include mainly the retrospect-
ive design of the study and the inclusion of only those morphokinetic para-
meters thought to predict blastocyst development. Furthermore, insulin
resistance and/or metformin treatment were not taken into consideration.
Time periods were normalized to tPNf to account further for fertilization meth-
od, as needed.
Wider implications of the ﬁndings: No obvious effect of PCOS was noted
on either early- or late-morphokinetic parameters assessed by TL-microscopy,
except when PCOS embryos were compared to a subgroup with no obvious
contributing oocyte factor, a ﬁnding suggestive of a subtle impact of PCOS on
oocyte quality.
Trial registration number:Not applicable.
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P-703 Impact of serum progesterone on embryo quality and
cumulative live birth rate in oocyte donation cycles
C. Blockeel1, A. Racca1, N. De Munck1, S. Santos-Ribeiro1,
J. Errazuriz Valenzuela1, P. Drakopoulos2, A. Galvao1, S. Mackens1,
M. De Vos1, H. Tournaye1
1Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Jette- Brussels,
Belgium
2University of Liège, Department of Reproductive Medicine, Liège, Belgium
Study question: Does late follicular elevated serum-progesterone (LFEP) dur-
ing ovarian stimulation for oocyte donation have an impact on embryo quality
(EQ) and cumulative live birth rates (CLBRs)?
Summary answer: LFEP does not have an inﬂuence on embryo quality and
CLBR in oocyte donation cycles.
What is known already: Ovarian stimulation promotes the production of
progesterone (P) which has been demonstrated to have deleterious effect on
IVF outcomes when elevated during the follicular phase. While there is robust
evidence that this elevation results in (epi)genetic changes impairing endomet-
rial receptivity, the impact on EQ remains a matter of debate. The oocyte-
donation model is the best tool to assess the effects of LFEP on EQ from those
on endometrium receptivity separately. Previous studies in oocyte donation
cycles investigating the inﬂuence of elevated P on pregnancy outcomes in
oocyte recipients gave conﬂicting results.
Study design, size, duration: This was a retrospective analysis including all
GnRH antagonist down-regulated cycles for fresh oocyte donation that took
place in a tertiary referral university hospital between 2010-2017. A total of
397 donor-acceptor cycles were included. Each donor was included only once
in the analysis and could be associated to a single acceptor.
Participants/materials, setting, methods: The sample was stratiﬁed
according to the following serum P levels on the day of ovulation triggering:
≤1.5 ng/mL and >1.5 ng/mL. The primary outcome parameter was the top-
quality embryo rate on day 3 and the secondary outcome was CLBR deﬁned as
a live-born delivery after 24 weeks.
Main results and the role of chance: 397 fresh oocyte donation cycles
were included in the analysis, of which 314 (79%) had a serum P ≤ 1.5 ng/ml
and 83 (20.9%) had a serum P>1.5 ng/ml. The average age of the two oocyte
donor groups was 31.4 ± 4.7 and 30 ± 4.6 years, respectively. The mean num-
ber of oocytes retrieved was signiﬁcantly higher in the elevated P group with
16.6 ± 10.6 vs 11.5 ± 6.7 in the P ≤ 1.5 group (p<0.001). Maturation rate, fer-
tilization rate and mean age of the acceptors did not vary signiﬁcantly between
the two study groups (p = 0.622; p = 0.767; p = 0.889, respectively). The total
number of good quality embryos on day 3 was signiﬁcantly higher in the ele-
vated P group with 6.1 ± 4.4 vs 8.7 ± 6.3, p<0.001); however, the good quality
embryo rate and the utilization rate (deﬁned as the number of transferred or
cryopreserved embryos to the number of fertilized oocytes) were similar
between the two arms (p = 0.386 and p = 0.098, respectively). Furthermore,
multivariable regression analysis accounting for donor age and number of
oocytes retrieved as potential confounders showed that CLBR was not nega-
tively inﬂuenced by LFEP (60.7% for P ≤ 1.5 ng/ml and 71.2% for P>1.5 ng/ml,
p = 0.115).
Limitations, reasons for caution: This is an observational study based on a
retrospective data analysis. Better extrapolation of the results could be valid-
ated by performing a prospective analysis.
Wider implications of the ﬁndings: This is the ﬁrst study providing evi-
dence that LFEP in oocyte donation programs does not inﬂuence embryo qual-
ity neither cumulative live birth rates in the oocyte recipient.
Trial registration number: not applicable.
P-704 Effects of progesterone on the regulation of luteinising
hormone surge in adult female rat
W. He1,2, X.F. Li2, K.T. O’Byrne2, Y.P. Kuang1
1Assisted Reproduction Department, Shanghai Ninth People’s Hospital, Shanghai
Jiaotong University School of Medicine, China
2Division of Women’s Health, King’s College London, United Kingdom
Study question:Our clinical studies have shown that progesterone acts as an
effective alternative for blocking premature LH surges in COH. What is the
underlying mechanisms of progesterone blocking LH surge?
Summary answer: Our results indicate progesterone prevents premature
LH surges during superovulation in women and rats. The hypothalamic AVPV
and ARC nuclei may be targeted for this.
What is known already: Premature LH surges are a major cause for cycle
cancellation during controlled ovarian stimulation (COH) in women undergoing
IVF. Efforts to minimize the occurrence of premature LH surges have mainly
relied on the use of GnRH agonist/antagonist, which exert greater risk of side
effects. Our clinical studies have shown that progesterone acts as an effective
alternative for blocking premature LH surges in COH. Early studies indicate the
hypothalamus mediates the feedback effect of progesterone on regulation of
LH level. However, the underlying mechanisms remain unknown, which exert
difﬁcult for clinical doctors to use this protocol.
Study design, size, duration: This study included a total of 64 adult female
Sprague-Dawley rats, who were given a single intraperitoneal injection of preg-
nant mare serum gonadotropin to induce ovarian hyperstimulation followed by
either progesterone or oil injection for 2 days.
Participants/materials, setting, methods: The collected data considered
the LH surge and pulse, progesterone and estradiol dynamic during hyerovula-
tion. Also, the follicle development and embryological result were examined.
We tested the hypothesis:1, progesterone can prevent premature LH surge
during superovulation without affecting oocyte quality in rat model; 2,
Progesterone may prevent premature LH surges via progesterone receptors in
the hypothalamic arcuate (ARC) and/or anteroventral periventricular (AVPV)
nuclei; loci known to be involved in LH pulse and LH surge generation.
Main results and the role of chance: Our results indicated that progester-
one prevents premature LH surges during superovulation in rats,without affect
the number of oocyte retrieved and further embryonic development, These
results coincide with our clinical observation. Meanwhile, progesterone admin-
istration prolonged the estrous cycle (P<0.05) in SD rats. Onset of the LH
surge was signiﬁcantly delayed when progesterone was administrated with
PMSG(P<0.05). Furthermore, bilateral microinjections of anti-progestin RU486
(5 ng/μl, 0.8 μl) into the AVPV and ARC inﬂuence LH levels. Therefore, The
hypothalamic AVPV and ARC nuclei may be targeted for progesterone regula-
tion of LH surges in the rat.
Limitations, reasons for caution: Transferability of our ﬁndings is chal-
lenged by the possible variation of hypothalamus nuclei corodinates, but posi-
tively affected by our intra-nuclei injection technique and observation on
microscopic histological inspection of stained brain sections to eliminate animals
with inappropriate bilateral cannulae placement.
Wider implications of the ﬁndings: Our present study enhances the cur-
rent understanding of the roles of progesterone in the regulation of the GnRH/
LH surge:1) progesterone can effectively blocking LH surges during superovula-
tion while maintaining normal follicle development ;2.The hypothalamic AVPV
and ARC nuclei may be targeted for progesterone blockade of LH surge in rats.
Trial registration number:Not applicable.
P-705 Retrospective analysis of DuoStim cycles shows similar
overall performance and oocyte quality between follicular and luteal
phase stimulation
G. Cecchino, M. Cerrillo, M. Cruz, J.A. Garcia-Velasco
IVI-RMA Global, Reproductive Endocrinology and Infertility, Madrid, Spain
Study question: Is there any difference in the overall performance of follicular
and luteal phase stimulation among patients undergoing double ovarian stimula-
tion (DuoStim)?
Summary answer:DuoStim shows similar results with respect to the number
of retrieved oocytes, fertilization and blastocyst formation rates in both the fol-
licular and luteal phase stimulation.
What is known already: Previous studies have demonstrated that several
waves of cyclic development of antral follicles may coexist within the same men-
strual cycle. Moreover, it has been shown that follicles formed during the luteal
phase have a similar ovulation potential. Often, physicians are compelled to
perform several stimulation cycles to obtain more eggs. Thus, the DuoStim
i464 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
protocol could be an attractive alternative to obtain a higher number of oocytes
in a shorter period, declining the time-to-pregnancy. It also emerges as an inter-
esting option for emergency fertility preservation in oncologic patients.
However, more studies are needed to validate its feasibility.
Study design, size, duration: Retrospective analysis of DuoStim cycles per-
formed over the past year in IVI-RMA Global clinic, Madrid, Spain. We aimed
to evaluate the potential usefulness of the DuoStim protocol by comparing
oocyte quality and overall performance between follicular and luteal phase
stimulation within the same menstrual cycle.
Participants/materials, setting, methods:We included 25 women who
underwent a total of 30 cycles using the DuoStim protocol in 2017 at IVI-
RMA Global clinic, Madrid, Spain. Data containing baseline and demographic
characteristics along with the variables of interest from both the follicular
and the luteal stimulation were exported from our institutional repository
software platform. Statistical analysis included ANOVA test for variables
with normal distribution and Mann-Whitney U test whenever the distribu-
tion was not normal.
Main results and the role of chance: Baseline characteristics revealed that
the median values of age, AMH, AFC and IMC were 39.2 years, 1.34, 5.88 and
20.8 kg/m2, respectively. Thus, our study population was mainly composed of
women with advanced age and low ovarian reserve. In fact, all patients pre-
sented with very poor reproductive prognosis and multiple IVF failures.
Variables of interest presented a normal distribution, except for the blastocyst
formation rate. ANOVA test demonstrated no signiﬁcant differences between
the follicular and luteal stimulation, respectively, regarding the median of: days
of stimulation (10.53 vs. 11.83; p = 0.077), amount of gonadotropin adminis-
tered (2059.26 UI vs. 2603.45 UI; p = 0.061), retrieved oocytes (4.83 vs. 5.17;
p = 0.737), MII oocytes (3.93 vs. 4.20; p = 0.741) and fertilization rate (60.75%
vs. 62.76%; p = 0.830). Likewise, Mann-Whitney U test did not show any differ-
ence with respect to the blastocyst formation rate (20.78% vs. 26.62%; p =
0.260). There was a trend to use greater amounts of gonadotropin during the
luteal phase, although not statistically signiﬁcant. In conclusion, the use of the
DuoStim protocol exhibited encouraging results irrespective of age and ovarian
reserve. Similar ﬁndings were reported by other few studies comprising patients
with a distinct clinical proﬁle. Randomized clinical trials are needed to legitimize
its use in daily practice.
Limitations, reasons for caution: Unequivocal limitations are essentially
related to the retrospective design. Therefore, the study is prone to sources of
error due to confounding factors. Nevertheless, considering the scarcity of pro-
spective data in literature, our results provide important insights on the effect-
iveness of the DuoStim.
Wider implications of the ﬁndings: This work contributes to conﬁrm the
efﬁciency of the DuoStim protocol. It may be especially convenient for oncolo-
gic patients or those with a poor reproductive prognosis pursuing infertility
treatments. Not only it reduces the time to obtain a higher number of eggs, but
it also attenuates the couple´s anxiety.
Trial registration number:Not clinical trial.
P-706 Primary subfertility is signiﬁcantly associated with higher
levels of Thyroid Stimulating Hormone within the normal range
preceding In Vitro Fertilization
C. Delprat1, E. Van Dam2, P. Van de Ven3, K. Aissa4, M. Ter Haar4,
Y. Feenstra4, A. De Roos4, G. Beelen4, R. Schats4, C. Lambalk4
1VUMC, IVF, Amsterdam, The Netherlands
2VUMC, Internal Medicine, Amsterdam, The Netherlands
3VUMC, Epidemiology and Biostatistics, Amsterdam, The Netherlands
4VUMC, Obstetrics- Gynaecology and Reproductive Medicine, Amsterdam, The
Netherlands
Study question: Is the distribution of Thyroid Stimulating Hormone (TSH)
levels within the normal range different in primary or secondary subfertile
women without thyroid hormone substitution?
Summary answer: In women with primary subfertility preceding In Vitro
Fertilization (IVF) the prevalence of higher TSH values is signiﬁcantly increased
compared to secondary subfertile women.
What is known already: Among healthy fecund women, TSH levels ≥ 2.5
mIU/L were not associated with fecundity, pregnancy loss, or live birth
(Plowden, et al., 2016). While in subfertile women the prevalence of TSH levels
2.5 mIU/L -4.5 mIU/L is much higher (20%) than in the general population (5
%) we don’t know the inﬂuence of primary or secondary subfertility on this dis-
tribution. In the context of the discussion whether the cut-off level for TSH for
subfertile women should be 2.5 mIU/L or 4.5 mIU/L we should ﬁll this gap of
knowledge and precise predicting factors for and deﬁne individual thyroid (dys)
function.
Study design, size, duration: In a cohort study in women starting In Vitro
Fertilization (n = 858) or Intra Cytoplasmatic Sperm Injection (n = 843)
between the ﬁrst of January 2008 and the ﬁrst of March 2012 the distribution of
TSH levels (0.3-2.49 and 2.50-4.5 mIU/L) was compared in primary and sec-
ondary subfertility women.
Participants/materials, setting, methods:Women aged 22-45 years with
TSH 0.3–4.5 mIU/L without thyroid hormone substitution were included at VU
University Medical Center, Amsterdam, the Netherlands, an Iodine-sufﬁcient
area. Chi-square tests were used to compare groups of patients based on TSH
values using 2.5 mIU/l as a cut-off, and primary or secondary subfertility.
Main results and the role of chance: In primary subfertile women TSH is
signiﬁcantly increased preceding IVF compared to secondary subfertile women
(p = 0.006): of the primary subfertile women 23.4 % has TSH levels in the high-
er reference range, while of the secondary subfertile women 16 % has TSH
levels in the higher reference range.
Limitations, reasons for caution: Unknown values of free thyroxine and
thyroid peroxidase antibodies limit the clinical interpretability.
Wider implications of the ﬁndings: Increased prevalence of higher TSH
levels in primary subfertile women preceding IVF corresponds with Plowdens
data that increased TSH values are of less importance in previous pregnant
women. In primary subfertile women preceding IVF on the other hand these
increased TSH values might disclose thyroid dysfunction.
Trial registration number: not applicable.
P-707 Caenorhabditis elegans, a model for polycystic ovary
syndrome
M. Muñoz1, C. Viera2, C. Lopez2, S.G.H. Viso2, M. Artal2,
J.A. Horcarjadas2, A.M. Brokate-Llanos2, A. Garzón2, J. Vioque3,
J. Girón3, M.S. Alaiz3
1Universidad Pablo de Olavide, Genética, Sevilla, Spain
2Andalusian Center for Developmental Biology-, Consejo Superior de Investigaciones
Cientíﬁcas/Junta de Andalucía/Universidad Pablo de Olavide, Seville, Spain
3Instituto de la grasa - CSIC, Componentes bioactivos y funcionales de productos
vegetales, Sevilla, Spain
Study question: Can C. elegans be used as a model for POCS suitable for
drug screening and gene target identiﬁcation?
Summary answer: We have found drugs, natural extracts and genes that
when inactivated reduce the infertility of a C. elegans POCS model.
What is known already: PCOS is the most common endocrine and meta-
bolic disorder affecting women in reproductive age. Although the ethology is
complex, in most cases this syndrome is related to the insulin signalling path-
way. In fact, two-thirds of adult women with PCOS suffer from insulin resist-
ance and hyperinsulinemia. Reduction of the insulin signalling pathway reduce
fertility in all biomedical model organism, including invertebrate like Drosophila
and the nematode Caenorhabditis elegans. C. elegans is a simple model organ-
ism that allow easily to search in high through put scale for genes, drugs and nat-
ural extracts that suppresses the reduction of fertility.
Study design, size, duration: We have selected C. elegans strains affected
in the insulin pathway which generate a strong reduction of the fertility.
Speciﬁcally, a mutant in the homologue gene to the insulin receptor and a
mutant in the phosphatidylinositol-3-kinases.
By using high through put RNAi screening we have tested reduction of activ-
ity in 16.000 genes in the PCOS models and observed if the infertility is
reduced. Furthermore, we have treated with 250 edible plant extracts and 50
puriﬁed compounds.
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Participants/materials, setting, methods: C. elegans allows high through
put screening of plant extracts and puriﬁed compounds. Plant extracts were
collected by our group and hydrophilic and hydrophobic extract were gener-
ated of each extract.
RNAi screening were performed, feeding C. elegans with bacteria that pro-
duce double strand RNAi of target genes.
In each case more than 10 individuals were treated and in three days all the
brood size was counted.
Main results and the role of chance: From 16.000 RNAi assays we have
found that inactivation of 42 genes suppress the infertility of the PCOS model.
We are currently analyzing those genes that are involved in different biological
processes among them oxidative stress and cell cycle control.
Some of those genes are targeted of already identiﬁed drugs, which we are
now testing for suppression of the infertility.
Two extracts form edible plants have also demonstrated a suppression of
the infertility of the PCOS models. We are now purifying the active principle.
Limitations, reasons for caution: C. elegans model is a very suitable to per-
form high through put screening of drugs, compounds or RNAi; However;
results needs to be validates in a mammal model.
Wider implications of the ﬁndings: Gen identiﬁcation of suppressor of the
infertility of the C. elegans model for PCOS will allow to better understand the
nature of the reduction of fertility.
Identiﬁcation of compounds or extracts can be of interest for future treat-
ment of the disease.
Trial registration number:Not application.
P-708 Could polymorphisms of some hormonal receptor genes,
involved in folliculogenesis help in predicting patient response to
controlled ovarian stimulation?
E. Prasnikar1, Čuš1, K. Repnik2, V. Vlaisavljević3, U. Potočnik2,
B. Kovačič4
1University medical centre Maribor, Department of reproductive medicine and
gynecological endocrinology, Maribor, Slovenia
2Medical faculty Maribor- University of Maribor, Centre for human molecular genetics
and pharmacogenomics, Maribor, Slovenia
3Biomedical Research Institute BRIS, Bris, Ljubljana, Slovenia
4University medical centre Maribor, Department of reproductive medicine and
gynecological endocrinology, Maribor, Slovenia
Study question: Are single-nucleotide polymorphisms (SNPs) in genes
involved in folliculogenesis associated with serum hormonal levels and recom-
binant FSH (rFSH) dose used in controlled ovarian stimulation (COS)?
Summary answer: FSHR rs1394205 was only SNP that was positively asso-
ciated with serum AMH level and used rFSH dose per retrieved oocyte.
What is known already: Despite of development in diagnostics, unex-
pected ovarian response in patients undergoing COS could still occur. For
COS in an in vitro fertilization (IVF) programme, exogenous gonadotrophins
are administered to patients. Numerous studies were focused on genetics
of ovarian hormonal receptors but the results are contradictory. It is sug-
gested that speciﬁc SNPs of hormonal receptor genes from granulosa cells
inﬂuence foliculogenesis, oocyte development and maturation. Ovarian
response to COS is usually determined by the number of growing antral
follicles and consequently by the number of retrieved oocytes and is char-
acterized as low, normal, or high.
Study design, size, duration: In a cross-sectional study (March–July 2015)
60 IVF patients were treated by GnRH antagonist and rFSH. Patients of advance
age (>39 years), PCOS, or endometriosis were excluded from the study.
Oocyte were retrieved from follicles >16 mm in diameter. Patients were nor-
mal- (7–15 oocytes)(n = 26), poor- (according to Bologna criteria)(n = 17) and
hyper (>15 oocytes)(n = 17) responders according to the oocyte number.
Blood samples were collected for basal FSH and AMH measurements and
SNPs genotyping.
Participants/materials, setting, methods: Genotyping SNPs (AMH
rs10407022, AMHR rs3741664, FSHR rs1394205, FSHR rs6166, and ESR1
rs2234693) was performed using high resolution melting (HRM) method. After
follicle puncture the number of retrieved oocyte was counted and the dose of
used rFSH per oocyte was calculated. Main outcomes measures were preva-
lence of genotypes among patient subgroups and associations between speciﬁc
genotypes and clinical parameters (serum FSH and AMH, rFSH dose adminis-
tered and number of oocytes retrieved).
Main results and the role of chance: AMHR rs3741664, FSHR rs1394205
and rs6166 and ESR1 rs2234693 were positively associated with serum AMH,
FSH and rFSH dose used, whereas AMH rs10407022 was not. Selected SNPs
do not show any association with oocyte number.
Patients with GG genotype of FSHR rs1394205 had lower measured serum
AMH level, compared to women with heterozygotes and AA homozygotes in
one group (AA+AG) (p = 0.016). No association with basal AMH level and
other SNPs were detected. Patients with GG genotype of FSHR rs1394205 also
required lower rFSH dose per oocyte than patients with AA+AG genotypes (p
= 0.036). When compared genotype and allele frequencies between groups,
we found higher frequency of GG genotype in poor- (76.5%) than in hyper-
responders (37.5%, p = 0.002). Distribution of other SNPs between patient
groups was not statistically signiﬁcant.
Patients with AA genotype of FSHR rs6166 had higher level of measured
basal serum FSH compared to those with AG+GG genotypes (p = 0.043). In
other genotypes, hormonal levels were not different.
Women with GG genotype of AMHR rs3741664 required higher rFSH
dose in COS in comparison with patients carrying genotypes AA+AG (p =
0.028).
Limitations, reasons for caution: Our results may be confounded by a
small sample size; further investigations including more patients are needed to
conﬁrm our ﬁndings. Gene analysis on granulosa cells could conﬁrm the impact
of SNPs to the level of speciﬁc hormonal receptor expression.
Wider implications of the ﬁndings: Based on our results, genotyping of
hormonal receptor SNPs from patient blood sample is not yet reliable
diagnostic method for prediction of patient’s ovarian response to rFSH
therapy.
Trial registration number: Study was approved by Slovenian Medical Ethics
Committee (012-347/2015-8). It is a part of research projects P3-0327 and J3-
7177 funded by the Slovenian Research Agency.
P-709 Does the phenotype of polycystic ovary syndrome inﬂuence
the ovarian response to controlled ovarian hyperstimulation for
IVF?
G. Robin1, C. Grysole1, A. Uk2, A.L. Barbotin2, C. Decanter1,
D. Dewailly1
1CHRU de Lille, Service d’Assistance Médicale à la Procréation et préservation de la
fertilité, Lille, France
2CHRU de Lille, Service de Biologie de la Reproduction, Lille, France
Study question: The aim of this study was to compare the ovarian response
pattern to controlled ovarian stimulation (HOC) for IVF between different
PCOS phenotypes.
Summary answer: Phenotype A seems to be the PCOS phenotype with the
higher cancellation rate and the longer duration of stimulation.
What is known already: PCOS phenotypes do not have the same endocrine
and metabolic proﬁles. But few studies have evaluated the impact of PCOS
phenotype in IVF.
Study design, size, duration: This is a retrospective cohort study, in which
178 PCOS patients completed 376 IVF +/- ICSI cycles, between January 2009
and Marsh 2016, at the University Hospital of Lille.
Participants/materials, setting, methods: This PCOS population was
divided into 4 phenotypes, deﬁned by the modiﬁed Rotterdam classiﬁcation,
according to the presence of oligo-anovulation (OA), hyperandrogenism (HA)
and polycystic ovarian morphology (PCOM) (on ultrasound and/or excessive
serum AMH level). Phenotype B (OA+HA, without PCOM) was excluded
because of its small size (n = 1). The response to HOC protocol was compared
between the 3 phenotypes.
Main results and the role of chance: The PCOS phenotypes were deﬁned
as A (OA+HA+PCOM, n = 194 cycles), C (HA+PCOM, n = 82 cycles) and D
(OA+PCOM, n = 100 cycles).
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Full phenotype A had signiﬁcantly higher LH and AMH levels than phenotypes
C and D.
The number of canceled cycles was signiﬁcantly higher in phenotype A com-
pared to phenotypes C and D (22.7%, 13.4% and 12.0%, respectively, p =
0.038). The majority of cycle’s cancellations in the phenotype A seemed to be
due to a poor ovarian response, but there was no signiﬁcant difference between
the groups. Patients with phenotype A had signiﬁcantly longer ovarian stimula-
tion than those with phenotype D.
Furthermore, doses of gonadotropins used were not signiﬁcantly different
between the phenotypes.
Thus, a resistance to exogenous FSH could explain the higher cancellation
rate for phenotype A, and could be associated with high AMH levels.
The hyperstimulation syndrome (OHSS) rates and clinico-biological out-
comes between the 3 phenotypes were not signiﬁcantly different.
Limitations, reasons for caution: The main limitation of this study is the
retrospective design. However, the high number of cycles adds strong value to
our study.
Wider implications of the ﬁndings: Our study suggests that patients with
phenotype A seem more difﬁcult to stimulate. A recent study showed that
phenotype A may be at greater risk of OHSS. A prospective study could con-
ﬁrm the need to increase gonadotropin doses for phenotype A, with GnRH
agonist trigger to limit OHSS.
Trial registration number: non applicable.
P-710 Multiple consecutive stimulation cycles as a method to
shorten duration of infertility treatment
K. Łukaszuk1, J. Palaszewski2, M. Jakubow3, A. Lukaszuk1,
M. Kunicki2
1Invicta Sp. z o.o., Fertility Clinic, Gdansk, Poland
2Invicta Sp. z o.o., Fertility Clinic, Warsaw, Poland
3Invicta Sp. z o.o., Fertility Clinic, Wroclaw, Poland
Study question: Can a multiple consecutive stimulation protocol help in
shortening duration of infertility treatment?
Summary answer: Multiple consecutive stimulation protocol has potential to
shorten IVF treatment duration.
What is known already: In infertility treatment there are many cases when
patients need to accumulate oocytes or embryos for fertility preservation, for
planned preimplantation genetic testing, or due to low ovarian reserve (patients
would beneﬁt from shortening duration of their treatment).
Study design, size, duration: Our objective in the this study is to develop
an effective multiple stimulation protocol (Gdansk protocol) that would allow
patients to safely undergo consecutive stimulations. This would enable them to
collect the desired number of oocytes or embryos in a short period of time.
Study included women aged over 37 who in previous attempts obtained few
or no transferrable embryos.
Participants/materials, setting, methods: The preliminary stage of the
study included 16 patients that underwent 2 (14 patients) or 4 (2 patients) con-
secutive stimulations. Mean age: 40.4 yo (SD 2.1) & mean basal AMH level:
1.78 ng/ml (SD 0.87 ng/ml).
Main results and the role of chance: Initial stimulation was performed with
contraception priming and gonadotropin dosage was based on patients basal
AMH level. As per standard procedure luteinizing hormone (LH), estradiol (E2)
and progesterone (PRG) levels were monitored and on day 7 decision was
made about extending the stimulation. Ovulation was triggered with triptorelin
34 hours prior to scheduled oocyte retrieval (OR).
Retrieved oocytes were fertilized using ICSI procedure and cultured for 5-6
days. Number of top quality embryos obtained was evaluated and based on
that the decision to start the consecutive stimulation cycle was made.
Hormonal parameters were assessed at the start of cycle 2. Gonadotropin
dosage was again based on patient’s AMH level. Patients did not receive any
medication to block premature LH surge due to the level of endogenous pro-
gesterone up to day 12 from the previous OR.
The reminder of the second cycle was managed as in the ﬁrst one. If needed,
again based on the number of embryos obtained, the decision was made to
either complete the protocol or continue with another consecutive stimulation.
Mean number of blastocysts were 1.6 and 1.4 in 1st and 2nd cycle, COC –
9.0 & 8.9, MII - 6,6 & 7,1 respectively.
Limitations, reasons for caution: This is a preliminary stage of the study
with a limited number of patients.
Wider implications of the ﬁndings: This appears to be a promising method
of shortening duration of treatment for patients who need to accumulate
embryos or face the pressure of time in their attempts to start a family. We are
continuing this study and working on optimizing the protocol.
Trial registration number:Not applicable.
P-711 Effect of resveratrol and metformin on ovarian reserve and
ultrastructure in PCOS: An experimental study
S. Furat Rencber1, S. Kurnaz Ozbek1, E. Guzel Meydanli2,
C. Eraldemir3, Z. Sezer2, S. Ceylan1
1Kocaeli University Faculty of Medicine, Department of Histology and Embryology,
Kocaeli, Turkey
2Istanbul University Cerrahpasa Faculty of Medicine, Department of Histology and
Embryology, Istanbul, Turkey
3Kocaeli University Faculty of Medicine, Department of Biochemistry, Kocaeli, Turkey
Study question: Can resveratrol be used instead of metformin or combin-
ation with metformin on PCOS treatment via SIRT1 and AMPK activation?
Summary answer: Resveratrol can be used in combination with metformin
to ameliorate PCOS symptoms such as impaired cell architecture, imbalanced
hormone proﬁle, oxydative stress, and inﬂammation.
What is known already: Polycystic ovary syndrome (PCOS) is a reproduct-
ive hormonal abnormality and a metabolic disorder. It is frequently associated
with hyperandrogenism, chronic inﬂammation, and oxidative stress (OS),
though the pathogenesis mechanism has not been well deﬁned. Resveratrol
(3,5,4-trihydroxystilbene) is a natural polyphenol synthesized by several plants
as a phytoalexin. This agent may have beneﬁcial effects such as antioxidant and
anti-inﬂammatory actions. Metformin (1,1-dimethylbiguanide hydrochloride) is
an oral antihyperglycemic drug widely used for the treatment of type 2 diabetes
and can cause reductions in body weight, restore ovulation and increase the
rate of pregnancy.
Study design, size, duration: 63 female Wistar albino rats (three weeks-
old) were initially divided into control (n = 9) and experimental(PCOS) groups
(n = 54). After DHEA administration, PCOS group (n = 54) were randomly
divided into 6 groups (n = 9) as follows. Group 1 (PCOS; no treatment),
Group 2 (Resveratrol; 20 mg/kg), Group 3 (Ethanol; resveratrol solvent),
Group 4 (Metformin; 300 mg/kg), Group 5 (Salin; metformin solvent) and
Group 6 (Metformin+Resveratrol). The daily treatments of both groups lasted
for up to 28 days.
Participants/materials, setting, methods: Estrous cyclicity was monitored
by vaginal smears. At the end of the treatment, body and ovary weights were
measured. Right and left ovaries were processed for electron and light micro-
scopic examination, respectively. For immunohistochemical examination, sec-
tions were performed anti-SIRT1 and AMPK antibodies. Apoptosis was
evaluated by TUNEL assay. Serum FSH, LH and Testosterone levels were ana-
lysed with bio-otoanalyzer, while plazma and tissue AMH and TNF-ɑ were
determined by ELISA. Serum MDA levels were also measured.
Main results and the role of chance: Metformin and combined treatment
groups reduced the body and organ weights compared to the PCOS group
(p<0.05 and p<0.001, respectively). Serum testosterone levels were signiﬁ-
cantly higher in the PCOS group than in the control group(p<0.001) and this
was reduced when PCOS was treated especially with resveratrol(p<0.001).
Higher plasma AMH level in the PCOS group was decreased in the resveratrol
group(p<0.05). TNF-α levels were signiﬁcantly increased in the PCOS group
compared to the control group(p<0.05) however, in all the treatment groups,
TNF-α levels were signiﬁcantly decreased compared to those in the PCOS
group(p<0.05). Serum MDA levels in the PCOS group signiﬁcantly increased
when compared to the control group(p<0.05) but resveratrol and combined
treatment reduced this oxidative stress marker levels compared to the PCOS
group(p<0.05). Primordial follicle pool was signiﬁcantly diminished in the PCOS
group(p<0.001) whereas primary follicle count remained unchanged.
Secondary, cystic and atretic follicles were increased in the ovarian sections of
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PCOS group(p<0.001) which were ameliorated in the treatment groups sup-
ported by light and electron microscopic ﬁndings(p<0.001). Increased number
of TUNEL(+) granulosa cells in the PCOS group were reduced signiﬁcantly in
the treatment groups(p<0.001). SIRT1 and AMPK immunreactivity in the com-
bined treatment groups were signiﬁcantly increased compared to the PCOS
group(p<0.001).
Limitations, reasons for caution: Because of ﬁnancial limitations, serum
hormone levels were measured by otoanalyser instead of ELISA which gives
more sensitive results.
Wider implications of the ﬁndings: According to our ﬁndings, resveratrol
may act through its antioxidant and anti-inﬂammatory effects via SIRT1 and
AMPK activation. However, using with metformin therapy gives better results
to solve the disease. But these results should be supported by further clinical
trials using different doses of these therapeutic agents.
Trial registration number:Not applicable.
POSTER VIEWING
Reproductive epidemiology, socio-cultural aspects and health
economy
P-712 Fertility preservation procedures for female andmale
patients facing gonadotoxic treatment - a micro-costing and
diagnostic related group payment comparison analysis
J. Olofsson1, L. Fajutrao2, J.W. Phoon3, K. Rodriguez-Wallberg4
1Karolinska Institutet, Division of Obstetrics and Gynecology- Department of
Women’s and Children’s Health, Stockholm, Sweden
2Merck AB, Health Economics, Stockholm, Sweden
3KK Women’s & Children’s Hospital, Reproductive Medicine Department, Singapore,
Singapore Rep. of
4Karolinska University Hospital and Karolinska Institutet, Department of
Reproductive Medicine and Department of Oncology-Pathology, Stockholm,
Sweden
Study question:What is the actual cost for fertility preservation (FP) within a
large established clinical program in Sweden and its relation to Diagnosis-
Related Groups (DRGs) tariffs?
Summary answer: Micro-costing analysis revealed a relative budget deﬁcit of
-27.1 % (total net value loss of €-250732) for all FP services performed in one
year.
What is known already: The DRG system of payment was designed to
encourage hospitals to operate efﬁciently and minimize overtreatment of
patients. However, this may be challenging to needs for individualization and
quality of services, as access to care risks being limited to selected patient
groups. Despite the recognized importance of FP to cancer patients, high costs
of the procedures and economic concerns are reported as main barriers limiting
access to FP, especially for female patients. Until now, the actual costs of proce-
dures involved in performing FP for both female and male patients have not yet
been reported.
Study design, size, duration: A micro-costing analysis was done to accur-
ately assess the costs of all FP-related procedures performed within one year in
our clinical program, speciﬁcally oocyte cryopreservation, oocyte-embryo cryo-
preservation combined, ovarian tissue cryopreservation, sperm cryopreserva-
tion by semen banking and surgical sperm retrieval by testicular extraction. The
costing exercise included all patients seen (n = 267) and all procedures directly
related to gamete or gonadal tissue cryopreservation. Published hospital DRG
prices were used for comparisons.
Participants/materials, setting, methods: Single-center study conducted
at Karolinska University Hospital, which provides FP healthcare to the
Stockholm region (population 2.2 million). Main health resource use categories
for each procedure were identiﬁed (personnel, equipment, pharmaceuticals,
laboratory related, single-use consumables and overhead charges), measured
and valued using 2015 as the reference year (data for 2017 are under way). The
bottom-up model included staff interviews and detailed real-life observations to
accurately estimate the intensity of resource use.
Main results and the role of chance: Excluding cost of pharmaceuticals for
ovarian stimulation, which are reimbursed directly to patients under the
national pharmaceutical beneﬁt scheme, the total cost of oocyte cryopreserva-
tion per patient (n = 38) was €2227, €3077 for oocyte-embryo cryopreserva-
tion (n = 50), €5990 for ovarian tissue cryopreservation (n = 28), €1356 for
semen banking (n = 368), and €1981 for cryopreservation of sperm obtained
by testicular biopsy (n = 10). Compared to the published DRG tariffs, the actual
costs found and hence payments that the hospital received, were lower in all
procedures evaluated (-14.4%, -38.0%, -8.7%, -32.1% and -27.8%, respect-
ively). Multiplied by the number of procedures performed this translated into a
net loss of €-250732 or in relative terms, a budget deﬁcit of -27.1% for the year
2015 for FP services.
Limitations, reasons for caution: All FP procedures in Sweden are offered
to the eligible population under the tax-funded health care services in academic
centers only. The derived costs may not be generalizable to other FP centers.
Wider implications of the ﬁndings: An increasing demand of FP urges the
complete evaluation of patient procedure costs to guide health care service for
delivery and future planning. These results may increase awareness of national,
regional and local health policy administrators to economic aspects of FP in
planning for appropriate allocation of health services’ budgets.
Trial registration number:Not applicable.
P-713 Knowledge of pregnancy and its danger signs among
Indonesian women not improved by Maternal and Child Health
Handbook
K. Tjandraprawira, I. Ghozali
Rumah Sakit Umum Daerah Majalengka, Emergency Department, Majalengka,
Indonesia
Study question: What is the efﬁcacy of the Indonesian Maternal and Child
Health Handbook in improving the knowledge of various stages of pregnancy
and its danger signs?
Summary answer: The Indonesian Maternal and Child Health handbook did
not exert a signiﬁcant inﬂuence in improving maternal knowledge around preg-
nancy and the associated obstetric danger signs.
What is known already: The ﬁrst Maternal and Child Health handbook was
introduced by Japan in the ﬁnal decade of the 20th century and it was cham-
pioned for empowering women in pregnancy, parturition and early childcare, as
well as the pressing obstetric danger signs.
Study design, size, duration: This is a primary cross-sectional study con-
ducted at Majalengka General District Hospital on recently delivering post-
partum women between August – September 2017. 127 women were
recruited, later divided into two separate groups according to their self-
admission on the degree they had read the Maternal and Child Health hand-
book (50% and <50%).
Participants/materials, setting, methods: All the participating women
were administered a pre-validated questionnaire to assess their knowledge
around pregnancy and its danger signs.
Main results and the role of chance: It was discovered that our population
had had high knowledge around pregnancy and its danger signs and the
Maternal and Child Health handbook did not hold a signiﬁcant role in effecting
this ﬁnding (p-value 0.295). Furthermore, various socio demographic factors
(age, maternal and paternal educational backgrounds, family welfare status, dis-
tance from healthcare center, parity and number of antenatal care visits) also
did not exert a statistically signiﬁcant inﬂuence on the level of knowledge in our
population (p-values 0.579, 0.521, 0.617, 0.908, 0.342, 0.618 and 0.939
respectively).
Limitations, reasons for caution: The relatively small sample size; selection
bias as only a single population of patients (from Majalengka General District
Hospital) was chosen; response bias in assessing the degree the handbook had
been read and from answering the questionnaire; possible confounders, e.g.
mass media and knowledge passed from relatives.
Wider implications of the ﬁndings:Our study revealed a satisfactorily high
level of knowledge about pregnancy and the associated obstetric danger signs
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among Indonesian women, but contrary to other studies, the use of Maternal
and Child Health Handbook was not signiﬁcantly responsible for such ﬁnding.
Trial registration number: not applicable.
P-714 Introducing Value Based Health Care as a new concept in
treating fertility patients
M. Curfs, C. Van Bavel, B. Cohlen
Isala Clinics, Isala Fertility Center, Zwolle, The Netherlands
Study question: Can we increase value for fertility patients by either raising
patient relevant outcomes resulting in the best possible health gain and/or by
decreasing costs?
Summary answer: Value Based Health Care provides us an all-encompassing
and powerful concept to provide better service for our patients against equal
or even lower costs.
What is known already: Health care costs rise dramatically and society has
major challenges to keep health care affordable for all. In The Netherlands the
costs rose from 10% of the gross domestic product in 2000 to 14% in 2015. To
turn the tide, a new concept in health care economics, Value Based Health
Care (VBHC), was introduced by Michael Porter (2006). There are numerous
examples where VBHC was successfully implemented (such as the UCLA
Medical Center, USA, for kidney transplantation and the Martini Klinik,
Germany, for the treatment of prostate cancer) but to our knowledge not yet
for the treatment of fertility patients.
Study design, size, duration: Representatives of all professionals involved in
fertility care were brought into a project team and during several sessions
deﬁned the necessary building blocks in close collaboration with actively
involved patients. During these sessions truly relevant clinical outcome mea-
sures in relation to initial patient conditions and case mix variables were
deﬁned. Besides these, patient reported outcome measures (PROMS) and
experience measures (PREMS) and the different care pathways were deﬁned
and described in detail.
Participants/materials, setting, methods: Professionals, such as physi-
cians, clinical embryologists, nurses, technicians but also psychologists and social
workers along with patients participated in deﬁning relevant clinical outcome
measures, PROMS, PREMS and the analysis of treatment pathways. Clinical out-
come measures and treatment pathways are analyzed by means of a query
from the electronic patient ﬁle. PROMS were linked to validated questionnaires
and the PREMS to a tool measuring patient satisfaction. All these blocks are
brought together into a management dashboard.
Main results and the role of chance: The most important clinical outcome
measure is the cumulative live birth rate per patient journey, starting with refer-
ral to our center and ending with discharge from our center. A journey may
consist of one or more treatment pathways, which in turn may consist of mul-
tiple treatment cycles. A ﬁrst analysis in the pathway intrauterine insemination
(IUI) with donor sperm, has revealed that a plateau is reached several treat-
ment cycles before the maximum number of cycles that local and professional
national guidelines propose. This knowledge can be shared with the patient and
through shared decision making might result in more patient value. Less treat-
ment cycles will be performed (and as a result a more rapid transition to a
more invasive treatment) resulting in a more efﬁcient treatment against lower
costs and a shorter time to pregnancy.
The registration of initial patient conditions and case mix variables related to
outcome measures enables us to a more individual approach, again increasing
patient value.
The registration of PROMS and PREMS helps us to detect and take necessary
measures for patients at risk for e.g depression and anxiety, sexual problems,
but also for quality of life in general, both during treatment and in the long term.
Limitations, reasons for caution: The implementation of VBHC can be
concerned as a prospective cohort study where results are systematically evalu-
ated over a long period of time.
Currently fertility centers are paid as a fee per service. To prevent that treat-
ments are offered which do not increase value, bundled payment arrangements
should be made.
Wider implications of the ﬁndings: VBHC increases value for patients by
increasing outcomes and/or by reducing costs. The implementation of an
internationally accepted standard makes it possible to compare fertility centers
corrected for initial patient conditions and case mix variables. Patient can then
choose for the best value for their money.
Trial registration number:Not applicable.
P-715 The effect of religious background on the attitude toward
sex selection
A. Salame1, J. Nassif2, J. Awwad3, E. Moubarak4, A. Hannoun3,
A. Abu Musa3
1American University of Beirut Medical Center, OBGYN/ REI, Beirut, Lebanon
2AUBMC, Obstetrics and Gynecology, Beirut, Lebanon
3AUBMC, Obstetrics and Gynecology/ REI, Beirut, Lebanon
4MLH, Obstetrics and Gynecology/ REI, Beirut, Lebanon
Study question: Does the difference in religious background affect the atti-
tude towards sex selection using pre-implantation genetic diagnosis (PGD)?
Summary answer: The study showed a negative attitude towards sex selec-
tion for non-medical reasons through PGD. Religious beliefs are the most
important factors affecting such decisions.
What is known already: Surveys of the general population regarding sex
selection using PGD are limited and were mainly conducted in the United
States and Northern Europe. In those Western societies, surveys have shown
that people’s interest in using sex selection techniques is driven solely by the
desire for a sexually balanced family, consisting of both sons and daughters. It is
important to determine attitudes towards sex selection in a wider range of
countries especially that cultural differences exists among countries.
Study design, size, duration: A questionnaire-based cross-sectional study
regarding attitudes towards sex selection for non-medical reasons was
designed. The population size targeted was 1500 participants. The surveys
were distributed during the period extending from January 2016 to September
2017.
Participants/materials, setting, methods: 1500 participants of the repro-
ductive age group presenting to the Women s Health Center at the American
University of Beirut Medical Center (AUBMC) were offered to complete the
survey. The questionnaire included demographic details, obstetric and infertility
history, opinions regarding sex selection, personal interest in expanding the
family, and personal interest in choosing the sex of a future child. Out of the
1500 patients approached, 1300 agreed to ﬁll the questionnaire.
Main results and the role of chance: The calculated response rate was
86.6%. Eighty six per cent of the respondents were females and 19.4 % were
males. Sixty three per cent of the respondents were Muslim, 26.2% were
Christian and 8.7 % were Druze. Seventy two percent of the participants were
fertile and 58.5% already had children. Nineteen per cent of the respondents
considered it strictly prohibited, 38.8% considered the technique’s acceptable
only if medically indicated while 33.4 % believed that it should be available to all
those who request it. Of those who opposed sex selection for non-medical rea-
sons, 40 % considered the intervention as playing God while 34 % reasoned
that the child is a gift that deserves to be loved irrespective of his/her sex. Only
20.1% of the respondents stated that they would use if the procedure was pro-
hibited by their religion. When asked about the gender preference of their ﬁrst
child, 71.5% said they didn’t care. Men and women equally stated that sex
selection should be available for medically indicated conditions. Forty nine per-
cent of Christians accepted the procedure when it was medically indicated
while 35.5 % of Muslims considered it to be acceptable if medically indicated.
Limitations, reasons for caution: Despite the large sample size, all the par-
ticipants were visitors of one clinic located in the center of the capital. Thus the
population that we had might not actually reﬂect the total population living in
the peripheral areas.
Wider implications of the ﬁndings: The knowledge of the factors that
affect decision making in reproductive issues will improve couple counseling in
this part of the world were religion plays an important role in decision making.
This is imperative especially in debated situations such as sex selection for med-
ical and non-medical reasons.
Trial registration number: not applicable.
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P-716 Socioeconomic deprivation and pregnancy rates in IVF
R. Imrie, S. Ghosh, K. Vigneswaren, N. Narvekar, M. Savvas
King’s College University Hospital, Assisted Conception Unit, London, United
Kingdom
Study question: Are higher levels of socioeconomic deprivation associated
with reduced success in IVF and ICSI cycles in terms of pregnancy and live birth
rate?
Summary answer: Our study suggests that there is a statistically signiﬁcant
correlation between socioeconomic deprivation and successful IVF/ICSI treat-
ment as an independent factor.
What is known already: Socioeconomic deprivation has been correlated
with poorer access to health care and health outcomes and this has been par-
ticularly studied in the diabetic and mental heath care populations. There is a
well reported ‘postcode lottery’ of access to assisted conception treatment in
England but as yet there have been no studies looking into whether socio-
economic deprivation based on patient postcode is an independent variable
inﬂuencing IVF /ICSI success rates.
Study design, size, duration: This was a retrospective cohort analysis. All
patients undergoing a fresh IVF or ICSI cycle from the point of egg collection
onwards between 1st January 2015 and 31st December 2016 were identiﬁed.
All patients undergoing an elective freeze-all cycle (e.g. fertility preservation)
were excluded. A total of 1661 patients were included in the study. Data was
collected using both electronic and paper patient records.
Participants/materials, setting, methods: Patients undergoing IVF/ICSI at
three south London hospitals were included, all using the King’s College
Hospital Assisted Conception Unit laboratory. Patient postcode, age at start of
treatment, number of eggs retrieved and pregnancy outcomes were collected.
The UK Index of Multiple Deprivation was used to assess deprivation based on
patient postcode. Logistical regression analysis was performed to determine
the effect of deprivation on pregnancy outcomes whilst controlling for patient
age and number of eggs collected.
Main results and the role of chance: Using the UK Index of Multiple
Deprivation, patients were categorised into deprivation quintiles (highest depriv-
ation = quintile 1, lowest deprivation = quintile 5). Compared with patients
undergoing IVF and ICSI in the lowest quintile of depravation, those in the highest
quintile showed a statistically signiﬁcant increase in both pregnancy and live birth/
ongoing clinical pregnancy rates when controlled for age and number of eggs col-
lected. The odds ratio for patients in the least deprived quintile relative to the
most deprived quintile for pregnancy rates was 1.8290 (95% CI 1.251 to 2.675,
p = 0.002). For live births and ongoing clinical pregnancy rates the odds ratio was
1.984 (95% CI 1.291 to 3.049, p = 0.002). There was a threshold level of depriv-
ation (patients at deprivation quintile 3 or above) beyond which further decreases
in deprivation had no further statistical impact for both pregnancy and live birth/
ongoing pregnancy rates. Of note, there were increasingly more patients under-
going IVF/ICSI treatment as deprivation levels reduced (174 patients in depriv-
ation quintile one compared to 410 in deprivation quintile 5).
Limitations, reasons for caution: This study included patients receiving
treatment from three south London hospitals and, whilst this is a socio-
economically diverse part of England, it is not necessarily reﬂective of the wider
IVF community. Inclusion of further co-variables such as duration of infertility
and BMI would help improve statistical analysis.
Wider implications of the ﬁndings: By identifying socioeconomic depriv-
ation as an independent variable affecting IVF/ICSI outcome, we may be able to
provide more accurate individual predictions of treatment success. Future stud-
ies would be needed to determine which aspects of patient deprivation are
most inﬂuential and whether there are any modiﬁable changes that can be
made.
Trial registration number: not applicable.
P-717 Fertility awareness and knowledge among Indian women
attending infertility clinic: A cross-sectional study
M. Gupta1, R. Mahey2, S. Kandpal2, N. Malhotra3, P. Vanamail2,
N. Singh4, A. Kriplani2
1Senior Resident, Obstetrics and Gynecology Department of Assisted Reproduction,
NEW DELHI, India
2All India Institute of Medical Sciences, Obstetrics Gynecology, New Delhi, India
3All India Institute of Medical Sciences, Obstetrics and Gynecology, New Delhi, India
4All Institute of Medical Sciences, Obstetrics Gynecology, New Delhi, India
Study question: How good is the knowledge and awareness of infertile Indian
females regarding fertility in relation to age and menstrual cycle and need of
assisted reproductive technique?
Summary answer: The study population had poor knowledge of fertility and
reproduction and the knowledge regarding assisted reproduction varied
according to socioeconomic status.
What is known already: Worldwide studies have shown that people are
unaware of biological aspects of conception, have poor knowledge about most
fertile period in the menstrual cycle, chances of getting pregnant in one cycle
and about steep decline in fertility potential after age of 34-35 years. Also both
men and women lack knowledge about effect of smoking, alcohol, job stress
and other life style factors on fertility potential. There is generalized lack of fer-
tility awareness irrespective of gender.
Study design, size, duration: Cross-sectional study of 205 infertile women
seeking fertility treatment at assisted reproductive unit between March 2017 to
August 2017.
Participants/materials, setting, methods: Total 205 infertile female
patients in the age group of 21 to 44 years were interviewed with the help of
nine item questionnaire designed after reviewing previous papers on fertility
awareness and modiﬁed according to patient population and level of under-
standing in an Indian set up. The study population was divided into four socio-
economic classes according to modiﬁed Kuppuswamy scale. The answers were
stratiﬁed according to socioeconomic status.
Main results and the role of chance: Majority of women (59%) belonged
to the age group of 20-30 years indicating a young age group in need of infertility
evaluation. More than half (63%) of the patients were from the middle socio-
economic strata. Even so, knowledge about fertility and reproduction was low:
85% missed the ovulatory period in the menstrual cycle, only 8% considered
age more than 35 years as the most signiﬁcant risk factor for infertility, approxi-
mately 60-80% were not aware when to seek treatment for infertility after try-
ing for pregnancy. Almost 97% participants associated past intake of combined
oral contraceptive pills with infertility. Participants in the upper SES scale had
better knowledge (39% indicated need of donor oocytes in aged females)
regarding ART treatment options. Terms like surrogacy, were signiﬁcantly (p =
0.002) better known to participants in upper SES category (more than 50% cor-
rectly answered) than in the lower category (24%).
Limitations, reasons for caution: Studies with larger study population and
a control group of fertile female patients will enable a better understanding of
need of fertility education.
Wider implications of the ﬁndings: There is a signiﬁcant lack of awareness
regarding effect of age on fertility among women belonging to all types of social
sections in India. There is need of educational interventions emphasizing on
ideal age of fertility, factors affecting fertility potential and fertility options avail-
able for sub-fertile couples.
Trial registration number:Not applicable.
P-718 Randomized trial of a home pregnancy test intervention to
improve cohort retention and detection of miscarriage
L.A.Wise1, K. Rothman1,2, A.Wesselink1, E. Mikkelsen3, S.Willis1,
E. Hatch1
1Boston University School of Public Health, Department of Epidemiology, Boston,
U.S.A.
2RTI International, RTI Health Solutions, Research Triangle Park, U.S.A.
3Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark
Study question: In a cohort study of female pregnancy planners, does offering
12 home pregnancy tests (HPT) at enrollment improve cohort retention and
detection of spontaneous abortion (SAB)?
Summary answer: Offering HPTs to female participants in a preconception
cohort study appears to increase cohort retention and SAB detection.
What is known already: In prospective cohort studies of time-to-pregnancy
(TTP), incorporating daily urinary human chorionic gonadotropin (hCG) testing
i470 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
to detect implantation is ideal because it increases identiﬁcation of early preg-
nancy loss, allows for examination of early vs. late pregnancy losses, and
reduces misclassiﬁcation of TTP. However, use of daily hCG testing is expen-
sive and time-intensive, and is not practical for most population-based epide-
miologic studies. No prospective cohort study of TTP has assessed the extent
to which offering HPTs to female pregnancy planners improves cohort reten-
tion, increases detection of SAB and advances the timing of SAB detection.
Study design, size, duration: Pregnancy Study Online (PRESTO) is a web-
based prospective preconception cohort study of ≥7,000 female pregnancy
planners residing in the U.S.A. and Canada (2013 to present).
Participants/materials, setting, methods: Participants were aged 21-45
years, not using fertility treatment, and attempting to conceive for ≤6 cycles at
study entry. Women completed baseline and bimonthly follow-up question-
naires. After enrollment, 401 U.S. participants were 1:1 randomized to receive
12 Clearblue HPTs, with guidance to test the day after a missed menstrual peri-
od (N = 198), or the standard protocol (N = 203). On follow-up question-
naires, women reported incident pregnancies, including SABs, and gestational
weeks at SAB. We performed an intent-to-treat analysis.
Main results and the role of chance: After a median of 32 weeks of follow-
up, cohort retention was higher among women randomized to receive HPTs
(N = 166; 83.8%) relative to the standard protocol (N = 139; 68.5%) (mean
difference = 15.4%, 95%CI = 7.1%-23.6%). Conception was reported by
62.7% in the HPT arm and 53.3% in the standard protocol arm. Among women
who conceived, SAB was reported by 22 (21.2%) in the HPT arm (gestational
weeks at SAB: median = 5.0, range: 4-10) and 13 (17.8%) in the standard
protocol arm (gestational weeks at SAB: median = 5.0, range = 4-9). The num-
ber of SABs reported at <8 weeks’ gestation was higher in the HPT arm (N =
18) than in the standard protocol arm (N = 11).
Limitations, reasons for caution: Numbers were small and results were
imprecise. Participants were not followed for the full 12 months of follow-up,
thus cohort retention will likely be higher than what we report above. Because
the study relies on self-reported data, some SABs may have been missed.
Wider implications of the ﬁndings: Preconception cohort studies might
beneﬁt from offering 12 HPTs to participants at study enrollment as a means of
increasing cohort retention and SAB detection.
Trial registration number:Not applicable.
P-719 The impact of night shift work onmenstruation among
nurses - a multi-center epidemiological investigation
Y.M. Lin1, B.Y. Miao2, J.P. Shu3, F.H. Liu4, M.F. Deng2, S.Z. Cheng5,
N. Zhou4, M.Q. Xie1, Y.W. Xu2, Y.J. Fan6
1Sun Yat-sen Memorial Hospital, General Gynecology, Guangzhou, China
2The First Afﬁliated Hospital of Sun Yat-sen University, Reproductive center,
Guangzhou, China
3Chinese PLA General Hospital, Department of Obstetrics and Gynecology, Beijing,
China
4GuangDong Women and Children Hospital, Department of Obstetrics and
Gynecology, Guangzhou, China
5The First Afﬁliated Hospital of Sun Yat-sen University, Department of Obstetrics and
Gynecology, Guangzhou, China
6China CDC, National Center for Women and Children’s Health, Beijing, China
Study question: To explore the impact of night shiftonmenstruation among
nurses.
Summary answer: Night shift might increase the likelihood of irregular men-
strual cycle and aggravated dysmenorrhoea among nurses.Menstruation status
alteration increased with the frequency of night shift increasing.
What is known already: Menstruation status was considered a symbolic of
female fertility. Irregular menstrural cycle, including shorter or longer cycles
were related to infertility. Some studies illuminated that stress was an important
inﬂuence to menstruation,besides other factors including age,weight, tumor,
imﬂammation or genetic factors.
Study design, size, duration: By questionnaires, a retrospective cohort
study was conducted among 702 married female nurses who were at childbear-
ing age and currently working at The First Afﬁliated Hospital of Sun Yat-Sen
University, GuangDong Women and Children Hospital or Chinese PLA
General Hospital from November 2014 to December 2014.
Participants/materials, setting, methods: By questionnaires, a retro-
spective cohort study was conducted among 702 married female nurses who
were at childbearing age and currently working at The First Afﬁliated Hospital
of Sun Yat-Sen University, GuangDong Women and Children Hospital or
Chinese PLA General Hospital.
Main results and the role of chance: A total of702 nurses were investi-
gated, among which 597nursesgave valid questionnaires, with an effective rate
of 85.04%.Potential confounding factors were adjusted. 134nurses(22.45%) had
a trend of irregular menstrual cycles, with apparent difference(P<0.05) if they
worked late night shift twice a week or more. 162nurses(27.14%) suffered
aggravated dysmenorrhea, especially when nurses worked no less than thrice
per week for late night shift (P<0.05). Corresponding OR values of late night
shift were larger than those of early night shift. After adjustment for sleeping
condition,OR values of both early and late night shifts on menstrual cycle and
dysmenorrhea decreasedin certain degree, suggesting that sleeping condition
may be the intermediaters.
Limitations, reasons for caution: Firstly, nurses without night shifts or
unmarried nurses weren’t included. Secondly, night shift workload and working
hours weren’t standardized.Thirdly, recalling bias and reporting bias was indel-
ible in this retrospective cohort study.
Wider implications of the ﬁndings: Late night working may be the key to
biological rhythm alteration. Further study on the machanism and among factors
to the change of menstruastion of nurses with night-shifts
should be conducted, to better understand reproductive impairment of night
shift work.
Trial registration number: not applicable
P-720 Mobile app utilization and fecundity in a north american
preconception cohort
J. Stanford1, S. Willis2, E. Hatch2, K. Rothman2, L.Wise2
1Ofﬁce of Cooperative Reproductive Health, Family and Preventive Medicine- Univ
Utah, Salt Lake City, U.S.A.
2Boston University School of Public Health, Epidemiology, Boston, U.S.A.
Study question: Do women trying to conceive who utilize fertility apps have
increased fecundability (shorter time to pregnancy) than women who use no
apps?
Summary answer: Individuals who utilized any fertility app in comparison to
no app had increased fecundability. Several apps designated a priori were asso-
ciated with higher fecundability.
What is known already: Many women who are trying to conceive use a
menstrual cycle or fertility app to identify the “fertile window,” or the days of
the menstrual cycle when intercourse is most likely to result in pregnancy. Prior
studies have found that some apps are more accurate than others to identify
the fertile window.
Study design, size, duration: Pregnancy Study Online (PRESTO) is an
internet-based prospective cohort study of women trying to conceive, ongoing
since 2013 in the U.S.A. and Canada. Women included in this analysis were
enrolled through October 2017, were aged 21-45, in a stable relationship with
a male partner, not utilizing contraception or fertility treatment, and had been
attempting to conceive for < = 6 months. A total of 4345 women were
included in this analysis.
Participants/materials, setting, methods: Female participants complete a
baseline questionnaire providing demographic, lifestyle, medical and reproduct-
ive histories. They completed bimonthly follow-up questionnaires in English
until conception or up to 12 months after study entry. Each baseline and follow-
up questionnaire asked about speciﬁc menstrual cycle or fertility apps used, and
any occurrence of pregnancy. A proportional probabilities model was used to
estimate fecundability ratios (FR) and 95% conﬁdence intervals (CI). Higher FR
indicate higher fecundability (reduced time to pregnancy).
Main results and the role of chance: Among 4345 participants, 2527 preg-
nancies were recorded within 17,185 observed cycles (14.7% crude fecundabil-
ity). Of participants, 72% used an app to record and possibly also interpret
menstrual cycle data and/or fertility signs. The total number of apps used was
78, with 31% using one of a group of likely “advanced” apps speciﬁed a priori
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because they can track multiple biomarkers of ovulation: Fertility Friend,
Kindara, Glow, Clue, or Ovia. At baseline and adjusting for woman’s age, grav-
idity, body-mass index, education, smoking, prior hormonal contraception,
cycle regularity, and sleep quality, relative to using no app, the FR for individuals
who used one of the a priori advanced apps, or any other app was 1.13 (CI:
1.03-1.23) and 1.07 (CI: 0.97-1.18), respectively. Results were similar in time-
varying analyses based on responses from follow-up questionnaires, but varied
somewhat when stratiﬁed based on duration of time attempting pregnancy.
Strengths of the study include the prospective reporting of app use.
Limitations, reasons for caution: Fertility app use was self-reported, with
no speciﬁc data on how intensively the app was used. Time to pregnancy was
also self-reported. We cannot rule out bias due to differential loss-to-follow-up
or residual confounding by subfertility history or attempt time at study entry.
Wider implications of the ﬁndings: A majority of women trying to con-
ceive are likely to use a fertility or menstrual cycle app. Such app use may
reduce time to pregnancy. Apps that track multiple biomarkers of fertility
appear to be more effective than others to reduce time to pregnancy.
Trial registration number:NA.
P-721 Impact of patient’s socioeconomic status on the outcome of
IVF cycles in India
K.D. Nayar, P. Nayar, N. Agarwal, M. Singh, M. Gupta, G. Kant,
R. Gahlot, D. Nayar
Aakansha IVF Centre - Mata Chanan Devi Hospital, Reproductive Medicine, New
Delhi, India
Study question: Does patient’s socioeconomic status like income, education
level and occupation affect IVF outcome?
Summary answer: Patients undergoing IVF treatment in India have different
success rates based on variables like income, occupation and education due to
disparity in awareness and affordability.
What is known already: Apart from medical problem infertility is also a
social problem affected by various factors like accessibility, availability and
knowledge. In India, Infertility is not insurance covered so service seeking is
comparatively difﬁcult for lower socioeconomic class. Women working in male
dominated occupational environment faces more work stress and time con-
straint in pursuing treatment. On the other hand, women working as teachers,
dealing in public relations and housewives feel free to discuss their problems
and are more comfortable in completing cycles. Education helps to counter the
various negative beliefs related to Assisted Reproductive Technology.
Study design, size, duration: Longitudinal study was performed at fertility
centre in Delhi, India where 800 patients were interviewed during the year
January 2017 to December 2017. Data were analyzed using SPSS software ver-
sion 20.
Participants/materials, setting, methods: The study included 800
patients who consented to participate. Data were analyzed using logistic regres-
sion model for the number of cycles undergone and clinical pregnancy rate on
the basis of monthly income (80 Indian Rupees, INR = 1 €) {< INR 25000 (n =
256), ≥25000–100,000 (n = 400), >100,000 (n = 144)}, education {≤12thstd
(n = 167), Graduate (n = 344), Postgraduate (n = 288)}, Occupation {women
working in male dominated areas (n = 287), working in non male dominated
areas (n = 304), housewives (n = 208)}.
Main results and the role of chance: A logistic regression was performed
to ascertain the affects of income and number of cycles of IVF on the likelihood
that participants achieved pregnancy. The logistic regression model was statis-
tically signiﬁcant, χ2(5) = 19.746, p< .0001. The model explained 37.5%
(Nagelkerke R2) of the variance in pregnancy and correctly classiﬁed 80.0% of
cases. Patients with monthly income > INR 1,00,000 group were associated
with an increased likelihood of pregnancy.
Similarly to ascertain the effects of education level on number of cycles of IVF
so that participants achieved pregnancy. The logistic regression model was statis-
tically signiﬁcant, χ2(5) = 83.615, p < .0001, model explained 30% (Nagelkerke
R2) of the variance in pregnancy and correctly classiﬁed 78.0% of cases.
Logistic regression model for area of occupation was statistically signiﬁcant,
χ2(5) = 98.748, p< .0001, model explained 30.7% (Nagelkerke R2) of the vari-
ance in pregnancy and correctly classiﬁed 77.0% of cases respectively.
As income, education level of patient increases and women working in non
male dominant ﬁelds were associated with an increased likelihood of pregnancy.
In the entire above model of logistic regression increasing number IVF cycle
were associated with an increased likelihood of pregnancy although demo-
graphic features were comparable.
Limitations, reasons for caution: Although it is prospective study, it has
limitation of small sample size.
Wider implications of the ﬁndings: People with low education level and
limited knowledge about infertility may delay efﬁcient interventions. Jobs that
put stress on women may also negatively affect results. Income status compro-
mises the affordability for repeated cycles of IVF. Clinicians may keep these in
mind while counselling the patients and discussing about their prognosis.
Trial registration number:MCDH/2017/5
P-722 The role of ovarian hormones in generating options for
social contact:Women scoring high on neuroticism show signiﬁcant
menstrual cycle ﬂuctuations
S. Schweizer1, K. Schmalenberger1, T. Eisenlohr-Moul2, B. Ditzen1
1Heidelberg University, Medical Faculty- Institute of Medical Psychology, Heidelberg,
Germany
2University of Chicago, Medical Faculty- Department of Psychiatry, Chicago, U.S.A.
Study question: This study investigates whether the process of generating
options for social decision-making is associated with ovarian hormone ﬂuctua-
tions during the menstrual cycle and women’s personality structures.
Summary answer: The study revealed quantitative and qualitative differences
in option generation between the ovulatory and the menstrual phases moder-
ated by women’s personality structures.
What is known already: Before making a decision, agents in less structured
environments generate a set of options. There is a recently accumulating body
of evidence on the affective, motivational, and cognitive effects of the menstrual
cycle. It was argued that the pre-ovulatory rise of estrogen and dopamine may
increase the quantity of options generated in everyday decision-making. There
are ﬁndings on qualitative changes in the creativity of options as associated with
situational effects, such as the familiarity of the situation. Individual and bio-
logical factors such as personality and endocrinology as well as the social quality
of option generation have been neglected so far.
Study design, size, duration: An observational study with repeated mea-
sures was conducted to compare the quantity and quality of generated options
in the ovulatory and the premenstrual phase of one menstrual cycle. In both the
ovulatory and the menstrual session, naturally cycling women (N = 21) with a
regular cycle (26-35 days) performed parallel versions of an option generation
task. Session dates were individually ﬁxed by ovulation test. The social quality of
the options was independently rated by two trained raters.
Participants/materials, setting, methods: Female psychology students
(mean age = 24) completed an option generation task consisting of vignettes of
everyday decision making scenarios followed by the question “What could you
do?” Personality was assessed using the NEO-FFI. Social option quality was
rated on the dimensions Social contact quality (whether and what kind of person
is involved) and Social afﬁliative quality (degree to which an option satisﬁes the
human need for afﬁliation). We performed a multi-level analysis using SAS.
Main results and the role of chance: Concerning the quality of the gener-
ated options our analyses revealed that Social afﬁliative quality varies signiﬁcantly
across the cycle when Neuroticism and Extraversion are used as moderators:
Signiﬁcantly lower afﬁliative quality of generated options was found at ovulation
compared to premenstrual testing in women scoring high on Neuroticism
(p<.05). Elevated E2 levels could be associated to more self-reliance, self-
sufﬁciency, conﬁdence and independence, and hence less tend and befriend at
ovulation. Also, women with a low extraversion score generated options with
signiﬁcantly higher afﬁliative quality at menstruation compared to ovulation
(p<.05). This could imply that even women with low Extraversion may have
increased needs for social connectedness in the pre-menstruum that is often
experienced as more difﬁcult than the ovulatory phase. Social contact quality
never varies signiﬁcantly as a function of the cycle, no matter which of the ﬁve
personality scales is used as a moderator. Concerning the quantity of the gener-
ated options women scoring low on agreeableness as well as women scoring
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low on Conscientiousness and also those scoring high on the Openness to
experience dimension generated signiﬁcantly more options at ovulation
(p<.001), whereas women with a low openness score generated more options
at menstruation (p<.01). Interrater reliability was excellent.
Limitations, reasons for caution: Limitations of the study are the rather
small number of participants and no counterbalancing of order of sessions.
Wider implications of the ﬁndings: This study provides ﬁrst empirical
insights into the mechanisms of how ovarian hormones could be associated
with social decision-making in different personalities. It also brings up more spe-
ciﬁc issues, for instance that strong social-cognitive ﬂuctuations during the men-
strual cycle may be less beneﬁcial to relationship stability in highly neurotic
women.
Trial registration number:Not applicable.
P-723 IVF outcome in Chinese versus Caucasian women
R. Pasin1, L. Perego2, M. Leonardi2, M.G. Corbucci2, V. Caccavari2,
D.R. Diaferia2, C. Colasante2, P. Boldi Cotti2, B. Lombardi2,
L. De Lauretis2
1ICCS, Centro fertilità, Milan, Italy
2ICCS, Centro PMA, Milan, Italy
Study question: Is there any difference between Chinese and Caucasian
women concerning IVF outcomes?
Summary answer: There is a higher abortion rate in Chinese than in
Caucasian women.
What is known already: Ethnicity is a common prognostic factor in medi-
cine, but there is little data on the relationship between ethnicity and IVF out-
come. It has been showed a reduced chance of live birth and clinical pregnancy
rate in South Asian population compared to White women despite the similar
choice of achieving pregnancy.
Study design, size, duration: In this retrospective cohort study, we investi-
gate differences in terms of background and IVF outcomes between Chinese
and Caucasian women underwent reproductive technologies in our Center
from January 2014 till July 2017.
Chinese women were 3% of the total population (48 Chinese women versus
1451 Caucasian women).
Participants/materials, setting, methods: We matched some epidemio-
logical characteristics and some outcomes of the two different groups (Chinese
and Caucasian): age, infertility etiology, results of the ART in terms of pregnancy
rate, miscarriage, serum estradiol values at the end of stimulation, number of
eggs recovered.
We used Chi-quadro and t-student tests to match our results.
Main results and the role of chance: Differences were observed between
age average, being signiﬁcantly lower in Chinese than in Caucasian women
(34,7 ± 4.8 vs 37.4 ± 4.1; P<0.01). The proportion of Tubal factor in Chinese
was signiﬁcantly higher in Chinese than in Caucasians (75% vs 18%; P<0.01),
and it was found to be the most common infertility factor of Chinese women
afferent to our Center.
We also observed signiﬁcantly higher serum estradiol values average at trig-
gering in Chinese than Caucasian women (2063.9 ± 1412.2 vs 1718.7 ±
1044.2; P<0.05) despite a similar oocyte recovery average (5.8 ± 3.3 vs 6.3 ±
4.6; ns)
Concerning IVF outcomes, we observe similar results in terms of pregnancy
rate for transfer, but with a higher abortion rate in Chinese than in Caucasian
women (27.0% vs 28.0% and 40.0% vs 18%; ns).
Limitations, reasons for caution: Further investigation and randomiza-
tions are needed in order to improve patient number and better understand
the possible mechanisms involved in poorer IVF results in Chinese than in
Caucasian women (systemic components, metabolic components, Other
factors)
Wider implications of the ﬁndings: Our data conﬁrm a reduced chance of
live birth and clinical pregnancy rate in South Asian population compared to
White women.
Trial registration number:Not applicable.
P-724 Infertility in the Middle East and North Africa region: a
systematic review with meta-analysis of prevalence surveys
A. Eldib1, O. Tashani2
1Leeds Beckett University - Leeds UK., School of Clinical & Applied Sciences,
BRADFORD, United Kingdom
2Leeds Beckett University, School of Clinical & Applied Sciences, Leeds, United
Kingdom
Study question: What are the overall estimate of the different indicators of
infertility in the Middle East and North African (MENA) region?
Summary answer: The overall clinical primary and total infertility rate in the
MENA region are (3.8%, 95% Cl = 1.7-8.4) and (17.2%, 95% Cl = 10.6-26.7)
respectively.
What is known already: Statistics on the birth rates in different regions of
the world including the developing countries suggested that there is a decrease
in the number of children per couple but there is limited epidemiological
research on direct estimates of infertility in the developing countries.
Study design, size, duration: A systematic review with meta-analysis of
infertility rates according to the clinical and demographic deﬁnitions was con-
ducted. Relevant publications providing data from MENA region were retrieved
from Science direct, Web of knowledge, Medline, Embase, Cinahl, google and
WHO website with no language or date restriction on July 2017. Data of preva-
lence, risk factors and causes of infertility were extracted and meta-analysed to
produce the overall effect sizes of the infertility estimates.
Participants/materials, setting, methods: Eight cross-sectional studies sur-
veyed 35274 women to estimate infertility according to the clinical and epidemio-
logical deﬁnitions, and one WHO report contained prevalence data from 4 MENA
countries (35494 women between the ages of 15 to 49 years) were included in this
study. Studies estimated clinical primary and total infertility were pooled in a forest
plot using comprehensive meta- analysis software. In addition, the four estimates
according to the demographic deﬁnition was also pooled together.
Main results and the role of chance: Research areas of studies were Iran
(7 surveys) and Saudi Arabia (one survey) in the peer reviewed journal and
demographic surveys on Egypt, Morocco, Jordan and Yemen which were
reported by the WHO DHS program. The clinical primary infertility deﬁned as
“.the failure to become pregnant after 12 months or more of continuous and unpro-
tected sexual intercourse” was estimated in 5 surveys as 3.8% (95% Cl = 1.7-8.4,
effect size = -7.564, p = 0.0001), with the total clinical infertility, both primary
and secondary infertility, estimate was 17.2% (95% Cl = 10.6-26.7, effect size
= -5.5, p = 0.0001). However, this only represents studies from two countries;
Iran and Saudi Arabia. Percentage of women who have been married for the past
ﬁve years, who have ever had sexual intercourse, who have not used contraception
during the past ﬁve years, and who have not had any births” was used to produce
the demographic estimate of infertility in surveys by a WHO programme.
Demographic primary infertility was 22.6% (95% CI = 13.4-35.5. effect size
= -3.8, p = 0.0001) and demographic total infertility rate was 38.5% (95% CI =
28.8-49.2, effect size = -2.11, p = 0.035).
Limitations, reasons for caution: There was more research in Iran than on
all other countries combined in MENA region which makes any overall pooling
of data biased. There are also two different deﬁnitions of infertility. Infertility
estimates in demographic surveys is extremely high possibly because of inclu-
sion of many unmarried women.
Wider implications of the ﬁndings: Data suggested that infertility in the
MENA region is low when it is deﬁned clinically and high when it is deﬁned
demographically suggesting the need for standardizing infertility indicators to
inform future health and social policy. There is limited information on causes of
infertility. More robust epidemiological research is needed.
Trial registration number:Not Applicable.
P-725 Follicular ﬂuid concentrations of phthalate metabolites and
early reproductive outcomes among women undergoing in vitro
fertilization
Y. Du1, N. Guo1, T. Deng1, X. Hua1, Y. Yao1, Y.Wang2, X. Teng1,
Y. Li1
1Tongji Hospital- Tongji Medical College- Huazhong University of Science and
Technology, Reproductive Medicine Center, Wuhan- Hubei, China
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2Tongji Medical College- Huazhong University of Science and Technology,
Department of Occupational and Environmental Health- School of Public Health,
Wuhan- Hubei, China
Study question: Are follicular ﬂuid (FF) concentrations of phthalate metabo-
lites associated with impaired oocyte development and embryo quality among
women from a fertility center?
Summary answer: Higher FF concentrations of certain phthalate metabolites
were associated with lower mature and fertilized oocyte count, and declined
embryo quality.
What is known already: Phthalates, a group of synthetic industrial chemicals,
has led to widespread exposure across the world. Evidence from toxicological
studies has established a role for phthalates in disrupting folliculogenesis, oocyte
maturation and embryonic development. However, whether phthalates mea-
sured in the most biologically relevant matrix of the ovary (i.e. FF) can affect the
developmental competence of in vivo exposed oocytes and result in impaired
embryo quality is unclear.
Study design, size, duration: In this prospective cohort study, we recruited
636 women seeking infertility treatment at the Reproductive Medicine Center
of Tongji Hospital, Wuhan, China, between 2014 and 2016.
Participants/materials, setting, methods: We measured eight phthalate
metabolites in FF samples collected at oocyte retrieval. Data on early in vitro
fertilization (IVF) outcomes, including total and mature oocyte count, number
of fertilized oocytes and high-quality cleavage stage embryos, and proportion of
high-quality blastocysts were obtained from electronic medical charts.
Generalized linear models were performed to estimate the associations of FF
phthalates and IVF outcomes. All models were adjusted for age, body mass
index, smoking status and infertility diagnosis.
Main results and the role of chance: Most phthalate metabolites were
highly detected in FF samples. The detection rates ranged from low (37.1%) for
mono-n-octyl phthalate to high (77.2-98.6%) for the other seven metabolites.
Mono(2-ethylhexyl) phthalate (MEHP) was the most abundant metabolite
found in FF, with a median level of 1.65 ng/mL, followed by monobutyl phthal-
ate (MBP) and mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP). A border-
line statistically signiﬁcant relationship was observed for higher quartiles of FF
MEHHP and lower oocyted yield (P-trend = 0.05). We found a negative dose-
response association between FF monobenzyl phthalate (MBzP) and MEHHP
relative to decreased mature and normal fertilized oocyte count, as well as
number of cleavage embryos (all P-trend <0.05). Moreover, MEHHP was
inversely associated with decreased number of high-quality cleavage stage
embryos (P-trend = 0.01). Women in the second to fourth quartiles of
MEHHP had a signiﬁcant decrease of -11.49 (95% CI: -19.51, -2.66), -12.45
(95% CI: -20.55, -3.54) and -12.37 (95% CI: -20.31, -3.63), respectively, in high-
quality Day 3 embryos compared with the ﬁrst quartile. At the blastocyst stage,
there was a signiﬁcant trend toward lower proportion of high-quality blastocysts
with increasing MBP, MBzP, MEHP, MEHHP and∑DEHP [molar sum of three di
(2-ethylhexyl) phthalate (DEHP) metabolites] quartiles (all P-trend <0.05).
Limitations, reasons for caution: The single measurement of FF may lead
to misclassiﬁcation of phthalate exposure owing to their short half-life and vari-
ability in individual behaviors. Our ﬁndings drawn from women undergoing IVF
may not extrapolate to the general population, and the possibility of bias from
uncontrolled confounding may also exist.
Wider implications of the ﬁndings: Our ﬁndings indicated that the intra-
ovarian environment of women undergoing IVF has been pervasively exposed
to most studied phthalates. Despite the low concentrations, certain FF metabo-
lites were associated with adverse IVF outcomes, which raise concerns over
exposure assessment at target organ and low-dose effect of phthalates on
female reproduction.
Trial registration number:NA.
P-726 Donor recruitment for heterologous art in italy; still an
uphill path
V. Carotenuto1, L. Parmegiani1, A. De Dominicis2, A. Arnone1,
E. Troilo1, A. Maccarini1, S. Amicucci1, S. Taraborrelli1,
W. Ciampaglia1, F. Infante1, G. Cognigni1, M. Filicori1
1Gynepro, Reproduction Unit, Bologna, Italy
2University of L’Aquila - San Salvatore Hospital, Division of Obstetrics and
Gynecology, L’Aquila, Italy
Study question: Can spontaneous and altruistic donation alone enable setting
up gamete donation programs for infertile couples?
Summary answer: Scarce heterologous oocyte supply in Italy four years after
legalization underlines difﬁculties to secure local availability; establishment of
sperm banks appears more easily achievable.
What is known already: In April 2014 the Italian Supreme Court legitimized
heterologous ART. Gamete donation cannot be remunerated. The issue of
reimbursement of expenses met by donors (e.g. absence from work, transpor-
tation) has not been clariﬁed. As a result, a large majority of heterologous ART
in Italy is based on gamete or embryo shipment from abroad.
Study design, size, duration: A total of 356 heterologous ART cycles were
performed from January 2015 to January 2018. Gametes were obtained from
donors recruited by our Center in Italy or shipped from abroad.
Participants/materials, setting, methods: Donors (314) were divided in
4 groups: 6 sperm internal donors (SID), 41 sperm external donors (SED), 3
oocyte internal donors (OID) and 258 oocyte external donors (OED). Number
of treatments, mean donor age and number of cycles for each donor class were
analyzed. Statistical signiﬁcance of results was tested by Student’s t-test for con-
tinuous variables, and by the χ2 test for nominal data. P < 0.05 was considered
statistically signiﬁcant.
Main results and the role of chance: In the study period we obtained 15
local donations, 12 SID (6 excluded due to sperm or screening test abnormal-
ities) and 3 OID. All OID were eligible. A total of 101 heterologous sperm IVF
cycles were performed: 53 cycles (52.5%) with SID and 48 cycles (47.5%) with
SED. A total of 275 heterologous oocyte IVF cycles were performed: 6 cycles
(2.2%) with OID and 269 cycles (97.8%) with OED. The difference between
the number of treatments performed with SID vs. OID was statistically signiﬁ-
cant (P<0.0001). The SID mean (±SD) age was 29.2 ± 1.5 years, whereas in
SED it was 26.2 ± 4.2 (P = 0.003). The OID age was 28.3 ± 5.5 years vs. 24.7
± 3.3 in OED (P=NS). The number of cycles for each donor group was 8.8 ±
4.8 with SID vs. 1.2 ± 0.4 with SED (P<0.05); and 2.0 ± 1.0 in OID vs. 1.1 ±
0.2 in OED (P=NS).
Limitations, reasons for caution: The number of local oocyte donors
(OID) was very low, due to the logistics of donor recruitment.
Wider implications of the ﬁndings: Local sperm donor recruitment
allowed to perform numerous procedures internally; the vast majority of
oocyte donations required external supply. In Italy, a local donor program is
possible for sperm, but still unfeasible for oocytes. It would be desirable that
Italian governmental institutions provide clariﬁcations regarding the economic
treatment of donors.
Trial registration number: not applicable.
P-727 Cost-effectiveness of diagnostic investigation of infertility
and subfertility: a systematic review
S. Kiatpongsan, A.A. Amornpetchsathaporn, R. Pawa,
L. Udomsrisumran
Chulalongkorn University, Dept. of Obstetrics and Gynecology, Bangkok, Thailand
Study question: Is diagnostic investigation of infertility and subfertility cost-
effective?
Summary answer: Diagnostic tests shown to be cost-effective were laparos-
copy, hysteroscopy and chlamydia antibody testing.
What is known already: There have been many studies on cost and cost-
effectiveness of treatment for infertility and subfertility. Studies on cost and
cost-effectiveness of diagnostic investigation of infertility and subfertility were
quite limited and diverse in scope and methodology.
Study design, size, duration: Systematic review was conducted by two
independent reviewers. English language, peer-reviewed journal articles from
January 1997 to December 2016 were screened with key search terms: cost-
effectiveness, infertility, subfertility and names of each diagnostic test (for both
female and male infertility/subfertility). Database search was done through
PubMed, Medline, Scopus and cross-references.
Participants/materials, setting, methods: Inclusion criteria
i474 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
• Diagnostic tests for infertility and subfertility in male and/or in female
patients.
• Cost-effectiveness analysis was performed with reporting of cost and effect-
iveness data.
• Published between January 1997 and December 2016
• English language.
• Exclusion criteria.
• Ongoing study.
• Review and systematic review articles.
• Therapeutic investigation.
Main results and the role of chance: 7 of 33 identiﬁed articles presented
actual cost and effectiveness data.
7 studies were reported from Canada (1), Italy (1), The Netherlands (3),
Turkey (1), and USA (1). None of the studies was conducted under the context
of a developing country. The identiﬁed studies exclusively focused on diagnostic
investigation of infertility in female patients. Investigations evaluated were lapar-
oscopy, hysterosalpingography, hysteroscopy, sonohysterosalpingography,
transvaginal hydrolaparoscopy and Chlamydia antibody testing.
5 studies used modeling models while 2 studies were a part of clinical trials.
Effectiveness was reported as expected live births and probability of pregnancy.
Cost was reported as mean cost per live birth, total direct procedural costs
(healthcare perspective) and total or average cost of care per patient. 4 out of
7 studies reported cost-effectiveness in term of incremental cost-effectiveness
ratio (ICER). Only one study used a societal perspective approach while most
studies used a healthcare perspective approach.
Diagnostic tests determined to be cost-effective were laparoscopy, hystero-
scopy and chlamydia antibody testing. Inﬂuential factors in sensitivity analyses
were female age and dropout rate.
Limitations, reasons for caution: There were a limited number of studies
on cost-effectiveness of diagnostic tests for infertility and subfertility.
Measurement of cost and effectiveness varied across studies.
Wider implications of the ﬁndings: Our systematic review shows that
there is a limited number of studies on cost-effectiveness of diagnostic tests for
infertility and subfertility especially in developing countries or in low-resource
settings. More studies should be conducted for new diagnostic tests and in low-
resource settings.
Trial registration number: not applicable.
P-728 The younger the better: the case for continuing use of IUI as
a ﬁrst-line infertility treatment in a Ghanaian population
M.B. Yakass1, B.Woodward2, M.A. Otoo1, J. Adoboe1, E.K. Hiadzi1
1Lister Hospital and Fertility Centre, Fertility Unit, Accra, Ghana
2X & Y Fertility, Assisted Conception Unit, Leicester, United Kingdom
Study question: In low-income countries, can performing lower technology
treatments such as intrauterine insemination (IUI), offer simple and less costly
fertility treatment with effective pregnancy rates?
Summary answer: IUI is an effective ﬁrst-line fertility treatment for unex-
plained and mild male factor infertility, particularly in younger women.
What is known already: Infertility in sub-Saharan Africa can be traumatic,
especially for the woman. Primary and secondary infertility is higher in younger
African women (<37 years). Mostly, younger couples are in low to middle-
income brackets without good economic standing. To the best of our knowl-
edge, no African country offer medical insurance covering fertility treatments,
pushing young infertile couples to seek loans at high-interest rates (over 30%)
for fertility treatments. Guidance from the National Institute for Clinical
Excellence in the UK advises against IUI as a ﬁrst-line fertility treatment.
However, in our setting, IUI offers a low-cost, low-tech option, providing effect-
ive results.
Study design, size, duration: This is a retrospective study involving 859 cou-
ples who were treated with IUI in a fertility clinic in sub-Saharan West Africa
between March 2012 and December 2017. Female participants were age-
stratiﬁed into three groups; ≤30 years, 31 – 36 years and ≥37 years. Sperm
count and motility data were collected and presented as mean ± SEM.
Pregnancy rates were reported as percentages. ANOVA was performed to
determine inter-group differences.
Participants/materials, setting, methods: All participants received IUI in
a stimulated cycle using clomiphene citrate for 5 days followed by FSH (150IU)
every other day for 3-5 times. HCG (10,000IU) was administered when leading
follicle was ≥16 mm and the ﬁrst insemination performed 36 hours post-HCG
administration. A second insemination was performed 60 hours post HCG (24
hours after the ﬁrst insemination). Ejaculated semen was prepared using density
gradient centrifugation and the prepared semen warmed to 37°C some 30
minutes prior to insemination.
Main results and the role of chance: Enrolled participants had at least one
patent Fallopian tube, with IUI only taking place if ovulation matched the side of
patency. The main causes of infertility were anovulation, mild male factor and unex-
plained infertility. Approximately half of the female participants were in the age
group 31 – 36 years (49.7%), with the remaining quarters in the age groups ≤30
(25.7%) and ≥37 years (24.6%) respectively. There was no signiﬁcant difference in
sperm count and percentage motility across age groups; [sperm count (million/ml):
18.3 ± 1.50, 19.3 ± 1.88 and 13.6 ± 2.20, p = 0.1296], [Motility (%): 34.1 ± 2.12,
31.8 ± 1.92 and 26.1 ± 2.91, p = 0.0697] respectively. There was a signiﬁcant dif-
ference in pregnancy rates across the three age categories: 14.9%, 9.1% and 4.7%,
p = 0.0142 for women ≤30, 31 – 36 and ≥37 years respectively.
Limitations, reasons for caution: A poorer pregnancy rate from IUI in
women ≥37 years does not preclude such women from undertaking IUI
treatments.
Wider implications of the ﬁndings: In resource-limited countries where
medical insurance does not cover fertility treatments, younger women (≤30
years) could perform a less costly procedure like IUI with respectable preg-
nancy rates.
Trial registration number:N/A.
P-729 Expert consensus for primary management of reproductive
health: a Delphi study
D. Orozco-Beltran1, A. Bernabeu1.2, C. Carratala-Munuera1,
J. Llacer1.2, A. Lopez-Pineda3, F. Sellers1.2, J. Quesada1,
V. Gil-Guillen1, R. Bernabeu1.2
1Miguel Hernandez University, Chair of community medicine and reproductive
health, San Juan de Alicante, Spain
2Instituto Bernabeu, Assisted reproduction department, Alicante, Spain
3Miguel Hernandez University, Cátedra de Medicina Comunitaria y Salud
Reproductiva, San Juan de Alicante, Spain
Study question: To identify barriers and enablers to appropriate primary
management of the reproductive health by healthcare professionals.
Summary answer: A good consensus was achieved by experts to identify
barriers and enablers to appropriate primary management of reproductive
health.
What is known already: Infertility affects more than 80 million people
worldwide. Fertility problems may be caused by genetic abnormalities, infec-
tious or environmental agents, and certain life styles. There are modiﬁable fac-
tors contribute to the burden of infertility. In addition to psychosocial problems
that may cause the infertility, the treatment of infertility contributes to increas-
ing the cost of healthcare. For many causes of infertility, primary prevention is
feasible. Thus, an appropriate management of reproductive health from the
very beginning might reduce the prevalence of infertility and improve health and
quality of life.
Study design, size, duration: This observational study was carried out from
September 10, 2017 to January 20, 2018 using the modiﬁed Delphi technique.
The coordinating project group selected the expert panel and deﬁned the items
of the questionnaire. The questionnaire was distributed online on November
2017 through a web page.
Participants/materials, setting, methods: 40 gynecologists from private
and public assisted reproduction clinics and from different Spanish regions were
selected randomly and were invited to participate as a panel member.
Individual and anonymous opinions were asked by answering a 58-items ques-
tionnaire via e-mail (two rounds were done). Level of agreement was assessed
using measures of central tendency and dispersion. Consensus was reached on
an item when more than 65% of level agreement or disagreement was
achieved.
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Main results and the role of chance: Response rate: 60%. After the ﬁrst
round, consensus items were 42 (72.4%): of which 35 in agreement and 7 in dis-
agreement. Eight items were modiﬁed in the questionnaire of second round
according to expert requests. All the items reaching consensus by experts will
be presented. Some examples of items with agreement are: ‘General popula-
tion have not enough information about vitriﬁcation’ (100%) or ‘Oncologic
patients are not the only patients where vitriﬁcation could be indicated’ (100%),
‘General gynecoligists must be more implicated in reproductive health’ (100%),
‘Family planning must include information about reproduction probabilities and
not be centered only on anticonception’ (100%).
Limitations, reasons for caution: The inherent limitations of Delphi study.
A further possible limitation was the use of a structured questionnaire but free
text responses were allowed in the ﬁrst-round questionnaire that were incor-
porated into the questionnaire used in the second round.
Wider implications of the ﬁndings: Consensus was reached between
assisted reproduction specialists on the most important concepts, which can
provide the basis for primary management of reproductive health in Spain.
Trial registration number:Not applicable.
P-730 The association between the number of oocytes retrieved
for IVF, perinatal outcomes and obstetric complications
Å. Magnusson1, U.B.Wennerholm2, K. Källén3, M. Petzold4,
A. Thurin-Kjellberg5, C. Bergh6
1Sahlgrenska University Hospital, Department of Gynecology and Reproductive
Medicine, Göteborg, Sweden
2Institute of Clinical Sciences- Sahlgrenska Academy- Gothenburg University-
Sahlgrenska University Hospital Östra East SE-416 85 Gothenburg- Sweden,
Department of Obstetrics and Gynaecology, Gothenburg, Sweden
3Department of Reproduction Epidemiology- Tornblad Institute- Department of
Clinical Sciences- Lund University- SE-223 62 Lund- Sweden, Department of
Reproduction Epidemiology, Lund, Sweden
4The Sahlgrenska Academy- Gothenburg University- SE-405 30 Gothenburg-
Sweden, Health Metrics Unit, Gothenburg, Sweden
5Department of Obstetrics and Gynaecology- Institute of Clinical Sciences-
Sahlgrenska Academy- Gothenburg University- Reproductive Medicine- Sahlgrenska
University Hospital- SE-413 45 Gothenburg- Sweden, Department of Obstetrics and
Gynaecology, Gothe
6Institute of Clinical Sciences- Sahlgrenska Academy- Gothenburg University-
Reproductive Medicine- Sahlgrenska University Hospital- SE-413 45 Gothenburg-
Sweden, Department of Obstetrics and Gynaecology-, Gothenburg, Sweden
Study question: Is there an association between the number of oocytes
retrieved for IVF and perinatal and obstetric outcomes?
Summary answer:No signiﬁcant association was found between the number
of oocytes retrieved and perinatal outcomes, while an association was found
for placenta praevia and male gender.
What is known already: Previous studies have shown that 8-15 oocytes
retrieved at oocyte pick up (OPU) are optimal for live birth in fresh cycles.
We showed in a recent study that cumulative live birth rate, including fresh
and all cryo cycles following one OPU, increases by the number of oocytes
retrieved up to around 20 oocytes, however also with an increase in ser-
ious side effects such as severe ovarian hyperstimulation syndrome (OHSS).
Few studies with contradicting results have investigated if the number of
oocytes retrieved also might be associated with negative obstetric and peri-
natal outcomes.
Study design, size, duration: Retrospective population-based registry
study including all singleton deliveries after fresh IVF cycles performed in
Sweden during the years 2002-2015 (n = 27,359). Treatment characteristics
from The Swedish National Quality Registries of Assisted Reproduction
including the number of oocytes retrieved, fertilization method, date of
embryo transfer, number of embryos transferred, embryo stage and num-
ber of sonographically visible gestational sacs at gestational weeks 7-8 were
cross-linked to the Medical Birth Registry (MBR) and the National Patient
Register (NPR).
Participants/materials, setting, methods: Main perinatal outcomes were
preterm birth (PTB), small for gestational age (SGA), and peri/neonatal death.
Main obstetric outcomes were gestational hypertension/preeclampsia and
placenta praevia. Multivariate analyses.were used to explore the association
between the number of oocytes retrieved and outcome variables. Adjustments
were performed for maternal age, parity, smoking, BMI, cause of infertility,
years of infertility, chronic diseases, paternal age, treatment period, embryo
stage and vanishing twin.
Main results and the role of chance: The number of oocytes retrieved
were categorized in <10, 10-14, 15-19 and >20 oocytes and 4-9 oocytes
was used as a reference. SET was performed in 76.4% of the cycles.
Blastocyst transfer was performed in 12.7% and cleavage stage embryo
transfer was performed in 87.3% of the cycles. No signiﬁcant association
was observed between the number of oocytes retrieved and PTB (OR
1.004, 95% CI 0.996 to 1.013), SGA (OR 0.999, 95% CI 0.998 to 1.009)
or peri/neonatal death (OR 0.992, 95% CI 0.960 to 1.025). A signiﬁcant
association was detected between the number of oocytes retrieved and
gender distribution, with a higher rate of males after > 20 versus 4-9
oocytes (AOR 1.121, 95% CI 1.042 to 1.206). Concerning obstetric out-
comes a signiﬁcant association was found for placenta praevia (AOR 1.016,
95% CI 1.001 to 1.032) while no association was found for preeclampsia
after adjustment for confounders.
Limitations, reasons for caution: Some of the OPUs performed in 2015
have resulted in births in 2016, thus the obstetric and perinatal outcomes are
not yet available in the registry for these treatment cycles.
Wider implications of the ﬁndings: These results are assuring concerning
children outcome with no indication of an adverse effect of a high number of
oocytes retrieved. The association between the number of oocytes and pla-
centa praevia was signiﬁcant, however weak. The new ﬁnding of an association
with gender should be interpreted with caution.
Trial registration number: 2018:0201
P-731 Dizygotic multiple pregnancy, Dutch trends over two
decades from 1995 through 2015
T. Konig1, C. Hukkelhoven2, C.B. Lambalk1
1VU University medical center VUmc, Department of Obstetrics and Gynaecology-
division of Reproductive Medicine, Amsterdam, The Netherlands
2Perined, Epidemiology, Utrecht, The Netherlands
Study question: To identify the contribution of natural conception, in vitro
fertilization (IVF), intra uterine insemination (IUI) and ovulation induction (OI)
to the occurrence of dizygotic twinning over time.
Summary answer: Twinning increased until 2001 and declined thereafter,
related to maternal age only in case of natural conception and not with IVF/ICSI.
What is known already: Over the past decades there has been a strong
increase followed by a decline of multiples in the Netherlands, similar to many
other developed countries. The increase has been associated with the introduc-
tion of artiﬁcial reproductive therapies (ART). Multiple pregnancies are often
seen as a complication rather than a success, because of the association with
pregnancy complications endangering mothers health as well as the foetus health.
It is important to keep closely tracking trends regarding multiple pregnancy rates
in relation to the various conception modes, including the natural way.
Study design, size, duration: Data from the national obstetric registration
(PRN) for a period of 20 years were analysed. The data represent all hospitals
in the Netherlands, as all twins are born in hospitals.
Participants/materials, setting, methods: The PRN data contains infor-
mation on all primiparous and multiparous twins from an amenorrhoea of ≥16
weeks classiﬁed by mode of conception and information about gender. The
number of opposite sex twins is multiplied by two to estimate the total dizyg-
otic twins (Weinberg rule). Data of the Dutch Central Bureau for Statistics on
total number of deliveries over the examined years was used in order to calcu-
late prevalence of twin births.
Main results and the role of chance: From 1995 to 2001 there was a
strong increase of twin births together with a gradually increase of the maternal
age. Both naturally conceived and IVF/ICSI twins accounted for this strong
increase, although the largest increase came from natural conception. Between
2001 and 2006 the number of dizygotic twin births was stable, both in the nat-
urally conceived group as in the IVF/ICSI group. From 2006 onwards a
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continuous decrease of naturally conceived dizygotic twins is seen, together
with a decrease of maternal age in twin mothers.
Remarkably on average, maternal age of all delivering women over that peri-
od remained just over 31 years, whereas age of primiparous mothers continued
to increase. The number of IVF/ICSI conceived dizygotic twin pregnancies
declines from 2006 onwards. With a strong accelerated decline as of 2012
associated with a strong increase of the maternal age. Furthermore, since 2014
the number of dizygotic twin pregnancies after OI and IUI is larger than after
IVF/ICSI in the Netherlands.
Limitations, reasons for caution: A limitation of this study that we have to
rely on accurate recordkeeping in all registering hospitals. The way of recording
information has not changed over the last years, therefore these data do pro-
vide accurate insight into valuable trends.
Wider implications of the ﬁndings: The decline of natural twinning from
2006 onwards in association with lower maternal age demonstrates decline of
age related twinning which could reﬂect that family completion takes place earl-
ier. This is supported by the ever increasing maternal age of primipara and the
stable maternal age for all deliveries.
Trial registration number: not applicable.
P-732 The sex ratio in twins and the inﬂuence of gender mix in
twins on gestational age, birth weight and perinatal mortality
B. Decommer, M. Verstraeten, O. Degomme, I. Dehaene,
C. Derom, C. Roelens
UGent, ICRH, Ghent, Belgium
Study question: Is the sex ratio in twins different from singletons? And does
the gender mix of a twin inﬂuence gestational age, birth weight and perinatal
mortality?
Summary answer: The sex ratio in twins is lower compared to singletons.
There is evidence for gender effect in twins on gestational age and perinatal
mortality.
What is known already: The sex ratio in singletons is generally male-biased,
and decreases in twins and triplets. This means that there are proportionally
more girls in twins than in singletons.
De gender of one fetus of the twin can have an inﬂuence on perinatal factors
of the other fetus of the twin, such as birth weight, gestational age and perinatal
mortality. This inﬂuence is known as gender effect. For example, the gestational
age in opposite gender twins is signiﬁcantly longer that the gestational age in
male same sex-twins.
Study design, size, duration: Our study group included 9563 twin pairs
(9591 boys and 9535 girls) of the East Flanders Prospective Twin Survey
(EFPTS). To study the sex ratio, the use of assisted reproductive techniques
(ART), the zygosity, chorionicity and amnionicity were also taken into consider-
ation. The sex ratio of singletons was based on the general register of East
Flanders. Statistical analyses were performed using IBM SPSS Statistics 24.
Participants/materials, setting, methods: We performed statistical ana-
lyses on 9563 twin pairs of the East Flanders Prospective Twin Survey (EFPTS),
which has been registering all multiple births of East Flanders since 1964. Perinatal
factors were obtained from the obstetric records. To evaluate differences in sex
ratio, we used Wilson score intervals and binary logistic regressions. To examine
whether gender has an inﬂuence on perinatal factors, multiple linear regressions
and multiple logistic regressions were used (α = 0,05).
Main results and the role of chance: The sex ratio in twins is lower than in
singletons (p<0,05). No signiﬁcant results were found comparing the sex ratio
between spontaneously conceived twins and twins conceived by ART, although
there was a trend towards a decreasing sex ratio for dizygotic twins conceived
through IVF+GIFT+ZIFT compared to spontaneously conceived dizygotic twins
(OR = 0,929; p = 0,093). There is also a trend towards an increasing sex ratio
for dizygotic twins compared to monozygotic twins (OR = 1,073; p = 0,087).
We found a signiﬁcant difference in sex ratio of dichorionic-diamniotic twins com-
pared to monochorionic-monoamniotic twins (OR = 2,794; p<0,001), and of
monochorionic-diamniotic twins compared to monochorionic-monoamniotic
twins (OR = 2,760; p<0,001). This shows that the chance for girls is much higher
in monochorionic-monoamniotic twins (in our dataset nearly 75% were girls).
There is an association between gender mix and gestational age, where the
gestational age for girls with a twin brother is approximately one day shorter
compared to female same-sex twins (p = 0,072), and approximately one day
longer for boys with a twin sister compared to male same-sex twins (p =
0,088). No direct association between gender mix and birth weight was found.
Comparing perinatal mortality, boys with a twin sister have a lower chance to
die than boys with a twin brother (OR = 0,680; p = 0,022).
Limitations, reasons for caution: One important limitation of this study is
that many confounding variables could have an inﬂuence on the results of gen-
der effect (like smoking, infections during the pregnancy…), which were
unknown in our database.
Wider implications of the ﬁndings: As our dataset is based on the
Caucasian population in East Flanders, extrapolation to other populations is
impossible. Although the effects are too small to be clinically signiﬁcant, the ﬁnd-
ings do have a theoretical signiﬁcance to help understand underlying mechan-
isms of twins.
Trial registration number:None.
P-733 Assessing the impact of obstetrics ultrasound on maternal
and perinatal health outcomes in African rural or low-income
settings
O.P. Shehu1, A. D’Angelo2
1Shefﬁeld Teaching Hospital NHS Trust, Medical Imaging, Manchester, United
Kingdom
2Cardiff University, School of Medicine, Cardiff, United Kingdom
Study question: Is there a direct association between obstetric ultrasound
and reduction of maternal and perinatal mortality in African rural or low-
income settings?
Summary answer: Use of obstetric ultrasound in African rural settings
showed signiﬁcant beneﬁts with potential to reduce maternal and perinatal
mortality rates.
What is known already: A disproportionate disparity exists in maternal and
neonatal mortality rates between developed and developing countries of the
world, with 99% of all maternal deaths occurring in developing countries.
Innovative and ground-breaking use of ultrasound in addressing disease bur-
dens is a feature of healthcare systems in developed countries. The evidence
base for routine use of ultrasound in antenatal care was mainly derived from
the developed world, where other factors may account for the low maternal
mortality rates.
Research done to establish a direct association between access to routine
obstetric and reduction in maternal/perinatal mortality rates in African rural
settings is sparse.
Study design, size, duration: Systematic review of journal articles on the use
of ultrasound by appropriately trained persons, in resource-poor, African rural
communities, as a diagnostic tool in obstetric care. 20 articles published between
2000-2017 which met the inclusion criteria were selected for the review.
Participants/materials, setting, methods: Electronic databases search
(PubMed/Medline, Cochrane library, CINAHL, google scholar) were con-
ducted using MeSH (Medical Subject Heading) keywords ‘Ultrasonography’,
‘Maternal mortality and foetal mortality’, ‘Africa AND rural communities OR
Low-income populations OR rural populations’ to extract relevant articles
which were screened for appropriateness and data extraction accuracy by a
second reviewer. The Quality Assessment of Diagnostic Accuracy Studies -2
(QUADAS-2) tool for assessing the quality of diagnostic studies for systematic
reviews was used for this review.
Main results and the role of chance: Results of this review should be inter-
preted with caution owing to the low quality of evidence supporting the
assumptions of the authors, However, ﬁndings from the reviewed studies indi-
cate increased rate of diagnosis of conditions associated with maternal and peri-
natal morbidity which has signiﬁcantly informed change in clinical management
decisions and early referral to specialist care. The power of ultrasound as a pull-
factor to attract pregnant women and their spouses was demonstrated through
increased attendance at antenatal care offered at health facilities. Opportunities
for role extension through focused ultrasound training for rural healthcare
workers was reported.
i477Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
Though there is dearth of quality data for robust analysis to validate these
observations, this review highlights the need for randomized controlled trials
(RCT’s)to evaluate the clinical and economic effectiveness of introducing ultra-
sound in African rural settings. Conceptual and methodological limitations of
the currently published ﬁndings on this question should be fully considered by
researchers, so that future trials will be rigorous in design and implementation
to ensure conclusive ﬁndings.
Limitations, reasons for caution: Due to paucity of quality research on the
study topic, the disparate nature of studies design/implementation and lack of
study control groups, performing a risk of bias and applicability analysis was difﬁ-
cult, resulting in high likelihood of bias and limitation to the generalizability of
the report’s conclusions.
Wider implications of the ﬁndings: Obstetric ultrasound in African rural
settings changes management of otherwise undetected high risk maternal
conditions, enables early referral and increases attendance to and uptake of
other beneﬁcial interventions at health facilities. Opportunities for further
research to generate the necessary evidence for use of ultrasound in ante-
natal care in rural Africa.
Trial registration number: not applicable
POSTER VIEWING
Reproductive surgery
P-734 Clinical analysis of gonads with ectopic adrenal tissue in
disorders of sex development patients
Q. Tian
Peking Union Medical College Hospital, OB/GYN, Beijing, China
Study question: To summaries the characteristics, diagnosis and management
of gonads with ectopic adrenal tissue in disorders of sex development(DSD)
patients.
Summary answer: Removal of ectopic adrenal tissue does not affect the
prognosis and may have some beneﬁts in CAH treatment.
What is known already: The risk of dysplasia gonad with ectopic adrenal tis-
sue in DSD patients is rare. Diagnosis relies on pathology, and hardly could be
found pre-surgery.
Study design, size, duration: A total of 139 patients of DSD underwent sur-
gery in Peking Union Medical College Hospital from Aug 2007 to Aug 2017.
Among them, 5 patients were complicated with ectopic adrenal tissue and their
clinical and pathology manifestation were analyzed.
Participants/materials, setting, methods: 5 patients, complicated with
ectopic adrenal tissue and their clinical and pathology manifestation, were
analyzed.
Main results and the role of chance: The ectopic adrenal tissue risk of
DSD was 3.60% (5/139). All the 5 patients were female phenotype with Y
chromosome or SRY gene. One patient was 45,XO, SRY(+) with dysgermi-
noma, the rest four patients were 46,XY, among which 3 were diagnosed
with 17-alpha-hydroxylase(17-OHD),1 was partial gonadal dysgenesis
(PGD). All the clinical manifestation and images before or in the surgery
didn’t show any sign but were testiﬁed of ectopic adrenal tissue in the
resected gonad by pathology. 2 patients with 17-OHD received lower dos-
age of glucocorticoid after the surgery in the follow up. Hormone replace-
ment therapy was given to maintain growth and development, and 2
patients obtained regular period.
Limitations, reasons for caution: Non-RCT study, only 5 patients were
analyzed.
Wider implications of the ﬁndings: Current understanding of characteris-
tics, diagnosis and management of dysplasia gonad with ectopic adrenal tissue in
disorders of sex development(DSD) patients is limited. This study provided
more data and evidence to learn about them.
Trial registration number:No.
P-735 Hemodynamic parameters and ICSI outcome in patients
undergoing anesthesia for oocyte retrieval using alfentanil, fentanyl
and remifentanil: a randomized clinical trial
F. Farzi1, M. Mehrafza2, A. Mirmansouri1, Z. Zahiri1, Z. Atrkar
Roushan1, A. Raouﬁ2, R. Shalkohi2, S. Samadnia2, A. Hosseni2
1Anesthesia Research Center- Department of anesthesiology- Alzahra Hospital-
School of Medicine- Guilan University of Medical Science- Rasht- Iran, Department of
anesthesiology, Rasht, Iran
2Mehr Medical Institute, Fertility research center, Rasht, Iran
Study question: What is the effect of alfentanil, fentanyl and remifentanil on
hemodynamic parameters and intracytoplasmic sperm injection (ICSI) outcome
in patients undergoing general anesthesia for transvaginal oocyte retrieval?
Summary answer: All opioids lead to similar hemodynamic characteristics
and pregnancy rate.
What is known already: In general anesthesia, there are some concerns
about impacts of anesthetics on ICSI outcome. No study has been found to
compare the effects of these three opioids in patients undergoing general anes-
thesia for oocyte retrieval and express the superiority of one opioid over
others.
Study design, size, duration: In the present double-blinded clinical trial, 340
patients were assessed for eligibility and randomized for transvaginal oocyte
retrieval following general anesthesia and 105 were lost to follow up. Data
were collected from December 2014 to May 2017. Participants were rando-
mized using block randomization method.
Participants/materials, setting, methods: Two hundred thirty ﬁve
women ≤ 40 years old, with normal ovarian reserve tests and fresh embryo
transfer were completed trial and divided among three groups: A (1.5 μg/kg, n
= 78), F (1.5 μg/kg, n = 77) and R (15 μg/kg, n = 80). Patients with ≥ 2 unsuc-
cessful ICSI cycle, history of cardiovascular disease, chronic opioid use and
allergy to anesthetic agents did not include. All patients underwent pituitary
suppression using long acting gonadotropin releasing hormone agonists.
Main results and the role of chance: There was no signiﬁcant difference
among groups with respect to demographic characteristics. Pre-induction and
post-induction systolic and diastolic blood pressure and heart rate were not sig-
niﬁcantly different among the three groups. Time of respond to verbal com-
mand (A: 1.99 ± 1.64, F: 2.56 ± 1.72, R: 1.78 ± 1.34, P = 0.014), terminal
systolic (101.61 ± 9.15, 105.29 ± 12.61, 102 ± 12.91, P = 0.01) and diastolic
(A: 59.97 ± 9, F: 65.63 ± 9.13, R: 63.69 ± 11.01, P = 0.003) blood pressure
and opioid induce cough (A: 21.8%, F: 11.7%, R: 31.3%, P = 0.021) was signiﬁ-
cantly different among groups.
No statistically signiﬁcant difference were found among groups with respect
to progesterone and estradiol level on human chorionic gonadotropin (hCG)
day, total number of retrieved and metaphase II oocytes and endometrial thick-
ness. The ratio two pronuclei (2PN) to total number of retrieved oocyte was
signiﬁcantly higher in remifentanil group than other groups (A: 51.6%, F: 54.4%,
R: 62.2%, P = 0.018). There was no signiﬁcant difference among groups with
regards to implantation rate (P = 0.814), chemical (P = 0.922) and clinical (P =
0.925) pregnancy rate.
Limitations, reasons for caution: Due to high plasma level of estradiol or
progesterone on hCG day in some patients and need to delay their embryo
transfer, they were excluded, so sampling and data collection were taken long
time.
Wider implications of the ﬁndings: Secondary endpoints revealed super-
iority of remifentanil due to shorter recovery time and higher ratio of 2PN to
total number of retrieved oocyte compared to fentanyl and alfentanil.
Trial registration number: IRCT201410258677N4
P-736 Complicated clinical course and poor reproductive
outcomes of women with tuboovarian abscess following fertility
treatments
Y. Fouks1, Y. Cohen2, L. Ishai3, B. Almog3, A. Cohen3
1Lis Maternity Hospital- Department of Obstetrics and Gynecology- Sourasky
Medical Center. Afﬁliated to the Sackler School of Medicine- Tel Aviv University
Address: 6 Weizmann Street- Tel Aviv- Zip code 64239- Israel., Obstetrics and
Gynecology-, Tel A
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2Department of Obstetrics and Gynecology- McGill University- Montreal- Quebec-
Canada- Department of Obstetrics and Gynecology- Lis Maternity Hospital- Tel-Aviv
Sourasky Medical Center- Sackler Faculty of Medicine, Department of Obstetrics and
Gynecology
3Lis Maternity Hospital- Department of Obstetrics and Gynecology- Sourasky
Medical Center. Afﬁliated to the Sackler School of Medicine- Tel Aviv University
Address: 6 Weizmann Street- Tel Aviv- Zip code 64239- Israel., Lis Maternity
Hospital- Department
Study question: To assess the clinical course, treatment and reproductive
outcome of women with tuboovarian abscess (TOA) following fertility
treatment.
Summary answer: TOA following fertility treatment has a substantial effect
on the clinical course, surgical and fertility outcome.
What is known already: There is limited data regarding the clinical course,
treatment and reproductive outcome of women with (TOA) following fertility
treatment.
Study design, size, duration: Retrospective cohort study over 10 consecu-
tive years.
Participants/materials, setting, methods: The study was performed in a
tertiary university-afﬁliated hospital. Electronic medical records were used to
identify patients who were diagnosed with fertility treatment associated TOA.
Fertility unit charts and phone survey were used to assess patient clinical
course, surgical and reproductive outcomes.
Main results and the role of chance: Thirty-seven women who were diag-
nosed with TOA following fertility treatments (in-vitro fertilization and intra-
uterine insemination) were compared with 313 women who were diagnosed
with TOA not associated with fertility treatments during the same time period.
Women with TOA following fertility treatments had signiﬁcantly higher inﬂam-
matory markers upon admission as compared to the non-fertility treatment
group (mean WBC 16.1 ×1000/mm3 (SD± 4.3) vs. 13.8 ×1000/mm3 (SD±
6.3), p = 0.001, respectively and mean CRP 149mg/L (SD± 78.3) vs. 78.2 mg/
L (SD± 68.5), p = 0.001, respectively). In addition, women with TOA following
fertility treatments were associated with signiﬁcantly higher surgical intervention
rate and a more complicated clinical course as was shown by shorter time inter-
val from admission to surgery (2.1 days vs. 3.2 days, p = 0.01), higher rates of
antibiotic failure, higher conversion rate from laparoscopy to laparotomy
(14.2% vs. 3.2%, p = 0.005), increased perioperative complications rate (25.0%
vs. 3.8%, p = 0.0001) and a longer hospitalization period (7.2 days vs. 4.8 days,
p = 0.01). Clinical pregnancy rate per cycle in women with TOA following fertil-
ity treatments was 9%. one case of live births was recorded.
Limitations, reasons for caution: Retrospective cohort analysis, based on
medical records.
Wider implications of the ﬁndings: Prophylactic treatment and embryo
transfer cancellation should be considered in patients that are at risk for
infection.
Trial registration number: ‘not applicable’.
P-737 Impact of laparoscopic myomectomy on reproductive and
obstetric outcomes in patients with intramural myomas
M. Sato, S. Hara, F. Suyama,W. Beck, Y. Mukoda, K. Sekigawa,
K. Sasaki, H. Okubo, H. Tajima, H. Asada, Y. Yoshimura, S. Ikuta,
R. Tokutomi, A. Jinno, S. Akimoto
Shin-Yurigaoka General Hospital, Obstetrics and Gynecology, Kawasaki-shi, Japan
Study question: Does removal of intramural myomas improve reproductive
outcomes?
Summary answer: Laparoscopic myomectomy (LM) may contribute to suc-
cess infertility treatment in patients with intramural myomas.
What is known already: Uterine myomas are the most common benign
tumors in women of reproductive age. Submucosal myomas have been shown
to lower fertility rates, and their removal improves reproductive outcomes.
However, the beneﬁt of LM in subserosal or intramural myomas has not been
clearly established.
Study design, size, duration: We performed a retrospective analysis at
Shin-Yurigaoka General Hospital between 2012 and 2016. Of 766 patients who
underwent LM during this time period, 81 infertile women with intramural myo-
mas alone or both intramural and subserosal myomas were examined. Patients
with submucosal myomas or those who discontinued infertility treatment at
our hospital were excluded.
Participants/materials, setting, methods: Medical records were retro-
spectively reviewed to analyse reproductive outcomes and obstetric complica-
tions. We collected data pertaining to age, the largest myoma diameter, the
number and total weight of the removed myomas, and distortion of the uterine
cavity. The pregnant and non-pregnant groups were compared. The rate of
pregnancy among 16 infertile patients who underwent resection of submucosal
myomas by hysteroscopy during the same period was also evaluated as part of
a secondary analysis.
Main results and the role of chance: Patient age in the pregnant and
non-pregnant groups was 36.3 ± 4.2 and 38.2 ± 3.7years (p = 0.04),
respectively. The number of intramural myomas (5.6 ± 4.6 vs 5.4 ± 3.7),
the largest diameter (7.5 ± 2.4 and 6.9 ± 2.2 cm), and the total weight of
myomas removed (225 ± 222 vs 169 ± 151 g) were not signiﬁcantly differ-
ent between the pregnant and non-pregnant groups. The rate of cavity dis-
tortion was also not signiﬁcantly different between groups (55.8% vs
48.3%). The pregnancy rate among patients with intramural myomas who
underwent LM was 64.2% (52/81), which is comparable to that in patients
who underwent submucosal myomas resection by hysteroscopy (68.8%,
11/16). Overall, 52 patients had 63 pregnancies via ART (assisted repro-
ductive technology) (n = 47) or non-ART (n = 16). The mean time period
between LM and the ﬁrst pregnancy was 12.3 months (range, 3-39 months;
median, 10.5 months). The rate of miscarriages and live birth were 36.5%
and 37.0%, respectively. Overall, 23 babies were born to 20 patients at
our hospital by Caesarean section. All deliveries were after 37 weeks of
gestation. No case of uterine rupture or placental abnormalities was
observed. We did not observe any detrimental effect on reproductive and
obstetric outcomes.
Limitations, reasons for caution: Our study is limited by its retrospective
design and small sample size. Additionally, the lack of a control group does not
allow for deﬁnitive conclusions.
Wider implications of the ﬁndings: Larger well-designed prospective ran-
domized trials are needed to further evaluate the effect of LM on reproductive
outcomes in patients with intramural myomas. LM may be offered to patients
who do not become pregnant after infertility treatment. Management should be
individualized considering age and infertility factors other than myomas.
Trial registration number:We did not receive a trial registration number.
P-738 Vaginoplasty and concomitant oocyte retrieval in
Rokitansky syndrome
V.S. Vanni1, D. Delprato1, M. Candiani1, A. Bartolacci1, V. Gervasio1,
G. Cermisoni1, L. Fedele2, E. Alleva1, E. Papaleo1
1IRCCS San Raffaele Hospital, Obstetrics and Gynecology, Milano, Italy
2Ospedale Policlinico Ca’ Granda, Obstetrics and Gynecology, Milan, Italy
Study question: Can invasiveness in the treatment of Mayer-Rokitansky-
Küster-Hauser (MRKH) patients be minimized by performing concomitant lap-
aroscopic oocyte retrieval and vaginoplasty?
Summary answer: We report the ﬁrst three MRKH cases in which laparo-
scopic vaginoplasty and oocyte retrieval were efﬁciently combined and oocytes
cryopreserved for future use.
What is known already: MRKH syndrome diagnosis is based on congenital
aplasia of the upper vagina and uterus, and affects approximately 1/4,500
women. Patients experience the early distress of lack of sexual activity and
infertility: thus, the main medical interests in this syndrome are to enable inter-
course through vaginoplasty and genetic motherhood through oocyte retrieval
and surrogacy or - more recently - uterus transplantation. Oocyte retrieval is
not standardized in MRKH patients: due to reduced vaginal length or to adhe-
sions resulting from previous surgical vaginoplasty,the routine transvaginal tech-
nique can be challenging and a laparoscopic or percutaneous approach can be
needed.
Study design, size, duration: MRKH patients undergoing laparoscopic
vaginoplasty between august 2017 and december 2017 at the IRCCS San
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Raffaele Hospital (Milan, Italy) who expressed a desire for future motherhood
were offered concomitant controlled ovarian stimulation and laparoscopic
oocyte retrieval.
Participants/materials, setting, methods: After psychological and medical
counselling, three patients aged 17, 17 and 21 gave informed consent and
underwent controlled ovarian stimulation according to a GnRH-antagonist
protocol. Final follicular maturation was induced with Gn-RH analogue to avoid
the risk of ovarian hyperstimulation and combined surgery was scheduled 36
hours after. A standard 19 G ovum aspiration needle (Cook, USA) was inserted
through the laparoscopic ports for oocyte retrieval and subsequent Davydov’s
laparoscopic vaginoplasty was performed.
Main results and the role of chance: In the ﬁrst, second and third case n =
12, n = 14 and n = 18 oocytes were retrieved and cryopreserved. Subsequent
steps were unchanged compared to the Davydov’s laparoscopic vaginoplasty,
without any additional technical difﬁculty. Postoperative care was also
unchanged and no complications occurred. Compared to delaying oocyte
retrieval, our concomitant approach abolishes the risks of ovarian aspiration in
the presence of post-surgical adhesions as well as the anesthesiologic risks of a
second procedure. Hence, referral to centers with expertise in vaginoplasty but
also in reproductive medicine should be considered in all MRKH patients,and
clinicians involved should contemplate this novel strategy for those MRKH
patients with an indication to laparoscopic vaginoplasty and a desire for future
motherhood.
Limitations, reasons for caution: Further evaluation of the safety of this
novel approach will be of ineterest.
Wider implications of the ﬁndings: Because the doctor-patient relation-
ship is crucial in MRKH syndrome, we envisage that simultaneous treatment of
both the sexual and reproductive functions by a single team will also enhance
patients’ emotional ease and compliance with cares.
Trial registration number:Not applicable.
P-739 A retrospective analysis of the effect of salpingectomy for
hydrosalpinx on in vitro fertilization – embryo transfer
Y. Mizusawa, N. Hayashi, E. Enatsju, K. Katayama, Y. Tokura,
E. Okamoto, S. Yamada, Y. Matsumoto, S. Kokeguchi, M. Shiotani
Hanabusa Women’s Clinic, reproductive health, Kobe, Japan
Study question: What is the indication of salpingectomy for hydrosalpinx in
the patient undergoing in vitro fertilization and embryo transfer?
Summary answer: Salpingectomy is not effective for the pregnancy after the
embryo transfer in patients older 41 years old.
What is known already: It has been demonstrated that, in patients with
hydrosalpinx, the overall success of in vitro fertilization and embryo transfer
(IVF-ET) is lower than expected due to implantation failure, miscarriage and
ectopic pregnancy and it is generally recognized that removal of a hydrosalpinx
can increase the implantation rate of IVF –ET. However, whether salpingec-
tomy affects ovarian reserve is uncertain and the indication of salpingectomy is
not clear as well.
Study design, size, duration: In this study, we compared the result of
oocyte numbers and embryo genesis in 46 and 209 oocyte retrieval cycles in
124 patients after and without salpingectomy for hydrosalpinx between January
2014 and December 2016. Also, we compared the result of 52 and 189
embryo transfer cycles in 124 patients after and without salpingectomy.
Participants/materials, setting, methods:We compared the number of
oocyte retrieval, fertilization rate and the rate of developing to the blasto-
cyst in 27 patients after salpingectomy and 97 patients without salpingec-
tomy for hydrosalpinx. Secondary, we compared the pregnancy rate,
miscarriage rate and the live birth rate after the embryo transfer cycles in
29 patients after salpingectomy and 95 without salpingectomy. For the ana-
lysis of the signiﬁcance, we used chi-square test and t-test and deﬁned the
signiﬁcance as P<0.05.
Main results and the role of chance: In this study, the patients at age 23 to
45 years old were included. There was no signiﬁcant difference in the number
of oocyte retrieval, fertilization rate, and embryogenesis in the patients after sal-
pingectomy and the patients without salpingectomy. Re the results after
embryo transfer, the pregnancy rate was signiﬁcantly higher in patients after
salpingectomy than that of patients without salpingectomy (55.8% versus
39.2%, P = 0.03). The live birth rate was signiﬁcantly higher in the patients after
salpingectomy than that of the patients without salpingectomy (40.4% versus
18.5%, P = 0.0009).The miscarriage rate was lower in patients after salpingec-
tomy than that of patients without salpingectomy (27.6% versus 48.6%, P =
0.07). Analysis by age showed that, in patients younger than 40 years old, the
pregnancy rate and live birth rate for embryo transfer were higher in the
patients after salpingectomy than that of the patients without salpingectomy.
The all result in patients older than 41 years old were similar between the two
groups.
Limitations, reasons for caution: The number of the patients who had sal-
pingectomy for hydrosalpinx was smaller than that who didn’t, and it means
that we need to pay attention to not only the rate of the result but the numbers
of oocyte retrieval and embryo transfer cycles.
Wider implications of the ﬁndings: Salpingectomy for hydrosalpinx is asso-
ciated with better result in embryo transfer, but no effect on retrieval oocyte
number or embryo genesis for the patients younger than 40. This means that
we need to consider carefully for the suggestion of salpingectomy before the
embryo transfer to the patients over 41.
Trial registration number: not applicable.
P-740 Effect of vitamin C on tissue damage and oxidative stress
following tunica vaginalis ﬂap coverage after testicular torsion
M. Shokoohi1, A.A. Khaki1, M. Moghimian2, H. Shoorei3, M. Soltani4,
H. Abtahi5
1Tabriz University of Medical Sciences, Anatomical sciences, Tabriz, Iran
2Gonabad University of Medical Sciences, Physiology, Gonabad, Iran
3Tabriz University of Medical Sciences, Anatomical sciences, Tehran, Iran
4Gonabad University of Medical Sciences, Anatomy and Histolgy, Gonabad, Iran
5Gonabad University of Medical Sciences, Clinical Biochemistry, Gonabad, Iran
Study question: Are the removal of compression syndrome by ﬂap method
and the use of vitamin C can lead to the reduction of testicular tissue damages
induced by testicular torsion/detorsion?
Summary answer: Eliminating the pressure caused by compartment syn-
drome and using vitamin C decreased injuries induced by reperfusion in long-
time testicular torsion.
What is known already: Tunica vaginalis ﬂap coverage may decrease oxida-
tive stress and tissue damage by reducing pressure on the testicles. It was found
that ﬂap coverage reduced tissue damage and oxidative stress as the duration
of ischemia increased. A tunica albuginea incision with a tunica vaginalis ﬂap can
increase oxidative stress after short-term (1 h) ischemia. This may be the result
of the surgical intervention; for this reason, the technique is useful only after
long-term (9 h) ischemia.
Study design, size, duration: This experimental study was performed on 70
adult male Wistar rats weighing 250–300 g. Rats were randomly divided into
two experimental groups: Group 1: testicular torsion for 5 h (T5) with 5 sub-
groups, including, TD5h, TDF5, TDVit.C5, TDFVit.C5, Sham 5h; Group 2: tes-
ticular torsion for 9 h (T9) with 5 subgroups, including, TD9h, TDF9, TDVit.C9,
TDFVit.C9, Sham9.
Participants/materials, setting, methods: Torsion/detorsion, in 28 adults
Wistar rats, was created by 720° counterclockwise rotation of the left testis.
Also, in the same number of rats, testicular torsion was maintained for 5 or 9h
followed by detorsion with tunica vaginalis ﬂap coverage. After blood sampling,
left testis was removed. Then, The Johnsen score, assessment of seminiferous
tubules, and serum’s oxidative stress markers were examined. The dates ana-
lyzed using SPSS 20 and ANOVA test applied for comparing the means.
Main results and the role of chance: The Johnsen score, the diameter of
seminiferous tubules, and thickness of the seminiferous tubule epithelium signiﬁ-
cantly increased in the 5 h testicular torsion group receiving treatment with vita-
min C and tunica vaginalis ﬂap coverage compared with the group receiving
tunica vaginalis ﬂap alone (p≤0.05). The level of testosterone decreased signiﬁ-
cantly in all groups except for the 5 h testicular torsion group receiving treat-
ment with vitamin C and tunica vaginalis ﬂap coverage. The MDA level also
decreased in the group receiving treatment with vitamin C and tunica vaginalis
ﬂap coverage compared with the group receiving tunica vaginalis ﬂap coverage
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alone. The levels of SOD and GPx were signiﬁcantly lower in the group receiving
treatment with vitamin C and tunica vaginalis ﬂap coverage than sham group.
Limitations, reasons for caution: Although this experimental study showed
that ﬂap method could prevent the reduction of spermatogenesis-related to
testicular tissue damages, there are still unknown potential errors and lack of
knowledge about possible side-effects of this method on this condition in the
human’s body; therefore, it can not use in clinical trials.
Wider implications of the ﬁndings: Testicular decompression after testicu-
lar torsion by tunica vaginalis ﬂap technique can provide a protective effect
against tissue damage and oxidative stress after prolonged ischemia and that
such effects were not observed for short-term ischemia. Other studies also
showed the same effect.
Trial registration number: The ethical considerations were based on the
guidelines for laboratory animals from the Research and Technology Deputy of
Gonabad University of Medical Sciences, Gonabad, Iran.
P-741 What is the optimal skin closure technique for 5mm
laparoscopic port-site? – a systematic review andmeta-analysis
N. Mohd Zulkiﬂi1, M. Hamdan1, S.Z. Omar1, W.A.H.Wan Ghazali2
1University Malaya Medical Centre, Department of Obstetrics & Gynaecology, Kuala
Lumpur, Malaysia
2Putrajaya Hospital, Department of Obstetrics & Gynaecology, Putrajaya, Malaysia
Study question: What is the outcome differences between sutured [subcuti-
cular (SC) or transcutaneous (TC)] and sutureless [Adhesive Skin Tape (ST) or
Tissue Adhesive (TA)] 5 mm laparoscopic port-site skin closure technique?
Summary answer: Sutured and sutureless techniques have comparable cos-
metic outcome. In sutured group, TC is better than SC while ST is better than
TA in sutureless group.
What is known already: As laparoscopy has become the access of choice
even in complex abdomino-pelvic surgery cases and more abdominal access
ports have been used to assist with the surgery, the concern has now diverted
into the cosmetic outcome of the skin closure. There are various techniques
available, but it is mainly based on the surgeon’s preference and ultimately
patients’ satisfaction and to date, there is no “gold standard” on the technique
particularly in small 5 mm laparoscopic port-site.
Study design, size, duration: Systematic review and Meta-Analysis
Participants/materials, setting, methods: A total of 1053 papers were
identiﬁed through electronic search and after screening, 5 studies (all RCT)
were included for data synthesis. The PRISMA guidelines for randomised con-
trolled trials were used to examine the quality of the studies. All suitable data
were extracted and analysed using Review Manager 5.3 software.
Main results and the role of chance:We found a total of ﬁve studies com-
paring sutured (n = 367) with sutureless (n = 266) techniques. No studies com-
pared closure with non-closure methods. From the studies using sutures, TC
has better cosmetic outcome than SC (MD -0.79 [-1.45, -0.13], n = 104) &
(OR 1.93 [1.29, 2.99], n = 118). In sutureless group, ST has comparable cosm-
esis with TA (OR 0.68 [0.28, 1.64], n = 88) but less reported pain (OR 5.75
[1.14, 28.88], n = 88). Compared with TC, TA has comparable cosmetic out-
come (MD -0.8, [-4.44 to 2.84], n = 112) and no infection or complication such
as hernia were observed in both techniques. Compared with both TC and SC,
ST has comparable cosmetic outcome (MD 0.25 [-0.48, 0.98]), n = 75) and
(MD -0.54 [-1.13, 0.05]), n = 75) respectively. Similarly no infection or compli-
cation were observed in these methods. Closure time were comparable
between sutured group and TA (MD 8.4 [-1.27, 18.07]), n = 89) but slightly
longer than ST (MD 9.7 [0.9, 18.5]), n = 89).
Limitations, reasons for caution: Despite the nature of the randomised
included studies, the results of this study are still subjected to confounders
relating to clinical and statistical heterogeneity. The studies reported the out-
comes differently.
Wider implications of the ﬁndings: Conventional suturing – TC is still an
optimal 5 mm laparoscopic skin closure technique. However, sutureless meth-
ods – TA and ST are able to eliminate risk of needle stick injury. The material
cost of TA is higher than sutures or ST. Further trials should be conducted to
evaluate total cost effectiveness.
Trial registration number: not applicable.
P-742 Robot-assisted myomectomymay improve pregnancy rates
after surgery
S. Huberlant, J. Lenot, V. Letouzey, F. Masia, R. DeTayrac,
S.Warembourg
University Hospital of Caremeau-, Department of Obstetrics and Gynecology and
ART, Nimes, France
Study question: Is robot-assisted myomectomy is efﬁcient for the manage-
ment of myoma?
Summary answer: Among the patients having a desire of pregnancy, more
than half obtained a pregnancy after myomectomy by surgery robot assisted,
mainly spontaneously.
What is known already: Uterine myoma affects 25% of women worldwide.
Conservative surgery for uterine myoma could be proposed in case of infertility,
whatever the size and the number of myomas. Long terms beneﬁts and obstet-
rical outcomes were not very evaluated with the robotic assistance myomect-
omy. The purpose of the study was to evaluate the outcomes of robot-assisted
myomectomy in terms of pregnancy rates (spontaneous and with assistance
reproductive technology).
Study design, size, duration: It is a monocentric retrospective study con-
duced between 2009 July and 2006 April in a French department of gynecology
surgery and assistance reproductive center. 82 patients were referred in the
center for the management of at least one uterine myoma. A robot-assisted
myomectomy was realized by an experimented surgeon. An ofﬁce hystero-
scopy was prescribed 3 months after the surgery.
Participants/materials, setting, methods: 82 patients were included and
36 patients suffering from infertility. with a main time 2,5 years. Inclusion criteria
were the indication of myomectomy (whatever the number) for patient suffer-
ing from infertility or abdominal pain. Age, BMI, time de conceive, number and
size of uterin myoma were reported. The details of surgery were reported as
the operative time and the surgical complications. The main objective was to
evaluated the clinical pregnancy rate.
Main results and the role of chance: The mean age of patients was 36
years old (± 6). 45% of the patients suffered from an overweight.
The mean number of myoma was 2 (± 1.5) with a mean size of 65.9mm (±
20.3) and a middleweight of 150 g (± 137) for the most voluminous myoma. The
opening of the uterine cavity was noticed in 15.8% of the cases investigated.
Post operative hysteroscopy was performed 3 months after the surgery for
31 patients (85%). 2 cases of intra uterine adhesions were diagnosed and trea-
ted during the ofﬁce hysteroscopy. 4 hysteroscopy resections for secondary
myoma and one septum resection were also reported.
The clinical pregnancy rate was 32.8% (25 patients) which 51% of the infertile
patients. The mean time to conceive was 18 months after surgery (±12.9). 8
pregnancies were obtained after assistance reproductive technology (28.6%).
Among clinical pregnancy, 4 (14.3%) miscarriages were diagnosed and 2 cases
of fœtal death (7,1%) and one pre term delivery (3,6%) were reported. Overall,
the live birth rate was 37 % (22 cases).
Caesarean was performed in 17 cases (70.8%). No case of uterine rupture
has been reported.
Limitations, reasons for caution: The main limitation was the absence of
comparison between robotic-assisted and conventional laparoscopy. These
encouraging results in favour of the robotic assisted myomectomy must be con-
ﬁrmed by randomized studies comparing to results with conventional
laparoscopy.
Wider implications of the ﬁndings: Our results suggest a beneﬁt to per-
form myomectomy with robotic assistance in agreement with the data of litera-
ture. The reduction of the opening uterine cavity could reduce the intra uterine
adhesions and improve the pregnancy rate.
Trial registration number: This study received the agreement of the Ethics
Committee of the university hospital (Institutional review board n°17.02.01)
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P-743 T-shape uterus in the 21st century (post DES era) - we need
to knowmore!
A. Sood1, M. Akhtar2
1Senior Clinical Fellow, Reproductive Medicine, Manchester, United Kingdom
2Consultant- St. Mary’s Hospital, Reproductive Medicine, Manchester, United
Kingdom
Study question: Is T-shaped uterus prevalent in sub-fertile women in post
DES era? What is the effect of hysteroscopic metroplasty on pregnancy rate,
miscarriage rate and live birth rate for these women?
Summary answer: Surprisingly, the prevalence of T shaped uterus is signiﬁ-
cant even today. Hysteroscopic metroplasty is a simple procedure which can
potentially improve outcomes in sub-fertile women.
What is known already: T-Shaped uterus is a rare uterine malformation,
and has classically been associated with “in-utero” exposure of DES (diethylstil-
bestrol). It can be seen as a congenital variant or post infection synechiae rarely.
The reproductive population of today’s date constitute all women who were
born well after the use of DES was completely stopped. The diagnosis of T
shaped uterus can be made with HSG and 2D USS; and today with increasing
use of 3D USS in Reproductive medicine, the detection rates have increased.
The diagnostic criteria, investigation of choice, reproductive outcomes and
treatment options are not well deﬁned for these women.
Study design, size, duration: Systematic review and meta-analysis of
literature.
Participants/materials, setting, methods:
• History of subfertility or poor reproductive outcomes.
• Diagnosis of T shaped uterus on HSG, USS or 3D scan.
• Hysteroscopic metroplasty done.
• Outcomes- pregnancy, miscarriage and live birth rates.
Total no of studies- 16 (7 published and 9 conference abstracts). There is
scarce data on reproductive outcomes after intervention. There is no rando-
mised controlled trial done, the only studies that are available are 9 retrospect-
ive analysis and 7 prospective case intervention studies.
Main results and the role of chance: Systematic review showed potential
beneﬁt from surgical intervention in the form of hysteroscopic metroplasty. It is
reported to improve pregnancy rates and live birth rates and concurrently
decrease miscarriage rates. It was difﬁcult to derive meaningful measure of
improvement due to potential differences and bias in reporting.
Meta-analysis of the data could not be done, because of following reasons:
• No randomised controlled trials.
• Heterogeneous study data – patient population, diagnostic modality and
procedure details.
• Only number of pregnancies achieved mentioned in most of the studies, it is
not clear if the same patient achieved multiple pregnancies subsequently.
• The interval between surgery and pregnancy is not clearly deﬁned and it is
difﬁcult to comment if the intervention in the form of hysteroscopic surgery
was the reason for improved outcome.
Limitations, reasons for caution: Scarce data and reporting bias.
Wider implications of the ﬁndings: There is a need for centralized data-
base for registration of women with T shaped uterine anomalies which can be
either a national or European registry database. This will help in deﬁning clear
diagnostic criteria, surgical indication & technique, and follow up of reproductive
outcomes after the procedure.
Trial registration number:Not applicable.
P-744 Two cases of successful pregnancy after treatment for
uterine cervical pregnancy by transcervical removing pregnancy
contents and hysteroscopic cauterization following laparoscopic
temporally uterine artery ligation
Y. Fukushi, S.Wada, Y. Ohara, T. Fujino
Teine Keijinkai Hospital, Obstetrics and Gynecology, Sapporo, Japan
Study question: Whether the case of uterine cervical pregnancy after treat-
ment of our surgical methods achieve successful pregnancy and have uneventful
delivery?
Summary answer: Two of the seven cases after treatment of our surgical
methods for uterine cervical pregnancy were achieved pregnancy and had
uneventful delivery.
What is known already: There were reports of treatment for uterine cer-
vical pregnancy, for example MTX and/or KCL local injection, uterine artery
embolization, Foley catheter balloon tamponade and hysterectomy, but our
surgical methods: Transcervical removing cervical pregnancy contents and hys-
teroscopic cauterization following laparoscopic temporally bilateral uterine
arteries ligation for uterine cervical pregnancy, has not been described.
Study design, size, duration: Study design: cohort study.
Size: Seven cases of uterine cervical pregnancy.
Duration: between 2003 and 2017.
Participants/materials, setting, methods: materials: Seven cases of uter-
ine cervical pregnancy treated at our hospital.
methods: We examined seven cases of uterine cervical pregnancy from the
medical records.
surgical methods: Transcervical removing cervical pregnancy contents and
hysteroscopic cauterization following laparoscopic temporally bilateral uterine
arteries ligation.
Main results and the role of chance: Two of the seven cases after treat-
ment for uterine cervical pregnancy were achieved pregnancy and had unevent-
ful delivery.
Four patients had a history of previous abortion with uterine cervical dilata-
tion and curettage, two patients had also a history of previous cesarean section.
Median age was 35 years-old( range 29-30), median operative times was
69.5 min(range 54-97), median estimated blood loss was 35 ml( range 10-200)
and median postoperative hospital stay was 2days( range 2-3). All patients had
no conversion to hysterectomy and intra- or postoperative complications.
Limitations, reasons for caution: Limitations: Our experienced cases are
too small numbers but a uterine cervical pregnancy is an extremely rare ectopic
pregnancy, the incidence ranging between 1 in 8000 to 18,000 pregnancies, and
uterine cervical pregnancy represents about 0.15% of all ectopic pregnancies.
Wider implications of the ﬁndings: We experienced seven cases of uter-
ine cervical pregnancy successfully treated with our surgical methods and two
of the seven cases after treatment were achieved pregnancy and had uneventful
delivery. This method may be an effective option in treatment of uterine cer-
vical pregnancy.
Trial registration number: non-clinical trials.
P-745 Clinical pregnancy outcome of secondary infertility treated
by transvaginal repair of previous cesarean scar defect
X. Liu1, W. Liu1, W. Deng1, H. Zhao1, K. Deng2, C.Wu1, J. Wang1
1Shenzhen IVF Maternity Hospital, obstetric and gynecology, Shenzhen, China
2Foshan women and children hospital, Obstetrics and Gynecology, Foshan, China
Study question: The clinical pregnancy outcome of secondary infertility trea-
ted by transvaginal repair of previous cesarean scar defect (PCSD) is still
unknown.
Summary answer: Transvaginal repair of previous cesarean scar defect
(PCSD) can effectively improve the clinical symptoms of PCSD and treatment
of secondary infertility.
What is known already: Transvaginal repair of previous cesarean scar defect
(PCSD) is simple and time-saving, however, its effect on symptoms improve-
ment and pregnancy outcome is not totally understood.
Study design, size, duration:Observation study.
Sample size is 56.
Follow-up duration is 12 months.
Participants/materials, setting, methods: 56 cases of patients with previ-
ous cesarean scar defect in our hospital were selected for transvaginal repair
from Aug, 2015 to Aug,2016. The average age was 35 ± 4.2 years old. The
infertility period is 2-8 years with abnormal uterine bleeding or pubis pelvic
pain. All cases were treated with standard transvaginal repair.Histological
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examination were perfromed after surgery and the size, location, the thickness
of the uterine myometrium were conﬁrmed by ultrasonic examination after 3
months.
Main results and the role of chance: All the operations were successful.
Histology showed ﬁbrous scar and lymphocytic inﬁltration. Abnormal uterine
bleeding or the pain of the pubis pelvis was obviously improved after operation.
Natural pregnancy was obtained in 55 cases after 1 year follow-up, of which 49
were given live birth (89.09%). 6 cases (10.9%) were aborted, and the patients
with abortion were re-examined by B-ultrasound without diverticulum.
Limitations, reasons for caution: The sample size needs further expande.
In this study, infertility was observed as the only complaint and exclused other
male or female-factor infertility. All cases have had a health child.
Wider implications of the ﬁndings: Transvaginal repair of previous cesar-
ean scar defect(PCSD) is desreved to popularization for treating second infertil-
ity due to PCSD.
Trial registration number: not applicable.
P-746 Skilled reproductive surgeons may ensure better outcomes
in infertile patients
V. Vargiu1, V. Versace1, V. Tagliaferri2, A.L. Astorri3,
P.A. Margariti1, A. Lanzone1, G. Scambia1, D. Romualdi1
1Policlinico A. Gemelli” Foundation, Department of Obstetrics and Gynecologic,
Rome, Italy
2Ospedale Generale Regionale Ente Ecclesiastico F.Miulli, Department of Obstetrics
and Gynaecology, Acquaviva delle Fonti, Italy
3International Scientiﬁc Institute “Paolo VI”- Catholic University of the Sacred Heart,
Department of Obstetrics and Gynecologic, Rome, Italy
Study question: Can a skilled reproductive surgeon improve the pregnancy
rate (PR) in patients who undergo laparoscopy for infertility?
Summary answer: A skilled reproductive surgeon can signiﬁcantly ameliorate
pregnancy rate in infertile patients undergoing surgery when a putative cause is
identiﬁed and treated intraoperatively.
What is known already: Unexplained infertility (UI) affects 1/3 of subfertile
couples. The use of laparoscopy in the work-up of these patients is still a subject
of debate, although laparoscopy remains the gold standard for diagnosis and
treatment of several pelvic pathologies. Actually, a high proportion of women
with unexplained infertility or minor abnormalities treated at the time of lapar-
oscopy, conceive spontaneously. In other ﬁelds of gynecological surgery, such
as oncology, the surgeon’s expertise plays a pivotal role in determining the out-
comes. Few data are to date available on this matter in the ﬁeld of reproductive
surgery.
Study design, size, duration: This retrospective observational study
included 83 infertile patients, who underwent surgery (diagnostic/operative
laparoscopy and diagnostic/operative hysteroscopy) at our Institution between
January 2015 and June 2017. The study population was divided in: group 1 (59
patients) operated by reproductive surgeons, and group 2 (24 patients) oper-
ated by non-speciﬁcally skilled surgeons. 9 patients were lost at follow-up. A
questionnaire was administrated in January 2018, in order to establish the PR of
the operated patients.
Participants/materials, setting, methods: The clinical records of women
undergoing laparoscopy for infertility were retrieved from a computerized data-
base. Exclusion criteria were: infertility male factor, overt metabolic or endo-
crine disorders, age >43 years. We analyzed the rate of spontaneous or ART-
induced pregnancies in the two groups after dividing patients on the basis of the
performed surgery (diagnostic-only vs operative). The analysis was conducted
with the Mann-Whitney, Fisher-Exact and Chi-square tests. A p value ≤ 0.05
was considered statistically signiﬁcant.
Main results and the role of chance: The two groups did not differ in
median age (36,0 vs 37,0) and BMI (21.5 vs 23). The PR in group 1 was 40%
(20/50) while in group 2 was 29.16% (7/24) with a p-value of 0.44.
Afterwards, we analyzed the percentage of spontaneous and ART-induced
pregnancy in each group and we found no statistical difference (12/20 vs 7/24,
p-value: 0.068). Even in the subgroups of spontaneous pregnancy, the two
populations did not differ in terms of age and BMI. As a secondary outcome we
found out that 34/83 patients had pathologic ﬁndings at laparoscopy (40.9%):
peritoneal adhesions, minimal-mild endometriosis and hydatid cysts. 4 of them
were lost at FU. Patients were divided into two subgroups: patients who under-
went 1: diagnostic laparoscopy (real UI) (44/74) and 2: operative laparoscopy
(30/74). The overall PR did not differ between subgroups (p-value 0.80).
Within subgroup 1, the PR was 38.6%, and no statistical difference between
patients operated by skilled or non-skilled surgeon was found (34.2% vs 55.5 %,
p-value 0.24). Interestingly, in subgroup 2 the PR of patients operated by a
reproductive surgeon was signiﬁcantly higher of one of patients operated by a
non-skilled surgeon (53.3% vs 13.3%) with a p-value of 0.020
Limitations, reasons for caution: This was a retrospective observational
analysis with a relatively small population. A further limitation is the use of data
obtained by telephone surveys, which implies the risk of under- and
misreporting.
Wider implications of the ﬁndings:Our ﬁndings suggest that skilled repro-
ductive surgeons may ensure better outcomes in infertile patients where puta-
tive causes for infertility are identiﬁed. Based on this contention, infertile
couples should be addressed to specialized Centers in order to maximize their
chance to conceive. Further randomized studies are needed to conﬁrm our
hypothesis.
Trial registration number:Not applicable.
P-747 Who is at risk of endometrial cavity breach at laparoscopic
myomectomy?
K. Rajah, Kriedt K., N. Balanchandren, M. Moghazy, E. Burt,
D. Mavrelos
Reproductive Medicine Unit, University College London Hospitals, London, United
Kingdom
Study question: To examine whether ﬁbroid ultrasound characteristics are
predictive of endometrial cavity breach at laparoscopic myomectomy.
Summary answer: The minimum distance of the ﬁbroid edge from the endo-
metrial cavity is the best predictor of endometrial cavity breach at laparoscopic
myomectomy.
What is known already: It is accepted that submucous ﬁbroids reduce the
chance of spontaneous conception. Intramural ﬁbroids larger than 3 cm have
also recently been shown to affect the chance of conception after embryo
transfer. Submucous ﬁbroids mostly in the myometrium can be removed lap-
aroscopically. One of the risks of surgery is breaching the endometrial cavity
and associated risk of endometrial adhesions. Caesarean Section is often
advised as the mode of delivery for women who have had their endometrial
cavity opened at myomectomy.
Study design, size, duration: This is a retrospective cohort study of women
who underwent a laparoscopic myomectomy from December 2014 to
November 2017. Ultrasound images and operation notes were reviewed. The
size, position and minimum distance of the ﬁbroid from the endometrial cavity
in the longitudinal plane were determined from ultrasound images (negative dis-
tance was scored when the ﬁbroid protruded into the cavity). Endometrial cav-
ity breaches at the time of surgery were identiﬁed from the operation notes.
Participants/materials, setting, methods: This study was carried out at a
central London university teaching hospital. All women who underwent a laparo-
scopic myomectomy were initially included in the study. Women who did not have
a pre-operative ultrasound and those who had more than two ﬁbroids removed
were excluded. Cases with incomplete ultrasound data were also excluded.
Main results and the role of chance: During the study period 74 women
who had laparoscopic myomectomy and a pre-operative ultrasound were iden-
tiﬁed. The median age was 36.0 (IQR 33 – 39.8) and the median ﬁbroid diam-
eter was 68.2 mm (IQR 47.7 – 80.6). 10/74 (13.5%, 95% CI 5.7 – 21.3) had a
breach of the endometrial cavity at laparoscopic myomectomy. Women who
suffered a breach had a ﬁbroid that was close to or within the endometrial cav-
ity (distance from cavity -9.9 vs. 8.9 mm, p = 0.001, degree of protrusion 17%
vs. 0.0% and intracavitary surface area 1463mm2 vs. 0.0). A logistic regression
model with cavity breach as independent variable and ultrasonic variables as
predictors selected minimum distance from cavity as the best predictor of cavity
breach (OR 0.79, 95% CI 0.73 – 0.92). 10/19 (52.6%, 95% CI 30.2 – 15.1) of
women with a submucosal component to their ﬁbroid did not have a cavity
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breach. No women with a ﬁbroid further than 5.2 mm from the endometrial
cavity had a breach identiﬁed at surgery.
Limitations, reasons for caution: This is a retrospective study which could
have led to selection bias. The ultrasound parameters were identiﬁed from
saved ultrasound images and this confers a degree of subjectivity and bias.
There is also possibility that an endometrial cavity breach may not have been
identiﬁed intra-operatively.
Wider implications of the ﬁndings: There has been no previous study
reporting the risk of endometrial cavity breach at laparoscopic myomectomy.
Identifying patients who are at increased risk based on ultrasound facilitates
appropriate pre-operative counselling regarding the risk of intrauterine adhe-
sions and the need for Caesarean Section and more vigilant intra-operative
endometrial cavity assessment.
Trial registration number:Not applicable.
POSTER VIEWING
Safety and quality of ART therapies
P-748 Fertility care: patient journey’s modelling through invoice
data
M. Pasquier1, N. Salaun-Penquer2, B. Haddad3, C. Piétin-Vialle1,
L. Vienet-Légue1, J. Labrosse1, M. Ortala4, H. Bry1, N. Massin1
1Intercommunal Hospital- University Paris XII, Department of reproductive medicine,
Creteil, France
2Kaduceo SAS, Data department, Toulouse, France
3Intercommunal Hospital- University Paris XII, Department of gynecology and
obstetrics, Creteil, France
4Kaduceo SAS, Board, Toulouse, France
Study question: The objective of this study was to build a model of the fertil-
ity care journey based solely on administrative data collected from invoices.
Summary answer: Analysis based on billing data alone is sufﬁcient to build
quick, reliable and usable model in fertility care which is a huge source of
information.
What is known already: Time in fertility care is the most important progno-
sis factor, whether considered as the patient’s age or duration of treatment.
Mastering it is a way to improve the global success rate and the patient’s experi-
ence. One way to tackle this issue is to take a look at the global patient journey
and try to identify pitfalls that could lead to delays in care and impact the
patient’s experience and chances of positive outcome.
Study design, size, duration: It is a longitudinal retrospective study.
Invoicing data usually used for economic purposes were collected and gathered
on a 7 year period and focused on our department of reproductive medicine.
Over 2.4 M patient ﬁles from January 2010 to December 2016 were studied.
After extraction, analyses were conducted on data related to all activities of the
center. We rebuilt each patient’s billing history, gathering speciﬁc information
including medical acts, medical units and date of provided care.
Participants/materials, setting, methods: Inspired by customer’s model-
ling and decision tree, we applied ‘big data” statistical approach to create a
model displaying in a universally readable format the overall patient journey.
We identiﬁed key steps, and calculated statistics to show time estimation and
proportion of patients between each steps. In order to verify the quality and
reliability of this model we conducted the same analysis, enriched with medical
data extracted from MediFirst, software specialized in medically assisted repro-
duction ﬁeld.
Main results and the role of chance: We deﬁned a patient journey by
detecting its beginning (ﬁrst appointment) and its end (delivery). 45% of the
patients having a ﬁrst appointment pursue a treatment, 39% with intra-uterine
insemination (IUI) and 61% with embryo transfer (ET). The ﬁrst attempt occurs
after 7 months (median) from the ﬁrst appointment, faster for IUI than for ET
(5 vs 6 months). We observed that 2 appointments were sufﬁcient for 80% of
the women to begin the IUI process but 3 or 4 were required for ET. Time for
delivery is shorter for ET than for IUI (17 vs 22 months). After // a 3-year fol-
low-up period the success rates are similar for IUI and ET: 64% of pregnancies
and 50% of deliveries. Comparison of the two models showed that there were
less than a 5% differences for each proportion tested. In conclusion, analysis
based on billing data alone is sufﬁcient to build quick, reliable and usable models
in fertility care. This model is a huge source of information for the patients and
the practitioners. The immediate results and concrete use of this study were a
drastic reorganization in our facility practices, leading to reduced waiting time
before beginning fertility treatment.
Limitations, reasons for caution: The reliability of the results depends on
the quality of track keepind and encoding by medical staff.
Wider implications of the ﬁndings: The model has the potential to not
only inform the patient about the overall process awaiting him, but also give a
clear picture of the organization of an healthcare unit and areas to be improved.
The strength of this model is to be transposable to virtually any medical unit.
Trial registration number: not applicable.
P-749 Risk evaluation for pronuclear transfer using for preventing
the transmisson of mitochondrial disease: a mousemodel
L. Tianjie1, Y. Yang2, Q. Jie2
1peking university third hospital, OB/GYN, Beijing, China
2Peking University Third Hospital, Reproductive Center- OB/GYN, Beijing, China
Study question: Is it safe to prevent transmission of mitochondrial disease
using pronuclear transfer as a mitochondrial replacement technology?
Summary answer: There is a potential risk in pronuclear transfer offspring in
metabolism.
What is known already: Pathogenic mitochondria DNA (mtDNA) mutation
is closely linked with many mitochondria diseases that usually lead to fatal
results such as premature death. MtDNA is transmitted maternally within
oocyte cytoplasm. Management of mitochondrial disease is limited due to its
characteristic inheritance. Pronuclear transfer is considered to be effective in
preventing the transmission of pathogenic mtDNA from mother to offspring.
Study design, size, duration: Pronuclear transfer technology were per-
formed between zygotes of CD-1 mice to obtain constrocted zygotes and off-
spring. We preformed 263 zygotes to assess embyoes development and 40
PNT offsprings to evaluate risk of PNT procedure.
Participants/materials, setting, methods: The constructed zygotes pro-
duced by PNT was fused by electrofusion. By testing mitochondria DNA copy
number, the ratio of donor mitochondria was calculated. The cell number of
balstocyst was counted and gene expression proﬁling was identiﬁed by NGS
technique. Then PNT blastocyst were transferd to pesodu-pregnant mice. For
PNT offspring, the body weight, ratio of fat/weight and energy expenditure
were measured. The reproductive function was also assessed both in female
and male PNT offspring.
Main results and the role of chance: The development efﬁciency was sig-
niﬁcantly decreased in PNT embryos compared with normal control embryos.
Compared with normal fertilized embryos, total cell numbers of the blastocysts
from PNT technology were decreased signiﬁcantly, and a large amount of genes
showed the abnormal expression levels. But there were no signiﬁcant differ-
ences between neonatal body weight and plancenta weight. the ratio of donor
mitochondria was no more than ﬁve percent. However, the quality of PNT
blastocysts was declined. Compared with control blastocysts, implantation rate
and birthrate in PNT blastocysts were all impaired.
For PNT offspring, compared to the controls, the body weight, ratio of fat/
weight, energy expenditure, blood pressure and glucose tolerance showed no
difference both in female and male pronuclear transfer mice. Estrous cycle, his-
togical analysis of ovary and fertility were normal in female pronuclear transfer
mice, so were the testicular morphology, sperm concentration and fertility in
male pronuclear transfer mice. However, a considerable of genes were differen-
tially expressed between pronuclear mice and control group.In tissues where
mebabolism were more vigorous like brain, heart, liver and muscle, an abun-
dant of genes showed the abnormal expression levels. Differentially expressed
genes were highly related in metabolism, which suggest a potential risk of pro-
nuclear transfer offspring.
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Limitations, reasons for caution: The ratio of donor mitochondria was not
assessed in all tissues of PNT offspring during the whole life cycle. In addition,
the F2 mice of PNT mice were not evaluated throughout the whole life.
Wider implications of the ﬁndings: The result not only emphasize the
potential risk associated with metabolism of PNT procedure using to prevent
transmission of mitochondrial disease but also facilitate a better understand of
the effects of PNT procedure on development of offspring and enhancing the
awareness of improving the outcome of PNT procedure.
Trial registration number:Not applicable.
P-750 To ﬂush or not to ﬂush: A retrospective analysis of follicle
ﬂushing during oocyte retrieval inWales
A. D’Angelo1, A. Mohd Azmil2, A. Ibrahim3,4, Z. Shehadeh5,
G. Kalra5
1University Hospital of Wales- Wales Fertility Institute - Cardiff University-, Wales
Fertility Institute, South Glamorgan- Cardiff, United Kingdom
2Cardiff University, Wales Fertility Institute, Cardiff, United Kingdom
3University Hospital of Wales, Wales Fertility Institute, Cardiff, United Kingdom
4Cairo University, Obstetrics and Gynaecology, Cairo, Egypt
5Neath Port Talbot, Wales Fertility Institute, Neath Port Talbot, United Kingdom
Study question: Is follicular ﬂushing during transvaginal ultrasound guided
eggs collection useful to improve outcomes in women undergoing IVF/ICSI
treatment for sub/infertility?
Summary answer: Lower n. of oocytes, mature oocytes, fertilised oocytes in
the ﬂushing, compared to the direct aspiration group. Fertilisation, clinical preg-
nancy rates were not different.
What is known already: The practice of follicle ﬂushing has been a topic of
discussion since ultrasound-guided transvaginal oocyte retrieval was introduced
in 1981. Theoretically, ﬂushing would allow for the retrieval of more oocytes,
and consequently result in greater fertilisation and pregnancy rates. However,
many studies have found no signiﬁcant increase. National Institute of Clinical
Excellence (NICE) guidelines suggest that follicle ﬂushing for women with 3 folli-
cles prior to oocyte retrieval should not be offered, as it increases the length of
the process, the pain experienced without the added beneﬁt of greater num-
bers of oocytes retrieved or higher pregnancy rates.
Study design, size, duration: Data from 221 women who underwent
oocyte retrieval at the University Hospital between May 2016 to April 2017
were retrospectively evaluated. 162 women were included in this study, as 59
had to be excluded due to inadequate information available. 39 women (24.1%)
were noted to have undergone oocyte retrieval with direct aspiration only,
while the remaining 123 (75.9%) had undergone oocyte retrieval with follicle
ﬂushing.
Participants/materials, setting, methods: Procedures at the centre were
performed using 16 gauge double lumen needles. Flushing medium used was
from Origio.Chi square tests performed with P < 0.05 considered statistically
signiﬁcant. To determine a cut off value for the number of follicles needed to be
present at the point of HCG administration, a Receiver Operating
Characteristic (ROC) curve was plotted and the Area under the Curve (AUC)
was calculated.SPSS version 24 was used.
Main results and the role of chance: The total number of oocytes (13.6 ±
6.5 vs 7.7 ± 5.2), the number of mature oocytes (11.7 ± 6.4 vs 6.3 ± 4.6), the
number of fertilised oocytes (7.5 ± 5.3 vs 4.4 ± 3.6), the duration of procedure
(21.8 ± 7.3 mins vs 20.2 ± 5.6 mins) as well as maturation (84.7% vs 83.7%)
and clinical pregnancy rates (30.8% vs 22.8%) were found to be higher in the
direct aspiration only group compared to the ﬂushing group. The chi square
test [χ2 (degree of freedom)] indicated that all of the above, except the dur-
ation of procedure and clinical pregnancy rate, were statistically signiﬁcant.On
the contrary, the ﬂushing group demonstrated higher fertilisation rates (57.8%
vs 54.7%) when compared to the direct aspiration only group. However, these
rates were not statistically signiﬁcant.The area under this curve was measured
to be 0.080 with 95% conﬁdence interval (0.000, 0.181). This area unfortu-
nately, being <0.5, implies that the cut off value of roughly 9 follicles at the point
of HCG administration, below which follicle ﬂushing would be recommended
to obtain at least 3 mature oocytes, may not be accurate.
Limitations, reasons for caution: The suggested cut off value of roughly 9
follicles at the point of HCG administration, below which follicle ﬂushing would
be recommended to obtain at least 3 mature oocytes, derived from the ROC
curve may not be accurate due to a small AUC of 0.080.
Wider implications of the ﬁndings: These ﬁndings, coupled with the ﬁrst
principles of surgery, which dictate that shorter and simpler procedures with
minimal tissue handling can result in fewer complications, form the basis of our
recommendation that follicle ﬂushing should not be routinely performed during
oocyte retrieval.
Trial registration number:None.
P-751 Monozygotic twin gestations after embryo biopsy in
blastocyst stage
F. Sellers1, J. Ten2, J. Ortiz3, J.C. Castillo1, B. Moliner1, R. Sellers2,
R. Bernabeu1
1Instituto Bernabeu, Reproductive Medicine, Alicante, Spain
2Instituto Bernabeu, Embryology, Alicante, Spain
3Instituto Bernabeu, Genetics and molecular biology, Alicante, Spain
Study question: Check if the incidence of monozygotic pregnancies increases
after the transfer of embryos biopsied at the blastocyst stage.
Summary answer: The risk of monozygotic pregnancy is double after the
transfer of embryo biopsied in blastocyst stage.
What is known already: Monozygotic twin pregnancies are associated with
a high number of perinatal complications. It has been demonstrated that the
use of Assisted Reproduction Techniques (ART), with the manipulation of
gametes, especially of the oocyte: intracytoplasmic sperm injection (ICSI),
assisted hatching and blastocyst biopsy, can increase the incidence of this type
of pregnancies.
However, there are no published studies on these monoclonal pregnancies
after biopsied embryos in the blastocyst stage.
Study design, size, duration: Retrospective study carried out from 2014 to
2016, to collect the cases of monozygotic twin gestation after single embryo
transfer with biopsy of the trophoectoderm of blastocysts, compared with a
control group of pregnancies obtained with single embryo transfer cycles with-
out biopsying the blastocysts always having carried out ICSI.
Participants/materials, setting, methods: In the study group we obtained
190 pregnancies after transfer of biopsied blastocysts, 107 were with fresh
embryo transfer and 83 were after cryotransfer of thawed embryos; 102 cases
were with own oocyte and 88 with donated oocyte.
In the control group we obtained 454 pregnancies after the transfer of non-
biopsied blastocysts, 330 were in fresh cycle and 124 after cryotransfer; 101
cases were with own oocyte and 353 with donated oocyte.
Main results and the role of chance: There were 6 monozygotic pregnan-
cies in the group of biopsied blastocysts, and 7 monozygotic pregnancies in the
control group.
The overall analysis shows a frequency of occurrence of monozygotic twin
pregnancies of 1.59% in gestation after transfer of non-biopsied embryos, com-
pared to 3.16% after transfers of biopsied blastocysts, with an ODR: 2.08 (95%
CI: 0.69-6.28) (p = 0.18).
In the individual analysis according to the type of treatment, an increased risk
of monozygotic pregnancies is always observed, except in the case of cryotrans-
fer with own oocyte, but without reaching any statistical signiﬁcance:
– Own oocyte fresh cycle: ODR: 3.1 (95% CI: 0.27-35.32%)
– Own oocyte and cryotransfer: ODR: 0.63 (95% CI: 0.04-10.33)
– Donated oocyte fresh cycle: ODR: 1.38 (95% CI: 0.14-13.43)
– Donated oocyte and cryotransfer: ODR: 4 (95% CI: 0.53-30.08)
Limitations, reasons for caution: Although the risk of monozygotic preg-
nancy is double after blastocyst biopsy, this increase does not become statistic-
ally signiﬁcant due to the few cases collected to date.
Wider implications of the ﬁndings: It is advisable to continue collecting
cases in order to increase the total number of cases to ﬁnd out if this tendency
can achieve any statistically signiﬁcant differences.
Trial registration number:NO.
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P-752 United States rates of elective single embryo transfer tightly
coincide with clinician preferences and approaches to patient
education
J. Anderson
FertilityIQ, Editorial Staff, San Francisco, U.S.A.
Study question: Do United States patients receive pressure from, or are
inﬂuenced by, their clinicians to have elective Single Embryo Transfer (eSET) or
elective Multiple Embryo Transfer (eMET) performed?
Summary answer: Clinician opinion, and the extent to which they educate
patients, strongly coincides with how many embryos a patient receives upon
ﬁrst transfer.
What is known already: Patients in the United States receive eSET in a dis-
tinct minority of cases. Elective single embryo transfer is pivotal in minimizes the
risks to both mother/carrier and offspring.
Study design, size, duration: Patient survey and retrospective analysis of
499 veriﬁed United States IVF patients treated after 2015.
Participants/materials, setting, methods: 499 IVF patients treated in the
United States and eligible for single or multiple embryo transfer were surveyed
on the ways in which they were educated by their clinician, the inﬂuence the
clinician had, and the number of embryos they had transferred. Results were
tabulated and characterized using multi-variate analysis using a 95% conﬁdence
interval isolating for variables pertaining to patient age when treated, year trea-
ted, use of PGS and ultimate treatment decision.
Main results and the role of chance: 91% of patients reported their doctor
made a clear recommendation on the number of embryos to transfer with
nearly-two thirds (65%) of patients believing their clinician had an “equal or
greater say” in the decision than they did. Ultimately, patients complied with
their doctor’s speciﬁc recommendation to a signiﬁcant degree (72% for eSET,
82% for eMET, p <.01).
24% of patients reported no discussion transpired on the risks of multiple
embryo transfer to the mother and 39% reported no discussion on the risks to
offspring. Those patients who were educated on the risks to mother or off-
spring appear more likely (p = .07) to ultimately have eSET performed.
We noted patients who underwent eSET (p=.05) and PGS (P <.01) believe
they were given more time to make a decision and with each passing year more
patients felt their opinion inﬂuenced the decision more than their doctor’s (p
= .06). We noted younger women (under age 37) were more likely to be edu-
cated by their clinician on the risks of multiple embryo transfer (p = .01) and
older women on the beneﬁt it confers (p=.02), in this case, higher rates of suc-
cess upon ﬁrst transfer.
Limitations, reasons for caution: Retrospective analysis without
randomization.
Wider implications of the ﬁndings: eSET rates in the United States are
notoriously low with clinicians claiming patients ask for this and prefer it. This
data suggests otherwise and that clinician practice and educational procedures
may have a meaningful inﬂuence. eSET is effective in helping avoid perinatal and
post-natal medical and ﬁnancial deleterious effects.
Trial registration number:Not applicable.
P-753 No differences found of Small for Gestational Age (SGA)
between Fresh Embryo Transfer (ET) babies and Spontaneously
Conceived (SC) ones
P. Boyer1, A. Beltran Anzola2, V. Pauly3, R. Sambuc2,3, O. Riviere4,
F. Venditelli4, M.J. Gervoise Boyer1
1Hôpital Saint-Joseph, Laboratoire de Biologie de la Reproduction, Marseille Cedex
08, France
2Aix-Marseille Université - Faculté de médecine, Département de Santé Publique et
Maladies Chroniques- Unité de recherche EA 3279, Marseille, France
3Assistance Publique Hôpitaux de Marseille, Service d’information médicale,
Marseille, France
4Université Claude Bernard Lyon 1, AUDIPOG Association des Utilisateurs de
Dossiers informatisés en Pédiatrie- Obstétrique et Gynécologie-, Lyon, France
Study question: Are babies born after Fresh Embryo Transfer more exposed
to a risk of being SGA rather than babies born after SC as previously published?
Summary answer: The incidence of SGA in babies conceived after fresh
embryo transfer (6.9%) is not higher than in babies born after a SC (6.8%).
What is known already: The literature has shown that singletons born after
a fresh Embryo Transfer (ET) conceived after In Vitro Fertilization (IVF) either
with or without micromanipulation IntraCytoplasmic Sperm Injection (ICSI)
have an increased risk of low birth weight under 2500 g, preterm birth before
37 gestational weeks, congenital anomalies and SGA, compared to singletons
born after SC. Several studies suggested that the increase for SGA in babies
born after fresh ET could be due to the ovarian stimulation.
Study design, size, duration: The study design was a historical exposed and
unexposed cohort of singletons conceived after Fresh ET (exposed group)
matched to singletons conceived after a SC (unexposed group). The exposed
group involved 1961 singletons conceived after IVF or ICSI between 1995 and
2015. The unexposed group involved 5883 singletons issued from French
AUDIPOG sentinel network, and born in the same period.
Participants/materials, setting, methods: The study involved 7844 single-
tons (>22 weeks or >500 g).Three babies born after a SC were matched on
the year of birth, maternal age, parity, and sex. SGA was deﬁned as a birth
weight below the 5th percentile. A univariate analysis using Generalized
Estimating Equations (GEE) for correlated data was performed to compare
maternal background, obstetric parameters and perinatal outcomes. To analyse
the factors inﬂuencing the incidence of SGA a multivariate analysis using GEE
were performed.
Main results and the role of chance: In univariate analyses, SGA incidence
was similar between babies born after fresh ET 135 (6.9%) and babies born
after a SC 399 (6.8%) (p = 0.856) while the incidence of low birth weight
(8.6%) was higher in the exposed group in comparison to SC babies (7.0%) (p
= 0.021).
In the multivariate analysis, the transfer of fresh embryos did not affect the
incidence of SGA (aOR 1.0 [95%CI 0.8-1.3]). This result contrasts with previ-
ous reports and may be partially due to the day of embryo transfer. Indeed, in
our exposed group, we have a considerable rate of transfer in D5 (47.6%). A
transfer at D5 is nearest to the physiology of implantation which may favour the
Single ET at this stage and increases the birth weight. In addition, selected
matching criteria could be also explaining this absence of SGA risk. In fact, these
factors are already known to be related to higher rates of SGA.
The signiﬁcant factors inﬂuencing the SGA incidence were a low rate of multi-
parity (aOR 0.5 [95%CI 0.3-0.7]), an advanced maternal age (aOR 1.0 [95%CI
1.0-1.0]), maternal underweight (aOR 1.5 [95%CI 1.1-2.1]), maternal smoking
behaviour (aOR 1.9 [95%CI 1.4-2.4]), and high blood pressure induced by preg-
nancy (aOR 2.4 [95%CI 1.8-3.4]).
Limitations, reasons for caution: The 5th percentile was used to deﬁne
SGA instead of 10th percentile used by most studies. In fact, this deﬁnition var-
ies across studies with conﬂicting results. We wanted to use thresholds which
may represent the more possible situations involving speciﬁc medical
conditions.
Wider implications of the ﬁndings: Fresh ET was often related to SGA.
However, our results suggested that it is rather maternal factors which inﬂuence
SGA incidence. Furthermore, a higher rate of D5 (47.6% vs 27.0% at national
level) could decrease this incidence, as suggested in a recent study.
Trial registration number: not applicable.
P-754 Obstetric outcome of women with in vitro fertilization
pregnancies hospitalized for ovarian hyperstimulation syndrome: a
retrospective cohort study
L. Hu1, R. Xie1, M.Wang1, Z. Bu1,W. Dai1, C.Wang2, Y. Sun1
1First Afﬁliated Hospital of Zhengzhou University, Center for Reproductive Medicine,
zhengzhou, China
2College of Public Health- Zhengzhou University, 100 Kexue Avenue, Zhengzhou,
China
Study question: The aim of this study was to investigate the effects of late
moderate-to-critical OHSS on pregnancy and neonatal outcomes.
Summary answer: OHSS was associated with higher rates of Venous throm-
bosis(VT) and Gestational diabetes mellitu (GDM).
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What is known already: Earlier studies have shown that the pregnancy and
abortion rates increase signiﬁcantly among OHSS patients and that these
patients are more likely to develop adverse pregnancy outcomes such as abor-
tion, growth restriction, PIH, GDM and low neonatal birth weight (LBW).
Study design, size, duration: This is a retrospective cohort study of 9143
eligible patients diagnosed with clinical pregnancy after IVF/ICSI-assisted con-
ception and fresh ET from June 2012 to July 2016. All patients were registered
in our data management system, which was used to save all medical information
of patients trying to conceive through ART.
Participants/materials, setting, methods: All eligible subjects were deter-
mined based on the established inclusion and exclusion criteria, then, a propen-
sity score matching analysis was performed with matching of nine maternal
baseline covariates and the number of multiple gestations. 385 patients (4.9%)
were hospitalized for late moderate-to-critical OHSS and compared to a
matched control group of 1540 patients. The primary outcomes were live birth
rate, preterm delivery rate, miscarriage rate, gestational age at birth (weeks),
obstetric complications and neonatal complications.
Main results and the role of chance: The primary strength of the present
study is elimination of multiple pregnancy impact on obstetric complications
and neonatal complications. Live birth and neonatal complication rates did not
signiﬁcantly differ. The obstetric complications of Venous thrombosis and
Gestational diabetes mellitus (GDM) were signiﬁcantly higher in the OHSS
group (0.5% vs. 0%, OR 0.995 (95% CI 0.988-1.002; P = 0.04); 1.8% vs. 0.6%,
OR 3.150 (95% CI 1.166-8.513; P = 0.017), respectively).The duration of ges-
tation was signiﬁcantly higher in the matched non-OHSS group than in the
OHSS group (38.0 ± 2.2 vs. 38.4 ± 2.2 (P = 0.011), OR 0.100, 95% CI 0.6-
0.08). During hospitalization, 147 (38.2%) OHSS patients underwent paracen-
tesis and/or multifetal pregnancy reduction (MFPR), and the mean hospitaliza-
tion duration was 12.7 ± 6.9 days. Hospital duration, obstetric complication
rate, preterm delivery rate, and HCT and WBC values were signiﬁcantly higher
in the severe and critical OHSS group.
Limitations, reasons for caution: Our study has a limitation, because our
center began measuring AMH from 2016, it was not included in the results of
AMH.
Wider implications of the ﬁndings:OHSS was associated with higher rates
of Venous thrombosis(VT) and Gestational diabetes mellitu (GDM). The surgi-
cal treatment group had increased hospitalization durations and neonatal com-
plications and decreased obstetric complications. OHSS severity increased the
incidences of obstetrical complications and preterm labor but had no effect on
neonatal complications.
Trial registration number:Not applicable.
P-755 Freeze-only versus fresh embryo transfer in full-term
singleton birth: a retrospective cohort study
J. Zhang, L. Sun, M. Du, Z. Li, J. Hu, Y. Feng, B. Zhao, L.Wang
Third Afﬁliated Hospital of Zhengzhou University, Third Afﬁliated Hospital of
Zhengzhou University, Zhengzhou, China
Study question: Investigate whether freeze-only embryo transfer is preferred
than fresh embryo transfer in the full-term singleton low birth weight (LBW)
and small for gestational age (SGA).
Summary answer: Our study suggested that freeze-only embryo transfer
was associated with statistically signiﬁcantly lower rate of LBW and SGA.
What is known already: Improvement in the technology of vitriﬁcation and
increase of single embryo transfer, frozen embryo transfer(FET) cycles have
rapidly increased. Meanwhile, some evidence suggested that FET may increase
the pregnancy rate and perinatal outcomes were less affected by the FET. But
whether freeze-only proposal is preferred than fresh embryo transfer in LBW
and SGA of full-term singleton birth remains controversy.
Study design, size, duration: Retrospective cohort study of none
pregnancy-related complications patients, undergoing freeze-only embryo
transfer (n = 2053) and fresh embryo transfer cycles (n = 2059) resulting in full-
term singletons births between July 2008 and September 2016 at the Center
for Reproductive Medicine of the Third Afﬁliated Hospital of Zhengzhou
University.
Participants/materials, setting, methods: The singleton full-term births
via IVF/ICSI were included. Cycles with pregnancy-related complications,
donor oocytes, PGD/PGS, vanishing twins or incomplete records were
excluded. Primary outcome measures were full-term LBW (birthweight
<2500 g) and SGA ( <10th percentile for gestational age). Secondary outcome
measures were neonatal birthweight, LGA (>90th percentile for gestational
age) and macrosomia (birthweight ≥4000 g). And we used logistic regression to
adjust for the baseline characteristics between two groups to minimize the
potential confounding factors.
Main results and the role of chance: Neonatal birthweight in singleton
born after freeze-only embryo transfer was higher compared with singleton
born after fresh embryo transfer (3468.7 ± 475.3 vs. 3386.7 ± 448.1;
p<0.001). The frequency of full term singleton LBW and SGA after freeze-only
embryo transfer was signiﬁcantly lower than that after fresh ET (1.7 % vs. 3%;
4.4 % vs. 6.7 %), for the adjusted rate ratio of 0.59(95% CI, 0.37 to 0.98; p =
0.026); 0.73(95% CI, 0.55 to 0.99; p = 0.041). While freeze-only embryo trans-
fer resulted in a higher frequency of macrosomia (15.1% vs 10.2%) than fresh
ET, for the adjusted rate ratio of 1.43(95% CI, 1.16 to 1.75; p = 0.001).
Furthermore, the incidence of LGA was signiﬁcantly higher in the freeze-only
embryo transfer than in the fresh-embryo group (22.8% vs. 17.5%), for a rate
ratio of 1.26 (95% CI, 1.07 to 1.49; P = 0.007).
Limitations, reasons for caution: The current study is a retrospective
cohort study, prospective studies are required to validate the freeze-only
protocol is preferred than fresh embryo transfer in LBW and SGA.
Furthermore, the pathogenesis of LBW in IVF/ICSI remains unclear, this study
did not explore other relevant mechanisms.
Wider implications of the ﬁndings: Our study suggested freeze-only
protocol was preferred than fresh embryo transfer of LBW and SGA. FET is an
important supplement for fresh embryo transfer, while whether freeze-only can
be the ﬁrst choice requires further clinical and fundamental research.
Trial registration number:N/A.
P-756 A survey on standardization of practice in Ultrasound in
ART, gynaecology and early pregnancy
A. Urazbayeva1, A. Horne2, N. Vermeulen3, E. Kirk4, A. D’Angelo5
1Pilgrim Hospital, United Lincolnshire Trust, Boston, United Kingdom
2MRC Centre for Reproductive Health- University of Edinburgh, Centre for
Reproductive Health, Edinburgh, United Kingdom
3ESHRE, Central Ofﬁce, Grimbergen, Belgium
4Royal Free Hospital, Obstetrics and Gynaecology, London, United Kingdom
5University Hospital of Wales- Cardiff University, Wales Fertility Institute, Cardiff,
United Kingdom
Study question: Is there a need for standardization of practice in Ultrasound
in ART, gynaecology and early pregnancy?
Summary answer: The results of this survey support the development of
good practice recommendations on the use of ultrasound in ART, for gynaeco-
logical pathology and early pregnancy.
What is known already: Ultrasound practise is essential in ART, as many
every day activities in the fertility units are ultrasound-based. However, there
seems to be a large variation in the way ultrasound is performed, both in indi-
vidual approach and between different countries. Only a small proportion of
countries have national guidance on ultrasound, although are not necessarily
focussed on fertility and early pregnancy. In other countries, ESHRE, RCOG,
NICE, ASRM and ISUOG guidelines are used instead.
Study design, size, duration: Between November 2016 and February 2017
a survey to explore these differences was carried out. The survey included 14
questions, aiming to explore whether there is a role for collating the different
recommendations or guidelines from other societies and for developing stan-
dards in ultrasound in ART and Early pregnancy that could be implemented in
Europe and beyond. The survey was disseminated via mailings and social media.
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Participants/materials, setting, methods: This online survey was con-
ducted among ESHRE members and 333 responses were collected. Most of the
responders (63%) were based in Europe, 20% in Asia, and the remaining 17% in
Africa, America and Australia. Regarding occupation, a majority of responders
(84.9%) was medically qualiﬁed, the remaining included embryologists, nurses,
midwifes, counsellors and managers. Given that experts’ views were extremely
valuable for drawing the conclusion, responders were felt to be with appropri-
ate level of knowledge/experience.
Main results and the role of chance: Regarding the fertility treatment, two-
thirds of the responders (68.4%), mainly from European countries, stated there
is a national body regulating fertility treatments in their country of residence.
Half of the responders from Asia, and approximately 80% of the South
American and African, responded that they do not have guidelines for ART in
their country. Interestingly, but not surprising, in countries with no national
guidelines for ART, ESHRE, ASRM and NICE were the most followed ones.
Regarding guidelines on Ultrasound, only a quarter of the responders stated
that there is a national guideline for ART, gynaecological pathology and early
pregnancy. Most of the responders (85%) stated there is a need for standar-
dized guidelines regulating USS in ART, gynaecological pathology and early preg-
nancy. Notably a number of responders (181) suggested these topics to be
covered in a potential guideline. Finally, a two third of the responders showed
initiative to be included into a guideline development group and a half of the
total number of responders provided their email addresses to be contacted.
Limitations, reasons for caution: Limitations are an absence of experts
interviews and different answers from the same country of residence on
national guidelines.
Wider implications of the ﬁndings: The strength of this survey results are
number of responses, targeted users included and broad views on different clin-
ical topics collected. The results of this survey will support the proposal of
developing recommendations for standardised practice in USS in different
aspects of ART, gynaecological pathologies and early pregnancy.
Trial registration number: none.
P-757 Comparison of pregnancy and perinatal outcomes after
frozen and fresh embryo transfer
S. Lijun, Z. Li, J. Hu, J. Zhang, B. Zhao, Y. Feng
reproductive center of the third afﬁliated Hospital of Zhengzhou University,
Zhengzhou University, Zhengzhou, China
Study question: Does frozen embryo transfer (FET) have better pregnancy
and perinatal outcomes than fresh embryo transfer?
Summary answer: We found no signiﬁcant improvement regarding preg-
nancy and perinatal outcomes in FET compared with fresh embryo transfer.
What is known already: FET has been progressively used during the past
few decades and it becomes an essential part of assisted reproductive technol-
ogy (ART). Extra good quality embryos are preserved in FET for women with
good response to ovarian stimulation, improving cumulative pregnancy rate,
increasing single embryo transfer, decreasing risk of multiple pregnancy and
hyperstimulation syndrome. However, whether FET can improve pregnancy
and perinatal outcomes is uncertain.
Study design, size, duration: A retrospective cohort study was performed
consisting of 8370 FET cycles and 8573 fresh embryo transfer cycles between
January 2008 and September 2016 at our reproductive center.
Participants/materials, setting, methods: Women who underwent FET
and fresh embryo transfer are divided into two groups: FET group (8370
patients) and fresh embryo transfer group (8573 patients). To compare the
rates of implantation, biochemical pregnancy, clinical pregnancy, ﬁrst-trimester
abortion and multiple pregnancy. The incidence of preterm delivery, live deliv-
ery,ectopic pregnancy, pregnancy-induced hypertension, gestational diabetes
mellitus, mean birthweight, low birth weight and congenital malformation were
evaluated.
Main results and the role of chance: After adjusting for confounding fac-
tors, no differences were observed in implantation [adjusted odd ratio (aOR)
0.98, 95% conﬁdence interval (CI) 0.97-1.13], biochemical pregnancy (aOR
0.88 ,95%CI 0.76-1.13), clinical pregnancy (aOR 0.94, 95%CI 0.89-1.02), mul-
tiple pregnancy (aOR 1.12 ,95%CI 0.96-1.27), gestational diabetes mellitus
(aOR 0.82 ,95%CI 0.62-1.12) and congenital malformation ( aOR 0.94 ,95%CI
0.57-1.36) rates of the two groups. Live birth rate (aOR 1.23 ,95%CI 1.15-
1.32) after FET was signiﬁcantly elevated compared with fresh embryo transfer.
And FET showed decreased risks of ectopic pregnancy(aOR 0.83 ,95%CI 0.60-
0.98) and low birth weight (aOR 0.83 ,95%CI 0.82-0.96). Mean birthweight was
higher in the FET versus the fresh embryo transfer (P<0.001). The signiﬁcantly
increased risks of preterm delivery(aOR 1.28 ,95%CI 1.10-1.50), ﬁrst-trimester
abortion(aOR 1.11 ,95%CI 1.07-1.25) and pregnancy-induced hypertension
(aOR 1.63 ,95%CI 1.29-2.12) in FET compared with fresh embryo transfer
were found.
Limitations, reasons for caution: As in all observational studies, the pos-
sible role of residual confounding factors and bias should be considered. In this
study, we were not able to control for confounding factors, such as smoking,
parity and child’s sex.
Wider implications of the ﬁndings: The study suggest that FET do not pre-
sent signiﬁcant beneﬁt in pregnancy and perinatal outcomes compared with
fresh embryo transfer. As a consequence, a comprehensive consideration
should be given when selecting a transplantation program.
Trial registration number:N/A.
P-758 The effect of the underlying type of infertility on
placental-mediated adverse outcomes for patients that used
IVF: a population-level study
A. Lanes1,2, A. Sprague2, A. Leader3, B. Potter4, M.Walker1,2,5
1Ottawa Hospital Research Institute, OMNI Research Group, Ottawa- Ontario,
Canada
2Children’s Hospital of Eastern Ontario, BORN Ontario, Ottawa- Ontario, Canada
3Ottawa Fertility Centre, Ottawa Fertility Centre, Ottawa, Canada
4University of Ottawa, Epidemiology and Public Health, Ottawa, Canada
5The Ottawa Hospital, Obstetrics- Gynecology and Newborn Care, Ottawa, Canada
Study question: To investigate associations between type of infertility and
placental-mediated adverse outcomes among women that used in vitro fertiliza-
tion (IVF) to conceive compared to spontaneous conception.
Summary answer: There was a statistically signiﬁcant increased association
found among births using IVF; speciﬁcally among cases where female factor
infertility was the underlying cause of infertility.
What is known already: Previous studies have found associations between
fertility treatment and stillbirth, and preeclampsia. Additionally, a recent meta-
analysis found an association between fertility treatment and gestational hyper-
tension and placental abruption. Multiple pregnancies among women who used
fertility treatments to conceive have been found to be associated with an
increased risk of preeclampsia. However, it is important to consider the role of
multiple gestations in driving the increased associated risk. Conversely, there
have been studies that found no signiﬁcant association between fertility treat-
ment and preeclampsia once they adjusted for maternal age and parity.
Study design, size, duration: This was a population-level retrospective
cohort study of 200,469 live births and stillbirths in Ontario, Canada from May
2013 through October 2014. This study used fertility treatment data from
CARTR (Canadian Assisted Reproductive Technologies Register) Plus, and
pregnancy and birth outcomes data from BORN (Better Outcomes Registry &
Network) Ontario and the Canadian Institute for Health Information. This
study included all documented births in Ontario, Canada during this period of
time.
Participants/materials, setting, methods: The exposed group included
live births and stillbirths from women that used IVF, frozen embryo transfer,
frozen oocyte IVF to conceive and a control group of births from spontaneous
conceptions during the same time period. Unadjusted logistic regression models
were performed using generalized estimating equations, as well as models
adjusted for maternal age, neighbourhood income level and smoking were gen-
erated for the composite outcome (preeclampsia (PE), placental abruption, still-
birth, small-for-gestational-age), and all individual outcomes.
Main results and the role of chance: Signiﬁcant differences were found for
maternal age, hospital level-of-care and pre-existing maternal health conditions
for births that used IVF to conceive. However, there were no signiﬁcant
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differences among the infertility groups with respect to characteristics of fertility
treatment except for method of insemination.
Births resulting from IVF conceptions were found to be statistically signiﬁ-
cantly associated with an increased risk of the composite outcome (RR: 1.15,
95%CI: 1.01-1.31), as well as PE (RR: 1.74, 95%CI: 1.28-2.35) and placental
abruption (RR: 1.65, 95%CI: 1.12-2.44), as compared to births from spontan-
eous conception. Similarly, female factor infertility was signiﬁcantly associated
with an increased risk of the composite outcome (RR: 1.21, 95%CI: 1.01-1.46),
as well as PE (RR: 2.01, 95%CI: 1.34-3.00). The results remained signiﬁcant
after adjusting for potential confounders.
IVF was associated with a higher risk of preterm birth (<37 weeks) and very
preterm birth (<32 weeks), relative to spontaneous conception, adjusted RRs,
1.64 (95%CI: 1.40-1.93) and 1.74 (95%CI: 1.19-2.56), respectively. When type
of infertility was investigated we found IVF for female factor infertility was most
strongly associated with a higher risk preterm birth: adjusted RRs, 1.77 (95%CI:
1.42-2.20) and 2.40 (95%CI: 1.52-3.80) for <37 weeks and <32 weeks,
respectively, compared to spontaneous conceptions.
Limitations, reasons for caution: This study used comprehensive adminis-
trative data; nevertheless this study was potentially affected by misclassiﬁcation
of the exposure and/or outcome variables, a data quality issue that plagues
studies that use administrative data.
Wider implications of the ﬁndings: The hormonal and/or structural fac-
tors associated with female factor infertility may have affected the implantation
and development of the placenta, leading to an increased associated risk of the
study outcomes. The increased risk among this group should be appropriately
considered and accounted for when delivering IVF conceptions.
Trial registration number: not applicable.
P-759 In Freeze-all strategy Cumulative Live Birth Rate (CLBR) is
increasing according to the number of blastocysts formed in women
<40 undergoing IntracytoplasmIc Sperm Injection (ICSI)
T. Chartomatsidou1, E. Timotheou1, P. Tatsi1, E. Katsoula2,
O. Zafeiratis3, R. Najdecki3, E. Papanikolaou3
1Assisting Nature- IVF Centre- Thessaloniki- Greece, Embryology Lab, Thessaloniki,
Greece
2Assisting Nature- IVF Centre- Thessaloniki- Greece, Midwifery Department,
Thessaloniki, Greece
3Assisting Nature- IVF Centre- Thessaloniki- Greece, Clinician, Thessaloniki, Greece
Study question: Does the number of the formed and vitriﬁed blastocysts
affect Cumulative Live Birth Rate in women undergoing Freeze-all strategy?
Summary answer: CLBR after three frozen/ thawed embryo transfers (ETs)
is increasing respectively according to the number of vitriﬁed blastocysts.
What is known already: Elective freezing of all embryos, followed by frozen/
thawed ET cycles emerged to prevent risk of Ovarian Hyperstimulation
Syndrome and to allow endometrium recovery after Controlled Ovarian
Stimulation. The efﬁcacy of embryo vitriﬁcation allowed Freeze-all policy to gain
popularity. Freeze-all policy, however, should preferentially be performed on
day 5 of embryo culture, in order to minimize the number of abnormal embryos
and consequently to decrease failed ETs and emotional cost. Previous studies
reported better In vitro Fertilization (IVF) outcomes after adopting the Freeze-
all policy, instead of fresh ET. Nevertheless, efﬁcacy in terms of CLBR has not
been studied yet.
Study design, size, duration: This prospective observational cohort study
was performed in 156 women undergoing ICSI with antagonist protocol, with-
out fresh ET. CLBR was compared in three groups of women according to the
number of blastocysts formed and cryopreserved; group A: 1-4 blastocysts (n
= 38), group B: 5-7 blastocysts (n = 66) and group C: ≥8 blastocysts (n = 52).
The CLBR was estimated separately for each group, after completing 3 cycles
of frozen/thawed ETs (two women still have blastocysts frozen for transfer).
Participants/materials, setting, methods: Study was performed from
January 2014 until March 2017 in Assisting Nature IVF Centre, Thessaloniki,
Greece. All cases concerned couples with a female age range of 21-39 years,
with fresh ejaculated sperm. Patients underwent estrogen preparation of endo-
metrium and were divided in three groups according to the number of the
blastocysts vitriﬁed. CLBR was calculated following blastocyst Freeze-all strat-
egy when three thawed cycles had been ﬁnalised.
Main results and the role of chance: There was no difference in the mean
age of each group (34 vs 33 vs 31). The mean blastulation rate was above 50%
of the number of 2 pronuclei (2PN) embryos in each group (p>0.05).
Cumulative Live Birth Rate was 31.51% in group A (1-4 blastocysts), 75.75% in
group B (5-7 blastocysts) and 84.61% in group C (≥8 blastocysts). The above
difference was statistically signiﬁcant (p<0.05) among the three groups.
Limitations, reasons for caution: No sperm quality was taken into account
and no natural cycles were used for endometrium preparation.
Wider implications of the ﬁndings: Adopting Freeze-all strategy after
blastocyst culture can contribute to improve delivery outcome after IVF in
terms of Cumulative Live Birth Rate. The number of the total cryopreserved
blastocysts produced might reﬂect the quality of the oocyte and can successfully
predict the pregnancy outcome.
Trial registration number: not applicable.
P-760 Hospitalization before pregnancy in infertile women treated
with ART, non-ART, or no fertility therapy compared with fertile
women
J.E. Stern1, C.L. Liu2, H.J. Cabal3, D. Gopal3, L. Harvey4,
C.C. Coddington5, S.A. Missmer6, H. Diop2
1Dartmouth-Hitchcock, Obstetrics & Gynecology, Lebanon, U.S.A.
2Massachusetts Department of Public Health, Bureau of Family Health and
Nutrition, Boston- MA, U.S.A.
3Boston University, Biostatistics, Boston- MA, U.S.A.
4Tennessee Department of Health, Division of Family Health and Wellness,
Nashville- TN, U.S.A.
5Mayo Clinic, Obstetrics & Gynecology, Rochester- MN, U.S.A.
6Michigan State University, Obstetrics- Gynecology- and Reproductive Biology, Grand
Rapids- MI, U.S.A.
Study question: Do diagnoses during pre-pregnancy hospitalizations in ART-
treated women, women using non-ART medically assisted reproduction(MAR),
or untreated infertile women, differ from hospitalization diagnoses for fertile
women?
Summary answer: Diagnoses during hospitalizations prior to pregnancy for
women who have ART, MAR, or untreated infertility all differ from pre-
pregnancy diagnoses for fertile women.
What is known already: Compared with fertile women, women who have
been treated with ART or MAR, and those who have unassisted pregnancies
but indicators of infertility, have a greater risk of adverse delivery outcomes
such as low birthweight and prematurity. Prior studies have shown that
infertility-related diagnoses may contribute to these adverse outcomes, but
whether adverse outcomes are most attributed to underlying disease or to
infertility treatment is unknown. One potential indicator of underlying disease
that can shed light on this issue is hospitalization prior to pregnancy and the rea-
sons associated with that hospitalization.
Study design, size, duration: We included 125,206 ﬁrst live-birth deliveries
between 2004 and 2010 to women ≥18 years of age with private health insur-
ance from the Massachusetts Outcome Study for Assisted Reproductive
Technology (MOSART) and evaluated hospital stays for the 5 years prior to
pregnancy. MOSART links ART deliveries from the Society for Assisted
Reproductive Technology Clinic Outcome Reporting System (SART CORS) to
birth certiﬁcates and hospital discharges in the Pregnancy to Early Life
Longitudinal (PELL) data system.
Participants/materials, setting, methods: The study included 7,080 ART
and 1,834 non-ART-MAR deliveries, 1,036 deliveries to women with infertility
diagnosis but no fertility treatment (infertile), and 115,256 deliveries with no
indicators of infertility or treatment (fertile). Demographics, gestational age and
birthweight were obtained from birth certiﬁcates. Diagnoses from PELL were
evaluated for prevalence in each group and then compared among all groups.
Multivariable logistic regression models with fertile group as reference were
adjusted for maternal age, race and education.
Main results and the role of chance: ART, MAR and infertile deliveries dif-
fered from fertile in adjusted odds of low birthweight (<2,500 gms: adjusted odds
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ratio [AOR], 95% conﬁdence interval [CI] 2.8, 2.6-3.0, ART; 2.2, 1.9-2.6, MAR;
1.9, 1.6-2.3 infertile) and prematurity (< 37 weeks gestational age: AOR, 95% CI:
2.9, 2.7-3.2 ART; 2.1, 1.8-2.4, MAR; 1.8, 1.5-2.2 infertile). Common diagnoses at
hospitalization in the ART, MAR and infertile groups included higher adjusted odds
than fertile women of endometriosis (AOR, 95% CI: 12.4, 9.4-16.3 ART; 6.0, 3.5-
10.6 MAR; 22.3, 14.7-33.7 Infertile), reproductive organ disease (AOR, 95% CI:
6.5, 5.5-7.8 ART; 2.1, 1.3-3.4 MAR; 8.1, 5.7-11.4 Infertile), ectopic pregnancy and
miscarriage (AOR, 95% CI: 5.5, 4.4-6.8 ART; 2.8, 1.7-4.6 MAR, 4.7, 2.9-7.6
Infertile), and disorders of menstruation, ovulation, and genital tract (AOR, 95%
CI: 3.8, 2.8-5.2 ART, 4.2 2.5-7.0 MAR, 7.3, 4.5-12.0 Infertile). Diagnoses of disor-
ders of ﬂuid and electrolyte imbalance, psychiatric disorders, and misuse of drugs,
which were most common in the fertile group, did not differ between the groups.
Odds of overweight and obesity diagnosed during hospitalization did not differ
among the fertile, ART, and infertile groups but were signiﬁcantly higher in the
MAR group (AOR, 95% CI 2.2, 1.4-3.6).
Limitations, reasons for caution: The time from pre-pregnancy diagnoses
to ﬁrst pregnancy was not evaluated and diagnoses out of hospital are not
included. ART and non-ART-MAR women may have greater access to care and
thus greater likelihood of hospitalization compared to untreated infertile or fer-
tile women. The population is from a single U.S. state.
Wider implications of the ﬁndings: Women treated with ART and non-
ART-MAR and who are infertile with no treatment, all have elevated odds of
pre-pregnancy hospitalizations for reproductive disorders. The data have impli-
cations for the health of deliveries to these women and suggest that underlying
disease plays a role in outcome in these populations.
Trial registration number: not applicable.
P-761 Single and double embryo transfer provide similar live birth
rates in frozen cycles
A. Racca1,2, P. Drakopoulus1, L. Van Landuyt1, C.WIllem1,
S. Santos-Ribeiro1,3, H. Tournaye1, C. Blockeel1,4, N. Polyzos1,5,6
1UZ Brussel, UZ Brussel Fertility clinic -CRG-, Brussels, Belgium
2University of Genoa- IRCCS AOU San Martino, Academic Unit of Obstetrics and
Gynecology, Genova, Italy
3Santa Maria University Hospital, Department of Obstetrics- Gynecology and
Reproductive Medicine, Lisbon, Portugal
4School of Medicine of the University of Zagreb, Department of Obstetrics and
Gynecology, Zagreb, Croatia
5Dexeus University Hospital, Department of Reproductive medicine, Barcelona, Spain
6Faculty of Health University of Aarhus, Department of Clinical Medicine, Aarhus,
Denmark
Study question: Do live birth rates (LBRs) differ in frozen cycles of women
who received single versus double embryo transfer?
Summary answer: LBRs are similar in women undergoing frozen embryo
transfer (FET) with one or two embryos.
What is known already: FET has become an intricate part of IVF treatment
and is no longer viewed as a mere supplement to fresh embryo transfer.
Although the policy in many IVF centers tends towards single embryo transfer
(SET) in case of a fresh embryo transfer, frozen cycles do not seem to follow
the same pattern since they are still frequently considered as a means to coun-
terbalance a previous failed fresh attempt.
Study design, size, duration: This was a large retrospective cohort study
including all consecutive women who underwent their ﬁrst FET in a tertiary
referral University Hospital between January 2009 and December 2014. Each
patient was included only once in the analysis.
Participants/materials, setting, methods: All eligible patients had vitriﬁca-
tion as the cryopreservation method and underwent single (SET) or double
(DET) FET with either cleavage or blastocyst stage embryos. Our primary out-
come was LBR. Secondary endpoints included biochemical/clinical/miscarriage
and multiple birth rates.
Main results and the role of chance: In total, 3601 patients were included
in the analysis with 1936 (53.8%) having a SET and 1665 (46.2%) having a DET.
Overall, 657/3601 (18.24%) had a live birth. LBR were similar between SET
and DET either for cleavage [100/757 (13.1%) versus 153/1032 (14.8%), p =
0.33] or blastocyst stage FET [256/1179 (21.7%) versus 148/633 (23.4%), p =
0.4). Similarly, ongoing pregnancy rates were comparable between DET and
SET [316/1665 (18.9%) versus 359/1936 (18.5%)]. However, biochemical
pregnancy rates were signiﬁcantly higher in DET, suggesting a higher risk for
early pregnancy loss in case of DET compared to SET [326/1665 (19.6%) ver-
sus 308/1936 (15.9%) p = 0.004]. Multiple delivery rates were signiﬁcantly
higher in women with DET compared to SET [53/316 (16.7%) versus 7/359
(1.9%), p<0.001]. Multivariate logistic regression analysis allowing adjustment
for relevant confounders showed that the number of embryos transferred in
the frozen cycle is not related to LBR.
Limitations, reasons for caution: This is an observational study based on
retrospective data collection. Despite our robust methodological approach, the
presence of biases related to the retrospective design cannot be excluded.
Wider implications of the ﬁndings: This is the largest study providing evi-
dence that both SET and DET may result in similar LBR, albeit multiple preg-
nancy rates are signiﬁcantly lower in case of SET. Therefore, SET should be the
main strategy in women undergoing FET. The higher miscarriage rates in
women with DET warrant further evaluation.
Trial registration number: not applicable.
P-762 Cumulative live birth rate following freeze-only versus
conventional fresh transfer cycles: a population-based cohort study
Z. Li1,2, A.Wang1, M. Bowman2, K. Hammarberg3,4, C. Farquhar5,
L. Johnson3, N. Saﬁ1, E. Sullivan1
1University of Technology Sydney, Faculty of Health, Sydney, Australia
2The University of Sydney, Sydney Medical School, Sydney, Australia
3Victorian Assisted Reproductive Treatment Authority, Victorian Assisted Reproductive
Treatment Authority, Melbourne, Australia
4Monash University, School of Public Health and Preventive Medicine, Melbourne,
Australia
5University of Auckland, Department of Obstetrics and Gynaecology, Auckland, New
Zealand
Study question: What is the cumulative live birth rate following a ‘freeze-
only’ strategy compared with a ‘fresh transfer’ strategy?
Summary answer: Compared with ‘fresh transfer’ strategy, ‘freeze-only’
strategy resulted in a similar cumulative live birth rate among high responders
but signiﬁcantly lower rate among normal/suboptimal responders.
What is known already: Frozen-thawed embryo transfer is associated with
decreased risk of adverse obstetric and perinatal outcomes compared with
fresh embryo transfer. It is unclear whether ‘freeze-only’ strategy should be
offered to all women undergoing assisted reproductive technology (ART)
treatment.
Study design, size, duration: A population-based retrospective cohort
study. This study included 14331 women undergoing their ﬁrst stimulated ART
cycle with at least one oocyte fertilized between 1 Jul 2009 and 30 Jun 2014 in
Victoria, Australia. ART treatment and resulting pregnancy and birth outcomes
were recorded for the stimulated cycle and associated thaw cycles until 30 June
2016, or until a live birth was achieved, or until all embryos from the stimulated
cycle had been used.
Participants/materials, setting, methods: Women were grouped by
whether they had undergone the ‘freeze-only’ strategy (n = 1028) where all
embryos were cryopreserved for future transfer, or the ‘fresh transfer’ strategy
(n = 13303) where the best embryo(s) were transferred in the stimulated fresh
cycle and remaining embryo(s) were cryopreserved for future use. A Cox pro-
portional hazard model was used to evaluate the cumulative live birth rate fol-
lowing ‘freeze-only’ and ‘fresh transfer’ strategy.
Main results and the role of chance: A total of 1028 women undergoing
‘freeze-only’ strategy and 13303 women undergoing ‘fresh transfer’ strategy
who had 1788 and 22334 embryo transfer cycles resulting in 452 and 5126 live
births respectively. The majority of women (61.3%) in the ‘freeze-only’ group
had more than 15 oocytes retrieved in the stimulated fresh cycle compared
with less than one ﬁfth (18.1%) of women in the ‘fresh transfer’ group
(p<0.001). The overall cumulative live birth rate was 44.0% in the ‘freeze-only’
group and 38.5% in the ‘fresh transfer’ group. For high responders (>15
oocytes), the adjusted likelihood of live birth in the ‘freeze-only’ group was
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similar to the ‘fresh transfer’ group (Adjusted hazard ratio (AHR) 0.96, 95%
conﬁdence interval (CI) 0.85–1.09). However, the likelihood of live birth was
lower in the ‘freeze-only’ group compared with the ‘fresh transfer’ group
among normal responders (10-15 oocytes) (AHR 0.71, 95% CI 0.54–0.93) and
suboptimal responders (<10 oocytes) (AHR 0.72, 95% CI 0.49–1.04).
Limitations, reasons for caution: A limitation of this population-based
study is the lack of information available on clinic-speciﬁc protocols for the
‘freeze-only’ strategy and the potential impact on outcomes. Data were not
available on whether the ‘freeze-only’ strategy was used to prevent ovarian
hyperstimulation syndrome.
Wider implications of the ﬁndings: This study presents population-based
evidence on clinical efﬁcacy associated with a ‘freeze-only’ and ‘fresh transfer’
strategy. The ‘freeze-only’ strategy may beneﬁt some subgroups of patients,
including women who are high responders and those who are at risk of OHSS,
but should not be offered universally.
Trial registration number: not applicable.
P-763 Double oocyte pick-up (OPU) for the patients with
diminished ovarian reserve (AHM less than 1.0 ng/ml) and showing
unsynchronized follicle growth during ART treatment
R. Sugiyama, K. Nakagawa, A. Moriyama, R. Sugiyama, K. Nakao,
T. Horikawa, K. Kuroda, S. Takamizawa
Sugiyama Clinic Shinjuku, Reproductive Medicine Center, Tokyo, Japan
Study question: Dose double OPU result in more oocytes available for
patients with diminished ovarian reserve (DOR) and who have shown unsyn-
chronized follicular growth during ART treatment?
Summary answer: For patients with DOR, double OPU could increase the
number of oocytes and usable embryos for embryo transfer in one treatment
cycle.
What is known already: In order to achieve pregnancy, ART treatment can
provide many oocytes in one OPU procedure, which could improve the
chances of selecting the best embryo or blastocyst for embryo transfer. It is dif-
ﬁcult, however, for DOR patients to obtain a plurality of oocytes in one OPU.
On the other hand, clinicians sometimes observe unsynchronized follicle
growth during ovarian stimulation. In those cases, the dominant follicle size is a
crucial maturation trigger, and, subsequently, inadequately developed follicles
are removed at a target of OPU, despite their value to DOR patients.
Study design, size, duration: This is an observational study of 13 women
with DOR (AMH level <1.0 ng/ml) who were recruited between January and
December in 2017. All patients were stimulated with clomiphene citrate (CC)
with or without gonadotropins for ART treatment. When the follicles had
reached ≥17 mm in diameter, this provide a maturation trigger and either
human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone
agonist (GnRH-a) was then administered 35 hours before OPU (ﬁrst OPU).
Participants/materials, setting, methods: During the ﬁrst OPU, smaller
follicles (≤12 mm in diameter) were not punctured. After OPU, ovarian stimu-
lation was restarted with CC with or without gonadotropins to develop the
missed follicles. When these follicles then reached 17 mm in diameter, a matur-
ation trigger using hCG or GnRH-a was administered, and 35 hours later a
second round of OPU was performed. The number of retrieved and developed
oocytes was evaluated. The cleaved embryos were cryopreserved.
Main results and the role of chance: The average age of the patients was
41.6 years, and the average AMH and FSH values on day 3 were 0.47 ng/ml
and 15.1 IU/L, respectively. For the ﬁrst round of OPU, the average progester-
one concentration was 0.6 ng/ml with no recorded incidences of elevated pro-
gesterone concentration. During the ﬁrst OPU session, at least one oocyte was
collected from 12 of the patients.
During the second OPU session, all patients were stimulated by CC with or
without gonadotropins. The average progesterone level at the time of the
second maturation trigger was 15.6 ng/ml. During the second round of OPU,
at least one oocyte was collected from 10 of the patients.
The mean numbers of collected oocytes (/patient) from the ﬁrst and second
rounds OPU were 1.3 and 1.2, respectively, and the total number of the col-
lected oocytes (/patient) was 2.5. During the ﬁrst and second rounds of OPU,
the total numbers of usable embryos for cryopreservation were 10 and 5,
respectively, and as a consequence 12 of the patients were able to obtain cryo-
preserved embryos. Of these 12 patients, 4 were not able to obtain cryopre-
served embryos without a second round of OPU.
Limitations, reasons for caution: This study was limited by a small sample
size. Moreover, only 6 patients received thawed embryo transfer, and 2 of
these achieved pregnancy.
Wider implications of the ﬁndings: Progesterone elevation did not
decrease the pregnancy rate when a fresh embryo transfer was avoided, and it
did not affect the embryo development rate. Furthermore, a random start was
reported for ovarian stimulation. This indicated that the start of ovarian stimula-
tion was not related to the menstrual cycles.
Trial registration number: This study has no RCT status, and, therefore, a
trial registration number was not assigned.
P-764 Assessment of preimplantation genetic testing for embryo
aneuploidies: a SWOT analysis
A. Alteri1, L. Corti1, E. Rabellotti1, L. Privitera1, D. Del Prato1,
E. Papaleo2, P. Vigano’2
1IRCCS San Raffaele Scientiﬁc Institute, Obstetrics and Gynecology Department,
Milan, Italy
2IRCCS San Raffaele Scientiﬁc Institute, Reproductive Sciences Laboratory- Division of
Genetics and Cell Biology, Milan, Italy
Study question: Can a SWOT analysis provide a comprehensive and object-
ive perspective to judge preimplantation genetic testing for embryo aneuploi-
dies (PGT-A) strategy?
Summary answer: This SWOT analysis highlights that preimplantation diag-
nosis has taken the slippery slope of implementation of a novel approach with-
out adequate evaluation of threats and weaknesses.
What is known already: The acceptance by the clinical community of the
PGT-A is still evolving. Currently, the use of PGT-A is steadily increasing due to
the evaluation of all 24 chromosomes by comprehensive chromosome screen-
ing. Moreover, blastocyst biopsy seems to be less harmful than Day-3 biopsy.
PGT-A is now actively marketed as increasing implantation rates, and conse-
quently decreasing time to pregnancy, recurrent miscarriages and repeated
implantation failures. However, current studies do not provide sufﬁciently
robust evidence to consider PGT-A as a proven and beneﬁcial treatment and
whether it should be offered routinely to IVF patients is still at the hearth of the
debate.
Study design, size, duration: The SWOT (strengths, weaknesses, oppor-
tunities, and threats) analysis represents a strategic planning tool of quality man-
agement usually used in business but also adaptable to every ﬁeld of medicine.
The SWOT analysis framework helps focus on the strengths, understands the
weaknesses that can assist in managing and minimizing the threats, and allows
to take the greatest possible advantage of the opportunities available.
Participants/materials, setting, methods: This study is based on material
obtained by searching PUBMED between January 2012 and January 2018, using
the following keywords: ‘preimplantation genetic screening’ or ‘PGS’ or ‘PGT-
A’, alone or in combination with ‘biopsy’, ‘clinical outcome’, ‘RCT’, ‘SET’,
‘obstetrical outcome’, ‘follow-up’. All pertinent articles were carefully assessed
and their reference lists were evaluated to detect other studies that could be
included in this SWOT analysis. Peer-reviewed, English-language journal articles
were included.
Main results and the role of chance: STRENGTHS: There is a general
agreement on ability of PGT-A to increase the implantation rate as conﬁrmed
by three randomized control trials (RCTs) in young and good prognosis popula-
tions and one RCT in advanced maternal age (AMA) patients. Moreover, a
reduction of miscarriage rate was observed only in AMA population, with a
consequent decrease of time to pregnancy.
WEAKNESSES: Only three RCTs, have been published with biopsy at the
blastocyst stage, all of which have been criticized because of poor study design.
The RCT in AMA patients was performed considering cleavage-stage biopsy.
Cumulative live birth rate remains unchanged. A critical issue is the manage-
ment of mosaicisms.
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OPPORTUNITIES: PGT-A offers the possibility (i) to perform a single
embryo transfer, decreasing multiple pregnancies, (ii) to reduce time to achieve
a healthy live birth and (iii) to assist with patient counseling regarding expecta-
tions and outcomes.
THREATS: The high cost, the invasive nature, the poor standardization and
the very limited data about obstetrical/perinatal outcomes and about long-
term effects represent drawbacks and hazards when PGT-A is offered routinely
to IVF patients.
Limitations, reasons for caution: It is necessary to consider that a SWOT
analysis only covers issues that can deﬁnitely be considered a strength, a weak-
ness, an opportunity or a threat. Moreover, it is not able to prioritize issues and
to provide solutions offering alternative decisions.
Wider implications of the ﬁndings: These ﬁndings are alarming in regard
to the effectiveness and accuracy of the procedure. They also highlight the
importance of high quality relevant RCTs that are urgently needed.
Trial registration number:Not applicable.
P-765 Letrozole and risk of major congenital malformations: a
systematic review andmeta-analysis
J. Pundir1, P. Bhide2, L. Sabatini1, R.S. Legro3, L. Rombauts4,
H. Teede5, A. Coomarasamy6, S. Thangaratinam7
1St Bartholomew’s Hospital, Centre of Reproductive Medicine, London, United
Kingdom
2Homerton University Hospital, Fertility and Assisted Reproduction-, London, United
Kingdom
3Penn State University College of Medicine, Obstetrics and Gynecology and Public
Health Sciences, Hershey- Pennsylvania, U.S.A.
4Monash University, Reproductive Medicine- Monash Health, Clayton, Australia
5Monash University, Monash Centre for Health Research and Implementation,
Clayton, Australia
6University of Birmingham, Tommy’s National Centre for Miscarriage Research,
Birmingham, United Kingdom
7Queen Mary University of London, Women’s Health Research Unit- The Blizard
Institute, London, United Kingdom
Study question: Is letrozole, used for ovulation induction (OI) or Assisted
reproductive treatment (ART) associated with increased risk of major congeni-
tal malformations compared with other agents?
Summary answer: Letrozole is associated with signiﬁcantly lower risk of
major congenital malformations compared with clomiphene and no signiﬁcant
difference when compared with natural conception or gonadotrophins.
What is known already: OI agents such as clomiphene have been used in
sub-fertile women with anovulatory cycles or unexplained infertility and in ART
cycles. Letrozole, an aromatase inhibitor, has many advantages over clomi-
phene, but has not been approved for OI. It is classiﬁed as a category ‘x’ drug,
primarily due to a conference presentation in 2005, suggesting that, it is asso-
ciated with higher risk of major congenital malformations when compared with
low risk naturally conceived babies, despite the fact that this paper had meth-
odological concerns, raising questions on its validity.
Study design, size, duration: Systematic review and meta-analysis of rando-
mised and non-randomised controlled trials that evaluated the risk of major
congenital malformations in babies born with the use of Letrozole in infertile
women.
Participants/materials, setting, methods: We searched MEDLINE,
EMBASE, Cochrane library, Register and Meta-register for RCTs, and WHO
trials’ search portal without any language restrictions. Studies that evaluated
infertile women undergoing fertility treatment (OI or ART cycles) and com-
pared letrozole with natural conception or other agents and reported on risk of
major congenital malformations in the newborn were included. We pooled the
results using ﬁxed effects meta-analysis and reported the ﬁndings as relative risk
(RR) with 95% conﬁdence intervals (CI).
Main results and the role of chance: We included seven studies which
enrolled 2603 babies born from OI and 5 studies with 37,349 babies born from
ART cycles.
Comparison with Clomiphene - Pooling the data from 8 studies which com-
pared letrozole with clomiphene (7 studies for OI; one study for fresh ART
cycle), letrozole was associated with signiﬁcantly lower risk of major congenital
malformations when compared with clomiphene (RR 0.62; 95% CI 0.39, 0.99;
p = 0.05; I2 = 0%; n = 2455).
Comparison with Natural conception/natural cycle ART - Pooling the data
from 7 studies which compared letrozole with natural conception or natural
cycle ART (3 studies for natural conception; one study for fresh ART natural
cycle; 3 studies for Frozen embryo transfer in natural cycle), there was no sig-
niﬁcant difference in risk of major congenital malformations between the two
groups (RR 1.13; 95% CI 0.86, 1.49; p = 0.37; I2 = 0%; n = 21,627).
Comparison with gonadotrophins/HRT ART - Pooling the data from 4 stud-
ies which compared letrozole with gonadotrophins or HRT (one study for
gonadotrophin OI; 3 studies for Frozen embryo transfer in HRT cycle) there
was no signiﬁcant risk of major congenital malformations between the two
groups (RR 1.18; 95% CI 0.86, 1.61; p = 0.31; I2 = 0%; n = 18168).
Limitations, reasons for caution: Even though limited to three RCTs and
nine observational cohort studies, this systematic review and meta-analysis pro-
vides safety data on large cohort of babies born following the use of letrozole
for infertility treatment.
Wider implications of the ﬁndings: Letrozole appears to be safe in terms
of risk of major congenital malformations in the newborn of infertile mothers
undergoing fertility treatment with OI or ART. These reassuring safety data
contradict undocumented concerns about the teratogenicity of letrozole and
support its use as a ﬁrst line OI agent.
Trial registration number:NA.
P-766 Analysing risk factors for monozygotic multiple pregnancy
after single embryo transfer in the Japanese national ART registry
Y. Ikemoto1, A. Ochiai1, S. Yamashita1,2, S. Ikuma1, S. Nojiri3,4,
K. Kuroda1,5
1Juntendo University Faculty of Medicine, Obstetrics and Gynecology, Tokyo, Japan
2Oita University Faculty of Medicine, Obstetrics and Gynecology, Oita, Japan
3Juntendo University, Medical Technology Innovation Center, Tokyo, Japan
4Juntendo University Hospital, Clinical Research and Trial Center, Tokyo, Japan
5Sugiyama Clinic Shinjuku, Obstetrics and Gynecology, Tokyo, Japan
Study question: To determine the prevalence and risk factors for monozy-
gotic multiple pregnancy (MMP) after single embryo transfer (SET).
Summary answer: The prevalence of MMP after SET was 0.68%. The risk
factors for MMP after SET included frozen-thawed embryo transfer, blastocyst
culture and assisted hatching (AH).
What is known already: In Japan, the prevalence of multiple pregnancy after
assisted reproductive technology (ART) decreased from approximately 10% in
2007 to 3% in 2014 owing to the proposed SET recommendation by the Japan
Society of Obstetrics and Gynecology (JSOG) for the reduction of multiple
births in 2008. Therefore, to improve the clinical pregnancy rate in Japan,
increased elective SET using blastocyst transfer, frozen-thawed embryo transfer
and AH had been increased. Blastocyst culture was reported to be a risk factor
for monozygotic twinning after SET. However, other risk factors for MMP after
SET were poorly understood.
Study design, size, duration: A retrospective observational study was per-
formed based on registered ART data from the JSOG between 2007 and 2014.
Among 937,848 SET cycles, 274,605 pregnancies were recognised. The present
study was approved by the Registration and Research Subcommittee of the
JSOG and our hospital’s ethics committee.
Participants/materials, setting, methods: MMP was deﬁned as one gesta-
tional sac (GS) with two or more foetuses or two GSs with three or more foe-
tuses. To identify possible factors affecting the prevalence of MMP, multiple
logistic regression analysis was performed using singleton pregnancy after SET
as control. A P value of <0.05 was deﬁned as statistically signiﬁcant.
Main results and the role of chance: Out of 274,605 pregnancies after
fresh and frozen-thawed SET, 1,863 were MMPs (prevalence rate of 0.68%),
including 1,808 monozygotic twin and 55 triplet pregnancies. Statistical analysis
revealed that the prevalence of MMP after frozen-thawed SET cycles [odds
ratio (OR): 1.34; 95% conﬁdence interval (CI): 1.16–1.55], blastocyst culture
(OR: 1.79; 95% CI: 1.54–2.09) or AH (OR: 1.21; 95% CI: 1.08–1.35) was high-
er than that of singleton pregnancy after SET. In fresh ET cycles, the prevalence
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rate of MMP after one blastocyst transfer was signiﬁcantly higher than that after
SET cycles with cleavage embryos (OR: 2.20; 95% CI: 1.83–2.66). However, no
signiﬁcant difference in ovarian stimulation and fertilisation methods had been
observed.
Limitations, reasons for caution: In the current Japanese ART registry sys-
tem, data regarding frozen-thawed ET do not include information about ovarian
stimulation and fertilisation methods. Moreover, registration for AH had only
been started in 2010.
Wider implications of the ﬁndings: Strict selection of good quality
embryos through blastocyst culture, as well as embryo manipulation using
frozen-thawed embryo transfer and AH to improve pregnancy rates, may
increase the risk of MMP. However, procedures involving an oocyte, such as
intracytoplasmic sperm injection, showed no such increase in risk.
Trial registration number: not applicable.
P-767 Anti-Mullerian hormone level decrease and efﬁcacy of ART
programs in HIV-infected women
F. Selimova1, E. Mityurina1, S. Perminova1, A. Abubakirov1,
N. Kozyrina2
1Research Center of Obstetrics- Gynecology and Perinatology- Ministry of Health of
Russia, 1st Gynecologic Department, Moscow, Russia C.I.S.
2Central Research Institute of Epidemiology of Rospotrebnadzor, Specialized research
labopratory for AIDS epidemiology, Moscow, Russia C.I.S.
Study question: To assess the levels of anti-Mullerian hormone (AMH) and
efﬁcacy of ART programs in HIV-infected women.
Summary answer: Decreased AMH level and low pregnancy rate were
found in HIV-infected women in IVF programs that might be associated both
with infection and HAART.
What is known already: The studies assessing ART efﬁcacy in couples with
HIV-infected women are sparse and controversial. Some of them have demon-
strated that HIV infected patient show a decrease of ovarian reserve para-
meters and a low efﬁcacy of ART programs. Other studies do not ﬁnd any
difference in ovarian reserve parameters, ovarian function stimulation and ovo-
and embryogenesis in HIV-infected women as compared to healthy patients.
Different evidence suggest that the frequency of developing pregnancy ranges
from 6.7 to 24.1%, which is signiﬁcantly lower as compared to non-HIV-
infected women. The reason of low efﬁcacy of IVF program in this patient group
remains unclear.
Study design, size, duration: The prospective case-control study included
113 patients seeking in IVF. The main group included 49 HIV-infected patients;
64 patients with HIV-negative serology were included in a control group. In the
main group, 111 IVF cycles were performed, including 62 treatment and 49
cryocycles; the corresponding number of cycles in control group was 68 and
33, respectively.
Participants/materials, setting, methods: Stimulation of superovulation
was performed according to long IVF protocols and GnRH-antagonist-based
protocols using recombinant FSH and hMG. While preparing the endometrium
in cryocycles, natural estrogen- and micronized progesterone-contaning medi-
cations were used. The infectious status of the patients was assessed based on
the data on the disease stage, viral load, CD4+ count and the duration of
HAART.
Main results and the role of chance: AMH concentration was signiﬁcantly
lower (median, 1.86 vs 2.8 ng/mL; p = 0.006), while FSH levels were statistic-
ally signiﬁcantly higher (7.9 IU/L vs 6.2 IU/L; p = 0.004) in HIV-infected women
group as compared to HIV-negative patients. Analysis of stimulation cycle para-
meters did not show any signiﬁcant differences in the initial or total gonado-
tropin doses or stimulation duration in both groups. However, a lower number
of oocytes (8.5 ± 0.9 vs 12.5 ± 0.7; р = 0.001), mature oocytes (7.1 ± 0.7 vs
9.6 ± 0.5; р = 0.002), zygotes (5.9 ± 0.6 and 8.1 ± 0.4; р = 0.001), cleavage
stage embryos (5.6 ± 0.6 vs 7.8 ± 0.4; р = 0.001) and blastocysts (2.7 ± 0.4 vs
4.5 ± 0.4; р = 0.004) were recovered in HIV-infected patients as compared to
control group. Selective single embryo transfer was conducted on the culture
days 3 or 5 in both groups. A lower frequency of clinical pregnancy was
revealed in patients with HIV infection as compared to HIV-negative women,
both in ART treatment cycles (12.8% vs 38.3%; p = 0.007) and cryocycles
(20.4% vs 51.5%; p = 0.002).
Limitations, reasons for caution: small scale.
Wider implications of the ﬁndings: can be applied on a large number of
patients.
Trial registration number: непригодный
P-768 Impact of vitriﬁcation of cleavage stage embryos versus
slow-freezing method on neonatal outcome: a multicenter
retrospective cohort study with propensity score analysis
F. Gu1, P. Li2, H. Du3, C. Ding1, C. Zhou1, Y. Xu1
1The First Afﬁliated Hospital of Sun Yatsen university, Center for Reproductive
Medicine, Guangzhou, China
2Jiangmen Central Hospital of Sun Yat-sen University, Department of Obstetrics and
Gynecology, Jiangmen, China
3Third Afﬁliated Hospital of Guangzhou Medical University, Center for Reproductive
Medicine, Guangzhou, China
Study question: Does the embryo cryopreservation method have an impact
on the neonatal birthweight of newborns from thawed embryo transfer (TET)
cycles?
Summary answer: Singleton birthweight did not vary signiﬁcantly after a vitri-
ﬁed embryo transfer compared with a slow-frozen cleavage embryo transfer.
Transfer of vitriﬁed Day 3 embryos did not increase the risk of low birthweight
(LBW), macrosomia or other adverse neonatal outcomes.
What is known already: Vitriﬁcation has been successfully used for embryo
cryopreservation and is superior to slow-freezing technique regarding the
embryo survival rate and live birth rate. However, whether the vitriﬁcation
method would affect fetal growth and thus the neonatal outcome is still contro-
versial. Most studies addressed this issue by comparing the neonatal outcome
after transferring vitriﬁed embryos with fresh embryo transfer. So far, compara-
tive data of two cryopreservation methods with respect to the singletons’ birth-
weight outcome is limited.
Study design, size, duration: This research was a multicenter cohort study,
including three large reproductive medical centers in South China. All singleton
neonates born after Day 3 frozen-thawed embryo transfer cycles from January
2012 to December 2015 were analyzed. Each patient contributed only one
cycle per group.
Participants/materials, setting, methods: All singletons born alive after
28th week of gestation were analyzed. Blastocyst transfer, preimplantation gen-
etic diagnosis and intrauterine insemination cycles were excluded. The main
outcome measure is neonatal birthweight outcome including average birth-
weight and the risk of both macrosomia (>4000 g) and LBW (<2500 g).
Propensity score matching was used to select equal-sized vitriﬁed and slow-
freezed cohorts with similar characteristics. Multivariable regression analysis
was then used to explore the impact of freezing methods on neonatal out-
comes by adjusting potential maternal and clinical confounders.
Main results and the role of chance: A total of 1667 cases from vitriﬁed
embryo transfer and 341 babies from slow-freezed group were included. After
propensity score matching, 281 pairs of newborns were ﬁnally generated for
comparison. The median gestational age was both 39 (38-40) weeks in each
cohort and the birthweights were comparable (3188.7 ± 479.0 g vs. 3231.0 ±
469.6 g, p>0.05). There were no signiﬁcant differences between the two groups
on the incidence of LBW (5.3% vs. 5.7%) and macrosomia (6.0% vs. 6.0%). The
incidence of other outcomes including very preterm birth (0.7% vs. 0.4%), pre-
term birth (6.4%vs.7.4%) and sex ratio (49.3% vs 47.2%) were all comparable
between the vitriﬁed and slow freeze groups, p>0.05. In multivariable regres-
sion analysis, freezing methods were not found to be associated with neonatal
birthweight.The odds ratio (OR) for LBW and macrosomia in the vitriﬁed
cohort is 0.93 (95%CI 0.45-1.93) and 1.00 (95% CI 0.50-2.00) compared to the
slow-freezed cohort without signiﬁcant difference.
Limitations, reasons for caution: As a retrospective study, our analysis
depends on previously recorded data. Moreover, researches for the long-term
effects of vitriﬁcation method on the health of children are essential in the near
future.
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Wider implications of the ﬁndings: Vitriﬁcation/warming is not inferior to
slow-freezing/thawing with regard to neonatal birthweight outcome. Based on
this evidence and its superiority regarding clinical outcomes, vitriﬁcation for
cryopreservation will gradually take over the use of slow-freezing in the near
future.
Trial registration number: The study was funded by the National Key
Research and Development Program (2016YFC100205). The authors have no
conﬂicts of interest to declare.
P-769 Key performance indicators (KPIs) based on poor prognosis
patients are more sensitive on evaluating IVF laboratory staff skills:
a prospective cohort study
Y. Du, Y. Chen, Y. Zou, J. Ma, Y. Geng, Y. Zhang
Tianjin Central Hospital Of Gynecology Obsterics, Department of Reproductive
Medicine, Tianjin, China
Study question: Is it better to follow the poor prognosis patients (PPP) com-
pared with the gold standard patients (GSP) in IVF during new lab staff
orientation?
Summary answer: The poor prognosis patients may be a more sensitive
group to the new staff skills.
What is known already: It is clear that given that cryopreservation proto-
cols, vitriﬁcation methods, evolved empirically and still depend heavily on oper-
ator skills, systems to monitor laboratorial performance gained much
importance in Frozen–thawed embryo transfer practice. Consequently, KPIs
are indicators deemed essential for evaluating before implementing a change,
the laboratory’s routine; establishing minimum standards for proﬁciency; moni-
toring ongoing performance within quality management. However, the largest
variable in an IVF laboratory is the patient. For the purpose of measuring the
outcome of the lab, this patient variable needs to be either factored into the
analysis, or attempted to be minimized.
Study design, size, duration: This study is the prospective cohort study
including 1048 infertile patients from June 2016 to December 2017. We per-
formed a two-part prospectively study in IVF. Part A involved 548 infertile poor
prognosis patients; Part B involved 500 infertile gold standard patients.
Participants/materials, setting, methods: Patients were categorized as
PPPs and GSPs group based on age and functional ovarian reserve parameters.
Embryos of both group patients were randomized at the time of cryopreserva-
tion to allocate to senior or junior embryologist group, and all embryos were
frozen with vitriﬁcation. The primary outcome of this study was the implant-
ation rate (IR) per embryo transferred after thawed. We then compared preg-
nancy rates and post-thaw outcome in terms of Morphological survival and fully
intact.
Main results and the role of chance: Part A revealed in 548 poor prognosis
patients, 987 embryos were thawed and Part B involved 912 embryos from
gold standard patients were warmed in 524 cycles. The IR per embryo thawed
by junior embryologists (16.6% (79/475)) was signiﬁcantly lower after transfer
than by senior ones (21.8% (112/512), P = 0.045; χ2 = 4.01) in poor prognosis
patients group. Similarly, embryos fully intact rate thawed by junior embryolo-
gists (79.2 %( 376/475)) was signiﬁcantly lower than by senior ones (84.6%
(433/512); P = 0.033; χ2 = 4.523). The survival rate was similar in both opera-
tors groups (97.3% (462/475) (96.7% (495/512); P = 0.728; χ2 = 0.121) in
poor prognosis patients group. In Part B, gold standard patients, no signiﬁcant
differences were found in implantation-, survival-, or fully intact rates after
transfering the cleavage stage day 3 embryos frozen-thawed by two embryolo-
gists groups, respectively.
Limitations, reasons for caution: Culture media, temperature and gas
levels were similar in the culturing and transfer, but cleavage stage day 3
embryos with poorer grades of morphology were not cryopreserved or trans-
ferred, limiting the ability to generalize our ﬁndings for grades of morphology
not included in this study.
Wider implications of the ﬁndings: The poor prognosis patients may be a
more sensitive group to potentially new product/procedure, even if preclinical
research has been completed.
Trial registration number: not applicable.
P-770 The rising use of ICSI for non-male factor infertility without
evidence of a clinical need or patient advantage
C. Leary, T.K. Cunningham, P. Lesny
Women and Children’s Hospital, The Hull IVF Unit, Kingston-upon-Hull, United
Kingdom
Study question: Is ICSI being increasingly used in Clinics across Europe for
non-male factor infertility and are there any beneﬁts to using the technique
when it is not clinically indicated.
Summary answer: A 16-year review of the incidence of male factor infertility
in a single clinic provides no evidence for declining semen parameters and
necessity for ICSI.
What is known already: Worldwide, approximately two thirds of all ART
procedures performed involved ICSI. It is widely reported that across Europe,
the proportion of ICSI treatment cycles has risen in recent years, regardless of
the etiology of infertility. ICSI carries a number of identiﬁed risks and the bene-
ﬁts for use in non-male factor infertility are limited to mitigating the risk of failed
fertilisation, which occurs in less than 10% of cycles.
Study design, size, duration: To address this question, we thus conducted
a retrospective review of patient notes over a 16 year period for ICSI indication,
usage and outcome (fertilisation and pregnancy).
Participants/materials, setting, methods: In a single clinical IVF setting, an
assessment was conducted of how many patients per annum presented with
semen parameters indicative of ICSI.
Main results and the role of chance: Between 2002 and 2017 a total of
5248 patients were investigated, 2032 were diagnosed as having male factor
infertility on the basis of having one or more semen parameters below the
WHO semen thresholds for normozoospermia. Male factor infertility
accounted for 38.7% (±4.1) patient aetiologies over the study period with no
evidence of rising incidence in recent years (r = 0.001; p = 0.9). Fertilisation
rates were similarly comparable as were pregnancy rates for IVF and ICSI treat-
ments on both an annual basis and for the time-course of the study (p>0.05).
Limitations, reasons for caution: Although statistical power has been
achieved, this is a retrospective study conducted within one clinic. Over the
course of the study period, reference ranges for normal semen parameters
have changed, however the stringency of the applied protocols have changed in
tandem to accommodate for this.
Wider implications of the ﬁndings: The data indicate that the rising use of
ICSI among ART facilities within the past decade has not been as a consequence
of declining semen quality, implying the technique is used for treatment of
non-male factor infertility without a clear clinical indication of its superiority
over IVF.
Trial registration number: not applicable.
P-771 Induced cellular lysis and increased laser exposure during
trophectoderm biopsies can generate low-level mosaic proﬁles: A
prospective study
J.B.Whitney1, C.M. Rios2, R.E. Anderson3, M.C. Schiewe1
1Ovation Fertility, ART Lab, Newport Beach, U.S.A.
2Ovation Fertility Genetics, Lab, Las Vegas, U.S.A.
3SCCRM, ART Clinic, Newport Beach CA, U.S.A.
Study question: Can trophectoderm biopsy technique induce mosaicism
using a technician-induced, manual cell lysis research model?
Summary answer: Prospective induction of cellular damage on research
aneuploid embryos revealed a positive correlation to mosaicism, suggesting that
mosaicism can be a laboratory created artifact.
What is known already: NextGenertion sequencing (NGS) has enhanced
the reporting of mosaicism. The importance of mosaic proﬁles on PGS results is
not well deﬁned, but viable pregnancies have been produced. As increased
mosaicism has been associated with decreased implantation potential, it is rela-
tively unknown how accurately mosaic proﬁles predict the ﬁnal ploidy of the
fetus. It has been proposed that mosaicism may be linked to biopsy technique,
but prospective studies have not been performed. Desiring to offer a transfer
for all patients and encouragement to perform mosaic embryo transfers, the
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reproducibility and accuracy of mosaic reports per entire embryo is not well
studied.
Study design, size, duration: Nine research consented embryos were
thawed as part of a sister concordance study. Upon completion of two stand-
ard biopsy procedures for the original study, the technician attempted to per-
form poor biopsies with emphasis on cellular lysis and increased laser ablations.
A total of 52 samples were tubed, 9-original biopsy, 26-sister concordance
study, 10-poor technique, 5-remaining ICM’s and 2-media blanks. All samples
were blindly analyzed (NGS) by two geneticists and reported according to lab
standards.
Participants/materials, setting, methods: Research consented aneuploid
embryos were selected based on single/dual chromosomal aneuploidies with-
out knowledge of original NGS proﬁles. Vitriﬁed blastocysts were warmed and
cultured in LifeGlobal medium under tri-gas, humidiﬁed atmospheric conditions
at 37°C (≤4 hours). Each blastocyst was biopsied according to standard proto-
cols and video recorded. Samples were blindly assessed using the MiSeq
(Illumia) NGS platform. Standard lab reporting procedures were applied with a
threshold of 30% gain/loss being considered euploid and 30-80% considered
mosaic.
Main results and the role of chance: Evaluating full gains and losses, 49 of
50 samples (98%) achieved concordance. Of the 10 samples with technician
induced lysis, 3 of 10 (30%) reported the full aneuploidy and an additional
mosaic proﬁle. The video review of biopsies showed that as cellular lysis
increased so did the level of genetic noise and presence of mosaicism. Of the 2
biopsies which had >30 additional zona ablations, mosaicism was not observed
but unique low-level noise was observed being strikingly different from all other
samples proﬁles from the same embryo. Most importantly, spent media from a
biopsy which had signiﬁcant lysis was tubed as a “blank”. The latter blank tube
showed ampliﬁcation portraying a chaotic proﬁle, whereas spent biopsy from a
clean biopsy (second blank control) exhibited no ampliﬁcation. The concord-
ance arm of this study, including ICM analysis, showed extreme repeatability.
The efforts made to induce mosaic proﬁles was successful. Of the 3 samples
showing mosaicism, none of the other samples from the embryo, including the
ICM, showed any of the same mosaic aneuploidies.
Limitations, reasons for caution: Mosaicism, and its importance on NGS
calling policies, ultimately impact patient transfer decisions. Mosaic embryos
graded as aneuploid can produce healthy live births, revealing a potential tech-
nical artifact. Upmost importance should focus on proper biopsy technique if
we are to better understand and reduce possible sources of mosaicism.
Wider implications of the ﬁndings: Mosaic proﬁles can be made from
known cell lines within genetic laboratories. Yet, mosaic proﬁles themselves are
not in question, but instead the possible loss of DNA by cellular lysis as a source
of low level mosaicism. Further scrutiny on laboratory procedures is needed to
properly identify true mosaic embryos.
Trial registration number: none.
P-772 Post-cervical ascites at day of oocyte pick-up (OPU) and
OPU+5 days and development of ovarian hyperstimulation
syndrome (OHSS)
A. Pinborg1, A.G.A.H. Grynnerup1, M. Toftager1, J.W. Bogstad1,
L. Praetorius1, A. Zedeler1, K. Loessl2
1Copenhagen University- Hvidovre Hospital, Department of Obstetrics and
Gynaecology, Hvidovre, Denmark
2Rigshospitalet, Fertility Clinic, Copenhagen, Denmark
Study question: Can we deﬁne a threshold of post-cervical ascites at day of
OPU or OPU+5 days that predicts development of moderate to severe OHSS?
Summary answer: A 1mm increase in post-cervical ascites at OPU and
OPU+5 increases OHSS risk by 3.7% (AOR1.037 95%CI 1.013-1.062) and
4.6% (AOR1.046, 95%CI 1.31-1.61), respectively.
What is known already: OHSS is the most severe side effect of ovarian
stimulation with gonadotrophins. Women with polycystic ovarian syndrome
(PCOS) and a high ovarian reserve are at a higher risk of developing OHSS.
During the ovarian stimulation cycle the number of follicles > 10-11 mm on the
day of ovulation trigger is the best clinical predictor of OHSS. Ascites is part of
the deﬁnition of OHSS, but it has never been investigated, whether a certain
cut-off level of post-cervical ascites at day of OPU or OPU+5 days can predict
OHSS and potentially guide when to use a freeze-all strategy.
Study design, size, duration: Secondary analyses of a multicenter RCT on
1050 patients randomized 1:1 to short GnRH-antagonist protocol or long
GnRH-agonist protocol including women from 2009 to 2013 in Denmark. We
used a ﬁxed rFSH (Puregon®) dose of 150IU or 225IU according to age ≤36
years or >36 years. Inclusion criteria were 1. ART cycle, and exclusion criteria
were uterine abnormality, age >40 years, testicular sperm extraction/aspir-
ation and severe co-morbidity. Both normo- and anovulatory women were
included.
Participants/materials, setting, methods: We pooled all patients from
the two arms, who were examined at day of OPU (n = 990). Prediction of
OHSS by the amount of post-cervical ascites in the anteroposterior plane was
examined by receiver operator characteristics (ROC) analyses. Further, the
ability of post-cervical ascites to predict development of OHSS at OPU and
OPU+5 was explored with multivariate logistic regression analyses including
the following explanatory parameters: Age, anovulatory infertility, GnRH-antag-
onist/agonist group and number of retrieved oocytes.
Main results and the role of chance: Of the 1008 patients reaching OPU,
990 patients had post-cervical ascites measured on the day of OPU and at
OPU+5 days. A total of 199 (20%) patients developed moderate to severe
OHSS, including both early and late onset. By ROC curve analysis post-
cervical ascites at day of OPU and at OPU+5 days predicted OHSS with an
area under the curve (AUC) of 0.599 (95% CI 0.559-0.638, p<0.01) and
0.737 (95% CI 0.699-0.774, p<0.01), respectively. The optimal cut-off value
at day of OPU was 4.8 mm with a sensitivity of 41% and speciﬁcity of 79%.
The optimal cut-off value at OPU+5 days was of 10.7 mm (sensitivity 81% and
speciﬁcity 61%).
By logistic regression analysis a 1 mm increase in post-cervical ascites at day
of OPU increased the odds of OHSS by 5.6% (OR 1.057, 95% CI 1.034-
1.080). This association remained signiﬁcant when adjusting for age, anovula-
tory infertility, GnRH-antagonist protocol and number of oocytes retrieved
(adjusted OR 1.037 95% CI 1.013-1.062). At OPU+5 days, a 1 mm increase
in post-cervical ascites increased the odds of OHSS by 6.3 % (OR 1.063, 95%
CI 1.049-1.077) and by 4.6% in the adjusted analysis (adjusted OR 1.046, 95%
CI 1.31-1.61).
Limitations, reasons for caution: We pooled the groups moderate and
severe OHSS including both early and late onset OHSS. This may cause a mis-
match as post-cervical ascites on day of OPU may be better to predict early
than late onset OHSS.
Wider implications of the ﬁndings: Identiﬁcation of early predictors is of
importance for avoiding OHSS. Post-cervical ascites at the day of OPU and
OPU+5 can predict OHSS. However, the accuracy of the test demonstrates
that we cannot rely solely on the threshold of post-cervical ascites in the deci-
sion making of whether to transfer an embryo.
Trial registration number: ClinicalTrial.gov: NCT00756028
P-773 Perinatal outcome in singletons after frozen-thawed
blastocyst transfer: hormone replacement treatment cycles versus
natural cycles
K. Sekigawa, F. Suyama,W. Beck, Y. Mukoda, K. Sasaki, H. Okubo,
M. Sato, S. Hara, S. Ikuta, R. Tokutomi, A. Jinno, S. Akimoto,
H. Tajima, H. Asada, Y. Yoshimura
Shin-yurigaoka General Hospital, Obstetrics and Gynecology, Kawasaki City-
Kanagawa Prefecture, Japan
Study question: Are there differences in perinatal outcomes between single-
tons after hormone replacement cycle frozen-thawed blastocyst transfer (HRT-
BT) and natural cycle frozen-thawed blastocyst transfer (NC-BT) deliveries?
Summary answer: A tendency toward more cases of heavy for date in HRT-
BT was observed, but the difference was not statistically signiﬁcant.
What is known already: Several studies show that the birthweights of single-
tons delivered after frozen-thawed embryo transfer are signiﬁcantly higher than
those delivered after fresh embryo transfer. A contributing factor to the
increased birthweight may be hormonal environment of the endometrium
before or after embryo transfer – and not the frozen-thawed procedure itself.
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There are few studies that compare the mean singleton birthweights after HRT
cycles versus natural cycles.
Study design, size, duration: We performed a retrospective case study of
women who underwent frozen-thawed blastocyst transfer at our hospital with
singleton pregnancy and a live birth after 22 weeks of gestation between 2013
and 2016. The study included 191 singletons born after blastocyst transfer (BT):
HRT-BT; n = 137 and NC-BT; n = 54.
Participants/materials, setting, methods: We compared HRT-BT deliv-
eries with NC-BT deliveries. We measured birth defects, preterm birth (PTB),
hypertensive disorder of pregnancy (HDP), placenta previa, and heavy for date
(HFD). The crude and adjusted odds ratios (AOR) and 95% conﬁdence interval
(CI) were calculated using a logistic regression analysis. Adjustment was made
for the maternal age at BT (categorized in 35≥, 35<) and parity.
Main results and the role of chance: HFD was observed in 30 cases
(21.9%) of HRT-BT and 6 cases (11.1%) of NC-BT (AOR, 2.30; 95% CI, 0.89—
5.9). HDP was observed in 8 cases (5.8%) of HRT-BT and in one case (1.9%) of
NC-BT (AOR, 3.20; 95% CI, 0.39—26.6). PTB was observed in 3 cases (3.2%)
of HRT-BT and 1 case (3.1%) of NC-BT. Placenta previa was observed in 3
cases (2.2%) of HRT-BT and did not occur in NC-BT. Birth defects were
observed in 5 cases (3.6%) of HRT-BT and 1 case (1.8%) of NC-BT. There
were 3 cases of congenital heart disease, 1 case of 7q-, and 1 case of Prader-
Willi syndrome in HRT-BT. There was one case of trisomy 21 in NC-BT. PTB
and placenta previa were rare in this study, thus, we could not calculate the
AOR. A tendency toward more cases of HFD in HRT-BT was observed, but
the difference was not statistically signiﬁcant.
Limitations, reasons for caution: This is a retrospective study based on a
small sample size, performed by a single medical center.
Wider implications of the ﬁndings: The primary factor of increasing cases
of HFD after BT may be the hormonal environment of the endometrium before
or after BT. If duplicated data are included, future studies may show that HRT
cycles are signiﬁcantly associated with more cases of HFD.
Trial registration number: none.
P-774 Twinning in Greece in the recent 10-year period of
2004-2013; comparison of between IVF-conceived and naturally-
conceived twins
I. Dedes1, S. Zachaki2, M. Kalomoiraki2, C. Giannakos3, D. Baroutis4,
S. Gavrili5
1General District Hospital Athens “Alexandra”- Greece, Neonatal Intensive Unit-,
Athens, Greece
2NCSR “Demokritos”- Athens- Greece., Laboratory of Health Physics- Radiobiology &
Cytogenetics-, Athens, Greece
3National Technical University of Athens- Athens- Greece, School of Electrical &
Computer Engineering, Athens, Greece
4University of Athens- Athens- Greece, Medical School of Athens, Athens, Greece
5General District Hospital Athens “Alexandra”- Greece., Neonatal Intensive Unit,
Athens, Greece
Study question: To estimate the twinning rate in Greece during 2004-2013
and possible differences on somatometric characteristics IVF-conceived and
naturally-conceived live born pairs of twins at birth.
Summary answer: The 10-year twinning frequency was 2.6%. The IVF-
conceived pregnancies were 26.7% showing lower birth-weight and gestational
age and higher IUGR frequency compared to the naturally-conceived.
What is known already: One of the consequences of the applied
medically-assisted reproduction, mainly in vitro fertilization (IVF) techniques
for treatment of infertility is the higher rate of multiple gestations and conse-
quently the higher number of high-risk pregnancies. The health problems of
multiple pregnancies in mothers and neonates are more pronounced than
the single type, presenting higher neonatal morbidity and mortality rates.
Comparison of somatometric characteristics between IVF-conceived and
naturally-conceived twins at birth may contribute to the evaluation of the
new medically-assisted reproductive methods to neonates’ health and
development.
Study design, size, duration: We studied all multiple births that took
place in General District Hospital Athens “Alexandra” during a recent 10-
year period, 2004-2013. The “Alexandra” Hospital is the biggest public
university hospital in Greece that carries out a large number of deliveries
annually. For each multiple delivery, number of neonates, mode of concep-
tion, delivery and gestational age were recorded. For all pairs of twins mor-
bidity, mortality, gender, birth weight, and intra-uterine growth retardation
(IUGR) data were recorded.
Participants/materials, setting, methods: We studied all multiple births
in all deliveries that took place in “Alexandra” during a recent 10-year period
(2004-2013). Gender, birth weight, gestational age, mode of conception, deliv-
ery and IUGR data were recorded. Annual incidence of twinning rate was calcu-
lated. Frequency of each characteristic was calculated to show possible
differences between IVF and naturally-conceived neonates. Statistical analysis
for comparing the categorical data chi-square test was used. All tests were per-
formed with p-values set to 0.05.
Main results and the role of chance: During the study period 1,235 mul-
tiple births in all 46,747 deliveries were noted; 45 (3.6%) were triple preg-
nancies and 1,190 (95.4%) double. The 10-year frequency of twinning rate
was 2.6%, with the highest in 2010 (3.4%) and the lower in 2007 (1.6%).
The in vitro fertilization (IVF) pregnancies were 330/1,235 multiple preg-
nancies (26.7%), while the rest 905/1,235 (73.3%) represent natural
conception.
The mortality rate was 82/1,235 deliveries (6.6%); 40 deliveries had one
dead baby and 42 both dead babies. The conception was achieved after IVF in
18/82 (22%) and 64/82 deliveries (78%) were conceived naturally. The mortal-
ity rate was similar between IVF and natural conception.
Concerning the live-born neonates, the frequency of IVF-pregnancies was
25.6% (305/1190) and naturally-conceived was 74.4% (885/1190). Male:
female ratio was 0.88 for IVF-conceived and 1.02 for naturally-conceived neo-
nates. Mean birth weight and gestational age were lower in IVF-conceived neo-
nates than in naturally-conceived neonates; 2096.83 g vs 2162.31 g and 34+1
and 34+5 wga, respectively.
Evaluation for intrauterine growth restriction showed similar frequency of
IUGR neonates between the 2 groups; 37% (113/305) in IVF (65.1% one
IUGR neonate and 34.9% both IUGR neonates) and 38.4% (340/885) in
naturally-conceived neonates (67% one IUGR neonate and 33% both
neonates).
Limitations, reasons for caution: Limitations of the present study include
lack of data concerning the medication taken by the mother during pregnancy
and other pathological conditions such as chorioamnionitis and gestational dia-
betes. Future studies focusing on long-term outcome of IVF-conceived and
naturally-conceived neonates should enable us to draw conclusions about their
course and development.
Wider implications of the ﬁndings: The present study comprises an
attempt to present the twinning rate and pregnancies outcome in Greece dur-
ing the 10-year period 2004-2013. Mortality rates and somatometric character-
istics of the IVF-conceived and naturally-conceived neonates at birth along with
long-term outcome will enable more precise description of growth and devel-
opmental outcomes among twins.
Trial registration number:Not applicable.
P-775 Oocyte donation is not an independent risk factor for
adverse perinatal outcomes in IVF pregnancies: results of a 5-year
cohort in a UK high-risk unit
P. Melo, P.R. Supramaniam, M. Mittal, L.N. Lim
Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Oxford, United
Kingdom
Study question: Does oocyte donation increase the risk of adverse perinatal
outcomes such as preterm birth, low birth weight, postpartum haemorrhage,
stillbirth, neonatal death and low Apgar?
Summary answer: Oocyte donation is not an independent risk factor for
adverse perinatal outcomes when compared with autologous IVF.
What is known already: Female age remains by far the main predictor of
success in IVF, largely due to a loss of ovarian follicle reserve and oocyte quality
as women get older. Oocyte donation has thus become a viable alternative in
recent decades for patients with reduced egg quality or quantity. However,
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there is a paucity of data on the implications of egg donation upon obstetric and
neonatal outcomes for the index pregnancy. In particular, previous analyses
have failed to identify predictors of adverse perinatal events, mainly due to a
lack of information on confounding variables such as maternal BMI and previous
uterine surgery.
Study design, size, duration: This was a retrospective cohort study con-
ducted at the John Radcliffe Hospital in Oxford, UK, a tertiary referral centre.
Demographic data and perinatal outcomes of women with singleton pregnan-
cies resulting in live births after autologous and donor-oocyte IVF were
obtained from electronic hospital records. A total of 792 singleton pregnancies,
delivering between December 2012 and January 2018, were included in the
analysis: 100 (12.6%) resulted from oocyte donation and 692 (87.3%) from
autologous IVF.
Participants/materials, setting, methods: Univariate analysis was initially
performed to identify signiﬁcant differences (p<0.05) between the donor-oocyte
and autologous IVF groups. A multivariate binary logistic regression model with
backward stepwise elimination was then created to identify potential confoun-
ders (e.g. age, smoking, BMI, ethnicity, low-dose aspirin at booking, gestation at
delivery, mode of birth) and determine predictors of poor outcomes (e.g. pre-
term birth [≥24and<37 weeks], need for operative delivery, blood loss
≥1000mL, birth weight<10th centile [small for gestational age, SGA]).
Main results and the role of chance: Overall there were 491/792 (62%)
primigravidas. Median age and BMI were lower in the autologous IVF group (35
vs 43 years,p<0.001; and 23.8 vs 25.4 kg/m2,p = 0.015). Those with donated
oocytes were more likely to take aspirin (18% vs 6.8%,p = 0.001). The rates of
obesity (BMI≥30,p = 0.104), pre-pregnancy diabetes (p = 147), smoking (p =
0.75), previous uterine surgery (e.g.myomectomy/caesarean,p = 0.318) and
chronic hypertension (p = 0.07) were similar in both groups.
Median gestation at delivery was 39 weeks in both groups (p = 0.66). There
was no difference in the rates of preterm birth (9.5%,p = 0.71) and SGA
between groups (9.6%,p = 0.137). Median Apgar at 5 minutes was 10 (p =
0.49). There were 2/792 (0.3%) stillbirths, both occurring in the autologous IVF
subgroup. There were no neonatal deaths.
Women conceiving with oocyte donation were more likely to require
caesarean delivery (72.4% vs 59.6%,p = 0.015) and sustain signiﬁcant haem-
orrhage (26.8% vs17.1%,p = 0.025). Following logistic regression analysis,
independent risk factors for caesarean included previous uterine surgery
(OR5.5, 95%CI 2.07-15.20), primiparity (OR2.88, 95%CI 2.02-4.11), increas-
ing age (OR1.12, 95%CI 1.09-1.16) and higher maternal BMI (OR1.061,
95%CI 1.02-1.10). Caesarean delivery was an independent risk factor for
postpartum haemorrhage ≥1000mL (OR4.18, 95%CI 2.52-6.93). Egg dona-
tion was not independently linked to risk of caesarean (OR0.94, 95%CI
0.51-1.72) or postpartum haemorrhage ≥1000 mL (OR1.23, 95%CI 0.67-
2.23).
Limitations, reasons for caution: The main limitation of this study was its
retrospective design. Prospectively collected data using a larger sample would
be required to corroborate our results.
Wider implications of the ﬁndings:We show that oocyte donation is safe
and does not increase the incidence of adverse perinatal outcomes in IVF when
adjusting for confounders. The higher risk of caesarean birth and subsequent
haemorrhage likely derives from the fact that women conceiving with donated
eggs are older and have a larger BMI.
Trial registration number:Not applicable.
P-776 Comparison of follicular ﬂuid candidate proteins involved in
inﬂammation or angiogenesis and prediction of OHSS in assisted
reproductive technology (ART); A pilot study
K. Lossl1,4, M. Toftager1, A. Zedeler1, J. Bogstad1, L. Prætorius1,
M.L. Grøndahl2.3, C. Yding Andersen3, A. Pinborg1
1The Fertility Clinic, Copenhagen University Hospital Hvidovre, Copenhagen,
Denmark
2Laboratory of Reproductive Biology, Copenhagen University Hospital Rigshospitalet,
Copenhagen, Denmark
3The Fertility Clinic, Copenhagen University Hospital Herlev, Copenhagen, Denmark
4The Fertility Clinic, Copenhagen University Hospital Rigshospitalet, Copenhagen,
Denmark
Study question: Does the pre-ovulatory follicular ﬂuid (FF) level of selected
candidate proteins differ between women with and without OHSS and guide
when to use ‘freeze-all’ strategy?
Summary answer: The pre-ovulatory FF level of soluble urokinase plasmino-
gen activator receptor (SuPAR), a potential new inﬂammatory biomarker, was
signiﬁcantly lower in women developing OHSS.
What is known already: In ART, number of follicles ≥10-11mm on trigger-
day correlates to OHSS-risk. However, some women with a high number of fol-
licles do not develop OHSS. This could reﬂect that not only the follicular quan-
tity but also the quality, the intra-follicular milieu, contribute to the syndrome.
Proteins involved in inﬂammation or angiogenesis may be involved in the devel-
opment of OHSS. As increasing SuPAR plasma levels are thought to reﬂect
increased activation state of the immune system, we hypothesized that the pre-
ovulatory FF SuPAR level could be a potential new inﬂammatory biomarker pre-
dicting OHSS. There are no previous publications on FF SuPAR levels.
Study design, size, duration: FF was collected during a RCT including 1050
women in their ﬁrst ART cycle during year 2009-2013 comparing OHSS in
short versus long protocol. This sub-study is a case control study including FF
measurements from subjects with ≥15 oocytes retrieved who developed
severe OHSS (n = 25, Cases), subjects with ≥15 oocytes who did NOT
develop moderate-severe OHSS (n = 25, Control1), and subjects with 5-8
oocytes who did NOT develop moderate-severe OHSS (n = 25, Control2).
Participants/materials, setting, methods: For each Case (n = 25), one
Control1 (n = 25) and one Control2 (n = 25) was selected by matching sub-
jects by treatment protocol (short versus long), pregnancy (+/-), age, BMI, and
anovulation (+/-). FF from one large pre-ovulatory follicle was collected, centri-
fuged and frozen until the study-related measurements of SuPAR, placental
growth factor (PlGH), vascular endothelial growth factor (VEGF), and angiopoi-
tin I and II levels by commercially available Elisa-kits, and C-reactive protein
(CRP) by a high-sensitivity immunoturbidimetric assay.
Main results and the role of chance: The FF levels of SuPAR differed signiﬁ-
cantly between the three groups (P = 0.018) with mean (SD) levels of 2.3 (0.4)
ng/ml, 2.6 (0.8) ng/ml and 2.8 (0.6) ng/ml in Cases, Control1’s and
Control2’s, respectively. When Cases (OHSS, n = 25) where compared to the
combined Control groups (no moderate-severe OHSS, n = 50) the mean dif-
ference between groups was -0.40 ng/ml (95% conﬁdence interval -0.71 to
-0.09) ng/ml, (P = 0.012). Receiver operating characteristic (ROC) curve ana-
lysis demonstrated that the level of SuPAR could predict severe OHSS (AUC
0.678; 95% CI 0.553-0.803) with a sensitivity of 64% and a speciﬁcity of 66%.
The level of CRP, another well-known marker of inﬂammation, as well as the
levels of selected candidate proteins involved in angiogenesis (VEGF, PlGF and
angiopoitin I and II) did not differ between the three groups or between Cases
and combined Controls. Patients in the three groups were matched for anovu-
lation (+/-) with a total of 23 subjects presenting anovulation and 52 without.
The follicular level of CRP was signiﬁcantly higher among subjects with anovula-
tion; median (range) 2.0 (0.2-8.5) mg/L compared to 0.85 (0.2-6.1) mg/L in
regular cycling women (P = 0.34).
Limitations, reasons for caution: Although the FF SuPAR level signiﬁcantly
predicted severe OHSS in the present dataset, the relatively low sensitivity and
speciﬁcity currently makes a clinical application unlikely. Further, as this is the
ﬁrst study of SuPAR levels in relation to ART, further studies are required to
determine possible predictive value of SuPAR.
Wider implications of the ﬁndings: Our ﬁndings indicate that the intra-
follicular activation state of the immune system at oocyte-pickup is not
increased in women developing severe OHSS. Furthermore, the FF level of the
selected candidate proteins involved in angiogenesis was unchanged, especially
VEGF that has been claimed to play an important role in OHSS.
Trial registration number: ClinicalTrial.gov: NCT00756028 (Primary RCT)
P-777 Achieving competency in embryo transfer andmonitoring
ongoing performance
M. Prior1, J. Hopkisson2, N. Raine-Fenning1
1University of Nottingham, Obstetrics and Gynaecology, Nottingham, United
Kingdom
2Nurture Fertility, Nurture Fertility, Nottingham, United Kingdom
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Study question: To evaluate cumulative summation (CUSUM) and mean
averages in assessing the learning curve and ongoing competency of reproduct-
ive medicine trainees performing embryo.
Summary answer: Learning curve cumulative summation (LC-CUSUM) can
provide a useful way of charting progress, but offers false reassurance, masking
the possibility the trainee requires further training.
What is known already: Critical to successful in vitro fertilisation (IVF) is the
ability to transfer embryos safely and efﬁciently into the uterus. When learning,
it is important for the trainee to achieve competency as quickly as possible.
Assessing the learning curve and ongoing competency can be achieved by plot-
ting mean averages of pregnancy outcome. However, this is limited by over sen-
sitivity in the initial phase and poor sensitivity as the number of procedures
increases. CUSUM provides an alternative statistical model to monitor per-
formance by detecting if a process is ‘out of control’ following a mathematical
model which can be easily interpreted graphically.
Study design, size, duration: This prospective study included ﬁve trainees
learning embryo transfer at a Nurture Fertility between November 2011 and
November 2016. All trainees underwent a theoretical embryo transfer training
session followed by a two-month period of observation before performing
embryo transfers.
Participants/materials, setting, methods: Embryo transfer was per-
formed in theatre with the woman in dorsal lithotomy position. Embryos were
transferred using a pre-loaded ﬂexible Wallace catheter or using an elective
malleable guide prior to passing the ﬂexible catheter within the obturator.
Embryos were placed 2 cm from the fundus, with trans-abdominal ultrasound
guidance. A successful outcome was deﬁned as a positive urine pregnancy test,
14 days after embryo transfer. Charts plotting the mean average and CUSUM
were prepared.
Main results and the role of chance: Five hundred embryo transfers were
analysed. One hundred consecutive embryo transfers and pregnancy outcome
data were available for each trainee. The overall pregnancy rates for each
trainee were 44%, 61%, 53%, 57% and 44% respectively. Once competency
was achieved the mean pregnancy rate for all trainees was 78%.
Plots of mean averages were unhelpful in determining when a trainee was
competence, showing initial wide swings before reaching steady state.
When assessing embryo transfer competency using LC-CUSUM the ﬁve trai-
nees achieved competency at the 5th, 5th, 8th 13th and 27th procedure respect-
ively. Each consecutive outcome was plotted on a chart using LC-CUSUM, with
a downward step for a success and upward step for failure, until the compe-
tency threshold was crossed. Graphical representation was helpful to demon-
strate when competency was reached.
Subsequent monitoring of embryo transfer performance was plotted on the
same chart using CUSUM to monitor their performance. Four trainees main-
tained their success rate within acceptable limits. The CUSUM chart for one
trainee alarmed at observation 17 into the monitoring period when their
CUSUM score breached the threshold. This allowed additional individualised
support and training to be initiated.
Limitations, reasons for caution: Results may be affected by confounders
such as the quality of embryos, number transferred, culture media, embryolo-
gist, patient characteristics and so on. CUSUM also offers false reassurance,
masking the possibility the trainee requires further training. Furthermore, statis-
tics ignore vital aspects of learning such as formative feedback, self-assessment
and reﬂection.
Wider implications of the ﬁndings: Statistical plots using mean average or
CUSUM can provide useful graphical information when learning new practical
procedures such as embryo transfer as part of a wider training program.
Further studies should assess CUSUM for long term quality control.
Trial registration number: not applicable.
P-778 Are course of the pregnancy and perinatal outcome any
different after transfer of poor quality day 5 embryos?
S. Korosec1, I. Virant Klun1, U. Belak2, T. Magdalenic2, E. Vrtacnik
Bokal1
1Univerzitetni Klinicni Center Ljubljana, Department for Human Reproduction,
Ljubljana, Slovenia
2University of Ljubljana, Medical Faculty, Ljubljana, Slovenia
Study question: Does the morphology of embryos transferred on day 5 after
oocyte retrieval affect pregnancy complications, birth complications or new-
born pathology rates?
Summary answer: Patients having embryos of different quality transferred on
day 5 after oocyte retrieval have similar rates of pregnancy complications, birth
complications and newborn pathology.
What is known already: Questioning child health remains the concern in
transfer of poor morphology embryos. Up to date, no signiﬁcant differences
between good and poor embryo quality have been observed in newborn con-
genital diseases. Lower implantation and higher abortion rates are known to be
directly connected to poor embryo morphology. Adverse pregnancy and birth
outcome, including low gestational age, premature birth and restricted intra-
uterine growth, have already been connected to the poor embryo quality indir-
ectly, through poor reproductive history of the patients.
Study design, size, duration: Retrospective cohort study included 380
patients and 451 newborns after IVF-ET procedure performed in University
Medical Centre Ljubljana between January 2011 and December 2015.
According to quality of embryos transferred, maternal characteristics, course of
pregnancy and perinatal outcome were observed.
Participants/materials, setting, methods: Data were collected through
Perinatal information system of Slovenia. Three-hundred-nine pregnancies (309
singleton and 71 twin) were divided in three groups regarding quality of trans-
ferred embryos in the IVF procedure (group A – one or two blastocysts of best
quality, group B - one good and one poor quality blastocyst, group C - one or
poor blastocysts or morulae). Blastocyst morphology was assessed accordning
to Gardner blastocyst score (development1-6, tropfoblast A-C and embryo-
blast A-C).
Main results and the role of chance: There were 239 patients in group A,
77 patients group B and 64 in group C. There were no signiﬁcant differences in
maternal age and number of IVF procedues. Mothers in group A had signiﬁ-
cantly more oocytes retrieved. Mothers of singletons in group C had signiﬁ-
cantly higher rate of BMI belov 18,5 (16% vs 3,5% and 1,6%; p<0,05, Student t-
test) and signiﬁcantly lower BMI overall. Comparison was also signiﬁcant
between individual groups (A versus C, p = 0,03; B versus C, p<0,005, Pearson
chi-square test). In group C there were signiﬁcantly more ceasarian sections
performed (40,6% vs 35.1% vs 22,1%, p = 0.44). Otherwise we found no other
signiﬁcant differences in pregnancy complications (bleeding in each trimester,
preeclampsia, multiple pregnancies, placental pathology), birth complications
(ceasarian section, bleeding, premature birth) or mobidity of the newborns
(birth weight, gestation, small for gestation, Apgar score, congenital disease,
admission to intensive care, mortality).
Limitations, reasons for caution: Beside relatively low number of patients
in groups B and C, the limitation of study was the composition of group C
deﬁned by transfer of poor quality embryos. Blastocysts with poor embryo-
blast/trophoblast were in the same group as normal morulae, which would be
better to observe separately.
Wider implications of the ﬁndings: Reassuring results showed no signiﬁ-
cant differences in pregnancy and birth pathology or neonatal morbidity regard-
ing quality of transferred embryos. However, we found a different insight into
the pathology and lifestyle of infertile women, showing that too low BMI can
affect embryo quality simiraly or even more than higher BMI.
Trial registration number: Republic Medical Ethical Comeete on
14.2.2017, number 0120-47/2017-3
P-779 Perinatal outcomes in children born after IVF using a
GnRh-agonist protocol versus a GnRh antagonist protocol: a
Catalan cohort study based on 4562 newborns
M. Vidal Segui, M. Sastre Cuadri, M.A. Checa Vizcaino
Hospital del Mar - Parc de Salut Mar, Obstètrics and Gynecology, Barcelona, Spain
Study question: To ascertain whether perinatal outcomes are affected by the
type of GnRH and/or gonadotrophins used for the controlled ovarian hypersti-
mulation (COH) cycle.
Summary answer: Perinatal outcomes are not affected by the protocol used
for the COH neither by the type of gonadotrophins.
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What is known already: One of the well established parts of assisted repro-
ductive techniques (ART) is the utilization of gonadotrophin-releasing hor-
mones (GnRh), antagonists or agonists, and gonadotrophins for the COH.
Several studies performed to compare distinct protocols of GnRh and gonado-
trophins showed no signiﬁcant differences between live birth rates (effective-
ness) neither among ovarian hyperstimulation syndrome rates (safety). Despite
this lack of differences, what is also described during COH is a hyperestrogenic
environment that could lead to biochemical alterations during implantation and
placentation, which may affect obstetric and perinatal results. Our study ascer-
tain whether perinatal outcomes are affected by drugs that generate higher
estradiol levels.
Study design, size, duration: We conducted a register-based cohort study
using prospective data from the Department of Health of the Regional
Government of Catalonia between 2008 and 2013. A total of 4562 women
were included.
Participants/materials, setting, methods: The participants were women
undergoing COH using autologous eggs who had a singleton pregnancy deliv-
ered from the 24th week onward. Two different groups were made for the
study: women undergoing COH using a GnRh antagonist based protocol and
women undergoing COH using a a GnRh-agonist based protocol. Additionally,
two subgroups were made according where recombinant or urinary gonadotro-
phins were used.Primary outcomes were birthweight and gestational age at
delivery.
Main results and the role of chance: Women undergoing COH with a
GnRh antagonist protocol and women using a GnRh-agonist protocol had com-
parable results regarding birthweight (BW) (3,144 ± 542.5 g and 3,161.6 ±
536.18 g, respectively; P = 1.08) and gestational age at delivery (GA) (38.7 ±
2.12 and 38.1 ± 2.08 weeks, respectively; P=.87) and these outcomes per-
sisted after adjusting for confounding factors. Furthermore, we observed no
statistically signiﬁcant differences in the main perinatal outcomes analyzed in the
subgroups of recombinant and urinary gonadotrophins (BW: 3,158.1 ± 539.6 g
and 3,140 ± 537.1 g, respectively; P = .96 and GA: 38.8 ± 2.04 and 38.6 ±
2.24 weeks, respectively; P = 1.6).
Limitations, reasons for caution: The main limitation of the study is the
retrospective design. This kind of evaluation precludes an analysis of some
potentially relevant data that were missing from the registry and also results in a
signiﬁcant loss of cases because of missing data in the main variables.
Wider implications of the ﬁndings: Perinatal outcomes are not affected by
the protocol used for COH. Hence, the choice of the GnRH analog, gonado-
trophins and their combinations should be based on other clinical aspects.
However, prospective studies would be required to support these ﬁndings.
Trial registration number:Not applicable.
P-780 Off-label use of androgens and letrozole in infertile women –
a multinational survey in Europe and Australia
M.F. Andersen1, P. Drakopoulos2, P. Humaidan3, J.L. Gomez4,
I. Bruna5, L. Rombauts6, S.D.S. Ribeiro7, C. Dosouto8, B. Coroleu8,
P.N. Barri8, N.P. Polyzos8
1The Fertility Clinic, Skive Regional Hospital, Department of Clinical Medicine
2Vrije Universiteit Brussel, Department of Reproductive Medicine, Brussel,
Belgium
3Department of Clinical Medicine- Aarhus University, The Fertility Clinic- Skive
Regional Hospital, Skive, Denmark
4FIVMadrid, Department of Reproductive Medicine, Madrid, Spain
5Director Médico de HM Fertility Centers, Hospital Universitario Madrid-
Montepríncipe, Madrid, Spain
6Monash University, Reproductive Medicine- Monash Health, Clayton Victoria,
Australia
7Universitair Ziekenhuis Brussel, Reproductive Medicine- Genetics and Immunology,
Brussel, Belgium
8Dexeus University Hospital, Department of Reproductive Medicine, Barcelona,
Spain
Study question: Do fertility experts often recommend off-label regimens
(androgens or letrozole) in reproductive medicine, and is this based on robust
scientiﬁc evidence?
Summary answer: Clinicians very often recommend off label androgens and
letrozole in reproductive medicine. This is not always driven by robust evidence
in favor of treatment.
What is known already: Although off-label use of drugs and supplements is
common in all medical domains, the magnitude of off-label regimen prescription
and the rationale behind this, remains unclear in the ﬁeld of reproductive medi-
cine. Androgens and letrozole are possibly the most widely used off–label drugs
among infertile women; still, available evidence regarding their safety and efﬁ-
cacy appear to be fairly different. Accumulating evidence support the beneﬁcial
effect of letrozole in unovulatory women undergoing ovulation induction, while
evidence regarding the use of androgens for poor ovarian responders is weak
and contradictory.
Study design, size, duration: This is a cross-sectional online survey con-
ducted in 5 different countries (Denmark, Norway, Spain, Belgium and
Australia), including all private and public specialists in reproductive medicine in
order to evaluate fertility specialists’ attitudes towards the use of off-label medi-
cation. The survey took place between October 2016 and December 2017.
Participants/materials, setting, methods: Online survey invitations were
sent to all members of the Danish, the Norwegian, the Spanish, the Australian
and the Belgian Fertility Society.
Main results and the role of chance: In total, 222 fertility specialists
responded among 1136 who were contacted electronically (response rate
20%).
Cumulatively, 75.5% of the physicians recommended off-label use of andro-
gens or letrozole for their patients. Overall, letrozole was used more frequently
by clinicians 65% (CI 57%-72%), as compared with testosterone 49.1% (CI
38%-59%), although the difference was not statistically signiﬁcant, p = 0.59 and
more frequently than DHEA 29.3% (CI 16%-41%), p<0.001. Signiﬁcantly more
fertility specialists recommended testosterone as compared with DHEA for
poor ovarian responders p<0.001.
Almost half (42.5%) of the fertility specialists who did not recommend the
use of androgens reported that their decision was based on the lack of scientiﬁc
evidence, whereas the 2 main reasons for not using letrozole was either
because this was not part of clinicians’ guidelines (24,9%) or because the drug
was not ofﬁcially approved for use in ART (19%).
Limitations, reasons for caution: Fertility care providers who recommend
androgens or letrozole might have been more likely to respond to the survey
and this could exaggerate the use of the procedure reported here.
Wider implications of the ﬁndings: A majority of clinicians are using off-
label letrozole which is supported by the accumulating evidence for treatment
of anovulatory patients. However it is remarkable that almost half of the clini-
cians continue to use androgens in poor responders, despite the lack of evi-
dence and the caution raised in published articles.
Trial registration number:Not applicable.
POSTER VIEWING
Stem cells
P-781 Impact of pluripotency state and Activin A supplementation
on derivation of primordial germ cell-like cells from human
embryonic stem cells
S. Mishra1, M. Van der Jeught1, J. Taelman1, M. Popovic1,
K.J. Szymańska2, D. Deforce3, P. De Sutter1, S.M. Chuva de Sousa
Lopes4, B. Heindryckx1
1Universitair Ziekenhuis Gent, Ghent-Fertility and Stem cell Team G-FaST-
Reproductive Medicine, Gent, Belgium
2Ghent University, Physiology Group- Department of Basic Medical Sciences, Ghent,
Belgium
3Ghent University, Laboratory of Pharmaceutical Biotechnology- Faculty of
Pharmaceutical Sciences, Ghent, Belgium
4Leiden University Medical Centre-, Department of Anatomy and Embryology,
Leiden, The Netherlands
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Study question: Is there an effect of the pluripotency state and Activin A sup-
plementation on differentiation of human embryonic stem cells towards the
germline?
Summary answer: Germline precursors were formed in all conditions, apart
from the naïve RSET condition. Activin A supplementation appeared to boost
this expression.
What is known already: Gametogenesis from human embryonic stem cells
(hESC) in vitro may provide new long-term perspectives for genetic parenthood
for patients currently facing sterility. Recent studies have shown that human
primordial germ cell-like cells (hPGCLCs) with SOX17/OCT4 expression can
be obtained from hESC grown in a ‘4i’ state, by culturing them as embryoid
bodies (EBs) with BMP4, EGF, SCF, hLIF and ROCKi. Moreover, our group pre-
viously showed that primed hESC cultured as EBs in presence of BMP4 and
Activin A showed increased propensity to express genes for post-migratory
germ cells compared to EBs exposed to BMP4 alone.
Study design, size, duration: The germline competence of different states
of pluripotency such as naive hESC and other states inhibiting one or more sig-
nalling pathways are yet to be studied in parallel and warrants further
investigation.
To study this we used: two in-house derived female hESC lines were cultured
in primed, primed-Wnt-inhibitor(Wnt-i), 4i (naive) and RSET (naive) conditions.
Participants/materials, setting, methods: The cells were tested for pluri-
potency markers using immunostaining and cultured as EBs in two groups; germ
cell differentiation medium with Activin A(20ug/ml) and other without Activin
A. Day 4 EBs were ﬁxed and stained for germ cell and pluripotency markers,
visualised as z-stacks on a Leica SP8 Confocal Microscope, and analysed using
IMAGEJ/FIJI.
Main results and the role of chance: We found that the speciﬁc pluripo-
tency state affects the germline induction potential of hESC. In both cell lines,
EBs from primed, Wnt-i and ‘4i’ cells expressed SOX17 and OCT4 double
positive cells at varying levels after 4 days. In contrast, EBs from the naïve RSET
condition did not show these markers. Positive cells also expressed Podoplanin
(PDPN) on their surface, a PGC marker in embryos of cynomogolous monkeys.
Therefore, the obtained hPGCLCs were positive for SOX17/OCT4 and
SOX17/PDPN. EBs from Wnt-i hESCs had a similar germline competence as
primed hESCs. EB’s from ’4i’ had the highest germline competence in the stand-
ard differentiation medium. Addition of Activin A to the differentiation medium
resulted in markedly increased proportion of hPGCLCs in EB’s all the three
conditions except RSET.
Limitations, reasons for caution: In order to present scientiﬁcally robust
data, the current study, which is based on confocal imaging only should be
further supported by transcriptome data of the obtained hPGCLCs,
which should be compared to the proﬁles of in vivo harvested early human
PGCs.
Wider implications of the ﬁndings: The current study aims to identify
embryonic germ cell markers on hPGCLCs and to standardise the process of
deriving gametes from pluripotent stem cells. Adaptation of culture conditions
based on this knowledge may ultimately advance efforts to derive germ cells
in vitro for patients currently facing sterility.
Trial registration number:Not Applicable.
P-782 Induction of spermatogenesis under 3-Dimentional tissue
culture conditions by in vitro transplantation of human
spermatogonial stem cells isolated from frozen-thawed testis tissue
M. Mohaqiq1, M. Movahedin2°, Z. Mazaheri3, N. Amir Janati4
1Medicine Faculty, Kateb University, Kabul
2Anatomical Sciences Department, Faculty of Medical sciences, Tarbiat Modares
University
3Anatomical Sciences Department, Faculty of Medical sciences, Tarbiat Modares
University
4Andrologia and Embryology Department, Avicenna Research Institute, Tehran
°Corresponding Address: P.O.Code: 14115-331, Department of Anatomical
Sciences, Faculty of Medical Sciences
Study question: Can testis organ culture support progression of spermato-
genesis after in vitro transplantation of spermatogonial stem cells under condi-
tions of testicular tissue culture?
Summary answer: Conditions of the 3-Dimentional testicular tissue culture
after spermatogonial stem cell transplantation can support the progress of
spermatogenesis to produce haploid cells.
What is known already: Inducing spermatogenesis by long term preserved
germ cells to produce mature and functional sperm is one of the main goals of
reproductive medicine. Germ cell transplantation is one of the ways reaching to
this goal. In vivo transplantation has been done successfully and frequently. But
in the in vitro transplantation and organ culture method Sato et al in 2013 are
ﬁrst one that published protocol. They reported sperm producing from in vitro
transplantation of mouse spermatogonial stem cells and organ culture.
Study design, size, duration: This study is based on 5 biopsy samples taken
from different azoospermic patients with 20 to 45 years old. For each experi-
mental group, 3 to 5 NMRI mouse were used at the age of 4 weeks.
Participants/materials, setting, methods: SSCs were obtained from
patient’s TESE (Testicular Sperm Extraction). To conﬁrm identiﬁcation of SSCs,
PLZF protein was detected. Labeled cells by DiI were transplanted to adult
mouse testis which treated by 40 mg/kg busulfan. Host testes set in organ cul-
ture condition. Another testis without transplantation set in organ culture con-
dition as control group. Cultured testes were assessed by histomorphometric
studies, tracing of DiI, immunohistochemistry and molecular (Real Time PCR)
studies after 8 weeks.
Main results and the role of chance: The results of histomorphometric
studies showed that the mean number of spermatogonial cells, spermatocytes
and spermatids in the transplantation group was signiﬁcantly more than the con-
trol group (P<0.05) and most of the cells responded positively to the detection
of DiI. Immunohistochemical studies in host testes fragments in the experimen-
tal group express the PLZF, SCP3 and ACRBP proteins in spermatogonial cells,
spermatocyte and spermatozoa, respectively, which conﬁrmed the human
nature of these cells. Also, in molecular studies of PLZF, Tekt1 and TP1, the
results indicated that the genes were positive in the test group, while not in the
control group.
Limitations, reasons for caution:Obtaining human samples were very difﬁ-
cult. There were few patients who gave satisfaction for researches.
Wider implications of the ﬁndings: The results of this study indicate that
the in vitro transplantation system and testicular tissue culture have the ability
to support the progression of spermatogenesis to obtaining haploid cells.
Trial registration number: our trial was non-clinical.
P-783 Transplantation of humanmenstrual blood-derived stromal
cells promotes recovery of cyclophosphamide-induced premature
ovarian insufﬁciency
F. Penghui, T. Jichun
China Medical University, Department of Obstetrics and Gynecology- Reproductive
Medical Center- Shengjing Hospital, Shenyang, China
Study question: How can menstrual blood-derived stromal cells (MenSCs)
take reparative effects on premature ovarian insufﬁciency?
Summary answer: Menstrual blood-derived stromal cells can effectively
inhibit apoptosis of granulosa cells and therefore renovate ovarian function
damaged by Cyclophosphamide.
What is known already: Premature ovarian insufﬁciency (POI) is characterized
by abnormal menstruation with hormonal disorders in female aged before 40, and
1%~3% female are suffering from it whereas certain etiologies and pathophysio-
logical mechanisms are not clearly deﬁned. Recently, different sources of mesen-
chymal stem cells have been found to be therapeutic in premature ovarian
insufﬁciency such as umbilical cord, skin, amniotic ﬂuid, endometrial mesenchymal
stem cells, etc. In these studies, paracrine fashions of mesenchymal stem cells play
the principal role in the restoration of ovarian function.
Study design, size, duration: Experiments were divided into three groups
(blank group without treatment, control group with cyclophosphamide injected
abdominally and treatment group with MenSCs and cyclophosphamide precon-
ditioned). In vivo, female mice were injected with cyclophosphamide in
advance; and one week later, those in experiment goups were treated with
MenSCs and the rest with PBS until 10 days. In vitro, KGN cells were cultured
with medium or cyclophosphamide or cocultured with MenSCs for 24 hours.
Participants/materials, setting, methods: Stromal cells were isolated
from menstrual blood, infected with green ﬂuorescence protein. KGN cells line
i500 Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
were cultured for experiments in vitro. Female mice were divided into three
groups (blank group without treatment, control group with cyclophosphamide
injected abdominally and treatment group with MenSCs through tail veins with
cyclophosphamide preconditioned). Then, identiﬁcating and proving the repara-
tive effects by CCK-8 assay, FACS, in-vitro differention, H&E staining, Western,
RT-PCR, immunoﬂuorescence, TUNEL-apoptosis assay, RNA Sequencing, etc.
Main results and the role of chance: In our present study, we demon-
strated that MenSCs showed properties of mesenchymal stem cells with surface
markers CD90+, CD73+, CD105+, CD44+, CD38-, CD45- and CD34-.
Osteogenic, chondrogenic and adipogenic defferentiation indicated the multi-
potency of MenSCs. In vivo, apoptotic cells in ovarian tissues especial granulosa
cells decreased compared with control group according to TNUEL and
Hoechst assays. Body weight of mice, ovarian and uterine weight and number
of live births were signiﬁcantly different among blank and experiment groups
compared with control group. In addition, MenSCs were able to up-regulate
the expression of MIS, VASA, Ki67, VEGF and LHR of ovarian tissues, modulat-
ing blood hormones with IFN-γand FSH down-regulated and E2 and AMH up-
regulated. In vitro, MenSCs reduced apoptosis of KGN cells in accordance with
the downward trend of caspase molecules. RNA sequencing demonstrated
that MenSCs restore ovarian function through regulating biological metabolism,
angiogenesis, muticellular organismal process, cell differentiation, apoptotic
process and so on with 82 related genes up-regulated and 261 relative genes
down-regulated.
Limitations, reasons for caution: Our study revealed the reparative effects
on POI induced by chemotherapeutic agent via inhibiting apoptosis of granulosa
cells. However, the etiologies of this syndrome is not only for this reason. Thus,
we need further investigation to explore the effect of MenSCs in different mod-
els such as immunogeneous POI.
Wider implications of the ﬁndings: MenSCs are capable of promoting
recovery of POI by inhibiting the activation of caspase signaling in granulosa
cells. It is noteworthy that related trials of MenSCs in POI treatment were
mainly conducted conﬁned to rodent animals; therefore it is necessary for us to
take further investigation in mammals.
Trial registration number: not applicable.
P-784 Transcriptomic features of KRT7 positive cells derived from
BMP4-treated human induced pluripotent stem cells (hiPSCs)
N. Tsuchida1, H. Akutsu2, J. Kojima1, H. Ito1, N. Kuji1, H. Nishi1
1Tokyo Medical University Hospital, Obstetrics and gynecology, Tokyo, Japan
2National Center for Child Health and Development, Center for regenerative
medicine, Tokyo, Japan
Study question: Do KRT7 positive cells derived from BMP4-treated hiPSCs
have trophoblast-speciﬁc features?
Summary answer: The KRT7 positive differentiated cells exhibit trophoblast
features.
What is known already: Early development of human placenta remains
poorly understood due to lack of proper model systems. Previous reports
demonstrated that human Embryonic Stem Cells (hESCs) and hiPSCs treated
with bone morphogenetic protein4 (BMP4) could differentiate into extra-
embryonic tissue and they could be a useful model of the early trophoblast dif-
ferentiation. However, the differentiated cells are heterogeneous, which include
both trophoblast (TB) and mesoderm lineage cells.
Study design, size, duration: In order to identify the characteristics of the
trophoblast lineage cells from BMP4-treated hiPSCs, cells were collected using
a pan-trophoblast marker, KRT7, with ﬂow cytometry and performed compre-
hensive gene expression analysis.
Participants/materials, setting, methods: Four types of hiPSCs were
treated with 50 ng/ml of BMP4 in a Xeno-free medium for 10 days. After the
expression of KRT7 was conﬁrmed by immunoﬂuorescence analysis, KRT7-
positive cells were collected using ﬂow cytometry and analyzed by DNA micro-
array (Agilent SurePrint G3 Human Gene Expression v3 8×60 K Microarray).
The difference of the gene expression proﬁles between KRT7-positive cells and
hiPSCs were compared, and the expressions of some genes were validated by
quantitative RT-PCR.
Main results and the role of chance: All the BMP4-treated cells were
stained by immunocytochemistry for KRT7. Microarray analysis demonstrated
that 833 genes were commonly expressed in all the four hiPSC groups, including
POU5F1, SOX2, and NANOG. 259 upregulated genes were commonly
expressed in all the four BMP4 treated cell groups, including some
trophectoderm-speciﬁc genes (GATA3 and GCM1) and TB-speciﬁc genes
(CGA, CGB, and syncytin2). Cluster analysis and Principal Component Analysis
revealed that most gene clusters were divided into two groups: hiPSCs and
KRT7-positive cells. Comparing our microarray data to the large-scale analysis
of human transcriptome, the features of KRT7-positive BMP-4 treated cells
were most similar to placenta.
Limitations, reasons for caution: Although the KRT7 positive BMP4-
treated hiPSCs are similar to the early stage of placenta in terms of the tran-
scriptomic character, it is difﬁcult to reproduce early placentation because there
is no in vivo model to compare with this model.
Wider implications of the ﬁndings: The results suggest that some of the
genes upregulated in all the BMP4-treated groups might play an important role in
early placental development. Further studies are needed to conﬁrm their functions.
Trial registration number:None.
P-785 Topical administration of human umbilical cord-derived
mesenchymal stem cells on scaffolds accelerates endometrial
regeneration in a rat model of Asherman’s syndrome by paracrine
effect
L. Xin1, Z. Songying2, M. Lie3
1Zhejiang University, School of Medicine, Hangzhou, China
2Sir Run Run Shaw Hospital, Assisted Reproduction Unit- Department of Obstetrics
and Gynecology, Hangzhou, China
3Zhejiang University, Department of polymer science and engineering, Hangzhou,
China
Study question: Can collagen/hu-mscs scaffolds provide a new treatment for
Asherman’s syndrome?
Summary answer: Transplantation of collagen/hu-mscs scaffolds was estab-
lished to be effective in promoting endometrial regeneration in a rat model of
Asherman’s syndrome.
What is known already: In women of reproductive age, severe injuries of
endometrium are often accompanied by endometrial scar formation, and a lack
of endometrial functional layer leads to infertility or miscarriage. Human umbil-
ical cord-derived mesenchymal stem cells have been conﬁrmed to promote tis-
sue recovery in many organs. Collagen scaffolds have been widely applicated in
regenerative medicine because of their abundant source, low immuogenicity,
wonderful biocompatibility and degradability.
Study design, size, duration: Collagen/hu-mscs scaffolds were constructed.
A total of 154 SD rats were involved and received different treatments. Uteri
were examined at 15, 30 and 60 days after surgery. The function of regenerated
endometrium was assessed at 60 days afer surgery. A non-contact co-culture
system was made to explore the mechanism of hu-mscs on endometrial regen-
eration in vitro.
Participants/materials, setting, methods: Hu-mscs were purchased from
Boyalife Group°Collagen scaffolds were obtained using dry-heat crosslinking
method. Hu-mscs were seeded onto degradable collagen scaffolds. The cell-
seeded scaffold was transplanted onto the inner uterine surface of a rat intra-
uterine adhesion model. At 15,30 and 60 days after surgery, uteri were exam-
ined by histological analysis. Fertility test was made 60 days afer surgery. The
paracrine effect of hu-mscs on endometrial regeneration was established by a
non-contact co-culture system in vitro.
Main results and the role of chance: Hu-mscs were mainly located to the
functional layer of regenerated endometrium. At 15,30 days after collagen/hu-
mscs scaffolds transplantation, the regenerated endometrium expressed higher
level of VEGFa, TGF-β, PDGFbb and MMP-2 than the endometrium in collagen
group or spontaneous repair group. The collagen/hu-mscs scaffold promoted
endometrial regeneration and collagen degradation, induced local endometrial
cells proliferation, facilitated microvasculature regeneration, and restored the
endometrium’s ability to receive embryos. Furthermore, we demonstrated that
i501Abstracts of the 34th Annual Meeting of the ESHRE, Barcelona, Spain 1 to 4 July 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/33/suppl_1/i1/5046210 by guest on 20 February 2019
hu-mscs promoted human endometrial stromal cells proliferation and inhibited
apoptosis through paracrine effect in vitro.
Limitations, reasons for caution: The results of this research are inad-
equate to apply directly in human because human uterine and rat uterus differ
in structure and function. Further large animal experiments, such as monkeys,
are needed.
Wider implications of the ﬁndings: Transplantation of collagen/hu-mscs
scaffold offers a reliable method in the treatment of women with Asherman’s
syndrome and promote fertility recovery.
Trial registration number: not applicable.
P-786 Germ-like cells generation from humanmenstrual
blood-derived stem cells on a 3-D composite nanoﬁbrous scaffold
S. Ghorbani1, H. Eyni1, M. Pourdonya2, Z. Kazemi2, S. Sarkhanloo2,
M. Soleimani3
1Tarbiat Modares University, Anatomical Sciences, Tehran, Iran
2Ardabil University of Medical Science, Medical, Ardabil, Iran
3Tarbiat Modares University, Hematology, Tehran, Iran
Study question: Can the fabricated 3-D nanoﬁbrous composite scaffolds with
retinoic acid trigger human menstrual blood-derived stem cells (MenSCs) to dif-
ferentiate towards germ-like cells?
Summary answer: The stem cell and germ cell-speciﬁc genes expression on
transcriptional in differentiated-MenSCs proofed 3-D composite scaffold-
seeded MenSCs could enhance germ-like generation.
What is known already: Several factors contributing to infertility can involve
men, women or both partners, and in some cases no cause can be identiﬁed.
Providing a platform to generate functional germ cells in laboratories could have
modiﬁed the current view on assisted reproduction technologies.
It has been proved that cells often exhibit unnatural characteristics when cul-
tured on a two dimensional (2D) surface as a monolayer in comparison with
native three-dimensional (3D) tissues. Therefore, in this study, usefulness of
PLA/MWCNTs scaffolds in germ line cell culture by taking advantage of the
afﬁnity exhibited by CNTs for MenSCs differentiation to germ-like cells has
been examined.
Study design, size, duration: The 3-D wet-electrospun composite scaffolds
were designed to compare inﬁltration, proliferation, and differentiation poten-
tial of menstrual blood-derived stem cells toward germ cell lineage with 2D cul-
ture. Therefore, isolated MenSCs at a density of 1.5104 cells/cm2 in inducing
media containing DMEM/F12 supplemented with 10% FBS and 10-7M retinoic
acid (RA) on 2D (without scaffolds) and 3D (with fabricated PLA and PLA/
MWCNTs scaffolds) culture vessels for 7 and 14 days were differentiated
towards germ cells.
Participants/materials, setting, methods: After MenSCs isolation and
scaffold fabrication, such assays as SEM, FTIR, Contact angel, Live/dead and
MTT was used to evaluate the biocompatibility and properties of the matrix as
well as morphology of differentiated-MenSCs. Reverse-transcription PCR
(Oct4, C-kit, VASA, DAZL, SYCP3 and STRA8) was used to assess the germ
cell development in 3-D engineered bio-scaffolds.
Main results and the role of chance: The results, showed that the porous
structure of PLA and PLA/MWCNTs scaffolds provide sufﬁcient dimensions
for cell ingrowths. This was evidenced in the SEM of differentiated MenSCs
showing excellent attachment, penetration, and aggregation of these cells on
the scaffolds where these parameters in the PLA/MWCNTs were better than
PLA. These results clearly demonstrated that scaffolds that were used not only
provided a suitable support for cell homing but also enhanced proliferation of
MenSCs.
The results of stem cell and germ-like cell genes expression showed that
MenSCs expressed stem cell and germ-like cell genes in 3D group (PLA, PLA/
MWCNTs) as well as 2D group. In this research, merging RA with carbon
nanotubes in the PLA/MWCNTs group showed more effect on germ-like cells
generation from MenSCs. The results from gene expression and differentiated
cells morphology in all groups demonstrate that the CNTs can enhance
MenSCs differentiation toward germ-like cells.
Limitations, reasons for caution: Germ-like cells produced by MenSCs
in vitro on such favorable 3-D porous microenvironments could provide a
continuous supply for gamete generation, but naturally, the clinical application
of MenSCs-derived germ cells in humans would require great caution.
Wider implications of the ﬁndings: The previous studies showed that gen-
eration of mature germ cells in vitro may require complex niches. Due to the
appropriate 3-D structure of the new fabricated scaffold, it seems be a powerful
microenvironment to support the germ cells generation from MenSCs and may
pave way for infertility treatment.
Trial registration number:Not applicable.
P-787 Different dynamic distribution of H3K27ac and H3K4me3
epigenetic active marks at imprinted genes during in vitro
primordial germ cells differentiation
I. Muñoa-Hoyos, I. Urizar-Arenaza, M. Gianzo, N. Subiran
University of the Basque Country, Physiology in the Faculty of Medicine and Dentistry,
Leioa, Spain
Study question: To elucidate the chromatin dynamics of histone modiﬁca-
tions at imprinted genes during primordial germ cell (PGCs) differentiation in
mouse.
Summary answer: Imprinted genes present differences in the dynamic distri-
bution of H3K27ac and H3K4me3 histone modiﬁcation marks compared to
whole genome distribution pattern during PGC differentiation.
What is known already: Epigenetic reprogramming plays an important role
in germ cell differentiation to guarantee the normal development of epigenetic
information transmitted across generations. In fact, it has been pointed out the
importance of a global genome demethylation and an optimal chromatin conﬁg-
uration for an efﬁcient reprogramming, among other epigenetic mechanisms.
However, some genes, such as imprinted genes, can escape the reprogramming
process and still be partially methylated at the end of reprogramming, suggest-
ing the presence of a potential mechanisms important for transgenerational epi-
genetic inheritance. In spite of that, the chromatin distribution of imprinted
genes during PGC differentiation is completely unknown.
Study design, size, duration: Chip-Sequencing analysis of histone active
marks (H3K27ac and H3K4me3) and histone repressive mark (H3K27me3)
during in vitro PGC differentiation. Induction of in vitro PGC was carried out
form mouse embryonic stem cells (ESCs), to epiblast-like cells (EpiLCs) and
ﬁnally into primordial germ cell-like cells (PGCLCs) at day 2 and 6 (d2PGCLCs
and d6PGCLCs respectively).
Participants/materials, setting, methods: Bioinformatic approaches from
Next-Generation Sequencing (NGS). NCBI database (GEO accession number:
GSE60204).
Main results and the role of chance: First, we have evaluated the normal
pattern of chromatin state dynamics in both active marks and the repressive
mark. H3K27ac and H3K4me3 levels showed a reduction from ESCs to EpiLCs
and d2PGCLCs, followed by a recovery in d6PGCLCs. In return, the transitions
of H3K27me3 during in vitro PGC speciﬁcation exhibited a small drop from
ESCs to EpiLCs, and reached the highest level in d2PGCLCs, to ﬁnally recover
the low level in d6PGCLCs.
Next, we have analyzed the transitions of these three epigenetic marks more
deeply focusing on imprinted genes. As a result, we have found out that, mater-
nally and paternally imprinted genes have different distribution in both active
marks, H3K27ac and H3K4me3, but not in the repressive mark, H3K27me3
that seems to maintain the same pattern as the general.
Finally, we have studied the chromatin dynamics of the repetitive elements
during PGC differentiation, as these elements also have been described to
escape from the demethylation process. Unlike the previous case, we have
observed that there is no change in the distribution of these three histone
marks in repetitive elements, compared to the general pattern.
Limitations, reasons for caution: To perform the in vitro analysis.
Wider implications of the ﬁndings: Maternally and paternally imprinted
genes seem to have a different chromatine remodeling pattern in H3K27ac and
H3K4me3 active marks, during PGC differentiation. This fact reafﬁrms
imprinted genes as potential candidates to escape the reprogramming process
and sheds light on the complex mechanism of epigenetic inheritance.
Trial registration number:Not applicable’ for non-clinical trials.
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P-788 The synergetic effects of multiwall carbon nanotubes/poly
lactic acid 3-D composite nanoﬁbrous scaffold containing naringenin
on spermatogenesis
H. Eyni Seen1, S. Ghorbani1, M. Pourdonya2, Z. Kazemi2,
S. Sarkhanloo2, R. Shabani3, M. Mehdizadeh3, F. Amjadi3
1Tarbiat Modares University, Anatomical Science, tehran, Iran
2Ardabil University of Medical Sciences, Medical, Ardabil, Iran
3Iran University of Medical Sciences, Anatomical Sciences, Tehran, Iran
Study question: Can the fabricated 3-D nanoﬁbrous composite scaffolds with
naringenin induct spermatogenesis in the spermatogonial stem cells (SSCs)?
Summary answer: The stem cell and germ cell-speciﬁc markers expression
on transcriptional and protein in the SSCs proofed successful spermatogenesis
induction 3-D composite scaffold-seeded SSCs.
What is known already: The efﬁciency of spermatogenesis concerns the
presence of the Sertoli cell–SSCs niche. This connection between proliferat-
ing SSCs and surrounding testicular environment enables them to receive a
variety of signals and factors necessary for SSC self-renewal and differenti-
ation. Fortunately, new developments in engineered three-dimensional cul-
tures have helped mimic the structure as well as function of the natural
extra cellular matrix to improve cellular behavior of SSCs in vitro.
Therefore, in this study, we have incorporated MWCNTs into PLA, with
hypothesis that this carbon-based scaffold combined with an antioxidant,
naringening, may have enhanced proliferation and differentiation of SSCs
compared to 2D-medium.
Study design, size, duration: The 3-D wet-electrospun composite scaffolds
were designed to compare proliferation, and differentiation SSCs with 2D cul-
ture. Therefore, isolated SSCs at a density of 104 cells/cm2 in inducing media
containing DMEM/F12 supplemented with 10% FBS, 50 ng/ml BMP4 and
20 ng/ml GDNF on 2D (without scaffolds and 10 μM naringenin) and 3D (with
fabricated PLA/ MWCNTs scaffolds and 10 μM naringenin) culture vessels for
7 and 14 days were differentiated towards germ cells.
Participants/materials, setting, methods: After SSCs isolation and scaf-
fold fabrication, such assays as SEM, FTIR and MTT was used to evaluate the
biocompatibility and properties of the matrix as well as morphology of
differentiated-SSCs. Reverse-transcription PCR (PLZF, C-kit, ID4 and SYCP3)
and immunocytochemistry (PLZF, C-kit and ID4) were used to assess the germ
cell development in 3-D engineered bio-scaffolds. Also, reactive oxygen species
(ROS) was used to asses ROS amount in 2D and 3D groups.
Main results and the role of chance: The results showed that the porous
structure PLA/MWCNTs scaffolds provide sufﬁcient dimensions for cell
ingrowths. This was evidenced in the SEM of differentiated SSCs showing excel-
lent attachment, penetration, and aggregation of these cells on the scaffolds.
These results clearly demonstrated that scaffolds that were used not only pro-
vided a suitable support for cell homing but also enhanced proliferation and dif-
ferentiation of SSCs.
The results of stem cell and germ cell markers expression showed that SSCs
expressed stem cell and germ cell genes in 3D group (PLA/MWCNTs) as well
as 2D group. In this research, merging naringenin with carbon nanotubes in the
PLA/MWCNTs group showed more effect on germ cells generation from
SSCs. The results from gene and protein expression and differentiated cells
morphology in all groups demonstrate that the CNTs can enhance SSCs differ-
entiation toward germ cells. Also, ROS level was less in 3D group in compari-
son with 2D group.
Limitations, reasons for caution: Germ cells produced by SSCs in vitro on
such favorable 3-D porous microenvironments could provide a continuous sup-
ply for gamete generation but the functionality of germ cells needs to be investi-
gated by other methods such ART.
Wider implications of the ﬁndings: The previous studies showed that gen-
eration of mature germ cells in vitro may require complex niches. Due to the
appropriate 3-D structure of the new fabricated scaffold, it seems be a powerful
microenvironment to support the germ cells generation from SSCs and may
pave way for infertility treatment.
Trial registration number:Not applicable.
P-789 Imprinting status of human parthenogenetic embryonic
stem cells: analysis of 63 imprinted genes expression levels in two
undifferentiated and early differentiated stages
Q. Mai1, X. Mai2, K. Huang3, C. Zhou3
1The First Afﬁliated Hospital of Sum Yat-sen University-, Reproductive Medical
Center, Guangzhou, China
2Guangzhou women and children’s medical center, Reproductive Medical Center,
Guangzhou, China
3The First Afﬁliated Hospital of Sum Yat-sen University, Reproductive Medical Center,
Guangzhou, China
Study question: What is imprinted genes expressive status of human pathe-
nogenetic embryonic stem cells (hPESCs)?
Summary answer: Human parthenogentic embryonic stem cells show a sub-
stantial degree of epigenetic stability with respect to imprinted genes.
What is known already: Human parthenogenetic embryonic stem cells
represent a source of histocompatible tissues for transplantation and thus their
use avoids immune rejection and ethical obstacles. Human parthenogenetic
embryonic stem cells carry two copies of the maternal genome and lack a
paternal genome. Given that the disruption of imprinting is associated with
human diseases, there are main concerns about imprinted genes expressive sta-
tus of human parthenogenetic stem cells and the inﬂuence of aberrant
imprinted genes on stem cell derivative.
Study design, size, duration: The expression levels of imprinted genes
were compared between human parthenogentic embryonic stem cells and
human biparental embryonic stem cells. Two undifferentiated human partheno-
gentic embryonic stem cell lines were cultured in vitro and digested for passa-
ging every 5 days. For early differentiation and collection of embryonic body,
human parthenogetic embryonic stem cells and human biparental embryonic
stem cells were cultured in the medium with RA for two weeks.
Participants/materials, setting, methods:We investigated the expression
proﬁle of all 63 genes that are known to be human imprinted (27 maternally
and 36 paternally expressed) in two undifferentiated human parthenogentic
embryonic stem cell lines by quantitative real Time reverse transcription-PCR
and the change of imprinted genes’ expression were compared with the result
of two human embryonic stem cell lines (hESCs). Four DMRs of different
expressive imprinted genes were detected in undifferentiated hPESCs and
hESCs by bisulﬁte sequencing.
Main results and the role of chance: All the maternally expressed genes
were expressed at similar levels in both human parthenogentic embryonic stem
cell lines and in human embryonic stem cell line except ZNF264 and ATP10A.
21 detected paternally expressed genes were expressed at the same levels in
two human parthenogentic embryonic stem cell lines as in the human embry-
onic stem cell line, whereas 15 paternally expressed genes were signiﬁcantly
downregulated or inactivated. During prolonged passage, the expression levels
of the majority of imprinted genes remained stable in two human parthenogen-
tic embryonic stem cell lines. PEG3/ZIM2 DMRs, SNURF/SNRPN DMRs and
KVDMR1 DMRs are highly methylated in two early passages (p27) undifferenti-
ated human parthenogentic embryonic stem cells and its embryonic bodies,
whereas DMRs in early passages (p27) undifferentiated human embryonic stem
cells and its EBs are half methylated, and clones are almost completely methy-
lated or demethylated. Comparing with human embryonic stem cells, two
human parthenogentic embryonic stem cell lines showed the same imprinted
genes expressive trending in early differentiation stage. The expression levels of
H19, IGF2, SLC22A2, SLC22A3/SLC22A18 and CPA4 were both signiﬁcantly
up-regulated in early differentiation process of human parthenogentic embry-
onic stem cells and human embryonic stem cells.
Limitations, reasons for caution: The limitation of this study is imprinted
gene expression levels were only detected in undifferentiated and early differen-
tiated hPESCs. The aberrant imprinted gene status was not detected in the
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derivative of hPESCs and their inﬂuence on hPESCs differentiation and derivate
cells function were still unknown.
Wider implications of the ﬁndings: This study quantitatively analyzed the
expression patterns of imprinted genes of undifferentiated and early differen-
tiated stage hESCs from parthenogenetic embryos. To our knowledge, this is by
far the most wide-range study on survey imprinting proﬁle of hPESCs and evalu-
ating epigenetic status of hPESCs from the aspect of imprinting genes
expression.
Trial registration number: not applicable.
P-790 human embryonic stem cells carrying an unbalanced
translocation demonstrate impaired differentiation capacity
Y. Sun, P. Xie, Q. Ouyang
School of Basic Medical Science- Central South University-, Institute of Reproductive
and Stem Cell Engineering-, Changsha-, China
Study question: whether human embryonic stem cells carrying unbalanced
translocation can be used as a model to analyze the development potential of
unbalanced translocation embryos?
Summary answer: HESC lines carrying unbalanced translocation after preim-
plantation genetic diagnosis (PGD) are excellent in vitro model of partial mono-
somy and/or trisomy for early embryonic development.
What is known already: Human embryonic stem cells (hESCs) have the abil-
ity of self-renewal and multiple differentiation potential. Unbalanced transloca-
tion was known as one of the common structural chromosomal defects
involved in abnormal embryogenesis. Differentiated translocated hESCs were
reported that impaired expression of the trophoblastic genes may be associated
with implantation failure.
Therefore, Unbalanced hESCs can serve as a tool for studying chromosome
partial segments abnormalities linked to early stages of embryonic
development.
Study design, size, duration: Six HESC lines were established from PGD
embryos carrying unbalanced translocation. Subsequently, we aimed to indenti-
fy the biological characteristics and genetic stability of such embryonic stem
cells. We further analyzed the consequences of copy number variation involved
in embryonic developmental potential.
Participants/materials, setting, methods: A total of nine hESC lines were
used, including three controls. HESC lines exhibit hallmarks of pluripotency,
pluripotency-associated gene expression was evaluated by RT-PCR and pluri-
potency markers were assessed by immunocytochemistry. The differentiation
capability was demonstrated by teratoma formation in vivo and embryoid body
(EB) formation in vitro. Genetic stability of hESC lines was evaluated using kar-
yotype analysis, ﬂuorescence in situ hybridization(FISH) and Next Generation
Sequencing(NGS). RNA-seq was used to compare differentially expressed gene
proﬁles.
Main results and the role of chance: Six abnormal hESC lines were estab-
lished from eleven blastocysts carried an unbalanced chromosomal defect. All
hESC lines expressed the pluripotency-related genes such as POU5F1, SOX2,
NANOG, KLF4, TERF1 and THY1 and stained positive for pluripotency mar-
kers POU5F1, NANOG, TRA-1-60 and TRA-1-81. Next Generation
Sequencing conﬁrmed that genome exactly matched between embryo and
hESCs. Moreover, these cell lines maintained a stable karyotype of the donors
during long-term culture. RNA-seq results identiﬁed that the expression level of
gene was signiﬁcant changes in chromosome imbalances hESC lines compared
to normal hESCs. The genes expression level of partial chromosome trisomy or
monosomy was upregulated or downregulated. Only three of hESC lines could
differentiate into all three germ lineages. For teratoma formation and analysis,
normal hESCs generated teratomas in a shorter time than unbalanced hESCs.
During homogenous embryoid body differentiation, the efﬁciency of unbalanced
hESCs aggregate formation was lower compared to normal hESCs. In conclu-
sion, affected differentiation capacities and cell apoptosis in differentiating
embryoid bodies may be caused by gene expression dosage imbalance.
Limitations, reasons for caution: Although we revealed that the embryonic
development potential was impaired by CNV, the dosage imbalances of chro-
mosomes and reduce of key gene expression may lead to lethality at early
stages of human embryonic development. The underlying mechanism for early
embryonic arrest or miscarriages has not been fully investigated.
Wider implications of the ﬁndings: Current research models for deter-
mining the cause of implantation failure are still very limited. These cell lines will
help us to explore developmental several aspects of translocated embryos.
Moreover, the effects of partial monosomy or trisomy on human development
and birth need to further search.
Trial registration number:No application.
P-791 Homing of mouse spermatogonial stem cells on acellular
testis following in vitro transplantation
N. Majidi Gharenaz, M. Movahedin
Department of Anatomical Sciences- Faculty of Medical Sciences- Tarbiat Modares
University- Tehran- Iran, Department of Anatomical Sciences, Tehran, Iran
Study question: Could acellular testis support homing of mouse spermato-
gonial stem cells after in vitro transplantation?Could acellular testis support
homing of mouse spermatogonial stem cells after in vitro transplantation?
Summary answer: In vitro transplantation of mouse spermatogonial stem
cells in to acellular testis and two week organ culture could initiate in vitro
spermatogenesis.
What is known already: Vermeulen et al reported culturing of Sertoli cells
with testicular scaffold could increase the proliferation rate of the cells.
Baert et al reported that primary adult and prepubertal human testicular cells
can assemble to testicular organoid with and without support of natural testicu-
lar scaffold.
Study design, size, duration: In this study we had two groups. Control
group: without transplantation of Spermatogonial stem cells. Experimental
group: with transplantation of Spermatogonial stem cells. For each group, 5
NMRI male mice were used at the age of 8 weeks for decellularization.
Spermatogonial stem cells isolated from 6 NMRI neonate male mice, then
injected to acellular testis and cultured for 2 weeks.
Participants/materials, setting, methods: Testes decellularized by 0.05%
SDS for 24 h+0.05% Triton X-100 for 24 h, then were washed with 1× PBS for
24 h, and disinfected using 0.1% peracetic acid in 4% ethanol for 2 h, rinsed
three times with sterile 1× PBS for 4 hours each. Spermatogonial stem cells iso-
lated from neonate testis with twice enzymatic treatment, injectod to acellular
testes and cultured on agarose gel for two weeks. Finally, immunohistochemis-
try and molecular studies were done.
Main results and the role of chance: Immunohistochemically studies in the
control and experimental group express PLZF proteins in spermatogonial cells.
Also, in molecular studies of PLZF, the results indicated that this genes was posi-
tive in the experimental group, while not in the control group.
Limitations, reasons for caution: If we want to use the result of this
research in clinic, we need to be able to decellularize human whole testis for
injection of spermatogonial stem cells. Decellularization human whole testis is
difﬁcult and need set up new protocol.
Wider implications of the ﬁndings:Our result showed that natural testicu-
lar scaffold could support of spermatogonial stem cells during 2 week culturing.
These results in agreement with literature that reported testicular scaffold could
increase proliferation of Sertoli cells and support of auto assembly testicular
organoid.
Trial registration number: 0
P-792 Are we losing valuable reserves by discarding post-TESE
(testicular sperm extraction) material? Analysis of the quantity and
distribution of spermatogonial stem cells (SSCs) after TESE
M. Afshani1, İ. Kaplanoğlu2, A. Öcal3, Ö. Çınar4
1Eastern Mediterranean University Dr. Fazıl Küçük Faculty of Medicine, Histology
and Embryology, Famagusta, Turkey
2Etlik Zübeyde Hanım Gynecology Education and Research Hospital, Assisted
Reproductive Techniques and IVF Unit, Ankara, Turkey
3Etlik Zübeyde Hanım Gynecology Education and Research Hospital, Assisted
Reproductive Techniques and ART Unit, Ankara, Turkey
4Ankara University School of Medicine, Histology and Embryology, Ankara, Turkey
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Study question: Assuming the relationship between IVF success and the
quantity of SSCs in discarded-TESE material, should we consider post-TESE
tubules as future sources of SSCs?
Summary answer: SSCs are found in post-TESE tubules which is routinely
discarded. There is a statistically signiﬁcant relationship between SSEA4 positiv-
ity and pregnancy rate.
What is known already: SSCs differentiate to mature spermatozoa by a pro-
cess called spermatogenesis, during which stage-speciﬁc proteins play roles and
can be used to evaluate the differentiation mechanisms. Spermatozoa from
azoospermia patients can be obtained via surgical methods like TESE. Following
TESE, not only operated region of testis heals with ﬁbrosis causing a loss in
sperm production but also remaining parts of the isolated seminiferous tubules,
which may harbor SSCs, are discarded after collection of spermatozoa. The
questions that what we lose after TESE in terms of SSCs and if there is a correl-
ation between amount of SSCs and IVF success still stand.
Study design, size, duration: After ethical board approval, materials were
obtained from 45 non-obstructive azoospermia patients who applied for a gov-
ernmental IVF-center between 2015 and 2017. After TESE operation and the col-
lection of spermatozoa for IVF treatment, remaining seminiferous tubules to be
discarded were collected for this study. Outcomes of IVF including, fertilization,
embryo development and pregnancy rates were obtained from the IVF center to
evaluate the relationship between IVF success and analyzed parameters.
Participants/materials, setting, methods: Obtained tissue materials were
stained with antibodies that were produced against DDX4, MAGEA4, SSEA4
and Oct4 proteins which are used to determine various differentiation steps of
spermatogenesis and considered as SSCs markers. The distribution and inten-
sity of those markers were evaluated by routinely used histological scoring tech-
inquetechnique (H-SCORE). The correlation between IVF outcomes and H-
SCORE analysis were evaluated by appropriate statistical tests. Values were
presented as mean±S.D.
Main results and the role of chance: Cytoplasmic MAGEA4 and SSEA4
expressions at the basal compartments of seminiferous tubules indicated the
presence of spermatogonia, while the strong juxta-luminal and mid-basal
expression of DDX4 demonstrated the presence of spermatocytes and sper-
matids. Cytoplasmic expression of Oct4 was also detected in spermatogonia
and spermatocytes but no evidence of expected nuclear expression was
encountered. Since the IVF center indicated that spermatozoa were found from
27 of total 45 patients for ICSI, hereupon these groups were considered as Sp
(+) and others Sp(-). First, H-SCORE outcomes of Sp(+) patients (n = 27)
were compared with Sp(-) (n = 18) ones, and found that albeit outcomes of
DDX4 staining in Sp(+) parameter reach to signiﬁcant levels. Considering the
pregnancy rates, 9 of the Sp(+) patients resulted with pregnancy, Pr(+) and
only SSEA4 outcomes reach to statistically signiﬁcant levels (121 ± 51) com-
pared to Pr(-) (n = 16) ones (74 ± 49), p = 0.048. The expression pattern of
germ cell markers suggested the possible chance of spermatogenesis failure at
different stages of spermatogenesis within the seminiferous tubules of Sp(-)
samples, whereas the H-Score values showed no signiﬁcant difference of germ
cell presence among the groups.
Limitations, reasons for caution: A comparison between obstructive and
non-obstructive cases would be informative to understand the SSCs reserve in
spermatogenesis and possible relationship with IVF success. Since seminiferous
tubules show high variations in terms of positivity of SSCs markers, similar stud-
ies with higher case numbers will decrease the role of chance factor.
Wider implications of the ﬁndings: This study highlights the requirement
of future studies aiming the isolation, freezing and also in-vitro maturation of
SSCs particularly in oligo/astheno/azoo-spermia patients who may lose their
SSCs reserve by a surgical application, TESE, and also concludes that testicular
reserve needs more attention for IVF treatments like ovarian reserve.
Trial registration number:N/A.
P-793 Characterization of human granulosa progenitor cells as a
potential source for the treatment of chemotherapy-induced
ovarian damage
B. Cai, L. Baomin, X. Yanwen, Z. Canquan
First Afﬁliated Hospital of SunYat-sen University, reproductive medicine center,
Guangzhou-Guangdong, China
Study question: Can human granulosa progenitor cells which derived from
human mural granulosa iPSCs (GiPSCs) restore chemotherapy-induced ovarian
damage and what’s the underlying molecular mechanism?
Summary answer: Human granulosa progenitor cells which derived from
human mural granulosa iPSCs, may restore damaged ovarian function through
the Paracrine pathway.
What is known already: Young female patients who received chemotherapy
frequently face premature ovarian failure (POF), for which there were currently
no ideal treatments or medications. Furthermore, apoptosis of ovarian granulo-
sa cells were an important mechanism underlying the decline in ovarian reserve
and function which can be effectively alleviated through some kinds of stem cell
transplantion.
Study design, size, duration: Mice ovaries were injured with cyclophospha-
mide to create a damaged ovary mice model. Transplanted GiPS-derived granu-
losa progenitor cells were injected into the tail vein of sterilized mice ( n = 20),
or cell culture medium was injected into the sterilized mice via the tail vein as
cell-media group (n = 20). Nonsterilized mice were untreated controls (n =
20). After 1 month,ovarian tissue weight,plasma E2 level,and the number of fol-
licles was compared in all groups.
Participants/materials, setting, methods: Human mural granulosa iPSCs
were reprogrammed from mural granulosa cells collected from egg follicles
retrieved from women undergoing infertility treatment using Sendai viral vec-
tors.Then we used two step approaches comprising in vitro treatments with
cocktails of growth factors (Wnt 3a,ActivinA,BMP4,ect) for 12days.After pas-
saged 3 times,we obtained the granulosa progenitor cells(GPCs). Expression of
granulosa cell, ES markers and metabolic culture medium were analyzed.These
cells and media were injected into the tail vein of sterilized mice.
Main results and the role of chance: GiPS-derived granulosa progenitor
cells expressed OCT4, but not GC lineage markers. Also are capable of clono-
genic self-renewal and extensive proliferation in vitro and could differentiate into
neural or mesenchymal cell lineages, as well as GCs, with the ability to produce
E2 from testosterone, under defned conditions. After transplanted into the
POF models 1 month,the Ovarian tissue weight,plasma E2 level,and the number
of follicles were all signiﬁcantly higher in cell treated group compared with che-
moablated group,but approached the same effect between cell and cell media
group. After using human cytokines array to analyze the cell media,revealed
that many key cytokines were in high level, participating in a variety of biological
processes including apoptosis, angiogenesis, cell cycle and immune response.
These results suggested that GiPS-derived granulosa progenitor cells may not
only effectively enhance granulosa cells growth and repair damaged ovarian tis-
sue, but regulating the ovarian tissue niche through the Paracrine pathway.
Limitations, reasons for caution: Although GiPSCs-derived granulosa pro-
genitor cells did not induce teratoma formation in vivo in the POF mice,the
undifferentiated iPSCs are still potential risk in clinical trial in future.
Wider implications of the ﬁndings: Our research results showed that
GiPSCs-derived granulosa progenitor cells can repair ovarian injury, stimulate
regeneration, and improve ovarian function. GiPSCs-derived granulosa progeni-
tor cells transplantation may provide an effective and novel method for treating
POF.
Trial registration number: not applicable.
P-794 Feasibility of CRISPR-Cas9 on the human sperm cell
D. Choi, B. Chin, C. O’Neill, S. Cheung, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question:What are the optimal transfection parameters to ensure via-
bility of spermatozoa in a CRISPR-Cas9 protocol?
Summary answer: Among all different parameters tested, 1100 V, 20 ms, 1
was the optimal set to successfully transfect CRISPR-Cas9 plasmid in human
spermatozoa retaining their motility.
What is known already: The CRISPR-Cas9 system recently made headway
in reproductive medicine by a group of researchers that used viable human
embryos to correct a mutation that causes hypertrophic cardiomyopathy, a
severe heart condition in humans. Through intracytoplasmic sperm injection
(ICSI), the researchers injected CRISPR-Cas9 solution and spermatozoa
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simultaneously into an egg. However, there is currently no research done on
using the CRISPR-Cas9 tool directly on human sperm. Importantly, to date, no
known transfection parameter optimal for human sperm cells has been
described, especially when compared to various known transfection para-
meters utilized for somatic cells.
Study design, size, duration: Our aim is to ﬁnd the optimal transfection
parameters for human spermatozoa that can ensure the highest viability and
motility of cells after exposing them to high voltage pulses. To meet this goal,
we designed a unique 24-well optimization protocol, in which 24 different sets
of transfection parameters were tested. We plan to use CRISPR-Cas9 on
sperm cells to knockout LAMA1, a gene that is found to be upregulated in male
infertility patients.
Participants/materials, setting, methods: As a preliminary experiment,
we transfected (Neon Transfection System, Invitrogen) embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs) grown in vitro with Oct3/4
CRISPR-Cas9 knockout plasmid utilizing a GFP reporter gene. Successful trans-
fection was the absence of GFP expression. We then began our ﬁrst attempt
using human sperm cells and evaluated different sets of parameters ranging
from 800 V, 27 ms, 5 to 1700 V, 20 ms, 1.
Main results and the role of chance: The results of our preliminary
experiment using ESCs and iPSCs were highly successful as they matched
the threshold of 79% transfection efﬁciency found in prior research with
DNA transfection of stem cells. Oct3/4 expression was remarkably
decreased by 81 ± 2% after transfection when compared to the initial
expression.
As for our experiment with human spermatozoa, we used a donor sperm
sample with initial concentration of 70 ± 6×106/ml and a motility of 40.3 ± 4%.
Following density gradient, concentration became 22 ± 11×106/ml and motility
86.2 ± 3%, respectively. The highest motility after transfection was only 5.9 ±
3%. Moreover, because spermatozoa were further diluted after transfection,
the concentration decreased to 0.03 ± 7×106/ml.
Going forward, we plan to use semen samples with higher concentration
and motility to obtain a higher motile fraction after density gradient. After
transfection, we intend to isolate the motile portion from the immotile by
microﬂuidics to avoid the decaying cells’ affect on viability of the motile sib-
ling spermatozoa due to leakage of acrosomal enzyme and production of
reactive oxygen species (ROS). In this way, we can allow more time for
plasmids to execute the double-stranded break and for the DNA to repair
itself while retaining cell viability.
Limitations, reasons for caution: The execution of transfection experi-
ments on spermatozoa dealt with the structural peculiarity and the innate
kinetic characteristics of this cell, which may have affected the accuracy and
reproducibility of our analysis. However, utilization of CRISPR-Cas9 on human
spermatozoa may ease qualms related to the direct genetic manipulation of
embryos.
Wider implications of the ﬁndings:Our results of ﬁnding motile spermato-
zoa after exposing them to high voltage pulses through electroporation gives
hope that correcting mutations in human sperm cells is possible. Genetic
manipulation on the male gamete may prove more reliable in granting the
desired effect on the resulting conceptus.
Trial registration number:N/A.
P-796 Intrauterine infusion of autologous peripheral blood
mononuclear cells in frozen blastocyst transfer improves clinical
outcome andmetabolomic proﬁle in repeated implantation
failure- A pilot study
B. Chakravarty1, S.Wasim1, S. Chakrabarti1, P. Banerjee1,
K. Chaudhury2, P. Chakraborty3
1Institute of Reproductive Medicine, Assisted Reproductive Technology, Kolkata, India
2Indian Institute Of Technology, smst, Kharagpur, India
3Institute of Reproductive Medicine, Infertility, Kolkata, India
Study question: Do autologous peripheral blood mononuclear cells (PBMC)
improve endometrial receptivity and clinical pregnancy in frozen embryo trans-
fer (FET) in women with repeated implantation failure (RIF)?
Summary answer: Infusion of PBMC improves clinical pregnancy and live
birth rate in RIF, which could be associated with down-regulation of metabolites
like tryptophan, valine and lysine.
What is known already: Despite advancement of IVF protocols and assess-
ment of embryo morphokinetics, methodologies continue to strive to optimize
IVF success in management of RIF. Autologous PBMC is a convenient source of
adult stem cell; usage being to increase implantation potential of embryos and
increase in endometrial receptivity. Recent studies document metabolic proﬁling
as a promising platform for assessment of endometrial receptivity. Furthermore,
infusion of stem cells into spiral arterioles of patients with refractory Asherman’s
syndrome has shown improvement in implantation rate. In view of these facts,
use of PBMC in the management of RIF holds a promising tool for the future.
Study design, size, duration: Prospective study from January 2016 to
January 2017; 160 patients with ≥ 3embryo transfer (ET) failure (fresh and fro-
zen) undergoing day5 FET were divided into Group A (n = 73; intrauterine infu-
sion of PBMC) and B (n = 87; without PBMC infusion). Mononuclear cells were
used as a source of stem cell, isolated from patient’s peripheral blood by density
gradient centrifugation using commercially available lymphoprep. Main outcome
measures were: implantation rate, clinical pregnancy rate and live birth rate.
Participants/materials, setting, methods: All patients received estradiol
valerate 2 mg thrice daily from d2 onwards. Intra-uterine infusion of PBMC was
done on D5 of cycle in Group A. Once endometrial thickness reached ≥7 mm,
progesterone was administered for ﬁve days. Blood samples were collected on
day of embryo transfer. Samples were analyzed using 700-MHz NMR spectrom-
eter and acquired spectra were subjected to chemometric and statistical ana-
lysis. p< 0.05 was considered to be signiﬁcant as evaluated by chi-square and t-
test.
Main results and the role of chance: Baseline clinical parameters and num-
ber of embryos transferred were found to be comparable in both groups. A sig-
niﬁcant increase (p< 0.01) in implantation rate was observed in group A
(23.97%) as compared to group B (9.2%). Clinical pregnancy rate was found to
be signiﬁcantly higher (p <0.05) in group A (38.36%) versus group B (17.24%).
Simultaneously, live birth rate in group A (24.66%) was signiﬁcantly higher than
Group B (11.49%). Miscarriage rate was higher in group A, difference being non
signiﬁcant. Valine, tryptophan, and l-lysine, were found to be signiﬁcantly down-
regulated (p< 0.03, p<0.01; p<0.02) with fold change values of 0.81, 0.76, 0.74
respectively in women with RIF after PBMC infusion when compared with those
without administration of PBMC. However, when metabolomic markers were
evaluated between pregnant and non-pregnant subjects in either group the dif-
ference was not statistically signiﬁcant. Since the interplay between these mole-
cules in RIF is complex, study holds merit for further exploration.
Limitations, reasons for caution: Owing to application of PBMC in FET
cycle, we cannot evaluate the potential receptivity markers in endometrium to
ascertain the immunomodulatory role of PBMC for successful blastocyst
implantation. In-depth studies of the arginine metabolic pathway in endometrial
tissues seem necessary to validate our ﬁndings.
Wider implications of the ﬁndings: Intra-uterine PBMC infusion can be
relatively inexpensive and minimally invasive treatment for patients with RIF;
simultaneously it may be beneﬁcial in recurrent pregnancy loss aiming to
improve endometrial receptivity. We speculate that serum metabolomics can
provide an improved understanding of increased clinical pregnancy after PBMC
infusion in women with RIF.
Trial registration number:Not applicable.
P-797 Proteomic proﬁling of the exosomes released by
endometrial mesenchymal stem cells: possible relations with
embryo development and implantation
F. Marinaro1, V. Alvarez1, R. Blázquez1,2, E. López Nieto1,
B. Macías-García3, M. Gómez Serrano4, I. Jorge Cerrudo2,4,
J. Vázquez2,4, F.M. Sánchez-Margallo2,5, J. García Casado1,2
1Jesús Usón Minimally Invasive Surgery Centre, Stem cell therapy unit, Cáceres, Spain
2CIBER de Enfermedades Cardiovasculares, CIBER de Enfermedades
Cardiovasculares, Madrid, Spain
3Jesús Usón Minimally Invasive Surgery Centre, Assisted reproduction Unit, Cáceres,
Spain
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4Centro Nacional Investigaciones Cardiovasculares CNIC, Cardiovascular Proteomics
Lab, Madrid, Spain
5Jesús Usón Minimally Invasive Surgery Centre, Jesús Usón Minimally Invasive Surgery
Centre, Cáceres, Spain
Study question: Is the proteomic proﬁle of exosomes derived from human
endometrial mesenchymal stem cells (exo-endMSCs) associated with embryo
development and implantation?
Summary answer: The bioinformatics analyses of exo-endMSCs have identi-
ﬁed exosomal proteins that are involved in the maternal-embryo cross-talk
inﬂuencing the embryo’s developmental competence and subsequent
implantation.
What is known already: Implantation failure is the most common cause of
recurrent pregnancy loss in humans who resort to assisted reproduction tech-
nologies (ARTs). Among others, hormonal or metabolic disorders, advanced
age, immunological factors, infections or uterine abnormalities can affect endo-
metrial receptivity. In addition, diminished embryo developmental competence
due to any of these conditions increases the likelihood of implantation failure.
The cross-talk between the endometrium and the embryo is mediated by para-
crine factors delivered by the exo-endMSCs, but a complete description of the
proteomic proﬁle of these microvesicles has not been reported yet.
Study design, size, duration: Endometrial Mesenchymal Stem Cells
(endMSCs) were isolated from menstrual blood of healthy women (n = 2).
Supernatants from these cells were collected every 72 hours. The collected
supernatants were enriched and puriﬁed to isolate the released exosomes.
Participants/materials, setting, methods: The endMSCs were in vitro
expanded and characterized by ﬂow cytometry. The exo-endMSCs were iso-
lated and characterized by nanoparticle tracking analysis and ﬂow cytometry.
Then, protein extracts from exo-endMSCs were processed by high-resolution
liquid chromatography coupled to mass spectrometry-based proteomic ana-
lyses (HPLC-MS). Finally, the functional enrichment analysis was performed by
using the DAVID functional annotation database (https://david.ncifcrf.gov/).
Main results and the role of chance: EndMSCs analysis did not demon-
strate positive staining for CD34, CD45 or HLA-DR while they expressed the
CD29, CD56, CD44, CD73, CD90, CD105 stemness markers. The mean size
of the isolated exo-endMSCs was 153.5 ± 63.05 nm (mean ± SD) and showed
a positive expression of the exosome-related proteins CD9 and CD63. A total
of 714 proteins (with more than two peptides per protein at 1% FDR) were
identiﬁed in the exo-endMSCs of both cell lines.
Among the 714 selected proteins, 517 of them were associated to the Gene
Ontology term extracellular exosome (GO:0070062, p < 0.01, 5% FDR) and 60
of them were present in the 100 top identiﬁed proteins in ExoCarta database.
Moreover, exo-endMSCs proteins were connected to several biological pro-
cesses and molecular functions related to embryo developmental competence
and implantation, such as cell-cell adhesion (n = 55 in GO:0098609), extracellular
matrix organization (n = 57 in GO:0030198), cadherin binding involved in cell-cell
adhesion (n = 65 in GO:0098641), and also to the Reactome pathway ECM pro-
teoglycans (n = 35 in R-HSA-3000178).
Finally, it is worth mentioning that 11 exosomal proteins have been previ-
ously identiﬁed in endometrial cells extracts from women during the peri-
implantation phase.
Limitations, reasons for caution: The microvesicles used were obtained
from 2 donors showing differing protein proﬁles. Increasing the number of
endMSC lines will help to fully identify the proteome of exo-endMSCs. Further
studies involving in vitro implantation assays and embryo transfers coupled to
exo-endMSCs are required to clarify their importance as ARTs coadjutants.
Wider implications of the ﬁndings: This study demonstrated that exo-
endMSCs may be involved in the embryo-maternal cross-talk. Several proteins
from exo-endMSCs are also released by endometrial cells and involved in
embryo implantation and development. These proteins could be considered
predictive biomarkers for implantation and exo-endMSCS could be used as
coadjutants during in vitro embryo culture.
Trial registration number:Not applicable.
P-798 Differentiating mouse induced pluripotent stem cells into
male germ cells through embryoid bodies
V. Lu, A. Parrella, S. Chow, B. Chin, D. Choi, M. Irani, Z. Rosenwaks,
G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: We assess the effectiveness of the hanging drop method
with speciﬁc growth factors to differentiate induced pluripotent stem cells into
male germ cells.
Summary answer: Embryoid bodies (EB) supplemented and maintained in
hanging droplets (HD) containing speciﬁc differentiating factors generated a
high proportion of mitotic germ cells.
What is known already: Many methods have been proposed to coax stem
cells into male germ cells. One simple method to induce germ cell differenti-
ation utilizes the formation of EBs, three-dimensional structures that create
microtissues which simulate in vivo conditions. While EBs can spontaneously dif-
ferentiate into various cell types without external inﬂuence, speciﬁc growth fac-
tors can be added in order to reproduce in vivo cell-signaling processes and
ensure differentiation of a higher proportion of stem cells into germ cells.
Study design, size, duration: Over a four-month period, 100 EBs were
formed from mouse induced pluripotent stem cells (miPSC) using the hanging
drop method. EBs were maintained in HDs after formation and differentiated in
a 2-step culture system, each with a speciﬁc medium composition. Expression
of PGC markers was assessed by immunoﬂuorescence staining.
Participants/materials, setting, methods: Prior to differentiation,
miPSCs were maintained on mouse embryonic ﬁbroblast (MEF) cells. Once
conﬂuent, colonies were trypsinized. HDs were formed from 25uL droplets
containing miPSCs at a concentration of 1×105 cells/ml. Step one medium
contained Activin A, bFGF, and KSR. After 3 days, EBs were transferred to
HDs containing step two medium composed of LIF, BMP4, BMP8b, SCF, and
EGF. On day 8, EBs were treated with collagenase and stained for OCT4,
VASA, and DAZL.
Main results and the role of chance: After the development of 100 EBs in
their respective HDs, EBs were re-plated on day 3 to corresponding HDs
containing step two medium. EBs were disaggregated through the usage of
collagenase IV in order to isolate cells for immunoﬂuorescence staining. In
order to identify the stage of in vitro spermatogenesis achieved, OCT4,
VASA, and DAZL expression was compared between EBs cultured in the 2-
stage growth factor-conditioned medium system and control EBs maintained
in standard culture medium. Of the isolated cells, 86% were strongly positive
for OCT4 compared to 54% of cells isolated from control EBs cultured with-
out differentiating factors. Additionally, EBs cultured with differentiating fac-
tors yielded 31% VASA-positive cells, whereas control EBs only yielded 1%
VASA-positive cells. Furthermore, EBs cultured with differentiating factors
yielded 4% DAZL-positive cells, whereas control EBs only yielded 1%
DAZL-positive cells. The retained expression of OCT4, along with the pres-
ence of VASA-positive and DAZL-positive cells, strongly indicate that the
cells reached the spermatogonia/spermatocyte cell stage. Cells that were
positive for VASA and DAZL without OCT4 expression also suggest that a
fraction of cells were able to progress to the advanced meiotic stages of
in vitro spermatogenesis.
Limitations, reasons for caution: This preliminary study only attempts to
achieve early stages of differentiation in miPSC. One possible direction can be
to use retinoic acid as a third-step culture medium to coax PGCs into meiosis.
Furthermore, for this to be applicable for clinical use, trials need to be con-
ﬁrmed in human iPSC.
Wider implications of the ﬁndings: Artiﬁcial gametogenesis is a developing
technology that will ultimately allow azoospermic men to develop spermatozoa
from their stem cells. Mouse iPSC provide a step towards raising genotyped
cells suitable for clinical treatment for patients with spermatogenic arrest or
even germ cell aplasia.
Trial registration number:N/A.
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P-799 In vitro generation of germ cells from human induced
pluripotent stem cells
M. Irani, S. Chow, V. Lu, D. Choi, Z. Rosenwaks, G. Palermo
Weill Cornell Medicine, The Ronald O. Perelman and Claudia Cohen Center for
Reproductive Medicine, New York, U.S.A.
Study question: Can we differentiate human induced pluripotent stem cells
(hiPSC) into male germ cells using the hanging drop (HD) culture system?
Summary answer: The culture of hiPSC within HDs containing several
growth factors generated male germ cells of different stages of development.
What is known already: Several monolayer culture systems have been sug-
gested for differentiating stem cells into male germ cells. However, the natural
three-dimensional (3D) condition for the cells within a tissue allows them to
establish important connections among each other. The culture of stem cells
within embryoid bodies (EBs) in HDs has been proposed as a simple method to
simulate the in vivo 3D environment. In fact, we have previously described the
use of EBs within HDs containing speciﬁc factors to successfully differentiate
mouse embryonic stem cells and mouse iPSC into male germ cells.
Study design, size, duration: Over a three-month period, 50 EBs were
formed from hiPSC using the hanging drop method. EBs were maintained in
HDs after formation and differentiated in a 2-step culture system, each with a
speciﬁc medium composition. Expression of germ cell markers was assessed by
immunoﬂuorescence staining.
Participants/materials, setting, methods: HiPSCs were originally main-
tained undifferentiated on ﬁbronectin in the presence of growth factors and
ROCK inhibitor. Colonies were trypsinized and HDs were formed from 25uL
droplets containing hiPSCs (1×105 cells/ml). In the ﬁrst three days, the medium
was composed of Activin A, bFGF, and KSR. Then, the medium of HDs was
modiﬁed to contain LIF, BMP4, BMP8b, SCF, and EGF. On day 12, cells were
stained for OCT4, VASA, DAZL, and BOULE.
Main results and the role of chance:On day 12, and after culturing 50 EBs
for 3 days in step-1 medium followed by 9 days in step-2 medium, collagenase
IV was used to disaggregate EBs. Cells were isolated and stained for OCT4,
VASA, DAZL, and BOULE to determine the stage of in vitro spermatogenesis.
The staining of EBs was compared to those of undifferentiated hiPSC, which
were 84% positive for OCT-4 but negative for VASA, DAZL, and BOULE. EBs
cultured with differentiating factors yielded 75% OCT-4-positive cells, 60%
VASA-positive cells, 40% DAZL-positive cells, and 5% BOULE-positive cells.
The detection of VASA–positive and DAZL–positive cells that preserved the
expression of OCT-4 is a strong evidence of the differentiation of hiPSC to
spermatogonia/spermatocyste cell stage. In addition, the presence of cells
expressing VASA, DAZL, and/or BOULE while they were negative for OCT-4
suggests an advanced differentiation of hiPSC reaching meiotic stages.
Limitations, reasons for caution: Despite the encouraging preliminary
data, this study did not conﬁrm the completion of in vitro spermatogenesis and
attainment of post-meiotic stages. A potential strategy to overcome this limita-
tion would be the addition of retinoic acid as a third-step culture medium to
coax primordial germ cells into meiosis.
Wider implications of the ﬁndings: In vitro gametogenesis is an important
technology that provides an option for azoospermic men to develop spermato-
zoa from either their stem cells or skin ﬁbroblasts. HiPSCs could potentially
help azoospermic men who fail testicular sperm extraction due to spermato-
genic arrest or germ cell aplasia to have biological children.
Trial registration number:N/A.
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